TY  - JOUR
AU  - Kumar, S
AU  - Gosain, M
AU  - Sharma, H
AU  - Swetts, E
AU  - Amarchand, R
AU  - Kumar, R
AU  - Lafond, KE
AU  - Dawood, FS
AU  - Jain, S
AU  - Widdowson, MA
AU  - Read, JM
AU  - Krishnan, A
TI  - Who interacts with whom? Social mixing insights from a rural population in India
T2  - PLOS ONE
KW  - GLOBAL BURDEN
KW  - SYSTEMATIC ANALYSIS
KW  - SEASONAL INFLUENZA
KW  - CONTACT PATTERNS
KW  - MORTALITY
KW  - PNEUMONIA
KW  - INFECTIONS
KW  - DYNAMICS
KW  - SPREAD
AB  - Acute lower respiratory infections (ALRI) are a leading cause of morbidity and mortality globally, with most ALRI deaths occurring in children in developing countries. Computational models can be used to test the efficacy of respiratory infection prevention interventions, but require data on social mixing patterns, which are sparse in developing countries. We describe social mixing patterns among a rural community in northern India. During October 2015-February 2016, trained field workers conducted cross-sectional face-to-face standardized surveys in a convenience sample of 330 households in Faridabad District, Haryana State, India. Respondents were asked about the number, duration, and setting of social interactions during the previous 24 hours. Responses were compared by age and gender. Among the 3083 residents who were approached, 2943 (96%) participated, of whom 51% were male and the median age was 22 years (interquartile range (IQR) 9-37). Respondents reported contact (defined as having had a face-to-face conversation within 3 feet, which may or may not have included physical contact) with a median of 17 (IQR 12-25) people during the preceding 24 hours. Median total contact time per person was 36 person-hours (IQR 26-52). Female older children and adults had significantly fewer contacts than males of similar age (Kruskal-Wallis chi 2 = 226.59, p<0.001), but spent a longer duration in contact with young children (Kruskal-Wallis chi 2 = 27.26, p<0.001), suggesting a potentially complex pattern of differential risk of infection between genders. After controlling for household size and day of the week, respondent age was significantly associated with number and duration of contacts. These findings can be used to model the impact of interventions to reduce lower respiratory tract infections in India.
AD  - Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA 15260 USAAD  - All India Inst Med Sci, Dept Community Med, New Delhi, IndiaAD  - Delhi Univ, New Delhi, IndiaAD  - Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USAAD  - Ctr Dis Control & Prevent, Atlanta, GA USAAD  - Ctr Dis Control & Prevent, Nairobi, KenyaAD  - Univ Lancaster, Lancaster Med Sch, Ctr Hlth Informat Comp & Stat, Lancaster, EnglandAD  - Bill & Melinda Gates Fdn, Seattle, WA 98109 USAC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of DelhiC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - Centers for Disease Control & Prevention - USAC3  - Lancaster UniversityC3  - Bill & Melinda Gates FoundationPU  - PUBLIC LIBRARY SCIENCE
PI  - SAN FRANCISCO
PA  - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
DA  - DEC 21
PY  - 2018
VL  - 13
IS  - 12
C7  - e0209039
DO  - 10.1371/journal.pone.0209039
AN  - WOS:000454149400025
ER  -

TY  - JOUR
AU  - Dixit, AB
AU  - Sharma, D
AU  - Tripathi, M
AU  - Srivastava, A
AU  - Paul, D
AU  - Prakash, D
AU  - Sarkar, C
AU  - Kumar, K
AU  - Banerjee, J
AU  - Chandra, PS
TI  - Genome-wide DNA Methylation and RNAseq Analyses Identify Aberrant Signalling Pathways in Focal Cortical Dysplasia (FCD) Type II
T2  - SCIENTIFIC REPORTS
KW  - SOMATIC MUTATIONS
KW  - GENE-EXPRESSION
KW  - EPILEPSY
KW  - REVEALS
KW  - MTOR
KW  - PATTERNS
KW  - TARGET
KW  - EPILEPTOGENESIS
KW  - MECHANISMS
KW  - SCLEROSIS
AB  - Focal cortical dysplasia (FCD) is one of the most common pathologies associated with drug-resistant epilepsy (DRE). The pharmacological targets remain obscured, as the molecular mechanisms underlying FCD are unclear. Implications of epigenetically modulated aberrant gene expression in disease progression are reported in various DRE pathologies except FCD. Here we performed genome-wide CpG-DNA methylation profiling by methylated DNA immunoprecipitation (MeDIP) microarray and RNA sequencing (RNAseq) on cortical tissues resected from FCD type II patients. A total of 19088 sites showed altered DNA methylation in all the CpG islands. Of these, 5725 sites were present in the promoter regions, of which 176 genes showed an inverse correlation between methylation and gene expression. Many of these 176 genes were found to belong to a cohesive network of physically interacting proteins linked to several cellular functions. Pathway analysis revealed significant enrichment of receptor tyrosine kinases (RTK), EGFR, PDGFRA, NTRK3, and mTOR signalling pathways. This is the first study that investigates the epigenetic signature associated with FCD type II pathology. The candidate genes and pathways identified in this study may play a crucial role in the regulation of the pathogenic mechanisms of epileptogenesis associated with FCD type II pathologies.
AD  - NBRC, Ctr Excellence Epilepsy, Manesar, IndiaAD  - Univ Delhi, Dr BR Ambedkar Ctr Biomed Res, Delhi, IndiaAD  - AIIMS, Dept Neurol, New Delhi, IndiaAD  - AIIMS, Dept Neurosurg, New Delhi, IndiaAD  - AIIMS, Dept Forens Med & Toxicol, New Delhi, IndiaAD  - AIIMS, Dept Pathol, New Delhi, IndiaAD  - AIIMS, Dept Biophys, New Delhi, IndiaC3  - Department of Biotechnology (DBT) IndiaC3  - National Brain Research Centre (NBRC)C3  - University of DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - NATURE PORTFOLIO
PI  - BERLIN
PA  - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
DA  - DEC 19
PY  - 2018
VL  - 8
C7  - 17976
DO  - 10.1038/s41598-018-35892-5
AN  - WOS:000453768800013
ER  -

TY  - JOUR
AU  - Prasad, K
AU  - Siemieniuk, R
AU  - Hao, Q
AU  - Guyatt, G
AU  - O'Donnell, M
AU  - Lytvyn, L
AU  - Heen, AF
AU  - Agoritsas, T
AU  - Vandvik, PO
AU  - Gorthi, SP
AU  - Fisch, L
AU  - Jusufovic, M
AU  - Muller, J
AU  - Booth, B
AU  - Horton, E
AU  - Fraiz, A
AU  - Siemieniuk, J
AU  - Fobuzi, AC
AU  - Katragunta, N
AU  - Rochwerg, B
TI  - Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline
T2  - BMJ-BRITISH MEDICAL JOURNAL
KW  - PREVENTION
KW  - GRADE
AB  - What is the role of dual antiplatelet therapy after high risk transient ischaemic attack or minor stroke? Specifically, does dual antiplatelet therapy with a combination of aspirin and clopidogrel lead to a greater reduction in recurrent stroke and death over the use of aspirin alone when given in the first 24 hours after a high risk transient ischaemic attack or minor ischaemic stroke? An expert panel produced a strong recommendation for initiating dual antiplatelet therapy within 24 hours of the onset of symptoms, and for continuing it for 10-21 days. Current practice is typically to use a single drug -
AD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaAD  - McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, CanadaAD  - Univ Toronto, Dept Med, Toronto, ON, CanadaAD  - Sichuan Univ, West China Hosp, Ctr Gerontol & Geriatr, Chengdu, Sichuan, Peoples R ChinaAD  - McMaster Univ, Dept Med, Hamilton, ON, CanadaAD  - NUI Galway, Dept Med, Galway, IrelandAD  - Innlandet Hosp, Dept Med, Trust Div, Gjovik, NorwayAD  - Univ Hosp Geneva, Div Gen Internal Med, Geneva, SwitzerlandAD  - Univ Hosp Geneva, Div Clin Epidemiol, Geneva, SwitzerlandAD  - Univ Oslo, Inst Hlth & Soc, Fac Med, Oslo, NorwayAD  - Kasturba Med Coll & Hosp, Dept Neurol, Manipal, Karnataka, IndiaAD  - Univ Hosp Geneva, Stroke Ctr, Div Neurol, Geneva, SwitzerlandAD  - Oslo Univ Hosp, Rikshosp, Dept Neurol, Oslo, NorwayAD  - Stroke Fdn Australia, Melbourne, Vic, AustraliaAD  - Queensland Univ Technol, Fac Hlth, Sch Publ Hlth & Social Work, Brisbane, Qld, AustraliaAD  - Univ Sunshine Coast, Sch Nursing Midwifery & Paramed, Maroochydore, AustraliaAD  - Peter Lougheed Hosp, Calgary, AB, CanadaAD  - Cochrane Consumers Grp, London, EnglandAD  - Stanford Univ, Dept Surg, Stanford, CA USAC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - McMaster UniversityC3  - University of TorontoC3  - Sichuan UniversityC3  - McMaster UniversityC3  - Ollscoil na Gaillimhe-University of GalwayC3  - Innlandet Hospital TrustC3  - University of GenevaC3  - University of GenevaC3  - University of OsloC3  - Manipal Academy of Higher Education (MAHE)C3  - Kasturba Medical College, ManipalC3  - University of GenevaC3  - University of OsloC3  - National Hospital NorwayC3  - Queensland University of Technology (QUT)C3  - University of the Sunshine CoastC3  - Stanford UniversityPU  - BMJ PUBLISHING GROUP
PI  - LONDON
PA  - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
DA  - DEC 18
PY  - 2018
VL  - 363
C7  - k5130
DO  - 10.1136/bmj.k5130
AN  - WOS:000454293000002
ER  -

TY  - JOUR
AU  - Singh, L
AU  - Kashyap, S
TI  - Update on pathology of retinoblastoma
T2  - INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
KW  - retinoblastoma
KW  - pathology
KW  - molecular biology
KW  - PROGNOSTIC-SIGNIFICANCE
KW  - HISTOPATHOLOGIC ANALYSIS
KW  - TUMOR DIFFERENTIATION
KW  - EXPRESSION
KW  - CANCER
KW  - GENE
KW  - RISK
KW  - EYES
KW  - PROTEINS
KW  - FEATURES
AB  - Retinoblastoma is caused by mutational inactivation of both alleles of the RB1 gene, which maps to chromosome 13q14 and encodes retinoblastoma protein that acts as a tumor suppressor. Histopathological high-risk features of retinoblastoma are predictive of metastasis or local recurrence. The focus of this update is to emphasize the recent advances in pathology, various molecular key pathways and genome wide approaches for newer potential therapeutic future targets associated with retinoblastoma tumor biology. This review article highlights the new biomarkers expressed by the retinoblastoma tumor for the better survival of patients.
AD  - All India Inst Med Sci, Dept Ocular Pathol, Dr RP Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - IJO PRESS
PI  - XI AN
PA  - NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
DA  - DEC 18
PY  - 2018
VL  - 11
IS  - 12
SP  - 2011
EP  - 2016
DO  - 10.18240/ijo.2018.12.22
AN  - WOS:000452830000022
ER  -

TY  - JOUR
AU  - Chawla, AS
AU  - Ankur, P
AU  - Mukherjee, A
AU  - Jain, V
AU  - Kaur, G
AU  - Coshic, P
AU  - Chatterjee, K
AU  - Wadhwa, N
AU  - Natchu, UCM
AU  - Sopory, S
AU  - Bhatnagar, S
AU  - Majumder, PP
AU  - George, A
AU  - Bal, V
AU  - Rath, S
AU  - Prabhu, SB
TI  - Cell-intrinsic regulation of peripheral memory-phenotype T cell frequencies
T2  - PLOS ONE
KW  - HUMAN IMMUNE-SYSTEM
KW  - BONE-MARROW
KW  - IMMUNOLOGICAL MEMORY
KW  - TOLERANCE
KW  - EVOLUTION
KW  - RESPONSES
KW  - MICE
KW  - VARIABILITY
KW  - VACCINATION
KW  - COMPETITION
AB  - Memory land B lymphocyte numbers are thought to be regulated by recent and cumulative microbial exposures. We report here that memory-phenotype lymphocyte frequencies in B, CD4 and CD8 T-cells in 3-monthly serial bleeds from healthy young adult humans were relatively stable over a 1-year period, while Plasmablast frequencies were not, suggesting that recent environmental exposures affected steady state levels of recently activated but not of memory lymphocyte subsets. Frequencies of memory B and CD4 T cells were not correlated, suggesting that variation in them was unlikely to be determined by cumulative antigenic exposures. Immunophenotyping of adult siblings showed high concordance in memory, but not of recently activated lymphocyte subsets. To explore the possibility of cell-intrinsic regulation of T cell memory, we screened effector memory-phenotype T cell (TEM) frequencies in common independent inbred mice strains. Using two pairs from these strains that differed predominantly in either CD4 TEM and/or CD8 TEM frequencies, we constructed bi-parental bone marrow chimeras in F1 recipient mice, and found that memory T cell frequencies in recipient mice were determined by donor genotypes. Together, these data suggest cell-autonomous determination of memory T niche size, and suggest mechanisms maintaining immune variability.
AD  - Natl Inst Immunol, New Delhi, IndiaAD  - Natl Inst Biomed Genom, Kalyani, W Bengal, IndiaAD  - All India Inst Med Sci, Lab Oncol, Rotary Canc Hosp, Dr BR Ambedkar Inst, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Transfus Med, New Delhi, IndiaAD  - Translat Hlth Sci & Technol Inst, Pediat Biol Ctr, Faridabad, Haryana, IndiaC3  - Department of Biotechnology (DBT) IndiaC3  - National Institute of Immunology (NII)C3  - Department of Biotechnology (DBT) IndiaC3  - National Institute of Biomedical Genomics (NIBMG)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)PU  - PUBLIC LIBRARY SCIENCE
PI  - SAN FRANCISCO
PA  - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
DA  - DEC 17
PY  - 2018
VL  - 13
IS  - 12
C7  - e0200227
DO  - 10.1371/journaI.pone.0200227
AN  - WOS:000453451000001
ER  -

TY  - JOUR
AU  - Grewal, KS
AU  - Bhatia, R
AU  - Singh, N
AU  - Singh, R
AU  - Dash, D
AU  - Tripathi, M
TI  - Confusional state in a pregnant woman: A case of NMDA receptor encephalitis during pregnancy
T2  - JOURNAL OF NEUROIMMUNOLOGY
AB  - We report the case of a pregnant female presenting with behavioral change and hallucinations followed by focal seizures with impaired awareness. EEG revealed generalized slowing interspersed with extreme delta-brush pattern and MRI brain was normal. Both Serum and CSF anti-N-methyl-D-aspartate receptor (NMDAR) antibodies were positive. Patient had a prolonged hospital stay with full recovery and delivered a healthy baby, highlighting the significance of early diagnosis and management in this disorder.
AD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - DEC 15
PY  - 2018
VL  - 325
SP  - 29
EP  - 31
DO  - 10.1016/j.jneuroim.2018.10.008
AN  - WOS:000452932200004
ER  -

TY  - JOUR
AU  - Dhiman, A
AU  - Anand, A
AU  - Malhotra, A
AU  - Khan, E
AU  - Santra, V
AU  - Kumar, A
AU  - Sharma, TK
TI  - Rational truncation of aptamer for cross-species application to detect krait envenomation
T2  - SCIENTIFIC REPORTS
KW  - VENOMS
KW  - SNAKEBITE
AB  - In majority of snakebite cases, the snake responsible for the bite remains unidentified. The traditional snakebite diagnostics method relies upon clinical symptoms and blood coagulation assays that do not provide accurate diagnosis which is important for epidemiological as well as diagnostics point of view. On the other hand, high batch-to-batch variations in antibody performance limit its application for diagnostic assays. In recent years, nucleic acid aptamers have emerged as a strong chemical rival of antibodies due to several obvious advantages, including but not limited to in vitro generation, synthetic nature, ease of functionalization, high stability and adaptability to various diagnostic formats. In the current study, we have rationally truncated an aptamer developed for alpha-Toxin of Bungarus multicinctus and demonstrated its utility for the detection of venom of Bungarus caeruleus. The truncated aptamer alpha-Tox-T2 (26mer) is found to have greater affinity than its 40-mer parent counterpart alpha-Tox-FL. The truncated aptamers are characterized and compared with parent aptamer for their binding, selectivity, affinity, alteration in secondary structure and limit of detection. Altogether, our findings establish the cross-species application of a DNA aptamer generated for alpha-Toxin of Bungarus multicinctus (a snake found in Taiwan and China) for the reliable detection of venom of Bungarus caeruleus (a snake found in the Indian subcontinent).
AD  - AIIMS, Dept Biotechnol, New Delhi 110029, IndiaAD  - THSTI, Ctr Biodesign & Diagnost, Faridabad 121001, Haryana, IndiaAD  - Bangor Univ, Sch Biol Sci, Coll Nat Sci, Bangor LL57 2UW, Gwynedd, WalesAD  - Indian Inst Technol Indore, Discipline Biosci & Biomed Engn, Indore 453552, Madhya Pradesh, IndiaAD  - Simultala Conservationists Fdn Wildlife, Hooghly 712407, W Bengal, IndiaAD  - UTU, Fac Pharm, Dehra Dun 248007, Uttarakhand, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)C3  - Bangor UniversityC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - IndoreC3  - Uttarakhand Technical UniversityPU  - NATURE PORTFOLIO
PI  - BERLIN
PA  - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
DA  - DEC 12
PY  - 2018
VL  - 8
C7  - 17795
DO  - 10.1038/s41598-018-35985-1
AN  - WOS:000452894200010
ER  -

TY  - JOUR
AU  - Gupta, A
AU  - Mallick, P
AU  - Sharma, O
AU  - Gupta, R
AU  - Duggal, R
TI  - PCSeg: Color model driven probabilistic multiphase level set based tool for plasma cell segmentation in multiple myeloma
T2  - PLOS ONE
KW  - IMAGE SEGMENTATION
KW  - ACTIVE CONTOURS
KW  - CT
KW  - FRAMEWORK
KW  - ATLAS
AB  - Plasma cell segmentation is the first stage of a computer assisted automated diagnostic tool for multiple myeloma (MM). Owing to large variability in biological cell types, a method for one cell type cannot be applied directly on the other cell types. In this paper, we present PCSeg Tool for plasma cell segmentation from microscopic medical images. These images were captured from bone marrow aspirate slides of patients with MM. PCSeg has a robust pipeline consisting of a pre-processing step, the proposed modified multiphase level set method followed by post-processing steps including the watershed and circular Hough transform to segment clusters of cells of interest and to remove unwanted cells. Our modified level set method utilizes prior information about the probability densities of regions of interest (ROIs) in the color spaces and provides a solution to the minimal-partition problem to segment ROls in one of the level sets of a two-phase level set formulation. PCSeg tool is tested on a number of microscopic images and provides good segmentation results on single cells as well as efficient segmentation of plasma cell clusters.
AD  - Indraprastha Inst Informat Technol Delhi IIIT Del, Dept ECE, SBILab, New Delhi, IndiaAD  - NYU, Courant Inst Math Sci, Dept Comp Sci, New York, NY 10012 USAAD  - Indraprastha Inst Informat Technol Delhi IIIT Del, Dept CSE, New Delhi, IndiaAD  - AIIMS, Dr BRA IRCH, Lab Oncol Unit, New Delhi, IndiaC3  - Indraprastha Institute of Information Technology DelhiC3  - New York UniversityC3  - Indraprastha Institute of Information Technology DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalPU  - PUBLIC LIBRARY SCIENCE
PI  - SAN FRANCISCO
PA  - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
DA  - DEC 12
PY  - 2018
VL  - 13
IS  - 12
C7  - e0207908
DO  - 10.1371/journal.pone.0207908
AN  - WOS:000452898600045
ER  -

TY  - JOUR
AU  - Hadda, V
AU  - Kumar, R
AU  - Khilnani, GC
AU  - Kalaivani, M
AU  - Madan, K
AU  - Tiwari, P
AU  - Mittal, S
AU  - Mohan, A
AU  - Bhalla, AS
AU  - Guleria, R
TI  - Trends of loss of peripheral muscle thickness on ultrasonography and its relationship with outcomes among patients with sepsis
T2  - JOURNAL OF INTENSIVE CARE
KW  - Ultrasonography
KW  - Muscle thickness
KW  - Critical illness
KW  - ICU
KW  - Sepsis
KW  - Outcome
KW  - INTENSIVE-CARE UNIT
KW  - ACQUIRED WEAKNESS
KW  - ULTRASOUND
KW  - STRENGTH
KW  - MORTALITY
AB  - Background and aimsData regarding trends of muscle loss on ultrasonography (USG) and its relationship with various outcomes among critically ill patients is limited. This study aimed to describe the trends of loss of muscle thickness of the arm and thigh (assessed using USG) and to determine the relationship between loss of muscle thickness and in-hospital and post-discharge outcomes.MethodsMuscle thickness of 70 patients with sepsis was measured at the level of the mid-arm and mid-thigh using bedside USG on days 1, 3, 5, 7, 10 and 14 and then weekly till discharge or death. Patients were followed up for 90days after discharge.ResultsThe muscle thickness (meanSD) at the level of the mid-arm and mid-thigh on day 1 was 23.13 +/- 4.83mm and 31.21 +/- 8.56mm, respectively. The percentage muscle thickness [median (min, max)] decline at the mid-arm and mid-thigh was 7.61 (-1.51, 32.05)% and 10.62 (-1.48, 32.06)%, respectively on day 7 as compared to baseline (p<0.001). The decline in muscle thickness at the mid-arm and mid-thigh were higher among non-survivors compared to survivors at all time points. Also, the decline in muscle thickness was significantly higher among patients with worse outcome at day 90. Patients with ICU-acquired weakness also had significantly higher decline in muscle thickness (p<0.05). Early decline (from day 1 to day 3) in muscle thickness was associated with in-hospital mortality. The probability of death by day 14 was higher for patients who had early decline (from day 1 to day 3) in muscle thickness of 6.59% and 5.20% at the mid-arm [HR 7.3 (95% CI 1.5, 34.2)] and the mid-thigh [HR 8.1 (95% CI 1.7, 37.9)], respectively. Decline in thickness from day 1 to day 3 was a good predictor of in-hospital mortality with area under the curve (AUC) of 0.81 and 0.86 for arm and thigh muscles, respectively.Conclusions p id=Par4 Critically ill patients with sepsis exhibit a gradual decline in muscle thickness of both the arm and thigh. Decline in muscle thickness was associated with in-hospital mortality. USG has a potential to identify patients at risk of worse in-hospital and post-discharge outcomes.
AD  - All India Inst Med Sci, Dept Pulm Med & Sleep Disorders, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - BMC
PI  - LONDON
PA  - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - DEC 12
PY  - 2018
VL  - 6
C7  - 81
DO  - 10.1186/s40560-018-0350-4
AN  - WOS:000453036800001
ER  -

TY  - JOUR
AU  - Sheth, J
AU  - Mistri, M
AU  - Bhavsar, R
AU  - Pancholi, D
AU  - Kamate, M
AU  - Gupta, N
AU  - Kabra, M
AU  - Mehta, S
AU  - Nampoothiri, S
AU  - Thakker, A
AU  - Jain, V
AU  - Shah, R
AU  - Sheth, F
TI  - Batten disease: biochemical and molecular characterization revealing novel <i>PPT1</i> and <i>TPP1</i> gene mutations in Indian patients
T2  - BMC NEUROLOGY
KW  - PPT1
KW  - TPP1
KW  - Batten disease
KW  - Neuronal ceroid lipofuscinoses (NCL)
KW  - NEURONAL CEROID-LIPOFUSCINOSIS
KW  - CLN2
KW  - DEFICIENCY
KW  - DIAGNOSIS
KW  - ENZYME
KW  - LINCL
KW  - ASSAY
AB  - BackgroundNeuronal ceroid lipofuscinoses type I and type II (NCL1 and NCL2) also known as Batten disease are the commonly observed neurodegenerative lysosomal storage disorder caused by mutations in the PPT1 and TPP1 genes respectively. Till date, nearly 76 mutations in PPT1 and approximately 140 mutations, including large deletion/duplications, in TPP1 genes have been reported in the literature. The present study includes 34 unrelated Indian patients (12 females and 22 males) having epilepsy, visual impairment, cerebral atrophy, and cerebellar atrophy.MethodsThe biochemical investigation involved measuring the palmitoyl protein thioesterase 1 and tripeptidy peptidase l enzyme activity from the leukocytes. Based on the biochemical analysis all patients were screened for variations in either PPT1 gene or TPP1 gene using bidirectional Sanger sequencing. In cases where Sanger sequencing results was uninformative Multiplex Ligation-dependent Probe Amplification technique was employed. The online tools performed the protein homology modeling and orthologous conservation of the novel variants.ResultsOut of 34 patients analyzed, the biochemical assay confirmed 12 patients with NCL1 and 22 patients with NCL2. Molecular analysis of PPT1 gene in NCL1 patients revealed three known mutations (p.Val181Met, p.Asn110Ser, and p.Trp186Ter) and four novel variants (p.Glu178Asnfs*13, p.Pro238Leu, p.Cys45Arg, and p.Val236Gly). In the case of NCL2 patients, the TPP1 gene analysis identified seven known mutations and eight novel variants. Overall these 15 variants comprised seven missense variants (p.Met345Leu, p.Arg339Trp, p.Arg339Gln, p.Arg206Cys, p.Asn286Ser, p.Arg152Ser, p.Tyr459Ser), four frameshift variants (p.Ser62Argfs*19, p.Ser153Profs*19, p.Phe230Serfs*28, p.Ile484Aspfs*7), three nonsense variants (p.Phe516*, p.Arg208*, p.Tyr157*) and one intronic variant (g.2023_2024insT). No large deletion/duplication was identifiedin three NCL1 patients where Sanger sequencing study was normal.ConclusionThe given study reports 34 patients with Batten disease. In addition, the study contributes four novel variants to the spectrum of PPT1 gene mutations and eight novel variants to the TPP1 gene mutation data. The novel pathogenic variant p.Pro238Leu occurred most commonly in the NCL1 cohort while the occurrence of a known pathogenic mutation p.Arg206Cys dominated in the NCL2 cohort. This study provides an insight into the molecular pathology of NCL1 and NCL2 disease for Indian origin patients.
AD  - FRIGEs Inst Human Genet, FRIGE House,Jodhpur Gam Rd, Ahmadabad 380015, Gujarat, IndiaAD  - KLES Prabhakar Kore Hosp, Dept Pediat Neurol, Belgaum 590010, Karnataka, IndiaAD  - All India Inst Med Sci, Div Genet Pediat, New Delhi 110029, IndiaAD  - Usha Deep Children Neurol & Epilepsy Clin, Ahmadabad 380014, Gujarat, IndiaAD  - Amrita Inst Med Sci & Res Ctr, Dept Pediat Genet, Kochi 682041, Kerala, IndiaAD  - Sion Hosp, Dept Neurol, Lokmanya Tilak Med Coll, Bombay 400022, Maharashtra, IndiaAD  - Santokba Durlabhji Hosp, Dept Neurol, Jaipur 302015, Rajasthan, IndiaAD  - Ankur Neonatal Nursery, Ahmadabad 380009, Gujarat, IndiaC3  - K.L.E. Academy of Higher Education & ResearchC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Amrita Vishwa VidyapeethamC3  - Amrita Vishwa Vidyapeetham KochiPU  - BMC
PI  - LONDON
PA  - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - DEC 12
PY  - 2018
VL  - 18
C7  - 203
DO  - 10.1186/s12883-018-1206-1
AN  - WOS:000452973800001
ER  -

TY  - JOUR
AU  - Singh, D
AU  - Pandey, PM
AU  - Kalyanasundaram, D
TI  - Optimization of pressure-less microwave sintering of Ti6Al4V by response surface methodology
T2  - MATERIALS AND MANUFACTURING PROCESSES
KW  - Microwave
KW  - sintering
KW  - Ti6Al4V
KW  - strength
KW  - density
KW  - shrinkage
KW  - RSM
KW  - DOE
KW  - TITANIUM-ALLOYS
KW  - MECHANICAL-PROPERTIES
AB  - Pressure-less microwave sintering of titanium alloy (Ti6Al4V) is an economical and viable solution for obtaining near net shape fabrication of complex shapes. Input process parameters such as sintering temperature (St), heating rate (Hr), and holding (Ht) were optimized in this work for maximal compressive yield strength, maximal density, and minimal volumetric shrinkage by response surface methodology (RSM). The individual and interactive influence/effects of the process parameters on each of the responses were studied. A statistical model was developed to predict each of the output responses. Analysis by X-ray diffractometry indicates the presence of alpha and beta phase Ti6Al4V. The optimal sintering parameters identified were: St of 1280 degrees C, Hr of 8 degrees C/minute, and Ht of 78 minutes. At the optimized parameters, a compressive yield strength of 541.34 +/- 48.81 MPa, density of 4022.59 +/- 87.38 kg/m(3), and volumetric shrinkage of 16.86 +/- 5% were obtained. The results of this study will help rapidly manufacture higher-strength titanium customized components using pressure-less microwave sintering method.
AD  - Indian Inst Technol Delhi, Ctr Biomed Engn, New Delhi, IndiaAD  - Indian Inst Technol Delhi, Dept Mech Engn, New Delhi, IndiaAD  - All India Inst Med Sci, Biomed Engn, New Delhi, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - TAYLOR & FRANCIS INC
PI  - PHILADELPHIA
PA  - 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
DA  - DEC 10
PY  - 2018
VL  - 33
IS  - 16
SP  - 1835
EP  - 1844
DO  - 10.1080/10426914.2018.1476765
AN  - WOS:000449300100013
ER  -

TY  - JOUR
AU  - Kalra, P
AU  - Mishra, SK
AU  - Kaur, S
AU  - Kumar, A
AU  - Prasad, HK
AU  - Sharma, TK
AU  - Tyagi, JS
TI  - G-Quadruplex-Forming DNA Aptamers Inhibit the DNA-Binding Function of HupB and <i>Mycobacterium tuberculosis</i> Entry into Host Cells
T2  - MOLECULAR THERAPY-NUCLEIC ACIDS
KW  - LAMININ-BINDING
KW  - CIRCULAR-DICHROISM
KW  - SSDNA APTAMERS
KW  - PROTEIN
KW  - RECEPTOR
KW  - GROWTH
KW  - RECOGNITION
KW  - ADHESIN
KW  - ANTIGEN
KW  - DESIGN
AB  - The entry and survival of Mycobacterium tuberculosis (Mtb) within host cells is orchestrated partly by an essential histone- like protein HupB (Rv2986c). Despite being an essential drug target, the lack of structural information has impeded the development of inhibitors targeting the indispensable and multifunctional C-terminal domain (CTD) of HupB. To bypass the requirement for structural information in the classical drug discovery route, we generated a panel of DNA aptamers against HupB protein through systemic evolution of ligands by exponential (SELEX) enrichment. Two G-quadruplex-forming high-affinity aptamers (HupB-4T and HupB-13T) were identified, each of which bound two distinct sites on full-length HupB, with an estimated K-D of similar to 1.72 mu M and similar to 0.17 mu M, respectively, for the high-affinity sites. While HupB-4T robustly inhibited DNA-binding activity of HupB in vitro, both the aptamers recognized surface-located HupB and significantly blocked Mtb entry into THP-1 monocytic cells (p < 0.0001). In summary, DNA aptamers generated in this study block DNA-binding activity of HupB, inhibit virulent Mtb infection in host cells, and demonstrate aptamers to be inhibitors of HupB functions. This study also illustrates the utility of SELEX in developing inhibitors against essential targets for whom structural information is not available.
AD  - All India Inst Med Sci, Dept Biotechnol, New Delhi, IndiaAD  - Indian Inst Technol Indore, Discipline Biosci & Biomed Engn, Simrol 453552, Madhya Pradesh, IndiaAD  - Translat Hlth Sci & Technol Inst, Ctr Biodesign & Diagnost, Faridabad 121001, Haryana, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - IndoreC3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)PU  - CELL PRESS
PI  - CAMBRIDGE
PA  - 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
DA  - DEC 7
PY  - 2018
VL  - 13
SP  - 99
EP  - 109
DO  - 10.1016/j.omtn.2018.08.011
AN  - WOS:000452325300009
ER  -

TY  - JOUR
AU  - Singh, CA
AU  - Sakthivel, P
TI  - Laryngocele
T2  - NEW ENGLAND JOURNAL OF MEDICINE
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MASSACHUSETTS MEDICAL SOC
PI  - WALTHAM
PA  - WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
DA  - DEC 6
PY  - 2018
VL  - 379
IS  - 23
SP  - E40
EP  - E40
DO  - 10.1056/NEJMicm1807310
AN  - WOS:000452259200012
ER  -

TY  - JOUR
AU  - Singh, RD
AU  - Shandilya, R
AU  - Bhargava, A
AU  - Kumar, R
AU  - Tiwari, R
AU  - Chaudhury, K
AU  - Srivastava, RK
AU  - Goryacheva, IY
AU  - Mishra, PK
TI  - Quantum Dot Based Nano-Biosensors for Detection of Circulating Cell Free miRNAs in Lung Carcinogenesis: From Biology to Clinical Translation
T2  - FRONTIERS IN GENETICS
KW  - lung cancer
KW  - circulating nucleic acids
KW  - environmental health
KW  - translational medicine
KW  - nanobiosensor
KW  - circulating miRNAs
KW  - quantum dots
KW  - translational research
KW  - RESONANCE ENERGY-TRANSFER
KW  - EXOSOME-MEDIATED TRANSFER
KW  - PREOPERATIVE CYFRA 21-1
KW  - NEURON-SPECIFIC ENOLASE
KW  - BREAST-CANCER CELLS
KW  - CARCINOEMBRYONIC ANTIGEN
KW  - MESENCHYMAL TRANSITION
KW  - MIR-200 FAMILY
KW  - TISSUE FACTOR
KW  - METALLOPROTEINASE-1 TIMP-1
AB  - Lung cancer is the most frequently occurring malignancy and the leading cause of cancer-related death for men in our country. The only recommended screening method is clinic based low-dose computed tomography (also called a low-dose CT scan, or LDCT). However, the effect of LDCT on overall mortality observed in lung cancer patients is not statistically significant. Over-diagnosis, excessive cost, risks associated with radiation exposure, false positive results and delay in the commencement of the treatment procedure questions the use of LDCT as a reliable technique for population-based screening. Therefore, identification of minimal-invasive biomarkers able to detect malignancies at an early stage might be useful to reduce the disease burden. Circulating nucleic acids are emerging as important source of information for several chronic pathologies including lung cancer. Of these, circulating cell free miRNAs are reported to be closely associated with the clinical outcome of lung cancer patients. Smaller size, sequence homology between species, low concentration and stability are some of the major challenges involved in characterization and specific detection of miRNAs. To circumvent these problems, synthesis of a quantum dot based nano-biosensor might assist in sensitive, specific and cost-effective detection of differentially regulated miRNAs. The wide excitation and narrow emission spectra of these nanoparticles result in excellent fluorescent quantum yields with a broader color spectrum which make them ideal bio-entities for fluorescence resonance energy transfer (FRET) based detection for sequential or simultaneous study of multiple targets. In addition, photo-resistance and higher stability of these nanoparticles allows extensive exposure and offer state-of-the art sensitivity for miRNA targeting. A major obstacle for integrating QDs into clinical application is the QD-associated toxicity. However, the use of non-toxic shells along with surface modification not only overcomes the toxicity issues, but also increases the ability of QDs to quickly detect circulating cell free miRNAs in a non-invasive mode. The present review illustrates the importance of circulating miRNAs in lung cancer diagnosis and highlights the translational prospects of developing QD-based nano-biosensor for rapid early disease detection.
AD  - ICMR Natl Inst Res Environm Hlth, Dept Mol Biol, Bhopal, IndiaAD  - Indian Inst Technol, Sch Med Sci & Technol, Kharagpur, W Bengal, IndiaAD  - All India Inst Med Sci, Dept Biotechnol, New Delhi, IndiaAD  - Saratov NG Chernyshevskii State Univ, Dept Gen & Inorgan Chem, Saratov, RussiaC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute for Research in Environmental Health (NIREH)C3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - KharagpurC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Saratov State UniversityPU  - FRONTIERS MEDIA SA
PI  - LAUSANNE
PA  - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
DA  - DEC 6
PY  - 2018
VL  - 9
C7  - 616
DO  - 10.3389/fgene.2018.00616
AN  - WOS:000452294100001
ER  -

TY  - JOUR
AU  - Agarwal, M
AU  - Asokan, K
AU  - Garg, SK
AU  - Dhamija, E
AU  - Kumar, P
TI  - Synthesis of OSL nanophosphor Li<sub>3</sub>B<sub>7</sub>O<sub>12</sub>:Mn and its dosimetric properties
T2  - JOURNAL OF RADIOLOGICAL PROTECTION
KW  - proton irradiation
KW  - gamma irradiation
KW  - XRD
KW  - TEM
KW  - optically stimulated luminescence (OSL)
KW  - thermoluminescence (TL) technique
KW  - Li3B7O12:Mn
KW  - OPTICALLY STIMULATED LUMINESCENCE
KW  - THERMOLUMINESCENCE
KW  - SUPERCAPACITORS
KW  - BEAM
AB  - The present paper reports the structural, morphological and optical properties of nanophosphor Li3B7O12:Mn with an optimised dopant concentration of 0.25 mol% and its surface modification under the irradiation of 250 keV proton beams and gamma photons for ion fluence ranging from 1 x 10(13) to 6.25 x 10(15) ions cm(-2) and doses from 100 mGy-100 Gy, respectively. This nanophosphor has been synthesised by the high temperature solid state reaction method. Its optical properties are characterised by optically stimulated luminescence (OSL) and thermo luminescence (TL) techniques. This nanophosphor is polycrystalline in nature with a grain size of 40-80 nm confirmed by x-ray diffraction (XRD) and transmission electron microscopy (TEM). The OSL decay and TL glow curve response of the proton beam irradiated samples exhibit significant intensity at a fluence of 2.5 x 10(14) ions cm(-2). Moreover, Li3B7O12:Mn displays a linear response for gamma doses in the range of 100 mGy-50 Gy. We have also investigated the reusability and reproducibility of this material. The above study demonstrates that Li3B7O12:Mn is a robust and promising candidate for medical proton dosimetry.
AD  - AIIMS, Med Phys Unit, IRCH, New Delhi 110029, IndiaAD  - AIIMS, Dept Radiol, IRCH, New Delhi 110029, IndiaAD  - Interuniv Accelerator Ctr, Aruna Asaf Ali Marg, New Delhi 110067, IndiaAD  - Patna Univ, Univ Dept Phys, Patna 800005, Bihar, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - Inter-University Accelerator CentreC3  - Patna UniversityPU  - IOP PUBLISHING LTD
PI  - BRISTOL
PA  - TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
DA  - DEC
PY  - 2018
VL  - 38
IS  - 4
SP  - 1311
EP  - 1320
DO  - 10.1088/1361-6498/aae002
AN  - WOS:000447046900001
ER  -

TY  - JOUR
AU  - Agha, RA
AU  - Borrelli, MR
AU  - Farwana, R
AU  - Koshy, K
AU  - Fowler, AJ
AU  - Orgill, DP
AU  - Zhu, HY
AU  - Alsawadi, A
AU  - Noureldin, A
AU  - Rao, A
AU  - Enam, A
AU  - Thoma, A
AU  - Bashashati, M
AU  - Vasudevan, B
AU  - Beamish, A
AU  - Challacombe, B
AU  - De Wilde, RL
AU  - Machado-Aranda, D
AU  - Laskin, D
AU  - Muzumdar, D
AU  - D'cruz, A
AU  - Manning, T
AU  - Healy, D
AU  - Pagano, D
AU  - Goel, P
AU  - Ranganathan, P
AU  - Pai, PS
AU  - Raja, S
AU  - Athe, MH
AU  - Kadioäzlu, H
AU  - Nixon, I
AU  - Mukherjee, I
AU  - Riva, JG
AU  - Raveendran, K
AU  - Derbyshire, L
AU  - Valmasoni, M
AU  - Chalkoo, M
AU  - Raison, N
AU  - Muensterer, O
AU  - Bradley, P
AU  - Roberto, C
AU  - Afifi, R
AU  - Rosin, D
AU  - Klappenbach, R
AU  - Wynn, R
AU  - Giordano, S
AU  - Basu, S
AU  - Surani, S
AU  - Suman, P
AU  - Thorat, M
AU  - Kasi, V
A1  - SCARE Grp
TI  - The SCARE 2018 statement: Updating consensus Surgical CAse REport (SCARE) guidelines
T2  - INTERNATIONAL JOURNAL OF SURGERY
AB  - Introduction: The SCARE Guidelines were published in 2016 to provide a structure for reporting surgical case reports. Since their publication, SCARE guidelines have been widely endorsed by authors, journal editors, and reviewers, and have helped to improve reporting transparency of case reports across a range of surgical specialties. In order to encourage further progress in reporting quality, the SCARE guidelines must themselves be kept up to date. We completed a Delphi consensus exercise to update the SCARE guidelines.
   Methods: A Delphi consensus exercise was undertaken. All members of the previous Delphi group were invited to participate, in addition to researchers who have previously studied case reports, and editors from the International Journal of Surgery Case Reports. The expert group was sent an online questionnaire where they were asked to rate their agreement with proposed changes to each of the 24 items.
   Results: 56 people agreed to participate and 45 (80%) invitees completed the survey which put forward modifications to the original guideline. The collated responses resulted in modifications. There was high agreement amongst the expert group.
   Conclusion: A modified and improved SCARE checklist is presented, after a Delphi consensus exercise was completed.
AD  - Chelsea & Westminster Hosp NHS Fdn Trust, London, EnglandAD  - Stanford Univ, Sch Med, Hagey Lab Pediat Regenerat Med, Dept Surg,Div Plast Surg, Stanford, CA 94305 USAAD  - Univ Birmingham, Med Sch, Birmingham, W Midlands, EnglandAD  - Newcastle Tyne Hosp NHS Fdn Trust, Dept Plast Surg, Royal Victoria Infirm, Newcastle Upon Tyne, Tyne & Wear, EnglandAD  - Royal London Hosp, Crit Care & Perioperat Med Res Grp, London, EnglandAD  - Brigham & Womens Hosp, Div Plast Surg, Boston, MA 02115 USAAD  - Harvard Med Sch, Boston, MA 02115 USAAD  - Univ Arizona, Tucson, AZ 85721 USAAD  - Colchester Hosp Univ NHS Fdn Trust, Colchester, Essex, EnglandAD  - Cumberland Royal Infirm, Carlisle, EnglandAD  - Saad Specialist Hosp, Khobar, Saudi ArabiaAD  - Aga Khan Univ, Karachi, PakistanAD  - McMaster Univ, Hamilton, ON, CanadaAD  - Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79409 USAAD  - MIOT Hosp, Madras, Tamil Nadu, IndiaAD  - Univ Gothenburg, Gothenburg, SwedenAD  - Guys Hosp, London, EnglandAD  - Pius Hosp Oldenburg, Oldenburg, GermanyAD  - Univ Michigan, Ann Arbor, MI 48109 USAAD  - Virginia Commonwealth Univ, Richmond, VA 23284 USAAD  - King Edward Mem Hosp, Bombay, Maharashtra, IndiaAD  - Tata Mem Hosp, Bombay, Maharashtra, IndiaAD  - Austin Hlth, Pune, Maharashtra, IndiaAD  - Univ Hosp Waterford, Waterford, IrelandAD  - ISMETT UPMC, Palermo, ItalyAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Tata Mem Hosp, Bombay, Maharashtra, IndiaAD  - Royal Brompton & Harefield NHS Fdn Trust, London, EnglandAD  - Bezmialem Vakif Univ, Istanbul, TurkeyAD  - East Kent Univ Hosp, Canterbury, Kent, EnglandAD  - Staten Isl Univ Hosp, Staten Isl, NY USAAD  - Hosp Univ La Paz, Madrid, SpainAD  - Fatimah Hosp, Ipoh, MalaysiaAD  - NW Deanery, Manchester, Lancs, EnglandAD  - Univ Padua, Padua, ItalyAD  - Kings Coll London, London, EnglandAD  - Univ Med Mainz, Mainz, GermanyAD  - Nottingham Univ Hosp, Nottingham, EnglandAD  - Campus Biomed Univ, Sch Med, Rome, ItalyAD  - Cairo Univ, Cairo, EgyptAD  - Univ West Indies, Kingston, JamaicaAD  - Simplemente Evita Hosp, Gonzalez Catan, Buenos Aires, ArgentinaAD  - Univ Tromso, Tromso, NorwayAD  - Turku Univ Hosp, Turku, FinlandAD  - Banarus Hindu Univ, Varanasi, Uttar Pradesh, IndiaAD  - Texas A&M Univ, College Stn, TX 77843 USAAD  - Queen Mary Univ London, Wolfson Inst Prevent Med, London, EnglandAD  - UCL, London, EnglandC3  - Imperial College LondonC3  - Stanford UniversityC3  - University of BirminghamC3  - Newcastle University - UKC3  - Newcastle Upon Tyne Hospitals NHS Foundation TrustC3  - Barts Health NHS TrustC3  - Royal London HospitalC3  - Harvard UniversityC3  - Brigham & Women's HospitalC3  - Harvard UniversityC3  - Harvard Medical SchoolC3  - University of ArizonaC3  - Saad Specialist HospitalC3  - Aga Khan UniversityC3  - McMaster UniversityC3  - Texas Tech University SystemC3  - Texas Tech University Health Science CenterC3  - University of GothenburgC3  - Guy's & St Thomas' NHS Foundation TrustC3  - Pius-Hospital OldenburgC3  - University of Michigan SystemC3  - University of MichiganC3  - Virginia Commonwealth UniversityC3  - Seth Gordhandas Sunderdas Medical College & King Edward Memorial HospitalC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalC3  - IRCCS Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalC3  - Royal Brompton & Harefield NHS Foundation TrustC3  - Bezmialem Vakif UniversityC3  - Northwell HealthC3  - Hospital Universitario La PazC3  - University of PaduaC3  - University of LondonC3  - King's College LondonC3  - Johannes Gutenberg University of MainzC3  - Nottingham University Hospital NHS TrustC3  - University of NottinghamC3  - University Campus Bio-Medico - Rome ItalyC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - University West Indies Mona JamaicaC3  - UiT The Arctic University of TromsoC3  - University of TurkuC3  - Banaras Hindu University (BHU)C3  - Texas A&M University SystemC3  - Texas A&M University College StationC3  - University of LondonC3  - Queen Mary University LondonC3  - University of LondonC3  - University College LondonPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - DEC
PY  - 2018
VL  - 60
SP  - 132
EP  - 136
DO  - 10.1016/j.ijsu.2018.10.028
AN  - WOS:000453422900016
ER  -

TY  - JOUR
AU  - Agrawal, M
AU  - Devarajan, LJ
AU  - Singh, PK
AU  - Garg, A
AU  - Kale, SS
TI  - Proposal of a New Safety Margin for Placement of C2 Pedicle Screws on Computed Tomography Angiography
T2  - WORLD NEUROSURGERY
KW  - C2 pedicle
KW  - Occupation ratio
KW  - Safety margin
KW  - Vertebral artery
KW  - VERTEBRAL ARTERY INJURY
KW  - CERVICAL PEDICLE
KW  - MORPHOMETRIC-ANALYSIS
KW  - ANATOMICAL VARIATIONS
KW  - TRANSVERSE FORAMEN
KW  - FIXATION
KW  - RISK
KW  - FEASIBILITY
KW  - POPULATION
KW  - DIAMETER
AB  - BACKGROUND: Screw diameters currently available are based on the literature available. No data are available for the safety margin available for C2 pedicle screw placement. The objective of this study was to define the average pedicle size available for placing C2 pedicle screws and to quantify the safety margin available in case of lateral breach of screw.
   METHODS: Computed tomography angiograms of 259 patients (161 men, 98 women) were analyzed to calculate the C2 pedicle width, the area of the transverse foramen (TF) and the vertebral artery (VA), and the occupation ratio (OR) of the VA within the TF. The VA was classified into groups based on its lie within the TF (anteromedial, anterolateral, posteromedial, posterolateral, central, ectatic). The distance which the pedicle screw can breach without encountering the VA was calculated (lateral pedicle to vertebral artery distance [LPVA]). The diameters of the VA and the TF were estimated, and their difference gives the safety margin in case of breach of the lateral cortex of the C2 pedicle.
   RESULTS: The mean mediolateral diameter of the pedicle isthmus, perpendicular to the pedicle axis, in women was 5.3 mm and in men it was 5.8 mm. This difference was statistically significant. In 53.9% (122/226) of patients, the VA was dominant on the left side. The overall mean OR at the C2 vertebral level was found to be 37.3%. The mean LPVA was 0.9 mm, and the average overall safety margin available was 2.5 mm (range, 0.4-5.3 mm).
   CONCLUSIONS: his study describes the relationship of the VA in the C2 TF and the relative risk during pedicle screw fixation.
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neuroradiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - DEC
PY  - 2018
VL  - 120
SP  - E282
EP  - E289
DO  - 10.1016/j.wneu.2018.08.052
AN  - WOS:000450668300036
ER  -

TY  - JOUR
AU  - Bagul, PK
AU  - Katare, PB
AU  - Bugga, P
AU  - Dinda, AK
AU  - Banerjee, SK
TI  - SIRT-3 Modulation by Resveratrol Improves Mitochondrial Oxidative Phosphorylation in Diabetic Heart through Deacetylation of TFAM
T2  - CELLS
KW  - diabetic cardiomyopathy
KW  - transcription factor A
KW  - mitochondria
KW  - acetylation
KW  - INSULIN-RESISTANCE
KW  - CARDIAC-FUNCTION
KW  - STRESS
KW  - COMPLICATIONS
KW  - HYPERGLYCEMIA
KW  - ACTIVATION
KW  - EXPRESSION
KW  - SIRTUINS
KW  - COMPLEX
AB  - Background and Purpose: Mitochondrial dysfunction remains the crucial cause for many heart diseases including diabetic cardiomyopathy (DCM). Sirtuin-3 (SIRT-3) is a protein deacetylase localized in the mitochondria and regulates mitochondrial function. Being a noteworthy mitochondrial protein deacetylase enzyme, the role of SIRT-3 in DCM is yet to be explored. Experimental Approach: Diabetes mellitus (Type-I, T1DM) was induced using streptozotocin (STZ, 50 mg/kg) in male Sprague Dawley (SD) rats. Rats with >200 mg/dL blood glucose levels were then divided randomly into two groups, DIA and DIA + RESV, where vehicle and resveratrol (25 mg/kg/day) were administered orally in both groups, respectively. Cardiac oxidative stress, fibrosis, and mitochondrial parameters were evaluated. H9c2 cells were transfected with SIRT-3 siRNA and shRNA, and ORF plasmid for silencing and overexpression, respectively. Key Results: After eight weeks, diabetic rat heart showed reduced cardiac cell size, increased oxidative stress and reduction of the activities of enzymes involved in mitochondrial oxidative phosphorylation (OXPHOS). There was reduced expression and activity of SIRT-3 and mitochondrial transcription factor (TFAM) in diabetic heart. Reduced SIRT-3 expression is also correlated with increased acetylation, decreased mitochondrial DNA (mtDNA) binding activity of TFAM, and reduced transcription of mitochondrial DNA encoded genes. Administration of resveratrol prevented the decrease in SIRT-3 and TFAM activity, which was corresponding to the reduced acetylation status of TFAM. Silencing SIRT-3 using siRNA in H9C2 cells showed increased acetylation of TFAM. Conclusion and Implications: Together our data shows that resveratrol activates SIRT-3, regulates the acetylation status of TFAM and preserves the mitochondrial function along with cellular size in diabetic rat heart.
AD  - THSTI, DDRC, Faridabad 121001, IndiaAD  - AIIMS, Dept Pathol, New Delhi 110029, IndiaAD  - Indian Inst Chem Technol, CSIR, Dept Med Chem & Pharmacol, Hyderabad 500007, Andhra Pradesh, IndiaC3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Indian Institute of Chemical Technology (IICT)PU  - MDPI
PI  - BASEL
PA  - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
DA  - DEC
PY  - 2018
VL  - 7
IS  - 12
C7  - 235
DO  - 10.3390/cells7120235
AN  - WOS:000455320700013
ER  -

TY  - JOUR
AU  - Bhargava, A
AU  - Srivastava, RK
AU  - Mishra, DK
AU  - Tiwari, RR
AU  - Sharma, RS
AU  - Mishra, PK
TI  - Dendritic cell engineering for selective targeting of female reproductive tract cancers
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
KW  - Cancer therapy
KW  - dendritic cells
KW  - nanomedicine
KW  - translational oncology
KW  - SOLID LIPID NANOPARTICLES
KW  - GASTROINTESTINAL TUMOR-IMMUNOTHERAPY
KW  - OVARIAN-CANCER
KW  - IN-VIVO
KW  - CERVICAL-CANCER
KW  - CONTAINING LIPOSOMES
KW  - IMMUNE-RESPONSE
KW  - DC-SIGN
KW  - ANTIGEN
KW  - DELIVERY
AB  - Female reproductive tract cancers (FRCs) are considered as one of the most frequently occurring malignancies and a foremost cause of death among women. The late-stage diagnosis and limited clinical effectiveness of currently available mainstay therapies, primarily due to the developed drug resistance properties of tumour cells, further increase disease severity. In the past decade, dendritic cell (DC)-based immunotherapy has shown remarkable success and appeared as a feasible therapeutic alternative to treat several malignancies, including FRCs. Importantly, the clinical efficacy of this therapy is shown to be restricted by the established immunosuppressive tumour microenvironment. However, combining nanoengineered approaches can significantly assist DCs to overcome this tumour-induced immune tolerance. The prolonged release of nanoencapsulated tumour antigens helps improve the ability of DC-based therapeutics to selectively target and remove residual tumour cells. Incorporation of surface ligands and co-adjuvants may further aid DC targeting (in vivo) to overcome the issues associated with the short DC lifespan, immunosuppression and imprecise uptake. We herein briefly discuss the necessity and progress of DC-based therapeutics in FRCs. The review also sheds lights on the future challenges to design and develop clinically effective nanoparticles-DC combinations that can induce efficient antitumour immune responses and prolong patients' survival.
AD  - ICMR Natl Inst Res Environm Hlth, Dept Mol Biol, Kamla Nehru Hosp Bldg,Gandhi Med Coll Campus, Bhopal 462001, Madhya Pradesh, IndiaAD  - All India Inst Med Sci, Dept Biotechnol, New Delhi, IndiaAD  - Indian Council Med Res, Div Reprod Biol Maternal & Child Hlth, New Delhi, IndiaAD  - Narsee Monjee Inst Management & Studies, Sch Pharm & Technol Management, Shirpur, IndiaC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute for Research in Environmental Health (NIREH)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Council of Medical Research (ICMR)C3  - SVKM's NMIMS (Deemed to be University)PU  - SCIENTIFIC SCHOLAR LLC
PI  - PITTSFORD
PA  - 50, WOODGREEN DR, PITTSFORD, NY 14534 USA
DA  - DEC
PY  - 2018
VL  - 148
SP  - 50
EP  - 63
DO  - 10.4103/ijmr.IJMR_224_18
AN  - WOS:000948175800006
ER  -

TY  - JOUR
AU  - Chandra, PS
AU  - Singh, P
TI  - Reply to the letter to editor regarding the article "Treatment of vertebral body hemangiomas with direct ethanol injection and short segment stabilization"
T2  - SPINE JOURNAL
KW  - INTRALESIONAL INJECTION
KW  - ALCOHOL
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - DEC
PY  - 2018
VL  - 18
IS  - 12
SP  - 2372
EP  - 2373
DO  - 10.1016/j.spinee.2018.07.011
AN  - WOS:000452738800023
ER  -

TY  - JOUR
AU  - Chandra, P
AU  - Bhoutekar, P
AU  - Azad, R
AU  - Agarwal, R
TI  - Large Spot Laser for Treatment of Retinopathy of Prematurity
T2  - OPHTHALMIC SURGERY LASERS & IMAGING RETINA
KW  - TRANSPUPILLARY THERMOTHERAPY
KW  - PAIN
AB  - BACKGROUND AND OBJECTIVE: To compare large spot versus standard spot laser for treatment of retinopathy of prematurity (ROP).
   PATIENTS AND METHODS: Eighty eyes of 40 infants with bilateral type 1 ROP were randomized for laser photocoagulation using laser indirect ophthalmoscope with either standard spot or large spot size laser. During the procedure, total time taken and Premature infant Pain Profile (PIPP) scores were noted. Regression of disease and refractive error were noted on follow-up.
   RESULTS: The infants were randomized into two groups. All infants in both groups had regression of ROP. Large spot laser significantly reduced total treatment duration in zone I by 32% (P = .005) and zone II by 63.4% = .0006). Moderate-to-severe pain occurred in PIPP scores in both groups throughout the procedure (under topical anesthesia) and was comparable between the groups. Mean change in refractive error (myopia) from pre-laser (2.090 diopters [D] +/- 1.345 D) to 3 months' post-laser (2.465 D +/- 1.399 D) was not statistically significant between the groups.
   CONCLUSIONS: Large spot laser significantly reduced total duration of laser treatment in zone I/II ROP. Large spot laser is a useful alternative for treatment of ROP in terms of faster procedure, lesser total duration of pain, and similar regression profile. It does not cause additional myopia and can be performed without additional training.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Neonatol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SLACK INC
PI  - THOROFARE
PA  - 6900 GROVE RD, THOROFARE, NJ 08086 USA
DA  - DEC
PY  - 2018
VL  - 49
IS  - 12
SP  - E233
EP  - E239
DO  - 10.3928/23258160-20181203-13
AN  - WOS:000455925900002
ER  -

TY  - JOUR
AU  - Choudhary, V
AU  - Sinha, VK
TI  - Transdiagnostic applications of dialectical behaviour therapy's distress tolerance skills in psychological management of OCD
T2  - ASIAN JOURNAL OF PSYCHIATRY
KW  - DISORDERS
KW  - ACCEPTANCE
AD  - All India Inst Med Sci, New Delhi, IndiaAD  - Cent Inst Psychiat, Jharkhand, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Central Institute of PsychiatryPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - DEC
PY  - 2018
VL  - 38
SP  - 1
EP  - 2
DO  - 10.1016/j.ajp.2018.10.012
AN  - WOS:000452790400006
ER  -

TY  - JOUR
AU  - Christopher, R
AU  - Devi, ARR
AU  - Gupta, N
AU  - Kabra, M
AU  - Kapoor, S
AU  - Mathur, R
AU  - Muranjan, M
AU  - Nigam, PK
AU  - Pandey, RM
AU  - Singh, A
AU  - Suresh, S
A1  - ICMR Task Force Inherited
TI  - High Risk Stratified Neonatal Screening
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Inborn metabolic errors
KW  - Sick care newborn units
KW  - High risk screening
KW  - India
KW  - CHILDREN EXPERIENCE
AB  - ObjectivesTo ascertain the proportion of neonates and infants presenting with suspicion of an inborn error of metabolism in the centers identified by ICMR for newborn screening.MethodsA set of red flag signs suggestive IEM were listed by the Taskforce members. The age group was limited to one year as it was understood that most of the small molecules with a severe phenotype would present before the age of one year. Further investigations were tandem mass spectrometry, gas chromatography mass spectrometry and high performance liquid chromatography.ResultsA total of 851 babies with an index of suspicion were investigated using a combination of these modalities. The yield from this sample was 31.7%, better than reported in literature owing to a more specific inclusion criteria. Methylmalonic acidemia followed by Propionic acidemia were the most common organic acidemias, while maple syrup urine disease and classic citrullinemia were the common aminoacidopathies.ConclusionsIf all the sick care neonatal unit patients would undergo high risk stratified screening, the likely benefit of the high end technologies currently available in India would become apparent. Though this is not the opportune moment to start the expanded screening program in the country, none of the neonates admitted for any of these errors should be bereft of the diagnosis. This has implications not only for the index case but for its impact on the family's reproductive decisions. The Task Force consitituted by the Indian Council of Medical Research definitely feels that the high risk expanded screening program should be implemented for the sick newborns getting admitted in the Neonatal Intensive Care Units or the Sick Care Newborn Units.
AD  - NIMHANS, Bangalore, Karnataka, IndiaAD  - Rainbow Children Hosp, Rd 3,Banjara Hills, Hyderabad, Telangana, IndiaAD  - Sandor Life Sci, Rd 3,Banjara Hills, Hyderabad, Telangana, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Maulana Azad Med Coll, New Delhi 110002, IndiaAD  - Indian Council Med Res, New Delhi, IndiaAD  - King Edward Mem Hosp, Bombay, Maharashtra, IndiaAD  - Vimta Labs, Hyderabad, Telangana, IndiaAD  - IPGMER, Kolkata, IndiaAD  - MEDISCAN, Madras, Tamil Nadu, IndiaC3  - National Institute of Mental Health & Neurosciences - IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Maulana Azad Medical CollegeC3  - Indian Council of Medical Research (ICMR)C3  - Seth Gordhandas Sunderdas Medical College & King Edward Memorial HospitalC3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - DEC
PY  - 2018
VL  - 85
IS  - 12
SP  - 1050
EP  - 1054
DO  - 10.1007/s12098-017-2545-4
AN  - WOS:000452597200003
ER  -

TY  - JOUR
AU  - Dada, T
AU  - Mittal, D
AU  - Mohanty, K
AU  - Faiq, MA
AU  - Bhat, MA
AU  - Yadav, RK
AU  - Sihota, R
AU  - Sidhu, T
AU  - Velpandian, T
AU  - Kalaivani, M
AU  - Pandey, RM
AU  - Gao, Y
AU  - Sabel, BA
AU  - Dada, R
TI  - Mindfulness Meditation Reduces Intraocular Pressure, Lowers Stress Biomarkers and Modulates Gene Expression in Glaucoma: A Randomized Controlled Trial
T2  - JOURNAL OF GLAUCOMA
KW  - apoptosis
KW  - genome-wide expression
KW  - glaucoma
KW  - inflammation
KW  - intraocular pressure
KW  - meditation
KW  - optic nerve head
KW  - oxidative stress
KW  - quality of life
KW  - relaxation
KW  - stress
KW  - vascular dysregulation
KW  - QUALITY-OF-LIFE
KW  - OXIDATIVE STRESS
KW  - DEPRESSION
KW  - PATHWAY
KW  - ANXIETY
KW  - TARGET
KW  - BRAIN
KW  - IOP
AB  - Background: Reducing intraocular pressure (IOP) in primary open-angle glaucoma (POAG) is currently the only approach to prevent further optic nerve head damage. However, other mechanisms such as ischemia, oxidative stress, glutamate excitotoxicity, neurotrophin loss, inflammation/glial activation, and vascular dysregulation are not addressed. Because stress is a key risk factor affecting these mechanisms, we evaluated whether mindfulness-based stress reduction can lower IOP and normalize typical stress biomarkers.
   Materials and Methods: In a prospective, randomized trial 90 POAG patients (180 eyes; age above 45 y) were assigned to a waitlist control or mindfulness meditation group which practiced daily for 21 days. We measured IOP (primary endpoint), quality of life (QOL), stress-related serum biomarkers [cortisol, ss-endorphins, IL6, TNF-alpha, brain-derived neurotrophic factor (BDNF), reactive oxygen species (ROS), total antioxidant capacity (TAC)], and whole genome expression.
   Results: Between-group comparisons revealed significantly lowered IOP in meditators (OD: 18.8 to 12.7, OS 19.0 to 13.1 mm Hg) which correlated with significantly lowered stress-biomarker levels including cortisol (497.3 to 392.3 ng/mL), IL6 (2.8 to 1.5 ng/mL), TNF-alpha (57.1 to 45.4 pg/mL), ROS (1625 to 987 RLU/min/104 neutrophils), and elevated ss-endorphins (38.4 to 52.7 pg/mL), BDNF (56.1 to 83.9 ng/mL), and TAC (5.9 to 9.3) (all P<0.001). These changes correlated well with gene expression profiling. Meditators improved in QOL (P < 0.05).
   Conclusions: A short course of mindfulness-based stress reduction by meditation in POAG, reduces IOP, improves QOL, normalizes stress biomarkers, and positively modifies gene expression. Mindfulness meditation can be recommended as adjunctive therapy for POAG.
AD  - AIIMS, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaAD  - AIIMS, Dept Anat, Lab Mol Reprod & Genet, New Delhi, IndiaAD  - AIIMS, Dept Physiol, New Delhi, IndiaAD  - AIIMS, Dept Biostat, New Delhi, IndiaAD  - Ottovon Guericke Univ Magdeburg, Inst Med Psychol, Med Fac, Magdeburg, GermanyC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Otto von Guericke UniversityPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - DEC
PY  - 2018
VL  - 27
IS  - 12
SP  - 1061
EP  - 1067
DO  - 10.1097/IJG.0000000000001088
AN  - WOS:000453564300010
ER  -

TY  - JOUR
AU  - Dhawan, V
AU  - Kumar, M
AU  - Deka, D
AU  - Malhotra, N
AU  - Dadhwal, V
AU  - Singh, N
AU  - Dada, R
TI  - Meditation & yoga: Impact on oxidative DNA damage & dysregulated sperm transcripts in male partners of couples with recurrent pregnancy loss
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
KW  - Dysregulation
KW  - meditation
KW  - oxidative stress
KW  - sperm DNA damage
KW  - sperm transcript
KW  - yoga
AB  - Background & objectives: Recurrent pregnancy loss (RPL) is one of the devastating complications of pregnancy and current focus lies in addressing the management of paternal factors. Dysregulation in selective transcripts delivered to oocyte at fertilization can result in pregnancy losses and adversely affect embryogenesis. The objective of this study was to assess the effect of yoga-based lifestyle intervention (YBLI) on seminal oxidative stress (OS), DNA damage and spermatozoal transcript levels.
   Methods: The present study was a part of a prospective ongoing exploratory study and 30 male partners of couples with RPL were included from August 2016 to June 2017. Semen samples were obtained at baseline and at the end of YBLI (21 days). Gene expression analysis was performed by quantitative polymerase chain reaction on spermatozoal FOXG1, SOX3, OGG1, PARP1, RPS6, RBM9, RPS17 and RPL29. The levels of seminal OS and sperm DNA damage was assessed by measuring levels of reactive oxygen species (ROS) by chemiluminescence and DNA fragmentation index (DFI) by sperm chromatin structure assay.
   Results: SOX3, OGG1 and PARP1 were observed to be upregulated, while FOXG1, RPS6, RBM9, RPS17 and RPL29 showed downregulation. A significant reduction in ROS levels, an increase in sperm motility, sperm count (done twice) and a decrease in DFI was seen after YBLI.
   Interpretation & conclusions: Adopting YBLI may help in a significant decline in oxidative DNA damage and normalization of sperm transcript levels. This may not only improve pregnancy outcomes but also improve the health trajectory of the offspring.
AD  - All India Inst Med Sci, Dept Anat, Lab Mol Reprod & Genet, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Obstet & Gynaecol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
DA  - DEC
PY  - 2018
VL  - 148
SP  - 134
EP  - 139
DO  - 10.4103/ijmr.IJMR_1988_17
AN  - WOS:000948175800016
ER  -

TY  - JOUR
AU  - Dhiman, R
AU  - Gorimanipalli, B
AU  - Swamy, DR
AU  - Sharma, S
AU  - Garg, A
AU  - Saxena, R
TI  - Congenital Third Nerve Palsy Associated With Midbrain Hypoplasia Due to Bilateral Segmental Internal Carotid Artery Agenesis
T2  - JOURNAL OF NEURO-OPHTHALMOLOGY
AB  - A 15-year-old girl, diagnosed with a partial right third nerve palsy, was found to have bilateral internal carotid artery agenesis. Neuroimaging with 3D-constructive interference in steady state scanning identified the possible etiology of the third nerve palsy as midbrain hypoplasia.
AD  - All India Inst Med Sci, Strabismus & Neuroophthalmol Serv, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - DEC
PY  - 2018
VL  - 38
IS  - 4
SP  - 483
EP  - 485
DO  - 10.1097/WNO.0000000000000666
AN  - WOS:000451240600014
ER  -

TY  - JOUR
AU  - Galhotra, P
AU  - Prabhakar, P
AU  - Meghwani, H
AU  - Mohammed, SA
AU  - Banerjee, SK
AU  - Seth, S
AU  - Hote, MP
AU  - Reeta, KH
AU  - Ray, R
AU  - Maulik, SK
TI  - Beneficial effects of fenofibrate in pulmonary hypertension in rats
T2  - MOLECULAR AND CELLULAR BIOCHEMISTRY
KW  - Monocrotaline
KW  - PPAR alpha agonist
KW  - Inflammation
KW  - Oxidative stress
KW  - ACTIVATED RECEPTOR-ALPHA
KW  - RIGHT-VENTRICULAR HYPERTROPHY
KW  - ARTERIAL-HYPERTENSION
KW  - POTENTIAL ROLE
KW  - PPAR-ALPHA
KW  - NONINVASIVE ASSESSMENT
KW  - TERMINALIA-ARJUNA
KW  - ENZYME-ACTIVITY
KW  - NADPH OXIDASES
KW  - NITRIC-OXIDE
AB  - Pulmonary hypertension (PH) is a morbid complication of cardiopulmonary as well as several systemic diseases in humans. It is rapidly progressive and fatal if left untreated. In the present study, we investigated the effect of PPAR alpha agonist fenofibrate (FF) on monocrotaline (MCT)-induced PH in rats. FF, because of its pleiotropic property, could be helpful in reducing inflammation, oxidative stress, and reactive oxygen species. On day 1, MCT (50 mg/kg, s.c.) was given to all the rats in MCT, sildenafil, and FF group except normal control rats. After 3 days of giving MCT, sildenafil (175 mu g/kg, orally) and FF (120 mg/kg, orally) were given for 25 days. Echocardiography, hemodynamic parameters, fulton's index, histopathology, oxidative stress parameters, inflammatory markers, Bcl2/Bax gene expression ratio in the right ventricle, and protein expression for NOX-1 in lungs were studied in all the groups. FF has shown to prevent decrease in ratio of pulmonary artery acceleration time to ejection time, increase in ratio of right ventricular outflow tract dimension to aortic outflow dimension, rise in right ventricular systolic pressure, right ventricular hypertrophy, increase in the percentage medial wall thickness (%MWT), increase in oxidative stress and inflammation, increase in NADPH oxidase-1 (NOX-1) expression, and decrease in mRNA expression of Bcl2/Bax ratio caused by MCT. To conclude, FF prevented MCT-induced PH in rats by various mechanisms. It might be helpful in preventing PH in patients who are likely to develop PH.
AD  - All India Inst Med Sci, Dept Pharmacol, Room 4017, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Cardiol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Cardiothorac & Vasc Surg, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaAD  - Translat Hlth Sci & Technol Inst, Dept Drug Discovery Res Ctr DDRC, Faridabad 121001, Haryana, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)PU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - DEC
PY  - 2018
VL  - 449
IS  - 1-2
SP  - 185
EP  - 194
DO  - 10.1007/s11010-018-3355-3
AN  - WOS:000456475800018
ER  -

TY  - JOUR
AU  - Gautam, S
AU  - Chawla, B
AU  - Bisht, S
AU  - Tolahunase, M
AU  - Dada, R
TI  - Impact of mindfulness based stress reduction on sperm DNA damage
T2  - JOURNAL OF THE ANATOMICAL SOCIETY OF INDIA
KW  - Yoga
KW  - Oxidative stress
KW  - Sporadic childhood cancer
KW  - Telomere
KW  - Sperm DNA damage
KW  - YOGA
AB  - Introduction: Sperm DNAdamage is the major cause of defective sperm function. Poor social habits take a toll not only on reproductive health of parents but the resultant offspring too. Adopting a holistic integrated approach like mindfulness based stress reduction (MBSR), a yoga based intervention have gained significant impetus in recent years. This study aimed to analyze how mere a simple lifestyle change can bring about balance in seminal oxidative stress parameters and related consequences in next generations.
   Methods: Out of 126 fathers of children with non-familial sporadic heritable Retinoblastoma (NFSHRb), 102 were randomized into 2 groups i.e. MBSR group and Non-MBSR group. Parameters of seminal oxidative stress (OS) and oxidative DNA damage (ODD) were measured at baseline (0 day) and after 4 weeks in both groups.
   Results: There was significant decrease (p < 0.0001) in mean reactive oxygen species (ROS), DNA fragmentation index (DFI) and 8-hydroxy-2'-deoxyguanosine (80HdG), increase (p < 0.0001) in mean total antioxidant capacity (TAC) post 4 weeks of MBSR whereas non-intervention group showed opposite trends when compared with baseline.
   Discussion: A 4-week MBSR resulted in significant improvement in sperm DNA integrity and regulation of OS may affect the sperm epigenome, reduces de novo germline mutation rate and affects lifelong health trajectory of offspring. In the era of limited space, commercial expansion and increased incidence of complex lifestyle diseases, there is a dire need to adopt an integrated system of mind body interventions which aims to achieve physical, mental, spiritual wellbeing and improve quality of life. (C) 2018 Anatomical Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd. All rights reserved.
AD  - All India Inst Med Sci, Dept Anat, Lab Mol Reprod & Genet, New Delhi, IndiaAD  - All India Inst Med Sci, Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - DEC
PY  - 2018
VL  - 67
IS  - 2
SP  - 124
EP  - 129
DO  - 10.1016/j.jasi.2018.07.003
AN  - WOS:000452321500006
ER  -

TY  - JOUR
AU  - Ghosh-Jerath, S
AU  - Singh, A
AU  - Lyngdoh, T
AU  - Magsumbol, MS
AU  - Kamboj, P
AU  - Goldberg, G
TI  - Estimates of Indigenous Food Consumption and Their Contribution to Nutrient Intake in Oraon Tribal Women of Jharkhand, India
T2  - FOOD AND NUTRITION BULLETIN
KW  - Oraon
KW  - indigenous foods
KW  - food security
KW  - dietary diversity
KW  - NUTRITIONAL-STATUS
KW  - BIODIVERSITY
KW  - DIET
KW  - POPULATION
KW  - COMMUNITY
KW  - SECURITY
KW  - HEALTH
KW  - POLICY
AB  - Introduction: Oraon tribes of India have high levels of undernutrition. Dietary diversification is one of the food-based interventions to ameliorate malnutrition. Objectives: This study assessed the awareness and availability of indigenous foods and estimated dietary intakes and nutritional status with emphasis on indigenous food consumption among women in the Oraon tribal community in Jharkhand, India. Design: A cross-sectional study with a longitudinal component on dietary intake assessment to capture seasonality. Setting: Selected villages in Raidih block of Gumla district of Jharkhand. Participants: Reproductive-age Oraon tribal women (N =143). Methods: Household and dietary surveys were conducted. A 24-hour dietary recall for 2 consecutive days (repeat surveys in 2 other seasons) and food frequency questionnaire were adminsitered on 1 woman per household. Anthropometric assessments were also carried out. Outcomes: Socioeconomic status, awareness about indigenous foods, dietary intake pattern, and contribution of indigenous food to nutrient intake of Oraon tribal women in the reproductive age-group. Results: Comprehensive awareness about indigenous food resources was present. However, household food security and actual intake of indigenous foods were low. Higher intake of key micronutrients, calcium and iron, was observed among those who consumed indigenous foods. About 40% of the woman had various degrees of chronic energy deficiency. Conclusion: Despite rich knowledge, nutrient-rich indigenous food resources remain underutilized in the Oraon tribal community of Jharkhand, India. Identifying strategies to promote dietary diversity via optimum indigenous food intake could contribute to both food and nutrition security.
AD  - PHFI, IIPH Delhi, Plot 47,Sect 44, Gurgaon 122002, Haryana, IndiaAD  - All India Inst Med Sci, Delhi, IndiaAD  - Publ Hlth Fdn India, Delhi, IndiaAD  - Delhi Univ, Lady Irwin Coll, Delhi, IndiaAD  - MRC Human Nutr Res, Nutr & Bone Hlth Res Grp, Cambridge, EnglandC3  - Public Health Foundation of IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Public Health Foundation of IndiaC3  - University of DelhiC3  - UK Research & Innovation (UKRI)C3  - Medical Research Council UK (MRC)C3  - MRC Human Nutrition ResearchPU  - SAGE PUBLICATIONS INC
PI  - THOUSAND OAKS
PA  - 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
DA  - DEC
PY  - 2018
VL  - 39
IS  - 4
SP  - 581
EP  - 594
DO  - 10.1177/0379572118805652
AN  - WOS:000454132200007
ER  -

TY  - JOUR
AU  - Godiyal, AK
AU  - Mondal, M
AU  - Joshi, SD
AU  - Joshi, D
TI  - Force Myography Based Novel Strategy for Locomotion Classification
T2  - IEEE TRANSACTIONS ON HUMAN-MACHINE SYSTEMS
KW  - Force myography (FMG)
KW  - gait cycle
KW  - linear discriminant analysis (LDA)
KW  - locomotion classification
KW  - SURFACE ELECTROMYOGRAPHY
KW  - TRANSTIBIAL AMPUTEES
KW  - PROSTHETIC CONTROL
KW  - INTERFACE
KW  - PRESSURE
KW  - PERFORMANCE
KW  - AMBULATION
KW  - DESCENT
KW  - FOREARM
KW  - WALKING
AB  - This paper presents a new, simple, and efficient strategy for locomotion classification using a force myography (FMG) system developed in-house. The FMG signals were acquired from eight calibrated force sensors. These sensors were wrapped around the thigh and captured volumetric changes in thigh muscles during locomotion. The data were collected from eight able-bodied subjects and two unilateral transfemoral amputees while walking in different terrains, i.e., level walk, ramp ascent, ramp descent, stair ascent, and stair descent (SD). The repeatability of FMG signals within all the five locomotion modes was expressed in terms of variance ratio (VR). For all locomotion modes, except SD, the VR ranges from 0.1 to 0.3, showing high repeatability within the locomotion modes for able-bodied and amputee subjects. Furthermore, these locomotion modes are characterized by computationally simplified time-domain features of FMG signals and classified using linear discriminant analysis (LDA). The subject-dependent LDA model gave an average classification accuracy of 99.5% (SD = 0.5) and 96.1% (SD = 1.9) for able-bodied and amputee subjects, respectively. These results show the potential of the FMG system in a real-time classification of locomotion modes for lower-limb prosthetic control.
AD  - Indian Inst Technol Delhi, New Delhi 110016, IndiaAD  - All India Inst Med Sci Delhi, New Delhi 110029, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI  - PISCATAWAY
PA  - 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
DA  - DEC
PY  - 2018
VL  - 48
IS  - 6
SP  - 648
EP  - 657
DO  - 10.1109/THMS.2018.2860598
AN  - WOS:000450208700009
ER  -

TY  - JOUR
AU  - Gupta, A
AU  - Kamal, G
AU  - Gupta, A
AU  - Sehgal, N
AU  - Bhatla, S
AU  - Kumar, R
TI  - Comparative evaluation of CMAC and Truview picture capture device for endotracheal intubation in neonates and infants undergoing elective surgeries: A prospective randomized control trial
T2  - PEDIATRIC ANESTHESIA
KW  - airway management
KW  - infant
KW  - neonate
KW  - video laryngoscopes
KW  - AIRWAY MANAGEMENT
KW  - DIFFICULT INTUBATION
KW  - VIDEO-LARYNGOSCOPES
KW  - TRACHEAL INTUBATION
KW  - CHILDREN
KW  - COMPLICATIONS
KW  - MACINTOSH
AB  - Background: Videolaryngoscopy has an established role in difficult airway management in adults. However, there is limited literature to support their efficacy in children. The Truview Picture Capture Device has shown promising results for endotracheal intubation in infants in the past. The CMAC videolaryngoscope has launched its novel infant Miller blade, but its performance has not been assessed clinically for routine intubation in infants and neonates. We hypothesized that the CMAC videolaryngoscope would reduce the total time to intubation as compared to the Truview Picture Capture Device in neonates and infants.
   Methods: After parental informed consent, 80 prospective infants posted for surgical procedures under general anesthesia were randomized to undergo intubation with either of the two. The two videolaryngoscopes were also compared in terms of time required for glottis view and intubation (primary outcome), modified Cormack and Lehane grade, first attempt and overall success rate, ease of intubation, number of attempts, and any complications.
   Results: The CMAC significantly reduced the time required for glottic view [8 s (5.25-9) vs 9 s (6.5-12); P = 0.02] and intubation [22 s (18-26) vs 26 s (21.5-32); P = 0.003]. The median difference (95% CI) for time to tracheal intubation and time to glottic view was 4 s (1-7) and 1 (0-4). It also improved the ease of intubation, the Cormack-Lehane grades, and first attempt success rate. Intubation with the CMAC was possible in 100% cases, whereas only 92.5% of patients could be intubated with the Truview. The failed intubations with the Truview could be successfully intubated with the CMAC.
   Conclusion: The CMAC Miller blade reduced the total time taken for tracheal intubation and intubation difficulty as compared to the Truview Picture Capture Device and may be a better tool for intubation in infants.
AD  - VMMC & Safdarjung Hosp, New Delhi, IndiaAD  - Chacha Nehru Bal Chikitsalya, New Delhi, IndiaAD  - Baba Saheb Ambedkar Hosp, New Delhi, IndiaAD  - AIIMS, DRBRAIRCH, New Delhi, IndiaC3  - Vardhman Mahavir Medical College & Safdarjung HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - DEC
PY  - 2018
VL  - 28
IS  - 12
SP  - 1148
EP  - 1153
DO  - 10.1111/pan.13524
AN  - WOS:000453482100013
ER  -

TY  - JOUR
AU  - Gupta, R
AU  - Kaur, G
AU  - Kumar, L
AU  - Rani, L
AU  - Mathur, N
AU  - Sharma, A
AU  - Dahiya, M
AU  - Shekhar, V
AU  - Khan, S
AU  - Mookerjee, A
AU  - Sharma, OD
TI  - Nucleic acid based risk assessment and staging for clinical practice in multiple myeloma
T2  - ANNALS OF HEMATOLOGY
KW  - R-ISS
KW  - t(4;14)
KW  - t(14;16)
KW  - del 17p
KW  - C-statistic
KW  - WORKING GROUP
KW  - TOTAL THERAPY
KW  - SYSTEM
KW  - BORTEZOMIB
KW  - DEXAMETHASONE
KW  - MAINTENANCE
KW  - THALIDOMIDE
KW  - CRITERIA
KW  - PHASE-3
KW  - TRIAL
AB  - The recently introduced Revised International Staging System (R-ISS) for multiple myeloma (MM) integrates albumin, beta 2 microglobulin, lactate dehydrogenase (LDH) with high-risk cytogenetic aberrations (CA), i.e., t(4;14) and t(14;16) and del17p using fluorescent in situ hybridization (FISH). We evaluated utility of nucleic acid-based tests of multiplex ligation-based probe amplification (MLPA) and quantitative real-time polymerase chain reaction (qRT-PCR) to define the CA and the R-ISS categories as per this approach were evaluated for their ability to predict outcome in terms of response, progression-free (PFS), and overall survival (OS). In this study (n = 180), 17 (9.4%), 118 (65.6%), and 45 (25%) patients were assigned to R-ISS1, R-ISS2, and R-ISS3 categories with statistically significant differences in median PFS (p = 0.02) and OS (p < 0.001).On univariate analysis, serum creatinine, LDH, 17p deletion, chromosome 1q gain, and response after first induction therapy were associated with statistically significant differences (p < 0.05) in PFS and in addition, age > 65 years and use of triplet therapy with OS. On multivariate analysis, only serum creatinine, LDH, and response after first induction therapy retained significance for predicting PFS and in addition, use of triplet therapy retained significance for the OS. The proposed nucleic acid-based algorithm using qRT-PCR and MLPA for R-ISS is resource-effective in terms of small quantities of sample required; feasibility of batch processing and reduced overall cost for the total number of regions evaluated and retained the prognostic significance of R-ISS, making it suitable for clinical practice for molecular characterization of MM.
AD  - All India Inst Med Sci, Dr BRA IRCH, Lab Oncol Unit, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dr BRA IRCH, Dept Med Oncol, Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - DEC
PY  - 2018
VL  - 97
IS  - 12
SP  - 2447
EP  - 2454
DO  - 10.1007/s00277-018-3457-8
AN  - WOS:000450356200020
ER  -

TY  - JOUR
AU  - Hari, P
AU  - Khandelwal, P
AU  - Satpathy, A
AU  - Hari, S
AU  - Thergaonkar, R
AU  - Lakshmy, R
AU  - Sinha, A
AU  - Bagga, A
TI  - Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial
T2  - PEDIATRIC NEPHROLOGY
KW  - Hydroxymethylglutaryl-CoA reductase inhibitors
KW  - Hyperlipidemia
KW  - LDL cholesterol
KW  - Apolipoprotein B-100
KW  - BRACHIAL-ARTERY
KW  - FAMILIAL HYPERCHOLESTEROLEMIA
KW  - ENDOTHELIAL FUNCTION
KW  - SIMVASTATIN THERAPY
KW  - STATIN THERAPY
KW  - LOW-DENSITY
KW  - HYPERLIPIDEMIA
KW  - CHOLESTEROL
KW  - RISK
KW  - GUIDELINES
AB  - BackgroundDyslipidemia is an important cardiovascular risk factor in steroid-resistant nephrotic syndrome (SRNS). Efficacy of statins for treatment of hyperlipidemia in children with SRNS is unclear.MethodsThis prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial enrolled 30 patients with SRNS, aged 5-18years, with serum low-density lipoprotein cholesterol (LDL-C) levels between 130 and 300mg/dl, to receive a fixed dose of atorvastatin (n=15, 10mg/d) or placebo (n=15) by block randomization in a 1:1 ratio. Primary outcome was change in serum LDL-C at 12months. Change in levels of other lipid fractions, carotid intima-media thickness (cIMT), flow-mediated dilation (FMD) of the brachial artery, and adverse events were also evaluated.ResultsAt the end of 12months, atorvastatin was not superior to placebo in reducing plasma LDL-C levels, median percentage reduction 15.8% and 9.5% respectively, in atorvastatin and placebo arms (n=14 in each; P=0.40). Apolipoprotein B levels significantly declined with atorvastatin in modified intention-to-treat analysis (P=0.01) but not in the per-protocol analysis. There was no significant effect on other lipid fractions, cIMT and FMD. Adverse events were similar between groups. Change in serum albumin was negatively associated with change in serum LDL-C, very low-density lipoprotein cholesterol, total cholesterol, triglyceride, and apolipoprotein B (P<0.001), irrespective of receiving atorvastatin, age, gender, body mass index, and serum creatinine.ConclusionsAtorvastatin, administered at a fixed daily dose of 10mg, was not beneficial in lowering lipid levels in children with SRNS; rise in serum albumin was associated with improvement in dyslipidemia.
AD  - All India Inst Med Sci, Dept Pediat, Div Nephrol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Cardiac Biochem, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - DEC
PY  - 2018
VL  - 33
IS  - 12
SP  - 2299
EP  - 2309
DO  - 10.1007/s00467-018-4036-x
AN  - WOS:000451762600010
ER  -

TY  - JOUR
AU  - Hasija, S
AU  - Talwar, S
AU  - Makhija, N
AU  - Chauhan, S
AU  - Malhotra, P
AU  - Chowdhury, UK
AU  - Krishna, NS
AU  - Sharma, G
TI  - Randomized Controlled Trial of Heparin Versus Bivalirudin Anticoagulation in Acyanotic Children Undergoing Open Heart Surgery
T2  - JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
KW  - bivalirudin
KW  - anticoagulation monitoring
KW  - heparin altematives
KW  - pediatric cardiac surgery
KW  - CORONARY-ARTERY-BYPASS
KW  - EXTRACORPOREAL MEMBRANE-OXYGENATION
KW  - MOLECULAR-WEIGHT HEPARIN
KW  - INDUCED THROMBOCYTOPENIA
KW  - CARDIOPULMONARY BYPASS
KW  - UNFRACTIONATED HEPARIN
KW  - CARDIAC-SURGERY
KW  - ASSIST DEVICE
KW  - PATIENT
KW  - TRANSPLANTATION
AB  - Objective: To determine the safety and efficacy of bivalirudin as an anticoagulant for pediatric open heart surgery (OHS) and to determine its appropriate dosage for this purpose.
   Design: Prospective, randomized controlled trial.
   Setting: Tertiary care hospital.
   Participants: Fifty acyanotic children aged 1-12 years undergoing OHS.
   Interventions: The children were randomized to receive either 4 mg/kg of heparin (n = 25, group H) or 1 mg/kg of bivalirudin bolus followed by 2.5 mg/kg/h infusion (n = 25, group B) as the anticoagulant. The doses were adjusted to maintain activated clotting time (ACT) above 480 seconds. At the conclusion of surgery, protamine (1.3 mg/100 U of heparin) was administered to children in group H.
   Measurements and Main Results: The children were comparable in both groups with regard to demographic characteristics. The mean age and weight were 51.5 months and 13.4 kg in group H, and 59.3 months and 13.4 kg in group B. The dose of anticoagulant required was 4.0 +/- 0.2 mg/kg in group H and 1.7 +/- 0.2 mg/kg followed by 3.0 +/- 0.7 mg/kg/h infusion in group B (p < 0.001). One child in group H required an additional dose compared to 13 (54.2%) children in group B. Intraoperatively, the ACT achieved was higher in group H compared to group B (p < 0.05). The ACT returned to baseline value after protamine administration in group H, but it remained elevated for 2 hours after termination of cardiopulmonary bypass (CPB) in group B (p < 0.01). The ACT was higher in group B compared to group H for 6 hours after termination of CPB (p < 0.05). Heparin prolonged the onset of clotting, decreased the rate and strength of thrombus formation, and inhibited platelet function to a greater extent than bivalirudin on viscoelastic coagulation testing. The total duration of surgery was prolonged in group B. The postoperative chest tube drainage was similar in group B (4.9 mL/kg) as in group H (5.9 mL/kg) in spite of higher ACT. The transfusion requirements were similar. No adverse event occurred in any patient.
   Conclusion: Bivalirudin is a safe and effective anticoagulant for pediatric OHS. Though it is not suitable as a routine anticoagulant for this purpose, it may be used as a heparin alternative in instances when heparin cannot be used. The dose required to maintain ACT for more than 480 seconds was 1.7 +/- 0.2 mg/kg followed by 3.0 +/- 0.7 mg/kg/h infusion. The ACT remained elevated for 2 hours after stopping the infusion. Bivalirudin did not increase postoperative bleeding and transfusion requirement. (C) 2018 Elsevier Inc. All rights reserved.
AD  - All India Inst Med Sci, Dept Cardiac Anaesthesia, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Cardiothorac Vasc Surg, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Perfus Technol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - W B SAUNDERS CO-ELSEVIER INC
PI  - PHILADELPHIA
PA  - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
DA  - DEC
PY  - 2018
VL  - 32
IS  - 6
SP  - 2633
EP  - 2640
DO  - 10.1053/j.jvca.2018.04.028
AN  - WOS:000453639400031
ER  -

TY  - JOUR
AU  - Jain, A
AU  - Sankar, J
AU  - Anubhuti, A
AU  - Yadav, DK
AU  - Sankar, MJ
TI  - Prevalence and Outcome of Sepsis-induced Myocardial Dysfunction in Children with 'Sepsis' 'With' and 'Without Shock'-A Prospective Observational Study
T2  - JOURNAL OF TROPICAL PEDIATRICS
KW  - cardiac troponin-I (cTnI)
KW  - sepsis-induced myocardial dysfunction (SIMD)
KW  - septic shock
KW  - systolic dysfunction
KW  - diastolic dysfunction
KW  - ejection fraction
KW  - E '
KW  - E/A
KW  - MPI
KW  - myocardial performance index
KW  - CARDIAC TROPONIN-I
KW  - SEPTIC SHOCK
KW  - DIASTOLIC FUNCTION
KW  - EUROPEAN-SOCIETY
KW  - CELL INJURY
KW  - STRAIN-RATE
KW  - TEI INDEX
KW  - ECHOCARDIOGRAPHY
KW  - PERFORMANCE
KW  - MORTALITY
AB  - Objective: To estimate the prevalence and effects of sepsis-induced myocardial dysfunction (SIMD) in children with septic shock.
   Methodology: Enrolled children with septic shock (n = 31) and sepsis (n = 30) underwent echocardiography and cardiac troponin-I (cTnI) estimation within first 3 h. SIMD was defined as presence of systolic/diastolic dysfunction by echocardiography.
   Results: The prevalence of SIMD was 71% in 'septic shock' and 23% in 'sepsis'. Diastolic dysfunction (45.2%) was more prevalent than systolic dysfunction (32.3%). Children with SIMD had higher requirement of inotropes [81 vs. 44%; adjusted odds ratio: 1.41 (1.04-1.92)] in first 48 h. cTnI had low sensitivity (62.5%) and specificity (55.1%) for detecting SIMD. On follow-up at 3 months, there was no residual dysfunction in the majority (71.3%).
   Conclusion: SIMD, especially diastolic dysfunction, is common in septic shock and may increase inotrope requirement. It is reversible in majority. Sepsis patients may have asymptomatic underlying SIMD. cTnI does not correlate with the degree of SIMD.
AD  - PGIMER, Dept Pediat, Delhi 110001, IndiaAD  - Dr RML Hosp, Delhi 110001, IndiaAD  - All India Inst Med Sci, Dept Pediat, Room 3055, Delhi 110001, IndiaAD  - PGIMER, Dept Biochem, Delhi 110001, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - OXFORD UNIV PRESS
PI  - OXFORD
PA  - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
DA  - DEC
PY  - 2018
VL  - 64
IS  - 6
SP  - 501
EP  - 509
DO  - 10.1093/tropej/fmx105
AN  - WOS:000456156500008
ER  -

TY  - JOUR
AU  - Jain, D
AU  - Sukumar, S
AU  - Mohan, A
AU  - Iyer, VK
TI  - Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas
T2  - CYTOPATHOLOGY
KW  - immunocytochemistry
KW  - immunohistochemistry
KW  - liquid-based cytology
KW  - lung cancer
KW  - PD-L1
KW  - PD-L1 EXPRESSION
KW  - CONVENTIONAL CYTOLOGY
KW  - CANCER
KW  - IMMUNOHISTOCHEMISTRY
KW  - DOCETAXEL
KW  - SPECIMENS
KW  - NIVOLUMAB
KW  - CYTOPATHOLOGY
KW  - ATEZOLIZUMAB
KW  - DIAGNOSIS
AB  - Objective Methods Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is essential in patients of advanced non-small-cell lung cancer to determine eligibility for immunotherapy. PD-L1 IHC assays have been clinically validated only on formalin-fixed paraffin-embedded tissue; however, lung cancer is frequently diagnosed on cytology. PD-L1 immunocytochemistry (ICC) has shown high concordance of immunoexpression between cytology samples and paired small biopsies. Feasibility of liquid-based cytology (LBC) smears for PD-L1 ICC has not been analysed previously. PD-L1 ICC and IHC (clone SP263) were performed on paired LBC smears and small biopsies, respectively, in patients with advanced non-small-cell lung cancer. Cases with fewer than 100 viable tumour cells on LBC smear/biopsy were excluded from analysis. PD-L1 was interpreted positive when 25% or more tumour cells showed membranous and/or cytoplasmic protein expression of any intensity greater than background staining. Results Conclusion A total of 26 patients, harbouring adenocarcinomas (50%) and squamous cell carcinomas (50%), had available bronchial brushings/washings processed as LBC smears and concurrently obtained endobronchial biopsies. PD-L1 IHC was interpreted positive in 46% (12/26) biopsies. PD-L1 ICC was interpreted positive in 35% (9/26) LBC smears, all of which were IHC-positive. No IHC-negative case was positive on cytology. The overall concordance between LBC smears and small biopsies was 88.4%. PD-L1 ICC can be performed on LBC processed smears, with certain challenges in interpretation inherent to LBC smears and their processing methods. Nevertheless, they represent a potential resource for ICC, especially when alternate histology material is not available. Future studies are required to validate the predictive value of PD-L1 ICC on LBC smears.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pulm Med & Sleep Disorders, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - DEC
PY  - 2018
VL  - 29
IS  - 6
SP  - 550
EP  - 557
DO  - 10.1111/cyt.12605
AN  - WOS:000450274200006
ER  -

TY  - JOUR
AU  - Jauhari, P
AU  - Saini, L
AU  - Chakrabarty, B
AU  - Kumar, A
AU  - Gulati, S
TI  - Juvenile Canavan Disease: A Leukodystrophy without White Matter Changes
T2  - NEUROPEDIATRICS
AD  - All India Inst Med Sci, Div Child Neurol, Dept Pediat, Room 3056,Third Floor,Teaching Block, New Delhi, IndiaAD  - All India Inst Med Sci, Jai Prakash Narayan Trauma Ctr, Dept Radiodiag, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterPU  - GEORG THIEME VERLAG KG
PI  - STUTTGART
PA  - RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
DA  - DEC
PY  - 2018
VL  - 49
IS  - 6
SP  - 420
EP  - 421
DO  - 10.1055/s-0038-1672175
AN  - WOS:000450212700015
ER  -

TY  - JOUR
AU  - Kapil, U
TI  - Adaptations in the IMCI Algorithm in Diagnosis of Acute Respiratory Tract Infections
T2  - INDIAN JOURNAL OF PEDIATRICS
AD  - All India Inst Med Sci, Human Nutr Unit, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - DEC
PY  - 2018
VL  - 85
IS  - 12
SP  - 1057
EP  - 1058
DO  - 10.1007/s12098-018-2804-z
AN  - WOS:000452597200005
ER  -

TY  - JOUR
AU  - Keeley, JW
AU  - Gaebel, W
AU  - First, MB
AU  - Peterson, DL
AU  - Rebello, T
AU  - Sharan, P
AU  - Reed, GM
TI  - Psychotic disorder symptom rating scales: Are dichotomous or multi-point scales more clinically useful?-An ICD-11 field study
T2  - SCHIZOPHRENIA RESEARCH
KW  - ICD-11
KW  - Schizophrenia
KW  - Positive symptoms
KW  - Negative symptoms
KW  - Rating scale
KW  - NEGATIVE SYNDROME SCALE
KW  - PSYCHOMETRIC PROPERTIES
KW  - SCHIZOPHRENIA
KW  - RELIABILITY
KW  - SUBTYPES
KW  - UTILITY
KW  - DSM-5
KW  - CLASSIFICATION
KW  - VALIDITY
KW  - PANSS
AB  - Classifications of psychotic disorders are moving towards utilizing dimensional symptom domains as the preferred mechanism for describing psychotic symptomatology. The ICD-11 has proposed six symptom domains (Positive symptoms, Negative symptoms, Depressive symptoms, Manic symptoms, Psychomotor symptoms, and Cognitive symptoms) that would be rated in addition to providing a psychotic disorder diagnosis. This study investigated clinicians' use of dichotomous versus multi-point scales for rating these six domains. Global mental health professionals (n = 273) rated case vignettes using both a 2-point and 4-point version of a rating scale for the six domains. Clinicians were more accurate using the 2-point scale in absolute terms, but after correcting for chance guessing and disagreements, the two versions of the scale were equally accurate. Clinicians believed the 2-point scale would be easier to use, although they also indicated that the 4-point scale would provide richer clinical information. Participants were able to detect the presence of psychotic symptom domains in the vignettes with good reliability with no special training using either scale. We recommend that clinicians and researchers use the version of the scale that best matches their purpose (i.e., to maximize accuracy or enhance case description). Future work should develop the implementation characteristics of the scale to improve its potential for global application. (C) 2018 Elsevier B.V. All rights reserved.
AD  - Virginia Commonwealth Univ, Richmond, VA 23284 USAAD  - Heinrich Heine Univ, Dept Psychiat & Psychotherapy, Dusseldorf, GermanyAD  - Columbia Univ, Global Mental Hlth Program, Med Ctr, New York, NY 10027 USAAD  - New York State Psychiat Inst & Hosp, New York, NY 10032 USAAD  - Mississippi State Univ, Starkville, MS USAAD  - All India Inst Med Sci, New Delhi, IndiaAD  - WHO, Geneva, SwitzerlandC3  - Virginia Commonwealth UniversityC3  - Heinrich Heine University DusseldorfC3  - Columbia UniversityC3  - New York State Psychiatry InstituteC3  - Mississippi State UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - World Health OrganizationPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - DEC
PY  - 2018
VL  - 202
SP  - 254
EP  - 259
DO  - 10.1016/j.schres.2018.07.006
AN  - WOS:000452298400038
ER  -

TY  - JOUR
AU  - Khanna, K
AU  - Dhua, AK
AU  - Bhatnagar, V
TI  - Antenatally Diagnosed Surgical Conditions: Fetus As Our Patient
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Fetal surgical anomalies
KW  - Fetal intervention
KW  - Congenital
KW  - Malformations
KW  - Antenatal diagnosis
KW  - CONGENITAL DIAPHRAGMATIC-HERNIA
KW  - CYSTIC ADENOMATOID MALFORMATION
KW  - FETAL SURGERY
KW  - OBSTRUCTIVE UROPATHY
KW  - PRENATAL-DIAGNOSIS
KW  - TRACHEAL OCCLUSION
KW  - MANAGEMENT
KW  - MYELOMENINGOCELE
KW  - HYDRONEPHROSIS
KW  - INTERVENTION
AB  - In today's era of improved antenatal care and screening modalities (3D high-resolution fetal ultrasound, fetal magnetic resonance imaging, fetal echocardiography, maternal serum markers and fetal blood sampling), an early diagnosis of surgical fetal abnormalities is routinely possible. A thorough knowledge about the incidence of such defects, the means of detection and evaluation, the scope of fetal intervention, postnatal management and long-term outcomes of common surgical conditions diagnosed antenatally is essential. This knowledge would not only help in proper patient care and management but also to ensure appropriate counselling of the expectant parents. This article highlights the fetal anomalies which are amenable to some form of fetal intervention from a pediatric surgical perspective as also those which can be treated after birth.
AD  - All India Inst Med Sci, Dept Pediat Surg, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - DEC
PY  - 2018
VL  - 85
IS  - 12
SP  - 1101
EP  - 1109
DO  - 10.1007/s12098-018-2732-y
AN  - WOS:000452597200014
ER  -

TY  - JOUR
AU  - Khokhar, S
AU  - Takkar, B
AU  - Agarwal, E
AU  - Gaur, N
AU  - Ravani, R
AU  - Venkatesh, P
TI  - Biometric evaluation of myopic eyes without posterior staphyloma: disproportionate ocular growth
T2  - INTERNATIONAL OPHTHALMOLOGY
KW  - Myopia
KW  - Refractive surgery
KW  - High myopia
KW  - Posterior elongation of eye
KW  - AXIAL LENGTH
KW  - ULTRASONIC MEASUREMENT
KW  - ANTERIOR-CHAMBER
KW  - SAGITTAL GROWTH
KW  - ATROPINE
KW  - COMPONENTS
KW  - BIRTH
KW  - DEPTH
AB  - PurposeTo evaluate changes in the anterior segment of myopic eyes and assess anterior biometry as a function of axial length (AL).DesignRetrospective investigational study.ParticipantsPatients evaluated for phakic intraocular lens surgery at a tertiary eye care centre.MethodsPatients with corrected visual acuity >20/40 and AL>24.5mm were included in the study. Posterior staphyloma and maculopathy were ruled out in all the patients, and 176 eyes were included for analysis. AL was measured with partial coherence interferometry, while keratometry, central corneal thickness (CCT), anterior chamber depth (ACD), and horizontal white to white (WTW) were measured with slit-scanning topography. Group 1 included 55 eyes with AL<26.5mm, group 2 had 57 eyes with AL between 26.5 and 28.5mm while group 3 had 64 eyes with AL>28.5mm.Main outcome measureCorrelation of AL with anterior biometry.ResultsThe mean AL of the study eyes was 27.88+2.14mm. The mean values of ACD (2.99mm), CCT (0.52mm), WTW (11.68mm), and keratometry (43.62D) were within the normal range. Overall, very weak correlations could be established between AL and CCT (R=0.17, p=0.02), AL and keratometry (R=-0.28, p<0.001), and AL and WTW (R=0.22, p=0.002), while ACD did not relate to AL significantly. The ACD and CCT did not relate significantly to AL in any of the three groups. Keratometry had a weak negative relation with AL in groups 1 and 2, while WTW had a weakly positive relation with AL in group 2 only. No variable had any significant relation with AL in group 3.ConclusionThere is disproportionate elongation of the eyeball in myopic patients with very weak or no correlation between anterior biometry and AL. This discord is more in longer eyes. Such a scenario can be challenging to a refractive surgeon treating highly myopic eyes and needs further evaluation.
AD  - All India Inst Med Sci, Retina & Uvea Serv, Dr R P Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - DEC
PY  - 2018
VL  - 38
IS  - 6
SP  - 2427
EP  - 2434
DO  - 10.1007/s10792-017-0745-6
AN  - WOS:000451676200023
ER  -

TY  - JOUR
AU  - Khokhar, S
AU  - Gupta, Y
AU  - Dhull, C
AU  - Surve, A
AU  - Mahabir, M
TI  - Cortical riders of zonular cataracts as "reverse cuneiform" cataracts: A hypothesis
T2  - MEDICAL HYPOTHESES
KW  - MORPHOLOGY
AB  - Zonular cataracts are childhood cataracts involving one or more zone(s) of lens. They often show 'riders' which are wedge-shaped opacifications of inner cortex of the lens seen to radiate towards the lens equator, though little is known about the exact mechanism behind their development. Cortical riders may be described as 'reverse cuneiform' cataracts on the basis of their evolution pattern being exact opposite to that of senile cuneiform cortical cataracts.
AD  - AIIMS, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 486, Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - CHURCHILL LIVINGSTONE
PI  - EDINBURGH
PA  - JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
DA  - DEC
PY  - 2018
VL  - 121
SP  - 49
EP  - 50
DO  - 10.1016/j.mehy.2018.09.009
AN  - WOS:000452568500014
ER  -

TY  - JOUR
AU  - Kovic, B
AU  - Jin, XJ
AU  - Kennedy, SA
AU  - Hylands, M
AU  - Pedziwiatr, M
AU  - Kuriyama, A
AU  - Gomaa, H
AU  - Lee, Y
AU  - Katsura, M
AU  - Tada, M
AU  - Hong, BY
AU  - Cho, SM
AU  - Hong, PJ
AU  - Yu, AM
AU  - Sivji, Y
AU  - Toma, A
AU  - Tsoi, L
AU  - Waligora, M
AU  - Prasad, M
AU  - Bhatnagar, N
AU  - Thabane, L
AU  - Brundage, M
AU  - Guyatt, G
AU  - Xie, F
TI  - Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology A Systematic Review and Quantitative Analysis
T2  - JAMA INTERNAL MEDICINE
KW  - RANDOMIZED PHASE-III
KW  - PATIENT-REPORTED OUTCOMES
KW  - CELL LUNG-CANCER
KW  - PEGYLATED LIPOSOMAL DOXORUBICIN
KW  - GEMCITABINE PLUS CETUXIMAB
KW  - TREATED JAPANESE PATIENTS
KW  - METASTATIC BREAST-CANCER
KW  - CLINICAL-TRIALS
KW  - OVARIAN-CANCER
KW  - EUROPEAN-ORGANIZATION
AB  - IMPORTANCE Progression-free survival (PFS) has become a commonly used outcome to assess the efficacy of new cancer drugs. However, it is not clear if delay in progression leads to improved quality of life with or without overall survival benefit.
   OBJECTIVE To evaluate the association between PFS and health-related quality of life (HRQoL) in oncology through a systematic review and quantitative analysis of published randomized clinical trials. Eligible trials addressed oral, intravenous, intraperitoneal, or intrapleural chemotherapy or biological treatments, and reported PFS or health-related quality of life.
   DATA SOURCES For this systematic review and quantitative analysis of randomized clinical trials of patients with cancer, we searched Medline, Embase, and the Cochrane Central Register of Controlled Trials from January 1, 2000, through May 4, 2016.
   STUDY SELECTION Paired reviewers independently screened citations, extracted data, and assessed risk of bias of included studies.
   DATA EXTRACTION AND SYNTHESIS We examined the association of difference in median PFS duration (in months) between treatment groups with difference in global, physical, and emotional HRQoL scores between groups (standardized to a range of 0-100, with higher scores representing better HRQoL) using weighted simple regressions.
   MAIN OUTCOME AND MEASURE The association between PFS duration and HRQoL.
   RESULTS Of 35 960 records screened, 52 articles reporting on 38 randomized clinical trials involving 13 979 patients across 12 cancer types using 6 different HRQoL instruments were included. The mean (SD) difference in median PFS between the intervention and the control arms was 1.91 (3.35) months. The mean (SD) differences in change of HRQoL adjusted to per-month values were -0.39 (3.59) for the global domain, 0.26 (5.56) for the physical domain, and 1.08 (3.49) for the emotional domain. The slope of the association between the difference in median PFS and the difference in change for global HRQoL (n = 30 trials) was 0.12 (95% CI, -0.27 to 0.52); for physical HRQoL (n = 20 trials) it was -0.20 (95% CI, -0.62 to 0.23); and for emotional HRQoL (n = 13 trials) it was 0.78 (95% CI, -0.05 to 1.60).
   CONCLUSIONS AND RELEVANCE We failed to find a significant association between PFS and HRQoL in cancer clinical trials. These findings raise questions regarding the assumption that interventions prolonging PFS also improve HRQoL in patients with cancer. Therefore, to ensure that patients are truly obtaining important benefit from cancer therapies, clinical trial investigators should measure HRQoL directly and accurately, ensuring adequate duration and follow-up.
AD  - McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, CanadaAD  - Univ Alberta, Li Ka Shing Ctr Hlth Res Innovat, Alberta PROMs & EQ Res & Support Unit 5D, Sch Publ Hlth, Edmonton, AB, CanadaAD  - Univ Toronto, Dept Diagnost Radiol, Toronto, ON, CanadaAD  - Univ Sherbrooke, CHU Sherbrooke, Dept Gen Surg, Sherbrooke, PQ, CanadaAD  - Jagiellonian Univ, Coll Med, Dept Gen Surg 2, Krakow, PolandAD  - Ctr Res Training & Innovat Surg CERTAIN Surg, Krakow, PolandAD  - Kurashiki Cent Hosp, Dept Gen Med, Miwa Kurashiki Okayama, JapanAD  - Alexandria Univ, High Inst Publ Hlth, Ibrahimeyah QebliWA Hadr, Alexandria Gove, EgyptAD  - Tanta Chest Hosp, Minist Hlth, Drug Informat Ctr, Tanta, EgyptAD  - McMaster Univ, Dept Med, Hamilton, ON, CanadaAD  - Okinawa Prefectural Nanbu Med Ctr, Dept Surg, Haebaru, Okinawa, JapanAD  - Childrens Med Ctr, Haebaru, Okinawa, JapanAD  - Kyoto Univ, Grad Sch Med, Sch Publ Hlth, Dept Clin Epidemiol,Sakyo Ku, Yoshida Konoe Cho, Kyoto, JapanAD  - Univ Toronto, Dept Surg, Div Plast & Reconstruct Surg, Toronto, ON, CanadaAD  - Univ Toronto, Fac Med, Toronto, ON, CanadaAD  - Univ Ottawa, Fac Med, Ottawa, ON, CanadaAD  - McMaster Univ, Dept Family Med, Hamilton, ON, CanadaAD  - Shanghai Jiao Tong Univ, Clin Res Ctr, Sch Med, Shanghai, Peoples R ChinaAD  - Queen Mary Hosp, Dept Accid & Emergency, Hong Kong, Hong Kong, Peoples R ChinaAD  - Jagiellonian Univ, Coll Med, Dept Philosophy & Bioeth, Res Ethics Med Study Grp REMEDY, Krakow, PolandAD  - All India Inst Med Sci, Ctr Community Med, New Delhi, IndiaAD  - McMaster Univ, Hlth Sci Lib, Hamilton, ON, CanadaAD  - St Josephs Healthcare Hamilton, Biostatist Unit FSORC, Hamilton, ON, CanadaAD  - McMaster Univ, Dept Anesthesia, Hamilton, ON, CanadaAD  - McMaster Univ, Dept Pediat, Hamilton, ON, CanadaAD  - Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, CanadaAD  - Kingston Gen Hosp, Canc Ctr Southeastern Ontario, Kingston Hlth Sci Ctr, Kingston, ON, CanadaAD  - Queens Univ Kingston, Canc Res Inst, Kingston, ON, CanadaAD  - McMaster Univ, Ctr Hlth Econ & Policy Anal, Hamilton, ON, CanadaAD  - Program Hlth Econ, Hamilton, ON, CanadaAD  - Program Outcome Measures, Hamilton, ON, CanadaC3  - McMaster UniversityC3  - University of AlbertaC3  - University of TorontoC3  - University of SherbrookeC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - Kurashiki Central HospitalC3  - Egyptian Knowledge Bank (EKB)C3  - Alexandria UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Tanta UniversityC3  - Ministry of Health & Population - EgyptC3  - McMaster UniversityC3  - Kyoto UniversityC3  - University of TorontoC3  - University of TorontoC3  - University of OttawaC3  - McMaster UniversityC3  - Shanghai Jiao Tong UniversityC3  - University of Hong KongC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - McMaster UniversityC3  - McMaster UniversityC3  - McMaster UniversityC3  - McMaster UniversityC3  - Population Health Research InstituteC3  - McMaster UniversityC3  - Queens University - CanadaC3  - Queens University - CanadaC3  - McMaster UniversityPU  - AMER MEDICAL ASSOC
PI  - CHICAGO
PA  - 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
DA  - DEC
PY  - 2018
VL  - 178
IS  - 12
SP  - 1586
EP  - 1596
DO  - 10.1001/jamainternmed.2018.4710
AN  - WOS:000452113900005
ER  -

TY  - JOUR
AU  - Kumar, A
AU  - Padhy, SK
TI  - Commentary: Influence of orientation of the external linear incision created by the 25-gauge trocar and related factors on sclerotomy closure: A clinical and optical coherence tomographic study
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - DEC
PY  - 2018
VL  - 66
IS  - 12
SP  - 1815
EP  - 1815
DO  - 10.4103/ijo.IJO_1640_18
AN  - WOS:000450676000026
ER  -

TY  - JOUR
AU  - Kumar, A
AU  - Hasan, N
AU  - Kakkar, P
AU  - Mutha, V
AU  - Karthikeya, R
AU  - Sundar, D
AU  - Ravani, R
TI  - Comparison of clinical outcomes between "heads-up" 3D viewing system and conventional microscope in macular hole surgeries: A pilot study
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - 3D heads-up viewing system
KW  - digitally assisted vitreoretinal surgery
KW  - macular hole
KW  - ENDOILLUMINATION
KW  - PHOTOTOXICITY
AB  - Purpose: To compare clinical outcomes of patients undergoing macular hole surgery with headsup three-dimensional (3D) viewing system and conventional microscope. Methods: In all, 50 eyes of 50 patients with stage 3 or 4 macular hole were randomized and macular hole surgery [inverted internal limiting membrane (ILM) flap technique] was performed in 25 eyes using 3D viewing system and 25 eyes using conventional microscope. All surgeries were performed by a single surgeon. Patients were followed up for a period of 3 months. Logarithm of the minimum angle of resolution (logMAR) visual acuity, macular hole index, intraoperative parameters such as total surgical time, total ILM peel time, number of flap initiations, duration of Brilliant Blue G dye exposure, illumination intensity, postoperative logMAR visual acuity, and macular hole closure rates were recorded and compared between the two groups. Results: The mean age was 67.92 +/- 7.95 and 67.96 +/- 4.78 years in both groups, respectively (P = 0.98). Gender (P = 0.38) and right versus left eye (P = 0.39) were also comparable. Preoperative and postoperative best-corrected visual acuity (P = 0.86, 0.92), macular hole index (P = 0.96), total surgical time (P = 0.56), total ILM peel time (P = 0.49), number of flap initiations (P = 0.11), and macular hole closure rates (P = 0.61) were not statistically significant when compared between the two groups. Illumination intensity of microscope (100% vs 45%) and endoillumination (40% vs 13%) were significantly less in the 3D viewing system. Conclusion: The clinical outcomes of macular hole surgery using 3D viewing system are not inferior to that of conventional microscopes, and it has the added advantages of better ergonomics, reduced phototoxicity, peripheral visualization, magnification, and less asthenopia, and it serves as a good educational tool.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - DEC
PY  - 2018
VL  - 66
IS  - 12
SP  - 1816
EP  - 1819
DO  - 10.4103/ijo.IJO_59_18
AN  - WOS:000450676000027
ER  -

TY  - JOUR
AU  - Kumar, J
AU  - Singh, A
AU  - Seth, R
AU  - Xess, I
AU  - Jana, M
AU  - Kabra, SK
TI  - Prevalence and Predictors of Invasive Fungal Infections in Children with Persistent Febrile Neutropenia Treated for Acute Leukemia - A Prospective Study
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Febrile neutropenia
KW  - Leukemia
KW  - Invasive fungal infection
KW  - Prevalence
KW  - Predictors
KW  - CANCER
KW  - DISEASE
KW  - CHEMOTHERAPY
KW  - EPISODES
KW  - FEVER
AB  - ObjectiveTo ascertain the prevalence of invasive fungal infections (IFI), predictors of IFI, identify etiological species and outcome (mortality/discharge) in persistent febrile neutropenia in children with acute leukemia.MethodsIt was a prospective, observational study conducted from January 2013 through June 2014 in a tertiary care centre in New Delhi. Children between 1 and 12 y of age, on chemotherapy for acute leukemia with persistent febrile neutropenia (> 96h) were enrolled. These children were not on any antifungal prophylaxis. Diagnosis of IFI was based on European Organization for Research and Treatment of Cancer and Mycoses Study Group (EORTC/MSG) criteria. Prevalence and outcome was reported in mean95% CI form and etiological species were presented in the form of the frequency distribution.ResultsThree hundred nineteen episodes involving 187 children of febrile neutropenia were screened and 74 were enrolled. Prevalence of IFI was 22.97% (13.99-34.21). Positive cases were further classified into proven 3(17.6%), probable 11(64.8%) and possible 3(17.6%) according to EORTC/MSG criteria. On multivariate analysis, abnormal CXR and clinical sinusitis were important predictors of IFI. Most common fungi isolated was Aspergillus sp. followed by Candida sp. Mortality rate was 9.45% (3.89-18.52).Conclusions Thus, prevalence of IFI is very high in children with persistent febrile neutropenia who are not on antifungal prophylaxis. Abnormal chest x- ray and clinical sinusitis are important predictors of IFI.
AD  - All India Inst Med Sci, Dept Pediat, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - DEC
PY  - 2018
VL  - 85
IS  - 12
SP  - 1090
EP  - 1095
DO  - 10.1007/s12098-018-2722-0
AN  - WOS:000452597200012
ER  -

TY  - JOUR
AU  - Kumar, R
AU  - Gautam, M
AU  - Prasoon, P
AU  - Gupta, S
AU  - Ray, SB
TI  - Comparison of the peripheral antinociceptive effect of somatostatin with bupivacaine and morphine in the rodent postoperative pain model
T2  - EUROPEAN JOURNAL OF ANAESTHESIOLOGY
KW  - NERVE GROWTH-FACTOR
KW  - WOUND INFILTRATION
KW  - COUNTER-IRRITATION
KW  - SPINAL-CORD
KW  - RECEPTOR
KW  - RAT
KW  - NOCICEPTION
KW  - INHIBITION
KW  - BEHAVIORS
KW  - INFLAMMATION
AB  - BACKGROUND AND OBJECTIVES Infiltration of surgical wound with local anaesthetics attenuate postoperative pain. However, side effects can also occur. Somatostatin (SST) and its analogues like octreotide reportedly reduce peripheral sensitisation. The current study evaluates peripherally mediated antinociceptive effect of SST in a rat model of postoperative pain. This was compared with bupivacaine and morphine under identical experimental conditions.
   DESIGN Randomised vehicle-controlled blind study.
   SETTING Pain research laboratory, All India Institute of Medical Sciences, New Delhi from February 2014 to July 2017.
   EXPERIMENTAL SUBJECT Rodent hind paw incision model.
   INTERVENTIONS Sprague-Dawley rats were subjected to incision and one of the following drugs administered into the open wound once by a micropipette: SST (10, 30 or 100mg), bupivacaine (3, 10, 30, 50 or 100mg) or morphine (100mg). Antinociceptive effect of SST was further evaluated for its reversibility, site of action, effect on spinal c-fos expression and blood glucose level. The site of action of morphine was also investigated.
   MAIN OUTCOME MEASURE Nociception was estimated by nonevoked (guarding behaviour) and evoked (mechanical allodynia and thermal hyperalgesia) pain behaviours between 2 h and days 4 to 7.
   RESULTS Nociception was maximum 2 h after incision. SST (10 to 100mg) significantly attenuated guarding behaviour between 2 h and day 2. A delayed inhibitory effect was observed on allodynia. Bupivacaine (10 to 100mg doses) similarly decreased guarding score up to day 2 though evoked pain behaviours were relatively unaffected. In contrast, morphine produced a potent but transient inhibitory effect on guarding score at 2 h, which was mediated by both peripheral and central opioid receptors. The antinociceptive effect of SST was peripherally mediated by type 2 receptors and was associated with decreased c-fos staining. Blood glucose level was unaltered.
   CONCLUSION Guarding behaviour, which likely represents pain-at-rest following surgery, was attenuated by both bupivacaine and SST to comparable extents. This novel peripherally mediated antinociceptive effect of SST needs further evaluation.
AD  - All India Inst Med Sci, Dept Anat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - DEC
PY  - 2018
VL  - 35
IS  - 12
SP  - 955
EP  - 965
DO  - 10.1097/EJA.0000000000000825
AN  - WOS:000455899400009
ER  -

TY  - JOUR
AU  - Kumar, R
AU  - Gupta, N
AU  - Himani
AU  - Sharma, A
TI  - Novel combination of tanshinone I and lenalidomide induces chemo-sensitivity in myeloma cells by modulating telomerase activity and expression of shelterin complex and its associated molecules
T2  - MOLECULAR BIOLOGY REPORTS
KW  - Myeloma
KW  - Tanshinone I
KW  - Lenalidomide
KW  - Apoptosis
KW  - Telomerase
KW  - Shelterin complex
KW  - INDUCED APOPTOSIS
KW  - DOWN-REGULATION
KW  - MULTIPLE
KW  - MECHANISM
KW  - VITRO
KW  - PROGRESSION
KW  - BORTEZOMIB
KW  - GROWTH
KW  - IMIDS
AB  - Shelterin complex and its associated molecules are imperative for proper functioning and maintenance of human telomeres. These molecules in association with human telomerase have been found altered in most cancers including multiple myeloma thereby proposed them as suitable therapeutic targets. Further, due to aggressive and recurring behavior of myeloma novel, efficacious and safe therapeutic agents for disease prevention are primary requirements for treatment of this disease. This maiden attempt evaluated the anti-proliferative properties of tanshinone I (TanI) alone or in combination with lenalidomide (Len) on myeloma cancer cell lines (RPMI8226 and U226). Further, after drug treatment levels of telomerase activity (TA) and molecular expression (mRNA & protein) of shelterin complex and its associated molecules have also been investigated. Results demonstrated that, TanI significantly inhibited proliferation of myeloma cells in dose and time dependent manner as observed through cytotoxicity assay. Additionally, induction of apoptosis by TanI and in combination with Len was observed in myeloma cells through propidium iodide (PI) staining, annexin V-FITC/PI staining, TUNEL and caspase-3/7 activity assays. Further, drug treatment significantly decreased (p < 0.01) TA and molecular expression of ACD, TERF2IP and TANK1 in comparison to vehicle control (0.1% DMSO) myeloma cells. Thus, this maiden in-vitro study provided initial evidences of therapeutic potential of TanI alone or in combination with chemotherapeutic agent Len as novel anticancer agents in myeloma cells which need further evaluation in future. Lastly, down-regulation of TA and decreased expression of these molecules underscores their potential as plausible therapeutic targets.
AD  - AIIMS, Dept Biochem, New Delhi 110029, IndiaAD  - NDMC Med Coll & Hindu Rao Hosp, Dept Biochem, New Delhi 110007, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - DEC
PY  - 2018
VL  - 45
IS  - 6
SP  - 2429
EP  - 2439
DO  - 10.1007/s11033-018-4409-z
AN  - WOS:000452543200084
ER  -

TY  - JOUR
AU  - Kumar, S
AU  - Sharawat, SK
TI  - Epigenetic regulators of programmed death-ligand 1 expression in human cancers
T2  - TRANSLATIONAL RESEARCH
KW  - CLASSICAL HODGKIN LYMPHOMA
KW  - ACUTE MYELOID-LEUKEMIA
KW  - CELL LUNG-CANCER
KW  - PD-L1 EXPRESSION
KW  - PROMOTER METHYLATION
KW  - HISTONE DEACETYLASE
KW  - OVER-EXPRESSION
KW  - IMMUNE-RESPONSE
KW  - COLORECTAL-CANCER
KW  - B7-H1 EXPRESSION
AB  - The programmed cell death protein 1-programmed death-ligand 1 (PD-L1) axis has been successfully targeted in clinics and the use of immune check-point inhibitors have shown durable antitumor response in untreated or heavily treated advanced stage cancer. PD-L1 upregulation has been found to correlate with poor prognosis in multiple cancer types and expression of PD-L1 in intratumoral compartment has been suggested to influence immune response and act as a key determinant of checkpoint immunotherapy efficacy. Hence it becomes critical to understand the regulation of PD-L1 expression in cancer. Role of oncogenic signaling pathways and transcription factors such as PI3K-AKT, MEK-ERK, JAK-STAT, MYC, HIF-1 alpha, AP-1 and NF-kappa B is well established in inducing PD-L1 expression. Even the structural variations resulting in the truncation of the 3' untranslated region (UTR) of PD-L1 has been shown to upregulate PD-L1 expression in multiple cancer types. Since microRNAs carry out post-transcriptional gene silencing by binding to the 3' UTR of its target messenger RNA, truncation of PD-Lt 3' UTR can result in alleviation of PD-L1 suppression mediated by microRNA, leading to its overexpression. Other epigenetic modifications, such as promoter DNA methylation and histone modifications can also play crucial role in regulating PD-L1 expression. Here, we review recent findings and evidence on epigenetic mechanisms that regulate PD-L1 expression and the biological and clinical implications of such regulation in cancer.
AD  - All India Inst Med Sci, Dr B R Ambedkar Inst Rotary Canc Hosp, Dept Med Oncol, Room 401,4th Floor, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - DEC
PY  - 2018
VL  - 202
SP  - 129
EP  - 145
DO  - 10.1016/j.trsl.2018.05.011
AN  - WOS:000450541800010
ER  -

TY  - JOUR
AU  - Kumar, V
AU  - Goel, N
TI  - Congenital retinal macrovessel in a patient with rhegmatogenous retinal detachment
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaAD  - ICARE Eye Hosp & Post Grad Inst, Noida, Uttar Pradesh, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - DEC
PY  - 2018
VL  - 66
IS  - 12
SP  - 1860
EP  - +
DO  - 10.4103/ijo.IJO_838_18
AN  - WOS:000450676000042
ER  -

TY  - JOUR
AU  - Kusuma, YS
AU  - Pal, M
AU  - Babu, BV
TI  - Health Insurance: Awareness, Utilization, and its Determinants among the Urban Poor in Delhi, India
T2  - JOURNAL OF EPIDEMIOLOGY AND GLOBAL HEALTH
KW  - Health insurance
KW  - urban poor
KW  - migrants
KW  - ACCESS
KW  - MIGRATION
KW  - MIGRANTS
KW  - EQUALITY
KW  - COVERAGE
KW  - SCHEMES
KW  - EQUITY
KW  - IMPACT
KW  - CARE
AB  - This study reports the awareness, access, and utilization of health insurance by the urban poor in Delhi, India. The study included 2998 households from 85 urban clusters spread across Delhi. The data were collected through a pretested, interviewer-administered questionnaire. Logistic regression was performed for determinants of health insurance possession. Only 19% knew about health insurance; 18% had health insurance (Employees State Insurance Scheme - ESIS - 8%; Central Government Health Scheme - CGHS - 1.4%; Rashtriya Swasthya Bima Yojana (RSBY) - 9.4% of the eligible households). In case of health needs, 95% of CGHS, 71% ESIS beneficiaries, and 9.5% of RSBY beneficiaries utilized the schemes for episodic and chronic illnesses. For hospitalization needs, 54% of RSBY, 86% of ESIS, 100% CGHS utilized respective services. Residential area, migration period, possession of ration card, household size, and occupation of the head of the household were significantly associated with possession of RSBY. RSBY played a limited role in meeting the healthcare needs of the people, thus may not be capable of contributing significantly in the efforts of achieving equity in healthcare for the poor. Relatively, ESIS and CGHS served the healthcare needs of the beneficiaries better. Expansion of ESIS to the informal workers may be considered.
   HIGHLIGHTS
   Urban poor have limited awareness and access to health insurance.
   The mandatory health insurance schemes better served the healthcare needs.
   RSBY played a limited role in meeting the healthcare needs of the people.
   The type of slum, migration duration, and ration card were associated with RSBY enrollment. (C) 2018 Atlantis Press International B.V.
AD  - All India Inst Med Sci, Ctr Community Med, New Delhi, IndiaAD  - Indian Council Med Res, Sociobehav & Hlth Syst Res Div, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Council of Medical Research (ICMR)PU  - ATLANTIS PRESS
PI  - PARIS
PA  - 29 AVENUE LAUMIERE, PARIS, 75019, FRANCE
DA  - DEC
PY  - 2018
VL  - 8
IS  - 1-2
SP  - 69
EP  - 76
DO  - 10.2991/j.jegh.2018.09.004
AN  - WOS:000484415000012
ER  -

TY  - JOUR
AU  - Kyu, HH
AU  - Maddison, ER
AU  - Henry, NJ
AU  - Ledesma, JR
AU  - Wiens, KE
AU  - Reiner, R 
AU  - Biehl, MH
AU  - Shields, C
AU  - Osgood-Zimmerman, A
AU  - Ross, JM
AU  - Carter, A
AU  - Frank, TD
AU  - Wang, HD
AU  - Srinivasan, V
AU  - Abebe, Z
AU  - Agarwal, SK
AU  - Alahdab, F
AU  - Alene, KA
AU  - Ali, BA
AU  - Alvis-Guzman, N
AU  - Andrews, JR
AU  - Antonio, CAT
AU  - Atique, S
AU  - Atre, SR
AU  - Awasthi, A
AU  - Ayele, HT
AU  - Badali, H
AU  - Badawi, A
AU  - Barac, A
AU  - Bedi, N
AU  - Behzadifar, M
AU  - Behzadifar, M
AU  - Bekele, BB
AU  - Belay, SA
AU  - Bensenor, IM
AU  - Butt, ZA
AU  - Carvalho, F
AU  - Cercy, K
AU  - Christopher, DJ
AU  - Daba, AK
AU  - Dandona, L
AU  - Dandona, R
AU  - Daryani, A
AU  - Demeke, FM
AU  - Deribe, K
AU  - Dharmaratne, SD
AU  - Doku, DT
AU  - Dubey, M
AU  - Edessa, D
AU  - El-Khatib, Z
AU  - Enany, S
AU  - Fernandes, E
AU  - Fischer, F
AU  - Garcia-Basteiro, AL
AU  - Gebre, AK
AU  - Gebregergs, GB
AU  - Gebremichael, TG
AU  - Gelano, TF
AU  - Geremew, D
AU  - Gona, PN
AU  - Goodridge, A
AU  - Gupta, R
AU  - Bidgoli, HH
AU  - Hailu, GB
AU  - Hassen, HY
AU  - Hedayati, MTT
AU  - Henok, A
AU  - Hostiuc, S
AU  - Hussen, MA
AU  - Ilesanmi, OS
AU  - Irvani, SSN
AU  - Jacobsen, KH
AU  - Johnson, SC
AU  - Jonas, JB
AU  - Kahsay, A
AU  - Kant, S
AU  - Kasaeian, A
AU  - Kassa, TD
AU  - Khader, YS
AU  - Khafaie, MA
AU  - Khalil, I
AU  - Khan, EA
AU  - Khang, YH
AU  - Kim, YJ
AU  - Kochhar, S
AU  - Koyanagi, A
AU  - Krohn, KJ
AU  - Kumar, GA
AU  - Lakew, AM
AU  - Leshargie, CT
AU  - Lodha, R
AU  - Macarayan, ERK
AU  - Majdzadeh, R
AU  - Martins-Melo, FR
AU  - Melese, A
AU  - Memish, ZA
AU  - Mendoza, W
AU  - Mengistu, DT
AU  - Mengistu, G
AU  - Mestrovic, T
AU  - Moazen, B
AU  - Mohammad, KA
AU  - Mohammed, S
AU  - Mokdad, AH
AU  - Moosazadeh, M
AU  - Mousavi, SM
AU  - Mustafa, G
AU  - Nachega, JB
AU  - Nguyen, LH
AU  - Nguyen, SH
AU  - Nguyen, TH
AU  - Ningrum, DNA
AU  - Nirayo, YL
AU  - Nong, VM
AU  - Ofori-Asenso, R
AU  - Ogbo, FA
AU  - Oh, IH
AU  - Oladimeji, O
AU  - Olagunju, AT
AU  - Oren, E
AU  - Pereira, DM
AU  - Prakash, S
AU  - Qorbani, M
AU  - Rafay, A
AU  - Rai, RK
AU  - Ram, U
AU  - Rubino, S
AU  - Safiri, S
AU  - Salomon, JA
AU  - Samy, AM
AU  - Sartorius, B
AU  - Satpathy, M
AU  - Seyedmousavi, S
AU  - Sharif, M
AU  - Silva, JP
AU  - Silveira, DGA
AU  - Singh, JA
AU  - Sreeramareddy, CT
AU  - Tran, BX
AU  - Tsadik, AG
AU  - Ukwaja, KN
AU  - Ullah, I
AU  - Uthman, OA
AU  - Vlassov, V
AU  - Vollset, SE
AU  - Vu, G
AU  - Weldegebreal, F
AU  - Werdecker, A
AU  - Yimer, EM
AU  - Yonemoto, N
AU  - Yotebieng, M
AU  - Naghavi, M
AU  - Vos, T
AU  - Hay, SI
AU  - Murray, CJL
A1  - GBD TB Collaborators
TI  - Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study
T2  - LANCET INFECTIOUS DISEASES
KW  - DRUG-RESISTANT TUBERCULOSIS
KW  - SYSTEMATIC ANALYSIS
KW  - XPERT MTB/RIF
KW  - 195 COUNTRIES
KW  - MORTALITY
KW  - CARE
KW  - TERRITORIES
KW  - DISABILITY
KW  - HIV
AB  - Background Although a preventable and treatable disease, tuberculosis causes more than a million deaths each year. As countries work towards achieving the Sustainable Development Goal (SDG) target to end the tuberculosis epidemic by 2030, robust assessments of the levels and trends of the burden of tuberculosis are crucial to inform policy and programme decision making. We assessed the levels and trends in the fatal and non-fatal burden of tuberculosis by drug resistance and HIV status for 195 countries and territories from 1990 to 2016.
   Methods We analysed 15 943 site-years of vital registration data, 1710 site-years of verbal autopsy data, 764 site-years of sample-based vital registration data, and 361 site-years of mortality surveillance data to estimate mortality due to tuberculosis using the Cause of Death Ensemble model. We analysed all available data sources, including annual case notifications, prevalence surveys, population-based tuberculin surveys, and estimated tuberculosis cause-specific mortality to generate internally consistent estimates of incidence, prevalence, and mortality using DisMod-MR 2.1, a Bayesian meta-regression tool. We assessed how the burden of tuberculosis differed from the burden predicted by the Socio-demographic Index (SDI), a composite indicator of income per capita, average years of schooling, and total fertility rate.
   Findings Globally in 2016, among HIV-negative individuals, the number of incident cases of tuberculosis was 9.02 million (95% uncertainty interval [UI] 8.05-10.16) and the number of tuberculosis deaths was 1.21 million (1.16-1.27). Among HIV-positive individuals, the number of incident cases was 1.40 million (1.01-1.89) and the number of tuberculosis deaths was 0.24 million (0.16-0.31). Globally, among HIV-negative individuals the agestandardised incidence of tuberculosis decreased annually at a slower rate (-1.3% [-1.5 to-1.2]) than mortality did (-4.5% [-5.0 to-4.1]) from 2006 to 2016. Among HIV-positive individuals during the same period, the rate of change in annualised age-standardised incidence was-4.0% (-4.5 to -3.7) and mortality was-8.9% (-9.5 to-8.4). Several regions had higher rates of age-standardised incidence and mortality than expected on the basis of their SDI levels in 2016. For drug-susceptible tuberculosis, the highest observed-to-expected ratios were in southern sub-Saharan Africa (13.7 for incidence and 14.9 for mortality), and the lowest ratios were in high-income North America (0.4 for incidence) and Oceania (0.3 for mortality). For multidrug-resistant tuberculosis, eastern Europe had the highest observed-to-expected ratios (67.3 for incidence and 73.0 for mortality), and high-income North America had the lowest ratios (0.4 for incidence and 0.5 for mortality).
   Interpretation If current trends in tuberculosis incidence continue, few countries are likely to meet the SDG target to end the tuberculosis epidemic by 2030. Progress needs to be accelerated by improving the quality of and access to tuberculosis diagnosis and care, by developing new tools, scaling up interventions to prevent risk factors for tuberculosis, and integrating control programmes for tuberculosis and HIV. Copyright 2018 (c) The Author(s). Published by Elsevier Ltd.
AD  - Univ Washington, Dept Hlth Metr Sci, Seattle, WA 98195 USAAD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - Univ Washington, Dept Global Hlth, Seattle, WA 98195 USAAD  - Univ Washington, Seattle, WA 98195 USAAD  - All India Inst Med Sci, Dept Nephrol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Paediat, New Delhi, IndiaAD  - Mayo Clin Fdn Med Educ & Res, Evidence Based Practice Ctr, Rochester, MN USAAD  - Univ Gondar, Inst Publ Hlth, Gondar, EthiopiaAD  - Univ Gondar, Dept Med Microbiol, Gondar, EthiopiaAD  - Univ Gondar, Epidemiol & Biostat, Gondar, EthiopiaAD  - Univ Gondar, Dept Human Nutr, Gondar, EthiopiaAD  - Australian Natl Univ, Res Sch Populat Hlth, Canberra, ACT, AustraliaAD  - Erbil Polytech Univ, Med Tech Inst, Erbil, IraqAD  - Ishik Univ, Fac Pharm, Erbil, IraqAD  - Univ Cartagena, Hlth Econ Res Grp, Cartagena, ColombiaAD  - Univ Coast, Res Grp Hosp Management & Hlth Policies, Barranquilla, ColombiaAD  - Stanford Univ, Div Infect Dis & Geog Med, Stanford, CA USAAD  - Stanford Univ, Ctr Hlth Policy, Stanford, CA USAAD  - Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA USAAD  - Univ Philippines, Dept Hlth Policy & Adm, Manila, PhilippinesAD  - Univ Philippines, Dev & Commun Studies, Manila, PhilippinesAD  - Univ Lahore, Univ Inst Publ Hlth, Lahore, PakistanAD  - Univ Hail, Hail, Saudi ArabiaAD  - Johns Hopkins Univ, Ctr Clin Global Hlth Educ, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USAAD  - Patil Vidyapeeth, Patil Med Coll, Pune, Maharashtra, IndiaAD  - Indian Inst Publ Hlth, Gandhinagar, IndiaAD  - Publ Hlth Fdn India, Gurugram, IndiaAD  - McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, CanadaAD  - Dilla Univ, Dept Publ Hlth, Dilla, EthiopiaAD  - Mazandaran Univ Med Sci, Dept Med Mycol, Sari, IranAD  - Mazandaran Univ Med Sci, Toxoplasmosis Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Hlth Sci Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Invas Fungi Res Ctr, Sari, IranAD  - Publ Hlth Agcy Canada, Publ Hlth Risk Sci Div, Toronto, ON, CanadaAD  - Univ Toronto, Dept Nutrit Sci, Toronto, ON, CanadaAD  - Clin Ctr Serbia, Clin Infect & Trop Dis, Belgrade, SerbiaAD  - Univ Belgrade, Fac Med, Belgrade, SerbiaAD  - Gandhi Med Coll Bhopal, Dept Community Med, Bhopal, IndiaAD  - Jazan Univ, Jazan, Saudi ArabiaAD  - Iran Univ Med Sci, Hlth Management & Econ Res Ctr, Tehran, IranAD  - Lorestan Univ Med Sci, Social Determinants Hlth Res Ctr, Khorramabad, IranAD  - Mizan Tepi Univ, Dept Publ Hlth, Teppi, EthiopiaAD  - Mizan Tepi Univ, Teppi, EthiopiaAD  - Tewelde Legesse Hlth Sci Coll, Mekelle, EthiopiaAD  - Univ Sao Paulo, Dept Internal Med, Sao Paulo, BrazilAD  - Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, CanadaAD  - Al Shifa Trust Eye Hosp, Al Shifa Sch Publ Hlth, Rawalpindi, PakistanAD  - Univ Porto, Inst Publ Hlth, Porto, PortugalAD  - Univ Porto, REQUIMTE LAQV, Porto, PortugalAD  - Univ Porto, Ucibio, Porto, PortugalAD  - Univ Porto, Appl Mol Biosci Unit, Porto, PortugalAD  - Christian Med Coll & Hosp CMC, Dept Pulm Med, Vellore, Tamil Nadu, IndiaAD  - Hawassa Univ, Coll Med & Hlth Sci, Hawassa, EthiopiaAD  - Brighton & Sussex Med Sch, Dept Global Hlth & Infect, Brighton, E Sussex, EnglandAD  - Univ Addis Ababa, Sch Publ Hlth, Addis Ababa, EthiopiaAD  - Univ Peradeniya, Dept Community Med, Peradeniya, Sri LankaAD  - Univ Cape Coast, Dept Populat & Hlth, Cape Coast, GhanaAD  - Univ Tampere, Fac Social Sci Hlth Sci, Tampere, FinlandAD  - United Nations World Food Programme, New Delhi, IndiaAD  - Haramaya Univ, Sch Pharm, Harar, EthiopiaAD  - Haramaya Univ, Dept Med, Lab Sci, Harar, EthiopiaAD  - Haramaya Univ, Harar, EthiopiaAD  - Karolinska Inst, Dept Publ Hlth Sci, Stockholm, SwedenAD  - Suez Canal Univ, Dept Microbiol & Immunol, Ismailia, EgyptAD  - Univ Bielefeld, Dept Publ Hlth Med, Bielefeld, GermanyAD  - Manhica Hlth Res Ctr, TB, Manhica, MozambiqueAD  - Barcelona Inst Global Hlth, TB Dept, Barcelona, SpainAD  - Mekelle Univ, Sch Pharm, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Publ Hlth, Mekelle, EthiopiaAD  - Mekelle Univ, Div Biomed Sci, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Nutr & Dietet, Mekelle, EthiopiaAD  - Mekelle Univ, Clin Pharm Unit, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Med, Mekelle, EthiopiaAD  - Univ Massachusetts, Nursing & Hlth Sci Dept, Boston, MA USAAD  - Inst Sci Res & High Technol Serv, TB Biomarker Res Unit, City Of Knowledge, PanamaAD  - West Virginia Bur Publ Hlth, Commissioner Publ Hlth, Charleston, WV USAAD  - West Virginia Univ, Dept Hlth Policy Management & Leadership, Sch Publ Hlth, Morgantown, WV USAAD  - UCL, Inst Global Hlth, London, EnglandAD  - Univ Antwerp Hosp, Epidemiol & Social Med, Antwerp, BelgiumAD  - Carol Davila Univ Med & Pharm, Dept Legal Med & Bioeth, Fac Dent, Bucharest, RomaniaAD  - Jimma Univ, Dept Hlth Educ & Behav Sci, Jimma, EthiopiaAD  - Univ Liberia, Dept Publ Hlth & Community Med, Monrovia, CA, LiberiaAD  - Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Tehran, IranAD  - Univ Tehran Med Sci, Non Communicable Dis Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Oncol & Stem Cell Transplantat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Comm Based Participatory Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Dept Hlth Management & Econ, Tehran, IranAD  - Univ Tehran Med Sci, Ctr Expertise Microbiol, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Malignancies Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Knowledge Utilizat Res Ctr, Tehran, IranAD  - George Mason Univ, Dept Global & Community Hlth, Fairfax, VA USAAD  - Heidelberg Univ, Dept Ophthalmol, Mannheim, GermanyAD  - Heidelberg Univ, Inst Publ Hlth, Mannheim, GermanyAD  - Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R ChinaAD  - King Georges Med Univ, Dept Resp Med, Lucknow, Uttar Pradesh, IndiaAD  - Jordan Univ Sci & Technol, Dept Publ Hlth & Community Med, Ramtha, JordanAD  - Ahvaz Jundishapur Univ Med Sci, Dept Publ Hlth, Ahvaz, IranAD  - Hlth Serv Acad, Epidemiol & Biostat Dept, Islamabad, PakistanAD  - Seoul Natl Univ, Inst Hlth Policy & Management, Seoul, South KoreaAD  - Seoul Natl Univ, Dept Hlth Policy & Management, Seoul, South KoreaAD  - Xiamen Univ Malaysia, Sch Med, Sepang, MalaysiaAD  - Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterham, NetherlandsAD  - San Juan de Dios Sanit Pk, Res & Dev Unit, Sant Boi De Llobregat, SpainAD  - Debre Markos Univ, Dept Publ Hlth, Debre Markos, EthiopiaAD  - Harvard Univ, Ariadne Labs, Boston, MA USAAD  - Fed Inst Educ Sci & Technol Ceara, Caucaia, BrazilAD  - Debre Tabor Univ, Coll Hlth Sci, Debre Tabor, EthiopiaAD  - Minist Hlth, Prince Mohammed Bin Abdulaziz Hosp, Res Dept, Riyadh, Saudi ArabiaAD  - Alfaisal Univ, Coll Med, Riyadh, Saudi ArabiaAD  - United Nations Populat Fund UNFPA, Peru Country Off, Lima, PeruAD  - Wollo Univ, Dept Pharm, Dessie, EthiopiaAD  - Zora Profoz Polyclin, Clin Microbiol & Parasitol Unit, Zagreb, CroatiaAD  - Univ North, Univ Ctr Varazdin, Varazhdin, CroatiaAD  - Frankfurt Univ Appl Sci, Res Inst Addict, Frankfurt, GermanyAD  - Salahaddin Univ, Dept Biol, Erbil, IraqAD  - Ahmadu Bello Univ, Hlth Syst & Policy Res Unit, Zaria, NigeriaAD  - Nishtar Med Univ, Dept Pediat, Multan, PakistanAD  - Inst Mother & Child Care, Pediat & Pediat Pulmonol, Multan, PakistanAD  - Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USAAD  - Nguyen Tat Thanh Univ, Ctr Excellence Behav Hlth, Ho Chi Minh City, VietnamAD  - Nguyen Tat Thanh Univ, Ctr Excellence Behav Med, Ho Chi Minh City, VietnamAD  - State Univ Semarang, Dept Publ Hlth Sci, Kota Semarang, IndonesiaAD  - Taipei Med Univ, Grad Inst Biomed Informat, Taipei, TaiwanAD  - Duy Tan Univ, Inst Global Hlth Innovat, Hanoi, VietnamAD  - Monash Univ, Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic, AustraliaAD  - Independent Consultant, Accra, GhanaAD  - Univ Western Sydney, Penrith, NSW, AustraliaAD  - Kyung Hee Univ, Dept Prevent Med, Dongdaemun, South KoreaAD  - Human Sci Res Council, Durban, South AfricaAD  - Univ Namibia, Fac Hlth Sci, Sch Publ Hlth, Osakhati, NamibiaAD  - Univ Adelaide, Adelaide, SA, AustraliaAD  - Univ Lagos, Dept Psychiat, Lagos, NigeriaAD  - San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA USAAD  - Cartagena Univ, Cartagena, ColombiaAD  - Sanjay Gandhi Postgrad Inst Med Sci, Dept Nephrol, Lucknow, Uttar Pradesh, IndiaAD  - Univ Med Sci, Non Communicable Dis Res Ctr Alborz, Karaj, IranAD  - Contech Sch Publ Hlth, Dept Epidemiol & Biostat, Lahore, PakistanAD  - Soc Hlth & Demog Surveillance, Suri, IndiaAD  - Univ Goettingen, Dept Econ, Gottingen, GermanyAD  - Int Inst Populat Sci, Dept Publ Hlth & Mortal Studies, Bombay, Maharashtra, IndiaAD  - Univ Sassari, Dept Biomed Sci, Sassari, ItalyAD  - Maragheh Univ Med Sci, Managerial Epidemiol Res Ctr, Maragheh, IranAD  - Ain Shams Univ, Dept Entomol, Cairo, EgyptAD  - Univ Kwazulu Natal, Dept Publ Hlth Med, Durban, South AfricaAD  - Utkal Univ, Ugc Ctr Adv Study Psychol, Bhubaneswar, IndiaAD  - Udyam Global Assoc Sustainable Dev, Bhubaneswar, IndiaAD  - Islamic Azad Univ, Dept Basic Sci, Sari, IranAD  - Univ Brasilia, Brasilia, DF, BrazilAD  - Fed Minist Hlth, Dept Hlth Ind Complex & Innovat Hlth, Brasilia, DF, BrazilAD  - Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USAAD  - Univ Alabama Birmingham, Dept Med, Birmingham, AL USAAD  - Int Med Univ, Div Community Med, Kuala Lumpur, MalaysiaAD  - Hanoi Med Univ, Dept Hlth Econ, Hanoi, VietnamAD  - Fed Teaching Hosp, Dept Internal Med, Abakaliki, NigeriaAD  - Gomal Univ, Dera Ismail Khan, PakistanAD  - Mufti Mehmood Mem Teaching Hosp, Tb Culture Lab, Dera Ismail Khan, PakistanAD  - Univ Warwick, Div Hlth Sci, Coventry, W Midlands, EnglandAD  - Natl Res Univ, Higher Sch Econ, Dept Hlth Care Adm & Econ, Moscow, RussiaAD  - Fed Inst Populat Res, Demog Change & Ageing Res Area, Wiesbaden, GermanyAD  - Natl Ctr Neurol & Psychiat, Dept Psychopharmacol, Tokyo, JapanAD  - Coll Publ Hlth Ohio State Univ, Columbus, OH USAAD  - Univ Kinshasa, Sch Publ Hlth, Kinshasa, DEM REP CONGOC3  - University of WashingtonC3  - University of Washington SeattleC3  - Institute for Health Metrics & EvaluationC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Mayo ClinicC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - Australian National UniversityC3  - Erbil Polytechnic UniversityC3  - Universidad de CartagenaC3  - Universidad de la CostaC3  - Stanford UniversityC3  - Stanford UniversityC3  - Stanford UniversityC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - University of LahoreC3  - University Ha'ilC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Dr DY Patil Vidyapeeth PuneC3  - Dr D Y Patil Medical College, Hospital & Research CentreC3  - Public Health Foundation of IndiaC3  - McGill UniversityC3  - Dilla UniversityC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Public Health Agency of CanadaC3  - University of TorontoC3  - Clinical Centre of SerbiaC3  - University of BelgradeC3  - Jazan UniversityC3  - Iran University of Medical SciencesC3  - Lorestan University of Medical SciencesC3  - Universidade de Sao PauloC3  - University of British ColumbiaC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Hawassa UniversityC3  - University of BrightonC3  - University of SussexC3  - Addis Ababa UniversityC3  - University of PeradeniyaC3  - University of Cape CoastC3  - Tampere UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Karolinska InstitutetC3  - Egyptian Knowledge Bank (EKB)C3  - Suez Canal UniversityC3  - University of BielefeldC3  - Centro de Investigacao em Saude de ManhicaC3  - ISGlobalC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - University of Massachusetts SystemC3  - University of Massachusetts BostonC3  - West Virginia UniversityC3  - University of LondonC3  - University College LondonC3  - University of AntwerpC3  - Carol Davila University of Medicine & PharmacyC3  - Jimma UniversityC3  - Shahid Beheshti University Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - George Mason UniversityC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Capital Medical UniversityC3  - King George's Medical UniversityC3  - Jordan University of Science & TechnologyC3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Health Services AcademyC3  - Seoul National University (SNU)C3  - Seoul National University (SNU)C3  - Xiamen University Malaysia CampusC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - Harvard UniversityC3  - Instituto Federal do Ceara (IFCE)C3  - King Saud Bin Abdulaziz University for Health SciencesC3  - Prince Mohammed bin Abdulaziz Hospital - Al MadinahC3  - Ministry of Health - Saudi ArabiaC3  - Alfaisal UniversityC3  - University North - CroatiaC3  - Salahaddin UniversityC3  - Ahmadu Bello UniversityC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - Nguyen Tat Thanh University (NTTU)C3  - Nguyen Tat Thanh University (NTTU)C3  - Universitas Negeri SemarangC3  - Taipei Medical UniversityC3  - Duy Tan UniversityC3  - Monash UniversityC3  - Western Sydney UniversityC3  - Kyung Hee UniversityC3  - Human Sciences Research Council-South AfricaC3  - University of NamibiaC3  - University of AdelaideC3  - University of LagosC3  - California State University SystemC3  - San Diego State UniversityC3  - Universidad de CartagenaC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - University of GottingenC3  - International Institute for Population SciencesC3  - University of SassariC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - University of Kwazulu NatalC3  - Utkal UniversityC3  - Islamic Azad UniversityC3  - Universidade de BrasiliaC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - International Medical University MalaysiaC3  - Hanoi Medical UniversityC3  - Gomal UniversityC3  - University of WarwickC3  - HSE University (National Research University Higher School of Economics)C3  - National Center for Neurology & Psychiatry - JapanC3  - Universite de KinshasaPU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - DEC
PY  - 2018
VL  - 18
IS  - 12
SP  - 1329
EP  - 1349
DO  - 10.1016/S1473-3099(18)30625-X
AN  - WOS:000450899900030
ER  -

TY  - JOUR
AU  - Lavania, S
AU  - Das, R
AU  - Dhiman, A
AU  - Myneedu, VP
AU  - Verma, A
AU  - Singh, N
AU  - Sharma, TK
AU  - Tyagi, JS
TI  - Aptamer-Based TB Antigen Tests for the Rapid Diagnosis of Pulmonary Tuberculosis: Potential Utility in Screening for Tuberculosis
T2  - ACS INFECTIOUS DISEASES
KW  - aptamer
KW  - Mycobacterium tuberculosis
KW  - sputum
KW  - HspX detection
KW  - point-of-care test
KW  - electrochemical sensor
KW  - MYCOBACTERIUM-TUBERCULOSIS
KW  - GOLD NANOPARTICLES
KW  - NANOZYME ACTIVITY
KW  - SMEAR MICROSCOPY
KW  - MESSENGER-RNA
KW  - HSPX
KW  - GENERATION
KW  - ASSAY
AB  - Pulmonary tuberculosis is the most common manifestation of tuberculosis, and to this day, sputum smear microscopy remains the most widely used diagnostic test in resource-limited settings despite its suboptimal sensitivity. Here we report the development of two DNA aptamer-based diagnostic tests, namely aptamer linked immobilized sorbent assay (Aptamer ALISA) and electrochemical sensor (ECS), for the direct detection of a TB biomarker HspX in sputum. First we compared the performance of Aptamer ALISA with anti-HspX polyclonal antibody-based enzyme linked immunosorbent assay (Antibody ELISA) in a blinded study of 314 sputum specimens. Aptamer ALISA displayed a high sensitivity of 94.1% (95% CI 86.8-98%) as compared to 68.2% sensitivity (95% CI 57.2-77.9%) of Antibody ELISA (p-value < 0.05) using culture as the reference standard without compromising test specificity of 100%. Out of nine smear-negative culture-positive samples, six were positive by Aptamer ALISA and only two were detected by Antibody ELISA. ALISA detected as positive 80 of 85 culture-positive TB as compared to 57 of 81 diagnosed as TB by X-ray (p-value < 0.0001). These findings demonstrate the superiority of the aptamer-based test over smear microscopy, antibody-based ELISA, and chest X-ray for TB detection (p-value < 0.0001 for all). Further, we have developed a similar to 30 min point-of-care ECS test that discriminates between tuberculous and nontuberculous sputum with a sensitivity of similar to 92.3% and specificity of 91.2%. The tests developed in the current study cost similar to$1-3/test and have potential utility in active case finding in high-risk groups and screening for pulmonary TB among presumptive TB subjects.
AD  - All India Inst Med Sci, Dept Biotechnol, New Delhi 110029, IndiaAD  - Gautam Buddha Univ, Sch Biotechnol, Greater Noida 201308, Uttar Pradesh, IndiaAD  - AptaBharat Innovat Private Ltd, Translat Hlth Sci & Technol Inst Incubator, Faridabad 121001, Haryana, IndiaAD  - UTU, Fac Pharm, Dehra Dun 248007, Uttarakhand, IndiaAD  - Natl Inst TB & Resp Dis, Dept Microbiol, New Delhi 110030, IndiaAD  - NCR Biotech Sci Cluster, Translat Hlth Sci & Technol Inst, Ctr Biodesign & Diagnost, Third Milestone,POB 04, Faridabad 121001, IndiaAD  - Indian Inst Technol, Dept Biochem Engn & Biotechnol, Room 335,Block 1, Delhi 110016, IndiaAD  - Indian Inst Technol, Ctr Biomed Engn, Mol Resolved Nanobiomed Lab, Delhi 110016, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Gautam Buddha UniversityC3  - Uttarakhand Technical UniversityC3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)C3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiPU  - AMER CHEMICAL SOC
PI  - WASHINGTON
PA  - 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
DA  - DEC
PY  - 2018
VL  - 4
IS  - 12
SP  - 1718
EP  - 1726
DO  - 10.1021/acsinfecdis.8b00201
AN  - WOS:000453803100008
ER  -

TY  - JOUR
AU  - Malgulwar, PB
AU  - Nambirajan, A
AU  - Pathak, P
AU  - Rajeshwari, M
AU  - Suri, V
AU  - Sarkar, C
AU  - Singh, M
AU  - Sharma, MC
TI  - Epithelial-to-mesenchymal transition related transcription factors are up-regulated in ependymomas and correlate with a poor prognosis
T2  - HUMAN PATHOLOGY
KW  - Ependymomas
KW  - EMT
KW  - Snail/SNA11
KW  - Slug/SNA12
KW  - Twist1
KW  - Molecular subgroups
KW  - C11ORF95-RELA FUSION PRESENT
KW  - E-CADHERIN
KW  - SUPRATENTORIAL EPENDYMOMA
KW  - DIFFERENTIAL EXPRESSION
KW  - BETA-CATENIN
KW  - N-CADHERIN
KW  - PATHWAY
KW  - GLIOBLASTOMA
KW  - COMPARTMENTS
KW  - INVASION
AB  - Epithelial-to-mesenchymal transition (EMT) plays an important role in invasion and metastasis of various cancers including gliomas. EMT has also been linked to cancer stem cells and resistance to chemotherapy. An initial in-silico data mining in a published ependymoma (EPN) patient series (GSE21687) revealed up-regulation of EMT transcription factors in tumor samples. Furthermore, quantitative real-time polymerase chain reaction based gene expression analysis of EMT transcription factors in 96 EPNs showed significant up-regulation of SNAI1, SNAI2,ZEB1, and TWIST] as compared with normal brain, associated with up-regulation of CDH2/N-cadherin and down-regulation of CDH1/E-cadherin. Although this was observed in varying degrees in all clinicopathological-molecular subgroups of EPNs, it was most evident in supratentorial EPNs harboring fusions of RELA (v-rel avian reticuloendotheliosis viral oncogene homolog A) gene and in posterior fossa EPNs. Immunohistochemistry performed in 60 of the above cases corroborated with gene expression patterns, and immunopositivity for Snail, Slug, Zeb1, and Twist1 was observed in 80%, 80%, 81%, and 63% of all EPNs. Immunopositivity for N-cadherin and E-cadherin was observed in 76.6% and 2% of the cases, respectively. Univariate Cox regression analysis showed that low expression of CDH1/E-cadherin (P =.002) and high expression levels of CDH2/N-cadherin (P<.001), SNAl1/Snail (P =.023), SNAI2/Slug (P <.001), and ZEB1 (P <.001) were associated with shorter progression-free survival. Here, we report for the first time the existence of EMT-like phenotype in EPNs. These factors could represent new prognostic and therapeutic targets in EPN. (C) 2018 Elsevier Inc. All rights reserved.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - W B SAUNDERS CO-ELSEVIER INC
PI  - PHILADELPHIA
PA  - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
DA  - DEC
PY  - 2018
VL  - 82
SP  - 149
EP  - 157
DO  - 10.1016/j.humpath.2018.07.018
AN  - WOS:000454968800018
ER  -

TY  - JOUR
AU  - Misra, A
AU  - Sattar, N
AU  - Tandon, N
AU  - Shrivastava, U
AU  - Vikram, NK
AU  - Khunti, K
AU  - Hills, AP
TI  - Clinical management of type 2 diabetes in south Asia
T2  - LANCET DIABETES & ENDOCRINOLOGY
KW  - CORONARY-HEART-DISEASE
KW  - GLYCEMIC CONTROL
KW  - METABOLIC SYNDROME
KW  - NONCOMMUNICABLE DISEASES
KW  - CARDIOVASCULAR OUTCOMES
KW  - ALTERNATIVE MEDICINES
KW  - INSULIN SENSITIVITY
KW  - DEVELOPING-COUNTRY
KW  - PHYSICAL-ACTIVITY
KW  - BODY-COMPOSITION
AB  - Compared with other ethnic groups, south Asian people with type 2 diabetes tend to develop the disease at a younger age and manifest with higher glycaemia, dyslipidaemia, nephropathy, and cardiovascular diseases. Additionally, specific issues that can affect treatment of type 2 diabetes in south Asia include poor awareness of the disease, delay in diagnosis, inadequate treatment, the use of ineffective and often harmful alternative medicines, and frequent noncompliance with lifestyle recommendations and drug treatment. Disease development at younger ages, delayed diagnosis, and inadequate management result in early development of severe complications and premature mortality. In this Series paper, we describe the challenges associated with the increasing burden of type 2 diabetes in south Asia and discuss ways to improve clinical care of people with the disorder in the region (defined to include Bangladesh, Bhutan, India, Nepal, Pakistan, and Sri Lanka). Treatment of diabetes in south Asia needs to be individualised on the basis of diverse and heterogeneous lifestyle, phenotype, environmental, social, cultural, and economic factors. Aggressive management of risk factors from diagnosis is necessary to reduce the risk of microvascular and macrovascular complications, focusing on provision of basic treatments (eg, metformin, low-cost statins, and blood pressure-lowering drugs) and other interventions such as smoking cessation. Strengthening of the primary care model of care, better referral linkages, and implementation of rehabilitation services to care for patients with chronic complications will be important. Finally, improvement of physicians' skills, provision of relevant training to nonphysician health-care workers, and the development and regular updating of national clinical management guidelines will also be crucial to improve diabetes care in the region.
AD  - Fortis C DOC Ctr Excellence Diabet Metab Dis & En, B16, New Delhi 110048, IndiaAD  - Natl Diabet Obes & Cholesterol Fdn, New Delhi, IndiaAD  - Diabet Fdn India, New Delhi, IndiaAD  - Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, ScotlandAD  - All India Inst Med Sci, Dept Endocrinol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Med, New Delhi, IndiaAD  - Univ Leicester, Diabet Res Ctr, Leicester Gen Hosp, Leicester, Leics, EnglandAD  - Univ Tasmania, Sch Hlth Sci, Coll Hlth & Med, Launceston, Tas, AustraliaC3  - University of GlasgowC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of LeicesterC3  - University Hospitals of Leicester NHS TrustC3  - Leicester General HospitalC3  - University of TasmaniaPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - DEC
PY  - 2018
VL  - 6
IS  - 12
SP  - 979
EP  - 991
DO  - 10.1016/S2213-8587(18)30199-2
AN  - WOS:000450920800014
ER  -

TY  - JOUR
AU  - Mochan, S
AU  - Bhatla, N
AU  - Luthra, K
AU  - Kumar, R
AU  - Dwivedi, S
AU  - Sharma, A
AU  - Dhingra, R
TI  - Role of sVEGFR (sFlt-1) in inducing endoplasmic reticulum stress in trophoblast cells and its status in preeclampsia
T2  - JOURNAL OF THE ANATOMICAL SOCIETY OF INDIA
KW  - sFlt-1
KW  - Endoplasmic reticulum stress
KW  - Trophoblast cells
KW  - Preeclampsia
KW  - OXIDATIVE STRESS
KW  - DEATH
AB  - Introduction: Preeclampsia (PE) and its subtypes (early and late onset) are serious concerns all across the globe affecting about 8% of overall pregnancies and accounts for approximately 60,000 deaths annually with a predominance in developing countries. The two-stage model, deficient spiral artery remodelling (stage I) and an imbalance between angiogenic and anti-angiogenic factor(s) (stage II) are well established facts so far. Increased sFlt-1 along with high oxidative stress and endoplasmic reticulum stress (ER stress) have recently been suggested in pregnancies with PE. The second decade of 21st century highlighted a new window to explore further the role of endoplasmic reticulum stress in the onset of the variant forms of PE. In our previous studies, we reported apoptosis and oxidative stress, induced by sFlt-1 in trophoblast cells. However, the role of sFlt-1 in inducing ER stress is still an unrevealed hugger-mugger till date.
   Methods: Study was divided into two parts (1) Serum Analysis of sFlt-1 and GRP78 was done using ELISA (2) In Vitro experiments: Activation of ER stress markers (GRP78, eIF2 alpha and CHOP) were assessed at various time points (8 h, 14 h, 24 h) at protein (Immunofluorescence, Western blot) and transcript level (qRT-PCR).
   Results: Significant raised levels of sFlt-1 and GRP78 in preeclamptic sera was found. We observed significant ER stress in the placental cells (BeWo Cells) (in vitro) when exposed to normotensive sera with recombinant sFlt-1 and also when treated with recombinant sFlt-1 alone.
   Discussion: We reported significant ER stress in the placental cells (BeWo Cells) (in vitro) when exposed to normotensive sera with recombinant sFlt-1 and also when treated with recombinant sFlt-1 alone. (C) 2018 Published by Elsevier, a division of RELX India, Pvt. Ltd on behalf of Anatomical Society of India.
AD  - AIIMS, Dept Anat, New Delhi 110029, IndiaAD  - AIIMS, Dept Obstet & Gynaecol, New Delhi 110029, IndiaAD  - AIIMS, Dept Biochem, New Delhi 110029, IndiaAD  - Med Council India, Pocket 14,Sect 8,Phase 1, New Delhi 110077, IndiaAD  - AIIMS, Dept Biostat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - DEC
PY  - 2018
VL  - 67
IS  - 2
SP  - 93
EP  - 103
DO  - 10.1016/j.jasi.2018.11.003
AN  - WOS:000452321500001
ER  -

TY  - JOUR
AU  - Mukhija, R
AU  - Gupta, N
AU  - Ganger, A
AU  - Kashyap, S
AU  - Hussain, N
AU  - Vanathi, M
AU  - Tandon, R
TI  - Isolated Primary Corneal Acremonium Eumycetoma: Case Report and Literature Review
T2  - CORNEA
KW  - fungal keratitis
KW  - Acremonium
KW  - eumycetoma
KW  - MYCETOMA
KW  - INFECTION
AB  - Purpose: To report an unusual case of isolated Acremonium eumycetoma presenting as a protuberant mass over the cornea. Methods: Case report and literature review. Results: A 55-year-old male patient referred to our center with a case of perforated corneal ulcer with uveal tissue prolapse was examined in the casualty department and found to have central melt, approximately 8 mm, along with suspected uveal tissue prolapse. A provisional diagnosis of sloughed corneal ulcer with uveal prolapse was made along with differential diagnoses of fungal ball and infected foreign body granuloma. Tectonic penetrating keratoplasty under general anesthesia was planned. Intraoperatively, the suspected uveal (brown colored) tissue was found to be an epicorneal mass growing over an intact and infiltrated cornea. Histopathological and microbiological analysis of the epicorneal mass and host cornea revealed it to be a fungal ball (mass full of septate hyphae) with growth of Acremonium species on culture. The patient was administered topical and oral antifungal agents postoperatively, in addition to topical antibiotics and cycloplegics. Conclusions: Isolated corneal Acremonium eumycetoma masquerading as a perforated corneal ulcer with prolapsed uveal tissue is a rare entity. Surgical intervention and appropriate antimicrobial therapy are key to successful outcome.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Cornea Cataract & Refract Surg Serv, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Ocular Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Ocular Microbiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - DEC
PY  - 2018
VL  - 37
IS  - 12
SP  - 1590
EP  - 1592
DO  - 10.1097/ICO.0000000000001750
AN  - WOS:000456287700023
ER  -

TY  - JOUR
AU  - Nagori, SA
AU  - Jose, A
AU  - Gopalakrishnan, V
AU  - Roy, ID
AU  - Chattopadhyay, PK
AU  - Roychoudhury, A
TI  - The efficacy of dextrose prolotherapy over placebo for temporomandibular joint hypermobility: A systematic review and meta-analysis
T2  - JOURNAL OF ORAL REHABILITATION
KW  - dextrose
KW  - dislocation
KW  - joint hypermobility
KW  - meta-analysis
KW  - prolotherapy
KW  - DOUBLE-BLIND
KW  - RECURRENT DISLOCATION
KW  - MANAGEMENT
KW  - SUBLUXATION
KW  - INJECTIONS
AB  - Objective The aim of the systematic review was to analyse the available evidence in order to assess the efficacy of dextrose prolotherapy in improving outcomes in temporomandibular joint (TMJ) hypermobility patients as compared to placebo. Methods An electronic search of PubMed, Scopus, CENTRAL and Google scholar databases was performed for English language papers published up to February 2018. Randomised clinical trials (RCTs) and controlled clinical trials (CCTs) comparing dextrose prolotherapy with placebo for TMJ hypermobility were included. Results Three RCTs were included in the review. Frequency of subluxation/dislocation was reported by two trials which found no difference between dextrose and placebo. A statistical significant difference in reduction of MMO with the use of dextrose prolotherapy was seen on pooling of data (random: MD = -3.32, 95% CI -5.26 to -1.28; P = 0.0008; I-2 = 0%). A statistical significant difference in pain reduction was also seen with dextrose as compared to placebo (random: MD = -1, 95% CI -1.58 to -0.42; P = 0.0007; I-2 = 0%). Conclusion Within the limitations of the study, dextrose prolotherapy may cause significant reduction in mouth opening and pain associated with TMJ hypermobility. Conclusion s with regard to reduction of episodes of subluxation/dislocation cannot be drawn. There is a need of more high-quality RCTs with larger sample size and homogenous prolotherapy protocol to draw stronger conclusions on the effect of dextrose prolotherapy in patients with TMJ hypermobility.
AD  - Army Dent Ctr Res & Referral, Div Oral & Maxillofacial Surg, New Delhi, IndiaAD  - Mil Dent Ctr Kirkee, Oral & Maxillofacial Surg, Pune, Maharashtra, IndiaAD  - All India Inst Med Sci, Dept Oral & Maxillofacial Surg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - DEC
PY  - 2018
VL  - 45
IS  - 12
SP  - 998
EP  - 1006
DO  - 10.1111/joor.12698
AN  - WOS:000449693300012
ER  -

TY  - JOUR
AU  - Nambirajan, A
AU  - Jain, D
TI  - Cell blocks in cytopathology: An update
T2  - CYTOPATHOLOGY
KW  - ancillary tests
KW  - cell block
KW  - Cellient
KW  - cytology
KW  - update
KW  - FINE-NEEDLE-ASPIRATION
KW  - IN-SITU HYBRIDIZATION
KW  - FACTOR RECEPTOR 2
KW  - YOUNG INVESTIGATOR CHALLENGE
KW  - HILAR ADENOPATHY SAMPLES
KW  - LAYER CERVICAL CYTOLOGY
KW  - LIQUID-BASED CYTOLOGY
KW  - LUNG-CANCER PATIENTS
KW  - BREAST-CANCER
KW  - PROGESTERONE-RECEPTOR
AB  - The cell block (CB) offers many advantages over other cytological preparations, particularly for immunocytochemical and molecular testing. However, inconsistent cellularity remains the most common reason for dissatisfaction among cytopathologists. In recent years, there has been a surge in the demand for CBs imposed by the increasing number of minimally invasive procedures performed to obtain material for diagnostic, prognostic and predictive purposes from advanced stage cancer patients. However, routine preparation of CBs significantly increases laboratory work load, operating cost and sample turn-around time. The objectives of our review were to: (a) identify scenarios where a CB is likely to improve diagnostic yield; (b) optimise CB preparatory methods; and (c) understand the factors influencing the success and validity of ancillary testing on various types of CBs. We performed an extensive literature search on CBs in cytology on internet search engines using the following keywords: cell block, cytoblock, cytology, cytopathology, methods, preparation, fixatives, diagnostic yield, ancillary and molecular studies. New CB methods, improvisations of previous CB methods, their utility for diagnosis, immunocytochemistry and molecular testing, and role in predictive biomarker testing are discussed in this review. CBs of good quality and cellularity outperform other cytology preparations in their reliability and versatility for ancillary testing. With many CB methods described in the literature, each with specific advantages and limitations, laboratories may choose to use one or more of the methods depending upon their infrastructure, expertise and workload.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - DEC
PY  - 2018
VL  - 29
IS  - 6
SP  - 505
EP  - 524
DO  - 10.1111/cyt.12627
AN  - WOS:000450274200001
ER  -

TY  - JOUR
AU  - Nayak, M
AU  - Nag, HL
AU  - Gaba, S
AU  - Nag, TC
AU  - Sharma, S
TI  - Quantitative correlation of mechanoreceptors in tibial remnant of ruptured human anterior cruciate ligament with duration of injury and its significance: an immunohistochemistry-based observational study
T2  - JOURNAL OF ORTHOPAEDICS AND TRAUMATOLOGY
KW  - Anterior cruciate ligament (ACL)
KW  - Proprioception
KW  - Mechanoreceptors
KW  - Immunohistochemistry
KW  - Neurofilament protein (NFP)
KW  - KNEE-JOINT
KW  - NERVE-ENDINGS
KW  - RECONSTRUCTION
KW  - PROPRIOCEPTION
KW  - INNERVATION
KW  - NEURONS
AB  - BackgroundProprioception is a specialized sensory modality encompassing the movement of the joint and its position in space. Reconstruction of the anterior cruciate ligament (ACL) does not always yield expected outcome, suggesting that successful reconstruction depends on not only the ultimate strength of the graft but also recovery of proprioception. Treatment delay is a significant concern in developing countries, e.g., in Asia. Thus, presence of mechanoreceptors is one of the factors having paramount importance for successful outcome. We conducted this study to identify mechanoreceptors via immunohistochemical staining and correlate their presence with duration of injury.Materials and methodsA total of 38 injured native ACL stumps were harvested from patients undergoing ACL reconstruction and stained with neurofilament protein stain to detect functional mechanoreceptors.ResultsOf the specimens, 44.7% stained positive for monoclonal antibody. No association was found between duration of injury and presence of mechanoreceptors (p=0.897). No correlation was seen between age and side.ConclusionsNo correlation was found between duration of injury and presence of viable mechanoreceptors, hence it is beneficial to preserve the native ACL stump irrespective of the time interval between injury and surgery.Level of EvidenceIII.
AD  - AIIMS, Dept Orthopaed, New Delhi 110029, IndiaAD  - AIIMS, Dept Anat, New Delhi, IndiaAD  - AIIMS, Jodhpur, Rajasthan, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) JodhpurPU  - SPRINGER
PI  - NEW YORK
PA  - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
DA  - DEC
PY  - 2018
VL  - 19
IS  - 1
C7  - 5
DO  - 10.1186/s10195-018-0498-7
AN  - WOS:000443703800001
ER  -

TY  - JOUR
AU  - Panda, S
AU  - Phalak, M
AU  - Thakar, A
AU  - Dharanipathy, S
TI  - Cerebrospinal Fluid Leak in Juvenile Nasopharyngeal Angiofibroma-Rare Sequelae of Flutamide-Induced Tumor Shrinkage
T2  - WORLD NEUROSURGERY
KW  - Anterior skull base
KW  - CSF rhinorrhea
KW  - Flutamide
KW  - JNA
KW  - Maxillary osteoplastic flap technique
KW  - Suprastructural maxillary swing
KW  - Tumor shrinkage
KW  - ENDOTHELIAL GROWTH-FACTOR
KW  - BONE-MINERAL DENSITY
AB  - BACKGROUND: Nonsteroidal androgen receptor blockers like flutamide have been described as an adjuvant treatment for preoperative shrinkage of extensive juvenile nasopharyngeal angiofibroma. We present a case of cerebrospinal fluid (CSF) leak due to flutamide-induced tumor shrinkage.
   CASE REPORT: A 15-year-old male with a prior diagnosis of juvenile naso-pharyngeal angiofibroma stage IIIB on preoperative flutamide for 3.5 weeks presented with altered sensorium, meningeal signs, and clear watery nasal discharge consistent with CSF leak. Computed tomogram of the head revealed air in the ventricle and repeat contrast-enhanced magnetic resonance imaging showed significant tumor shrinkage in the area of the anterior skull base. This patient had an atypical pattern of tumor extension into the anterior skull base through the roof of posterior ethmoid and sphenoid sinus, which are inherently weak areas of the skull base, thereby predisposing the CSF leak on tumor shrinkage.
   CONCLUSION: CSF leak is a rare complication following flutamide therapy, especially large areas of the anterior skull base are involved.
AD  - All India Inst Med Sci, Dept Otolaryngol & Head & Neck Surg, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - DEC
PY  - 2018
VL  - 120
SP  - 78
EP  - 81
DO  - 10.1016/j.wneu.2018.07.288
AN  - WOS:000450668300167
ER  -

TY  - JOUR
AU  - Panwar, R
AU  - Mohapatra, V
AU  - Raichurkar, K
AU  - Sahni, P
TI  - Development and validation of a new score for measuring post-operative complications
T2  - LANGENBECKS ARCHIVES OF SURGERY
KW  - Morbidity
KW  - Clavien-Dindo
KW  - Comprehensive complication index
KW  - Complication severity score
KW  - Post-operative complications
KW  - INTERNATIONAL STUDY-GROUP
KW  - INDEX
KW  - CLASSIFICATION
AB  - PurposeAssigning a numerical value to post-operative morbidity may improve its usefulness as an outcome measure. The recently developed Comprehensive Complication Index (CCI) is a step forward in this process but assigns an inappropriately high score to a combination of complications.MethodsWe developed a new score called the complication severity score (CSS) using a mathematical process and compared it with the CCI using a questionnaire-based survey of 49 experienced gastrointestinal and hepato-pancreatico-biliary surgeons. The CSS was modified based on the results of this survey and was correlated with other patient-centered outcomes in a prospective cohort of consecutive patients undergoing elective surgery.ResultsOf the nine sets of scenarios, experienced surgeons' opinion matched with CSS in 6, CSS as well as CCI in 1, and neither CSS nor CCI in 2 scenarios. Of the total 441 responses, 281 matched with CSS while 143 matched with CCI (p=0.0001, odds ratio: 3.7; 95% CI: 2.8 to 4.8). The modified CSS significantly correlated with the post-operative length of stay (r=0.76; 95% CI: 0.68 to 0.82; p<0.001), the length of ICU stay (r=0.61; 95% CI: 0.50 to 0.70; p<0.001) and with the difference between pre-operative and post-operative quality of life scores in the physical (r=0.29; 95% CI: 0.14 to 0.42; p<0.001) and social (r=0.29; 95% CI: 0.14 to 0.43; p<0.001) domains.ConclusionsThe CSS more often matched the opinion of experienced senior surgeons compared to CCI. The modified CSS significantly correlated with other patient-centered outcomes.
AD  - All India Inst Med Sci, Dept Gastrointestinal Surg & Liver Transplantat, Room 1007,Acad Block, Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - DEC
PY  - 2018
VL  - 403
IS  - 8
SP  - 1021
EP  - 1027
DO  - 10.1007/s00423-018-1701-2
AN  - WOS:000455498000013
ER  -

TY  - JOUR
AU  - Passah, A
AU  - Kaushik, P
AU  - Patel, C
AU  - Parakh, N
TI  - Gallium-68 DOTANOC scan in a patient withsuspected cardiac sarcoidosis
T2  - JOURNAL OF NUCLEAR CARDIOLOGY
AD  - All India Inst Med Sci, Dept Nucl Med, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - DEC
PY  - 2018
VL  - 25
IS  - 6
SP  - 2177
EP  - 2178
DO  - 10.1007/s12350-017-1178-3
AN  - WOS:000452340400049
ER  -

TY  - JOUR
AU  - Prabhakaran, D
AU  - Jeemon, P
AU  - Sharma, M
AU  - Roth, GA
AU  - Johnson, C
AU  - Harikrishnan, S
AU  - Gupta, R
AU  - Pandian, JD
AU  - Naik, N
AU  - Roy, A
AU  - Dhaliwal, RS
AU  - Xavier, D
AU  - Kumar, RK
AU  - Tandon, N
AU  - Mathur, P
AU  - Shukla, DK
AU  - Mehrotra, R
AU  - Venugopal, K
AU  - Kumar, GA
AU  - Varghese, CM
AU  - Furtado, M
AU  - Muraleedharan, P
AU  - Abdulkader, RS
AU  - Alam, T
AU  - Anjana, RM
AU  - Arora, M
AU  - Bhansali, A
AU  - Bhardwaj, D
AU  - Bhatia, E
AU  - Chakma, JK
AU  - Chaturvedi, P
AU  - Dutta, E
AU  - Glenn, S
AU  - Gupta, PC
AU  - Johnson, SC
AU  - Kaur, T
AU  - Kinra, S
AU  - Krishnan, A
AU  - Kutz, M
AU  - Mathur, MR
AU  - Mohan, V
AU  - Mukhopadhyay, S
AU  - Nguyen, M
AU  - Odell, CM
AU  - Oommen, AM
AU  - Pati, S
AU  - Pletcher, M
AU  - Prasad, K
AU  - Rao, P
AU  - Shekhar, C
AU  - Sinha, DN
AU  - Sylaja, PN
AU  - Thakur, JS
AU  - Thankappan, KR
AU  - Thomas, N
AU  - Yadgir, S
AU  - Yajnik, CS
AU  - Zacharia, G
AU  - Zipkin, B
AU  - Lim, SS
AU  - Naghavi, M
AU  - Dandona, R
AU  - Vos, T
AU  - Murray, CJL
AU  - Reddy, KS
AU  - Swaminathan, S
AU  - Dandona, L
A1  - India State Level Dis Burden Initi
TI  - The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990-2016
T2  - LANCET GLOBAL HEALTH
KW  - HEART-DISEASE
KW  - EPIDEMIOLOGY
KW  - HYPERTENSION
KW  - STROKE
KW  - HEALTH
AB  - Background The burden of cardiovascular diseases is increasing in India, but a systematic understanding of its distribution and time trends across all the states is not readily available. In this report, we present a detailed analysis of how the patterns of cardiovascular diseases and major risk factors have changed across the states of India between 1990 and 2016.
   Methods We analysed the prevalence and disability-adjusted life-years (DALYs) due to cardiovascular diseases and the major component causes in the states of India from 1990 to 2016, using all accessible data sources as part of the Global Burden of Diseases, Injuries, and Risk Factors Study 2016. We placed states into four groups based on epidemiological transition level (ETL), defined using the ratio of DALYs from communicable diseases to those from non-communicable diseases and injuries combined, with a low ratio denoting high ETL and vice versa. We assessed heterogeneity in the burden of major cardiovascular diseases across the states of India, and the contribution of risk factors to cardiovascular diseases. We calculated 95% uncertainty intervals (UIs) for the point estimates.
   Findings Overall, cardiovascular diseases contributed 28.1% (95% UI 26.5-29.1) of the total deaths and 14.1% (12.9-15.3) of the total DALYs in India in 2016, compared with 15.2% (13.7-16.2) and 6.9% (6.3-7.4), respectively, in 1990. In 2016, there was a nine times difference between states in the DALY rate for ischaemic heart disease, a six times difference for stroke, and a four times difference for rheumatic heart disease. 23.8 million (95% UI 22.6-25.0) prevalent cases of ischaemic heart disease were estimated in India in 2016, and 6.5 million (6.3-6.8) prevalent cases of stroke, a 2.3 times increase in both disorders from 1990. The age-standardised prevalence of both ischaemic heart disease and stroke increased in all ETL state groups between 1990 and 2016, whereas that of rheumatic heart disease decreased; the increase for ischaemic heart disease was highest in the low ETL state group. 53.4% (95% UI 52.6-54.6) of crude deaths due to cardiovascular diseases in India in 2016 were among people younger than 70 years, with a higher proportion in the low Ell state group. The leading overlapping risk factors for cardiovascular diseases in 2016 included dietary risks (56.4% [95% CI 48.5-63.9] of cardiovascular disease DALYs), high systolic blood pressure (54.6% [49.0-59.8]), air pollution (31.1% [29.0-33.4]), high total cholesterol (29.4% [24.3-34.8]), tobacco use (18.9% [16.6-21.3]), high fasting plasma glucose (16.7% [11.4-23.5]), and high body-mass index (14.7% [8.3-22.0]). The prevalence of high systolic blood pressure, high total cholesterol, and high fasting plasma glucose increased generally across all ETL state groups from 1990 to 2016, but this increase was variable across the states; the prevalence of smoking decreased during this period in all ETL state groups.
   Interpretation The burden from the leading cardiovascular diseases in India-ischaemic heart disease and stroke- varies widely between the states. Their increasing prevalence and that of several major risk factors in every part of India, especially the highest increase in the prevalence of ischaemic heart disease in the less developed low ETL states, indicates the need for urgent policy and health system response appropriate for the situation in each state. Copyright (C) 2018 The Author(s). Published by Elsevier Ltd.
AD  - Publ Hlth Fdn India, Gurugram 122002, National Capita, IndiaAD  - Achutha Menon Ctr Hlth Sci Studies, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Dept Cardiol, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Dept Neurol, Trivandrum, Kerala, IndiaAD  - Indian Council Med Res, New Delhi, IndiaAD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - Rajasthan Univ Hlth Sci, Jaipur, Rajasthan, IndiaAD  - Christian Med Coll & Hosp, Dept Neurol, Ludhiana, Punjab, IndiaAD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi, IndiaAD  - All India Inst Med Sci, Ctr Community Med, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaAD  - St Johns Med Coll, Dept Pharmacol, Bengaluru, IndiaAD  - St Johns Res Inst, Div Clin Res & Training, Bengaluru, IndiaAD  - Amrita Univ, Amrita Inst Med Sci, Dept Paediat Cardiol, Cochin, Kerala, IndiaAD  - Amrita Univ, Res Ctr, Cochin, Kerala, IndiaAD  - Indian Council Med Res, Natl Ctr Dis Informat & Res, Bengaluru, IndiaAD  - Indian Council Med Res, Natl Inst Canc Prevent & Res, Noida, IndiaAD  - Pushpagiri Inst Med Sci, Dept Cardiol, Tiruvalla, IndiaAD  - Manonmaniam Sundaranar Univ, Dept Stat, Tirunelveli, IndiaAD  - Madras Diabet Res Fdn, Madras, Tamil Nadu, IndiaAD  - Dr Mohans Diabet Special Ctr, Madras, Tamil Nadu, IndiaAD  - Postgrad Inst Med Educ & Res, Dept Endocrinol, Chandigarh, IndiaAD  - Postgrad Inst Med Educ & Res, Sch Publ Hlth, Chandigarh, IndiaAD  - Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrinol, Lucknow, Uttar Pradesh, IndiaAD  - Tata Mem Hosp, Dept Head & Neck Oncol, Bombay, Maharashtra, IndiaAD  - Healis Sekhsaria Inst Publ Hlth, Bombay, Maharashtra, IndiaAD  - London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, EnglandAD  - Inst Postgrad Med Educ & Res, Dept Endocrinol & Metab, Kolkata, IndiaAD  - Christian Med Coll & Hosp, Community Hlth Dept, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp, Dept Endocrinol Diabet & Metab, Vellore, Tamil Nadu, IndiaAD  - Indian Council Med Res, Reg Med Res Ctr, Bhubaneswar, IndiaAD  - Ramdevrao Hosp, Kumudini Devi Diabet Res Ctr, Hyderabad, Andhra Pradesh, IndiaAD  - Sch Prevent Oncol, Patna, Bihar, IndiaAD  - King Edward Mem Hosp Res Ctr, Kamalnayan Bajaj Diabetol Res Ctr, Pune, Maharashtra, IndiaAD  - Mother Hosp, Dept Cardiol, Trichur, IndiaC3  - Public Health Foundation of IndiaC3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Indian Council of Medical Research (ICMR)C3  - University of WashingtonC3  - University of Washington SeattleC3  - Institute for Health Metrics & EvaluationC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - St. John's National Academy of Health SciencesC3  - St. John's Medical CollegeC3  - St. John's National Academy of Health SciencesC3  - St. John's Research InstituteC3  - Amrita Vishwa VidyapeethamC3  - Amrita Vishwa Vidyapeetham KochiC3  - Amrita Vishwa VidyapeethamC3  - Amrita Vishwa Vidyapeetham KochiC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Centre for Disease Informatics & Research (NCDIR)C3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Cancer Prevention & Research (NICPR)C3  - Manonmaniam Sundaranar UniversityC3  - Madras Diabetes Research FoundationC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - Regional Medical Research Centre (RMRC), BhubaneswarPU  - ELSEVIER SCI LTD
PI  - London
PA  - 125 London Wall, London, ENGLAND
DA  - DEC
PY  - 2018
VL  - 6
IS  - 12
SP  - E1339
EP  - E1351
DO  - 10.1016/S2214-109X(18)30407-8
AN  - WOS:000449748200028
ER  -

TY  - JOUR
AU  - Prabhu, M
AU  - Kumari, G
AU  - Damle, NA
AU  - Arora, G
AU  - Kumar, P
AU  - Kumar, R
AU  - Tripathi, M
AU  - Bal, C
AU  - Khadgawat, R
AU  - Kumar, C
AU  - Agarwal, S
TI  - Assessment of the role of early dynamic PET/CT with <SUP>18</SUP>F-fluorocholine in detection of parathyroid lesions in patients with primary hyperparathyroidism
T2  - NUCLEAR MEDICINE COMMUNICATIONS
KW  - early dynamic imaging
KW  - fluorine-18-fluorocholine PET/CT
KW  - parathyroid adenoma
KW  - PREOPERATIVE LOCALIZATION
KW  - 4D MRI
KW  - ADENOMA
KW  - GLANDS
KW  - TOMOGRAPHY
KW  - ULTRASOUND
AB  - Objective The aim of the present study was to assess the utility of early dynamic PET/computed tomography with fluorine-18-fluorocholine (F-18-FCH) in detecting parathyroid lesions and in differentiating parathyroid lesions from cervical lymph nodes (LNs). Patients and methods A prospective study was conducted on 14 patients with clinical and biochemical evidence of primary hyperparathyroidism by having a positive Tc-99m-sestaMIBI scan. Patients underwent early dynamic F-18-FCH PET/computed tomography scan, after the administration of 5-8 mCi (185-296 MBq) at 1 min per frame for 15 min. Delayed static images of 2-3 min per bed position were taken between 45 and 60 min. 3D-VOI's were plotted on parathyroid adenoma, cervical LN and thyroid. Dynamic and static images were interpreted by two expert nuclear medicine physicians independently and the following parameters were calculated for parathyroid adenoma and cervical LN: maximum standardized uptake value (SUVmax), time activity curve for SUVmax, t-peak. Adenoma to thyroid ratio (A/T) and cervical LN to thyroid ratio were calculated for each dynamic and static image. Results Fourteen (eight females and six males) patients were included in the study. All patients showed a higher SUVmax in the adenoma and the cervical LN in the early dynamic images as compared with delayed static images. A/T ratio obtained in the dynamic and static images were compared and found to have insignificant difference (P=0.2255). The difference between mean A/T and LN to thyroid ratio was found to be significant (P=0.0117) during the dynamic study. Conclusion A possible explanation of higher SUVmax in the dynamic images in adenomas may be due to the increased vascularity/early F-18-FCH uptake. Results indicate early dynamic imaging could suffice, without the need for a delayed image after 45 min, and this technique could adequately differentiate a parathyroid adenoma from a cervical LN.
AD  - All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Surg Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - DEC
PY  - 2018
VL  - 39
IS  - 12
SP  - 1190
EP  - 1196
DO  - 10.1097/MNM.0000000000000924
AN  - WOS:000451811700017
ER  -

TY  - JOUR
AU  - Prasad, CP
AU  - Manchanda, M
AU  - Mohapatra, P
AU  - Andersson, T
TI  - WNT5A as a therapeutic target in breast cancer
T2  - CANCER AND METASTASIS REVIEWS
KW  - WNT5A
KW  - Breast cancer
KW  - Cell migration and invasion
KW  - Metastasis
KW  - Foxy5
KW  - MAMMARY EPITHELIAL-CELLS
KW  - INVASIVE MIGRATION
KW  - SIGNALING PATHWAY
KW  - WNT-5A
KW  - CATENIN
KW  - EXPRESSION
KW  - PROTEIN
KW  - CARCINOMA
KW  - GROWTH
KW  - ROLES
AB  - Despite the clinical development of novel adjuvant and neoadjuvant chemotherapeutic drugs, metastatic breast cancer is one of the leading causes of cancer-related death among women. The present review focuses on the relevance, mechanisms, and therapeutic potential of targeting WNT5A as a future anti-metastatic treatment strategy for breast cancer patients by restoring WNT5A signaling as an innovative therapeutic option. WNT5A is an auto- and paracrine -catenin-independent ligand that has been shown to induce tumor suppression as well as oncogenic signaling, depending upon cancer type. In breast cancer patients, WNT5A protein expression has been observed to be significantly reduced in between 45 and 75% of the cases and associated with early relapse and reduced disease-free survival. WNT5A triggers various downstream signaling pathways in breast cancer that primarily affect tumor cell migration and invasion. The accumulated in vitro results reveal that treatment of WNT5A-negative breast cancer cells with recombinant WNT5A caused different tumor-suppressive responses and in particular it impaired migration and invasion. The anti-migratory/invasive and anti-metastatic effects of reconstituting WNT5A signaling by the small WNT5A mimicking peptide Foxy5 form the basis for two successful clinical phase 1-studies aiming at determining safety and pharmacokinetics as well as defining dose-level for a subsequent phase 2-study. We conclude that re-installation of WNT5A signaling is an attractive and promising anti-metastatic therapeutic approach for future treatment of WNT5A-negative breast cancer patients.
AD  - Lund Univ, Dept Translat Med, CRC, Cell & Expt Pathol, Malmo, SwedenAD  - All India Inst Med Sci, Dr BR Ambedkar IRCH, Dept Med Oncol Lab, New Delhi, IndiaC3  - Lund UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - DEC
PY  - 2018
VL  - 37
IS  - 4
SP  - 767
EP  - 778
DO  - 10.1007/s10555-018-9760-y
AN  - WOS:000457482700015
ER  -

TY  - JOUR
AU  - Quigg, M
AU  - Barbaro, NM
AU  - Ward, MM
AU  - Chang, EF
AU  - Broshek, DK
AU  - Langfitt, JT
AU  - Yan, GF
AU  - Laxer, KD
AU  - Cole, AJ
AU  - Sneed, PK
AU  - Hess, CP
AU  - Yu, W
AU  - Newman, SA
AU  - Mueller, S
AU  - Tripathi, M
AU  - Heck, CN
AU  - Miller, JW
AU  - Garcia, PA
AU  - McEvoy, A
AU  - Fountain, NB
AU  - Salanova, V
AU  - Knowlton, RC
AU  - Bagic, A
AU  - Henry, T
AU  - Kapoor, S
AU  - McKhan, G
AU  - Palade, AE
AU  - Reuber, M
AU  - Tecoma, E
TI  - Visual field defects after radiosurgery versus temporal lobectomy for mesial temporal lobe epilepsy: Findings of the ROSE trial
T2  - SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
KW  - Visual field defects
KW  - gamma knife
KW  - Radiosurgery
KW  - Mesial temporal lobe epilepsy
KW  - Epilepsy surgery
KW  - Partial seizures
KW  - Randomized controlled trial
KW  - SURGERY
KW  - DEFICITS
KW  - AMYGDALOHIPPOCAMPECTOMY
KW  - RESECTION
AB  - Purpose: Stereotactic radiosurgery (SRS) may be an alternative to anterior temporal lobectomy (ATL) for mesial temporal lobe epilepsy (MTLE). Visual field defects (VFD) occur in 9-100% of patients following open surgery for MTLE. Postoperative VFD after minimally invasive versus open surgery may differ.
   Methods: This prospective trial randomized patients with unilateral hippocampal sclerosis and concordant video-EEG findings to SRS versus ATL. Humphries perimetry was obtained at 24 m after surgery. VFD ratios (VFDR = proportion of missing homonymous hemifield with 0 = no VFD, 0.5 = complete superior quad-rantanopsia) quantified VFD. Regressions of VFDR were evaluated against treatment arm and covariates. MRI evaluated effects of volume changes on VFDR. The relationships of VFDR with seizure remission and driving status 3 years after surgery were evaluated.
   Results: No patients reported visual changes or had abnormal bedside examinations, but 49 of 54 (91%) of patients experienced VFD on formal perimetry. Neither incidence nor severity of VFDR differed significantly by treatment arm. VFDR severity was not associated with seizure remission or driving status.
   Conclusion: The nature of VFD was consistent with lesions of the optic radiations. Effective surgery (defined by seizure remission) of the mesial temporal lobe results in about a 90% incidence of typical VFD regardless of method.
AD  - Univ Virginia, Charlottesville, VA USAAD  - Indiana Univ, Indianapolis, IN 46204 USAAD  - Univ Calif San Francisco, San Francisco, CA 94143 USAAD  - Univ Rochester, Rochester, NY USAAD  - Calif Pacific Med Ctr, San Francisco, CA USAAD  - Massachusetts Gen Hosp, Boston, MA 02114 USAAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Univ Southern Calif, Los Angeles, CA USAAD  - Univ Washington, Seattle, WA 98195 USAAD  - UCL, London, EnglandAD  - Univ Pittsburgh, Pittsburgh, PA 15260 USAAD  - Univ Minnesota, Minneapolis, MN USAAD  - Univ Kentucky, Lexington, KY USAAD  - Columbia Univ, New York, NY USAAD  - Univ Louisville, Louisville, KY 40292 USAAD  - Univ Sheffield, Sheffield, S Yorkshire, EnglandAD  - Univ Calif San Diego, San Diego, CA 92103 USAC3  - University of VirginiaC3  - Indiana University SystemC3  - Indiana University IndianapolisC3  - University of California SystemC3  - University of California San FranciscoC3  - University of RochesterC3  - California Pacific Medical CenterC3  - Harvard UniversityC3  - Massachusetts General HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of Southern CaliforniaC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of LondonC3  - University College LondonC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - University of Minnesota SystemC3  - University of Minnesota Twin CitiesC3  - University of KentuckyC3  - Columbia UniversityC3  - University of LouisvilleC3  - University of SheffieldC3  - University of California SystemC3  - University of California San DiegoPU  - W B SAUNDERS CO LTD
PI  - LONDON
PA  - 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
DA  - DEC
PY  - 2018
VL  - 63
SP  - 62
EP  - 67
DO  - 10.1016/j.seizure.2018.10.017
AN  - WOS:000454963600010
ER  -

TY  - JOUR
AU  - Raghav, R
AU  - Jain, R
AU  - Dhawan, A
AU  - Roy, TS
AU  - Kumar, P
TI  - Chronic co-administration of nalbuphine attenuates the development of opioid dependence
T2  - PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
KW  - Morphine
KW  - Naloxone
KW  - Addiction
KW  - Withdrawal
KW  - Motor activity
KW  - INDUCED RESPIRATORY DEPRESSION
KW  - MORPHINE-TOLERANCE
KW  - WITHDRAWAL SYNDROME
KW  - AGONIST-ANTAGONIST
KW  - OPIATE WITHDRAWAL
KW  - RECEPTOR-BINDING
KW  - MU
KW  - EFFICACY
KW  - ANALGESIA
KW  - NALOXONE
AB  - Nalbuphine is an agonist of kappa-opioid receptors and a partial agonist of mu-opioid receptors, which can stimulate kappa-receptors and antagonize the acute rewarding effects of morphine. It is widely used either as an analgesic or as an adjuvant with morphine. This present study aimed to compare the acute and chronic effects of nalbuphine on the naloxone-precipitated opiate-withdrawal in rats. Male adult Wistar albino rats (150-175 g, n = 160) were made physically dependent by administrating increasing dose of morphine (5-25 mg/kg; i.p.). Motor activity was measured for 25 min at five-minute intervals on days 0, 1, 3, 5, and 6 using Activity Monitor (Coulbourn Instruments, Inc. USA) and True-scan software. The withdrawal was precipitated with intraperitoneal injections of naloxone (1 mg/kg) 4 h after the last injection of morphine. Somatic signs of withdrawal were scored using the global Gellert-Holtzman rating scale. Nalbuphine was co-administered acutely and chronically at various doses (0.1, 0.3, 1.0, and 3.0 mg/kg; i.p.) with morphine. In general, the opiate-dependent rats showed a significant increase in motor activity and Gellert-Holtzman score. Animals co-administered with chronic doses of nalbuphine showed a significant decrease in motor activity and naloxone-precipitated opiate withdrawal, but acute nalbuphine treatment did not attenuate the development of opioid dependence. These findings suggest that nalbuphine could be used as an effective pharmacological adjunct in the treatment of opioid addiction.
AD  - All India Inst Med Sci, Dept Psychiat, Natl Drug Dependence Treatment Ctr, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Anat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - PERGAMON-ELSEVIER SCIENCE LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
DA  - DEC
PY  - 2018
VL  - 175
SP  - 130
EP  - 138
DO  - 10.1016/j.pbb.2018.10.001
AN  - WOS:000453494400017
ER  -

TY  - JOUR
AU  - Rajan, R
AU  - Pandey, S
AU  - Anandapadmanabhan, R
AU  - Srivastava, AK
TI  - Interrater and intrarater agreement on the 2018 consensus statement on classification of tremors
T2  - MOVEMENT DISORDERS
AD  - All India Inst Med Sci, Dept Neurol, New Delhi 110029, IndiaAD  - Gobind Ballabh Pant Inst Postgrad Med Educ & Res, Dept Neurol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Govind Ballabh Pant Institute of Postgraduate Medical Education & ResearchPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - DEC
PY  - 2018
VL  - 33
IS  - 12
SP  - 1966
EP  - 1967
DO  - 10.1002/mds.27513
AN  - WOS:000454126400020
ER  -

TY  - JOUR
AU  - Ravani, R
AU  - Kumar, A
AU  - Karthikeya, R
AU  - Kumar, P
AU  - Gupta, Y
AU  - Mutha, V
AU  - Singh, S
TI  - Comparison of Inverted ILM-Stuffing Technique and ILM Peeling Alone for Optic Disc Pit-Associated Maculopathy: Long-Term Results
T2  - OPHTHALMIC SURGERY LASERS & IMAGING RETINA
KW  - INTERNAL LIMITING MEMBRANE
KW  - CONGENITAL PITS
KW  - GAUGE VITRECTOMY
KW  - LASER TREATMENT
KW  - MANAGEMENT
AB  - BACKGROUND AND OBJECTIVE: To evaluate long-term outcomes of inverted internal limiting membrane (ILM) stuffing into the optic disc pit for optic disc pit maculopathy (ODP-M) compared with vitrectomy with ILM peeling alone.
   PATIENTS AND METHODS: Twelve eyes of 12 patients who underwent vitrectomy for ODP-M and followed up more than 12 months were included. We retrospectively analyzed outcomes of inverted ILM flap stuffing into ODP (group 1, n = 6) with ILM peeling alone (group 2, n = 6).
   RESULTS: At 12 months, both groups showed significant improvement in best-corrected visual acuity and central macular thickness. On comparison, significantly faster resolution of maculoschisis was found in group 1 compared with group 2 (P = .012).
   CONCLUSIONS: Pars plana vitrectomy (PPV) with ILM peeling and PPV with inverted ILM stuffing are effective treatment modalities for ODP-M, with inverted ILM stuffing showing faster resolution of maculoschisis.
AD  - AIIMS, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SLACK INC
PI  - THOROFARE
PA  - 6900 GROVE RD, THOROFARE, NJ 08086 USA
DA  - DEC
PY  - 2018
VL  - 49
IS  - 12
SP  - E226
EP  - E232
DO  - 10.3928/23258160-20181203-12
AN  - WOS:000455925900001
ER  -

TY  - JOUR
AU  - Ray, A
AU  - Kanabar, K
AU  - Upadhyay, V
AU  - Sharma, SK
TI  - A four year experience in narcolepsy from a sleep clinic at a tertiary care centre with a short review of contemporary Indian literature
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
KW  - Multiple sleep latency test
KW  - narcolepsy
KW  - polysomnography
KW  - sleep-onset rapid eye movements
KW  - POPULATION
KW  - EPIDEMIOLOGY
KW  - DIAGNOSIS
AB  - Narcolepsy is a common sleep disorder in Western countries but rarely reported from India. Here, we report a small case series of four narcolepsy patients seen over a four year period in the sleep clinic of a tertiary care hospital in north India. The diagnosis was established by clinical history and two or more sleep-onset rapid eye movements (SOREMs) on multiple sleep latency tests (MSLTs) following overnight polysomnography (PSG). The mean age of patients was 26.2 +/- 6.4 yr; one patient had associated cataplexy and another one had all four cardinal symptoms of narcolepsy. All these patients had a history of excessive daytime sleepiness (EDS). The mean body mass index was 24.2 +/- 4.7 kg/m(2). The mean sleep latency during MSLT was 2.7 +/- 1.3 min, and the mean REM latency was 5.7 +/- 2.9 min. Narcolepsy, although rarely reported from India, should be suspected in young non-obese patients complaining of EDS and confirmed by performing MSLT following overnight PSG.
AD  - All India Inst Med Sci, Dept Internal Med, New Delhi, IndiaAD  - Jamia Hamdard Inst Mol Med, Dept Mol Med, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jamia Hamdard UniversityPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - DEC
PY  - 2018
VL  - 148
IS  - 6
SP  - 748
EP  - 751
DO  - 10.4103/ijmr.IJMR_888_16
AN  - WOS:000458520000013
ER  -

TY  - JOUR
AU  - Sachdeva, S
AU  - Gupta, P
TI  - The <i>Desi</i> Ready-to-use Foods
T2  - INDIAN PEDIATRICS
AD  - AIIMS, Dept Pediat Cardiol, New Delhi, IndiaAD  - UCMS, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of DelhiC3  - University College of Medical SciencesPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - DEC
PY  - 2018
VL  - 55
IS  - 12
SP  - 1093
EP  - 1093
DO  - 10.1007/s13312-018-1450-x
AN  - WOS:000454565200016
ER  -

TY  - JOUR
AU  - Sahay, P
AU  - Singhal, D
AU  - Maharana, PK
AU  - Titiyal, JS
TI  - Is Nanothin Descemet Stripping Automated Endothelial Keratoplasty Comparable to Descemet Membrane Endothelial Keratoplasty?
T2  - CORNEA
KW  - ULTRATHIN
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - DEC
PY  - 2018
VL  - 37
IS  - 12
SP  - E56
EP  - E56
DO  - 10.1097/ICO.0000000000001768
AN  - WOS:000456287700001
ER  -

TY  - JOUR
AU  - Saini, I
AU  - Mukherjee, A
AU  - Gautam, H
AU  - Singla, M
AU  - Jat, KR
AU  - Lodha, R
AU  - Singh, UB
AU  - Kabra, SK
TI  - Diagnostic Yield of Xpert MTB/RIF in Bronchoalveolar Lavage in Children with Probable Pulmonary Tuberculosis
T2  - INDIAN PEDIATRICS
KW  - Bronchoscopy
KW  - CBNAAT
KW  - Pediatric TB
KW  - ASSAY
KW  - SPECIMENS
KW  - ACCURACY
KW  - AFRICA
AB  - ObjectiveTo evaluate utility of Xpert MTB/RIF in bronchoalveolar lavage fluid in children with probable pulmonary tuberculosis.MethodsChildren with probable pulmonary tuberculosis with negative smear and Xpert on induced sputum/gastric aspirate were subjected to bronchoalveolar lavage (BAL) for Xpert assay and mycobacterial liquid culture. Data of children <14 y undergoing bronchoscopy for suspected MDR-TB (n=12) were also analyzed. The sensitivity of Xpert in BAL fluid for diagnosis of probable and confirmed pulmonary tuberculosis was calculated with clinico-radiological diagnosis and culture as gold standards, respectively.ResultsOf 41 enrolled children, 24 (58.5%) had Xpert positive in BAL fluid and 11 (26.8%) had culture confirmed tuberculosis (BAL fluid;10; sputum,1). The sensitivity of Xpert in BAL fluid among probable and culture confirmed tuberculosis cases was 58.5% (24/41) and 81.8% (9/11), respectively.ConclusionXpert in bronchoalveolar lavage fluid has good sensitivity in both probable and confirmed pulmonary tuberculosis in children.
AD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - DEC
PY  - 2018
VL  - 55
IS  - 12
SP  - 1062
EP  - 1065
DO  - 10.1007/s13312-018-1443-9
AN  - WOS:000454565200009
ER  -

TY  - JOUR
AU  - Saluja, A
AU  - Singh, RK
AU  - Dash, D
AU  - Bhatia, R
AU  - Tripathi, M
TI  - Jaw clonus and opercular syndrome in ALS: a rare and interesting finding
T2  - ACTA NEUROLOGICA BELGICA
KW  - AMYOTROPHIC-LATERAL-SCLEROSIS
AD  - All India Inst Med Sci, CN Ctr, Dept Neurol, Room 703, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER HEIDELBERG
PI  - HEIDELBERG
PA  - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
DA  - DEC
PY  - 2018
VL  - 118
IS  - 4
SP  - 547
EP  - 548
DO  - 10.1007/s13760-018-0980-2
AN  - WOS:000450462100006
ER  -

TY  - JOUR
AU  - Salve, HR
AU  - Parthasarathy, R
AU  - Krishnan, A
AU  - Pattanaik, DR
TI  - Impact of ambient air temperature on human health in India
T2  - REVIEWS ON ENVIRONMENTAL HEALTH
KW  - air pollution
KW  - climate change
KW  - epidemiology
KW  - heat
KW  - public health
KW  - HEAT-WAVE
KW  - MORTALITY RISK
KW  - CLIMATE-CHANGE
KW  - STRESS
AB  - A systematic search was carried out in the databases of Pubmed, Indmed and Mausam for articles on the effect of ambient temperature on health. Relevant data were extracted using a standard data abstraction form by two authors independently. The overall effects of ambient air temperature are reported as odds ratio (OR) and 95% confidence intervals (CIs) on mortality. Of 812 records identified, only seven were included in the final review as per pre-defined criteria. An increase in the all-cause mortality rate of 41% are reported during a heat wave in India. Risk ratios for all-cause mortality was in the range of 1.7-2.1. The dose-response relationship of ambient temperature and all-cause mortality and cardiovascular diseases are been reported. Current evidence on the effect of ambient temperature and health is sufficient to initiate an integrated response from policy makers, climate scientists and public health practitioners in India. Continued advocacy and generation of more robust evidence is needed.
AD  - All India Inst Med Sci, Ctr Community Med, Old OT Block, New Delhi, IndiaAD  - Indian Meteorol Dept, Extended Range Forecast Grp, Numer Weather Predict Div, Publicat & Human Resource Dev, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Ministry of Earth Sciences (MoES) - IndiaC3  - India Meteorological Department (IMD)PU  - WALTER DE GRUYTER GMBH
PI  - BERLIN
PA  - GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
DA  - DEC
PY  - 2018
VL  - 33
IS  - 4
SP  - 433
EP  - 439
DO  - 10.1515/reveh-2018-0024
AN  - WOS:000452485000008
ER  -

TY  - JOUR
AU  - Salvi, S
AU  - Kumar, GA
AU  - Dhaliwal, RS
AU  - Paulson, K
AU  - Agrawal, A
AU  - Koul, PA
AU  - Mahesh, PA
AU  - Nair, S
AU  - Singh, V
AU  - Aggarwal, AN
AU  - Christopher, DJ
AU  - Guleria, R
AU  - Mohan, BVM
AU  - Tripathi, SK
AU  - Ghoshal, AG
AU  - Kumar, RV
AU  - Mehrotra, R
AU  - Shukla, DK
AU  - Dutta, E
AU  - Furtado, M
AU  - Bhardwaj, D
AU  - Smith, M
AU  - Abdulkader, RS
AU  - Arora, M
AU  - Balakrishnan, K
AU  - Chakma, JK
AU  - Chaturvedi, P
AU  - Dey, S
AU  - Ghorpade, D
AU  - Glenn, S
AU  - Gupta, PC
AU  - Gupta, T
AU  - Johnson, SC
AU  - Joshi, TK
AU  - Kutz, M
AU  - Mathur, MR
AU  - Mathur, P
AU  - Muraleedharan, P
AU  - Odell, CM
AU  - Pati, S
AU  - Sabde, Y
AU  - Sinha, DN
AU  - Thankappan, KR
AU  - Varghese, CM
AU  - Yadav, G
AU  - Lim, SS
AU  - Naghavi, M
AU  - Dandona, R
AU  - Reddy, KS
AU  - Vos, T
AU  - Murray, CJL
AU  - Swaminathan, S
AU  - Dandona, L
A1  - India State Level Dis Burden Initi
TI  - The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990-2016
T2  - LANCET GLOBAL HEALTH
KW  - OBSTRUCTIVE PULMONARY-DISEASE
KW  - ASTHMA
KW  - PREVALENCE
KW  - SYMPTOMS
KW  - COPD
AB  - Background India has 18% of the global population and an increasing burden of chronic respiratory diseases. However, a systematic understanding of the distribution of chronic respiratory diseases and their trends over time is not readily available for all of the states of India. Our aim was to report the trends in the burden of chronic respiratory diseases and the heterogeneity in their distribution in all states of India between 1990 and 2016.
   Methods Using all accessible data from multiple sources, we estimated the prevalence of major chronic respiratory diseases and the deaths and disability-adjusted life-years (DALYs) caused by them for every state of India from 1990 to 2016 as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016. We assessed heterogeneity in the burden of chronic obstructive pulmonary disease (COPD) and asthma across the states of India. The states were categorised into four groups based on their epidemiological transition level (Ell). ETL was defined as the ratio of DALYs from communicable diseases to those from non-communicable diseases and injuries combined, with a low ratio denoting high ETL and vice versa. We also assessed the contribution of risk factors to DALYs due to COPD. We compared the burden of chronic respiratory diseases in India against the global average in GBD 2016. We calculated 95% uncertainty intervals (UIs) for the point estimates.
   Findings The contribution of chronic respiratory diseases to the total DALYs in India increased from 4.5% (95% UI 4.0-4.9) in 1990 to 6.4% (5.8-7.0) in 2016. Of the total global DALYs due to chronic respiratory diseases in 2016, 32.0% occurred in India. COPD and asthma were responsible for 75.6% and 20.0% of the chronic respiratory disease DALYs, respectively, in India in 2016. The number of cases of COPD in India increased from 28.1 million (27.0-29.2) in 1990 to 55.3 million (53.1-57.6) in 2016, an increase in prevalence from 3.3% (3.1-3.4) to 4.2% (4.0-4.4). The age-standardised COPD prevalence and DALY rates in 2016 were highest in the less developed low Ell state group. There were 37.9 million (35.7-40.2) cases of asthma in India in 2016, with similar prevalence in the four ETL state groups, but the highest DALY rate was in the low ETL state group. The highest DALY rates for both COPD and asthma in 2016 were in the low ETL states of Rajasthan and Uttar Pradesh. The DALYs per case of COPD and asthma were 1.7 and 2.4 times higher in India than the global average in 2016, respectively; most states had higher rates compared with other locations worldwide at similar levels of Socio-demographic Index. Of the DALYs due to COPD in India in 2016, 53.7% (43.1-65.0) were attributable to air pollution, 25.4% (19.5-31.7) to tobacco use, and 16.5% (14.1-19.2) to occupational risks, making these the leading risk factors for COPD.
   Interpretation India has a disproportionately high burden of chronic respiratory diseases. The increasing contribution of these diseases to the overall disease burden across India and the high rate of health loss from them, especially in the less developed low ETL states, highlights the need for focused policy interventions to address this significant cause of disease burden in India. Copyright (C) 2018 The Author(s). Published by Elsevier Ltd.
AD  - Chest Res Fdn, Pune, Maharashtra, IndiaAD  - Publ Hlth Fdn India, Gurugram 122002, National Capita, IndiaAD  - Indian Council Med Res, New Delhi, IndiaAD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - CSIR, Inst Genom & Integrat Biol, New Delhi, IndiaAD  - Sherikashmir Inst Med Sci, Dept Internal & Pulm Med, Srinagar, Jammu & Kashmir, IndiaAD  - Jagadguru Sri Shivarathreeshwara Univ, Jagadguru Sri Shivarathreeshwara Med Coll, Dept Resp Med, Mysore, Karnataka, IndiaAD  - Med Coll, Dept Pulm Med, Trivandrum, Kerala, IndiaAD  - Asthma Bhawan, Jaipur, Rajasthan, IndiaAD  - Postgrad Inst Med Educ & Res, Dept Pulm Med, Chandigarh, IndiaAD  - Christian Med Coll & Hosp, Dept Pulm Med, Vellore, Tamil Nadu, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Narayana Hlth, Internal Med & Pulmonol, Bengaluru, IndiaAD  - King Georges Med Univ, Dept Resp Med, Lucknow, Uttar Pradesh, IndiaAD  - Natl Allergy Asthma Bronchitis Inst, Kolkata, IndiaAD  - Apollo Hosp, Hyderabad, Andhra Pradesh, IndiaAD  - Indian Council Med Res, Natl Inst Canc Prevent & Res, Noida, IndiaAD  - Manonmaniam Sundaranar Univ, Dept Stat, Tirunelveli, IndiaAD  - Sri Ramachandra Med Coll & Res Inst, Dept Environm Hlth Engn, Madras, Tamil Nadu, IndiaAD  - Tata Mem Hosp, Dept Head & Neck Oncol, Bombay, Maharashtra, IndiaAD  - Indian Inst Technol, Ctr Atmospher Sci, New Delhi, IndiaAD  - Healis Sekhsaria Inst Publ Hlth, Bombay, Maharashtra, IndiaAD  - Indian Inst Technol, Dept Civil Engn, Kanpur, Uttar Pradesh, IndiaAD  - Govt India, Minist Environm Forest & Climate Change, Kanpur, Uttar Pradesh, IndiaAD  - Indian Council Med Res, Natl Ctr Dis Informat & Res, Bengaluru, IndiaAD  - Indian Council Med Res, Reg Med Res Ctr, Bhubaneswar, IndiaAD  - Indian Council Med Res, Natl Inst Res Environm, Bhopal, IndiaAD  - Sch Prevent Oncol, Patna, Bihar, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Achutha Menon Ctr Hlth Sci Studies, Trivandrum, Kerala, IndiaC3  - Public Health Foundation of IndiaC3  - Indian Council of Medical Research (ICMR)C3  - University of WashingtonC3  - University of Washington SeattleC3  - Institute for Health Metrics & EvaluationC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Sher-i-Kashmir Institute of Medical SciencesC3  - JSS Academy of Higher Education & ResearchC3  - JSS Medical College, MysuruC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - King George's Medical UniversityC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Cancer Prevention & Research (NICPR)C3  - Manonmaniam Sundaranar UniversityC3  - Sri Ramachandra Institute of Higher Education & ResearchC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - KanpurC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Centre for Disease Informatics & Research (NCDIR)C3  - Indian Council of Medical Research (ICMR)C3  - ICMR - Regional Medical Research Centre (RMRC), BhubaneswarC3  - Indian Council of Medical Research (ICMR)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)PU  - ELSEVIER SCI LTD
PI  - London
PA  - 125 London Wall, London, ENGLAND
DA  - DEC
PY  - 2018
VL  - 6
IS  - 12
SP  - E1363
EP  - E1374
DO  - 10.1016/S2214-109X(18)30409-1
AN  - WOS:000449748200030
ER  -

TY  - JOUR
AU  - Sarkar, N
AU  - Saha, B
AU  - Singh, S
AU  - Ghosal, S
TI  - <i>Tropidia Curculioides:</i> Secondary Metabolites and Derivatives with Antimycobacterial and Leishmanicidal Activity
T2  - PHARMACOGNOSY MAGAZINE
KW  - 4,4 '-dihydroxydiphenylmethane
KW  - antimycobacterial
KW  - leishmanicidal activity
KW  - Tropidia curculioides
AB  - Background: Arunachal Pradesh the north-eastern state of India is a natural habitat of 550 species of orchids including 37 species of medicinal importance. Although these plants are regularly used by ethnic population, very few scientific investigations have been conducted to establish their pharmacological potential. In our previous study, we evaluated antimycobacterial and leishmanicidal activity of extracts prepared from three relatively unexplored medicinal orchids. In the present study, we conducted screening of the compounds isolated from Tropidia curculioides (Tc) for the above-mentioned activities. Furthermore, we prepared synthetic analogs of the most active compound. Objective: Evaluation of antimycobacterial and leishmanicidal activity of the isolated compounds and preparation of synthetic analogs of the most active compound followed by evaluation of biological activities. Materials and Methods: Antimycobacterial activity was evaluated by colorimetric redox indicator assay, and the leishmanicidal activity was assessed by 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide assay. The root, stem, and leaves of Tc were extracted with methanol: water (9:1) followed by fractionation with diethyl ether (Et2O) and n-butanol solvent. All these fractions were evaluated for biological activity to identify the most active fraction. Further, chromatography of the most active fraction (Tc root Et2O fraction) afforded three compounds, namely, 4-hydroxybenzaldehyde (1), 4,4'-dihydroxydiphenylmethane (2), and 3,5-dihydroxy-4-methoxybenzoic acid (3). Standard synthetic procedures were followed to prepare the analogs of the most active compound. Results: The screening result identified compound 2 with maximum antimycobacterial activity (minimum inhibitory concentration [MIC]-125 mu g/ml) and leishmanicidal activity (IC50 100 mu g/ml). Three synthetic analogs were prepared targeting the methane linkage of compound 2. The N-benzylmethylamine derivative (6) showed the highest activity with MIC 15.62 mu g/ml against Mycobacterium and IC50 31.25 mu g/ml against Leishmania spp. Conclusion: The promising result of N-benzylmethylamine analog could be explored to obtain new antimycobacterial and leishmanicidal agent.
AD  - AUUP, Ctr Plant & Environm Biotechnol, Amity Inst Biotechnol, Noida 201303, Uttar Pradesh, IndiaAD  - AIIMS, Dept Clin Microbiol & Lab Med, New Delhi, IndiaC3  - Amity University NoidaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - DEC
PY  - 2018
VL  - 14
IS  - 59
SP  - S535
EP  - S538
DO  - 10.4103/pm.pm_196_18
AN  - WOS:000456306000007
ER  -

TY  - JOUR
AU  - Saxena, A
TI  - Congenital Heart Disease in India: A Status Report
T2  - INDIAN PEDIATRICS
KW  - Epidemiology
KW  - Birth defects
KW  - Congenital heart defects
KW  - Echocardiography
KW  - BIRTH PREVALENCE
KW  - CARDIAC CARE
KW  - WORLDWIDE
KW  - DEFECTS
KW  - PROFILE
KW  - PATTERN
AB  - Considering a birth prevalence of congenital heart disease as 9/1000, the estimated number of children born with congenital heart disease in India is more than 200,000 per year. Of these, about one-fifth are likely to have serious defect, requiring an intervention in the first year of life. Currently advanced cardiac care is available to only a minority of such children. A number of cardiac centers have been developed over the last 10 years. However, most are in the private sector, and are not geographically well-distributed. Challenges to pediatric cardiac care include financial constraints, health-seeking behavior of community, and lack of awareness. Government of India is taking a number of steps for improving health of children through its various program and schemes that are likely to benefit children with congenital heart disease, especially those who are vulnerable and marginalized.
AD  - All India Inst Med Sci, Dept Cardiol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - DEC
PY  - 2018
VL  - 55
IS  - 12
SP  - 1075
EP  - 1082
DO  - 10.1007/s13312-018-1445-7
AN  - WOS:000454565200011
ER  -

TY  - JOUR
AU  - Selvan, H
AU  - Patil, M
AU  - Yadav, S
AU  - Tandon, R
TI  - Triple chamber: a clinical rarity after deep anterior lamellar keratoplasty and role of optical coherence tomography in management
T2  - INTERNATIONAL OPHTHALMOLOGY
KW  - Deep anterior lamellar keratoplasty
KW  - Dua's layer
KW  - Interface viscoelastic
KW  - MiOCT guided
KW  - Pre-Descemet layer
KW  - Triple chamber
KW  - DESCEMETS-MEMBRANE
AB  - PurposeTo report a case demonstrating triple chamber following deep anterior lamellar keratoplasty (DALK) and its successful intra-operative optical coherence tomography-guided management.MethodCase report of a young male with macular corneal dystrophy, who underwent DALK in his left eye by Big-Bubble technique. The surgery was uneventful. On the first post-operative day, triple chamber was observed and followed-up with serial clinical photography and anterior segment optical coherence tomography. Due to decrease in graft clarity and increase in volume of the two extra chambers, interface drainage along with descemetopexy was undertaken 4days later.ResultThe compartments constituting the triple chamber were those in-between the donor tissue and host pre-Descemet layer (Dua's layer), the latter and host Descemet membrane and the true anterior chamber. Presence of viscoelastic in the interface was identified as the cause. Microscope integrated optical coherence tomography (MiOCT) guided drainage followed by intracameral air tamponade ensured near total disappearance of the two extra chambers at the end of surgery. Examination on the next day confirmed complete apposition of the graft and host.ConclusionTo the best of our knowledge, this is a unique demonstration of Dua's layer in vivo by slit lamp biomicroscopy and description of MiOCT guided management of triple chamber.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Cornea & Refract Serv, Room 490,4th Floor, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - DEC
PY  - 2018
VL  - 38
IS  - 6
SP  - 2683
EP  - 2687
DO  - 10.1007/s10792-017-0755-4
AN  - WOS:000451676200056
ER  -

TY  - JOUR
AU  - Sharma, A
AU  - Pandey, AK
AU  - Mohan, A
AU  - Bhalla, AS
AU  - Vishnubhatla, S
AU  - Sharma, MC
AU  - Jain, D
AU  - Thulkar, S
AU  - Gupta, P
AU  - Bal, CS
AU  - Kumar, R
TI  - Standardization of image reconstruction parameters for dynamic fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography
T2  - NUCLEAR MEDICINE COMMUNICATIONS
KW  - dynamic F-18-FDG PET/CT
KW  - filter FWHM
KW  - iterations
KW  - ordered subset expectation maximization
KW  - PET
AB  - Aim The present study aimed to standardize the ordered subset expectation maximization (OSEM) reconstruction parameters for a dynamic PET/CT study. Participants and methods A locally fabricated phantom was filled with fluorine-18-fluorodeoxyglucose (F-18-FDG) for four different sphere to background ratios (SBRs), that is, 10 : 1, 8 : 1, 6 : 1, and 4 : 1, and dynamic PET/CT was acquired for 5 min. Transaxial slices were reconstructed using OSEM [full-width at half-maximum (FWHM): 1-7 mm and iterations: 1-8]. Two nuclear medicine physicians visually rated image quality on the basis of the following criteria: score 1: poor quality, score 2: average quality, and score 3: good quality. The quantitative assessment of image quality was performed on the basis of the calculation of noise, horizontal, and vertical line profiles. The standardized parameters were applied to the PET/CT study of seven non-small-cell lung cancer patients, and their image quality was compared with the vendor-provided default parameters. Results In the phantom study, for SBR 10 : 1, the images reconstructed with FWHM 4 mm and four iterations, for SBR 8 : 1 and 6 : 1, the image with FWHM 3 mm and five iterations, and for SBR 4 : 1, the image with FWHM 2 mm and five iterations were found to have the best quality. In the patient study, FWHM 4 mm and four iterations were found to be suitable for the reconstruction of dynamic F-18-FDG PET/CT studies with a tumor to background ratio of 10 : 1. With an increase in iterations, noise and sharpness in the image increased, whereas with an increase in FWHM, the image became smoother. Conclusion The standardized reconstruction parameters of OSEM for the dynamic PET/CT study were found to be 4-mm filter FWHM and four iterations in SBR 10 : 1.
AD  - All India Inst Med Sci, IRCH, Dept Nucl Med, New Delhi, IndiaAD  - All India Inst Med Sci, IRCH, Dept Pulm Med & Sleep Disorders, New Delhi, IndiaAD  - All India Inst Med Sci, IRCH, Dept Radiodiag, New Delhi, IndiaAD  - All India Inst Med Sci, IRCH, Dept Biostat, New Delhi, IndiaAD  - All India Inst Med Sci, IRCH, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - DEC
PY  - 2018
VL  - 39
IS  - 12
SP  - 1207
EP  - 1217
DO  - 10.1097/MNM.0000000000000923
AN  - WOS:000451811700019
ER  -

TY  - JOUR
AU  - Sharma, H
AU  - Chauhan, P
AU  - Singh, S
TI  - Evaluation of the anti-arthritic activity of <i>Cinnamomum cassia</i> bark extract in experimental models
T2  - INTEGRATIVE MEDICINE RESEARCH
KW  - Arthritis
KW  - Cinnamomum cassia
KW  - Complete Freund's adjuvant
KW  - Indomethacin
KW  - Formaldehyde
KW  - RHEUMATOID-ARTHRITIS
KW  - ESSENTIAL OIL
KW  - ISCHEMIA
KW  - ACID
AB  - Background: Cinnamomum cassia iswidely used as a traditional medicinal plant for the treatment of rheumatoid arthritis.
   Objective: The present study aimed to assess the anti-arthritic activity of C. cassia bark hydroalcoholic extract (CCHE) in different arthritic animal models.
   Methods: In formaldehyde model, sub-plantar administration of 0.1 ml of formaldehyde (2% v/v) into the right hind paws of Wistar albino rats on days 0 and 3. The rats were divided into six groups as follows: normal control, disease control, indomethacin group (3 mg/kg, p.o.) and three groups, treated with 50, 100 and 200 mg/kg CCHE (p.o.). Joint diameter was measured, and ankle joints were collected for MDA and GSH measurements. In complete Freund's adjuvant (CFA)-induced arthritis model, CFA was injected into the sub-plantar surface of the right hind paw in rats. Joint diameter was measured, and serum TNF-alpha and IL-1 beta were measured. Histopathological and immunohistochemical analyses were also performed.
   Results: CCHE treatment significantly (p < 0.01) reduced MDA levels and joint swelling in a concentration-dependent manner in rats with formaldehyde-induced arthritis, in which GSH levels were elevated (p < 0.01). In rats with CFA-induced arthritis, CCHE treatment significantly reduced joint swelling as well as IL-1 beta and TNF-alpha levels (p < 0.01). TNF-alpha receptor expression was decreased in rats treated with indomethacin or CCHE.
   Conclusion: Based on these findings, it can be concluded that C. cassia possesses anti-arthritic properties. (C) 2018 Korea Institute of Oriental Medicine. Publishing services by Elsevier B.V.
AD  - All India Inst Med Sci, Dept Pharmacol, New Delhi 110062, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - DEC
PY  - 2018
VL  - 7
IS  - 4
SP  - 366
EP  - 373
DO  - 10.1016/j.imr.2018.08.002
AN  - WOS:000453437300010
ER  -

TY  - JOUR
AU  - Sharma, JB
AU  - Sharma, E
AU  - Sharma, S
AU  - Dharmendra, S
TI  - Female genital tuberculosis: Revisited
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
KW  - Fallopian tubes
KW  - female genital tuberculosis
KW  - GeneXpert
KW  - infertility
KW  - Mycobacterium tuberculosis
KW  - INCREASED COMPLICATION RATES
KW  - INFERTILE WOMEN
KW  - EXTRAPULMONARY TUBERCULOSIS
KW  - CLINICAL PRESENTATION
KW  - TRACT TUBERCULOSIS
KW  - DIAGNOSIS
KW  - PCR
KW  - IVF
KW  - PREVALENCE
KW  - PREGNANCY
AB  - Female genital tuberculosis (FGTB) is caused by Mycobacterium tuberculosis (rarely Mycobacterium bovis and/or atypical mycobacteria) being usually secondary to TB of the lungs or other organs with infection reaching through haematogenous, lymphatic route or direct spread from abdominal TB. In FGTB, fallopian tubes are affected in 90 per cent women, whereas uterine endometrium is affected in 70 per cent and ovaries in about 25 per cent women. It causes menstrual dysfunction and infertility through the damage of genital organs. Some cases may be asymptomatic. Diagnosis is often made from proper history taking, meticulous clinical examination and judicious use of investigations, especially endometrial aspirate (or biopsy) and endoscopy. Treatment is through multi-drug antitubercular treatment for adequate time period (rifampicin, isoniazid, pyrazinamide, ethambutol daily for 60 days followed by rifampicin, isoniazid, ethambutol daily for 120 days). Treatment is given for 18-24 months using the second-line drugs for drug-resistant (DR) cases. With the advent of increased access to rapid diagnostics and newer drugs, the management protocol is moving towards achieving universal drug sensitivity testing and treatment with injection-free regimens containing newer drugs, especially for new and previously treated DR cases.
AD  - All India Inst Med Sci, Dept Obstet & Gynaecol, New Delhi 110029, IndiaAD  - Natl Inst TB & Resp Dis, Dept Paediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
DA  - DEC
PY  - 2018
VL  - 148
SP  - 71
EP  - 83
DO  - 10.4103/ijmr.IJMR_648_18
AN  - WOS:000948175800008
ER  -

TY  - JOUR
AU  - Singh, AN
AU  - Kilambi, R
TI  - Biomarker-guided Intervention to Prevent AKI or KDIGO Care Bundle to Prevent AKI in High-risk Patients Undergoing Major Surgery?
T2  - ANNALS OF SURGERY
AD  - AIIMS, Dept Gastrointestinal Surg & Liver Transplantat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - DEC
PY  - 2018
VL  - 268
IS  - 6
SP  - E67
EP  - E68
DO  - 10.1097/SLA.0000000000002634
AN  - WOS:000452668900031
ER  -

TY  - JOUR
AU  - Singh, AN
AU  - Kilambi, R
TI  - Pylorus Resection Does Not Reduce Delayed Gastric Emptying After Partial Pancreatoduodenectomy: A Blinded Randomized Controlled Trial
T2  - ANNALS OF SURGERY
AD  - AIIMS, Dept Gastrointestinal Surg & Liver Transplantat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - DEC
PY  - 2018
VL  - 268
IS  - 6
SP  - E72
EP  - E73
DO  - 10.1097/SLA.0000000000002641
AN  - WOS:000452668900037
ER  -

TY  - JOUR
AU  - Singh, A
AU  - Gupta, N
AU  - Ganger, A
AU  - Vashist, P
AU  - Tandon, R
TI  - Awareness Regarding Eye Donation in an Urban Slum Population: A Community-Based Survey
T2  - EXPERIMENTAL AND CLINICAL TRANSPLANTATION
KW  - Corneal transplantation
KW  - Cross-sectional study
KW  - Questionnaire
KW  - Urban poor
KW  - Willingness
KW  - ATTITUDES
KW  - KNOWLEDGE
AB  - Objectives: Our objective was to assess the awareness of eye donation in an urban slum population and willingness to donate eyes after death.
   Materials and Methods: A cross-sectional, population-based study was undertaken in 20 urban slum clusters of the Indian capital, New Delhi. A total of 2004 individuals aged 18 years and older were recruited. After written, informed consent was obtained, knowledge regarding eye donation was assessed through a predesigned close-ended questionnaire. The questionnaire was framed so as to understand the sociodemographic factors influencing the willingness to donate and the awareness of eye donation in this distinct population.
   Results: The mean age of the recruited individuals was 36.53 +/- 13.68 years. Age did not have any significant effect on awareness regarding eye donation. We observed that 34.3% of the study population had no knowledge of eye donation and that 7.78% of the study population had excellent knowledge. Education seemed to be an important determining factor regarding knowledge of eye donation. Multivariable logistic regression demonstrated better awareness among the Hindu population (81.1%) and those belonging to a higher caste (P < .05). The younger age group (those 18-30 years old) showed significant willingness to donate their eyes versus older age groups (P < .001). In our study population, male participants (P = .006), those classified as literate (P < .001), and those classified as Hindu (P < .001) were more willing to pledge their eyes for donation.
   Conclusions: Although there is substantial awareness about eye donation, willingness to pledge eyes was very low in the urban slum population. Additional efforts are needed to translate this awareness into actual eye donation in the urban poor population.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Cornea Cataract & Refract Surg Serv, New Delhi, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Community Ophthalmol Dept, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - BASKENT UNIV
PI  - ANKARA
PA  - TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
DA  - DEC
PY  - 2018
VL  - 16
IS  - 6
SP  - 730
EP  - 735
DO  - 10.6002/ect.2017.0077
AN  - WOS:000457783700015
ER  -

TY  - JOUR
AU  - Singh, D
AU  - Rana, A
AU  - Sharma, P
AU  - Pandey, PM
AU  - Kalyanasundaram, D
TI  - Microwave Sintering of Ti6Al4V: Optimization of Processing Parameters for Maximal Tensile Strength and Minimal Pore Size
T2  - METALS
KW  - microwave sintering
KW  - Ti6Al4V
KW  - tensile strength
KW  - pore
KW  - computed tomography
KW  - RSM
KW  - additive manufacturing
KW  - TOMOGRAPHY
KW  - QUANTIFICATION
KW  - POROSITY
AB  - Pressureless sintering is a powder metallurgical process wherein the powder particles are sintered without the aid of any compressive force. Though this additive manufacturing process is economical, the strength of the component is undermined due to the presence of pores; the elimination of which is a challenge. In this work, the optimal process parameters for the pressureless microwave sintering of a grade 5 titanium alloy that yields higher tensile strength and minimum sizes of pores were obtained. The three process parameters (sintering temperature, heating rate, and holding time) were experimented at five different levels using the design of experiments (DOE). Post sintering, the tensile strength was assessed as per ASTM standard B925-15, while the pore size was evaluated, non-destructively, using micro-computed tomography (mu-CT). The optimal process parameters that yielded minimum size pores were: sintering temperature-1293 degrees C, heating rate-6.65 degrees C/min; and holding time-72 min.
AD  - Indian Inst Technol Delhi, Ctr Biomed Engn, New Delhi 110016, IndiaAD  - Indian Inst Technol Delhi, Dept Mech Engn, New Delhi 110016, IndiaAD  - All India Inst Med Sci, Dept Biomed Engn, New Delhi 110016, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MDPI
PI  - BASEL
PA  - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
DA  - DEC
PY  - 2018
VL  - 8
IS  - 12
C7  - 1086
DO  - 10.3390/met8121086
AN  - WOS:000455072100110
ER  -

TY  - JOUR
AU  - Singh, G
AU  - Kohli, PS
AU  - Bagaria, D
TI  - Lateral Oncoplastic Breast Surgery (LOBS) - A new surgical technique and short term results
T2  - AMERICAN JOURNAL OF SURGERY
KW  - Lateral oncoplastic breast surgery
KW  - Breast conserving surgery
KW  - Level 1 oncoplasty
KW  - 20-YEAR FOLLOW-UP
KW  - CONSERVING SURGERY
KW  - CLASSIFICATION
KW  - MASTECTOMY
KW  - LUMPECTOMY
KW  - CANCER
AB  - Background: We present a new approach for BCS which we have named as the Lateral Oncoplastic Breast Surgery (LOBS) approach.
   Methods: Patients with biopsy proven breast cancer or phyllodes tumors in the outer quadrants of the breast were selected. The patients were operated in the lateral position using the principles of a Level 1 oncoplastic technique.
   Results: 106 patients (93 breast cancer; 13 phyllodes tumor) were operated using this technique. For patients with breast cancer the mean tumor size was 2.7 cms. 3 patients had a positive margin. The mean tumor size for phyllodes tumors was 6.7 cms. Surgical site infections (15 patients), marginal skin necrosis (2 patients) and superficial NAC necrosis (1 patient) were observed. Although the mean follow up was only 355.8 days there were no early detected recurrences.
   Conclusions: LOBS is a new approach for BCS which offers distinct advantages. The short term results, both oncological and aesthetic, are encouraging.
   Summary: A new approach for performing oncoplastic breast conserving surgery (BCS) is described and the short term results of our first 106 cases are presented. Advantages of this approach over conventional techniques are reviewed. (C) 2017 Elsevier Inc. All rights reserved.
AD  - Post Grad Inst Med Educ & Res, Dept Surg, Chandigarh, IndiaAD  - JIPMER, Dept Surg Oncol, Pondicherry, IndiaAD  - AIIMS, Dept Surg, New Delhi, IndiaC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Jawaharlal Institute of Postgraduate Medical Education & ResearchC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI  - BRIDGEWATER
PA  - 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
DA  - DEC
PY  - 2018
VL  - 216
IS  - 6
SP  - 1166
EP  - 1170
DO  - 10.1016/j.amjsurg.2017.09.016
AN  - WOS:000452304200023
ER  -

TY  - JOUR
AU  - Singh, K
AU  - Johnson, L
AU  - Devarajan, R
AU  - Shivashankar, R
AU  - Sharma, P
AU  - Kondal, D
AU  - Ajay, VS
AU  - Narayan, KMV
AU  - Prabhakaran, D
AU  - Ali, MK
AU  - Tandon, N
TI  - Acceptability of a decision-support electronic health record system and its impact on diabetes care goals in South Asia: a mixed-methods evaluation of the CARRS trial
T2  - DIABETIC MEDICINE
KW  - QUALITY IMPROVEMENT STRATEGIES
KW  - GLYCEMIC CONTROL
KW  - MANAGEMENT
AB  - Aims To describe physicians' acceptance of decision-support electronic health record system and its impact on diabetes care goals among people with Type 2 diabetes. Methods We analysed data from participants in the Centre for Cardiometabolic Risk Reduction in South Asia (CARRS) trial, who received the study intervention (care coordinators and use of a decision-support electronic health record system; n=575) using generalized estimating equations to estimate the association between acceptance/rejection of decision-support system prompts and outcomes (mean changes in HbA(1c), blood pressure and LDL cholesterol) considering repeated measures across all time points available. We conducted in-depth interviews with physicians to understand the benefits, challenges and value of the decision-support electronic health record system and analysed physicians' interviews using Rogers' diffusion of innovation theory. Results At end-of-trial, participants with diabetes for whom glycaemic, systolic blood pressure, diastolic blood pressure and LDL cholesterol decision-support electronic health record prompts were accepted vs rejected, experienced no reduction in HbA(1c) [mean difference: -0.05 mmol/mol (95% CI -0.22, 0.13); P=0.599], but statistically significant improvements were observed for systolic blood pressure [mean difference: -11.6 mmHg (95% CI -13.9, -9.3); P <= 0.001], diastolic blood pressure [mean difference: -5.2 mmHg (95% CI -6.5, -3.8); P <= 0.001] and LDL cholesterol [mean difference: -0.7 mmol/l (95% CI -0.6, -0.8); P <= 0.001], respectively. The relative advantages and compatibility of the decision-support electronic health record system with existing clinic set-ups influenced physicians' acceptance of it. Software complexities and data entry challenges could be overcome by task-sharing. Conclusion Wider adherence to decision-support electronic health record prompts could potentially improve diabetes goal achievement, particularly when accompanied by assistance from a non-physician health worker.
AD  - Publ Hlth Fdn India, Ctr Chron Condit & Injuries, Gurgaon, Haryana, IndiaAD  - Ctr Chron Dis Control, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi, IndiaAD  - Ctr Control Chron Condit, New Delhi, IndiaAD  - Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USAAD  - Ctr Cardiometab Risk Reduct South Asia, Ctr Excellence, New Delhi, IndiaAD  - St Georges Med Univ London, London, EnglandAD  - Plovdiv Med Univ, Plovdiv, BulgariaC3  - Public Health Foundation of IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Emory UniversityC3  - Rollins School Public HealthC3  - Medical University PlovdivPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - DEC
PY  - 2018
VL  - 35
IS  - 12
SP  - 1644
EP  - 1654
DO  - 10.1111/dme.13804
AN  - WOS:000451432800006
ER  -

TY  - JOUR
AU  - Singh, MK
AU  - Pushker, N
AU  - Meel, R
AU  - Chodsol, K
AU  - Sen, S
AU  - Bakhshi, S
AU  - Singh, L
AU  - Kashyap, S
TI  - Does NEMO/IKKγ protein have a role in determining prognostic significance in uveal melanoma?
T2  - CLINICAL & TRANSLATIONAL ONCOLOGY
KW  - Uveal melanoma
KW  - NEMO protein
KW  - Immunohistochemistry
KW  - qRT-PCR
KW  - Prognosis validation and translational studies
KW  - NF-KAPPA-B
KW  - IKK-GAMMA
KW  - HEPATOCELLULAR-CARCINOMA
KW  - INCONTINENTIA PIGMENTI
KW  - CHOROIDAL MELANOMA
KW  - SURVIVAL
KW  - CLASSIFICATION
KW  - MUTATIONS
KW  - PATHOLOGY
KW  - DELETION
AB  - PurposeUveal melanoma, although a rare form of cancer, is the most common primary malignancy of the eye in adults. Nuclear factor-B (NF-B) is a transcription factor that transactivates genes involved in the regulation of cell growth, apoptosis, angiogenesis, and metastasis, but the molecular mechanisms that negatively regulate NF-B activation are not fully understood. NF-B can also be activated by DNA damage pathway through NEMO protein. Therefore, the objective of this study is to elucidate the role of NEMO/IKK protein in uveal melanoma patients.MethodsSeventy-five formalin-fixed paraffin-embedded prospective tissues of uveal melanoma were included in the present study. These cases were reviewed and investigated for the expression of NEMO/IKK protein by immunohistochemistry and validated by western blotting along with the qRT-PCR for mRNA expression. Expression levels were correlated with the clinicopathological parameters and patients' outcome.ResultsImmunohistochemistry showed cytoplasmic expression of NEMO/IKK expression in only 22 out of 75 (29.33%) cases. This result was confirmed by western blotting, and correlated well with the immunohistochemical expression of NEMO/IKK protein (48kDa). In addition, downregulation of this gene was found in 87.93% of the cases when compared with the normal tissues. On statistical analysis, loss of NEMO/IKK protein was correlated with neovascularization, high mitotic count, and presence of vascular loop (p<0.05). There was less overall survival rate with low expression of NEMO/IKK protein in patients with uveal melanoma.ConclusionThis was the first study suggesting the relevant role of NEMO/IKK protein, and highlights the prognostic significance with outcome in uveal melanoma patients. This protein might be used as a screening biomarker in these patients after large-scale validation and translational studies.
AD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, Dept Ocular Pathol, New Delhi, IndiaAD  - AIIMS, Dept Biochem, New Delhi, IndiaAD  - AIIMS, IRCH, Dept Med Oncol, New Delhi, IndiaAD  - JMI, Dept Biosci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - Jamia Millia IslamiaPU  - SPRINGER INTERNATIONAL PUBLISHING AG
PI  - CHAM
PA  - GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
DA  - DEC
PY  - 2018
VL  - 20
IS  - 12
SP  - 1592
EP  - 1603
DO  - 10.1007/s12094-018-1895-3
AN  - WOS:000449253900011
ER  -

TY  - JOUR
AU  - Singh, NP
AU  - Makkar, JK
AU  - Singh, PM
TI  - Reporting of time to rescue analgesia Would it have made a difference in results?
T2  - EUROPEAN JOURNAL OF ANAESTHESIOLOGY
AD  - Univ Manitoba, Hlth Sci Ctr, Dept Anaesthesia, Winnipeg, MB, CanadaAD  - Post Grad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh, IndiaAD  - All India Inst Med Sci, Dept Anaesthesia & Intens Care, New Delhi, IndiaC3  - University of ManitobaC3  - Children's Hospital Research Institute of ManitobaC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - DEC
PY  - 2018
VL  - 35
IS  - 12
SP  - 986
EP  - 987
DO  - 10.1097/EJA.0000000000000847
AN  - WOS:000455899400016
ER  -

TY  - JOUR
AU  - Singh, P
AU  - Makharia, GK
TI  - Screening for Celiac Disease in Canada Reply
T2  - CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
AD  - Beth Israel Deaconess Med Ctr, Div Gastroenterol & Hepatol, Boston, MA 02215 USAAD  - All India Inst Med Sci, Dept Gastroenterol & Human Nutr, New Delhi, IndiaC3  - Harvard UniversityC3  - Beth Israel Deaconess Medical CenterC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - DEC
PY  - 2018
VL  - 16
IS  - 12
SP  - 2003
EP  - 2003
DO  - 10.1016/j.cgh.2018.08.030
AN  - WOS:000450331100034
ER  -

TY  - JOUR
AU  - Singh, S
AU  - Sahoo, AK
AU  - Ramam, M
AU  - Bhari, N
TI  - Mucocutaneous spider angiomas in an adolescent with chronic liver disease
T2  - ARCHIVES OF DISEASE IN CHILDHOOD
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - BMJ PUBLISHING GROUP
PI  - LONDON
PA  - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
DA  - DEC
PY  - 2018
VL  - 103
IS  - 12
SP  - 1145
EP  - 1145
DO  - 10.1136/archdischild-2017-314406
AN  - WOS:000458896100014
ER  -

TY  - JOUR
AU  - Singh, V
AU  - Reddy, KC
AU  - Kumar, IDV
AU  - Chauhan, BKS
AU  - Reddy, S
TI  - Morphometric study of Intratemporal course of facial nerve in relation to pneumatization of temporal bone-An original study
T2  - JOURNAL OF THE ANATOMICAL SOCIETY OF INDIA
KW  - Tympanic segment
KW  - Mastoid segment
KW  - Incus pointer
KW  - latrogenic injuries
KW  - Facial nerve
KW  - SURGICAL ANATOMY
KW  - MASTOID SEGMENT
KW  - LANDMARKS
AB  - Introduction: Facial nerve (C.N VII) is the nerve of facial expression and communication. The intratemporal part of this nerve comprising tympanic and mastoid segments, is very vulnerable to injury during ear surgeries. Hence to safely navigate around this part of the nerve one has to be very familiar with 3D anatomy of the temporal bone and crucial landmarks present in relation to the nerve. Aim of this study is to know the exact morphometry of Intratemporal part of the facial nerve in relation to Pneumatization of temporal bone.
   Material and methods: The present study was carried out on 54 cadaveric temporal bones obtained from the department of anatomy, Santosh Medical College, Santosh University, Delhi-NCR. With the pneumatization determined by computerized tomography (CT), the dissection was performed by standard techniques of 'canal wall up' mastoidectomy and 'canal wall down' mastoidectomy. Temporal bones have been classified into 3 groups: Group I-Well Pneumatised bones, Group II- Mixed type of Pneumatised bones and Group III- Sclerosed bones. The mean, standard deviation (S.D), maximum and minimum values were calculated in all the groups for the lengths of the facial nerve.
   Results: The total length of the intratemporal part of facial nerve ranged between 19.71-30.13 mm for group I, 21.77-27.27 mm in group II and 16.21-25.19 mm in group III respectively.
   Discussion: The distal segment of nerve is most commonly injured during otologic surgeries. Incus pointer can be considered as a landmark to identify the facial nerve. Accordingly the tympano mastoid part of the facial nerve can be divided into proximal, distal and stylomastoid foramen segments. Radiological evaluations such as Computed Tomographic (CT) imaging techniques and MRI techniques like FIESTA (Fast Imaging Employing Steady-state Acquisition) have become popular in identifying these segments. The morphometric values of facial nerve provided in the present study can help in assessment during procedures, like end to end anastamosis and cable nerve graft repairs in iatrogenic injuries. (C) 2018 Anatomical Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd. All rights reserved.
AD  - Santosh Univ, Santosh Med Coll & Hosp, Dept Anat, Delhi, Ncr, IndiaAD  - AIIMS, Dept Otorhinolaryngol, New Delhi, IndiaAD  - Santosh Univ, Santosh Med Coll & Hosp, Dept Radiol, Delhi, Ncr, IndiaAD  - Osmania Med Coll & Hosp, Dept ENT, Hyderabad, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - DEC
PY  - 2018
VL  - 67
IS  - 2
SP  - 110
EP  - 114
DO  - 10.1016/j.jasi.2018.03.002
AN  - WOS:000452321500003
ER  -

TY  - JOUR
AU  - Soni, S
AU  - Muthukrishnan, SP
AU  - Sood, M
AU  - Kaur, S
AU  - Mehta, N
AU  - Sharma, R
TI  - A novel method for assessing patients with schizophrenia and their first-degree relatives by increasing cognitive load of visuo-spatial working memory
T2  - ASIA-PACIFIC PSYCHIATRY
KW  - cognitive impairment
KW  - first-degree relative
KW  - memory load
KW  - schizophrenia
KW  - working memory
KW  - DEFICITS
KW  - CAPACITY
KW  - DISORDER
KW  - FEATURES
KW  - PREDICTS
AB  - Introduction: In patients with schizophrenia, social and functional outcome is determined by the cognitive impairment. Assessment of visuo-spatial working memory (VSWM) which can simulate the day-to-day activities by simultaneous involvement of various elements of working memory may reflect disorganized thinking and fragmentation of thoughts in schizophrenia.
   Methods: Thirty-six patients with schizophrenia, 29 first-degree relatives of patients, and 25 healthy controls performed a VSWM task with three memory loads (comprising three pairs, six pairs, and eight pairs of abstract pictures). They were administered Hindi version of the Mini Mental State Examination, Scale for the Assessment of Negative Symptoms and Scale for the Assessment of Positive Symptoms, and Edinburgh handedness inventory.
   Results: Patients (mean age 27.29(5.98) years) committed significantly higher number of errors than healthy controls (mean age 26.76(6.08) years) in load 3 (P = 0.012) and total errors (P = 0.018). Within all the groups, errors in load 3 were significantly higher than in load 2. Significant correlation was observed between years of education (r = -0.388, P = 0.021), treatment duration (r = -0.880, P < 0.001), negative symptoms scores (r = 0.345, P = 0.039), and the total errors committed by patients.
   Discussion: Visuo-spatial working memory was impaired in schizophrenia with increasing cognitive load with no difference in search time between the groups.
AD  - All India Inst Med Sci, Dept Physiol, Room 6004,Convergence Block, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - DEC
PY  - 2018
VL  - 10
IS  - 4
C7  - e12333
DO  - 10.1111/appy.12333
AN  - WOS:000456946200006
ER  -

TY  - JOUR
AU  - Takkar, B
AU  - Saxena, H
AU  - Rathi, A
AU  - Singh, R
TI  - Autoimmune thyroiditis and central serous chorioretinopathy may have a relation
T2  - MEDICAL HYPOTHESES
KW  - ASSOCIATION
KW  - ANTIBODIES
KW  - LOCULATION
KW  - DISEASE
KW  - FLUID
KW  - EYES
AB  - Autoimmune thyroiditis (AT) is an important cause of hypothyroidism, and central serous chorioretinopathy (CSCR) is an independent disease of the choroid and retina that leads to accumulation of fluid beneath the retina. While AT has been associated with multiple antibodies, CSCR is still regarded as idiopathic despite extensive research. We hypothesize a causative association between these 2 conditions on the basis of our experience of a case where both CSCR and AT presented simultaneously and depicted a parallel course. CSCR was documented with retinal imaging while AT was documented with serum antibody titers. Further, we discuss the possible mechanisms that may be involved in this intriguing association.
AD  - All India Inst Med Sci, Dept Ophthalmol, Bhopal, IndiaAD  - AIIMS, Dr RP Ctr Ophthalm Sci, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol & Metab, Bhopal, IndiaC3  - All India Institute of Medical Sciences (AIIMS) BhopalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) BhopalPU  - CHURCHILL LIVINGSTONE
PI  - EDINBURGH
PA  - JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
DA  - DEC
PY  - 2018
VL  - 121
SP  - 180
EP  - 182
DO  - 10.1016/j.mehy.2018.10.003
AN  - WOS:000452568500045
ER  -

TY  - JOUR
AU  - Tandon, N
AU  - Anjana, RM
AU  - Mohan, V
AU  - Kaur, T
AU  - Afshin, A
AU  - Ong, K
AU  - Mukhopadhyay, S
AU  - Thomas, N
AU  - Bhatia, E
AU  - Krishnan, A
AU  - Mathur, P
AU  - Dhaliwal, RS
AU  - Shukla, DK
AU  - Bhansali, A
AU  - Prabhakaran, D
AU  - Rao, P
AU  - Yajnik, CS
AU  - Kumar, GA
AU  - Varghese, CM
AU  - Furtado, M
AU  - Agarwal, SK
AU  - Arora, M
AU  - Bhardwaj, D
AU  - Chakma, JK
AU  - Cornaby, L
AU  - Dutta, E
AU  - Glenn, S
AU  - Gopalakrishnan, N
AU  - Gupta, R
AU  - Jeemon, P
AU  - Johnson, SC
AU  - Khanna, T
AU  - Kinra, S
AU  - Kutz, M
AU  - Muraleedharan, P
AU  - Naik, N
AU  - Odell, CM
AU  - Oommen, AM
AU  - Pandian, JD
AU  - Parameswaran, S
AU  - Pati, S
AU  - Prasad, N
AU  - Raju, DS
AU  - Roy, A
AU  - Sharma, M
AU  - Shekhar, C
AU  - Shukla, SR
AU  - Singh, NP
AU  - Thakur, JS
AU  - Unnikrishnan, R
AU  - Varughese, S
AU  - Xavier, D
AU  - Zachariah, G
AU  - Lim, SS
AU  - Naghavi, M
AU  - Dandona, R
AU  - Vos, T
AU  - Murray, CJL
AU  - Reddy, KS
AU  - Swaminathan, S
AU  - Dandona, L
A1  - India State-Level Dis Burden Initi
TI  - The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990-2016
T2  - LANCET GLOBAL HEALTH
KW  - URBAN-RURAL EPIDEMIOLOGY
KW  - 10-YEAR FOLLOW-UP
KW  - PREVALENCE
KW  - POPULATION
KW  - GLUCOSE
AB  - Background The burden of diabetes is increasing rapidly in India but a systematic understanding of its distribution and time trends is not available for every state of India. We present a comprehensive analysis of the time trends and heterogeneity in the distribution of diabetes burden across all states of India between 1990 and 2016.
   Methods We analysed the prevalence and disability-adjusted life-years (DALYs) of diabetes in the states of India from 1990 to 2016 using all available data sources that could be accessed as part of the Global Burden of Diseases, Injuries, and Risk Factors Study 2016, and assessed heterogeneity across the states. The states were placed in four groups based on epidemiological transition level (ETL), defined on the basis of the ratio of DALYs from communicable diseases to those from non-communicable diseases and injuries combined, with a low ratio denoting high ETL and vice versa. We assessed the contribution of risk factors to diabetes DALYs and the relation of overweight (body-mass index 25 kg/m(2) or more) with diabetes prevalence. We calculated 95% uncertainty intervals (UIs) for the point estimates.
   Findings The number of people with diabetes in India increased from 26.0 million (95% UI 23-4-28.6) in 1990 to 65.0 million (58.7-71.1) in 2016. The prevalence of diabetes in adults aged 20 years or older in India increased from 5.5% (4.9-6.1) in 1990 to 7.7% (6.9-8.4) in 2016. The prevalence in 2016 was highest in Tamil Nadu and Kerala (high ETL) and Delhi (higher-middle ETL), followed by Punjab and Goa (high ETL) and Karnataka (higher-middle ETL). The age-standardised DALY rate for diabetes increased in India by 39.6% (32.1-46.7) from 1990 to 2016, which was the highest increase among major non-communicable diseases. The age-standardised diabetes prevalence and DALYs increased in every state, with the percentage increase among the highest in several states in the low and lower-middle ETL state groups. The most important risk factor for diabetes in India was overweight to which 36.0% (22.6-49.2) of the diabetes DALYs in 2016 could be attributed. The prevalence of overweight in adults in India increased from 9.0% (8.7-9.3) in 1990 to 20.4% (19.9-20.8) in 2016; this prevalence increased in every state of the country. For every 100 overweight adults aged 20 years or older in India, there were 38 adults (34-42) with diabetes, compared with the global average of 19 adults (17-21) in 2016.
   Interpretation The increase in health loss from diabetes since 1990 in India is the highest among major non-communicable diseases. With this increase observed in every state of the country, and the relative rate of increase highest in several less developed low ETL states, policy action that takes these state-level differences into account is needed urgently to control this potentially explosive public health situation. Copyright (C) 2018 The Author(s). Published by Elsevier Ltd.
AD  - All India Inst Med Sci, Dept Endocrinol, New Delhi, IndiaAD  - All India Inst Med Sci, Ctr Community Med, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Nephrol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaAD  - Madras Diabet Res Fdn, Madras, Tamil Nadu, IndiaAD  - Dr Mohans Diabet Special Ctr, Madras, Tamil Nadu, IndiaAD  - Indian Council Med Res, New Delhi, IndiaAD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - Inst Postgrad Med Educ & Res, Dept Endocrinol & Metab, Kolkata, IndiaAD  - Christian Med Coll & Hosp, Dept Endocrinol Diabet & Metab, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp, Community Hlth Dept, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp, Dept Nephrol, Vellore, Tamil Nadu, IndiaAD  - Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrinol, Lucknow, Uttar Pradesh, IndiaAD  - Sanjay Gandhi Postgrad Inst Med Sci, Dept Nephrol, Lucknow, Uttar Pradesh, IndiaAD  - Indian Council Med Res, Natl Ctr Dis Informat & Res, Bengaluru, IndiaAD  - Postgrad Inst Med Educ & Res, Dept Endocrinol, Chandigarh, IndiaAD  - Postgrad Inst Med Educ & Res, Sch Publ Hlth, Chandigarh, IndiaAD  - Publ Hlth Fdn India, Gurugram, IndiaAD  - Ramdevrao Hosp, Kumudini Devi Diabet Res Ginter, Hyderabad, Telangana, IndiaAD  - King Edward Mem Hosp Res Ctr, Kamalnayan Bajaj Diabetol Res Ctr, Pune, Maharashtra, IndiaAD  - Madras Med Coll & Govt Gen Hosp, Inst Nephrol, Madras, Tamil Nadu, IndiaAD  - Rajasthan Univ Hlth Sci, Acad Res Dev Unit, Jaipur, Rajasthan, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Trivandrum, Kerala, IndiaAD  - London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, EnglandAD  - Christian Med Coll & Hosp, Dept Neurol, Ludhiana, Punjab, IndiaAD  - Jawaharlal Inst Postgrad Med Educ & Res, Dept Nephrol, Pondicherry, IndiaAD  - Indian Council Med Res, Reg Med Res Ctr, Bhubaneswar, Odisha, IndiaAD  - Nizams Inst Med Sci, Dept Nephrol, Hyderabad, Telangana, IndiaAD  - Symbiosis Int Univ, Symbiosis Stat Inst, Pune, Maharashtra, IndiaAD  - Super Special Hosp, Dept Internal Med, Ghaziabad, IndiaAD  - St Johns Med Coll, Dept Pharmacol, Bengaluru, IndiaAD  - St Johns Res Inst, Div Clin Res & Training, Bengaluru, IndiaAD  - Mother Hosp, Dept Cardiol, Trichur, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Madras Diabetes Research FoundationC3  - Indian Council of Medical Research (ICMR)C3  - Institute for Health Metrics & EvaluationC3  - University of WashingtonC3  - University of Washington SeattleC3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Centre for Disease Informatics & Research (NCDIR)C3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Public Health Foundation of IndiaC3  - Madras Medical College & General HospitalC3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - Jawaharlal Institute of Postgraduate Medical Education & ResearchC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - Regional Medical Research Centre (RMRC), BhubaneswarC3  - Nizam's Institute of Medical SciencesC3  - Symbiosis International UniversityC3  - St. John's National Academy of Health SciencesC3  - St. John's Medical CollegeC3  - St. John's National Academy of Health SciencesC3  - St. John's Research InstitutePU  - ELSEVIER SCI LTD
PI  - London
PA  - 125 London Wall, London, ENGLAND
DA  - DEC
PY  - 2018
VL  - 6
IS  - 12
SP  - E1352
EP  - E1362
DO  - 10.1016/S2214-109X(18)30387-5
AN  - WOS:000449748200029
ER  -

TY  - JOUR
AU  - Tomar, GS
AU  - Singh, GP
AU  - Lahkar, D
AU  - Sengar, K
AU  - Nigam, R
AU  - Mohan, M
AU  - Anindya, R
TI  - New biomarkers in brain trauma
T2  - CLINICA CHIMICA ACTA
KW  - Biomarkers
KW  - Traumatic brain injury
KW  - Cerebrospinal fluid
KW  - Serum
KW  - UCH-L1
KW  - C-TERMINAL HYDROLASE-L1
KW  - II-SPECTRIN
KW  - INJURY
KW  - SERUM
KW  - PROTEIN
KW  - BLOOD
KW  - MARINOBUFAGENIN
KW  - PREDICTORS
KW  - MORTALITY
KW  - DIAGNOSIS
AB  - Brain-specific biomolecules are being increasingly investigated as a viable alternative to the clinical scores and radiological features, on which we still rely upon for stratification, therapy and predicting outcome in traumatic brain injury (TBI). TBI generally leads to release of various chemical compound within the cerebrospinal fluid (CSF) or blood depending on the severity of injury, which were studied variedly in last decades. However, most of these compounds being non-specific to brain, their applicability was challenged further. This review encompasses the novel and promising biomarkers being studied in the present decade, with encouraging results in laboratory and animal or human models.
AD  - AIIMS, JPNA Trauma Ctr, Dept Neuroanaesthesiol & Crit Care, New Delhi 110029, IndiaAD  - Medanta, Dept Neurocrit Care & Neuroanesthesia, Gurugram, Haryana, IndiaAD  - AIIMS, JPNA Trauma Ctr, Dept Lab Med, New Delhi 110029, IndiaAD  - IIT Hyderabad, Dept Biotechnol, Sangareddy 502285, Telangana, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - HyderabadPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - DEC
PY  - 2018
VL  - 487
SP  - 325
EP  - 329
DO  - 10.1016/j.cca.2018.10.025
AN  - WOS:000451491300053
ER  -

TY  - JOUR
AU  - Tullus, K
AU  - Webb, H
AU  - Bagga, A
TI  - Management of steroid-resistant nephrotic syndrome in children and adolescents
T2  - LANCET CHILD & ADOLESCENT HEALTH
KW  - FOCAL SEGMENTAL GLOMERULOSCLEROSIS
KW  - MINIMAL CHANGE DISEASE
KW  - MYCOPHENOLATE-MOFETIL
KW  - RITUXIMAB TREATMENT
KW  - INTRAVENOUS CYCLOPHOSPHAMIDE
KW  - CLINICAL-TRIAL
KW  - CYCLOSPORINE-A
KW  - CASE SERIES
KW  - THERAPY
KW  - EFFICACY
AB  - More than 85% of children and adolescents (majority between 1-12 years old) with idiopathic nephrotic syndrome show complete remission of proteinuria following daily treatment with corticosteroids. Patients who do not show remission after 4 weeks' treatment with daily prednisolone are considered to have steroid-resistant nephrotic syndrome (SRNS). Renal histology in most patients shows presence of focal segmental glomerulosclerosis, minimal change disease, and (rarely) mesangioproliferative glomerulonephritis. A third of patients with SRNS show mutations in one of the key podocyte genes. The remaining cases of SRNS are probably caused by an undefined circulating factor. Treatment with calcineurin inhibitors (ciclosporin and tacrolimus) is the standard of care for patients with non-genetic SRNS, and approximately 70% of patients achieve a complete or partial remission and show satisfactory-long-term outcome. Additional treatment with drugs that inhibit the renin angiotensin axis is recommended for hypertension and for reducing remaining proteinuria. Patients with SRNS who do not respond to treatment with calcineurin inhibitors or other innnunosuppressive drugs can show declining kidney function and are at risk for end stage renal failure. Approximately a third of those who undergo renal transplantation show recurrent focal segmental glomerulosclerosis in the allograft and often respond to combined treatment with plasma exchange, rituximab, and intensified immunosuppression.
AD  - Great Ormond St Hosp Sick Children, Nephrol Unit, Great Ormond St, London WC1N 3JH, EnglandAD  - All India Inst Med Sci, Div Nephrol, Indian Council Med Res, Adv Ctr Res Nephrol, New Delhi, IndiaC3  - University of LondonC3  - University College LondonC3  - Great Ormond Street Hospital for Children NHS Foundation TrustC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Council of Medical Research (ICMR)PU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - DEC
PY  - 2018
VL  - 2
IS  - 12
SP  - 880
EP  - 890
DO  - 10.1016/S2352-4642(18)30283-9
AN  - WOS:000450156400015
ER  -

TY  - JOUR
AU  - Verma, R
AU  - Kumar, N
AU  - Mahapatra, A
AU  - Shah, B
TI  - Effectiveness of tDCS augmentation for co-morbid obsessive compulsive disorder in chronic schizophrenia: A case report
T2  - ASIAN JOURNAL OF PSYCHIATRY
KW  - Obsessive
KW  - Compulsive
KW  - Schizophrenia
KW  - tDCS
KW  - Transcranial
KW  - DIRECT-CURRENT STIMULATION
KW  - SYMPTOMS
KW  - PREVALENCE
AB  - Management of obsessive compulsive disorder (OCD) remains a challenge, particularly in individuals having co-existing psychotic symptoms. Even in patients with schizophrenia having a fair to good response in psychotic symptoms, these obsessive-compulsive symptoms defy response to antipsychotic and anti-obsessive pharmacotherapeutic approach to a great extent. Recently developed neuromodulation techniques such as transcranial direct current stimulation (tDCS) can serve a viable and effective approach to manage such cases. The present paper documents the first utilization of tDCS (cathode: supplementary motor area; anode: right occipital cortex) as an add-on approach to pharmacotherapy to manage co-morbid OCD in a case of chronic schizophrenia.
AD  - All India Inst Med Sci, Dept Psychiat, Room 4096,4th Floor,Teaching Block, New Delhi 110029, IndiaAD  - Dr Ram Manohar Lohia Hosp, Post Grad Inst Med Educ & Res, Dept Psychiat, New Delhi, IndiaAD  - Annapurna Neuro Hosp, Kathmandu, NepalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - DEC
PY  - 2018
VL  - 38
SP  - 9
EP  - 11
DO  - 10.1016/j.ajp.2018.10.013
AN  - WOS:000452790400008
ER  -

TY  - JOUR
AU  - Verma, S
AU  - Shah, R
AU  - Bhat, A
AU  - Bhat, GR
AU  - Dada, R
AU  - Kumar, R
TI  - A FAMILIAL CASE REPORT OF A 13;22 CHROMOSOMAL TRANSLOCATION WITH RECURRENT INTRACYTOPLASMIC SPERM INJECTION FAILURE
T2  - BALKAN JOURNAL OF MEDICAL GENETICS
KW  - Assisted reproductive technique (ART) center
KW  - Infertility
KW  - Intracytoplasmic sperm injection (ICSI)
KW  - In vitro fertilization (IVF)
KW  - Karyotyping
KW  - Translocation
KW  - Preimplantation genetic diagnosis (PGD)
KW  - Spontaneous abortions
KW  - PREIMPLANTATION GENETIC DIAGNOSIS
KW  - RECIPROCAL TRANSLOCATIONS
KW  - ANEUPLOIDY
KW  - INFERTILITY
KW  - CARRIERS
KW  - MALES
KW  - WOMEN
KW  - RISK
AB  - The importance of cytogenetic analysis in a family with reproductive failure in two siblings is highlighted, where two siblings and their mother presented with a balanced translocation between chromosomes 13; 22. The clinical evaluation had shown the female to be normal and the male to be oligoasthenoteratozoospermic despite repeated semen analysis. The couple was referred to our laboratory after three consecutive intracytoplasmic sperm injection (ICSI) failures at a local assisted reproductive technique (ART) center. Peripheral blood lymphocytes, obtained for karyotyping, were studied by a standard G-banding technique. Chromosomal analysis of the members of the pedigree, including the probands, showed the presence of the same translocation, t(13;22)(q21.2;q13.3), carried by three generations of the family. The sister and the mother of the proband had multiple spontaneous abortions in the first trimester. The spouses, when examined cytogenetically, were found to be normal. We propose the involvement of a balanced t(13;22)(q21.2;q13.3) chromosomal translocation in the pathogenesis of recurrent ART or spontaneous reproductive failures. Hence, it is suggested that all cases with structural chromosomal abnormalities be counseled prior to opting for ART and undergoing pre-implantation genetic diagnosis (PGD). This would prevent recurrent financial, physical and emotional stress in couples seeking ART.
AD  - Shri Mata Vaishno Devi Univ, Dept Biotechnol, Katra, Jammu & Kashmir, IndiaAD  - All India Inst Med Sci, Anat Dept, Lab Mol Reprod & Genet, New Delhi, IndiaC3  - Shri Mata Vaishno Devi UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MACEDONIAN ACAD SCIENCES ARTS
PI  - SKOPJE
PA  - BULEVAR KRSTE MISIRKOV 2, P. O. B. 428, SKOPJE, 1000, MACEDONIA
DA  - DEC
PY  - 2018
VL  - 21
IS  - 2
SP  - 73
EP  - 77
DO  - 10.2478/bjmg-2018-0017
AN  - WOS:000463021700013
ER  -

TY  - JOUR
AU  - Zilla, P
AU  - Yacoub, M
AU  - Zühlke, L
AU  - Beyersdorf, F
AU  - Sliwa, K
AU  - Khubulava, G
AU  - Bouzid, A
AU  - Mocumbi, AO
AU  - Velayoudam, D
AU  - Shetty, D
AU  - Ofoegbu, C
AU  - Geldenhuys, A
AU  - Brink, J
AU  - Scherman, J
AU  - du Toit, H
AU  - Hosseini, S
AU  - Zhang, H
AU  - Luo, XJ
AU  - Wang, W
AU  - Mejia, J
AU  - Kofidis, T
AU  - Higgins, RSD
AU  - Pomar, J
AU  - Bolman, RM
AU  - Mayosi, BM
AU  - Madansein, R
AU  - Bavaria, J
AU  - Yanes-Quintana, AA
AU  - Kumar, AS
AU  - Adeoye, O
AU  - Chauke, RF
AU  - Williams, DF
TI  - Global Unmet Needs in Cardiac Surgery
T2  - GLOBAL HEART
KW  - RHEUMATIC HEART-DISEASE
KW  - SUB-SAHARAN AFRICA
KW  - CHALLENGES
KW  - PREVALENCE
KW  - REGISTRY
KW  - ADULTS
KW  - MANAGEMENT
KW  - BURDEN
AB  - More than 6 billion people live outside industrialized countries and have insufficient access to cardiac surgery. Given the recently confirmed high prevailing mortality for rheumatic heart disease in many of these countries together with increasing numbers of patients needing interventions for lifestyle diseases due to an accelerating epidemiological transition, a significant need for cardiac surgery could be assumed. Yet, need estimates were largely based on extrapolated screening studies while true service levels remained unknown. A multi-author effort representing 16 high-, middle-, and low-income countries was undertaken to narrow the need assessment for cardiac surgery including rheumatic and lifestyle cardiac diseases as well as congenital heart disease on the basis of existing data deduction. Actual levels of cardiac surgery were determined in each of these countries on the basis of questionnaires, national databases, or annual reports of national societies. Need estimates range from 200 operations per million in low-income countries that are nonendemic for rheumatic heart disease to >1,000 operations per million in high- income countries representing the end of the epidemiological transition. Actually provided levels of cardiac surgery range from 0.5 per million in the assessed low- and lower-middle income countries (average 107 +/- 113 per million; representing a population of 1.6 billion) to 500 in the upper-middle-income countries (average 270 +/- 163 per million representing a population of 1.9 billion). By combining need estimates with the assessment of de facto provided levels of cardiac surgery, it emerged that a significant degree of underdelivery of often lifesaving open heart surgery does not only prevail in low- income countries but is also disturbingly high in middle-income countries.
AD  - Univ Cape Town, Christiaan Barnard Dept, Cape Town, South AfricaAD  - Imperial Coll, Harefield Heart Sci Ctr, London, EnglandAD  - Univ Cape Town, Dept Paediat Cardiol, Cape Town, South AfricaAD  - Albert Ludwigs Univ, Dept Cardiovasc Surg, Freiburg, GermanyAD  - Univ Cape Town, Hatter Inst Cardiovasc Res Africa, Cape Town, South AfricaAD  - State Dept Cardiovasc Surg, St Petersburg, RussiaAD  - Univ Constantine, Dept Cardiovasc Surg, Constantine, AlgeriaAD  - Univ Eduardo Mondlane Maputo, Dept Med Interna, Maputo, MozambiqueAD  - All India Inst Med Sci, Dept Cardiothorac & Vasc Surg, Delhi, IndiaAD  - Narayana Hlth, Cardiac Surg, Bangalore, Karnataka, IndiaAD  - Milpk Hosp, Johannesburg, South AfricaAD  - Roman Catholic Hosp, Windhoek, NamibiaAD  - Iran Univ Med Sci, Rajaie Cardiovasc Med & Res Ctr, Heart Valve Dis Res Ctr, Tehran, IranAD  - Chinese Acad Sci, Fuwai Hosp, Dept Struct Heart Dis, Beijing, Peoples R ChinaAD  - Hosp Messejana, Dept Cardiac Surg, Fortaleza, Ceara, BrazilAD  - Natl Univ Singapore, Natl Univ Hosp, Dept Cardiac Thorac & Vasc Surg, Singapore, SingaporeAD  - Johns Hopkins Univ, Dept Surg, Baltimore, MD USAAD  - Univ Barcelona, Hosp Clin Barcelona, Dept Cardiovasc Surg, Barcelona, SpainAD  - Univ Vermont, Volunteer Fac, Burlington, VT USAAD  - Univ Cape Town, Fac Hlth Sci, Deans Suite, Cape Town, South AfricaAD  - Inkosi Albert Luthuli Cent Hosp, Dept Cardiothorac Surg, Durban, South AfricaAD  - Hosp Univ Penn, Div Cardiovasc Surg, Heart & Vasc Ctr, 3400 Spruce St, Philadelphia, PA 19104 USAAD  - Hosp Manuel Fajardo, Dept Cardiol, Havana, CubaAD  - Univ Ilorin, Div Cardiothorac Surg, Ilorin, NigeriaAD  - Garankuwa Hosp, Sefako Makgatho Hlth Sci Fac, Dept Cardiothorac Surg, Pretoria, South AfricaAD  - Wake Forest Sch Med, Winston Salem, NC USAC3  - University of Cape TownC3  - Imperial College LondonC3  - University of Cape TownC3  - University of FreiburgC3  - University of Cape TownC3  - Universite ConstantineC3  - Eduardo Mondlane UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Iran University of Medical SciencesC3  - Chinese Academy of SciencesC3  - Chinese Academy of Medical Sciences - Peking Union Medical CollegeC3  - Fu Wai Hospital - CAMSC3  - National University of SingaporeC3  - Johns Hopkins UniversityC3  - University of BarcelonaC3  - Hospital Clinic de BarcelonaC3  - University of VermontC3  - University of Cape TownC3  - University of PennsylvaniaC3  - University of IlorinC3  - Sefako Makgatho Health Sciences UniversityC3  - Wake Forest UniversityPU  - UBIQUITY PRESS LTD
PI  - LONDON
PA  - Unit 3.22, East London Works, 65-75 Whitechapel Road, LONDON, E1 1DU, ENGLAND
DA  - DEC
PY  - 2018
VL  - 13
IS  - 4
SP  - 293
EP  - 303
DO  - 10.1016/j.gheart.2018.08.002
AN  - WOS:000448480300010
ER  -

TY  - JOUR
AU  - Zunt, JR
AU  - Kassebaum, NJ
AU  - Blake, N
AU  - Glennie, L
AU  - Wright, C
AU  - Nichols, E
AU  - Abd-Allah, F
AU  - Abdela, J
AU  - Abdelalim, A
AU  - Adamu, AA
AU  - Adib, MG
AU  - Ahmadi, A
AU  - Ahmed, MB
AU  - Aichour, AN
AU  - Aichour, I
AU  - Aichour, MTE
AU  - Akseer, N
AU  - Al-Raddadi, RM
AU  - Alahdab, F
AU  - Alene, KA
AU  - Aljunid, SM
AU  - AlMazora, MA
AU  - Khalid
AU  - Alvis-Guzman, N
AU  - Animut, MD
AU  - Anjomshoa, M
AU  - Ansha, MG
AU  - Asghar, RJ
AU  - Avokpaho, EFGA
AU  - Awasthi, A
AU  - Badali, H
AU  - Barac, A
AU  - Bärnighausen, TW
AU  - Bassat, Q
AU  - Bedi, N
AU  - Belachew, AB
AU  - Bhattacharyya, K
AU  - Bhutta, ZA
AU  - Bijani, A
AU  - Butt, ZA
AU  - Carvalho, F
AU  - Castañeda-Orjuela, CA
AU  - Chitheer, A
AU  - Choi, JYJ
AU  - Christopher, DJ
AU  - Dang, AK
AU  - Daryani, A
AU  - Demoz, GT
AU  - Djalalinia, S
AU  - Do, HP
AU  - Dubey, M
AU  - Dubljanin, E
AU  - Duken, EE
AU  - Zaki, ME
AU  - Elyazar, IR
AU  - Fakhim, H
AU  - Fernandes, E
AU  - Fischer, F
AU  - Fukumoto, T
AU  - Ganji, M
AU  - Gebre, AK
AU  - Gebremeskel, A
AU  - Gessner, BD
AU  - Gopalani, SV
AU  - Guo, YM
AU  - Gupta, R
AU  - Hailu, GB
AU  - Haj-Mirzaian, A
AU  - Hamidi, S
AU  - Hay, S
AU  - Henok, A
AU  - Irvani, SSN
AU  - Jha, RP
AU  - Jürisson, M
AU  - Kahsay, A
AU  - Karami, M
AU  - Karch, A
AU  - Kasaeian, A
AU  - Kassa, TD
AU  - Kefale, AT
AU  - Khader, YS
AU  - Khalil, IA
AU  - Khan, EA
AU  - Khang, YH
AU  - Khubchandani, J
AU  - Kimokoti, RW
AU  - Kisa, A
AU  - Lami, FH
AU  - Levi, M
AU  - Li, SS
AU  - Loy, CT
AU  - Majdan, M
AU  - Majeed, A
AU  - Mantovani, LG
AU  - Martins-Melo, FR
AU  - McAlinden, C
AU  - Mehta, V
AU  - Melese, A
AU  - Memish, ZA
AU  - Mengistu, G
AU  - Mestrovic, T
AU  - Mezgebe, HB
AU  - Miazgowski, B
AU  - Milosevic, B
AU  - Mokdad, AH
AU  - Monasta, L
AU  - Moradi, G
AU  - Moraga, P
AU  - Mousavi, SM
AU  - Mueller, UO
AU  - Murthy, S
AU  - Mustafa, G
AU  - Naheed, A
AU  - Naik, G
AU  - Newton, CRJ
AU  - Nirayo, YL
AU  - Nixon, MR
AU  - Ofori-Asenso, R
AU  - Ogbo, FA
AU  - Olagunju, TO
AU  - Olusanya, BO
AU  - Ortiz, JR
AU  - Owolabi, MO
AU  - Patel, S
AU  - Pinilla-Monsalve, GD
AU  - Postma, MJ
AU  - Qorbani, M
AU  - Rafiei, A
AU  - Rahimi-Movaghar, V
AU  - Reiner, RC
AU  - Renzaho, AMN
AU  - Rezai, MS
AU  - Roba, KT
AU  - Ronfani, L
AU  - Roshandel, G
AU  - Rostami, A
AU  - Safari, S
AU  - Safiri, S
AU  - Sagar, R
AU  - Samy, AM
AU  - Milicevic, MMS
AU  - Sartorius, B
AU  - Sarvi, S
AU  - Sawhney, M
AU  - Saxena, S
AU  - Shafieesabet, A
AU  - Shaikh, MA
AU  - Sharif, M
AU  - Shigematsu, M
AU  - Si, S
AU  - Skiadaresi, E
AU  - Smith, M
AU  - Somayaji, R
AU  - Sufiyan, MB
AU  - Tawye, NY
AU  - Temsah, MH
AU  - Tortajada-Girbés, M
AU  - Tran, KB
AU  - Ukwaja, KN
AU  - Ullah, I
AU  - Vujcic, IS
AU  - Wagnew, F
AU  - Waheed, Y
AU  - Weldegwergs, KG
AU  - Winkler, AS
AU  - Wiyeh, AB
AU  - Wiysonge, CS
AU  - Wyper, GMA
AU  - Yimer, EM
AU  - Yonemoto, N
AU  - Zaidi, Z
AU  - Zenebe, ZM
AU  - Feigin, VL
AU  - Vos, T
AU  - Murray, CJL
A1  - GBD 2016 Meningitis Collaborators
TI  - Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
T2  - LANCET NEUROLOGY
KW  - PNEUMOCOCCAL CONJUGATE VACCINE
KW  - BACTERIAL-MENINGITIS
KW  - MENINGOCOCCAL DISEASE
KW  - UNITED-STATES
KW  - RISK
KW  - IMPACT
KW  - EPIDEMIOLOGY
KW  - MORTALITY
KW  - CHILDREN
KW  - AFRICA
AB  - Background Acute meningitis has a high case-fatality rate and survivors can have severe lifelong disability. We aimed to provide a comprehensive assessment of the levels and trends of global meningitis burden that could help to guide introduction, continuation, and ongoing development of vaccines and treatment programmes.
   Methods The Global Burden of Diseases, Injuries, and Risk Factors (GBD) 2016 study estimated meningitis burden due to one of four types of cause: pneumococcal, meningococcal, Haemophilus influenzae type b, and a residual category of other causes. Cause-specific mortality estimates were generated via cause of death ensemble modelling of vital registration and verbal autopsy data that were subject to standardised data processing algorithms. Deaths were multiplied by the GBD standard life expectancy at age of death to estimate years of life lost, the mortality component of disability-adjusted life-years (DALYs). A systematic analysis of relevant publications and hospital and daims data was used to estimate meningitis incidence via a Bayesian meta-regression tool. Meningitis deaths and cases were split between causes with meta-regressions of aetiological proportions of mortality and incidence, respectively. Probabilities of long-term impairment by cause of meningitis were applied to survivors and used to estimate years of life lived with disability (YLDs). We assessed the relationship between burden metrics and Socio-demographic Index (SDI), a composite measure of development based on fertility, income, and education.
   Findings Global meningitis deaths decreased by 21.0% from 1990 to 2016, from 403 012 (95% uncertainty interval [UI] 319426-458 514) to 318 400 (265 218-408 705). Incident cases globally increased from 2.50 million (95% UI 2.19-2.91) in 1990 to 2.82 million (2.46-3.31) in 2016. Meningitis mortality and incidence were dosely related to SDI. The highest mortality rates and incidence rates were found in the peri-Sahelian countries that comprise the African meningitis belt, with six of the ten countries with the largest number of cases and deaths being located within this region. Haemophilus influenzae type b was the most common cause of incident meningitis in 1990, at 780 070 cases (95% UI 613 585-978 219) globally, but decreased the most (-494%) to become the least common cause in 2016, with 397 297 cases (291076-533 662). Meningococcus was the leading cause of meningitis mortality in 1990 (192833 deaths [95% UI 153 358-221 503] globally), whereas other meningitis was the leading cause for both deaths (136 423 [112 682-178 022]) and incident cases (1.25 million [1.06-1.49]) in 2016. Pneumococcus caused the largest number of YLDs (634458 [444 787-839 749]) in 2016, owing to its more severe long-term effects on survivors. Globally in 2016, 1.48 million (1.04-1.96) YLDs were due to meningitis compared with 21.87 million (18.20-28.28) DALYs, indicating that the contribution of mortality to meningitis burden is far greater than the contribution of disabling outcomes.
   Interpretation Meningitis burden remains high and progress lags substantially behind that of other vaccine-preventable diseases. Particular attention should be given to developing vaccines with broader coverage against the causes of meningitis, making these vaccines affordable in the most affected countries, improving vaccine uptake, improving access to low-cost diagnostics and therapeutics, and improving support for disabled survivors. Substantial uncertainty remains around pathogenic causes and risk factors for meningitis. Ongoing, active cause-specific surveillance of meningitis is crucial to continue and to improve monitoring of meningitis burdens and trends throughout the world. Copyright (C) The Author(s). Published by Elsevier Ltd.
AD  - Univ Washington, Dept Neurol, Seattle, WA 98104 USAAD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - Univ Washington, Dept Global Hlth, Seattle, WA 98104 USAAD  - Univ Washington, Dept Med, Seattle, WA 98195 USAAD  - Univ Washington, Dept Hlth Metr Sci, Seattle, WA 98195 USAAD  - Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, Seattle, WA USAAD  - Meningitis Res Fdn, Res Evidence & Policy Dept, Bristol, Avon, EnglandAD  - Cairo Univ, Dept Neurol, Cairo, EgyptAD  - Haramaya Univ, Sch Pharm, Harar, EthiopiaAD  - Haramaya Univ, Sch Nursing & Midwifery, Harar, EthiopiaAD  - Stellenbosch Univ, Dept Global Hlth, Cape Town, South AfricaAD  - South African Med Res Council, Cochrane South Africa, Cape Town, South AfricaAD  - St Mark Hosp, Emergency Dept, Alexandria, EgyptAD  - Kermanshah Univ Med Sci, Dept Anesthesiol, Kermanshah, IranAD  - Jimma Univ, Dept Epidemiol, Jimma, EthiopiaAD  - Jimma Univ, Mycobacteriol Res Ctr, Jimma, EthiopiaAD  - Univ Ferhat Abbas Setif, Setif, AlgeriaAD  - Higher Natl Sch Vet Med, Algiers, AlgeriaAD  - Univ Toronto, Hosp Sick Children, Ctr Global Child Hlth, Toronto, ON, CanadaAD  - King Abdulaziz Univ, Dept Family & Community Med, Jeddah, Saudi ArabiaAD  - Mayo Clin Fdn Med Educ & Res, Evidence Based Practice Ctr, Rochester, MN USAAD  - Syrian Amer Med Soc, Res Comm, Washington, DC USAAD  - Univ Gondar, Inst Publ Hlth, Gondar, EthiopiaAD  - Australian Natl Univ, Res Sch Populat Hlth, Canberra, ACT, AustraliaAD  - Kuwait Univ, Dept Hlth Policy & Management, Safat, KuwaitAD  - Natl Univ Malaysia, Int Ctr Casemix & Clin Coding, Bandar Tun Razak, MalaysiaAD  - King Saud Univ, Dept Pediat, Riyadh, Saudi ArabiaAD  - Univ Cartagena, Res Grp Hlth Econ, Cartagena, ColombiaAD  - Univ Coast, Res Grp Hosp Management & Hlth Policies, Barranquilla, ColombiaAD  - Arba Minch Univ, Arba Minch, EthiopiaAD  - Univ Tehran Med Sci, Dept Hlth Management & Econ, Tehran, IranAD  - Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Dept Pharmacol, Tehran, IranAD  - Univ Tehran Med Sci, Noncommunicable Dis Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Malignancies Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Oncol & Stem CellTransplantat Res Ctr, Tehran, IranAD  - Debre Berhan Univ, Dept Publ Hlth, Debre Berhan, EthiopiaAD  - South Asian Publ Hlth Forum, Lahore, PakistanAD  - Benin Clin Res Inst IRCB, Abomey Calavi, BeninAD  - Controle Malad Infect Lab Studies & Res Act Hlth, Porto Novo, BeninAD  - Indian Inst Publ Hlth, Gandhinagar, IndiaAD  - Publ Hlth Fdn India, Gurugram, IndiaAD  - Mazandaran Univ Med Sci, Dept Med Mycol, Sari, IranAD  - Mazandaran Univ Med Sci, Toxoplasmosis Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Mol & Cell Biol Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Pediat, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Immunol, Sari, IranAD  - Clin Infect & Trop Dis, Belgrade, SerbiaAD  - Clin Ctr Serbia, Belgrade, SerbiaAD  - Univ Belgrade, Fac Med, Belgrade, SerbiaAD  - Univ Belgrade, Fac Med, Inst Social Med, Ctr Sch Publ Hlth & Hlth Management, Belgrade, SerbiaAD  - Univ Belgrade, Fac Med, Inst Epidemiol, Belgrade, SerbiaAD  - Heidelberg Univ Hosp, Inst Publ Hlth, Heidelberg, GermanyAD  - Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USAAD  - Barcelona Inst Global Hlth, Barcelona, SpainAD  - Manhica Hlth Res Ctr, Manhica, MozambiqueAD  - Gandhi Med Coll Bhopal, Dept Community Med, Bhopal, IndiaAD  - Jazan Univ, Jazan, Saudi ArabiaAD  - Mekelle Univ, Sch Publ Hlth, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Pharm, Mekelle, EthiopiaAD  - Mekelle Univ, Coll Hlth Sci, Mekelle, EthiopiaAD  - Mekelle Univ, Biomed Sci Div, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Nutr & Dietet, Mekelle, EthiopiaAD  - Mekelle Univ, Clin Pharm Unit, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Med, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Midwifery, Mekelle, EthiopiaAD  - Natl Inst Biomed Genom, Dept Stat & Computat Genom, Kalyani, W Bengal, IndiaAD  - Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, PakistanAD  - Babol Univ Med Sci, Social Determinant Hlth Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Infect Dis & Trop Med Res Ctr, Babol Sar, IranAD  - Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, CanadaAD  - Univ British Columbia, Dept Pediat, Vancouver, BC, CanadaAD  - Al Shifa Trust Eye Hosp, Al Shifa Sch Publ Hlth, Rawalpindi, PakistanAD  - Univ Porto, Inst Publ Hlth, Porto, PortugalAD  - Univ Porto, REQUIMTE LAQV, Porto, PortugalAD  - Univ Porto, Appl Mol Biosci Unit, Porto, PortugalAD  - NIH, Colombian Natl Hlth Observ, Bogota, ColombiaAD  - Univ Nacl Colombia, Epidemiol & Publ Hlth Evaluat Grp, Bogota, ColombiaAD  - Minist Hlth, Dept Publ Hlth, Baghdad, IraqAD  - Minist Hlth, Res Dept, Prince Mohammed Bin Abdulaziz Hosp, Baghdad, IraqAD  - Seoul Natl Univ Hosp, Seoul, South KoreaAD  - Christian Med Coll & Hosp CMC, Dept Pulm Med, Vellore, Tamil Nadu, IndiaAD  - Duy Tan Univ, Inst Global Hlth Innovat, Hanoi, VietnamAD  - Aksum Univ, Dept Clin Pharm, Aksum, EthiopiaAD  - Addis Ababa Univ, Addis Ababa, EthiopiaAD  - Minist Hlth & Med Educ, Res & Technol, Tehran, IranAD  - United Nations World Food Programme, New Delhi, IndiaAD  - Wollega Univ, Dept Hlth Sci, Nekemte, EthiopiaAD  - Mansoura Univ, Dept Clin Pathol, Mansoura, EgyptAD  - Eijkman Inst Mol Biol, Eijkman Oxford Clin Res Unit, Jakarta, IndonesiaAD  - Urmia Univ Med Sci, Dept Med Parasitol & Mycol, Orumiyeh, IranAD  - Bielefeld Univ, Dept Publ Hlth Med, Bielefeld, GermanyAD  - Canc Inst WIA, Gene Express & Regulat Program, Philadelphia, PA USAAD  - Kobe Univ, Dept Dermatol, Kobe, Hyogo, JapanAD  - Pfizer Inc, Vaccine Program, Collegeville, PA USAAD  - Agcy Prevent Med, Paris, FranceAD  - Univ Oklahoma, Dept Biostat & Epidemiol, Oklahoma City, OK USAAD  - Govt Federated States Micronesia, Dept Hlth & Social Affairs, Palikir, MicronesiaAD  - Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, AustraliaAD  - Monash Univ, Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic, AustraliaAD  - West Virginia Bur Publ Hlth, Commissioner Publ Hlth, Charleston, WV USAAD  - West Virginia Univ, Dept Hlth Policy Management & Leadership, Sch Publ Hlth, Morgantown, WV USAAD  - Shahid Beheshti Univ Med Sci, Obes Res Ctr, Res Inst Endocrine Sci, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Emergency Dept, Tehran, IranAD  - Haan Bin Mohammed Smart Univ, Sch Hlth & Environm Studies, Dubai, U Arab EmiratesAD  - Mizan Tepi Univ, Pharm Dept, Teppi, EthiopiaAD  - Banaras Hindu Univ, Dept Community Med, Varanasi, Uttar Pradesh, IndiaAD  - Univ Tartu, Inst Family Med & Publ Hlth, Tartu, EstoniaAD  - Hamadan Univ Med Sci, Dept Epidemiol, Hamadan, IranAD  - Helmholtz Ctr Infect Res, Dept Epidemiol, Braunschweig, GermanyAD  - Debre Markos Univ, Coll Hlth Sci, Debre Markos, EthiopiaAD  - Debre Markos Univ, Dept Nursing, Debre Markos, EthiopiaAD  - Jordan Univ Sci & Technol, Dept Publ Hlth & Community Med, Ramtha, JordanAD  - Hlth Serv Acad, Epidemiol & Biostat Dept, Islamabad, PakistanAD  - Seoul Natl Univ, Inst Hlth Policy & Management, Seoul, South KoreaAD  - Seoul Natl Univ, Dept Hlth Policy, Seoul, South KoreaAD  - Ball State Univ, Dept Nutr & Hlth Sci, Muncie, IN 47306 USAAD  - Simmons Coll, Dept Nutr, Boston, MA 02115 USAAD  - Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, NorwayAD  - Univ Oslo, Inst Hlth & Soc, Oslo, NorwayAD  - Tulane Univ, Dept Global Community Hlth & Behav Sci, New Orleans, LA 70118 USAAD  - Acad Med Sci, Dept Community & Family Med, Baghdad, IraqAD  - Local Hlth Unit Tuscany Ctr, Reg Ctr Anal Data Occupat & Work Related Injuries, Florence, ItalyAD  - Univ Florence, Dept Hlth Sci, Florence, ItalyAD  - Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, AustraliaAD  - Trnava Univ, Dept Publ Hlth, Trnava, SlovakiaAD  - Imperial Coll London, Dept Primary Care & Publ Hlth, London, EnglandAD  - Imperial Coll London, Sch Publ Hlth, London, EnglandAD  - Univ Milano Bicocca, Sch Med & Surg, Monza, ItalyAD  - Fed Inst Educ, Sci & Technol Ceara, Campus Caucaia, Caucaia, BrazilAD  - Hywel Dda Univ Hlth Board, Dept Ophthalmol, Carmarthen, Dyfed, WalesAD  - Sevenhills Hosp, Dept Internal Med, Bombay, Maharashtra, IndiaAD  - Debre Tabor Univ, Coll Hlth Sci, Debre Tabor, EthiopiaAD  - Alfaisal Univ, Coll Med, Riyadh, Saudi ArabiaAD  - Wollo Univ, Dept Pharm, Dessie, EthiopiaAD  - Wollo Univ, Dept Adult Hlth Nursing, Dessie, EthiopiaAD  - Clin Microbiol & Parasitol Unit, Zagreb, CroatiaAD  - Univ Ctr Varazdin, Varazhdin, CroatiaAD  - Ethiopian Acad Med Sci, Mekelle, EthiopiaAD  - Pomeranian Med Univ, Emergency Dept, Szczecin, PolandAD  - Burlo Garofolo Inst Maternal & Child Hlth, Clin Epidemiol & Publ Hlth Res Unit, Trieste, ItalyAD  - Kurdistan Univ Med Sci, Dept Epidemiol & Biostat & Social Determinants Hl, Sanandaj, IranAD  - Univ Lancaster, Lancaster, EnglandAD  - Fed Inst Populat Res, Wiesbaden, GermanyAD  - Ctr Populat & Hlth, Wiesbaden, GermanyAD  - Nishtar Med Univ, Pediat Dept, Multan, PakistanAD  - Inst Mother & Child Care, Pediat & Pediat Pulmonol, Multan, PakistanAD  - Int Ctr Diarrhoeal Dis Res, Initiat Non Communicable Dis, Dhaka, BangladeshAD  - Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USAAD  - Univ Oxford, Dept Psychiat, Oxford, EnglandAD  - Kenya Govt Med Res Ctr, Neurosci, Wellcome Trust Res Programme, Kilifi, KenyaAD  - Western Sydney Univ, Sch Social Sci & Psychol, Penrith, NSW, AustraliaAD  - Univ Adelaide, Adelaide, SA, AustraliaAD  - Univ Lagos, Dept Psychiat, Lagos, NigeriaAD  - McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, CanadaAD  - Ctr Hlth Start Initiat, Ikoyi, NigeriaAD  - Univ Maryland, Ctr Vaccine Dev, Baltimore, MD 21201 USAAD  - Univ Ibadan, Inst Adv Med Res & Training, Ibadan, NigeriaAD  - Maimonides Hosp, Dept Med, Brooklyn, NY 11219 USAAD  - Johns Hopkins Univ, Dept Neurol & Neurosurg, Baltimore, MD USAAD  - Univ Groningen, Univ Med Ctr Groningen, Groningen, NetherlandsAD  - Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, IranAD  - Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, IranAD  - Ahvaz Jundishapur Univ Med Sci, Dept Neurosurg, Ahvaz, IranAD  - Maragheh Univ Med Sci, Managerial Epidemiol Res Ctr, Maragheh, IranAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - Ain Shams Univ, Dept Entomol, Cairo, EgyptAD  - Univ Kwazulu Natal, Dept Publ Hlth Med, Durban, South AfricaAD  - Univ North Carolina, Dept Publ Hlth Sci, Charlotte, NC USAAD  - NYU, Langone Med Ctr, New York, NY USAAD  - Islamic Azad Univ, Dept Lab Sci, Sari, IranAD  - Islamic Azad Univ, Dept Basic Sci, Sari, IranAD  - Natl Inst Infect Dis, Tokyo, JapanAD  - Univ Calgary, Dept med, Calgary, AB, CanadaAD  - Ahmadu Bello Univ, Dept Community Med, Zaria, NigeriaAD  - Alkan Hlth Sci, Selihom Sch Nursing, Business & Technol Coll, Dessie, EthiopiaAD  - Univ Hosp Doctor Peset, Pediat Dept, Valencia, SpainAD  - Univ Valencia, Dept Pediat Obstet & Gynecol, Valencia, SpainAD  - Hanoi Med Univ, Dept Hlth Econ, Hanoi, VietnamAD  - Univ Auckland, Mol Med & Pathol, Auckland, New ZealandAD  - Mil Med Univ, Clin Hematol & Toxicol, Hanoi, VietnamAD  - Fed Teaching Hosp, Dept Internal Med, Abakaliki, NigeriaAD  - Gomal Univ, Gomal Ctr Biochem & Biotechnol, Dera Ismail Khan, PakistanAD  - Mufti Mehmood Mem Teaching Hosp, TB Culture Lab, Dera Ismail Khan, PakistanAD  - Fdn Univ, Fdn Univ Med Coll, Rawalpindi, PakistanAD  - Tech Univ Munich, Dept Neurol, Munich, GermanyAD  - Med Res Council South Africa, Cochrane South Africa, Cape Town, South AfricaAD  - Natl Hlth Serv Scotland, Edinburgh, Midlothian, ScotlandAD  - Univ Strathclyde, Glasgow, Lanark, ScotlandAD  - Kyoto Univ, Dept Biostat, Kyoto, JapanAD  - ACS Med Coll & Hosp, Algiers, AlgeriaAD  - Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New ZealandC3  - University of WashingtonC3  - University of Washington SeattleC3  - Institute for Health Metrics & EvaluationC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - Seattle Children's HospitalC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Stellenbosch UniversityC3  - South African Medical Research CouncilC3  - Kermanshah University of Medical SciencesC3  - Jimma UniversityC3  - Jimma UniversityC3  - Universite Ferhat Abbas SetifC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - King Abdulaziz UniversityC3  - Mayo ClinicC3  - University of GondarC3  - Australian National UniversityC3  - Kuwait UniversityC3  - King Saud UniversityC3  - Universidad de CartagenaC3  - Universidad de la CostaC3  - Arba Minch UniversityC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - University of Abomey CalaviC3  - Public Health Foundation of IndiaC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Clinical Centre of SerbiaC3  - University of BelgradeC3  - University of BelgradeC3  - University of BelgradeC3  - Ruprecht Karls University HeidelbergC3  - Harvard UniversityC3  - Harvard T.H. Chan School of Public HealthC3  - ISGlobalC3  - Centro de Investigacao em Saude de ManhicaC3  - Jazan UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Department of Biotechnology (DBT) IndiaC3  - National Institute of Biomedical Genomics (NIBMG)C3  - Aga Khan UniversityC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - University of British ColumbiaC3  - University of British ColumbiaC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidad Nacional de ColombiaC3  - Ministry of Health IraqC3  - Ministry of Health IraqC3  - Seoul National University (SNU)C3  - Seoul National University HospitalC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Duy Tan UniversityC3  - Addis Ababa UniversityC3  - Ministry of Health & Medical Education (MOHME)C3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Eijkman InstituteC3  - Urmia University of Medical SciencesC3  - University of BielefeldC3  - Kobe UniversityC3  - PfizerC3  - Pfizer USAC3  - University of Oklahoma SystemC3  - University of Oklahoma Health Sciences CenterC3  - Monash UniversityC3  - Monash UniversityC3  - West Virginia UniversityC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Banaras Hindu University (BHU)C3  - University of TartuC3  - Hamadan University of Medical SciencesC3  - Helmholtz AssociationC3  - Helmholtz-Center for Infection ResearchC3  - Jordan University of Science & TechnologyC3  - Health Services AcademyC3  - Seoul National University (SNU)C3  - Seoul National University (SNU)C3  - Ball State UniversityC3  - Simmons UniversityC3  - University of OsloC3  - University of OsloC3  - Tulane UniversityC3  - University of FlorenceC3  - University of SydneyC3  - University of TrnavaC3  - Imperial College LondonC3  - Imperial College LondonC3  - University of Milano-BicoccaC3  - Alfaisal UniversityC3  - University North - CroatiaC3  - Pomeranian Medical UniversityC3  - IRCCS Burlo GarofoloC3  - Kurdistan University of Medical SciencesC3  - Lancaster UniversityC3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of OxfordC3  - Kenya Medical Research InstituteC3  - Western Sydney UniversityC3  - University of AdelaideC3  - University of LagosC3  - McMaster UniversityC3  - University System of MarylandC3  - University of Maryland BaltimoreC3  - University of IbadanC3  - Maimonides Medical CenterC3  - Johns Hopkins UniversityC3  - University of GroningenC3  - Golestan University of Medical SciencesC3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - University of Kwazulu NatalC3  - University of North CarolinaC3  - University of North Carolina CharlotteC3  - New York UniversityC3  - NYU Langone Medical CenterC3  - Islamic Azad UniversityC3  - Islamic Azad UniversityC3  - National Institute of Infectious Diseases (NIID)C3  - University of CalgaryC3  - Ahmadu Bello UniversityC3  - University of ValenciaC3  - Hanoi Medical UniversityC3  - University of AucklandC3  - Gomal UniversityC3  - Technical University of MunichC3  - NHS National Services ScotlandC3  - University of StrathclydeC3  - Kyoto UniversityC3  - Auckland University of TechnologyPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - DEC
PY  - 2018
VL  - 17
IS  - 12
SP  - 1061
EP  - 1082
DO  - 10.1016/S1474-4422(18)30387-9
AN  - WOS:000450119300016
ER  -

TY  - JOUR
AU  - Nyamathi, AM
AU  - Carpenter, CL
AU  - Ekstrand, ML
AU  - Yadav, K
AU  - Garfin, DR
AU  - Muniz, LC
AU  - Kelley, M
AU  - Sinha, S
TI  - Randomized controlled trial of a community-based intervention on HIV and nutritional outcomes at 6 months among women living with HIV/AIDS in rural India
T2  - AIDS
KW  - BMI
KW  - body weight
KW  - cluster randomized control trial
KW  - community interventions
KW  - food insecurity
KW  - social support
KW  - ANTIRETROVIRAL THERAPY
KW  - FOOD INSECURITY
KW  - MENTAL-HEALTH
KW  - DISEASE PROGRESSION
KW  - INFECTED ADULTS
KW  - ADHERENCE
KW  - PEOPLE
KW  - QUESTIONNAIRE
KW  - PERSPECTIVES
KW  - FRAMEWORK
AB  - Objective: To assess the impact of nurse-led Asha (Accredited Social Health Activist) support behavioral and nutritional intervention among women living with HIV/AIDS (WLH/A) in rural India.
   Design: Cluster randomized controlled trial.
   Methods: Sixteen Primary Health Centers serving WLH/A in Andhra Pradesh were grouped into four regional clusters that were randomly allocated into one of four arms. All four groups included Asha-support and consisted of: Asha-support only (control group); nutrition education; nutrition supplementation; and the combination of supplementation and education. Differences between baseline and 6-month follow-up for key physiological outcomes (BMI, CD4(+) cell count) were analyzed using factorial mixed models that accounted for geographic clustering.
   Results: At 6 months, all groups improved CD4(+) cell count: Asha only [mean difference score (D) = 343.97, standard deviation (SD) = 106.94], nutrition education (D = 356.15, SD = 0.69), nutrition supplement (D = 469.66, SD = 116.0), and nutrition supplement and education (D = 530.82, SD = 128.56). In multivariable models, Asha-support and nutrition, and Asha-support and nutrition supplement interventions demonstrated independent significant improvements in CD4(+) cell count; the interaction term was significant [estimate = 529.9; 95% confidence interval (CI) 512.0, 547.8; P=0.006]. BMI also increased for all groups: Asha only (D = 0.95, SD = 0.82), Asha and nutrition education (D = 1.28, SD = 0.53), Asha and nutrition supplement (D = 2.38, SD = 0.60), nutrition supplement, and nutrition supplement and education (D = 2.72, SD = 0.84). Nutrition supplementation and nutrition education demonstrated independent effects on BMI; the interaction term was not significant (estimate = 0.27; 95% CI =2.5, 2.7; P=0.80).
   Conclusion: Interventions supported by community workers were efficacious at improving physiological outcomes and may be beneficial at meeting critical healthcare needs of vulnerable WLH/A in India. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.
AD  - Univ Calif Irvine, Irvine, CA USAAD  - Univ Calif Los Angeles, Los Angeles, CA USAAD  - Univ Calif San Francisco, San Francisco, CA 94143 USAAD  - All India Inst Med Sci, Dept Med, AIIMS Campus, New Delhi, IndiaC3  - University of California SystemC3  - University of California IrvineC3  - University of California SystemC3  - University of California Los AngelesC3  - University of California SystemC3  - University of California San FranciscoC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - NOV 28
PY  - 2018
VL  - 32
IS  - 18
SP  - 2727
EP  - 2737
DO  - 10.1097/QAD.0000000000002016
AN  - WOS:000453912600008
ER  -

TY  - JOUR
AU  - Godolphin, PJ
AU  - Montgomery, AA
AU  - Woodhouse, LJ
AU  - Bereczki, D
AU  - Berge, E
AU  - Collins, R
AU  - Díez-Tejedor, E
AU  - Gommans, J
AU  - Lees, KR
AU  - Ozturk, S
AU  - Phillips, S
AU  - Pocock, S
AU  - Prasad, K
AU  - Szatmari, S
AU  - Wang, YJ
AU  - Bath, PM
AU  - Sprigg, N
A1  - ENOS Investigators
TI  - Central adjudication of serious adverse events did not affect trial's safety results: Data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial
T2  - PLOS ONE
KW  - CAUSE-SPECIFIC MORTALITY
KW  - INCREASING VALUE
KW  - CLINICAL-TRIALS
KW  - REDUCING WASTE
KW  - OUTCOMES
KW  - DESIGN
KW  - COPD
AB  - Background and purpose
   Central adjudication of serious adverse events (SAEs) can be undertaken in clinical trials, especially for open-label studies where outcome assessment may be at risk of bias. This study explored the effect of central adjudication of SAEs on the safety results of the Efficacy of Nitric Oxide in Stroke (ENOS) Trial.
   Methods
   ENOS assigned patients with acute stroke at random to receive either transdermal glyceryl trinitrate (GTN) or no GTN and to Stop or Continue previous antihypertensive treatment. SAEs were reported by local investigators who were not blinded to treatment allocation. Central adjudicators, blinded to treatment allocation, reviewed the investigators reports and used evidence available to confirm or re-categorise the classification of event, likely causality, diagnosis and expectedness of event.
   Results
   Of 4011 patients enrolled in ENOS, 1473 SAEs were reported by local investigators; this was reduced to 1444 after the review by adjudicators, with 29 re-classified as not an SAE. There was fair agreement between investigators and adjudicators regarding likely causality, with 808 agreements and 644 disagreements (56% crude agreement, weighted kappa, kappa = 0.31). Agreement increased upon dichotomisation of the causality categories, with 1432 agreements and 20 disagreements (99% crude agreement, kappa = 0.54). Repeating the main trial safety analysis with investigator reported events showed that adjudication had no effect on the main trial safety conclusions.
   Conclusions
   In a large trial, with many SAEs reported, central adjudication of these events did not affect trial conclusions. This suggests that adjudication of SAEs in a clinical trial where the intervention already has a well-established safety profile may not be necessary. Potential efficiency savings (financial, logistical) can be made through not adjudicating SAEs.
AD  - Univ Nottingham, Nottingham Clin Trials Unit, Nottingham, EnglandAD  - Univ Nottingham, Div Clin Neurosci, Stroke Trials Unit, Nottingham, EnglandAD  - Semmelweis Univ, Dept Neurol, Budapest, HungaryAD  - Oslo Univ Hosp, Dept Internal Med, Oslo, NorwayAD  - Tallaght Hosp, Dublin, IrelandAD  - Univ Autonoma Madrid, Dept Neurol, La Paz Univ Hosp, Madrid, SpainAD  - Hawkes Bay Hosp, Hastings, New ZealandAD  - Univ Glasgow, Glasgow, Lanark, ScotlandAD  - Selcuk Univ, Fac Med, Konya, TurkeyAD  - Dalhousie Univ, Div Neurol, Dept Med, Halifax, NS, CanadaAD  - London Sch Hyg & Trop Med, London, EnglandAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Univ Med & Pharm, Targu Mures, RomaniaAD  - Tian Tian Hosp, Beijing, Peoples R ChinaC3  - University of NottinghamC3  - University of NottinghamC3  - Semmelweis UniversityC3  - University of OsloC3  - Trinity College DublinC3  - Autonomous University of MadridC3  - Hospital Universitario La PazC3  - University of GlasgowC3  - Selcuk UniversityC3  - Dalhousie UniversityC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - George Emil Palade University of Medicine, Pharmacy, Science, & Technology of Targu MuresPU  - PUBLIC LIBRARY SCIENCE
PI  - SAN FRANCISCO
PA  - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
DA  - NOV 26
PY  - 2018
VL  - 13
IS  - 11
C7  - e0208142
DO  - 10.1371/journal.pone.0208142
AN  - WOS:000451325700106
ER  -

TY  - JOUR
AU  - Sharma, A
AU  - Singh, K
AU  - Biswas, A
AU  - Ranjan, R
AU  - Kishor, K
AU  - Pandey, H
AU  - Kumar, R
AU  - Mahapatra, M
AU  - Oldenburg, J
AU  - Saxena, R
TI  - Impact of interleukin 6 promoter polymorphisms (-174 G &gt; C,-572 G &gt; C and-597 G &gt; A) on plasma <i>IL-6</i> levels and their influence on the development of DVT: a study from India
T2  - HEMATOLOGY
KW  - Deep vein thrombosis
KW  - interleukin-6
KW  - gene polymorphisms
KW  - VENOUS THROMBOSIS
KW  - MYOCARDIAL-INFARCTION
KW  - REACTIVE PROTEIN
KW  - GENE
KW  - RISK
KW  - ATHEROSCLEROSIS
KW  - ASSOCIATION
KW  - CORONARY
KW  - DISEASE
AB  - Objectives: To evaluate the association of interleukin 6 (IL-6) levels with deep vein thrombosis (DVT) and to assess the impact of IL-6 promoter polymorphisms (-174G > C, -572G > C and -597G > A) on its plasma levels and their influence in the development of DVT in India. Methods: One hundred DVT patients and 100 age and sex-matched healthy controls were study subjects. IL-6 polymorphisms were identified by polymerase chain reaction-restriction fragment length polymorphism. IL-6 levels were detected by enzyme-linked immunosorbent assay. Results: Significantly raised IL-6 levels were observed in patients as compared to controls. (Patients: 13.73 +/- 6.30 pg/ml, Controls: 11.83 +/- 4.47 pg/ml, p = 0.014). The prevalence of C allele of -572G > C polymorphism was significantly higher in patients than controls (Patients: 39.5%, Controls: 27.5%, p = 0.011, chi(2)=6.463). Subjects with GC and CC genotype had significantly higher IL-6 levels than GG genotype (p=<0.001). Patients with GC and CC genotype increased the DVT risk by 1.39 fold (ORa: 1.39, CI: 0.74-2.62) and 2.69 fold (ORa: 2.42, CI: 1.08-6.70), respectively. IL-6 -174G > C and -597G > A polymorphisms were not associated with raised IL-6 levels and nor with thrombotic risk (-174G > C: p = 0.823 chi(2)=0.369; -597G > A: p = 0.678 chi(2)=1.08). Conclusion: Our study emphasizes the importance of -572G > C polymorphism in increasing IL-6 levels, thereby showing its significant role in DVT in India. IL-6 -174G > C and -597G > A were neither associated with raised plasma IL-6 levels nor with thrombotic risk. Thus -572G > C polymorphism detection may be one of the connecting links between IL-6 and thrombotic risk in Indian DVT patients.
AD  - All India Inst Med Sci, Dept Hematol, Room 205,2nd Floor New Private Ward, New Delhi 110029, IndiaAD  - Univ Clin Bonn, Inst Expt Hematol & Transfus Med, Bonn, GermanyC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of BonnPU  - TAYLOR & FRANCIS LTD
PI  - ABINGDON
PA  - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
DA  - NOV 26
PY  - 2018
VL  - 23
IS  - 10
SP  - 833
EP  - 838
DO  - 10.1080/10245332.2018.1483546
AN  - WOS:000448137100016
ER  -

TY  - JOUR
AU  - Pietrzak, B
AU  - Sharma, V
AU  - Wasalathanthri, D
AU  - Ellwanger, JH
TI  - Nurturing connections to the environment
T2  - SCIENCE
AD  - Univ Warsaw, Dept Hydrobiol, PL-02089 Warsaw, PolandAD  - All India Inst Med Sci, Dept Hematol, New Delhi 110029, IndiaAD  - Sanofi, Fiskdale, MA 01518 USAAD  - Univ Fed Rio Grande do Sul, Dept Genet, BR-91501970 Porto Alegre, RS, BrazilC3  - University of WarsawC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Sanofi-AventisC3  - Sanofi USAC3  - Universidade Federal do Rio Grande do SulPU  - AMER ASSOC ADVANCEMENT SCIENCE
PI  - WASHINGTON
PA  - 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
DA  - NOV 23
PY  - 2018
VL  - 362
IS  - 6417
SP  - 886
EP  - 886
DO  - 10.1126/science.aav9402
AN  - WOS:000451124500016
ER  -

TY  - JOUR
AU  - Sharma, V
TI  - Engage educators and the media
T2  - SCIENCE
AD  - All India Inst Med Sci, Dept Hematol, Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ASSOC ADVANCEMENT SCIENCE
PI  - WASHINGTON
PA  - 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
DA  - NOV 23
PY  - 2018
VL  - 362
IS  - 6417
SP  - 886
EP  - 886
AN  - WOS:000451124500060
ER  -

TY  - JOUR
AU  - Wasalathanthri, D
TI  - Relate to health and safety
T2  - SCIENCE
AD  - All India Inst Med Sci, Dept Hematol, Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ASSOC ADVANCEMENT SCIENCE
PI  - WASHINGTON
PA  - 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
DA  - NOV 23
PY  - 2018
VL  - 362
IS  - 6417
SP  - 886
EP  - 886
AN  - WOS:000451124500061
ER  -

TY  - JOUR
AU  - Sharma, K
AU  - Pandey, A
AU  - Chopra, V
AU  - Bahl, S
AU  - Kumar, P
AU  - Lochab, SP
AU  - Singh, B
TI  - Investigating thermoluminescent properties of nanocrystalline lithium borate doped with dysprosium
T2  - INTEGRATED FERROELECTRICS
KW  - Gamma radiation
KW  - nanoparticles
KW  - thermoluminescence
KW  - DOSIMETRIC CHARACTERISTICS
KW  - CU
KW  - TL
KW  - LUMINESCENCE
AB  - We investigate the thermoluminescence (TL) properties of nanocrystalline Li2B4O7:Dy. The TL properties of the said phosphor are of great interest as it has an effective atomic number close to that of a biological tissue. The phosphor is synthesized by combustion method and characterized by X-ray diffraction and transmission electron microscopy. When the nanophosphor is exposed to a range of gamma doses using cobalt-60, it exhibits a linear TL response for an extensive range of doses. Further, the reproducibility and batch homogeneity properties are also studied. In conclusion, nanocrystalline Li2B4O7:Dy shows potential as a radiation dosimeter of gamma rays.
AD  - Univ Delhi, Sri Venkateswara Coll, Dept Phys, New Delhi, IndiaAD  - DAV Coll, PG Dept Phys & Elect, Amritsar, Punjab, IndiaAD  - AIIMS, Med Phys Unit, IRCH, New Delhi, IndiaAD  - Interuniv Accelerator Ctr, New Delhi, IndiaC3  - University of DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - Inter-University Accelerator CentrePU  - TAYLOR & FRANCIS LTD
PI  - ABINGDON
PA  - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
DA  - NOV 22
PY  - 2018
VL  - 194
IS  - 1
SP  - 163
EP  - 169
DO  - 10.1080/10584587.2018.1514882
AN  - WOS:000466752600020
ER  -

TY  - JOUR
AU  - Sabharwal, PK
AU  - Chattopadhyay, S
AU  - Singh, H
TI  - Preparation and characterization of antimicrobial, biodegradable, triclosan-incorporated polyhydroxybutyrate-<i>co</i>-valerate films for packaging applications
T2  - JOURNAL OF APPLIED POLYMER SCIENCE
KW  - biodegradable
KW  - films
KW  - packaging
KW  - plasticizer
KW  - thermoplastics
KW  - L-LACTIDE/TRICLOSAN NANOPARTICLES
KW  - MECHANICAL-PROPERTIES
KW  - THERMAL-PROPERTIES
KW  - ELECTROSPUN NANOFIBERS
KW  - MEDICAL APPLICATIONS
KW  - ANTIBACTERIAL
KW  - NANOCOMPOSITES
KW  - COMPOSITE
KW  - CHITOSAN
KW  - BIOCOMPOSITES
AB  - The prospective application of polyhydroxybutyrate-co-valerate (PHB-VA) as a biodegradable polymer for packaging through the incorporation of triclosan (TCS) was studied via thermal, mechanical, and antimicrobial studies. The solvent-casting technique was used for the preparation of PHB-VA-TCS blend films. The blend films were characterized by differential scanning calorimetry, thermogravimetry, Fourier transform infrared spectroscopy, and mechanical properties measurements. The addition of TCS to PHB-VA resulted in increased film stretchability along with improved flexibility. The crystallization and melting temperatures of PHB-VA decreased with increasing concentration of TCS. Scanning electron microscopy images showed a homogeneous dispersion of TCS in PHB-VA. The bactericidal activities of the PHB-VA-TCS blend films were investigated against Escherichia coli and Staphylococcus aureus by the disc-diffusion method. The blend films exhibited higher antibacterial activities with increasing concentration of TCS. We concluded from the study that TCS could be successfully incorporated into PHB-VA to obtain flexible antimicrobial films for packaging applications. (c) 2018 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2018, 135, 46862.
AD  - Indian Inst Technol, Ctr Biomed Engn, New Delhi 110016, IndiaAD  - All India Inst Med Sci, New Delhi 110029, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - NOV 20
PY  - 2018
VL  - 135
IS  - 44
C7  - 46862
DO  - 10.1002/app.46862
AN  - WOS:000447641800007
ER  -

TY  - JOUR
AU  - Sadaf
AU  - Habib, M
AU  - Khan, MA
AU  - Najm, MZ
AU  - Mallick, MN
AU  - Sunita, K
AU  - Shukla, NK
AU  - Deo, SVS
AU  - Husain, SA
TI  - Hypermethylated <i>LATS2</i> gene with decreased expression in female breast cancer: A case control study from North India
T2  - GENE
KW  - Real time PCR
KW  - MS PCR (methylation specific PCR)
KW  - Immunohistochemistry
KW  - Tumor biomarkers
KW  - ENCODES
KW  - KINASE
AB  - Background: LATS2, a presumed tumor suppressor gene located on chromosome 13q11-12 is involved in cell growth related activity like regulation of cell cycle at G1/S. The reduced expression of LATS2 has been reported in many tumors; including tumors of Breast, which is to the best of our knowledge has not been studied in north Indian female breast cancer population.
   Objective: Here, we looked upon the expression pattern and methylation status of the LATS2 gene in north Indian female breast cancer cases to further strengthen its role as a tumor suppressor gene and more importantly as a cancer biomarker.
   Methods: mRNA expression level was determined by real time PCR in 140 Breast cancer patients, Protein expression was studied by Immunohistochemistry and Promoter methylation was studied by Methylation specific PCR. All findings were correlated with clinicopathological features.
   Results: LATS2 mRNA expression was remarkably downregulated in 67.85% (95/140) cases. The expression of Large Associated Tumor Suppressor 2 at protein level was also absent in 67.85% (95/140) cases. The absence of LATS2 protein strongly correlated with promoter hypermethylation where 91 out of a total of 107 hyper methylated cases showed absence of protein (91/107, 85%). The absence of LATS2 protein was strongly significant with HER2 neu status (0.01), TNM staging (0.009) and Molecular subtype (0.024).
   Conclusion: The decreased expression in breast cancer seems to be associated with hypermethylation of LATS2 promoter regions. Further LATS2 as a tumor suppressor can be recognized as a promising Biomarker in Breast cancer pathogenesis. Though, further studies, targeting larger sets of breast cancer population are required to establish LATS2 as a promising biomarker.
AD  - Jamia Millia Islamia, Dept Biosci, Lab 419, New Delhi 110025, IndiaAD  - Jamia Hamdard, Dept Biochem, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Surg Oncol, New Delhi, IndiaC3  - Jamia Millia IslamiaC3  - Jamia Hamdard UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - NOV 15
PY  - 2018
VL  - 676
SP  - 156
EP  - 163
DO  - 10.1016/j.gene.2018.07.033
AN  - WOS:000445989300020
ER  -

TY  - JOUR
AU  - Chowdhury, T
AU  - Singh, GP
AU  - Zeiler, FA
AU  - Hailu, A
AU  - Loewen, H
AU  - Schaller, B
AU  - Cappellani, RB
AU  - West, M
TI  - Anesthesia for Awake Craniotomy for Brain Tumors in an Intraoperative MRI Suite: Challenges and Evidence
T2  - FRONTIERS IN ONCOLOGY
KW  - anesthesia
KW  - awake craniotomy
KW  - intraoperative MRI
KW  - brain tumor
KW  - safety & hazards
KW  - GLIOMA SURGERY
KW  - RESECTION
KW  - SHIFT
KW  - COMPENSATION
KW  - EXPERIENCE
KW  - GUIDANCE
AD  - Univ Manitoba, Dept Anesthesiol Perioperat & Pain Med, Winnipeg, MB, CanadaAD  - All India Inst Med Sci, Dept Neuroanaesthesiol & Crit Care, Neurosci Ctr, New Delhi, IndiaAD  - Univ Manitoba, Sect Neurosurg, Dept Surg, Winnipeg, MB, CanadaAD  - Univ Manitoba, Clincian Investigator Program, Winnipeg, MB, CanadaAD  - Univ Cambridge, Div Anaesthesia, Dept Med, Addenbrookes Hosp, Cambridge, EnglandAD  - Univ Manitoba, Max Rady Coll Med, Winnipeg, MB, CanadaAD  - Univ Manitoba, Coll Rehabil Sci, Neil John Maclean Hlth Sci Lib, Winnipeg, MB, CanadaAD  - Univ Zurich, Dept Primary Care, Zurich, SwitzerlandC3  - University of ManitobaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of ManitobaC3  - University of ManitobaC3  - Cambridge University Hospitals NHS Foundation TrustC3  - Addenbrooke's HospitalC3  - University of CambridgeC3  - University of ManitobaC3  - University of ManitobaC3  - University of ZurichPU  - FRONTIERS MEDIA SA
PI  - LAUSANNE
PA  - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
DA  - NOV 14
PY  - 2018
VL  - 8
C7  - 519
DO  - 10.3389/fonc.2018.00519
AN  - WOS:000450079500001
ER  -

TY  - JOUR
AU  - Dicker, D
AU  - Nguyen, G
AU  - Abate, D
AU  - Abate, LH
AU  - Abay, SM
AU  - Abbafati, C
AU  - Abbasi, N
AU  - Abbastabar, H
AU  - Abd-Allah, F
AU  - Abdela, J
AU  - Abdelalim, A
AU  - Abdel-Rahman, O
AU  - Abdi, A
AU  - Abdollahpour, I
AU  - Abdulkader, RS
AU  - Abdurahman, AA
AU  - Abebe, HT
AU  - Abebe, M
AU  - Abebe, Z
AU  - Abebo, TA
AU  - Aboyans, V
AU  - Abraha, HN
AU  - Abrham, AR
AU  - Abu-Raddad, LJ
AU  - Abu-Rmeileh, NM
AU  - Mbessi, MMKA
AU  - Acharya, P
AU  - Adebayo, OM
AU  - Adedeji, IA
AU  - Adedoyin, RA
AU  - Adekanmbi, V
AU  - Adetokunboh, OO
AU  - Adhena, BM
AU  - Adhikari, TB
AU  - Adib, MG
AU  - Adou, AK
AU  - Adsuar, JC
AU  - Afaridern, M
AU  - Afshin, A
AU  - Agarwal, G
AU  - Aggarwal, R
AU  - Aghayan, SA
AU  - Agrawal, S
AU  - Agrawal, A
AU  - Ahmadi, M
AU  - Ahmadi, A
AU  - Ahmadieh, H
AU  - Ahmed, MLCB
AU  - Ahmed, S
AU  - Ahmed, MB
AU  - Aichour, AN
AU  - Aichour, I
AU  - Aichour, MTE
AU  - Akanda, AS
AU  - Akbari, ME
AU  - Akibu, M
AU  - Akinyemi, RO
AU  - Akinyemiju, T
AU  - Akseer, N
AU  - Alandab, F
AU  - Al-Aly, Z
AU  - Alam, K
AU  - Alebel, A
AU  - Aleman, AV
AU  - Alene, KA
AU  - Al-Eyadhy, A
AU  - Ali, R
AU  - Alijanzadely, M
AU  - Alizadeh-Navaei, R
AU  - Aljunid, SM
AU  - Alkerwi, A
AU  - Alla, F
AU  - Allebeck, P
AU  - Allen, CA
AU  - Alonso, J
AU  - Al-Raddadi, RM
AU  - Alsharif, U
AU  - Altirkawi, K
AU  - Alvis-Cituman, N
AU  - Amare, AT
AU  - Amini, E
AU  - Ammar, W
AU  - Amoako, YA
AU  - Anber, NH
AU  - Andrei, CL
AU  - Androudi, S
AU  - Animut, MD
AU  - Anjomshoa, M
AU  - Anlay, DZ
AU  - Ansari, H
AU  - Ansariadi, A
AU  - Ansha, MG
AU  - Antonio, CAT
AU  - Appiah, SCY
AU  - Aremu, O
AU  - Areri, HA
AU  - Ärnlöv, J
AU  - Aroma, M
AU  - Artaman, A
AU  - Aryal, KK
AU  - Asadi-Lari, M
AU  - Asayesh, H
AU  - Asfaw, ET
AU  - Asgedom, SW
AU  - Assadi, R
AU  - Ataro, Z
AU  - Atey, TMM
AU  - Athari, SS
AU  - Atique, S
AU  - Atre, SR
AU  - Atteraya, MS
AU  - Attia, EF
AU  - Ausloos, M
AU  - Avila-Burgos, L
AU  - Avokpaho, EFGA
AU  - Awasthi, AI
AU  - Awuah, B
AU  - Quintanilla, BPA
AU  - Ayele, HT
AU  - Ayele, Y
AU  - Ayer, R
AU  - Ayuk, TBB
AU  - Azzopardi, PS
AU  - Azzopardi-Muscat, N
AU  - Badali, H
AU  - Badawi, A
AU  - Balakrishnan, K
AU  - Bali, AG
AU  - Banach, M
AU  - Banstola, A
AU  - Barac, A
AU  - Barboza, MA
AU  - Barquera, S
AU  - Barrero, LH
AU  - Basaleem, H
AU  - Bassat, Q
AU  - Basu, A
AU  - Basu, S
AU  - Baune, BT
AU  - Bazargan-Hejazi, S
AU  - Bedi, N
AU  - Beghi, E
AU  - Behzadifar, M
AU  - Behzadifar, M
AU  - Béjot, Y
AU  - Bekele, BB
AU  - Belachew, AB
AU  - Belay, AG
AU  - Belay, E
AU  - Belay, SA
AU  - Belay, YA
AU  - Bell, ML
AU  - Bello, AK
AU  - Bennett, DA
AU  - Bensenor, IM
AU  - Berhane, A
AU  - Berman, AE
AU  - Bernabe, E
AU  - Bernstein, RS
AU  - Bertolacci, GJ
AU  - Beuran, M
AU  - Beyranvand, T
AU  - Bhala, N
AU  - Bhatia, E
AU  - Bhatt, S
AU  - Bhattarai, S
AU  - Bhaumik, S
AU  - Bhutta, ZA
AU  - Biadgo, B
AU  - Bijani, A
AU  - Bikbov, B
AU  - Bililign, N
AU  - Bin Sayeed, MS
AU  - Birlik, SM
AU  - Birungi, C
AU  - Bisanzio, D
AU  - Biswas, T
AU  - Bjorge, T
AU  - Bleyer, A
AU  - Basara, BB
AU  - Bose, D
AU  - Bosetti, C
AU  - Boufous, S
AU  - Bourne, R
AU  - Brady, OJ
AU  - Bragazzi, NL
AU  - Brant, LC
AU  - Brazinova, A
AU  - Breitborde, NJK
AU  - Brenner, H
AU  - Britton, G
AU  - Brugha, T
AU  - Burke, KE
AU  - Busse, R
AU  - Butt, ZA
AU  - Cahuana-Hurtado, L
AU  - Callender, CSKH
AU  - Campos-Nonato, IR
AU  - Rincon, JCC
AU  - Cano, J
AU  - Car, M
AU  - Cardenas, R
AU  - Caneras, G
AU  - Canero, JJ
AU  - Carter, A
AU  - Carvalho, F
AU  - Casañeda-Orjuela, CA
AU  - Rivas, JC
AU  - Castro, F
AU  - Catalá-López, F
AU  - Çavlin, A
AU  - Cerin, E
AU  - Chaiah, Y
AU  - Champs, AP
AU  - Chang, HY
AU  - Chang, JC
AU  - Chattopadhyay, A
AU  - Chaturvedi, P
AU  - Chen, WQ
AU  - Chiang, PPC
AU  - Chimed-Ochir, O
AU  - Chin, KL
AU  - Chisumpa, VH
AU  - Chitheer, A
AU  - Choi, JYJ
AU  - Christensen, H
AU  - Christopher, DJ
AU  - Chung, SC
AU  - Cicuttini, FM
AU  - Ciobanu, LG
AU  - Cirillo, M
AU  - Claro, RM
AU  - Cohen, AJ
AU  - Collado-Mateo, D
AU  - Constantin, MM
AU  - Conti, S
AU  - Cooper, C
AU  - Cooper, LT
AU  - Cortesi, PA
AU  - Cortinovis, M
AU  - Cousin, E
AU  - Criqui, MH
AU  - Cromwell, EA
AU  - Crowe, CS
AU  - Crump, JA
AU  - Cucu, A
AU  - Cunningham, M
AU  - Daba, AK
AU  - Dachew, BA
AU  - Dadi, AF
AU  - Dandona, L
AU  - Dandona, R
AU  - Dang, AK
AU  - Dargan, PI
AU  - Daryani, A
AU  - Das, SK
AU  - Das Gupta, R
AU  - das Neves, J
AU  - Dasa, TT
AU  - Dash, AP
AU  - Weaver, ND
AU  - Davitoiu, DV
AU  - Davletov, K
AU  - Dayama, A
AU  - de Courten, B
AU  - De la Hoz, FP
AU  - De Leo, D
AU  - De Neve, JW
AU  - Degefa, MG
AU  - Degenhardt, L
AU  - Degfie, TT
AU  - Deiparine, S
AU  - Dellavalle, RP
AU  - Demoz, GT
AU  - Demtsu, BB
AU  - Denova-Gutiérrez, E
AU  - Deribe, K
AU  - Dervenis, N
AU  - Des Jarlais, DC
AU  - Dessie, GA
AU  - Dey, S
AU  - Dharmaratne, SD
AU  - Dhimal, M
AU  - Ding, EL
AU  - Djalalinia, S
AU  - Doku, DT
AU  - Dolan, KA
AU  - Donnelly, CA
AU  - Dorsey, ER
AU  - Douwes-Schultz, D
AU  - Doyle, KE
AU  - Drake, TM
AU  - Driscoll, TR
AU  - Dubey, M
AU  - Dubljanin, E
AU  - Duken, EE
AU  - Duncan, BB
AU  - Duraes, AR
AU  - Ebrahimi, H
AU  - Ebrahimpour, S
AU  - Edessa, D
AU  - Edvardsson, D
AU  - Eggen, AE
AU  - El Bcheraoui, C
AU  - Zaki, ME
AU  - Elfaramawi, M
AU  - El-Khatib, Z
AU  - Ellingsen, CL
AU  - Elyazar, IRF
AU  - Enayati, A
AU  - Endries, AYY
AU  - Er, B
AU  - Ermakov, SP
AU  - Eshrati, B
AU  - Eskandarieff, S
AU  - Esmaeili, R
AU  - Esteghamati, A
AU  - Esteghamati, S
AU  - Fakhar, M
AU  - Fakhim, N
AU  - Farag, T
AU  - Faramarzi, M
AU  - Fareed, M
AU  - Farhadi, F
AU  - Farid, TA
AU  - Farinha, CSES
AU  - Farioli, A
AU  - Faro, A
AU  - Farvid, MS
AU  - Farzadfar, F
AU  - Farzaei, MH
AU  - Farzeli, MS
AU  - Feigin, VL
AU  - Feigl, AB
AU  - Feizy, F
AU  - Fentahum, N
AU  - Fereshtehnejad, SM
AU  - Fernandes, E
AU  - Fernandes, JC
AU  - Feyissa, GT
AU  - Fijabi, DO
AU  - Filip, I
AU  - Finegold, S
AU  - Fischer, F
AU  - Flor, LS
AU  - Foigt, NA
AU  - Ford, JA
AU  - Foreman, KJ
AU  - Harrod, C
AU  - Frank, TD
AU  - Franklin, RC
AU  - Fukumoto, T
AU  - Fuller, JE
AU  - Fullman, N
AU  - Fürst, T
AU  - Furtado, JM
AU  - Futran, ND
AU  - Galan, A
AU  - Gallus, S
AU  - Gambashidze, K
AU  - Gamkrelidze, A
AU  - Gankpe, FG
AU  - Garcia-Basteiro, AL
AU  - Garcia-Gordillo, MA
AU  - Gebre, T
AU  - Gebre, AK
AU  - Gebregergs, GB
AU  - Gebrehiwot, TT
AU  - Gebremedhin, AT
AU  - Gelano, TF
AU  - Gelaw, YA
AU  - Geleijnse, JN
AU  - Genova-Maleras, R
AU  - Gessner, BD
AU  - Getachew, S
AU  - Gething, PW
AU  - Gezae, KE
AU  - Ghadami, MR
AU  - Ghadimi, R
AU  - Falavarjani, KG
AU  - Ghaserni-Kasman, M
AU  - Ghiasvand, H
AU  - Ghirnire, M
AU  - Ghoshal, AG
AU  - Gill, PS
AU  - Gill, TK
AU  - Gillum, RF
AU  - Giussani, G
AU  - Goenka, S
AU  - Coll, S
AU  - Gomez, RS
AU  - Gomez-Cabrera, MC
AU  - Gómez-Dantés, H
AU  - Gona, PN
AU  - Goodridge, A
AU  - Gopalani, SV
AU  - Goto, A
AU  - Goulart, AC
AU  - Goulart, BNG
AU  - Grada, A
AU  - Grosso, G
AU  - Gugnani, HC
AU  - Guimaraes, ALS
AU  - Guo, YM
AU  - Gupta, PC
AU  - Gupta, R
AU  - Gupta, R
AU  - Gupta, T
AU  - Gyawali, B
AU  - Haagsma, JA
AU  - Hachinski, V
AU  - Hafezi-Nejad, N
AU  - Hagos, TB
AU  - Hailegiyorgis, TT
AU  - Hailu, GB
AU  - Haj-Mirzaian, A
AU  - Haj-Mirzaian, A
AU  - Hamadeh, RR
AU  - Hamidi, S
AU  - Handal, AJ
AU  - Hankey, GJ
AU  - Harb, HL
AU  - Harikrishnan, S
AU  - Haririan, H
AU  - Haro, JM
AU  - Hasan, M
AU  - Hassankhani, H
AU  - Hassen, HY
AU  - Havmoeller, R
AU  - Hay, RJ
AU  - Hay, SI
AU  - He, YH
AU  - Hedayatizadeh-Omran, A
AU  - Hegazy, MI
AU  - Heibati, B
AU  - Heidari, M
AU  - Hendrie, D
AU  - Henok, A
AU  - Henry, NJ
AU  - Heredia-Pi, I
AU  - Herteliu, C
AU  - Heydarpour, F
AU  - Heydarpour, P
AU  - Heydarpour, S
AU  - Hibstu, DT
AU  - Hoek, HW
AU  - Hole, MK
AU  - Rad, EH
AU  - Hoogar, P
AU  - Horino, M
AU  - Hosgood, HD
AU  - Hosseini, SM
AU  - Hosseinzadeh, M
AU  - Hostiuc, S
AU  - Hostiuc, M
AU  - Hotez, PJ
AU  - Hoy, DC
AU  - Hsairi, M
AU  - Htet, AS
AU  - Hu, GQ
AU  - Huang, JJ
AU  - Husseini, A
AU  - Hussen, MM
AU  - Hutfless, S
AU  - Iburg, KM
AU  - Igumbor, EU
AU  - Ikeda, CT
AU  - Illesanmi, OS
AU  - Iqbal, U
AU  - Irvani, SSN
AU  - Isehunwa, OO
AU  - Islam, SMS
AU  - Islam, F
AU  - Jahangiry, L
AU  - Jahanmehr, N
AU  - Jain, R
AU  - Jain, SK
AU  - Jakovljevic, M
AU  - James, SL
AU  - Jayanbakht, M
AU  - Jayaraman, S
AU  - Jayatilleke, AU
AU  - Jee, SH
AU  - Jeemon, P
AU  - Jha, RP
AU  - Jha, V
AU  - Ji, JS
AU  - Johnson, SC
AU  - Jonas, JB
AU  - Joshi, A
AU  - Jozwiak, JJ
AU  - Jungari, SB
AU  - Jürisson, M
AU  - Madhanraj, K
AU  - Kabir, Z
AU  - Kadel, R
AU  - Kahsay, A
AU  - Kahssay, M
AU  - Kalani, R
AU  - Kapil, U
AU  - Karami, M
AU  - Matin, BK
AU  - Karch, A
AU  - Karema, C
AU  - Karimi, N
AU  - Karimi, SM
AU  - Karimi-Sari, H
AU  - Kasaeian, A
AU  - Kassa, GM
AU  - Kassa, TD
AU  - Kassa, ZY
AU  - Kassebaum, NJ
AU  - Katibeh, M
AU  - Katikireddi, SV
AU  - Kaul, A
AU  - Kawakami, N
AU  - Kazemeini, H
AU  - Kazemi, Z
AU  - Karyani, AK
AU  - Prakash, KC
AU  - Kebede, S
AU  - Keiyoro, PN
AU  - Kemp, GR
AU  - Kengne, AP
AU  - Keren, A
AU  - Keresellidze, M
AU  - Khader, YS
AU  - Khafaie, MA
AU  - Khajavi, A
AU  - Khalid, N
AU  - Khalil, IA
AU  - Khan, EA
AU  - Khan, G
AU  - Khan, MS
AU  - Khan, MA
AU  - Khang, YH
AU  - Khanna, T
AU  - Khater, MM
AU  - Khatony, A
AU  - Khazaie, H
AU  - Khoja, AT
AU  - Khosravi, A
AU  - Khosravi, MH
AU  - Khubchandani, J
AU  - Kiadaliri, AA
AU  - Kibret, GDD
AU  - Kim, CI
AU  - Kim, D
AU  - Kim, JY
AU  - Kim, YE
AU  - Kimokoti, RN
AU  - Kinfu, Y
AU  - Kinra, S
AU  - Kisa, A
AU  - Kissimova-Skarbek, K
AU  - Kissoon, N
AU  - Kivimäki, M
AU  - Kleber, MF
AU  - Knibbs, LD
AU  - Knudsen, AKS
AU  - Kochhar, S
AU  - Kokubo, Y
AU  - Kolola, T
AU  - Kopec, JA
AU  - Kosek, MN
AU  - Kosen, S
AU  - Koul, PA
AU  - Koyanagi, A
AU  - Kravchenko, MA
AU  - Krishan, K
AU  - Krishnaswami, S
AU  - Defo, BK
AU  - Bicer, BK
AU  - Kudom, AA
AU  - Kuipers, EJ
AU  - Kulikoff, XR
AU  - Kumar, GA
AU  - Kumar, M
AU  - Kumar, P
AU  - Kumsa, FA
AU  - Kutz, MJ
AU  - Lad, SD
AU  - Lafranconi, A
AU  - Lal, DK
AU  - Lalloo, R
AU  - Lam, H
AU  - Lami, FH
AU  - Lan, Q
AU  - Langan, SM
AU  - Lansingh, V
AU  - Torisky, S
AU  - Larson, HJ
AU  - Laryea, DO
AU  - Lassi, ZS
AU  - Latifi, A
AU  - Lavados, PM
AU  - Laxmaiah, A
AU  - Lazarus, JV
AU  - Lebedev, G
AU  - Lee, PH
AU  - Leigh, J
AU  - Leshargie, CT
AU  - Leta, S
AU  - Levi, M
AU  - Li, SS
AU  - Li, YC
AU  - Li, XH
AU  - Hang, J
AU  - Liang, XF
AU  - Liben, ML
AU  - Lim, LL
AU  - Lim, SS
AU  - Limenih, MA
AU  - Linn, S
AU  - Liu, SW
AU  - Liu, Y
AU  - Lodha, R
AU  - Logroscino, G
AU  - Lonsdale, C
AU  - Lorch, SA
AU  - Lorkowski, S
AU  - Lotufo, PA
AU  - Lozano, R
AU  - Lucas, TCD
AU  - Lunevicius, R
AU  - Lyons, RA
AU  - Ma, S
AU  - Mabika, C
AU  - Macarayam, ERK
AU  - Mackay, MT
AU  - Maddison, ER
AU  - Maddison, R
AU  - Madotto, F
AU  - Abd El Razek, HM
AU  - Abd El Razek, MM
AU  - Maghavani, DP
AU  - Majdan, M
AU  - Majdzadeh, R
AU  - Majeed, A
AU  - Malekzadeh, R
AU  - Malik, MA
AU  - Malta, DC
AU  - Mamun, AA
AU  - Manamo, WA
AU  - Manda, AL
AU  - Mansoumia, MA
AU  - Mantovani, LG
AU  - Mapoma, CC
AU  - Marami, D
AU  - Marayilla, JC
AU  - Marcenes, W
AU  - Marina, S
AU  - Martinez-Raga, J
AU  - Martins, SCO
AU  - Martins-Melo, FR
AU  - März, N
AU  - Marzan, MB
AU  - Mashamba-Thompson, TP
AU  - Masiye, F
AU  - Massenburg, BB
AU  - Maulik, PK
AU  - Mazidi, M
AU  - McGrath, JJ
AU  - McKee, M
AU  - Mehata, S
AU  - Mehendale, SM
AU  - Mehndiratta, MM
AU  - Mehrotra, R
AU  - Mehta, KM
AU  - Mehta, V
AU  - Mekonen, T
AU  - Mekonnen, TC
AU  - Meles, HG
AU  - Meles, KG
AU  - Melese, A
AU  - Melku, M
AU  - Memiah, PTN
AU  - Memish, ZA
AU  - Mendoza, W
AU  - Mengistu, DT
AU  - Ntengistu, G
AU  - Mensah, GA
AU  - Mereta, ST
AU  - Meretoja, A
AU  - Meretoja, TJ
AU  - Mestrovic, T
AU  - Mezgebe, HB
AU  - Miangotar, Y
AU  - Miazgowski, B
AU  - Miazgowski, T
AU  - Miller, TR
AU  - Mini, GK
AU  - Mirica, A
AU  - Mirrakhimov, EM
AU  - Misganaw, AT
AU  - Moazen, B
AU  - Moges, NA
AU  - Mohammad, KA
AU  - Mohammadi, M
AU  - Mohammadifard, N
AU  - Mohammadi-Khanaposhtani, M
AU  - Mohammadnia-Afrouzi, M
AU  - Mohammed, S
AU  - Mohammed, MA
AU  - Mohan, V
AU  - Mokdad, AH
AU  - Molokhia, M
AU  - Monasta, L
AU  - Moradi, G
AU  - Moradi, M
AU  - Moradi-Lakeh, M
AU  - Moradinazar, M
AU  - Moraga, P
AU  - Morawska, L
AU  - Velásquez, TM
AU  - Morgado-da-Costa, J
AU  - Morrison, SD
AU  - Mosapour, A
AU  - Moschos, MM
AU  - Mousavi, SM
AU  - Muche, AA
AU  - Muchie, KF
AU  - Mueller, UO
AU  - Mukhopadhyay, S
AU  - Mullany, EC
AU  - Muller, K
AU  - Murhekar, M
AU  - Murphy, TB
AU  - Murthy, GVS
AU  - Murthy, S
AU  - Musa, J
AU  - Musa, KI
AU  - Mustafa, G
AU  - Muthupandian, S
AU  - Nachega, JB
AU  - Nagel, G
AU  - Naghavi, N
AU  - Naheed, A
AU  - Nahvijou, A
AU  - Naik, G
AU  - Nair, S
AU  - Najafi, F
AU  - Nangia, V
AU  - Nansseu, JR
AU  - Nascimento, BR
AU  - Nawaz, H
AU  - Ncama, BP
AU  - Neamati, N
AU  - Negoi, I
AU  - Negoi, RI
AU  - Neupane, S
AU  - Newton, CRJ
AU  - Ngalesoni, FN
AU  - Ngunjiri, JW
AU  - Nguyen, HT
AU  - Nguyen, HT
AU  - Nguyen, LH
AU  - Nguyen, M
AU  - Nguyen, TH
AU  - Ningrum, DNA
AU  - Nirayo, YL
AU  - Nisar, MI
AU  - Nixon, MR
AU  - Nolutshungu, N
AU  - Nomura, S
AU  - Norheim, OF
AU  - Noroozi, M
AU  - Norrving, B
AU  - Noubiap, JJ
AU  - Nouri, HR
AU  - Shiadeh, MN
AU  - Nowroozi, MR
AU  - Nsoesie, EO
AU  - Nyasulu, PS
AU  - Ofori-Asenso, R
AU  - Ogah, OS
AU  - Ogbo, FA
AU  - Oh, IH
AU  - Okoro, A
AU  - Oladimeji, O
AU  - Olagunju, AT
AU  - Olagunju, TO
AU  - Olivares, PR
AU  - Olusanya, BO
AU  - Olusanya, JO
AU  - Ong, SK
AU  - Opio, JN
AU  - Oren, E
AU  - Ortiz, JR
AU  - Ortiz, A
AU  - Ota, E
AU  - Otstavnov, SS
AU  - Overland, S
AU  - Owolabi, MO
AU  - Oyekale, AS
AU  - Mahesh, PA
AU  - Pacella, R
AU  - Pakhale, S
AU  - Pakhare, AP
AU  - Pana, A
AU  - Panda, BK
AU  - Panda-Jonas, S
AU  - Pandey, AR
AU  - Pandian, JD
AU  - Parisi, A
AU  - Park, EK
AU  - Parry, CDH
AU  - Parsian, H
AU  - Patel, S
AU  - Patle, A
AU  - Patten, SB
AU  - Patton, GC
AU  - Paudel, D
AU  - Pearce, N
AU  - Peprah, EK
AU  - Pereira, A
AU  - Pereira, DM
AU  - Perez, KM
AU  - Perico, N
AU  - Pervaiz, A
AU  - Pesudovs, K
AU  - Petri, WA
AU  - Petzold, M
AU  - Phillips, MR
AU  - Pigott, DM
AU  - Pillay, JD
AU  - Pirsaheb, M
AU  - Pishgar, F
AU  - Plass, D
AU  - Polinder, S
AU  - Pond, CD
AU  - Popova, S
AU  - Postma, MJ
AU  - Pourmalek, F
AU  - Pourshams, A
AU  - Poustchi, H
AU  - Prabhakaran, D
AU  - Prakash, V
AU  - Prakash, S
AU  - Prasad, N
AU  - Qorbani, M
AU  - Quistberg, DA
AU  - Radfar, A
AU  - Rafay, A
AU  - Rafiei, A
AU  - Rahim, F
AU  - Rahimi, K
AU  - Rahimi-Movaghar, A
AU  - Rahimi-Movaghar, V
AU  - Rahman, M
AU  - Rahman, MHU
AU  - Rahman, MA
AU  - Rahman, SU
AU  - Rai, RK
AU  - Rajati, P
AU  - Rajsic, S
AU  - Raju, SB
AU  - Ram, U
AU  - Ranabhat, CL
AU  - Ranjan, P
AU  - Ranta, A
AU  - Rasella, D
AU  - Rawaf, DF
AU  - Rawaf, S
AU  - Ray, SE
AU  - Razo-García, C
AU  - Rego, MAS
AU  - Rehm, J
AU  - Reiner, RC
AU  - Reinig, N
AU  - Reis, C
AU  - Remuzzi, G
AU  - Renzaho, AMN
AU  - Resnikoff, S
AU  - Rezaei, S
AU  - Rezaeian, S
AU  - Rezai, MS
AU  - Riahi, SM
AU  - Ribeiro, ALP
AU  - Riojas, H
AU  - Rios-Blancas, MJ
AU  - Roba, KT
AU  - Robinson, SR
AU  - Roever, L
AU  - Ronfani, L
AU  - Roshandel, G
AU  - Roshchin, D
AU  - Rostami, A
AU  - Rothenbacher, D
AU  - Rubagotti, E
AU  - Ruhago, GM
AU  - Saadat, S
AU  - Sabde, YD
AU  - Sachder, PS
AU  - Saddik, B
AU  - Sadeghi, E
AU  - Moghaddam, SS
AU  - Safari, H
AU  - Safari, Y
AU  - Safari-Faramani, R
AU  - Safdarian, M
AU  - Safi, S
AU  - Safiri, S
AU  - Sagar, R
AU  - Sahebkar, A
AU  - Sahraian, MA
AU  - Sajadi, HS
AU  - Salahshoor, M
AU  - Salam, N
AU  - Salama, JS
AU  - Salamati, P
AU  - Saldanha, RD
AU  - Salimi, Y
AU  - Salimzadeh, H
AU  - Salz, I
AU  - Sambala, EZ
AU  - Samy, AM
AU  - Sanabria, J
AU  - Nino, MDS
AU  - Santos, IS
AU  - Santos, JV
AU  - Milicevic, MMS
AU  - Jose, BPS
AU  - Sardana, M
AU  - Sacker, AR
AU  - Sarrafzadegan, N
AU  - Sartorius, B
AU  - Sarvi, S
AU  - Sathian, B
AU  - Satpathy, M
AU  - Savic, M
AU  - Sawant, AR
AU  - Sawhney, M
AU  - Saxena, S
AU  - Sayyah, M
AU  - Scaria, V
AU  - Schadffner, F
AU  - Schelonka, K
AU  - Schmidt, MI
AU  - Schneider, IJC
AU  - Schöttker, B
AU  - Schutte, AE
AU  - Schwebel, DC
AU  - Schwendicke, F
AU  - Scott, JG
AU  - Sekerija, M
AU  - Sepanlou, SG
AU  - Serván-Mori, E
AU  - Shabaninejad, H
AU  - Shackelford, KA
AU  - Shafieesabet, A
AU  - Shaheen, AA
AU  - Shaikh, MA
AU  - Shakir, RA
AU  - Shams-Beyranvand, M
AU  - Shamsi, M
AU  - Shamsizadeh, M
AU  - Sharafi, H
AU  - Sharafi, K
AU  - Sharit, M
AU  - Sharif-Alhoseini, M
AU  - Sharma, M
AU  - Sharma, J
AU  - Sharma, R
AU  - She, J
AU  - Sheikh, A
AU  - Sheth, KN
AU  - Shi, PL
AU  - Shibuya, K
AU  - Shifa, GT
AU  - Shiferaw, MS
AU  - Shigematsu, M
AU  - Shiri, R
AU  - Shirkoohi, R
AU  - Shiue, I
AU  - Shokraneh, F
AU  - Shrime, MC
AU  - Shukla, SR
AU  - Si, S
AU  - Siabani, S
AU  - Siddiqi, TJ
AU  - Sigfusdottir, ID
AU  - Sigurvinsdottir, R
AU  - Silpakit, N
AU  - Silva, DAS
AU  - Silva, JP
AU  - Silveira, DGA
AU  - Singam, NSV
AU  - Singh, JA
AU  - Singh, V
AU  - Sinha, AP
AU  - Sinha, DN
AU  - Sitas, F
AU  - Skirbekk, V
AU  - Sliwa, K
AU  - Soares, AM
AU  - Sobaih, BH
AU  - Sobhani, S
AU  - Soofi, M
AU  - Soriano, JB
AU  - Soyiri, IN
AU  - Sposato, LA
AU  - Sreeramareddy, CT
AU  - Srinivasan, V
AU  - Srivastava, RK
AU  - Starodubov, VI
AU  - Stathopoulou, V
AU  - Steel, N
AU  - Stein, DJ
AU  - Steiner, C
AU  - Stewart, LG
AU  - Stokes, MA
AU  - Sudaryanto, A
AU  - Sufiyan, MB
AU  - Sulo, G
AU  - Sunguya, BF
AU  - Sur, PJ
AU  - Sutradhar, I
AU  - Sykes, BL
AU  - Sylaja, PN
AU  - Sylte, DO
AU  - Szoeke, CFI
AU  - Tabarés-Seisdedos, R
AU  - Tabuchi, T
AU  - Tadakamadla, SK
AU  - Takahashi, K
AU  - Tandon, N
AU  - Tassew, AA
AU  - Tassew, SG
AU  - Tavakkoli, M
AU  - Taveira, N
AU  - Tawye, VY
AU  - Tehrani-Banihashemi, A
AU  - Tekalign, TG
AU  - Tekle, MG
AU  - Temesgen, H
AU  - Temsah, MH
AU  - Temsah, O
AU  - Terkawi, AS
AU  - Teshale, MY
AU  - Tessema, B
AU  - Teweldemedhin, M
AU  - Thakur, JS
AU  - Thankappan, KR
AU  - Thinmavukkarasu, S
AU  - Thomas, LA
AU  - Thomas, N
AU  - Thrift, AG
AU  - Tilahun, B
AU  - To, QG
AU  - Tobe-Gai, R
AU  - Tonelli, M
AU  - Topor-Madry, R
AU  - Topouzis, F
AU  - Torre, AE
AU  - Tortajada-Girbés, M
AU  - TIavani-Palone, MR
AU  - Towbin, JA
AU  - Tran, BX
AU  - Tran, KB
AU  - Tripathi, S
AU  - Tripathy, SP
AU  - Truelsen, TC
AU  - Truong, NT
AU  - Tsadik, AG
AU  - Tsilimparis, N
AU  - Car, LT
AU  - Tuzcu, EM
AU  - Tyrovolas, S
AU  - Ukwaja, KN
AU  - Ullah, I
AU  - Usman, MS
AU  - Uthman, OA
AU  - Uzun, SB
AU  - Vaduganathan, M
AU  - Vaezi, A
AU  - Vaidya, G
AU  - Valdez, PR
AU  - Varavikova, E
AU  - Varughese, S
AU  - Vasankari, TJ
AU  - Vasconcelos, AMN
AU  - Venketasubramanian, N
AU  - Vidavalur, R
AU  - Villafaina, S
AU  - Violante, FS
AU  - Vladimirov, SK
AU  - Vlassov, V
AU  - Vollset, SE
AU  - Vos, T
AU  - Vosoughi, K
AU  - Vujcic, IS
AU  - Wagner, GR
AU  - Wagnew, FWS
AU  - Waheed, Y
AU  - Wang, YP
AU  - Wang, YP
AU  - Wassie, MM
AU  - Weiderpass, E
AU  - Weintraub, RG
AU  - Weiss, DJ
AU  - Weiss, J
AU  - Weldegebreal, F
AU  - Weldegwergs, KG
AU  - Werdecker, A
AU  - Westerman, R
AU  - Whiteford, HA
AU  - Widecka, J
AU  - Widecka, K
AU  - Wijeratne, T
AU  - Winkler, AS
AU  - Wiysonge, CS
AU  - Wolfe, CDA
AU  - Wondemagegn, SA
AU  - Wu, SL
AU  - Wyper, GMA
AU  - Xu, GL
AU  - Yadav, R
AU  - Yakob, B
AU  - Yamada, T
AU  - Yan, LJL
AU  - Yano, Y
AU  - Yaseri, M
AU  - Yasin, YJ
AU  - Ye, PP
AU  - Yearwood, JA
AU  - Yentur, GK
AU  - Yeshaneh, A
AU  - Yimer, EM
AU  - Yip, P
AU  - Yisma, E
AU  - Yonemoto, N
AU  - Yoon, SJ
AU  - York, HW
AU  - Yotebieng, M
AU  - Younis, MZ
AU  - Yousefifard, M
AU  - Yu, CH
AU  - Zachariah, G
AU  - Zadnik, V
AU  - Zafar, S
AU  - Zaidi, Z
AU  - Bin Zaman, S
AU  - Zamani, M
AU  - Zare, Z
AU  - Zeeb, H
AU  - Zeleke, MM
AU  - Zenebe, ZM
AU  - Zerfu, TA
AU  - Zhang, K
AU  - Zhang, XY
AU  - Thou, MG
AU  - Zhu, J
AU  - Zodpey, S
AU  - Zucker, I
AU  - Zuhlke, LJJ
AU  - Lopez, AD
AU  - Gakidou, E
AU  - Murray, CJI
A1  - GBD 2017 Mortality Collaborators
TI  - Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017
T2  - LANCET
KW  - ESTIMATING ADULT MORTALITY
KW  - CHILD-MORTALITY
KW  - HEALTH
KW  - DEATH
KW  - COUNTRIES
KW  - TRENDS
KW  - HIV
AB  - Background Assessments of age-specific mortality and life expectancy have been done by the UN Population Division, Department of Economics and Social Affairs (UNPOP), the United States Census Bureau, WHO, and as part of previous iterations of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD). Previous iterations of the GBD used population estimates from UNPOP, which were not derived in a way that was internally consistent with the estimates of the numbers of deaths in the GBD. The present iteration of the GBD, GBD 2017, improves on previous assessments and provides timely estimates of the mortality experience of populations globally.
   Methods The GBD uses all available data to produce estimates of mortality rates between 1950 and 2017 for 23 age groups, both sexes, and 918 locations, including 195 countries and territories and subnational locations for 16 countries. Data used include vital registration systetns, sample registration systetns, household surveys (complete birth histories, summary birth histories, sibling histories), censuses (summary birth histories, household deaths), and Demographic Surveillance Sites. In total, this analysis used 8259 data sources. Estimates of the probability of death between birth and the age of 5 years and between ages 15 and 60 years are generated and then input into a model life table system to produce complete life tables for all locations and years. Fatal discontinuities and mortality due to HIV/AIDS are analysed separately and then incorporated into the estimation. We analyse the relationship between age-specific mortality and development status using the Socio-demographic Index, a composite measure based on fertility under the age of 25 years, education, and income. There are four main methodological improvements in GBD 2017 compared with GBD 2016: 622 additional data sources have been incorporated; new estimates of population, generated by the GBD study, are used; statistical methods used in different components of the analysis have been further standardised and improved; and the analysis has been extended backwards in time by two decades to start in 1950.
   Findings Globally, 18.7% (95% uncertainty interval 18.4-19.0) of deaths were registered in 1950 and that proportion has been steadily increasing since, with 58.8% (58.2-59.3) of all deaths being registered in 2015. At the global level, between 1950 and 2017, life expectancy increased from 48.1 years (46.5-49.6) to 70.5 years (70.1-70.8) for men and from 52.9 years (51.7-54.0) to 75.6 years (75.3-75.9) for women. Despite this overall progress, there remains substantial variation in life expectancy at birth in 2017, which ranges from 49.1 years (46.5-51.7) for men in the Central African Republic to 87.6 years (86.9-88.1) among women in Singapore. The greatest progress across age groups was for children younger than 5 years; under-5 mortality dropped from 216.0 deaths (196.3-238.1) per 1000 livebirths in 1950 to 38.9 deaths (35.6-42.83) per 1000 livebirths in 2017, with huge reductions across countries. Nevertheless, there were still 5.4 million (5.2-5.6) deaths among children younger than 5 years in the world in 2017. Progress has been less pronounced and more variable for adults, especially for adult tnales, who had stagnant or increasing mortality rates in several countries. The gap between male and female life expectancy between 1950 and 2017, while relatively stable at the global level, shows distinctive patterns across super-regions and has consistently been the largest in central Europe, eastern Europe, and central Asia, and smallest in south Asia. Performance was also variable across countries and time in observed mortality rates compared with those expected on the basis of development.
   Interpretation This analysis of age-sex-specific mortality shows that there are remarkably complex patterns in population mortality across countries. The findings of this study highlight global successes, such as the large decline in under-5 mortality, which reflects significant local, national, and global commitment and investment over several decades. However, they also bring attention to mortality patterns that are a cause for concern, particularly among adult men and, to a lesser extent, wotnen, whose mortality rates have stagnated in many countries over the time period of this study, and in some cases are increasing. Copyright C) 2018 The Author(s). Published by Elsevier Ltd.
AD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - Univ Washington, Dept Bioinformat & Med Educ, Seattle, WA 98195 USAAD  - Univ Washington, Dept Global Hlth, Seattle, WA 98195 USAAD  - Univ Washington, Dept Hlth Metr Sci, Seattle, WA 98195 USAAD  - Univ Washington, Dept Neurol, Seattle, WA 98195 USAAD  - Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USAAD  - Univ Washington, Dept Pediat, Seattle, WA 98195 USAAD  - Univ Washington, Dept Surg, Seattle, WA 98195 USAAD  - Univ Washington, Div Plast Surg, Seattle, WA 98195 USAAD  - Univ Washington, Div Pulm Crit Care & Sleep Med, Seattle, WA 98195 USAAD  - Univ Washington, Sch Social Work, Seattle, WA 98195 USAAD  - Univ Washington, Seattle, WA 98195 USAAD  - Haramaya Univ, Dept Med, Lab Sci, Harar, EthiopiaAD  - Haramaya Univ, Dept Pediat, Harar, EthiopiaAD  - Haramaya Univ, Sch Nursing & Midwifery, Harar, EthiopiaAD  - Haramaya Univ, Sch Pharm, Harar, EthiopiaAD  - Haramaya Univ, Sch Publ Hlth, Harar, EthiopiaAD  - Haramaya Univ, Harar, EthiopiaAD  - Jimma Univ, Dept Environm Hlth Sci & Technol, Jininta, EthiopiaAD  - Jimma Univ, Dept Epidemiol, Jininta, EthiopiaAD  - Jimma Univ, Dept Hlth Educ & Behav Sci, Jininta, EthiopiaAD  - Jimma Univ, Dept Populat & Family Hlth, Jininta, EthiopiaAD  - Jimma Univ, Mycobacteriol Res Ctr, Jininta, EthiopiaAD  - Univ Addis Ababa, Dept Pharmacol & Clin Pharm, Addis Ababa, EthiopiaAD  - Univ Addis Ababa, Sch Allied Hlth Sci, Addis Ababa, EthiopiaAD  - Univ Addis Ababa, Scltool Nursing & Midwifery, Addis Ababa, EthiopiaAD  - Univ Addis Ababa, Sch Publ Hlth, Addis Ababa, EthiopiaAD  - Univ Addis Ababa, Addis Ababa, EthiopiaAD  - Univ Tehran Med Sci, Canc Biol Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Canc Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Community Based Participatory Research CR PR CtR, Tehran, IranAD  - Univ Tehran Med Sci, Dept Anat, Tehran, IranAD  - Univ Tehran Med Sci, Dept Community Nutr, Tehran, IranAD  - Univ Tehran Med Sci, Dept Epidemiol & Riostat, Tehran, IranAD  - Univ Tehran Med Sci, Dept Hlth, Tehran, IranAD  - Univ Tehran Med Sci, Dept Hlth Management & Econ, Tehran, IranAD  - Univ Tehran Med Sci, Dept Pharmacol, Tehran, IranAD  - Univ Tehran Med Sci, Dept Urol, Tehran, IranAD  - Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, IranAD  - Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Malignancies Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Oncol & Stem Cell Transplantat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Iran Natl Inst Hlth Res, Tehran, IranAD  - Univ Tehran Med Sci, INCAS, Tehran, IranAD  - Univ Tehran Med Sci, KURC, Tehran, IranAD  - Univ Tehran Med Sci, Liver & Pancreaticobilliary Dis Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, MS Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Noncommunicable Dis Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Sch Med, Tehran, IranAD  - Univ Tehran Med Sci, Sirla Trauma & Surg Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Urooncol Res Ctr, Tehran, IranAD  - McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, CanadaAD  - McGill Univ, Montreal Neuroimaging Ctr, Montreal, PQ, CanadaAD  - McGill Univ, Montreal Neurol Inst, Montreal, PQ, CanadaAD  - Cairo Univ, Dept Med Parasitol, Cairo, EgyptAD  - Cairo Univ, Dept Neurol, Cairo, EgyptAD  - Univ Calgary, Community Hlth Sci, Calgary, AB, CanadaAD  - Univ Calgary, Dept Oncol, Calgary, AB, CanadaAD  - Univ Calgary, Dept Med, Calgary, AB, CanadaAD  - Ain Shams Univ, Dept Entomol, Cairo, EgyptAD  - Ain Shams Univ, Dept Oncol, Cairo, EgyptAD  - Kermanshah Univ Med Sci, Dept Anesthesiol, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Epidemiol 8 Biostat, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Food Technol & Qual Control, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Hlth Educ & Promot, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Psychiat, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Tradit & Complementary Med, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Urol, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Environm Determinants Hlth Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Fac Nursing & Midwifery, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Fac Nutr & Food Sci, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Fac Publ Hlth, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Imam Ali Cardiovasc Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Pharmaceut Sci Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Researclt Ctr Environm Determinants Hlth, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Sleep Disorders Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Sports Med 8 Rehabil, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Kermanshah, IranAD  - Arak Univ Med Sci, Dept Epidemiol, Arak, IranAD  - Multiple Sclerosis Res Ctr, Tehran, IranAD  - Manonmaniam Sundaranar Univ, Dept Stat, Tirunelveli, IndiaAD  - Mekelle Univ, Anat Unit, Mekelle, EthiopiaAD  - Mekelle Univ, Biomed Sci Div, Mekelle, EthiopiaAD  - Mekelle Univ, Clin Pharm Unit, Mekelle, EthiopiaAD  - Mekelle Univ, Coll Hlth Sci, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Biostat, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Epidemiol, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Microbiol & Immunol, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Midwifery, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Nutr & Dietet, Mekelle, EthiopiaAD  - Mekelle Univ, Inst Biomed Sci, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Med, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Pharm, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Publ Hlth, Mekelle, EthiopiaAD  - Mekelle Univ, Mekelle, EthiopiaAD  - Univ Gondar, Dept Clin Chem, Gondar, EthiopiaAD  - Univ Gondar, Dept Med Microbiol, Gondar, EthiopiaAD  - Univ Gondar, Human Nutr Dept, Gondar, EthiopiaAD  - Univ Gondar, Inst Publ Hlth, Gondar, EthiopiaAD  - Univ Gondar, Sch Nursing, Gondar, EthiopiaAD  - Univ Gondar, Gondar, EthiopiaAD  - Hawassa Univ, Coll Med & Hlth Sci, Hawassa, EthiopiaAD  - Hawassa Univ, Dept Reprod Hlth, Hawassa, EthiopiaAD  - Hawassa Univ, Sch Nursing & Midwifery, Hawassa, EthiopiaAD  - Dupuytren Univ, Dept Cardiol, Limoges, FranceAD  - Univ Limoges, Inst Epidemiol, Limoges, FranceAD  - Weill Cornell Med Coll Qatar, Dept Healthcare Policy & Res, Doha, QatarAD  - Birzeit Univ, Inst Community & Publ Hlth, Birzeit, PalestineAD  - Benin Clin Res Inst IRCB, Cotonou, BeninAD  - Nepal Dev Soc, Pokhara, NepalAD  - Univ Coll Hosp, Dept Med, Ibadan, NigeriaAD  - Olabisi Ortabardo Univ, Dept Sociol, Agolwoye, NigeriaAD  - Obaferni Awolowo Univ, Dept Med Rehabil, Ife, NigeriaAD  - Cardiff Univ, Sch Med, Cardiff, S Glam, WalesAD  - Stellenbosch Univ, Dept Global Hlth, Stellenbosch, South AfricaAD  - Stellenbosch Univ, Dept Psychiat, Stellenbosch, South AfricaAD  - Stellenbosch Univ, Fac Med & Hlth Sci, Stellenbosch, South AfricaAD  - South African Med Res Council, Unit Hypertens & Cardiovasc Dis, Cape Town, South AfricaAD  - South African Med Res Council, Cape Town, South AfricaAD  - Ctr Social Sci & Publ Hlth Res Nepal, Nepal Hlth Res Environm, Kathmandu, NepalAD  - Univ Southern Denmark, Unit Hlth Promot Res, Esbjerg, DenmarkAD  - St Mark Hosp, Emergency Dept, Alexandria, EgyptAD  - Ivorian Assoc Family Welf, Abidjan, Cote IvoireAD  - Univ Extremadura, Sport Sci Dept, Badajoz, SpainAD  - McMaster Univ, Dept Family Med, Hamilton, ON, CanadaAD  - McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, CanadaAD  - Sanjay Gandhi Postgrad Inst Med Sci, Dept Gastroenterol, Lucknow, Uttar Pradesh, IndiaAD  - Sanjay Gandhi Postgrad Inst Med Sci, Dept Nephrol, Lucknow, Uttar Pradesh, IndiaAD  - Sanjay Gandhi Postgrad Inst Med Sci, Lucknow, Uttar Pradesh, IndiaAD  - Yerevan State Univ, Dept Zool, Yerevan, ArmeniaAD  - Sci Ctr Zool & Hydroecol, Res Grp Mol Parasitol, Yerevan, ArmeniaAD  - Publ Hlth Fdn India, Dept Social & Behav Sci, New Delhi, IndiaAD  - Publ Hlth Fdn India, Indian Inst Publ Hlth, New Delhi, IndiaAD  - Publ Hlth Fdn India, New Delhi, IndiaAD  - Vital Strategies, Gurugram, IndiaAD  - CSIR, Inst Genom & Integrat Biol, Res Area Genom & Mol Med, Delhi, IndiaAD  - CSIR, Inst Genom & Integrat Biol, Res Area Informat & Big Data, Delhi, IndiaAD  - Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USAAD  - Baylor Coll Med, Natl Sch Trop Med, Houston, TX 77030 USAAD  - Ahvaz Jundishapur Univ Med Sci, Dept Neurosurg, Ahwaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Dept Publ Hlth, Ahwaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Educ Dev Ctr, Ahwaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Environm Technol Res Ctr, Ahwaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Thalassemia & Hemoglobinopallay Res Ctr, Ahwaz, IranAD  - Shahid Beheshti Univ Med Sci, Canc Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Dept Biostat, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Dept Epidemiol, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Dept Ophthalmol, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Ophthalm Epidemiol Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Safety Promot & Injury Prevent Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Sch Publ Hlth, Tehran, IranAD  - Univ Mohammed 5, Dept Biol, Rabat, MoroccoAD  - Bin Abdulaziz Hosp, Minist Hlth, Epidemiol & Dis Control, Nouakchott, MauritaniaAD  - Bin Abdulaziz Hosp, Minist Hlth, Gen Directorate Hlth Informat Syst, Nouakchott, MauritaniaAD  - Bin Abdulaziz Hosp, Minist Hlth, Hlth & Disabil Intelligence Grp, Nouakchott, MauritaniaAD  - Bin Abdulaziz Hosp, Minist Hlth, Israeli Ctr Dis Control, Nouakchott, MauritaniaAD  - Bin Abdulaziz Hosp, Minist Hlth, Prevent & Control Unit, Nouakchott, MauritaniaAD  - Bin Abdulaziz Hosp, Minist Hlth, Natl Inst Res Publ Hlth, Nouakchott, MauritaniaAD  - Bin Abdulaziz Hosp, Minist Hlth, Policy & Planning Div, Nouakchott, MauritaniaAD  - Bin Abdulaziz Hosp, Minist Hlth, Res Dept Prince Mohammed, Nouakchott, MauritaniaAD  - Int Ctr Diarrhoeal Dis Res, Hlth Econ & Financing Res Grp, Dhaka, BangladeshAD  - Int Ctr Diarrhoeal Dis Res, Hlth Syst & Populat Studies Div, Dhaka, BangladeshAD  - Int Ctr Diarrhoeal Dis Res, Initiat Non Communicable Dis, Dhaka, BangladeshAD  - Int Ctr Diarrhoeal Dis Res, Maternal & Child Hlth Div, Dhaka, BangladeshAD  - Karolinska Inst, Dept Learning Informat Management & Eth, Stockholm, SwedenAD  - Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, SwedenAD  - Karolinska Inst, Dept Neurobiol, Stockholm, SwedenAD  - Karolinska Inst, Dept Neurobiol, Care Sci & Soc, Stockholm, SwedenAD  - Karolinska Inst, Dept Publ Hlth Sci, Stockholm, SwedenAD  - Univ Ferhat Abbas Setif, Setif, AlgeriaAD  - Higher Natl Sch Vet Med, Algiers, AlgeriaAD  - Univ Rhode Isl, Dept Civil & Environm Engn, Kingston, RI 02881 USAAD  - Debre Berhan Univ, Dept Midwifery, Debre Berhan, EthiopiaAD  - Debre Berhan Univ, Dept Publ Hlth, Debre Berhan, EthiopiaAD  - Univ badan, Inst Adv Med Res & Training, Ibadan, NigeriaAD  - Univ Kentucky, Dept Epidemiol, Lexington, KY USAAD  - Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, CanadaAD  - Univ Toronto, Dept Nutrit Sci, Toronto, ON, CanadaAD  - Univ Toronto, Hosp Sick Children, Toronto, ON, CanadaAD  - Univ Toronto, Ctr Global Child Hlth, Hosp Sick Children, Toronto, ON, CanadaAD  - Mayo Clin, Fdn Med Educ & Res, Evidence Based Practice Ctr, Rochester, MN USAAD  - Syrian Amer Med Soc, Res Comm, Washington, DC USAAD  - Washington Univ, Internal Med Depat, St Louis, MO USAAD  - VA St Louis Hlth Care Syst, Clin Epidemiol Ctr, Dept Vet Affairs, St Louis, MO USAAD  - Univ Western Australia, Sch Med, Perth, WA, AustraliaAD  - Univ Western Australia, Sch Populat & Global Hlth, Perth, WA, AustraliaAD  - Debre Markos Univ, Coll Hlth Sci, Debre Markos, EthiopiaAD  - Debre Markos Univ, Dept Nursing, Debre Markos, EthiopiaAD  - Debre Markos Univ, Dept Publ Hlth, Debre Markos, EthiopiaAD  - Debre Markos Univ, Debre Markos, EthiopiaAD  - Univ Republica, Dept Prevent Med, Montevideo, UruguayAD  - Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, AustraliaAD  - Australian Natl Univ, Res Sch Populat Hlth, Canberra, ACT, AustraliaAD  - King Saud Univ, Dept Pediat, Riyadh, Saudi ArabiaAD  - King Saud Univ, Pediat Intens Care Unit, Riyadh, Saudi ArabiaAD  - King Saud Univ, Riyadh, Saudi ArabiaAD  - New York Univ Abu Dhabi, Publ Hlth Res Ctr, Abu Dhabi, U Arab EmiratesAD  - Univ Oxford, Dept Psychiat, London, EnglandAD  - Univ Oxford, Malaria Atlas Project, London, EnglandAD  - Univ Oxford, Nuffield Dept Populat Hlth, London, EnglandAD  - Univ Oxford, Nuffield Dept Med, London, EnglandAD  - Univ Oxford, Nuffield Dept Womens & Reprod Hlth, London, EnglandAD  - Univ Oxford, Big Data Inst, London, EnglandAD  - Univ Oxford, London, EnglandAD  - Qazvin Univ Med Sci, Qazvin, IranAD  - Mazandaran Univ Nied Sci, Dept Immunol, Sari, IranAD  - Mazandaran Univ Nied Sci, Dept Med Mycol, Sari, IranAD  - Mazandaran Univ Nied Sci, Dept Nied Mycol & Parasitol, Sari, IranAD  - Mazandaran Univ Nied Sci, Dept Neurol, Sari, IranAD  - Mazandaran Univ Nied Sci, Dept Pediat, Sari, IranAD  - Mazandaran Univ Nied Sci, Dept Physiol & Pharmacol, Sari, IranAD  - Mazandaran Univ Nied Sci, Gastrointestinal Canc Res Ctr, Sari, IranAD  - Mazandaran Univ Nied Sci, Immtmogenet Res Ctr, Sari, IranAD  - Mazandaran Univ Nied Sci, Mol & Cell Biol Res Ctr, Sari, IranAD  - Mazandaran Univ Nied Sci, Sch Publ Hlth, Sari, IranAD  - Mazandaran Univ Nied Sci, Toxoplasmosis Res Ctr, Sari, IranAD  - Kuwait Univ, Dept Hlth Policy & Management, Safat, KuwaitAD  - Natl Univ Malaysia, Int Ctr Casemix & Clin Coding, Bandar Tun Razak, MalaysiaAD  - Luxembourg Inst Hlth, Dept Populat Hlth, Strasser, LuxembourgAD  - Univ Bordeaux, Bordeaux, FranceAD  - Swedish Res Council Hlth Working Life & Welf, Stockholm, SwedenAD  - Hosp del Mar, Med Res Inst, Res Program Epidemiol & Publ Hlth, Barcelona, SpainAD  - Pompeu Fabra Univ, Dept Expt & Hlth Sci, Barcelona, SpainAD  - King Abdulaziz Univ, Dept Family & Community Med, Jeddah, Saudi ArabiaAD  - Charite Univ Med Ctr Berlin, Dept Operat & Prevent Dent, Berlin, GermanyAD  - Charite Univ Med Ctr Berlin, Inst Publ Hlth, Berlin, GermanyAD  - Univ Cartagena, Res Grp Hlth Econ, Cartagena, ColombiaAD  - Univ Coast, Res Grp, Hosp Management & Hlth Policies, Barranquilla, ColombiaAD  - South Australian Hlth & Med Res Inst, Sansom Inst, Adelaide, SA, AustraliaAD  - South Australian Hlth & Med Res Inst, Wardliparingga Aboriginal Res Unit, Adelaide, SA, AustraliaAD  - Bahir Dar Univ, Dept Psychiat, Bahir Dar, EthiopiaAD  - Bahir Dar Univ, Dept Publ Hlth Nutr, Bahir Dar, EthiopiaAD  - Bahir Dar Univ, Bahir Dar, EthiopiaAD  - Fed Minist Hlth, Dept Dis & Noncommunicable Dis & Hlth Promot, Beirut, LebanonAD  - Fed Minist Hlth, Dept Hlth Ind Complex & Innovat Hlth, Beirut, LebanonAD  - Fed Minist Hlth, Beirut, LebanonAD  - Amer Univ Beirut, Fac Hlth Sci, Beirut, LebanonAD  - Komfo Anokye Teaching Hosp, Dept Internal Med, Kumasi, GhanaAD  - Mansoura Univ, Dept Clin Pathol, Mansoura, EgyptAD  - Mansoura Univ, Fac Med, Mansoura, EgyptAD  - Mansoura Univ, Mansoura, EgyptAD  - Carol Davila Univ Med & Pharm, Dept Dermatol, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Anat & Embryol Dept, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Dept Gen Surg, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Dept Legal Med & Bioeth, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Emergency Hosp Bucharest, Bucharest, RomaniaAD  - Univ Thessaly, Dept Med, Volos, GreeceAD  - Arba Minch Univ, Dept Publ Hlth, Arba Minch, EthiopiaAD  - Arba Minch Univ, Med Lab Sci, Arba Minch, EthiopiaAD  - Zahedan Univ Med Sci, Zahedan, IranAD  - Hasanuddin Univ, Sch Publ Hlth, Makassar, IndonesiaAD  - Univ Philippines Manila, Dept Hlth Policy & Adm, Manila, PhilippinesAD  - Univ Philippines Manila, Dev & Commun Studies, Manila, PhilippinesAD  - Kwame Nkrumah Univ Sci & Technol, Dept Sociol & Social Work, Kumasi, GhanaAD  - Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Kumasi, GhanaAD  - Ludwig Maximilians Univ Munchen, Ctr Int Hlth, Munich, GermanyAD  - Birmingham City Univ, Sch Hlth Sci, Birmingham, W Midlands, EnglandAD  - Dalarna Univ, Sch Hlth & Social Studies, Falun, SwedenAD  - Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, CanadaAD  - Abt Associates Nepal, Monitoring Evaluat & Operat Res Project, Lalitpur, NepalAD  - Iran Univ Med Sci, Air Pollut Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Dept Community Med, Tehran, IranAD  - Iran Univ Med Sci, Dept Epidemiol, Tehran, IranAD  - Iran Univ Med Sci, Dept Hlth Policy, Tehran, IranAD  - Iran Univ Med Sci, Dept Neuroscience, Tehran, IranAD  - Iran Univ Med Sci, Dept Ophthalmol, Tehran, IranAD  - Iran Univ Med Sci, Management & Econ Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Physiol Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Prevent Med & Publ Hlth Res, Tehran, IranAD  - Iran Univ Med Sci, Tehran, IranAD  - Minist Hlth & Med Educ, Ctr Communicable Dis Control, Tehran, IranAD  - Minist Hlth & Med Educ, Deputy Res & Technol, Tehran, IranAD  - Minist Hlth & Med Educ, Int Relat Dept, Tehran, IranAD  - Minist Hlth & Med Educ, Tehran, IranAD  - Qom Univ Med Sci, Qom, IranAD  - Mashhad Univ Med Sci, Dept Med Biotechnol, Mashhad, IranAD  - Mashhad Univ Med Sci, Educ Dev Ctr, Mashhad, IranAD  - Univ Lahore, Dept Immunol, Lahore, PakistanAD  - Univ Lahore, Zanjan Univ Med Sci, Lahore, PakistanAD  - Univ Hail, Publ Hlth Dept, Hail, Saudi ArabiaAD  - Johns Hopkins Univ, Ctr Clin Global Hlth Educ, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Gastrointestinal & Hepatol, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Int Hlth, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Radiol, Baltimore, MD USAAD  - Johns Hopkins Univ, Sch Med, Baltimore, MD USAAD  - Dr DY Patil Vidyapeeth, Dr DY Patil Med Coll, Pune, Maharashtra, IndiaAD  - Keimyung Univ, Dept Social Welf, Daegu, South KoreaAD  - Univ Leicester, Dept Hlth Sci, Leicester, Leics, EnglandAD  - Univ Leicester, Sch Business, Leicester, Leics, EnglandAD  - Natl Inst Publ Hlth, Ctr Hlth Syst Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Ctr Nutr & Hlth Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Ctr Populat Hlth Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Environm Hlth Dept, Cuernavaca, Morelos, MexicoAD  - Lab Studies & Res Act Hlth, Non Communicable Dis Dept, Porto Novo, BeninAD  - Indian Inst Publ Hlth, Gandhinagar, IndiaAD  - Univ Witwatersrand, Radiat Oncl, Demog & Populat Studies, Johannesburg, South AfricaAD  - La Trobe Univ, Austin Clin Sch Nursing, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Dept Psychol & Counselling, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Sch Nursing & Midwifery, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Judith Lumley Ctr, Melbourne, Vic, AustraliaAD  - Peruvian Natl Inst Hlth, Gen Off Res & Technol Transfer, Lima, PeruAD  - Dilla Univ, Publ Hlth Dept, Dilla, EthiopiaAD  - Univ Tokyo, Dept & Global Hlth, Tokyo, JapanAD  - Univ Tokyo, Dept Diabet & Metab Dis, Tokyo, JapanAD  - Univ Tokyo, Dept Global Hlth Policy, Tokyo, JapanAD  - Univ Tokyo, Dept Mental Hlth, Tokyo, JapanAD  - Inst Med Res & Med Plant Studies, Ctr Food & Nutr Res, Yaounde, CameroonAD  - Univ South Africa, Dept Hlth Studies, Pretoria, South AfricaAD  - Burnet Inst, Global Adolescent Hlth Grp, Melbourne, Vic, AustraliaAD  - Univ Malta, Dept Heath Serv, Msida, MaltaAD  - Directorate Hlth Informat & Res, Directorate Policy, Pieta, MaltaAD  - Publ Hlth Agcy Canada, Hlth Risk Sci Div, Toronto, ON, CanadaAD  - Sri Ramachandra Med Coll & Res Inst, Dept Environm Hlth Engn, Madras, Tamil Nadu, IndiaAD  - Med Univ Lode, Dept Hypertens, Lodz, PolandAD  - Publ Hlth Perspect Nepal, Polish Mothers Mem Hosp Res Inst, Pokhara Lekhnath Metropo, NepalAD  - Publ Hlth Perspect Nepal, Dept Res, Pokhara Lekhnath Metropo, NepalAD  - Clin Ctr Serbia, Infect & Trop Dis, Belgrade, SerbiaAD  - Univ Belgrade, Ctr Sch Publ Hlth & Hlth Management, Belgrade, SerbiaAD  - Univ Belgrade, Fac Med, Belgrade, SerbiaAD  - Univ Belgrade, Fac Med, Inst Epidemiol, Belgrade, SerbiaAD  - Costa Rican Dept Social Secur, Dept Neurosci, San Jose, Costa RicaAD  - Univ Costa Rica, Sch Dent, San Jose, Costa RicaAD  - Univ Costa Rica, Sch Med, San Jose, Costa RicaAD  - Pontifical Javeriana Univ, Dept Ind Engn, Bogota, ColombiaAD  - Univ Aden, Aden, YemenAD  - Barcelona Inst Global Hlth, Manhica, MozambiqueAD  - Manhica Hlth Res Ctr, TB Dept, Manhica, MozambiqueAD  - Manhica Hlth Res Ctr, Manhica, MozambiqueAD  - Univ Canterbury, Sch Hlth Sci, Christchurch, New ZealandAD  - Stanford Univ, Dept Med, Palo Alto, CA 94304 USAAD  - Melbourne Med Sch, Melbourne, Vic, AustraliaAD  - Charles R Drew Univ Med & Sci, Dept Psychiat, 1621 E 120th St, Los Angeles, CA 90059 USAAD  - Univ Calif Los Angeles, Dept Psychiat & Biobeh Sci, Los Angeles, CA USAAD  - Gandhi Med Coll Bhopal, Dept Community Med, Bhopal, IndiaAD  - Jazan Univ, Jazan, Saudi ArabiaAD  - Mario Negri Inst Pharmacol Res, Dept Environm Hlth Sci, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Dept Neurosci, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Dept Oncol, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Dept Renal Med, Milan, ItalyAD  - Lorestan Univ Med Sci, Social Determinants Hlth Res Ctr, Khorrainabad, IranAD  - Univ Hosp Dijon, Dept Neurol, Dijon, FranceAD  - Univ Burgundy, Dijon Stroke Registry UF R Sci Sante, Dijon, FranceAD  - Mizan Tepi Univ, Dept Publ Hlth, Teppi, EthiopiaAD  - Dr Tewelde Legesse Hlth Sci Coll, Mekelle, EthiopiaAD  - Yale Univ, Dept Neurol, New Haven, CT USAAD  - Yale Univ, Dept Ophthalmol & Visual Sci, New Haven, CT USAAD  - Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USAAD  - Univ Alberta, Dept Med, Edmonton, AB, CanadaAD  - Univ Sao Paulo, Ctr Clin & Epidemiol Res, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Internal Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Pathol & Legal Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Psychiat, Sao Paulo, BrazilAD  - Univ Sao Paulo, Div Ophthalmol, Sao Paulo, BrazilAD  - Univ Sao Paulo, Lab Genet & Mol Cardiol, Sao Paulo, BrazilAD  - Univ Sao Paulo, Univ Hosp, Internal Med Dept, Sao Paulo, BrazilAD  - Augusta Univ, Med Coll Georgia, Div Cardiol, Augusta, GA USAAD  - London Sch Econ & Polit Sci, Dept Hlth Policy, London, EnglandAD  - London Sch Econ & Polit Sci, Personal Social Serv Res Unit, London, EnglandAD  - Kings Coll London, Inst Dent, London, EnglandAD  - Kings Coll London, Div Patient & Populat, London, EnglandAD  - Kings Coll London, Fac Life Sci & Med, London, EnglandAD  - Kings Coll London, Sch Populat Hlth K Environm Sci, London, EnglandAD  - Kings Coll London, St Johns Inst Dermatol, London, EnglandAD  - Emory Univ, Hubert Dept Global Hlth, Atlanta, GA 30322 USAAD  - Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USAAD  - Univ S Florida, Dept Global Hlth, Tampa, FL USAAD  - Queen Elizabeth Hosp Birmingham, Humil Appl Hlth Res & Translat Med, Birmingham, W Midlands, EnglandAD  - Univ Birmingham, IAHR ITM, Birmingham, W Midlands, EnglandAD  - Imperial Coll London, Dept Infect Dis Epidemiol, London, EnglandAD  - Imperial Coll London, Dept Primary Care & Publ Hlth, London, EnglandAD  - Imperial Coll London, Div Brain Sci, London, EnglandAD  - Imperial Coll London, Sch Publ Hlth, London, EnglandAD  - Imperial Coll London, WHO Collaborating Ctr Publ Hlth Educ & Training, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Dis Control, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Med Stat, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, EnglandAD  - London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, EnglandAD  - Nepal Acad Sci K Technol, Patan, NepalAD  - George Inst Global Hlth, New Delhi, IndiaAD  - Aga Khan Univ, Ctr Excellence Women & Child, Karachi, PakistanAD  - Aga Khan Univ, Dept Pediat & Child Hlth, Karachi, PakistanAD  - Babol Univ Med Sci, Cellular & Mol Biol Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Dept Clin Biochem, Babol Sar, IranAD  - Babol Univ Med Sci, Dept Immunol, Babol Sar, IranAD  - Babol Univ Med Sci, Dept Pharmacol, Babol Sar, IranAD  - Babol Univ Med Sci, Hlth Res Inst, Babol Sar, IranAD  - Babol Univ Med Sci, Infect Dis & Trop Med Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Social Determinant Hlth Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Student Res Comm, Babol Sar, IranAD  - Woldia Univ, Woldia, EthiopiaAD  - Dept Clin Pharm & Pharmacol, Ramna, BangladeshAD  - Univ Bologna, Dept Med & Surg Sci, Bologna, ItalyAD  - Chron Inflammatory Demyelinating Polyneuropathy F, Guillain Barre Syndrome, Liaison Turkey, Conshohocken, PA USAAD  - UCL, Dept Epidemiol & Publ Hlth, London, EnglandAD  - UCL, Dept Hlth Informat, London, EnglandAD  - UCL, Dept Psychol, London, EnglandAD  - UCL, UCL Ctr Global Hlth Econ, London, EnglandAD  - UNAIDS, HIV, AIDS, Implementat Dept,United Nations Programme, Gaborone, BotswanaAD  - Res Triangle Inst Int, Global Hlth Div, Res Triangle Pk, NC USAAD  - Univ Nottingham, Sch Med, Nottingham, EnglandAD  - AT Still Univ, Dept Hlth Sci, Brisbane, Qld, AustraliaAD  - Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, NorwayAD  - Univ Bergen, Dept Psychosocial Sci, Bergen, NorwayAD  - Canc Registry Norway, Dept Res, Oslo, NorwayAD  - Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USAAD  - Oregon Hlth & Sci Univ, Radiat Med, Portland, OR 97201 USAAD  - Univ Texas Houston, Dept Epidemiol Human Genet & Environm Sci, Houston, TX USAAD  - Univ Texas Houston, Dept Pediat, Houston, TX USAAD  - World Bank, 1818 H St NW, Washington, DC 20433 USAAD  - Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Med, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Psychiat, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Publ Hlth & Community Med, Sydney, NSW, AustraliaAD  - Univ New South Wales, TARS, Sydney, NSW, AustraliaAD  - Anglia Ruskin Univ, Vis & Eye Res Unit, Cambridge, EnglandAD  - Univ Genoa, Genoa, ItalyAD  - Univ Fed Minas Gerais, Dept Maternal & Child Nursing & Publ Hlth, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Dept Surg, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Hosp Fed Univ Minas Gerais, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Nutr Dept, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Postgrad Program Infect Dis & Trop Med, Sch Med, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Postgrad Program Infect Dis & Trop Med, Clin Hosp, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Serv Gynecol Obstet & Neonatol, Belo Horizonte, MG, BrazilAD  - Comenius Univ, Inst Epidemiol, Bratislava, SlovakiaAD  - Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USAAD  - Ohio State Univ, Dept Psychol, Columbus, OH 43210 USAAD  - Ohio State Univ, Psychiat & Behav lealth Dept, Columbus, OH 43210 USAAD  - German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, GermanyAD  - Inst Sci Res & High Technol Serv, TB Biomarker Res Unit, City Of Knowledge, PanamaAD  - Gorgas Mem Inst Hlth Studies, Dept Res & Hlth Technol Assessment, Panama City, PanamaAD  - Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USAAD  - Univ British Columbia, Dept Pediat, Vancouver, BC, CanadaAD  - Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, CanadaAD  - Al Shifa frost Eye Hosp, Al Shifa Sch Publ Hlth, Rawalpindi, PakistanAD  - Univ Valley Cuernavaca, Sch Med, Cuernavaca, Morelos, MexicoAD  - Metropolitan Autonomous Univ, Dept Populat & Hlth, Mexico City, DF, MexicoAD  - Inst Canc Res Prevent & Clin Network, Florence, ItalyAD  - Univ Porto, Appl Mol Biosci Unit, Porto, PortugalAD  - Univ Porto, Dept Community Med, Porto, PortugalAD  - Univ Porto, Inst Biomed Engn INEB, Porto, PortugalAD  - Univ Porto, Inst Res & Innovat Hlth i3S, Porto, PortugalAD  - Univ Porto, Inst Publ Hlth, Porto, PortugalAD  - Univ Porto, REQUIMTE, LAQV, Porto, PortugalAD  - Univ Porto, UCIBIO, Porto, PortugalAD  - Natl Inst Hlth, Colombian Natl Hlth Observ, Bogota, ColombiaAD  - Univ Nacl Colombia, Dept Publ Hlth, Bogota, ColombiaAD  - Univ Nacl Colombia, Epidemiol & Publ Hlth Evaluat Grp, Bogota, ColombiaAD  - Inst Hlth Carlos III, Dept Hlth Planning & Econ, Madrid, SpainAD  - Haccuepe Univ, Dept Publ Hlth, Ankara, TurkeyAD  - Haccuepe Univ, Inst Populat Studies, Ankara, TurkeyAD  - Australian Catholic Univ, Mary MacKillop Inst Hlth Res, Melbourne, Vic, AustraliaAD  - Australian Catholic Univ, Brain Inst, Melbourne, Vic, AustraliaAD  - Univ Hong Kong, Ctr Suicide Research & Prevent, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ Hong Kong, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R ChinaAD  - Alfaisa Univ, Coll Med, Riyadh, Saudi ArabiaAD  - Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhiman Township, TaiwanAD  - Natl Taiwan Univ, Coll Med, Taipei, TaiwanAD  - Int Inst Populat Sci, Dept Dev Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Dept fertil Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Dept Populat Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Dept Publ Hlth & Mortal Studies, Bombay, Maharashtra, IndiaAD  - Tata Mem Hosp, Surg Oncol, Bombay, Maharashtra, IndiaAD  - Chinese Acad Sci, Beijing, Peoples R ChinaAD  - Gold Coast Hlth, Clin Governance, Gold Coast, Qld, AustraliaAD  - Univ Occupat & Environm Hlth, Inst Ind Ecol Sci, Kitakyushu, Fukuoka, JapanAD  - Monash Univ, Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic, AustraliaAD  - Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, AustraliaAD  - Monash Univ, Monash Ctr Hlth Res & Implementat, Melbourne, Vic, AustraliaAD  - Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, AustraliaAD  - Univ Zambia, Dept Econ, Lusaka, ZambiaAD  - Univ Zambia, Dept Populat Studies, Lusaka, ZambiaAD  - Seoul Natl Univ Hosp, Biomed Sci, Biochem, Seoul, South KoreaAD  - Inst Clin Med, Dept Neurol, Copenhagen, DenmarkAD  - Bispebjerg Hosp, Copenhagen, DenmarkAD  - Christian Med Coll & Hosp CMC, Dept Endocrinol, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp CMC, Dept Neurol, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp CMC, Dept Pulm Med, Vellore, Tamil Nadu, IndiaAD  - Univ Adelaide, Adelaide Med Sch, Adelaide, SA, AustraliaAD  - Univ Adelaide, Joanna Briggs Inst, Adelaide, SA, AustraliaAD  - Univ Adelaide, Robinson Res Inst, Adelaide, SA, AustraliaAD  - Univ Adelaide, Adelaide, SA, AustraliaAD  - Univ Salerno, Scuola Med Salemitana, Baronissi, ItalyAD  - Hlth Effects Inst, Boston, MA USAAD  - Autonomous Univ Chile, Fac Business & Management, Talca, ChileAD  - Autonomous Univ Chile, Fac Educ, Talca, ChileAD  - Autonomous Univ Chile, Inst Phys Act & Hlth, Talca, ChileAD  - Colentina Clin Hosp, Dept Dermatol, Bucharest, RomaniaAD  - Univ Milano Bicocca, Sch Med & Surg, Monza, ItalyAD  - Univ Southampton, NIHR Oxford Biomed Res Ctr, Southampton, Hants, EnglandAD  - Mayo Clin, Dept Cardiovasc Med, Jacksonville, FL 32224 USAAD  - Univ Fed Rio Grande do Sul, Dept Internal Med Neurol, Porto Alegre, RS, BrazilAD  - Univ Fed Rio Grande do Sul, Postgrad Program Epidemiol, Porto Alegre, RS, BrazilAD  - Univ Calif San Diego, Dept Family Med & Publ lealth, La Jolla, CA 92093 USAAD  - Univ Otago, Ctr Int Hlth, Dunedin, New ZealandAD  - Univ Otago, Dept Med, Dunedin, New ZealandAD  - Duke Univ, Div Infect Dis & Int Hlth, Durham, NC USAAD  - Duke Univ, Duke Global Hlth Inst, Durham, NC USAAD  - Univ Queensland, Div Epidemiol & Mostat, Brisbane, Qld, AustraliaAD  - Univ Queensland, Social Sci Res Inst, Brisbane, Qld, AustraliaAD  - Univ Queensland, Queensland Brain Inst, Brisbane, Qld, AustraliaAD  - Univ Queensland, Sch Dent, Brisbane, Qld, AustraliaAD  - Univ Queensland, Sch Publ Hlth, Brisbane, Qld, AustraliaAD  - Natl Inst Publ Hlth, Natl Ctr Hlth Promot & Evaluat, Bucharest, RomaniaAD  - Flinders Univ S Australia, Discipline Publ Hlth, Adelaide, SA, AustraliaAD  - Duy Tan Univ, Inst Global Hlth Innovat, Hanoi, VietnamAD  - Guys & St Thomas NHS Fdn Trust, Biomed Res Council, London, EnglandAD  - Guys & St Thomas NHS Fdn Trust, Clin Toxicol Serv, London, EnglandAD  - KG Med Univ, Dept Rheumatul, Lucknow, Uttar Pradesh, IndiaAD  - BRAC Univ, James P Grant Sch Publ Hlth, Dhaka, BangladeshAD  - BRAC Univ, Res & Evaluat Div, Dhaka, BangladeshAD  - Cent Univ Tami Nadu, Thiruvarur, IndiaAD  - Clin Emergency Hosp SE Pantelimon, Dept Surg, Bucharest, RomaniaAD  - Kazakh Natl Med Univ, Alma Ata, KazakhstanAD  - San Joaquin Gen Hosp, French Camp, CA USAAD  - Monash Hlth, Dept Diabet & Vasc Med, Melbourne, Vic, AustraliaAD  - Griffith Univ, Australian Inst Suicide Res & Prevent, Mt Gravatt, Qld, AustraliaAD  - Griffith Univ, Menzies Hlth Inst Queensland, Mt Gravatt, Qld, AustraliaAD  - Heidelberg Univ, Augenpraxis Jonas, Heidelberg, GermanyAD  - Heidelberg Univ, Dept Ophthalmol, Heidelberg, GermanyAD  - Heidelberg Univ, Inst Publ Hlth, Heidelberg, GermanyAD  - Heidelberg Univ, Med Clin, Heidelberg, GermanyAD  - Heidelberg Univ, Dept Med, Heidelberg, GermanyAD  - African Populat Hlth Res Ctr, Maternal & Child Wellbeing Unit, Nairobi, KenyaAD  - African Populat Hlth Res Ctr, Populat Dynam & Reprod Hlth Unit, Nairobi, KenyaAD  - Univ Colorado Denver, Sch Med, Aurora, CO USAAD  - US Dept Vet Affairs VA, Dermatol Serv, Denver, CO USAAD  - Aksum Univ, Dept Clin Pharm, Aksum, EthiopiaAD  - Aksum Univ, Dept Med, Lab Sci, Aksum, EthiopiaAD  - Brighton & Sussex Med Sch, Dept Global Hlth & Infect, Brighton, E Sussex, EnglandAD  - Aristotle Univ Thessaloniki, Dept Ophthalmol, Thessaloniki, GreeceAD  - Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USAAD  - Disha Fdn, Gurgaon, IndiaAD  - Univ Peradeniya, Dept Community Med, Peradeniya, Sri LankaAD  - Nepal Hlth Res Council, Hlth Res Sect, Kathmandu, NepalAD  - Nepal Hlth Res Council, Res Sect, Kathmandu, NepalAD  - Harvard Med Sch, Ariadue Labs, Boston, MA USAAD  - Harvard Med Sch, Dept Environm Hlth, Boston, MA USAAD  - Harvard Med Sch, Dept Genet, Boston, MA USAAD  - Harvard Med Sch, Dept Global Hlth & Populat, Boston, MA USAAD  - Harvard Med Sch, Dept Nutr, Boston, MA USAAD  - Harvard Med Sch, Gen Internal Med & Primary Care, Boston, MA USAAD  - Harvard Univ, Heart & Vasc Ctr, Boston, MA 02115 USAAD  - Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USAAD  - Univ Cape Coast, Conservat Biol & Entomol, Cape Coast, GhanaAD  - Univ Cape Coast, Dept Populat & Hlth, Cape Coast, GhanaAD  - Univ Tampere, Fac Hlth Sci, Hlth Sci, Tampere, FinlandAD  - Univ Tampere, Hlth Sci, Fac Social Sci, Tampere, FinlandAD  - Univ Rochester, Rochester, NY USAAD  - RMIT Univ, Dept Psychol, Buudoora, Vic, AustraliaAD  - RMIT Univ, Sch Hlth & Biomed Sci, Buudoora, Vic, AustraliaAD  - Univ Edinburgh, Dept Clin Surg, Edinburgh, Midlothian, ScotlandAD  - Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, ScotlandAD  - Univ Sydney, Asbestos Dis Res Inst, Sydney, NSW, AustraliaAD  - Univ Sydney, Sydney Med Sch, Sydney, NSW, AustraliaAD  - Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, AustraliaAD  - Univ Sydney, Sydney, NSW, AustraliaAD  - United Nations World Food Programme, New Delhi, IndiaAD  - Wollega Univ, Dept Hlth Sci, Nekemte, EthiopiaAD  - Univ Fed Bahia, Inst Publ Hlth, Salvador, BA, BrazilAD  - Univ Fed Bahia, Sch Med, Salvador, BA, BrazilAD  - Roberto Santos Gen Hosp, Diretoria Mod, Salvador, BA, BrazilAD  - Ctr Infect Dis Res, Infect Dis, Babol Sar, IranAD  - Umea Univ, Dept Nursing, Umea, SwedenAD  - Univ Tromso, Dept Community Med, Tromso, NorwayAD  - Arkansas State Univ, Coll Publ Hlth, Little Rock, AR USAAD  - Stavanger Univ Hosp, Dept Pathol, Stavanger, NorwayAD  - Norwegian Inst Publ Hlth, Ctr Dis Burden, Oslo, NorwayAD  - Norwegian Inst Publ Hlth, Div Mental & Phys Hlth, Oslo, NorwayAD  - Norwegian Inst Publ Hlth, Oslo, NorwayAD  - Eijkman Inst Mol Biol, Eijkman Oxford Clin Res Unit, Jakarta, IndonesiaAD  - St Pauls Hosp Millennium Med Coll, Publ Hlth Dept, Addis Ababa, EthiopiaAD  - Russian Acad Sci, Lab Socioecon Issues Human Dev & Qual Life, Moscow, RussiaAD  - Fed Res Inst Hlth Org & Informat Minist Hlth FRIH, Cent Res Inst Cytol & Genet, Moscow, RussiaAD  - Fed Res Inst Hlth Org & Informat Minist Hlth FRIH, Dept Med Stat & Documentary, Moscow, RussiaAD  - Fed Res Inst Hlth Org & Informat Minist Hlth FRIH, Moscow, RussiaAD  - Gonahad Univ Med Sci, Dept Publ Hlth, Tehran, IranAD  - Gonahad Univ Med Sci, Social Dev K Hlth Promot Res Ctr, Tehran, IranAD  - Urmia Univ Med Sci, Dept Med Parasiiol & Mycol, Orumiyeh, IranAD  - Imam Muhammad Ibn Saud Islamic Univ, Coll Med, Riyadh, Saudi ArabiaAD  - Imam Muhammad Ibn Saud Islamic Univ, Dept Publ Hlth, Riyadh, Saudi ArabiaAD  - Univ Louisville, Div Cardiovas Med, Louisville, KY 40292 USAAD  - Natl Stat Off, Lisbon, PortugalAD  - Univ Fed Sergipe, Dept Psychol, Sao Crisiovao, BrazilAD  - Auckland Univ Technol, Auckland, New ZealandAD  - Org Econ Cooperat & Dev, Hlth Div, Paris, FranceAD  - Sarem Fertil & Infertil Res Ctr SAFIR, Dept Fertil & Infertil, Tehran, IranAD  - SCRC, Tehran, IranAD  - Catholic Univ Portugal, Ctr Biotechnol & Fine Chem, Porto, PortugalAD  - Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA USAAD  - Univ Memphis, Sch Publ Hlth, Memphis, TN USAAD  - Kaiser Permanente, Psychiat, Fontana, CA USAAD  - Bielefeld Univ, Dept Publ Hlth Med, Bielefeld, GermanyAD  - Sergio Arouca Natl Sch Publ Hlth, Rio De Janeiro, BrazilAD  - Fed Univ Espfrito Saute, Vitoria, BrazilAD  - Natl Acad Med Sci Ukraine, Inst Gerontol, Kiev, UkraineAD  - Univ East Anglia, Dept Primary Care & Publ Hlth, Norwich, Norfolk, EnglandAD  - Univ Milano Bicocca, Dept Med & Surg, Monza, ItalyAD  - James Cook Univ, Coll Publ Hlth Med & Vet Sci, Townsville, Qld, AustraliaAD  - Canc Inst, Gene Express & Regulat Program, Philadelphia, PA USAAD  - Kobe Univ, Dept Dermatol, Kobe, Hyogo, JapanAD  - Swiss Trop & Publ Hlth Inst, Epidemiol & Publ Hlth, Basel, SwitzerlandAD  - Swiss Trop & Publ Hlth Inst, Malaria Vaccines, Basel, SwitzerlandAD  - Univ Basel, Basel, SwitzerlandAD  - NCDC, Med Stat, Tbilisi, GeorgiaAD  - Univ Sidi Mohammed Ben Abdellah, Fac Med & Pharm Fez, Fes, MoroccoAD  - Task Force Global Hlth, Int Trachoma Initiat, Decatur, GA USAAD  - Curtin Univ, Sch Publ Hlth, Perth, WA, AustraliaAD  - Wageningen Univ & Res, Div Human Nutr & Hlth, Wageningen, NetherlandsAD  - Reg Hlth Council;, Directorate Gen Publ Hlth, Madrid, SpainAD  - Pfizer Inc, Vaccines, Collegeville, PA USAAD  - Agcy Prevent Med, Paris, FranceAD  - Martin Luther Univ Halle Wittenberg, Inst Epidemiol Biostat & informat, Halle, GermanyAD  - Martin Luther Univ Halle Wittenberg, Inst Med Epidemiol, Halle, GermanyAD  - Univ Social Welf & Rehabil Sci, Social Determinants Hlth Res Ctr, Tehran, IranAD  - Univ Social Welf & Rehabil Sci, Tehran, IranAD  - Univ Tsukuba, Dept Hlth Care Policy & Management, Tsukuba, Ibaraki, JapanAD  - Natl Allergy Asthma & Bronchitis Inst, Dept Resp Med, Kolkata, IndiaAD  - Fortis Hosp, Dept Resp Med, Kolkata, IndiaAD  - Univ Warwick, Div Hlth Sci, Coventry, W Midlands, EnglandAD  - Univ Warwick, Unit Acad Primary Care, Coventry, W Midlands, EnglandAD  - Howard Univ, Dept Community & Family Med, Washington, DC 20059 USAAD  - Howard Univ, Div Gen Internal Med, Washington, DC 20059 USAAD  - Ctr Chron Dis Control, Phys Act & Obes Prevent, New Delhi, IndiaAD  - Jawahar Lal Nehru Univ, Ctr Study Reg Dev, New Delhi, IndiaAD  - Jawahar Lal Nehru Univ, Ctr Eth, New Delhi, IndiaAD  - Univ Valencia, Dept Med, Valencia, SpainAD  - Univ Valencia, Dept Pediat Obstet & Gynecol, Valencia, SpainAD  - Univ Valencia, Dept Physiol, Valencia, SpainAD  - Univ Valencia, Dept Psychiat, Valencia, SpainAD  - Univ Massachusetts, Nursing & Hlth Sci Dept, Boston, MA 02125 USAAD  - Univ Oklahoma, Dept Biostat & Epidemiol, Oklahoma City, OK USAAD  - Govt Federated States Micronesia, Dept Hlth & Social Affairs, Palikir, MicronesiaAD  - Natl Canc Ctr, Chuo Ku, Tokyo, JapanAD  - Boston Univ, Sch Publ Hlth, Boston, MA USAAD  - Vittorio Emanuele Univ Hosp Polyclin, Registro Tumori Integrate, Catania, ItalyAD  - St James Sch Med, Dept Epidemiol, The Valley, AnguillaAD  - St James Sch Med, Dept Microbiol, The Valley, AnguillaAD  - Univ Estadual Montes Claros, Sch Dent, Montes Claros, BrazilAD  - Lealis Sekhsaria Inst Publ Hlth, Dept Epidemiol, Bombay, Maharashtra, IndiaAD  - West Virginia Bur Publ Healtlt, Commissioner Publ Healtlt, Charleston, WV USAAD  - West Virginia Univ, Sch Publ Hlth, Dept Hlth Policy Management & Leadership, Morgantown, WV 26506 USAAD  - Rajasthan Univ Hlth Sci, Acad & Res, Jaipur, Rajasthan, IndiaAD  - Eternal Heart Care Ctr & Res Inst, Dept Prevent Cardiol, Jaipur, Rajasthan, IndiaAD  - Montefriore Med Ctr, Dept Cardiol, Montefriore Med Ctr, Bronx, NY USAAD  - Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USAAD  - Aarhus Univ, Dept Publ Hlth, Aarhus, DenmarkAD  - Aarhus Univ, Natl Ctr Register Based Res, Aarhus, DenmarkAD  - Erasmus Univ, Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, NetherlandsAD  - Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, NetherlandsAD  - Univ Western Ontario, Clin Neurol Sci, London, ON, CanadaAD  - Univ Western Ontario, Dept Clin Neurol Sci, London, ON, CanadaAD  - Lawson Hlth Res Inst, London, EnglandAD  - Arabian Gulf Univ, Dept Family & Community Med, Manama, BahrainAD  - Hamdan Bin Mohammed Smart Univ, Sch Hlth & Environm Studies, Dubai, U Arab EmiratesAD  - Univ New Mexico, Populat Hlth Dept, Albuquerque, NM 87131 USAAD  - Sir Charles Gairdner Hosp, Neurol Dept, Perth, WA, AustraliaAD  - Minist Publ Hlth, Dept Dis Epidem & Pandem Control, Beirut, LebanonAD  - Minist Publ Hlth, Dept Vital & Hlth Stat, Beirut, LebanonAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Achutha Mellon Ctr Hlth Sci Studies, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Cardiol Dept, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Neurol Dept, Trivandrum, Kerala, IndiaAD  - Tabriz Univ Med Sci, Publ Hlth Dept, Tabriz, IranAD  - Tabriz Univ Med Sci, Tabriz, IranAD  - San Juan Dios Sanit Pk, Res & Dev Unit, St Boi De Llobregat, SpainAD  - Univ Barcelona, Dept Med, Barcelona, SpainAD  - Univ Antwerp Hosp, Unit Epidemiol & Social Med, Antwerp, BelgiumAD  - Karolinska Univ Hosp, Clin Sci, Stockholm, SwedenAD  - Int Fdn Dermatol, London, EnglandAD  - Hormozgan Univ Med Sci, Dept Environm Hlth, Bandar Abbas, IranAD  - Bucharest Univ Econ Studies, Dept Stat Econometr, Bucharest, RomaniaAD  - Univ Med Ctr Groningen, Dept Psychiat, Groningen, NetherlandsAD  - Columbia Univ, Dept Epidemiol, New York, NY USAAD  - Columbia Univ, Dept Hlth & Behav Studies, New York, NY USAAD  - Univ Texas Austin, Austin, TX 78712 USAAD  - Gillian Univ Med Sci, Guilan Rd Trauma Res Ctr, Rasht, IranAD  - Gillian Univ Med Sci, Sch Hlth, Rasht, IranAD  - Manipal Univ, Transdisciplinary Ctr Qualitat Methods, Manipal, Karnataka, IndiaAD  - Nevada Div Publ & Behav Hlth, Carson, CA USAAD  - Univ Human Dev, Dept Comp Sci, Sulaimaniyah, IranAD  - Univ Human Dev, Univ Human Dev, Sulaimaniyah, IraqAD  - Natl Inst Legal Med Mina Minovici, Clin Legal Med, Bucharest, RomaniaAD  - Bucharest Emergency Hosp, Dept Internal Med, Bucharest, RomaniaAD  - Med Sch Tunis, Fac Med Tunis, Baab Saadoun, TunisiaAD  - Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, NorwayAD  - Univ Oslo, Inst Hlth & Soc, Oslo, NorwayAD  - Cent South Univ, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R ChinaAD  - Qatar Univ, Hlth Sci Dept, Doha, QatarAD  - Univ Western Cape, Sch Publ Hlth, Cape Town, South AfricaAD  - Walter Sisulu Univ, Dept Publ Hlth, Mtthatha, South AfricaAD  - Univ Liberia, Dept Publ Hlth & Community Med, Monrovia, LiberiaAD  - Univ Liberia, Monrovia, LiberiaAD  - Taipei Med Univ, Global Hlth & Dev Dept, Taipei, TaiwanAD  - Taipei Med Univ, Grad Inst Biomed Informat, Taipei, TaiwanAD  - Deakin Univ, Dept Psychol, Burwood, Vic, AustraliaAD  - Deakin Univ, Inst Phys Act & Nutr, Burwood, Vic, AustraliaAD  - Deakin Univ, Sch Med, Burwood, Vic, AustraliaAD  - Amer Canc Soc, Surveillance & Hlth Serv Res, Atlanta, GA USAAD  - Natl Hlth Mission, Noncommunicable Dis Dept, Lucknow, Uttar Pradesh, IndiaAD  - Mahavir Sikshan Sansthan, Dept Med, Kanpur, Uttar Pradesh, IndiaAD  - Natl Ctr Dis Control Delhi, Dept Parasit Dis, Delhi, IndiaAD  - Univ Kragujevac, Med Sci Dept, Kragujevac, SerbiaAD  - Newcastle Univ, Tyne, EnglandAD  - Virginia Commonwealth Univ, Dept Surg, Richmond, VA USAAD  - Univ Colombo, Fac Grad Studies, Colombo, Sri LankaAD  - Univ Colombo, Inst Med, Colombo, Sri LankaAD  - Yonsei Univ, Dept Publ Hlth, Seoul, South KoreaAD  - Yonsei Univ, Inst Poverty Alleviat & Int Dev, Seoul, South KoreaAD  - Banaras Hindu Univ, Dept Community Med, Varanasi, Uttar Pradesh, IndiaAD  - Duke Kunshan Univ, Environm Res Ctr, Kunshan, Peoples R ChinaAD  - Duke Kunshan Univ, Global Hlth Res Ctr, Kunshan, Peoples R ChinaAD  - Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R ChinaAD  - All India Inst Med Sci, Ctr Community Med, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol Metab & Diabet, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Paediat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - Czestochowa Tech Univ, Inst Hlth & Nutr Sci, Czestochowa, PolandAD  - Univ Opole, Fac Med & Hlth Sci, Opole, PolandAD  - Savitnibai Phule Pune Univ, Sch Hlth Sci, Pune, Maharashtra, IndiaAD  - Univ Tartu, Inst Family Med & Publ Hlth, Tartu, EstoniaAD  - Employees State Insurance Model Hosp, Dept Community Med, Madras, Tamil Nadu, IndiaAD  - Univ Coll Cork, Sch Publ Hlth, Cork, IrelandAD  - Samara Univ, Dept Publ Hlth, Samara, EthiopiaAD  - ACS Med Coll & Hosp, Dept Obstet & Gynaecol, New Delhi, IndiaAD  - ACS Med Coll & Hosp, New Delhi, IndiaAD  - Hamadan Univ Med Sci, Chron Dis Home Care Res Ctr, Hamadan, IranAD  - Hamadan Univ Med Sci, Dept Epidemiol, Hamadan, IranAD  - Helmholtz Ctr Infect Res, Dept Epidemiol, Braunschweig, GermanyAD  - Qual & Equ Hlth Care, Qual & Equity Healthcare, Kigali, RwandaAD  - Univ Washington, Sch Interdisciplinary Arts & Sci, Tacoma, WA USAAD  - Bacqiyatallah Univ Med Sci, Baqiyatallah Res Ctr Gastroenterol & Liver Dis, Tehran, IranAD  - Bacqiyatallah Univ Med Sci, Student Res Comm, Tehran, IranAD  - Middle East Liver Dis Ctr, Dept Mol Hepatol, Tehran, IranAD  - Middle East Liver Dis Ctr, Dept Young Investigators, Tehran, IranAD  - Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, Seattle, WA USAAD  - Seattle Childrens Hosp, Seattle, WA USAAD  - Univ Glasgow, CSO Social & Publ Hlth Sci Unit, MRC, Glasgow, Lanark, ScotlandAD  - Oklahoma State Univ, Sch Hlth Care Adm, Tulsa, OK USAAD  - Univ Tulsa, Hlth Care Delivery Sci, Tulsa, OK 74104 USAAD  - Salale Univ, Midwifery Program, Fiche, EthiopiaAD  - Univ Nairobi, ODeL Campus, Nairobi, KenyaAD  - Univ Nairobi, Nairobi, KenyaAD  - Michigan State Univ, Dept Linguist & German, Slav Asian & African Languages, E Lansing, MI 48824 USAAD  - Med Res Council South Africa, Alcohol Tobacco K Other Drug Use Res Unit, Cape Town, South AfricaAD  - Med Res Council South Africa, Cochrane South Africa, Cape Town, South AfricaAD  - Med Res Council South Africa, Noncommunicable Dis Res Unit, Cape Town, South AfricaAD  - Univ Cape Town, Dept Med, Cape Town, South AfricaAD  - Univ Cape Town, Dept Paediat & Child Hlth, Cape Town, South AfricaAD  - Assuta Hosp, Inst Cardiol, Tel Aviv Yaffo, IsraelAD  - Hadassalt Hebrew Univ Hosp, Heart Failure & Cardiomyopaties Ctr, Jerusalem, IsraelAD  - Jordan Univ Sci & Technol, Dept Publ Hlth & Community Med, Ramtha, JordanAD  - Univ Management & Technol, Sch Food & Agr Sci, Lahore, PakistanAD  - Hlth Serv Acad, Epidemiol & Biostat Dept, Islamabad, PakistanAD  - United Arab Emirates Univ, Dept Med Microbiol & Immunol, Al Ain, U Arab EmiratesAD  - Jr Hosp Cook Country, Dept Internal Med, Chicago, IL USAAD  - Dow Univ Hlth Sci, Dept Internal Med, Karachi, PakistanAD  - Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USAAD  - Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USAAD  - Univ Alabama Birmingham, Dept Psychol, Birmingham, AL USAAD  - Univ Alabama Birmingham, Birmingham, AL USAAD  - Univ Tennessee, Dept Pediat, Knoxville, TN USAAD  - Seoul Natl Univ, Dept Hlth Policy & Management, Seoul, South KoreaAD  - Seoul Natl Univ, Inst Hlth Policy & Management, Seoul, South KoreaAD  - Indian Council Med Res, Dept Hlth Res, New Delhi, IndiaAD  - Indian Council Med Res, Div Noncommunicable Dis, New Delhi, IndiaAD  - Indian Council Med Res, Div Reprod & Child Hlth, New Delhi, IndiaAD  - Indian Council Med Res, Natl Inst Res Environm Hlth, New Delhi, IndiaAD  - Indian Council Med Res, Natl Inst Nutr, New Delhi, IndiaAD  - Indian Council Med Res, New Delhi, IndiaAD  - Int Otorhinolaryngol Res Assoc, Tehran, IranAD  - Ball Stare Univ, Dept Nutr & Hlth Sci, Muncie, IN USAAD  - Lund Univ, Clin Epidemiol Unit, Lund, SwedenAD  - Lund Univ, Dept Clin Sci, Lund, SwedenAD  - Korea Hlth Ind Dev Inst, Cheongju, South KoreaAD  - Northwestern Univ, Dept Hlth Sci, Boston, MA USAAD  - Korea Univ, Dept Prevent Med, Seoul, South KoreaAD  - Simmons Coll, Dept Nutr, Boston, MA 02115 USAAD  - Univ Canberra, Fac Hlth, Canberra, ACT, AustraliaAD  - Tulane Univ, Dept Global Community Hlth & Behav Sci, New Orleans, LA 70118 USAAD  - Jagiellonian Univ, Med Coll, Dept Hlth Econ & Social Secur, Krakow, PolandAD  - Jagiellonian Univ, Med Coll, Inst Publ Hlth, Krakow, PolandAD  - Univ Helsinki, Dept Publ Hlth, Helsinki, FinlandAD  - Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Suita, Osaka, JapanAD  - Arthrit Res Canada, Richmond, BC, CanadaAD  - Sheri Kashmir Inst Med Sci, Dept Internal & Pulm Med, Srinagar, Jammu & Kashmir, IndiaAD  - Res Ctr Neurol, Moscow, RussiaAD  - Panjab Univ, Dept Anthropol, Chandigarh, IndiaAD  - Univ Montreal, Dept Demog, Montreal, PQ, CanadaAD  - Univ Montreal, Dept Social & Prevent Med, Montreal, PQ, CanadaAD  - Yuksek Ihtisas Univ, Dept Publ Hlth, Ankara, TurkeyAD  - Univ Technol Sydney, Ctr Midwifery Child & Fanfily Hlth, Sydney, NSW, AustraliaAD  - Univ Technol Sydney, Sch Hlth, Sydney, NSW, AustraliaAD  - Post Grad Inst Med Educ & Res, Dept Pediat, Chandigarh, IndiaAD  - Post Grad Inst Med Educ & Res, Sch Publ Hlth, Chandigarh, IndiaAD  - Natl Inst Hlth, Ctr Translat Res & Implementat Sci, Manila, PhilippinesAD  - Natl Inst Hlth, Inst Hlth Policy & Dev Studies, Manila, PhilippinesAD  - Natl Inst Hlth, Natl Heart Lung & Blood Inst, Manila, PhilippinesAD  - Natl Inst Hlth, Manila, PhilippinesAD  - Acad Med Sci, Dept Community & Family Med, Baghdad, IraqAD  - NCI, Div Canc Epidemiol & Genet, Rockville, MD USAAD  - HelpMeSee, New York, NY USAAD  - Mexican Inst Ophthalmol, Relac Int, Queretaro, MexicoAD  - Municipal Hlth Dept Belo Horizonte, Belo Horizonte City Hall, Belo Horizonte, MG, BrazilAD  - Ghana Hlth Serv, Dis Control Dept, Accra, GhanaAD  - Maragheh Univ Med Sci, Dept Publ Hlth, Maragheh, IranAD  - Maragheh Univ Med Sci, Managerial Epidemiol Res Ctr, Maragheh, IranAD  - German Clin Santiago, Dept Neurol & Psychiat, Santiago, ChileAD  - Univ Chile, Dept Neurol Sci, Santiago, ChileAD  - IM Sechenov First Moscow State Med Univ, Dept Informat & Internet Technol, Moscow, RussiaAD  - Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Hong Kong, Peoples R ChinaAD  - Local Hlth Unit Tuscany Ctr, Reg Ctr Anal Data Occupat & Work Related Injuries, Florence, ItalyAD  - Univ Florence, Dept Hlth Sci, Florence, ItalyAD  - Shenzhen Sun Yat Sen Cardiovas Hosp, Dept Clin Res & Epidemiol, Shenzhen, Peoples R ChinaAD  - Sichuan Univ, West China Univ Hosp 2, Chengdu, Sichuan, Peoples R ChinaAD  - Natl Off Maternal & Child Hlth Surveillance, Chengdu, Sichuan, Peoples R ChinaAD  - Natl Ctr Birth Defects Monitoring China, Chengdu, Sichuan, Peoples R ChinaAD  - Chinese Ctr Dis Control & Prevent, Div Injury Prevent & Mental Hlth Improvement, Beijing, Peoples R ChinaAD  - Chinese Ctr Dis Control & Prevent, Noncommunicable Dis Control & Prevent Ctr, Beijing, Peoples R ChinaAD  - Univ Malaya, Dept Med, Kuala Lumpur, MalaysiaAD  - Chinese Univ Hong Kong, Dept Med & Therapeut, Sha Tin, Hong Kong, Peoples R ChinaAD  - Univ Haifa, Sch Publ Hlth, Haifa, IsraelAD  - Univ Bari Aldo Moro, Bari, ItalyAD  - Fdn Cardinale Giovanni Panico Hosp, Dept Clin Res Neurol, Tricase, ItalyAD  - Univ Penn, Dept Pediat, Philadelphia, PA 19104 USAAD  - Univ Penn, Ctr Populat Studies, Philadelphia, PA 19104 USAAD  - Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USAAD  - Friedrich Schiller Univ Jena, Inst Nutr, Jena, GermanyAD  - Competence Cluster Nutr & Cardiovas Hlth NutriCAR, Jena, GermanyAD  - Aintree Univ Hosp Natl Hlth Serv NHS Fdn Trust, Gen Surg Dept, Liverpool, Merseyside, EnglandAD  - Univ Liverpool, Gen Surg Dept, Liverpool, Merseyside, EnglandAD  - Swansea Univ, Hlth Data Res UK, Swansea, W Glam, WalesAD  - Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, SingaporeAD  - Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, SingaporeAD  - Univ Kinshasa, Sch Publ Hlth, Kinshasa, DEM REP CONGOAD  - Univ Kinshasa, Kinshasa, DEM REP CONGOAD  - Univ Melbourne, Dept Med, Melbourne, Qld, AustraliaAD  - Univ Melbourne, Dept Paediat, Melbourne, Qld, AustraliaAD  - Univ Melbourne, Sch Hlth Sci, Melbourne, Qld, AustraliaAD  - Univ Melbourne, Sch Hlth Sci, Melbourne, Qld, AustraliaAD  - Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Qld, AustraliaAD  - Royal Childrens Hosp, Cardiol Dept, Melbourne, Vic, AustraliaAD  - Royal Childrens Hosp, Neurol Dept, Melbourne, Vic, AustraliaAD  - Damietta Univ, Cardiol, Dumyat, EgyptAD  - Aswan Fac Med, Ophthalmol Dept, Aswan, EgyptAD  - Grant Med Coll, Dept Internal Med, Bombay, Maharashtra, IndiaAD  - Sir JJ Grp Hosp, Bombay, Maharashtra, IndiaAD  - Trnava Univ, Dept Publ Hlth, Trnava, SlovakiaAD  - Shiraz Univ Med Sci, Noncommunicable Dis Res Ctr, Shiraz, IranAD  - Indian Inst Technol, Dept Human & Social Sci, Roorkee, Haridwar, IndiaAD  - Emergency Univ Hosp Bucharest, Surg Dept, Bucharest, RomaniaAD  - Univ Hosp Doctor Peset, Pediat Dept, Valencia, SpainAD  - Univ Hosp Doctor Peset, Psychiat Dept, Valencia, SpainAD  - Hosp Moinhos Vento, Neurol Serv, Porto Alegre, RS, BrazilAD  - Fed Inst Educ Sci & Technol Ceara, Campus Caucaia, Caucaia, BrazilAD  - Med Univ Graz, Inst Clin Med, Graz, AustriaAD  - Med Univ Graz, Chem Lab Diagnost, Graz, AustriaAD  - Univ East Ramon Magsaysay, Mem Med Ctr, Grad Sch, Quezon City, PhilippinesAD  - Univ KwaZulu Natal, Dept Publ Hlth Med, Durban, South AfricaAD  - Chalmers Univ Technol, Dept Biol & Biol Engn, Gothenburg, SwedenAD  - Res Monitoring & Evaluat, Kathmandu, NepalAD  - Janakpuri Super Specialty Hosp Soc, Neurol Dept, New Delhi, IndiaAD  - Natl Inst Canc Prevent & Res, Prevent Oncol, Noida, IndiaAD  - Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USAAD  - Seven Hills Hosp, Dept Internal Med, Mumbai, Maharashtra, IndiaAD  - Wollo Univ, Dept Adult Hlth Nursing, Dessie, EthiopiaAD  - Wollo Univ, Dept Pharm, Dessie, EthiopiaAD  - Wollo Univ, Dept Publ Hlth, Dessie, EthiopiaAD  - Debre Tabor Univ, Dept Pharm, Coll Hlth Sci, Debre Tabor, EthiopiaAD  - Univ West Florida, Dept Publ Hlth, Pensacola, FL 32514 USAAD  - United Nations Populat Fund UNFPA, Peru Country Off, Lima, PeruAD  - Helsinki Univ Hosp, Breast Surg Unit, Helsinki, FinlandAD  - Helsinki Univ Hosp, Neuroctr, Helsinki, FinlandAD  - Clin Microbiol & Parasitol Unit, Zagreb, CroatiaAD  - Univ North, Univ Ctr Varazdin, Varazhdin, CroatiaAD  - Ethiopian Acad Med Sci, Sch Pharm, Mekelle, EthiopiaAD  - Univ NDjamena, Fac Humanitites & Social Sci, Ndiamena, ChadAD  - Pomeranian Med Univ, Dept Hypertens, Szczecin, PolandAD  - Pomeranian Med Univ, Doctoral Study, Szczecin, PolandAD  - Pomeranian Med Univ, Emergency Dept, Szczecin, PolandAD  - Pomeranian Med Univ, ZDROJE Hosp, Szczecin, PolandAD  - Pacific Inst Res & Evaluat, Calverton, MD USAAD  - Natl Inst Stat, Presidents Off, Bucharest, RomaniaAD  - Kyrgyz State Med Acad, Fac Gen Med, Bishkek, KyrgyzstanAD  - Natl Ctr Cardiol & Internal Dis, Dept Atherosclerosis & Coronary Heart Dis, Bishkek, KyrgyzstanAD  - Frankfurt Univ Appl Sci, Inst Addict Res ISFF, Frankfurt, GermanyAD  - Salahaddin Univ, Dept Biol, Erbil, IraqAD  - ISHIK Univ, Erbil, IraqAD  - Isfahan Univ Med Sci, Cardiovasc Res Inst, Esfahan, IranAD  - Ahmadu Bello Univ, Dept Community Med, Zaria, NigeriaAD  - Ahmadu Bello Univ, Hlth Syst & Policy Res Unit, Zaria, NigeriaAD  - Jigtiga Univ, Dept Publ Hlth, Jigjiga, EthiopiaAD  - Jigtiga Univ, Jigjiga, EthiopiaAD  - Madras Diabet Res Fdn, Dept Diabetol, Madras, Tamil Nadu, IndiaAD  - Burlo Garofolo Inst Maternal & Child Hlth, Clin Epidemiol & Publ Hlth Res Unit, Trieste, ItalyAD  - Kurdistan Univ Med Sci, Dept Epidemiol & Biostat, Sanandaj, IranAD  - Kurdistan Univ Med Sci, Social Determinants Hlth Res Ctr, Sanandaj, IranAD  - Univ Lancaster, Lancaster, EnglandAD  - Queensland Univ Technol, Australian Ctr Hlth Serv Innovat, Brisbane, Qld, AustraliaAD  - Queensland Univ Technol, Int Lab Air Qual & Hlth, Brisbane, Qld, AustraliaAD  - Queensland Univ Technol, Sch Exercise & Nutr Sci, Brisbane, Qld, AustraliaAD  - Hosp Ctr Porto, Hosp Stn Antonio, Porto, PortugalAD  - Tarbiat Modares Univ, Dept Clin Biochem, Tehran, IranAD  - Univ Athens, Dept Ophthalmol 1, Athens, GreeceAD  - Acad Athens, Biomed Res Fdn, Athens, GreeceAD  - Fed Inst Populat Res, Competence Ctr Mortal Follow Up, Wiesbaden, GermanyAD  - Fed Inst Populat Res, Demog Change & Ageing Res Area, Wiesbaden, GermanyAD  - Fed Inst Populat Res, Wiesbaden, GermanyAD  - Ctr Populat & Hlth, Wiesbaden, GermanyAD  - Inst Post Grad Med Educ & Res, Dept Endocrinol g Metab, Kolkata, IndiaAD  - Natl Inst Epidemiol, Madras, Tamil Nadu, IndiaAD  - Univ Jos, Dept Obstet & Gynecol, Jos, NigeriaAD  - Northwestern Univ, Ctr Global Hlth, Chicago, IL 60611 USAAD  - Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USAAD  - Univ Sci Malaysia, Sch Med Sci, Kubang Kerian, MalaysiaAD  - Nishtar Med Univ, Pediat Dept, Multan, PakistanAD  - Inst Mother & Child Care, Pediat & Pediat Pulmonol, Multan, PakistanAD  - Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USAAD  - Univ Ulm, Inst Epidemiol & Med Biometry, Ulm, GermanyAD  - Govt Med Coll Trivandrum, Dept Pulm Med, Trivandrum, Kerala, IndiaAD  - Hlth Act People, Trivandrum, Kerala, IndiaAD  - Suraj Eye Inst, Ophthalmol, Nagpur, Maharashtra, IndiaAD  - Univ Yaounde I, Dept Publ Heath, Yaounde, CameroonAD  - CardioAid, Bucharest, RomaniaAD  - Welcome Trust Res Programme, Kenya Med Res Inst, Neurosci, Kilifi, KenyaAD  - Community Dev Gender Elderly & Children, Minist Hlth, Dar Es Salaam, TanzaniaAD  - Univ Embu, Dept Biol Sci, Entbu, KenyaAD  - Hanoi Sch Publ Hlth, Hanoi, VietnamAD  - State Univ Semarang, Dept Publ Hlth Sci, Kota Semarang, IndonesiaAD  - South African Embassy, Natl Dept Hlth, Pretoria, South AfricaAD  - Natl Ctr Global lealth & Med, Inst Global Hlth Policy Res, Shinjyuku Ku, Tokyo, JapanAD  - Abia State Univ, Dept Med, Uturu, NigeriaAD  - Western Sydney Univ, Sch Social Sci & Psychol, Penrith, NSW, AustraliaAD  - Kyung Hee Univ, Dept Prevent Med, Dongdaemungu, South KoreaAD  - Soc Family Hlth, Res Measurement & Results, Fct, NigeriaAD  - Human Sci Res Council, Dept HIV, AIDS, STIs, Durban, South AfricaAD  - Human Sci Res Council, TB, Durban, South AfricaAD  - Univ Namibia, Sch Publ Hlth, Oshakati Campus, NamibiaAD  - Univ Lagos, Dept Psychiat, Lagos, NigeriaAD  - Ctr Healthy Start Initiat, Ikoyi, NigeriaAD  - Univ Brunei Darussalam, Inst Hlth Sci, Gadong, BruneiAD  - Lira Dist Local Govt, Dept Hlth, Lira, UgandaAD  - San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USAAD  - Univ Maryland, Ctr Vaccine Dev, Baltimore, MD 21201 USAAD  - Autonontous Univ Madrid, Serv Pneumol, Madrid, SpainAD  - Autonontous Univ Madrid, Sch Med, Madrid, SpainAD  - Jimenez Diaz Univ Hosp, Inst Hlth Res Fdn, Nephrol & Hypertens, Madrid, SpainAD  - St Lukes Int Univ, Dept Global Hlth Nursing, Tokyo, JapanAD  - Minist Hlth Russian Federat, Ctr Healthcare Qual Assessment & Control, Moscow, RussiaAD  - Moscow MV Lomonosov State Univ, Moscow Inst Phys & Technol, Dolgoprudnyi, RussiaAD  - North West Univ, Agr Econ Grp, Mafikeng, South AfricaAD  - North West Univ, Dept Pediat, Mafikeng, South AfricaAD  - Jagadguru Sri Shivarathreeswara Univ, Dept TB & Resp Med, Mysore, Karnataka, IndiaAD  - North West Univ, HART, Mafikeng, South AfricaAD  - Univ Ottowa, Dept Med, Ottawa, ON, CanadaAD  - Ctr Hlth Outcomes & Evaluat, Hlth Outcomes, Bucharest, RomaniaAD  - Kosin Univ, Dept Medicial Human & Social Med, Pusan, South KoreaAD  - Maimonides Hosp, Dept Med, Brooklyn, NY 11219 USAAD  - Int Inst Hlth Management Res, New Delhi, IndiaAD  - Murdoch Childrens Res Inst, Populat Hlth Grp, Melbourne, Vic, AustraliaAD  - Murdoch Childrens Res Inst, Melbourne, Vic, AustraliaAD  - Save Children, Hlth Nutr & HIV AIDS Program, Kathmandu, NepalAD  - Cartagena Univ, Cartagena, ColombiaAD  - Univ Virginia, Anesthesiol Dept, Charlottesville, VA USAAD  - Univ Virginia, Sch Med, Charlottesville, VA 22908 USAAD  - Univ Gothenburg, Inst Med, Gothenburg, SwedenAD  - Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South AfricaAD  - Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Shanghai, Peoples R ChinaAD  - Durban Univ Technol, Basic Med Sci Dept, Durban, South AfricaAD  - German Fed Environm Agcy, Dept Environm Hyg, Dessau Rosslau, GermanyAD  - Univ Newcastle, Discipline Gen Practice, Callaghan, NSW, AustraliaAD  - Ctr Addict & Mental Hlth, Inst Mental Hlth Policy Res, Toronto, ON, CanadaAD  - Univ Groningen, Univ Med Ctr Groningen, Groningen, NetherlandsAD  - Charotar Univ Sci & Technol, Askok & Rita Patel Inst Physiotherapy, Anand, Gujarat, IndiaAD  - Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, IranAD  - Drexel Univ, Dept Environm & Occupat Hlth, Philadelphia, PA 19104 USAAD  - Medichem, Barcelona, SpainAD  - Contech Sch Publ Hlth, Epidemiol & Biostat, Lahore, PakistanAD  - Sweidi Hosp, Dept Clin Pediat, Riyadh, Saudi ArabiaAD  - Soc Hlth & Demog Surveillance, Sufi, IndiaAD  - Univ Goettingen, Dept Econ, Gottingen, GermanyAD  - Med Univ Innsbruck, Innsbruck, AustriaAD  - Nizams Inst Med Sci, Dept Nephrol, Hyderabad, IndiaAD  - Capital & Coast Dist Hlth Board, Dept Neurol, Wellington, New ZealandAD  - Fundacao Oswaldo Cruz, Gongalo Moniz Inst, Salvador, BA, BrazilAD  - Fundacao Oswaldo Cruz, Inst Sci & Technol Commun & Informat Hlth, Salvador, BA, BrazilAD  - Univ Coll London Hosp, London, EnglandAD  - Publ Hlth England, London, EnglandAD  - Loma Linda Univ Med Ctr, Dept Prevent Med & Occupat Med, Loma Linda, CA USAAD  - Brien Holden Vision Inst, Sydney, NSW, AustraliaAD  - Org Prevent Blindness, Paris, FranceAD  - Birjand Univ Med Sci, Dept Epidemiol, Bushehr, IranAD  - Univ Fed Uberlandia, Dept Clin Res, Uberlandia, MG, BrazilAD  - Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, IranAD  - IKIAM Amazon Reg Univ, Ciudad De Tena, EcuadorAD  - Southern Univ Sci & Technol, Dept Ocean Sci & Engn, Shenzhen, Peoples R ChinaAD  - Muhimbili Univ Hlth & Allied Sci, Dept Community Hlth, Dar Es Salaam, TanzaniaAD  - Muhimbili Univ Hlth & Allied Sci, Sch Publ Hlth, Dar Es Salaam, TanzaniaAD  - Prince Wales Hosp, Neuropsychiat Inst, Randwick, NSW, AustraliaAD  - Univ Sharjah, Med Dept, Sharjah, U Arab EmiratesAD  - AL imam Mohammad Ibn Saud IslamIC UNIV, Coll Med, Riyadh, Saudi ArabiaAD  - York Univ, Sch Hlth & Policy Management, Fac Hlth, Toronto, ON, CanadaAD  - Marshall Univ, Dept Surg, Huntington, WV USAAD  - Case Western Reserve Univ, Dept Nutr & Prevent Med, Cleveland, OH USAAD  - Jimenez Diaz Fdn Univ Hosp Inst Hlth Res, Nephrol Grp, Madrid, SpainAD  - Reg Hlth Adm Norte IP, Dept Publ Hlth, Vila Nova De Gaia, PortugalAD  - Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USAAD  - Hamad Med Corp, Surg Dept, Doha, QatarAD  - Bournemouth Univ, Fac Hlth K Social Sci, Bournemouth, Dorset, EnglandAD  - Bournemouth Univ, Bournemouth, Dorset, EnglandAD  - Utkal Univ, UGC Ctr Adv Study Psychol, Bhubaneswar, IndiaAD  - Udyam Global Assoc Sustainable Dev, Bhubaneswar, IndiaAD  - GSK Biol, Wavre, BelgiumAD  - Univ N Carolina, Dept Publ Hlth Sci, Charlotte, NC USAAD  - Indrapastha Inst Informat Technol, Ctr Computat Biol, Delhi, IndiaAD  - Univ Fed Santa Catarina, Sch Hlth Sci, Ararangua, BrazilAD  - Queensland Ctr Mental Hlth Res, Child & Youth Mental Hlth, Brisbane, Qld, AustraliaAD  - Univ Zagreb, Dept Med Stat Epidemiol & Med Informat, Zagreb, CroatiaAD  - Croatian Inst Publ Hlth, Div Epidemiol & Prevent Chron Noncomunicable Dis, Zagreb, CroatiaAD  - NYU, Langone Med Ctr, New York, NY 10003 USAAD  - Natl Univ, Publ Hlth Div, Nablus, PalestineAD  - Islamic Azad Univ, Dept Basic Sci, Sari, IranAD  - Islamic Azad Univ, Dept Lab Sci, Sari, IranAD  - Delhi Technol Univ, Univ Sch Management & Entreprenuership, New Delhi, IndiaAD  - Fudan Univ, Dept Pulm Med, Shanghai, Peoples R ChinaAD  - Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USAAD  - Natl Inst Infect Dis, Tokyo, JapanAD  - Finnish Inst Occupat Hlth, Helsinki, FinlandAD  - Symbiosis Int Univ, Symbiosis Inst Hlth Sci, Pune, Maharashtra, IndiaAD  - Reykjavik Univ, Dept Psychol, Reykjavik, IcelandAD  - Univ Brasilia, Brasilia, DF, BrazilAD  - Asthma Bhawan, Dept Pulm Med, Jaipur, Rajasthan, IndiaAD  - Sch Prevent Oncol, Epidemiol, Patna, Bihar, IndiaAD  - King Khalid Univ Hosp, Pediat Dept, Riyadh, Saudi ArabiaAD  - Univ Hosp De La Princesa, Hlth Res Inst, Serv Pulmonol, Madrid, SpainAD  - Int Med Univ, Div Community Med, Kuala Lumpur, MalaysiaAD  - Wadhwani Initiat Sustainable Healthcare WISH Fd, Delhi, IndiaAD  - Athens Univ Appl Sci, Dept Occupat Therapy, Athens, GreeceAD  - Muhammadiyah Univ Surakarta, Dept Nursing, Kartasura, IndonesiaAD  - Univ Calif Riverside, Sch Med, Riverside, CA 92521 USAAD  - Univ Calif Irvine, Dept Criminol Law & Soc, Irvine, CA USAAD  - Biomed Res Networking Ctr Mental Hlth Network Cib, Carlos III Hlth Inst, Madrid, SpainAD  - Osaka Int Canc Inst, Canc Control Ctr, Canc Control Ctr, Osaka, JapanAD  - Asbestos Dis Res Inst, Sydney, NSW, AustraliaAD  - New York Med Coll, Dept Psychiat & Behav Sci, Valhalla, NY 10595 USAAD  - Univ Inst Egas Moniz, Monte De Caparica, PortugalAD  - Univ Lisbon, Res Inst Med, Fac Pharm Lisbon, Lisbon, PortugalAD  - Alkan Hlth Sci Business & Technol Coll, Selihom Sch Nursing, Dessie, EthiopiaAD  - SEMA, Charlottesville, VA USAAD  - Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, SingaporeAD  - Nanyang Technol Univ, Singapore, SingaporeAD  - Peter Doherty Inst Infect & Immun, WHO Collaborating Ctr Viral Hepatitis, Melbourne, Vic, AustraliaAD  - Natl Ctr Child Hlth & Dev, Dept Hlth Policy, Tokyo, JapanAD  - Agcy Hlth Technol Assessment & Tariff Syst, Warsaw, PolandAD  - Hanoi Med Univ, Dept Hlth Econ, Hanoi, VietnamAD  - Univ Auckland, Mol Med & Pathol, Auckland, New ZealandAD  - Mil Med Univ, Clin Hematol & Toxicol, Hanoi, VietnamAD  - King Georges Med Univ, Lucknow, Uttar Pradesh, IndiaAD  - Natl Inst Res TB, Director Charge, Madras, Tamil Nadu, IndiaAD  - Univ Heart Ctr Hamburg, Dept Vasc Med, Hamburg, GermanyAD  - Cleveland Clin, CV Med, Cleveland, OH 44106 USAAD  - Cleveland Clin Abu Dhabi, CV Med, Abu Dhabi, U Arab EmiratesAD  - Fed Teaching Hosp, Dept Internal Med, Abakaliki, NigeriaAD  - Gomal Univ, Gornal Ctr Biochem & Biotechnol, Dera Ismail Khan, PakistanAD  - Mufti Mehmood Mem Teaching Hosp, TB Culture Lab, Dera Ismail Khan, PakistanAD  - Ankara Univ, Ankara, TurkeyAD  - Argentine Soc Med, Buenos Aires, ArgentinaAD  - Velez Sarsfield Hosp, Intens Care Unit Staff, Buenos Aires, DF, ArgentinaAD  - UKK Inst, Tampere, FinlandAD  - Univ Brasilia, Dept Stat, Brasilia, DF, BrazilAD  - Fed Dist Planning Co, Directorate Social Studies & Policies, Brasilia, DF, BrazilAD  - Raffles Hosp, Raffles Neurosci Ctr, Singapore, SingaporeAD  - Cornell Univ, Weill Cornell Med Dept Pediat, Ithaca, NY USAAD  - St Orsola Malpighi Hosp, Occupat Hlth Unit, Bologna, ItalyAD  - Natl Res Univ, Higher Sch Econ, Dept Hlth Care Adm & Econ, Moscow, RussiaAD  - Fdn Univ, Coll Med, Rawalpindi, PakistanAD  - Tech Univ Munich, Dept Neurol, Munich, GermanyAD  - Kailuan Gen Hosp, Kailuan Gen Hosp, Tangshan, Peoples R ChinaAD  - Univ Strathclyde, Glasgow, Lanark, ScotlandAD  - Nanjing Univ, Sch Med, Nanjing, Jiangsu, Peoples R ChinaAD  - King Egad Univ Petr & Minerals, Dept Earth Sci, Dhahran, Saudi ArabiaAD  - Wolkite Univ, Wolkite, EthiopiaAD  - Kyoto Univ, Dept Biostat, Kyoto, JapanAD  - Jackson State Univ, Dept Hlth Policy & Management, Jackson, MS USAAD  - Tsinghua Univ, Beijing, Peoples R ChinaAD  - Wuhan Univ, Global Hlth Inst, Dept Epidemiol & Biostat, Wuhan, Hubei, Peoples R ChinaAD  - Wuhan Univ, Global Hlth Inst, Wuhan, Hubei, Peoples R ChinaAD  - Mother Hosp, Dept Cardiol, Trichur, IndiaAD  - Inst Oncol Ljubljana, Epidemiol & Canc Registry Sect, Ljubljana, SloveniaAD  - Univ Hosp Setif, Epidemiol, Setif, AlgeriaAD  - Leibniz Inst Prevent Res & Epidemiol, Dept Prevent & Evaluat, Bremen, GermanyAD  - Tel Aviv Univ, Sch Publ Hlth, Tel Aviv, IsraelC3  - Institute for Health Metrics & EvaluationC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - McGill UniversityC3  - McGill UniversityC3  - McGill UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - University of CalgaryC3  - University of CalgaryC3  - University of CalgaryC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Manonmaniam Sundaranar UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - Hawassa UniversityC3  - Hawassa UniversityC3  - Hawassa UniversityC3  - CHU LimogesC3  - Universite de LimogesC3  - Qatar Foundation (QF)C3  - Weill Cornell Medical College QatarC3  - Birzeit UniversityC3  - University of IbadanC3  - University College Hospital, IbadanC3  - Cardiff UniversityC3  - Stellenbosch UniversityC3  - Stellenbosch UniversityC3  - Stellenbosch UniversityC3  - South African Medical Research CouncilC3  - South African Medical Research CouncilC3  - University of Southern DenmarkC3  - Universidad de ExtremaduraC3  - McMaster UniversityC3  - McMaster UniversityC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - Yerevan State UniversityC3  - National Academy of Sciences of ArmeniaC3  - Public Health Foundation of IndiaC3  - Public Health Foundation of IndiaC3  - Public Health Foundation of IndiaC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Baylor College of MedicineC3  - Baylor College of MedicineC3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Mohammed V University in RabatC3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Universite Ferhat Abbas SetifC3  - University of Rhode IslandC3  - University of IbadanC3  - University College Hospital, IbadanC3  - University of KentuckyC3  - University of TorontoC3  - University of TorontoC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - Mayo ClinicC3  - Washington University (WUSTL)C3  - University of Western AustraliaC3  - University of Western AustraliaC3  - Universidad de la Republica, UruguayC3  - Australian National UniversityC3  - Australian National UniversityC3  - King Saud UniversityC3  - King Saud UniversityC3  - King Saud UniversityC3  - New York UniversityC3  - New York University Abu DhabiC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - Qazvin University of Medical Sciences (QUMS)C3  - Kuwait UniversityC3  - Luxembourg Institute of HealthC3  - Universite de BordeauxC3  - Hospital del Mar Research InstituteC3  - Hospital del MarC3  - Pompeu Fabra UniversityC3  - King Abdulaziz UniversityC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - Universidad de CartagenaC3  - Universidad de la CostaC3  - University of South AustraliaC3  - South Australian Health & Medical Research Institute (SAHMRI)C3  - South Australian Health & Medical Research Institute (SAHMRI)C3  - Bahir Dar UniversityC3  - Bahir Dar UniversityC3  - Bahir Dar UniversityC3  - American University of BeirutC3  - Kwame Nkrumah University Science & TechnologyC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - University of ThessalyC3  - Arba Minch UniversityC3  - Arba Minch UniversityC3  - Zahedan University of Medical SciencesC3  - Universitas HasanuddinC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - Kwame Nkrumah University Science & TechnologyC3  - Kwame Nkrumah University Science & TechnologyC3  - University of MunichC3  - Birmingham City UniversityC3  - Dalarna UniversityC3  - University of ManitobaC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Ministry of Health & Medical Education (MOHME)C3  - Ministry of Health & Medical Education (MOHME)C3  - Ministry of Health & Medical Education (MOHME)C3  - Ministry of Health & Medical Education (MOHME)C3  - Mashhad University of Medical SciencesC3  - Mashhad University of Medical SciencesC3  - University of LahoreC3  - University of LahoreC3  - University Ha'ilC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Dr DY Patil Vidyapeeth PuneC3  - Dr D Y Patil Medical College, Hospital & Research CentreC3  - Keimyung UniversityC3  - University of LeicesterC3  - University of LeicesterC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - University of WitwatersrandC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - Instituto Nacional de Salud - PeruC3  - Dilla UniversityC3  - University of TokyoC3  - University of TokyoC3  - University of TokyoC3  - University of TokyoC3  - University of South AfricaC3  - Burnet InstituteC3  - University of MaltaC3  - Public Health Agency of CanadaC3  - Sri Ramachandra Institute of Higher Education & ResearchC3  - Clinical Centre of SerbiaC3  - University of BelgradeC3  - University of BelgradeC3  - University of BelgradeC3  - Universidad Costa RicaC3  - Universidad Costa RicaC3  - Centro de Investigacao em Saude de ManhicaC3  - Centro de Investigacao em Saude de ManhicaC3  - University of CanterburyC3  - Stanford UniversityC3  - Charles R. Drew University of Medicine & ScienceC3  - University of California SystemC3  - University of California Los AngelesC3  - Jazan UniversityC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Lorestan University of Medical SciencesC3  - CHU Dijon BourgogneC3  - Universite de BourgogneC3  - Yale UniversityC3  - Yale UniversityC3  - Yale UniversityC3  - University of AlbertaC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - University System of GeorgiaC3  - Augusta UniversityC3  - University of LondonC3  - London School Economics & Political ScienceC3  - University of LondonC3  - London School Economics & Political ScienceC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - Emory UniversityC3  - Emory UniversityC3  - Rollins School Public HealthC3  - State University System of FloridaC3  - University of South FloridaC3  - University of BirminghamC3  - University of BirminghamC3  - Imperial College LondonC3  - Imperial College LondonC3  - Imperial College LondonC3  - Imperial College LondonC3  - Imperial College LondonC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - Nepal Academy of Science & Technology (NAST)C3  - Aga Khan UniversityC3  - Aga Khan UniversityC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - University of BolognaC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - Research Triangle InstituteC3  - University of NottinghamC3  - University of BergenC3  - University of BergenC3  - University of OsloC3  - Oregon Health & Science UniversityC3  - Oregon Health & Science UniversityC3  - University of Texas SystemC3  - University of Texas Health Science Center HoustonC3  - University of Texas SystemC3  - University of Texas Health Science Center HoustonC3  - The World BankC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - Anglia Ruskin UniversityC3  - University of GenoaC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Comenius University BratislavaC3  - University System of OhioC3  - Ohio State UniversityC3  - University System of OhioC3  - Ohio State UniversityC3  - University System of OhioC3  - Ohio State UniversityC3  - Helmholtz AssociationC3  - German Cancer Research Center (DKFZ)C3  - Instituto Conmemorativo Gorgas de Estudios de la SaludC3  - Harvard UniversityC3  - Massachusetts General HospitalC3  - University of British ColumbiaC3  - University of British ColumbiaC3  - Universidad Autonoma Metropolitana - MexicoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidad Nacional de ColombiaC3  - Universidad Nacional de ColombiaC3  - Australian Catholic UniversityC3  - Australian Catholic UniversityC3  - University of Hong KongC3  - University of Hong KongC3  - National Health Research Institutes - TaiwanC3  - National Taiwan UniversityC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalC3  - Chinese Academy of SciencesC3  - Gold Coast HealthC3  - University of Occupational & Environmental Health - JapanC3  - Monash UniversityC3  - Monash UniversityC3  - Monash UniversityC3  - Monash UniversityC3  - University of ZambiaC3  - University of ZambiaC3  - Seoul National University (SNU)C3  - Seoul National University HospitalC3  - University of CopenhagenC3  - Bispebjerg HospitalC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - University of AdelaideC3  - University of AdelaideC3  - University of AdelaideC3  - Robinson Research InstituteC3  - University of AdelaideC3  - University of SalernoC3  - Health Effects Institute (HEI)C3  - Universidad Autonoma de ChileC3  - Universidad Autonoma de ChileC3  - Universidad Autonoma de ChileC3  - University of Milano-BicoccaC3  - University of SouthamptonC3  - Mayo ClinicC3  - Universidade Federal do Rio Grande do SulC3  - Universidade Federal do Rio Grande do SulC3  - University of California SystemC3  - University of California San DiegoC3  - University of OtagoC3  - University of OtagoC3  - Duke UniversityC3  - Duke UniversityC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - Flinders University South AustraliaC3  - Duy Tan UniversityC3  - Guy's & St Thomas' NHS Foundation TrustC3  - Guy's & St Thomas' NHS Foundation TrustC3  - King George's Medical UniversityC3  - Bangladesh Rural Advancement Committee BRACC3  - BRAC UniversityC3  - Bangladesh Rural Advancement Committee BRACC3  - BRAC UniversityC3  - Central University of Tamil NaduC3  - Asfendiyarov Kazakh National Medical UniversityC3  - Monash HealthC3  - Griffith UniversityC3  - Griffith University - Mount Gravatt CampusC3  - Griffith UniversityC3  - Griffith University - Mount Gravatt CampusC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - African Population & Health Research CentreC3  - African Population & Health Research CentreC3  - Children's Hospital ColoradoC3  - University of Colorado SystemC3  - University of Colorado Anschutz Medical CampusC3  - University of BrightonC3  - University of SussexC3  - Aristotle University of ThessalonikiC3  - Icahn School of Medicine at Mount SinaiC3  - University of PeradeniyaC3  - Harvard UniversityC3  - Harvard Medical SchoolC3  - Harvard UniversityC3  - Harvard Medical SchoolC3  - Harvard UniversityC3  - Harvard Medical SchoolC3  - Harvard UniversityC3  - Harvard Medical SchoolC3  - Harvard UniversityC3  - Harvard Medical SchoolC3  - Harvard UniversityC3  - Harvard Medical SchoolC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard T.H. Chan School of Public HealthC3  - University of Cape CoastC3  - University of Cape CoastC3  - Tampere UniversityC3  - Tampere UniversityC3  - University of RochesterC3  - Royal Melbourne Institute of Technology (RMIT)C3  - Royal Melbourne Institute of Technology (RMIT)C3  - University of EdinburghC3  - University of EdinburghC3  - Asbestos Diseases Research InstituteC3  - University of SydneyC3  - University of SydneyC3  - University of SydneyC3  - University of SydneyC3  - Universidade Federal da BahiaC3  - Universidade Federal da BahiaC3  - Umea UniversityC3  - UiT The Arctic University of TromsoC3  - Arkansas State UniversityC3  - Stavanger University HospitalC3  - Norwegian Institute of Public Health (NIPH)C3  - Norwegian Institute of Public Health (NIPH)C3  - Norwegian Institute of Public Health (NIPH)C3  - Eijkman InstituteC3  - Russian Academy of SciencesC3  - Urmia University of Medical SciencesC3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - University of LouisvilleC3  - Universidade Federal de SergipeC3  - Auckland University of TechnologyC3  - Organisation for Economic Co-operation & Development (OECD)C3  - Universidade Catolica PortuguesaC3  - Brandeis UniversityC3  - University of MemphisC3  - Kaiser PermanenteC3  - University of BielefeldC3  - National Academy of Medical Sciences of UkraineC3  - D. F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of UkraineC3  - University of East AngliaC3  - University of Milano-BicoccaC3  - James Cook UniversityC3  - Kobe UniversityC3  - University of BaselC3  - Swiss Tropical & Public Health InstituteC3  - University of BaselC3  - Swiss Tropical & Public Health InstituteC3  - University of BaselC3  - National Center for Disease Control & Public Health - GeorgiaC3  - Sidi Mohamed Ben Abdellah University of FezC3  - Curtin UniversityC3  - Wageningen University & ResearchC3  - PfizerC3  - Pfizer USAC3  - Martin Luther University Halle WittenbergC3  - Martin Luther University Halle WittenbergC3  - University of TsukubaC3  - University of WarwickC3  - University of WarwickC3  - Howard UniversityC3  - Howard UniversityC3  - Jawaharlal Nehru University, New DelhiC3  - Jawaharlal Nehru University, New DelhiC3  - University of ValenciaC3  - University of ValenciaC3  - University of ValenciaC3  - University of ValenciaC3  - University of Massachusetts SystemC3  - University of Massachusetts BostonC3  - University of Oklahoma SystemC3  - University of Oklahoma Health Sciences CenterC3  - National Cancer Center - JapanC3  - Boston UniversityC3  - Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele Presidio FerraottoC3  - Universidade Estadual de Montes ClarosC3  - West Virginia UniversityC3  - Eternal Heart Care Centre & Research InstituteC3  - Yeshiva UniversityC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Aarhus UniversityC3  - Aarhus UniversityC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - Western University (University of Western Ontario)C3  - Western University (University of Western Ontario)C3  - Arabian Gulf UniversityC3  - University of New MexicoC3  - Sir Charles Gairdner HospitalC3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Tabriz University of Medical ScienceC3  - Tabriz University of Medical ScienceC3  - University of BarcelonaC3  - University of AntwerpC3  - Karolinska InstitutetC3  - Karolinska University HospitalC3  - Bucharest University of Economic StudiesC3  - University of GroningenC3  - Columbia UniversityC3  - Columbia UniversityC3  - University of Texas SystemC3  - University of Texas AustinC3  - Guilan University of Medical SciencesC3  - Guilan University of Medical SciencesC3  - Manipal Academy of Higher Education (MAHE)C3  - Universite de Tunis-El-ManarC3  - Faculte de Medecine de Tunis (FMT)C3  - University of OsloC3  - University of OsloC3  - Central South UniversityC3  - Qatar UniversityC3  - University of the Western CapeC3  - Walter Sisulu UniversityC3  - Taipei Medical UniversityC3  - Taipei Medical UniversityC3  - Deakin UniversityC3  - Deakin UniversityC3  - Deakin UniversityC3  - American Cancer SocietyC3  - University of KragujevacC3  - Newcastle University - UKC3  - Virginia Commonwealth UniversityC3  - University of ColomboC3  - University of ColomboC3  - Yonsei UniversityC3  - Yonsei UniversityC3  - Banaras Hindu University (BHU)C3  - Duke Kunshan UniversityC3  - Duke Kunshan UniversityC3  - Capital Medical UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Technical University CzestochowaC3  - University of OpoleC3  - Savitribai Phule Pune UniversityC3  - University of TartuC3  - University College CorkC3  - Samara UniversityC3  - Hamadan University of Medical SciencesC3  - Hamadan University of Medical SciencesC3  - Helmholtz AssociationC3  - Helmholtz-Center for Infection ResearchC3  - University of WashingtonC3  - University of Washington TacomaC3  - Seattle Children's HospitalC3  - Seattle Children's HospitalC3  - MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNITC3  - University of GlasgowC3  - University of TulsaC3  - University of NairobiC3  - University of NairobiC3  - Michigan State UniversityC3  - University of Cape TownC3  - University of Cape TownC3  - Jordan University of Science & TechnologyC3  - University of Management & Technology (UMT)C3  - Health Services AcademyC3  - United Arab Emirates UniversityC3  - Dow University of Health SciencesC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Tennessee SystemC3  - University of Tennessee Health Science CenterC3  - Seoul National University (SNU)C3  - Seoul National University (SNU)C3  - Indian Council of Medical Research (ICMR)C3  - Indian Council of Medical Research (ICMR)C3  - Indian Council of Medical Research (ICMR)C3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute for Research in Environmental Health (NIREH)C3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Nutrition (NIN)C3  - Indian Council of Medical Research (ICMR)C3  - Lund UniversityC3  - Lund UniversityC3  - Northwestern UniversityC3  - Korea UniversityC3  - Simmons UniversityC3  - University of CanberraC3  - Tulane UniversityC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - University of HelsinkiC3  - National Cerebral & Cardiovascular Center - JapanC3  - Arthritis Research CanadaC3  - Sher-i-Kashmir Institute of Medical SciencesC3  - Research Center of NeurologyC3  - Panjab UniversityC3  - Universite de MontrealC3  - Universite de MontrealC3  - Yuksek Ihtisas UniversityC3  - University of Technology SydneyC3  - University of Technology SydneyC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - National Institutes of Health (NIH) - USAC3  - NIH National Cancer Institute (NCI)C3  - NIH National Cancer Institute- Division of Cancer Epidemiology & GeneticsC3  - Ghana Health ServiceC3  - Clinica AlemanaC3  - Universidad de ChileC3  - Sechenov First Moscow State Medical UniversityC3  - Hong Kong Polytechnic UniversityC3  - University of FlorenceC3  - Sichuan UniversityC3  - Chinese Center for Disease Control & PreventionC3  - Chinese Center for Disease Control & PreventionC3  - Universiti MalayaC3  - Chinese University of Hong KongC3  - University of HaifaC3  - Universita degli Studi di Bari Aldo MoroC3  - University of PennsylvaniaC3  - University of PennsylvaniaC3  - University of PennsylvaniaC3  - Pennsylvania MedicineC3  - Childrens Hospital of PhiladelphiaC3  - Friedrich Schiller University of JenaC3  - University of LiverpoolC3  - Swansea UniversityC3  - National University of SingaporeC3  - National University of SingaporeC3  - Universite de KinshasaC3  - Universite de KinshasaC3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - Royal Children's Hospital MelbourneC3  - Royal Children's Hospital MelbourneC3  - Egyptian Knowledge Bank (EKB)C3  - Damietta UniversityC3  - University of TrnavaC3  - Shiraz University of Medical ScienceC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - RoorkeeC3  - Instituto Federal do Ceara (IFCE)C3  - Medical University of GrazC3  - Medical University of GrazC3  - UERM Memorial Medical CenterC3  - University of Kwazulu NatalC3  - Chalmers University of TechnologyC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Cancer Prevention & Research (NICPR)C3  - University of California SystemC3  - University of California San FranciscoC3  - State University System of FloridaC3  - University of West FloridaC3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - University North - CroatiaC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pacific Institute for Research & Evaluation (PIRE)C3  - Ministry of Health - KyrgyzstanC3  - Kyrgyz State Medical AcademyC3  - Salahaddin UniversityC3  - Isfahan University of Medical SciencesC3  - Ahmadu Bello UniversityC3  - Ahmadu Bello UniversityC3  - Madras Diabetes Research FoundationC3  - IRCCS Burlo GarofoloC3  - Kurdistan University of Medical SciencesC3  - Kurdistan University of Medical SciencesC3  - Lancaster UniversityC3  - Queensland University of Technology (QUT)C3  - Queensland University of Technology (QUT)C3  - Queensland University of Technology (QUT)C3  - Tarbiat Modares UniversityC3  - National & Kapodistrian University of AthensC3  - Academy of AthensC3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Epidemiology (NIE)C3  - University of JosC3  - Northwestern UniversityC3  - Northwestern UniversityC3  - Universiti Sains MalaysiaC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - Ulm UniversityC3  - Suraj Eye InstituteC3  - University of Yaounde IC3  - Kenya Medical Research InstituteC3  - Hanoi University of Public HealthC3  - Universitas Negeri SemarangC3  - Western Sydney UniversityC3  - Kyung Hee UniversityC3  - Human Sciences Research Council-South AfricaC3  - Human Sciences Research Council-South AfricaC3  - University of NamibiaC3  - University of LagosC3  - University Brunei DarussalamC3  - California State University SystemC3  - San Diego State UniversityC3  - University System of MarylandC3  - University of Maryland BaltimoreC3  - St. Luke's International HospitalC3  - Ministry of Health of the Russian FederationC3  - Lomonosov Moscow State UniversityC3  - Moscow Institute of Physics & TechnologyC3  - North West University - South AfricaC3  - North West University - South AfricaC3  - JSS Academy of Higher Education & ResearchC3  - North West University - South AfricaC3  - University of OttawaC3  - Maimonides Medical CenterC3  - International Institute of Health Management Research DelhiC3  - Murdoch Children's Research InstituteC3  - Murdoch Children's Research InstituteC3  - Save the ChildrenC3  - Universidad de CartagenaC3  - University of VirginiaC3  - University of VirginiaC3  - University of GothenburgC3  - University of WitwatersrandC3  - Shanghai Jiao Tong UniversityC3  - Durban University of TechnologyC3  - University of NewcastleC3  - University of TorontoC3  - Centre for Addiction & Mental Health - CanadaC3  - University of GroningenC3  - Charotar University of Science & Technology - CharusatC3  - Drexel UniversityC3  - University of GottingenC3  - Medical University of InnsbruckC3  - Nizam's Institute of Medical SciencesC3  - Fundacao Oswaldo CruzC3  - Fundacao Oswaldo CruzC3  - University College London Hospitals NHS Foundation TrustC3  - University of LondonC3  - University College LondonC3  - Public Health EnglandC3  - Loma Linda UniversityC3  - Brien Holden Vision InstituteC3  - Universidade Federal de UberlandiaC3  - Golestan University of Medical SciencesC3  - Southern University of Science & TechnologyC3  - Muhimbili University of Health & Allied SciencesC3  - Muhimbili University of Health & Allied SciencesC3  - University of New South Wales SydneyC3  - Prince of Wales Hospital (POWH)C3  - University of SharjahC3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - York University - CanadaC3  - Marshall UniversityC3  - University System of OhioC3  - Case Western Reserve UniversityC3  - University of Massachusetts SystemC3  - University of Massachusetts WorcesterC3  - Hamad Medical CorporationC3  - Bournemouth UniversityC3  - Bournemouth UniversityC3  - Utkal UniversityC3  - GlaxoSmithKlineC3  - GlaxoSmithKline BelgiumC3  - University of North CarolinaC3  - University of North Carolina CharlotteC3  - Indraprastha Institute of Information Technology DelhiC3  - Universidade Federal de Santa Catarina (UFSC)C3  - Queensland Centre for Mental Health ResearchC3  - University of ZagrebC3  - New York UniversityC3  - NYU Langone Medical CenterC3  - Islamic Azad UniversityC3  - Islamic Azad UniversityC3  - Delhi Technological UniversityC3  - Fudan UniversityC3  - Tufts UniversityC3  - National Institute of Infectious Diseases (NIID)C3  - Finnish Institute of Occupational HealthC3  - Symbiosis International UniversityC3  - Symbiosis Institute of Health Sciences (SIHS)C3  - Reykjavik UniversityC3  - Universidade de BrasiliaC3  - King Saud UniversityC3  - King Khalid University HospitalC3  - International Medical University MalaysiaC3  - University of West AtticaC3  - Universitas Muhammadiyah SurakartaC3  - University of California SystemC3  - University of California RiversideC3  - University of California SystemC3  - University of California IrvineC3  - Asbestos Diseases Research InstituteC3  - New York Medical CollegeC3  - Universidade de LisboaC3  - Nanyang Technological UniversityC3  - Nanyang Technological UniversityC3  - University of MelbourneC3  - Peter Doherty InstituteC3  - National Center for Child Health & Development - JapanC3  - Hanoi Medical UniversityC3  - University of AucklandC3  - King George's Medical UniversityC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute for Research in Tuberculosis (NIRT)C3  - University of HamburgC3  - University Medical Center Hamburg-EppendorfC3  - Cleveland Clinic FoundationC3  - Cleveland Clinic FoundationC3  - Gomal UniversityC3  - Ankara UniversityC3  - UKK InstituteC3  - Universidade de BrasiliaC3  - Raffles HospitalC3  - Cornell UniversityC3  - Weill Cornell MedicineC3  - IRCCS Azienda Ospedaliero-Universitaria di BolognaC3  - HSE University (National Research University Higher School of Economics)C3  - Technical University of MunichC3  - University of StrathclydeC3  - Nanjing UniversityC3  - Kyoto UniversityC3  - Jackson State UniversityC3  - Tsinghua UniversityC3  - Wuhan UniversityC3  - Wuhan UniversityC3  - Institute of Oncology - SloveniaC3  - Leibniz AssociationC3  - Leibniz Institute for Prevention Research & Epidemiology (BIPS)C3  - Tel Aviv UniversityPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - NOV 10
PY  - 2018
VL  - 392
IS  - 10159
SP  - 1684
EP  - 1735
DO  - 10.1016/S0140-6736(18)31891-9
AN  - WOS:000449710900003
ER  -

TY  - JOUR
AU  - Kyu, HH
AU  - Abate, D
AU  - Abate, KH
AU  - Abay, SM
AU  - Abbafati, C
AU  - Abbasi, N
AU  - Abbastabar, H
AU  - Abd-Allah, F
AU  - Abdela, J
AU  - Abdelalim, A
AU  - Abdollahpour, I
AU  - Suliankatchi Abdulkader, R
AU  - Abebe, M
AU  - Abebe, Z
AU  - Abil, OZ
AU  - Aboyans, V
AU  - Abrham, AR
AU  - Abu-Raddad, LJ
AU  - Abu-Rmeileh, NME
AU  - Accrombessi, MMK
AU  - Acharya, D
AU  - Acharya, P
AU  - Ackerman, IN
AU  - Adamu, AA
AU  - Adebayo, OM
AU  - Adekanmbi, V
AU  - Ademi, Z
AU  - Adetokunboh, OO
AU  - Adib, MG
AU  - Adsuar, JC
AU  - Afanvi, KA
AU  - Afarideh, M
AU  - Afshin, A
AU  - Agarwal, G
AU  - Agesa, KM
AU  - Aggarwal, R
AU  - Aghayan, SA
AU  - Agrawal, A
AU  - Ahmadi, A
AU  - Ahmadi, M
AU  - Ahmadieh, H
AU  - Ahmed, MB
AU  - Ahmed, S
AU  - Aichour, AN
AU  - Aichour, I
AU  - Aichour, MTE
AU  - Akinyemiju, T
AU  - Akseer, N
AU  - Ayman, ZA
AU  - Al-Eyadhy, A
AU  - Al-Mekhlafi, HM
AU  - Al-Raddadi, RM
AU  - Alahdab, F
AU  - Alam, K
AU  - Alam, T
AU  - Alashi, A
AU  - Alavian, SM
AU  - Alene, KA
AU  - Alijanzadeh, M
AU  - Alizadeh-Navaei, R
AU  - Aljunid, SM
AU  - Alkerwi, A
AU  - Alla, F
AU  - Allebeck, P
AU  - Alonso, J
AU  - Alsharif, U
AU  - Altirkawi, K
AU  - Alvis-Guzman, N
AU  - Aminde, LN
AU  - Amini, E
AU  - Amiresmaili, M
AU  - Ammar, W
AU  - Amoako, YA
AU  - Anber, NH
AU  - Andrei, CL
AU  - Androudi, S
AU  - Animut, MD
AU  - Anjomshoa, M
AU  - Ansha, MG
AU  - Antonio, CAT
AU  - Anwari, P
AU  - Arabloo, J
AU  - Aremu, O
AU  - Ärnlöv, J
AU  - Arora, A
AU  - Arora, M
AU  - Artaman, A
AU  - Aryal, KK
AU  - Asayesh, H
AU  - Ataro, Z
AU  - Ausloos, M
AU  - Avila-Burgos, L
AU  - Avokpaho, EFGA
AU  - Awasthi, A
AU  - Quintanilla, BPA
AU  - Ayer, R
AU  - Azzopardi, PS
AU  - Babazadeh, A
AU  - Badali, H
AU  - Balakrishnan, K
AU  - Bali, AG
AU  - Banach, M
AU  - Banoub, JAM
AU  - Barac, A
AU  - Barboza, MA
AU  - Barker-Collo, SL
AU  - Bämighausen, TW
AU  - Barquera, S
AU  - Barrero, LH
AU  - Bazargan-Hejazi, S
AU  - Bedi, N
AU  - Beghi, E
AU  - Behzadifar, M
AU  - Behzadifar, M
AU  - Bekele, BB
AU  - Bekru, ET
AU  - Belachew, AB
AU  - Belay, YA
AU  - Bell, ML
AU  - Bello, AK
AU  - Bennett, DA
AU  - Bensenor, IM
AU  - Berhane, A
AU  - Bernabe, E
AU  - Bernstein, RS
AU  - Beuran, M
AU  - Beyranvand, '
AU  - Bhala, N
AU  - Bhatt, S
AU  - Bhaumik, S
AU  - Bhutta, ZA
AU  - Biadgo, B
AU  - Biehl, MH
AU  - Bijani, A
AU  - Bikbov, B
AU  - Bilano, V
AU  - Bililign, N
AU  - Bin Sayeed, MS
AU  - Bisanzio, D
AU  - Bjorge, T
AU  - Bleyer, A
AU  - Bobasa, EM
AU  - Bou-Orm, IR
AU  - Boufous, S
AU  - Bourne, R
AU  - Brady, OJ
AU  - Brant, LC
AU  - Brayne, C
AU  - Brazinova, A
AU  - Breitborde, NJK
AU  - Brenner, H
AU  - Briant, PS
AU  - Briko, AN
AU  - Britton, G
AU  - Brugha, T
AU  - Buchbinder, R
AU  - Busse, R
AU  - Butt, ZA
AU  - Cahuana-Hurtado, L
AU  - Rincon, JCC
AU  - Cano, J
AU  - Cárdenas, R
AU  - Carrero, JJ
AU  - Carter, A
AU  - Carvalho, F
AU  - Castañeda-Orjuela, CA
AU  - Rivas, JC
AU  - Castro, F
AU  - Catalá-López, F
AU  - Cercy, KM
AU  - Cerin, E
AU  - Chaiah, Y
AU  - Chang, JC
AU  - Charlson, FJ
AU  - Chattu, VK
AU  - Chiang, PPC
AU  - Chitheer, A
AU  - Choi, JYJ
AU  - Christensen, H
AU  - Christopher, DJ
AU  - Chung, SC
AU  - Cicuttini, FM
AU  - Cirillo, M
AU  - Collado-Mateo, D
AU  - Cooper, C
AU  - Cortesi, PA
AU  - Cortinovis, M
AU  - Cousin, E
AU  - Criqui, MH
AU  - Cromwell, EA
AU  - Cross, M
AU  - Crump, JA
AU  - Daba, AK
AU  - Dachew, BA
AU  - Dadi, AF
AU  - Dandona, L
AU  - Dandona, R
AU  - Dargan, PI
AU  - Daryani, A
AU  - Das Gupta, R
AU  - Das Neves, J
AU  - Dasa, TT
AU  - Davitoiu, DV
AU  - De la Hoz, FP
AU  - De Leo, D
AU  - De Neve, JW
AU  - De Steur, H
AU  - Degefa, MG
AU  - Degenhardt, L
AU  - Deiparine, S
AU  - Demoz, GT
AU  - Denova-Gutiérrez, E
AU  - Deribe, K
AU  - Dervenis, N
AU  - Jarlais, DCD
AU  - Dey, S
AU  - Dharmaratne, SD
AU  - Dhimal, M
AU  - Dinberu, MT
AU  - Dirac, MA
AU  - Djalalinia, S
AU  - Doan, L
AU  - Dokova, K
AU  - Doku, DT
AU  - Dorsey, ER
AU  - Doyle, KE
AU  - Driscoll, TR
AU  - Dubey, M
AU  - Dubljanin, E
AU  - Duken, EE
AU  - Duncan, BB
AU  - Duraes, AR
AU  - Ebrahimi, H
AU  - Ebrahimpour, S
AU  - Echko, MM
AU  - Edessa, D
AU  - Edvardsson, D
AU  - Effiong, A
AU  - Eggen, AE
AU  - Ehrlich, JR
AU  - El Bcheraoui, C
AU  - El-Khatib, Z
AU  - Elyazar, IRF
AU  - Enayati, A
AU  - Endalifer, ML
AU  - Endries, AY
AU  - Er, B
AU  - Erskine, HE
AU  - Eskandarieh, S
AU  - Esteghamati, A
AU  - Esteghamati, S
AU  - Fakhim, H
AU  - Faramarzi, M
AU  - Fareed, M
AU  - Farhadi, F
AU  - Farid, TA
AU  - Farinha, CSES
AU  - Farioli, A
AU  - Faro, A
AU  - Farzadfar, F
AU  - Fazaeli, AA
AU  - Feigin, VL
AU  - Fentahun, N
AU  - Fereshtehnejad, SM
AU  - Fernandes, E
AU  - Fernandes, JC
AU  - Ferrari, AJ
AU  - Ferreira, ML
AU  - Filip, I
AU  - Fischer, F
AU  - Fitzmaurice, C
AU  - Foigt, NA
AU  - Foreman, KJ
AU  - Frank, TD
AU  - Fukumoto, T
AU  - Pullman, N
AU  - Fürst, T
AU  - Furtado, JM
AU  - Gakidou, E
AU  - Gall, S
AU  - Gallus, S
AU  - Ganji, M
AU  - Garcia-Basteiro, AL
AU  - Gardner, WM
AU  - Gebre, AK
AU  - Gebremedhin, AT
AU  - Gebremichael, TG
AU  - Gelano, TF
AU  - Geleijnse, JM
AU  - Genova-Maleras, R
AU  - Geramo, YCD
AU  - Gething, PW
AU  - Gezae, KE
AU  - Ghadami, MR
AU  - Ghadiri, K
AU  - Ghasemi-Kasman, M
AU  - Ghimire, M
AU  - Ghoshal, AG
AU  - Gill, PS
AU  - Gill, TK
AU  - Ginawi, IA
AU  - Giussani, G
AU  - Gnedovskaya, EV
AU  - Goldberg, EM
AU  - Goli, S
AU  - Gómez-Dantés, H
AU  - Gona, PN
AU  - Gopalani, SV
AU  - Gorman, TM
AU  - Goulart, AC
AU  - Goulart, BNG
AU  - Grada, A
AU  - Grosso, G
AU  - Gugnani, HC
AU  - Guillemin, F
AU  - Guo, YM
AU  - Gupta, PC
AU  - Gupta, R
AU  - Gupta, R
AU  - Gupta, T
AU  - Gutiérrez, RA
AU  - Gyawali, B
AU  - Haagsma, JA
AU  - Hachinski, V
AU  - Hafezi-Nejad, N
AU  - Bidgoli, HH
AU  - Hagos, TB
AU  - Hailegiyorgis, TT
AU  - Haj-Mirzaian, A
AU  - Haj-Mirzaian, A
AU  - Hamadeh, RR
AU  - Hamidi, S
AU  - Handal, AJ
AU  - Hankey, GJ
AU  - Hao, Y
AU  - Harb, HL
AU  - Harikrishnan, S
AU  - Haririan, H
AU  - Haro, JM
AU  - Hassankhani, H
AU  - Hassen, HY
AU  - Havmoeller, R
AU  - Hay, RJ
AU  - Hay, SI
AU  - Hedayatizadeh-Omran, A
AU  - Heibati, B
AU  - Hendrie, D
AU  - Henok, A
AU  - Heredia-Pi, I
AU  - Herteliu, C
AU  - Heydarpour, F
AU  - Heydarpour, P
AU  - Hibstu, DT
AU  - Hoek, HW
AU  - Hoffman, HJ
AU  - Hole, MK
AU  - Rad, EH
AU  - Hoogar, P
AU  - Hosgood, HD
AU  - Hosseini, SM
AU  - Hosseinzadeh, M
AU  - Hostiuc, M
AU  - Hostiuc, S
AU  - Hotez, PJ
AU  - Hoy, DG
AU  - Hsairi, M
AU  - Htet, AS
AU  - Huang, JJ
AU  - Iburg, KM
AU  - Ikeda, CT
AU  - Ilesanmi, OS
AU  - Irvani, SSN
AU  - Irvine, CMS
AU  - Islam, SMS
AU  - Islami, F
AU  - Jacobsen, KH
AU  - Jahangiry, L
AU  - Jahanmehr, N
AU  - Jain, SK
AU  - Jakovljevic, M
AU  - James, SL
AU  - Jayatilleke, AU
AU  - Jeemon, P
AU  - Jha, RP
AU  - Jha, V
AU  - Ji, JS
AU  - Johnson, CO
AU  - Jonas, JB
AU  - Jonnagaddala, J
AU  - Shushtari, ZJ
AU  - Joshi, A
AU  - Jozwiak, JJ
AU  - Jungari, SB
AU  - Jürisson, M
AU  - Kabir, Z
AU  - Kadel, R
AU  - Kahsay, A
AU  - Kalani, R
AU  - Kanchan, T
AU  - Kar, C
AU  - Karami, M
AU  - Matin, BK
AU  - Karch, A
AU  - Karema, C
AU  - Karimi, N
AU  - Karimi, SM
AU  - Kasaeian, A
AU  - Kassa, DH
AU  - Kassa, GM
AU  - Kassa, TD
AU  - Kassebaum, NJ
AU  - Katikireddi, SV
AU  - Kaul, A
AU  - Kawakami, N
AU  - Kazemi, Z
AU  - Karyani, AK
AU  - Keighobadi, MM
AU  - Keiyoro, PN
AU  - Kemmer, L
AU  - Kemp, GR
AU  - Kengne, AP
AU  - Keren, A
AU  - Khader, YS
AU  - Khafaei, B
AU  - Khafaie, MA
AU  - Khajavi, A
AU  - Khalid, N
AU  - Khalil, IA
AU  - Khan, EA
AU  - Khan, MS
AU  - Khan, MA
AU  - Khang, YH
AU  - Khater, MM
AU  - Khazaei, M
AU  - Khoja, AT
AU  - Khosravi, A
AU  - Khosravi, MH
AU  - Kiadaliri, AA
AU  - Kidanemariam, ZT
AU  - Kiirithio, DN
AU  - Kim, CI
AU  - Kim, D
AU  - Kim, YE
AU  - Kim, YJ
AU  - Kimokoti, RW
AU  - Kinfu, Y
AU  - Kisa, A
AU  - Kissimova-Skarbek, K
AU  - Knudsen, AKS
AU  - Kocarnik, JM
AU  - Kochhar, S
AU  - Kokubo, Y
AU  - Kolola, T
AU  - Kopec, JA
AU  - Kosen, S
AU  - Kotsakis, GA
AU  - Koul, PA
AU  - Koyanagi, A
AU  - Krishan, K
AU  - Krishnaswami, S
AU  - Krohn, KJ
AU  - Defo, BK
AU  - Bicer, BK
AU  - Kumar, GA
AU  - Kumar, M
AU  - Kuzin, I
AU  - Lad, DP
AU  - Lad, SD
AU  - Lafranconi, A
AU  - Lalloo, R
AU  - Lallukka, T
AU  - Lami, FH
AU  - Lang, JJ
AU  - Langan, SM
AU  - Itansingh, V
AU  - Latifi, A
AU  - Lau, KMM
AU  - Lazarus, JV
AU  - Leasher, JL
AU  - Ledesma, JR
AU  - Lee, PH
AU  - Leigh, J
AU  - Leili, M
AU  - Leshargie, CT
AU  - Leung, J
AU  - Levi, M
AU  - Lewycka, S
AU  - Li, SS
AU  - Li, YC
AU  - Liang, XF
AU  - Liao, Y
AU  - Liben, ML
AU  - Lim, LL
AU  - Lim, SS
AU  - Limenih, MA
AU  - Linn, S
AU  - Liu, SW
AU  - Looker, KJ
AU  - Lopez, AD
AU  - Lorkowski, S
AU  - Lotufo, PA
AU  - Lozano, R
AU  - Lucas, TCD
AU  - Lunevicius, R
AU  - Lyons, RA
AU  - Ma, S
AU  - Macarayan, ERK
AU  - Mackay, MT
AU  - Maddison, ER
AU  - Madotto, F
AU  - Maghavani, DP
AU  - Mai, HT
AU  - Majdan, M
AU  - Majdzadeh, R
AU  - Majeed, A
AU  - Malekzadeh, R
AU  - Malta, DC
AU  - Mamun, AA
AU  - Manda, AL
AU  - Manguerra, H
AU  - Mansournia, MA
AU  - Herrera, AMM
AU  - Mantovani, LG
AU  - Maravilla, JC
AU  - Marcenes, W
AU  - Marks, A
AU  - Martins-Melo, FR
AU  - Martopullo, I
AU  - März, W
AU  - Marzan, MB
AU  - Massano, J
AU  - Massenburg, BB
AU  - Mathur, MR
AU  - Maulik, PK
AU  - Mazidi, M
AU  - McAlinden, C
AU  - McGrath, JJ
AU  - McKee, M
AU  - McMahon, BJ
AU  - Mehata, S
AU  - Mehrotra, R
AU  - Mehta, KM
AU  - Mehta, V
AU  - Mejia-Rodriguez, F
AU  - Mekonen, T
AU  - Melese, A
AU  - Melku, M
AU  - Memiah, PTN
AU  - Memish, ZA
AU  - Mendoza, W
AU  - Mengistu, G
AU  - Mensah, GA
AU  - Mereta, ST
AU  - Meretoja, A
AU  - Meretoja, TJ
AU  - Mestrovic, T
AU  - Miazgowski, B
AU  - Miazgowski, T
AU  - Millear, AI
AU  - Miller, TR
AU  - Mini, GK
AU  - Mirarefin, M
AU  - Mirica, A
AU  - Mirrakhimov, EM
AU  - Misganaw, AT
AU  - Mitchell, PB
AU  - Mitiku, H
AU  - Moazen, B
AU  - Mohajer, B
AU  - Mohammad, KA
AU  - Mohammadi, M
AU  - Mohammadifard, N
AU  - Mohammadnia-Afrouzi, M
AU  - Mohammed, MA
AU  - Mohammed, S
AU  - Mohebi, F
AU  - Mokdad, AH
AU  - Molokhia, M
AU  - Monasta, L
AU  - Montañez, JC
AU  - Moosazadeh, M
AU  - Moradi, G
AU  - Moradi, M
AU  - Moradi-Lakeh, M
AU  - Moradinazar, M
AU  - Moraga, P
AU  - Morawska, L
AU  - Velásquez, IM
AU  - Morgado-Da-Costa, J
AU  - Morrison, SD
AU  - Moschos, MM
AU  - Mousavi, SM
AU  - Mruts, KB
AU  - Muche, AA
AU  - Muchie, KF
AU  - Mueller, UO
AU  - Muhammed, OS
AU  - Mukhopadhyay, S
AU  - Muller, K
AU  - Mumford, JE
AU  - Murthy, GVS
AU  - Musa, KI
AU  - Mustafa, G
AU  - Nabhan, AF
AU  - Nagata, C
AU  - Nagel, G
AU  - Naghavi, M
AU  - Naheed, A
AU  - Nahvijou, A
AU  - Naik, G
AU  - Najafi, F
AU  - Nam, HS
AU  - Nangia, V
AU  - Nansseu, JR
AU  - Neamati, N
AU  - Negoi, I
AU  - Negoi, RI
AU  - Neupane, S
AU  - Newton, CRJ
AU  - Ngunjiri, JW
AU  - Nguyen, AQ
AU  - Nguyen, G
AU  - Nguyen, HT
AU  - Nguyen, HLT
AU  - Nguyen, HT
AU  - Nguyen, LH
AU  - Nguyen, M
AU  - Nguyen, NB
AU  - Nguyen, SH
AU  - Nichols, E
AU  - Ningrum, DNA
AU  - Nixon, MR
AU  - Nomura, S
AU  - Noroozi, M
AU  - Norrving, B
AU  - Noubiap, JJ
AU  - Nouri, HR
AU  - Shiadeh, MN
AU  - Nowroozi, MR
AU  - Nsoesie, EO
AU  - Nyasulu, PS
AU  - Odell, CM
AU  - Ofori-Asenso, R
AU  - Ogbo, FA
AU  - Oh, IH
AU  - Oladimeji, O
AU  - Olagunju, AT
AU  - Olagunju, TO
AU  - Olivares, PR
AU  - Olsen, HE
AU  - Olusanya, BO
AU  - Olusanya, JO
AU  - Ong, KL
AU  - Ong, SK
AU  - Oren, E
AU  - Ortiz, A
AU  - Ota, E
AU  - Otstavnov, SS
AU  - Overland, S
AU  - Owolabi, MO
AU  - Mahesh, PA
AU  - Pacella, R
AU  - Pakhare, AP
AU  - Pakpour, AH
AU  - Pana, A
AU  - Panda-Jonas, S
AU  - Park, EK
AU  - Park, J
AU  - Parry, CDH
AU  - Parsian, H
AU  - Pasdar, Y
AU  - Patel, S
AU  - Patil, ST
AU  - Patle, A
AU  - Patton, GC
AU  - Paturi, VR
AU  - Paudel, D
AU  - Paulson, KR
AU  - Pearce, N
AU  - Pereira, A
AU  - Pereira, DM
AU  - Perico, N
AU  - Pesudovs, K
AU  - Petzold, M
AU  - Pham, HQ
AU  - Phillips, MR
AU  - Pigott, DM
AU  - Pillay, JD
AU  - Piradov, MA
AU  - Pirsaheb, M
AU  - Pishgar, F
AU  - Plana-Ripoll, O
AU  - Polinder, S
AU  - Popova, S
AU  - Postma, MJ
AU  - Pourshams, A
AU  - Poustchi, H
AU  - Prabhakaran, D
AU  - Prakash, S
AU  - Prakash, V
AU  - Prasad, N
AU  - Purcell, CA
AU  - Qorbani, M
AU  - Quistberg, DA
AU  - Radfar, A
AU  - Rafay, A
AU  - Rafiei, A
AU  - Rahim, F
AU  - Rahimi, K
AU  - Rahimi, Z
AU  - Rahimi-Movaghar, A
AU  - Rahimi-Movaghar, V
AU  - Rahman, M
AU  - Rahman, MHU
AU  - Rahman, MA
AU  - Rahman, SU
AU  - Rai, RK
AU  - Rajati, F
AU  - Ranjan, P
AU  - Rao, PC
AU  - Rasella, D
AU  - Rawaf, DL
AU  - Rawaf, S
AU  - Reddy, KS
AU  - Reiner, RC
AU  - Reitsma, MB
AU  - Remuzzi, G
AU  - Renzaho, AMN
AU  - Resnikoff, S
AU  - Rezaei, S
AU  - Rezai, MS
AU  - Ribeiro, ALP
AU  - Roberts, NLS
AU  - Robinson, SR
AU  - Roever, L
AU  - Ronfani, L
AU  - Roshandel, G
AU  - Rostami, A
AU  - Roth, GA
AU  - Rothenbacher, D
AU  - Rubagotti, E
AU  - Sachdev, PS
AU  - Sadat, N
AU  - Sadeghi, E
AU  - Moghaddam, SS
AU  - Safari, H
AU  - Safari, Y
AU  - Safari-Faramani, R
AU  - Safdarian, M
AU  - Safi, S
AU  - Safiri, S
AU  - Sagar, R
AU  - Sahebkar, A
AU  - Sahraian, MA
AU  - Sajadi, HS
AU  - Salam, N
AU  - Salama, JS
AU  - Salamati, P
AU  - Saleem, Z
AU  - Salimi, Y
AU  - Salimzadeh, H
AU  - Salomon, JA
AU  - Salvi, SS
AU  - Salz, I
AU  - Samy, AM
AU  - Sanabria, J
AU  - Sanchez-Niño, MD
AU  - Santomauro, DF
AU  - Santos, IS
AU  - Santos, JV
AU  - Milicevic, MMS
AU  - Jose, BPS
AU  - Sardana, M
AU  - Sarker, AR
AU  - Sarmiento-Suárez, R
AU  - Sarrafzadegan, N
AU  - Sartorius, B
AU  - Sarvi, S
AU  - Sathian, B
AU  - Satpathy, M
AU  - Sawant, AR
AU  - Sawhney, M
AU  - Saxena, S
AU  - Schaeffner, E
AU  - Schmidt, MI
AU  - Schneider, IJC
AU  - Schutte, AE
AU  - Schwebel, DC
AU  - Schwendicke, F
AU  - Scott, JG
AU  - Sekerija, M
AU  - Sepanlou, SG
AU  - Serván-Mori, E
AU  - Seyedmousavi, S
AU  - Shabaninejad, H
AU  - Shafieesabet, A
AU  - Shahbazi, M
AU  - Shaheen, AA
AU  - Shaikh, MA
AU  - Shams-Beyranvand, M
AU  - Shamsi, M
AU  - Sharafi, H
AU  - Sharafi, K
AU  - Sharif, M
AU  - Sharif-Alhoseini, M
AU  - Sharma, J
AU  - Sharma, R
AU  - She, J
AU  - Sheikh, A
AU  - Shi, PL
AU  - Shibuya, K
AU  - Shiferaw, MS
AU  - Shigematsu, M
AU  - Shiri, R
AU  - Shirkoohi, R
AU  - Shiue, I
AU  - Shokoohinia, Y
AU  - Shokraneh, F
AU  - Shoman, H
AU  - Shrime, MG
AU  - Si, S
AU  - Siabani, S
AU  - Sibai, AM
AU  - Siddiqi, TJ
AU  - Sigfusdottir, ID
AU  - Sigurvinsdottir, R
AU  - Silva, DAS
AU  - Silva, JP
AU  - Silveira, DGA
AU  - Singam, NSV
AU  - Singh, JA
AU  - Singh, NP
AU  - Singh, V
AU  - Sinha, DN
AU  - Skiadaresi, E
AU  - Skirbekk, V
AU  - Sliwa, K
AU  - Smith, DL
AU  - Smith, M
AU  - Soares, AM
AU  - Sobaih, BH
AU  - Sobhani, S
AU  - Soofi, M
AU  - Sorensen, RJD
AU  - Soyiri, IN
AU  - Sposato, LA
AU  - Sreeramareddy, CT
AU  - Srinivasan, V
AU  - Stanaway, JD
AU  - Starodubov, VI
AU  - Stein, DJ
AU  - Steiner, C
AU  - Steiner, TJ
AU  - Stokes, MA
AU  - Stovner, LJ
AU  - Subart, ML
AU  - Sudaryanto, A
AU  - Sufiyan, MB
AU  - Sulo, G
AU  - Sunguya, BF
AU  - Sur, PJ
AU  - Sykes, BL
AU  - Sylaja, PN
AU  - Sylte, DO
AU  - Szoeke, CEI
AU  - Tabarés-Seisdedos, R
AU  - Tabuchi, T
AU  - Tadakamadla, SK
AU  - Tandon, N
AU  - Tassew, SG
AU  - Tavakkoli, M
AU  - Taveira, N
AU  - Taylor, HR
AU  - Tehrani-Banihashemi, A
AU  - Tekalign, TG
AU  - Teikelemedhin, SW
AU  - Tekle, MG
AU  - Temsah, MH
AU  - Temsah, O
AU  - Terkawi, AS
AU  - Tessema, B
AU  - Teweldemedhin, M
AU  - Thankappan, KR
AU  - Theis, A
AU  - Thirunavukkarasu, S
AU  - Thomas, N
AU  - Tilahun, B
AU  - To, QG
AU  - Tonelli, M
AU  - Topor-Madry, R
AU  - Torre, AE
AU  - Tortajada-Girbés, M
AU  - Touvier, M
AU  - Tovani-Palone, MR
AU  - Towbin, JA
AU  - Tran, BX
AU  - Tran, KB
AU  - Troeger, CE
AU  - Tsadik, AG
AU  - Tsoi, D
AU  - Car, LT
AU  - Tyrovolas, S
AU  - Ukwaja, KN
AU  - Ullah, I
AU  - Undurraga, EA
AU  - Updike, RL
AU  - Usman, MS
AU  - Uthman, OA
AU  - Vaduganathan, M
AU  - Vaezi, A
AU  - Valdez, PR
AU  - Vanavikova, E
AU  - Varughese, S
AU  - Vasankari, TJ
AU  - Venketasubramanian, N
AU  - Villafaina, S
AU  - Violante, FS
AU  - Vladimirov, SK
AU  - Vlassov, V
AU  - Vollset, SE
AU  - Vos, T
AU  - Vosoughi, K
AU  - Vujcic, IS
AU  - Wagnew, FS
AU  - Waheed, Y
AU  - Wang, YF
AU  - Wang, YP
AU  - Weiderpass, E
AU  - Weintraub, RG
AU  - Weiss, DJ
AU  - Weldegebreal, F
AU  - Weldegwergs, KG
AU  - Werdecker, A
AU  - West, TE
AU  - Westerman, R
AU  - Whiteford, HA
AU  - Widecka, J
AU  - Wijeratne, T
AU  - Williams, HC
AU  - Wilner, LB
AU  - Wilson, S
AU  - Winkler, AS
AU  - Wiyeh, AB
AU  - Wiysonge, CS
AU  - Wolfe, CDA
AU  - Woolf, AD
AU  - Wyper, GMA
AU  - Xavier, D
AU  - Xu, GL
AU  - Yadgir, S
AU  - Jabbari, SHY
AU  - Yamada, T
AU  - Yan, LJL
AU  - Yano, Y
AU  - Yaseri, M
AU  - Yasin, YJ
AU  - Yeshaneh, A
AU  - Yimer, EM
AU  - Yip, P
AU  - Yisma, E
AU  - Yonemoto, N
AU  - Yoon, SJ
AU  - Yotebieng, M
AU  - Younis, MZ
AU  - Yousefifard, M
AU  - Yu, CH
AU  - Zadnik, V
AU  - Zaidi, Z
AU  - Bin Zaman, S
AU  - Zamani, M
AU  - Zandian, H
AU  - Zar, HJ
AU  - Zenebe, ZM
AU  - Zipkin, B
AU  - Zhou, MG
AU  - Zodpey, S
AU  - Zucker, I
AU  - Zuhlke, LJ
AU  - Murray, CJL
A1  - GBD 2017 DALYs & HALE Coll
TI  - Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
T2  - LANCET
KW  - IRON-DEFICIENCY
KW  - GENDER
KW  - INTERVENTIONS
KW  - PREVENTION
KW  - WEIGHTS
KW  - AIDS
KW  - HIV
AB  - Background How long one lives, how many years of life are spent in good and poor health, and how the population's state of health and leading causes of disability change over time all have implications for policy, planning, and provision of services. We comparatively assessed the patterns and trends of healthy life expectancy (HALE), which quantifies the number of years of life expected to be lived in good health, and the complementary measure of disability-adjusted life years (DALYs), a composite measure of disease burden capturing both premature mortality and prevalence and severity of ill health, for 359 diseases and injuries for 195 countries and territories over the past 28 years.
   Methods We used data for age-specific mortality rates, years of life lost (YLLs) due to premature mortality, and years lived with disability (YLDs) from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 to calculate HALE and DALYs from 1990 to 2017. We calculated HALE using age-specific mortality rates and YLDs per capita for each location, age, sex, and year. We calculated DALYs for 359 causes as the sum of YLLs and YLDs. We assessed how observed HALE and DALYs differed by country and sex from expected trends based on Sociodemographic Index (SDI). We also analysed HALE by decomposing years of life gained into years spent in good health and in poor health, between 1990 and 2017, and extra years lived by females compared with males.
   Findings Globally, from 1990 to 2017, life expectancy at birth increased by 7.4 years (95% uncertainty interval 74-7.8), from 65.6 years (65.3-65- 8) in 1990 to 73.0 years (72.7-73.3) in 2017. The increase in years of life varied from 5.1 years (5.0-5.3) in high SDI countries to 12.0 years (11.3-12.8) in low SDI countries. Of the additional years of life expected at birth, 26.3% (20.1-33.1) were expected to be spent in poor health in high SDI countries compared with 11.7% (8.8-15.1) in low-middle SDI countries. HALE at birth increased by 6.3 years (5.9-6.7), from 57.0 years (54.6-59.1) in 1990 to 63.3 years (60.5-65.7) in 2017. The increase varied from 3.8 years (3.4-4.1) in high SDI countries to 10.5 years (9.8-11.2) in low SDI countries. Even larger variations in HALE than these were observed between countries, ranging from 1.0 year (0.4-1.7) in Saint Vincent and the Grenadines (62.4 years [59.9-64.7] in 1990 to 63.5 years [60.9-65.8] in 2017) to 23.7 years (21.9-25.6) in Eritrea (30.7 years [28.9-32.2] in 1990 to 54.4 years [51.5-57.1] in 2017). In most countries, the increase in HALE was smaller than the increase in overall life expectancy, indicating more years lived in poor health. In 180 of 195 countries and territories, females were expected to live longer than males in 2017, with extra years lived varying from 1.4 years (0.6-2.3) in Algeria to 11.9 years (10.9-12.9) in Ukraine. Of the extra years gained, the proportion spent in poor health varied largely across countries, with less than 20% of additional years spent in poor health in Bosnia and Herzegovina, Burundi, and Slovakia, whereas in Bahrain all the extra years were spent in poor health. In 2017, the highest estimate of HALE at birth was in Singapore for both females (75.8 years [72.4-78.7]) and males (72.6 years [69 " 8-75.0]) and the lowest estimates were in Central African Republic (47.0 years [43.7-50.2] for females and 42.8 years [40.1-45.6] for males). Globally, in 2017, the five leading causes of DALYs were neonatal disorders, ischaemic heart disease, stroke, lower respiratory infections, and chronic obstructive pulmonary disease. Between 1990 and 2017, age-standardised DALY rates decreased by 41.3% (38.8-43.5) for communicable diseases and by 49"8% (47.9-51.6) for neonatal disorders. For non-communicable diseases, global DALYs increased by 40.1% (36.8-43.0), although age-standardised DALY rates decreased by 18.1% (16.0-20.2).
   Interpretation With increasing life expectancy in most countries, the question of whether the additional years of life gained are spent in good health or poor health has been increasingly relevant because of the potential policy implications, such as health-care provisions and extending retirement ages. In some locations, a large proportion of those additional years are spent in poor health. Large inequalities in HALE and disease burden exist across countries in different SDI quintiles and between sexes. The burden of disabling conditions has serious implications for health system planning and health-related expenditures. Despite the progress made in reducing the burden of communicable diseases and neonatal disorders in low S DI countries, the speed of this progress could be increased by scaling up proven interventions. The global trends among non-communicable diseases indicate that more effort is needed to maximise HALE, such as risk prevention and attention to upstream determinants of health. Copyright (C) 2018 The Author(s). Published by Elsevier Ltd.
AD  - Univ Washington, Dept Hlth Metr Sci, Seattle, WA 98195 USAAD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - Univ Washington, Dept Global Hlth, Seattle, WA 98195 USAAD  - Univ Washington, Div Hematol, Seattle, WA 98195 USAAD  - Univ Washington, Dept Neurol, Seattle, WA 98195 USAAD  - Univ Washington, Dept Periodont, Seattle, WA 98195 USAAD  - Univ Washington, Div Plast Surg, Seattle, WA 98195 USAAD  - Univ Washington, Dept Med, Seattle, WA 98195 USAAD  - Univ Washington, Dept Surg, Seattle, WA 98195 USAAD  - Univ Washington, Dept Biomed Informat & Med Educ, Seattle, WA 98195 USAAD  - Univ Washington, Dept Med, Div Cardiol, Seattle, WA 98195 USAAD  - Univ Washington, Seattle, WA 98195 USAAD  - Haramaya Univ, Sch Pharm, Harar, EthiopiaAD  - Haramaya Univ, Dept Pediat, Harar, EthiopiaAD  - Haramaya Univ, Dept Med Lab Sci, Harar, EthiopiaAD  - Haramaya Univ, Sch Publ Hlth, Harar, EthiopiaAD  - Haramaya Univ, Sch Nursing & Midwifery, Harar, EthiopiaAD  - Haramaya Univ, Coll Hlth & Med Sci, Harar, EthiopiaAD  - Haramaya Univ, Harar, EthiopiaAD  - Jimma Univ, Dept Populat & Family Hlth, Jimma, EthiopiaAD  - Jimma Univ, Dept Epidemiol, Jimma, EthiopiaAD  - Jimma Univ, Sch Pharm, Jimma, EthiopiaAD  - Jimma Univ, Mycobacteriol Res Ctr, Jimma, EthiopiaAD  - Jimma Univ, Dept Environm Hlth Sci & Technol, Jimma, EthiopiaAD  - Addis Ababa Univ, Dept Pharmacol & Clin Pharm, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Sch Publ Hlth, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Sch Allied Hlth Sci, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Addis Ababa, EthiopiaAD  - Univ Roma La Sapienza, Dept Law Philosophy & Econ Studies, Rome, ItalyAD  - Univ Tehran Med Sci, Noncommunicable Dis Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Dept Hlth, Tehran, IranAD  - Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Dept Urol, Tehran, IranAD  - Univ Tehran Med Sci, Dept Hlth Management & Econ, Tehran, IranAD  - Univ Tehran Med Sci, Liver & Pancreaticobilliary Dis Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Multiple Sclerosis Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Endocrine Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Sch Med, Tehran, IranAD  - Univ Tehran Med Sci, Dept Pharmacol, Tehran, IranAD  - Univ Tehran Med Sci, Dept Epidemiol & Biostat, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Malignancies Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Knowledge Utilizat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, IranAD  - Univ Tehran Med Sci, Iran Natl Inst Hlth Res, Tehran, IranAD  - Univ Tehran Med Sci, Canc Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Urooncol Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Iranian Natl Ctr Addict Studies, Tehran, IranAD  - Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Ctr Expertise Microbiol, Tehran, IranAD  - Univ Tehran Med Sci, Canc Biol Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Dept Anat, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Oncol & Stein Cell Transplantat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Community Based Participatory Res Ctr, Tehran, IranAD  - McGill Univ, Montreal Neuroimaging Ctr, Montreal, PQ, CanadaAD  - Cairo Univ, Dept Neurol, Cairo, EgyptAD  - Cairo Univ, Dept Med Parasitol, Cairo, EgyptAD  - Arak Univ Med Sci, Dept Epidemiol, Arak, IranAD  - Multiple Sclerosis Res Ctr, Tehran, IranAD  - Manonmaniam Sundaranar Univ, Dept Stat, Tirunelveli, IndiaAD  - Univ Gondar, Dept Clin Chem, Gondar, EthiopiaAD  - Univ Gondar, Human Nutr Dept, Gondar, EthiopiaAD  - Univ Gondar, Inst Publ Hlth, Gondar, EthiopiaAD  - Univ Gondar, Dept Med Microbiol, Gondar, EthiopiaAD  - Wollega Univ, Dept Med Lab Sci, Nekemte, EthiopiaAD  - Wollega Univ, Dept Hlth Sci, Nekemte, EthiopiaAD  - Univ Med Sci, Sch Publ Hlth, Ondo, NigeriaAD  - Dupuytren Univ Hosp, Dept Cardiol, Limoges, FranceAD  - Univ Limoges, Inst Epidemiol, Limoges, FranceAD  - Weill Cornell Med Coll Qatar, Dept Healthcare Policy & Res, Doha, QatarAD  - Birzeit Univ, Inst Community & Publ Hlth, Birzeit, IsraelAD  - Benin Clin Res Inst IRCB, Cotonou, BeninAD  - Dongguk Univ, Dept Prevent Med, Gyeongju, South KoreaAD  - Kathmandu Univ, Dept Community Med, Devdaha, NepalAD  - Nepal Dev Soc, Dept Noncommunicable Dis, Pokhara, NepalAD  - Nepal Dev Soc, Pokhara, NepalAD  - Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, AustraliaAD  - Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, AustraliaAD  - Monash Univ, Dept Med, Melbourne, Vic, AustraliaAD  - Monash Univ, Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic, AustraliaAD  - Stellenbosch Univ, Dept Global Hlth, Cape Town, South AfricaAD  - Stellenbosch Univ, Fac Med & Hlth Sci, Cape Town, South AfricaAD  - Stellenbosch Univ, Dept Psychiat, Cape Town, South AfricaAD  - South African Med Res Council, Cochrane South Africa, Cape Town, South AfricaAD  - South African Med Res Council, Unit Hypertens & Cardiovasc Dis, Cape Town, South AfricaAD  - South African Med Res Council, Cape Town, South AfricaAD  - Univ Coll Hosp, Dept Med, Ibadan, NigeriaAD  - Cardiff Univ, Sch Med, Cardiff, S Glam, WalesAD  - St Mark Hosp, Emergency Dept, Alexandria, EgyptAD  - Univ Extremadura, Sport Sci Dept, Badajoz, SpainAD  - Univ Extremadura, Badajoz, SpainAD  - Univ Lome, Dept Publ Hlth, Lome, TogoAD  - Minist Hlth & Social Protect, Prefectoral Direct Hlth Zio, Tsevie, TogoAD  - McMaster Univ, Dept Family Med, Hamilton, ON, CanadaAD  - McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, CanadaAD  - Sanjay Gandhi Postgrad Inst Med Sci, Dept Gastroenterol, Lucknow, Uttar Pradesh, IndiaAD  - Sanjay Gandhi Postgrad Inst Med Sci, Dept Nephrol, Lucknow, Uttar Pradesh, IndiaAD  - Yerevan State Univ, Dept Zool, Yerevan, ArmeniaAD  - Sci Ctr Zool & Hydroecol, Res Grp Mol Parasitol, Yerevan, ArmeniaAD  - CSIR, Inst Cenom & Integrat Biol, Res Area Informat & Big Data, Delhi, IndiaAD  - Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USAAD  - Baylor Coll Med, Natl Sch Trop Med, Houston, TX 77030 USAAD  - Kermanshah Univ Med Sci, Dept Anesthesiol, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Sleep Disorders Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Fac Nutr & Food Sci, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Fac Publ Hlth, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Urol, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Res Ctr Environm Determinants Hlth, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Epidemiol & Biostat, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Nutr Sci, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Clin Biochem, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Hlth Educ & Promot, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Environm Determinants Hlth Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Food Technol & Qual Control, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Sports Med & Rehabil, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Pharmaceut Sci Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Imam Ali Cardiovasc Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Kermanshah, IranAD  - Ahvaz Jundishapur Univ Med Sci, Environm Technol Res Ctr, Ahvaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Dept Publ Hlth, Ahvaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Thalassemia & Hemoglobinopathy Res Ctr, Ahvaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Dept Neurosurg, Ahvaz, IranAD  - Shahid Beheshti Univ Med Sci, Dept Ophthalmol, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Safety Promot & Injury Prevent Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Dept Biostat, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Sch Publ Hlth, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Ophthalm Epidemiol Res Ctr, Tehran, IranAD  - Int Ctr Diarrhoeal Dis Res, Hlth Syst & Populat Studies Div, Dhaka, BangladeshAD  - Int Ctr Diarrhoeal Dis Res, Initiat Non Communicable Dis, Dhaka, BangladeshAD  - Int Ctr Diarrhoeal Dis Res, Hlth Econ & Financing Res Grp, Dhaka, BangladeshAD  - Int Ctr Diarrhoeal Dis Res, Maternal & Child Hlth Div, Dhaka, BangladeshAD  - Karolinska Inst, Dept Learning Informat Management & Eth, Stockholm, SwedenAD  - Karolinska Inst, Dept Publ Hlth Sci, Stockholm, SwedenAD  - Karolinska Inst, Dept Neurobiol, Stockholm, SwedenAD  - Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, SwedenAD  - Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, SwedenAD  - Univ Eerhat Abbas Setif, Setif, AlgeriaAD  - Higher Natl Sch Vet Med, Algiers, AlgeriaAD  - Univ Kentucky, Dept Epidemiol, Lexington, KY USAAD  - Univ Toronto, Hosp Sick Children, Toronto, ON, CanadaAD  - Univ Toronto, Hosp Sick Children, Ctr Global Child Hlth, Toronto, ON, CanadaAD  - Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, CanadaAD  - Washington Univ, Internal Med Dept, St Louis, MO USAAD  - VA St Louis Hlth Care Syst, Dept Vet Affairs, Clin Epidemiol Ctr, St Louis, MO USAAD  - King Saud Univ, Pediat Intens Care Unit, Riyadh, Saudi ArabiaAD  - King Saud Univ, Dept Pediat, Riyadh, Saudi ArabiaAD  - King Saud Univ, Riyadh, Saudi ArabiaAD  - Jazan Univ, Med Res Ctr, Jazan, Saudi ArabiaAD  - Jazan Univ, Jazan, Saudi ArabiaAD  - Sanaa Univ, Dept Med Parasitol, Sanaa, YemenAD  - King Abdulaziz Univ, Dept Family & Community Med, Jeddah, Saudi ArabiaAD  - Mayo Clin, Fdn Med Educ & Res, Evidence Based Practice Ctr, Rochester, MN USAAD  - Univ Western Australia, Sch Populat & Global Hlth, Perth, WA, AustraliaAD  - Univ Western Australia, Sch Med, Perth, WA, AustraliaAD  - Cleveland Clin, Cardiovasc Med, Cleveland, OH 44106 USAAD  - Baqiyatallah Univ Med Sci, Baqiyatallah Res Ctr Gastroenterol & Liver Dis, Tehran, IranAD  - Baqiyatallah Univ Med Sci, Student Res Comm, Tehran, IranAD  - Australian Natl Univ, Res Sch Populat Hlth, Canberra, ACT, AustraliaAD  - Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, AustraliaAD  - Qazvin Univ Med Sci, Dept Publ Hlth, Qazvin, IranAD  - Qazvin Univ Med Sci, Qazvin, IranAD  - Mazandaran Univ Med Sci, Gastrointestinal Canc Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Med Mycol, Sari, IranAD  - Mazandaran Univ Med Sci, Toxoplasmosis Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Sch Publ Hlth, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Neurol, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Physiol & Pharmacol, Sari, IranAD  - Mazandaran Univ Med Sci, Hlth Sci Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Mol & Cell Biol Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Pediat, Sari, IranAD  - Mazandaran Univ Med Sci, Invas Fungi Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Med Mycol & Parasitol, Sari, IranAD  - Mazandaran Univ Med Sci, Immunogenet Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Pharmaceut Sci Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Immunol, Sari, IranAD  - Mazandaran Univ Med Sci, Sari, IranAD  - Kuwait Univ, Dept Hlth Policy & Management, Safat, KuwaitAD  - Natl Univ Malaysia, Int Ctr Casemix & Clin Coding, Bandar Tun Razak, MalaysiaAD  - Luxembourg Inst Hlth, Dept Populat Hlth, Strassern, LuxembourgAD  - Univ Bordeaux, Bordeaux, FranceAD  - Swedish Res Council Hlth Working Life & Welf, Stockholm, SwedenAD  - Hosp Del Mar, Med Res Inst, Res Program Epidemiol & Publ Hlth, Barcelona, SpainAD  - Pompeu Fabra Univ, Dept Expt & Hlth Sci, Barcelona, SpainAD  - Univ Hosp Knappschaftskrankenhaus Bochum, Dept Oral & Maxillofacial Surg, Bochum, GermanyAD  - Univ Cartagena, Res Grp Hlth Econ, Cartagena, ColombiaAD  - Univ Coast, Res Grp Hosp Management & Hlth Policies, Barranquilla, ColombiaAD  - Univ Queensland, Sch Publ Hlth, Brisbane, Qld, AustraliaAD  - Univ Queensland, Queensland Alliance Agr & Food Innovat, Brisbane, Qld, AustraliaAD  - Univ Queensland, Sch Dent, Brisbane, Qld, AustraliaAD  - Univ Queensland, Inst Social Sci Res, Brisbane, Qld, AustraliaAD  - Univ Queensland, Queensland Brain Inst, Brisbane, Qld, AustraliaAD  - Univ Queensland, Brisbane, Qld, AustraliaAD  - Kerman Univ Med Sci, Dept Hlth Management Policy & Econ, Kerman, IranAD  - Fed Minist Hlth, Dept Hlth Ind Complex:and Innovat Hlth, Beirut, LebanonAD  - Fed Minist Hlth, Dept Dis & Noncommunicable Dis & Hlth Promot, Beirut, LebanonAD  - Fed Minist Hlth, Beirut, LebanonAD  - Amer Univ Beirut, Fac Hlth Sci, Beirut, LebanonAD  - Amer Univ Beirut, Dept Epidemiol & Populat Hlth, Beirut, LebanonAD  - Komfo Anokye Teaching Hosp, Dept Internal Med, Kumasi, GhanaAD  - Mansoura Univ, Fac Med, Mansoura, EgyptAD  - Carol Davila Univ Med & Pharm, Emergency Hosp Bucharest, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Dept Gen Surg, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Dept Legal Med & Bioeth, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Anat & Embryol Dept, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Bucharest, RomaniaAD  - Univ Thessaly, Dept Med, Volos, GreeceAD  - Arba Minch Univ, Dept Publ Hlth, Arba Minch, EthiopiaAD  - Arba Minch Univ, Arba Minch, EthiopiaAD  - Debre Berhan Univ, Dept Publ Hlth, Debre Berhan, EthiopiaAD  - Debre Berhan Univ, Dept Midwifery, Debre Berhan, EthiopiaAD  - Rafsanjan Univ Med Sci, Social Determinants Hlth Res Ctr, Rafsanjan, IranAD  - Univ Philippines Manila, Dept Hlth Policy & Adm, Manila, PhilippinesAD  - Univ Philippines Manila, Dev & Commun Studies, Manila, PhilippinesAD  - Hong Kong Polytech Univ, Dept Appl Social Sci, Hong Kong, Hong Kong, Peoples R ChinaAD  - Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Hong Kong, Peoples R ChinaAD  - Iran Univ Med Sci, Hlth Management & Econ Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Pollut Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Prevent Med & Publ Hlth Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Dept Neurosci, Tehran, IranAD  - Iran Univ Med Sci, Dept Hlth Policy, Tehran, IranAD  - Iran Univ Med Sci, Dept Community Med, Tehran, IranAD  - Iran Univ Med Sci, Physiol Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Tehran, IranAD  - Birmingham City Univ, Sch Hlth Sci, Birmingham, W Midlands, EnglandAD  - Dalarna Univ, Sch Hlth & Social Studies, Falun, SwedenAD  - Western Sydney Univ, Sch Sci & Hlth, Sydney, NSW, AustraliaAD  - Western Sydney Univ, Sch Social Sci & Psychol, Sydney, NSW, AustraliaAD  - Western Sydney Univ, Sydney, NSW, AustraliaAD  - Sydney Local Hlth Dist, Oral Hlth Serv, Sydney, NSW, AustraliaAD  - Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, CanadaAD  - Abt Associates Nepal, Monitoring Evaluat & Operat Res Project, Lalitpur, NepalAD  - Qom Univ Med Sci, Qom, IranAD  - Univ Leicester, Sch Business, Leicester, Leics, EnglandAD  - Univ Leicester, Dept Hlth Sci, Leicester, Leics, EnglandAD  - Natl Inst Publ Hlth, Ctr Hlth Syst Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Ctr Nutr & Hlth Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Ctr Invest Nutr & Salud, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Cuernavaca, Morelos, MexicoAD  - Lab Studies & Res Act Hlth, Controle Malad Infect, Porto Novo, BeninAD  - Indian Inst Publ Hlth, Gandhinagar, IndiaAD  - Indian Inst Publ Hlth, Hyderabad, IndiaAD  - Publ Hlth Fdn India, Indian Inst Publ Hlth, Gurugram, IndiaAD  - Publ Hlth Fdn India, Gurugram, IndiaAD  - La Trobe Univ, Judith Lumley Ctr, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Sch Nursing & Midwifery, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Austin Clin Sch Nursing, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Dept Psychol & Counselling, Melbourne, Vic, AustraliaAD  - Peruvian Natl Inst Hlth, Gen Off Res & Technol Transfer, Lima, PeruAD  - Univ Tokyo, Dept Community & Global Hlth, Tokyo, JapanAD  - Univ Tokyo, Dept Mental Hlth, Tokyo, JapanAD  - Univ Tokyo, Dept Global Hlth Policy, Tokyo, JapanAD  - Univ Tokyo, Dept Diabet & Metab Dis, Tokyo, JapanAD  - Burnet Inst, Global Adolescent Hlth Grp, Melbourne, Vic, AustraliaAD  - South Australian Hlth & Med Res Inst, Wardliparingga Aboriginal Res Unit, Adelaide, SA, AustraliaAD  - Ctr Infect Dis Res, Babol Sar, IranAD  - Sri Ramachandra Med Coll & Res Inst, Dept Environm Hlth Engn, Madras, Tamil Nadu, IndiaAD  - Med Univ Lodz, Dept Hypertens, Lodz, PolandAD  - Polish Mothers Mem Hosp, Res Inst, Lodz, PolandAD  - Alexandria Univ, Fac Med, Alexandria, EgyptAD  - Univ Hosp Fdn Santa Fe De Bogota, Dept Transplant Serv, Bogota, ColombiaAD  - Clin Ctr Serbia, Clin Infect & Trop Dis, Belgrade, SerbiaAD  - Univ Belgrade, Fac Med, Belgrade, SerbiaAD  - Univ Belgrade, Ctr Sch Publ Hlth & Hlth Management, Belgrade, SerbiaAD  - Univ Belgrade, Fac Med Inst Epidemiol, Belgrade, SerbiaAD  - Costa Rican Dept Social Secur, Dept Neurosci, San Jose, Costa RicaAD  - Costa Rican Dept Social Secur, Area Estadist, Direcc Actuarial, San Jose, Costa RicaAD  - Univ Costa Rica, Sch Med, San Pedro, Costa RicaAD  - Univ Costa Rica, Sch Dent, San Pedro, Costa RicaAD  - Univ Auckland, Sch Psychol, Auckland, New ZealandAD  - Univ Auckland, Mol Med & Pathol, Auckland, New ZealandAD  - Heidelberg Univ, Inst Publ Hlth, Heidelberg, GermanyAD  - Heidelberg Univ, Inst Global Hlth, Heidelberg, GermanyAD  - Heidelberg Univ, Dept Ophthalmol, Heidelberg, GermanyAD  - Heidelberg Univ, Med Clin 5, Heidelberg, GermanyAD  - Heidelberg Univ, Augenpraxis Jonas, Heidelberg, GermanyAD  - Harvard Univ, Dept Global Hlth & Populat, Boston, MA 02115 USAAD  - Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USAAD  - Harvard Univ, Ariadne Labs, Boston, MA 02115 USAAD  - Harvard Univ, Dept Riostat, Boston, MA 02115 USAAD  - Harvard Univ, Dept Genet, Boston, MA 02115 USAAD  - Harvard Univ, Div Gen Internal Med & Primary Care, Boston, MA 02115 USAAD  - Harvard Univ, Heart & Vasc Ctr, Boston, MA 02115 USAAD  - Harvard Univ, Boston, MA 02115 USAAD  - Pontifical Javeriana Univ, Dept Ind Engn, Bogota, ColombiaAD  - Charles R Drew Univ Med & Sci, Dept Psychiat, 1621 E 120th St, Los Angeles, CA 90059 USAAD  - Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA USAAD  - Gandhi Med Coll Bhopal, Dept Community Med, Bhopal, IndiaAD  - Mario Negri Inst Pharmacol Res, Dept Neurosci, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Dept Renal Med, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Dept Oncol, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Dept Environm Hlth Sci, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Milan, ItalyAD  - Lorestan Univ Med Sci, Social Determinants Hlth Res Ctr, Khorramabad, IranAD  - Mizan Tepi Univ, Publ Hlth Dept, Teppi, EthiopiaAD  - Mizan Tepi Univ, Teppi, EthiopiaAD  - Wolaita Sodo Univ, Coll Hlth Sci & Med, Sodo, EthiopiaAD  - Mekelle Univ, Sch Publ Hlth, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Nutr & Dietet, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Pharm, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Biostat, Mekelle, EthiopiaAD  - Mekelle Univ, Anat Unit, Mekelle, EthiopiaAD  - Mekelle Univ, Clin Pharm Unit, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Midwifery, Mekelle, EthiopiaAD  - Mekelle Univ, Mekelle, EthiopiaAD  - Debre Markos Univ, Dept Publ Hlth, Debre Markos, EthiopiaAD  - Debre Markos Univ, Dept Nursing, Debre Markos, EthiopiaAD  - Debre Markos Univ, Coll Hlth Sci, Debre Markos, EthiopiaAD  - Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USAAD  - Yale Univ, Dept Ophthalmol & Visual Sci, New Haven, CT USAAD  - Univ Alberta, Dept Med, Edmonton, AB, CanadaAD  - Univ Oxford, Nuffield Dept Populat Hlth, Oxford, EnglandAD  - Univ Oxford, Big Data Inst, Nuffield Dept Med, Oxford, EnglandAD  - Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, EnglandAD  - Univ Oxford, Big Data Inst, Oxford, EnglandAD  - Univ Oxford, Dept Psychiat, Oxford, EnglandAD  - Univ Oxford, Nuffield Dept Womens & Reprod Hlth, Oxford, EnglandAD  - Univ Oxford, Oxford, EnglandAD  - Univ Sao Paulo, Dept Internal Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Div Ophthalmol, Sao Paulo, BrazilAD  - Univ Sao Paulo, Univ Hosp, Internal Med Dept, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Lab Genet & Mol Cardiol, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Pathol & Legal Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Psychiat, Sao Paulo, BrazilAD  - Univ Sao Paulo, Ctr Clin & Epidemiol Res, Sao Paulo, BrazilAD  - Kings Coll London, Dent Inst, London, EnglandAD  - Kings Coll London, Fac Life Sci & Med, London, EnglandAD  - Kings Coll London, St Johns Inst Dermatol, London, EnglandAD  - Kings Coll London, Div Patient & Populat, London, EnglandAD  - Kings Coll London, Sch Populat Hlth & Environm Sci, London, EnglandAD  - Emory Univ, Hubert Dept Global Hlth, Atlanta, CA USAAD  - Univ S Florida, Dept Global Hlth, Tampa, FL USAAD  - Queen Elizabeth Hosp Birmingham, Inst Appl Hlth Res & Translat Med, Birmingham, W Midlands, EnglandAD  - Univ Birmingham, IAHR ITM, Birmingham, W Midlands, EnglandAD  - Imperial Coll London, Dept Epidemiol & Biostat, London, EnglandAD  - Imperial Coll London, Dept Primary Care & Publ Hlth, London, EnglandAD  - Imperial Coll London, WHO, Collaborating Ctr Publ Hlth Educ & Training, London, EnglandAD  - Imperial Coll London, Sch Publ Hlth, London, EnglandAD  - Imperial Coll London, Div Brain Sci, London, EnglandAD  - Imperial Coll London, London, EnglandAD  - George Inst Global Hlth, New Delhi, IndiaAD  - Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, PakistanAD  - Babol Univ Med Sci, Social Determinants Hlth Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Hlth Res Inst, Babol Sar, IranAD  - Babol Univ Med Sci, Dept Immunol, Babol Sar, IranAD  - Babol Univ Med Sci, Dept Clin Biochem, Babol Sar, IranAD  - Babol Univ Med Sci, Cellular & Mol Biol Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Infect Dis & Trop Med Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Dept Microbiol & Immunol, Babol Sar, IranAD  - Babol Univ Med Sci, Student Res Comm, Babol Sar, IranAD  - Babol Univ Med Sci, Babol Sar, IranAD  - Woldia Univ, Woldia, EthiopiaAD  - Univ Dhaka, Dept Clin Pharm & Pharmacol, Ramna, BangladeshAD  - Res Triangle Inst Int, Global Hlth Div, Res Triangle Pk, NC USAAD  - Univ Nottingham, Sch Med, Nottingham, EnglandAD  - Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham, EnglandAD  - Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, NorwayAD  - Univ Bergen, Dept Psychosocial Sci, Bergen, NorwayAD  - Canc Registry Norway, Dept Res, Oslo, NorwayAD  - Canc Registry Norway, Oslo, NorwayAD  - Oregon Hlth & Sci Univ, Radiat Med, Portland, OR 97201 USAAD  - Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USAAD  - Univ Texas Houston, Dept Pediat, Houston, TX USAAD  - Minist Publ Hlth, Dept Vital & Hlth Stat, Beirut, LebanonAD  - Minist Publ Hlth, Dept Dis Epidem & Pandem Control, Beirut, LebanonAD  - Minist Publ Hlth, Beirut, LebanonAD  - Univ New South Wales, Transport & Rd Safety Res, Sydney, NSW, AustraliaAD  - Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Publ Hlth & Community Med, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Med, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Psychiat, Sydney, NSW, AustraliaAD  - Anglia Ruskin Univ, Vision & Eye Res Unit, Cambridge, EnglandAD  - London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Dis Control, London, EnglandAD  - London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Med Stat, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, EnglandAD  - Univ Fed Minas Gerais, Sch Med, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Clin Hosp, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Dept Maternal & Child Nursing & Publ Hlth, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Hosp Fed Univ Minas Gerais, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Postgrad Program Infect Dis & Trop Med, Belo Horizonte, MG, BrazilAD  - Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, EnglandAD  - Comenius Univ, Inst Epidemiol, Bratislava, SlovakiaAD  - Ohio State Univ, Dept Psychol, Columbus, OH 43210 USAAD  - Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USAAD  - Ohio State Univ, Psychiat & Behav Hlth Dept, Columbus, OH 43210 USAAD  - German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, GermanyAD  - Hlth Technol Assessment Assoc, Comm Comprehens Assessment Med Devices & informat, Moscow, RussiaAD  - Inst Sci Res & High Technol Serv, Neurosci, City Of Knowledge, PanamaAD  - Gorgas Mem Inst Hlth Studies, Dept Res & Hlth Technol Assessment, Panama City, PanamaAD  - Gorgas Mem Inst Hlth Studies, Panama City, PanamaAD  - Cabrini Inst, Monash Dept Clin Epidemiol, Melbourne, Vic, AustraliaAD  - Charite Univ Med Ctr Berlin, Inst Publ Hlth, Berlin, GermanyAD  - Charite Univ Med Ctr Berlin, Dept Operat & Prevent Dent, Berlin, GermanyAD  - Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, CanadaAD  - Univ British Columbia, Vancouver, BC, CanadaAD  - Al Shifa Trust Eye Hosp, Al shifa Sch Publ Hlth, Rawalpindi, PakistanAD  - Univ Valley Cuernavaca, Sch Med, Cuernavaca, Morelos, MexicoAD  - Metropolitan Autonomous Univ, Dept Populat & Hlth, Mexico City, DF, MexicoAD  - Univ Porto, Inst Publ Hlth, Porto, PortugalAD  - Univ Porto, Inst Biomed Engn, Porto, PortugalAD  - Univ Porto, REQUIMTE LAQV, Porto, PortugalAD  - Univ Porto, Dept Clin Neurosci & Mental Hlth, Fac Med, Porto, PortugalAD  - Univ Porto, Dept Community Med, Porto, PortugalAD  - Univ Porto, UCIBIO, Porto, PortugalAD  - Univ Porto, Appl Mol Biosci Unit, Porto, PortugalAD  - Univ Porto, Inst Res & Innovat Hlth, Porto, PortugalAD  - Natl Inst Hlth, Colombian Natl Hlth Observ, Bogota, ColombiaAD  - Natl Inst Hlth, Natl Inst Deafness & Other Commun Disorders, Bogota, ColombiaAD  - Univ Nacl Colombia, Epidemiol & Publ Hlth Evaluat Grp, Bogota, ColombiaAD  - Univ Nacl Colombia, Dept Publ Hlth, Bogota, ColombiaAD  - Inst Hlth Carlos III, Dept Hlth Planning & Econ, Madrid, SpainAD  - Australian Catholic Univ, Mary MacKillop Inst Hlth Res, Melbourne, Vic, AustraliaAD  - Australian Catholic Univ, Brain Inst, Melbourne, Vic, AustraliaAD  - Univ Hong Kong, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ Hong Kong, Ctr Suicide Res & Prevent, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ Hong Kong, Hong Kong, Hong Kong, Peoples R ChinaAD  - Alfaisal Univ, Coll Med, Riyadh, Saudi ArabiaAD  - Natl Taiwan Univ, Coll Med, Taipei, TaiwanAD  - Univ West Indies, Fac Med Sci, St Augustine, Trinidad TobagoAD  - Gold Coast Hlth, Clin Governance, Gold Coast, Qld, AustraliaAD  - Minist Hlth, Baghdad, IraqAD  - Seoul Natl Univ Hosp, Biomed Sci, Biochem, Seoul, South KoreaAD  - Univ Copenhagen, Inst Clin Med, Copenhagen, DenmarkAD  - Univ Copenhagen, Bispebjerg Hosp, Copenhagen, DenmarkAD  - Christian Med Coll & Hosp, Dept Pulm Med, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp, Dept Endocrinol, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp, Vellore, Tamil Nadu, IndiaAD  - UCL, Dept Hlth Informat, London, EnglandAD  - UCL, Inst Global Hlth, London, EnglandAD  - UCL, Dept Psychol, London, EnglandAD  - UCL, Dept Epidemiol & Publ Hlth, London, EnglandAD  - Hlth Data Res UK, London, EnglandAD  - Univ Salerno, Scuola Med Salernitana, Baronissi, ItalyAD  - Autonomous Univ Chile, Fac Educ, Talca, ChileAD  - Autonomous Univ Chile, Inst Phys Act & Hlth, Talca, ChileAD  - Univ Southampton, NIHR Oxford Biomed Res Ctr, Southampton, Hants, EnglandAD  - Univ Milano Bicocca, Sch Med & Surg, Monza, ItalyAD  - Univ Fed Rio Grande do Sul, Postgrad Program Epidemiol, Porto Alegre, RS, BrazilAD  - Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USAAD  - Univ Sydney, Inst Bone & Joint Res, Sydney, NSW, AustraliaAD  - Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, AustraliaAD  - Univ Sydney, Sydney Med Sch, Sydney, NSW, AustraliaAD  - Univ Sydney, Asbestos Dis Res Inst, Sydney, NSW, AustraliaAD  - Univ Sydney, Sydney, NSW, AustraliaAD  - Univ Otago, Ctr Int Hlth, Dunedin, New ZealandAD  - Duke Univ, Div Infect Dis & Int Hlth, Durham, NC USAAD  - Duke Univ, Duke Global Hlth Inst, Durham, NC USAAD  - Hawassa Univ, Coll Med & Hlth Sci, Hawassa, EthiopiaAD  - Hawassa Univ, Dept Reprod Hlth, Hawassa, EthiopiaAD  - Flinders Univ S Australia, Discipline Publ Hlth, Adelaide, SA, AustraliaAD  - Guys & St Thomas NHS Fdn Trust, Clin Toxicol Serv, London, EnglandAD  - Guys & St Thomas NHS Fdn Trust, Biomed Res Council, London, EnglandAD  - BRAC Univ, James P Grant Sch Publ Hlth, Dhaka, BangladeshAD  - BRAC Univ, Res & Evaluat Div, Dhaka, BangladeshAD  - Clin Emergency Hosp Sf Pantelimon, Dept Surg, Bucharest, RomaniaAD  - Griffith Univ, Australian Inst Suicide Res & Prevent, Mt Gravatt, Qld, AustraliaAD  - Griffith Univ, Menzies Hlth Inst Queensland, Mt Gravatt, Qld, AustraliaAD  - Univ Ghent, Dept Agr Econ, Ghent, BelgiumAD  - Aksum Univ, Dept Clin Pharm, Aksum, EthiopiaAD  - Aksum Univ, Dept Med Lab Sci, Aksum, EthiopiaAD  - Brighton & Sussex Med Sch, Dept Global Hlth & Infect, Brighton, E Sussex, EnglandAD  - Natl Hlth Serv Scotland, Informat Serv Div, Edinburgh, Midlothian, ScotlandAD  - Aristotle Univ Thessaloniki, Thessaloniki, GreeceAD  - Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USAAD  - Disha Fdn, Gurgaon, IndiaAD  - Univ Peradeniya, Dept Community Med, Peradeniya, Sri LankaAD  - Nepal Hlth Res Council, Hlth Res Sect, Kathmandu, NepalAD  - Swedish Family Med First Hill, Seattle, WA USAAD  - Minist Hlth & Med Educ, Deputy Res & Technol, Tehran, IranAD  - Minist Hlth & Med Educ, Tehran, IranAD  - Nguyen Tat Thanh Univ, Ctr Excellence Hlth Serv Management, Ho Chi Minh City, VietnamAD  - Nguyen Tat Thanh Univ, Ctr Excellence Behav Hlth, Ho Chi Minh City, VietnamAD  - Nguyen Tat Thanh Univ, Ctr Excellence Behav Med, Ho Chi Minh City, VietnamAD  - Med Univ Varna, Dept Social Med & Hlth Care Org, Varna, BulgariaAD  - Univ Cape Coast, Dept Populat & Hlth, Cape Coast, GhanaAD  - Univ Cape Coast, Cape Coast, GhanaAD  - Univ Tampere, Fac Social Sci, Hlth Sci, Tampere, FinlandAD  - Univ Tampere, Fac Hlth Sci, Hlth Sci, Tampere, FinlandAD  - Univ Rochester, Rochester, NY USAAD  - RMIT Univ, Sch Hlth & Biomed Sci, Bundoora, Vic, AustraliaAD  - RMIT Univ, Dept Psychol, Bundoora, Vic, AustraliaAD  - United Nations World Food Programme, New Delhi, IndiaAD  - Univ Fed Bahia, Sch Med, Salvador, BA, BrazilAD  - Univ Fed Bahia, Inst Publ Hlth, Salvador, BA, BrazilAD  - Roberto Santos Gen Hosp, Diretoria Med, Salvador, BA, BrazilAD  - Umea Univ, Dept Nursing, Umea, SwedenAD  - Univ Newcastle, Clin Epidemiol & Biostat, Newcastle, NSW, AustraliaAD  - Univ Tromso, Dept Community Med, Tromso, NorwayAD  - Univ Michigan, Inst Hlth Care Policy & Innovat, Ann Arbor, MI 48109 USAAD  - Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USAAD  - Eijkman Inst Mol Biol, Eijkman Oxford Clin Res Unit, Jakarta, IndonesiaAD  - St Pauls Hosp, Millennium Med Coll, Publ Hlth Dept, Addis Ababa, EthiopiaAD  - Minist Hlth, Epidemiol & Dis Control, Singapore, SingaporeAD  - Minist Hlth, Singapore, SingaporeAD  - Queensland Ctr Mental Hlth Res, Psychiat Epidemiol & Burden Dis Res, Brisbane, Qld, AustraliaAD  - Queensland Ctr Mental Hlth Res, Policy & Epidemiol Grp, Brisbane, Qld, AustraliaAD  - Queensland Ctr Mental Hlth Res, Child & Youth Mental Hlth, Brisbane, Qld, AustraliaAD  - Queensland Ctr Mental Hlth Res, Brisbane, Qld, AustraliaAD  - Urmia Univ Med Sci, Dept Med Parasitol & Mycol, Orumiyeh, IranAD  - Imam Muhammad Ibn Saud Islamic Univ, Coll Med, Riyadh, Saudi ArabiaAD  - Imam Muhammad Ibn Saud Islamic Univ, Dept Publ Hlth, Riyadh, Saudi ArabiaAD  - Univ Louisville, Div Cardiovasc Med, Louisville, KY 40292 USAAD  - Natl Stat Off, Lisbon, PortugalAD  - Univ Bologna, Dept Med & Surg Sci, Bologna, ItalyAD  - Univ Fed Sergipe, Dept Psychol, Sao Cristovao, BrazilAD  - Hamadan Univ Med Sci, Social Determinants Hlth Res Ctr, Hamadan, IranAD  - Hamadan Univ Med Sci, Dept Epidemiol, Hamadan, IranAD  - Hamadan Univ Med Sci, Dept Environm Hlth Engn, Hamadan, IranAD  - Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New ZealandAD  - Bahir Dar Univ, Dept Publ Hlth Nutr, Bahir Dar, EthiopiaAD  - Bahir Dar Univ, Dept Psychiat, Bahir Dar, EthiopiaAD  - Univ Ottawa, Div Neurol, Ottawa, ON, CanadaAD  - Catholic Univ Portugal, Ctr Biotechnol & Fine Chem, Porto, PortugalAD  - Kaiser Permanente, Psychiat, Fontana, CA USAAD  - AT Still Univ, Dept Hlth Sci, Mesa, AZ USAAD  - AT Still Univ, Mesa, AZ USAAD  - Bielefeld Univ, Dept Publ Hlth Med, Bielefeld, GermanyAD  - Natl Acad Med Sci Ukraine, Inst Gerontol, Kiev, UkraineAD  - Canc Inst, Gene Express & Regulat Program, Philadelphia, PA USAAD  - Kobe Univ, Dept Dermatol, Kobe, Hyogo, JapanAD  - Swiss Trop & Publ Hlth Inst, Epidemiol & Publ Hlth, Basel, SwitzerlandAD  - Swiss Trop & Publ Hlth Inst, Malaria Vaccines, Basel, SwitzerlandAD  - Univ Basel, Basel, SwitzerlandAD  - Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, AustraliaAD  - Manhica Hlth Res Ctr, TB, Manhica, MozambiqueAD  - Barcelona Inst Global Hlth, TB Dept, Barcelona, SpainAD  - Barcelona Inst Global Hlth, Barcelona, SpainAD  - Curtin Univ, Sch Publ Hlth, Perth, WA, AustraliaAD  - Wageningen Univ & Res, Div Human Nutr & Hlth, Wageningen, NetherlandsAD  - Reg Hlth Council, Directorate Gen Publ Hlth, Madrid, SpainAD  - Univ Tsukuba, Dept Hlth Care Policy & Management, Tsukuba, Ibaraki, JapanAD  - Natl Allergy Asthma & Bronchitis Inst, Dept Resp Med, Kolkota, IndiaAD  - Fortis Hosp, Dept Resp Med, Kolkata, IndiaAD  - Univ Warwick, Unit Acad Primary Care, Coventry, W Midlands, EnglandAD  - Univ Warwick, Div Hlth Sci, Coventry, W Midlands, EnglandAD  - Univ Adelaide, Adelaide Med Sch, Adelaide, SA, AustraliaAD  - Univ Adelaide, Adelaide, SA, AustraliaAD  - Univ Hail, Dept Family & Community Med, Hail, Saudi ArabiaAD  - Res Ctr Neurol, Moscow, RussiaAD  - Jawahar Lal Nehru Univ, Ctr Study Reg Dev, New Delhi, IndiaAD  - Int Inst Populat Sci, Dept Populat Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Dept Publ Hlth & Mortal Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Bombay, Maharashtra, IndiaAD  - Univ Massachusetts, Nursing & Hlth Sci Dept, Boston, MA 02125 USAAD  - Univ Oklahoma, Dept Biostat & Epidemiol, Oklahoma City, OK USAAD  - Govt Federated States Micronesia, Dept Hlth & Social Affairs, Palikir, MicronesiaAD  - Boston Univ, Sch Med, Boston, MA 02118 USAAD  - Vittorio Emanuele Univ, Hosp Polyclin, Registro Tumori Integra, Catania, ItalyAD  - St James Sch Med, Dept Epidemiol, The Valley, AnguillaAD  - St James Sch Med, Dept Microbiol, The Valley, AnguillaAD  - Univ Lorraine, Sch Publ Hlth, Vandoeuvre Les Nancy, FranceAD  - Healis Sekhsaria Inst Publ Hlth, Dept Epidemiol, Bombay, Maharashtra, IndiaAD  - West Virginia Bur Publ Hlth, Commissioner Publ Hlth, Charleston, WV USAAD  - West Virginia Univ, Sch Publ Hlth, Dept Hlth Policy Management & Leadership, Morgantown, WV 26506 USAAD  - Rajasthan Univ Hlth Sci, Acad & Res, Jaipur, Rajasthan, IndiaAD  - Eternal Heart Care Ctr & Res Inst, Dept Prevent Cardiol, Jaipur, Rajasthan, IndiaAD  - Montefiore Med Ctr, Dept Cardiol, 111 E 210th St, Bronx, NY 10467 USAAD  - Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USAAD  - Albert Einstein Coll Med, Bronx, NY 10467 USAAD  - Ramon De La Dictate Muniz Natl Inst Psychiat, Dept Epidemiol & Psychosociai Res, Mexico City, DF, MexicoAD  - Aarhus Univ, Dept Publ Hlth, Aarhus, DenmarkAD  - Aarhus Univ, Natl Ctr Register Based Res, Aarhus, DenmarkAD  - Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, NetherlandsAD  - Univ Western Ontario, Dept Clin Neurol Sci, London, ON, CanadaAD  - Univ Western Ontario, Clin Neurol Sci, London, ON, CanadaAD  - Lawson Hlth Res Inst, London, ON, CanadaAD  - Johns Hopkins Univ, Dept Radiol, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21218 USAAD  - Johns Hopkins Univ, Dept Gastroenterol & Hepatol, Baltimore, MD USAAD  - Arabian Gulf Univ, Dept Family & Community Med, Manama, BahrainAD  - Hamdan Bin Mohammed Smart Univ, Sch Hlth & Environm Studies, Dubai, U Arab EmiratesAD  - Univ New Mexico, Populat Hlth Dept, Albuquerque, NM 87131 USAAD  - Sir Charles Cairdner Hosp, Neurol Dept, Perth, WA, AustraliaAD  - Sun Yat Sen Univ, Sun Yat Sen Global Hlth Inst, Guangzhou, Guangdong, Peoples R ChinaAD  - Sun Yat Sen Univ, Dept Med Stat & Epidemiol, Guangzhou, Guangdong, Peoples R ChinaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Cardiol Dept, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Hlth Educ & Hlth Promot Dept, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Achutha Menon Ctr Hlth Sci Studies, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Neurol Dept, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Trivandrum, Kerala, IndiaAD  - Tabriz Univ Medical Sci, Tabriz, IranAD  - Sum Juan De Dios Sanitary Pk, Res & Dev Unit, St Boi De Llobregat, SpainAD  - Univ Barcelona, Dept Med, Barcelona, SpainAD  - Univ Barcelona, Barcelona, SpainAD  - Univ Hosp Antwerp, Unit Epidemiol & Social Med, Antwerp, BelgiumAD  - Karolinska Univ Hosp, Clin Sci, Stockholm, SwedenAD  - Int Fdn Dermatol, London, EnglandAD  - Bucharest Univ Econ Studies, Dept Stat & Econometr, Bucharest, RomaniaAD  - Univ Med Ctr Groningen, Dept Psychiat, Groningen, NetherlandsAD  - Univ Med Ctr Groningen, Groningen, NetherlandsAD  - Columbia Univ, Dept Epidemiol, New York, NY USAAD  - Columbia Univ, Dept Hlth & Behav Studies, New York, NY USAAD  - NIH, Div Sci Programs, Bldg 10, Bethesda, MD 20892 USAAD  - NIH, Ctr Translat Res & Implementat Sci, Bldg 10, Bethesda, MD 20892 USAAD  - Univ Texas Austin, Austin, TX 78712 USAAD  - Guilan Univ Med Sci, Sch Hlth, Rasht, IranAD  - Guilan Univ Med Sci, Guilan Rd Trauma Res Ctr, Rasht, IranAD  - Manipal Univ, Transdisciplinary Ctr Qualitat Methods, Manipal, Karnataka, IndiaAD  - Univ Human Dev, Dept Comp Sci, Sulaimaniyah, IraqAD  - Bucharest Emergency Hosp, Dept Internal Med, Bucharest, RomaniaAD  - Natl Inst Legal Med Mina Minovici, Clin Legal Med, Bucharest, RomaniaAD  - Med Sch Tunis, Fac Med Tunis, Baab Saadoun, TunisiaAD  - Minist Hlth & Sports, Int Relat Div, Naypyidaw, MyanmarAD  - Univ Oslo, Inst Hlth & Soc, Oslo, NorwayAD  - Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, NorwayAD  - Univ Liberia, Dept Publ Hlth & Community Med, Monrovia, LiberiaAD  - Deakin Univ, Inst Phys Act & Nutr, Burwood, Vic, AustraliaAD  - Deakin Univ, Sch Med, Burwood, Vic, AustraliaAD  - Deakin Univ, Dept Psychol, Burwood, Vic, AustraliaAD  - Amer Canc Soc, Surveillance & Hlth Serv Res, Atlanta, GA 30329 USAAD  - George Mason Univ, Dept Global & Community Hlth, Fairfax, VA 22030 USAAD  - Natl Ctr Dis Control Delhi, Dept Parasit Dis, Delhi, IndiaAD  - Univ Kragujevac, Med Sci Dept, Kragujevac, SerbiaAD  - Univ Colombo, Fac Grad Studies, Colombo, Sri LankaAD  - Univ Colombo, Inst Med, Colombo, Sri LankaAD  - Banaras Hindu Univ, Dept Community Med, Varanasi, Uttar Pradesh, IndiaAD  - Duke Kunshan Univ, Environm Res Ctr, Kunshan, Peoples R ChinaAD  - Duke Kunshan Univ, Global Hlth Res Ctr, Kunshan, Peoples R ChinaAD  - Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R ChinaAD  - New South Wales Hlth, Sydney, NSW, AustraliaAD  - Univ Social Welf & Rehabil Sci Tehran, Tehran, IranAD  - All India Inst Med Sci, Ctr Community Med, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Forens Med & Toxicol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol Metab & Diabet, New Delhi, IndiaAD  - Univ Opole, Fac Med & Hlth Sci, Opole, PolandAD  - Univ Opole, Dept Family Med & Publ Hlth, Opole, PolandAD  - Savitribai Phule Pune Univ, Sch Hlth Sci, Pune, Maharashtra, IndiaAD  - Univ Tartu, Inst Family Med & Publ Hlth, Tartu, EstoniaAD  - Univ Coll Cork, Sch Publ Hlth, Cork, IrelandAD  - London Sch Econ & Polit Sci, Personal Social Serv Res Unit, London, EnglandAD  - Srirama Chandra Bhanja Med Coll & Hosp, Dept Nephrol, Cuttack, Orissa, IndiaAD  - Helmholtz Ctr Infect Res, Dept Epidemiol, Braunschweig, GermanyAD  - Qual & Equity Hlth Care, Kigali, RwandaAD  - Univ Washington, Sch Interdisciplinary Arts & Sci, Tacoma, WA USAAD  - Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, Seattle, WA USAAD  - Univ Glasgow, CSO Social & Publ Hlth Sci Unit, MRC, Glasgow, Lanark, ScotlandAD  - Oklahoma State Univ, Sch Hlth Care Adm, Tulsa, OK USAAD  - Univ Tulsa, Hlth Care Delivery Sci, Tulsa, OK 74104 USAAD  - Univ Nairobi, ODeL Campus, Nairobi, KenyaAD  - Univ Nairobi, Dept Psychiat, Nairobi, KenyaAD  - Michigan State Univ, Slavic Asian & African Languages, Dept Linguist & German, E Lansing, MI 48824 USAAD  - Med Res Council South Africa, Noncommunicable Dis Res Unit, Cape Town, South AfricaAD  - Med Res Council South Africa, Alcohol Tobacco & Other Drug Use Res Unit, Cape Town, South AfricaAD  - Med Res Council South Africa, Cochrane South Africa, Cape Town, South AfricaAD  - Univ Cape Town, Dept Med, Cape Town, South AfricaAD  - Univ Cape Town, Dept Psychiat & Mental Hlth, Cape Town, South AfricaAD  - Univ Cape Town, Dept Paediat & Child Hlth, Cape Town, South AfricaAD  - Assuta Hosp, Inst Cardiol, Tel Aviv Yaffo, IsraelAD  - Hadassah Hebrew Univ Hosp, Heart Failure & Cardiomyopathies Ctr, Jerusalem, IsraelAD  - Jordan Univ Sci & Technol, Dept Publ Hlth & Community Med, Ramtha, JordanAD  - Azad Univ, Omidiyeh Branch, Dept Stat, Tehran, IranAD  - Univ Management & Technol, Sch Food & Agr Sci, Lahore, PakistanAD  - Hlth Serv Acad, Epidemiol & Biostat Dept, Islamabad, PakistanAD  - John H Stroger Jr Hosp Cook Cty, Dept Internal Med, Chicago, IL USAAD  - Dow Univ Hlth Sci, Dept Internal Med, Karachi, PakistanAD  - Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USAAD  - Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USAAD  - Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USAAD  - Univ Alabama Birmingham, Birmingham, AL 35294 USAAD  - Univ Tennessee, Dept Pediat, Knoxville, TN USAAD  - Univ Tennessee, Knoxville, TN USAAD  - Seoul Natl Univ, Inst Hlth Policy & Management, Seoul, South KoreaAD  - Seoul Natl Univ, Dept Hlth Policy & Management, Seoul, South KoreaAD  - Int Otorhinolaryngol Res Assoc, Tehran, IranAD  - Lund Univ, Clin Epidemiol Unit, Lund, SwedenAD  - Lund Univ, Dept Clin Sci, Lund, SwedenAD  - Kenya Revenue Author, Res Dept, Nairobi, KenyaAD  - Synotech Consultant, Res & Data Solut, Nairobi, KenyaAD  - Korea Hlth Ind Dev Inst, Cheongju, South KoreaAD  - Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USAAD  - Korea Univ, Dept Prevent Med, Seoul, South KoreaAD  - Xiamen Univ Malaysia, Sch Med, Sepang, MalaysiaAD  - Simmons Coll, Dept Nutr, Boston, MA 02115 USAAD  - Univ Canberra, Fac Hlth, Canberra, ACT, AustraliaAD  - Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, AustraliaAD  - Royal Childrens Hosp, Neurol Dept, Melbourne, Vic, AustraliaAD  - Royal Childrens Hosp, Cardiol Dept, Melbourne, Vic, AustraliaAD  - Tulane Univ, Dept Global Community Hlth & Behav Sci, New Orleans, LA 70118 USAAD  - Jagiellonian Univ, Med Coll, Dept Hlth Econ & Social Secur, Krakow, PolandAD  - Jagiellonian Univ, Med Coll, Inst Publ Hlth, Krakow, PolandAD  - Norwegian Inst Publ Hlth, Ctr Dis Burden, Bergen, NorwayAD  - Norwegian Inst Publ Hlth, Div Mental & Phys Hlth, Bergen, NorwayAD  - Norwegian Inst Publ Hlth, Bergen, NorwayAD  - Fred Hutchinson Canc Res Ctr, Publ Hlth Sci Div, 1124 Columbia St, Seattle, WA 98104 USAAD  - Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Suita, Osaka, JapanAD  - Arthrit Res Canada, Richmond, BC, CanadaAD  - Sheri Kashmir Inst Med Sci, Dept Internal & Pulm Med, Srinagar, Jammu & Kashmir, IndiaAD  - Panjab Univ, Dept Anthropol, Chandigarh, IndiaAD  - Univ Montreal, Dept Social & Prevent Med, Montreal, PQ, CanadaAD  - Univ Montreal, Dept Demog, Montreal, PQ, CanadaAD  - Yuksek Ihtisas Univ, Dept Publ Hlth, Ankara, TurkeyAD  - Hacettepe Univ, Dept Publ Hlth, Ankara, TurkeyAD  - Post Grad Inst Med Educ & Res, Dept Internal Med, Chandigarh, IndiaAD  - Post Grad Inst Med Educ & Res, Dept Pediat, Chandigarh, IndiaAD  - Finnish Inst Occupat Hlth, Populat & Work Abil Program, Helsinki, FinlandAD  - Finnish Inst Occupat Hlth, Helsinki, FinlandAD  - Univ Helsinki, Dept Publ Hlth, Helsinki, FinlandAD  - Univ Helsinki, Helsinki, FinlandAD  - Acad Med Sci, Dept Community & Family Med, Baghdad, IraqAD  - Publ Hlth Agcy Canada, Hlth Promot & Chron Dis Prevent Branch, Ottawa, ON, CanadaAD  - HelpMeSee, New York, NY USAAD  - Mexican Inst Ophthalmol, Int Relat, Queretaro, MexicoAD  - Maragheh Univ Med Sci, Dept Publ Hlth, Maragheh, IranAD  - Maragheh Univ Med Sci, Managerial Epidemiol Res Ctr, Maragheh, IranAD  - Nova Southeastern Univ, Coll Optometry, Ft Lauderdale, FL 33314 USAAD  - Local Hlth Unit Tuscany Ctr, Reg Ctr Anal Data Occupat & Work Related Injuries, Florence, ItalyAD  - Univ Florence, Dept Hlth Sci, Florence, ItalyAD  - Univ Oxford, Wellcome Trust Asia Programme, Clin Res Unit, Hanoi, VietnamAD  - Shenzhen Sun Yat Sen Cardiovasc Hosp, Dept Clin Res & Epidemiol, Shenzhen, Peoples R ChinaAD  - Chinese Ctr Dis Control & Prevent, Noncommunicable Dis Control & Prevent Ctr, Beijing, Peoples R ChinaAD  - Chinese Ctr Dis Control & Prevent, Beijing, Peoples R ChinaAD  - Alliance Improving Hlth Outcomes Inc, Quezon City, PhilippinesAD  - Samara Univ, Dept Publ Hlth, Samara, EthiopiaAD  - Univ Malaya, Dept Med, Kuala Lumpur, MalaysiaAD  - Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R ChinaAD  - Univ Haifa, Sch Publ Hlth, Haifa, IsraelAD  - Ctr Chron Dis Control, Beijing, Peoples R ChinaAD  - Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, EnglandAD  - Univ Melbourne, Dept Paediat, Melbourne, Qld, AustraliaAD  - Univ Melbourne, Sch Hlth Sci, Melbourne, Qld, AustraliaAD  - Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Qld, AustraliaAD  - Univ Melbourne, Dept Med, Melbourne, Qld, AustraliaAD  - Univ Melbourne, Melbourne, Qld, AustraliaAD  - Friedrich Schiller Univ Jena, Inst Nutr, Jena, GermanyAD  - Competence Cluster Nutr & Cardiovasc Hlth NUTRICA, Jena, GermanyAD  - Aintree Univ Hosp Natl Hlth Serv NHS Fdn Trust, Gen Surg Dept, Liverpool, Merseyside, EnglandAD  - Univ Liverpool, Surg Dept, Liverpool, Merseyside, EnglandAD  - Swansea Univ, Hlth Data Res UK, Swansea, W Glam, WalesAD  - Nat Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, SingaporeAD  - Nat Univ Singapore, Yong Loo Lin Sch Med, Singapore, SingaporeAD  - Grant Med Coll & Sir JJ Grp Hosp, Dept Internal Med, Bombay, Maharashtra, IndiaAD  - Duy Tan Univ, Inst Global Hlth Innovat, Hanoi, VietnamAD  - Trnava Univ, Dept Publ Hlth, Trnava, SlovakiaAD  - Shiraz Univ Med Sci, Noncommunicable Dis Res Ctr, Shiraz, IranAD  - Emergency Univ Hosp Bucharest, Surg Dept, Bucharest, RomaniaAD  - Fed Inst Educ Sci & Technol Ceara, Campus Caucaia, Caucaia, BrazilAD  - Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, Graz, AustriaAD  - Univ East, Grad Sch, Ramon Magsaysay Mem Med Ctr, Quezon City, PhilippinesAD  - Hosp Ctr St John, Dept Neurol, Porto, PortugalAD  - Chalmers Univ Technol, Dept Biol & Biol Engn, Gothenburg, SwedenAD  - Lywel Dda Univ Hlth Board, Dept Ophthalmol, Carmarthen, Dyfed, WalesAD  - Alaska Native Med Ctr, Liver Dis & Hepatitis Program, Anchorage, AK USAAD  - Ipas Nepal, Res Monitoring & Evaluat, Kathmandu, NepalAD  - Natl Inst Canc Prevent & Res, Prevent Oncol, Noida, IndiaAD  - Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USAAD  - Sevenhills Hosp, Dept Internal Med, Bombay, Maharashtra, IndiaAD  - Debre Tabor Univ, Coll Hlth Sci, Debre Tabor, EthiopiaAD  - Univ West Florida, Dept Publ Hlth, Pensacola, FL 32514 USAAD  - Minist Hlth, Prince Mohammed Bin Abdulaziz Hosp, Res Dept, Riyadh, Saudi ArabiaAD  - United Nations Populat Fund UNEPA, Peru Country Off, Lima, PeruAD  - Wollo Univ, Dept Pharm, Dessie, EthiopiaAD  - Helsinki Univ Hosp, Neuroctr, Helsinki, FinlandAD  - Helsinki Univ Hosp, Breast Surg Unit, Helsinki, FinlandAD  - Dr Zora Ozic Polyclin, Clin Microbiol & Parasitol Unit, Zagreb, CroatiaAD  - Univ North, Univ Ctr Varazdin, Varazhdin, CroatiaAD  - Pomeranian Med Univ, Dept Hypertens, Szczecin, PolandAD  - Pomeranian Med Univ, Zdroje Hosp, Szczecin, PolandAD  - Pomeranian Med Univ, Emergency Dept, Szczecin, PolandAD  - Pomeranian Med Univ, Szczecin, PolandAD  - Pacific Inst Res & Evaluat, Calverton, MD USAAD  - Nevada Div Publ & Behav Hlth, Carson City, NV USAAD  - Natl Inst Stat, Presidents Off, Bucharest, RomaniaAD  - Kyrgyz State Med Acad, Fac Gen Med, Bishkek, KyrgyzstanAD  - Natl Ctr Cardiol & Internal Dis, Dept Atherosclerosis & Coronary Heart Dis, Bishkek, KyrgyzstanAD  - Frankfurt Univ Appl Sci, Inst Addict Res ISFF, Frankfurt, GermanyAD  - Salahaddin Univ, Dept Biol, Erbil, IraqAD  - Ishik Univ, Erbil, IraqAD  - Isfahan Univ Med Sci, Cardiovasc Res Inst, Esfahan, IranAD  - Jigjiga Univ, Dept Publ Hlth, Jigjiga, EthiopiaAD  - Ahmadu Bello Univ, Hlth Syst & Policy Res Unit, Zaria, NigeriaAD  - Ahmadu Bello Univ, Dept Community Med, Zaria, NigeriaAD  - Burlo Garofolo Inst Maternal & Child Hlth, Clin Epidemiol & Publ Hlth Res Unit, Trieste, ItalyAD  - Natl Hlth Res Inst, Hlth Syst Res Ctr, Cuernavaca, Morelos, MexicoAD  - Kurdistan Univ Med Sci, Dept Epidemiol & Biostat, Sanandaj, IranAD  - Kurdistan Univ Med Sci, Social Determinants Hlth Res Ctr, Sanandaj, IranAD  - Univ Lancaster, Lancaster, EnglandAD  - Queensland Univ Technol, Int Lab Air Qual & Hlth, Brisbane, Qld, AustraliaAD  - Queensland Univ Technol, Australian Ctr Hlth Serv Innovat, Brisbane, Qld, AustraliaAD  - Queensland Univ Technol, Sch Exercise & Nutr Sci, Brisbane, Qld, AustraliaAD  - Hosp Sto Antonio, Hosp Ctr Porto, Porto, PortugalAD  - Univ Athens, Dept Ophthalmol 1, Athens, GreeceAD  - Acad Athens, Biomed Res Fdn, Athens, GreeceAD  - Fed Inst Populat Res, Demog Change & Ageing Res Area, Wiesbaden, GermanyAD  - Fed Inst Populat Res, Competence Ctr Mortal Follow Up, Wiesbaden, GermanyAD  - Fed Inst Populat Res, Wiesbaden, GermanyAD  - Ctr Populat & Hlth, Wiesbaden, GermanyAD  - Inst Post Grad Med Educ & Res, Dept Endocrinol & Metab, Kolkata, IndiaAD  - Sci Univ Malaysia, Sch Med Sci, Kubang Kerian, MalaysiaAD  - Nishtar Med Univ, Pediat Dept, Multan, PakistanAD  - Inst Mother & Child Care, Pediat & Pediat Pulmonol, Multan, PakistanAD  - Ain Shams Univ, Dept Obstet & Gynecol, Cairo, EgyptAD  - Ain Shams Univ, Dept Entomol, Cairo, EgyptAD  - Natl Ctr Child Hlth & Dev, Tokyo, JapanAD  - Ulm Univ, Inst Epidemiol & Med Biometry, Ulm, GermanyAD  - Chungnam Natl Univ, Sch Med, Dept Prevent Med & Publ Hlth, Daejeon, South KoreaAD  - Chungnam Natl Univ Hosp, Daejeon Reg Canc Ctr, Daejeon, South KoreaAD  - Suraj Eye Inst, Nagpur, Maharashtra, IndiaAD  - Univ Yaounde I, Dept Publ Hlth, Yaounde, CameroonAD  - Dept Cardiol, Cardio Aid, Bucharest, RomaniaAD  - Wellcome Trust Res Programme, Kenya Med Res Inst, Neurosci, Kilifi, KenyaAD  - Univ Embu, Dept Biol Sci, Embu, KenyaAD  - Hanoi Sch Publ Hlth, Hlth Econ & Finance, Hanoi, VietnamAD  - Hanoi Sch Publ Hlth, Dept Hlth Econ, Hanoi, VietnamAD  - Hanoi Sch Publ Hlth, Hanoi, VietnamAD  - State Univ Semarang, Publ Hlth Sci Dept, Kota Semarang, IndonesiaAD  - Taipei Med Univ, Grad Inst Biomed Informat, Taipei, TaiwanAD  - Natl Ctr Global Hlth & Med, Inst Global Hlth Policy Res, Shinjuku Ku, Tokyo, JapanAD  - Kyung Hee Univ, Dept Prevent Med, Seoul, South KoreaAD  - Human Sci Res Council, Dept HIV AIDS STIs & TB, Durban, South AfricaAD  - Univ Namibia, Sch Publ Hlth, Oshakati Campus, Windhoek, NamibiaAD  - Univ Lagos, Dept Psychiat, Lagos, NigeriaAD  - Ctr Hlth Start Initiat, Ikoyi, NigeriaAD  - Minist Hlth, NCD Prevent & Control Unit, Bandar Seri Begawan, BruneiAD  - Univ Brunei Darussalam, Inst Hlth Sci, Gadong, BruneiAD  - San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USAAD  - Autonomous Univ Madrid, Sch Med, Madrid, SpainAD  - Jimenez Diaz Univ Hosp, Inst Hlth Res Fdn, Dept Hypertens & Nephrol, Madrid, SpainAD  - St Lukes Int Univ, Dept Global Hlth Nursing, Chuo Ku, Tokyo, JapanAD  - Minist Hlth Russian Federat, Ctr Healthcare Qual Assessment & Control, Moscow, RussiaAD  - Moscow State Univ, Moscow Inst Phys & Technol, Dolgoprudnyi, RussiaAD  - Univ Ibadan, Inst Adv Med Res & Training, Ibadan, NigeriaAD  - Jagadguru Sri Shivarathreeswara Univ, Dept TB & Resp Med, Mysore, Karnataka, IndiaAD  - Univ Chichester, Chichester, EnglandAD  - Ctr Hlth Outcomes & Evaluat, Hlth Outcomes, Bucharest, RomaniaAD  - Kosin Univ, Dept Med Humanities & Social Med, Busan, South KoreaAD  - Maimonides Hosp, Dept Med, Brooklyn, NY 11219 USAAD  - Deemed Univ, Krishna Inst Med Sci, Karad, IndiaAD  - Int Inst Hlth Management Res, New Delhi, IndiaAD  - Murdoch Childrens Res Inst, Populat Hlth Grp, Melbourne, Vic, AustraliaAD  - Murdoch Childrens Res Inst, Melbourne, Vic, AustraliaAD  - Diabet Res Soc, Clin Res Dept, Hyderabad, IndiaAD  - DiabetOmics, Clin Res Dept, Portland, OR USAAD  - Save Children, Hlth Nutr & HIV AIDS Program, Kathmandu, NepalAD  - Ludwig Maximilians Univ Munchen, Ctr Int Hlth, Munich, GermanyAD  - Cartagena Univ, Cartagena, ColombiaAD  - Univ Gothenburg, Inst Med, Gothenburg, SwedenAD  - Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South AfricaAD  - Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Shanghai, Peoples R ChinaAD  - Durban Univ Technol, Basic Med Sci Dept, Durban, South AfricaAD  - Ctr Addict & Mental Hlth, Inst Mental Hlth Policy Res, Toronto, ON, CanadaAD  - Charotar Univ Sci & Technol, Ashok & Rita Patel Inst Physiotherapy, Anand, Gujarat, IndiaAD  - Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, IranAD  - Drexel Univ, Dept Environm & Occupat Hlth, Philadelphia, PA 19104 USAAD  - Medichem, Barcelona, SpainAD  - Contech Sch Publ Hlth, Dept Epidemiol & Biostat, Lahore, PakistanAD  - Sweidi Hosp, Dept Clin Pediat, Riyadh, Saudi ArabiaAD  - North West Univ, Dept Pediat, Peshawar, PakistanAD  - North West Univ, Hypertens Africa Res Team, Peshawar, PakistanAD  - Soc Hlth & Demog Surveillance, Suri, IndiaAD  - Univ Gottingen, Dept Econ, Gottingen, GermanyAD  - Fundacao Oswaldo Cruz, Goncalo Moniz Inst, Salvador, BA, BrazilAD  - Univ Coll London Hosp, London, EnglandAD  - Publ Hlth England, London, EnglandAD  - Brien Holden Vision Inst, Sydney, NSW, AustraliaAD  - Org Prevent Blindness, Paris, FranceAD  - Univ Fed Uberlandia, Dept Clin Res, Uberlandia, MG, BrazilAD  - Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, IranAD  - Ikiam Amazon Reg Univ, Biotechnol, Ciudad De Tena, EcuadorAD  - Southern Univ Sci & Technol, Dept Ocean Sci & Engn, Shenzhen, Peoples R ChinaAD  - Prince Wales Hosp, Neuropsychiat Inst, Randwick, NSW, AustraliaAD  - Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, IranAD  - Mashhad Univ Med Sci, Biotechnol Res Ctr, Mashhad, IranAD  - Al Imam Mohammad Ibn Saud Islamic Univ, Coll Med, Riyadh, Saudi ArabiaAD  - York Univ, Fac Hlth, Sch Hlth & Policy Management, Toronto, ON, CanadaAD  - Punjab Univ, Coll Pharm, Anarkali, PakistanAD  - Stanford Univ, Ctr Hlth Policy, Stanford, CA 94305 USAAD  - Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USAAD  - Chest Res Fdn, Clin Res Div, Pune, Maharashtra, IndiaAD  - Minist Hlth, Hlth & Disabil Intelligence Grp, Wellington, New ZealandAD  - Marshall Univ, Dept Surg, Huntington, WV USAAD  - Case Western Reserve Univ, Dept Nutr & Prevent Med, Cleveland, OH 44106 USAAD  - Jimenez Diaz Fdn Univ Hosp, Inst Hlth Res, Nephrol Grp, Madrid, SpainAD  - Reg Hlth Adm Norte IP, Dept Publ Hlth, Vila Nova De Gaia, PortugalAD  - Univ Massachusetts, Med Sch, Dept Med, Worcester, MA 01605 USAAD  - Univ Appl & Environm Sci, Fac Med, Dept Hlth & Soc, Bogota, ColombiaAD  - Univ Kwazulu Natal, Dept Publ Hlth Med, Durban, South AfricaAD  - Hamad Med Corp, Surg Dept, Doha, QatarAD  - Bournemouth Univ, Fac Hlth & Social Sci, Bournemouth, Dorset, EnglandAD  - Utkal Univ, UGC Ctr Adv Study Psychol, Bhubaneswar, IndiaAD  - Udyam Global Assoc Sustainable Dev, Bhubaneswar, IndiaAD  - Dr DY Patil Vidyapeeth, Pune, Maharashtra, IndiaAD  - Univ North Carolina, Dept Publ Hlth Sci, Charlotte, NC 28223 USAAD  - Univ Fed Santa Catarina, Sch Hlth Sci, Ararangua, BrazilAD  - Univ Zagreb, Dept Med Stat Epidemiol & Med Informat, Zagreb, CroatiaAD  - Croatian Inst Publ Hlth, Div Epidemiol & Prevent Chron Noncommunicable Dis, Zagreb, CroatiaAD  - NYU, Langone Med Ctr, New York, NY USAAD  - An Najah Natl Univ, Publ Hlth Div, Nablus, PalestineAD  - Middle East Liver Dis Ctr, Dept Mol Hepatol, Tehran, IranAD  - Islamic Azad Univ, Dept Lab Sci, Sari, IranAD  - Islamic Azad Univ, Dept Basic Sci, Sari, IranAD  - Minist Hlth, Policy & Planning Div, Thimphi, BhutanAD  - Delhi Technol Univ, Univ Sch Management & Entrepreneurship, New Delhi, IndiaAD  - Fudan Univ, Dept Pulm Med, Shanghai, Peoples R ChinaAD  - Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, ScotlandAD  - Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USAAD  - Natl Inst Infect Dis, Tokyo, JapanAD  - Martin Luther Univ Halle Wittenberg, Inst Med Epidemiol, Halle, GermanyAD  - Univ Technol Sydney, Sch Hlth, Sydney, NSW, AustraliaAD  - Reykjavik Univ, Dept Psychol, Reykjavik, IcelandAD  - Brasilia Univ, Brasilia, DF, BrazilAD  - Max Hosp, Ghaziabad, IndiaAD  - Asthma Bhawan, Dept Pulm Med, Jaipur, Rajasthan, IndiaAD  - Sch Prevent Oncol, Dept Epidemiol, Patna, Bihar, IndiaAD  - King Khalid Univ Hosp, Pediat Dept, Riyadh, Saudi ArabiaAD  - Int Med Univ, Div Community Med, Kuala Lumpur, MalaysiaAD  - Minist Hlth, FRIHOI, Cent Res Inst Cytol & Genet, Moscow, RussiaAD  - Minist Hlth, FRIHOI, Moscow, RussiaAD  - Norwegian Univ Sci & Technol, Dept Neuromed & Movement Sci, Trondheim, NorwayAD  - St Olavs Hosp, Neuro Ctr, Trondheim, NorwayAD  - Muhammadiyah Univ Surakarta, Dept Nursing, Kartasura, IndonesiaAD  - Muhimbili Univ Hlth & Allied Sci, Dept Community Hlth, Dar Es Salaam, TanzaniaAD  - Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, TanzaniaAD  - Univ Calif Riverside, Sch Med, Riverside, CA 92521 USAAD  - Univ Calif Irvine, Dept Criminol Law & Soc, Irvine, CA USAAD  - Univ Valencia, Dept Med, Valencia, SpainAD  - Univ Valencia, Dept Pediat Obstet & Gynecol, Valencia, SpainAD  - Biomed Res Networking Ctr Mental Hlth Network CIB, Carlos III Hlth Inst, Madrid, SpainAD  - Osaka Int Canc Inst, Canc Control Ctr, Osaka, JapanAD  - New York Med Coll, Dept Psychiat & Behav Sci, Valhalla, NY 10595 USAAD  - Univ Inst Egas Moniz, Monte De Caparica, PortugalAD  - Univ Lisbon, Fac Pharm Lisbon, Res Inst Med, Lisbon, PortugalAD  - Univ Virginia, Anesthesiol Dept, Charlottesville, VA USAAD  - Syrian Expatriate Med Assoc, Charlottesville, VA USAAD  - Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, SingaporeAD  - Nanyang Technol Univ, Singapore, SingaporeAD  - Univ Calgary, Dept Med, Calgary, AB, CanadaAD  - Agcy Hlth Technol Assessment & Tariff Syst, Warsaw, PolandAD  - Univ Hosp Doctor Peset, Pediat Dept, Valencia, SpainAD  - Natl Inst Hlth & Med Res, Nutr Epidemiol Res Team, Paris, FranceAD  - Hanoi Med Univ, Dept Hlth Econ, Hanoi, VietnamAD  - Mil Med Univ, Clin Hematol & Toxicol, Hanoi, VietnamAD  - Fed Teaching Hosp, Dept Internal Med, Abakaliki, NigeriaAD  - Gomal Univ, Gomal Ctr Biochem & Biotechnol, Dera Ismail Khan, PakistanAD  - Mufti Mehmood Mem Teaching Hosp, TB Culture Lab, Dera Ismail Khan, PakistanAD  - Pontificia Univ Catolica Chile, Sch Govt, Santiago, ChileAD  - Brandeis Univ, Schneider Inst Hlth Policy, Waltham, MA USAAD  - Argentine Soc Med, Buenos Aires, DF, ArgentinaAD  - Velez Sarsfield Hosp, Buenos Aires, DF, ArgentinaAD  - UKK Inst, Tampere, FinlandAD  - Raffles Hosp, Raffles Neurosci Ctr, Singapore, SingaporeAD  - St Orsola Malpighi Hosp, Occupat Hlth Unit, Bologna, ItalyAD  - IM Sechenov First Moscow State Med Univ, Dept Informat & Internet Technol, Moscow, RussiaAD  - Natl Res Univ, Dept Hlth Care Adm & Econ, Moscow, RussiaAD  - Fdn Univ, Fdn Univ Med Coll, Rawalpindi, PakistanAD  - Wuhan Univ, Dept Epidemiol & Biostat, Wuhan, Hubei, Peoples R ChinaAD  - Wuhan Univ, Global lealth Inst, Wuhan, Hubei, Peoples R ChinaAD  - Tech Univ Munich, Dept Neurol, Munich, GermanyAD  - Royal Cornwall Hosp, Bone & Joint Res Grp, Truro, EnglandAD  - Univ Strathclyde, Glasgow, Lanark, ScotlandAD  - St Johns Natl Acad Hlth Sci, Dept Pharmacol, Bangalore, Karnataka, IndiaAD  - Nanjing Univ, Sch Med, Nanjing, Jiangsu, Peoples R ChinaAD  - Milad Gen Hosp, Clin Canc Res Ctr, Tehran, IranAD  - Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USAAD  - King Fahd Univ Petr & Minerals, Dept Earth Sci, Dhahran, Saudi ArabiaAD  - Wolkite Univ, Wolkite, EthiopiaAD  - Natl Ctr Neurol & Psychiat, Dept Psychopharmacol, Tokyo, JapanAD  - Univ Kinshasa, Sch Publ Hlth, Kinshasa, DEM REP CONGOAD  - Jackson State Univ, Dept Hlth Policy & Management, Jackson, MS USAAD  - Tsinghua Univ, Beijing, Peoples R ChinaAD  - Inst Oncol Ljubljana, Epidemiol & Canc Registry Sect, Ljubljana, SloveniaAD  - Univ Hosp Setif, Dept Epidemiol, Setif, AlgeriaAD  - Ardebil Univ Med Sci, Social Determinants Hlth Res Ctr, Ardebil, IranAD  - Minist Hlth, Israeli Ctr Dis Control, Ramat Gan, IsraelAD  - Tel Aviv Univ, Sch Publ Hlth, Tel Aviv, IsraelC3  - University of WashingtonC3  - University of Washington SeattleC3  - Institute for Health Metrics & EvaluationC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Sapienza University RomeC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - McGill UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Manonmaniam Sundaranar UniversityC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - CHU LimogesC3  - Universite de LimogesC3  - Qatar Foundation (QF)C3  - Weill Cornell Medical College QatarC3  - Birzeit UniversityC3  - Dongguk UniversityC3  - Monash UniversityC3  - Monash UniversityC3  - Monash UniversityC3  - Monash UniversityC3  - Stellenbosch UniversityC3  - Stellenbosch UniversityC3  - Stellenbosch UniversityC3  - South African Medical Research CouncilC3  - South African Medical Research CouncilC3  - South African Medical Research CouncilC3  - University of IbadanC3  - University College Hospital, IbadanC3  - Cardiff UniversityC3  - Universidad de ExtremaduraC3  - Universidad de ExtremaduraC3  - University of LomeC3  - McMaster UniversityC3  - McMaster UniversityC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - Yerevan State UniversityC3  - National Academy of Sciences of ArmeniaC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - Baylor College of MedicineC3  - Baylor College of MedicineC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - University of KentuckyC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - University of TorontoC3  - Washington University (WUSTL)C3  - King Saud UniversityC3  - King Saud UniversityC3  - King Saud UniversityC3  - Jazan UniversityC3  - Jazan UniversityC3  - King Abdulaziz UniversityC3  - Mayo ClinicC3  - University of Western AustraliaC3  - University of Western AustraliaC3  - Cleveland Clinic FoundationC3  - Baqiyatallah University of Medical Sciences (BMSU)C3  - Baqiyatallah University of Medical Sciences (BMSU)C3  - Australian National UniversityC3  - Australian National UniversityC3  - Qazvin University of Medical Sciences (QUMS)C3  - Qazvin University of Medical Sciences (QUMS)C3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Kuwait UniversityC3  - Luxembourg Institute of HealthC3  - Universite de BordeauxC3  - Hospital del Mar Research InstituteC3  - Hospital del MarC3  - Pompeu Fabra UniversityC3  - Ruhr University BochumC3  - Universidad de CartagenaC3  - Universidad de la CostaC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - Kerman University of Medical SciencesC3  - American University of BeirutC3  - American University of BeirutC3  - Kwame Nkrumah University Science & TechnologyC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - University of ThessalyC3  - Arba Minch UniversityC3  - Arba Minch UniversityC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - Hong Kong Polytechnic UniversityC3  - Hong Kong Polytechnic UniversityC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Birmingham City UniversityC3  - Dalarna UniversityC3  - Western Sydney UniversityC3  - Western Sydney UniversityC3  - Western Sydney UniversityC3  - Sydney Local Health DistrictC3  - University of ManitobaC3  - University of LeicesterC3  - University of LeicesterC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Public Health Foundation of IndiaC3  - Public Health Foundation of IndiaC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - Instituto Nacional de Salud - PeruC3  - University of TokyoC3  - University of TokyoC3  - University of TokyoC3  - University of TokyoC3  - Burnet InstituteC3  - South Australian Health & Medical Research Institute (SAHMRI)C3  - Sri Ramachandra Institute of Higher Education & ResearchC3  - Medical University LodzC3  - Polish Mother's Memorial Hospital - Research InstituteC3  - Egyptian Knowledge Bank (EKB)C3  - Alexandria UniversityC3  - Clinical Centre of SerbiaC3  - University of BelgradeC3  - University of BelgradeC3  - University of BelgradeC3  - Universidad Costa RicaC3  - Universidad Costa RicaC3  - University of AucklandC3  - University of AucklandC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard T.H. Chan School of Public HealthC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Charles R. Drew University of Medicine & ScienceC3  - University of California SystemC3  - University of California Los AngelesC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Lorestan University of Medical SciencesC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Yale UniversityC3  - Yale UniversityC3  - University of AlbertaC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - Emory UniversityC3  - State University System of FloridaC3  - University of South FloridaC3  - University of BirminghamC3  - University of BirminghamC3  - Imperial College LondonC3  - Imperial College LondonC3  - Imperial College LondonC3  - World Health OrganizationC3  - Imperial College LondonC3  - Imperial College LondonC3  - Imperial College LondonC3  - Aga Khan UniversityC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - University of DhakaC3  - Research Triangle InstituteC3  - University of NottinghamC3  - University of NottinghamC3  - University of BergenC3  - University of BergenC3  - University of OsloC3  - University of OsloC3  - Oregon Health & Science UniversityC3  - Oregon Health & Science UniversityC3  - University of Texas SystemC3  - University of Texas Health Science Center HoustonC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - Anglia Ruskin UniversityC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - University of CambridgeC3  - Comenius University BratislavaC3  - University System of OhioC3  - Ohio State UniversityC3  - University System of OhioC3  - Ohio State UniversityC3  - University System of OhioC3  - Ohio State UniversityC3  - Helmholtz AssociationC3  - German Cancer Research Center (DKFZ)C3  - Instituto Conmemorativo Gorgas de Estudios de la SaludC3  - Instituto Conmemorativo Gorgas de Estudios de la SaludC3  - Monash UniversityC3  - Cabrini HealthC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - University of British ColumbiaC3  - University of British ColumbiaC3  - Universidad Autonoma Metropolitana - MexicoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do PortoC3  - Universidad Nacional de ColombiaC3  - Universidad Nacional de ColombiaC3  - Australian Catholic UniversityC3  - Australian Catholic UniversityC3  - University of Hong KongC3  - University of Hong KongC3  - University of Hong KongC3  - Alfaisal UniversityC3  - National Taiwan UniversityC3  - University West Indies Mona JamaicaC3  - University West Indies Saint AugustineC3  - Gold Coast HealthC3  - Ministry of Health IraqC3  - Seoul National University (SNU)C3  - Seoul National University HospitalC3  - University of CopenhagenC3  - University of CopenhagenC3  - Bispebjerg HospitalC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of SalernoC3  - Universidad Autonoma de ChileC3  - Universidad Autonoma de ChileC3  - University of SouthamptonC3  - University of Milano-BicoccaC3  - Universidade Federal do Rio Grande do SulC3  - University of California SystemC3  - University of California San DiegoC3  - University of SydneyC3  - University of SydneyC3  - University of SydneyC3  - Asbestos Diseases Research InstituteC3  - University of SydneyC3  - University of SydneyC3  - University of OtagoC3  - Duke UniversityC3  - Duke UniversityC3  - Hawassa UniversityC3  - Hawassa UniversityC3  - Flinders University South AustraliaC3  - Guy's & St Thomas' NHS Foundation TrustC3  - Guy's & St Thomas' NHS Foundation TrustC3  - Bangladesh Rural Advancement Committee BRACC3  - BRAC UniversityC3  - Bangladesh Rural Advancement Committee BRACC3  - BRAC UniversityC3  - Griffith UniversityC3  - Griffith University - Mount Gravatt CampusC3  - Griffith UniversityC3  - Griffith University - Mount Gravatt CampusC3  - Ghent UniversityC3  - University of BrightonC3  - University of SussexC3  - NHS National Services ScotlandC3  - Aristotle University of ThessalonikiC3  - Icahn School of Medicine at Mount SinaiC3  - University of PeradeniyaC3  - Swedish Medical CenterC3  - Ministry of Health & Medical Education (MOHME)C3  - Ministry of Health & Medical Education (MOHME)C3  - Nguyen Tat Thanh University (NTTU)C3  - Nguyen Tat Thanh University (NTTU)C3  - Nguyen Tat Thanh University (NTTU)C3  - Medical University VarnaC3  - University of Cape CoastC3  - University of Cape CoastC3  - Tampere UniversityC3  - Tampere UniversityC3  - University of RochesterC3  - Royal Melbourne Institute of Technology (RMIT)C3  - Royal Melbourne Institute of Technology (RMIT)C3  - Universidade Federal da BahiaC3  - Universidade Federal da BahiaC3  - Umea UniversityC3  - University of NewcastleC3  - UiT The Arctic University of TromsoC3  - University of Michigan SystemC3  - University of MichiganC3  - University of Michigan SystemC3  - University of MichiganC3  - Eijkman InstituteC3  - Ministry of Health-SingaporeC3  - Ministry of Health-SingaporeC3  - Queensland Centre for Mental Health ResearchC3  - Queensland Centre for Mental Health ResearchC3  - Queensland Centre for Mental Health ResearchC3  - Queensland Centre for Mental Health ResearchC3  - Urmia University of Medical SciencesC3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - University of LouisvilleC3  - University of BolognaC3  - Universidade Federal de SergipeC3  - Hamadan University of Medical SciencesC3  - Hamadan University of Medical SciencesC3  - Hamadan University of Medical SciencesC3  - Auckland University of TechnologyC3  - Bahir Dar UniversityC3  - Bahir Dar UniversityC3  - University of OttawaC3  - Universidade Catolica PortuguesaC3  - Kaiser PermanenteC3  - A.T. Still University of Health SciencesC3  - A.T. Still University of Health SciencesC3  - University of BielefeldC3  - National Academy of Medical Sciences of UkraineC3  - D. F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of UkraineC3  - Kobe UniversityC3  - University of BaselC3  - Swiss Tropical & Public Health InstituteC3  - University of BaselC3  - Swiss Tropical & Public Health InstituteC3  - University of BaselC3  - University of TasmaniaC3  - Menzies Institute for Medical ResearchC3  - Centro de Investigacao em Saude de ManhicaC3  - ISGlobalC3  - ISGlobalC3  - Curtin UniversityC3  - Wageningen University & ResearchC3  - University of TsukubaC3  - University of WarwickC3  - University of WarwickC3  - University of AdelaideC3  - University of AdelaideC3  - University Ha'ilC3  - Research Center of NeurologyC3  - Jawaharlal Nehru University, New DelhiC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - University of Massachusetts SystemC3  - University of Massachusetts BostonC3  - University of Oklahoma SystemC3  - University of Oklahoma Health Sciences CenterC3  - Boston UniversityC3  - Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele Presidio FerraottoC3  - Universite de LorraineC3  - West Virginia UniversityC3  - Eternal Heart Care Centre & Research InstituteC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Yeshiva UniversityC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Yeshiva UniversityC3  - Aarhus UniversityC3  - Aarhus UniversityC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - Western University (University of Western Ontario)C3  - Western University (University of Western Ontario)C3  - Western University (University of Western Ontario)C3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Arabian Gulf UniversityC3  - University of New MexicoC3  - Sun Yat Sen UniversityC3  - Sun Yat Sen UniversityC3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - University of BarcelonaC3  - University of BarcelonaC3  - University of AntwerpC3  - Karolinska InstitutetC3  - Karolinska University HospitalC3  - Bucharest University of Economic StudiesC3  - University of GroningenC3  - University of GroningenC3  - Columbia UniversityC3  - Columbia UniversityC3  - National Institutes of Health (NIH) - USAC3  - National Institutes of Health (NIH) - USAC3  - University of Texas SystemC3  - University of Texas AustinC3  - Guilan University of Medical SciencesC3  - Guilan University of Medical SciencesC3  - Manipal Academy of Higher Education (MAHE)C3  - Universite de Tunis-El-ManarC3  - Faculte de Medecine de Tunis (FMT)C3  - University of OsloC3  - University of OsloC3  - Deakin UniversityC3  - Deakin UniversityC3  - Deakin UniversityC3  - American Cancer SocietyC3  - George Mason UniversityC3  - University of KragujevacC3  - University of ColomboC3  - University of ColomboC3  - Banaras Hindu University (BHU)C3  - Duke Kunshan UniversityC3  - Duke Kunshan UniversityC3  - Capital Medical UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of OpoleC3  - University of OpoleC3  - Savitribai Phule Pune UniversityC3  - University of TartuC3  - University College CorkC3  - University of LondonC3  - London School Economics & Political ScienceC3  - Srirama Chandra Bhanja Medical College & HospitalC3  - Helmholtz AssociationC3  - Helmholtz-Center for Infection ResearchC3  - University of WashingtonC3  - University of Washington TacomaC3  - Seattle Children's HospitalC3  - MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNITC3  - University of GlasgowC3  - University of TulsaC3  - University of NairobiC3  - University of NairobiC3  - Michigan State UniversityC3  - University of Cape TownC3  - University of Cape TownC3  - University of Cape TownC3  - Hebrew University of JerusalemC3  - Hadassah University Medical CenterC3  - Jordan University of Science & TechnologyC3  - Islamic Azad UniversityC3  - University of Management & Technology (UMT)C3  - Health Services AcademyC3  - John H Stroger Junior Hospital Cook CountyC3  - University of Illinois SystemC3  - University of Illinois ChicagoC3  - University of Illinois Chicago HospitalC3  - Dow University of Health SciencesC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Tennessee SystemC3  - University of Tennessee Health Science CenterC3  - University of Tennessee SystemC3  - University of Tennessee KnoxvilleC3  - Seoul National University (SNU)C3  - Seoul National University (SNU)C3  - Lund UniversityC3  - Lund UniversityC3  - Northeastern UniversityC3  - Korea UniversityC3  - Xiamen University Malaysia CampusC3  - Simmons UniversityC3  - University of CanberraC3  - Murdoch Children's Research InstituteC3  - Royal Children's Hospital MelbourneC3  - Royal Children's Hospital MelbourneC3  - Royal Children's Hospital MelbourneC3  - Tulane UniversityC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - Norwegian Institute of Public Health (NIPH)C3  - Norwegian Institute of Public Health (NIPH)C3  - Norwegian Institute of Public Health (NIPH)C3  - Fred Hutchinson Cancer CenterC3  - National Cerebral & Cardiovascular Center - JapanC3  - Arthritis Research CanadaC3  - Sher-i-Kashmir Institute of Medical SciencesC3  - Panjab UniversityC3  - Universite de MontrealC3  - Universite de MontrealC3  - Yuksek Ihtisas UniversityC3  - Hacettepe UniversityC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Finnish Institute of Occupational HealthC3  - Finnish Institute of Occupational HealthC3  - University of HelsinkiC3  - University of HelsinkiC3  - Public Health Agency of CanadaC3  - Nova Southeastern UniversityC3  - University of FlorenceC3  - University of OxfordC3  - Shenzhen Sun Yatsen Cardiovascular HospitalC3  - Chinese Center for Disease Control & PreventionC3  - Chinese Center for Disease Control & PreventionC3  - Samara UniversityC3  - Universiti MalayaC3  - Chinese University of Hong KongC3  - University of HaifaC3  - University of BristolC3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - Friedrich Schiller University of JenaC3  - University of LiverpoolC3  - Swansea UniversityC3  - National University of SingaporeC3  - Duy Tan UniversityC3  - University of TrnavaC3  - Shiraz University of Medical ScienceC3  - Instituto Federal do Ceara (IFCE)C3  - Medical University of GrazC3  - University of the EastC3  - Chalmers University of TechnologyC3  - Alaska Native Medical CenterC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Cancer Prevention & Research (NICPR)C3  - University of California SystemC3  - University of California San FranciscoC3  - State University System of FloridaC3  - University of West FloridaC3  - Ministry of Health - Saudi ArabiaC3  - King Saud Bin Abdulaziz University for Health SciencesC3  - Prince Mohammed bin Abdulaziz Hospital - Al MadinahC3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - University North - CroatiaC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pacific Institute for Research & Evaluation (PIRE)C3  - Kyrgyz State Medical AcademyC3  - Ministry of Health - KyrgyzstanC3  - Salahaddin UniversityC3  - Isfahan University of Medical SciencesC3  - Ahmadu Bello UniversityC3  - Ahmadu Bello UniversityC3  - IRCCS Burlo GarofoloC3  - Kurdistan University of Medical SciencesC3  - Kurdistan University of Medical SciencesC3  - Lancaster UniversityC3  - Queensland University of Technology (QUT)C3  - Queensland University of Technology (QUT)C3  - Queensland University of Technology (QUT)C3  - National & Kapodistrian University of AthensC3  - Academy of AthensC3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataC3  - Universiti Sains MalaysiaC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - National Center for Child Health & Development - JapanC3  - Ulm UniversityC3  - Chungnam National UniversityC3  - Chungnam National UniversityC3  - Chungnam National University HospitalC3  - Suraj Eye InstituteC3  - University of Yaounde IC3  - Kenya Medical Research InstituteC3  - Hanoi University of Public HealthC3  - Hanoi University of Public HealthC3  - Hanoi University of Public HealthC3  - Universitas Negeri SemarangC3  - Taipei Medical UniversityC3  - National Center for Global Health & Medicine - JapanC3  - Kyung Hee UniversityC3  - Human Sciences Research Council-South AfricaC3  - University of NamibiaC3  - University of LagosC3  - University Brunei DarussalamC3  - California State University SystemC3  - San Diego State UniversityC3  - Autonomous University of MadridC3  - St. Luke's International HospitalC3  - Ministry of Health of the Russian FederationC3  - Lomonosov Moscow State UniversityC3  - Moscow Institute of Physics & TechnologyC3  - University of IbadanC3  - JSS Academy of Higher Education & ResearchC3  - University of ChichesterC3  - Maimonides Medical CenterC3  - Krishna Vishwa VidyapeethC3  - Krishna Institute of Medical SciencesC3  - International Institute of Health Management Research DelhiC3  - Murdoch Children's Research InstituteC3  - Murdoch Children's Research InstituteC3  - Save the ChildrenC3  - University of MunichC3  - Universidad de CartagenaC3  - University of GothenburgC3  - University of WitwatersrandC3  - Shanghai Jiao Tong UniversityC3  - Durban University of TechnologyC3  - University of TorontoC3  - Centre for Addiction & Mental Health - CanadaC3  - Charotar University of Science & Technology - CharusatC3  - Drexel UniversityC3  - University of GottingenC3  - Fundacao Oswaldo CruzC3  - University of LondonC3  - University College LondonC3  - University College London Hospitals NHS Foundation TrustC3  - Public Health EnglandC3  - Brien Holden Vision InstituteC3  - Universidade Federal de UberlandiaC3  - Golestan University of Medical SciencesC3  - Southern University of Science & TechnologyC3  - University of New South Wales SydneyC3  - Prince of Wales Hospital (POWH)C3  - Mashhad University of Medical SciencesC3  - Mashhad University of Medical SciencesC3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - York University - CanadaC3  - Stanford UniversityC3  - Stanford UniversityC3  - Marshall UniversityC3  - University System of OhioC3  - Case Western Reserve UniversityC3  - University of Massachusetts SystemC3  - University of Massachusetts WorcesterC3  - University of Kwazulu NatalC3  - Hamad Medical CorporationC3  - Bournemouth UniversityC3  - Utkal UniversityC3  - Dr DY Patil Vidyapeeth PuneC3  - University of North CarolinaC3  - University of North Carolina CharlotteC3  - Universidade Federal de Santa Catarina (UFSC)C3  - University of ZagrebC3  - NYU Langone Medical CenterC3  - New York UniversityC3  - An Najah National UniversityC3  - Islamic Azad UniversityC3  - Islamic Azad UniversityC3  - Delhi Technological UniversityC3  - Fudan UniversityC3  - University of EdinburghC3  - Tufts UniversityC3  - National Institute of Infectious Diseases (NIID)C3  - Martin Luther University Halle WittenbergC3  - University of Technology SydneyC3  - Reykjavik UniversityC3  - Universidade de BrasiliaC3  - King Saud UniversityC3  - King Khalid University HospitalC3  - International Medical University MalaysiaC3  - Ministry of Health of the Russian FederationC3  - Ministry of Health of the Russian FederationC3  - Norwegian University of Science & Technology (NTNU)C3  - Norwegian University of Science & Technology (NTNU)C3  - Universitas Muhammadiyah SurakartaC3  - Muhimbili University of Health & Allied SciencesC3  - Muhimbili University of Health & Allied SciencesC3  - University of California SystemC3  - University of California RiversideC3  - University of California SystemC3  - University of California IrvineC3  - University of ValenciaC3  - University of ValenciaC3  - New York Medical CollegeC3  - Universidade de LisboaC3  - University of VirginiaC3  - Nanyang Technological UniversityC3  - Nanyang Technological UniversityC3  - University of CalgaryC3  - Institut National de la Sante et de la Recherche Medicale (Inserm)C3  - Hanoi Medical UniversityC3  - Gomal UniversityC3  - Pontificia Universidad Catolica de ChileC3  - Brandeis UniversityC3  - UKK InstituteC3  - Raffles HospitalC3  - IRCCS Azienda Ospedaliero-Universitaria di BolognaC3  - Sechenov First Moscow State Medical UniversityC3  - Wuhan UniversityC3  - Wuhan UniversityC3  - Technical University of MunichC3  - Royal Cornwall HospitalC3  - University of StrathclydeC3  - St. John's National Academy of Health SciencesC3  - Nanjing UniversityC3  - Northwestern UniversityC3  - King Fahd University of Petroleum & MineralsC3  - National Center for Neurology & Psychiatry - JapanC3  - Universite de KinshasaC3  - Jackson State UniversityC3  - Tsinghua UniversityC3  - Institute of Oncology - SloveniaC3  - Ardabil University of Medical SciencesC3  - Tel Aviv UniversityPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - NOV 10
PY  - 2018
VL  - 392
IS  - 10159
SP  - 1859
EP  - 1922
DO  - 10.1016/S0140-6736(18)32335-3
AN  - WOS:000449710900006
ER  -

TY  - JOUR
AU  - Lozano, R
AU  - Fullman, N
AU  - Abate, D
AU  - Abay, SM
AU  - Abbafati, C
AU  - Abbasi, N
AU  - Abbastabar, H
AU  - Abd-Allah, F
AU  - Abdela, J
AU  - Abdelalim, A
AU  - Abdel-Rahman, O
AU  - Abdi, A
AU  - Abdollahpour, I
AU  - Abdulkader, RS
AU  - Abebe, ND
AU  - Abebe, Z
AU  - Abejie, AN
AU  - Abera, SP
AU  - Abil, OZ
AU  - Aboyans, V
AU  - Abraha, HN
AU  - Abrham, AR
AU  - Abu-Raddad, LJ
AU  - Abu-Rmeileh, NM
AU  - Abyu, GY
AU  - Accrombessi, MMK
AU  - Acharya, D
AU  - Acharya, P
AU  - Adamu, AA
AU  - Adebayo, OM
AU  - Adedeji, IA
AU  - Adedoyin, RA
AU  - Adekanmbi, V
AU  - Adetokunboh, O
AU  - Adhena, BM
AU  - Adhikari, TR
AU  - Adib, MG
AU  - Adou, AK
AU  - Adsuar, JC
AU  - Afarideh, M
AU  - Afshari, M
AU  - Afshin, A
AU  - Agarwal, G
AU  - Aghayan, SA
AU  - Agius, D
AU  - Agrawal, A
AU  - Agrawal, S
AU  - Ahmadi, A
AU  - Ahmadi, M
AU  - Ahmadieh, F
AU  - Ahmed, MB
AU  - Ahmed, S
AU  - Akalu, TY
AU  - Akanda, AS
AU  - Akbari, ME
AU  - Akibu, M
AU  - Akinyemi, RO
AU  - Akinyemiju, T
AU  - Akseer, N
AU  - Alandab, T
AU  - Al-Aly, Z
AU  - Alam, K
AU  - Alam, T
AU  - Abujeer, A
AU  - Alebel, A
AU  - Alene, KA
AU  - Al-Eyadhy, A
AU  - Athabib, S
AU  - Ali, R
AU  - Alijanzadeh, M
AU  - Alizadeh-Nayaei, R
AU  - Aljunid, SM
AU  - Alkerwi, A
AU  - Alla, F
AU  - Allebeck, P
AU  - Allen, CA
AU  - Almasi, A
AU  - Al-Maskari, F
AU  - Al-Mekhlafi, HM
AU  - Alonso, J
AU  - Al-Raddadi, RM
AU  - Alsharif, U
AU  - Altirkawi, K
AU  - Alvis-Guzman, N
AU  - Amare, AT
AU  - Amenu, K
AU  - Amini, E
AU  - Ammar, W
AU  - Anber, NH
AU  - Anderson, JA
AU  - Andrei, CL
AU  - Androudi, S
AU  - Animut, MD
AU  - Anjomshoa, M
AU  - Ansari, H
AU  - Ansariadi, A
AU  - Ansha, MG
AU  - Antonio, CAT
AU  - Anwari, P
AU  - Appiah, LT
AU  - Aremu, O
AU  - Areri, HA
AU  - Ärnlöv, J
AU  - Arora, M
AU  - Aryal, KK
AU  - Asayesh, H
AU  - Asfaw, ET
AU  - Asgedom, SW
AU  - Asghar, RJ
AU  - Assadi, R
AU  - Ataro, Z
AU  - Atique, S
AU  - Atre, SR
AU  - Atteraya, MS
AU  - Ausloos, M
AU  - Avila-Burgos, L
AU  - Avokpaho, EFGA
AU  - Awasthi, A
AU  - Quintanilla, BPA
AU  - Ayele, HT
AU  - Ayele, Y
AU  - Ayer, R
AU  - Azarpazhooh, MR
AU  - Azzopardi, PS
AU  - Azzopardi-Muscat, N
AU  - Babalola, TK
AU  - Babazadeh, A
AU  - Badali, H
AU  - Badawi, A
AU  - Balakrishnan, K
AU  - Bali, AG
AU  - Banach, M
AU  - Banerjee, A
AU  - Banoub, JAM
AU  - Banstola, A
AU  - Barac, A
AU  - Barboza, MA
AU  - Barker-Collo, SL
AU  - Bärnighausen, TW
AU  - Barrero, LH
AU  - Barthelemy, CM
AU  - Bassat, Q
AU  - Basu, A
AU  - Basu, S
AU  - Battista, RJ
AU  - Baune, BT
AU  - Baynes, HW
AU  - Bazargan-Hejazi, S
AU  - Bedi, N
AU  - Beghi, E
AU  - Behzadifar, M
AU  - Behzadifar, M
AU  - Béjot, Y
AU  - Bekele, BB
AU  - Belachew, AB
AU  - Belay, AG
AU  - Belay, SA
AU  - Belay, YA
AU  - Bell, ML
AU  - Bello, AK
AU  - Bennett, DA
AU  - Bensenor, IM
AU  - Benzian, H
AU  - Berhane, A
AU  - Berhe, AK
AU  - Berman, AE
AU  - Bernabe, E
AU  - Bernstein, RS
AU  - Bertolacci, GJ
AU  - Beuran, M
AU  - Beyranvand, T
AU  - Bhala, N
AU  - Bhalla, A
AU  - Bhansali, A
AU  - Bhattarai, S
AU  - Bhaumik, S
AU  - Bhutta, ZA
AU  - Biadgo, B
AU  - Biehl, MH
AU  - Bijani, A
AU  - Rikbov, B
AU  - Bililign, N
AU  - Bin Sayeed, MS
AU  - Birlik, SM
AU  - Birungi, C
AU  - Bisanzio, D
AU  - Biswas, T
AU  - Bitew, H
AU  - Bizuneh, H
AU  - Bjertness, E
AU  - Bobasa, EM
AU  - Boufous, S
AU  - Bourne, R
AU  - Bozorgmehr, K
AU  - Bragazzi, NL
AU  - Brainin, M
AU  - Brant, LC
AU  - Brauer, M
AU  - Brazinova, A
AU  - Breitborde, NJK
AU  - Briant, PS
AU  - Britton, G
AU  - Brugha, T
AU  - Bukhman, G
AU  - Busse, R
AU  - Butt, ZA
AU  - Cahuana-Hurtado, L
AU  - Callender, CSKH
AU  - Campos-Nonato, IR
AU  - Rincon, JCC
AU  - Cano, J
AU  - Car, J
AU  - Car, M
AU  - Cárdenas, R
AU  - Carrero, JJ
AU  - Carter, A
AU  - Carvalho, F
AU  - Castañeda-Oduela, CA
AU  - Rivas, JC
AU  - Castro, F
AU  - Causey, K
AU  - Çavlin, A
AU  - Cercy, KM
AU  - Cerin, E
AU  - Chaiah, Y
AU  - Chalek, J
AU  - Chang, HY
AU  - Chang, JC
AU  - Chattopadhyay, A
AU  - Chattu, VK
AU  - Chaturvedi, P
AU  - Chiang, PPC
AU  - Chin, KL
AU  - Chisumpa, VH
AU  - Chitheer, A
AU  - Choi, JYJ
AU  - Chowdhury, R
AU  - Christensen, H
AU  - Christopher, DJ
AU  - Chung, SC
AU  - Cicuttini, FM
AU  - Ciobanu, LG
AU  - CiriIlo, M
AU  - Claro, RM
AU  - Classen, TKD
AU  - Cohen, AJ
AU  - Collado-Mateo, D
AU  - Cooper, C
AU  - Cooper, LT
AU  - Cornaby, L
AU  - Cortinovis, M
AU  - Costa, M
AU  - Cousin, E
AU  - Cromwell, EA
AU  - Crowe, CS
AU  - Cunningham, M
AU  - Daba, AK
AU  - Dadi, AF
AU  - Dandona, L
AU  - Dandona, R
AU  - Hang, AK
AU  - Dargan, PI
AU  - Daryani, A
AU  - Das, SK
AU  - Das Gupta, R
AU  - das Neves, J
AU  - Dasa, TT
AU  - Dash, AP
AU  - Davis, AC
AU  - Davitoiu, DV
AU  - Davletov, K
AU  - Dayama, A
AU  - de Courten, B
AU  - De Leo, D
AU  - De Neve, JW
AU  - De Steur, H
AU  - Degefa, MG
AU  - Degenhardt, L
AU  - Degfie, TT
AU  - Deiparine, S
AU  - Dellavalle, RP
AU  - Demoz, GT
AU  - Demtsu, B
AU  - Denova-Gutiérrez, E
AU  - Deribe, K
AU  - Dervenis, N
AU  - Dessie, GA
AU  - Dey, S
AU  - Dharmaratne, SD
AU  - Dhimal, M
AU  - Dicker, D
AU  - Dinberu, MT
AU  - Ding, EI
AU  - Djalalinia, S
AU  - Do, HP
AU  - Dokova, K
AU  - Doku, DT
AU  - Douwes-Schultz, D
AU  - Driscoll, TR
AU  - Duan, LL
AU  - Dubey, M
AU  - Dubljanin, E
AU  - Duken, EE
AU  - Duncan, BB
AU  - Duraes, AR
AU  - Ebrahimpour, S
AU  - Edvardsson, D
AU  - El Bcheraoui, C
AU  - Eldrenkamp, E
AU  - El-Khatib, Z
AU  - Elyazar, IRF
AU  - Enayati, A
AU  - Endries, AY
AU  - Eshrati, B
AU  - Eskandanieh, S
AU  - Esteghamati, A
AU  - Esteghamati, S
AU  - Estep, K
AU  - Fakhar, M
AU  - Fakhim, H
AU  - Fanzo, J
AU  - Faramarzi, M
AU  - Fareed, M
AU  - Farhadi, F
AU  - Farid, TA
AU  - Farinha, CSES
AU  - Tarioli, A
AU  - Faro, A
AU  - Farvid, MS
AU  - Farzadfar, F
AU  - Farzaei, MH
AU  - Tarzam, H
AU  - Fazaeli, AA
AU  - Fazeli, MS
AU  - Feigin, VL
AU  - Feigl, AB
AU  - Fekadu, W
AU  - Feldman, R
AU  - Fentahun, N
AU  - Fereshtehnejad, SM
AU  - Fernandes, E
AU  - Fernandes, JC
AU  - Feyissa, GT
AU  - Fijabi, DO
AU  - Filip, I
AU  - Finegold, S
AU  - Finger, JD
AU  - Tischer, F
AU  - Fitzmaurice, C
AU  - Flor, LS
AU  - Foigt, NA
AU  - Foreman, KJ
AU  - Frank, TD
AU  - Franklin, RC
AU  - Fukumoto, T
AU  - Fukutaki, K
AU  - Fuller, JE
AU  - Fürst, T
AU  - Furtado, JM
AU  - Gakidou, E
AU  - Gallus, S
AU  - Gankpe, FG
AU  - Gansevoort, RT
AU  - Garcia, AC
AU  - Garcia-Basteiro, AL
AU  - Garcia-Gordillo, MA
AU  - Gardner, WM
AU  - Gebre, AK
AU  - Gebre, T
AU  - Gebregergs, GB
AU  - Gebrehiwot, TT
AU  - Gebremedhin, AT
AU  - Gebremichael, B
AU  - Gebremichael, TG
AU  - Gelano, TF
AU  - Geleijnse, JM
AU  - Geramo, YCD
AU  - Getachew, S
AU  - Gething, PW
AU  - Gezae, KE
AU  - Ghadami, MR
AU  - Ghadimi, R
AU  - Ghadiri, K
AU  - Ghasemi-Kasman, M
AU  - Ghiasvand, H
AU  - Ghimire, M
AU  - Choshal, AG
AU  - Giampaoli, S
AU  - Gill, PS
AU  - Gill, TK
AU  - Giussani, G
AU  - Gnedovskaya, EV
AU  - Goldberg, EM
AU  - Goli, S
AU  - Gona, PN
AU  - Goodridge, A
AU  - Gopalani, SV
AU  - Gorman, TM
AU  - Goto, A
AU  - Coulart, AC
AU  - Coulart, BNG
AU  - Grada, A
AU  - Griswold, MG
AU  - Grosso, G
AU  - Gugnani, HCC
AU  - Guillemin, F
AU  - Guimaraes, ALS
AU  - Guo, YM
AU  - Gupta, PC
AU  - Gupta, R
AU  - Gupta, R
AU  - Gupta, T
AU  - Ha, GH
AU  - Haagsma, JA
AU  - Hachinski, V
AU  - Hafezi-Nejad, N
AU  - Bidgoli, HH
AU  - Hagos, TB
AU  - Haile, MT
AU  - Hailegiyorgis, TT
AU  - Hailu, GB
AU  - Haj-Mirzaian, A
AU  - Haj-Mirzaian, A
AU  - Hamadeh, RR
AU  - Hamidi, S
AU  - Hankey, GJ
AU  - Harb, HL
AU  - Harikrishnan, S
AU  - Haririan, H
AU  - Haro, JM
AU  - Hasan, M
AU  - Hassankhani, H
AU  - Hassell, HY
AU  - Havmoeller, R
AU  - Hawley, CN
AU  - Hay, SI
AU  - He, YH
AU  - Hedayatizadeh-Omran, A
AU  - Hegazy, MI
AU  - Heibati, B
AU  - Heidari, B
AU  - Heidari, M
AU  - Hendrie, D
AU  - Henok, A
AU  - Heredia-Pi, I
AU  - Herteliu, C
AU  - Heydarpour, B
AU  - Heydarpour, F
AU  - Heydarpour, S
AU  - Hibstu, DT
AU  - Híjar, M
AU  - Hoek, HW
AU  - Hoffman, DJ
AU  - Hole, MK
AU  - Rad, EH
AU  - Hoogar, P
AU  - Horita, N
AU  - Hosgood, HD
AU  - Hosseini, SM
AU  - Hosseinzadeff, M
AU  - Hostiuc, A
AU  - Hostiuc, S
AU  - Hotez, PJ
AU  - Hoy, DG
AU  - Hsairi, M
AU  - Hsiao, T
AU  - Hu, GQ
AU  - Huang, JJ
AU  - Hughes, C
AU  - Huynh, CK
AU  - Igumbor, EU
AU  - Ikeda, CT
AU  - Ilesanmi, OS
AU  - Iqbal, U
AU  - Irvani, SSN
AU  - Irvine, CMS
AU  - Islam, SMS
AU  - Islami, F
AU  - Ivers, RQ
AU  - Izadi, N
AU  - Jacobsen, KH
AU  - Jahangiry, L
AU  - Jahanmehr, N
AU  - Jain, SK
AU  - Jakovljevic, M
AU  - Jalu, MT
AU  - Jamal, AA
AU  - James, SI
AU  - Jassal, SK
AU  - Javanbakht, M
AU  - Jayatilleke, AU
AU  - Jeemon, P
AU  - Jha, RP
AU  - Jha, V
AU  - Ji, JS
AU  - Johnson, CO
AU  - Johnson, SC
AU  - Jonas, JB
AU  - Jonnagaddala, J
AU  - Shushtari, ZJ
AU  - Joshi, A
AU  - Jozwiak, JJ
AU  - Jungari, SB
AU  - Jürisson, M
AU  - Madhanraj, K
AU  - Kabir, Z
AU  - Kadel, R
AU  - Kahsay, A
AU  - Kahssay, M
AU  - Kalani, R
AU  - Kapil, U
AU  - Karami, M
AU  - Marin, BK
AU  - Karanikolos, M
AU  - Karimi, N
AU  - Karimi, SM
AU  - Karimi-Sari, H
AU  - Kasaeian, A
AU  - Kassa, DH
AU  - Kassa, GM
AU  - Kassa, TD
AU  - Kassa, ZY
AU  - Kassebaum, NJ
AU  - Katikireddi, SV
AU  - Kaul, A
AU  - Kawakami, N
AU  - Kazemi, Z
AU  - Karyani, AK
AU  - Kazi, DS
AU  - Prakash, KC
AU  - Kebede, S
AU  - Keiyoro, PN
AU  - Kemmer, L
AU  - Kemp, GR
AU  - Kengne, AP
AU  - Keren, A
AU  - Kesavachandran, CN
AU  - Khader, YS
AU  - Khafaei, B
AU  - Khafaie, MA
AU  - Khajavi, A
AU  - Khalid, N
AU  - Khalil, IA
AU  - Khan, EA
AU  - Khan, MS
AU  - Khan, MA
AU  - Khang, YH
AU  - Khanna, T
AU  - Khater, MM
AU  - Khatony, A
AU  - Khazaeipour, Z
AU  - Khazaie, H
AU  - Khoja, AT
AU  - Khosravi, A
AU  - Khosravi, MH
AU  - Khubchandani, J
AU  - Kiadaliri, AA
AU  - Kiarie, HW
AU  - Kibret, GD
AU  - Kiirithio, DN
AU  - Kim, D
AU  - Kim, JY
AU  - Kim, YE
AU  - Kim, YJ
AU  - Kimokoti, RW
AU  - Kinfu, Y
AU  - Kinra, S
AU  - Kisa, A
AU  - Kissimova-Skarbek, K
AU  - Kissoon, N
AU  - Kivimäki, M
AU  - Kocamik, JM
AU  - Kochhar, S
AU  - Kokubo, Y
AU  - Kolola, T
AU  - Kopec, JA
AU  - Kosek, MN
AU  - Kosen, S
AU  - Koul, PA
AU  - Koyanagi, A
AU  - Kravchenko, MA
AU  - Krishan, K
AU  - Krohn, KJ
AU  - Defo, BK
AU  - Bicer, BK
AU  - Kudom, AA
AU  - Kulikoff, XR
AU  - Kumar, GA
AU  - Kumar, M
AU  - Kumar, P
AU  - Kutz, MJ
AU  - Kyu, HH
AU  - Lachat, C
AU  - Lad, DP
AU  - Lad, SD
AU  - Lafranconi, A
AU  - Lagat, AK
AU  - Lal, DK
AU  - Lalloo, R
AU  - Lam, H
AU  - Lami, FH
AU  - Lamichhane, P
AU  - Lan, Q
AU  - Lang, JJ
AU  - Lansingh, V
AU  - Lansky, S
AU  - Larson, HJ
AU  - Larsson, A
AU  - Laryea, DO
AU  - Lassi, ZS
AU  - Latifi, A
AU  - Lau, KMM
AU  - Laxmaiah, A
AU  - Lazarus, JV
AU  - Leasher, JL
AU  - Lebedev, G
AU  - Ledesma, JR
AU  - Lee, JB
AU  - Lee, PH
AU  - Leever, AT
AU  - Leigh, J
AU  - Leinsalu, M
AU  - Leshargie, CT
AU  - Leung, J
AU  - Lewycka, S
AU  - Li, SS
AU  - Li, XH
AU  - Li, YC
AU  - Liang, J
AU  - Hang, X
AU  - Liben, ML
AU  - Lim, LL
AU  - Limenih, MA
AU  - Linn, S
AU  - Liu, SW
AU  - Liu, Y
AU  - Lodha, R
AU  - Logroscino, G
AU  - Lopez, AD
AU  - Lorkowski, S
AU  - Lotufo, PA
AU  - Lucchesi, LR
AU  - Lyons, RA
AU  - Macarayan, ERK
AU  - Mackay, MT
AU  - Maddison, ER
AU  - Madotto, F
AU  - Maghavani, DP
AU  - Magis-Rodriguez, C
AU  - Mahotra, NB
AU  - Majdan, M
AU  - Majdzadeh, R
AU  - Majeed, A
AU  - Malekzadeh, R
AU  - Malta, DC
AU  - Mamun, AA
AU  - Manda, AL
AU  - Rano, LGM
AU  - Mangalam, S
AU  - Manguerra, H
AU  - Mansournia, MA
AU  - Mapoma, CC
AU  - Maravilla, JC
AU  - Marcenes, W
AU  - Marks, A
AU  - Martin, RV
AU  - Martins, SCO
AU  - Martins-Melo, FR
AU  - Madopullo, I
AU  - Mashamba-Thompson, TP
AU  - Massenburg, BB
AU  - Mathin, MR
AU  - Maulik, PK
AU  - Mazidi, M
AU  - McAlinden, C
AU  - McGrath, JJ
AU  - McKee, M
AU  - McMahon, BJ
AU  - Mehata, S
AU  - Mehndiratta, MM
AU  - Mehrotra, R
AU  - Mehta, KM
AU  - Mehta, V
AU  - Mejia-Rodriguez, F
AU  - Mekonen, T
AU  - Mekonnen, TCC
AU  - Meles, HG
AU  - Melese, A
AU  - Melku, M
AU  - Memiah, PTN
AU  - Memish, ZA
AU  - Mendoza, W
AU  - Mengistu, DT
AU  - Mengistu, G
AU  - Mensah, GA
AU  - Mensink, GBM
AU  - Mereta, ST
AU  - Meretoja, A
AU  - Meretoja, TJ
AU  - Mestrovic, T
AU  - Mezgebe, HB
AU  - Miazgowski, B
AU  - Miazgowski, T
AU  - Millear, AI
AU  - Miller, TR
AU  - Miller-Petrie, MK
AU  - Milne, GJ
AU  - Mini, GK
AU  - Minnig, SP
AU  - Mirabi, P
AU  - Mirarefin, M
AU  - Mintakhimoty, EM
AU  - Misganaw, AT
AU  - Mitchell, PB
AU  - Moazen, B
AU  - Moghadamnia, AA
AU  - Mohajer, B
AU  - Mohammad, KA
AU  - Mohammadi, M
AU  - Mohammadifard, N
AU  - Mohammadnia-Afrouzi, M
AU  - Mohammed, MA
AU  - Mohammed, S
AU  - Mohan, MBV
AU  - Mohan, V
AU  - Mohebi, F
AU  - Moltra, M
AU  - Mokdad, AH
AU  - Molokhia, M
AU  - Monasta, L
AU  - Montañez, JC
AU  - Moosazadeh, M
AU  - Moradi, G
AU  - Moradi, M
AU  - Moradi-Lakeh, M
AU  - Moradinazar, M
AU  - Moraga, P
AU  - Morawska, L
AU  - Morgado-da-Costa, J
AU  - Morisaki, N
AU  - Morrison, SD
AU  - Mosapour, A
AU  - Moschos, MM
AU  - Mountjoy-Venning, WC
AU  - Mouodi, S
AU  - Mousavi, SM
AU  - Muche, AA
AU  - Muchie, KF
AU  - Mueller, UO
AU  - Muhammed, OSS
AU  - Mukhopadhyay, S
AU  - Mullany, EC
AU  - Muller, K
AU  - Mumford, JE
AU  - Murhekar, M
AU  - Murthy, GVS
AU  - Murthy, S
AU  - Musa, J
AU  - Musa, KI
AU  - Mustafa, G
AU  - Muthupandian, S
AU  - Nabhan, AF
AU  - Nachega, JB
AU  - Nagarajan, AJ
AU  - Nagel, G
AU  - Naghavi, M
AU  - Naheed, A
AU  - Nahvijou, A
AU  - Naidoo, K
AU  - Naik, G
AU  - Naik, N
AU  - Najafi, F
AU  - Naldi, L
AU  - Nam, HS
AU  - Nangia, V
AU  - Nansseu, JR
AU  - Nascimento, BR
AU  - Nawaz, H
AU  - Neamati, N
AU  - Negoi, I
AU  - Negoi, RI
AU  - Neupane, S
AU  - Newton, CRJ
AU  - Ngalesoni, FN
AU  - Ngunjiri, JW
AU  - Nguyen, A
AU  - Nguyen, G
AU  - Nguyen, H
AU  - Nguyen, HLT
AU  - Nguyen, HT
AU  - Nguyen, M
AU  - Nichols, E
AU  - Nigatu, SG
AU  - Ningrum, DNA
AU  - Nirayo, YL
AU  - Nisar, MI
AU  - Nixon, MR
AU  - Nolutshungu, N
AU  - Nomura, M
AU  - Norheim, OF
AU  - Noroozi, M
AU  - Norrving, B
AU  - Noubiap, JJ
AU  - Nouri, HR
AU  - Shiadeh, MN
AU  - Nowroozi, MR
AU  - Nyasulu, PS
AU  - Obermeyer, CM
AU  - Ofori-Asenso, R
AU  - Ogah, OS
AU  - Ogbo, FA
AU  - Oh, IH
AU  - Okoro, A
AU  - Oladimeji, KE
AU  - Oladimeji, O
AU  - Olagunju, AT
AU  - Olagunju, T
AU  - Olivares, PR
AU  - Olsen, HE
AU  - Olusanya, BO
AU  - Olusanya, JO
AU  - Ong, KL
AU  - Ong, SK
AU  - Oommen, AM
AU  - Opio, JN
AU  - Oren, E
AU  - Oros, A
AU  - Ortega-Altamirano, DDV
AU  - Ortiz, A
AU  - Ortiz, JR
AU  - Ortiz-Panozo, E
AU  - Ota, E
AU  - Otstavnov, SS
AU  - Owolabi, MO
AU  - Mahesh, PA
AU  - Pakhale, S
AU  - Pakhare, AP
AU  - Pan, WH
AU  - Pana, A
AU  - Panda, BK
AU  - Panda-Jonas, S
AU  - Pandian, JD
AU  - Papantoniou, N
AU  - Park, EK
AU  - Parry, CDH
AU  - Parsian, H
AU  - Patel, S
AU  - Pati, S
AU  - Patle, A
AU  - Patton, GC
AU  - Paturi, VR
AU  - Paudel, D
AU  - Paulson, KR
AU  - Pearce, N
AU  - Peprah, EK
AU  - Pereira, DM
AU  - Perico, N
AU  - Pervaiz, A
AU  - Pesudovs, K
AU  - Petri, WA
AU  - Petzold, M
AU  - Phillips, MR
AU  - Pigott, DM
AU  - Pillay, JD
AU  - Pirsaheb, M
AU  - Pletcher, M
AU  - Pond, CD
AU  - Postma, MJ
AU  - Pourshams, A
AU  - Poustchi, H
AU  - Prabhakaran, D
AU  - Prakash, S
AU  - Prasad, N
AU  - Purcell, CA
AU  - Pyakurel, M
AU  - Qorbani, M
AU  - Quansah, R
AU  - Radfar, A
AU  - Rafay, A
AU  - Rafiei, A
AU  - Rahim, F
AU  - Rahimi, K
AU  - Rahimi-Movaghar, M
AU  - Rahimi-Movaghar, V
AU  - Rahman, M
AU  - Rahman, KS
AU  - Rahman, MHU
AU  - Rahman, MA
AU  - Rahman, SU
AU  - Rai, RK
AU  - Rajati, F
AU  - Rajsic, S
AU  - Ram, U
AU  - Rana, SM
AU  - Ranabhat, CL
AU  - Ranjan, P
AU  - Rasella, D
AU  - Rawaf, DL
AU  - Rawaf, S
AU  - Razo-García, C
AU  - Reddy, KS
AU  - Reiner, RC
AU  - Reis, C
AU  - Reitsma, MB
AU  - Remuzzi, G
AU  - Renzaho, AMN
AU  - Resnikoff, S
AU  - Reynales-Shigematsu, LM
AU  - Rezaei, S
AU  - Rezaeian, S
AU  - Rezai, MS
AU  - Riahi, SM
AU  - Ribeiro, ALP
AU  - Rios-Blancas, MJ
AU  - Roba, KT
AU  - Roberts, NLS
AU  - Roever, L
AU  - Ronfani, L
AU  - Roshandel, G
AU  - Rostami, A
AU  - Roth, GA
AU  - Roy, A
AU  - Rubagotti, E
AU  - Ruhago, GM
AU  - Sabde, YD
AU  - Sachdev, PS
AU  - Saddik, B
AU  - Sadeghi, E
AU  - Safari, H
AU  - Safari, Y
AU  - Safari-Faramani, R
AU  - Safdarian, M
AU  - Safi, S
AU  - Safiri, S
AU  - Sagar, R
AU  - Sahebkar, A
AU  - Sahraian, MA
AU  - Sajadi, HS
AU  - Salam, N
AU  - Salama, JS
AU  - Salamati, P
AU  - Saldanha, RD
AU  - Saleem, Z
AU  - Salimi, Y
AU  - Salimzadeh, H
AU  - Salomon, JA
AU  - Salvi, SS
AU  - Satz, I
AU  - Sambala, EZ
AU  - Samy, AM
AU  - Sanabria, J
AU  - Niño, MDS
AU  - Santos, IS
AU  - Milicevic, MMS
AU  - Jose, BPS
AU  - Sardana, M
AU  - Sarker, AR
AU  - Sarrafzadegan, N
AU  - Sartorius, B
AU  - Sarvi, S
AU  - Sathian, B
AU  - Satpathy, M
AU  - Savic, M
AU  - Sawant, AR
AU  - Sawhney, M
AU  - Saxena, S
AU  - Saylan, M
AU  - Sayyah, M
AU  - Schaeffner, E
AU  - Schmidt, MI
AU  - Schneider, IJC
AU  - Schötffer, B
AU  - Schutte, AE
AU  - Schwebel, DC
AU  - Schwendicke, F
AU  - Seedat, S
AU  - Sekerija, M
AU  - Sepanlou, SG
AU  - Serván-Mori, E
AU  - Seyedmousavi, S
AU  - Shabaninejad, H
AU  - Shackelford, KA
AU  - Shafieesabet, A
AU  - Shaheen, AA
AU  - Shaikh, MA
AU  - Shams-Beyranvand, M
AU  - Shamsi, MB
AU  - Shamsizadeff, M
AU  - Sharafi, H
AU  - Sharafi, K
AU  - Sharif, M
AU  - Sharif-Alhoseini, M
AU  - Sharma, J
AU  - Sharma, R
AU  - Sharma, SK
AU  - She, J
AU  - Sheikh, A
AU  - Shey, MS
AU  - Shi, PL
AU  - Shibuya, K
AU  - Shields, C
AU  - Shifa, GT
AU  - Shiferaw, MS
AU  - Shigematsu, M
AU  - Shin, R
AU  - Shirkoohi, R
AU  - Shirude, S
AU  - Shishani, K
AU  - Shiue, I
AU  - Shokraneh, F
AU  - Shoman, H
AU  - Shrime, MG
AU  - Shukla, SR
AU  - Si, S
AU  - Siabani, S
AU  - Sibai, AM
AU  - Siddiqi, TJ
AU  - Sigfusdottir, TD
AU  - Silpakit, N
AU  - Silva, DAS
AU  - Silva, JP
AU  - da Silva, NT
AU  - Silveira, DGA
AU  - Singh, JA
AU  - Singh, NP
AU  - Singh, OP
AU  - Singh, PK
AU  - Singh, V
AU  - Sinha, DN
AU  - Skiadaresi, E
AU  - Sliwa, K
AU  - Smith, AE
AU  - Smith, M
AU  - Soares, AM
AU  - Sobaih, BH
AU  - Sobhani, S
AU  - Soljak, M
AU  - Soofi, M
AU  - Soosaraei, M
AU  - Sorensen, RJD
AU  - Soriano, JB
AU  - Soshnikov, S
AU  - Soyiri, IN
AU  - Spinelli, A
AU  - Sposato, LA
AU  - Sreeramareddy, CT
AU  - Srinivasan, RG
AU  - Srinivasan, V
AU  - Stanaway, JD
AU  - Starodubov, VI
AU  - Stathopoulou, V
AU  - Steckling, N
AU  - Stein, DJ
AU  - Stewart, LG
AU  - Stockfelt, L
AU  - Stokes, MA
AU  - Straif, K
AU  - Sudaryanto, A
AU  - Sufiyan, MB
AU  - Sunguya, BF
AU  - Sur, PJ
AU  - Sutradhar, I
AU  - Sykes, BL
AU  - Sylaja, PN
AU  - Sylte, D
AU  - Szoeke, CEI
AU  - Tabarés-Seisdedos, R
AU  - Tabuchi, T
AU  - Tadakamatha, SK
AU  - Tamirat, KS
AU  - Tandon, N
AU  - Tanser, FC
AU  - Tassew, AA
AU  - Tassew, SG
AU  - Tavakkoli, M
AU  - Taveira, N
AU  - Tawye, NT
AU  - Tehrani-Banihashemi, A
AU  - Tekalign, TG
AU  - Tekle, MG
AU  - Temesgen, H
AU  - Temsah, MH
AU  - Temsah, O
AU  - Terkawi, AS
AU  - Teshale, MY
AU  - Teshome, DF
AU  - Tessema, B
AU  - Teweldemedhin, M
AU  - Thakur, JS
AU  - Thankappan, KR
AU  - Theis, A
AU  - Thintnavukkarasu, S
AU  - Thomas, LA
AU  - Thomas, N
AU  - Thomson, AJ
AU  - Thrift, AC
AU  - Tilahun, B
AU  - To, QG
AU  - Tobe-Gai, R
AU  - Tonelli, M
AU  - Topor-Madry, R
AU  - Torre, AE
AU  - Tortajada-Girbés, M
AU  - Tovani-Palone, MR
AU  - Towbin, JA
AU  - Tran, BX
AU  - Tran, KB
AU  - Tran, TT
AU  - Tripathy, SP
AU  - Troeger, CE
AU  - Truelsen, TC
AU  - Tsadik, AG
AU  - Car, LT
AU  - Tuzcu, EM
AU  - Tymeson, HD
AU  - Ukwaja, KN
AU  - Ullah, I
AU  - Updike, RI
AU  - Usman, MS
AU  - Uthman, OA
AU  - Vaduganathan, M
AU  - Vaezi, A
AU  - Vaidya, G
AU  - Valdez, PR
AU  - van Donkelaar, A
AU  - Varavikova, E
AU  - Vasankari, TJ
AU  - Venketasubramanian, N
AU  - Vidavalur, R
AU  - Villafaina, S
AU  - Violante, FS
AU  - Vladimirov, SK
AU  - Vlassov, V
AU  - Vollmer, S
AU  - Vollset, SE
AU  - Vbs, T
AU  - Vosoughi, K
AU  - Vujcic, IS
AU  - Wagner, GR
AU  - Wagnew, FS
AU  - Waheed, Y
AU  - Watson, JI
AU  - Wang, YP
AU  - Wang, YP
AU  - Wassie, MM
AU  - Weiderpass, E
AU  - Weintraub, RG
AU  - Weiss, J
AU  - Weldegebreal, F
AU  - Weldegwergs, KG
AU  - Werdecker, A
AU  - Ayaliew, A
AU  - West, WTL
AU  - Westerman, R
AU  - Whisnant, JL
AU  - Whiteford, HA
AU  - Widecka, J
AU  - Widecka, K
AU  - Wijeratne, T
AU  - Wither, LB
AU  - Winkler, AS
AU  - Wiyeh, AB
AU  - Wiysonge, CS
AU  - Wolde, HF
AU  - Wolfe, CDA
AU  - Wu, SL
AU  - Xavier, D
AU  - Xu, GL
AU  - Xu, RS
AU  - Yadollahpour, A
AU  - Jabbari, SHY
AU  - Yakob, B
AU  - Yamada, T
AU  - Tan, LJL
AU  - Yano, Y
AU  - Yaseri, M
AU  - Yasin, YJ
AU  - Ye, PP
AU  - Tearwood, JA
AU  - Yeshaneh, A
AU  - Yimer, EM
AU  - Yip, P
AU  - Yirsaw, BD
AU  - Yisma, E
AU  - Yonemoto, N
AU  - Yonga, G
AU  - Yoon, SJ
AU  - Yotebieng, M
AU  - Younis, MZ
AU  - Yousefifard, M
AU  - Yu, CH
AU  - Bin Zaman, S
AU  - Zamani, M
AU  - Zara, Z
AU  - Zavala-Arciniega, L
AU  - Zegeye, DT
AU  - Zegeye, EA
AU  - Zeleke, AJ
AU  - Zendehdel, K
AU  - Zerfit, TA
AU  - Zhang, AL
AU  - Zhang, XY
AU  - Zhou, MG
AU  - Zhu, J
AU  - Zimsen, SRM
AU  - Zodpey, S
AU  - Zoeckler, L
AU  - Zucker, I
AU  - Zuhlke, LJJ
AU  - Lim, SS
AU  - Murray, CJL
A1  - GBD 2017 SDG Collaborators
TI  - Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017
T2  - LANCET
KW  - CARDIOVASCULAR-DISEASE
KW  - GENDER-DIFFERENCES
KW  - LIFE EXPECTANCY
KW  - ALCOHOL-USE
KW  - SUICIDE
KW  - SMOKING
KW  - CONSUMPTION
KW  - CESSATION
KW  - MORTALITY
KW  - TOBACCO
AB  - Background Efforts to establish the 2015 baseline and monitor early implementation of the UN Sustainable Development Goals (SDGs) highlight both great potential for and threats to improving health by 2030. To fully deliver on the SDG aim of "leaving no one behind", it is increasingly important to examine the health-related SDGs beyond national-level estimates. As part of the Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017), we measured progress on 41 of 52 health -related SDG indicators and estimated the health-related SDG index for 195 countries and territories for the period 1990-2017, projected indicators to 2030, and analysed global attainment.
   Methods We measured progress on 41 health-related S DG indicators from 1990 to 2017, an increase of four indicators since GBD 2016 (new indicators were health worker density, sexual violence by non-intimate partners, population census status, and prevalence of physical and sexual violence [reported separately]). We also improved the measurement of several previously reported indicators. We constructed national-level estimates and, for a subset of health-related SDGs, examined indicator-level differences by sex and Socio-demographic Index (SDI) quintile. We also did subnational assessments of performance for selected countries. To construct the health related SDG index, we transformed the value for each indicator on a scale of 0-100, with 0 as the 2.5th percentile and 100 as the 97.5th percentile of 1000 draws calculated from 1990 to 2030, and took the geometric mean of the scaled indicators by target. To generate projections through 2030, we used a forecasting framework that drew estimates from the broader GBD study and used weighted averages of indicator-specific and country-specific annualised rates of change from 1990 to 2017 to inform future estimates. We assessed attainment of indicators with defined targets in two ways: first, using mean values projected for 2030, and then using the probability of attainment in 2030 calculated from 1000 draws. We also did a global attainment analysis of the feasibility of attaining SDG targets on the basis of past trends. Using 2015 global averages of indicators with defined SDG targets, we calculated the global annualised rates of change required from 2015 to 2030 to meet these targets, and then identified in what percentiles the required global annualised rates of change fell in the distribution of country-level rates of change from 1990 to 2015. We took the mean of these global percentile values across indicators and applied the past rate of change at this mean global percentile to all health-related SDG indicators, irrespective of target definition, to estimate the equivalent 2030 global average value and percentage change from 2015 to 2030 for each indicator.
   Findings The global median health-related SDG index in 2017 was 59.4 (IQR 35.4-67.3), ranging from a low of 11.6 (95% uncertainty interval 9.6-14.0) to a high of 84.9 (83.1-86.7). SDG index values in countries assessed at the subnational level varied substantially particularly in China and India, although scores in Japan and the UK were more homogeneous. Indicators also varied by SDI quintile and sex, with males having worse outcomes than females for non-communicable disease (NCD) mortality, alcohol use, and smoking, among others. Most countries were projected to have a higher health-related SDG index in 2030 than in 2017, while country-level probabilities of attainment by 2030 varied widely by indicator. Under-5 mortality, neonatal mortality, maternal mortality ratio, and malaria indicators had the most countries with at least 95% probability of target attainment. Other indicators, including NCD mortality and suicide mortality, had no countries projected to meet corresponding SDG targets on the basis of projected mean values for 2030 but showed some probability of attaimnent by 2030. For some indicators, including child malnutrition, several infectious diseases, and most violence measures, the annualised rates of change required to meet SDG targets far exceeded the pace of progress achieved by any country in the recent past. We found that applying the mean global annualised rate of change to indicators without defined targets would equate to about 19% and 22% reductions in global smoking and alcohol consumption, respectively; a 47% decline in adolescent birth rates; and a more than 85% increase in health worker density per 1000 population by 2030.
   Interpretation The GBD study offers a unique, robust platform for monitoring the health -related SDGs across demographic and geographic dimensions. Our findings underscore the importance of increased collection and analysis of disaggregated data and highlight where more deliberate design or targeting of interventions could accelerate progress in attaining the SDGs. Current projections show that many health -related SDG indicators, NCDs, NCD-related risks, and violence -related indicators will require a concerted shift away from what might have driven past gains curative interventions in the case of NCDs towards multisectoral, prevention -oriented policy action and investments to achieve SDG aims. Notably, several targets, if they are to be met by 2030, demand a pace of progress that no country has achieved in the recent past. The future is fundamentally uncertain, and no model can fully predict what breakthroughs or events might alter the course of the S DGs. What is clear is that our actions or inaction today will ultimately dictate how close the world, collectively, can get to leaving no one behind by 2030.
   Copyright (C) 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
AD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USAAD  - Univ Washington, Dept Global Hlth, Seattle, WA 98195 USAAD  - Univ Washington, Dept Hlth Metr Sci, Seattle, WA 98195 USAAD  - Univ Washington, Dept Med, Seattle, WA 98195 USAAD  - Univ Washington, Dept Neurol, Seattle, WA 98195 USAAD  - Univ Washington, Dept Surg, Seattle, WA 98195 USAAD  - Univ Washington, Div Cardiol, Seattle, WA 98195 USAAD  - Univ Washington, Div Hematol, Seattle, WA 98195 USAAD  - Univ Washington, Div Plast Surg, Seattle, WA 98195 USAAD  - Univ Washington, Seattle, WA 98195 USAAD  - Natl Inst Publ Hlth, Ctr Hlth Syst Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Dept Int Hlth & Collaborat, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Dept Tobacco Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Cuernavaca, Morelos, MexicoAD  - Haramaya Univ, Dept Med Lab Sci, Harar, EthiopiaAD  - Haramaya Univ, Dept Pediat, Harar, EthiopiaAD  - Haramaya Univ, Sch Nursing & Midwifery, Harar, EthiopiaAD  - Haramaya Univ, Sch Pharm, Harar, EthiopiaAD  - Haramaya Univ, Sch Publ Hlth, Harar, EthiopiaAD  - Haramaya Univ, Harar, EthiopiaAD  - Addis Ababa Univ, Coll Hlth Sci, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Coll Vet Med & Agr, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Dept Pharmacol & Clin Pharm, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Dept Prevent Med, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Dept Psychiat, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Sch Allied Hlth Sci, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Sch Nursing & Midwifery, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Sch Publ Hlth, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Addis Ababa, EthiopiaAD  - Univ Roma La Sapienza, Dept Law Philosophy & Econ Studies, Rome, ItalyAD  - Univ Tehran Med Sci, Brain & Spinal Cord Injury Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Canc Biol Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Canc Research Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Ctr Expertise Microbiol, Tehran, IranAD  - Univ Tehran Med Sci, Community Based Participatory Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Dept Anat, Tehran, IranAD  - Univ Tehran Med Sci, Dept Epidemiol & Biostat, Tehran, IranAD  - Univ Tehran Med Sci, Dept Hlth, Tehran, IranAD  - Univ Tehran Med Sci, Dept Hlth Management & Econ, Tehran, IranAD  - Univ Tehran Med Sci, Dept Pharmacol, Tehran, IranAD  - Univ Tehran Med Sci, Dept Urol, Tehran, IranAD  - Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, IranAD  - Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Oncol & Stein Cell Transplantat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Iran Natl Inst Hlth Res, Tehran, IranAD  - Univ Tehran Med Sci, Iranian Natl Ctr Addict Studies, Tehran, IranAD  - Univ Tehran Med Sci, Knowledge Utilizat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Multiple Sclerosis Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Noncommunicable Dis Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Sch Med, Tehran, IranAD  - Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Urooncol Res Ctr, Tehran, IranAD  - McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, CanadaAD  - McGill Univ, Montreal Neuroimaging Ctr, Montreal, PQ, CanadaAD  - McGill Univ, Montreal Neurol Inst, Montreal, PQ, CanadaAD  - Cairo Univ, Dept Med Parasitol, Cairo, EgyptAD  - Cairo Univ, Rmient Neurol, Cairo, EgyptAD  - Univ Calgary, Dept Oncol, Calgary, AB, CanadaAD  - Univ Calgary, Dept Med, Calgary, AB, CanadaAD  - Ain Shams Univ, Dept Entomol, Cairo, EgyptAD  - Ain Shams Univ, Dept Obstet & Gynecol, Cairo, EgyptAD  - Ain Shams Univ, Dept Oncol, Cairo, EgyptAD  - Kermanshah Univ Med Sci, Dept Anesthesiol, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Environm Hlth Engn, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Epidemiol & Biostat, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Food Technol & Qual Control, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Hlth Educ M Promot, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Psychiat, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Tradit & Complementary Med, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Urol, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Environm Determinants Hlth Research Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Fac Nursing & Midwifery, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Fac Nutr & Food Sci, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Fac Publ Hlth, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Imam Ali Cardiovasc Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Pharmaceut Sci Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Res Ctr Environm Determinants Hlth, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Sleep Disorders Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Sports Med & Rehabil, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Kermanshah, IranAD  - Arak Univ Med Sci, Dept Epidemiol, Arak, IranAD  - Multiple Sclerosis Res Ctr, Tehran, IranAD  - Manonmaniam Sundaranar Univ, Dept Stat, Tirunelveli, IndiaAD  - Univ Gondar, Dept Clin Chem, Gondar, EthiopiaAD  - Univ Gondar, Dept Epidemiol & Biostat, Gondar, EthiopiaAD  - Univ Gondar, Dept Med Microbiol, Gondar, EthiopiaAD  - Univ Gondar, Dept Med Parasitol, Gondar, EthiopiaAD  - Univ Gondar, Human Nutr Dept, Gondar, EthiopiaAD  - Univ Gondar, Inst Publ Hlth, Gondar, EthiopiaAD  - Univ Gondar, Gondar, EthiopiaAD  - Debre Markos Univ, Coll Hlth Sci, Debre Markos, EthiopiaAD  - Debre Markos Univ, Dept Publ Hlth, Debre Markos, EthiopiaAD  - Debre Markos Univ, Debre Markos, EthiopiaAD  - Mekelle Univ, Anat Unit, Mekelle, EthiopiaAD  - Mekelle Univ, Biomed Sci Div, Mekelle, EthiopiaAD  - Mekelle Univ, Clin Pharm Unit, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Diostat, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Environmental Hlth Sci, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Epidemiol, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Microbiol & Immunol, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Nutr & Dietet, Mekelle, EthiopiaAD  - Mekelle Univ, Inst Biomed Sci, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Med, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Nursing, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Pharm, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Publ Hlth, Mekelle, EthiopiaAD  - Mekelle Univ, Mekelle, EthiopiaAD  - Univ Hohenheim, Inst Biol Chem & Nutr, Stuttgart, GermanyAD  - Wollega Univ, Dept Hlth Sci, Nekentie, EthiopiaAD  - Wollega Univ, Dept Med, Lab Sci, Nekentie, EthiopiaAD  - Univ Med Sci, Sch Publ Hlth, Ondo, NigeriaAD  - Dupuytren Univ Hosp, Dept Cardiol, Limoges, FranceAD  - Univ Limoges, Inst Epidemiol, Limoges, FranceAD  - Weill Cornell Med Coll Qatar, Dept Healthcare Policy & Res, Doha, QatarAD  - Birzeit Univ, Inst Community & Publ Hlth, Birzeit, PalestineAD  - Baltir Dar Univ, Dept Nursing, Baltir Dar, EthiopiaAD  - Baltir Dar Univ, Dept Psychiat, Baltir Dar, EthiopiaAD  - Baltir Dar Univ, Dept Publ Hlth Nutr, Baltir Dar, EthiopiaAD  - Baltir Dar Univ, Baltir Dar, EthiopiaAD  - Benin Clin Res Inst, Cotonou, BeninAD  - Dongguk Univ, Dept Prevent Med, Gyeongju, South KoreaAD  - Kathmandu Univ, Dept Community Med, Devdaha, NepalAD  - Kathmandu Univ, Nepalgunj Med Coll, Devdaha, NepalAD  - Nepal Dev Soc, Pokhara, NepalAD  - Stellenbosch Univ, Dept Global Hlth, Cape Town, South AfricaAD  - Stellenbosch Univ, Dept Psychiat, Cape Town, South AfricaAD  - Stellenbosch Univ, Fac Med & Hlth Sci, Cape Town, South AfricaAD  - South African Med Res Council, Cochrane South Africa, Cape Town, South AfricaAD  - South African Med Res Council, Unit Hypertens & Cardiovasc Dis, Cape Town, South AfricaAD  - Univ Coll Hosp, Dept Med, Ibadan, NigeriaAD  - Univ Coll Hosp, Med, Ibadan, NigeriaAD  - Olabisi Onabanjo Univ, Dept Sociol, Ago Lwoye, NigeriaAD  - Obafemi Awolowo Univ, Dept Med Rehabilitadoil, Ife, NigeriaAD  - Cardiff Univ, Sch Med, Cardiff, WalesAD  - Ctr Social Sci & Publ Hlth Res Nepal, Nepal Hlth Res Environm, Lalitpur, NepalAD  - Univ Southern Denmark, Unit Hlth Promot Res, Esbjerg, DenmarkAD  - Lvorian Assoc Family Welf, Abidjan, Cote IvoireAD  - Univ Extremadura, Sport Sci Dept, Badajoz, SpainAD  - Zabol Univ Med Sci, Zabol, IranAD  - McMaster Univ, Dept Family Med, Hamilton, ON, CanadaAD  - McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, CanadaAD  - Yerevan State Univ, Dept Zool, Yerevan, ArmeniaAD  - Sci Ctr Zool & Hydroecol, Res Grp Mol Parasitol, Yerevan, ArmeniaAD  - Directorate Hlth informat & Res, Dept Hlth, Pieta, MaltaAD  - Directorate Hlth informat & Res, Directorate Policy, Pieta, MaltaAD  - CSIR, Inst Genom & Integrat Biol, Res Area Informat & Rig Data, Delhi, IndiaAD  - Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USAAD  - Baylor Coll Med, Natl Sch Trop Med, Houston, TX 77030 USAAD  - Publ Hlth Fdn India, Hlth Promot Div, Curugram, IndiaAD  - Publ Hlth Fdn India, Indian Inst Publ Hlth, Curugram, IndiaAD  - Publ Hlth Fdn India, Indian Inst Publ Hlth, Curugram, IndiaAD  - Vital Strategies, Gurugrain, IndiaAD  - Alwaz Jundishapur Univ Med Sci, Dept Neurosurg, Nhvaz, IranAD  - Alwaz Jundishapur Univ Med Sci, Dept Publ Hlth, Nhvaz, IranAD  - Alwaz Jundishapur Univ Med Sci, Educ Dev Ctr, Nhvaz, IranAD  - Alwaz Jundishapur Univ Med Sci, Environm Technol Res Ctr, Nhvaz, IranAD  - Alwaz Jundishapur Univ Med Sci, Med Phys Dept, Nhvaz, IranAD  - Alwaz Jundishapur Univ Med Sci, Thalassemia & Hemoglobinopathy Res Ctr, Nhvaz, IranAD  - Shahid Beheshti Univ Med Sci, Canc Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Dept Biostat, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Dept Epidemiol, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Dept Ophthalmol, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Ophthalm Epidemiol Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Safety Promot & Injury Prevent Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Sch Publ Hlth, Tehran, IranAD  - Jimma Univ, Dept Environm Hlth Sci & Technol, Jimma, EthiopiaAD  - Jimma Univ, Dept Epidemiol, Jimma, EthiopiaAD  - Jimma Univ, Dept Hlth Educ & Behav Sci, Jimma, EthiopiaAD  - Jimma Univ, Dept Populat & Family Hlth, Jimma, EthiopiaAD  - Jimma Univ, Mycobacteriol Res Ctr, Jimma, EthiopiaAD  - Jimma Univ, Sch Pharm, Jimma, EthiopiaAD  - Int Ctr Diarrltoeal Dis Res, Hlth Econ & Financing Res Grp, Dhaka, BangladeshAD  - Int Ctr Diarrltoeal Dis Res, Hlth Syst & Populat Studies Div, Dhaka, BangladeshAD  - Int Ctr Diarrltoeal Dis Res, Initiat Non Communicable Dis, Dhaka, BangladeshAD  - Karolinska Inst, Dept Learning Informat Management & Eth, Stockholm, SwedenAD  - Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, SwedenAD  - Karolinska Inst, Dept Med Huddinge, Stockholm, SwedenAD  - Karolinska Inst, Dept Neurobiol, Stockholm, SwedenAD  - Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, SwedenAD  - Karolinska Inst, Dept Publ Hlth Sci, Stockholm, SwedenAD  - Univ Rhode Isl, Dept Civil & Environm Engn, Kingston, RI 02881 USAAD  - Debre Berhan Univ, Dept Midwifery, Debre Berman, EthiopiaAD  - Debre Berhan Univ, Dept Publ Hlth, Debre Berman, EthiopiaAD  - Univ Ibadan, Inst Adv Med Res & Training, Ibadan, NigeriaAD  - Univ Kentucky, Dept Epidemiol, Lexington, KY USAAD  - Univ Toronto, Dept Nutrit Sci, Toronto, ON, CanadaAD  - Univ Toronto, Ctr Global Child Hlth, Hosp Sick Children, Toronto, ON, CanadaAD  - Univ Toronto, Hosp Sick Children, Toronto, ON, CanadaAD  - Mayo Clin, Fdn Med Educ & Res, Evidence Based Practice Ctr, Rochester, MN USAAD  - Syrian Amer Med Soc, Res Comm, Washington, DC USAAD  - Washington Univ, Internal Med Dept, St Louis, MO USAAD  - VA St Louis Hlth Care Syst, Clin Epidemiol Ctr, St Louis, MO USAAD  - Dept Vet Affairs, Dept Internal Med, St Louis, MO USAAD  - Univ Western Australia, Dept Comp Sci & Software Engn, Perth, WA, AustraliaAD  - Univ Western Australia, Sch Med, Perth, WA, AustraliaAD  - Univ Western Australia, Sch Populat & Global Hlth, Perth, WA, AustraliaAD  - Naba Al Hayat Fdn Med Sci & Hlth Care, Najaf, IraqAD  - Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, AustraliaAD  - Australian Natl Univ, Res Sch Populat Hlth, Canberra, ACT, AustraliaAD  - King Saud Univ, Dept Family & Community Med, Riyadh, Saudi ArabiaAD  - King Saud Univ, Dept Pediat, Riyadh, Saudi ArabiaAD  - King Saud Univ, Pediat Intens Care Unit, Riyadh, Saudi ArabiaAD  - King Abdullah Bin Abdulaziz Univ Hosp, Riyadh, Saudi ArabiaAD  - New York Univ Abu Dhabi, Publ Hlth Res Ctr, Abut Dhabi, U Arab EmiratesAD  - Univ Oxford, Ctr lot Trop Med & Global Hlth, Nuffield Dept Med, Oxford, EnglandAD  - Univ Oxford, Dept Psychiat, Oxford, EnglandAD  - Univ Oxford, Nuffield Dept Populat Hlth, Oxford, EnglandAD  - Univ Oxford, Nuffield Dept Womens & Reprod Hlth, Oxford, EnglandAD  - Qazvin Univ Med Sci, Qazvin, IranAD  - Mazandaran Univ Med Sci, Dept Immunol, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Med Mycol, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Med Mycol & Parasitol, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Neurol, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Pediat, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Physiol & Pharmacol, Sari, IranAD  - Mazandaran Univ Med Sci, Gastrointestinal Canc Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Hlth Sci Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Immunogenet Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Mol & Cell Biol Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Sch Publ Hlth, Sari, IranAD  - Mazandaran Univ Med Sci, Toxoplasmosis Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Sari, IranAD  - Kuwait Univ Safat, Dept Hlth Policy & Management, Kuwait, KuwaitAD  - Natl Univ Malaysia, Int Ctr Casemix & Clin Coding, Bandar Tun Rezak, MalaysiaAD  - Luxembourg Inst Hlth, Dept Populat Hlth, Strassen, LuxembourgAD  - Natl Univ Malaysia, Int Ctr Casemix & Clin Coding, Bandar Tun Rezak, MalaysiaAD  - Swedish Res Council Hlth Working Life & Welf, Stockholm, SwedenAD  - United Arab Emirates Univ, Al Ain, U Arab EmiratesAD  - Psychiat Hosp Ain Abessa Setif, Ain Abessa, AlgeriaAD  - Jazan Univ, Mes Res Ctr, Jazan, Saudi ArabiaAD  - Jazan Univ, Jazan, Saudi ArabiaAD  - Sanaa Univ, Dept Med Parasitol, Sanaa, YemenAD  - Hosp del Mar, Med Res Inst, Res Program Epidemiol & Publ Hlth, Barcelona, SpainAD  - Pompeu Fabra Univ, Dept Experimental & Hlth Sci, Barcelona, SpainAD  - King Abdulaziz Univ, Dept Family & Community Med, Jeddah, Saudi ArabiaAD  - Charite Univ Med Ctr Berlin, Dept Operat & Prevent Dent, Berlin, GermanyAD  - Charite Univ Med Ctr Berlin, Inst Publ Hlth, Berlin, GermanyAD  - Charite Univ Med Ctr Berlin, Berlin, GermanyAD  - Univ Cartagena, Res Grp Hlth Econ, Cartagena, ColombiaAD  - Univ Coast, Res Grp Hosp Management & Hlth Policies, Barranquilla, ColombiaAD  - South Australian Hlth & Med Res Inst, Sansom Inst, Adelaide, SA, AustraliaAD  - South Australian Hlth & Med Res Inst, Wardliparingga Aboriginal Researclt Unit, Adelaide, SA, AustraliaAD  - Fed Minist Hlth, Dept Dis & Noncommunicable Dis & Hlth Promot, Beirut, LebanonAD  - Fed Minist Hlth, Dept Hlth Ind Complex & Innovat Hlth, Beirut, LebanonAD  - Fed Minist Hlth, Policy & Planning Directorate, Beirut, LebanonAD  - Fed Minist Hlth, Beirut, LebanonAD  - Amer Univ Beirut, Ctr Res Populat & Hlth, Beirut, LebanonAD  - Amer Univ Beirut, Dept Epidemiol & Populat Hlth, Beirut, LebanonAD  - Amer Univ Beirut, Beirut, LebanonAD  - Mansoura Univ, Fac Med, Mansoura, EgyptAD  - Carol Davila Univ Med & Pharm, Anat & Embryol Dept, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Dept Gen Surg, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Dept Legal Med & Bioeth, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Emergency Hosp Bucharest, Bucharest, RomaniaAD  - Univ Thessaly, Dept Med, Volos, GreeceAD  - Arba Minch Univ, Dept Publ Hlth, Arba Minch, EthiopiaAD  - Zahedan Univ Med Sci, Zahedan, IranAD  - Hasanuddin Univ, Sch Publ Hlth, Makassar, IndonesiaAD  - Univ Philippines Manila, Dept Hlth Policy & Adm, Manila, PhilippinesAD  - Univ Philippines Manila, Dev & Commun Studies, Manila, PhilippinesAD  - Koinfo Anokye Teaching Hosp, Dept Internal Med, Admit, GhanaAD  - Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Kumasi, GhanaAD  - Birmingham City Univ, Sch Hlth Sci, Birmingham, W Midlands, EnglandAD  - Dalarna Univ, Sch Hlth & Social Studies, Falun, SwedenAD  - Hlth Related Informat Disseminat Youth, Res, New Delhi, IndiaAD  - Abt Associates Nepal, Monitoring Evaluat & Operat Res Project, Lalitpur, NepalAD  - South Asian Publ Hlth Forum, Lahore, PakistanAD  - Mashhad Univ Med Sci, Dept Med Biotechnol, Mashhad, IranAD  - Mashhad Univ Med Sci, Educ Dev Ctr, Mashhad, IranAD  - Univ Lahore, Univ Inst Publ Hlth, Lahore, PakistanAD  - Univ Hail, Publ Hlth Dept, Hail, Saudi ArabiaAD  - Johns Hopkins Univ, Herman Inst Bioeth, Baltimore, MD USAAD  - Johns Hopkins Univ, Ctr Clin Global Hlth Educ, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Gastrointestinal & Hepatol, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21218 USAAD  - Johns Hopkins Univ, Dept Int Hlth, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Radiol, Baltimore, MD USAAD  - DY Patil Vidyapeeth, DY Patil Med Coll, Pune, Maharashtra, IndiaAD  - Keirnyung Univ, Dept Social Welf, Daegu, South KoreaAD  - Univ Leicester, Dept Hlth Sci, Leicester, Leics, EnglandAD  - Univ Leicester, Sch Business, Leicester, Leics, EnglandAD  - Lab Studies & Res Act Hlth, Controle Malad Infect, Porto Novo, BeninAD  - Lab Studies & Res Act Hlth, Noncommunicable Dis Dept, Porto Novo, BeninAD  - Indian Inst Publ Hlth, Gandhinagar, IndiaAD  - La Trobe Univ, Austin Clint Sch Nursing, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Dept Psychol, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Sch Nursing & Midwifery, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Judith Lumley Ctr, Melbourne, Vic, AustraliaAD  - Peruvian Natl Inst Hlth, Gen Off Res & Technol Transfer, Lima, PeruAD  - Dilla Univ, Publ Hlth Dept, Dilla, EthiopiaAD  - Univ Tokyo, Dept Community & Global Hlth, Tokyo, JapanAD  - Univ Tokyo, Dept Diabet & Metab Dis, Tokyo, JapanAD  - Univ Tokyo, Dept Global Hlth Policy, Tokyo, JapanAD  - Univ Tokyo, Dept Mental Hlth, Tokyo, JapanAD  - Univ Western Ontario, Clin Neurol Sci, London, EnglandAD  - Univ Western Ontario, Dept Clin Neurol Sci, London, EnglandAD  - Burnet Inst, Global Adolescent Hlth Grp, Melbourne, Vic, AustraliaAD  - Univ Malta, Dept Hlth Serv, Msida, MaltaAD  - Univ KwaZulu Natal, Dept Publ Hlth Med, Durban, South AfricaAD  - Univ KwaZulu Natal, Durban, South AfricaAD  - Univ Lagos, Dept Community Hlth & Primary Care, Lagos, NigeriaAD  - Univ Lagos, Dept Psychiat, Lagos, NigeriaAD  - Ctr Infect Dis Res, Babol Sar, IranAD  - Publ Hlth Agcy Canada, Hlth Promot & Chron Dis Prevent Branch, Toronto, ON, CanadaAD  - Publ Hlth Agcy Canada, Publ Hlth Risk Sci Div, Toronto, ON, CanadaAD  - Sri Ramachandra Med Coll & Res Inst, Dept Environm Hlth Engn, Madras, Tamil Nadu, IndiaAD  - Med Univ Lodz, Dept Hypertens, Lodz, PolandAD  - Polish Mothers Mem Hosp, Res Inst, Lode, PolandAD  - UCL, Dept Epidemiol & Publ Hlth, London, EnglandAD  - UCL, Dept Hlth Informat, London, EnglandAD  - UCL, Dept Psychol, London, EnglandAD  - UCL, Ear Inst, London, EnglandAD  - UCL, Inst Global Hlth, London, EnglandAD  - UCL, Inst Hlth Informat, London, EnglandAD  - UCL, UCL Ctr Global Hlth Econ, London, EnglandAD  - Alexandria Univ, Fac Med, Alexandria, EgyptAD  - Univ Hosp Fdn Santa Fe Bogota, Dept Transplant Serv, Bogota, ColombiaAD  - Publ Hlth Perspect Nepal, Dept Res, Pokhara Lekhnath, NepalAD  - Clin Ctr Serbia, Clin Infect & Trop Dis, Belgrade, SerbiaAD  - Univ Belgrade, Ctr Sch Publ Hlth & Hlth Management, Belgrade, SerbiaAD  - Univ Belgrade, Fac Med, Belgrade, SerbiaAD  - Univ Belgrade, Fac Med Inst Epidemiol, Belgrade, SerbiaAD  - Costa Rican Dept Social Secur, Area Estadist, Direcc Actuarial, San Jose, Costa RicaAD  - Costa Rican Dept Social Secur, Dept Neurosci, San Jose, Costa RicaAD  - Univ Costa Rica, Sch Dent, San Pedro, Costa RicaAD  - Univ Costa Rica, Sch Med, San Pedro, Costa RicaAD  - Univ Auckland, Mol Med & Pathol, Auckland, New ZealandAD  - Univ Auckland, Sch Psychol, Auckland, New ZealandAD  - Heidelberg Univ, Augenpraxis Jonas, Heidelberg, GermanyAD  - Heidelberg Univ, Dept Ophthalmol, Heidelberg, GermanyAD  - Heidelberg Univ, Inst Publ Hlth, Heidelberg, GermanyAD  - Harvard Univ, Ariadne Labs, Boston, MA 02115 USAAD  - Harvard Univ, Dept Environm Hlth, Boston, MA 02115 USAAD  - Harvard Univ, Dept Global Hlth & Populat, Boston, MA 02115 USAAD  - Harvard Univ, Dept Global Hlth & Social Med, Boston, MA 02115 USAAD  - Harvard Univ, Dept Nutr, Boston, MA 02115 USAAD  - Harvard Univ, Div Gen Internal Med & Primary, Boston, MA 02115 USAAD  - Harvard Univ, Heart & Vasc Ctr, Boston, MA 02115 USAAD  - Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USAAD  - Harvard Univ, Boston, MA 02115 USAAD  - Pontifica Javeriana Univ, Dept Ind Engn, Bogota, ColombiaAD  - Barcelona Inst Global Hlth, Barcelona, SpainAD  - Barcelona Inst Global Hlth, TB Dept, Barcelona, SpainAD  - Manhica Hlth Res Ctr, TB, Manhica, MozambiqueAD  - Univ Canterbury, Sch Hlth Sci, Christchurch, New ZealandAD  - Stanford Univ, Ctr Hlth Policy & Ctr Primary Care & Outcomes Res, Palo Alto, CA 94304 USAAD  - Stanford Univ, Dept Med, Palo Alto, CA USAAD  - Doctor Evidence, Santa Monica, CA USAAD  - Melbourne Med Sch, Melbourne, Vic, AustraliaAD  - Charles R Drew Univ Med & Sci, Dept Psychiat, 1621 E 120th St, Los Angeles, CA 90059 USAAD  - Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USAAD  - Gandhi Med Coll Bhopal, Dept Community Med, Bhopal, IndiaAD  - Iran Univ Med Sci, Dept Environm Hlth Sci, Tehran, IranAD  - Iran Univ Med Sci, Dept Neurosci, Tehran, IranAD  - Iran Univ Med Sci, Dept Oncol, Tehran, IranAD  - Iran Univ Med Sci, Dept Renal Med, Tehran, IranAD  - Iran Univ Med Sci, Mario Negri Inst Pharmacol Res, Tehran, IranAD  - Iran Univ Med Sci, Air Pollut Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Dept Community Med, Tehran, IranAD  - Iran Univ Med Sci, Dept Hlth Policy, Tehran, IranAD  - Iran Univ Med Sci, Dept Hlth Policy, Tehran, IranAD  - Iran Univ Med Sci, Hlth Management & Econ Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Physiol Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Prevent Med & Publ Hlth Res Ctr, Tehran, IranAD  - Lorestart Univ Med Sci, Social Determinants Hlth Res Ctr, Kborramabad, IranAD  - Univ Hosp Dijon, Dept Neurol, Dijon, FranceAD  - Univ Burgundy, Dijon Stroke Registry, UFR Sci Sante, Dijon, FranceAD  - Mizan Tepi Univ, Publ Hlth Dept, Terri, EthiopiaAD  - Tewelde Legesse Hlth Sci Coll, Mekelle, EthiopiaAD  - Yale Univ, Dept Ophthalmol & Visual Sci, New Haven, CT USAAD  - Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USAAD  - Univ Alberta, Dept Med, Edmonton, AB, CanadaAD  - Univ Sao Paulo, Ctr Clin & Epidemiol Res, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Biomech, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Internal Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Pathol & Legal Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Psychiat, Sao Paulo, BrazilAD  - Univ Sao Paulo, Div Ophthalmol, Sao Paulo, BrazilAD  - Univ Sao Paulo, Univ Hosp, Internal Med Dept, Sao Paulo, BrazilAD  - NYU, Langone Med Ctr, New York, NY USAAD  - NYU, WHO Collaborating Ctr, New York, NY USAAD  - Wolaita Sodo Univ, Sch Publ Hlth, Addis Ababa, EthiopiaAD  - Augusta Univ, Med Coll Georgia, Div Cardiol, Augusta, GA USAAD  - London Sch Econ & Polit Sci, Dept Hlth Policy, London, EnglandAD  - London Sch Econ & Polit Sci, Personal Social Serv Res Unit, London, EnglandAD  - Kings Coll London, Dent Inst, London, EnglandAD  - Kings Coll London, Div Patient & Populat, London, EnglandAD  - Kings Coll London, Fac Life Sci & Med, London, EnglandAD  - Kings Coll London, Sch Populat Hlth & Environm Sci, London, EnglandAD  - Emory Univ, Hubert Dept Global Hlth, Atlanta, GA 30322 USAAD  - Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USAAD  - Univ S Florida, Dept Global Hlth, Tampa, FL USAAD  - Queen Elizabeth Hosp Birmingham, Inst Appl Hlth Res & Translat Med, Birmingham, W Midlands, EnglandAD  - Univ Birmingham, IAHR, ITM, Birmingham, W Midlands, EnglandAD  - Post Grad Inst Med Educ & Res, Dept Internal Med, Chandigarh, IndiaAD  - Post Grad Inst Med Educ & Res, Dept Pediat, Chandigarh, IndiaAD  - Post Grad Inst Med Educ & Res, Sch Publ Hlth, Chandigarh, IndiaAD  - London Sch Hyg & Trop Med, Ctr Global Chron Condit, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Dis Control, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Med Stat, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, EnglandAD  - London Sch Hyg & Trop Med, London, EnglandAD  - Nepal Acad Sci &Technol, Patan, NepalAD  - George Inst Global Hlth, Injury Div, New Delhi, IndiaAD  - George Inst Global Hlth, New Delhi, IndiaAD  - Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, PakistanAD  - Aga Khan Univ, Dept Pediat & Child Hlth, Karachi, PakistanAD  - Babol Univ Med Sci, Cellular & Mol Biol Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Dept Clin Biochem, Babol Sar, IranAD  - Babol Univ Med Sci, Dept Immunol, Babol Sar, IranAD  - Babol Univ Med Sci, Fatemelt Zaltra Iufertil & Reprod Hlth Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Hlth Res Inst, Babol Sar, IranAD  - Babol Univ Med Sci, Immunoregulat Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Infect Dis & Trop Med Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Social Determinant Hlth Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Student Res Comm, Babol Sar, IranAD  - Babol Univ Med Sci, Babol Sar, IranAD  - Woldia Univ, Woldia, EthiopiaAD  - Univ Dhaka, Dept Clin Pharm & Pharmacol, Ramna, BangladeshAD  - Univ Bologna, Dept Med & Surg Sci, Bologna, ItalyAD  - Polyneuropathy Fdn Int, Guillain Barre Syndrome, Chron Inflammatory Demyelinating, Conshohocken, PA USAAD  - United Nations Programme HIV AIDS UNAIDS, Ctr AID Program Res South Africa CAPRISA TB, Gaborone, BotswanaAD  - United Nations Programme HIV AIDS UNAIDS, HIV Pathogenesis Unit, Gaborone, BotswanaAD  - United Nations Programme HIV AIDS UNAIDS, Fast Track Implementat Dept, Gaborone, BotswanaAD  - Res Triangle Inst Int, Global Hlth Div, Res Triangle Pk, NC USAAD  - Univ Nottingham, Sch Med, Nottingham, EnglandAD  - AT Still Univ, Dept Hlth Sci, Brisbane, Qld, AustraliaAD  - St Pauls Hosp, Millennium Med Coll, Dept Nursing, Addis Ababa, EthiopiaAD  - St Pauls Hosp, Millennium Med Coll, Addis Ababa, EthiopiaAD  - Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, NorwayAD  - Univ Oslo, Inst Hlth & Soc, Oslo, NorwayAD  - Univ Oslo, Oslo, NorwayAD  - Univ Queensland, Inst Social Sci Res, Brisbane, Qld, AustraliaAD  - Univ Queensland, Queensland Alliance Agr & Food Innovat, Brisbane, Qld, AustraliaAD  - Univ Queensland, Queensland Brain Inst, Brisbane, Qld, AustraliaAD  - Univ Queensland, Sch Dent, Brisbane, Qld, AustraliaAD  - Univ Queensland, Brisbane, Qld, AustraliaAD  - Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Med, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Psychiat, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Publ Hlth & Community Med, Sydney, NSW, AustraliaAD  - Univ New South Wales, Transport & Rd Safety Res, Sydney, NSW, AustraliaAD  - Anglia Ruskin Univ, Vis & Eye Res Unit, Cambridge, EnglandAD  - Univ Heidelberg Hosp, Dept General Practice & Hlth Serv Res, Heidelberg, GermanyAD  - Univ Genoa, Genoa, ItalyAD  - Danube Univ Krems, Dept Clin Neurosci & Prevent Med, Krems, AustriaAD  - Univ Fed Minas Gerais, Dept Maternal & Child Nursing & Publ Hlth, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Hosp Fed Univ Minas Gerais, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Nutr Dept, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Postgrad Program Infect Dis & Trop Med, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Sch Med & Clin Hosp, Belo Horizonte, MG, BrazilAD  - Univ British Columbia, Dept Pediat, Vancouver, BC, CanadaAD  - Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, CanadaAD  - Univ British Columbia, Vancouver, BC, CanadaAD  - Comenius Univ, Inst Epidemiol, Bratislava, SlovakiaAD  - Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USAAD  - Ohio State Univ, Dept Psychol, Columbus, OH USAAD  - Ohio State Univ, Psychiat & Behav Hlth Dept, Columbus, OH 43210 USAAD  - Litstttiite Sci Res & High Technol Serv, Neurosci, City Of Knowledge, PanamaAD  - Litstttiite Sci Res & High Technol Serv, TB Biontarker Res Unit, City Of Knowledge, PanamaAD  - Gorgas Mem Inst Hlth Studies, Dept Res & Hlth Technol Assessment, Panama City, PanamaAD  - Gorgas Mem Inst Hlth Studies, Panama City, PanamaAD  - Partners Hlth, Boston, MA USAAD  - Al Shifa Trust Eye Hosp, Al Shifa Sch Publ Hlth, Rawalpindi, PakistanAD  - Univ Valley Cuernavaca, Sch Med, Cuernavaca, Morelos, MexicoAD  - Nanyang Technol Univ, Ctr Populat Hlth Sci, Singapore, SingaporeAD  - Nanyang Technol Univ, LKCMed, Singapore, SingaporeAD  - Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, SingaporeAD  - Nanyang Technol Univ, Singapore, SingaporeAD  - Imperial Coll London, Dept Primary Care & Publ Hlth, London, EnglandAD  - Imperial Coll London, Dept Surg & Canc, London, EnglandAD  - Imperial Coll London, Global eHlth Unit, London, EnglandAD  - Imperial Coll London, Sch Publ Hlth, London, EnglandAD  - Imperial Coll London, WHO Collaborating Ctr Publ Hlth Educ & Training, London, EnglandAD  - Minist Hlth, Zagreb, CroatiaAD  - Metropolitan Autonomous Univ, Dept Populat & Hlth, Mexico City, DF, MexicoAD  - Univ Porto, Appl Mol Biosci Unit, Porto, PortugalAD  - Univ Porto, Inst Res & Innovat Hlth i3S, Porto, PortugalAD  - Univ Porto, Inst Biomed Engn INEB, Porto, PortugalAD  - Univ Porto, Inst Publ Hlth, Porto, PortugalAD  - Univ Porto, REQUIMTE, LAQV, Porto, PortugalAD  - Univ Porto, UCIBIO, Porto, PortugalAD  - Natl Inst Hlth, Colombian Natl Hlth Observ, Bogota, ColombiaAD  - Natl Inst Hlth, Natl Ctr Prevent & Control HIV, Bogota, ColombiaAD  - Natl Inst Hlth, AIDS, Bogota, ColombiaAD  - Natl Inst Hlth, Natl Ctr Dis Prevent & Hlth Promot, Bogota, ColombiaAD  - Univ Nacl Colombia, Epidemiol & Publ Hlth Evaluat Grp, Bogota, ColombiaAD  - Hacettepe Univ, Dept Publ Hlth, Ankara, TurkeyAD  - Hacettepe Univ, Inst Populat Studies, Ankara, TurkeyAD  - Australian Catholic Univ, Mary MacKillop Inst Hlth Res, Melbourne, Vic, AustraliaAD  - Australian Catholic Univ, Brain Inst, Melbourne, Vic, AustraliaAD  - Univ Hong Kong, Ctr Suicide Res & Prevent, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ Hong Kong, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ Hong Kong, Hong Kong, Hong Kong, Peoples R ChinaAD  - Alfaisal Univ, Coll Med, Riyadh, Saudi ArabiaAD  - Natl Hlth Res Inst, Hlth Syst Res Ctr, Zhunan Township, TaiwanAD  - Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan Township, TaiwanAD  - Natl Taiwan Univ, Coll Med, Taipei, TaiwanAD  - Int Inst Populat Sci, Dept Dev Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Dept Fertil Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Dept Populat Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Dept Publ Hlth & Mortal Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Bombay, Maharashtra, IndiaAD  - Univ West Indies, Fac Med Sci, St Augustine, Trinidad TobagoAD  - Tata Mem Hosp, Surg Oncol, Bombay, Maharashtra, IndiaAD  - Gold Coast Hlth, Clin Governance, Cold Coast, Qld, AustraliaAD  - Monash Univ, Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic, AustraliaAD  - Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, AustraliaAD  - Monash Univ, Monash Ctr Hlth Res & Implementat, Melbourne, Vic, AustraliaAD  - Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, AustraliaAD  - Univ Zambia, Dept Populat Studies, Lusaka, ZambiaAD  - Univ Witwatersrand, Demog & Populat Studies, Johannesburg, South AfricaAD  - Minist Hlth, Baghdad, IraqAD  - Seoul Natl Univ Hosp, Biochem, Biomed Sci, Seoul, South KoreaAD  - Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, EnglandAD  - Univ Copenhagen, Dept Neurol, Copenhagen, DenmarkAD  - Univ Copenhagen, Inst Clin Med, Copenhagen, DenmarkAD  - Univ Copenhagen, Bispebjerg Hosp, Copenhagen, DenmarkAD  - Christian Med Coll & Hosp, Dept Community Hlth, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp, Dept Endocrinol, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp, Dept Neurol, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp, Dept Pulm Med, Vellore, Tamil Nadu, IndiaAD  - Hlth Data Res UK, London, EnglandAD  - Univ Adelaide, Adelaide Med Sch, Adelaide, SA, AustraliaAD  - Univ Adelaide, Joanna Briggs Inst, Adelaide, SA, AustraliaAD  - Univ Adelaide, Robinson Res Inst, Adelaide, SA, AustraliaAD  - Univ Salerno, Scuola Med Salernitana, Baronissi, ItalyAD  - North RhineWestphatia Ctr Hlth, Dept Hlth Assessments & Forecasting, Bochum, GermanyAD  - Bielefeld Univ, Bielefeld Sch Publ Hlth, Bielefeld, GermanyAD  - Bielefeld Univ, Dept Publ Hlth Med, Bielefeld, GermanyAD  - Hlth Effechs Inst, Boston, MA USAAD  - Autonomous Univ Chile, Fac Business & Management, Talca, ChileAD  - Autonomous Univ Chile, Fac Educ, Talca, ChileAD  - Autonomous Univ Chile, Inst Phys Act & Hlth, Talca, ChileAD  - Univ Southampton, NIHR Oxford Biomed Res Ctr, Southampton, Hants, EnglandAD  - Mayo Clin, Dept Cardiovasc Med, Jacksonville, FL 32224 USAAD  - Arizona State Univ, T Denny Sanford Sch Social & Family Dynam, Tempe, AZ USAAD  - Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USAAD  - Univ Fed Rio Grande do Sul, Dept Internal Med Neurol, Porto Alegre, RS, BrazilAD  - Univ Fed Rio Grande do Sul, Postgrad Program Epidemiol, Porto Alegre, RS, BrazilAD  - Hawassa Univ, Coll Med & Hlth Sci, Hawassa, EthiopiaAD  - Hawassa Univ, Dept Reprod Hlth, Hawassa, EthiopiaAD  - Hawassa Univ, Sch Nursing & Midwifery, Hawassa, EthiopiaAD  - Flinders Univ S Australia, Discipline Publ Hlth, Adelaide, SA, AustraliaAD  - Duy Tan Univ, Inst Global Hlth Innovat, Hanoi, VietnamAD  - Guys & St Thomas NHS Fdn Trust, Biomed Res Council, London, EnglandAD  - Guys & St Thomas NHS Fdn Trust, Clin Toxicol Serv, London, EnglandAD  - KG Med Univ, Dept Rheumatol, Lucknow, Uttar Pradesh, IndiaAD  - BRAC Univ, James P Grant Sch Publ Hlth, Dhaka, BangladeshAD  - BRAC Univ, Res & Evaluat Div, Dhaka, BangladeshAD  - Cent Univ Tamil Nadu, Thiruvarur, IndiaAD  - Clin Emergency Hosp Sf Pantelimon, Dept Surg, Bucharest, RomaniaAD  - Kazakh Natl Med Univ, Alma Ata, KazakhstanAD  - San Joaquin Gen Hosp, Dept Surg, French Camp, CA USAAD  - Monash Hlth, Dept Diabet & Vasc Med, Melbourne, Vic, AustraliaAD  - Griffith Univ, Australian Inst Suicide Res & Prevent, Mt Gravatt, Qld, AustraliaAD  - Griffith Univ, Menzies Hlth Inst Queensland, Mt Gravatt, Qld, AustraliaAD  - Univ Ghent, Dept Agr Econ, Ghent, BelgiumAD  - Univ Ghent, Dept Food Technol Safety & Hlth, Ghent, BelgiumAD  - African Populat Hlth Res Ctr, Maternal & Child Wellbeing Unit, Nairobi, KenyaAD  - African Populat Hlth Res Ctr, Populat Dynam & Reprod Hlth Unit, Nairobi, KenyaAD  - Univ Colorado, Sch Med, Aurora, CO USAAD  - US Dept Vet Affairs, Dermatol Serv, Denver, CO USAAD  - Aksum Univ, Dept Clinical Pharm, Aksum, EthiopiaAD  - Aksum Univ, Dept Med, Lab Sci, Aksum, EthiopiaAD  - Brighton & Sussex Med Sch, Dept Global Hlth & Infect, Brighton, E Sussex, EnglandAD  - Natl Hlth Serv Scotland, Edinburgh, Midlothian, ScotlandAD  - Aristotle Univ Thessaloniki, Thessaloniki, GreeceAD  - Disha Fdn, Gurgaon, IndiaAD  - Univ Peradeniya, Dept Community Med, Peradeniya, Sri LankaAD  - Nepal Hlth Res Council, Hlth Res Sect, Kathmandu, NepalAD  - Minist Hlth & Med Educ, Ctr Communicable Dis Control, Tehran, IranAD  - Minist Hlth & Med Educ, Deputy Res & Technol, Tehran, IranAD  - Minist Hlth & Med Educ, Tehran, IranAD  - Med Univ Varna, Dept Social Med & Hlth Care Org, Varna, BulgariaAD  - Univ Cape Coast, Conservat Biol & Entomol, Cape Coast, GhanaAD  - Univ Cape Coast, Dept Populat & Hlth, Cape Coast, GhanaAD  - Univ Tampere, Fac Social Sci, Tampere, FinlandAD  - Univ Tampere, Fac Social Sci, Hlth Sci, Tampere, FinlandAD  - Univ Sydney, Asbestos Dis Res Inst, Sydney, NSW, AustraliaAD  - Univ Sydney, Sydney Med Sch, Sydney, NSW, AustraliaAD  - Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, AustraliaAD  - Chinese Ctr Dis Control & Prevent, Div Injury Prevent & Mental Hlth Improvement, Beijing, Peoples R ChinaAD  - Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing, Peoples R ChinaAD  - Chinese Ctr Dis Control & Prevent, Beijing, Peoples R ChinaAD  - United Nations World Food Programme, New Delhi, IndiaAD  - Univ Fed Bahia, Inst Publ Hlth, Salvador, BA, BrazilAD  - Univ Fed Bahia, Sch Med, Salvador, BA, BrazilAD  - Roberto Santos Gen Hosp, Salvador, BA, BrazilAD  - Umea Univ, Dept Nursing, Umea, SwedenAD  - Eijkman Inst Mol Biol, Eijkman Oxford Clin Res Unit, Jakarta, IndonesiaAD  - St Pauls Hosp, Millennium Med Coll, Publ Hlth Dept, Addis Ababa, EthiopiaAD  - Urmia Univ Med Sci, Dept Med Parasitol & Mycol, Orumiyeh, IranAD  - Food & Agr Org United Nations, Nutr & Food Syst Div, Rome, ItalyAD  - Imam Muhammad Ibn Saud Islamic Univ, Coll Med, Riyadh, Saudi ArabiaAD  - Imam Muhammad Ibn Saud Islamic Univ, Dept Publ Hlth, Riyadh, Saudi ArabiaAD  - Univ Louisville, Div Cardiovasc Med, Louisville, KY 40292 USAAD  - Natl Stat Off, Lisbon, PortugalAD  - Univ Fed Sergipe, Dept Psychol, Sao Cristovao, BrazilAD  - Hamadan Univ Med Sci, Chron Dis Home Care Res Ctr, Hamadan, IranAD  - Hamadan Univ Med Sci, Dept Epidemiol, Hamadan, IranAD  - Hamadan Univ Med Sci, Social Determinant Hlth Res Ctr, Hamadan, IranAD  - Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New ZealandAD  - Org Econ Cooperat & Dev, Hlth Div, Paris, FranceAD  - Catholic Univ Portugal, Ctr Biotechnol & Fine Chem, Porto, PortugalAD  - Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA USAAD  - Univ Memphis, Sch Publ Hlth, Memphis, TN 38152 USAAD  - Univ Memphis, Sch Publ Hlth, Memphis, TN 38152 USAAD  - Robert Koch Inst, Dept Epidemiol & Hlth Monitoring, Berlin, GermanyAD  - Sergio Arouca Natl Sch Publ Hlth, Rio De Janeiro, BrazilAD  - Univ Fed Espirito Santo, Vitoria, BrazilAD  - Natl Acad Med Sci Ukraine, Inst Gerontol, Kiev, UkraineAD  - James Cook Univ, Coll Publ Hlth Med & Vet Sci, Townsville, Qld, AustraliaAD  - Inst Canc Res, Gene Express & Regulat Program, Philadelphia, PA USAAD  - Kobe Univ, Dept Dermatol, Kobe, Hyogo, JapanAD  - Swiss Trop & Publ Hlth Inst, Epidemiol & Publ Hlth, Basel, SwitzerlandAD  - Univ Basel, Basel, SwitzerlandAD  - Univ Sidi Mohammed Ben Abdellath, Fac Med & Pharm Fez, Fes, MoroccoAD  - Univ Med Ctr Groningen, Dept Nephrol, Groningen, NetherlandsAD  - Univ Med Ctr Groningen, Dept Psychiat, Groningen, NetherlandsAD  - Nova Univ Lisbon, Inst Hyg & Trop Med, Lisbon, PortugalAD  - Natl Hlth Inst Doutor Ricardo Jorge INSA, Epidemiol Dept, Lisbon, PortugalAD  - Task Force Global Hlth, Int Trachoma Initiat, Decatur, GA USAAD  - Curtin Univ, Sch Publ Hlth, Perth, WA, AustraliaAD  - Wageningen Univ & Res, Div Human Nutr & Hlth, Wageningen, NetherlandsAD  - Martin Luther Univ Halle Wittenberg, Inst Epidemiol Biostst & Informat, Halle, GermanyAD  - Martin Luther Univ Halle Wittenberg, Inst Med Epidemiol, Halle, GermanyAD  - Univ Social Welf & Rehabil Sci, Social Determinants Hlth Res Ctr, Tehran, IranAD  - Univ Social Welf & Rehabil Sci, Tehran, IranAD  - Univ Tsukuba, Dept Hlth Care Policy & Management, Tsukuba, Ibaraki, JapanAD  - Natl Allergy Asthma & Bronchitis Inst, Dept Resp Med, Kolkota, IndiaAD  - Fortis Hosp, Dept Resp Med, Kolkata, IndiaAD  - Natl Publ Hlth Inst, Dept Cardiovasc Dysmetabol & Ageing Associate Dis, Rome, ItalyAD  - Texas Tech Univ, Dept Publ Hlth, Lubbock, TX 79409 USAAD  - Univ Warwick, Div Hlth Sci, Coventry, W Midlands, EnglandAD  - Univ Warwick, Coventry, W Midlands, EnglandAD  - Res Ctr Neurol, Moscow, RussiaAD  - Jawahar Lal Nehru Univ, Ctr Study Reg Dev, New Delhi, IndiaAD  - Jawahar Lal Nehru Univ, Ctr Ethi, New Delhi, IndiaAD  - Univ Massachusetts, Nursing & Hlth Sci Dept, Boston, MA 02125 USAAD  - Univ Oklahoma, Dept Biostat & Epidemiol, Oklahoma City, OK USAAD  - Govt Federated States Micronesia, Dept Hlth & Social Affairs, Palikir, MicronesiaAD  - Natl Canc Ctr, Metab Epidemiol Sect, Chuo Ku, Tokyo, JapanAD  - Boston Univ, Sch Med, Boston, MA 02118 USAAD  - Vittorio Emanuele Univ Hosp Polyclin, Registro Tumori Integrato, Catania, ItalyAD  - St James Sch Med, Dept Epidemiol, The Valley, AnguillaAD  - St James Sch Med, Dept Microbiol, The Valley, AnguillaAD  - Univ Lorraine, Sch Publ Hlth, Vandoeuvre Les Nancy, FranceAD  - State Univ Monies Claros, Sch Dent, Montes Claros, BrazilAD  - Healis Selkhsaria Inst Publ Hlth, Dept Epidemiol, Bombay, Maharashtra, IndiaAD  - West Virginia Bur Publ Hlth, Commissioner Publ Hlth, Charleston, WV USAAD  - West Virginia Univ Sch Publ Hlth, Dept Hlth Policy Management & Leadership, Morgantown, WV USAAD  - Rajasthan Univ Hlth Sci, Acad & Res, Jaipur, Rajasthan, IndiaAD  - Eternal Heart Care Ctr & Res Inst, Dept Prevent Cardiol, Jaipur, Rajasthan, IndiaAD  - Montefiore Med Ctr, Dept Cardiol, 111 E 210th St, Bronx, NY 10467 USAAD  - Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USAAD  - Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, NetherlandsAD  - Lawson Hlth Res Inst, London, ON, CanadaAD  - Arabian Gulf Univ, Dept Family & Community Med, Manama, BahrainAD  - Hamdan Bin Mohammed Smart Univ, Sch Hlth & Environm Studies, Dubai, U Arab EmiratesAD  - Sir Charles Gairdner Hosp, Neurol Dept, Perth, WA, AustraliaAD  - Minist Publ Hlth, Dept Dis Epidem & Pandem Control, Beirut, LebanonAD  - Minist Publ Hlth, Dept Vital & Hlth Stat, Beirut, LebanonAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Achutha Menon Ctr Hlth Sci Studies, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Cardiol Dept, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Neurol Dept, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Trivandrum, Kerala, IndiaAD  - Tabriz Univ Med Sci, Hlth Educ & Hlth Promot Dept, Sch Publ Hlth, Tabriz, IranAD  - Tabriz Univ Med Sci, Tabriz, IranAD  - San Juan Dios Sanitary Pk, Res & Dev Unit, St Boi De Llobregat, SpainAD  - Univ Barcelona, Dept Med, Barcelona, SpainAD  - Univ Antwerp Hosp, Unit Epidemiol & Social Med, Antwerp, BelgiumAD  - Karolinska Univ Hosp, Clin Sci, Stockholm, SwedenAD  - Teikyo Univ, Sch Med, Endorinol & Metab Res Ctr, Tehran, IranAD  - Hormozgan Univ Med Sci, Dept Environm Hlth Engn, Bandar Abbas, IranAD  - Bucharest Univ Econ Studies, Dept Stat & Econometr, Bucharest, RomaniaAD  - ACS Med Coll & Hosp, Nastaran, IranAD  - AC Environm Fdn, Res Coordinat, Cuernavaca, Morelos, MexicoAD  - Columbia Univ, Dept Epidemiol, New York, NY USAAD  - Columbia Univ, Dept Hlth & Behav Studies, New York, NY USAAD  - Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ USAAD  - Univ Texas Austin, Austin, TX 78712 USAAD  - Guilan Univ Med Sci, Guilan Rd Trauma Res Ctr, Rasht, IranAD  - Guilan Univ Med Sci, Sch Hlth, Rasht, IranAD  - Manipal Univ, Transdiscipithary Ctr Qualitat Methods, Manipal, Karnataka, IndiaAD  - Yokohama City Univ, Dept Pulmonol, Kanazawa Ku, Yokohama, Kanagawa, JapanAD  - NIH, Ctr Translat Res & Implementat Sci, Bethesda, MD USAAD  - NIH, Inst Hlth Policy & Dev Studies, Bethesda, MD USAAD  - NIH, NHLBI, Bethesda, MD USAAD  - NIH, Bethesda, MD USAAD  - Univ Human Dev, Dept Comp Sci, Sulaimartiyah, IraqAD  - Univ Human Dev, Sulaimartiyah, IraqAD  - Bucharest Emergency Hosp, Dept Internal Med, Bucharest, RomaniaAD  - Natl Inst Legal Med Mina Minovici, Clin Legal Med, Bucharest, RomaniaAD  - Med Sch Tunis, Fac Med Tunis, Baab Saadoun, TunisiaAD  - Cent South Univ, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R ChinaAD  - Solar Cookers Int, Sacrementh, CA USAAD  - Univ Western Cape, Sch Publ Hlth, Cape Town, South AfricaAD  - Walter Sisulu Univ, Dept Publ Hlth, Mthatha, South AfricaAD  - Univ Liberia, Dept Publ Hlth & Community Med, Monrovia, LiberiaAD  - Univ Liberia, Monrovia, LiberiaAD  - Taipei Med Univ, Global Hlth & Dev Dept, Taipei, TaiwanAD  - Taipei Med Univ, Grad Inst Biomed Informat, Taipei, TaiwanAD  - Deakin Univ, Dept Psychol, Burwood, Vic, AustraliaAD  - Deakin Univ, Inst Phys Act & Nutr, Burwood, Vic, AustraliaAD  - Deakin Univ, Sch Med, Geelong, Vic 3217, AustraliaAD  - Amer Canc Soc, Surveillance & Hlth Serv Res, Atlanta, GA USAAD  - George Mason Univ, Dept Global & Community Hlth, Fairfax, VA 22030 USAAD  - Natl Ctr Dis Control Delhi, Dept Parasit Dis, Delhi, IndiaAD  - Univ Kragujevac, Med Sci Dept, Kragujevac, SerbiaAD  - Univ Calif San Diego, Dept Internal Med, San Diego, CA 92103 USAAD  - Newcastle Univ, Tyne, EnglandAD  - Univ Colombo, Fac Grad Studies, Colombo, Sri LankaAD  - Univ Colombo, Inst Med, Colombo, Sri LankaAD  - Bananas Hindu Univ, Dept Community Med, Varanasi, Uttar Pradesh, IndiaAD  - Bananas Hindu Univ, Dept Med, Varanasi, Uttar Pradesh, IndiaAD  - Duke Kurishan Univ, Environm Res Ctr, Kunshan, Peoples R ChinaAD  - Duke Kurishan Univ, Global Hlth Res Ctr, Kunshan, Peoples R ChinaAD  - Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R ChinaAD  - New South Wales Hlth, Sydney, NSW, AustraliaAD  - All India Inst Med Sci, Ctr Community Med, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol Metab & Diabet, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Paediat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - Czestochowa Tech Univ, Inst Hlth & Nutr Sci, Czestochowa, PolandAD  - Univ Opole, Fac Med & Hlth Sci, Opole, PolandAD  - Savitribai Phule Pune Univ, Sch Hlth Sci, Pune, Maharashtra, IndiaAD  - Univ Tartu, Inst Family Med & Publ Hlth, Tartu, EstoniaAD  - Employees State Insurance Model Hosp, Dept Community Med, Madras, Tamil Nadu, IndiaAD  - Univ Coll Cork, Sch Publ Hlth, Cork, IrelandAD  - Samara Univ, Dept Publ Hlth, Samara, EthiopiaAD  - European Observ Hlth Syst & Policies, London, EnglandAD  - European Observ Hlth Syst & Policies, London, EnglandAD  - Univ Washington, Sch Interdisciplinary Arts & Sci, Tacoma, WA USAAD  - Bagiyatallah Univ Med Sci, Baqiyatallah Res Ctr Gastroenterol & Liver Dis, Tehran, IranAD  - Bagiyatallah Univ Med Sci, Student Res Comm, Tehran, IranAD  - Middle East Liver Dis Ctr, Dept Mol Hepatol, Tehran, IranAD  - Middle East Liver Dis Ctr, Dept Young Investigators, Tehran, IranAD  - Seattle Childrens Hosp, Dept Anesthesioi Pain Med, Seattle, WA USAAD  - Univ G know, CSO Social & Publ Hlth Sci Unit, MRC, Glasgow, Lanark, ScotlandAD  - Oklahoma State Univ, Sch Hlth Care Adm, Tulsa, OK USAAD  - Univ Tulsa, Hlth Care Delivery Sci, Tulsa, OK 74104 USAAD  - Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USAAD  - Univ Calif San Francisco, Dept Med, San Francisco, CA USAAD  - Salale Univ, Midwifery Program, Fiche, EthiopiaAD  - Univ Nairobi, Sch Med, Nairobi, KenyaAD  - Univ Nairobi, Nairobi, KenyaAD  - Michigan State Univ, Dept Linguist & German Slav Asian & African Langu, E Lansing, MI 48824 USAAD  - Med Res Council South Africa, Alcohol Tobacco & Other Drug Use Res Unit, Cape Town, South AfricaAD  - Med Res Council South Africa, Cochrane South Africa, Cape Town, South AfricaAD  - Med Res Council South Africa, Noncommunicable Dis Res Unit, Cape Town, South AfricaAD  - Univ Cape Town, Dept Med, Cape Town, South AfricaAD  - Univ Cape Town, Dept Paediat & Child Hlth, Cape Town, South AfricaAD  - Univ Cape Town, Dept Psychiat & Mental Hlth, Cape Town, South AfricaAD  - Univ Cape Town, Inst Infect Dis & Mol Med, Cape Town, South AfricaAD  - Insiitthe Cardiol, Tel Aviv Yaffo, IsraelAD  - Hadassah Hebrew Univ Hosp, Heartfailue & Cardiontyopathies Ctr, Jerusalem, IsraelAD  - CSIR, Indian Inst Toxicol Res, CSIR, Lucknow, Uttar Pradesh, IndiaAD  - Jordan Univ Sci & Technol, Dept Publ Hlth & Community Med, Ramtha, JordanAD  - Azad Univ, Omidiyeh Branch, Dept Stat, Tehran, IranAD  - Univ Management & Technol, Sch Food & Agr Sci, Lahore, PakistanAD  - Hlth Serv Acad, Epidemiol & Biostatist Dept, Islamabad, PakistanAD  - Jr Hosp Cook Cty, Dept Internal Med, Chicago, IL USAAD  - Dow Univ Hlth Sci, Dept Internal Med, Karachi, PakistanAD  - Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USAAD  - Univ Alabama Birmingham, Dept Med, Birmingham, AL USAAD  - Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USAAD  - Univ Tennessee, Dept Pediat, Knoxville, TN USAAD  - Seoul Natl Univ, Dept Hlth Policy & Management, Seoul, South KoreaAD  - Seoul Natl Univ, Inst Hlth Policy & Management, Seoul, South KoreaAD  - Indian Council Med Res, Dept Hlth Res, New Delhi, IndiaAD  - Indian Council Med Res, Natl Inst Res Environm Hlth, New Delhi, IndiaAD  - Indian Council Med Res, Natl Inst Nutr, New Delhi, IndiaAD  - Indian Council Med Res, Reg Med Res Ctr, New Delhi, IndiaAD  - Int Otorhirtolaryngol Res Assoc, Tehran, IranAD  - Ball State Univ, Dept Nutr & Hlth Sci, Muncie, IN 47306 USAAD  - Lund Univ, Clin Epidemiol, Lund, SwedenAD  - Lund Univ, Dept Clin Sci, Lund, SwedenAD  - Minist Hlth, Nairobi, KenyaAD  - Kenya Revenue Author, Nairobi, KenyaAD  - Synotech Consultant, Res & Data Solut, Nairobi, KenyaAD  - Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USAAD  - Korea Univ, Dept Prevent Med, Seoul, South KoreaAD  - Xiamen Univ Malaysia, Sch Med, Sepang, MalaysiaAD  - Simmons Coll, Dept Nutr, Boston, MA 02115 USAAD  - Univ Canberra, Fac Hlth, Canberra, ACT, AustraliaAD  - Tulane Univ, Dept Global Community Hlth & Behav Sci, New Orleans, LA 70118 USAAD  - Jagiellonian Univ, Coll Med, Dept Hlth Econ & Social Secur, Krakow, PolandAD  - Jagiellonian Univ, Coll Med, Inst Publ Hlth, Krakow, PolandAD  - Univ Helsinki, Dept Publ Hlth, Helsinki, FinlandAD  - Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USAAD  - Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Suita, Osaka, JapanAD  - Arthrit Res Canada, Richmond, BC, CanadaAD  - Sheri Kashmir Inst Med Sci, Dept Internal & Pulm Med, Srinagar, Jammu & Kashmir, IndiaAD  - Panjab Univ, Dept Anthropol, Chandigarh, IndiaAD  - Univ Montreal, Dept Demog, Montreal, PQ, CanadaAD  - Univ Montreal, Dept Social & Prevent Med, Montreal, PQ, CanadaAD  - Yuksek Ihtisas Univ, Dept Publ Hlth, Ankara, TurkeyAD  - Univ Milano Bicocca, Sch Med & Surg, Monza, ItalyAD  - Kenya Govt Med Res Ctr, Trust Res Programme, Dept Hlth Syst & Res Eth, Nairobi, KenyaAD  - Join Kenyatta Univ Agr & Technol, Dept Basic Sci, Nairobi, KenyaAD  - Acad Med Sci, Dept Community & Family Med, Baghdad, IraqAD  - NCI, Div Canc Epidemiol & Genet, Rockville, MD USAAD  - HelpMeSee, New York, NY USAAD  - Mexican Inst Ophthalmol, Int Relat, Queretaro, MexicoAD  - Municipal Hlth Dept Belo Horizonte, Belo Horizonte City Hall, Belo Horizonte, MG, BrazilAD  - Uppsala Univ, Dept Med Sci, Uppsala, SwedenAD  - Uppsala Univ Hosp, Dept Clin Chem & Pharmacol, Uppsala, SwedenAD  - Ghana Hlth Serv, Dis Control Dept, Accra, GhanaAD  - Maragheh Univ Med Sci, Dept Publ Hlth, Maragheh, IranAD  - Maragheh Univ Med Sci, Managerial Epidemiol Res Ctr, Maragheh, IranAD  - Nova Southeastern Univ, Coll Optometry, Ft Lauderdale, FL 33314 USAAD  - JM Sechenov First Moscow State Med Univ, Dept Informat & Internet Technol, Moscow, RussiaAD  - Fed Res Inst Hlth Org & Informat, Minist Hlth, Cent Res Inst Cytol & Genet, Moscow, RussiaAD  - Fed Res Inst Hlth Org & Informat, Minist Hlth, Dept Math Modeling Hlth Care, Moscow, RussiaAD  - Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Hong Kong, Peoples R ChinaAD  - Sodertorn Univ, Sch Social Sci, Huddinge, SwedenAD  - Natl Inst Hlth Dev, Dept Epidemiol & Biostat, Tallinn, EstoniaAD  - Univ Clin Res Unit, Wellcome Trust Asia Programme, Hanoi, VietnamAD  - Sichuan Univ, West China Univ Hosp 2, Chengdu, Sichuan, Peoples R ChinaAD  - Shenzhen Sun Nat set Cardiovasc Hosp, Dept Clin Res & Epidemiol, Shenzhen, Peoples R ChinaAD  - Natl Off Maternal & Child Hlth Surveillance, Chengdu, Sichuan, Peoples R ChinaAD  - Natl Ctr Birth Defects Monitoring China, Chengdu, Sichuan, Peoples R ChinaAD  - Univ Malaya, Dept Med, Kuala Lumpur, MalaysiaAD  - Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R ChinaAD  - Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R ChinaAD  - Univ Haifa, Sch Publ Hlth, Haifa, IsraelAD  - Ctr Chron Dis Control, Beijing, Peoples R ChinaAD  - Univ Bari Aldo Moro, Bari, ItalyAD  - Fdn Cardinale Giovann Panico Hosp, Dept Clin Res Neurol, Tricase, ItalyAD  - Univ Melbourne, Dept Paediat, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Sch Hlth Sci, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Vic, AustraliaAD  - Friedrich Schiller Univ Jena, Inst Nutr, Jena, GermanyAD  - Competence Cluster Nutr & Cardiovascular Hlth nut, Jena, GermanyAD  - Swansea Univ, Hlth Data Res UK, Swansea, W Glam, WalesAD  - Royal Childrens Hosp, Cardiol Dept, Melbourne, Vic, AustraliaAD  - Royal Childrens Hosp, Neurol Dept, Melbourne, Vic, AustraliaAD  - Grant Med Coll, Dept Internal Med, Bombay, Maharashtra, IndiaAD  - Sir JJ Grp Hosp, Bombay, Maharashtra, IndiaAD  - Tribhuvan Univ, Inst Med, Kathmandu, NepalAD  - Trnava Univ, Dept Publ l lealth, Trnava, SlovakiaAD  - Shiraz Univ Med Sci, Noncommunicable Dis Res Ctr, Shiraz, IranAD  - Emergency Univ Hosp Bucharest, Surg Dept, Bucharest, RomaniaAD  - Publ Risk Management Inst, Mississauga, ON, CanadaAD  - World Bank, Trade & Competitiveness, New York, NY USAAD  - Dalhousie Univ, Dept Phys & Atmospher Sci, Halifax, NS, CanadaAD  - Hosp Moinhos Vento, Neurol Serv, Porto Alegre, RS, BrazilAD  - Fed Inst Educ Sci & Technol Ceara, Campus Caucaia, Caucaia, BrazilAD  - Chalmers Univ Technol, Dept Biol & Biol Engn, Gothenburg, SwedenAD  - Hywel Dda Univ Hlth Board, Dept Ophthalmol, Carmarthen, Dyfed, WalesAD  - Aarhus Univ, Natl Ctr Register Based Res, Aarhus, DenmarkAD  - Alaska Native Med Ctr, Liver Dis & Hepatitis Program, Anchorage, AK USAAD  - Res Monitoring & Evaluat, Kathmandu, NepalAD  - Janakpuri Super Specialty Hosp Soc, Neurol Dept, New Delhi, IndiaAD  - Natl Inst Canc Prevent & Res, Prevent Oncol, Noida, IndiaAD  - SevenHills Hosp, Dept Internal Med, Bombay, Maharashtra, IndiaAD  - Prince Mohammed Bin Abdulaziz Hosp, Res Dept, Riyadh, Saudi ArabiaAD  - Wollo Univ, Dept Adult Hlth Nursing, Dessie, EthiopiaAD  - Wollo Univ, Dept Pharm, Dessie, EthiopiaAD  - Wollo Univ, Dept Publ Hlth, Dessie, EthiopiaAD  - Debre Tabor Univ, Coll Hlth Sci, Debre Tabor, EthiopiaAD  - Univ West Florida, Dept Publ Hlth, Pensacola, FL 32514 USAAD  - United Nations Populat Fund UNITA, Peru Country Off, Lima, PeruAD  - Helsinki Univ Hosp, Breast Surg Unit, Helsinki, FinlandAD  - Helsinki Univ Hosp, Neuroctr, Helsinki, FinlandAD  - Dr Zora Profoz Polyclin, Clin Microbiol & Parasitol Unit, Zagreb, CroatiaAD  - Univ North, Univ Ctr Varazdin, Varazhdin, CroatiaAD  - Ethiopian Acad Med Sci, Mekelle, EthiopiaAD  - Pomeranian Med Univ, Dept Hypertens, Szczecin, PolandAD  - Pomeranian Med Univ, Emergency Dept, Szczecin, PolandAD  - Pomeranian Med Univ, Zddroje Hosp, Szczecin, PolandAD  - Pacific Inst Res & Evaluat, Calverton, MD USAAD  - Bellingham Tech Coll, Inst Res, Bellingham, WA USAAD  - Whatcom Community Coll, Inst Res, Bellingham, WA USAAD  - Nevada Div Publ & Behav Hlth, Carson City, NV USAAD  - Kyrgyz State Med Acad, Fac Gen Med, Bishkek, KyrgyzstanAD  - Natl Ctr Cardiol & Internal Dis, Dept Atherosclerosis & Coronary Heart Dis, Bishkek, KyrgyzstanAD  - Frankfurt Univ Appl Sci, Inst Addict Res ISFT, Frankfurt, GermanyAD  - Salaltaddin Univ, Dept Biol, Erbil, IraqAD  - ISHIK Univ, Erbil, IraqAD  - Isfahan Univ Med Sci, Cardiovasc Res Inst, Esfahan, IranAD  - Igjiga Univ, Dept Publ Hlth, Jigjiga, EthiopiaAD  - Allinadu Bello Univ, Dept Community Med, Zaria, NigeriaAD  - Allinadu Bello Univ, Hlth Syst & Policy Res Unit, Zaria, NigeriaAD  - Narayana Hlth, Pulnionol & Internal Med, Bangalore, Karnataka, IndiaAD  - Madras Diabet Res Fdn, Dept Diabetol, Madras, Tamil Nadu, IndiaAD  - Kurdistan Univ Med Sci, Clin Epidemiol & Publ Hlth Res Unit, Trieste, ItalyAD  - Kurdistan Univ Med Sci, Burlo Garofolo Inst Maternal & Child Hlth, Trieste, ItalyAD  - Kurdistan Univ Med Sci, Dept Epidemiol & Biostat, Sanandaj, IranAD  - Kurdistan Univ Med Sci, Social Determinants Hlth Res Ctr, Sanandaj, IranAD  - Univ Lancaster, Lancaster, EnglandAD  - Queensland Univ Technol, Int Lab Air Qual & Hlth, Brisbane, Qld, AustraliaAD  - Queensland Univ Technol, Sch Exercise & Nutr Sci, Brisbane, Qld, AustraliaAD  - Hosp Ctr Porto, Hosp Sto Antonio, Porto, PortugalAD  - Natl Ctr Child Hlth & Dev, Dept Hlth Policy, Tokyo, JapanAD  - Natl Ctr Child Hlth & Dev, Dept Social Med, Tokyo, JapanAD  - Tarbiat Modares Univ, Dept Clin Biochem, Tehran, IranAD  - Univ Athens, Dept Ophthalmol, Athens, GreeceAD  - Acad Athens, Biomed Res Fdn, Athens, GreeceAD  - Fed Inst Populat Res, Competence Ctr Mortal Follow Up, Wiesbaden, GermanyAD  - Fed Inst Populat Res, Demog Change & Ageing Res Area, Wiesbaden, GermanyAD  - Ctr Populat & Hlth, Wiesbaden, GermanyAD  - Inst Post Grad Med Educ & Res, Dept Endocrinol & Metab, Kolkata, IndiaAD  - Natl Inst Epidemiol, Madras, Tamil Nadu, IndiaAD  - Univ Jos, Dept Obstet & Gynecol, Jos, NigeriaAD  - Northwestern Univ, Ctr Global Hlth, Chicago, IL 60611 USAAD  - Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USAAD  - Sch Med Sci, Kubang Kerian, MalaysiaAD  - Nislitar Med Univ, Pediat Dept, Multan, PakistanAD  - Inst Mother & Child Care, Pediat & Pediat Pulnionol, Multi, PakistanAD  - Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USAAD  - Initiat Financing & Human Dev, Dept Res & Analyt, Madras, Tamil Nadu, IndiaAD  - Univ Ulm, Inst Epidemiol & Med Biometry, Ulm, GermanyAD  - Salus Univ, Dept Publ Hlth, Philadelphia, PA USAAD  - San Bortolo Hosp, Dept Dermatol, Vicenza, ItalyAD  - GISED Study Ctr, Bergamo, ItalyAD  - Chungnam Natl Univ, Dept Prevent Med & Publ l lealth, Sch Med, Daejeon, South KoreaAD  - Chungnani Natl Univ Hosp, Daejeon Reg Canc Ctr, Daejeon, South KoreaAD  - Suraj Eye Inst, Nagpur, Maharashtra, IndiaAD  - Univ Yaounde, Dept Publ Heath, Yaounde, CameroonAD  - Mercy St Vincent Med Ctr, Toledo, OH USAAD  - Univ Embu, Dept Biol Sci, Embu, KenyaAD  - Minist Hlth Community Dev Gender Elderly & Childr, Dar Es Salaam, TanzaniaAD  - Hanoi Sch Publ Hlth, Hanoi, VietnamAD  - State Univ Semarang, Publ Hlth Sci Dept, Kota Semarang, IndonesiaAD  - South African Embassy, Natl Dept Hlth, Pretoria, South AfricaAD  - Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, NorwayAD  - Aix Marseille Univ, Inst Adv Res, Marseille, FranceAD  - Abia State Univ, Dept Med, Uthrit, NigeriaAD  - Univ Western Sydney, Sch Social Sci & Psychol, Penrith, NSW, AustraliaAD  - Kyung Hee Univ, Dept Prevent Med, Seoul, South KoreaAD  - Soc Family Hlth, Res Measurement & Results, Fct, NigeriaAD  - Human Sci Res Council, Dept Hiv AIDS & TB, Durban, South AfricaAD  - Univ Namibia, Sch Publ Hlth, Oshakati Campus, Windhoek, NamibiaAD  - Ctr Healthy Start Initiat, Ikoyi, NigeriaAD  - Minist Hlth, NCD Prevent & Control Unit, Bandar Seri Begawan, BruneiAD  - Univ Brunei Darussalam, Inst Hlth Sci, Gadong, BruneiAD  - Lira Dist Local Govt, Dept Hlth, Lira, UgandaAD  - San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USAAD  - Autonomous Univ Madrid, Pneumol Serv, Madrid, SpainAD  - Autonomous Univ Madrid, Sch Med, Madrid, SpainAD  - Jinienez Diaz Univ Hosp, Inst Hlth Res Fdn, Nephrol & Hypertens, Madrid, SpainAD  - Univ Maryland, Ctr Vaccine Dev, Baltimore, MD 21201 USAAD  - Jonkoping Univ, Sch Hlth & Welf, Jonkoping, SwedenAD  - St Lukes Int Univ, Dept Global Hlth Nursing, Chuo Ku, Tokyo, JapanAD  - Minist Hlth Russian Federat, Ctr Healthcare Qual Assessment & Control, Moscow, RussiaAD  - Moscow MV Lomonosov State Univ, Moscow Inst Phys & Technol, Dolgoprudnyi, RussiaAD  - Jagadguru Sri Shivarathreeswara Univ, Dept TB & Resp Med, Mysore, Karnataka, IndiaAD  - Univ Ottawa, Dept Med, Ottawa, ON, CanadaAD  - Acad Sinica, Inst Biomed Sci, Taipei, TaiwanAD  - Ctr Hlth Outcomes Kee Evaluat, Lealth Outcomes, Bucharest, RomaniaAD  - Attikon Univ Hosp, Dept Obstet & Gynecol, Chaidrai, GreeceAD  - Kosin Univ, Dept Med Human & Social Med, Busan, South KoreaAD  - Maimonides Hosp, Dept Med, Brooklyn, NY 11219 USAAD  - Int Inst Hlth Management Res, New Delhi, IndiaAD  - Murdoch Childress Res Inst, Populat Hlth Grp, Melbourne, Vic, AustraliaAD  - Murdoch Childress Res Inst, Melbourne, Vic, AustraliaAD  - Diabet Res Soc, Clin Res Dept, Hyderabad, IndiaAD  - DiabetOnuics, Dept Clin Res, Portland, OR USAAD  - Save Children, Hlth Nutr & HIV AIDS Program, Kathmandu, NepalAD  - Ludwig Maximilians Univ Munchen, Ctr Int Hlth, Munich, GermanyAD  - Cartagena Univ, Cartagena, ColombiaAD  - Univ Virginia, Anesthesiol Dept, Charlottesville, VA USAAD  - Univ Virginia, Sch Med, Charlottesville, VA 22908 USAAD  - Univ Gothenburg, Inst Med, Gothenburg, SwedenAD  - Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South AfricaAD  - Shanghai Jiao Tong Univ, Mental Hlth Ctr, Shanghai, Peoples R ChinaAD  - Durban Univ Technol, Basic Med Sci Dept, Durban, South AfricaAD  - Univ Newcastle, Discipline Gen Practice, Callaghan, NSW, AustraliaAD  - Univ Groningen, Univ Med Ctr Groningen, Groningen, NetherlandsAD  - Sanjay Gandhi Postgraduate Inst Med Sci, Dept Nephrol, Lucknow, Uttar Pradesh, IndiaAD  - Alborg Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, IranAD  - Univ Ghana, Sch Publ Hlth, Accra, GhanaAD  - Medichem, Barcelona, SpainAD  - Contech Sch Publ Hlth, Dept Epidemiol & Biostat, Lahore, PakistanAD  - Contech Sch Publ Hlth, Dept Publ Hlth, Lahore, PakistanAD  - Global Publ Hlth Res Fdn, Div Res, Dhaka, BangladeshAD  - Sweidi Hosp, Dept Clin Pediat, Riyadh, Saudi ArabiaAD  - North West Univ, Dept Pediat, Peshawar, PakistanAD  - North West Univ, Hypertens Africa Res Team, Peshawar, PakistanAD  - Soc Hlth & Demog Surveillance, Sufi, IndiaAD  - Univ Gottingen, Dept Econ, Gottingen, GermanyAD  - Med Univ Innsbruck, Innsbruck, AustriaAD  - Univ Hlth Sci, Publ Hlth Dept, Lahore, PakistanAD  - Yonsei Univ, Inst Poverty Alleviat & Int Dev, Wonju, South KoreaAD  - Fundacao Oswaldo Cruz, Goncalo Moniz Inst, Salvador, BA, BrazilAD  - Fundacao Oswaldo Cruz, Inst Sci & Technol Commun & Informat Hlth, Salvador, BA, BrazilAD  - Univ Coll London Hosp, London, EnglandAD  - Publ Hlth England, London, EnglandAD  - Loma Linda Univ, Med Ctr, Dept Prevent Med & Occupat Med, Loma Linda, CA USAAD  - Brien Holden Vision Inst, Sydney, NSW, AustraliaAD  - Org Prevent Blindness, Paris, FranceAD  - Birjand Univ Med Sci, Dept Epidemiol, Birjand, IranAD  - Univ Fed Uberlandia, Dept Clin Res, Uberlandia, MG, BrazilAD  - Golestan Univ Med Sci, Gorestan Res Ctr Gastroenterol & Hepatol, Gorgan, IranAD  - IKIAM Amazon Reg Univ, Biotechnol, Ciudad De Tena, EcuadorAD  - Southern Univ Sci & Technol, Dept Ocean Sci & Engn, Shenzhen, Peoples R ChinaAD  - Muhimbili Univ Hlth & Allied Sci, Dept Community Hlth, Dar Es Salaam, TanzaniaAD  - Muhimbili Univ Hlth & Allied Sci, Sch Publ Hlth, Dar Es Salaam, TanzaniaAD  - Prince Wales Hosp, Neuropsychiat Inst, Randwick, NSW, AustraliaAD  - Univ Sharjah, Med Dept, Sharjah, U Arab EmiratesAD  - Al Imam Mohammad Ibn Saud IslamIc Univ, Coll Med, Riyadh, Saudi ArabiaAD  - York Univ, Sch Hlth & Policy Management, Toronto, ON, CanadaAD  - Punjab Univ Coll Pharm, Anarkali, PakistanAD  - Chest Res Fdn, Clin Res Div, Pune, Maharashtra, IndiaAD  - Minist Hlth, Hlth & Disabil Intelligence Grp, Wellington, New ZealandAD  - Marshall Univ, Dept Surg, Huntington, WV USAAD  - Case Western Reserve Univ, Dept Nutr & Prevent Med, Cleveland, OH 44106 USAAD  - Jimenez Diaz Fdn Univ, Hosp Inst Hlth Res, Jimenez Diaz Fdn Univ, Nephrol Grp, Madrid, SpainAD  - Univ Massachusetts, Med Sch, Dept Med, Worcester, MA 01605 USAAD  - Hamad Med Corp, Surg Dept, Doha, QatarAD  - Bournemouth Univ, Fac Hlth & Social Sci, Bournemouth, Dorset, EnglandAD  - Utkal Univ, UGC Ctr Adv Study Psychol, Bhubaneswar, IndiaAD  - UdyamGlobal Assoc Sustainable Dev, Bhubaneswar, IndiaAD  - GSK Biol, Wayne, NJ USAAD  - Univ N Carolina, Dept Publ Hlth Sci, Charlotte, NC USAAD  - Univ N Carolina, Dept Publ Hlth Sci, Charlotte, NC USAAD  - Univ Fed Santa Catarina, Sch Hlth Sci, Ararangua, BrazilAD  - German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, GermanyAD  - Univ Zagreb, Dept Med Stat Epidemiol arid Med Informat, Zagreb, CroatiaAD  - Croatian Inst Publ Hlth, Div Epidemiol & Prevent Chron Noncommunicable Dis, Zagreb, CroatiaAD  - An Najah Natl Univ, Publ Hlth Div, Nablus, PalestineAD  - Islamic Azad Univ, Dept Basic Sci, Sari, IranAD  - Islamic Azad Univ, Dept Lab Sci, Sari, IranAD  - Minist Hlth, Policy & Planning Div, Thimphi, BhutanAD  - Delhi Technol Univ, Univ Sch Management arid Entrepreneurship, New Delhi, IndiaAD  - Dept Hlth, Dept Hlth Serv, Kathmandu, NepalAD  - Fudan Univ, Dept Pulm Med, Shanghai, Peoples R ChinaAD  - Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, ScotlandAD  - Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA USAAD  - Natl Inst Infect Dis, Tokyo, JapanAD  - Finnish Inst Occupat Hlth, Helsinki, FinlandAD  - Washington State Univ, Pullman, WA 99164 USAAD  - Symbiosis Int Univ, Symbiosis Inst Hlth Sci, Pune, Maharashtra, IndiaAD  - Univ Technol Sydney, Sch Hlth, Sydney, NSW, AustraliaAD  - Reykjavik Univ, Dept Psychol, Reykjavik, IcelandAD  - Portuguese Inst Sport & Youth, Lisbon, PortugalAD  - Brasilia Univ, Brasilia, DF, BrazilAD  - Max Hosp, Ghaziabad, IndiaAD  - Energy & Resources Inst Sch Adv Studies, Dept Policy Studies, New Delhi, IndiaAD  - Asthma Bhawan, Dept Pulm Med, Jaipur, Rajasthan, IndiaAD  - Sch Prevent Oncol, Dept Epidemiol, Patna, Bihar, IndiaAD  - King Khalid Univ Hosp, Pediat Dept, Riyadh, Saudi ArabiaAD  - Hlth Res Inst Univ Hosp de la Princesa, Serv Pulmonol, Madrid, SpainAD  - Int Med Univ, Div Community Med, Kuala Lumpur, MalaysiaAD  - Inst Chartered Accountants India, Madras, Tamil Nadu, IndiaAD  - Athens Univ Appl Sci, Dept Occupat Therapy, Athens, GreeceAD  - Univ Hosp Munich, Inst & Outpatient Clin Occupat, Social & Environm Med, Munich, GermanyAD  - Med Informat & Technol, Dept Publ Hlth, Hlth Serv Res & Hlth, Technol Assessment, Hall In Tirol, AustriaAD  - Int Agcy Res Canc, Sect Evidence Synth & Classificat, Lyon, FranceAD  - Muhammadiyah Univ Surakarta, Dept Nursing, Kartasura, IndonesiaAD  - Univ Calif Riverside, Sch Med, Riverside, CA USAAD  - Univ Valencia, Dept Med, Valencia, SpainAD  - Univ Valencia, Dept Pediat Obstet & Gynecol, Valencia, SpainAD  - Biomed Res Networking Ctr Mental Hlth Network Cib, Carlos III Hlth Inst, Madrid, SpainAD  - Osaka Int Canc Inst, Canc Control Ctr, Osaka, JapanAD  - Africa Hlth Res Inst, Berea, South AfricaAD  - New York Med Coll, Dept Psychiat & Behav Sci, Valhalla, NY 10595 USAAD  - Univ Inst Egas Moniz, Monte De Caparica, PortugalAD  - Univ Lisbon, Res Inst Med, Fac Pharm Lisbon, Lisbon, PortugalAD  - Business & Technol Coll, Alkali Hlth Sci, Selihom Sch Nursing, Dessie, EthiopiaAD  - Syrian Expatriate Med Assoc, Charlottesville, VA USAAD  - Peter Doherty Inst Infect & Immun, WHO Collaborating Ctr Viral Hepatitis, Melbourne, Vic, AustraliaAD  - Adapt Knowledge Management, Dept Global Hlth Res, Victoria, BC, CanadaAD  - Agcy Hlth Technol Assessment & Tariff Syst, Warsaw, PolandAD  - Univ Hosp Doctor Peset, Pediat Dept, Valencia, SpainAD  - Hanoi Med Univ, Dept Hlth Econ, Hanoi, VietnamAD  - Mil Med Univ, Clin Hematol & Toxicol, Hanoi, VietnamAD  - Natl Inst Res TB, Madras, Tamil Nadu, IndiaAD  - Cleveland Clin, CV Med, Cleveland, OH 44106 USAAD  - Cleveland Clin Abu Dhabi, CV Med, Abu Dhabi, U Arab EmiratesAD  - Fed Teaching Hosp, Dept Internal Med, Abakaliki, NigeriaAD  - Gomal Univ, Gomal Ctr Biochem & Biotechnol, Dera Ismail Khan, PakistanAD  - Mufti Mehmood Mem Teaching Hosp, TB Culture Lab, Dera Ismail Khan, PakistanAD  - Argentine Soc Med, Buenos Aires, ArgentinaAD  - Velez Sarsfield Hosp, Buenos Aires, DF, ArgentinaAD  - UKK Inst, Tampere, FinlandAD  - Raffles Hosp, Raffles Neurosci Ctr, Singapore, SingaporeAD  - Natl Univ Singapore, Yong Loo fin Sch Med, Singapore, SingaporeAD  - Cornell Univ, Weill Cornell Med Dept Pediat, Ithaca, NY USAAD  - St Orsola Malpighi Hosp, Occupat Hlth Unit, Bologna, ItalyAD  - Natl Res Univ, Higher Sch Econ, Dept Hlth Care Adm & Econ, Moscow, RussiaAD  - Fdn Univ, Coll Med, Rawalpindi, PakistanAD  - Canc Registry Norway, Dept Res, Oslo, NorwayAD  - Univ Penn, Ctr Populat Studies, Philadelphia, PA 19104 USAAD  - Tech Univ Munich, Dept Neurol, Munich, GermanyAD  - Kailuan Gen Hosp, Kailuan Gen Hosp, Tangshan, Peoples R ChinaAD  - St Johns Natl Acad Hlth Sci, Dept Pharmacol, Bangalore, Karnataka, IndiaAD  - Nanjing Univ, Sch Med, Nanjing, Jiangsu, Peoples R ChinaAD  - Milad Gen Hosp, Clin Canc Res Ctr, Tehran, IranAD  - Duke Univ, Duke Global Hlth Inst, Durham, NC USAAD  - King Fand Univ Petr & Minerals, Dept Earth Sci, Dhahran, Saudi ArabiaAD  - Wolkite Univ, Wolkite, EthiopiaAD  - Univ South Australia, Adelaide, NSW, AustraliaAD  - Kyoto Univ, Dept Biostat, Kyoto, JapanAD  - Univ Kinshasa, Sch Publ Hlth, Kinshasa, DEM REP CONGOAD  - Jackson State Univ, Dept Hlth Policy & Management, Jackson, MS USAAD  - Tsinghtta Univ, Tsinghua Univ, Beijing, Peoples R ChinaAD  - Wuhan Univ, Dept Epidemiol & Biostat, Wuhan, Hubei, Peoples R ChinaAD  - Wuhan Univ, Global Hlth Inst, Wuhan, Hubei, Peoples R ChinaAD  - Clinton Hlth Access Initiat, Hlth Care Financing Program, Addis Ababa, EthiopiaAD  - RMIT Univ, Sch Hlth & Biomed Sci, Melbourne, Vic, AustraliaAD  - Univ Houston, Houston, TX USAAD  - Minist Hlth, Israeli Ctr Dis Control, Ramat Gan, IsraelAD  - Tel Aviv Univ, Sch Publ Hlth, Tel Aviv, IsraelC3  - Institute for Health Metrics & EvaluationC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Sapienza University RomeC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - McGill UniversityC3  - McGill UniversityC3  - McGill UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - University of CalgaryC3  - University of CalgaryC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Manonmaniam Sundaranar UniversityC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - University HohenheimC3  - CHU LimogesC3  - Universite de LimogesC3  - Qatar Foundation (QF)C3  - Weill Cornell Medical College QatarC3  - Birzeit UniversityC3  - Dongguk UniversityC3  - Stellenbosch UniversityC3  - Stellenbosch UniversityC3  - Stellenbosch UniversityC3  - South African Medical Research CouncilC3  - South African Medical Research CouncilC3  - University of IbadanC3  - University College Hospital, IbadanC3  - University of IbadanC3  - University College Hospital, IbadanC3  - Obafemi Awolowo UniversityC3  - Cardiff UniversityC3  - University of Southern DenmarkC3  - Universidad de ExtremaduraC3  - McMaster UniversityC3  - McMaster UniversityC3  - Yerevan State UniversityC3  - National Academy of Sciences of ArmeniaC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Baylor College of MedicineC3  - Baylor College of MedicineC3  - Public Health Foundation of IndiaC3  - Public Health Foundation of IndiaC3  - Public Health Foundation of IndiaC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - University of Rhode IslandC3  - University of IbadanC3  - University of KentuckyC3  - University of TorontoC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - Mayo ClinicC3  - Washington University (WUSTL)C3  - University of Western AustraliaC3  - University of Western AustraliaC3  - University of Western AustraliaC3  - Australian National UniversityC3  - Australian National UniversityC3  - King Saud UniversityC3  - King Saud UniversityC3  - King Saud UniversityC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - Qazvin University of Medical Sciences (QUMS)C3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Kuwait UniversityC3  - Luxembourg Institute of HealthC3  - United Arab Emirates UniversityC3  - Jazan UniversityC3  - Jazan UniversityC3  - Hospital del Mar Research InstituteC3  - Hospital del MarC3  - Pompeu Fabra UniversityC3  - King Abdulaziz UniversityC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - Universidad de CartagenaC3  - Universidad de la CostaC3  - University of South AustraliaC3  - South Australian Health & Medical Research Institute (SAHMRI)C3  - South Australian Health & Medical Research Institute (SAHMRI)C3  - American University of BeirutC3  - American University of BeirutC3  - American University of BeirutC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - University of ThessalyC3  - Arba Minch UniversityC3  - Zahedan University of Medical SciencesC3  - Universitas HasanuddinC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - Kwame Nkrumah University Science & TechnologyC3  - Birmingham City UniversityC3  - Dalarna UniversityC3  - Mashhad University of Medical SciencesC3  - Mashhad University of Medical SciencesC3  - University of LahoreC3  - University Ha'ilC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Dr DY Patil Vidyapeeth PuneC3  - Dr D Y Patil Medical College, Hospital & Research CentreC3  - University of LeicesterC3  - University of LeicesterC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - Instituto Nacional de Salud - PeruC3  - Dilla UniversityC3  - University of TokyoC3  - University of TokyoC3  - University of TokyoC3  - University of TokyoC3  - Western University (University of Western Ontario)C3  - Western University (University of Western Ontario)C3  - Burnet InstituteC3  - University of MaltaC3  - University of Kwazulu NatalC3  - University of Kwazulu NatalC3  - University of LagosC3  - University of LagosC3  - Public Health Agency of CanadaC3  - Public Health Agency of CanadaC3  - Sri Ramachandra Institute of Higher Education & ResearchC3  - Medical University LodzC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - Egyptian Knowledge Bank (EKB)C3  - Alexandria UniversityC3  - Clinical Centre of SerbiaC3  - University of BelgradeC3  - University of BelgradeC3  - University of BelgradeC3  - Universidad Costa RicaC3  - Universidad Costa RicaC3  - University of AucklandC3  - University of AucklandC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard T.H. Chan School of Public HealthC3  - Harvard UniversityC3  - ISGlobalC3  - ISGlobalC3  - Centro de Investigacao em Saude de ManhicaC3  - University of CanterburyC3  - Stanford UniversityC3  - Stanford UniversityC3  - Charles R. Drew University of Medicine & ScienceC3  - University of California SystemC3  - University of California Los AngelesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - CHU Dijon BourgogneC3  - Universite de BourgogneC3  - Yale UniversityC3  - Yale UniversityC3  - University of AlbertaC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - NYU Langone Medical CenterC3  - New York UniversityC3  - World Health OrganizationC3  - New York UniversityC3  - University System of GeorgiaC3  - Augusta UniversityC3  - University of LondonC3  - London School Economics & Political ScienceC3  - University of LondonC3  - London School Economics & Political ScienceC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - Emory UniversityC3  - Emory UniversityC3  - Rollins School Public HealthC3  - State University System of FloridaC3  - University of South FloridaC3  - University of BirminghamC3  - University of BirminghamC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - Nepal Academy of Science & Technology (NAST)C3  - Aga Khan UniversityC3  - Aga Khan UniversityC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - University of DhakaC3  - University of BolognaC3  - Research Triangle InstituteC3  - University of NottinghamC3  - University of OsloC3  - University of OsloC3  - University of OsloC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - Anglia Ruskin UniversityC3  - Ruprecht Karls University HeidelbergC3  - University of GenoaC3  - Danube University KremsC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - University of British ColumbiaC3  - University of British ColumbiaC3  - University of British ColumbiaC3  - Comenius University BratislavaC3  - University System of OhioC3  - Ohio State UniversityC3  - University System of OhioC3  - Ohio State UniversityC3  - University System of OhioC3  - Ohio State UniversityC3  - Instituto Conmemorativo Gorgas de Estudios de la SaludC3  - Instituto Conmemorativo Gorgas de Estudios de la SaludC3  - Partners Healthcare SystemC3  - Nanyang Technological UniversityC3  - Nanyang Technological UniversityC3  - Nanyang Technological UniversityC3  - Nanyang Technological UniversityC3  - Imperial College LondonC3  - Imperial College LondonC3  - Imperial College LondonC3  - Imperial College LondonC3  - Imperial College LondonC3  - Universidad Autonoma Metropolitana - MexicoC3  - Universidade do PortoC3  - Universidade do PortoC3  - i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidad Nacional de ColombiaC3  - Hacettepe UniversityC3  - Hacettepe UniversityC3  - Australian Catholic UniversityC3  - Australian Catholic UniversityC3  - University of Hong KongC3  - University of Hong KongC3  - University of Hong KongC3  - Alfaisal UniversityC3  - National Health Research Institutes - TaiwanC3  - National Health Research Institutes - TaiwanC3  - National Taiwan UniversityC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - University West Indies Mona JamaicaC3  - University West Indies Saint AugustineC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalC3  - Monash UniversityC3  - Monash UniversityC3  - Monash UniversityC3  - Monash UniversityC3  - University of ZambiaC3  - University of WitwatersrandC3  - Ministry of Health IraqC3  - Seoul National University (SNU)C3  - Seoul National University HospitalC3  - University of CambridgeC3  - University of CopenhagenC3  - University of CopenhagenC3  - University of CopenhagenC3  - Bispebjerg HospitalC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - University of AdelaideC3  - University of AdelaideC3  - University of AdelaideC3  - Robinson Research InstituteC3  - University of SalernoC3  - University of BielefeldC3  - University of BielefeldC3  - Universidad Autonoma de ChileC3  - Universidad Autonoma de ChileC3  - Universidad Autonoma de ChileC3  - University of SouthamptonC3  - Mayo ClinicC3  - Arizona State UniversityC3  - Arizona State University-TempeC3  - Centers for Disease Control & Prevention - USAC3  - Universidade Federal do Rio Grande do SulC3  - Universidade Federal do Rio Grande do SulC3  - Hawassa UniversityC3  - Hawassa UniversityC3  - Hawassa UniversityC3  - Flinders University South AustraliaC3  - Duy Tan UniversityC3  - Guy's & St Thomas' NHS Foundation TrustC3  - Guy's & St Thomas' NHS Foundation TrustC3  - King George's Medical UniversityC3  - Bangladesh Rural Advancement Committee BRACC3  - BRAC UniversityC3  - Bangladesh Rural Advancement Committee BRACC3  - BRAC UniversityC3  - Central University of Tamil NaduC3  - Asfendiyarov Kazakh National Medical UniversityC3  - Monash HealthC3  - Griffith UniversityC3  - Griffith University - Mount Gravatt CampusC3  - Griffith UniversityC3  - Griffith University - Mount Gravatt CampusC3  - Ghent UniversityC3  - Ghent UniversityC3  - African Population & Health Research CentreC3  - African Population & Health Research CentreC3  - University of Colorado SystemC3  - University of Colorado Anschutz Medical CampusC3  - US Department of Veterans AffairsC3  - University of BrightonC3  - University of SussexC3  - NHS National Services ScotlandC3  - Aristotle University of ThessalonikiC3  - University of PeradeniyaC3  - Ministry of Health & Medical Education (MOHME)C3  - Ministry of Health & Medical Education (MOHME)C3  - Ministry of Health & Medical Education (MOHME)C3  - Medical University VarnaC3  - University of Cape CoastC3  - University of Cape CoastC3  - Tampere UniversityC3  - Tampere UniversityC3  - University of SydneyC3  - Asbestos Diseases Research InstituteC3  - University of SydneyC3  - University of SydneyC3  - Chinese Center for Disease Control & PreventionC3  - Chinese Center for Disease Control & PreventionC3  - National Center for Chronic & Noncommunicable Disease Control & Prevention, Chinese Center for Disease Control & PreventionC3  - Chinese Center for Disease Control & PreventionC3  - Universidade Federal da BahiaC3  - Universidade Federal da BahiaC3  - Umea UniversityC3  - Eijkman InstituteC3  - Urmia University of Medical SciencesC3  - Food & Agriculture Organization of the United Nations (FAO)C3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - University of LouisvilleC3  - Universidade Federal de SergipeC3  - Hamadan University of Medical SciencesC3  - Hamadan University of Medical SciencesC3  - Hamadan University of Medical SciencesC3  - Auckland University of TechnologyC3  - Organisation for Economic Co-operation & Development (OECD)C3  - Universidade Catolica PortuguesaC3  - Brandeis UniversityC3  - University of MemphisC3  - University of MemphisC3  - Robert Koch InstituteC3  - Universidade Federal do Espirito SantoC3  - National Academy of Medical Sciences of UkraineC3  - D. F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of UkraineC3  - James Cook UniversityC3  - Kobe UniversityC3  - University of BaselC3  - Swiss Tropical & Public Health InstituteC3  - University of BaselC3  - Sidi Mohamed Ben Abdellah University of FezC3  - University of GroningenC3  - University of GroningenC3  - Universidade Nova de LisboaC3  - Institute of Hygiene & Tropical Medicine - UNLC3  - Instituto Nacional de Saude Dr. Ricardo JorgeC3  - Curtin UniversityC3  - Wageningen University & ResearchC3  - Martin Luther University Halle WittenbergC3  - Martin Luther University Halle WittenbergC3  - University of TsukubaC3  - Texas Tech University SystemC3  - Texas Tech UniversityC3  - University of WarwickC3  - University of WarwickC3  - Research Center of NeurologyC3  - Jawaharlal Nehru University, New DelhiC3  - Jawaharlal Nehru University, New DelhiC3  - University of Massachusetts SystemC3  - University of Massachusetts BostonC3  - University of Oklahoma SystemC3  - University of Oklahoma Health Sciences CenterC3  - National Cancer Center - JapanC3  - Boston UniversityC3  - Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele Presidio FerraottoC3  - Universite de LorraineC3  - Eternal Heart Care Centre & Research InstituteC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Yeshiva UniversityC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - Western University (University of Western Ontario)C3  - Arabian Gulf UniversityC3  - Sir Charles Gairdner HospitalC3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Tabriz University of Medical ScienceC3  - Tabriz University of Medical ScienceC3  - University of BarcelonaC3  - University of AntwerpC3  - Karolinska InstitutetC3  - Karolinska University HospitalC3  - Bucharest University of Economic StudiesC3  - Columbia UniversityC3  - Columbia UniversityC3  - Rutgers University SystemC3  - Rutgers University New BrunswickC3  - University of Texas SystemC3  - University of Texas AustinC3  - Guilan University of Medical SciencesC3  - Guilan University of Medical SciencesC3  - Manipal Academy of Higher Education (MAHE)C3  - Yokohama City UniversityC3  - National Institutes of Health (NIH) - USAC3  - National Institutes of Health (NIH) - USAC3  - National Institutes of Health (NIH) - USAC3  - NIH National Heart Lung & Blood Institute (NHLBI)C3  - National Institutes of Health (NIH) - USAC3  - Universite de Tunis-El-ManarC3  - Faculte de Medecine de Tunis (FMT)C3  - Central South UniversityC3  - University of the Western CapeC3  - Walter Sisulu UniversityC3  - Taipei Medical UniversityC3  - Taipei Medical UniversityC3  - Deakin UniversityC3  - Deakin UniversityC3  - Deakin UniversityC3  - American Cancer SocietyC3  - George Mason UniversityC3  - University of KragujevacC3  - University of California SystemC3  - University of California San DiegoC3  - Newcastle University - UKC3  - University of ColomboC3  - University of ColomboC3  - Banaras Hindu University (BHU)C3  - Banaras Hindu University (BHU)C3  - Capital Medical UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Technical University CzestochowaC3  - University of OpoleC3  - Savitribai Phule Pune UniversityC3  - University of TartuC3  - University College CorkC3  - Samara UniversityC3  - European Observatory on Health Systems & PoliciesC3  - European Observatory on Health Systems & PoliciesC3  - University of WashingtonC3  - University of Washington TacomaC3  - Seattle Children's HospitalC3  - MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNITC3  - University of TulsaC3  - University of California SystemC3  - University of California San FranciscoC3  - University of California SystemC3  - University of California San FranciscoC3  - University of NairobiC3  - University of NairobiC3  - Michigan State UniversityC3  - University of Cape TownC3  - University of Cape TownC3  - University of Cape TownC3  - University of Cape TownC3  - Hebrew University of JerusalemC3  - Hadassah University Medical CenterC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Indian Institute of Toxicology Research (IITR)C3  - Jordan University of Science & TechnologyC3  - Islamic Azad UniversityC3  - University of Management & Technology (UMT)C3  - Health Services AcademyC3  - Dow University of Health SciencesC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Tennessee SystemC3  - University of Tennessee Health Science CenterC3  - Seoul National University (SNU)C3  - Seoul National University (SNU)C3  - Indian Council of Medical Research (ICMR)C3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute for Research in Environmental Health (NIREH)C3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Nutrition (NIN)C3  - Indian Council of Medical Research (ICMR)C3  - Ball State UniversityC3  - Lund UniversityC3  - Lund UniversityC3  - Northeastern UniversityC3  - Korea UniversityC3  - Xiamen University Malaysia CampusC3  - Simmons UniversityC3  - University of CanberraC3  - Tulane UniversityC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - University of HelsinkiC3  - Fred Hutchinson Cancer CenterC3  - National Cerebral & Cardiovascular Center - JapanC3  - Arthritis Research CanadaC3  - Sher-i-Kashmir Institute of Medical SciencesC3  - Panjab UniversityC3  - Universite de MontrealC3  - Universite de MontrealC3  - Yuksek Ihtisas UniversityC3  - University of Milano-BicoccaC3  - Kenya Medical Research InstituteC3  - National Institutes of Health (NIH) - USAC3  - NIH National Cancer Institute (NCI)C3  - NIH National Cancer Institute- Division of Cancer Epidemiology & GeneticsC3  - Uppsala UniversityC3  - Uppsala UniversityC3  - Uppsala University HospitalC3  - Ghana Health ServiceC3  - Nova Southeastern UniversityC3  - Ministry of Health of the Russian FederationC3  - Ministry of Health of the Russian FederationC3  - Hong Kong Polytechnic UniversityC3  - Sodertorn UniversityC3  - National Institute for Health Development - EstoniaC3  - Sichuan UniversityC3  - Universiti MalayaC3  - Chinese University of Hong KongC3  - Chinese University of Hong KongC3  - University of HaifaC3  - Universita degli Studi di Bari Aldo MoroC3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - Friedrich Schiller University of JenaC3  - Swansea UniversityC3  - Royal Children's Hospital MelbourneC3  - Royal Children's Hospital MelbourneC3  - Tribhuvan UniversityC3  - Institute of Medicine (IoM) - NepalC3  - University of TrnavaC3  - Shiraz University of Medical ScienceC3  - The World BankC3  - Dalhousie UniversityC3  - Instituto Federal do Ceara (IFCE)C3  - Chalmers University of TechnologyC3  - Aarhus UniversityC3  - Alaska Native Medical CenterC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Cancer Prevention & Research (NICPR)C3  - King Saud Bin Abdulaziz University for Health SciencesC3  - Prince Mohammed bin Abdulaziz Hospital - Al MadinahC3  - State University System of FloridaC3  - University of West FloridaC3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - University North - CroatiaC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pacific Institute for Research & Evaluation (PIRE)C3  - Kyrgyz State Medical AcademyC3  - Ministry of Health - KyrgyzstanC3  - Isfahan University of Medical SciencesC3  - Madras Diabetes Research FoundationC3  - IRCCS Burlo GarofoloC3  - Kurdistan University of Medical SciencesC3  - Kurdistan University of Medical SciencesC3  - Lancaster UniversityC3  - Queensland University of Technology (QUT)C3  - Queensland University of Technology (QUT)C3  - National Center for Child Health & Development - JapanC3  - National Center for Child Health & Development - JapanC3  - Tarbiat Modares UniversityC3  - National & Kapodistrian University of AthensC3  - Academy of AthensC3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Epidemiology (NIE)C3  - University of JosC3  - Northwestern UniversityC3  - Northwestern UniversityC3  - Universiti Sains MalaysiaC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - Ulm UniversityC3  - ULSS 8 BericaC3  - Ospedale San Bortolo di VicenzaC3  - Chungnam National UniversityC3  - Suraj Eye InstituteC3  - University of Yaounde IC3  - Hanoi University of Public HealthC3  - Universitas Negeri SemarangC3  - University of BergenC3  - Aix-Marseille UniversiteC3  - Western Sydney UniversityC3  - Kyung Hee UniversityC3  - Human Sciences Research Council-South AfricaC3  - University of NamibiaC3  - University Brunei DarussalamC3  - California State University SystemC3  - San Diego State UniversityC3  - Autonomous University of MadridC3  - Autonomous University of MadridC3  - University System of MarylandC3  - University of Maryland BaltimoreC3  - Jonkoping UniversityC3  - St. Luke's International HospitalC3  - Ministry of Health of the Russian FederationC3  - Moscow Institute of Physics & TechnologyC3  - Lomonosov Moscow State UniversityC3  - JSS Academy of Higher Education & ResearchC3  - University of OttawaC3  - Academia Sinica - TaiwanC3  - University Hospital AttikonC3  - Maimonides Medical CenterC3  - International Institute of Health Management Research DelhiC3  - Save the ChildrenC3  - University of MunichC3  - Universidad de CartagenaC3  - University of VirginiaC3  - University of VirginiaC3  - University of GothenburgC3  - University of WitwatersrandC3  - Shanghai Jiao Tong UniversityC3  - Durban University of TechnologyC3  - University of NewcastleC3  - University of GroningenC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - University of GhanaC3  - University of GottingenC3  - Medical University of InnsbruckC3  - University of Health Science - PakistanC3  - Yonsei UniversityC3  - Fundacao Oswaldo CruzC3  - Fundacao Oswaldo CruzC3  - University College London Hospitals NHS Foundation TrustC3  - University of LondonC3  - University College LondonC3  - Public Health EnglandC3  - Loma Linda UniversityC3  - Brien Holden Vision InstituteC3  - Universidade Federal de UberlandiaC3  - Golestan University of Medical SciencesC3  - Southern University of Science & TechnologyC3  - Muhimbili University of Health & Allied SciencesC3  - Muhimbili University of Health & Allied SciencesC3  - University of New South Wales SydneyC3  - Prince of Wales Hospital (POWH)C3  - University of SharjahC3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - York University - CanadaC3  - Marshall UniversityC3  - University System of OhioC3  - Case Western Reserve UniversityC3  - University of Massachusetts SystemC3  - University of Massachusetts WorcesterC3  - Hamad Medical CorporationC3  - Bournemouth UniversityC3  - Utkal UniversityC3  - GlaxoSmithKlineC3  - University of North CarolinaC3  - University of North Carolina CharlotteC3  - University of North CarolinaC3  - University of North Carolina CharlotteC3  - Universidade Federal de Santa Catarina (UFSC)C3  - Helmholtz AssociationC3  - German Cancer Research Center (DKFZ)C3  - University of ZagrebC3  - An Najah National UniversityC3  - Islamic Azad UniversityC3  - Islamic Azad UniversityC3  - Delhi Technological UniversityC3  - Fudan UniversityC3  - University of EdinburghC3  - Tufts UniversityC3  - National Institute of Infectious Diseases (NIID)C3  - Finnish Institute of Occupational HealthC3  - Washington State UniversityC3  - Symbiosis International UniversityC3  - Symbiosis Institute of Health Sciences (SIHS)C3  - University of Technology SydneyC3  - Reykjavik UniversityC3  - Universidade de BrasiliaC3  - TERI UniversityC3  - King Saud UniversityC3  - King Khalid University HospitalC3  - International Medical University MalaysiaC3  - University of West AtticaC3  - University of MunichC3  - World Health OrganizationC3  - International Agency for Research on Cancer (IARC)C3  - Universitas Muhammadiyah SurakartaC3  - University of California SystemC3  - University of California RiversideC3  - University of ValenciaC3  - University of ValenciaC3  - Africa Health Research InstituteC3  - New York Medical CollegeC3  - Universidade de LisboaC3  - University of MelbourneC3  - Peter Doherty InstituteC3  - Hanoi Medical UniversityC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute for Research in Tuberculosis (NIRT)C3  - Cleveland Clinic FoundationC3  - Cleveland Clinic FoundationC3  - Gomal UniversityC3  - UKK InstituteC3  - Raffles HospitalC3  - National University of SingaporeC3  - Cornell UniversityC3  - Weill Cornell MedicineC3  - IRCCS Azienda Ospedaliero-Universitaria di BolognaC3  - HSE University (National Research University Higher School of Economics)C3  - University of OsloC3  - University of PennsylvaniaC3  - Technical University of MunichC3  - St. John's National Academy of Health SciencesC3  - Nanjing UniversityC3  - Duke UniversityC3  - King Fahd University of Petroleum & MineralsC3  - University of South AustraliaC3  - Kyoto UniversityC3  - Universite de KinshasaC3  - Jackson State UniversityC3  - Tsinghua UniversityC3  - Wuhan UniversityC3  - Wuhan UniversityC3  - Royal Melbourne Institute of Technology (RMIT)C3  - University of Houston SystemC3  - University of HoustonC3  - Tel Aviv UniversityPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - NOV 10
PY  - 2018
VL  - 392
IS  - 10159
SP  - 2091
EP  - 2138
DO  - 10.1016/S0140-6736(18)32281-5
AN  - WOS:000449710900010
ER  -

TY  - JOUR
AU  - Murray, CJL
AU  - Callender, CSKH
AU  - Kulikoff, XR
AU  - Srinivasan, V
AU  - Abate, D
AU  - Abate, KH
AU  - Abay, SM
AU  - Abbasi, N
AU  - Abbastabar, H
AU  - Abdela, J
AU  - Abdelalim, A
AU  - Abdel-Rahman, O
AU  - Abdi, A
AU  - Abdoli, N
AU  - Abdollahpour, I
AU  - Abdulkader, RS
AU  - Abebe, HT
AU  - Abebe, M
AU  - Abebe, Z
AU  - Abebo, TA
AU  - Abejie, AN
AU  - Aboyans, V
AU  - Abraha, HN
AU  - Abreu, DMX
AU  - Abrham, AR
AU  - Abu-Raddad, LJ
AU  - Abu-Rmeileh, NME
AU  - Accrombessi, MMK
AU  - Acharya, P
AU  - Adamu, AA
AU  - Adebayo, OM
AU  - Adedeji, IA
AU  - Adekanmbi, V
AU  - Adetokunboh, OO
AU  - Adhena, BM
AU  - Adhikari, TB
AU  - Adib, MC
AU  - Adou, AK
AU  - Adsuar, JC
AU  - Afarideh, M
AU  - Afshin, A
AU  - Agarwal, G
AU  - Agesa, KM
AU  - Aghayan, SA
AU  - Agrawal, S
AU  - Ahmadi, A
AU  - Ahmadi, M
AU  - Ahmed, MB
AU  - Ahmed, S
AU  - Aichour, AN
AU  - Aichour, I
AU  - Aichour, MTE
AU  - Akanda, AS
AU  - Akbari, ME
AU  - Akibu, M
AU  - Akinyemi, RO
AU  - Akinyemiju, T
AU  - Akseer, N
AU  - Alahdab, F
AU  - Al-Aly, Z
AU  - Alam, K
AU  - Alebel, A
AU  - Aleman, AV
AU  - Alene, KA
AU  - Al-Eyadhy, A
AU  - Ali, R
AU  - Alijanzadeh, M
AU  - Alizadeh-Navaei, R
AU  - Aljunid, SM
AU  - Alkerwi, A
AU  - Alla, F
AU  - Allebeck, P
AU  - Almasi, A
AU  - Alonso, J
AU  - Al-Raddadi, RM
AU  - Alsharif, U
AU  - Altirkawi, K
AU  - Alvis-Guzman, N
AU  - Amare, AT
AU  - Ammar, W
AU  - Anber, NF
AU  - Andrei, CL
AU  - Androudi, S
AU  - Animut, MD
AU  - Ansari, H
AU  - Ansha, MG
AU  - Antonio, CAT
AU  - Appiah, SCY
AU  - Aremu, O
AU  - Areri, HA
AU  - Arian, N
AU  - Ärnlöv, J
AU  - Artaman, A
AU  - Aryal, KK
AU  - Asayesh, H
AU  - Asfaw, ET
AU  - Asgedom, SW
AU  - Assadi, R
AU  - Atey, TMM
AU  - Afique, S
AU  - Atteraya, MS
AU  - Ausloos, M
AU  - Avokpaho, EFCA
AU  - Awasthi, A
AU  - Quintanilla, BPA
AU  - Ayele, Y
AU  - Ayer, R
AU  - Ayuk, TB
AU  - Azzopardi, PS
AU  - Babalola, TK
AU  - Babazadeh, A
AU  - Radali, H
AU  - Badawi, A
AU  - Bali, AG
AU  - Ranach, M
AU  - Barker-Collo, SL
AU  - Bärnighausen, TW
AU  - Barrero, LH
AU  - Basaleem, H
AU  - Bassat, Q
AU  - Basu, A
AU  - Baune, BT
AU  - Baynes, HW
AU  - Beghi, E
AU  - Behzadifar, M
AU  - Belazadifar, M
AU  - Bekele, BB
AU  - Belachew, AB
AU  - Belay, AG
AU  - Belay, E
AU  - Belay, SA
AU  - Belay, YA
AU  - Bell, ML
AU  - Bello, AK
AU  - Bennett, DA
AU  - Bensenor, IM
AU  - Bergeron, G
AU  - Berhane, A
AU  - Berman, AE
AU  - Bernabe, E
AU  - Bernstein, RS
AU  - Bertolacci, GJ
AU  - Beuran, M
AU  - Bhattarai, S
AU  - Bhaumik, S
AU  - Bhutia, ZA
AU  - Biadgo, B
AU  - Bijani, A
AU  - Rikbov, B
AU  - Bililign, N
AU  - Bin Sayeed, MS
AU  - Birlik, SM
AU  - Birungi, C
AU  - Diswas, T
AU  - Bizuneh, H
AU  - Bleyer, A
AU  - Basara, BB
AU  - Bosetti, C
AU  - Boufous, S
AU  - Brady, OJ
AU  - Bragazzi, NL
AU  - Brainin, M
AU  - Brazinova, A
AU  - Breitborde, NJK
AU  - Brenner, H
AU  - Brewer, JD
AU  - Briant, PS
AU  - Britton, G
AU  - Burstein, R
AU  - Busse, R
AU  - Riff, ZA
AU  - Cahuana-Hurtado, L
AU  - Campos-Nonato, IR
AU  - Rincon, JCC
AU  - Cano, J
AU  - Car, M
AU  - Cárdenas, R
AU  - Carrero, JJ
AU  - Carvalho, F
AU  - Castañeda-Orjuela, CA
AU  - Rivas, JC
AU  - Castro, F
AU  - Catalá-López, F
AU  - Çavin, A
AU  - Cerin, E
AU  - Chalek, J
AU  - Chang, HY
AU  - Chang, JC
AU  - Chattopadhyay, A
AU  - Chaturvedi, P
AU  - Chiang, PPC
AU  - Chin, KL
AU  - Chisumpa, VH
AU  - Chitheer, A
AU  - Choi, JYJ
AU  - Chowdhury, R
AU  - Christopher, DJ
AU  - Cicuttini, FM
AU  - Ciobanu, LG
AU  - Cirillo, M
AU  - Claro, RM
AU  - Collado-Mateo, D
AU  - Constantin, MM
AU  - Conti, S
AU  - Cooper, C
AU  - Cooper, LT
AU  - Cornaby, L
AU  - Cortesi, PA
AU  - Cortinovis, M
AU  - Costa, M
AU  - Cromwell, EA
AU  - Crowe, CS
AU  - Cukelj, P
AU  - Cunningham, M
AU  - Daba, AK
AU  - Dachew, BA
AU  - Dandona, L
AU  - Dandona, R
AU  - Dargan, PI
AU  - Daryani, A
AU  - Das Gupta, RT
AU  - Das Neves, J
AU  - Dasa, TT
AU  - Dash, AP
AU  - Weaver, ND
AU  - Davitoiu, DV
AU  - Davletov, K
AU  - De Leo, D
AU  - De Neve, JW
AU  - Degefa, MG
AU  - Degenhardt, L
AU  - Degfie, TT
AU  - Deiparine, S
AU  - Demoz, GT
AU  - Demtsu, E
AU  - Denova-Gutiérrez, E
AU  - Deribe, K
AU  - Dervenis, N
AU  - Des Jarlais, DC
AU  - Dessie, GA
AU  - Dharniaratne, SD
AU  - Dhimal, M
AU  - Dicker, D
AU  - Ding, EL
AU  - Dinsa, GD
AU  - Djalalinia, S
AU  - Do, HP
AU  - Dokova, K
AU  - Doku, DT
AU  - Dolan, KA
AU  - Doyle, KE
AU  - Driscoll, TR
AU  - Dubey, M
AU  - Dubljanin, E
AU  - Duken, EN
AU  - Duraes, AR
AU  - Ebrahimpour, S
AU  - Edvardsson, D
AU  - El Bcheraoui, C
AU  - El-Khatib, Z
AU  - Elyazar, IR
AU  - Enayati, A
AU  - Endries, AY
AU  - Ermakov, SP
AU  - Eshrati, B
AU  - Eskandarieh, S
AU  - Esmaeili, R
AU  - Esteghamati, A
AU  - Esteghamati, S
AU  - Estep, K
AU  - Fakhim, H
AU  - Farag, T
AU  - Faramarzi, M
AU  - Fareed, M
AU  - Farinha, CSES
AU  - Faro, A
AU  - Farvid, MS
AU  - Farzadfar, F
AU  - Farzaei, MH
AU  - Fay, KA
AU  - Fazeli, MS
AU  - Feigin, VI
AU  - Feigl, AB
AU  - Feizy, F
AU  - Fenny, AP
AU  - Fentahun, N
AU  - Fereshtehnejad, SM
AU  - Femandes, E
AU  - Feyissa, GT
AU  - Filip, I
AU  - Finegold, S
AU  - Fischer, F
AU  - Flor, LS
AU  - Foigt, NA
AU  - Foreman, KJ
AU  - Fornari, C
AU  - Fürst, T
AU  - Fukumoto, T
AU  - Fuller, JE
AU  - Fullman, N
AU  - Gakidou, E
AU  - Gallus, S
AU  - Gamkrelidze, A
AU  - Ganji, M
AU  - Gankpe, FG
AU  - Garcia, GN
AU  - Garcia-Gordillo, MA
AU  - Gebre, AK
AU  - Gebre, T
AU  - Gebregergs, GB
AU  - Gebrehiwot, TT
AU  - Gebremedhin, AT
AU  - Gelano, TF
AU  - Gelaw, YA
AU  - Geleijnse, 'N
AU  - Genova-Maleras, R
AU  - Gething, P
AU  - Gezae, KE
AU  - Ghadami, MR
AU  - Ghadimi, R
AU  - Ghadiri, K
AU  - Falavarjani, KG
AU  - Ghasemi-Kasman, M
AU  - Ghiasvand, H
AU  - Ghimire, M
AU  - Ghoshal, AG
AU  - Gill, PS
AU  - Gill, TK
AU  - Giussani, G
AU  - Gnedovskaya, EV
AU  - Goli, S
AU  - Gomez, RS
AU  - Gómez-Dantés, H
AU  - Gona, PN
AU  - Goodridge, A
AU  - Gopalani, SV
AU  - Goulart, AC
AU  - Niegia, B
AU  - Goulart, G
AU  - Grada, A
AU  - Grosso, G
AU  - Gugnani, HCC
AU  - Guo, JW
AU  - Guo, YM
AU  - Gupta, PC
AU  - Gupta, R
AU  - Gupta, R
AU  - Gupta, T
AU  - Haagsma, JA
AU  - Hachinski, V
AU  - Hafezi-Nejad, N
AU  - Hagos, TB
AU  - Hailegiyorgis, TT
AU  - Hailu, GB
AU  - Haj-Mirzaian, A
AU  - Haj-Mirzaian, A
AU  - Hamadeh, RR
AU  - Hamidi, S
AU  - Handal, AJ
AU  - Hankey, GJ
AU  - Hao, YT
AU  - Harb, HI
AU  - Haririan, H
AU  - Haro, JM
AU  - Hasan, M
AU  - Hassankhani, H
AU  - Hassen, HY
AU  - Havrnoeller, R
AU  - Hay, SI
AU  - He, YH
AU  - Hedayatizadeh-Omran, A
AU  - Hegazy, MI
AU  - Heibati, B
AU  - Heidari, B
AU  - Hendrie, D
AU  - Henok, A
AU  - Henry, NJ
AU  - Herteliu, C
AU  - Heydarpour, F
AU  - Hibstu, DT
AU  - Hole, MK
AU  - Rad, EH
AU  - Hoogar, P
AU  - Hosgood, HD
AU  - Hosseini, SM
AU  - Chavoshi, MMH
AU  - Hosseinzadeh, M
AU  - Hostiuc, M
AU  - Hostiuc, S
AU  - Hsairi, M
AU  - Hsiao, T
AU  - Hu, GQ
AU  - Huang, JJ
AU  - Iburg, KM
AU  - Igumbor, EU
AU  - Ikeda, CT
AU  - Ilesanmi, OS
AU  - Iqbal, U
AU  - Irenso, AA
AU  - Irvani, SSN
AU  - Isehunwa, OO
AU  - Islam, SMS
AU  - Jahangiry, L
AU  - Jahanmehr, N
AU  - Jam, SK
AU  - Jakovljevic, M
AU  - Jalu, MT
AU  - James, SL
AU  - Jassal, SK
AU  - Javanbakht, M
AU  - Jayatilleke, AU
AU  - Jeemon, P
AU  - Jha, RP
AU  - Jha, V
AU  - Ji, JS
AU  - Jonas, JB
AU  - Jozwiak, JJ
AU  - Jungari, SB
AU  - Jürisson, M
AU  - Kabir, Z
AU  - Kadel, R
AU  - Kahsay, A
AU  - Kalani, R
AU  - Kapil, U
AU  - Karami, M
AU  - Martin, BK
AU  - Karch, A
AU  - Karema, C
AU  - Karimi, SM
AU  - Kasacian, A
AU  - Kassa, DH
AU  - Kassa, GM
AU  - Kassa, TD
AU  - Kassa, ZY
AU  - Kassebaum, NJ
AU  - Kastor, A
AU  - Katikireddi, SV
AU  - Kaul, A
AU  - Kawakami, N
AU  - Karyani, AK
AU  - Kebede, S
AU  - Keiyoro, PN
AU  - Kemp, GR
AU  - Kengne, AP
AU  - Keren, A
AU  - Kereselidze, M
AU  - Khader, YS
AU  - Khafaie, MA
AU  - Khajavi, A
AU  - Khalid, N
AU  - Khalil, IA
AU  - Khan, EA
AU  - Khan, MS
AU  - Hang, YHK
AU  - Khanna, T
AU  - Khater, MM
AU  - Khatony, A
AU  - Khazaeipour, Z
AU  - Khazaie, H
AU  - Khoja, AT
AU  - Khosravi, A
AU  - Khosravi, MH
AU  - Kibret, GD
AU  - Kidenemariam, ZT
AU  - Kiirithio, DN
AU  - Kilgore, PE
AU  - Kim, D
AU  - Kim, JY
AU  - Kim, YE
AU  - Kim, YJ
AU  - Kimokoti, RW
AU  - Kinfu, Y
AU  - Kinra, S
AU  - Kisa, A
AU  - Kivimäki, M
AU  - Kochhar, S
AU  - Kokubo, Y
AU  - Kolola, T
AU  - Kopec, JA
AU  - Kosek, MN
AU  - Kosen, S
AU  - Koul, PA
AU  - Koyanagi, A
AU  - Krishan, K
AU  - Krishnaswami, S
AU  - Krohn, KJ
AU  - Defo, BK
AU  - Bicer, BK
AU  - Kumar, GA
AU  - Kumar, M
AU  - Kumar, P
AU  - Kumsa, FA
AU  - Kutz, MJ
AU  - Lad, SD
AU  - Lafranconi, A
AU  - Lal, DK
AU  - Lalloo, R
AU  - Lam, H
AU  - Lami, FH
AU  - Lang, JJ
AU  - Lansky, S
AU  - Lansingh, VC
AU  - Laryea, DO
AU  - Lassi, ZS
AU  - Latifi, A
AU  - Laxmaiah, A
AU  - Lazarus, JV
AU  - Lee, JB
AU  - Lee, PH
AU  - Leigh, J
AU  - Leshargie, CT
AU  - Leta, S
AU  - Levi, M
AU  - Li, SS
AU  - Li, XH
AU  - Li, YC
AU  - Liang, J
AU  - Liang, XF
AU  - Liben, MI
AU  - Lim, LL
AU  - Limenih, MA
AU  - Linn, S
AU  - Liu, SW
AU  - Lorkowski, S
AU  - Lotufo, PA
AU  - Lozano, R
AU  - Lunevicius, R
AU  - Mabika, CM
AU  - Macarayan, ERK
AU  - Mackay, MT
AU  - Madotto, F
AU  - Mahmood, TA
AU  - Mahotra, NB
AU  - Majdan, M
AU  - Majdzadeh, R
AU  - Majeed, A
AU  - Malekzadeh, R
AU  - Malik, MA
AU  - Mamun, AA
AU  - Mariano, WA
AU  - Manda, AL
AU  - Mangalam, S
AU  - Mansournia, MA
AU  - Mantovani, LG
AU  - Mapoma, CC
AU  - Marami, D
AU  - Maravilla, JC
AU  - Marcenes, W
AU  - Marina, S
AU  - Martins-Melo, FR
AU  - Märtz, W
AU  - Marzan, MB
AU  - Mashamba-Thompson, TP
AU  - Masiye, F
AU  - Mason-Jones, AJ
AU  - Massenburg, BB
AU  - Mathur, MR
AU  - Main, PK
AU  - Mazidi, M
AU  - McGrath, JJ
AU  - Mehata, S
AU  - Mehendale, SM
AU  - Mehndiratta, MM
AU  - Mehrotra, R
AU  - Mehrzadi, S
AU  - Mehta, KM
AU  - Mehta, V
AU  - Mekonnen, TC
AU  - Meles, HG
AU  - Meles, KG
AU  - Melese, A
AU  - Melku, M
AU  - Memiah, PTN
AU  - Memish, ZA
AU  - Mendoza, W
AU  - Mengesha, MM
AU  - Mengistu, DT
AU  - Mengistu, G
AU  - Mensah, GA
AU  - Mereta, ST
AU  - Meretoja, A
AU  - Meretoja, TJ
AU  - Mestrovic, T
AU  - Mezgebe, HB
AU  - Miangotar, Y
AU  - Miazgowski, B
AU  - Miazgowski, T
AU  - Miller, TR
AU  - Miller-Petrie, MK
AU  - Mini, GK
AU  - Mirabi, P
AU  - Mirica, A
AU  - Mirrakhimov, EM
AU  - Misganaw, AT
AU  - Moazen, B
AU  - Mohammad, KA
AU  - Mohammadi, M
AU  - Mohammadifard, N
AU  - Mohanmmdi-Khanaposhtani, M
AU  - Mohammed, MA
AU  - Mohammed, S
AU  - Mokdad, AH
AU  - Mola, GD
AU  - Molokhia, M
AU  - Monasta, L
AU  - Montañez, JC
AU  - Moradi, G
AU  - Moradi, M
AU  - Moradi-Lakeh, M
AU  - Moradinazar, M
AU  - Moraga, P
AU  - Morgado-Da-Costa, J
AU  - Mori, R
AU  - Morrison, SD
AU  - Mosapour, A
AU  - Moschos, MM
AU  - Mousavi, SM
AU  - Muche, AA
AU  - Muchie, KF
AU  - Mueller, UO
AU  - Mukhopadhyay, S
AU  - Murphy, TB
AU  - Muller, K
AU  - Murthy, GVS
AU  - Musa, J
AU  - Musa, KI
AU  - Mustafa, G
AU  - Muthupandian, S
AU  - Nachega, JB
AU  - Nagel, G
AU  - Naghavi, M
AU  - Naheed, A
AU  - Nahnjou, A
AU  - Naik, G
AU  - Naik, P
AU  - Najafi, F
AU  - Naldi, L
AU  - Nangia, V
AU  - Nansseu, JR
AU  - Naschnento, BR
AU  - Nawaz, H
AU  - Ncama, BP
AU  - Neamati, N
AU  - Negoi, I
AU  - Negoi, RI
AU  - Neupane, S
AU  - Newton, CRJ
AU  - Ngalesoni, FN
AU  - Ngunjiri, JW
AU  - Nguyen, G
AU  - Nguyen, LH
AU  - Nguyen, TH
AU  - Ningrum, DNA
AU  - Nirayo, YL
AU  - Nisar, MM
AU  - Nixon, MR
AU  - Nomura, S
AU  - Noroozi, M
AU  - Noubiap, JJ
AU  - Nouri, HR
AU  - Shiadeh, MN
AU  - Nowroozi, MR
AU  - Nyandwi, A
AU  - Nyasulu, PS
AU  - Odell, CM
AU  - Ofori-Asenso, R
AU  - Ogah, OS
AU  - Ogbo, FA
AU  - Oh, IH
AU  - Okoro, A
AU  - Oladimeji, O
AU  - Olagunju, AT
AU  - Olagunju, TO
AU  - Olivares, PR
AU  - Olusanya, BO
AU  - Olusanya, JO
AU  - Ong, SK
AU  - Ortiz, A
AU  - Osgood-Zimmerman, A
AU  - Ota, E
AU  - Otieno, BA
AU  - Otstavnov, SS
AU  - Owolabi, MO
AU  - Oyekale, AS
AU  - Pakhale, MPAS
AU  - Pakhare, AP
AU  - Pana, A
AU  - Panda, BK
AU  - Panda-Jonas, S
AU  - Pandey, AR
AU  - Park, EK
AU  - Parsian, H
AU  - Patel, S
AU  - Patil, ST
AU  - Patle, A
AU  - Patton, GC
AU  - Paturi, VR
AU  - Paudel, D
AU  - Pedroso, MM
AU  - Peprah, EK
AU  - Pereira, DM
AU  - Perico, N
AU  - Pesudovs, K
AU  - Petri, WA
AU  - Petzold, M
AU  - Pierce, M
AU  - Pigott, DM
AU  - Pillay, JD
AU  - Pirsaheb, M
AU  - Polanczyk, GV
AU  - Postma, MJ
AU  - Pourmalek, F
AU  - Pourshams, A
AU  - Poustchi, H
AU  - Prakash, S
AU  - Prasad, N
AU  - Purcell, CA
AU  - Purwar, MB
AU  - Qorbani, M
AU  - Quansah, R
AU  - Radfar, A
AU  - Rafay, A
AU  - Rafiei, A
AU  - Rahim, F
AU  - Rahimi-Movaghar, A
AU  - Rahimi-Movaghah, V
AU  - Rahman, M
AU  - Rahman, MS
AU  - Rahman, MHU
AU  - Rahman, MA
AU  - Rahman, SU
AU  - Rai, RK
AU  - Rajati, F
AU  - Rajsic, S
AU  - Ram, U
AU  - Ranabhat, CL
AU  - Ranjan, P
AU  - Rawaf, DL
AU  - Rawaf, S
AU  - Ray, SE
AU  - Razo-Garcia, C
AU  - Reiner, RC
AU  - Reis, C
AU  - Remuzzi, G
AU  - Renzaho, AMN
AU  - Resnikoff, S
AU  - Rezaei, S
AU  - Rezaeian, S
AU  - Rezai, MS
AU  - Riahi, SM
AU  - Rios-Blancas, MJ
AU  - Roba, KT
AU  - Roberts, NLS
AU  - Roever, L
AU  - Ronfani, L
AU  - Roshandel, G
AU  - Rostami, A
AU  - Rubagotti, E
AU  - Ruhago, GM
AU  - Sabde, YD
AU  - Sachdev, PS
AU  - Saddik, B
AU  - Moghaddam, SS
AU  - Safari, H
AU  - Safari, Y
AU  - Safari-Faramani, R
AU  - Safdarian, M
AU  - Safi, S
AU  - Safiri, S
AU  - Sagan, R
AU  - Sahebkar, A
AU  - Sahraian, MA
AU  - Sajadi, HS
AU  - Salahshoor, M
AU  - Salam, N
AU  - Salama, JS
AU  - Salamati, P
AU  - Saldanha, RDF
AU  - Sateen, Z
AU  - Salimi, Y
AU  - Salimzadeh, H
AU  - Salomon, JA
AU  - Santosh, S
AU  - Salz, I
AU  - Sanibala, EZ
AU  - Samy, AM
AU  - Sanabria, J
AU  - Sanchez-Nino, MD
AU  - Santos, IS
AU  - Milicevic, MMS
AU  - Jose, BPS
AU  - Sardana, M
AU  - Sarker, AR
AU  - Sanniento-Suarez, R
AU  - Saroshe, S
AU  - Sarrafradegan, N
AU  - Sartorius, B
AU  - Sarvi, S
AU  - Sathian, B
AU  - Satpathy, M
AU  - Sawant, AR
AU  - Sawhney, M
AU  - Saxena, S
AU  - Schaeffner, E
AU  - Schelonka, K
AU  - Schneider, IJC
AU  - Schwebel, DC
AU  - Schwendicke, F
AU  - Seedat, S
AU  - Sekerija, M
AU  - Sepanlou, SG
AU  - Servan-Mori, E
AU  - Shabaninejad, H
AU  - Shackelford, KA
AU  - Shafieesabet, A
AU  - Shaheen, AA
AU  - Shaikh, MA
AU  - Shakir, RA
AU  - Shams-Beyranvand, M
AU  - Shamsi, M
AU  - Sharnsizadeh, M
AU  - Sharafi, H
AU  - Sharafi, K
AU  - Sharif, M
AU  - Sharif-Alhoseini, M
AU  - Sharma, J
AU  - Sharma, R
AU  - She, J
AU  - Sheikh, A
AU  - Shi, PL
AU  - Shibuya, K
AU  - Shigematsu, M
AU  - Shiri, R
AU  - Shirkoohi, R
AU  - Shiue, I
AU  - Shokraneh, F
AU  - Shukla, SR
AU  - Si, S
AU  - Siabani, S
AU  - Sibai, AM
AU  - Siddiqi, TJ
AU  - Sigfusdottir, ID
AU  - Sigurvinsdottir, R
AU  - Silpakit, N
AU  - Silva, DAS
AU  - Silva, JP
AU  - Silveira, DGA
AU  - Singam, NSV
AU  - Singh, JA
AU  - Singh, NP
AU  - Singh, V
AU  - Sinha, DN
AU  - Sliwa, K
AU  - Soares, AM
AU  - Sobaih, BH
AU  - Sobhani, S
AU  - Soofi, M
AU  - Soriano, JB
AU  - Soyiri, IN
AU  - Sreeramareddy, CT
AU  - Starodubov, VI
AU  - Steiner, C
AU  - Stewart, LG
AU  - Stokes, MA
AU  - Strong, M
AU  - Subart, ML
AU  - Sufiyan, MB
AU  - Sulo, G
AU  - Sunguya, BF
AU  - Sur, PJ
AU  - Sutradhar, I
AU  - Sykes, BL
AU  - Sylaja, PN
AU  - Sylte, DO
AU  - Szoeke, CEI
AU  - Tabares-Seisdedos, R
AU  - Tabb, KM
AU  - Tadakamadla, SK
AU  - Tandon, N
AU  - Tassew, AA
AU  - Tassew, SG
AU  - Taveira, N
AU  - Tawye, NY
AU  - Tehrani-Banihashemi, A
AU  - Tekalign, TG
AU  - Tekle, MG
AU  - Temsah, MH
AU  - Terkawi, AS
AU  - Teshale, MY
AU  - Tessema, B
AU  - Teweldemedhin, M
AU  - Thakur, JS
AU  - Thankappan, KR
AU  - Thirunavukkarasu, S
AU  - Thomas, N
AU  - Thomson, AJ
AU  - Tilahun, B
AU  - To, QG
AU  - Tonelli, M
AU  - Topor-Madry, R
AU  - Torre, AE
AU  - Tortajada-Girbes, M
AU  - Tovani-Palone, MR
AU  - Toyoshima, H
AU  - Tran, BX
AU  - Tran, KB
AU  - Tripathy, SP
AU  - Truelsen, TC
AU  - Truong, NT
AU  - Tsadik, AG
AU  - Tsegay, A
AU  - Tsilimparis, N
AU  - Car, LT
AU  - Ukwaja, KN
AU  - Ullah, I
AU  - Usman, MS
AU  - Uthman, OA
AU  - Uzun, SB
AU  - Vaduganathan, M
AU  - Vaezi, A
AU  - Vaidya, G
AU  - Valdez, PR
AU  - Varavikova, E
AU  - Varughese, S
AU  - Vasankari, TJ
AU  - Vasconcelos, AMN
AU  - Venketasubramanian, N
AU  - Villafaina, S
AU  - Violante, FS
AU  - Vladimirov, SK
AU  - Vlassov, E
AU  - Vollset, SE
AU  - Vos, T
AU  - Vosoughi, K
AU  - Vujcic, IS
AU  - Wagnew, FS
AU  - Waheed, Y
AU  - Walson, JL
AU  - Wang, YP
AU  - Wang, YP
AU  - Weiderpass, E
AU  - Weintraub, RG
AU  - Weldegwergs, KG
AU  - Werdecker, A
AU  - Westerman, R
AU  - Whiteford, H
AU  - Widecka, J
AU  - Widecka, K
AU  - Wijeratne, T
AU  - Winkler, AS
AU  - Wiysonge, CS
AU  - Wolfe, CDA
AU  - Wu, SL
AU  - Wyper, GMA
AU  - Xu, G
AU  - Yamada, T
AU  - Yano, Y
AU  - Yaseri, M
AU  - Yasin, YJ
AU  - Ye, PP
AU  - Yentur, GK
AU  - Yeshaneh, A
AU  - Yimer, EM
AU  - Yip, P
AU  - Yisma, E
AU  - Yonemoto, N
AU  - Yoon, SJ
AU  - Yotebieng, M
AU  - Younis, MZ
AU  - Yousefifard, M
AU  - Yu, C
AU  - Zadnik, V
AU  - Zaidi, Z
AU  - Bin Zaman, S
AU  - Zamani, M
AU  - Zare, Z
AU  - Zeleke, MM
AU  - Zenebe, ZM
AU  - Zerfu, TA
AU  - Zhang, XY
AU  - Zhao, XJ
AU  - Zhou, MG
AU  - Zhu, J
AU  - Zimsen, SRM
AU  - Zodpey, S
AU  - Zoeckler, L
AU  - Lopez, AD
AU  - Lim, SS
A1  - GBD 2017 Population Fertility Coll
TI  - Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017
T2  - LANCET
KW  - HEALTH
KW  - PROJECTIONS
KW  - AFRICA
KW  - CONSEQUENCES
KW  - MORTALITY
KW  - POLICIES
KW  - BIRTH
AB  - Background Population estimates underpin demographic and epidemiological research and are used to track progress on numerous international indicators of health and development. To date, internationally available estimates of population and fertility, although useful, have not been produced with transparent and replicable methods and do not use standardised estimates of mortality. We present single-calendar year and single-year of age estimates of fertility and population by sex with standardised and replicable methods.
   Methods We estimated population in 195 locations by single year of age and single calendar year from 1950 to 2017 with standardised and replicable methods. We based the estimates on the demographic balancing equation, with inputs of fertility, mortality, population, and migration data. Fertility data came from 7817 location-years of vital registration data, 429 surveys reporting complete birth histories, and 977 surveys and censuses reporting summary birth histories. We estimated age-specific fertility rates (ASFRs; the annual number of livebirths to women of a specified age group per 1000 women in that age group) by use of spatiotemporal Gaussian process regression and used the ASFRs to estimate total fertility rates (TFRs; the average number of children a woman would bear if she survived through the end of the reproductive age span [age 10-54 years] and experienced at each age a particular set of ASFRs observed in the year of interest). Because of sparse data, fertility at ages 10-14 years and 50-54 years was estimated from data on fertility in women aged 15-19 years and 45-49 years, through use of linear regression. Age-specific mortality data came from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 estimates. Data on population came from 1257 censuses and 761 population registry location-years and were adjusted for underenumeration and age misreporting with standard demographic methods. Migration was estimated with the GBD Bayesian demographic balancing model, after incorporating information about refugee migration into the model prior. Final population estimates used the cohort-cotnponent method of population projection, with inputs of fertility, mortality, and migration data. Population uncertainty was estimated by use of out-of-sample predictive validity testing. With these data, we estimated the trends in population by age and sex and in fertility by age between 1950 and 2017 in 195 countries and territories.
   Findings From 1950 to 2017, TFRs decreased by 49.4% (95% uncertainty interval [UI] 46.4-52.0). The TFR decreased from 4.7 livebirths (4.5-4.9) to 2.4 livebirths (2.2-2.5), and the ASFR of mothers aged 10-19 years decreased from 37 livebirths (34-40) to 22 livebirths (19-24) per 1000 women. Despite reductions in the TFR, the global population has been increasing by an average of 83.8 million people per year since 1985. The global population increased by 197-2% (193.3-200.8) since 1950, from 2.6 billion (2.5-2.6) to 7.6 billion (7.4-7.9) people in 2017; much of this increase was in the proportion of the global population in south Asia and sub-Saharan Africa. The global annual rate of population growth increased between 1950 and 1964, when it peaked at 2.0%; this rate then remained nearly constant until 1970 and then decreased to 1.1% in 2017. Population growth rates in the southeast Asia, east Asia, and Oceania GBD super-region decreased from 2.5% in 1963 to O7% in 2017, whereas in sub-Saharan Africa, population growth rates were almost at the highest reported levels ever in 2017, when they were at 2.7%. The global average age increased from 26.6 years in 1950 to 32.1 years in 2017, and the proportion of the population that is of working age (age 15-64 years) increased from 59.9% to 65.3%. At the national level, the TFR decreased in all countries and territories between 1950 and 2017; in 2017, TFRs ranged from a low of 1.0 livebirths (95% UI 0. 9-1.2) in Cyprus to a high of 7.1 livebirths (6.8-7.4) in Niger. The TFR under age 25 years (TFU25; number of livebirths expected by age 25 years for a hypothetical woman who survived the age group and was exposed to current ASFRs) in 2017 ranged from 0.08 livebirths (0.07-0.09) in South Korea to 2.4 livebirths (2.2-2.6) in Niger, and the TFR over age 30 years (I F030; number of livebirths expected for a hypothetical woman ageing from 30 to 54 years who survived the age group and was exposed to current ASFRs) ranged from a low of 0.3 livebirths (0.3-0-4) in Puerto Rico to a high of 3.1 livebirths (3.0-3.2) in Niger. TF030 was higher than TFU25 in 145 countries and territories in 2017.33 countries had a negative population growth rate from 2010 to 2017, most of which were located in central, eastern, and western Europe, whereas population growth rates of more than 2.0% were seen in 33 of 46 countries in sub-Saharan Africa. In 2017, less than 65% of the national population was of working age in 12 of 34 high-income countries, and less than 50% of the national population was of working age in Mali, Chad, and Niger.
   Interpretation Population trends create demographic dividends and headwinds (ie, economic benefits and detriments) that affect national economies and determine national planning needs. Although TFRs are decreasing, the global population continues to grow as mortality declines, with diverse patterns at the national level and across age groups. To our knowledge, this is the first study to provide transparent and replicable estimates of population and fertility, which can be used to inform decision making and to monitor progress. Copyright (C) 2018 The Author(s). Published by Elsevier Ltd.
AD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - Univ Washington, Dept Hlth Metr Sci, Seattle, WA 98195 USAAD  - Univ Washington, Dept Neurol, Seattle, WA 98195 USAAD  - Univ Washington, Dept Global Hlth, Seattle, WA 98195 USAAD  - Univ Washington, Dept Surg, Seattle, WA 98195 USAAD  - Univ Washington, Div Plast Surg, Seattle, WA 98195 USAAD  - Univ Washington, Sch Social Work, Seattle, WA 98195 USAAD  - Haramaya Univ, Coll Hlth & Med Sci, Harar, EthiopiaAD  - Haramaya Univ, Dept Epidemiol & Biostat, Harar, EthiopiaAD  - Haramaya Univ, Dept Med Lab Sci, Harar, EthiopiaAD  - Haramaya Univ, Dept Pediat, Harar, EthiopiaAD  - Haramaya Univ, Sch Nursing & Midwifery, Harar, EthiopiaAD  - Haramaya Univ, Sch Pharm, Harar, EthiopiaAD  - Haramaya Univ, Sch Publ Hlth, Harar, EthiopiaAD  - Haramaya Univ, Sch Publ Hlth, Harar, EthiopiaAD  - Jimma Univ, Dept Environm Hlth Sci & Technol, Jimma, EthiopiaAD  - Jimma Univ, Dept Epidemiol, Jimma, EthiopiaAD  - Jimma Univ, Dept Hlth Educ & Behav Sci, Jimma, EthiopiaAD  - Jimma Univ, Dept Populat & Family Hlth, Jimma, EthiopiaAD  - Jimma Univ, Mycobacteriol Res Ctr, Jimma, EthiopiaAD  - Addis Ababa Univ, Dept Pharmacol & Clin Pharm, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Sch Allied Hlth Sci, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Sch Nursing & Midwifery, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Sch Publ Hlth, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Addis Ababa, EthiopiaAD  - Univ Tehran Med Sci, Brain & Spinal Cord Injury Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Canc Biol Research Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Canc Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Community Based Participatory Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Dept Anat, Tehran, IranAD  - Univ Tehran Med Sci, Dept Epidemiol & Piostat, Tehran, IranAD  - Univ Tehran Med Sci, Dept Hlth, Tehran, IranAD  - Univ Tehran Med Sci, Dept Hlth Management & Econ, Tehran, IranAD  - Univ Tehran Med Sci, Dept Pharmacol, Tehran, IranAD  - Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, IranAD  - Univ Tehran Med Sci, Endocrine Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Malignancies Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Oncol & Stem Cell Transplantat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Irani Natl Inst Hlth Res, Tehran, IranAD  - Univ Tehran Med Sci, Iranian Natl Ctr Addict Studies, Tehran, IranAD  - Univ Tehran Med Sci, Knowledge Utilizat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Multiple Sclerosis Res Critter, Tehran, IranAD  - Univ Tehran Med Sci, Noncommunicable Dis Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Sch Med, Tehran, IranAD  - Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Urooncol Res Ctr, Tehran, IranAD  - McGill Univ, Montreal Neuroimaging Ctr, Montreal, PQ, CanadaAD  - McGill Univ, Montreal Neurol Inst, Montreal, PQ, CanadaAD  - Cairo Univ, Dept Med Parasitol, Cairo, EgyptAD  - Cairo Univ, Dept Neurol, Cairo, EgyptAD  - Univ Calgary, Dept Oncol, Calgary, AB, CanadaAD  - Univ Calgary, Dept Med, Calgary, AB, CanadaAD  - Ain Shams Univ, Dept Entomol, Cairo, EgyptAD  - Ain Shams Univ, Dept Oncol, Cairo, EgyptAD  - Kerrnanshah Univ Med Sci, Dept Anesthesiol, Kerrnanshah, IranAD  - Kerrnanshah Univ Med Sci, Dept Environm Hlth Engn, Kerrnanshah, IranAD  - Kerrnanshah Univ Med Sci, Dept Epidemiol & Biostat, Kerrnanshah, IranAD  - Kerrnanshah Univ Med Sci, Dept Hlth Educ & Promot, Kerrnanshah, IranAD  - Kerrnanshah Univ Med Sci, Dept Psychiat, Kerrnanshah, IranAD  - Kerrnanshah Univ Med Sci, Dept Tradit & Complementary Med, Kerrnanshah, IranAD  - Kerrnanshah Univ Med Sci, Dept Urol, Kerrnanshah, IranAD  - Kerrnanshah Univ Med Sci, Environm Determinants Hlth Res Ctr, Kerrnanshah, IranAD  - Kerrnanshah Univ Med Sci, Fac Nursing & Midwifery, Kerrnanshah, IranAD  - Kerrnanshah Univ Med Sci, Fac Nutr & Food Sci, Kerrnanshah, IranAD  - Kerrnanshah Univ Med Sci, Fac Publ Hlth, Kerrnanshah, IranAD  - Kerrnanshah Univ Med Sci, Imam Ali Cardiovasc Res Ctr, Kerrnanshah, IranAD  - Kerrnanshah Univ Med Sci, Pharmaceut Sci Res Ctr, Kerrnanshah, IranAD  - Kerrnanshah Univ Med Sci, Res Ctr Environm Determinants Hlth, Kerrnanshah, IranAD  - Kerrnanshah Univ Med Sci, Sleep Disorders Res Ctr, Kerrnanshah, IranAD  - Kerrnanshah Univ Med Sci, Sports Med R Rehabil, Kerrnanshah, IranAD  - Kerrnanshah Univ Med Sci, Kerrnanshah, IranAD  - Arak Univ Med Sci, Dept Epidemiol, Arak, IranAD  - Multiple Sclerosis Res Ctr, Tehran, IranAD  - Manonmaniam Sundaranar Univ, Dept Stat, Tirunelveli, IndiaAD  - Mekelle Univ, Anat Unit, Mekelle, EthiopiaAD  - Mekelle Univ, Biomed Sci Div, Mekelle, EthiopiaAD  - Mekelle Univ, Clin Pharm Unit, Mekelle, EthiopiaAD  - Mekelle Univ, Coll Hlth Sci, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Biostat, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Epidemiol, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Microbiol & Immunol, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Midwifery, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Nutr & Dietet, Mekelle, EthiopiaAD  - Mekelle Univ, Inst Biomed Sci, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Med, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Pharm, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Publ Hlth, Mekelle, EthiopiaAD  - Mekelle Univ, Mekelle, EthiopiaAD  - Univ Gondar, Dept Clin Chem, Gondar, EthiopiaAD  - Univ Gondar, Dept Med Microbiol, Gondar, EthiopiaAD  - Univ Gondar, Human Nutr Dept, Gondar, EthiopiaAD  - Univ Gondar, Inst Publ Hlth, Gondar, EthiopiaAD  - Univ Gondar, Gondar, EthiopiaAD  - Hawassa Univ, Coll Med & Hlth Sci, Hawassa, EthiopiaAD  - Hawassa Univ, Dept Reprod Hlth, Hawassa, EthiopiaAD  - Hawassa Univ, Sch Nursing & Midwifery, Hawassa, EthiopiaAD  - Debre Markos Univ, Coll Hlth Sci, Debre Markos, EthiopiaAD  - Debre Markos Univ, Dept Nursing, Debre Markos, EthiopiaAD  - Debre Markos Univ, Dept Publ Hlth, Debre Markos, EthiopiaAD  - Debre Markos Univ, Debre Markos, EthiopiaAD  - Dupuytren Univ Hosp, Dept Cardiol, Limoges, FranceAD  - Univ Limoges, Inst Epidemiol, Limoges, FranceAD  - Univ Fed Minas Gerais, Dept Surg, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Educ Ctr Publ Hlth, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Hosp Fed Univ Minas Gerais, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Nutr Dept, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Postgrad Program Infect Dis & Trop Med, Belo Horizonte, MG, BrazilAD  - Weill Cornell Med Coll Qatar, Dept Healthcare Policy & Res, Doha, QatarAD  - Birzeit Univ, Inst Community & Publ Hlth, Birzeit, PalestineAD  - Benin Clin Res Inst IRCM, Cotonou, BeninAD  - Nepal Dev Soc, Pokhara, NepalAD  - Stellenbosch Univ, Dept Global Hlth, Cape Town, South AfricaAD  - Stellenbosch Univ, Dept Psychiat, Cape Town, South AfricaAD  - Stellenbosch Univ, Fac Med & Hlth Sci, Cape Town, South AfricaAD  - South African Med Res Council, Cochrane South Africa, Cape Town, South AfricaAD  - Univ Coll Hosp, Dept Med, Ibadan, NigeriaAD  - Olabisi Onabanjo Univ, Dept Sociol, Ago Iwoye, NigeriaAD  - Cardiff Univ, Sch Med, Cardiff, S Glam, WalesAD  - Ctr Social Sci & Publ Hlth Res Nepal, Nepal Hlth Res Environm, Lalitpur, NepalAD  - Univ Southern Denmark, Unit Hlth Promot Res, Esbjerg, DenmarkAD  - St Mark Hosp, Emergency Dept, Alexandria, EgyptAD  - Ivorian Assoc Family Welf, Abidjan, Cote IvoireAD  - Univ Extremadura, Sport Sci Dept, Caceresi, SpainAD  - Univ Extremadura, Caceresi, SpainAD  - McMaster Univ, Dept Family Med, Hamilton, ON, CanadaAD  - McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, CanadaAD  - Yerevan State Univ, Dept Zool, Yerevan, ArmeniaAD  - Sci Ctr Zool & Hydroecol, Res Grp Mol Parasitol, Yerevan, ArmeniaAD  - Publ Hlth Fdn India, Indian Inst Publ Hlth, Gurugram, IndiaAD  - Publ Hlth Fdn India, Indian Inst Publ Hlth Hyderabad, Gurugram, IndiaAD  - Publ Hlth Fdn India, Gurugram, IndiaAD  - Vital Strategies, Gurugram, IndiaAD  - Ahvaz Jundishapur Univ Med Sci, Dept Neurosurg, Ahvaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Dept Publ Hlth, Ahvaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Environm Technol Res Ctr, Ahvaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Thalassemia & Hemoglobinopathy Res Ctr, Ahvaz, IranAD  - Int Ctr Diarrhoeal Dis Res, Hlth Econ & Financing Res Grp, Dhaka, BangladeshAD  - Int Ctr Diarrhoeal Dis Res, Hlth Syst & Populat Studies Div, Dhaka, BangladeshAD  - Int Ctr Diarrhoeal Dis Res, Initiat Non Communicable Dis, Dhaka, BangladeshAD  - Int Ctr Diarrhoeal Dis Res, Maternal & Child Hlth Div, Dhaka, BangladeshAD  - Karolinska Inst, Dept Learning Informat Management & Eth, Stockholm, SwedenAD  - Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, SwedenAD  - Karolinska Inst, Dept Neurobiol, Stockholm, SwedenAD  - Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, SwedenAD  - Karolinska Inst, Dept Publ Hlth Sci, Stockholm, SwedenAD  - Univ Ferhat Abbas Setif, Setif, AlgeriaAD  - Higher Natl Sch Vet Med, Algiers, AlgeriaAD  - Univ Rhode Isl, Dept Civil & Environm Engn, Kingston, RI 02881 USAAD  - Shahid Beheshti Univ Med Sci, Canc Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Dept Biostat, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Dept Epidemiol, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Ophthalm Epidemiol Researclt Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Safety Promot & Injury Prevent Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Sch Publ Hlth, Tehran, IranAD  - Debre Berhan Univ, Dept Midwifery, Debre Berhan, EthiopiaAD  - Debre Berhan Univ, Dept Publ Hlth, Debre Berhan, EthiopiaAD  - Univ Ibadan, Inst Adv Med Res & Training, Ibadan, NigeriaAD  - Univ Kentucky, Dept Epidemiol, Lexington, KY USAAD  - Univ Toronto, Dept Nutr Sci, Toronto, ON, CanadaAD  - Univ Toronto, Hosp Sick Children, Toronto, ON, CanadaAD  - Mayo Clin, Fdn Med Educ & Res, Evidence Based Practice Ctr, Rochester, MN USAAD  - Syrian Amer Med Soc, Res Comm, Washington, DC USAAD  - Washington Univ, Internal Med Dept, St Louis, MO USAAD  - VA St Louis Hlth Care Syst, Clin Epidemiol Ctr, St Louis, MO USAAD  - Dept Internal Med, St Louis, MO USAAD  - Dept Vet Affairs, St Louis, MO USAAD  - Univ Western Australia, Sch Med, Perth, WA, AustraliaAD  - Univ Western Australia, Sch Populat & Global Hlth, Perth, WA, AustraliaAD  - Univ Republica, Dept Prevent Med, Montevideo, UruguayAD  - Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, AustraliaAD  - Australian Natl Univ, Res Sch Populat Hlth, Canberra, ACT, AustraliaAD  - King Saud Univ, Dept Pediat, Riyadh, Saudi ArabiaAD  - King Saud Univ, Pediat Intens Care Unit, Riyadh, Saudi ArabiaAD  - New York Univ Abu Dhabi, Publ Hlth Res Ctr, Abu Dhabi, U Arab EmiratesAD  - Univ Oxford, Big Data Inst, Oxford, EnglandAD  - Univ Oxford, Dept Psychiat, Oxford, EnglandAD  - Univ Oxford, Nuffield Dept Popuilal Hlth, Oxford, EnglandAD  - Univ Oxford, Oxford, EnglandAD  - Qazvin Univ Med Sci, Qazvin, IranAD  - Mazandaran Univ Med Sci, Dept Immunol, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Med Mycol, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Med Mycol & Parasitol, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Pediat, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Physiol & Pharmacol, Sari, IranAD  - Mazandaran Univ Med Sci, Gastrointestinal Canc Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Mol & Cell Biol Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Sch Publ Hlth, Sari, IranAD  - Mazandaran Univ Med Sci, Toxoplasmosis Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Sari, IranAD  - Kuwait Univ, Dept Hlth Policy & Management, Safat, KuwaitAD  - Natl Univ Malaysia, Int Ctr Casemix & Clin Coding, Bandar Tun Razak, MalaysiaAD  - Luxembourg Inst Hlth, Dept Populat Hlth, Strassen, LuxembourgAD  - Univ Bordeaux, Bordeaux, FranceAD  - Swedish Res Council Hlth Working Life & Welf, Stockholm, SwedenAD  - Hosp del Mar, Med Res Inst, Res Program Epidemiol & Publ Hlth, Barcelona, SpainAD  - Pompeu Fabra Univ, Dept Expt & Hlth Sci, Barcelona, SpainAD  - King Abdulaziz Univ, Dept Family & Community Med, Jeddah, Saudi ArabiaAD  - Charite Univ Med Ctr Berlin, Dept Operat & Prevent Dent, Berlin, GermanyAD  - Charite Univ Med Ctr Berlin, Inst Publ Hlth, Berlin, GermanyAD  - Charite Univ Med Ctr Berlin, Berlin, GermanyAD  - Univ Cartagena, Res Grp Hlth Econ, Cartagena, ColombiaAD  - Univ Coast, Hosp Management & Hlth Policies, Res Grp, Barranquilla, ColombiaAD  - South Australian Hlth & Med Res Inst, Sansom Inst, Adelaide, SA, AustraliaAD  - South Australian Hlth & Med Res Inst, Wardliparingga Aboriginal Res Unit, Adelaide, SA, AustraliaAD  - Bahir Dar Univ, Dept Publ Hlth Nutr, Bahir Dar, EthiopiaAD  - Bahir Dar Univ, Bahir Dar, EthiopiaAD  - Fed Minist Hlth, Beirut, LebanonAD  - Amer Univ Beirut, Dept Epidemiol & Populat Hlth, Beirut, LebanonAD  - Amer Univ Beirut, Fac Hlth Sci, Beirut, LebanonAD  - Mansoura Univ, Fac Med, Mansoura, EgyptAD  - Mansoura Univ, Mansoura, EgyptAD  - Carol Davila Univ Med & Pharm, Anat & Embryol Dept, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Dept Gen Surg, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Dept Legal Med & Bioeth, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Emergency Hosp Bucharest, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Dept Dermatol 2, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Bucharest, RomaniaAD  - Univ Thessaly, Dept Med, Volos, GreeceAD  - Arba Minch Univ, Dept Publ Hlth, Arba Minch, EthiopiaAD  - Arba Minch Univ, Arba Minch, EthiopiaAD  - Zahedan Univ Med Sci, Zahedan, IranAD  - Univ Philippines Manila, Dept Hlth Policy & Adm, Manila, PhilippinesAD  - Univ Philippines Manila, Dev & Commun Studies, Manila, PhilippinesAD  - Hong Kong Polytech Univ, Dept Appl Social Sci, Hong Kong, Hong Kong, Peoples R ChinaAD  - Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Hong Kong, Peoples R ChinaAD  - Kwame Nkrumah Univ Sci & Technol, Dept Sociol & Social Work, Kumasi, GhanaAD  - Ludwig Maximilians Univ Munchen, Ctr Int Hlth, Munich, GermanyAD  - Birmingham City Univ, Sch Hlth Sci, Birmingham, W Midlands, EnglandAD  - Dalarna Univ, Sch Hlth & Social Studies, Falun, SwedenAD  - Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, CanadaAD  - Abt Associates Nepal, Monitoring Evaluat & Operat Res Project, Lalitpur, NepalAD  - Qom Univ Med Sci, Qom, IranAD  - Mashhad Univ Med Sci, Dept Med Biotechnol, Mashhad, IranAD  - Mashhad Univ Med Sci, Educ Dev Ctr, Mashhad, IranAD  - Univ Lahore, Univ Inst Publ Hlth, Lahore, PakistanAD  - Univ Hail, Publ Hlth Dept, Hail, Saudi ArabiaAD  - Keimyung Univ, Dept Social Welf, Daegu, South KoreaAD  - Univ Leicester, Sch Business, Leicester, Leics, EnglandAD  - Lab Studies & Res Act Hlth, Controle Malad Infect, Porto Novo, BeninAD  - Lab Studies & Res Act Hlth, Non Communicable Dis Dept, Porto Novo, BeninAD  - Indian Inst Publ Hlth, Gandhinagar, IndiaAD  - La Trobe Univ, Austin Clin Sch Nursing, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Dept Psychol & Counselling, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Sch Nursing & Midwifery, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Judith Lumley Ctr, Melbourne, Vic, AustraliaAD  - Peruvian Natl Inst Hlth, Gen Off Res & Technol Transfer, Lima, PeruAD  - Univ Tokyo, Dept Community & Global Hlth, Tokyo, JapanAD  - Univ Tokyo, Dept Diabet & Metab Dis, Tokyo, JapanAD  - Univ Tokyo, Dept Global Hlth Policy, Tokyo, JapanAD  - Univ Tokyo, Dept Mental Hlth, Tokyo, JapanAD  - Inst Med Res & Med Plant Studies, Ctr Food & Nutr Res, Yaounde, CameroonAD  - Univ South Africa, Dept Hlth Studies, Pretoria, South AfricaAD  - Burnet Inst, Global Adolescent Hlth Grp, Melbourne, Vic, AustraliaAD  - Univ KwaZulu Natal, Dept Publ Hlth Med, Durban, South AfricaAD  - Univ Lagos, Dept Community Hlth & Primary Care, Lagos, NigeriaAD  - Univ Lagos, Dept Psychiat, Lagos, NigeriaAD  - Ctr Infect Dis Res, Babol Sar, IranAD  - Publ Hlth Agcy Canada, Hlth Promot & Chron Dis Prevent Branch, Toronto, ON, CanadaAD  - Publ Hlth Agcy Canada, Publ Hlth Risk Sci Div, Toronto, ON, CanadaAD  - Med Univ Lodz, Dept Hypertens, Lodz, PolandAD  - Polish Mothers Mem Hosp, Res Inst, Lodz, PolandAD  - Univ Auckland, Mol Med & Pathol, Auckland, New ZealandAD  - Univ Auckland, Sch Psychol, Auckland, New ZealandAD  - Heidelberg Univ, Augenpraxis Jonas, Heidelberg, GermanyAD  - Heidelberg Univ, Dept Ophthalmol, Heidelberg, GermanyAD  - Heidelberg Univ, Inst Publ Hlth, Heidelberg, GermanyAD  - Heidelberg Univ, Med Clin 5, Heidelberg, GermanyAD  - Harvard Univ, Ariadne Labs, Boston, MA 02115 USAAD  - Harvard Univ, Dept Global Hlth & Populat, Boston, MA 02115 USAAD  - Harvard Univ, Dept Nutr, Boston, MA 02115 USAAD  - Harvard Univ, Div Gen Internal Med & Primary Care, Boston, MA 02115 USAAD  - Harvard Univ, Fenot Project, Boston, MA 02115 USAAD  - Harvard Univ, Heart & Vasc Ctr, Boston, MA 02115 USAAD  - Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USAAD  - Pontif javeriana Univ, Dept Ind Engn, Bogota, ColombiaAD  - Univ Aden, Aden, YemenAD  - Barcelona Inst Global Hlth, Barcelona, SpainAD  - Manhica Hlth Res Ctr, Manhica, MozambiqueAD  - Univ Canterbury, Sch Hlth Sci, Christchurch, New ZealandAD  - Melbourne Med Sch, Melbourne, Vic, AustraliaAD  - Mario Negri Inst Pharmacol Res, Dept Environm Hlth Sci, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Dept Neurosci, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Dept Oncol, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Dept Renal Med, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Milan, ItalyAD  - Iran Univ Med Sci, Air Pollut Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Dept Community Med, Tehran, IranAD  - Iran Univ Med Sci, Dept Hlth Policy, Tehran, IranAD  - Iran Univ Med Sci, Dept Neurosci, Tehran, IranAD  - Iran Univ Med Sci, Dept Ophthalmol, Tehran, IranAD  - Iran Univ Med Sci, Hlth Management & Econ Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Pharmacol Dept, Tehran, IranAD  - Iran Univ Med Sci, Physiol Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Prevent Med & Publ Health Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Tehran, IranAD  - Lorestan Univ Med Sci, Social Determinants Hlth Res Ctr, Khorramabad, IranAD  - Lorestan Univ Med Sci, Khorramabad, IranAD  - Mizan Tepi Univ, Publ Hlth Dept, Teppi, EthiopiaAD  - Mizan Tepi Univ, Teppi, EthiopiaAD  - Dr Tewelde Legesse Hlth Sci Coll, Mekelle, EthiopiaAD  - Yale Univ, Dept Ophthalmol & Visual Sci, New Haven, CT USAAD  - Yale Univ, Sch Forestry & Environm Studies, New Haven, CT USAAD  - Univ Alberta, Dept Med, Edmonton, AB, CanadaAD  - Univ Sao Paulo, Ctr Clin & Epidemiol Res, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Internal Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Pathol & Legal Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Psychiat, Sao Paulo, BrazilAD  - Univ Sao Paulo, Univ Hosp, Internal Med Dept, Sao Paulo, BrazilAD  - New York Acad Sci, Sackler Inst Nutr Sci, New York, NY USAAD  - Augusta Univ, Med Coll Georgia, Div Cardiol, Augusta, GA USAAD  - London Sch Econ & Polit Sci, Dept Hlth Policy, London, EnglandAD  - London Sch Econ & Polit Sci, Personal Social Serv Res Unit, London, EnglandAD  - Kings Coll London, Dent Inst, London, EnglandAD  - Kings Coll London, Div Patient & Populat, London, EnglandAD  - Kings Coll London, Fac Life Sci & Med, London, EnglandAD  - Kings Coll London, Sch Populat Hlth & Environm Sci, London, EnglandAD  - Emory Univ, Hubert Dept Global Hlth, Atlanta, GA 30322 USAAD  - Univ S Florida, Dept Global Hlth, Tampa, FL USAAD  - London Sch Hyg & Trop Med, Dept Dis Control, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, EnglandAD  - London Sch Hyg & Trop Med, London, EnglandAD  - Nepal Acad Sci & Technol, Patin, NepalAD  - George Inst Global Hlth, New Delhi, IndiaAD  - Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, PakistanAD  - Aga Khan Univ, Dept Pediat & Child Hlth, Karachi, PakistanAD  - Babol Univ Med Sci, Cellular & Mol Biol Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Dept Clin Biochem, Babol Sar, IranAD  - Babol Univ Med Sci, Dept Pharmacol, Babol Sar, IranAD  - Babol Univ Med Sci, Fatemeh Zahra Infertil & Reprod Hlth Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Hlth Res Inst, Babol Sar, IranAD  - Babol Univ Med Sci, Infect Dis & Trop Med Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Social Determinants Hlth Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Student Res Comm, Babol Sar, IranAD  - Babol Univ Med Sci, Babol Sar, IranAD  - Woldia Univ, Woldia, EthiopiaAD  - Univ Dhaka, Dept Clin Pharm & Pharmacol, Ramna, BangladeshAD  - Univ Bologna, Dept Med & Surg Sci, Bologna, ItalyAD  - Univ Bologna, Bologna, ItalyAD  - Cuillain Barre Syndrome Chron Inflammatory Demye, Liaison Turkey, Conshohocken, PA USAAD  - UCL, Dept Epidemiol & Publ Hlth, London, EnglandAD  - UCL, Dept Psychol, London, EnglandAD  - UCL, Ctr Global Hlth Econ, London, EnglandAD  - United Nations Programme HIV AIDS UNAIDS, Fast Track Implementat Dept, Gaborone, BotswanaAD  - AT Still Univ, Dept Hlth Sci, Brisbane, Qld, AustraliaAD  - AT Still Univ, Brisbane, Qld, AustraliaAD  - St Pauls Hosp, Millennium Med Coll, Dept Publ Hlth, Addis Ababa, EthiopiaAD  - Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USAAD  - Oregon Hlth & Sci Univ, Radiat Med, Portland, OR 97201 USAAD  - Univ Texas Houston, Dept Pediat, Houston, TX USAAD  - Univ Texas Houston, Houston, TX USAAD  - Minist Hlth, Gen Directorate Hlth Informat Syst, Ankara, TurkeyAD  - Minist Hlth, Dept Hlth Stat, Ankara, TurkeyAD  - Minist Hlth, Ankara, TurkeyAD  - Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Med, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Psychiat, Sydney, NSW, AustraliaAD  - Univ New South Wales, Transport & Rd Safety Res, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sydney, NSW, AustraliaAD  - Univ Genoa, Genoa, ItalyAD  - Danube Univ Krems, Dept Clin Neurosci & Prevent Med, Krems, AustriaAD  - Comenius Univ, Inst Epidemiol, Bratislava, SlovakiaAD  - Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USAAD  - Ohio State Univ, Dept Psychol, Columbus, OH 43210 USAAD  - Ohio State Univ, Psychiat & Behav Hlth Dept, Columbus, OH 43210 USAAD  - German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, GermanyAD  - Mayo Clin, Dept Cardiovasc Med, Rochester, MN USAAD  - Mayo Clin, Dept Dermatol, Rochester, MN USAAD  - Inst Sci Res & High Technol Serv, TB Riomarker Res Unit, City Of Knowledge, PanamaAD  - Inst Sci Res & High Technol Serv, City Of Knowledge, PanamaAD  - Gorgas Mem Inst Hlth Studies, Dept Res & Hlth Technol Assessment, Panama City, PanamaAD  - Gorgas Mem Inst Hlth Studies, Panama City, PanamaAD  - Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, CanadaAD  - Univ British Columbia, Vancouver, BC, CanadaAD  - Al Shifa Trust Eye Hosp, Al Shifa Sch Publ Hlth, Rawalpindi, PakistanAD  - Natl Inst Publ Hlth, Ctr Hlth Syst Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Ctr Nutr & Hlth Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Ctr Populat Hlth Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Cuernavaca, Morelos, MexicoAD  - Univ Valley Cuernavaca, Sch Med, Cuernavaca, Morelos, MexicoAD  - Imperial Coll London, Dept Primary Care & Publ Hlth, London, EnglandAD  - Imperial Coll London, Div Brain Sci, London, EnglandAD  - Imperial Coll London, Sch Publ Hlth, London, EnglandAD  - Imperial Coll London, WHO, Collaborating Ctr Publ Hlth Educ & Training, London, EnglandAD  - Metropolitan Autonomous Univ, Dept Populat & Hlth, Mexico City, DF, MexicoAD  - Univ Porto, Appl Mol Biosci Unit, Porto, PortugalAD  - Univ Porto, Inst Res & Innovat Hlth I3S, Porto, PortugalAD  - Univ Porto, Inst Biomed Engn, Porto, PortugalAD  - Univ Porto, Inst Publ Hlth, Porto, PortugalAD  - Univ Porto, REQUIMTE, LAQV, Porto, PortugalAD  - Univ Porto, UCIBIO, Porto, PortugalAD  - Natl Inst Hlth, Colombian Natl Hlth Observ, Bogota, ColombiaAD  - Univ Nacl Colombia, Epidemiol & Publ Hlth Evaluat Grp, Bogota, ColombiaAD  - Costa Rican Dept Social Secur, Area Bstadist, Direcc Actuarial, San Jose, Costa RicaAD  - Univ Costa Rica, Sch Dent, San Pedro, Costa RicaAD  - Inst Hlth Carlos III, Dept Hlth Planning & Econ, Madrid, SpainAD  - Hacettepe Univ, Dept Publ Hlth, Ankara, TurkeyAD  - Hacettepe Univ, Inst Populat Studies, Ankara, TurkeyAD  - Australian Catholic Univ, Mary MacKillop Inst Hlth Res, Melbourne, Vic, AustraliaAD  - Australian Catholic Univ, Brain Inst, Melbourne, Vic, AustraliaAD  - Univ Hong Kong, Ctr Suicide Res & Prevent, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ Hong Kong, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R ChinaAD  - Natl Hlth Res Inst, Hlth Syst Res Ctr, Zhunan Township, TaiwanAD  - Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan Township, TaiwanAD  - Natl Taiwan Univ, Coll Med, Taipei, TaiwanAD  - Int Inst Populat Sci, Dept Dev Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Dept Fertil Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Dept Populat Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Dept Publ Hlth & Mortal Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Bombay, Maharashtra, IndiaAD  - Tata Mem Hosp, Surg Oncol, Bombay, Maharashtra, IndiaAD  - Gold Coast Hlth, Clin Governance, Gold Coast, Qld, AustraliaAD  - Monash Univ, Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic, AustraliaAD  - Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, AustraliaAD  - Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, AustraliaAD  - Univ Zambia, Dept Econ, Lusaka, ZambiaAD  - Univ Zambia, Dept Populat Studies, Lusaka, ZambiaAD  - Univ Witwatersrand, Demog & Populat Studies, Johannesburg, South AfricaAD  - Seoul Natl Univ Hosp, Biochem Biomed Sci, Seoul, South KoreaAD  - Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, EnglandAD  - Christian Med Coll & Hosp CMC, Dept Endocrinol, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp CMC, Dept Pulm Med, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp CMC, Vellore, Tamil Nadu, IndiaAD  - Univ Adelaide, Adelaide Med Sch, Adelaide, SA, AustraliaAD  - Univ Adelaide, Robinson Res Inst, Adelaide, SA, AustraliaAD  - Univ Adelaide, Adelaide, SA, AustraliaAD  - Univ Salerno, Scuola Med Salernitana, Baronissi, ItalyAD  - Autonomous Univ Chile, Fac Business & Management, Talca, ChileAD  - Autonomous Univ Chile, Fac Educ, Talca, ChileAD  - Autonomous Univ Chile, Inst Phys Act & Hlth, Talca, ChileAD  - Univ Milano Bicocca, Sch Med & Surg, Monza, ItalyAD  - Univ Southampton, NIHR Oxford Biomed Res Ctr, Southampton, Hants, EnglandAD  - Arizona State Univ, T Denny Sanford Sch Social & Family Dynam, Tempe, AZ USAAD  - Ctr Dis Control & Prevent, CDC, Div Reprod Hlth, Atlanta, GA USAAD  - Croatian Inst Publ Hlth, Div Epidemiol & Prevent Chron Noncommuicable Dis, Zagreb, CroatiaAD  - Univ Queensland, Sch Publ Hlth, Div Epidemiol & Biostat, Brisbane, Qld, AustraliaAD  - Univ Queensland, Inst Social Sci Res, Brisbane, Qld, AustraliaAD  - Univ Queensland, Queensland Brain Inst, Brisbane, Qld, AustraliaAD  - Univ Queensland, Sch Dent, Brisbane, Qld, AustraliaAD  - Univ Queensland, Sch Publ Hlth, Brisbane, Qld, AustraliaAD  - Univ Queensland, Brisbane, Qld, AustraliaAD  - Guys & St Thomas NHS Fdn Trust, Biomed Res Council, London, EnglandAD  - Guys & St Thomas NHS Fdn Trust, Clin Toxicol Serv, London, EnglandAD  - BRAC Univ, James P Grant Sch Publ Hlth, Dhaka, BangladeshAD  - BRAC Univ, Res & Evaluat Div, Dhaka, BangladeshAD  - Cent Univ Tamil Nadu, Thiruvarur, IndiaAD  - Clin Emergency Hosp Sf Pantelimon, Dept Surg, Bucharest, RomaniaAD  - Natl Med Univ, Alma Ata, KazakhstanAD  - Griffith Univ, Australian Inst Suicide Res & Prevent, Mt Gravatt, Qld, AustraliaAD  - Griffith Univ, Menzies Hlth Inst Queensland, Mt Gravatt, Qld, AustraliaAD  - African Populat Hlth Res Ctr, Maternal & Child Wellbeing Unit, Nairobi, KenyaAD  - African Populat Hlth Res Ctr, Populat Dynam & Reprod Hlth Unit, Nairobi, KenyaAD  - Aksum Univ, Dept Clin Pharm, Aksum, EthiopiaAD  - Aksum Univ, Dept Med Lab Sci, Aksum, EthiopiaAD  - Brighton & Sussex Med Sch, Dept Global Hlth & Infect, Brighton, E Sussex, EnglandAD  - Natl Hlth Serv Scotland, Informat Serv Div, Edinburgh, Midlothian, ScotlandAD  - Natl Hlth Serv Scotland, Edinburgh, Midlothian, ScotlandAD  - Aristotle Univ Thessaloniki, Thessaloniki, GreeceAD  - Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USAAD  - Univ Peradeniya, Dept Community Med, Peradeniya, Sri LankaAD  - Nepal Hlth Res Council, Hlth Res Sect, Kathmandu, NepalAD  - Nepal Hlth Res Council, Res Sect, Kathmandu, NepalAD  - Minist Hlth & Med Educ, Ctr Communicable Dis Control, Tehran, IranAD  - Minist Hlth & Med Educ, Deputy Res & Technol, Tehran, IranAD  - Minist Hlth & Med Educ, Tehran, IranAD  - Nguyen Tat Thanh Univ, Inst Global Hlth Innovat, Hanoi, VietnamAD  - Med Univ Varna, Dept Social Med & Hlth Care Org, Varna, BulgariaAD  - Univ Cape Coast, Dept Populat & Hlth, Cape Coast, GhanaAD  - Univ Tampere, Fac Social Sci, Tampere, FinlandAD  - Univ Tampere, Fac Hlth Sci, Tampere, FinlandAD  - RMIT Univ, Sch Hlth & Biomed Sci, Bundoora, Vic, AustraliaAD  - Univ Sydney, Asbestos Dis Res Inst, Sydney, NSW, AustraliaAD  - Univ Sydney, Sydney Med Sch, Sydney, NSW, AustraliaAD  - Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, AustraliaAD  - United Nations World Food Programme, New Delhi, IndiaAD  - Univ Belgrade, Ctr Sch Publ Hlth & Hlth Management, Belgrade, SerbiaAD  - Univ Belgrade, Fac Med, Belgrade, SerbiaAD  - Univ Belgrade, Fac Med, Inst Epidemiol, Belgrade, SerbiaAD  - Wollega Univ, Dept Hlth Sci, Nekemte, EthiopiaAD  - Univ Fed Bahia, Sch Med, Salvador, BA, BrazilAD  - Roberto Santos Gen Hosp, Diretoria Med, Salvador, BA, BrazilAD  - Umea Univ, Dept Nursing, Umea, SwedenAD  - Eijkman Inst Mol Biol, Eijkman Oxford Clin Res Unit, Jakarta, IndonesiaAD  - St Pauls Hosp, Millennium Med Coll, Publ Hlth Dept, Addis Ababa, EthiopiaAD  - Russian Acad Sci, Lab Socioecon Issues Human Dev & Qual Life, Moscow, RussiaAD  - Minist Hlth, Fed Res Inst Hlth Org & Informat, Cent Res Inst Cytol & Genet, Moscow, RussiaAD  - Minist Hlth, Fed Res Inst Hlth Org & Informat, Dept Med Stat & Documentary, Moscow, RussiaAD  - Minist Hlth, Fed Res Inst Hlth Org & Informat, Moscow, RussiaAD  - Gonabad Univ Med Sci, Dept Publ Hlth, Conabad, IranAD  - Urmia Univ Med Sci, Dept Med Parasitol & Mycol, Orumiyeh, IranAD  - Imam Muhammad Inn Saud Islamic Univ, Coll Med, Riyadh, Saudi ArabiaAD  - Imam Muhammad Inn Saud Islamic Univ, Dept Publ Hlth, Riyadh, Saudi ArabiaAD  - Natl Stat Off, Lisbon, PortugalAD  - Univ Fed Sergipe, Dept Psychol, Sao Cristovao, BrazilAD  - Doctor Evidence, Santa Monica, CA USAAD  - Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New ZealandAD  - Org Econ Cooperat & Dev, Hlth Div, Paris, FranceAD  - Sarem Fertil & Infertil Res Ctr, Fertil & Infertil, Tehran, IranAD  - Univ Ghana, Inst Stat Social & Econ Res, Legon, GhanaAD  - Univ Ghana, Sch Publ Hlth, Legon, GhanaAD  - Kaiser Permanente, Psychiat, Fontana, CA USAAD  - Bielefeld Univ, Dept Publ Hlth Med, Bielefeld, GermanyAD  - Sergio Arouca Natl Sch Publ Hlth, Rio De Janeiro, BrazilAD  - Univ Fed Espirito Santo, Vitoria, BrazilAD  - Natl Acad Med Sci Ukraine, Inst Gerontol, Kiev, UkraineAD  - Univ Milano Bicocca, Dept Med & Surg, Monza, ItalyAD  - Swiss Trop & Publ Hlth Inst, Epidemiol & Publ Hlth, Basel, SwitzerlandAD  - Swiss Trop & Publ Hlth Inst, Malaria Vaccines, Basel, SwitzerlandAD  - Univ Basel, Basel, SwitzerlandAD  - Canc Inst, Gene Express & Regulat Program, Philadelphia, PA USAAD  - Kobe Univ, Dept Dermatol, Kobe, Hyogo, JapanAD  - Natl Ctr Dis Control, Med Stat, Tbilisi, GeorgiaAD  - Natl Ctr Dis Control, Tbilisi, GeorgiaAD  - Univ Sidi Mohammed Ben Abdellah, Fac Med & Pharm Fez, Fes, MoroccoAD  - Task Force Global Hlth, Int Trachoma Initiat, Decatur, GA USAAD  - Curtin Univ, Sch Publ Hlth, Perth, WA, AustraliaAD  - Wageningen Univ & Res, Div Human Nutr & Hlth, Wageningen, NetherlandsAD  - Reg Hlth Council, Directorate Gen Publ Hlth, Madrid, SpainAD  - Univ Social Welf & Rehabilitat Sci, Social Determinants Hlth Res Ctr, Tehran, IranAD  - Univ Social Welf & Rehabilitat Sci, Tehran, IranAD  - Univ Isukuba, Dept Hlth Care Policy & Management, Tsukuba, Ibaraki, JapanAD  - Natl Allergy Asthma & Bronchitis Inst, Dept Resp Med, Kolkota, IndiaAD  - Fortis Hosp, Dept Resp Med, Kolkota, IndiaAD  - Univ Warwick, Div Hlth Sci, Coventry, W Midlands, EnglandAD  - Univ Warwick, Unit Acad Primary Care, Coventry, W Midlands, EnglandAD  - Res Ctr Neurol, Moscow, RussiaAD  - Jawahar Lal Nehru Univ, Ctr Study Reg Dev, New Delhi, IndiaAD  - Jawahar Lal Nehru Univ, Ctr Eth, New Delhi, IndiaAD  - Univ Massachusetts, Nursing & Hlth Sci Dept, Boston, MA 02125 USAAD  - Univ Oklahoma, Dept Biostat & Epidemiol, Oklahoma City, OK USAAD  - Govt Federated States Micronesia, Dept Hlth & Social Affairs, Palikir, MicronesiaAD  - Univ Fed Rio Grande do Sul, Postgrad Program Epidemiol, Porto Alegre, RS, BrazilAD  - Boston Univ, Sch Med, Boston, MA 02118 USAAD  - Boston Univ, Sch Publ Hlth, Boston, MA 02215 USAAD  - Vittorio Emanuele Univ Hosp Polyclin, Registro Tumori Integrato, Catania, ItalyAD  - St James Sch Med, Dept Epidemiol, The Valley, AnguillaAD  - St James Sch Med, Dept Microbiol, The Valley, AnguillaAD  - Healis Sekhsaria Inst Publ Hlth, Dept Epidemiol, Bombay, Maharashtra, IndiaAD  - West Virginia Bur Publ Hlth, Commissioner Publ Hlth, Charleston, WV USAAD  - West Virginia Univ Sch Publ Hlth, Deparmient Hlth Policy Management & Leadership, Morgantown, WV USAAD  - Rajasthan Univ Hlth Sci, Acad & Res, Jaipur, Rajasthan, IndiaAD  - Eternal Heart Care Ctr & Res Inst, Dept Prevent Cardiol, Jaipur, Rajasthan, IndiaAD  - Montefiore Med Ctr, Dept Cardiol, 111 E 210th St, Bronx, NY 10467 USAAD  - Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USAAD  - Albert Einstein Coll Med, Bronx, NY 10467 USAAD  - Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, NetherlandsAD  - Univ Western Ontario, Dept Clin Neurol Sci, London, ON, CanadaAD  - Lawson Hlth Res Inst, London, ON, CanadaAD  - Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Gastroenterol & Hepatol, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21218 USAAD  - Johns Hopkins Univ, Dept Int Hlth, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Radiol, Baltimore, MD USAAD  - Arabian Gulf Univ, Dept Family & Community Med, Manama, BahrainAD  - Hamdan Bin Mohammed Smart Univ, Sch Hlth & Environm Studies, Dubai, U Arab EmiratesAD  - Univ New Mexico, Populat Hlth Dept, Albuquerque, NM 87131 USAAD  - Sir Charles Gairdner Hosp, Neurol Dept, Perth, WA, AustraliaAD  - Sun Yat Sen Univ, Dept Med Stat & Epidemiol, Guangzhou, Guangdong, Peoples R ChinaAD  - Sun Yat Sen Univ, Sun Yat Sen Global Hlth Inst, Guangzhou, Guangdong, Peoples R ChinaAD  - Minist Publ Hlth, Dept Dis Epidem & Pandem Control, Beirut, LebanonAD  - Minist Publ Hlth, Dept Vital & Hlth Stat, Beirut, LebanonAD  - Tabriz Univ Med Sci, Hlth Educ & Hlth Promot Dept, Tabriz, IranAD  - Tabriz Univ Med Sci, Tabriz, IranAD  - San Juan Dios Sanitary Pk, Res & Dev Unit, St Boi De Llobregat, SpainAD  - Univ Barcelona, Dept Med, Barcelona, SpainAD  - Univ Hosp Antwerp, Unit Epidemiol & Social Med, Antwerp, BelgiumAD  - Karolinska Univ Hosp, Clin Sci, Stockholm, SwedenAD  - Teikyo Univ, Sch Med, Endocrinol & Metab Res Ctr, Tehran, IranAD  - Bucharest Univ Econ Studies, Dept Stat & Economet, Bucharest, RomaniaAD  - Univ Texas Austin, Austin, TX 78712 USAAD  - Guilan Univ Med Sci, Guilan Rd Trauma Res Ctr, Rasht, IranAD  - Guilan Univ Med Sci, Sch Hlth, Rasht, IranAD  - Manipal Univ, Transdisciplinary Ctr Qualitat Methods, Manipal, Karnataka, IndiaAD  - Univ Melbourne, Dept Med, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Dept Paediat, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Sch Hlth Sci, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Melbourne, Vic, AustraliaAD  - Univ Human Dev, Dept Comp Sci, Sulaimaniyah, IraqAD  - Bucharest Emergency Hosp, Dept Internal Med, Bucharest, RomaniaAD  - Natl Inst Legal Med Mina Minovici, Clin Legal Med, Bucharest, RomaniaAD  - Med Sch Tunis, Fac Med Tunis, Baab Saadoun, TunisiaAD  - Cent South Univ, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R ChinaAD  - Aarhus Univ, Dept Publ Hlth, Aarhus, DenmarkAD  - Aarhus Univ, Natl Ctr Register Based Res, Aarhus, DenmarkAD  - Univ Western Cape, Sch Publ Hlth, Cape Town, South AfricaAD  - Walter Sisulu Univ, Dept Publ Hlth, Mthatha, South AfricaAD  - Univ Liberia, Dept Publ Hlth & Community Med, Monrovia, LiberiaAD  - Taipei Med Univ, Global Hlth & Dev Dept, Taipei, TaiwanAD  - Taipei Med Univ, Grad Inst Biomed Informat, Taipei, TaiwanAD  - Univ Memphis, Sch Publ Hlth, Memphis, TN 38152 USAAD  - Deakin Univ, Dept Psychol, Burwood, Vic, AustraliaAD  - Deakin Univ, Inst Phys Act & Nutr, Burwood, Vic, AustraliaAD  - Deakin Univ, Sch Med, Burwood, Vic, AustraliaAD  - Natl Ctr Dis Control Delhi, Dept Parasit Dis, Delhi, IndiaAD  - Univ Kragujevac, Med Sci Dept, Kragujevac, SerbiaAD  - Univ Calif San Diego, Dept Internal Med, San Diego, CA 92103 USAAD  - Newcastle Univ, Tyne, EnglandAD  - Univ Colombo, Fac Grad Studies, Colombo, Sri LankaAD  - Univ Colombo, Inst Med, Colombo, Sri LankaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Achutha Menon Ctr Hlth Sci Studies, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Neurol Dept, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Trivandrum, Kerala, IndiaAD  - Banaras Hindu Univ, Dept Community Med, Varanasi, Uttar Pradesh, IndiaAD  - Duke Kunshan Univ, Environm Res Ctr, Kunshan, Peoples R ChinaAD  - Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R ChinaAD  - Czestochowa Univ Tech, Inst Hlth & Nutr Sci, Czestochowa, PolandAD  - Univ Opole, Fac Med & Hlth Sci, Opole, PolandAD  - Savitribai Phule Pune Univ, Sch Hlth Sci, Pune, Maharashtra, IndiaAD  - Univ Tartu, Inst Family Med & Publ Hlth, Tartu, EstoniaAD  - Univ Coll Cork, Sch Publ Hlth, Cork, IrelandAD  - ACS Med Coll & Hosp, New Delhi, IndiaAD  - Hamadan Univ Med Sci, Chron Dis Home Care Res Ctr, Hamadan, IranAD  - Hamadan Univ Med Sci, Dept Epidemiol, Hamadan, IranAD  - Helmholtz Ctr Infect Res, Dept Epidemiol, Braunschweig, GermanyAD  - Qual & Equ Hlth Care, Kigali, RwandaAD  - Univ Washington, Sch Interdisciplinary Arts & Sci, Tacoma, WA USAAD  - Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, Seattle, WA USAAD  - Seattle Childrens Hosp, Seattle, WA USAAD  - Univ Glasgow, CSO Social & Publ Hlth Sci Unit, MRC, Glasgow, Lanark, ScotlandAD  - Oklahoma State Univ, Sch Hlth Care Adm, Tulsa, OK USAAD  - Univ Tulsa, Hlth Care Delivery Sci, Tulsa, OK 74104 USAAD  - Salale Univ, Midwifery Program, Fiche, EthiopiaAD  - Univ Nairobi, ODeL Campus, Nairobi, KenyaAD  - Michigan State Univ, Dept Linguist & German, Slavic Asian & African Languages, E Lansing, MI 48824 USAAD  - Med Res Council South Africa, Cochrane South Africa, Cape Town, South AfricaAD  - Med Res Council South Africa, Noncommunicable Dis Res Unit, Cape Town, South AfricaAD  - Univ Cape Town, Dept Med, Cape Town, South AfricaAD  - Assuta Hosp, Inst Cardiol, Tel Aviv, Yaffo, IsraelAD  - Hadassah Hebrew Univ Hosp, Heart Failure & Cardiomyopathies Ctr, Jerusalem, IsraelAD  - Jordan Univ Sci & Technol, Dept Publ Hlth & Community Med, Ramtha, JordanAD  - Univ Management & Technol, Sch Food & Agr Sci, Lahore, PakistanAD  - Hlth Serv Acad, Epidemiol & Biostat Dept, Islamabad, PakistanAD  - John H Stroger Jr Hosp Cook Cty, Dept Internal Med, Chicago, IL USAAD  - Dow Univ Hlth Sci, Dept Internal Med, Karachi, PakistanAD  - Seoul Natl Univ, Dept Hlth Policy & Management, Seoul, South KoreaAD  - Seoul Natl Univ, Inst Hlth Policy & Management, Seoul, South KoreaAD  - Indian Council Med Res, Dept Hlth Res, New Delhi, IndiaAD  - Indian Council Med Res, Natl Inst Res Environm Hlth, New Delhi, IndiaAD  - Indian Council Med Res, Natl Inst Nutr, New Delhi, IndiaAD  - Indian Council Med Res, New Delhi, IndiaAD  - Baqiyatallah Univ Med Sci, Student Res Comm, Tehran, IranAD  - Int Otorhinolaryngol Res Assoc, Tehran, IranAD  - Kenya Revenue Author, Res Dept, Nairobi, KenyaAD  - Synotech Consultant, Res & Data Solut, Nairobi, KenyaAD  - Wayne State Univ, Dept Pharm Practice, Detroit, MI USAAD  - Wayne State Univ, Dept Publ Hlth Sci, Detroit, MI USAAD  - Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USAAD  - Korea Univ, Dept Prevent Med, Seoul, South KoreaAD  - Xiamen Univ Malaysia, Sch Med, Sepang, MalaysiaAD  - Simmons Coll, Dept Nutr, Boston, MA 02115 USAAD  - Univ Canberra, Fac Hlth, Canberra, ACT, AustraliaAD  - Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, NorwayAD  - Univ Oslo, Inst Hlth & Soc, Oslo, NorwayAD  - Tulane Univ, Dept Global Community Hlth & Behav Sci, New Orleans, LA 70118 USAAD  - Univ Helsinki, Dept Publ Hlth, Helsinki, FinlandAD  - Univ Helsinki, Helsinki, FinlandAD  - Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Suita, Osaka, JapanAD  - Arthrit Res Canada, Richmond, BC, CanadaAD  - Sheri Kashmir Inst Med Sci, Dept Internal & Pulm Med, Srinagar, Jammu & Kashmir, IndiaAD  - Pathab Univ, Dept Anthropol, Chandigarh, IndiaAD  - Univ Montreal, Dept Demog, Montreal, PQ, CanadaAD  - Univ Montreal, Dept Social & Prevent Med, Montreal, PQ, CanadaAD  - Yuksek Ithisas Univ, Dept Publ Hlth, Ankara, TurkeyAD  - Univ Technol Sydney, Ctr Midwifery Child & Family Hlth, Sydney, NSW, AustraliaAD  - Univ Technol Sydney, Sch Hlth, Sydney, NSW, AustraliaAD  - Post Grad Inst Med Educ & Res, Dept Pediat, Chandigarh, IndiaAD  - Post Grad Inst Med Educ & Res, Sch Publ Hlth, Chandigarh, IndiaAD  - Natl Inst Hlth, Ctr Translat Res & Implementat Sci, Manila, PhilippinesAD  - Natl Inst Hlth, Inst Hlth Policy & Dev Studies, Manila, PhilippinesAD  - Natl Inst Hlth, Natl Heart Lung & Blood Inst, Manila, PhilippinesAD  - Acad Med Sci, Dept Community & Family Med, Baghdad, IraqAD  - HehpMeSee, New York, NY USAAD  - Mexican Inst Ophthalmol, Int Relat, Queretaro, MexicoAD  - Municipal Hlth Dept Belo Horizonte, Belo Horizonte City Hall, Belo Horizonte, MG, BrazilAD  - Ghana Hlth Serv, Dis Control Dept, Accra, GhanaAD  - Maragheh Univ Med Sci, Dept Publ Hlth, Maragheh, IranAD  - Maragheh Univ Med Sci, Managerial Epidemiol Res Ctr, Maragheh, IranAD  - Local Hlth Unit Tuscany Ctr, Reg Ctr Anal Data Occupat & Work Related Injuries, Florence, ItalyAD  - Univ Florence, Dept Hlth Sci, Florence, ItalyAD  - Sichuan Univ, West China Univ Hosp 2, Chengdu, Sichuan, Peoples R ChinaAD  - Shenzhen Sun Yat Sen Cardiovasc Hosp, Dept Clin Res & Epidemiol, Shenzhen, Peoples R ChinaAD  - Natl Off Maternal & Child Hlth Surveillance, Chengdu, Sichuan, Peoples R ChinaAD  - Natl Ctr Birth Defects Monitoring China, Chengdu, Sichuan, Peoples R ChinaAD  - Chinese Ctr Dis Control & Prevent, Div Injury Prevent & Mental Hlth Improvement, Beijing, Peoples R ChinaAD  - Chinese Ctr Dis Control & Prevent, Noncommunicable Dis Control & Prevent Ctr, Beijing, Peoples R ChinaAD  - Chinese Ctr Dis Control & Prevent, Beijing, Peoples R ChinaAD  - Samara Univ, Dept Publ Hlth, Samara, EthiopiaAD  - Univ Malaya, Dept Med, Kuala Lumpur, MalaysiaAD  - Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R ChinaAD  - Univ Haifa, Sch Publ Hlth, Haifa, IsraelAD  - Ctr Chron Dis Control, Beijing, Peoples R ChinaAD  - Friedrich Schiller Univ Jena, Inst Nutr, Jena, GermanyAD  - Competence Cluster Nutr & Cardiovasc Hlth NutriCA, Jena, GermanyAD  - Aintree Univ Hosp Natl Hlth Serv NHS Fdn Trust, Gen Surg Dept, Liverpool, Merseyside, EnglandAD  - Univ Liverpool, Surg Dept, Liverpool, Merseyside, EnglandAD  - Univ Kinshasa, Sch Publ Hlth, Kinshasa, DEM REP CONGOAD  - Univ Kinshasa, Kinshasa, DEM REP CONGOAD  - Royal Childrens Hosp, Cardiol Dept, Melbourne, Vic, AustraliaAD  - Royal Childrens Hosp, Neurol Dept, Melbourne, Vic, AustraliaAD  - Minist Hlth & Populat, Prevent Dept, Cairo, EgyptAD  - Tribhuvan Univ, Inst Med, Kathmandu, NepalAD  - Trnava Univ, Dept Publ Hlth, Trnava, SlovakiaAD  - Shiraz Univ Med Sci, Noncommunicable Dis Res Ctr, Shiraz, IranAD  - Indian Inst Technol, Dept Humanities & Social Sci, Roorkee, Haridwar, IndiaAD  - Emergency Univ Hosp Bucharest, Surg Dept, Bucharest, RomaniaAD  - Publ Risk Management Inst, Mississauga, ON, CanadaAD  - World Bank, Trade & Competitiveness, New York, NY USAAD  - Fed Inst Educ Sci & Technol Ceara, Campus Caucaia, Caucaia, BrazilAD  - Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, Graz, AustriaAD  - Univ East Ramon Magsaysay Mem Med Ctr, Grad Sch, Quezon City, PhilippinesAD  - Univ York, Dept Hlth Sci, York, N Yorkshire, EnglandAD  - Chalmers Univ Technol, Dept Biol & Biol Engn, Gothenburg, SwedenAD  - Ipas Nepal, Res Monitoring & Evaluat, Kathmandu, NepalAD  - Janakpuri Super Specialty Hosp Soc, Neurol Dept, New Delhi, IndiaAD  - Natl Inst Canc Prevent & Res, Prevent Oncol, Noida, IndiaAD  - Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USAAD  - SevenHills Hosp, Dept Internal Med, Bombay, Maharashtra, IndiaAD  - Wollo Univ, Dept Adult Hlth Nursing, Dessie, EthiopiaAD  - Wollo Univ, Dept Pharm, Dessie, EthiopiaAD  - Wollo Univ, Dept Publ Hlth, Dessie, EthiopiaAD  - Debre Tabor Univ, Coll Hlth Sci, Debre Tabor, EthiopiaAD  - Debre Tabor Univ, Dept Pharm, Debre Tabor, EthiopiaAD  - Univ West Florida, Dept Publ Hlth, Pensacola, FL 32514 USAAD  - Minist Hlth, Prince Mohammed Bin Abdulaziz Hosp, Res Dept, Riyadh, Saudi ArabiaAD  - Alfaisal Univ, Coll Med, Riyadh, Saudi ArabiaAD  - United Nations Populat Fund UNFPA, Peru Country Off, Lima, PeruAD  - Helsinki Univ Hosp, Breast Surg Unit, Helsinki, FinlandAD  - Helsinki Univ Hosp, Neuroctr, Helsinki, FinlandAD  - Dr Zorn Profozic Polyclin, Clin Microbiol & Parasitol Unit, Zagreb, CroatiaAD  - Univ North, Univ Ctr Varazdin, Varazhdin, CroatiaAD  - Ethiopian Acad Med Sci, Pharm, Addis Ababa, EthiopiaAD  - Univ Ndjamena, Fac Humanities & Social Sci, Ndjamena, ChadAD  - Pomeranian Med Univ, Dept Hypertens, Szczecin, PolandAD  - Pomeranian Med Univ, Emergency Dept, Szczecin, PolandAD  - Pomeranian Med Univ, Zdroje Hosp, Szczecin, PolandAD  - Pomeranian Med Univ, Szczecin, PolandAD  - Pacific Inst Res & Evaluat, Calverton, MD USAAD  - Natl Inst Stat, Presidents Off, Bucharest, RomaniaAD  - Kyrgyz State Med Acad, Fac Gen Med, Bishkek, KyrgyzstanAD  - Natl Ctr Cardiol & Internal Dis, Dept Atherosclerosis & Coronary Heart Dis, Bishkek, KyrgyzstanAD  - Frankfurt Univ Appl Sci, Inst Addict Res ISFF, Frankfurt, GermanyAD  - Salahaddin Univ, Dept Biol, Erbil, IraqAD  - ISHIK Univ, Erbil, IraqAD  - Isfahan Univ Med Sci, Cardiovasc Res Inst, Esfahan, IranAD  - Jigjiga Univ, Dept Publ Hlth, Jigjiga, EthiopiaAD  - Jigjiga Univ, Jigjiga, EthiopiaAD  - Ahmadu Bello Univ, Dept Community Med, Zaria, NigeriaAD  - Ahmadu Bello Univ, Hlth Syst & Policy Res Unit, Zaria, NigeriaAD  - Univ Papua New Guinea, Sch Med & Hlth Sci, Obstet & Gynecol Dept, Boroko, Papua N GuineaAD  - Port Moresby Gen Hosp, Dept Obstet & Gynaecol, Port Moresby, Papua N GuineaAD  - Burlo Garofolo Inst Maternal & Child Hlth, Clin Epidemiol & Publ Hlth Res Unit, Trieste, ItalyAD  - Kurdistan Univ Med Sci, Dept Epidemiol & Biostat, Sanandaj, IranAD  - Kurdistan Univ Med Sci, Determinants Hlth Res Ctr, Sanandaj, IranAD  - Univ Lancaster, Lancaster, EnglandAD  - Hosp Ctr Porto, Hosp Sto Antonio, Porto, PortugalAD  - Natl Ctr Child Hlth & Dev, Dept Hlth Policy, Tokyo, JapanAD  - Tarbiat Modares Univ, Dept Clin Biochem, Tehran, IranAD  - Univ Athens, Dept Ophthalmol 1, Athens, GreeceAD  - Acad Athens, Biomed Res Fdn, Athens, GreeceAD  - Fed Inst Populat Res, Competence Ctr Mortal Follow Up, Wiesbaden, GermanyAD  - Fed Inst Populat Res, Demog Change & Ageing Res Area, Wiesbaden, GermanyAD  - Fed Inst Populat Res, Wiesbaden, GermanyAD  - Ctr Populat & Hlth, Wiesbaden, GermanyAD  - Inst Post Grad Med Educ & Res, Dept Endocrinol & Metab, Kolkata, IndiaAD  - Univ Jos, Dept Obstet & Gynecol, Jos, NigeriaAD  - Northwestern Univ, Ctr Global Hlth, Chicago, IL 60611 USAAD  - Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USAAD  - Sci Univ Malaysia, Sch Med Sci, Kubang Kerian, MalaysiaAD  - Nishtar Med Univ, Pediat Dept, Multan, PakistanAD  - Inst Mother & Child Care, Pediat & Pediat Pulmonol, Multan, PakistanAD  - Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USAAD  - Ulm Univ, Inst Epidemiol & Med Biometry, Ulm, GermanyAD  - Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USAAD  - Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USAAD  - Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USAAD  - San Bortolo Hosp, Dept Dermatol, Vicenza, ItalyAD  - GISED Study Ctr, Direct, Bergamo, ItalyAD  - Suraj Eye Inst, Nagpur, Maharashtra, IndiaAD  - Univ Yaounde I, Dept Publ Heath, Yaounde, CameroonAD  - Mercy St Vincent Med Ctr, Toledo, OH USAAD  - Cardio Aid, Dept Cardiol, Bucharest, RomaniaAD  - Wellcome Trust Res Programme, Kenya Med Res Inst, Kilifi, KenyaAD  - Minist Hlth, Gender Elderly & Children, Community Dev, Dar Es Salaam, TanzaniaAD  - Univ Embu, Dept Biol Sci, Embu, KenyaAD  - State Univ Semarang, Publ Hlth Sci Dept, Kota Semarang, IndonesiaAD  - Natl Ctr Global Hlth & Med, Inst Global Hlth Policy Res, Shinjuku Ku, Tokyo, JapanAD  - Rwanda Minist Hlth, Directorate Gen Planning Monitoring & Evolut, Kigali, RwandaAD  - Univ Rwanda, Coll Med & Hlth Sci, Kigali, RwandaAD  - Abia State Univ, Dept Med, Uturu, NigeriaAD  - Western Sydney Univ, Sch Social Sci & Psychol, Penrith, NSW, AustraliaAD  - Western Sydney Univ, Penrith, NSW, AustraliaAD  - Kyung Hee Univ, Dept Prevent Med, Seoul, South KoreaAD  - Soc Family Hlth, Res Measurement & Results, Abuja, NigeriaAD  - Human Sci Res Council, Dept HIV AIDS STIs & TB, Durban, South AfricaAD  - Univ Namibia, Sch Publ Hlth, Oshakati Campus, Windhoek, NamibiaAD  - Ctr Hlth Start Initiat, Ikoyi, NigeriaAD  - Minist Hlth, NCD Prevent & Control Unit, Bandar Seri Begawan, BruneiAD  - Univ Brunei Darussalam, Inst Hlth Sci, Gadong, BruneiAD  - Autonomous Univ Madrid, Pneumol Serv, Madrid, SpainAD  - Autonomous Univ Madrid, Sch Med, Madrid, SpainAD  - Jimenez Diaz Univ Hosp, Inst Hlth Res Fdn, Dept Hypertens & Nephrol, Madrid, SpainAD  - St Lukes Int Univ, Dept Global Hlth Nursing, Chuo Ku, Tokyo, JapanAD  - Kisumu Med & Educ Trust, Res Monitoring & Evaluat, Kisumu, KenyaAD  - Minist Hlth Russian Federat, Moscow, RussiaAD  - Moscow State Univ, Moscow Inst Phys & Technol, Dolgoprudnyi, RussiaAD  - North West Univ, Agr Econ Grp, Mafikeng, South AfricaAD  - North West Univ, Dept Pediat, Mafikeng, South AfricaAD  - Jagadguru Sri Shivarathreeswara Univ, Dept TB & Resp Med, Mysore, Karnataka, IndiaAD  - Univ Ottawa, Dept Med, Ottawa, ON, CanadaAD  - All India Inst Med Sci, Ctr Community Med, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol Metab & Diabet, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - Ctr Hlth Outcomes & Evaluat, Hlth Outcomes, Bucharest, RomaniaAD  - Kosin Univ, Dept Med Humanities & Social Med, Busan, South KoreaAD  - Maimonides Hosp, Dept Med, Brooklyn, NY 11219 USAAD  - Deemed Univ, Krishna Inst Med Sci, Karad, IndiaAD  - Int Inst Hlth Management Res, New Delhi, IndiaAD  - Murdoch Childrens Res Inst, Populat Hlth Grp, Melbourne, Vic, AustraliaAD  - Murdoch Childrens Res Inst, Melbourne, Vic, AustraliaAD  - Diabet Res Soc, Clin Res Dept, Hyderabad, IndiaAD  - DiabetOmics, Clin Res Dept, Portland, OR USAAD  - Save Children, Hlth Nutr & HIV AIDS Program, Kathmandu, NepalAD  - Fundacao Oswaldo Cruz, Inst Sci & Technol Commun & Informat Hlth, Rio De Janeiro, BrazilAD  - Cartagena Univ, Cartagena, ColombiaAD  - Univ Virginia, Anesthesiol Dept, Charlottesville, VA USAAD  - Univ Virginia, Sch Med, Charlottesville, VA 22908 USAAD  - Univ Gothenburg, Inst Med, Gothenburg, SwedenAD  - Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South AfricaAD  - Durban Univ Technol, Basic Med Sci Dept, Durban, South AfricaAD  - Univ Groningen, Univ Med Ctr Groningen, Groningen, NetherlandsAD  - Sanjay Gandhi Postgrad Inst Med Sci, Dept Nephrol, Lucknow, Uttar Pradesh, IndiaAD  - Govt Med Coll, Nagpur, Maharashtra, IndiaAD  - Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, IranAD  - Medichem, Barcelona, SpainAD  - Contech Sch Publ Hlth, Dept Epidemiol & Biostat, Lahore, PakistanAD  - Global Publ Hlth Res Fdn, Res Div, Dhaka, BangladeshAD  - Sweidi Hosp, Dept Clin Pediat, Riyadh, Saudi ArabiaAD  - Soc Hlth & Demog Surveillance, Suri, IndiaAD  - Univ Gottingen, Dept Econ, Gottingen, GermanyAD  - Med Univ Innsbruck, Innsbruck, AustriaAD  - Yonsei Univ, Inst Poverty Alleviat & Int Dev, Seoul, South KoreaAD  - Univ Coll London Hosp, London, EnglandAD  - Publ Hlth England, London, EnglandAD  - Loma Linda Univ, Med Ctr, Dept Prevent Med & Occupat Med, Loma Linda, CA 92350 USAAD  - Brien Holden Vision Inst, Sydney, NSW, AustraliaAD  - Org Prevent Blindness, Paris, FranceAD  - Birjand Univ Med Sci, Dept Epidemiol, Birjand, IranAD  - Univ Fed Uberlandia, Dept Clin Res, Uberlandia, MG, BrazilAD  - Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, IranAD  - IKIAM Amazon Reg Univ, Biotechnol, Ciudad De Tena, EcuadorAD  - Southern Univ Sci & Technol, Dept Ocean Sci & Engn, Shenzhen, Peoples R ChinaAD  - Muhimbili Univ Hlth & Allied Sci, Dept Community Hlth, Dar Es Salaam, TanzaniaAD  - Muhimbili Univ Hlth & Allied Sci, Sch Publ Hlth, Dar Es Salaam, TanzaniaAD  - Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, TanzaniaAD  - Prince Wales Hosp, Neuropsychiat Inst, Randwick, NSW, AustraliaAD  - Univ Sharjah, Med Dept, Sharjah, U Arab EmiratesAD  - Al Imam Mohammad Ibn Saud Islamic Univ, Coll Med, Riyadh, Saudi ArabiaAD  - York Univ, Fac Hlth, Sch Hlth & Policy Management, Toronto, ON, CanadaAD  - Punjab Univ, Coll Pharm, Anarkali, PakistanAD  - Stanford Univ, Ctr Hlth Policy, Stanford, CA 94305 USAAD  - Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USAAD  - Chest Res Fdn, Clin Res Div, Pune, Maharashtra, IndiaAD  - Marshall Univ, Dept Surg, Huntington, WV USAAD  - Minist Hlth, Hlth & Disabil Intelligence Grp, Wellington, New ZealandAD  - Case Western Reserve Univ, Dept Nutr & Prevent Med, Cleveland, OH 44106 USAAD  - Jimenez Diaz Fdn Univ Hosp Inst Hlth Res, Nephrol Grp, Madrid, SpainAD  - Univ Massachusetts, Med Sch, Dept Med, Worcester, MA 01605 USAAD  - Univ Appl & Environm Sci, Fac Med, Dept Hlth & Soc, Bogota, ColombiaAD  - Mahatma Gandhi Mem Med Coll, Dept Community Med, Indore, Madhya Pradesh, IndiaAD  - Hamad Med Corp, Surg Dept, Doha, QatarAD  - Bournemouth Univ, Fac Hlth & Social Sci, Bournemouth, Dorset, EnglandAD  - Utkal Univ, UGC Ctr Adv Study Psychol, Bhubaneswar, IndiaAD  - Udyam Global Assoc Sustainable Dev, Bhubaneswar, IndiaAD  - Dr DY Patil Vidyapeeth, Pune, Maharashtra, IndiaAD  - Univ North Carolina, Dept Publ Hlth Sci, Charlotte, NC 28223 USAAD  - Univ Fed Santa Catarina, Sch Hlth Sci, Ararangua, BrazilAD  - Univ Zagreb, Dept Med Stat Epidemiol & Med Informat, Zagreb, CroatiaAD  - NYU, Langone Med Ctr, New York, NY USAAD  - An Najah Natl Univ, Publ Hlth Div, Nablus, PalestineAD  - Middle East Liver Dis Ctr, Dept Mol lepatol, Tehran, IranAD  - Islamic Azad Univ, Dept Basic Sci, Sari, IranAD  - Islamic Azad Univ, Dept Lab Sci, Sari, IranAD  - Minist Hlth, Policy & Planning Div, Thimphi, BhutanAD  - Delhi Technol Univ, Univ Sch Management & Entrepreneurship, New Delhi, IndiaAD  - Fudan Univ, Dept Pulmonary Med, Shanghai, Peoples R ChinaAD  - Univ Edinburgh, Usher Inst Populat Hlth Sci & informat, Edinburgh, Midlothian, ScotlandAD  - Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA USAAD  - Natl Inst Infect Dis, Tokyo, JapanAD  - Finnish Inst Occupat Hlth, Helsinki, FinlandAD  - Martin Luther Univ Halle Wittenberg, Inst Med Epidemiol, Halle, GermanyAD  - Univ Nottingham, Sch Med, Nottingham, EnglandAD  - Symbiosis Int Univ, Symbiosis Inst Hlth Sci, Pune, Maharashtra, IndiaAD  - Reykjavik Univ, Dept Psychol, Reykjavik, IcelandAD  - Columbia Univ, Dept Hlth & Behav Studies, New York, NY USAAD  - Brasilia Univ, Brasilia, DF, BrazilAD  - Fed Minist Hlth, Dept Hlth Ind Complex & Innovat Hlth, Brasilia, DF, BrazilAD  - Fed Minist Hlth, Dept Dis & Noncommunicable Dis & Hlth Promot, Brasilia, DF, BrazilAD  - Univ Louisville, Div Cardiovasc Med, Louisville, KY 40292 USAAD  - Max Hosp, Ghaziabad, IndiaAD  - Asthma Bhawan, Dept Pulm Med, Jaipur, Rajasthan, IndiaAD  - Sch Prevent Oncol, Dept Epidemiol, Patna, Bihar, IndiaAD  - King Khalid Univ Hosp, Pediat Dept, Riyadh, Saudi ArabiaAD  - Univ Hosp De La Princesa, Hlth Res Inst, Serv Pulmonol, Madrid, SpainAD  - Univ Hull, Hull York Med Sch, Kingston Upon Hull, N Humberside, EnglandAD  - Int Med Univ, Div Community Med, Kuala Lumpur, MalaysiaAD  - Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, EnglandAD  - Norwegian Inst Publ Hlth, Bergen, NorwayAD  - Univ Calif Riverside, Sch Med, Riverside, CA 92521 USAAD  - Univ Calif Irvine, Dept Criminol Law & Soc, Irvine, CA USAAD  - Univ Valencia, Dept Med, Valencia, SpainAD  - Univ Valencia, Dept Pediat Obstet & Gynecol, Valencia, SpainAD  - Biomed Res Networking Ctr Mental Hlth Network Cib, Carlos III Hlth Inst, Madrid, SpainAD  - Univ Illinois, Sch Social Work, Urbana, IL 61801 USAAD  - Univ Inst Egas Moniz, Monte De Caparica, PortugalAD  - Univ Lisbon, Fac Pharm Lisbon, Res Inst Med, Lisbon, PortugalAD  - Business & Technol Coll, Alkan Hlth Sci, Selihom Sch Nursing, Dessie, EthiopiaAD  - Syrian Expatriate Med Assoc, Charlottesville, VA USAAD  - Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, SingaporeAD  - Nanyang Technol Univ, Singapore, SingaporeAD  - Adapt Knowledge Management, Dept Global Hlth Res, Victoria, BC, CanadaAD  - Queensland Univ Technol, Sch Exercise & Nutr Sci, Brisbane, Qld, AustraliaAD  - Jagiellonian Univ, Med Coll, Inst Publ Hlth, Krakow, PolandAD  - Agcy Hlth Technol Assessment & Tariff Syst, Warsaw, PolandAD  - Univ Hosp Doctor Peset, Pediat Dept, Valencia, SpainAD  - Nagoya Univ, Nagoya, Aichi, JapanAD  - Hanoi Med Univ, Dept Hlth Econ, Hanoi, VietnamAD  - Mil Med Univ, Clin Hematol & Toxicol, Hanoi, VietnamAD  - Natl Inst Res TB, Madras, Tamil Nadu, IndiaAD  - Univ Copenhagen, Dept Neurol, Copenhagen, DenmarkAD  - Duy Tan Univ, Inst Global Hlth Innovat, Hanoi, VietnamAD  - Univ Heart Ctr Hamburg, Dept Vasc Med, Hamburg, GermanyAD  - Fed Teaching Hosp, Dept Internal Med, Abakaliki, NigeriaAD  - Gomal Univ, Gomal Ctr Biochem & Biotechnol, Dera Ismail Khan, PakistanAD  - Mufti Mehmood Mem Teaching Hosp, TB Culture Lab, Dera Ismail Khan, PakistanAD  - Ankara Univ, Ankara, TurkeyAD  - Argentine Soc Med, Buenos Aires, DF, ArgentinaAD  - Velez Sarsfield Hosp, Buenos Aires, DF, ArgentinaAD  - UKK Inst, Tampere, FinlandAD  - Univ Brasilia, Dept Stat, Brasilia, DF, BrazilAD  - Fed Dist Planning Co, Directorate Social Studies & Policies, Brasilia, DF, BrazilAD  - Raffles Hosp, Raffles Neurosci Ctr, Singapore, SingaporeAD  - Natl Univ Singapore, Yong Lou Lin Sch Med, Singapore, SingaporeAD  - St Orsola Malpighi Hosp, Occupat Hlth Unit, Bologna, ItalyAD  - IM Sechenov First Moscow State Med Univ, Dept Informat & Internet Technol, Moscow, RussiaAD  - Natl Res Univ, Higher Sch Econ, Dept Hlth Care Adm & Econ, Moscow, RussiaAD  - Fdn Univ, Med Coll, Rawalpindi, PakistanAD  - Canc Registry Norway, Dept Res, Oslo, NorwayAD  - Tech Univ Munich, Dept Neurol, Munich, GermanyAD  - Kailuan Gen Hosp, Kailuan Gen Hosp, Tangshan, Peoples R ChinaAD  - Univ Strathclyde, Glasgow, Lanark, ScotlandAD  - Nanjing Univ, Sch Med, Nanjing, Jiangsu, Peoples R ChinaAD  - King Fand Univ Petr & Minerals, Dept Earth Sci, Dhahran, Saudi ArabiaAD  - Wolkite Univ, Wolkite, EthiopiaAD  - Kyoto Univ, Dept Biostat, Kyoto, JapanAD  - Jackson State Univ, Dept Hlth Policy & Management, Jackson, MS USAAD  - Tsinghua Univ, Beijing, Peoples R ChinaAD  - Wuhan Univ, Dept Epidemiol & Biostat, Wuhan, Hubei, Peoples R ChinaAD  - Wuhan Univ, Global Hlth Inst, Wuhan, Hubei, Peoples R ChinaAD  - Inst Oncol Ljubljana, Epidemiol & Canc Registry Sect, Ljubljana, SloveniaAD  - Univ Hosp Setif, Dept Epidemiol, Setif, AlgeriaAD  - Dilla Univ, Publ Hlth Dept, Dilla, EthiopiaAD  - Wuhan Polytech Univ, Wuhan, Hubei, Peoples R ChinaC3  - University of WashingtonC3  - University of Washington SeattleC3  - Institute for Health Metrics & EvaluationC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - McGill UniversityC3  - McGill UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - University of CalgaryC3  - University of CalgaryC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - Manonmaniam Sundaranar UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - Hawassa UniversityC3  - Hawassa UniversityC3  - Hawassa UniversityC3  - CHU LimogesC3  - Universite de LimogesC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Qatar Foundation (QF)C3  - Weill Cornell Medical College QatarC3  - Birzeit UniversityC3  - Stellenbosch UniversityC3  - Stellenbosch UniversityC3  - Stellenbosch UniversityC3  - South African Medical Research CouncilC3  - University of IbadanC3  - University College Hospital, IbadanC3  - Cardiff UniversityC3  - University of Southern DenmarkC3  - Universidad de ExtremaduraC3  - Universidad de ExtremaduraC3  - McMaster UniversityC3  - McMaster UniversityC3  - Yerevan State UniversityC3  - National Academy of Sciences of ArmeniaC3  - Public Health Foundation of IndiaC3  - Public Health Foundation of IndiaC3  - Public Health Foundation of IndiaC3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Universite Ferhat Abbas SetifC3  - University of Rhode IslandC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - University of IbadanC3  - University of KentuckyC3  - University of TorontoC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - Mayo ClinicC3  - Washington University (WUSTL)C3  - University of Western AustraliaC3  - University of Western AustraliaC3  - Universidad de la Republica, UruguayC3  - Australian National UniversityC3  - Australian National UniversityC3  - King Saud UniversityC3  - King Saud UniversityC3  - New York UniversityC3  - New York University Abu DhabiC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - Qazvin University of Medical Sciences (QUMS)C3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Kuwait UniversityC3  - Luxembourg Institute of HealthC3  - Universite de BordeauxC3  - Hospital del Mar Research InstituteC3  - Hospital del MarC3  - Pompeu Fabra UniversityC3  - King Abdulaziz UniversityC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - Universidad de CartagenaC3  - Universidad de la CostaC3  - South Australian Health & Medical Research Institute (SAHMRI)C3  - University of South AustraliaC3  - South Australian Health & Medical Research Institute (SAHMRI)C3  - Bahir Dar UniversityC3  - Bahir Dar UniversityC3  - American University of BeirutC3  - American University of BeirutC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - University of ThessalyC3  - Arba Minch UniversityC3  - Arba Minch UniversityC3  - Zahedan University of Medical SciencesC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - Hong Kong Polytechnic UniversityC3  - Hong Kong Polytechnic UniversityC3  - Kwame Nkrumah University Science & TechnologyC3  - University of MunichC3  - Birmingham City UniversityC3  - Dalarna UniversityC3  - University of ManitobaC3  - Mashhad University of Medical SciencesC3  - Mashhad University of Medical SciencesC3  - University of LahoreC3  - University Ha'ilC3  - Keimyung UniversityC3  - University of LeicesterC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - Instituto Nacional de Salud - PeruC3  - University of TokyoC3  - University of TokyoC3  - University of TokyoC3  - University of TokyoC3  - University of South AfricaC3  - Burnet InstituteC3  - University of Kwazulu NatalC3  - University of LagosC3  - University of LagosC3  - Public Health Agency of CanadaC3  - Public Health Agency of CanadaC3  - Medical University LodzC3  - Polish Mother's Memorial Hospital - Research InstituteC3  - University of AucklandC3  - University of AucklandC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard T.H. Chan School of Public HealthC3  - ISGlobalC3  - Centro de Investigacao em Saude de ManhicaC3  - University of CanterburyC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Lorestan University of Medical SciencesC3  - Lorestan University of Medical SciencesC3  - Yale UniversityC3  - Yale UniversityC3  - University of AlbertaC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - University System of GeorgiaC3  - Augusta UniversityC3  - University of LondonC3  - London School Economics & Political ScienceC3  - University of LondonC3  - London School Economics & Political ScienceC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - Emory UniversityC3  - State University System of FloridaC3  - University of South FloridaC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - Nepal Academy of Science & Technology (NAST)C3  - Aga Khan UniversityC3  - Aga Khan UniversityC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - University of DhakaC3  - University of BolognaC3  - University of BolognaC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - Oregon Health & Science UniversityC3  - Oregon Health & Science UniversityC3  - University of Texas SystemC3  - University of Texas Health Science Center HoustonC3  - University of Texas SystemC3  - University of Texas Health Science Center HoustonC3  - Ministry of Health - TurkeyC3  - Ministry of Health - TurkeyC3  - Ministry of Health - TurkeyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of GenoaC3  - Danube University KremsC3  - Comenius University BratislavaC3  - University System of OhioC3  - Ohio State UniversityC3  - University System of OhioC3  - Ohio State UniversityC3  - University System of OhioC3  - Ohio State UniversityC3  - Helmholtz AssociationC3  - German Cancer Research Center (DKFZ)C3  - Mayo ClinicC3  - Mayo ClinicC3  - Instituto Conmemorativo Gorgas de Estudios de la SaludC3  - Instituto Conmemorativo Gorgas de Estudios de la SaludC3  - University of British ColumbiaC3  - University of British ColumbiaC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Imperial College LondonC3  - Imperial College LondonC3  - Imperial College LondonC3  - World Health OrganizationC3  - Imperial College LondonC3  - Universidad Autonoma Metropolitana - MexicoC3  - Universidade do PortoC3  - Universidade do PortoC3  - i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidad Nacional de ColombiaC3  - Universidad Costa RicaC3  - Hacettepe UniversityC3  - Hacettepe UniversityC3  - Australian Catholic UniversityC3  - Australian Catholic UniversityC3  - University of Hong KongC3  - University of Hong KongC3  - National Health Research Institutes - TaiwanC3  - National Health Research Institutes - TaiwanC3  - National Taiwan UniversityC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalC3  - Gold Coast HealthC3  - Monash UniversityC3  - Monash UniversityC3  - Monash UniversityC3  - University of ZambiaC3  - University of ZambiaC3  - University of WitwatersrandC3  - Seoul National University (SNU)C3  - Seoul National University HospitalC3  - University of CambridgeC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - University of AdelaideC3  - Robinson Research InstituteC3  - University of AdelaideC3  - University of AdelaideC3  - University of SalernoC3  - Universidad Autonoma de ChileC3  - Universidad Autonoma de ChileC3  - Universidad Autonoma de ChileC3  - University of Milano-BicoccaC3  - University of SouthamptonC3  - Arizona State UniversityC3  - Arizona State University-TempeC3  - Centers for Disease Control & Prevention - USAC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - Guy's & St Thomas' NHS Foundation TrustC3  - Guy's & St Thomas' NHS Foundation TrustC3  - Bangladesh Rural Advancement Committee BRACC3  - BRAC UniversityC3  - Bangladesh Rural Advancement Committee BRACC3  - BRAC UniversityC3  - Central University of Tamil NaduC3  - Asfendiyarov Kazakh National Medical UniversityC3  - Griffith UniversityC3  - Griffith University - Mount Gravatt CampusC3  - Griffith UniversityC3  - Griffith University - Mount Gravatt CampusC3  - African Population & Health Research CentreC3  - African Population & Health Research CentreC3  - University of BrightonC3  - University of SussexC3  - NHS National Services ScotlandC3  - NHS National Services ScotlandC3  - Aristotle University of ThessalonikiC3  - Icahn School of Medicine at Mount SinaiC3  - University of PeradeniyaC3  - Ministry of Health & Medical Education (MOHME)C3  - Ministry of Health & Medical Education (MOHME)C3  - Ministry of Health & Medical Education (MOHME)C3  - Nguyen Tat Thanh University (NTTU)C3  - Medical University VarnaC3  - University of Cape CoastC3  - Tampere UniversityC3  - Tampere UniversityC3  - Royal Melbourne Institute of Technology (RMIT)C3  - Asbestos Diseases Research InstituteC3  - University of SydneyC3  - University of SydneyC3  - University of SydneyC3  - University of BelgradeC3  - University of BelgradeC3  - University of BelgradeC3  - Universidade Federal da BahiaC3  - Umea UniversityC3  - Eijkman InstituteC3  - Russian Academy of SciencesC3  - Ministry of Health of the Russian FederationC3  - Ministry of Health of the Russian FederationC3  - Ministry of Health of the Russian FederationC3  - Urmia University of Medical SciencesC3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - Universidade Federal de SergipeC3  - Auckland University of TechnologyC3  - Organisation for Economic Co-operation & Development (OECD)C3  - University of GhanaC3  - University of GhanaC3  - Kaiser PermanenteC3  - University of BielefeldC3  - Universidade Federal do Espirito SantoC3  - National Academy of Medical Sciences of UkraineC3  - D. F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of UkraineC3  - University of Milano-BicoccaC3  - University of BaselC3  - Swiss Tropical & Public Health InstituteC3  - University of BaselC3  - Swiss Tropical & Public Health InstituteC3  - University of BaselC3  - Kobe UniversityC3  - National Center for Disease Control & Public Health - GeorgiaC3  - National Center for Disease Control & Public Health - GeorgiaC3  - Sidi Mohamed Ben Abdellah University of FezC3  - Curtin UniversityC3  - Wageningen University & ResearchC3  - University of WarwickC3  - University of WarwickC3  - Research Center of NeurologyC3  - Jawaharlal Nehru University, New DelhiC3  - Jawaharlal Nehru University, New DelhiC3  - University of Massachusetts SystemC3  - University of Massachusetts BostonC3  - University of Oklahoma SystemC3  - University of Oklahoma Health Sciences CenterC3  - Universidade Federal do Rio Grande do SulC3  - Boston UniversityC3  - Boston UniversityC3  - Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele Presidio FerraottoC3  - Eternal Heart Care Centre & Research InstituteC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Yeshiva UniversityC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Yeshiva UniversityC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - Western University (University of Western Ontario)C3  - Western University (University of Western Ontario)C3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Arabian Gulf UniversityC3  - University of New MexicoC3  - Sir Charles Gairdner HospitalC3  - Sun Yat Sen UniversityC3  - Sun Yat Sen UniversityC3  - Tabriz University of Medical ScienceC3  - Tabriz University of Medical ScienceC3  - University of BarcelonaC3  - University of AntwerpC3  - Karolinska InstitutetC3  - Karolinska University HospitalC3  - Tehran University of Medical SciencesC3  - Bucharest University of Economic StudiesC3  - University of Texas SystemC3  - University of Texas AustinC3  - Guilan University of Medical SciencesC3  - Guilan University of Medical SciencesC3  - Manipal Academy of Higher Education (MAHE)C3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - Universite de Tunis-El-ManarC3  - Faculte de Medecine de Tunis (FMT)C3  - Central South UniversityC3  - Aarhus UniversityC3  - Aarhus UniversityC3  - University of the Western CapeC3  - Walter Sisulu UniversityC3  - Taipei Medical UniversityC3  - Taipei Medical UniversityC3  - University of MemphisC3  - Deakin UniversityC3  - Deakin UniversityC3  - Deakin UniversityC3  - University of KragujevacC3  - University of California SystemC3  - University of California San DiegoC3  - Newcastle University - UKC3  - University of ColomboC3  - University of ColomboC3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Banaras Hindu University (BHU)C3  - Duke Kunshan UniversityC3  - Capital Medical UniversityC3  - University of OpoleC3  - Savitribai Phule Pune UniversityC3  - University of TartuC3  - University College CorkC3  - Hamadan University of Medical SciencesC3  - Hamadan University of Medical SciencesC3  - Helmholtz AssociationC3  - Helmholtz-Center for Infection ResearchC3  - University of WashingtonC3  - University of Washington TacomaC3  - Seattle Children's HospitalC3  - Seattle Children's HospitalC3  - MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNITC3  - University of GlasgowC3  - University of TulsaC3  - University of NairobiC3  - Michigan State UniversityC3  - University of Cape TownC3  - Hebrew University of JerusalemC3  - Hadassah University Medical CenterC3  - Jordan University of Science & TechnologyC3  - University of Management & Technology (UMT)C3  - Health Services AcademyC3  - John H Stroger Junior Hospital Cook CountyC3  - University of Illinois SystemC3  - University of Illinois ChicagoC3  - University of Illinois Chicago HospitalC3  - Dow University of Health SciencesC3  - Seoul National University (SNU)C3  - Seoul National University (SNU)C3  - Indian Council of Medical Research (ICMR)C3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute for Research in Environmental Health (NIREH)C3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Nutrition (NIN)C3  - Indian Council of Medical Research (ICMR)C3  - Baqiyatallah University of Medical Sciences (BMSU)C3  - Wayne State UniversityC3  - Wayne State UniversityC3  - Northeastern UniversityC3  - Korea UniversityC3  - Xiamen University Malaysia CampusC3  - Simmons UniversityC3  - University of CanberraC3  - University of OsloC3  - University of OsloC3  - Tulane UniversityC3  - University of HelsinkiC3  - University of HelsinkiC3  - National Cerebral & Cardiovascular Center - JapanC3  - Arthritis Research CanadaC3  - Sher-i-Kashmir Institute of Medical SciencesC3  - Universite de MontrealC3  - Universite de MontrealC3  - University of Technology SydneyC3  - University of Technology SydneyC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Ghana Health ServiceC3  - University of FlorenceC3  - Sichuan UniversityC3  - Shenzhen Sun Yatsen Cardiovascular HospitalC3  - Chinese Center for Disease Control & PreventionC3  - Chinese Center for Disease Control & PreventionC3  - Chinese Center for Disease Control & PreventionC3  - Samara UniversityC3  - Universiti MalayaC3  - Chinese University of Hong KongC3  - University of HaifaC3  - Friedrich Schiller University of JenaC3  - University of LiverpoolC3  - Universite de KinshasaC3  - Universite de KinshasaC3  - Royal Children's Hospital MelbourneC3  - Royal Children's Hospital MelbourneC3  - Egyptian Knowledge Bank (EKB)C3  - Ministry of Health & Population - EgyptC3  - Tribhuvan UniversityC3  - Institute of Medicine (IoM) - NepalC3  - University of TrnavaC3  - Shiraz University of Medical ScienceC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - RoorkeeC3  - The World BankC3  - Instituto Federal do Ceara (IFCE)C3  - Medical University of GrazC3  - UERM Memorial Medical CenterC3  - University of York - UKC3  - Chalmers University of TechnologyC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Cancer Prevention & Research (NICPR)C3  - University of California SystemC3  - University of California San FranciscoC3  - State University System of FloridaC3  - University of West FloridaC3  - Ministry of Health - Saudi ArabiaC3  - King Saud Bin Abdulaziz University for Health SciencesC3  - Prince Mohammed bin Abdulaziz Hospital - Al MadinahC3  - Alfaisal UniversityC3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - University North - CroatiaC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pacific Institute for Research & Evaluation (PIRE)C3  - Ministry of Health - KyrgyzstanC3  - Kyrgyz State Medical AcademyC3  - Salahaddin UniversityC3  - Isfahan University of Medical SciencesC3  - Ahmadu Bello UniversityC3  - Ahmadu Bello UniversityC3  - University of Papua New GuineaC3  - IRCCS Burlo GarofoloC3  - Kurdistan University of Medical SciencesC3  - Kurdistan University of Medical SciencesC3  - Lancaster UniversityC3  - National Center for Child Health & Development - JapanC3  - Tarbiat Modares UniversityC3  - National & Kapodistrian University of AthensC3  - Academy of AthensC3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataC3  - University of JosC3  - Northwestern UniversityC3  - Northwestern UniversityC3  - Universiti Sains MalaysiaC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - Ulm UniversityC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - ULSS 8 BericaC3  - Ospedale San Bortolo di VicenzaC3  - Suraj Eye InstituteC3  - University of Yaounde IC3  - Kenya Medical Research InstituteC3  - Universitas Negeri SemarangC3  - National Center for Global Health & Medicine - JapanC3  - University of RwandaC3  - Western Sydney UniversityC3  - Western Sydney UniversityC3  - Kyung Hee UniversityC3  - Human Sciences Research Council-South AfricaC3  - University of NamibiaC3  - University Brunei DarussalamC3  - Autonomous University of MadridC3  - Autonomous University of MadridC3  - St. Luke's International HospitalC3  - Ministry of Health of the Russian FederationC3  - Lomonosov Moscow State UniversityC3  - Moscow Institute of Physics & TechnologyC3  - North West University - South AfricaC3  - North West University - South AfricaC3  - JSS Academy of Higher Education & ResearchC3  - University of OttawaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Maimonides Medical CenterC3  - Krishna Vishwa VidyapeethC3  - Krishna Institute of Medical SciencesC3  - International Institute of Health Management Research DelhiC3  - Murdoch Children's Research InstituteC3  - Murdoch Children's Research InstituteC3  - Save the ChildrenC3  - Fundacao Oswaldo CruzC3  - Universidad de CartagenaC3  - University of VirginiaC3  - University of VirginiaC3  - University of GothenburgC3  - University of WitwatersrandC3  - Durban University of TechnologyC3  - University of GroningenC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - University of GottingenC3  - Medical University of InnsbruckC3  - Yonsei UniversityC3  - University of LondonC3  - University College LondonC3  - University College London Hospitals NHS Foundation TrustC3  - Public Health EnglandC3  - Loma Linda UniversityC3  - Brien Holden Vision InstituteC3  - Universidade Federal de UberlandiaC3  - Golestan University of Medical SciencesC3  - Southern University of Science & TechnologyC3  - Muhimbili University of Health & Allied SciencesC3  - Muhimbili University of Health & Allied SciencesC3  - Muhimbili University of Health & Allied SciencesC3  - University of New South Wales SydneyC3  - Prince of Wales Hospital (POWH)C3  - University of SharjahC3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - York University - CanadaC3  - Stanford UniversityC3  - Stanford UniversityC3  - Marshall UniversityC3  - University System of OhioC3  - Case Western Reserve UniversityC3  - University of Massachusetts SystemC3  - University of Massachusetts WorcesterC3  - MGM Medical College IndoreC3  - Hamad Medical CorporationC3  - Bournemouth UniversityC3  - Utkal UniversityC3  - Dr DY Patil Vidyapeeth PuneC3  - University of North CarolinaC3  - University of North Carolina CharlotteC3  - Universidade Federal de Santa Catarina (UFSC)C3  - University of ZagrebC3  - New York UniversityC3  - NYU Langone Medical CenterC3  - An Najah National UniversityC3  - Islamic Azad UniversityC3  - Islamic Azad UniversityC3  - Delhi Technological UniversityC3  - Fudan UniversityC3  - University of EdinburghC3  - Tufts UniversityC3  - National Institute of Infectious Diseases (NIID)C3  - Finnish Institute of Occupational HealthC3  - Martin Luther University Halle WittenbergC3  - University of NottinghamC3  - Symbiosis International UniversityC3  - Symbiosis Institute of Health Sciences (SIHS)C3  - Reykjavik UniversityC3  - Columbia UniversityC3  - Universidade de BrasiliaC3  - University of LouisvilleC3  - King Saud UniversityC3  - King Khalid University HospitalC3  - University of HullC3  - University of York - UKC3  - International Medical University MalaysiaC3  - University of SheffieldC3  - Norwegian Institute of Public Health (NIPH)C3  - University of California SystemC3  - University of California RiversideC3  - University of California SystemC3  - University of California IrvineC3  - University of ValenciaC3  - University of ValenciaC3  - University of Illinois SystemC3  - University of Illinois Urbana-ChampaignC3  - Universidade de LisboaC3  - Nanyang Technological UniversityC3  - Nanyang Technological UniversityC3  - Queensland University of Technology (QUT)C3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - Nagoya UniversityC3  - Hanoi Medical UniversityC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute for Research in Tuberculosis (NIRT)C3  - University of CopenhagenC3  - Duy Tan UniversityC3  - University of HamburgC3  - University Medical Center Hamburg-EppendorfC3  - Gomal UniversityC3  - Ankara UniversityC3  - UKK InstituteC3  - Universidade de BrasiliaC3  - Raffles HospitalC3  - National University of SingaporeC3  - IRCCS Azienda Ospedaliero-Universitaria di BolognaC3  - Sechenov First Moscow State Medical UniversityC3  - HSE University (National Research University Higher School of Economics)C3  - University of OsloC3  - Technical University of MunichC3  - University of StrathclydeC3  - Nanjing UniversityC3  - King Fahd University of Petroleum & MineralsC3  - Kyoto UniversityC3  - Jackson State UniversityC3  - Tsinghua UniversityC3  - Wuhan UniversityC3  - Wuhan UniversityC3  - Institute of Oncology - SloveniaC3  - Dilla UniversityC3  - Wuhan Polytechnic UniversityPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - NOV 10
PY  - 2018
VL  - 392
IS  - 10159
SP  - 1995
EP  - 2051
DO  - 10.1016/S0140-6736(18)32278-5
AN  - WOS:000449710900008
ER  -

TY  - JOUR
AU  - Roth, GA
AU  - Abate, D
AU  - Abate, KH
AU  - Abay, SM
AU  - Abbafati, C
AU  - Abbasi, N
AU  - Abbastabar, H
AU  - Abd-Allah, L
AU  - Abdela, J
AU  - Abdelalim, A
AU  - Abdollahpour, I
AU  - Abdulkader, RS
AU  - Abebe, HT
AU  - Abebe, M
AU  - Abebe, Z
AU  - Abejie, AN
AU  - Abera, SF
AU  - Abil, OZ
AU  - Abraha, HN
AU  - Abrham, AR
AU  - Abu-Raddad, LJ
AU  - Accrombessi, MMK
AU  - Acharya, D
AU  - Adamu, AA
AU  - Adebayo, O
AU  - Adedoyin, RA
AU  - Adekanmbi, V
AU  - Adookunboh, O
AU  - Adhena, BM
AU  - Adib, MG
AU  - Admasie, A
AU  - Afshin, A
AU  - Agarwal, G
AU  - Agesa, KM
AU  - Agrawal, A
AU  - Agrawal, S
AU  - Ahmadi, A
AU  - Ahmadi, M
AU  - Ahmed, MB
AU  - Ahmed, S
AU  - Aichour, AN
AU  - Aichour, I
AU  - Aichour, MTF
AU  - Akbari, ME
AU  - Akinyeniti, RO
AU  - Akseer, N
AU  - Al-Aly, Z
AU  - Al-Eyadhy, A
AU  - Al-Raddadi, RM
AU  - Alandab, F
AU  - Alam, K
AU  - Alam, T
AU  - Alebel, A
AU  - Alene, KA
AU  - Alijanzadeh, M
AU  - Alizadeh-Navaei, R
AU  - Aljunid, SM
AU  - Alkerwi, A
AU  - Alla, F
AU  - Allebeck, P
AU  - Alonso, J
AU  - Altirkawi, K
AU  - Alvis-Guzman, N
AU  - Amare, AT
AU  - Aminde, LN
AU  - Amini, E
AU  - Ammar, W
AU  - Amoako, YA
AU  - Anber, NH
AU  - Andrei, CL
AU  - Androudi, S
AU  - Animut, MD
AU  - Anjomshoa, M
AU  - Ansari, H
AU  - Aniha, MG
AU  - Antonio, CAT
AU  - Anwari, P
AU  - Aremu, O
AU  - Ärnlöv, J
AU  - Arora, A
AU  - Arora, M
AU  - Artaman, A
AU  - Aryal, KK
AU  - Asayesh, H
AU  - Asfaw, ET
AU  - Ataro, Z
AU  - Atique, S
AU  - Atre, SR
AU  - Ausloos, M
AU  - Avokpaho, EFGA
AU  - Awasthi, A
AU  - Quintattilla, BPA
AU  - Ayele, Y
AU  - Ayer, R
AU  - Azzopardi, PS
AU  - Babazadeh, A
AU  - Bacha, U
AU  - Badali, H
AU  - Badawi, A
AU  - Bali, AG
AU  - Ballesteros, KE
AU  - Banach, M
AU  - Banerjee, K
AU  - Bannick, MS
AU  - Banoub, JAM
AU  - Barboza, MA
AU  - Barker-Collo, SL
AU  - Bärnighausen, TW
AU  - Barquera, S
AU  - Barrero, L
AU  - Bassat, Q
AU  - Base, S
AU  - Baune, BT
AU  - Baynes, HW
AU  - Bazargan-Hejazi, S
AU  - Beth, N
AU  - Beghi, E
AU  - Behzadifar, M
AU  - Behzadifar, M
AU  - Béjot, Y
AU  - Bekele, BB
AU  - Belacliew, AB
AU  - Belay, E
AU  - Belay, YA
AU  - Bell, ML
AU  - Bello, AK
AU  - Bennett, DA
AU  - Bensenor, IM
AU  - Berman, AF
AU  - Bernabe, E
AU  - Bernstein, RS
AU  - Bertolacci, GJ
AU  - Beuran, M
AU  - Beyranvand, T
AU  - Bhalla, A
AU  - Bhattarai, S
AU  - Bhaumik, S
AU  - Bhutta, ZA
AU  - Biadgo, B
AU  - Biehl, MH
AU  - Bijani, A
AU  - Bikbov, B
AU  - Bilano, V
AU  - Bililign, N
AU  - Bin Sayeed, MS
AU  - Bisanzio, D
AU  - Biswas, T
AU  - Blacker, BF
AU  - Basara, BB
AU  - Borschmann, R
AU  - Bosetti, C
AU  - Bozorgmehr, K
AU  - Brady, OJ
AU  - Brant, LC
AU  - Brayne, C
AU  - Brazinova, A
AU  - Breitborde, NJK
AU  - Brenner, H
AU  - Briant, PS
AU  - Britton, G
AU  - Brugha, T
AU  - Busse, R
AU  - Butt, ZA
AU  - Callender, CSKH
AU  - Campos-Nonato, IR
AU  - Rincon, JCC
AU  - Cano, J
AU  - Car, M
AU  - Cárdenas, R
AU  - Carreras, G
AU  - Carrero, JJ
AU  - Carter, A
AU  - Carvalho, F
AU  - Castaneda-Orjuela, CA
AU  - Rivas, JC
AU  - Castle, CD
AU  - Castro, C
AU  - Castro, F
AU  - Catalá-López, F
AU  - Cerin, E
AU  - Chaiah, Y
AU  - Chang, JC
AU  - Chanson, FJ
AU  - Chaturvedi, P
AU  - Chiang, PPC
AU  - Chimed-Ochir, O
AU  - Chisumpa, VH
AU  - Chitheet, A
AU  - Chowdhury, R
AU  - Christensen, H
AU  - Christopher, DJ
AU  - Chiang, SC
AU  - Cicuttini, FM
AU  - Ciobanu, LG
AU  - Cirillo, M
AU  - Cohen, AJ
AU  - Cooper, LT
AU  - Cortesi, PA
AU  - Cortinovis, M
AU  - Cousin, E
AU  - Cowie, BC
AU  - Criqui, MH
AU  - Cromwell, EA
AU  - Crowe, CS
AU  - Crump, JA
AU  - Cunningham, M
AU  - Daba, AK
AU  - Dadi, AF
AU  - Dandona, L
AU  - Dandona, R
AU  - Dang, AK
AU  - Dargan, PI
AU  - Daryani, A
AU  - Das, SK
AU  - Das Gupta, R
AU  - Das Neves, J
AU  - Dasa, TT
AU  - Dash, AP
AU  - Davis, AC
AU  - Weaver, ND
AU  - Davitoiu, DV
AU  - Davletov, K
AU  - De La Hoz, FP
AU  - De Neve, JW
AU  - Degefa, MG
AU  - Degenhardt, L
AU  - Degfie, TT
AU  - Deiparine, S
AU  - Demoz, GT
AU  - Demtsu, BB
AU  - Denova-Gutiérrez, E
AU  - Deribe, K
AU  - Dervenis, N
AU  - Jarlais, DCD
AU  - Dessie, GA
AU  - Dey, S
AU  - Dhannaratne, SD
AU  - Dicker, D
AU  - Dinberu, MT
AU  - Ding, EL
AU  - Dirac, MA
AU  - Djalalinia, S
AU  - Dokova, K
AU  - Ter Doku, D
AU  - Donnelly, CA
AU  - Dorsey, ER
AU  - Doshi, PP
AU  - Douwes-Schultz, D
AU  - Doyle, KE
AU  - Driscoll, TR
AU  - Dubey, M
AU  - Dubljanin, E
AU  - Duken, EE
AU  - Duncan, BB
AU  - Duraes, AR
AU  - Ebrahimi, H
AU  - Ebrahimpour, S
AU  - Edessa, D
AU  - Edvardsson, D
AU  - Eggen, AE
AU  - El Bcheraoui, C
AU  - Zaki, ME
AU  - El-Khatib, Z
AU  - Elkout, H
AU  - Eltinsel, CL
AU  - Endres, M
AU  - Endries, AY
AU  - Er, B
AU  - Erskine, HE
AU  - Eshrati, B
AU  - Eskandarieh, S
AU  - Esmaeili, R
AU  - Esteghamati, A
AU  - Fakhar, M
AU  - Fakhim, H
AU  - Faramarzi, M
AU  - Fareed, M
AU  - Farhadi, F
AU  - Faninha, CSES
AU  - Faro, A
AU  - Farvid, MS
AU  - Farzadfar, F
AU  - Farzaei, MH
AU  - Feign, VL
AU  - Feigl, AB
AU  - Fentahun, N
AU  - Eereshtehnejad, SM
AU  - Fernandes, E
AU  - Fernandes, JC
AU  - Ferrari, AJ
AU  - Feyissa, GT
AU  - Filip, I
AU  - Finegold, S
AU  - Fischer, F
AU  - Eitzmaurice, C
AU  - Foigt, NA
AU  - Foreman, KJ
AU  - Fornari, C
AU  - Frank, TD
AU  - Fukumoto, T
AU  - Fuller, JE
AU  - Fullman, N
AU  - Furst, T
AU  - Furtado, JM
AU  - Futran, ND
AU  - Gallus, S
AU  - Garcia-Basteiro, AL
AU  - Garcia-Gordillo, MA
AU  - Gardner, WM
AU  - Gebre, AK
AU  - Gebrehiwol, TT
AU  - Gebremedhin, AT
AU  - Gebremichael, B
AU  - Gebremichael, TG
AU  - Gelano, TF
AU  - Geleijinse, JM
AU  - Genova-Maleras, R
AU  - Geramo, YCD
AU  - Gething, PW
AU  - Gezae, KE
AU  - Ghadami, MR
AU  - Ghadimi, R
AU  - Falavarjani, KG
AU  - Ghasemi-Kasman, M
AU  - Ghimire, M
AU  - Gibney, KB
AU  - Gill, PS
AU  - Gill, TK
AU  - Gillum, RF
AU  - Ginawi, IA
AU  - Giroud, M
AU  - Giussani, G
AU  - Goenka, S
AU  - Goldberg, EM
AU  - Goli, S
AU  - Gómez-Dantés, H
AU  - Gona, PN
AU  - Gopalani, SV
AU  - Gorman, TM
AU  - Goto, A
AU  - Goulart, AC
AU  - Gnedovskaya, EV
AU  - Grada, A
AU  - Grosso, G
AU  - Gugnani, HC
AU  - Guimaraes, ALS
AU  - Guo, YM
AU  - Gupta, PC
AU  - Gupta, R
AU  - Gupta, R
AU  - Gupta, T
AU  - Gutierrez, RA
AU  - Gyawali, B
AU  - Haagsma, JA
AU  - Hafezi-Nejad, N
AU  - Hagos, TB
AU  - Hailegiyorgis, TT
AU  - Hailu, GB
AU  - Haj-Mirzaian, A
AU  - Haj-Mirzaian, A
AU  - Hamadeh, RR
AU  - Hamidi, S
AU  - Handal, MJ
AU  - Hankey, GJ
AU  - Harb, HL
AU  - Harikrishnan, S
AU  - Haro, JM
AU  - Hasan, M
AU  - Hassankhani, H
AU  - Hassen, HY
AU  - Havmoeller, R
AU  - Hay, RJ
AU  - Hay, SI
AU  - He, Y
AU  - Hedayatizadeh-Omran, A
AU  - Hegazy, MI
AU  - Heibati, B
AU  - Heidari, M
AU  - Hendrie, D
AU  - Henok, A
AU  - Henry, NJ
AU  - Herteliu, C
AU  - Heydarpour, F
AU  - Heydarpour, P
AU  - Heydarpour, S
AU  - Hibstu, DT
AU  - Hoek, HW
AU  - Hole, MK
AU  - Red, EH
AU  - Hoogar, P
AU  - Hosgood, HD
AU  - Hosseini, SM
AU  - Hosseinzadeh, M
AU  - Hostiuc, M
AU  - Hostiuc, S
AU  - Hotez, PJ
AU  - Hoy, DC
AU  - Hsiao, T
AU  - Hu, G
AU  - Huang, JJ
AU  - Husseini, A
AU  - Hussen, MM
AU  - Hutfless, S
AU  - Idrisov, B
AU  - Ilesanmi, OS
AU  - Iqbal, U
AU  - Irvani, SSN
AU  - Irvine, CMS
AU  - Islam, N
AU  - Islam, SMS
AU  - Islami, F
AU  - Jacobsen, KH
AU  - Jahangiry, L
AU  - Jahanmehr, N
AU  - Jain, SK
AU  - Jakovlievic, M
AU  - Jalu, MT
AU  - James, SL
AU  - Javanbakht, M
AU  - Jayatilleke, AU
AU  - Jeemon, P
AU  - Jenkins, KJ
AU  - Jha, RP
AU  - Jha, V
AU  - Johnson, CO
AU  - Johnson, SC
AU  - Jonas, JB
AU  - Joshi, A
AU  - Jozwiak, JJ
AU  - Jungari, SB
AU  - Jürisson, M
AU  - Kabir, Z
AU  - Kadel, R
AU  - Kahsay, A
AU  - Kalani, R
AU  - Karami, M
AU  - Matin, BK
AU  - Karch, A
AU  - Karema, C
AU  - Karimi-Sari, H
AU  - Kasaeian, A
AU  - Kassa, DH
AU  - Kassa, GM
AU  - Kassa, TD
AU  - Kassebaum, NJ
AU  - Katikireddi, SV
AU  - Kaul, A
AU  - Kazemi, Z
AU  - Karyani, AK
AU  - Kazi, DS
AU  - Kefale, AT
AU  - Keiyoro, PN
AU  - Kemp, GR
AU  - Kengne, AP
AU  - Keren, A
AU  - Kesavachandran, CN
AU  - Khader, YS
AU  - Khafaei, B
AU  - Khafaie, MA
AU  - Khajavi, A
AU  - Khalid, N
AU  - Khalil, IA
AU  - Khan, EA
AU  - Khan, MS
AU  - Khan, MA
AU  - Khang, YH
AU  - Khater, MM
AU  - Khoja, AT
AU  - Khosravi, A
AU  - Khosravi, MH
AU  - Khubchandani, J
AU  - Kiadaliri, AA
AU  - Kibret, GD
AU  - Kidanemariam, ZT
AU  - Kiirithio, DN
AU  - Kim, D
AU  - Kim, YE
AU  - Kim, YJ
AU  - Kimokoti, RW
AU  - Kinfu, Y
AU  - Kisa, A
AU  - Kissimova-Skarbek, K
AU  - Kivimäki, M
AU  - Knudsen, AKS
AU  - Kocarnik, JM
AU  - Kochhar, S
AU  - Kokubo, Y
AU  - Kolola, T
AU  - Kopec, JA
AU  - Koul, PA
AU  - Koyanagi, A
AU  - Kravchenko, MA
AU  - Krishan, K
AU  - Defo, BK
AU  - Bicer, BK
AU  - Kumar, GA
AU  - Kumar, M
AU  - Kumar, P
AU  - Kutz, MJ
AU  - Kuzin, I
AU  - Kyu, HH
AU  - Lad, DP
AU  - Lad, SD
AU  - Lafranconi, A
AU  - Lal, DK
AU  - Lalloo, R
AU  - Lallukka, T
AU  - Lam, JO
AU  - Lami, FH
AU  - Lansingh, VC
AU  - Lansky, S
AU  - Larson, HJ
AU  - Latifi, A
AU  - Lau, KMM
AU  - Lazarus, JV
AU  - Lebedev, G
AU  - Lee, PH
AU  - Leigh, J
AU  - Leili, M
AU  - Leshargie, CT
AU  - Li, SS
AU  - Li, YC
AU  - Liang, J
AU  - Lim, LL
AU  - Lim, SS
AU  - Limenih, MA
AU  - Linn, S
AU  - Liu, SW
AU  - Liu, Y
AU  - Lodha, R
AU  - Lansdale, C
AU  - Lopez, AD
AU  - Lorkowski, S
AU  - Lotufo, PA
AU  - Lozano, R
AU  - Lunevicius, R
AU  - Ma, S
AU  - Macarayan, ERK
AU  - Mackay, MT
AU  - MacLachlan, JH
AU  - Maddison, ER
AU  - Nadotto, F
AU  - Abd El Razek, HM
AU  - Abd El Razek, MM
AU  - Maghavani, DP
AU  - Majdan, M
AU  - Majdzadeh, R
AU  - Majeed, A
AU  - Malekzadeh, R
AU  - Malta, DC
AU  - Manda, AL
AU  - Mandarano, LG
AU  - Manguerra, H
AU  - Mansournia, MA
AU  - Mapoma, CC
AU  - Marami, D
AU  - Maravilla, JC
AU  - Marcenes, W
AU  - Marczak, L
AU  - Marks, A
AU  - Marks, GB
AU  - Martinez, G
AU  - Martins-Melo, FR
AU  - Martopullo, I
AU  - März, W
AU  - Marron, MB
AU  - Masci, JR
AU  - Lylassenburg, BB
AU  - Mathur, MR
AU  - Mathur, P
AU  - Matzopoulos, R
AU  - Maulik, PK
AU  - Mazidi, M
AU  - McAlinden, C
AU  - McGrath, JJ
AU  - McKee, M
AU  - McMahon, BJ
AU  - Mehata, S
AU  - Mehndiratta, MM
AU  - Mehrotra, R
AU  - Mehta, KM
AU  - Mehta, V
AU  - Mekonnen, TC
AU  - Melese, A
AU  - Melku, M
AU  - Memiah, PTN
AU  - Memish, ZA
AU  - Mendoza, W
AU  - Mengistu, DT
AU  - Mengistu, G
AU  - Mensah, GA
AU  - Mereta, ST
AU  - Meretoja, A
AU  - Meretoja, TJ
AU  - Meshovic, T
AU  - Mezgebe, HB
AU  - Miazgowski, B
AU  - Miazgowski, T
AU  - Millear, AI
AU  - Miller, TR
AU  - Katherine, M
AU  - Petrie, M
AU  - Mini, GK
AU  - Mirabi, P
AU  - Mirarefin, M
AU  - Mirica, A
AU  - Mirrakhimov, EM
AU  - Misganaw, AT
AU  - Mitiku, H
AU  - Moazen, B
AU  - Mohammad, KA
AU  - Mohammad, M
AU  - Mohammadifard, N
AU  - Mohammed, MA
AU  - Mohammed, S
AU  - Mohan, V
AU  - Mokdad, AH
AU  - Molokhia, M
AU  - Monasta, L
AU  - Moradi, G
AU  - Moradi-Lakeh, M
AU  - Moradinazar, M
AU  - Moraga, P
AU  - Morawska, L
AU  - Velasquez, IM
AU  - Morgado-Da-Costa, J
AU  - Morrison, SD
AU  - Moschos, MM
AU  - Mouodi, S
AU  - Mousavi, SM
AU  - Muchie, KE
AU  - Mueller, UO
AU  - Mukhopadhyay, S
AU  - Muller, K
AU  - Mumford, JE
AU  - Musa, J
AU  - Musa, KI
AU  - Mustafa, G
AU  - Muthupandian, S
AU  - Nachega, JB
AU  - Nagel, G
AU  - Naheed, A
AU  - Nahvijou, A
AU  - Naik, G
AU  - Nair, S
AU  - Najafi, F
AU  - Naldi, L
AU  - Nam, HS
AU  - Nangia, V
AU  - Nansseu, JR
AU  - Nascirnento, BR
AU  - Natarajan, G
AU  - Nearnati, N
AU  - Negoi, I
AU  - Negoi, RI
AU  - Nettpane, S
AU  - Newton, CRJ
AU  - Ngalesoni, FN
AU  - Ngunjiri, JW
AU  - Nguyen, AQ
AU  - Nguyen, G
AU  - Nguyen, HT
AU  - Nguyen, LT
AU  - Nguyen, LH
AU  - Nguyen, M
AU  - Nguyen, TH
AU  - Nichols, E
AU  - Ningnun, DNA
AU  - Nirayo, YL
AU  - Nixon, MR
AU  - Nolutshungu, N
AU  - Nomura, S
AU  - Norhelin, OF
AU  - Noroozi, M
AU  - Norrving, B
AU  - Noubiap, JJ
AU  - Nouri, HR
AU  - Shiadeh, MN
AU  - Nowroozi, MR
AU  - Nyasulu, PS
AU  - Odell, CM
AU  - Ofori-Asenso, R
AU  - Ogbo, FA
AU  - Oh, IH
AU  - Oladimeji, O
AU  - Olagunju, AT
AU  - Olivares, PR
AU  - Olsen, HE
AU  - Olusanya, BO
AU  - Olusanya, JO
AU  - Ong, KL
AU  - Ong, SKS
AU  - Oren, E
AU  - Orpana, HM
AU  - Ortiz, A
AU  - Ortiz, JR
AU  - Otstavnov, SS
AU  - Overland, S
AU  - Owolabi, MO
AU  - Özdemir, R
AU  - Mahesh, PA
AU  - Pacella, R
AU  - Pakhale, S
AU  - Pakhare, AP
AU  - Pakpour, AH
AU  - Pana, A
AU  - Panda-Jonas, S
AU  - Pandian, JD
AU  - Parisi, A
AU  - Park, EK
AU  - Parry, CDH
AU  - Parsian, H
AU  - Patel, S
AU  - Pati, S
AU  - Patton, GC
AU  - Paturi, VR
AU  - Paulson, KR
AU  - Pereira, A
AU  - Pereira, DM
AU  - Perico, N
AU  - Pesudovs, K
AU  - Petzold, M
AU  - Phillips, MR
AU  - Piel, FB
AU  - Pigott, DM
AU  - Pillay, JD
AU  - Pirsaheb, M
AU  - Pishgar, F
AU  - Polinder, S
AU  - Postma, MJ
AU  - Pourshams, A
AU  - Poustchi, H
AU  - Pujar, A
AU  - Prakash, S
AU  - Prasad, N
AU  - Purcell, CA
AU  - Qorbani, M
AU  - Quintana, H
AU  - Quistberg, DA
AU  - Rade, KW
AU  - Radfah, A
AU  - Rafay, A
AU  - Rafiei, A
AU  - Rahim, F
AU  - Rahimi, K
AU  - Rahimi-Movaghar, A
AU  - Rahman, M
AU  - Rahman, MHU
AU  - Rahman, MA
AU  - Rai, RK
AU  - Rajsic, S
AU  - Ram, U
AU  - Ranabhat, CL
AU  - Ranjan, P
AU  - Rao, PC
AU  - Rawaf, DL
AU  - Rawaf, S
AU  - Razo-Garcia, C
AU  - Reddy, KS
AU  - Reiner, RC
AU  - Reitsma, MB
AU  - Remuzzi, G
AU  - Renzaho, AMN
AU  - Resnikoff, S
AU  - Rezaei, S
AU  - Rezaeian, S
AU  - Rezai, MS
AU  - Riahi, SM
AU  - Ribeiro, ALP
AU  - Rios-Blancas, MJ
AU  - Roba, KT
AU  - Roberts, NLS
AU  - Robinson, SR
AU  - Roever, L
AU  - Ronfani, L
AU  - Roshandel, G
AU  - Rostami, A
AU  - Rothenbacher, D
AU  - Roy, A
AU  - Rubagotti, E
AU  - Sachdev, PS
AU  - Saddik, B
AU  - Sadeghi, E
AU  - Safari, H
AU  - Safdarian, M
AU  - Safi, S
AU  - Safiri, S
AU  - Sagar, R
AU  - Sahebkar, A
AU  - Sahraian, MA
AU  - Salam, N
AU  - Salama, JS
AU  - Salamati, P
AU  - Saldanha, RD
AU  - Saleem, Z
AU  - Salimi, Y
AU  - Salvi, SS
AU  - Salz, I
AU  - Sambala, EZ
AU  - Samy, AM
AU  - Sanabria, J
AU  - Sanchez-Nino, MD
AU  - Santomauro, DF
AU  - Santos, IS
AU  - Santos, JV
AU  - Milicevic, MMS
AU  - Jose, BPS
AU  - Sarker, AR
AU  - Sarmiento-Suárez, R
AU  - Sarrafzadegan, N
AU  - Sartorius, B
AU  - Sarvi, S
AU  - Sathian, B
AU  - Satpathy, M
AU  - Sawant, AR
AU  - Sawhney, M
AU  - Saxena, S
AU  - Sayyah, M
AU  - Schaeffher, E
AU  - Schmidt, MI
AU  - Schneider, IJC
AU  - Schöttker, B
AU  - Schutte, AE
AU  - Schwebel, DC
AU  - Schwendicke, F
AU  - Scott, JG
AU  - Sekerija, M
AU  - Sepanlou, SG
AU  - Serván-Mori, E
AU  - Seyedmousavi, S
AU  - Shabaninejad, H
AU  - Shackelford, KA
AU  - Shafieesabet, A
AU  - Shahbazi, M
AU  - Shaheen, AA
AU  - Shaikh, MA
AU  - Shams-Beyranvand, M
AU  - Shamsi, M
AU  - Shamsizadeh, M
AU  - Sharafi, K
AU  - Sharif, M
AU  - Sharif-Alhoseini, M
AU  - Sharma, R
AU  - She, J
AU  - Sheikh, A
AU  - Shi, PL
AU  - Shiferaw, MS
AU  - Shigematsu, M
AU  - Shiri, R
AU  - Shirkoohi, R
AU  - Shiue, I
AU  - Shokraneh, F
AU  - Shrine, MG
AU  - Si, S
AU  - Siabani, S
AU  - Siddiqi, TJ
AU  - Sigfusdottir, ID
AU  - Sigurvinsdottir, R
AU  - Silberberg, DH
AU  - Silva, DAS
AU  - Silva, JP
AU  - Da Silva, NT
AU  - Silveira, DBA
AU  - Singh, JA
AU  - Singh, NP
AU  - Singh, PK
AU  - Singh, V
AU  - Sinha, DN
AU  - Sliwa, K
AU  - Smith, M
AU  - Sobaih, BH
AU  - Sobhani, S
AU  - Solangwi, E
AU  - Soneji, SS
AU  - Soofi, M
AU  - Sorensen, RJD
AU  - Soriano, JB
AU  - Soyiri, IN
AU  - Sposato, LA
AU  - Sreeramareddy, CF
AU  - Srinivasan, V
AU  - Stanaway, JD
AU  - Starodubov, VI
AU  - Stathopoulou, V
AU  - Stein, DJ
AU  - Steiner, C
AU  - Stewart, LG
AU  - Stokes, MA
AU  - Subart, ML
AU  - Sudaryanto, A
AU  - Sufiyan, MB
AU  - Sur, PJ
AU  - Sutradhar, I
AU  - Sykes, BL
AU  - Sylaja, PN
AU  - Sylte, DO
AU  - Szoeke, CEI
AU  - Tabarés-Seisdedos, R
AU  - Tabuchi, T
AU  - Tadakamadla, SK
AU  - Takahashi, K
AU  - Tandon, N
AU  - Tassew, SG
AU  - Taveira, N
AU  - Tehrani-Banihashemi, A
AU  - Tekalign, TG
AU  - Tekle, MG
AU  - Temsah, MH
AU  - Temsah, O
AU  - Terkawi, AS
AU  - Teshale, MY
AU  - Tesserna, B
AU  - Tessema, GA
AU  - Thankappan, KR
AU  - Thirinavukkarasu, S
AU  - Thomas, N
AU  - Thrift, AG
AU  - Thurston, GD
AU  - Tilahun, B
AU  - To, QG
AU  - Tobe-Gai, R
AU  - Tonellli, M
AU  - Topor-Madry, R
AU  - Torre, AE
AU  - Tortajada-Cirbés, M
AU  - Touvier, M
AU  - Tovani-Palone, MR
AU  - Tran, BX
AU  - Tran, KB
AU  - Tripathi, S
AU  - Troeger, CE
AU  - Truelsen, TC
AU  - Truong, NT
AU  - Tsadik, AG
AU  - Tsoi, D
AU  - Car, LT
AU  - Tuzcu, EM
AU  - Tyrovolas, S
AU  - Ukwaja, KN
AU  - Whiff, I
AU  - Undurraga, EA
AU  - Updike, RL
AU  - Usman, MS
AU  - Uthman, OA
AU  - Uzun, SB
AU  - Vaduganathan, M
AU  - Vaezi, A
AU  - Vaidya, G
AU  - Valdez, PR
AU  - Varavikova, E
AU  - Vasankari, TJ
AU  - Venketasubramanian, N
AU  - Villafaina, S
AU  - Violante, FS
AU  - Vladimirov, SK
AU  - Vlassov, V
AU  - Vollset, SE
AU  - Vos, T
AU  - Wagner, GR
AU  - Wagnew, FS
AU  - Waheed, Y
AU  - Wallin, MT
AU  - Watson, JL
AU  - Wang, YP
AU  - Wang, YP
AU  - Wassie, MM
AU  - Weiderpass, E
AU  - Weintraub, RG
AU  - Weldegebreal, E
AU  - Weldegwergs, KG
AU  - Werdecker, A
AU  - Werkneh, AA
AU  - West, TE
AU  - Westerman, R
AU  - Whiteford, HA
AU  - Widecka, J
AU  - Wilner, LB
AU  - Wilson, S
AU  - Winkler, AS
AU  - Wiysonge, CS
AU  - Wolfe, CDA
AU  - Wu, SL
AU  - Wu, YC
AU  - Wyper, GMA
AU  - Xavier, D
AU  - Xu, GL
AU  - Yadgir, S
AU  - Yadollahpour, A
AU  - Jabbari, SHY
AU  - Yakob, B
AU  - Yan, LJL
AU  - Yano, Y
AU  - Yaseri, M
AU  - Yasin, YJ
AU  - Yentür, GK
AU  - Yeshaneh, A
AU  - Yimer, EM
AU  - Yip, P
AU  - Yirsaw, BD
AU  - Yisma, E
AU  - Yonemoto, N
AU  - Yonga, G
AU  - Yoon, SJ
AU  - Yotebieng, M
AU  - Younis, MZ
AU  - Yousefifard, M
AU  - Yu, CH
AU  - Zadnik, V
AU  - Zaidi, Z
AU  - Bin Zaman, S
AU  - Zamani, M
AU  - Zare, Z
AU  - Zeleke, AJ
AU  - Zenebe, ZM
AU  - Zhang, AL
AU  - Zhang, K
AU  - Zhou, MG
AU  - Zodpey, S
AU  - Zuhlke, LJ
AU  - Naghavi, N
AU  - Murray, CJL
A1  - GBD Causes Death Collaborotors
TI  - Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017
T2  - LANCET
KW  - ALZHEIMERS-DISEASE
KW  - PREVALENCE
KW  - TRENDS
KW  - REGISTRATION
KW  - INDIVIDUALS
KW  - INJURIES
KW  - DEMENTIA
KW  - BARRIERS
KW  - PRIORITY
KW  - CHILDREN
AB  - Background Global development goals increasingly rely on country-specific estimates for benchmarking a nation's progress. To meet this need, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 estimated global, regional, national, and, for selected locations, subnational cause-specific mortality beginning in the year 1980. Here we report an update to that study, making use of newly available data and improved methods. GBD 2017 provides a comprehensive assessment of cause-specific mortality for 282 causes in 195 countries and territories from 1980 to 2017.
   Methods The causes of death database is composed of vital registration (VR), verbal autopsy (VA), registry, survey, police, and surveillance data. GBD 2017 added ten VA studies, 127 country-years of VR data, 502 cancer-registry country-years, and an additional surveillance country-year. Expansions of the GBD cause of death hierarchy resulted in 18 additional causes estimated for GBD 2017. Newly available data led to subnational estimates for five additional countries Ethiopia, Iran, New Zealand, Norway, and Russia. Deaths assigned International Classification of Diseases (ICD) codes for non-specific, implausible, or intermediate causes of death were reassigned to underlying causes by redistribution algorithms that were incorporated into uncertainty estimation. We used statistical modelling tools developed for GBD, including the Cause of Death Ensemble model (CODErn), to generate cause fractions and cause specific death rates for each location, year, age, and sex. Instead of using UN estimates as in previous versions, GBD 2017 independently estimated population size and fertility rate for all locations. Years of life lost (YLLs) were then calculated as the sum of each death multiplied by the standard life expectancy at each age. All rates reported here are age-standardised.
   Findings At the broadest grouping of causes of death (Level 1), non-communicable diseases (NC Ds) comprised the greatest fraction of deaths, contributing to 73.4% (95% uncertainty interval [UI] 72.5-74.1) of total deaths in 2017, while communicable, maternal, neonatal, and nutritional (CMNN) causes accounted for 186% (17.9-19.6), and injuries 8.0% (7.7-8.2). Total numbers of deaths from NCD causes increased from 2007 to 2017 by 22.7% (21.5-23.9), representing an additional 7.61 million (7. 20-8.01) deaths estimated in 2017 versus 2007. The death rate from NCDs decreased globally by 7.9% (7.08.8). The number of deaths for CMNN causes decreased by 222% (20.0-24.0) and the death rate by 31.8% (30.1-33.3). Total deaths from injuries increased by 2.3% (0-5-4-0) between 2007 and 2017, and the death rate from injuries decreased by 13.7% (12.2-15.1) to 57.9 deaths (55.9-59.2) per 100 000 in 2017. Deaths from substance use disorders also increased, rising from 284 000 deaths (268 000-289 000) globally in 2007 to 352 000 (334 000-363 000) in 2017. Between 2007 and 2017, total deaths from conflict and terrorism increased by 118.0% (88.8-148.6). A greater reduction in total deaths and death rates was observed for some CMNN causes among children younger than 5 years than for older adults, such as a 36.4% (32.2-40.6) reduction in deaths from lower respiratory infections for children younger than 5 years compared with a 33.6% (31.2-36.1) increase in adults older than 70 years. Globally, the number of deaths was greater for men than for women at most ages in 2017, except at ages older than 85 years. Trends in global YLLs reflect an epidemiological transition, with decreases in total YLLs from enteric infections, respirator}, infections and tuberculosis, and maternal and neonatal disorders between 1990 and 2017; these were generally greater in magnitude at the lowest levels of the Socio-demographic Index (SDI). At the same time, there were large increases in YLLs from neoplasms and cardiovascular diseases. YLL rates decreased across the five leading Level 2 causes in all SDI quintiles. The leading causes of YLLs in 1990 neonatal disorders, lower respiratory infections, and diarrhoeal diseases were ranked second, fourth, and fifth, in 2017. Meanwhile, estimated YLLs increased for ischaemic heart disease (ranked first in 2017) and stroke (ranked third), even though YLL rates decreased. Population growth contributed to increased total deaths across the 20 leading Level 2 causes of mortality between 2007 and 2017. Decreases in the cause-specific mortality rate reduced the effect of population growth for all but three causes: substance use disorders, neurological disorders, and skin and subcutaneous diseases.
   Interpretation Improvements in global health have been unevenly distributed among populations. Deaths due to injuries, substance use disorders, armed conflict and terrorism, neoplasms, and cardiovascular disease are expanding threats to global health. For causes of death such as lower respiratory and enteric infections, more rapid progress occurred for children than for the oldest adults, and there is continuing disparity in mortality rates by sex across age groups. Reductions in the death rate of some common diseases are themselves slowing or have ceased, primarily for NCDs, and the death rate for selected causes has increased in the past decade. Copyright (C) 2018 The Author(s). Published by Elsevier Ltd.
AD  - Univ Washington, Dept Med, Div Cardiol, Seattle, WA 98195 USAAD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - Univ Washington, Dept Global Hlth, Seattle, WA 98195 USAAD  - Univ Washington, Div Plast Surg, Dept Surg, Seattle, WA 98195 USAAD  - Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USAAD  - Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USAAD  - Univ Washington, Dept Neurol, Seattle, WA 98195 USAAD  - Univ Washington, Dept Med, Seattle, WA 98195 USAAD  - Univ Washington, Dept Surg, Seattle, WA 98195 USAAD  - Univ Washington, Dept Bioinformat & Med Educ, Seattle, WA 98195 USAAD  - Univ Washington, Dept Hlth Metr Sci, Seattle, WA 98195 USAAD  - Univ Washington, Seattle, WA 98195 USAAD  - Haramaya Univ, Sch Pharm, Harar, EthiopiaAD  - Haramaya Univ, Dept Pediat, Harar, EthiopiaAD  - Haramaya Univ, Dept Med Lab Sci, Harar, EthiopiaAD  - Haramaya Univ, Sch Publ Hlth, Harar, EthiopiaAD  - Haramaya Univ, Sch Nursing & Midwifery, Harar, EthiopiaAD  - Haramaya Univ, Coll Hlth & Med Sci, Harar, EthiopiaAD  - Haramaya Univ, Harar, EthiopiaAD  - Jimma Univ, Dept Populat & Family Hlth, Jimma, EthiopiaAD  - Jimma Univ, Dept Epidemiol, Jimma, EthiopiaAD  - Jimma Univ, Mycobacteriol Res Ctr, Jimma, EthiopiaAD  - Jimma Univ, Dept Hlth Educ R Behav Sci, Jimma, EthiopiaAD  - Jimma Univ, Dept Environm Hlth Sci & Technol, Jimma, EthiopiaAD  - Addis Ababa Univ, Dept Pharmacol & Clin Pharm, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Sch Publ Hlth, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Coll Hlth Sci, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Sch Allied Hlth Sci, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Addis Ababa, EthiopiaAD  - Univ Roma La Sapienza, Dept Law Philosophy & Econ Studies, Rome, ItalyAD  - Univ Tehran Med Sci, Noncommunicable Dis Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Dept Hlth, Tehran, IranAD  - Univ Tehran Med Sci, Dept Urol, Tehran, IranAD  - Univ Tehran Med Sci, Dept Hlth Management & Econ, Tehran, IranAD  - Univ Tehran Med Sci, Liver & Pancreaticobilliary Dis Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Multiple Sclerosis Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Sch Med, Tehran, IranAD  - Univ Tehran Med Sci, Dept Pharmacol, Tehran, IranAD  - Univ Tehran Med Sci, Dept Epidemiol & Biostat, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Malignancies Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Knowledge Utilizat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, IranAD  - Univ Tehran Med Sci, Canc Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Urooncol Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, INCAS, Tehran, IranAD  - Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Ctr Expertise Microbiol, Tehran, IranAD  - Univ Tehran Med Sci, Canc Biol Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Dept Anat, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Oncol & Stem Cell Transplantat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Community Based Participatory Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Canc Res Inst, Tehran, IranAD  - McGill Univ, Montreal Neuroimaging Ctr, Montreal, PQ, CanadaAD  - McGill Univ, Montreal Neurol Inst, Montreal, PQ, CanadaAD  - Cairo Univ, Dept Neurol, Cairo, EgyptAD  - Cairo Univ, Dept Med Parasitol, Cairo, EgyptAD  - Arak Univ Med Sci, Dept Epidemiol, Arak, IranAD  - Manonmaniam Sundaranar Univ, Dept Stat, Tirunelveli, IndiaAD  - Mekelle Univ, Coll Hlth Sci, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Publ Hlth, Mekelle, EthiopiaAD  - Mekelle Univ, Clin Pharm Unit, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Biostat, Mekelle, EthiopiaAD  - Mekelle Univ, Anat Unit, Mekelle, EthiopiaAD  - Mekelle Univ, Biomed Sci Div, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Med, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Microbiol & Immunol, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Environm Hlth Sci, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Midwifery, Mekelle, EthiopiaAD  - Mekelle Univ, Mekelle, EthiopiaAD  - Univ Gondar, Dept Clin Chem, Gondar, EthiopiaAD  - Univ Gondar, Human Nutr Dept, Gondar, EthiopiaAD  - Univ Gondar, Inst Publ Hlth, Gondar, EthiopiaAD  - Univ Gondar, Dept Med Microbiol, Gondar, EthiopiaAD  - Univ Gondar, Dept Med Parasitol, Gondar, EthiopiaAD  - Univ Gondar, Gondar, EthiopiaAD  - Debre Markos Univ, Dept Nursing, Debre Markos, EthiopiaAD  - Debre Markos Univ, Dept Publ Hlth, Debre Markos, EthiopiaAD  - Debre Markos Univ, Coll Hlth Sci, Debre Markos, EthiopiaAD  - Debre Markos Univ, Debre Markos, EthiopiaAD  - Univ Hohenheim, Inst Biol Chem & Nutr, Stuttgart, GermanyAD  - Wollega Univ, Dept Med Lab Sci, Nekemte, EthiopiaAD  - Wollega Univ, Dept Hlth Sci, Nekemte, EthiopiaAD  - Univ Med Sci, Sch Publ Hlth, Ondo, NigeriaAD  - Weill Cornell Med Coll Qatar, Dept Healthcare Policy & Res, Doha, QatarAD  - Benin Clin Res Inst IRCB, Epidemiol, Cotonou, BeninAD  - Benin Clin Res Inst IRCB, Cotonou, BeninAD  - Dongguk Univ, Dept Prevent Med, Gyeongju, South KoreaAD  - Kathmandu Univ, Dept Community Med, Devdaha, NepalAD  - Stellenbosch Univ, Dept Global Hlth, Cape Town, South AfricaAD  - Stellenbosch Univ, Fac Med & Hlth Sci, Cape Town, South AfricaAD  - Stellenbosch Univ, Dept Psychiat, Cape Town, South AfricaAD  - South African Med Res Council, Cochrane South Africa, Cape Town, South AfricaAD  - South African Med Res Council, Burden Dis Res Unit, Cape Town, South AfricaAD  - South African Med Res Council, Unit Hypertens & Cardiovasc Dis, Cape Town, South AfricaAD  - South African Med Res Council, Cape Town, South AfricaAD  - Univ Coll Hosp, Med, Ibadan, NigeriaAD  - Obafemi Awolowo Univ, Dept Med Rehabil, Ife, NigeriaAD  - Cardiff Univ, Sch Med, Cardiff, S Glam, WalesAD  - St Mark Hosp, Emergency Dept, Alexandria, EgyptAD  - Wolaita Sodo Univ, Sch Publ Hlth, Addis Ababa, EthiopiaAD  - McMaster Univ, Dept Family Med, Hamilton, ON, CanadaAD  - Inst Genont & Integrat Biol, CSIR, Res Area Informat & Big Data, Delhi, IndiaAD  - Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USAAD  - Baylor Coll Med, Natl Sch Trop Med, Houston, TX 77030 USAAD  - Publ Hlth Fdn India, Hlth Promot Div, New Delhi, IndiaAD  - Publ Hlth Fdn India, Dept Social & Behav Sci, New Delhi, IndiaAD  - Publ Hlth Fdn India, Non Communicable Dis, New Delhi, IndiaAD  - Publ Hlth Fdn India, Indian Inst Publ Hlth, New Delhi, IndiaAD  - Publ Hlth Fdn India, New Delhi, IndiaAD  - Vital Strategies, Gurugram, IndiaAD  - Kermanshah Univ Med Sci, Dept Anesthesiol, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Tradit & Complementary Med, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Sleep Disorders Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Fac Nutr & Food Sci, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Fac Publ Hlth, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Epidemiol 8 Biostat, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Environm Determinants Hlth Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Food Technol & Qual Control, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Sports Med & Rehabil, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Imam Ali Cardiovasc Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Pharmaceut Sci Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Kermanshah, IranAD  - Ahvaz Jundishapur Univ Med Sci, Environm Technol Res Ctr, Ahvaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Dept Publ Hlth, Ahvaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Thalassemia & Hemoglobinopathy Res Ctr, Ahvaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Dept Neurosurg, Ahvaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Educ Dev Ctr, Ahvaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Med Phys Dept, Ahvaz, IranAD  - Int Ctr Diarrhoeal Dis Res, Hlth Syst & Populat Studies Div, Dhaka, BangladeshAD  - Int Ctr Diarrhoeal Dis Res, Initiat Non Communicable Dis, Dhaka, BangladeshAD  - Int Ctr Diarrhoeal Dis Res, Hlth Econ & Financing Res Grp, Dhaka, BangladeshAD  - Int Ctr Diarrhoeal Dis Res, Maternal & Child Hlth Div, Dhaka, BangladeshAD  - Karolinska Inst, Informat Management & Eth, Dept Learning, Stockholm, SwedenAD  - Karolinska Inst, Dept Publ Hlth Sci, Stockholm, SwedenAD  - Karolinska Inst, Dept Neurobiol, Stockholm, SwedenAD  - Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, SwedenAD  - Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, SwedenAD  - Univ Ferhat Abbas Setif, Setif, AlgeriaAD  - Higher Natl Sch Vet Med, Algiers, AlgeriaAD  - Shahid Beheshti Univ Med Sci, Canc Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Safety Promot & Injury Prevent Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Dept Biostat, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Dept Epidemiol, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Sch Publ Hlth, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Ophthalm Epidemiol Res Ctr, Tehran, IranAD  - Univ Ibadan, Inst Adv Med Res & Training, Ibadan, NigeriaAD  - Univ Toronto, Ctr Global Child Hlth, Hosp Sick Children, Toronto, ON, CanadaAD  - Univ Toronto, Dept Nutr Sci, Toronto, ON, CanadaAD  - Univ Toronto, Ctr Global Child Hlth, Hosp Sick Children, Toronto, ON, CanadaAD  - Washington Univ, Internal Med Dept, St Louis, MO USAAD  - VA St Louis Hlth Care Syst, Dept Vet Affairs, Clin Epidemiol Ctr, St Louis, MO USAAD  - King Saud Univ, Pediat Intens Care Unit, Riyadh, Saudi ArabiaAD  - King Saud Univ, Dept Pediat, Riyadh, Saudi ArabiaAD  - King Saud Univ, Riyadh, Saudi ArabiaAD  - King Abdulaziz Univ, Dept Family & Community Med, Jeddah, Saudi ArabiaAD  - Mayo Clin, Fdn Med Educ & Res, Evidence Based Practice Ctr, Rochester, MN USAAD  - Syrian Amer Med Soc, Res Comm, Washington, DC USAAD  - Univ Western Australia, Sch Populat & Global Hlth, Perth, WA, AustraliaAD  - Univ Western Australia, Sch Med, Perth, WA, AustraliaAD  - Australian Natl Univ, Res Sch Populat Hlth, Canberra, ACT, AustraliaAD  - Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, AustraliaAD  - Qazvin Univ Med Sci, Dept Publ Hlth, Qazyin, IranAD  - Qazvin Univ Med Sci, Qazyin, IranAD  - Mazandaran Univ Med Sci, Gastrointestinal Canc Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Med Mycol, Sari, IranAD  - Mazandaran Univ Med Sci, Toxoplasittosis Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Physiol & Pharmacol, Sari, IranAD  - Mazandaran Univ Med Sci, Mol & Cell Biol Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Pediat, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Med Mycol & Parasitol, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Immunol, Sari, IranAD  - Mazandaran Univ Med Sci, Sari, IranAD  - Kuwait Univ, Dept Hlth Policy & Management, Safat, KuwaitAD  - Natl Univ Malaysia, Int Ctr Casemix & Clin Coding, Bandar Tun Razak, MalaysiaAD  - Luxembourg Inst Hlth, Dept Populat Hlth, Strassen, LuxembourgAD  - Univ Bordeaux, Isped, Bordeaux, FranceAD  - Swedish Res Council Hlth, Working Life & Welf, Stockholm, SwedenAD  - Hosp del Mar, Res Program Epidemiol K Publ Hlth, Res Inst, Barcelona, SpainAD  - Pompeu Fabra Univ, Dept Expt & Hlth Sci, Barcelona, SpainAD  - Univ Cartagena, Res Grp Hlth Econ, Cartagena, ColombiaAD  - Univ Cartagena, Epiunit, Inst Saude Publ, Cartagena, ColombiaAD  - Univ Coast, Hosp Management & Hlth Policies, Res Grp, Barranquilla, ColombiaAD  - South Australian Hlth & Med Res Inst, Sansont Inst, Adelaide, SA, AustraliaAD  - South Australian Hlth & Med Res Inst, Wardliparingga Aboriginal Res Unit, Adelaide, SA, AustraliaAD  - Bahir Dar Univ, Dept Publ Hlth Nutr, Bahir Dar, EthiopiaAD  - Bahir Dar Univ, Bahir Dar, EthiopiaAD  - Univ Queensland, Sch Publ Hlth, Brisbane, Qld, AustraliaAD  - Univ Queensland, Sch Dent, Brisbane, Qld, AustraliaAD  - Univ Queensland, Inst Social Sci Res, Brisbane, Qld, AustraliaAD  - Univ Queensland, Queensland Brain Inst, Brisbane, Qld, AustraliaAD  - Univ Queensland, Brisbane, Qld, AustraliaAD  - Fed Minist Hlth, Dept Hlth Ind Complex & Innovat Hlth, Beirut, LebanonAD  - Fed Minist Hlth, Beirut, LebanonAD  - Amer Univ Beirut, Fac Hlth Sci, Beirut, LebanonAD  - Komfo Anokye Teaching Hosp, Dept Internal Med, Kumasi, GhanaAD  - Mansoura Univ, Fac Med, Mansoura, EgyptAD  - Mansoura Univ, Dept Clin Pathol, Mansoura, EgyptAD  - Mansoura Univ, Mansoura, EgyptAD  - Carol Davila Univ Med & Pharm, Emergency Hosp Bucharest, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Dept Gen Surg, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Dept Legal Med & Bioeth, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Anat & Embryol Dept, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Bucharest, RomaniaAD  - Univ Thessaly, Dept Med, Volos, GreeceAD  - Arba Minch Univ, Dept Publ Hlth, Arba Minch, EthiopiaAD  - Arba Minch Univ, Med Lab Sci, Arba Minch, EthiopiaAD  - Arba Minch Univ, Arba Minch, EthiopiaAD  - Rafsanjan Univ Med Sci, Social Determinants Hlth Res Ctr, Rafsanjan, IranAD  - Zahedan Univ Med Sci, Zahedan, IranAD  - Debre Berhan Univ, Dept Publ Hlth, Debre Berhan, EthiopiaAD  - Debre Berhan Univ, Dept Midwifery, Debre Berhan, EthiopiaAD  - Univ Philippines Manila, Dept Hlth Policy & Adm, Manila, PhilippinesAD  - Univ Philippines Manila, Dev & Commun Studies, Manila, PhilippinesAD  - Birmingham City Univ, Sch Hlth Sci, Birmingham, W Midlands, EnglandAD  - Dalarna Univ, Sch Hlth & Social Studies, Falun, SwedenAD  - Western Sydney Univ, Sch Sci & Hlth, Sydney, NSW, AustraliaAD  - Western Sydney Univ, Sch Social Sci & Psychol, Sydney, NSW, AustraliaAD  - Western Sydney Univ, Sydney, NSW, AustraliaAD  - Sydney Local Hlth Dist, Oral Hlth Serv, Sydney, NSW, AustraliaAD  - Hlth Related Informat Disseminat Youth, New Delhi, IndiaAD  - Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, CanadaAD  - Abt Associates Nepal, Monitoring Evaluat & Operat Res Project, DfID Nepal Hlth Sect Programme 3, Lalitpur, NepalAD  - Qom Univ Med Sci, Qom, IranAD  - Univ Lahore, Univ Inst Publ Hlth, Lahore, PakistanAD  - Univ Hail, Publ Hlth Dept, Hail, Saudi ArabiaAD  - Univ Hail, Dept Family & Community Med, Hail, Saudi ArabiaAD  - Johns Hopkins Univ, Ctr Clin Global Hlth Educ, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Radiol, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD USAAD  - Johns Hopkins Univ, Sch Med, Baltimore, MD USAAD  - Dr D Y Patil Vidyapeeth, Dr D Y Patil Med Coll, Pune, Maharashtra, IndiaAD  - Dr D Y Patil Vidyapeeth, Pune, Maharashtra, IndiaAD  - Univ Leicester, Sch Business, Leicester, Leics, EnglandAD  - Univ Leicester, Dept Hlth Sci, Leicester, Leics, EnglandAD  - Lab Studies & Res Act Hlth, Conrol Infect Dis, Porto Novo, BeninAD  - Indian Inst Publ Hlth, Gandhinagar, IndiaAD  - La Trobe Univ, Judith Lumley Ctr, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Sch Nursing & Midwifery, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Austin Clin Sch Nursing, Melbourne, Vic, AustraliaAD  - Peruvian Natl Inst Hlth, Gen Off Res & Technol Transfer, Lima, PeruAD  - Univ Tokyo, Dept Community & Global Hlth, Tokyo, JapanAD  - Univ Tokyo, Dept Global Hlth Policy, Tokyo, JapanAD  - Burnet Inst, Global Adolescent Hlth Grp, Melbourne, Vic, AustraliaAD  - Ctr Infect Dis Res, Dept Infect Dis, Babol Sar, IranAD  - Univ Management & Technol, Sch Hlth Sci, Lahore, PakistanAD  - Univ Management & Technol, Sch Food & Agr Sci, Lahore, PakistanAD  - Publ Hlth Agcy Canada, Publ Hlth Risk Sci Div, Toronto, ON, CanadaAD  - Publ Hlth Agcy Canada, Appl Res Div, Toronto, ON, CanadaAD  - Med Univ Lodz, Dept Hypertens, Lodz, PolandAD  - Polish Mothers Mem Hosp, Res Inst, Lodz, PolandAD  - Int Inst Populat Sci, Dept Math Demog & Stat, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Dept Publ Hlth & Mortal Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Bombay, Maharashtra, IndiaAD  - Alexandria Univ, Fac Med, Alexandria, EgyptAD  - Univ Hosp Fdn Santa Fe Bogota, Dept Transplant Serv, Bogota, ColombiaAD  - Costa Rican Dept Social Secur, Rafael A Calderon Guardia Hosp, Dept Neurosci, San Jose, Costa RicaAD  - Costa Rican Dept Social Secur, Area Estadist, Direct Actuarial, San Jose, Costa RicaAD  - Univ Costa Rica, Sch Med, San Pedro, Costa RicaAD  - Univ Costa Rica, Sch Dent, San Pedro, Costa RicaAD  - Univ Auckland, Sch Psychol, Auckland, New ZealandAD  - Univ Auckland, Mol Med & Pathol, Auckland, New ZealandAD  - Heidelberg Univ, Inst Publ Hlth, Heidelberg, GermanyAD  - Heidelberg Univ, Dept Ophthalmol, Heidelberg, GermanyAD  - Heidelberg Univ, Med Clin 5, Heidelberg, GermanyAD  - Heidelberg Univ, Augenpraxis Jonas, Heidelberg, GermanyAD  - Harvard Univ, Dept Global Hlth & Populat, Boston, MA 02115 USAAD  - Harvard Univ, Dept Nutr, Boston, MA 02115 USAAD  - Harvard Univ, T H Chan Sch Publ Hlth, Boston, MA 02115 USAAD  - Harvard Univ, Ariadne Labs, Boston, MA 02115 USAAD  - Harvard Univ, Dept Genet, Boston, MA 02115 USAAD  - Harvard Univ, Div Gen Internal Med & Primary Care, Boston, MA 02115 USAAD  - Harvard Univ, Heart & Vasc Ctr, Boston, MA 02115 USAAD  - Harvard Univ, Dept Environm Hlth, Boston, MA 02115 USAAD  - Harvard Univ, Boston, MA 02115 USAAD  - Natl Inst Publ Hlth, Ctr Nutr & Hlth Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Ctr Hlth Syst Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Ctr Populat Hlth Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Cuernavaca, Morelos, MexicoAD  - Pontifical Javeriana Univ, Dept Ind Engn, Bogota, ColombiaAD  - Barcelona Inst Global Hlth, Barcelona, SpainAD  - Barcelona Inst Global Hlth, TB Dept, Barcelona, SpainAD  - Manhica Hlth Res Ctr, TB, Manhica, MozambiqueAD  - Manhica Hlth Res Ctr, Manhica, MozambiqueAD  - Stanford Univ, Dept Med, Palo Alto, CA 94304 USAAD  - Melbourne Med Sch, Melbourne, Vic, AustraliaAD  - Charles R Drew Univ Med & Sci, Dept Psychiat, 1621 E 120th St, Los Angeles, CA 90059 USAAD  - Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USAAD  - Gandhi Med Coll Bhopal, Dept Community Med, Bhopal, IndiaAD  - Jazan Univ, Jazan, Saudi ArabiaAD  - Mario Negri Inst Pharmacol Res, Dept Neurosci, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Dept Renal Med, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Dept Oncol, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Dept Environm Hlth Sci, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Milan, ItalyAD  - Iran Univ Med Sci, Hlth Management & Econ Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Dept Ophthalmol, Tehran, IranAD  - Iran Univ Med Sci, Air Pollut Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Prevent Med & Publ Hlth Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Dept Neurosci, Tehran, IranAD  - Iran Univ Med Sci, Dept Hlth Policy, Tehran, IranAD  - Iran Univ Med Sci, Dept Community Med, Tehran, IranAD  - Iran Univ Med Sci, Physiol Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Tehran, IranAD  - Lorestan Univ Med Sci, Social Determinants Hlth Res Ctr, Khorramabad, IranAD  - Lorestan Univ Med Sci, Khorramabad, IranAD  - Univ Hosp Dijon, Dept Neurol, Dijon, FranceAD  - Univ Burgundy, Dijon Stroke Registry Ufr Sci Sante, Dijon, FranceAD  - Mizan Tepi Univ, Publ Hlth Dept, Teppi, EthiopiaAD  - Mizan Tepi Univ, Pharm Dept, Teppi, EthiopiaAD  - Mizan Tepi Univ, Teppi, EthiopiaAD  - Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USAAD  - Yale Univ, Dept Ophthalmol & Visual Sci, New Haven, CT USAAD  - Univ Alberta, Dept Med, Edmonton, AB, CanadaAD  - Univ Oxford, Nuffield Dept Populat Hlth, Oxford, EnglandAD  - Univ Oxford, Nuffield Dept Med, Oxford, EnglandAD  - Univ Oxford, Dept Psychiat, Oxford, EnglandAD  - Univ Oxford, Nuffield Dept Womens & Reprod Hlth, Oxford, EnglandAD  - Univ Oxford, Oxford, EnglandAD  - Univ Sao Paulo, Dept Internal Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Div Ophthalmol, Ribeirao Preto Med Sch, Sao Paulo, BrazilAD  - Univ Sao Paulo, Univ Hosp, Internal Med Dept, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Biomech, Sao Paulo, BrazilAD  - Univ Sao Paulo, Lab Genet & Mol Cardiol, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Pathol & Legal Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Psychiat, Sao Paulo, BrazilAD  - Univ Sao Paulo, Ctr Clin & Epidemiol Res, Sao Paulo, BrazilAD  - Augusta Univ, Med Coll Georgia, Div Cardiol, Augusta, GA USAAD  - London Sch Econ & Polit Sci, Dept Hlth Policy, London, EnglandAD  - London Sch Econ & Polit Sci, Personal Social Serv Res Unit, London, EnglandAD  - Kings Coll London, Dent Inst, London, EnglandAD  - Kings Coll London, Fac Life Sci & Med, London, EnglandAD  - Kings Coll London, St Johns Inst Dermatol, London, EnglandAD  - Kings Coll London, Div Patient & Populat, London, EnglandAD  - Kings Coll London, Sch Populat Hlth & Environm Sci, London, EnglandAD  - Emory Univ, Hubert Dept Global Hlth, Atlanta, GA 30322 USAAD  - Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USAAD  - Univ S Florida, Dept Global Hlth, Tampa, FL USAAD  - Post Grad Inst Med Educ & Res, Dept Internal Med, Chandigarh, IndiaAD  - Post Grad Inst Med Educ & Res, Dept Pediat, Chandigarh, IndiaAD  - London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Dis Control, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, EnglandAD  - London Sch Hyg & Trop Med, London, EnglandAD  - Nepal Acad Sci & Technol, Patan, NepalAD  - George Inst Global Hlth, George Inst, New Delhi, IndiaAD  - George Inst Global Hlth, Res, New Delhi, IndiaAD  - George Inst Global Hlth, New Delhi, IndiaAD  - Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, PakistanAD  - Babol Univ Med Sci, Social Determinant Hlth Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Hlth Res Inst, Babol Sar, IranAD  - Babol Univ Med Sci, Fatemeh Zahra Infertil & Reprod Hlth Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Dept Clin Biochem, Babol Sar, IranAD  - Babol Univ Med Sci, Cellular & Mol Biol Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Infect Dis & Trop Med Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Immunoregulat Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Dept Microbiol & Immunol, Babol Sar, IranAD  - Babol Univ Med Sci, Student Res Comm, Babol Sar, IranAD  - Babol Univ Med Sci, Babol Sar, IranAD  - Imperial Coll London, Dept Epidemiol & Biosiat, London, EnglandAD  - Imperial Coll London, Dept Primary Care & Publ Hlth, London, EnglandAD  - Imperial Coll London, Dept Surg & Canc, London, EnglandAD  - Imperial Coll London, Dept Infect Dis Epidemiol, London, EnglandAD  - Imperial Coll London, WHO Collaborating Ctr Publ Hlth Educ & Training, London, EnglandAD  - Imperial Coll London, Sch Publ Hlth, London, EnglandAD  - Woldia Univ, Woldia, EthiopiaAD  - Univ Dhaka, Dept Clin Pharm & Pharmacol, Ramna, BangladeshAD  - Res Triangle Inst Int, Global Hlth Div, Res Triangle Pk, NC USAAD  - Univ Nottingham, Sch Med, Nottingham, EnglandAD  - A T Still Univ, Dept Hlth Sci, Brisbane, Qld, AustraliaAD  - A T Still Univ, Brisbane, Qld, AustraliaAD  - Minist Hlth, Gen Directorate Hlth Informat Syst, Ankara, TurkeyAD  - Minist Hlth, Dept Publ Hlth, Ankara, TurkeyAD  - Minist Hlth, Epidemiol & Dis Control, Ankara, TurkeyAD  - Minist Hlth, Res Dept, Prince Mohammed Bin Abdulaziz Hosp, Ankara, TurkeyAD  - Minist Hlth, NCD Prevent & Control Unit, Ankara, TurkeyAD  - Minist Hlth, Hlth & Disabil Intelligence Grp, Ankara, TurkeyAD  - Minist Hlth, Dept Hlth Stat, Ankara, TurkeyAD  - Minist Hlth, Ankara, TurkeyAD  - Murdoch Childrens Res Inst, Ctr Adolescent Hlth, Melbourne, Vic, AustraliaAD  - Murdoch Childrens Res Inst, Populat Hlth Grp, Melbourne, Vic, AustraliaAD  - Murdoch Childrens Res Inst, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Dept Med, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Dept Paediat, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Sch Hlth Sci, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Melbourne, Vic, AustraliaAD  - Heidelberg Univ Hosp, Dept Gen Practice & Hlth Serv Res, Heidelberg, GermanyAD  - Univ Fed Minas Gerais, Sch Med, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Clin Hosp, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Dept Maternal & Child Nursing & Publ Hlth, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Hosp Fed Univ Minas Gerais, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Postgrad Program Infect Dis & Trop Med, Belo Horizonte, MG, BrazilAD  - Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, EnglandAD  - Univ Cambridge, MRC Epidemiol, Cambridge, EnglandAD  - Comenius Univ, Inst Epidemiol, Bratislava, SlovakiaAD  - Ohio State Univ, Dept Psychol, Columbus, OH 43210 USAAD  - Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USAAD  - Ohio State Univ, Psychiat & Behav Hlth Dept, Columbus, OH 43210 USAAD  - German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, GermanyAD  - Inst Sci Res & High Technol Serv, Dept Neurosci, City Of Knowledge, PanamaAD  - Gorgas Mem Inst Hlth Studies, Dept Res & Hlth Technol Assessment, Panama City, PanamaAD  - Gorgas Mem Inst Hlth Studies, Panama City, PanamaAD  - Charite Univ Med Ctr Berlin, Inst Publ Hlth, Berlin, GermanyAD  - Charite Univ Med Ctr Berlin, Dept Neurol, Berlin, GermanyAD  - Charite Univ Med Ctr Berlin, Dept Operat & Prevent Dent, Berlin, GermanyAD  - Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, CanadaAD  - Univ British Columbia, Vancouver, BC, CanadaAD  - Al Shifa Trust Eye Hosp, Al Shifa Sch Publ Hlth, Rawalpindi, PakistanAD  - Univ Valley Cuernavaca, Sch Med, Cuernavaca, Morelos, MexicoAD  - Metropolitan Autonomous Univ, Dept Populat & Hlth, Mexico City, DF, MexicoAD  - Inst Canc Res Prevent & Clin Network, Florence, ItalyAD  - Univ Porto, Inst Publ Hlth, Porto, PortugalAD  - Univ Porto, Inst Biomed Engn, Porto, PortugalAD  - Univ Porto, REQUIMTE LAQV, Porto, PortugalAD  - Univ Porto, Dept Community Med Informat & Hlth Decis Sci Cint, Facithy Med, Porto, PortugalAD  - Univ Porto, Ucibio, Porto, PortugalAD  - Univ Porto, Appl Mol Biosci Unit, Porto, PortugalAD  - Univ Porto, Inst Res & Innovat Hlth I3S, Porto, PortugalAD  - Natl Inst Hlth, Colombian Natl Hlth Observ, Bogota, ColombiaAD  - Univ Nacl Colombia, Epidemiol & Publ Hlth Evaluat Grp, Bogota, ColombiaAD  - Univ Nacl Colombia, Dept Publ Hlth, Bogota, ColombiaAD  - Portuguese Oncol Inst Porto, Dept Epidemiol, Porto, PortugalAD  - Inst Hlth Carlos III, Dept Hlth Planning & Econ, Madrid, SpainAD  - Australian Catholic Univ, Mary Mackillop Inst Hlth Res, Melbourne, Vic, AustraliaAD  - Australian Catholic Univ, Inst Posit Psychol & Educ, Melbourne, Vic, AustraliaAD  - Australian Catholic Univ, Brain Inst, Melbourne, Vic, AustraliaAD  - Univ Hong Kong, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ Hong Kong, Ctr Suicide Res & Prevent, Hong Kong, Hong Kong, Peoples R ChinaAD  - Alfaisal Univ, Coll Med, Riyadh, Saudi ArabiaAD  - Natl Taiwan Univ, Coll Med, Taipei, TaiwanAD  - Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Taipei, TaiwanAD  - Tata Mem Hosp, Surg Oncol, Bombay, Maharashtra, IndiaAD  - Clin Governance Gold Coast Hlth, Gold Coast, Qld, AustraliaAD  - Univ Occupat & Environm Hlth, Inst Ind Ecol Sci, Kitakyushu, Fukuoka, JapanAD  - Univ Zambia, Dept Populat Studies, Lusaka, ZambiaAD  - Univ Witwatersrand, Demog & Populat Studies, Johannesburg, South AfricaAD  - Univ Copenhagen, Inst Clin Med, Copenhagen, DenmarkAD  - Univ Copenhagen, Bispebjerg Hosp, Copenhagen, DenmarkAD  - Univ Copenhagen, Dept Neurol, Copenhagen, DenmarkAD  - Christian Med Coll & Hosp CMC, Dept Pulm Med, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp CMC, Dept Neurol, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp CMC, Dept Endocrinol, Vellore, Tamil Nadu, IndiaAD  - UCL, Dept Hlth Informat, London, EnglandAD  - UCL, Ear Inst, London, EnglandAD  - UCL, Dept Epidemiol & Publ Hlth, London, EnglandAD  - UCL, Dept Psychol, London, EnglandAD  - Hlth Data Res UK, London, EnglandAD  - Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, AustraliaAD  - Monash Univ, Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic, AustraliaAD  - Monash Univ, Melbourne, Vic, AustraliaAD  - Univ Adelaide, Adelaide Med Sch, Adelaide, SA, AustraliaAD  - Univ Adelaide, Sch Publ Hlth, Adelaide, SA, AustraliaAD  - Univ Adelaide, Adelaide, SA, AustraliaAD  - Univ Salerno, Scuola Med Salernitana, Baronissi, ItalyAD  - Hlth Effects Inst, Boston, MA USAAD  - Mayo Clin, Dept Cardiovasc Med, Jacksonville, FL 32224 USAAD  - Swiss Trop & Publ Hlth Inst, Malaria Vaccines, Basel, SwitzerlandAD  - Swiss Trop & Publ Hlth Inst, Epidemiol & Publ Hlth, Basel, SwitzerlandAD  - Qual & Equity Hlth Care, Kigali, RwandaAD  - Univ Milano Bicocca, Sch Med & Surg, Monza, ItalyAD  - Univ Fed Rio Grande do Sul, Postgrad Program Epidemiol, Porto Alegre, RS, BrazilAD  - Peter Doherty Inst Infect & Immun, WHO Collaborating Ctr Vical Hepatitis, Melbourne, Vic, AustraliaAD  - Peter Doherty Inst Infect & Immun, VIDS, Melbourne, Vic, AustraliaAD  - Peter Doherty Inst Infect & Immun, Epidemiol Discipline, Melbourne, Vic, AustraliaAD  - Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USAAD  - Univ Otago, Ctr Int Hlth, Dunedin, New ZealandAD  - Duke Univ, Div Infect Dis & Int Hlth, Durham, NC USAAD  - Duke Univ, Sch Med, Durham, NC USAAD  - Duke Univ, Duke Global Hlth Inst, Durham, NC USAAD  - Hawassa Univ, Coll Med & Hlth Sci, Hawassa, EthiopiaAD  - Hawassa Univ, Dept Reprod Hlth, Hawassa, EthiopiaAD  - Flinders Univ S Australia, Discipline Publ Hlth, Adelaide, SA, AustraliaAD  - Duy Tan Univ, Inst Global Hlth Innovat, Hanoi, VietnamAD  - Guys & St Thomas NHS Fdn Trust, Clin Toxicol Serv, London, EnglandAD  - Guys & St Thomas NHS Fdn Trust, Biomed Res Council, London, EnglandAD  - K G Med Univ, Dept Rheumatol, Lucknow, Uttar Pradesh, IndiaAD  - BRAC Univ, James P Grant Sch Publ Hlth, Dhaka, BangladeshAD  - BRAC Univ, Res & Evaluat Div, Dhaka, BangladeshAD  - Cent Univ Tamil Nadu, Thiruvarur, IndiaAD  - Clin Emergency Hosp St Pantelimon, Dept Surg, Bucharest, RomaniaAD  - Kazakh Natl Med Univ, Alma Ata, KazakhstanAD  - Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, AustraliaAD  - Univ New South Wales, South Western Sydney Clin Sch, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Med, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Psychiat, Sydney, NSW, AustraliaAD  - African Populat Hlth Res Ctr, Populat Dynam & Reprod Hlth Unit, Nairobi, KenyaAD  - Aksum Univ, Dept Clin Pharm, Aksum, EthiopiaAD  - Brighton & Sussex Med Sch, Dept Global Hlth & Infect, Brighton, E Sussex, EnglandAD  - Natl Hlth Serv Scotland, Edinburgh, Midlothian, ScotlandAD  - Aristotle Univ Thessaloniki, Thessaloniki, GreeceAD  - Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USAAD  - Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USAAD  - Disha Fdn, Gurgaon, IndiaAD  - Univ Peradeniya, Dept Community Med, Peradeniya, Sri LankaAD  - Swedish Family Med First Hill, Seattle, WA USAAD  - Minist Hlth & Med Educ, Deputy Res & Technol, Tehran, IranAD  - Minist Hlth & Med Educ, Ctr Communicable Dis Control, Tehran, IranAD  - Minist Hlth & Med Educ, Dept Human Resources, Tehran, IranAD  - Minist Hlth & Med Educ, Tehran, IranAD  - Med Univ Varna, Dept Social Med & Hlth Care Org, Varna, BulgariaAD  - Univ Cape Coast, Dept Populat & Hlth, Cape Coast, GhanaAD  - Univ Tampere, Fac Social Sci, Hlth Sci, Tampere, FinlandAD  - Univ Rochester, Rochester, NY USAAD  - RMIT Univ, Sch Hlth & Biomed Sci, Bundoora, Vic, AustraliaAD  - RMIT Univ, Dept Psychol, Bundoora, Vic, AustraliaAD  - Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, AustraliaAD  - Univ Sydney, Sydney Med Sch, Sydney, NSW, AustraliaAD  - Univ Sydney, Asbestos Dis Res Inst, Sydney, NSW, AustraliaAD  - Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, AustraliaAD  - Univ Sydney, Sydney, NSW, AustraliaAD  - United Nations World Food Programme, New Delhi, IndiaAD  - Univ Belgrade, Fac Med, Belgrade, SerbiaAD  - Univ Belgrade, Inst Social Med, Ctr Sch Publ Hlth & Hlth Management, Belgrade, SerbiaAD  - Univ Fed Bahia, Sch Med, Salvador, BA, BrazilAD  - Roberto Santos Gen Hosp, Diretoria Med, Salvador, BA, BrazilAD  - Umea Univ, Dept Nursing, Umea, SwedenAD  - Univ Tromso, Dept Community Med, Tromso, NorwayAD  - Tripoli Univ, Dept Community Med, Tripoli, LibyaAD  - WHO, Hlth Informat, Tripoli, LibyaAD  - WHO, TB Hlth Top, Tripoli, LibyaAD  - Stavanger Univ Hosp, Dept Pathol, Stavanger, NorwayAD  - Norwegian Inst Publ Hlth, Ctr Dis Burden, Oslo, NorwayAD  - Norwegian Inst Publ Hlth, Div Mental & Phys Hlth, Oslo, NorwayAD  - Norwegian Inst Publ Hlth, Oslo, NorwayAD  - St Pauls Hosp, Millennium Med Coll, Publ Hlth Dept, Addis Ababa, EthiopiaAD  - Queensland Ctr Mental Hlth Res, Policy & Epidemiol Grp, Brisbane, Qld, AustraliaAD  - Queensland Ctr Mental Hlth Res, Child & Youth Mental Hlth, Brisbane, Qld, AustraliaAD  - Queensland Ctr Mental Hlth Res, Brisbane, Qld, AustraliaAD  - Gonabad Univ Med Sci, Dept Publ Hlth, Gonabad, IranAD  - Urmia Univ Med Sci, Dept Med Parasitol & Mycol, Orumiyeh, IranAD  - Imam Muhammad Ibn Saud Islamic Univ, Coll Med, Riyadh, Saudi ArabiaAD  - Imam Muhammad Ibn Saud Islamic Univ, Dept Publ Hlth, Riyadh, Saudi ArabiaAD  - Natl Stat Off, Lisbon, PortugalAD  - Univ Fed Sergipe, Dept Psychol, Sao Cristovao, BrazilAD  - Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New ZealandAD  - Org Econ Cooperat & Dev, Hlth Div, Paris, FranceAD  - Catholic Univ Portugal, Ctr Biotechnol & Fine Chem, Associate Lab, Fac Biotechnol, Porto, PortugalAD  - Kaiser Permanente, Dept Psychiat, Fontana, CA USAAD  - Kaiser Permanente, Div Res, Fontana, CA USAAD  - Bielefeld Univ, Dept Publ Hlth Med, Bielefeld, GermanyAD  - Natl Acad Med Sci Ukraine, Inst Gerontol, Kiev, UkraineAD  - Canc Inst, Gene Express & Regulat Program, Philadelphia, PA USAAD  - Kobe Univ, Dept Dermatol, Kobe, Hyogo, JapanAD  - Univ Basel, Basel, SwitzerlandAD  - Autonomous Univ Chile, Fac Business & Management, Talca, ChileAD  - Autonomous Univ Chile, Inst Phys Act & Hlth, Talca, ChileAD  - Curtin Univ, Sch Publ Hlth, Perth, WA, AustraliaAD  - Wageningen Univ & Res, Div Human Nutr & Hlth, Wageningen, NetherlandsAD  - Reg Hlth Council, Directorate Gen Publ Hlth, Madrid, SpainAD  - Univ Tsukuba, Dept Hlth Care Policy & Management, Tsukuba, Ibaraki, JapanAD  - Royal Melbourne Hosp, Melbourne, Vic, AustraliaAD  - Univ Warwick, Unit Acad Primary Care, Coventry, W Midlands, EnglandAD  - Univ Warwick, Div Hlth Sci, Coventry, W Midlands, EnglandAD  - Howard Univ, Dept Community & Family Med, Washington, DC 20059 USAAD  - Howard Univ, Div Gen Internal Med, Washington, DC 20059 USAAD  - Minist Publ Hlth, Dept Neurol, Dijon, FranceAD  - Minist Publ Hlth, Dept Vital & Hlth Stat, Dijon, FranceAD  - Minist Publ Hlth, Dept Dis Epidem & Pandem Control, Dijon, FranceAD  - Postgrad Med Inst, Fac Med, Dijon, FranceAD  - Ctr Chron Dis Control, Phys Act & Obes Prevent, New Delhi, IndiaAD  - Ctr Chron Dis Control, New Delhi, IndiaAD  - Jawahar Lal Nehru Univ, Ctr Study Reg Dev, New Delhi, IndiaAD  - Univ Massachusetts, Nursing & Hlth Sci Dept, Boston, MA 02125 USAAD  - Univ Oklahoma, Dept Biostat & Epidemiol, Oklahoma City, OK USAAD  - Govt Federated States Micronesia, Dept Hlth & Social Affairs, Palikir, MicronesiaAD  - Natl Canc Ctr, Metab Epidemiol Sect, Chuo Ku, Tokyo, JapanAD  - Boston Univ, Sch Med, Boston, MA 02215 USAAD  - Vittorio Emanuele Univ Hosp Polyclin, Registro Tumori Integrato, Catania, ItalyAD  - St James Sch Med, Dept Epidemiol, The Valley, AnguillaAD  - St James Sch Med, Dept Microbiol, The Valley, AnguillaAD  - Univ Estadual Montes Claros, Sch Dent, Montes Claros, BrazilAD  - Healis Sekhsaria Inst Publ Hlth, Dept Epidemiol, Bombay, Maharashtra, IndiaAD  - West Virginia Bur Publ Hlth, Commissioner Publ Hlth, Charleston, WV USAAD  - West Virginia Univ, Sch Publ Hlth, Dept Hlth Policy Management & Leadership, Morgantown, WV 26506 USAAD  - Rajasthan Univ Hlth Sci, Acad & Res, Jaipur, Rajasthan, IndiaAD  - Eternal Heart Care Ctr & Res Inst, Dept Prevent Cardiol, Jaipur, Rajasthan, IndiaAD  - Montefiore Med Ctr, Dept Cardiol, 111 E 210th St, Bronx, NY 10467 USAAD  - Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USAAD  - Albert Einstein Coll Med, Bronx, NY 10467 USAAD  - Ramon de la Fuente Muniz Natl Inst Psychiat, Dept Epidemiol & Psychosocial Res, Mexico City, DF, MexicoAD  - Aarhus Univ, Dept Publ Hlth, Aarhus, DenmarkAD  - Aarhus Univ, Natl Ctr Register Based Res, Aarhus, DenmarkAD  - Nepal Dev Soc, Pokhara, NepalAD  - Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, NetherlandsAD  - Arabian Gulf Univ, Dept Family & Community Med, Manama, BahrainAD  - Hamdan Bin Mohammed Smart Univ, Sch Hlth & Environm Studies, Dubai, U Arab EmiratesAD  - Univ New Mexico, Populat Hlth Dept, Albuquerque, NM 87131 USAAD  - Sir Charles Gairdner Hosp, Neurol Dept, Perth, WA, AustraliaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Cardiol Dept, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Achutha Menon Ctr Hlth Sci Studies, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Neurol Dept, Trivandrum, Kerala, IndiaAD  - Res & Dev Unit, San Juan de Dios Sanitary Pk, St Boi De Llobregat, SpainAD  - Univ Barcelona, Dept Med, Barcelona, SpainAD  - Univ Barcelona, Barcelona, SpainAD  - Tabriz Univ Med Sci, Publ Hlth Dept, Tabriz, IranAD  - Tabriz Univ Med Sci, Tabriz, IranAD  - Univ Hosp Antwerp, Unit Epidemiol & Social Med, Antwerp, BelgiumAD  - Karolinska Univ Hosp, Clin Sci Dept, Stockholm, SwedenAD  - Int Fdn Dermatol, London, EnglandAD  - Hormozgan Univ Med Sci, Dept Environm Hlth Engn, Bandar Abbas, IranAD  - Bucharest Univ Econ Studies, Dept Stat & Econometr, Bucharest, RomaniaAD  - Bucharest Univ Econ Studies, Bucharest, RomaniaAD  - Univ Med Ctr Groningen, Dept Psychiat, Groningen, NetherlandsAD  - Columbia Univ, Dept Epidemiol, New York, NY USAAD  - Columbia Univ, Dept Hlth & Behav Studies, New York, NY USAAD  - Univ Texas Austin, Austin, TX 78712 USAAD  - Guilan Univ Med Sci, Sch Hlth, Rasht, ItalyAD  - Guilan Univ Med Sci, Guilan Rd Trauma Res Ctr, Rasht, ItalyAD  - Manipal Univ, Transdisciplinary Ctr Qualitat Methods, Manipal, Karnataka, IndiaAD  - Univ Human Dev, Dept Comp Sci, Sulaimaniyah, IraqAD  - Bucharest Emergency Hosp, Dept Internal Med, Bucharest, RomaniaAD  - Natl Inst Legal Med Mina Minovici, Clin Legal Med, Bucharest, RomaniaAD  - Cent South Univ, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R ChinaAD  - Birzeit Univ, Inst Community & Publ Hlth, Birzeit, IsraelAD  - Qatar Univ, Hlth Sci Dept, Doha, QatarAD  - Bashkir State Med Univ, Infect Dis Dept, Ufa, RussiaAD  - Univ Liberia, Dept Publ Hlth & Community Med, Monrovia, LiberiaAD  - Taipei Med Univ, Global Hlth & Dev Dept, Taipei, TaiwanAD  - Taipei Med Univ, Grad Inst Biomed Informat, Taipei, TaiwanAD  - Deakin Univ, Inst Phys Act & Nutr, Burwood, Vic, AustraliaAD  - Deakin Univ, Sch Med, Burwood, Vic, AustraliaAD  - Deakin Univ, Dept Psychol, Burwood, Vic, AustraliaAD  - Amer Canc Soc, Surveillance & Hlth Serv Res, Atlanta, GA 30329 USAAD  - George Mason Univ, Dept Global & Community Hlth, Fairfax, VA 22030 USAAD  - Tabriz Univ Med Sci, Publ Hlth Dept, Tabriz, IranAD  - Natl Ctr Dis Control Delhi, Dept Parasit Dis, Delhi, IndiaAD  - Univ Kragujevac, Med Sci Dept, Kragujevac, SerbiaAD  - Newcastle Univ, Tyne, EnglandAD  - Univ Colombo, Fac Grad Studies, Colombo, Sri LankaAD  - Univ Colombo, Inst Med, Colombo, Sri LankaAD  - Boston Childrens Hosp, Ctr Appl Pediat Qual Analyt, Boston, MA USAAD  - Banaras Hindu Univ, Dept Community Med, Varanasi, Uttar Pradesh, IndiaAD  - Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R ChinaAD  - All India Inst Med Sci, Ctr Community Med, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Paediat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol Metab & Diabet, New Delhi, IndiaAD  - Czestochowa Tech Univ, Inst Hlth & Nutr Sci, Czestochowa, PolandAD  - Univ Opole, Fac Med & Hlth Sci, Opole, PolandAD  - Savitribai Phule Pune Univ, Sch Hlth Sci, Pune, Maharashtra, IndiaAD  - Univ Tartu, Inst Family Med & Publ Hlth, Tartu, EstoniaAD  - Univ Coll Cork, Sch Publ Hlth, Cork, IrelandAD  - Hamadan Univ Med Sci, Chron Dis Home Care Res Ctr, Dept Epidemiol, Hamadan, IranAD  - Hamadan Univ Med Sci, Chron Dis Home Care Res Ctr, Dept Environm Hlth Engn, Hamadan, IranAD  - Hamadan Univ Med Sci, Chron Dis Home Care Res Ctr, Hamadan, IranAD  - Hamadan Univ Med Sci, Hamadan, IranAD  - Helmholtz Ctr Infect Res, Dept Epidemiol, Braunschweig, GermanyAD  - Baqiyatallah Univ Med Sci, Baqiyatallah Res Ctr Gastroenterol & Liver Dis, Tehran, IranAD  - Baqiyatallah Univ Med Sci, Student Res Comm, Tehran, IranAD  - Middle East Liver Dis Ctr, Dept Young Investigators, Tehran, IranAD  - Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, Seattle, WA USAAD  - Univ Glasgow, MRC CSO Social & Publ Hlth Sci Unit, Glasgow, Lanark, ScotlandAD  - Oklahoma State Univ, Sch Hlth Care Adm, Tulsa, OK USAAD  - Univ Tulsa, Hlth Care Delivery Sci, Tulsa, OK 74104 USAAD  - Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USAAD  - Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USAAD  - Univ Nairobi, ODeL Campus, Nairobi, KenyaAD  - Univ Nairobi, Sch Med, ODeL Campus, Nairobi, KenyaAD  - Michigan State Univ, Dept Linguist & German Slav Asian & African Langu, E Lansing, MI 48824 USAAD  - Med Res Council South Africa, Noncommunicable Dis Res Unit, Cape Town, South AfricaAD  - Med Res Council South Africa, Alcohol Tobacco & Other Drug Use Res Unit, Cape Town, South AfricaAD  - Med Res Council South Africa, Cochrane South Africa, Cape Town, South AfricaAD  - Univ Cape Town, Dept Med, Cape Town, South AfricaAD  - Univ Cape Town, Sch Publ Hlth & Family Med, Cape Town, South AfricaAD  - Univ Cape Town, Dept Psychiat & Mental Hlth, Cape Town, South AfricaAD  - Univ Cape Town, Dept Paediat & Child Hlth, Cape Town, South AfricaAD  - Assuta Hosp, Inst Cardiol, Tel Aviv Yaffo, IsraelAD  - Hadassah Hebrew Univ Hosp, Heart Failure & Cardiomyopath Ctr, Jerusalem, IsraelAD  - CSIR, Indian Inst Toxicol Res, Lucknow, Uttar Pradesh, IndiaAD  - Jordan Univ Sci & Technol, Dept Publ Hlth & Community Med, Ramtha, JordanAD  - Azad Univ, Omidiyeh Branch, Dept Stat, Omidiyeh, IranAD  - Hlth Serv Acad, Epidemiol & Biostat Dept, Islamabad, PakistanAD  - John H Stroger Jr Hosp Cook Cty, Dept Internal Med, Chicago, IL USAAD  - Dow Univ Hlth Sci, Dept Internal Med, Karachi, PakistanAD  - Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USAAD  - Univ Alabama Birmingham, Dept Med, Birmingham, AL USAAD  - Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USAAD  - Univ Alabama Birmingham, Birmingham, AL USAAD  - Univ Tennessee, Knoxville, TN USAAD  - Seoul Natl Univ, Inst Hlth Policy & Management, Seoul, South KoreaAD  - Seoul Natl Univ, Dept Hlth Policy & Management, Seoul, South KoreaAD  - Int Otorhinolaryngol Res Assoc, Tehran, IranAD  - Ball State Univ, Dept Nutr & Hlth Sci, Muncie, IN 47306 USAAD  - Lund Univ, Clin Epidemiol Unit, Lund, SwedenAD  - Lund Univ, Dept Clin Sci, Lund, SwedenAD  - Kenya Revenue Author, Nairobi, KenyaAD  - Synotech Consultant, Res & Data Solut, Nairobi, KenyaAD  - Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USAAD  - Korea Univ, Dept Prevent Med, Seoul, South KoreaAD  - Xiamen Univ Malaysia, Sch Med, Sepang, MalaysiaAD  - Simmons Coll, Dept Nutr, Boston, MA 02115 USAAD  - Univ Canberra, Fac Hlth, Canberra, ACT, AustraliaAD  - Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, NorwayAD  - Univ Oslo, Inst Hlth & Soc, Oslo, NorwayAD  - Tulane Univ, Dept Global Community Hlth & Behav Sci, New Orleans, LA 70118 USAAD  - Jagiellonian Univ, Med Coll, Dept Hlth Econ & Social Secur, Krakow, PolandAD  - Jagiellonian Univ, Med Coll, Inst Publ Hlth, Krakow, PolandAD  - Univ Helsinki, Dept Publ Hlth, Helsinki, FinlandAD  - Univ Helsinki, Helsinki, FinlandAD  - Univ Bergen, Dept Psychosocial Sci, Bergen, NorwayAD  - Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, NorwayAD  - Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USAAD  - Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Suita, Osaka, JapanAD  - Arthrit Res Canada, Richmond, BC, CanadaAD  - Sheri Kashmir Inst Med Sci, Dept Internal & Pulm Med, Srinagar, Jammu & Kashmir, IndiaAD  - Res Ctr Neurol, Moscow, RussiaAD  - Panjab Univ, Dept Anthropol, Chandigarh, IndiaAD  - Univ Montreal, Dept Social & Prevent Med, Montreal, PQ, CanadaAD  - Univ Montreal, Dept Demog, Montreal, PQ, CanadaAD  - Yuksek Ihtisas Univ, Dept Publ Hlth, Ankara, TurkeyAD  - Hacettepe Univ, Dept Publ Hlth, Ankara, TurkeyAD  - Finnish Inst Occupat Hlth, Populat & Work Abil Program, Helsinki, FinlandAD  - Finnish Inst Occupat Hlth, Helsinki, FinlandAD  - Acad Med Sci, Dept Community & Family Med, Baghdad, IraqAD  - Acad Med Sci, Epidemiol, Baghdad, IraqAD  - HelpMeSee, New York, NY USAAD  - Municipal Hlth Dept Belo Horizonte, Belo Horizonte City Hall, Belo Horizonte, MG, BrazilAD  - Mexican Inst Ophthalmol, Relac Int, Queretaro, MexicoAD  - Maragheh Univ Med Sci, Dept Publ Hlth, Maragheh, IranAD  - Maragheh Univ Med Sci, Managerial Epidemiol Res Ctr, Maragheh, IranAD  - I M Sechenov First Moscow State Med Univ, Dept Informat & Internet Technol, Moscow, RussiaAD  - Minist Hlth FRIHOI, Fed Res Inst Hlth Org & Informat, Cent Res Inst Cytol & Genet, Moscow, RussiaAD  - Minist Hlth FRIHOI, Fed Res Inst Hlth Org & Informat, Moscow, RussiaAD  - Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Hong Kong, Peoples R ChinaAD  - Shenzhen Sun Yat Sen Cardiovasc Hosp, Dept Clin Res & Epidemiol, Shenzhen, Peoples R ChinaAD  - Natl Off Maternal & Child Hlth Surveillance, Chengdu, Sichuan, Peoples R ChinaAD  - Natl Ctr Birth Defects Monitoring China, Chengdu, Sichuan, Peoples R ChinaAD  - Univ Malaya, Dept Med, Kuala Lumpur, MalaysiaAD  - Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R ChinaAD  - Univ Haifa, Sch Publ Hlth, Haifa, IsraelAD  - Friedrich Schiller Univ Jena, Inst Nutr, Jena, GermanyAD  - Competence Cluster Nutr & Cardiovasc Hlth NUTRICA, Jena, GermanyAD  - Aintree Univ Hosp Natl Hlth Serv Fdn Trust NHS, Gen Surg Dept, Liverpool, Merseyside, EnglandAD  - Univ Liverpool, Surg Dept, Liverpool, Merseyside, EnglandAD  - Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, SingaporeAD  - Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, SingaporeAD  - Royal Childrens Hosp, Neurol Dept, Melbourne, Vic, AustraliaAD  - Royal Childrens Hosp, Cardiol Dept, Melbourne, Vic, AustraliaAD  - Damietta Univ, Cardiol, Dumyat, EgyptAD  - Aswan Fac Med, Ophthalmol Dept, Aswan, EgyptAD  - Grant Med Coll & Sir J J Grp Hosp, Dept Internal Med, Bombay, Maharashtra, IndiaAD  - Trnava Univ, Dept Publ Hlth, Trnava, SlovakiaAD  - Shiraz Univ Med Sci, Noncommunicable Dis Res Ctr, Shiraz, IranAD  - Emergency Univ Hosp Bucharest, Surg Dept, Bucharest, RomaniaAD  - Autonomous Technol Inst Mexico, Dept Econ, Mexico City, DF, MexicoAD  - Fed Inst Educ Sci & Technol Ceara, Campus Caucaia, Caucaia, BrazilAD  - Med Univ Graz, Clin Inst Med, Graz, AustriaAD  - Med Univ Graz, Chem Lab Diagnost, Graz, AustriaAD  - Univ East Ramon Magsaysay, Mem Med Ctr, Grad Sch, Quezon City, PhilippinesAD  - Indian Council Med Res, Natl Ctr Dis Informat & Res, Bengaluru, IndiaAD  - Indian Council Med Res, Reg Med Res Ctr, Bengaluru, IndiaAD  - Chalmers Univ Technol, Dept Biol & Biol Engn, Gothenburg, SwedenAD  - Hywel Dda Univ, Dept Ophthalmol, Hlth Board, Carmarthen, Dyfed, WalesAD  - Alaska Native Med Ctr, Liver Dis & Hepatitis Program, Anchorage, AK USAAD  - Ipas Nepal, Res Monitoring & Evaluat, Kathmandu, NepalAD  - Janakpuri Super Specialty Hosp Soc, Neurol Dept, New Delhi, IndiaAD  - Natl Inst Canc Prevent & Res, Prevent Oncol, Noida, IndiaAD  - Sevenhills Hosp, Dept Internal Med, Bombay, Maharashtra, IndiaAD  - Wollo Univ, Dept Publ Hlth, Dessie, EthiopiaAD  - Wollo Univ, Dept Pharm, Dessie, EthiopiaAD  - Debre Tabor Univ, Coll Hlth Sci, Debre Tabor, EthiopiaAD  - Univ West Florida, Dept Publ Hlth, Pensacola, FL 32514 USAAD  - United Nations Populat Fund UNFPA, Peru Country Off, Lima, PeruAD  - NIH, Ctr Translat Res & Implementat Sci, Bldg 10, Bethesda, MD 20892 USAAD  - Helsinki Univ Hosp, Neuroctr, Helsinki, FinlandAD  - Helsinki Univ Hosp, Breast Surg Unit, Helsinki, FinlandAD  - Clin Microbiol & Parasitol Unit, Zagreb, CroatiaAD  - Univ North, Univ Ctr Varazdin, Varazhdin, CroatiaAD  - Ethiopian Acad Med Sci, Dept Pharm, Mekelle, EthiopiaAD  - Pomeranian Med Univ, Dept Hypertens, Szczecin, PolandAD  - Pomeranian Med Univ, Zdroje Hosp, Szczecin, PolandAD  - Pomeranian Med Univ, Emergency Dept, Szczecin, PolandAD  - Pacific Inst Res & Evaluat, Calverton, MD USAAD  - Nevada Div Publ & Behav Hlth, Carson, CA USAAD  - Natl Inst Stat, Presidents Off, Bucharest, RomaniaAD  - Kyrgyz State Med Acad, Fac Gen Med, Bishkek, KyrgyzstanAD  - Natl Ctr Cardiol & Internal Dis, Dept Atherosclerosis & Coronary Heart Dis, Bishkek, KyrgyzstanAD  - Frankfurt Univ Appl Sci, Inst Addict Res ISFF, Frankfurt, GermanyAD  - Salahaddin Univ, Dept Biol, Erbil, IraqAD  - Ishik Univ, Erbil, IraqAD  - Isfahan Univ Med Sci, Cardiovasc Res Inst, Esfahan, IranAD  - Jigjiga Univ, Dept Publ Hlth, Jigjiga, EthiopiaAD  - Ahmadu Bello Univ, Hlth Syst & Policy Res Unit, Zaria, NigeriaAD  - Ahmadu Bello Univ, Dept Community Med, Zaria, NigeriaAD  - Madras Diabet Res Fdn, Dept Diabetol, Madras, Tamil Nadu, IndiaAD  - Burlo Garofolo Inst Maternal & Child Hlth, Clin Epidemiol & Publ Hlth Res Unit, Trieste, ItalyAD  - Kurdistan Univ Med Sci, Dept Epidemiol & Biostat, Sanandaj, IranAD  - Kurdistan Univ Med Sci, Social Determinants Hlth Res Ctr, Sanandaj, IranAD  - Univ Lancaster, Lancaster, EnglandAD  - Queensland Univ Technol, Int Lab Air Qual & Hlth, Brisbane, Qld, AustraliaAD  - Queensland Univ Technol, Australian Ctr Hlth Serv Innovat, Brisbane, Qld, AustraliaAD  - Queensland Univ Technol, Sch Exercise & Nutr Sci, Brisbane, Qld, AustraliaAD  - Santo Antonio Hosp, Hosp Ctr Porto, Porto, PortugalAD  - Univ Athens, Gen Hosp Athens, Dept Ophthalmol 1, Athens, GreeceAD  - Acad Athens, Biomed Res Fdn, Athens, GreeceAD  - Fed Inst Populat Res, Demog Change & Ageing Res Area, Wiesbaden, GermanyAD  - Fed Inst Populat Res, Competence Ctr Mortal Follow, Wiesbaden, GermanyAD  - Fed Inst Populat Res, Wiesbaden, GermanyAD  - Ctr Populat & Hlth, Wiesbaden, GermanyAD  - Inst Post Grad Med Educ & Res, Dept Endocrinol & Metab, Kolkata, IndiaAD  - Univ Jos, Dept Obstet & Gynecol, Jos, NigeriaAD  - Northwestern Univ, Ctr Global Hlth, Chicago, IL 60611 USAAD  - Northwestern Univ, Dept Preventat Med, Chicago, IL 60611 USAAD  - Sci Univ Malaysia, Sch Med Sci, Kubang Kerian, MalaysiaAD  - Nishtar Med Univ, Pediat Dept, Multan, PakistanAD  - Inst Mother & Child Care, Pediat & Pediat Pulmonol, Multan, PakistanAD  - Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USAAD  - Ulm Univ, Inst Epidemiol & Med Biometry, Ulm, GermanyAD  - Govt Med Coll Trivandrum, Dept Pulm Med, Trivandrum, Kerala, IndiaAD  - Hlth Act People, Trivandrum, Kerala, IndiaAD  - San Bortolo Hosp, Dept Dermatol, Vicenza, ItalyAD  - GISED Study Ctr, Direct, Bergamo, ItalyAD  - Chungnam Natl Univ, Sch Med, Dept Prevent Med & Publ Hlth, Daejeon, South KoreaAD  - Chungrtam Natl Univ Hosp, Daejeon Reg Canc Ctr, Daejeon, South KoreaAD  - Suraj Eye Inst, Ophthalmol, Nagpur, Maharashtra, IndiaAD  - Univ Yaounde I, Dept Publ Heath, Yaounde, CameroonAD  - Univ Yaounde I, Dept Internal Med & Specialties, Yaounde, CameroonAD  - Madras Med Coll & Govt Gen Hosp, Dept Nephrol, Madras, Tamil Nadu, IndiaAD  - Cardioaid, Dept Cardiol, Bucharest, RomaniaAD  - Kenya Govt Med Res Ctr, Welcome Trust Res Programme, Dept Neurosci, Kilifi, KenyaAD  - Minist Hlth Community Dev Gender Elderly & Childr, Dar Es Salaam, TanzaniaAD  - Univ Embu, Dept Biol Sci, Embu, KenyaAD  - Hanoi Sch Publ Hlth, Hanoi, VietnamAD  - State Univ Semarang, Publ Hlth Sci Dept, Kota Semarang, IndonesiaAD  - South African Embassy, Natl Dept Hlth, Pretoria, South AfricaAD  - Natl Ctr Global Hlth & Med, Inst Global Hlth Policy Res, Shinjuku Ku, Tokyo, JapanAD  - Univ Social Welf & Rehabil Sci, Tehran, IranAD  - Kyung Hee Univ, Dept Prevent Med, Seoul, South KoreaAD  - Human Sci Res Council, Dept HIV AIDS STIs & TB, Durban, South AfricaAD  - Univ Namibia, Sch Publ Hlth, Oshakati Campus, Oshakati, NamibiaAD  - Univ Lagos, Dept Psychiat, Lagos, NigeriaAD  - Ctr Hlth Start Initiat, Ikoyi, NigeriaAD  - Univ Brunei Darussalam, Inst Hlth Sci, Gadong, BruneiAD  - San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USAAD  - Univ Ottawa, Sch Psychol, Ottawa, ON, CanadaAD  - Autonomous Univ Madrid, Sch Med, Madrid, SpainAD  - Autonomous Univ Madrid, Pneumol Serv, Madrid, SpainAD  - Jimenez Diaz Univ Hosp, Inst Hlth Res Fdn, Hypertens & Nephrol Dept, Madrid, SpainAD  - Univ Maryland, Ctr Vaccine Dev, Baltimore, MD 21201 USAAD  - Univ Maryland, Sch Med, Baltimore, MD 21201 USAAD  - Minist Hlth Russian Federat, Ctr Healthcare Qual Assessment & Control, Moscow, RussiaAD  - Moscow MV Lomonosov State Univ, Moscow Inst Phys & Technol, Dolgoprudnyi, RussiaAD  - Karabuk Univ, Occupat Hlth & Safety Dept, Karabuk, TurkeyAD  - Jagadguru Sri Shivarathreeswara Univ, Dept TB & Resp Med, Mysore, Karnataka, IndiaAD  - Univ Chichester, Chichester, EnglandAD  - Univ Ottowa, Dept Med, Ottawa, ON, CanadaAD  - Ctr Hlth Outcomes & Evaluat, Bucharest, RomaniaAD  - Kosin Univ, Dept Med Humanities & Social Med, Pusan, South KoreaAD  - Maimonides Hosp, Dept Med, Brooklyn, NY 11219 USAAD  - Diabet Res Soc, Clin Res Dept, Hyderabad, IndiaAD  - Diabetomics, Clin Res Dept, Portland, OR USAAD  - Cartagena Univ, Cartagena, ColombiaAD  - Univ Gothenburg, Inst Med, Gothenburg, SwedenAD  - Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South AfricaAD  - Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Shanghai, Peoples R ChinaAD  - Durban Univ Technol, Basic Med Sci Dept, Durban, South AfricaAD  - Univ Groningen, Univ Med Ctr Groningen, Groningen, NetherlandsAD  - Sanjay Gandhi Postgrad Inst Med Sci, Dept Nephrol, Lucknow, Uttar Pradesh, IndiaAD  - Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, IranAD  - Drexel Univ, Dept Environm & Occupat Hlth, Philadelphia, PA 19104 USAAD  - Medichem, Barcelona, SpainAD  - Contech Sch Publ Hlth, Epidemiol & Biostat, Lahore, PakistanAD  - Soc Hlth & Demog Surveillance, Suri, IndiaAD  - Univ Gottingen, Dept Econ, Gottingen, GermanyAD  - Med Univ Innsbruck, Innsbruck, AustriaAD  - Yonsei Univ, Inst Poverty Alleviat & Int Dev, Kathmandu, NepalAD  - Univ Coll London Hosp, London, EnglandAD  - Publ Hlth England, London, EnglandAD  - Brien Holden Vis Inst, Sydney, NSW, AustraliaAD  - Org Prevent Blindness, Paris, FranceAD  - Birjand Univ Med Sci, Dept Epidemiol, Birjand, IranAD  - Univ Fed Uberlandia, Dept Clin Res, Uberlandia, MG, BrazilAD  - Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, IranAD  - Ikiam Amazon Reg Univ, Biotechnol, Ciudad De Tena, EcuadorAD  - Southern Univ Sci & Technol, Dept Ocean Sci & Engn, Shenzhen, Peoples R ChinaAD  - Prince Wales Hosp, Neuropsychiat Inst, Randwick, NSW, AustraliaAD  - Univ Sharjah, Med Dept, Sharjah, U Arab EmiratesAD  - Mashhad Univ Med Sci, Dept Med Biotechnol, Mashhad, IranAD  - Al Imam Mohammad Ibn Saud Islamic Univ, Coll Med, Riyadh, Saudi ArabiaAD  - York Univ, Fac Hlth, Sch Hlth & Policy Management, Toronto, ON, CanadaAD  - Fundacao Oswaldo Cruz, Inst Sci & Technol Commun & Informat Hlth, Rio De Janeiro, BrazilAD  - Punjab Univ, Coll Pharm, Anarkali, PakistanAD  - Chest Res Fdn, Clin Res Div, Pune, Maharashtra, IndiaAD  - Ain Shams Univ, Dept Entomol, Cairo, EgyptAD  - Marshall Univ, Dept Surg, Huntington, WV USAAD  - Case Western Reserve Univ, Dept Nutr & Prevent Med, Cleveland, OH 44106 USAAD  - Jimenez Diaz Fdn Univ Hosp, Inst Hlth Res, Nephrol Grp, Madrid, SpainAD  - Reg Hlth Adm Do Norte IP, Dept Publ Hlth, Vila Nova De Gaia, PortugalAD  - Univ Appl & Environm Sci, Dept Hlth & Soc, Fac Med, Bogota, ColombiaAD  - Univ Kwazulu Natal, Dept Publ Hlth Med, Durban, South AfricaAD  - Hamad Med Corp, Surg Dept, Doha, QatarAD  - Bournemouth Univ, Fac Hlth & Social Sci, Bournemouth, Dorset, EnglandAD  - Utkal Univ, UGC Ctr Adv Study Psychol, Bhubaneswar, IndiaAD  - Udyam Global Assoc Sustainable Dev, Bhubaneswar, IndiaAD  - Univ N Carolina, Dept Publ Hlth Sci, Charlotte, NC USAAD  - Univ Fed Santa Catarina, Sch Hlth Sci, Ararangua, BrazilAD  - North West Univ, HART, Potchefstroom, South AfricaAD  - Univ Zagreb, Dept Med Stat Epidemiol & Med Informat, Zagreb, CroatiaAD  - Croatian Inst Publ Hlth, Div Epidemiol & Prevent Chron Noncommunicable Dis, Zagreb, CroatiaAD  - NYU, Langone Med Ctr, New York, NY USAAD  - NYU, Inst Environm Med, 550 1St Ave, New York, NY 10016 USAAD  - An Najah Natl Univ, Publ Hlth Div, Nablus, PalestineAD  - Islamic Azad Univ, Dept Lab Sci, Sari, IranAD  - Islamic Azad Univ, Dept Basic Sci, Sari, IranAD  - Delhi Technol Univ, Univ Sch Management & Entrepreneurship, New Delhi, IndiaAD  - Fudan Univ, Dept Pulm Med, Shanghai, Peoples R ChinaAD  - Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, ScotlandAD  - Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USAAD  - Natl Inst Infect Dis, Tokyo, JapanAD  - Martin Luther Univ Halle Wittenberg, Inst Med Epidemiol, Halle, GermanyAD  - Univ Technol Sydney, Sch Hlth, Sydney, NSW, AustraliaAD  - Reykjavik Univ, Dept Psychol, Reykjavik, IcelandAD  - Univ Penn, Dept Neurol, Philadelphia, PA 19104 USAAD  - Portuguese Inst Sport & Youth, Lisbon, PortugalAD  - Brasilia Univ, Brasilia, DF, BrazilAD  - Max Hosp, Ghaziabad, IndiaAD  - Sch Adv Studies TERI, Energy & Resources Inst, Dept Policy Studies, New Delhi, IndiaAD  - Asthma Bhawan, Dept Pulm Med, Jaipur, Rajasthan, IndiaAD  - Sch Prevent Oncol, Epidemiol, Patna, Bihar, IndiaAD  - King Khalid Univ Hosp, Pediat Dept, Riyadh, Saudi ArabiaAD  - Yaounde Cent Hosp, Dept Endocrinol & Diabet, Yaounde, CameroonAD  - Dartmouth Coll, Dartmouth Inst Hlth Policy, 1 Med Ctr Dr, Lebanon, NH 03756 USAAD  - Univ Hosp La Princesa, Hlth Res Inst, Serv Pulmonol, Madrid, SpainAD  - Univ Western Ontario, Clin Neurol Sci, London, ON, CanadaAD  - Int Med Univ, Div Community Med, Kuala Lumpur, MalaysiaAD  - Athens Univ Appl Sci, Dept Occupat Therapy, Athens, GreeceAD  - Muhammadiyah Univ Surakarta, Dept Nursing, Kartasura, IndonesiaAD  - Univ Calif Riverside, Sch Med, Riverside, CA 92521 USAAD  - Univ Calif Irvine, Dept Criminol Law & Soc, Irvine, CA USAAD  - Univ Valencia, Dept Med, Valencia, SpainAD  - Univ Valencia, Dept Pediat Obstet & Gynecol, Valencia, SpainAD  - Carlos III Hlth Inst, Biomed Res Networking Ctr Mental Hlth Network CIB, Madrid, SpainAD  - Osaka Int Canc Inst, Canc Control Ctr, Osaka, JapanAD  - Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast, Qld, AustraliaAD  - Asbestos Dis Res Inst, Sydney, NSW, AustraliaAD  - Univ Inst Egas Moniz, Monte De Caparica, PortugalAD  - Univ Lisbon, Res Inst Med, Fac Pharm Lisbon, Lisbon, PortugalAD  - Univ Virginia, Anesthesiol Dept, Charlottesville, VA USAAD  - SEMA, Charlottesville, VA USAAD  - Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, SingaporeAD  - Natl Ctr Child Hlth & Dev, Dept Hlth Policy, Tokyo, JapanAD  - Univ Calgary, Dept Med, Calgary, AB, CanadaAD  - Agcy Hlth Technol Assessment & Tariff Syst, Warsaw, PolandAD  - Univ Hosp Doctor Peset, Pediat Dept, Valencia, SpainAD  - Natl Inst Hlth & Med Res, Nutr Epidemiol Res Team, Paris, FranceAD  - Hanoi Med Univ, Dept Hlth Econ, Hanoi, VietnamAD  - Mil Med Univ, Clin Hematol & Toxicol, Hanoi, VietnamAD  - King Georges Med Univ, Lucknow, Uttar Pradesh, IndiaAD  - Cleveland Clin, CV Med, Cleveland, OH 44106 USAAD  - Cleveland Clin Abu Dhabi, Abu Dhabi, U Arab EmiratesAD  - Fed Teaching Hosp, Dept Internal Med, Abakaliki, NigeriaAD  - Goma Univ, Gomal Ctr Biochem & Biotechnol, Dera Ismail Khan, PakistanAD  - Mufti Mehmood Mem Teaching Hosp, TB Culture Lab, Dera Ismail Khan, PakistanAD  - Pontificia Univ Catolica Chile, Sch Govt, Santiago, ChileAD  - Brandeis Univ, Schneider Inst Hlth Policy, Waltham, MA USAAD  - Ankara Univ, Ankara, TurkeyAD  - Univ Louisville, Div Cardiovasc Med, Louisville, KY 40292 USAAD  - Argentine Soc Med, Buenos Aires, DF, ArgentinaAD  - Velez Sarstield Hosp, Buenos Aires, DF, ArgentinaAD  - UKK Inst, Tampere, FinlandAD  - Raffles Hosp, Raffles Neurosci Ctr, Singapore, SingaporeAD  - Univ Extremadura, Sport Sci Dept, Caceres, SpainAD  - Univ Bologna, Dept Med & Surg Sci, Bologna, ItalyAD  - St Orsola Malpighi Hosp, Occupat Hlth Unit, Bologna, ItalyAD  - Natl Res Univ, Higher Sch Econ, Dept Hlth Care Management & Econ, Moscow, RussiaAD  - Fdn Univ, Med Coll, Rawalpindi, PakistanAD  - George Washington Univ, Dept Neurol, Washington, DC USAAD  - Canc Registry Norway, Dept Res, Oslo, NorwayAD  - Tech Univ Munich, Dept Neurol, Munich, GermanyAD  - Kailuan Gen Hosp, Tangshan, Peoples R ChinaAD  - Univ Strathclyde, Glasgow, Lanark, ScotlandAD  - St Johns Natl Acad Hlth Sci, Dept Pharmacol, Bangalore, Karnataka, IndiaAD  - Nanjing Univ, Sch Med, Nanjing, Jiangsu, Peoples R ChinaAD  - Milad Gen Hosp, Clin Canc Res Ctr, Tehran, IranAD  - Duke Kunshan Univ, Global Hlth Res Ctr, Kunshan, Peoples R ChinaAD  - King Fand Univ Petr & Minerals, Dept Earth Sci, Dhahran, Saudi ArabiaAD  - Wolkite Univ, Wolkite, EthiopiaAD  - Univ South Australia, Adelaide, NSW, AustraliaAD  - Kyoto Univ, Dept Biostat, Kyoto, JapanAD  - Univ Kinshasa, Sch Publ Hlth, Kinshasa, DEM REP CONGOAD  - Jackson State Univ, Dept Hlth Policy & Management, Jackson, MS USAAD  - Tsinghua Univ, Beijing, Peoples R ChinaAD  - Wuhan Univ, Global Hlth Inst, Wuhan, Hubei, Peoples R ChinaAD  - Wuhan Univ, Dept Epidemiol & Biostat, Wuhan, Hubei, Peoples R ChinaAD  - Inst Oncol Ljubljana, Epidemiol & Canc Registry Sect, Ljubljana, SloveniaAD  - Univ Hosp Setif, Dept Epidemiol, Setif, AlgeriaAD  - Univ Texas Houston, Dept Epidemiol Human Genet & Environm Sci, Houston, TX USAAD  - Chinese Ctr Dis Control & Prevent, Noncommunicable Dis Control & Prevent Ctr, Beijing, Peoples R ChinaC3  - University of WashingtonC3  - University of Washington SeattleC3  - Institute for Health Metrics & EvaluationC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Sapienza University RomeC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - McGill UniversityC3  - McGill UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Manonmaniam Sundaranar UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University HohenheimC3  - Qatar Foundation (QF)C3  - Weill Cornell Medical College QatarC3  - Dongguk UniversityC3  - Stellenbosch UniversityC3  - Stellenbosch UniversityC3  - Stellenbosch UniversityC3  - South African Medical Research CouncilC3  - South African Medical Research CouncilC3  - South African Medical Research CouncilC3  - South African Medical Research CouncilC3  - University of IbadanC3  - University College Hospital, IbadanC3  - Obafemi Awolowo UniversityC3  - Cardiff UniversityC3  - McMaster UniversityC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Baylor College of MedicineC3  - Baylor College of MedicineC3  - Public Health Foundation of IndiaC3  - Public Health Foundation of IndiaC3  - Public Health Foundation of IndiaC3  - Public Health Foundation of IndiaC3  - Public Health Foundation of IndiaC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Universite Ferhat Abbas SetifC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - University of IbadanC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - University of TorontoC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - Washington University (WUSTL)C3  - King Saud UniversityC3  - King Saud UniversityC3  - King Saud UniversityC3  - King Abdulaziz UniversityC3  - Mayo ClinicC3  - University of Western AustraliaC3  - University of Western AustraliaC3  - Australian National UniversityC3  - Australian National UniversityC3  - Qazvin University of Medical Sciences (QUMS)C3  - Qazvin University of Medical Sciences (QUMS)C3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Kuwait UniversityC3  - Luxembourg Institute of HealthC3  - Universite de BordeauxC3  - Hospital del Mar Research InstituteC3  - Hospital del MarC3  - Pompeu Fabra UniversityC3  - Universidad de CartagenaC3  - Universidad de CartagenaC3  - Universidad de la CostaC3  - South Australian Health & Medical Research Institute (SAHMRI)C3  - South Australian Health & Medical Research Institute (SAHMRI)C3  - Bahir Dar UniversityC3  - Bahir Dar UniversityC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - American University of BeirutC3  - Kwame Nkrumah University Science & TechnologyC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - University of ThessalyC3  - Arba Minch UniversityC3  - Arba Minch UniversityC3  - Arba Minch UniversityC3  - Zahedan University of Medical SciencesC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - Birmingham City UniversityC3  - Dalarna UniversityC3  - Western Sydney UniversityC3  - Western Sydney UniversityC3  - Western Sydney UniversityC3  - Sydney Local Health DistrictC3  - University of ManitobaC3  - University of LahoreC3  - University Ha'ilC3  - University Ha'ilC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Dr DY Patil Vidyapeeth PuneC3  - Dr D Y Patil Medical College, Hospital & Research CentreC3  - Dr DY Patil Vidyapeeth PuneC3  - University of LeicesterC3  - University of LeicesterC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - Instituto Nacional de Salud - PeruC3  - University of TokyoC3  - University of TokyoC3  - Burnet InstituteC3  - University of Management & Technology (UMT)C3  - University of Management & Technology (UMT)C3  - Public Health Agency of CanadaC3  - Public Health Agency of CanadaC3  - Medical University LodzC3  - Polish Mother's Memorial Hospital - Research InstituteC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - Egyptian Knowledge Bank (EKB)C3  - Alexandria UniversityC3  - Universidad Costa RicaC3  - Universidad Costa RicaC3  - University of AucklandC3  - University of AucklandC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard T.H. Chan School of Public HealthC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - ISGlobalC3  - ISGlobalC3  - Centro de Investigacao em Saude de ManhicaC3  - Centro de Investigacao em Saude de ManhicaC3  - Stanford UniversityC3  - Charles R. Drew University of Medicine & ScienceC3  - University of California SystemC3  - University of California Los AngelesC3  - Jazan UniversityC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Lorestan University of Medical SciencesC3  - Lorestan University of Medical SciencesC3  - CHU Dijon BourgogneC3  - Universite de BourgogneC3  - Yale UniversityC3  - Yale UniversityC3  - University of AlbertaC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - University System of GeorgiaC3  - Augusta UniversityC3  - University of LondonC3  - London School Economics & Political ScienceC3  - University of LondonC3  - London School Economics & Political ScienceC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - Emory UniversityC3  - Emory UniversityC3  - Rollins School Public HealthC3  - State University System of FloridaC3  - University of South FloridaC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - Nepal Academy of Science & Technology (NAST)C3  - Aga Khan UniversityC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Imperial College LondonC3  - Imperial College LondonC3  - Imperial College LondonC3  - Imperial College LondonC3  - Imperial College LondonC3  - Imperial College LondonC3  - University of DhakaC3  - Research Triangle InstituteC3  - University of NottinghamC3  - Ministry of Health - TurkeyC3  - Ministry of Health - TurkeyC3  - Ministry of Health - TurkeyC3  - Ministry of Health - TurkeyC3  - Ministry of Health - TurkeyC3  - Ministry of Health - TurkeyC3  - Ministry of Health - TurkeyC3  - Ministry of Health - TurkeyC3  - Murdoch Children's Research InstituteC3  - Murdoch Children's Research InstituteC3  - Murdoch Children's Research InstituteC3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - Ruprecht Karls University HeidelbergC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - University of CambridgeC3  - University of CambridgeC3  - Comenius University BratislavaC3  - University System of OhioC3  - Ohio State UniversityC3  - University System of OhioC3  - Ohio State UniversityC3  - University System of OhioC3  - Ohio State UniversityC3  - Helmholtz AssociationC3  - German Cancer Research Center (DKFZ)C3  - Instituto Conmemorativo Gorgas de Estudios de la SaludC3  - Instituto Conmemorativo Gorgas de Estudios de la SaludC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - University of British ColumbiaC3  - University of British ColumbiaC3  - Universidad Autonoma Metropolitana - MexicoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do PortoC3  - Universidad Nacional de ColombiaC3  - Universidad Nacional de ColombiaC3  - Portuguese Institute of OncologyC3  - Australian Catholic UniversityC3  - Australian Catholic UniversityC3  - Australian Catholic UniversityC3  - University of Hong KongC3  - University of Hong KongC3  - Alfaisal UniversityC3  - National Taiwan UniversityC3  - National Taiwan UniversityC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalC3  - University of Occupational & Environmental Health - JapanC3  - University of ZambiaC3  - University of WitwatersrandC3  - University of CopenhagenC3  - University of CopenhagenC3  - Bispebjerg HospitalC3  - University of CopenhagenC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - Monash UniversityC3  - Monash UniversityC3  - Monash UniversityC3  - University of AdelaideC3  - University of AdelaideC3  - University of AdelaideC3  - University of SalernoC3  - Health Effects Institute (HEI)C3  - Mayo ClinicC3  - University of BaselC3  - Swiss Tropical & Public Health InstituteC3  - University of BaselC3  - Swiss Tropical & Public Health InstituteC3  - University of Milano-BicoccaC3  - Universidade Federal do Rio Grande do SulC3  - University of MelbourneC3  - Peter Doherty InstituteC3  - University of MelbourneC3  - Peter Doherty InstituteC3  - University of MelbourneC3  - Peter Doherty InstituteC3  - University of California SystemC3  - University of California San DiegoC3  - University of OtagoC3  - Duke UniversityC3  - Duke UniversityC3  - Duke UniversityC3  - Hawassa UniversityC3  - Hawassa UniversityC3  - Flinders University South AustraliaC3  - Duy Tan UniversityC3  - Guy's & St Thomas' NHS Foundation TrustC3  - Guy's & St Thomas' NHS Foundation TrustC3  - King George's Medical UniversityC3  - Bangladesh Rural Advancement Committee BRACC3  - BRAC UniversityC3  - Bangladesh Rural Advancement Committee BRACC3  - BRAC UniversityC3  - Central University of Tamil NaduC3  - Asfendiyarov Kazakh National Medical UniversityC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - African Population & Health Research CentreC3  - University of SussexC3  - University of BrightonC3  - NHS National Services ScotlandC3  - Aristotle University of ThessalonikiC3  - Icahn School of Medicine at Mount SinaiC3  - Icahn School of Medicine at Mount SinaiC3  - University of PeradeniyaC3  - Swedish Medical CenterC3  - Ministry of Health & Medical Education (MOHME)C3  - Ministry of Health & Medical Education (MOHME)C3  - Ministry of Health & Medical Education (MOHME)C3  - Ministry of Health & Medical Education (MOHME)C3  - Medical University VarnaC3  - University of Cape CoastC3  - Tampere UniversityC3  - University of RochesterC3  - Royal Melbourne Institute of Technology (RMIT)C3  - Royal Melbourne Institute of Technology (RMIT)C3  - University of SydneyC3  - University of SydneyC3  - Asbestos Diseases Research InstituteC3  - University of SydneyC3  - University of SydneyC3  - Woolcock Institute of Medical ResearchC3  - University of SydneyC3  - University of BelgradeC3  - University of BelgradeC3  - Universidade Federal da BahiaC3  - Umea UniversityC3  - UiT The Arctic University of TromsoC3  - University of TripoliC3  - World Health OrganizationC3  - World Health OrganizationC3  - Stavanger University HospitalC3  - Norwegian Institute of Public Health (NIPH)C3  - Norwegian Institute of Public Health (NIPH)C3  - Norwegian Institute of Public Health (NIPH)C3  - Queensland Centre for Mental Health ResearchC3  - Queensland Centre for Mental Health ResearchC3  - Queensland Centre for Mental Health ResearchC3  - Urmia University of Medical SciencesC3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - Universidade Federal de SergipeC3  - Auckland University of TechnologyC3  - Organisation for Economic Co-operation & Development (OECD)C3  - Universidade Catolica PortuguesaC3  - Kaiser PermanenteC3  - Kaiser PermanenteC3  - University of BielefeldC3  - National Academy of Medical Sciences of UkraineC3  - D. F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of UkraineC3  - Kobe UniversityC3  - University of BaselC3  - Universidad Autonoma de ChileC3  - Universidad Autonoma de ChileC3  - Curtin UniversityC3  - Wageningen University & ResearchC3  - University of TsukubaC3  - Melbourne HealthC3  - Royal Melbourne HospitalC3  - University of WarwickC3  - University of WarwickC3  - Howard UniversityC3  - Howard UniversityC3  - Universite de BourgogneC3  - Jawaharlal Nehru University, New DelhiC3  - University of Massachusetts SystemC3  - University of Massachusetts BostonC3  - University of Oklahoma SystemC3  - University of Oklahoma Health Sciences CenterC3  - National Cancer Center - JapanC3  - Boston UniversityC3  - Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele Presidio FerraottoC3  - Universidade Estadual de Montes ClarosC3  - West Virginia UniversityC3  - Eternal Heart Care Centre & Research InstituteC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Yeshiva UniversityC3  - Yeshiva UniversityC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Instituto Nacional de Psiquiatria Ramon de la Fuente MunizC3  - Aarhus UniversityC3  - Aarhus UniversityC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - Arabian Gulf UniversityC3  - University of New MexicoC3  - Sir Charles Gairdner HospitalC3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - University of BarcelonaC3  - University of BarcelonaC3  - Tabriz University of Medical ScienceC3  - Tabriz University of Medical ScienceC3  - University of AntwerpC3  - Karolinska InstitutetC3  - Karolinska University HospitalC3  - Bucharest University of Economic StudiesC3  - Bucharest University of Economic StudiesC3  - University of GroningenC3  - Columbia UniversityC3  - Columbia UniversityC3  - University of Texas SystemC3  - University of Texas AustinC3  - Manipal Academy of Higher Education (MAHE)C3  - Central South UniversityC3  - Birzeit UniversityC3  - Qatar UniversityC3  - Bashkir State Medical UniversityC3  - Taipei Medical UniversityC3  - Taipei Medical UniversityC3  - Deakin UniversityC3  - Deakin UniversityC3  - Deakin UniversityC3  - American Cancer SocietyC3  - George Mason UniversityC3  - Tabriz University of Medical ScienceC3  - University of KragujevacC3  - Newcastle University - UKC3  - University of ColomboC3  - University of ColomboC3  - Harvard UniversityC3  - Boston Children's HospitalC3  - Banaras Hindu University (BHU)C3  - Capital Medical UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Technical University CzestochowaC3  - University of OpoleC3  - Savitribai Phule Pune UniversityC3  - University of TartuC3  - University College CorkC3  - Hamadan University of Medical SciencesC3  - Hamadan University of Medical SciencesC3  - Hamadan University of Medical SciencesC3  - Hamadan University of Medical SciencesC3  - Helmholtz AssociationC3  - Helmholtz-Center for Infection ResearchC3  - Baqiyatallah University of Medical Sciences (BMSU)C3  - Baqiyatallah University of Medical Sciences (BMSU)C3  - Seattle Children's HospitalC3  - MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNITC3  - University of GlasgowC3  - University of TulsaC3  - University of California SystemC3  - University of California San FranciscoC3  - University of California SystemC3  - University of California San FranciscoC3  - University of NairobiC3  - University of NairobiC3  - Michigan State UniversityC3  - University of Cape TownC3  - University of Cape TownC3  - University of Cape TownC3  - University of Cape TownC3  - Hebrew University of JerusalemC3  - Hadassah University Medical CenterC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Indian Institute of Toxicology Research (IITR)C3  - Jordan University of Science & TechnologyC3  - Health Services AcademyC3  - University of Illinois SystemC3  - University of Illinois ChicagoC3  - University of Illinois Chicago HospitalC3  - John H Stroger Junior Hospital Cook CountyC3  - Dow University of Health SciencesC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Tennessee SystemC3  - University of Tennessee KnoxvilleC3  - Seoul National University (SNU)C3  - Seoul National University (SNU)C3  - Ball State UniversityC3  - Lund UniversityC3  - Lund UniversityC3  - Northeastern UniversityC3  - Korea UniversityC3  - Xiamen University Malaysia CampusC3  - Simmons UniversityC3  - University of CanberraC3  - University of OsloC3  - University of OsloC3  - Tulane UniversityC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - University of HelsinkiC3  - University of HelsinkiC3  - University of BergenC3  - University of BergenC3  - Fred Hutchinson Cancer CenterC3  - National Cerebral & Cardiovascular Center - JapanC3  - Arthritis Research CanadaC3  - Sher-i-Kashmir Institute of Medical SciencesC3  - Research Center of NeurologyC3  - Panjab UniversityC3  - Universite de MontrealC3  - Universite de MontrealC3  - Yuksek Ihtisas UniversityC3  - Hacettepe UniversityC3  - Finnish Institute of Occupational HealthC3  - Finnish Institute of Occupational HealthC3  - Sechenov First Moscow State Medical UniversityC3  - Hong Kong Polytechnic UniversityC3  - Shenzhen Sun Yatsen Cardiovascular HospitalC3  - Universiti MalayaC3  - Chinese University of Hong KongC3  - University of HaifaC3  - Friedrich Schiller University of JenaC3  - University of LiverpoolC3  - National University of SingaporeC3  - National University of SingaporeC3  - Royal Children's Hospital MelbourneC3  - Royal Children's Hospital MelbourneC3  - Egyptian Knowledge Bank (EKB)C3  - Damietta UniversityC3  - University of TrnavaC3  - Shiraz University of Medical ScienceC3  - Instituto Tecnologico Autonomo de MexicoC3  - Instituto Federal do Ceara (IFCE)C3  - Medical University of GrazC3  - Medical University of GrazC3  - UERM Memorial Medical CenterC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Centre for Disease Informatics & Research (NCDIR)C3  - Indian Council of Medical Research (ICMR)C3  - Chalmers University of TechnologyC3  - Alaska Native Medical CenterC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Cancer Prevention & Research (NICPR)C3  - State University System of FloridaC3  - University of West FloridaC3  - National Institutes of Health (NIH) - USAC3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - University North - CroatiaC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pacific Institute for Research & Evaluation (PIRE)C3  - Ministry of Health - KyrgyzstanC3  - Kyrgyz State Medical AcademyC3  - Salahaddin UniversityC3  - Isfahan University of Medical SciencesC3  - Ahmadu Bello UniversityC3  - Ahmadu Bello UniversityC3  - Madras Diabetes Research FoundationC3  - IRCCS Burlo GarofoloC3  - Kurdistan University of Medical SciencesC3  - Kurdistan University of Medical SciencesC3  - Lancaster UniversityC3  - Queensland University of Technology (QUT)C3  - Queensland University of Technology (QUT)C3  - Queensland University of Technology (QUT)C3  - National & Kapodistrian University of AthensC3  - General Hospital of N. Ionia Agia OlgaC3  - Academy of AthensC3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataC3  - University of JosC3  - Northwestern UniversityC3  - Northwestern UniversityC3  - Universiti Sains MalaysiaC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - Ulm UniversityC3  - ULSS 8 BericaC3  - Ospedale San Bortolo di VicenzaC3  - Chungnam National UniversityC3  - Suraj Eye InstituteC3  - University of Yaounde IC3  - University of Yaounde IC3  - Madras Medical College & General HospitalC3  - Kenya Medical Research InstituteC3  - Hanoi University of Public HealthC3  - Universitas Negeri SemarangC3  - National Center for Global Health & Medicine - JapanC3  - Kyung Hee UniversityC3  - Human Sciences Research Council-South AfricaC3  - University of NamibiaC3  - University of LagosC3  - University Brunei DarussalamC3  - California State University SystemC3  - San Diego State UniversityC3  - University of OttawaC3  - Autonomous University of MadridC3  - Autonomous University of MadridC3  - University System of MarylandC3  - University of Maryland BaltimoreC3  - University System of MarylandC3  - University of Maryland BaltimoreC3  - Ministry of Health of the Russian FederationC3  - Moscow Institute of Physics & TechnologyC3  - Lomonosov Moscow State UniversityC3  - Karabuk UniversityC3  - JSS Academy of Higher Education & ResearchC3  - University of ChichesterC3  - University of OttawaC3  - Maimonides Medical CenterC3  - Universidad de CartagenaC3  - University of GothenburgC3  - University of WitwatersrandC3  - Shanghai Jiao Tong UniversityC3  - Durban University of TechnologyC3  - University of GroningenC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - Drexel UniversityC3  - University of GottingenC3  - Medical University of InnsbruckC3  - University College London Hospitals NHS Foundation TrustC3  - University of LondonC3  - University College LondonC3  - Public Health EnglandC3  - Brien Holden Vision InstituteC3  - Universidade Federal de UberlandiaC3  - Golestan University of Medical SciencesC3  - Southern University of Science & TechnologyC3  - University of New South Wales SydneyC3  - Prince of Wales Hospital (POWH)C3  - University of SharjahC3  - Mashhad University of Medical SciencesC3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - York University - CanadaC3  - Fundacao Oswaldo CruzC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - Marshall UniversityC3  - University System of OhioC3  - Case Western Reserve UniversityC3  - University of Kwazulu NatalC3  - Hamad Medical CorporationC3  - Bournemouth UniversityC3  - Utkal UniversityC3  - University of North CarolinaC3  - University of North Carolina CharlotteC3  - Universidade Federal de Santa Catarina (UFSC)C3  - North West University - South AfricaC3  - University of ZagrebC3  - NYU Langone Medical CenterC3  - New York UniversityC3  - New York UniversityC3  - An Najah National UniversityC3  - Islamic Azad UniversityC3  - Islamic Azad UniversityC3  - Delhi Technological UniversityC3  - Fudan UniversityC3  - University of EdinburghC3  - Tufts UniversityC3  - National Institute of Infectious Diseases (NIID)C3  - Martin Luther University Halle WittenbergC3  - University of Technology SydneyC3  - Reykjavik UniversityC3  - University of PennsylvaniaC3  - Universidade de BrasiliaC3  - TERI UniversityC3  - King Saud UniversityC3  - King Khalid University HospitalC3  - Dartmouth CollegeC3  - Western University (University of Western Ontario)C3  - International Medical University MalaysiaC3  - University of West AtticaC3  - Universitas Muhammadiyah SurakartaC3  - University of California SystemC3  - University of California RiversideC3  - University of California SystemC3  - University of California IrvineC3  - University of ValenciaC3  - University of ValenciaC3  - Griffith UniversityC3  - Griffith University - Gold Coast CampusC3  - Menzies Health Institute QueenslandC3  - Asbestos Diseases Research InstituteC3  - Universidade de LisboaC3  - University of VirginiaC3  - Nanyang Technological UniversityC3  - National Center for Child Health & Development - JapanC3  - University of CalgaryC3  - Institut National de la Sante et de la Recherche Medicale (Inserm)C3  - Hanoi Medical UniversityC3  - King George's Medical UniversityC3  - Cleveland Clinic FoundationC3  - Cleveland Clinic FoundationC3  - Pontificia Universidad Catolica de ChileC3  - Brandeis UniversityC3  - Ankara UniversityC3  - University of LouisvilleC3  - UKK InstituteC3  - Raffles HospitalC3  - Universidad de ExtremaduraC3  - University of BolognaC3  - IRCCS Azienda Ospedaliero-Universitaria di BolognaC3  - HSE University (National Research University Higher School of Economics)C3  - George Washington UniversityC3  - University of OsloC3  - Technical University of MunichC3  - University of StrathclydeC3  - St. John's National Academy of Health SciencesC3  - Nanjing UniversityC3  - Duke Kunshan UniversityC3  - King Fahd University of Petroleum & MineralsC3  - University of South AustraliaC3  - Kyoto UniversityC3  - Universite de KinshasaC3  - Jackson State UniversityC3  - Tsinghua UniversityC3  - Wuhan UniversityC3  - Wuhan UniversityC3  - Institute of Oncology - SloveniaC3  - University of Texas SystemC3  - University of Texas Health Science Center HoustonC3  - Chinese Center for Disease Control & PreventionPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - NOV 10
PY  - 2018
VL  - 392
IS  - 10159
SP  - 1736
EP  - 1788
DO  - 10.1016/S0140-6736(18)32203-7
AN  - WOS:000449710900004
ER  -

TY  - JOUR
AU  - Stanaway, JD
AU  - Afshin, A
AU  - Gakidou, E
AU  - Lim, SS
AU  - Abate, D
AU  - Abate, KH
AU  - Abbafati, C
AU  - Abbasi, N
AU  - Abbastabar, H
AU  - Abd-Allah, F
AU  - Abdela, J
AU  - Abdelalim, A
AU  - Abdollahpour, I
AU  - Abdulkader, RS
AU  - Abebe, M
AU  - Abebe, Z
AU  - Abera, SF
AU  - Abil, OZ
AU  - Abraha, HN
AU  - Abrham, AR
AU  - Abu-Raddad, LJ
AU  - Abu-Rmeileh, NME
AU  - Accrombessi, MMK
AU  - Acharya, D
AU  - Acharya, P
AU  - Adamu, AA
AU  - Adane, AA
AU  - Adebayo, OM
AU  - Adedoyin, RA
AU  - Adekanmbi, V
AU  - Ademi, Z
AU  - Adetokunboh, O
AU  - Adib, MG
AU  - Admasie, A
AU  - Adsuar, JC
AU  - Afanvi, KA
AU  - Afarideh, M
AU  - Agarwal, G
AU  - Aggarwal, A
AU  - Aghayan, SA
AU  - Agrawal, A
AU  - Agrawal, S
AU  - Ahmadi, A
AU  - Ahmadi, M
AU  - Ahmadieh, H
AU  - Ahmed, MB
AU  - Aichour, AN
AU  - Aichour, I
AU  - Aichour, MTE
AU  - Akbari, ME
AU  - Akinyemiju, T
AU  - Akseer, N
AU  - Al-Aly, Z
AU  - Al-Eyadhy, A
AU  - Al-Mekhlafi, HM
AU  - Alandab, F
AU  - Alam, K
AU  - Alam, S
AU  - Alam, T
AU  - Alashi, A
AU  - Alavian, SM
AU  - Alene, KA
AU  - Ali, K
AU  - Ali, SM
AU  - Alijanzadeh, M
AU  - Alizadeh-Navaei, R
AU  - Aljunid, SM
AU  - Alkerwi, A
AU  - Alla, F
AU  - Alsharif, U
AU  - Altirkawi, K
AU  - Alvis-Guzman, N
AU  - Amare, AT
AU  - Ammar, W
AU  - Anber, NH
AU  - Anderson, JA
AU  - Andrei, CL
AU  - Androudi, S
AU  - Animut, MD
AU  - Anjomshoa, M
AU  - Ansha, MG
AU  - Anto, JM
AU  - Antonio, CAT
AU  - Anwari, P
AU  - Appiah, LT
AU  - Appiah, SCY
AU  - Arabloo, J
AU  - Aremu, O
AU  - Amlov, J
AU  - Artaman, A
AU  - Aryal, KK
AU  - Asayesh, H
AU  - Ataro, Z
AU  - Ausloos, M
AU  - Avokpaho, EFGA
AU  - Awasthi, A
AU  - Quintanilla, BPA
AU  - Ayer, R
AU  - Ayuk, TB
AU  - Azzopardi, PS
AU  - Babazadeff, A
AU  - Badali, H
AU  - Badawi, A
AU  - Balakrishnan, K
AU  - Bali, AG
AU  - Ball, K
AU  - Bellew, SH
AU  - Banach, M
AU  - Banoub, JAM
AU  - Barac, A
AU  - Barker-Collo, SL
AU  - Bamighausen, TW
AU  - Barrero, LH
AU  - Basu, S
AU  - Baune, BT
AU  - Bazargan-Hejazi, S
AU  - Bedi, N
AU  - Beghi, E
AU  - Behzadifar, M
AU  - Behzadifar, M
AU  - Bejoy, Y
AU  - Bekele, BB
AU  - Bekru, FT
AU  - Belay, E
AU  - Belay, YA
AU  - Bell, ML
AU  - Bello, AK
AU  - Bennett, DA
AU  - Bensenor, IM
AU  - Bergeron, G
AU  - Berhane, A
AU  - Bemabe, E
AU  - Bemstein, RS
AU  - Beuran, M
AU  - Beyranvand, T
AU  - Bhala, N
AU  - Bhalla, A
AU  - Bhattarai, S
AU  - Bhutta, ZA
AU  - Biadgo, B
AU  - Bijani, A
AU  - Bikbov, B
AU  - Bilano, V
AU  - Bililign, N
AU  - Bin Sayeed, MS
AU  - Bisanzio, D
AU  - Biswas, T
AU  - Bjorge, T
AU  - Blacker, BF
AU  - Bleyer, A
AU  - Borschmann, R
AU  - Bou-Orm, IR
AU  - Boufous, S
AU  - Bourne, R
AU  - Brady, OJ
AU  - Brauer, M
AU  - Brazinova, A
AU  - Breitborde, NJK
AU  - Brenner, H
AU  - Briko, AN
AU  - Britton, G
AU  - Brugha, T
AU  - Buchbindet, R
AU  - Burnett, RT
AU  - Busse, R
AU  - Butt, ZA
AU  - Cahill, LE
AU  - Cahuana-Hurtado, L
AU  - Campos-Nonato, IR
AU  - Cardenas, R
AU  - Carreras, G
AU  - Carrero, JJ
AU  - Carvalho, F
AU  - Castaneda-Orjuela, CA
AU  - Rivas, JC
AU  - Castro, F
AU  - Catala-Lopez, F
AU  - Causey, K
AU  - Cercy, KM
AU  - Cerin, E
AU  - Chaiah, Y
AU  - Chang, HT
AU  - Chang, JC
AU  - Chang, KL
AU  - Charlson, FJ
AU  - Chattopadhyay, A
AU  - Chattu, VK
AU  - Chee, ML
AU  - Cheng, CY
AU  - Chew, A
AU  - Chiang, PPC
AU  - Chimed-Ochir, O
AU  - Chin, KL
AU  - Chitheer, A
AU  - Choi, JYJ
AU  - Chowdhury, R
AU  - Christensen, H
AU  - Christopher, DJ
AU  - Chung, SC
AU  - Cicuttini, FM
AU  - Grillo, M
AU  - Cohen, AJ
AU  - Collado-Mateo, D
AU  - Cooper, C
AU  - Cooper, OR
AU  - Coresh, J
AU  - Cornaby, L
AU  - Cortesi, PA
AU  - Cortinovis, M
AU  - Costa, M
AU  - Cousin, E
AU  - Criqui, MH
AU  - Cromwell, EA
AU  - Cundiff, DK
AU  - Daba, AK
AU  - Dachew, BA
AU  - Dadi, AF
AU  - Damasceno, AAM
AU  - Dandona, L
AU  - Dandona, R
AU  - Darby, SC
AU  - Dargan, PI
AU  - Daryani, A
AU  - Das Gupta, R
AU  - Das Neves, J
AU  - Dasa, TT
AU  - Dash, AP
AU  - Davitoiu, DV
AU  - Davletov, K
AU  - De la Cruz-Gongora, V
AU  - De la Hoz, FP
AU  - De Leo, D
AU  - De Neve, JW
AU  - Degenhardt, L
AU  - Deiparine, S
AU  - Dellavalle, RP
AU  - Demoz, GT
AU  - Denova-Gutierrez, E
AU  - Deribe, K
AU  - Dervenis, N
AU  - Deshpande, A
AU  - Jarlais, DCD
AU  - Dessie, GA
AU  - Deveber, GA
AU  - Dey, S
AU  - Dharmaratne, SD
AU  - Dhimal, M
AU  - Dinberu, MT
AU  - Ding, EL
AU  - Diro, HD
AU  - Djalalinia, S
AU  - Do, HP
AU  - Dokova, K
AU  - Doku, DT
AU  - La Doyle, K
AU  - Driscoll, TR
AU  - Dubey, M
AU  - Dubljanin, E
AU  - Duken, EE
AU  - Duncan, BB
AU  - Duraes, AR
AU  - Ebert, N
AU  - Ebrahimi, H
AU  - Ebrahimpour, S
AU  - Edvardsson, D
AU  - Elfiong, A
AU  - Eggen, AE
AU  - El Bcheraoui, C
AU  - El-Khatib, I
AU  - Elyazar, IR
AU  - Enayati, A
AU  - Endries, AY
AU  - Er, B
AU  - Erskine, HE
AU  - Eskandarieh, S
AU  - Esteghamati, A
AU  - Estep, K
AU  - Fakhim, H
AU  - Faramarzi, M
AU  - Fareed, M
AU  - Farid, TA
AU  - Farinha, CSES
AU  - Farioli, A
AU  - Faro, A
AU  - Farvid, MS
AU  - Farzaei, MH
AU  - Fatima, B
AU  - Fay, KA
AU  - Fazaeli, AA
AU  - Feigin, VL
AU  - Feigl, AB
AU  - Fereshtehnejad, SM
AU  - Fernandes, E
AU  - Fernandes, JC
AU  - Ferrara, G
AU  - Ferrari, AJ
AU  - Ferreira, ML
AU  - Filip, I
AU  - Finger, JD
AU  - Fischer, F
AU  - Foigt, NA
AU  - Foreman, KJ
AU  - Fukumoto, T
AU  - Fullman, N
AU  - Furst, T
AU  - Furtado, JM
AU  - Futran, ND
AU  - Gall, S
AU  - Gallus, S
AU  - Gamkrelidze, A
AU  - Ganji, M
AU  - Garcia-Basteiro, AL
AU  - Gardner, WN
AU  - Gebre, AK
AU  - Gebremedhin, AT
AU  - Gebremichael, TG
AU  - Gelano, TF
AU  - Geleijnse, JM
AU  - Geramo, YCD
AU  - Gething, PW
AU  - Geese, KE
AU  - Ghadimi, R
AU  - Ghadiri, K
AU  - Falavarjani, KG
AU  - Ghasemi-Kasman, M
AU  - Ghimire, M
AU  - Ghosh, R
AU  - Ghoshal, AG
AU  - Giampaoli, S
AU  - Gill, PS
AU  - Gill, TK
AU  - Gillum, RF
AU  - Ginawi, IA
AU  - Giussani, G
AU  - Gnedovskaya, EV
AU  - Godwin, WW
AU  - Goli, S
AU  - Gomez-Dantes, H
AU  - Gona, PN
AU  - Gopalani, SV
AU  - Goulart, AC
AU  - Grada, A
AU  - Grams, ME
AU  - Grosso, G
AU  - Gugnani, HC
AU  - Guo, Y
AU  - Gupta, R
AU  - Gupta, R
AU  - Gupta, T
AU  - Gutierrez, RA
AU  - Gutierrez-Torres, DS
AU  - Haagsma, JA
AU  - Habtewold, TD
AU  - Hachinski, V
AU  - Hafezi-Nejad, N
AU  - Hagos, TB
AU  - Hailegiyorgis, TT
AU  - Hailu, GB
AU  - Haj-Mirzaian, A
AU  - Haj-Mirzaian, A
AU  - Hamadeh, RR
AU  - Hamidi, S
AU  - Handal, AJ
AU  - Hankey, GJ
AU  - Liao, Y
AU  - Harb, HL
AU  - Harikrishnan, S
AU  - Haro, JM
AU  - Hassankhani, H
AU  - Hassen, HY
AU  - Havmoeller, R
AU  - Hawley, CN
AU  - Hay, SI
AU  - Hedayatizadeh-Omran, A
AU  - Heibati, B
AU  - Heidari, B
AU  - Heidari, M
AU  - Hendrie, D
AU  - Henok, A
AU  - Heredia-Pi, I
AU  - Herteliu, C
AU  - Heydarpour, F
AU  - Heydarpour, S
AU  - Hibstu, DT
AU  - Higazi, TB
AU  - Hilawe, EH
AU  - Hoek, HW
AU  - Hoffiman, HJ
AU  - Hole, MK
AU  - Rad, EH
AU  - Hoogar, P
AU  - Hosgood, HD
AU  - Hosseini, SM
AU  - Hosseinzadeh, M
AU  - Hostiuc, M
AU  - Hostiuc, S
AU  - Hoy, DG
AU  - Hsairi, M
AU  - Hsiao, T
AU  - Hu, G
AU  - Ha, H
AU  - Huang, JJ
AU  - Hussen, MA
AU  - Huynh, CK
AU  - Iburg, KM
AU  - Ikeda, N
AU  - Ilesanmi, OS
AU  - Iqbal, U
AU  - Irvani, SSN
AU  - Irvine, CMS
AU  - Islam, SMS
AU  - Islami, F
AU  - Jackson, MD
AU  - Jacobsen, KH
AU  - Jahangiry, L
AU  - Jahanmehr, N
AU  - Jain, SK
AU  - Jakovljevic, M
AU  - James, SL
AU  - Jassal, SK
AU  - Jayatilleke, AU
AU  - Jeemon, P
AU  - Jha, RP
AU  - Jha, V
AU  - Ji, JS
AU  - Jonas, JB
AU  - Jonnagaddala, J
AU  - Shushtari, ZJ
AU  - Joshi, A
AU  - Jozwiak, JJ
AU  - Jurisson, M
AU  - Kabir, Z
AU  - Kahsay, A
AU  - Kalani, R
AU  - Kanchan, T
AU  - Kant, S
AU  - Kar, C
AU  - Karami, M
AU  - Matin, BK
AU  - Karch, A
AU  - Karema, C
AU  - Karimi, N
AU  - Karimi, SM
AU  - Kasaeian, A
AU  - Kassa, DH
AU  - Kassa, GM
AU  - Kassa, TD
AU  - Kassebaum, NJ
AU  - Katikireddi, SV
AU  - Kaul, A
AU  - Kawakami, N
AU  - Kazemi, Z
AU  - Karyani, AK
AU  - Kefale, AT
AU  - Keiyoro, PN
AU  - Kemp, GR
AU  - Kengne, AP
AU  - Keren, A
AU  - Kesavachandran, CN
AU  - Khader, YS
AU  - Khafaei, B
AU  - Khafaie, MA
AU  - Khajavi, A
AU  - Khalid, N
AU  - Khalil, IA
AU  - Khan, G
AU  - Khan, MS
AU  - Khan, MA
AU  - Khang, YH
AU  - Khater, MM
AU  - Khazaei, M
AU  - Khazaie, H
AU  - Khoja, AT
AU  - Khosravi, A
AU  - Khosravi, MH
AU  - Kiadaliri, AA
AU  - Kiirithio, DN
AU  - Kim, CI
AU  - Kim, D
AU  - Kim, YE
AU  - Kim, YJ
AU  - Kimokoti, RW
AU  - Kinfh, Y
AU  - Kisa, A
AU  - Kissimova-Skarbek, K
AU  - Kivimaki, M
AU  - Knibbs, LD
AU  - Knudsen, AKS
AU  - Kochhar, S
AU  - Kokubo, Y
AU  - Kolola, T
AU  - Kopec, JA
AU  - Kosen, S
AU  - Koul, PA
AU  - Koyanagi, A
AU  - Kravchenko, MA
AU  - Krishan, K
AU  - Krohn, KJ
AU  - Kromhout, H
AU  - Defo, BK
AU  - Bicer, BK
AU  - Kumar, GA
AU  - Kumar, M
AU  - Kuzin, I
AU  - Kyu, HH
AU  - Lachat, C
AU  - Lad, DP
AU  - Lad, SD
AU  - Lafranconi, A
AU  - Lalloo, R
AU  - Lallukka, T
AU  - Lami, FH
AU  - Lang, JJ
AU  - Lansingh, VC
AU  - Larson, SL
AU  - Latifi, A
AU  - Lazarus, JV
AU  - Lee, PH
AU  - Leigh, J
AU  - Leili, M
AU  - Leshargie, CT
AU  - Leung, J
AU  - Levi, M
AU  - Lewycka, S
AU  - Li, S
AU  - Li, Y
AU  - Liang, J
AU  - Liang, X
AU  - Lian, Y
AU  - Liben, ML
AU  - Lim, LL
AU  - Linn, S
AU  - Liu, S
AU  - Lodha, R
AU  - Logroscino, G
AU  - Lopez, AD
AU  - Lorkowski, S
AU  - Lotufo, PA
AU  - Lozano, R
AU  - Lucas, TCD
AU  - Lunevicius, R
AU  - Ma, S
AU  - Macarayan, ERK
AU  - Machado, IE
AU  - Madotto, F
AU  - Mai, HT
AU  - Majdan, M
AU  - Majdzadeh, R
AU  - Majeed, A
AU  - Malekzadeh, R
AU  - Malta, DC
AU  - Mamum, AA
AU  - Manda, AL
AU  - Manguerra, H
AU  - Mansournia, MA
AU  - Mantovani, LG
AU  - Maravilla, JC
AU  - Marcenes, W
AU  - Marks, A
AU  - Martin, RV
AU  - Martins, SC
AU  - Martins-Melo, FR
AU  - Marz, W
AU  - Marzan, MB
AU  - Massenburg, BB
AU  - Mathur, MR
AU  - Mathur, P
AU  - Matsushita, K
AU  - Maulik, PK
AU  - Mazidi, M
AU  - McAlinden, C
AU  - McGrath, JJ
AU  - Mckee, M
AU  - Mehrotra, R
AU  - Mehta, KM
AU  - Mehta, V
AU  - Meier, T
AU  - Mekonnen, FA
AU  - Melaku, YA
AU  - Melese, A
AU  - Melku, M
AU  - Memiah, PTN
AU  - Memish, ZA
AU  - Mendoza, W
AU  - Mengistu, DT
AU  - Mensah, GA
AU  - Mensink, GBM
AU  - Mereta, ST
AU  - Meretola, A
AU  - Meretoja, TJ
AU  - Mestrovic, T
AU  - Mezgebe, HB
AU  - Miazgowski, B
AU  - Miazgowski, T
AU  - Millear, AI
AU  - Miller, TR
AU  - Miller-Petrie, MK
AU  - Mini, GK
AU  - Mirarefin, M
AU  - Mirica, A
AU  - Mirrakhimov, EM
AU  - Misganaw, AT
AU  - Mitiku, H
AU  - Moazen, B
AU  - Mohajer, B
AU  - Mohammad, KA
AU  - Mohammadi, M
AU  - Mohammadifard, N
AU  - Mohammadnia-Afrouzi, M
AU  - Mohammed, S
AU  - Mohebi, F
AU  - Mokdad, AH
AU  - Molokhia, M
AU  - Momeniha, F
AU  - Monasta, L
AU  - Moodley, Y
AU  - Moradi, G
AU  - Moradi-Lakeh, M
AU  - Moradinazar, M
AU  - Moraga, P
AU  - Morawska, L
AU  - Morgado-Da-Costa, J
AU  - Morrison, SD
AU  - Moschos, MM
AU  - Mouodi, S
AU  - Mousavi, SM
AU  - Mozaffarian, D
AU  - Mruts, KB
AU  - Muche, AA
AU  - Muchie, KF
AU  - Mueller, UO
AU  - Muhammed, OS
AU  - Mukhopadhyay, S
AU  - Muller, K
AU  - Musa, KI
AU  - Mustafa, G
AU  - Nabhan, AF
AU  - Naghavi, M
AU  - Naheed, A
AU  - Nahvijou, A
AU  - Naik, G
AU  - Naik, N
AU  - Najafi, F
AU  - Nangia, V
AU  - Nansseu, JR
AU  - Nascimento, BR
AU  - Neal, B
AU  - Neamati, N
AU  - Negoi, IT
AU  - Negoi, RI
AU  - Neupane, S
AU  - Newton, CRJ
AU  - Ngunjiri, JV
AU  - Nguyen, AQ
AU  - Nguyen, G
AU  - Nguyen, HT
AU  - Nguyen, HLT
AU  - Nguyen, HT
AU  - Nguyen, M
AU  - Nguyen, NB
AU  - Nichols, E
AU  - Nie, J
AU  - Ningrum, DNA
AU  - Nirayo, YL
AU  - Nishi, N
AU  - Nixon, MR
AU  - Nojomi, M
AU  - Nomura, S
AU  - Norheim, OF
AU  - Noroozi, M
AU  - Norrving, B
AU  - Noubiap, JJ
AU  - Nouri, HR
AU  - Shiadeh, MN
AU  - Nowroozi, MR
AU  - Nsoesie, EO
AU  - Nyasulu, PS
AU  - Obermeyer, CM
AU  - Odell, CM
AU  - Ofori-Asenso, R
AU  - Ogbo, FA
AU  - Oh, IH
AU  - Oladimeji, O
AU  - Olagunju, AT
AU  - Olagunju, TO
AU  - Olivares, PR
AU  - Olsen, HE
AU  - Olusanya, BO
AU  - Olusanya, JO
AU  - Ong, KL
AU  - Ong, SK
AU  - Oren, E
AU  - Orpana, HM
AU  - Ortiz, A
AU  - Ota, E
AU  - Otstavnov, SS
AU  - Overland, S
AU  - Owolabi, MO
AU  - Pacella, MPAR
AU  - Pakhare, AP
AU  - Pakpour, AH
AU  - Pana, A
AU  - Panda-Jonas, S
AU  - Park, EK
AU  - Parry, CDH
AU  - Parisian, H
AU  - Patel, S
AU  - Pati, S
AU  - Patil, ST
AU  - Patle, A
AU  - Patton, GC
AU  - Paudel, D
AU  - Paulson, KR
AU  - Ballesteros, WCP
AU  - Pearce, N
AU  - Pereira, A
AU  - Pereira, DM
AU  - Perico, N
AU  - Pesudovs, K
AU  - Petzold, M
AU  - Pham, HQ
AU  - Phillips, MR
AU  - Pillay, JD
AU  - Piradov, MA
AU  - Pirsaheb, M
AU  - Pischon, T
AU  - Pishgar, F
AU  - Plana-Ripoll, O
AU  - Plass, D
AU  - Polinder, S
AU  - Polkinghorne, KR
AU  - Postma, MJ
AU  - Poulton, R
AU  - Pourshams, A
AU  - Poustchi, H
AU  - Prabhakaran, D
AU  - Prakash, S
AU  - Prasad, N
AU  - Purcell, CA
AU  - Purwar, MB
AU  - Qorbani, M
AU  - Radfar, A
AU  - Rafay, A
AU  - Rafiei, A
AU  - Rahim, F
AU  - Rahimi, Z
AU  - Rahimi-Movaghar, A
AU  - Rahimi-Movaghar, V
AU  - Rahman, M
AU  - Rahman, MHU
AU  - Rahman, MA
AU  - Rai, RK
AU  - Rajati, F
AU  - Rajsic, S
AU  - Raju, SB
AU  - Ram, U
AU  - Ranabhat, CL
AU  - Ranjan, P
AU  - Rath, GK
AU  - Rawaf, DL
AU  - Rawaf, S
AU  - Reddy, KS
AU  - Rehm, CD
AU  - Rehm, J
AU  - Reiner, RC
AU  - Reitsma, MB
AU  - Remuzzi, G
AU  - Renzaho, AMN
AU  - Resnikoff, S
AU  - Reynales-Shigematsu, LM
AU  - Rezaei, S
AU  - Ribeiro, ALP
AU  - Rivera, JA
AU  - Roba, KT
AU  - Rodrigues-Ramirez, S
AU  - Roever, L
AU  - Roman, Y
AU  - Ronfani, L
AU  - Roshandel, G
AU  - Rostami, A
AU  - Roth, GA
AU  - Rothenbacher, D
AU  - Roy, A
AU  - Rubagotti, E
AU  - Rushton, L
AU  - Sabanayagam, C
AU  - Sachdev, PS
AU  - Saddik, B
AU  - Sadeghi, E
AU  - Moghaddam, SS
AU  - Safari, H
AU  - Safari, Y
AU  - Safari-Faramani, R
AU  - Safdarian, M
AU  - Safi, S
AU  - Safiri, S
AU  - Sagar, R
AU  - Sahebkar, A
AU  - Sahraian, MA
AU  - Sajadi, HS
AU  - Salam, N
AU  - Salamati, P
AU  - Saleem, Z
AU  - Salimi, Y
AU  - Salimeadeh, H
AU  - Salomon, JA
AU  - Salvi, DD
AU  - Satz, I
AU  - Samy, AM
AU  - Sanabria, J
AU  - Sanchez-Nino, MD
AU  - Sanchez-Pimienta, TG
AU  - Sanders, T
AU  - Sang, Y
AU  - Santomauro, DF
AU  - Santos, IS
AU  - Santos, JV
AU  - Milicevic, MMS
AU  - Jose, BPS
AU  - Sardana, M
AU  - Sacker, AR
AU  - Sarmiento-Suarez, R
AU  - Sarrafzadegan, N
AU  - Sartorius, B
AU  - Sarvi, S
AU  - Sathian, B
AU  - Satpathy, M
AU  - Sawant, AR
AU  - Sawhney, M
AU  - Saylan, M
AU  - Sayyah, M
AU  - Schaeffner, E
AU  - Schmidt, MI
AU  - Schneider, IJC
AU  - Schöttker, B
AU  - Schutte, AE
AU  - Schwehel, DC
AU  - Schwendicke, F
AU  - Scott, JG
AU  - Seedat, S
AU  - Sekerija, M
AU  - Sepanlou, SG
AU  - Serre, ML
AU  - Servan-Mori, E
AU  - Seyedmousavi, S
AU  - Shabaninejad, H
AU  - Shaddick, G
AU  - Shafieesabet, A
AU  - Shahbazi, M
AU  - Shaheen, AA
AU  - Shaikh, MA
AU  - Levy, TS
AU  - Shams-Beyranvand, M
AU  - Shamsi, M
AU  - Sharafi, H
AU  - Sharafi, K
AU  - Sharif, M
AU  - Sharif-Alhoseini, M
AU  - Sharifi, H
AU  - Sharma, J
AU  - Sharma, M
AU  - Sharma, R
AU  - She, J
AU  - Sheikh, A
AU  - Shi, P
AU  - Shibuya, K
AU  - Shiferaw, MS
AU  - Shigematsu, M
AU  - Shin, MJ
AU  - Shirt, R
AU  - Shirkoohi, R
AU  - Shiue, I
AU  - Shokraneh, F
AU  - Shoman, H
AU  - Shrime, MG
AU  - Shupler, MS
AU  - Si, S
AU  - Siabani, S
AU  - Sibai, AM
AU  - Siddiqi, TJ
AU  - Sigfusdottir, ID
AU  - Sigurvinsdottir, R
AU  - Silva, DAS
AU  - Silva, JP
AU  - Silveira, DGA
AU  - Singh, JA
AU  - Singh, NP
AU  - Singh, V
AU  - Sinha, DN
AU  - Skiadaresi, E
AU  - Skirbekk, V
AU  - Smith, DL
AU  - Smith, M
AU  - Sobaih, BH
AU  - Sobhani, S
AU  - Somayaji, R
AU  - Soofi, M
AU  - Sorensen, RJD
AU  - Soriano, JB
AU  - Soyiri, IN
AU  - Spinelli, A
AU  - Sposato, LA
AU  - Sreeramareddy, CT
AU  - Srinivasan, V
AU  - Starodubow, VI
AU  - Steckling, N
AU  - Stein, DJ
AU  - Stein, MB
AU  - Stevanovic, G
AU  - Stockfelt, L
AU  - Stokes, MA
AU  - Sturua, L
AU  - Subart, ML
AU  - Sudaryanto, A
AU  - Sufiyan, MB
AU  - Sulo, G
AU  - Sunguya, BF
AU  - Sur, PJ
AU  - Sykes, BI
AU  - Szoeke, CEI
AU  - Tabares-Seisdedos, R
AU  - Tabuchi, T
AU  - Tadakamadla, SK
AU  - Takahashi, K
AU  - Tandon, N
AU  - Tassew, SG
AU  - Tavakkoli, M
AU  - Taveira, N
AU  - Tehrani-Banihashemi, A
AU  - Tekalign, TG
AU  - Tekelemedhin, SW
AU  - Tekle, MG
AU  - Temesgen, H
AU  - Temsah, MR
AU  - Temsah, O
AU  - Terkawi, AS
AU  - Tessema, B
AU  - Teweldemedhin, M
AU  - Thankappan, KR
AU  - Theis, A
AU  - Thirunavukkarasu, S
AU  - Thomas, HJ
AU  - Thomas, ML
AU  - Thomas, N
AU  - Thurston, GD
AU  - Tilahun, B
AU  - Tillmana, T
AU  - To, QG
AU  - Tobollik, M
AU  - Tonelli, M
AU  - Topor-Madry, R
AU  - Torre, AE
AU  - Tortajada-Girbes, M
AU  - Touvier, M
AU  - Tovani-Palone, MR
AU  - Towbin, JA
AU  - Tran, BX
AU  - Tran, KB
AU  - Truelsen, TC
AU  - Truong, NT
AU  - Tsadik, AG
AU  - Car, LT
AU  - Tuzcu, EM
AU  - Tymeson, HD
AU  - Tyrovolas, S
AU  - Ukwaja, KN
AU  - Ullah, I
AU  - Updike, RL
AU  - Usman, MS
AU  - Uthman, OA
AU  - Vaduganathan, M
AU  - Vaezi, A
AU  - Valdez, PR
AU  - Van Donkelaar, A
AU  - Varavikova, E
AU  - Varughese, S
AU  - Vasankari, TJ
AU  - Venkateswaran, V
AU  - Venketasubramanian, N
AU  - Villafaina, S
AU  - Violante, FS
AU  - Vladimirov, SK
AU  - Vlassov, V
AU  - Vollset, SE
AU  - Vos, T
AU  - Vbsoughi, K
AU  - Vu, GT
AU  - Vujcic, IS
AU  - Wagnew, FS
AU  - Waheed, Y
AU  - Waller, SG
AU  - Walson, JL
AU  - Wang, Y
AU  - Wang, Y
AU  - Wang, YP
AU  - Weiderpass, E
AU  - Weintraub, RG
AU  - Weldegebreal, F
AU  - Werdecker, A
AU  - Weiknah, AA
AU  - West, JJ
AU  - Westerman, R
AU  - Whiteford, HA
AU  - Widecka, J
AU  - Wijeratne, T
AU  - Winkler, AS
AU  - Wiyeh, AB
AU  - Wiysonge, CS
AU  - Wolfe, CDA
AU  - Wong, TY
AU  - Wu, S
AU  - Xavier, D
AU  - Xu, G
AU  - Yadgir, S
AU  - Yadollahpour, A
AU  - Jabbari, SHY
AU  - Yamada, T
AU  - Yan, LL
AU  - Yano, Y
AU  - Yaseri, M
AU  - Yasin, YJ
AU  - Yeshanely, A
AU  - Yimer, EM
AU  - Yip, P
AU  - Yisma, E
AU  - Yonemoto, N
AU  - Yoon, SJ
AU  - Yotebieng, M
AU  - Younis, MZ
AU  - Yousefifard, M
AU  - Yu, C
AU  - Zaidi, Z
AU  - Bin Zaman, S
AU  - Zamani, M
AU  - Zavala-Arciniega, L
AU  - Zhang, AL
AU  - Zhang, H
AU  - Zhang, K
AU  - Thou, M
AU  - Zimsen, SM
AU  - Zodpey, S
AU  - Murray, CJL
TI  - Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
T2  - LANCET
KW  - CARDIOVASCULAR-DISEASES
KW  - BLOOD-PRESSURE
KW  - CHOLESTEROL
KW  - TRENDS
AB  - Background The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 comparative risk assessment (CRA) is a comprehensive approach to risk factor quantification that offers a useful tool for synthesising evidence on risks and risk outcome associations. With each annual GBD study, we update the GBD CRA to incorporate improved methods, new risks and risk outcome pairs, and new data on risk exposure levels and risk outcome associations.
   Methods We used the CRA framework developed for previous iterations of GBD to estimate levels and trends in exposure, attributable deaths, and attributable disability-adjusted life-years (DALYs), by age group, sex, year, and location for 84 behavioural, environmental and occupational, and metabolic risks or groups of risks from 1990 to 2017. This study included 476 risk outcome pairs that met the GBD study criteria for convincing or probable evidence of causation. We extracted relative risk and exposure estimates from 46 749 randomised controlled trials, cohort studies, household surveys, census data, satellite data, and other sources. We used statistical models to pool data, adjust for bias, and incorporate covariates. Using the counterfactual scenario of theoretical minimum risk exposure level (TMREL), we estimated the portion of deaths and DALYs that could be attributed to a given risk. We explored the relationship between development and risk exposure by modelling the relationship between the Socio-demographic Index (SDI) and risk-weighted exposure prevalence and estimated expected levels of exposure and risk-attributable burden by SDI. Finally, we explored temporal changes in risk-attributable DALYs by decomposing those changes into six main component drivers of change as follows: (1) population growth; (2) changes in population age structures; (3) changes in exposure to environmental and occupational risks; (4) changes in exposure to behavioural risks; (5) changes in exposure to metabolic risks; and (6) changes due to all other factors, approximated as the risk-deleted death and DALY rates, where the risk-deleted rate is the rate that would be observed had we reduced the exposure levels to the TMREL for all risk factors included in GBD 2017.
   Findings In 2017,34.1 million (95% uncertainty interval [UI] 33.3-35.0) deaths and 121 billion (144-1.28) DALYs were attributable to GBD risk factors. Globally, 61.0% (59.6-62.4) of deaths and 48.3% (46.3-50.2) of DALYs were attributed to the GBD 2017 risk factors. When ranked by risk-attributable DALYs, high systolic blood pressure (SBP) was the leading risk factor, accounting for 10.4 million (9.39-11.5) deaths and 218 million (198-237) DALYs, followed by smoking (7.10 million [6.83-7.37] deaths and 182 million [173-193] DALYs), high fasting plasma glucose (6.53 million [5.23-8.23] deaths and 171 million [144-201] DALYs), high body-mass index (BMI; 4.72 million [2.99-6.70] deaths and 148 million [98.6-202] DALYs), and short gestation for birthweight (1.43 million [1.36-1.51] deaths and 139 million [131-147] DALYs). In total, risk-attributable DALYs declined by 4.9% (3.3-6.5) between 2007 and 2017. In the absence of demographic changes (ie, population growth and ageing), changes in risk exposure and risk-deleted DALYs would have led to a 23.5% decline in DALYs during that period. Conversely, in the absence of changes in risk exposure and risk-deleted DALYs, demographic changes would have led to an 18.6% increase in DALYs during that period. The ratios of observed risk exposure levels to exposure levels expected based on SDI (O/E ratios) increased globally for unsafe drinking water and household air pollution between 1990 and 2017. This result suggests that development is occurring more rapidly than are changes in the underlying risk structure in a population. Conversely, nearly universal declines in O/E ratios for smoking and alcohol use indicate that, for a given SDI, exposure to these risks is declining. In 2017, the leading Level 4 risk factor for age-standardised DALY rates was high SBP in four super-regions: central Europe, eastern Europe, and central Asia; north Africa and Middle East; south Asia; and southeast Asia, east Asia, and Oceania. The leading risk factor in the high-income super-region was smoking, in Latin America and Caribbean was high BMI, and in sub-Saharan Africa was unsafe sex. O/E ratios for unsafe sex in sub-Saharan Africa were notably high, and those for alcohol use in north Africa and the Middle East were notably low.
   Interpretation By quantifying levels and trends in exposures to risk factors and the resulting disease burden, this assessment offers insight into where past policy and programme efforts might have been successful and highlights current priorities for public health action. Decreases in behavioural, environmental, and occupational risks have largely offset the effects of population growth and ageing, in relation to trends in absolute burden. Conversely, the combination of increasing metabolic risks and population ageing will probably continue to drive the increasing trends in non-communicable diseases at the global level, which presents both a public health challenge and opportunity. We see considerable spatiotemporal heterogeneity in levels of risk exposure and risk-attributable burden. Although levels of development underlie some of this heterogeneity, O/E ratios show risks for which countries are overperforming or underperforming relative to their level of development. As such, these ratios provide a benchmarking tool to help to focus local decision making. Our findings reinforce the importance of both risk exposure monitoring and epidemiological research to assess causal connections between risks and health outcomes, and they highlight the usefulness of the GBD study in synthesising data to draw comprehensive and robust conclusions that help to inform good policy and strategic health planning. Copyright (C) 2018 The Author(s). Published by Elsevier Ltd.
AD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - Univ Washington, Dept Hlth Metr Sci, Seattle, WA 98195 USAAD  - Univ Washington, Dept Epidemiol, Seattle, WA 98195 USAAD  - Univ Washington, Dept Global Hlth, Seattle, WA 98195 USAAD  - Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USAAD  - Univ Washington, Dept Environm Occupat Hlth Sci, Seattle, WA 98195 USAAD  - Univ Washington, Dept Neurol, Seattle, WA 98195 USAAD  - Univ Washington, Div Plast Surg, Seattle, WA 98195 USAAD  - Univ Washington, Dept Surg, Seattle, WA 98195 USAAD  - Univ Washington, Dept Bioinformat & Med Educ, Seattle, WA 98195 USAAD  - Univ Washington, Div Cardiol, Dept Med, Seattle, WA 98195 USAAD  - Univ Washington, Dept Med, Seattle, WA 98195 USAAD  - Haramaya Univ, Sch Pharm, Harar, EthiopiaAD  - Haramaya Univ, Dept Pediat, Harar, EthiopiaAD  - Haramaya Univ, Dept Med, Lab Sci, Harar, EthiopiaAD  - Haramaya Univ, Sch Publ Hlth, Harar, EthiopiaAD  - Haramaya Univ, Sch Nursing & Midwifery, Harar, EthiopiaAD  - Haramaya Univ, Coll Hlth & Med Sci, Harar, EthiopiaAD  - Haramaya Univ, Harar, EthiopiaAD  - Jimma Univ, Dept Populat & Family Hlth, Jimma, EthiopiaAD  - Jimma Univ, Dept Epidemiol, Jimma, EthiopiaAD  - Jimma Univ, Mycobacteriol Res Ctr, Jimma, EthiopiaAD  - Jimma Univ, Dept Hlth Educ & Behav Sci, Jimma, EthiopiaAD  - Jimma Univ, Dept Environm Hlth Sci & Technol, Jimma, EthiopiaAD  - Univ Roma La Sapienza, Dept Law Philosophy & Econ Studies, Rome, ItalyAD  - Univ Tehran Med Sci, Noncommunicable Dis Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Dept Hlth, Tehran, IranAD  - Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Dept Hlth Management & Econ, Tehran, IranAD  - Univ Tehran Med Sci, Liver & Pancreaticobilliary Dis Research Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Multiple Sclerosis Res Ctr, Neurosci Inst, Tehran, IranAD  - Univ Tehran Med Sci, Sch Med, Tehran, IranAD  - Univ Tehran Med Sci, Dept Pharmacol, Tehran, IranAD  - Univ Tehran Med Sci, Dept Epidemiol & Biostatist, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Malignancies Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Knowledge Utilizat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, IranAD  - Univ Tehran Med Sci, Iran Natl Inst Hlth Res, Tehran, IranAD  - Univ Tehran Med Sci, Canc Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Urooncol Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, INCAS, Tehran, IranAD  - Univ Tehran Med Sci, Sina Trauma & Surg Researct Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Ctr Expertise Microbiol, Tehran, IranAD  - Univ Tehran Med Sci, Canc Biol Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Dept Anat, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Oncol & Stem Cell Transplantat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Community Based Participatory Research Ctr, Tehran, IranAD  - McGill Univ, Montreal Neuroimaging Ctr, Montreal, PQ, CanadaAD  - McGill Univ, Montreal Neurol Inst, Montreal, PQ, CanadaAD  - Cairo Univ, Dept Neurol, Cairo, EgyptAD  - Cairo Univ, Dept Med Parasitol, Cairo, EgyptAD  - Arak Univ Med Sci, Dept Epidemiol, Arak, IranAD  - Multiple Sclerosis Res Ctr, Tehran, IranAD  - Manonmaniam Sundarartar Univ, Dept Stat, Tirunelveli, IndiaAD  - Univ Gondar, Dept Clin Chem, Gondar, EthiopiaAD  - Univ Gondar, Human Nutr Dept, Gondar, EthiopiaAD  - Univ Gondar, Inst Publ Hlth, Gondar, EthiopiaAD  - Univ Gondar, Dept Epidemiol & Riostat, Gondar, EthiopiaAD  - Univ Gondar, Dept Med Microbiol, Gondar, EthiopiaAD  - Mekelle Univ, Sch Publ Hlth, Mekelle, EthiopiaAD  - Mekelle Univ, Clin Pharm Unit, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Pharm, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Riostat, Mekelle, EthiopiaAD  - Mekelle Univ, Anat Unit, Mekelle, EthiopiaAD  - Mekelle Univ, Biomed Sci Div, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Nutr & Dietet, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Med, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Environm Hlth Sci, Mekelle, EthiopiaAD  - Mekelle Univ, Mekelle, EthiopiaAD  - Univ Holhenhein, Inst Biol Chem & Nutr, Stuttgart, GermanyAD  - Wollega Univ, Dept Med Lab Sci, Nekemte, EthiopiaAD  - Wollega Univ, Dept Hlth Sci, Nekemte, EthiopiaAD  - Univ Med Sci, Sch Publ Hlth, Ondo, NigeriaAD  - Weill Cornell Med Coll Qatar, Dept Healthcare Policy & Res, Doha, QatarAD  - Birzeit Univ, Inst Community & Publ Heath, Birzeit, PalestineAD  - Benin Clin Res Inst IRCB, Dept Epidemiol, Cotonou, BeninAD  - Dongguk Univ, Dept Prevent Med, Gyeongju, South KoreaAD  - Dongguk Univ, Gyeongju, South KoreaAD  - Kathmandu Univ, Dept Community Med, Devdaha, NepalAD  - Nepal Dev Soc, Pokhara, NepalAD  - Univ Stellenbosch, Dept Global Hlth, Cape Town, South AfricaAD  - Univ Stellenbosch, Fac Med & Hlth Sci, Cape Town, South AfricaAD  - Univ Stellenbosch, Dept Psychiatry, Cape Town, South AfricaAD  - South African Med Res Council, Cochrane South Africa, Cape Town, South AfricaAD  - South African Med Res Council, Unit Hypertens & Cardiovasc Dis, Cape Town, South AfricaAD  - South African Med Res Council, Cape Town, South AfricaAD  - Univ Queensland, Sch Publ Hlth, Brisbane, Qld, AustraliaAD  - Univ Queensland, Sch Dent, Brisbane, Qld, AustraliaAD  - Univ Queensland, Social Sci Res Inst, Brisbane, Qld, AustraliaAD  - Univ Queensland, Social Sci Res Inst, Brisbane, Qld, AustraliaAD  - Univ Queensland, Queensland Brain Inst, Brisbane, Qld, AustraliaAD  - Univ Queensland, Clin Res Ctr, Brisbane, Qld, AustraliaAD  - Univ Queensland, Brisbane, Qld, AustraliaAD  - Univ Coll Hosp, Ibadan, NigeriaAD  - Obafemi Awolowo Univ, Dept Rehabil Med, Ife, NigeriaAD  - Cardiff Univ, Sch Med, Cardiff, S Glam, WalesAD  - Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, AustraliaAD  - Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, AustraliaAD  - Monash Univ, Dept Med, Melbourne, Vic, AustraliaAD  - Monash Univ, Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic, AustraliaAD  - St Mark Hosp, Emergency Dept, Alexandria, EgyptAD  - Wolaita Sodo Univ, Sch Publ Hlth, Addis Ababa, EthiopiaAD  - Wolaita Sodo Univ, Coll Hlth Sci & Med, Addis Ababa, EthiopiaAD  - Univ Extremadura, Sport Sci Dept, Badajoz, SpainAD  - Univ Extremadura, Badajoz, SpainAD  - Univ Lome, Dept Publ Hlth, Lome, TogoAD  - Minist Hlth & Social Protect, Prefectoral Direct Hlth Zio, Tsevie, TogoAD  - McMaster Univ, Dept Family Med, Hamilton, ON, CanadaAD  - McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, CanadaAD  - Yerevan State Univ Yerevan, Dept Zool, Yerevan, ArmeniaAD  - Sci Ctr Zool & Hydroecol, Res Grp Mol Parasitol, Yerevan, ArmeniaAD  - CSIR, Inst Genom & Integrat Biol, Res Area Informat & Big Data, Delhi, IndiaAD  - Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USAAD  - Publ Hlth Fdn India, Non Communicable Dis, Gurugram, IndiaAD  - Publ Hlth Fdn India, Indian Inst Publ Hlth, Gurugram, IndiaAD  - Publ Hlth Fdn India, Gurugram, IndiaAD  - Vital Strategies, Gurugram, IndiaAD  - Kermanshah Univ Med Sci, Dept Anesthesiol, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Tradit & Complementary Med, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Fac Nutr & Food Sci, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Fac Publ Hlth, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Psychiat, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Res Ctr Environm Determinants Hlth, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Epidemiol & Biostat, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Clin Biochem, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Hlth Educ & Promot, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Environm Determinants Hlth Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Dept Food Technol & Qual Control, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Sports Med & Rehabil, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Imam Ali Cardiovasc Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Pharntaceut Sci Res Ctr, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Kermanshah, IranAD  - Ahvaz Jundishapur Univ Med Sci, Dept Publ Hlth, Ahvaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Dept Neurosurg, Ahvaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Educ Dev Ctr, Ahvaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Med Phys Dept, Ahvaz, IranAD  - Shahid Reheshti Univ Med Sci, Dept Ophthalmol, Tehran, IranAD  - Shahid Reheshti Univ Med Sci, Canc Res Ctr, Tehran, IranAD  - Shahid Reheshti Univ Med Sci, Res Inst Endocrine Sci, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Safety Promot & Injury Prevent Res Ctr, Tehran, IranAD  - Shahid Reheshti Univ Med Sci, Dept Mostat, Tehran, IranAD  - Shahid Reheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Sch Publ Hlth, Tehran, IranAD  - Shahid Reheshti Univ Med Sci, Ophthalm Epidemiol Res Ctr, Tehran, IranAD  - Univ Ferhat Abbas Setif, Setif, AlgeriaAD  - Higher Natl Sch Vet Med, Algiers, AlgeriaAD  - Univ Kentucky, Dept Epidemiol, Lexington, KY USAAD  - Univ Toronto, Ctr Global Child Hlth, Toronto, ON, CanadaAD  - Univ Toronto, Hosp Sick Children, Toronto, ON, CanadaAD  - Univ Toronto, Dept Nutr Sci, Toronto, ON, CanadaAD  - Univ Toronto, Ctr Global Child Hlth, Hosp Sick Children, Toronto, ON, CanadaAD  - Washington Univ, Internal Med Dept, St Louis, MO USAAD  - VA St Louis Hlth Care Syst, Clin Epidemiol Ctr, St Louis, MO USAAD  - Dept Vet Affairs, Dept Internal Med, St Louis, MO USAAD  - King Saud Univ, Pediat Intens Care Unit, Riyadh, Saudi ArabiaAD  - King Saud Univ, Dept Pediat, Riyadh, Saudi ArabiaAD  - King Saud Univ, Riyadh, Saudi ArabiaAD  - Jazan Univ, Med Res Ctr, Jazan, Saudi ArabiaAD  - Jazan Univ, Jazan, Saudi ArabiaAD  - Sanaa Univ, Dept Med Parasitol, Sanaa, YemenAD  - Mayo Clin, Fdn Med Educ & Res, Evidence Based Practice Ctr, Rochester, MN USAAD  - Syrian Amer Med Soc, Res Comm, Washington, DC USAAD  - Univ Western Australia, Sch Populat & Global Hlth, Perth, WA, AustraliaAD  - Univ Western Australia, Sch Med, Perth, WA, AustraliaAD  - Dalhousie Univ, Dept Med, Halifax, NS, CanadaAD  - Dalhousie Univ, Dept Phys & Atmospher Sci, Halifax, NS, CanadaAD  - Cleveland Clin, Cardiovasc Med, Cleveland, OH 44106 USAAD  - Baqiyatallah Univ Med Sci, Baqiyatallah Res Ctr Gastroenterol & Liver Dis, Tehran, IranAD  - Baqiyatallah Univ Med Sci, Student Res Comm, Tehran, IranAD  - Australian Natl Univ, Res Sch Populat Hlth, Canberra, ACT, AustraliaAD  - Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, AustraliaAD  - Mercy Corps, Monitoring Evaluat & Learning Unit, Islamabad, PakistanAD  - Qazvin Univ Med Sci, Dept Publ Hlth, Qazvin, IranAD  - Qazvin Univ Med Sci, Qazvin, IranAD  - Mazandaran Univ Med Sci, Gastrointestinal Canc Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Med Mycol, Sari, IranAD  - Mazandaran Univ Med Sci, Toxoplasmosis Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Sch Publ Hlth, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Physiol & Pharmacol, Sari, IranAD  - Mazandaran Univ Med Sci, Mol & Cell Biol Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Immunogenet Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Immunol, Sari, IranAD  - Mazandaran Univ Med Sci, Sari, IranAD  - Kuwait Univ, Dept Hlth Policy & Management, Safat, KuwaitAD  - Natl Univ Malaysia, Int Ctr Casemix & Clin Coding, Bandar Tun Razak, MalaysiaAD  - Luxembourg Inst Hlth, Dept Populat Hlth, Strassen, LuxembourgAD  - Univ Bordeaux, Bordeaux, FranceAD  - Charite, Inst Publ Hlth, Berlin, GermanyAD  - Charite, Dept Operat & Prevent Dent, Berlin, GermanyAD  - Univ Cartagena, Res Grp Hlth Econ, Cartagena, ColombiaAD  - Univ Coast, Res Grp Hosp Management & Hlth Policies, Barranquilla, ColombiaAD  - South Australian Hlth & Med Res Inst, Sansom Inst, Adelaide, SA, AustraliaAD  - South Australian Hlth & Med Res Inst, Wardliparingga Aboriginal Res Unit, Adelaide, SA, AustraliaAD  - Bahir Dar Univ, Bahir Dar, EthiopiaAD  - Fed Minist Hlth, Dept Hlth Ind Complex & Innovat Hlth, Beirut, LebanonAD  - Fed Minist Hlth, Beirut, LebanonAD  - Amer Univ Beirut, Fac 1 Hlth Sci, Beirut, LebanonAD  - Amer Univ Beirut, Ctr Res Populat & Hlth, Beirut, LebanonAD  - Amer Univ Beirut, Dept Epidemiol & Populat Hlth, Beirut, LebanonAD  - Mansoura Univ, Fac Med, Mansoura, EgyptAD  - Carol Davila Univ Med & Pharm, Emergency Hosp Bucharest, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Dept Gen Surg, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Dept Legal Med & Bioeth, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Anat & Embryol Dept, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Bucharest, RomaniaAD  - Univ Thessaly, Dept Med, Volos, GreeceAD  - Arba Minch Univ, Dept Publ Hlth, Arba Minch, EthiopiaAD  - Rafsanjan Univ Med Sci, Social Determinants Hlth Res Ctr, Rafsanjan, IranAD  - Debre Berhan Univ, Dept Publ Hlth, Debre Berhan, EthiopiaAD  - Debre Berhan Univ, Dept Midwifery, Debre Berhan, EthiopiaAD  - Barcelona Inst Global Hlth, TB Dept, Barcelona, SpainAD  - Barcelona Inst Global Hlth, Barcelona, SpainAD  - Pompeu Fabra Univ, Dept Expt & Hlth Sci, Barcelona, SpainAD  - Univ Philippines Manila, Dept Hlth Policy & Adm, Manila, PhilippinesAD  - Univ Philippines Manila, Dev & Commun Studies, Manila, PhilippinesAD  - Hong Kong Polytech Univ, Dept Appl Social Sci, Hong Kong, Hong Kong, Peoples R ChinaAD  - Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Hong Kong, Peoples R ChinaAD  - Komfo Anokye Teaching Hosp, Dept Internal Med, Adum, GhanaAD  - Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Kumasi, GhanaAD  - Kwame Nkrumah Univ Sci & Technol, Dept Sociol & Social Work, Kumasi, GhanaAD  - Ludwig Maximilians Univ Munchen, Ctr Int Hlth, Munich, GermanyAD  - Iran Univ Med Sci, Hlth Management & Econ Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Dept Ophthalmol, Tehran, IranAD  - Iran Univ Med Sci, Air Pollut Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Prevent Med & Publ Hlth Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Dept Neurosci, Tehran, IranAD  - Iran Univ Med Sci, Dept Hlth Policy, Tehran, IranAD  - Iran Univ Med Sci, Physiol Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Tehran, IranAD  - Birmingham City Univ, Sch Hlth Sci, Birmingham, W Midlands, EnglandAD  - Karolinska Inst, Dept Neurobiol, Stockholm, SwedenAD  - Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, SwedenAD  - Karolinska Inst, Dept Publ Hlth Sci, Stockholm, SwedenAD  - Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, SwedenAD  - Dalarna Univ, Sch Hlth & Social Studies, Falun, SwedenAD  - Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, CanadaAD  - Abt Associates Nepal, Monitoring Evaluat & Operat Res Project, Lalitpur, NepalAD  - Qom Univ Med Sci, Qom, IranAD  - Univ Leicester, Sch Business, Leicester, Leics, EnglandAD  - Univ Leicester, Dept Hlth Sci, Leicester, Leics, EnglandAD  - Lab Studies & Res Act Hlth, Controle Malad Infect, Berlin, GermanyAD  - Indian Inst Publ Hlth, Gandhinagar, IndiaAD  - La Trobe Univ, Judith Lumley Ctr, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Sch Nursing & Midwifery, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Austin Clin Sch Nursing, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Dept Psychol & Counselling, Melbourne, Vic, AustraliaAD  - Peruvian Natl Inst Hlth, Gen Off Res & Technol Transfer, Lima, PeruAD  - Univ Tokyo, Dept Community & Global Hlth, Tokyo, JapanAD  - Univ Tokyo, Dept Mental Hlth, Tokyo, JapanAD  - Univ Tokyo, Dept Global Hlth Policy, Tokyo, JapanAD  - Univ Tokyo, Dept Diabet & Metab Dis, Tokyo, JapanAD  - Inst Med Res & Med Plant Studies, Ctr Food & Nutr Res, Yaounde, CameroonAD  - Univ South Africa, Dept Hlth Studies, Pretoria, South AfricaAD  - Burnet Inst, Global Adolescent Hlth Grp, Melbourne, Vic, AustraliaAD  - Ctr Infect Dis Res, Babol Sar, IranAD  - Publ Hlth Agcy Canada, Publ Hlth Risk Sci Div, Toronto, ON, CanadaAD  - Publ Hlth Agcy Canada, Hlth Promot & Chron Dis Prevent Branch, Toronto, ON, CanadaAD  - Publ Hlth Agcy Canada, Appl Res Div, Toronto, ON, CanadaAD  - Sri Ramachandra Med Coll & Res Inst, Dept Environm Hlth Engn, Madras, Tamil Nadu, IndiaAD  - Deakin Univ, Inst Phys Act & Nut Mon, Burwood, Vic, AustraliaAD  - Deakin Univ, Sch Med, Burwood, Vic, AustraliaAD  - Deakin Univ, Dept Psychol, Burwood, Vic, AustraliaAD  - Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USAAD  - Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USAAD  - Johns Hopkins Univ, Sch Med, Baltimore, MD USAAD  - Johns Hopkins Univ, Div Cardiovasc & Clin Epidemiol, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Radiol, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD USAAD  - Johns Hopkins Univ, Dept Gastrointestinal & Hepatol, Baltimore, MD USAAD  - Med Univ Lodz, Dept Hypertens, Lodz, PolandAD  - Polish Mothers Mem Hosp, Res Inst, Lodz, PolandAD  - Univ Alexandria, Fac Med, Alexandria, EgyptAD  - Univ Hosp Fdn Santa Fe Bogota, Dept Transplant Serv, Bogota, ColombiaAD  - Clin Ctr Serbia, Infect & Trop Dis, Belgrade, SerbiaAD  - Univ Belgrade, Fac Med, Belgrade, SerbiaAD  - Univ Belgrade, Ctr Sch Publ Hlth & Hlth Management, Belgrade, SerbiaAD  - Univ Belgrade, Fac Med, Inst Epidemiol, Belgrade, SerbiaAD  - Univ Auckland, Sch Psychol, Auckland, New ZealandAD  - Univ Auckland, Mol Med & Pathol, Auckland, New ZealandAD  - Heidelberg Univ, Inst Publ Hlth, Heidelberg, GermanyAD  - Heidelberg Univ, Med Clin 5, Heidelberg, GermanyAD  - Heidelberg Univ, Augenpraxis Jonas, Heidelberg, GermanyAD  - Harvard Univ, Dept Global Hlth & Populat, Boston, MA 02115 USAAD  - Harvard Univ, Dept Nutr, Boston, MA 02115 USAAD  - Harvard Univ, Ariadne Labs, Boston, MA 02115 USAAD  - Harvard Univ, Dept Genet, Boston, MA 02115 USAAD  - Harvard Univ, Div Gen Internal Med & Primary Care, Boston, MA 02115 USAAD  - Harvard Univ, Heart & Vasc Ctr, Boston, MA 02115 USAAD  - Harvard Univ, Dept Epidemiol, Boston, MA 02115 USAAD  - Harvard Univ, Boston, MA 02115 USAAD  - Pontifical Javeriana Univ, Dept Ind Engn, Bogota, ColombiaAD  - Stanford Univ, Dept Med, Palo Alto, CA 94304 USAAD  - Stanford Univ, Ctr Hlth Policy, Palo Alto, CA 94304 USAAD  - Stanford Univ, Ctr Primary Care & Outcomes Res, Palo Alto, CA 94304 USAAD  - Melbourne Med Sch, Melbourne, Vic, AustraliaAD  - Charles R Drew Univ Med & Sci, Dept Psychiat, 1621 E 120th St, Los Angeles, CA 90059 USAAD  - Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USAAD  - Gandhi Med Coll Bhopal, Dept Community Med, Bhopal, IndiaAD  - Mario Negri Inst Pharmacol Res, Dept Neurosci, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Dept Renal Med, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Dept Oncol, Milan, ItalyAD  - Mario Negri Inst Pharmacol Res, Dept Environm Hlth Sci, Milan, ItalyAD  - Loresun Univ Medical Sci, Social Determinants Hlth Res Ctr, Khorramabad, IranAD  - Loresun Univ Medical Sci, Khorramabad, IranAD  - Univ Hosp Dijon, Dept Neurol, Dijon, FranceAD  - Univ Burgundy, Dijon Stroke Registry Ufr Sci Sante, Dijon, FranceAD  - Mizan Tepi Univ, Publ Hlth Dept, Teppi, EthiopiaAD  - Mizan Tepi Univ, Pharm Dept, Teppi, EthiopiaAD  - Debre Markos Univ, Dept Publ Hlth, Debre Markos, EthiopiaAD  - Debre Markos Univ, Dept Nursing, Debre Markos, EthiopiaAD  - Debre Markos Univ, Coll Hlth Sci, Debre Markos, EthiopiaAD  - Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USAAD  - Yale Univ, Dept Ophthalmol & Visual Sci, New Haven, CT USAAD  - Univ Alberta, Dept Med, Edmonton, AB, CanadaAD  - Univ Oxford, Nuffield Dept Populat Hlth, Oxford, EnglandAD  - Univ Oxford, Nuffield Dept Med, Oxford, EnglandAD  - Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, EnglandAD  - Univ Oxford, Big Data Inst, Oxford, EnglandAD  - Univ Oxford, Dept Psychiat, Oxford, EnglandAD  - Univ Oxford, Oxford, EnglandAD  - Univ Sao Paulo, Dept Internal Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Div Ophthalmol, Sao Paulo, BrazilAD  - Univ Sao Paulo, Univ Hosp, Internal Med Dept, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Pathol & Legal Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Psychiat, Sao Paulo, BrazilAD  - Univ Sao Paulo, Ctr Clin & Epidemiol Res, Sao Paulo, BrazilAD  - New York Acad Sci, Sackler Inst Nutr Sci, New York, NY USAAD  - Univ Addis Ababa, Sch Publ Hlth, Addis Ababa, EthiopiaAD  - Univ Addis Ababa, Dept Pharm, Addis Ababa, EthiopiaAD  - Univ Addis Ababa, Sch Allied Hlth Sci, Addis Ababa, EthiopiaAD  - Kings Coll London, Dent Inst, London, EnglandAD  - Kings Coll London, Fac Life Sci & Med, London, EnglandAD  - Kings Coll London, Div Patient & Populat, London, EnglandAD  - Kings Coll London, Sch Populat Hlth & Environm Sci, London, EnglandAD  - Emory Univ, Hubert Dept Global Hlth, Atlanta, GA 30322 USAAD  - Univ S Florida, Dept Global Hlth, Tampa, FL USAAD  - Queen Elizabeth Hosp Birmingham, Inst Appl Hlth Res & Translat Med, Birmingham, W Midlands, EnglandAD  - Univ Birmingham, IAHR, ITM, Birmingham, W Midlands, EnglandAD  - Post Grad Inst Med Educ & Res, Dept Interna Med, Chandigarh, IndiaAD  - Post Grad Inst Med Educ & Res, Dept Pediat, Chandigarh, IndiaAD  - London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Med Stat, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, EnglandAD  - London Sch Hyg & Trop Med, London, EnglandAD  - Nepal Acad Sci & Technol, Patan, NepalAD  - Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, PakistanAD  - Aga Khan Univ, Human Dev Programme, Karachi, PakistanAD  - Babol Univ Med Sci, Social Determinants Hlth Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Hlth Res Inst, Babol Sar, IranAD  - Babol Univ Med Sci, Dept Immunol, Babol Sar, IranAD  - Babol Univ Med Sci, Dept Clin Biochem, Babol Sar, IranAD  - Babol Univ Med Sci, Cellular & Mol Biol Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Infect Dis & Trop Med Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Immunoregulat ves Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Dept Microbiol & Immunol, Babol Sar, IranAD  - Babol Univ Med Sci, Student Res Comm, Babol Sar, IranAD  - Babol Univ Med Sci, Babol Sar, IranAD  - Imperial Coll London, Dept Epidemiol & Biostat, London, EnglandAD  - Imperial Coll London, Dept Primary Care & Publ Hlth, London, EnglandAD  - Imperial Coll London, WHO Collaborating Ctr Publ Hlth Educ & Training, London, EnglandAD  - Woldia Univ, Woldia, EthiopiaAD  - Univ Dhaka, Dept Clin Pharm & Pharmacol, Ramna, BangladeshAD  - Res Triangle Inst Int, Global Hlth Div, Res Triangle Pk, NC USAAD  - Univ Nottingham, Sch Med, Nottingham, EnglandAD  - AT Still Univ, Dept Hlth Sci, Brisbane, Qld, AustraliaAD  - Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, NorwayAD  - Univ Bergen, Dept Psychosocial Sci, Bergen, NorwayAD  - Canc Registry Norway, Dept Res, Oslo, NorwayAD  - Canc Registry Norway, Radiat Med, Portland, OR USAAD  - Univ Texas Houston, Dept Pediat, Houston, TX USAAD  - Univ Texas Houston, Dept Epidemiol Human Genet & Environm Sci, Houston, TX USAAD  - Murdoch Childress Res Inst, Ctr Adolescent Hlth, Melbourne, Vic, AustraliaAD  - Murdoch Childress Res Inst, Populai Hlth Grp, Melbourne, Vic, AustraliaAD  - Murdoch Childress Res Inst, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Sch Hlth Sci, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Dept Paediat, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Dept Med, Melbourne, Vic, AustraliaAD  - Minist Publ Hlth, Dept Vital & Hlth Stat, Beirut, LebanonAD  - Minist Publ Hlth, Dept Dis Epidem & Pandem Control, Beirut, LebanonAD  - Minist Publ Hlth, Beirut, LebanonAD  - Univ New South Wales, Transport & Rd Safety Res, Sydney, NSW, AustraliaAD  - Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Publ Hlth & Community Med, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Med, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Psychiat, Sydney, NSW, AustraliaAD  - Anglia Ruskin Univ, Vis & Eye Res Unit, Cambridge, EnglandAD  - Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, CanadaAD  - Univ British Columbia, Div Occupat & Environm Hlth, Vancouver, BC, CanadaAD  - Univ British Columbia, Vancouver, BC, CanadaAD  - Comenius Univ, Inst Epidemiol, Bratislava, SlovakiaAD  - Ohio State Univ, Dept Psychol, Columbus, OH USAAD  - Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USAAD  - Ohio State Univ, Psychiat & Behav Hlth Dept, Columbus, OH 43210 USAAD  - German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, GermanyAD  - Hlth Technol Assessment Assoc, Comm Comprehens Assessment Med Devices & Informat, Moscow, RussiaAD  - Inst Sci Res & ligh Technol Serv, Neurosci Dept, City Of Knowledge, PanamaAD  - Gorgas Mem Inst Hlth Studies, Dept Res & Hlth Technol Assessment, Panama City, PanamaAD  - Gorgas Mem Inst Hlth Studies, Panama City, PanamaAD  - Cabrini Inst, Monash Dept Clin Epidemiol, Melbourne, Vic, AustraliaAD  - Cabrini Inst, Melbourne, Vic, AustraliaAD  - Hlth Canada, Populat Studies Div, Ottawa, ON, CanadaAD  - Al Shifa Trust Eye Hosp, Al Shifa Sch Publ Hlth, Rawalpindi, PakistanAD  - Natl Inst Publ Hlth, Ctr Hlth Syst Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Ctr Evaluat & Surveys Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Ctr Nutr & Hlth Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Dept Tobacco Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Director Gen, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Cuernavaca, Morelos, MexicoAD  - Metropolitan Autonomous Univ, Dept Populat & Hlth, Mexico City, DF, MexicoAD  - Inst Canc Res Prevent & Clin Network, Florence, ItalyAD  - Univ Porto, Inst Publ Hlth, Porto, PortugalAD  - Univ Porto, Inst Biomedical Engn, Porto, PortugalAD  - Univ Porto, REQUIMTEI, LAQV, Porto, PortugalAD  - Univ Porto, Dept Community Med, Porto, PortugalAD  - Univ Porto, Appl Mol Biosci Unit, Porto, PortugalAD  - Univ Porto, Inst Res & Innovat Hlth, Porto, PortugalAD  - Natl Inst Hlth, Colombian Natl Hlth Observ, Bogota, ColombiaAD  - Natl Inst Hlth, Natl Inst Deafness & Other Commun Disorders, Bogota, ColombiaAD  - Natl Inst Hlth, Natl Ctr Dis Prevent & Hlth Promot, Bogota, ColombiaAD  - Univ Nacl Colombia, Epidemiol & Publ Hlth Evaluat Grp, Bogota, ColombiaAD  - Univ Nacl Colombia, Dept Publ Hlth, Bogota, ColombiaAD  - Costa Rican Dept Social Secur, Area Estadist, Direct Actuarial, San Jose, Costa RicaAD  - Univ Costa Rica, Sch Dent, San Pedro, Costa RicaAD  - Inst Hlth Carlos Ill, Dept Hlth Planning & Econ, Madrid, SpainAD  - Australian Catholic Univ, Mary Mackillop Inst Hlth Res, Melbourne, Vic, AustraliaAD  - Australian Catholic Univ, Inst Posit Psychol & Educ, Melbourne, Vic, AustraliaAD  - Australian Catholic Univ, Brain Inst, Melbourne, Vic, AustraliaAD  - Univ Hong Kong, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ Hong Kong, Ctr Suicide Res & Prevent, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ Hong Kong, Hong Kong, Hong Kong, Peoples R ChinaAD  - Alfaisal Univ, Coll Med, Riyadh, Saudi ArabiaAD  - Inst Populat Hlth Sci, Natl Hlth Res Inst, Zhunan Township, TaiwanAD  - Natl Taiwan Univ, Coll Med, Taipei, TaiwanAD  - NOVA Earth Syst Res Lab, Chem Sci Div, Boulder, CO USAAD  - Int Inst Populat Sci, Dept Dev Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Dept Populat Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Dept Publ Hlth & Mortal Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Bombay, Maharashtra, IndiaAD  - Univ West Indies, Fac Med Sci, St Augustine, Trinidad TobagoAD  - Univ West Indies, Dept Community Hlth & Psychiat, St Augustine, Trinidad TobagoAD  - Singapore Eye Res Inst, Dept Stat, Singapore, SingaporeAD  - Singapore Eye Res Inst, Ocular Epidemiol Res Grp, Singapore, SingaporeAD  - Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program, Singapore, SingaporeAD  - Gold Coast Hlth, Clin Governance, Gold Cost, Qld, AustraliaAD  - Univ Occupat & Environm Hlth, Inst Ind Ecol Sci, Kitakyushu, Fukuoka, JapanAD  - Minist Hlth, Dept Paediat Cardiol, Baghdad, IraqAD  - Minist Hlth, Epidemiol & Dis Control, Baghdad, IraqAD  - Minist Hlth, Res Dept, Prince Mohammed Bin Abdulaziz Hosp, Baghdad, IraqAD  - Minist Hlth, NCD Prevent & Control Unit, Baghdad, IraqAD  - Minist Hlth, Hlth & Disabil Intelligence Grp, Baghdad, IraqAD  - Minist Hlth, Policy & Planning Div, Baghdad, IraqAD  - Minist Hlth, Baghdad, IraqAD  - Seoul Natl Univ Hosp, Biochem, Biomed Sci, Seoul, South KoreaAD  - Univ Cambridge, Dept Hlth & Primary Care, Cambridge, EnglandAD  - Univ Copenhagen, Inst Clin Med, Copenhagen, DenmarkAD  - Univ Copenhagen, Bispebjerg Hosp, Copenhagen, DenmarkAD  - Univ Copenhagen, Dept Neurol, Copenhagen, DenmarkAD  - Christian Med Coll & Hosp CMC, Dept Pulm Med, London, EnglandAD  - Christian Med Coll & Hosp CMC, Dept Endocrinol, London, EnglandAD  - Christian Med Coll & Hosp CMC, Vellore, Tamil Nadu, IndiaAD  - UCL, Agcy Hlth Technol Assessment & Tariff Syst, London, EnglandAD  - UCL, Dept Hlth Informat, London, EnglandAD  - UCL, Dept Epidemiol & Publ Hlth, London, EnglandAD  - UCL, Dept Psychol, London, EnglandAD  - Hlth Data Res UK, London, EnglandAD  - Univ Salerno, Scuola Med Salernitana, Baronissi, ItalyAD  - Hlth Effects Inst, Boston, MA USAAD  - Autonomous Univ Cltile, Fac Educ, Talca, ChileAD  - Autonomous Univ Cltile, Inst Phys Activ & Hlth, Talca, ChileAD  - Univ Southampton, NIHR Oxford Biomed Res Ctr, Southampton, Hants, EnglandAD  - Univ Colorado, Cooperat Inst Res Environm Sci, Boulder, CO 80309 USAAD  - Univ Milano Bicocca, Sch Med & Surg, Monza, ItalyAD  - Arizona Slate Univ, T Denny Sanford Sch Social & Family Dynam, Tempe, AZ USAAD  - Ctr Dis Control & Prevent CDC, Div Reprod Hlth, Atlanta, GA USAAD  - Fed Univ Rio Grande, Postgrad Program Epidemiol, Porto Alegre, RS, BrazilAD  - Fed Univ Rio Grande, Dept Internal Med Neurol, Porto Alegre, RS, BrazilAD  - Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USAAD  - Univ Calif San Diego, Dept Internal Med, La Jolla, CA 92093 USAAD  - Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USAAD  - Univ Southern Calif, Internal Med Dept, Los Angeles, CA 90033 USAAD  - Hawassa Univ, Coll Med & Hlth Sci, Hawassa, EthiopiaAD  - Hawassa Univ, Dept Reprod Hlth, Hawassa, EthiopiaAD  - Flinders Univ S Australia, Discipline Publ Hlth, Adelaide, SA, AustraliaAD  - Eduardo Mondlane Univ, Fac Med, Maputo, MozambiqueAD  - Guys & St Thomas NI IS Fdn Trust, Clin Toxicol Serv, London, EnglandAD  - Guys & St Thomas NI IS Fdn Trust, Biomed Res Council, London, EnglandAD  - BRAG Univ, James P Grant Sch Publ Hlth, Dhaka, BangladeshAD  - BRAG Univ, Res & Evaluat Div, Dhaka, BangladeshAD  - Cent Univ Tamil Nadu, Thiruvarur, IndiaAD  - Clin Emergency Hosp Sf Pantelimon, Dept Surg, Bucharest, RomaniaAD  - Kazakh Natl Med Univ, Alma Ata, KazakhstanAD  - Griffith Univ, Australian Inst Suicide Res & Prevent, Mt Gravan, Qld, AustraliaAD  - Griffith Univ, Menzies Hlth Inst Queensland, Mt Gravan, Qld, AustraliaAD  - Univ Colorado, Sch Med, Aurora, CO USAAD  - US Dept Vet Affairs, Dermatol Serv, Denver, CO USAAD  - Aksum Univ, Dept Clin Pharm, Aksum, EthiopiaAD  - Aksum Univ, Dept Med, Lab Sci, Aksum, EthiopiaAD  - Brighton & Sussex Med Sch, Dept Global Hlth & Infect, Brighton, E Sussex, EnglandAD  - Natl Hlth Serv Scotland, Edinburgh, Midlothian, ScotlandAD  - Aristotle Univ Thessaloniki, Thessaloniki, GreeceAD  - Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USAAD  - Disha Fdn, Gurgaon, IndiaAD  - Univ Peradeniya, Dept Community Med, Peradeniya, Sri LankaAD  - Nepal Hlth Res Council, Hlth Res Sect, Kathmandu, NepalAD  - Nepal Hlth Res Council, Journal Nepal Hlth Res Council, Kathmandu, NepalAD  - Minist Hlth & Med Educ, Deputy Res & Technol, Tehran, IranAD  - Minist Hlth & Med Educ, Tehran, IranAD  - Duy Tan Univ, Inst Global Hlth Innovat, Hanoi, VietnamAD  - Med Univ Varna, Dept Social Med & Hlth Care Org, Varna, BulgariaAD  - Univ Cape Coast, Dept Populat & Hlth, Cape Coast, GhanaAD  - Univ Tampere, Fac Social Sci, Tampere, FinlandAD  - Univ Tampere, Fac Hlth Sci, Tampere, FinlandAD  - RMIT Univ, Sch Hlth & Biomed Sci, Bundoora, Vic, AustraliaAD  - Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, AustraliaAD  - Univ Sydney, Inst Bone & Joint Res, Sydney, NSW, AustraliaAD  - Univ Sydney, Asbestos Dis Res Inst, Sydney, NSW, AustraliaAD  - Univ Sydney, Sydney, NSW, AustraliaAD  - United Nations World Food Programme, New Delhi, IndiaAD  - Univ Fed Bahia, Sch Med, Salvador, BA, BrazilAD  - Roberto Santos Gen Hosp, Med Directory, Salvador, BA, BrazilAD  - Umea Univ, Dept Nursing, Umea, SwedenAD  - Univ Newcastle, Clin Epidemiol & Biostat, Newcastle, NSW, AustraliaAD  - Univ Tromso, Dept Community Med, Tromso, NorwayAD  - Eijkman Inst Mol Biol, Eijkman Oxford Clin Res Unit, Jakarta, IndonesiaAD  - St Pauls Hosp, Millennium Med Coll, Publ Hlth Dept, Addis Ababa, EthiopiaAD  - Queensland Ctr Mental Hlth Res, Policy & Epidemiol Grp, Brisbane, Qld, AustraliaAD  - Queensland Ctr Mental Hlth Res, Child & Youth Mental Hlth, Brisbane, Qld, AustraliaAD  - Queensland Ctr Mental Hlth Res, Brisbane, Qld, AustraliaAD  - Urmia Univ Med Sci, Deparmtent Med Parasitol & Mycol, Orumiyeh, IranAD  - Imam Muhammad Ibn Saud Islamic Univ, Coll Med, Riyadh, Saudi ArabiaAD  - Imam Muhammad Ibn Saud Islamic Univ, Dept Publ Hlth, Riyadh, Saudi ArabiaAD  - Univ Louisville, Div Cardiovasc Med, Louisville, KY 40292 USAAD  - Natl Stat Off, Lisbon, PortugalAD  - Univ Bologna, Dept Med & Surg Sci, Bologna, ItalyAD  - Univ Fed Sergipe, Dept Psychol, Sao Cristovao, BrazilAD  - Hamadan Univ Med Sci, Social Determinants Hlth Res Ctr, Hamadan, IranAD  - Hamadan Univ Med Sci, Dept Epidemiol, Hamadan, IranAD  - Hamadan Univ Med Sci, Dept Environm Hlth Engn, Hamadan, IranAD  - Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New ZealandAD  - Org Econ Cooperat arid Dev, Hlth Div, Paris, FranceAD  - Catholic Univ Portugal, Ctr Biotechnol & Fine Chem, Porto, PortugalAD  - Kaiser Permanente, Psychiat Dept, Fontana, CA USAAD  - Robert Koch Inst, Dept Epidemiol & Hlth Monitoring, Berlin, GermanyAD  - Univ Bielefeld, Dept Publ Hlth Med, Bielefeld, GermanyAD  - Natl Acad Med Sci Ukraine, Inst Gerontol, Kiev, UkraineAD  - Canc Inst, Gene Express & Regulat Program, Philadelphia, PA USAAD  - Kobe Univ, Dept Dermatol, Kobe, Hyogo, JapanAD  - Swiss Trop & Publ Hlth Inst, Epidemiol & Publ Hlth, Basel, SwitzerlandAD  - Swiss Trop & Publ Hlth Inst, Malaria Vaccines, Basel, SwitzerlandAD  - Univ Basel, Basel, SwitzerlandAD  - Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, AustraliaAD  - NCDC, Tbilisi, GeorgiaAD  - Manhica Hlth Res Ctr, Manhica, MozambiqueAD  - Curtin Univ, Sch Publ Hlth, Perth, WA, AustraliaAD  - Wageningen Univ & Res, Div Human Nutr & Hlth, Wageningen, NetherlandsAD  - Univ Tsukuba, Dept Hlth Care Policy & Management, Tsukuba, Ibaraki, JapanAD  - Univ Calif San Francisco, Inst Global Hlth Sci, San Francisco, CA 94143 USAAD  - Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USAAD  - Natl Allergy Asthma & Bronchitis Inst, Kolkota, IndiaAD  - Fortis Hosp, Dept Resp Med, Kolkata, IndiaAD  - Natl Publ Hlth Inst, Dept Cardiovasc Dysmetabol & Ageing Associated Di, Rome, ItalyAD  - Natl Publ Hlth Inst, Ctr Res Evaluat & Surveys, Rome, ItalyAD  - Texas Tech Univ, Dept Publ Hlth, Lubbock, TX 79409 USAAD  - Univ Warwick, Unit Acad Primary Care, Coventry, W Midlands, EnglandAD  - Univ Warwick, Div Hlth Sci, Coventry, W Midlands, EnglandAD  - Univ Adelaide, Adelaide Med Sch, Adelaide, SA, AustraliaAD  - Univ Adelaide, Adelaide, SA, AustraliaAD  - Howard Univ, Dept Community & Family Med, Washington, DC 20059 USAAD  - Howard Univ, Div Gen Internal Med, Washington, DC 20059 USAAD  - Univ Hail, Dept Family & Community Med, Hail, Saudi ArabiaAD  - Res Ctr Neurol, Moscow, RussiaAD  - Jawahar Lal Nehru Univ, Ctr Study Reg Dev, New Delhi, IndiaAD  - Univ Massachusetts, Nursing & Hlth Sci Dept, Boston, MA 02125 USAAD  - Univ Oklahoma, Dept Biostat & Epidemiol, Oklahoma City, OK USAAD  - Govt Federated States Micronesia, Dept Hlth & Social Affairs, Palikir, MicronesiaAD  - Boston Univ, Federated States Micronesia, Boston, MA 02215 USAAD  - Boston Univ, Sch Med, Boston, MA 02215 USAAD  - Boston Univ, Sch Publ Hlth, Boston, MA 02215 USAAD  - Vittorio Emanuele Univ Hosp Polyclin, Registro Tumor Integrato, Catania, ItalyAD  - St James Sch Med, Dept Epidemiol, The Valley, AnguillaAD  - St James Sch Med, Dept Microbiol, The Valley, AnguillaAD  - West Virginia Bur Publ Hlth, Commissioner Publ Hlth, Charleston, WV USAAD  - West Virginia Univ, Sch Publ Hlth, Dept Hlth Policy Management & Leadership, Morgantown, WV USAAD  - Rajasthan Univ Hlth Sci, Acad & Res, Jaipur, Rajasthan, IndiaAD  - Eternal Heart Care Ctr & Res Inst, Dept Prevent Cardiol, Jaipur, Rajasthan, IndiaAD  - Montefiore Med Ctr, Dept Cardiol, 111 E 210th St, Bronx, NY 10467 USAAD  - Montefiore Med Ctr, Dept Epidemiol & Populat Hlth, 111 E 210th St, Bronx, NY 10467 USAAD  - Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USAAD  - Albert Einstein Coll Med, Bronx, NY 10467 USAAD  - Ramon Fuente Muniz Natl Inst Psychiat, Dept Epidemiol & Psychosocial Res, Mexico City, DF, MexicoAD  - Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, NetherlandsAD  - Univ Med Ctr Groningen, Dept Epidemiol, Groningen, NetherlandsAD  - Univ Med Ctr Groningen, Dept Psychiat, Groningen, NetherlandsAD  - Univ Western Ontario, Dept Clin Neurol Sci, London, ON, CanadaAD  - Univ Western Ontario, Clin Neurol Sci, London, ON, CanadaAD  - Lawson Hlth Res Inst, London, ON, CanadaAD  - Arabian Gulf Univ, Dept Family & Community Med, Manama, BahrainAD  - Hamdan Bin Mohammed Smart Univ, Sch Hlth & Environm Studies, Dubai, U Arab EmiratesAD  - Univ New Mexico, Populat Hlth Dept, Albuquerque, NM 87131 USAAD  - Sir Charles Gairdner Hosp, Neurol Dept, Perth, WA, AustraliaAD  - Sun Yat Sen Univ, Sun Yatsen Global Hlth Inst, Guangzhou, Guangdong, Peoples R ChinaAD  - Sun Yat Sen Univ, Dept Med Stat & Epidemiol, Guangzhou, Guangdong, Peoples R ChinaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Cardiol Dept, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Achmttha Menon Ctr Hlth Sci Studies, Trivandrum, Kerala, IndiaAD  - Res & Dev Unit, San Juan Dios Sanitary Pk, Sant Boi De Llobregat, SpainAD  - Univ Barcelona, Dept Med, Barcelona, SpainAD  - Tabriz Univ Med Sci, Hlth Educ & Hlth Promot Dept, Sch Publ Hlth, Tabriz, IranAD  - Tabriz Univ Med Sci, Tabriz, IranAD  - Univ Hosp Antwerp, Unit Epidemiol & Social Med, Antwerp, BelgiumAD  - Karolinska Univ Hosp, Clin Sci Dept, Stockholm, SwedenAD  - Teikyo Univ, Sch Med, Endocrinol & Metab Res Ctr, Tehran, IranAD  - Hormozgan Univ Med Sci, Dept Environm Hlth Engn, Bandar Abbas, IranAD  - Bucharest Univ Econ Studies, Dept Stat & Econometr, Bucharest, RomaniaAD  - Ohio Univ, Dept Biol Sci, Zanesville, OH USAAD  - Tigray Hlth Res Inst, Mekelle, EthiopiaAD  - Columbia Univ, Dept Epidemiol, New York, NY USAAD  - Columbia Univ, Dept Epidemiol, New York, NY USAAD  - NIH, Div Sci Programs, Bldg 10, Bethesda, MD 20892 USAAD  - NIH, Ctr Translat Res & Implementat Sci, Bldg 10, Bethesda, MD 20892 USAAD  - Univ Texas Austin, Austin, TX 78712 USAAD  - Guilan Univ Med Sci, Sch Hlth, Rasht, IranAD  - Guilan Univ Med Sci, Guilan Rd Trauma Res Ctr, Rasht, IranAD  - Manipal Univ, Transdisciplinary Ctr Qualitat Methods, Manipal, IndiaAD  - Univ Human Dev, Univ Human Dev, Sulaimaniyah, IraqAD  - Univ Human Dev, Dept Comp Sci, Sulaimaniyah, IraqAD  - Bucharest Emergency Hosp, Dept Internal Med, Bucharest, RomaniaAD  - Natl Inst Legal Med Mina Minovici, Clin Legal Med, Bucharest, RomaniaAD  - Med Sch Tunis, Fac Med Tunis, Baab Saadoun, TunisiaAD  - Cent South Univ, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R ChinaAD  - Aarhus Univ, Dept Publ Hlth, Aarhus, DenmarkAD  - Aarhus Univ, Natl Ctr Register Based Res, Aarhus, DenmarkAD  - Natl Inst Biomed lunovat Hlth & Nutr, Sect Populat Hlth Metr, Shinjuku Ku, Ibaraki, JapanAD  - Natl Inst Biomed lunovat Hlth & Nutr, Int Ctr Nutr & Informat, Shinjuku Ku, Ibaraki, JapanAD  - Univ Lib, Monrovia, LiberiaAD  - Univ Lib, Dept Publ Hlth & Community Med, Monrovia, LiberiaAD  - Taipei Med Univ, Global Hlth & Dev Dept, Taipei, TaiwanAD  - Taipei Med Univ, Grad Inst Biomed Informat, Taipei, TaiwanAD  - Amer Canc Soc, Surveillance & Hlth Serv Res, Atlanta, GA 30329 USAAD  - George Mason Univ, Dept Global & Community Hlth, Fairfax, VA 22030 USAAD  - Natl Ctr Dis Control Delhi, Dept Parasit Dis, Delhi, IndiaAD  - Univ Kragujevac, Med Sci Dept, Kragujevac, SerbiaAD  - Univ Colombo, Fac Grad Studies, Colombo, Sri LankaAD  - Univ Colombo, Inst Med, Colombo, Sri LankaAD  - Bananas Hindu Univ, Dept Community Med, Varanasi, Uttar Pradesh, IndiaAD  - George Inst Global Hlth, Cardiometabol Grp, New Delhi, IndiaAD  - Duke Kunshan Univ, Environm Res Ctr, Kunshan, Peoples R ChinaAD  - Duke Kunshan Univ, Global Hlth Res Ctr, Kunshan, Peoples R ChinaAD  - Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R ChinaAD  - New South Wales Hlth, Sydney, NSW, AustraliaAD  - Univ Social Welf & Rehabil Sci, Tehran, IranAD  - All India Inst Med Sci, Ctr Community Med, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Forens Med & Toxicol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Paediat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiat Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol Metab Diabet, New Delhi, IndiaAD  - Czestochowa Tech Univ, Inst Hlth & Nutr Sci, Czestochowa, PolandAD  - Univ Opole, Fac Med & Hlth Sci, Opole, PolandAD  - Univ Tartu, Inst Family Med & Publ Hlth, Tartu, EstoniaAD  - Univ Coll Cork, Sch Publ Hlth, Cork, IrelandAD  - King Georges Med Univ, Dept Resp Med, Lucknow, Uttar Pradesh, IndiaAD  - Srirama Chandra Blianja Med Coll & Hosp, Dept Nephrol, Cuttack, Orissa, IndiaAD  - Dept Epidemiol, Helmholtz Ctr Infect Res, Braunschweig, GermanyAD  - Qual & Equity Healthcare, Kigali, RwandaAD  - Univ Washington, Sch Interdisciplinary Arts & Sci, Tacoma, WA USAAD  - Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, Seattle, WA USAAD  - Univ Glasgow, CSO Social & Publ Hlth Sci Unit, MRC, Glasgow, Lanark, ScotlandAD  - Oklahoma State Univ, Sch Hlth Care Adm, Tulsa, OK USAAD  - Univ Tulsa, Hlth Care Delivery Sci, Tulsa, OK 74104 USAAD  - Univ Nairobi, ODeL Campus, Nairobi, KenyaAD  - Univ Nairobi, Nairobi, KenyaAD  - Michigan State Univ, Dept Linguist & German Slav Asian & African Langu, E Lansing, MI 48824 USAAD  - Med Res Council South Africa, Noncommunicable Dis Res Unit, Cape Town, South AfricaAD  - Med Res Council South Africa, Alcohol Tobacco 8t Other Drug Use Res Unit, Cape Town, South AfricaAD  - Med Res Council South Africa, Cochrane South Africa, Cape Town, South AfricaAD  - Univ Cape Town, Dept Med, Cape Town, South AfricaAD  - Univ Cape Town, Dept Psychiat & Mental Hlth, Cape Town, South AfricaAD  - Inst Cardiol, Assuta Hosp, Tel Aviv, IsraelAD  - Hadassah Hebrew Univ Hosp, Heart Failure & Cardionlyopathies Ctr, Jerusalem, IsraelAD  - CSIR, Indian Inst Toxicol Res Council Sci & Ind Res, Lucknow, Uttar Pradesh, IndiaAD  - Jordan Univ Sci Technol, Dept Publ Hlth & Community Med, Ramtha, JordanAD  - Azad Univ, Dept Stat, Ontidiyelt Branch, Tehran, IranAD  - Univ Management & Technol, Sch Food & Agr Sci, Lahore, PakistanAD  - United Arab Emirates Univ, Dept Med Microbiol & Immunol, Al Ain, U Arab EmiratesAD  - Jr Hosp Cook Cty, Dept Internal Med, Chicago, IL USAAD  - Dow Univ Hlth Sci, Dept Internal Med, Karachi, PakistanAD  - Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USAAD  - Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USAAD  - Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USAAD  - Univ Alabama Birmingham, Birmingham, AL USAAD  - Univ Tennessee, Dept Pediat, Knoxville, TN USAAD  - Univ Tennessee, Knoxville, TN USAAD  - Seoul Natl Univ, Inst Hlth Policy & Management, Seoul, South KoreaAD  - Seoul Natl Univ, Dept Hlth Policy & Management, Seoul, South KoreaAD  - Lund Univ, Clin Epidemiol Unit, Lund, SwedenAD  - Lund Univ, Dept Clin Sci, Lund, SwedenAD  - Kenya Revenue Author, Nairobi, KenyaAD  - Synotech Consultant, Res & Data Solut, Nairobi, KenyaAD  - Korea Hlth Ind Dev Inst, Cheongju, South KoreaAD  - Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USAAD  - Korea Univ, Dept Prevent Med, Seoul, South KoreaAD  - Korea Univ, Seoul, South KoreaAD  - Xiamen Univ Malaysia, Sch Med, Sepang, MalaysiaAD  - Simmons Coll, Dept Nutr, Boston, MA 02115 USAAD  - Univ Canberra, Fac Hlth, Canberra, ACT, AustraliaAD  - Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, NorwayAD  - Univ Oslo, Inst Hlth & Soc, Oslo, NorwayAD  - Tulane Univ, Dept Global Community Hlth & Behav Sci, New Orleans, LA USAAD  - Jagiellonian Univ, Med Coll, Dept Hlth Econ & Social Secur, Krakow, PolandAD  - Jagiellonian Univ, Med Coll, Inst Publ Hlth, Krakow, PolandAD  - Univ Helsinki, Dept Publ Hlth, Helsinki, FinlandAD  - Univ Helsinki, Helsinki, FinlandAD  - Norwegian Inst Publ Hlth, Ctr Dis Burden, Bergen, NorwayAD  - Norwegian Inst Publ Hlth, Div Mental & Phys Hlth, Bergen, NorwayAD  - Norwegian Inst Publ Hlth, Bergen, NorwayAD  - Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Suita, Osaka, JapanAD  - Arthrit Res Canada, Richmond, BC, CanadaAD  - Sheri Kashmir Inst Med Sci, Dept Internal & Pulm Med, Srinagar, Jammu & Kashmir, IndiaAD  - Panjab Univ, Dept Anthropol, Chandigarh, IndiaAD  - Univ Utrecht, Inst Risk Assessment Sci, Utrecht, NetherlandsAD  - Univ Montreal, Dept Social & Prevent Med, Montreal, PQ, CanadaAD  - Univ Montreal, Dept Demog, Montreal, PQ, CanadaAD  - Yuksek Ihtisas Univ, Dept Publ Hlth, Ankara, TurkeyAD  - Hacettepe Univ, Dept Publ Hlth, Ankara, TurkeyAD  - Univ Ghent, Dept Food Technol Safety & Hlth, Ghent, BelgiumAD  - Finnish Inst Occupat Hlth, Populat & Work Abil Program, Helsinki, FinlandAD  - Finnish Inst Occupat Hlth, Helsinki, FinlandAD  - Acad Med Sci, Dept Community & Family Med, Baghdad, IraqAD  - HelpMeSee, New York, NY USAAD  - Mexican Inst Ophthalmol, Relac Int, Queretaro, MexicoAD  - Maragheh Univ Med Sci, Dept Publ Hlth, Maragheh, IranAD  - Maragheh Univ Med Sci, Managerial Epidemiol Res Ctr, Maragheh, IranAD  - Local Hlth Unit Tuscany Ctr, Reg Ctr Anal Data Occupat & Work Related Injuries, Florence, ItalyAD  - Univ Florence, Dept Hlth Sci, Florence, ItalyAD  - Wellcome Trust Asia Programme, Oxford Univ Clin Res Unit, Hanoi, VietnamAD  - Shenzhen Sun Yat Sen Cardiovasc Hosp, Dept Clin Res & Epidemiol, Shenzhen, Peoples R ChinaAD  - Natl Off Maternal & Child Hlth Surveillance, Chengdu, Sichuan, Peoples R ChinaAD  - Natl Ctr Birth Defects Monitoring China, Chengdu, Sichuan, Peoples R ChinaAD  - Chinese Ctr Dis Control & Prevent, Noncommunicable Dis Control & Prevent Ctr, Beijing, Peoples R ChinaAD  - Chinese Ctr Dis Control & Prevent, Beijing, Peoples R ChinaAD  - Alliance Improving Hlth Outcomes Inc, Quezon City, PhilippinesAD  - Samara Univ, Dept Publ Hlth, Samara, EthiopiaAD  - Univ Malaya, Dept Med, Kuala Lumpur, MalaysiaAD  - Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R ChinaAD  - Univ Haifa, Sch Publ Hlth, Haifa, IsraelAD  - Ctr Chron Dis Control, Beijing, Peoples R ChinaAD  - Univ Bari Aldo Moro, Bari, ItalyAD  - Fdn Cardinale Giovanni Panico Hosp, Dept Clin Res Neurol, Tricase, ItalyAD  - Friedrich Schiller Univ Jena, Inst Nutr, Jena, GermanyAD  - Competence Cluster Nutr & Cardiovasc Hlth NUTRICA, Innovat Off, Jena, GermanyAD  - Competence Cluster Nutr & Cardiovasc Hlth NUTRICA, Jena, GermanyAD  - Aintree Univ Hosp Natl Hlth Serv Fdn Trust NHS, Gen Surg Dept, Liverpool, Merseyside, EnglandAD  - Univ Liverpool, Surg Dept, Liverpool, Merseyside, EnglandAD  - Natl Univ Singapore, Saw Swee Hods Sch Publ Hlth, Singapore, SingaporeAD  - Natl Univ Singapore, Yong Lou Lin Sch Med, Singapore, SingaporeAD  - Fed Univ Iviinas Gerais, Nursing Sch, Belo Horizonte, MG, BrazilAD  - Fed Univ Iviinas Gerais, Dept Maternal & Child Nursing & Publ Hlth, Belo Horizonte, MG, BrazilAD  - Fed Univ Iviinas Gerais, Hosp Fed Univ Minas Gerais, Belo Horizonte, MG, BrazilAD  - Fed Univ Iviinas Gerais, Postgrad Program Infect Dis & Trop Med, Belo Horizonte, MG, BrazilAD  - Trnava Univ, Dept Publ Hlth, Trnava, SlovakiaAD  - Shiraz Univ Med Sci, Noncommunicable Dis Res Ctr, Shiraz, IranAD  - Emergency Univ Hosp Bucharest, Surg Dept, Bucharest, RomaniaAD  - Hosp Moinhos Vento, Neurol Serv, Porto Alegre, RS, BrazilAD  - Fed Inst Educ Sci & Technol Ceara, Campus Caucaia, Caucaia, BrazilAD  - Med Univ Graz, Clin Inst Med & Chem, Lab Diagnost, Graz, AustriaAD  - Univ East Ramon, Magsaysay Mem Med Ctr, Grad Sch, Quezon City, PhilippinesAD  - Indian Council Med Res, Natl Ctr Dis Informat & Res, Bengaluru, IndiaAD  - Indian Council Med Res, Reg Med Res Ctr, Bengaluru, IndiaAD  - Indian Council Med Res, Div Noncommunicable Dis, Bengaluru, IndiaAD  - Chalmers Univ Technol, Dept Biol & Biol Engn, Gothenburg, SwedenAD  - Hywel Dda Univ Hlth Board, Dept Ophthalmol, Carmarthen, Dyfed, WalesAD  - Natl Inst Canc Prevent & Res, Prevent Oncol, Noida, IndiaAD  - Sevenhills Hosp, Dept Internal Med, Bombay, Maharashtra, IndiaAD  - Martin Luther Univ Halle Wittenberg, Inst Agr & Nutrit Sci, Halle, GermanyAD  - Martin Luther Univ Halle Wittenberg, Inst Med Epidemiol, Halle, GermanyAD  - Debre Tabor Univ, Coll Hlth Sci, Debre Tabor, EthiopiaAD  - Univ West Florida, Dept Publ Hlth, Pensacola, FL 32514 USAAD  - United Nations Populat Fund UNFPA, Peru Country Off, Lima, PeruAD  - Helsinki Univ Hosp, Neuroctr, Helsinki, FinlandAD  - Helsinki Univ Hosp, Breast Surg Unit, Helsinki, FinlandAD  - Ctr Excellence Behav Med, Clin Microbiol & Parasitol Unit, Zagreb, CroatiaAD  - Univ North, Univ Ctr Varazdin, Varaedin, CroatiaAD  - Ethiopian Acad Med Sci, Dept Pharm, Mekelle, EthiopiaAD  - Pomeranian Med Univ, Dept Hypertens, Szczecin, PolandAD  - Pomeranian Med Univ, Zdroje Hosp, Szczecin, PolandAD  - Pomeranian Med Univ, Emergency Dept, Szczecin, PolandAD  - Pomeranian Med Univ, Szczecin, PolandAD  - Pacific Inst Res & Evaluat, Calverton, MD USAAD  - Nevada Div Publ & Behav Hlth, Carson, CA USAAD  - Natl Inst Stat, Presidents Off, Bucharest, RomaniaAD  - Kyrgyz State Med Acad, Fac Gen Med, Bishkek, KyrgyzstanAD  - Natl Ctr Cardiol & Internal Dis, Dept Atherosclerosis & Coronary Heart Dis, Bishkek, KyrgyzstanAD  - Frankfurt Univ Appl Sci, Inst Addict Res, Frankfurt, GermanyAD  - Salahaddin Univ, Dept Biol, Erbil, IraqAD  - Ishik Univ, Erbil, IraqAD  - Isfahan Univ Med Sci, Cardiovasc Res Inst, Esfahan, IranAD  - Ahmadu Bello Univ, Hlth Syst & Policy Res Unit, Zaria, NigeriaAD  - Ahmadu Bello Univ, Dept Community Med, Zaria, NigeriaAD  - Burka Garofolo Inst Maternal & Child Hlth, Clin Epidemiol & Publ Hlth Res Unit, Trieste, ItalyAD  - Univ Kwazulu Natal, Dept Publ Hlth Med, Durban, South AfricaAD  - Kurdistan Univ Med Sci, Dept Epidemiol & Biostat, Sanandaj, IranAD  - Kurdistan Univ Med Sci, Social Determinants Hlth Res Ctr, Sanandaj, IranAD  - Univ Lancaster, Lancaster, EnglandAD  - Queensland Univ Technol, Int Lab Air Qual & Hlth, Brisbane, Qld, AustraliaAD  - Queensland Univ Technol, Australian Ctr Hlth Serv Innovat, Brisbane, Qld, AustraliaAD  - Queensland Univ Technol, Sch Exercise & Nutr Sci, Brisbane, Qld, AustraliaAD  - Hosp Ctr Porto, Santo Antonio Hosp, Porto, PortugalAD  - Univ Athens, Dept Ophthalmol 1, Athens, GreeceAD  - Acad Athens, Biomed Res Fdn, Athens, GreeceAD  - Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA USAAD  - Fed Inst Populat Res, Demog Change & Ageing Res Area, Wiesbaden, GermanyAD  - Fed Inst Populat Res, Competence Ctr Mortal Follow Up, Wiesbaden, GermanyAD  - Fed Inst Populat Res, Wiesbaden, GermanyAD  - Ctr Populat & Hlth, Wiesbaden, GermanyAD  - Inst Post Grad Med Educ & Res, Dept Endocrinol & Metab, Kolkata, IndiaAD  - Sci Univ Malaysia, Sch Med Sci, Kubang Kerian, MalaysiaAD  - Nishtar Med Univ, Pediat Dept, Multan, PakistanAD  - Inst Mother Child Care, Pediat 8x Pediat Pulmonol, Multan, PakistanAD  - Ain Shams Univ, Dept Obstet & Gynecol, Cairo, EgyptAD  - Ain Shams Univ, Dept Entomol, Cairo, EgyptAD  - Int Ctr Diarrhoeal Dis Res, Initiat Non Communicable Dis, Dhaka, BangladeshAD  - Int Ctr Diarrhoeal Dis Res, Hlth Econ & Financing Res Grp, Dhaka, BangladeshAD  - Int Ctr Diarrhoeal Dis Res, Maternal & Child Hlth Div, Dhaka, BangladeshAD  - Suraj Eye Inst, Ophthalmol, Nagpur, Maharashtra, IndiaAD  - Univ Yaounde, Dept Publ Hlth, Yaounde, CameroonAD  - Cardioaid, Cardiol Dept, Bucharest, RomaniaAD  - Wellcome Inst Trust Res Programme, Neurosciences Dept, Kenya Med Res Inst, Kilifi, KenyaAD  - Univ Embu, Dept Biol Sci, Embu, KenyaAD  - Hanoi Sch Publ Hlth, Hlth Econ & Finance, Hanoi, VietnamAD  - Hanoi Sch Publ Hlth, Dept Hlth Econ, Hanoi, VietnamAD  - Xi An Jiao Tong Univ, Sch Humanities & Social Sci, Dept Sociol, Xian, Shaanxi, Peoples R ChinaAD  - Xi An Jiao Tong Univ, Sch Humanities & Social Sci, Inst Empir Social Sci Res, Xian, Shaanxi, Peoples R ChinaAD  - State Univ Semarang, Dept Publ Hlth Sci, Kota Semarang, IndonesiaAD  - Natl Ctr Global Hlth & Med, Inst Global Hlth Policy Res, Shinjyuku Ku, Tokyo, JapanAD  - Univ Aix Marseille, Inst Adv Res, Marseille, FranceAD  - Univ Western Sydney, Sch Social Sci & Psychol, Penrith, NSW, AustraliaAD  - Univ Western Sydney, Penrith, NSW, AustraliaAD  - Kyung Hee Univ, Dept Prevent Med, Seoul, South KoreaAD  - Human Sci Res Council, Dept HIV, AIDS STIs & TB, Durban, South AfricaAD  - Univ Namibia, Sch Publ Hlth, Oshakati Campus, Windhoek, NamibiaAD  - Univ Lagos, Dept Psychiat, Lagos, NigeriaAD  - Ctr Hlth Start Initiat, Ikoyi, NigeriaAD  - Univ Brunei Darussalam, Inst Hlth Sci, Gadong, BruneiAD  - San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USAAD  - Univ Ottawa, Sch Psychol, Ottawa, ON, CanadaAD  - Autonomous Univ Madrid, Sch Medicine, Madrid, SpainAD  - Autonomous Univ Madrid, Pneumol Serv, Madrid, SpainAD  - Jimenez Diaz Univ Hosp, Inst Hlth Res Fdn, Dept Hypertens & Nephrol, Madrid, SpainAD  - St Lukes Int Univ, Dept Global Hlth Nursing, Chuo Ku, Tokyo, JapanAD  - Minist Hlth Russian Federat, Ctr Healthcare Qual Assessment & Control, Moscow, RussiaAD  - Moscow MV Lomonosov State Univ, Moscow Inst Phys & Technol, Dolgoprudnyi, RussiaAD  - Univ Ibadan, Inst Adv Med Res & Training, Ibadan, NigeriaAD  - Jagadgunt Sri Shivarathreeswara Univ, Dept TB & Resp Med, Mysore, Karnataka, IndiaAD  - Univ Chichester, Chichester, EnglandAD  - Ctr Hlth Outcomes Evaluat, Bucharest, RomaniaAD  - Kosin Univ, Dept Med Human & Social Med, Busan, South KoreaAD  - Maimonides Hosp, Dept Med, Brooklyn, NY 11219 USAAD  - Deemed Univ, Krishna Inst Med Sci, Kanad, IndiaAD  - Int Inst Hlth Management Res, New Delhi, IndiaAD  - Save Children, Hlth Nutr & HIV, AIDS, Kathmandu, NepalAD  - Cartagena Univ, Cartagena, ColombiaAD  - Univ Gothenburg, Inst Med, Gothenburg, SwedenAD  - Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South AfricaAD  - Shanghai Tiao Tong Univ, Shanghai Mental Hlth Ctr, Shanghai, Peoples R ChinaAD  - Durban Univ Technol, Basic Med Sci Dept, Durban, South AfricaAD  - Max Delbrueck Ctr Mol Med, Mol Epidemiol Res Grp, Berlin, GermanyAD  - German Fed Environm Agcy, Dept Environm Hyg, Dessau Rosslau, GermanyAD  - German Fed Environm Agcy, Dessau Rosslau, GermanyAD  - Univ Med Ctr Groningen, Univ Groningen, Groningen, NetherlandsAD  - Univ Otago, Dept Psychol, Dunedin, New ZealandAD  - Sanjay Gandhi Postgrad Inst Med Sci, Dept Nephrol, Lucknow, Uttar Pradesh, IndiaAD  - Govt Med Coll, Nagpur, Maharashtra, IndiaAD  - Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, IranAD  - Medichem, Barcelona, SpainAD  - Contech Sch Publ Hlth, Epidemiol & Biostat, Lahore, PakistanAD  - Soc Hlth & Demog Surveillance, Suri, IndiaAD  - Univ Gottingen, Dept Econ, Gottingen, GermanyAD  - Med Univ Innsbruck, Innsbruck, AustriaAD  - Nizarns Inst Med Sci, Dept Nephrol, Hyderabad, IndiaAD  - Yonsei Univ, Inst Poverty Alleviat & Int Dev, Seoul, South KoreaAD  - Univ Coll London Hosp, London, EnglandAD  - Publ Hlth England, London, EnglandAD  - Ctr Addict & Mental Hlth, Inst Mental Hlth Policy Res, Toronto, ON, CanadaAD  - Sydney NSW, Brien Holden Vis Inst, Sydney, NSW, AustraliaAD  - Org Prevent Blindness, Paris, FranceAD  - Univ Fed Uberlandia, Dept Clin Res, Uberlandia, MG, BrazilAD  - Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepa tology, Gorgan, IranAD  - Univ Ulm, Inst Epidemiol & Med Biometry, Ulm, GermanyAD  - Ikiarn Amazon Reg Univ, Biotechnol, Ciudad De Tena, EcuadorAD  - Southern Univ Sci & Technol, Dept Ocean Sci & Engn, Shenzhen, Peoples R ChinaAD  - Prince Wales Hosp, Neuropsychiat Inst, Randwick, NSW, AustraliaAD  - Univ Sharjah, Med Dept, Sharjah, U Arab EmiratesAD  - Mashhad Univ Med Sci, Dept Med Biotechnol, Mashhad, IranAD  - Al Imam Mohammad Ibn Saud Islamic Univ, Coll Med, Riyadh, Saudi ArabiaAD  - York Univ, Sch Hlth & Policy Management, Fac Hlth, Toronto, ON, CanadaAD  - Punjab Univ, Coll Pharm, Anarkali, PakistanAD  - Marshall Univ, Dept Surg, Huntington, WV USAAD  - Case Western Reserve Univ, Dept Nutr & Prevent Med, Cleveland, OH 44106 USAAD  - Jimenez Diaz Fdn Univ, Hosp Inst Hlth Res, Nephrol Grp, Madrid, SpainAD  - Reg Hlth Adm Norte IP, Dept Publ Hlth, Vila Nova De Gaia, PortugalAD  - Univ Massachusetts, Med Sch, Dept Med, Worcester, MA USAAD  - Univ Appl & Environm Sci, Dept Hlth & Soc, Fac Med, Bogota, ColombiaAD  - Hamad Med Corp, Surg Dept, Doha, QatarAD  - Bournemouth Univ, Fac Hlth Social Sci, Bournemouth, Dorset, EnglandAD  - Utkal Univ, UGC Ctr Adv Study Psychol, Bhubaneswar, IndiaAD  - UdyamGlobal Assoc Sustainable Dev, Bhubaneswar, IndiaAD  - Dr D Y Patti Vidyapeeth, Pune, Maharashtra, IndiaAD  - Univ N Carolina, Dept Publ Hlth Sci, Charlotte, NC USAAD  - Bayer, Istanbul, TurkeyAD  - Univ Fed Santa Catarina, Sch Hlth Sci, Ararangua, BrazilAD  - North West Univ, Africa Res Team HART, Potchefstroom, South AfricaAD  - Univ Zagreb, Dept Med Stat Epidemiol & Med Informat, Zagreb, CroatiaAD  - Croatian Inst Publ Hlth, Div Epidemiol & Prevent Chron Noncommunicable Dis, Zagreb, CroatiaAD  - Univ N Carolina, Dept Environm Sci & Engn, Chapel Hill, NC 27515 USAAD  - Univ Exeter, Dept Math, Exeter, Devon, EnglandAD  - NYU, Langone Med Ctr, New York, NY USAAD  - NYU, Inst Environm Med, 550 1St Ave, New York, NY 10016 USAAD  - An Najah Natl Univ, Publ Hlth Div, Nablus, PalestineAD  - Middle East Liver Dis Ctr, Dept Mol Hepatol, Tehran, IranAD  - Islamic Azad Univ, Dept Lab Sci, Sari, IranAD  - Islamic Azad Univ, Dept Basic Sci, Sari, IranAD  - Kerman Univ Med Sci, HIV, STI Surveillance Res Ctr, Kerman, IranAD  - Kerman Univ Med Sci, WHO Collaborating Ctr HIV Surveillance, Inst Futures Studies Hlth, Kerman, IranAD  - Delhi Technol Univ, Univ Sch Management & Entrepreneurship, New Delhi, IndiaAD  - Fudan Univ, Dept Pulm Med, Shanghai, Peoples R ChinaAD  - Fudan Univ, Dept Prevent Dent, Shanghai, Peoples R ChinaAD  - Fudan Univ, Shanghai, Peoples R ChinaAD  - Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, ScotlandAD  - Natl Inst Infect Dis, Tokyo, JapanAD  - Univ Technol Sydney, Sch Hlth, Sydney, NSW, AustraliaAD  - Reykjavik Univ, Dept Psychol, Reykjavik, IcelandAD  - Univ Brasilia, Brasilia, DF, BrazilAD  - Max Hosp, Ghaziabad, IndiaAD  - Dept Pulm Med, Jaipur, Rajasthan, IndiaAD  - Sch Prevent Oncol, Dept Epidemiol, Patna, Bihar, IndiaAD  - Healis Sekhsaria Inst Publ Hlth, Dept Epidemiol, Bombay, Maharashtra, IndiaAD  - King Khalid Univ Hosp, Pediat Dept, Riyadh, Saudi ArabiaAD  - Univ Calgary, Dept Med, Calgary, AB, CanadaAD  - Univ Hosp De La Princesa, Hlth Res Inst, Serv Pulmonol, Madrid, SpainAD  - Int Med Univ, Div Community Med, Kuala Lumpur, MalaysiaAD  - Fed Res Inst Hlth Org & Informat Minist Hlth FRIH, Moscow, RussiaAD  - Univ Hosp Munich, Inst & Outpatient Clin Occupat Social & Environm, Munich, GermanyAD  - Univ Hlth Sci Med Informat & Technol, Hlth Serv Res & Hlth Technol Assessment, Dept Publ Hlth, Hall In Tirol, AustriaAD  - Natl Ctr Dis Control & Publ Hlth, Noncommunicable Dis Dept, Tbilisi, GeorgiaAD  - Muhammadiyah Univ Surakarta, Dept Nursing, Kartasura, IndonesiaAD  - Muhimbili Univ Hlth & Allied Sci, Dept Community Hlth, Dar Es Salaam, TanzaniaAD  - Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, TanzaniaAD  - Univ Calif Riverside, Sch Med, Riverside, CA 92521 USAAD  - Univ Calif Irvine, Dept Criminol Law & Soc, Irvine, CA USAAD  - Univ Valencia, Dept Med, Valencia, SpainAD  - Univ Valencia, Dept Pediat Obstet & Gynecol, Valencia, SpainAD  - Biomed Res Networking Ctr Mental Hlth Network CIB, Carlos III Hlth Inst, Madrid, SpainAD  - Osaka Int Canc Inst, Canc Control Ctr, Osaka, JapanAD  - Asbestos Dis Res Inst Sydney, Sydney, NSW, AustraliaAD  - New York Med Coll, Dept Psychiat & Behav Sci, Valhalla, NY 10595 USAAD  - Univ Inst Egas Moniz, Monte Da Capanica, PortugalAD  - Univ Lisbon, Res Inst Med, Fac Pharm Lisbon, Lisbon, PortugalAD  - Univ Virginia, Anesthesiol Dept, Charlottesville, VA USAAD  - SEMA, Charlottesville, VA USAAD  - Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, SingaporeAD  - Univ Bath, Dept Math Sci, Bath, Avon, EnglandAD  - Univ Hosp Doctor Peset, Pediat Dept, Valencia, SpainAD  - Natl Inst Hlth & Med Res, Nutrit Epidemiol Res Team, Paris, FranceAD  - Hanoi Med Univ, Dept Hlth Econ, Hanoi, VietnamAD  - Mil Med Univ, Clin Hematol & Toxicol, Hanoi, VietnamAD  - Cleveland Clin Abu Dhabi, Cardiovasc Med, Abu Dhabi, U Arab EmiratesAD  - Fed Teaching Hosp, Dept Internal Med, Abakaliki, NigeriaAD  - Cornal Univ, Gomal Ctr Biochem & Biotechnol, Dera Ismail Khan, PakistanAD  - Mufti Mehmood Mem Teaching Hosp, TB Culture Lab, Dera Ismail Khan, PakistanAD  - Argentine Soc Med, Buenos Aires, ArgentinaAD  - Velez Sarsfield Hosp, Buenos Aires, DF, ArgentinaAD  - UKK Inst, Tampere, FinlandAD  - Raffles Hosp, Neurosci Ctr, Singapore, SingaporeAD  - St Orsola Malpighi Hosp, Occupat Hlth Unit, Bologna, ItalyAD  - IM Sechenov First Moscow State Med Univ, Dept Informat & Internet Technol, Moscow, RussiaAD  - Natl Res Univ, Higher Sch Econ, Dept Hlth Care Adm & Econ, Moscow, RussiaAD  - Fdn Univ, Med Coll, Rawalpindi, PakistanAD  - Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biostat, Bethesda, MD 20814 USAAD  - Royal Childrens Hosp, Cardiol Dept, Melbourne, Vic, AustraliaAD  - Tech Univ Munich, Dept Neurol, Munich, GermanyAD  - Singapore Natl Eye Ctr, Med Retina, Singapore, SingaporeAD  - Kailuan Gen Hosp, Tangshan, Peoples R ChinaAD  - St Johns Natl Acad Hlth Sci, Dept Pharmacol, Bangalore, Karnataka, IndiaAD  - Nanjing Univ, Sch Med, Nanjing, Jiangsu, Peoples R ChinaAD  - Milad Gen Hosp, Clin Canc Res Ctr, Tehran, IranAD  - Duke Univ, Duke Global Hlth Inst, Durham, NC USAAD  - Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USAAD  - King Eand Univ Petr & Minerals, Dept Earth Sci, Dhahran, Saudi ArabiaAD  - Wolkite Univ, Wolkite, EthiopiaAD  - Kyoto Univ, Dept Biostat, Kyoto, JapanAD  - Univ Kinshasa, Sch Publ Hlth, Kinshasa, DEM REP CONGOAD  - Jackson State Univ, Dept Hlth Policy & Management, Jackson, MS USAAD  - Tsinghua Univ, Tsinghua Univ, Beijing, Peoples R ChinaAD  - Wuhan Univ, Global Hlth Inst, Wuhan, Hubei, Peoples R ChinaAD  - Wuhan Univ, Dept Epidemiol & Biostat, Wuhan, Hubei, Peoples R ChinaAD  - Univ Hosp Setif, Epidemiol, Setif, AlgeriaC3  - University of WashingtonC3  - University of Washington SeattleC3  - Institute for Health Metrics & EvaluationC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Jimma UniversityC3  - Sapienza University RomeC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - McGill UniversityC3  - McGill UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Manonmaniam Sundaranar UniversityC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Qatar Foundation (QF)C3  - Weill Cornell Medical College QatarC3  - Birzeit UniversityC3  - Dongguk UniversityC3  - Dongguk UniversityC3  - Stellenbosch UniversityC3  - Stellenbosch UniversityC3  - Stellenbosch UniversityC3  - South African Medical Research CouncilC3  - South African Medical Research CouncilC3  - South African Medical Research CouncilC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of IbadanC3  - University College Hospital, IbadanC3  - Obafemi Awolowo UniversityC3  - Cardiff UniversityC3  - Monash UniversityC3  - Monash UniversityC3  - Monash UniversityC3  - Monash UniversityC3  - Universidad de ExtremaduraC3  - Universidad de ExtremaduraC3  - University of LomeC3  - McMaster UniversityC3  - McMaster UniversityC3  - National Academy of Sciences of ArmeniaC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Baylor College of MedicineC3  - Public Health Foundation of IndiaC3  - Public Health Foundation of IndiaC3  - Public Health Foundation of IndiaC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Universite Ferhat Abbas SetifC3  - University of KentuckyC3  - University of TorontoC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - University of TorontoC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - Washington University (WUSTL)C3  - King Saud UniversityC3  - King Saud UniversityC3  - King Saud UniversityC3  - Jazan UniversityC3  - Jazan UniversityC3  - Mayo ClinicC3  - University of Western AustraliaC3  - University of Western AustraliaC3  - Dalhousie UniversityC3  - Dalhousie UniversityC3  - Cleveland Clinic FoundationC3  - Baqiyatallah University of Medical Sciences (BMSU)C3  - Baqiyatallah University of Medical Sciences (BMSU)C3  - Australian National UniversityC3  - Australian National UniversityC3  - Qazvin University of Medical Sciences (QUMS)C3  - Qazvin University of Medical Sciences (QUMS)C3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Kuwait UniversityC3  - Luxembourg Institute of HealthC3  - Universite de BordeauxC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - Universidad de CartagenaC3  - Universidad de la CostaC3  - University of South AustraliaC3  - South Australian Health & Medical Research Institute (SAHMRI)C3  - South Australian Health & Medical Research Institute (SAHMRI)C3  - Bahir Dar UniversityC3  - American University of BeirutC3  - American University of BeirutC3  - American University of BeirutC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - University of ThessalyC3  - Arba Minch UniversityC3  - ISGlobalC3  - ISGlobalC3  - Pompeu Fabra UniversityC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - Hong Kong Polytechnic UniversityC3  - Hong Kong Polytechnic UniversityC3  - Kwame Nkrumah University Science & TechnologyC3  - Kwame Nkrumah University Science & TechnologyC3  - Kwame Nkrumah University Science & TechnologyC3  - University of MunichC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Birmingham City UniversityC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Dalarna UniversityC3  - University of ManitobaC3  - University of LeicesterC3  - University of LeicesterC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - Instituto Nacional de Salud - PeruC3  - University of TokyoC3  - University of TokyoC3  - University of TokyoC3  - University of TokyoC3  - University of South AfricaC3  - Burnet InstituteC3  - Public Health Agency of CanadaC3  - Public Health Agency of CanadaC3  - Public Health Agency of CanadaC3  - Sri Ramachandra Institute of Higher Education & ResearchC3  - Deakin UniversityC3  - Deakin UniversityC3  - Deakin UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins Bloomberg School of Public HealthC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Medical University LodzC3  - Polish Mother's Memorial Hospital - Research InstituteC3  - Egyptian Knowledge Bank (EKB)C3  - Alexandria UniversityC3  - Clinical Centre of SerbiaC3  - University of BelgradeC3  - University of BelgradeC3  - University of BelgradeC3  - University of AucklandC3  - University of AucklandC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Stanford UniversityC3  - Stanford UniversityC3  - Stanford UniversityC3  - Charles R. Drew University of Medicine & ScienceC3  - University of California SystemC3  - University of California Los AngelesC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - CHU Dijon BourgogneC3  - Universite de BourgogneC3  - Yale UniversityC3  - Yale UniversityC3  - University of AlbertaC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - Emory UniversityC3  - State University System of FloridaC3  - University of South FloridaC3  - University of BirminghamC3  - University of BirminghamC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - Nepal Academy of Science & Technology (NAST)C3  - Aga Khan UniversityC3  - Aga Khan UniversityC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Imperial College LondonC3  - Imperial College LondonC3  - Imperial College LondonC3  - University of DhakaC3  - Research Triangle InstituteC3  - University of NottinghamC3  - University of BergenC3  - University of BergenC3  - University of OsloC3  - University of Texas SystemC3  - University of Texas Health Science Center HoustonC3  - University of Texas SystemC3  - University of Texas Health Science Center HoustonC3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - Anglia Ruskin UniversityC3  - University of British ColumbiaC3  - University of British ColumbiaC3  - University of British ColumbiaC3  - Comenius University BratislavaC3  - University System of OhioC3  - Ohio State UniversityC3  - University System of OhioC3  - Ohio State UniversityC3  - University System of OhioC3  - Ohio State UniversityC3  - Helmholtz AssociationC3  - German Cancer Research Center (DKFZ)C3  - Instituto Conmemorativo Gorgas de Estudios de la SaludC3  - Instituto Conmemorativo Gorgas de Estudios de la SaludC3  - Monash UniversityC3  - Cabrini HealthC3  - Cabrini HealthC3  - Health CanadaC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - Universidad Autonoma Metropolitana - MexicoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do PortoC3  - Universidad Nacional de ColombiaC3  - Universidad Nacional de ColombiaC3  - Universidad Costa RicaC3  - Australian Catholic UniversityC3  - Australian Catholic UniversityC3  - Australian Catholic UniversityC3  - University of Hong KongC3  - University of Hong KongC3  - University of Hong KongC3  - Alfaisal UniversityC3  - National Health Research Institutes - TaiwanC3  - National Taiwan UniversityC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - University West Indies Mona JamaicaC3  - University West Indies Saint AugustineC3  - University West Indies Mona JamaicaC3  - University West Indies Saint AugustineC3  - National University of SingaporeC3  - Singapore National Eye CenterC3  - National University of SingaporeC3  - Singapore National Eye CenterC3  - National University of SingaporeC3  - University of Occupational & Environmental Health - JapanC3  - Ministry of Health IraqC3  - Ministry of Health IraqC3  - Ministry of Health IraqC3  - Ministry of Health IraqC3  - Ministry of Health IraqC3  - Ministry of Health IraqC3  - Ministry of Health IraqC3  - Seoul National University (SNU)C3  - Seoul National University HospitalC3  - University of CambridgeC3  - University of CopenhagenC3  - University of CopenhagenC3  - Bispebjerg HospitalC3  - University of CopenhagenC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of SalernoC3  - Health Effects Institute (HEI)C3  - University of SouthamptonC3  - University of Colorado SystemC3  - University of Colorado BoulderC3  - University of Milano-BicoccaC3  - Centers for Disease Control & Prevention - USAC3  - Universidade Federal do Rio GrandeC3  - Universidade Federal do Rio de JaneiroC3  - Universidade Federal do Rio Grande do SulC3  - Universidade Federal do Rio Grande do SulC3  - Universidade Federal do Rio de JaneiroC3  - Universidade Federal do Rio GrandeC3  - University of California SystemC3  - University of California San DiegoC3  - University of California SystemC3  - University of California San DiegoC3  - University of California SystemC3  - University of California San DiegoC3  - University of Southern CaliforniaC3  - Hawassa UniversityC3  - Hawassa UniversityC3  - Flinders University South AustraliaC3  - Eduardo Mondlane UniversityC3  - Central University of Tamil NaduC3  - Asfendiyarov Kazakh National Medical UniversityC3  - Griffith UniversityC3  - Menzies Health Institute QueenslandC3  - Griffith UniversityC3  - University of Colorado SystemC3  - University of Colorado Anschutz Medical CampusC3  - US Department of Veterans AffairsC3  - University of SussexC3  - University of BrightonC3  - NHS National Services ScotlandC3  - Aristotle University of ThessalonikiC3  - Icahn School of Medicine at Mount SinaiC3  - University of PeradeniyaC3  - Ministry of Health & Medical Education (MOHME)C3  - Ministry of Health & Medical Education (MOHME)C3  - Duy Tan UniversityC3  - Medical University VarnaC3  - University of Cape CoastC3  - Tampere UniversityC3  - Tampere UniversityC3  - Royal Melbourne Institute of Technology (RMIT)C3  - University of SydneyC3  - University of SydneyC3  - Asbestos Diseases Research InstituteC3  - University of SydneyC3  - University of SydneyC3  - Universidade Federal da BahiaC3  - Umea UniversityC3  - University of NewcastleC3  - UiT The Arctic University of TromsoC3  - Eijkman InstituteC3  - Queensland Centre for Mental Health ResearchC3  - Queensland Centre for Mental Health ResearchC3  - Queensland Centre for Mental Health ResearchC3  - Urmia University of Medical SciencesC3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - University of LouisvilleC3  - University of BolognaC3  - Universidade Federal de SergipeC3  - Hamadan University of Medical SciencesC3  - Hamadan University of Medical SciencesC3  - Hamadan University of Medical SciencesC3  - Auckland University of TechnologyC3  - Universidade Catolica PortuguesaC3  - Kaiser PermanenteC3  - Robert Koch InstituteC3  - University of BielefeldC3  - National Academy of Medical Sciences of UkraineC3  - D. F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of UkraineC3  - Kobe UniversityC3  - University of BaselC3  - Swiss Tropical & Public Health InstituteC3  - University of BaselC3  - Swiss Tropical & Public Health InstituteC3  - University of BaselC3  - University of TasmaniaC3  - Menzies Institute for Medical ResearchC3  - National Center for Disease Control & Public Health - GeorgiaC3  - Centro de Investigacao em Saude de ManhicaC3  - Curtin UniversityC3  - Wageningen University & ResearchC3  - University of TsukubaC3  - University of California SystemC3  - University of California San FranciscoC3  - University of California SystemC3  - University of California San FranciscoC3  - Texas Tech University SystemC3  - Texas Tech UniversityC3  - University of WarwickC3  - University of WarwickC3  - University of AdelaideC3  - University of AdelaideC3  - Howard UniversityC3  - Howard UniversityC3  - University Ha'ilC3  - Research Center of NeurologyC3  - Jawaharlal Nehru University, New DelhiC3  - University of Massachusetts SystemC3  - University of Massachusetts BostonC3  - University of Oklahoma SystemC3  - University of Oklahoma Health Sciences CenterC3  - Boston UniversityC3  - Boston UniversityC3  - Boston UniversityC3  - Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele Presidio FerraottoC3  - West Virginia UniversityC3  - Eternal Heart Care Centre & Research InstituteC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Yeshiva UniversityC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Yeshiva UniversityC3  - Instituto Nacional de Psiquiatria Ramon de la Fuente MunizC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - University of GroningenC3  - University of GroningenC3  - Western University (University of Western Ontario)C3  - Western University (University of Western Ontario)C3  - Western University (University of Western Ontario)C3  - Arabian Gulf UniversityC3  - University of New MexicoC3  - Sir Charles Gairdner HospitalC3  - Sun Yat Sen UniversityC3  - Sun Yat Sen UniversityC3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - University of BarcelonaC3  - Tabriz University of Medical ScienceC3  - Tabriz University of Medical ScienceC3  - University of AntwerpC3  - Karolinska InstitutetC3  - Karolinska University HospitalC3  - Tehran University of Medical SciencesC3  - Bucharest University of Economic StudiesC3  - University System of OhioC3  - Ohio UniversityC3  - Columbia UniversityC3  - Columbia UniversityC3  - National Institutes of Health (NIH) - USAC3  - National Institutes of Health (NIH) - USAC3  - University of Texas SystemC3  - University of Texas AustinC3  - Guilan University of Medical SciencesC3  - Guilan University of Medical SciencesC3  - Manipal Academy of Higher Education (MAHE)C3  - Universite de Tunis-El-ManarC3  - Faculte de Medecine de Tunis (FMT)C3  - Central South UniversityC3  - Aarhus UniversityC3  - Aarhus UniversityC3  - Taipei Medical UniversityC3  - Taipei Medical UniversityC3  - American Cancer SocietyC3  - George Mason UniversityC3  - University of KragujevacC3  - University of ColomboC3  - University of ColomboC3  - Banaras Hindu University (BHU)C3  - Duke Kunshan UniversityC3  - Duke Kunshan UniversityC3  - Capital Medical UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Technical University CzestochowaC3  - University of OpoleC3  - University of TartuC3  - University College CorkC3  - King George's Medical UniversityC3  - Srirama Chandra Bhanja Medical College & HospitalC3  - Helmholtz AssociationC3  - Helmholtz-Center for Infection ResearchC3  - University of WashingtonC3  - University of Washington TacomaC3  - Seattle Children's HospitalC3  - University of GlasgowC3  - MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNITC3  - University of TulsaC3  - University of NairobiC3  - University of NairobiC3  - Michigan State UniversityC3  - University of Cape TownC3  - University of Cape TownC3  - Hebrew University of JerusalemC3  - Hadassah University Medical CenterC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Indian Institute of Toxicology Research (IITR)C3  - Jordan University of Science & TechnologyC3  - Islamic Azad UniversityC3  - University of Management & Technology (UMT)C3  - United Arab Emirates UniversityC3  - Dow University of Health SciencesC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Tennessee SystemC3  - University of Tennessee Health Science CenterC3  - University of Tennessee SystemC3  - University of Tennessee KnoxvilleC3  - Seoul National University (SNU)C3  - Seoul National University (SNU)C3  - Lund UniversityC3  - Lund UniversityC3  - Northeastern UniversityC3  - Korea UniversityC3  - Korea UniversityC3  - Xiamen University Malaysia CampusC3  - Simmons UniversityC3  - University of CanberraC3  - University of OsloC3  - University of OsloC3  - Tulane UniversityC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - University of HelsinkiC3  - University of HelsinkiC3  - Norwegian Institute of Public Health (NIPH)C3  - Norwegian Institute of Public Health (NIPH)C3  - Norwegian Institute of Public Health (NIPH)C3  - National Cerebral & Cardiovascular Center - JapanC3  - Arthritis Research CanadaC3  - Sher-i-Kashmir Institute of Medical SciencesC3  - Panjab UniversityC3  - Utrecht UniversityC3  - Universite de MontrealC3  - Universite de MontrealC3  - Yuksek Ihtisas UniversityC3  - Hacettepe UniversityC3  - Ghent UniversityC3  - Finnish Institute of Occupational HealthC3  - Finnish Institute of Occupational HealthC3  - University of FlorenceC3  - Shenzhen Sun Yatsen Cardiovascular HospitalC3  - Chinese Center for Disease Control & PreventionC3  - Chinese Center for Disease Control & PreventionC3  - Samara UniversityC3  - Universiti MalayaC3  - Chinese University of Hong KongC3  - University of HaifaC3  - Universita degli Studi di Bari Aldo MoroC3  - Friedrich Schiller University of JenaC3  - University of LiverpoolC3  - National University of SingaporeC3  - National University of SingaporeC3  - University of TrnavaC3  - Shiraz University of Medical ScienceC3  - Instituto Federal do Ceara (IFCE)C3  - Medical University of GrazC3  - UERM Memorial Medical CenterC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Centre for Disease Informatics & Research (NCDIR)C3  - Indian Council of Medical Research (ICMR)C3  - Indian Council of Medical Research (ICMR)C3  - Chalmers University of TechnologyC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Cancer Prevention & Research (NICPR)C3  - Martin Luther University Halle WittenbergC3  - Martin Luther University Halle WittenbergC3  - State University System of FloridaC3  - University of West FloridaC3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - University North - CroatiaC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pacific Institute for Research & Evaluation (PIRE)C3  - Kyrgyz State Medical AcademyC3  - Ministry of Health - KyrgyzstanC3  - Salahaddin UniversityC3  - Isfahan University of Medical SciencesC3  - Ahmadu Bello UniversityC3  - Ahmadu Bello UniversityC3  - University of Kwazulu NatalC3  - Kurdistan University of Medical SciencesC3  - Kurdistan University of Medical SciencesC3  - Lancaster UniversityC3  - Queensland University of Technology (QUT)C3  - Queensland University of Technology (QUT)C3  - Queensland University of Technology (QUT)C3  - National & Kapodistrian University of AthensC3  - Academy of AthensC3  - Tufts UniversityC3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataC3  - Universiti Sains MalaysiaC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - Suraj Eye InstituteC3  - University of Yaounde IC3  - Kenya Medical Research InstituteC3  - Hanoi University of Public HealthC3  - Hanoi University of Public HealthC3  - Xi'an Jiaotong UniversityC3  - Xi'an Jiaotong UniversityC3  - Universitas Negeri SemarangC3  - National Center for Global Health & Medicine - JapanC3  - Aix-Marseille UniversiteC3  - Western Sydney UniversityC3  - Western Sydney UniversityC3  - Kyung Hee UniversityC3  - Human Sciences Research Council-South AfricaC3  - University of NamibiaC3  - University of LagosC3  - University Brunei DarussalamC3  - California State University SystemC3  - San Diego State UniversityC3  - University of OttawaC3  - Autonomous University of MadridC3  - Autonomous University of MadridC3  - St. Luke's International HospitalC3  - Ministry of Health of the Russian FederationC3  - Lomonosov Moscow State UniversityC3  - Moscow Institute of Physics & TechnologyC3  - University of IbadanC3  - JSS Academy of Higher Education & ResearchC3  - University of ChichesterC3  - Maimonides Medical CenterC3  - International Institute of Health Management Research DelhiC3  - Save the ChildrenC3  - Universidad de CartagenaC3  - University of GothenburgC3  - University of WitwatersrandC3  - Durban University of TechnologyC3  - Helmholtz AssociationC3  - Max Delbruck Center for Molecular MedicineC3  - University of GroningenC3  - University of OtagoC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - University of GottingenC3  - Medical University of InnsbruckC3  - Yonsei UniversityC3  - University College London Hospitals NHS Foundation TrustC3  - University of LondonC3  - University College LondonC3  - Public Health EnglandC3  - University of TorontoC3  - Centre for Addiction & Mental Health - CanadaC3  - Brien Holden Vision InstituteC3  - Universidade Federal de UberlandiaC3  - Golestan University of Medical SciencesC3  - Ulm UniversityC3  - Southern University of Science & TechnologyC3  - University of New South Wales SydneyC3  - Prince of Wales Hospital (POWH)C3  - University of SharjahC3  - Mashhad University of Medical SciencesC3  - Imam Mohammad Ibn Saud Islamic University (IMSIU)C3  - York University - CanadaC3  - Marshall UniversityC3  - University System of OhioC3  - Case Western Reserve UniversityC3  - University of Massachusetts SystemC3  - University of Massachusetts WorcesterC3  - Hamad Medical CorporationC3  - Bournemouth UniversityC3  - Utkal UniversityC3  - Dr DY Patil Vidyapeeth PuneC3  - University of North CarolinaC3  - University of North Carolina CharlotteC3  - Bayer TurkeyC3  - Universidade Federal de Santa Catarina (UFSC)C3  - North West University - South AfricaC3  - University of ZagrebC3  - University of North CarolinaC3  - University of North Carolina Chapel HillC3  - University of ExeterC3  - NYU Langone Medical CenterC3  - New York UniversityC3  - New York UniversityC3  - An Najah National UniversityC3  - Islamic Azad UniversityC3  - Islamic Azad UniversityC3  - Kerman University of Medical SciencesC3  - World Health OrganizationC3  - Kerman University of Medical SciencesC3  - Delhi Technological UniversityC3  - Fudan UniversityC3  - Fudan UniversityC3  - Fudan UniversityC3  - University of EdinburghC3  - National Institute of Infectious Diseases (NIID)C3  - University of Technology SydneyC3  - Reykjavik UniversityC3  - Universidade de BrasiliaC3  - King Saud UniversityC3  - King Khalid University HospitalC3  - University of CalgaryC3  - International Medical University MalaysiaC3  - University of MunichC3  - National Center for Disease Control & Public Health - GeorgiaC3  - Universitas Muhammadiyah SurakartaC3  - Muhimbili University of Health & Allied SciencesC3  - Muhimbili University of Health & Allied SciencesC3  - University of California SystemC3  - University of California RiversideC3  - University of California SystemC3  - University of California IrvineC3  - University of ValenciaC3  - University of ValenciaC3  - New York Medical CollegeC3  - Universidade de LisboaC3  - University of VirginiaC3  - Nanyang Technological UniversityC3  - University of BathC3  - Institut National de la Sante et de la Recherche Medicale (Inserm)C3  - Hanoi Medical UniversityC3  - Cleveland Clinic FoundationC3  - UKK InstituteC3  - Raffles HospitalC3  - IRCCS Azienda Ospedaliero-Universitaria di BolognaC3  - Sechenov First Moscow State Medical UniversityC3  - HSE University (National Research University Higher School of Economics)C3  - Uniformed Services University of the Health Sciences - USAC3  - Royal Children's Hospital MelbourneC3  - Technical University of MunichC3  - Singapore National Eye CenterC3  - St. John's National Academy of Health SciencesC3  - Nanjing UniversityC3  - Duke UniversityC3  - Northwestern UniversityC3  - Kyoto UniversityC3  - Universite de KinshasaC3  - Jackson State UniversityC3  - Tsinghua UniversityC3  - Wuhan UniversityC3  - Wuhan UniversityPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - NOV 10
PY  - 2018
VL  - 392
IS  - 10159
SP  - 1923
EP  - 1994
DO  - 10.1016/S0140-6736(18)32225-6
AN  - WOS:000449710900007
ER  -

TY  - JOUR
AU  - Gupta, H
AU  - Mishra, P
AU  - Kataria, H
AU  - Jain, V
AU  - Tyagi, AR
AU  - Mahajan, H
AU  - Upadhyay, AD
TI  - Optimal Angle of the Bone Tunnel for Avoiding Axillary Nerve Injuries During Arthroscopic Transosseous Rotator Cuff Repair: A Magnetic Resonance Imaging-Based Simulation Study
T2  - ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE
KW  - arthroscopic transosseous
KW  - axillary nerve
KW  - rotator cuff
KW  - SUTURE REPAIR
KW  - EQUIVALENT
KW  - ADVANTAGES
KW  - TENDON
KW  - FIXATION
KW  - TIME
AB  - Background: Axillary nerve injury and suture cutout through the roof of the tunnel are potential complications of arthroscopic transosseous rotator cuff repair (ATORCR). Purpose: To determine a safe angle of drilling for the bone tunnel during ATORCR such that the axillary nerve is not at risk. The thickness of the bone bridge over the tunnel for different angles of drilling was also determined. Study Design: Descriptive laboratory study. Methods: The drilling of a straight tunnel was simulated on 30 magnetic resonance imaging (MRI) scans in the oblique coronal plane by drawing a straight line that passed at a "safe distance" of 5 mm from the axillary nerve and emerging at the medial border of the insertion of the rotator cuff on the greater tuberosity. The angle made by this line with the horizontal axis of the humerus was measured on 3 MRI sections: anterior (passing just posterior to the lateral lip of the bicipital groove), middle (at the most lateral point of the proximal humerus), and posterior (an equal number of cuts away from the middle section as between anterior and middle). The thickness of the overlying bone roof was measured for this line as well as for simulation lines drawn at 50 degrees, 55 degrees, 60 degrees, and 65 degrees with the horizontal axis. A "safe limit," defined as the mean - 2SD, was also calculated. Results: The axillary nerve was found to be safe, with a safety margin of 5 mm, at drill angles of less than 61.1 degrees and 60.3 degrees in the posterior and middle sections, respectively. The safe limit value for thickness of the overlying bone roof for the tunnel drilled at 60 degrees was 5.0 mm in the posterior section (mean, 8.2 +/- 0.3 mm) and 5.5 mm in the middle section (mean, 8.1 +/- 0.2 mm). In the anterior section, the minimum safe angle was 57.7 degrees, and the mean thickness of the bone roof for the 55 degrees angle was 6.3 +/- 0.2 mm (safe limit, 3.7 mm). Conclusion: Straight bone tunnels in ATORCR surgery should be drilled at an angle of 60 degrees to the horizontal axis of the humerus or 30 degrees to the humeral shaft to ensure the safety of the axillary nerve while at the same time ensuring adequate thickness of the overlying bone roof. The anterior tunnel close to the bicipital groove should be drilled cautiously at 55 degrees to the horizontal axis or 35 degrees to the humeral shaft.
AD  - Vardhman Mahavir Med Coll, Safdarjung Hosp, Sports Injury Ctr, New Delhi 110029, IndiaAD  - Safdarjang Hosp, Sports Injury Ctr, Mahajan Imaging, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - Vardhman Mahavir Medical College & Safdarjung HospitalC3  - Vardhman Mahavir Medical College & Safdarjung HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SAGE PUBLICATIONS INC
PI  - THOUSAND OAKS
PA  - 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
DA  - NOV 9
PY  - 2018
VL  - 6
IS  - 11
C7  - 2325967118806295
DO  - 10.1177/2325967118806295
AN  - WOS:000450084700001
ER  -

TY  - JOUR
AU  - Paliwal, S
AU  - Chaudhuri, R
AU  - Agrawal, A
AU  - Mohanty, S
TI  - Human tissue-specific MSCs demonstrate differential mitochondria transfer abilities that may determine their regenerative abilities
T2  - STEM CELL RESEARCH & THERAPY
KW  - Mitochondrial transfer
KW  - Tissue-specific MSCs
KW  - Mitochondrial bioenergetics
KW  - MESENCHYMAL STEM-CELLS
KW  - TUNNELING NANOTUBES
KW  - STROMAL CELLS
KW  - IN-VITRO
KW  - OXIDATIVE STRESS
KW  - RESCUE
KW  - CARDIOMYOCYTES
KW  - INJURY
KW  - TRANSPORT
KW  - PROTECTS
AB  - BackgroundRecent studies have demonstrated mesenchymal stem cells (MSCs) as effective mitochondrial donors with therapeutic success in multiple experimental models of human disease. MSCs obtained from different tissue sources such as bone marrow (BM), adipose (AD), dental pulp (DP), and Wharton's jelly (WJ) are routinely used in clinical trials with no known study of their mitochondrial donor capacity. Here, we show for the first time that MSCs derived from different tissue sources have different mitochondrial donor properties and that this is correlated with their intrinsic respiratory states.MethodsMitoTracker((R))-labeled MSCs were co-cultured with Cell Trace-labeled U87-MG cells or rat cardiomyocytes. Mitochondrial transfer abilities of MSCs were assessed by using flow cytometry analysis and fluorescence imaging. Mitochondrial reactive oxygen species (mtROS) levels were analyzed by using MitoSOX red-based staining, and mitochondrial respiration parameters were analyzed by using a Seahorse XF Analyzer.ResultsAD-MSCs and BM-MSCs displayed higher mitochondrial transfer than DP-MSCs and WJ-MSCs. Counterintuitively, DP-MSCs and WJ-MSCs were more effective in suppressing mtROS levels in stressed recipient cells than AD-MSCs or BM-MSCs. Interestingly, the oxygen consumption rates and intrinsic mitochondrial respiration parameters like ATP levels, basal and maximal respiration, and mitochondrial DNA copy number in donor MSCs showed a highly significant inverse correlation with their mitochondrial donation.ConclusionsWe find that there are intrinsic differences in the mitochondrial respiration, donation capacity, and therapeutic efficacy among MSCs of different tissue origin. MSCs with high mitochondrial respiration capacities are associated with lower mitochondrial transfer but more effective suppression of mtROS in stressed recipient cells. This is most compatible with a model where recipient cells optimally regulate mitochondrial transfer such that they take more mitochondria from MSCs with lower mitochondrial function. Furthermore, it appears to be advantageous to use MSCs such as DP-MSCs or WJ-MSCs with higher mitochondrial respiratory abilities that achieved better therapeutic effect with lower mitochondrial transfer in our study. This opens up a new direction in stem cell therapeutics.
AD  - All India Inst Med Sci, DBT Ctr Excellence Stem Cell Res, Stem Cell Facil, New Delhi 110029, IndiaAD  - Banasthali Vidyapith, Dept Biosci & Biotechnol, Vanasthali 304022, Rajasthan, IndiaAD  - CSIR, Mol Immunogenet Lab, Inst Genom & Integrat Biol, Mall Rd, Delhi 110007, IndiaAD  - CSIR, Ctr Excellence Translat Res Asthma & Lung Dis, Inst Genom & Integrat Biol, Mall Rd, Delhi 110007, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Banasthali VidyapithC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)PU  - BMC
PI  - LONDON
PA  - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - NOV 8
PY  - 2018
VL  - 9
C7  - 298
DO  - 10.1186/s13287-018-1012-0
AN  - WOS:000449785300006
ER  -

TY  - JOUR
AU  - George, A
AU  - Panwar, R
AU  - Pal, S
TI  - Surgical Management of Life Threatening Bleeding after Endoscopic Cystogastrostomy
T2  - JOURNAL OF INVESTIGATIVE SURGERY
KW  - endoscopic cystogastrostomy
KW  - endoscopic ultrasound
KW  - complications
KW  - bleeding
KW  - surgery
KW  - transgastric
KW  - PSEUDOCYST DRAINAGE
KW  - NECROSIS
AB  - Postprocedural bleeding is a rare but life threatening complication of endoscopic cystogastrostomy which may require surgical management in some patients. The presence of adhesions and inflammation due to antecedent acute pancreatitis, difficult location of the bleeding site and breach in the posterior wall of stomach pose significant challenges during the surgical management. Here we have described the surgical approach and technique that we used to manage three patients who required surgery for life threatening bleeding after endoscopic cystogastrostomy.
AD  - All India Inst Med Sci, Dept Gastrointestinal Surg & Liver Transplantat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - TAYLOR & FRANCIS INC
PI  - PHILADELPHIA
PA  - 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
DA  - NOV 2
PY  - 2018
VL  - 31
IS  - 6
SP  - 503
EP  - 508
DO  - 10.1080/08941939.2017.1362081
AN  - WOS:000466370000009
ER  -

TY  - JOUR
AU  - Rashid, A
AU  - Bhat, JA
AU  - Ganie, MA
AU  - Wani, IA
AU  - Bhat, MH
AU  - Shah, ZA
AU  - Masoodi, SR
AU  - Marwaha, RK
TI  - Evaluation of serum anti-nuclear antibody among women with PCOS: a hospital based single center cross sectional study
T2  - GYNECOLOGICAL ENDOCRINOLOGY
KW  - PCOS
KW  - Rotterdam criteria
KW  - anti-nuclear antibody
KW  - autoimmunity
KW  - POLYCYSTIC-OVARY-SYNDROME
KW  - D-CHIRO-INOSITOL
KW  - HIGH PREVALENCE
KW  - AUTOIMMUNITY
KW  - THYROIDITIS
KW  - MECHANISM
KW  - MARKERS
AB  - Polycystic ovary syndrome (PCOS), a major endocrinopathy is associated with barrage of metabolic aberrations. Reports in literature on association of PCOS and autoimmunity are conflicting. We aim to evaluate serum levels of anti-nuclear antibody (ANA) among Indian women with PCOS. In this hospital-based single center cross-sectional study, women qualifying a diagnosis of PCOS by Rotterdam criteria 2003 were recruited. Eighty-nine eligible women who consented were enrolled. All these women along with 87 age-matched, healthy controls underwent, clinical (menstrual history, anthropometry, hirsutism scoring), biochemical, hormonal assessment and serum ANA estimation. OGTT after overnight (8-12 h) fast with 75 g oral glucose load was done for 1 h, 2 h glucose and insulin measurements. The mean age of cases and controls was comparable (22.67 +/- 5.53 vs. 22.84 +/- 3.64 years). The prevalence of ANA positivity was significantly higher among women with PCOS (18.4% vs. 2.29%; p < .001). Though significant correlation was observed between ANA positivity and clinical signs of hyperandrogenism and plasma glucose, no significant correlation was noted between ANA status and other hormonal parameters. Higher prevalence of ANA positivity among women with PCOS, being a marker of autoimmunity, suggests a possible role of autoimmunity in causation of PCOS and needs further elucidation.
AD  - Sheri Kashmir Inst Med Sci, Dept Endocrinol, Srinagar, Jammu & Kashmir, IndiaAD  - Sheri Kashmir Inst Med Sci, Dept Immunol & Mol Med, Srinagar, Jammu & Kashmir, IndiaAD  - Int Life Sci Inst India, Delhi, IndiaC3  - Sher-i-Kashmir Institute of Medical SciencesC3  - Sher-i-Kashmir Institute of Medical SciencesPU  - TAYLOR & FRANCIS LTD
PI  - ABINGDON
PA  - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
DA  - NOV 2
PY  - 2018
VL  - 34
IS  - 11
SP  - 965
EP  - 969
DO  - 10.1080/09513590.2018.1469613
AN  - WOS:000452225200012
ER  -

TY  - JOUR
AU  - Angmo, D
AU  - Selvan, H
AU  - Behera, AK
AU  - Suman, PK
TI  - Unilateral corneal edema in young: A diagnostic dilemma
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Congenital hereditary corneal dystrophy
KW  - corneal edema
KW  - Harboyan syndrome
KW  - polymegathism
KW  - polymorphism
KW  - specular microscopy
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 374,Third Floor, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV
PY  - 2018
VL  - 66
IS  - 11
SP  - 1612
EP  - +
DO  - 10.4103/ijo.IJO_564_18
AN  - WOS:000448596100021
ER  -

TY  - JOUR
AU  - Azad, SV
AU  - Gogia, V
AU  - Venkatesh, P
AU  - Takkar, B
TI  - Hypothyroidism and non-infectious uveitis
T2  - EYE
KW  - PATTERN
AD  - AIIMS, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - NATURE PUBLISHING GROUP
PI  - LONDON
PA  - MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - NOV
PY  - 2018
VL  - 32
IS  - 11
SP  - 1795
EP  - 1796
DO  - 10.1038/s41433-018-0171-7
AN  - WOS:000449564900019
ER  -

TY  - JOUR
AU  - Braun, DA
AU  - Shril, S
AU  - Sinha, A
AU  - Schneider, R
AU  - Tan, WZ
AU  - Ashraf, S
AU  - Hermle, T
AU  - Jobst-Schwan, T
AU  - Widmeier, E
AU  - Majmundar, AJ
AU  - Daga, A
AU  - Warejko, JK
AU  - Nakayama, M
AU  - Schapiro, D
AU  - Chen, J
AU  - Airik, M
AU  - Rao, J
AU  - Schmidt, JM
AU  - Hoogstraten, CA
AU  - Hugo, H
AU  - Meena, J
AU  - Lek, M
AU  - Laricchia, KM
AU  - Bagga, A
AU  - Hildebrandt, F
TI  - Mutations in <i>WDR4</i> as a new cause of Galloway-Mowat syndrome
T2  - AMERICAN JOURNAL OF MEDICAL GENETICS PART A
KW  - Galloway-Mowat syndrome
KW  - Mendelian diseases
KW  - rare syndromic diseases
KW  - variable phenotypic expressivity
KW  - whole-exome sequencing
KW  - NEPHROTIC SYNDROME
KW  - KEOPS-COMPLEX
KW  - VARIANTS
KW  - NEURODEGENERATION
KW  - BIOSYNTHESIS
KW  - SPECTRUM
KW  - FORM
AB  - Galloway-Mowat syndrome (GAMOS) is a phenotypically heterogeneous disorder characterized by neurodevelopmental defects combined with renal-glomerular disease, manifesting with proteinuria. To identify additional monogenic disease causes, we here performed whole exome sequencing (WES), linkage analysis, and homozygosity mapping in three affected siblings of an Indian family with GAMOS. Applying established criteria for variant filtering, we identify a novel homozygous splice site mutation in the gene WDR4 as the likely disease-causing mutation in this family. In line with previous reports, we observe growth deficiency, microcephaly, developmental delay, and intellectual disability as phenotypic features resulting from WDR4 mutations. However, the newly identified allele additionally gives rise to proteinuria and nephrotic syndrome, a phenotype that was never reported in patients with WDR4 mutations. Our data thus expand the phenotypic spectrum of WDR4 mutations by demonstrating that, depending on the specific mutated allele, a renal phenotype may be present. This finding suggests that GAMOS may occupy a phenotypic spectrum with other microcephalic diseases. Furthermore, WDR4 is an additional example of a gene that encodes a tRNA modifying enzyme and gives rise to GAMOS, if mutated. Our findings thereby support the recent observation that, like neurons, podocytes of the renal glomerulus are particularly vulnerable to cellular defects resulting from altered tRNA modifications.
AD  - Harvard Med Sch, Boston Childrens Hosp, Dept Med, Enders 561,300 Longwood Ave, Boston, MA 02115 USAAD  - All India Inst Med Sci, Div Nephrol, Dept Pediat, New Delhi, IndiaAD  - Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USAC3  - Harvard UniversityC3  - Harvard Medical SchoolC3  - Boston Children's HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Harvard UniversityC3  - Massachusetts Institute of Technology (MIT)C3  - Broad InstitutePU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - NOV
PY  - 2018
VL  - 176
IS  - 11
SP  - 2460
EP  - 2465
DO  - 10.1002/ajmg.a.40489
AN  - WOS:000456950200031
ER  -

TY  - JOUR
AU  - Chhabra, A
AU  - Subramaniam, R
AU  - Srivastava, A
TI  - Anesthesia During Awake Breast Surgery <i>Additional Questions</i> Reply
T2  - REGIONAL ANESTHESIA AND PAIN MEDICINE
KW  - BLOCK
AD  - All India Inst Med Sci, Dept Anesthesiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Surg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - BMJ PUBLISHING GROUP
PI  - LONDON
PA  - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
DA  - NOV
PY  - 2018
VL  - 43
IS  - 8
SP  - 890
EP  - 891
DO  - 10.1097/AAP.0000000000000872
AN  - WOS:000457895100023
ER  -

TY  - JOUR
AU  - Christopher, R
AU  - Devi, ARR
AU  - Kabra, M
AU  - Kapoor, S
AU  - Mathur, R
AU  - Muranjan, M
AU  - Nigam, PK
AU  - Pandey, RM
AU  - Singh, A
AU  - Suresh, S
A1  - ICMR Task Force Inherited Metab Di
TI  - The Journey of Newborn Screening: Inception to Conclusion
T2  - INDIAN JOURNAL OF PEDIATRICS
AD  - NIMHANS, Bangalore, Karnataka, IndiaAD  - Rainbow Children Hosp & Sandor Life Sci, Rd 3,Banjara Hills, Hyderabad, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Maulana Azad Med Coll, New Delhi 110002, IndiaAD  - Indian Council Med Res, New Delhi, IndiaAD  - King Edward Mem Hosp, Bombay, Maharashtra, IndiaAD  - Vimta Labs, Hyderabad, IndiaAD  - IPGMER, Kolkata, IndiaAD  - MEDISCAN, Madras, Tamil Nadu, IndiaC3  - National Institute of Mental Health & Neurosciences - IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Maulana Azad Medical CollegeC3  - Indian Council of Medical Research (ICMR)C3  - Seth Gordhandas Sunderdas Medical College & King Edward Memorial HospitalC3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - NOV
PY  - 2018
VL  - 85
IS  - 11
SP  - 933
EP  - 934
DO  - 10.1007/s12098-017-2544-5
AN  - WOS:000448226100001
ER  -

TY  - JOUR
AU  - Christopher, R
AU  - Devi, ARR
AU  - Kabra, M
AU  - Kapoor, S
AU  - Mathur, R
AU  - Muranjan, M
AU  - Nigam, PK
AU  - Pandey, RM
AU  - Singh, A
AU  - Suresh, S
A1  - ICMR Task Force Inherited Metab Di
TI  - Newborn Screening for Congenital Hypothyroidism and Congenital Adrenal Hyperplasia
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Newborn screening
KW  - Congenital hypothyroidism
KW  - Congenital adrenal hyperplasia
KW  - India
KW  - INDIA
KW  - DISORDERS
AB  - Objective The Task Force formed by ICMR aimed at studying the prevalence of congenital hypothyroidism and congenital adrenal hyperplasia, the template disorders included in all newborn screening programs, and to evaluate the unidentified challenges in its execution in health care services. It also intended to evaluate the feasibility of newborn screening with regards to different geo-ethnic regions from India.
   Methods Five metropolitan centers identified had further 2 to 11 centers; both the urban and the rural sectors were included and were considered representative of the northern, southern, eastern, western and central parts of the country. A uniform protocol was developed to screen 100,000 neonates (20,000 from each center) beyond 34 wk of gestation for congenital hypothyroidism and congenital adrenal hyperplasia. Samples were collected by heel prick after 24 h of age. The parameters studied were prevalence of these diseases, percentage births covered, the turnaround time, recall rate and follow up of identified neonates as feasibility indicators. All centers participated in the Newborn Screening Quality Assurance Programme (NSQAP), of CDC, Atlanta, USA.
   Results In the participating hospitals attached to the centers, 151,765 babies were intramural births. Of these 143,344 (94.5%) babies were eligible for screening. Amongst these births, a sample of 104,094 (73.2%) babies could be covered by the personnel. Overall prevalence of congenital hypothyroidism (CH) was 1 in 722 births; if babies with transient hypothyroidisms were excluded the prevalence was calculated to be 1:1130. The collective prevalence of congenital adrenal hyperplasia was 1 in 5762 with marked regional differences.
   Conclusions This collaborative study has demonstrated the feasibility of establishing a network of committed laboratories and scientists for executing newborn screening. This is expected to have a potential impact on morbidity and mortality and therefore this should be immediately taken up in a national newborn screening program.
AD  - NIMHANS, Bangalore, Karnataka, IndiaAD  - Rainbow Children Hosp & Sandor Life Sci, Rd 3,Banjara Hills, Hyderabad, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Maulana Azad Med Coll, New Delhi 110002, IndiaAD  - Indian Council Med Res, New Delhi, IndiaAD  - King Edward Mem Hosp, Bombay, Maharashtra, IndiaAD  - Vimta Labs, Hyderabad, IndiaAD  - IPGMER, Kolkata, IndiaAD  - MEDISCAN, Madras, Tamil Nadu, IndiaC3  - National Institute of Mental Health & Neurosciences - IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Maulana Azad Medical CollegeC3  - Indian Council of Medical Research (ICMR)C3  - Seth Gordhandas Sunderdas Medical College & King Edward Memorial HospitalC3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - NOV
PY  - 2018
VL  - 85
IS  - 11
SP  - 935
EP  - 940
DO  - 10.1007/s12098-018-2645-9
AN  - WOS:000448226100002
ER  -

TY  - JOUR
AU  - Christopher, R
AU  - Devi, ARR
AU  - Kabra, M
AU  - Kapoor, S
AU  - Mathur, R
AU  - Muranjan, M
AU  - Nigam, PK
AU  - Pandey, RM
AU  - Singh, A
AU  - Suresh, S
A1  - ICMR Task Force Inherited Metab Di
TI  - Normative Data for Thyroid Stimulating Hormone for Screening of Congenital Hypothyroidism
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Newborn screening
KW  - TSH
KW  - Normative values
KW  - PRADESH
AB  - Objective To generate normative data for thyroid stimulating hormone (TSH) levels in heel prick samples collected from newborns from 24 h to 7 d of age.
   Methods Five regional laboratories were designated as the testing laboratories. Dried blood spots (DBS) from babies (> or = 34 wk of gestation) were collected by heel prick at least after 24 h and within seven days after birth. TSH estimation was done using time resolved fluoroimmunoassay. Values above 20mIU/L were labelled as presumptive positive. Hour interval specific normative data was categorized at 6 h intervals. Another category placed was division into 24-72 h category, 73-96 h and 99-168 h. Percentile charts were calculated across these specified intervals.
   Results Samples analysed were 104,006 collected cumulatively from the 5 centers. Of the total samples analysed for TSH, 92.8% had values less than 5 mIU/l. When TSH values were interpreted with respect to time, a steady decrease with time was observed. Of the babies' samples, 48,839 were collected between 24 and 48 h, 23,983 between 49 to 72 h and 30,883 were collected after 72 h. The mean TSH concentration demonstrated a steady decline from 24 h to 168 h. It is apparent that 10 mIU/l is the 97.5th percentile value even when corrected for gender, birth weight and age at sampling. Thus 10 mIU/l seems to be the right cutoff beyond which a second sample should be sought.
   Conclusions This is the largest series reported with a broader population mix with representations of both urban (including slums) as well as a rural population. As this study excluded preterm babies, the utility of cut offs generated is not applicable to this subset and also to critically sick neonates. However, this study gives a true representation of the normative values for majority of the newborns born at term with weight appropriate for the gestation.
AD  - NIMHANS, Bangalore, Karnataka, IndiaAD  - Rainbow Children Hosp & Sandor Life Sci, Rd 3,Banjara Hills, Hyderabad 500082, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Maulana Azad Med Coll, New Delhi 110002, IndiaAD  - Indian Council Med Res, New Delhi, IndiaAD  - King Edward Mem Hosp, Bombay, Maharashtra, IndiaAD  - Vimta Labs, Hyderabad, IndiaAD  - IPGMER, Kolkata, IndiaAD  - MEDISCAN, Madras, Tamil Nadu, IndiaC3  - National Institute of Mental Health & Neurosciences - IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Maulana Azad Medical CollegeC3  - Indian Council of Medical Research (ICMR)C3  - Seth Gordhandas Sunderdas Medical College & King Edward Memorial HospitalC3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - NOV
PY  - 2018
VL  - 85
IS  - 11
SP  - 941
EP  - 947
DO  - 10.1007/s12098-017-2550-7
AN  - WOS:000448226100003
ER  -

TY  - JOUR
AU  - Desai, A
AU  - Yadav, MA
AU  - Gupta, V
AU  - Gupta, S
TI  - Wavefront analysis to diagnose blunt trauma-induced Weigert ligament dialysis: Isolated peripheral posterior lenticonus
T2  - JOURNAL OF CATARACT AND REFRACTIVE SURGERY
KW  - AGE-RELATED CATARACT
AB  - A 15-year-old male patient presented with vision loss after blunt trauma to the right eye and with clinical evidence of posterior lenticonus. The posttraumatic lenticonus was eccentric (superotemporal). Irregular astigmatism with high myopia on dilated retinoscopy within the lenticonus, localized posterior convexity of peripheral capsule on ultrasound biomicroscopy, and increased higher-order aberrations (HOAs) on wavefront aberrometry compared with fellow-eye findings confirmed the diagnosis. To our knowledge, acquired peripheral posterior lenticonus representing dialysis of Weigert ligament after acute blunt trauma is a new finding. This case provides an insight into the pattern of higher HOAs associated with any type of lenticonus. (C) 2018 ASCRS and ESCRS
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - NOV
PY  - 2018
VL  - 44
IS  - 11
SP  - 1390
EP  - 1393
DO  - 10.1016/j.jcrs.2018.06.058
AN  - WOS:000449308900017
ER  -

TY  - JOUR
AU  - Dimitrov, A
AU  - Dolachee, AA
AU  - AbdulAzeez, MM
AU  - Hoz, SS
AU  - Narvaez-Rojas, A
AU  - Satyarthee, GD
AU  - Moscote-Salazar, LR
TI  - Dos and Don'ts of virtual reality-based simulators for cranial tumor surgery
T2  - NEUROLOGY INDIA
KW  - PERFORMANCE
KW  - RESECTION
KW  - SKILLS
AD  - Univ Hosp Sofiamed, Dept Neurosurg, Sofia, BulgariaAD  - Univ Al Qadisiyah, Dept Neurosurg, Coll Med, Diwaniyah, IraqAD  - Baghdad Univ, Dept Neurosurg, Coll Med, Baghdad, IraqAD  - Neurosurg Teaching Hosp, Dept Neurosurg, Baghdad, IraqAD  - Univ Nacl Autonoma Nicaragua, Dept Neurosurg, Managua, NicaraguaAD  - AIIMS, Dept Neurosurg, Neurosci Ctr, New Delhi, IndiaAD  - Univ Cartagena, Dept Neurosurg, Cartagena, ColombiaC3  - Medical University SofiaC3  - University of Al-QadisiyahC3  - University of BaghdadC3  - Universidad Nacional Autonoma de Nicaragua - ManaguaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Universidad de CartagenaPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV-DEC
PY  - 2018
VL  - 66
IS  - 6
SP  - 1857
EP  - 1858
DO  - 10.4103/0028-3886.246244
AN  - WOS:000452798000075
ER  -

TY  - JOUR
AU  - Dwarakanathan, V
AU  - Kumar, A
AU  - Nongkynrih, B
AU  - Kant, S
AU  - Gupta, SK
TI  - Challenges in the conduct of community-based research
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
AB  - Community-based research is an excellent opportunity for medical students to learn outside the boundaries of a medical college, where health-related conditions and factors can be studied in a larger social context. It also brings a variety of other educational and social learning with it. The research question is usually a community-driven issue. There are multiple ways to arrive at a research question. Sampling poses a unique challenge, especially in terms of availability of a sampling frame. However, accessing electoral rolls, census data and approaching community leaders of voluntary agencies working in a particular area can be a suitable way. The interview schedule should be culturally and socially appropriate and locally validated if possible. Prior preparation of a timetable of activities is much needed, includingslack time and contingency plans to fall back on as some social situations might make the area inaccessible. An important team member in these situations is a chaperone from the community who can facilitate these social interactions, including negotiations for the time of the participant. There may be sociocultural problems, which plague the research as much as they affect the community, which the researcher has to be sensitized to. Extra effort is needed to achieve a high response rate in community-based studies. Refusals by selected participants and their non-availability despite 2-3 household visits need to be addressed with patience and perseverance. Several ethical issues arise during the research, and careful thought has to be given to avoid exploitation of the communities.
AD  - All India Inst Med Sci, Ctr Community Med, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - NOV-DEC
PY  - 2018
VL  - 31
IS  - 6
SP  - 366
EP  - 369
DO  - 10.4103/0970-258X.262911
AN  - WOS:000479098700014
ER  -

TY  - JOUR
AU  - Elavarasi, AM
AU  - Singh, A
AU  - Goyal, V
TI  - Retrograde migration and expulsion of ventriculoperitoneal shunt from the neck
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
AD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - NOV-DEC
PY  - 2018
VL  - 31
IS  - 6
SP  - 375
EP  - 375
DO  - 10.4103/0970-258X.262907
AN  - WOS:000479098700018
ER  -

TY  - JOUR
AU  - Gour, SSK
AU  - Agrawal, M
AU  - Borkar, SA
TI  - Laminotomy outcomes in pediatric patients
T2  - JOURNAL OF NEUROSURGERY-PEDIATRICS
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ASSOC NEUROLOGICAL SURGEONS
PI  - ROLLING MEADOWS
PA  - 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
DA  - NOV
PY  - 2018
VL  - 22
IS  - 5
SP  - 595
EP  - 595
DO  - 10.3171/2018.5.PEDS18225
AN  - WOS:000448982800019
ER  -

TY  - JOUR
AU  - Goyal, A
AU  - Khadgawat, R
TI  - Diagnosis of childhood growth hormone deficiency: Controversies, consensus and the need for new diagnostic tools
T2  - NEUROLOGY INDIA
KW  - PREVALENCE
AD  - All India Inst Med Sci, Dept Endocrinol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
DA  - NOV-DEC
PY  - 2018
VL  - 66
IS  - 6
SP  - 1685
EP  - 1686
DO  - 10.4103/0028-3886.246229
AN  - WOS:000452798000027
ER  -

TY  - JOUR
AU  - Gulati, S
TI  - Dietary Therapies: Emerging Paradigms in Therapy of Drug Resistant Epilepsy in Children Based on 6th Dr. I. C. Verma Excellence in Research Award Oration
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Ketogenic diet
KW  - Modified Atkin's diet
KW  - Low glycemic index treatment
KW  - Drug resistant epilepsy
KW  - Children
KW  - MODIFIED ATKINS DIET
KW  - GLYCEMIC-INDEX TREATMENT
KW  - RANDOMIZED CONTROLLED-TRIAL
KW  - KETOGENIC DIET
KW  - REFRACTORY EPILEPSY
KW  - CHILDHOOD EPILEPSY
KW  - SEIZURE CONTROL
KW  - YOUNG-ADULTS
KW  - EFFICACY
KW  - EXPERIENCE
AB  - About one-third of childhood epilepsy ultimately becomes drug resistant epilepsy. Only about one-third of drug resistant epilepsy is amenable for epilepsy surgery. Epilepsy surgery and vagal nerve stimulation is still beyond the reach of huge proportion of children with pharmacoresistant epilepsy. Ketogenic diet (KD) has been in use for almost a century now all over the world for drug resistant epilepsy, although in between there was a decline in its popularity with advent of newer antiepileptic drugs like valproate, phenytoin and carbamazepine. Again from 1990s there was resurgence of interest in KD for pharmacoresistant epilepsy and in the last two decades several randomized controlled trials and systemic reviews have proved its efficacy beyond any suspicion. Ketogenic diet is a high fat low carbohydrate and low protein diet, which has been found to reduce epileptogenesis in body most probably by production of ketone bodies. Modified Atkin's Diet (MAD) first introduced in 2003 and Low Glycemic Index Treatment (LGIT) first introduced in 2005 are another two dietary therapies, which are less restrictive, more palatable with fewer adverse effects and comparable efficacy. MAD is also a high fat, low carbohydrate diet, in which high sugar foods are discouraged and protein and fluids are unrestricted. In LGIT, only carbohydrates with Glycemic Index <50 are allowed and carbohydrate intake is restricted to 40-60 g per day. Medium Chain Triglyceride KD (MCT KD) is another alternative, in which there are more food choices as compared to classic KD, with comparable efficacy.
AD  - All India Inst Med Sci, Child Neurol Div, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - NOV
PY  - 2018
VL  - 85
IS  - 11
SP  - 1000
EP  - 1005
DO  - 10.1007/s12098-018-2779-9
AN  - WOS:000448226100018
ER  -

TY  - JOUR
AU  - Gulati, S
AU  - Sondhi, V
TI  - Cerebral Palsy: An Overview
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Spasticity
KW  - Birth asphyxia
KW  - Prematurity
KW  - Botulinum toxin
KW  - Rehabilitation
KW  - CHILDREN
KW  - SPASTICITY
KW  - STIMULATION
KW  - IMPAIRMENT
KW  - MANAGEMENT
AB  - Cerebral palsy (CP) is a neurodevelopmental disorder characterized by abnormalities of muscle tone, movement and motor skills, and is attributed to injury to the developing brain. The clinical features of this entity evolve over time and the specific CP syndrome may be recognizable only after 3-5 y of age; although suggestive signs and symptoms may be present at an earlier age. The management involves neurological rehabilitation (addressing muscle tonal abnormalities, and devising physical and occupational therapies) and diagnosis and management of co-morbidities (including epilepsy, impairment of cognition, vision, hearing, and disturbances of growth and gastrointestinal function). The management, therefore, is multidisciplinary involving the treating physician working with a team of rehabilitation-, orthopedic-, psychologic-, and social care- providers.
AD  - All India Inst Med Sci, Child Neurol Div, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - NOV
PY  - 2018
VL  - 85
IS  - 11
SP  - 1006
EP  - 1016
DO  - 10.1007/s12098-017-2475-1
AN  - WOS:000448226100019
ER  -

TY  - JOUR
AU  - Gunjan, D
AU  - Jain, S
AU  - Garg, P
TI  - Dislodged hood stuck in submucosal tunnel: retrieval during peroral endoscopic myotomy
T2  - ENDOSCOPY
AD  - All India Inst Med Sci, Dept Gastroenterol, Room 3111,3rd Floor,Teaching Block, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - GEORG THIEME VERLAG KG
PI  - STUTTGART
PA  - RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
DA  - NOV
PY  - 2018
VL  - 50
IS  - 11
SP  - E314
EP  - E315
DO  - 10.1055/a-0658-0955
AN  - WOS:000449988000008
ER  -

TY  - JOUR
AU  - Guo, JT
AU  - Giovannini, M
AU  - Sahai, AV
AU  - Saftoiu, A
AU  - Dietrich, CF
AU  - Santo, E
AU  - Fusaroli, P
AU  - Siddiqui, AA
AU  - Bhutani, MS
AU  - Teoh, AYB
AU  - Irisawa, A
AU  - Arias, BLA
AU  - Achanta, CR
AU  - Jenssen, C
AU  - Seo, DW
AU  - Adler, DG
AU  - Kalaitzakis, E
AU  - Artifon, E
AU  - Itokawa, F
AU  - Poley, JW
AU  - Mishra, G
AU  - Ho, KY
AU  - Wang, HP
AU  - Okasha, HH
AU  - Lachter, J
AU  - Vila, JJ
AU  - Iglesias-Garcia, J
AU  - Yamao, K
AU  - Yasuda, K
AU  - Kubota, K
AU  - Palazzo, L
AU  - Sabbagh, LC
AU  - Sharma, M
AU  - Kida, M
AU  - El-Nady, M
AU  - Nguyen, NQ
AU  - Vilmann, P
AU  - Garg, PK
AU  - Rai, P
AU  - Mukai, S
AU  - Carrara, S
AU  - Parupudi, S
AU  - Sridhar, S
AU  - Lakhtakia, S
AU  - Rana, SS
AU  - Ogura, T
AU  - Baron, TH
AU  - Dhir, V
AU  - Sun, SY
TI  - A multi-institution consensus on how to perform EUS-guided biliary drainage for malignant biliary obstruction
T2  - ENDOSCOPIC ULTRASOUND
KW  - Consensue
KW  - EUS-guided biliary drainage
KW  - questionnarie survey
KW  - EXPANDABLE METAL STENTS
KW  - COMMON BILE-DUCT
KW  - ENDOSCOPIC ULTRASOUND
KW  - FAILED ERCP
KW  - PERCUTANEOUS DRAINAGE
KW  - HEPATICOGASTROSTOMY
KW  - CHOLEDOCHODUODENOSTOMY
KW  - MULTICENTER
KW  - PLACEMENT
KW  - ACCESS
AB  - Background and Objectives: EUS-guided biliary drainage (EUS-BD) w as shown to be useful for malignant bill obstruction (MBO). However. there is lack of consensus on how EUS-BD should be performed. Methods: This was a worldivide multi-institutional survey among members of the International Society of EUS conducted in February 2018. The survey consisted of 10 questions related to the practice of EUS-BD. Results; Forty-six endoscopists of them completed the survey. The majority of endoscopists felt that EUS-BD could replace percutaneous transhepatic biliary drainage after failure of ERCP. Among all EUS-BD methods, the rendezvous stewing technique should be the first choice. Self-expandable metal steins (SEMSs) mere recommended by most endoscopists. For EUS-guided hepaticogastrostomy (HGS), superiority of partially-covered SEMS over fully-covered SEMS was not in agreement. 6-Fr cystotomes were recommended for fistula creation. During the HGS approach. longer SEMS (8 or 10 cm) was recommended. During the choledochoduodenostomy approach. 6-cm SEMS was recommended. During the intrahepatic (IH) approach. the IH segment 3 eras recommended. Conclusion: This is the first worldwide survey on the practice of EUS-BD for MBO. There were wide variations in practice. and randomized studies arc urgently needed to establish the best approach for the management of this condition.
AD  - China Med Univ, Endoscopy Ctr, Shengjing Hosp, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R ChinaAD  - Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R ChinaAD  - Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, TaiwanAD  - Inst Paoli Calmettes, Pathol Unit Flora Poizat, Marseille, FranceAD  - Trocadero Clin, Paris, FranceAD  - Univ Montreal, Ctr Hosp, Montreal, PQ, CanadaAD  - Univ Med & Pharm, Dept Endoscopy, Craiova, RomaniaAD  - Caritas Hosp, Med Dept 2, Bad Mergentheim, GermanyAD  - Krankenhaus Markisch Oderland Strausberg, Wriezen, GermanyAD  - Tel Aviv Sourasky Med Ctr, Tel Aviv, IsraelAD  - Rambam Hlth Care Campus, Haifa, IsraelAD  - Univ Bologna, Hosp Imola, Dept Med & Surg Sci, Gastroenterol Unit, Bologna, ItalyAD  - Humanitas Res Hosp, Div Gastroenterol, Digest Endoscopy Unit, Milan, ItalyAD  - Thomas Jefferson Univ Hosp, Div Gastroenterol & Hepatol, Philadelphia, PA 19107 USAAD  - Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol, Houston, TX 77030 USAAD  - Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USAAD  - Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT USAAD  - Wake Forest Baptist Hlth, Dept Gastroenterol, Winston Salem, NC USAAD  - Univ North Carolina Chapel Hill, Div Gastroenterol, Chapel Hill, NC USAAD  - Augusta Univ, Sect Gastroenterol Hepatol, Augusta, GA USAAD  - Dokkyo Med Univ, Dept Gastroenterol, Mibu, Tochigi, JapanAD  - Tokyo Adventist Hosp, Dept Gastroenterol & Hepatol, Tokyo, JapanAD  - Tokyo Med Univ, Dept Gastroenterol & Hepatol, Tokyo, JapanAD  - Aichi Canc Ctr Hosp, Nagoya, Aichi, JapanAD  - Kyoto Second Red Cross Hosp, Dept Gastroenterol, Kyoto, JapanAD  - Yokohama City Univ, Dept Endoscopy, Sch Med, Yokohama, Kanagawa, JapanAD  - Kitasato Univ, Dept Gastroenterol, East Hosp, Sagamihara, Kanagawa, JapanAD  - Osaka Med Coll, Dept Internal Med 2, Osaka, JapanAD  - Univ Caldas, Surg Clin Gastroenterol, Manizales, ColombiaAD  - Clin Reina Sofia, Bogota, ColombiaAD  - Queens NRI Hosp, Visakhapatnam, Andhra Pradesh, IndiaAD  - Jaswant Rai Specialty Hosp, Dept Gastroenterol, Meerut, Uttar Pradesh, IndiaAD  - Sanjay Gandhi Postgrad Inst Med Sci, Dept Gastroenterol, Lucknow, Uttar Pradesh, IndiaAD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaAD  - Asian Inst Gastroenterol, Hyderabad, Telangana, IndiaAD  - Postgrad Inst Med Educ & Res, Dept Gastroenterol, Chandigarh, IndiaAD  - SL Raheja Hosp, Dept Gastroenterol, Bombay, Maharashtra, IndiaAD  - Univ Ulsan, Dept Internal Med, Div Gastroenterol, Coll Med, Seoul, South KoreaAD  - Univ Copenhagen, Div Endoscopy, Gastro Unit, Hosp Herlev, Copenhagen, DenmarkAD  - Univ Sao Paulo, Dept Surg, Sao Paulo, BrazilAD  - Erasmus MC Univ, Med Ctr Rotterdam, Rotterdam, NetherlandsAD  - Natl Univ Singapore, Dept Med, Singapore, SingaporeAD  - Cairo Univ, Internal Med Dept, Cairo, EgyptAD  - Cairo Univ, Fac Med, Internal Med Dept, Cairo, EgyptAD  - Complejo Hosp Navarra, Endoscopy Unit, Pamplona, SpainAD  - Univ Hosp Santiago de Compostela, Dept Gastroenterol & Hepatol, Santiago, SpainAD  - Royal Adelaide Hosp, Dept Gastroenterol & Hepatol, North Terrace, Adelaide, SA, AustraliaC3  - China Medical UniversityC3  - Chinese University of Hong KongC3  - Prince of Wales HospitalC3  - National Taiwan UniversityC3  - National Taiwan University HospitalC3  - UNICANCERC3  - Institut Paoli-Calmette (IPC)C3  - Universite de MontrealC3  - University of Medicine & Pharmacy of CraiovaC3  - Caritas Hospital Bad MergentheimC3  - Tel Aviv UniversityC3  - Sackler Faculty of MedicineC3  - Tel Aviv Sourasky Medical CenterC3  - Rambam Health Care CampusC3  - University of BolognaC3  - Azienda USL di ImolaC3  - Thomas Jefferson UniversityC3  - University of Texas SystemC3  - UTMD Anderson Cancer CenterC3  - Texas Tech University SystemC3  - Texas Tech University Health Science CenterC3  - Utah System of Higher EducationC3  - University of UtahC3  - Wake Forest UniversityC3  - Wake Forest Baptist Medical CenterC3  - University of North Carolina School of MedicineC3  - University of North CarolinaC3  - University of North Carolina Chapel HillC3  - University System of GeorgiaC3  - Augusta UniversityC3  - Dokkyo Medical UniversityC3  - Tokyo Medical UniversityC3  - Aichi Cancer CenterC3  - Yokohama City UniversityC3  - Kitasato UniversityC3  - Osaka Medical & Pharmaceutical UniversityC3  - Universidad de CaldasC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - University of UlsanC3  - University of CopenhagenC3  - Universidade de Sao PauloC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - National University of SingaporeC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Servicio Navarro de Salud - OsasunbideaC3  - Complexo Hospitalario Universitario de Santiago de CompostelaC3  - Royal Adelaide HospitalPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV-DEC
PY  - 2018
VL  - 7
IS  - 6
SP  - 356
EP  - 365
DO  - 10.4103/eus.eus_53_18
AN  - WOS:000452433500002
ER  -

TY  - JOUR
AU  - Gupta, S
AU  - Lodha, R
AU  - Kabra, SK
TI  - Antimicrobial Therapy in Community-Acquired Pneumonia in Children
T2  - CURRENT INFECTIOUS DISEASE REPORTS
KW  - Acute lower respiratory tract infection
KW  - Children
KW  - Community-acquired pneumonia
KW  - Pneumococcal
KW  - RANDOMIZED CONTROLLED-TRIAL
KW  - GRAM-POSITIVE BACTERIA
KW  - IN-VITRO ACTIVITY
KW  - AGED 2-59 MONTHS
KW  - DOUBLE-BLIND
KW  - CHILDHOOD PNEUMONIA
KW  - ORAL AMOXICILLIN
KW  - STAPHYLOCOCCUS-AUREUS
KW  - ANTIBIOTIC-TREATMENT
KW  - PROCAINE PENICILLIN
AB  - Purpose of ReviewEmpirical antibiotic therapy remains the cornerstone of treatment in community-acquired pneumonia (CAP). However, the best option for empirical antibiotics for treatment on an ambulatory basis, as well as in those requiring hospitalization, is still unclear. This review tries to answer the question regarding the most appropriate antibiotics in different settings in children with CAP as well as duration of therapy.Recent FindingsRecent studies have provided insights regarding use of oral antibiotics in children with mild to moderate CAP, and severe CAP with lower chest retractions but no hypoxia. In view of rapidly emerging resistance among various causative pathogens, several new drugs have been currently approved, or are under trial for CAP in children.SummaryCurrent knowledge suggests that the choice of antibiotics for ambulatory treatment of CAP is oral amoxicillin with a duration of 3-5days. Children with CAP with lower chest retractions but no hypoxia can be treated with oral amoxicillin. Severe pneumonia can be treated with intravenous antibiotics consisting of penicillin/ampicillin with or without an aminoglycoside. Several new drugs have been developed and approved for use in CAP caused by multidrug-resistant organisms, but these should be used judiciously to avoid emergence of further resistance. Future research is needed regarding the safety and efficacy of newer drugs in children.
AD  - All India Inst Med Sci, Dept Pediat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
DA  - NOV
PY  - 2018
VL  - 20
IS  - 11
C7  - 47
DO  - 10.1007/s11908-018-0653-6
AN  - WOS:000445211500001
ER  -

TY  - JOUR
AU  - Gupta, S
AU  - Selvan, H
AU  - Agrawal, S
AU  - Gupta, V
TI  - Dynamic gonioscopy and ultrasound biomicroscopy for diagnosis of latent or low-lying cyclodialysis clefts
T2  - CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
AD  - All India Inst Med Sci, Glaucoma Serv, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - NOV
PY  - 2018
VL  - 46
IS  - 8
SP  - 960
EP  - 962
DO  - 10.1111/ceo.13316
AN  - WOS:000450064600018
ER  -

TY  - JOUR
AU  - Gupta, S
AU  - Selvan, H
AU  - Kishan, A
AU  - Jayaraman, N
AU  - Gupta, V
TI  - Single-point pivot for combined repair of concurrent iridodialysis and cyclodialysis
T2  - JOURNAL OF CATARACT AND REFRACTIVE SURGERY
KW  - SUTURE
AB  - Iridodialysis and cyclodialysis can occur simultaneously in patients with blunt trauma to the eye, and both might necessitate surgical correction when symptoms emerge. Numerous techniques are used to repair each dialysis individually; thus, the patient will have to return to the operating room for each additional surgery. To our knowledge, the literature lacks techniques to manage both conditions simultaneously. We developed a new approach in which both dialyses can be repaired using a single suture, pivoting both at the same point. The suture that passes through the eyelet of the capsular tension ring placed in the sulcus (for internal cyclopexy) is further passed through the detached iris root and retracted via the ciliary cleft to be tied over the sclera! bed, facilitating closure of both dialyses at the same time. This is an effective approach for the repair of concurrent iridodialysis and cyclodialysis. (C) 2018 ASCRS and ESCRS
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Glaucoma Serv, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - NOV
PY  - 2018
VL  - 44
IS  - 11
SP  - 1306
EP  - 1309
DO  - 10.1016/j.jcrs.2018.08.004
AN  - WOS:000449308900003
ER  -

TY  - JOUR
AU  - Gupta, S
AU  - Jain, S
TI  - Comment on: Diagnostic positron emission tomography-computed tomography in clinically elusive giant cell arteritis
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
AD  - Birmingham & Midland Eye Ctr, Dudley Rd, Birmingham B18 7QH, W Midlands, EnglandAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV
PY  - 2018
VL  - 66
IS  - 11
SP  - 1655
EP  - +
DO  - 10.4103/ijo.IJO_1185_18
AN  - WOS:000448596100044
ER  -

TY  - JOUR
AU  - Gupta, V
AU  - Sharma, VK
TI  - Four views of trichomycosis axillaris: Clinical, Wood's lamp, dermoscopy and microscopy
T2  - INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV-DEC
PY  - 2018
VL  - 84
IS  - 6
SP  - 748
EP  - 749
DO  - 10.4103/ijdvl.IJDVL_567_17
AN  - WOS:000448226700027
ER  -

TY  - JOUR
AU  - Haffar, S
AU  - Shalimar
AU  - Kaur, RJ
AU  - Wang, Z
AU  - Prokop, LJ
AU  - Murad, MH
AU  - Bazerbachi, F
TI  - Acute liver failure caused by hepatitis E virus genotype 3 and 4: A systematic review and pooled analysis
T2  - LIVER INTERNATIONAL
KW  - acute liver failure
KW  - hepatitis
KW  - hepatitis E virus
KW  - human
KW  - systematic review
KW  - virology
KW  - FULMINANT-HEPATITIS
KW  - EXTRAHEPATIC MANIFESTATIONS
KW  - INFECTION
KW  - TRANSMISSION
KW  - PROGNOSIS
KW  - FREQUENCY
KW  - HOKKAIDO
KW  - FEATURES
KW  - PATIENT
KW  - STRAIN
AB  - Background & Aims
   Acute liver failure caused by hepatitis E virus genotype 3 and 4 has been rarely described. Because of the presence of a short golden therapeutic window in patients with viral acute liver failure from other causes, it is possible that early recognition and treatment might reduce the morbidity and mortality. We performed a systematic review and pooled analysis of acute liver failure caused by hepatitis E virus genotype 3 and 4.
   MethodsResultsTwo reviewers appraised studies after searching multiple databases on June 12th, 2017. Appropriate tests were used to compare hepatitis E virus genotype 3 vs 4, suspected vs confirmed genotypes, hepatitis E virus-RNA positive vs negative, and to discern important mortality risk factors.
   We identified 65 patients, with median age 58years (range: 3-79), and a male to female ratio of 1.2:1. The median bilirubin, ALT, AST and alkaline phosphatase (expressed by multiplication of the upper limit of normal) levels were 14.8, 45.3, 34.8 and 1.63 respectively. Antihepatitis E virus IgG, antihepatitis E virus IgM and hepatitis E virus-RNA were positive in 84%, 91% and 86% of patients respectively. The median interval from symptoms onset to acute liver failure was 23days, and 16 patients underwent liver transplantation. Final outcome was reported in 58 patients and mortality was 46%. Age was a predictor of poor prognosis in multivariate analysis. No important differences were found between patients infected with genotype 3 vs 4,patients with confirmed vs suspected genotypes, or patients with positive vs negative RNA.
   ConclusionAcute liver failure caused by hepatitis E virus genotype 3 and 4 is rare, similar between genotypes, occurs commonly in middle-aged/elderly patients and has a very high mortality. Age is predictive of poor prognosis in multivariate analysis.
AD  - Digest Ctr Diag & Treatment, Damascus, SyriaAD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaAD  - Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USAAD  - Mayo Clin, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Rochester, MN USAAD  - Mayo Clin, Lib Publ Serv, Rochester, MN USAC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Mayo ClinicC3  - Mayo ClinicC3  - Mayo ClinicPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - NOV
PY  - 2018
VL  - 38
IS  - 11
SP  - 1965
EP  - 1973
DO  - 10.1111/liv.13861
AN  - WOS:000448181200010
ER  -

TY  - JOUR
AU  - Hari, S
AU  - Paul, SB
AU  - Vidyasagar, R
AU  - Dhamija, E
AU  - Adarsh, AD
AU  - Thulkar, S
AU  - Mathur, S
AU  - Sreenivas, V
AU  - Sharma, S
AU  - Srivastava, A
AU  - Seenu, V
AU  - Prashad, R
TI  - Breast mass characterization using shear wave elastography and ultrasound
T2  - DIAGNOSTIC AND INTERVENTIONAL IMAGING
KW  - Shear wave elastography
KW  - Ultrasound
KW  - Breast mass
KW  - Image analysis
KW  - BI-RADS
KW  - PROBABLY BENIGN
KW  - FOLLOW-UP
KW  - DIAGNOSTIC PERFORMANCE
KW  - US
KW  - SPECIFICITY
KW  - MAMMOGRAPHY
KW  - AGREEMENT
KW  - EDITION
AB  - Purpose: To evaluate the role of SWE in characterizing breast masses and ascertain whether additional use of SWE to ultrasound for evaluating BI-RADS 3 and 4a masses could help reduce long-term follow-up and unnecessary biopsies of these suspicious breast masses.
   Materials and methods: This prospective, cross-sectional study was performed between June 2013 and November 2014. All enrolled patients underwent clinical breast examination, ultrasound, SWE and ultrasound-guided core biopsy of the breast mass. Breast Imaging Reporting and Data System (BI-RAD) categories were assigned to breast masses. For qualitative and quantitative variables of SWE, cut-off values for differentiation between benign and malignant breast masses were estimated. Modified BIRADS' (up/downgrading of BIRADS category) was done for BI-RADS 3/4a masses by combining individual SWE parameters and ultrasound findings. Sensitivity, specificity, positive and negative predictive value of modified BI-RADS' and ultrasound BI-RADS were compared.
   Results: A total of 119 women (mean age, 42.3 +/- 13.6 [SD] years; range: 13-87 years) with a single breast mass each were enrolled. Histopathologically, 57/119 (48%) breast masses were benign and 62 (52%) were malignant. On ultrasound, 42 breast masses were BI-RADS3 and 77 were BI-RADS 4 (4a, n = 10; 4b, n = 24; 4c, n = 43) leading to 96.8% sensitivity and 70.2% specificity. On SWE, benign breast masses were oval/round, homogenous/reasonably homogenous, blue/green with lower elasticity values and malignant breast masses were irregular, inhomogeneous, red/orange with high elasticity values. On modified BI-RADS' using E-color and E-mean/E-max, specificity improved to 78.9% and 75.4% respectively.
   Conclusion Addition of SWE to ultrasound improves characterization of BI-RADS 3 and 4a masses. E-max, E-mean and E-color are the most useful SWE parameters to differentiate between malignant and benign breast masses. (C) 2018 Societe francaise de radiologie. Published by Elsevier Masson SAS. All rights reserved.
AD  - All India Inst Med Sci, Dept Radiol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Surg, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER MASSON, CORPORATION OFFICE
PI  - PARIS
PA  - 65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE
DA  - NOV
PY  - 2018
VL  - 99
IS  - 11
SP  - 699
EP  - 707
DO  - 10.1016/j.diii.2018.06.002
AN  - WOS:000451085100004
ER  -

TY  - JOUR
AU  - Jain, V
AU  - Arora, S
AU  - Passah, A
AU  - Mani, K
AU  - Yadav, DK
AU  - Goel, P
AU  - Gupta, DK
TI  - Comparison of the renal dynamic scan performed with <SUP>99m</SUP>Tc-L, L-EC and <SUP>99m</SUP>Tc-MAG3 in children with pelviureteric junction obstruction
T2  - NUCLEAR MEDICINE COMMUNICATIONS
KW  - hydronephrosis
KW  - renal scan
KW  - technetium-99-L,L-ethylene dicysteine
KW  - technetium-99-mercaptoacetyltriglycine
KW  - TECHNETIUM-99M-MAG3
KW  - IODINE-131-OIH
KW  - SCINTIGRAPHY
AB  - The aim was to compare the renal dynamic scan (RDS) performed with technetium-(99)-L, L-ethylene dicysteine (Tc-99m-L, L-EC) and technetium-(99)-mercaptoacetyltriglycine (Tc-99m-MAG3) in children with pelviureteric junction (PUJ) obstruction. A retrospective study was carried out and children with PUJ obstruction who had RDS performed with both Tc-99m-L, L-EC and Tc-99m-MAG3. Children with any intervention in between the two scans or a gap of more than 2 months in between renal scans were excluded. The dose of each radiotracer used was 0.1 mCi/kg (3.7 MBq/kg), with a minimum dose of 1 mCi (37MBq). RDS was performed using the F+0 protocol. The differential renal function, Tmax, T1/2, drainage pattern, and hepatic uptake of the radiotracer were recorded and compared. A Bland-Altman plot was used to assess agreement between the two radiotracers. Sixteen children were included in the study. A total of 18 obstructed and 14 normal renal units were available to us for study. The values of differential renal function as well as Tmax and T1/2 of the two radiotracers were in agreement. In three obstructed kidneys in which T1/2 on Tc-99m-MAG3 was greater than 20 min, 99mTc-L, L-EC showed T1/2 values of 13.3 min or less. Tc-99m-L, L-EC showed nonobstructive drainage in three patients who had shown partial obstruction on Tc-99m-MAG3 scan. The hepatic uptake of Tc-99m-L, L-EC was also lower compared with Tc-99m-MAG3. To conclude Tc-99m-L, L-EC is a useful radiotracer for the evaluation of children with PUJ obstruction, with better assessment of drainage and lower hepatic uptake compared with Tc-99m-MAG3. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.
AD  - All India Inst Med Sci, Dept Pediat Surg, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Nucl Med, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - NOV
PY  - 2018
VL  - 39
IS  - 11
SP  - 1053
EP  - 1058
DO  - 10.1097/MNM.0000000000000902
AN  - WOS:000452656300013
ER  -

TY  - JOUR
AU  - Jose, A
AU  - Nagori, SA
AU  - Roy, ID
AU  - Roychoudhury, A
TI  - Orthodromic transfer of the temporalis tendon with extension of the fascia lata to reanimate the smile in facial palsy
T2  - BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY
KW  - Facial palsy
KW  - lengthening temporalis myoplasty
KW  - smile reconstruction
AD  - Army Dent Ctr Res & Referral, Div Oral & Maxillofacial Surg, New Delhi, IndiaAD  - 303 Field Hosp, 56 APO, Srinagar, Jammu & Kashmir, IndiaAD  - All India Inst Med Sci, Dept Oral & Maxillofacial Surg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - CHURCHILL LIVINGSTONE
PI  - EDINBURGH
PA  - JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
DA  - NOV
PY  - 2018
VL  - 56
IS  - 9
SP  - 890
EP  - 892
DO  - 10.1016/j.bjoms.2018.08.011
AN  - WOS:000450589300022
ER  -

TY  - JOUR
AU  - Kapil, U
AU  - Bhadoria, AS
TI  - Concerns with Urinary Iodine Excretion Level in a Single Random Sample
T2  - INDIAN PEDIATRICS
KW  - CHILDREN
AD  - AIIMS, Human Nutr Unit, New Delhi, IndiaAD  - AIIMS, Dept Community & Family Med, Rishikesh, Uttarakhand, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) RishikeshPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - NOV
PY  - 2018
VL  - 55
IS  - 11
SP  - 1007
EP  - 1007
AN  - WOS:000452047700023
ER  -

TY  - JOUR
AU  - Kapoor, D
AU  - Iqbal, R
AU  - Singh, K
AU  - Jaacks, LM
AU  - Shivashankar, R
AU  - Sudha, V
AU  - Anjana, RM
AU  - Kadir, M
AU  - Mohan, V
AU  - Ali, MK
AU  - Narayan, KMV
AU  - Tandon, N
AU  - Prabhakaran, D
AU  - Merchant, AT
TI  - Association of dietary patterns and dietary diversity with cardiometabolic disease risk factors among adults in South Asia: The CARRS study
T2  - ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION
KW  - principal component analysis
KW  - prudent diet
KW  - hypertension
KW  - diabetes
KW  - India
KW  - Pakistan
KW  - CORONARY-HEART-DISEASE
KW  - METABOLIC SYNDROME
KW  - BODY-WEIGHT
KW  - VARIETY
KW  - QUALITY
KW  - WOMEN
KW  - EPIDEMIOLOGY
KW  - HYPERTENSION
KW  - PREVALENCE
KW  - VALIDITY
AB  - Background and Objectives: To investigate the association of dietary patterns and dietary diversity with cardio-metabolic disease risk factors among South Asians. Methods and Study Design: In a population based study conducted in 2010-11, we recruited 16,287 adults aged >20 years residing in Delhi, Chennai, and Karachi. Diet was assessed using an interviewer-administered 26-item food frequency questionnaire. Principal component analysis identified three dietary patterns: Prudent, Indian, and Non-Vegetarian. We also computed a dietary diversity score. Multinomial and binary logistic regressions were used to calculate adjusted prevalence (95% confidence intervals) of cardio-metabolic disease risk factors across quartiles of dietary pattern and dietary diversity scores. Results: The adjusted prevalence of diagnosed diabetes was lower among participants in the highest versus lowest quartile of the Prudent Pattern (4.7% [3.8-5.6] versus 10.3% [8.5-12.0]), and the Indian Pattern (4.8% [3.7-5.9] versus 8.7% [6.7-10.6] in highest versus lowest quartile, respectively). Participants following the Indian Pattern also had lower adjusted prevalence of diagnosed hypertension (7.0% [5.4-8.5] versus 10.6% [8.6-12.5] in highest versus lowest quartile, respectively). Participants in the highest versus lowest quartile of the dietary diversity score had a lower adjusted prevalence of diagnosed diabetes (4.1% [3.0-5.2] versus 8.2% [7.1-9.3]), diagnosed hypertension (6.7% [5.3-8.1] versus 10.3% [9.1-11.5]), and undiagnosed hypertension (14.2% [12.0-16.4] versus 18.5% [16.9-20.1]). Conclusions: High dietary diversity appears to be protective against cardio-metabolic disease risk factors in this urban cohort of South Asian adults. Further investigation to understand the underlying mechanism of this observation is warranted.
AD  - All India Inst Med, New Delhi, IndiaAD  - Aga Khan Univ, Karachi, PakistanAD  - Publ Hlth Fdn India, Bengaluru, IndiaAD  - Harvard Univ, Dept Global Hlth & Populat, Boston, MA 02115 USAAD  - Ctr Chron Dis Control, Gurgaon, IndiaAD  - Madras Diabet Res Fdn, Chennai, IndiaAD  - Emory Univ, Dept Global Hlth, Atlanta, GA 30322 USAAD  - Univ South Carolina, Dept Epidemiol & Biostat, Columbia, SC 29208 USAC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Aga Khan UniversityC3  - Public Health Foundation of IndiaC3  - Harvard UniversityC3  - Madras Diabetes Research FoundationC3  - Emory UniversityC3  - University of South Carolina SystemC3  - University of South Carolina ColumbiaPU  - H E C PRESS, HEALTHY EATING CLUB PTY LTD
PI  - MCKINNON
PA  - PO BOX 4121, MCKINNON, VIC 3204, AUSTRALIA
DA  - NOV
PY  - 2018
VL  - 27
IS  - 6
SP  - 1332
EP  - 1343
DO  - 10.6133/apjcn.201811_27(6).0021
AN  - WOS:000458019300021
ER  -

TY  - JOUR
AU  - Katiyar, V
AU  - Dharanipathy, S
AU  - Gurjar, H
AU  - Vora, Z
AU  - Sharma, R
TI  - Post-traumatic hydrocephalus following decompressive craniectomy: how well can it be predicted?
T2  - ACTA NEUROCHIRURGICA
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER WIEN
PI  - WIEN
PA  - SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
DA  - NOV
PY  - 2018
VL  - 160
IS  - 11
SP  - 2125
EP  - 2125
DO  - 10.1007/s00701-018-3684-8
AN  - WOS:000449674300007
ER  -

TY  - JOUR
AU  - Kaur, C
AU  - Pal, I
AU  - Saini, S
AU  - Jacob, TG
AU  - Nag, TC
AU  - Thakar, A
AU  - Bhardwaj, DN
AU  - Roy, TS
TI  - Comparison of unbiased stereological estimation of total number of cresyl violet stained neurons and parvalbumin positive neurons in the adult human spiral ganglion
T2  - JOURNAL OF CHEMICAL NEUROANATOMY
KW  - Spiral ganglion neurons
KW  - Immunohistochemistry
KW  - Parvalbumin
KW  - Cresyl violet
KW  - Stereology
KW  - CALCIUM-BINDING PROTEINS
KW  - HUMAN COCHLEAR NUCLEUS
KW  - CELL POPULATIONS
KW  - RAT HIPPOCAMPUS
KW  - AGE
KW  - DEGENERATION
KW  - DISECTOR
AB  - Estimation of total number of neurons in the spiral ganglion (SG) at various ages and their functional status is important as these neurons are constantly exposed to noise and other environmental factors that may lead to neuronal loss with aging due to excitotoxic damage. Parvalbumin (PV) is a calcium-binding protein (CBP), found in highly metabolically active neurons. It helps in buffering cytosolic calcium, which is essential for neurotransmitter release. The neurons in the adult human SG express PV more strongly than other CBPs like calbindin and calretinin. These CBPs can be used as signatures to recognise neurons. In the present study, we quantified the number of neurons expressing PV by unbiased stereology and compared it to the number of neurons stained by cresyl violet (CV), which is a Nissl stain, in the adult human SG. Five adult human cadaveric temporal bones were obtained from the forensic science mortuary, after due clearance from the institute ethics committee. Independent CV stained and PV immunostained sections were used to estimate the total number of neurons (optical fractionator), with Stereolnvestigator (SI) software. The estimated total number of SG neurons was 27,485 +/- 3251 and 26,705 +/- 1823 in the PV and CV stained sections, respectively. There was no significant difference between the estimates (p = 0.552). Therefore, CV staining is simpler and more cost effective when estimating neuronal number. Although PV stains spiral ganglion neurons (SGNs) with a greater intensity and provides a functional status, its tedious protocol limits its use for quantification. (C) 2017 Elsevier B.V. All rights reserved.
AD  - All India Inst Med Sci, Dept Anat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Otorhinolaryngol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Forens Med & Toxicol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - NOV
PY  - 2018
VL  - 93
SP  - 30
EP  - 37
DO  - 10.1016/j.jchemneu.2017.06.004
AN  - WOS:000448099900004
ER  -

TY  - JOUR
AU  - Khan, R
AU  - Sharma, A
AU  - Bhushan, A
AU  - Basnet, B
AU  - Sharma, VK
AU  - Gupta, S
TI  - Relationship between α-melanocyte stimulating hormone levels and therapeutic outcome of melanocyte transplantation and phototherapy in non-segmental patients with vitiligo: A prospective study
T2  - AUSTRALASIAN JOURNAL OF DERMATOLOGY
AD  - All India Inst Med Sci, Dept Biochem, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - NOV
PY  - 2018
VL  - 59
IS  - 4
SP  - E315
EP  - E318
DO  - 10.1111/ajd.12769
AN  - WOS:000449686900045
ER  -

TY  - JOUR
AU  - Khangembam, VC
AU  - Srivastava, SK
AU  - Leishangthem, GD
AU  - Kataria, M
AU  - Thakuria, D
TI  - Evaluation of Apoptosis Inducing Ability of <i>Parkia javanica</i> Seed Extract in Cancer Cells
T2  - INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES
KW  - Parkia javanica
KW  - methanolic extract
KW  - apoptosis
KW  - cancer cells
KW  - MORPHOLOGICAL-CHANGES
KW  - DNA FRAGMENTATION
KW  - GAMBOGIC ACID
KW  - THIOPROLINE
KW  - QUANTIFICATION
KW  - INDUCTION
KW  - KINETICS
AB  - Bioactive compounds present in Parkia javanica seeds are reported to have anticancer effect. The present study was taken up to evaluate the apoptosis inducing ability of methanol extract of Parkia javanica seeds in cancer cells. The extract was found to cause 50 % cell death in HeLa and MCF-7 cells at 0.54 and 0.74 mg/ml, respectively, which is lower than that of normal healthy cells. In haematoxylin-eosin and fluorescent staining of the extract-treated cancer cells, chromatin condensation and nuclear fragmentation were observed. Fluorescent-activated cell sorting analysis using Annexin V-fluorescein isothiocyanate/propidium iodide also revealed the presence of apoptotic and secondary necrotic cell populations in the extract-treated cancer cells. In gel electrophoresis, DNA fragmentation, a biochemical hallmark of apoptosis was also observed. Caspase-3, an enzyme activated both in extrinsic and intrinsic pathways of apoptosis was detected in extract-treated HeLa cells by immunocytochemistry. The results of the present study suggested that Parkia javanica seed has the ability to induce apoptosis in cancer cells and could be considered in future endeavours for development of safer natural anticancer agent.
AD  - ICAR Indian Vet Res Inst, Div Anim Biochem, Bareilly 243122, Uttar Pradesh, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaAD  - ICAR Directorate Coldwater Fisheries Res, Bhimtal 263136, Uttarakhand, IndiaC3  - Indian Council of Agricultural Research (ICAR)C3  - ICAR - Indian Veterinary Research InstituteC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Council of Agricultural Research (ICAR)C3  - ICAR - Directorate of Coldwater Fisheries ResearchPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV-DEC
PY  - 2018
VL  - 80
IS  - 6
SP  - 1069
EP  - 1077
DO  - 10.4172/pharmaceutical-sciences.1000457
AN  - WOS:000455184700011
ER  -

TY  - JOUR
AU  - Khokhar, S
AU  - Mahabir, M
TI  - Phacoemulsification in phakic iris-claw lens with cataract
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Artisan
KW  - iris-claw
KW  - phacoemulsification
KW  - phakic
KW  - INTRAOCULAR-LENS
KW  - SURGERY
KW  - IMPLANTATION
KW  - EYES
KW  - HYPEROPIA
AB  - In this new technique of cataract surgery in patients with iris- fixated phakic intraocular lens with cataract, phakic IOL is explanted at the end of surgery. Phakic IOL remains stable and securely enclaved to the iris during phacoemulsification which is performed through a small 2.2 mm incision. Endothelial protection is provided by viscodispersive OVD above the phakic IOL and space for surgery is created by high molecular weight viscocohesive OVD beneath the phakic IOL. This technique provides significant advantages from the previously described techniques in terms of chamber stability, endothelial protection, iris trauma and surgical ease.
AD  - AIIMS, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 490,Fourth Floor, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV
PY  - 2018
VL  - 66
IS  - 11
SP  - 1609
EP  - 1610
DO  - 10.4103/ijo.IJO_423_18
AN  - WOS:000448596100019
ER  -

TY  - JOUR
AU  - Khor, WB
AU  - Prajna, VN
AU  - Garg, P
AU  - Mehta, JS
AU  - Xie, LX
AU  - Liu, ZG
AU  - Padilla, MDB
AU  - Joo, CK
AU  - Inoue, Y
AU  - Goseyarakwong, P
AU  - Hu, FR
AU  - Nishida, K
AU  - Kinoshita, S
AU  - Puangsricharern, V
AU  - Tan, AL
AU  - Beuerman, R
AU  - Young, A
AU  - Sharma, N
AU  - Haaland, B
AU  - Mah, FS
AU  - Tu, EY
AU  - Stapleton, FJ
AU  - Abbott, RL
AU  - Tan, DTH
A1  - ACSIKS Grp
TI  - The Asia Cornea Society Infectious Keratitis Study: A Prospective Multicenter Study of Infectious Keratitis in Asia
T2  - AMERICAN JOURNAL OF OPHTHALMOLOGY
KW  - SOUTH-EAST-ASIA
KW  - FUNGAL KERATITIS
KW  - ULCERATIVE KERATITIS
KW  - MICROBIAL KERATITIS
KW  - VILLAGE LEVEL
KW  - PENETRATING KERATOPLASTY
KW  - ETIOLOGIC DIAGNOSIS
KW  - VISUAL IMPAIRMENT
KW  - NORTH CHINA
KW  - INDIA
AB  - PURPOSE: To survey the demographics, risk factors, microbiology, and outcomes for infectious keratitis in Asia.
   DESIGN: Prospective, nonrandomized clinical study.
   METHODS: Thirteen study centers and 30 sub-centers recruited consecutive subjects over 12-18 months, and performed standardized data collection. A microbiological protocol standardized the processing and reporting of all isolates. Treatment of the infectious keratitis was decided by the managing ophthalmologist. Subjects were observed for up to 6 months. Main outcome measures were final visual acuity and the need for surgery during infection.
   RESULTS: A total of 6626 eyes of 6563 subjects were studied. The majority of subjects were male (n = 3992). Trauma (n = 2279, 34.7%) and contact lens wear (n = 704, 10.7%) were the commonest risk factors. Overall, bacterial keratitis was diagnosed in 2521 eyes (38.0%) and fungal keratitis in 2166 eyes (32.7%). Of the 2831 microorganisms isolated, the most common were Fusarium species (n = 518, 18.3%), Pseudomonas aeruginosa (n = 302, 10.7%), and Aspergillus flavus (n = 236, 8.3%). Cornea transplantation was performed in 628 eyes to manage ongoing infection, but 289 grafts (46%) had failed by the end of the study. Moderate visual impairment (Snellen vision less than 20/60) was documented in 3478 eyes (53.6%).
   CONCLUSION: Demographic and risk factors for infection vary by country, but infections occur predominantly in male subjects and are frequently related to trauma. Overall, a similar percentage of bacterial and fungal infections were diagnosed in this study. Visual recovery after infectious keratitis is guarded, and corneal transplantation for active infection is associated with a high failure rate. (C) 2018 Elsevier Inc. All rights reserved.
AD  - Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, SingaporeAD  - Singapore Eye Res Inst, Singapore, SingaporeAD  - Aravind Eye Care Syst, Madurai, Tamil Nadu, IndiaAD  - LV Prasad Eye Inst, Hyderabad, IndiaAD  - Duke NUS Grad Med Sch, Singapore, SingaporeAD  - Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, SingaporeAD  - Shandong Eye Inst, Qingdao, Shandong, Peoples R ChinaAD  - Xiemen Eye Ctr, Xiemen, Peoples R ChinaAD  - Univ Philippines Manila, Philippine Gen Hosp, Manila, PhilippinesAD  - Catholic Univ Korea, St Mary Hosp, Seoul, South KoreaAD  - Tottori Univ, Fac Med, Div Ophthalmol & Visual Sci, Tottori, Tottori, JapanAD  - Mahidol Univ, Siriraj Hosp, Fac Med, Bangkok, ThailandAD  - Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, TaiwanAD  - Osaka Univ, Osaka Univ Hosp, Grad Sch Med, Osaka, JapanAD  - Kyoto Prefectural Univ Med, Kyoto, JapanAD  - Chulalongkorn Univ, King Chulalongkorn Mem Hosp, Fac Med, Bangkok, ThailandAD  - Singapore Gen Hosp, Dept Microbiol, Singapore, SingaporeAD  - Chinese Univ Hong Kong, Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R ChinaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaAD  - Scripps Clin Torrey Pines, La Jolla, CA USAAD  - Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL USAAD  - Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, AustraliaAD  - Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USAAD  - St Lukes Med Ctr, Manila, PhilippinesC3  - Singapore National Eye CenterC3  - National University of SingaporeC3  - Singapore National Eye CenterC3  - L. V. Prasad Eye InstituteC3  - National University of SingaporeC3  - National University of SingaporeC3  - Shandong First Medical University & Shandong Academy of Medical SciencesC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - Seoul St. Mary's HospitalC3  - Catholic University of KoreaC3  - Tottori UniversityC3  - Mahidol UniversityC3  - National Taiwan UniversityC3  - National Taiwan University HospitalC3  - Osaka UniversityC3  - Kyoto Prefectural University of MedicineC3  - Chulalongkorn UniversityC3  - Singapore General HospitalC3  - Chinese University of Hong KongC3  - Prince of Wales HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - Scripps Research InstituteC3  - University of Illinois SystemC3  - University of Illinois ChicagoC3  - University of Illinois Chicago HospitalC3  - University of New South Wales SydneyC3  - University of California SystemC3  - University of California San FranciscoC3  - Saint Lukes Medical Center - PhilippinesPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - NOV
PY  - 2018
VL  - 195
SP  - 161
EP  - 170
DO  - 10.1016/j.ajo.2018.07.040
AN  - WOS:000450020300021
ER  -

TY  - JOUR
AU  - Kumar, H
AU  - Mansoori, T
AU  - Warjri, GB
AU  - Somarajan, BI
AU  - Bandil, S
AU  - Gupta, V
TI  - Lasers in glaucoma
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Cyclophotocoagulation
KW  - laser iridotomy
KW  - laser iridoplasty
KW  - laser trabeculoplasty
KW  - PRIMARY ANGLE-CLOSURE
KW  - TERM FOLLOW-UP
KW  - YTTRIUM-ALUMINUM-GARNET
KW  - ARGON-LASER
KW  - DIODE-LASER
KW  - SELECTIVE LASER
KW  - PERIPHERAL IRIDOPLASTY
KW  - ENDOSCOPIC CYCLOPHOTOCOAGULATION
KW  - INTRAOCULAR-PRESSURE
KW  - TRANSSCLERAL CYCLOPHOTOCOAGULATION
AB  - While lasers have been used for many years for the treatment of glaucoma, proper indications and use of the procedures need to be considered before their application. This review summarizes the important laser procedures in Glaucoma.
AD  - Safdarjung Enclave, Ctr Sight, New Delhi, IndiaAD  - Sita Lakshmi Glaucoma Ctr, Anand Eye Inst, Hyderabad, Telangana, IndiaAD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV
PY  - 2018
VL  - 66
IS  - 11
SP  - 1539
EP  - 1553
DO  - 10.4103/ijo.IJO_555_18
AN  - WOS:000448596100005
ER  -

TY  - JOUR
AU  - Kumar, S
AU  - Singh, S
AU  - Deep, R
TI  - Mental and behavioural emergencies at a tertiary healthcare centre in India: Pattern and profile
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
KW  - MANAGEMENT
KW  - PSYCHIATRY
AB  - Background. Sparse data are available on service utilization, pattern and profile of mental and behavioural emergencies in India. We explored the pattern and clinical profile of consecutively referred psychiatric emergencies at a premier tertiary healthcare centre in India.
   Methods. We reviewed the consecutive referrals for acute mental and behavioural problems made by the emergency department and recorded in an emergency psychiatry register between January 2015 and January 2016.
   Results. Over a 13-month period, 666 patients were assessed; of whom 473 (71%) had no prior/known psychiatric history and 84 (12.6%) had a comorbid medical condition. Nearly one-third of patients had potential legal issues associated with their emergency. The most common reasons for presentation were: an attempt at self-harm (130; 19.5%), aggression/agitation (122; 18.3%) and psychoactive substance use-related problems (69; 10.3%). Schizophrenia and other psychotic disorders (89; 13.4%) and mood disorders (87; 13.1%) formed the 2 most common diagnostic groups seen in emergency. Most commonly prescribed medications were benzodiazepines (296; 44.4%) followed by antipsychotics (187; 28.1%) and antidepressants (90; 13.5%). Notably, 11% of patients (76) were advised immediate admission under psychiatry, half of whom could be admitted directly from the emergency.
   Conclusion. Our findings suggest that there is a need to optimize emergency mental healthcare and develop service delivery models for common psychiatric emergencies in India.
AD  - All India Inst Med Sci, Dept Psychiat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - NOV-DEC
PY  - 2018
VL  - 31
IS  - 6
SP  - 339
EP  - 342
DO  - 10.4103/0970-258X.262895
AN  - WOS:000479098700005
ER  -

TY  - JOUR
AU  - Kumar, V
AU  - Chatra, K
TI  - Fibrotic pillar leads to focal choroidal excavation in Best vitelliform dystrophy
T2  - GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
KW  - Focal choroidal excavation
KW  - Optical coherence tomography
KW  - Best vitelliform dystrophy
KW  - Fibrotic pillar
KW  - EYES
AB  - PurposeTo study focal choroidal excavations in patients with Best vitelliform dystrophy using optical coherence tomography and their topographical relation with fibrotic pillars.MethodsThis is a retrospective cross-sectional study of consecutive patients diagnosed with Best vitelliform dystrophy at a tertiary eye care center. Records of patients with Best vitelliform dystrophy were reviewed for best-corrected visual acuity, color fundus photographs, shortwave autofluorescence, optical coherence tomography, and electrooculogram with special emphasis on the presence of focal choroidal excavation (FCE) and fibrotic pillar. Main outcome measure was to study the fibrotic pillar in relation to the FCE.ResultsThirty-eight eyes of 19 patients with mean age of 34.6years were enrolled in the study. FCE was seen in eight eyes of six patients. Two patients had bilateral FCE and all the FCEs were located in the area of vitelliform lesion. Six out of eight eyes with FCE were in vitelliruptive stage of disease; one was in pseudohypopyon stage and one in atrophic stage. A fibrotic pillar was seen lying directly above the FCE in seven eyes. In one eye, hyper-reflective material not amounting to fibrotic pillar was seen lying above the FCE.ConclusionA focal choroidal excavation in the setting of Best vitelliform dystrophy is seen predominantly in the vitelliruptive stage of the disease. Fibrotic pillars appear to play a role in the formation of these FCEs.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SPRINGER
PI  - NEW YORK
PA  - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
DA  - NOV
PY  - 2018
VL  - 256
IS  - 11
SP  - 2083
EP  - 2087
DO  - 10.1007/s00417-018-4120-8
AN  - WOS:000448042400009
ER  -

TY  - JOUR
AU  - Madhusudhan, KS
AU  - Vyas, S
AU  - Sharma, S
AU  - Srivastava, DN
AU  - Gupta, AK
TI  - Portal vein abnormalities: an imaging review
T2  - CLINICAL IMAGING
KW  - Portal vein
KW  - Portal vein anomalies
KW  - Abernathy malformation
KW  - Portal vein variations
KW  - TIPS
KW  - Portal vein embolization
KW  - RETROGRADE TRANSVENOUS OBLITERATION
KW  - CONGENITAL PORTOSYSTEMIC SHUNTS
KW  - VENOUS STENT PLACEMENT
KW  - SEPTIC THROMBOPHLEBITIS
KW  - COLLATERAL PATHWAYS
KW  - LIVER
KW  - CT
KW  - MANAGEMENT
KW  - THROMBOSIS
KW  - DIAGNOSIS
AB  - The portal vein is the main vascular channel of the liver and is affected by many pathologies. Imaging plays an important role in the detection and characterization of these abnormalities, guiding the surgeon and the interventional radiologist in planning further management. We discuss the imaging appearances of various abnormalities affecting the portal vein and the imaging modalities used in their diagnosis. We also briefly discuss the radiological interventions done in some of these cases.
AD  - All India Inst Med Sci, Dept Radiodiag, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - NOV-DEC
PY  - 2018
VL  - 52
SP  - 70
EP  - 78
DO  - 10.1016/j.clinimag.2018.07.002
AN  - WOS:000454569100014
ER  -

TY  - JOUR
AU  - Maitra, S
AU  - Som, A
AU  - Bhattacharjee, S
TI  - Accuracy of quick Sequential Organ Failure Assessment (qSOFA) score and systemic inflammatory response syndrome (SIRS) criteria for predicting mortality in hospitalized patients with suspected infection: a meta-analysis of observational studies
T2  - CLINICAL MICROBIOLOGY AND INFECTION
KW  - Sepsis
KW  - qSOFA
KW  - SIRS
KW  - Prognosis
KW  - Mortality
KW  - INTERNATIONAL CONSENSUS DEFINITIONS
KW  - INTENSIVE-CARE-UNIT
KW  - EMERGENCY-DEPARTMENT PATIENTS
KW  - SEPTIC SHOCK
KW  - PROGNOSTIC ACCURACY
KW  - CLINICAL-CRITERIA
KW  - SOFA SCORES
KW  - SEPSIS
KW  - PERFORMANCE
KW  - ADMISSION
AB  - Objective: To identify sensitivity, specificity and predictive accuracy of quick sequential organ failure assessment (qSOFA) score and systemic inflammatory response syndrome (SIRS) criteria to predict in-hospital mortality in hospitalized patients with suspected infection.
   Methods: This meta-analysis followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) group consensus statement for conducting and reporting the results of systematic review. PubMed and EMBASE were searched for the observational studies which reported predictive utility of qSOFA score for predicting mortality in patients with suspected or proven infection with the following
   search words: 'qSOFA', 'q-SOFA', 'quick-SOFA', 'Quick Sequential Organ Failure Assessment', 'quick SOFA'. Sensitivity, specificity, area under receiver operating characteristic (ROC) curves with 95% confidence interval (CI) of qSOFA and SIRS criteria for predicting in-hospital mortality was collected for each study and a 2 x 2 table was created for each study.
   Results: Data of 406 802 patients from 45 observational studies were included in this meta-analysis. Pooled sensitivity (95% CI) and specificity (95% CI) of qSOFA >= 2 for predicting mortality in patients who were not in an intensive care unit (ICU) was 0.48 (0.41 - 0.55) and 0.83 (0.78 - 0.87), respectively. Pooled sensitivity (95% CI) of qSOFA >= 2 for predicting mortality in patients (both ICU and non-ICU settings) with suspected infection was 0.56 (0.47 - 0.65) and pooled specificity (95% CI) was 0.78 (0.71 - 0.83).
   Conclusion: qSOFA has been found to be a poorly sensitive predictive marker for in-hospital mortality in hospitalized patients with suspected infection. It is reasonable to recommend developing another scoring system with higher sensitivity to identify high-risk patients with infection. (C) 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
AD  - All India Inst Med Sci, Dept Anaesthesiol Pain Med & Crit Care, New Delhi, IndiaAD  - Max Super Specialty Hosp, MAMBS, Dept Anaesthesiol, Press Enclave Rd, New Delhi 110017, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - NOV
PY  - 2018
VL  - 24
IS  - 11
SP  - 1123
EP  - 1129
DO  - 10.1016/j.cmi.2018.03.032
AN  - WOS:000448188200005
ER  -

TY  - JOUR
AU  - Malik, R
TI  - Pediatric Inflammatory Bowel Disease in India: Time to Prepare for Challenges and Opportunities
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - CHILDREN
AD  - All India Inst Med Sci, Dept Pediat, Div Pediat Gastroenterol Hepatol & Clin Nutr, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - NOV
PY  - 2018
VL  - 85
IS  - 11
SP  - 959
EP  - 960
DO  - 10.1007/s12098-018-2778-x
AN  - WOS:000448226100009
ER  -

TY  - JOUR
AU  - Marwaha, RK
AU  - Mithal, A
AU  - Bhari, N
AU  - Sethuraman, G
AU  - Gupta, S
AU  - Shukla, M
AU  - Narang, A
AU  - Chadda, A
AU  - Gupta, N
AU  - Sreenivas, V
AU  - Ganie, MA
TI  - Supplementation with Three Different Daily Doses of Vitamin D<sub>3</sub> in Healthy Pre-pubertal School Girls: A Cluster Randomized Trial
T2  - INDIAN PEDIATRICS
KW  - Micronutrient supplementation
KW  - Prevention
KW  - Vitamin D deficiency
KW  - URINARY CALCIUM EXCRETION
KW  - D-FORTIFIED MILK
KW  - 25-HYDROXYVITAMIN D
KW  - AFRICAN-AMERICAN
KW  - D DEFICIENCY
KW  - CHILDREN
KW  - OBESE
AB  - Objective: To compare the adequacy and efficacy of different doses of vitamin D3 in pre-pubertal girls.
   Design: Cluster Randomized controlled trial.
   Setting: Public school in Delhi, India, between August 2015 and February 2016.
   Participants: 216 healthy pre-pubertal girls, aged 6.1-11.8 years.
   Intervention: Daily supplementation with 600 IU (n=74), 1000 IU (n=67) or 2000 IU (n=75) of vitamin D3 under supervision for 6 months.
   Outcome measures: Primary: Rise in serum 25 hydroxy Vitamin D (25(OH) D); Secondary: Change in bone formation and resorption markers.
   Results: Following 6 months of supplementation, the mean (SD) rise in serum 25(OH) D was maximum with 2000 IU (24.09 (8.28) ng/mL), followed by with 1000 IU (17.96 (6.55) ng/mL) and 600 IU (15.48 (7.00) ng/mL). Serum 25(OH) D levels of >= 20 ng/mL were seen in 91% in 600 IU group, 97% in 1000 IU group and 100% in 2000 IU group. The overall mean (SD) rise in urinary calcium creatinine ratio (0.05 (0.28) to 0.13 (0.12) mg/mg), and serum procollagen type I N-terminal propeptide (538.9 (199.78) to 655.5 (218.24) ng/mL), and reduction in serum carboxy-terminal telopeptide (0.745 (0.23) to 0.382 (0.23) ng/mL) was significant (P<0.01). The change in the above parameters was comparable among the three groups after adjustment for age.
   Conclusion: Daily vitamin D supplementation with 600 IU to 2000 IU for 6 months results in Vitamin D sufficiency in >90% of prepubertal girls.
AD  - Int Life Sci Inst, New Delhi, IndiaAD  - Medanta Hosp Gurgaon, Gurgaon, Haryana, IndiaAD  - AIIMS, Dept Dermatol, New Delhi, IndiaAD  - AIIMS, Dept Endocrinol, New Delhi, IndiaAD  - AIIMS, Dept Biostat, New Delhi, IndiaAD  - SGPGI, Lucknow, Uttar Pradesh, IndiaAD  - Dr BR Sur Homeopath Med Coll, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - NOV
PY  - 2018
VL  - 55
IS  - 11
SP  - 951
EP  - 956
DO  - 10.1007/s13312-018-1416-z
AN  - WOS:000452047700003
ER  -

TY  - JOUR
AU  - Meena, P
AU  - Bhalla, AS
AU  - Goyal, A
AU  - Sharma, R
AU  - Kumar, A
AU  - Srivastva, DN
AU  - Sreenivas, V
AU  - Guleria, R
TI  - Single-phase Split-bolus Dual Energy Computed Tomography Angiography for Evaluation of Hemoptysis
T2  - JOURNAL OF THORACIC IMAGING
KW  - dual energy
KW  - computed tomography
KW  - hemoptysis
KW  - radiation
KW  - single-phase CT
KW  - split-bolus CT
KW  - CT angiography
KW  - image quality
KW  - bronchial arteries
KW  - bronchial artery embolization
KW  - MULTIDETECTOR ROW CT
KW  - NONBRONCHIAL SYSTEMIC ARTERIES
KW  - MASSIVE HEMOPTYSIS
KW  - PULMONARY ANGIOGRAPHY
KW  - EMBOLIZATION
KW  - MANAGEMENT
KW  - ORIGIN
KW  - CHEST
KW  - SITE
KW  - BRONCHOSCOPY
AB  - Purpose: The purpose of this study was to assess feasibility and overall utility of single-phase split-bolus dual energy computed tomography (DECT) angiography (DECTA) for evaluation of hemoptysis, and to establish an injection protocol for evaluation of hemoptysis, by comparing 2 contrast injection protocols.
   Materials and Methods: Using dual-source (80 and 140 kV), 2x128-slice equipment, DECTA was performed using 400 mg iodine/mL, 50 to 80 mL iodinated contrast in 257 patients (189 male individuals, 68 female individuals, age range: 15 to 76 y) presenting with hemoptysis. Initially, 50 patients were randomized into 2 groups for 2 different injection protocols (A and B). Images were assessed quantitative and qualitatively. Later, 207 patients were randomized using protocol B, which was technically simpler, and single-CT acquisition, for simultaneous opacification of systemic and pulmonary vessels.
   Results: Injection protocol A resulted in higher vessel attenuation, both in the aorta and in the pulmonary artery and its segmental branches; however, the difference was not statistically significant. No significant difference was noted in signal-to-noise ratio, contrast-to-noise ratio, as well as subjective image quality parameters. Overall optimal opacification of both systemic and pulmonary arteries was achieved in 247/257 patients. A total of 308 abnormal bronchial arteries were noted. A total of 392 nonbronchial systemic arteries were noted, the majority arising from posterior intercostals and subclavian artery branches. The pulmonary source of hemoptysis was identified in 9 patients (3 pulmonary thromboembolisms, 5 pulmonary artery pseudoaneurysms, and 1 pulmonary venous ectasia).
   Conclusion: Combined DECTA is a novel technique that enables simultaneous evaluation of both systemic and pulmonary vascular cause of hemoptysis in a single acquisition with small contrast dose. Both injection protocols "A" and "B" were equally efficacious in simultaneous opacification of both the aorta and pulmonary arteries. To the best of our knowledge, such a protocol has never been described for hemoptysis evaluation.
AD  - AIIMS, Dept Radiodiag, Room 66, New Delhi 110029, IndiaAD  - AIIMS, Dept Biostat, New Delhi, IndiaAD  - AIIMS, Dept Pulmonol & Sleep Related Disorders, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - NOV
PY  - 2018
VL  - 33
IS  - 6
SP  - 366
EP  - 376
DO  - 10.1097/RTI.0000000000000337
AN  - WOS:000448391700011
ER  -

TY  - JOUR
AU  - Midha, N
AU  - Sidhu, T
AU  - Chaturvedi, N
AU  - Sinha, R
AU  - Shende, DR
AU  - Dada, T
AU  - Gupta, V
AU  - Sihota, R
TI  - Systemic Associations of Childhood Glaucoma: A Review
T2  - JOURNAL OF PEDIATRIC OPHTHALMOLOGY & STRABISMUS
KW  - AXENFELD-RIEGER-SYNDROME
KW  - ATRIAL SEPTAL-DEFECT
KW  - MUTATIONS
KW  - BLINDNESS
AB  - Purpose: To review systemic associations of childhood glaucoma.
   Methods: Patients younger than 15 years and diagnosed as having glaucoma were divided into four groups: isolated primary congenital glaucoma, glaucoma with other congenital ocular anomalies, congenital glaucoma with known systemic diseases, and secondary glaucoma. Prevalence and type of systemic associations in each group were studied.
   Results: A retrospective analysis of 371 patients diagnosed as having glaucoma was done. In the primary congenital glaucoma group, 13 of 218 (5.9%) patients had an associated systemic illness: congenital heart disease and global developmental delay were the most common systemic manifestations. In the congenital ocular anomalies group, 10 of 63 (15.8%) patients had an associated systemic illness. Axenfeld-Reiger syndrome, aniridia, and Peters' anomaly frequently had systemic comorbidities with congenital heart disease. In the known systemic diseases group, all 18 (100%) patients had systemic manifestations of an associated syndrome: Sturge-Weber and Down syndrome were the most frequent. In the secondary glaucoma group, 9 of 72 (12.5%) patients had systemic involvement, which was often seen as the most common cause after congenital cataract surgery. These children had congenital heart disease and global developmental delay as a consequence of congenital rubella and congenital cytomegalovirus infection.
   Conclusions: The study found that 12.9% of patients with childhood glaucoma had an associated systemic abnormality. Patients with congenital glaucoma and other ocular anomalies have a three times higher risk of an underlying systemic anomaly than patients with isolated primary congenital glaucoma. A team comprising an ophthalmologist, pediatrician, and anesthesiologist is recommended to treat these cases.
AD  - All India Inst Med Sci, Ctr Ophthalm Sci, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Anaesthesia, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SLACK INC
PI  - THOROFARE
PA  - 6900 GROVE RD, THOROFARE, NJ 08086 USA
DA  - NOV-DEC
PY  - 2018
VL  - 55
IS  - 6
SP  - 397
EP  - 402
DO  - 10.3928/01913913-20180905-01
AN  - WOS:000450581400011
ER  -

TY  - JOUR
AU  - Mishra, S
AU  - Roy, TS
AU  - Wadhwa, S
TI  - Morphological and morphometrical maturation of ventral cochlear nucleus in human foetus
T2  - JOURNAL OF CHEMICAL NEUROANATOMY
KW  - Human ventral cochlear nucleus
KW  - Development
KW  - Stereology
KW  - Parvalbumin
KW  - Synaptophysin
KW  - CALCIUM-BINDING PROTEINS
KW  - FETAL AUDITORY-SYSTEM
KW  - BRAIN-STEM
KW  - SYNAPTOPHYSIN IMMUNOREACTIVITY
KW  - POSTNATAL-DEVELOPMENT
KW  - GESTATIONAL-AGE
KW  - NERVOUS-SYSTEM
KW  - RAT
KW  - NEURONS
KW  - GROWTH
AB  - Auditory impulses perceived by the hair cells of the organ of corti are relayed in the cochlear nucleus, the first relay station in the brainstem, by the cochlear nerve. The human foetus is well known to respond to sound during the last trimester of gestation. On the contrary, studies conducted in rat, cat and mouse have shown that these mammals have an immature auditory system at the time of birth. There are very few reports available regarding the morphological and functional maturation of the cochlear nucleus in human. Although the human cochlear nucleus neurons attain adult morphological characters by mid gestation, there are hardly any studies discussing the functional maturation of the cochlear nucleus. Hence the present study was aimed at observing the morphological as well as functional maturation of the human foetal cochlear nuclei at various gestational ages. Morphological maturation was observed qualitatively while stereological estimation of the volume of well defined ventral cochlear nucleus (VCN) was calculated by the Cavalieri principle; neuronal count and density was estimated by dissector principle. The functional maturation was assessed by observing the expression of synaptophysin, a synaptic marker, at different gestational ages and by the presence of parvalbumin, a calcium binding functional neuronal marker by immunohistochemistry. Neurons showed coarse Nissl's substance and well developed cell processes and gradual increase in cell size by the 24th-30th gestational week. Synaptophysin labeling in the complete cochlear nucleus was observed at 20 weeks of gestation. Adult pattern of synaptophysin labeling was observed finally at37weeks of gestation. Earliest presence of parvalbumin expression was detected at 16 weeks of gestation and a distinct adult pattern was seen at 37 weeks of gestation. This study concluded that morphological and functional maturation of the human cochlear nuclei occurs simultaneously during mid-gestation which represents the critical period of development and continues up to term. (C) 2017 Elsevier B.V. All rights reserved.
AD  - All India Inst Med Sci, New Delhi, IndiaAD  - NDMC Med Coll, Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - NOV
PY  - 2018
VL  - 93
SP  - 38
EP  - 47
DO  - 10.1016/j.jchemneu.2017.03.002
AN  - WOS:000448099900005
ER  -

TY  - JOUR
AU  - Mohanty, S
AU  - Jain, KG
AU  - Nandy, SB
AU  - Kakkar, A
AU  - Kumar, M
AU  - Dinda, AK
AU  - Singh, H
AU  - Ray, A
TI  - Iron oxide labeling does not affect differentiation potential of human bone marrow mesenchymal stem cells exhibited by their differentiation into cardiac and neuronal cells
T2  - MOLECULAR AND CELLULAR BIOCHEMISTRY
KW  - Human bone marrow mesenchymal stem cells
KW  - Iron oxide labeling
KW  - Cardiac differentiation
KW  - Neuronal differentiation
KW  - IN-VIVO
KW  - TRANSFECTION AGENT
KW  - INFARCTED MYOCARDIUM
KW  - MOUSE MODEL
KW  - NANOPARTICLES
KW  - TRACKING
KW  - FERUMOXIDES
KW  - MIGRATION
KW  - RAT
KW  - TRANSPLANTATION
AB  - Mesenchymal stem cells (MSCs) have shown promising outcomes in cardiac and neuronal diseases. Efficient and noninvasive tracking of MSCs is essential to harness their therapeutic potential. Iron oxide nanoparticles (IONPs) have emerged as effective means to label stem cells and visualize them using magnetic resonance imaging (MRI). It is known that IONPs do not affect viability and cell proliferation of stem cells. However, very few studies have demonstrated differentiation potential of iron oxide-labeled MSCs and their differentiation into specific lineages that can contribute to cellular therapies. The differentiation of IONP-labeled human bone marrow mesenchymal stem cells (hBM-MSCs) into cardiac and neuronal lineages has never been studied. In this study, we have shown that IONP-labeled hBM-MSCs retain their differentiation potential to cardiac and neuronal cell lineages. We also confirmed that labeling hBM-MSCs with IONP does not affect their characteristic properties such as viability, cellular proliferation rate, surface marker profiling, and trilineage differentiation capacity. This study shows that IONP can be efficiently tracked, and its labeling does not alter stemness and differentiation potential of hBM-MSCs. Thus, the labeled hBM-MSCs can be used in clinical therapies and regenerative medicine.
AD  - AIIMS, Ctr Excellence Stem Cell Res, Stem Cell Facil, New Delhi, IndiaAD  - IIT Delhi, Ctr Biomed Engn, New Delhi, IndiaAD  - AIIMS, Dept Pathol, New Delhi, IndiaAD  - Northern New Mexico Coll, Dept Biol Chem & Environm Sci, Espanola, NM USAC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - NOV
PY  - 2018
VL  - 448
IS  - 1-2
SP  - 17
EP  - 26
DO  - 10.1007/s11010-018-3309-9
AN  - WOS:000446385800003
ER  -

TY  - JOUR
AU  - Nadella, V
AU  - Singh, S
AU  - Jain, A
AU  - Jain, M
AU  - Vasquez, KM
AU  - Sharma, A
AU  - Tanwar, P
AU  - Rath, GK
AU  - Prakash, H
TI  - Low dose radiation primed iNOS+M1macrophages modulate angiogenic programming of tumor derived endothelium
T2  - MOLECULAR CARCINOGENESIS
KW  - angiogenesis
KW  - endothelium
KW  - gamma irradiation
KW  - immune cells infiltration
KW  - M1 macrophages
KW  - tumor therapy
KW  - INDUCIBLE FACTOR-I
KW  - GROWTH-FACTOR
KW  - NITRIC-OXIDE
KW  - HYPOXIA
KW  - MACROPHAGES
KW  - HIF-1-ALPHA
KW  - ACTIVATION
KW  - EXPRESSION
KW  - HIF-1
KW  - BLOCKADE
AB  - Solid tumors are covered by stroma, which is hypoxic in nature and composed of various non-malignant components such as endothelial cells, fibroblasts, and pericytes that support tumor growth. Tumor stroma represents a mechanical barrier for tumor infiltration of CD8+ effector T cells in particular. In this context, our previous studies have demonstrated the therapeutic impact of Low-Dose Radiation (LDR)-primed and M1-retuned (iNOS+) peritumoral macrophages that produce inducible nitric oxide, have immunological roles on tumor infiltration of effector T cells, cancer-related inflammation, and subsequent tumor immune rejection in a mouse model of pancreatic cancer. These findings suggested a possible modification of tumor endothelium by LDR-primed macrophages. In line with these observations, here we demonstrate the influence of LDR in down-modulating HIF-1 in irradiated tumors in the course of polarization of irradiated tumor-associated macrophages toward an M1 phenotype. Furthermore, we demonstrate that M1 macrophages which are primed by LDR can directly influence angiogenic responses in eNOS+ endothelial cells which produce nitric oxide having both vascular and physiological roles. Furthermore, we demonstrate that naive macrophages, upon differentiating to an M1 phenotype either by Th1 stimuli or LDR, potentially modify sphingosine-1-phosphate/VEGF-induced angiogenic signaling in tumor-derived endothelial cells with tumorigenic potential, thus indicating the significance of iNOS+ macrophages in modulating signaling in eNOS+ tumor-derived endothelium. Our study suggests that iNOS+ macrophages can activate tumor endothelium which may contribute to cancer-directed immunotherapy in particular.
AD  - Univ Hyderabad, Lab Translat Med, Sch Life Sci, Hyderabad, Telangana, IndiaAD  - Univ Hyderabad, Dept Anim Biol, Sch Life Sci, Hyderabad, Telangana, IndiaAD  - Cent Univ Punjab, Dept Anim Sci, Bathinda, Punjab, IndiaAD  - Univ Texas Austin, Coll Pharm, Div Pharmacol & Toxicol, Dell Pediat Res Inst, Austin, TX 78712 USAAD  - All India Inst Med Sci, Dept Biochem, New Delhi, IndiaAD  - All India Inst Med Sci, Dr BR Ambedkar Inst, Rotary Canc Hosp, New Delhi, IndiaAD  - Amity Univ, Amity Inst Virol & Immunol, New Delhi, IndiaAD  - German Canc Res Ctr, Translat Immunol Div, Natl Ctr Tumor Dis, Heidelberg, GermanyC3  - University of HyderabadC3  - University of HyderabadC3  - Central University of PunjabC3  - University of Texas SystemC3  - University of Texas AustinC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - Helmholtz AssociationC3  - German Cancer Research Center (DKFZ)C3  - Ruprecht Karls University HeidelbergPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - NOV
PY  - 2018
VL  - 57
IS  - 11
SP  - 1664
EP  - 1671
DO  - 10.1002/mc.22879
AN  - WOS:000446311200020
ER  -

TY  - JOUR
AU  - Narain, P
AU  - Pandey, A
AU  - Gupta, S
AU  - Gomes, J
AU  - Bhatia, R
AU  - Vivekanandan, P
TI  - Targeted next-generation sequencing reveals novel and rare variants in Indian patients with amyotrophic lateral sclerosis
T2  - NEUROBIOLOGY OF AGING
KW  - Amyotrophic lateral sclerosis
KW  - India
KW  - Novel mutations
KW  - Targeted next generation sequencing
KW  - GENETIC-VARIATION
KW  - MUTATIONS
KW  - HELICASE
KW  - FAMILY
AB  - Studies on genetic aberrations among Indian amyotrophic lateral sclerosis (ALS) patients are limited to C9orf72 and ATXN2 repeat expansions and mutations in the SOD1 gene. In this study, we used targeted next-generation sequencing to analyze 25 ALS-associated genes in a cohort of 154 Indian ALS patients. We identified known pathogenic mutations in SOD1 (G148D; H44R), TARDBP (M337V; N267S), DAO (R199Q), and ANG (K41I). In addition, we also identified 7 potentially pathogenic missense variants that have not been previously reported in ALS patients; this includes 3 novel variants (OPTN: K489E, DAO: E121K, and SETX: L2163V) that are not reported in large population databases and 4 rare variants (CHMP2B: E45K, SQSTM1: G262R and P438L, ERBB4: R103H) with a minor allele frequency of < 0.01 in large population databases. All known pathogenic, novel, and rare variants were detected in only 1 ALS patient each with the exception of the OPTN (K489E) variant that was detected in 2 patients in our cohort. In sum, we identified known and potentially pathogenic novel and rare mutations in 14 (9.1%) ALS patients in our cohort. This study represents the first comprehensive genetic analysis in the ethnically diverse population and thus provides a new insight into the genetics of Indian ALS patients. (C) 2018 Elsevier Inc. All rights reserved.
AD  - IIT Delhi, Kusuma Sch Biol Sci, New Delhi 110016, IndiaAD  - Jawahar Lal Nehru Univ JNU, Sch Computat & Integrat Sci, New Delhi, IndiaAD  - AIIMS, Dept Neurol, New Delhi, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - Jawaharlal Nehru University, New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - NOV
PY  - 2018
VL  - 71
C7  - 265.e9
DO  - 10.1016/j.neurobiolaging.2018.05.012
AN  - WOS:000445521400026
ER  -

TY  - JOUR
AU  - Narang, R
AU  - Saxena, A
AU  - Desai, A
AU  - Ramakrishnan, S
AU  - Thangjam, RS
AU  - Kulkarni, S
AU  - Narvencar, K
AU  - Costa, AKJ
AU  - Dias, A
AU  - Sukharamwala, R
AU  - Cleland, J
TI  - Prevalence and determinants of hypertension in apparently healthy schoolchildren in India: A multi-center study
T2  - EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
KW  - Hypertension
KW  - children
KW  - blood pressure
KW  - epidemiology
KW  - BLOOD-PRESSURE-MEASUREMENT
KW  - EDUCATION-PROGRAM GUIDELINES
KW  - CARDIOVASCULAR RISK-FACTORS
KW  - 2016 CANADIAN HYPERTENSION
KW  - CHINESE CHILDREN
KW  - ADOLESCENTS
KW  - CHILDHOOD
KW  - ASSOCIATION
KW  - OVERWEIGHT
KW  - PREHYPERTENSION
AB  - Background Hypertension in children is often under recognized, especially in developing countries. Data from rural areas of developing countries is particularly lacking. Objectives To study prevalence of hypertension and its determinants in apparently health school children from predominantly rural populations of India. Methods Apparently healthy schoolchildren (n = 14,957) aged 5-15 years (mean (standard deviation) age 10.8 (2.8) years; 55.5% boys) at four predominantly rural sites in separate states of India were studied. Systolic and diastolic blood pressures were recorded by trained staff in addition to age, gender, height, weight, type of school and season. Waist circumference was also recorded in 12,068 children. Geographic location and type of school (government, government-aided or private) were used to determine socio-economic status. Results Systolic and/or diastolic hypertension was present in 3443 (23%) children. Systolic hypertension was present in 13.6%, diastolic hypertension in 15.3% and both in 5.9%. Isolated systolic hypertension was present in 7.7% while isolated diastolic hypertension was present in 9.4%. On univariate analysis, age, gender, geographical location, socio-economic status, season and anthropometric parameters (z-scores of height, weight and waist circumference, waist/height ratio and body mass index) were all significantly related to risk of hypertension (p < 0.0001 for each). Similar association was observed with weight group (normal, overweight and obese). Multiple regression analysis showed lower age, female gender, richer socio-economic status, certain geographical locations, higher weight and larger waist circumference to be independently associated with a greater risk of hypertension. Conclusion There is a high prevalence of hypertension in apparently healthy schoolchildren even in predominantly rural areas of India. Screening and management programs targeted to high risk groups identified may prove cost-effective.
AD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaAD  - Goa Med Coll, Dept Med, Bambolim, Goa, IndiaAD  - Goa Med Coll, Dept Prevent & Social Med, Bambolim, Goa, IndiaAD  - Jawaharlal Nehru Inst Med Sci, Dept Med, Imphal, Manipur, IndiaAD  - Kokilaben Dhirubhai Ambani Hosp, Bombay, Maharashtra, IndiaAD  - Univ Glasgow, Robertson Ctr Biostat & Clin Trials, Glasgow, Lanark, ScotlandC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Goa Medical College & HospitalC3  - Goa Medical College & HospitalC3  - University of GlasgowPU  - OXFORD UNIV PRESS
PI  - OXFORD
PA  - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
DA  - NOV
PY  - 2018
VL  - 25
IS  - 16
SP  - 1775
EP  - 1784
DO  - 10.1177/2047487318790056
AN  - WOS:000448077100015
ER  -

TY  - JOUR
AU  - Pal, A
AU  - Pegwal, N
AU  - Kaur, S
AU  - Mehta, N
AU  - Behari, M
AU  - Sharma, R
TI  - Deficit in specific cognitive domains associated with dementia in Parkinson's disease
T2  - JOURNAL OF CLINICAL NEUROSCIENCE
KW  - Parkinson's disease
KW  - Dementia
KW  - Cognitive impairment
KW  - Executive functions
KW  - Semantic memory
KW  - NEUROPSYCHOLOGICAL TEST-PERFORMANCE
KW  - IMPAIRMENT
KW  - MEMORY
KW  - MULTICENTER
KW  - EDUCATION
KW  - ELDERS
AB  - Impairment in different cognitive domains such as executive functions, language, memory and visuospatial skills occur frequently in Parkinson disease (PD) leading to significant disability and deterioration in quality of life. Heterogeneity of cognitive impairment enhances risk of developing dementia as disease progress. The objective is to explore the pattern of cognitive impairment with reference to the affected domains in PD with or without dementia relative to healthy controls. In this study, 110 PD patients and 26 healthy control were categorized into groups using Mini Mental State Examination and Clinical Dementia Rating scores as PD without dementia (PDND, n = 65; MMSE score >24; CDR = 0-1), PD with dementia (PDD, n = 45; MMSE score <= 24; CDR = 0.5-3) and healthy control (HC, n = 26; MMSE score >26; CDR = 0). Both Patients and controls underwent individual assessments of working memory, semantic memory, attention, language, executive functions, psychomotor and visuospatial skills and dementia using different cognitive function tests. Findings revealed lower scores of word memory, attention, psychomotor speed, visuospatial skills and executive functions in PDD compared to PDND. Interestingly, in PDD scores of picture memory, semantic memory and language functions were comparable with PDND. Compared to HC, PDND had no impairment in working memory, attention and executive functions, whereas PDD had lower scores in all the cognitive domains tested. Results indicate that the deficits in word memory, attention, psychomotor speed, visuospatial skills and executive functions distinguishes PDD from PDND. Impairment in specific cognitive domains may be a biomarker for predicting onset of dementia in Parkinson's disease. (C) 2018 Elsevier Ltd. All rights reserved.
AD  - All India Inst Med Sci, Dept Physiol, Stress & Cognit Electroimaging Lab, New Delhi 110029, IndiaAD  - Fortis Hosp, Dept Neurol, New Delhi 110070, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - NOV
PY  - 2018
VL  - 57
SP  - 116
EP  - 120
DO  - 10.1016/j.jocn.2018.08.016
AN  - WOS:000448494000021
ER  -

TY  - JOUR
AU  - Pandav, CS
AU  - Yadav, K
AU  - Salve, HR
AU  - Kumar, R
AU  - Goel, AD
AU  - Chakrabarty, A
TI  - High national and sub-national coverage of iodised salt in India: evidence from the first National Iodine and Salt Intake Survey (NISI) 2014-2015
T2  - PUBLIC HEALTH NUTRITION
KW  - Iodine deficiency disorders
KW  - Salt iodisation
KW  - Salt intake
KW  - Survey
KW  - IODIZED SALT
KW  - CHILDREN
KW  - OUTCOMES
AB  - Objective: The National Iodine and Salt Intake Survey (NISI) 2014-2015 was undertaken to estimate household iodised salt coverage at national and sub-national levels in India.
   Design: Cross-sectional survey with multistage stratified random sampling.
   Setting: India was divided into six geographic zones (South, West, Central, North, East and North-East) and each zone was further stratified into rural and urban areas to yield twelve distinct survey strata.
   Subjects: The target respondent from each household was selected as per predefined priority; wife of the household head, followed by women of reproductive age, followed by any adult available during the visit.
   Results: Households (n 5717) were surveyed and salt samples (n 5682) were analysed. Household coverage of iodised salt (iodine >= 5 ppm) was 91.7 (95% CI 91.0, 92.7) %. Adequately iodised salt (iodine >= 15 ppm) was consumed in 77.5 (95% CI 76.4, 78.6) % of households. Significant differences in coverage were seen across six geographic regions, with North and North-East zones on the verge of achieving the universal salt iodisation target of >90% coverage. Coverage of households with adequately iodised salt (adjusted OR; 95% CI) was significantly less in rural households (0.55; 0.47, 0.64), lower/backward castes (0 . 84; 0 . 72, 0.98), deprived households (0.72; 0.61, 0.85) as assessed by multidimensional poverty index, households with non-diverse diet (0.73; 0.62, 0.86) and households using non-packaged salt (0.48; 0.39, 0.59) and non-refined salt (0.17; 0.15, 0.20).
   Conclusions: India is within striking reach of achieving universal salt iodisation. However, significant differentials by rural/urban, zonal and socio-economic indicators exist, warranting accelerated efforts and targeted interventions for high-risk groups.
AD  - ICCIDD, New Delhi, IndiaAD  - AIIMS, Ctr Community Med, New Delhi 10023, IndiaAD  - AIIMS, Dept Community Med & Family Med, Jodhpur, Rajasthan, IndiaAD  - GAIN, Bestseller Project, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) JodhpurPU  - CAMBRIDGE UNIV PRESS
PI  - CAMBRIDGE
PA  - EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
DA  - NOV
PY  - 2018
VL  - 21
IS  - 16
SP  - 3027
EP  - 3036
DO  - 10.1017/S1368980018002306
AN  - WOS:000447315300012
ER  -

TY  - JOUR
AU  - Patel, NK
AU  - Nivethitha, L
AU  - Mooventhan, A
TI  - EFFECT OF A YOGA BASED MEDITATION TECHNIQUE ON EMOTIONAL REGULATION, SELF-COMPASSION AND MINDFULNESS IN COLLEGE STUDENTS
T2  - EXPLORE-THE JOURNAL OF SCIENCE AND HEALING
KW  - College students
KW  - Emotional regulation
KW  - Meditation
KW  - Mindfulness
KW  - Yoga
KW  - AFFECT SCHEDULE PANAS
AB  - Background: Emotion regulation is often a challenge for the college students. Yoga practice has been shown to reduce stress and improve mindfulness that is related to emotion regulation. Mastering emotions technique (MEMT) is one of the yoga-based meditation techniques that are designed to control emotions among practitioners. However, to the best of our knowledge, there is no known study reporting its scientific evidence-based effects on emotion and its related variables. Thus, this study was conducted to evaluate the effect of MEMT on emotion regulation, self-compassion, and mindfulness in college students.
   Materials and methods: Seventy-two subjects with the age varied from 18 to 25 years were recruited from a residential college. All the subjects underwent MEMT for the duration of 45 min a day for a period of 2 weeks. Assessments such as Emotional Regulation Questionnaire (ERQ), The Positive and Negative Affect Schedule (PANAS), Self-Compassion Scale (SCS), and Mindful Attention Awareness Scale (MAAS) were taken before and after the intervention.
   Results: Results of this study showed a significant increase in the scores of cognitive reappraisal, positive affect, self-compassion, and MAAS along with a significant reduction in the scores of negative affect, and expressive suppression after the practice of MEMT compared to its respective baseline.
   Conclusions: Results of this study suggest that practice of MEMT is effective in improving emotion regulation, positive affects, self-compassion, and mindfulness while in reducing negative affects among college students.
AD  - S VYASA Univ, Dept Yoga, Bengaluru, Karnataka, IndiaAD  - AIIMS, CIMR, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - NOV-DEC
PY  - 2018
VL  - 14
IS  - 6
SP  - 443
EP  - 447
DO  - 10.1016/j.explore.2018.06.008
AN  - WOS:000455559200010
ER  -

TY  - JOUR
AU  - Pathania, A
AU  - Haldar, P
AU  - Kant, S
AU  - Gupta, SK
AU  - Pandav, CS
AU  - Bachani, D
TI  - Prevalence of fall, and determinants of repeat incidents of fall in older persons living in old age homes in the National Capital Territory of Delhi, India
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
KW  - ADULTS
KW  - WOMEN
AB  - Background. Fall is a common morbidity in older persons. In India, the number of old age homes and persons living in them are increasing. We studied the prevalence of fall among older persons living in old age homes.
   Methods. We did a cross-sectional survey among persons aged 60 years or above, living in old age homes of Delhi, India. Information on location, type and bed-strength was collected for old age homes, and using their combination, 28 clusters of almost equal sizes (25-35) were created, of which, 13 were selected randomly to meet an estimated sample size of 340. All residents of the selected old age homes were recruited for the study. A self-developed, semi-structured interview schedule was used for recording the sociodemographic profile and history of fall in the past 6 months. Logistic regression was used to explore factors that might be associated with fall. Poisson regression was used to model the frequency of incidents of fall.
   Results. A total of 335 older persons, with mean (SD) age of 75.2 (8.6) years were studied. At least 1 episode of fall was reported by 55 (16.4%), of whom, injury and disability were sustained by 54.5% and 23.3%, respectively. On multivariate logistic regression, for each additional morbidity, odds ratio of fall was 1.5 (95% confidence interval [CI] 1.09-1.95). Multivariate Poisson regression showed that age and tobacco use were significantly associated with the incidents of fall. For each unit increase in age, the incident rate ratio increased by 1.02 times (95% CI 1.01-1.03). Being a past user of tobacco had a statistically significant incident rate of 1.57 times (95% CI 1.01-2.45) compared to non-users of tobacco.
   Conclusion. One-sixth of individuals living in old age homes had experienced a fall in the past 6 months. Measures should be taken to prevent falls in old age home settings in India.
AD  - All India Inst Med Sci, New Delhi 110029, IndiaAD  - Lady Hardinge Med Coll & Hosp, Dept Community Med, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Lady Hardinge Medical College & HospitalPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - NOV-DEC
PY  - 2018
VL  - 31
IS  - 6
SP  - 329
EP  - 333
DO  - 10.4103/0970-258X.262912
AN  - WOS:000479098700003
ER  -

TY  - JOUR
AU  - Pathania, A
AU  - Kabra, SK
TI  - Depression Among Caregivers of Children with Cystic Fibrosis: Causes and Solutions
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - ANXIETY
KW  - PARENTS
KW  - PREVALENCE
KW  - BURDEN
AD  - All India Inst Med Sci, Dept Pediat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - NOV
PY  - 2018
VL  - 85
IS  - 11
SP  - 955
EP  - 956
DO  - 10.1007/s12098-018-2763-4
AN  - WOS:000448226100007
ER  -

TY  - JOUR
AU  - Prabhu, M
AU  - Kumari, G
AU  - Damle, NA
AU  - Arora, G
AU  - Tripathi, M
AU  - Bal, C
AU  - Kumar, P
AU  - Kumar, R
TI  - Comparability of Early Dynamic and Conventional Static Imaging With 18F-Fluorocholine PET/CT in a Patient With Primary Hyperparathyroidism
T2  - CLINICAL NUCLEAR MEDICINE
KW  - early dynamic imaging
KW  - parathyroid adenoma
KW  - F-18-fluorocholine PET
KW  - CT
KW  - HYPERFUNCTIONING PARATHYROID-GLANDS
KW  - PREOPERATIVE LOCALIZATION
KW  - F-18-FLUOROCHOLINE PET/CT
AB  - Recent studies have established the superiority of FCH PET/CT over MIBI scan in accurate preoperative localization of parathyroid adenomas. In this patient, we compared both early dynamic and conventional static imaging to see if early imaging could suffice. We describe a 15-year-old boy with primary hyperparathyroidism, in whom early dynamic FCH PET/CT was performed for 15 minutes after injection, followed by conventional static image at 60 minutes. Early dynamic images accurately localized the parathyroid adenoma. Also, higher SUVmax was observed on dynamic imaging when compared with conventional static images, but parathyroid-to-thyroid ratio was higher in the latter.
AD  - All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - NOV
PY  - 2018
VL  - 43
IS  - 11
SP  - E400
EP  - E401
DO  - 10.1097/RLU.0000000000002261
AN  - WOS:000447734700003
ER  -

TY  - JOUR
AU  - Priyadarshi, M
AU  - Sankar, MJ
AU  - Gupta, N
AU  - Agarwal, R
AU  - Paul, V
AU  - Deorari, A
TI  - Efficacy of daily supplementation of 800 IU vitamin D on vitamin D status at 6 months of age in term healthy Indian infants
T2  - JOURNAL OF PERINATOLOGY
KW  - D DEFICIENCY
KW  - PREVENTION
KW  - WOMEN
AB  - Objectives Most authorities recommend daily supplementation of 400 IU vitamin D for all term healthy neonates throughout infancy, however this dose was shown to be inadequate in an earlier study from our institution. We planned to evaluate if supplementation of 800 IU/day in term Indian infants would reduce the prevalence of vitamin D insufficiency (VDI) at 6 months of age.
   Methods In a prospective study, we supplemented 800 IU/day of vitamin D in 70 term infants from birth till 6 months of age. Serum 25-hydroxy cholecalciferol [25(OH)D] was measured at birth and 6 months for all infants; and at 6, 10 and 14 weeks of age in subsets of 23 infants each. The primary outcome was prevalence of VDI (defined as serum 25(OH)D level < 50 nmol/L) at 6 months of age.
   Results A total of 58 out of 70 (83%) infants were followed up until 6 months of age. The median (nmol/L; IQR) serum 25 (OH)D at birth and 6 months of age was 25 (12.5-35) and 92.5 (72.5-137.5), respectively. The prevalence of VDI at birth was 91.3% (63/69), which reduced to 6.9% (4/58) at 6 months of age. However, four infants (6.9%, 95% CI 1.9-16.7) developed vitamin D excess (serum 25(OH)D 250-375 nmol/L) requiring reduction of the dose of supplementation. No infant developed vitamin D toxicity (serum 25(OH)D > 375 nmol/L).
   Conclusions Daily supplementation of 800 IU of vitamin D resulted in vitamin D sufficiency in most term healthy infants at 6 months of age but with potential risk of toxicity.
AD  - All India Inst Med Sci, Dept Paediat, Div Neonatol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGERNATURE
PI  - LONDON
PA  - CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
DA  - NOV
PY  - 2018
VL  - 38
IS  - 11
SP  - 1566
EP  - 1572
DO  - 10.1038/s41372-018-0216-6
AN  - WOS:000449174800020
ER  -

TY  - JOUR
AU  - Pujari, A
AU  - Mukhija, R
AU  - Urkude, J
AU  - Singh, R
AU  - Agarwal, D
AU  - Sharma, N
TI  - Intraoperative assessment of corneal injuries using microscope-integrated optical coherence tomography
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Integrated optical coherence tomography
KW  - pediatric corneal injuries
KW  - surgery
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV
PY  - 2018
VL  - 66
IS  - 11
SP  - 1614
EP  - 1615
DO  - 10.4103/ijo.IJO_546_18
AN  - WOS:000448596100022
ER  -

TY  - JOUR
AU  - Pujari, A
AU  - Mukhija, R
AU  - Chawla, R
AU  - Phuljhele, S
AU  - Saxena, R
AU  - Sharma, P
TI  - Smartphone-based evaluation of the optic nerve head
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Imaging
KW  - optic disc
KW  - smartphones
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 212,Second Floor,RPC 1, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV
PY  - 2018
VL  - 66
IS  - 11
SP  - 1617
EP  - 1618
DO  - 10.4103/ijo.IJO_394_18
AN  - WOS:000448596100024
ER  -

TY  - JOUR
AU  - Pujari, A
AU  - Sharma, P
AU  - Phuljhele, S
AU  - Kapoor, S
AU  - Chawla, R
AU  - Saxena, R
AU  - Sharma, N
TI  - Intraoperative optical coherence tomography-guided scleral suture passage while performing surgery on extraocular muscles
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 212,Second Floor,RPC-1, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV
PY  - 2018
VL  - 66
IS  - 11
SP  - 1654
EP  - +
DO  - 10.4103/ijo.IJO_769_18
AN  - WOS:000448596100043
ER  -

TY  - JOUR
AU  - Quadri, JA
AU  - Sarwar, S
AU  - Sinha, A
AU  - Kalaivani, M
AU  - Dinda, AK
AU  - Bagga, A
AU  - Roy, TS
AU  - Das, TK
AU  - Shariff, A
TI  - Fluoride-associated ultrastructural changes and apoptosis in human renal tubule: a pilot study
T2  - HUMAN & EXPERIMENTAL TOXICOLOGY
KW  - Fluoride-associated nephrotoxicity
KW  - renal tubular injury
KW  - apoptosis
KW  - transmission electron microscopy
KW  - ultrastructural analysis
KW  - EPITHELIAL LUNG-CELLS
KW  - SODIUM-FLUORIDE
KW  - KIDNEY
KW  - RATS
KW  - ACTIVATION
KW  - LIVER
KW  - FLUOROSIS
KW  - INJURY
KW  - JNK
AB  - The susceptibility of the kidneys to fluoride toxicity can largely be attributed to its anatomy and function. As the filtrate moves along the complex tubular structure of each nephron, it is concentrated in the proximal and distal tubules and collecting duct. It has been frequently observed that the children suffering from renal impairments also have some symptoms of dental and skeletal fluorosis. The findings suggest that fluoride somehow interferes with renal anatomy and physiology, which may lead to renal pathogenesis. The aim of this study was to evaluate the fluoride-associated nephrotoxicity. A total of 156 patients with childhood nephrotic syndrome were screened and it was observed that 32 of them had significantly high levels (p <= 0.05) of fluoride in urine (4.01 +/- 1.83 ppm) and serum (0.1 +/- 0.013 ppm). On the basis of urinary fluoride concentration, patients were divided into two groups, namely group 1 (G-1) (n = 32) containing normal urine fluoride (0.61 +/- 0.17 ppm) and group 2 (G-2) (n = 32) having high urine fluoride concentration (4.01 +/- 1.83 ppm). Age-matched healthy subjects (n = 33) having normal levels of urinary fluoride (0.56 +/- 0.15 ppm) were included in the study as control (group 0 (G-0)). Kidney biopsies were taken from G-1 and G-2 only, who were subjected to ultrastructural (transmission electron microscopy) and apoptotic (terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling) analysis. Various subcellular ultrastructural changes including nuclear disintegration, chromosome condensation, cytoplasmic ground substance lysis, and endoplasmic reticulum blebbing were observed. Increased levels of apoptosis were observed in high fluoride group (G-2) compared to normal fluoride group (G-1). Various degrees of fluoride-associated damages to the architecture of tubular epithelia, such as cell swelling and lysis, cytoplasmic vacuolation, nuclear condensation, apoptosis, and necrosis, were observed.
AD  - All India Inst Med Sci, Dept Anat, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SAGE PUBLICATIONS LTD
PI  - LONDON
PA  - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
DA  - NOV
PY  - 2018
VL  - 37
IS  - 11
SP  - 1199
EP  - 1206
DO  - 10.1177/0960327118755257
AN  - WOS:000448078500007
ER  -

TY  - JOUR
AU  - Radhakrishnan, DM
AU  - Ramanujam, B
AU  - Srivastava, P
AU  - Dash, D
AU  - Tripathi, M
TI  - Effect of providing sudden unexpected death in epilepsy (SUDEP) information to persons with epilepsy (PWE) and their caregiversExperience from a tertiary care hospital
T2  - ACTA NEUROLOGICA SCANDINAVICA
KW  - depression and anxiety
KW  - drug adherence
KW  - Modified Morisky Medication Adherence Scale
KW  - Persons with Epilepsy
KW  - Quality of life in epilepsy
KW  - Sudden Unexpected Death in Epilepsy
KW  - QUALITY-OF-LIFE
KW  - RISK-FACTORS
KW  - MEDICATION ADHERENCE
KW  - DEFINITIONS
KW  - MECHANISMS
KW  - INVENTORY
KW  - VALIDITY
KW  - COHORT
AB  - ObjectiveThe primary objective of present study was to observe the effect of providing SUDEP (Sudden Unexpected Death in Epilepsy) information on drug adherence in persons with epilepsy (PWE). We also looked at impact of disclosing SUDEP information on patient's quality of life and mood.
   Material and MethodsThis prospective study had a pretest/post-test design. A total of 231 consecutive PWE (>15years) were enrolled. Of these 121 PWE received information about SUDEP in addition to standard epilepsy care. One hundred and ten PWE (control group) received routine standard epilepsy care but did not receive SUDEP information. Follow up assessment was done at 6months. The primary outcome was a change in drug adherence (measured by Modified Morisky Medication Adherence Scale, MMAS) in PWE following disclosure of SUDEP information.
   ResultsAfter 6months, 116 PWE in the SUDEP information group and 106 in control group were available for follow up. A non-significant higheradherence was observed in the SUDEP information group as compared to the control group (Mean MMAS change 0.511.66 vs 0.25 +/- 1.26, P value=0.194). No significant change was perceived in patient's anxiety and depression levels or quality of life in either group.
   ConclusionThe present study suggests that providing information on SUDEP to PWE and their caregivers may increase drug adherence without adverse effect on quality of life or mood. Well-designed studies with high methodological quality arerequired todetermine the precise effect size associated with disclosure of SUDEP information on drug adherence in PWE.
AD  - All India Inst Med Sci, Dept Neurol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - NOV
PY  - 2018
VL  - 138
IS  - 5
SP  - 417
EP  - 424
DO  - 10.1111/ane.12994
AN  - WOS:000446549700005
ER  -

TY  - JOUR
AU  - Rajagopal, R
AU  - Sharma, S
TI  - Comments to "Usefulness of Hydrogel-Coated Coils in Embolization of Pulmonary Arteriovenous Malformations"
T2  - CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
AD  - All India Inst Med Sci, Dept Cardiovascular Radiol & Endovasc Intervent, Room 10 A, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - NOV
PY  - 2018
VL  - 41
IS  - 11
SP  - 1807
EP  - 1807
DO  - 10.1007/s00270-018-2013-1
AN  - WOS:000451930300022
ER  -

TY  - JOUR
AU  - Ramanujam, B
AU  - Dash, D
AU  - Tripathi, M
TI  - Can home videos made on smartphones complement video-EEG in diagnosing psychogenic nonepileptic seizures?
T2  - SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
KW  - Home videos
KW  - Mobile phones
KW  - PNES
KW  - Epilepsy
KW  - SEMIOLOGY
AB  - Purpose: To assess the contribution home-videos made on mobile phones can make to the diagnosis of Psychogenic Nonepileptic Seizures (PNES).
   Methods: Consecutive patients 10-50 years old, with episodes of altered behavior or abnormal movements, unresponsiveness, or falls, were recruited after they had obtained 'good' or 'fair' quality (quality of video scale (QOV)) home-videos of their episodes on personal mobile phones; these subjects underwent video-electro-encephalography (VEEG). Diagnoses of PNES, other physiological events or epileptic seizure (ES) on home videos (by the epilepsy fellow, step 1) and on VEEGs (by a fully trained epileptologist unaware of the home-video recording, step 2) were compared.
   Results: We screened 783 patients, and finally analyzed 269; 155 subjects had 'fair' (QOV 5-7) and 114 had 'good'(QOV 8-10) quality home-videos. Concordance between steps 1 and 2 was seen in 261 of 269 (97.2%) subjects, and no significant difference was noted between the two modalities in diagnosing PNES. Differentiation between PNES, ES and other physiological events using home-videos was correct in 49.1% subjects if 532 (all subjects asked to make home-videos) and 70.7% if 369 (subjects with 'good' or 'fair' home videos), were used as denominators. Home-videos diagnosed PNES with the sensitivity of 95.4% (95% CI: 87.2%-99.1%), specificity of 97.5% (95% CI: 94.3%-99.2%), positive and negative predictive values of 92.65% (95% CI: 84.1%-96.8%) and 98.5% (95% CI: 95.6%-99.5%) respectively.
   Conclusion: Home-videos of good quality can complement VEEG in diagnosing PNES in a cost-effective way and help initiate appropriate management.
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - W B SAUNDERS CO LTD
PI  - LONDON
PA  - 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
DA  - NOV
PY  - 2018
VL  - 62
SP  - 95
EP  - 98
DO  - 10.1016/j.seizure.2018.10.003
AN  - WOS:000452576100017
ER  -

TY  - JOUR
AU  - Ravani, R
AU  - Kumar, V
AU  - Kumar, A
AU  - Kumar, P
AU  - Chawla, S
AU  - Ghosh, S
TI  - Fleck-like deposits and swept source optical coherence tomography characteristics in a case of confirmed ocular chalcosis
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Chalcosis
KW  - pars plana vitrectomy
KW  - penetrating injury
KW  - retained intraocular foreign body
AB  - A 36-year-old male presented with history of injury in the left eye 3 years back with a copper wire. Examination revealed the presence of typical sunflower cataract with golden yellow deposits over the anterior lens capsule with dull glow and old vitreous hemorrhage. Non-contrast computerized tomography revealed retained intraocular foreign body in the pars plana region. The patient underwent phacoemulsification with intraocular lens implantation followed by pars plana vitrectomy and foreign body removal. Intraoperatively, fleck-like deposits were noted on the retinal surface in a circinate manner around the fovea and also over mid-peripheral retina. Postoperative swept source optical coherence tomography ( SS-OCT) was performed to document the location of deposits and their characteristics. Limited literature exists regarding SS-OCT characteristics of ocular chalcosis.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Text Technol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV
PY  - 2018
VL  - 66
IS  - 11
SP  - 1640
EP  - +
DO  - 10.4103/ijo.IJO_437_18
AN  - WOS:000448596100037
ER  -

TY  - JOUR
AU  - Relan, J
AU  - Gupta, SK
AU  - Saxena, A
TI  - Right superior caval vein to the left atrium in a child with vein of Galen malformation
T2  - ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES
KW  - anomalous systemic venous connection
KW  - heart failure
KW  - vein of galen malformation
KW  - SALINE CONTRAST ECHOCARDIOGRAPHY
KW  - BUBBLING-IT-RIGHT
KW  - ARTERIOVENOUS-FISTULA
KW  - VENA-CAVA
KW  - EMBOLIZATION
KW  - AORTA
AB  - Vein of Galen malformation (VGM) is a rare intracranial vascular malformation. High output heart failure is common in infancy and is characterized by dilatation of all the cardiac chambers. We report an unusual case of VGM in a 3-month-old infant without dilatation of the right-sided cardiac chambers. We then demonstrate importance of comprehensive evaluation in detecting rare coexistence of anomalous right superior caval vein connection to the left atrium.
AD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - NOV
PY  - 2018
VL  - 35
IS  - 11
SP  - 1868
EP  - 1871
DO  - 10.1111/echo.14165
AN  - WOS:000449697000021
ER  -

TY  - JOUR
AU  - Samaddar, S
AU  - Sankar, J
AU  - Kabra, SK
AU  - Lodha, R
TI  - Association of Fluid Overload with Mortality in Critically-ill Mechanically Ventilated Children
T2  - INDIAN PEDIATRICS
KW  - Intensive Care
KW  - Mechanical Ventilation
KW  - Outcome
KW  - EXTRAVASCULAR LUNG WATER
KW  - MORBIDITY
KW  - SURVIVAL
KW  - BALANCE
AB  - Objectives: To study the association of fluid overload with mortality and morbidity in critically-ill mechanically ventilated children.
   Design: Prospective observational study.
   Setting: Pediatric Intensive Care Unit (PICU) of a tertiary care hospital, New Delhi, India.
   Participants: 118 children (age 1 mo - 15 y) requiring mechanical ventilation.
   Outcome measures: Primary: Association of fluid overload with mortality. Secondary: Association of fluid overload with oxygenation, organ dysfunction, duration of mechanical ventilation and PICU stay.
   Results: Cumulative fluid overload of >= 15% was observed in 74 (62.7%) children. About 50% of these children reached cumulative fluid overload of >= 15% within the first 5 days of PICU stay. The mortality was 40.5% in those with >= 15% cumulative fluid compared to 34% in the rest [OR (95% CI): 1.02 (0.97, 1.07)]. On multivariate analysis, after adjusting for confounders, cumulative fluid overload >= 15% was associated with higher maximum PELOD (pediatric logistic organ dysfunction) score (Median: 21 vs. 12; P = 0.03), longer median duration of mechanical ventilation (10 vs. 4 d; P<0.0001) and PICU stay (13.5 vs. 6 d; P<0.0001). There was no significant association of fluid overload with oxygenation index (P=0.32).
   Conclusion: There is no association of fluid overload with mortality. However, it is associated with poor organ function, longer duration of mechanical ventilation and PICU stay in critically-ill, mechanically ventilated children.
AD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - NOV
PY  - 2018
VL  - 55
IS  - 11
SP  - 957
EP  - 961
DO  - 10.1007/s13312-018-1417-y
AN  - WOS:000452047700004
ER  -

TY  - JOUR
AU  - Sandeep-Goyal
AU  - Shekhar-Jadaun
AU  - Saurabh-Kedia
AU  - Kumar-Acharya, S
AU  - Sharat-Varma
AU  - Baibaswata-Nayak
AU  - Bhaskar-Thakur
AU  - Shalimar
TI  - Thromboelastography Parameters in Patients with Acute on Chronic Liver Failure
T2  - ANNALS OF HEPATOLOGY
KW  - Acute decompensation
KW  - Cirrhosis
KW  - Liver failure
KW  - Hemostasis
KW  - Conventional coagulation parameters
KW  - HEMOSTASIS
KW  - CIRRHOSIS
KW  - TRANSFUSION
KW  - DISTINCT
KW  - DISEASE
AB  - Introduction and aim. Patients with acute on chronic liver failure (ACLF) have abnormal conventional coagulation tests- platelet count and international normalized ratio (INR). Thromboelastography (TEG) is a rapid, point-of-care assay, more comprehensive than platelet count and INR as it assesses for platelet adequacy(number and function), coagulation factors and clot retraction. The aim of the study was to evaluate the TEG parameters in patients with ACLF, chronic liver disease having acute decompensation (AD) and healthy subjects (HC). Material and methods. TEG parameters were assessed in patients with ACLF and AD within 24 h of admission. Consecutive patients were included in the study over 12 months. Healthy subjects were recruited as controls. Results. 179 patients were included-68 ACLF, 53 AD and 58 HC. The mean values of INR in ACLF, AD and HC groups were 2.9 +/- 1.4, 1.6 +/- 0.4 and 1.1 +/- 0.2; P < 0.001. Among TEG parameters - maximum amplitude (MA) was low in ACLF and AD patients as compared with HC (53.8 +/- 15, 58.3 +/- 13.9 mm and 67.2 +/- 12.1 mm, respectively; P < 0.001). Lysis at 30 min (LY30) was high in ACLF patients, as compared to AD and HC (8.6 +/- 14.1%, 5.0 +/- 9.5% and 4.9 +/- 9.8%, respectively; P = 0.060). There were no differences in r time, k time, and alpha angle between groups; normal in > 90% patients. There was no difference in TEG parameters between different ACLF grades, whereas CCTs were more deranged with increasing grades of ACLF. Conclusion. Despite abnormal conventional coagulation tests, TEG parameters in ACLF patients are essentially normal, except reduced maximum amplitude. Future studies are needed to explore the utility of TEG in clinical management of ACLF patients.
AD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaAD  - Max Hosp, Dept Pediat Hepatol & Gastroenterol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MEXICAN ASSOC HEPATOLOGY
PI  - MEXICO
PA  - PUNTE DE PIEDRA 150, COLONIA TORIELLO GUERRA, MEXICO, DF CP 14040, MEXICO
DA  - NOV-DEC
PY  - 2018
VL  - 17
IS  - 6
SP  - 1042
EP  - 1051
DO  - 10.5604/01.3001.0012.7205
AN  - WOS:000460750300019
ER  -

TY  - JOUR
AU  - Sankar, J
AU  - Gulla, KM
AU  - Kumar, UV
AU  - Lodha, R
AU  - Kabra, SK
TI  - Comparison of Outcomes using Pediatric Index of Mortality (PIM)-3 and PIM-2 Models in a Pediatric Intensive Care Unit
T2  - INDIAN PEDIATRICS
KW  - Critical Illness
KW  - Outcomes
KW  - Prognosis
KW  - Scoring system
KW  - RISK
KW  - PRISM
AB  - Objectives: To compare patient outcomes using the Pediatric Index of Mortality-3 (PIM-3) model with PIM-2 model for children admitted to the intensive care unit. Methods: We prospectively recorded the baseline characteristics, variables of PIM-3 and PIM-2 at admission, and outcomes of children <= 17 years over a period of 11 months. We used Area Under Receiver Operating Characteristics (AU-ROC) curves and Goodness-of-fit (GOF) tests to determine which of the two models had better discrimination and calibration. Results: Out of 202 children enrolled, 69 (34%) died. Sepsis and pneumonia were the common admitting diagnoses. The AU-ROC was better for PIM-3 (0.75) as compared to PIM-2 (0.69; P=0.001). The GOF-P value was 0.001 for both models, that indicated poor calibration of both (P<0.001). The AU-ROC curves were acceptable across different age and diagnostic sub-groups. Conclusion: PIM-3 had better discrimination when compared to PIM-2 in our unit. Both models had poor calibration across deciles of risk.
AD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - NOV
PY  - 2018
VL  - 55
IS  - 11
SP  - 972
EP  - 974
DO  - 10.1007/s13312-018-1421-2
AN  - WOS:000452047700008
ER  -

TY  - JOUR
AU  - Sebastian, S
AU  - Malhotra, R
AU  - Sreenivas, V
AU  - Kapil, A
AU  - Chaudhry, R
AU  - Dhawan, B
TI  - Utility of 16S rRNA PCR in the Synovial Fluid for the Diagnosis of Prosthetic Joint Infection
T2  - ANNALS OF LABORATORY MEDICINE
KW  - SENSITIVITY
AD  - All India Inst Med Sci, Dept Microbiol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Orthopaed, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - KOREAN SOC LABORATORY MEDICINE
PI  - SEOUL
PA  - A505-ASTERIUM SEOUL, 372 HANGANG-DAERO, YONGSAN-GU, SEOUL, 04323, SOUTH KOREA
DA  - NOV
PY  - 2018
VL  - 38
IS  - 6
SP  - 610
EP  - 612
DO  - 10.3343/alm.2018.38.6.610
AN  - WOS:000442866200018
ER  -

TY  - JOUR
AU  - Sen, S
AU  - Singh, P
AU  - Saini, P
AU  - Desai, A
TI  - Comment on: Evaluation of retinal nerve fiber layer thickness after optic canal decompression
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaAD  - Maulana Azad Med Coll, Guru Nanak Eye Ctr, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - Maulana Azad Medical CollegePU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV
PY  - 2018
VL  - 66
IS  - 11
SP  - 1658
EP  - +
DO  - 10.4103/ijo.IJO_876_18
AN  - WOS:000448596100048
ER  -

TY  - JOUR
AU  - Shah, R
AU  - Verma, S
AU  - Bhat, A
AU  - Bhat, GR
AU  - Kamal, K
AU  - Dada, R
AU  - Kumar, R
TI  - Pericentric inversion of chromosome 7 in human associated with recurrent ICSI failure: A case report
T2  - INDIAN JOURNAL OF GENETICS AND PLANT BREEDING
KW  - ICSI
KW  - inversion
KW  - oligoasthenoteratozoospermia
KW  - primary infertility
KW  - swm
KW  - CFTR
KW  - INFERTILE MEN
KW  - ABNORMALITIES
AB  - Assisted reproductive techniques is specially a boon for severe male factor infertility with non-obstructive azoospermia (NOAZ) and severe oligospermia (<5 million/ ml). To study the unusual pericentric inversion in a recurrent ICSI failure case, cytogenetic analysis was done from peripheral blood lymphocytes. Semen analysis revealed that the man had Oligoasthenoteratozoospermia with sperm count of 0.9 million/ml. A karyogram revealed pericentromeric inversion of Chromosome 7. It could be accommodated on models that location of the breakpoint harbours critical genes for spermatogenesis (swm, swm2 and STAG3). Pericentromeric Inversion for chromosome 7 is a rare finding. It may be the etiopathogenic for partial spermatogenetic arrest and recurrent ICSI failure. The children born to such couples must also be analyzed and kept under observation for any clinical indications.
AD  - SMVDU, Sch Biotechnol, Katra 182320, J&K, IndiaAD  - All India Inst Med Sci, Dept Anat, Lab Mol Reprod & Genet, New Delhi 110029, IndiaC3  - Shri Mata Vaishno Devi UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - INDIAN SOC GENET PLANT BREEDING
PI  - NEW DELHI
PA  - PO BOX 11312, INDIAN AGRICULTURE RES INST, NEW DELHI 110012, INDIA
DA  - NOV
PY  - 2018
VL  - 78
IS  - 4
SP  - 515
EP  - 518
DO  - 10.31742/IJGPB.78.4.14
AN  - WOS:000458467600014
ER  -

TY  - JOUR
AU  - Shalimar
AU  - Rout, G
AU  - Jadaun, SS
AU  - Ranjan, G
AU  - Kedia, S
AU  - Gunjan, D
AU  - Nayak, B
AU  - Acharya, SK
AU  - Kumar, A
AU  - Kapil, A
TI  - Prevalence, predictors and impact of bacterial infection in acute on chronic liver failure patients
T2  - DIGESTIVE AND LIVER DISEASE
KW  - Acute decompensation
KW  - Bacteremia
KW  - Sepsis
KW  - Systemic inflammatory response
KW  - CIRRHOSIS
KW  - MORTALITY
KW  - DECOMPENSATION
KW  - ASSOCIATION
KW  - HEPATITIS
KW  - DISEASE
AB  - Background: Acute on chronic liver failure (ACLF) is associated with high short term mortality. We aimed to evaluate the prevalence, predictors and impact of bacterial infection in ACLF.
   Methods: Consecutive hospitalized patients with cirrhosis and acute decompensation (AD), from January 2011-March 2017, were included. Predictors of survival and infection were assessed.
   Results: 572 patients with cirrhosis and AD were classified into 3 groups - no infection (group 1, n=190, 33.2%), infection at admission/within 48h (group 2, n = 298, 52.1%) and infection after 48h (group 3, n = 84, 14.7%). Higher frequency of organ failures - kidney, brain, circulation and respiratory failure were seen in groups 2 and 3 as compared with group 1 (P<0.001 for all). Most common site of infection was lungs, followed by spontaneous bacterial peritonitis and urinary tract infection. The frequency of infection increased with higher ACLF grades. Among ACLF patients, on Cox-proportional multivariate analysis, presence of infection was associated with significantly higher mortality [group 2 (HR 2.93; 95%CI, 1.97-4.38, P < 0.001) and group 3 (HR 1.84; 95%CI, 1.16-2.91, P=0.009)], as compared with group 1. On multivariate logistic regression analysis, advanced hepatic encephalopathy and elevated total leucocyte count were independently associated with development of infection.
   Conclusions: Infections are common in ACLF, and associated with poor outcome. (C) 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
AD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaAD  - Govind Ballabh Pant Inst Postgrad Med Educ & Res, Dept Gastroenterol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Govind Ballabh Pant Institute of Postgraduate Medical Education & ResearchC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - NOV
PY  - 2018
VL  - 50
IS  - 11
SP  - 1225
EP  - 1231
DO  - 10.1016/j.dld.2018.05.013
AN  - WOS:000448191600017
ER  -

TY  - JOUR
AU  - Sharma, N
AU  - Singhal, D
AU  - Maharana, PK
AU  - Agarwal, T
AU  - Sinha, R
AU  - Satpathy, G
AU  - Bageshwar, LMS
AU  - Titiyal, JS
TI  - Spectral Domain Anterior Segment Optical Coherence Tomography in Fungal Keratitis
T2  - CORNEA
KW  - keratitis
KW  - fungal keratitis
KW  - anterior segment optical coherence tomography
KW  - corneal thickness
AB  - Purpose: To evaluate the use of spectral domain anterior segment optical coherence tomography (SD-ASOCT) in fungal keratitis. Methods: Fifty eyes of 50 patients with fungal keratitis were recruited. Serial ASOCT was performed on days 0, 7, 14, 21, 28, 42, and 56. Corneal thickness (CT) in the infiltrate area, infiltrate thickness (IT), and infiltrate width were measured at each follow-up. The presence of any specific feature on ASOCT was evaluated. Results: Mean CT and IT at presentation were 650.5 +/- 108 mu m and 401.1 +/- 91 mu m, which reduced significantly at each follow-up [on days 7, 14, 28, and 42; 626.8 +/- 113 mu m (P < 0.001) and 367.3 +/- 94 mu m (P = 0.002), 601.4 +/- 109 mu m and 344.7 +/- 94 mu m (P < 0.001), 544.8 +/- 103 mu m and 305.1 +/- 80 mu m (P < 0.001), and 522.8 +/- 97 mu m and 291.4 +/- 79 mu m (P < 0.001), respectively]. The mean CT and scar depth at complete healing were 496.3 +/- 101 mu m and 283.2 +/- 77 mu m, respectively. In 10/50 (20%) eyes, the posterior border of the cornea was not clearly visible because of posterior shadowing; therefore, IT was measured along the maximum visible area of hyperreflectivity, whereas CT was measured just adjacent to the area of shadowing. The infiltrate width was measured in 35 eyes, and the mean values at days 0, 7, 14, 28, 42, and 56 were 5.5 +/- 0.8 mm, 4.6 +/- 0.7 mm, 4.4 +/- 0.6 mm, 4.2 +/- 0.6 mm, 4.1 +/- 0.6 mm, and 4.1 +/- 0.6 mm, respectively. A satellite lesion and endothelial plaque were seen in 30% (15/50) and 44% (22/50) eyes, respectively. Conclusions: ASOCT is a useful adjunct in monitoring fungal keratitis especially in cases with deep stromal involvement and endothelial plaques. In addition, it also provides insight into the activity of keratitis.
AD  - All India Inst Med Sci, Dept Ophthalmol, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Ocular Microbiol, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - NOV
PY  - 2018
VL  - 37
IS  - 11
SP  - 1388
EP  - 1394
DO  - 10.1097/ICO.0000000000001715
AN  - WOS:000456481500015
ER  -

TY  - JOUR
AU  - Sharma, S
AU  - Shalimar
TI  - Albumin administration in patients with cirrhosis: Should it be done routinely?
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
KW  - INFUSION
KW  - IMPROVES
KW  - ASCITES
AD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - NOV-DEC
PY  - 2018
VL  - 31
IS  - 6
SP  - 349
EP  - +
DO  - 10.4103/0970-258X.262916
AN  - WOS:000479098700009
ER  -

TY  - JOUR
AU  - Shukla, G
TI  - Moving the clock on comprehensive post-surgical outcome assessment in specific etiological categories of epilepsy
T2  - NEUROLOGY INDIA
KW  - FOCAL CORTICAL DYSPLASIA
AD  - Queens Univ, Dept Med, Div Neurol, Kingston, ON, CanadaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - Queens University - CanadaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV-DEC
PY  - 2018
VL  - 66
IS  - 6
SP  - 1598
EP  - 1600
DO  - 10.4103/0028-3886.246222
AN  - WOS:000452798000011
ER  -

TY  - JOUR
AU  - Sikary, AK
AU  - Kumar, M
AU  - Dhaka, S
AU  - Subramanian, A
TI  - A Rare Fatal Complication of Llizarov Procedure
T2  - JOURNAL OF FORENSIC SCIENCES
KW  - forensic science
KW  - autopsy
KW  - fat embolism
KW  - limb lengthening
KW  - limb shortening
KW  - pathology
KW  - surgical fracture
KW  - sudden collapse
KW  - ILIZAROV TECHNIQUE
AB  - Ilizarov process is used for the management of multiple fractures, polytrauma conditions, cosmetic limb lengthening, and fracture malunion. Complications associated with the process are nerve palsy, joint contracture, premature or delayed osseous consolidation, a nonunion and permanent stiffness of the joint, pin tract infection, edema, and transient paresthesia, etc. In our case, there was a fatal complication. A 25-year-old African lady underwent the Ilizarov procedure for femur lengthening in a hospital in New Delhi, India. During her first distraction process, she suddenly collapsed at the hospital and could not be revived. At postmortem, a small hematoma was seen around the surgically fractured area. On histopathology of internal organs, fat globules were present in the vasculature of brain and lungs. Cause of death was opined as due to fat embolism. This is the first case reported of a fatal fat embolism following Ilizarov procedure for limb lengthening in a healthy adult.
AD  - All India Inst Med Sci, Dept Forens Med & Toxicol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, JPN Apex Trauma Ctr, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - NOV
PY  - 2018
VL  - 63
IS  - 6
SP  - 1895
EP  - 1898
DO  - 10.1111/1556-4029.13769
AN  - WOS:000449834200040
ER  -

TY  - JOUR
AU  - Singh, G
AU  - Ganguly, KK
AU  - Banerji, M
AU  - Addlakha, R
AU  - Shah, U
AU  - Tripathi, M
AU  - Saxena, V
AU  - Vohra, H
AU  - Wakankar, Y
AU  - Sharma, M
AU  - Radhakrishnan, K
TI  - Marriage in people with epilepsy: A compelling theme for psycho-behavioral research
T2  - SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
KW  - Epilepsy
KW  - Marriage
KW  - Stigma
KW  - Outcome
KW  - Satisfaction
KW  - MARITAL-STATUS
KW  - SOCIOCULTURAL CONTEXT
KW  - ARRANGED MARRIAGE
KW  - STIGMA
KW  - IMPACT
KW  - ONSET
AB  - People with epilepsy frequently experience problems in marriage including reduced marital prospects, poor marital outcomes and diminished quality of married life. Conversely, marriage might impact epilepsy self management and quality of life in people with epilepsy. There is little in published literature on marriage and epilepsy, so there is a need for psycho-behavioral research. Here, we focus on arranged marriages which, although now rare in western cultures, are widely prevalent in South Asian communities. Arranged marriages, in which families rather than individuals choose marital partners, are particularly problematic because epilepsy is frequently hidden during marital negotiations as well as later. From the psycho-behavioral perspective, marital prospects, outcomes and satisfaction should be examined in relation to the type of marriage (arranged vs. love) and whether or not epilepsy is hidden. Additionally, culturally-relevant tools to appraise marital quality and epilepsy self-management within marriage should be developed. The main objective should be to develop a multi-sectorial action plan with interventions at several different levels involving different stakeholders to mitigate stigma associated with epilepsy in matrimony.
AD  - Dayanand Med Coll, Dept Neurol, Ludhiana, Punjab, IndiaAD  - Dayanand Med Coll, Dept Anat, Ludhiana, Punjab, IndiaAD  - UCL Inst Neurol, Dept Clin & Expt Epilepsy, Queen Sq, London, EnglandAD  - Indian Council Med Res, Sociobehav Res Unit, New Delhi, IndiaAD  - Indian Council Med Res, Noncommunicable Res Div, New Delhi, IndiaAD  - Ambedkar Univ, Sch Educ Studies, New Delhi, IndiaAD  - Ctr Womens Dev Studies, New Delhi, IndiaAD  - King Edward Mem Hosp, Dept Neurol, Bombay, Maharashtra, IndiaAD  - All India Inst Med Sci, Dept Neurol, Neurosci Ctr, New Delhi, IndiaAD  - Indian Epilepsy Assoc, Gurgaon, IndiaAD  - Sanvedana Fdn, Epilepsy Support Grp, Pune, Maharashtra, IndiaAD  - Amrita Inst Med Sci, Dept Neurol, Cochin 682041, Kerala, IndiaC3  - Dayanand Medical College & HospitalC3  - Dayanand Medical College & HospitalC3  - University of LondonC3  - University College LondonC3  - Indian Council of Medical Research (ICMR)C3  - Indian Council of Medical Research (ICMR)C3  - Ambedkar University DelhiC3  - Seth Gordhandas Sunderdas Medical College & King Edward Memorial HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Amrita Vishwa VidyapeethamC3  - Amrita Vishwa Vidyapeetham KochiPU  - W B SAUNDERS CO LTD
PI  - LONDON
PA  - 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
DA  - NOV
PY  - 2018
VL  - 62
SP  - 127
EP  - 130
DO  - 10.1016/j.seizure.2018.08.005
AN  - WOS:000452576100023
ER  -

TY  - JOUR
AU  - Singh, MB
TI  - What should drive epilepsy research?
T2  - SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
AD  - All India Inst Med Sci, Dept Neurol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - W B SAUNDERS CO LTD
PI  - LONDON
PA  - 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
DA  - NOV
PY  - 2018
VL  - 62
SP  - 1
EP  - 2
DO  - 10.1016/j.seizure.2018.08.018
AN  - WOS:000452576100001
ER  -

TY  - JOUR
AU  - Soni, S
AU  - Muthukrishnan, SP
AU  - Sood, M
AU  - Kaur, S
AU  - Sharma, R
TI  - Hyperactivation of left inferior parietal lobule and left temporal gyri shortens resting EEG microstate in schizophrenia
T2  - SCHIZOPHRENIA RESEARCH
KW  - EEG microstates
KW  - First-degree relatives
KW  - SLORETA
KW  - State marker
KW  - Second generation antipsychotics
KW  - Sensory integration
KW  - NEUROLEPTIC-NAIVE
KW  - ELECTROMAGNETIC TOMOGRAPHY
KW  - BRAIN
KW  - 1ST-EPISODE
KW  - NETWORKS
KW  - DURATION
AB  - Objective: The momentary spatial configuration of the brain electric field at the scalp reflects quasi-stable "functional microstates" caused by activity of different intracranial generators. There is paucity in literature on the intracranial generators of resting state EEG microstate alterations in stable patients with schizophrenia. The present study aimed to investigate resting state microstate alterations and their neural generators in patients with schizophrenia and their first-degree relatives as compared to healthy controls in an attempt to establish state and trait marker.
   Method: Thirty-four patients with schizophrenia (DSM-5 criteria), 29 first-degree relatives and 25 matched healthy controls participated in the study. Brain activity during eyes closed condition was recorded using 128 channel electroencephalography. Microstates were clustered into 5 maps across groups according to their topography. Microstate map parameters and their cortical sources were compared among groups.
   Results: Map 5 mean duration (chi(2)(2) = 7.617, p = 0.022) was significantly lower in patients compared to controls (U = 256, p = 0.010). Maximum activation was seen in left inferior parietal lobule (MNI coordinates:-65,-35, 25, Log-F-max = 0.748). Suprathreshold cortical voxels with increased activations were found localized at left temporal gyri.
   Conclusion: Hyperactivation in left inferior parietal lobule and temporal gyri might have shortened Map 5 duration at rest in patients with schizophrenia. This could imply microstate alterations as the potential state marker of schizophrenia. (C) 2018 Elsevier B.V. All rights reserved.
AD  - All India Inst Med Sci, Dept Physiol, Stress & Cognit Electroimaging Lab, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Physiol, Room 6010,Convergence Block, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Psychiat, 4th Floor,Teaching Block, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Physiol, 2nd Floor,Teaching Block, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - NOV
PY  - 2018
VL  - 201
SP  - 204
EP  - 207
DO  - 10.1016/j.schres.2018.06.020
AN  - WOS:000450604800030
ER  -

TY  - JOUR
AU  - Tandon, PN
TI  - Professor B. Ramamurthi (1922-2003): Personal reminiscences
T2  - NEUROLOGY INDIA
AD  - Natl Brain Res Inst, Manesar, Haryana, IndiaAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - Department of Biotechnology (DBT) IndiaC3  - National Brain Research Centre (NBRC)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV-DEC
PY  - 2018
VL  - 66
IS  - 6
SP  - 1543
EP  - 1549
DO  - 10.4103/0028-3886.246297
AN  - WOS:000452798000003
ER  -

TY  - JOUR
AU  - Tomar, GS
AU  - Mishra, RK
AU  - Chaturvedi, A
TI  - Glossopharyngeal vagal reflex: A matter of concern during neurosurgery
T2  - NEUROLOGY INDIA
AD  - All India Inst Med Sci, Dept Neuroanaesthesiol & Crit Care, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV-DEC
PY  - 2018
VL  - 66
IS  - 6
SP  - 1822
EP  - +
DO  - 10.4103/0028-3886.246267
AN  - WOS:000452798000055
ER  -

TY  - JOUR
AU  - Troeger, C
AU  - Blacker, BF
AU  - Khalil, IA
AU  - Rao, PC
AU  - Cao, SJ
AU  - Zimsen, SRM
AU  - Albertson, S
AU  - Stanaway, JD
AU  - Deshpande, A
AU  - Farag, T
AU  - Forouzanfar, MH
AU  - Abebe, Z
AU  - Adetifa, IMO
AU  - Adhikari, TB
AU  - Akibu, M
AU  - Al Lami, FH
AU  - Al-Eyadhy, A
AU  - Alvis-Guzman, N
AU  - Amare, AT
AU  - Amoako, YA
AU  - Antonio, CAT
AU  - Aremu, O
AU  - Asfaw, ET
AU  - Asgedom, SW
AU  - Atey, TM
AU  - Attia, EF
AU  - Avokpaho, EFGA
AU  - Ayele, HT
AU  - Ayuk, TB
AU  - Balakrishnan, K
AU  - Barac, A
AU  - Bassat, Q
AU  - Behzadifar, M
AU  - Behzadifar, M
AU  - Bhaumik, S
AU  - Bhutta, ZA
AU  - Bijani, A
AU  - Brauer, M
AU  - Brown, A
AU  - Camargos, PAM
AU  - Castaneda-Orjuela, CA
AU  - Colombara, D
AU  - Conti, S
AU  - Dadi, AF
AU  - Dandona, L
AU  - Dandona, R
AU  - Do, HP
AU  - Dubljanin, E
AU  - Edessa, D
AU  - Elkout, H
AU  - Endries, AY
AU  - Fijabi, DO
AU  - Foreman, KJ
AU  - Fullman, N
AU  - Garcia-Basteiro, AL
AU  - Gessner, BD
AU  - Gething, PW
AU  - Gupta, R
AU  - Gupta, T
AU  - Hailu, GB
AU  - Hassen, HY
AU  - Hedayati, MT
AU  - Heidari, M
AU  - Hibstu, DT
AU  - Horita, N
AU  - Ilesanmi, OS
AU  - Jakovljevic, MB
AU  - Jamal, AA
AU  - Kahsay, A
AU  - Kasaeian, A
AU  - Kassa, DH
AU  - Khader, YS
AU  - Khan, EA
AU  - Khan, MN
AU  - Khang, YH
AU  - Kim, YJ
AU  - Kissoon, N
AU  - Knibbs, LD
AU  - Kochhar, S
AU  - Koul, PA
AU  - Kumar, GA
AU  - Lodha, R
AU  - Abd El Razek, HM
AU  - Malta, DC
AU  - Mathew, JL
AU  - Mengistu, DT
AU  - Mezgebe, HB
AU  - Mohammad, KA
AU  - Mohammed, MA
AU  - Momeniha, F
AU  - Murthy, S
AU  - Nguyen, CT
AU  - Nielsen, KR
AU  - Ningrum, DNA
AU  - Nirayo, YL
AU  - Oren, E
AU  - Ortiz, JR
AU  - Mahesh, PA
AU  - Postma, MJ
AU  - Qorbani, M
AU  - Quansah, R
AU  - Rai, RK
AU  - Rana, SM
AU  - Ranabhat, CL
AU  - Ray, SE
AU  - Rezai, MS
AU  - Ruhago, GM
AU  - Safiri, S
AU  - Salomon, JA
AU  - Sartorius, B
AU  - Savic, M
AU  - Sawhney, M
AU  - She, J
AU  - Sheikh, A
AU  - Shiferaw, MS
AU  - Shigematsu, M
AU  - Singh, JA
AU  - Somayaji, R
AU  - Sufiyan, MB
AU  - Taffere, GR
AU  - Temsah, MH
AU  - Thompson, MJ
AU  - Tobe-Gai, R
AU  - Topor-Madry, R
AU  - Tran, BX
AU  - Tran, TT
AU  - Tuem, KB
AU  - Ukwaja, KN
AU  - Vollset, SE
AU  - Walson, JL
AU  - Weldegebreal, F
AU  - Werdecker, A
AU  - West, TE
AU  - Yonemoto, N
AU  - Zaki, ME
AU  - Zhou, L
AU  - Zodpey, S
AU  - Vos, T
AU  - Lim, SS
AU  - Naghavi, M
AU  - Murray, CJL
AU  - Mokdad, AH
AU  - Hay, SI
AU  - Reiner, RC 
A1  - GBD 2016 Lower Respiratory Infecti
TI  - Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
T2  - LANCET INFECTIOUS DISEASES
KW  - HOUSEHOLD AIR-POLLUTION
KW  - CHILDHOOD PNEUMONIA
KW  - CHILDREN YOUNGER
KW  - STREPTOCOCCUS-PNEUMONIAE
KW  - SOLID-FUEL
KW  - RISK
KW  - MALNUTRITION
KW  - PREVENTION
KW  - DIAGNOSIS
KW  - FEATURES
AB  - Background Lower respiratory infections are a leading cause of morbidity and mortality around the world. The Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study 2016, provides an up-to-date analysis of the burden of lower respiratory infections in 195 countries. This study assesses cases, deaths, and aetiologies spanning the past 26 years and shows how the burden of lower respiratory infection has changed in people of all ages.
   Methods We used three separate modelling strategies for lower respiratory infections in GBD 2016: a Bayesian hierarchical ensemble modelling platform (Cause of Death Ensemble model), which uses vital registration, verbal autopsy data, and surveillance system data to predict mortality due to lower respiratory infections; a compartmental meta-regression tool (DisMod-MR), which uses scientific literature, population representative surveys, and healthcare data to predict incidence, prevalence, and mortality; and modelling of counterfactual estimates of the population attributable fraction of lower respiratory infection episodes due to Streptococcus pneumoniae, Haemophilus influenzae type b, influenza, and respiratory syncytial virus. We calculated each modelled estimate for each age, sex, year, and location. We modelled the exposure level in a population for a given risk factor using DisMod-MR and a spatiotemporal Gaussian process regression, and assessed the effectiveness of targeted interventions for each risk factor in children younger than 5 years. We also did a decomposition analysis of the change in LRI deaths from 2000-16 using the risk factors associated with LRI in GBD 2016.
   Findings In 2016, lower respiratory infections caused 652 572 deaths (95% uncertainty interval [UI] 586 475-720 612) in children younger than 5 years (under-5s), 1 080 958 deaths (943 749-1 170 638) in adults older than 70 years, and 2 377 697 deaths (2145 584-2 512 809) in people of all ages, worldwide. Streptococcus pneumoniae was the leading cause of lower respiratory infection morbidity and mortality globally, contributing to more deaths than all other aetiologies combined in 2016 (1189 937 deaths, 95% UI 690 445-1 770 660). Childhood wasting remains the leading risk factor for lower respiratory infection mortality among children younger than 5 years, responsible for 61.4% of lower respiratory infection deaths in 2016 (95% UI 45.7-69.6). Interventions to improve wasting, household air pollution, ambient particulate matter pollution, and expanded antibiotic use could avert one under-5 death due to lower respiratory infection for every 4000 children treated in the countries with the highest lower respiratory infection burden.
   Interpretation Our findings show substantial progress in the reduction of lower respiratory infection burden, but this progress has not been equal across locations, has been driven by decreases in several primary risk factors, and might require more effort among elderly adults. By highlighting regions and populations with the highest burden, and the risk factors that could have the greatest effect, funders, policy makers, and programme implementers can more effectively reduce lower respiratory infections among the world's most susceptible populations. Copyright (C) The Author(s). Published by Elsevier Ltd.
AD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USAAD  - Univ Washington, Ctr Hlth Trends & Forecasts, Seattle, WA 98195 USAAD  - Univ Washington, Dept Global Hlth, Seattle, WA 98195 USAAD  - Univ Washington, Dept Med, Seattle, WA USAAD  - Univ Washington, Dept Pediat, Seattle, WA 98195 USAAD  - Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USAAD  - Univ Washington, Seattle, WA 98195 USAAD  - Univ Gondar, Gondar, EthiopiaAD  - London Sch Hyg & Trop Med, London, EnglandAD  - KEMRI, Wellcome Trust Res Programme, Kilifi, KenyaAD  - Ctr Social Sci & Publ Hlth Res Nepal, Hlth Res, Lalitpur, NepalAD  - Univ Southern Denmark, Unit Hlth Promot Res, Fac Hlth Sci, Esbjerg, DenmarkAD  - Debere Berhan Univ, Debre Berhan, EthiopiaAD  - Acad Med Sci, Community & Family Med, Baghdad, IraqAD  - Acad Med Sci, Dept Pharm, Baghdad, IraqAD  - King Saud Univ, Riyadh, Saudi ArabiaAD  - King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi ArabiaAD  - Univ Cartagena, Res Grp Hlth Econ, Cartagena, ColombiaAD  - Sansom Inst, South Australian Hlth & Med Res Inst, Adelaide, SA, AustraliaAD  - Bahir Dar Univ, Bahir Dar, EthiopiaAD  - Komfo Anokye Teaching Hosp, Kumasi, GhanaAD  - Univ Philippines Manila, Dept Hlth Policy & Adm, Coll Publ Hlth, Manila, PhilippinesAD  - Univ Birmingham, Dept Publ Hlth & Therapies, Birmingham, W Midlands, EnglandAD  - Mekelle Univ, Biomed Sci Div, Mekelle, EthiopiaAD  - Mekelle Univ, Coll Hlth Sci, Inst Biomed Sci, Med Microbiol & Immunol Unit, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Environm Hlth & Behav Sci, Mekelle, EthiopiaAD  - Mekelle Univ, Mekelle, EthiopiaAD  - IRCB, Cotonou, BeninAD  - Lab Etud & Rech Act Sante LERAS Afrique, Parakou, BeninAD  - McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, CanadaAD  - Dilla Univ, Dept Publ Hlth, Dilla, EthiopiaAD  - Inst Med Res & Plant Med Studies Cameroon IMPM, Ctr Food & Nutr Res, Yaounde, CameroonAD  - Univ South Africa, Pretoria, South AfricaAD  - Sri Ramachandra Univ, Dept Environm Hlth Engn, Madras, Tamil Nadu, IndiaAD  - Univ Belgrade, Fac Med, Belgrade, SerbiaAD  - Univ Belgrade, Inst Microbiol & Immunol, Fac Med, Belgrade, SerbiaAD  - Univ Barcelona, Barcelona Inst Global Hlth ISGlobal, Barcelona, SpainAD  - Manhica Hlth Res Ctr, Manhica, MozambiqueAD  - Lorestan Univ Med Sci, Khorramabad, IranAD  - George Inst Global Hlth, New Delhi, IndiaAD  - Hosp Sick Children, Ctr Global Child Hlth, Toronto, ON, CanadaAD  - Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, PakistanAD  - Babol Univ Med Sci, Hlth Res Inst, Social Determinants Hlth Res Ctr, Babol Sar, IranAD  - Univ British Columbia, Vancouver, BC, CanadaAD  - Fed Univ Minas Gerias, Belo Horizonte, MG, BrazilAD  - Natl Inst Hlth, Colombian Natl Hlth Observ, Bogota, ColombiaAD  - Univ Nacl Colombia, Publ Hlth Dept, Epidemiol & Publ Hlth Evaluat Grp, Bogota, ColombiaAD  - Univ Milano Bicocca, Monza, ItalyAD  - Flinders Univ S Australia, Adelaide, NSW, AustraliaAD  - Publ Hlth Fdn India, Gurugram, IndiaAD  - Duy Tan Univ, Inst Global Hlth Innovat, Da Nang, VietnamAD  - Haramaya Univ, Sch Pharm, Harar, EthiopiaAD  - Haramaya Univ, Harar, EthiopiaAD  - Tripoli Univ, Community & Family Med, Tripoli, LibyaAD  - WHO, Tripoli, LibyaAD  - St Pauls Hosp Millennium, Med Coll, Addis Ababa, EthiopiaAD  - Brandeis Univ, Heller Grad Sch, Waltham, MA USAAD  - Univ Memphis, Sch Publ Hlth, Memphis, TN 38152 USAAD  - Imperial Coll London, London, EnglandAD  - Barcelona Inst Global Hlth, Barcelona, SpainAD  - Agence Med Prevent, Paris, FranceAD  - Univ Oxford, Big Data Inst, Nuffield Dept Med, Oxford, EnglandAD  - West Virginia Bur Publ Hlth, Charleston, WV USAAD  - Indian Inst Technol Kanpur, Kanpur, Uttar Pradesh, IndiaAD  - Kilte Awlaelo Hlth & Demog Surveillance Syst, Mekelle, EthiopiaAD  - Mizan Tepi Univ, Mizan Teferi, EthiopiaAD  - Mazandaran Univ Med Sci, Dept Med Mycol & Parasitol, Sch Med, Sari, IranAD  - Mazandaran Univ Med Sci, Invas Fungi Res Ctr, Sari, IranAD  - Hormozgan Univ Med Sci, Fac Hlth, Bandar Abbas, IranAD  - Hawassa Univ, Dept Reprod Hlth, Hawassa, EthiopiaAD  - Yokohama City Univ, Grad Sch Med, Dept Pulmonol, Yokohama, Kanagawa, JapanAD  - Fdn Natl Inst Hlth, Bethesda, MD USAAD  - Natl Publ Hlth Inst, Monrovia, LiberiaAD  - Univ Kragujevac, Fac Med Sci, Kragujevac, SerbiaAD  - Univ Tehran Med Sci, Hematol Oncol & Stem Cell Transplantat Res Ctr, Hematol Malignancies Res Ctr, Tehran, IranAD  - Debre Markos Univ, Debre Markos, EthiopiaAD  - Jordan Univ Sci & Technol, Dept Community Med Publ Hlth & Family Med, Irbid, JordanAD  - Hlth Serv Acad, Islamabad, PakistanAD  - Univ Newcastle, Newcastle, NSW, AustraliaAD  - Jatiya Kabi Kazi Nazrul Islam Univ, Mymensingh, BangladeshAD  - Seoul Natl Univ, Coll Med, Dept Hlth Policy & Management, Seoul, South KoreaAD  - Seoul Natl Univ, Med Ctr, Inst Hlth Policy & Management, Seoul, South KoreaAD  - Xiamen Univ, Sch Med, Malaysia Campus, Xiamen, MalaysiaAD  - Univ Queensland, Sch Publ Hlth, Brisbane, Qld, AustraliaAD  - Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, NetherlandsAD  - Sheri Kashmir Inst Med Sci, Dept Internal & Pulm Med, Srinagar, Jammu & Kashmir, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Damietta Univ, Dumyat, EgyptAD  - Univ Fed Minas Gerais, Belo Horizonte, MG, BrazilAD  - Postgrad Inst Med Educ & Res, Chandigarh, IndiaAD  - Salahaddin Univ, Erbil, IraqAD  - Ishik Univ, Erbil, IraqAD  - JigJiga Univ, Jigjiga, EthiopiaAD  - Univ Sydney, Sydney, NSW, AustraliaAD  - Iran Univ Med Sci, Dept Environm Hlth Engn, Sch Publ Hlth, Tehran, IranAD  - Semarang State Univ, Dept Publ Hlth, Semarang, IndonesiaAD  - Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Biomed Informat, Taipei, TaiwanAD  - San Diego State Univ, Grad Sch Publ Hlth, Div Epidemiol & Biostat, San Diego, CA 92182 USAAD  - Univ Maryland, Ctr Vaccine Dev, Baltimore, MD 21201 USAAD  - Jagadguru Sri Shivarathreeswara Univ, Dept Pulm Med, Mysore, Karnataka, IndiaAD  - Univ Med Ctr Groningen, Groningen, NetherlandsAD  - Univ Groningen, Groningen, NetherlandsAD  - Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, IranAD  - Univ Ghana, Accra, GhanaAD  - Noguchi Mem Inst Med Res, Accra, GhanaAD  - Soc Hlth & Demog Surveillance, Suri, IndiaAD  - Univ Gottingen, Gottingen, GermanyAD  - Contech Sch Publ Hlth, Lahore, PakistanAD  - Contech Int Hlth Consultants, Lahore, PakistanAD  - Yonsei Univ, Inst Poverty Alleviat & Int Dev, Wonju, South KoreaAD  - Hlth Sci Fdn & Study Ctr, Kathmandu, NepalAD  - Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, TanzaniaAD  - Maragheh Univ Med Sci, Managerial Epidemiol Res Ctr, Dept Publ Hlth, Sch Nursing & Midwifery, Maragheh, IranAD  - Stanford Univ, Ctr Hlth Policy, Stanford, CA 94305 USAAD  - Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USAAD  - Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Publ Hlth Med, Durban, South AfricaAD  - South African Med Res Council, UKZN Gastrointestinal Canc Res Ctr, Durban, South AfricaAD  - GSK Biol, Wavre, BelgiumAD  - Univ North Carolina, Dept Publ Hlth Sci, Charlotte, NC USAAD  - Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai, Peoples R ChinaAD  - Univ Edinburgh, Edinburgh, Midlothian, ScotlandAD  - Harvard Univ, Div Gen Internal Med & Primary Care, Boston, MA USAAD  - Natl Inst Infect Dis, Tokyo, JapanAD  - Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USAAD  - Univ Calgary, Calgary, AB, CanadaAD  - Ahmadu Bello Univ, Dept Community Med, Zaria, NigeriaAD  - Alfaisal Univ, Coll Med, Riyadh, Saudi ArabiaAD  - Natl Ctr Child Hlth & Dev, Dept Hlth Policy, Tokyo, JapanAD  - Jagiellonian Univ, Coll Med, Fac Hlth Sci, Inst Publ Hlth, Krakow, PolandAD  - Wroclaw Med Univ, Fac Hlth Sci, Wroclaw, PolandAD  - Hanoi Med Univ, Hanoi, VietnamAD  - Fed Teaching Hosp, Dept Internal Med, Abakaliki, NigeriaAD  - Fed Inst Populat Res, Dept Demog Change & Ageing, Wiesbaden, GermanyAD  - Kyoto Univ, Sch Publ Hlth, Dept Biostat, Kyoto, JapanAD  - Mansoura Univ, Fac Med, Mansoura, EgyptAD  - Jinan Cent Hosp, Jinan, Shandong, Peoples R ChinaC3  - Institute for Health Metrics & EvaluationC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of GondarC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of Southern DenmarkC3  - King Saud UniversityC3  - King Faisal Specialist Hospital & Research CenterC3  - Universidad de CartagenaC3  - University of South AustraliaC3  - South Australian Health & Medical Research Institute (SAHMRI)C3  - Bahir Dar UniversityC3  - Kwame Nkrumah University Science & TechnologyC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - University of BirminghamC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - McGill UniversityC3  - Dilla UniversityC3  - University of South AfricaC3  - Sri Ramachandra Institute of Higher Education & ResearchC3  - University of BelgradeC3  - University of BelgradeC3  - ISGlobalC3  - University of BarcelonaC3  - Centro de Investigacao em Saude de ManhicaC3  - Lorestan University of Medical SciencesC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - Aga Khan UniversityC3  - Babol University of Medical SciencesC3  - University of British ColumbiaC3  - Universidad Nacional de ColombiaC3  - University of Milano-BicoccaC3  - Flinders University South AustraliaC3  - Public Health Foundation of IndiaC3  - Duy Tan UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - University of TripoliC3  - World Health OrganizationC3  - Brandeis UniversityC3  - University of MemphisC3  - Imperial College LondonC3  - ISGlobalC3  - Agence de Medecine PreventiveC3  - University of OxfordC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - KanpurC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Hawassa UniversityC3  - Yokohama City UniversityC3  - National Institutes of Health (NIH) - USAC3  - University of KragujevacC3  - Tehran University of Medical SciencesC3  - Jordan University of Science & TechnologyC3  - Health Services AcademyC3  - University of NewcastleC3  - Seoul National University (SNU)C3  - Seoul National University (SNU)C3  - Xiamen University Malaysia CampusC3  - University of QueenslandC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - Sher-i-Kashmir Institute of Medical SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Egyptian Knowledge Bank (EKB)C3  - Damietta UniversityC3  - Universidade Federal de Minas GeraisC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Salahaddin UniversityC3  - University of SydneyC3  - Iran University of Medical SciencesC3  - Universitas Negeri SemarangC3  - Taipei Medical UniversityC3  - California State University SystemC3  - San Diego State UniversityC3  - University System of MarylandC3  - University of Maryland BaltimoreC3  - JSS Academy of Higher Education & ResearchC3  - University of GroningenC3  - University of GroningenC3  - University of GhanaC3  - University of GhanaC3  - University of GottingenC3  - Yonsei UniversityC3  - Muhimbili University of Health & Allied SciencesC3  - Stanford UniversityC3  - Stanford UniversityC3  - University of Kwazulu NatalC3  - South African Medical Research CouncilC3  - GlaxoSmithKlineC3  - GlaxoSmithKline BelgiumC3  - University of North CarolinaC3  - University of North Carolina CharlotteC3  - Fudan UniversityC3  - University of EdinburghC3  - Harvard UniversityC3  - National Institute of Infectious Diseases (NIID)C3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of CalgaryC3  - Ahmadu Bello UniversityC3  - Alfaisal UniversityC3  - National Center for Child Health & Development - JapanC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - Wroclaw Medical UniversityC3  - Hanoi Medical UniversityC3  - Kyoto UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Shandong First Medical University & Shandong Academy of Medical SciencesPU  - ELSEVIER SCI LTD
PI  - London
PA  - 125 London Wall, London, ENGLAND
DA  - NOV
PY  - 2018
VL  - 18
IS  - 11
SP  - 1191
EP  - 1210
DO  - 10.1016/S1473-3099(18)30310-4
AN  - WOS:000448325300030
ER  -

TY  - JOUR
AU  - Turel, MK
AU  - Tripathi, M
AU  - Aggarwa, A
AU  - Singial, N
AU  - KAhuja, C
AU  - Takkar, A
AU  - Mehta, S
AU  - Garg, K
AU  - Yadav, R
AU  - Mehrotra, A
AU  - Das, KK
TI  - A summary of some of the recently published, seminal papers in neuroscience
T2  - NEUROLOGY INDIA
AD  - Wockhardt Hosp, Dept Neurosurg, Bombay, Maharashtra, IndiaAD  - Sir JJ Grp Hosp, Bombay, Maharashtra, IndiaAD  - Postgrad Inst Med Educ & Res, Dept Neurosurg, Chandigarh, IndiaAD  - Postgrad Inst Med Educ & Res, Dept Radiol, Chandigarh, IndiaAD  - Postgrad Inst Med Educ & Res, Dept Neurol, Chandigarh, IndiaAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaAD  - Natl Inst Mental Hlth & Neurosci, Dept Neurol, Bangalore, Karnataka, IndiaAD  - Sanjay Gandhi Postgrad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, IndiaC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Institute of Mental Health & Neurosciences - IndiaC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV-DEC
PY  - 2018
VL  - 66
IS  - 6
SP  - 1776
EP  - 1792
DO  - 10.4103/0028-3886.246289
AN  - WOS:000452798000043
ER  -

TY  - JOUR
AU  - Venkatesh, P
AU  - Kumar, S
AU  - Tandon, N
AU  - Takkar, B
AU  - Praveen, PA
TI  - Selfie fundus imaging: Innovative approach to retinopathy screening
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
AB  - The currently available methods of screening for diabetic retinopathy (DR) depend on the availability of healthcare professionals and technology. The high prevalence of diabetes in India, and the need to repeatedly screen such patients for DR and treat them, places an enormous economic and logistic burden. We introduce the concept of screening for DR with 'selfie retinal imaging' through this report of 3 patients. The patients can themselves capture retinal images and transfer to a grading centre for further deliberation. If incorporated into the current technological revolution of smartphones, this futuristic concept is likely to be of huge benefit in preventing loss of vision due to diabetes.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Endocrinol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - NOV-DEC
PY  - 2018
VL  - 31
IS  - 6
SP  - 345
EP  - 346
DO  - 10.4103/0970-258X.262914
AN  - WOS:000479098700007
ER  -

TY  - JOUR
AU  - Yadav, K
AU  - Pandav, CS
TI  - National Iodine Deficiency Disorders Control Programme: Current status & future strategy
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
KW  - ICCIDD
KW  - iodine deficiency disorder
KW  - iodized salt
KW  - last mile
KW  - public health nutrition
KW  - success story
KW  - way forward
KW  - ENDEMIC GOITER
KW  - PREVENTION
KW  - NUTRITION
KW  - CHILDREN
KW  - IDD
AB  - Iodine deficiency disorders (IDDs) constitute a significant public health problem globally. In India, the entire population is prone to IDDs due to deficiency of iodine in the soil of the sub-continent and thus both animal and plant source food grown on the iodine-deficient soil. IDDs encompass the spectrum of disability and disease and include goitre, cretinism, hypothyroidism, abortion, stillbirth, brain damage, learning disabilities, mental retardation, psychomotor defects, hearing and speech impairment. Iodine deficiency is known to be the single largest cause of preventable brain damage. IDDs with their causal association with brain development, cognition, and learning disabilities impair the human resource development and progress of the country. The children born in iodine-deficient regions on an average have 13.5 intelligence quotient (IQ) points lesser than children born in iodine-sufficient regions. IDD control programme in India is a public health success story, with 92 per cent of the population consuming iodized salt. The partnership between government agencies, academic institutions, salt industry, development agencies and civil society has been key to achieve this success story. The sustainable elimination of iodine deficiency in India is within reach, what is required is accelerated and coordinated effort by all key stakeholder at national and State level.
AD  - All India Inst Med Sci, Ctr Community Med, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Indian Coalit Control Iodine Deficiency Disorders, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - NOV
PY  - 2018
VL  - 148
IS  - 5
SP  - 503
EP  - 510
DO  - 10.4103/ijmr.IJMR_1717_18
AN  - WOS:000456436400006
ER  -

TY  - JOUR
AU  - Mahey, R
AU  - Gupta, M
AU  - Kandpal, S
AU  - Malhotra, N
AU  - Vanamail, P
AU  - Singh, N
AU  - Kriplani, A
TI  - Fertility awareness and knowledge among Indian women attending an infertility clinic: a cross-sectional study
T2  - BMC WOMENS HEALTH
KW  - Fertility
KW  - Awareness
KW  - Infertility
KW  - Knowledge
KW  - Parenthood
KW  - CHILDBEARING
KW  - ATTITUDES
KW  - MYTHS
KW  - AGE
AB  - BackgroundTo evaluate fertility knowledge and awareness among infertile women attending an Indian assisted fertility clinic and their understanding of the menstrual cycle, how age affects fertility and need for assisted fertility treatment.MethodsA cross sectional study was conducted including 205 women seeking fertility treatment at an assisted reproductive unit between March 2017 to August 2017. Patients were interviewed with the help of structured questionnaire by a fertility counsellor. The previous studies were reviewed and a questionnaire was made according to our patient profile and sociodemographic characteristics. Knowledge and awareness was stratified according to socioeconomic status (SES).ResultsMost women (59%) were aged between 20 to 30years indicating concern about their fertility and need for evaluation. More than half (63%) women were from the middle socio-economic strata. Knowledge about fertility and reproduction was low: 85% were not aware of the ovulatory period in the menstrual cycle, only 8% considered age more than 35years as the most significant risk factor for infertility and most were unaware of when to seek treatment for infertility after trying for pregnancy. Less than half of women understood the need for assisted fertility treatment and donor oocytes in advanced age.ConclusionsMost Indian women across different SES are unaware of the effect of age on fertility. Targeted educational interventions are needed to improve knowledge regarding ideal age of fertility, factors affecting fertility potential and fertility options available for sub-fertile couples. Fertility counselling and information should be provided to young people at every contact with health care professionals.
AD  - All India Inst Med Sci, Dept Obstet & Gynecol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Obstet & Gynecol, Reprod Med, Room 3076,Third Floor,Teaching Block, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - BMC
PI  - LONDON
PA  - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - OCT 29
PY  - 2018
VL  - 18
C7  - 177
DO  - 10.1186/s12905-018-0669-y
AN  - WOS:000448753300001
ER  -

TY  - JOUR
AU  - Nair, J
AU  - Velpandian, T
AU  - Das, US
AU  - Sharma, P
AU  - Nag, T
AU  - Mathur, SR
AU  - Mathur, R
TI  - Molecular and Metabolic Markers of Fructose Induced Hepatic Insulin Resistance in Developing and Adult Rats are Distinct and <i>Aegle marmelos</i> is an Effective Modulator
T2  - SCIENTIFIC REPORTS
KW  - ADIPOSE-TISSUE
KW  - CONSUMPTION
KW  - ZONATION
KW  - DISEASE
KW  - GLUCOSE
KW  - WEIGHT
KW  - ONSET
AB  - The time course of pathogenesis of fructose mediated hepatic insulin resistance (HepIR) is not well-delineated and we chronicle it here from post-weaning to adulthood stages. Weaned rats were provided for either 4 or 8 weeks, i.e., upto adolescence or adulthood, chow+ drinking water, chow +fructose, 15% or chow +/- fructose, 15% +/- hydroalcoholic extract of leaves of Aegle marmelos (AM-HM, 500 mg/kg/d, po) and assessed for feed intake, fructose intake, body weight, fasting blood sugar, oral glucose tolerance test, HOMA-IR, insulin tolerance test and lipid profile. Activities of enzymes (glucose-6-phosphatase, hexokinase, phosphofructokinase, aldehyde dehydrogenase), hormones (leptin, ghrelin, insulin), insulin signaling molecules (Akt-PI3k, AMPK, JNK) hallmarks of inflammation (TNF-alpha), angiogenesis (VEGF), hypoxia (HIF-1), lipogenesis (mTOR) and regulatory nuclear transcription factors of de novo lipogenesis and hepatic insulin resistance gene (SREBP-1, FoxO1) that together govern the hepatic fructose metabolism, were also studied. The effect of fructose-rich environment on metabolic milieu of hepatocytes was confirmed using (human hepatocellular carcinoma) HepG2 cells. Using in vitro model, fructose uptake and glucose output from isolated murine hepatocytes were measured to establish the HepIR under fructose environment and delineate the effect of AM-HM. The leaves from the plant Aegle marmelos (L) Correa were extracted, fractionated and validated for rutin content using LC-MS/MS. The rutin content of extract was quantified and correlated with oral pharmacokinetic parameters in rat. The outcomes of the study suggest that the molecular and metabolic markers of fructose induced HepIR in developing and adult rats are distinct. Further, AM-HM exerts a multi-pronged attack by raising insulin secretion, augmenting insulin action, improving downstream signaling of insulin, reducing overall requirement of insulin and modulating hepatic expression of glucose transporter (Glut2). The butanol fraction of AM-HM holds promise for future development.
AD  - Delhi Inst Pharmaceut Sci & Res, Dept Pharmacol, Sec 3,MB Rd, New Delhi 110017, IndiaAD  - All India Inst Med Sci, Dept Ocular Pharmacol, Dr RP Ctr Ophthalm Sci, Aurobindo Marg, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Anat, Aurobindo Marg, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, Aurobindo Marg, New Delhi 110029, IndiaC3  - Delhi Pharmaceutical Sciences & Research University (DPSRU)C3  - Delhi Institute of Pharmaceutical Sciences & ResearchC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - NATURE PORTFOLIO
PI  - BERLIN
PA  - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
DA  - OCT 29
PY  - 2018
VL  - 8
C7  - 15950
DO  - 10.1038/s41598-018-33503-x
AN  - WOS:000448589200026
ER  -

TY  - JOUR
AU  - Pollock, JA
AU  - Sharma, N
AU  - Ippagunta, SK
AU  - Redecke, V
AU  - Häcker, H
AU  - Katzenellenbogen, JA
TI  - Triaryl Pyrazole Toll-Like Receptor Signaling Inhibitors: Structure-Activity Relationships Governing Pan- and Selective Signaling Inhibitors
T2  - CHEMMEDCHEM
KW  - drug design
KW  - heterocycles
KW  - immune response
KW  - structure-activity relationships
KW  - toll-like receptor signaling
KW  - TLR9
KW  - ANTAGONISTS
KW  - DISEASE
KW  - SEPSIS
KW  - UPDATE
KW  - INJURY
KW  - LUPUS
AB  - The immune system uses members of the toll-like receptor (TLR) family to recognize a variety of pathogen- and host-derived molecules in order to initiate immune responses. Although TLR-mediated, pro-inflammatory immune responses are essential for host defense, prolonged and exaggerated activation can result in inflammation pathology that manifests in a variety of diseases. Therefore, small-molecule inhibitors of the TLR signaling pathway might have promise as anti-inflammatory drugs. We previously identified a class of triaryl pyrazole compounds that inhibit TLR signaling by modulation of the protein-protein interactions essential to the pathway. We have now systematically examined the structural features essential for inhibition of this pathway, revealing characteristics of compounds that inhibited all TLRs tested (pan-TLR signaling inhibitors) as well as compounds that selectively inhibited certain TLRs. These findings reveal interesting classes of compounds that could be optimized for particular inflammatory diseases governed by different TLRs.
AD  - Univ Illinois, Dept Chem, 505 South Mathews Ave, Urbana, IL 61801 USAAD  - Univ Richmond, Dept Chem, 28 Westhampton Way, Richmond, VA 23173 USAAD  - St Jude Childrens Res Hosp, Dept Infect Dis, 262 Danny Thomas Pl, Memphis, TN 38105 USAAD  - All India Inst Med Sci, Dept Biotechnol, Delhi 110029, IndiaC3  - University of Illinois SystemC3  - University of Illinois Urbana-ChampaignC3  - University of RichmondC3  - St Jude Children's Research HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY-V C H VERLAG GMBH
PI  - WEINHEIM
PA  - POSTFACH 101161, 69451 WEINHEIM, GERMANY
DA  - OCT 22
PY  - 2018
VL  - 13
IS  - 20
SP  - 2208
EP  - 2216
DO  - 10.1002/cmdc.201800417
AN  - WOS:000448061600008
ER  -

TY  - JOUR
AU  - Pandey, H
AU  - Ranjan, R
AU  - Singh, K
AU  - Sharma, A
AU  - Kishor, K
AU  - Seth, T
AU  - Saxena, R
TI  - Contrasting co-inheritance of alpha and beta mutations in delta beta thalassemia and hereditary persistence of fetal hemoglobin: a study from India
T2  - HEMATOLOGY
KW  - Coinheritance
KW  - HbF
KW  - delta beta thal
KW  - alpha beta thal
KW  - HPFH
KW  - MOLECULAR CHARACTERIZATION
KW  - DELETIONS
KW  - POPULATION
KW  - ALPHA-THALASSEMIA-1
KW  - INTERMEDIA
KW  - BREAKPOINT
KW  - DIAGNOSIS
KW  - HPFH
KW  - PCR
AB  - Background and objectives: Coinheritance of delta beta thalassemia and HPFH with inherited factors is sparsely documented and may affect treatment modalities. So, we screened the presence of alpha deletion and beta mutations in delta beta thalassemia and HPFH disorders in 52 cases with high Hb F concentration. Material and methods: Fifty-two individuals with raised HbF levels were study subjects. CZE was done for quantitative assessment of hemoglobin variants. Asian Indian inversion deletion break point type A, B and HPFH-3 were done by GAP-PCR. Results: 18/52 cases of delta beta G gamma (A gamma delta beta)0 thalassemia and 28/52 cases of HPFH-3 deletion were characterized. 6/52 patients with raised HbF levels were negative for delta beta G gamma (A gamma delta beta)0 and HPFH-3 deletion. 9/18 (50%) were heterozygous for G gamma(A gamma delta beta)0 break point type A, 6/18 (33%) were heterozygous for break point type B and 3/18 (17%) were homozygous. Of the nine patients heterozygous for G gamma(A gamma delta beta)0 break point type A, three (33%) patients were double heterozygous with alpha 3.7 kb deletion and two (22%) patients showed compound heterozygosity with IVS 1-5(G-C) mutation. 4/9 (45%) patients were G gamma(A gamma delta beta)0 heterozygous. Discussion and conclusion: We found 5/18(27.beta) delta beta-thalassemia cases with co-inherited alpha 3.7 deletion and 3/18 (16 beta) cases with IVS 1-5(G-C) mutation. Patients showed features of thalassemia intermedia phenotype among which those with co-inherited IVS 1-5(G-C) mutation showed severe phenotype as compared to those with co-inherited alpha 3.7 deletion. So, we highlight importance of genotyping of patients with delta beta thalassemia or HPFH and coinheritance with inherited factors which plays crucial role in clinicopathological profile and setting up prenatal diagnostic protocol.
AD  - AIIMS, Dept Hematol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - TAYLOR & FRANCIS LTD
PI  - ABINGDON
PA  - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
DA  - OCT 21
PY  - 2018
VL  - 23
IS  - 9
SP  - 692
EP  - 696
DO  - 10.1080/10245332.2018.1458934
AN  - WOS:000449958000018
ER  -

TY  - JOUR
AU  - Vashist, A
AU  - Malhotra, V
AU  - Sharma, G
AU  - Tyagi, JS
AU  - Clark-Curtiss, JE
TI  - Interplay of PhoP and DevR response regulators defines expression of the dormancy regulon in virulent <i>Mycobacterium tuberculosis</i>
T2  - JOURNAL OF BIOLOGICAL CHEMISTRY
KW  - Mycobacterium tuberculosis
KW  - bacterial signal transduction
KW  - gene expression
KW  - protein-protein interaction
KW  - protein-DNA interaction
KW  - DevR
KW  - DosR
KW  - dormancy regulon
KW  - negative regulation
KW  - PhoP
KW  - two-component system
KW  - DNA-BINDING DOMAIN
KW  - 2-COMPONENT SYSTEM
KW  - ESCHERICHIA-COLI
KW  - HYPOXIC RESPONSE
KW  - CARBON-MONOXIDE
KW  - DOSR
KW  - TRANSCRIPTION
KW  - OPERON
KW  - SENSOR
KW  - GENE
AB  - The DevR response regulator of Mycobacterium tuberculosis is an established regulator of the dormancy response in mycobacteria and can also be activated during aerobic growth conditions in avirulent strains, suggesting a complex regulatory system. Previously, we reported culture medium-specific aerobic induction of the DevR regulon genes in avirulent M. tuberculosis H37Ra that was absent in the virulent H37Rv strain. To understand the underlying basis of this differential response, we have investigated aerobic expression of the Rv3134c-devR-devS operon using M. tuberculosis H37Ra and H37Rv devR overexpression strains, designated as LIX48 and LIX50, respectively. Overexpression of DevR led to the up-regulation of a large number of DevR regulon genes in aerobic cultures of LIX48, but not in LIX50. To ascertain the involvement of PhoP response regulator, also known to co-regulate a subset of DevR regulon genes, we complemented the naturally occurring mutant phoP(Ra) gene of LIX48 with the WT phoP(Rv) gene. PhoP(Rv) dampened the induced expression of the DevR regulon by >70-80%, implicating PhoP in the negative regulation of devR expression. Electrophoretic mobility shift assays confirmed phosphorylation-independent binding of PhoP(Rv) to the Rv3134c promoter and further revealed that DevR and PhoP(Rv) proteins exhibit differential DNA binding properties to the target DNA. Through co-incubations with DNA, ELISA, and protein complementation assays, we demonstrate that DevR forms a heterodimer with PhoP(Rv) but not with the mutant PhoP(Ra) protein. The study puts forward a new possible mechanism for coordinated expression of the dormancy regulon, having implications in growth adaptations critical for development of latency.
AD  - Univ Delhi, Sri Venkateswara Coll, Dept Biochem, New Delhi 110021, IndiaAD  - Arizona State Univ, Ctr Infect Dis & Vaccinol, Biodesign Inst, Tempe, AZ 85287 USAAD  - Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USAAD  - All India Inst Med Sci, Dept Biotechnol, New Delhi 110029, IndiaAD  - Univ Florida, Coll Med, Dept Med, Div Infect Dis & Global Med, Gainesville, FL 32610 USAC3  - University of DelhiC3  - Arizona State UniversityC3  - Arizona State University-TempeC3  - Arizona State UniversityC3  - Arizona State University-TempeC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - State University System of FloridaC3  - University of FloridaPU  - AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI  - BETHESDA
PA  - 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
DA  - OCT 19
PY  - 2018
VL  - 293
IS  - 42
SP  - 16413
EP  - 16425
DO  - 10.1074/jbc.RA118.004331
AN  - WOS:000447833600024
ER  -

TY  - JOUR
AU  - Batabyal, T
AU  - Muthukrishnan, SP
AU  - Sharma, R
AU  - Tayade, P
AU  - Kaur, S
TI  - Neural substrates of emotional interference: A quantitative EEG study
T2  - NEUROSCIENCE LETTERS
KW  - Cortical sources
KW  - Emotional interference
KW  - Frontoparietal attentional networks
KW  - Inhibition
KW  - Amygdala
KW  - ANTERIOR CINGULATE CORTEX
KW  - PREFRONTAL CORTEX
KW  - HUMAN BRAIN
KW  - AMYGDALA
KW  - FMRI
KW  - ATTENTION
KW  - CIRCUITRY
KW  - PATHWAYS
KW  - FEELINGS
KW  - STIMULI
AB  - Emotional stimuli are known to capture attention and disrupt the executive functioning. However, the dynamic interplay of neural substrates of emotion and executive attentional network is widely unexplored. The present study attempts to elucidate the areas implicated during emotional interference condition.
   Fifteen right handed individuals [24.64 +/- 2.63 years] performed two emotional interference tasks - Face Word Interference and Word Face Interference. Single trial EEG was recorded during baseline (eyes open) and during the tasks. The activity of the cortical sources was compared between the tasks and baseline for 66 gyri using sLORETA software.
   Eighteen gyri in Face Word Interference and fifty-four gyri in Word Face Interference have shown significantly decreased activity [p < 0.05/66] with respect to baseline respectively.
   Interestingly, in both the interference tasks, there was disengagement of fronto-parietal attentional networks (implicating the probable ability of emotional stimuli to disrupt cognition) and the areas associated with default mode network. Further, during baseline there was significant activity in premotor cortical areas, which may be due to active inhibition of motor movements associated with response.
AD  - All India Inst Med Sci, Dept Physiol, Stress & Cognit Electroimaging Lab, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER IRELAND LTD
PI  - CLARE
PA  - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
DA  - OCT 15
PY  - 2018
VL  - 685
SP  - 1
EP  - 6
DO  - 10.1016/j.neulet.2018.07.019
AN  - WOS:000449128900001
ER  -

TY  - JOUR
AU  - Paudel, YN
AU  - Shaikh, MF
AU  - Shah, S
AU  - Kumari, Y
AU  - Othman, I
TI  - Role of inflammation in epilepsy and neurobehavioral comorbidities: Implication for therapy
T2  - EUROPEAN JOURNAL OF PHARMACOLOGY
KW  - Inflammation
KW  - Epilepsy
KW  - Depression
KW  - Cognitive decline
KW  - Comorbidities
KW  - Anxiety
KW  - TEMPORAL-LOBE EPILEPSY
KW  - DEPRESSIVE-LIKE BEHAVIOR
KW  - MOBILITY GROUP BOX-1
KW  - COGNITIVE IMPAIRMENT
KW  - OXIDATIVE STRESS
KW  - INDOLEAMINE 2,3-DIOXYGENASE
KW  - MOUSE MODEL
KW  - HORMONAL-REGULATION
KW  - BRAIN INFLAMMATION
KW  - ANIMAL-MODEL
AB  - Epilepsy is a devastating condition affecting around 70 million people worldwide. Moreover, the quality of life of people with epilepsy (PWE) is worsened by a series of comorbidities. The neurobehavioral comorbidities discussed herein share a reciprocal and complex relationship with epilepsy, which ultimately complicates the treatment process in PWE. Understanding the mechanistic pathway by which these comorbidities are associated with epilepsy might be instrumental in developing therapeutic interventions. Inflammatory cytokine signaling in the brain regulates important brain functions including neurotransmitter metabolism, neuroendocrine function, synaptic plasticity, dopaminergic transmission, the kynurenine pathway, and affects neurogenesis as well as the neural circuitry of moods. In this review, we hypothesize that the complex relationship between epilepsy and its related comorbidities (cognitive impairment, depression, anxiety, autism, and schizophrenia) can be unraveled through the inflammatory mechanism that plays a prominent role in all these individual conditions. An ample amount of evidence is available reporting the role of inflammation in epilepsy and all individual comorbid condition but their complex relationship with epilepsy has not yet been explored through the prospective of inflammatory pathway. Our review suggests that epilepsy and its neurobehavioral comorbidities are associated with elevated levels of several key inflammatory markers. This review also sheds light on the mechanistic association between epilepsy and its neurobehavioral comorbidities. Moreover, we analyzed several anti-inflammatory therapies available for epilepsy and its neurobehavioral comorbidities. We suggest, these anti-inflammatory therapies might be a possible intervention and could be a promising strategy for preventing epileptogenesis and its related neurobehavioral comorbidities.
AD  - Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, Neuropharmacol Res Lab, Jalan Lagoon Selatan, Bandar Sunway, Selangor, MalaysiaAD  - All India Inst Med Sci, Dept Pharmacol, New Delhi, IndiaC3  - Monash UniversityC3  - Monash University MalaysiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - OCT 15
PY  - 2018
VL  - 837
SP  - 145
EP  - 155
DO  - 10.1016/j.ejphar.2018.08.020
AN  - WOS:000444963400017
ER  -

TY  - JOUR
AU  - Chowdhury, T
AU  - Zeiler, FA
AU  - Singh, GP
AU  - Hailu, A
AU  - Loewen, H
AU  - Schaller, B
AU  - Cappellani, RB
AU  - West, M
TI  - The Role of Intraoperative MRI in Awake Neurosurgical Procedures: A Systematic Review
T2  - FRONTIERS IN ONCOLOGY
KW  - intraoperative magnetic resonance imaging (iMRI)
KW  - awake craniotomies
KW  - outcome
KW  - complications
KW  - brain tumors
KW  - GLIOMA RESECTION
KW  - GENERAL-ANESTHESIA
KW  - SURGICAL RESECTION
KW  - SINGLE-CENTER
KW  - CRANIOTOMY
KW  - SURGERY
KW  - BRAIN
KW  - EXTENT
KW  - SURVIVAL
KW  - SAFETY
AB  - Background: Awake craniotomy for brain tumors remains an important tool in the arsenal of the treating neurosurgeon working in eloquent areas of the brain. Furthermore, with the implementation of intraoperative magnetic resonance imaging (I-MRI), one can afford the luxury of imaging to assess surgical resection of the underlying gross imaging defined neuropathology and the surrounding eloquent areas. Ideally, the combination of I-MRI and awake craniotomy could provide the maximal lesion resection with the least morbidity and mortality. However, more resection with the aid of real time imaging and awake craniotomy techniques might give opposite outcome results. The goal of this systematic review. is to identify the available literature on combined I-MRI and awake craniotomy techniques, to better understand the potential morbidity and mortality associated.
   Methods: MEDLINE, EMBASE, and CENTRAL were searched from inception up to December 2016. A total of 10 articles met inclusion in to the review, with a total of 324 adult patients.
   Results: All studies showed transient neurological deficits between 2.9 to 76.4%. In regards to persistent morbidity, the mean was similar to 10% (ranges from zero to 35.3%) with a follow up period between 5 days and 6 months.
   Conclusion: The preliminary results of this review also suggest this combined technique may impose acceptable post-operative complication profiles and morbidity. However, this is based on low quality evidence, and is therefore questionable. Further, well-designed future trials with the long-term follow-up are needed to provide various aspects of feasibility and outcome data for this approach.
AD  - Univ Manitoba, Dept Anesthesiol Perioperat & Pain Med, Winnipeg, MB, CanadaAD  - Univ Manitoba, Dept Surg, Sect Neurosurg, Winnipeg, MB, CanadaAD  - Univ Manitoba, Clincian Investigator Program, Winnipeg, MB, CanadaAD  - Univ Cambridge, Dept Med, Addenbrookes Hosp, Div Anaesthesia, Cambridge, EnglandAD  - All India Inst Med Sci, Neurosci Ctr, Dept Neuroanaesthesiol & Crit Care, New Delhi, IndiaAD  - Univ Manitoba, Max Rady Coll Med, Winnipeg, MB, CanadaAD  - Univ Manitoba, Neil John Maclean Hlth Sci Lib, Coll Rehabil Sci Librarian, Winnipeg, MB, CanadaAD  - Univ Zurich, Dept Primary Care, Zurich, SwitzerlandC3  - University of ManitobaC3  - University of ManitobaC3  - University of ManitobaC3  - Cambridge University Hospitals NHS Foundation TrustC3  - Addenbrooke's HospitalC3  - University of CambridgeC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of ManitobaC3  - University of ManitobaC3  - University of ZurichPU  - FRONTIERS MEDIA SA
PI  - LAUSANNE
PA  - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
DA  - OCT 10
PY  - 2018
VL  - 8
C7  - 434
DO  - 10.3389/fonc.2018.00434
AN  - WOS:000446861200001
ER  -

TY  - JOUR
AU  - Acharya, P
AU  - Kutum, R
AU  - Pandey, R
AU  - Mishra, A
AU  - Saha, R
AU  - Munjal, A
AU  - Ahuja, V
AU  - Mukerji, M
AU  - Makharia, GK
TI  - First Degree Relatives of Patients with Celiac Disease Harbour an Intestinal Transcriptomic Signature that Might Protect them from Enterocyte Damage
T2  - CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
KW  - NF-KAPPA-B
KW  - GENE-EXPRESSION
KW  - HOMEOSTASIS
KW  - PSEUDOGENES
KW  - MAINTENANCE
KW  - MODEL
AB  - Introduction: Celiac disease (CeD) is an autoimmune enteropathy which affects approximately 0.7% of the global population. While first-degree relatives (FDR) of patients with CeD have a 7.5% risk of developing enteropathy, many remain protected. Therefore, intestinal mucosa of FDR might have protective compensatory mechanisms against immunological injury. We have explored the protective mechanisms that may be active in intestinal mucosa of FDR.
   Methods: Intestinal mucosal biopsies (4-5 pieces) from treatment naive patients with CeD (n = 12), FDR (n = 12) (antitTG negative) and controls (n = 12) (anti-tTG negative) were obtained from each individual and subjected to microarray analysis using HT-12-v4 Human Expression BeadChips (Illumina). Differential gene expression analysis was carried out among CeD, FDR and controls; and resulting gene lists were analyzed using gene ontology and pathway enrichment tools.
   Results: Patients with CeD, FDR and control groups displayed significant differential gene expression. Thirty seven genes were upregulated and 372 were downregulated in the intestinal mucosa of FDR in comparison to CeD and controls. Pseudogenes constituted about 18% (315/1751) of FDR differentially expressed genes, and formed "clusters" that associated uniquely with individual study groups. The three study groups segregated into distinct clusters in unsupervised (PCA) and supervised (random forests) modelling approaches. Pathways analysis revealed an emphasis on crypt-villous maintenance and immune regulation in the intestinal mucosa of FDR.
   Conclusions: Our analysis suggests that the intestinal mucosa of celiac FDR consist of a unique molecular phenotype that is distinct from CeD and controls. The transcriptomic landscape of FDR promotes maintenance of crypt-villous axis and modulation of immune mechanisms. These differences clearly demonstrate the existence of compensatory protective mechanisms in the FDR intestinal mucosa.
AD  - All India Inst Med Sci, Dept Biochem, New Delhi, IndiaAD  - Inst Genom & Integrat Biol, Council Sci & Ind Res, Gen & Mol Med, New Delhi, IndiaAD  - Inst Genom & Integrat Biol, Council Sci & Ind Res, TRISUTRA Ayurgen Unit, CSIR, New Delhi, IndiaAD  - IGIB, Acad Sci & Innovat Res, CSIR, Delhi, IndiaAD  - All India Inst Med Sci, Dept Gastroenterol & Human Nutr, New Delhi 110029, IndiaAD  - MRC Harwell Inst, Mammalian Genet Unit, Harwell Sci & Innovat Campus, Didcot OX11 0RD, Oxon, EnglandC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Academy of Scientific & Innovative Research (AcSIR)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - MRC HarwellPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - OCT 8
PY  - 2018
VL  - 9
C7  - 195
DO  - 10.1038/s41424-018-0059-7
AN  - WOS:000447543900001
ER  -

TY  - JOUR
AU  - Goyal, K
AU  - Konar, A
AU  - Kumar, BSH
AU  - Koul, V
TI  - Lactoferrin-conjugated pH and redox-sensitive polymersomes based on PEG-S-S-PLA-PCL-OH boost delivery of bacosides to the brain
T2  - NANOSCALE
KW  - IRON-OXIDE NANOPARTICLES
KW  - SOLID LIPID NANOPARTICLES
KW  - BACOPA-MONNIERI EXTRACT
KW  - MRI CONTRAST AGENT
KW  - LONG-TERM-MEMORY
KW  - DRUG-DELIVERY
KW  - OXIDATIVE STRESS
KW  - NEURODEGENERATIVE DISEASES
KW  - STANDARDIZED EXTRACT
KW  - PLGA NANOPARTICLES
AB  - In the present study, engineered lactoferrin (Lf)-conjugated pH and redox-sensitive polymersomes derived from the triblock copolymer polyethylene glycol-S-S-polylactic acid-polycaprolactone (PEG-S-S-PLA-PCL-OH) have been used to deliver bacosides to the brain. Bacosides are classified as triterpenoid saponins and are used in Indian Ayurveda for reversal of amnesia; however, no study has extensively demonstrated their efficacy as a nano-formulation in an animal model. The polymer was synthesized by ring opening polymerization of lactide and epsilon-caprolactone. The nanoparticles obtained by nanoprecipitation showed a core-shell morphology, with an average size of 110 nm, by transmission electron microscopy (TEM). The colloidal stability, hemocompatibility and cytocompatibility of the polymersomes proved their biocompatibility. pH and disulfide linkages in the polymeric chain accelerated the disintegration of the polymersomes at pH 6.6 and at pH 6.6 with glutathione (GSH) in comparison to pH 7.4, supporting their degradation behavior. Supermagnetic iron oxide nanoparticles (SPIONs, 74.99 mu g mg(-1) polymer) encapsulated into the polymersomes demonstrated their uptake in a mouse model by MRI. Furthermore, bacosides encapsulated in the polymersomes (10% loading) showed significant memory loss reversal in chemically induced amnesic mice, supported by the gene expression profiles of Arc, BDNF and CREB as well as by histopathology.
AD  - Indian Inst Technol Delhi, Ctr Biomed Engn, New Delhi, IndiaAD  - Inst Genom & Integrat Biol, New Delhi, IndiaAD  - Inst Nucl Med & Allied Sci INMAS, NMR Res Ctr, New Delhi, IndiaAD  - All India Inst Med Sci, Biomed Engn Unit, New Delhi, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Defence Research & Development Organisation (DRDO)C3  - Institute of Nuclear Medicine & Allied Sciences (INMAS)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ROYAL SOC CHEMISTRY
PI  - CAMBRIDGE
PA  - THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND
DA  - OCT 7
PY  - 2018
VL  - 10
IS  - 37
SP  - 17781
EP  - 17798
DO  - 10.1039/c8nr03828g
AN  - WOS:000450934400037
ER  -

TY  - JOUR
AU  - Jain, S
AU  - Mahapatra, SJ
AU  - Gupta, S
AU  - Shalimar
AU  - Garg, PK
TI  - Infected Pancreatic Necrosis due to Multidrug-Resistant Organisms and Persistent Organ failure Predict Mortality in Acute Pancreatitis
T2  - CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
KW  - CONSERVATIVE TREATMENT
KW  - NECROSECTOMY
KW  - DETERMINANTS
KW  - GUIDELINES
KW  - EXTENT
KW  - SCORE
AB  - Background: Organ failure determines outcome in acute pancreatitis (AP). It is controversial if infected pancreatic necrosis (IPN) is also an independent determinant of mortality. We hypothesized that the predictors of mortality in AP might have changed with advances in management and consequent decline in mortality over the past decades. Our objective was to study the predictors of mortality in patients with AP.
   Methods: Consecutive patients with a first episode of AP hospitalized from January 2015 to December 2016 were included in an observational study. Patients with IPN were treated with a conservative first approach followed by intervention. Necrosectomy, if required, was delayed beyond 4 weeks and done primarily employing minimally invasive techniques. The primary outcome measure was independent predictors of in-hospital mortality.
   Results: Of 209 patients with AP, 81 (39%) had persistent organ failure (OF) and 108 (52%) developed IPN. Overall, 46/209 (22%) patients died. Independent predictors of mortality were OF (odds ratio [OR] 19; 95% CI: 6.1-58.8), and IPN due to infection with multidrug resistant (MDR) organisms (OR: 8.4; 95% CI: 3.1-22.5). Infected pancreatic necrosis by itself was not found to be a significant predictor of mortality (OR 2; 95% CI: 0.4-9.5).
   Conclusion: Persistent OF and complicated IPN due to MDR infection were independent predictors of mortality in patients with AP. Renewed efforts to prevent MDR infection with antibiotic stewardship and strategies for early control of sepsis are urgently required.
AD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - OCT 5
PY  - 2018
VL  - 9
C7  - 190
DO  - 10.1038/s41424-018-0056-x
AN  - WOS:000447542700001
ER  -

TY  - JOUR
AU  - Sharma, V
TI  - Respect and trust
T2  - SCIENCE
AD  - All India Inst Med Sci, Dept Hematol, Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ASSOC ADVANCEMENT SCIENCE
PI  - WASHINGTON
PA  - 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
DA  - OCT 5
PY  - 2018
VL  - 362
IS  - 6410
SP  - 24
EP  - 24
AN  - WOS:000446547100070
ER  -

TY  - JOUR
AU  - Dutta, S
AU  - Jain, K
AU  - Siddharth, V
TI  - Retrofitting Healthcare Facilities for Bariatric Patients: A Cost Analysis Study in a Public Sector Hospital of a Developing Country
T2  - BARIATRIC SURGICAL PRACTICE AND PATIENT CARE
KW  - bariatric facility
KW  - cost analysis
KW  - traditional method of costing
KW  - OBESITY
KW  - LENGTH
KW  - STAY
AB  - Background: The rising trend of obesity and morbid obesity around the world emphasizes the need for designing healthcare facilities that fit the needs of these patients. Keeping in view the safety of morbidly obese patients and also the staff handling them, it was thought pertinent to study and analyze the structural, manpower, and financial aspects that need consideration while planning a bariatric facility.
   Materials and Methods: This study was carried out in an apex tertiary care hospital in India through review of literature and in-depth interviews of stakeholders providing care and facilities as well as from the market to determine the spacing needs and cost of retrofitting a 10-bedded bariatric facility in an existing hospital. Traditional method of cost analysis was used to arrive at the cost estimates for the financial year 2016-2017.
   Results: An estimated cost of U.S. $39,139 (INR 2,616,500) per bed has been projected in retrofitting the setting of this study with a 10-bedded bariatric facility with an existing manpower pool for the same. For a retrofitting facility requiring additional manpower, an estimated cost of U.S. $90,496 (INR 6,049,700) per bed has been projected in this study setting.
   Conclusion: Given the growth of bariatric population both worldwide and in India, it is need of the hour to consider retrofitting existing healthcare facilities for bariatric patients. Although hospitals would incur an initial cost in such retro-fittings, in the long run, they would overrun their value in terms of patient needs and satisfaction, which indeed is the ultimate goal in healthcare.
AD  - Agartala Govt Med Coll, Agartala, Tripura, IndiaAD  - All India Inst Med Sci, Hosp Adm, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MARY ANN LIEBERT, INC
PI  - NEW ROCHELLE
PA  - 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
DA  - DEC 1
PY  - 2018
VL  - 13
IS  - 4
SP  - 185
EP  - 189
DO  - 10.1089/bari.2018.0032
C6  - OCT 2018
AN  - WOS:000446271500001
ER  -

TY  - JOUR
AU  - Li, ZX
AU  - Pandian, J
AU  - Sylaja, PN
AU  - Wang, YL
AU  - Zhao, XQ
AU  - Liu, LP
AU  - Wang, CJ
AU  - Khurana, D
AU  - Srivastava, MVP
AU  - Kaul, S
AU  - Arora, D
AU  - Schwamm, LH
AU  - Wang, YJ
AU  - Singhal, AB
TI  - Quality of care for ischemic stroke in China vs India Findings from national clinical registries
T2  - NEUROLOGY
KW  - RISK-FACTORS
KW  - GLOBAL BURDEN
KW  - GUIDELINES
KW  - COUNTRIES
KW  - MORTALITY
KW  - DISEASE
AB  - Objective
   To understand stroke risk factors, status of stroke care, and opportunities for improvement as China and India develop national strategies to address their disproportionate and growing burden of stroke.
   Methods
   We compared stroke risk factors, acute management, adherence to quality performance measures, and clinical outcomes among hospitalized ischemic stroke patients using data from the Indo-US Collaborative Stroke Project (IUCSP) and China National Stroke Registry-II (CNSR-II). The IUCSP included 5 academic stroke centers from different geographic regions (n = 2,066). For comparison, the CNSR-II dataset was restricted to 31 academic hospitals among 219 participating sites from 31 provinces (n = 1,973).
   Results
   Indian patients were significantly younger, had health insurance less often, and had significantly different risk factors (more often diabetes mellitus, dyslipidemia, and coronary heart disease; less often prior stroke, hypertension, atrial fibrillation, and smoking). Hospitalized Indian patients had greater stroke severity (median NIH Stroke Scale score 10 vs 4), higher rates of IV thrombolysis within 3 hours (7.5% vs 2.4%), greater in-hospital mortality (7.9% vs 1.2%), and worse outcome (3-month modified Rankin Scale score 0-2, 49.3% vs 78.1%) (all p < 0.001). The poorer clinical outcomes were attributable mainly to greater stroke severity in IUCSP patients. Chinese patients more often received antithrombotics, stroke education, and dysphagia screening during hospitalization.
   Conclusion
   These data provide insights into the status of ischemic stroke care in academic urban centers within 2 large Asian countries. Further research is needed to determine whether these patterns are representative of care across the countries, to explain differences in observed severity, and to drive improvements.
AD  - Capital Med Univ, Beijing TianTan Hosp, Vasc Neurol, Beijing, Peoples R ChinaAD  - Capital Med Univ, Beijing TianTan Hosp, Tiantan Clin Trial & Res Ctr Stroke, Beijing, Peoples R ChinaAD  - Capital Med Univ, Beijing TianTan Hosp, Dept Neurol, Neurointens Care Unit, Beijing, Peoples R ChinaAD  - China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R ChinaAD  - Christian Med Coll & Hosp, Dept Neurol, Ludhiana, Punjab, IndiaAD  - SreeChitra Tirunal Inst Med Sci & Technol, Dept Neurol, Trivandrum, Kerala, IndiaAD  - Beijing Inst Brain Disorders, Ctr Stroke, Beijing, Peoples R ChinaAD  - Postgrad Inst Med Educ & Res, Dept Neurol, Chandigarh, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaAD  - Nizams Inst Med Sci, Dept Neurol, Hyderabad, IndiaAD  - Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USAC3  - Capital Medical UniversityC3  - Capital Medical UniversityC3  - Capital Medical UniversityC3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Nizam's Institute of Medical SciencesC3  - Harvard UniversityC3  - Massachusetts General HospitalPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - OCT 2
PY  - 2018
VL  - 91
IS  - 14
SP  - E1348
EP  - E1354
DO  - 10.1212/WNL.0000000000006291
AN  - WOS:000452498100009
ER  -

TY  - JOUR
AU  - Agarwal, N
AU  - Agrawal, M
AU  - Sawarkar, DP
TI  - Ligamentum nuchae as a graft material for duraplasty in patients with Chiari malformation type I
T2  - JOURNAL OF NEUROSURGERY-PEDIATRICS
KW  - DECOMPRESSION
KW  - PERICRANIUM
KW  - SURGERY
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ASSOC NEUROLOGICAL SURGEONS
PI  - ROLLING MEADOWS
PA  - 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
DA  - OCT
PY  - 2018
VL  - 22
IS  - 4
SP  - 463
EP  - 464
DO  - 10.3171/2018.4.PEDS18301
AN  - WOS:000446245200022
ER  -

TY  - JOUR
AU  - Agrawal, K
AU  - Majhi, S
AU  - Gupta, N
AU  - Garg, R
TI  - Iatrogenic alkalosis during high-dose methotrexate therapy: An avertable cause
T2  - INDIAN JOURNAL OF CANCER
AD  - AIIMS, Dr BRA IRCH, Dept Oncoanaesthesia & Palliat Care, New Delhi, IndiaAD  - Max Super Special Hosp, Dept Anaesthesiol, Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - OCT-DEC
PY  - 2018
VL  - 55
IS  - 4
SP  - 423
EP  - 423
DO  - 10.4103/ijc.IJC_92_18
AN  - WOS:000460297000025
ER  -

TY  - JOUR
AU  - Anang, S
AU  - Kaushik, N
AU  - Hingane, S
AU  - Kumari, A
AU  - Gupta, J
AU  - Asthana, S
AU  - Shalimar
AU  - Nayak, B
AU  - Ranjith-Kumar, CT
AU  - Surjit, M
TI  - Potent Inhibition of Hepatitis E Virus Release by a Cyclic Peptide Inhibitor of the Interaction between Viral Open Reading Frame 3 Protein and Host Tumor Susceptibility Gene 101
T2  - JOURNAL OF VIROLOGY
KW  - HEV release
KW  - hepatitis E virus
KW  - cyclic peptide inhibitor
KW  - ORGAN-TRANSPLANT RECIPIENTS
KW  - PEGYLATED INTERFERON-ALPHA
KW  - CULTURED-CELLS
KW  - INFECTION
KW  - RIBAVIRIN
KW  - TSG101
KW  - DOMAIN
KW  - REPLICATION
KW  - SOFOSBUVIR
KW  - THERAPY
AB  - Hepatitis E virus (HEV) generally causes self-limiting acute viral hepatitis in normal individuals. It causes a more severe disease in immunocompromised persons and pregnant women. Due to the lack of an efficient cell culture system or animal model, the life cycle of the virus is understudied, few antiviral targets are known, and very few antiviral candidates against HEV infection have been identified. Inhibition of virus release is one possible antiviral development strategy, which limits the spread of the virus. Previous studies have demonstrated the essential role of the interaction between the PSAP motif of the viral open reading frame 3 protein (ORF3-PSAP) and the UEV domain of the host tumor susceptibility gene 101 (TSG101) protein (UEV-TSG101) in mediating the release of genotype 3 HEV. Cyclic peptide (CP) inhibitors of the interaction between the human immunodeficiency virus (HIV) gag-PTAP motif and UEV-TSG101 are known to block the release of HIV. Using a molecular dynamic simulation, we observed that both gag-PTAP and ORF3-PSAP motifs bind to the same site in UEV-TSG101 by hydrogen bonding. HIV-released inhibitory CPs also displayed binding to the same site in UEV-TSG101, indicating that they may compete with ORF3-PSAP or gag-PTAP for binding to UEV-TSG101. Two independent assays confirmed the ability of a cyclic peptide (CP11) to inhibit the ORF3-TSG101 interaction. CP11 treatment also reduced the release of both genotype 1 and genotype 3 HEV by approximately 90%, with a 50% inhibitory concentration (IC) of 2/AM. Thus, CP11 appears to be an attractive candidate for further validation of its anti-HEV properties.
   IMPORTANCE There is no specific therapy against hepatitis E virus (HEV)-induced hepatic and nonhepatic health problems. Prevention of the release of the progeny viruses from infected cells is an attractive strategy to limit the spread of the virus. Interactions between the viral open reading frame 3 and the host tumor susceptibility gene 101 proteins have been shown to be essential for the release of genotype 3 HEV from infected cells. In this study, we have identified a cyclic peptide inhibitor of the above-mentioned interaction and demonstrate the efficiency of the inhibitor in preventing virus release from infected cells. Thus, our findings uncover the possibility of developing a specific antiviral agent against HEV by blocking its release from infected cells.
AD  - Translat Hlth Sci & Technol Inst, Virol Lab, Vaccine & Infect Dis Res Ctr, NCR Biotech Sci Cluster, Faridabad, Haryana, IndiaAD  - Translat Hlth Sci & Technol Inst, Drug Discovery Res Ctr, NCR Biotech Sci Cluster, Faridabad, Haryana, IndiaAD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaAD  - Guru Gobind Singh Indraprastha Univ, Univ Sch Biotechnol, New Delhi, IndiaC3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)C3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - GGS Indraprastha UniversityPU  - AMER SOC MICROBIOLOGY
PI  - WASHINGTON
PA  - 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
DA  - OCT
PY  - 2018
VL  - 92
IS  - 20
C7  - e00684-18
DO  - 10.1128/JVI.00684-18
AN  - WOS:000445668400006
ER  -

TY  - JOUR
AU  - Aron, N
AU  - Sinha, R
AU  - Sharma, N
AU  - Agarwal, T
TI  - Isoexpansile sulfur hexafluoride gas to repair near-total iris disinsertion
T2  - JOURNAL OF CATARACT AND REFRACTIVE SURGERY
KW  - INTRAOCULAR-LENS IMPLANTATION
KW  - DESCEMETS-MEMBRANE DETACHMENT
KW  - IRIDODIALYSIS REPAIR
KW  - SUBTOTAL IRIDODIALYSIS
KW  - TRAUMATIC ANIRIDIA
KW  - CATARACT-SURGERY
KW  - MANAGEMENT
KW  - COMPLICATIONS
KW  - DEFECTS
KW  - SUTURE
AB  - Iridodialysis is commonly encountered after blunt trauma to the eye. Most iris detachments are small, superior, and asymptomatic and require no surgical intervention. However, large areas of iridodialysis require early surgical repair to prevent the onset of iris necrosis, pigment dispersion, and secondary glaucoma. Suture fixation of iris to the sclera is the most commonly used method for iris repair; however, this technique becomes difficult in cases of near-total iris disinsertion, even in expert hands. We describe a case of posttraumatic near-total iris disinsertion with subluxated cataract managed with phacoemulsification and iris preservation with the help of intracameral injection of isoexpansile sulfur hexafluoride. (C) 2018 ASCRS and ESCRS
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Cornea Cataract & Refract Surg Serv, Room 476, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - OCT
PY  - 2018
VL  - 44
IS  - 10
SP  - 1175
EP  - 1178
DO  - 10.1016/j.jcrs.2018.06.024
AN  - WOS:000446646200003
ER  -

TY  - JOUR
AU  - Arora, K
AU  - Thukral, A
AU  - Sankar, MJ
AU  - Gulati, S
AU  - Deorari, AK
AU  - Paul, VK
AU  - Agarwal, R
TI  - Postnatal Maturation of Amplitude Integrated Electroencephalography (aEEG) in Preterm Small for Gestational Age Neonates
T2  - INDIAN PEDIATRICS
KW  - Electrophysiology
KW  - Neuronal maturation
KW  - Outcome
KW  - CEREBRAL FUNCTION MONITOR
KW  - PREMATURE-INFANTS
KW  - BRAIN-FUNCTION
KW  - TERM
KW  - EEG
KW  - BORN
KW  - BIRTH
KW  - MIDAZOLAM
AB  - ObjectiveThe primary objective was to evaluate the postnatal maturation pattern on aEEG during first two weeks of life in clinically stable and neurologically normal preterm small for gestational age (PSGA) and gestation matched (1 week) preterm appropriate for gestational age (PAGA) neonates born between 30(0/7) and 34(6/7) weeks of gestation.MethodsSerial aEEG tracings were recorded on 3rd, 7th and 14th day of life. The primary outcome was total aEEG maturation score. Three blinded assessors assigned the scores.ResultsWe analyzed a total of 117 aEEG recordings in 40 (19 PSGA and 21 PAGA) neonates. The baseline characteristics were comparable except for birthweight [1186 (263) vs 1666 (230) g]. There was no difference in the mean (SD) total scores on day 3 (9.0 (1.8) vs. 9.5 (1.1), P=0.32) and day 14 of life, but was lower in PSGA infants on day 7 (8.6 (2.4) vs. 10.1 (1.1), P=0.02). On multivariate analysis, maturation of PSGA neonates was found to be significantly delayed at any point of life from day 3 to day 14 (mean difference, -0.8, 95 % CI: -1.6 to -0.02, P=0.04).ConclusionLower aEEG maturation score on day 7 possibly indicates delayed maturation in PSGA neonates in the first week of life.
AD  - All India Inst Med Sci, WHO Collaborating Ctr Training & Res Neonatal Car, Dept Pediat, Newborn Hlth Knowledge Ctr, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - OCT
PY  - 2018
VL  - 55
IS  - 10
SP  - 865
EP  - 870
DO  - 10.1007/s13312-018-1396-z
AN  - WOS:000447807900005
ER  -

TY  - JOUR
AU  - Aslam, MKM
AU  - Sharma, VK
AU  - Pandey, S
AU  - Kumaresan, A
AU  - Srinivasan, A
AU  - Datta, TK
AU  - Mohanty, TK
AU  - Yadav, S
TI  - Identification of biomarker candidates for fertility in spermatozoa of crossbred bulls through comparative proteomics
T2  - THERIOGENOLOGY
KW  - Infertility
KW  - Crossbred bulls
KW  - 2D-DIGE
KW  - Sperm proteomics
KW  - Fertility biomarkers
KW  - BETA-GALACTOSIDASE
KW  - SEMINAL PLASMA
KW  - SPERM
KW  - PROTEINS
KW  - CAPACITATION
KW  - SUBFERTILITY
KW  - INFERTILITY
KW  - PDC-109
KW  - BINDING
KW  - ENZYME
AB  - Associations between expression of some proteins in spermatozoa and fertility have been sought in recent years to identify the male fertility markers. Since the incidence of sub-fertility is high in crossbred bulls, the present investigation was carried out on high- and low-fertile crossbred bulls to identify fertility markers in spermatozoa through proteomics approach. Sperm proteome of high-fertile bulls were compared with low-fertile bulls using 2D-DIGE and MALDI-TOF-MS techniques and the results were validated with immuno-blotting. The proteins MDH2, ENO1, RIBCI, CAPN7, ATP5D, LacA like protein-2 like, NCAPD3, DECRI, GCNT2, GDI2, TOP and USP12 were over expressed in high-fertile spermatozoa, whereas DST like isoform 1, TMEM43 and BSPI were over expressed in low-fertile spermatozoa (P < 0.05). The differential expression ranged from 1.57 (GDI2) to 5.1 (BSP1) fold between the two groups. Based on the GO annotation, majority of them were involved in cellular and metabolic processes, with catalytic and binding activities, and localized in cell and organelles. Among these proteins, ENO1 and BSPI were selected based on the degree of differential expression and reliability in identification, for further validation. Immuno-blotting studies indicated that ENO1 expression was positively correlated (P < 0.05) while the expression of BSPI was negatively (P < 0.01) correlated with bull fertility. The proportion of capacitated spermatozoa in frozen thawed spermatozoa of low-fertile bulls was higher (P < 0.05) as compared to high-fertile bulls. Collectively, the study identified some potential molecules in spermatozoa of bulls, which may act as a panel of biomarkers for fertility. (C) 2018 Elsevier Inc. All rights reserved.
AD  - Natl Dairy Res Inst, Theriogenol Lab, Anim Reprod Gynecol & Obstet, Karnal 132001, Haryana, IndiaAD  - All India Inst Med Sci, Dept Biophys, New Delhi 110029, IndiaAD  - Natl Dairy Res Inst, Anim Biotechnol Ctr, Karnal 132001, Haryana, IndiaAD  - Natl Dairy Res Inst, Artificial Breeding Res Ctr, Karnal, Haryana, IndiaC3  - Indian Council of Agricultural Research (ICAR)C3  - ICAR - National Dairy Research InstituteC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Council of Agricultural Research (ICAR)C3  - ICAR - National Dairy Research InstituteC3  - Indian Council of Agricultural Research (ICAR)C3  - ICAR - National Dairy Research InstitutePU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - OCT 1
PY  - 2018
VL  - 119
SP  - 43
EP  - 51
DO  - 10.1016/j.theriogenology.2018.06.021
AN  - WOS:000443530200006
ER  -

TY  - JOUR
AU  - Berek, JS
AU  - Kehoe, ST
AU  - Kumar, L
AU  - Friedlander, M
TI  - Cancer of the ovary, fallopian tube, and peritoneum
T2  - INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
KW  - Cancer staging
KW  - Chemotherapy
KW  - Fallopian tube
KW  - FIGO Cancer Report
KW  - Ovarian
KW  - Ovary
KW  - Peritoneum
KW  - GERM-CELL TUMORS
KW  - PHASE-III TRIAL
KW  - PEGYLATED LIPOSOMAL DOXORUBICIN
KW  - RECURRENT EPITHELIAL OVARIAN
KW  - GRADE SEROUS CARCINOMA
KW  - SECONDARY CYTOREDUCTIVE SURGERY
KW  - OLAPARIB MAINTENANCE THERAPY
KW  - CARBOPLATIN PLUS PACLITAXEL
KW  - GYNECOLOGIC-ONCOLOGY-GROUP
KW  - TERM-FOLLOW-UP
AB  - The Gynecologic Oncology Committee of FIGO in 2014 revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSC). Stage IC is now divided into three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface); and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis <= 10 mm in greatest dimension), and IIIA1(ii) (metastasis >10 mm in greatest dimension). Stage IIIA2 is now microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, and the treatment of ovarian germ cell and stromal malignancies.
AD  - Stanford Univ, Sch Med, Stanford Canc Inst, Stanford Womens Canc Ctr, Stanford, CA 94305 USAAD  - Univ Birmingham, Inst Canc & Genom, Birmingham, W Midlands, EnglandAD  - All India Inst Med Sci, Dept Med Oncol, New Delhi, IndiaAD  - Royal Hosp Women, Sydney, NSW, AustraliaAD  - Univ New South Wales, Clin Sch, Sydney, NSW, AustraliaC3  - Stanford Cancer InstituteC3  - Stanford UniversityC3  - University of BirminghamC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - NSW HealthC3  - South Eastern Sydney Local Health DistrictC3  - The Royal Hospital for WomenC3  - University of New South Wales SydneyPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - OCT
PY  - 2018
VL  - 143
SP  - 59
EP  - 78
DO  - 10.1002/ijgo.12614
AN  - WOS:000446989500008
ER  -

TY  - JOUR
AU  - Bhadu, D
AU  - Das, SK
AU  - Wakhlu, A
AU  - Dhakad, U
TI  - Articular cartilage of knee and first MTP joint are the preferred sites to find double contour sign as an evidence of urate crystal deposition in asymptomatic hyperuricemic individuals
T2  - ACTA REUMATOLOGICA PORTUGUESA
KW  - Musculoskeletal ultrasonography
KW  - Asymptomatic hyperuricemia
KW  - GOUT
KW  - DIAGNOSIS
AB  - Background/Objective: A cross-sectional study to determine the preferred sites of urate crystal deposition in asymptomatic hyperuricemic individuals by ultrasound.
   Methods: In two years period, twenty-four asymptomatic hyperuricemic individuals (serum uric acid >= 7mg/d1) and fifty controls (serum uric acid <7mg/dl) aged more than 18 years were included in this study. Double contour sign was examined at three articular cartilage sites (first metatarsophalangeal, tibiotalar and femoral condyle) whereas hyperechoic aggregates were looked for at one joint site (radiocarpal joint) and two tendon sites (patellar tendon and triceps tendon). The Chi-square test was used to compare the categorical variables and discrete variables were compared by one-way analysis of variance. The p-value<0.05 was considered significant.
   Results: Eight out of 24 asymptomatic hyperuricemic individuals had ultrasound evidence of urate crystal deposition in first metatarsophalangeal joint area followed by knee joint area which was detected in 6 patients. The detection rate of ultrasound abnormalities in asymptomatic hyperuricemic individuals was 45.8% with two joint area (knee and first metatarsophalangeal) and 50% with six sites assessment. Amongst controls, 16% were found to have these abnormal ultrasound findings.
   Conclusion: The highest predilection of urate crystal deposition in asymptomatic hyperuricemic individuals is the articular cartilage of the first metatarsophalangeal and knee joints. This might explain the frequent clinical presentation of arthritis in these joint areas.
AD  - All India Inst Med Sci, Rheumatol, New Delhi, IndiaAD  - King George Med Univ, Rheumatol, Lucknow, Uttar Pradesh, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - King George's Medical UniversityPU  - PUBLISAUDE-EDICOES MEDICAS LDA
PI  - ALGES
PA  - ALAMEDA ANTONIO SERGIO 22, 4 B EDIF AMADEO SOUZA-CARDOSO, ALGES, 1495-132, PORTUGAL
DA  - OCT-DEC
PY  - 2018
VL  - 43
IS  - 4
SP  - 264
EP  - 268
AN  - WOS:000454629200003
ER  -

TY  - JOUR
AU  - Bhatia, D
AU  - Sinha, A
AU  - Hari, P
AU  - Sopory, S
AU  - Saini, S
AU  - Puraswani, M
AU  - Saini, H
AU  - Mitra, DK
AU  - Bagga, A
TI  - Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome
T2  - PEDIATRIC RESEARCH
KW  - ANTI-CD20 ANTIBODY
KW  - TH17 CELLS
KW  - CHILDREN
KW  - RECONSTITUTION
KW  - MULTICENTER
KW  - ACTIVATION
KW  - EXPRESSION
KW  - RESISTANT
KW  - EFFICACY
KW  - SAFETY
AB  - BACKGROUND: Rituximab, a monoclonal antibody targeting B lymphocytes, effectively sustains remission in steroid-dependent nephrotic syndrome (SDNS). We studied its effects on lymphocyte subsets and urinary CD80 excretion (uCD80) in patients with SDNS.
   METHODS: Blood and urine samples were collected from 18 SDNS patients before rituximab, and after 1 month and 1 year or at first relapse. T and B lymphocytes and uCD80 were determined by flow cytometry and ELISA, respectively.
   RESULTS: Treatment was associated with reduction in counts of Th17, Th2, and memory T cells, and increased T-regulatory (Treg) cells. The Th17/Treg ratio declined from baseline (median 0.6) to 1 month (0.2, P= 0.006) and increased during relapse (0.3, P= 0.016). Ratios of Th1/Th2 cells at baseline, 1 month after rituximab, and during relapse were 7.7, 14.0 (P= 0.0102), and 8.7, respectively. uCD80 decreased 1 month following rituximab (45.5 vs. 23.0 ng/g creatinine; P= 0.0039). B lymphocytes recovered earlier in relapsers (60.0 vs.183.0 days; P< 0.001). Memory B cells were higher during relapse than remission (29.7 vs.18.0 cells/mu L; P = 0.029).
   CONCLUSION: Rituximab-induced sustained remission and B-cell depletion was associated with reduced numbers of Th17 and Th2 lymphocytes, and increased Treg cells; these changes reversed during relapses. Recovery of B cells and memory B cells predicted the occurrence of a relapse.
AD  - All India Inst Med Sci, Dept Pediat, Div Nephrol, New Delhi, IndiaAD  - Translat Hlth Sci & Technol Inst, Pediat Biol Ctr, Faridabad, IndiaAD  - All India Inst Med Sci, Dept Transplant Immunol & Immunogenet, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - NATURE PUBLISHING GROUP
PI  - NEW YORK
PA  - 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
DA  - OCT
PY  - 2018
VL  - 84
IS  - 4
SP  - 520
EP  - 526
DO  - 10.1038/s41390-018-0088-7
AN  - WOS:000451811200014
ER  -

TY  - JOUR
AU  - Bhatla, N
AU  - Denny, L
TI  - FIGO Cancer Report 2018
T2  - INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
AD  - All India Inst Med Sci, New Delhi, IndiaAD  - Univ Cape Town, Groote Schuur Hosp, Cape Town, South AfricaAD  - Univ Cape Town, Gynaecol Canc Res Ctr, South African Med Res Council, SA MRC UCT GCRC, Cape Town, South AfricaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of Cape TownC3  - University of Cape TownC3  - South African Medical Research CouncilPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - OCT
PY  - 2018
VL  - 143
SP  - 2
EP  - 3
DO  - 10.1002/ijgo.12608
AN  - WOS:000446989500002
ER  -

TY  - JOUR
AU  - Bhatla, N
AU  - Aoki, D
AU  - Sharma, DN
AU  - Sankaranarayanan, R
TI  - Cancer of the cervix uteri
T2  - INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
KW  - Cervix
KW  - FIGO Cancer Report
KW  - Gynecologic cancer
KW  - HPV vaccination
KW  - Radiation
KW  - Screening
KW  - Staging
KW  - Surgery
KW  - GYNECOLOGIC-ONCOLOGY-GROUP
KW  - POSITRON-EMISSION-TOMOGRAPHY
KW  - SQUAMOUS-CELL CARCINOMA
KW  - OF-THE-LITERATURE
KW  - SENTINEL NODE IDENTIFICATION
KW  - PELVIC RADIATION-THERAPY
KW  - INDIVIDUAL PATIENT DATA
KW  - PARAAORTIC LYMPH-NODES
KW  - III RANDOMIZED-TRIAL
KW  - HIGH-DOSE-RATE
AB  - Since the publication of the last FIGO Cancer Report there have been giant strides in the global effort to reduce the burden of cervical cancer, with WHO announcing a call for elimination. In over 80 countries, including LMICs, HPV vaccination is now included in the national program. Screening has also seen major advances with implementation of HPV testing on a larger scale. However, these interventions will take a few years to show their impact. Meanwhile, over half a million new cases are added each year. Recent developments in imaging and increased use of minimally invasive surgery have changed the paradigm for management of these cases. The FIGO Gynecologic Oncology Committee has revised the staging system based on these advances. This chapter discusses the management of cervical cancer based on the stage of disease, including attention to palliation and quality of life issues.
AD  - All India Inst Med Sci, Dept Obstet & Gynecol, New Delhi, IndiaAD  - Keio Univ, Dept Obstet & Gynecol, Sch Med, Tokyo, JapanAD  - All India Inst Med Sci, Dept Radiat Oncol, New Delhi, IndiaAD  - Int Agcy Res Canc, Early Detect & Prevent Grp, Lyon, FranceC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Keio UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - World Health OrganizationC3  - International Agency for Research on Cancer (IARC)PU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - OCT
PY  - 2018
VL  - 143
SP  - 22
EP  - 36
DO  - 10.1002/ijgo.12611
AN  - WOS:000446989500005
ER  -

TY  - JOUR
AU  - Cathcart, AL
AU  - Chan, HLY
AU  - Bhardwaj, N
AU  - Liu, Y
AU  - Marcellin, P
AU  - Pan, CQ
AU  - Shalimar
AU  - Buti, M
AU  - Cox, S
AU  - Parhy, B
AU  - Zhou, E
AU  - Martin, R
AU  - Chang, S
AU  - Lin, LJ
AU  - Flaherty, JF
AU  - Kitrinos, KM
AU  - Gaggar, A
AU  - Izumi, N
AU  - Lim, YS
TI  - No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection
T2  - ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
KW  - tenofovir
KW  - hepatitis B virus
KW  - resistance
KW  - tenofovir alafenamide
KW  - antiviral agents
KW  - NUCLEOSIDE-NAIVE PATIENTS
KW  - LONG-TERM EFFICACY
KW  - DISOPROXIL FUMARATE
KW  - ADEFOVIR DIPIVOXIL
KW  - DOUBLE-BLIND
KW  - VIRUS POLYMERASE
KW  - LAMIVUDINE
KW  - THERAPY
KW  - EMTRICITABINE
KW  - REPLICATION
AB  - Tenofovir alafenamide (TAF) has shown equivalent efficacy and improved safety profiles for patients with chronic hepatitis B (CHB) compared to tenofovir disoproxil fumarate (TDF). However, limited data are available for its resistance profiles. In two clinical trials, 1,298 hepatitis E antigen-positive and -negative patients with CHB were randomized 2:1 and treated with TAF (n = 866) or TDF (n = 432). Baseline nucleos( t)ide analog resistance substitutions in HBV polymerase/reverse transcriptase (Pol/RT) were assessed using INNO-LiPA Multi-DR v2/v3. Resistance surveillance was conducted for patients with viremia (HBV DNA >= 69IU/ml) by HBV Pol/RT sequencing at week 96 or at discontinuation. In vitro phenotypic analysis was performed for patients with conserved site substitutions or virologic breakthrough while adherent to the study drug. At baseline, the majority of patients harbored virus with wild-type Pol/RT (89.2%), with 10.8% harboring resistance associated mutations. A similar percentage of patients in the TAF or TDF groups qualified for sequence analysis through week 96 (TAF, 11.1%; TDF, 10.9%). Of these, a small percentage of patients experienced virologic breakthrough (TAF, 2.8%; TDF, 3.2%) that was often associated with drug nonadherence (TAF, 30%; TDF, 50%). Across treatment groups, 132 patients qualified for sequence analysis through week 96, with nearly half having no sequence changes from baseline (43.2%). Most sequence changes occurred at polymorphic positions, and no isolates showed a reduction in susceptibility in vitro. After 96 weeks, the proportion of patients achieving virus suppression (HBV DNA , 69 IU/ml) was similar across treatment groups, and no substitutions associated with resistance to TAF or TDF were detected. (These studies have been registered at ClinicalTrials.gov under identifiers NCT01940471 and NCT01940341.)
AD  - Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USAAD  - Chinese Univ Hong Kong, Inst Digest Dis, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R ChinaAD  - Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R ChinaAD  - Hop Beaujon, Serv Hepatol, Clichy, FranceAD  - NYU, Sch Med, Dept Med, Div Gastroenterol & Hepatol, New York, NY USAAD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaAD  - Hosp Univ Vall Hebron, Barcelona, SpainAD  - Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Tokyo, JapanAD  - Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol, Seoul, South KoreaC3  - Gilead SciencesC3  - Chinese University of Hong KongC3  - Chinese University of Hong KongC3  - Assistance Publique Hopitaux Paris (APHP)C3  - Universite Paris CiteC3  - Hopital Universitaire Beaujon - APHPC3  - New York UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Hospital Universitari Vall d'HebronC3  - University of UlsanC3  - Asan Medical CenterPU  - AMER SOC MICROBIOLOGY
PI  - WASHINGTON
PA  - 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
DA  - OCT
PY  - 2018
VL  - 62
IS  - 10
C7  - e01064-18
DO  - 10.1128/AAC.01064-18
AN  - WOS:000445405500044
ER  -

TY  - JOUR
AU  - Chadda, RK
TI  - Youth mental health: Challenges ahead
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
KW  - ADOLESCENT HEALTH
KW  - GLOBAL BURDEN
KW  - YOUNG-PEOPLE
KW  - DISORDERS
KW  - DISEASE
AD  - All India Inst Med Sci, Dept Psychiat, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Natl Drug Dependence Treatment Ctr, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)PU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - OCT
PY  - 2018
VL  - 148
IS  - 4
SP  - 359
EP  - 361
DO  - 10.4103/ijmr.IJMR_1585_18
AN  - WOS:000456435900001
ER  -

TY  - JOUR
AU  - Chakrabarty, B
TI  - Pediatric Sleep Related Problems: The Tip of the Iceberg
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - ADOLESCENTS
KW  - CHILDREN
KW  - DISORDERS
AD  - AIIMS, Child Neurol Div, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - OCT
PY  - 2018
VL  - 85
IS  - 10
SP  - 825
EP  - 826
DO  - 10.1007/s12098-018-2762-5
AN  - WOS:000445955200002
ER  -

TY  - JOUR
AU  - Chaudhuri, R
AU  - Khanna, K
AU  - Desiraju, K
AU  - Pattnaik, B
AU  - Vatsa, D
AU  - Agrawal, A
AU  - Ghosh, B
TI  - Novel nuclear translocation of inositol polyphosphate 4-phosphatase is associated with cell cycle, proliferation and survival
T2  - BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
KW  - INPP4A
KW  - Nuclear localization
KW  - Nucleocytoplasmic shuttling
KW  - Proliferation
KW  - Apoptosis
KW  - PHOSPHOINOSITIDE 3-KINASE C2-BETA
KW  - PHOSPHATIDYLINOSITOL 3,4-BISPHOSPHATE
KW  - PTEN
KW  - ACTIVATION
KW  - APOPTOSIS
KW  - PROTEINS
KW  - ISOFORMS
KW  - PATHWAY
KW  - SIGNALS
KW  - GROWTH
AB  - Inositol polyphosphate 4 phosphatase type I enzyme (INPP4A) has a well-documented function in the cytoplasm where it terminates the phosphatidylinositol 3-kinase (PI 3-K) pathway by acting as a negative regulator. In this study, we demonstrate for the first time that INPP4A shuttles between the cytoplasm and the nucleus. Nuclear INPP4A is enzymatically active and in dynamic equilibrium between the nucleus and cytoplasm depending on the cell cycle stage, with highest amounts detected in the nucleus during the G(0)/G(1) phase. Moreover, nuclear INPP4A is found to have direct proliferation suppressive activity. Cells constitutively overexpressing nuclear INPP4A exhibit massive apoptosis. In human tissues as well as cell lines, lower nuclear localization of INPP4A correlate with cancerous growth. Together, our findings suggest that nuclear compartmentalization of INPP4A may be a mechanism to regulate cell cycle progression, proliferation and apoptosis. Our results imply a role for nuclear-localized INPP4A in tumor suppression in humans.
AD  - CSIR Inst Genom & Integrat Biol, Immunogenet Mol Lab, Delhi 110007, IndiaAD  - CSIR Inst Genom & Integrat Biol, Ctr Excellence Translat Res Asthma & Lung Dis, Delhi 110007, IndiaAD  - CSIR Inst Genom & Integrat Biol, Acad Sci & Innovat Res, Delhi 110007, IndiaAD  - All India Inst Med Sci, Dept Pulm Med & Sleep Disorders, New Delhi 110029, IndiaC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Academy of Scientific & Innovative Research (AcSIR)C3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - OCT
PY  - 2018
VL  - 1865
IS  - 10
SP  - 1501
EP  - 1514
DO  - 10.1016/j.bbamcr.2018.07.013
AN  - WOS:000444929400010
ER  -

TY  - JOUR
AU  - Chawla, R
AU  - Nath, M
AU  - Moksha, L
AU  - Nag, TC
AU  - Velpandian, T
TI  - An experimental study to evaluate safety/toxicity of intravitreal natalizumab
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - alpha 4 integrin intravitreal injection
KW  - electroretinogram
KW  - natalizumab
KW  - uveitis
KW  - EXPERIMENTAL AUTOIMMUNE UVEITIS
KW  - RELAPSING MULTIPLE-SCLEROSIS
KW  - ADALIMUMAB
KW  - MECHANISMS
KW  - DISEASE
KW  - RETINA
KW  - VCAM-1
KW  - RABBIT
KW  - CELLS
AB  - Purpose: The purpose of this prospective experimental study was to evaluate the safety/toxicity of alpha 4 beta 1 integrin blockade in rabbit retina using its monoclonal antibody (Natalizumab). Methods: Twelve New Zealand albino rabbits were divided into three groups (n = 4). Unilateral intravitreal injections of three different concentrations of natalizumab were performed in every rabbit of each group (Group A: 0.625 mg, Group B: 1.25 mg, and Group C: 2.5 mg). Baseline electroretinogram (ERG) and fundus photography were performed prior to injection. At days 1, 7, and 21 postinjection, ERG and fundus photography of each eye were performed. At last follow-up, Group C animals with highest drug concentration were sacrificed and the enucleated eyes were evaluated for retinal toxicity using transmission electron microscopy (TEM). Results: No difference in ERG responses was observed in eyes injected with low and intermediate concentration of natalizumab between day 0 and day 21. Furthermore, rabbits injected intravitreally with highest dose showed reduction in amplitude of "a" wave (P = 0.0017) and a reduction in amplitude of "b" wave of ERG at day 21 (P = 0.0117). TEM revealed changes in the outer plexiform layer and inner nuclear layer, suggestive of toxicity primarily to the photoreceptor synaptic terminals and bipolar cells. Conclusion: Low-dose (0.625 mg) and intermediate-dose (1.25 mg) intravitreal injection of natalizumab appears safe for rabbit retina. However, functional and anatomical changes were observed in rabbit retina following a high-dose (2.5 mg) intravitreal injection of a monoclonal antibody blocking alpha 4 beta 1 integrin.
AD  - All India Inst Med Sci, Dept Ophthalmol, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Ocular Pharmacol & Pharm, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Anat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - OCT
PY  - 2018
VL  - 66
IS  - 10
SP  - 1441
EP  - 1445
DO  - 10.4103/ijo.IJO_425_18
AN  - WOS:000445668500014
ER  -

TY  - JOUR
AU  - Dandona, R
AU  - Kumar, GA
AU  - Dhaliwal, RS
AU  - Naghavi, M
AU  - Vos, T
AU  - Shukla, DK
AU  - Vijayakumar, L
AU  - Gururaj, G
AU  - Thakur, JS
AU  - Ambekar, A
AU  - Sagar, R
AU  - Arora, M
AU  - Bhardwaj, D
AU  - Chakma, JK
AU  - Dutta, E
AU  - Furtado, M
AU  - Glenn, S
AU  - Hawley, C
AU  - Johnson, SC
AU  - Khanna, T
AU  - Kutz, M
AU  - Mountjoy-Venning, WC
AU  - Muraleedharan, P
AU  - Rangaswamy, T
AU  - Varghese, CM
AU  - Varghese, M
AU  - Reddy, KS
AU  - Murray, CJL
AU  - Swaminathan, S
AU  - Dandona, L
A1  - India State-Level Dis Burden In
TI  - Gender differentials and state variations in suicide deaths in India: the Global Burden of Disease Study 1990-2016
T2  - LANCET PUBLIC HEALTH
KW  - HEALTH
KW  - DETERMINANTS
KW  - PREVENTION
KW  - MORTALITY
KW  - TRENDS
KW  - IMPACT
KW  - WOMEN
AB  - Background A systematic understanding of suicide mortality trends over time at the subnational level for India's 1.3 billion people, 18% of the global population, is not readily available. Thus, we aimed to report time trends of suicide deaths, and the heterogeneity in its distribution between the states of India from 1990 to 2016.
   Methods As part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016, we estimated suicide death rates (SDRs) for both sexes in each state of India from 1990 to 2016. We used various data sources for estimating cause-specific mortality in India. For suicide mortality in India before 2000, estimates were based largely on GBD covariates. For each state, we calculated the ratio of the observed SDR to the rate expected in geographies globally with similar GBD Socio-demographic Index in 2016 (ie, the observed-to-expected ratio); and assessed the age distribution of suicide deaths, and the men-to-women ratio of SDR over time. Finally, we assessed the probability for India and the states of reaching the Sustainable Development Goal (SDG) target of a one-third reduction in SDR from 2015 to 2030, using location-wise trends of the age-standardised SDR from 1990 to 2016. We calculated 95% uncertainty intervals (UIs) for the point estimates.
   Findings There were 230 314 (95% UI 194 058-250 260) suicide deaths in India in 2016. India's contribution to global suicide deaths increased from 25.3% in 1990 to 36.6% in 2016 among women, and from 18.7% to 24.3% among men. Age-standardised SDR among women in India reduced by 26.7% from 20.0 (95% UI 16.5-23.5) in 1990 to 14.7 (13.1-16.2) per 100 000 in 2016, but the age-standardised SDR among men was the same in 1990 (22.3 [95% UI 14.4-27.4] per 100 000) and 2016 (21.2 [14.6-23.6] per 100 000). SDR in women was 2.1 times higher in India than the global average in 2016, and the observed-to-expected ratio was 2.74, ranging from 0.45 to 4.54 between the states. SDR in men was 1.4 times higher in India than the global average in 2016, with an observed-to-expected ratio of 1.31, ranging from 0.40 to 2.42 between the states. There was a ten-fold variation between the states in the SDR for women and six-fold variation for men in 2016. The men-to-women ratio of SDR for India was 1.34 in 2016, ranging from 0.97 to 4.11 between the states. The highest age-specific SDRs among women in 2016 were for ages 15-29 years and 75 years or older, and among men for ages 75 years or older. Suicide was the leading cause of death in India in 2016 for those aged 15-39 years; 71.2% of the suicide deaths among women and 57.7% among men were in this age group. If the trends observed up to 2016 continue, the probability of India achieving the SDG SDR reduction target in 2030 is zero, and the majority of the states with 81.3% of India's population have less than 10% probability, three states have a probability of 10.3-15.0%, and six have a probability of 25.1-36.7%.
   Interpretation India's proportional contribution to global suicide deaths is high and increasing. SDR in India is higher than expected for its Socio-Demographic Index level, especially for women, with substantial variations in the magnitude and men-to-women ratio between the states. India must develop a suicide prevention strategy that takes into account these variations in order to address this major public health problem. Copyright (c) 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
AD  - Publ Hlth Fdn India, Gurugram 122002, National Capita, IndiaAD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - Indian Council Med Res, New Delhi, IndiaAD  - SNEHA India, Madras, Tamil Nadu, IndiaAD  - Voluntary Hlth Serv, Dept Psychiat, Madras, Tamil Nadu, IndiaAD  - Natl Inst Mental Hlth & Neurosci, Dept Epidemiol, Bengaluru, IndiaAD  - Natl Inst Mental Hlth & Neurosci, Dept Psychiat, Bengaluru, IndiaAD  - Postgrad Inst Med Educ & Res, Sch Publ Hlth, Chandigarh, IndiaAD  - All India Inst Med Sci, Natl Drug Dependence Treatment Ctr, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - Schizophrenia Res Fdn, Madras, Tamil Nadu, IndiaC3  - Public Health Foundation of IndiaC3  - University of WashingtonC3  - University of Washington SeattleC3  - Institute for Health Metrics & EvaluationC3  - Indian Council of Medical Research (ICMR)C3  - National Institute of Mental Health & Neurosciences - IndiaC3  - National Institute of Mental Health & Neurosciences - IndiaC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCI LTD
PI  - London
PA  - 125 London Wall, London, ENGLAND
DA  - OCT
PY  - 2018
VL  - 3
IS  - 10
SP  - E478
EP  - E489
DO  - 10.1016/S2468-2667(18)30138-5
AN  - WOS:000446908100012
ER  -

TY  - JOUR
AU  - Dar, HY
AU  - Pal, S
AU  - Shukla, P
AU  - Mishra, PK
AU  - Tomar, GB
AU  - Chattopadhyay, N
AU  - Srivastava, RK
TI  - <i>Bacillus clausii</i> inhibits bone loss by skewing Treg-Th17 cell equilibrium in postmenopausal osteoporotic mice model
T2  - NUTRITION
KW  - Probiotics
KW  - Bacillus clausii
KW  - Bone mass
KW  - Treg cells
KW  - Th17 cells
KW  - Osteoporosis
KW  - REGULATORY T-CELLS
KW  - MINERAL DENSITY
KW  - RHEUMATOID-ARTHRITIS
KW  - CROSS-TALK
KW  - IFN-GAMMA
KW  - OSTEOCLASTOGENESIS
KW  - PROBIOTICS
KW  - IL-17
KW  - TH17
KW  - MACROPHAGES
AB  - Objectives: Postmenopausal osteoporosis is one of most commonly occurring skeletal diseases leading to bone loss and fragility. Probiotics have been associated with various immunomodulatory properties and thus can be exploited to enhance bone health. In the present study, we report, to our knowledge for the first time, that oral administration of Bacillus clausii (BC) in postmenopausal osteoporotic (OVX) mice model enhances bone health.
   Methods: BC was selected as probiotic of choice due to its established immunomodulatory properties. BC skews the Treg-Th17 cell balance in vivo by inhibiting osteoclastogenic Th17 cells and promoting antiosteoclastogenic Treg cell development in postmenopausal osteoporotic mice. Mice were divided into three groups (sham, OVX, and OVX + BC), and BC was administered orally in drinking water for 6 wk post-ovariectomy. At the end of experiment, mice were sacrificed and bones were analyzed for various parameters, along with lymphoid tissues for Treg-Th17 cells and serum cytokines.
   Results: We observed that BC administration enhanced bone health. This effect of BC administration was found due to skewing of Treg-Th17 cell balance (enhanced Treg and decreased Th17 cells) in vivo. BC administration reduced levels of proinflammatory cytokines (interleukin [IL]-6, IL-17, IFN-gamma and tumor necrosis factor-alpha) and increased levels of anti-inflammatory cytokine (IL-10).
   Conclusions: The present study strongly supports and establishes the osteoprotective potential of BC leading to enhanced bone health in postmenopausal osteoporotic mice model. (C) 2018 Elsevier Inc. All rights reserved.
AD  - Dr Harisingh Gour Cent Univ, Sch Biol Sci, Dept Zool, Sagar, IndiaAD  - CDRI, Div Endocrinol, Lucknow, Uttar Pradesh, IndiaAD  - Dr Harisingh Gour Cent Univ, Sch Math & Phys Sci, Dept Phys, Sagar, IndiaAD  - ICMR Natl Inst Res Environm Hlth, Dept Mol Biol, Bhopal, IndiaAD  - Savitribai Phule Pune Univ, Inst Bioinformat & Biotechnol, Pune, Maharashtra, IndiaAD  - AIIMS, Dept Biotechnol, New Delhi 110029, IndiaC3  - Dr. Hari Singh Gour UniversityC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Central Drug Research Institute (CDRI)C3  - Dr. Hari Singh Gour UniversityC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute for Research in Environmental Health (NIREH)C3  - Savitribai Phule Pune UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - OCT
PY  - 2018
VL  - 54
SP  - 118
EP  - 128
DO  - 10.1016/j.nut.2018.02.013
AN  - WOS:000445322100019
ER  -

TY  - JOUR
AU  - Devaraja, K
AU  - Kumar, R
AU  - Sagar, P
AU  - Kumar, R
TI  - Delayed Presentation of Tracheal Injury After Thyroidectomya Case Report
T2  - INDIAN JOURNAL OF SURGERY
KW  - Thyroidectomy
KW  - Total thyroidectomy
KW  - Tracheal rupture
KW  - Subcutaneous emphysema
KW  - Complications
KW  - RUPTURE
KW  - NECROSIS
AB  - Complications of thyroidectomy are common and few of these could be life threatening. Although rare, the delayed tracheal rupture is one such complication and needs to be managed promptly. A male patient presented with neck swelling and on evaluation diagnosed to have papillary carcinoma thyroid T4a N1b M0. Patient underwent total thyroidectomy and neck dissection. On post-operative day 5, he developed subcutaneous emphysema. The subcutaneous emphysema was managed non-surgically with close observation and took 6days to resolve completely. Management algorithm has been formulated after literature review. Delayed subcutaneous emphysema following thyroidectomy can be managed non-surgically in selected cases with mild emphysema and non-progressive course.
AD  - Kasturba Med Coll & Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Manipal 576104, Karnataka, IndiaAD  - All India Inst Med Sci, Dept Otorhinolaryngol & Head & Neck Surg, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept ENT, Teaching Block 4057, New Delhi 110029, IndiaC3  - Manipal Academy of Higher Education (MAHE)C3  - Kasturba Medical College, ManipalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - OCT
PY  - 2018
VL  - 80
IS  - 5
SP  - 530
EP  - 532
DO  - 10.1007/s12262-018-1748-x
AN  - WOS:000447726900024
ER  -

TY  - JOUR
AU  - Devasenapathy, S
AU  - Midha, R
AU  - Naskar, T
AU  - Mehta, A
AU  - Prajapati, B
AU  - Ummekulsum, M
AU  - Sagar, R
AU  - Singh, NC
AU  - Sinha, S
TI  - A pilot Indian family-based association study between dyslexia and Reelin pathway genes, <i>DCDC2</i> and <i>ROBO1</i>, identifies modest association with a triallelic unit TAT in the gene <i>RELN</i>
T2  - ASIAN JOURNAL OF PSYCHIATRY
KW  - Dyslexia
KW  - Reelin (RELN)
KW  - Family-Based Association Test (FBAT)
KW  - Neuronal migration
KW  - DCDC2
KW  - ROBO1
KW  - NEURONAL MIGRATION
KW  - GENOME
KW  - TESTS
KW  - POWER
KW  - POLYMORPHISMS
KW  - NEUROBIOLOGY
KW  - ENVIRONMENT
KW  - POPULATION
KW  - VARIANTS
KW  - NETWORKS
AB  - Dyslexia is a neurodevelopmental disorder that manifests as a reading disability despite normal intelligence and adequate educational opportunity. Twin and family studies have indicated a genetic component, while genome-wide studies have implicated a number of susceptibility genes, most of which have direct or indirect roles in neuronal migration. Reelin (RELN) has important biological functions facilitating migration of neurons. Polymorphisms in RELN have been implicated in related disorders like autism and schizophrenia but have not been examined in dyslexia. We hypothesized that not only RELN, but its interactors in the neuronal migration pathway may play roles in the etiology of dyslexia.
   Twenty two functional variants across six RELN signalling genes (RELN, VLDLR, APOER2, DAB1, LIS1 and NDEL1) and two dyslexia candidate genes (DCDC2 and ROBO1) were analyzed for association in twenty six nuclear and three extended families with individuals affected with dyslexia. Univariate association analysis was suggestive of association (P-uncorrected = 0.01) with rs362746 in RELN which however did not withstand Bonferroni corrections (P-corrected = 0.21). Multimarker tests indicated significant association (p = 0.037), based on which we tested for haplotype associations. Although there were no significant haplotypic associations, we found that a three marker unit with rs3808039 and rs2072403 flanking and independently in linkage disequilibrium with rs362746 was significantly overtransmitted (risk allelic combination - TAT) to dyslexia affected individuals in the sample (p = 0.002). Our results suggest preliminary evidence for a new potential risk variant in the RELN locus for dyslexia.
AD  - Natl Brain Res Ctr, Manesar 122051, Haryana, IndiaAD  - Inst Neurosci, Kolkata 700017, W Bengal, IndiaAD  - All India Inst Med Sci, Dept Psychiat, New Delhi 110026, IndiaAD  - Natl Inst Mental Hlth & Neurosci, Dept Clin Psychol, Bengaluru 560029, IndiaC3  - Department of Biotechnology (DBT) IndiaC3  - National Brain Research Centre (NBRC)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Institute of Mental Health & Neurosciences - IndiaPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - OCT
PY  - 2018
VL  - 37
SP  - 121
EP  - 129
DO  - 10.1016/j.ajp.2018.08.020
AN  - WOS:000448471300025
ER  -

TY  - JOUR
AU  - Dhillon, PK
AU  - Mathur, P
AU  - Nandakumar, A
AU  - Fitzmaurice, C
AU  - Kumar, GA
AU  - Mehrotra, R
AU  - Shukla, DK
AU  - Rath, GK
AU  - Gupta, PC
AU  - Swaminathan, R
AU  - Thakur, JS
AU  - Dey, S
AU  - Allen, C
AU  - Badwe, RA
AU  - Dikshit, R
AU  - Dhaliwal, RS
AU  - Kaur, T
AU  - Kataki, AC
AU  - Visvveswara, RN
AU  - Gangadharan, P
AU  - Dutta, E
AU  - Furtado, M
AU  - Varghese, CM
AU  - Bhardwaj, D
AU  - Muraleedharan, P
AU  - Odell, CM
AU  - Glenn, S
AU  - Bal, MS
AU  - Bapsy, PP
AU  - Bennett, J
AU  - Bodal, VK
AU  - Chakma, JK
AU  - Chakravarty, S
AU  - Chaturvedi, M
AU  - Das, P
AU  - Deshmane, V
AU  - Gangane, N
AU  - Harvey, J
AU  - Jayalekshmi, P
AU  - Jerang, K
AU  - Johnson, SC
AU  - Julka, PK
AU  - Kaushik, D
AU  - Khamo, V
AU  - Koyande, S
AU  - Kutz, M
AU  - Langstieh, WB
AU  - Lingegowda, KB
AU  - Mahajan, RC
AU  - Mahanta, J
AU  - Majumdar, G
AU  - Manoharan, N
AU  - Mathew, A
AU  - Nene, BM
AU  - Pati, S
AU  - Pradhan, PK
AU  - Raina, V
AU  - Rama, R
AU  - Ramesh, C
AU  - Sathishkumar, K
AU  - Schelonka, K
AU  - Sebastian, P
AU  - Shackelford, K
AU  - Shah, J
AU  - Shanta, 
AU  - Sharma, JD
AU  - Shrivastava, A
AU  - Tawsik, S
AU  - Tyagi, BB
AU  - Vaitheeswaran, K
AU  - Vallikad, E
AU  - Verma, Y
AU  - Zomawia, E
AU  - Lim, SS
AU  - Vos, T
AU  - Dandona, R
AU  - Reddy, KS
AU  - Naghavi, M
AU  - Murray, CJL
AU  - Swaminathan, S
AU  - Dandona, L
A1  - India State-Level Dis Burden Initi
TI  - The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990-2016
T2  - LANCET ONCOLOGY
KW  - STOMACH-CANCER
KW  - BREAST-CANCER
KW  - TOBACCO USE
KW  - EPIDEMIOLOGY
KW  - POPULATION
KW  - MIZORAM
KW  - RISK
KW  - INFECTION
KW  - ADULTS
KW  - MIDDLE
AB  - Background Previous efforts to report estimates of cancer incidence and mortality in India and its different parts include the National Cancer Registry Programme Reports, Sample Registration System cause of death findings, Cancer Incidence in Five Continents Series, and GLOBOCAN. We present a comprehensive picture of the patterns and time trends of the burden of total cancer and specific cancer types in each state of India estimated as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 because such a systematic compilation is not readily available.
   Methods We used all accessible data from multiple sources, including 42 population-based cancer registries and the nationwide Sample Registration System of India, to estimate the incidence of 28 types of cancer in every state of India from 1990 to 2016 and the deaths and disability-adjusted life-years (DALYs) caused by them, as part of GBD 2016. We present incidence, DALYs, and death rates for all cancers together, and the trends of all types of cancers, highlighting the heterogeneity in the burden of specific types of cancers across the states of India. We also present the contribution of major risk factors to cancer DALYs in India.
   Findings 8.3% (95% uncertainty interval [UI] 7.9-8-6) of the total deaths and 5.0% (4.6-5-5) of the total DALYs in India in 2016 were due to cancer, which was double the contribution of cancer in 1990. However, the age-standardised incidence rate of cancer did not change substantially during this period. The age-standardised cancer DALY rate had a 2.6 times variation across the states of India in 2016. The ten cancers responsible for the highest proportion of cancer DALYs in India in 2016 were stomach (9.0% of the total cancer DALYs), breast (8.2%), lung (7.5%), lip and oral cavity (7.2%), pharynx other than nasopharynx (6.8%), colon and rectum (5.8%), leukaemia (5.2%), cervical (5.2%), oesophageal (4.3%), and brain and nervous system (3.5%) cancer. Among these cancers, the age-standardised incidence rate of breast cancer increased significantly by 40.7% (95% UI 7.0-85.6) from 1990 to 2016, whereas it decreased for stomach (39.7%; 34.3-44.0), lip and oral cavity (6.4%; 0.4-18-6), cervical (39.7%; 26.5-57-3), and oesophageal cancer (31.2%; 27.9-34.9), and leukaemia (16.1%; 4.3-24.2). We found substantial inter-state heterogeneity in the age-standardised incidence rate of the different types of cancers in 2016, with a 3.3 times to 11.6 times variation for the four most frequent cancers (lip and oral, breast, lung, and stomach). Tobacco use was the leading risk factor for cancers in India to which the highest proportion (10.9%) of cancer DALYs could be attributed in 2016.
   Interpretation The substantial heterogeneity in the state-level incidence rate and health loss trends of the different types of cancer in India over this 26-year period should be taken into account to strengthen infrastructure and human resources for cancer prevention and control at both the national and state levels. These efforts should focus on the ten cancers contributing the highest DALYs in India, including cancers of the stomach, lung, pharynx other than nasopharynx, colon and rectum, leukaemia, oesophageal, and brain and nervous system, in addition to breast, lip and oral cavity, and cervical cancer, which are currently the focus of screening and early detection programmes. Copyright (C) The Author(s). Published by Elsevier Ltd.
AD  - Publ Hlth Fdn India, Gurugram 122002, National Capita, IndiaAD  - Indian Council Med Res, Natl Ctr Dis Informat & Res, Bengaluru, IndiaAD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - Indian Council Med Res, Natl Inst Canc Prevent & Res, Noida, IndiaAD  - Indian Council Med Res, New Delhi, IndiaAD  - All India Inst Med Sci, Dr BRA Inst Rotary Canc Hosp, New Delhi, IndiaAD  - Healis Sekhsaria Inst Publ Hlth, Bombay, Maharashtra, IndiaAD  - Canc Inst WIA, Dept Biostat & Canc Registry, Madras, Tamil Nadu, IndiaAD  - Canc Inst WIA, Madras, Tamil Nadu, IndiaAD  - Postgrad Inst Med Educ & Res, Sch Publ Hlth, Chandigarh, IndiaAD  - Postgrad Inst Med Educ & Res, Chandigarh, IndiaAD  - Publ Hlth Fdn India, Indian Inst Publ Hlth Delhi, Gurugram, IndiaAD  - Tata Mem Hosp, Bombay, Maharashtra, IndiaAD  - Tata Mem Hosp, Canc Epidemiol, Bombay, Maharashtra, IndiaAD  - Dr B Borooah Canc Inst, Gauhati, IndiaAD  - Amrita Inst Med Sci & Res Ctr, Kochi, Kerala, IndiaAD  - Govt Med Coll, Patiala, Punjab, IndiaAD  - Apollo Hosp, Bengaluru, IndiaAD  - Silchar Med Coll & Hosp, Silchar, IndiaAD  - Indian Canc Soc, Bombay, Maharashtra, IndiaAD  - Mahatma Gandhi Inst Med Sci, Dept Pathol, Wardha, IndiaAD  - Reg Canc Ctr, Thiruvananthapuram, Kerala, IndiaAD  - Bakin Perlin Gen Hosp, Dept Pathol, Pasighat, IndiaAD  - Max Oncol Daycare Ctr, New Delhi, IndiaAD  - Reg Inst Med Sci, Imphal, IndiaAD  - Naga Hosp Author Kohirna, Healthcare Lab & Res Ctr, Kohirna, IndiaAD  - Civil Hosp, Shillong, Meghalayn, IndiaAD  - Kidwai Mem Inst Oncol, Bengaluru, IndiaAD  - Kidwai Mem Inst Oncol, Dept Epidemiol & Biostat, Bengaluru, IndiaAD  - Indian Council Med Res, Reg Med Res Ctr, Dibrugarh, Assam, IndiaAD  - Reg Canc Glum, Agartala, IndiaAD  - Nargis Dutt Mem Canc Hosp, Barshi, IndiaAD  - Indian Council Med Res, Reg Med Res Ctr, Bhubaneswar, IndiaAD  - Sir Thodup Namgyal Mem Hosp, Dept Pathol, Gangtok, IndiaAD  - Fortis Mem Res Inst, Dept Med Oncol & Haematol, Gurugram, IndiaAD  - Gujarat Canc Res Inst, Ahmadabad, Gujarat, IndiaAD  - Gandhi Med Coll, Dept Pathol, Bhopal, IndiaAD  - Tomo Riba Inst Hlth & Med Sci, Dept Pathol, Naharlagun, IndiaAD  - St Johns Med Coll, Dept Gynaecol Oncol, Bengaluru, IndiaAD  - Sikkim Manipal Inst Med Sci, Dept Pathol, Gangtok, IndiaAD  - Govt Mizoram, Hlth & Family Welf Dept, Aizawl, IndiaC3  - Public Health Foundation of IndiaC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Centre for Disease Informatics & Research (NCDIR)C3  - Institute for Health Metrics & EvaluationC3  - University of WashingtonC3  - University of Washington SeattleC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Cancer Prevention & Research (NICPR)C3  - Indian Council of Medical Research (ICMR)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Public Health Foundation of IndiaC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalC3  - Tata Memorial Centre (TMC)C3  - Dr. Bhubaneswar Borooah Cancer InstituteC3  - Amrita Vishwa VidyapeethamC3  - Amrita Vishwa Vidyapeetham KochiC3  - Mahatma Gandhi Institute of Medical Sciences, SevagramC3  - Regional Institute of Medical Sciences, ImphalC3  - Kidwai Memorial Institute of OncologyC3  - Kidwai Memorial Institute of OncologyC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - Regional Medical Research Centre, North East Region (RMRC NE)C3  - Indian Council of Medical Research (ICMR)C3  - ICMR - Regional Medical Research Centre (RMRC), BhubaneswarC3  - The Gujarat Cancer & Research InstituteC3  - St. John's National Academy of Health SciencesC3  - St. John's Medical CollegeC3  - Sikkim Manipal UniversityPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - OCT
PY  - 2018
VL  - 19
IS  - 10
SP  - 1289
EP  - 1306
DO  - 10.1016/S1470-2045(18)30447-9
AN  - WOS:000446052800050
ER  -

TY  - JOUR
AU  - Dixit, S
AU  - Arora, NK
AU  - Rahman, A
AU  - Howard, NJ
AU  - Singh, RK
AU  - Vaswani, M
AU  - Das, MK
AU  - Ahmed, F
AU  - Mathur, P
AU  - Tandon, N
AU  - Dasgupta, R
AU  - Chaturvedi, S
AU  - Jethwaney, J
AU  - Dalpath, S
AU  - Prashad, R
AU  - Kumar, R
AU  - Gupta, R
AU  - Dube, L
AU  - Daniel, M
TI  - Establishing a Demographic, Development and Environmental Geospatial Surveillance Platform in India: Planning and Implementation
T2  - JMIR PUBLIC HEALTH AND SURVEILLANCE
KW  - geospatial surveillance
KW  - health and nonhealth data harmonization
KW  - spatial epidemiology
KW  - participatory GIS
KW  - caste
KW  - socioeconomic transition
KW  - ground truthing
KW  - built environment
KW  - EXPOSURE ASSESSMENT
KW  - HEALTH
KW  - POLLUTION
KW  - SYSTEMS
AB  - Background: Inadequate administrative health data, suboptimal public health infrastructure, rapid and unplanned urbanization, environmental degradation, and poor penetration of information technology make the tracking of health and well-being of populations and their social determinants in the developing countries challenging. Technology-integrated comprehensive surveillance platforms have the potential to overcome these gaps.
   Objective: This paper provides methodological insights into establishing a geographic information system (GIS)-integrated, comprehensive surveillance platform in rural North India, a resource-constrained setting.
   Methods: The International Clinical Epidemiology Network Trust International established a comprehensive SOMAARTH Demographic, Development, and Environmental Surveillance Site (DDESS) in rural Palwal, a district in Haryana, North India. The surveillance platform evolved by adopting four major steps: (1) site preparation, (2) data construction, (3) data quality assurance, and (4) data update and maintenance system. Arc GIS 10.3 and QGIS 2.14 software were employed for geospatial data construction. Surveillance data architecture was built upon the geospatial land parcel datasets. Dedicated software (SOMAARTH-1) was developed for handling high volume of longitudinal datasets. The built infrastructure data pertaining to land use, water bodies, roads, railways, community trails, landmarks, water, sanitation and food environment, weather and air quality, and demographic characteristics were constructed in a relational manner.
   Results: The comprehensive surveillance platform encompassed a population of 0.2 million individuals residing in 51 villages over a land mass of 251.7 sq km having 32,662 households and 19,260 nonresidential features (cattle shed, shops, health, education, banking, religious institutions, etc). All land parcels were assigned georeferenced location identification numbers to enable space and time monitoring. Subdivision of villages into sectors helped identify socially homogenous community clusters (418/676, 61.8%, sectors). Water and hygiene parameters of the whole area were mapped on the GIS platform and quantified. Risk of physical exposure to harmful environment (poor water and sanitation indicators) was significantly associated with the caste of individual household (P=.001), and the path was mediated through the socioeconomic status and density of waste spots (liquid and solid) of the sector in which these households were located. Ground-truthing for ascertaining the land parcel level accuracies, community involvement in mapping exercise, and identification of small habitations not recorded in the administrative data were key learnings.
   Conclusions: The SOMAARTH DDESS experience allowed us to document and explore dynamic relationships, associations, and pathways across multiple levels of the system (ie, individual, household, neighborhood, and village) through a geospatial interface. This could be used for characterization and monitoring of a wide range of proximal and distal determinants of health.
AD  - INCLEN Trust Int, SOMAARTH Demog Dev & Environm Surveillance Site, Res, New Delhi, IndiaAD  - INCLEN Trust Int, Res, Epidemiol, F-1-5 Okhla Ind Area,Phase 1, New Delhi 110025, IndiaAD  - Jamia Millia Islamia, Fac Nat Sci, Dept Geog, New Delhi, IndiaAD  - Univ South Australia, Sansom Inst Hlth Res, Div Hlth Sci, Adelaide, SA, AustraliaAD  - South Australian Hlth & Med Res Inst, Adelaide, SA, AustraliaAD  - Aditya Diagnost & Hosp, Acad Dept, Dibrugarh, Assam, IndiaAD  - Indian Council Med Res, Natl Ctr Dis Informat & Res, Natl Canc Registry Program, Bangalore, Karnataka, IndiaAD  - All India Inst Med Sci, Dept Endocrinol, New Delhi, IndiaAD  - Jawaharlal Nehru Univ, Ctr Social Med & Community Hlth, New Delhi, IndiaAD  - Univ Delhi, Univ Coll Med Sci, Dept Community Med, New Delhi, IndiaAD  - Indian Council Social Sci Res, Dept Res, New Delhi, IndiaAD  - Dept Hlth, Panchkula, IndiaAD  - Dept Hlth, Off Chief Med Officer, Palwal, IndiaAD  - Indian Council Med Res, New Delhi, IndiaAD  - Off Chief Minister, Chandigarh, IndiaAD  - McGill Univ, McGill Ctr Convergence Hlth & Econ, Montreal, PQ, CanadaAD  - Univ Canberra, Hlth Res Inst, Ctr Res & Act Publ Hlth, Canberra, ACT, AustraliaAD  - Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, AustraliaC3  - Jamia Millia IslamiaC3  - University of South AustraliaC3  - South Australian Health & Medical Research Institute (SAHMRI)C3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Centre for Disease Informatics & Research (NCDIR)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jawaharlal Nehru University, New DelhiC3  - University of DelhiC3  - University College of Medical SciencesC3  - Indian Council of Medical Research (ICMR)C3  - McGill UniversityC3  - University of CanberraC3  - NSW HealthC3  - St Vincents Hospital SydneyC3  - St Vincent's HealthC3  - St Vincent's Hospital MelbourneC3  - University of MelbournePU  - JMIR PUBLICATIONS, INC
PI  - TORONTO
PA  - 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
DA  - OCT-DEC
PY  - 2018
VL  - 4
IS  - 4
SP  - 13
EP  - 30
C7  - e66
DO  - 10.2196/publichealth.9749
AN  - WOS:000526815900002
ER  -

TY  - JOUR
AU  - Dogra, K
AU  - Kaur, G
AU  - Basu, S
AU  - Chawla, D
TI  - Red Cell Transfusion Practices in Neonatal Intensive Care Unit: An Experience from Tertiary Care Centre
T2  - INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
KW  - Red cell transfusions
KW  - Neonatal intensive care unit
KW  - Clinical outcome
KW  - BLOOD-TRANSFUSION
KW  - PREMATURITY
KW  - INFANTS
KW  - ANEMIA
KW  - APNEA
KW  - TRIAL
AB  - Red cells are the most often transfused blood components during the neonatal period. The aim of the present study was to obtain information regarding the relationship of red cell transfusion with clinical outcomes and to evaluate red cell transfusion practices in neonatal centre of a tertiary care centre. The clinical history, blood componentdetails and laboratory parameters were evaluated with clinical outcomes. The neonates requiring transfusion of red cells were then followed up in the Blood bank for various laboratory parameters. Clinical parameters and clinical outcome were noted from case files. During the study period, 291 neonates were admitted in NICU. 2 neonates were excluded as they were congenitally malformed. Out of 289 admitted neonates, 61 neonates (21.1%) received blood and blood component transfusions. Out of 61 neonates, 20 received red cell transfusions. Mean donor exposure of red cells was 1.2. The mean volume of transfused red cell was 39.6ml with mean age of red cells was 3.6days. The mean pre- and post-transfusion Hct was 25.3 and 30.4%, respectively. The most common indication for red cell transfusion was low haemoglobin. There was a significant increase in lactate level and decrease in base excess in transfused neonates. However, no statistically significant correlations were found between transfusions and neonatal weight gain, apnoea, respiratory support and mortality. Transfusion of red cells has significant effect on laboratory parameters as compared to clinical parameters such as weight gain, episodes of apnoea and respiratory support.
AD  - AIIMS, Dept Transfus Med, New Delhi, IndiaAD  - GMCH, Dept Transfus Med, Sect 32, Chandigarh, IndiaAD  - Tata Med Ctr, Dept Transfus Med, Kolkata, IndiaAD  - GMCH, Dept Peadiat, Chandigarh, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - OCT
PY  - 2018
VL  - 34
IS  - 4
SP  - 671
EP  - 676
DO  - 10.1007/s12288-018-0959-4
AN  - WOS:000451752900014
ER  -

TY  - JOUR
AU  - Elavarasi, A
AU  - Vishnu, VY
AU  - Srivastava, MVP
AU  - Goyal, V
AU  - Singh, MB
AU  - Khanna, G
AU  - Suri, V
AU  - Sharma, MC
TI  - Polymyositis with too Many Associations: A Paraneoplastic Syndrome
T2  - ANNALS OF INDIAN ACADEMY OF NEUROLOGY
AD  - All India Inst Med Sci, Dept Neurol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - OCT-DEC
PY  - 2018
VL  - 21
IS  - 4
SP  - 331
EP  - +
DO  - 10.4103/aian.AIAN_432_17
AN  - WOS:000449166400023
ER  -

TY  - JOUR
AU  - Ganie, MA
AU  - Chakraborty, S
AU  - Sehgal, A
AU  - Sreejith, M
AU  - Kandasamy, D
AU  - Jana, M
AU  - Rashid, A
TI  - Bone Mineral Density is Unaltered in Women with Polycystic Ovary Syndrome
T2  - HORMONE AND METABOLIC RESEARCH
KW  - polycystic ovary syndrome
KW  - bone mineral density
KW  - dual energy X-ray absorptiometry
KW  - adolescent women
KW  - body mass index
KW  - INSULIN-RESISTANCE
KW  - INDIAN WOMEN
KW  - PREVALENCE
KW  - HYPERINSULINEMIA
KW  - PREMENOPAUSAL
KW  - ASSOCIATION
KW  - CONSENSUS
KW  - CRITERIA
KW  - COMPLEX
KW  - MASS
AB  - Context The effects of endocrine aberrations associated with polycystic ovary syndrome (PCOS) on bone mineral density (BMD) in young women is a matter of debate.
   Objectives To compare BMD in young women with PCOS to age and body mass index (BMI) matched controls and to elucidate its correlation to BMI, insulin resistance and serum testosterone.
   Design and Methods We recruited 60 women with PCOS aged 14-24 years, diagnosed based on Rotterdam 2003 criteria, and 58 age matched controls. BMD was measured by dual energy X-ray absorptiometry. In addition, these subjects underwent biochemical and hormonal analysis including oral glucose tolerance test, calculation of Homeostatic Model Assessment-Insulin Resistance Index, measurement of serum thyroxine, thyrotropin, prolactin, total testosterone, dehydroepiandrosterone sulfate, follicular phase luteinizing hormone and follicle stimulating hormone.
   Results There was no difference of BMD between women with PCOS and control women (1.103 +/- 0.08 vs 1.126 +/- 0.083 g/cm2; p=0.122). In subgroup analysis based on BMI, BMD in obese women with PCOS was significantly higher than their overweight and lean counterparts at lumbar spine (p<0.001), neck of femur (p=0.005) and total hip (p<0.001). BMD was not different at any site between oligomenorrheic and non-oligomenorrheic women with PCOS. It positively correlated with BMI, waist and hip circumference in women with PCOS. No correlation was found with HOMA-IR or Testosterone.
   Conclusions BMI is the most important determinant of BMD in women with PCOS. BMD is not different between healthy young women and those with PCOS.
AD  - All India Inst Med Sci New Delhi, Endocrinol & Metab, New Delhi 110029, IndiaAD  - Sherikashmir Inst Med Sci, Srinagar, Jammu & Kashmir, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Sher-i-Kashmir Institute of Medical SciencesPU  - GEORG THIEME VERLAG KG
PI  - STUTTGART
PA  - RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
DA  - OCT
PY  - 2018
VL  - 50
IS  - 10
SP  - 754
EP  - 760
DO  - 10.1055/a-0733-7768
AN  - WOS:000447196900006
ER  -

TY  - JOUR
AU  - Garg, P
AU  - Jaryal, AK
AU  - Kachhawa, G
AU  - Deepak, KK
AU  - Kriplani, A
TI  - Estimation of asymmetric dimethylarginine (ADMA), placental growth factor (PLGF) and pentraxin 3 (PTX 3) in women with preeclampsia
T2  - PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH
KW  - Preeclampsia
KW  - Pregnancy
KW  - ADMA
KW  - PLGF
KW  - PTX 3
KW  - MATERNAL PLASMA-CONCENTRATIONS
KW  - ANGIOGENIC FACTORS
KW  - NORMAL-PREGNANCY
KW  - ENDOTHELIAL DYSFUNCTION
KW  - DEVELOP PREECLAMPSIA
KW  - BIOCHEMICAL MARKERS
KW  - TYROSINE KINASE-1
KW  - LONG PENTRAXIN-3
KW  - WEEKS GESTATION
KW  - PREDICTION
AB  - Objective: To evaluate the sequential trend of asymmetric dimethylarginine (ADMA), placental growth factor (PLGF) and pentraxin 3 (PTX 3) in pregnancies developing preeclampsia (PE) as compared to healthy pregnancy (HP) and to estimate their predictive value for development of PE later in pregnancy.
   Study design: Nested case control design, sampling was done in 13 women with PE and 21 age matched healthy pregnant women at 11-13 weeks, 20-22 weeks and 30-32 weeks of gestation.
   Main outcome measure: PLGF, ADMA, and PTX 3 were estimated temporally.
   Results: Serum ADMA and PTX 3 levels were higher in PE than HP even at 11-13 weeks and remained elevated throughout the gestation. PTX 3 concentration increased in both the groups with advancing gestation however significant rise was observed only in HP group. PLGF levels also increased with advancing gestation in HP group while in PE, there was a rise fill 20-22 weeks of gestation followed by fall at 30-32 weeks. PLGF levels were lower in PE at 30-32 weeks than healthy pregnancy. Area under curve (AUC) for ADMA and PTX 3 were: at 11-13 weeks; 95.95% and 83.33% and 20-22 weeks; 89.88% and 90.06% respectively. At 30-32 weeks, PLGF and ADMA demonstrated an AUC of 86.51% and 86.51% respectively.
   Conclusion: Abnormally elevated ADMA and PTX 3 levels precede the manifestation of PE and suggest endothelial dysfunction with exaggerated inflammatory response in PE. Both ADMA and PTX 3 can be used to segregate high risk women for development of PE than others in early pregnancy.
AD  - All India Inst Med Sci, Dept Physiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Obstet & Gynecol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - OCT
PY  - 2018
VL  - 14
SP  - 245
EP  - 251
DO  - 10.1016/j.preghy.2018.03.005
AN  - WOS:000452454500040
ER  -

TY  - JOUR
AU  - Garg, S
AU  - Sharma, V
AU  - Kumar, R
AU  - Kumar, L
AU  - Chopra, A
TI  - Rapid Onset Anemia in Chronic Myeloid Leukemia Due to Red Cell Agglutination: A Rare Occurrence
T2  - INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
KW  - Red cell agglutination
KW  - Chronic myeloid leukemia
KW  - Cold agglutinins
KW  - CHRONIC LYMPHOCYTIC-LEUKEMIA
KW  - AUTOIMMUNE HEMOLYTIC-ANEMIA
AD  - Dr BRA IRCH, All India Inst Med Sci, Lab Oncol Unit, Room 423, New Delhi, IndiaAD  - Dr BRA IRCH, All India Inst Med Sci, Med Oncol Unit, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - OCT
PY  - 2018
VL  - 34
IS  - 4
SP  - 758
EP  - 759
DO  - 10.1007/s12288-018-0944-y
AN  - WOS:000451752900034
ER  -

TY  - JOUR
AU  - George, A
AU  - Thottian, F
AU  - Gandhi, AK
AU  - Ramateke, PP
AU  - Gogia, A
TI  - Acinic cell carcinoma of parotid gland with cavernous sinus metastasis: A case report
T2  - JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
KW  - Acinic cell carcinoma
KW  - cavernous sinus
KW  - metastasis
KW  - parotid cancer
AB  - Acinic cell carcinoma (AciCC) is a low-grade malignancy which rarely metastasizes to bone or cavernous sinuses. A 62-year-old male patient, previously treated for AciCC of right parotid with surgery and local radiotherapy, presented 10 years later with progressive visual impairment and restriction of ocular movements. Magnetic resonance imaging of the head and orbit showed an expansile lobulated mass with heterogeneous signal intensity in bilateral cavernous sinus with encasement of the internal carotid artery on both sides. Fluorodeoxyglucose positron emission tomography/computed tomography showed multiple lytic lesions with increased uptake in the left clavicle (with soft tissue component), sternum, multiple cervico-dorso-lumbar vertebrae, and ribs. Biopsy from the clavicular lesion showed AciCC. He was treated with palliative radiotherapy to cavernous sinuses and other metastatic site followed by palliative chemotherapy with six cycles of paclitaxel and carboplatin. He had a partial response to palliative treatment and had good symptomatic relief at 12 months of follow-up.
AD  - Dr BR Ambedkar Inst Rotary Canc Hosp, All India Inst Med Sci, Dept Radiat Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Med Oncol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - OCT-DEC
PY  - 2018
VL  - 14
IS  - 6
SP  - 1428
EP  - 1430
C7  - PMID 30488869
DO  - 10.4103/0973-1482.192850
AN  - WOS:000452548200046
ER  -

TY  - JOUR
AU  - Godiyal, AK
AU  - Verma, HK
AU  - Khanna, N
AU  - Joshi, D
TI  - A Force Myography-Based System for Gait Event Detection in Overground and Ramp Walking
T2  - IEEE TRANSACTIONS ON INSTRUMENTATION AND MEASUREMENT
KW  - Force myography (FMG)
KW  - gait cycle
KW  - heel strike (HS)
KW  - locomotion
KW  - toe-off (TO)
KW  - transitions
KW  - TIME-FREQUENCY ANALYSIS
KW  - AUTOMATED DETECTION
KW  - KINEMATIC DATA
KW  - LOCOMOTION
KW  - SENSORS
KW  - LEVEL
KW  - PHASE
KW  - TOE
KW  - TRANSITIONS
AB  - In this paper, we present a novel method to determine the heel strike (HS) and toe-off (TO) during overground (OG) and ramp walking, including the transition. The method utilizes force myography (FMG) signals from thighs while subjects walked on OG and ramp. Five adult male subjects wore a wireless FMG data acquisition system, developed in-house using force resistive sensors and electronic components. A heuristic approach for subject-dependent and terrain-independent model was developed to determine HS and TO in a given gait cycle in steady state and transition. The average error in HS determination was 9.66 +/- 8.29, 938 +/- 9.35, and 13.94 +/- 18.95 ms, while TO was determined with an average error of 16.99 +/- 18.12, 13.35 +/- 15.10, and 17.29 +/- 21.92 ms for OG, ramp, and transition, respectively. The proposed system is less expensive, simple to develop, and friendly to wear. The reported errors are comparable to previously reported errors using pressure sensitive insole, gyroscope, accelerometers, and electromyography, which are much complex and expensive in comparison to proposed FMG-based system. Although the tests were conducted on healthy subjects, the system promises to be generalizable to amputee and other pathological gaits also. While the tests were conducted on young adults at self-selected speeds, the system also promises to be generalizable for a wide range of walking speeds across the population.
AD  - IIT Delhi, Ctr Biomed Engn, New Delhi 110016, IndiaAD  - All India Inst Med Sci, Dept Biomed Engn, New Delhi 110029, IndiaAD  - IIT Gandhinagar, Dept Elect Engn, Gandhinagar 382355, IndiaAD  - IIT Gandhinagar, Elect Engn, Gandhinagar 382355, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - GandhinagarC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - GandhinagarPU  - IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI  - PISCATAWAY
PA  - 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
DA  - OCT
PY  - 2018
VL  - 67
IS  - 10
SP  - 2314
EP  - 2323
DO  - 10.1109/TIM.2018.2816799
AN  - WOS:000445241500006
ER  -

TY  - JOUR
AU  - Gogia, A
AU  - Raina, V
AU  - Deo, SVS
AU  - Shukla, NK
AU  - Mathur, S
AU  - Mohanti, BK
AU  - Sharma, DN
TI  - Clinico-pathological characteristics and treatment outcome in invasive lobular carcinoma of the breast: An Indian experience
T2  - INDIAN JOURNAL OF CANCER
KW  - Invasive lobular carcinoma
KW  - outcome
KW  - pathological characteristics
KW  - CANCER
KW  - CHEMOTHERAPY
KW  - TAMOXIFEN
AB  - BACKGROUND: Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer and accounts for 10%u15% of all breast cancers in the west. There is a scarcity of data on ILC from the Indian subcontinent. This report intends to present the patterns of care, survival outcomes, and prognostic factors of ILC treated in a tertiary care institute. MATERIALS AND METHODS: This retrospective analysis included consecutive patients diagnosed with ILC and registered at our Institute between 2009 and 2016. RESULTS: We included 97 patients with a median age of 53 years (range 28u80). American Joint Committee on Cancer (7(th) edition) stage distribution was stage I-8.24%, stage II-45.36%, stage III- 34.10%, and stage IV-12.30%. Bilateral breast cancer was seen in 8 cases. Estrogen receptor, progesterone receptor, and HER 2/neu positivity was 90%, 85%, and 9%, respectively. Triple-negative breast cancer constituted 5% of cases. Twenty-nine events were recorded (systemic and locoregional relapse) with a median follow-up of 3.5 years. Three years relapse-free survival (RFS) and overall survival were 80% and 60%, respectively. Bones were the most common site of metastasis. Age <45 years [HR-1.4 (0.8u2.1), P < 0.001] and advanced clinical tumor stage [T4, HR-2.1 (1.1u3.8), P = 0.001] were associated with poor RFS. CONCLUSION: ILC constituted 2.5% of breast cancer cases at our institute. Triple negativity and HER-2/neu positivity were seen in 9% and 5% of cases, respectively. Age <45 years and advanced clinical tumor stage were associated with poor RFS.
AD  - All India Inst Med Sci, Dept Med Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Surg Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiat Oncol, New Delhi, IndiaAD  - Fortis Mem Res Inst, Dept Med Oncol, Gurgaon, Haryana, IndiaAD  - Fortis Mem Res Inst, Dept Radiat Oncol, Gurgaon, Haryana, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - OCT-DEC
PY  - 2018
VL  - 55
IS  - 4
SP  - 344
EP  - 347
DO  - 10.4103/ijc.IJC_428_18
AN  - WOS:000460297000006
ER  -

TY  - JOUR
AU  - Gordon, T
AU  - Balakrishnan, K
AU  - Dey, S
AU  - Rajagopalan, S
AU  - Thornburg, J
AU  - Thurston, G
AU  - Agrawal, A
AU  - Collman, G
AU  - Guleria, R
AU  - Limaye, S
AU  - Salvi, S
AU  - Kilaru, V
AU  - Nadadur, S
TI  - Air pollution health research priorities for India: Perspectives of the Indo-US Communities of Researchers
T2  - ENVIRONMENT INTERNATIONAL
KW  - Indoor and outdoor air pollution
KW  - India
KW  - Biomass burning
KW  - Pollution sources
KW  - COMPARATIVE RISK-ASSESSMENT
KW  - GLOBAL BURDEN
KW  - PARTICULATE MATTER
KW  - POPULATION EXPOSURE
KW  - SYSTEMATIC ANALYSIS
KW  - PUBLIC-HEALTH
KW  - MORTALITY
KW  - DISEASE
KW  - QUALITY
KW  - HOUSEHOLD
AD  - NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY 10987 USAAD  - Sri Ramachandra Univ, Fac Publ Hlth, Dept Environm Hlth Engn, Madras 600116, Tamil Nadu, IndiaAD  - Indian Inst Technol Delhi, Ctr Atmospher Sci, Hauz Khas, New Delhi 110016, IndiaAD  - Case Western Reserve Univ, Dept Internal Med, 11100 Euclid Ave, Cleveland, OH 44106 USAAD  - RTI Int, Res Triangle Pk, NC USAAD  - Delhi Univ, CSIR Inst Genom & Integrat Biol, New Delhi, IndiaAD  - NIEHS, Div Extramural Res & Training, POB 12233, Res Triangle Pk, NC 27709 USAAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Chest Res Fdn, Pune, Maharashtra, IndiaAD  - US EPA, Off Res & Dev, Res Triangle Pk, NC 27711 USAC3  - New York UniversityC3  - Sri Ramachandra Institute of Higher Education & ResearchC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - University System of OhioC3  - Case Western Reserve UniversityC3  - Research Triangle InstituteC3  - University of DelhiC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - National Institutes of Health (NIH) - USAC3  - NIH National Institute of Environmental Health Sciences (NIEHS)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - United States Environmental Protection AgencyPU  - PERGAMON-ELSEVIER SCIENCE LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
DA  - OCT
PY  - 2018
VL  - 119
SP  - 100
EP  - 108
DO  - 10.1016/j.envint.2018.06.013
AN  - WOS:000444918100010
ER  -

TY  - JOUR
AU  - Gour, SSK
AU  - Agrawal, M
AU  - Sawarkar, D
TI  - Altered intracranial venous physiology
T2  - JOURNAL OF NEUROSURGERY-PEDIATRICS
KW  - CRANIOSYNOSTOSIS
KW  - CHILDREN
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ASSOC NEUROLOGICAL SURGEONS
PI  - ROLLING MEADOWS
PA  - 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
DA  - OCT
PY  - 2018
VL  - 22
IS  - 4
SP  - 464
EP  - 465
DO  - 10.3171/2018.5.PEDS18288
AN  - WOS:000446245200024
ER  -

TY  - JOUR
AU  - Gupta, R
AU  - Talwar, P
AU  - Talwar, P
AU  - Khurana, S
AU  - Kushwaha, S
AU  - Jalan, N
AU  - Thakur, R
TI  - Diagnostic accuracy of nucleic acid amplification based assays for tuberculous meningitis: A meta-analysis
T2  - JOURNAL OF INFECTION
KW  - Tuberculous meningitis
KW  - Gene targets
KW  - M. tuberculosis
KW  - Nucleic Acid Amplification Tests
KW  - Diagnostic accuracy
KW  - GeneXpert
KW  - POLYMERASE-CHAIN-REACTION
KW  - MEDIATED ISOTHERMAL AMPLIFICATION
KW  - RAPID DIAGNOSIS
KW  - MYCOBACTERIUM-TUBERCULOSIS
KW  - CEREBROSPINAL-FLUID
KW  - GENEXPERT MTB/RIF
KW  - IS6110 PRIMERS
KW  - PCR
KW  - TESTS
KW  - IDENTIFICATION
AB  - Background: Numerous in-house and commercial nucleic acid amplification tests (NAAT) have been evaluated using variable reference standards for diagnosis of TBM but their diagnostic potential is still not very clear.
   Methods: We conducted a meta-analysis to assess the diagnostic accuracy of different NAAT based assays for diagnosing TBM against 43 data sets of confirmed TBM (n = 1066) and 61 data sets of suspected TBM (n=3721) as two reference standards. The summary estimate of the sensitivity and the specificity were obtained using the bivariate model. QUADAS-2 tool was used to perform the Quality assessment for bias and applicability. Publication bias was assessed with Deeks' funnel plot.
   Results: Studies with confirmed TBM had better summary estimates as compared to studies with clinically suspected TBM irrespective of NAAT and index tests used. Among in-house assays, MPB as the gene target had best summary estimates in both confirmed [sensitivity:90%(83-95), specificity:97%(87-99), DOR:247 (50-1221), AUC:99%(97-100), PLR:38.8-(6.6-133), NLR:0.11(0.05-0.18), h=15%] and clinically suspected [sensitivity:69%(47-85), specificity:96%(90-98), DOR:62(16.8-232), AUC:94%(92-97), PLR:16.9(6.5-36.8), NLR:0.33(0.16-0.56), P:15.3%] groups. GeneXpert revealed good diagnostic accuracy only in confirmed TBM group [sensitivity -57%(38-74), specificity -98%(89-100), DOR-62(7-589), AUC-87%(79-96), PLR-33.2(3.8-128), NLR 0.45(0.26-0.68), I-2 = 0%].
   Conclusions: This meta-analysis identified potential role of MPB gene among in-house assays and GeneXpert as commercial assay for diagnosing TBM. (C) 2018 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
AD  - Inst Human Behav & Allied Sci, Dept Microbiol, Delhi 110095, IndiaAD  - Inst Human Behav & Allied Sci, Dept Neurol, Delhi 110095, IndiaAD  - Inst Human Behav & Allied Sci, Dept Epidemiol, Delhi 110095, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - W B SAUNDERS CO LTD
PI  - LONDON
PA  - 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
DA  - OCT
PY  - 2018
VL  - 77
IS  - 4
SP  - 302
EP  - 313
DO  - 10.1016/j.jinf.2018.04.017
AN  - WOS:000444886500006
ER  -

TY  - JOUR
AU  - Gupta, S
AU  - Lodha, R
AU  - Kabra, SK
TI  - Asthma, GERD and Obesity: Triangle of Inflammation
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Asthma
KW  - Gastroesophageal reflux
KW  - Obesity
KW  - Sleep disordered breathing
KW  - Inflammation
KW  - GASTROESOPHAGEAL-REFLUX DISEASE
KW  - OBSTRUCTIVE SLEEP-APNEA
KW  - QUALITY-OF-LIFE
KW  - BODY-MASS
KW  - MECHANISMS
KW  - THERAPY
KW  - ACID
KW  - ASSOCIATION
KW  - ADOLESCENTS
KW  - CHILDREN
AB  - There is increasing prevalence of both asthma and obesity in children globally in recent years. Various epidemiological studies link obesity as a risk factor for asthma and suggest a possible causal association. Obesity asthma phenotype is considered as distinct in view of greater severity and poor asthma control. Various mechanisms underlying this phenotype have been suggested including mechanical effects of obesity and systemic inflammation, but still the exact mechanism is unclear. Also, the comorbidities like gastroesophageal reflux disease (GERD) and sleep disordered breathing (SDB) lead to inflammation in airways and contribute to asthma obesity association. A better understanding of mechanisms by which obesity and GERD lead to inflammation in airways and increase the risk of asthma may provide insight towards targeted treatment approach of these patients.
AD  - All India Inst Med Sci, Dept Pediat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - OCT
PY  - 2018
VL  - 85
IS  - 10
SP  - 887
EP  - 892
DO  - 10.1007/s12098-017-2484-0
AN  - WOS:000445955200017
ER  -

TY  - JOUR
AU  - Gupta, SK
AU  - Siddharth, V
AU  - Belagere, MR
AU  - Stewardson, AJ
AU  - Kant, S
AU  - Singh, S
AU  - Singh, N
TI  - National survey of infection control programmes in South Asian association for Regional Cooperation countries in the era of patient safety
T2  - INDIAN JOURNAL OF MEDICAL MICROBIOLOGY
KW  - Healthcare-associated infection
KW  - infection control
KW  - infection prevention
KW  - patient safety
KW  - HOSPITALS
KW  - ORGANIZATION
AB  - Background: The implementation of hospital infection prevention and control (IPC) in south Asia is not well described. We aimed to assess IPC programmes in hospitals in this region and explore opportunities for improvement. Methods: Attendees from hospitals in the South Asian Association for Regional Cooperation (SAARC) region who were at one of four National Initiative for Patient Safety workshops organised by All India Institute of Medical Sciences (New Delhi) from 2009 to 2012 were invited to complete a semi-structured questionnaire. The survey addressed six main components of IPC programmes. Results: We received responses from 306 participants from 82 hospitals. Five key opportunities for improvement emerged: (1) lack of healthcare epidemiologists, (2) relative infrequency of antibiotic guidelines (53%) and prescribing audits (33%) (3) lack of awareness of needle stick injury rates (84%) (4) only 47% of hospitals were prepared for surge capacity for patients with infectious diseases, and (5) limited coordination of hospital infection control personnel with other support services (55%-66%). Conclusion: These results outline IPC challenges in the SAARC region and may be useful to guide future quality improvement initiatives.
AD  - All India Inst Med Sci, Dr RP Ctr, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Hosp Adm, New Delhi 110029, IndiaAD  - Armed Forces Med Coll, Dept Hosp Adm, Pune, Maharashtra, IndiaAD  - Amrita Inst Med Sci, Sch Med, Kochi, Kerala, IndiaAD  - Alfred Hlth, Dept Infect Dis, Melbourne, Vic, AustraliaAD  - Monash Univ, Cent Clin Sch, Melbourne, Vic, AustraliaAD  - George Washington Univ, Dept Pediat Global Hlth & Epidemiol, Childrens Natl Hlth Syst, Washington, DC USAC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Armed Forces Medical CollegeC3  - Amrita Vishwa VidyapeethamC3  - Amrita Vishwa Vidyapeetham KochiC3  - Monash UniversityC3  - Children's National Health SystemC3  - George Washington UniversityPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - OCT-DEC
PY  - 2018
VL  - 36
IS  - 4
SP  - 577
EP  - 581
DO  - 10.4103/ijmm.IJMM_18_82
AN  - WOS:000462457300021
ER  -

TY  - JOUR
AU  - Gutman, T
AU  - Hanson, CS
AU  - Bernays, S
AU  - Craig, JC
AU  - Sinha, A
AU  - Dart, A
AU  - Eddy, AA
AU  - Gipson, DS
AU  - Bockenhauer, D
AU  - Yap, HK
AU  - Groothoff, J
AU  - Zappitelli, M
AU  - Webb, NJA
AU  - Alexander, SI
AU  - Goldstein, SL
AU  - Furth, S
AU  - Samuel, S
AU  - Blydt-Hansen, T
AU  - Dionne, J
AU  - Michael, M
AU  - Wenderfer, SE
AU  - Winkelmayer, WC
AU  - Currier, H
AU  - McTaggart, S
AU  - Walker, A
AU  - Ralph, AF
AU  - Ju, A
AU  - James, LJ
AU  - Carter, S
AU  - Tong, A
TI  - Child and Parental Perspectives on Communication and Decision Making in Pediatric CKD: A Focus Group Study
T2  - AMERICAN JOURNAL OF KIDNEY DISEASES
KW  - CHRONIC KIDNEY-DISEASE
KW  - HEALTH-CARE
KW  - CHRONIC ILLNESS
KW  - YOUNG-ADULTS
KW  - ADOLESCENTS
KW  - PARTICIPATION
KW  - MODEL
KW  - FRAMEWORK
KW  - EXPERIENCES
KW  - ENCOUNTER
AB  - Background & Objectives: Effective communication and shared decision making improve quality of care and patient outcomes but can be particularly challenging in pediatric chronic disease because children depend on their parents and clinicians to manage complex health care and developmental needs. We aimed to describe the perspectives of children with chronic kidney disease (CKD) and their parents with regard to communication and decision making.
   Study Design: Qualitative study.
   Setting & Participants: Children with CKD (n = 34) and parents (n = 62) from 6 centers across 6 cities in Australia, Canada, and the United States participated in 16 focus groups.
   Analytical Approach: Transcripts were analyzed thematically.
   Results: We identified 4 themes: (1) dis-empowered by knowledge imbalance (unprepared and ill-informed, suspicion of censorship, and inadequacy as technicians), (2) recognizing own expertise (intuition and instinct unique to parental bond, emerging wisdom and confidence, identifying opportunities for control and inclusion, and empowering participation in children), (3) striving to assert own priorities (negotiating broader life impacts, choosing to defer decisional burden, overprotected and overruled, and struggling to voice own preferences), and (4) managing child's involvement (respecting child's expertise, attributing "risky" behaviors to rebellion, and protecting children from illness burden).
   Limitations: Only English-speaking participants were recruited, which may limit the transferability of the findings. We collected data from child and parent perspectives; however, clinician perspectives may provide further understanding of the difficulties of communication and decision making in pediatrics.
   Conclusions: Parents value partnership with clinicians and consider long-term and quality-of-life implications of their child's illness. Children with CKD want more involvement in treatment decision making but are limited by vulnerability, fear, and uncertainty. There is a need to support the child to better enable him or her to become a partner in decision making and prepare him or her for adulthood. Collaborative and informed decision making that addresses the priorities and concerns of both children and parents is needed.
AD  - Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, AustraliaAD  - Childrens Hosp Westmead, Ctr Kidney Res, Westmead, NSW, AustraliaAD  - All India Inst Med Sci, Dept Pediat, Div Nephrol, New Delhi, IndiaAD  - Univ Manitoba, Childrens Hosp Res Inst Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, CanadaAD  - BC Childrens Hosp, Dept Pediat, Vancouver, BC, CanadaAD  - Univ British Columbia, Vancouver, BC, CanadaAD  - Univ Michigan, Dept Pediat, Div Nephrol, Ann Arbor, MI 48109 USAAD  - UCL Ctr Nephrol, London, EnglandAD  - Great Ormond St Hosp Children NHS Fdn Trust, London, EnglandAD  - Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pediat, Singapore, SingaporeAD  - Emma Childrens Hosp, Dept Pediat Nephrol, AMC Acad Med Ctr, Amsterdam, NetherlandsAD  - Univ Toronto, Toronto Hosp Sick Children, Dept Pediat, Div Nephrol, Toronto, ON, CanadaAD  - Univ Manchester, Royal Manchester Childrens Hosp, Manchester Acad Hlth Sci Ctr, Dept Pediat Nephrol, Manchester, Lancs, EnglandAD  - Univ Manchester, Royal Manchester Childrens Hosp, Manchester Acad Hlth Sci Ctr, NIHR Manchester Clin Res Facil, Manchester, Lancs, EnglandAD  - Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USAAD  - Childrens Hosp Philadelphia, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USAAD  - Childrens Hosp Philadelphia, Dept Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USAAD  - Childrens Hosp Philadelphia, Div Nephrol, Philadelphia, PA 19104 USAAD  - Univ Calgary, Dept Pediat, Sect Nephrol, Calgary, AB, CanadaAD  - Texas Childrens Hosp, Dept Pediat, Baylor Coll Med, Renal Sect, Houston, TX 77030 USAAD  - Baylor Coll Med, Selzman Inst Kidney Hlth, Sect Nephrol, Houston, TX 77030 USAAD  - Lady Cilento Childrens Hosp, Child & Adolescent Renal Serv, South Brisbane, Qld, AustraliaAD  - Univ Melbourne, Dept Nephrol, Dept Paediat, Royal Childrens Hosp Melbourne, Parkville, Vic, AustraliaAD  - Murdoch Childrens Res Inst, Parkville, Vic, AustraliaC3  - University of SydneyC3  - NSW HealthC3  - Sydney Childrens Hospitals NetworkC3  - The Children's Hospital at WestmeadC3  - University of SydneyC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of ManitobaC3  - Children's Hospital Research Institute of ManitobaC3  - BC Childrens HospitalC3  - University of British ColumbiaC3  - University of British ColumbiaC3  - University of Michigan SystemC3  - University of MichiganC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - Great Ormond Street Hospital for Children NHS Foundation TrustC3  - National University of SingaporeC3  - University of AmsterdamC3  - Academic Medical Center AmsterdamC3  - Emma Children's HospitalC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - Royal Manchester Children's HospitalC3  - University of ManchesterC3  - University of ManchesterC3  - Royal Manchester Children's HospitalC3  - Cincinnati Children's Hospital Medical CenterC3  - University of PennsylvaniaC3  - Pennsylvania MedicineC3  - Childrens Hospital of PhiladelphiaC3  - University of PennsylvaniaC3  - Pennsylvania MedicineC3  - Childrens Hospital of PhiladelphiaC3  - University of PennsylvaniaC3  - Pennsylvania MedicineC3  - Childrens Hospital of PhiladelphiaC3  - University of CalgaryC3  - Baylor College of MedicineC3  - Baylor College Medical HospitalC3  - Baylor College of MedicineC3  - Childrens Health Queensland Hospital & Health ServiceC3  - Queensland Childrens HospitalC3  - Royal Children's Hospital MelbourneC3  - University of MelbourneC3  - Murdoch Children's Research InstitutePU  - W B SAUNDERS CO-ELSEVIER INC
PI  - PHILADELPHIA
PA  - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
DA  - OCT
PY  - 2018
VL  - 72
IS  - 4
SP  - 547
EP  - 559
DO  - 10.1053/j.ajkd.2018.05.005
AN  - WOS:000445122300011
ER  -

TY  - JOUR
AU  - Gyawali, S
AU  - Sarkar, S
AU  - Balhara, YPS
AU  - Kumar, S
AU  - Patil, V
AU  - Singh, S
TI  - Perceived stigma and its correlates among treatment seeking alcohol and opioid users at a tertiary care centre in India
T2  - ASIAN JOURNAL OF PSYCHIATRY
KW  - Stigma
KW  - Substance use
KW  - Perceived stigma
KW  - India
KW  - SCHIZOPHRENIA SPECTRUM DISORDERS
KW  - MENTAL-ILLNESS
KW  - INTERNALIZED STIGMA
KW  - SELF-ESTEEM
KW  - SUBSTANCE USERS
KW  - PEOPLE
KW  - HEALTH
KW  - DISCRIMINATION
KW  - CONSEQUENCES
KW  - EFFICACY
AB  - Background and aims: Perceived stigma is related to the beliefs that members of stigmatized group have about the stigmatizing attitudes present in society. We present the data on perceived stigma in alcohol and opioid users seeking treatment.
   Methods: This study was conducted at a tertiary care de-addiction facility with recruitment of patients with substance use disorders (alcohol and opioid use). Perceived stigma was assessed using Perceived Stigma of Substance Abuse Scale (PSAS).
   Results: The study included 201 participants, majority of whom were males (99.5%), educated up to 10th std. (65.7%), with mean duration of substance use of 11.4 years. Opiates were the primary substance of abuse in the majority (83.6%) with ever-injecting drug use present in a considerable proportion (29.4%). The mean perceived stigma scale score was 21.23 +/- 3.03. The perceived stigma was higher in patients from rural background, but was not associated with age, educational status, current living situation, duration of substance use and injecting drug use.
   Conclusion: Stigma remains an important issue among patients with alcohol and opioid use disorders. Perceived stigma could affect participation in society and health seeking behavior in substance using population, thus needs further exploration.
AD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - All India Inst Med Sci, Natl Drug Dependence Treatment Ctr, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)PU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - OCT
PY  - 2018
VL  - 37
SP  - 34
EP  - 37
DO  - 10.1016/j.ajp.2018.07.018
AN  - WOS:000448471300008
ER  -

TY  - JOUR
AU  - Ismail, J
AU  - Sankar, J
TI  - Triage Nurse-Ordered Diagnostic Studies - An Evolving Strategy to Reduce Emergency Department Length of Stay?
T2  - INDIAN JOURNAL OF PEDIATRICS
AD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - OCT
PY  - 2018
VL  - 85
IS  - 10
SP  - 827
EP  - 828
DO  - 10.1007/s12098-018-2780-3
AN  - WOS:000445955200003
ER  -

TY  - JOUR
AU  - Ismail, J
AU  - Chidambaram, M
AU  - Sankar, J
AU  - Agarwal, S
AU  - Lodha, R
TI  - Disseminated Cryptococcosis Presenting as Miliary Lung Shadows in an Immunocompetent Child
T2  - JOURNAL OF TROPICAL PEDIATRICS
KW  - miliary lung shadow
KW  - disseminated cryptococcosis
KW  - child
AB  - Disseminated cryptococcosis is infrequent in immunocompetent children. Pulmonary and central nervous system are the commonly involved sites of infection in an immunocompromised host. We report a fatal case of disseminated cryptococcosis in an immunocompetent host presenting as fever of unknown origin with miliary shadows on chest radiograph, mimicking tuberculosis. In countries with the heavy burden of tuberculosis, a high index of suspicion is needed for early diagnosis of its close mimics like disseminated cryptococcosis.
AD  - All India Inst Med Sci, Dept Pediat, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - OXFORD UNIV PRESS
PI  - OXFORD
PA  - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
DA  - OCT
PY  - 2018
VL  - 64
IS  - 5
SP  - 434
EP  - 437
DO  - 10.1093/tropej/fmx083
AN  - WOS:000446114500012
ER  -

TY  - JOUR
AU  - Jat, KR
AU  - Kumar, A
TI  - Sublingual Immunotherapy in Allergic Rhinitis: Search for a Suitable Biomarker Continues!
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - LEVEL
AD  - All India Inst Med Sci, Dept Pediat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - OCT
PY  - 2018
VL  - 85
IS  - 10
SP  - 834
EP  - 835
DO  - 10.1007/s12098-018-2773-2
AN  - WOS:000445955200007
ER  -

TY  - JOUR
AU  - Jauhari, P
TI  - Current Knowledge, Attitude and Practice (KAP) of Pediatricians on Infantile Spasms and the Way Forward
T2  - INDIAN JOURNAL OF PEDIATRICS
AD  - AIIMS, Child Neurol Div, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - OCT
PY  - 2018
VL  - 85
IS  - 10
SP  - 823
EP  - 824
DO  - 10.1007/s12098-018-2760-7
AN  - WOS:000445955200001
ER  -

TY  - JOUR
AU  - Kakkar, A
AU  - Pradeep, I
AU  - Singh, G
AU  - Dinda, A
AU  - Agarwal, SK
TI  - Peripheral T-Cell Lymphoma: A Posttransplant Lymphoproliferative Disorder Presenting as a Jejunal Mass in a Renal Transplant Recipient
T2  - EXPERIMENTAL AND CLINICAL TRANSPLANTATION
KW  - Epstein-Barr virus
KW  - Kidney
KW  - Non-Hodgkin lymphoma
KW  - Transplant
KW  - RISK-FACTORS
AB  - Posttransplant lymphoproliferative disorders are a spectrum of lymphoproliferative disorders seen in recipients of solid-organ, bone marrow, and stem cell allografts. They include polyclonal early lesions mimicking infectious mononucleosis and monoclonal proliferations of B and T cells, indistinguishable from lymphomas occurring in immunocompetent individuals. Although most posttransplant lymphoproliferative disorders are B-cell neoplasms, T-cell posttransplant lymphoproliferative disorders are very rare. Among solid-organ transplants, renal allografts have low risk for development of posttransplant lymphopro liferative disorders. We describe the case of an adult male who developed a T-cell posttransplant lympho proliferative disorder involving the small intestine after renal transplant, which was diagnosed as peripheral T-cell lymphoma, not otherwise specified.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Nephrol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - BASKENT UNIV
PI  - ANKARA
PA  - TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
DA  - OCT
PY  - 2018
VL  - 16
IS  - 5
SP  - 617
EP  - 619
DO  - 10.6002/ect.2016.0042
AN  - WOS:000451460400019
ER  -

TY  - JOUR
AU  - Kamath-Rayne, BD
AU  - Thukral, A
AU  - Visick, MK
AU  - Schoen, E
AU  - Amick, E
AU  - Deorari, A
AU  - Cain, CJ
AU  - Keenan, WJ
AU  - Singhal, N
AU  - Little, GA
AU  - Niermeyer, S
TI  - Helping Babies Breathe, Second Edition: A Model for Strengthening Educational Programs to Increase Global Newborn Survival
T2  - GLOBAL HEALTH-SCIENCE AND PRACTICE
KW  - CARDIOVASCULAR CARE SCIENCE
KW  - NEONATAL RESUSCITATION
KW  - CARDIOPULMONARY-RESUSCITATION
KW  - INTERNATIONAL CONSENSUS
KW  - VILLAGE MIDWIVES
KW  - MORTALITY
KW  - STILLBIRTH
KW  - OUTCOMES
KW  - QUALITY
KW  - IMPACT
AB  - Background: Helping Babies Breathe (HBB), a skills-based program in neonatal resuscitation for birth attendants in resource-limited settings, has been implemented in over 80 countries since 2010. Implementation studies of HBB incorporating low-dose high-frequency practice and quality improvement show substantial reductions in fresh stillbirth and first-day neonatal mortality. Revision of the program aimed to further augment provider and facilitator skills and address gaps in implementation with the goal of improving neonatal survival.
   Methods: The Utstein Formula for Survival-Medical Science X Educational Efficiency X Local Implementation = Survival-provided a framework for the revisions. The 2015 Neonatal Resuscitation Consensus on Science and Treatment Recommendations by the International Liaison Committee on Resuscitation informed scientific updates, which were harmonized with the 2012 World Health Organization Basic Newborn Resuscitation Guidelines. Published literature and program reports, consensus guidelines on reprocessing equipment, systematic collection of suggestions from frontline users, and responses to a semistructured online questionnaire informed educational/implementation revisions. Links to maternal care were added. Draft materials underwent Delphi review and field testing in India and Sierra Leone. An Utstein-style meeting of stakeholders identified key actions for successful implementation.
   Results: Scientific revisions included expectant management of infants with meconium-stained amniotic fluid, limitation of suctioning, and initiating and continuing effective ventilation until spontaneous respirations. Frontline users (N=102) suggested augmented simulation methods to build confidence and competence and additional guidance for facilitators on implementation. Users identified a need for sufficient practice during the workshop, systematized ongoing practice, and enough simulators for participants. Field trials refined approaches to self-reflection, feedback and debriefing, and quality improvement. Utstein meeting stakeholders validated the importance of quality improvement and use of data to improve outcomes.
   Conclusions: The second edition of HBB provides a newer paradigm of learning for providers that incorporates workshop practice, self-reflection, and feedback and debriefing to reinforce learning as well as the promotion of mentorship and development of facilitators, systems for low-dose high-frequency practice in facilities, and quality improvement related to neonatal resuscitation.
AD  - Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45220 USAAD  - Cincinnati Childrens Hosp Med Ctr, Perinatal Inst & Global Child Hlth, Cincinnati, OH 45229 USAAD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaAD  - Latter Day St Char, Salt Lake City, UT USAAD  - Amer Acad Pediat, Div Life Support, Itasca, IL USAAD  - World Hope Int, Alexandria, VA USAAD  - World Hope Int, Freetown, Sierra LeoneAD  - St Louis Univ, Div Neonatol, St Louis, MO 63103 USAAD  - Univ Calgary, Div Neonatol, Calgary, AB, CanadaAD  - Geisel Sch Med Dartmouth, Div Neonatol, Hanover, NH USAAD  - Univ Colorado, Sch Med, Sect Neonatol, Aurora, CO USAC3  - University System of OhioC3  - University of CincinnatiC3  - Cincinnati Children's Hospital Medical CenterC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - American Academy of PediatricsC3  - Saint Louis UniversityC3  - University of CalgaryC3  - Dartmouth CollegeC3  - University of Colorado SystemC3  - University of Colorado Anschutz Medical CampusPU  - JOHNS HOPKINS CENTER COMMUNICATION PROGRAMS-CCP
PI  - BALTIMORE
PA  - KNOWLEDGE SUCCESS PROJECT, 111 MARKET PLACE, STE 310, BALTIMORE, MD, UNITED STATES
DA  - OCT
PY  - 2018
VL  - 6
IS  - 3
SP  - 538
EP  - 551
DO  - 10.9745/GHSP-D-18-00147
AN  - WOS:000446354000013
ER  -

TY  - JOUR
AU  - Katwa, U
AU  - Kabra, SK
TI  - Advances in Asthma - III
T2  - INDIAN JOURNAL OF PEDIATRICS
AD  - Harvard Univ, Boston Childrens Hosp, Dept Med, Div Resp Dis, Boston, MA 02115 USAAD  - All India Inst Med Sci, Dept Pediat, New Delhi 110029, IndiaC3  - Harvard UniversityC3  - Boston Children's HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - OCT
PY  - 2018
VL  - 85
IS  - 10
SP  - 885
EP  - 886
DO  - 10.1007/s12098-018-2784-z
AN  - WOS:000445955200016
ER  -

TY  - JOUR
AU  - Kedia, S
AU  - Jain, S
AU  - Goyal, S
AU  - Bopanna, S
AU  - Yadav, DP
AU  - Sachdev, V
AU  - Sahni, P
AU  - Pal, S
AU  - Dash, NR
AU  - Makharia, G
AU  - Travis, SPL
AU  - Ahuja, V
TI  - Potential of Fecal Calprotectin as an Objective Marker to Discriminate Hospitalized Patients with Acute Severe Colitis from Outpatients with Less Severe Disease
T2  - DIGESTIVE DISEASES AND SCIENCES
KW  - Fecal calprotectin
KW  - Acute severe colitis
KW  - Ulcerative colitis
KW  - Mayo score
KW  - Hospitalization
KW  - INFLAMMATORY-BOWEL-DISEASE
KW  - C-REACTIVE PROTEIN
KW  - ULCERATIVE-COLITIS
KW  - LACTOFERRIN
KW  - PREDICT
KW  - RELAPSE
AB  - BackgroundAcute severe colitis (ASC) is conventionally diagnosed by Truelove and Witts' criteria which are non-specific and can be affected by other pathologic conditions. Fecal calprotectin (FCP) is a gut-specific marker of inflammation which can predict short-term outcomes in patients with ASC. We aimed to define the role of FCP in the diagnosis of ASC. MethodsThis prospective observational cohort study included adult patients (>18years) with ulcerative colitis (UC) for whom FCP was measured and was under follow-up from April 2015 to December 2016. Patients were divided into two cohorts: (1) all consecutive hospitalized patients with ASC as defined by Truelove and Witts' criteria; (2) outpatients with active UC (defined by Mayo score) who did not fulfill Truelove and Witts' criteria. FCP levels were compared between the two cohorts, and a cutoff for FCP to diagnose ASC was determined.ResultsOf 97 patients, 49 were diagnosed with ASC (mean age: 36.111.9years, 36 males) and 48 with active UC (mean age: 37.9 +/- 12.4years, 25 males). Median FCP levels were significantly higher in patients with ASC [1776(952-3123) vs 282(43-568) mu g/g, p<0.001] than mild to moderately active UC (n=48) or moderately active UC [n=35, 1776(952-3123) vs 332(106-700) mu g/g, p<0.001]. A FCP cutoff of 782g/g of stool had excellent diagnostic accuracy, with an area under the curve of 0.92(95% CI 0.87-0.97), sensitivity of 84% and specificity of 88% to differentiate ASC from active UC.Conclusion FCP could differentiate ASC from mild to moderate patients with UC, but requires validation before clinical use.
AD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept GI Surg, New Delhi, IndiaAD  - John Radcliffe Hosp, Translat Gastroenterol Unit, Headley Way, Oxford, EnglandC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of OxfordPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - OCT
PY  - 2018
VL  - 63
IS  - 10
SP  - 2747
EP  - 2753
DO  - 10.1007/s10620-018-5157-6
AN  - WOS:000444614000034
ER  -

TY  - JOUR
AU  - Khanduja, S
AU  - Takkar, B
AU  - Khanduja, N
AU  - Venkatesh, P
TI  - Post-transplant erythrocytosis-related maculopathy: successful management of hyperviscosity with phlebotomy
T2  - INTERNATIONAL OPHTHALMOLOGY
KW  - Cystoid macular edema
KW  - Hyperviscosity retinopathy
KW  - Phlebotomy
KW  - Post-renal transplant erythrocytosis
KW  - OCULAR COMPLICATIONS
KW  - PATIENT
AB  - PurposeTo report clinical features in a case of hyperviscosity retinopathy following post-renal transplant erythrocytosis (PTE) and its outcome after phlebotomy.MethodsFundus fluorescein angiography and optical coherence tomography (OCT) were carried out for a 29-year-old renal allograft recipient who presented with acute unilateral visual loss.ResultThere was mild retinal vascular dilation in both eyes with retinal hemorrhages and retinal opaqueness in left eye. Cystoid macular edema was noted on OCT. Microvascular leaks and micro-occlusions were seen all around the foveal avascular zone on fluorescein angiogram. Investigations revealed hemoglobin to be 16.8g%, and a PTE was diagnosed. The patient underwent phlebotomy following which there was near complete resolution of macular edema with improvement in vision.ConclusionHyperviscosity retinopathy can cause acute visual loss in cases of renal allograft recipients who develop PTE. Prompt management with phlebotomy can lead to reversal of macular edema in such cases.
AD  - Kalpana Chawla Govt Med Coll & Hosp, Head Dept, Karnal 132001, Haryana, IndiaAD  - All India Inst Med Sci, Retina & Uvea Serv, Dr RP Ctr Ophthalm Sci, New Delhi 110029, IndiaAD  - IGMC, Dept Ophthalmol, Shimla, Himachal Prades, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - Indira Gandhi Medical College & Hospital ShimlaPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - OCT
PY  - 2018
VL  - 38
IS  - 5
SP  - 2163
EP  - 2166
DO  - 10.1007/s10792-017-0660-x
AN  - WOS:000444586400042
ER  -

TY  - JOUR
AU  - Kumar, P
AU  - Kakkar, P
AU  - Ravani, R
AU  - Karthikeya, R
AU  - Kumar, A
TI  - Splenic tuberculosis and multifocal serpiginoid choroiditis
T2  - INTERNATIONAL OPHTHALMOLOGY
KW  - Splenic
KW  - Tuberculosis
KW  - Multifocal
KW  - Serpiginoid
KW  - Choroiditis
KW  - INTRAOCULAR TUBERCULOSIS
AB  - Serpiginoid multifocal choroiditis is a distinct morphological identity with a reported causal association with Mycobacterium tuberculosis. We report a case of serpiginoid multifocal choroiditis in a 17-year-old boy who was suffering from isolated splenic tuberculosis. He was treated with systemic steroids along with anti-tubercular treatment with good visual recovery. This case was unique as no other organs except spleen and choroid showed tubercular involvement. We hereby emphasize association of extrapulmonary sites with multifocal serpiginoid choroiditis and propose a thorough investigation for primary to be included in routine protocol of choroiditis workup.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Unit 2, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - OCT
PY  - 2018
VL  - 38
IS  - 5
SP  - 2191
EP  - 2194
DO  - 10.1007/s10792-017-0689-x
AN  - WOS:000444586400049
ER  -

TY  - JOUR
AU  - Kumar, V
AU  - Chawla, A
AU  - Kaur, A
TI  - Multiple Idiopathic Cervical Root Resorptions in Patients with Hepatitis B Virus Infection
T2  - JOURNAL OF ENDODONTICS
KW  - Hepatitis B virus
KW  - idiopathic root resorption
KW  - multiple idiopathic cervical root resorption
KW  - root resorption
KW  - BONE-MINERAL DENSITY
KW  - HEALTH
KW  - TEETH
AB  - Multiple idiopathic cervical root resorptions are a rare finding. The diagnosis is perplexing, and treatment is a challenge. It is a debilitating condition that often leads to extraction of all the involved teeth. Various theories have been given for explanation of the disease entity; however, the etiology remains elusive. This report describes a case of an 18-year-old man with idiopathic cervical resorption that progressed aggressively and involved 20 teeth. The medical history of hepatitis B virus infection made this case unique in the literature. The mechanism of increased osteoclastic activity in patients with hepatitis B virus infection is discussed as a predisposing factor for the development of root resorption.
AD  - All India Inst Med Sci, Div Conservat Dent & Endodont, Ctr Dent Educ & Res, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - OCT
PY  - 2018
VL  - 44
IS  - 10
SP  - 1575
EP  - 1577
DO  - 10.1016/j.joen.2018.06.017
AN  - WOS:000447225900020
ER  -

TY  - JOUR
AU  - Kumar, V
AU  - Kumar, P
AU  - Roy, S
AU  - Padhy, SK
TI  - Pars Plana Cysts
T2  - OPHTHALMIC SURGERY LASERS & IMAGING RETINA
AB  - A 62-year-old male underwent pars plana vitrectomy for diabetic tractional retinal detachment. Multiple pars plana cysts varying from 2 to 0.5 disc diameter size were noted intraoperatively. These images highlight the utility of intra-operative widefield systems in combination with scleral depression for visualization of periphery of retina. The images also illustrate the details of cysts clearly along with their anatomical relation with era serrata.
AD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SLACK INC
PI  - THOROFARE
PA  - 6900 GROVE RD, THOROFARE, NJ 08086 USA
DA  - OCT
PY  - 2018
VL  - 49
IS  - 10
SP  - E169
EP  - E170
DO  - 10.3928/23258160-20181002-24
AN  - WOS:000448839800012
ER  -

TY  - JOUR
AU  - Kumar, V
AU  - Yadav, B
TI  - HOLE-DOOR SIGN A Novel Intraoperative Optical Coherence Tomography Feature Predicting Macular Hole Closure
T2  - RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
KW  - optical coherence tomography
KW  - microscope integrated
KW  - intraoperative
KW  - macular hole
KW  - 25 gauge
KW  - vitrectomy
KW  - SURGERY
AB  - Purpose: To describe a novel intraoperative finding during pars plana vitrectomy for macular hole using operating microscope-integrated spectral domain optical coherence tomography that predicts the closure of macular hole.
   Methods: Twenty-five eyes of 25 patients with macular hole, who underwent 25-gauge pars plana vitrectomy over a period of 16 months at a tertiary eye care center by a single surgeon, were recruited in this retrospective interventional study. All eyes were assessed with intraoperative spectral domain optical coherence tomography before and after internal limiting membrane peeling. The patients were assessed in terms of best-corrected visual acuity, preoperative minimal hole diameter, and type of hole closure.
   Results: After the internal limiting membrane was peeled, vertical pillars of tissue were seen at the edges of hole projecting into the vitreous cavity. This appearance was similar to that of an open door over the macular hole and was termed "hole-door sign." Hole-door sign was seen in 15 of 25 eyes (60%). All the eyes with hole-door sign had Type-1 closure of macular hole (100%), whereas only 6 of 10 eyes (60%) without hole-door sign had Type-1 closure of the macular hole.
   Conclusion: Hole-door sign is a novel intraoperative finding that predicts postoperative Type-1 closure of macular hole. This may add to the utility of intraoperative optical coherence tomography in clinical practice.
AD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - OCT
PY  - 2018
VL  - 38
IS  - 10
SP  - 2045
EP  - 2050
DO  - 10.1097/IAE.0000000000001791
AN  - WOS:000454005600028
ER  -

TY  - JOUR
AU  - Lamsal, R
AU  - Rath, GP
TI  - Pediatric neuroanesthesia
T2  - CURRENT OPINION IN ANESTHESIOLOGY
KW  - bleeding
KW  - epilepsy surgery
KW  - intraoperative neuromonitoring
KW  - pediatric neurotoxicity
KW  - tranexamic acid
KW  - ACID-ASSOCIATED SEIZURES
KW  - TRANEXAMIC ACID
KW  - SEVOFLURANE ANESTHESIA
KW  - BLOOD-LOSS
KW  - GENERAL-ANESTHESIA
KW  - REPEATED EXPOSURE
KW  - TRAUMA PATIENTS
KW  - TRANSFUSION
KW  - MEMORY
KW  - ISOFLURANE
AB  - Purpose of reviewPediatric neuroanesthesia is a fascinating, yet challenging branch of anesthesia. This review highlights some of the recent insights into pediatric neuroanesthesia from the past 18 months.Recent findingsAlthough there are incontrovertible evidences in animals suggesting that prolonged exposure to general anesthesia causes long-term neurological impairment, the translational relevance of these findings in humans is debatable. Early surgery for pediatric drug-refractory epilepsy is supported by emerging literature, but poses unique perioperative problems for the treating neuroanesthesiologist. Similarly, minimizing intraoperative blood loss and blood transfusion concerns every anesthesiologist managing small children. The usefulness of tranexamic acid in children is further enhanced by some studies in spine surgeries. Some pertinent issues related to intraoperative neuromonitoring are also discussed in the text.SummaryThere are several logistical and ethical problems of carrying out high-quality prospective studies in children but important findings on prevention of anesthetic neurotoxicity; minimizing intraoperative blood loss, intraoperative neurophysiological monitoring, examining optimal doses and choices of anesthetic agents in epilepsy surgery have been published recently.
AD  - All India Inst Med Sci, Dept Neuroanaesthesiol & Crit Care, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - OCT
PY  - 2018
VL  - 31
IS  - 5
SP  - 539
EP  - 543
DO  - 10.1097/ACO.0000000000000630
AN  - WOS:000452775000008
ER  -

TY  - JOUR
AU  - Madhusudhan, KS
AU  - Srivastava, DN
AU  - Sharma, S
AU  - Sharma, S
TI  - Interventional Radiology in India
T2  - AMERICAN JOURNAL OF ROENTGENOLOGY
KW  - India
KW  - Indian Society of Vascular and Interventional Radiology
KW  - interventional radiology
KW  - ENDOVASCULAR EMBOLIZATION
KW  - STEEL COILS
KW  - CATHETER
KW  - DISEASE
AB  - OBJECTIVE. The purpose of this article is to review the status of interventional radiology (IR) in India.
   CONCLUSION. After a few initial challenges, the specialty of interventional radiology (IR) is well established in most cities in India, where various quality procedures are now regularly performed. The national IR society, the Indian Society of Vascular and Interventional Radiology, is still new, but its collaboration with other international societies will help its progress. Education and training in IR are fast evolving in India, and as more radiologists choose IR as their career, IR is bound to progress.
AD  - All India Inst Med Sci, Dept Radiodiag, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Cardiac Radiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ROENTGEN RAY SOC
PI  - RESTON
PA  - 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
DA  - OCT
PY  - 2018
VL  - 211
IS  - 4
SP  - 730
EP  - 735
DO  - 10.2214/AJR.18.19777
AN  - WOS:000445211300011
ER  -

TY  - JOUR
AU  - Mallick, S
AU  - Kunhiparambath, H
AU  - Gupta, S
AU  - Benson, R
AU  - Sharma, S
AU  - Laviraj, MA
AU  - Upadhyay, AD
AU  - Julka, PK
AU  - Sharma, D
AU  - Rath, GK
TI  - Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial)
T2  - JOURNAL OF NEURO-ONCOLOGY
KW  - Glioblastoma
KW  - Hypofractionated radiotherapy
KW  - Accelerated radiotherapy
KW  - Temozolomide
KW  - Surgery
KW  - INTENSITY-MODULATED RADIOTHERAPY
KW  - HIGH-GRADE GLIOMAS
KW  - RADIATION-THERAPY
KW  - PLUS CONCOMITANT
KW  - VALPROIC ACID
KW  - INSTITUTIONAL EXPERIENCE
KW  - OPEN-LABEL
KW  - MULTIFORME
KW  - SURVIVAL
KW  - MUTATIONS
AB  - Maximal safe surgical resection followed by adjuvant chemoradiation has been standard for newly diagnosed glioblastoma multiforme (GBM). Hypofractionated accelerated radiotherapy (HART) has the potential to improve outcome as it reduces the overall treatment time and increases the biological effective dose.
   Between October 2011 and July 2017, a total of 89 newly diagnosed GBM patients were randomized to conventional fractionated radiotherapy (CRT) or HART. Radiotherapy was delivered in all patients with a three-dimensional conformal radiotherapy technique in CRT arm (60 Gy in 30 fractions over 6 weeks @ 2 Gy/per fraction) or simultaneous integrated boost intensity modulated radiotherapy in HART arm (60 Gy in 20 fractions over 4 weeks @ 3 Gy/per fraction to high-risk planning target volume (PTV) and 50 Gy in 20 fractions over 4 weeks @ 2.5 Gy/per fraction to low-risk PTV). The primary endpoint of the trial was overall survival (OS).
   After a median follow-up of 11.4 months (Range: 2.9-42.5 months), 26 patients died and 39 patients had progression of the disease. Median OS for the entire cohort was 23.4 months. Median OS in the CRT and HART arms were 18.07 months (95% CI 14.52-NR) and 25.18 months (95% CI 12.89-NR) respectively, p = 0.3. Median progression free survival (PFS) for the entire cohort was 13.5 months (Range: 11.7-15.7 months). In multivariate analysis patients younger than 40 years of age, patients with a gross total resection of tumor and a mutated IDH-1 had significantly better OS. PFS was significantly better for patients with a gross total resection of tumor and a mutated IDH-1. All patients included in the trial completed the planned course of radiation. Only two patients required hospital admission for features of raised intracranial tension. One patient in the HART arm required treatment interruption.
   HART is comparable to CRT in terms of survival outcome. HART arm had no excess treatment interruption and minimal toxicity. Dose escalation, reduction in overall treatment time, is the advantages with use of HART.
AD  - All India Inst Med Sci, Dept Radiat Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - OCT
PY  - 2018
VL  - 140
IS  - 1
SP  - 75
EP  - 82
DO  - 10.1007/s11060-018-2932-3
AN  - WOS:000446612400009
ER  -

TY  - JOUR
AU  - Mandal, A
AU  - Sahi, PK
TI  - Iron Pots for the Prevention and Treatment of Anemia in Preschoolers: Correspondence
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - COOKING
AD  - Sitaram Bhartia Inst Sci & Res, Dept Pediat, New Delhi, IndiaAD  - All India Inst Med Sci & Res, Dept Pediat, New Delhi, IndiaC3  - Sitaram Bhartia Institute of Science & ResearchC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - OCT
PY  - 2018
VL  - 85
IS  - 10
SP  - 931
EP  - 931
DO  - 10.1007/s12098-018-2644-x
AN  - WOS:000445955200030
ER  -

TY  - JOUR
AU  - Mazzeo, AT
AU  - Gupta, D
TI  - Monitoring the injured brain
T2  - JOURNAL OF NEUROSURGICAL SCIENCES
KW  - Brain injuries, traumatic
KW  - Intracranial pressure
KW  - Microdialysis
KW  - CEREBRAL PERFUSION-PRESSURE
KW  - INTRACRANIAL-PRESSURE
KW  - TISSUE OXYGEN
KW  - DECOMPRESSIVE CRANIECTOMY
KW  - CONSENSUS STATEMENT
KW  - BILATERAL SAMPLES
KW  - METABOLIC CRISIS
KW  - INTENSIVE-CARE
KW  - CYCLOSPORINE-A
KW  - ILL PATIENTS
AB  - Traumatic brain injury can be defined as the most complex disease in the most complex organ. When an acute brain injury occurs, several pathophysiological cascades are triggered, leading to further exacerbation of the primary damage. A number of events potentially occurring after TBI can compromise the availability or utilization of energy substrates in the brain, ultimately leading to brain energy crisis. The frequent occurrence of secondary insults in the acute phase after TBI, such as intracranial hypertension, hypotension, hypoxia, hypercapnia, hyperthermia, seizures, can then increase cerebral damage, and adversely affect outcome. Neuromonitoring techniques provide clinicians and researchers with a mean to detect and reverse those processes that lead to this energy crisis, especially ischemic processes, and have become a critical component of modern neurocritical care. Which is the best way to monitoring the brain after an acute injury has been a matter of debate for decades. This review will discuss how monitoring the injured brain can reduce secondary brain damage and ameliorate outcome after acute brain injury.
AD  - Univ Turin, Dept Surg Sci, Unit Anesthesia & Intens Care, Turin, ItalyAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaAD  - Associated JPN Apex Trauma Ctr, New Delhi, IndiaC3  - University of TurinC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterPU  - EDIZIONI MINERVA MEDICA
PI  - TURIN
PA  - CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
DA  - OCT
PY  - 2018
VL  - 62
IS  - 5
SP  - 549
EP  - 562
DO  - 10.23736/S0390-5616.18.04465-X
AN  - WOS:000445393500004
ER  -

TY  - JOUR
AU  - Meel, R
AU  - Devi, S
AU  - Ganger, A
AU  - Manasa, S
AU  - Pushker, N
TI  - Isolated severe microblepharon in a neonate: a rare case
T2  - INTERNATIONAL OPHTHALMOLOGY
KW  - Congenital anomaly
KW  - Eyelid
KW  - Microblepharon
AB  - PurposeTo report a rare case of isolated severe microblepharon in a neonate.MethodsA 27 days old male child was brought by parents with redness, photophobia and discharge for two weeks. Thorough ophthalmological and systemic examination was performed.ResultsThe diagnosis of isolated severe microblepharon with infectious keratitis was made. After the appropriate management of infectious keratitis and achieving complete resolution, the child was subjected to bilateral lid reconstruction was done in the form of upper lid skin grafting and tarsorrhaphy and the patient is being followed up. ConclusionA rare case of bilateral isolated severe microblepharon affecting all four eyelids is being reported. Urgent surgical intervention is recommended in such cases in order to achieve good corneal coverage which results in faster healing of infective keratitis and a good visual outcome.
AD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, Oculoplasty & Ocular Oncol Serv, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, Cornea & Refract Serv, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - OCT
PY  - 2018
VL  - 38
IS  - 5
SP  - 2175
EP  - 2178
DO  - 10.1007/s10792-017-0675-3
AN  - WOS:000444586400045
ER  -

TY  - JOUR
AU  - Mehrotra, R
AU  - Tulsyan, S
AU  - Hussain, S
AU  - Mittal, B
AU  - Saluja, SS
AU  - Singh, S
AU  - Tanwar, P
AU  - Khan, A
AU  - Javle, M
AU  - Hassan, MM
AU  - Pant, S
AU  - De Aretxabala, X
AU  - Sirohi, B
AU  - Rajaraman, P
AU  - Kaur, T
AU  - Rath, GK
TI  - Genetic landscape of gallbladder cancer: Global overview
T2  - MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
KW  - Gallbladder
KW  - Cancer
KW  - Mutations
KW  - Germline
KW  - Somatic
KW  - Candidate gene
KW  - Genome wide association
KW  - Next generation sequencing
KW  - BILIARY-TRACT CANCERS
KW  - CONFER INCREASED SUSCEPTIBILITY
KW  - DNA-REPAIR GENES
KW  - K-RAS
KW  - TUMOR HETEROGENEITY
KW  - ANOMALOUS JUNCTION
KW  - CANDIDATE GENE
KW  - INCREASED RISK
KW  - VARIANTS
KW  - POLYMORPHISMS
AB  - Gallbladder cancer (GBC) is a rare malignancy of biliary tract cancer (BTC), characterized by late presentation and poor prognosis. It exhibits wide geographical as well as ethnical variations. So, diverse epidemiology along with etiological factors have been discussed in the current article. Present review unravels the germ line polymorphisms contributing to GBC susceptibility through candidate gene approach and GWAS. GBC is enriched with multiple mutations consisting of both passenger and driver mutations. The identification of the hotspot driver mutations which are involved in the etiopathogenesis of this cancer is necessary, before targeted therapies could be implemented clinically. Thus, this review sheds lights on both traditional low throughput methods along with high throughput NGS used to determine somatic mutations in cancer. With the advent of GWAS and high throughput sequencing methods, it is possible to comprehend the mutational landscape of this enigmatic disease. This article is the first one to provide insights into the genetic heterogeneity of GBC along with somatic mutational data from Catalogue of Somatic Mutations in Cancer (COSMIC) database. In addition, management of tumor heterogeneity as a therapeutic challenge has been discussed. Future goals involve liquid biopsy based research for better clinical management of the disease. Therefore, research efforts involving discovery of non-invasive markers for early stage cancer detection along with novel therapies should be directed.
AD  - Natl Inst Canc Prevent & Res, Div Prevent Oncol, Noida, IndiaAD  - Natl Inst Canc Prevent & Res, Div Mol Oncol, Noida, IndiaAD  - Babasaheb Bhimrao Ambedkar Univ, Dept Biotechnol, Lucknow, Uttar Pradesh, IndiaAD  - GB Pant Hosp, Dept Surg Gastroenterol & Hepatol, New Delhi, IndiaAD  - Acad Med Ctr, Clin Epidemiol Biost & Bioinformat, Amsterdam, NetherlandsAD  - All India Inst Med Sci, Rotary Canc Ctr, Lab Oncol Unit, New Delhi, IndiaAD  - Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USAAD  - Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Invest Canc Therapeut, Houston, TX 77030 USAAD  - Clin Alemcma, Dept Surg, Santiago, ChileAD  - Tata Mem Hosp, New India Canc Char Initiat, Res & Educ Canc, Bombay, Maharashtra, IndiaAD  - Tata Mem Hosp, Dept Med Oncol, Bombay, Maharashtra, IndiaAD  - US Hlth Attache, Delhi, IndiaAD  - DHHS, Off Global Affairs, Delhi, IndiaAD  - ICMR, New Delhi, IndiaC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Cancer Prevention & Research (NICPR)C3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Cancer Prevention & Research (NICPR)C3  - Babasaheb Bhimrao Ambedkar UniversityC3  - Govind Ballabh Pant Institute of Postgraduate Medical Education & ResearchC3  - University of AmsterdamC3  - Academic Medical Center AmsterdamC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of Texas SystemC3  - UTMD Anderson Cancer CenterC3  - University of Texas SystemC3  - UTMD Anderson Cancer CenterC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalC3  - Indian Council of Medical Research (ICMR)PU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - OCT-DEC
PY  - 2018
VL  - 778
SP  - 61
EP  - 71
DO  - 10.1016/j.mrrev.2018.08.003
AN  - WOS:000451491400007
ER  -

TY  - JOUR
AU  - Menon, V
AU  - Kattimani, S
AU  - Sarkar, S
AU  - Sathyanarayanan, G
AU  - Subramanian, K
AU  - Velusamy, SK
TI  - Age at onset of first suicide attempt: Exploring the utility of a potential candidate variable to subgroup attempters
T2  - ASIAN JOURNAL OF PSYCHIATRY
KW  - Attempted suicide
KW  - Suicide
KW  - Age at onset
KW  - Mixture analysis
KW  - Psychiatry
KW  - ADMIXTURE ANALYSIS
KW  - COPING STRATEGIES
KW  - CHILDHOOD TRAUMA
KW  - FAMILY-HISTORY
KW  - LIFE EVENTS
KW  - HOPELESSNESS
AB  - Purpose: Our objective was to explore the utility of age at first suicide attempt in identifying subgroups of suicide attempters.
   Methods: In a retrospective study design, we collected information from the clinical charts of 895 patients assessed over a seven-year period. Admixture analysis was used to determine the best fitting theoretical model for distribution of age at first attempt that divided the sample. Subsequently, multivariate analysis was performed to identify variables that distinguished the subgroups identified.
   Results: The theoretical solution that best explained the observed distribution of age at first suicide attempt was a mixture of two Gaussian distributions with a cut-off of 31 years for the two subgroups. In logistic regression analysis, male gender (Odds ratios [OR] 3.047, 95% Confidence Interval (CI) 1.818-5.106), fewer years of formal schooling (OR 3.384, 95% CI 1.701-6.734) and being married (OR 23.36, 95% CI 10.753-50.000), were more commonly associated with the late onset subgroup (age at first attempt > 31 years). Further, the late onset subgroup had poorer global functioning (OR 0.980, 95% CI 0.962 to 0.998).
   Conclusion: Age at onset of first suicide attempt is a useful candidate marker to delineate an early and late onset subgroup among suicide attempters. These results are likely to inform customization of suicide prevention strategies.
AD  - JIPMER, Dept Psychiat, Pondicherry 605006, IndiaAD  - ICMR, Div Epidemiol & Biostat, NIE, Madras 600077, Tamil Nadu, IndiaAD  - All India Inst Med Sci, Dept Psychiat, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Natl Drug Dependence Treatment Ctr, New Delhi 110029, IndiaAD  - MGMCRI, Dept Psychiat, Pondicherry 607402, IndiaC3  - Jawaharlal Institute of Postgraduate Medical Education & ResearchC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Epidemiology (NIE)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)C3  - Mahatma Gandhi Medical College & Research InstitutePU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - OCT
PY  - 2018
VL  - 37
SP  - 40
EP  - 45
DO  - 10.1016/j.ajp.2018.08.006
AN  - WOS:000448471300010
ER  -

TY  - JOUR
AU  - Mondal, D
AU  - Jana, M
AU  - Julka, PK
AU  - Roy, S
TI  - Synchronous orbital and mandibular metastases from squamous cell carcinoma of lung as initial disease presentation in a young female: First report of a rare occurrence
T2  - JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
KW  - Lung
KW  - metastasis
KW  - orbit and mandible
KW  - squamous cell carcinoma
KW  - EYE
KW  - DIAGNOSIS
KW  - TUMORS
KW  - CHINA
AB  - Metastatic tumor to orbit or mandible as initial presentation is rare. According to the available literature, majority of these described cases had its origin from lung and breast. Adenocarcinoma is the most commonly described histology. Concurrence of both of these metastases from a squamous cell carcinoma of the lung has not been reported in literature as initial presenting symptom. A young female patient with synchronous orbital and mandibular metastases as initial presentation of squamous cell carcinoma of the lung is being presented. The patient was treated with palliative radiation and chemotherapy but unfortunately died of progressive disease. To the best our knowledge, this is the first report describing such unusual presentation.
AD  - All India Inst Med Sci, Dept Radiat Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - OCT-DEC
PY  - 2018
VL  - 14
IS  - 6
SP  - 1425
EP  - 1427
C7  - PMID 30488868
DO  - 10.4103/0973-1482.199429
AN  - WOS:000452548200045
ER  -

TY  - JOUR
AU  - Nagori, SA
AU  - Chowdhury, SKR
AU  - Thukral, H
AU  - Jose, A
AU  - Roychoudhury, A
TI  - Single puncture versus standard double needle arthrocentesis for the management of temporomandibular joint disorders: A systematic review
T2  - JOURNAL OF ORAL REHABILITATION
KW  - arthrocentesis
KW  - needle technique
KW  - temporomandibular joint disorders
KW  - HYALURONIC-ACID
KW  - SODIUM HYALURONATE
KW  - DISC DISPLACEMENT
KW  - DISEASE
KW  - LAVAGE
AB  - The aim of this systematic review was to investigate the current evidence in order to assess the efficacy of single puncture arthrocentesis vs standard double needle arthrocentesis in the management of temporomandibular joint(TMJ) disorders. An electronic search of the PubMed, Scopus, Cochrane CENTRAL and Google Scholar databases was performed to identify English studies published up until October 2017. Eligible studies were selected based on inclusion criteria and included randomised controlled trials(RCTs) comparing single puncture arthrocentesis and standard double needle arthrocentesis for the management TMJ disorders. The initial screening identified 984 records, of which only 5 fulfilled the inclusion criteria. A high degree of heterogeneity was found in the 5 studies with each reporting different sample selection and arthrocentesis protocol. All 5 studies reported no difference in reduction in pain intensity and improvement in maximal mouth opening between the single puncture technique and standard double needle technique. This review provides some evidence that single puncture arthrocentesis is clinically as efficacious as standard double needle arthrocentesis. There is a need of well-designed RCT with standard protocol of arthrocentesis comparing different single puncture techniques and standard double needle technique for the management of TMJ disorders.
AD  - 56 APO, Field Hosp 303, New Delhi, IndiaAD  - Armed Forces Med Coll, Div Oral & Maxillofacial Surg, Pune, Maharashtra, IndiaAD  - Army Dent Ctr Res & Referral, Dept Oral & Maxillofacial Surg, New Delhi 10, IndiaAD  - All India Inst Med Sci, Dept Oral & Maxillofacial Surg, New Delhi, IndiaC3  - Armed Forces Medical CollegeC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - OCT
PY  - 2018
VL  - 45
IS  - 10
SP  - 810
EP  - 818
DO  - 10.1111/joor.12665
AN  - WOS:000444418600010
ER  -

TY  - JOUR
AU  - Naithani, R
AU  - Seth, T
AU  - Tandon, N
AU  - Chandra, J
AU  - Choudhry, VP
AU  - Pati, H
AU  - Saxena, R
TI  - Zoledronic Acid for Treatment of Low Bone Mineral Density in Patients with Beta Thalassemia Major
T2  - INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
KW  - Thalassemia
KW  - Osteoporosis
KW  - Bisphosphonate
KW  - OSTEOPOROSIS
KW  - BISPHOSPHONATES
KW  - MANAGEMENT
AB  - To determine the efficacy of zoledronic acid (ZA) in thalassemia major associated low bone mineral density. Prospective, open label, single arm trial. Bone mineral density (BMD) at lumbar, hip and forearm region were performed at baseline and after 1year of therapy. Initial, 9 patients received a first dose of 4mg. Due to severe adverse effects, further doses for these patients and all new recruited patients were 1mg once every 3months for 4 doses. All patients were receiving 500mg of calcium carbonate twice daily and 0.25g alfacalcidol once daily before and during the entire study period. Dual energy X-ray absoptiometry was performed at baseline and after 1year. Twenty-seven patients with transfusion dependent thalassemia with a median age 19.5year (15-38years) were eligible for ZA treatment. Seven patients had bony pains. Four patients developed grade 4 hypocalcemia (3 developed tetany) and 2 developed infusion related toxicity with initial dose of 4mg. One mg dose was well tolerated. At the end of 1year, bone pains had completely resolved. There was significant increase in BMD at lumbar (p=0.002) and forearm regions (p=0.04) and intertrochantric area (p=0.041). The % change in BMD at 1year was +3.7 +/- 3.2%. ZA is an efficacious agent in treatment of low BMD in these patients. ZA produces significant adverse reactions at 4mg dose but 1mg dose is well tolerated and is efficacious.
AD  - All India Inst Med Sci, Dept Hematol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi, IndiaAD  - Lady Hardinge Med Coll & Hosp, Dept Pediat, New Delhi, IndiaAD  - Kalawati Saran Childrens Hosp, New Delhi, IndiaAD  - Max Superspecial Hosp Saket, Div Hematol & Bone Marrow Transplantat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Lady Hardinge Medical College & HospitalPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - OCT
PY  - 2018
VL  - 34
IS  - 4
SP  - 648
EP  - 652
DO  - 10.1007/s12288-018-0953-x
AN  - WOS:000451752900010
ER  -

TY  - JOUR
AU  - Nakra, T
AU  - Jain, D
AU  - Madan, K
AU  - Mallick, S
AU  - Mathur, SR
AU  - Iyer, VK
AU  - Ramteke, P
TI  - Endobronchial ultrasound guided transbronchial needle aspirate from subcarinal lymph node: Mesothelial lesion, a diagnostic dilemma
T2  - CYTOPATHOLOGY
AB  - Endoscopic ultrasound guided needle aspirates in the mediastinum can occasionally produce diagnostic difficulties. We describe a mesothelial lesion which presented in this way and outline the process used to make the final diagnosis.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Pulm Med & Sleep Disorders, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - OCT
PY  - 2018
VL  - 29
IS  - 5
SP  - 486
EP  - 488
DO  - 10.1111/cyt.12547
AN  - WOS:000444462500014
ER  -

TY  - JOUR
AU  - Nambirajan, A
AU  - Sashidharan, A
AU  - Garg, A
AU  - Dash, D
AU  - Bhatia, R
AU  - Sharma, MC
AU  - Mathur, SR
TI  - Cytological diagnosis of cerebrotendinous xanthomatosis in two siblings presenting with bilateral ankle swellings and neurological decline
T2  - CYTOPATHOLOGY
AB  - A rare cytological diagnosis of tendon xanthomas leading to a final diagnosis of cerebrotendinous xanthomatosis in two female siblings presenting with bilateral ankle swellings and neurological decline.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neuroradiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - OCT
PY  - 2018
VL  - 29
IS  - 5
SP  - 482
EP  - 485
DO  - 10.1111/cyt.12573
AN  - WOS:000444462500013
ER  -

TY  - JOUR
AU  - Padhy, S
AU  - Kumar, V
TI  - Dramatic response to intravitreal Bevacizumab in hypertensive retinopathy
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Bevacizumab
KW  - disc edema
KW  - hypertensive retinopathy
KW  - macular edema
KW  - serous macular detachment
AB  - Hypertensive retinopathy is seen frequently in patients with systemic hypertension and is usually asymptomatic. An acute rise in blood pressure may lead to exudative changes in the form of macular edema, hemorrhages, and serous macular detachment that can lead to visual decline. The authors report prompt resolution of exudative changes in a case of hypertensive retinopathy following intravitreal bevacizumab.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - OCT
PY  - 2018
VL  - 66
IS  - 10
SP  - 1494
EP  - 1495
DO  - 10.4103/ijo.IJO_214_18
AN  - WOS:000445668500035
ER  -

TY  - JOUR
AU  - Pal, A
AU  - Kumar, S
AU  - Jain, S
AU  - Nag, TC
AU  - Mathur, R
TI  - Neuroregenerative Effects of Electromagnetic Field and Magnetic Nanoparticles on Spinal Cord Injury in Rats
T2  - JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
KW  - Iron Oxide Nanoparticles
KW  - Spinal Cord Injury
KW  - GAP-43
KW  - IRON-OXIDE NANOPARTICLES
KW  - EVOKED-POTENTIALS
KW  - EXPOSURE
KW  - MODEL
KW  - MOTOR
KW  - RECOVERY
KW  - SYSTEMS
KW  - TRANSECTION
KW  - STIMULATION
KW  - HEMISECTION
AB  - The present study aimed to evaluate the effect of iron oxide nanoparticles (IONPs) along with electromagnetic fields (MF) exposure on spontaneous and induced axonal sprouting after spinal cord injury (SCI). Adult male Wistar rats were subjected to spinal cord transection at the T13 segment. The IONP (25 mu g/mL) embedded in 3% agarose gel was implanted at the injury site and subsequently exposed to MF (50 Hz, 17.96 mu T, 2 hours/day for 5 weeks). Histological analysis of spinal cord tissue showed a significant increase in the expression of the growth-associated protein GAP-43 and it was found to be co-localized with neuronal nuclei marker and neurofilaments. The results show sprouting from mature neurons and axons, significantly less demyelination and more myelinated fibers were evident at the lesion site. However, no motor or somatosensory evoked potential response was observed, suggesting lack of long-distance functional connectivity. These findings highlight the therapeutic potential of IONPs along with MF exposure in promoting neuroregeneration after SCI.
AD  - All India Inst Med Sci, Dept Physiol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Anat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER SCIENTIFIC PUBLISHERS
PI  - VALENCIA
PA  - 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
DA  - OCT
PY  - 2018
VL  - 18
IS  - 10
SP  - 6756
EP  - 6764
DO  - 10.1166/jnn.2018.15820
AN  - WOS:000436243500010
ER  -

TY  - JOUR
AU  - Patil, S
AU  - Singh, N
TI  - Spatially controlled functional group grafting of silk films to induce osteogenic and chondrogenic differentiation of human mesenchymal stem cells
T2  - MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
KW  - Differentiation
KW  - Functional groups
KW  - Mesenchymal stem cells
KW  - Silk film
KW  - IN-VITRO
KW  - PROLIFERATION
KW  - SCAFFOLDS
KW  - CHEMISTRY
KW  - ADHESION
AB  - For tissue engineering, fabrication of appropriate biomaterials, which not only support cellular attachment and proliferation but also direct lineage-specific differentiation of stem cells is crucial. It is widely reported in literature that biomaterial surface chemistry modulates human mesenchymal stem cell (hMSC) differentiation in a lineage dependent manner. In recent years, natural materials such as silk have been used for hMSC culture because of its superior mechanical strength, biocompatibility, and biodegradability. We report here a simple strategy for differentiating hMSCs into two different lineages on the same surface. We have grafted functional groups such as acrylic acid and phosphates to guide the differentiation of hMSCs into chondrocytes and osteocytes respectively. Unlike other strategies, our strategy does not require growth factors and other added signals in the media and is initiated due to the difference of functional groups present on the surface. We believe this study will foster the development of effective silk based tissue engineered constructs.
AD  - Indian Inst Technol Delhi, Ctr Biomed Engn, Hauz Khas 110016, IndiaAD  - All India Inst Med Sci, Biomed Engn Unit, New Delhi 110029, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - OCT 1
PY  - 2018
VL  - 91
SP  - 796
EP  - 805
DO  - 10.1016/j.msec.2018.06.008
AN  - WOS:000442192000082
ER  -

TY  - JOUR
AU  - Paul, D
AU  - Dixit, A
AU  - Srivastava, A
AU  - Tripathi, M
AU  - Prakash, D
AU  - Sarkar, C
AU  - Ramanujam, B
AU  - Banerjee, J
AU  - Chandra, PS
TI  - Altered transforming growth factor beta/SMAD3 signalling in patients with hippocampal sclerosis
T2  - EPILEPSY RESEARCH
KW  - Drug resistant epilepsy
KW  - Epileptogenesis
KW  - SMAD3
KW  - Inflammation
KW  - Tumour periphery
KW  - Autopsy
KW  - TEMPORAL-LOBE EPILEPSY
KW  - CEREBROSPINAL-FLUID
KW  - BETA
KW  - REVEALS
KW  - EPILEPTOGENESIS
KW  - FIBRONECTIN
KW  - ACTIVATION
KW  - EXPRESSION
KW  - MECHANISM
KW  - NETWORK
AB  - Transforming growth factor beta (TGF beta) signalling cascade has been implicated in enhancing neuronal excitability and excitatory synaptogenesis following blood brain barrier (BBB) damage and inflammation. We aimed to study if TGF beta signalling expression is altered in patients with Hippocampal Sclerosis (HS). We probed into the protein expression level of the ligand transforming growth factor beta 1 (TGF beta 1), transforming growth factor beta receptor II (TGF beta RII) and downstream signalling molecule SMAD3 and phosphorylated SMAD3 (pSMAD3) on surgically resected hippocampal samples of thirty-four patients with HS through immuno-blotting. The increase in protein expression level of the ligand TGF beta 1 was 285 +/- 1.15% higher and its receptor TGF beta RII was 170 +/- 0.98% higher in hippocampus of patients with HS in comparison to the autopsy hippocampal control samples. The expression of the downstream signalling molecules, SMAD3 is 157 +/- 0.13% and 106 +/- 0.17% higher in patients with HS as compared to both types of non-seizure controls. The expression of active form of SMAD3, pSMAD3 (2.6010 +/- 1.2735) was significantly upregulated in hippocampus of patients with HS compared to autopsy hippocampal controls (0.7899 +/- 0.3688). While the expression of pSMAD3 (1.527 +/- 0.9425) was significantly upregulated in hippocampus of patients with HS with another type of non-seizure control viz. tumour periphery tissue (0.5791 +/- 0.2679), hence strongly supporting the altered expression of the pathway. This study provides the first evidence of alteration of TGF beta pathway in patients with HS which could be a potential therapeutic target.
AD  - AIIMS, Dept Neurosurg, New Delhi, IndiaAD  - Joint Collaborat NBRC & AIIMS, Ctr Excellence Epilepsy, New Delhi, IndiaAD  - AIIMS, Dept Neurol, New Delhi, IndiaAD  - AIIMS, Dept Forens Med & Toxicol, New Delhi, IndiaAD  - AIIMS, Dept Pathol, New Delhi, IndiaAD  - Univ Delhi, Dr BR Ambedkar Ctr Biomed Res, New Delhi, IndiaAD  - AIIMS, Dept Biophys, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - OCT
PY  - 2018
VL  - 146
SP  - 144
EP  - 150
DO  - 10.1016/j.eplepsyres.2018.08.004
AN  - WOS:000445168400019
ER  -

TY  - JOUR
AU  - Phillips, LM
AU  - Vitola, JV
AU  - Shaw, LJ
AU  - Giubbini, R
AU  - Karthikeyan, G
AU  - Alexanderson, E
AU  - Dondi, M
AU  - Paez, D
AU  - Peix, A
TI  - Value of gated-SPECT MPI for ischemia-guided PCI of non-culprit vessels in STEMI patients with multivessel disease after primary PCI
T2  - JOURNAL OF NUCLEAR CARDIOLOGY
KW  - CAD
KW  - myocardial ischemia and infarction
KW  - gated-SPECT
KW  - diagnostic and prognostic application
KW  - PERCUTANEOUS CORONARY INTERVENTION
KW  - ELEVATION MYOCARDIAL-INFARCTION
KW  - FRACTIONAL FLOW RESERVE
KW  - OPTIMAL MEDICAL THERAPY
KW  - PRIMARY ANGIOPLASTY
KW  - MULTICENTER TRIAL
KW  - RANDOMIZED-TRIAL
KW  - REVASCULARIZATION
KW  - OUTCOMES
KW  - CARDIOLOGY
AB  - There remains a clinical question of which patients benefit from revascularization of non-culprit coronary artery stenosis in the setting of acute ST-segment elevation myocardial infraction (STEMI). This is a large population of patients with prior studies showing 40 to 70% of patients with STEMI having non-culprit stenosis. This article reviews the current state of the literature evaluating outcomes of those previously randomized to revascularization of non-culprit stenosis around the time of the STEMI. We propose a new study design to utilize gated-SPECT in the decision process by using an ischemic burden of > 5% as a cut-off for revascularization vs. complete revascularization without ischemia assessment.
AD  - New York Univ Langone Hlth, Dept Med, Div Cardiol, New York, NY 10016 USAAD  - Quanta Diagnost & Terapia, Curitiba, Parana, BrazilAD  - Emory Univ, Dept Med, Div Cardiol, Atlanta, GA 30322 USAAD  - Univ Brescia, Brescia, ItalyAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Univ Nacl Autonoma Mexico, Fac Med, Dept Fisiol, Mexico City, DF, MexicoAD  - Inst Nacl Cardiol, Mexico City, DF, MexicoAD  - IAEA, Nucl Med & Diagnost Imaging Sect, Vienna, AustriaAD  - Inst Cardiol, Dept Nucl Med, Havana, CubaC3  - New York UniversityC3  - Emory UniversityC3  - University of BresciaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Universidad Nacional Autonoma de MexicoC3  - National Institute of Cardiology - MexicoC3  - International Atomic Energy AgencyPU  - SPRINGER
PI  - NEW YORK
PA  - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
DA  - OCT
PY  - 2018
VL  - 25
IS  - 5
SP  - 1616
EP  - 1620
DO  - 10.1007/s12350-018-1368-7
AN  - WOS:000445447000018
ER  -

TY  - JOUR
AU  - Pujari, A
AU  - Swamy, DR
AU  - Singh, R
AU  - Mukhija, R
AU  - Chawla, R
AU  - Kumar, A
TI  - Ultrasonographic assessment of ophthalmic diseases in low-income countries
T2  - TROPICAL DOCTOR
KW  - Diagnosis
KW  - ocular
KW  - ocular ultrasound
KW  - ophthalmic diseases
AB  - We undertook a study between December 2016 and February 2017 on 1637 of 2101 patients with clearly documented findings. These underwent ocular B-scan ultrasonography (USG). Their ages were in the range of 10 days to 92 years; among these patients, 921 (56.26%) were male and 224 (13.68%) were children. Among the adults, 669 (40.86%) patients had anterior segment and 636 (38.85%) had posterior segment pathology. In addition, there were 108 (6.59%) with orbital pathology. Our experience is that USG is an effective, quick, low-cost and non-invasive diagnostic tool for the diagnosis of various ocular and orbital conditions in high patient volume centres (including children and adults) especially where resources are limited.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 212,Second Floor,RPC 1, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SAGE PUBLICATIONS INC
PI  - THOUSAND OAKS
PA  - 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
DA  - OCT
PY  - 2018
VL  - 48
IS  - 4
SP  - 294
EP  - 297
DO  - 10.1177/0049475518787379
AN  - WOS:000452268500009
ER  -

TY  - JOUR
AU  - Purakayastha, DR
AU  - Vishnubhatla, S
AU  - Rai, SK
AU  - Broor, S
AU  - Krishnan, A
TI  - Estimation of Burden of Influenza among under-Five Children in India: A Meta-Analysis
T2  - JOURNAL OF TROPICAL PEDIATRICS
KW  - influenza
KW  - death
KW  - hospitalization
KW  - outpatients
KW  - review
KW  - meta-analysis
KW  - RESPIRATORY-TRACT INFECTIONS
KW  - VIRAL ETIOLOGY
KW  - HOSPITALIZED CHILDREN
KW  - YOUNG-CHILDREN
KW  - CHILDHOOD PNEUMONIA
KW  - SEASONAL INFLUENZA
KW  - PEDIATRIC-PATIENTS
KW  - RISK-FACTORS
KW  - RNA VIRUSES
KW  - SURVEILLANCE
AB  - Background: We estimated the burden of influenza-related acute respiratory tract infection (ARI) among under-fives in India through meta-analysis.
   Methodology: We estimated pooled incidence and proportional positivity of laboratory-diagnosed influenza among under-fives using data from observational studies published from 1 January 1961 to 31 December 2016. Death due to influenza was estimated using a multiplier model.
   Results: Influenza-associated ARI incidence was estimated as 132 per 1000 child-years (115-149). The patients positive for influenza among ARI in outpatients and inpatients were estimated to be 11.2% (8.8-13.6) and 7.1% (5.5-8.8), respectively. We estimated total influenza cases during 2016 as 16 009 207 (13 942 916-18 082 769) in India. Influenza accounted for 10 913 476 (9 504 66612 362 310) outpatient visits and 109 431 (83 882-134 980) hospitalizations. A total of 27 825 (21 382-34 408) influenza-associated under-five deaths were estimated in India in 2016.
   Conclusion: Influenza imposes a substantial burden among under-fives in India. Public health approach for its prevention and control needs to be explored.
AD  - All India Inst Med Sci, Ctr Community Med, AIIMS Campus, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Biostat, AIIMS Campus, New Delhi 110029, IndiaAD  - SGT Univ, Fac Med & Hlth Sci, Dept Microbiol, Gurugram Badli Rd, Gurgaon 122505, Haryana, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - OXFORD UNIV PRESS
PI  - OXFORD
PA  - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
DA  - OCT
PY  - 2018
VL  - 64
IS  - 5
SP  - 441
EP  - 453
DO  - 10.1093/tropej/fmx087
AN  - WOS:000446114500014
ER  -

TY  - JOUR
AU  - Rajagopal, R
AU  - Sharma, S
TI  - Comment on "Common Origin of Brachiocephalic and Left Common Carotid Arteries: Proposal of New Terminology"
T2  - AMERICAN JOURNAL OF NEURORADIOLOGY
KW  - AORTIC-ARCH
AD  - All India Inst Med Sci, Dept Cardiovasc Radiol & Endovasc Intervent, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER SOC NEURORADIOLOGY
PI  - DENVILLE
PA  - PO BOX 3000, DENVILLE, NJ 07834-9349 USA
DA  - OCT
PY  - 2018
VL  - 39
IS  - 10
SP  - E105
EP  - E105
DO  - 10.3174/ajnr.A5761
AN  - WOS:000445849400001
ER  -

TY  - JOUR
AU  - Rana, BS
AU  - Kumar, S
AU  - Ahuja, CK
AU  - Singh, NP
AU  - Yadav, MK
AU  - Sandhu, IS
TI  - ESTIMATION OF RADIATION EXPOSURE TO THE PATIENTS IN DIAGNOSTIC AND THERAPEUTIC INTERVENTIONAL PROCEDURES
T2  - RADIATION PROTECTION DOSIMETRY
KW  - DOSE-AREA PRODUCT
KW  - SKIN INJURIES
KW  - PART I
KW  - RADIOLOGY
KW  - FLUOROSCOPY
KW  - ANGIOGRAPHY
KW  - STAFF
KW  - NEURORADIOLOGY
KW  - LEVEL
AB  - The present work reports data of the radiation exposure to the patient in various diagnostic and therapeutic interventional radiological (IR) procedures. The study includes 260 diagnostic and 195 therapeutic exposure data in 455 IR procedures. All the IR procedures were performed on a biplane angiographic machine in a tertiary care hospital. The radiation exposure was estimated from dose-area product (DAP), fluoroscopy time (FT), number of fluoroscopic runs, number of images and cumulative dose (CD) value recorded during the procedure. The data reported in the present study show significant variability in DAP values in diagnostic and therapeutic IR procedures. In diagnostic procedures, the minimum median DAP value is 8.93 Gy cm(2) for upper limb angiography with mean FT of 2.7 min and maximum DAP value is 108.8 Gy cm(2) for inferior vena cava angiography with mean FT of 12.55 min. For therapeutic procedures, the median value of DAP ranges from 2.43 Gy cm(2) for sclerotherapy with mean FT 0.65 min to 267.23 Gy cm(2) for coiling of cerebral aneurysm with mean FT of 60.52 min. The DAP value for each procedure was also correlated with FT, number of fluoroscopic runs, number of images and CD. The reported DAP values in this study are within the range of earlier published results which suggest that our finding provides at least approximate applicability to other hospitals. The third quartile DAP values of the procedures having significant number of patient data (n = 10) serves as provisional reference values for the optimization of procedure protocols.
AD  - PGIMER, Dept Radiodiagnosis, Chandigarh, IndiaAD  - GGDSD Coll, Dept Phys, Chandigarh, IndiaAD  - IK Gujral PTU, Jalandhar, IndiaAD  - AIIMS, Dept Radiodiag, New Delhi, IndiaAD  - Chitkara Univ, Rajpura, Punjab, IndiaC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Goswami Ganesh Dutta S. D. CollegeC3  - I. K. Gujral Punjab Technical UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Chitkara University, PunjabPU  - OXFORD UNIV PRESS
PI  - OXFORD
PA  - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
DA  - OCT
PY  - 2018
VL  - 181
IS  - 3
SP  - 290
EP  - 300
DO  - 10.1093/rpd/ncy025
AN  - WOS:000452548800014
ER  -

TY  - JOUR
AU  - Ray, MD
AU  - Jakhetiya, A
AU  - Kumar, S
AU  - Mishra, A
AU  - Singh, S
AU  - Shukla, NK
TI  - Minimizing Post-operative Complications of Groin Dissection Using Modified Skin Bridge Technique: A Single-Centre Descriptive Study Showing Post-operative and Early Oncological Outcomes
T2  - WORLD JOURNAL OF SURGERY
KW  - SQUAMOUS-CELL CARCINOMA
KW  - LYMPH-NODE DISSECTION
KW  - PENILE CARCINOMA
KW  - LYMPHADENECTOMY
KW  - MORBIDITY
KW  - CANCER
KW  - EXPERIENCE
KW  - MELANOMA
AB  - IntroductionHistorically, groin dissections are associated with high morbidity. Various modifications have been described in the literature with inconsistent outcomes. The aim of this paper is to highlight modified skin bridge technique to minimize all post-operative complications of groin dissection without compromising early oncological outcomes.MethodsA retrospective descriptive study of the computerized cancer database was performed to retrieve details of all the cancer patients who had undergone groin dissections during January 2012 to September 2016. Data pertaining to clinical profile including demographics, clinical and histopathological details, treatment profile, procedure-related morbidity and relapse patterns were extracted and analysed.ResultsA total of 75 patients underwent 105 groin dissections during this period. Out of 105 groin dissections, 43 were inguinal lymph node dissection (ILND) and 62 were combined ilio-inguinal lymph node dissection (IILND). The most common diagnosis was carcinoma penis (25%) followed by malignant melanoma (14.6%) and squamous cell carcinoma (13.33%) of lower extremities. Overall, the most common complications were seroma (14.28%) and skin edge necrosis (7.61%) followed by surgical site infection (4.76%). After a median follow-up of 17.64months (IQR 5-61.53), a total of 18 patients (24%) developed recurrence.ConclusionGroin dissection still remains an important diagnostic as well as therapeutic procedure justifying its potential of morbidity. Modified skin bridge technique is a very effective method to minimize all post-operative complications with optimal early oncological outcomes.
AD  - All India Inst Med Sci, Dept Surg Oncol, Dr BRA IRCH, New Delhi, IndiaAD  - VMMC, Dept Canc Surg, New Delhi, IndiaAD  - Safdarjang Hosp, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - Vardhman Mahavir Medical College & Safdarjung HospitalC3  - Vardhman Mahavir Medical College & Safdarjung HospitalPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - OCT
PY  - 2018
VL  - 42
IS  - 10
SP  - 3196
EP  - 3201
DO  - 10.1007/s00268-018-4604-z
AN  - WOS:000443995400018
ER  -

TY  - JOUR
AU  - Reed, GM
AU  - Keeley, JW
AU  - Rebello, TJ
AU  - First, MB
AU  - Gureje, O
AU  - Ayuso-Mateos, JL
AU  - Kanba, S
AU  - Khoury, B
AU  - Kogan, CS
AU  - Krasnov, VN
AU  - Maj, M
AU  - Mari, JD
AU  - Sharan, P
AU  - Stein, DJ
AU  - Zhao, M
AU  - Akiyama, T
AU  - Andrews, HF
AU  - Asevedo, E
AU  - Cheour, M
AU  - Dominguez-Martínez, T
AU  - El-Khoury, J
AU  - Fiorillo, A
AU  - Grenier, J
AU  - Gupta, N
AU  - Kola, L
AU  - Kulygina, M
AU  - Leal-Leturia, I
AU  - Luciano, M
AU  - Lusu, B
AU  - Martínez-López, JNI
AU  - Matsumoto, C
AU  - Odunleye, M
AU  - Onofa, LU
AU  - Paterniti, S
AU  - Purnima, S
AU  - Robles, R
AU  - Sahu, MK
AU  - Sibeko, G
AU  - Zhong, N
AU  - Gaebel, W
AU  - Lovell, AM
AU  - Maruta, T
AU  - Pike, KM
AU  - Roberts, MC
AU  - Medina-Mora, ME
TI  - Clinical utility of ICD-11 diagnostic guidelines for high-burden mental disorders: results from mental health settings in 13 countries
T2  - WORLD PSYCHIATRY
KW  - International Classification of Diseases
KW  - ICD-11
KW  - diagnosis
KW  - mental disorders
KW  - clinical utility
KW  - ease of use
KW  - goodness of fit
KW  - treatment selection
KW  - assessing prognosis
KW  - BEHAVIORAL-DISORDERS
KW  - COMMON LANGUAGE
KW  - FIELD TRIAL
KW  - CLASSIFICATION
KW  - PSYCHIATRY
KW  - CRITERIA
KW  - PROGRESS
KW  - DSM-5
AB  - In this paper we report the clinical utility of the diagnostic guidelines for ICD-11 mental, behavioural and neurodevelopmental disorders as assessed by 339 clinicians in 1,806 patients in 28 mental health settings in 13 countries. Clinician raters applied the guidelines for schizophrenia and other primary psychotic disorders, mood disorders (depressive and bipolar disorders), anxiety and fear-related disorders, and disorders specifically associated with stress. Clinician ratings of the clinical utility of the proposed ICD-11 diagnostic guidelines were very positive overall. The guidelines were perceived as easy to use, corresponding accurately to patients' presentations (i.e., goodness of fit), clear and understandable, providing an appropriate level of detail, taking about the same or less time than clinicians' usual practice, and providing useful guidance about distinguishing disorder from normality and from other disorders. Clinicians evaluated the guidelines as less useful for treatment selection and assessing prognosis than for communicating with other health professionals, though the former ratings were still positive overall. Field studies that assess perceived clinical utility of the proposed ICD-11 diagnostic guidelines among their intended users have very important implications. Classification is the interface between health encounters and health information; if clinicians do not find that a new diagnostic system provides clinically useful information, they are unlikely to apply it consistently and faithfully. This would have a major impact on the validity of aggregated health encounter data used for health policy and decision making. Overall, the results of this study provide considerable reason to be optimistic about the perceived clinical utility of the ICD-11 among global clinicians.
AD  - Columbia Univ, Coll Physicians & Surg, Dept Psychiat, New York, NY 10027 USAAD  - Natl Inst Psychiat Ramon de la Fuente Muniz, Mexico City, DF, MexicoAD  - Virginia Commonwealth Univ, Dept Psychol, Box 2018, Richmond, VA 23284 USAAD  - New York State Psychiat Inst & Hosp, New York, NY 10032 USAAD  - Univ Ibadan, Dept Psychiat, Ibadan, NigeriaAD  - Univ Autonoma Madrid, Dept Psychiat, Madrid, SpainAD  - Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, SpainAD  - Inst Invest Sanitaria La Princesa, Madrid, SpainAD  - Kyushu Univ, Dept Neuropsychiat, Fukuoka, Fukuoka, JapanAD  - Amer Univ, Beirut Med Ctr, Dept Psychiat, Beirut, LebanonAD  - Univ Ottawa, Sch Psychol, Ottawa, ON, CanadaAD  - Moscow Res Inst Psychiat, Natl Med Res Ctr Psychiat & Narcol, Moscow, RussiaAD  - Univ Campania I Vanvitelli, Dept Psychiat, Naples, ItalyAD  - Univ Fed Sao Paulo, Dept Psychiat, Sao Paulo, BrazilAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - Univ Cape Town, Dept Psychiat, Cape Town, South AfricaAD  - South African Med Res Council Unit Risk & Resilie, Cape Town, South AfricaAD  - Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth, Shanghai, Peoples R ChinaAD  - Shanghai Jiao Tong Univ, Sch Med, Dept Psychiat, Shanghai, Peoples R ChinaAD  - NTT Med Ctr Tokyo, Tokyo, JapanAD  - Columbia Univ, Dept Biostat, Coll Physicians & Surg, New York, NY USAAD  - Tunis Al Manar Univ, Dept Psychiat, Tunis, TunisiaAD  - Al Razi Hosp, Tunis, TunisiaAD  - Natl Council Sci & Technol, Catedras CONACYT, Mexico City, DF, MexicoAD  - Hop Montfort, Institut Savoir Montfort, Ottawa, ON, CanadaAD  - Univ Ottawa, Ottawa, ON, CanadaAD  - Govt Med Coll & Hosp, Dept Psychiat, Chandigarh, IndiaAD  - Japanese Soc Psychiat & Neurol, Tokyo, JapanAD  - Univ Coll Hosp, Dept Psychiat, Ibadan, NigeriaAD  - Hosp Aro, Fed Neuropsychiat, Abeokuta, NigeriaAD  - Univ Ottawa, Royal Ottawa Mental Hlth Ctr, Inst Mental Hlth Res, Ottawa, ON, CanadaAD  - Univ Ottawa, Dept Psychiat, Ottawa, ON, CanadaAD  - Pt Jawahar Lal Nehru Mem Med Coll, Raipur, Chhattisgarh, IndiaAD  - Heinrich Heine Univ, Med Fac, Dept Psychiat & Psychotherapy, Dusseldorf, GermanyAD  - INSERM, U988, Paris, FranceAD  - Seitoku Univ, Hlth Management Ctr, Matsudo, Chiba, JapanAD  - Univ Kansas, Off Grad Studies, Lawrence, KS 66045 USAAD  - Univ Kansas, Clin Child Psychol Program, Lawrence, KS 66045 USAC3  - Columbia UniversityC3  - Instituto Nacional de Psiquiatria Ramon de la Fuente MunizC3  - Virginia Commonwealth UniversityC3  - New York State Psychiatry InstituteC3  - University of IbadanC3  - Autonomous University of MadridC3  - Instituto de Salud Carlos IIIC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERSAMC3  - Kyushu UniversityC3  - American University of BeirutC3  - Beirut Medical CenterC3  - University of OttawaC3  - Universidade Federal de Sao Paulo (UNIFESP)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of Cape TownC3  - Shanghai Jiao Tong UniversityC3  - Shanghai Jiao Tong UniversityC3  - Kanto Medical Center NTT ECC3  - Columbia UniversityC3  - Universite de Tunis-El-ManarC3  - Universite de Tunis-El-ManarC3  - Hopital RaziC3  - University of OttawaC3  - University of OttawaC3  - University of IbadanC3  - University College Hospital, IbadanC3  - University of OttawaC3  - University of OttawaC3  - Heinrich Heine University DusseldorfC3  - Institut National de la Sante et de la Recherche Medicale (Inserm)C3  - Universite Paris CiteC3  - University of KansasC3  - University of KansasPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - OCT
PY  - 2018
VL  - 17
IS  - 3
SP  - 306
EP  - 315
DO  - 10.1002/wps.20581
AN  - WOS:000443949200017
ER  -

TY  - JOUR
AU  - Roychoudhury, A
AU  - Basu, S
AU  - Jha, SK
TI  - Surface Functionalized Prussian Blue-coated Nanostructured Nickel Oxide as a New Biosensor Platform for Catechol Detection
T2  - ANALYTICAL SCIENCES
KW  - Electrochemical biosensor
KW  - amperometry
KW  - catechol
KW  - tyrosinase
KW  - NiO nanoparticles
KW  - Prussian blue
KW  - POLYPHENOL OXIDASE
KW  - TYROSINASE
KW  - NANOPARTICLES
KW  - COMPOSITE
KW  - DOPAMINE
KW  - FILM
AB  - An amperometric biosensor has been developed for highly efficient and sensitive detection of catechol using Prussian blue (PB)-coated nickel oxide (NiO) nanoparticles (NPs) as a matrix for the immobilization of tyrosinase enzyme. The NiO NPs were synthesized by sol-gel method using sodium dodecyl sulphate as anionic surfactant and the surface of the synthesized NiO NPs was modified with PB to enhance electrocatalytic activity and to prevent surface aggregation. After confirmation of successful synthesis of the PB-NiO NPs from transmission electron microscopy (TEM) and energy dispersive X-ray spectroscopic (EDS) studies, the prepared NPs were deposited onto a working electrode of a commercially available screen printed carbon electrode (SPCE) substrate. The tyrosinase enzyme was covalently immobilized onto the PB-NiO deposited SPCE for selective detection and estimation of catechol through electrochemical methods via cyclic voltammetry (CV) and chronoamperometric techniques. The functionalization of tyrosinase on the electrode surface was verified by atomic force microscopy (AFM) and scanning electron microscopic (SEM) techniques and the electrochemical response studies of the proposed biosensor showed high sensitivity of 0.954 mu A/mu M for catechol in a wide linear range (1- 50 mu M) with low detection limit (LOD) of 0.087 mu M. The developed sensor also exhibited a fast response time of 27 s and decent selectivity for catechol detection.
AD  - Indian Inst Technol Delhi, Ctr Biomed Engn, New Delhi 110016, IndiaAD  - All India Inst Med Sci, Dept Biomed Engn, New Delhi 110029, IndiaAD  - Indian Inst Technol Delhi, Dept Chem Engn, New Delhi 110016, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiPU  - JAPAN SOC ANALYTICAL CHEMISTRY
PI  - TOKYO
PA  - 26-2 NISHIGOTANDA 1 CHOME SHINAGAWA-KU, TOKYO, 141, JAPAN
DA  - OCT
PY  - 2018
VL  - 34
IS  - 10
SP  - 1163
EP  - 1169
DO  - 10.2116/analsci.17P377
AN  - WOS:000449243900010
ER  -

TY  - JOUR
AU  - Sahay, P
AU  - Dhanda, S
AU  - Singhal, D
AU  - Maharana, PK
AU  - Titiyal, JS
AU  - Sharma, N
TI  - Scleritis in congenital erythropoietic porphyria - infective or inflammatory?
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Congenital erythropoietic porphyria
KW  - necrotizing scleritis
KW  - scleritis
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - OCT
PY  - 2018
VL  - 66
IS  - 10
SP  - 1467
EP  - 1468
DO  - 10.4103/ijo.IJO_513_18
AN  - WOS:000445668500021
ER  -

TY  - JOUR
AU  - Sankar, J
AU  - Das, RR
TI  - Asthma - A Disease of How We Breathe: Role of Breathing Exercises and Pranayam
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Pediatric
KW  - Asthma
KW  - Yoga
KW  - Pranayam
KW  - Breathing exercise
KW  - Lung function
KW  - Allergy
KW  - Quality of life
KW  - COMPLEMENTARY
KW  - THERAPY
KW  - CHILDREN
KW  - FLOW
AB  - To describe the role of breathing exercises or yoga and/or pranayama in the management of childhood asthma. We conducted an updated literature search and retrieved relevant literature on the role of breathing exercises or yoga and/or pranayama in the management of childhood asthma. We found that the breathing exercises or yoga and/or pranayama are generally multi-component packaged interventions, and are described as follows: Papworth technique, Buteyko technique, Yoga and/or Pranayam. These techniques primarily modify the pattern of breathing to reduce hyperventilation resulting in normalisation of CO2 level, reduction of bronchospasm and resulting breathlessness. In addition they also change the behaviour, decrease anxiety, improve immunological parameters, and improve endurance of the respiratory muscles that may ultimately help asthmatic children. We found 10 clinical trials conducted in children with asthma of varying severity, and found to benefit children with chronic (mild and moderate) and uncontrolled asthma, but not acute severe asthma. Breathing exercises or yoga and/or pranayama may benefit children with chronic (mild and moderate) and uncontrolled asthma, but not acute severe asthma. Before these techniques can be incorporated into the standard care of asthmatic children, important outcomes like quality of life, medication use, and patient reported outcomes need to be evaluated in future clinical trials.
AD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pediat, Bhuvaneshwar, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) BhubaneswarPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - OCT
PY  - 2018
VL  - 85
IS  - 10
SP  - 905
EP  - 910
DO  - 10.1007/s12098-017-2519-6
AN  - WOS:000445955200020
ER  -

TY  - JOUR
AU  - Saxena, R
AU  - Singh, D
AU  - Sharma, M
AU  - James, M
AU  - Sharma, P
AU  - Menon, V
TI  - Steroids versus No Steroids in Nonarteritic Anterior Ischemic Optic Neuropathy <i>A Randomized Controlled Trial</i>
T2  - OPHTHALMOLOGY
KW  - SYSTEMIC CORTICOSTEROID-THERAPY
KW  - RODENT MODEL
KW  - METHYLPREDNISOLONE
KW  - INJECTIONS
KW  - NAION
KW  - RAION
AB  - Purpose: To examine the role of oral steroid therapy in the treatment of nondiabetic cases of acute nonarteritic anterior ischemic optic neuropathy (NAAION).
   Design: Randomized double-blind clinical trial.
   Participants: Thirty-eight patients with acute nondiabetic NAAION divided into 2 arms of 19 patients each. One arm constituted the cases and the other constituted the controls.
   Methods: Cases received oral steroid therapy and were designated the steroid group, whereas controls received placebo and were designated the nonsteroid group. Best-corrected visual acuity (BCVA), visual evoked response (VER), and OCT were performed at baseline, 1 month, 3 months, and 6 months after recruitment into the trial.
   Main Outcome Measures: Best-corrected visual acuity, VER, and retinal nerve fiber layer changes on OCT.
   Results: Both groups showed significant improvement in BCVA, VER latency, and resolution of disc edema on OCT parameters over 6 months. Final outcome showed no statistically significant difference with regard to visual acuity, although VER was better in the steroid group (P = 0.011). Best-corrected visual acuity, VER amplitude, and VER latency (P = 0.02, P = 0.02, and P = 0.04, respectively) showed a greater percentage improvement in the steroid group, which also saw a faster resolution of disc edema on OCT (1-month follow-up).
   Conclusions: Oral steroids in acute NAAION did not improve the visual acuity significantly at 6 months. However, they improved resolution of disc edema significantly and enabled a greater improvement in VER parameters. This subtle benefit of oral steroids in NAAION is clinically unimportant and does not provide support for its use. (C) 2018 by the American Academy of Ophthalmology
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 377, New Delhi 110029, IndiaAD  - Noble Eye Care, Gurgaon, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - OCT
PY  - 2018
VL  - 125
IS  - 10
SP  - 1623
EP  - 1627
DO  - 10.1016/j.ophtha.2018.03.032
AN  - WOS:000445012100029
ER  -

TY  - JOUR
AU  - Sebastian, S
AU  - Malhotra, R
AU  - Dhawan, B
TI  - Prosthetic joint infection: A major threat to successful total joint arthroplasty
T2  - INDIAN JOURNAL OF MEDICAL MICROBIOLOGY
KW  - Biofilm
KW  - revision arthroplasty
KW  - sonication
KW  - total joint arthroplasty
KW  - TOTAL HIP-ARTHROPLASTY
KW  - POLYMERASE-CHAIN-REACTION
KW  - RIBOSOMAL-RNA GENE
KW  - KNEE ARTHROPLASTY
KW  - SYNOVIAL-FLUID
KW  - RISK-FACTORS
KW  - MICROBIOLOGIC DIAGNOSIS
KW  - ANTIBIOTIC-PROPHYLAXIS
KW  - SONICATION FLUID
KW  - MULTIPLEX PCR
AB  - Total joint arthroplasty (TJA) is one of the most common and reliable orthopaedic procedures that has significantly improved the quality of life of patients with degenerative joint diseases. Following the increase in the ageing population, availability of trained orthopaedic surgeons and advances in implantation procedures, demand for TJA both globally and in India is significantly increasing. Though TJA is one of the most cost-successful orthopaedic procedures, prosthetic joint infection (PJI) is one of the major complications of joint arthroplasty. Accurate diagnosis of PJI is challenging. Since total hip and knee arthroplasties comprises the majority of TJAs, this review focuses on the current understanding of incidence, risk factors, pathogenesis, causative microorganisms, diagnosis, treatment and prevention of PJI related to these two procedures.
AD  - All India Inst Med Sci, Dept Microbiol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Orthopaed, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - OCT-DEC
PY  - 2018
VL  - 36
IS  - 4
SP  - 475
EP  - 487
DO  - 10.4103/ijmm.IJMM_19_11
AN  - WOS:000462457300004
ER  -

TY  - JOUR
AU  - Sharma, N
AU  - Singhal, D
AU  - Maharana, PK
AU  - Jain, R
AU  - Sahay, P
AU  - Titiyal, JS
TI  - Response to comment on: Continuous intraoperative optical coherence tomography-guided shield ulcer debridement with tuck in multilayered amniotic membrane transplantation
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
AD  - All India Inst Med Sci, Dept Ophthalmol, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - OCT
PY  - 2018
VL  - 66
IS  - 10
SP  - 1521
EP  - +
DO  - 10.4103/ijo.IJO_1029_18
AN  - WOS:000445668500048
ER  -

TY  - JOUR
AU  - Sharma, P
AU  - Saraya, A
AU  - Sharma, R
TI  - Serum-based six-miRNA signature as a potential marker for EC diagnosis: Comparison with TCGA miRNAseq dataset and identification of miRNA-mRNA target pairs by integrated analysis of TCGA miRNAseq and RNAseq datasets
T2  - ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
KW  - circulating microRNAs
KW  - diagnosis
KW  - esophageal cancer
KW  - miRNA Panel
KW  - TCGA
KW  - SQUAMOUS-CELL CARCINOMA
KW  - HUMAN ESOPHAGEAL CANCER
KW  - MICRORNA EXPRESSION
KW  - DIFFERENTIAL EXPRESSION
KW  - PARTICULATE MATTER
KW  - ADENOCARCINOMA
KW  - PROFILES
KW  - BIOMARKERS
KW  - SURVIVAL
KW  - MIR-205
AB  - AimTo evaluate the diagnostic potential of a six microRNAs (miRNAs) panel consisting of miR-21, miR-144, miR-107, miR-342, miR-93 and miR-152 for esophageal cancer (EC) detection.
   MethodsThe expression of miRNAs was analyzed in EC sera samples using quantitative real-time PCR. Risk score analysis was performed and linear regression models were then fitted to generate the six-miRNA panel. In addition, we made an effort to identify significantly dysregulated miRNAs and mRNAs in EC using theCancerGenome Atlas (TCGA) miRNAseq and RNAseq datasets, respectively. Further, we identified significantly correlated miRNA-mRNA target pairs by integrating TCGA EC miRNAseq dataset with RNAseq dataset.
   ResultsThe panel of circulating miRNAs showed enhanced sensitivity (87.5%) and specificity (90.48%) in terms of discriminating EC patients from normal subjects (area under the curve [AUC]=0.968). Pathway enrichment analysis for potential targets of six miRNAs revealed 48 significant (P<0.05) pathways, viz. pathways in cancer, mRNA surveillance, MAPK, Wnt, mTOR signaling, and so on. The expression data for mRNAs and miRNAs, downloaded from TCGA database, lead to identification of 2309 differentially expressed genes and 189 miRNAs. Gene ontology and pathway enrichment analysis showed that cell-cycle processes were most significantly enriched for differentially expressed mRNA. Integrated analysis of TCGA miRNAseq and RNAseq datasets resulted in identification of 53063 significantly and negatively correlated miRNA-mRNA pairs.
   ConclusionIn summary, a novel and highly sensitive signature of serummiRNAswas identified for EC detection. Moreover, this is the first report identifying miRNA-mRNA target pairs from EC TCGA dataset, thus providing a comprehensive resource for understanding the interactions existing between miRNA and their target mRNAs in EC.
AD  - Guru Gobind Singh Indraprastha Univ, Univ Sch Biotechnol, Sect 16C, New Delhi 110078, IndiaAD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaC3  - GGS Indraprastha UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - OCT
PY  - 2018
VL  - 14
IS  - 5
SP  - e289
EP  - e301
DO  - 10.1111/ajco.12847
AN  - WOS:000444798000011
ER  -

TY  - JOUR
AU  - Sharma, R
AU  - Phalak, M
AU  - Sharma, P
TI  - Is the serum glucose/potassium ratio a reliable prognostic factor for aneurysmal SAH?
T2  - JOURNAL OF NEUROSURGERY
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ASSOC NEUROLOGICAL SURGEONS
PI  - ROLLING MEADOWS
PA  - 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
DA  - OCT
PY  - 2018
VL  - 129
IS  - 4
SP  - 1098
EP  - 1098
DO  - 10.3171/2018.2.JNS18434
AN  - WOS:000446085200031
ER  -

TY  - JOUR
AU  - Shashni, A
AU  - Pujari, A
AU  - Bajaj, MS
AU  - Kumar, P
TI  - Superior oblique muscle cysticercosis: importance of long-term assessment by a single observer
T2  - CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - CANADIAN OPHTHAL SOC
PI  - OTTAWA
PA  - 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
DA  - OCT
PY  - 2018
VL  - 53
IS  - 5
SP  - E193
EP  - E195
DO  - 10.1016/j.jcjo.2017.11.007
AN  - WOS:000447644300012
ER  -

TY  - JOUR
AU  - Sihota, R
AU  - Kumar, S
AU  - Sidhu, T
AU  - Midha, N
AU  - Sharma, A
AU  - Yadav, S
AU  - Gupta, V
AU  - Dada, T
TI  - Is combined mechanism glaucoma a distinct entity?
T2  - GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
KW  - Combined mechanism glaucoma
KW  - Anterior segment OCT in glaucoma
KW  - Open-angle glaucoma with narrow recess
KW  - Mixed mechanism glaucoma
KW  - ANGLE-CLOSURE GLAUCOMA
KW  - TRABECULAR MESHWORK
KW  - OCCLUDABLE ANGLES
KW  - PARAMETERS
AB  - Primary adult glaucomas that have an occludable angle with peripheral anterior synechiae which are too few to account for the chronically raised IOP, or the glaucomatous optic neuropathy, do not fit the definition of either POAG or PACG and can be considered as combined mechanism glaucoma (CMG). We aimed to compare the clinical features and anatomical parameters of combined mechanism glaucoma with age, sex, and refraction-matched POAG and chronic PACG eyes.
   Consecutive adult patients with definitive optic nerve head and perimetric changes of glaucoma were screened at a tertiary care center. All glaucomatous eyes having an IOP > 22 mmHg on at least three separate occasions and glaucomatous optic neuropathy consistent with moderate visual field loss in the eye were divided as POAG, PACG, and CMG. Eyes with occludable angles having < 90A degrees of goniosynechiae were diagnosed as CMG. A detailed clinical examination, ocular biometry, and ASOCT were performed in the better eye of all individuals.
   A total of 93 patients with similar visual field index or pattern standard deviation on perimetry were evaluated: 32 POAG, 31 CMG, and 30 PACG. The mean anterior chamber depth was 3.47 +/- 0.37 mm in POAG, 2.81 +/- 0.32 mm in PACG, and 3.06 +/- 0.26 mm in CMG (p < 0.0001). Mean lens thickness was 4.22 +/- 0.27 mm in POAG, 4.53 +/- 0.35 mm in PACG, and 4.44 +/- 0.29 mm in CMG (p = 0.0004). Iridotrabecular contact on ASOCT was nil in POAG, a mean of 87.60 +/- 12.802% in PACG eyes, and 15.23 +/- 14.19% in CMG eyes, p < 0.0001. CMG was similar to PACG in terms of corneal diameters and lens thickness and had an axial length in between PACG and POAG. On ASOCT, all parameters had highest values in POAG eyes and the least in PACG eyes, with CMG eyes having values in between the other two groups, p value of < 0.0001 between each group for all parameters.
   This study has demonstrated significantly different anatomical parameters in eyes with CMG, in addition to the differences on gonioscopy and iridotrabecular contact, indicating that CMG is discernibly dissimilar to PACG and POAG.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Glaucoma Serv, Room 494,4th Floor, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - OCT
PY  - 2018
VL  - 256
IS  - 10
SP  - 1961
EP  - 1969
DO  - 10.1007/s00417-018-4050-5
AN  - WOS:000444744500021
ER  -

TY  - JOUR
AU  - Singh, A
AU  - Kumar, R
AU  - Irugu, DVK
AU  - Kumar, R
AU  - Sagar, P
TI  - Morphometric analysis of arcuate eminence: A distinctive landmark for middle cranial fossa approach
T2  - JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY
KW  - Arcuate eminence
KW  - Anatomy
KW  - Middle cranial fossa approach
KW  - Superior semicircular canal
KW  - SURGERY
AB  - Background: The arcuate eminence (AE) is a bony prominence on the middle fossa plate of the temporal bone, hypothesized to be variably associated with superior semicircular canal (SSC) relief, temporal lobe sulcus, and subjacent air cells. We present various morphometric parameters of the AE, as seen using a middle fossa approach.
   Materials and methods: The study used 18 formalin-preserved cadaveric human temporal bones. Various morphological and morphometric parameters pertaining to topographic orientation of the AE in relation to surrounding landmarks used in a middle mossa approach were noted, before and after microdissection of the AE under a Leica M320 F12 microscope, using otologic microdrills and suction irrigation. The morphometric parameters were analyzed using ImageJ 1.46r software.
   Results: The overall incidence of AE was 83% (n = 15/18). The most common shape and pattern noted were linear (53.3%, 8/15) and dual arc (46.7%, 7/15), respectively. Mean angle between the AE and SSC was 19 degrees, with a standard deviation of 15 degrees and a range of 2-49 degrees. The AE overlapped the SSC in 40% (6/15) of bones, and did not correspond to the SSC in 7% of cases. A partially overlapping positional correspondence was noted in 53.3% (8/15).
   Conclusion: When present, the AE corresponds to the SSC in 40% of cases, but it can serve as a rough guide to the SSC in up to 93% of cases. Surgeons need to be familiar with the varying morphology of AEs in order to execute a rapid and safe dissection during middle fossa approaches. (C) 2018 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.
AD  - All India Inst Med Sci, Dept Otorhinolaryngol & Head & Neck Surg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - CHURCHILL LIVINGSTONE
PI  - EDINBURGH
PA  - JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
DA  - OCT
PY  - 2018
VL  - 46
IS  - 10
SP  - 1703
EP  - 1706
DO  - 10.1016/j.jcms.2018.07.013
AN  - WOS:000446990500002
ER  -

TY  - JOUR
AU  - Singh, MB
TI  - Telephonic review of patients with epilepsy - An underutilized resource
T2  - EPILEPSY & BEHAVIOR
AD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ACADEMIC PRESS INC ELSEVIER SCIENCE
PI  - SAN DIEGO
PA  - 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
DA  - OCT
PY  - 2018
VL  - 87
SP  - 246
EP  - 246
DO  - 10.1016/j.yebeh.2018.08.015
AN  - WOS:000448805600038
ER  -

TY  - JOUR
AU  - Singh, M
AU  - Prasad, CP
AU  - Singh, TD
AU  - Kumar, L
TI  - Cancer research in India: Challenges opportunities
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
KW  - MORTALITY
KW  - PRIORITIES
KW  - ONCOLOGY
AD  - All India Inst Med Sci, Inst Rotary Canc Hosp, Dept Med Oncol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
DA  - OCT
PY  - 2018
VL  - 148
IS  - 4
SP  - 362
EP  - 365
DO  - 10.4103/ijmr.IJMR_1711_18
AN  - WOS:000456435900002
ER  -

TY  - JOUR
AU  - Singh, NP
AU  - Makkar, JK
AU  - Wourms, V
AU  - Singh, PM
TI  - Topical benzydamine for preventing postoperative sore throat
T2  - ANAESTHESIA
KW  - CONTROLLED-TRIAL
KW  - TUBE
KW  - HYDROCHLORIDE
KW  - HOARSENESS
KW  - EFFICACY
AD  - PGIMER, Chandigarh, IndiaAD  - Max Rady Coll Med, Winnipeg, MB, CanadaAD  - All India Inst Med Sci, New Delhi, IndiaC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - OCT
PY  - 2018
VL  - 73
IS  - 10
SP  - 1297
EP  - 1297
DO  - 10.1111/anae.14437
AN  - WOS:000444538000021
ER  -

TY  - JOUR
AU  - Singh, PM
AU  - Borle, A
AU  - Panwar, R
AU  - Makkar, JK
AU  - McGrath, I
AU  - Trikha, A
AU  - Sinha, A
TI  - Perioperative antiemetic efficacy of dexamethasone versus 5-HT3 receptor antagonists: a meta-analysis and trial sequential analysis of randomized controlled trials
T2  - EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
KW  - Dexamethasone PONV
KW  - 5-HT3 receptor antagonists vs dexamethasone
KW  - Dexamethasone analgesia
KW  - Non-inferiority meta-analysis
KW  - Perioperative nausea vomiting
KW  - POSTOPERATIVE NAUSEA
KW  - LAPAROSCOPIC CHOLECYSTECTOMY
KW  - GYNECOLOGICAL SURGERY
KW  - REDUCES NAUSEA
KW  - META-ANALYSIS
KW  - DOUBLE-BLIND
KW  - ONDANSETRON
KW  - PREVENTION
KW  - TROPISETRON
KW  - THERAPY
AB  - BackgroundDexamethasone has many desirable pharmacologic properties for perioperative use. Its antiemetic potential has been a focus of many recent trials.MethodsTrials comparing dexamethasone to 5-HT3-receptor antagonists (5HT3-RA) for 24h postoperative vomiting incidences published till August 2017 were searched in the medical database. Comparisons for antiemetic efficiency variables (vomiting incidence, nausea incidence, rescue antiemetic need, and patients with complete response) during early (until 6h) and late postoperative phase were made. Comparative analgesic requirements were also evaluated.ResultsTwenty randomized controlled double-blinded trials were included in the final analysis. Twenty-four-hour vomiting incidence was similar (Fixed-effects, P=0.86, I-2=2.94%). Trial sequential analysis (TSA) confirmed non-inferiority of dexamethasone for 24-h vomiting incidence. (=5%, =20%, =10%) with information size being 1619 (required >573). Equivalence was also verified from early and delayed nausea rate as well using TSA. Pooled results did not demonstrate superiority/inferiority of 5-HT3-RAs over dexamethasone in all other antiemetic efficacy variables (early and delayed). Heterogeneity was found to be low in all of the comparisons. Linear-positive dose-response curve for dexamethasone 24-h vomiting and nausea incidence was seen (correlation coefficient being 0.21 and 0.28, respectively). Dexamethasone reduced the analgesic need (MH-odds of 0.64 (95% CI being 0.44 to 0.93) P=0.02, I2=0)). Possibility of publication bias could not be ruled out (Egger's test, X-intercept=1.41, P=0.04).ConclusionsDexamethasone demonstrates equal antiemetic efficacy compared to 5-HT3 receptor antagonists. The agents perform equally well both in early postoperative phase and up to 24h after surgery. Use of dexamethasone replacing 5-HT3 RAs offers an additional advantage of lowering the opioid requirements during the perioperative period.
AD  - All India Inst Med Sci, Dept Anesthesia, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Gastrointestinal Surg & Liver Transplantat, New Delhi 110029, IndiaAD  - Post Grad Inst Med Educ & Res, Dept Anesthesia, Chandigarh 160012, IndiaAD  - Temple Univ, Katz Sch Med, Philadelphia, PA 19122 USAAD  - Temple Univ Hlth Syst, Lewis Katz Sch Med, Anesthesiol & Perioperat Med, Philadelphia, PA 19140 USAC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - Temple UniversityC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - Temple UniversityPU  - SPRINGER HEIDELBERG
PI  - HEIDELBERG
PA  - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
DA  - OCT
PY  - 2018
VL  - 74
IS  - 10
SP  - 1201
EP  - 1214
DO  - 10.1007/s00228-018-2495-4
AN  - WOS:000444387700001
ER  -

TY  - JOUR
AU  - Singh, R
AU  - Suri, JC
AU  - Sharma, R
AU  - Suri, T
AU  - Adhikari, T
TI  - Sleep Pattern of Adolescents in a School in Delhi, India: Impact on their Mood and Academic Performance
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Sleep deprivation
KW  - Depression
KW  - Sleep
KW  - Students
KW  - Adolescents
KW  - Mood
KW  - School performance
KW  - DURATION
KW  - ASSOCIATION
KW  - DEPRESSION
KW  - INSOMNIA
KW  - STUDENTS
KW  - RISK
AB  - ObjectivesTo examine the sleep pattern and observe differences in sleep routines, phase preferences, mood, attendance, and academic performance among different adolescent age students. Secondly, to observe the age at which sleep phase transition and changes in sleep requirement become evident.MethodsA cross-sectional study was conducted among 501 students (aged 11-15 y) of a school in Delhi, India. Students were evaluated for their sleep patterns, sleep duration, habits of napping, quality of sleep, sleepiness, depression, phase preferences by self-reported school sleep habits survey questionnaire along with school performance and attendance.ResultsSignificant differences were found in sleep pattern of students aged 11-12 y and 13-15 y. Bedtime shifted to a later time with increasing age but early morning schools kept the wake time same, leading to a decline in total sleep duration of older adolescents. Older adolescents had higher depression but poor attendance and academic performance. Prevalence of sleep deprivation increased with age, from 83.7% to 87.1% in 11-12 y to 90.5% to 92.5% in 13-15 y.ConclusionsThe study clearly identifies 12-13 y as age of transition of sleep pattern among adolescents. Though significant differences were found in the academic performance, mood and attendance among preteens and teens but no direct association was seen between academic performances and sleep pattern. A complex multifactorial association between sleep patterns, attendance, mood and academic performance which may change over days, months, or years should be explored further in a longitudinal follow up study.
AD  - VMMC & Safdarjung Hosp, Dept Physiol, Delhi, IndiaAD  - Safdarjang Hosp, Dept Pulm Crit Care & Sleep Med, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Med, New Delhi, IndiaAD  - Natl Inst Med Stat ICMR, New Delhi, IndiaC3  - Vardhman Mahavir Medical College & Safdarjung HospitalC3  - Vardhman Mahavir Medical College & Safdarjung HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Medical Statistics (NIMS)PU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - OCT
PY  - 2018
VL  - 85
IS  - 10
SP  - 841
EP  - 848
DO  - 10.1007/s12098-018-2647-7
AN  - WOS:000445955200009
ER  -

TY  - JOUR
AU  - Sofi, R
AU  - Qureshi, T
AU  - Gupta, V
TI  - Electric cataracts: a cause of bilateral blindness in Kashmir
T2  - EYE
AD  - Govt Med Coll Srinagar, Srinagar, Jammu & Kashmir, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - NATURE PUBLISHING GROUP
PI  - LONDON
PA  - MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - OCT
PY  - 2018
VL  - 32
IS  - 10
SP  - 1676
EP  - 1677
DO  - 10.1038/s41433-018-0128-x
AN  - WOS:000447270200019
ER  -

TY  - JOUR
AU  - Sreenivasan, SA
AU  - Phalak, M
AU  - Borkar, SA
AU  - Kale, SS
TI  - Percutaneous transforaminal endoscopic discectomy versus microendoscopic discectomy
T2  - JOURNAL OF NEUROSURGERY-SPINE
KW  - LUMBAR DISC HERNIATION
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ASSOC NEUROLOGICAL SURGEONS
PI  - ROLLING MEADOWS
PA  - 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
DA  - OCT
PY  - 2018
VL  - 29
IS  - 4
SP  - 481
EP  - 482
DO  - 10.3171/2018.4.SPINE18472
AN  - WOS:000446246000019
ER  -

TY  - JOUR
AU  - Suhani
TI  - Harmonic scalpel versus conventional diathermy: Is one really better than the other
T2  - INDIAN JOURNAL OF CANCER
KW  - BREAST-CANCER
KW  - SEROMA FORMATION
KW  - PREVENTION
AD  - All India Inst Med Sci, Dept Surg Disciplines, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - OCT-DEC
PY  - 2018
VL  - 55
IS  - 4
SP  - 359
EP  - 360
DO  - 10.4103/ijc.IJC_551_18
AN  - WOS:000460297000008
ER  -

TY  - JOUR
AU  - Suhani
AU  - Chintamani
TI  - Publish-flourish or Perish
T2  - INDIAN JOURNAL OF SURGERY
AD  - All India Inst Med Sci, Dept Surg, New Delhi 110023, IndiaAD  - Safdarjang Hosp, Dept Surg VMMC, New Delhi 110023, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Vardhman Mahavir Medical College & Safdarjung HospitalPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - OCT
PY  - 2018
VL  - 80
IS  - 5
SP  - 403
EP  - 404
DO  - 10.1007/s12262-018-1815-3
AN  - WOS:000447726900001
ER  -

TY  - JOUR
AU  - Takkar, B
AU  - Venkatesh, P
AU  - Gaur, N
AU  - Garg, SP
AU  - Vohra, R
AU  - Ghose, S
TI  - Patterns of uveitis in children at the apex institute for eye care in India: analysis and review of literature
T2  - INTERNATIONAL OPHTHALMOLOGY
KW  - Intraocular tuberculosis
KW  - Pediatric uveitis
KW  - Idiopathic uveitis
KW  - Uveitis in childhood
KW  - PEDIATRIC UVEITIS
KW  - EPIDEMIOLOGY
KW  - CHILDHOOD
AB  - AimTo study patterns of uveitis in Indian children and compare with data sets published earlier in the literature.MethodsConsecutive patients below 16years of age presenting to the uvea clinic of a tertiary eye care center were included prospectively through the period of July 2009-August 2013. Children with retinal vasculitis, exogenous endophthalmitis and masquerade syndromes were excluded from analysis. Uveitis was classified as per the nomenclature system adopted by the International Uveitis Study Group. Hemogram, Mantoux test and chest X-ray were done for each patient, along with tailored investigations and pediatric review as per clinical profile. Clinical pattern and etiology were the main outcome measures.Results One hundred and thirty-four children were analyzed. Anterior uveitis (40%) was the commonest pattern followed by intermediate uveitis (25%), panuveitis (18%) and posterior uveitis (17%). Bilateral disease was present in 54%, 15% had infectious uveitis, 10% had granulomatous uveitis and 54% had idiopathic uveitis. Complications were present in half of the patients. Juvenile idiopathic arthritis (22), followed by toxoplasmosis (10) and tuberculosis (5), was the commonest etiology. Intermediate uveitis, non-granulomatous inflammation and older onset of disease had the high odds ratio of having idiopathic disease.ConclusionPatterns of pediatric uveitis can vary between regions from even within the same geopolitical region. Anterior uveitis is commonest, and juvenile idiopathic arthritis and toxoplasmosis are the most frequent etiologies. Diagnosis of pediatric ocular tuberculosis is more difficult than in adults and needs better and well-defined criteria.
AD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, Retina Serv, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, Uvea Serv, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - OCT
PY  - 2018
VL  - 38
IS  - 5
SP  - 2061
EP  - 2068
DO  - 10.1007/s10792-017-0700-6
AN  - WOS:000444586400030
ER  -

TY  - JOUR
AU  - Takkar, B
AU  - Khokhar, S
AU  - Agarwal, E
TI  - Re: Weakley et al.: Myopic shift 5 years after intraocular lens implantation in the infant aphakia treatment study (<i>Ophthalmology</i>. 2017;124:822-827)
T2  - OPHTHALMOLOGY
AD  - AIIMS, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - OCT
PY  - 2018
VL  - 125
IS  - 10
SP  - E69
EP  - E69
DO  - 10.1016/j.ophtha.2018.03.056
AN  - WOS:000445012100001
ER  -

TY  - JOUR
AU  - Talwar, S
AU  - Chigurupati, BS
AU  - Choudhary, SK
TI  - Ruptured sinus of Valsalva aneurysm with tetralogy of Fallot in an adult
T2  - JOURNAL OF CARDIAC SURGERY
KW  - congenital heart disease
KW  - FISTULA
KW  - REPAIR
AB  - A combination of ruptured sinus of Valsalva (RSOV) aneurysm with tetralogy of Fallot (TOF) is a very rare condition. We report a 32-year-old male who underwent repair of a RSOV aneurysm with TOF.
AD  - All India Inst Med Sci, Ctr Cardiothorac, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - OCT
PY  - 2018
VL  - 33
IS  - 10
SP  - 688
EP  - 690
DO  - 10.1111/jocs.13803
AN  - WOS:000446280600026
ER  -

TY  - JOUR
AU  - Talwar, S
AU  - Gupta, A
AU  - Choudhary, SK
TI  - d-transposition of great arteries, dextrocardia with aberrant origin of right subclavian artery from pulmonary artery
T2  - JOURNAL OF CARDIAC SURGERY
AD  - All India Inst Med Sci, Ctr Cardiothorac, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - OCT
PY  - 2018
VL  - 33
IS  - 10
SP  - 691
EP  - 692
DO  - 10.1111/jocs.13812
AN  - WOS:000446280600027
ER  -

TY  - JOUR
AU  - Thakran, S
AU  - Gupta, PK
AU  - Kabra, V
AU  - Saha, I
AU  - Jain, P
AU  - Gupta, RK
AU  - Singh, A
TI  - Characterization of breast lesion using T<sub>1</sub>-perfusion magnetic resonance imaging: Qualitative vs. quantitative analysis
T2  - DIAGNOSTIC AND INTERVENTIONAL IMAGING
KW  - Magnetic resonance imaging (MRI)
KW  - Perfusion MR imaging
KW  - Breast tumor
KW  - Lesion grading
KW  - Quantitative and qualitative analysis
KW  - CONTRAST-ENHANCED MRI
KW  - DIAGNOSIS
KW  - CANCER
KW  - DIFFERENTIATION
KW  - QUANTIFICATION
KW  - SPECTROSCOPY
KW  - ACQUISITION
KW  - BENIGN
KW  - MASSES
KW  - TUMORS
AB  - Objectives: The objective of this study was to quantify the hemodynamic parameters using first pass analysis of T-1-perfusion magnetic resonance imaging (MRI) data of human breast and to compare these parameters with the existing tracer kinetic parameters, semi-quantitative and qualitative Ty-perfusion analysis in terms of lesion characterization.
   Materials and methods: MRI of the breast was performed in 50 women (mean age, 44 +/- 11 [SD] years; range: 26-75) years with a total of 15 benign and 35 malignant breast lesions. After pre- processing, T-1-perfusion MRI data was analyzed using qualitative approach by two radiologists visual inspection of the kinetic curve into types I, II or III), semi-quantitative (characterization of kinetic curve types using empirical parameters), generalized-tracer-kinetic-model (tracer kinetic parameters) and first pass analysis (hemodynamic-parameters). Chi-squared test, t-test, one-way analysis-of-variance (ANOVA) using Bonferroni post-hoc test and receiver-operatingcharacteristic (ROC) curve were used for statistical analysis.
   Results: All quantitative parameters except leakage volume (ye), qualitative (type-I and III) and semi-quantitative curves (type-1 and III) provided significant differences (P< 0.05) between benign and malignant lesions. Kinetic parameters, particularly volume transfer coefficient (K-trans) provided a significant difference (P<0.05) between all grades except grade-II vs III. The hemodynamic parameter (relative-leakage-corrected-breast-blood-volume [rBBVcorr) provided a statistically significant difference (P < 0.05) between all grades. It also provided highest sensitivity and specificity among all parameters in differentiation between different grades of malignant breast lesions.
   Conclusion: Quantitative parameters, particularly rBBVcorr and K(trans)provided similar sensitivity and specificity in differentiating benign from malignant breast lesions for this cohort. Moreover, rBBVcorr provided better differentiation between different grades of malignant breast lesions among all the parameters. (C) 2018 Published by Elsevier Masson SAS on behalf of Societe francaise de radiologie.
AD  - IIT Delhi, Ctr Biomed Engn, Hauz Khas,Block 2,Room 299, New Delhi 110016, IndiaAD  - Fortis Mem Res Inst, Dept Radiol & Imaging, Gurgaon, IndiaAD  - Fortis Mem Res Inst, Dept Surg Oncol, Gurgaon, IndiaAD  - Philips India Ltd, Philips Healthcare, Gurgaon, IndiaAD  - Fortis Mem Res Inst, SRL Diagnost, Gurgaon, IndiaAD  - All India Inst Med Sci Delhi, Dept Biomed Engn, New Delhi, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - PhilipsC3  - Philips HealthcareC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER MASSON, CORPORATION OFFICE
PI  - PARIS
PA  - 65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE
DA  - OCT
PY  - 2018
VL  - 99
IS  - 10
SP  - 633
EP  - 642
DO  - 10.1016/j.diii.2018.05.006
AN  - WOS:000447849300007
ER  -

TY  - JOUR
AU  - Tolahunase, MR
AU  - Sagar, R
AU  - Dada, R
TI  - 5-HTTLPR and MTHFR 677C&gt;T polymorphisms and response to yoga-based lifestyle intervention in major depressive disorder: Arandomized active-controlled trial
T2  - INDIAN JOURNAL OF PSYCHIATRY
KW  - 5-HTTLPR
KW  - depression
KW  - gene-environment
KW  - meditation
KW  - MTHFR 677C > T
KW  - yoga
KW  - SEROTONIN TRANSPORTER GENE
KW  - PROMOTER POLYMORPHISM
KW  - REDUCTASE MTHFR
KW  - ANTIDEPRESSANT EFFICACY
KW  - PSYCHIATRIC-DISORDERS
KW  - HATHA YOGA
KW  - ASSOCIATION
KW  - METAANALYSIS
KW  - MEDITATION
KW  - BRAIN
AB  - Background: There is growing evidence suggesting that both genetic and environmental factors modulate treatment outcome in, a highly heterogeneous, major depressive disorder (MDD). 5-HTTLPR variant of the serotonin transporter gene (SLC6A4) and MTHFR 677C> T polymorphisms have been linked to the pathogenesis of MDD, and antidepressant treatment response. The evidence is lacking on the clinical utility of yoga in patients with MDD who have 5-HTTLPR and MTHFR 677C> T polymorphisms and less likely to respond to medications (SSRIs). Aims: We aimed to examine the impact of YBLI in those who have susceptible 5-HTTLPR and MTHFR 677C> T polymorphisms and are less likely to drug therapy with SSRIs. Settings and Design: In a 12 week randomized active-controlled trial, MDD patients (n = 178) were randomized to receive YBLI or drug therapy. Methods: Genotyping was conducted using PCR-based methods. The clinical remission was defined as BDI-II score < 9. Statistical Analysis Used: An intent-to-treat analysis was performed, and the association of genotype with treatment remission consisted of the logistic regression model. A P value of < 0.05 was considered statistically significant. Results: Multivariate logistic regression models for remission including either 5-HTTLPR or MTHFR 677C> T genotypes showed statistically significant odds of remission in YOGA arm vs. DRUG arm. Neither 5-HTTLPR nor MTHFR 677C> T genotype showed any influence on remission to YBLI (P = 0.73 and P = 0.64, respectively). Further analysis showed childhood adversity interact with 5-HTTLPR and MTHFR 677C> T polymorphisms to decrease treatment response in DRUG treatment arm, but not in YOGA arm. Conclusions: YBLI provides MDD remission in those who have susceptible 5-HTTLPR and MTHFR 677C> T polymorphisms and are resistant to SSRIs treatment. YBLI may be therapeutic for MDD independent of heterogeneity in its etiopathogenesis.
AD  - All India Inst Med Sci, Dept Anat, Lab Mol Reprod & Genet, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - OCT-DEC
PY  - 2018
VL  - 60
IS  - 4
SP  - 410
EP  - 426
DO  - 10.4103/psychiatry.IndianJPsychiatry_398_17
AN  - WOS:000452794600007
ER  -

TY  - JOUR
AU  - Velpandian, T
AU  - Halder, N
AU  - Nath, M
AU  - Das, U
AU  - Moksha, L
AU  - Gowtham, L
AU  - Batta, SP
TI  - Un-segregated waste disposal: an alarming threat of antimicrobials in surface and ground water sources in Delhi
T2  - ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
KW  - Delhi
KW  - Environment
KW  - Water pollution
KW  - Antibiotics
KW  - Landfill
KW  - Drug disposal
KW  - Multi-drug resistance
KW  - AQUATIC ENVIRONMENT
KW  - ANTIBIOTICS
KW  - CARE
KW  - OCCURRENCES
KW  - RESISTANCE
KW  - INDIA
AB  - Exposure of active pharmaceutical compounds (APCs) to the environment during human use is of potential importance in the emergence of drug resistance, changing soil microbiota and their residual effect on living organisms. Thus, this study aimed to assess the extent of exposure of APCs in the hydrologic cycle in and around New Delhi. This study analyzed the presence of 28 drugs from different classes in the surface water (river Yamuna) and aquifers collected from 48 places in Delhi (within the radius of 40 km). The collected water samples were quantified for APCs content using LC-MS/MS. This study revealed that aquifers are extensively affected in most areas based on the accumulation of APCs in water resources to the levels > 0.01 mu g/L. Interestingly, a geographical plot of total APCs studied indicated clustering in aquifers with such high levels closer to an unscientific landfill. This 30-year-old un-segregated landfill is found to drain leachate into surface water that had high APCs. This study further revealed that apart from therapeutic usage, the main source of ecological exposure could be due to the disposal of unused and expired pharmaceutical compounds into landfills. For the first time, this study revealed the existence of antimicrobial agents and other APCs in the aquifers of Delhi with levels > 0.1 mu g/L, which is a matter of serious concern in terms of multi-drug resistance and other environmental perils. This study warrants the enforcement of regulations for the disposal of unused/expired APCs in high-density population areas.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Ocular Pharmacol & Pharm, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SPRINGER HEIDELBERG
PI  - HEIDELBERG
PA  - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
DA  - OCT
PY  - 2018
VL  - 25
IS  - 29
SP  - 29518
EP  - 29528
DO  - 10.1007/s11356-018-2927-9
AN  - WOS:000445273500071
ER  -

TY  - JOUR
AU  - Verma, R
AU  - Verma, K
TI  - Virtual reality compared with <i>in vivo</i> exposure in the treatment of social anxiety disorder
T2  - BRITISH JOURNAL OF PSYCHIATRY
AD  - All India Inst Med Sci New Delhi, Dept Psychiat, Psychiat, New Delhi, IndiaAD  - All India Inst Med Sci New Delhi, Dept Psychiat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - CAMBRIDGE UNIV PRESS
PI  - CAMBRIDGE
PA  - EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
DA  - OCT
PY  - 2018
VL  - 213
IS  - 4
SP  - 617
EP  - 617
DO  - 10.1192/bjp.2018.184
AN  - WOS:000451166000009
ER  -

TY  - JOUR
AU  - Vijay, G
AU  - Mandal, A
AU  - Sankar, J
AU  - Kapil, A
AU  - Lodha, R
AU  - Kabra, SK
TI  - Ventilator Associated Pneumonia in Pediatric Intensive Care Unit: Incidence, Risk Factors and Etiological Agents
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Acinetobacter
KW  - Enteral feeding
KW  - Proton pump inhibitor
KW  - Ventilator associated pneumonia
KW  - MECHANICAL VENTILATION
KW  - NOSOCOMIAL PNEUMONIA
KW  - CHILDREN
KW  - SURVEILLANCE
KW  - TRACHEOBRONCHITIS
KW  - INTUBATION
KW  - INFECTIONS
KW  - OUTCOMES
KW  - IMPACT
AB  - ObjectivesTo study the incidence, etiology and risk factors associated with ventilator associated pneumonia (VAP) in children.MethodsThis prospective cohort study was conducted on patients admitted to the Pediatric Intensive Care Unit (PICU) of a tertiary care institute of North India, from June 2012 through March 2014, who received mechanical ventilation for more than 24h. All enrolled children were assessed daily for development of ventilator associated pneumonia (VAP) using the case definition given by Centers for Disease Control and Prevention (CDC). Chest radiograph and microbiologic samplings were performed in children suspected to have VAP. Risk factors associated with VAP were calculated by doing bivariate and multivariate analysis.ResultsA total of 128 patients were screened and 86 were enrolled (median age 30mo 95% CI 4.0-84.0; 72% boys). The most common admitting diagnosis was sepsis (16%) followed by acyanotic congenital heart disease with pneumonia (14%) and the most common indication for ventilation was respiratory failure (45.3%). The incidence of VAP according to CDC criteria was 38.4%, while the incidence of microbiologically confirmed VAP was 24.4%. The incidence of ventilator associated tracheobronchitis (VAT) was found to be 11.6%. Acinetobacter was the most frequently isolated organism (47%) followed by Pseudomonas (28%), Klebsiella (15%), E. coli (5%) and Enterobacter (5%). Risk factors for VAP on bivariate analysis were use of proton pump inhibitor (PPI) (p=0.027, OR 5.2, 95% CI 1.1-24.3), enteral feeding (p<0.001, OR 6.5, 95% CI 2.1-19.4) and re-intubation (p=0.024, OR 3.3 and 95% CI 1.1-9.6). On multivariate analysis, use of PPI (p=0.03, OR 8.47, 95% CI 1.19-60.33) and enteral feeding (p<0.001, OR 12.2, 95% CI 2.58-57.78) were identified as independent risk factors for VAP.ConclusionsVentilator associated pneumonia is an important complication in children receiving mechanical ventilation in PICU and Gram negative bacilli (Acinetobacter and Pseudomonas) being the important causative agents. Ventilator associated tracheobronchitis is an emerging entity; recognition and treatment of same might prevent the development of VAP.
AD  - All India Inst Med Sci, Dept Pediat, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - OCT
PY  - 2018
VL  - 85
IS  - 10
SP  - 861
EP  - 866
DO  - 10.1007/s12098-018-2662-8
AN  - WOS:000445955200012
ER  -

TY  - JOUR
AU  - Vispute, T
AU  - Suhani
AU  - Seenu, V
AU  - Parshad, R
AU  - Hari, S
AU  - Thulkar, S
AU  - Mathur, S
TI  - Comparison of resection margins and cosmetic outcome following intraoperative ultrasound-guided excision versus conventional palpation-guided breast conservation surgery in breast cancer: A randomized controlled trial
T2  - INDIAN JOURNAL OF CANCER
KW  - Breast cancer
KW  - breast conservation surgery
KW  - ultrasonography-guided WLE
KW  - wide local excision
KW  - LUMPECTOMY
AB  - INTRODUCTION: Use of intraoperative ultrasound (IOUS) has been shown to help achieve satisfactory cosmesis and negative margins in breast conserving surgery (BCS). This study has been done to compare the oncological and cosmetic outcomes following BCS using conventional palpatory method and IOUS. MATERIALS AND METHODS: This is a prospective randomized controlled trial conducted at a tertiary care teaching and research institute in India. Patients with early operable breast cancer willing for BCS were included. Tumors were excised with 1 cm margin. In palpatory group, tumor was palpated and 1 cm margin was taken with a measuring scale while in the second group, IOUS was used to mark the margins. Histopathological evaluation was done to assess margins and cosmesis was assessed by patient, resident doctor, and nurse independently. RESULTS: Sixty patients were included, 32 in the ultrasonography-guided and 28 in palpation-guided wide local excision. The mean age of patients was 48.78 years. In both groups, mean tumor size was 3.18 cm. Margin thickness and positivity was higher in palpatory group (though P 0.05). Most patients were satisfied with cosmesis. There was no significant difference in complications and specimen volume in both groups. Presence of ductal carcinoma in situ component and expression of Her2neu by tumor cells had a significant impact on margin positivity. CONCLUSIONS: Intraoperative use of ultrasound offers a real-time assessment of margin status and may reduce the margin positivity rate compared to conventional palpation-guided method.
AD  - All India Inst Med Sci, Dept Surg Oncol, BRA IRCH, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Surg Disciplines, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radio Diag, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - OCT-DEC
PY  - 2018
VL  - 55
IS  - 4
SP  - 361
EP  - 365
DO  - 10.4103/ijc.IJC_2_18
AN  - WOS:000460297000009
ER  -

TY  - JOUR
AU  - Viswanathan, S
AU  - Hung, SKY
AU  - Goyal, V
AU  - Apiwattanakul, M
AU  - Thirugnanam, UN
AU  - Abdullah, S
AU  - Aye, SMM
AU  - Ohnmar, O
AU  - Si, LT
AU  - Keosodsay, S
AU  - Estiasari, R
AU  - Khalife, N
AU  - Hiew, FL
TI  - Second regional plasmapheresis conference and workshop for Southeast Asia (SEA) on the immunomodulatory role of plasma exchange in central and peripheral nervous system disorders, Kuala Lumpur, Malaysia, 9th December 2017
T2  - JOURNAL OF CLINICAL APHERESIS
KW  - central nervous system demyelination
KW  - immunomodulatory therapy
KW  - peripheral nervous system demyelination
KW  - Southeast Asia
KW  - therapeutic plasma exchange
KW  - THERAPEUTIC APHERESIS
KW  - MYASTHENIA-GRAVIS
KW  - IMMUNOGLOBULIN
KW  - ENCEPHALITIS
KW  - GUIDELINES
KW  - NEUROLOGY
KW  - SERIES
AB  - In December 2017, 79 delegates attended the 2nd regional plasmapheresis conference and workshop for Southeast Asia (SEA) on the immunomodulatory role of plasma exchange in central and peripheral nervous system disorders in Kuala Lumpur, Malaysia. This meeting featured 6 plenary lectures, interactive sessions dedicated for experience sharing, case presentations, and a practical session for paramedics. Clinical experts and researchers from 7 SEA countries and India shared experience and challenges in treating autoimmune neurological disorders. While the spectrum of diseases and neurology practice remained largely similar, there was great disparities in accessibility of therapeutic plasma exchange (TPE) within SEA countries and between urban or rural settings. Costs, human resources, and healthcare policies are common challenges in providing sustainable TPE services. Novel techniques and innovative ideas in performing TPE were explored. A working consortium comprising of key opinion leaders was proposed to improve standards of TPE and enhance future research.
AD  - Kuala Lumpur Hosp, Dept Neurol, Kuala Lumpur, MalaysiaAD  - All India Inst Med Sci, Neurosci Ctr, Dept Neurol, New Delhi, IndiaAD  - Prasat Neurol Inst, Dept Neurol, Bangkok, ThailandAD  - Tan Tock Seng Hosp, Dept Neurol, Singapore, SingaporeAD  - Univ Melaya, Med Ctr, Med Fac, Kuala Lumpur, MalaysiaAD  - Asia Royal Hosp, Yangon, MyanmarAD  - Univ Med 1, Yangon, MyanmarAD  - Med Ctr, Ho Chi Minh City, VietnamAD  - Mittaphab Hosp, Viangchan, LaosAD  - Univ Indonesia, Cipto Mangunkusumo Hosp, Fac Med, Dept Neurol, Jakarta, IndonesiaAD  - Terumo BCT, Global Med Affairs, Zaventem, BelgiumC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Tan Tock Seng HospitalC3  - University of IndonesiaPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - OCT
PY  - 2018
VL  - 33
IS  - 5
SP  - 559
EP  - 568
DO  - 10.1002/jca.21630
AN  - WOS:000447410600001
ER  -

TY  - JOUR
AU  - Yadav, D
AU  - Agarwal, S
AU  - Sharma, A
AU  - Malik, E
AU  - Kandasamy, D
AU  - Thakar, A
AU  - Yadav, R
AU  - Barward, A
AU  - Kini, L
TI  - Synovial sarcoma masquerading as medullary thyroid carcinoma
T2  - CYTOPATHOLOGY
KW  - biphasic
KW  - medullary thyroid carcinoma
KW  - primary synovial sarcoma
KW  - RET mutation
KW  - thyroid
KW  - GLAND
AB  - Primary synovial sarcoma of thyroid gland is rare and rarer still is its occurrence in a patient with germline RET mutation. The cytological, histological and molecular details of one such case are presented which was thought pre-operatively to be medullary thyroid carcinoma.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Anat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Otorhinolaryngol, New Delhi, IndiaAD  - CORE Diagnost, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - OCT
PY  - 2018
VL  - 29
IS  - 5
SP  - 468
EP  - 470
DO  - 10.1111/cyt.12582
AN  - WOS:000444462500009
ER  -

TY  - JOUR
AU  - Yenamandra, VK
AU  - Vellarikkal, SK
AU  - Chowdhury, MR
AU  - Jayarajan, R
AU  - Verma, A
AU  - Scaria, V
AU  - Sivasubbu, S
AU  - Basu Ray, S
AU  - Dinda, AK
AU  - Kabra, M
AU  - Sharma, VK
AU  - Sethuraman, G
TI  - Genotype-Phenotype Correlations of Dystrophic Epidermolysis Bullosa in India: Experience from a Tertiary Care Centre
T2  - ACTA DERMATO-VENEREOLOGICA
KW  - dystrophic EB
KW  - collagen VII
KW  - whole exome sequencing
KW  - GLYCINE SUBSTITUTION MUTATIONS
KW  - CARTILAGE MATRIX PROTEIN
KW  - COLLAGEN GENE COL7A1
KW  - VII COLLAGEN
KW  - DISEASE SEVERITY
KW  - MMP1 PROMOTER
KW  - DOMINANT
KW  - DIAGNOSIS
KW  - DATABASE
KW  - DOMAIN
AB  - Recent advances in the field of genomics have seen the successful implementation of whole exome sequencing as a rapid and efficient diagnostic strategy in several genodermatoses. The aim of this study was to explore the potential of molecular studies in dystrophic epidermolysis bullosa (DEB) in India. Whole exome sequencing was performed using genomic DNA from each case of epidermolysis bullosa, followed by massively parallel sequencing. Resulting reads were mapped to the human reference genome hg19. Sanger sequencing subsequently confirmed the potentially pathogenic mutations. Whole exome sequencing of 18 patients with DEB from 17 unrelated Indian families revealed 20 distinct sequence variants in the COL7A1 gene including 2 widely prevalent mutations. Dominant inheritance was seen in 7 patients, while 11 patients showed a highly variable recessive DEB. This preliminary study using exome sequencing is clearly encouraging and will serve as the basis for future large-scale molecular studies to actively identify and understand DEB in the Indian population.
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Anat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - CSIR Inst Genom & Integrat Biol, Mathura Rd, New Delhi, IndiaAD  - CSIR, Acad Sci & Innovat Res, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - Academy of Scientific & Innovative Research (AcSIR)PU  - ACTA DERMATO-VENEREOLOGICA
PI  - UPPSALA
PA  - TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN
DA  - OCT
PY  - 2018
VL  - 98
IS  - 9
SP  - 873
EP  - 879
DO  - 10.2340/00015555-2929
AN  - WOS:000446657500009
ER  -

TY  - JOUR
AU  - Zeitler, P
AU  - Arslanian, S
AU  - Fu, JF
AU  - Pinhas-Hamiel, O
AU  - Reinehr, T
AU  - Tandon, N
AU  - Urakami, T
AU  - Wong, J
AU  - Maahs, DM
TI  - ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth
T2  - PEDIATRIC DIABETES
KW  - ISPAD
KW  - type 2 diabetes
KW  - youth
KW  - CARDIOVASCULAR RISK-FACTORS
KW  - FATTY LIVER-DISEASE
KW  - QUALITY-OF-LIFE
KW  - IMPAIRED GLUCOSE-TOLERANCE
KW  - POLYCYSTIC-OVARY-SYNDROME
KW  - OBESE WHITE-CHILDREN
KW  - SHORT-SLEEP DURATION
KW  - FOLLOW-UP
KW  - INSULIN-RESISTANCE
KW  - METABOLIC SYNDROME
AD  - Univ Colorado, Sch Med, Childrens Hosp Colorado, Aurora, CO 80045 USAAD  - Univ Pittsburgh, Med Ctr, Childrens Hosp, Pittsburgh, PA USAAD  - Zhejiang Univ, Sch Med, Childrens Hosp, Hangzhou, Zhejiang, Peoples R ChinaAD  - Edmond & Lily Safra Childrens Hosp, Tel Hashomer, IsraelAD  - Sackler Sch Med, Tel Aviv, IsraelAD  - Univ Witten Herdecke, Vestische Childrens Hosp, Witten, GermanyAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Nihon Univ, Sch Med, Tokyo, JapanAD  - Univ Sydney, Royal Prince Alfred Hosp, Sydney, NSW, AustraliaAD  - Stanford Univ, Lucile Packard Childrens Hosp, Stanford, CA 94305 USAC3  - Children's Hospital ColoradoC3  - University of Colorado SystemC3  - University of Colorado Anschutz Medical CampusC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - Zhejiang UniversityC3  - Tel Aviv UniversityC3  - Sackler Faculty of MedicineC3  - Witten Herdecke UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Nihon UniversityC3  - NSW HealthC3  - Royal Prince Alfred HospitalC3  - University of SydneyC3  - Lucile Packard Children's Hospital (LPCH)C3  - Stanford UniversityPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - OCT
PY  - 2018
VL  - 19
SP  - 28
EP  - 46
DO  - 10.1111/pedi.12719
AN  - WOS:000446312300004
ER  -

TY  - JOUR
AU  - Gupta, SC
AU  - Kunnumakkara, AB
AU  - Aggarwal, S
AU  - Aggarwal, BB
TI  - Inflammation, a Double-Edge Sword for Cancer and Other Age-Related Diseases
T2  - FRONTIERS IN IMMUNOLOGY
KW  - cancer
KW  - chronic disease
KW  - cytokine
KW  - inflammation
KW  - nutraceutical
KW  - FACTOR-KAPPA-B
KW  - REGULATED GENE-PRODUCTS
KW  - ALPHA KINASE ACTIVATION
KW  - HUMAN MULTIPLE-MYELOMA
KW  - FATTY LIVER-DISEASE
KW  - GREEN TEA
KW  - PROSTATE-CANCER
KW  - CURCUMIN DIFERULOLYLMETHANE
KW  - CHEMOTHERAPEUTIC-AGENTS
KW  - COLORECTAL-CANCER
AB  - Increasing evidence from diverse sources during the past several years has indicated that long-term, low level, chronic inflammation mediates several chronic diseases including cancer, arthritis, obesity, diabetes, cardiovascular diseases, and neurological diseases. The inflammatory molecules and transcription factors, adhesion molecules, AP-1, chemokines, C-reactive protein (CRP), cyclooxygenase (COX)-2, interleukins (ILs), 5-lipooxygenase (5-LOX), matrix metalloproteinases (MMPs), nuclear factor (NF)-kB, signal transducer and activator of transcription 3 (STAT3), tumor necrosis factor (TNF), and vascular endothelial growth factor (VEGF) are molecular links between inflammation and chronic diseases. Thus, suppression of inflammatory molecules could be potential strategy for the prevention and therapy of chronic diseases. The currently available drugs against chronic diseases are highly expensive, minimally effective and produce several side effects when taken for long period of time. The focus of this review is to discuss the potential of nutraceuticals derived from "Mother Nature" such as apigenin, catechins, curcumin, ellagic acid, emodin, epigallocatechin gallate, escin, fisetin, flavopiridol, genistein, isoliquiritigenin, kaempferol, mangostin, morin, myricetin, naringenin, resveratrol, silymarin, vitexin, and xanthohumol in suppression of these inflammatory pathways. Thus, these nutraceuticals offer potential in preventing or delaying the onset of chronic diseases. We provide evidence for the potential of these nutraceuticals from pre-clinical and clinical studies.
AD  - Banaras Hindu Univ, Inst Sci, Dept Biochem, Varanasi, Uttar Pradesh, IndiaAD  - Indian Inst Technol, Dept Biosci & Bioengn, Gauhati, IndiaAD  - All India Inst Med Sci, Dept Biotechnol, New Delhi, IndiaAD  - Inflammat Res Ctr, San Diego, CA USAC3  - Banaras Hindu University (BHU)C3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - GuwahatiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - FRONTIERS MEDIA SA
PI  - LAUSANNE
PA  - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
DA  - SEP 27
PY  - 2018
VL  - 9
C7  - 2160
DO  - 10.3389/fimmu.2018.02160
AN  - WOS:000445770200001
ER  -

TY  - JOUR
AU  - Jindal, D
AU  - Gupta, P
AU  - Jha, D
AU  - Ajay, VS
AU  - Goenka, S
AU  - Jacob, P
AU  - Mehrotra, K
AU  - Perel, P
AU  - Nyong, J
AU  - Roy, A
AU  - Tandon, N
AU  - Prabhakaran, D
AU  - Patel, V
TI  - Development of mWellcare: an mHealth intervention for integrated management of hypertension and diabetes in low-resource settings
T2  - GLOBAL HEALTH ACTION
KW  - Clinical decision support system
KW  - complex intervention
KW  - evidence-based management
KW  - longitudinal patient monitoring
KW  - primary care
KW  - noncommunicable diseases
KW  - CARDIOVASCULAR-DISEASE
KW  - DEPRESSION
KW  - PREVALENCE
KW  - BARRIERS
KW  - CARE
AB  - Background: Cardiovascular diseases and diabetes are among the leading causes of premature adult deaths in India. Innovative approaches such as clinical decision support (CDS) software could play a major role in improving the quality of hypertension/diabetes care in primary care settings.Objective: To describe the steps and processes in the development of mWellcare, a complex intervention based on mobile health (mHealth) technology.Methods: The Medical Research Council framework was used to develop mWellcare in four steps: (1) identify gaps in usual care through literature review and health facility assessments; (2) identify the components of the intervention through discussions and consultations with experts; (3) develop intervention (clinical algorithms and mHealth system); and (4) evaluate acceptability and feasibility through pilot testing in five community health centers.Results: Lack of evidence-based, integrated, and systematic management of chronic conditions were major gaps identified. Experts in information technology, clinical fields, and public health professionals identified intervention components to address these gaps. Thereafter, clinical algorithm contextualized to primary care settings were prepared and the mWellcare intervention was developed. During the 2-month pilot, 631 patients diagnosed with hypertension and/or diabetes were registered, with a follow-up rate of 36.2%. The major barrier was resistance to follow mWellcare recommended patient workflow, and to overcome it, we emphasized onsite training and orientation program to cover all health care team member in each CHC.Conclusion: A pilot-tested mWellcare intervention is an mHealth system with important components, i.e. integrated management of chronic conditions, evidence-based CDS, longitudinal health data and automated short-messaging service to reinforce compliance to drug intake and follow-up visit, which will be used by nurses at primary health care settings in India. The effectiveness and cost-effectiveness of the intervention will be tested through a cluster randomized trial (trial registration number NCT02480062).
AD  - Ctr Chron Dis Control, Clin Trials, New Delhi, IndiaAD  - Publ Hlth Fdn India, Ctr Control Chron Condit, New Delhi, IndiaAD  - Dimagi Software Innovat Pvt Ltd, Global Serv, New Delhi, IndiaAD  - London Sch Hyg & Trop Med, Ctr Global Non Communicable Dis, London, EnglandAD  - All India Inst Med Sci, Ctr Control Chron Condit, New Delhi, IndiaAD  - Harvard Med Sch, Dept Global Hlth & Social Med, 25 Shattuck St, Boston, MA 02115 USAC3  - Public Health Foundation of IndiaC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Harvard UniversityC3  - Harvard Medical SchoolPU  - TAYLOR & FRANCIS LTD
PI  - ABINGDON
PA  - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
DA  - SEP 26
PY  - 2018
VL  - 11
IS  - 1
C7  - 1517930
DO  - 10.1080/16549716.2018.1517930
AN  - WOS:000445649900001
ER  -

TY  - JOUR
AU  - Misra, S
AU  - Talwar, P
AU  - Kumar, A
AU  - Kumar, P
AU  - Sagar, R
AU  - Vibha, D
AU  - Pandit, AK
AU  - Gulati, A
AU  - Kushwaha, S
AU  - Prasad, K
TI  - Association between matrix metalloproteinase family gene polymorphisms and risk of ischemic stroke: A systematic review and meta-analysis of 29 studies
T2  - GENE
KW  - Ischemic stroke
KW  - Matrix metalloproteinase
KW  - Single nucleotide polymorphism
KW  - Systematic review
KW  - Meta-analysis
KW  - PROMOTER POLYMORPHISMS
KW  - EXPRESSION
KW  - DISRUPTION
KW  - VARIANTS
KW  - CORONARY
KW  - SUSCEPTIBILITY
KW  - LOCALIZATION
KW  - DISEASE
KW  - BRAIN
AB  - Background: Ischemic stroke (IS) is a complex and devastating vascular disease that has become one of the leading causes of disability and mortality worldwide. Several studies have shown the association between matrix metalloproteinase (MMP) family gene polymorphisms and IS. However, the results have been indecisive.
   Objective: To investigate the association between Matrix Metalloproteinase gene polymorphisms and risk of IS.
   Methods: A literature search for eligible candidate gene studies published before, 28 June 2017, was conducted in the PubMed, EMBASE, Cochrane and Google Scholar databases. The following combinations of main keywords were used: ('Matrix Metalloproteinase' or 'INAMP' or 'Stromelysin-1' or 'Gelatinase b') AND ('ischemic stroke' or 'IS') AND ('single nucleotide polymorphism' or 'gene polymorphism' or 'SNP'). Fixed or random effects models were used to estimate the Pooled Odds ratio (OR) and 95% confidence interval (CI). Statistical analysis was carried out by using STATA version 13.0 software.
   Results: Total 29 studies were included in our meta-analysis. A significant association was observed for MMP-9 (- 1562C/T) (OR 1.27; 95% CI 1.06 to 1.53; p value = 0.01) and MMP-12 (- 1082 A/G) (OR 2.55; 95% CI 1.75 to 3.71; p value < 0.001) gene polymorphisms and risk of IS. No significant association was found for any of the MMP-1(- 1607 1G/2G), MMP-2 (- 1306C/T) & (- 735C/T) and MMP-3 (- 1612 5A/6A) gene polymorphisms with the risk of IS.
   Conclusion: Our meta-analysis suggests that MMP-9 (- 1562C/T) and MMP-12 (- 1082 A/G) gene polymorphisms could be a risk factor for IS while MMP-1 (- 1607 1G/2G), MMP-2 (- 1306C/T) & (- 735C/T) and MMP-3 (-1612 5A/6A) have no association with the risk of causing IS. However, large prospective studies with sufficient power are required to validate our findings.
AD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaAD  - Army Hosp Res & Referral, Dept Paediat, New Delhi, IndiaAD  - All India Inst Med Sci, Clin Epidemiol Unit, New Delhi, IndiaAD  - Inst Human Behav & Allied Sci, Dept Neurol, Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - SEP 25
PY  - 2018
VL  - 672
SP  - 180
EP  - 194
DO  - 10.1016/j.gene.2018.06.027
AN  - WOS:000440391200023
ER  -

TY  - JOUR
AU  - Griswold, MG
AU  - Fullman, N
AU  - Hawley, C
AU  - Arian, N
AU  - Zimsen, SRM
AU  - Tymeson, HD
AU  - Venkateswaran, V
AU  - Tapp, AD
AU  - Forouzanfar, MH
AU  - Salama, JS
AU  - Abate, KH
AU  - Abate, D
AU  - Abay, SM
AU  - Abbafati, C
AU  - Abdulkader, RS
AU  - Abebe, Z
AU  - Aboyans, V
AU  - Abrar, MM
AU  - Acharya, P
AU  - Adetokunboh, OO
AU  - Adhikari, TB
AU  - Adsuar, JC
AU  - Afarideh, M
AU  - Agardh, EE
AU  - Agarwal, G
AU  - Aghayan, SA
AU  - Agrawal, S
AU  - Ahmed, MB
AU  - Akibu, M
AU  - Akinyemiju, T
AU  - Akseer, N
AU  - Al Asfoor, DH
AU  - Al-Aly, Z
AU  - Alahdab, F
AU  - Alam, K
AU  - Albujeer, A
AU  - Alene, KA
AU  - Ali, R
AU  - Ali, SD
AU  - Alijanzadeh, M
AU  - Aljunid, SM
AU  - Alkerwi, A
AU  - Allebeck, P
AU  - Alvis-Guzman, N
AU  - Amare, AT
AU  - Aminde, LN
AU  - Ammar, W
AU  - Amoako, YA
AU  - Amul, GGH
AU  - Andrei, CL
AU  - Angus, C
AU  - Ansha, MG
AU  - Antonio, CAT
AU  - Aremu, O
AU  - Ärnlöv, J
AU  - Artaman, A
AU  - Aryal, KK
AU  - Assadi, R
AU  - Ausloos, M
AU  - Avila-Burgos, L
AU  - Avokpaho, EFGA
AU  - Awasthi, A
AU  - Ayele, HT
AU  - Ayer, R
AU  - Ayuk, TB
AU  - Azzopardi, PS
AU  - Badali, H
AU  - Badawi, A
AU  - Banach, M
AU  - Barker-Collo, SL
AU  - Barrero, LH
AU  - Basaleem, H
AU  - Baye, E
AU  - Bazargan-Hejazi, S
AU  - Bedi, N
AU  - Béjot, Y
AU  - Belachew, AB
AU  - Belay, SA
AU  - Bennett, DA
AU  - Bensenor, IM
AU  - Bernabe, E
AU  - Bernstein, RS
AU  - Beyene, AS
AU  - Beyranvand, T
AU  - Bhaumik, S
AU  - Bhutta, ZA
AU  - Biadgo, B
AU  - Bijani, A
AU  - Bililign, N
AU  - Birlik, SM
AU  - Birungi, C
AU  - Bizuneh, H
AU  - Bjerregaard, P
AU  - Bjorge, T
AU  - Borges, G
AU  - Bosetti, C
AU  - Boufous, S
AU  - Bragazzi, NL
AU  - Brenner, H
AU  - Butt, ZA
AU  - Cahuana-Hurtado, L
AU  - Calabria, B
AU  - Campos-Nonato, IR
AU  - Rincon, JCC
AU  - Carreras, G
AU  - Carrero, JJ
AU  - Carvalho, F
AU  - Castañeda-Orjuela, CA
AU  - Rivas, JC
AU  - Catalá-López, F
AU  - Chang, JC
AU  - Charlson, FJ
AU  - Chattopadhyay, A
AU  - Chaturvedi, P
AU  - Chowdhury, R
AU  - Christopher, DJ
AU  - Chung, SC
AU  - Ciobanu, LG
AU  - Claro, RM
AU  - Conti, S
AU  - Cousin, E
AU  - Criqui, MH
AU  - Dachew, BA
AU  - Dargan, P
AU  - Daryani, A
AU  - Das Neves, J
AU  - Davletov, K
AU  - De Castro, F
AU  - De Courten, B
AU  - De Neve, JW
AU  - Degenhardt, L
AU  - Demoz, GT
AU  - Des Jarlais, DC
AU  - Dey, S
AU  - Dhaliwal, RS
AU  - Dharmaratne, SD
AU  - Dhimal, M
AU  - Doku, DT
AU  - Doyle, KE
AU  - Dubey, M
AU  - Dubljanin, E
AU  - Duncan, BB
AU  - Ebrahimi, H
AU  - Edessa, D
AU  - Zaki, ME
AU  - Ermakov, SP
AU  - Erskine, HE
AU  - Esteghamati, A
AU  - Faramarzi, M
AU  - Farioli, A
AU  - Faro, A
AU  - Farvid, MS
AU  - Farzadfar, F
AU  - Feigin, VL
AU  - Felisbino-Mendes, MS
AU  - Fernandes, E
AU  - Ferrari, AJ
AU  - Ferri, CP
AU  - Fijabi, DO
AU  - Filip, I
AU  - Finger, JD
AU  - Fischer, F
AU  - Flaxman, AD
AU  - Franklin, RC
AU  - Futran, ND
AU  - Gallus, S
AU  - Ganji, M
AU  - Gankpe, FG
AU  - Gebregergs, GB
AU  - Gebrehiwot, TT
AU  - Geleijnse, JM
AU  - Ghadimi, R
AU  - Ghandour, LA
AU  - Ghimire, M
AU  - Gill, PS
AU  - Ginawi, IA
AU  - Giref, AZZ
AU  - Gona, PN
AU  - Gopalani, SV
AU  - Gotay, CC
AU  - Goulart, AC
AU  - Greaves, F
AU  - Grosso, G
AU  - Guo, YM
AU  - Gupta, R
AU  - Gupta, R
AU  - Gupta, V
AU  - Gutiérrez, RA
AU  - Gvs, M
AU  - Hafezi-Nejad, N
AU  - Hagos, TB
AU  - Hailu, GB
AU  - Hamadeh, RR
AU  - Hamidi, S
AU  - Hankey, GJ
AU  - Harb, HL
AU  - Harikrishnan, S
AU  - Haro, JM
AU  - Hassen, HY
AU  - Havmoeller, R
AU  - Hay, S
AU  - Heibati, B
AU  - Henok, A
AU  - Heredia-Pi, I
AU  - Hernández-Llanes, NF
AU  - Herteliu, C
AU  - Hibstu, DTT
AU  - Hoogar, P
AU  - Horita, N
AU  - Hosgood, HD
AU  - Hosseini, M
AU  - Hostiuc, M
AU  - Hu, GQ
AU  - Huang, H
AU  - Husseini, A
AU  - Idrisov, B
AU  - Ileanu, BV
AU  - Ilesanmi, OS
AU  - Irvani, SSN
AU  - Islam, SMS
AU  - Jackson, MD
AU  - Jakovljevic, M
AU  - Jayatilleke, AU
AU  - Jha, RP
AU  - Jonas, JB
AU  - Jozwiak, JJ
AU  - Kabir, Z
AU  - Kadel, R
AU  - Kahsay, A
AU  - Kapil, U
AU  - Kasaeian, A
AU  - Kassa, TDD
AU  - Katikireddi, SV
AU  - Kawakami, N
AU  - Kebede, S
AU  - Kefale, AT
AU  - Keiyoro, PN
AU  - Kengne, AP
AU  - Khader, Y
AU  - Khafaie, MA
AU  - Khalil, IA
AU  - Khan, MN
AU  - Khang, YH
AU  - Khater, MM
AU  - Khubchandani, J
AU  - Kim, CI
AU  - Kim, D
AU  - Kim, YJ
AU  - Kimokoti, RW
AU  - Kisa, A
AU  - Kivimäki, M
AU  - Kochhar, S
AU  - Kosen, S
AU  - Koul, PA
AU  - Koyanagi, A
AU  - Krishan, K
AU  - Defo, BK
AU  - Bicer, BK
AU  - Kulkarni, VS
AU  - Kumar, P
AU  - Lafranconi, A
AU  - Balaji, AL
AU  - Lalloo, R
AU  - Lallukka, T
AU  - Lam, H
AU  - Lami, FH
AU  - Lan, Q
AU  - Lang, JJ
AU  - Lansky, S
AU  - Larsson, AO
AU  - Latifi, A
AU  - Leasher, JL
AU  - Lee, PH
AU  - Leigh, J
AU  - Leinsalu, M
AU  - Leung, J
AU  - Levi, M
AU  - Li, YC
AU  - Lim, LL
AU  - Linn, S
AU  - Liu, SW
AU  - Lobato-Cordero, A
AU  - Lotufo, PA
AU  - Macarayan, ERK
AU  - Machado, IE
AU  - Madotto, F
AU  - Abd El Razek, HM
AU  - Abd El Razek, MM
AU  - Majdan, M
AU  - Majdzadeh, R
AU  - Majeed, A
AU  - Malekzadeh, R
AU  - Malta, DC
AU  - Mapoma, CC
AU  - Martinez-Raga, J
AU  - Maulik, PK
AU  - Mazidi, M
AU  - Mckee, M
AU  - Mehta, V
AU  - Meier, T
AU  - Mekonen, T
AU  - Meles, KG
AU  - Melese, A
AU  - Memiah, PTN
AU  - Mendoza, W
AU  - Mengistu, DT
AU  - Mensah, GA
AU  - Meretoja, TJ
AU  - Mezgebe, HB
AU  - Miazgowski, T
AU  - Miller, TR
AU  - Mini, GK
AU  - Mirica, A
AU  - Mirrakhimov, EM
AU  - Moazen, B
AU  - Mohammad, KA
AU  - Mohammadifard, N
AU  - Mohammed, S
AU  - Monasta, L
AU  - Moraga, P
AU  - Morawska, L
AU  - Jalu, MT
AU  - Mousavi, SM
AU  - Mukhopadhyay, S
AU  - Musa, KI
AU  - Naheed, A
AU  - Naik, G
AU  - Najafi, F
AU  - Nangia, V
AU  - Nansseu, JR
AU  - Nayak, MSDP
AU  - Nejjari, C
AU  - Neupane, S
AU  - Neupane, SP
AU  - Ngunjiri, JW
AU  - Nguyen, CT
AU  - Nguyen, LH
AU  - Nguyen, TH
AU  - Ningrum, DNA
AU  - Nirayo, YL
AU  - Noubiap, JJ
AU  - Ofori-Asenso, R
AU  - Ogbo, FA
AU  - Oh, IH
AU  - Oladimeji, O
AU  - Olagunju, AT
AU  - Olivares, PR
AU  - Olusanya, BO
AU  - Olusanya, JO
AU  - Oommen, AM
AU  - Oren, E
AU  - Orpana, HM
AU  - Ortega-Altamirano, DD
AU  - Ortiz, JR
AU  - Ota, E
AU  - Owolabi, MO
AU  - Oyekale, AS
AU  - Mahesh, PA
AU  - Pana, A
AU  - Park, EK
AU  - Parry, CDH
AU  - Parsian, H
AU  - Patle, A
AU  - Patton, GC
AU  - Paudel, D
AU  - Petzold, M
AU  - Phillips, MR
AU  - Pillay, JD
AU  - Postma, MJ
AU  - Pourmalek, F
AU  - Prabhakaran, D
AU  - Qorbani, M
AU  - Radfar, A
AU  - Rafay, A
AU  - Rafiei, A
AU  - Rahim, F
AU  - Rahimi-Movaghar, A
AU  - Rahman, M
AU  - Rahman, MA
AU  - Rai, RK
AU  - Rajsic, S
AU  - Raju, SB
AU  - Ram, U
AU  - Rana, SM
AU  - Ranabhat, CL
AU  - Rawaf, DL
AU  - Rawaf, S
AU  - Reiner, RC
AU  - Reis, C
AU  - Renzaho, AMN
AU  - Rezai, MS
AU  - Roever, L
AU  - Ronfani, L
AU  - Room, R
AU  - Roshandel, G
AU  - Rostami, A
AU  - Roth, GA
AU  - Roy, A
AU  - Sabde, YD
AU  - Saddik, B
AU  - Safiri, S
AU  - Sahebkar, A
AU  - Saleem, Z
AU  - Salomon, JA
AU  - Salvi, SS
AU  - Sanabria, J
AU  - Sanchez-Niño, MD
AU  - Santomauro, DF
AU  - Santos, IS
AU  - Milicevic, MMMS
AU  - Sarker, AR
AU  - Sarmiento-Suárez, R
AU  - Sarrafzadegan, N
AU  - Sartorius, B
AU  - Satpathy, M
AU  - Sawhney, M
AU  - Saxena, S
AU  - Saylan, M
AU  - Schaub, MP
AU  - Schmidt, MI
AU  - Schneider, IJC
AU  - Schöttker, B
AU  - Schutte, AE
AU  - Schwendicke, F
AU  - Sepanlou, SG
AU  - Shaikh, MAA
AU  - Sharif, M
AU  - She, J
AU  - Sheikh, A
AU  - Shen, JB
AU  - Shiferaw, MS
AU  - Shigematsu, M
AU  - Shiri, R
AU  - Shishani, K
AU  - Shiue, I
AU  - Shukla, SR
AU  - Sigfusdottir, ID
AU  - Silva, DAS
AU  - Da Silva, NT
AU  - Silveira, DGA
AU  - Sinha, DNN
AU  - Sitas, F
AU  - Soares, AM
AU  - Soofi, M
AU  - Sorensen, RJD
AU  - Soriano, JB
AU  - Sreeramareddy, CT
AU  - Steckling, N
AU  - Stein, DJ
AU  - Sufiyan, MB
AU  - Sur, PJ
AU  - Sykes, BL
AU  - Tabarés-Seisdedos, R
AU  - Tabuchi, T
AU  - Tavakkoli, M
AU  - Tehrani-Banihashemi, A
AU  - Tekle, MG
AU  - Thapa, S
AU  - Thomas, N
AU  - Topor-Madry, R
AU  - Topouzis, F
AU  - Tran, BX
AU  - Troeger, CE
AU  - Truelsen, TC
AU  - Tsilimparis, N
AU  - Tyrovolas, S
AU  - Ukwaja, KN
AU  - Ullah, I
AU  - Uthman, OA
AU  - Valdez, PR
AU  - Van Boven, JFM
AU  - Vasankari, TJ
AU  - Venketasubramanian, N
AU  - Violante, FS
AU  - Vladimirov, SK
AU  - Vlassov, V
AU  - Vollset, SE
AU  - Vos, T
AU  - Wagnew, FWS
AU  - Waheed, Y
AU  - Wang, YP
AU  - Weiderpass, E
AU  - Weldegebreal, F
AU  - Weldegwergs, KG
AU  - Werdecker, A
AU  - Westerman, R
AU  - Whiteford, HA
AU  - Widecka, J
AU  - Wijeratne, T
AU  - Wyper, GMA
AU  - Xu, GL
AU  - Yamada, T
AU  - Yano, Y
AU  - Ye, PP
AU  - Yimer, EM
AU  - Yip, P
AU  - Yirsaw, BD
AU  - Yisma, E
AU  - Yonemoto, N
AU  - Yoon, SJ
AU  - Yotebieng, M
AU  - Younis, MZ
AU  - Zachariah, G
AU  - Zaidi, Z
AU  - Zamani, M
AU  - Zhang, XY
AU  - Zodpey, S
AU  - Mokdad, AH
AU  - Naghavi, M
AU  - Murray, CJL
AU  - Gakidou, E
A1  - GBD 2016 Alcohol Collaborators
TI  - Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
T2  - LANCET
KW  - ALL-CAUSE MORTALITY
KW  - REDUCED MORTALITY
KW  - RISK-FACTORS
KW  - DRINKING
KW  - CONSUMPTION
KW  - METAANALYSIS
KW  - DEPENDENCE
AB  - Background Alcohol use is a leading risk factor for death and disability, but its overall association with health remains complex given the possible protective effects of moderate alcohol consumption on some conditions. With our comprehensive approach to health accounting within the Global Burden of Diseases, Injuries, and Risk Factors Study 2016, we generated improved estimates of alcohol use and alcohol-attributable deaths and disability-adjusted life-years (DALYs) for 195 locations from 1990 to 2016, for both sexes and for 5-year age groups between the ages of 15 years and 95 years and older.
   Methods Using 694 data sources of individual and population-level alcohol consumption, along with 592 prospective and retrospective studies on the risk of alcohol use, we produced estimates of the prevalence of current drinking, abstention, the distribution of alcohol consumption among current drinkers in standard drinks daily (defined as 10 g of pure ethyl alcohol), and alcohol-attributable deaths and DALYs. We made several methodological improvements compared with previous estimates: first, we adjusted alcohol sales estimates to take into account tourist and unrecorded consumption; second, we did a new meta-analysis of relative risks for 23 health outcomes associated with alcohol use; and third, we developed a new method to quantify the level of alcohol consumption that minimises the overall risk to individual health.
   Findings Globally, alcohol use was the seventh leading risk factor for both deaths and DALYs in 2016, accounting for 2.2% (95% uncertainty interval [UI] 1.5-3.0) of age-standardised female deaths and 6.8% (5.8-8.0) of age-standardised male deaths. Among the population aged 15-49 years, alcohol use was the leading risk factor globally in 2016, with 3.8% (95% UI 3.2-4-3) of female deaths and 12.2% (10.8-13-6) of male deaths attributable to alcohol use. For the population aged 15-49 years, female attributable DALYs were 2.3% (95% UI 2.0-2.6) and male attributable DALYs were 8.9% (7.8-9.9). The three leading causes of attributable deaths in this age group were tuberculosis (1.4% [95% UI 1. 0-1. 7] of total deaths), road injuries (1.2% [0.7-1.9]), and self-harm (1.1% [0.6-1.5]). For populations aged 50 years and older, cancers accounted for a large proportion of total alcohol-attributable deaths in 2016, constituting 27.1% (95% UI 21.2-33.3) of total alcohol-attributable female deaths and 18.9% (15.3-22.6) of male deaths. The level of alcohol consumption that minimised harm across health outcomes was zero (95% UI 0.0-0.8) standard drinks per week.
   Interpretation Alcohol use is a leading risk factor for global disease burden and causes substantial health loss. We found that the risk of all-cause mortality, and of cancers specifically, rises with increasing levels of consumption, and the level of consumption that minimises health loss is zero. These results suggest that alcohol control policies might need to be revised worldwide, refocusing on efforts to lower overall population-level consumption.
AD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USAAD  - Univ Washington, Dept Global Hlth, Seattle, WA 98121 USAAD  - Univ Washington, Sch Med, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98121 USAAD  - Univ Washington, Seattle, WA 98121 USAAD  - Harvard Univ, Dept Epidemiol, Boston, MA USAAD  - Harvard Univ, Dept Nutr, Boston, MA USAAD  - Harvard Univ, Ariadne Labs, Boston, MA USAAD  - Harvard Univ, BWH Div Gen Internal Med & Primary Care, Boston, MA USAAD  - Seattle Genet, Seattle, WA USAAD  - Jimma Univ, Dept Populat & Family Hlth, Jimma, EthiopiaAD  - Jimma Univ, Dept Epidemiol, Jimma, EthiopiaAD  - Haramaya Univ, Sch Publ Hlth, Harar, EthiopiaAD  - Haramaya Univ, Sch Pharm, Harar, EthiopiaAD  - Haramaya Univ, Dept Med Lab Sci, Harar, EthiopiaAD  - Haramaya Univ, Harar, EthiopiaAD  - Addis Ababa Univ, Dept Pharmacol & Clin Pharm, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Dept Reprod Hlth & Hlth Serv Management, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Sch Alaide Hlth Sci, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Addis Ababa, EthiopiaAD  - Univ Roma La Sapienza, Dept Law Philosophy & Econ Studies, Rome, ItalyAD  - Minist Hlth, Dept Publ Hlth, Riyadh, Saudi ArabiaAD  - Minist Hlth, Off Undersecretary Hlth Affairs, Riyadh, Saudi ArabiaAD  - Univ Gondar, Human Nutr, Gondar, EthiopiaAD  - Univ Gondar, Inst Publ Hlth, Gondar, EthiopiaAD  - Univ Gondar, Dept Clin Chem, Gondar, EthiopiaAD  - Dupuytren Univ Hosp, Dept Cardiol, Limoges, FranceAD  - Univ Limoges, Inst Epidemiol, Limoges, FranceAD  - Nepal Dev Soc, Chitwan, NepalAD  - Stellenbosch Univ, Dept Global Hlth, Cape Town, South AfricaAD  - Stellenbosch Univ, Dept Psychiat, Cape Town, South AfricaAD  - South African Med Res Council, Cochrane South Africa, Cape Town, South AfricaAD  - South African Med Res Council, Unit Hypertens & Cardiovasc Dis, Cape Town, South AfricaAD  - South African Med Res Council, Cape Town, South AfricaAD  - Ctr Social Sci & Publ Hlth Res Nepal, Nepal Hlth Res Environm, Kathmandu, NepalAD  - Univ Southern Denmark, Unit Hlth Promot Res, Odense, DenmarkAD  - Univ Southern Denmark, Natl Inst Publ Hlth, Odense, DenmarkAD  - Univ Southern Denmark, Dept Publ Hlth, Odense, DenmarkAD  - Univ Extremadura, Fac Sport Sci, Badajoz, SpainAD  - Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, IranAD  - Univ Tehran Med Sci, Noncommun Dis Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Sch Med, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Malignancies Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Oncol & Stem Cell Transplantat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, KURC, Tehran, IranAD  - Univ Tehran Med Sci, Dept Hlth Management & Econ, Sch Publ Hlth, Tehran, IranAD  - Univ Tehran Med Sci, INCAS, Tehran, IranAD  - Univ Tehran Med Sci, Community Based Participatory Res Ctr CBP, Tehran, IranAD  - Univ Tehran Med Sci, Tehran, IranAD  - Karolinska Inst, Dept Publ Hlth Sci, Stockholm, SwedenAD  - Karolinska Inst, Dept Neurobiol, Stockholm, SwedenAD  - Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, SwedenAD  - McMaster Univ, Dept Family Med, Hamilton, ON, CanadaAD  - Yerevan State Univ, Chair Zool, Yerevan, ArmeniaAD  - Sci Ctr Zool & Hydroecol, Res Grp Mol Parasitol, Yerevan, ArmeniaAD  - PHFI, Indian Inst Publ Hlth, Gurugram, IndiaAD  - PHFI, Gurugram, IndiaAD  - Vital Strategies, Gurugram, IndiaAD  - Dept Midwifery, Lexington, KY USAAD  - Dept Publ Hlth, Lexington, KY USAAD  - Debre Berhan Univ, Debre Berhan, EthiopiaAD  - Univ Kentucky, Dept Epidemiol, Lexington, KY 40506 USAAD  - Univ Toronto, Hosp Sick Children, Fac Med, Nutr Sci, Toronto, ON, CanadaAD  - Univ Toronto, Hosp Sick Children, Ctr Global Child Hlth, Toronto, ON, CanadaAD  - Univ Oxford, Nuffield Dept Populat Hlth, Oxford, EnglandAD  - Washington Univ, Dept Internal Med, St Louis, MO USAAD  - Dept Vet Affairs, VA St Louis Hlth Care Syst, Clin Epidemiol Ctr, St Louis, MO USAAD  - Mayo Clin Fdn Med Educ & Res, Evidence Based Pract Ctr, Rochester, MN USAAD  - Syrian Amer Med Soc, Res Comm Educ Comm & Avicenna Journal Med Editor, Washington, DC USAAD  - Univ Western Australia, Sch Populat & Global Hlth, Perth, WA, AustraliaAD  - Univ Western Australia, Med Sch, Perth, WA, AustraliaAD  - Naba Al Hayat Fdn Med Sci & Hlth Care, Najaf, IraqAD  - Australian Natl Univ, Res Sch Populat Hlth, Canberra, ACT, AustraliaAD  - Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, AustraliaAD  - New York Univ Abu Dhabi, Publ Hlth Res Ctr, Abu Dhabi, U Arab EmiratesAD  - Univ London, Islamabad, PakistanAD  - Qazvin Univ Med Sci, Social Determinants Hlth Res Ctr, Qazvin, IranAD  - Kuwait Univ, Dept Hlth Policy & Management, Kuwait, KuwaitAD  - Natl Univ Malaysia, Int Ctr Casemix & Clin Coding, Bandar Tun Razak, MalaysiaAD  - Luxembourg Inst Hlth, Dept Populat Hlth, Strassen, LuxembourgAD  - Swedish Res Council Hlth Working Life & Welfare, Stockholm, SwedenAD  - Univ Cartagena, Res Grp Hlth Econ, Cartagena, ColombiaAD  - Univ Coast, Res Grp Hosp Management & Hlth Pol, Barranquilla, ColombiaAD  - Univ South Australia, Sansom Inst, Adelaide, SA, AustraliaAD  - South Australian Hlth & Med Res Inst, Wardliparingga Aboriginal Res Unit, Adelaide, SA, AustraliaAD  - Bahir Dar Univ, Psychiat, Bahir Dar, EthiopiaAD  - Bahir Dar Univ, Bahir Dar, EthiopiaAD  - Univ Queensland, Sch Publ Hlth, Brisbane, Qld, AustraliaAD  - Univ Queensland, Sch Dent, Brisbane, Qld, AustraliaAD  - Univ Queensland, Brisbane, Qld, AustraliaAD  - Fed Minist Hlth, Dept Hlth Ind Complex & Innovat Hlth, Brasilia, DF, BrazilAD  - Fed Minist Hlth, Dept Dis & Noncommun Dis & Hlth Promot, Brasilia, DF, BrazilAD  - Fed Minist Hlth, Beirut, LebanonAD  - Amer Univ Beirut, Fac Hlth Sci, Beirut, LebanonAD  - Amer Univ Beirut, Dept Epidemiol & Populat Hlth, Beirut, LebanonAD  - Komfo Anokye Teaching Hosp, Dept Internal Med, Kumasi, GhanaAD  - Natl Univ Singapore, Lee Kuan Yew Sch Publ Pol, Singapore, SingaporeAD  - Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, SingaporeAD  - Carol Davila Univ Med & Pharm, Dept Legal Med & Bioeth, Bucharest, RomaniaAD  - Carol Davila Univ Med & Pharm, Bucharest, RomaniaAD  - Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, EnglandAD  - Univ Philippines Manila, Dept Hlth Policy & Adm, Manila, PhilippinesAD  - Univ Philippines Manila, Dev & Commun Studies, Manila, PhilippinesAD  - Birmingham City Univ, Sch Hlth Sci, Birmingham, W Midlands, EnglandAD  - Dalarna Univ, Sch Hlth & Social Studies, Falun, SwedenAD  - Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, CanadaAD  - ABT Associates Nepal, Monitoring Evaluat & Operat Res Project, DFID Nepal Hlth Sect Programme 3, Lalitpur, NepalAD  - Mashhad Univ Med Sci, Educ Dev Ctr, Mashhad, IranAD  - Mashhad Univ Med Ci, Dept Med Biotechnol, Mashhad, IranAD  - Univ Leicester, Sch Business, Leicester, Leics, EnglandAD  - Natl Inst Publ Hlth, Ctr Hlth Syst Res, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, Cuernavaca, Morelos, MexicoAD  - Benin Clin Res Inst IRCB, Project Deworm3, Calavi, BeninAD  - Lab Studies & Res Act Hlth LERAS, Control Infect Dis Project, Porto Novo, BeninAD  - Lab Studies & Res Act Hlth LERAS, Noncommun Dis Dept, Porto Novo, BeninAD  - Indian Inst Publ Hlth, Gandhinagar, IndiaAD  - McGill Univ, Dept Epidemiol & Occupational Hlth, Montreal, PQ, CanadaAD  - Dilla Univ, Dept Publ Hlth, Dilla, EthiopiaAD  - Univ Tokyo, Dept Community & Global Hlth, Tokyo, JapanAD  - Univ Tokyo, Dept Mental Hlth, Tokyo, JapanAD  - Univ Tokyo, Dept Diabet & Metab Dis, Tokyo, JapanAD  - Inst Med Res & Plant Med Studies, Ctr Food & Nutr Res, Yaounde, CameroonAD  - Univ South Africa, Dept Hlth Studies, Pretoria, South AfricaAD  - Burnet Inst, Discipline Int Dev, Maternal & Child Hlth Program, Global Adolescent Hlth Grp, Melbourne, Vic, AustraliaAD  - Mazandaran Univ Med Sci, Dept Med Mycol, Invas Fungi Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Toxoplasmosis Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Mol & Cell Biol Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Pediat, Sari, IranAD  - Mazandaran Univ Med Sci, Dept Immunol, Sari, IranAD  - Publ Hlth Agcy Canada, Publ Hlth Risk Sci Div, Toronto, ON, CanadaAD  - Publ Hlth Agcy Canada, Hlth Promot & Chron Dis Prevent Branch, Toronto, ON, CanadaAD  - Publ Hlth Agcy Canada, Appl Res Div, Toronto, ON, CanadaAD  - Med Univ Lodz, Dept Hypertens, Lodz, PolandAD  - PMMHRI, Lodz, PolandAD  - Univ Auckland, Sch Psychol, Auckland, New ZealandAD  - Pontificia Univ Javeriana, Dept Ind Engn, Bogota, ColombiaAD  - Univ Aden, Aden, YemenAD  - Wollo Univ, Dept Publ Hlth, Dessie, EthiopiaAD  - Charles R Drew Univ Med & Sci, Dept Psychiat, 1621 E 120th St, Los Angeles, CA 90059 USAAD  - Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USAAD  - Gandhi Med Coll Bhopal, Dept Community Med, Bhopal, IndiaAD  - Jazan Univ, Jizan, Saudi ArabiaAD  - Univ Hosp Dijon, Dept Neurol, Dijon, FranceAD  - Univ Burgundy, Fac Hlth Sci, Dijon Stroke Registry, Dijon, FranceAD  - Mekelle Univ, Sch Publ Hlth, Mekelle, EthiopiaAD  - Mekelle Univ, Coll Hlth Sci, Inst Biomed Sci, Dept Anat & Embryol, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Med, Biomed Sci Div, Mekelle, EthiopiaAD  - Mekelle Univ, Nutr & Dietet, Mekelle, EthiopiaAD  - Mekelle Univ, Clin Pharm Unit, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Pharm, Mekelle, EthiopiaAD  - Mekelle Univ, Mekelle, EthiopiaAD  - Dr Tewelde Legesse Hlth Sci Coll, Mekelle, EthiopiaAD  - Univ Sao Paulo, Dept Internal Med, Sao Paulo, BrazilAD  - Univ Sao Paulo, Ctr Clin & Epidemiol Res, Sao Paulo, BrazilAD  - Univ Sao Paulo, Dept Psychiat, Sao Paulo, BrazilAD  - Kings Coll London, Dent Inst, London, EnglandAD  - Kings Coll London, Fac Life Sci & Med, London, EnglandAD  - Emory Univ, Hubert Dept Global Hlth, Atlanta, GA 30322 USAAD  - Univ S Florida, Dept Global Hlth, Tampa, FL USAAD  - Univ Newcastle, Sch Publ Hlth & Med, Newcastle, NSW, AustraliaAD  - Iran Univ Med Sci, Air Pollut Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Community Med Dept, Tehran, IranAD  - Iran Univ Med Sci, Prevent Med & Publ Hlth Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Tehran, IranAD  - George Inst Global Hlth, Res, New Delhi, IndiaAD  - George Inst Global Hlth, New Delhi, IndiaAD  - Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, PakistanAD  - Babol Univ Med Sci, Social Determinants Hlth Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Hlth Res Inst, Babol Sar, IranAD  - Babol Univ Med Sci, Dept Clin Biochem, Babol Sar, IranAD  - Babol Univ Med Sci, Infect Dis & Trop Med Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Student Res Comm, Babol Sar, IranAD  - Babol Univ Med Sci, Babol Sar, IranAD  - Woldia Univ, Woldia, EthiopiaAD  - Univ Bologna, Dept Med & Surg Sci, Bologna, ItalyAD  - Univ Bologna, Bologna, ItalyAD  - GBS CIDP Fdn Int, Conshohocken, PA USAAD  - UCL, UCL Ctr Global Hlth Econ, London, EnglandAD  - UCL, Dept Hlth Informat, London, EnglandAD  - UCL, Dept Epidemiol & Publ Hlth, London, EnglandAD  - United Nations Programme HIV AIDS UNAIDS, Fast Track Implementat Dept, Gaborone, BotswanaAD  - St Pauls Hosp, Publ Hlth, Millennium Med Coll, Addis Ababa, EthiopiaAD  - Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, NorwayAD  - Canc Registry Norway, Dept Res, Oslo, NorwayAD  - Canc Registry Norway, Oslo, NorwayAD  - Natl Inst Psychiat Ramon de la Fuente Muniz, Dept Epidemiol & Psychosocial Res, Mexico City, DF, MexicoAD  - IRCCS, Dept Oncol, Mario Negri Inst Pharmacol Res, Milan, ItalyAD  - IRCCS, Dept Environm Hlth Sci, Mario Negri Inst Pharmacol Res, Milan, ItalyAD  - Univ New South Wales, Transport & Rd Safety TARS Res, Sydney, NSW, AustraliaAD  - Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Med, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sch Publ Hlth & Community Med, Sydney, NSW, AustraliaAD  - Univ Genoa, Genoa, ItalyAD  - German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, GermanyAD  - Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, CanadaAD  - Univ British Columbia, Vancouver, BC, CanadaAD  - Al Shifa Trust Eye Hosp, Al Shifa Sch Publ Hlth, Rawalpindi, PakistanAD  - Univ Valley Cuernavaca, Sch Med, Cuernavaca, Morelos, MexicoAD  - Inst Canc Res Prevent & Clin Network ISPRO, Florence, ItalyAD  - Univ Porto, Appl Mol Biosci Unit, Porto, PortugalAD  - Univ Porto, Inst Biomed Engn INEB, Porto, PortugalAD  - Univ Porto, Dept Chem, Porto, PortugalAD  - Univ Porto, Inst Res & Innovat Hlth I3s, Porto, PortugalAD  - Natl Inst Hlth, Colombian Natl Hlth Observ, Bogota, ColombiaAD  - Univ Nacl Colombia, Epidemiol & Publ Hlth Evaluat Grp, Bogota, ColombiaAD  - Costa Rican Dept Social Secur, San Jose, Costa RicaAD  - Univ Costa Rica, Sch Dent, San Pedro, Costa RicaAD  - Inst Hlth Carlos III, Natl Sch Publ Hlth, Dept Hlth Planning & Econ, Madrid, SpainAD  - Natl Taiwan Univ, Coll Med, Taipei, TaiwanAD  - Int Inst Populat Sci, Dept Dev Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Dept Publ Hlth & Mortal Studies, Bombay, Maharashtra, IndiaAD  - Int Inst Populat Sci, Bombay, Maharashtra, IndiaAD  - Tata Mem Hosp, Bombay, Maharashtra, IndiaAD  - Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, EnglandAD  - Christian Med Coll & Hosp CMC, Dept Pulm Med, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp CMC, Dept Community Hlth, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp CMC, Dept Endocrinol, Vellore, Tamil Nadu, IndiaAD  - Hlth Data Res UK, London, EnglandAD  - Univ Adelaide, Sch Med, Adelaide, SA, AustraliaAD  - Univ Adelaide, Adelaide, SA, AustraliaAD  - Univ Fed Minas Gerais, Dept Nutr, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Dept Maternal & Child Nursing & Publ Hlth, Belo Horizonte, MG, BrazilAD  - Univ Fed Minas Gerais, Sch Nursing, Belo Horizonte, MG, BrazilAD  - Univ Milano Bicocca, Dept Med & Surg, Monza, ItalyAD  - Univ Fed Rio Grande do Sul, Postgrad Program Epidemiol, Porto Alegre, RS, BrazilAD  - Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USAAD  - Guys & St Thomas NHS Fdn Trust, Clin Toxicol Serv, London, EnglandAD  - Kazakh Natl Med Univ, Alma Ata, KazakhstanAD  - Monash Univ, Monash Ctr Hlth Res & Implementat, Melbourne, Vic, AustraliaAD  - Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, AustraliaAD  - Monash Univ, Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic, AustraliaAD  - Monash Hlth, Melbourne, Vic, AustraliaAD  - Heidelberg Univ, Inst Publ Hlth, Heidelberg, GermanyAD  - Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, GermanyAD  - Aksum Univ, Dept Clin Pharm, Aksum, EthiopiaAD  - Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USAAD  - Disha Fdn, Gurgaon, IndiaAD  - Indian Council Med Res, New Delhi, IndiaAD  - Univ Peradeniya, Dept Community Med, Peradeniya, Sri LankaAD  - Nepal Hlth Res Council, Hlth Res Sect, Kathmandu, NepalAD  - Univ Cape Coast, Dept Populat & Hlth, Cape Coast, GhanaAD  - Univ Tampere, Sch Hlth Sci, Tampere, FinlandAD  - RMIT Univ, Sch Hlth & Biomed Sci, Royal Melbourne Inst Technol, Bundoora, Vic, AustraliaAD  - United Nations World Food Programme, New Delhi, IndiaAD  - Univ Belgrade, Fac Med, Belgrade, SerbiaAD  - Mansoura Univ, Dept Clin Pathol, Mansoura, EgyptAD  - Russian Acad Sci, Lab Socioecon Issues Human Dev & Qual Life, Moscow, RussiaAD  - Minist Hlth FRIHOI, Dept Med Stat & Documentary, Fed Res Inst Hlth Org & Informat, Moscow, RussiaAD  - Minist Hlth FRIHOI, Fed Res Inst Hlth Org & Informat, Moscow, RussiaAD  - Queensland Ctr Mental Hlth Res, Policy & Epidemiol Grp, Brisbane, Qld, AustraliaAD  - Queensland Ctr Mental Hlth Res, Brisbane, Qld, AustraliaAD  - Univ Fed Sergipe, Dept Psychol, Sao Cristovao, BrazilAD  - Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New ZealandAD  - Univ Fed Sao Paulo, Sao Paulo, BrazilAD  - Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA USAAD  - Univ Memphis, Sch Publ Hlth, Memphis, TN 38152 USAAD  - Kaiser Permanente, Fontana, CA USAAD  - AT Still Univ, Dept Hlth Sci, Mesa, AZ USAAD  - AT Still Univ, Mesa, AZ USAAD  - Robert Koch Inst, Dept Epidemiol & Hlth Monitoring, Berlin, GermanyAD  - Bielefeld Univ, Dept Publ Hlth Med, Bielefeld, GermanyAD  - James Cook Univ, Coll Publ Hlth Med & Vet Sci, Townsville, Qld, AustraliaAD  - Sidi Mohamed Ben Abdellah Univ, Neurosurg Dept, Fes, MoroccoAD  - Wageningen Univ & Res, Div Human Nutr & Hlth, Wageningen, NetherlandsAD  - Univ Tsukuba, Dept Hlth Care Policy & Management, Tsukuba, Ibaraki, JapanAD  - Univ Warwick, Unit Acad Primary Care, Coventry, W Midlands, EnglandAD  - Univ Warwick, Div Hlth Sci, Coventry, W Midlands, EnglandAD  - Univ Hail, Dept Family & Community Med, Hail, Saudi ArabiaAD  - Univ Massachusetts, Coll Nursing & Hlth Sci, Boston, MA 02125 USAAD  - Univ Oklahoma, Dept Biostat & Epidemiol, Oklahoma City, OK USAAD  - Govt Federated States Micronesia, Dept Hlth & Social Affairs, Palikir, MicronesiaAD  - Imperial Coll London, Dept Primary Care & Publ Hlth, London, EnglandAD  - Imperial Coll London, WHO Collaborating Ctr Publ Hlth Educ & Training, London, EnglandAD  - Imperial Coll London, Sch Publ Hlth, London, EnglandAD  - Publ Hlth England, Hlth Improvement Directorate, London, EnglandAD  - Publ Hlth England, London, EnglandAD  - Univ Hosp Polyclin Vittorio Emanuele, Integrated Tumor Registry, Catania, ItalyAD  - West Virginia Bur Publ Hlth, Commissioner Publ Hlth, Charleston, WV USAAD  - West Virginia Univ, Dept Hlth Policy Management & Leadership, Morgantown, WV USAAD  - Rajasthan Univ Hlth Sci, Jaipur, Rajasthan, IndiaAD  - Eternal Heart Care Ctr & Res Inst, Dept Prevent Cardiol, Jaipur, Rajasthan, IndiaAD  - Univ Delhi, Dept Anthropol, Delhi, IndiaAD  - Publ Hlth Fdn India, Indian Inst Publ Hlth, Hyderabad, IndiaAD  - Johns Hopkins Univ, Dept Radiol, Baltimore, MD USAAD  - Arabian Gulf Univ, Dept Family & Community Med, Manama, BahrainAD  - Hamdan Bin Mohammed Smart Univ, Sch Hlth & Environm Studies, Dubai, U Arab EmiratesAD  - Sir Charles Gairdner Hosp, Neurol Dept, Perth, WA, AustraliaAD  - Minist Publ Hlth, Dept Vital & Hlth Stat, Beirut, LebanonAD  - Minist Publ Hlth, Dept Dis Epidem & Pandem Control, Lebanon, NH USAAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Cardiol Dept, Trivandrum, Kerala, IndiaAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Trivandrum, Kerala, IndiaAD  - Parc Sanit St Joan de Deu CIBERSAM, Res & Dev Unit, St Boi De Llobregat, SpainAD  - Univ Barcelona, Dept Med, Barcelona, SpainAD  - Univ Barcelona, Barcelona, SpainAD  - Mizan Tepi Univ, Publ Hlth Dept, Mizan Teferi, EthiopiaAD  - Mizan Tepi Univ, Pharm Dept, Mizan Teferi, EthiopiaAD  - Mizan Tepi Univ, Mizan Teferi, EthiopiaAD  - Univ Hosp Antwerp, Unit Epidemiol & Social Med, Antwerp, BelgiumAD  - Karolinska Univ Hosp, Stockholm, SwedenAD  - Natl Commission Against Addict, Secretary Hlth, Subdirectorate Regulat Guidelines & Tech Procedur, Mexico City, DF, MexicoAD  - Bucharest Univ Econ Studies, Dept Stat & Econometr, Bucharest, RomaniaAD  - Bucharest Univ Econ Studies, Bucharest, RomaniaAD  - Hawassa Univ, Dept Reprod Hlth, Hawassa, EthiopiaAD  - Manipal Univ, Transdisciplinary Ctr Qualitat Methods, Manipal, Karnataka, IndiaAD  - Yokohama City Univ, Dept Pulmonol, Yokohama, Kanagawa, JapanAD  - NHGRI, NIH, Bethesda, MD 20892 USAAD  - Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USAAD  - Emergency Hosp Bucharest, Dept Internal Med, Bucharest, RomaniaAD  - Cent South Univ, Xiangya Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R ChinaAD  - Cambridge Hlth Alliance, Dept Psychiat, Cambridge, MA USAAD  - Birzeit Univ, Inst Community & Publ Hlth, Birzeit, PalestineAD  - Qatar Univ, Doha, QatarAD  - Bashkir State Med Univ, Infect Dis Dept, Ufa, RussiaAD  - Univ Liberia, Dept Publ Hlth & Community Med, Monrovia, LiberiaAD  - Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Tehran, IranAD  - Deakin Univ, Inst Phys Act & Nutr, Waurn Ponds, Vic, AustraliaAD  - Deakin Univ, Natl Ctr Farmer Hlth, Sch Med, Waurn Ponds, Vic, AustraliaAD  - Univ West Indies, Dept Community Hlth & Psychiat, Jamaica, NY USAAD  - Univ Kragujevac, Fac Med Sci, Kragujevac, SerbiaAD  - Univ Colombo, Fac Grad Studies, Colombo, Sri LankaAD  - Univ Colombo, Postgrad Inst Med, Colombo, Sri LankaAD  - Banaras Hindu Univ, Inst Med Sci, Dept Community Med, Varanasi, Uttar Pradesh, IndiaAD  - Capital Med Univ, Beijing Inst Ophthalmol, Beijing, Peoples R ChinaAD  - Czestochowa Tech Univ, Inst Hlth & Nutr Sci, Czestochowa, PolandAD  - Univ Opole, Fac Med & Hlth Sci, Opole, PolandAD  - Univ Coll Cork, Sch Publ Hlth, Cork, IrelandAD  - London Sch Econ & Polit Sci, Dept Hlth Policy, Personal Social Serv Res Unit, London, EnglandAD  - ACS Med Coll & Hosp, New Delhi, IndiaAD  - Univ Glasgow, MRC CSO Social & Publ Hlth Sci Unit, Glasgow, Lanark, ScotlandAD  - Salale Univ, Midwifery Program, Fiche, EthiopiaAD  - Univ Nairobi, Odel Campus, Nairobi, KenyaAD  - Med Res Council South Africa, Noncommun Dis Res Unit, Cape Town, South AfricaAD  - Med Res Council South Africa, Alcohol Tobacco & Other Drug Use Res Unit, Cape Town, South AfricaAD  - Univ Cape Town, Dept Med, Cape Town, South AfricaAD  - Univ Cape Town, Groote Schuur Hosp, Cape Town, South AfricaAD  - Univ Cape Town, Dept Psychiat & Mental Hlth, Cape Town, South AfricaAD  - Jordan Univ Sci & Technol, Dept Publ Hlth & Community Med, Alramtha, JordanAD  - Ahvaz Jundishapur Univ Med Sci, Dept Publ Hlth, Ahvaz, IranAD  - Ahvaz Jundishapur Univ Med Sci, Thalassemia & Hemoglobinopathy Res Ctr, Hlth Res Inst, Ahvaz, IranAD  - Jatiya Kabi Kazi Nazrul Islam Univ, Dept Populat Sci, Mymensingh, BangladeshAD  - Seoul Natl Univ, Inst Hlth Policy & Management, SNU Med Res Ctr, Seoul, South KoreaAD  - Seoul Natl Univ, Dept Hlth Policy & Management, Seoul, South KoreaAD  - Cairo Univ, Dept Med Parasitol, Cairo, EgyptAD  - Ball State Univ, Dept Nutr & Hlth Sci, Muncie, IN 47306 USAAD  - Korea Hlth Ind Dev Inst, Cheongju, South KoreaAD  - Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USAAD  - Xiamen Univ Malaysia, Sch Med, Sepang, MalaysiaAD  - Simmons Coll, Dept Nutr, Boston, MA 02115 USAAD  - Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, NorwayAD  - Univ Oslo, Norwegian Ctr Addict Res SERAF, Oslo, NorwayAD  - Tulane Univ, Dept Global Community Hlth & Behav Sci, New Orleans, LA 70118 USAAD  - Univ Helsinki, Dept Publ Hlth, Helsinki, FinlandAD  - Univ Helsinki, Helsinki, FinlandAD  - Erasmus Univ, Dept Publ Hlth, Med Ctr Rotterdam, Rotterdam, NetherlandsAD  - Erasmus MC, Rotterdam, NetherlandsAD  - Int Inst Hlth Management Res, New Delhi, IndiaAD  - Sher Ashmir Inst Med Sci, Dept Internal & Pulm Med, Srinagar, Jammu & Kashmir, IndiaAD  - Panjab Univ, Dept Anthropol, Chandigarh, IndiaAD  - Univ Montreal, Dept Social & Prevent Med, Montreal, PQ, CanadaAD  - Univ Montreal, Dept Demog, Montreal, PQ, CanadaAD  - Yuksek Ihtisas Univ, Fac Med, Dept Publ Hlth, Ankara, TurkeyAD  - Hacettepe Univ, Fac Med, Dept Publ Hlth, Ankara, TurkeyAD  - Arkansas State Univ, State Univ, AR 72467 USAAD  - Univ Melbourne, Dept Paediat, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Australian Inst Muscular Skeletal Sci, Dept Med & Neurol, Melbourne, Vic, AustraliaAD  - Rajiv Gandhi Univ Hlth Sci, Dept Community Med, Bangalore, Karnataka, IndiaAD  - Rajiv Gandhi Univ Hlth Sci, Bangalore, Karnataka, IndiaAD  - Finnish Inst Occupat Hlth, Populat & Work Abil Program, Helsinki, FinlandAD  - Finnish Inst Occupat Hlth, Helsinki, FinlandAD  - Natl Inst Hlth, Inst Hlth Policy & Dev Studies, Manila, PhilippinesAD  - Acad Med Sci, Dept Community & Family Med, Baghdad, IraqAD  - NCI, Div Canc Epidemiol & Genet, Rockville, MD USAAD  - Municipal Hlth Dept Belo Horizonte, Belo Horizonte City Hall, Belo Horizonte, MG, BrazilAD  - Uppsala Univ, Dept Med Sci, Uppsala, SwedenAD  - Akad Sjukhuset, Dept Clin Chem & Pharmacol, Uppsala, SwedenAD  - Maragheh Univ Med Sci, Managerial Epidemiol Res Ctr, Sch Nursing & Midwifery, Dept Publ Hlth, Maragheh, IranAD  - Maragheh Univ Med Sci, Sch Publ Hlth, Dept Publ Hlth, Maragheh, IranAD  - Nova Southeastern Univ, Coll Optometry, Ft Lauderdale, FL 33314 USAAD  - Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ Sydney, Asbestos Dis Res Inst, Sydney, NSW, AustraliaAD  - Univ Sydney, Sch Publ Hlth, Sydney, NSW, AustraliaAD  - Sodertorn Univ, Scohost, Huddinge, SwedenAD  - Natl Inst Hlth Dev, Dept Epidemiol & Biostat, Tallinn, EstoniaAD  - Tuscany Ctr, CERIMP, Local Hlth Unit, Florence, ItalyAD  - Univ Florence, Dept Hlth Sci, Florence, ItalyAD  - Shenzen Inst Cardiovasc Dis, Dept Clin & Epidemiol Res, Shenzhen, Peoples R ChinaAD  - Univ Malaya, Dept Med, Kuala Lumpur, MalaysiaAD  - Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R ChinaAD  - Univ Haifa, Sch Publ Hlth, Haifa, IsraelAD  - Ctr Chron Dis Control, Beijing, Peoples R ChinaAD  - Natl Inst Energy Efficiency & Renewable Energies, Quito, EcuadorAD  - Damietta Univ, Dumyat, EgyptAD  - Aswan Fac Med, Opthamol Dept, Aswan, EgyptAD  - Trnava Univ, Dept Publ Hlth, Trnava, SlovakiaAD  - Shiraz Univ Med Sci, Noncommun Dis Res Ctr, Shiraz, IranAD  - Univ Zambia, Dept Populat Studies, Lusaka, ZambiaAD  - Doctor Peset Univ Hosp, Psychiat Dept, Valencia, SpainAD  - Univ Valencia, Dept Med, Valencia, SpainAD  - Chalmers Univ Technol, Dept Biol & Biol Engn, Gothenburg, SwedenAD  - London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, EnglandAD  - London Sch Hyg & Trop Med, Dept Noncommun Dis Epidemiol, London, EnglandAD  - Sevenhills Hosp, Dept Internal Med, Bombay, Maharashtra, IndiaAD  - Martin Luther Univ Halle Wittenberg, Inst Agr & Nutr Sci, Halle, GermanyAD  - Martin Luther Univ Halle Wittenberg, Inst Epidemiol Biostat & Informat, Halle, GermanyAD  - Competence Cluster Nutr & Cardiovasc Hlth NUTRICA, Innovat Off Nutricard, Halle, GermanyAD  - Debre Tabor Univ, Coll Hlth Sci, Debre Tabor, EthiopiaAD  - Univ West Florida, Dept Publ Hlth, Pensacola, FL USAAD  - United Nations Populat Fund UNFPA, Peru Country Off UNFPA, Lima, PeruAD  - NHLBI, Ctr Translat Res & Implementat Sci, Bldg 10, Bethesda, MD 20892 USAAD  - Helsinki Univ Hosp, Comprehens Canc Ctr, Breast Surg Unit, Helsinki, FinlandAD  - Ethiopian Acad Med Sci, Mekelle, EthiopiaAD  - Pomeranian Med Univ, Dept Hypertens & Internal Med, Szczecin, PolandAD  - Pomeranian Med Univ, Zdroje Hosp, Szczecin, PolandAD  - Pacific Inst Res & Evaluat, Calverton, MD USAAD  - Curtin Univ, Sch Publ Hlth, Perth, WA, AustraliaAD  - Amrita Inst Med Sci, Dept Publ Hlth, Kochi, Kerala, IndiaAD  - Natl Inst Stat Romania, Presidents Off, Bucharest, RomaniaAD  - Kyrgyz State Med Acad, Bishkek, KyrgyzstanAD  - Natl Ctr Cardiol & Internal Dis, Dept Atherosclerosis & Coronary Heart Dis, Bishkek, KyrgyzstanAD  - Frankfurt Univ Appl Sci, Inst Addict Res ISFF, Dept Hlth & Social Work, Frankfurt, GermanyAD  - Salahaddin Univ, Dept Biol, Erbil, IraqAD  - Isfahan Univ Med Sci, Isfahan Cardiovasc Res Inst, Nutr & Cohort Studies Dept, Esfahan, IranAD  - Isfahan Univ Med Sci, Cardiovasc Res Inst, Esfahan, IranAD  - Ahmadu Bello Univ, Hlth Syst & Policy Res Unit, Zaria, NigeriaAD  - Ahmadu Bello Univ, Dept Community Med, Zaria, NigeriaAD  - IRCCS Burlo Garofolo, Clin Epidemiol & Publ Hlth Res Unit, Inst Maternal & Child Hlth, Trieste, ItalyAD  - Univ Lancaster, Lancaster, EnglandAD  - Queensland Univ Technol, Sci & Engn Fac, Int Lab Air Qual & Hlth, Brisbane, Qld, AustraliaAD  - St Pauls Hosp, Millennium Med Coll, Addis Ababa, EthiopiaAD  - Inst Postgrad Med Educ & Res, Dept Endocrinol & Metab, Kolkata, IndiaAD  - Univ Sains Malaysia, Sch Med Sci, Kubang Kerian, MalaysiaAD  - Int Ctr Diarrhoeal Dis Res, Initiat Non Commun Dis, Dhaka, BangladeshAD  - Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USAAD  - Kermanshah Univ Med Sci, Epidemiol Dept, Kermanshah, IranAD  - Kermanshah Univ Med Sci, Res Ctr Environm Determinants Hlth, Kermanshah, IranAD  - Suraj Eye Inst, Nagpur, Maharashtra, IndiaAD  - Univ Yaounde, Fac Med & Biomed Sci, Dept Publ Heath, Yaounde, CameroonAD  - Univ Sidi Mohammed Ben Abdellah, Dept Epidemiol & Publ Hlth, Fes, MoroccoAD  - Mohammed Vi Univ Hlth Sci, Int Sch Publ Hlth, Casablanca, MoroccoAD  - Innlandet Hosp Trust, Norwegian Natl Advisory Unit Concurrent Subst Abu, Brumunddal, NorwayAD  - Univ Embu, Dept Biol Sci, Embu, KenyaAD  - Duy Tan Univ, Inst Global Hlth Innovat, Hanoi, VietnamAD  - Semarang State Univ, Publ Hlth Dept, Kota Semarang, IndonesiaAD  - Taipei Med Univ, Grad Inst Biomed Informat, Taipei, TaiwanAD  - Hlth Policy Consult, Res Unit, Accra, GhanaAD  - Western Sydney Univ, Sch Social Sci, Penrith, NSW, AustraliaAD  - Western Sydney Univ, Psychol Dept, Penrith, NSW, AustraliaAD  - Western Sydney Univ, Penrith, NSW, AustraliaAD  - Kyung Hee Univ, Sch Med, Dept Prevent Med, Seoul, South KoreaAD  - HSRC, HIV AIDS STIs & TB HAST Programme, Durban, South AfricaAD  - Univ Namibia, Fac Hlth Sci, Sch Publ Hlth, Osakhati, NamibiaAD  - Univ Lagos, Dept Psychiat, Lagos, NigeriaAD  - Autonomous Univ Chile, Providencia, ChileAD  - Ctr Hlth Start Initiat, Ikoyi, NigeriaAD  - San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USAAD  - Univ Ottawa, Sch Psychol, Ottawa, ON, CanadaAD  - Univ Maryland, Ctr Vaccine Dev, Baltimore, MD 21201 USAAD  - St Lukes Int Univ, Global Hlth Nursing, Chuo Ku, Tokyo, JapanAD  - Univ Ibadan, Coll Med, Ibadan, NigeriaAD  - North West Univ, Agr Econ Grp, Mafikeng, South AfricaAD  - North West Univ, HART, Mafikeng, South AfricaAD  - Jagadguru Sri Shivarathreeswara Univ, Dept TB & Resp Med, Mysore, Karnataka, IndiaAD  - Ctr Hlth Outcomes & Evaluat, Bucharest, RomaniaAD  - Kosin Univ, Dept Med Humanities & Social Med, Busan, South KoreaAD  - Murdoch Childrens Res Inst, Populat Hlth Grp, Melbourne, Vic, AustraliaAD  - Save Children, Hlth Nutr & HIV AIDS Program, Kathmandu, NepalAD  - Ludwigs Maximillians Univ, Ctr Int Hlth, Munich, GermanyAD  - Univ Gothenburg, Inst Med, Gothenburg, SwedenAD  - Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South AfricaAD  - Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Shanghai, Peoples R ChinaAD  - Durban Univ Technol, Basic Med Sci Dept, Durban, South AfricaAD  - Univ Groningen, Dept Econ & Business, Groningen, NetherlandsAD  - Univ Groningen, Univ Med Ctr Groningen, Groningen, NetherlandsAD  - Alborz Univ Med Sci, Noncommun Dis Res Ctr, Karaj, IranAD  - Medichem, St Joan Despi, SpainAD  - Contech Sch Publ Hlth, Lahore, PakistanAD  - BRAC, Res & Evaluat Div, Dhaka, BangladeshAD  - La Trobe Univ, Austin Clin Sch Nursing, Heidelberg, Vic, AustraliaAD  - La Trobe Univ, Ctr Alcohol Policy Res, Heidelberg, Vic, AustraliaAD  - La Trobe Univ, Dept Psychol & Counselling, Heidelberg, Vic, AustraliaAD  - Soc Hlth & Demog Surveillance, Suri, IndiaAD  - Univ Gottingen, Dept Econ, Gottingen, GermanyAD  - Med Univ Innsbruck, Innsbruck, AustriaAD  - Nizams Inst Med Sci, Dept Nephrol, Hyderabad, IndiaAD  - Univ Hlth Sci, Publ Hlth Dept, Lahore, PakistanAD  - Yonsei Univ, Inst Poverty Alleviat & Int Dev, Kathmandu, NepalAD  - Univ Coll London Hosp, London, EnglandAD  - Loma Linda Univ, Med Ctr, Dept Prevent Med & Occupat Med, Loma Linda, CA USAAD  - Univ Uberlandia, Dept Clin Res, Uberlandia, MG, BrazilAD  - Stockholm Univ, Ctr Social Res Alcohol & Drugs, Dept Publ Hlth Sci, Stockholm, SwedenAD  - Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, IranAD  - AIIMS, Dept Cardiol, New Delhi, IndiaAD  - Indian Council Med Res, Natl Inst Res Environm Hlth, Bhopal, IndiaAD  - Univ Sharjah, Coll Med, Sharjah, U Arab EmiratesAD  - Punjab Univ, Coll Pharm, Chandigarh, IndiaAD  - Stanford Univ, Ctr Hlth Policy, Stanford, CA 94305 USAAD  - Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USAAD  - Chest Res Fdn, Clin Res Div, Pune, Maharashtra, IndiaAD  - Marshall Univ, Dept Surg, Huntington, WV USAAD  - Case Western Reserve Univ, Dept Nutr & Prevent Med, Cleveland, OH 44106 USAAD  - Nephrol Grp, LIS Fdn Jimenez Diaz, Madrid, SpainAD  - Univ Belgrade, Fac Med, Ctr Sch Publ Hlth & Hlth Management, Inst Social Med, Belgrade, SerbiaAD  - Int Ctr Diarrhoeal Dis Res, Hlth Econ & Financing Res Grp, Dhaka, BangladeshAD  - Univ Appl & Environm Sci, Fac Med, Dept Hlth & Soc, Bogota, ColombiaAD  - Univ Kwazulu Natal, Dept Publ Hlth Med, Howard Coll Campus, Durban, South AfricaAD  - Utkal Univ, UGC Ctr Adv Study Psychol, Bhubaneswar, IndiaAD  - Udyam Global Assoc Sustainable Dev, Bhubaneswar, IndiaAD  - Univ North Carolina Charlotte, Dept Publ Hlth Sci, Charlotte, NC USAAD  - Bayer, Market Access, Istanbul, TurkeyAD  - Univ Zurich, Swiss Res Inst Publ Hlth & Addict, Zurich, SwitzerlandAD  - Univ Fed Santa Catarina, Hlth Sci Dept, Florianopolis, SC, BrazilAD  - Char Univ Med Ctr Berlin, Dept Operat & Prevent Dent, Berlin, GermanyAD  - Islamic Azad Univ, Dept Lab Sci, Sari, IranAD  - Islamic Azad Univ, Dept Basic Sci, Sari, IranAD  - Fudan Univ, Dept Pulm Med, Shanghai, Peoples R ChinaAD  - Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, ScotlandAD  - Nationwide Children sHosp, Res Inst, Columbus, OH USAAD  - Natl Inst Infect Dis, Tokyo, JapanAD  - Washington State Univ, Pullman, WA 99164 USAAD  - Symbiosis Int Univ, Symbiosis Inst Hlth Sci, Pune, Maharashtra, IndiaAD  - Reykjavik Univ, Dept Psychol, Reykjavik, IcelandAD  - Columbia Univ, Dept Hlth & Behav Studies, New York, NY USAAD  - Portuguese Inst Sport & Youth, Lisbon, PortugalAD  - Brasilia Univ, Brasilia, DF, BrazilAD  - Sch Prevent Oncol, Patna, Bihar, IndiaAD  - Healis Sekhsaria Inst Publ Hlth, Dept Epidemiol, Bombay, Maharashtra, IndiaAD  - Univ Hosp Princess IISP, Pneumol Serv, Res Inst, Madrid, SpainAD  - Autonomous Univ Madrid, Pneumol Serv, Madrid, SpainAD  - Int Med Univ, Div Community Med, Kuala Lumpur, MalaysiaAD  - Univ Hosp Munich, Inst & Outpatient Clin Occupat Social & Environm, Munich, GermanyAD  - Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth, Hlth Serv Res & Hlth Technol Assessment, Hall In Tirol, AustriaAD  - Univ Calif Irvine, Dept Criminol Law & Soc, Irvine, CA USAAD  - Carlos III Hlth Inst, CIBERSAM, Madrid, SpainAD  - Osaka Int Canc Inst, Canc Control Ctr, Osaka, JapanAD  - New York Med Coll, Dept Psychiat & Behav Sci, Valhalla, NY 10595 USAAD  - Jagiellonian Univ Med Coll, Inst Publ Hlth, Krakow, PolandAD  - Aristotle Univ Thessaloniki, Med Sch, Dept Ophthalmol, Thessaloniki, GreeceAD  - Hanoi Univ, Dept Hlth Econ, Hanoi, VietnamAD  - Univ Copenhagen, Dept Neurol, Copenhagen, DenmarkAD  - Univ Heart Ctr Hamburg, Dept Vasc Med, Hamburg, GermanyAD  - Fed Teaching Hosp, Dept Internal Med, Abakaliki, NigeriaAD  - Gomal Univ, Gomal Ctr Biochem & Biotechnol, Dera Ismail Khan, PakistanAD  - Mufti Mehmood Mem Teaching Hosp, Programmat Management Drug Resistant TB Unit, TB Culture Lab, Dera Ismail Khan, PakistanAD  - Argentine Soc Med, Buenos Aires, DF, ArgentinaAD  - Hosp Velez Sarsfield, Intens Care Unit, Buenos Aires, DF, ArgentinaAD  - UKK Inst, Tampere, FinlandAD  - Raffles Hosp, Raffles Neurosci Ctr, Singapore, SingaporeAD  - Sechenov First Moscow State Med Univ, Dept Informat & Internet Technol, Moscow, RussiaAD  - Natl Res Univ Higher Sch Econ, Dept Hlth Care Adm & Econ, Moscow, RussiaAD  - Norwegian Inst Publ Hlth, Ctr Dis Burden, Bergen, NorwayAD  - Debre Markos Univ, Dept Nursing, Debremarkos, EthiopiaAD  - Fdn Univ, Fdn Univ Med Coll, Rawalpindi, PakistanAD  - Fed Inst Populat Res, Demog Change & Ageing Res Area, Wiesbaden, GermanyAD  - Fed Inst Populat Res, Competence Ctr Mortal Follow Up, German Natl Cohort, Wiesbaden, GermanyAD  - NHS Scotland, Informat Serv Div, Edinburgh, Midlothian, ScotlandAD  - Univ Strathclyde, Glasgow, Lanark, ScotlandAD  - Nanjing Univ, Sch Med, Nanjing, Jiangsu, Peoples R ChinaAD  - Univ Mississippi, Med Ctr, Dept Prevent Med, Jackson, MS 39216 USAAD  - Chinese Ctr Dis Control & Prevent, Div Injury Prevent & Mental Hlth Provement, Beijing, Peoples R ChinaAD  - Univ Hong Kong, Ctr Suicide Res & Prevent, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ South Australia, Adelaide, SA, AustraliaAD  - Kyoto Univ, Sch Publ Hlth, Dept Biostat, Kyoto, JapanAD  - Korea Univ, Dept Prevent Med, Seoul, South KoreaAD  - Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USAAD  - Univ Kinshasa, Sch Publ Hlth, Kinshasa, DEM REP CONGOAD  - Jackson State Univ, Dept Hlth Pol & Management, Jackson, MS USAAD  - Tsinghua Univ, Beijing, Peoples R ChinaAD  - Mother Hosp, Dept Cardiol, Trichur, IndiaAD  - Univ Texas Houston, Houston, TX USAC3  - University of WashingtonC3  - University of Washington SeattleC3  - Institute for Health Metrics & EvaluationC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard UniversityC3  - Seattle GeneticsC3  - Jimma UniversityC3  - Jimma UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Sapienza University RomeC3  - Ministry of Health - Saudi ArabiaC3  - Ministry of Health - Saudi ArabiaC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - CHU LimogesC3  - Universite de LimogesC3  - Stellenbosch UniversityC3  - Stellenbosch UniversityC3  - South African Medical Research CouncilC3  - South African Medical Research CouncilC3  - South African Medical Research CouncilC3  - University of Southern DenmarkC3  - University of Southern DenmarkC3  - University of Southern DenmarkC3  - Universidad de ExtremaduraC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - McMaster UniversityC3  - Yerevan State UniversityC3  - National Academy of Sciences of ArmeniaC3  - Public Health Foundation of IndiaC3  - Public Health Foundation of IndiaC3  - University of KentuckyC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - University of OxfordC3  - Washington University (WUSTL)C3  - Mayo ClinicC3  - University of Western AustraliaC3  - University of Western AustraliaC3  - Australian National UniversityC3  - Australian National UniversityC3  - New York UniversityC3  - New York University Abu DhabiC3  - Qazvin University of Medical Sciences (QUMS)C3  - Kuwait UniversityC3  - Luxembourg Institute of HealthC3  - Universidad de CartagenaC3  - Universidad de la CostaC3  - University of South AustraliaC3  - South Australian Health & Medical Research Institute (SAHMRI)C3  - Bahir Dar UniversityC3  - Bahir Dar UniversityC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - American University of BeirutC3  - American University of BeirutC3  - Kwame Nkrumah University Science & TechnologyC3  - National University of SingaporeC3  - National University of SingaporeC3  - Carol Davila University of Medicine & PharmacyC3  - Carol Davila University of Medicine & PharmacyC3  - University of SheffieldC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - Birmingham City UniversityC3  - Dalarna UniversityC3  - University of ManitobaC3  - Mashhad University of Medical SciencesC3  - University of LeicesterC3  - Instituto Nacional de Salud PublicaC3  - Instituto Nacional de Salud PublicaC3  - McGill UniversityC3  - Dilla UniversityC3  - University of TokyoC3  - University of TokyoC3  - University of TokyoC3  - University of South AfricaC3  - Burnet InstituteC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Public Health Agency of CanadaC3  - Public Health Agency of CanadaC3  - Public Health Agency of CanadaC3  - Medical University LodzC3  - University of AucklandC3  - Pontificia Universidad JaverianaC3  - Charles R. Drew University of Medicine & ScienceC3  - University of California SystemC3  - University of California Los AngelesC3  - Jazan UniversityC3  - CHU Dijon BourgogneC3  - Universite de BourgogneC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - Emory UniversityC3  - State University System of FloridaC3  - University of South FloridaC3  - University of NewcastleC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Aga Khan UniversityC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - University of BolognaC3  - University of BolognaC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of BergenC3  - University of OsloC3  - University of OsloC3  - Instituto Nacional de Psiquiatria Ramon de la Fuente MunizC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - University of GenoaC3  - Helmholtz AssociationC3  - German Cancer Research Center (DKFZ)C3  - University of British ColumbiaC3  - University of British ColumbiaC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do PortoC3  - Universidad Nacional de ColombiaC3  - Universidad Costa RicaC3  - National Taiwan UniversityC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - International Institute for Population SciencesC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalC3  - University of CambridgeC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - University of AdelaideC3  - University of AdelaideC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - Universidade Federal de Minas GeraisC3  - University of Milano-BicoccaC3  - Universidade Federal do Rio Grande do SulC3  - University of California SystemC3  - University of California San DiegoC3  - Guy's & St Thomas' NHS Foundation TrustC3  - Asfendiyarov Kazakh National Medical UniversityC3  - Monash UniversityC3  - Monash UniversityC3  - Monash UniversityC3  - Monash HealthC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Icahn School of Medicine at Mount SinaiC3  - Indian Council of Medical Research (ICMR)C3  - University of PeradeniyaC3  - University of Cape CoastC3  - Tampere UniversityC3  - Royal Melbourne Institute of Technology (RMIT)C3  - University of BelgradeC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Russian Academy of SciencesC3  - Queensland Centre for Mental Health ResearchC3  - Queensland Centre for Mental Health ResearchC3  - Universidade Federal de SergipeC3  - Auckland University of TechnologyC3  - Universidade Federal de Sao Paulo (UNIFESP)C3  - Brandeis UniversityC3  - University of MemphisC3  - Kaiser PermanenteC3  - A.T. Still University of Health SciencesC3  - A.T. Still University of Health SciencesC3  - Robert Koch InstituteC3  - University of BielefeldC3  - James Cook UniversityC3  - Sidi Mohamed Ben Abdellah University of FezC3  - Wageningen University & ResearchC3  - University of TsukubaC3  - University of WarwickC3  - University of WarwickC3  - University Ha'ilC3  - University of Massachusetts SystemC3  - University of Massachusetts BostonC3  - University of Oklahoma SystemC3  - University of Oklahoma Health Sciences CenterC3  - Imperial College LondonC3  - Imperial College LondonC3  - Imperial College LondonC3  - Public Health EnglandC3  - Public Health EnglandC3  - Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele Presidio FerraottoC3  - West Virginia UniversityC3  - Eternal Heart Care Centre & Research InstituteC3  - University of DelhiC3  - Public Health Foundation of IndiaC3  - Johns Hopkins UniversityC3  - Arabian Gulf UniversityC3  - Sir Charles Gairdner HospitalC3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERSAMC3  - University of BarcelonaC3  - University of BarcelonaC3  - University of AntwerpC3  - Karolinska InstitutetC3  - Karolinska University HospitalC3  - Bucharest University of Economic StudiesC3  - Bucharest University of Economic StudiesC3  - Hawassa UniversityC3  - Manipal Academy of Higher Education (MAHE)C3  - Yokohama City UniversityC3  - National Institutes of Health (NIH) - USAC3  - NIH National Human Genome Research Institute (NHGRI)C3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Yeshiva UniversityC3  - Central South UniversityC3  - Harvard UniversityC3  - Cambridge Health AllianceC3  - Birzeit UniversityC3  - Qatar UniversityC3  - Bashkir State Medical UniversityC3  - Shahid Beheshti University Medical SciencesC3  - Deakin UniversityC3  - Deakin UniversityC3  - University of KragujevacC3  - University of ColomboC3  - University of ColomboC3  - Banaras Hindu University (BHU)C3  - Capital Medical UniversityC3  - Technical University CzestochowaC3  - University of OpoleC3  - University College CorkC3  - University of LondonC3  - London School Economics & Political ScienceC3  - MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNITC3  - University of GlasgowC3  - University of NairobiC3  - University of Cape TownC3  - University of Cape TownC3  - University of Cape TownC3  - Jordan University of Science & TechnologyC3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Seoul National University (SNU)C3  - Seoul National University (SNU)C3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Ball State UniversityC3  - Northeastern UniversityC3  - Xiamen University Malaysia CampusC3  - Simmons UniversityC3  - University of OsloC3  - University of OsloC3  - Tulane UniversityC3  - University of HelsinkiC3  - University of HelsinkiC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - International Institute of Health Management Research DelhiC3  - Sher-i-Kashmir Institute of Medical SciencesC3  - Panjab UniversityC3  - Universite de MontrealC3  - Universite de MontrealC3  - Yuksek Ihtisas UniversityC3  - Hacettepe UniversityC3  - Arkansas State UniversityC3  - University of MelbourneC3  - University of MelbourneC3  - Finnish Institute of Occupational HealthC3  - Finnish Institute of Occupational HealthC3  - National Institutes of Health (NIH) - USAC3  - NIH National Cancer Institute (NCI)C3  - NIH National Cancer Institute- Division of Cancer Epidemiology & GeneticsC3  - Uppsala UniversityC3  - Uppsala UniversityC3  - Uppsala University HospitalC3  - Nova Southeastern UniversityC3  - Hong Kong Polytechnic UniversityC3  - Asbestos Diseases Research InstituteC3  - University of SydneyC3  - University of SydneyC3  - Sodertorn UniversityC3  - National Institute for Health Development - EstoniaC3  - University of FlorenceC3  - Universiti MalayaC3  - Chinese University of Hong KongC3  - University of HaifaC3  - Egyptian Knowledge Bank (EKB)C3  - Damietta UniversityC3  - University of TrnavaC3  - Shiraz University of Medical ScienceC3  - University of ZambiaC3  - University of ValenciaC3  - Chalmers University of TechnologyC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - Martin Luther University Halle WittenbergC3  - Martin Luther University Halle WittenbergC3  - State University System of FloridaC3  - University of West FloridaC3  - National Institutes of Health (NIH) - USAC3  - NIH National Heart Lung & Blood Institute (NHLBI)C3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - Pomeranian Medical UniversityC3  - Pomeranian Medical UniversityC3  - Pacific Institute for Research & Evaluation (PIRE)C3  - Curtin UniversityC3  - Amrita Vishwa VidyapeethamC3  - Amrita Vishwa Vidyapeetham KochiC3  - Kyrgyz State Medical AcademyC3  - Ministry of Health - KyrgyzstanC3  - Salahaddin UniversityC3  - Isfahan University of Medical SciencesC3  - Isfahan University of Medical SciencesC3  - Ahmadu Bello UniversityC3  - Ahmadu Bello UniversityC3  - IRCCS Burlo GarofoloC3  - Lancaster UniversityC3  - Queensland University of Technology (QUT)C3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataC3  - Universiti Sains MalaysiaC3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - Kermanshah University of Medical SciencesC3  - Kermanshah University of Medical SciencesC3  - Suraj Eye InstituteC3  - University of Yaounde IC3  - Sidi Mohamed Ben Abdellah University of FezC3  - Mohammed VI University of Sciences & Health-UM6SSC3  - Innlandet Hospital TrustC3  - Duy Tan UniversityC3  - Universitas Negeri SemarangC3  - Taipei Medical UniversityC3  - Western Sydney UniversityC3  - Western Sydney UniversityC3  - Western Sydney UniversityC3  - Kyung Hee UniversityC3  - Human Sciences Research Council-South AfricaC3  - University of NamibiaC3  - University of LagosC3  - Universidad Autonoma de ChileC3  - California State University SystemC3  - San Diego State UniversityC3  - University of OttawaC3  - University System of MarylandC3  - University of Maryland BaltimoreC3  - St. Luke's International HospitalC3  - University of IbadanC3  - North West University - South AfricaC3  - North West University - South AfricaC3  - JSS Academy of Higher Education & ResearchC3  - Murdoch Children's Research InstituteC3  - Save the ChildrenC3  - University of GothenburgC3  - University of WitwatersrandC3  - Shanghai Jiao Tong UniversityC3  - Durban University of TechnologyC3  - University of GroningenC3  - University of GroningenC3  - Bangladesh Rural Advancement Committee BRACC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - University of GottingenC3  - Medical University of InnsbruckC3  - Nizam's Institute of Medical SciencesC3  - University of Health Science - PakistanC3  - University of LondonC3  - University College LondonC3  - University College London Hospitals NHS Foundation TrustC3  - Loma Linda UniversityC3  - Stockholm UniversityC3  - Golestan University of Medical SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute for Research in Environmental Health (NIREH)C3  - University of SharjahC3  - Panjab UniversityC3  - Stanford UniversityC3  - Stanford UniversityC3  - Marshall UniversityC3  - University System of OhioC3  - Case Western Reserve UniversityC3  - University of BelgradeC3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - University of Kwazulu NatalC3  - Utkal UniversityC3  - University of North CarolinaC3  - University of North Carolina CharlotteC3  - Bayer TurkeyC3  - University of ZurichC3  - Universidade Federal de Santa Catarina (UFSC)C3  - Islamic Azad UniversityC3  - Islamic Azad UniversityC3  - Fudan UniversityC3  - University of EdinburghC3  - National Institute of Infectious Diseases (NIID)C3  - Washington State UniversityC3  - Symbiosis International UniversityC3  - Symbiosis Institute of Health Sciences (SIHS)C3  - Reykjavik UniversityC3  - Columbia UniversityC3  - Universidade de BrasiliaC3  - Autonomous University of MadridC3  - International Medical University MalaysiaC3  - University of MunichC3  - University of California SystemC3  - University of California IrvineC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERSAMC3  - New York Medical CollegeC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - Aristotle University of ThessalonikiC3  - University of HanoiC3  - University of CopenhagenC3  - University of HamburgC3  - University Medical Center Hamburg-EppendorfC3  - Gomal UniversityC3  - UKK InstituteC3  - Raffles HospitalC3  - Sechenov First Moscow State Medical UniversityC3  - HSE University (National Research University Higher School of Economics)C3  - Norwegian Institute of Public Health (NIPH)C3  - NHS National Services ScotlandC3  - University of StrathclydeC3  - Nanjing UniversityC3  - University of Mississippi Medical CenterC3  - University of MississippiC3  - Chinese Center for Disease Control & PreventionC3  - University of Hong KongC3  - University of South AustraliaC3  - Kyoto UniversityC3  - Korea UniversityC3  - University System of OhioC3  - Ohio State UniversityC3  - Universite de KinshasaC3  - Jackson State UniversityC3  - Tsinghua UniversityC3  - University of Texas SystemC3  - University of Texas Health Science Center HoustonPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - SEP 22
PY  - 2018
VL  - 392
IS  - 10152
SP  - 1015
EP  - 1035
DO  - 10.1016/S0140-6736(18)31310-2
AN  - WOS:000445098800025
ER  -

TY  - JOUR
AU  - Ranjan, R
AU  - Gaba, S
AU  - Goel, L
AU  - Asif, N
AU  - Kalra, M
AU  - Kumar, R
AU  - Kumar, A
TI  - In vivo comparison of a fixed loop (EndoButton CL) with an adjustable loop (TightRope RT) device for femoral fixation of the graft in ACL reconstruction: A prospective randomized study and a literature review
T2  - JOURNAL OF ORTHOPAEDIC SURGERY
KW  - anterior cruciate ligament reconstruction
KW  - EndoButton
KW  - knee stability
KW  - TightRope
KW  - CRUCIATE LIGAMENT RECONSTRUCTION
KW  - CORTICAL SUSPENSION DEVICES
KW  - BONE TUNNEL
AB  - Introduction: There is a lack of in vivo studies comparing the functional outcome and knee stability after anterior cruciate ligament reconstruction (ACLR) using fixed loop (EndoButton (EB) CL) and adjustable loop (TightRope (TR) RT) devices for femoral fixation of soft tissue grafts. Materials and methods: Functional outcomes were assessed in terms of the International Knee Documentation Committee (IKDC) and Lysholm scores, knee stability by anteroposterior laxity and side-to-side difference (SSD) using KT-1000 arthrometer. The evaluation was performed preoperatively and post-operatively at 6 months and 2 years. Results: Both groups were matched in terms of demographic, preoperative, intraoperative and post-operative covariates. EB (n = 52) appeared to have better IKDC and Lysholm scores at 6 months post-operative when compared to TR (n = 50). However, at a final follow-up of 2 years, the results were similar. The anterior tibial translation and SSD were statistically insignificant between the two groups at 6 months and 2 years. Conclusion: ACLR using EB or TR for femoral fixation gives substantially equivalent functional results and knee stability at mid-term follow-up.
AD  - Lady Hardinge Med Coll & Associated Hosp, New Delhi, IndiaAD  - All India Inst Med Sci, Room 4, New Delhi 110029, IndiaAD  - Aligarh Muslim Univ, JN Med Coll & Hosp, Aligarh, Uttar Pradesh, IndiaC3  - Lady Hardinge Medical College & HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Aligarh Muslim UniversityPU  - SAGE PUBLICATIONS INC
PI  - THOUSAND OAKS
PA  - 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
DA  - SEP 20
PY  - 2018
VL  - 26
IS  - 3
DO  - 10.1177/2309499018799787
AN  - WOS:000445281800001
ER  -

TY  - JOUR
AU  - Deb, K
AU  - Tuli, A
AU  - Sood, M
AU  - Chadda, R
AU  - Verma, R
AU  - Kumar, S
AU  - Ganesh, R
AU  - Singh, P
TI  - Is India ready for mental health apps (MHApps)? A quantitative-qualitative exploration of caregivers' perspective on smartphone-based solutions for managing severe mental illnesses in low resource settings
T2  - PLOS ONE
KW  - BIPOLAR DISORDER
KW  - SERVICE DELIVERY
KW  - FAMILY BURDEN
KW  - MOBILE PHONES
KW  - INTERVENTIONS
KW  - MHEALTH
KW  - SCHIZOPHRENIA
KW  - SMS
KW  - PREVENTION
KW  - MANAGEMENT
AB  - Background
   Mobile application based delivery of psycho-social interventions may help reduce the treatment gap for severe mental illnesses (SMIs) and decrease the burden on caregivers. Apps developed in high income settings show effectiveness, but they suffer from lack of applicability in low resource scenarios due to the difference in technology penetration, affordability, and acceptance.
   Objective
   This study aimed to understand health technology usage, perceived needs, and acceptability of app based interventions in patients with SMIs to improve illness management and reduce caregiver burden.
   Methods
   The study was conducted in inpatient and outpatient settings of a tertiary care center in North India. A cross-sectional survey assessed smartphone and health app usage. Further, three focus group discussions evaluated the needs and apprehensions in using apps in management of SMIs.
   Results
   A total of 176 participants including 88 patients and 88 caregivers completed the survey. Smartphone ownership was similar to the national average (30%) in both caregivers (38.6%) and in patients (31.8%). Although subjects regularly used a third party app, health app usage was very low. Cost, unfamiliarity, and language were significant barriers to adoption. The focus group discussions provided insight into the various apprehensions of caregivers in using and in allowing patients to use smartphones and such apps. Caregivers wanted mobile apps for accessing information regarding services and resources available for people with SMI, and they felt such apps can be helpful if they could automate some of their routine caregiving activities. However, the significant difficulty was perceived in regards to the cost of the device, language of the medium, and unfamiliarity in using technology. Apprehensions that SMI patients might misuse technology, or damage the device were also prevalent.
   Conclusions
   The study systematically looks into the scope, design considerations and limitations of implementing a mobile technology based intervention for low resource settings. With only one-third of the patients and caregivers having access to smartphones and internet, parallel outreach strategies like IVRS should be actively considered while designing interventions. The difficulty of understanding and searching in a non-native language needs to be addressed. Hand holding of caregivers and frequent encouragement from treating doctors might significantly help in technology adoption and in surmounting the apprehensions related to using technology. To make the solution acceptable and useful to the already overburdened caregivers, developers need to work closely with patients' family members and follow a ground-up collaborative approach to app development. The scope of delivering mental health services through technology is immense in resource constrained settings like India, provided we, researchers, appreciate and accept the fact that in the varied landscape of a divergent economic, educational, and cultural milieu, a single solution will never suffice for all, and intervention modality matching with end user capacity will be of paramount importance in determining the success of the endeavor.
AD  - AIIMS, Dept Psychiat, New Delhi, IndiaAD  - IIIT Delhi, Dept Comp Sci, Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indraprastha Institute of Information Technology DelhiPU  - PUBLIC LIBRARY SCIENCE
PI  - SAN FRANCISCO
PA  - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
DA  - SEP 19
PY  - 2018
VL  - 13
IS  - 9
C7  - e0203353
DO  - 10.1371/journal.pone.0203353
AN  - WOS:000445164300040
ER  -

TY  - JOUR
AU  - Watkins, DA
AU  - Beaton, AZ
AU  - Carapetis, JR
AU  - Karthikeyan, G
AU  - Mayosi, BM
AU  - Wyber, R
AU  - Yacoub, MH
AU  - Zühlke, LJ
TI  - Rheumatic Heart Disease Worldwide <i>JACC</i> Scientific Expert Panel
T2  - JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
KW  - PERCUTANEOUS BALLOON VALVULOPLASTY
KW  - BENZATHINE PENICILLIN-G
KW  - INFECTIVE ENDOCARDITIS
KW  - ATRIAL-FIBRILLATION
KW  - PREGNANT-WOMEN
KW  - STREPTOCOCCAL PHARYNGITIS
KW  - PRIMARY PREVENTION
KW  - CLINICAL-OUTCOMES
KW  - VALVE-REPLACEMENT
KW  - MITRAL-STENOSIS
AB  - Rheumatic heart disease (RHD) is a preventable heart condition that remains endemic among vulnerable groups in many countries. After a period of relative neglect, there has been a resurging interest in RHD worldwide over the past decade. In this Scientific Expert Panel, the authors summarize recent advances in the science of RHD and sketch out priorities for current action and future research. Key questions for laboratory research into disease pathogenesis and epidemiological research on the burden of disease are identified. The authors present a variety of pressing clinical research questions on optimal RHD prevention and advanced care. In addition, they propose a policy and implementation research agenda that can help translate current evidence into tangible action. The authors maintain that, despite knowledge gaps, there is sufficient evidence for national and global action on RHD, and they argue that RHD is a model for strengthening health systems to address other cardiovascular diseases in limited-resource countries. (c) 2018 by the American College of Cardiology Foundation.
AD  - Univ Washington, Dept Med, Div Gen Internal Med, 325 9th Ave,Box 359780, Seattle, WA 98104 USAAD  - Univ Cape Town, Dept Med, Cape Town, South AfricaAD  - Groote Schuur Hosp, Cape Town, South AfricaAD  - Univ Cape Town, Dept Paediat, Cape Town, South AfricaAD  - Red Cross War Mem Childrens Hosp, Cape Town, South AfricaAD  - Childrens Natl Hlth Syst, Washington, DC USAAD  - Univ Western Australia, Telethon Kids Inst, Subiaco, WA, AustraliaAD  - Princess Margaret Hosp Children, Perth, WA, AustraliaAD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaAD  - Univ Cape Town, Fac Hlth Sci, Deans Suite, Cape Town, South AfricaAD  - UNSW Sydney, George Inst Global Hlth, Off Chief Scientist, Camperdown, NSW, AustraliaAD  - Aswan Heart Ctr, Aswan, EgyptC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of Cape TownC3  - University of Cape TownC3  - University of Cape TownC3  - Children's National Health SystemC3  - The Kids Research Institute AustraliaC3  - University of Western AustraliaC3  - Princess Margaret Hospital for ChildrenC3  - University of Western AustraliaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of Cape TownC3  - George Institute for Global HealthC3  - University of SydneyC3  - University of New South Wales SydneyC3  - Egyptian Knowledge Bank (EKB)C3  - Aswan UniversityPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - SEP 18
PY  - 2018
VL  - 72
IS  - 12
SP  - 1397
EP  - 1416
DO  - 10.1016/j.jacc.2018.06.063
AN  - WOS:000444236800012
ER  -

TY  - JOUR
AU  - Rani, D
AU  - Saxena, R
AU  - Nayak, B
AU  - Srivastava, S
TI  - Cloning and expression of truncated ORF2 as a vaccine candidate against hepatitis E virus
T2  - 3 BIOTECH
KW  - Chitosan
KW  - Nanoemulsion
KW  - Hepatitis E virus
KW  - Truncated ORF2
KW  - PARTICLES
AB  - Hepatitis E virus infection is responsible for acute viral hepatitis and associated with high mortality and still birth in pregnant women in developing countries. We report expression of truncated forms of HEV ORF2 as potential vaccine candidates for nanoparticle-based delivery. These two truncated ORF2 proteins (54 kDa and 26 kDa) have been reported to be highly immunogenic and can be used as nanoparticle-based vaccine candidate. The bacterial expressed protein was purified by affinity chromatography and further confirmed by western blot using anti-HEV antibody. The chitosan nanoemulsion was synthesized using ultrasonic waves. The nanoparticle size was found to be 120-160 nm and the entrapment efficiency of purified truncated ORF2 proteins within these nanoparticles was 70% (26 kDa) and 59% (54 kDa). In cell cytotoxicity analysis, 100 mu g/mL nanoemulsion was found suitable for cell viability in both HeLa and THP1 cell lines. Release kinetics of encapsulated proteins at physiological pH 7.4 showed 26-59% and 9.7-40% release of 26 kDa and 54 kDa protein within 1 h that gradually increased with time (48 h). Encapsulated proteins were found to be unstable at pH 1.2.
AD  - Jaypee Inst Informat Technol, Dept Biotechnol, Noida 201309, UP, IndiaAD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi 110029, IndiaC3  - Jaypee Institute of Information Technology (JIIT)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER HEIDELBERG
PI  - HEIDELBERG
PA  - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
DA  - SEP 15
PY  - 2018
VL  - 8
IS  - 10
C7  - 414
DO  - 10.1007/s13205-018-1437-2
AN  - WOS:000444688600002
ER  -

TY  - JOUR
AU  - Soni, A
AU  - Surana, RK
AU  - Jha, SK
TI  - Smartphone based optical biosensor for the detection of urea in saliva
T2  - SENSORS AND ACTUATORS B-CHEMICAL
KW  - Smartphone based biosensor
KW  - Non-invasive biosensor
KW  - Salivary urea
KW  - Optical biosensor
KW  - CHRONIC KIDNEY-DISEASE
KW  - BLOOD UREA
KW  - CREATININE
KW  - LACTATE
KW  - SYSTEM
KW  - DEVICE
KW  - SENSOR
KW  - IMMOBILIZATION
KW  - NITROGEN
KW  - GLUCOSE
AB  - In the present study, we have developed a smartphone based handheld optical biosensor for determination of urea in saliva. A simple strategy was adopted by immobilization of urease enzyme along with a pH indicator on a filter paper based strip. The strip changed color upon the reaction with urea present in saliva and the color change can be estimated using our smartphone based application based on RGB profiling. Calibration of the biosensor was carried out using spiked saliva samples and an exponentially decreasing calibration curve has been obtained for green pixel intensity in the broad range (10-1000 mgdL(-1)) with a linear detection range of 10-260 mgdL(-1) and a response time of 20 s. The sensitivity reported for the biosensor in the clinically significant range was -0.005 average pixels sec(-1)/mgdL(-1) with a LOD of 10.4 mgdL(-1). Studies carried out on spiked saliva samples showed a good correlation between salivary urea estimated using our biosensor against phenol-hypochlorite based spectroscopic procedure. Development of a smartphone based biosensor for urea estimation eliminates the need for procuring a dedicated instrument as well as trained technician for daily monitoring and saves time as compared to traditional laboratory methods of analysis. (C) 2018 Elsevier B.V. All rights reserved.
AD  - Indian Inst Technol Delhi, Ctr Biomed Engn, New Delhi 110016, IndiaAD  - All India Inst Med Sci, Dept Biomed Engn, New Delhi 110029, IndiaAD  - Indian Inst Technol Delhi, Dept Text Technol, New Delhi 110016, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiPU  - ELSEVIER SCIENCE SA
PI  - LAUSANNE
PA  - PO BOX 564, 1001 LAUSANNE, SWITZERLAND
DA  - SEP 15
PY  - 2018
VL  - 269
SP  - 346
EP  - 353
DO  - 10.1016/j.snb.2018.04.108
AN  - WOS:000433211100042
ER  -

TY  - JOUR
AU  - Chatterjee, P
AU  - Kumar, P
AU  - Kandel, R
AU  - Madan, R
AU  - Tyagi, M
AU  - Kumar, DA
AU  - Khan, MA
AU  - Desai, G
AU  - Chaudhary, P
AU  - Gupta, S
AU  - Grover, K
AU  - Dey, AB
TI  - Nordic walking training and nutritional supplementation in pre-frail older Indians: an open-labelled experimental pre-test and post-test pilot study to develop intervention model
T2  - BMC GERIATRICS
KW  - Frailty
KW  - Adapted indoor Nordic walk
KW  - Individualized nutritional supplementation
KW  - PHYSICAL PERFORMANCE
KW  - ELDERLY POPULATION
KW  - PEOPLE
KW  - DEPRESSION
KW  - ADULTS
KW  - RISK
AB  - Background: Identifying and treating people in a pre-frail state may be an effective way to prevent or delay frailty and preserve their functional capacity. This study aimed to assess the efficacy of, and compliance with, a 12 week individualized nutritional supplementation (INS) and Nordic walking (NW) program in pre-frail older Indians. The primary measure is physical performance, as indicated by Fried's Frailty scale. Other measures include: cognition, as indicated by the Hindi Mental Status Examination; mood, by the Geriatric Depression Scale; and nutritional status, by the Mini Nutritional Assessment.
   Methods: This is an open-labeled experimental pre-test and post-test study, which took place from October 2012 to December 2014. The study was approved by Institute Ethics committee (IEC/NP-350/2012/RP-26/2012) at the All India Institute of Medical Sciences (AIIMS), New Delhi. Participants were sixty-six pre-frail elderly, who were randomly allocated into three subgroups, namely: A (NW only), B (INS only), and C (NW and INS). One-way ANOVA was used to statistically assess differences in baseline characteristics for quantitative variables, with the Chi-Square/Fischer exact test utilized for qualitative variables. Paired t-tests were used to assess pre and post intervention difference within the group for quantitative variables, with McNemar's Chi-Square test used for qualitative variables. Kruskal Wallis test was used to assess significant intervention effects among the groups. A p-value < 0.05 was considered as statistically significant.
   Results: There was significant effect of intervention in gait speed in group A (p = 0.001) and C (p = 0.002), but not in group B (p = 0.926). While there was no significant change in grip strength in Group A (p = 0.488) and B (p = 0.852), a statistically significant increase was observed in group C (p = 0.013). Mood significantly improved in group B (p = 0.025) and C (p = 0.021). No significant difference was noted in cognitive status across groups. Following the interventions, a total of 18.18% of pre-frail participants were classified as non-frail.
   Conclusions: Combining NW and INS provides a simple, pragmatic intervention with efficacy in the management of functionally vulnerable older adults, and allows their maintained independence. Future studies should replicate this readily applicable intervention in a larger cohort with a longer follow-up period.
AD  - All India Inst Med Sci, Dept Geriatr Med, New Delhi, IndiaAD  - Patan Acad Hlth Sci, Div Geriatr Med, Patan, NepalAD  - Hlth Aging India, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - Corner Off Advisors, New Delhi, IndiaAD  - Univ Manitoba, Winnipeg, MB, CanadaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of ManitobaPU  - BMC
PI  - LONDON
PA  - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - SEP 14
PY  - 2018
VL  - 18
C7  - 212
DO  - 10.1186/s12877-018-0890-4
AN  - WOS:000444654300001
ER  -

TY  - JOUR
AU  - Sharma, S
AU  - Kumar, G
AU  - Vashishta, M
AU  - Pandey, R
AU  - Rathore, S
AU  - Chourasia, BK
AU  - Singhal, J
AU  - Deshmukh, A
AU  - Kalamuddin, M
AU  - Paul, G
AU  - Panda, A
AU  - Tatiya, S
AU  - Rawat, K
AU  - Gupta, D
AU  - Mohmmed, A
AU  - Natarajan, K
AU  - Malhotra, P
TI  - Biochemical characterization of <i>Plasmodium</i> complement factors binding protein for its role in immune modulation
T2  - BIOCHEMICAL JOURNAL
KW  - TUBERCULOSIS SECRETORY ANTIGEN
KW  - DENDRITIC CELLS
KW  - LCCL PROTEINS
KW  - FALCIPARUM
KW  - MALARIA
KW  - ACTIVATION
KW  - EXPRESSION
KW  - SEQUENCE
KW  - BERGHEI
KW  - DIFFERENTIATION
AB  - Complement system is the first line of human defence against intruding pathogens and is recognized as a potentially useful therapeutic target. Human malaria parasite Plasmodium employs a series of intricate mechanisms that enables it to evade different arms of immune system, including the complement system. Here, we show the expression of a multi-domain Plasmodium Complement Control Protein 1, PfCCp1 at asexual blood stages and its binding affinity with C3b as well as C4b proteins of human complement cascade. Using a biochemical assay, we demonstrate that PfCCp1 binds with complement factors and inhibits complement activation. Active immunization of mice with PfCCp1 followed by challenge with Plasmodium berghei resulted in the loss of biphasic growth of parasites and early death in comparison to the control group. The study also showed a role of PfCCp1 in modulating Toll-like receptor (TLR)-mediated signalling and effector responses on antigen-presenting cells. PfCCp1 binds with dendritic cells that down-regulates the expression of signalling molecules and pro-inflammatory cytokines, thereby dampening the TLR2-mediated signalling; hence acting as a potent immunomodulator. In summary, PfCCp1 appears to be an important component of malaria parasite directed immuno-modulating strategies that promote the adaptive fitness of pathogens in the host.
AD  - Int Ctr Genet Engn & Biotechnol, Malaria Grp, POB 10504,Aruna Asaf Ali Marg, New Delhi 110067, IndiaAD  - All India Inst Med Sci, Dept Biotechnol, New Delhi 110029, IndiaAD  - Univ Delhi, Dr BR Ambedkar Ctr Biomed Res, Infect Dis Immunol Lab, Delhi 110007, IndiaAD  - Int Ctr Genet Engn & Biotechnol, Translat Bioinformat Grp, Aruna Asaf Ali Marg, New Delhi 110067, IndiaAD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaC3  - Department of Biotechnology (DBT) IndiaC3  - International Center for Genetic Engineering & Biotechnology (ICGEB)C3  - International Center for Genetic Engineering & Biotechnology (ICGEB), New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of DelhiC3  - Department of Biotechnology (DBT) IndiaC3  - International Center for Genetic Engineering & Biotechnology (ICGEB)C3  - International Center for Genetic Engineering & Biotechnology (ICGEB), New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - PORTLAND PRESS LTD
PI  - LONDON
PA  - CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
DA  - SEP 14
PY  - 2018
VL  - 475
SP  - 2877
EP  - 2891
DO  - 10.1042/BCJ20180142
AN  - WOS:000445511900002
ER  -

TY  - JOUR
AU  - Agarwal, M
AU  - Garg, SK
AU  - Asokan, K
AU  - Thulkar, S
AU  - Chander, S
AU  - Dalai, MK
AU  - Kumar, P
TI  - Design optimisation of C ion implantation of α-Al<sub>2</sub>O<sub>3</sub> for medical dosimetry
T2  - MATERIALS & DESIGN
KW  - Carbon ion implantation
KW  - Single crystalline Al2O3
KW  - Sapphire Al2O3
KW  - High energy ion irradiation
KW  - Optical stimulated luminescence
KW  - Thermo-luminescence dosimetry
KW  - TOF-SIMS
KW  - LUMINESCENCE
KW  - ENERGY
KW  - CARBON
KW  - THERMOLUMINESCENCE
KW  - ALUMINUM
KW  - ELECTRON
KW  - PROTON
AB  - The present work reports the fabrication and characterization of alpha-Al2O3:C, a highly sensitive low effective atomic number (Z(eff)= 10.7) OSL material for medical dosimetry, through a new approach of doping via implantation. In this study, a Single Crystallinea-Al2O3 (SCALO) and a Sapphire alpha-Al2O3 (SALO) are used and implanted with 100 keV of C+ at various fluences (mol%) from 2.5 x 10(14) ions cm(-2) (similar to 0.04%) to 6.25x 10(15) ions cm(-2) (similar to 1%) and are pre-heated up to 220 degrees C. The structural, optical, morphological and luminescent studies of the Carbon doped a-Al2O3 (alpha-Al2O3:C) are carried out using X-ray diffraction, Ultraviolet-visible spectroscopy (UV-Vis), Photo-luminescence (PL), Time of Flight Secondary Ion Mass Spectrometry (TOF-SIMS), Optically Stimulated Luminescence (OSL), and Thermo-Luminescence (TL). The doping of similar to 1 mol% of C+ is found at an optimized doping level due to its high intensity of luminescence. This phenomenon is studied for heavy charged particle (HCP) dosimetry, which might prove effective for cancer treatment. It is found that alpha-ALO:C (both the single crystalline and the sapphire alumina) has the capability to measure large radiation doses (similar to kGy). This is attributed to the generation of stable defects after the incorporation of Carbon that results in a linear response with the dose and in extraordinary efficiency. Thus, this study confirms the development of alpha-Al2O3 by the novel approach of C+ implantation method and the findings result in an efficient medical radiation dosimeter. (C) 2018 Elsevier Ltd. All rights reserved.
AD  - AIIMS, IRCH, Med Phys Unit, New Delhi 110029, IndiaAD  - Patna Univ, Univ Dept Phys, Patna 800005, Bihar, IndiaAD  - Interuniv Accelerator Ctr, Aruna Asaf Ali Marg, New Delhi 110067, IndiaAD  - AIIMS, IRCH, Radiol Unit, New Delhi 110029, IndiaAD  - AIIMS, IRCH, Dept Radiotherapy, New Delhi 110029, IndiaAD  - CSIR Natl Phys Lab, Dr KS Krishnan Marg, New Delhi 110012, IndiaAD  - CSIR Inst Minerals & Mat Technol, Bhubaneswar 751013, Odisha, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - Patna UniversityC3  - Inter-University Accelerator CentreC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - National Physical Laboratory (NPL)C3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Minerals & Materials Technology (IMMT)PU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - SEP 5
PY  - 2018
VL  - 153
SP  - 317
EP  - 326
DO  - 10.1016/j.matdes.2018.04.079
AN  - WOS:000436433600031
ER  -

TY  - JOUR
AU  - Shewade, HD
AU  - Gupta, V
AU  - Satyanarayana, S
AU  - Kharate, A
AU  - Sahai, KN
AU  - Murali, L
AU  - Kamble, S
AU  - Deshpande, M
AU  - Kumar, N
AU  - Kumar, S
AU  - Pandey, P
AU  - Bajpai, UN
AU  - Tripathy, JP
AU  - Kathirvel, S
AU  - Pandurangan, S
AU  - Mohanty, S
AU  - Ghule, VH
AU  - Sagili, KD
AU  - Prasad, BM
AU  - Nath, S
AU  - Singh, P
AU  - Singh, K
AU  - Singh, R
AU  - Jayaraman, G
AU  - Rajeswaran, P
AU  - Srivastava, BK
AU  - Biswas, M
AU  - Mallick, G
AU  - Bera, OP
AU  - Jaisingh, AJJ
AU  - Naqvi, AJ
AU  - Verma, P
AU  - Ansari, MS
AU  - Mishra, PC
AU  - Sumesh, G
AU  - Barik, S
AU  - Mathew, V
AU  - Lohar, MRS
AU  - Gaurkhede, CS
AU  - Parate, G
AU  - Bale, SY
AU  - Koli, I
AU  - Bharadwaj, AK
AU  - Venkatraman, G
AU  - Sathiyanarayanan, K
AU  - Lal, J
AU  - Sharma, AK
AU  - Rao, R
AU  - Kumar, AMV
AU  - Chadha, SS
A1  - Axshya SAMVAD Study Grp
TI  - Active case finding among marginalised and vulnerable populations reduces catastrophic costs due to tuberculosis diagnosis
T2  - GLOBAL HEALTH ACTION
KW  - tuberculosis/prevention and control
KW  - systematic screening
KW  - vulnerable populations
KW  - health care costs
KW  - health equity
KW  - ECONOMIC BURDEN
KW  - CARE
KW  - EXPENDITURE
KW  - HOUSEHOLDS
KW  - AFRICA
KW  - ACCESS
AB  - Background: There is limited evidence on whether active case finding (ACF) among marginalised and vulnerable populations mitigates the financial burden during tuberculosis (TB) diagnosis.
   Objectives: To determine the effect of ACF among marginalised and vulnerable populations on prevalence and inequity of catastrophic costs due to TB diagnosis among TB-affected households when compared with passive case finding (PCF).
   Methods: In 18 randomly sampled ACF districts in India, during March 2016 to February 2017, we enrolled all new sputum-smear-positive TB patients detected through ACF and an equal number of randomly selected patients detected through PCF. Direct (medical and non-medical) and indirect costs due to TB diagnosis were collected through patient interviews at their residence. We defined costs due to TB diagnosis as 'catastrophic' if the total costs (direct and indirect) due to TB diagnosis exceeded 20% of annual pre-TB household income. We used concentration curves and indices to assess the extent of inequity.
   Results: When compared with patients detected through PCF (n = 231), ACF patients (n = 234) incurred lower median total costs (US$ 4.6 and 20.4, p < 0.001). The prevalence of catastrophic costs in ACF and PCF was 10.3 and 11.5% respectively. Adjusted analysis showed that patients detected through ACF had a 32% lower prevalence of catastrophic costs relative to PCF [adjusted prevalence ratio (95% CI): 0.68 (0.69, 0.97)]. The concentration indices (95% CI) for total costs in both ACF (-0.15 (-0.32, 0.11)] and PCF [-0.06 (-0.20, 0.08)] were not significantly different from the line of equality and each other. The concentration indices (95% CI) for catastrophic costs in both ACF [-0.60 (-0.81, -0.39)] and PCF [-058 (-0.78, -0.38)] were not significantly different from each other: however, both the curves had a significant distribution among the poorest quintiles.
   Conclusion: ACF among marginalised and vulnerable populations reduced total costs and prevalence of catastrophic costs due to TB diagnosis, but could not address inequity.
AD  - Int Union TB & Lung Dis Union, Dept Operat Res, South East Asia Off, New Delhi, IndiaAD  - Int Union TB & Lung Dis Union, Ctr Operat Res, Paris, FranceAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaAD  - Govt Madhya Pradesh, Dept Hlth & Family Welf, State TB Cell, Bhopal, IndiaAD  - Govt Bihar, Dept Hlth & Family Welf, State TB Cell, Patna, Bihar, IndiaAD  - Govt Tamil Nadu, Dept Hlth & Family Welf, State TB Cell, Madras, Tamil Nadu, IndiaAD  - Govt Maharashtra, Hlth Dept, State TB Cell, Pune, Maharashtra, IndiaAD  - Govt Chattisgarh, Dept Hlth & Family Welf, State TB Cell, Raipur, Madhya Pradesh, IndiaAD  - Govt Punjab, Dept Hlth & Family Welf, State TB Cell, Chandigarh, IndiaAD  - Govt Kerala, Dept Hlth & Family Welf, State TB Cell, Thiruvananthapuram, Kerala, IndiaAD  - Int Union TB & Lung Dis Union, Dept TB & Communicable Dis, New Delhi, IndiaAD  - Voluntary Hlth Assoc India, New Delhi, IndiaAD  - PGIMER, Dept Community Med, Chandigarh, IndiaAD  - MAMTA Hlth Inst Mother & Child, New Delhi, IndiaAD  - Catholic Hlth Assoc India, Hyderabad, Telangana, IndiaAD  - Resource Grp Educ & Advocacy Community Hlth REACH, Madras, Tamil Nadu, IndiaAD  - Populat Serv Int, New Delhi, IndiaAD  - CBCI CARD, New Delhi, IndiaAD  - EHA, New Delhi, IndiaAD  - Govt India, Cent TB Div, Revised Natl TB Control Programme, Minist Hlth & Family Welf, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhPU  - TAYLOR & FRANCIS LTD
PI  - ABINGDON
PA  - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
DA  - SEP 3
PY  - 2018
VL  - 11
IS  - 1
C7  - 1494897
DO  - 10.1080/16549716.2018.1494897
AN  - WOS:000443874700001
ER  -

TY  - JOUR
AU  - Adhikari, N
AU  - Biswas, A
AU  - Bakhshi, S
AU  - Khanna, G
AU  - Suri, V
TI  - A rare case of paediatric primary central nervous system lymphoma treated with high-dose methotrexate and rituximab-based chemoimmunotherapy and whole brain radiotherapy followed by tumour bed boost with three-dimensional conformal radiation technique
T2  - CHILDS NERVOUS SYSTEM
KW  - Paediatric
KW  - Primary CNS lymphoma
KW  - Chemoimmunotherapy
KW  - Whole brain radiotherapy
KW  - PRIMARY CNS LYMPHOMA
KW  - ONCOLOGY GROUP-REPORT
KW  - CHILDREN
KW  - CHEMOTHERAPY
KW  - ADOLESCENTS
KW  - CHILDHOOD
KW  - SURVIVAL
AB  - Primary central nervous system lymphomas ( PCNSL) are rare in the paediatric population.
   A 12-year-old boy presented to our clinic with complaints of multiple episodes of generalised tonic-clonic seizures for 1 year and gradual loss of vision in both eyes for 3 months. Baseline magnetic resonance imaging (MRI) of the brain showed a large (7.2 x 7 cm) enhancing soft tissue lesion in the right frontal lobe causing mass effect and midline shift. With a radiological diagnosis of supratentorial primitive neuroectodermal tumour, he underwent subtotal resection of tumour. The post-operative histopathology revealed diffuse large B cell lymphoma (DLBCL). Systemic lymphoma workup was essentially normal. He received five cycles of chemoimmunotherapy with rituximab, high-dose methotrexate (HDMTX), vincristine and procarbazine and had complete radiological response (CR). This was followed by whole brain radiotherapy (WBRT) to a dose of 36 Gy in 20 fractions and sequential tumour bed boost to a dose of 9 Gy in 5 fractions by three-dimensional conformal technique. Subsequently, he received two cycles of consolidation chemotherapy with high-dose cytarabine. At completion of treatment, 3 and 6 months thereafter, MRI brain showed CR. At last follow-up visit, 13 months from the date of diagnosis, he was disease-free and asymptomatic with the exception of dimness of vision in both eyes due to long-standing bilateral optic atrophy.
   This report highlights the fact that paediatric PCNSL may be effectively treated by a combination of HDMTX and rituximab-based chemoimmunotherapy followed by consolidation with conformal WBRT and tumour bed boost. Lack of awareness of this rare entity may lead to diagnostic delay and potential ramifications as exemplified by chronic atrophic papilloedema and visual loss in the illustrative case.
AD  - All India Inst Med Sci, Dept Radiotherapy & Oncol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Med Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - SEP
PY  - 2018
VL  - 34
IS  - 9
SP  - 1777
EP  - 1783
DO  - 10.1007/s00381-018-3807-9
AN  - WOS:000441188200024
ER  -

TY  - JOUR
AU  - Agarwal, A
AU  - Agarwal, M
AU  - Khandelwal, V
AU  - Mathur, P
TI  - Adult-Onset Still Disease Masquerading as Multiple Organ Failure: Neither Benign Nor So Rare
T2  - JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
KW  - CLASSIFICATION
KW  - CRITERIA
AD  - Narayana Multispecial Hosp, Dept Internal Med, New Delhi, IndiaAD  - Apex Hosp, New Delhi, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - SEP
PY  - 2018
VL  - 24
IS  - 6
SP  - 342
EP  - 346
DO  - 10.1097/RHU.0000000000000660
AN  - WOS:000443539400010
ER  -

TY  - JOUR
AU  - Agarwal, N
AU  - Agrawal, M
AU  - Sawarkar, DP
TI  - Timing of Tracheostomy Procedures in Patients with Spinal Cord Injury Requiring Cervical Spine Surgery: Is Early Tracheostomy Really Associated with Fewer Wound Infections?
T2  - WORLD NEUROSURGERY
KW  - STABILIZATION
KW  - FIXATION
KW  - TRAUMA
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - SEP
PY  - 2018
VL  - 117
SP  - 469
EP  - 469
DO  - 10.1016/j.wneu.2018.05.204
AN  - WOS:000442440400170
ER  -

TY  - JOUR
AU  - Agarwal, R
AU  - Chawla, D
AU  - Sharma, M
AU  - Nagaranjan, S
AU  - Dalpath, SK
AU  - Gupta, R
AU  - Kumar, S
AU  - Chaudhuri, S
AU  - Mohanty, P
AU  - Sankar, MJ
AU  - Agarwal, K
AU  - Rani, S
AU  - Thukral, A
AU  - Jain, S
AU  - Yadav, CP
AU  - Gathwala, G
AU  - Kumar, P
AU  - Sarin, J
AU  - Sreenivas, V
AU  - Aggarwal, KC
AU  - Kumar, Y
AU  - Kharya, P
AU  - Bisht, SS
AU  - Shridhar, G
AU  - Arora, R
AU  - Joshi, K
AU  - Bhalla, K
AU  - Soni, A
AU  - Singh, S
AU  - Devakirubai, P
AU  - Samuel, R
AU  - Yadav, R
AU  - Bahi, R
AU  - Kumar, V
AU  - Paul, VK
AU  - Jajoo, M
AU  - Kulkarni, V
AU  - Gupta, N
AU  - Huria, A
AU  - Murry, L
AU  - Agarwal, P
AU  - Kaur, H
AU  - Duggal, A
AU  - Khatri, J
AU  - Gupta, V
AU  - Passi, MR
AU  - Mann, VP
AU  - Malik, A
AU  - Jain, B
AU  - Jain, VK
AU  - Sharma, D
A1  - QI Haryana Study Collaboration
TI  - Improving quality of care during childbirth in primary health centres: a stepped-wedge cluster-randomised trial in India
T2  - BMJ GLOBAL HEALTH
KW  - MORTALITY
KW  - FACILITIES
KW  - PROGRAM
KW  - DESIGN
KW  - BIRTH
AB  - Background Low/middle-income countries need a large-scale improvement in the quality of care (QoC) around the time of childbirth in order to reduce high maternal, fetal and neonatal mortality. However, there is a paucity of scalable models.
   Methods We conducted a stepped-wedge cluster-randomised trial in 15 primary health centres (PHC) of the state of Haryana in India to test the effectiveness of a multipronged quality management strategy comprising capacity building of providers, periodic assessments of the PHCs to identify quality gaps and undertaking improvement activities for closure of the gaps. The 21-month duration of the study was divided into seven periods (steps) of 3 months each. Starting from the second period, a set of randomly selected three PHCs (cluster) crossed over to the intervention arm for rest of the period of the study. The primary outcomes included the number of women approaching the PHCs for childbirth and 12 directly observed essential practices related to the childbirth. Outcomes were adjusted with random effect for cluster (PHC) and fixed effect for 'months of intervention'.
   Results The intervention strategy led to increase in the number of women approaching PHCs for childbirth (26 vs 21 women per PHC-month, adjusted incidence rate ratio: 1.22; 95% CI 1.17 to 1.28). Of the 12 practices, 6 improved modestly, 2 remained near universal during both intervention and control periods, 3 did not change and 1 worsened. There was no evidence of change in mortality with a majority of deaths occurring either during referral transport or at the referral facilities.
   Conclusion A multipronged quality management strategy enhanced utilisation of services and modestly improved key practices around the time of childbirth in PHCs in India.
AD  - All India Inst Med Sci, Dept Pediat, Div Neonatol, New Delhi, IndiaAD  - Govt Med Coll Hosp, Dept Neonatol, Chandigarh, IndiaAD  - Survival Women & Children Fdn SWACH, Panchkula, IndiaAD  - Saha Manthran Pvt Ltd, Gurugram, IndiaAD  - Govt India, Natl Hlth Mission Haryana, Panchkula, IndiaAD  - Maulana Azad Med Coll, New Delhi, IndiaAD  - LNJP Hosp, New Delhi, IndiaAD  - Govt Med Coll Hosp, Dept Obstet & Gynecol, Chandigarh, IndiaAD  - Natl Inst Malaria Res, New Delhi, IndiaAD  - Pt BD Sharma PGIMS, Rohtak, Haryana, IndiaAD  - PGIMER, Chandigarh, IndiaAD  - MM Coll Nursing, Mullana, Ambala, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - Safadarjung Hosp, New Delhi, IndiaAD  - Vardhman Mahavir Med Coll, New Delhi, IndiaAD  - Govt Med Coll, Kannauj, IndiaAD  - Swami Dayanand Hosp, New Delhi, IndiaAD  - Western Command Hosp, Panchkula, IndiaAD  - Santosh Med Coll, Gaziabad, IndiaAD  - UNICEF Rajasthan, Jaipur, Rajasthan, IndiaAD  - UNICEF Chhattisgarh, Raipur, Madhya Pradesh, IndiaAD  - Lady Hardinge Med Coll & Hosp, New Delhi, IndiaAD  - WHO, Geneva, SwitzerlandC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Maulana Azad Medical CollegeC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Malaria Research (NIMR)C3  - Pt. B.D. Sharma Post Graduate Institute of Medical Sciences (PGIMS), RohtakC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Vardhman Mahavir Medical College & Safdarjung HospitalC3  - Vardhman Mahavir Medical College & Safdarjung HospitalC3  - Lady Hardinge Medical College & HospitalC3  - World Health OrganizationPU  - BMJ PUBLISHING GROUP
PI  - LONDON
PA  - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
DA  - SEP
PY  - 2018
VL  - 3
IS  - 5
C7  - e000907
DO  - 10.1136/bmjgh-2018-000907
AN  - WOS:000457716300020
ER  -

TY  - JOUR
AU  - Agrawal, M
AU  - Jain, N
AU  - Borkar, SA
TI  - Unusual Clinical Presentation and Magnetic Resonance Imaging Findings in Supratentorial Epidermoid Cyst
T2  - WORLD NEUROSURGERY
KW  - Atypical epidermoid
KW  - Seizures
KW  - Unusual imaging
AB  - Epidermoid cysts in the lateral temporal lobe presenting with seizures are rare accounting for <5% of all intracranial epidermoid cysts. Preoperative diagnosis can be further confounded by unusual imaging as presented in this case, thus leading to the wrong preoperative diagnosis of the case as a neoplastic pathology.
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - SEP
PY  - 2018
VL  - 117
SP  - 235
EP  - 236
DO  - 10.1016/j.wneu.2018.05.200
AN  - WOS:000442440400175
ER  -

TY  - JOUR
AU  - Agrawal, M
AU  - Garg, M
AU  - Kumar, A
AU  - Singh, PK
AU  - Satyarthee, GD
AU  - Agrawal, D
AU  - Chandra, PS
AU  - Kale, SS
TI  - Management of Pediatric Posttraumatic Thoracolumbar Vertebral Body Burst Fractures by Use of Single-Stage Posterior Transpedicular Approach
T2  - WORLD NEUROSURGERY
KW  - Pediatric trauma
KW  - Thoracolumbar vertebral body burst fracture
KW  - Transpedicular corpectomy
KW  - EXPANDABLE CAGE RECONSTRUCTION
KW  - PEDICLE SCREW INSTRUMENTATION
KW  - ADJACENT SEGMENT PATHOLOGY
KW  - 47-YEAR FOLLOW-UP
KW  - LUMBAR SPINE
KW  - NONOPERATIVE TREATMENT
KW  - HOSPITAL ADMISSIONS
KW  - ANTERIOR APPROACH
KW  - CLINICAL ARTICLE
KW  - FUSION CAGES
AB  - PURPOSE: The posterior transpedicular approach (PTA) is a posterior approach that has the advantage of achieving circumferential arthrodesis by a single posterior-only approach. The purpose of this study was to analyze our experience with PTA in the management of pediatric traumatic thoracolumbar burst fractures (TTLBFs).
   METHODS: Consecutive pediatric patients (age <= 18 years) with TTLBFs treated with PTA for 6 years were included in this retrospective study. Correction of kyphotic deformity and change in neurologic status were analyzed to assess outcome. The Cobb angle and American Spinal Injury Association (ASIA) grade were used for this purpose.
   RESULTS: There were 6 male and 8 female patients. Five patients had complete injury (ASIA-A), and 9 had incomplete injury. The mean Thoracolumbar Injury Classification and Severity score was 6.71. The mean preoperative Cobb angle was 14.71 degrees and improved to -3.35 degrees postoperatively (mean kyphosis correction -18.05 degrees). Two of the patients experienced iatrogenic nerve root injury. There was 1 postoperative mortality due to complications unrelated to the surgery. The mean Cobb angle was -0.07 degrees at the 32.2-month follow-up visit. Six patients experienced cage subsidence, but none required revision surgery. Post-operatively, 11 (78.5%) patients showed neurologic improvement, and none experienced deterioration. The average ASIA score improved from 2.5 to 3.78. A fusion rate of 100% (n = 12) was observed at the last follow-up visit.
   CONCLUSIONS: The present study demonstrates that PTA is a feasible approach in selected pediatric patients with unstable traumatic thoracolumbar burst fractures, with results comparable with those in the adult population. This study demonstrates in detail the procedure, along with the neurologic and radiologic outcomes of this approach in the pediatric population.
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaAD  - Jai Prakash Narayan Trauma Ctr, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - SEP
PY  - 2018
VL  - 117
SP  - E22
EP  - E33
DO  - 10.1016/j.wneu.2018.05.088
AN  - WOS:000442440400005
ER  -

TY  - JOUR
AU  - Ahmed, SA
AU  - Kumar, A
AU  - Sethi, P
AU  - Kapil, A
AU  - Pandey, RM
AU  - Wig, N
TI  - Effectiveness of education and antibiotic control programme at All India Institute of Medical Sciences, New Delhi
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
AB  - Background. We aimed to assess the impact of antibiotic optimization education along with understanding the antibiogram on antibiotic-prescribing practices, antibiotic consumption, antimicrobial resistance and cost of antibiotics in a tertiary care hospital in New Delhi.
   Methods. We divided the study into 3 phases-before and after intervention and a phase of education in between. We collected data on demographics, indication for antibiotic prescription, appropriateness or reasons for inappropriate antibiotic uses, antibiotic consumption (i.e. the rate and duration of antibiotic use), bacterial resistance and antibiotic cost. Interventions included education, introduction of an antibiogram and use of antibiotic prescription forms. Similar data were collected for the post-interventional phase. The study was conducted at the Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
   Results. There was an improvement in the number of patients who underwent de-escalation of antibiotics, 21/100 v. 36/100 (p=0.019); appropriate antibiotic usage, 25/100 v. 46/100 (p=0.002); switching from intravenous to oral promptly, 16/52 v. 19/36 (p=0.003) and decrease in expenditure, '24 207.5 v. '16 517.5 per patient (p=0.001); in the post-interventional phase. Significant reductions in the incidence of infections due to Acinetobacter (60% v. 31%; p< 0.001) and improvement in sensitivity pattern with cephalosporin sulbactam (80% v. 100%; p< 0.001) were seen. Multivariate analysis revealed that Acute Physiology and Chronic Health Evaluation (APACHE) score, hospital stay < 10 days, ventilator-associated pneumonia and methicillinresistant Staphylococcus aureus coverage were independent predictors of mortality with odds ratio of 1.14, 0.1, 9.7 and 1.14, respectively.
   Conclusion. Education and an antibiotic control programme constituted an effective and cost-saving strategy to optimise antibiotic use at a tertiary care centre.
AD  - All India Inst Med Sci, Dept Med, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Microbiol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SCIENTIFIC SCHOLAR LLC
PI  - PITTSFORD
PA  - 50, WOODGREEN DR, PITTSFORD, NY 14534 USA
DA  - SEP-OCT
PY  - 2018
VL  - 31
IS  - 5
SP  - 262
EP  - 267
DO  - 10.4103/0970-258X.261176
AN  - WOS:000473690700002
ER  -

TY  - JOUR
AU  - Arora, R
AU  - Kumar, R
AU  - Agarwal, A
AU  - Reeta, KH
AU  - Gupta, YK
TI  - Comparison of three different extracts of <i>Centella asiatica </i>for anti-amnesic, antioxidant and anticholinergic activities: <i>in vitro </i>and <i>in vivo </i>study
T2  - BIOMEDICINE & PHARMACOTHERAPY
KW  - Centella asiatica
KW  - Triterpenes
KW  - Enriched
KW  - Scopolamine
KW  - Amnesia
KW  - Antioxidant
KW  - INDIAN MEDICINAL-PLANTS
KW  - INDUCED COGNITIVE IMPAIRMENT
KW  - INDUCED OXIDATIVE STRESS
KW  - ENRICHED EXTRACT
KW  - ALZHEIMERS-DISEASE
KW  - MEMORY IMPAIRMENT
KW  - ACID-DERIVATIVES
KW  - PREPUBERTAL MICE
KW  - BRAIN-REGIONS
KW  - SCOPOLAMINE
AB  - Centella asiatica (CA) has been used by Ayurvedic medical practitioners in India for almost 3000 years. The neuropharmacological properties of CA and its constituents have been studied extensively. Anti-oxidant, free radical scavenging and cholinergic modulatory activities are the reported mechanisms of action for its efficacy in memory disorders. Its medicinal values are mainly attributed to the presence of several triterpenes, namely asiatic acid, madecassic acid, asiaticoside, and madecassoside. The present study was aimed to investigate the role of these triterpenes content in CA extract on the antioxidant, cholinesterase modulation and anti-amnesic properties. The fractions of CA extract enriched for (CAE-EF) and depleted/freed of (CAE-FF) triterpenes contents were compared with methanolic extract (CAE). Both in vitro and in vivo methods for evaluation of antioxidant and anticholinergic activities were used. In vitro, free radical scavenging assays (ABTS, DPPH, NO, NORAC, and ORAC) and cholinesterase (AChE and BuChE) inhibition assays were used. For evaluation of antiamnesic effect, scopolamine induced amnesia in rats, as the acute model of memory loss was used. Following behavioural assessments (MWM, PA, EPM), biomarkers of oxidative stress (reduced GSH, MDA and SOD activity) and cholinesterase (AChE and BuChE) status were also estimated in cerebral cortex and hippocampus of rat brain. The methanolic extract (CAE) was found to perform best among all three fractions for in vitro free radical scavenging, cholinesterase inhibition, improvement of scopolamine-induced amnesia and also in vivo antioxidant effect and cholinesterase inhibitory activities. Interestingly triterpenes free fraction (CAE-FF) showed better antioxidant activity than triterpenes enriched fraction (CAE-EF) along with comparable anti-amnesic effect. This indicates that triterpenes are not solely responsible for antioxidant activity, cholinesterase inhibitory and antiamnesic effect of CA.
AD  - All India Inst Med Sci, Dept Pharmacol, New Delhi, IndiaAD  - Nat Remedies Pvt Ltd, Bangalore, Karnataka, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Natural Remedies Pvt. Ltd.PU  - ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI  - ISSY-LES-MOULINEAUX
PA  - 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
DA  - SEP
PY  - 2018
VL  - 105
SP  - 1344
EP  - 1352
DO  - 10.1016/j.biopha.2018.05.156
AN  - WOS:000438312600154
ER  -

TY  - JOUR
AU  - Balhara, YPS
AU  - Bhargava, R
AU  - Pakhre, A
AU  - Bhati, N
TI  - The "Blue Whale Challenge"?: The first report on a consultation from a health care setting for carrying out "tasks" accessed through a mobile phone application
T2  - ASIA-PACIFIC PSYCHIATRY
AD  - All India Inst Med Sci, Dept Psychiat, Natl Drug Dependence Treatment Ctr, Behav Addict Clin, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)PU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - SEP
PY  - 2018
VL  - 10
IS  - 3
C7  - e12317
DO  - 10.1111/appy.12317
AN  - WOS:000442565500007
ER  -

TY  - JOUR
AU  - Banik, S
AU  - Rath, GP
AU  - Ramsal, R
AU  - Singh, GP
TI  - Balloon-assisted coil embolization of intracranial aneurysm and zero bispectral index
T2  - NEUROLOGY INDIA
AD  - All India Inst Med Sci, Dept Neuroanaesthesiol & Crit Care, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - SEP-OCT
PY  - 2018
VL  - 66
IS  - 5
SP  - 1501
EP  - 1502
DO  - 10.4103/0028-3886.241341
AN  - WOS:000447605100056
ER  -

TY  - JOUR
AU  - Chakraborty, D
AU  - Rangamani, S
AU  - Kulothungan, V
AU  - Chaturvedi, M
AU  - Stephen, S
AU  - Das, P
AU  - Sudarshan, KL
AU  - Surya, RJ
AU  - Kumar, KS
AU  - John, A
AU  - Manoharan, N
AU  - Koyande, SS
AU  - Swaminathan, R
AU  - Ramesh, C
AU  - Shrivastava, A
AU  - Ganesh, B
AU  - Mathur, P
AU  - Nandakumar, A
TI  - Trends in incidence of Ewing sarcoma of bone in India - Evidence from the National Cancer Registry Programme (1982-2011)
T2  - JOURNAL OF BONE ONCOLOGY
KW  - Ewing sarcoma
KW  - Bone
KW  - Incidence
KW  - Cancer Registry
KW  - India
KW  - CHILDHOOD-CANCER
KW  - SURVIVAL
KW  - TUMORS
KW  - EPIDEMIOLOGY
KW  - FAMILY
AB  - Background: Ewing sarcoma is a malignant tumour found mainly in childhood and adolescence. The present study aims at analyzing the data on Ewing sarcoma cases of bone from the National Cancer Registry Programme, India to provide incidence, patterns, and trends in the Indian population.
   Materials and Methods: The data of five Population Based Cancer Registries (PBCR) of Bangalore, Mumbai, Chennai, Bhopal and Delhi over 30 years period (1982-2011) were used to calculate the Age Specific and Age Standardized Incidence Rates (ASpR and ASIR), and trends in incidence was analyzed by linear and Joinpoint Regression.
   Results: Ewing sarcoma comprised around 15 % of all bone malignancies. Sixty-eight percent were 0-19 years, with 1.6 times risk of tumour in bones of limbs as compared to other bones. The highest incidence rate (per million) was in the 10-14 years age group (male - 4.4, female - 2.9) with significantly increasing trend in ASpR observed in both sexes. Pooled ASIR per million for all ages was higher in male (1.6) than female (1.0) with an increasing rate ratio of ASIR with increase in age. Trend of pooled ASIR for all ages was significantly increased in both sexes. Twelve percent cases were reported in >= 30 years of age.
   Conclusion: This paper has described population based measurements on burden and trends in incidence of skeletal Ewing in India. These may steer further research questions on the clinical and molecular epidemiology to explain factors associated with the increasing incidence of Ewing sarcoma bone observed in India.
AD  - ICMR, NCDIR, Bengaluru, IndiaAD  - Inst Rotary Canc Hosp, Populat Based Canc Registry, New Delhi, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Indian Canc Soc, Mumbai Canc Registry, Bombay, Maharashtra, IndiaAD  - Canc Inst WIA, Dept Biostat & Canc Registry, Madras, Tamil Nadu, IndiaAD  - Kidwai Mem Inst Oncol, Dept Epidemiol & Biostat, Bengaluru, IndiaAD  - Gandhi Med Coll, Dept Pathol, Populat Based Canc Registry, Bhopal, IndiaAD  - Tata Mem Hosp, Dept Epidemiol & Biostat, Bombay, Maharashtra, IndiaC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Centre for Disease Informatics & Research (NCDIR)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Kidwai Memorial Institute of OncologyC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - SEP
PY  - 2018
VL  - 12
SP  - 49
EP  - 53
DO  - 10.1016/j.jbo.2018.04.002
AN  - WOS:000444900200010
ER  -

TY  - JOUR
AU  - Chandra, P
AU  - Tewari, R
AU  - Dolma, Y
AU  - Das, D
AU  - Kumawat, D
TI  - Reducing Preoperative Waiting-time in a Pediatric Eye Operation Theater by Optimizing Process Flow: A Pilot Quality Improvement Project
T2  - INDIAN PEDIATRICS
KW  - Healthcare delivery
KW  - Plan-do-study-act cycle
KW  - Start-time delay
KW  - HEALTH-CARE
AB  - ObjectiveTo decrease the preoperative area waiting-time for children posted for eye surgery.MethodsA pilot quality improvement project was conducted in a single paediatric eye operation theatre in our tertiary-care hospital. Operation theatre process flow was analyzed, baseline data was collected, and two Plan-Do-Study-Act cycles were performed on consecutive days. Average and maximal waiting-time were recorded across six operation theatre days.ResultsThe average and maximal waiting time at baseline were 221 and 390 minutes, respectively. After two rapid Plan-Do-Study- Act cycles, these were reduced to 29 (87% reduction) and 52 minutes (87% reduction) from baseline, respectively, and could subsequently be sustained.ConclusionPreoperative waiting time in ophthalmic operation theatre was significantly reduced by simple process flow optimization, thereby improving quality of care.
AD  - AIIMS, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - SEP
PY  - 2018
VL  - 55
IS  - 9
SP  - 773
EP  - 775
DO  - 10.1007/s13312-018-1379-0
AN  - WOS:000445093300011
ER  -

TY  - JOUR
AU  - Chandra, P
AU  - Kumawat, D
AU  - Tewari, R
AU  - Panyala, RR
AU  - Sreeshankar, SS
TI  - Reducing Waiting-time of Preterm Babies at a Retinopathy of Prematurity Clinic: A Quality Improvement Project
T2  - INDIAN PEDIATRICS
KW  - Consultation time
KW  - Hospital planning
KW  - Intervention
KW  - Quality of health care
AB  - ObjectiveTo decrease the waiting time for preterm babies visiting the Retinopathy of prematurity clinic in a tertiary eye hospital.DesignInterventional study.SettingTertiary eye care hospital.PatientsAll preterm babies reporting for screening and follow up at Retinopathy of prematurity clinic.Intervention/ProcedureA quality improvement team comprising of a faculty (team leader), two senior residents, two junior residents, one nursing officer, and a registration staff was constituted. Fish bone analysis was done to understand various reasons for the high waiting time for preterm babies. Baseline data was collected followed by multiple Plan-Do-Study-Act (PDSA) cycles.Main outcome measuresAverage waiting-time, maximum waiting-time, and last baby entry-time were measured.ResultsThe median average waiting-time, maximum waiting-time and last baby entry-time at baseline were 90.5 min (range 74.1 to 118.8 min), 177.5 min (range 160 to 190 min) and 111 min (90 to 118 min), respectively. At the end of 3rd PDSA cycle, these reduced to 77.6 min (range 55.2 to 94.3 min), 122 min (range 110 to 135 min), and 60 min (range 45 to 80 min), respectively and were sustained; the decrease from baseline being 14.3%, 31.2%, and 46%, respectively.ConclusionThe time spent in the waiting area at the Retinopathy of Prematurity clinic was significantly reduced by simple changes in the process flow.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 373,Third Floor, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - SEP
PY  - 2018
VL  - 55
IS  - 9
SP  - 776
EP  - 779
DO  - 10.1007/s13312-018-1380-7
AN  - WOS:000445093300012
ER  -

TY  - JOUR
AU  - Chauhan, S
TI  - Severe acute respiratory distress syndrome: Does ECMO have a role?
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
AD  - All India Inst Med Sci, Dept Cardiac Anaesthesia, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - SEP-OCT
PY  - 2018
VL  - 31
IS  - 5
SP  - 287
EP  - +
DO  - 10.4103/0970-258X.261184
AN  - WOS:000473690700008
ER  -

TY  - JOUR
AU  - Deorari, A
AU  - Livesley, N
TI  - Delivering Quality Healthcare in India: Beginning of Improvement Journey
T2  - INDIAN PEDIATRICS
AD  - AIIMS, WHO Collaborating Ctr Educ & Res Newborn Care, Dept Pediat, New Delhi, IndiaAD  - Univ Res Co, USAID ASSIST Project, Bethesda, MD USAC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - SEP
PY  - 2018
VL  - 55
IS  - 9
SP  - 735
EP  - 737
DO  - 10.1007/s13312-018-1370-9
AN  - WOS:000445093300002
ER  -

TY  - JOUR
AU  - Devaraja, K
AU  - Sagar, P
AU  - Singh, CA
AU  - Kumar, R
TI  - Nondisseminated rhinosporidiosis with multisite involvement in the head and neck
T2  - ENT-EAR NOSE & THROAT JOURNAL
AB  - Rhinosporidiosis is a communicable disease prevalent in tropical countries that affects one or more mucocutaneous sites such as the nasal cavity, pharynx, skin, bronchus, genitals, and bone, in isolation or together. We report a case of multicentric rhinosporidiosis involving the nasal cavity, oropharynx, larynx, and cheek skin without disseminated disease outside the head and neck. Although the appearance of mucocutaneous lesions in our patient was similar to that of papilloma or neoplasm, the distinct clinicopathologic characteristics of the rhinosporidiosis guided us in managing the case successfully. In our own experience with 11 patients with rhinosporidiosis on whom we operated over the past 5 years, the nasal cavity and pharynx were the most commonly involved sites in the head and neck. Surgical excision of all lesions along with cauterization of the base and long-term dapsone therapy is the current standard of care for multicentric rhinosporidiosis.
AD  - Manipal Acad Higher Educ, Kasturba Med Coll, Dept Otorhinolaryngol & Head & Neck Surg, Manipal 576104, Karnataka, IndiaAD  - All India Inst Med Sci, Dept Otorhinolaryngol & Head & Neck Surg, New Delhi, IndiaC3  - Manipal Academy of Higher Education (MAHE)C3  - Kasturba Medical College, ManipalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SAGE PUBLICATIONS INC
PI  - THOUSAND OAKS
PA  - 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
DA  - SEP
PY  - 2018
VL  - 97
IS  - 9
SP  - E15
EP  - E17
AN  - WOS:000469030000004
ER  -

TY  - JOUR
AU  - Devnani, B
AU  - Kumar, R
AU  - Pathy, S
AU  - Phulware, RH
AU  - Mathur, S
AU  - Kumar, L
TI  - Cutaneous metastases from neuroendocrine carcinoma of the cervix-An unusual metastatic lesion from an uncommon malignancy
T2  - CURRENT PROBLEMS IN CANCER
KW  - Metastases
KW  - Neuroendocrine
KW  - Cervix
KW  - Cutaneous
KW  - SMALL-CELL CARCINOMA
AB  - Neuroendocrine carcinoma (NEC) is an uncommon and aggressive type of small cell cervical cancer. NECs mostly arise from gastro-entero-pancreatic tract and the lung, but rarely from other organs like cervix. NEC of the cervix is a rare malignancy and constitutes 0.9%-1.5% of cervical tumors. NECs of cervix are common in perimenopausal females and present with abnormal vaginal bleeding and mimic squamous cell cancers, usually with no distinguishing features. On Immunohistochemistry, presence of chromogranin, synaptophysin, and CD-56 is necessary to make a diagnosis of small cell carcinoma. These tumors are notorious for local as well as distant relapses in comparison to their squamous and adenocarcinoma counterpart. NECs are characterized by highly aggressive clinical behavior and carry a poor prognosis. They commonly metastases to lung, liver, brain, and bones even in early stages of the disease. Metastasis to skin is a rare occurrence. We herein report a case of a NEC of the uterine cervix with multiple cutaneous metastases. After the initial diagnosis of NEC of cervix, the patient received concurrent chemoradiation followed by intracavitary brachytherapy. On subsequent follow-up, the patient developed multiple cutaneous metastasis along with liver metastases. This case is reported in view of rarity of the case with skin metastases. To the best of our knowledge, only 3 cases of cutaneous metastases from NEC of the cervix are reported till date. Being a rare malignancy, evidence in the literature is in form of case reports and small case series. Thus, the optimal treatment strategy varies for these patients. Multimodality management with teamwork is necessary to manage individual patients. (C) 2018 Elsevier Inc. All rights reserved.
AD  - All India Inst Med Sci, Dept Radiotherapy, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Med Oncol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MOSBY-ELSEVIER
PI  - NEW YORK
PA  - 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - SEP-OCT
PY  - 2018
VL  - 42
IS  - 5
SP  - 527
EP  - 533
DO  - 10.1016/j.currproblcancer.2018.04.004
AN  - WOS:000454463600009
ER  -

TY  - JOUR
AU  - Dhiman, A
AU  - Haldar, S
AU  - Mishra, SK
AU  - Sharma, N
AU  - Bansal, A
AU  - Ahmad, Y
AU  - Kumar, A
AU  - Sharma, TK
AU  - Tyagi, JS
TI  - Generation and application of DNA aptamers against HspX for accurate diagnosis of tuberculous meningitis
T2  - TUBERCULOSIS
KW  - Aptamer
KW  - Mycobacterium tuberculosis
KW  - Detection
KW  - Aptamer linked immobilized sorbent assay
KW  - Tuberculous meningitis
KW  - MYCOBACTERIUM-TUBERCULOSIS
KW  - GENEXPERT MTB/RIF
KW  - NANOZYME ACTIVITY
KW  - SSDNA APTAMERS
KW  - SELEX
KW  - ANTIBODY
KW  - ANTIGEN
KW  - PROTEIN
KW  - ASSAY
KW  - OPTIMIZATION
AB  - Tuberculous meningitis (TBM) is the most severe manifestation of tuberculosis and its diagnosis remains a challenge even today due to the lack of an adequate test. HspX antigen of Mycobacterium tuberculosis was previously established as a reliable diagnostic biomarker for TBM in an ELISA test format using anti-HspX polyclonal antibodies. Towards overcoming the limitations of batch-to-batch variation and challenges of scalability in antibody generation, we utilized Systematic Evolution of Ligands by EXponential enrichment (SELEX) to develop high affinity DNA aptamers against HspX as an alternative diagnostic reagent. Post-SELEX optimization of the best-performing aptamer candidate, H63, established its derivative H63 SL-2 M6 to be superior to its parent. Aptamer H63 SL-2 M6 displayed a specific and high affinity interaction with HspX (K-d similar to 9.0x10(-8) M). In an Aptamer Linked Immobilized Sorbent Assay (ALISA), H63 SL-2 M6 significantly differentiated between cerebrospinal fluid specimens from TBM and non-TBM subjects (n = 87, *** p < 0.0001) with similar to 100% sensitivity and similar to 91% specificity. Notably, ALISA exhibited comparable performance with previously reported antibody-based ELISA and qPCR. Altogether, our findings establish the utility of HspX aptamer for the reliable diagnosis of TBM and pave the way for developing an aptamer-based point-of-care test for TBM.
AD  - AIIMS, Dept Biotechnol, New Delhi 110029, IndiaAD  - THSTI, Ctr Biodesign & Diagnost, Faridabad 121001, Haryana, IndiaAD  - Indian Inst Technol Indore, Discipline Biosci & Biomed Engn, Indore 453552, Madhya Pradesh, IndiaAD  - Dr Ram Manohar Lohia Hosp, Dept Biochem, New Delhi 110001, IndiaAD  - Dr Ram Manohar Lohia Hosp, Dept Pediat, New Delhi 110001, IndiaAD  - UTU, Fac Pharm, Dehra Dun 248007, Uttarakhand, IndiaAD  - AptaBharat Innovat Private Ltd, Translat Hlth Sci & Technol Inst Incubator, Faridabad 121001, Haryana, IndiaAD  - PGIMER, Dept Expt Med & Biotechnol, Sect 12, Chandigarh 160012, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)C3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - IndoreC3  - Uttarakhand Technical UniversityC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhPU  - CHURCHILL LIVINGSTONE
PI  - EDINBURGH
PA  - JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
DA  - SEP
PY  - 2018
VL  - 112
SP  - 27
EP  - 36
DO  - 10.1016/j.tube.2018.07.004
AN  - WOS:000443991700005
ER  -

TY  - JOUR
AU  - Dhiman, R
AU  - Meel, R
TI  - Giant Ocular Surface Squamous Neoplasia Wrapping the Whole Cornea
T2  - EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE
AD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, Ocuoplasty & Ocular Oncol Serv, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - SEP
PY  - 2018
VL  - 44
SP  - S374
EP  - S375
DO  - 10.1097/ICL.0000000000000473
AN  - WOS:000457837000074
ER  -

TY  - JOUR
AU  - Dhiman, R
AU  - Singh, D
AU  - Gantayala, SP
AU  - Ganesan, VL
AU  - Sharma, P
AU  - Saxena, R
TI  - Neuro-Ophthalmology at a Tertiary Eye Care Centre in India
T2  - JOURNAL OF NEURO-OPHTHALMOLOGY
KW  - TRAUMATIC OPTIC NEUROPATHY
AB  - Background: Neuro-ophthalmology as a specialty is under-developed in India. The aim of our study was to determine the spectrum and profile of patients presenting to a tertiary eye care center with neuro-ophthalmic disorders.
   Methods: A retrospective hospital-based study was conducted, and records of all patients seen at the neuro-ophthalmology clinic of Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India, over a 1-year period were retrieved and evaluated.
   Results: Of a total of 30,111 patients referred to various specialty clinics in a span of 1 year, 1597 (5%) were referred for neuro-ophthalmology evaluation. The mean patient age was 30.8 +/- 19.5 years, with a male dominance (M:F = 2.02: 1). Among these patients, optic nerve disorders were noted in 63.8% (n = 1,020), cranial nerve palsy in 7% (n = 114), cortical visual impairment in 6.5% (n = 105), and others (eye/optic nerve hypophasia, blepharospasm, and optic disc drusen) in 6% (n = 95). Among the patients with optic nerve disorders, optic neuropathy without disc edema/(traumatic optic neuropathy, hereditary, tumor-related, retrobulbar neuritis, toxic, and idiopathic) was noted in 42.8% (n = 685) and optic neuropathy with disc edema (ischemic optic neuropathy, papilledema, post-papilledema optic atrophy, papillitis, neuroretinitis, and inflammatory optic neuropathy) in 20.9% (n = 335). Sixteen percent of patients (n = 263) were incorrect referrals.
   Conclusion: The neuro-ophthalmic clinic constitutes a significant referral unit in a tertiary eye care center in India. Traumatic and ischemic optic neuropathies are the most common diagnoses. Neuro-ophthalmology requires further development as a subspecialty in India to better serve the nation's population.
AD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, Strabismus & Neuroophthalmol Serv, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - SEP
PY  - 2018
VL  - 38
IS  - 3
SP  - 308
EP  - 311
DO  - 10.1097/WNO.0000000000000586
AN  - WOS:000451239400009
ER  -

TY  - JOUR
AU  - Elavarasi, A
AU  - Goyal, V
AU  - Vishnu, V
AU  - Singh, MB
AU  - Srivastava, P
TI  - Chronic Inflammatory Demyelinating Polyneuropathy: A Case Series
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - CHALLENGES
AD  - All India Inst Med Sci, Dept Neurol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - SEP
PY  - 2018
VL  - 85
IS  - 9
SP  - 790
EP  - 791
DO  - 10.1007/s12098-017-536-5
AN  - WOS:000442536800016
ER  -

TY  - JOUR
AU  - Gupta, A
AU  - Kapil, R
AU  - Kapil, U
TI  - Reduction in prevalence of anaemia in pregnant women
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
AD  - Lady Irwin Coll, Dept Food & Nutr, Delhi 110001, IndiaAD  - All India Inst Med Sci, Dept Human Nutr, New Delhi 110029, IndiaAD  - Jawaharlal Nehru Med Coll, Dept Pathol, Belagavi 590010, Karnataka, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - K.L.E. Academy of Higher Education & ResearchPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - SEP
PY  - 2018
VL  - 148
IS  - 3
SP  - 345
EP  - +
DO  - 10.4103/ijmr.IJMR_1429_18
AN  - WOS:000450121500016
ER  -

TY  - JOUR
AU  - Gupta, M
AU  - Aggarwal, M
AU  - Bhari, N
TI  - Acneiform eruptions: An unusual dermatological side effect of ribavirin
T2  - DERMATOLOGIC THERAPY
KW  - acneiform eruptions
KW  - chronic hepatitis C
KW  - ribavirin
KW  - HEPATITIS-C
KW  - INFECTION
AD  - Maulana Azad Med Coll, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi, IndiaC3  - Maulana Azad Medical CollegeC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - SEP-OCT
PY  - 2018
VL  - 31
IS  - 5
C7  - e12679
DO  - 10.1111/dth.12679
AN  - WOS:000447276900030
ER  -

TY  - JOUR
AU  - Gupta, N
AU  - Vashist, P
AU  - Ganger, A
AU  - Tandon, R
AU  - Gupta, SK
TI  - Eye donation and eye banking in India
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
KW  - CORNEAL
KW  - POPULATION
KW  - AWARENESS
AB  - Corneal blindness is a priority condition under the National Programme for Control of Blindness and an important cause of avoidable blindness in India. A multipronged approach is needed to eliminate corneal blindness. Curable or treatable blindness requires a spectrum of care including medication, optical rehabilitation and corneal transplantation. Corneal transplantation is dependent on the availability of safe, donor eyes; however, there is scarcity of donor corneal tissues in India. To improve the eye banking system, the Government of India supports eye banks through recurring grants for operational costs and non-recurring grants for infrastructure costs. Strategic interventions by the government and non-governmental organizations include awareness by health promotion and education, community participation, sustainable source of donor cornea, quality medical standards, accreditation and endeavours to strengthen eye banking systems and procedures through training and research. A model eye banking system in India can be achieved only when it is linked with the targeted infrastructure proposed under 'Vision 2020: Right to SightIndia'. Considering these targets, there is a requirement of at least 20 eye bank training centres, 200 eye banks with corneal transplant facility (collection of nearly 500 corneas per year) and 2000 eye donation centres in the country. This would become a reality if the Hospital Cornea Retrieval Programme is strengthened at all private and government hospitals, uniform medical standards are made mandatory for all eye banks and eye donation centres and the process of registration and eye donation is simplified to enhance community participation.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Ctr Community Med, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - SEP-OCT
PY  - 2018
VL  - 31
IS  - 5
SP  - 283
EP  - 286
DO  - 10.4103/0970-258X.261189
AN  - WOS:000473690700007
ER  -

TY  - JOUR
AU  - Gupta, P
AU  - Singh, J
AU  - Mahapatra, A
AU  - Sharan, P
TI  - Tacrolimus-associated mania with psychotic symptoms in a child after renal transplant
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
KW  - FKBP5
AB  - Tacrolimus is one of the mainstays for post-transplant immunosuppression. A variety of neuropsychiatric adverse effects have been reported above the levels of its therapeutic use. Manic symptoms associated with its use have been rarely reported. We report possibly the first such case in a child post-renal transplantation and discuss the potential neuro-immunological basis of these symptoms.
AD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - SEP-OCT
PY  - 2018
VL  - 31
IS  - 5
SP  - 281
EP  - 282
DO  - 10.4103/0970-258X.261183
AN  - WOS:000473690700006
ER  -

TY  - JOUR
AU  - Gupta, P
AU  - Parshad, R
AU  - Balakrishna, P
AU  - Saraya, A
AU  - Makharia, GK
AU  - Sachdeva, S
AU  - Sharma, R
TI  - Angle of His Accentuation Is a Viable Alternative to Dor Fundoplication as an Adjunct to Laparoscopic Heller Cardiomyotomy: Results of a Randomized Clinical Study
T2  - DIGESTIVE DISEASES AND SCIENCES
KW  - Achalasia
KW  - Laparoscopic Heller cardiomyotomy
KW  - Angle of his accentuation
KW  - Dor fundoplication
KW  - Achalasia-specific quality of life
KW  - QUALITY-OF-LIFE
KW  - FOLLOW-UP
KW  - ANTERIOR FUNDOPLICATION
KW  - GASTROESOPHAGEAL-REFLUX
KW  - NISSEN FUNDOPLICATION
KW  - PNEUMATIC DILATION
KW  - CONTROLLED-TRIAL
KW  - ACHALASIA
KW  - MYOTOMY
KW  - ESOPHAGOMYOTOMY
AB  - Background There is no consensus regarding the type of anti-reflux procedure to be used as an adjunct to laparoscopic Heller cardiomyotomy (LHCM). The aim of this study was to compare Angle of His accentuation (AOH) with Dor Fundoplication (Dor) as an adjunct to LHCM.
   Methods A total of 110 patients with achalasia cardia presenting for LHCM from March 2010 to July 2015 were randomized to Dor and AOH. Symptom severity, achalasia-specific quality of life (ASQOL), new onset heartburn, and patient satisfaction were assessed using standardized scores preoperatively, at 3, 6 months, and then yearly. The primary outcome was relief of esophageal symptoms while secondary outcomes were new onset heartburn and ASQOL.
   Results Both groups were comparable with respect to the baseline demographic characteristics. There was no conversion to open and no mortality in either group. Median operative time was 128 min in AOH and 144 min in Dor group (p < 0.01). Mean follow-up was 36 months and was available in 98% patients. There was significant improvement in esophageal symptoms in both groups with no statistically significant difference between the two groups (p > 0.05). There was no difference in cumulative symptom scores between the two groups over the period of follow-up. New onset heartburn was seen in 11% in AOH and 9% in Dor group. Mean ASQOL score improved in both groups with no difference between the two groups (p = 0.83). Patient satisfaction was similar in both groups.
   Conclusion AOH is similar to Dor as an adjunct to LHCM in safety and efficacy and can be performed in shorter time.
AD  - AIIMS, Dept Surg Disciplines, Delhi, IndiaAD  - AIIMS, Dept Gastroenterol, Delhi, IndiaAD  - GB Pant Hosp, Dept Gastroenterol, Delhi, IndiaAD  - AIIMS, Dept Radiodiag, Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Govind Ballabh Pant Institute of Postgraduate Medical Education & ResearchC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - SEP
PY  - 2018
VL  - 63
IS  - 9
SP  - 2395
EP  - 2404
DO  - 10.1007/s10620-018-5130-4
AN  - WOS:000441941000032
ER  -

TY  - JOUR
AU  - Gupta, RK
AU  - Batra, VV
AU  - Singh, D
AU  - Sharma, MC
AU  - Kumar, V
TI  - Is spindle cell oncocytoma a true entity or a variant of pituicytoma? A case report with review of literature
T2  - NEUROLOGY INDIA
KW  - Folliculo-stellate cell
KW  - pituicyte
KW  - pituitary
KW  - spindle cell oncocytoma
KW  - TTF-1
KW  - OF-THE-LITERATURE
KW  - ADENOHYPOPHYSIS REPORT
KW  - TUMOR
KW  - PITUITARY
KW  - RECURRENCE
AB  - Spindle cell oncocytoma (SCO) is a newly described rare entity simulating clinicoradiological features of a nonfunctional pituitary adenoma and is corresponding to the category of World Health Organization grade I tumor. However, because of the reported incidence of recurrence and invasive presentation in some cases, its categorization as a low grade tumor is questionable. Earlier, it was thought to arise from the folliculostellate cells of adenohypophysis. Recently, few reports have described expression of thyroid transcription factor-1 [TTF-1], which is a specific marker for pituicytes of neurohypophysis, suggesting this tumor to be a variant of pituicytoma. We describe a case of SCO in a 28-year-old young female patient with TTF-1 immunopositivity, and ultra-structurally showing abundant mitochondria along with few neurosecretory granules.
AD  - GB Pant Inst Postgrad Med Educ & Res, Dept Pathol, Jawahar Lal Nehru Marg, New Delhi 110002, IndiaAD  - GB Pant Inst Postgrad Med Educ & Res, Dept Neurosurg, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - Govind Ballabh Pant Institute of Postgraduate Medical Education & ResearchC3  - Govind Ballabh Pant Institute of Postgraduate Medical Education & ResearchC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - SEP-OCT
PY  - 2018
VL  - 66
IS  - 5
SP  - 1413
EP  - 1418
DO  - 10.4103/0028-3886.241353
AN  - WOS:000447605100038
ER  -

TY  - JOUR
AU  - Gupta, R
AU  - Dahiya, M
AU  - Kumar, L
AU  - Shekhar, V
AU  - Sharma, A
AU  - Ramakrishnan, L
AU  - Sharma, OD
AU  - Begum, A
TI  - Prevalence of Monoclonal Gammopathy of Undetermined Significance in India-A Hospital-based Study
T2  - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
KW  - Cancer screening
KW  - Incidental myeloma
KW  - MGUS
KW  - M-protein
KW  - Prevalence in India
KW  - PRECEDES MULTIPLE-MYELOMA
KW  - SIGNIFICANCE MGUS
KW  - LONG-TERM
KW  - RISK
KW  - POPULATION
KW  - PROGRESSION
KW  - MANAGEMENT
KW  - DIAGNOSIS
KW  - EXPOSURE
KW  - CRITERIA
AB  - A cross-sectional hospital-based study was undertaken during a 3-month period to ascertain the prevalence of monoclonal gammopathy of undetermined significance (MGUS) in North India. Of the 3429 patients evaluated, MGUS was detected in 49 (1.43%) and multiple myeloma (MM) in 6 (0.17%). To the best of our knowledge, the present study is the first systematic study of the prevalence of MGUS in an Indian population. Our results highlight the relatively low incidence of MGUS in Indians compared with that in white and black populations. The incidental detection of MM in our study points to the need for creating awareness regarding myeloma-related symptoms in appropriate age groups.
   Background: We sought to determine the prevalence of monoclonal gammopathy of undetermined significance (MGUS) in a hospital-based cohort in India. Patients and Methods: From March 2015 to May 2015, 3429 patients (age range, 40-88 years) were enrolled in the present study. Of the 3429 enrolled patients, 2354 (68.6%) were men and 1075 (31.4%) were women. Serum samples were collected from all patients and analyzed using serum protein electrophoresis (SPEP). The positive SPEP samples were subjected to immunofixation. The patients with positive results for both SPEP and immunofixation were registered in the oncology department and investigated further for plasma cell dyscrasias. Results: Of the 3429 study patients, 49 (1.43%) were found to have MGUS, and multiple myeloma was diagnosed in another 6 (0.17%). The prevalence rate of MGUS in patients aged 40 to 49, 50 to 59, 60 to 69, and 70 to 80 years was 0.83%, 1%, 2.62%, and 1.75%, respectively. Of the 49 MGUS patients, 5 (10.2%) were in the high-intermediate risk category using the Mayo Clinic criteria for risk stratification. At 30 months of follow-up, 1 patient in the high-intermediate category had developed multiple myeloma. Conclusion: To the best of our knowledge, the present study is the first systematic study on the prevalence of MGUS in an Indian population. The overall prevalence of MGUS was 1.43% in the evaluated Indian cohort, lower than that reported for white and black populations. The incidental detection of 6 subjects with multiple myeloma of 3429 screened subjects in our study was high compared with the reported incidence of multiple myeloma in India of only 1.9 per 100,000 persons. This finding indicates the need to create awareness about myeloma-related symptoms and screening studies in appropriate age groups, at least in the hospital-based setting. (C) 2018 Elsevier Inc. All rights reserved.
AD  - All India Inst Med Sci, Dr BRA Inst Rotary Canc Hosp, Lab Oncol Unit, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dr BRA Inst Rotary Canc Hosp, Dept Med Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Cardiac Biochem, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - CIG MEDIA GROUP, LP
PI  - DALLAS
PA  - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
DA  - SEP
PY  - 2018
VL  - 18
IS  - 9
SP  - E345
EP  - E350
DO  - 10.1016/j.clml.2018.06.005
AN  - WOS:000441579300002
ER  -

TY  - JOUR
AU  - Gupta, SK
AU  - Kothari, SS
AU  - Ramakrishnan, S
AU  - Saxena, A
TI  - Large Ventricular Septal Defect and Coexisting Chronic Constrictive Pericarditis: "Reversible Eisenmenger Syndrome"-5 Years After Corrective Surgery
T2  - CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
KW  - HEMODYNAMICS
KW  - HYPERTENSION
AD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - SEP 1
PY  - 2018
VL  - 92
IS  - 3
SP  - E210
EP  - E211
DO  - 10.1002/ccd.27028
AN  - WOS:000447198600012
ER  -

TY  - JOUR
AU  - Gupta, VG
AU  - Gogia, A
AU  - Sharma, V
AU  - Mallick, S
TI  - Lymphomatoid Granulomatosis with Isolated Cutaneous Lesions: Prolonged Remission After DA-EPOCH Protocol
T2  - TURKISH JOURNAL OF HEMATOLOGY
KW  - Lymphomatoid granulomatosis
KW  - Remission
KW  - Chemotherapy
KW  - INVOLVEMENT
AD  - Max Super Special Hosp, Clin Med Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Med Oncol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - GALENOS YAYINCILIK
PI  - FINDIKZADE
PA  - ERKAN MOR, MOLLA GURANI CAD 21-1, FINDIKZADE, ISTANBUL 34093, TURKEY
DA  - SEP
PY  - 2018
VL  - 35
IS  - 3
SP  - 213
EP  - 214
DO  - 10.4274/tjh.2018.0020
AN  - WOS:000440491800018
ER  -

TY  - JOUR
AU  - Jain, D
AU  - Roy-Chowdhuri, S
TI  - Molecular Pathology of Lung Cancer Cytology Specimens A Concise Review
T2  - ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
KW  - CIRCULATING TUMOR-CELLS
KW  - LIQUID-BASED CYTOLOGY
KW  - TRANSTHORACIC NEEDLE ASPIRATION
KW  - MUTATION DETECTION
KW  - EGFR MUTATIONS
KW  - DNA YIELD
KW  - DIAGNOSIS
KW  - SMEARS
KW  - CYTOPATHOLOGY
KW  - SAMPLES
AB  - Context.-There has been a paradigm shift in the understanding of molecular pathogenesis of lung cancer. A number of oncogenic drivers have been identified in non-small cell lung carcinoma, such as the epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) gene rearrangement. Because of the clinical presentation at an advanced stage of disease in non-small cell lung carcinoma patients, the use of minimally invasive techniques is preferred to obtain a tumor sample for diagnosis. These techniques include image-guided biopsies and fine-needle aspirations, and frequently the cytology specimen may be the only tissue sample available for the diagnosis and molecular testing for these patients.
   Objective.-To review the current literature and evaluate the role of cytology specimens in lung cancer mutation testing. We reviewed the types of specimens received in the laboratory, specimen processing, the effect of preanalytic factors on downstream molecular studies, and the commonly used molecular techniques for biomarker testing in lung cancer.
   Data Sources.-PubMed and Google search engines were used to review the published literature on the topic.
   Conclusions.-Mutation testing is feasible on a variety of cytologic specimen types and preparations. However, a thorough understanding of the cytology workflow for the processing of samples and appropriate background knowledge of the molecular tests are necessary for triaging, and optimum use of these specimens is necessary to guide patient management.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - Univ Texas MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med, 1515 Holcombe Blvd,Unit 85, Houston, TX 77030 USAC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of Texas SystemC3  - UTMD Anderson Cancer CenterPU  - COLL AMER PATHOLOGISTS
PI  - NORTHFIELD
PA  - C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA
DA  - SEP
PY  - 2018
VL  - 142
IS  - 9
SP  - 1127
EP  - 1133
DO  - 10.5858/arpa.2017-0444-RA
AN  - WOS:000442630100015
ER  -

TY  - JOUR
AU  - Jain, V
AU  - Jana, M
AU  - Upadhyay, B
AU  - Ahmad, N
AU  - Jain, O
AU  - Upadhyay, AD
AU  - Ramakrishnan, L
AU  - Vikram, NK
TI  - Prevalence, clinical & biochemical correlates of non-alcoholic fatty liver disease in overweight adolescents
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
KW  - Abdominal obesity
KW  - alanine aminotransferase
KW  - body fat percentage
KW  - insulin resistance
KW  - steatohepatitis
KW  - childhood obesity
KW  - WAIST CIRCUMFERENCE PERCENTILES
KW  - METABOLIC SYNDROME
KW  - INSULIN-RESISTANCE
KW  - CHILDREN
KW  - ASSOCIATION
KW  - AMERICAN
KW  - INDIANS
KW  - OBESITY
AB  - Background & objectives: Non-alcoholic fatty liver disease (NAFLD) characterized by excessive accumulation of fat in the liver, which can progress to inflammation, and cirrhosis, has emerged as an important complication of obesity in adults as well as children. This study was undertaken to assess the prevalence of NAFLD and its correlation with clinical and biochemical parameters in overweight Indian adolescents.
   Methods: In this cross-sectional study, 218 overweight adolescents aged 10 to 16 yr and their parents were included. Measurements included anthropometry, ultrasonography to diagnose NAFLD, fasting glucose, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and lipids for adolescents and parents, and additional parameters of blood pressure, body fat percentage (BF%), fasting insulin, apolipoprotein C3, tumour necrosis factor-alpha and adiponectin for adolescents. The variables were compared between adolescents with and without NAFLD, and logistic regression analysis was performed.
   Results: Mean age and body mass index (BMI)SD score (SDS) were 11.9 +/- 1.6 yr and 2.3 +/- 1.1, respectively. NAFLD was seen in 62.5 per cent of the adolescents. The prevalence of NAFLD in the parents was similar among the adolescents with and without NAFLD, while BMI and waist circumference SDS, BF per cent, blood pressure (BP), ALT, AST, insulin and homeostatic model assessment of insulin resistance (HOMA-IR) were significantly higher in the adolescents with NAFLD. On multiple logistic regression, abdominal obesity, HOMA-IR and BF per cent were independently associated with NAFLD with odds ratios (95% confidence interval) of 2.77 (1.40-5.47), 2.21 (1.16-4.21) and 2.17 (1.12-4.22), respectively.
   Interpretation & conclusions: NAFLD was noted among nearly two-thirds of the overweight adolescents. An independent association was observed between abdominal obesity, HOMA-IR and body fat percentage and NAFLD in overweight adolescents.
AD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Cardiac Biochem, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Med, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
DA  - SEP
PY  - 2018
VL  - 148
IS  - 3
SP  - 291
EP  - 301
C7  - PMID 30425219
DO  - 10.4103/ijmr.IJMR_1966_16
AN  - WOS:000450121500008
ER  -

TY  - JOUR
AU  - Jana, M
AU  - Gupta, AK
TI  - Expanding Applications of Prenatal MR Imaging: Detection of Complex Multisystem Anomalies Made Easy
T2  - INDIAN JOURNAL OF PEDIATRICS
AD  - All India Inst Med Sci, Dept Radiodiag, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - SEP
PY  - 2018
VL  - 85
IS  - 9
SP  - 716
EP  - 717
DO  - 10.1007/s12098-018-2726-9
AN  - WOS:000442536800003
ER  -

TY  - JOUR
AU  - Jassi, R
AU  - Burman, KD
AU  - Swarnkar, B
AU  - Agarwal, R
TI  - Identical twins with borderline lepromatous leprosy mimicking extensive alopecia areata: A rare presentation
T2  - LEPROSY REVIEW
KW  - identical twins
KW  - leprosy
KW  - alopecia
KW  - contacts of leprosy
AB  - Nineteen-year old identical female twins presented with complaints of progressive hair loss all over the body, sparing the scalp, axillae and pubic region along with a few atrophic scars on the knees, thighs and elbows. A possible diagnosis of atypical presentation of alopecia areata was made. However, in view of history of borderline tuberculoid leprosy in their younger sibling, a complete examination for leprosy was done. There was asymmetrical enlargement of multiple peripheral nerves without any sensory or motor loss. Histopathology confirms the diagnosis of BL Hansens. Such a presentation of leprosy in identical twins is not reported in literature.
AD  - All India Inst Med Sci, New Delhi, IndiaAD  - Maulana Azad Med Coll, Bahadur Shah Zafar Rd, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Maulana Azad Medical CollegePU  - LEPRA
PI  - COLCHESTER
PA  - 28 MIDDLEBOROUGH, COLCHESTER CO1 1TG, ESSEX, ENGLAND
DA  - SEP
PY  - 2018
VL  - 89
IS  - 3
SP  - 301
EP  - 305
AN  - WOS:000452250000013
ER  -

TY  - JOUR
AU  - Jha, P
AU  - Arora, G
AU  - Shamim, SA
AU  - Mukherjee, A
AU  - Gautam, D
AU  - Ballal, S
AU  - Kumar, U
AU  - Ansari, TM
AU  - Bal, C
TI  - Lutetium-177 tin colloid radiosynovectomy in patients with inflammatory knee joint conditions intractable to prevailing therapy
T2  - NUCLEAR MEDICINE COMMUNICATIONS
KW  - lutetium
KW  - radiosynovectomy
KW  - tin colloid
KW  - RADIATION SYNOVECTOMY
KW  - SYNOVITIS
KW  - INJECTION
KW  - Y-90
AB  - ObjectiveTo evaluate the treatment response of lutetium-177 tin colloid radiosynovectomy (Lu-177-RSV) in patients with inflammatory knee joint conditions refractory to conventional treatment.Patients and methodsOverall, 29 knee joints in 29 patients with chronic synovitis caused by various inflammatory knee joint diseases refractory to conventional therapy were included in this prospective study. All patients were assessed clinically for pain, tenderness, joint swelling, mobility, analgesic intake, and blood pool activity on bone scan. Different scores were assigned to all these parameters. RSV of knee joint was done using intra-articular injection of Lu-177 tin colloid. Response was assessed at 3 months using various clinical parameter scores and blood pool bone scan as mentioned before and categorized as responders and nonresponders on the basis of change in percentage of cumulative scores.ResultsOf the 29 joints, 21 were responders and eight were nonresponders at 3 months after RSV. There was a statistically significant reduction in clinical parameters cumulative scores at follow-up when compared with baseline (P<0.0001). Blood pool scintigraphy also showed decrease in blood pool activity compared with the baseline. There was statistically significant association between the responder group and absence of radiological abnormality.Conclusion(177)Lu tin colloid synovectomy is a useful treatment modality in patients with chronic inflammatory knee joint conditions refractory to conventional treatment. Patients with shorter duration of disease and normal or minor radiographic findings are better candidates for RSV.
AD  - AIIMS, Dept Nucl Med, New Delhi 110029, IndiaAD  - AIIMS, Dept Orthopaed, New Delhi, IndiaAD  - AIIMS, Dept Med, New Delhi, IndiaAD  - Eastern Diagnost, Dept Nucl Med, Kolkata, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - SEP
PY  - 2018
VL  - 39
IS  - 9
SP  - 803
EP  - 808
DO  - 10.1097/MNM.0000000000000871
AN  - WOS:000442508600001
ER  -

TY  - JOUR
AU  - Joshi, M
AU  - Sahoo, T
AU  - Thukral, A
AU  - Joshi, P
AU  - Sethi, A
AU  - Agarwal, R
TI  - Improving Duration of Kangaroo Mother Care in a Tertiary-care Neonatal Unit : A Quality Improvement Initiative
T2  - INDIAN PEDIATRICS
KW  - Breastfeeding
KW  - Neonate
KW  - Skin-to-skin contact
KW  - Survival
AB  - ObjectivesTo increase the duration of Kangaroo mother care (KMC) in preterm infants from an average of 3 hours/day to at least 6 hours/day over 7 weeks through a Quality improvement (QI) approach in a tertiary-care neonatal unit.MethodsPreterm mother-infant dyads who were admitted in the Neonatal intensive care unit and KMC ward were enrolled in this study. A QI team comprising of nurses, nurse educators, resident physicians and nursing-in-charge of unit was formed. The potential barriers for prolonged KMC were evaluated using fish bone analysis. A variety of measures (allowing family members including male members during night for doing KMC, making KMC an integral part of treatment order, introducing the concept of weekly KMC champions, etc.) were introduced and subsequently tested by multiple Plan-do-study-act (PDSA) cycles. Data on duration of KMC per day was measured by bedside nurses on daily basis.Results20 eligible mother-infant dyads were studied during implementation period (50 d). The mean (SD) weight and gestation of infants were 1199 (356) g and 31.1 ( 2.3) wks, respectively. We achieved our goal by step-wise implementation of changes through construction of 3 PDSA cycles. The duration of KMC increased to 6 hours-a-day over a period of 7 weeks. Evaluation at 6 and 12 months in the post-implementation phase suggested sustenance of improved KMC duration up to 9 h/day in the unit.ConclusionsOngoing quality improvement measures increased the duration of KMC from a baseline of 3 h to 6 h in eligible preterm infants, and the results were sustained at 6-12 month.
AD  - All India Inst Med Sci, Coll Nursing, New Delhi, IndiaAD  - All India Inst Med Sci, Div Neonatol, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - SEP
PY  - 2018
VL  - 55
IS  - 9
SP  - 744
EP  - 747
DO  - 10.1007/s13312-018-1372-7
AN  - WOS:000445093300004
ER  -

TY  - JOUR
AU  - Kalra, S
AU  - Gupta, Y
TI  - Osteovigilance in diabetes
T2  - JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION
KW  - Calcium
KW  - Fracture risk
KW  - Osteoporosis
KW  - Type 1 diabetes
KW  - Type2 diabetes
KW  - Vitamin D deficiency
KW  - BONE-MINERAL DENSITY
KW  - MANAGEMENT
KW  - OSTEOPOROSIS
KW  - ASSOCIATION
KW  - STATEMENT
AB  - Osteovigilance is a state of clinical suspicion for abnormalities of bone and mineral metabolism, including efforts to optimize bone mineral health. In this article, we discuss various factors which contribute to coexistence of diabetes and bone mineral disease, the risk factors that they share, and iatrogenic and therapeutic considerations of importance. We highlight the need to practice osteovigilance as an integral part of diabetes management.
AD  - Bharti Hosp, Dept Endocrinol, Karnal, IndiaAD  - AIIMS, Dept Endocrinol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - PAKISTAN MEDICAL ASSOC
PI  - KARACHI
PA  - PMA HOUSE, AGA KHAN III RD, KARACHI, 00000, PAKISTAN
DA  - SEP
PY  - 2018
VL  - 68
IS  - 9
SP  - 1410
EP  - 1411
AN  - WOS:000444097000028
ER  -

TY  - JOUR
AU  - Kanwat, H
AU  - Trikha, V
AU  - Mittal, S
AU  - Jain, A
TI  - Risk Factors Associated With Cephalomedullary Nail Cutout in the Treatment of Trochanteric Hip Fractures
T2  - JOURNAL OF ORTHOPAEDIC TRAUMA
AD  - AIIMS, Dept Orthopaed, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - SEP
PY  - 2018
VL  - 32
IS  - 9
SP  - E385
EP  - E386
DO  - 10.1097/BOT.0000000000001272
AN  - WOS:000451356800010
ER  -

TY  - JOUR
AU  - Katwa, U
AU  - Kabra, SK
TI  - Advances in Management of Asthma
T2  - INDIAN JOURNAL OF PEDIATRICS
AD  - Harvard Univ, Boston Childrens Hosp, Sleep Lab Attending Pulm & Sleep Med, Boston, MA 02115 USAAD  - All India Inst Med Sci, Dept Pediat, New Delhi 110029, IndiaC3  - Harvard UniversityC3  - Boston Children's HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - SEP
PY  - 2018
VL  - 85
IS  - 9
SP  - 746
EP  - 747
DO  - 10.1007/s12098-018-2748-3
AN  - WOS:000442536800008
ER  -

TY  - JOUR
AU  - Kaur, A
AU  - Das, R
AU  - Nigam, MR
AU  - Elangovan, R
AU  - Pandya, D
AU  - Jha, S
AU  - Kalyanasundaram, D
TI  - Rapid Detection Device for <i>Salmonella typhi</i> in Milk, Juice, Water and Calf Serum
T2  - INDIAN JOURNAL OF MICROBIOLOGY
KW  - Salmonella typhi
KW  - Loop-mediated isothermal amplification (LAMP)
KW  - Optical detection
KW  - Milk
KW  - Raw/unprocessed milk
KW  - Fruit juice
KW  - Tap water
KW  - Turbid water
KW  - Calf serum
KW  - Rapid detection
KW  - MEDIATED ISOTHERMAL AMPLIFICATION
KW  - GOLD NANOPARTICLES
KW  - ASSAY
KW  - LAMP
KW  - BIOMARKERS
AB  - A limit of detection of 200 CFU/mL of Salmonella typhi spiked in various sample matrices were achieved in 30 min. The sample matrices were raw/unprocessed milk, commercially available milk, juice from packed bottles, fresh juice from carts, potable water, turbid water and calf serum. The complete protocol comprised of three steps: (a) cell lysis (b) nucleic acid amplification and (c) an in situ optical detection. The cell lysis was carried out using a simple heating based protocol, while the loop-mediated isothermal amplification of DNA was carried out by an in-house designed and fabricated system. The developed system consists of an aluminum block fitted with two cartridge heaters along with a thermocouple. The system was coupled to a light source and spectrometer for a simultaneous in situ detection. Primers specific for STY2879 gene were used to amplify the nucleic acid sequence, isolated from S. typhi cells. The protocol involves 15 min of cell lysis and DNA isolation followed by 15 min for isothermal amplification and simultaneous detection. No cross-reactivity of the primers were observed at 10(6) CFU/mL of Escherichia coli, Vibrio cholerae, Salmonella typhimurium, Salmonella paratyphi A, Pseudomonas aeruginosa, Bacillus cereus, Lysteria monocytogenes, Clostridium botulinum, Staphylococcus aureus and Salmonella havana. In addition, the system was able to detect S. typhi of 200 CFU/mL in a concoction of 10(6) CFU/mL of E. coli, 10(6) CFU/mL of V. cholerae, and 10(6) CFU/mL of hepatocyte-derived cellular carcinoma HUH7 cells. The proposed rapid diagnostic system shows a promising future in the field of food and medical diagnostics.
AD  - Indian Inst Technol Delhi, Ctr Biomed Engn, Device Testing Lab, New Delhi 110016, IndiaAD  - Indian Inst Technol Delhi, Dept Biochem & Biotechnol, New Delhi 110016, IndiaAD  - AmpliGene India Biotech Private Ltd, Ahmadabad, Gujarat, IndiaAD  - Indian Inst Technol Delhi, Ctr Biomed Engn, Lab On A Chip & Biosensors Lab, New Delhi 110016, IndiaAD  - All India Inst Med Sci, Dept Biomed Engn, New Delhi 110029, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - SEP
PY  - 2018
VL  - 58
IS  - 3
SP  - 381
EP  - 392
DO  - 10.1007/s12088-018-0730-4
AN  - WOS:000436819400015
ER  -

TY  - JOUR
AU  - Khandelwal, M
AU  - Anand, V
AU  - Appunni, S
AU  - Seth, A
AU  - Singh, P
AU  - Mathur, S
AU  - Sharma, A
TI  - Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A
T2  - MOLECULAR AND CELLULAR BIOCHEMISTRY
KW  - Urinary bladder cancer
KW  - RASSF1A
KW  - Hippo pathway
KW  - CTGF, CYR61, Chemosensitivity
KW  - Cytotoxicity
KW  - DRUG-RESISTANCE
KW  - UROTHELIAL CARCINOMA
KW  - CHEMOTHERAPY
KW  - METHYLATION
KW  - PROLIFERATION
KW  - EXPRESSION
KW  - PROMOTER
KW  - YAP
AB  - Genetic abnormalities and epigenetic alterations both play vital role in initiation as well as progression of cancer. Whereas genetic mutations cannot be reversed, epigenetic alterations such as DNA methylation can be reversed by the application of DNA methyltransferase inhibitor decitabine. Epigenetic silencing of RASSF1A and involvement of hippo pathway both have been shown to involve in chemo-resistance. Purpose of this study was to observe the effect of combination treatment of decitabine with cisplatin or doxorubicin on bladder cancer cells involving hippo pathway through RASSF1A. Bladder cancer cells (HT1376 & T24) were treated with decitabine and its effect on RASSF1A expression, hippo pathway molecules (MST & YAP), and its downstream targets (CTGF, CYR61 & CTGF) was observed. Effect of decitabine pretreatment on sensitivity of bladder cancer cells towards chemotherapeutic drugs was also studied. Decitabine treatment leads to restoration of RASSF1A, activation of hippo pathway followed by decreased expression of its oncogenic downstream targets (CTGF & CYR61). Further pretreatment of decitabine enhanced cytotoxicity of cisplatin and doxorubicin to bladder cancer cells.
AD  - AIIMS, Dept Biochem, New Delhi, IndiaAD  - AIIMS, Dept Urol, New Delhi, IndiaAD  - Aiims, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - SEP
PY  - 2018
VL  - 446
IS  - 1-2
SP  - 105
EP  - 114
DO  - 10.1007/s11010-018-3278-z
AN  - WOS:000440595700011
ER  -

TY  - JOUR
AU  - Khokhar, S
AU  - Dhull, C
AU  - Mahalingam, K
AU  - Agarwal, P
TI  - Posterior lenticonus with persistent fetal vasculature
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Congenital cataract
KW  - persistant fetal vasculature
KW  - PFV
KW  - posterior lenticonus
KW  - INTRAOCULAR-LENS IMPLANTATION
AB  - A 10 year old girl present with both eyes central cataract with posterior lenticonus. Intraoperative, she was noted to have both eyes persistent fetal vasculature (PFV). To the best of our knowledge, association of bilateral posterior lenticonus and PFV has not been reported before. This supports the hypothesis that PFV has a role in pathogenesis of posterior lenticonus.
AD  - AIIMS, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - SEP
PY  - 2018
VL  - 66
IS  - 9
SP  - 1335
EP  - 1336
DO  - 10.4103/ijo.IJO_276_18
AN  - WOS:000442780400034
ER  -

TY  - JOUR
AU  - Khurana, S
AU  - Kumari, M
AU  - Bhardwaj, N
AU  - Kumar, S
AU  - Sagar, S
AU  - Malhotra, R
AU  - Mathur, P
TI  - T-helper-17, Regulatory T-helper Cells Related Serum Markers and IL-13 in the Outcome of Polytraumatic Patients with Bacteremia
T2  - IRANIAN JOURNAL OF IMMUNOLOGY
KW  - Anti-inflammatory
KW  - Cytokine
KW  - Pro-inflammatory
KW  - Sepsis
KW  - Trauma
KW  - Antimicrobials
KW  - SEPSIS
AB  - Background: Bacteremia and sepsis are associated with high mortality, increased hospital stays, and associated costs, especially in trauma patients. Sepsis is a fatal immunological disorder and its pathophysiology is still poorly understood. Objective: To ascertain the role of T-helper lymphocyte-related inflammatory serum cytokines in trauma patients with blood culture positive with Gram-negative bacteria. Methods: Peripheral blood samples (5 ml) were collected from 40 trauma patients on the day of obtaining positive blood culture (i.e., day 0), followed by an appropriate antimicrobial treatment and sample acquisition on day 4 and only once from 40 age-matched healthy controls. Bead-based cytometric analysis was used to quantify extracellular levels of 16 serum cytokines. The cytokine profiles were compared with those in healthy controls and then correlated to clinical outcomes. Results: A total of 40 patients were enrolled during the study period. Of these, 24 patients (60%) were discharged while 16 (40%) had a fatal outcome. Statistically significant elevated levels of serum IL-6, IFN-gamma, TNF-alpha, IL-17A, IL-17F, and IL-4 were observed in septic patients, while lowered IL-13 levels correlated significantly with a favorable outcome. Conclusion: Sepsis following trauma elicits a heightened immune response in the body and provokes the production of a diverse array of cytokines that is both pro-inflammatory and anti-inflammatory. However, the unique cytokine profile of septic trauma patients is still not well understood.
AD  - All India Inst Med Sci, Jai Prakash Narayan Apex Trauma Ctr, Dept Lab Med, New Delhi, IndiaAD  - All India Inst Med Sci, Jai Prakash Narayan Apex Trauma Ctr, Div Trauma Surg & Crit Care, New Delhi, IndiaAD  - All India Inst Med Sci, Jai Prakash Narayan Apex Trauma Ctr, Dept Surg, New Delhi, IndiaAD  - All India Inst Med Sci, Jai Prakash Narayan Apex Trauma Ctr, Dept Orthopaed, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterPU  - SHIRAZ INST CANCER RES
PI  - SHIRAZ
PA  - SHIRAZ UNIV MED SCI, IRANIAN SOC IMMUNOL & ALLERGY, PO BOX 71345-3119, SHIRAZ, 00000, IRAN
DA  - FAL
PY  - 2018
VL  - 15
IS  - 4
SP  - 302
EP  - 308
AN  - WOS:000454542900005
ER  -

TY  - JOUR
AU  - Konanki, R
AU  - Gulati, S
AU  - Prasad, K
AU  - Saini, L
AU  - Pandey, RM
AU  - Paul, VK
TI  - Comparison of telephone with face to face consultation for follow up of Neurocysticercosis
T2  - EPILEPSY RESEARCH
KW  - Neurocysticercosis
KW  - Telemedicine
KW  - Teleneurology
KW  - Telephone
KW  - Seizures
KW  - Epilepsy
KW  - RANDOMIZED CONTROLLED TRIAL
KW  - EPILEPSY
KW  - TELEMEDICINE
KW  - ALBENDAZOLE
KW  - SEIZURES
KW  - COST
KW  - CARE
KW  - CHILDREN
KW  - THERAPY
KW  - LESIONS
AB  - Objectives: There is significant scarcity of specialists to provide care for children with epilepsy in many parts of the world. Telemedicine is a potential future option. This study was planned to estimate the diagnostic accuracy of telephone consultation to identify Critical Clinical Events (breakthrough seizures, drug non-compliance, drug adverse events, features of raised intracranial pressure, and other disease-related events),compared to the Faceto-Face consultation (gold standard), in children with Neurocysticercosis (NCC) and symptomatic seizures, following the completion of cysticidal therapy.
   Methods: Children aged 2-15 years attending a tertiary health care facility with a diagnosis of NCC and symptomatic seizures were enrolled after completion of the cysticidal therapy. The parents were contacted by a Pediatric Neurology Resident on Telephone before the scheduled hospital visit. Subsequently, all the children were seen directly in hospital the next day by another Pediatric Neurology Resident. The information was noted on a structured questionnaire. The diagnostic accuracy of telephone consultation for identifying the Critical Clinical Events was estimated using Face-to-Face consultation as the gold standard.
   Results: A total of 1145 potential events were evaluated. Of these, the face-to-face consultation identified 56 events that would need hospital visit for detailed evaluation (breakthrough seizures in 19, drug non-compliance in 15, adverse drug events in 11, features of raised intracranial pressure in 8, and other disease-related events in 3), and 1089 events that did not require hospital consultation. The sensitivity, specificity, positive and negative predictive values of telephone consultation were 89.28% (78.12-95.96), 97.61% (96.52-98.43), 65.79% (54.01-76.30), and 99.43% (98.78-99.79) respectively. The likelihood ratios when telephone consultation was positive and negative were 37.3 and 0.11 respectively.
   Significance: Telephone consultation is an acceptable mode of follow-up for children with mild Neurocysticercosis and symptomatic seizures after completion of cysticidal therapy.
AD  - All India Inst Med Sci, Dept Pediat, Div Child Neurol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaAD  - Rainbow Hosp Women & Children, Hyderabad, IndiaAD  - PGIMER Chandigarh, Div Pediat Neurol, Chandigarh, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - SEP
PY  - 2018
VL  - 145
SP  - 110
EP  - 115
DO  - 10.1016/j.eplepsyres.2018.06.005
AN  - WOS:000445280500015
ER  -

TY  - JOUR
AU  - Koul, PA
AU  - Mir, H
AU  - Saha, S
AU  - Chadha, MS
AU  - Potdar, V
AU  - Widdowson, MA
AU  - Lal, RB
AU  - Krishnan, A
TI  - Respiratory viruses in returning Hajj & Umrah pilgrims with acute respiratory illness in 2014-2015
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
KW  - Acute respiratory infection
KW  - coronavirus
KW  - Hajj pilgrims
KW  - influenza virus
KW  - respiratory syncytial virus
KW  - respiratory viruses
KW  - REAL-TIME PCR
KW  - OBSTRUCTIVE PULMONARY-DISEASE
KW  - MERS-COV
KW  - ACUTE EXACERBATIONS
KW  - MASS GATHERINGS
KW  - INFECTIONS
KW  - INFLUENZA
KW  - INDIA
KW  - KASHMIR
KW  - ASSAY
AB  - Background & objectives: Respiratory tract infections are common among Hajj and Umrah pilgrims which pose a public health risk of spread of respiratory infections. Influenza has been reported from Indian Hajj and Umrah returning pilgrims, but data on other respiratory pathogens are sparse in India. Here we report the presence of common respiratory viral pathogens in returning Hajj and Umrah pilgrims suffering from acute respiratory illness (ARI) in 2014-2015.
   Methods: Respiratory specimens (nasopharyngeal and throat swabs) were collected from 300 consenting pilgrims with ARI in the past one week and tested for influenza and Middle East Respiratory Syndrome coronavirus (MFRS-CoV) and other respiratory viruses using in-house standardized quantitative realtime reverse-transcription polymerase chain reaction. Clinical features among the pathogen positive and negative patients were compared. The patients received symptomatic treatment and antivirals where appropriate and were followed telephonically to collect data on illness outcome.
   Resuks: Ninety seven (32.3%) of the 300 participants were tested positive for any virus, most common being influenza viruses (n=33, 11%). Other respiratory viruses that were detected included human comnaviruses [n=26, 8.7%; 0C43 (n=19, 6.3%) and C229E (n=7, 2.3%)], rhinovirus (n=20, 6%), adenoviruses (n=2.6%), parainfluenza viruses (n=7, 2.3%), respiratory syncytial virus (n=3, 1%) and bocaviruses (n=2, 0.6%). Clinical features observed in pathogen positive and pathogen negative patients did not differ significantly. Eighteen influenza positive patients were treated with oseltamivir.
   Interpretation & conclusions: Pilgrims returning from mass gatherings are often afflicted with respiratory pathogens with a potential to facilitate transmission of respiratory pathogens across international borders. The study reinforces the need for better infection prevention and control measures such as vaccination, health education on cough etiquette and hand hygiene.
AD  - Sherikashmir Inst Med Sci, Dept Internal & Pulm Med, Srinagar 190011, Jammu & Kashmir, IndiaAD  - ICMR Natl Inst Virol, Influenza Grp, Pune, Maharashtra, IndiaAD  - All India Inst Med Sci, Ctr Community Med, New Delhi, IndiaAD  - US Ctr Dis Control Prevent, Influenza Div, Atlanta, GA USAC3  - Sher-i-Kashmir Institute of Medical SciencesC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Virology (NIV)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Centers for Disease Control & Prevention - USAPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - SEP
PY  - 2018
VL  - 148
IS  - 3
SP  - 329
EP  - 333
C7  - PMID 30425224
DO  - 10.4103/ijmr.IJMR_890_17
AN  - WOS:000450121500013
ER  -

TY  - JOUR
AU  - Lalwani, S
AU  - Hasan, F
AU  - Khurana, S
AU  - Mathur, P
TI  - Epidemiological trends of fatal pediatric trauma A single-center study
T2  - MEDICINE
KW  - fatal
KW  - head injury
KW  - infection
KW  - trauma
KW  - INTENSIVE-CARE-UNIT
KW  - INFECTIONS
KW  - PREVALENCE
KW  - RESISTANCE
KW  - PATTERNS
KW  - CHILDREN
AB  - To evaluate the potential risk factors which increase the incidence of post-trauma complications and mortality in pediatric population.
   A retrospective cohort study was conducted on patients below 18 years of age with a fatal outcome who were admitted to an Indian level-1 trauma center between January 2013 and December 2015. This cohort was analyzed to determine the demographics, injury mechanism, injury severity, microbiological profile, and cause of death.
   In total, 320 pediatric patients with a fatal outcome were studied which showed male preponderance (71.56%). The median age of the patients was 11 years (range, 0.14-18 years). Median duration of stay was 1 day (range, 0-183 days). Fall and road traffic accidents were the common mechanisms of trauma while the main injury was head injury. In total, 857 clinical samples were received from 56 patients. The clinical samples from 35 (10.94%) patients were culture positive. Culture-proven infections were significantly correlated with the length of hospital stay (P = .001). In total, 212 organisms were isolated from 193 positive samples of which gram-negative bacteria were predominant (89.15%). The most common gram-positive bacterial isolate was Staphylococcus aureus (12, 52.17%), while Acinetobacter baumannii (66, 34.92%) was the most prevalent gram-negative bacterial isolate followed by Pseudomonas spp. (36, 19.05%), Klebsiella pneumoniae (35, 18.52%), and Escherichia coli (16, 8.47%). Up to 100% multidrug resistance was seen in both gram-positive and gram-negative bacterial isolates. The first 24 hours after trauma were the deadliest for our patients. Head/central nervous system injury was the primary cause of disabilities and early death whereas infection attributed to prolonged hospital stay.
   From these observations we concluded that management of pediatric trauma requires expert, multidisciplinary, and timely interventions. Moreover, nosocomial infections with multidrug resistant gram-negative bacteria challenges the accepted tenets of trauma care affecting the outcome of the pediatric population. Early identification of such high-risk patients' infection may facilitate early intervention. Thus, many deaths in pediatric group are preventable.
AD  - All India Inst Med Sci, Jai Prakash Narayan Apex Trauma Ctr, Dept Forens Med, New Delhi, IndiaAD  - All India Inst Med Sci, Jai Prakash Narayan Apex Trauma Ctr, Dept Lab Med, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - SEP
PY  - 2018
VL  - 97
IS  - 39
C7  - e12280
DO  - 10.1097/MD.0000000000012280
AN  - WOS:000449373500021
ER  -

TY  - JOUR
AU  - Maharana, PK
AU  - Sahay, P
AU  - Sen, S
AU  - Venugopal, R
AU  - Titiyal, JS
AU  - Sharma, N
TI  - Corneal Ectasia in Stevens-Johnson Syndrome: A Sequela of Chronic Disease
T2  - AMERICAN JOURNAL OF OPHTHALMOLOGY
KW  - EPIDERMAL NECROLYSIS
AB  - PURPOSE: To describe corneal ectasia in cases of chronic Stevens-Johnson syndrome (SJS).
   DESIGN: Prospective observational study.
   METHODS: Setting: Institutional. Patients: Fifteen consecutive cases of chronic SJS. Main Outcome Measures: Best-corrected distance visual acuity (BCDVA), maximum corneal curvature (Kmax), anterior elevation, posterior elevation, thinnest pachymetry, and Sotozono severity score.
   RESULTS: Thirty eyes of 15 patients were included. Corneal tomography using Scheimpflug technology (Pentacam-HR, Oculus GmbH) was performed. Nine eyes were excluded owing to poor-quality scans. The median age was 26 years. The median time from onset of disease to assessment for corneal ectasia was 7 years. The median BCDVA was 0.8 logMAR units at presentation. The median Sotozono severity score was 11. Corneal ectasia (Kmax>48 diopters [D]) was noted in 76.2% of eyes. The mean Kmax was 58.37 +/- 14.89 D. On Belin/Ambrosio enhanced ectasia display the median front and back elevation was 42 mu m (10-176 mu m) and 267 mu m (15-2392 mu m), respectively. The mean pachymetry was 377.76 +/- 165.05 mu m (133-448 mu m). The point of maximum ectasia was peripheral in 57.1%, both central and peripheral in 19.1%, and central in 23.8% of eyes. On Spearman correlation analysis, deterioration in BCDVA (R=0.759, P<.001) and increase in Kmax (R=0.589, P=.005) was associated with higher disease severity (Sotozono grading).=
   CONCLUSION: Corneal ectasia is a common but often missed entity in cases of chronic SJS that may be a cause for poor visual acuity in these cases. All cases of SJS must be evaluated for corneal ectasia, especially when the visual acuity is disproportionate to the disease severity. ((C) 2018 Elsevier Inc. All rights reserved.)
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - SEP
PY  - 2018
VL  - 193
SP  - 1
EP  - 9
DO  - 10.1016/j.ajo.2018.05.030
AN  - WOS:000444068100004
ER  -

TY  - JOUR
AU  - Maharana, PK
AU  - Chhablani, JK
AU  - Das, T
AU  - Kumar, A
AU  - Sharma, N
TI  - Response to: Transzonular drug delivery during cataract surgery: Is dropless cataract surgery really beneficial?
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaAD  - LV Prasad Eye Inst, Srimati Kanuri Santhamma Ctr Vitreoretinal Dis, Hyderabad, Telangana, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - L. V. Prasad Eye InstitutePU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - SEP
PY  - 2018
VL  - 66
IS  - 9
SP  - 1380
EP  - 1380
DO  - 10.4103/ijo.IJO_1040_18
AN  - WOS:000442780400053
ER  -

TY  - JOUR
AU  - Malaviya, AN
AU  - Mehra, NK
TI  - A fascinating story of the discovery & development of biologicals for use in clinical medicine
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
KW  - Biological drugs
KW  - drug discovery
KW  - history of medicine
KW  - infliximab
KW  - monoclonal antibody
KW  - tumour necrosis factor-alpha
KW  - TUMOR-NECROSIS-FACTOR
KW  - RHEUMATOID SYNOVIAL-CELLS
KW  - FACTOR-ALPHA CA2
KW  - STIMULATES COLLAGENASE
KW  - MONOCLONAL-ANTIBODY
KW  - IN-VITRO
KW  - PROSTAGLANDIN PRODUCTION
KW  - HUMAN-FIBROBLASTS
KW  - IFN-GAMMA
KW  - ARTHRITIS
AB  - A young physician starting a fresh career in medicine in this millennium would hardly stop to think about the genesis of a particular biological drug that he/she will be prescribing for a patient evaluated in the morning outpatient department. For him/her, this is now routine, and the question of 'Who', 'How' and 'When' about these biologicals would be the last thing on their mind. However, for those who came to the medical profession in the 1950s, 1960s and 1970s, these targeted drugs are nothing short of 'miracles'. It would be a fascinating story for the young doctor to learn about the long journey that the dedicated biomedical scientists of yesteryears took to reach the final destination of producing such wonder drugs. The story is much like an interesting novel, full of twists and turns, heart-breaking failures and glorious successes. The biologicals acting as 'targeted therapy' have not only changed the natural history of a large number of incurable/uncontrollable diseases but have also transformed the whole approach towards drug development. From the classical empirical process, there is now a complete shift towards understanding the disease pathobiology focusing on the dysregulated molecule(s), targeting them with greater precision and aiming for better results. Seminal advances in understanding the disease mechanism, development of remarkably effective new technologies, greater knowledge of the human genome and genetic medicine have all made it possible to reach the stage where artificially developed 'targeted' drugs are now therapeutically used in routine clinical medicine.
AD  - ISIC Superspecial Hosp, Dept Rheumatol, New Delhi 110070, IndiaAD  - All India Inst Med Sci, Dept Transplant Immunol & Immunogenet, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - SEP
PY  - 2018
VL  - 148
IS  - 3
SP  - 263
EP  - 278
DO  - 10.4103/ijmr.IJMR_1471_18
AN  - WOS:000450121500005
ER  -

TY  - JOUR
AU  - Mathur, P
AU  - Hasan, F
AU  - Singh, PK
AU  - Malhotra, R
AU  - Walia, K
AU  - Chowdhary, A
TI  - Five-year profile of candidaemia at an Indian trauma centre: High rates of <i>Candida auris</i> blood stream infections
T2  - MYCOSES
KW  - antifungal susceptibility testing
KW  - Candida auris
KW  - candidaemia
KW  - India
KW  - MALDI-TOF MS
KW  - VITEK 2
KW  - CLINICAL CHARACTERISTICS
KW  - FLUCONAZOLE RESISTANCE
KW  - MOLECULAR-MECHANISMS
KW  - INVASIVE CANDIDIASIS
KW  - SPECIES DISTRIBUTION
KW  - EPIDEMIOLOGY
KW  - IDENTIFICATION
KW  - ALBICANS
AB  - Candidaemia is a potentially fatal infection with varied distribution of Candida species and their antifungal susceptibility profiles. The recent emergence of Candida auris in invasive candidiasis is a cause for concern. This study describes the profile of candidaemia at an Indian tertiary care hospital and reports the emergence of C.auris. All patients diagnosed with candidaemia between 2012 and 2017 were studied. The isolates were identified using conventional methods, VITEK 2 and MALDI-TOF MS. The isolates not identified by MALDI-TOF were sequenced. Antifungal susceptibility testing was done by the CLSI broth microdilution method and VITEK 2. Atotal of 114 isolates of Candida species were analysed. Candida tropicalis (39.4%) was the most common species, followed by C.auris (17.5%), C.albicans (14%) and C.parapsilosis (11.4%). Notably, Diutina mesorugosa isolates (n=10) were not identified by MALDI-TOF and were confirmed by sequencing. Furthermore, 45% (n=9) C.auris strains exhibited low MICs of FLU (0.05-4g/mL) and the remaining 55% (n=11) isolates had high MICs64g/mL. Also, D.mesorugosa exhibited high MICs of FLU (32g/mL) in 2 isolates. A high rate of errors in antifungal susceptibility was noted with the VITEK 2 as compared to the CLSI method. Candida auris was the second most prevalent species causing candidaemia warranting infection control practices to be strengthened to prevent its spread.
AD  - All India Inst Med Sci, Jai Prakash Narayan Apex Trauma Ctr, Dept Lab Med, New Delhi, IndiaAD  - Univ Delhi, Vallabhbhai Patel Chest Inst, Dept Med Mycol, Delhi, IndiaAD  - All India Inst Med Sci, Dept Orthopaed, New Delhi, IndiaAD  - AIIMS, JaiPrakash Narayan Apex Trauma Ctr, New Delhi, IndiaAD  - Indian Council Med Res, Div Epidemiol & Communicable Dis, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterC3  - University of DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Council of Medical Research (ICMR)PU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - SEP
PY  - 2018
VL  - 61
IS  - 9
SP  - 674
EP  - 680
DO  - 10.1111/myc.12790
AN  - WOS:000441441800009
ER  -

TY  - JOUR
AU  - Mehta, R
AU  - Sharma, KA
TI  - Use of Learning Platforms for Quality Improvement
T2  - INDIAN PEDIATRICS
KW  - E-Learning
KW  - Learning management system
KW  - Online learning
KW  - MEDICAL-STUDENTS
AB  - Ensuring quality in healthcare today has become extremely essential to ensure adequate utilization of healthcare services and improved outcomes. In addition to essential infrastructure in terms of safe and adequate space, knowledgeable and skilled health workers, and essential equipment and supply, the healthcare teams and administrators must also acquire knowledge and skills related to quality improvement (QI) methodologies. This review describes the role of learning platforms in teaching QI skills to the busy healthcare teams. Through Review of the published literature, we discuss challenges of learning and applying new skills of QI in day-to-day work by healthcare teams, and how learning platforms can assist in capacity building. There is a significant body of literature on the role of web-based teaching technology and learning platforms in medical education. Using modern communication technology, learning platforms can be established to bring together the healthcare teams, with QI experts to collaboratively learn, execute and share their experiences in improving quality of care in their own healthcare settings.
AD  - WHO, South East Asia Reg Off, Div Newborn Child & Adolescent Hlth, New Delhi, IndiaAD  - AIIMS, Dept Obstet & Gynecol, Room 3086, New Delhi, IndiaC3  - World Health OrganizationC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - SEP
PY  - 2018
VL  - 55
IS  - 9
SP  - 803
EP  - 808
DO  - 10.1007/s13312-018-1385-2
AN  - WOS:000445093300018
ER  -

TY  - JOUR
AU  - Murki, S
AU  - Kiran, S
AU  - Kumar, P
AU  - Chawla, D
AU  - Thukral, A
TI  - Quality Improvement Collaborative for Preterm Infants in Healthcare Facilities
T2  - INDIAN PEDIATRICS
KW  - Evidence-based medicine
KW  - Neonatal intensive care unit
KW  - Outcome
KW  - PDSA cycle
KW  - NEONATAL INTENSIVE-CARE
KW  - OUTCOMES
KW  - PROGRAM
AB  - Across all healthcare settings, it is important not only to provide safe and effective healthcare, but also to ensure that it is timely, patient-centered, efficient and equitable. There is a wide variability in neonatal and perinatal outcomes in India and other developing countries, with certain units demonstrating clinical outcomes that match the developed world, while others showing higher than expected mortality and morbidity. Collaborative quality improvement initiatives offer a pragmatic way to improve performance of healthcare delivery within and between neonatal units. Variations in application of evidence-based healthcare process and dependent health outcomes can be identified and targeted for improvement in quality improvement cycles. We herein describe the concept of Collaborative quality improvement, and the success stories of the best-known Collaborative quality improvement initiatives across the world. We also highlight the process and progress of creating Collaborative quality improvement in our country.
AD  - Fernandez Hosp, Dept Neonatol, Hyderabad, IndiaAD  - PGIMER, Dept Pediat, Div Neonatol, Chandigarh, IndiaAD  - GMH, Dept Pediat, Chandigarh, IndiaAD  - AIIMS, Dept Pediat, New Delhi, IndiaC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - SEP
PY  - 2018
VL  - 55
IS  - 9
SP  - 818
EP  - 823
DO  - 10.1007/s13312-018-1387-0
AN  - WOS:000445093300020
ER  -

TY  - JOUR
AU  - Nandini, B
AU  - Mooventhan, A
AU  - Manjunath, NK
TI  - ADD-ON EFFECT OF HOT SAND FOMENTATION To YOGA ON PAIN, DISABILITY, AND QUALITY OF LIFE IN CHRONIC NECK PAIN PATIENTS
T2  - EXPLORE-THE JOURNAL OF SCIENCE AND HEALING
KW  - Chronic pain
KW  - Fomentation
KW  - Naturopathy
KW  - Neck pain
KW  - Yoga
KW  - CONTROLLED-TRIAL
KW  - INDEX
KW  - RELIABILITY
KW  - SLEEP
AB  - Background: Neck pain is one of the commonest complaints and an important public health problem across the globe. Yoga has reported to be useful for neck pain and hot sand has reported to be useful for chronic rheumatism. The present study was conducted to evaluate the add-on effect of hot sand fomentation (HSF) to yoga on pain, disability, quality of sleep (QOS) and quality of life (QOL) of the patients with non-specific neck pain.
   Materials and Methods: A total of 60 subjects with non-specific or common neck pain were recruited and randomly divided into either study group or control group. Both the groups have received yoga and sesame seed oil (Sesamum Indicum L.) application. In addition to yoga and sesame seed oil, study group received HSF for 15 min per day for 5-days. Assessments were taken prior to and after the intervention.
   Results: Results of the study showed a significant reduction in the scores of visual analogue scale for pain, neck disability index (NDI), The Pittsburgh Sleep Quality Index (PSQI), and a significant increase in physical function, physical health, emotional problem, pain, and general health both in study and control groups. However, reductions in pain and NDI along with improvement in social functions were better in the study group as compared with control group.
   Conclusion: Results of this study suggest that addition of HSF to yoga provides a better reduction in pain and disability along with improvement in the social functioning of the patients with non-specific neck pain than yoga alone.
AD  - S VYASA Univ, Sch Yoga & Naturopath Med, Div Yoga & Life Sci, Bengaluru, Karnataka, IndiaAD  - All India Inst Med Sci, CIMR, New Delhi, IndiaAD  - S VYASA Univ, Div Yoga & Life Sci, Bengaluru, Karnataka, IndiaAD  - S VYASA Univ, Dept Res & Dev, Bengaluru, Karnataka, IndiaAD  - S VYASA Univ, Div Yoga & Life Sci, Dept Res & Dev, Bengaluru, Karnataka, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - SEP-OCT
PY  - 2018
VL  - 14
IS  - 5
SP  - 373
EP  - 378
DO  - 10.1016/j.explore.2018.01.002
AN  - WOS:000451937000009
ER  -

TY  - JOUR
AU  - Negi, N
AU  - Mojumdar, K
AU  - Singh, R
AU  - Sharma, A
AU  - Das, BK
AU  - Sreenivas, V
AU  - Vajpayee, M
TI  - Comparative Proliferation Capacity of Gag-C-Specific Naive and Memory CD4+and CD8+T Lymphocytes in Rapid, Viremic Slow, and Slow Progressors During Human Immunodeficiency Virus Infection
T2  - VIRAL IMMUNOLOGY
KW  - HIV
KW  - T cell exhaustion
KW  - Ki67 nuclear antigen
KW  - proliferation
KW  - flow cytometer
KW  - CD4(+) T-CELLS
KW  - HIV-1 INFECTION
KW  - LONGITUDINAL ANALYSIS
KW  - INDIAN INDIVIDUALS
KW  - IMMUNE ACTIVATION
KW  - KINETICS
KW  - KI-67
KW  - EXPRESSION
KW  - DEPLETION
KW  - TURNOVER
AB  - The exact cause of altered dynamics in T cells compartment during HIV infection remains elusive to date. In this longitudinal study, the proliferation frequency of different T cell subsets was investigated in untreated HIV-1-infected Indian individuals stratified as rapid (R), viremic slow (VS), slow (S) progressors, and healthy controls. Ten healthy and 20 treatment-naive HIV-1-infected individuals were enrolled. Expression of Ki67 nuclear antigen was examined on HIV-specific T cell subsets in peripheral blood lymphocytes. Upon stimulation with HIV-1 Gag-C peptide pools, effector memory (EM) CD4 T cells (R vs. S, EM CD4, p<0.05) of R progressors proliferated significantly compared with those of S progressors at baseline. However, central memory (CM) CD8 T cell subsets proliferated significantly in VS and S progressors compared with those in R progressors, wherein highest proliferation frequency of EM CD8 T cells was observed. At follow-up visit, the proliferation frequency of naive CD8 T cells was significantly higher in R progressors than S progressors (R vs. S naive CD8, p<0.05). The findings suggest altered dynamics of different CD4+ and CD8+ T cell subsets in R, VS, and S progressors. The increase in CM T cell proliferation in VS and S progressors could be attributed to slower progression of the HIV infection. Hence, treatment strategies must be focused on restoring the homeostatic balance to restore T cell functionality.
AD  - All India Inst Med Sci, Dept Microbiol, New Delhi 110029, IndiaAD  - Meakins Christie Labs, Montreal, PQ, CanadaAD  - All India Inst Med Sci, Dept Paediat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MARY ANN LIEBERT, INC
PI  - NEW ROCHELLE
PA  - 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
DA  - SEP
PY  - 2018
VL  - 31
IS  - 7
SP  - 513
EP  - 524
DO  - 10.1089/vim.2018.0012
AN  - WOS:000443818300005
ER  -

TY  - JOUR
AU  - Parakh, N
AU  - Baliyan, V
AU  - Jain, P
AU  - Sharma, S
AU  - Kumar, A
TI  - Bizarre Arterial Beading in a Child With Stroke
T2  - PEDIATRIC NEUROLOGY
KW  - Thalassemia major
KW  - Vasculopathy
KW  - Stroke
KW  - Susceptibility effect
AD  - Lady Harding Med Coll, Dept Pediat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi, IndiaAD  - Hosp Sick Children, Dept Pediat, Div Neurol, Toronto, ON, CanadaAD  - Lady Harding Med Coll, Div Pediat Neurol, Dept Pediat, New Delhi, IndiaC3  - Lady Hardinge Medical College & HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - Lady Hardinge Medical College & HospitalPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - SEP
PY  - 2018
VL  - 86
SP  - 75
EP  - 76
DO  - 10.1016/j.pediatrneurol.2018.06.010
AN  - WOS:000451361400015
ER  -

TY  - JOUR
AU  - Parveen, B
AU  - Tripathi, M
AU  - Vohora, D
TI  - A Cross-Sectional Study to Assess the Modulation of Wnt Inhibitors following Anti-Epileptic Drug Therapy and their Correlation with Vitamin D and Receptor Activator of Nuclear Factor B Ligand in Indian Women with Epilepsy
T2  - BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
KW  - BONE-MINERAL DENSITY
KW  - CIRCULATING SCLEROSTIN
KW  - ANTICONVULSANT THERAPY
KW  - POSTMENOPAUSAL WOMEN
KW  - BODY-COMPOSITION
KW  - CARBAMAZEPINE
KW  - OSTEOPOROSIS
KW  - METABOLISM
KW  - MONOTHERAPY
KW  - LEVETIRACETAM
AB  - Long-term anti-epileptic drug (AED) therapy compromises bone health. Although vitamin D deficiency is proposed to be involved, it alone is not held responsible. This accounts for investigating other mechanisms in bone accrual. Recent studies have shown modulation of inhibitors of wnt pathway, sclerostin and dickkopf-1 (DKK-1), in glucocorticoids-induced osteoporosis. We investigated whether AED monotherapy modulates wnt inhibitors in Indian women with epilepsy. Women of age > 20-40 years with the diagnosis of epilepsy and receiving AEDs (carbamazepine, valproate and levetiracetam) for at least a year were enrolled. The results were compared with age-matched healthy controls with no evidence of metabolic bone disease. Women undergoing treatment with AEDs (mean duration: 50.59 +/- 37.929 months) exhibited higher serum sclerostin and receptor activator of nuclear factor B ligand (RANKL) and lower vitamin D (25-hydroxy vitamin D) and DKK-1 levels when compared to age-matched healthy controls. Sclerostin showed a positive correlation with RANKL, while DKK-1 presented no such relationship. However, no association was evident after adjusting for age, duration of treatment and total daily dose. Although a correlation between wnt inhibitors and RANKL could not be obtained, AEDs displayed changes in serum levels of wnt inhibitors in persons with epilepsy and hence these drugs may compromise bone health through a disturbance in wnt signalling mechanisms.
AD  - Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmacol, Pharmaceut Med, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurol, Neurosci Ctr, New Delhi, IndiaC3  - Jamia Hamdard UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - SEP
PY  - 2018
VL  - 123
IS  - 3
SP  - 271
EP  - 276
DO  - 10.1111/bcpt.12996
AN  - WOS:000441237300008
ER  -

TY  - JOUR
AU  - Patel, A
AU  - Sharma, MC
AU  - Bakhshi, S
TI  - Outcome of Early Stage Pediatric Non-Lymphoblastic Non-Hodgkin Lymphoma
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Non-Hodgkin lymphoma
KW  - Early stage
KW  - Outcome
KW  - CHILDHOOD
KW  - PROTOCOL
KW  - CHILDREN
KW  - RISK
KW  - AGE
AB  - There is lack of data on outcome of limited stage pediatric non-Hodgkin lymphoma (NHL) from south Asia. In view of this lacuna, authors evaluated patients of early stage (stage 1 and 2) non-lymphoblastic pediatric NHL patients treated with uniform short course, reduced-intensity protocol from Jan 2003 through Dec 2016. Of the total 280 subjects with pediatric NHL, 50 were of early stage of which 42 received uniform protocol. B-cell subtype was observed in 83% patients. Event-free-survival (EFS) and overall-survival (OS) were 85% and 90% respectively at 5 y (median-not reached). Age > 13 y emerged as the only poor risk factor for EFS (p = 0.05) on univariate analysis and same had a trend toward inferior prognosis in OS (p = 0.09). Vincristine-induced neuropathy occurred in five patients. Febrile neutropenia was observed in 16% subjects with one patient requiring hospitalization. There was no treatment-related death. This largest data of limited stage pediatric non-lymphoblastic NHL from south Asia highlights that good outcomes may be achieved with less intense short course therapy without hospitalization, and that adolescent age is the only poor prognostic factor for outcome.
AD  - All India Inst Med Sci, Dr BRA Inst Rotary Canc Hosp, Dept Med Oncol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - SEP
PY  - 2018
VL  - 85
IS  - 9
SP  - 782
EP  - 784
DO  - 10.1007/s12098-017-2585-9
AN  - WOS:000442536800013
ER  -

TY  - JOUR
AU  - Pujari, A
AU  - Mukhija, R
AU  - Shashni, A
AU  - Obedulla, H
AU  - Meel, R
AU  - Bajaj, MS
TI  - Bilateral hemorrhagic proptosis due to an uncommon cause in ocular emergency
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Hemophilia B
KW  - hemorrhagic proptosis
KW  - ophthalmic emergency
KW  - CHRISTMAS DISEASE
AB  - A 19-year-old male patient presented to the ocular emergency services with sudden onset of proptosis, pain, and bloody discharge. Further evaluation revealed bilateral visual acuity of finger counting dose to face vision with an accurate projection of rays. Computed tomography scan of the head and orbit revealed diffuse orbital hemorrhage (mainly along the ocular coats) in the absence of any subperiosteal or intracranial hemorrhage. A complete hematological workup was done and it revealed decreased factor IX levels (9% of normal) consistent with hemophilia B (Christmas disease). The patient was managed medically with factor IX supplementation. At the end of 6 weeks, patient's visual acuity improved to 20/20 in both the eyes.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 212,Second Floor,RPC 1, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - SEP
PY  - 2018
VL  - 66
IS  - 9
SP  - 1370
EP  - 1371
DO  - 10.4103/ijo.IJO_399_18
AN  - WOS:000442780400047
ER  -

TY  - JOUR
AU  - Pujari, A
AU  - Mukhija, R
AU  - Singh, AB
AU  - Chawla, R
AU  - Sharma, N
AU  - Kumar, A
TI  - Smartphone-based high definition anterior segment photography
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 212,RPC 1 Hostel,Second Floor, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - SEP
PY  - 2018
VL  - 66
IS  - 9
SP  - 1375
EP  - +
DO  - 10.4103/ijo.IJO_544_18
AN  - WOS:000442780400050
ER  -

TY  - JOUR
AU  - Pujari, A
AU  - Swamy, DR
AU  - Singh, R
AU  - Mukhija, R
AU  - Chawla, R
AU  - Sharma, P
TI  - Ultrasonographic assessment of paediatric ocular emergencies: A tertiary eye hospital based observation
T2  - WORLD JOURNAL OF EMERGENCY MEDICINE
KW  - Paediatric ocular emergencies
KW  - Ultrasound B scan
KW  - Posterior segment and orbital pathologies
KW  - OF-CARE ULTRASONOGRAPHY
KW  - RETINAL-DETACHMENT
KW  - POINT
KW  - ULTRASOUND
AB  - BACKGROUND: The purpose of this study is to assess the utility of ocular ultrasound B scan in the emergency at the first point of care for detecting posterior segment and orbital pathologies in cases of paediatric ocular emergencies.
   METHODS: A prospective observational study involving 122 paediatric patients presenting to eye emergency over a period of ninety days were assessed with ultrasonography for the posterior segment as well as orbital pathology whenever indicated. The ocular ultrasound was performed gently over closed eyelids.
   RESULTS: Posttraumatic globe injuries were the most common indication for posterior segment evaluation, which constituted 80 (65.57%) eyes. Among these 52 patients had an anechoic posterior segment and 28 patients had variable findings such as vitreous haemorrhage (8.19%), retinal detachment (6.55%), choroidal detachment (4.91%), posteriorly dislocated clear lens (0.81%) and retained intraocular foreign body (5.73%). Non-traumatic cases constituted around 42 (34.42%) eyes, which included corneal ulcer (7.37%), retinoblastoma (6.55%), endophthalmitis (4.91%), extra-ocular muscle cysticercosis (4.91%), orbital cellulitis (4.09%), periocular haemorrhage (2.45%), proptosis(1.63%), paediatric cataract (1.63%) and cryptophthalmos (0.81%). No adverse events of performing the ultrasound was noted.
   CONCLUSION: First point ultrasonography in paediatric ocular emergencies is a cheap, portable and an effective tool in the assertion of significant posterior segment and orbital diseases.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - ZHEJIANG UNIV SCH MEDICINE
PI  - HANGZHOU
PA  - SECOND AFFILIATED HOSPITAL, 88 JIEFANG RD, HANGZHOU, 310009, PEOPLES R CHINA
DA  - SEP
PY  - 2018
VL  - 9
IS  - 4
SP  - 272
EP  - 275
DO  - 10.5847/wjem.j.1920-8642.2018.04.006
AN  - WOS:000443605600006
ER  -

TY  - JOUR
AU  - Pushpam, D
AU  - Bakhshi, S
TI  - Impact of Pediatric Malignancies on Parent's Quality of Life
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - CHILDHOOD-CANCER
AD  - All India Inst Med Sci, Dr BRA Inst Rotary Canc Hosp, Dept Med Oncol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - SEP
PY  - 2018
VL  - 85
IS  - 9
SP  - 713
EP  - 714
DO  - 10.1007/s12098-018-2735-8
AN  - WOS:000442536800001
ER  -

TY  - JOUR
AU  - Radhakrishnan, DM
AU  - Shukla, G
AU  - Goyal, V
TI  - Hemi masticatory spasm with facial hemi atrophy and localized scleroderma: Report of a case with bilateral involvement
T2  - NEUROLOGY ASIA
KW  - hemi masticatory spasm (HMS)
KW  - scleroderma
KW  - facial hemi atrophy
KW  - bilateral
KW  - botulinum toxin
KW  - HEMIMASTICATORY SPASM
KW  - HEMIATROPHY
AB  - We report a rare case of a 45 year old female with 15 year history of progressive left facial thinning with frequent episodes of involuntary jaw closure and almost continuous rippling movements over her left sided masticatory muscles. There was localized scleroderma, left facial hemi atrophy and left hemi masticatory spasm. Localized scleroderma was proven histopathologically. Electrophysiological studies revealed normal blink reflex on both sides. Her masseter inhibitory reflex was absent bilaterally and surface electromyogram showed spontaneous bursts of high frequency activity over bilateral masseter and left temporalis muscles. The patient responded remarkably with bilateral botulinum toxin injection. This case highlights presence of rare bilateral involvement of HMS especially on EMG and excellent response to botulinum toxin.
AD  - All India Inst Med Sci, Dept Neurol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ASEAN NEUROLOGICAL ASSOC
PI  - KUALA LUMPUR
PA  - UNIV MALAYA MEDICAL CENTRE, NEUROLOGY LABORATORY, KUALA LUMPUR, 59100, MALAYSIA
DA  - SEP
PY  - 2018
VL  - 23
IS  - 3
SP  - 263
EP  - 266
AN  - WOS:000445885400010
ER  -

TY  - JOUR
AU  - Raizada, N
AU  - Jyotsna, VP
AU  - Kandasamy, D
AU  - Xess, I
AU  - Thakar, A
AU  - Tandon, N
TI  - Invasive fungal rhinosinusitis in patients with diabetes
T2  - JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
KW  - invasive fungal rhinosinusitis
KW  - diabetes
KW  - liposomal amphotericin B
KW  - mucormycosis
KW  - ORBITAL-CEREBRAL MUCORMYCOSIS
KW  - ZYGOMYCOSIS
KW  - OUTCOMES
AB  - Introduction: We report the clinical and radiological features as well as outcomes of invasive fungal rhinosinusitis in patients with diabetes from a tertiary care center in North India.
   Methodology: All patients admitted with a diagnosis of invasive fungal rhinosinusitis with pre-existing or newly diagnosed diabetes from 1st January 2008 to 31st December 2015 were included. Hospital records were used to identify clinical features, biochemical investigations and treatment modalities used. The imaging findings were reported at baseline, 30, 60,90 and 120 days of admission and progression of disease was reported as static, worse or improved. The outcomes were sight loss and survival at end of hospital stay.
   Results: 22 patients of invasive fungal sinusitis and diabetes were identified. At presentation, 5 had ketoacidosis, all of whom died at the end of hospital stay. Loss of vision in one eye was seen in 70% cases. The survival at end of hospital stay was 72.7% and at six months after end of study period was 57.8%. No patients had radiological improvement at day 30 imaging (including those who subsequently improved).
   Conclusion: Radiological improvement is not apparent before two months of therapy. Ketoacidosis is a predictor of mortality in invasive fungal sinusitis with diabetes.
AD  - All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Otorhinolaryngol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - J INFECTION DEVELOPING COUNTRIES
PI  - TRAMANIGLIO
PA  - JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
DA  - SEP
PY  - 2018
VL  - 12
IS  - 9
SP  - 787
EP  - 793
DO  - 10.3855/jidc.9699
AN  - WOS:000447036000014
ER  -

TY  - JOUR
AU  - Rajendran, A
AU  - Dhoble, P
AU  - Sundaresan, P
AU  - Saravanan, V
AU  - Vashist, P
AU  - Nitsch, D
AU  - Smeeth, L
AU  - Chakravarthy, U
AU  - Ravindran, RD
AU  - Fletcher, AE
TI  - Genetic risk factors for late age-related macular degeneration in India
T2  - BRITISH JOURNAL OF OPHTHALMOLOGY
KW  - VARIANTS
KW  - POLYMORPHISM
KW  - ASSOCIATION
KW  - PREVALENCE
KW  - LOCI
KW  - APOE
KW  - CFH
AB  - Background/Aims There are limited data from India on genetic variants influencing late age-related macular degeneration (AMD). We have previously reported associations from a population-based study in India (the India age-related eye disease study (INDEYE)) of early AMD and single nucleotide polymorphisms (SNPs) in ARMS2/HTRA1 and no association with CFH, C2 or CFB. Late AMD cases were too few for meaningful analyses. We aimed to investigate SNPs for late AMD through case enrichment and extend the loci for early AMD.
   Methods Fundus images of late AMD hospital cases were independently graded by the modified Wisconsin AMD grading scheme. In total 510 cases with late AMD (14 geographic atrophy and 496 neovascular AMD (nvAMD)), 1876 with early AMD and 1176 with no signs of AMD underwent genotyping for selected SNPs. We investigated genotype and per-allele additive associations (OR and 95% CIs) with nvAMD or early AMD. Bonferroni adjusted P values are presented.
   Results We found associations with nvAMD for CFHY402H variant (rs1061170) (OR=1.99, 95% CI 1.67 to 2.37, P=10(-6)), ARMS2 (rs10490924) (OR=2.94, 95% CI 2.45 to 3.52, P=10(-9)), C2 (rs547154) (OR=0.67, 95% CI 0.53 to 0.85, P=0.01), ABCA1 (rs1883025) (OR=0.77, 95% CI 0.65 to 0.92, P=0.04) and an SNP near VEGFA (rs4711751) (OR=0.64, 95% CI 0.54 to 0.77, P=10(-3)). We found no associations of TLR3 (rs3775291), CFD (rs3826945), FRK (rs1999930) or L1PC (rs10468017) or APOE epsilon 4 alleles with nvAMD or early AMD, nor between early AMD and rs1883025 or rs4711751.
   Conclusions The major genetic determinants of nvAMD risk in India are similar to those in other ancestries, while findings for early AMD suggest potential differences in the pathophysiology of AMD development.
AD  - Aravind Eye Hosp, Madurai, Tamil Nadu, IndiaAD  - Aravind Eye Hosp, Pondicherry, Tamil Nadu, IndiaAD  - Aravind Med Res Fdn, Dept Genet, Dr G Venkataswamy Res Inst, Madurai, Tamil Nadu, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaAD  - London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1E 7HT, EnglandAD  - Queens Univ, Ctr Publ Hlth, Belfast, Antrim, North IrelandC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - Queens University BelfastPU  - BMJ PUBLISHING GROUP
PI  - LONDON
PA  - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
DA  - SEP
PY  - 2018
VL  - 102
IS  - 9
SP  - 1213
EP  - 1217
DO  - 10.1136/bjophthalmol-2017-311384
AN  - WOS:000445109700008
ER  -

TY  - JOUR
AU  - Ramadass, S
AU  - Rai, SK
AU  - Gupta, SK
AU  - Kant, S
AU  - Wadhwa, S
AU  - Sood, M
AU  - Sreenivas, V
TI  - Prevalence of disability and its association with sociodemographic factors and quality of life in a rural adult population of northern India
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
KW  - HEALTH
AB  - Background. Globally, around 1 billion persons are disabled as per the WHO report on disability in 2011. The bio-psycho-social model of disability was developed by the WHO as the International Classification of Functioning, Disability and Health. We studied the prevalence of disability and its association with sociodemographic factors and quality of life among adults in a rural area.
   Methods. We did a community-based, cross-sectional study among 418 randomly selected adult participants aged 18 years and above in a rural area of Ballabgarh, Haryana. Participants were interviewed by administering WHO Disability Assessment Schedule 2.0 (WHODAS 2.0) for assessing disability and WHO Quality of Life-BREF (WHOQOL-BREF) scale for assessing quality of life. Multivariate analyses were done for the predictors of disability. Correlation was applied to find the association between disability and quality of life.
   Results. The prevalence of disability was 7.7% (95% confidence interval [CI]: 5.3%-10.6%) based on the cut-off > 40 summary score. More women (10.9%) than men (4.1%) were disabled (p= 0.009). Being = 60 years of age was independently associated with disability (adjusted odds ratio 12.3; 95% CI 4.45-33.97). The mean (SD) of the WHOQOL-BREF healthrelated quality of life (HRQOL) summary score was 67.6 (11.6) and the median was 66.43. HRQOL summary scores decreased as age increased. There was a negative correlation between summary scores of WHODAS 2.0 and WHOQOLBREF (r -0.57, p< 0.001).
   Conclusion. Prevalence of disability was higher than the estimate given by Census 2011. The elderly and women experience more disability. As age increases, quality of life decreases. Increase in the level of disability decreases the quality of life.
AD  - All India Inst Med Sci, Dept Community Med, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Phys Med & Rehabil, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Psychiat, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - SEP-OCT
PY  - 2018
VL  - 31
IS  - 5
SP  - 268
EP  - 273
DO  - 10.4103/0970-258X.261179
AN  - WOS:000473690700003
ER  -

TY  - JOUR
AU  - Ramadass, S
AU  - Gupta, SK
TI  - Need-based approach for cost-effective tuberculosis control in India
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
KW  - DIAGNOSIS
AD  - All India Inst Med Sci, Ctr Community Med, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SCIENTIFIC SCHOLAR LLC
PI  - PITTSFORD
PA  - 50, WOODGREEN DR, PITTSFORD, NY 14534 USA
DA  - SEP-OCT
PY  - 2018
VL  - 31
IS  - 5
SP  - 290
EP  - 292
DO  - 10.4103/0970-258X.261173
AN  - WOS:000473690700010
ER  -

TY  - JOUR
AU  - Rao, PV
AU  - Makkar, BM
AU  - Kumar, A
AU  - Das, AK
AU  - Singh, AK
AU  - Mithal, A
AU  - Bhansali, A
AU  - Misra, A
AU  - Maheshwari, A
AU  - Gupta, A
AU  - Rustogi, A
AU  - Saboo, B
AU  - Kumar, CHV
AU  - Moses, CRA
AU  - Thacker, H
AU  - Panda, J
AU  - Jana, J
AU  - Kesavdev, J
AU  - Setty, KRN
AU  - Chawla, M
AU  - Deshpande, N
AU  - Tandon, N
AU  - Chawla, R
AU  - Kovil, R
AU  - Sahay, R
AU  - Madhu, SV
AU  - Banerjee, S
AU  - Agarwal, S
AU  - Kalra, S
AU  - Bajaj, S
AU  - Joshi, SR
AU  - Aravind, SR
AU  - Chowdhury, S
AU  - Ghosh, S
AU  - Gupta, S
AU  - Mohan, V
AU  - Panikar, V
AU  - Viswanathan, V
TI  - RSSDI consensus on self-monitoring of blood glucose in types 1 and 2 diabetes mellitus in India
T2  - INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES
KW  - Diabetes Mellitus
KW  - Glucose Meters
KW  - Glycemic Control
KW  - SMBG
KW  - Self-monitoring of blood glucose
KW  - Type 1 DM
KW  - Type 2 DM
KW  - GLYCEMIC CONTROL
KW  - INSULIN THERAPY
KW  - MICROVASCULAR COMPLICATIONS
KW  - PARALLEL-GROUP
KW  - MANAGEMENT
KW  - CARE
KW  - ASSOCIATION
KW  - LONG
KW  - COST
KW  - VARIABILITY
AB  - Maintaining a good glycemic control is crucial in the management of diabetes mellitus (DM) as it is associated with the reduction in both macro and microvascular complications of the disease. Self-monitoring of blood glucose (SMBG), which provides the day-to-day blood glucose levels, is a simple and practical tool for maintaining a good glycemic control. Although SMBG is widely practiced in other countries, its use in India is very limited. Even when used, it is not carried out is a structured manner. There seems to be a lack of education about the purpose of SMBG and the correct process and schedule to be followed. This highlights the unmet need for country-specific SMBG recommendations. In order to fulfil this need, a panel of expert endocrinologists/ diabetologists came together under the aegis of Research Society for the Study of Diabetes in India (RSSDI). They reviewed the current literature, combined the evidences with their clinical knowledge and expertise, and developed consensus recommendations for SMBG practice in India. This document provides a comprehensive review of the current literature on SMBG and presents the recommendations made by the expert panel.
AD  - Ramdevrao Hosp, Kumudini Devi Diabet Res Ctr, Hyderabad, Telangana, IndiaAD  - Dr Makkars Diabet & Obes Ctr, Delhi, IndiaAD  - Diabet Care & Res Ctr, Patna, Bihar, IndiaAD  - Pondicherry Inst Med Sci, Dept Endocrinol, Pondicherry, IndiaAD  - GD Hosp & Diabet Inst, Kolkata, IndiaAD  - Medanta Medicity, Gurgaon, IndiaAD  - PGIMER, Dept Endocrinol, Chandigarh, IndiaAD  - Fortis CDOC Ctr Excellence Diabet Metab Dis & End, New Delhi, IndiaAD  - Natl Diabet Obes & Cholesterol Fdn, New Delhi, IndiaAD  - Diabet Fdn, New Delhi, IndiaAD  - BBD Univ, Dept Internal Med, Lucknow, Uttar Pradesh, IndiaAD  - Jaipur Diabet Res Ctr, Jaipur, Rajasthan, IndiaAD  - Post Grad Inst Med Educ & Res PGIMER, Dept Endocrinol & Metab, Chandigarh, IndiaAD  - DIA Care Diabet Care & Hormone Clin, Ahmadabad, Gujarat, IndiaAD  - Apollo Hosp, Hyderabad, Telangana, IndiaAD  - Tamil Nadu Dr MGR Med Univ, Chennai, Tamil Nadu, IndiaAD  - Jaslok Breach Candy & Bhatia Hosp, Bombay, Maharashtra, IndiaAD  - SCB Med Coll, Dept Med, Cuttack, Orissa, IndiaAD  - Jyothydevs Diabet Res Ctr, Thiruvananthapuram, Kerala, IndiaAD  - Karnataka Inst Diabetol, Bengaluru, IndiaAD  - Asian Heart Inst & SL Raheja Fortis, Lina Diabet Care Ctr, Bombay, Maharashtra, IndiaAD  - USM KLE Int Med Programme, Belgaum, IndiaAD  - Belgaum Diabet Ctr, Belgaum, IndiaAD  - All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi 110029, IndiaAD  - North Delhi Diabet Ctr, Delhi, IndiaAD  - BSES Global Hosp, Nanavati Hosp, S LRaheja Hosp Arogya, Nidhi Hosp,Dr Kovils Diabet Care Ctr, Bombay, Maharashtra, IndiaAD  - Osmania Med Coll & Gen Hosp, Dept Endocrinol, Hyderabad, Telangana, IndiaAD  - Univ Coll Med Sci, Dept Med, Delhi, IndiaAD  - Vivekananda Inst Med Sci, Dept Med, Kolkata, IndiaAD  - Aegle Clin Diabet Care, Pune, Maharashtra, IndiaAD  - Bharti Res Inst Diabet & Endocrinol BRIDE, Chandigarh, Haryana, IndiaAD  - MLN Med Coll, Dept Med, Allahabad, Uttar Pradesh, IndiaAD  - Joshi Hosp, Bombay, Maharashtra, IndiaAD  - Diacon Hosp, Bangalore, Karnataka, IndiaAD  - PGME&R & SSKM Hosp, Dept Endocrinol & Metab, Kolkata, IndiaAD  - AMRI Hosp, Kolkata, IndiaAD  - Sunils Diabet Care N Res Ctr Pvt Ltd, Nagpur, Maharashtra, IndiaAD  - Dr Mohans Diabet Special Ctr, Madras, Tamil Nadu, IndiaAD  - Dr Panikars Special Care Ctr, Bombay, Maharashtra, IndiaAD  - MV Hosp Diabetes, Madras, Tamil Nadu, IndiaC3  - Pondicherry Institute of Medical SciencesC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Babu Banarasi Das UniversityC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Srirama Chandra Bhanja Medical College & HospitalC3  - K.L.E. Academy of Higher Education & ResearchC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of DelhiC3  - University College of Medical SciencesC3  - Moti Lal Nehru Medical CollegeC3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - SEP
PY  - 2018
VL  - 38
IS  - 3
SP  - 260
EP  - 279
DO  - 10.1007/s13410-018-0677-3
AN  - WOS:000444005700002
ER  -

TY  - JOUR
AU  - Razik, A
AU  - Das, CJ
AU  - Sharma, S
AU  - Seth, A
AU  - Srivastava, DN
AU  - Mathur, S
AU  - Kumar, R
AU  - Gupta, AK
TI  - Diagnostic performance of diffusion-weighted MR imaging at 3.0 T in predicting muscle invasion in urinary bladder cancer: utility of evaluating the morphology of the reactive tumor stalk
T2  - ABDOMINAL RADIOLOGY
KW  - Diffusion-weighted MRI
KW  - Urinary bladder cancer
KW  - Tumor staging
KW  - UROTHELIAL CARCINOMA
KW  - ACCURACY
KW  - GRADE
AB  - To evaluate the diagnostic performance of stalk morphology on diffusion-weighted imaging (DWI) in comparison with conventional MRI in predicting muscle invasion in urinary bladder cancer.
   The study was prospective and approved by the institutional ethics committee. A written informed consent was obtained from all the patients. The study included 56 patients who presented with bladder mass between January 2014 and November 2015. After excluding 16 patients, 40 patients with 92 tumors were assessed. All the 40 patients underwent MRI at 3.0 Tesla (Achieva, Philips) inclusive of DWI (b0, 500, 1000 and 1500). Two radiologists evaluated the images independently, and disparities were resolved through consensus. For predicting muscle invasion on T2-weighted images, tumor morphology (papillary versus non-papillary), distensibility of the underlying bladder wall, and perivesical fat infiltration were evaluated. On DWI, the criterion used in a previous study (Takeuchi et al.) was used along with tumor stalk morphology. Findings were compared with histopathology using Pearson's chi (2) test, and diagnostic performance indices were calculated.
   All the evaluated features were present with significantly higher frequency in muscle-invasive tumors (p < 0.001). The finding of absent or distorted stalk on DWI had the highest sensitivity (87.5%) and specificity (97.6%). Conventional imaging features of non-papillary stalk morphology, restricted distension of underlying bladder wall, perivesical fat infiltration, as well as the previous DWI criterion were less sensitive (56.3%, 68.8%, 56.3% and 56.3%, respectively) in predicting muscle invasion.
   Assessment of the morphology of the reactive tumor stalk on DWI has better diagnostic performance in predicting muscle invasion than conventional MRI.
AD  - All India Inst Med Sci, Dept Radiol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Urol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - SEP
PY  - 2018
VL  - 43
IS  - 9
SP  - 2431
EP  - 2441
DO  - 10.1007/s00261-018-1458-7
AN  - WOS:000442351800025
ER  -

TY  - JOUR
AU  - Rumpf, HJ
AU  - Achab, S
AU  - Billieux, J
AU  - Bowden-Jones, H
AU  - Carragher, N
AU  - Demetrovics, Z
AU  - Higuchi, S
AU  - King, DL
AU  - Mann, K
AU  - Potenza, M
AU  - Saunders, JB
AU  - Abbott, M
AU  - Ambekar, A
AU  - Aricak, OT
AU  - Assanangkornchai, S
AU  - Bahar, N
AU  - Borges, G
AU  - Brand, M
AU  - Chan, EML
AU  - Chung, T
AU  - Derevensky, J
AU  - El Kashef, A
AU  - Farrell, M
AU  - Fineberg, NA
AU  - Gandin, C
AU  - Gentile, DA
AU  - Griffiths, MD
AU  - Goudriaan, AE
AU  - Grall-Bronnec, M
AU  - Hao, W
AU  - Hodgins, DC
AU  - Ip, P
AU  - Kiraly, O
AU  - Lee, HK
AU  - Kuss, D
AU  - Lemmens, JS
AU  - Long, J
AU  - Lopez-Fernandez, O
AU  - Mihara, S
AU  - Petry, NM
AU  - Pontes, HM
AU  - Rahimi-Movaghar, A
AU  - Rehbein, F
AU  - Rehm, J
AU  - Scafato, E
AU  - Sharma, M
AU  - Spritzer, D
AU  - Stein, DJ
AU  - Tam, P
AU  - Weinstein, A
AU  - Wittchen, HU
AU  - Wölfling, K
AU  - Zullino, D
AU  - Poznyak, V
TI  - Including gaming disorder in the ICD-11: The need to do so from a clinical and public health perspective
T2  - JOURNAL OF BEHAVIORAL ADDICTIONS
KW  - gaming disorder
KW  - ICD-11
KW  - clinical perspective
KW  - public health
KW  - ON SCHOLARS OPEN-DEBATE-PAPER-ON-THE-WORLD-HEALTH-ORGANIZATION-ICD-11-GAMING-DISORDER-PROPOS
KW  - AARSETH-ET-AL.
KW  - ALCOHOL-USE
KW  - INCLUSION
KW  - ADDICTION
KW  - INTERNET
KW  - DIAGNOSIS
AB  - The proposed introduction of gaming disorder (GD) in the 11th revision of the International Classification of Diseases (ICD-11) developed by the World Health Organization (WHO) has led to a lively debate over the past year. Besides the broad support for the decision in the academic press, a recent publication by van Rooij et al. (2018) repeated the criticism raised against the inclusion of GD in ICD-11 by Aarseth et al. (2017). We argue that this group of researchers fails to recognize the clinical and public health considerations, which support the WHO perspective. It is important to recognize a range of biases that may influence this debate; in particular, the gaming industry may wish to diminish its responsibility by claiming that GD is not a public health problem, a position which maybe supported by arguments from scholars based in media psychology, computer games research, communication science, and related disciplines. However, just as with any other disease or disorder in the ICD-11, the decision whether or not to include GD is based on clinical evidence and public health needs. Therefore, we reiterate our conclusion that including GD reflects the essence of the ICD and will facilitate treatment and prevention for those who need it.
AD  - Univ Lubeck, Dept Psychiat & Psychotherapy, Ratzeburger Allee 160, D-23538 Lubeck, GermanyAD  - Geneva Univ Hosp, Dept Mental Hlth & Psychiat, Serv Addictol, Geneva, SwitzerlandAD  - Univ Geneva, Geneva WHO Collaborating Ctr Training & Res, Geneva, SwitzerlandAD  - Univ Luxembourg, Inst Hlth & Behav, Addict & Compuls Behav Lab, Esch Sur Alzette, LuxembourgAD  - Imperial Coll London, Div Brain Sci, Cent North West London NHS Trust, London, EnglandAD  - WHO Headquarters, Dept Mental Hlth & Subst Abuse, Geneva, SwitzerlandAD  - Eotvos Lorand Univ, Inst Psychol, Budapest, HungaryAD  - Natl Hosp Org Kurihama Med & Addict Ctr, Yokosuka, Kanagawa, JapanAD  - Univ Adelaide, Sch Psychol, Adelaide, SA, AustraliaAD  - Heidelberg Univ, Cent Inst Mental Hlth, Mannheim, GermanyAD  - Yale Univ, Sch Med, Ctr Child Study,Connecticut Mental Hlth Ctr, Dept Psychiat & Neurosci,Natl Ctr Addict & Subst, New Haven, CT 06510 USAAD  - Univ Queensland, Ctr Youth Subst Abuse Res, Brisbane, Qld, AustraliaAD  - Auckland Univ Technol, Fac Hlth & Environm Sci, Auckland, New ZealandAD  - All India Inst Med Sci, Natl Drug Dependence Treatment Ctr, Dept Psychiat, New Delhi, IndiaAD  - Hasan Kalyoncu Univ, Dept Psychol, Gaziantep, TurkeyAD  - Prince Songkla Univ, Fac Med, Epidemiol Unit, Hat Yai, Songkhla, ThailandAD  - Prince Songkla Univ, Fac Med, Ctr Alcohol Studies, Hat Yai, Songkhla, ThailandAD  - Hosp Selayang, Dept Psychiat & Mental Hlth, Selangor, MalaysiaAD  - Natl Inst Psychiat, Mexico City, DF, MexicoAD  - Univ Duisburg Essen, Gen Psychol Cognit Ctr Behav Addict Res, Duisburg, GermanyAD  - Erwin L Hahn Inst Magnet Resonance Imaging, Essen, GermanyAD  - Tung Wah Grp Hosp, Integrated Ctr Addict Prevent & Treatment, Hong Kong, Hong Kong, Peoples R ChinaAD  - Dept Hlth, Hong Kong, Hong Kong, Peoples R ChinaAD  - McGill Univ, Appl Child Psychol, Montreal, PQ, CanadaAD  - McGill Univ, Dept Psychiat, Montreal, PQ, CanadaAD  - Natl Rehabil Ctr, Abu Dhabi, U Arab EmiratesAD  - Univ New South Wales, Natl Drug & Alcohol Res Ctr, Randwick, NSW, AustraliaAD  - Hertfordshire Partnership Univ NHS Fdn Trust, Stevenage, Herts, EnglandAD  - Univ Hertfordshire, Dept Postgrad Med, Hatfield, Herts, EnglandAD  - Italian Natl Inst Hlth, Natl Observ Alcohol, Natl Ctr Addict & Doping, Rome, ItalyAD  - Iowa State Univ, Dept Psychol, Ames, IA USAAD  - Nottingham Trent Univ, Dept Psychol, Int Gaming Res Unit, Nottingham, EnglandAD  - Univ Amsterdam, Acad Med Ctr, Dept Psychiat, Mental Hlth Care, Amsterdam, NetherlandsAD  - CHU Nantes, Addictol & Psychiat Dept, Nantes, FranceAD  - Cent S Univ, Xiangya Hosp 2, Mental Hlth Inst, Changsha, Hunan, Peoples R ChinaAD  - Univ Calgary, Dept Psychol, Calgary, AB, CanadaAD  - Univ Hong Kong, Dept Paediat & Adolescent Med, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R ChinaAD  - Catholic Univ Korea, Coll Med, Dept Psychiat, Seoul, South KoreaAD  - Univ Amsterdam, Amsterdam Sch Commun Res, Ctr Res Children Adolescents & Media, Amsterdam, NetherlandsAD  - Univ Connecticut, Dept Psychiat, Sch Med, Farmington, CT 06107 USAAD  - Univ Tehran Med Sci, Iranian Natl Ctr Addict Studies, Tehran, IranAD  - Criminol Res Inst Lower Saxony, Hannover, GermanyAD  - Ctr Addict & Mental Hlth, Inst Mental Hlth Policy Res, Toronto, ON, CanadaAD  - Univ Toronto, Dalla Lana Sch Publ Hlth, Inst Med Sci, Dept Psychiat,Fac Med, Toronto, ON, CanadaAD  - Tech Univ Dresden, Inst Clin Psychol & Psychotherapy, Epidemiol Res Unit, Dresden, GermanyAD  - Natl Inst Hlth, Natl Observ Alcohol, Rome, ItalyAD  - Natl Inst Mental Hlth & Neurosci, Bengaluru, IndiaAD  - Study Grp Technol Addict, Porto Alegre, RS, BrazilAD  - Univ Cape Town, SA MRC Unit Risk & Resilience Mental Disorders, Dept Psychiat & Mental Hlth, Cape Town, South AfricaAD  - Delta Clin, Network Internet Invest & Res Australia, Sydney, NSW, AustraliaAD  - Univ Ariel, Dept Behav Sci, Ariel, IsraelAD  - Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Psychosomat Med & Psychotherapy, Outpatient Clin Behav Addict, Mainz, GermanyC3  - University of LubeckC3  - University of GenevaC3  - University of GenevaC3  - University of LuxembourgC3  - Imperial College LondonC3  - World Health OrganizationC3  - Eotvos Lorand UniversityC3  - University of AdelaideC3  - Central Institute of Mental HealthC3  - Ruprecht Karls University HeidelbergC3  - Yale UniversityC3  - University of QueenslandC3  - Auckland University of TechnologyC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)C3  - Hasan Kalyoncu UniversityC3  - Prince of Songkla UniversityC3  - Prince of Songkla UniversityC3  - Instituto Nacional de Psiquiatria Ramon de la Fuente MunizC3  - University of Duisburg EssenC3  - University of Duisburg EssenC3  - McGill UniversityC3  - McGill UniversityC3  - University of New South Wales SydneyC3  - University of HertfordshireC3  - Istituto Superiore di Sanita (ISS)C3  - Iowa State UniversityC3  - Nottingham Trent UniversityC3  - University of AmsterdamC3  - Academic Medical Center AmsterdamC3  - Nantes UniversiteC3  - CHU de NantesC3  - Central South UniversityC3  - University of CalgaryC3  - University of Hong KongC3  - Catholic University of KoreaC3  - University of AmsterdamC3  - University of ConnecticutC3  - Tehran University of Medical SciencesC3  - University of TorontoC3  - Centre for Addiction & Mental Health - CanadaC3  - University of TorontoC3  - Technische Universitat DresdenC3  - Istituto Superiore di Sanita (ISS)C3  - National Institute of Mental Health & Neurosciences - IndiaC3  - University of Cape TownC3  - Ariel UniversityC3  - Johannes Gutenberg University of MainzPU  - AKADEMIAI KIADO ZRT
PI  - BUDAPEST
PA  - BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY
DA  - SEP
PY  - 2018
VL  - 7
IS  - 3
SP  - 556
EP  - 561
DO  - 10.1556/2006.7.2018.59
AN  - WOS:000446106300012
ER  -

TY  - JOUR
AU  - Saibu, Y
AU  - Kumar, S
AU  - Jamwal, A
AU  - Peak, D
AU  - Niyogi, S
TI  - A FTIRM study of the interactive effects of metals (zinc, copper and cadmium) in binary mixtures on the biochemical constituents of the gills in rainbow trout (<i>Oncorhynchus mykiss</i>)
T2  - COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY
KW  - Metals
KW  - Interactions
KW  - Rainbow trout
KW  - Gill
KW  - FTIRM
KW  - BIOTIC LIGAND MODEL
KW  - ACUTE TOXICITY
KW  - WATER
KW  - EXPOSURE
KW  - MECHANISMS
KW  - FISH
KW  - ACCUMULATION
KW  - TOXICANTS
KW  - BINDING
KW  - PROTEIN
AB  - We employed Fourier Transform Infrared Microspectroscopy to examine, in situ, the effects of waterborne Cu, Cd and Zn, alone and in binary mixtures, during acute exposure on the integrity of major lipid and protein constituents of the gill of a model teleost species, rainbow trout (Oncorhynchus mykiss). Our findings demonstrated that acute exposure to metals, both individually and in binary mixture, resulted in the degradations of various components of proteins and lipids in the gill tissue. Generally, when comparing the effects of individual metals, Cu was found to induce the maximum adverse effects followed by Cd and Zn, respectively. Among the binary metal mixture combinations, Cu and Cd produced additive effects on the degradation of major proteins and lipid moieties, whereas the co-exposure of Zn with Cd or Cu elicited ameliorative effects, indicating antagonistic (less than additive) interactions between Zn and Cd or Cu m the rainbow trout gill. Overall, the present study demonstrates that FTIRM can be a useful tool to gain novel mechanistic insights into the biochemical changes induced by metals m the fish gill, which could influence the overall toxicity of metals to fish.
AD  - Univ Saskatchewan, Toxicol Ctr, 44 Campus Dr, Saskatoon, SK S7N 5B3, CanadaAD  - Uppsala Univ, Dept Engn Sci, Uppsala, SwedenAD  - All India Inst Med Sci, Dept Biophys, New Delhi, IndiaAD  - Univ Saskatchewan, Dept Biol, 112 Sci Pl, Saskatoon, SK, CanadaAD  - Univ Saskatchewan, Dept Soil Sci, 114 Sci Pl, Saskatoon, SK, CanadaC3  - University of SaskatchewanC3  - Uppsala UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of SaskatchewanC3  - University of SaskatchewanPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - SEP
PY  - 2018
VL  - 211
SP  - 48
EP  - 56
DO  - 10.1016/j.cbpc.2018.05.009
AN  - WOS:000437815100007
ER  -

TY  - JOUR
AU  - Saito, S
AU  - Horinouchi, T
AU  - Nakagami, Y
AU  - Ii, T
AU  - Sarkar, S
AU  - McSweeney, A
AU  - Yoshida, L
AU  - Aniwattanapong, D
AU  - Xin, LM
AU  - Segrec, N
AU  - Varbanov, SV
AU  - Shams, SF
AU  - Suzuki, K
AU  - Mariano, MPV
AU  - Tomlin, SC
AU  - Kuno, K
AU  - Freedman, R
AU  - Riba, MB
AU  - Akiyama, T
AU  - Kawanishi, C
TI  - Approaches to suicide prevention: Ideas and models presented by Japanese and international early career psychiatrists
T2  - PSYCHIATRY AND CLINICAL NEUROSCIENCES
AD  - Tenjinkai Amekudai Hosp, Med Corp, Okinawa, JapanAD  - Japan Young Psychiatrists Org, Tokyo, JapanAD  - Hokkaido Univ, Grad Sch Med, Dept Psychiat & Neurol, Sapporo, Hokkaido, JapanAD  - Kyoto Univ, Grad Sch Med, Dept Psychiat, Kyoto, JapanAD  - Nagoya City Univ, Grad Sch Med Sci, Dept Psychiat, Nagoya, Aichi, JapanAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - All India Inst Med Sci, NDDTC, New Delhi, IndiaAD  - Univ Coll Cork, Cork, IrelandAD  - Natl Suicide Res Fdn, Cork, IrelandAD  - Chulalongkorn Univ, Dept Psychiat, Fac Med, Bangkok, ThailandAD  - Peking Univ, Huilongguan Clin Med Sch, Beijing Huilongguan Hosp, Beijing, Peoples R ChinaAD  - Univ Psychiat Clin Ljubljana, Ctr Treatment Drug Addict, Ljubljana, SloveniaAD  - Med Univ Varna, Dept Psychiat & Med Psychol, Varna, BulgariaAD  - Uttara Adhunik Med Coll Hosp, Dept Psychiat, Dhaka, BangladeshAD  - Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, JapanAD  - Univ East Ramon Magsaysay Mem Med Ctr Inc, Dept Psychiat, Quezon City, PhilippinesAD  - South London & Maudsley NHS Fdn Trust, Maudsley Hosp, Dept Eating Disorders, Beckenham, Kent, EnglandAD  - Mie Prefectural Mental Med Ctr, Clin Dept Psychiat, Tsu, Mie, JapanAD  - Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO USAAD  - Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USAAD  - NTT Med Ctr Tokyo, Dept Neuropsychiat, Tokyo, JapanAD  - Sapporo Med Univ, Grad Sch Med, Dept Neuropsychiat, Sapporo, Hokkaido, JapanC3  - Hokkaido UniversityC3  - Kyoto UniversityC3  - Nagoya City UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)C3  - University College CorkC3  - Chulalongkorn UniversityC3  - Peking UniversityC3  - University Medical Centre LjubljanaC3  - Medical University VarnaC3  - Keio UniversityC3  - UERM Memorial Medical CenterC3  - South London & Maudsley NHS TrustC3  - University of Colorado SystemC3  - University of Colorado Anschutz Medical CampusC3  - University of Michigan SystemC3  - University of MichiganC3  - Kanto Medical Center NTT ECC3  - Sapporo Medical UniversityPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - SEP
PY  - 2018
VL  - 72
IS  - 9
SP  - 741
EP  - 741
DO  - 10.1111/pcn.12737
AN  - WOS:000443700900010
ER  -

TY  - JOUR
AU  - Samal, P
AU  - Goyal, V
AU  - Makharia, GK
AU  - Das, CJ
AU  - Gorthi, SP
AU  - Vishnu, VY
AU  - Singh, MB
AU  - Srivastava, MVP
TI  - Transfer Dysphagia Due to Focal Dystonia
T2  - JOURNAL OF MOVEMENT DISORDERS
KW  - Transfer dysphagia
KW  - focal dystonia
KW  - eating dystonia
KW  - videofluoroscopy
KW  - barium swallow
KW  - SWALLOWING FUNCTION
AB  - Objective The inability to propel a bolus of food successfully from the posterior part of the oral cavity to the oropharynx is defined as transfer dysphagia. The present case series describes the varied presentation of transfer dysphagia due to focal dystonia and highlights the importance of early detection by following up on strong suspicions.
   Methods We describe seven cases of transfer dysphagia due to focal dystonia. Transfer dysphagia as a form of focal dystonia may appear as the sole presenting complaint or may present with other forms of focal dystonia.
   Results Four out of seven patients had pure transfer dysphagia and had previously been treated for functional dysphagia. A high index of suspicion, barium swallow including videofluoroscopy, associated dystonia in other parts of the body and response to drug therapy with trihexyphenidyl/tetrabenazine helped to confirm the diagnosis.
   Conclusion Awareness of these clinical presentations among neurologists and non-neurologists can facilitate an early diagnosis and prevent unnecessary investigations.
AD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiol, New Delhi, IndiaAD  - Kasturba Med Coll & Hosp, Dept Neurol, Manipal, Karnataka, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Manipal Academy of Higher Education (MAHE)C3  - Kasturba Medical College, ManipalPU  - KOREAN MOVEMENT DISORDERS SOC
PI  - SEOUL
PA  - 2011 MAPO HANWHA OBELISK, 555, DOHWA-DONG, MAPO-GU, SEOUL, 04167, SOUTH KOREA
DA  - SEP
PY  - 2018
VL  - 11
IS  - 3
SP  - 129
EP  - 132
DO  - 10.14802/jmd.17081
AN  - WOS:000446122100004
ER  -

TY  - JOUR
AU  - Sarangi, SC
AU  - Kaur, N
AU  - Tripathi, M
AU  - Gupta, YK
TI  - Cost analysis study of neuropsychiatric drugs: Role of National List of Essential Medicines, India
T2  - NEUROLOGY INDIA
KW  - Cost per defined daily dose
KW  - cost variation
KW  - National List of Essential Medicines
KW  - neuropsychiatric drugs
AB  - Context: This study investigated the cost variation among neuropsychiatric drugs prevalent in the Indian market with reference to the National List of Essential Medicines (NLEM, 2015).
   Aims: To promote the rational use of medicines through cost variation analysis among drugs for neuropsychiatric disorders enlisted in NLEM and those not included in NLEM (NNLEM).
   Study Design: This study included drugs used for epilepsy, migraine, psychosis, depression, generalized anxiety disorder (GAD), bipolar disorder, and obsessive-compulsive disorder (OCD).
   Materials and Methods: The unit drug cost for the selected strengths of different manufacturers mentioned in the Current Index of Medical Specialities 2016 was used for calculating cost/defined daily dose (DDD).
   Statistical Analysis: Comparison was done among individual drugs and groups (NLEM and NNLEM) by cost/DDD in terms of interquartile range, percentage cost variation, and cost ratio.
   Results: The cost variation is wide for neuropsychiatric drugs (maximum, 1724.3% for risperidone in NLEM, and 1780% for olanzapine in NNLEM). The drug-to-cost ratio is the highest (168.8 times) for bipolar disorder and the lowest (9.7 times) for GAD. The NLEM drugs were found to be more economical than the NNLEM drugs among antiepileptic drugs, antidepressants, and drugs for bipolar disorder; however, the reverse was noted for antimigraine drugs and drugs for GAD. Antipsychotic medications and drugs for OCD in the NLEM group have a wider range than in the NNLEM group.
   Conclusions: The NLEM group has economical drugs in some disease categories; there is a need to consider the cost effectiveness of all drug categories while revising the NLEM next time and attention should focus on drug price regulation policies to accomplish the goal of rational use of medicines.
AD  - All India Inst Med Sci, Dept Pharmacol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
DA  - SEP-OCT
PY  - 2018
VL  - 66
IS  - 5
SP  - 1427
EP  - 1433
DO  - 10.4103/0028-3886.241345
AN  - WOS:000447605100040
ER  -

TY  - JOUR
AU  - Satpathy, G
AU  - Behera, HS
AU  - Sharma, A
AU  - Mishra, AK
AU  - Mishra, D
AU  - Sharma, N
AU  - Tandon, R
AU  - Agarwal, T
AU  - Titiyal, JS
TI  - A 20-year experience of ocular herpes virus detection using immunofluorescence and polymerase chain reaction
T2  - CLINICAL AND EXPERIMENTAL OPTOMETRY
KW  - herpetic keratitis
KW  - immunofluorescence assay
KW  - ocular HSV infection
KW  - polymerase chain reaction
KW  - VARICELLA-ZOSTER-VIRUS
KW  - SIMPLEX-VIRUS
KW  - EPITHELIAL KERATITIS
KW  - RAPID DIAGNOSIS
KW  - EYE DISEASE
KW  - EPIDEMIOLOGY
KW  - PREVENTION
KW  - DNA
AB  - Background: To detect the presence of herpes virus in corneal scrapings/corneal grafts of suspected herpetic keratitis patients attending the outpatient department/casualty of the Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi for the past 20 years with immunofluorescence assay and to analyse the efficacy of polymerase chain reaction over immunofluorescence for routine laboratory diagnosis in some of the specimens.
   Methods: Corneal scrapings and corneal grafts were collected by the ophthalmologists from 1,926 suspected herpetic keratitis patients between 1996 and 2015, among whom 1,863 patients were processed with immunofluorescence assay and 302 patients were processed with polymerase chain reaction assay for the detection of herpes virus. Of the 302 patients, clinical specimens from 239 patients were analysed by both polymerase chain reaction and immunofluorescence assay.
   Results: Of the 1,863 suspected herpetic keratitis patients diagnosed with immunofluorescence assay, 277 (14.9 per cent) were found positive for herpes simplex virus 1 antigen. Similarly, of the 302 suspected herpetic keratitis patients diagnosed by polymerase chain reaction, 70 (23.2 per cent) were found positive for herpes simplex virus DNA. Of the 239 patients diagnosed by both polymerase chain reaction and immunofluorescence assay, 35 (14.6 per cent) were found positive with immunofluorescence assay, 59 (24.7 per cent) were found positive with polymerase chain reaction, 30 (12.5 per cent) were positive with both immunofluorescence and polymerase chain reaction assay.
   Conclusion: Efficacy and accuracy of the polymerase chain reaction assay was greater compared to the immunofluorescence assay for detection of herpes virus in corneal scrapings/corneal grafts of suspected herpetic keratitis patients. Although the immunofluorescence assay is a rapid test for the detection of herpes virus in suspected herpetic keratitis patients, a combination of polymerase chain reaction with immunofluorescence assay will provide higher reliable and accurate results.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Ocular Microbiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - TAYLOR & FRANCIS LTD
PI  - ABINGDON
PA  - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
DA  - SEP
PY  - 2018
VL  - 101
IS  - 5
SP  - 648
EP  - 651
DO  - 10.1111/cxo.12669
AN  - WOS:000442986200005
ER  -

TY  - JOUR
AU  - Seddon, JA
AU  - Schaaf, HS
AU  - Marais, B
AU  - McKenna, L
AU  - Garcia-Prats, AJ
AU  - Hesseling, AC
AU  - Hughes, J
AU  - Howell, P
AU  - Detjen, A
AU  - Amanullah, F
AU  - Singh, U
AU  - Master, I
AU  - Perez-Velez, CM
AU  - Misra, N
AU  - Becerra, MC
AU  - Furin, JJ
TI  - Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis
T2  - LANCET RESPIRATORY MEDICINE
KW  - REPURPOSED DRUGS
AD  - Stellenbosch Univ, Dept Paediat & Child Hlth, Desmond Tutu TB Ctr, Fac Med & Hlth Sci, ZA-7505 Cape Town, South AfricaAD  - Imperial Coll London, Dept Paediat, London, EnglandAD  - Univ Sydney, Childrens Hosp Westmead, Sydney, NSW, AustraliaAD  - Univ Sydney, Discipline Paediat & Adolescent Med, Sydney, NSW, AustraliaAD  - Treatment Act Grp, New York, NY USAAD  - Univ Witwatersrand, Dept Med, Clin HIV Res Unit, Johannesburg, South AfricaAD  - UNICEF, New York, NY USAAD  - Indus Hosp, Karachi, PakistanAD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaAD  - Kwazulu Natal Dept Hlth, King Dinizulu Hosp Complex, Durban, South AfricaAD  - Pima Cty Hlth Dept, TB Control & Prevent Program, Tucson, AZ USAAD  - Univ Arizona, Coll Med, Div Infect Dis, Tucson, AZ USAAD  - Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA USAC3  - Stellenbosch UniversityC3  - Imperial College LondonC3  - NSW HealthC3  - The Children's Hospital at WestmeadC3  - University of SydneyC3  - University of SydneyC3  - Treatment Action GroupC3  - University of WitwatersrandC3  - UNICEFC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of ArizonaC3  - Harvard UniversityC3  - Harvard Medical SchoolPU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - SEP
PY  - 2018
VL  - 6
IS  - 9
SP  - 662
EP  - 664
DO  - 10.1016/S2213-2600(18)30329-1
AN  - WOS:000443315800018
ER  -

TY  - JOUR
AU  - Sengupta, A
AU  - Agarwal, S
AU  - Gupta, PK
AU  - Ahlawat, S
AU  - Patir, R
AU  - Gupta, RK
AU  - Singh, A
TI  - On differentiation between vasogenic edema and non-enhancing tumor in high-grade glioma patients using a support vector machine classifier based upon pre and post-surgery MRI images
T2  - EUROPEAN JOURNAL OF RADIOLOGY
KW  - High grade glioma
KW  - Tumor segmentation
KW  - Non-enhancing tumor
KW  - Vasogenic edema
KW  - DCE-MRI
KW  - SVM
KW  - BRAIN-TUMOR
KW  - SEGMENTATION
KW  - RECURRENCE
KW  - PERFUSION
KW  - CRITERIA
KW  - AREA
KW  - DCE
AB  - Purpose: High grade gliomas (HGGs) are infiltrative in nature. Differentiation between vasogenic edema and non-contrast enhancing tumor is difficult as both appear hyperintense in T-2-W/FLAIR images. Most studies involving differentiation between vasogenic edema and non-enhancing tumor consider radiologist-based tumor delineation as the ground truth. However, analysis by a radiologist can be subjective and there remain both inter- and intra-rater differences. The objective of the current study is to develop a methodology for differentiation between non-enhancing tumor and vasogenic edema in HGG patients based on T-1 perfusion MRI parameters, using a ground truth which is independent of a radiologist's manual delineation of the tumor.
   Material and Methods: This study included 9 HGG patients with pre- and post-surgery MRI data and 9 metastasis patients with pre-surgery MRI data. MRI data included conventional T-1-W, T-2-W, and FLAIR images and DCE-MRI dynamic images. In this study, the authors hypothesize that surgeried non-enhancing FLAIR hyperintense tissue, which was obtained using pre- and post-surgery MRI images of glioma patients, should be largely comprised of non-enhancing tumor. Hence this could be used as an alternative ground truth for the non-enhancing tumor region. Histological examination of the resected tissue was done for validation. Vasogenic edema was obtained from the non-enhancing FLAIR hyperintense region of metastasis patients, as they have a clear boundary between enhancing tumor and edema. DCE-MRI data analysis was performed to obtain T-1 perfusion MRI parameters. Support Vector Machine (SVM) classification was performed using T-1 perfusion MRI parameters to differentiate between non-enhancing tumor and vasogenic edema. Receiver-operating-characteristic (ROC) analysis was done on the results of the SVM classifier. For improved classification accuracy, the SVM output was post-processed via neighborhood smoothing.
   Results: Histology results showed that resected tissue consists largely of tumorous tissue with 7.21 +/- 4.05% edema and a small amount of healthy tissue. SVM-based classification provided a misclassification error of 8.4% in differentiation between non-enhancing tumor and vasogenic edema, which was further reduced to 2.4% using neighborhood smoothing.
   Conclusion: The current study proposes a semiautomatic method for segmentation between non-enhancing tumor and vasogenic edema in HGG patients, based on an SVM classifier trained on an alternative ground truth to a radiologist's manual delineation of a tumor. The proposed methodology may prove to be a useful tool for pre- and post-operative evaluation of glioma patients.
AD  - IIT Delhi, Ctr Biomed Engn, Block 2,Room 299, New Delhi 110016, IndiaAD  - IIT Delhi, Dept Elect Engn, New Delhi, IndiaAD  - Fortis Mem Res Inst, Dept Radiol, Gurgaon, IndiaAD  - Fortis Mem Res Inst, SRL Diagnost, Gurgaon, IndiaAD  - Fortis Mem Res Inst, Dept Neurosurg, Gurgaon, IndiaAD  - AIIMS Delhi, Dept Biomed Engn, New Delhi, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER IRELAND LTD
PI  - CLARE
PA  - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
DA  - SEP
PY  - 2018
VL  - 106
SP  - 199
EP  - 208
DO  - 10.1016/j.ejrad.2018.07.018
AN  - WOS:000442592500029
ER  -

TY  - JOUR
AU  - Sharma, A
AU  - Gupta, V
AU  - Shashikant, K
TI  - Optimizing Management of Open Fractures in Children
T2  - INDIAN JOURNAL OF ORTHOPAEDICS
KW  - Antibiotics
KW  - children
KW  - debridement
KW  - open fracture
KW  - FEMORAL-SHAFT FRACTURES
KW  - OPEN TIBIAL FRACTURES
KW  - I OPEN FRACTURES
KW  - EXTERNAL FIXATION
KW  - FOREARM FRACTURES
KW  - LOWER-EXTREMITY
KW  - SEVERITY SCORE
KW  - INJURIES
KW  - TRAUMA
KW  - COMPLICATIONS
AB  - Open fractures in children differ front adults owing to their better healing potential. Management strategies for open fracture in children are changing with improvement in our understanding of soft-tissue reconstruction and fracture fixation. A literature review was ix-thinned for articles covering management of open fractures in children. The cornerstones of management include prevention of infection, debridement, and skeletal stabilization with soft-tissue coverage. The injury should be categorized according to the established trauma classification systems. Timely administration of appropriate antibiotics is important for preventing infections. Soft-tissue management includes copious irrigation and debridement of the wound. Fractures can be stabilized by a variety of nonoperative and operative means, taking into consideration the special needs of the growing skeleton and the role of a thick and active periosteum in the healing of fractures. The soft-tissue coverage required depends on the grade of injury.
AD  - KUMC GURO Hosp, Dept Paediat Orthopaed, Seoul, South KoreaAD  - Safdarjang Hosp, Cent Inst Orthopaed, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Orthopaed, New Delhi, IndiaC3  - Korea UniversityC3  - Korea University Medicine (KU Medicine)C3  - Vardhman Mahavir Medical College & Safdarjung HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - SEP-OCT
PY  - 2018
VL  - 52
IS  - 5
SP  - 470
EP  - 480
DO  - 10.4103/ortho.IJOrtho_319_17
AN  - WOS:000445829900005
ER  -

TY  - JOUR
AU  - Sharma, A
AU  - Bakhshi, S
TI  - Midostaurin in acute myeloid leukaemia with a <i>FLT3</i> mutation: Testing the waters
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
KW  - INTERNAL TANDEM DUPLICATION
KW  - AML
KW  - EXPRESSION
AD  - All India Inst Med Sci, Dr BR Ambedkar Inst Rotary Canc Hosp, Dept Med Oncol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - SEP-OCT
PY  - 2018
VL  - 31
IS  - 5
SP  - 288
EP  - +
DO  - 10.4103/0970-258X.261188
AN  - WOS:000473690700009
ER  -

TY  - JOUR
AU  - Sharma, N
AU  - Agrawal, N
AU  - Maharana, PK
AU  - Agarwal, T
AU  - Vanathi, M
AU  - Vajpayee, RB
TI  - Comparison of Hospital Cornea Retrieval and Voluntary Eye Donation Program in Eye Banking
T2  - EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE
KW  - Hospital cornea retrieval program
KW  - Voluntary eye donation
KW  - Eye banking
KW  - Keratoplasty
KW  - AGE
AB  - Objectives: Comparison of demographic, clinical, microbiological, and utility profile of the corneas obtained through hospital corneal retrieval program (HCRP) and voluntary eye donation (VED) program.
   Methods: Donor corneas retrieved during a 14 months period at National eye bank, India were included in the study. The donor cornea grading was done according to the cornea donor study. The corneal swabs were taken from the donor eyes and were sent for microbiological evaluation. The quality of the donor corneas and their utility was assessed.
   Results: Out of 1,014 donor corneas collected (700 through HCRP, 314 through VED), 455 were of optical grade (91.2% [415/455] through the HCRP and 8.7% [40/455] through the VED). HCRP had a higher proportion of donors in younger age (81.6% vs. 21%, P<0.0001), clear lens (78.6% vs. 66.2%, P<0.0001), and endothelial cell counts of more than2,000 cells per squared millimeter (64.9% vs. 28%, P<0.0001). Higher proportions of corneas in HCRP were used for optical indications (Penetrating keratoplasty, 24.5% vs. 13.3%, P<0.0001 and endothelial keratoplasty, 18.14% vs. 4.14%, P<0.0001). VED had a greater number of corneas found unsuitable for keratoplasty (37.4% vs. 6.4%, P<0.001). Most of the donors in the HCRP belonged to lower socioeconomic status (59.4% vs. 17.9%, P<0.0001). No significant difference was found in the microbial contamination between the two groups.
   Conclusions: Most corneas retrieved through HCRP were of optical grade quality and efforts should be focused on HCRP to reduce the demand-supply deficit in cornea transplantation.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Ophthalmol, Bhubaneswar, IndiaAD  - Univ Melbourne, Royal Victorian Eye & Ear Hosp, North West Acad Ctr, Vis Eye Inst Melbourne, Melbourne, Vic, AustraliaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) BhubaneswarC3  - Royal Victorian Eye & Ear HospitalC3  - University of MelbournePU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - SEP
PY  - 2018
VL  - 44
SP  - S54
EP  - S58
DO  - 10.1097/ICL.0000000000000320
AN  - WOS:000457837000009
ER  -

TY  - JOUR
AU  - Sharma, R
AU  - Tandon, V
AU  - Sawarkar, D
AU  - Phalak, M
AU  - Raheja, A
AU  - Kale, SS
TI  - Intracranial pressure (ICP) monitoring in diffuse brain injury: to do or not to do?
T2  - ACTA NEUROCHIRURGICA
KW  - DECOMPRESSIVE CRANIECTOMY
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER WIEN
PI  - WIEN
PA  - SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
DA  - SEP
PY  - 2018
VL  - 160
IS  - 9
SP  - 1699
EP  - 1700
DO  - 10.1007/s00701-018-3610-0
AN  - WOS:000441915100005
ER  -

TY  - JOUR
AU  - Sharma, VK
AU  - Bhatia, R
AU  - Yadav, CP
TI  - Clinical Profile and Allergens in Pigmented Cosmetic Dermatitis and Allergic Contact Dermatitis to Cosmetics in India
T2  - DERMATITIS
AB  - Background Pigmented cosmetic dermatitis (PCD) is frequently encountered in dark-skinned individuals as gradual hyperpigmentation on the face without preceding erythema or itching. Little is known about the allergen profile in PCD.
   Objectives The aim of the study was to describe the clinical profile and common allergens in PCD and allergic contact dermatitis (ACD) to cosmetics in Delhi.
   Methods Records of patients suspected of PCD and ACD to cosmetics were analyzed. All patients were patch tested with the Indian standard series, Indian cosmetic and fragrance series, and personal cosmetics and, in relevant cases, hairdresser series.
   Results One hundred six patients were analyzed. Patch test was positive in 77 cases (72.6%). Cetrimonium, gallate mix, thiomerosal, and skin lightening creams were more frequently positive in cases of PCD (P = 0.019-0.003), whereas p-phenylenediamine, toluene-2,5 diamine sulfate, p-aminophenol, m-aminophenol, and nitro-p-phenylenediamine were predominantly positive in ACD to cosmetics (P < 0.001).
   Conclusions Preservatives, antioxidants, and skin lightening creams seem to play a role in causation of PCD, whereas hair dye allergens cause ACD to cosmetics in India.
AD  - All India Inst Med Sci, Dermatol & Venereol, Room 4070,4th Floor Teaching Block, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dermatol & Venereol, Rishikesh, IndiaAD  - All India Inst Med Sci, Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) RishikeshC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - SEP-OCT
PY  - 2018
VL  - 29
IS  - 5
SP  - 264
EP  - 269
DO  - 10.1097/DER.0000000000000407
AN  - WOS:000445209400005
ER  -

TY  - JOUR
AU  - Shekhar, S
AU  - Yadav, Y
AU  - Singh, AP
AU  - Pradhan, R
AU  - Desai, GR
AU  - Dey, AB
AU  - Dey, S
TI  - Neuroprotection by ethanolic extract of <i>Syzygium aromaticum</i> in Alzheimer's disease like pathology via maintaining oxidative balance through SIRT1 pathway
T2  - EXPERIMENTAL GERONTOLOGY
KW  - Syzygium aromaticum
KW  - Alzheimer's disease
KW  - SIRT1
KW  - Serum
KW  - SH-SY5Y
KW  - BETA-PEPTIDE NEUROTOXICITY
KW  - SIRTUINS
KW  - STRESS
KW  - SERUM
KW  - DEACETYLASES
KW  - MARKERS
KW  - CELLS
KW  - GENE
KW  - NAD
AB  - The oxidative stress plays a key role in Alzheimer's disease (AD) and Sirtuin (SIRT1) is potential mediator of oxidative pathway. This study explored the role of Syzygium aromaticum on SIRT1 and oxidative balance in amyloid beta induced toxicity. Anti-oxidative capacity of Syzygium aromaticum was performed in A beta(25-35) induced neurotoxicity in neuronal cells. Superoxide dismutase, Catalase and Glutathione enzyme activity were determined by the treatment of Syzygium aromaticum. Both recombinant and endogenous SIRT1 activity were performed in its presence. The expression of gamma-secretase and SIRT1 were evaluated by western blot. Syzygium aromaticum was capable to scavenge ROS and elevate the percentage of anti-oxidant enzymes. It also activated and elevated the level of SIRT1 and downregulated gamma-secretase level. These findings show a holistic approach towards the neurodegenerative disease management by Syzygium aromaticum which could lead to the formulation of new drug for AD.
   This Ayurvedic product can give a healthy aging with no side effects and also be cost effectives. It may meet unmet medical needs of current relevance.
AD  - All India Inst Med Sci, Dept Biophys, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Geriatr Med, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - PERGAMON-ELSEVIER SCIENCE LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
DA  - SEP
PY  - 2018
VL  - 110
SP  - 277
EP  - 283
DO  - 10.1016/j.exger.2018.06.026
AN  - WOS:000442386400037
ER  -

TY  - JOUR
AU  - Shridhar, K
AU  - Singh, G
AU  - Dey, S
AU  - Dhatt, SS
AU  - Gill, JPS
AU  - Goodman, M
AU  - Magsumbol, MS
AU  - Pearce, N
AU  - Singh, S
AU  - Singh, A
AU  - Singh, P
AU  - Thakur, JS
AU  - Dhillon, PK
TI  - Dietary Patterns and Breast Cancer Risk: A Multi-Centre Case Control Study among North Indian Women
T2  - INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
KW  - breast cancer
KW  - diet
KW  - vegetarian
KW  - egg
KW  - India
KW  - METAANALYSIS
KW  - CONSUMPTION
KW  - COHORT
AB  - Evidence from India, a country with unique and distinct food intake patterns often characterized by lifelong adherence, may offer important insight into the role of diet in breast cancer etiology. We evaluated the association between Indian dietary patterns and breast cancer risk in a multi-centre case-control study conducted in the North Indian states of Punjab and Haryana. Eligible cases were women 30-69 years of age, with newly diagnosed, biopsy-confirmed breast cancer recruited from hospitals or population-based cancer registries. Controls (hospital- or population-based) were frequency matched to the cases on age and region (Punjab or Haryana). Information about diet, lifestyle, reproductive and socio-demographic factors was collected using a structured interviewer-administered questionnaire. All participants were characterized as non-vegetarians, lacto-vegetarians (those who consumed no animal products except dairy) or lacto-ovo-vegetarians (persons whose diet also included eggs). The study population included 400 breast cancer cases and 354 controls. Most (62%) were lacto-ovo-vegetarians. Breast cancer risk was lower in lacto-ovo-vegetarians compared to both non-vegetarians and lacto-vegetarians with odds ratios (95% confidence intervals) of 0.6 (0.3-0.9) and 0.4 (0.3-0.7), respectively. The unexpected difference between lacto-ovo-vegetarian and lacto-vegetarian dietary patterns could be due to egg-consumption patterns which requires confirmation and further investigation.
AD  - Publ Hlth Fdn India, Ctr Chron Dis Control, Ctr Chron Condit & Injures, Gurgaon 122002, IndiaAD  - Postgrad Inst Med Educ & Res, Chandigarh 160012, IndiaAD  - Publ Hlth Fdn India, Indian Inst Publ Hlth, Gurgaon 122002, IndiaAD  - Guru Angad Dev Vet & Anim Sci Univ, Ludhiana 141004, Punjab, IndiaAD  - Emory Univ, Rollins Sch Publ Hlth, Claudia Nance Rollins Bldg,1518 Clifton Rd, Atlanta, GA 30322 USAAD  - Publ Hlth Fdn India, Gurgaon 122002, IndiaAD  - London Sch Hyg & Trop Med, London WC1E 7HT, EnglandAD  - Cent Univ Punjab, Ctr Human Genet & Mol Med, Bathinda 151001, IndiaAD  - All India Inst Med Sci, New Delhi 110029, IndiaAD  - Indian Sch Business, Sahibzada Ajit Singh Nag 160062, Punjab, IndiaC3  - Public Health Foundation of IndiaC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Public Health Foundation of IndiaC3  - Guru Angad Dev Veterinary & Animal Sciences University (GADVASU)C3  - Emory UniversityC3  - Rollins School Public HealthC3  - Public Health Foundation of IndiaC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - Central University of PunjabC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian School of Business (ISB)PU  - MDPI
PI  - BASEL
PA  - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
DA  - SEP
PY  - 2018
VL  - 15
IS  - 9
C7  - 1946
DO  - 10.3390/ijerph15091946
AN  - WOS:000445765600155
ER  -

TY  - JOUR
AU  - Singh, AN
AU  - Kilambi, R
TI  - Single-stage laparoscopic common bile duct exploration and cholecystectomy versus two-stage endoscopic stone extraction followed by laparoscopic cholecystectomy for patients with gallbladder stones with common bile duct stones: systematic review and meta-analysis of randomized trials with trial sequential analysis
T2  - SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
KW  - Laparoscopic common bile duct exploration
KW  - LCBDE
KW  - Endoscopic stone extraction
KW  - ERCP with laparoscopic cholecystectomy
KW  - Choledocholithiasis
KW  - Meta-analysis
KW  - GALLSTONE DISEASE
KW  - CONCOMITANT GALLSTONES
KW  - RETROGRADE CHOLANGIOPANCREATOGRAPHY
KW  - COMPARING 2-STAGE
KW  - UNITED-STATES
KW  - MANAGEMENT
KW  - CHOLEDOCHOLITHIASIS
KW  - ERCP
KW  - CHOLANGIOGRAPHY
KW  - COMPLICATIONS
AB  - The ideal management of common bile duct (CBD) stones associated with gall stones is a matter of debate. We planned a meta-analysis of randomized trials comparing single-stage laparoscopic CBD exploration and cholecystectomy (LCBDE) with two-stage preoperative endoscopic stone extraction followed by cholecystectomy (ERCP + LC).
   We searched the Pubmed/Medline, Web of science, Science citation index, Google scholar and Cochrane Central Register of Controlled trials electronic databases till June 2017 for all English language randomized trials comparing the two approaches. Statistical analysis was performed using Review Manager (RevMan) [Computer program], Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014 and results were expressed as odds ratio for dichotomous variables and mean difference for continuous. p value ae<currency> 0.05 was considered significant. Trial sequential analysis (TSA) was performed using TSA version 0.9.5.5 (Copenhagen: The Copenhagen Trial Unit, Centre for Clinical Intervention Research, 2016). PROSPERO trial registration number is CRD42017074673.
   A total of 11 trials were included in the analysis, with a total of 1513 patients (751-LCBDE; 762-ERCP + LC). LCBDE was found to have significantly lower rates of technical failure [OR 0.59, 95% CI (0.38, 0.93), p = 0.02] and shorter hospital stay [MD - 1.63, 95% CI (- 3.23, - 0.03), p = 0.05]. There was no significant difference in mortality [OR 0.37, 95% CI (0.09, 1.51), p = 0.17], morbidity [OR 0.97, 95% CI (0.70, 1.33), p = 0.84], cost [MD - 379.13, 95% CI (- 784.80, 111.2), p = 0.13] or recurrent/retained stones [OR 1.01, 95% CI (0.38, 2.73), p = 0.98]. TSA showed that although the Z-curve crossed the boundaries of conventional significance, the estimated information size is yet to be achieved.
   Single-stage LCBDE is superior to ERCP + LC in terms of technical success and shorter hospital stay in good-risk patients with gallstones and CBD stones, where expertise, operative time and instruments are available.
AD  - All India Inst Med Sci, Dept Gastrointestinal Surg & Liver Transplantat, New Delhi, IndiaAD  - ILBS, Dept HPB Surg, Room 3026,3rd Floor,Phase 1, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Institute of Liver & Biliary Sciences (ILBS)PU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - SEP
PY  - 2018
VL  - 32
IS  - 9
SP  - 3763
EP  - 3776
DO  - 10.1007/s00464-018-6170-8
AN  - WOS:000440416500003
ER  -

TY  - JOUR
AU  - Singh, N
AU  - Gupta, DK
AU  - Sharma, S
AU  - Sahu, DK
AU  - Mishra, A
AU  - Yadav, DK
AU  - Rawat, J
AU  - Singh, AK
TI  - Single-nucleotide and copy-number variance related to severity of hypospadias
T2  - PEDIATRIC SURGERY INTERNATIONAL
KW  - Hypospadias
KW  - Copy number variations
KW  - PRSS3P2
KW  - TSC1
KW  - DMBT1
KW  - STS
KW  - SRD5A2
KW  - STARD3
KW  - GENETIC POLYMORPHISMS
KW  - REPEAT POLYMORPHISM
KW  - INDIAN CHILDREN
KW  - RISK
KW  - ASSOCIATION
KW  - METABOLISM
KW  - GENOME
AB  - The genetic association of hypospadias-risk studies has been conducted in Caucasians, Chinese-Han populations and few in Indian populations. However, no comprehensive approach has been followed to assess genetic involvement in the severity of the disorder.
   The study evaluated to establish the correlation between genotyped single nucleotide and copy number variants (SNPs/CNVs) and severity of hypospadias by an association in a total 30 SNPs in genes related to sex hormone-biosynthesis and metabolism; embryonic-development and phospholipase-d-signalling pathways on 138 surgery-confirmed hypospadias-cases from North India (84 penile and 28 cases of penoscrotal-hypospadias as compared with 31 cases of glanular + coronal), and analyzed and identified CNVs in four familial cases (18 members) and three paired-sporadic cases (6 members) using array-based comparative-genomic-hybridization and validated in 32 hypospadias samples by TaqMan assay.
   Based on odds ratio at 95% CI, Z Statistic and Significance Levels, STS gene-rs17268974 was associated with Penile-Hypospadias and 9-SNPs [seven-SNPs (rs5934740; rs5934842; rs5934913; rs6639811; rs3923341; rs17268974; rs5934937)] of STS gene; rs7562326-SRD5A2 and rs1877031-STARD3 were associated with penoscrotal-hypospadias. On aggregate analysis with p < 0.001, we identified homozygous-loss of Ch7:q34 (PRSS3P2, PRSS2). On validation in previously CNV-characterized and new (32 hypospadias cases), we identified PRSS3P2-loss in most of the grade 3 and 4 hypospadias. Hence, Grade 1 and 2 (coronal and granular) show no-PRSS3P2-loss and no-association with SNPs in STS; SRD5A2; STARD3-gene but Grade 3 and 4 (Penile and Penoscrotal) show PRSS3P2-loss accompanied with the association of SNPs in STS; SRD5A2; STARD3.
   Hence, homozygous-loss of PRSS3P2 accompanied with the association of STS; SRD5A2; STARD3 may link to the severity of the disease.
AD  - King Georges Med Univ, Ctr Advance Res, Mol Biol Unit, Lucknow 226003, Uttar Pradesh, IndiaAD  - All India Inst Med Sci, Dept Pediat Surg, New Delhi 110029, IndiaAD  - King Georges Med Univ, Dept Pediat Surg, Lucknow 226003, Uttar Pradesh, IndiaAD  - King Georges Med Univ, Dept Plast Surg, Lucknow 226003, Uttar Pradesh, IndiaC3  - King George's Medical UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - King George's Medical UniversityC3  - King George's Medical UniversityPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - SEP
PY  - 2018
VL  - 34
IS  - 9
SP  - 991
EP  - 1008
DO  - 10.1007/s00383-018-4330-5
AN  - WOS:000442203300011
ER  -

TY  - JOUR
AU  - Singh, S
AU  - Kashyap, JA
AU  - Chandhiok, N
AU  - Kumar, V
AU  - Singh, V
AU  - Goel, R
TI  - Labour & delivery monitoring patterns in facility births across five districts of India: A cross-sectional observational study
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
KW  - Guidelines
KW  - labour monitoring
KW  - partograph
KW  - quality of care
KW  - skilled birth attendance
KW  - MATERNAL MORTALITY
KW  - CARE
AB  - Background & objectives: India has recorded a marked increase in facility births due to government's conditional cash benefit scheme initiated in 2005. However, concerns have been raised regarding the need for improvement in the quality of care at facilities. Here we report the monitoring patterns during labour and delivery documented by direct observation in reference to the government's evidence-based guidelines on skilled birth attendance in five districts of India.
   Methods: A cross-sectional study design with multistage sampling was used for observation of labour and delivery processes of low-risk women with singleton pregnancy in live districts of the country. Trained research staff recorded the findings on pre-tested case record sheets.
   Results: A total of 1479 women were observed during active first stage of labour and delivery in 55 facilities. The overall frequency of monitoring of temperature, pulse and blood pressure was low at all facilities. The frequency of monitoring uterine contractions and foetal heart sounds was less than the expected norm, while the frequency of vaginal examinations was high at all levels of facilities. Partograph plotting was done in only 15.8 per cent deliveries, and labour was augmented in about half of the cases.
   Interpretation & conclusions: The findings of our study point towards a need for improvement in monitoring of maternal and foetal parameters during labour and delivery in facility births and to improve adherence to government guidelines for skilled birth attendance.
AD  - Indian Council Med Res, Div Reprod Biol Maternal & Child Hlth, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - Sir Sayajirao Gen Hosp, Dept Obstet & Gynaecol, Med Coll, Vadodara, IndiaAD  - ICMR Natl Inst Canc Prevent & Res, Div Clin Oncol, Noida, IndiaC3  - Indian Council of Medical Research (ICMR)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Maharaja Sayajirao University BarodaC3  - Baroda Medical CollegeC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Cancer Prevention & Research (NICPR)PU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
DA  - SEP
PY  - 2018
VL  - 148
IS  - 3
SP  - 309
EP  - 316
C7  - PMID 30425221
DO  - 10.4103/ijmr.IJMR_103_18
AN  - WOS:000450121500010
ER  -

TY  - JOUR
AU  - Sivanandan, S
AU  - Sethi, T
AU  - Lodha, R
AU  - Thukral, A
AU  - Sankar, MJ
AU  - Agarwal, R
AU  - Paul, VK
AU  - Deorari, AK
TI  - Target Oxygen Saturation Among Preterm Neonates on Supplemental Oxygen Therapy: A Quality Improvement Study
T2  - INDIAN PEDIATRICS
KW  - Monitoring
KW  - Oxygen management
KW  - Pulse oximetry
KW  - BIRTH-WEIGHT INFANTS
KW  - PREMATURITY
KW  - RETINOPATHY
KW  - DECREASE
AB  - ObjectiveTo avoid excessive oxygen exposure and achieve target oxygen saturation (SpO(2)) within intended range of 88%-95% among preterm neonates on oxygen therapy.Methods20 preterm neonates receiving supplemental oxygen in the first week of life were enrolled. The percentage of time per epoch (a consecutive time interval of 10 hours/day) spent by them within the target SpO(2) range was measured in phase 1 followed by implementation of a unit policy on oxygen administration and targeting in phase 2. In phase 3, oxygen saturation histograms constructed from pulse-oximeter data were used as daily feedback to nurses and compliance with oxygen-targeting was measured again.Results48 epochs in phase 1 and 69 in phase 3 were analyzed. The mean (SD) percent time spent within target SpO(2) range increased from 65.9% (21.4) to 76.5% (12.6) (P=0.001).ConclusionEffective implementation of oxygen targeting policy and feedback using oxygen saturation histograms may improve compliance with oxygen targeting.
AD  - All India Inst Med Sci, Div Neonatol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - SEP
PY  - 2018
VL  - 55
IS  - 9
SP  - 793
EP  - 796
DO  - 10.1007/s13312-018-1391-4
AN  - WOS:000445093300016
ER  -

TY  - JOUR
AU  - Sivanandan, S
AU  - Sethi, A
AU  - Joshi, M
AU  - Thukral, A
AU  - Sankar, MJ
AU  - Deorari, AK
AU  - Agarwal, R
TI  - Gains from Quality Improvement Initiatives Experience from a Tertiary-care Institute in India
T2  - INDIAN PEDIATRICS
KW  - Point of care quality improvement (POCQI)
KW  - Run chart
KW  - QI tools
KW  - HEALTH-CARE
KW  - FRAMEWORK
KW  - TOOL
AB  - Quality improvement (QI) in healthcare involves implementing small iterative changes by a team of people using a simple structured framework to resolve problems, improve systems, and to improve patient outcomes. These efforts are especially important in a resource-limited setting where infrastructure, staff and funds are meagre. The concept of QI often appears complex to a new careprovider who feels intimidated to participate in change activities. In this article, we describe our experience with QI activities to address various issues in the Neonatal intensive care unit. QI efforts resulted in improved patient outcomes, and motivated careproviders. QI is a continuous activity and can be done easily if the team is willing to learn from their experiences and use those lessons to adapt, adopt or abandon changes, and improve further. Our institute has also developed Point of Care Quality Improvement (POCQI), a free online resource for learning the science of QI, and also serves as a platform for sharing QI work.
AD  - All India Inst Med Sci, WHO Collaborating Ctr Training & Res, Dept Pediat, Div Neonatol,NHKC, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - SEP
PY  - 2018
VL  - 55
IS  - 9
SP  - 809
EP  - 817
DO  - 10.1007/s13312-018-1386-1
AN  - WOS:000445093300019
ER  -

TY  - JOUR
AU  - Sreenivasan, SA
AU  - Garg, K
AU  - Singh, M
AU  - Chandra, PS
TI  - Cervical intramedullary tumor resection and kyphotic malalignment
T2  - JOURNAL OF NEUROSURGERY-SPINE
KW  - POSTERIOR LONGITUDINAL LIGAMENT
KW  - SPINAL-CORD TUMORS
KW  - OSSIFICATION
KW  - LAMINOPLASTY
KW  - MORBIDITY
KW  - ADULTS
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ASSOC NEUROLOGICAL SURGEONS
PI  - ROLLING MEADOWS
PA  - 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
DA  - SEP
PY  - 2018
VL  - 29
IS  - 3
SP  - 348
EP  - 349
DO  - 10.3171/2018.1.SPINE1896
AN  - WOS:000443292000020
ER  -

TY  - JOUR
AU  - Srivastava, MVP
AU  - Vishnu, VY
TI  - Exercises after stroke: The essential endurance
T2  - NEUROLOGY INDIA
KW  - REHABILITATION
KW  - TRIAL
AD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - SEP-OCT
PY  - 2018
VL  - 66
IS  - 5
SP  - 1306
EP  - 1308
DO  - 10.4103/0028-3886.241380
AN  - WOS:000447605100016
ER  -

TY  - JOUR
AU  - Srivastava, S
AU  - Ramanujam, B
AU  - Ihtisham, K
AU  - Tripathi, M
TI  - A case of narcolepsy with HLA-typing from North India
T2  - NEUROLOGY INDIA
KW  - ASSOCIATION
AD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - SEP-OCT
PY  - 2018
VL  - 66
IS  - 5
SP  - 1485
EP  - +
DO  - 10.4103/0028-3886.241338
AN  - WOS:000447605100048
ER  -

TY  - JOUR
AU  - Srivastava, S
AU  - Mahey, R
AU  - Kachhawa, G
AU  - Bhatla, N
AU  - Upadhyay, AD
AU  - Kriplani, A
TI  - Comparison of intramyometrial vasopressin plus rectal misoprostol with intramyometrial vasopressin alone to decrease blood loss during laparoscopic myomectomy: Randomized clinical trial
T2  - EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
KW  - Myomectomy
KW  - Laparoscopy
KW  - Vasopressin
KW  - Misoprostol
KW  - HEMORRHAGE
AB  - Objective: To compare the efficacy and safety of intramyometrial vasopressin plus rectal misoprostol with intramyometrial vasopressin alone to reduce blood loss during laparoscopic myomectomy.
   Study design: A randomized, single-blind, controlled trial was conducted at All India Institute of Medical Sciences, New Delhi, India. Sixty women with symptomatic leiomyoma scheduled for laparoscopic myomectomy were recruited for the study. Thirty women received intramyometrial vasopressin plus rectal misoprostol (30 min before procedure) (Group I) and 30 women received intramyometrial vasopressin alone (Group II) during laparoscopic myomectomy. The primary outcome measure was intra-operative blood loss during surgery. Secondary outcome measures included decrease in postoperative haemoglobin, ease of enucleation of myomas, duration of surgery, need for additional haemostatic measures or blood transfusion, intra- and postoperative morbidity, and duration of hospital stay.
   Results: The baseline demographic features and characteristics of leiomyomas were comparable in both groups. The mean ( standard deviation) blood loss in Group I was 139 +/- 96.7 ml, which was significantly less than that for Group II (206 +/- 101.2 ml) (p = 0.008). The mean postoperative haemoglobin was 11.6 +/- 1.3 g/dl in Group I and 10.0 +/- 1.2 g/dl in Group II (p = 0.001). Although blood loss was not clinically significant in either group, the decrease in haemoglobin was significantly higher in Group II. The mean score for ease of enucleation (surgeon-rated measure) was significantly lower in Group I (2.6 +/- 1.1) compared with Group II (3.4 +/- 1.1) (p = 0.029). Intra- and postoperative vital signs, duration of surgery, need for blood transfusion and postoperative morbidity were comparable in both groups.
   Conclusions: The addition of rectal misoprostol to intramyometrial vasopressin led to a significant reduction in blood loss and decreased the postoperative drop in haemoglobin. The combination also improved the ease of enucleation of myomas. (C) 2018 Elsevier B.V. All rights reserved.
AD  - All India Inst Med Sci, Dept Obstet & Gynaecol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - SEP
PY  - 2018
VL  - 228
SP  - 279
EP  - 283
DO  - 10.1016/j.ejogrb.2018.07.006
AN  - WOS:000445991800047
ER  -

TY  - JOUR
AU  - Sundar, D
AU  - Takkar, B
AU  - Venkatesh, P
AU  - Chawla, R
AU  - Temkar, S
AU  - Azad, SV
AU  - Vohra, R
TI  - Evaluation of hyaloid-retinal relationship during triamcinolone-assisted vitrectomy for primary rhegmatogenous retinal detachment
T2  - EUROPEAN JOURNAL OF OPHTHALMOLOGY
KW  - Retinal detachment
KW  - vitreoretinal interface
KW  - proliferative vitreoretinopathy
KW  - vitrectomy for retinal detachment
KW  - POSTERIOR VITREOUS DETACHMENT
KW  - VITREORETINAL INTERFACE
KW  - PATHOLOGY
KW  - CORTEX
AB  - Aims: To determine hyaloid-retinal relationship in primary rhegmatogenous retinal detachment during vitreous surgery.
   Methods: This is a prospective, interventional study of patients (n = 72) undergoing triamcinolone-assisted 25G vitreous surgery for primary rhegmatogenous retinal detachment. Hyaloid-retinal relationship was noted intraoperatively to identify regions and patterns of firm attachment and was classified into subgroups. Analysis was done to determine association between hyaloid-retinal relationship patterns and preoperative findings: posterior vitreous detachment, proliferative vitreoretinopathy, type of retinal tear, the presence of peripheral degenerations, and postoperative outcomes.
   Results: Three patterns of hyaloid-retinal relationship were identified: type 1 (complete absence of posterior vitreous detachment (21%)), type 2 (incomplete posterior vitreous detachment (47%)) and type 3 (complete posterior vitreous detachment (32%)). Posterior vitreous detachment in some form was present in 84% of the cases with retinal tears as the causative break but none of the cases with retinal holes (p < 0.001). None of the cases with vitreoretinal degeneration had complete posterior vitreous detachment (p = 0.001). 69% of proliferative vitreoretinopathy-C cases had type 1 hyaloid-retinal relationship as compared to 11% cases with no proliferative vitreoretinopathy (p < 0.001). Proliferative vitreoretinopathy-related anatomical failure was seen in 7.5%, and 80% of these eyes with recurrent RD had type 1 hyaloid-retinal relationship (p<0.001). Nearly half the patients diagnosed as complete posterior vitreous detachment preoperatively were found to have incomplete posterior vitreous detachment intraoperatively.
   Conclusions: Majority of the cases with rhegmatogenous retinal detachment have some form of strong vitreoretinal adhesion. Hyaloid-retinal relationship varies with types of retinal breaks, retinal degeneration, and proliferative vitreoretinopathy. Intraoperative hyaloid-retinal relationship is frequently different from that assessed before surgery and the proposed classification may improve surgical decision making and prognostication.
AD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SAGE PUBLICATIONS LTD
PI  - LONDON
PA  - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
DA  - SEP
PY  - 2018
VL  - 28
IS  - 5
SP  - 607
EP  - 613
DO  - 10.1177/1120672118754301
AN  - WOS:000445460800017
ER  -

TY  - JOUR
AU  - Sundar, D
AU  - Kumar, A
AU  - Chawla, R
AU  - Sen, S
AU  - Ravani, R
AU  - Kakkar, P
AU  - Chatra, K
TI  - Microscope-integrated optical coherence tomography-aided intraoperative diagnosis and management of peripheral tractional retinoschisis
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - iOCT
KW  - retinoschisis
KW  - retinectomy
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Ophthalmol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - SEP
PY  - 2018
VL  - 66
IS  - 9
SP  - 1323
EP  - +
C7  - PMID 30127155
DO  - 10.4103/ijo.IJO_331_18
AN  - WOS:000442780400025
ER  -

TY  - JOUR
AU  - Talwar, S
AU  - Bhoje, A
AU  - Khadagawat, R
AU  - Chaturvedi, P
AU  - Sreenivas, V
AU  - Makhija, N
AU  - Sahu, M
AU  - Choudhary, SK
AU  - Airan, B
TI  - Oral thyroxin supplementation in infants undergoing cardiac surgery: A double-blind placebo-controlled randomized clinical trial
T2  - JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
KW  - oral thyroxin
KW  - infants
KW  - postoperative cardiac index
KW  - THYROID-HORMONE TREATMENT
KW  - CONGENITAL HEART-DISEASE
KW  - CARDIOPULMONARY BYPASS
KW  - PEDIATRIC-PATIENTS
KW  - TRIIODOTHYRONINE
KW  - CHILDREN
KW  - SYSTEM
AB  - Background: Decreases in serum total thyroxin and total triiodothyronine occurs after cardiopulmonary bypass, and is reflected as poor immediate outcome. We studied effects of oral thyroxin supplementation in infants who underwent open-heart surgery.
   Methods: In this prospective study, 100 patients were randomized into 2 groups: 50 in the thyroxin group (TH) and 50 in the placebo group (PL). Patients in the TH group received oral thyroxin (5 mg/kg) 12 hours before surgery and once daily for the remainder of their intensive care unit (ICU) stay. Data on intraoperative and postoperative variables were recorded. Cardiac index (CI) was measured. Perioperative serum thyroid hormone levels and serum interleukin-6 and tumor necrosis factor-a were measured. Secondary analysis was performed by dividing patients into simple and complex subcategories.
   Results: Results of the primary analysis indicated a higher CI in the TH compared with the PL. In the complex category, the mean duration of mechanical ventilation was 3.85 +/- 0.93 and 4.66 +/- 1.55 days in the TH and PL, respectively (P =.001). Mean ICU stay was 6.79 +/- 2.26 and 8.33 +/- 3.09 days (P =.03), and mean hospital stay was 15.70 +/- 4.77 and 18.90 +/- 4.48 days (P =.01) in the TH and PL, respectively. There were no significant differences between the TH and the PL in the simple category. CI was higher in the TH at all time points (P =.004). The average therapeutic intervention scoring system scores for the first 2 days were higher in the PL in the complex category.
   Conclusions: Oral thyroxin supplementation improves the CI and reduces the inotropic requirement. In addition, it reduces the duration of mechanical ventilation, ICU and hospital stay, and therapeutic intervention scoring system in infants after surgery for complex congenital heart defects.
AD  - All India Inst Med Sci, Cardiothorac Ctr, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MOSBY-ELSEVIER
PI  - NEW YORK
PA  - 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - SEP
PY  - 2018
VL  - 156
IS  - 3
SP  - 1209
EP  - +
DO  - 10.1016/j.jtcvs.2018.05.044
AN  - WOS:000441556000078
ER  -

TY  - JOUR
AU  - Temkar, S
AU  - Bafna, RK
AU  - Damodaran, S
AU  - Agarwal, D
AU  - Kumar, V
TI  - Retinal necklace: Chain of cysts in retinal detachment
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - MACROCYST
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - SEP
PY  - 2018
VL  - 66
IS  - 9
SP  - 1331
EP  - 1332
C7  - PMID 30127162
DO  - 10.4103/ijo.IJO_56_18
AN  - WOS:000442780400032
ER  -

TY  - JOUR
AU  - Titiyal, JS
AU  - Karunakaran, A
AU  - Kaur, M
AU  - Rathi, A
AU  - Agarwal, T
AU  - Sharma, N
TI  - Collagen Cross-Linked Therapeutic Grafts in Fungal Keratitis
T2  - OPHTHALMOLOGY
KW  - LINKING
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Cornea Cataract & Refract Surg Serv, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - SEP
PY  - 2018
VL  - 125
IS  - 9
SP  - 1471
EP  - 1473
DO  - 10.1016/j.ophtha.2018.04.005
AN  - WOS:000442285800037
ER  -

TY  - JOUR
AU  - Tiwari, A
AU  - Kumar, L
TI  - Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
KW  - PHASE-III TRIAL
KW  - NAB-PACLITAXEL
KW  - ONCOLOGY-GROUP
KW  - CANCER
KW  - GEMCITABINE
KW  - COMBINATION
KW  - EXPRESSION
KW  - RISK
AD  - All India Inst Med Sci, Dr BRA Inst Rotary Canc Hosp IRCH, Dept Med Oncol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - SEP
PY  - 2018
VL  - 148
IS  - 3
SP  - 254
EP  - 257
DO  - 10.4103/ijmr.IJMR_615_18
AN  - WOS:000450121500003
ER  -

TY  - JOUR
AU  - Turankar, RP
AU  - Lavania, M
AU  - Singh, I
AU  - Singh, V
AU  - Ahuja, M
AU  - Pathak, VK
AU  - Jakhmola, P
AU  - Das, L
AU  - Darlong, J
AU  - Hembrom, U
AU  - Ramesh, V
AU  - Khanna, N
AU  - John, AS
AU  - Sengupta, U
TI  - Paucibacillary Leprosy: Reappraisal using Ziehl-Neelsen staining of slit skin smears and <i>16S rRNA</i> Real Time Polymerase Chain Reaction of nasal swabs
T2  - LEPROSY REVIEW
KW  - PB leprosy cases
KW  - AFB
KW  - M. leprae
KW  - Real Time PCR
KW  - BI negative
KW  - 16S rRNA gene target
KW  - Z-N staining
KW  - TRANSMISSION
KW  - INFECTION
KW  - MUCOSA
AB  - Background: Leprosy is diagnosed by cardinal signs. Classification of paucibacillary (PB) and multibacillary (MB) leprosy is based on the number of skin lesions and nerve involvement.
   Objective: The study was conducted to determine the role played by acid fast bacilli (AFB) positivity of slit skin smear (SSS) in clinical classification.
   Methodology: SSSs and nasal swab smears (NSSs) were stained by Ziehl-Neelsen staining. RNAs was extracted from 120 NSSs. NSSs and SSSs were examined by microscopy and M. leprae viability in NSS was determined by real time polymerase chain reaction (RT-PCR). NSSs from 50 healthy individuals were used as controls.
   Results: Group-A PB cases, classified simply by presenting with <5 patches, showed the presence of AFB in NSSs (7.5%) and SSSs (15%). Group-B PB cases, classified on the basis of a negative skin smear were AFB negative. Control group NSSs were AFB negative. RT-PCR of NSSs of PB cases of Group A and Group B were 65% and 87% positive for viable M. leprae respectively. All NSSs were positive for 16S rRNA gene with variable copy numbers. It was noted that 3 SSSs negative AFB cases from Group-A were positive for AFB in NSS. It was also observed that 6 SSSs positive AFB (Group-A) cases were negative for AFB in NSS. It was interesting to note that none of the patients in Group-A was AFB positive in both NSS and SSS. However, all of these patients were positive for 16S rRNA qPCR in NSSs.
   Conclusion: Our findings strongly suggest immediate inclusion of AFB staining of SSS for classification of leprosy.
AD  - TLM Community Hosp, Stanley Browne Lab, Nand Nagri Delhi 110093, IndiaAD  - Leprosy Mission Hosp, Naini 211008, Uttar Pradesh, IndiaAD  - Leprosy Mission Home & Hosp, Purulia 2723101, W Bengal, IndiaAD  - Leprosy Mission Hosp, Muzaffarpur 842002, Bihar, IndiaAD  - Safdarjang Hosp, New Delhi 110029, IndiaAD  - All India Inst Med Sci, New Delhi 110029, IndiaC3  - Vardhman Mahavir Medical College & Safdarjung HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LEPRA
PI  - COLCHESTER
PA  - 28 MIDDLEBOROUGH, COLCHESTER CO1 1TG, ESSEX, ENGLAND
DA  - SEP
PY  - 2018
VL  - 89
IS  - 3
SP  - 272
EP  - 279
AN  - WOS:000452250000009
ER  -

TY  - JOUR
AU  - Venkatesh, P
TI  - Compulsory training in ophthalmoscopy as part of undergraduate general medicine training: Need of the hour
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
KW  - DIABETIC-RETINOPATHY
KW  - TELEMEDICINE
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 477,4th Floor,Ansari Nagar, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - SEP-OCT
PY  - 2018
VL  - 31
IS  - 5
SP  - 306
EP  - 307
DO  - 10.4103/0970-258X.261174
AN  - WOS:000473690700015
ER  -

TY  - JOUR
AU  - Wood, WA
AU  - Brazauskas, R
AU  - Hu, ZH
AU  - Abdel-Azim, H
AU  - Ahmed, IA
AU  - Aljurf, M
AU  - Badawy, S
AU  - Beitinjaneh, A
AU  - George, B
AU  - Buchbinder, D
AU  - Cerny, J
AU  - Dedeken, L
AU  - Diaz, MA
AU  - Freytes, CO
AU  - Ganguly, S
AU  - Gergis, U
AU  - Almaguer, DG
AU  - Gupta, A
AU  - Hale, G
AU  - Hashmi, SK
AU  - Inamoto, Y
AU  - Kamble, RT
AU  - Adekola, K
AU  - Kindwall-Keller, T
AU  - Knight, J
AU  - Kumar, L
AU  - Kuwatsuka, Y
AU  - Law, J
AU  - Lazarus, HM
AU  - LeMaistre, C
AU  - Olsson, RF
AU  - Pulsipher, MA
AU  - Savani, BN
AU  - Schultz, KR
AU  - Saad, AA
AU  - Seftel, M
AU  - Seo, S
AU  - Shea, TC
AU  - Steinberg, A
AU  - Sullivan, K
AU  - Szwajcer, D
AU  - Wirk, B
AU  - Yared, J
AU  - Yong, A
AU  - Dalal, J
AU  - Hahn, T
AU  - Khera, N
AU  - Bonfim, C
AU  - Atsuta, Y
AU  - Saber, W
TI  - Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis
T2  - BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
KW  - Hematopoietic stem cell transplantation
KW  - Precursor cell lymphoblastic leukemia-lymphoma
KW  - Bone marrow
KW  - Health expenditures
KW  - Outcome assessment (Health care)
KW  - OUTCOMES
KW  - ASSOCIATION
KW  - MORTALITY
KW  - ADULTS
KW  - MANAGEMENT
KW  - RECIPIENTS
KW  - ONCOLOGY
KW  - MARROW
KW  - SYSTEM
KW  - BLOOD
AB  - For patients with acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation (alloHCT) offers a potential cure. Life-threatening complications can arise from alloHCT that require the application of sophisticated health care delivery. The impact of country-level economic conditions on post-transplantation outcomes is not known. Our objective was to assess whether these variables were associated with outcomes for patients transplanted for ALL. Using data from the Center for Blood and Marrow Transplant Research, we included 11,261 patients who received a first alloHCT for ALL from 303 centers across 38 countries between the years of 2005 and 2013. Cox regression models were constructed using the following macroeconomic indicators as main effects: Gross national income per capita, health expenditure per capita, and Human Development Index (HDI). The outcome was overall survival at 100 days following transplantation. In each model, transplants performed within lower resourced environments were associated with inferior overall survival. In the model with the HDI as the main effect, transplants performed in the lowest HDI quartile (n = 697) were associated with increased hazard for mortality (hazard ratio, 2.42; 95% confidence interval, 1.64 to 3.57; P < .001) in comparison with transplants performed in the countries with the highest HDI quartile. This translated into an 11% survival difference at 100 days (77% for lowest HDI quartile versus 88% for all other quartiles). Country-level macroeconomic indices were associated with lower survival at 100 days after alloHCT for ALL. The reasons for this disparity require further investigation. (C) 2018 American Society for Blood and Marrow Transplantation.
AD  - Univ N Carolina, Div Hematol Oncol, Dept Med, Chapel Hill, NC 27515 USAAD  - Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USAAD  - Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USAAD  - Univ Southern Calif, Childrens Hosp Los Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, Keck Sch Med, Los Angeles, CA USAAD  - Childrens Mercy Hosp & Clin, Dept Hematol Oncol & Bone Marrow Transplantat, Kansas City, MO USAAD  - King Faisal Specialist Hosp & Res Ctr, Dept Oncol, Riyadh, Saudi ArabiaAD  - Ann & Robert H Lurie Childrens Hosp Chicago, Div Hematol Oncol & Stem Cell Transplantat, Chicago, IL 60611 USAAD  - Univ Miami, Dept Hematol Oncol, Miami, FL USAAD  - Christian Med Coll & Hosp, Vellore, Tamil Nadu, IndiaAD  - Childrens Hosp Orange Cty, Div Pediat Hematol, Orange, CA 92668 USAAD  - UMass Mem Med Ctr, Div Hematol Oncol, Worcester, MA USAAD  - Hop Univ Enfants Reine Fabiola, Dept Hematol Oncol, Brussels, BelgiumAD  - Hosp Infantil Univ Nino Jesus, Dept Hematol Oncol, Madrid, SpainAD  - Texas Transplant Inst, San Antonio, TX USAAD  - Univ Kansas, Med Ctr, Blood & Marrow Transplantat, Div Hematol & Oncol, Kansas City, KS 66103 USAAD  - Presbyterian Hosp, Hematolg Malignancies & Bone Marrow Transplant, Dept Med Oncol, Weill Cornell Med Ctr, New York, NY USAAD  - Hosp Univ Autonoma Nuevo Leon, Monterrey, MexicoAD  - Univ Hosp Cleveland, Seidman Canc Ctr, Med Ctr, Cleveland, OH 44106 USAAD  - Johns Hopkins All Childrens Hosp, Dept Hematol Oncol, St Petersburg, FL USAAD  - Mayo Clin, Dept Internal Med, Rochester, MN USAAD  - King Faisal Specialist Hosp & Res Ctr, Oncol Ctr, Riyadh, Saudi ArabiaAD  - Natl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, JapanAD  - Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX 77030 USAAD  - Northwestern Univ, Div Hematol Oncol, Dept Med, Chicago, IL 60611 USAAD  - Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USAAD  - Univ Virginia Hlth Syst, Div Hematol Oncol, Charlottesville, VA USAAD  - Med Coll Wisconsin, Dept Psychol, Milwaukee, WI 53226 USAAD  - All India Inst Med Sci, Inst Rotary Canc Hosp, Dept Med Oncol, New Delhi, IndiaAD  - Nagoya Univ, Ctr Adv Med & Clin Res, Grad Sch Med, Nagoya, Aichi, JapanAD  - Floating Hosp Children, Tufts Med Ctr, Dept Pediat, Boston, MA USAAD  - Sarah Cannon, Hematol & Bone Marrow Transplant, Nashville, TN USAAD  - Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, SwedenAD  - Uppsala Univ, Ctr Clin Res Sormland, Uppsala, SwedenAD  - Univ Southern Calif, Childrens Hosp Los Angeles, Div Hematol & Blood & Marrow Transplantat, Keck Sch Med, Los Angeles, CA USAAD  - Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USAAD  - Univ British Columbia, British Columbias Childrens Hosp, Dept Pediat Hematol Oncol & Bone Marrow Transplan, Vancouver, BC, CanadaAD  - Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USAAD  - CancerCare Manitoba, Dept Med Oncol & Hematol, Winnipeg, MB, CanadaAD  - Natl Canc Res Ctr East, Dept Hematol & Oncol, Chiba, JapanAD  - Mt Sinai Hosp, Dept Hematol Oncol, New York, NY 10029 USAAD  - Duke Univ, Med Ctr, Durham, NC USAAD  - Seattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USAAD  - Univ Maryland, Dept Med, Greenebaum Canc Ctr, Blood & Marrow Transplantat Program,Div Hematol O, Baltimore, MD 21201 USAAD  - Univ Adelaide, Royal Adelaide Hosp, SA Pathol, Adelaide, SA, AustraliaAD  - Univ Adelaide, Sch Med, Adelaide, SA, AustraliaAD  - Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USAAD  - Mayo Clin, Dept Hematol Oncol, Phoenix, AZ USAAD  - Hosp Clin Fed Univ Parana, Curitiba, Parana, BrazilC3  - University of North CarolinaC3  - University of North Carolina Chapel HillC3  - Medical College of WisconsinC3  - Center for International Blood & Marrow Transplant ResearchC3  - Medical College of WisconsinC3  - University of Southern CaliforniaC3  - Children's Hospital Los AngelesC3  - Children's Mercy HospitalC3  - King Faisal Specialist Hospital & Research CenterC3  - Ann & Robert H. Lurie Children's Hospital of ChicagoC3  - University of MiamiC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Childrens Hospital of Orange CountyC3  - University of Massachusetts SystemC3  - University of Massachusetts WorcesterC3  - University of KansasC3  - University of Kansas Medical CenterC3  - Cornell UniversityC3  - Weill Cornell MedicineC3  - NewYork-Presbyterian HospitalC3  - Weill Cornell Medical CenterC3  - Universidad Autonoma de Nuevo LeonC3  - University Hospital Autonomous University of Nuevo LeonC3  - University Hospitals of ClevelandC3  - University System of OhioC3  - Case Western Reserve UniversityC3  - Case Western Reserve University HospitalC3  - Johns Hopkins UniversityC3  - Johns Hopkins MedicineC3  - Mayo ClinicC3  - King Faisal Specialist Hospital & Research CenterC3  - National Cancer Center - JapanC3  - Baylor College of MedicineC3  - Baylor College Medical HospitalC3  - Northwestern UniversityC3  - Northwestern UniversityC3  - Feinberg School of MedicineC3  - Ann & Robert H. Lurie Children's Hospital of ChicagoC3  - Robert H. Lurie Comprehensive Cancer CenterC3  - University of VirginiaC3  - University of Virginia (UVA) Health SystemC3  - Medical College of WisconsinC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - Nagoya UniversityC3  - Tufts Medical CenterC3  - Floating Hospital For ChildrenC3  - Sarah Cannon Research InstituteC3  - Karolinska InstitutetC3  - Uppsala UniversityC3  - Children's Hospital Los AngelesC3  - University of Southern CaliforniaC3  - Vanderbilt UniversityC3  - University of British ColumbiaC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - CancerCare Manitoba FoundationC3  - Icahn School of Medicine at Mount SinaiC3  - Duke UniversityC3  - Seattle Cancer Care AllianceC3  - University System of MarylandC3  - University of Maryland BaltimoreC3  - Royal Adelaide HospitalC3  - University of AdelaideC3  - SA PathologyC3  - University of AdelaideC3  - Roswell Park Comprehensive Cancer CenterC3  - Mayo ClinicC3  - Mayo Clinic PhoenixPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - SEP
PY  - 2018
VL  - 24
IS  - 9
SP  - 1928
EP  - 1935
DO  - 10.1016/j.bbmt.2018.03.016
AN  - WOS:000446644300026
ER  -

TY  - JOUR
AU  - Naghavi, M
AU  - Marczak, LB
AU  - Kutz, M
AU  - Shackelford, KA
AU  - Arora, M
AU  - Miller-Petrie, M
AU  - Aichour, MTE
AU  - Akseer, N
AU  - Al-Raddadi, RM
AU  - Alam, K
AU  - Alghnam, SA
AU  - Antonio, CAT
AU  - Aremu, O
AU  - Arora, A
AU  - Asadi-Lari, M
AU  - Assadi, R
AU  - Atey, TM
AU  - Avila-Burgos, L
AU  - Awasthi, A
AU  - Quintanilla, BPA
AU  - Barker-Collo, SL
AU  - Bärnighausen, TW
AU  - Bazargan-Hejazi, S
AU  - Behzadifar, M
AU  - Behzadifar, M
AU  - Bennett, JR
AU  - Bhalla, A
AU  - Bhutta, ZA
AU  - Bilal, AI
AU  - Borges, G
AU  - Borschmann, R
AU  - Brazinova, A
AU  - Rincon, JCC
AU  - Carvalho, F
AU  - Castañeda-Orjuela, CA
AU  - Dandona, L
AU  - Dandona, R
AU  - Dargan, PI
AU  - De Leo, D
AU  - Dharmaratne, SD
AU  - Ding, EL
AU  - Do, HP
AU  - Doku, DT
AU  - Doyle, KE
AU  - Driscoll, T
AU  - Edessa, D
AU  - El-Khatib, Z
AU  - Endries, AY
AU  - Esteghamati, A
AU  - Faro, A
AU  - Farzadfar, F
AU  - Feigin, VL
AU  - Fischer, F
AU  - Foreman, KJ
AU  - Franklin, RC
AU  - Fullman, N
AU  - Futran, ND
AU  - Gebrehiwot, TT
AU  - Gutiérrez, RA
AU  - Hafezi-Nejad, N
AU  - Bidgoli, HH
AU  - Hailu, GB
AU  - Haro, JM
AU  - Hassen, HY
AU  - Hawley, C
AU  - Hendrie, D
AU  - Híjar, M
AU  - Hu, GQ
AU  - Ilesanmi, OS
AU  - Jakovljevic, M
AU  - James, SL
AU  - Jayaraman, S
AU  - Jonas, JB
AU  - Kahsay, A
AU  - Kasaeian, A
AU  - Keiyoro, PN
AU  - Khader, Y
AU  - Khalil, IA
AU  - Khang, YH
AU  - Khubchandani, J
AU  - Kiadaliri, AA
AU  - Kieling, C
AU  - Kim, YJ
AU  - Kosen, S
AU  - Krohn, KJ
AU  - Kumar, GA
AU  - Lami, FH
AU  - Lansingh, VC
AU  - Larson, HJ
AU  - Linn, S
AU  - Lunevicius, R
AU  - Abd El Razek, HM
AU  - Abd El Razek, MM
AU  - Malekzadeh, R
AU  - Malta, DC
AU  - Mason-Jones, AJ
AU  - Matzopoulos, R
AU  - Memiah, PTN
AU  - Mendoza, W
AU  - Meretoja, TJ
AU  - Mezgebe, HB
AU  - Miller, TR
AU  - Mohammed, S
AU  - Moradi-Lakeh, M
AU  - Mori, R
AU  - Nand, D
AU  - Nguyen, CT
AU  - Nguyen, QL
AU  - Ningrum, DNA
AU  - Ogbo, FA
AU  - Olagunju, AT
AU  - Patton, GC
AU  - Phillips, MR
AU  - Polinder, S
AU  - Pourmalek, F
AU  - Qorbani, M
AU  - Rahimi-Movaghar, A
AU  - Rahimi-Movaghar, V
AU  - Rahman, M
AU  - Rai, RK
AU  - Ranabhat, CL
AU  - Rawaf, DL
AU  - Rawaf, S
AU  - Rowhani-Rahbar, A
AU  - Safdarian, M
AU  - Safiri, S
AU  - Sagar, R
AU  - Salama, JS
AU  - Sanabria, J
AU  - Milicevic, MMS
AU  - Sarmiento-Suárez, R
AU  - Sartorius, B
AU  - Satpathy, M
AU  - Schwebel, DC
AU  - Seedat, S
AU  - Sepanlou, SG
AU  - Shaikh, MA
AU  - Sharew, NT
AU  - Shiue, I
AU  - Singh, JA
AU  - Sisay, M
AU  - Skirbekk, V
AU  - Soares, AM
AU  - Stein, DJ
AU  - Stokes, MA
AU  - Sufiyan, MB
AU  - Swaroop, M
AU  - Sykes, BL
AU  - Tabarés-Seisdedos, R
AU  - Tadese, F
AU  - Tran, BX
AU  - Tran, TT
AU  - Ukwaja, KN
AU  - Vasankari, TJ
AU  - Vlassov, V
AU  - Werdecker, A
AU  - Ye, PP
AU  - Yip, P
AU  - Yonemoto, N
AU  - Younis, MZ
AU  - Zaidi, Z
AU  - Zaki, ME
AU  - Hay, SI
AU  - Lim, SS
AU  - Lopez, AD
AU  - Mokdad, AH
AU  - Vos, T
AU  - Murray, CJL
A1  - Global Burden Dis 2016 Injury Col
TI  - Global Mortality From Firearms, 1990-2016
T2  - JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
KW  - HOMICIDE RATES
KW  - SUICIDE
KW  - GUN
KW  - VIOLENCE
KW  - RISK
KW  - LAWS
AB  - IMPORTANCE Understanding global variation in firearm mortality rates could guide prevention policies and interventions.
   OBJECTIVE To estimate mortality due to firearm injury deaths from 1990 to 2016 in 195 countries and territories.
   DESIGN, SETTING, AND PARTICIPANTS This study used deidentified aggregated data including 13 812 location-years of vital registration data to generate estimates of levels and rates of death by age-sex-year-location. The proportion of suicides in which a firearm was the lethal means was combined with an estimate of per capita gun ownership in a revised proxy measure used to evaluate the relationship between availability or access to firearms and firearm injury deaths.
   EXPOSURES Firearm ownership and access.
   MAIN OUTCOMES AND MEASURES Cause-specific deaths by age, sex, location, and year.
   RESULTS Worldwide, it was estimated that 251 000 (95% uncertainty interval [UI], 195 000-276 000) people died from firearm injuries in 2016, with 6 countries (Brazil, United States, Mexico, Colombia, Venezuela, and Guatemala) accounting for 50.5%(95% UI, 42.2%-54.8%) of those deaths. In 1990, there were an estimated 209 000 (95% UI, 172 000 to 235 000) deaths from firearm injuries. Globally, the majority of firearm injury deaths in 2016 were homicides (64.0%[95% UI, 54.2%-68.0%]; absolute value, 161 000 deaths [95% UI, 107 000-182 000]); additionally, 27% were firearm suicide deaths (67 500 [95% UI, 55 400-84 100]) and 9% were unintentional firearm deaths (23 000 [95% UI, 18 200-24 800]). From 1990 to 2016, there was no significant decrease in the estimated global age-standardized firearm homicide rate (-0.2%[95% UI, -0.8% to 0.2%]). Firearm suicide rates decreased globally at an annualized rate of 1.6%(95% UI, 1.1-2.0), but in 124 of 195 countries and territories included in this study, these levels were either constant or significant increases were estimated. There was an annualized decrease of 0.9% (95% UI, 0.5%-1.3%) in the global rate of age-standardized firearm deaths from 1990 to 2016. Aggregate firearm injury deaths in 2016 were highest among persons aged 20 to 24 years (for men, an estimated 34 700 deaths [95% UI, 24 900-39 700] and for women, an estimated 3580 deaths [95% UI, 2810-4210]). Estimates of the number of firearms by country were associated with higher rates of firearm suicide (P<.001; R-2 = 0.21) and homicide (P<.001; R-2 = 0.35).
   CONCLUSIONS AND RELEVANCE This study estimated between 195 000 and 276 000 firearm injury deaths globally in 2016, the majority of which were firearm homicides. Despite an overall decrease in rates of firearm injury death since 1990, there was variation among countries and across demographic subgroups.
AD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - Higher Natl Sch Vet Med, Algiers, AlgeriaAD  - Univ Toronto, Hosp Sick Children, Ctr Global Child Hlth, Toronto, ON, CanadaAD  - King Abdulaziz Univ, Dept Family & Community Med, Jeddah, Saudi ArabiaAD  - Univ Western Australia, Sch Populat & Global Hlth, Perth, WA, AustraliaAD  - King Abdullah Int Med Res Ctr, Dept Populat Hlth, Riyadh, Saudi ArabiaAD  - Univ Philippines Manila, Dept Hlth Policy & Adm, Manila, PhilippinesAD  - Birmingham City Univ, Dept Publ & Community Hlth, Birmingham, EnglandAD  - Western Sydney Univ, Sch Sci & Hlth, Penrith, NSW, AustraliaAD  - Sydney Local Hlth Dist, Oral Hlth Serv, Sydney, NSW, AustraliaAD  - Iran Univ Med Sci, Dept Epidemiol & Biostat, Tehran, IranAD  - Iranian Minist Hlth & Med Educ, Int Relat Dept, Tehran, IranAD  - Mashhad Univ Med Sci, Educ Dev Ctr, Mashhad, IranAD  - Mekelle Univ, Dept Pharm, Mekelle, EthiopiaAD  - Natl Inst Publ Hlth, Ctr Hlth Syst Res, Cuernavaca, Morelos, MexicoAD  - Indian Inst Publ Hlth, Gandhinagar, IndiaAD  - Publ Hlth Fdn India, Gurugram, IndiaAD  - La Trobe Univ, Judith Lumley Ctr, Melbourne, Vic, AustraliaAD  - Peruvian Natl Inst Hlth, Gen Off Res & Technol Transfer, Lima, PeruAD  - Univ Auckland, Sch Psychol, Auckland, New ZealandAD  - Heidelberg Univ, Inst Publ Hlth, Heidelberg, GermanyAD  - Harvard Univ, Dept Global Hlth & Populat, Boston, MA 02115 USAAD  - Charles R Drew Univ Med & Sci, Dept Psychiat, 1621 E 120th St, Los Angeles, CA 90059 USAAD  - Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USAAD  - Lorestan Univ Med Sci, Social Determinants Hlth Res Ctr, Khorranmabad, IranAD  - Lorestan Univ Med Sci, Fac Hlth & Nutr, Khorranmabad, IranAD  - Post Grad Inst Med Educ & Res, Dept Internal Med, Chandigarh, IndiaAD  - Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, PakistanAD  - Addis Ababa Univ, Sch Pharm, Addis Ababa, EthiopiaAD  - Natl Inst Psychiat Ramon Fuente, Dept Epidemiol, Mexico City, DF, MexicoAD  - Murdoch Childrens Res Inst, Ctr Adolescent Hlth, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, AustraliaAD  - Comenius Univ, Inst Epidemiol, Bratislava, SlovakiaAD  - Natl Inst Hlth, Cuernavaca, Morelos, MexicoAD  - Univ Valle Cuernavaca, Escuela Med, Cuernavaca, Morelos, MexicoAD  - Univ Porto, Ucibio Requimte Fac Pharm, Porto, PortugalAD  - Inst Nacl Salud, Colombian Natl Hlth Observ, Bogota, ColombiaAD  - Univ Nacl Colombia, Epidemiol & Publ Hlth Evaluat Grp, Bogota, ColombiaAD  - Guys & St Thomas NHS Fdn Trust, Dept Clin Toxicol, London, EnglandAD  - Kings Coll London, Dept Fac Life Sci & Med, London, EnglandAD  - Griffith Univ, Australian Inst Suicide Res & Prevent, Mt Gravatt, Qld, AustraliaAD  - Univ Peradeniya, Dept Community Med, Peradeniya, Sri LankaAD  - Harvard Univ, Harvard Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USAAD  - Duy Tan Univ, Inst Global Hlth Innovat, Hanoi, VietnamAD  - Univ Cape Coast, Dept Populat & Hlth, Cape Coast, GhanaAD  - Univ Tampere, Fac Social Sci, Tampere, FinlandAD  - Royal Melbourne Inst Technol Univ RMIT, Sch Hlth & Biomed Sci, Bundoora, Vic, AustraliaAD  - Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, AustraliaAD  - Haramaya Univ, Sch Pharm, Harar, EthiopiaAD  - Karolinska Inst, Dept Publ Hlth Sci, Stockholm, SwedenAD  - St Pauls Hosp, Millennium Med Coll, Dept Publ Hlth, Addis Ababa, EthiopiaAD  - Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Tehran, IranAD  - Univ Fed Sergipe, Dept Psychol, Sao Cristovao, BrazilAD  - Univ Tehran Med Sci, Noncommunicable Dis Res Ctr, Tehran, IranAD  - Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New ZealandAD  - Univ Bielefeld, Dept Publ Hlth Med, Bielefeld, GermanyAD  - James Cook Univ, Coll Publ Hlth Med & Vet Sci, Douglas, Qld, AustraliaAD  - Univ Washington, Sch Med, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USAAD  - Jimma Univ, Dept Epidemiol & Biostat, Jimma, EthiopiaAD  - Natl Inst Psychiat Ramon de la Fuente, Epidemiol & Psychosocial Invest, Mexico City, DF, MexicoAD  - Univ Tehran Med Sci, Sch Med, Tehran, IranAD  - Johns Hopkins Univ, Dept Radiol, Baltimore, MD USAAD  - UCL, Inst Global Hlth, London, EnglandAD  - Mekelle Univ, Sch Med, Biomed Sci Div, Mekelle, EthiopiaAD  - Parc Sanitari Sant Joan Deu CIBERSAM, Res Unit, Sant Boi De Llobregat, SpainAD  - Univ Barcelona, Dept Med, Barcelona, SpainAD  - Mizan Tepi Univ, Dept Publ Hlth, Mizan Teferi, EthiopiaAD  - Univ Hosp Antwerp, Unit Epidemiol & Social Med, Antwerp, BelgiumAD  - Curtin Univ, Sch Publ Hlth, Perth, WA, AustraliaAD  - Fdn Entornos AC, Res Coordinat, Cuernavaca, Morelos, MexicoAD  - Natl Inst Publ Hlth, CISS, Cuernavaca, Morelos, MexicoAD  - Cent South Univ, Xiangya Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R ChinaAD  - Univ Liberia, Dept Publ Hlth & Community Med, Monrovia, LiberiaAD  - Univ Kragujevac, Fac Med Sci, Kragujevac, SerbiaAD  - Virginia Commonwealth Univ, Dept Surg, Richmond, VA USAAD  - Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, GermanyAD  - Capital Med Univ, Beijing Ophthalmol & Visual Sci Key Lab, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R ChinaAD  - Mekelle Univ, Dept Nutr & Dietet, Mekelle, EthiopiaAD  - Univ Tehran Med Sci, Hemat Oncol & Stem Cell Transplantat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Malignancies Res Ctr, Tehran, IranAD  - Univ Nairobi, Sch Continuing & Distance Educ, Nairobi, KenyaAD  - Jordan Univ Sci & Technol, Publ Hlth & Community Med, Alramtha, JordanAD  - Seoul Natl Univ, Coll Med, Dept Hlth Policy & Management, Seoul, South KoreaAD  - Seoul Natl Univ, SNU Med Res Ctr, Inst Hlth Policy & Management, Seoul, South KoreaAD  - Ball State Univ, Dept Nutr & Hlth Sci, Muncie, IN 47306 USAAD  - Lund Univ, Clin Epidemiol Unit, Lund, SwedenAD  - Univ Fed Rio Grande do Sul, Dept Psychiat, Porto Alegre, RS, BrazilAD  - Hosp Clin Porto Alegre, Child & Adolescent Psychiat Div, Porto Alegre, RS, BrazilAD  - Xiamen Univ Malaysia, Sch Med, Sepang, MalaysiaAD  - Acad Med Sci, Dept Community & Family Med, Baghdad, IraqAD  - Helpmesee, New York, NY USAAD  - Mexican Inst Ophthalmol, Dept Int Relat, Queretaro, MexicoAD  - London Sch Hyg & Trop Med London, Dept Infect Dis Epidemiol, London, EnglandAD  - Univ Haifa, Sch Publ Hlth, Haifa, IsraelAD  - Aintree Univ Hosp Natl Hlth Serv Fdn Trust NHS, Gen Surg Dept, Liverpool, Merseyside, EnglandAD  - Univ Liverpool, Sch Med, Liverpool, Merseyside, EnglandAD  - Damietta Univ, Dept Cardiol, Dumyat, EgyptAD  - Aswan Fac Med, Ophthalmol Dept, Aswan, EgyptAD  - Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, IranAD  - Shiraz Univ Med Sci, Noncommunicable Dis Res Ctr, Shiraz, IranAD  - Univ Fed Minas Gerais, Dept Materno Infantil & Saude Publ, Belo Horizonte, MG, BrazilAD  - Univ York, Dept Hlth Sci, York, N Yorkshire, EnglandAD  - South African Med Res Council, Burden Dis Res Unit, Cape Town, South AfricaAD  - Univ Cape Town, Sch Publ Hlth & Family Med, Cape Town, South AfricaAD  - Univ West Florida, Dept Publ Hlth, Pensacola, FL 32514 USAAD  - United Nations Populat Fund UNFPA, Peru Country Off, Lima, PeruAD  - Helsinki Univ Hosp, Breast Surg Unit, Comprehens Canc Ctr, Helsinki, FinlandAD  - Univ Helsinki, Dept Surg, Helsinki, FinlandAD  - Acad Med Sci, Sch Pharm, Baghdad, IraqAD  - Pacific Inst Res & Evaluat, Calverton, MD USAAD  - Ahmadu Bello Univ, Hlth Syst & Policy Res Unit, Zaria, NigeriaAD  - Iran Univ Med Sci, Prevent Med & Publ Hlth Res Ctr, Tehran, IranAD  - Natl Ctr Child Hlth & Dev, Dept Hlth Policy, Tokyo, JapanAD  - Minist Hlth, Hlth Informat Unit, Suva, FijiAD  - Accamargo Canc Ctr, Sao Paulo, BrazilAD  - Semarang State Univ, Publ Hlth Dept, Kota Semarang, IndonesiaAD  - Taipei Med Univ, Grad Inst Biomed Informat, Taipei, TaiwanAD  - Western Sydney Univ, Penrith, NSW, AustraliaAD  - Univ Adelaide, Sch Med, Adelaide, SA, AustraliaAD  - Univ Lagos, Dept Psychiat, Lagos, NigeriaAD  - Univ Melbourne, Dept Paediat, Melbourne, Vic, AustraliaAD  - Murdoch Childrens Res Inst, Dept Paediat, Melbourne, Vic, AustraliaAD  - Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Shanghai, Peoples R ChinaAD  - Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, NetherlandsAD  - Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, CanadaAD  - Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, IranAD  - Univ Tehran Med Sci, INCAS, Tehran, IranAD  - Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, IranAD  - BRAC, Res & Evaluat Div, Dhaka, BangladeshAD  - Soc Hlth & Demog Surveillance, Suri, IndiaAD  - Univ Gottingen, Dept Econ, Gottingen, GermanyAD  - Yonsei Univ, Inst Poverty Alleviat & Int Dev, Seoul, South KoreaAD  - Imperial Coll London, WHO Collaborating Ctr Publ Hlth Educ & Training, London, EnglandAD  - Univ Coll London Hosp, London, EnglandAD  - Imperial Coll London, Dept Primary Care & Publ Hlth, London, EnglandAD  - Publ Hlth England, London, EnglandAD  - Univ Washington, Dept Epidemiol, Seattle, WA 98195 USAAD  - Iran Univ Med Sci, Sina Trauma & Surg Ctr, Tehran, IranAD  - Maragheh Univ Med Sci, Sch Nursing & Midwifery, Dept Publ Hlth, Managerial Epidemiol Res Ctr, Maragheh, IranAD  - AIIMS, Dept Psychiat, New Delhi, IndiaAD  - Marshall Univ, Dept Surg, Huntington, WV USAAD  - Case Western Reserve Univ, Dept Nutr & Prevent Med, Cleveland, OH 44106 USAAD  - Univ Belgrade, Ctr Sch Publ Hlth & Hlth Management, Inst Social Med, Fac Med, Belgrade, SerbiaAD  - Univ Ciencias Aplicadas & Ambient, Fac Med, Dept Hlth & Soc, Bogota, ColombiaAD  - Univ Kwazulu Natal, Dept Publ Hlth Med, Durban, South AfricaAD  - Utkal Univ, UGC Ctr Adv Study Psychol, Bhubaneswar, IndiaAD  - Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USAAD  - Stellenbosch Univ, Dept Psychiat, Cape Town, South AfricaAD  - Debre Berhan Univ, Coll Hlth Sci, Debre Berhan, EthiopiaAD  - Martin Luther Univ Halle Wittenberg, Inst Med Epidemiol Biometrie & Informat, Haale, GermanyAD  - Univ Alabama Birmingham, Sch Med, Birmingham, AL USAAD  - Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USAAD  - Haramaya Univ, Sch Pharm, Harar, EthiopiaAD  - Norwegian Inst Publ Hlth, Oslo, NorwayAD  - Fed Minist Hlth, Dept Dis & Noncommunicable Dis & Hlth Promot, Brasilia, DF, BrazilAD  - South African Med Res Council, Cape Town, South AfricaAD  - Univ Cape Town, Dept Psychiat & Mental Hlth, Cape Town, South AfricaAD  - Deakin Univ, Sch Psychol, Burwood, Vic, AustraliaAD  - Ahmadu Bello Univ, Dept Community Med, Zaria, NigeriaAD  - Northwestern Univ, Dept Surg, Chicago, IL 60611 USAAD  - Univ Calif Irvine, Dept Criminol Law & Soc, Irvine, CA USAAD  - Univ Valencia, Dept Med, Valencia, SpainAD  - Wollo Univ, Dept Publ Hlth, Dessie, EthiopiaAD  - Hanoi Med Univ, Dept Hlth Econ, Hanoi, VietnamAD  - Fed Teaching Hosp, Dept Internal Med, Abakaliki, NigeriaAD  - UKK Inst Hlth Promot Res, Tampere, FinlandAD  - Natl Res Univ, Higher Sch Econ, Dept Hlth Care Management & Econ, Moscow, RussiaAD  - Fed Inst Populat Res, Demog Change & Ageing, Wiesbaden, GermanyAD  - Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pr, Div Injury Prevent & Mental Hlth Improvement, Xicheng Dist, Peoples R ChinaAD  - Univ Hong Kong, Ctr Suicide Res & Prevent, Hong Kong, Hong Kong, Peoples R ChinaAD  - Kyoto Univ, Sch Publ Hlth, Dept Biostat, Kyoto, JapanAD  - Jackson State Univ, Healthcare Management Hlth Econ & Finance Global, Jackson, MO USAAD  - Tsinghua Univ, Res Ctr Publ Hlth, Beijing, Peoples R ChinaAD  - Univ Hosp Setif, Dept Epidemiol, Setif, AlgeriaAD  - ACS Med Coll & Hosp, Fac Med Sci, Algiers, AlgeriaAD  - Mansoura Univ, Fac Med, Mansoura, EgyptAD  - Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Vic, AustraliaC3  - University of WashingtonC3  - University of Washington SeattleC3  - Institute for Health Metrics & EvaluationC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - King Abdulaziz UniversityC3  - University of Western AustraliaC3  - King Saud Bin Abdulaziz University for Health SciencesC3  - King Abdullah International Medical Research Center (KAIMRC)C3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - Birmingham City UniversityC3  - Western Sydney UniversityC3  - Sydney Local Health DistrictC3  - Iran University of Medical SciencesC3  - Ministry of Health & Medical Education (MOHME)C3  - Mashhad University of Medical SciencesC3  - Mekelle UniversityC3  - Instituto Nacional de Salud PublicaC3  - Public Health Foundation of IndiaC3  - La Trobe UniversityC3  - Instituto Nacional de Salud - PeruC3  - University of AucklandC3  - Ruprecht Karls University HeidelbergC3  - Harvard UniversityC3  - Charles R. Drew University of Medicine & ScienceC3  - University of California SystemC3  - University of California Los AngelesC3  - Lorestan University of Medical SciencesC3  - Lorestan University of Medical SciencesC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Aga Khan UniversityC3  - Addis Ababa UniversityC3  - Instituto Nacional de Psiquiatria Ramon de la Fuente MunizC3  - Murdoch Children's Research InstituteC3  - University of MelbourneC3  - Comenius University BratislavaC3  - Universidade do PortoC3  - Instituto Nacional de Salud (Colombia)C3  - Universidad Nacional de ColombiaC3  - Guy's & St Thomas' NHS Foundation TrustC3  - University of LondonC3  - King's College LondonC3  - Griffith UniversityC3  - Griffith University - Mount Gravatt CampusC3  - University of PeradeniyaC3  - Harvard UniversityC3  - Harvard T.H. Chan School of Public HealthC3  - Duy Tan UniversityC3  - University of Cape CoastC3  - Tampere UniversityC3  - Royal Melbourne Institute of Technology (RMIT)C3  - University of SydneyC3  - Haramaya UniversityC3  - Karolinska InstitutetC3  - Tehran University of Medical SciencesC3  - Universidade Federal de SergipeC3  - Tehran University of Medical SciencesC3  - Auckland University of TechnologyC3  - University of BielefeldC3  - James Cook UniversityC3  - University of WashingtonC3  - University of Washington SeattleC3  - Jimma UniversityC3  - Instituto Nacional de Psiquiatria Ramon de la Fuente MunizC3  - Tehran University of Medical SciencesC3  - Johns Hopkins UniversityC3  - University of LondonC3  - University College LondonC3  - Mekelle UniversityC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERSAMC3  - University of BarcelonaC3  - University of AntwerpC3  - Curtin UniversityC3  - Instituto Nacional de Salud PublicaC3  - Central South UniversityC3  - University of KragujevacC3  - Virginia Commonwealth UniversityC3  - Ruprecht Karls University HeidelbergC3  - Capital Medical UniversityC3  - Mekelle UniversityC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - University of NairobiC3  - Jordan University of Science & TechnologyC3  - Seoul National University (SNU)C3  - Seoul National University (SNU)C3  - Ball State UniversityC3  - Lund UniversityC3  - Universidade Federal do Rio Grande do SulC3  - Xiamen University Malaysia CampusC3  - University of HaifaC3  - University of LiverpoolC3  - Egyptian Knowledge Bank (EKB)C3  - Damietta UniversityC3  - Tehran University of Medical SciencesC3  - Shiraz University of Medical ScienceC3  - Universidade Federal de Minas GeraisC3  - University of York - UKC3  - South African Medical Research CouncilC3  - University of Cape TownC3  - State University System of FloridaC3  - University of West FloridaC3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - University of HelsinkiC3  - Pacific Institute for Research & Evaluation (PIRE)C3  - Ahmadu Bello UniversityC3  - Iran University of Medical SciencesC3  - National Center for Child Health & Development - JapanC3  - A.C.Camargo Cancer CenterC3  - Universitas Negeri SemarangC3  - Taipei Medical UniversityC3  - Western Sydney UniversityC3  - University of AdelaideC3  - University of LagosC3  - University of MelbourneC3  - Murdoch Children's Research InstituteC3  - Shanghai Jiao Tong UniversityC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - University of British ColumbiaC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Bangladesh Rural Advancement Committee BRACC3  - University of GottingenC3  - Yonsei UniversityC3  - Imperial College LondonC3  - University of LondonC3  - University College LondonC3  - University College London Hospitals NHS Foundation TrustC3  - Imperial College LondonC3  - Public Health EnglandC3  - University of WashingtonC3  - University of Washington SeattleC3  - Iran University of Medical SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Marshall UniversityC3  - University System of OhioC3  - Case Western Reserve UniversityC3  - University of BelgradeC3  - University of Kwazulu NatalC3  - Utkal UniversityC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - Stellenbosch UniversityC3  - Martin Luther University Halle WittenbergC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - Haramaya UniversityC3  - Norwegian Institute of Public Health (NIPH)C3  - South African Medical Research CouncilC3  - University of Cape TownC3  - Deakin UniversityC3  - Ahmadu Bello UniversityC3  - Northwestern UniversityC3  - University of California SystemC3  - University of California IrvineC3  - University of ValenciaC3  - Hanoi Medical UniversityC3  - UKK InstituteC3  - HSE University (National Research University Higher School of Economics)C3  - Chinese Center for Disease Control & PreventionC3  - National Center for Chronic & Noncommunicable Disease Control & Prevention, Chinese Center for Disease Control & PreventionC3  - University of Hong KongC3  - Kyoto UniversityC3  - Tsinghua UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - University of MelbournePU  - AMER MEDICAL ASSOC
PI  - CHICAGO
PA  - 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
DA  - AUG 28
PY  - 2018
VL  - 320
IS  - 8
SP  - 792
EP  - 814
DO  - 10.1001/jama.2018.10060
AN  - WOS:000442958800024
ER  -

TY  - JOUR
AU  - Jain, S
AU  - Goyal, A
AU  - Kumar, V
TI  - Lipaemia retinalis in familial chylomicronaemia syndrome
T2  - LANCET
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Endocrinol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - AUG 25
PY  - 2018
VL  - 392
IS  - 10148
SP  - E7
EP  - E7
AN  - WOS:000442585300001
ER  -

TY  - JOUR
AU  - Susheela, AK
AU  - Mondal, NK
AU  - Gupta, R
AU  - Sethi, M
AU  - Pandey, RM
TI  - Fluorosis is linked to anaemia
T2  - CURRENT SCIENCE
KW  - Anaemia
KW  - fluoride toxicity
KW  - school children
KW  - treatment procedure
KW  - FLUORIDE INGESTION
KW  - HEMOGLOBIN
KW  - PREVALENCE
KW  - ETIOLOGY
KW  - CHILDREN
KW  - HEMOCUE
AB  - We report here a simple, easy-to-practice treatment procedure for anaemia, by focusing on withdrawal of fluoride consumption and promotion of nutrients through diet. The approach to improve nutrient intake as supplementation of iron and folic acid or iron tonic does not yield beneficial results. The reason being highly destructive F- enters the body through food, water, habit forming substances and dental products destroys the lining of the intestine and prevents absorption of nutrients. Testing of Hb, F- in urine, drinking water and body mass index are necessary to assess the problem. The study was made on 2420 adolescent students from 6 schools in Delhi. F- removal through diet editing and improved nutrients through counselling without prescription of drugs led to correction of anaemia. This treatment procedure is beneficial to pregnant and lactating mothers and patients in hospital OPDs due to ill health issues aggravated due to low Hb/anaemia.
AD  - Fluorosis Fdn India, B-1,Saransh Apartment,34-I P Extens, Delhi 110092, IndiaAD  - S-150 First Floor,Greater Kailash 2, New Delhi 110048, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - INDIAN ACAD SCIENCES
PI  - BANGALORE
PA  - C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
DA  - AUG 25
PY  - 2018
VL  - 115
IS  - 4
SP  - 692
EP  - 700
DO  - 10.18520/cs/v115/i4/692-700
AN  - WOS:000442271400020
ER  -

TY  - JOUR
AU  - Mandal, PK
AU  - Banerjee, A
AU  - Tripathi, M
AU  - Sharma, A
TI  - A Comprehensive Review of Magnetoencephalography (MEG) Studies for Brain Functionality in Healthy Aging and Alzheimer's Disease (AD)
T2  - FRONTIERS IN COMPUTATIONAL NEUROSCIENCE
KW  - magnetoencephalography
KW  - mild cognitive impairment
KW  - Alzheimer's disease
KW  - functional connectivity
KW  - effective connectivity
KW  - network analysis
KW  - machine learning
KW  - multimodal imaging
KW  - MILD COGNITIVE IMPAIRMENT
KW  - GRAPH-THEORETICAL ANALYSIS
KW  - CONNECTIVITY ESTIMATION
KW  - OSCILLATORY ACTIVITY
KW  - HIPPOCAMPAL ATROPHY
KW  - BACKGROUND ACTIVITY
KW  - THETA OSCILLATIONS
KW  - NONLINEAR-ANALYSIS
KW  - MAGNETIC ACTIVITY
KW  - EEG COHERENCE
AB  - Neural oscillations were established with their association with neurophysiological activities and the altered rhythmic patterns are believed to be linked directly to the progression of cognitive decline. Magnetoencephalography (MEG) is a non-invasive technique to record such neuronal activity due to excellent temporal and fair amount of spatial resolution. Single channel, connectivity as well as brain network analysis using MEG data in resting state and task-based experiments were analyzed from existing literature. Single channel analysis studies reported a less complex, more regular and predictable oscillations in Alzheimer's disease (AD) primarily in the left parietal, temporal and occipital regions. Investigations on both functional connectivity (FC) and effective (EC) connectivity analysis demonstrated a loss of connectivity in AD compared to healthy control (HC) subjects found in higher frequency bands. It has been reported from multiplex network of MEG study in AD in the affected regions of hippocampus, posterior default mode network (DMN) and occipital areas, however, conclusions cannot be drawn due to limited availability of clinical literature. Potential utilization of high spatial resolution in MEG likely to provide information related to in-depth brain functioning and underlying factors responsible for changes in neuronal waves in AD. This review is a comprehensive report to investigate diagnostic biomarkers for AD may be identified by from MEG data. It is also important to note that MEG data can also be utilized for the same pursuit in combination with other imaging modalities.
AD  - Natl Brain Res Ctr, Neuroimaging & Neurospect Lab, Gurgaon, IndiaAD  - Florey Inst Neurosci & Mental Hlth, Dept Neurodegenerat, Melbourne, Vic, AustraliaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - Department of Biotechnology (DBT) IndiaC3  - National Brain Research Centre (NBRC)C3  - Florey Institute of Neuroscience & Mental HealthC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - FRONTIERS MEDIA SA
PI  - LAUSANNE
PA  - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
DA  - AUG 23
PY  - 2018
VL  - 12
C7  - 60
DO  - 10.3389/fncom.2018.00060
AN  - WOS:000442549200001
ER  -

TY  - JOUR
AU  - Sharma, U
AU  - Agarwal, K
AU  - Sah, RG
AU  - Parshad, R
AU  - Seenu, V
AU  - Mathur, S
AU  - Gupta, SD
AU  - Jagannathan, NR
TI  - Can Multi-Parametric MR Based Approach Improve the Predictive Value of Pathological and Clinical Therapeutic Response in Breast Cancer Patients?
T2  - FRONTIERS IN ONCOLOGY
KW  - breast cancer
KW  - neoadjuvant chemotherapy
KW  - magnetic resonance spectroscopy
KW  - total choline
KW  - apparent diffusion coefficient
KW  - tumor volume
KW  - pathological response
KW  - clinical response
KW  - NEOADJUVANT CHEMOTHERAPY
KW  - PHYSICAL-EXAMINATION
KW  - DIFFUSION MRI
KW  - DCE-MRI
KW  - SPECTROSCOPY
KW  - MAMMOGRAPHY
KW  - TUMORS
KW  - LESIONS
KW  - SIZE
AB  - The potential of total choline (tCho), apparent diffusion coefficient (ADC) and tumor volume, both individually and in combination of all these three parameters (multi-parametric approach), was evaluated in predicting both pathological and clinical responses in 42 patients with locally advanced breast cancer (LABC) enrolled for neoadjuvant chemotherapy (NACT). Patients were sequentially examined by conventional MRI; diffusion weighted imaging and in vivo proton MR spectroscopy at 4 time points (pre-therapy, after I, II, and III NACT) at 1.5 T. Miller Payne grading system was used for pathological assessment of response. Of the 42 patients, 24 were pathological responders (pR) while 18 were pathological non-responders (pNR). Clinical response determination classified 26 patients as responders (cR) while 16 as non-responders (cNR). tCho and ADC showed significant changes after I NACT, however, MR measured tumor volume showed reduction only after II NACT both in pR and cR. After III NACT, the sensitivity to detect responders was highest for MR volume (83.3% for pR and 96.2% for cR) while the specificity was highest for ADC (76.5% for pR and 100% for cR). Combination of all three parameters exhibited lower sensitivity (66.7%) than MR volume for pR prediction, however, a moderate improvement was seen in specificity (58.8%). For the prediction of clinical response, multi-parametric approach showed 84.6% sensitivity with 100% specificity compared to MR volume (sensitivity 96.2%; specificity 80%). Kappa statistics demonstrated substantial agreement of clinical response with MR volume (k = 0.78) and with multi-parametric approach (k = 0.80) while moderate agreement was seen for tCho (k = 0.48) and ADC (k = 0.46). The values of k for tCho, MR volume and ADC were 0.31, 0.38, and 0.18 indicating fair, moderate, and slight agreement, respectively with pathological response. Moderate agreement (k = 0.44) was observed between clinical and pathological responses. Our study demonstrated that both tCho and ADC are strong predictors of assessment of early pathological and clinical responses. Multi-parametric approach yielded 100% specificity in predicting clinical response. Following III NACT, MR volume emerged as highly suitable predictor for both clinical and pathological assessments. PCA demonstrated separate clusters of pR vs. pNR and cR vs. cNR at post-therapy while with some overlap at pre-therapy.
AD  - All India Inst Med Sci, Dept NMR & MRI Facil, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Surg Disciplines, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - FRONTIERS MEDIA SA
PI  - LAUSANNE
PA  - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
DA  - AUG 15
PY  - 2018
VL  - 8
C7  - 319
DO  - 10.3389/fonc.2018.00319
AN  - WOS:000441558300001
ER  -

TY  - JOUR
AU  - Ippagunta, SK
AU  - Pollock, JA
AU  - Sharma, N
AU  - Lin, WW
AU  - Chen, TS
AU  - Tawaratsumida, K
AU  - High, AA
AU  - Min, J
AU  - Chen, YZ
AU  - Guy, RK
AU  - Redecke, V
AU  - Katzenellenbogen, JA
AU  - Häcker, H
TI  - Identification of Toll-like receptor signaling inhibitors based on selective activation of hierarchically acting signaling proteins
T2  - SCIENCE SIGNALING
KW  - NECROSIS-FACTOR RECEPTOR
KW  - NF-KAPPA-B
KW  - ESTROGEN-RECEPTOR
KW  - ADAPTER MOLECULE
KW  - INNATE IMMUNITY
KW  - KINASE-ACTIVITY
KW  - IRAK-4 INHIBITORS
KW  - INTERFERON-BETA
KW  - IL-1 RECEPTOR
KW  - CPG-DNA
AB  - Toll-like receptors (TLRs) recognize various pathogen-and host tissue-derived molecules and initiate inflammatory immune responses. Exaggerated or prolonged TLR activation, however, can lead to etiologically diverse diseases, such as bacterial sepsis, metabolic and autoimmune diseases, or stroke. Despite the apparent medical need, no small-molecule drugs against TLR pathways are clinically available. This may be because of the complex signaling mechanisms of TLRs, which are governed by a series of protein-protein interactions initiated by Tollinterleukin-1 receptor homology domains (TIR) found in TLRs and the cytoplasmic adaptor proteins TIRAP and MyD88. Oligomerization of TLRs with MyD88 or TIRAP leads to the recruitment of members of the IRAK family of kinases and the E3 ubiquitin ligase TRAF6. We developed a phenotypic drug screening system based on the inducible homodimerization of either TIRAP, MyD88, or TRAF6, that ranked hits according to their hierarchy of action. From a bioactive compound library, we identified methyl-piperidino-pyrazole (MPP) as a TLRspecific inhibitor. Structure-activity relationship analysis, quantitative proteomics, protein-protein interaction assays, and cellular thermal shift assays suggested that MPP targets the TIR domain of MyD88. Chemical evolution of the original MPP scaffold generated compounds with selectivity for distinct TLRs that interfered with specific TIR interactions. Administration of an MPP analog to mice protected them from TLR4-dependent inflammation. These results validate this phenotypic screening approach and suggest that the MPP scaffold could serve as a starting point for the development of anti-inflammatory drugs.
AD  - St Jude Childrens Res Hosp, Dept Infect Dis, 262 Danny Thomas Pl, Memphis, TN 38105 USAAD  - Univ Illinois, Dept Chem, Urbana, IL 61801 USAAD  - St Jude Childrens Res Hosp, Dept Chem Biol & Therapeut, 332 N Lauderdale St, Memphis, TN 38105 USAAD  - St Jude Childrens Res Hosp, St Jude Prote Facil, 332 N Lauderdale St, Memphis, TN 38105 USAAD  - All India Inst Med Sci, Dept Biotechnol, Delhi 110029, IndiaAD  - Univ Richmond, Dept Chem, Richmond, VA 23173 USAC3  - St Jude Children's Research HospitalC3  - University of Illinois SystemC3  - University of Illinois Urbana-ChampaignC3  - St Jude Children's Research HospitalC3  - St Jude Children's Research HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of RichmondPU  - AMER ASSOC ADVANCEMENT SCIENCE
PI  - WASHINGTON
PA  - 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
DA  - AUG 14
PY  - 2018
VL  - 11
IS  - 543
C7  - eaaq1077
DO  - 10.1126/scisignal.aaq1077
AN  - WOS:000442309700003
ER  -

TY  - JOUR
AU  - Webster, R
AU  - Salam, A
AU  - Silva, HA
AU  - Selak, V
AU  - Stepien, S
AU  - Rajapakse, S
AU  - Amarasekara, S
AU  - Amarasena, N
AU  - Billot, L
AU  - de Silva, AP
AU  - Fernando, M
AU  - Guggilla, R
AU  - Jan, S
AU  - Jayawardena, J
AU  - Maulik, PK
AU  - Mendis, S
AU  - Mendis, S
AU  - Munasinghe, J
AU  - Naik, N
AU  - Prabhakaran, D
AU  - Ranasinghe, G
AU  - Thom, S
AU  - Tisserra, N
AU  - Senaratne, V
AU  - Wijekoon, S
AU  - Wijeyasingam, S
AU  - Rodgers, A
AU  - Patel, A
A1  - TRIUMPH Study Grp
TI  - Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka A Randomized Clinical Trial
T2  - JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
KW  - LOW-INCOME COUNTRIES
KW  - THERAPEUTIC INERTIA
KW  - CARDIOVASCULAR-DISEASE
KW  - MIDDLE-INCOME
KW  - METAANALYSIS
KW  - MANAGEMENT
KW  - SAFETY
KW  - AGENTS
KW  - AFFORDABILITY
KW  - AVAILABILITY
AB  - IMPORTANCE Poorly controlled hypertension is a leading global public health problem requiring new treatment strategies.
   OBJECTIVE To assess whether a low-dose triple combination antihypertensive medication would achieve better blood pressure (BP) control vs usual care.
   DESIGN, SETTING, AND PARTICIPANTS Randomized, open-label trial of a low-dose triple BP therapy vs usual care for adults with hypertension (systolic BP >140 mm Hg and/or diastolic BP >90 mm Hg; or in patients with diabetes or chronic kidney disease: >130 mm Hg and/or >80 mm Hg) requiring initiation (untreated patients) or escalation (patients receiving monotherapy) of antihypertensive therapy. Patients were enrolled from 11 urban hospital clinics in Sri Lanka from February 2016 to May 2017; follow-up ended in October 2017.
   INTERVENTIONS A once-daily fixed-dose triple combination pill (20 mg of telmisartan, 2.5 mg of amlodipine, and 12.5 mg of chlorthalidone) therapy (n = 349) or usual care (n = 351).
   MAIN OUTCOMES AND MEASURES The primary outcome was the proportion achieving target systolic/diastolic BP (<140/90 mm Hg or <130/80 mm Hg in patients with diabetes or chronic kidney disease) at 6 months. Secondary outcomes included mean systolic/diastolic BP difference during follow-up and withdrawal of BP medications due to an adverse event.
   RESULTS Among 700 randomized patients (mean age, 56 years; 58% women; 29% had diabetes; mean baseline systolic/diastolic BP, 154/90 mm Hg), 675 (96%) completed the trial. The triple combination pill increased the proportion achieving target BP vs usual care at 6 months (70% vs 55%, respectively; risk difference, 12.7% [95% CI, 3.2% to 22.0%]; P < .001). Mean systolic/diastolic BP at 6 months was 125/76 mm Hg for the triple combination pill vs 134/81 mm Hg for usual care (adjusted difference in postrandomization BP over the entire follow-up: systolic BP, -9.8 [95% CI, -7.9 to -11.6] mm Hg; diastolic BP, -5.0 [95% CI, -3.9 to -6.1] mm Hg; P < .001 for both comparisons). Overall, 419 adverse events were reported in 255 patients (38.1% for triple combination pill vs 34.8% for usual care) with the most common being musculoskeletal pain (6.0% and 8.0%, respectively) and dizziness, presyncope, or syncope (5.2% and 2.8%). There were no significant between-group differences in the proportion of patient withdrawal from BP-lowering therapy due to adverse events (6.6% for triple combination pill vs 6.8% for usual care).
   CONCLUSIONS AND RELEVANCE Among patients with mild to moderate hypertension, treatment with a pill containing low doses of 3 antihypertensive drugs led to an increased proportion of patients achieving their target BP goal vs usual care. Use of such medication as initial therapy or to replace monotherapy may be an effective way to improve BP control.
AD  - Univ New South Wales, George Inst Global Hlth, Sydney, NSW, AustraliaAD  - Univ New South Wales, George Inst Global Hlth, Hyderabad, IndiaAD  - Univ Kelaniya, Clin Trials Unit, Fac Med, Ragama, Sri LankaAD  - Univ Auckland, Dept Epidemiol & Biostat, Auckland, New ZealandAD  - Univ Colombo, Dept Med, Fac Med, Colombo, Sri LankaAD  - Natl Hosp Sri Lanka, Colombo, Sri LankaAD  - Sri Jayawardenapura Gen Hosp, Nugegoda, Sri LankaAD  - Univ Kelaniya, Dept Med, Fac Med, Ragama, Sri LankaAD  - Minist Hlth, Gen Directorate Hlth Affairs Jizan, Sabya, Saudi ArabiaAD  - Univ New South Wales, George Inst Global Hlth, New Delhi, IndiaAD  - Colombo North Teaching Hosp, Ragama, Sri LankaAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Ctr Chron Dis Control, New Delhi, IndiaAD  - Imperial Coll London, Int Ctr Circulatory Hlth, London, EnglandAD  - Univ Sri Jayawardenapura, Dept Med, Fac Med Sci, Nugegoda, Sri LankaC3  - University of SydneyC3  - University of New South Wales SydneyC3  - George Institute for Global HealthC3  - University KelaniyaC3  - University of AucklandC3  - University of ColomboC3  - University KelaniyaC3  - University of ColomboC3  - Colombo North Teaching HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Imperial College LondonC3  - University Sri JayewardenepuraPU  - AMER MEDICAL ASSOC
PI  - CHICAGO
PA  - 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
DA  - AUG 14
PY  - 2018
VL  - 320
IS  - 6
SP  - 566
EP  - 579
DO  - 10.1001/jama.2018.10359
AN  - WOS:000441642500011
ER  -

TY  - JOUR
AU  - Sarkar, S
AU  - Jain, R
AU  - Kethawath, SM
AU  - Gupta, R
AU  - Kumar, M
TI  - Serum BDNF levels in patients with opioid dependence during the early withdrawal period: A case control study
T2  - NEUROSCIENCE LETTERS
KW  - BDNF
KW  - Neuropeptide
KW  - Opioid dependence
KW  - Withdrawal
KW  - NEUROTROPHIC FACTOR LEVELS
KW  - NICOTINE DEPENDENCE
KW  - FAGERSTROM TEST
KW  - RELAPSE
KW  - GDNF
AB  - Background and aims: Brain-Derived Neurotrophic Factor (BDNF), a neuropeptide important for neural growth and differentiation has been explored in patients with opioid dependence. We aimed to compare the serum BDNF levels in patients with opioid dependence with age and gender matched controls, and to assess change in BDNF levels during initial withdrawal period.
   Methods: Thirty cases with a diagnosis of opioid dependence were compared to forty healthy controls. BDNF levels were measured at inclusion for all participants. Additionally, BDNF levels were measured in patients with opioid dependence after 10 days of inpatient detoxification.
   Results: There were no group differences in BDNF levels between cases and controls for day 1 BDNF levels. Also, there was no significant difference observed in the BDNF levels in patients at day 1 and 10 of inpatient detoxification. BDNF levels did not correlate with severity of nicotine dependence, age of the cases or duration of opioid dependence.
   Conclusion: The results from the study provide further insights into the relationship of BDNF levels and opioid dependence.
AD  - AIIMS, NDDTC, Room 4096,Teaching Block, New Delhi 110029, IndiaAD  - AIIMS, Dept Psychiat, Room 4096,Teaching Block, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER IRELAND LTD
PI  - CLARE
PA  - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
DA  - AUG 10
PY  - 2018
VL  - 681
SP  - 100
EP  - 104
DO  - 10.1016/j.neulet.2018.05.048
AN  - WOS:000442191200019
ER  -

TY  - JOUR
AU  - Sharma, SC
AU  - Sakthivel, P
TI  - Whistling Cough
T2  - NEW ENGLAND JOURNAL OF MEDICINE
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MASSACHUSETTS MEDICAL SOC
PI  - WALTHAM
PA  - WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
DA  - AUG 9
PY  - 2018
VL  - 379
IS  - 6
C7  - e10
DO  - 10.1056/NEJMicm1716704
AN  - WOS:000441110600011
ER  -

TY  - JOUR
AU  - Venkateshmurthy, NS
AU  - Ajay, VS
AU  - Mohan, S
AU  - Jindal, D
AU  - Anand, S
AU  - Kondal, D
AU  - Tandon, N
AU  - Rao, MB
AU  - Prabhakaran, D
TI  - m-Power Heart Project - a nurse care coordinator led, mHealth enabled intervention to improve the management of hypertension in India: study protocol for a cluster randomized trial
T2  - TRIALS
KW  - Hypertension
KW  - Chronic kidney disease (CKD)
KW  - Nurse care coordinator (NCC)
KW  - Electronic decision support system (EDSS)
KW  - Task-sharing
KW  - Public health system
KW  - India
KW  - CONSTRAINED RANDOMIZATION
AB  - Background: The proportion of patients with controlled hypertension (<140/90 mmHg) is very low in India. Thus, there is a need to improve blood pressure management among patients with uncontrolled hypertension through innovative strategies directed at health system strengthening.
   Methods: We designed an intervention consisting of two important components -an electronic decision support system (EDSS) used by a trained nurse care coordinator (NCC). Based on preliminary data, we hypothesized that this intervention will be able to reduce mean systolic blood pressure by 6.5 mmHg among those with uncontrolled blood pressure in the intervention arm compared to the standard treatment arm (paper-based hypertension treatment guidelines). The study will adopt a cluster randomized trial design with the community health center (CHC) as the unit of randomization. The trial will be conducted in Visakhapatnam district (southern India). A total of 1876 participants aged >= 30 years with high blood pressure - systolic blood pressure (SBP) >= 160 mmHg or diastolic blood pressure (DBP) >= 90 mmHg will be enrolled from 12 CHCs. The intervention consists of trained NCCs equipped with an evidence-based hypertension treatment algorithm in the form of the EDSS with regular SMSs to patients with hypertension to promote hypertension treatment and blood pressure control for 12 months. The primary outcome will be difference in the mean change of SBP, from baseline to 12 months, between the intervention and the standard treatment arm. The secondary outcomes are the difference in mean change of DBP; difference in the proportion of patients with controlled blood pressure (<140/90 mmHg); difference in mean change of fasting blood sugar, HbA1C, eGFR, and albumin to creatinine ratio; difference in the proportion of patients visiting the CHC regularly (number of actual visits to the CHC/number of visits suggested by the EDSS >80%); difference in proportion of patients compliant to anti-hypertensive medication/s; cost-effectiveness of intervention versus enhanced care. All the outcomes will be assessed at 12 months.
   Discussion: The study is expected to provide evidence on the effectiveness of NCC-led, EDSS-based hypertension management in India and can likely offer an exemplar for improving cardiovascular disease (CVD) management in India within the resource-constrained public healthcare system.
AD  - Publ Hlth Fdn India, Plot 47,Sect 44, Gurgaon, IndiaAD  - Ctr Chron Dis Control, Safdarjung Dev Area, C-1-52,2nd Floor, New Delhi, IndiaAD  - Stanford Univ, Sch Med, Div Nephrol, Palo Alto, CA 94304 USAAD  - All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi, IndiaAD  - KIMS Hosp, Visakhapatnam, Andhra Prades, IndiaC3  - Public Health Foundation of IndiaC3  - Stanford UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - BMC
PI  - LONDON
PA  - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - AUG 7
PY  - 2018
VL  - 19
C7  - 429
DO  - 10.1186/s13063-018-2813-2
AN  - WOS:000441361100005
ER  -

TY  - JOUR
AU  - Gupta, P
AU  - Mohan, S
AU  - Johnson, C
AU  - Garg, V
AU  - Thout, SR
AU  - Shivashankar, R
AU  - Krishnan, A
AU  - Neal, B
AU  - Prabhakaran, D
TI  - Stakeholders' perceptions regarding a salt reduction strategy for India: Findings from qualitative research
T2  - PLOS ONE
KW  - SYSTEMATIC ANALYSIS
KW  - RISK-FACTORS
KW  - DISEASE
KW  - BURDEN
AB  - Background
   Scientific evidence indicates that high dietary salt intake has detrimental effects on blood pressure and associated cardiovascular disease (CVD). However, limited information is available on how to implement salt reduction in low and middle-income countries (LMICs) such as India, where the burden of hypertension and CVD is increasing rapidly. As part of a large study to create the evidence base required to develop a salt reduction strategy for India, we assessed the perspectives of various stakeholders regarding developing an India specific salt reduction strategy.
   Methods
   A qualitative research design was deployed to elicit various stakeholder's (government and policy-related stakeholders, industry, civil Society, consumers) perspectives on a salt reduction strategy for India, using in-depth interviews (IDIs) and focus group discussions (FGDs). We used an inductive approach for data analysis. Data were analyzed using thematic content analysis method.
   Results
   Forty-two IDIs and eight FGDs were conducted with various stakeholders of interest and relevance. Analysis indicated three major themes: 1. Barriers for salt reduction 2. Facilitators for salt reduction; 3. Strategies for salt reduction. Most of the stakeholders were in alignment with the need for a salt reduction programme in India to prevent and control hypertension and related CVD. Major barriers indicated by the stakeholders for salt reduction in India were social and cultural beliefs, a large unorganized food retail sector, and the lack of proper implementation of even existing food policies. Stakeholders from the food industry reported that there might be decreased sales due to salt reduction. Major facilitators included the fact that: salt reduction is currently a part of the National Multi-Sectoral Action Plan for the prevention and control of NCDs, salt reduction and salt iodine programme are compatible, and that few of the multinational food companies have already started working in the direction of initiating efforts for salt reduction. Based on the barriers and facilitators, few of the recommendations are to generate awareness among consumers, promote salt reduction by processed food industry, and implement consumer friendly food labelling.
   Conclusions
   In this study of multiple key influential stakeholders in India, most of the stakeholders were in alignment with the need for a salt reduction programme in India to prevent and control hypertension and related CVD. The development and adoption of the National Multi-sectoral Action Plan to reduce premature non-communicable diseases (NCDs) in India, provides a potential platform that can be leveraged to drive, implement and monitor salt reduction efforts.
AD  - Ctr Chron Dis Control, New Delhi, IndiaAD  - Publ Hlth Fdn India, Gurgaon, Haryana, IndiaAD  - Univ Sydney, Sydney, NSW, AustraliaAD  - George Inst Global Hlth, Sydney, NSW, AustraliaAD  - George Inst Global Hlth, Hyderabad, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Royal Prince Alfred Hosp, Sydney, NSW, AustraliaAD  - Imperial Coll, London, EnglandC3  - Public Health Foundation of IndiaC3  - University of SydneyC3  - George Institute for Global HealthC3  - University of SydneyC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of SydneyC3  - NSW HealthC3  - Royal Prince Alfred HospitalC3  - Imperial College LondonPU  - PUBLIC LIBRARY SCIENCE
PI  - SAN FRANCISCO
PA  - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
DA  - AUG 6
PY  - 2018
VL  - 13
IS  - 8
C7  - e0201707
DO  - 10.1371/journal.pone.0201707
AN  - WOS:000440780000016
ER  -

TY  - JOUR
AU  - Khandelwal, S
AU  - Swamy, MK
AU  - Patil, K
AU  - Kondal, D
AU  - Chaudhry, M
AU  - Gupta, R
AU  - Divan, G
AU  - Kamate, M
AU  - Ramakrishnan, L
AU  - Bellad, MB
AU  - Gan, A
AU  - Kodkany, BS
AU  - Martorell, R
AU  - Reddy, KS
AU  - Prabhakaran, D
AU  - Ramakrishnan, U
AU  - Tandon, N
AU  - Stein, AD
TI  - The impact of DocosaHexaenoic Acid supplementation during pregnancy and lactation on Neurodevelopment of the offspring in India (DHANI): trial protocol
T2  - BMC PEDIATRICS
KW  - Docosahexaenoic acid (DHA)
KW  - Omega 3 fatty acids
KW  - Polyunsaturated fatty acids
KW  - n3PUFA
KW  - Neurodevelopment
KW  - Development assessment scale for Indian infants (DASII)
KW  - Maternal supplementation
KW  - Pregnancy outcomes
KW  - Newborn outcomes
KW  - POLYUNSATURATED FATTY-ACIDS
KW  - AGED 6 MONTHS
KW  - DEVELOPING-COUNTRIES
KW  - CHILD-DEVELOPMENT
KW  - SEAFOOD INTAKE
KW  - BIRTH-WEIGHT
KW  - CONSUMPTION
KW  - OUTCOMES
KW  - MOTHERS
KW  - WOMEN
AB  - Background: Evidence suggests a strong association between nutrition during the first 1000 days (conception to 2 years of life) and cognitive development Maternal docosahexaenoic acid (DHA) supplementation has been suggested to be linked with cognitive development of their offspring. DHA is a structural component of human brain and retina, and can be derived from marine algae, fatty fish and marine oils. Since Indian diets are largely devoid of such products, plasma DHA levels are low. We are testing the effect of pre- and post-natal DHA maternal supplementation in India on infant motor and mental development, anthropometry and morbidity patterns.
   Methods: DHANI is a double-blinded, parallel group, randomized, placebo controlled trial supplementing 957 pregnant women aged 18-35 years from 520 weeks gestation through 6 months postpartum with 400 mg/d algal-derived DHA or placebo. Data on the participants socio-demographic profile, anthropometric measurements and dietary intake are being recorded at baseline. The mother-infant dyads are followed through age 12 months. The primary outcome variable is infant motor and mental development quotient at 12 months of age evaluated by Development Assessment Scale in Indian Infants (DASII). Secondary outcomes are gestational age, APGAR scores, and infant anthropometry. Biochemical indices (blood and breast-milk) from mother-child dyads are being collected to estimate changes in DHA levels in response to supplementation.
   All analyses will follow the intent-to-treat principle. Two-sample t test will be used to test unadjusted difference in mean DASII score between placebo and DHA group. Adjusted analyses will be performed using multiple linear regression.
   Discussion: Implications for maternal and child health and nutrition in India: DHANI is the first large pre- and post natal maternal dietary supplementation trial in India. If the trial finds substantial benefit, it can serve as a learning to scale up the DHA intervention in the country.
AD  - Publ Hlth Fdn India, 47,Sect 44, Gurugram, Haryana, IndiaAD  - Ctr Chron Dis Control, Gurugram, IndiaAD  - KLEUs JN Med Coll, Belgavi, IndiaAD  - Sangath, Delhi, Goa, IndiaAD  - Prabhakar Kore Hosp, Child Dev Ctr, Belgavi, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaAD  - KLE Univ, Res Fdn, Belgavi, IndiaAD  - Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USAC3  - Public Health Foundation of IndiaC3  - K.L.E. Academy of Higher Education & ResearchC3  - Jawaharlal Nehru Medical College, BelgaumC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - K.L.E. Academy of Higher Education & ResearchC3  - Emory UniversityC3  - Rollins School Public HealthPU  - BMC
PI  - LONDON
PA  - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - AUG 4
PY  - 2018
VL  - 18
C7  - 261
DO  - 10.1186/s12887-018-1225-5
AN  - WOS:000440662700001
ER  -

TY  - JOUR
AU  - Adhikari, N
AU  - Biswas, A
AU  - Gogia, A
AU  - Sahoo, RK
AU  - Garg, A
AU  - Nehra, A
AU  - Sharma, MC
AU  - Bhasker, S
AU  - Singh, M
AU  - Sreenivas, V
AU  - Chawla, R
AU  - Joshi, G
AU  - Kumar, L
AU  - Chander, S
TI  - A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome
T2  - JOURNAL OF NEURO-ONCOLOGY
KW  - Primary CNS lymphoma
KW  - High dose methotrexate
KW  - Whole brain radiotherapy
KW  - PRIMARY CNS LYMPHOMA
KW  - RITUXIMAB
KW  - CYTARABINE
KW  - REGIMEN
AB  - The treatment of primary CNS lymphoma (PCNSL) comprises high dose methotrexate (HDMTX) based chemotherapy followed by whole brain radiotherapy (WBRT), the major drawback of which is long term neurotoxicity. We intended to assess the feasibility of response adapted WBRT in PCNSL in the Indian setting.
   We screened 32 patients and enrolled 22 eligible patients with PCNSL from 2015 to 2017 in a prospective phase II trial. The patients underwent five 2-weekly cycles of induction chemotherapy with rituximab, methotrexate, vincristine, procarbazine. Patients with complete response(CR) to induction chemotherapy were given reduced dose WBRT 23.4 Gy/13 fractions/2.5 weeks while those with partial response (PR), stable or progressive disease (SD or PD) were given standard dose WBRT 45 Gy/25 fractions/5 weeks. Thereafter two cycles of consolidation chemotherapy with cytarabine were given. The primary endpoints of the study were assessment of response rate (RR) and progression free survival (PFS). The secondary endpoints of the study were assessment of overall survival (OS), toxicity profile of treatment and serial changes in quality of life and neuropsychological parameters.
   Out of 19 patients who completed HDMTX based chemotherapy, 10 (52.63%) patients achieved CR, 8 (42.11%) patients had PR and 1 patient had PD. After a median follow-up period of 11.25 months, the estimated median OS was 19 months. The actuarial rates of PFS and OS were respectively 94.1 and 68.2% at 1 year and 50.2 and 48.5% at 2 years. Three patients in reduced dose WBRT arm had recurrence and two of them died of progressive disease, whereas there was no recurrence or disease related death in standard dose WBRT arm. On univariate analysis of PFS, age ae<currency> 50 years and use of standard dose WBRT (45 Gy) led to significantly improved outcome (p value 0.03 and 0.02 respectively).
   In patients with PCNSL, reduced dose WBRT after CR to HDMTX based chemotherapy may lead to suboptimal clinical outcome due to higher risk of recurrence, progression and early death. Trial Registration No CTRI/2015/10/006268.
AD  - All India Inst Med Sci, Dept Radiat Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Med Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neuroradiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Clin Neuropsychol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Ophthalmol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - AUG
PY  - 2018
VL  - 139
IS  - 1
SP  - 153
EP  - 166
DO  - 10.1007/s11060-018-2856-y
AN  - WOS:000437255200017
ER  -

TY  - JOUR
AU  - Agarwal, N
TI  - Utility of folate receptor-targeted fluorescent dye for resection of pituitary adenomas
T2  - JOURNAL OF NEUROSURGERY
AD  - All India Inst Med Sci, Neurosci Ctr, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ASSOC NEUROLOGICAL SURGEONS
PI  - ROLLING MEADOWS
PA  - 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
DA  - AUG
PY  - 2018
VL  - 129
IS  - 2
SP  - 554
EP  - 555
DO  - 10.3171/2017.10.JNS172443
AN  - WOS:000440659400036
ER  -

TY  - JOUR
AU  - Agarwal, N
AU  - Gupta, D
TI  - Endoscopic endonasal versus transcranial approach to tuberculum sellae and planum sphenoidale meningiomas: unanswered questions
T2  - JOURNAL OF NEUROSURGERY
KW  - ANTICONVULSANT PROPHYLAXIS
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ASSOC NEUROLOGICAL SURGEONS
PI  - ROLLING MEADOWS
PA  - 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
DA  - AUG
PY  - 2018
VL  - 129
IS  - 2
SP  - 560
EP  - 560
DO  - 10.3171/2018.3.JNS18598
AN  - WOS:000440659400044
ER  -

TY  - JOUR
AU  - Agrawal, M
AU  - Borkar, SA
AU  - Khanna, G
AU  - Sharma, MC
AU  - Kale, SS
TI  - Pigmented Ganglioglioma of the Cerebellum: Case Report and Review
T2  - WORLD NEUROSURGERY
KW  - Cerebellar seizures
KW  - Pigmented ganglioglioma
KW  - CORTICAL DYSPLASIA
KW  - SEIZURE CONTROL
KW  - EPILEPSY
KW  - RESECTION
KW  - MRI
AB  - BACKGROUND: Gangliogliomas (GGs) are rare intra-axial tumors. Cerebellar seizures caused by GGs have been described only rarely. Pigmented neural cell tumors are well described in the literature but are infrequent, especially when presenting as primary neuroepithelial tumors. Only 5 cases of pigmented GG have been reported previously, including 4 in the pediatric population.
   CASE DESCRIPTION: A 17-year-old female presented to us with cerebellar seizures, which resolved after tumor excision. Histopathological examination revealed a pigmented GG.
   CONCLUSIONS: We present the sixth documented case of a pigmented ganglioglioma, the first such case reported in cerebellar location, associated with a rare presentation of cerebellar seizures.
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - AUG
PY  - 2018
VL  - 116
SP  - 18
EP  - 24
DO  - 10.1016/j.wneu.2018.04.219
AN  - WOS:000439498500159
ER  -

TY  - JOUR
AU  - Anand, S
AU  - Patcharu, R
AU  - Yadav, DK
AU  - Kandasamy, D
AU  - Sharma, S
TI  - Does Pneumomediastinum and Pneumoretroperitoneum Always Necessitate Surgical Treatment?
T2  - INDIAN JOURNAL OF PEDIATRICS
AD  - All India Inst Med Sci, Dept Pediat Surg, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - AUG
PY  - 2018
VL  - 85
IS  - 8
SP  - 688
EP  - 689
DO  - 10.1007/s12098-017-2578-8
AN  - WOS:000438768300021
ER  -

TY  - JOUR
AU  - Arora, S
AU  - Passah, A
AU  - Damle, NA
AU  - Narang, R
AU  - Sharma, A
AU  - Yadav, MP
AU  - Ballal, S
AU  - Bhasin, D
AU  - Bal, C
TI  - Somatostatin Receptor PET/CT Features of Carcinoid Heart Disease
T2  - CLINICAL NUCLEAR MEDICINE
KW  - Ga-68-DOTANOC PET
KW  - CT
KW  - carcinoid heart disease
KW  - Lu-177-DOTATATE
AB  - We present the case of a 35-year-old woman with metastatic neuroendocrine tumor undergoing treatment with long-acting octreotide and Lu-177-DOTATATE therapy. We present features of carcinoid heart disease on Ga-68-DOTANOC PET/CT, which revealed dilated right atrium, pericardial effusion, ascites, and congestive hepatopathy apart from the metastatic lesions in the liver. The scan cardiac findings were confirmed by echocardiography. This highlights the significance of identifying such patients early because additional management is required for carcinoid heart disease per se and a cautious approach is needed in administering amino acid infusion during PRRT that can result in fluid overload.
AD  - All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Med Oncol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - AUG
PY  - 2018
VL  - 43
IS  - 8
SP  - E280
EP  - E281
DO  - 10.1097/RLU.0000000000002139
AN  - WOS:000439523100008
ER  -

TY  - JOUR
AU  - Ayachit, A
AU  - Kumar, V
AU  - Raj, N
AU  - Ayachit, G
TI  - Smokestack leak on indocyanine green angiography in acute central serous chorioretinopathy
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Central serous chorioretinopathy
KW  - fundus fluorescein angiography
KW  - indocyanine green angiography
KW  - smokestack leak
AD  - MM Joshi Eye Inst, Dept Vitreoretina, Hubballi, Karnataka, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - AUG
PY  - 2018
VL  - 66
IS  - 8
SP  - 1181
EP  - 1182
DO  - 10.4103/ijo.IJO_140_18
AN  - WOS:000439924900030
ER  -

TY  - JOUR
AU  - Balhara, YPS
TI  - Behavioural addictions: Need to correct misnomers
T2  - ASIAN JOURNAL OF PSYCHIATRY
AD  - All India Inst Med Sci, Natl Drug Dependence Treatment Ctr, Dept Psychiat, BAC, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)PU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - AUG
PY  - 2018
VL  - 36
SP  - 118
EP  - 118
DO  - 10.1016/j.ajp.2018.07.014
AN  - WOS:000446249900038
ER  -

TY  - JOUR
AU  - Biswal, S
AU  - Barhwal, KK
AU  - Das, D
AU  - Dhingra, R
AU  - Dhingra, N
AU  - Nag, TC
AU  - Hota, SK
TI  - Salidroside mediated stabilization of Bcl -X<sub>L</sub> prevents mitophagy in CA3 hippocampal neurons during hypoxia
T2  - NEUROBIOLOGY OF DISEASE
KW  - Hypoxia
KW  - Lipofuscin
KW  - Mitophagy
KW  - Bcl-X-L
KW  - FUNDC1
KW  - Salidroside
KW  - INDUCED MEMORY IMPAIRMENT
KW  - CYTOCHROME-C RELEASE
KW  - CORTICAL-NEURONS
KW  - SPATIAL MEMORY
KW  - RECEPTOR
KW  - FUNDC1
KW  - ACCUMULATION
KW  - MECHANISMS
KW  - EXPRESSION
KW  - LIPOFUSCIN
AB  - Chronic hypoxic stress results in deposition of lipofuscin granules in the CA3 region of hippocampal neurons which contributes to neurodegeneration and accelerated neuronal aging. Oxidative stress and mitophagy during hypoxia are crucial to cause aggregation of these lipofuscin granules in hypoxic neurons. Salidroside, a glucoside derivative of beta-Tyrosol, has been reported to protect hypoxic neurons through maintenance of mitochondria] activity. The resent study is aimed at investigating the potential of Salidroside in preventing mitophagy during chronic hypoxia and identification of the molecular targets and underlying signaling mechanisms. In-silico analysis for interaction of salidroside with Bc1-X-L was carried out using VLife MDS software. The prophylactic efficacy of Salidroside for amelioration of global hypoxia induced neuronal aging was studied in adult male Sprague-Dawley rats exposed to hypobaric hypoxia simulating an altitude of 7600 m for 21 days. Salidroside was supplemented at a daily dose of 25 mg kg (-1)b.w. p.o. during hypoxic exposure. Ultra-structural and immune histological studies were conducted to study lipofuscin aggregation and mitophagy. In-silico findings on salidroside mediated stabilization of Bcl-xL were validated by investigating its effect on downstream signaling molecules involved in mitophagy. Administration of Salidroside reduced deposition of lipofuscin in hypoxic CA3 hippocampal neurons and prevented mitophagy. Salidroside stabilizes Bcl-x(L) in hypoxic neurons resulting in inhibition of PGAM5 phosphatase activity and maintenance of FUNDCI in phosphorylated state. Salidroside mediated inhibition of pFUNDCI dephosphorylation prevents FUNDC1-LC3 II interaction which is crucial for mitophagy. The present study demonstrates potential of Salidroside in preventing lipofuscin deposition during chronic hypoxic stress.
AD  - DRDO, Def Inst High Altitude Res, 56 APO, Leh Ladakh 901205, Jammu & Kashmir, IndiaAD  - All India Inst Med Sci, Dept Physiol, Bhubaneswar 751019, Odisha, IndiaAD  - Panjab Univ, Univ Inst Pharmaceut Sci, Chandigarh, IndiaAD  - All India Inst Med Sci, Dept Anat, New Delhi, IndiaC3  - Defence Research & Development Organisation (DRDO)C3  - Defence Institute of High Altitude Research (DIHAR)C3  - All India Institute of Medical Sciences (AIIMS) BhubaneswarC3  - Panjab UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ACADEMIC PRESS INC ELSEVIER SCIENCE
PI  - SAN DIEGO
PA  - 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
DA  - AUG
PY  - 2018
VL  - 116
SP  - 39
EP  - 52
DO  - 10.1016/j.nbd.2018.04.019
AN  - WOS:000436384100004
ER  -

TY  - JOUR
AU  - Bychkov, A
AU  - Jain, D
TI  - Multiple Sections per Slide for Immunohistochemistry: A Cost-Effective Alternative in Resource-Limited Settings
T2  - ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY
KW  - automated immunostaining
KW  - automation
KW  - laboratory
KW  - clinical laboratory techniques
KW  - histological labeling
KW  - immunohistochemistry
KW  - staining
KW  - staining and labeling
KW  - EXPRESSION
KW  - CANCER
AD  - Chulalongkorn Univ, Dept Pathol, Fac Med, Rama 4 Rd, Bangkok 10330, ThailandAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - Chulalongkorn UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SCI PRINTERS & PUBL INC
PI  - ST LOUIS
PA  - PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA
DA  - AUG
PY  - 2018
VL  - 40
IS  - 4
SP  - 211
EP  - 212
AN  - WOS:000444016800009
ER  -

TY  - JOUR
AU  - Chakraborty, S
AU  - Chopra, M
AU  - Mani, K
AU  - Giri, AK
AU  - Banerjee, P
AU  - Sahni, NS
AU  - Siddhu, A
AU  - Tandon, N
AU  - Bharadwaj, D
TI  - Prevalence of vitamin B<sub>12</sub> deficiency in healthy Indian school-going adolescents from rural and urban localities and its relationship with various anthropometric indices: a cross-sectional study
T2  - JOURNAL OF HUMAN NUTRITION AND DIETETICS
KW  - Indian juvenile health
KW  - micronutrient deficiency
KW  - obesity in adolescence
KW  - vitamin B-12 intake
KW  - GENOME-WIDE ASSOCIATION
KW  - CHILDHOOD MALNUTRITION
KW  - INSULIN-RESISTANCE
KW  - TOTAL HOMOCYSTEINE
KW  - CLINICAL-FEATURES
KW  - AMERICAN CHILDREN
KW  - HIGHLY PREVALENT
KW  - LIFE-STYLE
KW  - B-VITAMINS
KW  - FOLATE
AB  - BackgroundMicronutrient deficiency is a global health burden, especially among developing countries. The present cross-sectional study aimed to determine the prevalence of vitamin B-12 deficiency in healthy Indian school-going adolescents, based on area of residence, sex and body mass index (BMI). Furthermore, the relationship of serum B-12 concentration with dietary vitamin B-12 intake and anthropometric indices was assessed among adolescents from rural and urban India.
   MethodsA total of 2403 school-going adolescents (11-17years) from National Capital Region and rural areas of Haryana, India were selected. Serum B-12 concentrations were estimated using an electrochemiluminescence immunoassay. Dietary assessments were conducted on 65% of total participants (n=1556) by two 24-h diet recalls.
   ResultsThe prevalence of vitamin B-12 deficiency in the total study population was 32.4% (rural: 43.9% versus urban: 30.1%, P<0.001; male: 34.4% versus female: 31.0%, P<0.05; normal weight: 28.1%, versus overweight: 39.8%, versus obese: 51.2%, P<0.001). More than half (51.2%) of obese adolescents were vitamin B-12 deficient. On multiple linear regression analysis, serum B-12 in rural adolescents was associated with age (=-0.12, P<0.05). Among urban adolescents, serum B-12 was associated with BMI (=-0.08, P<0.05) and adjusted dietary vitamin B-12 intake (=0.14, P<0.001). Serum vitamin B-12 levels were found to be lower in rural females (=-0.12, P=0.030) and urban males (: 0.11, P<0.001) compared to their respective contemporaries.
   ConclusionsVitamin B-12 deficiency was higher among rural school-going adolescents. Boys had a higher B-12 deficiency than girls. Inverse associations of serum B-12 with adiposity indices were observed. Serum B-12 levels were positively associated with dietary vitamin B-12 intake.
AD  - CSIR Inst Genom & Integrat Biol, Genom & Mol Med Unit, New Delhi, IndiaAD  - CSIR Inst Genom & Integrat Biol, Acad Sci & Innovat Res, New Delhi, IndiaAD  - Univ Delhi, Dept Food & Nutr, Lady Irwin Coll, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - Jawaharlal Nehru Univ, Sch Computat & Integrat Sci, New Delhi, IndiaAD  - Univ Delhi, Dept Home Sci, Lady Irwin Coll, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi 110029, IndiaAD  - Jawaharlal Nehru Univ, Sch Biotechnol, Syst Genom Lab, New Delhi 110067, IndiaC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Academy of Scientific & Innovative Research (AcSIR)C3  - University of DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jawaharlal Nehru University, New DelhiC3  - University of DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jawaharlal Nehru University, New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - AUG
PY  - 2018
VL  - 31
IS  - 4
SP  - 513
EP  - 522
DO  - 10.1111/jhn.12541
AN  - WOS:000438723800008
ER  -

TY  - JOUR
AU  - Chauhan, S
AU  - Khan, SA
AU  - Prasad, A
TI  - Irradiation-Induced Compositional Effects on Human Bone After Extracorporeal Therapy for Bone Sarcoma
T2  - CALCIFIED TISSUE INTERNATIONAL
KW  - Malignant bone tumor
KW  - Osteosarcoma
KW  - ECRT
KW  - Extra corporeal irradiation
KW  - Raman spectroscopy
KW  - Demineralization
KW  - Amide I
KW  - COLLAGEN CROSS-LINKS
KW  - AGE-RELATED-CHANGES
KW  - CORTICAL BONE
KW  - RAMAN MICROSPECTROSCOPY
KW  - TISSUE
KW  - TUMORS
KW  - REIMPLANTATION
KW  - TOUGHNESS
KW  - STRENGTH
AB  - The present study investigates Raman scattering of human bone irradiated with 50 Gy single dose during therapeutic treatment of Ewing and Osteosarcoma. Bone quality was evaluated via mineral-to-matrix ratio, degree of crystallinity, change in amount of calcium, and carbonate substitution. Alteration in collagen and its cross-links was quantified through second-derivative deconvolution of Amide I peak. A dose of 50 Gy radiation leads to almost 50% loss of mineral content, while maintaining mineral crystallinity, and small changes in carbonate substitution. Deconvolution of Amide I suggested modifications in collagen structure via increase in amount of enzymatic trivalent cross-linking (p < 0.05). Overall irradiation led to detrimental effect on bone quality via changes in its composition, consequently reducing its elastic modulus with increased plasticity. The study thus quantifies effect of single-dose 50 Gy radiation on human bone, which in turn is necessary for designing improved radiation dosage during ECRT and for better understanding post-operative care.
AD  - Indian Inst Technol, Appl Mech, Delhi, IndiaAD  - GBPUAT, Mech Engn, Pant Nagar, IndiaAD  - All India Inst Med Sci, Orthoped, New Delhi, IndiaAD  - South Dakota State Univ, Mech Engn, Brookings, SD USAC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - Govind Ballabh Pant University of Agriculture TechnologyC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - South Dakota State UniversityPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - AUG
PY  - 2018
VL  - 103
IS  - 2
SP  - 175
EP  - 188
DO  - 10.1007/s00223-018-0408-2
AN  - WOS:000438413700007
ER  -

TY  - JOUR
AU  - Chowdhury, UK
AU  - Avneesh, S
AU  - Ray, R
AU  - Reddy, SM
AU  - Kalaivani, M
AU  - Hasija, S
AU  - Kumari, L
TI  - A Comparative Study of Histopathological Changes in the Ascending Aorta and the Risk Factors Related to Histopathological Conditions and Aortic Dilatation in Patients With Tetralogy of Fallot and a Functionally Univentricular Heart
T2  - HEART LUNG AND CIRCULATION
KW  - Tetralogy of Fallot
KW  - Univentricular heart
KW  - Aortic dilatation
KW  - VENTRICULAR SEPTAL-DEFECT
KW  - ROOT DILATATION
KW  - PULMONARY-ATRESIA
KW  - NEURAL CREST
KW  - REPAIR
KW  - ADULTS
KW  - DISEASE
KW  - ABNORMALITIES
KW  - DISSECTION
KW  - MANAGEMENT
AB  - Background The purposes of this study were to prospectively evaluate the histologic characteristics of the aortic wall of patients undergoing univentricular type of repair and compare the same with the findings observed in patients undergoing intracardiac repair of tetralogy of Fallot (TOF).
   Patients and Methods Operatively excised full-thickness aortic wall tissue from 99 consecutive patients undergoing either intra- Methods cardiac repair of TOF (group I; n = 42) or univentricular repair (group II; n = 57) were studied by light microscopy. Age at operation was 13 months to 28 years (mean 99.97 +/- 73.21 months) for group I and 9 months to 25 years (mean 79.52 +/- 60.09) months for group II patients.
   Results Dilatation of the ascending aorta was present in 85.7% patients with TOF and 91.2% patients with a univentricular heart. Seventeen (17.2%) aortic specimens were histologically normal and were used as normal controls (group I, n = 5; group II, n = 12). A lamellar count of less than 60 was associated with a sensitivity of 97.2% and a specificity of 66.7% in patients undergoing repair of TOF and a sensitivity of 84.6% and a specificity of 80% in patients undergoing univentricular type of repairs respectively. Patients undergoing intracardiac repair of TOF and those undergoing univentricular repair exhibited 23.67 times (15.91-147.40) and 8.48 times (3.62-15.84) increased risk of aortic dilatation respectively.
   Conclusions Our findings indicate the existence of significant elastic fragmentation, muscle disarray, medionecrosis and fibrosis involving the ascending aortic media in patients with a functionally univentricular heart and dilated aorta. These histopathological changes are similar to those encountered in patients with TOF and dilated aorta.
AD  - All India Inst Med Sci, Cardiothorac Surg, New Delhi, IndiaAD  - All India Inst Med Sci, Cardiac Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Biostat, New Delhi, IndiaAD  - All India Inst Med Sci, Cardiac Anaesthesia, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - AUG
PY  - 2018
VL  - 27
IS  - 8
SP  - 1004
EP  - 1010
DO  - 10.1016/j.hlc.2017.08.011
AN  - WOS:000438118200019
ER  -

TY  - JOUR
AU  - Dabas, Y
AU  - Xess, I
AU  - Bakshi, S
AU  - Mahapatra, M
AU  - Seth, R
TI  - Emergence of Azole-Resistant <i>Aspergillus fumigatus</i> from Immunocompromised Hosts in India
T2  - ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
KW  - immunocompromised hosts
KW  - invasive aspergillosis
KW  - risk factor
KW  - antifungal susceptibility testing
KW  - azole-resistant Aspergillus fumigatus
KW  - cyp51A mutations
KW  - India
KW  - EPIDEMIOLOGIC CUTOFF VALUES
KW  - CELL TRANSPLANT RECIPIENTS
KW  - INVASIVE ASPERGILLOSIS
KW  - FUNGAL-INFECTIONS
KW  - CROSS-RESISTANCE
KW  - TR34/L98H MUTATIONS
KW  - DRUG-RESISTANCE
KW  - CYP51A GENE
KW  - WILD-TYPE
KW  - SUSCEPTIBILITY
AB  - This prospective study shows that the rate of azole-resistant Aspergillus fumigatus (ARAF) in an immunocompromised Indian patient population with invasive aspergillosis (IA) is low, 6/706 (0.8%). This low rate supports the continued use of voriconazole as the first line of treatment. However, the ARAF isolates from India in this study exhibited three kinds of unreported cyp51A mutations, of which two were at hot spots, G54R and P216L, while one was at codon Y431C.
AD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Med Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Hematol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Paediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER SOC MICROBIOLOGY
PI  - WASHINGTON
PA  - 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
DA  - AUG
PY  - 2018
VL  - 62
IS  - 8
DO  - 10.1128/AAC.02264-17;e02264-17
AN  - WOS:000440008400042
ER  -

TY  - JOUR
AU  - Das, S
AU  - Maras, JS
AU  - Maiwall, R
AU  - Shasthry, SM
AU  - Hussain, S
AU  - Sharma, S
AU  - Sukriti, S
AU  - Singh, TP
AU  - Sarin, SK
TI  - Molecular Ellipticity of Circulating Albumin-Bilirubin Complex Associates With Mortality in Patients With Severe Alcoholic Hepatitis
T2  - CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
KW  - MELD
KW  - AUROC
KW  - Survival
KW  - Prognosis
KW  - HUMAN-SERUM-ALBUMIN
KW  - EXTRACORPOREAL LIVER SUPPORT
KW  - BINDING-SITES
KW  - AFFINITY
KW  - PREDNISOLONE
KW  - DICHROISM
KW  - CAPACITY
AB  - BACKGROUND & AIMS: Hyperbilirubinemia and hypoalbuminemia are features of hepatic dysfunction that associate with disease severity. This is because hepatic insufficiency causes hypoalbuminemia, which indirectly increases the circulating levels of free bilirubin. Circular dichroism (CD) spectroscopy can be used to quantify the molecular ellipticity (ME) of the albumin-bilirubin complex, and might associate with the severity or outcome of severe alcoholic hepatitis (SAH).
   METHODS: We performed a cross-sectional study of 265 patients with SAH admitted in the Department of Hepatology, Institute of Liver and Biliary Sciences in New Delhi, India from January 2014 through January 2016. Blood samples were collected and patients were followed for 12 months or death. The molar ratios of bilirubin: albumin and albumin-bilirubin complexes were determined for a discovery cohort (30 patients who survived the study period and 60 patients who did not survive) and compared with those of 60 patients with alcoholic cirrhosis and 30 healthy individuals (controls). Optical activities of albumin-bilirubin complexes in blood samples were determined by CD spectroscopy and compared among groups. Findings were validated in a separate cohort of 150 patients with SAH from the same institute. We studied the correlation between ME and albumin binding capacity (ABiC).
   RESULTS: The molar ratio of bilirubin: albumin was higher in patients with SAH than with alcoholic cirrhosis or controls (P < .05). Patients with SAH had different CD spectra and higher ME than the other groups (P < .01); ME correlated with model for end-stage liver disease score (with and without Na) and discriminant function (r(2) > .3; P < .01). ME values above a cut off of 1.84 mdeg predicted 3-month mortality in patients with SAH with an area under receiver operating characteristic curve of 0.87 (95% CI, 0.79-0.95), a 77% positive predictive value, and a 90% negative predictive value. The hazard ratio and concordance index of ME values for 3-month mortality in patients with SAH was 10% higher than the hazard ratio and concordance index of model for end-stage liver disease score. In patients with SAH, there was an inverse correlation between ME and ABiC (r(2) > 0.7; P < .01). We observed a significant reduction in ABiC with increasing levels of bilirubin in vitro prepared albumin-bilirubin complex.
   CONCLUSION: In a cross-sectional study of patients with SAH, we associated ME of the albumin-bilirubin complex, measured by CD spectroscopy, with outcomes of patients with SAH. Increased loading of bilirubin on albumin could explain reduced albumin function. Bilirubin removal by albumin dialysis might benefit patients with SAH.
AD  - Inst Liver & Biliary Sci, Dept Mol & Cellular Med, New Delhi, IndiaAD  - Inst Liver & Biliary Sci, Dept Hepatol, New Delhi 110070, IndiaAD  - All India Inst Med Sci, Dept Biophys, New Delhi, IndiaC3  - Institute of Liver & Biliary Sciences (ILBS)C3  - Institute of Liver & Biliary Sciences (ILBS)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - AUG
PY  - 2018
VL  - 16
IS  - 8
SP  - 1322
EP  - +
DO  - 10.1016/j.cgh.2017.11.022
AN  - WOS:000439415400030
ER  -

TY  - JOUR
AU  - Deshmukh, A
AU  - Chourasia, BK
AU  - Mehrotra, S
AU  - Kana, IH
AU  - Paul, G
AU  - Panda, A
AU  - Kaur, I
AU  - Singh, SK
AU  - Rathore, S
AU  - Das, A
AU  - Gupta, P
AU  - Kalamuddin, M
AU  - Gakhar, SK
AU  - Mohmmed, A
AU  - Theisen, M
AU  - Malhotra, P
TI  - <i>Plasmodium falciparum</i> MSP3 Exists in a Complex on the Merozoite Surface and Generates Antibody Response during Natural Infection
T2  - INFECTION AND IMMUNITY
KW  - Plasmodium
KW  - parasite
KW  - merozoite surface proteins
KW  - malaria vaccine
KW  - Plasmodium falciparum
KW  - apicomplexan parasites
KW  - GLUTAMATE-RICH PROTEIN
KW  - MALARIA VACCINE
KW  - CHIMERIC PROTEIN
KW  - ERYTHROCYTES
KW  - PARASITE
KW  - PROTECTION
KW  - INVASION
KW  - INHIBIT
KW  - IMMUNOGENICITY
KW  - IMMUNITY
AB  - Plasmodium falciparum merozoite surface protein 3 (MSP3) is an abundantly expressed secreted merozoite surface protein and a leading malaria vaccine candidate antigen. However, it is unclear how MSP3 is retained on the surface of merozoites without a glycosylphosphatidylinositol (GPI) anchor or a transmembrane domain. In the present study, we identified an MSP3-associated network on the Plasmodium merozoite surface by immunoprecipitation of Plasmodium merozoite lysate using antibody to the N terminus of MSP3 (anti-MSP3N) followed by mass spectrometry analysis. The results suggested the association of MSP3 with other merozoite surface proteins: MSP1, MSP6, MSP7, RAP2, and SERA5. Protein-protein interaction studies by enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR) analysis showed that MSP3 complex consists of MSP1, MSP6, and MSP7 proteins. Immunological characterization of MSP3 revealed that MSP3N is strongly recognized by hyperimmune serum from African and Asian populations. Furthermore, we demonstrate that human antibodies, affinity purified against recombinant MSP3N (rMSP3N), promote opsonic phagocytosis of merozoites in cooperation with monocytes. At nonphysiological concentrations, anti-MSP3N antibodies inhibited the growth of P. falciparum in vitro. Together, the data suggest that MSP3 and especially its N-terminal region containing known BIT cell epitopes are targets of naturally acquired immunity against malaria and also comprise an important candidate for a multisubunit malaria vaccine.
AD  - Int Ctr Genet Engn & Biotechnol, Malaria Biol Grp, Aruna Asaf Ali Marg, New Delhi, IndiaAD  - Int Ctr Genet Engn & Biotechnol, Parasite Cell Biol Grp, Aruna Asaf Ali Marg, New Delhi, IndiaAD  - Statens Serum Inst, Dept Congenital Disorders, Copenhagen, DenmarkAD  - Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Ctr Med Parasitol, Copenhagen, DenmarkAD  - Copenhagen Univ Hosp, Rigs Hosp, Dept Infect Dis, Copenhagen, DenmarkAD  - Maharshi Dayanand Univ, Ctr Biotechnol, Rohtak, Haryana, IndiaAD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biotechnol, New Delhi, IndiaAD  - ICMR Natl Inst Res Tribal Hlth NIRTH Complex, Jabalpur, Madhya Pradesh, IndiaC3  - Department of Biotechnology (DBT) IndiaC3  - International Center for Genetic Engineering & Biotechnology (ICGEB)C3  - International Center for Genetic Engineering & Biotechnology (ICGEB), New DelhiC3  - Department of Biotechnology (DBT) IndiaC3  - International Center for Genetic Engineering & Biotechnology (ICGEB)C3  - International Center for Genetic Engineering & Biotechnology (ICGEB), New DelhiC3  - Statens Serum InstitutC3  - University of CopenhagenC3  - University of CopenhagenC3  - Maharshi Dayanand UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute for Research in Tribal Health (NIRTH)PU  - AMER SOC MICROBIOLOGY
PI  - WASHINGTON
PA  - 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
DA  - AUG
PY  - 2018
VL  - 86
IS  - 8
C7  - e00067-18
DO  - 10.1128/IAI.00067-18
AN  - WOS:000439474900008
ER  -

TY  - JOUR
AU  - Dhiman, R
AU  - Prakash, SC
AU  - Sreenivas, V
AU  - Puliyel, J
TI  - Correlation between Non-Polio Acute Flaccid Paralysis Rates with Pulse Polio Frequency in India
T2  - INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
KW  - polio surveillance
KW  - AFP
KW  - oral polio vaccine
KW  - non-polio acute flaccid paralysis
KW  - Guillain Barre Syndrome
KW  - GUILLAIN-BARRE-SYNDROME
KW  - VACCINE CAMPAIGN
KW  - ERADICATION
KW  - SURVEILLANCE
AB  - The last case of polio from India was reported in 2011. That year, the non-polio acute flaccid paralysis (NPAFP) rate in India was 13.35/100,000, where the expected rate is 1-2/100,000. A previous study of data from 2000 to 2010 has detailed the NPAFP rate in a state correlated with the pulse polio rounds conducted there, and the strongest correlation with the NPAFP rate was found when the number of doses from the previous 4 years were used. However, a simple association being found with regression analysis does not prove a causal relationship. After publication of those findings, as the threat of polio had lessened, the number of rounds of OPV administration was brought down. The present study has been done to look at data till the end of 2017, to see if the incidence of NPAFP declined with this reduction in polio immunization rounds. We used polio surveillance data acquired by the Government of India from 2000-2017. Correlation of the NAFP rate to the number of polio rounds in the state was examined, and the cumulative effect of polio doses administered in previous years was sought. NPAFP rate correlated with the OPV pulse polio rounds in that year (R = 0.46; p < 0.001), and the NPAFP rate started to decrease from 2012 when the number of pulse polio rounds had decreased. NPAFP rates in the states of Uttar Pradesh (UP) and Bihar were the highest in the country. Looking at the high-NPAFP states of UP and Bihar, we found that the correlation coefficient was strongest when doses used over 5 years was considered (R = 0.76; p < 0.001). The response to the reduction in OPV rounds (de-challenging) adds credence to the assumption that OPV was responsible for the change in the NPAFP rate. Now that India has been polio-free for over 6 years, we propose that we may be able to reduce NPAFP by further reducing pulse polio rounds.
AD  - St Stephens Hosp, Dept Pediat, Delhi 110054, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi 10029, IndiaC3  - St. Stephen's HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MDPI
PI  - BASEL
PA  - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
DA  - AUG
PY  - 2018
VL  - 15
IS  - 8
C7  - 1755
DO  - 10.3390/ijerph15081755
AN  - WOS:000443168200195
ER  -

TY  - JOUR
AU  - Garg, M
AU  - Shambanduram, S
AU  - Singh, PK
AU  - Sebastian, LJD
AU  - Sawarkar, DP
AU  - Kumar, A
AU  - Gaikwad, S
AU  - Chandra, PS
AU  - Kale, SS
TI  - Management of Pediatric Posterior Circulation Aneurysms-12-Year Single-Institution Experience
T2  - WORLD NEUROSURGERY
KW  - Clipping
KW  - Endovascular treatment
KW  - Pediatric population
KW  - Posterior circulation
KW  - RUPTURED INTRACRANIAL ANEURYSMS
KW  - CEREBRAL ANEURYSMS
KW  - ENDOVASCULAR TREATMENT
KW  - CLINICAL ARTICLE
KW  - ARTERIAL ANEURYSMS
KW  - SURGICAL-TREATMENT
KW  - CHILDHOOD
KW  - CHILDREN
KW  - ADOLESCENCE
KW  - POPULATION
AB  - BACKGROUND: Pediatric posterior circulation aneurysms are rare, complex, poorly understood lesions on which only limited literature is currently available. We report our 12-year experience of managing this condition to enhance knowledge of this rare entity.
   METHODS: Patients <18 years old with posterior circulation aneurysms managed at our institution from January 2005 to April 2017 were included. Demographic, clinical, radiologic and management details were retrieved from hospital records and characteristics of the aneurysms and treatment were analyzed.
   RESULTS: During this period, 20 pediatric patients (maleto-female ratio 15:6; mean age, 13.1 years) with posterior circulation aneurysms were treated. Most of the patients (75%) presented with subarachnoid hemorrhage. The most common location was the vertebrobasilar junction and vertebral artery (31.81%) followed by the basilar artery and the posterior cerebral artery (27.72% each). Dissecting (81.8%) and large (63.63%) aneurysms were the most common types noted. Of the15 patients with 22 aneurysms treated, 13 underwent endovascular management (parent vessel sacrifice in 8 aneurysms and parent vessel preservation in 5 aneurysms), 1 patient underwent surgery, and 1 patient received medical management for central nervous system tuberculosis. During follow-up, 1 patient had recurrence of aneurysm, and 1 patient died after discharge from the hospital. Overall good outcome was recorded in 90% of patients (Glasgow Outcome Scale score 4-5).
   CONCLUSIONS: Vertebrobasilar junction and vertebral artery was the most common location for posterior circulation aneurysms and most were dissecting aneurysms. Endovascular treatment was the mainstay of management. Overall good outcome was observed at long-term follow-up.
AD  - All India Inst Med Sci, Dept Neurosurg, Jodhpur, Rajasthan, IndiaAD  - All India Inst Med Sci, Dept Neuroradiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) JodhpurC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - AUG
PY  - 2018
VL  - 116
SP  - E624
EP  - E633
DO  - 10.1016/j.wneu.2018.05.056
AN  - WOS:000439498500080
ER  -

TY  - JOUR
AU  - Goyal, A
AU  - Gupta, Y
AU  - Kalaivani, M
AU  - Sankar, MJ
AU  - Kachhawa, G
AU  - Bhatla, N
AU  - Gupta, N
AU  - Tandon, N
TI  - Long term (&gt;1year) postpartum glucose tolerance status among Indian women with history of Gestational Diabetes Mellitus (GDM) diagnosed by IADPSG criteria
T2  - DIABETES RESEARCH AND CLINICAL PRACTICE
KW  - Gestational diabetes mellitus
KW  - IADPSG
KW  - Postpartum
KW  - Dysglycemia
KW  - South Asian
KW  - India
KW  - PREGNANCY OUTCOMES
KW  - INSULIN-RESISTANCE
KW  - CELL FUNCTION
KW  - HIGH-RISK
KW  - INDEX
KW  - METAANALYSIS
KW  - PREVALENCE
KW  - COHORT
AB  - Aim: To determine prevalence of long term dysglycemia and its risk factors among women with history of GDM diagnosed using IADPSG criteria at a tertiary care hospital in North India.
   Methods: Women with GDM diagnosed between 2012 and 2016 were invited. Socio-demographic, anthropometric, medical data were collected and 75 gm OGTT with serum insulin estimation, HbA1c and fasting lipid profile were done at the hospital visit.
   Results: Women (N = 267) were tested at 32.5 (+/- 4.6) years of age and at a median (q25-q75) of 20 (12-44) months following the index delivery. Dysglycemia was found in 57.7% by ADA criteria [Diabetes in 10.5% and prediabetes in 47.2%]. Risk factors for cardiovascular disease were significantly more prevalent among these women. On multivariable analysis, HOMA-IR correlated positively, while insulinogenic index correlated negatively with postpartum dysglycemia.
   Conclusion: This is possibly the first long term (>1 year) glucose tolerance outcome study in South Asian women with history of GDM diagnosed by IADPSG criteria, which demonstrates significantly elevated risk of postpartum dysglycemia. While the IADPSG criteria identify women with a lower future conversion to diabetes compared with previous criteria, prediabetes conversion remains high, thereby offering an opportunity to intervene early and prevent progression to future diabetes. (C) 2018 Elsevier B.V. All rights reserved.
AD  - All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Obstet & Gynaecol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER IRELAND LTD
PI  - CLARE
PA  - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
DA  - AUG
PY  - 2018
VL  - 142
SP  - 154
EP  - 161
DO  - 10.1016/j.diabres.2018.05.027
AN  - WOS:000440297500018
ER  -

TY  - JOUR
AU  - Gupta, A
AU  - Mishra, P
AU  - Pati, HP
AU  - Tyagi, S
AU  - Mahapatra, M
AU  - Seth, T
AU  - Saxena, R
TI  - Spectrum of hemostatic disorders in Indian females presenting with bleeding manifestations
T2  - INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
KW  - bleeding
KW  - females
KW  - hemostasis
KW  - Indian
KW  - VON-WILLEBRAND-DISEASE
KW  - WOMEN
KW  - MENORRHAGIA
KW  - DEFICIENCY
KW  - DIAGNOSIS
KW  - RISK
AB  - IntroductionHemostatic disorders are often missed in women with bleeding particularly menorrhagia. Preexisting hemostatic disorders are now known as common risk factor for postpartum hemorrhage and prolonged bleeding in puerperium. Females with bleeding complaints constitute an important population referred to hematology clinic. Hence, we aim to evaluate the type and frequency of hemostatic disorders among females presenting with bleeding in a tertiary care hospital and a basic hemostatic laboratory.
   MethodsThree-year data were retrospectively analyzed for 200 females with various bleeding complaints. Due to resource constraints, a hemostatic workup was done with prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen assay, clot solubility test, mixing studies, specific factor assays, platelet function test, and von Willebrand factor antigen level.
   ResultsA total of 200 females were investigated to identify the cause of their bleeding. Thirty-five of 200 (17.5%) females were found with an underlying bleeding disorder. Of these 35 females, 65.7% presented with bleeding from more than 1 site. Most common bleeding manifestation was spontaneous bruising in 18 of 35 (51.4%) patients followed by petechiae (48.6%). Inherited bleeding disorders were noted in majority. The most common inherited bleeding disorder identified was von Willebrand disease (VWD) in 34.3% females. Second most common disorder was Glanzmann's thrombasthenia accounting for 22.8%. Rare coagulation factor deficiency, such as factors VII, X, and XIII deficiencies, was noted. Three cases revealed acquired causes of coagulation defects.
   ConclusionUnderlying hemostatic defects should be searched for in women with unexplained bleeding complaints. This will not only help in diagnosis but also in proper management for future hemostatic challenges.
AD  - All India Inst Med Sci, Dept Hematol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - AUG
PY  - 2018
VL  - 40
IS  - 4
SP  - 437
EP  - 441
DO  - 10.1111/ijlh.12806
AN  - WOS:000438651300014
ER  -

TY  - JOUR
AU  - Gurjar, BS
AU  - Manikanta Sriharsha, T
AU  - Bhasym, A
AU  - Prabhu, S
AU  - Puraswani, M
AU  - Khandelwal, P
AU  - Saini, H
AU  - Saini, S
AU  - Verma, AK
AU  - Chatterjee, P
AU  - Guchhait, P
AU  - Bal, V
AU  - George, A
AU  - Rath, S
AU  - Sahu, A
AU  - Sharma, A
AU  - Hari, P
AU  - Sinha, A
AU  - Bagga, A
TI  - Characterization of genetic predisposition and autoantibody profile in atypical haemolytic-uraemic syndrome
T2  - IMMUNOLOGY
KW  - complement factor H autoantibodies
KW  - genetic predisposition to autoimmunity
KW  - haemolytic-uraemic syndrome
KW  - COMPLEMENT FACTOR-H
KW  - MACULAR DEGENERATION
KW  - ESCHERICHIA-COLI
KW  - PLASMA EXCHANGES
KW  - C-TERMINUS
KW  - ANTIBODIES
KW  - MUTATIONS
KW  - AFFINITY
KW  - RECOGNITION
KW  - ASSOCIATION
AB  - We previously reported that Indian paediatric patients with atypical haemolytic-uraemic syndrome (aHUS) showed high frequencies of anti-complement factor H (FH) autoantibodies that are correlated with homozygous deletion of the genes for FH-related proteins 1 and 3 (FHR1 and FHR3) (FHR1/3(-/-)). We now report that Indian paediatric aHUS patients without anti-FH autoantibodies also showed modestly higher frequencies of the FHR1/3(-/-) genotype. Further, when we characterized epitope specificities and binding avidities of anti-FH autoantibodies in aHUS patients, most anti-FH autoantibodies were directed towards the FH cell-surface anchoring polyanionic binding site-containing C-terminal short conservative regions (SCRs) 17-20 with higher binding avidities than for native FH. FH SCR17-20-binding anti-FH autoantibodies also bound the other cell-surface anchoring polyanionic binding site-containing region FH SCR5-8, at lower binding avidities. Anti-FH autoantibody avidities correlated with antibody titres. These anti-FH autoantibody characteristics did not differ between aHUS patients with or without the FHR1/3(-/-) genotype. Our data suggest a complex matrix of interactions between FHR1-FHR3 deletion, immunomodulation and anti-FH autoantibodies in the aetiopathogenesis of aHUS.
AD  - Natl Inst Immunol, Aruna Asaf Ali Rd, New Delhi 110067, IndiaAD  - Natl Ctr Cell Sci, SP Pune Univ Campus, Pune, Maharashtra, IndiaAD  - Reg Ctr Biotechnol, Faridabad, IndiaAD  - Manipal Acad Higher Educ, Dept Biotechnol, Manipal, Karnataka, IndiaAD  - Translat Hlth Sci & Technol Inst, Paediat Biol Ctr, Faridabad, IndiaAD  - All India Inst Med Sci, Dept Paediat, New Delhi, IndiaAD  - Univ Delhi, Kirori Mal Coll, Delhi, IndiaAD  - Agharkar Res Inst, Pune, Maharashtra, IndiaC3  - Department of Biotechnology (DBT) IndiaC3  - National Institute of Immunology (NII)C3  - Department of Biotechnology (DBT) IndiaC3  - National Centre for Cell Science, Pune (NCCS)C3  - Department of Biotechnology (DBT) IndiaC3  - Regional Centre for BiotechnologyC3  - Manipal Academy of Higher Education (MAHE)C3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of DelhiC3  - Department of Science & Technology (India)C3  - Agharkar Research Institute (ARI)PU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - AUG
PY  - 2018
VL  - 154
IS  - 4
SP  - 663
EP  - 672
DO  - 10.1111/imm.12916
AN  - WOS:000439506200015
ER  -

TY  - JOUR
AU  - Hermle, T
AU  - Schneider, R
AU  - Schapiro, D
AU  - Braun, DA
AU  - van der Ven, AT
AU  - Warejko, JK
AU  - Daga, A
AU  - Widmeier, E
AU  - Nakayama, M
AU  - Jobst-Schwan, T
AU  - Majmundar, AJ
AU  - Ashraf, S
AU  - Rao, J
AU  - Finn, LS
AU  - Tasic, V
AU  - Hernandez, JD
AU  - Bagga, A
AU  - Jalalah, SM
AU  - El Desoky, S
AU  - Kari, JA
AU  - Laricchia, KM
AU  - Lek, M
AU  - Rehm, HL
AU  - MacArthur, DG
AU  - Mane, S
AU  - Lifton, RP
AU  - Shril, S
AU  - Hildebrandt, F
TI  - <i>GAPVD1</i> and <i>ANKFY1</i> Mutations Implicate RAB5 Regulation in Nephrotic Syndrome
T2  - JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
KW  - nephrotic syndrome
KW  - podocyte
KW  - nephrin
KW  - endocytosis
KW  - genetic renal disease
KW  - nephrocyte
KW  - FOCAL SEGMENTAL GLOMERULOSCLEROSIS
KW  - GROWTH-FACTOR RECEPTOR
KW  - OF-FUNCTION MUTATIONS
KW  - NEPHRIN ENDOCYTOSIS
KW  - SLIT DIAPHRAGM
KW  - GENOTYPE/PHENOTYPE CORRELATIONS
KW  - EFFECTOR RABANKYRIN-5
KW  - MESANGIAL SCLEROSIS
KW  - GLOMERULAR PROTEIN
KW  - GENE
AB  - BackgroundSteroid-resistant nephrotic syndrome (SRNS) is a frequent cause of CKD. The discovery of monogenic causes of SRNS has revealed specific pathogenetic pathways, but these monogenic causes do not explain all cases of SRNS.MethodsTo identify novel monogenic causes of SRNS, we screened 665 patients by whole-exome sequencing. We then evaluated the in vitro functional significance of two genes and the mutations therein that we discovered through this sequencing and conducted complementary studies in podocyte-like Drosophila nephrocytes.ResultsWe identified conserved, homozygous missense mutations of GAPVD1 in two families with early-onset NS and a homozygous missense mutation of ANKFY1 in two siblings with SRNS. GAPVD1 and ANKFY1 interact with the endosomal regulator RAB5. Coimmunoprecipitation assays indicated interaction between GAPVD1 and ANKFY1 proteins, which also colocalized when expressed in HEK293T cells. Silencing either protein diminished the podocyte migration rate. Compared with wild-type GAPVD1 and ANKFY1, the mutated proteins produced upon ectopic expression of GAPVD1 or ANKFY1 bearing the patient-derived mutations exhibited altered binding affinity for active RAB5 and reduced ability to rescue the knockout-induced defect in podocyte migration. Coimmunoprecipitation assays further demonstrated a physical interaction between nephrin and GAPVD1, and immunofluorescence revealed partial colocalization of these proteins in rat glomeruli. The patient-derived GAPVD1 mutations reduced nephrin-GAPVD1 binding affinity. In Drosophila, silencing Gapvd1 impaired endocytosis and caused mistrafficking of the nephrin ortholog.ConclusionsMutations in GAPVD1 and probably in ANKFY1 are novel monogenic causes of NS. The discovery of these genes implicates RAB5 regulation in the pathogenesis of human NS.
AD  - Harvard Med Sch, Boston Childrens Hosp, Dept Med, Boston, MA USAAD  - Univ Freiburg, Univ Med Ctr Freiburg, Div Renal, Fac Med, Freiburg, GermanyAD  - Univ Washington, Dept Pathol, Seattle Childrens Hosp, Seattle, WA 98195 USAAD  - Univ Childrens Hosp, Dept Pediat Nephrol, Med Fac Skopje, Skopje, MacedoniaAD  - Providence Sacred Heart Med Ctr, Dept Pediat Nephrol, Spokane, WA USAAD  - Childrens Hosp, Spokane, WA USAAD  - All India Inst Med Sci, Div Nephrol, New Delhi, IndiaAD  - King Abdulaziz Univ, Dept Pathol, Coll Med, Jeddah, Saudi ArabiaAD  - King Abdulaziz Univ, Pediat Nephrol Ctr Excellence, Fac Med, Jeddah, Saudi ArabiaAD  - King Abdulaziz Univ, Dept Pediat, Fac Med, Jeddah, Saudi ArabiaAD  - Broad Inst Massachusetts Inst Technol & Harvard, Broad Ctr Mendelian Genet, Cambridge, MA USAAD  - Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USAAD  - Rockefeller Univ, Lab Human Genet & Genom, 1230 York Ave, New York, NY 10021 USAC3  - Harvard UniversityC3  - Harvard Medical SchoolC3  - Boston Children's HospitalC3  - University of FreiburgC3  - University of WashingtonC3  - University of Washington SeattleC3  - Seattle Children's HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - King Abdulaziz UniversityC3  - King Abdulaziz UniversityC3  - King Abdulaziz UniversityC3  - Harvard UniversityC3  - Massachusetts Institute of Technology (MIT)C3  - Broad InstituteC3  - Yale UniversityC3  - Rockefeller UniversityPU  - AMER SOC NEPHROLOGY
PI  - WASHINGTON
PA  - 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
DA  - AUG
PY  - 2018
VL  - 29
IS  - 8
SP  - 2123
EP  - 2138
DO  - 10.1681/ASN.2017121312
AN  - WOS:000445764500014
ER  -

TY  - JOUR
AU  - Islamuddin, M
AU  - Khan, WH
AU  - Gupta, S
AU  - Tiku, VR
AU  - Khan, N
AU  - Akdag, AI
AU  - Chaudhary, S
AU  - Upadhyay, A
AU  - Kumar, P
AU  - Ghatwala, G
AU  - Ray, P
TI  - Surveillance and genetic characterization of rotavirus strains circulating in four states of North Indian children (Publication with Expression of Concern. See vol. 62, 2018)
T2  - INFECTION GENETICS AND EVOLUTION
KW  - Rotavirus
KW  - Gastroenteritis
KW  - Genetic diversity
KW  - North India
KW  - G12 strain
KW  - Vaccine
KW  - HOSPITAL-BASED SURVEILLANCE
KW  - MOLECULAR CHARACTERIZATION
KW  - ACUTE GASTROENTERITIS
KW  - DISEASE BURDEN
KW  - DIARRHEA
KW  - EMERGENCE
KW  - DIVERSITY
KW  - G12
KW  - VACCINATION
KW  - PREVALENCE
AB  - Acute gastroenteritis due to Rotavirus (RV) infection is a major cause of morbidity and mortality in infants and young children worldwide. In India, around 0.1 million death reported annually due to RV illness. So, to assess the disease burden continuous surveillance of the circulating genotypes is needed. This study aimed to ascertain the genetic variance of 429 rotavirus positive specimens observed during the period October 2013-September 2014 at four study centers from North India. Out of 1057 patients enrolled, 1018 stool samples were collected at four centers in four different states of North India. Children aged < 5 years who showed the symptoms of severe diarrhea and needed hospitalization were enrolled. The stool samples collected were screened by Enzyme Immuno Assay (EIA), and the RV positive samples were characterized by semi-nested PCR. During the study period October 2013 through September 2014, similar to 42% patients were found to be rotavirus positive of 1018 collected specimen. In Delhi, Rohtak and Meerut, we observed that Rotavirus is seasonal compared to Tanda (HP). The rate of rotavirus detection was significantly higher among children aged below 2 years, and a total of 21.5% of rotavirus infections comprised children aged < 6 months. Genotype G1(48.0%) was predominant and frequently circulating strain whereas G12 (16.8%) and G9 (10.0%) was second and third prevalent strain in the four states of North India. High frequency of G1 genotypes was detected under the age group of 6-11 months which is followed by G12, similarly high rate severe disease was observed due to G1 genotypes followed by P[8], P[6] and G12. The most common types of strains were G1P[8] (27.73% of strains), G12P[6] (13.28%), G9P[4] (7.23%) and G1P[6] (6.75%). The rare strain reported were G1P[9]; P[11] strain was detected in combination with G1, G2, and G12. These data emphasized G12 is the second most predominant strain circulating among Northern Indian children highlights the needs for inclusion in the future polyvalent vaccine to break the burden of rotavirus infection.
AD  - Jamia Hamdard, Sch Chem & Life Sci, Dept Biotechnol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaAD  - Rajendra Prasad Govt Med Coll, Dept Pediat, Tanda, HP, IndiaAD  - LalaLajpatRai Mem Med Coll, Dept Pediat, Meerut, Uttar Pradesh, IndiaAD  - Lady Hardinge Med Coll & Hosp, Dept Pediat, New Delhi, IndiaAD  - Post Grad Inst Med Sci, Dept Pediat, Rohtak, Haryana, IndiaAD  - Indian Inst Technol Delhi, Kusuma Sch Biol Sci, New Delhi, IndiaAD  - Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, New Delhi, IndiaC3  - Jamia Hamdard UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Lady Hardinge Medical College & HospitalC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - Jamia Millia IslamiaPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - AUG
PY  - 2018
VL  - 62
SP  - 253
EP  - 261
DO  - 10.1016/j.meegid.2018.04.030
AN  - WOS:000453654100032
ER  -

TY  - JOUR
AU  - Jain, K
AU  - Sahran, D
AU  - Singhal, M
AU  - Misra, MC
TI  - A Novel Way of Linen Management in an Acute Care Surgical Center
T2  - INDIAN JOURNAL OF SURGERY
KW  - Linen management
KW  - Centralized
KW  - Acute care surgical centre
KW  - Satisfaction
AB  - Efficiency-driven services are the need of the hour in the healthcare organizations of today. Authors envisaged an efficient linen management system by creating a hybrid amongst the two most prevalent methods of linen management which they have been practicing. The study was conducted with the aim to ascertain the impacts of a streamlined centralized linen management system on clinical care and patient and staff satisfaction at an acute care surgical centre. The study is a cross sectional observational study conducted at a 200 bedded acute care surgical centre of the country over a period of 2 years. All stock registers and complaints with respect to linen management received during the study duration were perused and compiled. Patients and staff satisfaction with respect to linen being supplied in the centre were studied using a structured validated questionnaire. Cost implications of setting up such a department has also been determined by considering the different cost heads required to set up such a facility in an already existing set up. Data was compiled and analysed using appropriate statistical tests such as t test and percent increase. A central linen facility was created at the centre with the aim to streamline linen distribution and handling. Since the inception of this facility, it was found that there was a -0.89% increase in the number of complaints received with respect to linen in August 2014 and February 2016.The amount of linen received by the laundry (including blankets) for washing over the years has increased significantly. On measuring satisfaction, it was ascertained that almost all patients were satisfied with the linen being provided at the centre. Amongst the staff, it was observed that the staff was satisfied with the quantity, quality and timeliness of the linen provided. In addition, 66.66% respondents agreed that the linen in the centre was better than the ones being provided in other hospital, while 78.57% agreed that the location of the central linen facility was apt. i >><inverted question mark>The total cost determined to set up a central linen facility is approximately Rs.5,56,000. Centralised facilities in high turnover acute surgical facilities could be a successful model which can be adopted by other healthcare organizations who are trying to bring efficiency in their systems. In additions, creation of such systems annuls surgical delays which happen due to improper linen supply.
AD  - All India Inst Med Sci, Dept Hosp Adm, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Surg Discipline, 5 Floor,PC Teaching Block, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - AUG
PY  - 2018
VL  - 80
IS  - 4
SP  - 303
EP  - 308
DO  - 10.1007/s12262-016-1573-z
AN  - WOS:000439798500001
ER  -

TY  - JOUR
AU  - Jain, S
AU  - Kumawat, D
AU  - Kumar, V
TI  - Multimodal imaging of torpedo-shaped fundus lesions: New insights
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Multimodal imaging
KW  - swept-source optical coherence tomography
KW  - torpedo maculopathy
KW  - OPTICAL COHERENCE TOMOGRAPHY
KW  - MACULOPATHY
AB  - The purpose of this case series is to describe the varied presentation of Torpedo lesions of the fundus and multimodal imaging features in three eyes of three patients. Two patients presented with typical topography, i.e., temporal to the fovea. One patient revealed lesion inferonasal to disc with the head pointing toward the disc. All three patients had an attenuation of outer retinal layers on optical coherence tomography. One patient showed an additional large subretinal cleft. Variable hypoautofluorescence in the area of the torpedo was noted. To conclude torpedo lesions can present at atypical locations, have both retinal and choroidal atrophy and head point toward the optic disc.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - AUG
PY  - 2018
VL  - 66
IS  - 8
SP  - 1211
EP  - +
DO  - 10.4103/ijo.IJO_118_18
AN  - WOS:000439924900046
ER  -

TY  - JOUR
AU  - Jaiswal, RK
AU  - Kumar, P
AU  - Kumar, M
AU  - Yadava, PK
TI  - hTERT promotes tumor progression by enhancing TSPAN13 expression in osteosarcoma cells
T2  - MOLECULAR CARCINOGENESIS
KW  - hTERT
KW  - microarray
KW  - shRNA
KW  - telomerase
KW  - tetraspanin
KW  - BREAST-CANCER
KW  - GENE-EXPRESSION
KW  - TELOMERASE ACTIVITY
KW  - PROSTATE-CANCER
KW  - POOR-PROGNOSIS
KW  - OVARIAN-CANCER
KW  - TARGET GENE
KW  - MIGRATION
KW  - PROLIFERATION
KW  - METASTASIS
AB  - Telomerase complex maintains the length of the telome, cbre, and protects erosion of the physical ends of the eukaryotic chromosome in all actively dividing cells including cancer cells. Telomerase activation extends the lifespan of cells in culture by maintaining the length of the telomere. Compared to terminally differentiated somatic cells, telomerase activity remains high in over 90% of cancer cells. It has now become clear that the role of telomerase is much more complex than just telomere lengthening. The remaining 10% of cancers deploy ALT (alternative lengthening of telomeres) pathway to maintain telomere length. Telomerase inhibitors offer a good therapeutic option. Also, telomerase-associated molecules can be targeted provided their roles are clearly established. In any case, it is necessary to understand the major role of telomerase in cancer cells. Many studies have already been done to explore gene profiling of a telomerase positive cell by knocking down expression of hTERT (telomerase reverse transcriptase). To complement these studies, we performed global gene profiling of a telomerase negative cell by ectopically expressing hTERT and studied changes in the global gene expression patterns. Analysis of microarray data for telomerase negative cells ectopically expressing telomerase showed 76 differentially regulated genes, out of which 39 genes were upregulated, and 37 were downregulated. Three upregulated genes such as TSPAN13, HMGCS2, DLX5, and three downregulated genes like DHRS2, CRYAB, and PDLIM1 were validated by real-time PCR. Knocking down of TSAPN13 in hTERT overexpressing U2OS cells enhanced the apoptosis of the cells. TSPAN13 knockdown in these cells suppressed mesenchymal properties and enhanced epithelial character.
AD  - Jawaharlal Nehru Univ, Sch Life Sci, Appl Mol Biol Lab, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Reprod Biol, New Delhi, IndiaC3  - Jawaharlal Nehru University, New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - AUG
PY  - 2018
VL  - 57
IS  - 8
SP  - 1038
EP  - 1054
DO  - 10.1002/mc.22824
AN  - WOS:000436870600009
ER  -

TY  - JOUR
AU  - Jha, S
AU  - Salve, HR
AU  - Goswami, K
AU  - Sagar, R
AU  - Kant, S
TI  - Burden of common mental disorders among pregnant women: A systematic review
T2  - ASIAN JOURNAL OF PSYCHIATRY
KW  - Common mental disorders
KW  - Pregnancy
KW  - Antenatal
KW  - Mental illness
KW  - Maternal mental health
KW  - MIDDLE-INCOME COUNTRIES
KW  - RISK-FACTORS
KW  - ANTENATAL DEPRESSION
KW  - POSTNATAL DEPRESSION
KW  - BIRTH COHORT
KW  - CHILD
KW  - PREVALENCE
KW  - OUTCOMES
KW  - ANXIETY
KW  - INFANT
AB  - Introduction: Common mental disorders (CMDs) including depressive and anxiety disorders during antenatal period is reported to affect both mother and child health outcomes. There is scarce evidence about burden of CMDs during pregnancy from Lower and Middle Income Countries.
   Objective: To review the evidence about the burden of common mental disorders among pregnant women
   Methods: Major databases were searched systematically for English language studies on prevalence of CMDs. Quality assessment of studies was done with the modified version of Newcastle-Ottawa Scale for non-analytical studies.
   Results: Twenty three studies were included in the review. The prevalence of CMDs among pregnant women ranged from 1%-37%. Depression was more commonly studied (ranged from 1%-30%). Prevalence of GAD ranged from 1%-26%. Factors commonly associated with CMDs were lower SES, intimate partner violence, history of previous episode of CMDs, history of mental illness in family and unmarried status. Effect of CMDs on child health outcome was also detected.
   Conclusion: CMDs are common during pregnancy with varying prevalence depending on various settings and scales used.
AD  - All India Inst Med Sci, Ctr Community Med, Room 37, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Psychiat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - AUG
PY  - 2018
VL  - 36
SP  - 46
EP  - 53
DO  - 10.1016/j.ajp.2018.06.020
AN  - WOS:000446249900018
ER  -

TY  - JOUR
AU  - Katiyar, V
AU  - Vora, Z
AU  - Agarwal, S
AU  - Sharma, R
AU  - Gurjar, H
TI  - Prognostic Scoring for Chronic Subdural Hematoma: Is Decision Making Easier?
T2  - WORLD NEUROSURGERY
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - AUG
PY  - 2018
VL  - 116
SP  - 481
EP  - 481
DO  - 10.1016/j.wneu.2018.03.056
AN  - WOS:000439498500249
ER  -

TY  - JOUR
AU  - Katwa, U
AU  - Kabra, SK
TI  - Advances in Asthma
T2  - INDIAN JOURNAL OF PEDIATRICS
AD  - Harvard Med Sch, Boston Childrens Hosp, Sleep Lab Attending Pulm & Sleep Med, Boston, MA USAAD  - All India Inst Med Sci, Dept Pediat, New Delhi 110029, IndiaC3  - Harvard UniversityC3  - Boston Children's HospitalC3  - Harvard Medical SchoolC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - AUG
PY  - 2018
VL  - 85
IS  - 8
SP  - 641
EP  - 642
DO  - 10.1007/s12098-018-2709-x
AN  - WOS:000438768300010
ER  -

TY  - JOUR
AU  - Kaur, M
AU  - Goth, A
AU  - Subramaniam, R
TI  - Low flow vascular malformations of cervico facial area: An airway challenge
T2  - JOURNAL OF CLINICAL ANESTHESIA
AD  - All India Inst Med Sci, Dept Anaesthesia & Intens Care, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - AUG
PY  - 2018
VL  - 48
SP  - 58
EP  - 59
DO  - 10.1016/j.jclinane.2018.04.016
AN  - WOS:000436901600022
ER  -

TY  - JOUR
AU  - Kumar, A
AU  - Jat, KR
AU  - Srinivas, M
AU  - Lodha, R
TI  - Nebulized N-Acetylcysteine for Management of Plastic Bronchitis
T2  - INDIAN PEDIATRICS
KW  - Bronchial asthma
KW  - Bronchial casts
KW  - Foreign body
KW  - Refractory
KW  - CHILDREN
AB  - Plastic bronchitis is characterized by formation of extensive obstructive endobronchial casts and high recurrence rates.
   Two children (1-year-old girl, 7-year-old boy) who had recurrent episodes of respiratory distress with acute worsening. Bronchoscopy revealed membrane-like casts. Both children were managed with nebulized N-acetylcysteine in addition to management for asthma.
   Symptom-free without recurrence for more than 9 months of follow-up.
   Nebulized N-acetylcysteine may be helpful in prevention of recurrence of plastic bronchitis due to asthma.
AD  - All India Inst Med Sci, Dept Pediat, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pediat Surg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - AUG
PY  - 2018
VL  - 55
IS  - 8
SP  - 701
EP  - 703
DO  - 10.1007/s13312-018-1363-8
AN  - WOS:000442246600014
ER  -

TY  - JOUR
AU  - Kumar, A
AU  - Nayak, S
AU  - Pathak, P
AU  - Purkait, S
AU  - Malgulawar, PB
AU  - Sharma, MC
AU  - Suri, V
AU  - Mukhopadhyay, A
AU  - Suri, A
AU  - Sarkar, C
TI  - Identification of miR-379/miR-656 (C14MC) cluster downregulation and associated epigenetic and transcription regulatory mechanism in oligodendrogliomas
T2  - JOURNAL OF NEURO-ONCOLOGY
KW  - miRNA cluster
KW  - C14MC
KW  - MEG3
KW  - MEF2
KW  - Oligodendrogliomas
KW  - CENTRAL-NERVOUS-SYSTEM
KW  - LUNG ADENOCARCINOMA
KW  - MICRORNA EXPRESSION
KW  - MIR-487B
KW  - GLIOMAS
KW  - CANCER
KW  - TUMORS
KW  - MUTATIONS
KW  - SUBTYPES
KW  - BRAIN
AB  - Although role of individual microRNAs (miRNAs) in the pathogenesis of gliomas has been well studied, their role as a clustered remains unexplored in gliomas.
   In this study, we performed the expression analysis of miR-379/miR-656 miRNA-cluster (C14MC) in oligodendrogliomas (ODGs) and also investigated the mechanism underlying modulation of this cluster.
   We identified significant downregulation of majority of the miRNAs from this cluster in ODGs. Further data from The Cancer Genome Atlas (TCGA) also confirmed the global downregulation of C14MC. Furthermore, we observed that its regulation is maintained by transcription factor MEF2. In addition, epigenetic machinery involving DNA and histone-methylation are also involved in its regulation, which is acting independently or in synergy. The post- transcriptionally regulatory network of this cluster showed enrichment of key cancer-related biological processes such as cell adhesion and migration. Also, there was enrichment of several cancer related pathways viz PIK3 signaling pathway and glioma pathways. Survival analysis demonstrated association of C14MC (miR-487b and miR-409-3p) with poor progression free survival in ODGs.
   Our work demonstrates tumor-suppressive role of C14MC and its role in pathogenesis of ODGs and therefore could be relevant for the development of new therapeutic strategies.
AD  - All India Inst Med Sci, Neurosci Ctr, Dept Neurosurg, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaAD  - CSIR Inst Genom & Integrat Biol, Genom & Mol Med, Room 331,Mathura Rd,Near Sukhdev Vihar, New Delhi 110020, IndiaAD  - Univ Salford, Sch Environm & Life Sci, Room 203a,Cockcroft Bldg, Salford M5 4WT, Lancs, EnglandC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - University of SalfordPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - AUG
PY  - 2018
VL  - 139
IS  - 1
SP  - 23
EP  - 31
DO  - 10.1007/s11060-018-2840-6
AN  - WOS:000437255200003
ER  -

TY  - JOUR
AU  - Kumar, A
AU  - Sharma, DS
AU  - Verma, M
AU  - Lamba, AK
AU  - Gupta, MM
AU  - Sharma, S
AU  - Perumal, V
TI  - Association between periodontal disease and gestational diabetes mellitusA prospective cohort study
T2  - JOURNAL OF CLINICAL PERIODONTOLOGY
KW  - diabetes
KW  - gestational diabetes mellitus
KW  - gingivitis
KW  - periodontal disease
KW  - periodontitis
KW  - pregnancy
KW  - pregnancy outcome
KW  - risk factor(s)
KW  - ADVERSE PREGNANCY OUTCOMES
KW  - RISK-FACTORS
KW  - PREECLAMPSIA
KW  - PREVALENCE
KW  - WOMEN
AB  - AimThis study aimed to determine the association between periodontal disease and gestational diabetes mellitus (GDM) and the effect of this association on pregnancy outcome in North Indian population.
   Materials and MethodsA total of 584 primigravidae were recruited at 12-14weeks of gestation. Their periodontal examination was carried out along with 75g oral glucose load test at the time of recruitment. GDM was diagnosed as per the DIPSI (The Diabetes in Pregnancy Study group India) guidelines (140mg/dl). Women with normal plasma glucose values underwent a repeat 75g oral glucose load test at 24-28weeks of gestation. All patients were followed up for pregnancy outcomes.
   ResultsOf 584 primigravida, 184 (31.5%) had gingivitis and 148 (25.3%) had periodontitis. Overall, 332 (56.8%) pregnant women had periodontal disease. It was associated with GDM with adjusted hazard ratio (aHR) of 2.85 (95%CI=1.47-5.53). The occurrence of pre-eclampsia was associated with periodontal disease with aHR of 2.20 (95%CI=0.86-5.60). If primigravidae had periodontal disease along with GDM, the risk of pre-eclampsia had shown increased aHR of 18.79 (95% CI=7.45-47.40).
   ConclusionsThe study shows a significant association of periodontal disease with GDM and an increased risk of developing pre-eclampsia due to this association.
AD  - Maulana Azad Med Coll, Dept Obstet & Gynaecol, New Delhi, IndiaAD  - Maulana Azad Inst Dent Sci, New Delhi, IndiaAD  - Inst Cytol & Prevent Oncol, Noida, Uttar Pradesh, IndiaAD  - All India Inst Med Sci, Dept Obstet & Gynaecol, New Delhi, IndiaC3  - Maulana Azad Medical CollegeC3  - Maulana Azad Institute of Dental Sciences New DelhiC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Cancer Prevention & Research (NICPR)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - AUG
PY  - 2018
VL  - 45
IS  - 8
SP  - 920
EP  - 931
DO  - 10.1111/jcpe.12902
AN  - WOS:000441751000003
ER  -

TY  - JOUR
AU  - Kumar, A
AU  - Sundar, DM
AU  - Mutha, V
TI  - Commentary: The changing scenario of cluster endophthalmitis
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - POSTOPERATIVE ENDOPHTHALMITIS
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - AUG
PY  - 2018
VL  - 66
IS  - 8
SP  - 1079
EP  - 1079
DO  - 10.4103/ijo.IJO_530_18
AN  - WOS:000439924900005
ER  -

TY  - JOUR
AU  - Kumar, A
AU  - Mutha, V
AU  - Sundar, DM
TI  - Commentary: Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - TRIAMCINOLONE ACETONIDE
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - AUG
PY  - 2018
VL  - 66
IS  - 8
SP  - 1128
EP  - 1129
DO  - 10.4103/ijo.IJO_529_18
AN  - WOS:000439924900016
ER  -

TY  - JOUR
AU  - Kumar, A
AU  - Ravani, R
AU  - Mehta, A
AU  - Simakurthy, S
AU  - Dhull, C
TI  - Outcomes of microscope-integrated intraoperative optical coherence tomography-guided center-sparing internal limiting membrane peeling for myopic traction maculopathy: a novel technique
T2  - INTERNATIONAL OPHTHALMOLOGY
KW  - Myopic foveoschisis
KW  - Myopic traction maculopathy (MTM)
KW  - Center-sparing ILM peeling
KW  - Pathological myopia
KW  - Intraoperative optical coherence tomography (I-OCT)
KW  - Internal limiting membrane peeling
KW  - Posterior staphyloma
KW  - Fovea-sparing ILM peeling
KW  - RETINAL-DETACHMENT
KW  - MACULAR HOLE
KW  - NATURAL COURSE
KW  - FOVEOSCHISIS
KW  - EYES
KW  - VITRECTOMY
KW  - RETINOSCHISIS
KW  - PREVALENCE
KW  - REMOVAL
KW  - DISEASE
AB  - To evaluate the outcomes of pars plana vitrectomy (PPV) with microscope-integrated intraoperative optical coherence tomography (I-OCT)-guided traction removal and center-sparing internal limiting membrane (cs-ILM) peeling.
   Nine eyes with myopic traction maculopathy as diagnosed on SD-OCT underwent PPV with I-OCT-guided cs-ILM peeling and were evaluated prospectively for resolution of central macular thickness (CMT) and improvement in best-corrected visual acuity (BCVA), and complications, if any, were noted. All patients were followed up for more than 9 months.
   Resolution of the macular retinoschisis was seen in all nine eyes on SD-OCT. At 36 weeks, there was a significant improvement in mean BCVA from the preoperative BCVA (P = 0.0089) along with a reduction in the CMT from 569.77 +/- 263.19 to 166.0 +/- 43.91 um (P = 0.0039). None of the eyes showed worsening of BCVA or development of full-thickness macular hole in the intraoperative or follow-up period.
   PPV with I-OCT-guided cs-ILM peeling helps in complete removal of traction, resolution of retinoschisis and good functional recovery with low intraoperative and postoperative complications.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - AUG
PY  - 2018
VL  - 38
IS  - 4
SP  - 1689
EP  - 1696
DO  - 10.1007/s10792-017-0644-x
AN  - WOS:000439166500040
ER  -

TY  - JOUR
AU  - Kumar, D
AU  - Hussain, A
AU  - Srivastava, AK
AU  - Mukerji, M
AU  - Mukherjee, O
AU  - Faruq, M
TI  - Generation of three spinocerebellar ataxia type-12 patients derived induced pluripotent stem cell lines (IGIBi002-A, IGIBi003-A and IGIBi004-A)
T2  - STEM CELL RESEARCH
AB  - Spinocerebellar ataxia type-12 (SCA12) is a neurological disorder caused due to triplet (CAG) repeat expansion in 5' UTR of PPP2R2B. It is one of the most prominent SCA-subtype in Indian population and fill date no patient specific models have been described. Human-induced-pluripotent-stem cell (HiPSC) based disease modelling has become the next generation tool for studying various human pathologies. In the present study we established three SCA12 patient specific iPSC lines. All the generated lines have shown pluripotency markers, normal karyotype, in-vitro three germ layers differentiation potential, vector clearance, SCA12 mutation, parental genomic identity and contamination free culture.
AD  - IGIB, CSIR, Genom & Mol Med, Mall Rd, Delhi 110007, IndiaAD  - All India Inst Med Sci, Neurosci Ctr, Dept Neurol, New Delhi 110029, IndiaAD  - Hamdard Univ, Jamia Hamdard, New Delhi, IndiaAD  - Inst Stem Cell Biol & Regenerat Med InStem, Bangalore, Karnataka, IndiaC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jamia Hamdard UniversityC3  - Department of Biotechnology (DBT) IndiaC3  - Institute for Stem Cell Biology & Regenerative Medicine - inStemPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - AUG
PY  - 2018
VL  - 31
SP  - 216
EP  - 221
DO  - 10.1016/j.scr.2018.08.008
AN  - WOS:000444011900033
ER  -

TY  - JOUR
AU  - Kumar, P
AU  - Ravani, R
AU  - Kakkar, P
AU  - Sharma, A
AU  - Kumar, A
TI  - Crystalline retinopathy association with flupentixol intake
T2  - INTERNATIONAL OPHTHALMOLOGY
KW  - Crystalline
KW  - Retinopathy
KW  - Flupentixol
KW  - DYSTROPHY
AB  - To report the first case report of an association between flupentixol and crystalline retinopathy.
   Observational, Case report.
   We report a case of crystalline retinopathy in a 36-year-old female who was suffering from depression and being treated with tablet flupentixol in a cumulative dose of 4380 mg over two years. Fundus examination of both eyes showed multiple, discrete, yellowish white refractile intraretinal deposits over the macula and peripapillary region, located in the inner retina as shown by OCT.
   We propose regular retinal evaluation in patients with chronic flupentixol intake and larger studies to establish causal relationship between flupentixol and crystalline retinopathy.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Unit 2, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - AUG
PY  - 2018
VL  - 38
IS  - 4
SP  - 1769
EP  - 1773
DO  - 10.1007/s10792-017-0624-1
AN  - WOS:000439166500052
ER  -

TY  - JOUR
AU  - Kumar, S
AU  - Singh, S
AU  - Parmar, A
AU  - Verma, R
AU  - Kumar, N
TI  - Effect of high-frequency repetitive transcranial magnetic stimulation (rTMS) in patients with comorbid panic disorder and major depression
T2  - AUSTRALASIAN PSYCHIATRY
KW  - rTMS
KW  - panic disorder
KW  - depression
KW  - DLPFC
KW  - magnetic stimulation
KW  - DORSOLATERAL PREFRONTAL CORTEX
KW  - EXCITABILITY
AB  - Objective: To explore the role of dorsolateral prefrontal cortex (DLPFC) stimulation in the treatment of panic disorder with comorbid depression.
   Methods: The present study reports findings from retrospective analysis of 13 treatment-resistant patients diagnosed with comorbid panic disorder and depression, given 20 sessions of high-frequency transcranial magnetic stimulation (rTMS) over left-DLPFC over a period of 1month.
   Results: There was a significant reduction in both the panic and depressive symptom severity, assessed by applying Panic Disorder Severity Scale (PDSS) and Hamilton Depression Rating Scale (HDRS) at baseline and after 20 sessions of rTMS. There was a 38% and 40% reduction of PDSS and HDRS scores, respectively, in the sample. The changes in PDSS and HDRS scores were not significantly correlated (=-0.103, p=0.737).
   Conclusions: High-frequency rTMS delivered at left-DLPFC may have a potential role in treatment of comorbid panic disorder and depression. Future studies done on a larger sample in a controlled environment are required to establish its role.
AD  - All India Inst Med Sci, Dept Psychiat, Fourth Floor,Teaching Block, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SAGE PUBLICATIONS LTD
PI  - LONDON
PA  - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
DA  - AUG
PY  - 2018
VL  - 26
IS  - 4
SP  - 398
EP  - 400
DO  - 10.1177/1039856218771517
AN  - WOS:000442386200013
ER  -

TY  - JOUR
AU  - Kumar, S
AU  - Singh, MS
AU  - Kumar, A
AU  - Shukla, G
AU  - Srivastava, MVP
AU  - Goyal, V
AU  - Vishnu, VY
TI  - Are epilepsy patients bypassing primary care? A cross-sectional study from India
T2  - SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
KW  - Epilepsy care
KW  - Tertiary care referral
KW  - Reasons of consultation
KW  - DEFINITION
KW  - IMPACT
AB  - Purpose: Lack of epilepsy primary and secondary care and an arbitrary referral system causes many epilepsy patients to seek tertiary care even when they may not need it. This causes overcrowding, increased waiting times and also compromises the quality of tertiary care. We conducted this study to identify what proportion of epilepsy patients presenting to tertiary care actually needed it.
   Methods: To test appropriateness of candidacy for tertiary care, we formulated Modified NICE criteria (MNC) based on NICE criteria. Modified NICE criteria were used to dichotomize participants into two groups: a) those who needed tertiary care and b) those who did not need tertiary care. We also looked at agreement between MNC and original NICE criteria.
   Results: Four hundred and twenty two patients were recruited. According to the MNC, 240 patients (57%) qualified for tertiary care while 182 (43%) did not. The agreement between MNC and original NICE criteria was 86.7%, kappa 0.73(95% CI 0.66-0.79, p < 0.001). The most frequently cited reason for seeking tertiary care was 'Unsatisfactory response to treatment', although; many of these patients were actually non-adherent to treatment. Amongst variables that predicted non-eligibility for tertiary care, the most important was not having been referred.
   Conclusion: Many epilepsy patients seeking tertiary care do not need it. Access and quality of epilepsy care can be improved if there is a rational and need-based distribution of patients between primary, secondary and tertiary care. Referral systems also need to be developed and used to transition patients from one level of care to another.
AD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - W B SAUNDERS CO LTD
PI  - LONDON
PA  - 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
DA  - AUG
PY  - 2018
VL  - 60
SP  - 149
EP  - 154
DO  - 10.1016/j.seizure.2018.07.001
AN  - WOS:000445300300026
ER  -

TY  - JOUR
AU  - Kumar, S
AU  - Jain, S
AU  - Mohanty, S
AU  - Velpandian, T
AU  - Sreenivas, V
AU  - Mathur, R
TI  - Rat bone marrow stromal cell transplantation ameliorates complete spinal cord injury induced sensorimotor dysfunctions and associated neurotransmitters
T2  - INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY
KW  - Allodynia
KW  - Hyperalgesia
KW  - H-reflex
KW  - M-response
KW  - Nociceptive flexion reflex
KW  - MESENCHYMAL STEM-CELLS
KW  - FUNCTIONAL RECOVERY
KW  - LOCOMOTOR RECOVERY
KW  - FLUID LEVELS
KW  - PAIN
KW  - TRAUMA
KW  - MECHANISMS
KW  - EXPOSURE
KW  - MICE
KW  - HEMISECTION
AB  - Traumatic spinal cord injury (SCI) leads to sensorimotor dysfunction with significant impact on the patient and their family's quality of life, social, and economic status. There is no complete restorative treatment so far. Bone marrow stromal cells (BMSCs) have anti-inflammatory and neuroprotective effects and recently emerged as a therapeutic candidate for SCI repair. Here, we examined the role of rat BMSCs transplantation on thoracic (T11) complete SCI induced dysfunctions, namely hyperalgesia, allodynia, locomotion, spinal reflexes, and spinal neurotransmitters in rats. Pre-labelled BMSCs were injected on day 9 after SCI locally. We observed that BMSCs transplantation facilitate locomotor recovery (week 2-8) and attenuated hyperalgesia and allodynia to varying sensory stimuli (week 6-8) after SCI. In addition, spinal reflexes and neurotransmitters were affected significantly by complete SCI, which were partially restored by BMSCs transplantation. Histological analyses also revealed the presence of BMSCs at the injury site and appear to fill the lesion cavities, thereby significantly reducing the lesion volume. Our data shows the beneficial effects of BMSCs transplantation on complete SCI-induced sensorimotor functional deficits in rats.
AD  - All India Inst Med Sci, Dept Physiol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Stem Cell Facil, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Ocular Pharm & Pharmacol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Biostat, New Delhi 110029, IndiaAD  - Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08854 USAC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Rutgers University SystemC3  - Rutgers University New BrunswickPU  - NATL INST SCIENCE COMMUNICATION-NISCAIR
PI  - NEW DELHI
PA  - DR K S KRISHNAN MARG, PUSA CAMPUS, NEW DELHI 110 012, INDIA
DA  - AUG
PY  - 2018
VL  - 56
IS  - 8
SP  - 535
EP  - 546
AN  - WOS:000441368200001
ER  -

TY  - JOUR
AU  - Kumar, V
AU  - Gupta, PN
AU  - Christy, MC
AU  - Azad, SV
TI  - Retinal incarceration in the needle perforation track
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - AUG
PY  - 2018
VL  - 66
IS  - 8
SP  - 1194
EP  - 1194
DO  - 10.4103/ijo.IJO_517_18
AN  - WOS:000439924900038
ER  -

TY  - JOUR
AU  - Mahalingam, K
AU  - Chaurasia, AK
AU  - Gowtham, L
AU  - Gupta, S
AU  - Somarajan, BI
AU  - Velpandian, T
AU  - Sihota, R
AU  - Gupta, V
TI  - Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - End-stage glaucoma
KW  - glaucoma
KW  - neuroprotection
KW  - valproic acid
KW  - MULTIFOCAL ELECTRORETINOGRAM
KW  - RETINAL DEGENERATION
KW  - RETINITIS-PIGMENTOSA
KW  - EPILEPSY PATIENTS
KW  - SODIUM VALPROATE
KW  - EFFICACY
KW  - RESPONSES
KW  - EXTRACT
KW  - SAFETY
KW  - BLIND
AB  - Purpose: Oral valproic acid (VPA) used as an anticonvulsant has been shown to improve contrast threshold sensitivities in patients receiving it on long-term. This study aimed to evaluate the efficacy of oral VPA in improving visual function in eyes with advanced stage glaucoma. Methods: In this prospective randomized study, 31 patients (n = 31 eyes) with advanced stage glaucoma (with an intraocular pressure <16 mmHg) in at least one eye received oral VPA 500 mg once a day for 3 months and 33 patients (n = 33 eyes) continued on glaucoma therapy. Patients were followed up at 3 and 12 months (to evaluate the legacy effect of the drug). Blood VPA concentrations were measured at 3 months. Following parameters were assessed at baseline, 3 months and 12 months: log of the minimum angle of resolution (LogMAR) visual acuity, mean deviation on visual fields, and multifocal electroretinogram (ERG). Results: Median LogMar visual acuity in the VPA group improved from 0.3 at baseline to 0.18 and 0.18 at 3 and 12 months, respectively (P < 0.01). In comparison, the median visual acuity in control group at baseline was 0.18 and showed neither worsening nor improvement over 3 and 12 months (P = 0.56). The improvement in VPA group was significant compared to the control group (P < 0.01; Wilcoxon Signed-rank test). An improvement in one line was experienced in 11 out of 31 eyes in the VPA group compared to 1 out of 33 eyes among controls (P = 0.003). No significant improvement was noted in the mean deviation, and the multifocal ERG (Latency and amplitudes) in the VPA-treated patients. The average blood VPA concentration measured at 3 months of therapy was 26 +/- 8.9 mu g/ml (range 8-55 mu g/ml) which is much lower than that achieved during anticonvulsant therapy. None of the patients complained of any adverse effects that required stopping VPA therapy. Conclusion: A 3 months oral VPA therapy results in some improvement in visual acuity in a subgroup of eyes with advanced glaucoma and the effect was seen to persist 9 months after the drug was stopped.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Ocular Pharmacol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - AUG
PY  - 2018
VL  - 66
IS  - 8
SP  - 1104
EP  - 1108
DO  - 10.4103/ijo.IJO_108_18
AN  - WOS:000439924900011
ER  -

TY  - JOUR
AU  - Mallick, S
AU  - Benson, R
AU  - Melgandi, W
AU  - Giridhar, P
AU  - Rath, GK
TI  - Grade II Pleomorphic Xanthoastrocytoma; a meta-analysis of data from previously reported 167 cases
T2  - JOURNAL OF CLINICAL NEUROSCIENCE
KW  - Pleomorphic Xanthoastrocytoma
KW  - Adjuvant
KW  - Chemotherapy
KW  - Radiotherapy
KW  - Surgery
KW  - ATYPICAL TERATOID/RHABDOID TUMOR
KW  - BRAF V600E MUTATION
KW  - MALIGNANT-TRANSFORMATION
KW  - NEUROFIBROMATOSIS TYPE-1
KW  - GLIONEURONAL TUMOR
KW  - SPINAL-CORD
KW  - GANGLIOGLIOMA
KW  - PATIENT
KW  - RECURRENCE
KW  - HEMORRHAGE
AB  - Pleomorphic Xanthoastrocytoma [PXA] is a rare low grade glial tumor commonly affecting young adults. We did this systematic review and meta-analysis to identify prognostic factors and optimal treatment in these patients. A thorough search of the PubMed, Google scholar was made to find all possible publications related to grade II PXA. A total of 167 patients from 89 articles were included in the analysis. Median age of the entire cohort was 20 years. Headache was the most common presentation in 49.1% of the patients followed by seizure in 27.9%. Temporal lobe was the most common location of the tumor. 63% patents underwent a gross total resection [GTR] and 26.7% underwent a sub total excision [STR]. Adjuvant radiation was given to 17.6% of patients. Median follow-up for the entire cohort was 33 months. Estimated median overall survival [OS] for the entire cohort was 209.0 months [96% Cl: 149.7-268.3]. Estimated median progression free survival [PFS] was 48 months [95% CI: 31.9-64.0]. In univariate and multivariate analysis younger patients and patients who underwent a GTR had a significantly better survival outcome. Use of adjuvant therapy was not found to be a significant factor affecting PFS or OS. Radiotherapy was used in salvage treatment in 76.1% of the patients. Younger patients and patients who undergo a GTR, have better survival outcomes. There is inadequate evidence to recommend routine adjuvant radiation or chemotherapy in all patients with grade II PXA. (C) 2018 Elsevier Ltd. All rights reserved.
AD  - All India Inst Med Sci, Dept Radiat Oncol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - AUG
PY  - 2018
VL  - 54
SP  - 57
EP  - 62
DO  - 10.1016/j.jocn.2018.05.003
AN  - WOS:000439673900011
ER  -

TY  - JOUR
AU  - Mittal, S
AU  - Madan, K
TI  - Bronchial Stenosis Another "Rheumatoid" Pulmonary Manifestation
T2  - CHEST
KW  - ARTHRITIS
AD  - All India Inst Med Sci, Dept Pulm Med & Sleep Disorders, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - AUG
PY  - 2018
VL  - 154
IS  - 2
SP  - 462
EP  - 464
DO  - 10.1016/j.chest.2018.01.058
AN  - WOS:000440664300046
ER  -

TY  - JOUR
AU  - Panda, PK
AU  - Sriranga, R
AU  - Kaur, K
AU  - Sood, R
TI  - Lane Hamilton Syndrome
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - CELIAC-DISEASE
KW  - INDIA
AD  - All India Inst Med Sci, Dept Med, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - AUG
PY  - 2018
VL  - 85
IS  - 8
SP  - 699
EP  - 699
DO  - 10.1007/s12098-017-2548-1
AN  - WOS:000438768300027
ER  -

TY  - JOUR
AU  - Pandey, H
AU  - Talukdar, A
AU  - Gangte, JS
AU  - Gupta, SD
AU  - Chandra, NC
TI  - Cholesterol homeostasis and cell proliferation by mitogenic homologs: insulin, benzo-<i>α</i>-pyrene and UV radiation
T2  - CELL BIOLOGY AND TOXICOLOGY
KW  - Benzo-alpha-pyrene
KW  - Cholesterol
KW  - Insulin
KW  - Cell proliferation
KW  - UV radiation
KW  - LDLR
KW  - RAT-LIVER REGENERATION
KW  - RECEPTOR ACTIVITY
KW  - NUCLEAR LIPIDS
KW  - METABOLISM
KW  - PATHWAY
KW  - LDL
KW  - MACROPHAGES
KW  - EXPRESSION
KW  - ESTRADIOL
KW  - MEMBRANES
AB  - Low-Density Lipoprotein (LDL) is known to promote the unregulated proliferation of cells that is progression of cancer. We aimed to investigate the effect of mitogens on the expression of cell cycle proteins, nuclear cholesterol and cell proliferation. We observed that insulin and benzo-alpha-pyrene (BaP) induced the expression of Low-Density Lipoprotein receptor (LDLR) on HepG2 cells, thereby enhancing the uptake of LDL. The internalized LDL increased the concentration of cholesterol in the cytoplasm and nucleus of the cell. At the same time, insulin and BaP also stimulated the expression of cell cycle proteins viz., Cyclin E and Cdk2, and thus induced more incorporation of Bromodeoxyuridine (BrdU) in cultured cells indicating increased DNA synthesis. Increased expression of cell cycle proteins and DNA synthesis are the indications of DNA replication and new cell synthesis. This suggests a link between the enhanced nuclear cholesterol concentration and new cell formation. On the other hand, UV irradiation with selectively given dose of cell death eventually decreases nuclear cholesterol concentration and LDLR expression. Reduced LDLR shows low functional activity. This, again, repeated the plausibility of the same link between intracellular cholesterol concentration and cell population. The biasness of adverse effect observed by UV irradiation has been compromised by inactivating LDLR with anti-LDLR antibody, resulting in similar effects on Cyclin E expression in the cultured cells. Hence, we concluded that in all the conditions, LDLR expression was found to be a translational event of its transcription factor, SREBP-2, by the induction of insulin, BaP and UV irradiation.
AD  - All India Inst Med Sci, Dept Biochem, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biochem, Patna 801507, Bihar, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) PatnaPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - AUG
PY  - 2018
VL  - 34
IS  - 4
SP  - 305
EP  - 319
DO  - 10.1007/s10565-017-9415-8
AN  - WOS:000436564400006
ER  -

TY  - JOUR
AU  - Parmar, V
AU  - Kumar, A
AU  - Sankar, MM
AU  - Datta, S
AU  - Prakash, GV
AU  - Mohanty, S
AU  - Kalyanasundaram, D
TI  - Oxidation facilitated antimicrobial ability of laser micro-textured titanium alloy against gram-positive <i>Staphylococcus</i> <i>aureus</i> for biomedical applications
T2  - JOURNAL OF LASER APPLICATIONS
KW  - Staphylococcus aureus
KW  - nanosecond pulsed laser
KW  - micro-texturing
KW  - Ti6Al4V
KW  - surgical tool
KW  - reduced adhesion and growth
KW  - CELL-SURFACE ADHESION
KW  - BACTERIAL ADHESION
KW  - PROTEIN ADSORPTION
KW  - INFECTIONS
KW  - BEHAVIOR
AB  - Micro-textures were engineered on titanium samples by a rapid, highly repeatable, and cost effective nanosecond laser texturing process. The controlled and repeatable micro-texture was effective in the reduction of adhesion and proliferation of Staphylococcus aureus. However, the adhesion and proliferation of human bone marrow mesenchymal stem cells were found unaffected. The authors observed time-delayed saturation of oxidation on laser micro-textured Ti6Al4V as compared to pristine material yielding a super-hydrophobic surface (contact angle of similar to 158.2 degrees). An in-house setup was designed to expose a three-dimensionally laser micro-textured Ti6Al4V sample to S. aureus-spiked nutrient broth for 24 h in a closed loop continuous flow system. The authors observed a 50% reduction of S. aureus adhesion and proliferation over the laser micro-textured surface compared to pristine samples. In vitro tests confirmed that blood coagulation remains largely unaffected, while protein adsorption was decreased by fourfold on the micro-textured surfaces, a desirable property for surgical tools. Nanosecond laser micro-textured surfaces were effective in reducing S. aureus adhesion and its proliferation due to phase evolution, oxidative transformation of Ti6Al4V, and reduction of surface potential. In addition, laser based micro-texturing is a nontoxic, environment friendly green process that is also a cost effective alternative to conventional surface modification techniques such as mechanical micromachining and chemical treatments. (C) 2018 Laser Institute of America.
AD  - Indian Inst Technol Delhi, Ctr Biomed Engn, Lab Fabricat Biomed Devices, New Delhi 110016, IndiaAD  - Indian Inst Technol Delhi, Dept Phys, Nanophoton Lab, New Delhi 110016, IndiaAD  - Indian Inst Technol Delhi, Dept Mech Engn, Micro & Nanofluid Lab, New Delhi 110016, IndiaAD  - All India Inst Med Sci, Dept Cardiol, Stem Cell Res Facil, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Biomed Engn, New Delhi 110029, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER INST PHYSICS
PI  - MELVILLE
PA  - 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
DA  - AUG
PY  - 2018
VL  - 30
IS  - 3
C7  - 032001
DO  - 10.2351/1.5039860
AN  - WOS:000443892000004
ER  -

TY  - JOUR
AU  - Parveen, B
AU  - Tiwari, AK
AU  - Jain, M
AU  - Pal, S
AU  - Chattopadhyay, N
AU  - Tripathi, M
AU  - Vohora, D
TI  - The anti-epileptic drugs valproate, carbamazepine and levetiracetam cause bone loss and modulate Wnt inhibitors in normal and ovariectomised rats
T2  - BONE
KW  - Antiepileptic drugs
KW  - Sodium valproate
KW  - Carbamazepine
KW  - Levetiracetam
KW  - Sclerostin
KW  - DKK-1
KW  - MINERAL DENSITY
KW  - POSTMENOPAUSAL WOMEN
KW  - PARATHYROID-HORMONE
KW  - EPILEPTIC PATIENTS
KW  - SCLEROSTIN LEVELS
KW  - MONOTHERAPY
KW  - HEALTH
KW  - MASS
KW  - OSTEOPOROSIS
KW  - METABOLISM
AB  - Secondary osteoporosis is the major concern associated with long term intake of antiepileptic drugs (AEDs). Women are the vulnerable targets owing to post-menopausal bone loss. In the present work, we evaluated the effect of 10 weeks of treatment with AED therapy (carbamazepine, CBZ, 75 mg/kg; sodium valproate, SVP, 300 mg/kg; levetiracetam, LTM, 150 mg/kg) on bone mineral density and microarchitecture at femoral epiphysis, lumbar vertebrae and proximal tibia of normal and ovariectomised Wistar rats. In addition, we measured serum levels of vitamin D, receptor activator of nuclear factor kappa beta-ligand (RANKL), procollagen type 1 amino-terminal propeptide (P1NP) and wnt inhibitors (sclerostin and DKK-1) following AED therapy. Micro-computed tomography analysis of bones revealed significant reduction in BMD at femur epiphysis and lumbar vertebrae with all the three AEDs evaluated. At proximal tibia, only CBZ showed a significant decline. The reduction in BMD was more pronounced in ovariectomised rats. AEDs also resulted in alteration of micro-CT parameters. These changes were accompanied by an increased serum RANKL with all AEDs while vitamin D levels were reduced only with CBZ treatment and P1NP levels were reduced with SVP and CBZ. Serum sclerostin levels were elevated following all AEDs in normal and ovariectomised rats except with CBZ in normal rats. However, increase in DKK-1 levels was observed with only LTM. Ovariectomy itself resulted in increased RANKL, sclerostin and DKK-1 and reduced vitamin D and P1NP levels. Significant differences were discernible between normal and ovariectomised rats treated with AEDs in all the parameters. However, while sclerostin increased further upon AEDs treatment, P1NP decreased with SVP and CBZ and serum DKK-1 levels showed a declining trend with all the three AEDs studied. We confirm adverse effects on bone following AEDs in female rats. Further, our results demonstrate for the first time that these effects are more pronounced in ovariectomised rats as compared to normal rats and that this could be related to estrogen deficiency which in turn enhances bone resorption via increased RANKL and reduces bone formation via increased sclerostin and reduced P1NP. Finally, our study demonstrated for the first time that AED treatment displayed changes in the serum levels of wnt inhibitors and hence modulation of wnt inhibitors might be partly involved in their adverse effects on bone.
AD  - Jamia Hamdard, Pharmaceut Med, Dept Pharmacol, Sch Pharmaceut Educ & Res, New Delhi 110062, IndiaAD  - Jamia Hamdard, Cent Anim House Facil, New Delhi 110062, IndiaAD  - Cent Drug Res Inst, Div Pharmacol, Lucknow 226031, Uttar Pradesh, IndiaAD  - Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, IndiaAD  - All India Inst Med Sci, Neurosci Ctr, Dept Neurol, New Delhi 110029, IndiaC3  - Jamia Hamdard UniversityC3  - Jamia Hamdard UniversityC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Central Drug Research Institute (CDRI)C3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Central Drug Research Institute (CDRI)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - AUG
PY  - 2018
VL  - 113
SP  - 57
EP  - 67
DO  - 10.1016/j.bone.2018.05.011
AN  - WOS:000437550800007
ER  -

TY  - JOUR
AU  - Patel, A
AU  - Sharma, MC
AU  - Bakhshi, S
TI  - Demographic Challenges of Pediatric NHL: A Report on 280 Patients
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - NON-HODGKIN-LYMPHOMA
KW  - CHILDHOOD
KW  - CHILDREN
AD  - All India Inst Med Sci, Dept Med Oncol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - AUG
PY  - 2018
VL  - 85
IS  - 8
SP  - 697
EP  - 698
DO  - 10.1007/s12098-017-2563-2
AN  - WOS:000438768300026
ER  -

TY  - JOUR
AU  - Peshin, SS
AU  - Gupta, YK
TI  - Poisoning due to household products: A ten years retrospective analysis of telephone calls to the National Poisons Information Centre, All India Institute of Medical Sciences, New Delhi, India
T2  - JOURNAL OF FORENSIC AND LEGAL MEDICINE
KW  - Poisoning
KW  - Household products
KW  - Accidental poisoning
KW  - Children
KW  - Pesticides
KW  - Pyrethroids
KW  - Household cleaners
KW  - Prevention
KW  - CHANGING TRENDS
KW  - SOUTH-AFRICA
KW  - CHILDREN
KW  - INJURIES
KW  - PROFILE
KW  - RISK
KW  - CARE
KW  - EPIDEMIOLOGY
KW  - MANAGEMENT
KW  - PYRETHRIN
AB  - Extensive use of different chemicals in various fields and their easy availability has led to an increased incidence of accidental and intentional poisoning in developing countries including India. A diverse range of household products commonly used for domestic purposes comprise pesticides, household cleaners, thermometer mercury, antiseptics, kerosene, paint thinners etc. Any of these products, if misused or mishandled can cause poisoning. In India, the National Poisons Centre (NPIC) at the All India Institute of Medical Sciences, New Delhi, provides information on management of poisoning to treating physicians. Analysis of data based on telephone calls received by the NPIC (April 2006-March 2016) has highlighted a high incidence of poisoning due to household products, followed by pharmaceuticals, agricultural pesticides and industrial chemicals. The objective of the present retrospective study was to determine the incidence of poisoning due to various household products as reported to the NPIC during the ten years period. The total number of calls received by the Centre was 16,420. There were 7114 calls (45.5%) due to household products with adults (> 18yrs.) and children (< 1-18yrs.) constituting 38.7% and 61.2% calls respectively. Males outnumbered females (M = 62.4%, F = 37.5%). The mode of poisoning was mainly unintentional (66.8%) followed by intentional mode (33.2%). The commonest route of exposure was oral (95.6%). Household pesticides were commonly implicated (43.7%) followed by household cleaners (21.8%), thermometer mercury (5.2%) naphthalene balls (5%), antiseptics (3%), kerosene (2%) and paint thinner (2%). Miscellaneous products comprising of camphor, silica gel, hair dye, nail polish remover, cosmetics, adhesives etc were also involved in poisoning (17.1%). The trend and pattern of poisoning varies in different parts of the country, because all calls on poisoning are not reported to the Centre. So the data as such may not be a true reflection of the scenario in India. However, the results do indicate an increasing incidence of poisoning due to household products especially in children. The probable reasons for high incidence could be careless storage, ignorance, non compliance with prescribed instructions for use and negligible parental supervision in case of children. The results of the study highlight, an urgent need to identify high risk circumstances, common toxic products involved and implementation of prevention and awareness programmes, to achieve poisons control at home.
AD  - All India Inst Med Sci, Dept Pharmacol, Natl Poisons Informat Ctr, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - AUG
PY  - 2018
VL  - 58
SP  - 205
EP  - 211
DO  - 10.1016/j.jflm.2018.07.005
AN  - WOS:000440035700036
ER  -

TY  - JOUR
AU  - Prasad, J
AU  - Goswami, B
AU  - Gowda, SH
AU  - Gupta, N
AU  - Kumar, S
AU  - Agarwal, K
AU  - Mehra, P
AU  - Pahuja, BK
AU  - Chauhan, A
TI  - Does Hypoxia-Inducible Factor-1 (HIF-1) C1772T polymorphism predict short-term prognosis in patients with oral squamous cell carcinoma (OSCC)?
T2  - JOURNAL OF ORAL PATHOLOGY & MEDICINE
KW  - HIF-1
KW  - OSCC
KW  - BREAST-CANCER
KW  - EXPRESSION
AB  - BackgroundOral squamous cell carcinoma (OSCC) is a cancer of the oral cavity that is a major health problem in India. There is an urgent need to identify biomarkers that have prognostic significance. We studied HIF-1 levels as well as single-nucleotide polymorphism of HIF-1 gene in cancer and healthy controls.
   MethodsFifty newly diagnosed OSCC patients and 50 age and sex-matched healthy control were included in the study. Serum concentrations of HIF-1 were measured by sandwich ELISA; whereas HIF-1 gene polymorphism study was performed using restriction enzyme digestion by HpH I.
   ResultsThe major genotype observed was CC genotype in both control (84%) and patients (86%) followed by CT genotype (control 16%, cases 14%). CT genotype led to more aggressive tumors. On subgroup analysis based on prognosis, the median overall survival of patients who were treatment responders was 488days (16.2months) and that of the patients with progressive disease was 365days (12.1months). The patients who expired during the study observation period had median survival of 330days (11months).
   ConclusionOur study showed that CT genotype for C1772T polymorphism of HIF-1 predisposes to aggressive tumor phenotype in patients with OSCC. Moreover, patients with CT genotype had poor survival rate as compared to CC genotype. A cut-off value of 460pg/mL of HIF-1 can help to segregate patients with OSCC from healthy controls.
AD  - All India Inst Med Sci, New Delhi, IndiaAD  - Maulana Azad Med Coll & Associated Hosp, New Delhi, IndiaAD  - Dr Ram Manohar Lohia Hosp, Post Grad Inst Med Educ & Res, New Delhi, IndiaAD  - Lady Hardinge Med Coll & Associated Hosp, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Maulana Azad Medical CollegeC3  - Lady Hardinge Medical College & HospitalPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - AUG
PY  - 2018
VL  - 47
IS  - 7
SP  - 660
EP  - 664
DO  - 10.1111/jop.12718
AN  - WOS:000440926500004
ER  -

TY  - JOUR
AU  - Quadri, JA
AU  - Sarwar, S
AU  - Pinky
AU  - Kar, P
AU  - Singh, S
AU  - Mallick, SR
AU  - Arava, S
AU  - Nag, TC
AU  - Roy, TS
AU  - Shariff, A
TI  - Fluoride induced tissue hypercalcemia, IL-17 mediated inflammation and apoptosis lead to cardiomyopathy: Ultrastructural and biochemical findings
T2  - TOXICOLOGY
KW  - Fluoride toxicity
KW  - Cardiotoxicity
KW  - Cardiomyopathies
KW  - Apoptosis
KW  - Atomic force microscopy (AFM)
KW  - SEM-EDX
KW  - Interleukin-17
KW  - MMP-9
KW  - Ultrastructure
KW  - Inflammation
KW  - SODIUM-FLUORIDE
KW  - ISCHEMIA/REPERFUSION-INJURY
KW  - MITOCHONDRIAL DYSFUNCTION
KW  - OXIDATIVE STRESS
KW  - CARDIAC-FUNCTION
KW  - CELL-DEATH
KW  - RECEPTORS
KW  - HYPERTROPHY
KW  - CONTRIBUTES
KW  - FLUOROSIS
AB  - An increased prevalence of cardiac complications has been observed in residents of fluorosis endemic areas chronically exposed to fluoride. Fluoride induces soft tissue injury due to oxidative stress, lipid peroxidation (LPO) and mitochondriopathy. It was hypothesized that chronic fluoride exposure induces apoptosis in cardiomyocytes due to inflammation, lysis of extra cellular matrix and altered calcium metabolism. This study was planned to evaluate the effects of chronic fluoride exposure and the mechanism of action in the cardiac muscle. Fifteen week old male Wistar rats were administered a human equivalent dose of fluoride (50 and 100 ppm adlibitum, HED = 5 & 10 ppm in human) for 75-days. After 75-days of fluoride exposure, the animals were euthanized and fluoride, oxidative stress (SOD, GPX, Catalase activities) and LPO were measured. Histopathological and ultrastructural pathological examinations were conducted on the cardiac tissues using light, atomic force and electron microscopies. The cardiac tissues were also assessed for apoptosis (TUNEL/Caspase assays), and tissue calcium levels (Alizarin-assay and SEM-EDX). Tissue inflammation and expression of IL-17, MMP-9, Caspase-3 and Bcl-2 were evaluated. In the fluoride exposed groups, a significant (<= 0.05) increase in levels of oxidative stress, LPO and apoptosis were observed. The IL-17, MMP-9 and Caspase-3 were significantly (<= 0.05) higher in the cardiac muscle after chronic fluoride exposure. The fluoride seems to have induced inflammation in the cardiac tissues, as well as an increase in tissue calcium (<= 0.05). There was significant damage to cardiac muscle fibres including, thinning, distortion and neo-vasculogenesis following chronic fluoride exposure. Mitochondriopathy, lysis of ground substance, oedema, and hyper-vacuolation was seen in fluoride treated groups. Remarkable levels of distortion and bending in Z band were observed under the AFM. Many of these observed changes mimic those occurring in cardiomegaly, cardiac hypertrophy and cardiomyopathies.
AD  - AIIMS, Dept Anat, New Delhi 110029, IndiaAD  - AIIMS, Dept Endocrinol & Metab, New Delhi, IndiaAD  - AIIMS, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER IRELAND LTD
PI  - CLARE
PA  - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
DA  - AUG 1
PY  - 2018
VL  - 406
SP  - 44
EP  - 57
DO  - 10.1016/j.tox.2018.05.012
AN  - WOS:000444660200005
ER  -

TY  - JOUR
AU  - Quan, WW
AU  - Zheng, DN
AU  - McEvoy, RD
AU  - Barbe, F
AU  - Chen, R
AU  - Liu, ZH
AU  - Loffler, K
AU  - Lorenzi, G
AU  - Luo, YM
AU  - Mukherjee, S
AU  - Tripathi, M
AU  - Woodman, R
AU  - Li, Q
AU  - Wang, X
AU  - Arima, H
AU  - Xiao, Y
AU  - Zhang, XL
AU  - Anderson, CS
A1  - SAVE Investigators
TI  - High Risk Characteristics for Recurrent Cardiovascular Events among Patients with Obstructive Sleep Apnoea in the SAVE Study
T2  - ECLINICALMEDICINE
KW  - Obstructive sleep apnoea
KW  - Phenotype
KW  - Cardiovascular disease
KW  - Stroke
KW  - Latent class analysis
KW  - POSITIVE AIRWAY PRESSURE
KW  - CORONARY-HEART-DISEASE
KW  - PHENOTYPES
KW  - STROKE
KW  - CPAP
KW  - ASSOCIATION
KW  - OUTCOMES
KW  - THERAPY
KW  - ADULTS
AB  - Background: Obstructive sleep apnoea (OSA) is a common comorbidity in patients with cardiovascular (CV) disease. We aimed to identify specific OSA clinical phenotypes relating to risks of serious CV events and response to continuous positive airway pressure (CPAP) treatment.
   Methods: Post-hoc analyses of the Sleep Apnea Cardiovascular Endpoints (SAVE) study in participants with moderate-to-severe OSA and coronary artery disease (CAD) and/or cerebrovascular disease (CeVD) randomised to CPAP plus usual care or usual care alone. Latent class analysis (LCA) was used to identify OSA clinical phenotypes among 2649 (out of 2687 total) patients with complete data on 19 patient-centered variables, supported by Bayesian information criteria and clinical interpretability. Cox regression models were used to evaluate risks of composite cardiac and stroke outcome events in phenotype groups. Preferential response to CPAP treatment was evaluated using interaction terms as well as the Chi-square test.
   Findings: LCA identified four OSA clinical phenotypes: CAD alone and with diabetes mellitus (CAD+DM), and CeVD alone and with DM (CeVD+DM), in 39%, 15%, 37% and 9% of participants, respectively. The rates of composite CV events were the highest in CAD+DM phenotype (HR 2.08, 95% CI 1.57-2.76) and for stroke were highest in CeVD+DM phenotype (HR 6.84, 95% CI 3.77-12.42). Adherence to CPAP treatment (nil or <4 h vs >= 4 h in the first two years of the study) was shown to influence the risk of composite CV outcome in the phenotypes (P-interaction=0.04); CPAP adherent patients of the CeVD+ DM phenotype had the lowest risk of CV outcome (P=0.02).
   Interpretation: High risk clinical phenotypes were identified in relation to CV events and response to CPAP treatment, which may allow improved targeting of therapies in OSA patients. (C) 2018 Published by Elsevier Ltd.
AD  - Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Cardiol, Sch Med, Shanghai, Peoples R ChinaAD  - Shanghai Jiao Tong Univ, Inst Cardiovasc Dis, Sch Med, Shanghai, Peoples R ChinaAD  - Univ New South Wales, Ctr Big Data Res Hlth, Sydney, NSW, AustraliaAD  - Univ New South Wales, George Inst Global Hlth, Fac Med, Sydney, NSW, AustraliaAD  - Flinders Univ S Australia, Adelaide Inst Sleep Hlth, Adelaide, SA, AustraliaAD  - Southern Adelaide Local Hlth Network, Resp & Sleep Serv, Adelaide, SA, AustraliaAD  - Hosp Univ Arnau de Vilanova Santa Maria, Resp Dept, Lleida, SpainAD  - Soochow Univ, Affiliated Hosp 2, Suzhou, Peoples R ChinaAD  - Fuwai Hosp, Dept Cardiol, Beijing, Peoples R ChinaAD  - Inst Coracao Incor, Sao Paulo, BrazilAD  - Hosp Univ, Sao Paulo, BrazilAD  - Guangzhou Med Univ, State Key Lab Resp Dis, Affiliated Hosp 1, Guangzhou, Peoples R ChinaAD  - All India Inst Med Sci, Neurol Dept, Delhi, IndiaAD  - Flinders Univ S Australia, Flinders Ctr Epidemiol & Biostat, Adelaide, SA, AustraliaAD  - Fukuoka Univ, Dept Prevent Med & Publ Hlth, Fukuoka, JapanAD  - Peking Univ, Resp Dept, Med Coll, Beijing, Peoples R ChinaAD  - Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R ChinaAD  - Royal Prince Alfred Hosp, Neurol Dept, Sydney, NSW, AustraliaAD  - Peking Univ, George Inst China, Hlth Sci Ctr, Beijing, Peoples R ChinaC3  - Shanghai Jiao Tong UniversityC3  - Shanghai Jiao Tong UniversityC3  - University of New South Wales SydneyC3  - University of SydneyC3  - University of New South Wales SydneyC3  - George Institute for Global HealthC3  - Adelaide Institute for Sleep HealthC3  - Flinders University South AustraliaC3  - University Hospital Arnau de VilanovaC3  - Soochow University - ChinaC3  - Chinese Academy of Medical Sciences - Peking Union Medical CollegeC3  - Fu Wai Hospital - CAMSC3  - Guangzhou Medical UniversityC3  - State Key Laboratory of Respiratory DiseaseC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Flinders University South AustraliaC3  - Fukuoka UniversityC3  - Peking UniversityC3  - Nanjing Medical UniversityC3  - NSW HealthC3  - Royal Prince Alfred HospitalC3  - University of SydneyC3  - Peking UniversityPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - AUG-SEP
PY  - 2018
VL  - 2-3
SP  - 59
EP  - 65
DO  - 10.1016/j.eclinm.2018.09.002
AN  - WOS:000646939400012
ER  -

TY  - JOUR
AU  - Radhakrishnan, DM
AU  - Goyal, V
AU  - Shukla, G
TI  - Nocardia: a rare cause of brain abscess
T2  - QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
KW  - TREATMENT STRATEGIES
AD  - AIIMS, Dept Neurol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - OXFORD UNIV PRESS
PI  - OXFORD
PA  - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
DA  - AUG
PY  - 2018
VL  - 111
IS  - 8
SP  - 561
EP  - 562
DO  - 10.1093/qjmed/hcy073
AN  - WOS:000440955400008
ER  -

TY  - JOUR
AU  - Ray, A
AU  - Nayan, A
AU  - Katariya, K
AU  - Sharma, SK
TI  - BODY PACKER SYNDROME: A RADIOLOGICAL DENOUEMENT!
T2  - JOURNAL OF EMERGENCY MEDICINE
KW  - LOW-DOSE CT
KW  - PACKING
AD  - AIIMS, Dept Med, New Delhi 110048, IndiaAD  - AIIMS, Dept Surg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - AUG
PY  - 2018
VL  - 55
IS  - 2
SP  - 260
EP  - 263
DO  - 10.1016/j.jemermed.2018.04.005
AN  - WOS:000439469800024
ER  -

TY  - JOUR
AU  - Saini, C
AU  - Tarique, M
AU  - Ramesh, V
AU  - Khanna, N
AU  - Sharma, A
TI  - γδ T cells are associated with inflammation and immunopathogenesis of leprosy reactions
T2  - IMMUNOLOGY LETTERS
KW  - Leprosy reaction
KW  - ENL
KW  - RR
KW  - TCR gamma delta
KW  - IL-17
KW  - IMMUNE SUPPRESSION
KW  - EXPRESSION
KW  - PROGRESSION
KW  - PLASTICITY
KW  - RESPONSES
KW  - FOXP3
KW  - IL-17
KW  - INTERLEUKIN-17
KW  - MYCOBACTERIAL
KW  - CYTOKINES
AB  - Background: Leprosy reactions appear episodically in leprosy patients, which lead to high inflammation, morbidity and peripheral nerve damage. The role of Th17 cell has been well studied in leprosy reactions but the role of gamma delta or unconventional T cells which is an other major source of IL-17 in many diseases, not studied in leprosy reactional episodes.
   Objective: The aim of the present study to elucidate the role of gamma delta T cells in leprosy reactions.
   Methodology: A total of 40 untreated non-reaction and reactions patients were recruited. PBMCs were isolated and stimulated with M. leprae sonicated antigen (MLSA) for 48 h and immuno-phenotyping was done using flow cytometry. Moreover, gamma delta T cells were isolated by Magnetic beads technology and mRNA expression of IL-17, IFN gamma, TGF-beta and FOXP3 were analyzed by real-time PCR (qPCR) and cytokine was estimated in the culture supernatant by ELISA.
   Results: gamma delta T cells were significantly increased in both Reversal reaction (RR) and Erythema nodosum leprosum (ENL) reaction patients. These cells produced significant amount of IL-17 and IFN-gamma. Furthermore, CD3(+)TCR gamma delta T cells expressed transient FOXP3 with a low amount of TGF-beta in both reactions as compared to stable patients. Moreover, low TGF-beta producing TCR-gamma delta cells were associated with low phosphorylation of STAT5A.
   Conclusion: This study will add to our understanding of the immunological features that mediate and regulate the pathogenesis of leprosy and may helpful to reduce the immuno-pathogenesis of leprosy reaction by targeting these cells.
AD  - All India Inst Med Sci, Dept Biochem, New Delhi 110029, IndiaAD  - Dermatol & Venereol SJH, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Vardhman Mahavir Medical College & Safdarjung HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - AUG
PY  - 2018
VL  - 200
SP  - 55
EP  - 65
DO  - 10.1016/j.imlet.2018.07.005
AN  - WOS:000442972200009
ER  -

TY  - JOUR
AU  - Saluja, G
AU  - Takkar, B
AU  - Agarwal, E
AU  - Sharma, B
AU  - Khokhar, S
TI  - Planning a new intraocular lens library in the Indian scenario
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - BLINDNESS
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Ophthalmol, Bhopal 462020, Madhya Pradesh, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) BhopalPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - AUG
PY  - 2018
VL  - 66
IS  - 8
SP  - 1227
EP  - +
DO  - 10.4103/ijo.IJO_634_18
AN  - WOS:000439924900053
ER  -

TY  - JOUR
AU  - Sandhu, MS
AU  - Gulati, A
AU  - Saritha, J
AU  - Nayak, B
TI  - Urolithiasis: Comparison of diagnostic performance of digital tomosynthesis and ultrasound. Which one to choose and when?
T2  - EUROPEAN JOURNAL OF RADIOLOGY
KW  - Urolithiasis
KW  - Digital tomosynthesis
KW  - Ultrasound
KW  - ACUTE FLANK PAIN
KW  - NON-CONTRAST CT
KW  - COMPUTED-TOMOGRAPHY
KW  - RENAL STONE
KW  - INTRAVENOUS UROGRAPHY
KW  - RADIATION-EXPOSURE
KW  - REFERENCE-STANDARD
KW  - MANAGEMENT
KW  - ACCURACY
KW  - IMPACT
AB  - Objective: To assess the diagnostic performance of digital tomosynthesis (DT) in detecting urolithiasis and compare it with ultrasonography (USG), keeping standard volumetric multi-detector computed tomography (MDCT) as the reference.
   Materials and methods: This prospective analytical study was approved by our institutional ethical committee. A total of 66 patients were enrolled who had either clinical suspicion of urolithiasis or history of recurrent urolithiasis. All patients underwent DT, USG and MDCT within 24 h. In all these three investigations, the calculi were categorised according to their location and size by two radiologists. Sensitivity, specificity, positive and negative predictive values of DT and USG were calculated with MDCT as a reference standard.
   Results: Our study comprised of 66 patients (36 males and 30 females with age range of 19-73 years). A total of 121 calculi were assessed with 52 calculi < 5 mm in size, 32 calculi measuring 5-10 mm and 37 calculi > 10 mm. Kappa test of agreement was used to assess the interobserver agreement for all observations. The measurement of agreement kappa value was 1. The overall sensitivity of DT and USG in detecting urolithaisis was 50% (p value < 0.001) and 50.4% (p value 0.005) respectively. No statistically significant difference was noted between USG and DT in detecting urolithiasis. The sensitivity of DT and USG in detecting renal calculi was 47.1% and 50.9% respectively and the sensitivity of DT and USG in detecting ureteric calculi was 74.9% and 39.2% respectively. We observed statistically significant difference between USG and DT in detecting ureteric calculi.
   Conclusion: In our study, there was no statistically significant difference noted between USG and DT in diagnosis of urolithiasis. DT performed significantly better than USG in detecting ureteric calculi with a higher sensitivity. Hence, we are tempted to opine that DT may be preferred over USG for initial evaluation of patients with suspected ureteric calculi. However considering the strength of ultrasound in demonstrating associated signs as hydroureteronephosis, we are still of the opinion, that both DT and USG should be used as complementary techniques in resolving these common clinical screnarios.
AD  - PGIMER, Dept Radiodiag & Imaging, Chandigarh 160012, IndiaAD  - AIIMS, Dept Urol, New Delhi, IndiaC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER IRELAND LTD
PI  - CLARE
PA  - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
DA  - AUG
PY  - 2018
VL  - 105
SP  - 25
EP  - 31
DO  - 10.1016/j.ejrad.2018.05.017
AN  - WOS:000438559400005
ER  -

TY  - JOUR
AU  - Sankaranarayanan, R
AU  - Joshi, S
AU  - Muwonge, R
AU  - Esmy, PO
AU  - Basu, P
AU  - Prabhu, P
AU  - Bhatla, N
AU  - Nene, BM
AU  - Shaw, J
AU  - Poli, URR
AU  - Verma, Y
AU  - Zomawia, E
AU  - Pimple, S
AU  - Tommasino, M
AU  - Pawlita, M
AU  - Gheit, T
AU  - Waterboer, T
AU  - Sehr, P
AU  - Pilla, MR
A1  - Indian HPV Vaccine Study Grp
TI  - Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study
T2  - VACCINE
KW  - HPV vaccination
KW  - Single dose
KW  - Two dose
KW  - Three dose
KW  - Cervix cancer prevention
KW  - Immunogenicity
KW  - HPV infection
KW  - Prevention
KW  - COSTA-RICA VACCINE
KW  - METAANALYSIS
KW  - EFFICACY
KW  - TRIALS
KW  - WOMEN
KW  - FEWER
KW  - ASSAY
AB  - Background: Human papillomavirus (HPV) vaccination is a major strategy for preventing cervical and other ano-genital cancers. Worldwide HPV vaccination introduction and coverage will be facilitated if a single dose of vaccine is as effective as two or three doses or demonstrates significant protective effect compared to 'no vaccination'.
   Methods: In a multi-centre cluster randomized trial of two vs three doses of quadrivalent HPV vaccination (Gardasillm) in India, suspension of the vaccination due to events unrelated to the study led to per protocol and partial vaccination of unmarried 10-18 year old girls leading to four study groups, two by design and two by default. They were followed up for the primary outcomes of immunogenicity in terms of Ll genotype-specific binding antibody titres, neutralising antibody titres, and antibody avidity for the vaccine-targeted HPV types and HPV infections. Analysis was per actual number of vaccine doses received. This study is registered with ISRCTN, number 1SRCTN98283094; and with ClinicalTrials.gov, number NCT00923702.
   Findings: Of the 17,729 vaccinated girls, 4348 (25%) received three doses on days 1, 60, 180 or later, 4979 (28%) received two doses on days 1 and 180 or later, 3452 (19%) received two doses on days 1 and 60, and 4950 (28%) received one dose. One dose recipients demonstrated a robust and sustained immune response against HPV 16 and 18, albeit inferior to that of 3- or 2-doses and the antibody levels were stable over a 4 year period. The frequencies of cumulative incident and persistent HPV 16 and 18 infections up to 7 years of follow-up were similar and uniformly low in all the vaccinated study groups; the frequency of HPV 16 and 18 infections were significantly higher in unvaccinated age-matched control women than among vaccine recipients. The frequency of vaccine non-targeted HPV types was similar in the vaccinated groups but higher in the unvaccinated control women.
   Conclusion: Our results indicate that a single dose of quadrivalent HPV vaccine is immunogenic and provides lasting protection against HPV 16 and 18 infections similar to the three- and two-dose vaccine schedules, although the study suffer from some limitations. Data on long term protection beyond 7 years against HPV infection and cervical precancerous lesions are needed before policy guidelines regarding a single dose can be formulated and implemented. Significant and long-lasting protective effect of a single dose can be a strong argument to introduce one dose of the HPV vaccine in many low income countries where the current standard of care for cervical cancer prevention is 'no intervention'. (C) 2018 The Authors. Published by Elsevier Ltd.
AD  - Int Agcy Res Canc, Screening Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, FranceAD  - Jehangir Hosp, Jehangir Clin Dev Ctr, Pune, Maharashtra, IndiaAD  - Christian Fellowship Community Hlth Ctr, Ambillikai, IndiaAD  - Raj Gandhi Ctr Biotechnol, Thiruvananthapuram, Kerala, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Nargis Dutt Mem Canc Hosp, Tata Mem Ctr Rural Canc Project, Barshi, Maharashtra, IndiaAD  - MP Shaw Canc Hosp, Gujarat Canc & Res Inst, Ahmadabad, Gujarat, IndiaAD  - Mehdi Nawaj Jung Inst Oncol & Reg Canc Ctr, Red Hills, Hyderabad, Andhra Prades, IndiaAD  - Sikkim Manipal Inst Med Sci, Gangtok, Sikkim, IndiaAD  - Civil Hosp, Aizawl, Mizoram, IndiaAD  - Tata Mem Hosp, Dept Prevent Oncol, Bombay, Maharashtra, IndiaAD  - Int Agcy Res Canc, Infect Sect, Infect & Canc Biol Grp, Lyon, FranceAD  - German Canc Res Ctr, Mol Diagnost Oncogen Infect Infect Inflammat & Ca, Heidelberg, GermanyAD  - European Mol Biol Lab, EMBL DKFZ Chem Biol Core Facil, Heidelberg, GermanyC3  - World Health OrganizationC3  - International Agency for Research on Cancer (IARC)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Tata Memorial Centre (TMC)C3  - The Gujarat Cancer & Research InstituteC3  - Sikkim Manipal UniversityC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalC3  - World Health OrganizationC3  - International Agency for Research on Cancer (IARC)C3  - Helmholtz AssociationC3  - German Cancer Research Center (DKFZ)C3  - European Molecular Biology Laboratory (EMBL)PU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - AUG
PY  - 2018
VL  - 36
IS  - 32
SP  - 4783
EP  - 4791
DO  - 10.1016/j.vaccine.2018.02.087
AN  - WOS:000440880900005
ER  -

TY  - JOUR
AU  - Seth, R
AU  - Kumar, J
TI  - Galactomannan Antigen Test for Invasive Aspergillus Infection in Febrile Neutropenic Children Reply
T2  - INDIAN PEDIATRICS
AD  - AIIMS, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - AUG
PY  - 2018
VL  - 55
IS  - 8
SP  - 710
EP  - 710
AN  - WOS:000442246600022
ER  -

TY  - JOUR
AU  - Sharma, P
AU  - Gaur, N
TI  - Commentary: Reoperation following strabismus surgery among Medicare beneficiaries: Associations with geographic region, academic affiliation, surgeon volume, and adjustable suture technique - Operations again! What lessons do we gain?
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - RATES
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Pediat Ophthalmol & Strabismus Serv, Room 484, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - AUG
PY  - 2018
VL  - 66
IS  - 8
SP  - 1154
EP  - 1155
DO  - 10.4103/ijo.IJO_949_18
AN  - WOS:000439924900023
ER  -

TY  - JOUR
AU  - Sharma, R
AU  - Katiyar, V
AU  - Sharma, P
AU  - Vora, Z
AU  - Gurjar, H
TI  - Posterior fossa crowdedness in idiopathic trigeminal neuralgia: Is it the real perpetrator?
T2  - JOURNAL OF CLINICAL NEUROSCIENCE
KW  - HEMIFACIAL SPASM
KW  - NERVE ATROPHY
KW  - ANGLE
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - AUG
PY  - 2018
VL  - 54
SP  - 165
EP  - 166
DO  - 10.1016/j.jocn.2018.04.068
AN  - WOS:000439673900033
ER  -

TY  - JOUR
AU  - Sharma, R
AU  - Katiyar, V
AU  - Gurjar, H
AU  - Monga, A
AU  - Vora, Z
TI  - Clinical Utility of Diffusion Tensor Imaging Metrics in Lumbar Disk Herniation
T2  - WORLD NEUROSURGERY
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - AUG
PY  - 2018
VL  - 116
SP  - 475
EP  - 475
DO  - 10.1016/j.wneu.2018.03.215
AN  - WOS:000439498500244
ER  -

TY  - JOUR
AU  - Sharma, S
AU  - Singh, AD
AU  - Sharma, SK
AU  - Tripathi, M
AU  - Das, CJ
AU  - Kumar, R
TI  - Gallium-68 DOTA-NOC PET/CT as an alternate predictor of disease activity in sarcoidosis
T2  - NUCLEAR MEDICINE COMMUNICATIONS
KW  - disease activity score
KW  - Ga-68-DOTA-NOC
KW  - positron emission tomography
KW  - computerized tomography
KW  - sarcoidosis
KW  - serum angiotensin-converting enzyme
KW  - SOMATOSTATIN RECEPTOR SCINTIGRAPHY
AB  - Introduction We evaluated the role of gallium-68-labeled [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-1-Nal3-octreotide (Ga-68-DOTA-NOC) PET/CT in assessing sarcoidosis disease activity.
   Patients and methods Patients diagnosed with sarcoidosis underwent Ga-68-DOTA-NOC-PET/CT. The maximum standardized uptake value (SUVmax) at the pathological site and in the descending thoracic aorta (reference standard, SUVmed) were assessed. A SUVmax/SUVmed ratio (disease activity score) of more than one was considered a marker of active disease and was compared with the clinical symptoms and serum angiotensin-converting enzyme and computed tomography (CT) scan. The primary outcome was to assess the efficacy of the scan in estimating disease activity.
   Results Of the 39 patients enrolled in the study, 27 patients were symptomatic and the rest were asymptomatic at enrollment. Increased disease activity was present in 25 (92%) of the 27 symptomatic patients and two (16%) of the 12 asymptomatic patients. The sensitivity and specificity of the test were 92.5% (95% confidence interval=75.7-99.0) and 83.3% (95% confidence interval=51.5-97.9), respectively. Seven out of nine patients who became asymptomatic after treatment showed a significant decrease in the mean disease activity score in post-treatment scans (3.381.05 vs 1.20 +/- 0.82, P<0.001).
   Conclusion
   Ga-68-DOTA-NOC PET/CT emerged as a useful tool to assess the disease activity and treatment response in patients with sarcoidosis with thoracic involvement.
AD  - All India Inst Med Sci, Ctr Excellence EPTB MOH & FW Gol, WHO Collaborating Ctr Res & Training TB, Dept Med,Div Infect Dis, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Nucl Med, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi, IndiaAD  - Hamdard Univ, Jamia Hamdard Inst Mol Med, Dept Mol Med, New Delhi, IndiaAD  - DMIMS, Dept Gen Med & Pulm Med, JNMC, Wardha, Maharashtra, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jamia Hamdard UniversityC3  - Datta Meghe Institute of Higher Education & Research (Deemed to be University)C3  - Jawaharlal Nehru Medical College WardhaPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - AUG
PY  - 2018
VL  - 39
IS  - 8
SP  - 768
EP  - 778
DO  - 10.1097/MNM.0000000000000869
AN  - WOS:000439525500009
ER  -

TY  - JOUR
AU  - Shaw, SC
AU  - Sankar, MJ
AU  - Thukral, A
AU  - Agarwal, R
AU  - Deorari, AK
AU  - Paul, VK
TI  - Assisted Physical Exercise and Stress in Preterm Neonates
T2  - INDIAN PEDIATRICS
KW  - Cortisol
KW  - PIPP score
KW  - Prematurity
KW  - SALIVARY CORTISOL
KW  - PREMATURE-INFANTS
KW  - MASSAGE
KW  - PAIN
AB  - To evaluate the markers of stress before and after a session of assisted physical exercise in infants born before 35 weeks' gestation.
   25 infants born at 28(0/7) to 34(6/7) weeks were subjected to assisted physical exercise daily for about 10-15 min at one week of postnatal age or 33 weeks of post menstrual age, whichever was later. Primary outcome was salivary cortisol and secondary outcome was Premature infant pain profile (PIPP) score. Outcomes were measured, on day 5 (+/- 1) of exercise.
   There was no difference in salivary cortisol between baseline and immediately after (P=0.16), at 90 min (P=0.6) or 120 min (P=0.7) after exercise. Salivary cortisol was lower at 30 min after exercise as compared to baseline (mean difference -0.08 mu g/dL; 95% CI -0.16 to -0.002; P=0.04). The median (IQR) PIPP score was significantly higher at 5 min into exercise (4 (3-6) vs 4 (3-5); P=0.04) and at completion of exercise 6 (4-8) vs 4 (3-5); P < 0.01), as compared to baseline.
   Assisted physical exercise does not seem to result in stress in premature infants.
AD  - All India Inst Med Sci, Div Neonatol, Dept Pediat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - AUG
PY  - 2018
VL  - 55
IS  - 8
SP  - 679
EP  - 682
DO  - 10.1007/s13312-018-1358-5
AN  - WOS:000442246600009
ER  -

TY  - JOUR
AU  - Sihota, R
AU  - Agarwal, E
AU  - James, M
AU  - Verma, M
AU  - Kumar, L
AU  - Dada, T
AU  - Gupta, V
AU  - Kapoor, KS
TI  - In Reply: Long-term Evaluation of Specular Microscopic Changes Following Nd: YAG Iridotomy in Chronic Primary Angle-closure Glaucoma Eyes <i>Reply</i>
T2  - JOURNAL OF GLAUCOMA
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - AUG
PY  - 2018
VL  - 27
IS  - 8
SP  - E143
EP  - E144
DO  - 10.1097/IJG.0000000000000975
AN  - WOS:000441257100007
ER  -

TY  - JOUR
AU  - Singh, J
AU  - Gupta, R
AU  - Prajapati, DC
AU  - Rao, R
TI  - Use of opium containing herbal drug and associated mania
T2  - ASIAN JOURNAL OF PSYCHIATRY
KW  - MEDICINES
AD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - Suny Downstate Med Ctr, Dept Psychiat, Brooklyn, NY 11203 USAAD  - All India Inst Med Sci, Natl Drug Dependence Treatment Ctr, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - State University of New York (SUNY) SystemC3  - SUNY Downstate Health Sciences UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)PU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - AUG
PY  - 2018
VL  - 36
SP  - 36
EP  - 37
DO  - 10.1016/j.ajp.2018.06.006
AN  - WOS:000446249900014
ER  -

TY  - JOUR
AU  - Singh, P
AU  - Surana, R
AU  - Soni, S
AU  - Agnihotri, A
AU  - Ahuja, V
AU  - Makharia, GK
AU  - Staller, K
AU  - Kuo, B
TI  - Cross cultural comparison of constipation profiles at tertiary care centers between India and USA
T2  - NEUROGASTROENTEROLOGY AND MOTILITY
KW  - anxiety
KW  - Asia
KW  - depression
KW  - functional constipation
KW  - IBS-C
KW  - stool consistency
KW  - stool frequency
KW  - IRRITABLE-BOWEL-SYNDROME
KW  - QUALITY-OF-LIFE
KW  - FUNCTIONAL GASTROINTESTINAL DISORDERS
KW  - SELF-DEFINED CONSTIPATION
KW  - MULTINATIONAL SURVEY
KW  - PATIENT ASSESSMENT
KW  - DEPRESSION SCALE
KW  - HOSPITAL ANXIETY
KW  - SOMATIC SYMPTOMS
KW  - LAXATIVE USE
AB  - BackgroundDespite potential differences in patient perception of chronic constipation (CC) in geographically and culturally distinct regions, head-to-head studies comparing the clinical profile, constipation severity, impact on quality of life (QOL) and economic impact are lacking.
   MethodsWe conducted a cross-sectional cohort study of patients presenting with CC to tertiary care centers in the USA and India. Standardized instruments were used to assess constipation subtype, disease severity, disease-specific QOL, somatization, and psychiatric comorbidities. We used multivariable linear regression to determine the predictors of QOL and number of healthcare visits.
   Key ResultsSixty-six and 98 patients with CC were enrolled in the USA and India, respectively. Indian patients with CC had significantly more frequent bowel movements/week compared to their USA counterparts (Median 5 vs 3, P<.0001). The proportion of patients with Bristol stool form scale type 1 and 2 was significantly higher in the USA compared to India (65.5% vs 48%, P=.04). Higher depression score (P=.001), more severe constipation symptoms (P=.001) and site of the study being USA (P=.008) independently predicted worse QOL. Indian patients (P<.001) and worse QOL (P=.02) were independent predictors of number of healthcare visits in the last 12months.
   Conclusions and InferencesIndian patients with CC have more frequent and softer bowel movements compared to those in the USA suggesting significant differences in perception of CC in different geographic and cultural settings. QOL and economic impact related to constipation varies with geographic/cultural setting irrespective of other clinical and psychosomatic features.
AD  - Massachusetts Gen Hosp, Ctr Neurointestinal Hlth, Div Gastroenterol, Boston, MA 02114 USAAD  - All India Inst Med Sci, Div Gastroenterol & Human Nutr, New Delhi, IndiaC3  - Harvard UniversityC3  - Massachusetts General HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - AUG
PY  - 2018
VL  - 30
IS  - 8
C7  - e13324
DO  - 10.1111/nmo.13324
AN  - WOS:000439856900002
ER  -

TY  - JOUR
AU  - Singh, R
AU  - Pandey, D
AU  - Devi, N
AU  - Chand, D
TI  - Bench scale production of butyramide using free and immobilized cells of <i>Bacillus</i> sp APB-6
T2  - BIOPROCESS AND BIOSYSTEMS ENGINEERING
KW  - Bacillus sp APB-6
KW  - Nitrile hydratase
KW  - Bioconversion
KW  - Immobilization
KW  - Butyronitrile
KW  - Butyramide
KW  - HYDRATASE-CATALYZED PRODUCTION
KW  - RHODOCOCCUS-RHODOCHROUS PA-34
KW  - NITRILE HYDRATASE
KW  - RESTING CELLS
KW  - ACRYLAMIDE
KW  - NICOTINAMIDE
KW  - ACRYLONITRILE
KW  - OPTIMIZATION
KW  - PURIFICATION
KW  - DEGRADATION
AB  - Butyramide is a commodity chemical having wide range of applications from material science to biological sciences including synthesis of therapeutic drugs, hydroxamic acids, and electrorheological fluids. The nitrile hydratase protein of Bacillus sp. APB-6 was explored to develop an efficient biocatalytic process for the biotransformation of butyronitrile to butyramide using free and immobilized cells. The reaction conditions for nitrile hydratase activity were not affected after immobilization of the free cells and the optimum pH and temperature for both free and immobilized cells were 8.0 and 55 A degrees C, respectively. In a 1-l batch reaction, complete conversion of 3000 mM butyronitrile to butyramide was achieved using free and immobilized cells. Immobilization of the cells further enhanced their operational stability and reusability in repetitive cycles of butyramide production. This bioconversion resulted in the formation of butyramide at a rate of 522.0 g h(-1) g(-1) dcw.
AD  - Himachal Pradesh Univ, Dept Biotechnol, Summer Hill, Shimla 171005, IndiaAD  - All India Inst Med Sci, Dept Reprod Biol, Delhi 110029, IndiaC3  - Himachal Pradesh UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - AUG
PY  - 2018
VL  - 41
IS  - 8
SP  - 1225
EP  - 1232
DO  - 10.1007/s00449-018-1951-y
AN  - WOS:000438788700015
ER  -

TY  - JOUR
AU  - Singh, S
AU  - Chouhan, RS
AU  - Bindra, A
AU  - Radhakrishna, N
TI  - Comparison of effect of dexmedetomidine and lidocaine on intracranial and systemic hemodynamic response to chest physiotherapy and tracheal suctioning in patients with severe traumatic brain injury
T2  - JOURNAL OF ANESTHESIA
KW  - Dexmedetomidine
KW  - Lidocaine
KW  - Hemodynamic response
KW  - Tracheal suctioning
KW  - Head injury
KW  - CEREBRAL-BLOOD-FLOW
KW  - HEAD-INJURY
KW  - PRESSURE
KW  - SEDATION
KW  - HYPERTENSION
KW  - TRIAL
KW  - CARE
AB  - Chest physiotherapy and tracheal suction cause sympathetic stimulation and increase heart rate (HR), mean arterial pressure (MAP) and intracranial pressure (ICP) which may have deleterious effect in the head injured. We planned to compare the effect of intravenous dexmedetomidine and lidocaine on intracerebral and systemic hemodynamic response to chest physiotherapy (CP) and tracheal suctioning (TS) in patients with severe traumatic brain injury (sTBI).
   Prospective, randomized study in patients with sTBI, 18-60 years of age, undergoing mechanical ventilation and intraparenchymal ICP monitoring. Patients were randomized to receive either iv dexmedetomidine 0.5 mcg/kg (group I; n = 30) or iv lidocaine 2 mg/kg (group II; n = 30) over 10 min. After infusion of test drug, CP with vibrator and manual compression was performed for 2 min and TS was done over next 15-20 s. The hemodynamic response was recorded before, during and at interval of 1 min for 10 min after CP and TS. A 20% change in hemodynamic parameters was considered significant.
   The baseline hemodynamic (HR, MAP), intracranial (ICP, CPP) and respiratory (SPO2, AWP(peak)) parameters were normal and comparable in both the groups. After dexmedetomidine infusion, MAP and CPP decreased significantly from baseline value. In group II, there was no significant change in HR, MAP, ICP and CPP. At end of CP and TS, HR, MAP and CPP in group I was lower as compared to group II. During the 10-min observation period following CP and TS, MAP and CPP in group I remained significantly lower as compared to baseline and group II. There was no significant change in value of other measured parameters.
   Both dexmedetomidine and lidocaine were effective to blunt rise in HR, MAP and ICP in response to CP and TS in patients with sTBI. However, intravenous dexmedetomidine caused significant decrease in MAP and CPP as compared to the baseline and lidocaine.
AD  - All India Inst Med Sci, Dept Neuroanaesthesiol & Crit Care, New Delhi, IndiaAD  - Army Res & Referral Hosp, Dept Anaesthesia, Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER JAPAN KK
PI  - TOKYO
PA  - CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN
DA  - AUG
PY  - 2018
VL  - 32
IS  - 4
SP  - 518
EP  - 523
DO  - 10.1007/s00540-018-2505-9
AN  - WOS:000440112700006
ER  -

TY  - JOUR
AU  - Singhal, R
AU  - Chawla, S
AU  - Batra, H
AU  - Gupta, S
AU  - Ojha, A
AU  - Rathore, DK
AU  - Seth, T
AU  - Guchhait, P
TI  - Engulfment of Hb-activated platelets differentiates monocytes into pro-inflammatory macrophages in PNH patients
T2  - EUROPEAN JOURNAL OF IMMUNOLOGY
KW  - Free Hb
KW  - Intravascular hemolysis
KW  - Macrophages
KW  - Paroxysmal nocturnal hemoglobinuria
KW  - Platelets
KW  - CELLS
KW  - POLARIZATION
KW  - PLASTICITY
KW  - HOMEOSTASIS
KW  - PHENOTYPE
KW  - SUBSETS
KW  - ORIGINS
KW  - FATE
KW  - LIFE
AB  - The distinct response shown by different phenotypes of macrophages and monocytes under various clinical conditions has put the heterogeneity of these cells into focus of investigation for several diseases. Recently, we have described that after engulfing hemoglobin (Hb)-activated platelets, classical monocytes differentiated into pro-inflammatory phenotypes, which were abundant in the circulation of paroxysmal nocturnal hemoglobinuria (PNH) and sickle cell disease patients. Our current study shows that upon engulfment of Hb-activated platelets, monocytes differentiate into M1-macrophages under M1-polarization stimulus (GM-CSF, IFN- + LPS). When grown under M2-polarization stimulus (M-CSF, IL-4 + IL13), the cells exhibited an M1-like phenotype, secreted elevated levels of pro-inflammatory cytokines including TNF- and IL-1, and displayed loss of the secretion of cytokine such as IL-10 and also phagocytic ability unlike the conventional M2 macrophages. Interestingly, when differentiated under the above polarization stimulus, monocytes from PNH patients expressed high levels of CD80 and phospho-STAT1, like M1 macrophages. Hemolytic mice also exhibited a gradual increase in monocyte-platelet aggregates in circulation and accumulation of CD80(high) macrophages in thioglycollate-induced inflamed peritoneum. The spleen of the mice was also populated by CD80(high) macrophages with compromised phagocytic capacity. Our findings suggest that the hemolytic environment and specifically the Hb-activated platelets, which are abundant in circulation during intravascular hemolysis, closely regulate monocyte differentiation.
AD  - Natl Capital Reg Biotech Sci Cluster, Dis Biol Lab, Reg Ctr Biotechnol, Faridabad 121001, Haryana, IndiaAD  - All India Inst Med Sci, Dept Med, New Delhi, IndiaAD  - Natl Capital Reg Biotech Sci Cluster, Translat Hlth Sci & Technol Inst, Faridabad, Haryana, IndiaC3  - Department of Biotechnology (DBT) IndiaC3  - Regional Centre for BiotechnologyC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)PU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - AUG
PY  - 2018
VL  - 48
IS  - 8
SP  - 1285
EP  - 1294
DO  - 10.1002/eji.201747449
AN  - WOS:000440918400005
ER  -

TY  - JOUR
AU  - Sinha, A
AU  - Bagga, A
TI  - Screening Urinalysis in Detection of Chronic Kidney Disease in Children
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - PROTEINURIA
KW  - POPULATION
KW  - HISTORY
AD  - All India Inst Med Sci, Dept Pediat, Div Nephrol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - AUG
PY  - 2018
VL  - 85
IS  - 8
SP  - 603
EP  - 604
DO  - 10.1007/s12098-018-2707-z
AN  - WOS:000438768300002
ER  -

TY  - JOUR
AU  - Sirohi, B
AU  - Chalkidou, K
AU  - Pramesh, CS
AU  - Anderson, BO
AU  - Loeher, P
AU  - El Dewachi, O
AU  - Shamieh, O
AU  - Shrikhande, SV
AU  - Venkataramanan, R
AU  - Parham, G
AU  - Mwanahamuntu, M
AU  - Eden, T
AU  - Tsunoda, A
AU  - Purushotham, A
AU  - Stanway, S
AU  - Rath, GK
AU  - Sullivan, R
TI  - Developing institutions for cancer care in low-income and middle-income countries: from cancer units to comprehensive cancer centres
T2  - LANCET ONCOLOGY
KW  - THERAPEUTIC GEOGRAPHIES
KW  - RADIATION-THERAPY
KW  - HEALTH SYSTEMS
KW  - BREAST-CANCER
KW  - LATIN-AMERICA
KW  - SURGERY
KW  - CHALLENGES
KW  - ONCOLOGY
KW  - BURDEN
KW  - INFRASTRUCTURE
AB  - Global cancer centres operate across different sizes, scales, and ecosystems. Understanding the essential aspects of the creation, organisation, accreditation, and activities within these settings is crucial for developing an affordable, equitable, and quality cancer care, research, and education system. Robust guidelines are scarce for cancer units, cancer centres, and comprehensive cancer centres in low-income and middle-income countries. However, some robust examples of the delivery of complex cancer care in centres in emerging economies are available. Although it is impossible to create an optimal system to fit the unique needs of all countries for the delivery of cancer care, we summarise what has been published about the development and management of cancer centres in low-income and middle-income countries so far and highlight the need for clinical and political leadership.
AD  - Barts Hlth NHS Trust, London, EnglandAD  - Imperial Coll London, London, EnglandAD  - Ctr Global Dev, London, EnglandAD  - Tata Mem Hosp, Bombay, Maharashtra, IndiaAD  - Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USAAD  - Indiana Univ, Med Ctr, Indianapolis, IN 46204 USAAD  - Amer Univ Beirut, Global Hlth Inst, Beirut, LebanonAD  - King Hussein Canc Ctr, Amman, JordanAD  - Tata Trusts, Bombay, Maharashtra, IndiaAD  - Univ N Carolina, Chapel Hill, NC 27515 USAAD  - Univ Zambia, Lusaka, ZambiaAD  - Univ Manchester, Manchester, Lancs, EnglandAD  - Hosp Erasto Gaertner, Inst Oncol Parana, Curitiba, Parana, BrazilAD  - Univ Posit, Curitiba, Parana, BrazilAD  - Kings Coll London, Ctr Comprehens Canc, Kings Hlth Partners, London, EnglandAD  - Kings Coll London, Sch Canc Sci, Inst Canc Policy, London, EnglandAD  - Royal Marsden NHS Fdn Trust, London, EnglandAD  - All India Inst Med Sci, New Delhi, IndiaC3  - Barts Health NHS TrustC3  - Imperial College LondonC3  - Center for Global Development - EuropeC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalC3  - Fred Hutchinson Cancer CenterC3  - Indiana University SystemC3  - Indiana University IndianapolisC3  - American University of BeirutC3  - King Hussein Cancer CenterC3  - University of North CarolinaC3  - University of North Carolina Chapel HillC3  - University of ZambiaC3  - University of ManchesterC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - Royal Marsden NHS Foundation TrustC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - AUG
PY  - 2018
VL  - 19
IS  - 8
SP  - E395
EP  - E406
DO  - 10.1016/S1470-2045(18)30342-5
AN  - WOS:000440573800032
ER  -

TY  - JOUR
AU  - Takkar, B
AU  - Gaur, N
AU  - Obedulla, H
AU  - Chauhan, RC
AU  - Temkar, S
AU  - Venkatesh, P
AU  - Chawla, R
AU  - Kumar, A
TI  - Observer variation in quantitative assessment of retinal shortening with ultrasound in patients of total rhegmatogenous retinal detachment
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Ocular ultrasound
KW  - proliferative vitreoretinopathy
KW  - retinal detachment
KW  - retinal shortening
KW  - PROLIFERATIVE VITREORETINOPATHY
KW  - RISK-FACTORS
KW  - INDIA
AB  - Purpose: To evaluate the interobserver variation in the assessment of retinal length to choroidal length ratio (RCR) as a marker for proliferative vitreoretinopathy (PVR) in cases of rhegmatogenous retinal detachment (RRD). Methods: This was a double-masked, prospective study at a tertiary center. Ultrasound was used to calculate RCR in 50 eyes with total RRD by two observers. Both observers were trained after the first round of calculations, and all the calculations were repeated as before. Difference between the RCR values was stratified into four categories (<0.01, 0.01-0.05, 0.06-0.1, and >0.1) for descriptive analysis. A difference of 0.05 was set as the maximal limit for defining interobserver agreement. Correlation between RCR and interobserver difference was assessed. Results: The mean interobserver difference in RCR values was found to be 0.06 +/- 0.0 (P = 0.41) and was reduced to 0.04 +/- 0.02 (P = 0.81) following training. The interobserver difference was <0.1 in 82% of the cases before training and in 98% of cases after training. The worst interobserver agreement was noted in cases with RCR < 0.8, and there was a good negative correlation between RCR and interobserver difference (r = -0.6, P <= 0.001). Conclusion: There is good interobserver agreement in assessing RCR with ultrasound in eyes with RRD, which improves further with training. RCR needs careful assessment in eyes with very low RCR. This technique may be useful in prognostication of surgical outcomes in cases with advanced PVR.
AD  - All India Inst Med Sci, Dept Ophthalmol, Bhopal 462020, Madhya Pradesh, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Community & Family Med, Bhopal, IndiaC3  - All India Institute of Medical Sciences (AIIMS) BhopalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) BhopalPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - AUG
PY  - 2018
VL  - 66
IS  - 8
SP  - 1115
EP  - 1118
DO  - 10.4103/ijo.IJO_186_18
AN  - WOS:000439924900014
ER  -

TY  - JOUR
AU  - Tanwar, P
AU  - Das, P
AU  - Barwad, A
AU  - Shukla, N
AU  - Ramteke, P
TI  - Aspirate from an abdominal lump in a known case of breast carcinoma
T2  - CYTOPATHOLOGY
AB  - In this report we describe the means of diagnosing an incidental abdominal wall lump in an otherwise asymptomatic patient who had a history of previously treated breast carcinoma. FNAC and excision showed the lesion to be a granular cell tumor. Granular cell tumors are quite rare in subcutaneous tissue. FNAC is easily available, widely acceptable and minimally invasive and it can readily be used to screen and characterize such lesions.
AD  - All India Inst Med Sci, Lab Oncol, IRCH, Dr BRA, New Delhi, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - AUG
PY  - 2018
VL  - 29
IS  - 4
SP  - 394
EP  - 395
DO  - 10.1111/cyt.12546
AN  - WOS:000439927300015
ER  -

TY  - JOUR
AU  - Thanusha, AV
AU  - Dinda, AK
AU  - Koul, V
TI  - Evaluation of nano hydrogel composite based on gelatin/HA/CS suffused with Asiatic acid/ZnO and CuO nanoparticles for second degree burns
T2  - MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
KW  - Hydrogel composite
KW  - Gelatin
KW  - Hyaluronic acid
KW  - Chondroitin sulfate
KW  - Asiatic acid
KW  - ZnO & CuO nanoparticles
KW  - MECHANISMS
KW  - TISSUE
KW  - SKIN
KW  - TOXICITY
KW  - RELEASE
KW  - ASSAY
AB  - In the present work, a hydrogel platform composed of biopolymer gelatin, and glycosaminoglycan's (Hyaluronic acid and Chondroitin sulfate) incorporated with Asiatic acid (a triterpenoid) and nanoparticles (Zinc oxide and Copper oxide) has been designed and developed to find out the efficacy of healing in second degree bum wounds in Wistar rats. The developed hydrogel composite has been characterized by physico-chemical methods such as; SEM, swelling, mechanical strength, degradation and drug release kinetics. Results showed that the morphology of composite scaffolds are porous with maximum water uptake capacity of 1068% and possessed tensile strength of similar to 0.196 MPa. Anti-microbial evaluation depicted increase in zone of inhibition with hydrogel containing gelatin + ZnO (5.3 +/- 0.2 mm in E. colt and 4.9 +/- 0.6 mm in S. aureus) and gelatin + CuO (4.8 +/- 0.7 mm in E. coli, 3.8 +/- 0.3 mm in S. aureus) in comparison to hydrogel composite scaffold. In-vitro cytocompatibility of developed hydrogel composite was assessed in terms of MTT and DNA quantification on L929 fibroblast cells. In vivo studies for the composite scaffolds were evaluated on Wistar rats after second degree bum wounds were induced and studied for 28 days which showed the significant wound healing activity in comparison to the control (NeuSkin (TM) and Cotton guaze) in terms of DNA, total protein, hexosamine and hydroxyproline content. Histopathology studies showed the significant progress in re-epithelization, collagen fibers arrangement and angiogenesis in comparison to control. Additionally, a decrease of TNF-alpha and increase of MMP-2 expression on day 7 of animal experiment support healing. Furthermore, no toxicity was seen with the developed scaffolds suggesting their suitability to use as a wound dressing in second degree burns.
AD  - Indian Inst Technol Delhi, Ctr Biomed Engn, New Delhi, IndiaAD  - All India Inst Med Sci, Biomed Engn Unit, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - AUG 1
PY  - 2018
VL  - 89
SP  - 378
EP  - 386
DO  - 10.1016/j.msec.2018.03.034
AN  - WOS:000434239100040
ER  -

TY  - JOUR
AU  - Tripathy, K
AU  - Chawla, R
TI  - Letter to the Editor: Optical Coherence Tomography Angiography of Choroidal Hemangioma
T2  - OPHTHALMIC SURGERY LASERS & IMAGING RETINA
AD  - ICARE Eye Hosp & Postgrad Inst, Noida, Uttar Pradesh, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SLACK INC
PI  - THOROFARE
PA  - 6900 GROVE RD, THOROFARE, NJ 08086 USA
DA  - AUG
PY  - 2018
VL  - 49
IS  - 8
SP  - 560
EP  - 560
DO  - 10.3928/23258160-20180803-01
AN  - WOS:000441934200001
ER  -

TY  - JOUR
AU  - Vellarikkal, SK
AU  - Jayarajan, R
AU  - Verma, A
AU  - Ravi, R
AU  - Senthilvel, V
AU  - Kumar, A
AU  - Saini, L
AU  - Gulati, S
AU  - Lal, M
AU  - Mathur, A
AU  - Chhetri, MK
AU  - Faruq, M
AU  - Scaria, V
AU  - Sivasubbu, S
TI  - A founder mutation <i>MLC1</i> c.736delA associated with megalencephalic leukoencephalopathy with subcortical cysts-1 in north Indian kindred
T2  - CLINICAL GENETICS
AD  - CSIR, Genom & Mol Med Unit, IGIB, Mathura Rd, New Delhi 110025, IndiaAD  - Acad Sci & Innovat Res AcSIR, CSIR IGIB South Campus, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaAD  - Alshifa Multispecial Hosp, New Delhi, IndiaAD  - CSIR, GN Ramachandran Knowledge Ctr Genome Informat, Inst Genom & Integrat Biol, New Delhi, IndiaC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Academy of Scientific & Innovative Research (AcSIR)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)PU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - AUG
PY  - 2018
VL  - 94
IS  - 2
SP  - 271
EP  - 273
DO  - 10.1111/cge.13251
AN  - WOS:000438199300012
ER  -

TY  - JOUR
AU  - Verma, P
AU  - Sharma, AK
AU  - Shankar, H
AU  - Sharma, A
AU  - Rao, DN
TI  - Role of Trace Elements, Oxidative Stress and Immune System: a Triad in Premature Ovarian Failure
T2  - BIOLOGICAL TRACE ELEMENT RESEARCH
KW  - B cells
KW  - Premature ovarian failure
KW  - Plasma mass spectrometry
KW  - Reactive oxygen species
KW  - Trace elements
KW  - GLUTATHIONE-PEROXIDASE ACTIVITY
KW  - AUTOIMMUNE-THYROIDITIS
KW  - FOLLICULAR-FLUID
KW  - SELENIUM LEVELS
KW  - IN-VITRO
KW  - ZINC
KW  - DISEASES
KW  - COPPER
KW  - INSUFFICIENCY
KW  - UPDATE
AB  - The risk of premature ovarian failure (POF) increases in association with alteration in immunological parameters and oxidative stress (OS). Adequate intake of trace elements is required for antioxidant property and immune defense mechanism. The aim of this study was to explore the involvement of trace elements, OS, and immunological parameters in POF. This was a cross-sectional, case-control study, involving 65 participants divided into the POF (n = 35) and control (n = 30) groups. Serum levels of Se, Zn, and Cu were determined along with hormonal, OS, and immunological markers. POF group had significantly lower levels of Zn, Cu, Se, and Zn:Cu ratio. However, Se:Cu ratio was not significant between the groups. FSH and LH levels were negatively correlated with Zn and Cu levels and positively correlated with Se levels. Estrogen levels were negatively correlated with all the studied trace elements. Inter-element association between Zn and Se was significant in POF (r = - 0.39, p = 0.02) compared to control group (r = - 0.078, p = 0.65). In all the POF patients, SOD and GPx activities were significantly (p < 0.05) lower and MDA level was higher (p > 0.05) than control group. B cell marker CD19 was significantly (p < 0.0001) high in POF group. There are involvement of trace elements in hormonal regulation and antioxidant defense mechanism, which once gets altered leads to high ROS generation and affect functions of the immune system. Exaggereative immune system causing higher expression of B cell associated markers (CD19) leading to autoimmune condition in POF.
AD  - All India Inst Med Sci, Dept Biochem, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Obstet & Gynaecol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - HUMANA PRESS INC
PI  - TOTOWA
PA  - 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
DA  - AUG
PY  - 2018
VL  - 184
IS  - 2
SP  - 325
EP  - 333
DO  - 10.1007/s12011-017-1197-6
AN  - WOS:000437757500005
ER  -

TY  - JOUR
AU  - Singh, AD
AU  - Mian, A
TI  - Letter by Singh and Mian Regarding Article, "Mental Stress-Induced-Myocardial Ischemia in Young Patients With Recent Myocardial Infarction: Sex Differences and Mechanisms"
T2  - CIRCULATION
KW  - WOMEN
AD  - All India Inst Med Sci, Dept Med, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - JUL 31
PY  - 2018
VL  - 138
IS  - 5
SP  - 546
EP  - 547
DO  - 10.1161/CIRCULATIONAHA.118.034499
AN  - WOS:000440196500020
ER  -

TY  - JOUR
AU  - Kuijpers, T
AU  - Spencer, FA
AU  - Siemieniuk, RAC
AU  - Vandvik, PO
AU  - Otto, CM
AU  - Lytvyn, L
AU  - Mir, H
AU  - Jin, AY
AU  - Manja, V
AU  - Karthikeyan, G
AU  - Hoendermis, E
AU  - Martin, J
AU  - Carballo, S
AU  - O'Donnell, M
AU  - Vartdal, T
AU  - Baxter, C
AU  - Patrick-Lake, B
AU  - Scott, J
AU  - Agoritsas, T
AU  - Guyatt, G
TI  - Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline
T2  - BMJ-BRITISH MEDICAL JOURNAL
KW  - MEDICAL THERAPY
KW  - PERCUTANEOUS CLOSURE
KW  - DEVICE CLOSURE
KW  - PREVENTION
KW  - OUTCOMES
KW  - GRADE
AB  - Options for the secondary prevention of stroke in patients younger than 60 years who have had a cryptogenic ischaemic stroke thought to be secondary to patent foramen ovale (PFO) include PFO closure (with antiplatelet therapy), antiplatelet therapy alone, or anticoagulants. International guidance and practice differ on which option is preferable.
   The BMJ Rapid Recommendations panel used a linked systematic review(1) triggered by three large randomised trials published in September 2017 that suggested PFO closure might reduce the risk of ischaemic stroke more than alternatives.(2-4) The panel felt that the studies, when considered in the context of the full body of evidence, might change current clinical practice. 5 The linked systematic review finds that PFO closure prevents recurrent stroke relative to antiplatelet therapy, but possibly not relative to anticoagulants, and is associated with procedural complications and persistent atrial fibrillation. 1 The review also presents evidence regarding the role of anticoagulants or antiplatelet therapy when PFO closure is not acceptable or is contraindicated.
   This expert panel make a
   Strong recommendation in favour of PFO closure plus antiplatelet therapy compared with antiplatelet therapy alone
   Weak recommendation in favour of PFO closure plus antiplatelet therapy compared with anticoagulants
   Weak recommendation in favour of anticoagulants compared with antiplatelet therapy.
   The largest challenge in making our recommendation was the low quality evidence for the comparisons that included anticoagulants. We summarised all the highest quality available evidence separately for antiplatelet therapy and anticoagulants because the evidence suggests it is likely their effectiveness and adverse effects differ, and clinicians and patients should be aware of these likely differences. Our panel believes that the mechanism of benefit with PFO closure is prevention of venous clots crossing the PFO. Anticoagulants are likely to be substantially more effective in preventing such clots from initially arising than antiplatelet agents.
   Box 1 shows the articles and linked evidence in this Rapid Recommendation package. The main infographic presents the recommendations as three paired comparisons, together with an overview of the absolute benefits and harms informing each re-commendation, according to the GRADE methodology.
AD  - Dutch Coll Gen Practitioners, Dept Guideline Dev & Res, Utrecht, NetherlandsAD  - McMaster Univ, Hamilton, ON, CanadaAD  - McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON L8S 4L8, CanadaAD  - Univ Toronto, Dept Med, Toronto, ON, CanadaAD  - Norwegian Inst Publ Hlth, Oslo, NorwayAD  - Innlandet Hosp Trust, Div Gjovik, Dept Med, Gjovik, NorwayAD  - Univ Washington, Seattle, WA 98195 USAAD  - Queens Univ, Dept Med, Div Neurol, Kingston, ON, CanadaAD  - Univ Calif Davis, Sacramento, CA 95817 USAAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Univ Med Ctr Groningen, Groningen, NetherlandsAD  - Western Univ, Dept Anesthesia & Perioperat Med, London, ON, CanadaAD  - Western Univ, Dept Epidemiol & Biostat, London, ON, CanadaAD  - Univ Hosp Geneva, Div Gen Internal Med, CH-1211 Geneva, SwitzerlandAD  - NUI Galway, Galway, IrelandAD  - Oslo Univ Hosp, Oslo, NorwayAD  - Univ Hosp Geneva, Div Clin Epidemiol, CH-1211 Geneva, SwitzerlandC3  - McMaster UniversityC3  - McMaster UniversityC3  - University of TorontoC3  - Norwegian Institute of Public Health (NIPH)C3  - Innlandet Hospital TrustC3  - University of WashingtonC3  - University of Washington SeattleC3  - Queens University - CanadaC3  - University of California SystemC3  - University of California DavisC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of GroningenC3  - Western University (University of Western Ontario)C3  - Western University (University of Western Ontario)C3  - University of GenevaC3  - University of OsloC3  - University of GenevaPU  - BMJ PUBLISHING GROUP
PI  - LONDON
PA  - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
DA  - JUL 25
PY  - 2018
VL  - 362
C7  - k2515
DO  - 10.1136/bmj.k2515
AN  - WOS:000440406200001
ER  -

TY  - JOUR
AU  - Tarique, M
AU  - Naz, H
AU  - Kurra, SV
AU  - Saini, C
AU  - Naqvi, RA
AU  - Rai, R
AU  - Suhail, M
AU  - Khanna, N
AU  - Rao, DN
AU  - Sharma, A
TI  - Interleukin-10 Producing Regulatory B Cells Transformed CD4<SUP>+</SUP>CD25<SUP>-</SUP> Into Tregs and Enhanced Regulatory T Cells Function in Human Leprosy
T2  - FRONTIERS IN IMMUNOLOGY
KW  - leprosy
KW  - regulatory B cells
KW  - Tregs
KW  - interleukin-10
KW  - FoxP3
KW  - Teff cells
KW  - DISEASE PROGRESSION
KW  - IL-10
KW  - AUTOIMMUNITY
KW  - PROFILES
KW  - MICE
KW  - LIPOPOLYSACCHARIDE
KW  - POPULATION
KW  - EXPRESSION
KW  - RESPONSES
KW  - SUBSETS
AB  - Regulatory B cells (Bregs) are known to exhibit their regulatory functions through interleukin-10 (IL-10) cytokine which suppress inflammation. There are only a few studies explaining the phenotype and functioning of these cells in contribution to host immunity in leprosy. Here, we evaluated the role of IL-10 producing Bregs in the pathogenesis of leprosy and assessed their immunoregulatory effects on Tregs and effector T cells. We found an increased frequency of Bregs and increased expression of their immune modulatory molecules (IL-10, FoxP3, and PDL-1) in leprosy patients. The potential immunoregulatory mechanism of Bregs was also investigated using MACS sorted Teff (CD4+CD25 ) and Treg (CD4+CD25+) cells were cocultured with Bregs to elucidate the effects of Bregs on effector T and regulatory T cells. Cell coculture results showed that purified Bregs cells from leprosy patients convert CD4(+)CD25(-) cells into CD4(+)CD25(+) cells. Cell coculture experiments also demonstrated that leprosy derived IL-10 producing Bregs enhance FoxP3 and PD-1 expression in Tregs and enhanced Tregs activity. Blocking of IL-10 receptor confirmed that IL-10 producing Breg has immunomodulatory effect on Tregs and effector T cells as effector T cells are not converted into Tregs and enhanced expression of FoxP3 and PD-1 was not observed on Tregs. Collectively, these findings demonstrate that IL-10 producing Breg cells play an important mechanism in controlling the immunopathogenesis of leprosy and have an immunomodulatory effect on Tregs and effector T cells. Our findings may pave way for novel targets of IL-10 producing Bregs for immunotherapy in leprosy patients.
AD  - All India Inst Med Sci AIIMS, Dept Biochem, New Delhi, IndiaAD  - Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, New Delhi, IndiaAD  - King Abdulaziz Univ, King Fahd Med Res Ctr, Jeddah, Saudi ArabiaAD  - All India Inst Med Sci AIIMS, Dept Dermatovenerol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jamia Millia IslamiaC3  - King Abdulaziz UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - FRONTIERS MEDIA SA
PI  - LAUSANNE
PA  - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
DA  - JUL 23
PY  - 2018
VL  - 9
C7  - 1636
DO  - 10.3389/fimmu.2018.01636
AN  - WOS:000439455700001
ER  -

TY  - JOUR
AU  - Singh, GP
AU  - Nigam, R
AU  - Tomar, GS
AU  - Monisha, M
AU  - Bhoi, SK
AU  - Arulselvi, S
AU  - Sengar, K
AU  - Akula, D
AU  - Panta, P
AU  - Anindya, R
TI  - Early and rapid detection of UCHL1 in the serum of brain-trauma patients: a novel gold nanoparticle-based method for diagnosing the severity of brain injury
T2  - ANALYST
KW  - C-TERMINAL HYDROLASE
KW  - INTRACRANIAL LESIONS
KW  - UBIQUITIN
KW  - MILD
KW  - L1
KW  - UTILITY
AB  - The clinical diagnosis of traumatic brain injury (TBI) is based on neurological examination and neuroimaging tools such as CT scanning and MRI. However, neurological examination at times may be confounded by consumption of alcohol or drugs and neuroimaging facilities may not be available at all centers. Human ubiquitin C-terminal hydrolase (UCHL1) is a well-accepted serum biomarker for severe TBI and can be used to detect the severity of a head injury. A reliable, rapid, cost effective, bedside and easy to perform method for the detection of UCHL1 is a pre-requisite for wide clinical applications of UCHL1 as a TBI biomarker. We developed a rapid detection method for UCHL1 using surface plasmon resonance of gold nanoparticles with a limit of detection (LOD) of 0.5 ng mL(-1). It has a sensitivity and specificity of 100% each and meets an analytical precision similar to that of conventional sandwich ELISA but can be performed rapidly. Using this method we successfully detected UCHL1 in a cohort of 66 patients with TBI and were reliably able to distinguish mild TBI from moderate to severe TBI.
AD  - All India Inst Med Sci, Dept Neuroanaesthesiol & Crit Care, JPN Apex Trauma Ctr, New Delhi 110029, IndiaAD  - Indian Inst Technol IIT Hyderabad, Dept Biotechnol, Sangareddy 502285, Telangana, IndiaAD  - All India Inst Med Sci, Dept Emergency Med, JPN Apex Trauma Ctr, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Lab Med, JPN Apex Trauma Ctr, New Delhi 110029, IndiaAD  - MNR Dent Coll & Hosp, Dept Oral Med & Radiol, Sangareddy 502294, Telangana, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - HyderabadC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterPU  - ROYAL SOC CHEMISTRY
PI  - CAMBRIDGE
PA  - THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND
DA  - JUL 21
PY  - 2018
VL  - 143
IS  - 14
SP  - 3366
EP  - 3373
DO  - 10.1039/c8an00533h
AN  - WOS:000438056400013
ER  -

TY  - JOUR
AU  - Chaudhury, A
AU  - Dendi, VSR
AU  - Chaudhury, M
AU  - Jain, A
AU  - Kasarla, MR
AU  - Panuganti, K
AU  - Jain, G
AU  - Ramanujam, A
AU  - Rena, B
AU  - Koyagura, SR
AU  - Fogla, S
AU  - Kumar, S
AU  - Shekhawat, NS
AU  - Maddur, S
TI  - HSV1/2 Genital Infection in Mice Cause Reversible Delayed Gastrointestinal Transit: A Model for Enteric Myopathy
T2  - FRONTIERS IN MEDICINE
KW  - enteric nervous system
KW  - nitrergic neurotransmission
KW  - virus
KW  - guanylyl cyclase
KW  - megacolon
KW  - HERPES-SIMPLEX-VIRUS
KW  - CLOSTRIDIUM-DIFFICILE INFECTION
KW  - NERVOUS-SYSTEM INFECTION
KW  - TOXIC MEGACOLON
KW  - ULCERATIVE-COLITIS
KW  - BOWEL DISTENSION
KW  - ORAL INOCULATION
KW  - HOMOSEXUAL MEN
KW  - MOUSE MODELS
KW  - NEURONS
AB  - In an interesting investigation by Khoury-Hanold et al. (1), genital infection of mice with herpes simplex virus 1 (HSV1) were reported to cause multiple pelvic organ involvement and obstruction. A small subset of mice succumbed after the first week of HSV1 infection. The authors inferred that the mice died due to toxic megacolon. In a severe form of mechanical and/or functional obstruction involving gross dilation of the colon and profound toxemia, the presentation is called "toxic megacolon." The representative observations by Khoury-Hanold likely do not resemble toxic megacolon. The colon was only slightly dilated and benign appearing. Importantly, HSV1 infection affected the postjunctional mechanisms of smooth muscle relaxation like the sildenafil-response proteins, which may have been responsible for defective nitrergic neurotransmission and the delayed transit. Orally administered polyethylene glycol reversed the gastrointestinal "obstruction," suggesting a mild functional type of slowed luminal transit, resembling constipation, rather than toxic megacolon, which cannot be reversed by an osmotic laxative without perforating the gut. The authors suggest that the mice did not develop HSV1 encephalitis, the commonly known cause of mortality. The premature death of some of the mice could be related to the bladder outlet obstruction, whose backflow effects may alter renal function, electrolyte abnormalities and death. Muscle strip recordings of mechanical relaxation after electrical field stimulation of gastrointestinal, urinary bladder or cavernosal tissues shall help obtain objective quantitative evidence of whether HSV infection indeed cause pelvic multi-organ dysfunction and impairment of autonomic neurotransmission and postjunctional electromechanical relaxation mechanisms of these organs.
AD  - GIM Fdn, Little Rock, AR 72225 USAAD  - Christus Trinity Mother Frances Hosp, Tyler, TX USAAD  - Univ Southern Calif, Wanderful Media, Los Angeles, CA USAAD  - Pkwy Surg & Cardiovasc Hosp, Ft Worth, TX USAAD  - Presbyterian Hosp, Denton, TX USAAD  - Berkshire Med Ctr, Pittsfield, MA USAAD  - Woodland Mem Hosp, Sacramento, CA USAAD  - Xenco Labs, Houston, TX USAAD  - Northwest Med Ctr, Bentonville, AR USAAD  - Beaumont Hosp, Grosse Pointe, MI USAAD  - Neshoba Cty Gen Hosp, Philadelphia, MS USAAD  - Baptist Hosp, Conway, AR USAAD  - All India Inst Med Sci, New Delhi, IndiaAD  - ESIC Med Coll, Sanathnagar, IndiaC3  - University of Southern CaliforniaC3  - Beaumont HealthC3  - Beaumont Hospital Grosse PointeC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - FRONTIERS MEDIA SA
PI  - LAUSANNE
PA  - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
DA  - JUL 17
PY  - 2018
VL  - 5
C7  - 176
DO  - 10.3389/fmed.2018.00176
AN  - WOS:000439001600001
ER  -

TY  - JOUR
AU  - Karthikeyan, G
AU  - Guilherme, L
TI  - Acute rheumatic fever
T2  - LANCET
KW  - GROUP-A STREPTOCOCCUS
KW  - HEART-DISEASE
KW  - SYDENHAMS CHOREA
KW  - M-PROTEIN
KW  - JONES CRITERIA
KW  - FOLLOW-UP
KW  - INTRAVENOUS IMMUNOGLOBULIN
KW  - PROSPECTIVE SURVEILLANCE
KW  - BENZATHINE PENICILLIN
KW  - INTERMOUNTAIN AREA
AB  - Acute rheumatic fever is caused by an autoimmune response to throat infection with Streptococcus pyogenes. Cardiac involvement during acute rheumatic fever can result in rheumatic heart disease, which can cause heart failure and premature mortality. Poverty and household overcrowding are associated with an increased prevalence of acute rheumatic fever and rheumatic heart disease, both of which remain a public health problem in many low-income countries. Control efforts are hampered by the scarcity of accurate data on disease burden, and effective approaches to diagnosis, prevention, and treatment. The diagnosis of acute rheumatic fever is entirely clinical, without any laboratory gold standard, and no treatments have been shown to reduce progression to rheumatic heart disease. Prevention mainly relies on the prompt recognition and treatment of streptococcal pharyngitis, and avoidance of recurrent infection using long-term antibiotics. But evidence for the effectiveness of either approach is not strong. High-quality research is urgently needed to guide efforts to reduce acute rheumatic fever incidence and prevent progression to rheumatic heart disease.
AD  - All India Inst Med Sci, Dept Cardiol, Cardiothorac Sci Ctr, New Delhi 110029, IndiaAD  - Univ Sao Paulo, Heart Inst InCor, Inst Invest Immunol, Natl Inst Sci & Technol, Sao Paulo, BrazilC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Universidade de Sao PauloPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - JUL 14
PY  - 2018
VL  - 392
IS  - 10142
SP  - 161
EP  - 174
DO  - 10.1016/S0140-6736(18)30999-1
AN  - WOS:000438501300031
ER  -

TY  - JOUR
AU  - Seale, AC
AU  - Agarwal, R
TI  - Improving management of neonatal infections
T2  - LANCET
KW  - INJECTABLE PROCAINE BENZYLPENICILLIN
KW  - SIMPLIFIED ANTIBIOTIC REGIMENS
KW  - EQUIVALENCE TRIAL
KW  - YOUNG INFANTS
KW  - OPEN-LABEL
KW  - BACTERIAL-INFECTION
KW  - CLINICAL SIGNS
KW  - GENTAMICIN
AD  - London Sch Hyg & Trop Med, Epidemiol & Populat Hlth, London WC1E 7HT, EnglandAD  - Haramaya Univ, Coll Hlth & Med Sci, Haramaya, EthiopiaAD  - KEMRI Wellcome Trust Res Programme, Kilifi, KenyaAD  - All India Inst Med Sci, Newborn Hlth Knowledge Ctr, WHO Collaborating Ctr Training & Res Newborn Care, Neonatal Div,Dept Paediat, New Delhi, IndiaC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - Haramaya UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - JUL 14
PY  - 2018
VL  - 392
IS  - 10142
SP  - 100
EP  - 102
DO  - 10.1016/S0140-6736(18)31432-6
AN  - WOS:000438501300007
ER  -

TY  - JOUR
AU  - Bhatt, SP
AU  - Guleria, R
AU  - Vikram, NK
AU  - Nandhan, SV
AU  - Singh, Y
AU  - Gupta, AK
TI  - Association of inflammatory genes in obstructive sleep apnea and non alcoholic fatty liver disease in Asian Indians residing in north India
T2  - PLOS ONE
KW  - INSULIN-RESISTANCE SYNDROME
KW  - C-REACTIVE PROTEIN
KW  - METABOLIC SYNDROME
KW  - INTERMITTENT HYPOXIA
KW  - OBESITY
KW  - LEPTIN
KW  - INTERLEUKIN-6
KW  - ACTIVATION
KW  - RECEPTOR
KW  - POLYMORPHISM
AB  - Background
   Previous studies have indicated that variants of the high sensitive C-reactive protein (CRP), Interleukin (IL)-6 and leptin receptor (LEPR) genes are associated with the presence of obstructive sleep apnea (OSA) but not in non-alcoholic fatty liver disease (NAFLD) in Asian Indians. The study was conducted to investigate the association of CRP rs1130864 (1444c/T), IL-6 rs1800795 (-174G/c) and LEPR rs1137101 (Q223R) genes with OSA and NAFLD in Asian Indians residing in North India.
   Methods
   240 overweight/obese subjects [body mass index (BMI>23kg/m(2))], 124 with OSA and with NAFLD (group 1), 47 with OSA without NAFLD (group 2), 44 without OSA and with NAFLD (group 3) and 25 without OSA and without NAFLD (group 4) were recruited in this study. The severity of NAFLD was based on abdomen liver ultrasound and of OSA on overnight polysomnography. Clinical details, anthropometry profile, body composition, biochemical parameters and inflammatory markers were measured. Polymerase chain reaction and restriction fragment length polymorphism of CRP, IL-6 and LEPR gene was performed. The associations of these polymorphisms with clinical, anthropometric and biochemical profiles were investigated. The genotypes were confirmed by DNA sequencing analysis.
   Results
   The C, T and R alleles of IL-6, CRP and LEPR genes was more frequent in OSA and NAFLD subjects and significantly correlated with higher protein levels. The prevalence of variant genotypes c/T of CRP, G/c of IL-6 and Q/R of LEPR genes was significantly higher in OSA subjects as compared to non OSA subjects. Further, c/c genotype of IL-6 (G/c), T/T of CRP (c/T) and RR genotype of LEPR (Q/R) was associated with significantly higher BMI, fat mass (kg), % body fat, waist circumference, serum triglycerides, total cholesterol, alkaline phosphate, aspartate transaminase and fasting insulin levels in OSA and NAFLD subjects. Using a multivariate analysis, the combined effect of three polymorphisms of CRP, IL6 and LEPR gene variants on OSA and NAFLD risk was evaluated. Odds ratio for OSA and NAFLD with the combination of the three gene polymorphisms increased to 2.84 (95% CI: 1.08-6.54; p = 0.04) even when adjusted for sex, age and BMI.
   Conclusion
   Polymorphisms of pro-inflammatory cytokine genes were associated with increased risk of OSA and NAFLD in Asian Indians.
AD  - All India Inst Med Sci, Dept Pulm Med & Sleep Disorders, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Med, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurobiochem, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - PUBLIC LIBRARY SCIENCE
PI  - SAN FRANCISCO
PA  - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
DA  - JUL 12
PY  - 2018
VL  - 13
IS  - 7
C7  - e0199599
DO  - 10.1371/journal.pone.0199599
AN  - WOS:000438457400014
ER  -

TY  - JOUR
AU  - Das, B
AU  - Ghosh, TS
AU  - Kedia, S
AU  - Rampal, R
AU  - Saxena, S
AU  - Bag, S
AU  - Mitra, R
AU  - Dayal, M
AU  - Mehta, O
AU  - Surendranath, A
AU  - Travis, SPL
AU  - Tripathi, P
AU  - Nair, GB
AU  - Ahuja, V
TI  - Analysis of the Gut Microbiome of Rural and Urban Healthy Indians Living in Sea Level and High Altitude Areas
T2  - SCIENTIFIC REPORTS
KW  - BACTERIA
KW  - PREVOTELLA
KW  - DIVERSITY
KW  - DIET
AB  - The diversity and basic functional attributes of the gut microbiome of healthy Indians is not well understood. This study investigated the gut microbiome of three Indian communities: individuals residing in rural and urban (n = 49) sea level Ballabhgarh areas and in rural high altitude areas of Leh, Ladakh in North India (n = 35). Our study revealed that the gut microbiome of Indian communities is dominated by Firmicutes followed by Bacteroidetes, Actinobateria and Proteobacteria. Although, 54 core bacterial genera were detected across the three distinct communities, the gut bacterial composition displayed specific signatures and was observed to be influenced by the topographical location and dietary intake of the individuals. The gut microbiome of individuals living in Leh was observed to be significantly similar with a high representation of Bacteroidetes and low abundance of Proteobacteria. In contrast, the gut microbiome of individuals living in Ballabhgarh areas harbored higher number of Firmicutes and Proteobacteria and is enriched with microbial xenobiotic degradation pathways. The rural community residing in sea level Ballabhgarh areas has unique microbiome characterized not only by a higher diversity, but also a higher degree of interindividual homogeneity.
AD  - NCR Biotech Sci Cluster, Translat Hlth Sci & Technol Inst, Ctr Human Microbial Ecol, Mol Genet Lab, Faridabad 121001, IndiaAD  - All India Inst Med Sci, Dept Gastroenterol & Human Nutr, New Delhi, IndiaAD  - Oxford Univ Hosp, Translat Gastroenterol Unit, Oxford, EnglandAD  - WHO, Res Policy & Cooperat Unit, Communicable Dis Dept, Mahatma Gandhi Marg,Indraprastha Estate, New Delhi 110002, IndiaC3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - World Health OrganizationC3  - National Centre for Disease Control (NCDC)PU  - NATURE PORTFOLIO
PI  - BERLIN
PA  - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
DA  - JUL 4
PY  - 2018
VL  - 8
C7  - 10104
DO  - 10.1038/s41598-018-28550-3
AN  - WOS:000437249200031
ER  -

TY  - JOUR
AU  - Gupta, S
AU  - Rawat, S
AU  - Arora, V
AU  - Kottarath, SK
AU  - Dinda, AK
AU  - Vaishnav, PK
AU  - Nayak, B
AU  - Mohanty, S
TI  - An improvised one-step sucrose cushion ultracentrifugation method for exosome isolation from culture supernatants of mesenchymal stem cells
T2  - STEM CELL RESEARCH & THERAPY
KW  - Mesenchymal stem cells
KW  - Exosomes
KW  - Sucrose cushion ultracentrifugation
AB  - Background: Exosomes are nanovesicles (30-120 nm) of endosomal origin. These exosomes contain various functional proteins and RNAs that could be used for therapeutic purposes. Currently, having a standard method for exosome isolation retaining its biological properties with increased yield and purity is a major challenge. The most commonly used method is differential ultracentrifugation but it has its own disadvantages, which include high time consumption, low yield due to disruption of exosome integrity, and high protein contaminants. In this study, we have identified an improved method addressing these problems for exosome isolation using ultracentrifugation since it is cost-effective and used worldwide.
   Method: We have compared differential ultracentrifugation with the modified method called one-step sucrose cushion ultracentrifugation for exosome isolation. The conditioned serum-free media from human mesenchymal stem cells cultured for 48 h was collected for exosome isolation. The cellular debris was removed by centrifugation at 300g for 10 min, followed by centrifugation at 10,000g for 30 min to remove microvesicles. Equal volumes of pre-processed conditioned media were used for exosome isolation by direct ultracentrifugation and one-step sucrose cushion ultracentrifugation. The exosomes isolated using these methods were characterized for their size, morphology, concentration, and surface marker protein expression.
   Result: It was observed that the recovery of exosomes with cup-shaped morphology from one-step sucrose cushion ultracentrifugation was comparatively high as estimated by nanoparticle tracking analysis and electron microscopy. These results were confirmed by Western blotting and flow cytometry.
   Conclusion: We conclude that this one-step sucrose cushion ultracentrifugation method provides an effective and reproducible potential standard method which could be used for various starting materials for isolating exosomes. We believe that this method will have a wide application in the field of extracellular vesicle research where exosome isolation with high yield and purity is an imperative step.
AD  - All India Inst Med Sci, DBT Ctr Excellence Stem Cell Res, Stem Cell Facil, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Sophisticated Adv Instrument Facil, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaAD  - All India Inst Med Sci, Human Nutr Unit, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - BMC
PI  - LONDON
PA  - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - JUL 4
PY  - 2018
VL  - 9
C7  - 180
DO  - 10.1186/s13287-018-0923-0
AN  - WOS:000437301100005
ER  -

TY  - JOUR
AU  - Real, SAS
AU  - Parveen, F
AU  - Rehman, AU
AU  - Khan, MA
AU  - Deo, SVS
AU  - Shukla, NK
AU  - Husain, SA
TI  - Aberrant Promoter Methylation of YAP Gene and its Subsequent Downregulation in Indian Breast Cancer Patients
T2  - BMC CANCER
KW  - Downregulation
KW  - Hippo pathway
KW  - mRNA
KW  - Tumor suppressor gene
KW  - YAP
KW  - YES-ASSOCIATED PROTEIN
KW  - HIPPO PATHWAY
KW  - TUMOR-SUPPRESSOR
KW  - EXPRESSION
KW  - ONCOGENE
KW  - GENOMICS
KW  - CELLS
AB  - Background: YAP, a potent oncogene and major downstream effector of the mammalian Hippo tumor suppressor pathway can act as either oncogene or tumor suppressor gene based on the type of tissue involved. Despite various studies, the role and mechanism through which YAP mediates its tumor suppressor or oncogenic effects are not yet fully understood. Therefore in the present study we aimed to investigate YAP at DNA, mRNA and protein level and also attempted to correlate our molecular findings with various clinicopathological variables of the patients.
   Methods: The study comprised of a total 137 genetically unrelated women with sporadic breast cancer cases and normal adjacent tissues not infiltrated with tumor. Mutation of YAP gene was analyzed by automated DNA sequencing. YAP promoter methylation was studied using MS-PCR. Expression at mRNA and protein level was studied using qPCR and IHC respectively.
   Results: In our study YAP mRNA expression was found to be 8.65 +/- 6.17 fold downregulated in 67.15% cases. The expression of YAP when analyzed at the protein level by IHC was found to be absent in 78.83% cases. Results from MS-PCR analysis showed that YAP promoter methylation plays an important role in declining the expression of YAP protein. The absence of YAP protein coincided with 86.60% methylated cases thereby showing a very strong correlation (p = 0.001). We also investigated YAP mutation at the major check point sites in the Hippo pathway and observed no mutation. A significant association was observed on correlating mRNA expression with clinical stages (p = 0.038) and protein expression with ER status (p = 0.018) among Indian breast cancer patients.
   Conclusion: The expression of YAP was found to be downregulated in response to aberrant promoter methylation. The downregulation of YAP are consistent with previous studies suggesting it to have a tumor suppressive role in breast cancer. We did not observe any mutation at the major check point sites in the Hippo pathway.
AD  - Jamia Millia Islamia, Dept Biosci, New Delhi 110025, IndiaAD  - All India Inst Med Sci, Dept Surg Oncol, New Delhi 110608, IndiaC3  - Jamia Millia IslamiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - BMC
PI  - LONDON
PA  - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - JUL 3
PY  - 2018
VL  - 18
C7  - 711
DO  - 10.1186/s12885-018-4627-8
AN  - WOS:000437512200009
ER  -

TY  - JOUR
AU  - Aggarwal, M
AU  - Mirgh, S
AU  - Bansal, D
AU  - Totadri, S
TI  - Hepatic and Cardiac Iron Overload - Revising the Role of Deferiprone
T2  - INDIAN PEDIATRICS
KW  - THALASSEMIA MAJOR PATIENTS
AD  - All India Inst Med Sci, Dept Hematol, New Delhi, IndiaAD  - Postgrad Inst Med Educ & Res, Dept Pediat, Adv Pediat Ctr, Pediat Hematol Oncol Unit, Chandigarh, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUL
PY  - 2018
VL  - 55
IS  - 7
SP  - 557
EP  - 559
DO  - 10.1007/s13312-018-1296-2
AN  - WOS:000439806500002
ER  -

TY  - JOUR
AU  - Aggarwal, S
AU  - Ahuja, V
AU  - Paul, J
TI  - Dysregulation of GABAergic Signalling Contributes in the Pathogenesis of Diarrhea-predominant Irritable Bowel Syndrome
T2  - JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY
KW  - Cytokines
KW  - Gamma-aminobutyric acid
KW  - Inflammation
KW  - Irritable bowel syndrome
KW  - Lipopolysaccharides
KW  - GABA(B) RECEPTOR AGONIST
KW  - GAMMA-AMINOBUTYRIC-ACID
KW  - IMMUNE ACTIVATION
KW  - EXPRESSION
KW  - MODULATORS
KW  - SYMPTOMS
KW  - BACLOFEN
KW  - INHIBIT
KW  - CELLS
KW  - RATS
AB  - Background/Aims
   Diarrhea-predominant irritable bowel syndrome (IBS-D) is a prevalent functional bowel disorder. Abdominal pain, discomfort and altered intestinal habits are the salient features of IBS-D. Low grade inflammation and altered neurotransmitters are the 2 recently identified factors contributing to the pathogenesis of IBS-D, but their role and interactions has not been elucidated in detail. Here we investigate the potential role of gamma-aminobutyric acid (GABA) in regulating gut inflammation during IBS-D.
   Methods
   Blood samples and colonic mucosal biopsies from clinically diagnosed IBS-D patients and controls were collected. Levels of GABA were measured in serum samples through enzyme-linked immunosorbent assay (ELISA). Expression of GABAergic system and proinflammatory cytokines were analyzed in biopsy samples by reverse transcriptase polymerase chain reaction (RT-PCR). Effect of GABA and its antagonist on the expression of proinflammatory cytokines in lipopolysaccharide (LPS)-stimulated HT-29 cells was examined through RT-PCR.
   Results
   ELISA data revealed diminished level of GABA in IBS-D patients as compared to controls. RT-PCR analysis showed altered GABAergic signal system in IBS-D patients as compared to controls. GABA reduced the expression of proinflammatory cytokines in LPS stimulated HT-29 cells, whereas bicuculline methiodide (GABA antagonist) upregulated the expression of same cytokines in LPS stimulated HT-29 cells.
   Conclusions
   Our sets of data indicate that diminished level of GABA and altered GABAergic signal system contributes to pathogenesis of IBS-D by regulating inflammatory processes. These results provide novel evidence for anti-inflammatory role of GABA in IBS-D patients by altering the expression of pro-inflammatory cytokines.
AD  - Jawaharlal Nehru Univ, Sch Life Sci, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaC3  - Jawaharlal Nehru University, New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - KOREAN SOC NEUROGASTROENTEROLOGY & MOTILITY
PI  - GANGNAM-GU
PA  - RM 305, LOTTE GOLD ROSE VILL II, 31 SEOLLEUNG-RO 86-GIL, GANGNAM-GU, SEOUL 135-839, SOUTH KOREA
DA  - JUL
PY  - 2018
VL  - 24
IS  - 3
SP  - 422
EP  - 430
DO  - 10.5056/jnm17100
AN  - WOS:000439696400012
ER  -

TY  - JOUR
AU  - Alampalli, SV
AU  - Grover, M
AU  - Chandran, S
AU  - Tatu, U
AU  - Acharya, P
TI  - Proteome and Structural Organization of the Knob Complex on the Surface of the <i>Plasmodium</i> Infected Red Blood Cell
T2  - PROTEOMICS CLINICAL APPLICATIONS
KW  - cytoadhesion
KW  - knobs
KW  - malaria
KW  - modeling
KW  - Plasmodium falciparum
KW  - MEMBRANE PROTEIN-1 PFEMP1
KW  - STRUCTURE PREDICTION
KW  - FALCIPARUM
KW  - MALARIA
KW  - DOMAIN
KW  - BINDING
KW  - MESA
KW  - ANTIGEN
KW  - LIGAND
AB  - PurposeThe cell membrane of the erythrocytes infected with the malaria parasite Plasmodium falciparum undergoes several changes during the course of parasite life cycle and forms protrusions known as knobs' on its surface during the mature trophozoite and schizont stages. The structural organization of knob components especially PfEMP1 on the iRBC surface is the main determinant for the cytoadhesive and rosetting capacity of the iRBC by binding to various host receptors as well as for the variable antigenicity, which is crucial for immunoevasion. Although several studies report individual interactions among knob constituents, a comprehensive identification of the knob proteome is lacking.
   Experimental designThe detergent-resistant membrane (DRM) rafts are isolated from the infected erythrocyte membrane and knob (KAHRP) positive fractions are subjected to proteomics analysis. In addition, structures of various knob components are modeled and assembled ab initio based on experimentally established protein interactions.
   ResultsProteins of various functional classes are found to be present in the knobs including the newly identified knob constituents which include host Hsp70, elongation factor 1A, acyl CoA synthetase, and some hypothetical proteins. Ab initio structural prediction of PfEMP1, KHARP, PfEMP2, PfEMP3, and PHIST shows that these proteins are intrinsically disordered and can have varying number of protein-protein interactions depending on their lowest energy structure. Further in silico mathematical modeling of a single repeat unit of PfEMP1-PHIST is present 63-112 times along the periphery of a single knob.
   Conclusions and clinical relevanceThis study provides structural insight into the organization of the core knob components and uncovers novel proteins as knob components. This structural information can be used for the development of better vaccine design strategies or drug design to destabilize the knob structure, which is a major virulence determinant in P. falciparum malaria.
AD  - Indian Inst Sci, Dept Biochem, Bangalore, Karnataka, IndiaAD  - All India Inst Med Sci, Dept Biochem, New Delhi, IndiaC3  - Indian Institute of Science (IISC) - BangaloreC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY-V C H VERLAG GMBH
PI  - WEINHEIM
PA  - POSTFACH 101161, 69451 WEINHEIM, GERMANY
DA  - JUL
PY  - 2018
VL  - 12
IS  - 4
C7  - 1600177
DO  - 10.1002/prca.201600177
AN  - WOS:000438731400004
ER  -

TY  - JOUR
AU  - Ambekar, A
AU  - Rao, R
AU  - Agrawal, A
AU  - Kathiresan, P
TI  - Research on opioid substitution therapy in India: A brief, narrative review
T2  - INDIAN JOURNAL OF PSYCHIATRY
KW  - Buprenorphine
KW  - methadone
KW  - opioid dependence
KW  - opioid substitution treatment
KW  - MAINTENANCE TREATMENT
KW  - SUBLINGUAL BUPRENORPHINE
KW  - DEPENDENCE SYNDROME
KW  - AGONIST
AB  - Opioid dependence is a significant clinical and public health issue in India. Opioid substitution therapy (OST) is the most evidence-based treatment for opioid dependence. Although available in India for about three decades now, Indian research on this treatment modality has not been adequately reviewed so far. We conducted a narrative review of Indian research on OST. We conducted an online search for relevant literature in the peer-reviewed journals as well as the general online search for books and monographs. We present the findings of the review in the form of description of literature according to certain identified themes. Considering that methadone has became available in India, only recently, the Indian research on OST predominantly features buprenorphine as the agent. Effectiveness of OST among Indian opioid-dependent patients has been well established through prospective, experimental designs as well as through naturalistic studies using retrospective, chart-review approach. Naturalistic and observational postmarketing surveillance studies have demonstrated the safety of buprenorphine and methadone when used as OST. There are certain areas in which more research on OST will be beneficial for Indian clinicians as well as policy-makers. However, the quantum of evidence base that exists in India is more than adequate to justify the scale-up of this modality of treatment. A conducive policy environment for scaling-up OST is need of the hour.
AD  - All India Inst Med Sci, Natl Drug Dependence Treatment Ctr, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)PU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
DA  - JUL-SEP
PY  - 2018
VL  - 60
IS  - 3
SP  - 265
EP  - 270
DO  - 10.4103/psychiatry.IndianJPsychiatry_385_18
AN  - WOS:000447749800003
ER  -

TY  - JOUR
AU  - Arif, N
AU  - Rawre, J
AU  - Patra, S
AU  - Sreenivas, V
AU  - Khanna, N
AU  - Dhawan, B
TI  - Increase in prevalence of <i>Ureaplasma</i> spp. in patients with genital tract infections in a tertiary care hospital of North India
T2  - INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY
KW  - CHLAMYDIA-TRACHOMATIS
KW  - MYCOPLASMA
KW  - PARVUM
AD  - All India Inst Med Sci, Dept Microbiol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Dermatol & Venerol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-AUG
PY  - 2018
VL  - 84
IS  - 4
SP  - 457
EP  - +
C7  - PMID 29770783
DO  - 10.4103/ijdvl.IJDVL_862_17
AN  - WOS:000436616500019
ER  -

TY  - JOUR
AU  - Arora, NK
AU  - Nair, MKC
AU  - Gulati, S
AU  - Deshmukh, V
AU  - Mohapatra, A
AU  - Mishra, D
AU  - Patel, V
AU  - Pandey, RM
AU  - Das, BC
AU  - Divan, G
AU  - Murthy, GVS
AU  - Sharma, TD
AU  - Sapra, S
AU  - Aneja, S
AU  - Juneja, M
AU  - Reddy, SK
AU  - Suman, P
AU  - Mukherjee, SB
AU  - Dasgupta, R
AU  - Tudu, P
AU  - Das, MK
AU  - Bhutani, VK
AU  - Durkin, MS
AU  - Pinto-Martin, J
AU  - Silberberg, DH
AU  - Sagar, R
AU  - Ahmed, F
AU  - Babu, N
AU  - Bavdekar, S
AU  - Chandra, V
AU  - Chaudhuri, Z
AU  - Dada, T
AU  - Dass, R
AU  - Gourie-Devi, M
AU  - Remadevi, S
AU  - Gupta, JC
AU  - Handa, KK
AU  - Kalra, V
AU  - Karande, S
AU  - Konanki, R
AU  - Kulkarni, M
AU  - Kumar, R
AU  - Maria, A
AU  - Masoodi, MA
AU  - Mehta, M
AU  - Mohanty, SK
AU  - Nair, H
AU  - Natarajan, P
AU  - Niswade, AK
AU  - Prasad, A
AU  - Rai, SK
AU  - Russell, PSS
AU  - Saxena, R
AU  - Sharma, S
AU  - Singh, AK
AU  - Singh, GB
AU  - Sumaraj, L
AU  - Suresh, S
AU  - Thakar, A
AU  - Parthasarathy, S
AU  - Vyas, B
AU  - Panigrahi, A
AU  - Saroch, MK
AU  - Shukla, R
AU  - Rao, KVR
AU  - Silveira, MP
AU  - Singh, S
AU  - Vajaratkar, V
TI  - Neurodevelopmental disorders in children aged 2-9 years: Population-based burden estimates across five regions in India
T2  - PLOS MEDICINE
KW  - INCLEN DIAGNOSTIC-TOOL
KW  - AUTISM SPECTRUM DISORDER
KW  - 10 QUESTIONS SCREEN
KW  - CHILDHOOD DISABILITY
KW  - VISUAL-ACUITY
KW  - DEVELOPING-COUNTRIES
KW  - CEREBRAL-PALSY
KW  - PREVALENCE
KW  - EPILEPSY
KW  - IMPAIRMENT
AB  - Background
   Neurodevelopmental disorders (NDDs) compromise the development and attainment of full social and economic potential at individual, family, community, and country levels. Paucity of data on NDDs slows down policy and programmatic action in most developing countries despite perceived high burden.
   Methods and findings
   We assessed 3,964 children (with almost equal number of boys and girls distributed in 2-< 6 and 6-9 year age categories) identified from five geographically diverse populations in India using cluster sampling technique (probability proportionate to population size). These were from the North-Central, i.e., Palwal (N = 998; all rural, 16.4% non-Hindu, 25.3% from scheduled caste/tribe [SC-ST] [these are considered underserved communities who are eligible for affirmative action]); North, i.e., Kangra (N = 997; 91.6% rural, 3.7% non-Hindu, 25.3% SC-ST); East, i.e., Dhenkanal (N = 981; 89.8% rural, 1.2% non-Hindu, 38.0% SC-ST); South, i.e., Hyderabad (N = 495; all urban, 25.7% non-Hindu, 27.3% SC-ST) and West, i.e., North Goa (N = 493; 68.0% rural, 11.4% non-Hindu, 18.5% SC-ST). All children were assessed for vision impairment (VI), epilepsy (Epi), neuromotor impairments including cerebral palsy (NMI-CP), hearing impairment (HI), speech and language disorders, autism spectrum disorders (ASDs), and intellectual disability (ID). Furthermore, 6-9-year-old children were also assessed for attention deficit hyperactivity disorder (ADHD) and learning disorders (LDs). We standardized sample characteristics as per Census of India 2011 to arrive at district level and all-sites-pooled estimates. Site-specific prevalence of any of seven NDDs in 2-< 6 year olds ranged from 2.9% (95% CI 1.6-5.5) to 18.7% (95% CI 14.7-23.6), and for any of nine NDDs in the 6-9-year-old children, from 6.5% (95% CI 4.6-9.1) to 18.5% (95% CI 15.3-22.3). Two or more NDDs were present in 0.4% (95% CI 0.1-1.7) to 4.3% (95% CI 2.2-8.2) in the younger age category and 0.7% (95% CI 0.2-2.0) to 5.3% (95% CI 3.3-8.2) in the older age category. All-site-pooled estimates for NDDs were 9.2% (95% CI 7.5-11.2) and 13.6% (95% CI 11.3-16.2) in children of 2-<6 and 6-9 year age categories, respectively, without significant difference according to gender, rural/urban residence, or religion; almost one-fifth of these children had more than one NDD. The pooled estimates for prevalence increased by up to three percentage points when these were adjusted for national rates of stunting or low birth weight (LBW). HI, ID, speech and language disorders, Epi, and LDs were the common NDDs across sites. Upon risk modelling, noninstitutional delivery, history of perinatal asphyxia, neonatal illness, postnatal neurological/brain infections, stunting, LBW/prematurity, and older age category (6-9 year) were significantly associated with NDDs. The study sample was underrepresentative of stunting and LBW and had a 15.6% refusal. These factors could be contributing to underestimation of the true NDD burden in our population.
   Conclusions
   The study identifies NDDs in children aged 2-9 years as a significant public health burden for India. HI was higher than and ASD prevalence comparable to the published global literature. Most risk factors of NDDs were modifiable and amenable to public health interventions.
AD  - INCLEN Trust Int, New Delhi, IndiaAD  - Kerala Univ Hlth Sci, Med Coll PO, Trichur, Kerala, IndiaAD  - All India Inst Med Sci, Dept Paediat, New Delhi, IndiaAD  - Maulana Azad Med Coll, Dept Paediat, New Delhi, IndiaAD  - Sangath, Bardez, Goa, IndiaAD  - Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA USAAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - Kalinga Inst Med Sci, Dept Community Med, Bhubaneswar, Odisha, IndiaAD  - Indian Inst Publ Hlth, Hyderabad, Telangana, IndiaAD  - Himachal Fdn, Kangra, Himachal Prades, IndiaAD  - Lady Hardinge Med Coll & Hosp, Dept Paediat, New Delhi, IndiaAD  - Ctr Appl Res & Educ Neurodev Impairments & Disabi, New Delhi, IndiaAD  - Sir Ganga Ram Hosp, Dept Paediat, New Delhi, IndiaAD  - Jawaharlal Nehru Univ, Dept Social Med & Community Hlth, New Delhi, IndiaAD  - Stanford Univ, Dept Paediat, Sch Med, Stanford, CA 94305 USAAD  - Lucile Packard Childrens Hosp, Palo Alto, CA USAAD  - Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci & Paediat, Madison, WI USAAD  - Univ Wisconsin, Waisman Ctr, Sch Med & Publ Hlth, Madison, WI 53705 USAAD  - Univ Penn, Sch Nursing, Philadelphia, PA 19104 USAAD  - Univ Penn, Sch Med, Philadelphia, PA 19104 USAAD  - Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USAAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - Integral Univ, Integral Inst Med Sci & Res, Lucknow, Uttar Pradesh, IndiaAD  - Delhi Univ, Dept Psychol, New Delhi, IndiaAD  - Seth GS Med Coll & KEM Hosp, Dept Paediat, Bombay, Maharashtra, IndiaAD  - Paras Hosp, Dept Neurol, Gurugram, Haryana, IndiaAD  - Lady Hardinge Med Coll & Hosp, Dept Ophthalmol, New Delhi, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaAD  - Hlth City Hosp, Dept Paediat Disciplines, Gauhati, Assam, IndiaAD  - Sir Ganga Ram Hosp, Dept Neurol, Inst Human Behav & Allied Sci, New Delhi, IndiaAD  - Sir Ganga Ram Hosp, Dept Neurophysiol, New Delhi, IndiaAD  - Kerala Univ Hlth Sci, Sch Hlth Policy & Planning, Thiruvananthapuram, Kerala, IndiaAD  - Ali Yavar Jung Natl Inst Speech & Hearing Disabil, Dept Empowerment Persons Disabil, New Delhi, IndiaAD  - Medanta Medicity, Dept ENT & Head Neck Surg, Gurugram, Haryana, IndiaAD  - Indraprastha Apollo Hosp, Dept Paediat, New Delhi, IndiaAD  - Rainbow Childrens Hosp, Dept Paediat Neurol, Hyderabad, Telangana, IndiaAD  - Mumbai Port Trust Hosp, Dept Paediat, Bombay, Maharashtra, IndiaAD  - King George Med Univ, Dept Paediat, Lucknow, Uttar Pradesh, IndiaAD  - Post Grad Inst Med Educ & Res, Dept Neonatol, Delhi, IndiaAD  - Dr Ram Manohar Lohia Hosp, Delhi, IndiaAD  - Govt Med Coll, Dept Community Med, Srinagar, Kashmir, IndiaAD  - Govt India, Natl Trust, Dept Empowerment Persons Disabil, Minist Social Justice & Empowerment, Delhi, IndiaAD  - Vidya Sagar, Madras, Tamil Nadu, IndiaAD  - Govt Med Coll, Dept Paediat, Nagpur, Maharashtra, IndiaAD  - Govt Bihar, Social Welf Dept, Patna, Bihar, IndiaAD  - All India Inst Med Sci, Dept Community Med, New Delhi, IndiaAD  - Christian Med Coll & Hosp, Dept Child & Adolescent Psychiat, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp, Facil Children Intellectual Disabil, Vellore, Tamil Nadu, IndiaAD  - Nirman Bhawan, Minist Hlth & Family Welf, Rashtriya Bal Swasthya Karyakram, New Delhi, IndiaAD  - Lady Hardinge Med Coll & Hosp, Dept Otorhinolaryngol & Head & Neck Surg ENT, New Delhi, IndiaAD  - Child Dev Ctr, Med Coll Campus, Thiruvananthapuram, Kerala, IndiaAD  - Samarth, Madras, Tamil Nadu, IndiaAD  - All India Inst Med Sci, Dept Otolaryngol & Head Neck Surg, New Delhi, IndiaAD  - Hosp Sick Children SickKids, Peter Gilgan Ctr Res & Learning, Dept Pediat Neurol, Toronto, ON, CanadaAD  - MP Shah Govt Med Coll, Dept Paediat, Jamnagar, Gujarat, IndiaAD  - GG Hosp, Jamnagar, Gujarat, IndiaAD  - Dr Rajender Prasad Govt Med Coll, Dept ENT, Kangra, Himachal Prades, IndiaAD  - RVM Inst Med Sci & Res Ctr, Laxmakkapally, Telangana, IndiaAD  - Goa Med Coll, Dept Paediat, Bambolim, Goa, IndiaAD  - Goa Med Coll, Dept Orthoped Surg, Bambolim, Goa, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Maulana Azad Medical CollegeC3  - Harvard UniversityC3  - Harvard Medical SchoolC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Kalinga Institute of Industrial Technology (KIIT)C3  - Lady Hardinge Medical College & HospitalC3  - Jawaharlal Nehru University, New DelhiC3  - Stanford UniversityC3  - Lucile Packard Children's Hospital (LPCH)C3  - University of Wisconsin SystemC3  - University of Wisconsin MadisonC3  - University of Wisconsin SystemC3  - University of Wisconsin MadisonC3  - University of PennsylvaniaC3  - University of PennsylvaniaC3  - University of PennsylvaniaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Integral UniversityC3  - University of DelhiC3  - Seth Gordhandas Sunderdas Medical College & King Edward Memorial HospitalC3  - Lady Hardinge Medical College & HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - King George's Medical UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Lady Hardinge Medical College & HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - Goa Medical College & HospitalC3  - Goa Medical College & HospitalPU  - PUBLIC LIBRARY SCIENCE
PI  - SAN FRANCISCO
PA  - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
DA  - JUL
PY  - 2018
VL  - 15
IS  - 7
C7  - e1002615
DO  - 10.1371/journal.pmed.1002615
AN  - WOS:000440339700022
ER  -

TY  - JOUR
AU  - Bagra, I
AU  - Krishnan, V
AU  - Rao, R
AU  - Agrawal, A
TI  - Does Cannabis Use Influence Opioid Outcomes and Quality of Life Among Buprenorphine Maintained Patients? A Cross-sectional, Comparative Study
T2  - JOURNAL OF ADDICTION MEDICINE
KW  - buprenorphine
KW  - cannabis use
KW  - opioid agonist treatment
KW  - ILLICIT DRUG-USE
KW  - SELF-DETOXIFICATION
KW  - OPIATE ADDICTS
KW  - HEROIN USE
KW  - METHADONE
KW  - PREDICTORS
KW  - RETENTION
KW  - DRINKING
KW  - THERAPY
KW  - ALCOHOL
AB  - Objectives: Use of various psychoactive substances can influence outcomes of patients on opioid agonist treatment (OAT). While use of alcohol and cocaine has shown to adversely affect OAT results, associated cannabis use shows mixed results. This study aimed to assess the pattern of cannabis use among opioid-dependent patients maintained on buprenorphine. Additionally, the study compared the dose of buprenorphine, opioid-related craving and withdrawals, productivity, and also quality of life between those with and without recent (past 90-day) cannabis use.
   Methods: We collected data on demographic and drug use details in 100 randomly selected adult male patients attending a community drug treatment clinic, who were stabilized on buprenorphine for more than 3 months. Other measures included scores on World Health Organization (WHO)-Alcohol, Smoking and Substance Involvement Screening Tool and WHO-Quality of Life-Brief (WHOQOL-Bref) version.
   Results: The average duration of maintenance treatment with buprenorphine was 96 months, with excellent compliance for buprenorphine (86.92 +/- 9.58 days in 90 days). Thirty-five per cent had used cannabis in past 90 days, with lifetime use of cannabis in 77%. Participants using cannabis currently were on lower doses of buprenorphine (mean dose per day: 7.9 mg vs 8.9 mg; P = 0.04). Yet, there was no significant difference in the rates of opioid use or opioid withdrawals and craving between the 2 groups. Compliance to OAT, number of days of employment, daily earning, and WHOQOL-Bref scores in all domains were comparable between those with and without cannabis use. Duration of cannabis use, current use of alcohol, and dose of buprenorphine predicted current cannabis use in multivariable logistic regression analysis.
   Conclusions: Cannabis use does not negatively influence opioid outcomes among patients receiving buprenorphine maintenance treatment. There is no difference in productivity and quality of life between individuals maintained on buprenorphine with and without current cannabis use.
AD  - All India Inst Med Sci, New Delhi, IndiaAD  - Western Sydney Local Hlth Dist, North Parramatta, NSW, AustraliaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Western NSW Local Health DistrictPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - JUL-AUG
PY  - 2018
VL  - 12
IS  - 4
SP  - 315
EP  - 320
DO  - 10.1097/ADM.0000000000000406
AN  - WOS:000448416100011
ER  -

TY  - JOUR
AU  - Bansal, D
AU  - Seth, T
AU  - Kumar, R
AU  - Saxena, R
AU  - Mishra, P
AU  - Xess, I
TI  - Efficacy of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Induction Chemotherapy: An Observational Study in Resource Limited Settings
T2  - INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
KW  - Antifungals
KW  - Triazoles
KW  - Prophylaxis
KW  - Neutropenia
KW  - Invasive fungal infections
KW  - PRIMARY ANTIFUNGAL PROPHYLAXIS
KW  - FUNGAL-INFECTIONS
KW  - MARROW-TRANSPLANTATION
KW  - CLINICAL EFFECTIVENESS
KW  - FLUCONAZOLE
AB  - Large randomized controlled trials have shown significant decrease in incidence of invasive fungal infection in acute myeloid leukemia patients with Posaconazole prophylaxis. However, very less is known about value of Posaconazole prophylaxis in resource limited settings. This observational cohort study evaluated the incidence of fungal infection in patients with hematological malignancies undergoing induction chemotherapy with Posaconazole as antifungal prophylaxis and was compared with historical controls who received Fluconazole as fungal prophylaxis. The study was conducted from Oct 2013 to July 2015 in Department of Hematology of a tertiary care center. Fifty-three patients of acute myeloid leukemia on Posaconazole as fungal prophylaxis and 53 historical controls on Fluconazole as fungal prophylaxis were included for final analysis. Baseline characteristics were well matched between groups. Patients on Fluconazole were more likely to experience breakthrough IFDs (28.3 and 11.3%; p = 0.028) than in patients receiving Posaconazole prophylaxis. No significant difference was observed in overall, attributable mortality or in shift to first line antifungal. Both Posaconazole and Fluconazole were well tolerated with no major adverse effects requiring discontinuation of the drug. Minor side effects were seen in 39 and 47% patients in study and control group respectively. Vomiting and nausea were the commonest side effects seen in both study and control group (26 vs. 34% and 38 vs. 40% of patients, respectively). The results of our study in patients with acute myeloid leukemia provide evidence that Posaconazole prophylaxis significantly decreases the incidence of fungal infection and is well tolerated.
AD  - All India Inst Med Sci, Dept Hematol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUL
PY  - 2018
VL  - 34
IS  - 3
SP  - 460
EP  - 465
DO  - 10.1007/s12288-018-0916-2
AN  - WOS:000441120900009
ER  -

TY  - JOUR
AU  - Berrocal, I
AU  - Peix, A
AU  - Mut, F
AU  - Shaw, LJ
AU  - Karthikeyan, G
AU  - Lobato, EE
AU  - Paez, D
TI  - Appropriate use of noninvasive ischemia testing to guide revascularization decision making following acute ST elevation myocardial infarction in Latin American countries: Results from an expert panel meeting of the International Atomic Energy Agency
T2  - REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
KW  - Multivessel disease
KW  - Percutaneous coronary intervention
KW  - ST-segment elevation myocardial infarction
KW  - Gated-SPECT myocardial perfusion imaging
KW  - CORONARY-ARTERY-DISEASE
KW  - FRACTIONAL FLOW RESERVE
KW  - CARDIAC MAGNETIC-RESONANCE
KW  - NUCLEAR CARDIOLOGY
KW  - MEDICAL THERAPY
KW  - DIAGNOSTIC PERFORMANCE
KW  - VENTRICULAR-FUNCTION
KW  - NONCULPRIT STENOSIS
KW  - COMPUTED-TOMOGRAPHY
KW  - PERFUSION
AB  - Across Latin American and Caribbean countries, cardiovascular disease and especially ischemic heart disease is currently the main cause of death both in men and in women. For most Latin American and Caribbean countries, public and community health efforts aim to define care strategies which are both clinically and cost effective and promote primary and secondary prevention, resulting in improved patient outcomes. The optimal approach to deal with acute events such as ST-elevation myocardial infarction (STEMI) is a matter of controversy; however, there is an expanding role for assessing residual ischemic burden in STEMI patients following primary percutaneous coronary intervention. Although randomized clinical trials have established the value of staged fractional flow reserve-guided revascularization, the use of noninvasive functional imaging modalities may play a similar role at a much lower cost. For LAC, available stress imaging techniques could be applied to define residual ischemia in the non-infarct related artery and to target revascularization in a staged procedure after primary percutaneous coronary intervention The use of nuclear cardiac imaging, supported by its relatively wide availability, moderate cost, and robust quantitative capabilities, may serve to guide effective care and to reduce subsequent cardiac events in patients with coronary artery disease. This noninvasive approach may avert potential safety issues with repeat and lengthy invasive procedures, and serve as a baseline for subsequent follow-up stress testing following the index STEMI event. This consensus document was devised from an expert panel meeting of the International Atomic Energy Agency, highlighting available evidence with a focus on the utility of stress myocardial perfusion imaging in post-STEMI patients. The document could serve as guidance to the prudent and appropriate use of nuclear imaging for targeting therapeutic management and avoiding unnecessary invasive procedures within Latin American and Caribbean countries, where resources could be scarce. (C) 2018 Published by Elsevier Espana, S.L.U.
AD  - Hosp San Juan Dios, San Jose, Costa RicaAD  - Inst Cardiol, Dept Med Nucl, Havana, CubaAD  - Hosp Asociac Espanola, Montevideo, UruguayAD  - Emory Clin Cardiovasc Res Inst, Atlanta, GA USAAD  - All India Inst Med Sci, New Delhi, IndiaAD  - IAEA, Viena, AustriaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - International Atomic Energy AgencyPU  - ELSEVIER ESPANA SLU
PI  - BARCELONA
PA  - AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN
DA  - JUL-AUG
PY  - 2018
VL  - 37
IS  - 4
SP  - 237
EP  - 243
DO  - 10.1016/j.remn.2018.01.005
AN  - WOS:000439013700007
ER  -

TY  - JOUR
AU  - Bhatt, SP
AU  - Misra, A
AU  - Gulati, S
AU  - Singh, N
AU  - Pandey, RM
TI  - Lower vitamin D levels are associated with higher blood glucose levels in Asian Indian women with pre-diabetes: a population-based cross-sectional study in North India
T2  - BMJ OPEN DIABETES RESEARCH & CARE
KW  - INSULIN-RESISTANCE
KW  - D SUPPLEMENTATION
KW  - ABDOMINAL OBESITY
KW  - GLYCEMIC CONTROL
KW  - D INSUFFICIENCY
KW  - INDIVIDUALS
KW  - PROGRESSION
KW  - PREVALENCE
KW  - DEFICIENCY
KW  - TOLERANCE
AB  - Background Asian Indian women are predisposed to develop obesity, metabolic syndrome and vitamin D deficiency. Relationship of vitamin D deficiency with blood glucose levels has not been explored in Asian Indian women with pre-diabetes.
   Objective We evaluated the associations of serum 25-hydroxy vitamin D (25(OH) D) concentrations among adult women with the pre-diabetes residing in North India (Delhi).
   Methods This cross-sectional population-based study involved 797 women with pre-diabetes aged 20-60 years. Blood pressure, body mass index (BMI), fasting blood glucose (FBG), extent of sun exposure and serum 25(OH) D levels were assessed. For purpose of analysis, serum 25(OH) D levels (nmol/L) were categorized in quintiles as follows: 0-21.5 (first quintile), 21.51-35.60 (second quintile), 35.61-46.50 (third quintile), 46.51-62.30 (fourth quintile) and >62.31 (fifth quintile).
   Result The prevalence (%) of vitamin D deficiency, insufficiency and sufficiency was 68.6, 25.9 and 5.5, respectively. Mean age (p=0.004), systolic (p=0.05) and diastolic (p=0.04) blood pressure, weight (p=0.03), BMI (p=0.04) and FBG (p=0.02) were significantly higher in subjects with vitamin D deficiency as compared with those with vitamin D insufficiency and sufficiency. Unadjusted mean values of FBG were significantly decreased in fourth (p=0.02) and fifth quintiles (p=0.030) of 25(OH) D levels as compared with second quintile. Furthermore, after adjusting for age and family income FBG levels were significantly increased in first quintile (compared with fourth (p=0.012) and fifth (p=0.018) quintiles) and second quintile (compared with fourth (p=0.003) and fifth (p=0.004) quintiles) of 25(OH) D levels, respectively.
   Conclusion Lower vitamin D levels are associated with higher blood glucose values in Asian Indian women with pre-diabetes. These findings need confirmation in case-control and prospective studies.
AD  - Diabet Fdn India, Safdarjung Dev Area, New Delhi, IndiaAD  - Natl Diabet Obes & Cholesterol Fdn N DOC, Safdarjung Dev Area, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pulm Med & Sleep Disorders, New Delhi, IndiaAD  - Fortis C DOC Ctr Excellence Diabet Metab Dis & En, New Delhi, IndiaAD  - All India Inst Med Sci, Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - BMJ PUBLISHING GROUP
PI  - LONDON
PA  - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
DA  - JUL
PY  - 2018
VL  - 6
IS  - 1
C7  - e000501
DO  - 10.1136/bmjdrc-2017-000501
AN  - WOS:000439045100022
ER  -

TY  - JOUR
AU  - Bresee, J
AU  - Fitzner, J
AU  - Campbell, H
AU  - Cohen, C
AU  - Cozza, V
AU  - Jara, J
AU  - Krishnan, A
AU  - Lee, V
A1  - WHO Working Grp Burden Influenza
TI  - Progress and Remaining Gaps in Estimating the Global Disease Burden of Influenza
T2  - EMERGING INFECTIOUS DISEASES
KW  - SEASONAL INFLUENZA
KW  - VACCINATION
KW  - VACCINES
KW  - MORTALITY
KW  - OUTCOMES
KW  - CHILDREN
KW  - AREAS
AB  - Influenza has long been a global public health priority because of the threat of another global pandemic. Although data are available for the annual burden of seasonal influenza in many developed countries, fewer disease burden data are available for low-income and tropical countries. In recent years, however, the surveillance systems created as part of national pandemic preparedness efforts have produced substantial data on the epidemiology and impact of influenza in countries where data were sparse. These data are leading to greater interest in seasonal influenza, including implementation of vaccination programs. However, a lack of quality data on severe influenza, nonrespiratory outcomes, and high-risk groups, as well as a need for better mathematical models and economic evaluations, are some of the major gaps that remain. These gaps are the focus of multilateral research and surveillance efforts that will strengthen global efforts in influenza control in the future.
AD  - Ctr Dis Control & Prevent, Global Hlth Affairs Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USAAD  - WHO, Geneva, SwitzerlandAD  - Univ Edinburgh, Edinburgh, Midlothian, ScotlandAD  - Natl Inst Communicable Dis, Johannesburg, South AfricaAD  - Univ Valle Guatemala, Guatemala City, GuatemalaAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Minist Hlth, Singapore, SingaporeC3  - Centers for Disease Control & Prevention - USAC3  - CDC National Center for Immunization & Respiratory Diseases (NCIRD)C3  - World Health OrganizationC3  - University of EdinburghC3  - National Institute for Communicable Diseases (NICD)C3  - Universidad del Valle de GuatemalaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Ministry of Health-SingaporePU  - CENTERS  DISEASE CONTROL & PREVENTION
PI  - ATLANTA
PA  - 1600 CLIFTON RD, ATLANTA, GA 30333 USA
DA  - JUL
PY  - 2018
VL  - 24
IS  - 7
SP  - 1173
EP  - 1177
DO  - 10.3201/eid2407.171270
AN  - WOS:000435635900001
ER  -

TY  - JOUR
AU  - Chaudhry, R
AU  - Sreenath, K
AU  - Agrawal, SK
AU  - Valavane, A
TI  - <i>Legionella</i> and Legionnaires' Disease: Time to Explore in India
T2  - INDIAN JOURNAL OF MEDICAL MICROBIOLOGY
KW  - Legionella
KW  - Legionnaires' disease
KW  - pneumonia
KW  - COMMUNITY-ACQUIRED PNEUMONIA
KW  - POLYMERASE-CHAIN-REACTION
KW  - PNEUMOPHILA SEROGROUP 1
KW  - BIOFILM FORMATION
KW  - WATER-SYSTEM
KW  - PCR ASSAY
KW  - DIAGNOSIS
KW  - GROWTH
KW  - TEMPERATURE
KW  - INFECTION
AB  - Legionella pneumophila was first recognised as a fatal cause of pneumonia more than four decades ago, during the 1976-American Legion convention in Philadelphia, USA. Legionella spp. continue to cause disease outbreaks of public health significance, and at present, Legionnaires' disease (LD) has emerged as an important cause of community and hospital-acquired pneumonia. Parallel to this, the understanding of LD has also increased exponentially. However, the disease is likely to be underreported in many countries because of the dearth of common definitions, diagnostic tests and active surveillance systems. In this review, we outline the basic concepts of Legionella including clinical presentations, epidemiology, laboratory diagnosis and the status of LD in India. This article also summarises the progress of research related to Legionella in this country, identifying the research gaps and discussing priorities to explore this unexplored pathogen in India.
AD  - All India Inst Med Sci, Dept Microbiol, New Delhi 110029, IndiaAD  - Indira Gandhi Med Coll & Res Inst, Dept Microbiol, Pondicherry, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - JUL-SEP
PY  - 2018
VL  - 36
IS  - 3
SP  - 324
EP  - 333
DO  - 10.4103/ijmm.IJMM_18_298
AN  - WOS:000450218100004
ER  -

TY  - JOUR
AU  - Chauhan, M
AU  - Behera, C
AU  - Madireddi, S
AU  - Mandal, S
AU  - Khanna, SK
TI  - Sudden death due to an invasive mole in a young primigravida: Precipitous presentation masquerading the natural manner
T2  - MEDICINE SCIENCE AND THE LAW
KW  - Invasive mole
KW  - sudden death
KW  - pulmonary metastasis
KW  - haemoptysis
AB  - Pulmonary metastasis is a well-known complication of an invasive mole. However, sudden death due to haemoptysis resulting from a metastatic invasive mole is extremely rare. We report the sudden unexpected death of an 18-year-old primigravida following a molar pregnancy. The death event was complicated within a few days of presentation by a clinically unsuspected mole invading the lung vasculature with associated widespread metastatic calcifications in the liver and brain. Death was due to haemorrhagic shock as a result of massive haemoptysis resulting from the invasive mole metastasising to the pulmonary vasculature. This was substantiated with a post-mortem computed tomography and gross and histopathological findings at autopsy. This case highlights the need for a high index of suspicion about potentially life-threatening pulmonary metastasis in women with trophoblastic diseases.
AD  - Shree Guru Gobind Singh Tricentenary Univ, Dept Forens Med, Gurugram 122505, Haryana, IndiaAD  - All India Inst Med Sci, Dept Forens Med, New Delhi, IndiaAD  - Maulana Azad Med Coll, Dept Forens Med, New Delhi, IndiaAD  - Maulana Azad Med Coll, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Maulana Azad Medical CollegeC3  - Maulana Azad Medical CollegePU  - SAGE PUBLICATIONS INC
PI  - THOUSAND OAKS
PA  - 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
DA  - JUL
PY  - 2018
VL  - 58
IS  - 3
SP  - 189
EP  - 193
DO  - 10.1177/0025802418786120
AN  - WOS:000440022200009
ER  -

TY  - JOUR
AU  - Chauhan, S
AU  - Sen, S
AU  - Sharma, A
AU  - Kashyap, S
AU  - Tandon, R
AU  - Pushker, N
AU  - Vanathi, M
AU  - Chauhan, SS
TI  - Loss of pRB in Conjunctival Squamous Cell Carcinoma: A Predictor of Poor Prognosis
T2  - APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
KW  - eye
KW  - conjunctiva
KW  - SCC
KW  - IHC
KW  - cell cycle regulatory protein (p16(INK4a), pRb, Cyclin D1)
KW  - RETINOBLASTOMA PROTEIN
KW  - HUMAN-PAPILLOMAVIRUS
KW  - REGULATORY PROTEINS
KW  - P16 GENE
KW  - EXPRESSION
KW  - P16(INK4A)
KW  - BREAST
KW  - CANCER
KW  - HYPERPHOSPHORYLATION
KW  - OVEREXPRESSION
AB  - Conjunctival squamous cell carcinoma (SCC) is the most common tumor of conjunctival epithelium. It is associated with risk of permanent visual impairment and has the capability to recur, metastasize, and cause death. Deregulation of cell cycle control has been reported in a number of malignancies. The aim of the present study was to assess expression of G1/S cell cycle regulatory proteins [retinoblastoma protein (pRb)/P16(INK4a)/cyclin D1] in conjunctival SCC. Forty-four prospective cases of conjunctival SCC from a tertiary eye care referral center in northern India were included in this study. American Joint Committee on Cancer (AJCC) staging was performed and patients were followed up for 46 +/- 3.2 months. pRb loss was seen in 87% and overexpression of p16(INK4a) and cyclin D1 in 36% and 66%, respectively. Kaplan-Meier analysis revealed reduced disease-free survival in patients with pRb loss (P = 0.006). On univariate analysis, pRb loss (P = 0.02), orbital invasion (P = 0.03), and AJCC stage >= T3 (P = 0.03) emerged as significant high-risk features. On multivariate analysis pRb loss emerged as the most significant poor prognostic indicator in conjunctival SCC cases. Our findings suggest pRb loss to be a useful indicator of aggressive behavior and is recommended for identifying high-risk conjunctival SCC patients.
AD  - All India Inst Med Sci, Dept Ocular Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Ocular Microbiol, New Delhi, IndiaAD  - All India Inst Med Sci, Cornea & Ocular Surface Serv, New Delhi, IndiaAD  - All India Inst Med Sci, Ophthalmoplasty Serv, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biochem, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - JUL
PY  - 2018
VL  - 26
IS  - 6
SP  - E70
EP  - E76
DO  - 10.1097/PAI.0000000000000592
AN  - WOS:000446143600001
ER  -

TY  - JOUR
AU  - Chowdhury, UK
AU  - Rizvi, A
AU  - Narang, R
AU  - Seth, S
AU  - Kalaivani, M
AU  - Hasija, S
AU  - Kumari, L
TI  - Mitral Valve Replacement Using Carpentier-Edwards Pericardial Bioprosthesis in Patients With Rheumatic Heart Disease Aged Below 40 Years: 17-Year Results
T2  - HEART LUNG AND CIRCULATION
KW  - Mitral valve replacement
KW  - Carpentier-Edwards pericardial prosthesis
KW  - Bioprosthetic degeneration
KW  - QUALITY-OF-LIFE
KW  - PORCINE BIOPROSTHESIS
KW  - PROSTHESES
KW  - PRESERVATION
KW  - EXPERIENCE
KW  - SELECTION
AB  - Background This study was designed to evaluate patients aged less than 40 years implanted with tissue heart valves with respect to survival, thromboembolism, structural degeneration and quality of life.
   Methods Between January, 2000 and December, 2016, 132 patients (51 males) with rheumatic heart disease underwent mitral valve replacement using Carpentier-Edwards, perimount, pericardial bioprostheses. The patients' ages ranged between 12 and 39 years (mean +/- SD 30.12 +/- 5.51 years).
   Results The hospital and late mortality were 1.5% and 1.5% respectively. The total cumulative follow-up period was 1330.98 patient-years with a mean of 124.78 +/- 50.3 months (range, 1-204 months). The actuarial survival and actuarial event-free survival at 204 months was 96.9% (+/- 0.01%) and 93.4%(+/- 0.03%) respectively. There was one episode of thromboembolism (0.32 events per 100 patient years). Six (4.7%) patients underwent redo mitral valve replacement for severe bioprosthetic degeneration with stiffening and calcification using a Medtronic mechanical prosthesis (Medtronic Open Pivot, MN, USA).
   Conclusions We conclude that Carpentier-Edwards perimount pericardial prosthesis provides satisfactory clinical performance in a young population with a low risk of degeneration and other valve-related events.
AD  - All India Inst Med Sci, Dept Cardiothorac & Vasc Surg, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Cardiac Anaesthesia, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - JUL
PY  - 2018
VL  - 27
IS  - 7
SP  - 864
EP  - 871
DO  - 10.1016/j.hlc.2017.05.147
AN  - WOS:000433897100016
ER  -

TY  - JOUR
AU  - Dalal, V
AU  - Kumar, R
AU  - Kumar, S
AU  - Sharma, A
AU  - Kumar, L
AU  - Sharma, JB
AU  - Roy, KK
AU  - Singh, N
AU  - Vanamail, P
TI  - Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients
T2  - CLINICA CHIMICA ACTA
KW  - Epithelial ovarian cancer (EOC)
KW  - Ascitic fluid
KW  - Interleukin-6 (IL-6)
KW  - Vascular endothelial growth factor (VEGF-A)
KW  - Diagnostic bio-marker
KW  - Prognostic bio-marker
KW  - Progression free survival
KW  - PROGNOSTIC-FACTORS
KW  - INTERLEUKIN-6 EXPRESSION
KW  - MALIGNANT ASCITES
KW  - PROGRESSION
KW  - RESISTANCE
KW  - CARCINOMA
KW  - PATHWAY
KW  - HEAD
AB  - Background: Ovarian cancer is represented with significantly higher mortality rate predominately due to asymptomatic behaviour during initial disease course and at diagnosis majority patients already progressed to advanced stage. Acellular fraction of ascites in epithelial ovarian cancer (EOC) has been suggested to promote growth of tumor cells by providing ambient micro-environment for their proliferation. This acellular fraction contains multiple growth factors including IL-6 and VEGF-A, which were exploited to establish their bio-marker significance in EOC patients.
   Methods: IL-6 and VEGF-A levels in ascitic fluid of 30 EOC patients and 15 controls were measured using high sensitivity sandwich enzyme linked immune sorbent (ELISA) assay. Their levels were correlated with clinicopathological characteristics and bio-marker potential was assessed.
   Results and conclusion: EOC patients showed significantly higher levels for IL-6 (median-5636 pg/ml) and VEGF-A (median-4556 pg/ml) in ascitic fluid compared to controls. Levels of IL-6 and VEGF-A significantly correlated with clinico-pathological parameters. ROC curves of IL-6 and VEGF-A showed absolute combination of sensitivity and specificity. Kaplan Meier analysis demonstrated that higher levels of IL-6 and VEGF-A were significantly associated with shorter progression free survival. Thus, this study revealed that IL-6 and VEGF-A have great potential to be used as superior bio-markers for progression free survival in future after validation in larger patients' cohort.
AD  - AIIMS, Dept Gynecol & Obstet, New Delhi, IndiaAD  - AIIMS, Dept Biochem, New Delhi, IndiaAD  - AIIMS, Dept Med Oncol, BRA IRCH, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUL
PY  - 2018
VL  - 482
SP  - 27
EP  - 32
DO  - 10.1016/j.cca.2018.03.019
AN  - WOS:000435049800006
ER  -

TY  - JOUR
AU  - Dar, HY
AU  - Lone, Y
AU  - Koiri, RK
AU  - Mishra, PK
AU  - Srivastava, RK
TI  - Microcystin-leucine arginine (MC-LR) induces bone loss and impairs bone micro-architecture by modulating host immunity in mice: Implications for bone health
T2  - ENVIRONMENTAL POLLUTION
KW  - Microcystin-LR
KW  - Bone loss
KW  - T cell
KW  - B cell
KW  - Bone heterogeneity
KW  - CELL-FORMATION
KW  - T-LYMPHOCYTES
KW  - OSTEOCLASTOGENESIS
KW  - GROWTH
KW  - WATER
KW  - CYANOBACTERIA
KW  - SECRETION
KW  - MECHANISM
KW  - TOXICITY
KW  - EXPOSURE
AB  - Osteoporosis or enhanced bone loss is one of the most commonly occurring bone conditions in the world, responsible for higher incidence of fractures leading to increased morbidity and mortality in adults. Bone loss is affected by various environmental factors including diet, age, drugs, toxins etc. Microcystins are toxins produced by cyanobacteria with microcystin-LR being the most abundantly found around the world effecting both human and animal health. The present study demonstrates that MC-LR treatment induces bone loss and impairs both trabecular and cortical bone microarchitecture along with decreasing the mineral density and heterogeneity of bones in mice. This effect of MC-LR was found due to its immunomodulatory effects on the host immune system, wherein MC-LR skews both T cell (CD4(+) and CD8(+) T cells) and B cell populations in various lymphoid tissues. MC-LR further was found to significantly enhance the levels of osteoclastogenic cytokines (IL-6, IL-17 and INF-alpha) along with simultaneously decreasing the levels of anti-osteoclastogenic cytokines (IL-10 and IFN-gamma). Taken together, our study for the first time establishes a direct link between MC-LR intake and enhanced bone loss thereby giving a strong impetus to the naive field of "osteo-toxicology", to delineate the effects of various toxins (including cyanotoxins) on bone health. (C) 2018 Elsevier Ltd. All rights reserved.
AD  - Dr Harisingh Gour Cent Univ, Sch Biol Sci, Dept Zool, Sagar 70003, MP, IndiaAD  - ICMR Natl Inst Res Environm Hlth, Dept Mol Biol, Bhopal 462001, MP, IndiaAD  - AIIMS, Dept Biotechnol, New Delhi 110029, IndiaC3  - Dr. Hari Singh Gour UniversityC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute for Research in Environmental Health (NIREH)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - JUL
PY  - 2018
VL  - 238
SP  - 792
EP  - 802
DO  - 10.1016/j.envpol.2018.03.059
AN  - WOS:000434754600084
ER  -

TY  - JOUR
AU  - Das, CJ
AU  - Soneja, M
AU  - Tayal, S
AU  - Chahal, A
AU  - Srivastava, S
AU  - Kumar, A
AU  - Baruah, U
TI  - Role of radiological imaging and interventions in management of Budd-Chiari syndrome
T2  - CLINICAL RADIOLOGY
KW  - INTRAHEPATIC PORTOSYSTEMIC SHUNT
KW  - INFERIOR VENA-CAVA
KW  - SINGLE-CENTER EXPERIENCE
KW  - CATHETER-DIRECTED THROMBOLYSIS
KW  - MAGNETIC-RESONANCE ANGIOGRAPHY
KW  - DEEP-VEIN THROMBOSIS
KW  - TERM-FOLLOW-UP
KW  - LIVER-TRANSPLANTATION
KW  - HEPATIC PORTION
KW  - ENDOVASCULAR TREATMENT
AB  - Budd-Chiari syndrome (BCS) is a clinical condition resulting from impaired hepatic venous drainage, in which there is obstruction to the hepatic venous outflow at any level from the small hepatic veins to the junction of the inferior vena cava and the right atrium leading to hepatic congestion. The diagnosis of BCS is based on imaging, which can be gathered from noninvasive investigations such as ultrasonography coupled with venous Doppler, triphasic computed tomography (CT) and magnetic resonance imaging (MRI). Apart from diagnosis, various interventional radiology procedures aid in the successful management of this syndrome. In this article, we present various imaging features of BCS along with various interventional procedures that are used to treat this diverse condition. (C) 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
AD  - All India Inst Med Sci, Dept Radiol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Med, New Delhi 110029, IndiaAD  - GB Pant Hosp, Dept Gastroenterol, New Delhi 110002, IndiaAD  - All India Inst Med Sci, Dept Anaesthesiol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Govind Ballabh Pant Institute of Postgraduate Medical Education & ResearchC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - W B SAUNDERS CO LTD
PI  - LONDON
PA  - 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
DA  - JUL
PY  - 2018
VL  - 73
IS  - 7
SP  - 610
EP  - 624
DO  - 10.1016/j.crad.2018.02.003
AN  - WOS:000434289900002
ER  -

TY  - JOUR
AU  - Das, CJ
AU  - Razik, A
AU  - Sharma, S
TI  - Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy of the Prostate-An Update
T2  - SEMINARS IN ROENTGENOLOGY
KW  - PRIOR NEGATIVE BIOPSY
KW  - MRI-TRUS FUSION
KW  - COGNITIVE FUSION
KW  - CANCER-DETECTION
KW  - TARGETED BIOPSY
AD  - All India Inst Med Sci, Dept Radiol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - W B SAUNDERS CO-ELSEVIER INC
PI  - PHILADELPHIA
PA  - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
DA  - JUL
PY  - 2018
VL  - 53
IS  - 3
SP  - 219
EP  - 226
DO  - 10.1053/j.ro.2018.04.003
AN  - WOS:000440262900006
ER  -

TY  - JOUR
AU  - Das, P
AU  - Rawat, R
AU  - Verma, AK
AU  - Singh, G
AU  - Vallonthaiel, AG
AU  - Yadav, R
AU  - Gahlot, GPS
AU  - Dinda, AK
AU  - Ahuja, V
AU  - Gupta, SD
AU  - Agarwal, SK
AU  - Makharia, GK
TI  - Immunohistochemical Expression of Antitissue Transglutaminase 2 in Tissue Injuries: An Interpretation Beyond Celiac Disease
T2  - APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
KW  - antitissue transglutaminase 2
KW  - immunohistochemical stain
KW  - marker of tissue injury
KW  - celiac disease
KW  - extraintestinal celiac disease
KW  - IgA nephropathy
KW  - GASTROENTEROLOGY
KW  - ANTIBODIES
KW  - DIAGNOSIS
KW  - IGA1
AB  - Tissue transglutaminase 2 enzyme plays a diverse role in intracellular and extracellular functioning. Aberrant expression of anti-TG2 antibody has recently been proposed for extraintestinal identification of celiac disease (CeD), but its utility is questionable. To examine whether anti-TG2 immunohistochemical (IHC) staining can be of diagnostic value in identifying extraintestinal involvement in CeD, tissue blocks of patients with IgA nephropathies (IgAN), minimal change disease, membranous glomerulonephritis, membrano-proliferative glomerulonephritis, normal kidney, intestinal biopsies from CeD, tropical sprue, nonspecific duodenitis, and inflammatory bowel disease; liver biopsies from patients with chronic hepatitis B and C, acute liver failure (ALF), and CeD-associated liver diseases were retrieved and subjected to IHC staining for antitissue transglutaminase 2 enzyme. H-score was calculated by multiplying the area of positivity and stain intensity. Anti-TG2 stain H-scores were almost similar in IgAN and non-IgANs (H-score 6.31 +/- 3 vs. 7.03 +/- 2.7); however, H-scores in both of these groups were significantly higher than in normal renal parenchyma (1.6 +/- 1.5). Only 6.2% patients with IgAN with anti-TG2 immunostain positivity showed a positive anti-tTG antibody serology and villous abnormalities, suggestive of CeD. Intestinal biopsies from patients with CeD, tropical sprue, nonspecific duodenitis, and inflammatory bowel disease also showed high anti-TG2 H-scores, with no statistically significant differences. Liver biopsies from patients with both ALF, as well as chronic liver diseases showed high anti-TG2 H-scores; with highest stain expression in ALF. In conclusion, IHC expression of anti-TG2 stain correlates with both acute and chronic tissue injuries, irrespective of etiology and organ involvement. It is not a reliable marker for diagnosis of CeD.
AD  - All India Inst Med Sci, Dept Gastroenterol & Human Nutr, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Nephrol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - JUL
PY  - 2018
VL  - 26
IS  - 6
SP  - 425
EP  - 430
DO  - 10.1097/PAI.0000000000000430
AN  - WOS:000446143600013
ER  -

TY  - JOUR
AU  - Deepti, S
AU  - Roy, A
TI  - A system of care for patients with ST-segment elevation myocardial infarction in India
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
AD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - JUL-AUG
PY  - 2018
VL  - 31
IS  - 4
SP  - 222
EP  - 223
DO  - 10.4103/0970-258X.258223
AN  - WOS:000469074900009
ER  -

TY  - JOUR
AU  - Deshpande, S
AU  - Patil, S
AU  - Singh, N
TI  - Enhancing Gene-Knockdown Efficiency of Poly(<i>N</i>-isopropylacrylamide) Nanogels
T2  - ACS OMEGA
KW  - POLO-LIKE KINASES
KW  - SIRNA DELIVERY
KW  - CANCER-THERAPY
KW  - IN-VITRO
KW  - PLK1
KW  - CELLS
KW  - INDUCTION
KW  - TOXICITY
KW  - LOCALIZATION
KW  - CARCINOMA
AB  - Polo-like-kinase 1 (PLK1), which is a serine-threonine protein kinase overexpressed in cancer cells, is known to regulate tumor growth and have recently gathered attention as a target gene for RNA interference because of the poor bioavailability and nonspecificity of the available inhibitors. However, the lower transfection efficiency of siRNA and its poor stability in biological mileu necessitate the need of efficient siRNA delivery systems. Here, we report efficacious polymeric nanoparticles for the delivery of PLK1 siRNA in mammalian cancer cells. N-Isopropylacrylamide (NIPAm) and N-isopropylmethacrylamide-co-NIPAm nanogels were synthesized and modified using poly-epsilon-lysine. Furthermore, their ability to induce gene silencing was investigated by flow cytometry and real-time polymerase chain reaction, and the silencing efficiency observed was related to the polymer composition and its effect on the gene loading and protection ability and the endosomal escape capability. This study attempts to leverage the understanding of the cell-material interaction, thus, addressing the bottlenecks of siRNA delivery for enhancing the efficacy of the poly(N-isopropylacrylamide)-based delivery vehicle.
AD  - Indian Inst Technol Delhi, Ctr Biomed Engn, New Delhi 110016, IndiaAD  - All India Inst Med Sci, Biomed Engn Unit, New Delhi 110029, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER CHEMICAL SOC
PI  - WASHINGTON
PA  - 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
DA  - JUL
PY  - 2018
VL  - 3
IS  - 7
SP  - 8042
EP  - 8049
DO  - 10.1021/acsomega.8b00738
AN  - WOS:000440615900009
ER  -

TY  - JOUR
AU  - Dhar, P
AU  - Kaushal, P
AU  - Kumar, P
TI  - Antioxidant supplementation upregulates calbindin expression in cerebellar Purkinje cells of rat pups subjected to post natal exposure to sodium arsenite
T2  - BRAIN RESEARCH
KW  - Arsenic
KW  - Calcium binding protein
KW  - Curcumin
KW  - Alpha lipoic acid
KW  - Rapid brain growth period
KW  - CALCIUM-BINDING PROTEIN
KW  - SYNAPSE ELIMINATION
KW  - GABAERGIC NEURONS
KW  - NERVOUS-SYSTEM
KW  - PARVALBUMIN
KW  - LOCALIZATION
KW  - CORTEX
KW  - D-28K
KW  - GABA
KW  - AREA
AB  - Optimal cytoplasmic calcium (Ca2+) levels have been associated with adequate cell functioning and neuronal survival. Altered intracellular Ca2+ levels following impaired Ca2+ homeostasis could induce neuronal degeneration or even cell death. There are reports of arsenite induced oxidative stress and the associated disturbances in intracellular calcium homeostasis. The present study focused on determining the strategies that would modulate tissue redox status and calcium binding protein (CaBP) (Calbindin D28k-CB) expression affected adversely by sodium arsenite (NaAsO2) exposure (postnatal) of rat pups.
   NaAsO2 alone or along with antioxidants (AOXs) (alpha lipoic acid or curcumin) was administered by intraperitoneal (i.p.) route from postnatal day (PND) 1-21 (covering rapid brain growth period - RBGP) to experimental groups and animals receiving sterile water by the same route served as the controls. At the end of the experimental period, the animals were subjected to euthanasia and the cerebellar tissue obtained therefrom was processed for immunohistochemical localization and western blot analysis of CB protein. CB was diffusely expressed in cell body as well as dendritic processes of Purkinje cells (PCs) along the PC Layer (PCL) in all cerebellar folia of the control and the experimental animals. The multilayered pattern of CB +ve cells along with their downregulated expression and low packing density was significantly evident in the arsenic (iAs) alone exposed group as against the controls and AOX supplemented groups.
   The observations are suggestive of AOX induced restoration of CaBP expression in rat cerebellum following early postnatal exposure to NaAsO2. (C) 2018 Elsevier B.V. All rights reserved.
AD  - All India Inst Med Sci, Dept Anat, Room 1003, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUL 1
PY  - 2018
VL  - 1690
SP  - 23
EP  - 30
DO  - 10.1016/j.brainres.2018.04.003
AN  - WOS:000432759000003
ER  -

TY  - JOUR
AU  - Eachempati, KK
AU  - Malhotra, R
AU  - Pichai, S
AU  - Reddy, AVG
AU  - Subramani, AKP
AU  - Gautam, D
AU  - Bollavaram, VR
AU  - Sheth, NP
TI  - Results of trabecular metal augments in Paprosky IIIA and IIIB defects A MULTICENTRE STUDY
T2  - BONE & JOINT JOURNAL
KW  - ACETABULAR BONE LOSS
KW  - TOTAL HIP-ARTHROPLASTY
KW  - FOLLOW-UP
KW  - REVISION
KW  - COMPONENT
KW  - RECONSTRUCTION
KW  - CUP
KW  - MANAGEMENT
KW  - ALLOGRAFTS
KW  - MINIMUM
AB  - Aims
   The advent of trabecular metal (TM) augments has revolutionized the management of severe bone defects during acetabular reconstruction. The purpose of this study was to evaluate patients undergoing revision total hip arthroplasty (THA) with the use of TM augments for reconstruction of Paprosky IIIA and IIIB defects.
   Patients and Methods
   A retrospective study was conducted at four centres between August 2008 and January 2015. Patients treated with TM augments and TM shell for a Paprosky grade IIIA or IIIB defect, in the absence of pelvic discontinuity, and who underwent revision hip arthroplasty with the use of TM augments were included in the study. A total of 41 patients with minimum follow-up of two years were included and evaluated using intention-to-treat analysis.
   Results
   There were 36 (87.8%) patients with a Paprosky IIIA defect and five (12.2%) patients with a Paprosky IIIB defect. The mean age was 56.7 years (28 to 94). There were 21 (51.2%) women and 20 (48.8%) men. The mean follow-up was 39.4 months (12 to 96). One (2%) patient died after eight years. No failures were noted in the series. The mean survivorship was 100% at the time of latest follow-up.
   Conclusion
   The results of this multicentre study showed encouraging short-and mid-term results for the use of TM augments in the management of Paprosky grade IIIA and IIIB defects.
AD  - Maxcure Hosp, Hyderabad, IndiaAD  - Max Cure Hosp, Dept Orthopaed, Hyderabad, IndiaAD  - AIIMS, Dept Orthopaed, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Orthopaed, New Delhi, IndiaAD  - Asian Joint Reconstruct Inst, Chennai, Tamil Nadu, IndiaAD  - Sunshine Hosp, Hyderabad, IndiaAD  - Sunshine Hosp, Orthopaed, Hyderabad, IndiaAD  - Univ Penn, Dept Orthopaed Surg, Perelman Sch Med, Philadelphia, PA USAC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of PennsylvaniaPU  - BRITISH EDITORIAL SOC BONE JOINT SURGERY
PI  - LONDON
PA  - 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND
DA  - JUL
PY  - 2018
VL  - 100B
IS  - 7
SP  - 903
EP  - 908
DO  - 10.1302/0301-620X.100B7.BJJ-2017-1604.R1
AN  - WOS:000459145300012
ER  -

TY  - JOUR
AU  - Ganger, A
AU  - Gupta, N
AU  - Tomar, AS
AU  - Vanathi, M
AU  - Tandon, R
TI  - Infective keratitis in Indian patients with corneal dystrophies
T2  - TROPICAL DOCTOR
KW  - Infective keratitis
KW  - epithelial-subepithelial corneal dystrophy
KW  - TGFB1 corneal dystrophy
KW  - stromal corneal dystrophy
KW  - recurrent erosions
KW  - corneal transplantation
KW  - MEMBRANE DYSTROPHY
KW  - LATTICE DYSTROPHY
KW  - EROSION
AB  - All eight patients seen with various types of corneal dystrophy, a rare hereditary corneal disease, presented with infective keratitis. Unilateral microbial invasion was seen in all patients and the visual acuity of the affected eyes was <6/60 at presentation. We highlight our impression that microbial invasion can occur with all types of epithelial and stromal corneal dystrophy, including macular corneal dystrophy. Regular follow-up to maintain a healthy ocular surface is recommended to avert blindness in such patients.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Cornea Cataract & Refract Surg Serv, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SAGE PUBLICATIONS INC
PI  - THOUSAND OAKS
PA  - 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
DA  - JUL
PY  - 2018
VL  - 48
IS  - 3
SP  - 199
EP  - 206
DO  - 10.1177/0049475517736709
AN  - WOS:000438672900006
ER  -

TY  - JOUR
AU  - Garland, SM
AU  - Pitisuttithum, P
AU  - Ngan, HYS
AU  - Cho, CH
AU  - Lee, CY
AU  - Chen, CA
AU  - Yang, YC
AU  - Chu, TY
AU  - Twu, NF
AU  - Samakoses, R
AU  - Takeuchi, Y
AU  - Cheung, TH
AU  - Kim, SC
AU  - Huang, LM
AU  - Kim, BG
AU  - Kim, YT
AU  - Kim, KH
AU  - Song, YS
AU  - Lalwani, S
AU  - Kang, JH
AU  - Sakamoto, M
AU  - Ryu, HS
AU  - Bhatla, N
AU  - Yoshikawa, H
AU  - Ellison, MC
AU  - Han, SR
AU  - Moeller, E
AU  - Murata, S
AU  - Ritter, M
AU  - Sawata, M
AU  - Shields, C
AU  - Walia, A
AU  - Perez, G
AU  - Luxembourg, A
TI  - Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries
T2  - JOURNAL OF INFECTIOUS DISEASES
KW  - 9vHPV
KW  - Asia
KW  - cervical cancer
KW  - human papillomavirus
KW  - vaccine
KW  - HPV VACCINE
KW  - COST-EFFECTIVENESS
KW  - PHASE-III
KW  - GENOTYPE ATTRIBUTION
KW  - PARTICLE VACCINE
KW  - CLINICAL-TRIALS
KW  - CERVICAL-CANCER
KW  - IMPACT
KW  - QUADRIVALENT
KW  - METAANALYSIS
AB  - Background. A 9-valent human papillomavirus-6/11/16/18/31/33/45/52/58 (9vHPV) vaccine extends coverage to 5 next most common oncogenic types (31/33/45/52/58) in cervical cancer versus quadrivalent HPV (qHPV) vaccine. We describe efficacy, immunogenicity, and safety in Asian participants (India, Hong Kong, South Korea, Japan, Taiwan, and Thailand) from 2 international studies: a randomized, double-blinded, qHPV vaccine-controlled efficacy study (young women aged 16-26 years; NCT00543543; Study 001); and an immunogenicity study (girls and boys aged 9-15 years; NCT00943722; Study 002).
   Methods. Participants (N = 2519) were vaccinated at day 1 and months 2 and 6. Gynecological samples (Study 001 only) and serum were collected for HPV DNA and antibody assessments, respectively. Injection-site and systemic adverse events (AEs) were monitored. Data were analyzed by country and vaccination group.
   Results. 9vHPV vaccine prevented HPV-31/33/45/52/58-related persistent infection with 90.4%-100% efficacy across included countries. At month 7, >= 97.9% of participants seroconverted for each HPV type. Injection-site AEs occurred in 77.7%-83.1% and 81.9%-87.5% of qHPV and 9vHPV vaccine recipients in Study 001, respectively, and 62.4%-85.7% of girls/boys in Study 002; most were mild to moderate.
   Conclusions. The 9vHPV vaccine is efficacious, immunogenic, and well tolerated in Asian participants. Data support 9vHPV vaccination programs in Asia.
AD  - Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst,Dept Infect Dis & Micr, Royal Womens Hosp,Western Pacific Reg HPV Labnet, Parkville, Vic, AustraliaAD  - Univ Melbourne, Dept Obstet & Gynaecol, Parkville, Vic, AustraliaAD  - Mahidol Univ, Vaccine Trial Ctr, Salaya, Nakhon Pathom, ThailandAD  - Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R ChinaAD  - Keimyung Univ, Sch Med, Dept Obstet & Gynecol, Daegu, South KoreaAD  - Chang Gung Mem Hosp, Chiayi Branch, Dept Gynecol, Taipei, TaiwanAD  - Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei, TaiwanAD  - MacKay Mem Hosp, Taipei, TaiwanAD  - Tzu Chi Med Ctr, Hualien, TaiwanAD  - Taipei Vet Gen Hosp, Dept Obstet & Gynecol, Taipei, TaiwanAD  - Phramongkutklao Hosp, Dept Pediat, Bangkok, ThailandAD  - Fukui Gen Hosp, Fukui, JapanAD  - Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R ChinaAD  - Ewha Womans Univ, Sch Med, Mokdong Hosp, Div Gynecol Oncol, Seoul, South KoreaAD  - Natl Taiwan Univ Hosp, Dept Pediat, Taipei, TaiwanAD  - Sungkyunkwan Univ, Dept Obstet & Gynecol, Samsung Med Ctr, Sch Med, Seoul, South KoreaAD  - Univ Ulsan, Coll Med, Dept Obstet & Gynecol, Asian Med Ctr, Ulsan, South KoreaAD  - Ewha Womans Univ, Coll Med, Dept Pediat, Seoul, South KoreaAD  - Ewha Womans Univ, Coll Med, Ctr Vaccine Evaluat & Study, Seoul, South KoreaAD  - Seoul Natl Univ, Coll Med, Obstet & Gynecol, Seoul, South KoreaAD  - Bharati Vidyapeeth Deemed Univ Med Coll & Hosp, Pune, Maharashtra, IndiaAD  - Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Pediat, Seoul, South KoreaAD  - Jikei Univ, Sasaki Fdn Kyoundo Hosp, Dept Gynaecol, Tokyo, JapanAD  - Jikei Univ, Sch Med, Dept Obstet & Gynaecol, Tokyo, JapanAD  - Ajou Univ, Sch Med, Dept Obstet & Gynecol, Suwon, South KoreaAD  - All India Inst Med Sci, Dept Obstet & Gynaecol, New Delhi, IndiaAD  - Ibaraki Cent Hosp, Kasama, Ibaraki, JapanAD  - Merck & Co Inc, Kenilworth, NJ USAAD  - MSD KK, Tokyo, JapanC3  - The Royal Women's HospitalC3  - Royal Children's Hospital MelbourneC3  - University of MelbourneC3  - Murdoch Children's Research InstituteC3  - University of MelbourneC3  - Mahidol UniversityC3  - University of Hong KongC3  - Keimyung UniversityC3  - Chang Gung Memorial HospitalC3  - National Taiwan UniversityC3  - National Taiwan University HospitalC3  - Mackay Memorial HospitalC3  - Buddhist Tzu Chi General HospitalC3  - Taipei Veterans General HospitalC3  - Phramongkutklao HospitalC3  - Chinese University of Hong KongC3  - Ewha Womans UniversityC3  - National Taiwan UniversityC3  - National Taiwan University HospitalC3  - Sungkyunkwan University (SKKU)C3  - Samsung Medical CenterC3  - University of UlsanC3  - Ewha Womans UniversityC3  - Ewha Womans UniversityC3  - Seoul National University (SNU)C3  - Bharati Vidyapeeth Deemed UniversityC3  - Catholic University of KoreaC3  - Seoul St. Mary's HospitalC3  - Jikei UniversityC3  - Jikei UniversityC3  - Ajou UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Merck & CompanyC3  - Merck & Company USAC3  - Merck & CompanyPU  - OXFORD UNIV PRESS INC
PI  - CARY
PA  - JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
DA  - JUL 1
PY  - 2018
VL  - 218
IS  - 1
SP  - 95
EP  - 108
DO  - 10.1093/infdis/jiy133
AN  - WOS:000434930900012
ER  -

TY  - JOUR
AU  - Goel, N
AU  - Kumar, V
AU  - Arora, S
AU  - Ghosh, B
TI  - Massive choroidal granuloma as the presenting feature of disseminated tuberculosis in immunocompetent patients
T2  - CLINICAL AND EXPERIMENTAL OPTOMETRY
KW  - INTRAOCULAR TUBERCULOSIS
KW  - MILIARY TUBERCULOSIS
KW  - DIAGNOSIS
AD  - ICARE Eye Hosp & Postgrad Inst, Noida, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaAD  - Maulana Azad Med Coll, Guru Nanak Eye Ctr, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - Maulana Azad Medical CollegePU  - TAYLOR & FRANCIS LTD
PI  - ABINGDON
PA  - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
DA  - JUL 1
PY  - 2018
VL  - 101
IS  - 4
SP  - 607
EP  - 610
DO  - 10.1111/cxo.12576
AN  - WOS:000640419700026
ER  -

TY  - JOUR
AU  - Gogia, A
AU  - Deo, SVS
AU  - Shukla, NK
AU  - Mathur, S
AU  - Sharma, DN
AU  - Tiwari, A
TI  - Clinicopathological profile of breast cancer: An institutional experience
T2  - INDIAN JOURNAL OF CANCER
KW  - Breast cancer
KW  - clinicopathological profile
KW  - North India
KW  - NEOADJUVANT
KW  - PROGESTERONE
KW  - CHEMOTHERAPY
KW  - EXPRESSION
KW  - ESTROGEN
KW  - RECEPTOR
KW  - AGE
AB  - INTRODUCTION: This study was undertaken to evaluate the clinicopathological characteristics of patients with breast cancer at our institute, a tertiary-care cancer center in northern India. MATERIALS AND METHODS: This retrospective study included all patients with breast cancer registered at our institute from January 1(st), 2014 to December 31(st), 2016. We retrieved data (demographic, baseline clinical characteristics, pathology, and treatment details) from prospectively maintained clinical case records. Patients with incomplete case records or missing baseline information were excluded. RESULTS: We included 550 patients with breast cancer. The median age was 48 years (23u85). The median clinical tumor size was 5.0 cm. The TNM (AJCC-7(th) edition) stage distribution was stage I, 22 (4%); stage II, 182 (33%); stage III, 247 (44.9%); and stage IV, 99 (18%). Locally advanced breast cancer constituted 40% of the cases. Bone (48 [48.5%]) was the most common site for metastasis followed by lung. Infiltrating ductal carcinoma (528 [96%]) was the most common histologic subtype. Majority of patients, 325 (59%), were positive for estrogen receptor/progesterone receptor whereas 160 (29%) patients were HER2/neu positive. Triple negative breast cancer (TNBC) constituted 28% (154) of patients. In the nonmetastatic subgroup, 343 (76%) patients underwent modified radical mastectomy. Neoadjuvant chemotherapy (NACT) was given in 120 (26.6%) patients, of these 23 (19%) achieved pathological complete remission. Sequential anthracyline and taxane were used as NACT/adjuvant chemotherapy in most cases. Of the eligible patients, 48 (30%) received anti-HER2/neu therapy. CONCLUSION: This is one of the largest comprehensive data from a single center in India. Majority of our patients are younger in age and have advanced disease. TNBC and HER2/neu positive breast cancer are more common in our population.
AD  - All India Inst Med Sci, Dept Med Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Surg Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiat Oncol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-SEP
PY  - 2018
VL  - 55
IS  - 3
SP  - 210
EP  - 213
DO  - 10.4103/ijc.IJC_73_18
AN  - WOS:000457044700002
ER  -

TY  - JOUR
AU  - Guda, NM
AU  - Muddana, V
AU  - Whitcomb, DC
AU  - Levy, P
AU  - Garg, P
AU  - Cote, G
AU  - Uc, A
AU  - Varadarajulu, S
AU  - Vege, SS
AU  - Chari, ST
AU  - Forsmark, CE
AU  - Yadav, D
AU  - Reddy, DN
AU  - Tenner, S
AU  - Johnson, CD
AU  - Akisik, F
AU  - Saluja, AK
AU  - Lerch, MM
AU  - Mallery, JS
AU  - Freeman, ML
TI  - Recurrent Acute Pancreatitis: International State-of-the-Science Conference With Recommendations
T2  - PANCREAS
KW  - recurrent acute pancreatitis
KW  - etiology
KW  - diagnostic algorithm
KW  - treatment efficacies
KW  - workup
KW  - IDIOPATHIC ACUTE-PANCREATITIS
KW  - CATIONIC TRYPSINOGEN GENE
KW  - CYSTIC-FIBROSIS GENE
KW  - LONG-TERM-OUTCOMES
KW  - ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY
KW  - CALCIFIC CHRONIC-PANCREATITIS
KW  - MINOR PAPILLA SPHINCTEROTOMY
KW  - ACUTE ALCOHOLIC PANCREATITIS
KW  - INHIBITOR KAZAL TYPE-1
KW  - HEREDITARY PANCREATITIS
AB  - Recurrent acute pancreatitis (RAP) is a clinically significant problem globally. The etiology remains unclear in approximately 10% to 15% of patients despite a thorough workup. Data on natural history and efficacy of treatments are limited. We aimed to establish criteria for diagnosis, evaluate the causative factors, and arrive at a consensus on the appropriate workup and management of patients with RAP. The organizing committee was formed, and a set of questions was developed based on the current evidence, controversies, and topics that needed further research. After a vetting process, these topics were assigned to a group of experts from around the world with special interest in RAP. Data were presented as part of a workshop on RAP organized as a part of the annual meeting of the America Pancreatic Association. Pretest and Posttest questions were administered, and the responses were tabulated by the current Grades of Recommendation Assessment, Development and Evaluation system. The consensus guidelines were established in the format of a diagnostic algorithm. Several deficiencies were identified with respect to data on etiology, treatment efficacies, and areas that need immediate research.
AD  - Aurora St Lukes Med Ctr, Dept Gastroenterol, Milwaukee, WI USAAD  - Univ Pittsburgh, Dept Med, Pittsburgh, PA USAAD  - Hop Beaujon, AP HP, Serv Gastroenterol Pancreatol, Pole Malad Appareil Digestif, Clichy, FranceAD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaAD  - Med Univ South Carolina, Dept Gastroenterol, Charleston, SC 29425 USAAD  - Univ Iowa, Stead Family Childrens Hosp, Iowa City, IA USAAD  - Florida Hosp, Ctr Intervent Endoscopy, Orlando, FL USAAD  - Mayo Clin, Dept Gastroenterol, Rochester, MN USAAD  - Univ S Florida, Dept Gastroenterol, Gainesville, FL USAAD  - Asian Inst Gastroenterol, Hyderabad, Telangana, IndiaAD  - State Univ New York, Dept Gastroenterol, Brooklyn, NY USAAD  - Univ Southampton, Dept Surg, Southampton, Hants, EnglandAD  - Indiana Univ Sch Med, Dept Radiol, Indianapolis, IN 46202 USAAD  - Univ Miami, Dept Surg, Miami, FL USAAD  - Univ Med Greifswald, Dept Med A, Greifswald, GermanyAD  - Univ Minnesota, Div Gastroenterol, Minneapolis, MN USAC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - Universite Paris CiteC3  - Assistance Publique Hopitaux Paris (APHP)C3  - Hopital Universitaire Beaujon - APHPC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Medical University of South CarolinaC3  - University of IowaC3  - Adventist Health ServicesC3  - AdventHealthC3  - Mayo ClinicC3  - State University System of FloridaC3  - University of South FloridaC3  - State University of New York (SUNY) SystemC3  - SUNY DelhiC3  - University of SouthamptonC3  - Indiana University SystemC3  - Indiana University BloomingtonC3  - University of MiamiC3  - Greifswald Medical SchoolC3  - University of Minnesota SystemC3  - University of Minnesota Twin CitiesPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - JUL
PY  - 2018
VL  - 47
IS  - 6
SP  - 653
EP  - 666
DO  - 10.1097/MPA.0000000000001053
AN  - WOS:000435963800009
ER  -

TY  - JOUR
AU  - Gupta, A
AU  - Kapil, U
AU  - Khandelwal, R
AU  - Khenduja, P
AU  - Sareen, N
AU  - Pandey, RM
AU  - Upadhyay, AD
TI  - Prevalence and risk factors of underweight , overweight and obesity among a geriatric population living in a high-altitude region of rural Uttarakhand, India
T2  - PUBLIC HEALTH NUTRITION
KW  - Underweight
KW  - Overweight
KW  - Obesity
KW  - Geriatric
KW  - High altitude
KW  - HEALTH CONSEQUENCES
KW  - ELDERLY POPULATION
KW  - NUTRITIONAL-STATUS
KW  - BODY-COMPOSITION
KW  - MALNUTRITION
KW  - PEOPLE
KW  - BURDEN
KW  - AGE
AB  - Objective: To assess the prevalence and risk factors of underweight, overweight and obesity among a geriatric population living in a high-altitude region of India.
   Design: Community-based cross-sectional study. Data were collected on socio-demographic profile and anthropometric parameters. Weight and height measurements were utilized for calculation of BMI. Nutrient intake data were collected using 24 h dietary recall.
   Setting: High-altitude region of Nainital District, Uttarakhand State, North India.
   Subjects: Community-dwelling geriatric subjects (n 981) aged 60 years or above.
   Results: We found that 26-6% of the elderly, subjects were underweight (BMI <18.5 kg/m(2)). Overweight (BMI 25.0-29.9 kg/m(2)) and obesity (BMI >= 30.0 kg/m(2)) was seen among 18.0% and 4.6%, respectively. After controlling for potential cofounders, risk factors such as low level of education and income, chewing problems and lower number of daily meals were found to be associated with underweight. On the other hand, risk factors for overweight/obesity were lower age, high income and unskilled work.
   Conclusions: There is a need to develop and implement intervention strategies to prevent underweight, overweight and obesity among the geriatric population of India.
AD  - All India Inst Med Sci, Dept Human Nutr, First Floor Room 18,Old OT Block, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - CAMBRIDGE UNIV PRESS
PI  - CAMBRIDGE
PA  - EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
DA  - JUL
PY  - 2018
VL  - 21
IS  - 10
SP  - 1904
EP  - 1911
DO  - 10.1017/S1368980018000447
AN  - WOS:000451002000013
ER  -

TY  - JOUR
AU  - Gupta, S
AU  - Rout, G
AU  - Patel, AH
AU  - Mahanta, M
AU  - Kalra, N
AU  - Sahu, P
AU  - Sethia, R
AU  - Agarwal, A
AU  - Ranjan, G
AU  - Kedia, S
AU  - Acharya, SK
AU  - Nayak, B
AU  - Shalimar,
TI  - Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection
T2  - JOURNAL OF VIRAL HEPATITIS
KW  - chronic hepatitis C
KW  - cirrhosis
KW  - RAV
KW  - SVR12
KW  - treatment
KW  - GENOTYPE 3 INFECTION
KW  - REAL-LIFE
KW  - SOFOSBUVIR
KW  - DISEASE
KW  - RIBAVIRIN
KW  - COHORT
KW  - PLUS
KW  - LEDIPASVIR
KW  - DIAGNOSIS
KW  - SAFETY
AB  - Novel direct-acting antivirals (DAAs) are now the standard of care for the management of hepatitis C virus (HCV) infection. Branded DAAs are associated with high sustained virological response at 12weeks post-completion of therapy (SVR12), but are costly. We aimed to assess the efficacy of generic oral DAAs in a real-life clinical scenario. Consecutive patients with known HCV infection who were treated with generic-oral DAA regimens (May 2015 to January 2017) were included. Demographic details, prior therapy and SVR12 were documented. Four hundred and ninety patients (mean age: 38.9 +/- 12.7years) were treated with generic DAAs in the study time period. Their clinical presentations included chronic hepatitis (CHC) in 339 (69.2%) of cases, compensated cirrhosis in 120 (24.48%) cases and decompensated cirrhosis in 31 (6.32%) cases. Genotype 3 was most common (n=372, 75.9%) followed by genotype 1 (n=97, 19.8%). Treatment naive and treatment-experienced (defined as having previous treatment with peginterferon and ribavirin) were 432 (88.2%) and 58 (11.8%), respectively. Generic DAA treatment regimens included sofosbuvir in combination with ribavirin (n=175), daclatasvir alone (n=149), ribavirin and peginterferon (n=80), ledipasvir alone (n=43), daclatasvir and ribavirin (n=37), and ledipasvir and ribavirin (n=6). Overall SVR12 was 95.9% (470/490) for all treatment regimens. SVR12 for treatment naive and experienced patients was 97.0% (419/432) and 87.9% (51/58), respectively, P=.005. High SVR12 was observed with various regimens, irrespective of genotype and underlying liver disease status. There were no differences in SVR12 with 12 or 24weeks therapy. No major adverse event occurred requiring treatment stoppage. Generic oral DAAs are associated with high SVR rates in patients with HCV infection in a real-life clinical scenario.
AD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaAD  - Univ Michigan, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Ann Arbor, MI USAC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of Michigan SystemC3  - University of MichiganPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUL
PY  - 2018
VL  - 25
IS  - 7
SP  - 771
EP  - 778
DO  - 10.1111/jvh.12870
AN  - WOS:000436112700002
ER  -

TY  - JOUR
AU  - Gupta, S
AU  - Upadhayay, D
AU  - Sharma, U
AU  - Jagannathan, NR
AU  - Gupta, YK
TI  - Citalopram attenuated neurobehavioral, biochemical, and metabolic alterations in transient middle cerebral artery occlusion model of stroke in male Wistar rats
T2  - JOURNAL OF NEUROSCIENCE RESEARCH
KW  - apoptosis
KW  - citalopram
KW  - graphpad prism RRID: SCR_002798
KW  - MCAo
KW  - oxidative stress
KW  - neuroinflammation
KW  - neurometabolites
KW  - paravision RRID: SCR_001964
KW  - proton nuclear magnetic resonance spectroscopy
KW  - OXIDATIVE STRESS
KW  - BRAIN-INJURY
KW  - BLOOD-FLOW
KW  - ENDOTHELIN ANTAGONIST
KW  - LIPID-PEROXIDATION
KW  - FOCAL ISCHEMIA
KW  - MECHANISMS
KW  - FLUOXETINE
KW  - TAURINE
KW  - DEPRESSION
AB  - Oxidative stress and inflammation are implicated as cardinal mechanisms of neuronal death following stroke. In the present study citalopram (Cit) was investigated in a 2 h middle cerebral artery occlusion (MCAo) model of stroke in male Wistar rats. Pretreatment, posttreatment (Post Cit) and pre plus posttreatment (Pre+Post Cit) with Cit were evaluated for its neuroprotective effect. In pretreatment protocol, effect of Cit at three doses (2, 4, and 8 mg/kg) administered i.p., 1 h prior to MCAo was evaluated using neurological deficit score (NDS), motor deficit paradigms, and cerebral infarction 24 h post-MCAo. In posttreatment and pre plus posttreatment protocol, the effective dose of Cit (4 mg/kg) was administered i.p., 0.5 h post-reperfusion (Post Cit) only, and 1 h prior to MCAo and again at 0.5 h post-reperfusion (Pre+Post Cit), respectively. These two groups were assessed for NDS and cerebral infarction. Though NDS was significantly reduced in both Post Cit and Pre+Post Cit groups, significant reduction in cerebral infarction was evident only in Pre+Post Cit group. Infarct volume assessed by magnetic resonance imaging was significantly attenuated in Pre+Post Cit group (10.6 +/- 1.1%) compared to MCAo control group (18.5 +/- 3.0%). Further, Pre+Post Cit treatment significantly altered 17 metabolites along with attenuation of malondialdehyde, reduced glutathione, matrix metalloproteinases, and apoptotic markers as compared to MCAo control. These results support the neuroprotective effect of Cit, mediated through amelioration of oxidative stress, inflammation, apoptosis, and altered metabolic profile.
AD  - All India Inst Med Sci, Dept Pharmacol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept NMR, New Delhi 110029, IndiaAD  - All India Inst Med Sci, MRI Facil, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUL
PY  - 2018
VL  - 96
IS  - 7
SP  - 1277
EP  - 1293
DO  - 10.1002/jnr.24226
AN  - WOS:000433583800012
ER  -

TY  - JOUR
AU  - Gupta, V
AU  - Sharma, VK
TI  - Ashy dermatosis, lichen planus pigmentosus and pigmented cosmetic dermatitis: Are we splitting the hair?
T2  - INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY
KW  - ERYTHEMA DYSCHROMICUM PERSTANS
KW  - INDIAN PATIENTS
KW  - HISTOPATHOLOGY
KW  - DERMOSCOPY
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-AUG
PY  - 2018
VL  - 84
IS  - 4
SP  - 470
EP  - +
DO  - 10.4103/ijdvl.IJDVL_549_17
AN  - WOS:000436616500025
ER  -

TY  - JOUR
AU  - Jain, D
TI  - Tru-cut/core Biopsy versus FNAC: Pulmonary Tumors
T2  - JOURNAL OF CYTOLOGY
KW  - Biopsy
KW  - fine-needle aspiration cytology
KW  - lung cancer
KW  - FINE-NEEDLE-ASPIRATION
KW  - MOLECULAR TESTING GUIDELINE
KW  - KINASE INHIBITORS GUIDELINE
KW  - OF-AMERICAN-PATHOLOGISTS
KW  - LUNG-CANCER PATIENTS
KW  - INTERNATIONAL-ASSOCIATION
KW  - ENDOBRONCHIAL ULTRASOUND
KW  - CORE BIOPSY
KW  - DIAGNOSIS
KW  - CARCINOMA
AB  - Primary lung epithelial malignancies are the most common neoplasms among all pulmonary tumors. Lung cancer (LC) is the leading cause of cancer-related mortality for which a histologic or cytologic confirmation of malignancy is required before treatment. Specimen management is an important task for pathologists in the field of LC. Biopsy and fine needle aspiration are comparable. It is desirable to have both for diagnosis and mutation testing to maximize their use for patient care.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
DA  - JUL-SEP
PY  - 2018
VL  - 35
IS  - 3
SP  - 183
EP  - 186
DO  - 10.4103/JOC.JOC_73_18
AN  - WOS:000439319800012
ER  -

TY  - JOUR
AU  - Jain, S
AU  - Midha, S
AU  - Mahapatra, SJ
AU  - Gupta, S
AU  - Sharma, MK
AU  - Nayak, B
AU  - Jacob, TG
AU  - Shalimar
AU  - Garg, PK
TI  - Interleukin-6 significantly improves predictive value of systemic inflammatory response syndrome for predicting severe acute pancreatitis
T2  - PANCREATOLOGY
KW  - Interleukin-6
KW  - Systemic inflammatory response syndrome
KW  - Prediction
KW  - Severe acute pancreatitis
KW  - MONOCYTE CHEMOATTRACTANT PROTEIN-1
KW  - MULTIORGAN DYSFUNCTION
KW  - CONSERVATIVE TREATMENT
KW  - NATURAL-HISTORY
KW  - CYTOKINE LEVELS
KW  - ORGAN FAILURE
KW  - ASSOCIATION
KW  - MORTALITY
KW  - SCORE
KW  - RISK
AB  - Background: Predicting severe acute pancreatitis (AP) is important for triage, prognosis, and designing therapeutic trials. Persistent systemic inflammatory response syndrome (SIRS) predicts severe AP but its diagnostic accuracy is suboptimal. Our objective was to study if cytokine levels could improve the predictive value of clinical variables for the development of severe AP.
   Methods: Consecutive patients with AP were included in a prospective cohort study at a tertiary care center. Serum levels of IL-6, TNF-alpha, IL-10, MCP-1, GM-CSF and IL-1 beta were measured at day 3 of onset of AP. Variables such as age, co-morbidity, etiology, SIRS, and cytokines were modeled to predict severe AP by multivariable regression analysis. Genotyping was done to correlate IL-6, TNF-alpha and MCP-1 gene polymorphisms with cytokine levels.
   Results: Of 236 patients with AP, 115 patients admitted within 7 days of onset formed the study group. 37 of the 115 (32%) patients developed organ failure. Independent predictors of organ failure were persistent SIRS (OR 34; 95% CI: 7.2-159) and day 3 serum IL-6 of > 160 pg/ml (OR 16.1; 95% CI:1.8-142). IL-6 gene (-174 G/C) GG genotype was associated with significantly higher levels of IL-6 compared to CC/CG genotype. Serum IL-6 > 160 pg/ml increased the positive predictive value of persistent SIRS from 56% to 85% and specificity from 64% to 95% for predicting OF without compromising its sensitivity and negative predictive value.
   Conclusion: Serum IL-6 of > 160 ng/ml added significantly to the predictive value of SIRS for severe AP. (C) 2018 IAP and EPC. Published by Elsevier B.V. All rights reserved.
AD  - All India Inst Med Sci, Dept Gastroenterol & Human Nutr, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Anat, 1st Floor,Teaching Block, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUL
PY  - 2018
VL  - 18
IS  - 5
SP  - 500
EP  - 506
DO  - 10.1016/j.pan.2018.05.002
AN  - WOS:000437632900007
ER  -

TY  - JOUR
AU  - Jain, S
AU  - Gupta, S
AU  - Kumar, V
TI  - Ultra-widefield imaging in Coats'-type retinitis pigmentosa
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Coats'-type response
KW  - retinitis pigmentosa
KW  - ultra-widefield imaging
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaAD  - Dr Ram Manohar Lohia Hosp, PGIMER, Dept Ophthalmol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL
PY  - 2018
VL  - 66
IS  - 7
SP  - 997
EP  - 998
DO  - 10.4103/ijo.IJO_1109_17
AN  - WOS:000437197400025
ER  -

TY  - JOUR
AU  - Joaquim, AF
AU  - Tedeschi, H
AU  - Chandra, PS
TI  - Controversies in the surgical management of congenital craniocervical junction disorders - A critical review
T2  - NEUROLOGY INDIA
KW  - Atlanto-axial dislocation
KW  - basilar invagination
KW  - Chiari malformation
KW  - concepts
KW  - craniovertebral junction
KW  - surgery
KW  - treatment
KW  - IRREDUCIBLE ATLANTOAXIAL DISLOCATION
KW  - BASILAR INVAGINATION
KW  - CRANIOVERTEBRAL JUNCTION
KW  - I MALFORMATION
KW  - CHIARI MALFORMATION
KW  - TRANSORAL DECOMPRESSION
KW  - HINDBRAIN HERNIATION
KW  - FACETAL ORIENTATION
KW  - JOINT DISTRACTION
KW  - CLINICAL ARTICLE
AB  - Introduction: Congenital disorders of the craniovertebral junction (CVJ) include a wide range of conditions, such as Chiari malformation (CM), basilar Invagination (BI), and atlantoaxial dislocation (AAD). The objective of this paper is to critically review the literature related to the management of congenital CVJ disorders focusing on: the significant developments in the past (from anterior open ventral decompression to modern CVJ realignment); the diagnosis of CVJ instability; the role of atlantoaxial fixation without posterior fossa decompression in patients with tonsillar herniation and no evidence of CVJ instability; use of C1-2 inter-articular spacers and use of C1-2 interarticular spacers with intra-operative manipulations to correct BI with AAD along with its deformity.
   Materials and Methods: We performed a review of articles showing up on PubMed database without time restriction. Articles were included according to the purpose of our review and selected by two authors (AFJ and PSC).
   Results: CVJ instability may be inferred when there is atlantoaxial abnormal motion seen on dynamic studies, facet joint subluxation or severe symptomatic CVJ kyphosis; routine fixation of patients with CM without clear CCJ instability, while based on an interesting hypothesis, still requires further studies; use of C1-2 inter-articular spacers for re-establishing CVJ alignment is probably the most effective surgery for posterior CVJ realignment and reduction of AAD and BI, potentially avoiding the need for an open or endoscopic anterior odontoidectomy (AO); current development of deformity correcting surgeries and the measurement of joint indices to plan surgery have provided new strategies for treatment.
   Conclusion: We present a critical review of important new concepts involved in the surgical treatment of CVJ congenital disease.
AD  - Univ Campinas UNICAMP, Neurosurg Div, Dept Neurol, Campinas, SP, BrazilAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - Universidade Estadual de CampinasC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-AUG
PY  - 2018
VL  - 66
IS  - 4
SP  - 1003
EP  - 1015
C7  - PMID 30038084
DO  - 10.4103/0028-3886.237025
AN  - WOS:000447540700020
ER  -

TY  - JOUR
AU  - John, T
AU  - Subramanyam, AA
AU  - Sagar, R
TI  - Strength and weakness of the guidelines of Rights of Persons with Disabilities Act, 2016 (dated January 5, 2018): With respect to the persons with neurodevelopmental disorders
T2  - INDIAN JOURNAL OF PSYCHIATRY
AD  - Thomas Clin, Kochi, Kerala, IndiaAD  - TNMC & BYL Nair Ch Hosp, Dept Psychiat, Bombay, Maharashtra, IndiaAD  - AIIMS, Dept Psychiat, New Delhi, IndiaC3  - Topiwala National Medical College & B Y L Nair Charitable HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-SEP
PY  - 2018
VL  - 60
IS  - 3
SP  - 261
EP  - 264
DO  - 10.4103/psychiatry.IndianJPsychiatry_326_18
AN  - WOS:000447749800002
ER  -

TY  - JOUR
AU  - Jose, A
AU  - Nagori, SA
AU  - Chattopadhyay, PK
AU  - Roychoudhury, A
TI  - Greater Occipital Nerve Decompression for Occipital Neuralgia
T2  - JOURNAL OF CRANIOFACIAL SURGERY
KW  - Headache
KW  - neurolysis
KW  - orofacial pain
KW  - surgery
KW  - CERVICOGENIC HEADACHE
KW  - PULSED RADIOFREQUENCY
KW  - OUTCOMES
AB  - The aim of the study was to evaluate the effectiveness of greater occipital nerve decompression for the management of occipital neuralgia. Eleven patients of medical refractory occipital neuralgia were enrolled in the study. Local anaesthetic blocks were used for confirming diagnosis. All of them underwent surgical decompression of greater occipital nerve at the level of semispinalis capitis and trapezial tunnel. A pre and postoperative questionnaire was used to compare the severity of pain and number of pain episodes/month. Mean pain episodes reported by patients before surgery were 17.1 +/- 5.63 episodes per month. This reduced to 4.1 +/- 3.51 episodes per month (P<0.0036) postsurgery. The mean intensity of pain also reduced from a preoperative 7.18 +/- 1.33 to a postoperative of 1.73 +/- 1.95 (P<0.0033). Three patients reported complete elimination of pain after surgery while 6 patients reported significant relief of their symptoms. Only 2 patients failed to notice any significant improvement. The mean follow-up period was 12.45 +/- 1.29 months. Surgical decompression of greater occipital nerve is a simple and viable treatment modality for the management of occipital neuralgia.
AD  - Army Dent Ctr Res & Referral, Corps Dent Unit 15, Delhi, IndiaAD  - Army Dent Ctr Res & Referral, Field Hosp 303, Delhi, IndiaAD  - Army Dent Ctr Res & Referral, Dept Oral & Maxillofacial Surg, Delhi, IndiaAD  - All India Inst Med Sci, Dept Oral & Maxillofacial surg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - JUL
PY  - 2018
VL  - 29
IS  - 5
SP  - E518
EP  - E521
DO  - 10.1097/SCS.0000000000004549
AN  - WOS:000446576600029
ER  -

TY  - JOUR
AU  - Kapil, U
AU  - Joshi, S
TI  - Markers of Maternal and Neonatal Cobalamin Status and Risk Assessment of Neurodevelopmental Disorders in Infants
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - VITAMIN-B-12 STATUS
KW  - PREGNANT-WOMEN
KW  - DEFICIENCY
KW  - FOLATE
KW  - NEWBORNS
KW  - CHILDREN
AD  - All India Inst Med Sci, Human Nutr Unit, New Delhi 110019, IndiaAD  - Bharati Vidyapeeth Deemed Be Univ, Interact Res Sch Hlth Affairs, Mother & Child Hlth, Pune, Maharashtra, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Bharati Vidyapeeth Deemed UniversityPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUL
PY  - 2018
VL  - 85
IS  - 7
SP  - 491
EP  - 492
DO  - 10.1007/s12098-018-2683-3
AN  - WOS:000436093400003
ER  -

TY  - JOUR
AU  - Kapil, U
AU  - Pandey, RM
AU  - Bansal, R
AU  - Pant, B
AU  - Varshney, AM
AU  - Yadav, CP
AU  - Sinha, S
AU  - Sareen, N
AU  - Sachdev, HS
TI  - Mid-upper arm circumference in detection of weight-for-height Z-score below-3 in children aged 6-59 months
T2  - PUBLIC HEALTH NUTRITION
KW  - Severe wasting
KW  - Severe acute malnutrition
KW  - Under-5 children
KW  - Mid-upper arm circumference cut-offs
KW  - BODY-COMPOSITION
KW  - ANTHROPOMETRY
KW  - MALNUTRITION
KW  - COMMUNITY
KW  - ADMISSION
KW  - MUAC
AB  - Objective: To evaluate the predictive ability of mid-upper arm circumference (MIJAC) for detecting severe wasting (weight-for-height. Z-score (WHZ) <-3) among children aged 6-59 months.
   Design: Cross-sectional survey.
   Setting: Rural Uttar Pradesh, India.
   Subjects: Children (n 18456) for whom both WHZ (n 18463) and MUAC were available.
   Results: The diagnostic test accuracy of MUAC for severe wasting was excellent (area under receiver-operating characteristic curve = 0.933). Across the lower range of MUAC cut-offs (110-120 mm), specificity was excellent (99.1-99.9%) but sensitivity was poor (13.4-37.2 %); with higher cut-offs (140-150 mm), sensitivity increased substantially (94.9-98.8%) but at the expense of specificity (37.6-71.9%). The optimal MUAC cut-off to detect severe wasting was 135 mm. Although the prevalence of severe wasting was constant at 2.2%, the burden of severe acute malnutrition, defined as either severe wasting or low MUAC, increased from 2.46 to 17.26% with cut-offs of <115 and <135 mm, respectively. An MUAC cut-off <115 mm preferentially selected children aged <= 12 months (OR= 11.8; 95% CI 8.4, 16.6) or <= 24 months (OR = 23.4; 95% CI 12.7, 43.4) and girls (OR = 2.2; 95% CI 1.6, 3.2).
   Conclusions: Based on important considerations for screening and case detection in the community, modification of the current WHO definition of severe acute malnutrition may not be warranted, especially in the Indian context.
AD  - All India Inst Med Sci, Dept Gastroenterol & Human Nutr, New Delhi 110608, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - Subharti Med Coll, Dept Community Med, Meerut, Uttar Pradesh, IndiaAD  - Sitaram Bhartia Inst Sci & Res, Dept Pediat & Clin Epidemiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Sitaram Bhartia Institute of Science & ResearchPU  - CAMBRIDGE UNIV PRESS
PI  - CAMBRIDGE
PA  - EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
DA  - JUL
PY  - 2018
VL  - 21
IS  - 10
SP  - 1794
EP  - 1799
DO  - 10.1017/S1368980017004165
AN  - WOS:000451002000002
ER  -

TY  - JOUR
AU  - Kashyap, S
AU  - Kumar, U
AU  - Pandey, AK
AU  - Kanjilal, M
AU  - Chattopadhyay, P
AU  - Yadav, C
AU  - Thelma, BK
TI  - Functional characterisation of ADP ribosylaysion factor-like protein 15 in rheumatoid arthritis synovial fibroblasts
T2  - CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
KW  - rheumatoid arthritis
KW  - synovial fibroblasts
KW  - ARL15
KW  - GENOME-WIDE ASSOCIATION
KW  - INSULIN-RESISTANCE
KW  - HORMONE ADIPONECTIN
KW  - PATHOGENESIS
KW  - INFLAMMATION
KW  - CYTOKINES
KW  - GENOTYPES
KW  - GENETICS
KW  - IL-6
AB  - Objective
   ARL15 is a novel susceptibility gene identified in a recent GWAS in a north Indian rheumatoid arthritis (RA) cohort. However, the role of ARL15 or ARF family genes in RA aetiology remains unknown. Therefore, we aimed to i) establish the expression of ARL15 in rheumatoid arthritis synovial fibroblasts (RASF) and ii) its functional characterisation by assessing its effects on major inflammatory cytokines and interacting partners using a knockdown approach.
   Methods
   RASF were cultured from synovial tissue obtained from RA patients (n=5) and osteoarthritis (OA) patients (n=3) serving as controls. Expression of ARL15, ARF1 and ARF6 in RASF was checked by semi-quantitative PCR and western blots; and altered expression of ARL15, if any, by induction of RASF with TNF using real-time PCR. The effect of ARL15 on the expression of adiponectin, adiponectin receptor I, IL6 and GAPDH and on cell mobility by invasion and migration assays were assessed by siRNA mediated gene knockdown.
   Results
   Expression of ARL15, ARF1 and ARF6 was confirmed in RASF and OASF samples but ARL15 expression remained unaltered on TNF induction. Notably, ARL15 knockdown resulted in downregulation of IL6 and GAPDH, upregulation of adiponectin and adiponectin receptor I genes; and significant reduction in migration and invasion of RASF. Genemania showed significant interactions of ARL15 with genes responsible for insulin resistance and phospholipase D.
   Conclusion
   This first report on ARL15 expression in RASF and its likely role in inflammation and metabolic syndromes through a TNF independent pathway, encourages hypothesis-free studies to identify additional pathways underlying RA disease biology.
AD  - Univ Delhi South Campus, Dept Genet, Benito Jurez Rd, New Delhi 110021, IndiaAD  - All India Inst Med Sci, Dept Rheumatol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Orthopaed, New Delhi, IndiaC3  - University of DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - CLINICAL & EXPER RHEUMATOLOGY
PI  - PISA
PA  - VIA SANTA MARIA 31, 56126 PISA, ITALY
DA  - JUL-AUG
PY  - 2018
VL  - 36
IS  - 4
SP  - 581
EP  - 588
AN  - WOS:000440741300010
ER  -

TY  - JOUR
AU  - Kasturia, S
AU  - Ali, MK
AU  - Narayan, KMV
AU  - Tandon, N
AU  - Shivashankar, R
AU  - Garg, V
AU  - Kapoor, D
AU  - Mohanasundaram, A
AU  - Mohan, D
AU  - Kadir, MM
AU  - Prabhakaran, D
AU  - Mohan, V
AU  - Jaacks, LM
TI  - Diets for South Asians with diabetes: recommendations, adherence, and outcomes
T2  - ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION
KW  - type 2 diabetes mellitus
KW  - India
KW  - Pakistan
KW  - lifestyle modifications
KW  - secondary prevention
KW  - LIFE-STYLE INTERVENTION
KW  - RISK-FACTORS
KW  - CARDIOVASCULAR-DISEASE
KW  - MEDITERRANEAN DIET
KW  - PREVENTION
KW  - MELLITUS
KW  - ADULTS
KW  - INDIA
KW  - COMPLICATIONS
KW  - TRIAL
AB  - Background and Objectives: To determine how frequently diabetic diets are recommended to individuals with diabetes in South Asia, whether they are followed, and if they are associated with healthier dietary choices and clinical benefits. Methods and Study Design: Data are from the Centre for cArdiometabolic Risk Reduction in South-Asia Cohort Study. Participants with self-reported physician-diagnosed diabetes (n=1849) were divided into four groups based on whether they reported being prescribed and/or were following a diabetic diet. Linear regression was used to estimate associations between these groups and outcomes. Results: 53% of participants with self-reported diabetes reported not being prescribed or following a diabetic diet. Among those prescribed and following a diet, mean whole grain consumption was 1.18 times/day and refined grain consumption was 0.75 times/day compared to 0.88 times/day and 1.74 times/day, respectively, among those neither prescribed nor following a diet (both p<0.0001). Following a diet despite not being prescribed a diet was not associated with glycemic control, blood pressure, or body mass index, but was associated with a -8.54 mg/dL (95% confidence interval: -15.5, -1.58) lower low-density lipoprotein cholesterol compared to not following and not being prescribed a diet after adjustment for confounders. Conclusion: Though participants who were prescribed diabetic diets and followed them exhibited healthier dietary choices, the majority of participants with diabetes in urban South Asia was neither prescribed nor followed such diets. Moreover, there was no statistically significant clinical benefit, thus indicating that current dietary modifications may not be large enough or consistent enough to produce meaningful changes in health outcomes in this population.
AD  - Emory Univ, Sch Med, Atlanta, GA USAAD  - Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USAAD  - Emory Univ, Emory Global Diabet Res Ctr, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA USAAD  - All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi, Ncr, IndiaAD  - Publ Hlth Fdn India, Ctr Chron Dis Control, Gurgaon, Haryana, IndiaAD  - Madras Diabet Res Fdn, Madras, Tamil Nadu, IndiaAD  - Aga Khan Univ, Dept Community Hlth Sci, Karachi, Sindh, PakistanAD  - Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USAC3  - Emory UniversityC3  - Emory UniversityC3  - Rollins School Public HealthC3  - Emory UniversityC3  - Rollins School Public HealthC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Public Health Foundation of IndiaC3  - Madras Diabetes Research FoundationC3  - Aga Khan UniversityC3  - Harvard UniversityC3  - Harvard T.H. Chan School of Public HealthPU  - H E C PRESS, HEALTHY EATING CLUB PTY LTD
PI  - MCKINNON
PA  - PO BOX 4121, MCKINNON, VIC 3204, AUSTRALIA
DA  - JUL
PY  - 2018
VL  - 27
IS  - 4
SP  - 823
EP  - 831
DO  - 10.6133/apjcn.112017.03
AN  - WOS:000440318000011
ER  -

TY  - JOUR
AU  - Khandpur, S
AU  - Gupta, V
AU  - Das, D
AU  - Sharma, A
TI  - Is there a correlation of serum and tissue T helper-1 and-2 cytokine profiles with psoriasis activity and severity? A cross-sectional study
T2  - INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY
KW  - Cytokine profile
KW  - disease activity
KW  - psoriasis
KW  - severity
KW  - DISEASE SEVERITY
KW  - IFN-GAMMA
KW  - VULGARIS
KW  - CELLS
KW  - TH17
KW  - TH2
AB  - Background: Previous studies correlating Th1 and Th2 cytokine profiles with psoriasis activity provided inconsistent results. Correlation of tissue cytokine levels with psoriasis severity has not been studied till now.
   Objective: To compare serum and tissue Th1 and Th2 cytokine profiles of patients with active and stable psoriasis as well as healthy controls, and to correlate them with psoriasis severity.
   Methodology: This was a cross-sectional study involving adult patients with 'active' psoriasis (untreated progressive chronic plaque psoriasis, guttate psoriasis, and erythrodermic psoriasis), 'stable' psoriasis (stable plaque psoriasis or those with completely resolved lesions) and healthy subjects with non-inflammatory skin lesions as controls. Mean levels of Th1 and Th2 cytokines in serum [interleukin 2 (IL-2), interferon-gamma (IFN-gamma), IL-4, IL-10] and tissue mRNA expression (IFN-gamma, IL-4) were compared among these three groups.
   Results: There were 30 patients each in active and stable psoriasis groups, and 15 in the control group. Mean serum IL-2, IFN-gamma, and IL-10 levels of patients with psoriasis patients were significantly higher than the controls (P < 0.001 for both active and stable psoriasis), whereas mean serum IL-4 level of patients was significantly lower than the controls (P < 0.001). However, there was no statistically significant difference of serum cytokine levels between active and stable psoriasis groups. Mean quantitative tissue mRNA expression of IFN-gamma and IL-4 of patients with active and stable psoriasis were significantly lower than the controls (P < 0.001 and < 0.01, respectively), but were not significantly different between active and stable psoriasis groups. Serum and tissue cytokines showed weak correlation with psoriasis area and severity index.
   Limitations: Small sample size and heterogenous nature of patients with psoriasis in terms of disease activity, morphology and treatment are limitations of this study.
   Conclusions: There is no significant change in the serum or tissue levels of Th1 and Th2 cytokines with activity or severity of psoriasis.
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Biochem, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-AUG
PY  - 2018
VL  - 84
IS  - 4
SP  - 414
EP  - 418
C7  - PMID 29491194
DO  - 10.4103/ijdvl.IJDVL_471_17
AN  - WOS:000436616500006
ER  -

TY  - JOUR
AU  - Kinra, P
AU  - Gahlot, GPS
AU  - Yadav, R
AU  - Baloda, V
AU  - Makharia, GK
AU  - Gupta, SD
AU  - Das, P
TI  - Histological assessment & use of immunohistochemical markers for detection of dysplasia in Barrett's esophageal mucosa
T2  - PATHOLOGY RESEARCH AND PRACTICE
KW  - Barrett
KW  - Esophagus
KW  - Dysplasia
KW  - Histology
KW  - Immunohistochemistry
KW  - Agreement
KW  - HIGH-GRADE DYSPLASIA
KW  - P53 PROTEIN OVEREXPRESSION
KW  - FOLLOW-UP
KW  - VIENNA CLASSIFICATION
KW  - DISEASE PROGRESSION
KW  - CYCLIN D1
KW  - ADENOCARCINOMA
KW  - EXPRESSION
KW  - DIAGNOSIS
KW  - SURVEILLANCE
AB  - Background: Histological assessment of dysplasia in Barrett's esophagus (BE) has high inter-observer variability. Hence, use of ancillary markers for early detection of dysplasia in BE is an important clinical question.
   Methods: In this retrospective study consecutive cases of BE (n = 59), over a period of 4 years were included. Hematoxylin and eosin stained sections were reviewed independently by 3 senior qualified pathologists, who graded the dysplasia according to the Vienna Classification system and inter-observer agreement was analysed using the Kappa statistics. Subsequently Alpha-Methyl Acyl-CoA Racemase (AMACR), p53, CyclinD1, beta-catenin, H2AX and M30 immunohistochemical (IHC) stains were examined on the following disease categories: BE with no dysplasia [NFD] (45), BE with indefinite for dysplasia (IFD) (4), low grade dysplasia (LGD) (3), high grade dysplasia (HGD) (2) and in adenocarcinomas (5). H score was calculated by adding up products of different grades of stain distribution and stain intensities (range of scores 0-300).
   Results: Among the 3 pathologists, overall agreement was poor (k 0.06; 95% CI -0.089 to 0.145), with highest disagreement noted for differentiating the LGD and IFDs (k = 0.21). After revising the histological criteria, the kappa improved to 0.53. Among the IHC stains performed, p53, beta-catenin, H2AX and M30 stains were significantly useful to differentiate between IFD and LGD (P values: 0.04, 0.004, 0.05 & 0.04, respectively). AMACR and beta-catenin stains though were up-regulated in HGD/adenocarcinomas than in other categories, their expression were not statistically different between the IFD and LGDs.
   Conclusions: A detail histological scoring system may bring uniformity in histological interpretation of dysplasia in BE. Using a combined panel of IHC stains seems helpful in detection of dysplasia in BE, especially to differentiate the IFD and LGD changes in BE.
AD  - All India Inst Med Sci, Dept Pathol & Gastroenterol & Human Nutr, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI  - JENA
PA  - OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
DA  - JUL
PY  - 2018
VL  - 214
IS  - 7
SP  - 993
EP  - 999
DO  - 10.1016/j.prp.2018.05.006
AN  - WOS:000439254000011
ER  -

TY  - JOUR
AU  - Kishor, K
AU  - Sharma, A
AU  - Singh, K
AU  - Ranjan, R
AU  - Pandey, H
AU  - Kumar, R
AU  - Kamal, VK
AU  - Mishra, P
AU  - Mahapatra, M
AU  - Saxena, R
TI  - Influence of tissue factor polymorphisms (603A&gt;G and 5466A&gt;G) on plasma tissue factor levels and their impact on deep vein thrombosis risk in young Indian population
T2  - JOURNAL OF THROMBOSIS AND THROMBOLYSIS
KW  - Deep vein thrombosis
KW  - Tissue factor
KW  - Single nucleotide polymorphisms
KW  - Genotype
KW  - FACTOR PATHWAY INHIBITOR
KW  - ACUTE MYOCARDIAL-INFARCTION
KW  - CORONARY-ARTERY-DISEASE
KW  - VENOUS THROMBOSIS
KW  - FACTOR GENE
KW  - THROMBOEMBOLISM
KW  - EPIDEMIOLOGY
KW  - EXPRESSION
KW  - MONOCYTES
KW  - EVENTS
AB  - Deep vein thrombosis (DVT) is multifactorial disorder and well known to cause substantial morbidity and mortality. There is sparse data in the Asian population, particularly India regarding association of tissue factor (TF) gene single nucleotide polymorphisms (SNPs) with plasma TF levels in DVT. So, we analyzed the distribution of SNPs (603A > G and 5466A > G) in India, to evaluate their effect on TF levels in DVT patients. Plasma level and SNPs (603A > G and 5466A > G) of TF gene were screened in subjects (100 DVT patients and 100 controls). Patients had significantly higher TF levels than controls (patients: 84.95 +/- 17.16 pg/ml, controls: 70.55 +/- 15.87 pg/ml, p < 0.001). G allele of 603A > G polymorphism was significantly higher in patients than controls (patients: 40.5% controls: 27.5%, p = 0.004). Subjects with AG and GG genotype had significantly higher TF levels than AA genotype (p = 0.001). After multiple logistic regression analysis, risk of DVT was increased 1.398 fold (95% CI 0.738-2.651) and 4.41 fold (95% CI 1.404-13.884) with AG and GG genotype respectively. Allelic and genotypic frequencies of 5466A > G polymorphism was neither associated with TF levels nor with DVT. We found high TF level in patients with TF 603A > G polymorphism, which is an important predisposing factor in increasing risk of DVT in young Indians. Furthermore, GG genotype of 603A > G polymorphism augments the risk of thrombosis by 4.4 fold, thus highlighting the significance of this polymorphism in the development of DVT. So, we suggest that inclusion of 603A > G polymorphism in prothrombotic work-up may be helpful in making the treatment strategy in DVT patients.
AD  - All India Inst Med Sci, Dept Hematol, Room 205,2nd Floor New Private Ward, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - JUL
PY  - 2018
VL  - 46
IS  - 1
SP  - 88
EP  - 94
DO  - 10.1007/s11239-018-1666-6
AN  - WOS:000434801900019
ER  -

TY  - JOUR
AU  - Krishnan, S
AU  - Katiyar, V
AU  - Phalak, M
AU  - Sharma, R
TI  - <i>Streptococcus mutans</i> with Collagen-Binding Protein: From Oral Cavity to Brain
T2  - WORLD NEUROSURGERY
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - JUL
PY  - 2018
VL  - 115
SP  - 486
EP  - 486
DO  - 10.1016/j.wneu.2018.03.156
AN  - WOS:000436519600193
ER  -

TY  - JOUR
AU  - Kumar, A
AU  - Mutha, V
AU  - Gupta, Y
AU  - Karthikeya, R
AU  - Behera, A
TI  - Commentary on "Community care for diabetic retinopathy and glaucoma in India: A panel discussion"
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - PREVALENCE
KW  - DISEASE
AD  - AIIMS, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL
PY  - 2018
VL  - 66
IS  - 7
SP  - 921
EP  - 923
DO  - 10.4103/ijo.IJO_309_18
AN  - WOS:000437197400007
ER  -

TY  - JOUR
AU  - Kumar, A
AU  - Vohra, R
AU  - Agrawal, S
AU  - Chawla, R
AU  - Azad, SV
AU  - Venkatesh, P
AU  - Sharma, A
TI  - Characterization of Idiopathic Choroidal Neovascularization Using Fluorescein Angiography, Indocyanine Green Angiography, and Optical Coherence Tomography Angiography
T2  - OPHTHALMIC SURGERY LASERS & IMAGING RETINA
KW  - TYPE-2 NEOVASCULARIZATION
AB  - BACKGROUND AND OBJECTIVE: To assess the usefulness of optical coherence tomography angiography (OCTA) in cases of idiopathic choroidal neovascularization (iCNV).
   PATIENTS AND METHODS: Seven eyes with suspected iCNV were evaluated using OCT, OCTA, fluorescein angiography (FA), and indocyanine green angiography (ICGA) and were followed up between 3 weeks and 4 weeks following an intravitreal anti-vascular endothelial growth factor (VEGF) injection. The utility of OCTA in the diagnosis and characterization of morphology of iCNV at baseline and follow-up was assessed.
   RESULTS: Morphology of vasculature comprising iCNV could be detected in all cases (100%) on OCTA and in 57% cases on ICGA. FA only detected hyperfluorescence and not individual vessel morphology. After anti-VEGF injection, the mean logMAR visual acuity improved from 0.55 to 0.27. A qualitative scale to assess response of therapy is suggested.
   CONCLUSIONS: OCTA is a useful, noninvasive tool to detect, characterize, and follow-up on cases of suspected iCNV with utility comparable to or even better than traditional angiography techniques.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SLACK INC
PI  - THOROFARE
PA  - 6900 GROVE RD, THOROFARE, NJ 08086 USA
DA  - JUL
PY  - 2018
VL  - 49
IS  - 7
SP  - 516
EP  - 522
DO  - 10.3928/23258160-20180628-08
AN  - WOS:000441803700008
ER  -

TY  - JOUR
AU  - Kumar, L
AU  - Ganesan, P
TI  - Induction therapy for multiple myeloma: more is not necessarily better!
T2  - BRITISH JOURNAL OF HAEMATOLOGY
KW  - multiple myeloma
KW  - induction therapy
KW  - stem cell transplant
KW  - stem cell mobilization
KW  - STEM-CELL TRANSPLANTATION
KW  - DEXAMETHASONE VCD
KW  - IMWG CONSENSUS
KW  - BORTEZOMIB
KW  - CYCLOPHOSPHAMIDE
KW  - THALIDOMIDE
KW  - REGIMENS
KW  - TRIAL
KW  - VTD
AD  - All India Inst Med Sci, Dept Med Oncol, Room 234,IRCH Bldg, New Delhi 110029, IndiaAD  - Canc Inst WIA, Dept Med Oncol, Madras, Tamil Nadu, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUL
PY  - 2018
VL  - 182
IS  - 1
SP  - 7
EP  - 8
DO  - 10.1111/bjh.15242
AN  - WOS:000436244700001
ER  -

TY  - JOUR
AU  - Kumar, V
AU  - Gadkar, A
TI  - Multimodal imaging of Bietti's crystalline dystrophy
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Autofluorescence
KW  - Bietti's crystalline dystrophy
KW  - en face imaging
KW  - multimodal
KW  - red-free photographs
KW  - spectral-domain optical coherence tomography
AB  - Bietti's crystalline dystrophy (BCD) is a rare autosomal recessive retinal dystrophy characterized by deposition of crystals in the retina. The purpose of this article is to describe retinal abnormalities in BCD using multimodal imaging. An 18-year-old girl presented with decrease of vision and nyctalopia. She was assessed with color fundus picture, red-free photographs, short-wave autofluorescence, spectral-domain optical coherence tomography (OCT) and enface OCT and was diagnosed to have BCD based on typical presentation. Retinal crystals were better visualized on en face OCT as compared to conventional B scan OCT.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL
PY  - 2018
VL  - 66
IS  - 7
SP  - 1024
EP  - 1026
DO  - 10.4103/ijo.IJO_39_18
AN  - WOS:000437197400039
ER  -

TY  - JOUR
AU  - Kumar, V
AU  - Gupta, P
TI  - Parapapillary Optic Nerve Head Drusen in Leber Congenital Amaurosis
T2  - OPHTHALMIC SURGERY LASERS & IMAGING RETINA
AD  - AIIMS, Dr RP Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SLACK INC
PI  - THOROFARE
PA  - 6900 GROVE RD, THOROFARE, NJ 08086 USA
DA  - JUL
PY  - 2018
VL  - 49
IS  - 7
SP  - 554
EP  - 554
DO  - 10.3928/23258160-20180628-15
AN  - WOS:000441803700015
ER  -

TY  - JOUR
AU  - Kumari, R
AU  - Kumar, D
AU  - Brahmachari, SK
AU  - Srivastava, AK
AU  - Faruq, M
AU  - Mukerji, M
TI  - Paradigm for disease deconvolution in rare neurodegenerative disorders in Indian population: insights from studies in cerebellar ataxias
T2  - JOURNAL OF GENETICS
KW  - cerebellar ataxias
KW  - spinocerebellar ataxia
KW  - autosomal recessive cerebellar ataxia
KW  - next-generation sequencing
KW  - gene network
KW  - induced pluripotent stem cells
KW  - neurodegeneration
KW  - Indian population
KW  - MACHADO-JOSEPH-DISEASE
KW  - PLURIPOTENT STEM-CELLS
KW  - LATE-ONSET CEREBELLAR
KW  - GAA REPEAT EXPANSION
KW  - SPINOCEREBELLAR ATAXIA
KW  - FRIEDREICH-ATAXIA
KW  - POLYGLUTAMINE EXPANSIONS
KW  - CLINICAL-FEATURES
KW  - CAG REPEAT
KW  - REDUCED PENETRANCE
AB  - Cerebellar ataxias are a group of rare progressive neurodegenerative disorders with an average prevalence ranges from 4.8 to 13.8 in 100,000 individuals. The inherited disorders affect multiple members of the families, or a community that is endogamous or consanguineous. Presence of more than 3000 mutations in different genes with overlapping clinical symptoms, genetic anticipation and pleiotropy, as well as incomplete penetrance and variable expressivity due to modifiers pose challenges in genotype-phenotype correlation. Development of a diagnostic algorithm could reduce the time as well as cost in clinicogenetic diagnostics and also help in reducing the economic and social burden of the disease. In a unique research collaboration spanning over 20 years, we have been able to develop a paradigm for studying cerebellar ataxias in the Indian population which would also be relevant in other rare diseases. This has involved clinical and genetic analysis of thousands of families from diverse Indian populations. The extensive resource on ataxia has led to the development of a clinicogenetic algorithm for cost-effective screening of ataxia and a unique ataxia clinic in the tertiary referral centre in All India Institute of Medical Sciences. Utilizing a population polymorphism scanning approach, we have been able to dissect the mechanisms of repeat instability and expansion in many ataxias, and also identify founders, and trace the mutational histories in the Indian population. This provides information for genetic testing of at-risk as well as protected individuals and populations. To dissect uncharacterized cases which comprises more than 50% of the cases, we have explored the potential of next-generation sequencing technologies coupled with the extensive resource of baseline data generated in-house and other public domains. We have also developed a repository of patient-derived peripheral blood mononuclear cells, lymphoblastoid cell lines and neuronal lineages (derived from iPSCs) for ascribing functionality to novel genes/mutations. Through integrating these technologies, novel genes have been identified that has broadened the diagnostic panel, increased the diagnostic yield to over 75%, helped in ascribing pathogenicity to novel mutations and enabled understanding of disease mechanisms. It has also provided a platform for testing novel molecules for amelioration of pathophysiological phenotypes. This review through a perspective on CAs suggests a generic paradigm from diagnostics to therapeutic interventions for rare disorders in the context of heterogeneous Indian populations.
AD  - CSIR Inst Genom & Integrat Biol CSIR IGIB, Mathura Rd, New Delhi 110025, IndiaAD  - Acad Sci & Innovat Res, CSIR IGIB South Campus,Mathura Rd, New Delhi 110025, IndiaAD  - All India Inst Med Sci, Neurosci Ctr, New Delhi 110029, IndiaC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Academy of Scientific & Innovative Research (AcSIR)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - INDIAN ACAD SCIENCES
PI  - BANGALORE
PA  - C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
DA  - JUL
PY  - 2018
VL  - 97
IS  - 3
SP  - 589
EP  - 609
DO  - 10.1007/s12041-018-0948-2
AN  - WOS:000439132900002
ER  -

TY  - JOUR
AU  - Madaan, P
AU  - Gulati, S
AU  - Chakrabarty, B
AU  - Sapra, S
AU  - Sagar, R
AU  - Mohammad, A
AU  - Pandey, RM
AU  - Tripathi, M
TI  - Clinical spectrum of psychogenic non epileptic seizures in children; an observational study
T2  - SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
KW  - Psychogenic nonepileptic seizures
KW  - Short term video EEG
KW  - House tree person test
KW  - Dialeptic PNES
KW  - VIDEO-EEG-ANALYSIS
KW  - DETAILED SEMIOLOGICAL ANALYSIS
KW  - NONEPILEPTIC SEIZURES
KW  - PAROXYSMAL EVENTS
KW  - RISK-FACTORS
KW  - CLASSIFICATION
KW  - PNES
KW  - PSEUDOSEIZURES
AB  - Purpose: The current study was designed to analyze the clinical spectrum of Psychogenic non -epileptic seizures (PNES) in children.
   Methods: Children aged 6-16years with clinically suspected PNES, confirmed by short-term VEEG (STVEEG{video electroencephalogram]) and induction were classified as per Seneviratne classification. Stressors, associated co morbidities, Verbal IQ(Intelligence Quotient) and behavioral abnormalities were assessed using HTP(House tree person) test, DSM IV (Diagnostic and statistical manual of mental disorders) TR criteria, MISIC (Malin intelligence scale for Indian children) and CBCL (Child behaviour checklist).
   Results: Eighty children with PNES {45 boys; mean age: 10.5 (+/- 1.6) years) were enrolled. Median delay in diagnosis was 5 months {IQR(interguartile range)- 0.5 to 48 months)) and 45% patients were already on AED5 (antiepileptic drugs). Commonest semiology was dialeptic (42.5%), followed by mixed (28.8%), motor (15%) and nonepileptic aura (13.8%). Family stressors were the commonest followed by school related issues. The most common psychiatric comorbidity was adjustment disorder. Somatic complaints were observed in 50% children.
   Conclusions: Dialeptic PNES is commonest in children. In resource constrained settings, STVEEG along with induction is a reliable method to diagnose PNES. A comprehensive assessment protocol (including assessment of stressors) is needed for holistic management of pediatric PNES. (C) 2018 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
AD  - All India Inst Med Sci, Dept Pediat, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Psychiat, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - W B SAUNDERS CO LTD
PI  - LONDON
PA  - 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
DA  - JUL
PY  - 2018
VL  - 59
SP  - 60
EP  - 66
DO  - 10.1016/j.seizure.2018.04.024
AN  - WOS:000437818500012
ER  -

TY  - JOUR
AU  - Malhotra, S
AU  - Vashist, P
AU  - Gupta, N
AU  - Kalaivani, M
AU  - Rath, R
AU  - Gupta, SK
TI  - Prevalence and causes of visual impairment among adults aged 15-49 years in a rural area of north India - A population-based study
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Adults
KW  - Jhajjar
KW  - prevalence
KW  - rural
KW  - visual impairment
KW  - NATIONAL BLINDNESS
KW  - VISION IMPAIRMENT
KW  - REFRACTIVE ERROR
KW  - RAPID ASSESSMENT
KW  - DISTRICT
KW  - TRENDS
AB  - Purpose: Very few studies have been conducted in India and other parts of the world on visual impairment among individuals aged 15-49 years. This study was conducted to determine the prevalence, causes, and associated factors of visual impairment among adults aged 15-49 years in a rural population of Jhajjar district, Haryana, north India. Methods: A population-based cross-sectional study was conducted in two blocks of Jhajjar district. A total of 34 villages were selected using probability proportionate to size sampling method. Adults aged 15-49 years were selected using compact segment cluster sampling approach. As part of the house-to-house survey, presenting visual acuity using screening chart corresponding to five "E" 6/12 optotypes was measured along with collection of other demographic details. The optometrists performed detailed eye assessment including repeat measurement of visual acuity using retro-illuminated conventional logMAR tumbling "E" charts, torch light examination, and non-cycloplegic refraction at a clinic site within the village to ascertain visual impairment and its cause. Results: Of 5,470 enumerated adults, 5,117 (94%) completed all study procedures. The age-and sex-adjusted prevalence of visual impairment was found to be 1.85% [95% confidence interval (CI): 1.48, 2.23] and blindness was 0.09% (95% CI: 0.01, 0.18). The age-and sex-adjusted prevalence of unilateral visual impairment was 1.11% (95% CI: 0.81, 1.41). Uncorrected refractive errors (84%) contributed maximum to visual impairment in this age group. The visual impairment in study participants was found to be associated with age and educational status. Conclusion: At the community level, uncorrected refractive errors contribute largely to visual impairment in the age group of 15-49 years.
AD  - All India Inst Med Sci, Ctr Community Med, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Community Ophthalmol, New Delhi, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Ophthalmol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL
PY  - 2018
VL  - 66
IS  - 7
SP  - 951
EP  - 956
DO  - 10.4103/ijo.IJO_1333_17
AN  - WOS:000437197400014
ER  -

TY  - JOUR
AU  - Mandula, PP
AU  - Malik, R
AU  - Khanna, G
TI  - Protein Losing Enteropathy in Hennekam Syndrome
T2  - INDIAN JOURNAL OF PEDIATRICS
AD  - All India Inst Med Sci, Dept Pediat, Div Gastroenterol Hepatol & Clin Nutr, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUL
PY  - 2018
VL  - 85
IS  - 7
SP  - 587
EP  - 588
DO  - 10.1007/s12098-017-2602-z
AN  - WOS:000436093400031
ER  -

TY  - JOUR
AU  - Manoharan, D
AU  - Sharma, S
AU  - Das, CJ
AU  - Kumar, R
AU  - Singh, G
AU  - Kumar, P
TI  - Single-Acquisition Triple-Bolus Dual-Energy CT Protocol for Comprehensive Evaluation of Renal Masses: A Single-Center Randomized Noninferiority Trial
T2  - AMERICAN JOURNAL OF ROENTGENOLOGY
KW  - CT
KW  - dual-energy CT
KW  - noninferiority randomized trial
KW  - radiation dose
KW  - renal cell carcinoma
KW  - renal mass
KW  - triple-bolus technique
KW  - CELL CARCINOMA
KW  - TRACT OPACIFICATION
KW  - MULTIDETECTOR CT
KW  - MDCT UROGRAPHY
KW  - IMAGE QUALITY
KW  - PHASE
KW  - ENHANCEMENT
KW  - IODINE
KW  - ANGIOGRAPHY
KW  - ONCOCYTOMA
AB  - OBJECTIVE. The primary objective of this study was to compare triple-bolus dual-energy CT (DECT) against standard triple-phase MDCT in terms of appropriateness of patient treatment.
   SUBJECTS AND METHODS. One hundred twenty-four patients with suspected renal masses seen at ultrasound were randomized into triple-bolus DECT and triple-phase MDCT groups. Patients in the triple-bolus DECT group underwent synchronous corticomedullary nephrographic delayed-phase triple-bolus DECT. In the triple-phase MDCT group, single-energy triple-phase scans were acquired after an unenhanced scan. The primary outcome was appropriateness of treatment received at 1 year. The predefined noninferiority limit was 10%. Histopathologic analysis or follow-up confirmed the benign or malignant nature of the masses. Diagnostic accuracy to differentiate benign from malignant masses was calculated. Size-specific dose estimates were compared.
   RESULTS. After excluding six patients, 118 patients were analyzed ( 62 triple-bolus DECT; 56 triple-phase MDCT). Treatment appropriateness was not significantly different (p = 0.9397) between the two groups (61/ 62 [98.39%; 95% CI, 95.26-101.52%] for triple-bolus DECT vs 55/56 [98.21%; 95% CI, 94.74-101.68%] for triple-phase MDCT). The absolute difference was 0.18% (95% CI, -4.48% to 4.84%). Both techniques had similar diagnostic accuracy (sensitivity, 98.25% vs 96.67%; specificity, 98.17% vs 97.97%). The mean (+/- SD) size-specific dose estimate was significantly lower for triple-bolus DECT than for triple-phase MDCT (19.02 +/- 4.07 vs 57.04 +/- 15.17 mGy; p < 0.0001).
   CONCLUSION. Single-acquisition triple-bolus DECT is noninferior to triple-phase MDCT, with similar diagnostic accuracy but delivering significantly less radiation.
AD  - All India Inst Med Sci, Dept Radiol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Urol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Med Phys, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ROENTGEN RAY SOC
PI  - RESTON
PA  - 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
DA  - JUL
PY  - 2018
VL  - 211
IS  - 1
SP  - W22
EP  - W32
DO  - 10.2214/AJR.17.18786
AN  - WOS:000439842000003
ER  -

TY  - JOUR
AU  - Mazzeo, AT
AU  - Gupta, DK
TI  - Intraoperative visual evoked potential monitoring for a safer endoscopic transsphenoidal surgery
T2  - NEUROLOGY INDIA
AD  - Univ Turin, Dept Surg Sci, Unit Anesthesia & Intens Care, Turin, ItalyAD  - All India Inst Med Sci, Neurosci Ctr, New Delhi, IndiaAD  - All India Inst Med Sci, JPN Apex Trauma Ctr, New Delhi, IndiaC3  - University of TurinC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-AUG
PY  - 2018
VL  - 66
IS  - 4
SP  - 955
EP  - 957
C7  - PMID 30038077
DO  - 10.4103/0028-3886.236996
AN  - WOS:000447540700013
ER  -

TY  - JOUR
AU  - Meel, R
AU  - Dhiman, R
TI  - Proposal for a new classification for ocular surface squamous neoplasia
T2  - EYE
AD  - All India Inst Med Sci, Dr R P Ctr Ophthalm Sci, Oculoplasty & Ocular Oncol Serv, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - NATURE PUBLISHING GROUP
PI  - LONDON
PA  - MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - JUL
PY  - 2018
VL  - 32
IS  - 7
SP  - 1284
EP  - 1285
DO  - 10.1038/s41433-018-0058-7
AN  - WOS:000438467100019
ER  -

TY  - JOUR
AU  - Mishra, RC
AU  - Mishra, S
TI  - Olfactory groove meningiomas: The surgical approaches and factors influencing prognosis
T2  - NEUROLOGY INDIA
AD  - Global Rainbow Healthcare, Dept Neurosurg, Agra, Uttar Pradesh, IndiaAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-AUG
PY  - 2018
VL  - 66
IS  - 4
SP  - 964
EP  - 966
C7  - PMID 30038081
DO  - 10.4103/0028-3886.236997
AN  - WOS:000447540700017
ER  -

TY  - JOUR
AU  - Misra, A
AU  - Chauhan, S
AU  - Tanwar, P
AU  - Singh, S
AU  - Sharma, S
AU  - Rai, S
TI  - Real-Time Compensation in Flow Cytometry: A Real Need of Time
T2  - INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
AD  - Indian Council Med Res, NIOP, New Delhi, IndiaAD  - Ananta Inst Med Sci & Res Ctr, Rajasamand, Rajasthan, IndiaAD  - All India Inst Med Sci, DR B R A IRCH, Dept Lab Oncol, New Delhi, IndiaAD  - Indian Council Med Res, NIMS, New Delhi, IndiaC3  - Indian Council of Medical Research (ICMR)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Council of Medical Research (ICMR)PU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUL
PY  - 2018
VL  - 34
IS  - 3
SP  - 585
EP  - 588
DO  - 10.1007/s12288-018-0914-4
AN  - WOS:000441120900041
ER  -

TY  - JOUR
AU  - Mittal, S
AU  - Tiwari, P
AU  - Madan, K
AU  - Khilnani, GC
AU  - Mohan, A
AU  - Hadda, V
TI  - Isoniazid-resistant, rifampicin-susceptible tuberculosis in India
T2  - LANCET RESPIRATORY MEDICINE
AD  - All India Inst Med Sci, Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - JUL
PY  - 2018
VL  - 6
IS  - 7
SP  - E29
EP  - E29
DO  - 10.1016/S2213-2600(18)30209-1
AN  - WOS:000436820300002
ER  -

TY  - JOUR
AU  - Nair, R
AU  - Kakroo, A
AU  - Bapna, A
AU  - Gogia, A
AU  - Vora, A
AU  - Pathak, A
AU  - Korula, A
AU  - Chakrapani, A
AU  - Doval, D
AU  - Prakash, G
AU  - Biswas, G
AU  - Menon, H
AU  - Bhattacharya, M
AU  - Chandy, M
AU  - Parihar, M
AU  - Krishna, MV
AU  - Arora, N
AU  - Gadhyalpatil, N
AU  - Malhotra, P
AU  - Narayanan, P
AU  - Nair, R
AU  - Basu, R
AU  - Shah, S
AU  - Bhave, S
AU  - Bondarde, S
AU  - Bhartiya, S
AU  - Nityanand, S
AU  - Gujral, S
AU  - Tilak, TVS
AU  - Radhakrishnan, V
TI  - Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group
T2  - INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
KW  - Lymphoma
KW  - Consensus statement
KW  - Management
KW  - Common regimens
KW  - HODGKINS-LYMPHOMA
KW  - CHEMOTHERAPY
KW  - RADIOTHERAPY
KW  - REGIMEN
AB  - The clinical course of lymphoma depends on the indolent or aggressive nature of the disease. Hence, the optimal management of lymphoma needs a correct diagnosis and classification as B cell, T-cell or natural killer (NK)/T-cell as well as indolent or high-grade type lymphoma. The current consensus statement, developed by experts in the field across India, is intended to help healthcare professionals manage lymphomas in adults over 18 years of age. However, it should be noted that the information provided may not be appropriate to all patients and individual patient circumstances may dictate alternative approaches. The consensus statement discusses the diagnosis, staging and prognosis applicable to all subtypes of lymphoma, and detailed treatment regimens for specific entities of lymphoma including diffuse large B-cell lymphoma, Hodgkin's lymphoma, follicular lymphoma, T-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Burkitt's lymphoma, and anaplastic large cell lymphoma.
AD  - TMC, Dept Clin Hematol, Kolkata 700160, W Bengal, IndiaAD  - Vedant Inst Med Sci, Ahmadabad, Gujarat, IndiaAD  - BMCHRC, Jaipur, Rajasthan, IndiaAD  - AIIMS, New Delhi, IndiaAD  - Pratiksha Hosp, Gurgaon, IndiaAD  - NCI, Nagpur, Maharashtra, IndiaAD  - CMC, Vellore, Tamil Nadu, IndiaAD  - Apollo Gleneagles Hosp, Kolkata, IndiaAD  - Rajiv Gandhi Canc Inst & Res Ctr RGCI, Delhi, IndiaAD  - PGIMER, Chandigarh, IndiaAD  - Sparsh Hosp, AOI, Bhubaneswar, IndiaAD  - Cytecare Canc Hosp, Bangalore, Karnataka, IndiaAD  - Calcutta Med Coll, Kolkata, IndiaAD  - Apollo Hosp, Hyderabad, IndiaAD  - Yashoda Hosp Somajiguda, Hyderabad, IndiaAD  - RCC, Thiruvananthapuram, Kerala, IndiaAD  - Shatabdi Super Special Hosp, Nasik, IndiaAD  - SGPGIMS, Lucknow, Uttar Pradesh, IndiaAD  - Tata Mem Hosp, Bombay, Maharashtra, IndiaAD  - Command Hosp, Air Force Bangalore, Bangalore, Karnataka, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUL
PY  - 2018
VL  - 34
IS  - 3
SP  - 398
EP  - 421
DO  - 10.1007/s12288-018-0991-4
AN  - WOS:000441120900003
ER  -

TY  - JOUR
AU  - Nair, S
AU  - Vanathi, M
AU  - Mahapatra, M
AU  - Seth, T
AU  - Kaur, J
AU  - Velpandian, T
AU  - Ravi, A
AU  - Titiyal, JS
AU  - Tandon, R
TI  - Tear inflammatory mediators and protein in eyes of post allogenic hematopoeitic stem cell transplant patients
T2  - OCULAR SURFACE
KW  - Ocular GVHD
KW  - Graft versus host disease
KW  - Hematopoetic stem cell transplant
KW  - Dry eye
KW  - Tear cytokines
KW  - Inflammatory mediators
KW  - Tear proteins
KW  - VERSUS-HOST-DISEASE
KW  - NECROSIS-FACTOR-ALPHA
KW  - PREDICT CHRONIC GVHD
KW  - CHRONIC GRAFT
KW  - DRY EYE
KW  - MATRIX METALLOPROTEINASES
KW  - DESICCATING STRESS
KW  - CYTOKINES
KW  - EXPRESSION
KW  - BIOMARKERS
AB  - Aim: To analyze tear cytokines levels and their correlation to ocular surface parameters in allogenic hematopoietic stem cell transplants (allo-HSCT) patients.
   Methods: Prospective longitudinal study of allo-HSCT patients and controls for ocular surface evaluation (OSDI, TBUT, Schirmer's test, staining scores), tear biochemical analysis for protein, cytokines [IL-10, IL-12, IL-2, IL-4, IL-6, IL-17, interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, VEGF], MMPs [MMP 2, 9, 7, 13, 10 and chemokine (IL-8)], & VEGF on three consecutive follow up visits (at three monthly interval) was done.
   Results: Of 24 post allo-HSCT patients (19 males, 5 females) & 12 controls (mean age 34.3 + 5.8 years) enrolled, 20 patients [mean age 33.4 + 7.77 years; mean time of recruitment of 5.2 + 2.12 months following alloHSCT] who completed three consecutive follow up visits were included for analysis. Ocular GVHD (oGVHD) was seen in 8 patients (33.3%). Tears biochemical analysis showed elevated levels of interferon gamma, IL 6, IL 8, IL 10, IL 12AP70, IL 17A, MMP 9 and VEGF in oGVHD eyes as compared to non-oGVHD & control eyes. Non-oGVHD eyes showed elevated tear MMP 7 and MMP 9 as compared to healthy controls. Tear protein levels were significantly decreased in oGVHD eyes and were equivocal in nonGVHD and control eyes. TBUT and ocular staining scores to correlate best with tear interleukins and MMPs.
   Conclusion: Evaluation of levels of tear VEGF, total protein & MMP 9 can be of significance in identifying oGVHD in post alloHSCT patients.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Cornea & Ocular Surface Serv, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Hematol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Ocular Biochem Serv, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Ocular Pharmacol Serv, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUL
PY  - 2018
VL  - 16
IS  - 3
SP  - 352
EP  - 367
DO  - 10.1016/j.jtos.2018.04.007
AN  - WOS:000436496600013
ER  -

TY  - JOUR
AU  - Nambirajan, A
AU  - Suri, V
AU  - Kedia, S
AU  - Goyal, K
AU  - Malgulwar, P
AU  - Khanna, G
AU  - Panda, P
AU  - Gulati, S
AU  - Garg, A
AU  - Sharma, M
TI  - Paediatric diffuse leptomeningeal tumor with glial and neuronal differentiation harbouring chromosome 1p/19q co-deletion and <i>H3.3 K27M</i> mutation: unusual molecular profile and its therapeutic implications
T2  - BRAIN TUMOR PATHOLOGY
KW  - Diffuse leptomeningeal glioneuronal tumor
KW  - 1p deletion
KW  - 19q deletion
KW  - H3K27M
KW  - Paediatric
KW  - GLIONEURONAL TUMORS
KW  - CHILDHOOD
KW  - DISEASE
KW  - ENTITY
KW  - V600E
AB  - Diffuse leptomeningeal glioneuronal tumor (DL-GNT) is a newly introduced tumor entity of uncertain prognosis characterised by a primary diffuse leptomeningeal growth pattern, oligodendroglial-like morphology and dual glial/neuronal differentiation. Predominantly occurring in children, these tumors present as chronic meningitis and mimic infectious/inflammatory diseases. They are surgically challenging tumors with a high incidence of delayed morbidity and mortality despite low-grade histology. Their molecular genetic profile is not fully elucidated and few reports have identified chromosome 1p and 19q deletions, and BRAF alterations. We present a rare instance of a DL-GNT in a 13-year-old female who presented with slowly progressive and sequential neurological deficits over a 12-month duration. Imaging showed leptomeningeal thickening and spinal lesions. Biopsy from the spinal mass showed histomorphological features characteristic of DL-GNT. Further molecular analysis revealed 1p and 19q co-deletion and H3K27M mutation, while no mutation were identified in IDH, TERT, or BRAF genes. Patient died 4 months after diagnosis. Only one previous case of DL-GNT has been reported to harbour H3K27M mutation. Although H3K27M mutations have been described in rare examples of low-grade glial and glioneuronal tumors, whether DL-GNTs with H3K27M represent a rare growth pattern of the aggressive H3K27M-mutant diffuse midline gliomas needs further clarification.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pediat, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Neuroradiol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER JAPAN KK
PI  - TOKYO
PA  - CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN
DA  - JUL
PY  - 2018
VL  - 35
IS  - 3
SP  - 186
EP  - 191
DO  - 10.1007/s10014-018-0325-0
AN  - WOS:000440083500007
ER  -

TY  - JOUR
AU  - Nehate, C
AU  - Raynold, AAM
AU  - Haridas, V
AU  - Koul, V
TI  - Comparative Assessment of Active Targeted Redox Sensitive Polymersomes Based on pPEGMA-S-S-PLA Diblock Copolymer with Marketed Nanoformulation
T2  - BIOMACROMOLECULES
KW  - DRUG-DELIVERY
KW  - FOLIC-ACID
KW  - IN-VITRO
KW  - DOXORUBICIN DELIVERY
KW  - CANCER-CELLS
KW  - CO-DELIVERY
KW  - NANOPARTICLES
KW  - NANOCARRIERS
KW  - THERAPY
KW  - OPTIMIZATION
AB  - In the present work, polymersomes based on self assembled, folate-targeted, redox-responsive, ATRP-based amphiphilic diblock copolymer poly(polyethylene glycol)-S-S-polylactide with disulfide linkage were developed for efficient doxorubicin (DOX) delivery and compared with marketed DOXIL nano formulation. The polymersomes formulation was optimized by quality by design approach providing monodisperse nanostructures of similar to 110 nm and enhanced DOX loading of similar to 20%. Polymersomes showed excellent stability as per the ICH guidelines over the extended storage period of 3 months. The in vitro drug release profile confirmed the redox sensitive behavior of polymersomes providing 80% drug release in endosomal pH 5 with 10 mmol GSH as compared to similar to 20% release at pH 7.4. The targeted polymersomes achieved enhanced cellular internalization in folate receptor overexpressing cell lines, MDA-MB-231 and HeLa, providing similar to 24% higher tumor reduction than DOXIL in Ehrlich ascites tumor bearing Swiss albino mice.
AD  - Indian Inst Technol Delhi, Ctr Biomed Engn, New Delhi 110016, IndiaAD  - All India Inst Med Sci, Biomed Engn Unit, New Delhi 110029, IndiaAD  - Indian Inst Technol Delhi, Dept Chem, New Delhi 110016, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiPU  - AMER CHEMICAL SOC
PI  - WASHINGTON
PA  - 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
DA  - JUL
PY  - 2018
VL  - 19
IS  - 7
SP  - 2549
EP  - 2566
DO  - 10.1021/acs.biomac.8b00178
AN  - WOS:000438470800019
ER  -

TY  - JOUR
AU  - Panda, S
AU  - Sengupta, T
AU  - Kaur, T
TI  - RETRACTED: A mathematical model to study the relationship between the dietary profiles, core body temperature and sleep profile in the high school students (Retracted Article)
T2  - SLEEP AND BIOLOGICAL RHYTHMS
KW  - Daily habits
KW  - Delayed sleep
KW  - Late night eating
KW  - Altered circadian rhythm
KW  - Mathematical model
KW  - Body temperature regulation
KW  - CIRCADIAN-RHYTHMS
KW  - MASS INDEX
KW  - ALERTNESS
KW  - DURATION
KW  - PERFORMANCE
KW  - PHASE
AB  - Body temperature (T-b), food intake and sleep cycle follows a circadian rhythm. Circadian variations of T-b may be influenced by changes in sleep time, late night consumption of high calorie diet and less physical activities. Deviations in any of these daily habits may alter the acrophase, mesor and amplitude of the cosinor curve of T-b. Changes in these confounding factors may also contribute to the body mass index (BMI) of the individual. This study was conducted on 29 high school going adolescents. We have employed an ideal cosinor model to study the changes in the 24 h cyclical changes in T-b (n = 12). Academic overload during examination days was seen in these high school going adults. Sleep duration and dietary habits were also studied in them to find out the relationship with BMI and circadian variations if any (n = 17). Higher BMI was observed in individuals having shorter sleep duration. BMI was high in students consuming high calorie diet at the time of the day when the body metabolism is normally low. A mathematical model exhibiting altered circadian rhythms is proposed that may be used to modify strategies to restore biorhythms for better health.
AD  - DPS, New Delhi, IndiaAD  - AIIMS, Dept Physiol, Baldev Singh Sleep Lab, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER JAPAN KK
PI  - TOKYO
PA  - SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN
DA  - JUL
PY  - 2018
VL  - 16
IS  - 3
SP  - 307
EP  - 313
DO  - 10.1007/s41105-018-0157-7
AN  - WOS:000436086500006
ER  -

TY  - JOUR
AU  - Pandey, S
AU  - Dash, D
TI  - Cellular Age in the Manifestation of Disease-Relevant Phenotypes in Huntington's Disease
T2  - MOVEMENT DISORDERS
AD  - Govind Ballabh Pant Postgrad Inst Med Educ & Res, Dept Neurol, Acad Block,Room 507, New Delhi 110002, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - Govind Ballabh Pant Institute of Postgraduate Medical Education & ResearchC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUL
PY  - 2018
VL  - 33
IS  - 7
SP  - 1096
EP  - 1096
DO  - 10.1002/mds.27425
AN  - WOS:000442851800007
ER  -

TY  - JOUR
AU  - Panwar, R
TI  - Letter to the Editor for "Low Versus Standard Urine Output Targets in Patients Undergoing Major Abdominal Surgery''
T2  - ANNALS OF SURGERY
AD  - All India Inst Med Sci, Dept GI Surg & Liver Transplantat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - JUL
PY  - 2018
VL  - 268
IS  - 1
SP  - E22
EP  - E23
DO  - 10.1097/SLA.0000000000002488
AN  - WOS:000452662400022
ER  -

TY  - JOUR
AU  - Patra, S
AU  - Nimitha, P
AU  - Kaul, S
AU  - Valakkada, J
AU  - Verma, KK
AU  - Ramam, M
AU  - Bhari, N
TI  - Primary cutaneous histoplasmosis in an immunocompetent patient presenting with severe pruritus
T2  - INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-AUG
PY  - 2018
VL  - 84
IS  - 4
SP  - 465
EP  - +
DO  - 10.4103/ijdvl.IJDVL_695_17
AN  - WOS:000436616500023
ER  -

TY  - JOUR
AU  - Pragasam, AK
AU  - Veeraraghavan, B
AU  - Anandan, S
AU  - Narasiman, V
AU  - Sistla, S
AU  - Kapil, A
AU  - Mathur, P
AU  - Ray, P
AU  - Wattal, C
AU  - Bhattacharya, S
AU  - Deotale, V
AU  - Subramani, K
AU  - Peter, JV
AU  - Hariharan, TD
AU  - Ramya, I
AU  - Iniyan, S
AU  - Walia, K
AU  - Ohri, VC
TI  - Dominance of International High-Risk Clones in Carbapenemase-Producing <i>Pseudomonas aeruginosa</i>: Multicentric Molecular Epidemiology Report from India
T2  - INDIAN JOURNAL OF MEDICAL MICROBIOLOGY
KW  - Carbapenem
KW  - clonality
KW  - high-risk clones
KW  - Pseudomonas aeruginosa
KW  - resistance
KW  - RESISTANCE
KW  - MARKERS
AB  - Background: Pseudomonas aeruginosa is one of the most common opportunistic pathogens that cause severe infections in humans. The burden of carbapenem resistance is particularly high and is on the rise. Very little information is available on the molecular mechanisms and its clonal types of carbapenem-resistant P. aeruginosa seen in Indian hospitals. This study was undertaken to monitor the beta-lactamase profile and to investigate the genetic relatedness of the carbapenemase-producing (CP) P. aeruginosa collected across different hospitals from India. Materials and Methods: A total of 507 non-duplicate, carbapenem-resistant P. aeruginosa isolated from various clinical specimens collected during 2014-2017 across seven Indian hospitals were included. Conventional multiplex polymerase chain reaction for the genes encoding beta-lactamases such as extended-spectrum beta-lactamase (ESL) and carbapenemase were screened. A subset of isolates (n = 133) of CP P. aeruginosa were genotyped by multilocus sequence typing (MLST) scheme. Results: Of the total 507 isolates, 15%, 40% and 20% were positive for genes encoding ESBLs, carbapenemases and ESBLs+ carbapenemases, respectively, whilst 25% were negative for the beta-lactamases screened. Amongst the ESBL genes, bla<INF><INF>VEB</INF></INF> is the most predominant followed by bla<INF>PER</INF> and bla<INF>TEM</INF>, whilst bla<INF>VIM</INF> and bla<INF>NDM</INF> were the most predominant carbapenemases seen. However, regional differences were noted in the beta-lactunases profile across the study sites. Genotyping by MLST revealed 54 different sequence types (STs). The most common are ST357, ST235, ST233 and ST244. Six clonal complexes were found (CC357, CC235, CC244, CC1047, CC664 and CC308). About 24% of total STs are of novel types and these were found to emerge from the high-risk clones. Conclusion: This is the first large study from India to report the baseline data on the molecular resistance mechanisms and its association with genetic relatedness of CP P. aeruginosa circulating in Indian hospitals. bla<INF>VIM</INF>-and bla<INF>NDM</INF>-producing P. aeruginosa is the most prevalent carbapenemase seen in India. Majority of the isolates belongs to the high-risk international clones ST235, ST357 and ST664 which is a concern.
AD  - Christian Med Coll & Hosp, Dept Clin Microbiol, Vellore 632004, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp, Dept Crit Care, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp, Dept Orthopaed Surg, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp, Dept Med, Unit 5, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp, Dept Surg, Vellore, Tamil Nadu, IndiaAD  - Jawaharlal Inst Postgrad Med Educ & Res, Dept Microbiol, Pondicherry, IndiaAD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaAD  - Sir Ganga Ram Hosp, Dept Microbiol, New Delhi, IndiaAD  - Indian Council Med Res, Div Epidemiol & Communicable Dis, Dept Microbiol, New Delhi, IndiaAD  - Postgrad Inst Med Educ & Res, Dept Microbiol, Chandigarh, IndiaAD  - Tata Med Ctr, Dept Microbiol, Kolkata, W Bengal, IndiaAD  - Mahatma Gandhi Inst Med Sci, Dept Microbiol, Sevagram, Maharashtra, IndiaC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Jawaharlal Institute of Postgraduate Medical Education & ResearchC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Council of Medical Research (ICMR)C3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Mahatma Gandhi Institute of Medical Sciences, SevagramPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - JUL-SEP
PY  - 2018
VL  - 36
IS  - 3
SP  - 344
EP  - 351
C7  - PMID 30429385
DO  - 10.4103/ijmm.IJMM_18_294
AN  - WOS:000450218100006
ER  -

TY  - JOUR
AU  - Prasad, GL
AU  - Sinha, S
AU  - Krishna, G
TI  - Rupture of spinal dermoid cyst with intracranial dissemination: Report of a case and review of the literature
T2  - NEUROLOGY INDIA
KW  - CENTRAL CANAL RUPTURE
KW  - FATTY DROPLETS
KW  - SPREAD
KW  - TUMORS
KW  - DROPS
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-AUG
PY  - 2018
VL  - 66
IS  - 4
SP  - 1195
EP  - 1199
DO  - 10.4103/0028-3886.236984
AN  - WOS:000447540700062
ER  -

TY  - JOUR
AU  - Pujari, A
AU  - Temkar, S
AU  - Agarwal, S
AU  - Garg, G
AU  - Chawla, R
AU  - Kumar, A
TI  - Foveolar simple retinal pigment epithelial hamartoma
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Optical coherence tomography angiography
KW  - retinal pigment epithelial hamartoma
KW  - Swept source optical coherence tomography
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 212,Second Floor,RPC-1, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL
PY  - 2018
VL  - 66
IS  - 7
SP  - 999
EP  - 1000
DO  - 10.4103/ijo.IJO_54_18
AN  - WOS:000437197400026
ER  -

TY  - JOUR
AU  - Puliyel, J
AU  - Naik, P
AU  - Puliyel, A
AU  - Agarwal, K
AU  - Lal, V
AU  - Kansal, N
AU  - Nandan, D
AU  - Tripathi, V
AU  - Tyagi, P
AU  - Singh, SK
AU  - Srivastava, R
AU  - Sharma, U
AU  - Sreenivas, V
TI  - Evaluation of the Protection Provided by Hepatitis B Vaccination in India
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Immunization
KW  - Passive immunity
KW  - Hepatitis B surface antigen
KW  - Hepatitis B core antigen
KW  - Antibody to hepatitis B surface antigen
KW  - Antibody to hepatitis B core antigen
KW  - IMMUNIZATION
KW  - TRANSMISSION
KW  - INFECTION
KW  - INFANTS
KW  - MOTHERS
KW  - VIRUS
AB  - Objective In India, Hepatitis B vaccination is recommended at 6 wk except for hospital-deliveries. The authors examined protection afforded by the birth dose.
   Methods A case-control study was done. HBsAg and HBcAb were tested in 2671 children, 1 to 5 y and HBsAb was evaluated in a subset of 1413 children. Vaccination history was recorded. Cases were HBsAg carriers. In another analysis, children who got infected (HBsAg and/or HBcAb positive) were considered as cases. Exposed were the unvaccinated. In another analysis, exposed were those vaccinated without the birth dose.
   Results The odds ratio (OR) for HBsAg positivity with birth vaccination was 0.35 (95% CI 0.19-0.66); while with vaccination at 6 wk was 0.29 (95% CI 0.14-0.61), both compared to unvaccinated. Birth vaccination has no added protection when compared to the unvaccinated. Unvaccinated children in index study had HBsAg positivity of 4.38%. The number needed to treat (NNT) to prevent one case of HBsAg positivity was 32.6 (95% CI, 20.9 to 73.6). The odds of getting HBV infection was 0.42 (CI 0.25-0.68) with birth dose and 0.49 (CI 0.30-0.82) without the birth dose compared to the unvaccinated. Protective antibody (HBsAb) was present in about 70% of the vaccinated. In the unimmunised, in the first 2 y HBsAb protection was present in 40%. The odds ratio (OR) for HBsAb in the fully vaccinated between 4 and 5 y was 1.4 (95% CI 0.9-2.18) compared to the unvaccinated.
   Conclusions The present study lends support to the pragmatic approach of the Government to vaccinate babies born at home starting at 6 wk.
AD  - St Stephens Hosp, Dept Pediat, Delhi 110054, IndiaAD  - Pathik Childrens Hosp, Dept Pediat, Surat, IndiaAD  - Consumer CAP HPI, London, EnglandAD  - Sardarmal Khandaka Mem Hosp, Dept Pediat, Jaipur, Rajasthan, IndiaAD  - Dr Lal PathLabs, Dept Biochem, Delhi, IndiaAD  - Dr RML Hosp, PGIMER, Dept Pediat, New Delhi, IndiaAD  - Pt Madan Mohan Malaviya Hosp, Dept Pediat, Delhi, IndiaAD  - Nazareth Hosp, Dept Pediat, Allahabad, Uttar Pradesh, IndiaAD  - SMI Hosp, SGRRIM&S, Dept Pediat, Patel Nagar, Dehradun, IndiaAD  - Thiranker Mahhavir Med Coll, Dept Pediat, Muradabad, IndiaAD  - All India Inst Med Sci, Dept Biostat, Delhi, IndiaC3  - St. Stephen's HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUL
PY  - 2018
VL  - 85
IS  - 7
SP  - 510
EP  - 516
DO  - 10.1007/s12098-017-2601-0
AN  - WOS:000436093400007
ER  -

TY  - JOUR
AU  - Rawat, C
AU  - Guin, D
AU  - Talwar, P
AU  - Grover, S
AU  - Baghel, R
AU  - Kushwaha, S
AU  - Sharma, S
AU  - Agarwal, R
AU  - Bala, K
AU  - Srivastavas, AK
AU  - Kukreti, R
TI  - Clinical predictors of treatment outcome in North Indian patients on antiepileptic drug therapy: A prospective observational study
T2  - NEUROLOGY INDIA
KW  - Age at onset
KW  - cryptogenic epilepsy
KW  - epilepsy
KW  - pretreatment seizure frequency
KW  - prognostic factors
KW  - REFRACTORY EPILEPSY
KW  - MONOTHERAPY
KW  - POLYTHERAPY
KW  - SEIZURES
KW  - REMISSION
KW  - ONSET
AB  - Background: Nearly 40%-50% of the individuals fail to respond to first line antiepileptic drug (AED) monotherapy and 30% are refractory, which calls for the need to recognize predictive markers for treatment failure. This study aims to identify clinical factors predictive of a poor prognosis in patients on AED therapy.
   Materials and Methods: A prospective follow-up study involving 1056 patients with epilepsy (PWE) aged 5-67 years from North India on phenytoin (PHT, n = 247), carbamazepine (CBZ, n = 369), valproate (VA, n = 271), phenobarbital (PB, n = 50), and multitherapy (MultiT, n = 119) was conducted between 2005 and 2015. Seizure and epilepsy types were diagnosed based on the classifications by the International League Against Epilepsy (ILAE). Patients remaining seizure-free during the past 1 year were assigned to the "no seizure" group and patients experiencing seizure recurrence were assigned to the "recurrent seizures" group.
   Results: Of the total, 786 (74.4%) patients were successfully followed up with 60% achieving 1-year seizure remission. Seizure recurrence was observed in the remaining 40% of the patients with a high likelihood in patients with the disease onset at = 5 years of age [55% vs. 38%, P = 0.0016, odds ratio (OR) = 2.02 (95% confidence interval (CI) = 1.31-3.13)], in patients with cryptogenic epilepsy than with idiopathic/symptomatic epilepsy (48% vs. 32%, P = 0.0049, OR = 1.61 [95% CI = 1.16-2.24]), and in patients with pretreatment seizure frequency = 12/year (46% vs. 27%, P < 0.0001, OR = 2.21 [95% CI = 1.61-3.05]). Logistic regression analysis also revealed a significant association of seizure recurrence (P < 0.05) with the three variables.
   Conclusion: Our findings suggest that an early disease onset, cryptogenic epilepsy, and a higher pretreatment seizure frequency are related to a poor prognosis or poor remission in people with epilepsy (PWE) on AED therapy.
AD  - All India Inst Med Sci, CSIR, IGIB, New Delhi, IndiaAD  - All India Inst Med Sci, CSIR, Acad Sci & Innovat Res AcSIR, New Delhi, IndiaAD  - All India Inst Med Sci, CSIR, IHBAS, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaAD  - Univ Lubeck, Inst Med Blometrie & Stat, Lubeck, GermanyC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - Academy of Scientific & Innovative Research (AcSIR)C3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of LubeckPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-AUG
PY  - 2018
VL  - 66
IS  - 4
SP  - 1052
EP  - 1059
DO  - 10.4103/0028-3886.237000
AN  - WOS:000447540700029
ER  -

TY  - JOUR
AU  - Rawre, J
AU  - Rai, M
AU  - Namdeo, D
AU  - Das, R
AU  - Khanna, N
AU  - Dar, L
AU  - Dhawan, B
TI  - Herpes Simplex Virus Type 2 and Cytomegalovirus Perigenital Ulcer in an HIV Infected Woman
T2  - INDIAN JOURNAL OF MEDICAL MICROBIOLOGY
KW  - Cytomegalovirus
KW  - herpes simplex virus
KW  - human immunodeficiency virus
AB  - We report a case of mucocutaneous herpes Simplex Virus (HSV)-2 and Cytomegalovirus (CMV) infection in a 39-year-old female with acquired immunodeficiency syndrome, who presented with a perigenital ulcer. The patient was receiving antiretroviral treatment (ART) for 3 months before presentation. Scraping from the perigenital ulcer was positive for HSV-2 and Treponema pallidum using polymerase chain reactions (PCR). The extent and duration of the lesions led us to consider the possibility of coinfection with CMV. The patient also tested positive for CMV by PCR. On subsequent follow-up after 8 weeks, the genital lesions had healed completely. This is possibly ascribable to the ART, which led to significant immune reconstitution.
AD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Dermatol & Venerol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - JUL-SEP
PY  - 2018
VL  - 36
IS  - 3
SP  - 441
EP  - 443
C7  - PMID 30429404
DO  - 10.4103/ijmm.IJMM_18_203
AN  - WOS:000450218100025
ER  -

TY  - JOUR
AU  - Roy, S
AU  - Takkar, B
AU  - Khandelwal, P
AU  - Chawla, R
TI  - Full thickness macular hole without necrosis in a case of viral retinitis
T2  - TROPICAL DOCTOR
KW  - Viral infection
KW  - Disease
KW  - Ocular
KW  - Physiology
KW  - VASCULITIS
AD  - Susrut Eye Fdn & Res Ctr, Kolkata, IndiaAD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, Retina & Uvea Serv, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Ophthalmol, Bhopal 460020, IndiaAD  - Susrut Eye Fdn & Res Ctr, Vitreo Retina Serv, Kolkata, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) BhopalPU  - SAGE PUBLICATIONS INC
PI  - THOUSAND OAKS
PA  - 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
DA  - JUL
PY  - 2018
VL  - 48
IS  - 3
SP  - 250
EP  - 252
DO  - 10.1177/0049475518766126
AN  - WOS:000438672900022
ER  -

TY  - JOUR
AU  - Sachdeva, A
AU  - Gunasekaran, V
AU  - Ramya, HN
AU  - Dass, J
AU  - Kotwal, J
AU  - Seth, T
AU  - Das, S
AU  - Garg, K
AU  - Kalra, M
AU  - Rani, SS
AU  - Prakash, A
TI  - Consensus Statement of the Indian Academy of Pediatrics in Diagnosis and Management of Hemophilia
T2  - INDIAN PEDIATRICS
KW  - Coagulation
KW  - Factor VIII deficiency
KW  - Prophylaxis
KW  - Treatment
KW  - LOW-DOSE PROPHYLAXIS
KW  - RECOMBINANT FACTOR-IX
KW  - FACTOR-VIII
KW  - INHIBITORS
KW  - GENE
KW  - METAANALYSIS
KW  - CHILDREN
KW  - THERAPY
AB  - Despite having standard principles of management of hemophilia, treatment differs in various countries depending on available resources. Guideline for management of hemophilia in Indian setting is essential.
   Indian Academy of Pediatrics conducted a consultative meeting on Hemophilia on 18th September, 2016 in New Delhi, which was attended by experts in the field working across India. Scientific literature was reviewed, and guidelines were drafted. All expert committee members reviewed the final manuscript.
   To bring out consensus guidelines in diagnosis and management of Hemophilia in India.
   Specific factor assays confirm diagnosis and classify hemophilia according to residual factor activity (mild 5-40%, moderate 1-5%, severe < 1%). Genetic testing helps in identifying carriers, and providing genetic counseling and prenatal diagnosis. Patients with hemophilia should be managed by multi-specialty team approach. Continuous primary prophylaxis (at least low-dose regimen of 10-20 IU/kg twice or thrice per week) is recommended in severe hemophilia with dose tailored as per response. Factor replacement remains the mainstay of treating acute bleeds (dose and duration depends on body weight, site and severity of bleed). Factor concentrates (plasma derived or recombinant), if available, are preferred over blood components. Other supportive measures (rest, ice, compression, and elevation) should be instantly initiated. Long-term complications include musculoskeletal problems, development of inhibitors and transfusion-transmitted infections, which need monitoring. Adequate vaccination of children with hemophilia (with precautions) is emphasized.
AD  - Sir Ganga Ram Hosp, New Delhi, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Army Hosp Res & Referral, New Delhi, IndiaAD  - Indraprastha Apollo Hosp, New Delhi, IndiaAD  - Sawai Man Singh Med Coll, Jaipur, Rajasthan, IndiaAD  - Rainbow Childrens Hosp, Hyderabad, IndiaAD  - St Johns Med Coll Hosp, Bangalore, Karnataka, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - SMS Medical College & HospitalC3  - St. John's National Academy of Health SciencesC3  - St. John's Medical CollegePU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUL
PY  - 2018
VL  - 55
IS  - 7
SP  - 582
EP  - 590
DO  - 10.1007/s13312-018-1302-8
AN  - WOS:000439806500008
ER  -

TY  - JOUR
AU  - Sagar, R
AU  - Gupta, T
TI  - Psychological Aspects of Obesity in Children and Adolescents
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Childhood obesity
KW  - Psycho-social
KW  - Cognitive behavior therapy
KW  - Depression
KW  - Lowself-esteem
KW  - ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
KW  - CHILDHOOD OBESITY
KW  - SELF-ESTEEM
KW  - BODY DISSATISFACTION
KW  - OVERWEIGHT CHILDREN
KW  - MENTAL-DISORDERS
KW  - EXTREME OBESITY
KW  - SCHOOL-CHILDREN
KW  - PSYCHOPATHOLOGY
KW  - DEPRESSION
AB  - Childhood obesity is multi factorial health condition, so the simple evaluation of body fat will not be sufficed to manage the global epidemic of childhood obesity. Literature consistently provides evidence for physical health risks associated with childhood obesity; however in recent times, mental health of the obese children has also gained attention of the researchers as well as clinicians. Obese children experience number of psycho-social problems that significantly affect their quality of life and wellbeing. Co-morbid psychosocial and emotional problems of obesity generally act as causal or maintaining factors of obesity and thus significantly affect the treatment outcome. Therefore it becomes imperative for the clinicians/pediatricians to broaden their clinical assessment and include screening of important psychosocial factors within the clinical examination of childhood obesity. This article provides an evidence based comprehensive overview about the psychological factors and psychiatric factors (depression, anxiety, eating disorder, stress, body shape concerns, low self esteem) associated with childhood obesity that can further be utilized in the evaluation and management of this epidemic. The article also elaborates the role of current evidence based psychological approaches such as Cognitive Behavior Therapy (CBT) for management of obesity in children and adolescents. CBT techniques combined with lifestyle intervention and involving parents have been recommended by literature repetitively. However, there are a number of environmental, familial and personal barriers that hinder the whole process of weight loss in children. The article also discusses potential strategies to overcome those barriers.
AD  - AIIMS, Dept Psychiat, New Delhi, IndiaAD  - AIIMS, Dept Psychiat, Jodhpur, Rajasthan, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) JodhpurPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUL
PY  - 2018
VL  - 85
IS  - 7
SP  - 554
EP  - 559
DO  - 10.1007/s12098-017-2539-2
AN  - WOS:000436093400013
ER  -

TY  - JOUR
AU  - Sakthivel, P
AU  - Sikka, K
AU  - Thakar, A
AU  - Singh, CA
AU  - Sharma, SC
AU  - Rajeshwari, M
AU  - Kakkar, A
TI  - Role of narrow band imaging in the diagnosis of laryngeal lesions: Pilot study from India
T2  - INDIAN JOURNAL OF CANCER
KW  - Endoscopy
KW  - laryngeal cancer
KW  - laryngoscopy
KW  - narrow band imaging
KW  - SQUAMOUS-CELL CARCINOMA
KW  - HEAD
AB  - INTRODUCTION: Narrow band imaging (NBI) is a new imaging technique developed to improve the diagnostic accuracy of head and neck cancers by depiction of tumor-specific neo-angiogenesis. The purpose of this study was to assess the value of NBI in the diagnosis of laryngeal lesions. AIM: To assess the sensitivity and specificity of combined white light endoscopy (WLE) and NBI compared with WLE alone in the diagnosis of laryngeal lesions. SETTINGS AND DESIGN: Prospective study. MATERIALS AND METHODS: Thirty consecutive patients with various laryngeal lesions scheduled for microlaryngoscopic evaluation underwent WLE followed by NBI. Endoscopic NBI findings were classified into five types (IuV) according to the intraepithelial papillary capillary loop features. Types IuIV are considered benign, whereas type V is considered malignant. The observations were compared with histopathology. STATISTICAL ANALYSIS: Sensitivity, specificity, and positive and negative predictive values for the diagnosis of malignancy (i.e., invasive carcinoma and carcinoma in situ) by means of NBI with WLE were calculated. RESULTS: The sensitivity of WLE combined with NBI (100%) was higher than WLE alone (82.6%) in detecting laryngeal cancers. NBI helped in identifying four malignant lesions missed by WLE alone. Two children with respiratory papillomatosis also demonstrated type V pattern, a potential pitfall, leading to an overall positive predictive value of 92% and a negative predictive value of 100%. CONCLUSION: Combining NBI with WLE increases the sensitivity of detection of laryngeal cancer and its precursor lesions. NBI is also useful in some benign lesions as well as in post-radiotherapy patients.
AD  - All India Inst Med Sci, Dept Otorhinolaryngol & Head & Neck Surg, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-SEP
PY  - 2018
VL  - 55
IS  - 3
SP  - 242
EP  - 247
DO  - 10.4103/ijc.IJC_590_17
AN  - WOS:000457044700009
ER  -

TY  - JOUR
AU  - Selekman, RE
AU  - Shapiro, DJ
AU  - Boscardin, J
AU  - Williams, G
AU  - Craig, JC
AU  - Brandstroem, P
AU  - Pennesi, M
AU  - Roussey-Kesler, G
AU  - Hari, P
AU  - Copp, HL
TI  - Uropathogen Resistance and Antibiotic Prophylaxis: A Meta-analysis
T2  - PEDIATRICS
KW  - URINARY-TRACT-INFECTION
KW  - PEDIATRIC VESICOURETERAL REFLUX
KW  - PREVENTING PYELONEPHRITIS
KW  - RISK-FACTORS
KW  - RENAL SCARS
KW  - CHILDREN
KW  - MANAGEMENT
KW  - PATTERNS
KW  - MULTICENTER
KW  - ADHERENCE
AB  - CONTEXT: Limited data exist regarding uropathogen resistance in randomized controlled trials of urinary tract infection (UTI) prevention and antibiotic prophylaxis.
   OBJECTIVE: To assess the effect of prophylaxis on developing a multidrug-resistant first recurrent UTI among children with vesicoureteral reflux.
   DATA SOURCES: Cochrane Kidney and Transplant Specialized Register through May 25, 2017.
   STUDY SELECTION: Randomized controlled trials of patients 18 years of age with a history of vesicoureteral reflux being treated with continuous antibiotic prophylaxis compared with no treatment or placebo with available antibiotic sensitivity profiles.
   DATA EXTRACTION: Two independent observers abstracted data and assessed quality and validity per Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Adjusted meta-analyses were performed by using a mixed-effects logistic regression model.
   RESULTS: One thousand two hundred and ninety-nine patients contributed 224 UTIs. Patients treated with prophylaxis were more likely to have a multidrug-resistant infection (33% vs 6%, P < .001) and were more likely to receive broad-spectrum antibiotics (68% vs 49%, P = .004). Those receiving prophylaxis had 6.4 times the odds (95% confidence interval: 2.7-15.6) of developing a multidrug-resistant infection. One multidrug-resistant infection would develop for every 21 reflux patients treated with prophylaxis.
   LIMITATIONS: Variables that may contribute to resistance such as medication adherence and antibiotic exposure for other illnesses could not be evaluated.
   CONCLUSIONS: Prophylaxis increases the risk of multidrug resistance among recurrent infections. This has important implications in the risk-benefit assessment of prophylaxis as a management strategy and in the selection of empirical treatment of breakthrough infections in prophylaxis patients.
AD  - Univ Calif San Francisco, Dept Urol, San FranciscoMission Bay 550 16th St, San Francisco, CA 94158 USAAD  - Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USAAD  - Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USAAD  - Boston Childrens Hosp, Boston Combined Residency Program, Boston, MA USAAD  - Boston Med Ctr, Boston, MA USAAD  - Univ Sydney, Sch Publ Hlth, Camperdown, NSW, AustraliaAD  - Univ Gothenburg, Sahlgrenska Acad, Pediat Uro Nephrol Ctr, Gothenburg, SwedenAD  - Queen Slivias Childrens Hosp, Gothenburg, SwedenAD  - Univ Trieste, Inst Child & Maternal Hlth, Dept Pediat, Trieste, ItalyAD  - Univ Hosp Nantes, Dept Pediat, Nantes, FranceAD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaC3  - University of California SystemC3  - University of California San FranciscoC3  - University of California SystemC3  - University of California San FranciscoC3  - University of California SystemC3  - University of California San FranciscoC3  - Harvard UniversityC3  - Boston Children's HospitalC3  - Boston Medical CenterC3  - University of SydneyC3  - University of GothenburgC3  - University of TriesteC3  - Nantes UniversiteC3  - CHU de NantesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ACAD PEDIATRICS
PI  - Itasca
PA  - 345 Park Boulevard, Itasca, IL, UNITED STATES
DA  - JUL
PY  - 2018
VL  - 142
IS  - 1
C7  - e20180119
DO  - 10.1542/peds.2018-0119
AN  - WOS:000437262600028
ER  -

TY  - JOUR
AU  - Selvan, H
AU  - Yadav, S
AU  - Tandon, R
TI  - Big double bubble trouble: in vivo real time demonstration of 'mixed-type bubble' and its consequent effects during deep anterior lamellar keratoplasty
T2  - EYE
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Cornea & Refract Serv, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - NATURE PUBLISHING GROUP
PI  - LONDON
PA  - MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - JUL
PY  - 2018
VL  - 32
IS  - 7
SP  - 1282
EP  - 1283
DO  - 10.1038/s41433-018-0038-y
AN  - WOS:000438467100018
ER  -

TY  - JOUR
AU  - Sharma, A
AU  - Kumar, S
AU  - Jagia, P
TI  - Pulmonary Artery Pseudoaneurysm in Hyper-IgE Syndrome: Rare Complication With Successful Endovascular Management
T2  - VASCULAR AND ENDOVASCULAR SURGERY
KW  - Job syndrome
KW  - lung abscess
KW  - pulmonary artery pseudoaneurysm
KW  - hyper-IgE syndrome
KW  - coil embolization
KW  - HEMOPTYSIS
AB  - Hyper-IgE syndrome also known as Job syndrome is characterized by elevation of circulating immunoglobulin (IgE) levels and is usually associated with recurrent bacterial infections of the skin and sinopulmonary tract. Though bacterial pulmonary abscess and pneumatocele formation have been described, pulmonary artery pseudoaneurysm in Job syndrome has not been reported in literature. Our report describes a case of large pulmonary artery pseudoaneurysm in a child with Job syndrome, who presented with massive hemoptysis. Emergent endovascular management was performed with percutaneous coil occlusion of the feeding artery.
AD  - All India Inst Med Sci, Dept Cardiovasc Radiol & Endovasc Intervent, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SAGE PUBLICATIONS INC
PI  - THOUSAND OAKS
PA  - 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
DA  - JUL
PY  - 2018
VL  - 52
IS  - 5
SP  - 375
EP  - 377
DO  - 10.1177/1538574418762656
AN  - WOS:000433540500011
ER  -

TY  - JOUR
AU  - Sharma, R
AU  - Sharma, P
AU  - Katiyar, V
AU  - Vora, Z
AU  - Gurjar, H
TI  - Timing of Early Cranioplasty for Traumatic Brain Injury-the Debate Goes On
T2  - WORLD NEUROSURGERY
KW  - DECOMPRESSIVE CRANIECTOMY
KW  - CLINICAL ARTICLE
KW  - MULTICENTER
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - JUL
PY  - 2018
VL  - 115
SP  - 477
EP  - 477
DO  - 10.1016/j.wneu.2018.02.145
AN  - WOS:000436519600186
ER  -

TY  - JOUR
AU  - Sharma, R
AU  - Sharma, P
AU  - Katiyar, V
AU  - Vora, Z
AU  - Gurjar, H
TI  - Hyponatremia Following Aneurysmal Subarachnoid Hemorrhage
T2  - WORLD NEUROSURGERY
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - JUL
PY  - 2018
VL  - 115
SP  - 481
EP  - 481
DO  - 10.1016/j.wneu.2018.02.197
AN  - WOS:000436519600189
ER  -

TY  - JOUR
AU  - Shukla, G
AU  - Bajpai, G
AU  - Gupta, A
AU  - Katoch, J
AU  - Mohammed, A
AU  - Pandey, RM
AU  - Goyal, V
AU  - Srivastava, A
AU  - Behari, M
TI  - Evaluation of the diagnostic yield of ARQIP: A new restless legs syndrome diagnostic questionnaire and validation of its Hindi translation
T2  - NEUROLOGY INDIA
KW  - AIIMS Restless legs Syndrome Questionnaire
KW  - Hindi version
KW  - validation
KW  - QUALITY-OF-LIFE
KW  - PARKINSONS-DISEASE
KW  - PREVALENCE
KW  - ASSOCIATION
KW  - EPIDEMIOLOGY
KW  - DISORDERS
KW  - COMMUNITY
KW  - CRITERIA
KW  - ADULTS
KW  - IMPACT
AB  - Background: Restless legs syndrome (RLS) is misdiagnosed due to a variety of clinical presentations and lack of a diagnostic biomarker. Sociocultural differences in patients' reporting of symptoms further contribute to this under diagnosis. We developed an expanded diagnostic tool for RLS, incorporating all International RLS Study Group (IRLSSG) diagnostic criteria with a number of additional questions mainly focusing on specific sociocultural influences in RLS symptom reporting among Indians. The purpose of this study was to examine the change in the diagnostic yield of RLS, if any, through administration of this expanded questionnaire.
   Materials and Methods: The AIIMS RLS questionnaire for Indian patients (ARQIP) was developed in English language, and then translated into Hindi. All consecutive patients attending Neurology and sleep disorders clinic with complaints of leg discomfort were recruited in the study. Two examiners evaluated all patients with complaints of leg discomfort seen by a senior Sleep Medicine expert, one using only IRLSSG diagnostic criteria and the other using the ARQIP. Patients were categorized as RLS or "no-RLS" by the expert, and this was considered as the "standard" for analysis.
   Results: A total of 155 participants (78 males, 50.3%) with a mean age of 44.1 +/- 14.5 years were enrolled. A total of 105 patients were diagnosed as having RLS (group 1) and the rest as having "non-RLS" (group 2). The ARQIP was found to have a much higher sensitivity (100% vs 73%), specificity (44% vs 32.7%), negative predictive value (100% vs 36.4%), and positive predictive value (79% vs 70%) compared to the standard questionnaire. The diagnostic yield of this tool was 26.7% (Confidence interval = 100-73.3).
   Conclusions: The ARQIP for RLS diagnosis, validated in this study, has been observed to have a high sensitivity and a negative predictive value with a high diagnostic accuracy.
AD  - All India Inst Med Sci, Dept Neurol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-AUG
PY  - 2018
VL  - 66
IS  - 4
SP  - 1020
EP  - 1027
DO  - 10.4103/0028-3886.236962
AN  - WOS:000447540700022
ER  -

TY  - JOUR
AU  - Shukla, P
AU  - Vashist, P
AU  - Singh, SS
AU  - Gupta, V
AU  - Gupta, N
AU  - Wadhwani, M
AU  - Bharadwaj, A
AU  - Arora, L
TI  - Assessing the inclusion of primary school children in vision screening for refractive error program of India
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Compliance
KW  - primary school
KW  - school vision screening
KW  - screening
KW  - spectacle
KW  - teacher training
KW  - POPULATION
KW  - DISTRICT
KW  - PRADESH
AB  - Purpose: In India, teachers screen middle school children using the 6/9 Snellen's optotype. Recently, the National Program for Control of Blindness included primary school students also. The present cross-sectional study was planned to assess the inclusion of primary school students. Compliance to spectacles was ascertained after 6 months follow-up. Methods: Randomly selected 23 Government primary schools. A total of 30 teachers were nominated and given hands-on training in vision screening and recording formats. Teachers conducted vision screening of primary school students of their respective schools using the 6/12 Snellen's chart and referred students with subnormal vision to optometrist. Optometrist also validated the screening done by teachers. Optometrist screened the vision of 5% randomly selected children screened by teachers as having normal vision. Descriptive statistics used STATA version 13.0. Results: A total of 6056 students screened by the teachers. Sensitivity and specificity of teacher screening were 92.3% (confidence interval [CI] 88.6-95.0) and 72.6% (CI 68.2-76.6)), respectively. About 277 students underwent refraction and 186 prescribed spectacles. The prevalence of myopia, hypermetropia, and astigmatism is 2.5% (2.1-2.9), 0.6% (0.4-0.8), and 1.3% (1.0-1.6), respectively. Compliance to spectacles usage is 36%. Conclusion: Burden of refractive error in primary school is very low. Trained teachers can identify children with subnormal vision, but the false-positive rate is very high. Compliance to spectacle use among primary school children is also less. Vision screening by teachers prioritized in secondary schools and preschool screening should be done by more skilled eye care workers preferably optometrist.
AD  - AIIMS, Dr RP Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL
PY  - 2018
VL  - 66
IS  - 7
SP  - 935
EP  - 939
DO  - 10.4103/ijo.IJO_1036_17
AN  - WOS:000437197400011
ER  -

TY  - JOUR
AU  - Singh, AN
AU  - Pal, S
AU  - Kilambi, R
AU  - Madhusudhan, KS
AU  - Dash, NR
AU  - Tandon, N
AU  - Sahni, P
TI  - Diabetes after pancreaticoduodenectomy: can we predict it?
T2  - JOURNAL OF SURGICAL RESEARCH
KW  - Diabetes
KW  - Pancreatic volume
KW  - Pancreaticoduodenectomy
KW  - Pancreatic resection
KW  - Endocrine insufficiency
KW  - Type III diabetes
KW  - Pancreatoduodenectomy
KW  - DISTAL PANCREATECTOMY
KW  - CHRONIC-PANCREATITIS
KW  - GLUCOSE-INTOLERANCE
KW  - VOLUME
KW  - KIDNEY
KW  - CANCER
KW  - DONORS
KW  - LIVER
KW  - RISK
AB  - Background: There is limited literature about the perioperative factors which can predict endocrine insufficiency after pancreaticoduodenectomy (PD). The primary aim was to correlate percentage pancreatic remnant volume (% RV) after PD in nondiabetic patients with the development of new-onset impaired glucose tolerance/diabetes mellitus (IGT/DM). The secondary aim was to identify the risk factors for new-onset IGT/DM.
   Methods: In this prospective study, all consecutive patients with resectable periampullary carcinoma and without IGT/DM were evaluated with fasting and postprandial plasma glucose, HbA1c, insulin, and C-peptide levels preoperatively and at 3 mo postoperatively. After that, all patients were followed up with fasting and postprandial plasma glucose level assessed at 3-mo intervals for 24 mo or till death, whichever occurred earlier. The % RV was determined from computed tomography measurements preoperatively.
   Results: Of the 50 patients, 11 (22%) patients developed IGT/DM after median follow-up of 32 mo. The patients' with/without IGT/DM were similar in demographic/perioperative variables. The % RV was found to be an independent factor associated with new-onset IGT/ DM. A % RV of < 48.8% was found to be a predictor of new-onset IGT/DM (sensitivity, 89.7%; specificity, 73.6%). Plasma sugar and glycosylated hemoglobin levels were significantly higher postoperatively after PD than the preoperative levels. Insulin and C-peptide levels were significantly lower after PD, irrespective of new-onset IGT/DM.
   Conclusions: The incidence of IGT/DM after PD was 22%, and % RV < 48.8% was found to be a significant risk factor for new-onset IGT/DM. (C) 2018 Elsevier Inc. All rights reserved.
AD  - All India Inst Med Sci, Dept Gastrointestinal Surg & Liver Transplantat, 1005 Teaching Block, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol Metab & Diabet, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ACADEMIC PRESS INC ELSEVIER SCIENCE
PI  - SAN DIEGO
PA  - 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
DA  - JUL
PY  - 2018
VL  - 227
SP  - 211
EP  - 219
DO  - 10.1016/j.jss.2018.02.010
AN  - WOS:000433059300027
ER  -

TY  - JOUR
AU  - Singh, K
AU  - Sazawal, S
AU  - Chhikara, S
AU  - Mahapatra, M
AU  - Saxena, R
TI  - Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms
T2  - INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY
KW  - Chronic myeloproliferative neoplasms
KW  - JAK2V617F mutation
KW  - thrombosis
KW  - ESSENTIAL THROMBOCYTHEMIA
KW  - POLYCYTHEMIA-VERA
KW  - COAGULATION ACTIVATION
KW  - JAK2(V617F) MUTATION
KW  - RISK-FACTORS
KW  - JAK2
KW  - LEUKOCYTOSIS
KW  - PLATELET
KW  - DISEASE
KW  - EVENTS
AB  - Background: It is still a matter of debate regarding the association of JAK2V617F mutation with thrombosis in BCR-ABL negative CMPN patients. The role of JAK2V617F mutation in increasing the thrombotic risk in CMPNs is yet unequivocal. Aims: To clarify the contribution of JAK2V617F mutation in thrombosis in CMPN patients. Settings and Design: This retrospective study was done to evaluate role of JAK2V617F mutation in thrombosis in CMPNs. Materials and Methods: 65 CMPN patients (PV, ET and PMF) were analyzed for JAK2V617F mutation using ARMS-PCR and detailed history of thrombosis was recorded in these patients. Statistical Analysis: P values were 2 tailed, and statistical significance was set at P < 0.05. Results: 46/65 were males and 19/65 were females [M:F: 2.4: 1] with median age 46 years [range, 14-80 years]. Patients had median Hb 15.6 g/dl [range, 5.1-20.3], median TLC 10.7 x 10(9)/l [range 2.4-216] and platelet count 360 x 10(9)/l [range, 20-1859]. 32 were JAK2V617F positive and 33 were negative for this mutation. On comparing the prevalence of thrombosis in JAK2V617F positive patients with JAK2V617F negative patients, we observed that 20/32 (62.5%) JAK2V617F positive patients had thrombosis as compared to 16/33 (48%) in JAK2V617F negative patients (P = 0.04). We observed significant association of JAK2V617F mutation with thrombosis, however no association of this mutation with thrombosis was observed among the JAK2V617F negative patients. Conclusion: Our study suggests that JAK2V617F mutation may increase the risk of thrombosis in CMPNs. This finding could lead to risk stratification, setting up the treatment strategy in CMPNs.
AD  - All India Inst Med Sci, Dept Hematol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-SEP
PY  - 2018
VL  - 61
IS  - 3
SP  - 371
EP  - 374
DO  - 10.4103/IJPM.IJPM_781_17
AN  - WOS:000439282500014
ER  -

TY  - JOUR
AU  - Singh, K
AU  - Crossan, C
AU  - Laba, TL
AU  - Roy, A
AU  - Hayes, A
AU  - Salam, A
AU  - Jan, S
AU  - Lord, J
AU  - Tandon, N
AU  - Rodgers, A
AU  - Patel, A
AU  - Thom, S
AU  - Prabhakaran, D
TI  - Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial
T2  - INTERNATIONAL JOURNAL OF CARDIOLOGY
KW  - Fixed dose combination (FDC)
KW  - Cardiovascular polypill
KW  - Cost-effectiveness analysis (CEA)
KW  - Cardiovascular disease (CVD)
KW  - Secondary prevention
KW  - India
KW  - LOW-INCOME COUNTRIES
KW  - MIDDLE-INCOME
KW  - GLOBAL BURDEN
KW  - ADHERENCE
KW  - HEALTH
KW  - FUTURE
KW  - RISK
KW  - AFFORDABILITY
KW  - AVAILABILITY
KW  - METAANALYSIS
AB  - Background: The Use of Multidrug Pill In Reducing cardiovascular Events (UMPIRE) trial, showed that access to a cardiovascular polypill (aspirin, statin and two blood pressure lowering drugs) significantly improved adherence, lowered systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDLc) in patients with or at high risk of cardiovascular disease (CVD). We aimed to analyze the within-trial cost-effectiveness of the polypill strategy versus usual care in India.
   Methods: Relative effectiveness and costs of polypill versus usual care groups in UMPIRE were estimated from the health sector perspective. Only direct medical costs were considered. The effectiveness of the polypill was reported as a percentage increase in adherence and mean reductions in SBP, and LDL-c, over the 15-month trial period. Healthcare resource utilization and costs were collected for each patient during the trial. Polypill price was constructed using a range of scenarios: $0.06-$0.94/day. The cost-effectiveness of the polypill was measured as the additional cost for 10% increase in adherence, and per unit reduction in SBP and LDL-c.
   Results: Overall, the mean cost per patient was significantly lower with the polypill strategy (-$ 203 per person, (95% CI: -286, -119, p < 0.01). In scenario analyses that varied polypill price assumptions, incremental cost-effectiveness ratios for a polypill strategy ranged between cost-saving to $75 per 10% increase in adherence for polypill price of $0.94 per day.
   Conclusions: The polypill strategy was cost-saving compared to usual care among patients with or at high risk of CVD in India. (C) 2018 Elsevier B.V. All rights reserved.
AD  - All India Inst Med Sci, New Delhi, IndiaAD  - Ctr Chron Dis Control, New Delhi, IndiaAD  - Publ Hlth Fdn India, 4th Floor,Plot 47,Sect 44, Gurgaon 122002, Haryana, IndiaAD  - BresMed, Dublin, IrelandAD  - Univ New South Wales NSW, George Inst Global Hlth, Sydney, NSW, AustraliaAD  - Univ Sydney, Menzies Ctr Hlth Policy, Sch Publ Hlth, Sydney Med Sch, Sydney, NSW, AustraliaAD  - Univ Sydney, Sydney, NSW, AustraliaAD  - George Inst Global Hlth, Hyderabad, Telangana, IndiaAD  - Univ Southampton, Southampton, Hants, EnglandAD  - Imperial Coll London, London, EnglandAD  - London Sch Hyg & Trop Med, London, EnglandC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Public Health Foundation of IndiaC3  - University of SydneyC3  - George Institute for Global HealthC3  - University of New South Wales SydneyC3  - University of SydneyC3  - University of SydneyC3  - University of SouthamptonC3  - Imperial College LondonC3  - University of LondonC3  - London School of Hygiene & Tropical MedicinePU  - ELSEVIER IRELAND LTD
PI  - CLARE
PA  - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
DA  - JUL 1
PY  - 2018
VL  - 262
SP  - 71
EP  - 78
DO  - 10.1016/j.ijcard.2018.03.082
AN  - WOS:000432917300016
ER  -

TY  - JOUR
AU  - Singh, N
AU  - Ray, S
AU  - Srivastava, A
TI  - Clinical Mimickers of Amyotrophic Lateral Sclerosis-Conditions We Cannot Afford to Miss
T2  - ANNALS OF INDIAN ACADEMY OF NEUROLOGY
KW  - Amyotrophic lateral sclerosis
KW  - lower motor neuron
KW  - mimickers
KW  - upper motor neuron
KW  - INCLUSION-BODY MYOSITIS
KW  - MOTOR-NEURON DISEASE
KW  - MYASTHENIA-GRAVIS
KW  - NEUROPATHY
KW  - DIAGNOSIS
KW  - ALS
KW  - ELECTRODIAGNOSIS
AB  - Giving a diagnosis of amyotrophic lateral sclerosis to a patient is akin to handing out a death certificate. However, not all patients presenting with the classical dysphagia, wasting, and weakness may have motor neuron diseases. In these cases, it is extremely important not to miss little cues which can suggest an alternative diagnosis and in many cases a lease of life in terms of a treatment option. In this review, we consider some clinical scenarios that can present with the same symptom complex as diseases involving motor neurons but have a different anatomical or etiopathological basis and in many cases even a therapeutic option.
AD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurol, Neurosci Ctr, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-SEP
PY  - 2018
VL  - 21
IS  - 3
SP  - 173
EP  - 178
DO  - 10.4103/aian.AIAN_491_17
AN  - WOS:000444334400002
ER  -

TY  - JOUR
AU  - Singh, R
AU  - Mukherjee, A
AU  - Singla, M
AU  - Vajpayee, M
AU  - Negi, N
AU  - Kabra, SK
AU  - Lodha, R
AU  - Das, BK
TI  - Impact of HIV infection and highly active antiretroviral therapy (HAART) on B cell subpopulations in children
T2  - JOURNAL OF MEDICAL VIROLOGY
KW  - activation
KW  - apoptosis
KW  - exhaustion
KW  - partial reconstitution
KW  - HUMAN-IMMUNODEFICIENCY-VIRUS
KW  - HIV-1-INFECTED CHILDREN
KW  - MEMORY
KW  - AGE
KW  - INDIVIDUALS
KW  - LYMPHOCYTES
KW  - RESPONSES
KW  - DISEASE
KW  - VIREMIA
KW  - ADULTS
AB  - B-cells play an important role in defending children against various infections. In view of scare data, we undertook this prospective cohort study to describe B cell compartment in HIV infected children (<5 years of age) and the effect of HAART on B cell subpopulations. HIV infected children (<5 years) from Pediatric HIV services of the Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, were recruited (April 2012-December 2015). The enrolled HIV-1 infected children (n = 59) were followed up regularly for 12 months; healthy controls (n = 51) included HIV uninfected children with no major illness. Flow cytometry was performed on fresh EDTA-treated blood samples to characterize B cell subpopulations. In HIV-infected children, marked depletion of naive (P = 0.003), non-switched memory (P = 0.02), mature (P = 0.0005), resting memory (P < 0.0001) B cells, and expansion of double negative memory (P < 0.0001), activated memory (P < 0.0001) and tissue like memory (P < 0.0001) B cells were observed as compared to healthy controls. In children started on HAART, at the end of 12 months of therapy, frequencies of non-switched memory (P = 0.04), switched memory (P = 0.01), and resting memory (P = 0.003) B cells were lower; activated memory (P = 0.04), and tissue-like memory (P = 0.0001) B cells were still higher than healthy controls. HIV infection resulted in reduced memory B cells in HIV infected children. Following HAART, there was normalization of some B cell subpopulations. The study emphasizes the need of re-vaccination in HIV infected children to maintain the memory B cell pool and adequate humoral immune response against infections.
AD  - AIIMS, Dept Pediat, Delhi, IndiaAD  - AIIMS, Dept Microbiol, Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUL
PY  - 2018
VL  - 90
IS  - 7
SP  - 1222
EP  - 1231
DO  - 10.1002/jmv.25074
AN  - WOS:000433583300006
ER  -

TY  - JOUR
AU  - Singh, S
AU  - Bhari, N
AU  - Rai, M
AU  - Gupta, S
TI  - Orangechrome Due to Carotenemia Presenting as Trichrome Vitiligo
T2  - JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
KW  - KERATINOCYTES
KW  - MELANOCYTES
KW  - RETINOL
AD  - AIIMS, Dept Dermatol & Venereol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SAGE PUBLICATIONS INC
PI  - THOUSAND OAKS
PA  - 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
DA  - JUL-AUG
PY  - 2018
VL  - 22
IS  - 4
SP  - 422
EP  - 422
DO  - 10.1177/1203475418755764
AN  - WOS:000436044400008
ER  -

TY  - JOUR
AU  - Srivastava, AK
AU  - Warrier, AR
TI  - Not to forget: Seizures in acute stroke
T2  - NEUROLOGY INDIA
KW  - POSTSTROKE SEIZURES
KW  - INTRACEREBRAL HEMORRHAGE
KW  - EPILEPSY
KW  - MULTICENTER
KW  - MANAGEMENT
KW  - FUTURE
AD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-AUG
PY  - 2018
VL  - 66
IS  - 4
SP  - 952
EP  - 954
C7  - PMID 30038076
DO  - 10.4103/0028-3886.237006
AN  - WOS:000447540700012
ER  -

TY  - JOUR
AU  - Swain, R
AU  - Bakshi, MS
AU  - Dhaka, S
AU  - Singh, KK
AU  - Sikary, AK
TI  - Self-Strangulation Turning into Partial Hanging for a Suicide Victim
T2  - JOURNAL OF FORENSIC SCIENCES
KW  - forensic science
KW  - forensic pathology
KW  - double asphyxia
KW  - suicidal strangulation
KW  - partial hanging
KW  - death scene investigation
KW  - electric cable
KW  - LIGATURE STRANGULATION
KW  - COMPLETE DECAPITATION
KW  - AGONAL SEQUENCES
KW  - COMPLEX SUICIDE
KW  - FILMED HANGINGS
KW  - AUTOPSY-REPORT
KW  - RESPONSES
AB  - Hanging is the most common asphyxial method of suicide, whereas suicide by strangulation is unusual. Here, we are reporting a particular methodology of the asphyxial method of suicide in which a case of self-strangulation culminated into partial hanging. A 30-year-old male wrapped one end of the cable wire around his neck. He then passed the other end over a curtain rod and tied that end around the right hand. He pulled the hand down, using the curtain rod as a fulcrum, to tighten the noose around the neck in an attempt to strangulate himself. However, he lost consciousness during the process and the body slipped down, pulling the right hand up which got stuck at the curtain rod. This led the body hanged in the kneeling position. This bizarre scenario raised suspicion of homicide but the crime scene, autopsy and victim characteristics were in favor of suicide.
AD  - Andaman & Nicobar Isl Inst Med Sci, Dept Forens Med, Port Blair 744101, Andaman & Nicob, IndiaAD  - Southmead Hosp, Clin Fellow Orthopaed, Bristol BS10 5NB, Avon, EnglandAD  - All India Inst Med Sci, Dept Forens Med, New Delhi 110029, IndiaAD  - ESIC Med Coll & Hosp, Dept Forens Med, NH3,NIT3 Faridabad, Faridabad 121001, Haryana, IndiaC3  - Southmead HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUL
PY  - 2018
VL  - 63
IS  - 4
SP  - 1309
EP  - 1311
DO  - 10.1111/1556-4029.13680
AN  - WOS:000436939200043
ER  -

TY  - JOUR
AU  - Swain, R
AU  - Dhaka, S
AU  - Sharma, M
AU  - Bakshi, MS
AU  - Murty, OP
AU  - Sikary, AK
TI  - Accidental cut-throat injuries from the broken windshield of an auto rickshaw: Two unusual cases
T2  - MEDICINE SCIENCE AND THE LAW
KW  - Auto-rickshaw driver
KW  - fatal wound
KW  - glass wound
KW  - road traffic accident
KW  - seat belt
KW  - stab wound
KW  - GLASS
KW  - FATALITIES
AB  - Accidental cut-throat injuries are extremely rare and usually involve a sharp-edged weapon. In this paper, two cases of a cut-throat wound to two auto-rickshaw drivers are presented where the broken windshield of the auto-rickshaws was responsible for the wounds. In both the cases, fatal incised wounds were present over the neck, cutting the soft tissue along with the major vessels. The death occurred due to exsanguination caused by neck-vessel injury in one case and trachea along with neck-vessel injury in the second case. Although the wounds on the neck initially suggested homicide, they were found to have occurred accidentally as a result of a road traffic accident involving a head-on collision of auto rickshaws. The injuries were inflicted by the shattered glass of the windshield.
AD  - All India Inst Med Sci, Dept Forens Med, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SAGE PUBLICATIONS INC
PI  - THOUSAND OAKS
PA  - 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
DA  - JUL
PY  - 2018
VL  - 58
IS  - 3
SP  - 183
EP  - 185
DO  - 10.1177/0025802418768320
AN  - WOS:000440022200007
ER  -

TY  - JOUR
AU  - Tandon, PN
TI  - Second career: Life after superannuation
T2  - NEUROLOGY INDIA
AD  - Natl Brain Res Inst, Dept Neurosurg, Manesar, Haryana, IndiaAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - Department of Biotechnology (DBT) IndiaC3  - National Brain Research Centre (NBRC)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-AUG
PY  - 2018
VL  - 66
IS  - 4
SP  - 907
EP  - 913
DO  - 10.4103/0028-3886.236983
AN  - WOS:000447540700003
ER  -

TY  - JOUR
AU  - Titiyal, JS
AU  - Falera, R
AU  - Kaur, M
AU  - Arora, T
TI  - Management of late-onset flocculent after-cataract with capsular bag lavage and posterior continuous curvilinear capsulorhexis
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Capsular bag lavage
KW  - late-onset after-cataract
KW  - posterior continuous curvilinear capsulorhexis
KW  - LIQUEFIED AFTERCATARACT
KW  - BLOCK SYNDROME
KW  - LENS
AB  - We describe our technique for the management of late-onset liquefied after-cataract (LAC) to ensure long-term visual axis clarity. The densely adherent anterior capsular rim over the intraocular lens (IOL) optic was released with the help of microvitreoretinal blade, and multiple relaxing radial incisions were made on the capsular rim to facilitate easy access to the capsular bag. A thorough capsular bag lavage was performed with the help of bimanual irrigation-aspiration. Posterior continuous curvilinear capsulorhexis (PCCC) was performed after complete aspiration of fluid after-cataract to prevent recurrence. This technique was successfully performed in 14 cases. Postoperatively, IOL was stable and an uncorrected distance visual acuity of >20/32 was achieved in all cases. No recurrence was observed in any case over a follow-up of 1 year. Our technique of capsular bag lavage with PCCC is safe and effective for the management of LAC with optimal visual and anatomical outcomes.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL
PY  - 2018
VL  - 66
IS  - 7
SP  - 984
EP  - 987
DO  - 10.4103/ijo.IJO_1324_17
AN  - WOS:000437197400020
ER  -

TY  - JOUR
AU  - Togarsimalemath, SK
AU  - Si-Mohammed, A
AU  - Puraswani, M
AU  - Gupta, A
AU  - Vabret, A
AU  - Liguori, S
AU  - Mariani-Kurkdjian, P
AU  - Bagga, A
AU  - Dragon-Durey, MA
TI  - Gastrointestinal pathogens in anti-FH antibody positive and negative Hemolytic Uremic Syndrome
T2  - PEDIATRIC RESEARCH
KW  - COMPLEMENT FACTOR-H
KW  - PNEUMOCOCCAL PNEUMONIA
KW  - CFHR1/CFHR3 DEFICIENCY
KW  - AUTOIMMUNE FORM
KW  - INFECTION
KW  - AUTOANTIBODIES
KW  - CHILDREN
KW  - TRANSPLANT
KW  - RECIPIENTS
KW  - PROTEIN-1
AB  - BACKGROUND: Prodromal symptoms are frequently reported in the atypical form of Hemolytic uremic syndrome (aHUS) suggesting implication of infectious triggers. Some pathogens may also play a role in the mechanisms of production of autoantibody directed against Factor H (FH), a complement regulator, leading to aHUS.
   METHODS: The presence of 15 gastrointestinal (GI) pathogens was investigated by using xTAG-based multiplex PCR techniques on stools collected at the acute phase in a cohort of Indian HUS children classified according to the presence or absence of anti-FH autoantibodies.
   RESULTS: Prevalence of pathogens in patients with anti-FH antibody (62.5%) was twice that in those without (31.5%). Different pathogens were detected, the most frequent being Clostridium difficile, Giardia intestinalis, Salmonella, Shigella, Rotavirus, Norovirus and Entamoeba histolytica. No stool was positive for Shigatoxin.
   CONCLUSION: This study reveals a higher prevalence of GI pathogens in anti-FH positive than in negative patients. No single pathogen was implicated exclusively in one form of HUS. These pathogens may play a role in the disease initiation by inducing complement activation or an autoimmune response.
AD  - INSERM, Cordeliers Res Ctr, Team Complement & Dis, UMRS 1138, Paris, FranceAD  - Paris Descartes Univ, Paris, FranceAD  - CHU Dijon, Ctr Natl Reference CNR Virus Enter, Lab Virol, Dijon, FranceAD  - All India Inst Med Sci, Div Nephrol, Dept Pediat, New Delhi, IndiaAD  - CHU Caen, CNR Rougeole & Paramyxoviridae Resp Humains, Lab Virol, Caen, FranceAD  - CHU Robert Debre, AP HP, CNR Associe Escherichia Coli, Serv Microbiol, Paris, FranceAD  - Hop Europeen Georges Pompidou, AP HP, Lab Immunol, Paris, FranceC3  - Sorbonne UniversiteC3  - Institut National de la Sante et de la Recherche Medicale (Inserm)C3  - Universite Paris CiteC3  - Universite Paris CiteC3  - CHU Dijon BourgogneC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Universite de Caen NormandieC3  - CHU de Caen NORMANDIEC3  - Assistance Publique Hopitaux Paris (APHP)C3  - Universite Paris CiteC3  - Hopital Universitaire Robert-Debre - APHPC3  - Assistance Publique Hopitaux Paris (APHP)C3  - Universite Paris CiteC3  - Hopital Universitaire Europeen Georges-Pompidou - APHPPU  - NATURE PUBLISHING GROUP
PI  - NEW YORK
PA  - 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
DA  - JUL
PY  - 2018
VL  - 84
IS  - 1
SP  - 118
EP  - 124
DO  - 10.1038/s41390-018-0009-9
AN  - WOS:000442163400021
ER  -

TY  - JOUR
AU  - Tripathy, SK
AU  - Aggarwal, B
AU  - Mandal, A
AU  - Bagri, NK
TI  - Atypical Kawasaki disease: Diagnosis underneath diapers
T2  - JOURNAL OF POSTGRADUATE MEDICINE
KW  - MANAGEMENT
AD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-SEP
PY  - 2018
VL  - 64
IS  - 3
SP  - 190
EP  - 191
DO  - 10.4103/jpgm.JPGM_201_18
AN  - WOS:000439223400015
ER  -

TY  - JOUR
AU  - Tyagi, A
AU  - Pramanik, R
AU  - Vishnubhatl, S
AU  - Ali, S
AU  - Bakhshi, R
AU  - Chopra, A
AU  - Singh, A
AU  - Bakhshi, S
TI  - Pattern of mitochondrial D-loop variations and their relation with mitochondrial encoded genes in pediatric acute myeloid leukemia
T2  - MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
KW  - AML
KW  - Mitochondrial DNA
KW  - D-loop
KW  - Variations
KW  - DNA SEQUENCE VARIATION
KW  - MUTATIONS
KW  - TUMORS
KW  - SURVIVAL
KW  - CANCER
AB  - Role of mitochondrial DNA variations, particularly in D loop region, remains investigational in acute myeloid leukaemia (AML). Consecutive 151 pediatric AML patients were prospectively enrolled from June 2013 to August 2016, for evaluating pattern of variations in mitochondrial D-loop region and to determine their association, if any, with expression of mitochondrial-encoded genes. For each patient, D-loop region was sequenced on baseline bone marrow, buccal swab and mother's blood sample. Real time PCR was used for relative gene expression of four mitochondrial DNA encoded genes viz. Nicotinamide-adenine-dineucleotide-dehydrogenase subunit 3 (ND3), Cytochrome-B (Cyt-B), Cytochrome c oxidase-I (COX1) and ATP-synthetase F-0 subunit-6 (ATP6). Total 1490 variations were found at 237 positions in D-Loop; 1206 (80.9%) were germline and 284 (19.1%) were somatic. Positions 73-263 were identified as a probable hotspot region. G bases appeared to be most stable nucleotide (least number of single base substitutions) whereas T appeared to be most susceptible to variations with germline T-C being the commonest. Gene expression of Cyt-B was found to be significantly higher for any variation (somatic or germline) at positions 16,192 and 16,327 while it was significantly lower for variations at positions 16,051 and 207. Any variation at positions 152, 207 and 513 significantly decreased COX1 expression while those at positions 16,051 and 152 attenuated ATP6 expression. This first study evaluated type and overall pattern of D-loop variations in AML, and also showed that some of these variations in D loop region might have an effect on the mitochondrial-encoded genes which is new and valuable information in AML genomics.
AD  - Dept Med Oncol, New Delhi, IndiaAD  - Dr BRA Inst Rotary Canc Hosp, New Delhi, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Dept Biostat, New Delhi, IndiaAD  - Shaheed Rajguru Coll Appl Sci, Delhi, IndiaAD  - Univ Delhi, New Delhi, IndiaAD  - Dept Lab Oncol, New Delhi, IndiaAD  - Dept Biochem, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUL
PY  - 2018
VL  - 810
SP  - 13
EP  - 18
DO  - 10.1016/j.mrfmmm.2018.05.002
AN  - WOS:000438948200003
ER  -

TY  - JOUR
AU  - Vashist, A
AU  - Kaushik, A
AU  - Vashist, A
AU  - Bala, J
AU  - Nikkhah-Moshaie, R
AU  - Sagar, V
AU  - Nair, M
TI  - Nanogels as potential drug nanocarriers for CNS drug delivery
T2  - DRUG DISCOVERY TODAY
KW  - CENTRAL-NERVOUS-SYSTEM
KW  - SELF-ASSEMBLED NANOGELS
KW  - CHITOSAN NANOGELS
KW  - LOADED NANOGELS
KW  - IN-VITRO
KW  - BRAIN
KW  - HYDROGELS
KW  - NANOPARTICLES
KW  - RELEASE
KW  - NANOTECHNOLOGY
AB  - Hydrogel-based drug delivery systems (DDSs) have versatile applications such, as tissue engineering, scaffolds, drug delivery, and regenerative medicines. The drawback of higher size and poor stability in such DDSs are being addressed by developing nano-sized hydrogel particles, known as nanogels, to achieve the desired biocompatibility and encapsulation efficiency for better efficacy than conventional bulk hydrogels. In this review, we describe advances in the development of nanogels and their promotion as nanocarriers to deliver therapeutic agents to the central nervous system (CNS). We also discuss the challenges, possible solutions, and future prospects for the use of nanogel-based DDSs for CNS therapies.
AD  - Florida Int Univ, Herbert Wertheim Coll Med, Ctr Personalized Nanomed, Inst Neuroimmune Pharmacol,Dept Immunol, Miami, FL 33199 USAAD  - All India Inst Med Sci, Dept Biotechnol, New Delhi 110029, IndiaC3  - State University System of FloridaC3  - Florida International UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - JUL
PY  - 2018
VL  - 23
IS  - 7
SP  - 1436
EP  - 1443
DO  - 10.1016/j.drudis.2018.05.018
AN  - WOS:000440119400015
ER  -

TY  - JOUR
AU  - Verma, B
AU  - Akinyi, MV
AU  - Norppa, AJ
AU  - Frilander, MJ
TI  - Minor spliceosome and disease
T2  - SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
KW  - U12-type introns
KW  - Minor spliceosome
KW  - Human diseases
KW  - Pre-mRNA splicing
KW  - Cryptic splice sites
KW  - Exon skipping
KW  - Intron retention
KW  - U12-TYPE INTRONS
KW  - DEVELOPMENTAL DISORDER
KW  - SMN DEFICIENCY
KW  - GENE-MUTATIONS
KW  - U12 SNRNA
KW  - PROTEIN
KW  - DEFECTS
KW  - COMPONENT
KW  - RARE
KW  - IDENTIFICATION
AB  - The U12-dependent (minor) spliceosome excises a rare group of introns that are characterized by a highly conserved 5' splice site and branch point sequence. Several new congenital or somatic diseases have recently been associated with mutations in components of the minor spliceosome. A common theme in these diseases is the detection of elevated levels of transcripts containing U12-type introns, of which a subset is associated with other splicing defects. Here we review the present understanding of minor spliceosome diseases, particularly those associated with the specific components of the minor spliceosome. We also present a model for interpreting the molecular-level consequences of the different diseases. (C) 2017 The Authors. Published by Elsevier Ltd.
AD  - Univ Helsinki, Inst Biotechnol, PL56 Viikinkaari 5, FIN-00014 Helsinki, FinlandAD  - All India Inst Med Sci, Dept Biotechnol, New Delhi, IndiaC3  - University of HelsinkiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI  - LONDON
PA  - 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
DA  - JUL
PY  - 2018
VL  - 79
SP  - 103
EP  - 112
DO  - 10.1016/j.semcdb.2017.09.036
AN  - WOS:000433227500012
ER  -

TY  - JOUR
AU  - Verma, KK
AU  - Zimerson, E
AU  - Bruze, M
AU  - Engfeldt, M
AU  - Svedman, C
AU  - Isaksson, M
TI  - Is a high concentration of hexavalent chromium in Indian cement causing an increase in the frequency of cement dermatitis in India?
T2  - CONTACT DERMATITIS
KW  - chromium
KW  - cobalt
KW  - contact eczema
KW  - Indian cement
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi 110029, IndiaAD  - Lund Univ, Skane Univ Hosp, Dept Occupat & Environm Dermatol, Malmo, SwedenC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Lund UniversityC3  - Skane University HospitalPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUL
PY  - 2018
VL  - 79
IS  - 1
SP  - 49
EP  - +
DO  - 10.1111/cod.12986
AN  - WOS:000434217900016
ER  -

TY  - JOUR
AU  - Verma, R
AU  - Kumar, N
AU  - Kumar, S
TI  - Effectiveness of adjunctive repetitive transcranial magnetic stimulation in management of treatment-resistant depression: A retrospective analysis
T2  - INDIAN JOURNAL OF PSYCHIATRY
KW  - Brain stimulation
KW  - depression
KW  - transcranial magnetic stimulation
KW  - transcranial magnetic stimulation
KW  - MAJOR DEPRESSION
KW  - RTMS
KW  - FREQUENCY
KW  - DISORDER
KW  - THERAPY
AB  - Background: There is limited number of studies from India investigating role of repetitive transcranial magnetic stimulation (rTMS) in treatment-resistant depression (TRD). This clinic-based study reports on the efficacy of rTMS as an add-on treatment in patients suffering from TRD.
   Materials and Methods: Twenty-two right-handed patients suffering from major depressive disorder who failed to respond to adequate trials of at least two antidepressants drugs in the current episode received rTMS as an augmenting treatment. High-frequency (Hf) rTMS at 110% of the estimated resting motor threshold (MT) was given over the left dorsolateral prefrontal cortex (DLPFC). A total of 15 sessions were given over 3 weeks with 3000 pulses per session. The outcome was assessed based on the changes in scores of Hamilton Rating Scale for Depression or Montgomery-Asberg Depression Rating Scale.
   Results: There was a significant reduction in final assessment scores after rTMS intervention as compared to baseline with almost 50% of the participants showing response in either scale.
   Conclusion: Hf rTMS applied over left DLPFC is an effective add-on treatment strategy in patients with TRD.
AD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUL-SEP
PY  - 2018
VL  - 60
IS  - 3
SP  - 329
EP  - 333
DO  - 10.4103/psychiatry.IndianJPsychiatry_182_16
AN  - WOS:000447749800013
ER  -

TY  - JOUR
AU  - Vijayakumar, V
AU  - Mavathur, R
AU  - Aruchunan, M
AU  - Krishnamurthy, MN
TI  - Moving beyond HbA1c and plasma glucose levels to understand glycemic status in type 2 diabetes mellitus
T2  - JOURNAL OF DIABETES
AD  - S VYASA Univ, Div Yoga & Life Sci, 19 Eknath Bhavan, Bengaluru 560019, Karnataka, IndiaAD  - All India Inst Med Sci, Ctr Integrat Med & Res, Dept Yoga, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUL
PY  - 2018
VL  - 10
IS  - 7
SP  - 609
EP  - 610
DO  - 10.1111/1753-0407.12649
AN  - WOS:000436111600010
ER  -

TY  - JOUR
AU  - Vikram, NK
TI  - Cardiovascular and Metabolic Complications - Diagnosis and Management in Obese Children
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Childhood obesity
KW  - Asian Indians
KW  - Insulin resistance
KW  - Metabolic syndrome
KW  - INSULIN-RESISTANCE SYNDROME
KW  - 3RD NATIONAL-HEALTH
KW  - TREATMENT-PANEL-III
KW  - INDIAN ADOLESCENTS
KW  - SYNDROME PHENOTYPE
KW  - DIABETES-MELLITUS
KW  - PEDIATRIC OBESITY
KW  - RISK-FACTORS
KW  - PREVALENCE
KW  - DEFINITIONS
AB  - The world at present is facing a burden of rising prevalence of obesity in children and adolescents. The developing countries are particularly facing the dual burden on under-nutrition and obesity. This is associated with appearance and clustering of cardiometabolic abnormalities at an early age with development of chronic complications early and possible decrease in life span of these children and adolescents. In adults this clustering has been termed as 'metabolic syndrome' with definitions that can be used universally. However, in children and adolescents there is no consensus on a uniform definition of metabolic syndrome that can be applicable across the age groups and various ethnicities. Further, as childhood is a period of growth and development, changes in body composition and insulin sensitivity that occur with puberty may influence the thresholds of components used to define metabolic syndrome. Children of South Asian ethnicity appear to be more predisposed to develop abnormalities of metabolic syndrome, possible due to their adverse body fat patterning and genetic influences. The definition of pediatric metabolic syndrome proposed by International Diabetes Federation is useful across different ethnicities. Presence of at least one component of metabolic syndrome should lead to detailed screening for other components and complications. A multimodality approach including therapeutic lifestyle changes targeted at the individual, family and community is essential for management. Pharmacotherapy for individual components may be required if initial management strategies fail to achieve the goals.
AD  - All India Inst Med Sci, Metab Res Grp, Dept Med, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUL
PY  - 2018
VL  - 85
IS  - 7
SP  - 535
EP  - 545
DO  - 10.1007/s12098-017-2504-0
AN  - WOS:000436093400011
ER  -

TY  - JOUR
AU  - Vishwakarma, VK
AU  - Goyal, A
AU  - Gupta, JK
AU  - Upadhyay, PK
AU  - Yadav, HN
TI  - Involvement of atrial natriuretic peptide in abrogated cardioprotective effect of ischemic preconditioning in ovariectomized rat heart
T2  - HUMAN & EXPERIMENTAL TOXICOLOGY
KW  - Atrial natriuretic peptide
KW  - nitric oxide
KW  - ischemic preconditioning
KW  - ovariectomy
KW  - mitochondrial K-ATP channels
KW  - MYOCARDIAL INFARCT SIZE
KW  - NITRIC-OXIDE SYNTHASE
KW  - REPERFUSION INJURY
KW  - FEMALE RATS
KW  - DISEASE
KW  - ACTIVATION
KW  - INDUCTION
KW  - MECHANISM
KW  - CHANNELS
AB  - Background: Nitric oxide (NO) is an effective mediator of ischemic preconditioning (IPC)-induced cardioprotection. Atrial natriuretic peptide (ANP) is downregulated after ovariectomy, which results in reduction in the level of NO. The present study deals with the investigation of the role of ANP in abrogated cardioprotective effect of IPC in the ovariectomized rat heart.
   Methods: Heart was isolated from ovariectomized rat and mounted on Langendorff's apparatus, subjected to 30 min of ischemia and 120 min of reperfusion. IPC was given by four cycles of 5 min of ischemia and 5 min of reperfusion with Krebs-Henseleit solution. The myocardial infract size was estimated employing triphenyltetrazolium chloride stain, and coronary effluent was analyzed for creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH) release to consider the degree of myocardial injury. The cardiac release of NO was estimated by measuring the level of nitrite in coronary effluent.
   Results: IPC-mediated cardioprotection was significantly attenuated in ovariectomized rat as compared to normal rat, which was restored by perfusion with ANP. However, this observed cardioprotection was significantly attenuated by perfusion with L-NAME, an endothelial nitric oxide synthase inhibitor, and Glibenclamide, a K-ATP channel blocker, alone or in combination noted in terms of increase in myocardial infract size, release of CK-MB and LDH, and also decrease in release of NO.
   Conclusion: Thus, it is suggested that ANP restores the attenuated cardioprotective effect of IPC in the ovariectomized rat heart which may be due to increase in the availability of NO and consequent increase activation of mitochondrial K-ATP channels.
AD  - GLA Univ, Pharmaceut Res Inst, Mathura, IndiaAD  - AIIMS, New Delhi, IndiaC3  - GLA UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SAGE PUBLICATIONS LTD
PI  - LONDON
PA  - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
DA  - JUL
PY  - 2018
VL  - 37
IS  - 7
SP  - 704
EP  - 713
DO  - 10.1177/0960327117730878
AN  - WOS:000433607900005
ER  -

TY  - JOUR
AU  - Whitcomb, DC
AU  - Shimosegawa, T
AU  - Chari, ST
AU  - Forsmark, CE
AU  - Frulloni, L
AU  - Garg, P
AU  - Hegyi, P
AU  - Hirooka, Y
AU  - Irisawa, A
AU  - Ishikawa, T
AU  - Isaji, S
AU  - Lerch, MM
AU  - Levy, P
AU  - Masamune, A
AU  - Wilcox, CM
AU  - Windsor, J
AU  - Yadav, D
AU  - Sheel, A
AU  - Neoptolemos, JP
A1  - Working Grp Int IAP APA JPS EPC Co
TI  - International consensus statements on early chronic Pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with The International Association of Pancreatology, American Pancreatic Association, Japan Pancreas Society, PancreasFest Working Group and European Pancreatic Club
T2  - PANCREATOLOGY
KW  - Acute pancreatitis
KW  - Chronic pancreatitis
KW  - Endoscopic ultrasound
KW  - Fibrosis
KW  - Diagnosis
KW  - Classification
KW  - Model
KW  - Genetic
KW  - Alcohol
KW  - QUALITY-OF-LIFE
KW  - NATIONWIDE EPIDEMIOLOGIC SURVEY
KW  - IDIOPATHIC CHRONIC-PANCREATITIS
KW  - ALCOHOLIC CHRONIC-PANCREATITIS
KW  - CLDN2-MORC4 LOCI ASSOCIATE
KW  - GENETIC RISK-FACTORS
KW  - CHRONIC HEPATITIS-C
KW  - AGE-RELATED-CHANGES
KW  - HEREDITARY PANCREATITIS
KW  - ENDOSCOPIC ULTRASOUND
AB  - Background: Chronic pancreatitis (CP) is a progressive inflammatory disorder currently diagnosed by morphologic features. In contrast, an accurate diagnosis of Early CP is not possible using imaging criteria alone. If this were possible and early treatment instituted, the later, irreversible features and complications of CP could possibly be prevented.
   Method: An international working group supported by four major pancreas societies (IAP, APA, JPS, and EPC) and a PancreasFest working group sought to develop a consensus definition and diagnostic criteria for Early CP. Ten statements (S1-10) concerning Early CP were used to gauge consensus on the Early CP concept using anonymous voting with a 9 point Likert scale. Consensus required an alpha >= 0.80.
   Results: No consensus statement could be developed for a definition of Early-CP or diagnostic criteria. There was consensus on 5 statements: (S2) The word "Early" in early chronic pancreatitis is used to describe disease state, not disease duration. (S4) Early CP defines a stage of CP with preserved pancreatic function and potentially reversible features. (S8) Genetic variants are important risk factors for Early CP and can add specificity to the likely etiology, but they are neither necessary nor sufficient to make a diagnosis. (S9) Environmental risk factors can provide evidence to support the diagnosis of Early CP, but are neither necessary nor sufficient to make a diagnosis. (S10) The differential diagnosis for Early CP includes other disorders with morphological and functional features that overlap with CP.
   Conclusions: Morphology based diagnosis of Early CP is not possible without additional information. New approaches to the accurate diagnosis of Early CP will require a mechanistic definition that considers risk factors, biomarkers, clinical context and new models of disease. Such a definition will require prospective validation. (C) 2018 Published by Elsevier B.V. on behalf of IAP and EPC.
AD  - Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USAAD  - Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15213 USAAD  - Tohoku Univ, Grad Sch Med, Div Gastroenterol, Sendai, Miyagi, JapanAD  - Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USAAD  - Univ Florida, Div Gastroenterol Hepatol & Nutr, Gainesville, FL USAAD  - Univ Verona, Dept Med, Gastroenterol Unit, Verona, ItalyAD  - Univ Verona, Pancreas Inst, Verona, ItalyAD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaAD  - Univ Pecs, Med Sch, Inst Translat Med, Pecs, HungaryAD  - MTA SZTE Translat Gastroenterol Res Grp, Szeged, HungaryAD  - Nagoya Univ Hosp, Dept Endoscopy, Nagoya, Aichi, JapanAD  - Dokkyo Med Univ, Dept Gastroenterol, Mibu, Tochigi, JapanAD  - Nagoya Univ, Grad Sch Med, Dept Gastroenterol, Nagoya, Aichi, JapanAD  - Mie Univ, Dept Hepatobiliary Pancreat & Transplant Surg, Tsu, Mie, JapanAD  - Univ Med Greifswald, Dept Med A, Greifswald, GermanyAD  - Hop Beaujon, AP HP, Serv Pancreatol,Pole Malad Appareil Digestif,Ctr, Fac Denis Diderot,DHU UNITY,Ctr Reference Malad R, Clichy, FranceAD  - Univ Alabama Birmingham, Div Gastroenterol & Hepatol, Birmingham, AL USAAD  - Univ Auckland, Fac Med & Hlth Sci, Dept Surg, Auckland, New ZealandAD  - Univ Liverpool, Inst Translat Med, Dept Mol & Clin Canc Med, Liverpool L69 3GE, Merseyside, EnglandAD  - Heidelberg Univ, Dept Gen Visceral & Transplantat Surg, Heidelberg, GermanyC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - Tohoku UniversityC3  - Mayo ClinicC3  - State University System of FloridaC3  - University of FloridaC3  - University of VeronaC3  - University of VeronaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of PecsC3  - Nagoya UniversityC3  - Dokkyo Medical UniversityC3  - Nagoya UniversityC3  - Mie UniversityC3  - Greifswald Medical SchoolC3  - Universite Paris CiteC3  - Assistance Publique Hopitaux Paris (APHP)C3  - Hopital Universitaire Beaujon - APHPC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of AucklandC3  - University of LiverpoolC3  - Ruprecht Karls University HeidelbergPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUL
PY  - 2018
VL  - 18
IS  - 5
SP  - 516
EP  - 527
DO  - 10.1016/j.pan.2018.05.008
AN  - WOS:000437632900010
ER  -

TY  - JOUR
AU  - White, SM
AU  - Altermatt, F
AU  - Barry, J
AU  - Ben-David, B
AU  - Coburn, M
AU  - Coluzzi, F
AU  - Degoli, M
AU  - Dillane, D
AU  - Foss, NB
AU  - Gelmanas, A
AU  - Griffiths, R
AU  - Karpetas, G
AU  - Kim, JH
AU  - Kluger, M
AU  - Lau, PW
AU  - Matot, I
AU  - McBrien, M
AU  - McManus, S
AU  - Montoya-Pelaez, LF
AU  - Moppett, IK
AU  - Parker, M
AU  - Porrill, O
AU  - Sanders, RD
AU  - Shelton, C
AU  - Sieber, F
AU  - Trikha, A
AU  - Xuebing, X
TI  - International Fragility Fracture Network Delphi consensus statement on the principles of anaesthesia for patients with hip fracture
T2  - ANAESTHESIA
KW  - hip fracture
KW  - anaesthesia
KW  - hip fracture: management
KW  - consensus guidelines
KW  - INTRAOPERATIVE HYPOTENSION
KW  - GENERAL-ANESTHESIA
KW  - SPINAL-ANESTHESIA
KW  - ELDERLY-PATIENTS
KW  - 30-DAY MORTALITY
KW  - SURGERY
KW  - MANAGEMENT
KW  - DELIRIUM
KW  - CARE
KW  - OUTCOMES
AD  - Brighton & Sussex Univ Hosp NHS Trust, Brighton, E Sussex, EnglandAD  - Pontificia Univ Catolica Chile, Escuela Med, Div Anestesiol, Santiago, ChileAD  - Cairns Hosp, Cairns, Qld, AustraliaAD  - Univ Pittsburgh, Med Ctr, Anesthesiol, Pittsburgh, PA USAAD  - Rhein Westfal TH Aachen, Fac Med, Aachen, GermanyAD  - Sapienza Univ Rome, Dept Med & Surg Sci & Biotechnol, Anaesthesia, Latina, ItalyAD  - Azienda Osped Univ Modena, Osped Civile Baggiovara, Modena, ItalyAD  - Univ Alberta, Anesthesiol & Pain Med, Edmonton, AB, CanadaAD  - Hvidovre Univ Hosp, Dept Anaesthesiol & Intens Care Med, Hvidovre, DenmarkAD  - Hosp Lithuanian Univ Hlth Sci, Kauno Klin, Kaunas, LithuaniaAD  - Peterborough & Stamford Hosp NHS Trust, Peterborough, Cambs, EnglandAD  - Gen Univ Hosp Patras, Rion, GreeceAD  - Korea Univ, Coll Med, Anaesthesiol & Pain Med, Seoul, South KoreaAD  - Waitemata DHB, Auckland, New ZealandAD  - Univ Hong Kong, Hong Kong, Hong Kong, Peoples R ChinaAD  - Tel Aviv Med Ctr & Sch Med, Sackeler Sch Med, Anesthesiol Crit Care & Pain, Tel Aviv, IsraelAD  - Royal Victoria Hosp, Belfast, Antrim, North IrelandAD  - Univ Cape Town, Groote Schuur Hosp, Dept Anaesthesia & Perioperat Med, Emergency Anaesthesia Serv, Cape Town, South AfricaAD  - Univ Nottingham, Anaesthesia & Crit Care Sect, Div Clin Neurosci, Nottingham Univ Hosp NHS Trust, Queens Med Ctr Campus, Nottingham, EnglandAD  - Univ Cape Town, New Somerset Hosp, Cape Town, South AfricaAD  - Univ Wisconsin, Anaesthesia, Madison, IN USAAD  - Lancaster Med Sch, Manchester, Lancs, EnglandAD  - Wythenshawe Hosp, Manchester, Lancs, EnglandAD  - Johns Hopkins Bayview Med Ctr, Anesthesiol, Baltimore, MD USAAD  - All India Inst Med Sci, Anaesthesia, New Delhi, IndiaAD  - Univ Hong Kong Shenzhen Hosp, Shenzhen, Peoples R ChinaC3  - Brighton and Sussex University Hospitals NHS TrustC3  - University of BrightonC3  - Pontificia Universidad Catolica de ChileC3  - Queensland HealthC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - RWTH Aachen UniversityC3  - Sapienza University RomeC3  - Universita di Modena e Reggio EmiliaC3  - Universita di Modena e Reggio Emilia HospitalC3  - University of AlbertaC3  - University of CopenhagenC3  - Hospital of Lithuanian University of Health Sciences Kauno KlinikosC3  - Korea UniversityC3  - Korea University Medicine (KU Medicine)C3  - University of Hong KongC3  - Tel Aviv UniversityC3  - Sackler Faculty of MedicineC3  - University of Cape TownC3  - Nottingham University Hospital NHS TrustC3  - University of NottinghamC3  - University of Cape TownC3  - Wythenshawe Hospital NHS Foundation TrustC3  - Wythenshawe HospitalC3  - Johns Hopkins UniversityC3  - Johns Hopkins MedicineC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of Hong KongPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUL
PY  - 2018
VL  - 73
IS  - 7
SP  - 863
EP  - 874
DO  - 10.1111/anae.14225
AN  - WOS:000434947800011
ER  -

TY  - JOUR
AU  - Agarwal, M
AU  - Garg, SK
AU  - Asokan, K
AU  - Kumar, P
TI  - Temperature-dependent OSL properties of nano-phosphors LiAlO<sub>2</sub>:C and α-Al<sub>2</sub>O<sub>3</sub>:C
T2  - APPLIED SURFACE SCIENCE
KW  - Optically Stimulated Luminescence
KW  - OSL
KW  - Thermally Assisted OSL (TA-OSL)
KW  - Deep traps
KW  - Thermal activation energy
KW  - OPTICALLY STIMULATED LUMINESCENCE
KW  - THERMOLUMINESCENCE
KW  - PHOTOLUMINESCENCE
KW  - TL
KW  - NANOPHOSPHOR
KW  - SIGNAL
AB  - The present study focuses on the synthesis and characterization of carbon doped nano-phosphors, LiAlO2 and alpha-Al2O3 and their temperature-dependent optically stimulated luminescence (TA-OSL) characteristics in the temperature ranges of 25-350 degrees C. These nano-phosphors with the carbon concentration of 0.01 mol% exhibits high luminescent intensity for LiAlO2:C in the low dose range of 1 mGy-7 Gy and for alpha-Al2O3:C in the range of 100 mGy-1 kGy. Both these nano-phosphors are of polycrystalline in nature, having grain size 15-50 nm as confirmed by the X-ray diffraction (XRD) and Transmission Electron Microscopy (TEM), respectively. The maximum TA-OSL intensities are observed at 125 degrees C for LiAlO2:C and 200 degrees C for Al2O3:C, and reveal the presence of deep defect centres. The Arrhenius analysis shows the activation energies E-a = 0.06 +/- 0.02 eV for LiAlO2:C and E-a = 0.04 +/- 0.01 eV, & E-b = 0.48 +/- 0.07 eV for Al2O3:C. The TA-OSL and OSL characteristics are discussed with special reference to the medical and high radiation dosimetry. These compounds, LiAlO2:C and alpha-Al2O3:C, are non-toxic, robust and are potential candidates for reusable dosimetry. (C) 2018 Elsevier B.V. All rights reserved.
AD  - AIIMS, IRCH, Med Phys Unit, New Delhi 110029, IndiaAD  - Patna Univ, Univ Dept Phys, Patna 800005, Bihar, IndiaAD  - Interuniv Accelerator Ctr, Aruna Asaf Ali Marg, New Delhi 110067, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - Patna UniversityC3  - Inter-University Accelerator CentrePU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUN 30
PY  - 2018
VL  - 444
SP  - 819
EP  - 828
DO  - 10.1016/j.apsusc.2018.03.023
AN  - WOS:000429343200096
ER  -

TY  - JOUR
AU  - Jajoo, M
AU  - Manchanda, V
AU  - Chaurasia, S
AU  - Sankar, MJ
AU  - Gautam, H
AU  - Agarwal, R
AU  - Yadav, CP
AU  - Aggarwal, LC
AU  - Chellani, H
AU  - Ramji, S
AU  - Deb, M
AU  - Gaind, R
AU  - Kumar, S
AU  - Arya, S
AU  - Sreenivas, V
AU  - Kapii, A
AU  - Mathur, P
AU  - Rasaiiy, R
AU  - Deorari, AK
AU  - Paul, VK
A1  - Investigators DeNIS Collaboration
TI  - Alarming rates of antimicrobial resistance and fungal sepsis in outborn neonates in North India
T2  - PLOS ONE
KW  - INTENSIVE-CARE UNITS
KW  - IMPROVED OUTCOMES
KW  - NOSOCOMIAL INFECTIONS
KW  - INFANTS
KW  - DISSEMINATION
KW  - PHILIPPINES
KW  - PROFILE
KW  - HEALTH
KW  - IMPACT
AB  - Background
   There is a paucity of data on the epidemiology of sepsis in outborn neonates being referred to level-3 units in low- and middle-income countries (LMIC). The objective of the present study was to evaluate the prevalence of sepsis and outcomes of outborn neonates with sepsis, and to characterize the pathogen profile and antimicrobial resistance (AMR) patterns of common isolates in them.
   Methods
   In this prospective observational cohort study (2011-2015), a dedicated research team enrolled all neonates admitted to an outborn level-3 neonatal unit and followed them until discharge/death. Sepsis work-up including blood culture(s) was performed upon suspicion of sepsis. All the isolates were identified and tested for antimicrobial susceptibility. Gram-negative pathogens resistant to any three of the five antibiotic classes (extended-spectrum cephalosporins, carbapenems, aminoglycosides, fluoroquinolones, and piperacillin-tazobactam) were labeled multi-drug resistant.
   Results
   Of the total of 2588 neonates enrolled, culture positive sepsis and total sepsis-i.e. culture positive and/or culture negative sepsis-was diagnosed in 13.1% (95% CI 11.8% to 14.5%) and 54.7% (95% CI 52.8% to 56.6%), respectively. The case fatality rates were 23.4% and 11.0% in culture-positive and total sepsis, respectively. Sepsis accounted for two-thirds of total neonatal deaths (153/235, 63.0%). Bacterial isolates caused about three-fourths (296/401; 73.8%) of the infections. The two common pathogens-Klebsiella pneumoniae (n = 50, 12.5%) and Acinetobacter baumannii (n = 46, 11.5%)-showed high degree of multi-drug resistance (78.0% and 91.3%, respectively) and carbapenem resistance (84.0% and 91.3%, respectively). About a quarter of infections were caused by Candida spp. (n = 91; 22.7%); almost three-fourths (73.7%) of these infections occurred in neonates born at or after 32 weeks' gestation and about two-thirds (62.1%) in those weighing 1500 g or more at birth.
   Conclusions
   In this large outborn cohort, we report high burden of sepsis, high prevalence of systemic fungal infections, and alarming rates of antimicrobial resistance among bacterial pathogens.
AD  - Chacha Nehru Bal Chikitsalaya, Dept Pediat, New Delhi, IndiaAD  - Chacha Nehru Bal Chikitsalaya, Dept Microbiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - Natl Inst Malaria Res, New Delhi, IndiaAD  - Vardhman Mahaveer Med Coll, Dept Pediat, New Delhi, IndiaAD  - Safdarjang Hosp, New Delhi, IndiaAD  - Maulana Azad Med Coll, Dept Pediat, New Delhi, IndiaAD  - LNJP Hosp, New Delhi, IndiaAD  - Vardhman Mahaveer Med Coll, Dept Microbiol, New Delhi, IndiaAD  - Maulana Azad Med Coll, Dept Microbiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaAD  - AIIMS, JPNA Trauma Ctr, Dept Lab Med, New Delhi, IndiaAD  - ICMR, Div Reprod Hlth & Nutr, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Malaria Research (NIMR)C3  - Vardhman Mahavir Medical College & Safdarjung HospitalC3  - Vardhman Mahavir Medical College & Safdarjung HospitalC3  - Maulana Azad Medical CollegeC3  - Vardhman Mahavir Medical College & Safdarjung HospitalC3  - Maulana Azad Medical CollegeC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterC3  - Indian Council of Medical Research (ICMR)PU  - PUBLIC LIBRARY SCIENCE
PI  - SAN FRANCISCO
PA  - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
DA  - JUN 28
PY  - 2018
VL  - 13
IS  - 6
C7  - e0180705
DO  - 10.1371/journal.pone.0180705
AN  - WOS:000436645400001
ER  -

TY  - JOUR
AU  - Attergrim, J
AU  - Sterner, M
AU  - Claeson, A
AU  - Dharap, S
AU  - Gupta, A
AU  - Khajanchi, M
AU  - Kumar, V
AU  - Wärnberg, MG
TI  - Predicting mortality with the international classification of disease injury severity score using survival risk ratios derived from an Indian trauma population: A cohort study
T2  - PLOS ONE
KW  - MIDDLE-INCOME COUNTRIES
KW  - MULTIPLE INJURIES
KW  - GLOBAL BURDEN
KW  - CARE
KW  - PERFORMANCE
KW  - VALIDATION
KW  - SYSTEMS
KW  - MODELS
KW  - ICISS
AB  - Background
   Trauma is predicted to become the third leading cause of death in India by 2020, which indicate the need for urgent action. Trauma scores such as the international classification of diseases injury severity score (ICISS) have been used with great success in trauma research and in quality programmes to improve trauma care. To this date no valid trauma score has been developed for the Indian population.
   Study design
   This retrospective cohort study used a dataset of 16047 trauma-patients from four public university hospitals in urban India, which was divided into derivation and validation subsets. All injuries in the dataset were assigned an international classification of disease (ICD) code. Survival Risk Ratios (SRRs), for mortality within 24 hours and 30 days were then calculated for each ICD-code and used to calculate the corresponding ICISS. Score performance was measured using discrimination by calculating the area under the receiver operating characteristics curve (AUROCC) and calibration by calculating the calibration slope and intercept to plot a calibration curve.
   Results
   Predictions of 30-day mortality showed an AUROCC of 0.618, calibration slope of 0.269 and calibration intercept of 0.071. Estimates of 24-hour mortality consistently showed low AUR-OCCs and negative calibration slopes.
   Conclusions
   We attempted to derive and validate a version of the ICISS using SRRs calculated from an Indian population. However, the developed ICISS-scores overestimate mortality and implementing these scores in clinical or policy contexts is not recommended. This study, as well as previous reports, suggest that other scoring systems might be better suited for India and other Low- and middle-income countries until more data are available.
AD  - Karolinska Inst, Dept Publ Hlth Sci, Stockholm, SwedenAD  - Lokmanya Tilak Municipal Med Coll & Gen Hosp, Dept Gen Surg, Bombay, Maharashtra, IndiaAD  - JPN Apex Trauma Ctr, Div Trauma Surg & Crit Care, New Delhi, IndiaAD  - Seth GS Med Coll & KEM Hosp, Dept Gen Surg, Mumbai, Maharashtra, IndiaC3  - Karolinska InstitutetC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterC3  - Seth Gordhandas Sunderdas Medical College & King Edward Memorial HospitalPU  - PUBLIC LIBRARY SCIENCE
PI  - SAN FRANCISCO
PA  - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
DA  - JUN 27
PY  - 2018
VL  - 13
IS  - 6
C7  - e0199754
DO  - 10.1371/journal.pone.0199754
AN  - WOS:000436549200064
ER  -

TY  - JOUR
AU  - Bhattacharjee, S
AU  - Soni, KD
AU  - Maitra, S
TI  - Recruitment maneuver does not provide any mortality benefit over lung protective strategy ventilation in adult patients with acute respiratory distress syndrome: a meta-analysis and systematic review of the randomized controlled trials
T2  - JOURNAL OF INTENSIVE CARE
KW  - ARDS
KW  - Recruitment maneuver
KW  - Open lung
KW  - PEEP titration
KW  - END-EXPIRATORY PRESSURE
KW  - MECHANICAL VENTILATION
KW  - INJURY
KW  - TITRATION
KW  - ARDS
AB  - Background: Clinical benefits of recruitment maneuver in ARDS patients are controversial. A number of previous studies showed possible benefits; a large recent study reported that recruitment maneuver and PEEP titration may even be harmful. This meta-analysis was designed to compare the clinical utility of recruitment maneuver with low tidal volume ventilation in adult patients with ARDS.
   Methods: Randomized controlled trials comparing recruitment maneuver and lung protective ventilation strategy with lung protective strategy ventilation protocol alone in adult patients with ARDS has been included in this meta-analysis. PubMed and Cochrane Central Register of Controlled Trials were searched from inception to 10 November 2017 to identify potentially eligible trials. Pooled risk ratio (RR) and standardized mean difference (SMD) were calculated for binary and continuous variables respectively.
   Results: Data of 2480 patients from 7 randomized controlled trials have been included in this meta-analysis and systemic review. Reported mortality at the longest available follow-up [RR (95% CI) 0.93 (0.80, 1.08); p = 0.33], ICU mortality [RR (95% CI) 0.91 (0.76, 1.10); p = 0.33] and in-hospital mortality [RR (95% CI) 0.95 (0.83, 1.08); p = 0.45] were similar between recruitment maneuver group and standard lung protective ventilation group. Duration of hospital stay [SMD (95% CI) 0.00 (-0.09, 0.10); p = 0.92] and duration of ICU stays [SMD (95% CI) 0.05 (-0.09, 0.19); p = 0.49] were also similar between recruitment maneuver group and standard lung protective ventilation group. Risk of barotrauma was also similar.
   Conclusion: Use of recruitment maneuver along with co-interventions such as PEEP titration does not provide any benefit in terms of mortality, length of ICU, and hospital stay in ARDS patients.
AD  - All India Inst Med Sci, Dept Anaesthesiol Pain Med & Crit Care, Room 5011,5th Floor Teaching Block, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Trauma Crit Care, Jai Prakash Narayan Apex Trauma Ctr, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterPU  - BMC
PI  - LONDON
PA  - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - JUN 26
PY  - 2018
VL  - 6
C7  - 35
DO  - 10.1186/s40560-018-0305-9
AN  - WOS:000436513200001
ER  -

TY  - JOUR
AU  - Pathak, M
AU  - Dwivedi, SN
AU  - Deo, SVS
AU  - Thakur, B
AU  - Sreenivas, V
AU  - Rath, GK
TI  - Neoadjuvant chemotherapy regimens in treatment of breast cancer: a systematic review and network meta-analysis protocol
T2  - SYSTEMATIC REVIEWS
KW  - Anthracycline
KW  - Taxane
KW  - Trastuzumab
KW  - Bevacizumab
KW  - Network meta-analysis
KW  - Breast cancer
KW  - PATHOLOGICAL COMPLETE RESPONSE
KW  - CYCLOPHOSPHAMIDE
KW  - DOXORUBICIN
KW  - TRIAL
KW  - BEVACIZUMAB
KW  - TRASTUZUMAB
KW  - PACLITAXEL
KW  - DOCETAXEL
KW  - SURVIVAL
KW  - THERAPY
AB  - Background: Neoadjuvant chemotherapy (NACT), a standard of care for locally advanced breast cancer patients, is widely used for early breast cancer patients also. The varying role of regimens used as NACT needs to be investigated. Despite availability of some randomized controlled trials (RCTs), it is unclear which treatment regimen suits best. Further, there is no study comparing all the three regimens. Accordingly, present study will compare the efficacy of anthracyclines, taxanes, and targeted therapy administered in neoadjuvant setting on the basis of oncological outcomes and functional outcomes.
   Method/design: Online databases PubMed and Cochrane Register of Controlled Trials will be searched to acquire eligible studies. Further, content of relevant journals, references of relevant articles, and proceedings of major related conference will also be searched. The RCTs comparing any of abovementioned regimen as NACT on breast cancer patients will be eligible. Two reviewers independently and in duplicate will screen the records on the basis of title and abstract and complete full-text review to determine eligibility. Similarly, data extraction and risk of bias assessment will be done by two independent reviewers. The pair-wise meta-analysis as well as network meta-analysis will be conducted to assess the relative efficacy of anthracyclines, taxanes, and targeted therapy regimens.
   Discussion: The present systematic review will improve the understanding of the relative efficacies of the three treatment regimens and possibly guide the clinical practices by providing the current best evidence on the efficacy of various regimens of NACT in the management of breast cancer patients.
AD  - All India Inst Med Sci, Dept Biostat, Room 5, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Surg Oncol, Dr BRA IRCH, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Radiotherapy, Dr BRA IRCH, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalPU  - BMC
PI  - LONDON
PA  - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - JUN 26
PY  - 2018
VL  - 7
C7  - 89
DO  - 10.1186/s13643-018-0754-1
AN  - WOS:000450901500001
ER  -

TY  - JOUR
AU  - Vasaikar, N
AU  - Mahajan, U
AU  - Patil, KR
AU  - Suchal, K
AU  - Patil, CR
AU  - Ojha, S
AU  - Goyal, SN
TI  - D-pinitol attenuates cisplatin-induced nephrotoxicity in rats: Impact on pro-inflammatory cytokines
T2  - CHEMICO-BIOLOGICAL INTERACTIONS
KW  - Nephrotoxicity
KW  - D-pinitol
KW  - Cisplatin
KW  - Sutherlandia fruitcence
KW  - ACUTE-RENAL-FAILURE
KW  - OXIDATIVE STRESS
KW  - CANCER-THERAPY
KW  - UP-REGULATION
KW  - IN-VITRO
KW  - APOPTOSIS
KW  - DNA
KW  - ACCUMULATION
KW  - SUPPRESSION
KW  - MECHANISMS
AB  - Cisplatin has been widely used as a first-line agent against various forms of solid cancers. However, nephrotoxicity is the major limiting factor for its clinical use. Several clinical and pre-clinical studies have suggested different strategies for the reduction of cisplatin-induced nephrotoxicity. The present study was conducted to investigate the efficacy of D-Pinitol, against cisplatin-induced nephrotoxicity in Swiss albino mice. A single intraperitoneal injection of cisplatin (20 mg/kg) was used to induce nephrotoxicity in mice. Administration of cisplatin in mice is linked with elevated oxidative stress, imbalanced biochemical parameters, apoptosis and stimulation of mitogen-activated protein kinase (MAPK) pathway. D-Pinitol is a member of the flavonoid family and a chief constituent of Sutherlandia fruitesecnce. It was administered with saline water (10, 20, 40 mg/kg, p.o.) for seven consecutive days after a single dose of cisplatin. At the end of experiment, animals were sacrificed and biochemical parameters in serum and urine were recorded. Kidneys were isolated for the estimation of tumor necrosis factor-alpha, interleukin-1 beta, interlukin-6 levels and histopathological evaluations. It was noted that D-Pinitol significantly ameliorated biochemical levels of serum and urinary creatinine and blood urea nitrogen. Tissue homogenate levels of TNF-alpha, IL-6, IL-1 beta and the renal expression of tissue nitrites were also significantly decreased in D-Pinitol treated mice. These results were supplemented by histopathological findings. This study highlights the potential role of D-Pinitol against cisplatin-induced toxicity, exhibited through favorable alterations in biochemical and histological changes as well as reduction in oxidative stress and cytokine levels.
AD  - RC Patel Inst Pharmaceut Educ & Res, Dept Pharmacol, Cardiovasc & Diabet Div, Dhule 425405, Maharashtra, IndiaAD  - HR Patel Inst Pharmaceut Educ & Res, Dept Pharmacol, Dhule 425405, Maharashtra, IndiaAD  - All India Inst Med Sci, Dept Pharmacol, New Delhi 110029, IndiaAD  - UAE Univ, Coll Med & Hlth Sci, Dept Pharmacol & Therapeut, Al Ain, U Arab EmiratesAD  - SVKM, Inst Pharm, Dhule 424001, Maharashtra, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - United Arab Emirates UniversityPU  - ELSEVIER IRELAND LTD
PI  - CLARE
PA  - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
DA  - JUN 25
PY  - 2018
VL  - 290
SP  - 6
EP  - 11
DO  - 10.1016/j.cbi.2018.05.003
AN  - WOS:000436773500002
ER  -

TY  - JOUR
AU  - Biswas, A
AU  - Das, S
AU  - Kapoor, M
AU  - Shamsudheen, KV
AU  - Jayarajan, R
AU  - Verma, A
AU  - Seth, S
AU  - Bhargava, B
AU  - Scaria, V
AU  - Sivasubbu, S
AU  - Rao, VR
TI  - Familial Hypertrophic Cardiomyopathy - Identification of cause and risk stratification through exome sequencing
T2  - GENE
KW  - Troponin T
KW  - Phenotypic heterogeneity
KW  - Cardiac hypertrophy
KW  - Next generation sequencing
KW  - CARDIAC-TROPONIN-T
KW  - SUDDEN-DEATH
KW  - MUTATIONS
KW  - DIAGNOSIS
KW  - GENETICS
KW  - MICE
AB  - Background: Hypertrophic Cardiomyopathy (HCM) with variable clinical presentations and heterogeneity is the common cause of sudden cardiac death. Genetic diagnosis is challenging in these complex diseases but exome sequencing as a genetic diagnostic tool provides explainable results.
   Methods: In a familial Hypertrophic Cardiomyopathy with multigenerational inheritance with apparent phenotype, had a history of sudden death and severe arrhythmia followed by implantation of Implantable cardioverter defibrillator (ICD). Exome sequencing (100 x) trailed by effective filtering steps for exome variants on the basis of different parameters, segregated variants are prioritized for the disease and further clinical relevance are evaluated for the variants.
   Results: A rare causal variant in troponin-T gene (TNNT2, NM_000364.3;c.274C > T;p.Arg92Trp) is identified, shared by only affected members, absent in unaffected members and also in 200 unrelated control chromosomes. TNNT2 mutation act as a driver mutation but mutations in other disease-related genes, KCNMB1, LPL, APOE and other biochemical factors provides risk stratification within affected family members.
   Conclusion: This study contributes to the role of "rare variants" in complex disease phenotypes and heterogeneity within family and the necessity of whole exome targeted approaches in complex cardiomyopathy, which are known to harbor private mutations.
AD  - Delhi Univ, Dept Anthropol, Delhi, IndiaAD  - CSIR Inst Genom & Integrat Biol IGIB, New Delhi, IndiaAD  - AIIMS, Dept Cardiol, New Delhi, IndiaAD  - Genome Fdn, Hyderabad, Telangana, IndiaAD  - Osmania Univ, Dept Genet, Hyderabad 500007, Andhra Pradesh, IndiaAD  - Arba Minch Univ, Coll Nat Sci, Arba Minch, EthiopiaC3  - University of DelhiC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Osmania UniversityC3  - Arba Minch UniversityPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUN 20
PY  - 2018
VL  - 660
SP  - 151
EP  - 156
DO  - 10.1016/j.gene.2018.03.062
AN  - WOS:000432881700018
ER  -

TY  - JOUR
AU  - Rufai, SB
AU  - Singh, J
AU  - Kumar, P
AU  - Mathur, P
AU  - Singh, S
TI  - Association of <i>gyrA</i> and <i>rrs</i> gene mutations detected by MTBDR<i>sl</i> V1 on <i>Mycobacterium tuberculosis</i> strains of diverse genetic background from India
T2  - SCIENTIFIC REPORTS
KW  - DRUG-RESISTANT TUBERCULOSIS
KW  - 2ND-LINE DRUGS
KW  - MULTIPLEX PCR
KW  - VERSION V2.0
KW  - PERFORMANCE
KW  - TB
KW  - DIFFERENTIATION
KW  - ASSAY
KW  - SUBLINEAGES
KW  - DIAGNOSIS
AB  - There is limited data on the use of Genotype MTBDRslVersion 1 (MTBDRslV1) as an initial rapid screening test to rule out XDR-TB and most importantly its performance in various genotypes of Mycobacterium tuberculosis is scarcely studied. A total of 359 MDR-TB isolates were tested for gene mutations representing second line drug resistance, using the MTBDRsl_V.1 and the results were compared with phenotypic method (Bactec MGIT-960 system) for second-line drug (SLD) susceptibility testing. Genetic lineages of all these isolates were also determined using spoligotyping and SITVIT2 WEB database. The MTBDRsl V1 detected mutations in the gyrA, rrs, and emb genes in 108 (30%), 2 (0.5%) and 129 (35.9%) isolates, respectively. Remaining 120 (33.4%) had no second line drug (SLD) resistance. In 17 (4.7%) isolates mutations were detected in both gyrA and rrs genes. Its concordance with MGIT-960 culture drug susceptibility testing (DST) was 97% and 94.1%, 93.5%, 60.5% and 50% for the detection of XDR-TB, pre-XDR, Ethambutol, and Aminoglycosides/Cyclopeptides resistance. The Beijing lineage was predominant (46%) between both the pre-XDR/XDR-TB isolates. We conclude that MTBDRsl is useful for rapid detection of SLD resistance. Also in pre-XDR and XDR-TB isolates the frequency of relevant genetic mutations was significantly higher in the Beijing strains.
AD  - All India Inst Med Sci, Dept Lab Med, Div Clin Microbiol & Mol Med, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - NATURE PORTFOLIO
PI  - BERLIN
PA  - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
DA  - JUN 18
PY  - 2018
VL  - 8
C7  - 9295
DO  - 10.1038/s41598-018-27299-z
AN  - WOS:000435448300038
ER  -

TY  - JOUR
AU  - Ghose, S
AU  - Biswas, S
AU  - Datta, K
AU  - Tyagi, RK
TI  - Dynamic Hyaluronan drives liver endothelial cells towards angiogenesis
T2  - BMC CANCER
KW  - Hyaluronic acid or Hyaluronan
KW  - Liver endothelial cells
KW  - Angiogenesis
KW  - BINDING PROTEIN-1 HABP1/P32/GC1QR
KW  - PRIMARY BILIARY-CIRRHOSIS
KW  - CHRONIC HEPATITIS-C
KW  - ACTIN-BASED MOTILITY
KW  - FAT-STORING CELLS
KW  - LOBODA ET-AL
KW  - BETA-CATENIN
KW  - RAT-LIVER
KW  - COLORECTAL-CANCER
KW  - SERUM HYALURONAN
AB  - Background: Angiogenesis, the formation of new blood vessels from pre-existing vasculature is essential in a number of physiological processes such as embryonic development, wound healing as well as pathological conditions like, tumor growth and metastasis. Hyaluronic acid (HA), a high molecular weight polysaccharide, major component of extracellular matrix is known to associate with malignant phenotypes in melanomas and various other carcinomas. Hyaluronic acid binding protein 1 (HABP1) has been previously reported to trigger enhanced cellular proliferation in human liver cancer cells upon its over-expression. In the present study, we have identified the HA mediated cellular behaviour of liver endothelial cells during angiogenesis.
   Methods: Endothelial cells have been isolated from perfused liver of mice. Cell proliferation was studied using microwell plates with tetrazole dye. Cell migration was evaluated by measuring endothelial monolayer wound repair as well as through transwell migration assay. Alterations in proteins and mRNA expression were estimated by immunobloting and quantitative real time PCR using Applied Biosystems. The paraformaldehyde fixed endothelial cells were used for immuno-florescence staining and F-actin detection with conjugated antibodies. The images were captured by using Olympus florescence microscope (IX71).
   Results: We observed that administration of HA enhanced cell proliferation, adhesion, tubular sprout formation as well as migration of liver endothelial cells (ECs). The effect of HA in the rearrangement of the actins confirmed HA -mediated cytoskeleton re-organization and cell migration. Further, we confirmed enhanced expression of angiogenic factors like VEGF-A and VEGFR1 in endothelial cells upon HA treatment. HA supplementation led to elevated expression of HABP1 in murine endothelial cells. It was interesting to note that, although protein levels of beta- catenin remained unaltered, but translocation of this protein from membrane to nucleus was observed upon HA treatment, suggesting its role not only in vessel formation but also its involvement in angiogenesis signalling.
   Conclusions: The elucidation of molecular mechanism (s) responsible for HA mediated regulation of endothelial cells and angiogenesis contributes not only to our understanding the mechanism of disease progression but also offer new avenues for therapeutic intervention.
AD  - All India Inst Med Sci, Dept Med Oncol, New Delhi 110029, IndiaAD  - Jawaharlal Nehru Univ, Special Ctr Mol Med, New Delhi, IndiaAD  - Amity Univ Uttar Pradesh, Amity Inst Mol Med & Stem Cell Res, Sect 125, NOIDA 201313, Uttar Pradesh, IndiaAD  - Jawaharlal Nehru Univ, Sch Environm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jawaharlal Nehru University, New DelhiC3  - Amity University NoidaC3  - Jawaharlal Nehru University, New DelhiPU  - BIOMED CENTRAL LTD
PI  - LONDON
PA  - 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
DA  - JUN 11
PY  - 2018
VL  - 18
C7  - 648
DO  - 10.1186/s12885-018-4532-1
AN  - WOS:000435378600001
ER  -

TY  - JOUR
AU  - Sharma, SK
AU  - Mohan, A
AU  - Singh, AD
AU  - Mishra, H
AU  - Jhanjee, S
AU  - Pandey, RM
AU  - Singh, BK
AU  - Sharma, R
AU  - Pallipamu, PB
AU  - Pai, M
AU  - Dheda, K
TI  - Impact of nicotine replacement therapy as an adjunct to anti-tuberculosis treatment and behaviour change counselling in newly diagnosed pulmonary tuberculosis patients: an open-label, randomised controlled trial
T2  - SCIENTIFIC REPORTS
KW  - SMOKING-CESSATION
KW  - CARE
KW  - MULTICENTER
AB  - We evaluated the impact of intensive smoking cessation activities as an adjunct to anti-tuberculosis treatment on patient-related treatment outcomes. In this open-label, randomised controlled trial, selfreporting smokers with pulmonary tuberculosis who initiated standard anti-tuberculosis treatment were randomised to either nicotine replacement therapy and behaviour change counselling (n = 400) or counselling alone (n = 400) provided at baseline and two follow-up visits. The primary outcomes were change in TBscore at 24-weeks and culture conversion at 8-weeks. Biochemical smoking quit rates defined as serum cotinine levels < 10 ng/mL and/or exhaled carbon monoxide levels < 6 ppm (47.8% vs 32.4%, p-value =< 0 . 001) and self-reported quit rates (69.3% vs 38.7%, p-value =< 0 . 001) were significantly higher in the intervention arm at 24-weeks. Though the TBscores at 24 weeks (95% CI) were lower in the intervention arm [2.07 (1.98, 2.17) versus 2.12 (2 .02, 2.21)], the difference was not clinically meaningful. Patients in the control arm required treatment extension more often than intervention arm (6.4% vs 2.6%, p-value = 0 . 02). Combining nicotine replacement therapy with behaviour change counselling resulted in significantly higher quit rates and lower cotinine levels, however, impact on patient-related (TBscore) or microbiological outcomes (culture conversion) were not seen.
AD  - Jamia Hamdard Inst Mol Med, Dept Mol Med, New Delhi 110062, IndiaAD  - All India Inst Med Sci, Dept Med, New Delhi 110029, IndiaAD  - Sri Venkateshwara Inst Med Sci, Dept Med, Tirupati 517507, Andhra Pradesh, IndiaAD  - All India Inst Med Sci, Psychiat, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Biostat, New Delhi 110029, IndiaAD  - McGill Univ, Canada Res Chair Epidemiol & Global Hlth, Dept Epidemiol & Biostat, 1020 Pine Ave, West Montreal, PQ H3A 1A2, CanadaAD  - McGill Univ, McGill Global Hlth Programs, Dept Epidemiol & Biostat, 1020 Pine Ave, West Montreal, PQ H3A 1A2, CanadaAD  - McGill Univ, McGill Int TB Ctr, Dept Epidemiol & Biostat, 1020 Pine Ave, West Montreal, PQ H3A 1A2, CanadaAD  - Univ Cape Town, Groote Schuur Hosp, Dept Med, Lung Infect & Immun Unit,Div Pulmonol, Old Main Bldg, Cape Town, South AfricaAD  - Univ Cape Town, Groote Schuur Hosp, UCT Lung Inst, Old Main Bldg, Cape Town, South AfricaAD  - Datta Meghe Inst Med Sci, JNMC, Dept Gen Med & Pulm Med, Wardha 442004, Maharashtra, IndiaC3  - Jamia Hamdard UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - McGill UniversityC3  - McGill UniversityC3  - McGill UniversityC3  - University of Cape TownC3  - University of Cape TownC3  - Datta Meghe Institute of Higher Education & Research (Deemed to be University)C3  - Jawaharlal Nehru Medical College WardhaPU  - NATURE PORTFOLIO
PI  - BERLIN
PA  - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
DA  - JUN 11
PY  - 2018
VL  - 8
C7  - 8828
DO  - 10.1038/s41598-018-26990-5
AN  - WOS:000434776600034
ER  -

TY  - JOUR
AU  - Mourao, LC
AU  - Baptista, RD
AU  - de Almeida, ZB
AU  - Grynberg, P
AU  - Pucci, MM
AU  - Castro-Gomes, T
AU  - Fontes, CJF
AU  - Rathore, S
AU  - Sharma, YD
AU  - da Silva-Pereira, RA
AU  - Bemquerer, MP
AU  - Braga, ÉM
TI  - Anti-band 3 and anti-spectrin antibodies are increased in <i>Plasmodium vivax</i> infection and are associated with anemia
T2  - SCIENTIFIC REPORTS
KW  - NATURALLY-OCCURRING ANTI-BAND-3
KW  - MEROZOITE SURFACE PROTEIN-1
KW  - RED-BLOOD-CELLS
KW  - MALARIA
KW  - FALCIPARUM
KW  - ERYTHROCYTES
KW  - PARASITE
KW  - MEMBRANE
KW  - RECEPTOR
KW  - RESPONSES
AB  - Clearance of non-infected red blood cells (nRBCs) is one of the main components of anemia associated with Plasmodium vivax malaria. Recently, we have shown that anemic patients with P. vivax infection had elevated levels of anti-RBCs antibodies, which could enhance in vitro phagocytosis of nRBCs and decrease their deformability. Using immunoproteomics, here we characterized erythrocytic antigens that are differentially recognized by autoantibodies from anemic and non-anemic patients with acute vivax malaria. Protein spots exclusively recognized by anemic P. vivax-infected patients were identified by mass spectrometry revealing band 3 and spectrin as the main targets. To confirm this finding, antibody responses against these specific proteins were assessed by ELISA. In addition, an inverse association between hemoglobin and anti-band 3 or anti-spectrin antibodies levels was found. Anemic patients had higher levels of IgG against both band 3 and spectrin than the non-anemic ones. To determine if these autoantibodies were elicited because of molecular mimicry, we used in silico analysis and identified P. vivax proteins that share homology with human RBC proteins such as spectrin, suggesting that infection drives autoimmune responses. These findings suggest that band 3 and spectrin are potential targets of autoantibodies that may be relevant for P. vivax malaria-associated anemia.
AD  - Univ Fed Minas Gerais, Dept Parasitol, Belo Horizonte, MG, BrazilAD  - Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USAAD  - Embrapa Recursos Genet & Biotecnol, Brasilia, DF, BrazilAD  - Fundacao Oswaldo Cruz, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, BrazilAD  - Univ Fed Mato Grosso, Fac Ciencias Med, Cuiaba, MT, BrazilAD  - All India Inst Med Sci, Dept Biotechnol, New Delhi, IndiaC3  - Universidade Federal de Minas GeraisC3  - University System of GeorgiaC3  - University of GeorgiaC3  - Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA)C3  - Fundacao Oswaldo CruzC3  - Universidade Federal de Mato GrossoC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - NATURE PORTFOLIO
PI  - BERLIN
PA  - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
DA  - JUN 8
PY  - 2018
VL  - 8
C7  - 8762
DO  - 10.1038/s41598-018-27109-6
AN  - WOS:000434640800016
ER  -

TY  - JOUR
AU  - Beveridge, LA
AU  - Khan, F
AU  - Struthers, AD
AU  - Armitage, J
AU  - Barchetta, I
AU  - Bressendorff, I
AU  - Cavallo, MG
AU  - Clarke, R
AU  - Dalan, R
AU  - Dreyer, G
AU  - Gepner, AD
AU  - Forouhi, NG
AU  - Harris, RA
AU  - Hitman, GA
AU  - Larsen, T
AU  - Khadgawat, R
AU  - Marckmann, P
AU  - Mose, FH
AU  - Pilz, S
AU  - Scholze, A
AU  - Shargorodsky, M
AU  - Sokol, SI
AU  - Stricker, H
AU  - Zoccali, C
AU  - Witham, MD
TI  - Effect of Vitamin D Supplementation on Markers of Vascular Function: A Systematic Review and Individual Participant Meta-Analysis
T2  - JOURNAL OF THE AMERICAN HEART ASSOCIATION
KW  - endothelial function
KW  - paricalcitol
KW  - systematic review
KW  - vascular function
KW  - vitamin D
KW  - RANDOMIZED CONTROLLED-TRIAL
KW  - PLACEBO-CONTROLLED TRIAL
KW  - CHRONIC KIDNEY-DISEASE
KW  - CARDIOVASCULAR RISK-FACTORS
KW  - TYPE-2 DIABETES-MELLITUS
KW  - FLOW-MEDIATED DILATION
KW  - ENDOTHELIAL FUNCTION
KW  - BLOOD-PRESSURE
KW  - DOUBLE-BLIND
KW  - CHOLECALCIFEROL SUPPLEMENTATION
AB  - Background-Low 25-hydroxyvitamin D levels are associated with an increased risk of cardiovascular events, but the effect of vitamin D supplementation on markers of vascular function associated with major adverse cardiovascular events is unclear.
   Methods and Results-We conducted a systematic review and individual participant meta-analysis to examine the effect of vitamin D supplementation on flow-mediated dilatation of the brachial artery, pulse wave velocity, augmentation index, central blood pressure, microvascular function, and reactive hyperemia index. MEDLINE, CINAHL, EMBASE, Cochrane Central Register of Controlled Trials, and were searched until the end of 2016 without language restrictions. Placebo-controlled randomized trials of at least 4 weeks duration were included. Individual participant data were sought from investigators on included trials. Trial-level meta-analysis was performed using random-effects models; individual participant meta-analyses used a 2-stage analytic strategy, examining effects in prespecified subgroups. 31 trials (2751 participants) were included; 29 trials (2641 participants) contributed data to trial-level meta-analysis, and 24 trials (2051 participants) contributed to individual-participant analyses. Vitamin D3 daily dose equivalents ranged from 900 to 5000 IU; duration was 4 weeks to 12 months. Trial-level meta-analysis showed no significant effect of supplementation on macrovascular measures (flow-mediated dilatation, 0.37% [95% confidence interval, -0.23 to 0.97]; carotid-femoral pulse wave velocity, 0.00 m/s [95% confidence interval, -0.36 to 0.37]); similar results were obtained from individual participant data. Microvascular function showed a modest improvement in trial-level data only. No consistent benefit was observed in subgroup analyses or between different vitamin D analogues.
   Conclusions-Vitamin D supplementation had no significant effect on most markers of vascular function in this analysis.
AD  - NHS Tayside, Dept Med Elderly, Dundee, ScotlandAD  - Univ Dundee, Sch Med, Dundee, ScotlandAD  - Univ Oxford, Clin Trial Serv Unit, Oxford, EnglandAD  - Univ Oxford, MRC Populat Hlth Res, Oxford, EnglandAD  - Sapienza Univ Rome, Dept Expt Med, Rome, ItalyAD  - Herlev & Gentofte Hosp, Dept Nephrol, Copenhagen, DenmarkAD  - Nanyang Technol Univ, Lee Kong Chian Sch Med, Tan Tock Seng Hosp, Singapore, SingaporeAD  - Barts Hlth NHS Trust, Dept Nephrol, London, EnglandAD  - Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USAAD  - William S Middleton Vet Affairs Hosp, Madison, WI USAAD  - Univ Cambridge, MRC Epidemiol Unit, Sch Clin Med, Cambridge, EnglandAD  - Augusta Univ, Georgia Prevent Inst, Dept Populat Hlth Sci, Augusta, GA USAAD  - Queen Mary Univ London, Blizard Inst, London, EnglandAD  - Reg Hosp West Jutland, Dept Med Res, Univ Clin Nephrol & Hypertens, Aarhus, DenmarkAD  - Aarhus Univ, Aarhus, DenmarkAD  - All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi, IndiaAD  - Zealand Univ Hosp, Dept Internal Med, Roskilde, DenmarkAD  - Med Univ Graz, Dept Internal Med, Div Endocrinol & Diabetol, Graz, AustriaAD  - Univ Southern Denmark, Odense Univ Hosp, Dept Nephrol, Odense, DenmarkAD  - Univ Southern Denmark, Inst Clin Res, Odense, DenmarkAD  - Tel Aviv Univ, Wolfson Med Ctr, Dept Endocrinol, Tel Aviv, IsraelAD  - Tel Aviv Univ, Sackler Fac Med, Tel Aviv, IsraelAD  - Jacobi Med Ctr, Div Cardiol, New York, NY USAAD  - Osped La Carita, Dept Angiol, Locarno, SwitzerlandAD  - CNR IFC Clin Epidemiol & Pathphysiol Renal Dis &, Reggio Di Calabria, ItalyC3  - University of DundeeC3  - University of DundeeC3  - University of OxfordC3  - University of OxfordC3  - Sapienza University RomeC3  - Tan Tock Seng HospitalC3  - Nanyang Technological UniversityC3  - Barts Health NHS TrustC3  - University of Wisconsin SystemC3  - University of Wisconsin MadisonC3  - University of CambridgeC3  - University System of GeorgiaC3  - Augusta UniversityC3  - University of LondonC3  - Queen Mary University LondonC3  - Aarhus UniversityC3  - Aarhus UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Medical University of GrazC3  - University of Southern DenmarkC3  - Odense University HospitalC3  - University of Southern DenmarkC3  - Tel Aviv UniversityC3  - Tel Aviv UniversityC3  - Sackler Faculty of MedicineC3  - Jacobi Medical CenterPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUN 5
PY  - 2018
VL  - 7
IS  - 11
C7  - e008273
DO  - 10.1161/JAHA.117.008273
AN  - WOS:000434979100015
ER  -

TY  - JOUR
AU  - Fullman, N
AU  - Yearwood, J
AU  - Abay, SM
AU  - Abbafati, C
AU  - Abd-Allah, F
AU  - Abdela, J
AU  - Abdelalim, A
AU  - Abebe, Z
AU  - Abebo, TA
AU  - Aboyans, V
AU  - Abraha, HN
AU  - Abreu, DMX
AU  - Abu-Raddad, LJ
AU  - Adane, AA
AU  - Adedoyin, RA
AU  - Adetokunboh, O
AU  - Adhikari, TB
AU  - Afarideh, M
AU  - Afshin, A
AU  - Agarwal, G
AU  - Agius, D
AU  - Agrawal, A
AU  - Agrawal, S
AU  - Kiadaliri, AA
AU  - Aichour, MTE
AU  - Akibu, M
AU  - Akinyemi, RO
AU  - Akinyemiju, TF
AU  - Akseer, N
AU  - Al Lami, FH
AU  - Alahdab, F
AU  - Al-Aly, Z
AU  - Alam, K
AU  - Alam, T
AU  - Alasfoor, D
AU  - Albittar, MI
AU  - Alene, KA
AU  - Al-Eyadhy, A
AU  - Ali, SD
AU  - Alijanzadeh, M
AU  - Aljunid, SM
AU  - Alkerwi, A
AU  - Alla, F
AU  - Allebeck, P
AU  - Allen, C
AU  - Alomari, MA
AU  - Al-Raddadi, R
AU  - Alsharif, U
AU  - Altirkawi, KA
AU  - Alvis-Guzman, N
AU  - Amare, AT
AU  - Amenu, K
AU  - Ammar, W
AU  - Amoako, YA
AU  - Anber, N
AU  - Andrei, CL
AU  - Androudi, S
AU  - Antonio, CAT
AU  - Araújo, VEM
AU  - Aremu, O
AU  - Ärnlöv, J
AU  - Artaman, A
AU  - Aryal, KK
AU  - Asayesh, H
AU  - Asfaw, ET
AU  - Asgedom, SW
AU  - Asghar, RJ
AU  - Ashebir, MM
AU  - Asseffa, NA
AU  - Atey, TM
AU  - Atre, SR
AU  - Atteraya, MS
AU  - Avila-Burgos, L
AU  - Avokpaho, EFGA
AU  - Awasthi, A
AU  - Quintanilla, BPA
AU  - Ayalew, AA
AU  - Ayele, HT
AU  - Ayer, R
AU  - Ayuk, TB
AU  - Azzopardi, P
AU  - Azzopardi-Muscat, N
AU  - Babalola, TK
AU  - Badali, H
AU  - Badawi, A
AU  - Banach, M
AU  - Banerjee, A
AU  - Banstola, A
AU  - Barber, RM
AU  - Barboza, MA
AU  - Barker-Collo, SL
AU  - Bärnighausen, T
AU  - Barquera, S
AU  - Barrero, LH
AU  - Bassat, Q
AU  - Basu, S
AU  - Baune, BT
AU  - Bazargan-Hejazi, S
AU  - Bedi, N
AU  - Beghi, E
AU  - Behzadifar, M
AU  - Behzadifar, M
AU  - Bekele, BB
AU  - Belachew, AB
AU  - Belay, SA
AU  - Belay, YA
AU  - Bell, ML
AU  - Bello, AK
AU  - Bennett, DA
AU  - Bennett, JR
AU  - Bensenor, IM
AU  - Berhe, DF
AU  - Bernabé, E
AU  - Bernstein, RS
AU  - Beuran, M
AU  - Bhalla, A
AU  - Bhatt, P
AU  - Bhaumik, S
AU  - Bhutta, ZA
AU  - Biadgo, B
AU  - Bijani, A
AU  - Bikbov, B
AU  - Birungi, C
AU  - Biryukov, S
AU  - Bizuneh, H
AU  - Bolliger, IW
AU  - Bolt, K
AU  - Bou-Orm, IR
AU  - Bozorgmehr, K
AU  - Brady, OJ
AU  - Brazinova, A
AU  - Breitborde, NJK
AU  - Brenner, H
AU  - Britton, G
AU  - Brugha, TS
AU  - Butt, ZA
AU  - Cahuana-Hurtado, L
AU  - Campos-Nonato, IR
AU  - Campuzano, JC
AU  - Car, J
AU  - Car, M
AU  - Cárdenas, R
AU  - Carrero, JJ
AU  - Carvalho, F
AU  - Castañeda-Orjuela, CA
AU  - Rivas, JC
AU  - Catalá-López, F
AU  - Cercy, K
AU  - Chalek, J
AU  - Chang, HY
AU  - Chang, JC
AU  - Chattopadhyay, A
AU  - Chaturvedi, P
AU  - Chiang, PPC
AU  - Chisumpa, VH
AU  - Choi, JYJ
AU  - Christensen, H
AU  - Christopher, DJ
AU  - Chung, SC
AU  - Ciobanu, LG
AU  - Cirillo, M
AU  - Colombara, D
AU  - Conti, S
AU  - Cooper, C
AU  - Cornaby, L
AU  - Cortesi, PA
AU  - Cortinovis, M
AU  - Pereira, AC
AU  - Cousin, E
AU  - Criqui, MH
AU  - Cromwell, EA
AU  - Crowe, CS
AU  - Crump, JA
AU  - Daba, AK
AU  - Dachew, BA
AU  - Dadi, AF
AU  - Dandona, L
AU  - Dandona, R
AU  - Dargan, PI
AU  - Daryani, A
AU  - Daryani, M
AU  - Das, J
AU  - Das, SK
AU  - das Neves, J
AU  - Weaver, ND
AU  - Davletov, K
AU  - de Courten, B
AU  - De Leo, D
AU  - De Neve, JW
AU  - Dellavalle, RP
AU  - Demoz, G
AU  - Deribe, K
AU  - Des Jarlais, DC
AU  - Dey, S
AU  - Dharmaratne, SD
AU  - Dhimal, M
AU  - Djalalinia, S
AU  - Doku, DT
AU  - Dolan, K
AU  - Dorsey, ER
AU  - dos Santos, KPB
AU  - Doyle, KE
AU  - Driscoll, TR
AU  - Dubey, M
AU  - Dubljanin, E
AU  - Duncan, BB
AU  - Echko, M
AU  - Edessa, D
AU  - Edvardsson, D
AU  - Ehrlich, JR
AU  - Eldrenkamp, E
AU  - El-Khatib, Z
AU  - Endres, M
AU  - Endries, AY
AU  - Eshrati, B
AU  - Eskandarieh, S
AU  - Esteghamati, A
AU  - Fakhar, M
AU  - Farag, T
AU  - Faramarzi, M
AU  - Faraon, EJA
AU  - Faro, A
AU  - Farzadfar, F
AU  - Fatusi, A
AU  - Fazeli, MS
AU  - Feigin, VL
AU  - Feigl, AB
AU  - Fentahun, N
AU  - Fereshtehnejad, SM
AU  - Fernandes, E
AU  - Fernandes, JC
AU  - Fijabi, DO
AU  - Filip, I
AU  - Fischer, F
AU  - Fitzmaurice, C
AU  - Flaxman, AD
AU  - Flor, LS
AU  - Foigt, N
AU  - Foreman, KJ
AU  - Frostad, JJ
AU  - Fürst, T
AU  - Futran, ND
AU  - Gakidou, E
AU  - Gallus, S
AU  - Gambashidze, K
AU  - Gamkrelidze, A
AU  - Ganji, M
AU  - Gebre, AK
AU  - Gebrehiwot, TT
AU  - Gebremedhin, AT
AU  - Gelaw, YA
AU  - Geleijnse, JM
AU  - Geremew, D
AU  - Gething, PW
AU  - Ghadimi, R
AU  - Falavarjani, KG
AU  - Ghasemi-Kasman, M
AU  - Gill, PS
AU  - Giref, AZ
AU  - Giroud, M
AU  - Gishu, MD
AU  - Giussani, G
AU  - Godwin, WW
AU  - Goli, S
AU  - Gomez-Dantes, H
AU  - Gona, PN
AU  - Goodridge, A
AU  - Gopalani, SV
AU  - Goryakin, Y
AU  - Goulart, AC
AU  - Grada, A
AU  - Griswold, M
AU  - Grosso, G
AU  - Gugnani, HC
AU  - Guo, YM
AU  - Gupta, R
AU  - Gupta, R
AU  - Gupta, T
AU  - Gupta, T
AU  - Gupta, V
AU  - Haagsma, JA
AU  - Hachinski, V
AU  - Hafezi-Nejad, N
AU  - Hailu, GB
AU  - Hamadeh, RR
AU  - Hamidi, S
AU  - Hankey, GJ
AU  - Harb, HL
AU  - Harewood, HC
AU  - Harikrishnan, S
AU  - Haro, JM
AU  - Hassen, HY
AU  - Havmoeller, R
AU  - Hawley, C
AU  - Hay, SI
AU  - He, JW
AU  - Hearps, SJC
AU  - Hegazy, MI
AU  - Heibati, B
AU  - Heidari, M
AU  - Hendrie, D
AU  - Henry, NJ
AU  - Ballesteros, VHH
AU  - Herteliu, C
AU  - Hibstu, DT
AU  - Hiluf, MK
AU  - Hoek, HW
AU  - Rad, EH
AU  - Horita, N
AU  - Hosgood, HD
AU  - Hosseini, M
AU  - Hosseini, SR
AU  - Hostiuc, M
AU  - Hostiuc, S
AU  - Hoy, DG
AU  - Hsairi, M
AU  - Htet, AS
AU  - Hu, GQ
AU  - Huang, JJ
AU  - Iburg, KM
AU  - Idris, F
AU  - Igumbor, EU
AU  - Ikeda, C
AU  - Ileanu, BV
AU  - Ilesanmi, OS
AU  - Innos, K
AU  - Irvani, SSN
AU  - Irvine, CMS
AU  - Islami, F
AU  - Jacobs, TA
AU  - Jacobsen, KH
AU  - Jahanmehr, N
AU  - Jain, R
AU  - Jain, SK
AU  - Jakovljevic, MM
AU  - Jalu, MT
AU  - Jamal, AA
AU  - Javanbakht, M
AU  - Jayatilleke, AU
AU  - Jeemon, P
AU  - Jha, RP
AU  - Jha, V
AU  - Józwiak, J
AU  - John, O
AU  - Johnson, SC
AU  - Jonas, JB
AU  - Joshua, V
AU  - Jürisson, M
AU  - Kabir, Z
AU  - Kadel, R
AU  - Kahsay, A
AU  - Kalani, R
AU  - Kar, C
AU  - Karanikolos, M
AU  - Karch, A
AU  - Karema, CK
AU  - Karimi, SM
AU  - Kasaeian, A
AU  - Kassa, DH
AU  - Kassa, GM
AU  - Kassa, TD
AU  - Kassebaum, NJ
AU  - Katikireddi, SV
AU  - Kaul, A
AU  - Kawakami, N
AU  - Kazanjan, K
AU  - Kebede, S
AU  - Keiyoro, PN
AU  - Kemp, GR
AU  - Kengne, AP
AU  - Kereselidze, M
AU  - Ketema, EB
AU  - Khader, YS
AU  - Khafaie, MA
AU  - Khajavi, A
AU  - Khalil, IA
AU  - Khan, EA
AU  - Khan, G
AU  - Khan, MN
AU  - Khan, MA
AU  - Khanal, MN
AU  - Khang, YH
AU  - Khater, MM
AU  - Khoja, ATA
AU  - Khosravi, A
AU  - Khubchandani, J
AU  - Kibret, GD
AU  - Kiirithio, DN
AU  - Kim, D
AU  - Kim, YJ
AU  - Kimokoti, RW
AU  - Kinfu, Y
AU  - Kinra, S
AU  - Kisa, A
AU  - Kissoon, N
AU  - Kochhar, S
AU  - Kokubo, Y
AU  - Kopec, JA
AU  - Kosen, S
AU  - Koul, PA
AU  - Koyanagi, A
AU  - Kravchenko, M
AU  - Krishan, K
AU  - Krohn, KJ
AU  - Defo, BK
AU  - Kumar, GA
AU  - Kumar, P
AU  - Kutz, M
AU  - Kuzin, I
AU  - Kyu, HH
AU  - Lad, DP
AU  - Lafranconi, A
AU  - Lal, DK
AU  - Lalloo, R
AU  - Lam, H
AU  - Lan, Q
AU  - Lang, JJ
AU  - Lansingh, V
AU  - Lansky, S
AU  - Larsson, A
AU  - Latifi, A
AU  - Lazarus, JV
AU  - Leasher, JL
AU  - Lee, PH
AU  - Legesse, Y
AU  - Leigh, J
AU  - Leshargie, CT
AU  - Leta, S
AU  - Leung, J
AU  - Leung, R
AU  - Levi, M
AU  - Li, YM
AU  - Liang, J
AU  - Liben, ML
AU  - Lim, LL
AU  - Lim, SS
AU  - Lind, M
AU  - Linn, S
AU  - Listl, S
AU  - Liu, PY
AU  - Liu, SW
AU  - Lodha, R
AU  - Lopez, AD
AU  - Lorch, SA
AU  - Lorkowski, S
AU  - Lotufo, PA
AU  - Lucas, TCD
AU  - Lunevicius, R
AU  - Lurton, G
AU  - Lyons, RA
AU  - Maalouf, F
AU  - Macarayan, ERK
AU  - Mackay, MT
AU  - Maddison, ER
AU  - Madotto, F
AU  - Abd El Razek, HM
AU  - Abd El Razek, MM
AU  - Majdan, M
AU  - Majdzadeh, R
AU  - Majeed, A
AU  - Malekzadeh, R
AU  - Malhotra, R
AU  - Malta, DC
AU  - Mamun, AA
AU  - Manguerra, H
AU  - Manhertz, T
AU  - Mansournia, MA
AU  - Mantovani, LG
AU  - Manyazewal, T
AU  - Mapoma, CC
AU  - Margono, C
AU  - Martinez-Raga, J
AU  - Martins, SCO
AU  - Martins-Melo, FR
AU  - Martopullo, I
AU  - März, W
AU  - Massenburg, BB
AU  - Mathur, MR
AU  - Maulik, PK
AU  - Mazidi, M
AU  - McAlinden, C
AU  - McGrath, JJ
AU  - McKee, M
AU  - Mehata, S
AU  - Mehrotra, R
AU  - Mehta, KM
AU  - Mehta, V
AU  - Meier, T
AU  - Mejia-Rodriguez, F
AU  - Meles, KG
AU  - Melku, M
AU  - Memiah, P
AU  - Memish, ZA
AU  - Mendoza, W
AU  - Mengiste, DA
AU  - Mengistu, DT
AU  - Menota, BG
AU  - Mensah, GA
AU  - Meretoja, A
AU  - Meretoja, TJ
AU  - Mezgebe, HB
AU  - Miazgowski, T
AU  - Micha, R
AU  - Milam, R
AU  - Millear, A
AU  - Miller, TR
AU  - Mini, GK
AU  - Minnig, S
AU  - Mirica, A
AU  - Mirrakhimov, EM
AU  - Misganaw, A
AU  - Mitchell, PB
AU  - Mlashu, FW
AU  - Moazen, B
AU  - Mohammad, KA
AU  - Mohammadibakhsh, R
AU  - Mohammed, E
AU  - Mohammed, MA
AU  - Mohammed, S
AU  - Mokdad, AH
AU  - Mola, GLD
AU  - Molokhia, M
AU  - Momeniha, F
AU  - Monasta, L
AU  - Hernandez, JCM
AU  - Moosazadeh, M
AU  - Moradi-Lakeh, M
AU  - Moraga, P
AU  - Morawska, L
AU  - Velasquez, IM
AU  - Mori, R
AU  - Morrison, SD
AU  - Moses, M
AU  - Mousavi, SM
AU  - Mueller, UO
AU  - Murhekar, M
AU  - Murthy, GVS
AU  - Murthy, S
AU  - Musa, J
AU  - Musa, KI
AU  - Mustafa, G
AU  - Muthupandian, S
AU  - Nagata, C
AU  - Nagel, G
AU  - Naghavi, M
AU  - Naheed, A
AU  - Naik, GA
AU  - Naik, N
AU  - Najafi, F
AU  - Naldi, L
AU  - Nangia, V
AU  - Nansseu, JRN
AU  - Narayan, KMV
AU  - Nascimento, BR
AU  - Negoi, I
AU  - Negoi, RI
AU  - Newton, CR
AU  - Ngunjiri, JW
AU  - Nguyen, G
AU  - Nguyen, L
AU  - Nguyen, TH
AU  - Nichols, E
AU  - Ningrum, DNA
AU  - Nolte, E
AU  - Nong, VM
AU  - Norheim, OF
AU  - Norrving, B
AU  - Noubiap, JJN
AU  - Nyandwi, A
AU  - Obermeyer, CM
AU  - Ofori-Asenso, R
AU  - Ogbo, FA
AU  - Oh, IH
AU  - Oladimeji, O
AU  - Olagunju, AT
AU  - Olagunju, TO
AU  - Olivares, PR
AU  - de Oliveira, PPV
AU  - Olsen, HE
AU  - Olusanya, BO
AU  - Olusanya, JO
AU  - Ong, K
AU  - Opio, JN
AU  - Oren, E
AU  - Ortega-Altamirano, DV
AU  - Ortiz, A
AU  - Ozdemir, R
AU  - Mahesh, PA
AU  - Pain, AW
AU  - Palone, MRT
AU  - Pana, A
AU  - Panda-Jonas, S
AU  - Pandian, JD
AU  - Park, EK
AU  - Parsian, H
AU  - Patel, T
AU  - Pati, S
AU  - Patil, ST
AU  - Patle, A
AU  - Patton, GC
AU  - Paturi, VR
AU  - Paudel, D
AU  - Pedroso, MD
AU  - Pedroza, SP
AU  - Pereira, DM
AU  - Perico, N
AU  - Peterson, H
AU  - Petzold, M
AU  - Peykari, N
AU  - Phillips, MR
AU  - Piel, FB
AU  - Pigott, DM
AU  - Pillay, JD
AU  - Piradov, MA
AU  - Polinder, S
AU  - Pond, CD
AU  - Postma, MJ
AU  - Pourmalek, F
AU  - Prakash, S
AU  - Prakash, V
AU  - Prasad, N
AU  - Prasad, NM
AU  - Purcell, C
AU  - Qorbani, M
AU  - Quintana, HK
AU  - Radfar, A
AU  - Rafay, A
AU  - Rafiei, A
AU  - Rahimi, K
AU  - Rahimi-Movaghar, A
AU  - Rahimi-Movaghar, V
AU  - Rahman, M
AU  - Rahman, MA
AU  - Rahman, SU
AU  - Rai, RK
AU  - Raju, B
AU  - Ram, U
AU  - Rana, SM
AU  - Rankin, Z
AU  - Rasella, D
AU  - Rawaf, DL
AU  - Rawaf, S
AU  - Ray, SE
AU  - Razo-García, CA
AU  - Reddy, P
AU  - Reiner, RC
AU  - Reis, C
AU  - Reitsma, MB
AU  - Remuzzi, G
AU  - Renzaho, AMN
AU  - Resnikoff, S
AU  - Rezaei, S
AU  - Rezai, MS
AU  - Ribeiro, AL
AU  - Blancas, MJR
AU  - Rivera, JA
AU  - Roever, L
AU  - Ronfani, L
AU  - Roshandel, G
AU  - Rostami, A
AU  - Roth, GA
AU  - Rothenbacher, D
AU  - Roy, A
AU  - Roy, N
AU  - Ruhago, GM
AU  - Sabde, YD
AU  - Sachdev, PS
AU  - Sadat, N
AU  - Safdarian, M
AU  - Safiri, S
AU  - Sagar, R
AU  - Sahebkar, A
AU  - Sahraian, MA
AU  - Sajadi, HS
AU  - Salama, J
AU  - Salamati, P
AU  - Saldanha, RD
AU  - Salimzadeh, H
AU  - Salomon, JA
AU  - Samy, AM
AU  - Sanabria, JR
AU  - Sancheti, PK
AU  - Sanchez-Niño, MD
AU  - Santomauro, D
AU  - Santos, IS
AU  - Milicevic, MMS
AU  - Sarker, AR
AU  - Sarrafzadegan, N
AU  - Sartorius, B
AU  - Satpathy, M
AU  - Savic, M
AU  - Sawhney, M
AU  - Saxena, S
AU  - Saylan, MI
AU  - Schaeffner, E
AU  - Schmidhuber, J
AU  - Schmidt, MI
AU  - Schneider, IJC
AU  - Schumacher, AE
AU  - Schutte, AE
AU  - Schwebel, DC
AU  - Schwendicke, F
AU  - Sekerija, M
AU  - Sepanlou, SG
AU  - Servan-Mori, EE
AU  - Shafieesabet, A
AU  - Shaikh, MA
AU  - Shakh-Nazarova, M
AU  - Shams-Beyranvand, M
AU  - Sharafi, H
AU  - Sharif-Alhoseini, M
AU  - Islam, SMS
AU  - Sharma, M
AU  - Sharma, R
AU  - She, J
AU  - Sheikh, A
AU  - Shfare, MT
AU  - Shi, PL
AU  - Shields, C
AU  - Shigematsu, M
AU  - Shinohara, Y
AU  - Shiri, R
AU  - Shirkoohi, R
AU  - Shiue, I
AU  - Shrime, MG
AU  - Shukla, SR
AU  - Siabani, S
AU  - Sigfusdottir, ID
AU  - Silberberg, DH
AU  - Silva, DAS
AU  - Silva, JP
AU  - Silveira, DGA
AU  - Singh, JA
AU  - Singh, L
AU  - Singh, NP
AU  - Singh, V
AU  - Sinha, DN
AU  - Sinke, AH
AU  - Sisay, M
AU  - Skirbekk, V
AU  - Sliwa, K
AU  - Smith, A
AU  - Soares, AM
AU  - Sobaih, BHA
AU  - Somai, M
AU  - Soneji, S
AU  - Soofi, M
AU  - Sorensen, RJD
AU  - Soriano, JB
AU  - Soyiri, IN
AU  - Sposato, LA
AU  - Sreeramareddy, CT
AU  - Srinivasan, V
AU  - Stanaway, JD
AU  - Stathopoulou, V
AU  - Steel, N
AU  - Stein, DJ
AU  - Stokes, MA
AU  - Sturua, L
AU  - Sufiyan, MB
AU  - Suliankatchi, RA
AU  - Sunguya, BF
AU  - Sur, PJ
AU  - Sykes, BL
AU  - Sylaja, PN
AU  - Szoeke, CEI
AU  - Tabarés-Seisdedos, R
AU  - Tadakamadla, SK
AU  - Tadesse, AH
AU  - Taffere, GR
AU  - Tandon, N
AU  - Tariku, AT
AU  - Taveira, N
AU  - Tehrani-Banihashemi, A
AU  - Shifa, GT
AU  - Temsah, MH
AU  - Terkawi, AS
AU  - Tesema, AG
AU  - Tesfaye, DJ
AU  - Tessema, B
AU  - Thakur, JS
AU  - Thomas, N
AU  - Thompson, MJ
AU  - Tillmann, T
AU  - To, QG
AU  - Tobe-Gai, R
AU  - Tonelli, M
AU  - Topor-Madry, R
AU  - Topouzis, F
AU  - Torre, A
AU  - Tortajada, M
AU  - Tran, BX
AU  - Tran, KB
AU  - Tripathi, A
AU  - Tripathy, SP
AU  - Troeger, C
AU  - Truelsen, T
AU  - Tsoi, D
AU  - Car, LT
AU  - Tuem, KB
AU  - Tyrovolas, S
AU  - Uchendu, US
AU  - Ukwaja, KN
AU  - Ullah, I
AU  - Updike, R
AU  - Uthman, OA
AU  - Uzochukwu, BSC
AU  - Valdez, PR
AU  - van Boven, JFM
AU  - Varughese, S
AU  - Vasankari, T
AU  - Venketasubramanian, N
AU  - Violante, FS
AU  - Vladimirov, SK
AU  - Vlassov, VV
AU  - Vollset, SE
AU  - Vos, T
AU  - Wagnew, F
AU  - Waheed, Y
AU  - Wallin, MT
AU  - Walson, JL
AU  - Wang, YF
AU  - Wang, YP
AU  - Wassie, MM
AU  - Weaver, MR
AU  - Weiderpass, E
AU  - Weintraub, RG
AU  - Weiss, J
AU  - Weldegwergs, KG
AU  - Werdecker, A
AU  - West, TE
AU  - Westerman, R
AU  - White, RG
AU  - Whiteford, HA
AU  - Widecka, J
AU  - Winkler, AS
AU  - Wiysonge, CS
AU  - Wolfe, CDA
AU  - Wondimkun, YA
AU  - Workicho, A
AU  - Wyper, GMA
AU  - Xavier, D
AU  - Xu, GL
AU  - Yan, LJL
AU  - Yano, Y
AU  - Yaseri, M
AU  - Yimer, NB
AU  - Yin, P
AU  - Yip, P
AU  - Yirsaw, BD
AU  - Yonemoto, N
AU  - Yonga, G
AU  - Yoon, SJ
AU  - Yotebieng, M
AU  - Younis, MZ
AU  - Yu, CH
AU  - Zadnik, V
AU  - Zaidi, Z
AU  - Zaki, ME
AU  - Bin Zaman, S
AU  - Zamani, M
AU  - Zenebe, ZM
AU  - Zhou, MG
AU  - Zhu, J
AU  - Zimsen, SRM
AU  - Zipkin, B
AU  - Zodpey, S
AU  - Zuhlke, LJ
AU  - Murray, CJL
AU  - Lozano, R
A1  - GBD 2016 Healthcare Access & Qua
TI  - Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016
T2  - LANCET
KW  - AMENABLE MORTALITY
KW  - LIFE EXPECTANCY
KW  - COVERAGE
KW  - TRENDS
KW  - INEQUALITIES
KW  - INDICATOR
KW  - NATIONS
KW  - STATES
KW  - CHINA
AB  - Background A key component of achieving universal health coverage is ensuring that all populations have access to quality health care. Examining where gains have occurred or progress has faltered across and within countries is crucial to guiding decisions and strategies for future improvement. We used the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) to assess personal health-care access and quality with the Healthcare Access and Quality (HAQ) Index for 195 countries and territories, as well as subnational locations in seven countries, from 1990 to 2016.
   Methods Drawing from established methods and updated estimates from GBD 2016, we used 32 causes from which death should not occur in the presence of effective care to approximate personal health-care access and quality by location and over time. To better isolate potential effects of personal health-care access and quality from underlying risk factor patterns, we risk-standardised cause-specific deaths due to non-cancers by location-year, replacing the local joint exposure of environmental and behavioural risks with the global level of exposure. Supported by the expansion of cancer registry data in GBD 2016, we used mortality-to-incidence ratios for cancers instead of risk-standardised death rates to provide a stronger signal of the effects of personal health care and access on cancer survival. We transformed each cause to a scale of 0-100, with 0 as the first percentile (worst) observed between 1990 and 2016, and 100 as the 99th percentile (best); we set these thresholds at the country level, and then applied them to subnational locations. We applied a principal components analysis to construct the HAQ Index using all scaled cause values, providing an overall score of 0-100 of personal health-care access and quality by location over time. We then compared HAQ Index levels and trends by quintiles on the Socio-demographic Index (SDI), a summary measure of overall development. As derived from the broader GBD study and other data sources, we examined relationships between national HAQ Index scores and potential correlates of performance, such as total health spending per capita.
   Findings In 2016, HAQ Index performance spanned from a high of 97.1 (95% UI 95.8-98.1) in Iceland, followed by 96.6 (94.9-97.9) in Norway and 96.1 (94.5-97.3) in the Netherlands, to values as low as 18.6 (13.1-24.4) in the Central African Republic, 19.0 (14.3-23.7) in Somalia, and 23.4 (20.2-26.8) in Guinea-Bissau. The pace of progress achieved between 1990 and 2016 varied, with markedly faster improvements occurring between 2000 and 2016 for many countries in sub-Saharan Africa and southeast Asia, whereas several countries in Latin America and elsewhere saw progress stagnate after experiencing considerable advances in the HAQ Index between 1990 and 2000. Striking subnational disparities emerged in personal health-care access and quality, with China and India having particularly large gaps between locations with the highest and lowest scores in 2016. In China, performance ranged from 91.5 (89.1-936) in Beijing to 48.0 (43.4-53.2) in Tibet (a 43.5-point difference), while India saw a 30.8-point disparity, from 64.8 (59.6-68.8) in Goa to 34.0 (30.3-38.1) in Assam. Japan recorded the smallest range in subnational HAQ performance in 2016 (a 4.8-point difference), whereas differences between subnational locations with the highest and lowest HAQ Index values were more than two times as high for the USA and three times as high for England. State-level gaps in the HAQ Index in Mexico somewhat narrowed from 1990 to 2016 (from a 20.9-point to 17.0-point difference), whereas in Brazil, disparities slightly increased across states during this time (a 17.2-point to 20.4-point difference). Performance on the HAQ Index showed strong linkages to overall development, with high and high-middle SDI countries generally having higher scores and faster gains for non-communicable diseases. Nonetheless, countries across the development spectrum saw substantial gains in some key health service areas from 2000 to 2016, most notably vaccine-preventable diseases. Overall, national performance on the HAQ Index was positively associated with higher levels of total health spending per capita, as well as health systems inputs, but these relationships were quite heterogeneous, particularly among low-to-middle SDI countries.
   Interpretation GBD 2016 provides a more detailed understanding of past success and current challenges in improving personal health-care access and quality worldwide. Despite substantial gains since 2000, many low-SDI and middle-SDI countries face considerable challenges unless heightened policy action and investments focus on advancing access to and quality of health care across key health services, especially non-communicable diseases. Stagnating or minimal improvements experienced by several low-middle to high-middle SDI countries could reflect the complexities of re-orienting both primary and secondary health-care services beyond the more limited foci of the Millennium Development Goals. Alongside initiatives to strengthen public health programmes, the pursuit of universal health coverage upon improving both access and quality worldwide, and thus requires adopting a more comprehensive view and subsequent provision of quality health care for all populations. Copyright (C) 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
AD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USAAD  - Univ Washington, Ctr Hlth Trends & Forecasts, Seattle, WA 98195 USAAD  - Univ Washington, Dept Global Hlth, Seattle, WA 98195 USAAD  - Univ Washington, Dept Surg, Div Plast Surg, Seattle, WA 98195 USAAD  - Univ Washington, Seattle, WA 98195 USAAD  - Addis Ababa Univ, Coll Vet Med & Agr, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Sch Publ Hlth, Addis Ababa, EthiopiaAD  - Addis Ababa Univ, Addis Ababa, EthiopiaAD  - Univ Roma La Sapienza, Rome, ItalyAD  - Cairo Univ, Dept Neurol, Cairo, EgyptAD  - Cairo Univ, Fac Med, Cairo, EgyptAD  - Cairo Univ, Cairo, EgyptAD  - Haramaya Univ, Coll Hlth & Med Sci, Harar, EthiopiaAD  - Haramaya Univ, Harar, EthiopiaAD  - Univ Gondar, Coll Med & Hlth Sci, Gondar, EthiopiaAD  - Univ Gondar, Inst Publ Hlth, Dept Epidemiol & Biostat, Gondar, EthiopiaAD  - Univ Gondar, Inst Publ Hlth, Gondar, EthiopiaAD  - Univ Gondar, Gondar, EthiopiaAD  - Hawassa Univ, Coll Med & Hlth Sci, Hawassa, EthiopiaAD  - Hawassa Univ, Hawassa, EthiopiaAD  - Dupuytren Univ Hosp, Limoges, FranceAD  - Mekelle Univ, Coll Hlth Sci, Mekelle, EthiopiaAD  - Mekelle Univ, Inst Biomed Sci, Mekelle, EthiopiaAD  - Mekelle Univ, Dept Med Microbiol, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Pharm, Mekelle, EthiopiaAD  - Mekelle Univ, Sch Publ Hlth, Mekelle, EthiopiaAD  - Mekelle Univ, Coll Hlth Sci, Mekelle, EthiopiaAD  - Mekelle Univ, Mekelle, EthiopiaAD  - Univ Fed Minas Gerais, Belo Horizonte, MG, BrazilAD  - Weill Cornell Med Coll Qatar, Infect Dis Epidemiol Grp, Doha, QatarAD  - Univ Queensland, Queensland Brain Inst, Brisbane, Qld, AustraliaAD  - Univ Queensland, Sch Dent, Brisbane, Qld, AustraliaAD  - Univ Queensland, Sch Publ Hlth, Brisbane, Qld, AustraliaAD  - Univ Queensland, Brisbane, Qld, AustraliaAD  - Obafemi Awolowo Univ, Coll Hlth Sci, Dept Community Hlth, Ife, NigeriaAD  - Obafemi Awolowo Univ, Dept Med Rehabil, Ife, NigeriaAD  - Stellenbosch Univ, Cape Town, South AfricaAD  - Univ Southern Denmark, Fac Hlth Sci, Unit Hlth Promot Res, Esbjerg, DenmarkAD  - Univ Tehran Med Sci, Canc Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Dept Epidemiol & Biostat, Tehran, IranAD  - Univ Tehran Med Sci, Sch Publ Hlth, Dept Hlth Management & Econ, Tehran, IranAD  - Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, IranAD  - Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Malignancies Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Hematol Oncol & Stem Cell Transplantat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Iranian Natl Ctr Addict Studies, Tehran, IranAD  - Univ Tehran Med Sci, Knowledge Utilizat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Community Based Participatory Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, MS Res Ctr, Neurosci Inst, Tehran, IranAD  - Univ Tehran Med Sci, Natl Inst Hlth Res, Tehran, IranAD  - Univ Tehran Med Sci, Noncommun Dis Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Noncommun Dis Res Ctr, Endocrinol & Metab Res Inst, Tehran, IranAD  - Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, IranAD  - McMaster Univ, Hamilton, ON, CanadaAD  - Directorate Hlth Informat & Res, Pieta, MaltaAD  - Malta Coll Family Doctors, Gzira, MaltaAD  - CSIR, Inst Genom & Integrat Biol, Delhi, IndiaAD  - Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USAAD  - Ctr Control Chron Condit, Gurugram, IndiaAD  - Indian Inst Publ Hlth, Gurugram, IndiaAD  - Publ Hlth Fdn India, Gurugram, IndiaAD  - Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Dept Clin Sci Lund,Orthoped,Clin Epidemiol Unit,N, Lund, SwedenAD  - High Natl Sch Vet Med, Algiers, AlgeriaAD  - Debere Berhan Univ, Debre Berhan, EthiopiaAD  - Univ Ibadan, Ibadan, NigeriaAD  - Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, EnglandAD  - Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USAAD  - Hosp Sick Children, Ctr Global Child Hlth, Toronto, ON, CanadaAD  - Univ Toronto, Fac Med, Dalla Lana Sch Publ Hlth, Dept Nutr Sci, Toronto, ON, CanadaAD  - Baghdad Coll Med, Baghdad, IraqAD  - Mayo Clin, Fdn Med Educ & Res, Rochester, MN USAAD  - Syrian Amer Med Soc, Washington, DC USAAD  - Washington Univ St Louis, St Louis, MO USAAD  - Univ Western Australia, Sch Populat & Global Hlth, Perth, WA, AustraliaAD  - Minist Hlth, Int Relat Div, Al Khuwair, OmanAD  - Australian Natl Univ, Res Sch Populat Hlth, Dept Global Hlth, Canberra, ACT, AustraliaAD  - King Saud Univ, Riyadh, Saudi ArabiaAD  - King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi ArabiaAD  - Univ London, London, EnglandAD  - SIR Management Consultants, Oxford, EnglandAD  - Inst & Fac Actuaries, Oxford, EnglandAD  - Qazvin Univ Med Sci, Qavin, IranAD  - Kuwait Univ, Fac Publ Hlth, Kuwait, KuwaitAD  - Natl Univ Malaysia, Int Ctr Casemix & Clin Coding, Kuala Lumpur, MalaysiaAD  - Luxembourg Inst Hlth, Strassen, LuxembourgAD  - Univ Lorraine, Sch Publ Hlth, Nancy, FranceAD  - Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, SwedenAD  - Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Family Med & Primary Care, Stockholm, SwedenAD  - Karolinska Inst, Dept Publ Hlth Sci, Stockholm, SwedenAD  - Jordan Univ Sci & Technol, Dept Community Med Publ Hlth & Family Med, Irbid, JordanAD  - Jordan Univ Sci & Technol, Fac Appl Med Sci, Dept Rehabil Sci, Div Phys Therapy, Irbid, JordanAD  - King Abdulaziz Univ, Dept Family & Community Med, Coll Med, Jeddah, Saudi ArabiaAD  - Charite Univ Med Berlin, Berlin, GermanyAD  - Univ Cartagena, Cartagena De Indias, ColombiaAD  - Univ Adelaide, Sch Med, Discipline Psychiat, Adelaide, SA, AustraliaAD  - Bahir Dar Univ, Coll Med & Hlth Sci, Bahir Dar, EthiopiaAD  - Minist Publ Hlth, Beirut, LebanonAD  - Komfo Anokye Teaching Hosp, Dept Med, Kumasi, GhanaAD  - Mansoura Univ, Fac Med, Mansoura, EgyptAD  - Carol Davila Univ Med & Pharm, Bucharest, RomaniaAD  - Univ Thessaly, Larisa, GreeceAD  - Univ Philippines Manila, Coll Publ Hlth, Manila, PhilippinesAD  - Univ Philippines Manila, Coll Publ Hlth, Dept Hlth Policy & Adm, Manila, PhilippinesAD  - Minist Hlth Brazil, Brasilia, DF, BrazilAD  - Birmingham City Univ Dept Publ Hlth & Therapies, Birmingham, W Midlands, EnglandAD  - Dalama Univ, Sch Hlth & Social Studies, Falun, SwedenAD  - Univ Manitoba, Winnipeg, MB, CanadaAD  - Nepal Hlth Res Council, Kathmandu, NepalAD  - Univ Oslo, Oslo, NorwayAD  - Qom Univ Med Sci, Sch Paramed, Dept Emergency Med, Qom, IranAD  - South Asian Publ Hlth Forum, Islamabad, PakistanAD  - Wolaita Sodo Univ, Wolaita Sodo, EthiopiaAD  - Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Clin Global Hlth Educ, Baltimore, MD USAAD  - Dr D Y Patil Vidyapeeth Pune, Pune, Maharashtra, IndiaAD  - Keimyung Univ, Daegu, South KoreaAD  - Natl Inst Publ Hlth, Cuemavaca, MexicoAD  - Inst Rech Clin Benin, Cotonou, BeninAD  - Lab Etudes & Rech Act St LERAS Afrique, Parakou, BeninAD  - Indian Inst Publ Hlth, Gandhinagar, IndiaAD  - La Trobe Univ, Austin Clin Sch Nursing, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Judith Lumley Ctr Mother Infant & Family Hlth Res, Melbourne, Vic, AustraliaAD  - La Trobe Univ, Bundoora, Vic, AustraliaAD  - Peruvian Natl Inst Hlth, Lima, PeruAD  - Debre Markos Univ, Debre Markos, EthiopiaAD  - McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, CanadaAD  - Dilla Univ, Dilla, EthiopiaAD  - Univ Tokyo, Tokyo, JapanAD  - Inst Med Res & Plant Med Studies Cameroon, Yaounde, CameroonAD  - Univ South Africa, Pretoria, South AfricaAD  - Burnet Inst, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Dept Paediat, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Murdoch Childrens Res Inst, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Dept Med, Melbourne, Vic, AustraliaAD  - Univ Melbourne, Inst Hlth & Ageing, Melbourne, Vic 3010, AustraliaAD  - Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic 3010, AustraliaAD  - Univ Melbourne, Melbourne, Vic 3010, AustraliaAD  - South Australian Hlth & Med Res Inst, Wardliparingga Aboriginal Res Unit, Adelaide, SA, AustraliaAD  - Univ Malta, Isl & Small States Inst, Dept Hlth Serv Management, Msida, MaltaAD  - Univ Lagos, Dept Community Hlth & Primary Care, Lagos, NigeriaAD  - Univ Lagos, Coll Med, Dept Psychiat, Lagos, NigeriaAD  - Invas Fungi Res Ctr, Sari, IranAD  - Ctr Expertise Mycol Radboudumc CWZ, Nijmegen, NetherlandsAD  - Publ Hlth Agcy Canada, Toronto, ON, CanadaAD  - Med Univ Lodz, Dept Hypertens, Lodz, PolandAD  - UCL, Inst Epidemiol & Hlth, London, EnglandAD  - UCL, Inst Hlth Informat, Farr Inst Hlth Informat Res, London, EnglandAD  - UCL, London, EnglandAD  - Publ Hlth Perspect Nepal, Pokhara, NepalAD  - Hosp Dr Rafael A Calderon Guardia, CCSS, San Jose, Costa RicaAD  - Univ Costa Rica, San Pedro, Costa RicaAD  - Univ Auckland, Sch Psychol, Auckland, New ZealandAD  - Harvard Univ, Ariadne Labs, Boston, MA 02115 USAAD  - Harvard Univ, Harvard T H Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USAAD  - Harvard Univ, Harvard T H Chan Sch Publ Hlth, Boston, MA 02115 USAAD  - Africa Hlth Res Inst, Mtubatuba, South AfricaAD  - Heidelberg Univ, Inst Publ Hlth, Heidelberg, GermanyAD  - Heidelberg Univ, Heidelberg, GermanyAD  - Pontificia Univ Javeriana, Sch Engn, Dept Ind Engn, Bogota, ColombiaAD  - Univ Barcelona, Barcelona Inst Global Hlth, Barcelona, SpainAD  - ICREA, Barcelona, SpainAD  - Stanford Univ, Stanford, CA USAAD  - Charles R Drew Univ Med & Sci, Coll Med, Los Angeles, CA USAAD  - Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USAAD  - Jazan Univ, Coll Publ Hlth & Trop Med, Jazan, Saudi ArabiaAD  - IRCCS, Ist Ric Farmacol Mario Negri, Milan, ItalyAD  - Lorestan Univ Med Sci, Social Determinants Hlth Res Ctr, Khorramabad, IranAD  - Lorestan Univ Med Sci, Khorramabad, IranAD  - Iran Univ Med Sci, Air Pollut Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Dept Community Med, Tehran, IranAD  - Iran Univ Med Sci, Prevent Med & Publ Hlth Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Hlth Management & Econ Res Ctr, Tehran, IranAD  - Iran Univ Med Sci, Sch Publ Hlth, Dept Environm Hlth Engn, Tehran, IranAD  - Mizan Tepi Univ, Mizan Aman, EthiopiaAD  - Dr Tewelde Legesse Hlth Sci Coll, Mekelle, EthiopiaAD  - Yale Univ, New Haven, CT USAAD  - Univ Alberta, Edmonton, AB, CanadaAD  - Univ Oxford, Li Ka Shing Ctr Hlth Informat & Discovery, Oxford Big Data Inst, Oxford, EnglandAD  - Univ Oxford, Nuffield Dept Med, Oxford, EnglandAD  - Univ Oxford, Dept Zool, Oxford, EnglandAD  - Univ Oxford, NIHR Musculoskeletal Biomed Res Ctr, Oxford, EnglandAD  - Univ Oxford, Nuffield Dept Populat Hlth, Oxford, EnglandAD  - Univ Oxford, Oxford, EnglandAD  - Univ Sao Paulo, Univ Hosp, Ctr Clin, Sao Paulo, BrazilAD  - Univ Sao Paulo, Univ Hosp, Epidemiol Res Ctr, Sao Paulo, BrazilAD  - Univ Sao Paulo, Internal Med Dept, Sao Paulo, BrazilAD  - Univ Sao Paulo, Sao Paulo, BrazilAD  - Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Groningen, NetherlandsAD  - Univ Groningen, Univ Med Ctr Groningen, Groningen, NetherlandsAD  - Univ Groningen, Groningen, NetherlandsAD  - Kings Coll London, Div Hlth & Social Care Res, London, EnglandAD  - Kings Coll London, London, EnglandAD  - Emory Univ, Rollins Sch Publ Hlth, Dept Global Hlth, Atlanta, GA 30322 USAAD  - Emory Univ, Atlanta, GA 30322 USAAD  - Univ South Honda, Coll Publ Hlth, Dept Global Hlth, Tampa, FL USAAD  - Emergency Hosp Bucharest, Bucharest, RomaniaAD  - Post Grad Inst Med Educ & Res, Sch Publ Hlth, Chandigarh, IndiaAD  - Postgrad Inst Med Educ & Res, Chandigarh, IndiaAD  - Medtron Philanthropy, Minneapolis, MN USAAD  - Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, PakistanAD  - Aga Khan Univ, Dept Paediat & Child Hlth, Karachi, PakistanAD  - Babol Univ Med Sci, Hlth Res Inst, Babol Sar, IranAD  - Babol Univ Med Sci, Sch Med, Infect Dis & Trop Med Res Ctr, Babol Sar, IranAD  - Babol Univ Med Sci, Social Determinants Hlth Res Ctr, Hlth Res Inst, Babol Sar, IranAD  - Babol Univ Med Sci, Babol Sar, IranAD  - St Pauls Hosp, Millennium Med Coll, Addis Ababa, EthiopiaAD  - Jigjiga Univ, Jigjiga, EthiopiaAD  - Univ Heidelberg Hosp, Dept Gen Practice & Hlth Serv Res, Heidelberg, GermanyAD  - London Sch Hyg & Trop Med, European Observ Hlth Syst & Policies, London, EnglandAD  - London Sch Hyg & Trop Med, London, EnglandAD  - Comenius Univ, Inst Epidemiol, Fac Med, Bratislava, SlovakiaAD  - Ohio State Univ, Columbus, OH 43210 USAAD  - German Canc Res Ctr, Heidelberg, GermanyAD  - INDICASAT AIP, Panama City, PanamaAD  - Univ Leicester, Leicester, Leics, EnglandAD  - Al Shifa Trust Eye Hosp, Rawalpindi, PakistanAD  - Nanyang Technol Univ, LKCMed, Singapore, SingaporeAD  - Imperial Coll London, Dept Epidemiol & Biostat, London, EnglandAD  - Imperial Coll London, Dept Infect Dis Epidemiol, London, EnglandAD  - Imperial Coll London, Dept Primary Care & Publ Hlth, London, EnglandAD  - Imperial Coll London, WHO Collaborating Ctr, London, EnglandAD  - Imperial Coll London, London, EnglandAD  - Minist Hlth Republ Croatia, Zagreb, CroatiaAD  - Metropolitan Autonomous Univ, Mexico City, DF, MexicoAD  - Univ Porto, Dept Chem Sci, Porto, PortugalAD  - Univ Porto, Fac Pharm, Porto, PortugalAD  - Univ Porto, INEB Inst Engn Biomed, Porto, PortugalAD  - Univ Porto, Fac Pharm, Toxicol Grp, UCIBIO REQUIMTE, Porto, PortugalAD  - Univ Porto, Inst Invest & Inovacao Sande I3S, Porto, PortugalAD  - Inst Nacl Salud, Colombian Natl Hlth Observ, Bogota, ColombiaAD  - Univ Nacl Colombia, Publ Hlth Dept, Epidemiol & Publ Hlth Evaluat Grp, Bogota, ColombiaAD  - Caja Costarricense Seguro Social, San Jose, Costa RicaAD  - Univ Valencia, INCLIVA Hlth Res Inst, Dept Med, Valencia, SpainAD  - Univ Valencia, CIBERSAM, Dept Med, Valencia, SpainAD  - Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, CanadaAD  - Natl Hlth Res Inst, Zgunan Town, TaiwanAD  - Natl Yang Ming Univ, Taipei, TaiwanAD  - Natl Taiwan Univ, Coll Med, Sch Nursing, Taipei, TaiwanAD  - Int Inst Populat Sci, Mumbai, Maharashtra, IndiaAD  - Tata Mem Hosp, Mumbai, Maharashtra, IndiaAD  - Gold Coast Hlth, Clin Governance Unit, Southport, Qld, AustraliaAD  - Univ Zambia, Lusaka, ZambiaAD  - Univ Witwatersrand, Johannesburg, South AfricaAD  - Seoul Natl Univ, Dept Hlth Policy & Management, Coll Hlth Sci, Seoul, South KoreaAD  - Seoul Natl Univ, Seoul, South KoreaAD  - Seoul Natl Univ, Med Lib, Seoul, South KoreaAD  - Bispebjerg Hosp, Copenhagen, DenmarkAD  - Christian Med Coll & Hosp, Vellore, Tamil Nadu, IndiaAD  - Univ Salerno, Baronissi, ItalyAD  - Univ Milano Bicocca, Res Ctr Publ Hlth, Monza, ItalyAD  - Univ Milano Bicocca, Monza, ItalyAD  - Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, EnglandAD  - Univ Sao Paulo, Inst Heart, Sao Paulo, BrazilAD  - Univ Fed Rio Grande do Sul, Porto Alegre, RS, BrazilAD  - Univ Calif San Diego, San Diego, CA 92103 USAAD  - Univ Otago, Dunedin Sch Med, Ctr Int Hlth, Dunedin, New ZealandAD  - Flinders Univ S Australia, Adelaide, SA, AustraliaAD  - Guys & St Thomas NHS Fdn Trust, London, EnglandAD  - Mazandaran Univ Med Sci, Hlth Sci Res Ctr, Addict Inst, Sari, IranAD  - Mazandaran Univ Med Sci, Sch Med, Mol & Cell Biol Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Toxoplasmosis Res Ctr, Sari, IranAD  - Mazandaran Univ Med Sci, Sari, IranAD  - KG Med Univ, Lucknow, Uttar Pradesh, IndiaAD  - Kazakh Natl Med Univ, Sch Publ Hlth, Alma Ata, KazakhstanAD  - Monash Univ, Melbourne, Vic, AustraliaAD  - Monash Med Ctr, Clayton, Vic, AustraliaAD  - Griffith Univ, Brisbane, Qld, AustraliaAD  - Heidelberg Inst Publ Hlth, Heidelberg, GermanyAD  - Univ Colorado, Sch Med, Aurora, CO USAAD  - Colorado Sch Publ Hlth, Aurora, CO USAAD  - Aksum Univ, Coll Hlth Sci & Referral Hosp, Aksum, EthiopiaAD  - Aksum Univ, Aksum, EthiopiaAD  - Brighton & Sussex Med Sch, Brighton, E Sussex, EnglandAD  - Mt Sinai Beth Israel, New York, NY USAAD  - Icahn Sch Med Mt Sinai, New York, NY 10029 USAAD  - Univ Peradeniya, Fac Med, Dept Community Med, Peradeniya, Sri LankaAD  - Govt Nepal, Nepal Hlth Res Council, Kathmandu, NepalAD  - Minist Hlth & Med Educ, Res & Technol, Tehran, IranAD  - Minist Hlth & Med Educ, Tehran, IranAD  - Univ Cape Coast, Cape Coast, GhanaAD  - Univ Tampere, Tampere, FinlandAD  - UNSW, Sydney, NSW, AustraliaAD  - Univ Rochester, Med Ctr, Rochester, NY 14642 USAAD  - Univ Estado Santa Catarina, Florianopolis, SC, BrazilAD  - RMIT Univ, Bundoora, Vic, AustraliaAD  - Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, AustraliaAD  - Univ Sydney, Sydney, NSW, AustraliaAD  - Univ Belgrade, Ctr Sch Publ Hlth & Hlth Management, Belgrade, SerbiaAD  - Univ Belgrade, Inst Microbiol & Immunol, Belgrade, SerbiaAD  - Univ Belgrade, Fac Med, Inst Social Med, Belgrade, SerbiaAD  - Univ Fed Rio Grande do Sul, Porto Alegre, RS, BrazilAD  - Univ North Carolina, Chapel Hill, NC 27515 USAAD  - Umea Univ, Umea, SwedenAD  - Univ Michigan, Ann Arbor, MI 48109 USAAD  - Harvard Med Sch, Dept Global Hlth & Social Med, Kigali, RwandaAD  - Harvard Med Sch, Program Global Surg & Social Change, Kigali, RwandaAD  - Harvard Med Sch, Kigali, RwandaAD  - Arba Minch Univ, Arba Minch, EthiopiaAD  - Arak Univ Med Sci, Arak, IranAD  - Multiple Sclerosis Res Ctr, Tehran, IranAD  - Dept Hlth, Manila, PhilippinesAD  - Univ Fed Sergipe, Aracaju, BrazilAD  - Doctor Evidence, Santa Monica, CA USAAD  - Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New ZealandAD  - Jimma Univ, Inst Hlth, Fac Publ Hlth, Dept Hlth Behav & Soc, Jimma, EthiopiaAD  - Jimma Univ, Jimma, EthiopiaAD  - Catholic Univ Portugal, Fac Biotechnol, CBQF Ctr Biotechnol & Fine Chem Associate Lab, Porto, PortugalAD  - Brandeis Univ, Heller Grad Sch, Waltham, MA USAAD  - Kaiser Permanente, Fontana, CA USAAD  - Univ Bielefeld, Sch Publ Hlth, Bielefeld, GermanyAD  - Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USAAD  - Escola Nacl Sande Publ Sergio Arouca, Rio De Janeiro, BrazilAD  - Univ Fed Espirito Santo, Vitoria, BrazilAD  - Acad Med Sci, Inst Gerontol, Kiev, UkraineAD  - Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, SwitzerlandAD  - Swiss Trop & Publ Hlth Inst, Basel, SwitzerlandAD  - Univ Basel, Basel, SwitzerlandAD  - Natl Ctr Dis Control & Publ Hlth, Tbilisi, GeorgiaAD  - Ludwig Maximilians Univ Munchen, Munich, GermanyAD  - Wageningen Univ, Div Human Nutr, Wageningen, NetherlandsAD  - Dept Nutr, Babol Sar, IranAD  - Univ Hosp Dijon, Dijon, FranceAD  - Kersa Hlth & Demog Surveillance Syst, Harar, EthiopiaAD  - Jawaharlal Nehru Univ, New Delhi, IndiaAD  - Univ Massachusetts, Boston, MA 02125 USAAD  - Inst Invest Cient Serv Alta Tecnol INDICASAT AIP, Ciudad Saber, PanamaAD  - Govt Federated States Micronesia, Dept Hlth & Social Affairs, Palikir, MicronesiaAD  - Org Econ Cooperat & Dev, Paris, FranceAD  - Boston Univ, Sch Med, Boston, MA 02215 USAAD  - Univ Hosp Policlin Vittorio Emanuele, Catania, ItalyAD  - NNEdPro Global Ctr Nutr & Hlth, Cambridge, EnglandAD  - St James Sch Med, Dept Microbiol, Quarter, AnguillaAD  - St James Sch Med, Dept Epidemiol & Biostat, Quarter, AnguillaAD  - West Virginia Bur Publ Hlth, Charleston, WV USAAD  - Eternal Heart Care Ctr & Res Inst, Jaipur, Rajasthan, IndiaAD  - Montefiore Med Ctr, Bronx, NY 10467 USAAD  - Albert Einstein Coll Med, Bronx, NY 10467 USAAD  - Indian Inst Technol Kanpur, Kanpur, Uttar Pradesh, IndiaAD  - Univ Delhi, Dept Anthropol, Delhi, IndiaAD  - Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, NetherlandsAD  - Univ Med Ctr Rotterdam, Erasmus MC, Rotterdam, NetherlandsAD  - Western Univ, Dept Clin Neurol Sci, London, ON, CanadaAD  - Western Univ, London, ON, CanadaAD  - Kilte Awlaelo Hlth & Demog Surveillance Syst, Mekelle, EthiopiaAD  - Arabian Gulf Univ, Manama, BahrainAD  - Hamdan Bin Mohammed Smart Univ, Abu Dhabi, U Arab EmiratesAD  - Univ Western Australia, Sch Med & Pharmacol, Perth, WA, AustraliaAD  - Univ Western Australia, Nedlands, WA, AustraliaAD  - Harry Perkins Inst Med Res, Nedlands, WA, AustraliaAD  - Western Australian Neurosci Res Inst, Nedlands, WA, AustraliaAD  - Eunice Gibson Polyclin, Bridgetown, BarbadosAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Trivandrum, Kerala, IndiaAD  - Parc Sanitari St Joan Deu CIBERSAM, Res & Dev Unit, Barcelona, SpainAD  - Parc Sanitari St Joan Deu CIBERSAM, Barcelona, SpainAD  - Murdoch Childrens Res Hosp, Child Neuropsychol, Parkville, Vic, AustraliaAD  - Hormozgan Univ Med Sci, Fac Hlth, Bandar Abbas, IranAD  - Curtin Univ, Sch Publ Hlth, Perth, WA, AustraliaAD  - Gorgas Mem Inst Studies Hlth, Panama City, PanamaAD  - Univ Panama, Panama City, PanamaAD  - Bucharest Univ Econ Studies, Dept Stat & Econometr, Bucharest, RomaniaAD  - Bucharest Univ Econ Studies, Bucharest, RomaniaAD  - Samara Univ, Samara, EthiopiaAD  - Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USAAD  - Columbia Univ, New York, NY 10027 USAAD  - Guilan Univ Med Sci, Guilan Rd Trauma Res Ctr, Rasht, IranAD  - Yokohama City Univ, Grad Sch Med, Dept Pulmonol, Yokohama, Kanagawa, JapanAD  - Pacific Community, Publ Hlth Div, Noumea, New CaledoniaAD  - Salah Azaiz Inst, Dept Epidemiol, Tunis, TunisiaAD  - Cent South Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha, Peoples R ChinaAD  - Aarhus Univ, Aarhus Sch Business & Social Sci, Natl Ctr Register Based Res, Aarhus, DenmarkAD  - Aarhus Univ, Aarhus, DenmarkAD  - Sriwijaya Univ, Palembang, IndonesiaAD  - Social Secur Administering Body Hlth, Jakarta, IndonesiaAD  - US Ctr Dis Control & Prevent, Pretoria, South AfricaAD  - Univ Western Cape, Sch Publ Hlth, Cape Town, South AfricaAD  - Natl Publ Hlth Inst, Monrovia, CA, LiberiaAD  - Natl Inst Hlth Dev, Tallinn, EstoniaAD  - Prevent Metab Disorders Res Ctr, Res Inst Endocrine Sci, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Sch Publ Hlth, Tehran, IranAD  - Shahid Beheshti Univ Med Sci, Tehran, IranAD  - Amer Canc Soc, Surveillance & Hlth Serv Res, Atlanta, GA 30329 USAAD  - USAID Global Hlth Bur, HIDN, MCH Div, Washington, DC USAAD  - George Mason Univ, Dept Global & Community Hlth, Fairfax, VA 22030 USAAD  - Jain Hosp MSS, Kanpur, Uttar Pradesh, IndiaAD  - Natl Ctr Dis Control Delhi, Delhi, IndiaAD  - Univ Kragujevac, Fac Med Sci, Kragujevac, SerbiaAD  - Univ Aberdeen, Aberdeen, ScotlandAD  - Postgrad Inst Med, Colombo, Sri LankaAD  - Inst Violence & Injury Prevent, Colombo, Sri LankaAD  - Ctr Chron Dis Control, New Delhi, IndiaAD  - Banaras Hindu Univ, Varanasi, Uttar Pradesh, IndiaAD  - George Inst Global Hlth, New Delhi, IndiaAD  - Czestochowa Tech Univ, Inst Hlth & Nutr Sci, Czestochowa, PolandAD  - Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, GermanyAD  - Indian Council Med Res, Natl Inst Epidemiol, Chennai, Tamil Nadu, IndiaAD  - Univ Tartu, Inst Family Med & Publ Hlth, Tartu, EstoniaAD  - Univ Coll Cork, Cork, IrelandAD  - London Sch Econ & Polit Sci, London, EnglandAD  - SCB Med Coll, Cuttack, Orissa, IndiaAD  - European Observ Hlth Syst & Policies, London, EnglandAD  - Helmholtz Ctr Infect Res, Epidemiol & Stat Methods Res Grp, Braunschweig, GermanyAD  - German Ctr Infect Res, Hannover, GermanyAD  - Qual & Equity Hlth Care, Kigali, RwandaAD  - Univ Washington Tacoma, Tacoma, WA USAAD  - Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, Seattle, WA USAAD  - Univ Glasgow, MRC CSO Social Publ Hlth Sci Unit, Glasgow, Lanark, ScotlandAD  - Oklahoma State Univ, Tulsa, OK USAAD  - Univ Tokyo, Sch Publ Hlth, Tokyo, JapanAD  - Inst Trop & Infect Dis, Nairobi, KenyaAD  - Sch Continuing & Distance Educ, Nairobi, KenyaAD  - South African Med Res Council, UKZN Gastrointestinal Canc Res Ctr, Cape Town, South AfricaAD  - Univ Cape Town, Fac Hlth Sci, Hatter Inst Cardiovasc Res Africa, Dept Psychiat, Cape Town, South AfricaAD  - Ahvaz Jundishapur Univ Med Sci, Ahvaz, IranAD  - Hlth Serv Acad, Islamabad, PakistanAD  - United Arab Emirates Univ, Coll Med Hlth Sci, Dept Microbiol & Immunol, Al Ain, U Arab EmiratesAD  - Univ Newcastle, Newcastle, NSW, AustraliaAD  - Jatiya Kabi Kazi Nazrul Islam Univ, Mymensingh, BangladeshAD  - Univ Tennessee, Hlth Sci Ctr, Memphis, TN 38163 USAAD  - Dept Hlth Serv Hlth Management Informat Syst, Kathmandu, NepalAD  - Seoul Natl Univ, Med Ctr, Inst Hlth Policy & Management, Seoul, South KoreaAD  - Mohammed Ibn Saudi Univ, Coll Med, Dept Publ Hlth, Riyadh, Saudi ArabiaAD  - Mohammed Ibn Saudi Univ, Coll Med, Dept Family Med, Riyadh, Saudi ArabiaAD  - Iranian Minist Hlth & Med Educ, Tehran, IranAD  - Ball State Univ, Dept Nutr & Hlth Sci, Muncie, IN 47306 USAAD  - Kenya Revenue Author, Nairobi, KenyaAD  - Synotech Consultants, Nairobi, KenyaAD  - Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USAAD  - Xiamen Univ, Sch Med, Malaysia Campus, Sepang, MalaysiaAD  - Simmons Coll, Boston, MA 02115 USAAD  - Univ Canberra, Ctr Res & Action Publ Hlth, Canberra, ACT, AustraliaAD  - Univ Oslo, Oslo, NorwayAD  - Univ British Columbia, Fac Med, Sch Populat & Publ Hlth, Vancouver, BC, CanadaAD  - Global Healthcare Consulting, New Delhi, IndiaAD  - Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Suita, Osaka, JapanAD  - Natl Inst Hlth Res Dev, Ctr Community Empowerment Hlth Policy & Humanitie, Jakarta, IndonesiaAD  - Sher Kashmir Inst Med Sci, Srinagar, Jammu & Kashmir, IndiaAD  - Res Ctr Neurol, Moscow, RussiaAD  - Panjab Univ, Chandigarh, IndiaAD  - Univ Montreal, Sch Publ Hlth, Dept Demog, Montreal, PQ, CanadaAD  - Univ Montreal, Sch Publ Hlth, Publ Hlth Res Inst, Montreal, PQ, CanadaAD  - Univ Montreal, Sch Publ Hlth, Dept Social & Prevent Med, Montreal, PQ, CanadaAD  - Minist Hlth Ukraine, State Inst Publ Hlth Ctr, Kiev, UkraineAD  - NHLBI, Ctr Translat Res & Implementat Sci, Inst Hlth Policy & Dev Studies, Natl Inst Hlth, Manila, PhilippinesAD  - NCI, Rockville, MD USAAD  - Childrens Hosp, Eastern Ontario Res Inst, Ottawa, ON, CanadaAD  - Help Me See Inc, New York, NY USAAD  - Inst Mexicano Oftalmol, Queretaro, MexicoAD  - Univ Fed Minas Gerais, Sch Med, Belo Horizonte, MG, BrazilAD  - Secretaria Municipal Sande, Belo Horizonte, MG, BrazilAD  - Uppsala Univ, Dept Med Sci, Uppsala, SwedenAD  - Maragheh Univ Med Sci, Managerial Epidemiol Res Ctr, Sch Nursing & Midwifery, Dept Publ Hlth, Maragheh, IranAD  - Univ Barcelona, Hosp Clin, ISGlobal, Barcelona, SpainAD  - Univ Copenhagen, Rigshosp, CHIP, Copenhagen, DenmarkAD  - Univ Copenhagen, Rigshosp, Dept Neurol, Copenhagen, DenmarkAD  - Nova Southeastern Univ, Coll Optometry, Ft Lauderdale, FL 33314 USAAD  - Hong Kong Polytech Univ, Hong Kong, Hong Kong, Peoples R ChinaAD  - SUNY Albany, Albany, NY 12222 USAAD  - Tuscany Reg Ctr Occupat Injuries & Dis, Florence, ItalyAD  - San Francisco VA Med Ctr, San Francisco, CA USAAD  - Sichuan Univ, West China Univ Hosp 2, Natl Off Maternal & Child Hlth Surveillance, Chengdu, Sichuan, Peoples R ChinaAD  - Univ Malaya, Kuala Lumpur, MalaysiaAD  - Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R ChinaAD  - Univ Haifa, Haifa, IsraelAD  - Radboud Univ Nijmegen Med Ctr, Nijmegen, NetherlandsAD  - Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing, Peoples R ChinaAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Univ Penn, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USAAD  - Friedrich Schiller Univ Jena, Inst Nutr, Jena, GermanyAD  - Competence Cluster Nutr & Cardiovasc Hlth NutriCA, Jena, GermanyAD  - Aintree Univ Hosp Natl Hlth Serv Fdn Trust, Liverpool, Merseyside, EnglandAD  - Univ Liverpool, Sch Med, Liverpool, Merseyside, EnglandAD  - Swansea Univ, Farr Inst, Swansea, W Glam, WalesAD  - Amer Univ Beirut, Fac Hlth Sci, Ctr Res Populat & Hlth, Dept Psychiat, Beirut, LebanonAD  - Royal Childrens Hosp Melbourne, Melbourne, Vic, AustraliaAD  - Mansoura Fac Med, Mansoura, EgyptAD  - Aswan Univ Hosp, Aswan Fac Med, Aswan, EgyptAD  - Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Trnava, SlovakiaAD  - Natl Inst Hlth Res, Tehran, IranAD  - Univ Fed Minas Gerais, Belo Horizonte, MG, BrazilAD  - Ethiopian Publ Hlth Assoc, Addis Ababa, EthiopiaAD  - Hosp Univ Doctor Peset, Valencia, SpainAD  - CEU Cardinal Herrera Univ, Moncada, SpainAD  - Hosp Clin Porto Alegre, Porto Alegre, RS, BrazilAD  - Hosp Moinhos Vento, Porto Alegre, RS, BrazilAD  - Fed Inst Educ Sci & Technol Ceara, Caucaia, BrazilAD  - Synlab Acad, Mannheim, GermanyAD  - Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, Graz, AustriaAD  - George Inst Global Hlth India, New Delhi, IndiaAD  - Univ Oxford, George Inst Global Hlth, Oxford, EnglandAD  - Chalmers Univ Technol, Dept Biol & Biol Engn Food & Nutr Sci, Gothenburg, SwedenAD  - Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, EnglandAD  - Publ Hlth Wales, Swansea, W Glam, WalesAD  - Queensland Ctr Mental Hlth Res, Pk Ctr Mental Hlth, Wacol, Qld, AustraliaAD  - Ipas Nepal, Kathmandu, NepalAD  - Natl Inst Canc Prevent Res, Noida, IndiaAD  - Univ Calif San Francisco, San Francisco, CA 94143 USAAD  - MGM Med Coll, Navi Mumbai, IndiaAD  - Martin Luther Univ Halle Wittenberg, Inst Medizin Epidemiol Biometrie & Informat, Competence Cluster Nutr & Cardiovasc Hlth NutriCA, Saale, GermanyAD  - Univ West Florida, Pensacola, FL 32514 USAAD  - Saudi Minist Hlth, Riyadh, Saudi ArabiaAD  - Alfaisal Univ, Coll Med, Riyadh, Saudi ArabiaAD  - United Nations Populat Fund, Lima, PeruAD  - Helsinki Univ Hosp, Comprehens Canc Ctr, Dept Neurol, Breast Surg Unit, Helsinki, FinlandAD  - Univ Helsinki, Fac Med, Finnish Inst Occupat Hlth, Dept Publ Hlth,Work Org,Work Disability Program, Helsinki, FinlandAD  - Pomeranian Med Univ, Szczecin, PolandAD  - Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USAAD  - Pacific Inst Res Evaluat, Calverton, MD USAAD  - Sree Chitra Tirunal Inst Med Sci & Technol, Thiruvananthapuram, Kerala, IndiaAD  - Amrita Inst Med Sci, Kochi, IndiaAD  - Kyrgyz State Med Acad, Bishkek, KyrgyzstanAD  - Natl Ctr Cardiol & Internal Dis, Bishkek, KyrgyzstanAD  - Univ New South Wales, Sch Optometry & Vision Sci, Brien Holden Vision Inst, Kensington, NSW, AustraliaAD  - Heidelberg Univ, Fac Med Mannheim, Inst Publ Hlth, Dept Ophthalmol, Heidelberg, GermanyAD  - Salahaddin Univ, Erbil, IraqAD  - Ishik Univ, Erbil, IraqAD  - Hamedan Univ Med Sci, Hamadan, IranAD  - Jigjiga Univ, Jigjiga, EthiopiaAD  - Ahmadu Bello Univ, Hlth Syst & Policy Res Unit, Zaria, NigeriaAD  - Univ Papua New Guinea, Sch Med & Hlth Sci, Reprod Hlth & ObGyn, Boroko, Papua N GuineaAD  - IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, Trieste, ItalyAD  - Univ Lancaster, Lancaster Med Sch, Lancaster, EnglandAD  - Queensland Univ Technol, Int Lab Air Qual & Hlth, Brisbane, Qld, AustraliaAD  - Gorgas Mem Inst Hlth Studies, Panama City, PanamaAD  - Natl Ctr Child Hlth & Dev, Tokyo, JapanAD  - Fed Inst Populat Res, Competence Ctr Mortal Follow Up German Natl Cohor, Wiesbaden, GermanyAD  - ICMR Natl Inst Epidemiol, Chennai, Tamil Nadu, IndiaAD  - London Sch Hyg & Trop Med, London, EnglandAD  - Univ Jos, Jos, NigeriaAD  - Jos Univ, Teaching Hosp, Jos, NigeriaAD  - Univ Sci Malaysia, Sch Med Sci, Kubang Kerian, MalaysiaAD  - Helping Hands Fdn, Multan, PakistanAD  - Nishtar Med Univ, Multan, PakistanAD  - Ulm Univ, Inst Epidemiol & Med Biometry, Ulm, GermanyAD  - Int Ctr Diarrhoeal Dis Res, Dhaka, BangladeshAD  - Kermanshah Univ Med Sci, Sch Publ Hlth, Res Ctr Environm Determinants Hlth, Kermanshah, IranAD  - Azienda Osped Papa Giovanni XXIII, Bergamo, ItalyAD  - Suraj Eye Inst, Nagpur, Maharashtra, IndiaAD  - Univ Yaounde, Fac Med & Biomed Sci, Dept Publ Hlth, Yaounde, CameroonAD  - Minist Publ Hlth, Dept Control Dis Epidem & Pandem, Yaounde, CameroonAD  - Univ Fed Minas Gerais, Hosp Clin, Belo Horizonte, MG, BrazilAD  - Hosp Univ Ciencias Med, Belo Horizonte, MG, BrazilAD  - KEMRI Wellcome Trust, Kilifi, KenyaAD  - Univ Nairobi, Nairobi, KenyaAD  - Duy Tan Univ, Inst Global Hlth Innovat, Da Nang, VietnamAD  - Semarang State Univ, Dept Publ Hlth, Semarang City, IndonesiaAD  - Taipei Med Univ, Grad Inst Biomed Informat, Taipei, TaiwanAD  - Univ Bergen, Bergen, NorwayAD  - Med Diagnost Ctr, Yaounde, CameroonAD  - Rwanda Minist Hlth, Kigali, RwandaAD  - Western Sydney Univ, Ctr Hlth Res, Sydney, NSW, AustraliaAD  - Kyung Hee Univ, Sch Med, Dept Prevent Med, Seoul, South KoreaAD  - South Africa & Univ KwaZulu Natal, Human Sci Res Council, Durban, South AfricaAD  - Lagos Univ, Teaching Hosp, Dept Psychiat, Lagos, NigeriaAD  - Univ Autonoma Chile, Talca, ChileAD  - Ctr Healthy Start Initiat, Lagos, NigeriaAD  - Lira Municipal Council, Lira Dist Local Govt, Kampala, UgandaAD  - San Diego State Univ, Grad Sch Publ Hlth, Div Epidemiol & Biostat, San Diego, CA 92182 USAAD  - UAM, IIS Fdn Jimenez Diaz, Madrid, SpainAD  - Karabuk Univ, Karabuk, TurkeyAD  - JSS Univ, JSS Med Coll, Mysore, Karnataka, IndiaAD  - Christian Med Coll Ludhiana, Ludhiana, Punjab, IndiaAD  - Kosin Univ, Coll Med, Dept Med Humanities & Social Med, Busan, South KoreaAD  - White Plains Hosp, White Plains, NY USAAD  - Deemed Univ, Krishan Inst Med Sci, Sch Dent Sci, Karad, IndiaAD  - Minist Hlth Family Welf, Natl Hlth Syst Resource Ctr, New Delhi, IndiaAD  - Diabet Res Soc, Clin Res, Hyderabad, IndiaAD  - DiabetOmics, Portland, OR USAAD  - UK Dept Int Dev, Lalitpur, NepalAD  - Fundacao Oswaldo Cruz, Inst Comunicacao & Informacao Cientif & Tecnol Sa, Rio De Janeiro, BrazilAD  - Univ Porto, Fac Farm, Dept Quim, REQUIMTE,LAQV,Lab Farmacognosia, Porto, PortugalAD  - Univ Gothenburg, Hlth Metr Unit, Gothenburg, SwedenAD  - Univ Witwatersrand, Johannesburg, South AfricaAD  - Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R ChinaAD  - Durban Univ Technol, Durban, South AfricaAD  - Univ Newcastle, Callaghan, NSW, AustraliaAD  - Univ Med Ctr Groningen, Groningen, NetherlandsAD  - Sanjay Gandhi Postgrad Inst Med Sci, Lucknow, Uttar Pradesh, IndiaAD  - Charotar Univ Sci & Technol, Anand, Gujarat, IndiaAD  - Sanjay Gandhi Post Grad Inst Med Sci, Lucknow, Uttar Pradesh, IndiaAD  - Fred Hollows Fdn, Melbourne, Vic, AustraliaAD  - Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, IranAD  - Commemorat Gorgas Inst Hlth Studies, Panama City, PanamaAD  - AT Still Univ, Kirksville, MO USAAD  - Contech Int Hlth Consultants, Lahore, PakistanAD  - Contech Sch Publ Hlth, Lahore, PakistanAD  - BRAC, Res & Evaluat Div, Dhaka, BangladeshAD  - Sweidi Hosp, Riyadh, Saudi ArabiaAD  - Soc Hlth & Demog Surveillance, Sufi, IndiaAD  - Nizams Inst Med Sci, Hyderabad, IndiaAD  - Fundacao Oswaldo Cruz, Inst Goncalo Muniz, Salvador, BA, BrazilAD  - North Hampshire Hosp, Basingstoke, Hants, EnglandAD  - Univ Coll London Hosp, London, EnglandAD  - Human Sci Res Council, Cape Town, South AfricaAD  - Loma Linda Univ Med Ctr, Loma Linda, CA USAAD  - Azienda Sociosanitaria Terr, Bergamo, ItalyAD  - Univ Milan, Dept Biomed & Clin Sci L Sacco, Milan, ItalyAD  - Univ Fed Uberlandia, Uberlandia, MG, BrazilAD  - Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, IranAD  - HBNI Univ, BARC Hosp, Mumbai, Maharashtra, IndiaAD  - Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, TanzaniaAD  - Natl Inst Res Environm Hlth, Bhopal, IndiaAD  - Prince Wales Hosp, Randwick, NSW, AustraliaAD  - Mashhad Univ Med Sci, Mashhad, IranAD  - Fiocruz MS, Rio De Janeiro, BrazilAD  - Ain Shams Univ, Fac Sci, Cairo, EgyptAD  - Marshall Univ, Edwards Sch Med, Dept Publ Hlth, Huntington, WV USAAD  - Case Western Reserve Univ, Cleveland, OH 44106 USAAD  - Sancheti Inst Orthopaed Rehabil, Pune, Maharashtra, IndiaAD  - IIS Fdn Jimenez Diaz, Madrid, SpainAD  - Queensland Ctr Mental Hlth Res, Brisbane, Qld, AustraliaAD  - Isfahan Cardiovasc Res Inst, Esfahan, IranAD  - Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Publ Hlth Med, Durban, South AfricaAD  - Utkal Univ, Ctr Adv Study Psychol, Bhubaneswar, IndiaAD  - Norwegian Inst Publ Hlth, Ctr Dis Burden, Oslo, NorwayAD  - Bayer Turkey, Istanbul, TurkeyAD  - Food & Agr Org, Global Perspect Studies, Rome, ItalyAD  - Univ Fed Santa Catarina, Florian6poliss, BrazilAD  - North West Univ, Hypertens Africa Res Team, Potchefstroom, South AfricaAD  - Croatian Inst Publ Hlth, Croatian Natl Canc Registry, Zagreb, CroatiaAD  - Univ Zagreb, Sch Publ Hlth Dr Andrija A Tampar, Sch Med, Zagreb, CroatiaAD  - NYU, Langone Med Ctr, Dept Rehabil Med, New York, NY 10003 USAAD  - Deakin Univ, Middle East Liver Dis Ctr, Inst Phys Activ & Nutr, Burwood, Vic, AustraliaAD  - Delhi Technol Univ, Univ Sch Management & Entrepreneurship, Delhi, IndiaAD  - Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai, Peoples R ChinaAD  - Natl Inst Infect Dis, Tokyo, JapanAD  - Tachikawa Hosp, Tokyo, JapanAD  - Univ Edinburgh, Alzheimer Scotland Dementia Res Ctr, Edinburgh, Midlothian, ScotlandAD  - Symbiosis Int Univ, Symbiosis Inst Hlth Sci, Pune, Maharashtra, IndiaAD  - KEM Hosp Res Ctr, Diabet Unit, Pune, Maharashtra, IndiaAD  - Univ Technol Sydney, Sydney, NSW, AustraliaAD  - Reykjavik Univ, Reykjavik, IcelandAD  - Univ Penn, Philadelphia, PA 19104 USAAD  - Brasilia Univ, Brasilia, DF, BrazilAD  - Max Hosp, Ghaziabad, IndiaAD  - Asthma Bhawan, Jaipur, Rajasthan, IndiaAD  - Sch Prevent Oncol, Patna, Bihar, IndiaAD  - Natl Inst Canc Prevent, CTC Global Knowledge Hub Smokeless Tobacco, Noida, IndiaAD  - Ethiopian Med Assoc, Addis Ababa, EthiopiaAD  - King Khalid Univ Hosp, Riyadh, Saudi ArabiaAD  - Tunisian Ctr Publ Hlth, Les Berges Du Lac, TunisiaAD  - Dartmouth Coll, Hanover, NH 03755 USAAD  - Inst Invest Hosp Univ Princesa IISP, Madrid, SpainAD  - Univ Autonoma Madrid, Madrid, SpainAD  - Int Med Univ, Dept Community Med, Kuala Lumpur, MalaysiaAD  - Attikon Univ Hosp, Athens, GreeceAD  - Univ East Anglia, Norwich, Norfolk, EnglandAD  - Publ Hlth England, London, EnglandAD  - South African Med Res Council, Unit Anxiety & Stress Disorders, Cape Town, South AfricaAD  - Minist Hlth, Riyadh, Saudi ArabiaAD  - Univ Calif Irvine, Dept Criminol Law & Soc Sociol & Publ Hlth, Irvine, CA USAAD  - Mizan Tepi Univ, Mizan Teferi, EthiopiaAD  - Inst Super Ciencias Sande Egas Moniz, Almada, PortugalAD  - Univ Lisbon, Fac Pharm, Lisbon, PortugalAD  - Univ Virginia, Dept Anesthesiol, Charlottesville, VA USAAD  - King Fahad Med City, Dept Anesthesiol, Riyadh, Saudi ArabiaAD  - Cleveland Clin, Consortium Cleveland Clin, Cleveland, OH 44106 USAAD  - Univ Calgary, Calgary, AB, CanadaAD  - Jagiellonian Univ, Med Coll, Fac Hlth Sci, Inst Publ Hlth, Krakow, PolandAD  - Wroclaw Med Univ, Fac Hlth Sci, Wroclaw, PolandAD  - Aristotle Univ Thessaloniki, Thessaloniki, GreeceAD  - Univ Valencia, Sch Med, Valencia, SpainAD  - Med Univ Hanoi, Hanoi, VietnamAD  - Univ Auckland, Auckland Canc Soc Res Ctr, Auckland, New ZealandAD  - Univ Louisville, Sch Med, Louisville, KY 40292 USAAD  - Natl Inst Res TB, Chennai, Tamil Nadu, IndiaAD  - Univ Barcelona, CIBERSAM, Fundaci6 Sant de Joan Deu, Parc Sanitari Sant Joan de Deu, Barcelona, SpainAD  - US Dept Vet Affairs, Washington, DC USAAD  - Fed Teaching Hosp, Dept Internal Med, Abakaliki, NigeriaAD  - Gomal Univ, Gomal Ctr Biochem & Biotechnol, Dera Ismail Khan, PakistanAD  - Mufti Mehmood Mem Teaching Hosp, Programmat Management Drug Resistant TB Unit, TB Culture Lab, Dera Ismail Khan, PakistanAD  - Univ Warwick, Warwick Med Sch, Coventry, W Midlands, EnglandAD  - Univ Nigeria, Enugu Campus, Enugu, NigeriaAD  - Sociedad Argentina Med, Buenos Aires, DF, ArgentinaAD  - Hosp Velez Sarsfield, Buenos Aires, DF, ArgentinaAD  - UKK Inst Hlth Promot Res, Tampere, FinlandAD  - Raffles Hosp, Raffles Neurosci Ctr, Singapore, SingaporeAD  - Univ Bologna, Bologna, ItalyAD  - Fed Res Inst Hlth Org & Informat, Moscow, RussiaAD  - Natl Res Univ Higher Sch Econ, Moscow, RussiaAD  - Fdn Univ, Islamabad, PakistanAD  - VA Med Ctr, Washington, DC USAAD  - Georgetown Univ, Neurol Dept, Washington, DC USAAD  - Nat Hist Museum, London, EnglandAD  - Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R ChinaAD  - Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Shaanxi, Peoples R ChinaAD  - Univ Sao Paulo, Med Sch, Sao Paulo, SP, BrazilAD  - Univ Adelaide, Adelaide, SA, AustraliaAD  - Canc Registry Norway, Inst Populat Based Canc Res, Dept Res, Oslo, NorwayAD  - Arctic Univ Norway, Univ Tromso, Fac Hlth Sci, Dept Community Med, Tromso, NorwayAD  - Folkhalsan Res Ctr, Genet Epidemiol Grp, Helsinki, FinlandAD  - Royal Childrens Hosp, Melbourne, Vic, AustraliaAD  - Murdoch Childrens Res Inst, Melbourne, Vic, AustraliaAD  - German Natl Cohort Consortium, Heidelberg, GermanyAD  - VitroLive Sp Zoo, Szczecin, PolandAD  - Tech Univ Munich, Klinikum Rechts Isar, Ctr Global Hlth, Dept Neurol, Munich, GermanyAD  - Univ Oslo, Ctr Global Hlth, Inst Hlth & Soc, Oslo, NorwayAD  - South African Med Res Council, Cape Town, South AfricaAD  - Guys & St Thomas NHS Fdn Trust, Natl Inst Hlth, Res Comprehens Biomed Res Ctr, London, EnglandAD  - Kings Coll London, London, EnglandAD  - Univ Ghent, Ghent, BelgiumAD  - NHS Natl Serv Scotland, Glasgow, Lanark, ScotlandAD  - Univ Strathclyde, Glasgow, Lanark, ScotlandAD  - St Johns Med Coll & Res Inst, Bangalore, Karnataka, IndiaAD  - Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurol, Nanjing, Jiangsu, Peoples R ChinaAD  - Duke Kunshan Univ, Global Hlth Res Ctr, Kunshan, Peoples R ChinaAD  - Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USAAD  - Woldia Univ, Woldia, EthiopiaAD  - Univ Hong Kong, Hong Kong Jockey Club Ctr Suicide Res & Prevent, Social Work & Social Adm Dept, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ South Australia, Mawson Lakes, SA, AustraliaAD  - Kyoto Univ, Sch Publ Hlth, Dept Biostat, Kyoto, JapanAD  - Aga Khan Univ, NCD Res Policy Unit, Nairobi, KenyaAD  - Korea Univ, Coll Med, Dept Prevent Med, S, Seoul, South KoreaAD  - Univ Kinshasa, Sch Publ Hlth, Kinshasa, DEM REP CONGOAD  - Jackson State Univ, Jackson, MS 39217 USAAD  - Wuhan Univ, Sch Publ Hlth, Global Hlth Inst, Dept Epidemiol & Biostat, Wuhan, Hubei, Peoples R ChinaAD  - Inst Oncol Ljubljana, Epidemiol & Canc Registry, Ljubljana, SloveniaAD  - Univ Hosp Setif, Setif, AlgeriaAD  - Natl Off MCH Surveillance China, Chengdu, Peoples R ChinaAD  - Red Cross War Mem Childrens Hosp, Cape Town, South AfricaC3  - Institute for Health Metrics & EvaluationC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of WashingtonC3  - University of Washington SeattleC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Addis Ababa UniversityC3  - Sapienza University RomeC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Haramaya UniversityC3  - Haramaya UniversityC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - University of GondarC3  - Hawassa UniversityC3  - Hawassa UniversityC3  - CHU LimogesC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Mekelle UniversityC3  - Universidade Federal de Minas GeraisC3  - Qatar Foundation (QF)C3  - Weill Cornell Medical College QatarC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - University of QueenslandC3  - Obafemi Awolowo UniversityC3  - Obafemi Awolowo UniversityC3  - Stellenbosch UniversityC3  - University of Southern DenmarkC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - McMaster UniversityC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Baylor College of MedicineC3  - Public Health Foundation of IndiaC3  - Lund UniversityC3  - Skane University HospitalC3  - University of IbadanC3  - Newcastle University - UKC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - University of TorontoC3  - Mayo ClinicC3  - Washington University (WUSTL)C3  - University of Western AustraliaC3  - Australian National UniversityC3  - King Saud UniversityC3  - King Faisal Specialist Hospital & Research CenterC3  - University of LondonC3  - Qazvin University of Medical Sciences (QUMS)C3  - Kuwait UniversityC3  - Universiti Kebangsaan MalaysiaC3  - Luxembourg Institute of HealthC3  - Universite de LorraineC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Karolinska InstitutetC3  - Jordan University of Science & TechnologyC3  - Jordan University of Science & TechnologyC3  - King Abdulaziz UniversityC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - Universidad de CartagenaC3  - University of AdelaideC3  - Bahir Dar UniversityC3  - Kwame Nkrumah University Science & TechnologyC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Carol Davila University of Medicine & PharmacyC3  - University of ThessalyC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - Dalarna UniversityC3  - University of ManitobaC3  - University of OsloC3  - Johns Hopkins UniversityC3  - Johns Hopkins Bloomberg School of Public HealthC3  - Dr DY Patil Vidyapeeth PuneC3  - Keimyung UniversityC3  - Instituto Nacional de Salud PublicaC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - La Trobe UniversityC3  - Instituto Nacional de Salud - PeruC3  - McGill UniversityC3  - Dilla UniversityC3  - University of TokyoC3  - University of South AfricaC3  - Burnet InstituteC3  - University of MelbourneC3  - University of MelbourneC3  - Murdoch Children's Research InstituteC3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - University of MelbourneC3  - South Australian Health & Medical Research Institute (SAHMRI)C3  - University of MaltaC3  - University of LagosC3  - University of LagosC3  - Public Health Agency of CanadaC3  - Medical University LodzC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - University of LondonC3  - University College LondonC3  - Universidad Costa RicaC3  - University of AucklandC3  - Harvard UniversityC3  - Harvard UniversityC3  - Harvard T.H. Chan School of Public HealthC3  - Harvard UniversityC3  - Harvard T.H. Chan School of Public HealthC3  - Africa Health Research InstituteC3  - Ruprecht Karls University HeidelbergC3  - Ruprecht Karls University HeidelbergC3  - Pontificia Universidad JaverianaC3  - University of BarcelonaC3  - ISGlobalC3  - ICREAC3  - Stanford UniversityC3  - Charles R. Drew University of Medicine & ScienceC3  - University of California SystemC3  - University of California Los AngelesC3  - University of California Los Angeles Medical CenterC3  - David Geffen School of Medicine at UCLAC3  - Jazan UniversityC3  - Istituto di Ricerche Farmacologiche Mario Negri IRCCSC3  - Lorestan University of Medical SciencesC3  - Lorestan University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Iran University of Medical SciencesC3  - Yale UniversityC3  - University of AlbertaC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - University of OxfordC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - Universidade de Sao PauloC3  - University of GroningenC3  - University of GroningenC3  - University of GroningenC3  - University of LondonC3  - King's College LondonC3  - University of LondonC3  - King's College LondonC3  - Emory UniversityC3  - Rollins School Public HealthC3  - Emory UniversityC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Aga Khan UniversityC3  - Aga Khan UniversityC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Babol University of Medical SciencesC3  - Ruprecht Karls University HeidelbergC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - European Observatory on Health Systems & PoliciesC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - Comenius University BratislavaC3  - University System of OhioC3  - Ohio State UniversityC3  - Helmholtz AssociationC3  - German Cancer Research Center (DKFZ)C3  - Instituto de Investigacion Cientificas y Servicios de Alta Tecnologia (INDICASAT-AIP)C3  - University of LeicesterC3  - Nanyang Technological UniversityC3  - Imperial College LondonC3  - Imperial College LondonC3  - Imperial College LondonC3  - World Health OrganizationC3  - Imperial College LondonC3  - Imperial College LondonC3  - Universidad Autonoma Metropolitana - MexicoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - Universidade do PortoC3  - i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do PortoC3  - Instituto Nacional de Salud (Colombia)C3  - Universidad Nacional de ColombiaC3  - University of ValenciaC3  - University of ValenciaC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERSAMC3  - University of OttawaC3  - Ottawa Hospital Research InstituteC3  - National Health Research Institutes - TaiwanC3  - National Yang Ming Chiao Tung UniversityC3  - National Taiwan UniversityC3  - International Institute for Population SciencesC3  - Tata Memorial Centre (TMC)C3  - Tata Memorial HospitalC3  - Gold Coast HealthC3  - University of ZambiaC3  - University of WitwatersrandC3  - Seoul National University (SNU)C3  - Seoul National University (SNU)C3  - Seoul National University (SNU)C3  - University of CopenhagenC3  - Bispebjerg HospitalC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - University of SalernoC3  - University of Milano-BicoccaC3  - University of Milano-BicoccaC3  - University of SouthamptonC3  - Universidade de Sao PauloC3  - Universidade Federal do Rio Grande do SulC3  - University of California SystemC3  - University of California San DiegoC3  - University of OtagoC3  - Flinders University South AustraliaC3  - Guy's & St Thomas' NHS Foundation TrustC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - King George's Medical UniversityC3  - Asfendiyarov Kazakh National Medical UniversityC3  - Kazakhstan Medical University "KSPH"C3  - Monash UniversityC3  - Monash HealthC3  - Monash Medical CentreC3  - Monash UniversityC3  - Griffith UniversityC3  - University of Colorado SystemC3  - University of Colorado Anschutz Medical CampusC3  - Colorado School of Public HealthC3  - University of BrightonC3  - University of SussexC3  - Icahn School of Medicine at Mount SinaiC3  - University of PeradeniyaC3  - Ministry of Health & Medical Education (MOHME)C3  - Ministry of Health & Medical Education (MOHME)C3  - University of Cape CoastC3  - University of New South Wales SydneyC3  - University of RochesterC3  - Universidade do Estado de Santa CatarinaC3  - Royal Melbourne Institute of Technology (RMIT)C3  - University of SydneyC3  - University of SydneyC3  - University of BelgradeC3  - University of BelgradeC3  - University of BelgradeC3  - Universidade Federal do Rio Grande do SulC3  - University of North CarolinaC3  - University of North Carolina Chapel HillC3  - Umea UniversityC3  - University of Michigan SystemC3  - University of MichiganC3  - Arba Minch UniversityC3  - Philippine Department HealthC3  - Universidade Federal de SergipeC3  - Auckland University of TechnologyC3  - Jimma UniversityC3  - Jimma UniversityC3  - Universidade Catolica PortuguesaC3  - Brandeis UniversityC3  - Kaiser PermanenteC3  - University of BielefeldC3  - Fred Hutchinson Cancer CenterC3  - Universidade Federal do Espirito SantoC3  - National Academy of Medical Sciences of UkraineC3  - D. F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of UkraineC3  - University of BaselC3  - Swiss Tropical & Public Health InstituteC3  - University of BaselC3  - Swiss Tropical & Public Health InstituteC3  - University of BaselC3  - National Center for Disease Control & Public Health - GeorgiaC3  - University of MunichC3  - Wageningen University & ResearchC3  - CHU Dijon BourgogneC3  - Jawaharlal Nehru University, New DelhiC3  - University of Massachusetts SystemC3  - University of Massachusetts BostonC3  - Organisation for Economic Co-operation & Development (OECD)C3  - Boston UniversityC3  - Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele Presidio FerraottoC3  - Eternal Heart Care Centre & Research InstituteC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Montefiore Medical CenterC3  - Albert Einstein College of MedicineC3  - Yeshiva UniversityC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - KanpurC3  - University of DelhiC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - Western University (University of Western Ontario)C3  - Western University (University of Western Ontario)C3  - Arabian Gulf UniversityC3  - University of Western AustraliaC3  - University of Western AustraliaC3  - Harry Perkins Institute of Medical ResearchC3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERSAMC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERSAMC3  - Curtin UniversityC3  - Universidad de PanamaC3  - Bucharest University of Economic StudiesC3  - Bucharest University of Economic StudiesC3  - Samara UniversityC3  - Columbia UniversityC3  - Columbia UniversityC3  - Guilan University of Medical SciencesC3  - Yokohama City UniversityC3  - Universite de Tunis-El-ManarC3  - Institut Salah AzaiezC3  - Central South UniversityC3  - Aarhus UniversityC3  - Aarhus UniversityC3  - Universitas SriwijayaC3  - University of the Western CapeC3  - National Institute for Health Development - EstoniaC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - Shahid Beheshti University Medical SciencesC3  - American Cancer SocietyC3  - George Mason UniversityC3  - University of KragujevacC3  - University of AberdeenC3  - Banaras Hindu University (BHU)C3  - Technical University CzestochowaC3  - Ruprecht Karls University HeidelbergC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Epidemiology (NIE)C3  - University of TartuC3  - University College CorkC3  - University of LondonC3  - London School Economics & Political ScienceC3  - Srirama Chandra Bhanja Medical College & HospitalC3  - European Observatory on Health Systems & PoliciesC3  - Helmholtz AssociationC3  - Helmholtz-Center for Infection ResearchC3  - German Center for Infection ResearchC3  - University of WashingtonC3  - University of Washington TacomaC3  - Seattle Children's HospitalC3  - MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNITC3  - University of GlasgowC3  - University of TokyoC3  - South African Medical Research CouncilC3  - University of Cape TownC3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Health Services AcademyC3  - United Arab Emirates UniversityC3  - University of NewcastleC3  - University of Tennessee SystemC3  - University of Tennessee Health Science CenterC3  - Seoul National University (SNU)C3  - Ministry of Health & Medical Education (MOHME)C3  - Ball State UniversityC3  - Northeastern UniversityC3  - Xiamen University Malaysia CampusC3  - Simmons UniversityC3  - University of CanberraC3  - University of OsloC3  - University of British ColumbiaC3  - National Cerebral & Cardiovascular Center - JapanC3  - National Institute of Health Research & Development - IndonesiaC3  - Sher-i-Kashmir Institute of Medical SciencesC3  - Research Center of NeurologyC3  - Panjab UniversityC3  - Universite de MontrealC3  - Universite de MontrealC3  - Universite de MontrealC3  - Ministry of Health of UkraineC3  - Public Health Center of the Ministry of Health of UkraineC3  - National Institutes of Health (NIH) - USAC3  - NIH National Cancer Institute (NCI)C3  - University of OttawaC3  - Children's Hospital of Eastern OntarioC3  - Universidade Federal de Minas GeraisC3  - Uppsala UniversityC3  - University of BarcelonaC3  - Hospital Clinic de BarcelonaC3  - ISGlobalC3  - University of CopenhagenC3  - RigshospitaletC3  - RigshospitaletC3  - University of CopenhagenC3  - Nova Southeastern UniversityC3  - Hong Kong Polytechnic UniversityC3  - State University of New York (SUNY) SystemC3  - University at Albany, SUNYC3  - US Department of Veterans AffairsC3  - Veterans Health Administration (VHA)C3  - San Francisco VA Medical CenterC3  - Sichuan UniversityC3  - Universiti MalayaC3  - Chinese University of Hong KongC3  - University of HaifaC3  - Radboud University NijmegenC3  - Chinese Center for Disease Control & PreventionC3  - National Center for Chronic & Noncommunicable Disease Control & Prevention, Chinese Center for Disease Control & PreventionC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of PennsylvaniaC3  - Pennsylvania MedicineC3  - Childrens Hospital of PhiladelphiaC3  - Friedrich Schiller University of JenaC3  - University of LiverpoolC3  - Swansea UniversityC3  - American University of BeirutC3  - Royal Children's Hospital MelbourneC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Aswan UniversityC3  - University of TrnavaC3  - Universidade Federal de Minas GeraisC3  - Universidad CEU Cardenal HerreraC3  - Instituto Federal do Ceara (IFCE)C3  - SYNLAB GroupC3  - Medical University of GrazC3  - University of OxfordC3  - Chalmers University of TechnologyC3  - University of BristolC3  - Queensland Centre for Mental Health ResearchC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Cancer Prevention & Research (NICPR)C3  - University of California SystemC3  - University of California San FranciscoC3  - Martin Luther University Halle WittenbergC3  - State University System of FloridaC3  - University of West FloridaC3  - Alfaisal UniversityC3  - United Nations Population FundC3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - University of HelsinkiC3  - Finnish Institute of Occupational HealthC3  - Pomeranian Medical UniversityC3  - Tufts UniversityC3  - Pacific Institute for Research & Evaluation (PIRE)C3  - Department of Science & Technology (India)C3  - Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)C3  - Amrita Vishwa VidyapeethamC3  - Amrita Vishwa Vidyapeetham KochiC3  - Ministry of Health - KyrgyzstanC3  - Kyrgyz State Medical AcademyC3  - University of New South Wales SydneyC3  - Brien Holden Vision InstituteC3  - Ruprecht Karls University HeidelbergC3  - Salahaddin UniversityC3  - Hamadan University of Medical SciencesC3  - Ahmadu Bello UniversityC3  - University of Papua New GuineaC3  - IRCCS Burlo GarofoloC3  - Lancaster UniversityC3  - Queensland University of Technology (QUT)C3  - Instituto Conmemorativo Gorgas de Estudios de la SaludC3  - National Center for Child Health & Development - JapanC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Epidemiology (NIE)C3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of JosC3  - Universiti Sains MalaysiaC3  - Ulm UniversityC3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - Kermanshah University of Medical SciencesC3  - ASST Papa Giovanni XXIIIC3  - Suraj Eye InstituteC3  - University of Yaounde IC3  - Universidade Federal de Minas GeraisC3  - University of NairobiC3  - Duy Tan UniversityC3  - Universitas Negeri SemarangC3  - Taipei Medical UniversityC3  - University of BergenC3  - Western Sydney UniversityC3  - Kyung Hee UniversityC3  - Human Sciences Research Council-South AfricaC3  - Universidad Autonoma de ChileC3  - California State University SystemC3  - San Diego State UniversityC3  - Autonomous University of MadridC3  - Fundacion Jimenez DiazC3  - Karabuk UniversityC3  - JSS Academy of Higher Education & ResearchC3  - JSS Medical College, MysuruC3  - Fundacao Oswaldo CruzC3  - Universidade do PortoC3  - University of GothenburgC3  - University of WitwatersrandC3  - Shanghai Jiao Tong UniversityC3  - Durban University of TechnologyC3  - University of NewcastleC3  - University of GroningenC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - Charotar University of Science & Technology - CharusatC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - Fred Hollows FoundationC3  - A.T. Still University of Health SciencesC3  - Bangladesh Rural Advancement Committee BRACC3  - Nizam's Institute of Medical SciencesC3  - Fundacao Oswaldo CruzC3  - University of LondonC3  - University College LondonC3  - University College London Hospitals NHS Foundation TrustC3  - Human Sciences Research Council-South AfricaC3  - Loma Linda UniversityC3  - University of MilanC3  - Luigi Sacco HospitalC3  - Universidade Federal de UberlandiaC3  - Golestan University of Medical SciencesC3  - Homi Bhabha National InstituteC3  - Bhabha Atomic Research Center (BARC)C3  - Muhimbili University of Health & Allied SciencesC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute for Research in Environmental Health (NIREH)C3  - University of New South Wales SydneyC3  - Prince of Wales Hospital (POWH)C3  - Mashhad University of Medical SciencesC3  - Fundacao Oswaldo CruzC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - Marshall UniversityC3  - University System of OhioC3  - Case Western Reserve UniversityC3  - Fundacion Jimenez DiazC3  - Queensland Centre for Mental Health ResearchC3  - University of Kwazulu NatalC3  - Utkal UniversityC3  - Norwegian Institute of Public Health (NIPH)C3  - Food & Agriculture Organization of the United Nations (FAO)C3  - Universidade Federal de Santa Catarina (UFSC)C3  - North West University - South AfricaC3  - University of ZagrebC3  - NYU Langone Medical CenterC3  - New York UniversityC3  - Deakin UniversityC3  - Delhi Technological UniversityC3  - Fudan UniversityC3  - National Institute of Infectious Diseases (NIID)C3  - Tachikawa HospitalC3  - University of EdinburghC3  - Symbiosis International UniversityC3  - Symbiosis Institute of Health Sciences (SIHS)C3  - University of Technology SydneyC3  - Reykjavik UniversityC3  - University of PennsylvaniaC3  - Universidade de BrasiliaC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Cancer Prevention & Research (NICPR)C3  - King Saud UniversityC3  - King Khalid University HospitalC3  - Dartmouth CollegeC3  - Hospital de La PrincesaC3  - Autonomous University of MadridC3  - International Medical University MalaysiaC3  - University Hospital AttikonC3  - University of East AngliaC3  - Public Health EnglandC3  - South African Medical Research CouncilC3  - Ministry of Health - Saudi ArabiaC3  - University of California SystemC3  - University of California IrvineC3  - Universidade de LisboaC3  - University of VirginiaC3  - King Fahad Medical CityC3  - Cleveland Clinic FoundationC3  - University of CalgaryC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - Wroclaw Medical UniversityC3  - Aristotle University of ThessalonikiC3  - University of ValenciaC3  - Hanoi Medical UniversityC3  - University of AucklandC3  - University of LouisvilleC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute for Research in Tuberculosis (NIRT)C3  - University of BarcelonaC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERSAMC3  - US Department of Veterans AffairsC3  - Gomal UniversityC3  - University of WarwickC3  - UKK InstituteC3  - Raffles HospitalC3  - University of BolognaC3  - HSE University (National Research University Higher School of Economics)C3  - Georgetown UniversityC3  - Natural History Museum LondonC3  - Fudan UniversityC3  - Xi'an Jiaotong UniversityC3  - Universidade de Sao PauloC3  - University of AdelaideC3  - University of OsloC3  - UiT The Arctic University of TromsoC3  - Folkhalsan Research CenterC3  - Royal Children's Hospital MelbourneC3  - Murdoch Children's Research InstituteC3  - Technical University of MunichC3  - University of OsloC3  - South African Medical Research CouncilC3  - Guy's & St Thomas' NHS Foundation TrustC3  - University of LondonC3  - King's College LondonC3  - Ghent UniversityC3  - NHS National Services ScotlandC3  - University of StrathclydeC3  - St. John's National Academy of Health SciencesC3  - St. John's Medical CollegeC3  - Nanjing UniversityC3  - Duke Kunshan UniversityC3  - Northwestern UniversityC3  - University of Hong KongC3  - University of South AustraliaC3  - Kyoto UniversityC3  - Aga Khan UniversityC3  - Korea UniversityC3  - Korea University Medicine (KU Medicine)C3  - Universite de KinshasaC3  - Jackson State UniversityC3  - Wuhan UniversityC3  - Institute of Oncology - SloveniaPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - JUN 2
PY  - 2018
VL  - 391
IS  - 10136
SP  - 2236
EP  - 2271
DO  - 10.1016/S0140-6736(18)30994-2
AN  - WOS:000433904700029
ER  -

TY  - JOUR
AU  - Agarwal, K
AU  - Sharma, U
AU  - Mathur, S
AU  - Seenu, V
AU  - Parshad, R
AU  - Jagannathan, NR
TI  - Study of lipid metabolism by estimating the fat fraction in different breast tissues and in various breast tumor sub-types by in vivo <SUP>1</SUP>H MR spectroscopy
T2  - MAGNETIC RESONANCE IMAGING
KW  - Magnetic resonance spectroscopy
KW  - Breast cancer
KW  - Lipid metabolism
KW  - Hormonal factors
KW  - Fat fraction
KW  - MAGNETIC-RESONANCE-SPECTROSCOPY
KW  - THERAPEUTIC RESPONSE
KW  - CANCER
KW  - LESIONS
KW  - CELL
KW  - ACCUMULATION
KW  - CHEMOTHERAPY
KW  - MDA-MB-231
KW  - CARCINOMA
KW  - PATHWAYS
AB  - Purpose: To evaluate the utility of fat fraction (FF) for the differentiation of different breast tissues and in various breast tumor subtypes using in vivo proton (H-1) magnetic resonance spectroscopy (MRS).
   Methods: H-1 MRS was performed on 68 malignant, 35 benign, and 30 healthy volunteers at 1.5 T. Malignant breast tissues of patients were characterized into different subtypes based on the differences in the expression of hormone receptors and the FF was calculated. Further, the sensitivity and specificity of FF to differentiate malignant from benign and from normal breast tissues of healthy volunteers was determined using receiver operator curve (ROC) analysis.
   Results: A significantly lower FF of malignant (median 0.12; range 0.01-0.70) compared to benign lesions (median 0.28; range 0.02-0.71) and normal breast tissue of healthy volunteers (median 0.39; range 0.06-0.76) was observed. No significant difference in FF was seen between benign lesions and normal breast tissues of healthy volunteers. Sensitivity and specificity of 75% and 68.6%, respectively was obtained to differentiate malignant from benign lesions. For the differentiation of malignant from healthy breast tissues, 76% sensitivity and 74.5% specificity was achieved. Higher FF was seen in patients with ER - /PR - status as compared to ER+ /PR + patients. Similarly, FF of HER2neu + tumors were significantly higher than in HER2neu - breast tumors.
   Conclusion: The results showed the potential of in vivo H-1 MRS in providing insight into the changes in the fat content of different types of breast tissues and in various breast tumor subtypes.
AD  - All India Inst Med Sci, Dept NMR, Delhi 110029, IndiaAD  - All India Inst Med Sci, MRI Facil, Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Surg Disciplines, Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - JUN
PY  - 2018
VL  - 49
SP  - 116
EP  - 122
DO  - 10.1016/j.mri.2018.02.004
AN  - WOS:000433526000016
ER  -

TY  - JOUR
AU  - Agarwal, M
AU  - Bakhshi, S
AU  - Dwivedi, SN
AU  - Kabra, M
AU  - Shukla, R
AU  - Seth, R
TI  - <i>Cyclin dependent kinase inhibitor 2A/B</i> gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia
T2  - PEDIATRIC BLOOD & CANCER
KW  - CDKN2A
KW  - B gene deletion
KW  - childhood ALL
KW  - MULTIPLE GENES
KW  - CHILDHOOD
KW  - CELL
KW  - METHYLATION
KW  - CDKN2A
KW  - ABNORMALITIES
KW  - CANCER
KW  - RISK
KW  - ASSOCIATION
KW  - DNA
AB  - BackgroundCyclin dependent kinase inhibitor 2A/B (CDKN2A/B) genes are implicated in many malignancies including acute lymphoblastic leukemia (ALL). These tumor suppressor genes, with a key regulatory role in cell cycle are located on chromosome 9p21.3. Previous studies involving CDKN2A/B gene deletions have shown mixed associations with survival outcome in childhood ALL.
   ProcedureHundred and four newly diagnosed children with ALL (1-14 years) were enrolled in this study. Genomic DNA from pretreatment bone marrow/peripheral blood samples of these children was investigated for copy number alterations in CDKN2A/B genes using multiplex ligation dependent probe amplification assay. Immunophenotype subtyping and cytogenetic and molecular analysis of ALL was performed at start of induction chemotherapy in all children. Children were monitored for response to prednisolone (Day 8), complete morphological remission, and minimal residual disease at the end of induction. The minimum postinduction follow-up period was 6 months.
   ResultsCDKN2A/B deletions were seen in 19.8% (18/91) of B lineage acute lymphoblastic leukemia (B-ALL) and 38.5% (5/13) of T lineage acute lymphoblastic leukemia (T-ALL). Monoallelic CDKN2A/B deletions were found in 61.1% of total deletions in B-ALL while all the children with T-ALL harbored biallelic deletions. The prevalence of CDKN2A/B gene deletions was found to be significantly higher in older children (P=0.002), in those with higher leukocyte count (P=0.037), and in National Cancer Institute high risk group patients (P=0.001) in the B-ALL subgroup. Hazard ratio was significantly high for children with CDKN2A/B deletions in total cohort (P=0.004). Children with CDKN2A/B deletion had significantly lesser event free survival (P=0.03).
   ConclusionsCDKN2A/B deletions were significantly more prevalent in T-ALL subgroup and were found to have higher hazard ratio and lesser event free survival in total cohort in our study.
AD  - All India Inst Med Sci, Div Oncol, Dept Paediat, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dr BR Ambedkar Inst Rotary Club & Hosp, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - All India Inst Med Sci, Div Genet, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUN
PY  - 2018
VL  - 65
IS  - 6
C7  - e27001
DO  - 10.1002/pbc.27001
AN  - WOS:000433025800032
ER  -

TY  - JOUR
AU  - Agarwal, N
TI  - Intraoperative aneurysm rupture during awake clipping of cerebral aneurysms
T2  - JOURNAL OF NEUROSURGERY
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ASSOC NEUROLOGICAL SURGEONS
PI  - ROLLING MEADOWS
PA  - 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
DA  - JUN
PY  - 2018
VL  - 128
IS  - 6
SP  - 1906
EP  - 1906
DO  - 10.3171/2017.9.JNS172142
AN  - WOS:000440653000049
ER  -

TY  - JOUR
AU  - Aggarwal, B
AU  - Jain, V
TI  - Obesity in Children: Definition, Etiology and Approach
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Body mass index
KW  - Body fat
KW  - Childhood obesity
KW  - Endocrine obesity
KW  - Exogenous obesity
KW  - Overweight
KW  - WAIST CIRCUMFERENCE
KW  - BODY-COMPOSITION
KW  - SCHOOL-CHILDREN
KW  - OVERWEIGHT
KW  - GROWTH
KW  - FAT
KW  - ASSOCIATION
KW  - PREVENTION
KW  - ADIPOSITY
KW  - RATIO
AB  - Childhood obesity is an important public health issue worldwide. Urbanization, sedentary lifestyle and change in food habits are the chief reasons behind this pandemic. In a small proportion of children, obesity is the result of endocrine, syndromic or monogenic causes. The present paper summarizes the methods, definitions and cut-offs for identification of obesity in children. We have briefly reviewed the various techniques used for estimation of body fat in children and the cut-offs for defining obesity based on body fat percentage, and the reference curves based on body mass index and waist circumference. The etiology of obesity in children, including individual behaviors, macro- and micro-environmental influences, and endocrine causes have been discussed, and an approach to etiological assessment of obese children has been presented. Special emphasis has been laid on clinical pointers that suggest the presence of syndromic, endocrine or monogenic forms of obesity, such as, short stature, dysmorphism, neurocognitive impairment and early age at onset.
AD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaAD  - All India Inst Med Sci, Div Pediat Endocrinol, Dept Pediat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUN
PY  - 2018
VL  - 85
IS  - 6
SP  - 463
EP  - 471
DO  - 10.1007/s12098-017-2531-x
AN  - WOS:000432220600012
ER  -

TY  - JOUR
AU  - Animesh, R
AU  - Vyas, S
TI  - Chest CT Scan Signs A Few Noteworthy Additions
T2  - CHEST
AD  - All India Inst Med Sci, Ringgold Stand Inst, Dept Med, Delhi, IndiaAD  - All India Inst Med Sci, Ringgold Stand Inst, Dept Radiol, Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUN
PY  - 2018
VL  - 153
IS  - 6
SP  - 1516
EP  - 1517
DO  - 10.1016/j.chest.2018.03.014
AN  - WOS:000434249300048
ER  -

TY  - JOUR
AU  - Arora, S
AU  - Damle, NA
AU  - Aggarwal, S
AU  - Passah, A
AU  - Behera, A
AU  - Arora, G
AU  - Bal, C
AU  - Tripathi, M
TI  - Prostate-Specific Membrane Antigen Expression in Adrenocortical Carcinoma on <SUP>68</SUP>Ga-Prostate-Specific Membrane Antigen PET/CT
T2  - CLINICAL NUCLEAR MEDICINE
KW  - adrenocortical carcinoma
KW  - metastasis
KW  - PET
KW  - CT
KW  - PSMA
KW  - SURVIVAL
KW  - CANCER
AD  - All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, IndiaAD  - Postgrad Inst Med Educ & Res, Dept Med, Rohtak, Haryana, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - JUN
PY  - 2018
VL  - 43
IS  - 6
SP  - 449
EP  - 451
DO  - 10.1097/RLU.0000000000002064
AN  - WOS:000432581400030
ER  -

TY  - JOUR
AU  - Arora, U
AU  - Kedia, S
AU  - Garg, P
AU  - Bopanna, S
AU  - Jain, S
AU  - Yadav, DP
AU  - Goyal, S
AU  - Gupta, V
AU  - Sahni, P
AU  - Pal, S
AU  - Dash, NR
AU  - Madhusudhan, KS
AU  - Sharma, R
AU  - Makharia, G
AU  - Ahuja, V
TI  - Colonic Crohn's Disease Is Associated with Less Aggressive Disease Course Than Ileal or Ileocolonic Disease
T2  - DIGESTIVE DISEASES AND SCIENCES
KW  - Crohn's disease
KW  - Surgery
KW  - Steroids
KW  - Hospitalization
KW  - INFLAMMATORY-BOWEL-DISEASE
KW  - COLITIS
KW  - METAANALYSIS
KW  - PHENOTYPE
KW  - VARIANTS
KW  - SMOKING
KW  - NOD2
AB  - Background The literature on disease characteristics of colonic Crohn's disease (CD) is sparse, especially from Asia, where the burden of inflammatory bowel disease is on the rise. The present study aims to describe the disease characteristics of colonic CD, and compare it with that of ileal/ileocolonic disease.
   Methods This retrospective study included adult patients of CD (diagnosed by standard criteria, follow-up duration > 6 months) on follow-up between August 2004 and January 2016. The disease location was classified by Montreal classification. The data were recorded on demographic characteristics, smoking status, disease phenotype, disease course, treatment received, hospitalization and surgeries.
   Results Of 406 CD patients, 123 had colonic [mean age (at onset) 30.4 +/- 13.2 years, 59.3% males] and 265 had ileal/ileocolonic disease [mean age (at onset) 32.9 +/- 13.8 years, 61.5% males] while 18 patients had isolated upper GI disease. The frequency of inflammatory behavior (B1 phenotype; 61.8 vs. 46.4%, p = 0.003), perianal disease (23.6 vs. 4.5%, p < 0.001), and extra-intestinal manifestation (42.3 vs. 30.2%, p = 0.019) was higher in colonic than ileal/ileocolonic CD. Though not statistically significant, requirement of atleast one course of steroid was lower in colonic CD (72.7 vs. 84.2%, p = 0.098). Although there was no difference in the frequency of hospitalization (30.1 vs. 27.1%, p = 0.45), the overall requirement for surgery was significantly lower in colonic CD (17.1 vs. 26.1%, p = 0.032) and patients with colonic disease had a lower cumulative probability of first surgery in the first 10 years of follow-up [Hazard ratio 0.556 (95% CI 0.313-0.985), p = 0.045].
   Conclusion Colonic CD was associated with less aggressive disease behavior and lower requirement of surgery as compared to ileal/ileocolonic CD.
AD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept GI Surg, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Radiol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - JUN
PY  - 2018
VL  - 63
IS  - 6
SP  - 1592
EP  - 1599
DO  - 10.1007/s10620-018-5041-4
AN  - WOS:000432319200029
ER  -

TY  - JOUR
AU  - Bagchi, S
AU  - Subbiah, AK
AU  - Bhowmik, D
AU  - Mahajan, S
AU  - Yadav, RK
AU  - Kalaivani, M
AU  - Singh, G
AU  - Dinda, A
AU  - Agarwal, SK
TI  - Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience
T2  - CLINICAL KIDNEY JOURNAL
KW  - immunosuppression
KW  - membranous nephropathy
KW  - outcome
KW  - proteinuria
KW  - rituximab
KW  - NEPHROTIC SYNDROME
KW  - TRIAL
AB  - Background: Persistent significant proteinuria has been associated with increased risk of progression to end-stage kidney disease in patients with idiopathic membranous nephropathy (IMN). Rituximab (RTX) therapy has given encouraging results in IMN, but most of the studies have used a higher dose, which is limited by the high cost as well as a potential increased risk of infections. Our study aimed to assess the efficacy and safety of low-dose RTX in patients with immunosuppression-resistant IMN.
   Methods: A total of 21 patients with treatment-resistant IMN treated with RTX from 2015 to 2016 at our center were included in the study. They received two doses of RTX (500mg each) infusion 7 days apart. CD19 count was performed after 4 weeks. A single dose of RTX was repeated after 4-6 weeks if CD19 count was not depleted.
   Results: The mean standard deviation age of patients was 33.3 +/- 12.3years and 33.3% were females. Mean proteinuria before RTX therapy was 6.2 +/- 2.2 g/day, serum creatinine was 0.9 +/- 0.3mg/dL and estimated glomerular filtration rate (eGFR) was 95.8 +/- 26.9mL/min/1.73m(2). All the patients were non-responders to prior immunosuppressive treatment. Twenty (95.2%) patients achieved targeted CD19 depletion with two doses of RTX. One patient required one additional RTX dose due to inadequate B-cell suppression. A total of 13 (61.9%) patients achieved remission with RTX therapy: 4 (19.0%) complete and 9 (42.9%) partial remission. Patients who did not respond to RTX had a significantly lower baseline eGFR compared with those who achieved remission (P = 0.022). One patient developed respiratory tract infection following RTX during the follow-up, which responded to a course of oral antibiotics. During median follow-up of 13.1 (10-23.9) months, four (19%) patients had deterioration in renal function and one patient relapsed after achieving partial remission. Renal survival was significantly better in patients who responded to RTX therapy as compared with those who did not achieve remission (P = 0.0037).
   Conclusion: Low-dose RTX therapy is effective and safe in immunosuppression-resistant IMN.
AD  - All India Inst Med Sci, Dept Nephrol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - OXFORD UNIV PRESS
PI  - OXFORD
PA  - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
DA  - JUN
PY  - 2018
VL  - 11
IS  - 3
SP  - 337
EP  - 341
DO  - 10.1093/ckj/sfx105
AN  - WOS:000449486200006
ER  -

TY  - JOUR
AU  - Balhara, YPS
AU  - Verma, K
AU  - Bhargava, R
TI  - Screen time and screen addiction: Beyond gaming, social media and pornography-A case report
T2  - ASIAN JOURNAL OF PSYCHIATRY
AD  - All India Inst Med Sci, BAC, Dept Psychiat, Natl Drug Dependence Treatment Ctr, New Delhi, IndiaAD  - All India Inst Med Sci, Natl Drug Dependence Treatment Ctr, New Delhi, IndiaAD  - All India Inst Med Sci, Natl Drug Dependence Treatment Ctr, Dept Psychiat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)PU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUN
PY  - 2018
VL  - 35
SP  - 77
EP  - 78
DO  - 10.1016/j.ajp.2018.05.020
AN  - WOS:000436398300026
ER  -

TY  - JOUR
AU  - Barbaro, NM
AU  - Quigg, M
AU  - Ward, MM
AU  - Chang, EF
AU  - Broshek, DK
AU  - Langfitt, JT
AU  - Yan, G
AU  - Laxer, KD
AU  - Cole, AJ
AU  - Sneed, PK
AU  - Hess, CP
AU  - Yu, W
AU  - Tripathi, M
AU  - Heck, CN
AU  - Miller, JW
AU  - Garcia, PA
AU  - McEvoy, A
AU  - Fountain, NB
AU  - Salanova, V
AU  - Knowlton, RC
AU  - Bagic, A
AU  - Henry, T
AU  - Kapoor, S
AU  - McKhann, G
AU  - Palade, AE
AU  - Reuber, M
AU  - Tecoma, E
TI  - Radiosurgery versus open surgery for mesial temporal lobe epilepsy: The randomized, controlled ROSE trial
T2  - EPILEPSIA
KW  - clinical trial
KW  - epilepsy surgery
KW  - focal epilepsy
KW  - quality of life
KW  - radiosurgery
KW  - GAMMA-KNIFE SURGERY
KW  - STEREOTACTIC RADIOSURGERY
KW  - ARTERIOVENOUS-MALFORMATIONS
KW  - PROSPECTIVE MULTICENTER
KW  - VERBAL MEMORY
KW  - LOBECTOMY
KW  - COMPLICATIONS
KW  - DEPRESSION
KW  - RESECTION
KW  - OUTCOMES
AB  - ObjectiveTo compare stereotactic radiosurgery (SRS) versus anterior temporal lobectomy (ATL) for patients with pharmacoresistant unilateral mesial temporal lobe epilepsy (MTLE).
   MethodsThis randomized, single-blinded, controlled trial recruited adults eligible for open surgery among 14 centers in the USA, UK, and India. Treatment was either SRS at 24 Gy to the 50% isodose targeting mesial structures, or standardized ATL. Outcomes were seizure remission (absence of disabling seizures between 25 and 36 months), verbal memory (VM), and quality of life (QOL) at 36-month follow-up.
   ResultsA total of 58 patients (31 in SRS, 27 in ATL) were treated. Sixteen (52%) SRS and 21 (78%) ATL patients achieved seizure remission (difference between ATL and SRS = 26%, upper 1-sided 95% confidence interval = 46%, P value at the 15% noninferiority margin = .82). Mean VM changes from baseline for 21 English-speaking, dominant-hemisphere patients did not differ between groups; consistent worsening occurred in 36% of SRS and 57% of ATL patients. QOL improved with seizure remission. Adverse events were anticipated cerebral edema and related symptoms for some SRS patients, and cerebritis, subdural hematoma, and others for ATL patients.
   SignificanceThese data suggest that ATL has an advantage over SRS in terms of proportion of seizure remission, and both SRS and ATL appear to have effectiveness and reasonable safety as treatments for MTLE. SRS is an alternative to ATL for patients with contraindications for or with reluctance to undergo open surgery.
AD  - Indiana Univ, Dept Neurol Surg, Indianapolis, IN 46204 USAAD  - Univ Virginia, Dept Neurol, Charlottesville, VA 22904 USAAD  - Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USAAD  - Univ Virginia, Dept Psychiat, Charlottesville, VA USAAD  - Univ Rochester, Dept Neurol, Rochester, NY USAAD  - Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA USAAD  - Calif Pacific Med Ctr, Dept Neurol, San Francisco, CA USAAD  - Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USAAD  - Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USAAD  - Univ Calif San Francisco, Dept Radiol, San Francisco, CA USAAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaAD  - Univ Southern Calif, Dept Neurol, Los Angeles, CA USAAD  - Univ Washington, Dept Neurol, Seattle, WA 98195 USAAD  - Univ Calif San Francisco, Dept Neurol, San Francisco, CA USAAD  - UCL, Dept Clin & Expt Epilepsy, London, EnglandAD  - Indiana Univ, Dept Neurol, Indianapolis, IN 46204 USAAD  - Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USAAD  - Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USAAD  - Univ Kentucky, Dept Neurol, Lexington, KY 40536 USAAD  - Columbia Univ, Dept Neurosurg, New York, NY USAAD  - Univ Louisville, Dept Neurol, Louisville, KY 40292 USAAD  - Univ Sheffield, Dept Neurosci, Sheffield, S Yorkshire, EnglandAD  - Univ Calif San Diego, Dept Neurol, San Diego, CA 92103 USAC3  - Indiana University SystemC3  - Indiana University IndianapolisC3  - University of VirginiaC3  - University of California SystemC3  - University of California San FranciscoC3  - University of VirginiaC3  - University of RochesterC3  - University of VirginiaC3  - California Pacific Medical CenterC3  - Harvard UniversityC3  - Massachusetts General HospitalC3  - University of California SystemC3  - University of California San FranciscoC3  - University of California SystemC3  - University of California San FranciscoC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of Southern CaliforniaC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of California SystemC3  - University of California San FranciscoC3  - University of LondonC3  - University College LondonC3  - Indiana University SystemC3  - Indiana University IndianapolisC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - University of Minnesota SystemC3  - University of Minnesota Twin CitiesC3  - University of KentuckyC3  - Columbia UniversityC3  - University of LouisvilleC3  - University of SheffieldC3  - University of California SystemC3  - University of California San DiegoPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUN
PY  - 2018
VL  - 59
IS  - 6
SP  - 1198
EP  - 1207
DO  - 10.1111/epi.14045
AN  - WOS:000434354000018
ER  -

TY  - JOUR
AU  - Bhattacharjee, S
AU  - Maitra, S
AU  - Baidya, DK
TI  - A comparison between video laryngoscopy and direct laryngoscopy for endotracheal intubation in the emergency department: A meta-analysis of randomized controlled trials
T2  - JOURNAL OF CLINICAL ANESTHESIA
KW  - Video laryngoscopy
KW  - Emergency intubation
KW  - Direct laryngoscopy
KW  - Video laryngoscope
KW  - Emergency department
KW  - TRACHEAL INTUBATION
KW  - C-MAC
KW  - MACINTOSH LARYNGOSCOPE
KW  - DIFFICULT AIRWAY
KW  - VIDEOLARYNGOSCOPE
KW  - MANAGEMENT
KW  - ADULTS
AB  - Study objectives: Direct laryngoscopy is the most commonly used modality for endotracheal intubation in the emergency department. Video laryngoscopy may improve glottic view during laryngoscopy and intubation success rate in such patients. This meta-analysis has been designed to compare clinical efficacy of video laryngoscopy with direct laryngoscopy for endotracheal intubation in the emergency department.
   Design: Meta-analysis of randomized controlled trial.
   Setting: Randomized controlled trials comparing video laryngoscopy and direct laryngoscopy for endotracheal intubation in adult patients in emergency department. PubMed (1946 to 20th October 2017) and The Cochrane Library databases (CENTRAL) were searched for potentially eligible trials on 20th October 2017.
   Patients: Adult patients presenting in the emergency department.
   Interventions: Video laryngoscopy & direct laryngoscopy for intubation in emergency department.
   Measurement Primary outcome was 'first intubation success rate' and secondary outcomes were overall intubation success rate, in-hospital mortality and oesophageal intubation rate.
   Main results: Data of 1250 patients from 5 randomized controlled trials have been included in this study. Video laryngoscopy offers no advantage over direct laryngoscopy in terms of first intubation success rate (odds ratio 1.28, 95% CI 0.70, 2.36; p = 0.42), overall intubation success rate (OR 1.26, 95% CI 0.53, 3.01; p = 0.6) or inhospital mortality (OR 1.25, 95% CI 0.8, 1.95; p = 0.32). However, oesophageal intubation rate is lower with the use of video laryngoscopy (OR 0.09, 95% CI 0.01, 0.7; p = 0.02).
   Conclusion: Use of video laryngoscopy for emergency endotracheal intubation in adult patients is associated with reduced oesophageal intubation over direct laryngoscopy. However, no benefit was found in terms of overall intubation success.
AD  - All India Inst Med Sci, Dept Anaesthesiol Pain Med & Crit Care, Room 5011,5th Floor Teaching Block, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - JUN
PY  - 2018
VL  - 47
SP  - 21
EP  - 26
DO  - 10.1016/j.jclinane.2018.03.006
AN  - WOS:000432233000010
ER  -

TY  - JOUR
AU  - Bhattacharjee, S
AU  - Maitra, S
AU  - Baidya, DK
TI  - Comparison between ultrasound guided technique and digital palpation technique for radial artery cannulation in adult patients: An updated meta-analysis of randomized controlled trials
T2  - JOURNAL OF CLINICAL ANESTHESIA
KW  - Ultrasound
KW  - Radial artery cannulation
KW  - Palpation
KW  - Arterial catheterization
KW  - Monitoring
KW  - Hemodynamic monitoring
KW  - SUCCESS RATE
KW  - GUIDANCE
KW  - CATHETERIZATION
KW  - ACCESS
KW  - PUNCTURE
AB  - Study objective: Possible advantages and risks associated with ultrasound guided radial artery cannulation incomparison to digital palpation guided method in adult patients are not fully known. We have compared ultrasound guided radial artery cannulation with digital palpation technique in this meta-analysis.
   Design: Meta-analysis of randomized controlled trials.
   Setting: Trials conducted in operating room, emergency department, cardiac catheterization laboratory.
   Patients: PubMed and Cochrane Central Register of Controlled Trials (CENTRAL) were searched (from 1946 to 20th November 2017) to identify prospective randomized controlled trials in adult patients.
   Intervention: Two-dimensional ultrasound guided radial artery catheterization versus digital palpation guided radial artery cannulation.
   Measurements: Overall cannulation success rate, first attempt success rate, time to cannulation and mean number of attempts to successful cannulation. Odds ratio (OR) and standardized mean difference (SMD) or mean difference (MD) with 95% confidence interval (CI) were calculated for categorical and continuous variables respectively.
   Results: Data of 1895 patients from 10 studies have been included in this meta-analysis. Overall cannulation success rate was similar between ultrasound guided technique and digital palpation [OR (95% CI) 2.01 (1.00, 4.06); p = 0.05]. Ultrasound guided radial artery cannulation is associated with higher first attempt success rate of radial artery cannulation in comparison to digital palpation [OR (95% CI) 2.76 (186, 4.10); p < 0.001]. No difference was seen in time to cannulate [SMD (95% CI) -0.31 ( - 0.65, 0.04); p = 0.30] and mean number of attempt [MD (95% CI) -0.65 ( -1.32, 0.02); p = 0.06] between USG guided technique with palpation technique.
   Conclusion: Radial artery cannulation by ultrasound guidance may increase the first attempt success rate but not the overall cannulation success when compared to digital palpation technique. However, results of this meta-analysis should be interpreted with caution due presence of heterogeneity.
AD  - All India Inst Med Sci, Dept Anaesthesiol Pain Med & Crit Care, Room 5013,5th Floor,Teaching Block, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - JUN
PY  - 2018
VL  - 47
SP  - 54
EP  - 59
DO  - 10.1016/j.jclinane.2018.03.019
AN  - WOS:000432233000018
ER  -

TY  - JOUR
AU  - Bradshaw, CJ
AU  - Bandi, AS
AU  - Muktar, Z
AU  - Hasan, MA
AU  - Chowdhury, TK
AU  - Banu, T
AU  - Hailemariam, M
AU  - Ngu, F
AU  - Croaker, D
AU  - Bankolé, R
AU  - Sholadoye, T
AU  - Olaomi, O
AU  - Ameh, E
AU  - Di Cesare, A
AU  - Leva, E
AU  - Ringo, Y
AU  - Abdur-Rahman, L
AU  - Salama, R
AU  - Elhalaby, E
AU  - Perera, H
AU  - Parsons, C
AU  - Cleeve, S
AU  - Numanoglu, A
AU  - Van As, S
AU  - Sharma, S
AU  - Lakhoo, K
TI  - International Study of the Epidemiology of Paediatric Trauma: PAPSA Research Study
T2  - WORLD JOURNAL OF SURGERY
KW  - INJURY PATTERN
KW  - MORTALITY
KW  - COUNTRIES
KW  - SEVERITY
KW  - OUTCOMES
KW  - CHILDREN
KW  - CARE
AB  - Trauma is a significant cause of morbidity and mortality worldwide. The literature on paediatric trauma epidemiology in low- and middle-income countries (LMICs) is limited. This study aims to gather epidemiological data on paediatric trauma.
   This is a multicentre prospective cohort study of paediatric trauma admissions, over 1 month, from 15 paediatric surgery centres in 11 countries. Epidemiology, mechanism of injury, injuries sustained, management, morbidity and mortality data were recorded. Statistical analysis compared LMICs and high-income countries (HICs).
   There were 1377 paediatric trauma admissions over 31 days; 1295 admissions across ten LMIC centres and 84 admissions across five HIC centres. Median number of admissions per centre was 15 in HICs and 43 in LMICs. Mean age was 7 years, and 62% were boys. Common mechanisms included road traffic accidents (41%), falls (41%) and interpersonal violence (11%). Frequent injuries were lacerations, fractures, head injuries and burns. Intra-abdominal and intra-thoracic injuries accounted for 3 and 2% of injuries. The mechanisms and injuries sustained differed significantly between HICs and LMICs. Median length of stay was 1 day and 19% required an operative intervention; this did not differ significantly between HICs and LMICs. No mortality and morbidity was reported from HICs. In LMICs, in-hospital morbidity was 4.0% and mortality was 0.8%.
   The spectrum of paediatric trauma varies significantly, with different injury mechanisms and patterns in LMICs. Healthcare structure, access to paediatric surgery and trauma prevention strategies may account for these differences. Trauma registries are needed in LMICs for future research and to inform local policy.
AD  - Oxford Univ Hosp NHS Fdn Trust, Dept Paediat Surg, Headley Way, Oxford OX3 9DU, EnglandAD  - St Georges Univ Hosp NHS Fdn Trust, Blackshaw Rd, London SW17 0QT, EnglandAD  - Chittagong Med Coll Hosp, 57 KB Fazlul Kader Rd, Chittagong, BangladeshAD  - Tikur Anbessa Specialized Hosp, Addis Ababa, EthiopiaAD  - Canberra Univ Hosp, Yamba Dr, Canberra, ACT, AustraliaAD  - Ctr Hosp Univ Treichville, Abidjan, Cote IvoireAD  - Ahmadu Bello Univ, Zaria, Kaduna State, NigeriaAD  - Natl Hosp, Abuja, NigeriaAD  - Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Milan, ItalyAD  - Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, TanzaniaAD  - Univ Ilorin, Teaching Hosp, Ilorin, Kwara State, NigeriaAD  - Tanta Univ Hosp, Tanta, EgyptAD  - Royal London Hosp, Whitechapel Rd, London E1 1BB, EnglandAD  - Red Cross War Mem Childrens Hosp, Klipfontein Rd, ZA-7700 Cape Town, South AfricaAD  - All India Inst Med Sci, New Delhi 110029, IndiaC3  - Oxford University Hospitals NHS Foundation TrustC3  - Chittagong Medical CollegeC3  - University Hospital Medical Center at TreichvilleC3  - Ahmadu Bello UniversityC3  - IRCCS Ca Granda Ospedale Maggiore PoliclinicoC3  - Muhimbili University of Health & Allied SciencesC3  - University of IlorinC3  - Egyptian Knowledge Bank (EKB)C3  - Tanta UniversityC3  - Barts Health NHS TrustC3  - Royal London HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
DA  - JUN
PY  - 2018
VL  - 42
IS  - 6
SP  - 1885
EP  - 1894
DO  - 10.1007/s00268-017-4396-6
AN  - WOS:000431425300043
ER  -

TY  - JOUR
AU  - Bychkov, A
AU  - Keelawat, S
AU  - Agarwal, S
AU  - Jain, D
AU  - Jung, CK
AU  - Hong, S
AU  - Lai, CR
AU  - Satoh, S
AU  - Kakudo, K
TI  - Impact of non-invasive follicular thyroid neoplasm with papillary-like nuclear features on the Bethesda system for reporting thyroid cytopathology: a multi-institutional study in five Asian countries
T2  - PATHOLOGY
KW  - Non-invasive follicular thyroid neoplasm with papillary-like nuclear features
KW  - NIFTP
KW  - the Bethesda system for reporting thyroid cytopathology
KW  - fine-needle aspiration (FNA)
KW  - risk of malignancy (ROM)
KW  - thyroid nodules
KW  - Asia
KW  - papillary thyroid carcinoma
KW  - follicular variant of papillary thyroid carcinoma
KW  - NEEDLE-ASPIRATION-CYTOLOGY
KW  - VARIANT
KW  - CARCINOMA
KW  - MALIGNANCY
KW  - NODULES
KW  - PERFORMANCE
KW  - PREVALENCE
KW  - MUTATION
KW  - LESIONS
KW  - CANCER
AB  - Several Western studies showed that the recent introduction of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) significantly decreased risk of malignancy for cytological diagnostic categories. We aimed to determine the impact of NIFTP on risk of malignancy within a cohort of thyroid nodules from Asian countries, and to compare distribution of diagnostic categories between NIFTP and invasive encapsulated follicular variant of papillary thyroid carcinoma (eFV-PTC). Consecutive thyroid fine-needle aspirates from six institutions were retrospectively analysed. Histopathology slides with a diagnosis of eFV-PTC were reviewed and reclassified into invasive eFV-PTC and NIFTP. The risk of malignancy was calculated with and without NIFTP. Of 11,372 thyroid nodules, 2044 had available surgical follow-up. NIFTP was diagnosed in 59 cases, which constituted 2.9% of all excised nodules, and 5.3% of malignant nodules. Preoperative cytological diagnoses for NIFTP were non-diagnostic (10.2%), benign (18.6%), atypia of undetermined significance/follicular lesion of undetermined significance (22.0%), follicular neoplasm/suspicious for follicular neoplasm (FN/SFN) (32.2%), suspicious for malignancy (SM) (11.9%), and malignant (5.1%). The only category which showed a relative reduction in risk of malignancy after reclassification of more than 20%, was FN/SFN (24.4%). There was a significantly higher prevalence of benign cytology in NIFTP (p = 0.04) and SM/malignant in invasive eFV-PTC (p = 0.05). A majority of NIFTP cases were classified in indeterminate categories, which decreased the corresponding risk of malignancy. However, the magnitude of NIFTP impact was much lower than in the Western reports. Asian countries may not experience significant effects of NIFTP reclassification on the practice of thyroid cytopathology.
AD  - Chulalongkorn Univ, Dept Pathol, Fac Med, Bangkok, ThailandAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - Catholic Univ Korea, Dept Hosp Pathol, Coll Med, Seoul, South KoreaAD  - Yonsei Univ, Dept Pathol, Coll Med, Seoul, South KoreaAD  - Taipei Vet Gen Hosp, Dept Pathol, Taipei, TaiwanAD  - Yamashita Thyroid Hosp, Dept Endocrine Surg, Fukuoka, JapanAD  - Kindai Univ, Nara Hosp, Dept Pathol, Fac Med, Nara, JapanC3  - Chulalongkorn UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Catholic University of KoreaC3  - Yonsei UniversityC3  - Yonsei University Health SystemC3  - Taipei Veterans General HospitalC3  - Kindai University (Kinki University)PU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - JUN
PY  - 2018
VL  - 50
IS  - 4
SP  - 411
EP  - 417
DO  - 10.1016/j.pathol.2017.11.088
AN  - WOS:000434474000007
ER  -

TY  - JOUR
AU  - Chatterji, S
AU  - Mallik, S
AU  - Pal, D
AU  - Lahre, D
AU  - Chakraborty, S
AU  - Ghosh, MK
AU  - Naskar, A
AU  - Pandey, R
AU  - Saha, B
TI  - A cross-sectional study on renal involvement among HIV-infected patients attending a tertiary care hospital in Kolkata
T2  - TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
KW  - antiretroviral therapy
KW  - CD4
KW  - estimated glomerular filtration rate
KW  - HIV
KW  - HIVAN
KW  - Tenofovir disoproxyl fumarate
KW  - CHRONIC KIDNEY-DISEASE
KW  - NEPHROPATHY
KW  - NEPHROTOXICITY
KW  - EPIDEMIOLOGY
KW  - PATHOGENESIS
KW  - PROTEINURIA
KW  - GUIDELINES
KW  - MANAGEMENT
AB  - Background and objectives: The HIV-associated renal diseases represent a spectrum. Indian data on this is sparse. This study was undertaken to find out the prevalence and clinicopathological spectrum of renal involvement in HIV among antiretroviral therapy (ART) naive patients (Group 1) and among those on ART (Group 2).
   Methods: Systematic random sampling was undertaken to select 109 patients each from virology outpatient department (VOPD) and ART centre of a tertiary care hospital. They were screened and further investigated if renal involvement was found.
   Results: Renal involvement was present in 25/109 (22.94%) and 15/109 (13.76%) patients of Groups 1 and 2, respectively. Among patients of Groups 1 and 2, 9/24 (37.5%) and 2/13 (15.4%), respectively, had clinically significant proteinuria, but none in the nephrotic range. Statistically significant relationships of renal involvement were observed with CD4 count <100/mu l and with Low BMI. Of the patients of Group 2, 20% of those on a tenofovir-based regimen had renal involvement with tubular changes, while only 4.6% of those on other regimens had renal involvement. This difference was statistically significant (p<0.05; OR=5.25).
   Conclusion: Renal involvement was Less common among those on ART. Low CD4 count and body mass index (BMI) were associated with renal dysfunction. Patients on a tenofovir-based regimen had more renal involvement compared with not on a tenofovir-based regimen.
AD  - Sch Trop Med, Dept Trop Med, Kolkata 700073, IndiaAD  - All India Inst Hyg & Publ Hlth, Dept Epidemiol, Kolkata 700073, IndiaAD  - SSKM Hosp, IPGME & R, Dept Nephrol, Kolkata 700020, IndiaAD  - All India Inst Med Sci, Dept Med, New Delhi 110029, IndiaAD  - Chattisgarh Inst Med Sci, Bilaspur, IndiaC3  - Calcutta School of Tropical Medicine (CSTM)C3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - OXFORD UNIV PRESS
PI  - OXFORD
PA  - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
DA  - JUN
PY  - 2018
VL  - 112
IS  - 6
SP  - 294
EP  - 299
DO  - 10.1093/trstmh/try056
AN  - WOS:000449731200006
ER  -

TY  - JOUR
AU  - Chauhan, S
AU  - Sen, S
AU  - Sharma, A
AU  - Kashyap, S
AU  - Tandon, R
AU  - Bajaj, MS
AU  - Pushker, N
AU  - Vanathi, M
AU  - Chauhan, SS
TI  - p16<SUP>INK4a</SUP> overexpression as a predictor of survival in ocular surface squamous neoplasia
T2  - BRITISH JOURNAL OF OPHTHALMOLOGY
KW  - ocular surface
KW  - TUMOR-SUPPRESSOR GENE
KW  - HUMAN-PAPILLOMAVIRUS
KW  - CELL CARCINOMA
KW  - BREAST-CANCER
KW  - EXPRESSION
KW  - METHYLATION
KW  - P16
KW  - HYPERMETHYLATION
KW  - INACTIVATION
KW  - SENESCENCE
AB  - Aims To evaluate the expression and methylation status of the p16(INK4a) gene in early and advanced American Joint Committee on Cancer (AJCC) stages of ocular surface squamous neoplasia (OSSN) and to correlate its association with clinicopathological features and survival.
   Methods Sixty-four (35 early and 29 advanced AJCC stage) patients with OSSN formed part of this study and were followed up for 36-58 (mean 483.6) months. Immunohistochemical expression of the p16(INK4a) protein and methylation status of the p16(INK4a) gene were determined by methylation-specific PCR.
   Results Overexpression of p16(INK4a) was observed in 18/64 (28%) and hypermethylation in 35/64 (54.7%) OSSN cases. A gradual significant increase in the expression of p16(INK4a) (0%-48%, P=0.03) and decrease in its methylation (75%-16%, P=0.001) was observed with disease progression from early to advanced tumour stage. Overexpression of p16(INK4a) was significantly associated with palpebral location and diffuse growth pattern in both early and advanced T stage. Hypermethylation of p16(INK4a) was significantly associated with history of longer sunlight exposure in both early and advanced T stage of OSSN cases. In advanced T stage, p16(INK4a) overexpression was associated with reduced disease-free survival (P=0.02) and poor prognosis (HR, 0.2; P=0.03).
   Conclusions OSSN patients presenting at an advanced AJCC stage with p16(INK4a) overexpression may require more aggressive treatment. Epigenetic inactivation of the p16(INK4a) gene due to sunlight exposure could be responsible for pathogenesis of OSSN.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Ocular Pathol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Ocular Microbiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Cornea & Ocular Surface Serv, New Delhi, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Ophthalmoplasty Serv, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biochem, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - BMJ PUBLISHING GROUP
PI  - LONDON
PA  - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
DA  - JUN
PY  - 2018
VL  - 102
IS  - 6
SP  - 840
EP  - 847
DO  - 10.1136/bjophthalmol-2017-311276
AN  - WOS:000433231300021
ER  -

TY  - JOUR
AU  - Chawla, R
AU  - Azad, SV
AU  - Takkar, B
AU  - Sharma, A
TI  - Swept source optical coherence tomography-angiography of an infarct of a small intra-neural branch of central retinal artery simulating cilio-retinal artery
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Cilio-retinal artery occlusion
KW  - deep retinal capillary plexus infarct
KW  - intraneural branch retinal artery occlusion
KW  - retinal artery occlusion
AD  - AIIMS, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - JUN
PY  - 2018
VL  - 66
IS  - 6
SP  - 850
EP  - 851
C7  - PMID 29785999
DO  - 10.4103/ijo.IJO_1085_17
AN  - WOS:000433099600023
ER  -

TY  - JOUR
AU  - Desai, MP
AU  - Sharma, R
AU  - Riaz, I
AU  - Sudhanshu, S
AU  - Parikh, R
AU  - Bhatia, V
TI  - Newborn Screening Guidelines for Congenital Hypothyroidism in India: Recommendations of the Indian Society for Pediatric and Adolescent Endocrinology (ISPAE) - Part I: Screening and Confirmation of Diagnosis
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Clinical practice guidelines
KW  - Cord blood
KW  - Dried blood spot
KW  - Newborn thyroid screening
KW  - THYROID-STIMULATING-HORMONE
KW  - LOW-BIRTH-WEIGHT
KW  - NEONATAL-HYPOTHYROIDISM
KW  - GESTATIONAL-AGE
KW  - PRETERM INFANTS
KW  - THYROTROPIN
KW  - THYROXINE
KW  - CHILDREN
KW  - STRATEGIES
KW  - PROGRAM
AB  - The Indian Society for Pediatric and Adolescent Endocrinology has formulated locally relevant Clinical Practice Guidelines for newborn screening, diagnosis and management of primary congenital hypothyroidism (CH). Recommendations: Screening should be done for every newborn using cord blood, or postnatal blood, ideally at 48 to 72 h of age. On this screen sample, neonates with TSH > 20 mIU/L serum units (or > 34 mIU/L for samples taken between 24 to 48 h of age) should be recalled for confirmation. For screen TSH > 40 mIU/L, immediate confirmatory venous T4/FT4 and TSH, and for milder elevation of screen TSH, a second screening TSH at 7 to 10 d of age, should be taken. Preterm and low birth weight infants should undergo screening at 48-72 h postnatal age. Sick babies should be screened at least by 7 d of age. Venous confirmatory TSH >20 mIU/L before age 2 wk and > 10 mIU/L after age 2 wk, with low T4 (<10 mu g/dL) or FT4 (<1.17 ng/dL) indicate primary CH and treatment initiation. Imaging is recommended by radionuclide scintigraphy and ultrasonography after CH is biochemically confirmed but treatment should not be delayed till scans are performed. Levothyroxine is commenced at 10 to 15 mu g/kg in the neonatal period. Serum T4/FT4 is measured at 2 wk and TSH and T4/FT4 at 1 mo, then 2 monthly till 6 mo, 3 monthly from 6 mo-3 y and every 3-6 mo thereafter. Babies with the possibility of transient congenital hypothyroidism should be re-evaluated at age 3 y, to assess the need for lifelong therapy.
AD  - Bai Jerbai Wadia Hosp Children, Inst Child Hlth & Res Ctr, Div Pediat Endocrinol, Bombay, Maharashtra, IndiaAD  - All India Inst Med Sci, Dept Pediat, Div Pediat Endocrinol, Room 3058,Teaching Block, New Delhi 110029, IndiaAD  - SAT Hosp, Govt Med Coll, Dept Pediat, Thiruvananthapuram, Kerala, IndiaAD  - Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrinol, Lucknow, Uttar Pradesh, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUN
PY  - 2018
VL  - 85
IS  - 6
SP  - 440
EP  - 447
DO  - 10.1007/s12098-017-2575-y
AN  - WOS:000432220600008
ER  -

TY  - JOUR
AU  - Dey, P
AU  - Bairagya, HR
AU  - Roy, A
TI  - Putative role of invariant water molecules in the X-ray structures of family G fungal endoxylanases
T2  - JOURNAL OF BIOSCIENCES
KW  - Conserved invariant water molecules
KW  - family G xylanases
KW  - structural bioinformatics
KW  - 'W' shaped geometry
KW  - AMINO-ACID-SEQUENCE
KW  - THERMOPHILIC XYLANASE
KW  - WEB SERVER
KW  - ION-PAIRS
KW  - DYNAMICS
KW  - INSIGHT
KW  - CLASSIFICATION
KW  - RECOGNITION
KW  - HYDROLASES
KW  - RESOLUTION
AB  - Fungal endo-1,4-beta-xylanases (EC3.2.1.8), because of their widespread industrial applications have become one of the most researched industrial enzymes in recent times. Despite its significance, the role of conserved water molecules in the catalytic activities and structural stability of these enzymes from the fungi have not been studied to a great extent. Our computational structural bioinformatics and MD simulation studies have identified the existence of seven invariant water molecules (IW1-IW7) and reveals the stereo-chemical and electronic consequences of those conserved water molecules in G-xylanase enzyme from eight different fungi. The buried water molecules IW1 and IW2 may have decisive roles in catalysis and may also be associated with ligand binding process of the enzyme, whereas IW3, IW4, IW5, IW6 and IW7 may be involved in stabilizing the important (H144/R145) residues through H-bonds. Possibly they are also involved in the stabilization of secondary structures and anchor to maintain its stereo-chemical architecture. Moreover, a distorted 'W' shaped signature geometry that is observed at the surface of the enzyme can be used to identify the hydrophilic centers in the electron density map of other unknown members of the family G xylanases. The results from this computational investigation could be of interest to a large number of researchers working with the xylanases.
AD  - Visva Bharati Univ, Dept Biotechnol, Santini Ketan 731235, W Bengal, IndiaAD  - AIIMS, Dept Biophys, New Delhi 110029, IndiaC3  - Visva Bharati UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - INDIAN ACAD SCIENCES
PI  - BANGALORE
PA  - C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
DA  - JUN
PY  - 2018
VL  - 43
IS  - 2
SP  - 339
EP  - 349
DO  - 10.1007/s12038-018-9752-7
AN  - WOS:000431998100014
ER  -

TY  - JOUR
AU  - Drewes, AM
AU  - Campbell, CM
AU  - Ceyhan, GO
AU  - Delhaye, M
AU  - Garg, PK
AU  - van Goor, H
AU  - Laquente, B
AU  - Morlion, B
AU  - Olesen, SS
AU  - Singh, VK
AU  - Sjogren, P
AU  - Szigethy, E
AU  - Windsor, JA
AU  - Salvetti, MG
AU  - Talukdar, R
TI  - Pain in pancreatic ductal adenocarcinoma: A multidisciplinary, International guideline for optimized management
T2  - PANCREATOLOGY
KW  - Pain management
KW  - Pancreatic ductal adenocarcinoma
KW  - Analgesics
KW  - Neurolysis
KW  - Supportive care
KW  - Surgery
KW  - Endoscopy
KW  - Radiotherapy
KW  - CELIAC PLEXUS NEUROLYSIS
KW  - QUALITY-OF-LIFE
KW  - CLINICAL-PRACTICE GUIDELINE
KW  - CANCER PAIN
KW  - THORACOSCOPIC SPLANCHNICECTOMY
KW  - PALLIATIVE CARE
KW  - DOUBLE-BLIND
KW  - SUPPORTIVE CARE
KW  - I-125 SEEDS
KW  - BLOCK
AB  - Abdominal pain is an important symptom in most patients with pancreatic ductal adenocarcinoma (PDAC). Adequate control of pain is often unsatisfactory due to limited treatment options and significant variation in local practice, emphasizing the need for a multidisciplinary approach. This review contends that improvement in the management of PDAC pain will result from a synthesis of best practice and evidence around the world in a multidisciplinary way. To improve clinical utility and evaluation, the evidence was rated according to the GRADE guidelines by a group of international experts. An algorithm is presented, which brings together all currently available treatment options. Pain is best treated early on with analgesics with most patients requiring opioids, but neurolytic procedures are often required later in the disease course. Celiac plexus neurolysis offers medium term relief in a substantial number of patients, but other procedures such as splanchnicectomy are also available. Palliative chemotherapy also provides pain relief as a collateral benefit. It is stressed that the assessment of pain must take into account the broader context of other physical and psychological symptoms. Adjunctive treatments for pain, depression and anxiety as well as radiotherapy, endoscopic therapy and neuromodulation may be required in selected patients. There are few comparative studies to help define which combination and order of these treatment options should be applied. New pain therapies are emerging and could for example target neural transmitters. However, until better methods are available, management of pain should be individualized in a multidisciplinary setting to ensure optimal care. (C) 2018 IAP and EPC. Published by Elsevier B.V.
AD  - Aalborg Univ Hosp, Dept Gastroenterol, Ctr Pancreat Dis, Aalborg, DenmarkAD  - Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USAAD  - Tech Univ Munich, Klinikum Rechts Isar, Dept Surg, Munich, GermanyAD  - Erasme Univ Hosp, Dept Gastroenterol, Brussels, BelgiumAD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaAD  - Radboud Univ Nijmegen, Med Ctr, Dept Surg, Nijmegen, NetherlandsAD  - Catalan Inst Oncol, Dept Med Oncol, Barcelona, SpainAD  - Univ Hosp Leuven, Ctr Algol & Pain Management, Pellenberg, BelgiumAD  - Johns Hopkins Univ Hosp, Dept Gastroenterol & Hepatol, Baltimore, MD 21205 USAAD  - Copenhagen Univ Hosp, Sect Palliat Med, Copenhagen, DenmarkAD  - Univ Pittsburgh, Div Gastroenterol, Pittsburgh, PA USAAD  - UPMC, Pittsburgh, PA USAAD  - Univ Auckland, Dept Surg, Fac Med & Hlth Sci, Auckland, New ZealandAD  - Univ Sao Paulo, Sch Nursing, Med Surg Dept, Sao Paulo, BrazilAD  - Asian Inst Gastroenterol, Dept Gastroenterol, Hyderabad, IndiaC3  - Aalborg UniversityC3  - Aalborg University HospitalC3  - Johns Hopkins UniversityC3  - Technical University of MunichC3  - Universite Libre de BruxellesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Radboud University NijmegenC3  - Institut Catala d'OncologiaC3  - KU LeuvenC3  - University Hospital LeuvenC3  - Johns Hopkins UniversityC3  - Johns Hopkins MedicineC3  - University of CopenhagenC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - University of AucklandC3  - Universidade de Sao PauloPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUN
PY  - 2018
VL  - 18
IS  - 4
SP  - 446
EP  - 457
DO  - 10.1016/j.pan.2018.04.008
AN  - WOS:000434689500016
ER  -

TY  - JOUR
AU  - First, MB
AU  - Rebello, TJ
AU  - Keeley, JW
AU  - Bhargava, R
AU  - Dai, YF
AU  - Kulygina, M
AU  - Matsumoto, C
AU  - Robles, R
AU  - Stona, AC
AU  - Reed, GM
TI  - Do mental health professionals use diagnostic classifications the way we think they do? A global survey
T2  - WORLD PSYCHIATRY
KW  - Classifications of mental disorders
KW  - ICD-11
KW  - ICD-10
KW  - DSM-5
KW  - Global Clinical Practice Network
KW  - ordinary clinical practice
KW  - psychiatric diagnosis
KW  - use for administrative purposes
KW  - clinical utility
KW  - residual diagnostic categories
KW  - DSM-III-R
KW  - BEHAVIORAL-DISORDERS
KW  - PSYCHIATRISTS VIEWS
KW  - CLINICAL UTILITY
KW  - UNITED-STATES
KW  - GUIDELINES
KW  - ATTITUDES
KW  - SYSTEMS
KW  - ICD-10
AB  - We report on a global survey of diagnosing mental health professionals, primarily psychiatrists, conducted as a part of the development of the ICD-11 mental and behavioural disorders classification. The survey assessed these professionals' use of various components of the ICD-10 and the DSM, their attitudes concerning the utility of these systems, and usage of residual (i.e., other or unspecified) categories. In previous surveys, most mental health professionals reported they often use a formal classification system in everyday clinical work, but very little is known about precisely how they are using those systems. For example, it has been suggested that most clinicians employ only the diagnostic labels or codes from the ICD-10 in order to meet administrative requirements. The present survey was conducted with clinicians who were members of the Global Clinical Practice Network (GCPN), established by the World Health Organization as a tool for global participation in ICD-11 field studies. A total of 1,764 GCPN members from 92 countries completed the survey, with 1,335 answering the questions with reference to the ICD-10 and 429 to the DSM (DSM-IV, DSM-IV-TR or DSM-5). The most frequent reported use of the classification systems was for administrative or billing purposes, with 68.1% reporting often or routinely using them for that purpose. A bit more than half (57.4%) of respondents reported often or routinely going through diagnostic guidelines or criteria systematically to determine whether they apply to individual patients. Although ICD-10 users were more likely than DSM-5 users to utilize the classification for administrative purposes, other differences were either slight or not significant. Both classifications were rated to be most useful for assigning a diagnosis, communicating with other health care professionals and teaching, and least useful for treatment selection and determining prognosis. ICD-10 was rated more useful than DSM-5 for administrative purposes. A majority of clinicians reported using residual categories at least sometimes, with around 12% of ICD-10 users and 19% of DSM users employing them often or routinely, most commonly for clinical presentations that do not conform to a specific diagnostic category or when there is insufficient information to make a more specific diagnosis. These results provide the most comprehensive available information about the use of diagnostic classifications of mental disorders in ordinary clinical practice.
AD  - Columbia Univ, Dept Psychiat, Coll Phys & Surg, New York, NY 10032 USAAD  - New York State Psychiat Inst & Hosp, New York, NY 10032 USAAD  - Columbia Univ, Coll Phys & Surg, Global Mental Hlth Program, New York, NY USAAD  - Res Fdn Mental Hyg, New York, NY USAAD  - Virginia Commonwealth Univ, Dept Psychol, Box 2018, Richmond, VA 23284 USAAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai, Peoples R ChinaAD  - Moscow Res Inst Psychiat, Natl Med Res Ctr Psychiat & Narcol, Moscow, RussiaAD  - Japanese Soc Psychiat & Neurol, Tokyo, JapanAD  - Natl Inst Psychiat Ramon de la Fuente Muniz, Mexico City, DF, MexicoAD  - Minist Solidar & Hlth, Paris, FranceAD  - WHO, Geneva, SwitzerlandC3  - Columbia UniversityC3  - New York State Psychiatry InstituteC3  - Columbia UniversityC3  - Virginia Commonwealth UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Shanghai Jiao Tong UniversityC3  - Instituto Nacional de Psiquiatria Ramon de la Fuente MunizC3  - World Health OrganizationPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUN
PY  - 2018
VL  - 17
IS  - 2
SP  - 187
EP  - 195
DO  - 10.1002/wps.20525
AN  - WOS:000434185800019
ER  -

TY  - JOUR
AU  - George, J
AU  - Sankaramangalam, KP
AU  - Sinha, A
AU  - Hari, P
AU  - Dinda, AK
AU  - Bagga, A
TI  - Lupus Nephritis in Indian Children: Flares and Refractory Illness
T2  - INDIAN PEDIATRICS
KW  - Glomerulonephritis
KW  - Prognosis
KW  - Systemic lupus erythematosus
KW  - Treatment
KW  - CHILDHOOD-ONSET
KW  - CYCLOPHOSPHAMIDE
KW  - ERYTHEMATOSUS
KW  - EXPERIENCE
KW  - FEATURES
KW  - ADULT
AB  - To evaluate the incidence of flares and treatment resistance in children with lupus nephritis and their association with renal outcomes.
   We retrospectively reviewed the case records of 34 children treated for lupus nephritis (Class II-IV) at a single center. Patients were followed for a minimum of five years to evaluate treatment response, onset of flares, and renal survival. Regression analyses were performed to identify the factors associated with treatment refractoriness, incidence of flares and renal survival.
   The incidence of flares was 0.16 episodes/person/year. Eight patients (23.5%) were refractory to treatment. The five-year renal survival was 79%. Multiple episodes of flares (P=0.028) and therapy refractoriness (P=0.003) were associated with poor renal survival.
   Prevention and aggressive management of renal flares is expected to prevent progression to end stage renal disease in lupus nephritis.
AD  - All India Inst Med Sci, Dept Pediat, Div Nephrol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUN
PY  - 2018
VL  - 55
IS  - 6
SP  - 478
EP  - 481
DO  - 10.1007/s13312-018-1337-x
AN  - WOS:000439992700005
ER  -

TY  - JOUR
AU  - Guleria, P
AU  - Husain, N
AU  - Shukla, S
AU  - Kumar, S
AU  - Parshad, R
AU  - Jain, D
TI  - PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature
T2  - ANNALS OF DIAGNOSTIC PATHOLOGY
KW  - Thymoma
KW  - PD-L1 expression
KW  - Immunohistochemistry
KW  - Immunotherapy
KW  - SP263
KW  - LIGAND 1 EXPRESSION
KW  - ANTI-PD-L1 ANTIBODY
KW  - MYASTHENIA-GRAVIS
KW  - TOXICITIES
KW  - MPDL3280A
KW  - MELANOMA
KW  - THERAPY
KW  - PATIENT
AB  - Background and aims: Programmed death ligand 1 (PD-L1), an immune check point inhibitor, is known to be expressed in several malignancies and is being considered as a prognostic factor and a potential immunotherapeutic target. The aim of this study was to characterize PD-L1 expression in thymomas and to determine correlation with clinicopathological features and previously published studies in the literature.
   Methods: Tissue microarrays were prepared from selected blocks of thymomas and immunohistochemistry (IHC) for PD-L1 was performed. Cases were considered as PD-L1 positive or negative depending on whether the percentage of stained thymic epithelial cells were < 25 or > 25%. Results were compared clinically and with previously published studies using Google and Pubmed search engines.
   Results: Of 84 cases of thymoma, 69 (82.1%) revealed PD-Ll positivity in > 25% cells. 94.23% of type B thy mama subtypes (B1/B2/B3) were PD-L1 positive (P < 0.001). There was no correlation of PD-L1 with age, gender, myasthenia gravis, the tumor size or stage of disease. Nine studies were available in the literature; most of which showed PD-L1 expression in higher stage and B subtype however percentage positivity varied from 53.7% to over 90%.
   Conclusions: PD-L1 expression is frequent in type B (B1/B2/B3) thymomas. It can be easily evaluated by IHC even on small biopsies in unresectable cases, thereby enabling improved clinical evaluation as well as prognostic stratification of patients. It will serve as a potential indicator for benefit from anti-PD-L1 antibody immunotherapy in thymomas.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Surg Oncol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Surg, New Delhi 110029, IndiaAD  - Dr Ram Manohar Lohia Inst Med Sci, Dept Pathol, Lucknow, Uttar Pradesh, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - JUN
PY  - 2018
VL  - 34
SP  - 135
EP  - 141
DO  - 10.1016/j.anndiagpath.2018.03.012
AN  - WOS:000436900200025
ER  -

TY  - JOUR
AU  - Gupta, S
AU  - Jangra, RS
AU  - Ashique, KT
AU  - Gupta, S
TI  - Autologous Biological Dressing for the Recipient Area in Cellular Grafting of Vitiligo
T2  - DERMATOLOGIC SURGERY
AD  - Maharishi Markandeshwar Inst Med Sci & Res, Dept Dermatol & Venereol, Ambala, IndiaAD  - KIMS Alshifa Super Special Hosp, Dept Dermatol, MEDCOSMETOL, Perinthalmanna, Kerala, IndiaAD  - All India Inst Med Sci, Dept Dermatol, New Delhi, IndiaC3  - Maharishi Markandeshwar UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - JUN
PY  - 2018
VL  - 44
IS  - 6
SP  - 895
EP  - 896
DO  - 10.1097/DSS.0000000000001205
AN  - WOS:000440272800026
ER  -

TY  - JOUR
AU  - Jayaraj, P
AU  - Sen, S
AU  - Rangarajan, S
AU  - Ray, N
AU  - Vasu, K
AU  - Singh, VK
AU  - Phartyal, R
AU  - Yadav, S
AU  - Verma, A
TI  - Immunohistochemical evaluation of stress-responsive protein sestrin2 and its correlation with p53 mutational status in eyelid sebaceous gland carcinoma
T2  - BRITISH JOURNAL OF OPHTHALMOLOGY
KW  - pathology
KW  - eye lids
KW  - neoplasia
KW  - TP53 MUTATIONS
KW  - HIGH-FREQUENCY
KW  - SKIN-CANCER
KW  - EXPRESSION
KW  - SUNLIGHT
KW  - PATTERNS
KW  - DATABASE
KW  - GENE
AB  - Background p53 is a stress-activated tumour suppressor gene, and its mutation has been associated with solid tumours including non-melanoma skin cancers. Sestrin2 expression is associated with DNA damage and oxidative stress and has been described as a downstream target of p53 network. However, its role in sebaceous gland carcinoma (SGC) remains unexplored.
   Objectives To determine the role of p53 and its downstream target gene sestrin2 expression and p53 gene mutation status in SGC.
   Methods Twenty cases of eyelid SGC tumour and circulating cell-free DNA (ccfDNA) were subjected to mutational analysis of p53 gene. p53 and sesrin2 expression was evaluated by immunohistochemistry. Results were correlated with the clinicopathological features of eyelid SGC.
   Results p53 gene mutations was detected in 25% of the SGC cases. A C>Ttransition was identified in exon 6 in a single patient in both tumour and ccfDNA. A G>Ttransversion leading to amino acid change D259Y was seen in four patients. A splice site mutation affected a single case in exon 6. p53 expression was observed in 55% SGC. Loss of sestrin2 in 55% SGC cases correlated with poor tumour differentiation (P=0.0001), upper eyelid involvement (P=0.004), p53 mutation (P=0.039) and with mutant p53 expression (P=0.0001).
   Conclusion Sestrin2 expression was found to be significantly reduced in p53 mutated SGC cases and in cases with strong p53 nuclear immunopositivity, suggesting that loss of sestrin2 may be of biological significance in the development of SGC and as a key downstream component of p53 tumour suppression network in eyelid SGC.
AD  - Univ Delhi, Sri Venkateswara Coll, Dept Zool, New Delhi 110021, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Ocular Pathol, New Delhi, IndiaAD  - Univ Delhi, Sri Venkateswara Coll, Dept Biochem, New Delhi, IndiaAD  - Univ Delhi, Sri Venkateswara Coll, Dept Biol Sci, New Delhi, IndiaC3  - University of DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - University of DelhiC3  - University of DelhiPU  - BMJ PUBLISHING GROUP
PI  - LONDON
PA  - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
DA  - JUN
PY  - 2018
VL  - 102
IS  - 6
SP  - 848
EP  - 854
DO  - 10.1136/bjophthalmol-2017-311283
AN  - WOS:000433231300022
ER  -

TY  - JOUR
AU  - Jose, A
AU  - Nagori, SA
AU  - Agarwal, B
AU  - Roychoudhury, A
TI  - Closed technique for naso-orbito-ethmoid fracture management: Technical note
T2  - JOURNAL OF STOMATOLOGY ORAL AND MAXILLOFACIAL SURGERY
KW  - Medial canthal tendon
KW  - Naso-orbito-ethmoid fractures
KW  - MEDIAL CANTHOPEXY
AB  - Trauma to the naso-orbito-ethmoid region invariably results in detachment of medial canthal tendon. The shape of medial canthus is of important esthetic and functional concern. Accurate reposition of the medial canthus is important to achieve normal form and function. The various available techniques advocate open approach leaving an obvious scar in the esthetically prominent region. This technique intends to address these fractures through a closed approach with the possibility to make finer adjustments as and when required. We report the experience of treating 4 naso-orbito-ethmoid fractures with a new innovative technique with predictable results. (C) 2017 Elsevier Masson SAS. All rights reserved.
AD  - 56 APO, 15 Corps Dent Unit, New Delhi, IndiaAD  - 56 APO, 303 Field Hosp, New Delhi, IndiaAD  - All India Inst Med Sci, CDER, Dept Oral & Maxillofacial Surg, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUN
PY  - 2018
VL  - 119
IS  - 3
SP  - 242
EP  - 244
DO  - 10.1016/j.jormas.2017.12.004
AN  - WOS:000438172700019
ER  -

TY  - JOUR
AU  - Kalra, S
AU  - Priya, G
AU  - Gupta, Y
TI  - Glucocrinology
T2  - JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION
KW  - Adrenal
KW  - Diabetes
KW  - Endocrinology
KW  - Gonads
KW  - Hormones
KW  - Metformin
KW  - Pituitary
KW  - Thyroid
AB  - Diabetes is a complex syndrome, with multiple pathophysiologic connections. While the vasculometabolic aspects are certainly important, current discourse tends to ignore the endocrine facets of diabetes. We propose the term 'glucocrinology', to define the study of medicine that relates to the relationship of glycaemia with the endocrine system. Glucocrinology includes in its ambit, endocrinopathies that may cause secondary diabetes, coexist with metabolic syndrome, precipitate hypoglycaemia, lead to refractory hyperglycaemia, or simply coexist with diabetes. The concept also covers the role of endocrinotropic drugs in unmasking latent diabetes, worsening hyperglycaemia, or managing diabetes in specific situations, as well as antidiabetic drugs in modulating endocrine disease. Highlighting glucocrinology as a distinct field will enhance the quality of diabetes care, by making it more holistic, comprehensive and clinically oriented. This article will be followed by gland-specific reviews of glucocrinology.
AD  - Bharti Hosp, Dept Endocrinol, Karnal, Haryana, IndiaAD  - Fortis Hosp, Dept Endocrinol, Mohali, IndiaAD  - AIIMS, Dept Endocrinol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - PAKISTAN MEDICAL ASSOC
PI  - KARACHI
PA  - PMA HOUSE, AGA KHAN III RD, KARACHI, 00000, PAKISTAN
DA  - JUN
PY  - 2018
VL  - 68
IS  - 6
SP  - 963
EP  - 965
AN  - WOS:000432457500031
ER  -

TY  - JOUR
AU  - Kapil, R
AU  - Gupta, A
TI  - Anemia, Iron Deficiency and Iodine Deficiency among Nepalese School Children: Correspondence
T2  - INDIAN JOURNAL OF PEDIATRICS
AD  - Jawaharlal Nehru Med Coll, Dept Pathol, Belgaum, Karnataka, IndiaAD  - All India Inst Med Sci, Dept Human Nutr, New Delhi, IndiaC3  - K.L.E. Academy of Higher Education & ResearchC3  - Jawaharlal Nehru Medical College, BelgaumC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUN
PY  - 2018
VL  - 85
IS  - 6
SP  - 487
EP  - 487
DO  - 10.1007/s12098-017-2581-0
AN  - WOS:000432220600016
ER  -

TY  - JOUR
AU  - Kaur, M
AU  - Dass, C
TI  - Anaesthetic challenges of Ellis-van Creveld syndrome
T2  - JOURNAL OF CLINICAL ANESTHESIA
AD  - All India Inst Med Sci, Dept Anaesthesia & Intens Care, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - JUN
PY  - 2018
VL  - 47
SP  - 60
EP  - 61
DO  - 10.1016/j.jclinane.2018.03.016
AN  - WOS:000432233000019
ER  -

TY  - JOUR
AU  - Kaushal, P
AU  - Kumar, P
AU  - Mehra, RD
AU  - Dhar, P
TI  - Dendritic processes as targets for arsenic induced neurotoxicity: Protective role of curcumin
T2  - JOURNAL OF THE ANATOMICAL SOCIETY OF INDIA
KW  - Microtubule associated protein
KW  - Sodium arsenite
KW  - Cerebellum
KW  - Molecular layer thickness
KW  - Oxidative stress
KW  - Antioxidant
KW  - MICROTUBULE-ASSOCIATED PROTEINS
KW  - SODIUM ARSENITE
KW  - RAT CEREBELLUM
KW  - CELLS
KW  - BRAIN
KW  - MAP2
KW  - ACID
AB  - Introduction: Microtubule associated protein2 (MAP2) plays a vital role in morphological stabilization and plasticity of the neuronal dendritic processes. Any alteration in the expression of this protein following exposure to environmental contaminants such as arsenic (iAs) could induce functional deficits in neurons. In India, over 1.5 million people are exposed to iAs with over 200,000 reported cases of arsenicosis. Oxidative stress has been identified as one of the key factors underlying iAs induced toxicity. Hence, the need of the hour is to identify cost effective and safe therapeutic approaches for combating iAs induced adverse effects. The present study aimed at determining the ameliorative potential of Curcumin (Cur) supplementation on dendritic profile of cerebellar Purkinje cells in rats subjected to iAs exposure during postnatal period.
   Methods: Mother reared rats were divided into control and experimental groups (receiving NaAsO2 alone or along with Cur by intraperitoneal route from postnatal day (PND) 1-21. Cerebellar tissue obtained from perfusion fixed animals was processed for Cresyl Violet staining and immunohistochemical localization of MAP2.
   Results: An overall decrease in molecular layer thickness (MLT) of cerebellar cortex along with disrupted morphology of Purkinje dendritic processes was evident in iAs alone treated animals as compared to controls and Cur co-treated animals. Also, decrease in MAP2 immunostained area (%) was noted in the ML of iAs alone treated animals.
   Discussion: Preliminary observations suggest modulating effect of Cur on MAP2 expression and dendritic morphology of cerebellar Purkinje cells in rats following NaAsO2 exposure. (C) 2018 Anatomical Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd. All rights reserved.
AD  - All India Inst Med Sci, Dept Anat, Room 1003, New Delhi, IndiaAD  - Jamia Hamdard, Hamdard Inst Med Sci, Dept Anat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jamia Hamdard UniversityPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUN
PY  - 2018
VL  - 67
IS  - 1
SP  - 1
EP  - 5
DO  - 10.1016/j.jasi.2018.05.001
AN  - WOS:000433987700001
ER  -

TY  - JOUR
AU  - Kedia, S
AU  - Madhusudhan, KS
AU  - Sharma, R
AU  - Bopanna, S
AU  - Yadav, DP
AU  - Goyal, S
AU  - Jain, S
AU  - Das, P
AU  - Dattagupta, S
AU  - Makharia, G
AU  - Ahuja, V
TI  - Combination of increased visceral fat and long segment involvement: Development and validation of an updated imaging marker for differentiating Crohn's disease from intestinal tuberculosis
T2  - JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
KW  - computed tomography
KW  - Crohn's disease
KW  - intestinal tuberculosis
KW  - lymph nodes
KW  - visceral fat
KW  - INFLAMMATORY-BOWEL-DISEASE
KW  - PREDICTIVE MODEL
KW  - ENTEROGRAPHY
KW  - DIAGNOSIS
KW  - INDIA
KW  - MANIFESTATIONS
KW  - METAANALYSIS
KW  - ACCURACY
KW  - BIOPSY
AB  - Background and AimComputed tomographic (CT) features (long segment, ileocaecal area involvement, and lymph nodes>1cm) have demonstrated good specificity but poor sensitivity, while visceral to subcutaneous fat ratio on CT (VF/SC>0.63) has moderate sensitivity and specificity in differentiating Crohn's disease (CD) and intestinal tuberculosis (ITB). This study aims to develop and validate an updated model incorporating CT features and VF/SC to improve the diagnostic accuracy of imaging in differentiating CD/ITB.
   MethodsComputed tomographic features and VF/SC were documented in two cohorts (development [n=59, follow-up: January 2012 to November 2014] and validation [n=69, follow-up: December 2014 to December 2015]) of CD/ITB patients diagnosed by standard criteria. Patients with normal CT were excluded. Features significantly different between CD/ITB were incorporated into a model.
   ResultsIn both the cohorts, necrotic lymph nodes were exclusive for ITB (23.1% vs 0% and 43.3% vs 0%), while long segment involvement (57.6% vs 7.7%, P<0.001, and 52.6% vs 16.1%, P<0.001) and VF/SC ratio>0.63 (72.7% vs 19.2%, P<0.001, and 81.6% vs 25.8%, P<0.001) were significantly more common in CD. A risk score of 2, based upon long segment involvement and VF/SC ratio>0.63, had an excellent specificity of 100% and 100% and sensitivity of 54% and 50% for CD in development and validation cohorts, respectively. Based upon these features, in 43% patients with the diagnostic dilemma of CD/ITB, a definite diagnosis based only on imaging could be made.
   ConclusionNecrotic lymph nodes are exclusive for ITB, and the combination of long segment involvement and VF/SC ratio>0.63 is exclusive for CD, and these features can make a definite diagnosis in 43% patients with a CD/ITB dilemma.
AD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUN
PY  - 2018
VL  - 33
IS  - 6
SP  - 1234
EP  - 1241
DO  - 10.1111/jgh.14065
AN  - WOS:000433581300015
ER  -

TY  - JOUR
AU  - Khanna, G
AU  - Ghosh, S
AU  - Barwad, A
AU  - Yadav, R
AU  - Das, P
TI  - Mucosal Schwann cell hamartoma of gall bladder: a novel observation
T2  - PATHOLOGY
KW  - GALLBLADDER
AD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUN
PY  - 2018
VL  - 50
IS  - 4
SP  - 480
EP  - 482
DO  - 10.1016/j.pathol.2017.11.095
AN  - WOS:000434474000025
ER  -

TY  - JOUR
AU  - Khanna, P
AU  - Saini, K
AU  - Sinha, R
AU  - Nisa, N
AU  - Kumar, S
AU  - Maitra, S
TI  - Correlation between duration of preoperative fasting and emergence delirium in pediatric patients undergoing ophthalmic examination under anesthesia: A prospective observational study
T2  - PEDIATRIC ANESTHESIA
KW  - emergence delirium
KW  - pediatric
KW  - preoperative fasting
KW  - sevoflurane
AB  - BackgroundPreoperative fasting in children can cause anxiety, which may ultimately lead to postoperative emergence delirium. However, no data are available whether duration of preoperative fasting correlates with postoperative emergence delirium.
   AimsThe aim of this study was to identify if there is any correlation between the duration of preoperative fasting and emergence delirium in children undergoing ophthalmic examination under anesthesia.
   MethodsIn this prospective observational study, 100 children between the age group 2-6years of American Society of Anesthesiologists physical status I or II, scheduled for examination of the eye under general anesthesia with sevoflurane were recruited. Data regarding preoperative fasting was recorded and presence of emergence delirium was assessed by the Pediatric Anesthesia Emergence Delirium (PAED) scale at 5minute interval till 30minutes from the time of leaving the operation theater. No premedication was used in any patients but parental presence was allowed in all of them.
   ResultsMean (standard deviation) duration of fasting to clear liquid was 6.3 (1.7) hrs. Twenty-four children (24%) had at least 1 recorded PAED score >10 at any time point in the postoperative period. PAED scores at 15 and 25minutes were significantly correlated with duration of fasting (r(2) [95% CI]=.24 [0.04, 0.41], P=.02, Pearsons's correlation and r(2) [95% CI]=.23 [0.04, 0.41], P=.02, Pearsons's correlation, respectively). No correlation has been found between duration of fasting and blood glucose level (r(2) [95% CI]=-.05 [-0.24, 0.15], P=.65, Pearsons's correlation) between fasting blood glucose and PAED score at any time point.
   ConclusionIncreased preoperative fasting duration may be a risk factor for postoperative emergence delirium in children undergoing ophthalmic examination under general anesthesia.
AD  - All India Inst Med Sci, Dept Anaesthesiol Pain Med & Crit Care, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUN
PY  - 2018
VL  - 28
IS  - 6
SP  - 547
EP  - 551
DO  - 10.1111/pan.13381
AN  - WOS:000434418900008
ER  -

TY  - JOUR
AU  - Khullar, B
AU  - Balyan, R
AU  - Oswal, N
AU  - Jain, N
AU  - Sharma, A
AU  - Abdin, MZ
AU  - Bagga, A
AU  - Bhatnagar, S
AU  - Wadhwa, N
AU  - Natchu, UCM
AU  - George, A
AU  - Rath, S
AU  - Bal, V
AU  - Sopory, S
TI  - Interaction of CD80 with Neph1: a potential mechanism of podocyte injury
T2  - CLINICAL AND EXPERIMENTAL NEPHROLOGY
KW  - CD80
KW  - Podocytes
KW  - TNF alpha
KW  - Neph1
KW  - Lipopolysaccharide
KW  - Minimal change disease
KW  - MINIMAL-CHANGE DISEASE
KW  - PROTEINURIC KIDNEY-DISEASE
KW  - NEPHROTIC-SYNDROME
KW  - URINARY CD80
KW  - GLOMERULAR PODOCYTE
KW  - ACTIN CYTOSKELETON
KW  - EXPRESSION
KW  - MICE
KW  - B7-1
KW  - REORGANIZATION
AB  - The induction of CD80 on podocytes has been shown in animal models of podocyte injury and in certain cases of nephrotic syndrome. In a lipopolysaccharide (LPS)-induced mouse model of albuminuria, we have recently shown a signalling axis of LPS-myeloid cell activation-TNF alpha production-podocyte CD80 induction-albuminuria. Therefore, in this report, we investigated the cellular and molecular consequences of TNF alpha addition and CD80 expression on cultured podocytes.
   A murine podocyte cell line was used for TNF alpha treatment and for over-expressing CD80. Expression and localization of various podocyte proteins was analysed by reverse transcriptase-polymerase chain reaction, western blotting and immunofluorescence. HEK293 cells were used to biochemically characterize interactions.
   Podocytes treated with LPS in vitro did not cause CD80 upregulation but TNF alpha treatment was associated with an increase in CD80 levels, actin derangement and poor wound healing. Podocytes stably expressing CD80 showed actin derangement and co-localization with Neph1. CD80 and Neph1 interaction was confirmed by pull down assays of CD80 and Neph1 transfected in HEK293 cells.
   Addition of TNF alpha to podocytes causes CD80 upregulation, actin reorganization and podocyte injury. Overexpressed CD80 and Neph1 interact via their extracellular domain. This interaction implies a mechanism of slit diaphragm disruption and possible use of small molecules that disrupt CD80-Neph1 interaction as a potential for treatment of nephrotic syndrome associated with CD80 upregulation.
AD  - NCR Biotech Sci Cluster, Pediat Biol Ctr, Translat Hlth Sci & Technol Inst, 3rd Milestone,Faridabad Gurgaon Expressway, Faridabad 121001, IndiaAD  - Natl Inst Immunol, New Delhi, IndiaAD  - Jamia Hamdard, Fac Sci, Dept Biotechnol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Paediat, Div Paediat Nephrol, New Delhi, IndiaC3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)C3  - Department of Biotechnology (DBT) IndiaC3  - National Institute of Immunology (NII)C3  - Jamia Hamdard UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - JUN
PY  - 2018
VL  - 22
IS  - 3
SP  - 508
EP  - 516
DO  - 10.1007/s10157-017-1489-3
AN  - WOS:000432518900003
ER  -

TY  - JOUR
AU  - Kokkayil, P
AU  - Agarwal, R
AU  - Mohapatra, S
AU  - Bakhshi, S
AU  - Das, B
AU  - Sood, S
AU  - Dhawan, B
AU  - Kapil, A
TI  - Bacterial profile and antibiogram of blood stream infections in febrile neutropenic patients with haematological malignancies
T2  - JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
KW  - bloodstream infection
KW  - Klebsiella pneumoniae
KW  - antibiotic resistance
KW  - febrile neutropenia
KW  - haematological malignancy
KW  - RISK-FACTORS
KW  - RESISTANCE
KW  - PREVALENCE
KW  - BACTEREMIA
KW  - CHILDREN
KW  - THERAPY
KW  - CANCER
AB  - Introduction: Studies have shown a shift in the prevalence from Gram-positive to Gram-negative bacteraemia in patients with haematological malignancies who develop febrile neutropenia. There are also reports on the spread of drug resistant bacteria among these patients. Information about locally prevalent bacteria and their resistance is important to guide empirical therapy. The aim of this study was to characterise the bacterial spectrum and antibiotic resistance pattern of bacteraemia in neutropenic patients with haematological malignancies
   Methodology: In this retrospective study, patients admitted to Haematology and Oncology units over a period of 6 months with laboratory-confirmed positive blood cultures were enrolled. Information regarding demographic profile, clinical features, and microbiological profile were recorded. Standard procedures were applied to identify the isolates and their resistance patterns. The data collected was analysed statistically.
   Results: 56 isolates from 53 patients were isolated of which majority were gram negative bacilli (GNB; n = 52 or 93%). Klebsiella pneumoniae (43%, n = 24) was the most frequently isolated bacteria followed by Enterobacter sp (20%, n = 11) and Escherichia coli (12%, n = 7). All isolates were susceptible to colistin. Susceptibility to cefaperazone-sulbactam, piperacillin-tazobactam and carbapenems were 32%, 28.6% and 26.8% respectively. The outcome was fatal for 25 patients.
   Conclusions: The study documented an alarming rise in the prevalence of GNB and their resistance. Though the results of the study may represent only the tip of the iceberg, the results demonstrate the need for treatment options for drug resistant isolates and for surveillance cultures.
AD  - Govt Med Coll, Dept Microbiol, Palakkad, Kerala, IndiaAD  - All India Inst Med Sci, Dept Microbiol, New Delhi 110001, IndiaAD  - All India Inst Med Sci, Dr BRA Inst Rotary Canc Hosp, Dept Med Oncol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalPU  - J INFECTION DEVELOPING COUNTRIES
PI  - TRAMANIGLIO
PA  - JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
DA  - JUN
PY  - 2018
VL  - 12
IS  - 6
SP  - 442
EP  - 447
DO  - 10.3855/jidc.9725
AN  - WOS:000437992000005
ER  -

TY  - JOUR
AU  - Kumar, A
AU  - Lodha, R
TI  - Biomarkers for Diagnosing Ventilator Associated Pneumonia: Is that the Way Forward?
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - LAVAGE FLUID
KW  - PROCALCITONIN
KW  - PROTEIN
AD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUN
PY  - 2018
VL  - 85
IS  - 6
SP  - 411
EP  - 412
DO  - 10.1007/s12098-018-2672-6
AN  - WOS:000432220600002
ER  -

TY  - JOUR
AU  - Kumar, A
AU  - Sehgal, R
AU  - Roy, TS
TI  - Ossified ligaments in relation to foramina and bony landmarks of the middle cranial fossa
T2  - JOURNAL OF THE ANATOMICAL SOCIETY OF INDIA
KW  - accessory foramina
KW  - middle cranial fossa (MCF)
KW  - ossified ligament
KW  - skull base surgery
KW  - MICROSURGICAL ANATOMY
KW  - CLINICAL-SIGNIFICANCE
KW  - INFRATEMPORAL FOSSA
KW  - CASTE POPULATIONS
KW  - NERVE
KW  - ENTRAPMENT
AB  - Introduction: Sporadic reports on individual ossified ligaments of the middle cranial fossa (MCF) fail to do justice to their grave clinical consequences. The present study attempts a comprehensive search for all ossified ligaments and associated accessory foramina in relation to MCF, in order to standardize baseline prevalence pertinent for the Indian subcontinent.
   Methods: Fifty well-preserved and intact, adult (age >20 yrs), dry, macerated skulls were obtained from the Anatomy departments of medical colleges in Delhi, including the All India Institute of Medical Sciences. All the skulls were subjected to a meticulous, bilateral examination and digital photography of internal & external aspects of the skull base, to look for presence of partially or completely ossified ligaments and resulting accessory foramina.
   Results: The incidence values recorded from the present sample (n=50 x 2) for completely (C) and incompletely (IC) ossified MCF ligaments are as follows: Caroticoclinoid: C=6 (6%), IC=2 (2%); Interclinoid: C=3 (3%), IC=2 (2%); Pterygospinous: C=2 (2%), IC=3 (3%); Pterygoalar: C=1 (1%), IC=2 (2%); Petrosphenoid/petroclinoid: C=2 (2%), IC=0 (0%). All completely ossified ligaments were found to be associated with accessory foramina.
   Discussion: Presence of ossified MCF ligaments cannot be overlooked in patients with symptoms arising from compression of neurovascular structures and those undergoing skull-base neurosurgery, necessitating pre-surgical screening for presence of calcified ligaments in close proximity to vital structures - a scenario that may influence surgical outcome. (C) 2018 Anatomical Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd. All rights reserved.
AD  - AIIMS, Dept Anat, Teaching Block, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUN
PY  - 2018
VL  - 67
IS  - 1
SP  - 55
EP  - 60
DO  - 10.1016/j.jasi.2018.03.001
AN  - WOS:000433987700010
ER  -

TY  - JOUR
AU  - Kumar, IDV
AU  - Chaitanya, DK
AU  - Singh, V
AU  - Reddy, DS
TI  - A morphometric study of human middle ear ossicles in cadaveric temporal bones of Indian population and a comparative analysis
T2  - JOURNAL OF THE ANATOMICAL SOCIETY OF INDIA
KW  - Middle ear
KW  - Ossicles
KW  - Morphology
KW  - ImageJ
KW  - TORP
KW  - PORP
KW  - MORPHOLOGICAL VARIATIONS
AB  - Introduction: Malleus, Incus and Stapes are the three middle ear ossicles which form an articulated chain and help in conduction of sound from external ear to inner ear. Morphometric study of these ossicles has been going since the early 60s. Although the methods of been changing due to advent of newer technologies and treatments.
   Methods: We studied ossicles of 60 temporal bones. The ossicles have been obtained by 'canal wall down' mastoidectomy technique. They have been measured by an open software, Fiji (https://imagej.nih.gov ) where the scale was standardized and set to mm (millimeter).
   Results: The mean total length of the malleus is 8.23 mm; a mean angle of 128.76 degrees, mean width of the head 2.56 mm, and mean length of manubrium is 4.17 mm. The mean total length of incus is 7.04 mm, mean angle of 97.23 degrees, mean total width of 5.31 mm, and mean length of long process is 3.27 mm. The mean total height of stapes is 3.44 mm; mean width of the footplate is 1.10 mm and a mean angle of 51.01 degrees.
   Discussion: Morphometric data obtained in the present study can be useful for the reconstructive procedures. Preoperative radiological assessment is advised for these small bones. The present study also emphasizes on the future directions where in reconstructive procedures can be improved with the artistic renderings of the blueprints provided, for new prosthetic designs which can be manufactured by using Teflon materials. (C) 2018 Anatomical Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd. All rights reserved.
AD  - AIIMS, Dept Otorhinolaryngol & Head & Neck Surg, New Delhi, IndiaAD  - Santosh Univ, Santosh Med Coll, Dept Anat, Delhi NCR, Ghaziabad, IndiaAD  - Osmania Med Coll & Hosp, Dept ENT, Hyderabad, IndiaAD  - Govt ENT Hosp, Hyderabad, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUN
PY  - 2018
VL  - 67
IS  - 1
SP  - 12
EP  - 17
DO  - 10.1016/j.jasi.2018.01.001
AN  - WOS:000433987700003
ER  -

TY  - JOUR
AU  - Kumar, H
AU  - Gupta, A
AU  - Gupta, V
TI  - A microinvasive technique for management of corneal edema secondary to glaucoma drainage device tube-corneal touch
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Ahmed glaucoma valve
KW  - glaucoma drainage device
KW  - tube-corneal touch
KW  - IMPLANTATION
KW  - CHAMBER
KW  - SULCUS
KW  - VALVE
AB  - We present a case of tube endothelial touch where a suture technique for repositioning of the Ahmed glaucoma valve was performed. Advantage of this technique is that it is minimally invasive and anterior chamber stability is maintained during the procedure.
AD  - Ctr Sight, B5-24 Safdarjung Encl, New Delhi, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - JUN
PY  - 2018
VL  - 66
IS  - 6
SP  - 861
EP  - 862
C7  - PMID 29786005
DO  - 10.4103/ijo.IJO_987_17
AN  - WOS:000433099600029
ER  -

TY  - JOUR
AU  - Kumar, P
AU  - John, V
AU  - Gupta, A
AU  - Bhaskarli, S
TI  - Enhanced survival of BCG-stimulated dendritic cells: involvement of anti-apoptotic proteins and NF-κB
T2  - BIOLOGY OPEN
KW  - BCG
KW  - Dendritic cell
KW  - Lifespan
KW  - Apoptosis
KW  - Antiapoptotic proteins
KW  - MyD88
KW  - NF-kappa B
KW  - MYCOBACTERIUM-TUBERCULOSIS INFECTION
KW  - MACROPHAGE ACTIVATION
KW  - IMMUNE-RESPONSE
KW  - INDICUS-PRANII
KW  - BLADDER-CANCER
KW  - LIFE-SPAN
KW  - BOVIS
KW  - RECEPTOR
KW  - IMMUNOGENICITY
KW  - IMMUNOTHERAPY
AB  - BCG (Bacillus Calmette-Guerin) is the only available vaccine against TB and is also used for the treatment of superficial bladder cancer. BCG-mediated protection against TB and bladder cancer has been shown to rely on its ability to induce superior CD4(+) and CD8(+) T cell responses. As the magnitude of T cell responses is defined by dendritic cell (DC) lifespan, we examined the effect of BCG on DC survival and its underlying mechanisms. It was observed that BCG stimulation enhanced DC survival and prolonged DC lifespan in a dose-dependent manner. Live BCG led to a higher DC survival compared with heat-killed BCG. FITC-Annexin V staining showed that BCG promoted DC survival by inhibiting apoptosis. Consistently, higher expressions of anti-apoptotic proteins Bcl-2 and Bcl-x(L) were observed in BCG-stimulated DCs. Pharmacological inhibition of Bcl-2 and Bcl-x(L) drastically reduced the DC survival efficacy of BCG. Comparable survival of BCG-stimulated wild-type and MyD88(-/-) DCs suggested that MyD88 signaling is dispensable for BCG-induced DC survival. NF-kB is one of the key regulators of innate immune responses. We observed that pharmacological inhibition of NF-kB abrogated BCG-mediated increase in DC survival and expression of anti-apoptotic proteins. These findings provide a novel insight into the effect of BCG on DC physiology.
AD  - Natl Inst Immunol, Prod Dev Cell 1, Aruna Asaf Ali Marg, New Delhi 110067, IndiaAD  - All India Inst Med Sci, Dept Prevent Oncol, New Delhi 110029, IndiaAD  - Univ Wurzburg, Inst Virol & Immunobiol, Wurzburg, GermanyC3  - Department of Biotechnology (DBT) IndiaC3  - National Institute of Immunology (NII)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of WurzburgPU  - COMPANY BIOLOGISTS LTD
PI  - CAMBRIDGE
PA  - BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
DA  - JUN
PY  - 2018
VL  - 7
IS  - 6
C7  - bio032045
DO  - 10.1242/bio.032045
AN  - WOS:000437758700004
ER  -

TY  - JOUR
AU  - Kumar, S
AU  - Singh, S
AU  - Chadda, RK
AU  - Verma, R
AU  - Kumar, N
TI  - The Effect of Low-Frequency Repetitive Transcranial Magnetic Stimulation at Orbitofrontal Cortex in the Treatment of Patients With Medication-Refractory Obsessive-Compulsive Disorder: A Retrospective Open Study
T2  - JOURNAL OF ECT
KW  - transcranial
KW  - brain stimulation
KW  - neuromodulation
KW  - OCD
KW  - orbitofrontal cortex
KW  - depression
KW  - OCD
AB  - Objective Obsessive-compulsive disorder (OCD) is a chronic debilitating psychiatric disorder, with significant proportion of patients failing to respond with current first-line treatments. The present study assesses the safety and effectiveness of low-frequency repetitive transcranial magnetic stimulation (LF-rTMS) over left-orbitofrontal cortex (Lt-OFC) as a potential augmentation strategy in treatment of patients with medication-refractory OCD in real-world clinical setting. The present report also aims to examine the factors affecting response to rTMS and the durability of effects produced by rTMS over 1 month of follow-up period.
   Methods Retrospective review and analysis of clinical case files of 25 patients with medication-refractory OCD, all of whom had received 20 sessions of LF-rTMS over Lt-OFC as part of routine clinical care. A reduction of 25% and 35% in Yale-Brown Obsessive Compulsive Scale scores was used to determine the proportion of partial and complete responders, respectively.
   Results There was a significant decrease in mean Yale-Brown Obsessive Compulsive Scale score at the end of 20 sessions of rTMS compared with baseline (7.04 5.07; P < 0.001), with no further significant change during the subsequent 1-month follow-up period (0.20 +/- 1.38; P = 0.47). Thirteen patients (52%) met criteria for partial response, of which 11 patients (44%) showed complete response. Furthermore, higher number of failed medication trials was found to be significantly associated with greater chances of nonresponse to rTMS treatment.
   Conclusions There is a role of applying LF-rTMS over Lt-OFC as an augmentation strategy in ameliorating clinical symptoms among patients with medication-refractory OCD.
AD  - All India Inst Med Sci, Dept Psychiat, 4th Floor,Teaching Block,Ansari Nagar, New Delhi 110029, Nct Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - JUN
PY  - 2018
VL  - 34
IS  - 2
SP  - E16
EP  - E19
DO  - 10.1097/YCT.0000000000000462
AN  - WOS:000433902900001
ER  -

TY  - JOUR
AU  - Kumar, V
AU  - Kumawat, D
AU  - Dhakal, S
TI  - Leukemic retinopathy and foveal infiltrates
T2  - INTERNATIONAL OPHTHALMOLOGY
KW  - Chronic myeloid leukemia
KW  - Leukemic retinopathy
KW  - Foveal infiltrates
KW  - Spectral domain
KW  - Optical coherence tomography
AB  - The authors describe leukemic retinopathy with foveal leukemic infiltrates as the presenting feature of chronic myeloid leukemia. Spectral domain optical coherence tomography (SD-OCT) features of leukemic foveal infiltrates are presented. Though the retinopathy resolved with remission of disease, visual recovery was not complete due to loss of ellipsoid zone on SD-OCT.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Ansari Nagar, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - JUN
PY  - 2018
VL  - 38
IS  - 3
SP  - 1301
EP  - 1303
DO  - 10.1007/s10792-017-0562-y
AN  - WOS:000434373500048
ER  -

TY  - JOUR
AU  - Kumar, V
TI  - Reticular Pseudodrusen and Thin Choroid are Associated With Angioid Streaks
T2  - OPHTHALMIC SURGERY LASERS & IMAGING RETINA
KW  - PSEUDOXANTHOMA ELASTICUM
KW  - BRUCH MEMBRANE
KW  - THICKNESS
KW  - MUTATIONS
KW  - DYSTROPHY
KW  - UPDATE
KW  - EYES
AB  - BACKGROUND AND OBJECTIVE: To report the association of angioid streaks in patients with Pseudo-xanthoma elasticum (PXE) with reticular pseudo-drusen (RPD), thin choroid, and retinal pigment epithelium (RPE) atrophy using swept-source optical coherence tomography (SS-OCT) and short-wave autofluorescence (SWAF).
   PATIENTS AND METHODS: Retrospective cross-sectional study. Records of consecutive patients with angioid streaks due to PXE, who presented with a decrease of vision due to choroidal neovascularization (CNV), were reviewed for best-corrected visual acuity, color fundus photographs, SS-OCT, SWAF, and red-free images with special emphasis on presence or absence of RPD, subfoveal choroidal thickness (SFCT), and RPE atrophy.
   RESULTS: Sixteen eyes of eight patients with a mean age of 45.5 years +/- 9.4 years were enrolled in the study. RPD were seen in 10 of the 16 eyes and were seen commonly along the superotemporal quadrant. Mean subfoveal thickness in study eyes (175.7 mu m +/- 37.2 mu m) was significantly reduced when compared to controls (286.4 mu m +/- 40.8 mu m). The mean SFCT was similar between the eyes with and without CNV. Four eyes had RPE atrophy in the macular area, whereas four eyes had peripapillary RPE atrophy.
   CONCLUSIONS: Angioid streaks in PXE are associated with RPD, thin choroid, and RPE atrophy. These features occur at a younger age as compared to age-related macular degeneration and appear to be interrelated because of single pathophysiological mechanism.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SLACK INC
PI  - THOROFARE
PA  - 6900 GROVE RD, THOROFARE, NJ 08086 USA
DA  - JUN
PY  - 2018
VL  - 49
IS  - 6
SP  - 402
EP  - 408
DO  - 10.3928/23258160-20180601-04
AN  - WOS:000436108300004
ER  -

TY  - JOUR
AU  - Kumawat, D
AU  - Chandra, P
AU  - Tewari, R
TI  - Asymmetric Presentation of Retinopathy of Prematurity
T2  - INDIAN PEDIATRICS
KW  - Cryotherapy
KW  - Neonate
KW  - Screening
AB  - Retinopathy of prematurity (ROP) usually has symmetric presentation and progression between fellow eyes. In this retrospective review of records, asymmetric presentation was noted in 16 (3.9%) out of 410 babies over a period of one year. Management and final outcome differed in 10 and 11 infants respectively. ROP need not always be symmetric and may require variable management.
AD  - AIIMS, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUN
PY  - 2018
VL  - 55
IS  - 6
SP  - 523
EP  - 524
DO  - 10.1007/s13312-018-1346-9
AN  - WOS:000439992700014
ER  -

TY  - JOUR
AU  - Lallar, M
AU  - Rai, A
AU  - Srivastava, P
AU  - Mandal, K
AU  - Gupta, N
AU  - Kabra, M
AU  - Phadke, SR
TI  - Molecular Testing of <i>MECP2</i> Gene in Rett Syndrome Phenotypes in Indian Girls
T2  - INDIAN PEDIATRICS
KW  - MLPA
KW  - Mutation testing
KW  - Sanger sequencing
KW  - LARGE DELETIONS
KW  - MUTATIONS
KW  - DISORDER
KW  - DATABASE
KW  - VARIANT
AB  - To assess yield of MECP2 gene sequence variations analysis and large deletions in suspected cases of Rett syndrome.
   Descriptive study.
   Tertiary-care medical genetics center.
   Girls with neuroregression, postnatal microcephaly and signs and symptoms suggestive of classical and atypical Rett syndrome were classified into two groups. Group I consisted of girls with Classical and atypical Rett syndrome on basis on the Revised Rett Syndrome diagnostic criteria, 2010. Group II included girls with neuroregression and postnatal microcephaly and other Rett like features but not fulfilling the above criteria.
   Sanger sequencing of coding regions and large deletional analysis of MECP2 gene.
   Identification of mutation in MECP2 gene.
   Mutation in MECP2 gene was identified in 74% (14/19) in group I and none (0/17) in group II. The mutation detection rate was 93% (13/14) in group I classical Rett syndrome girls (2 with large deletions identified with Multiplex ligation dependent probe amplification) and 20% (1/5) in group I atypical Rett syndrome girls. One novel MECP2 sequence variation was identified in group I classical Rett syndrome.
   The yield of the mutation detection in MECP2 is higher in classical Rett syndrome. In girls with some Rett like features, but not fulfilling revised Rett syndrome diagnostic criteria, mutation testing for MECP2 gene has a low yield.
AD  - SGPGI, Dept Med Genet, Lucknow, Uttar Pradesh, IndiaAD  - AIIMS, Dept Pediat, Genet Div, New Delhi, IndiaC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUN
PY  - 2018
VL  - 55
IS  - 6
SP  - 474
EP  - 477
DO  - 10.1007/s13312-018-1336-y
AN  - WOS:000439992700004
ER  -

TY  - JOUR
AU  - Magoon, R
AU  - Malik, V
AU  - Choudhury, A
AU  - Chauhan, S
AU  - Hote, MP
AU  - Ramakrishnan, S
AU  - Singh, V
TI  - A Comparison of the Strain and Tissue Doppler-Based Indices as Echocardiographic Correlates of the Left Ventricular Filling Pressures
T2  - JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
KW  - diastolic strain
KW  - diastolic strain rate
KW  - diastolic function
KW  - left ventricular filling pressures
KW  - speckle tracking echocardiography
KW  - DIASTOLIC HEART-FAILURE
KW  - SYSTOLIC FUNCTION
KW  - GLOBAL STRAIN
KW  - RELAXATION
KW  - E/E'
KW  - ACCURACY
AB  - Objectives: Diastolic strain and strain rate, combined with E (peak transmittal velocity), have been proposed as novel noninvasive predictors of left ventricle (LV) filling pressures, avoiding angulation errors inherent to tissue Doppler indices (TDI). The primary objective was to study the correlation of strain-based indices (SBI) and TDI with pulmonary artery catheter-derived LV end-diastolic pressures (LVEDP). The secondary aim was to determine appropriate cut-off of indices to predict LVEDP >= 15 mmHg.
   Design: A prospective observational clinical study.
   Setting: Single university hospital.
   Participants: One hundred twenty adults with preserved ejection fraction (EF) undergoing coronary artery bypass grafting.
   Interventions: None.
   Measurements and Main Results: Two-dimensional speckle-tracking echocardiography estimated global longitudinal diastolic strain (Ds) and strain rate (DSr) at peak mitral filling to compute E/Ds and E/lODSr. TDI was measured as the ratio of E and e' (mitral annular diastolic velocity). E/e', E/Ds, and E/lODSr were significantly higher (p < 0.001) in patients with LVEDP >= 15 mm Hg (31/120). Correlation of E/Ds, E/lODSr with LVEDP was R = 0.86 and 0.88 (p < 0.001), respectively, compared with a correlation of R = 0.63 (p < 0.001) for E/e'. SBI correlated well with LVEDP >= 15 mm Hg compared with TDI. E/Ds >= 11 and E/lODSr >= 12 had higher sensitivity and specificity (96.77%, 93.26%; 100%, 96.63%, respectively; area under the curve [AUC] = 0.99) than E/e' >= 13 (74%,75%; AUC = 0.84) for prediction of LVEDP >= 15 mmHg. SBI accurately predicted elevated LVEDP in the indeterminate zone of 8 < E/e' < 13.
   Conclusions: SBI were better predictors of LVEDP, compared with TDI, in patients with preserved EF and indeterminate E/e' values. (C) 2017 Elsevier Inc. All rights reserved.
AD  - All India Inst Med Sci, Cardiothorac Ctr, Dept Cardiac Anaesthesia, CNC, New Delhi, IndiaAD  - All India Inst Med Sci, Cardiothorac Ctr, Dept Cardiothorac & Vasc Surg, CNC, New Delhi, IndiaAD  - All India Inst Med Sci, Cardiothorac Ctr, Dept Cardiol, CNC, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - W B SAUNDERS CO-ELSEVIER INC
PI  - PHILADELPHIA
PA  - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
DA  - JUN
PY  - 2018
VL  - 32
IS  - 3
SP  - 1297
EP  - 1304
DO  - 10.1053/j.jvca.2017.11.047
AN  - WOS:000433384200032
ER  -

TY  - JOUR
AU  - Mahajan, S
AU  - Agarwal, S
AU  - Kocheri, N
AU  - Jain, D
AU  - Mathur, SR
AU  - Iyer, VK
TI  - Cytopathology of non-invasive follicular thyroid neoplasm with papillary-like nuclear features: A comparative study with similar patterned papillary thyroid carcinoma variants
T2  - CYTOPATHOLOGY
KW  - cytology
KW  - follicular variant of papillary thyroid carcinoma
KW  - NIFTP
KW  - papillary thyroid carcinoma
KW  - papillary thyroid carcinoma with predominant follicular pattern
KW  - CYTOLOGIC DIAGNOSIS
KW  - CANCER INCIDENCE
KW  - BETHESDA SYSTEM
KW  - NIFTP
KW  - DISTINCT
KW  - IMPACT
KW  - MALIGNANCY
KW  - CRITERIA
KW  - RISK
KW  - BRAF
AB  - ObjectiveNoninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is a recently described, indolent thyroid tumor, with well-defined histopathological diagnostic criteria. Cytology features are not well documented. We reviewed cytology of histologically proven cases of NIFTP and some of its common differentials to look for salient diagnostic features.
   MethodsCases reported on histopathology as follicular variant of papillary thyroid carcinoma (FVPTC), or NIFTP between July 2015 and April 2017 having available cytology smears were retrieved and reclassified as NIFTP, FVPTC, and classical papillary thyroid carcinoma with predominant follicular pattern (PTC-FP). Cytological features were assessed, classified as per The Bethesda System for Reporting Cytopathology and compared.
   ResultsThere were 23 NIFTP cases, 18 FVPTC and 8 PTC-FP. A microfollicle-predominant pattern was seen in all. Nuclear score was 2 in most NIFTP cases (61%). Pseudoinclusions were absent. NIFTP showed features of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) (III) in 61%, follicular neoplasm/suspicious for a follicular neoplasm (FN/SFN) (IV) in 35% and suspicious for malignancy (SFM) (V) in 4%. Most of the FVPTCs were also called FN/SFN (IV) (56%) or AUS/FLUS (III) (22%). Nuclear features did not statistically differ from NIFTP. PTC-FP showed high-grade cytology in 75%, and higher nuclear score (3 in 75%) in contrast to NIFTP (P=.003).
   ConclusionNIFTP and FVPTC show a similar distribution among the Bethesda categories hence precluding conclusive distinction on cytology. PTC-FP, in contrast, was found to have a statistically significant higher nuclear score and more commonly showed malignant cytology.
   Non-invasive follicular thyroid neoplasm with papillary like nuclear features (NIFTP), an indolent tumor, differs from its malignant counterpart follicular variant of papillary thyroid carcinoma (FVPTC) and papillary thyroid carcinoma with predominant follicular pattern (PTC-FP) in prognosis and required management although it mimics them in architectural pattern. The feasibility of distinguishing between these differentials cytologically was evaluated, and it was found that while NIFTP and FVPTC cannot be separated out on cytology, PTC-FP can usually be diagnosed correctly.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUN
PY  - 2018
VL  - 29
IS  - 3
SP  - 233
EP  - 240
DO  - 10.1111/cyt.12537
AN  - WOS:000434088600005
ER  -

TY  - JOUR
AU  - Mahapatra, A
AU  - Sharma, P
TI  - Association of Internet addiction and alexithymia - A scoping review
T2  - ADDICTIVE BEHAVIORS
KW  - Problematic Internet Use
KW  - Internet addiction
KW  - Alexithymia
KW  - MAJOR DEPRESSIVE DISORDER
KW  - PERSONALITY-DISORDERS
KW  - PSYCHOMETRIC PROPERTIES
KW  - EMOTIONAL INTELLIGENCE
KW  - FACTORIAL VALIDITY
KW  - CHARACTER MODEL
KW  - DEFENSE STYLES
KW  - SUBSTANCE USE
KW  - SCALE
KW  - TEMPERAMENT
AB  - It has been hypothesized that individuals with alexithymia who have difficulty in identifying, expressing, and communicating emotions may overuse Internet as a tool of social interaction to better regulate their emotions and to fulfill their unmet social needs. Similarly, an increasing body of evidence suggests that alexithymia may also play an essential role in the etiopathogenesis of addictive disorders. We conducted a scoping review of questionnaire-based studies of problematic Internet use/Internet addiction and alexithymia. From initial 51 studies, all of the final 12 included studies demonstrated a significant positive association between scores of alexithymia and severity of Internet addiction. However, the causal direction of the association is not clear because the interplay of numerous other variables that could affect the relation has not been studied. There are limitations in the methodology of the studies conducted. Hence, we emphasise the need for longitudinal studies with stronger methodologies.
AD  - AIIMS, Dept Psychiat, New Delhi, IndiaAD  - Patan Acad Hlth Sci, Sch Med, Dept Psychiat, Lalitpur, NepalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - PERGAMON-ELSEVIER SCIENCE LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
DA  - JUN
PY  - 2018
VL  - 81
SP  - 175
EP  - 182
DO  - 10.1016/j.addbeh.2018.02.004
AN  - WOS:000429500000026
ER  -

TY  - JOUR
AU  - Maharana, PK
AU  - Chhablani, JK
AU  - Das, TP
AU  - Kumar, A
AU  - Sharma, N
TI  - All India Ophthalmological Society members survey results: Cataract surgery antibiotic prophylaxis current practice pattern 2017
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Antibiotic prophylaxis
KW  - cataract
KW  - endophthalmitis
KW  - moxifloxacin
KW  - POSTOPERATIVE ENDOPHTHALMITIS
AB  - Purpose: The purpose of this article is to document the current practice pattern of Indian ophthalmologists for antibiotic prophylaxis in cataract surgery to prevent endophthalmitis. Methods: Fifteen structured questions were sent online to all ophthalmologists registered with the All India Ophthalmological Society. The questionnaire was divided into three main categories of prophylaxis - preoperative, intraoperative, and postoperative. A web-based anonymous survey was conducted, and a unique response link allowed completing the survey only once. We compared the results with a similar 2014 survey among the members of the American Society of Cataract and Refractive Surgeons (ASCRS). Results: The response was received from 30.2% (n = 4292/14,170) ophthalmologists. The results were as follows: all respondents do not prepare the eye with 5% povidone-iodine (83% of them use povidone iodine), majority (90%) use topical antibiotic both pre- and post-operatively, 46% use subconjunctival antibiotic at the end of surgery, and 40% use intracameral antibiotic (46% of them in high-risk patients only). Moxifloxacin was the preferred antibiotic for topical and intracameral use. Comparison with the 2014 ASCRS survey results showed a similarity in decision for pre-and post-operative antibiotics and intracameral antibiotic but dissimilarity in the choice of intracameral antibiotic and decision for subconjunctival antibiotic. Conclusion: The antibiotic prophylaxis practice by the Indian ophthalmologists is not too dissimilar from the practice in North American Ophthalmologists (ASCRS) though all ophthalmologists in India must be nudged to preoperative preparation of the eye with povidone-iodine and discontinue the practice of postoperative subconjunctival and systemic antibiotic.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 482,4th Floor, New Delhi 110029, IndiaAD  - LV Prasad Eye Inst, Srimati Kanuri Santhamma Ctr Vitreoretinal Dis, Hyderabad, Telangana, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - L. V. Prasad Eye InstitutePU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - JUN
PY  - 2018
VL  - 66
IS  - 6
SP  - 820
EP  - 824
C7  - PMID 29785991
DO  - 10.4103/ijo.IJO_1336_17
AN  - WOS:000433099600015
ER  -

TY  - JOUR
AU  - Mallick, S
AU  - Benson, R
AU  - Melgandi, W
AU  - Giridhar, P
AU  - Rath, GK
TI  - Impact of surgery, adjuvant treatment, and other prognostic factors in the management of anaplastic ganglioglioma
T2  - CHILDS NERVOUS SYSTEM
KW  - Anaplastic ganglioglioma
KW  - Surgery
KW  - Radiotherapy
KW  - Chemotherapy Survival
KW  - OF-THE-LITERATURE
KW  - CENTRAL-NERVOUS-SYSTEM
KW  - SPINAL-CORD
KW  - MALIGNANT GANGLIOGLIOMA
KW  - CEREBELLOPONTINE ANGLE
KW  - CELL GLIOBLASTOMA
KW  - TUMOR RECURRENCE
KW  - FEATURES
KW  - COMPONENT
KW  - DISSEMINATION
AB  - Anaplastic ganglioglioma (AGG) is a rare tumor with both glial and neuronal component accounting for less than 1% of all CNS tumors with limited information about the optimum treatment and outcome of these tumors.
   We did a thorough search of the PubMed with the following MesH terms: "Ganglioglioma; Anaplastic ganglioglioma; Ganglioglioma AND treatment; and Anaplastic ganglioglioma AND survival" to find all possible publications related to AGG to perform an individual patient data analysis and derive the survival outcome and optimum treatment of these tumors.
   A total of 56 articles were retrieved pertaining to AGG with 88 patients. However, a total of 40 publications found eligible with 69 patients for individual patient data analysis. Median age for the entire cohort was 16 years (range 0.2-77 years). Surgical details were available for 64 patients. A gross total or near total resection was reported in 21 cases (32.8%), subtotal resection or debulking was reported in 25 cases (39.1%). Surgical details were available for 64 patients. A gross total or near total resection was reported in 21 cases (32.8%), and subtotal resection or debulking was reported in 25 cases (39.1%). Median overall survival (OS) was 29 months [95% CI 15.8-42.2 months] with 2- and 5-year OS 61 and 39.4% respectively.
   AGG is associated with a dismal. Pediatric age and a gross total resection of tumor confer a better progression-free survival and OS. Hence, surgery should remain the cornerstone of therapy. However, because of modest survival, there is enough opportunity to improve survival with addition of adjuvant radiation and chemotherapy. A whole genome sequencing and molecular characterization would help to derive the best treatment option.
AD  - All India Inst Med Sci, Dept Radiat Oncol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - JUN
PY  - 2018
VL  - 34
IS  - 6
SP  - 1207
EP  - 1213
DO  - 10.1007/s00381-018-3780-3
AN  - WOS:000433025700018
ER  -

TY  - JOUR
AU  - Mankotia, DS
AU  - Sawarkar, DP
AU  - Singh, PK
AU  - Kumar, A
AU  - Verma, SK
AU  - Chandra, PS
AU  - Kale, SS
TI  - Rare Case of Cerebrospinal Fluid Proctorrhea Caused by Anterior Sacral Meningocele with Rectothecal Fistula
T2  - WORLD NEUROSURGERY
KW  - Anterior sacral meningocele
KW  - CSF leak
KW  - Rectothecal fistula
KW  - CAUDA-EQUINA SYNDROME
KW  - OF-THE-LITERATURE
KW  - BACTERIAL-MENINGITIS
KW  - SECONDARY
KW  - TRIAD
AB  - BACKGROUND: Anterior sacral meningocele (ASM) leading to secondary rectothecal fistula is extremely rare, and to date only 5 such cases have been described in the world literature.
   CASE DESCRIPTION: We describe an uncomplicated case of a 52-year-old female patient presenting with cerebrospinal fluid leak from the anus who was investigated and found to have an ASM with rectothecal fistula. The ASM and rectothecal fistula were subsequently repaired using a posterior approach. Pertinent literature review, clinical findings, neuroimaging, and surgical management are described for these rare lesions.
   CONCLUSION: Early diagnosis and surgical disconnection of the fistulous tract led to satisfactory outcome in the present case and avoided the catastrophic complication of meningitis.
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - JUN
PY  - 2018
VL  - 114
SP  - 323
EP  - 325
DO  - 10.1016/J.WNEU.2018.03.087
AN  - WOS:000432959600217
ER  -

TY  - JOUR
AU  - Mittal, R
AU  - Kumar, A
AU  - Singh, DP
AU  - Bishnoi, M
AU  - Nag, TC
TI  - Ameliorative potential of rutin in combination with nimesulide in STZ model of diabetic neuropathy: targeting Nrf2/HO-1/NF-kB and COX signalling pathway
T2  - INFLAMMOPHARMACOLOGY
KW  - Diabetic neuropathy
KW  - Inflammation
KW  - Nrf-2
KW  - HO-1
KW  - Rutin
KW  - Nimesulide
KW  - NF-KAPPA-B
KW  - OXIDATIVE STRESS
KW  - HEME OXYGENASE-1
KW  - SCIATIC-NERVE
KW  - NRF2 PATHWAY
KW  - RATS
KW  - ACTIVATION
KW  - GLUCOSE
KW  - INJURY
KW  - PAIN
AB  - Emerging role of Nrf-2/HO-1 in pathogenesis of diabetic neuropathy has been suggested. Diabetic neuropathy is one of the most common complications of diabetes and more than 50% patients of diabetes develop diabetic neuropathy. Rutin has been well documented to show protective effect in various complications, e.g., diabetic neuropathy. However, its mechanistic insight is still not completely understood. The present study has been designed to explore the protective effect of rutin and its interaction with COX-2 inhibitor, nimesulide in diabetic neuropathy. DN (diabetic neuropathy) rats were maintained with or without rutin (100 and 200 mg/kg), nimesulide (5 and 10 mg/kg), and their combinations for 8 weeks. Body weight, serum glucose, pain assessment (mechanical allodynia, cold allodynia, mechanical hyperalgesia, and thermal hyperalgesia), and motor nerve conduction velocity (MNCV) were measured in all groups. Oxidative damage was assessed through biochemical estimation and mitochondrial ROS production, followed by inflammatory and apoptotic markers (TNF-alpha, caspase-3, Nrf-2, HO-1, and NF-kBp65) for their activity, protein, and gene expression. The structural changes were also reported through transmission electron microscope. Streptozotocin injection (55 mg/kg) induced diabetes reduced body weight, reduced the threshold for pain in various pain assessment parameters. Oxidative damage (increased MDA, decreased SOD, catalase, and GSH levels) increased mitochondrial ROS production followed by increased expression of inflammatory markers and decreased expression of Nrf-2/HO-1 in sciatic nerve. Treatment with rutin (100 and 200 mg/kg) and nimesulide (5 and 10 mg/kg) significantly attenuates these alterations as compared to DN control rats. Furthermore, combination of rutin (200 mg/kg) and nimesulide (10 mg/kg) significantly potentiated their protective effect which was significant as compared to their effect alone in streptozotocin-treated rats. The present study suggests the involvement of Nrf-2/HO-1 pathway in the protective effect of rutin against streptozotocin-induced diabetic neuropathy.
AD  - Panjab Univ, Univ Inst Pharmaceut Sci, Neuropharmacol Div, UGC Ctr Adv Study, Chandigarh 160014, IndiaAD  - Natl Agri Food Biotechnol Inst NABI, Sect 81, Mohali 140306, Punjab, IndiaAD  - All India Inst Med Sci, Dept Anat, New Delhi, IndiaC3  - Panjab UniversityC3  - Department of Biotechnology (DBT) IndiaC3  - National Agri Food Biotechnology Institute (NABI)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER BASEL AG
PI  - BASEL
PA  - PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
DA  - JUN
PY  - 2018
VL  - 26
IS  - 3
SP  - 755
EP  - 768
DO  - 10.1007/s10787-017-0413-5
AN  - WOS:000432737600011
ER  -

TY  - JOUR
AU  - Mohan, S
AU  - Jarhyan, P
AU  - Ghosh, S
AU  - Venkateshmurthy, NS
AU  - Gupta, R
AU  - Rana, R
AU  - Malhotra, C
AU  - Rao, MB
AU  - Kalra, S
AU  - Tandon, N
AU  - Reddy, KS
AU  - Prabhakaran, D
TI  - UDAY: A comprehensive diabetes and hypertension prevention and management program in India
T2  - BMJ OPEN
KW  - LIFE
KW  - INTERVENTIONS
KW  - COMMUNITY
KW  - COUNTRIES
KW  - DISEASES
KW  - WORK
AB  - Introduction Diabetes and hypertension are two leading non-communicable conditions, which are suboptimally managed in India. Thus, innovative comprehensive approaches that can concomitantly improve their detection, prevention and control are warranted.
   Methods and analysis UDAY, a 5-year initiative, aims to reduce the risk of diabetes and hypertension and Improve management by implementing a comprehensive intervention programme in the two selected study sites, Sonipat and Visakhapatnam (Vizag). It has a pre-post evaluation design with representative cross-sectional surveys before and after intervention. Within these two sites, urban and rural subsites each with a total population of approximately 100 000 people each were selected and a baseline and postintervention assessment was conducted deploying five surveys [among general population (including body measurements or biosamples), patients, healthcare providers including physicians and pharmacists, health facilities], which will determine the knowledge levels about diabetes and hypertension, the proportion treated and controlled; the patient knowledge and self management skills; healthcare providers' management practices; the level of access and barriers to obtaining care. The interventions will include: tailored health promotion for improving public knowledge; screening of adults aged 30 years for identifying those at high risk of diabetes and/or hypertension for linkage to the healthcare system; patient education using technology enabled community health workers, geographic information system (GIS) based mapping of the communities, healthcare provider training on management guidelines, community based diabetes registry and; advocacy to improve access to healthcare. The baseline surveys have been completed, the study areas mapped using GIS and the interventions are being implemented. UDAY is expected to increase over baseline the levels of: public knowledge about diabetes and hypertension; those treated and controlled; patient self-management skills; the use of guideline based management by providers and; access to healthcare, leading to improved health outcomes and inform development of a India relevant chronic care model.
   Ethics and dissemination Ethical clearance for conduct of the study was obtained from the Institutional Ethics Committee (IEC) of the Public Health Foundation of India. The findings will be targeted primarily at public health policymakers and advocates, but will he disseminated widely through other mechanisms including conference presentations and peer-reviewed publications, as well as to the participating communities.
AD  - Publ Hlth Fdn India, Ctr Chron Condit & Injuries, Gurgaon, Haryana, IndiaAD  - Populat Serv Int, Delhi, IndiaAD  - Project HOPE, Delhi, IndiaAD  - Manipal Hosp, Visakhapatnam, Andhra Pradesh, IndiaAD  - Bharti Hosp, Karnal, Haryana, IndiaAD  - All India Inst Med Sci, Delhi, IndiaC3  - Public Health Foundation of IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - BMJ PUBLISHING GROUP
PI  - LONDON
PA  - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
DA  - JUN
PY  - 2018
VL  - 8
IS  - 6
C7  - e015919
DO  - 10.1136/bmjopen-2017-015919
AN  - WOS:000442924700008
ER  -

TY  - JOUR
AU  - Pandey, M
AU  - Singh, G
AU  - Agarwal, R
AU  - Dabas, Y
AU  - Jyotsna, VP
AU  - Kumar, R
AU  - Xess, I
TI  - Emerging <i>Rhizopus microsporus</i> Infections in India
T2  - JOURNAL OF CLINICAL MICROBIOLOGY
KW  - mucormycosis
KW  - Rhizopus microsporus
KW  - uncontrolled diabetes mellitus
KW  - India
KW  - MUCORMYCOSIS
KW  - ZYGOMYCOSIS
KW  - EXPERIENCE
AD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Otorhinolaryngol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER SOC MICROBIOLOGY
PI  - WASHINGTON
PA  - 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
DA  - JUN
PY  - 2018
VL  - 56
IS  - 6
C7  - e00433-18
DO  - 10.1128/JCM.00433-18
AN  - WOS:000433507300019
ER  -

TY  - JOUR
AU  - Panduranga, MS
AU  - Vibha, D
AU  - Prasad, K
AU  - Srivastava, AK
AU  - Shukla, G
TI  - Clinical spectrum and quality of life in patients with chronic polyneuropathy: A cross-sectional study
T2  - JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
KW  - chronic
KW  - polyneuropathy
KW  - quality of life
KW  - SF-36
KW  - PERIPHERAL NEUROPATHY
KW  - EPIDEMIOLOGY
KW  - ASSOCIATION
AB  - Chronic polyneuropathy is a disabling condition of the peripheral nerves, characterized by symmetrical sensory motor symptoms and signs. There is paucity of studies on the etiological spectrum of polyneuropathy and its impact on quality of life (QoL). The present cross-sectional study in a referral based tertiary care center in North India found diabetic neuropathy as the commonest cause (25.5%) amongst 212 patients with chronic polyneuropathy. Idiopathic axonal polyneuropathy was present in 14.2% patients. Leprosy presenting as confluent mononeuritis multiplex constituted 11.3% of the patients. Additionally, it revealed a significantly worse QoL in these patients in all domains measured by short form (SF-36). This is the first study conducted in India to determine the QoL in chronic neuropathy patients. The current study demonstrates the clinical feasibility and applicability of the SF-36 generic health status in patients with polyneuropathies.
AD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUN
PY  - 2018
VL  - 23
IS  - 2
SP  - 120
EP  - 123
DO  - 10.1111/jns.12269
AN  - WOS:000435265300007
ER  -

TY  - JOUR
AU  - Passah, A
AU  - Arora, S
AU  - Damle, NA
AU  - Tripathi, M
AU  - Bal, C
AU  - Subudhi, TK
AU  - Arora, G
TI  - <SUP>68</SUP>Ga-Prostate-Specific Membrane Antigen PET/CT in Triple-Negative Breast Cancer
T2  - CLINICAL NUCLEAR MEDICINE
KW  - PSMA PET
KW  - CT
KW  - theranostics
KW  - triple-negative breast cancer
KW  - PSMA EXPRESSION
KW  - GA-68-PSMA
KW  - CARCINOMA
AD  - All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - JUN
PY  - 2018
VL  - 43
IS  - 6
SP  - 460
EP  - 461
DO  - 10.1097/RLU.0000000000002071
AN  - WOS:000432581400035
ER  -

TY  - JOUR
AU  - Prakash, S
AU  - Sharan, P
AU  - Sood, M
TI  - A qualitative study on psychopathology of dhat syndrome in men: Implications for classification of disorders
T2  - ASIAN JOURNAL OF PSYCHIATRY
KW  - Dhat syndrome
KW  - Culture bound syndrome
KW  - Psychosomatic medicine
KW  - Psychopathology
KW  - CULTURE-BOUND SYNDROMES
KW  - SEX NEUROSIS
KW  - LEUKORRHEA
KW  - ENTITY
AB  - Background: Dhat syndrome is regarded by many as a culture bound syndrome of the Indian sub-continent. However the nosological status, conceptual understanding of the condition as well as the diagnostic guidelines are all mired in controversy.
   Aims: The current study aims to study the psychopathology of Dhat syndrome in men by using a qualitative approach and to arrive at an operational definition for diagnosing Dhat syndrome.
   Method: The qualitative approach consisted of five Focus Group Discussions (FGD) and five Key Individual Interviews (KII) with participants, consisting of patients as well as doctors - both allopathic as well as traditional.
   Results: Detailed analysis revealed valuable data regarding the symptoms, causes, treatment measures, sociocultural context, psychiatric co-morbidity, nature of the disorder and various other phenomenological dimensions. Ideas for future nosological positioning were also specifically looked for. Operational definition and diagnostic guidelines were also arrived at based on the analysis as well as on previous literature.
   Conclusion: Although lot of agreement existed among various stakeholders about symptoms and presentation, they varied significantly in their opinion on nature of the condition and treatment. Suggestions for ICD 11 have been made.
AD  - All India Inst Med Sci, Dept Psychiat, Fourth Floor,Acad Block, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - JUN
PY  - 2018
VL  - 35
SP  - 79
EP  - 88
DO  - 10.1016/j.ajp.2018.05.007
AN  - WOS:000436398300027
ER  -

TY  - JOUR
AU  - Pramanik, R
AU  - Tyagi, A
AU  - Chopra, A
AU  - Kumar, A
AU  - Vishnubhatla, S
AU  - Bakhshi, S
TI  - Myeloid Sarcoma Predicts Superior Outcome in Pediatric AML; Can Cytogenetics Solve the Puzzle?
T2  - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
KW  - Chloroma
KW  - Extramedullary leukemia
KW  - Myeloid leukemia
KW  - Survival
KW  - t (8;21)
KW  - NONLEUKEMIC-GRANULOCYTIC-SARCOMA
KW  - EXTRAMEDULLARY LEUKEMIA
KW  - CHILDREN
KW  - CANCER
KW  - DIAGNOSIS
KW  - PROGNOSIS
KW  - SURVIVAL
KW  - OOGS
AB  - We retrospectively evaluated the clinical, cytogenetic, and molecular profiles, and survival outcomes of pediatric acute myeloid leukemias (AMLs) with and without myeloid sarcoma (MS). MS was present in 121 of 570 patients (21.2%). The most frequent site was the orbit. Event-free survival (P = .003) and overall survival (P = .001) were better among AML with MS. The t (8; 21) was significantly associated with MS (odds ratio = 3.92).
   Background: The purpose of our study was to evaluate the clinical, cytogenetic, and molecular features, and survival outcomes in patients with acute myeloid leukemia (AML) with myeloid sarcoma (MS) and compare them with patients with AML without MS. Patients and Methods: This was a retrospective analysis of de novo pediatric AML patients with or without MS diagnosed at our cancer center between June 2003 and June 2016. Results: MS was present in 121 of 570 (21.2%), the most frequent site being the orbit. Patients with MS had a younger median age (6 years vs. 10 years) and presented with higher hemoglobin and platelet but lower white blood cell count compared with patients without MS. Further, t (8; 21) (P < .01), loss of Y chromosome (P < .01), and deletion 9q (P = .03) were significantly higher in patients with AML with MS. Event-free survival (EFS; P = .003) and overall survival (OS; P = .001) were better among patients with AML with MS (median EFS 21.0 months and median OS 37.1 months) compared with those with AML without MS (median EFS 11.2 months and median OS 16.2 months). The t (8; 21) was significantly associated with MS (odds ratio, 3.92). In a comparison of the 4 groups divided according to the presence or absence of MS and t (8; 21), the subgroup of patients having MS without concomitant t (8; 21) was the only group to have a significantly better OS (hazard ratio, 0.53; 95% confidence interval, 0.34-0.82; P = .005). Conclusion: Although t (8; 21) was more frequently associated with MS, it did not appear to be the reason for better outcome.
AD  - All India Inst Med Sci, Dept Med Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Lab Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - CIG MEDIA GROUP, LP
PI  - DALLAS
PA  - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
DA  - JUN
PY  - 2018
VL  - 18
IS  - 6
SP  - E249
EP  - E254
DO  - 10.1016/j.clml.2018.03.013
AN  - WOS:000432995800003
ER  -

TY  - JOUR
AU  - Prea, SM
AU  - Kong, YXG
AU  - Mehta, A
AU  - He, MG
AU  - Crowston, JG
AU  - Gupta, V
AU  - Martin, KR
AU  - Vingrys, AJ
TI  - Six-month Longitudinal Comparison of a Portable Tablet Perimeter With the Humphrey Field Analyzer
T2  - AMERICAN JOURNAL OF OPHTHALMOLOGY
KW  - GLAUCOMA
KW  - VARIABILITY
KW  - THRESHOLD
AB  - PURPOSE: To establish the medium-term repeatability of the iPad perimetry app Melbourne Rapid Fields (MRF) compared to Humphrey Field Analyzer (HFA) 24-2 SITA-standard and SITA-fast programs.
   DESIGN: Multicenter longitudinal observational clinical study.
   METHODS: Sixty patients (stable glaucoma/ocular hypertension/glaucoma suspects) were recruited into a 6-month longitudinal clinical study with visits planned at baseline and at 2, 4, and 6 months. At each visit patients undertook visual field assessment using the MRF perimetry application and either HFA SITA-fast (n = 21) or SITA-standard (n = 39). The primary outcome measure was the association and repeatability of mean deviation (MD) for the MRF and HFA tests. Secondary measures were the point-wise threshold and repeatability for each test, as well as test time.
   RESULTS: MRF was similar to SITA-fast in speed and significantly faster than SITA-standard (MRF 4.6 +/- 0.1 minutes vs SITA-fast 4.3 +/- 0.2 minutes vs SITA-standard 6.2 +/- 0.1 minutes, P < .001). Intraclass correlation coefficients (ICC) between MRF and SITA-fast for MD at the 4 visits ranged from 0.71 to 0.88. ICC values between MRF and SITA-standard for MD ranged from 0.81 to 0.90. Repeatability of MRF MD outcomes was excellent, with ICC for baseline and the 6-month visit being 0.98 (95% confidence interval: 0.96-0.99). In comparison, ICC at 6-month retest for SITA-fast was 0.95 and SITA-standard 0.93. Fewer points changed with the MRF, although for those that did, the MRF gave greater point-wise variability than did the SITA tests.
   CONCLUSIONS: MRF correlated strongly with HFA across 4 visits over a 6-month period, and has good test retest reliability. MRF is suitable for monitoring visual fields in settings where conventional perimetry is not readily accessible. (C) 2018 Elsevier Inc. All rights reserved.
AD  - Univ Melbourne, Dept Optometry & Vis Sci, Level 4,Alice Hoy Bldg,Monash Rd, Parkville, Vic 3010, AustraliaAD  - Royal Victorian Eye & Ear Hosp, East Melbourne, AustraliaAD  - Univ Melbourne, Ctr Eye Res Australia, Dept Ophthalmol, Melbourne, Vic, AustraliaAD  - Cambridge Univ Hosp NHS Fdn Trust, Dept Ophthalmol, Cambridge, Cambs, EnglandAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - University of MelbourneC3  - Royal Victorian Eye & Ear HospitalC3  - Centre for Eye Research AustraliaC3  - University of MelbourneC3  - University of CambridgeC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - JUN
PY  - 2018
VL  - 190
SP  - 9
EP  - 16
DO  - 10.1016/j.ajo.2018.03.009
AN  - WOS:000434102800006
ER  -

TY  - JOUR
AU  - Pujari, A
AU  - Kumar, A
AU  - Chawla, R
AU  - Khokhar, S
AU  - Agarwal, D
AU  - Gagrani, M
AU  - Sharma, N
AU  - Sharma, P
TI  - Impact on the pattern of ocular injuries and awareness following a ban on firecrackers in New Delhi: A tertiary eye hospital-based study
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Awareness
KW  - firecracker ban
KW  - ocular injuries
KW  - FIREWORKS-RELATED INJURIES
AB  - Purpose: To review the nature of firecracker-related ocular injuries at a tertiary eye hospital in northern India following the firecracker ban and also to review the level of awareness among the victims. Methods: A cross-sectional observational study involving the patients presenting with firecracker-related ocular injuries from October 18 to 27, 2017 were assessed for demographic distribution, detailed ocular evaluation, and a questionnaire related to the awareness about the injuries. Results: A total of 68 patients were observed. Fifty patients (74.5%) were males. This year, a majority of patients were from outside Delhi. Uttar Pradesh constituted the most 38.23% of the patients followed by Haryana 30.88%, Delhi 23.5%, and Bihar 7.35%. Visual acuity varied from 6/6 to no perception of light. Open globe injury was observed in 56 patients (82.35%) who commonly had zone I injury. A significant number of patients (88.23%) were aware of firecracker-related injuries, and a large number of such injuries (58.8%) occurred in those who were not actively involved in the ignition of firecrackers but were in the vicinity. Conclusion: This year, following a ban, the number of firecracker-related ocular injuries reported from areas outside Delhi outnumbered as compared to within Delhi. However, firecracker-related ocular injuries are still a major cause of significant visual loss, especially involving the bystanders. Thus, firecracker-related celebrations should be monitored with a stringent protocol.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - JUN
PY  - 2018
VL  - 66
IS  - 6
SP  - 837
EP  - 840
C7  - PMID 29785995
DO  - 10.4103/ijo.IJO_1290_17
AN  - WOS:000433099600019
ER  -

TY  - JOUR
AU  - Rai, S
AU  - Bhardwaj, U
AU  - Misra, A
AU  - Singh, S
AU  - Gupta, R
TI  - Comparison between photostability of Alexa Fluor 448 and Alexa Fluor 647 with conventional dyes FITC and APC by flow cytometry
T2  - INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
KW  - FLUORESCENT DYES
KW  - CANCER
AD  - AIIMS, Dept Lab Oncol, New Delhi, IndiaAD  - Maharaj Vinayak Global Univ, Jaipur, Rajasthan, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUN
PY  - 2018
VL  - 40
IS  - 3
SP  - E52
EP  - E54
DO  - 10.1111/ijlh.12809
AN  - WOS:000440789300006
ER  -

TY  - JOUR
AU  - Rastogi, N
AU  - Thergaonkar, R
AU  - Khandelwal, P
TI  - Genetics of Acute Myeloid Leukemia - A Paradigm Shift
T2  - INDIAN PEDIATRICS
KW  - ADULTS
AD  - Medanta Medicity, Inst Canc, Dept Pediat Hematol Oncol & Bone Marrow Transplan, Gurgaon, IndiaAD  - INHS Kalyani, Dept Pediat, Visakhpatnam, IndiaAD  - AIIMS, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUN
PY  - 2018
VL  - 55
IS  - 6
SP  - 465
EP  - 468
DO  - 10.1007/s13312-018-1334-0
AN  - WOS:000439992700002
ER  -

TY  - JOUR
AU  - Rathod, S
AU  - Irfan, M
AU  - Bhargava, R
AU  - Pinninti, N
AU  - Scott, J
AU  - Algahtani, HM
AU  - Guo, ZH
AU  - Gupta, R
AU  - Nadkarni, P
AU  - Naeem, F
AU  - Howells, F
AU  - Sorsdahi, K
AU  - Thorne, K
AU  - Osman-Hicks, V
AU  - Pallikadavath, S
AU  - Phiri, P
AU  - Carr, H
AU  - Graves, L
AU  - Kingdon, D
TI  - Multinational comparative cross-sectional survey of views of medical students about acceptable terminology and subgroups in schizophrenia
T2  - BMJ OPEN
KW  - RENAMING SCHIZOPHRENIA
KW  - MENTAL-ILLNESS
KW  - SERVICE USERS
KW  - STIGMA
KW  - CONSEQUENCES
KW  - PSYCHOSIS
KW  - DISORDER
KW  - VALIDITY
KW  - HEALTH
KW  - NAME
AB  - Aim The aim of this study was to inform thinking around the terminology for 'schizophrenia' in different countries.
   Objectives The objective of this study was to investigate: (1) whether medical students view alternative terminology (psychosis subgroups), derived from vulnerability-stress models of schizophrenia, as acceptable and less stigmatising than the term schizophrenia; (2) if there are differences in attitudes to the different terminology across countries with different cultures and (3) whether clinical training has an impact in reducing stigma.
   Design This is a cross-sectional survey that examined the attitudes of medical students towards schizophrenia and the alternative subgroups.
   Setting The study was conducted across eight sites: (1) University of Southampton, UK; (2) All India Institute of Medical Science, India; (3) Rowan University, USA; (4) Peshawar Medical College, Pakistan; (5) Capital Medical University, China; (6) College of Medicine and Medical sciences, Bahrain; (7) Queens University, Kingston, Canada and (8) University of Cape Town, South Africa.
   Method This study extended an initial pilot conducted by the Royal College of Psychiatrists on the term schizophrenia and psychosis subgroups to assess whether the subgroup terminology might have an effect on the attitudes of a convenience sample of medical students from eight different countries and potentially play a role in reducing stigmatisation.
   Results 1873 medical students completed a questionnaire recording their attitudes to schizophrenia and the psychosis subgroups. A reduction in negative perceptions were found for the psychosis subgroups, especially for the stress sensitivity psychosis and anxiety psychosis subgroups. Negative perceptions were found for drug-related psychosis. Participants who had undergone clinical training had overall positive attitudes. Differences across different countries were found.
   Conclusion The attitudes towards psychosis subgroups used in this study have shown mixed results and variation across countries. Further research is warranted to investigate acceptability of terminology. Methods of reducing stigma are discussed in line with the findings.
   Ethics The study received ethical approval from ERGO (Ethics and Research Governance Online; ID: 15972) and subsequently from the ethics committee at each site.
AD  - Southern Hlth NHS Fdn Trust, Clin Trials Facil, Tom Rudd Unit, Southampton, Hants, EnglandAD  - Univ Portsmouth, Portsmouth Brawijaya Ctr Global Hlth Populat & Po, Portsmouth, Hants, EnglandAD  - Peshawar Med Coll, Islamabad, PakistanAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - All India Inst Med Sci, Natl Drug Dependence Treatment Ctr, New Delhi, IndiaAD  - Rowan Univ, Sch Osteopath Med, Stratford, NJ USAAD  - Maine Behav Hlth Org, Biddeford, ME USAAD  - Arabian Gulf Univ, Coll Med & Med Sci, Manama, BahrainAD  - Capital Med Univ, Beijing, Peoples R ChinaAD  - Queens Univ, Kingston, ON, CanadaAD  - Univ Cape Town, Div Psychopharmacol & Biol Psychiat, Translat Neurosci Grp, Cape Town, South AfricaAD  - Univ Cape Town, Div Publ Mental Hlth, Cape Town, South AfricaAD  - Univ Hosp Southampton NHS Fdn Trust, Dept Psychiat, Southampton, Hants, EnglandC3  - University of PortsmouthC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)C3  - Rowan UniversityC3  - Rowan University School of Osteopathic MedicineC3  - Arabian Gulf UniversityC3  - Capital Medical UniversityC3  - Queens University - CanadaC3  - University of Cape TownC3  - University of Cape TownC3  - University of SouthamptonC3  - University Hospital Southampton NHS Foundation TrustPU  - BMJ PUBLISHING GROUP
PI  - LONDON
PA  - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
DA  - JUN
PY  - 2018
VL  - 8
IS  - 6
C7  - e021461
DO  - 10.1136/bmjopen-2017-021461
AN  - WOS:000435567900087
ER  -

TY  - JOUR
AU  - Reed, GM
AU  - Sharan, P
AU  - Rebello, TJ
AU  - Keeley, JW
AU  - Medina-Mora, ME
AU  - Gureje, O
AU  - Ayuso-Mateos, JL
AU  - Kanba, S
AU  - Khoury, B
AU  - Kogan, CS
AU  - Krasnov, VN
AU  - Maj, M
AU  - Mari, JD
AU  - Stein, DJ
AU  - Zhao, M
AU  - Akiyama, T
AU  - Andrews, HF
AU  - Asevedo, E
AU  - Cheour, M
AU  - Domínguez-Martínez, T
AU  - El-Khoury, J
AU  - Fiorillo, A
AU  - Grenier, J
AU  - Gupta, N
AU  - Kola, L
AU  - Kulygina, M
AU  - Leal-Leturia, I
AU  - Luciano, M
AU  - Lusu, B
AU  - Martínez-López, JNI
AU  - Matsumoto, C
AU  - Onofa, LU
AU  - Paterniti, S
AU  - Purnima, S
AU  - Robles, R
AU  - Sahu, MK
AU  - Sibeko, G
AU  - Zhong, N
AU  - First, MB
AU  - Gaebel, W
AU  - Lovell, AM
AU  - Maruta, T
AU  - Roberts, MC
AU  - Pike, KM
TI  - The ICD-11 developmental field study of reliability of diagnoses of high-burden mental disorders: results among adult patients in mental health settings of 13 countries
T2  - WORLD PSYCHIATRY
KW  - International Classification of Diseases
KW  - ICD-11
KW  - diagnosis
KW  - mental disorders
KW  - reliability
KW  - schizophrenia
KW  - mood disorders
KW  - anxiety disorders
KW  - disorders specifically associated with stress
KW  - TEST-RETEST RELIABILITY
KW  - BEHAVIORAL-DISORDERS
KW  - CLINICAL UTILITY
KW  - DSM-IV
KW  - SUBSTANCE DEPENDENCE
KW  - COMMON LANGUAGE
KW  - UNITED-STATES
KW  - CLASSIFICATION
KW  - TRIALS
KW  - CRITERIA
AB  - Reliable, clinically useful, and globally applicable diagnostic classification of mental disorders is an essential foundation for global mental health. The World Health Organization (WHO) is nearing completion of the 11th revision of the International Classification of Diseases and Related Health Problems (ICD-11). The present study assessed inter-diagnostician reliability of mental disorders accounting for the greatest proportion of global disease burden and the highest levels of service utilization - schizophrenia and other primary psychotic disorders, mood disorders, anxiety and fear-related disorders, and disorders specifically associated with stress - among adult patients presenting for treatment at 28 participating centers in 13 countries. A concurrent joint-rater design was used, focusing specifically on whether two clinicians, relying on the same clinical information, agreed on the diagnosis when separately applying the ICD-11 diagnostic guidelines. A total of 1,806 patients were assessed by 339 clinicians in the local language. Intraclass kappa coefficients for diagnoses weighted by site and study prevalence ranged from 0.45 (dysthymic disorder) to 0.88 (social anxiety disorder) and would be considered moderate to almost perfect for all diagnoses. Overall, the reliability of the ICD-11 diagnostic guidelines was superior to that previously reported for equivalent ICD-10 guidelines. These data provide support for the suitability of the ICD-11 diagnostic guidelines for implementation at a global level. The findings will inform further revision of the ICD-11 diagnostic guidelines prior to their publication and the development of programs to support professional training and implementation of the ICD-11 by WHO member states.
AD  - Columbia Univ Coll Phys & Surg, Dept Psychiat, 722 W 168th St, New York, NY 10032 USAAD  - Natl Inst Psychiat Ramon de la Fuente Muniz, Mexico City, DF, MexicoAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - New York State Psychiat Inst & Hosp, New York, NY 10032 USAAD  - Virginia Commonwealth Univ, Dept Psychol, Box 2018, Richmond, VA 23284 USAAD  - Univ Ibadan, Dept Psychiat, Ibadan, NigeriaAD  - Univ Autonoma Madrid, Dept Psychiat, IIS P, Madrid, SpainAD  - Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, SpainAD  - Kyushu Univ, Dept Neuropsychiat, Fukuoka, Fukuoka, JapanAD  - Amer Univ Beirut, Dept Psychiat, Med Ctr, Beirut, LebanonAD  - Univ Ottawa, Sch Psychol, Ottawa, ON, CanadaAD  - Moscow Res Inst Psychiat, Natl Med Res Ctr Psychiat & Narcol, Moscow, RussiaAD  - Univ Campania L Vanvitelli, Dept Psychiat, Naples, ItalyAD  - Univ Fed Sao Paulo, Dept Psychiat, Sao Paulo, BrazilAD  - Univ Cape Town, Dept Psychiat, Cape Town, South AfricaAD  - South African Med Res Council Unit Risk & Resilie, Cape Town, South AfricaAD  - Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai, Peoples R ChinaAD  - Shanghai Jiao Tong Univ, Sch Med, Dept Psychiat, Shanghai, Peoples R ChinaAD  - NTT Med Ctr Tokyo, Tokyo, JapanAD  - Columbia Univ Coll Phys & Surg, Dept Biostat, 630 W 168th St, New York, NY 10032 USAAD  - Tunis Al Manar Univ, Dept Psychiat, Tunis, TunisiaAD  - Al Razi Hosp, Tunis, TunisiaAD  - Natl Council Sci & Technol, Catedras CONACYT, Mexico City, DF, MexicoAD  - Hop Montfort, Inst Savoir Montfort, Ottawa, ON, CanadaAD  - Univ Ottawa, Ottawa, ON, CanadaAD  - Govt Med Coll & Hosp, Dept Psychiat, Chandigarh, IndiaAD  - Japanese Soc Psychiat & Neurol, Tokyo, JapanAD  - Fed Neuropsychiat Hosp Aro, Abeokuta, NigeriaAD  - Royal Ottawa Mental Hlth Ctr, Mental Hlth Res Inst, Ottawa, ON, CanadaAD  - Univ Ottawa, Dept Psychiat, Ottawa, ON, CanadaAD  - Pt Jawahar Lal Nehru Mem Med Coll, Raipur, Chhattisgarh, IndiaAD  - Heinrich Heine Univ, Fac Med, Dept Psychiat & Psychotherapy, Dusseldorf, GermanyAD  - INSERM, U988, Paris, FranceAD  - Seitoku Univ, Hlth Management Ctr, Matsudo, Chiba, JapanAD  - Univ Kansas, Off Grad Studies, Lawrence, KS 66045 USAAD  - Univ Kansas, Clin Child Psychol Program, Lawrence, KS 66045 USAC3  - Columbia UniversityC3  - Instituto Nacional de Psiquiatria Ramon de la Fuente MunizC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - New York State Psychiatry InstituteC3  - Virginia Commonwealth UniversityC3  - University of IbadanC3  - Autonomous University of MadridC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERSAMC3  - Instituto de Salud Carlos IIIC3  - Kyushu UniversityC3  - American University of BeirutC3  - University of OttawaC3  - Universita della Campania VanvitelliC3  - Universidade Federal de Sao Paulo (UNIFESP)C3  - University of Cape TownC3  - Shanghai Jiao Tong UniversityC3  - Shanghai Jiao Tong UniversityC3  - Kanto Medical Center NTT ECC3  - Columbia UniversityC3  - Universite de Tunis-El-ManarC3  - Universite de Tunis-El-ManarC3  - Hopital RaziC3  - University of OttawaC3  - University of OttawaC3  - University of OttawaC3  - University of OttawaC3  - Heinrich Heine University DusseldorfC3  - Institut National de la Sante et de la Recherche Medicale (Inserm)C3  - Universite Paris CiteC3  - University of KansasC3  - University of KansasPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUN
PY  - 2018
VL  - 17
IS  - 2
SP  - 174
EP  - 186
DO  - 10.1002/wps.20524
AN  - WOS:000434185800018
ER  -

TY  - JOUR
AU  - Roth, CL
AU  - Jain, V
TI  - Rising Obesity in Children: A Serious Public Health Concern
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - CHILDHOOD
AD  - Univ Washington, Seattle Childrens Hosp, Div Endocrinol & Diabet, Dept Pediat, 4800 Sand Point Way NE, Seattle, WA 98105 USAAD  - Seattle Childrens Res Inst, Ctr Integrat Brain Res, Seattle, WA USAAD  - All India Inst Med Sci, Div Pediat Endocrinol, Dept Pediat, New Delhi 110029, IndiaC3  - University of WashingtonC3  - University of Washington SeattleC3  - Seattle Children's HospitalC3  - Seattle Children's HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUN
PY  - 2018
VL  - 85
IS  - 6
SP  - 461
EP  - 462
DO  - 10.1007/s12098-018-2639-7
AN  - WOS:000432220600011
ER  -

TY  - JOUR
AU  - Sabel, BA
AU  - Wang, JQ
AU  - Cárdenas-Morales, L
AU  - Faiq, M
AU  - Heim, C
TI  - Mental stress as consequence and cause of vision loss: the dawn of psychosomatic ophthalmology for preventive and personalized medicine
T2  - EPMA JOURNAL
KW  - Low vision
KW  - Psychology
KW  - Psychosomatic medicine
KW  - Relaxation
KW  - Restoration
KW  - Stress
KW  - Predictive
KW  - Preventive
KW  - Personalized medicine
KW  - QUALITY-OF-LIFE
KW  - OPEN-ANGLE GLAUCOMA
KW  - ALTERNATING-CURRENT STIMULATION
KW  - NORMAL-TENSION GLAUCOMA
KW  - PROBLEM-SOLVING ABILITIES
KW  - PSYCHOGENIC VISUAL-LOSS
KW  - HEART-RATE-VARIABILITY
KW  - INTRAOCULAR-PRESSURE
KW  - OLDER-ADULTS
KW  - BLOOD-PRESSURE
AB  - The loss of vision after damage to the retina, optic nerve, or brain has often grave consequences in everyday life such as problems with recognizing faces, reading, or mobility. Because vision loss is considered to be irreversible and often progressive, patients experience continuous mental stress due to worries, anxiety, or fear with secondary consequences such as depression and social isolation. While prolonged mental stress is clearly a consequence of vision loss, it may also aggravate the situation. In fact, continuous stress and elevated cortisol levels negatively impact the eye and brain due to autonomous nervous system (sympathetic) imbalance and vascular dysregulation; hence stress may also be one of the major causes of visual system diseases such as glaucoma and optic neuropathy. Although stress is a known risk factor, its causal role in the development or progression of certain visual system disorders is not widely appreciated. This review of the literature discusses the relationship of stress and ophthalmological diseases. We conclude that stress is both consequence and cause of vision loss. This creates a vicious cycle of a downward spiral, in which initial vision loss creates stress which further accelerates vision loss, creating even more stress and so forth. This new psychosomatic perspective has several implications for clinical practice. Firstly, stress reduction and relaxation techniques (e.g., meditation, autogenic training, stress management training, and psychotherapy to learn to cope) should be recommended not only as complementary to traditional treatments of vision loss but possibly as preventive means to reduce progression of vision loss. Secondly, doctors should try their best to inculcate positivity and optimism in their patients while giving them the information the patients are entitled to, especially regarding the important value of stress reduction. In this way, the vicious cycle could be interrupted. More clinical studies are now needed to confirm the causal role of stress in different low vision diseases to evaluate the efficacy of different anti-stress therapies for preventing progression and improving vision recovery and restoration in randomized trials as a foundation of psychosomatic ophthalmology.
AD  - Otto von Guericke Univ, Inst Med Psychol, Med Fac, Magdeburg, GermanyAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaAD  - NYU, Dept Ophthalmol, NYU Langone Hlth, 550 1St Ave, New York, NY 10016 USAAD  - Humboldt Univ, Freie Univ Berlin, Charite Univ Med Berlin, BIH,Inst Med Psychol, Berlin, GermanyAD  - Penn State Univ, Dept Biobehav Hlth, University Pk, PA 16802 USAC3  - Otto von Guericke UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - New York UniversityC3  - NYU Langone Medical CenterC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - Pennsylvania State UniversityC3  - Pennsylvania State University - University ParkPU  - SPRINGER INTERNATIONAL PUBLISHING AG
PI  - CHAM
PA  - GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
DA  - JUN
PY  - 2018
VL  - 9
IS  - 2
SP  - 133
EP  - 160
DO  - 10.1007/s13167-018-0136-8
AN  - WOS:000433378900003
ER  -

TY  - JOUR
AU  - Sarkar, S
AU  - Patra, BN
AU  - Patil, V
AU  - Gupta, S
AU  - Mallanik, S
AU  - Pandey, A
TI  - Patient and Caregiver Perspectives on Ethical Issues in Mental Health Care: an Exploratory Study from India
T2  - INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION
KW  - Caregiver
KW  - Confidentiality
KW  - Ethics
KW  - Mental health
KW  - Patient
KW  - RATING-SCALE
KW  - MEDICAL-RECORDS
KW  - CONFIDENTIALITY
KW  - PERCEPTIONS
KW  - SENSITIVITY
KW  - PSYCHIATRY
KW  - ATTITUDES
KW  - NURSES
AB  - Ethical viewpoints about the correct course of action in a clinical situation can vary across individuals. The views of patients and their caregivers are also important considerations while exploring solutions to ethical dilemmas. This study aimed to ascertain the perspectives of patients and caregivers on ethical issues in mental health care. This vignette-based study included patients with psychiatric disorders and their caregivers. Patients were included if they were in clinical remission determined by psychiatric rating scales. Caregivers were included if they resided with the patient for the last I year. Both patients and caregivers were in the adult age group. The vignettes pertained to confidentiality and coercive care and elicited a yes or no type of responses. Ten short vignettes were presented to the patient caregiver dyad. The types of responses and agreement between the patients and their caregivers were assessed. Responses were available from 160 dyads of patients and their caregivers. The mean age of the patients was 35.6 years while that of the caregivers was 40.5 years. A slight majority of the patients and caregivers were males and were educated above high school. There was considerable variation in the views about correct course in a particular clinical situation. The responses from patients and caregivers endorsing disclosure of confidential information or coercive treatment varied from about 50% to more than 90% depending upon the clinical situation. The responses of patients generally had a fair agreement with responses of the caregivers (kappa values largely between 0.21 and 0.40). Viewpoints of patients and their caregivers provide an important stakeholder insight in approach to resolving ethical dilemmas. In the present cultural context, patients and caregivers were amenable to disclosure of contidential information in for a variety of clinical situations.
AD  - AIIMS, Dept Psychiat, New Delhi 110029, IndiaAD  - AIIMS, NDDTC, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)PU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - JUN
PY  - 2018
VL  - 16
IS  - 3
SP  - 714
EP  - 721
DO  - 10.1007/s11469-017-9833-0
AN  - WOS:000434275700017
ER  -

TY  - JOUR
AU  - Saxena, R
AU  - Sharma, M
AU  - Singh, D
AU  - Sharma, P
TI  - Full tendon medial transposition of lateral rectus with augmentation sutures in cases of complete third nerve palsy
T2  - BRITISH JOURNAL OF OPHTHALMOLOGY
KW  - treatment surgery
KW  - muscles
KW  - MUSCLE
KW  - FIXATION
KW  - GLOBE
AB  - Management options in third nerve palsy are limited as four of the six extraocular muscles are involved. Surgery has to be tailored on a case-to-case basis. Aim of this retrospective case series is to report 1-year outcomes of a modified surgical technique entailing full tendon transposition of lateral rectus to medial rectus augmented with posterior fixation sutures in four patients with complete third nerve palsy. All four cases showed significant improvement of vertical and horizontal deviation with long-term stability of correction. Choice of route of full tendon augmented transposition of lateral rectus to medial rectus can aid in achieving good correction of the vertical misalignment in addition to horizontal correction.
AD  - All India Inst Med Sci, Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaAD  - Noble Eye Care, Paediat Ophthalmol & Strabismus Serv, Gurgaon, Haryana, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - BMJ PUBLISHING GROUP
PI  - LONDON
PA  - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
DA  - JUN
PY  - 2018
VL  - 102
IS  - 6
SP  - 715
EP  - 717
DO  - 10.1136/bjophthalmol-2017-311376
AN  - WOS:000433231300001
ER  -

TY  - JOUR
AU  - Sebastian, S
AU  - Malhotra, R
AU  - Pande, A
AU  - Gautam, D
AU  - Xess, I
AU  - Dhawan, B
TI  - Staged Reimplantation of a Total Hip Prosthesis After Co-infection with <i>Candida tropicalis</i> and <i>Staphylococcus haemolyticus</i>: A Case Report
T2  - MYCOPATHOLOGIA
KW  - Antibiotic-impregnated cement spacers
KW  - Prosthetic joint infection
KW  - Sonication of biomaterials
KW  - TOTAL KNEE ARTHROPLASTY
KW  - JOINT INFECTION
AB  - Fungal prosthetic joint infection is a rare complication in total joint arthroplasty. There are no established guidelines for management of these infections. We present a case of a 53-year-old male with a hip joint prosthesis co-infected with Candida tropicalis and Staphylococcus haemolyticus. A two-stage exchange arthroplasty was performed. The patient underwent implant removal, debridement, irrigation with saline solution and application of cement spacer impregnated with vancomycin followed by aggressive antimicrobial treatment in first stage. Complete eradication of infection was demonstrated by negative culture of sonicated cement spacer fluid and negative 16S rRNA and 18S rRNA gene PCR of sonicate fluid, synovial fluid and periprosthetic tissue samples. He underwent second-stage revision hip arthroplasty after 9 months of the first stage. At the latest follow-up, there was no evidence of recurrence of infection. This case illustrates the utility of sonication of biomaterials and molecular techniques for microbiological confirmation of absence of infection in staged surgeries which is required for a successful outcome.
AD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Orthopaed, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - JUN
PY  - 2018
VL  - 183
IS  - 3
SP  - 579
EP  - 584
DO  - 10.1007/s11046-017-0177-x
AN  - WOS:000432624300012
ER  -

TY  - JOUR
AU  - Selvan, H
AU  - Gupta, S
TI  - Transconjunctival rectus muscle bridle: an adjunct in surgical exposure
T2  - EYE
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - NATURE PUBLISHING GROUP
PI  - LONDON
PA  - MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - JUN
PY  - 2018
VL  - 32
IS  - 6
SP  - 1151
EP  - 1153
DO  - 10.1038/s41433-018-0020-8
AN  - WOS:000434982700026
ER  -

TY  - JOUR
AU  - Shah, B
AU  - Gupta, R
AU  - Sarkar, S
AU  - Balhara, YPS
TI  - Injection Butorphanol dependence: A case report
T2  - ASIAN JOURNAL OF PSYCHIATRY
KW  - PRESCRIPTION OPIOID ABUSE
KW  - STADOL DEPENDENCE
AD  - Patan Acad Hlth Sci, Dept Psychiat, Lalitpur, NepalAD  - Suny Downstate Med Ctr, Dept Psychiat, Brooklyn, NY 11203 USAAD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaAD  - All India Inst Med Sci, Natl Drug Dependence Treatment Ctr, New Delhi, IndiaC3  - State University of New York (SUNY) SystemC3  - SUNY Downstate Health Sciences UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)PU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - JUN
PY  - 2018
VL  - 35
SP  - 45
EP  - 46
DO  - 10.1016/j.ajp.2018.05.008
AN  - WOS:000436398300017
ER  -

TY  - JOUR
AU  - Sharma, N
AU  - Singhal, D
AU  - Maharana, PK
AU  - Jain, R
AU  - Sahay, P
AU  - Titiyal, JS
TI  - Continuous intraoperative optical coherence tomography-guided shield ulcer debridement with tuck in multilayered amniotic membrane transplantation
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Amniotic membrane transplant
KW  - intraoperative optical coherence tomography
KW  - shield ulcer
KW  - vernal keratoconjunctivitis
KW  - VERNAL KERATOCONJUNCTIVITIS
KW  - MANAGEMENT
KW  - PLAQUES
AB  - Purpose: The aim of this study is to describe a modified surgical technique of continuous intraoperative optical coherence tomography (iOCT)-guided shield ulcer debridement with tuck-in multilayered Amniotic membrane transplantation (ML AMT) in vernal keratoconjunctivitis (VKC) with shield ulcer with plaque. Methods: Seven eyes of seven patients presenting with VKC with shield ulcer with plaque were enrolled in this prospective case series and planned for shield ulcer debridement with ML AMT. Debridement of the ulcer base with double-layered AMT was done under the continuous guidance of iOCT. The main outcome measure was the time for complete reepithelialization. Statistical analysis was performed using the Stata-14.0 program for Windows. Data were presented as mean +/- standard deviation/median (minimum-maximum) and frequency percentage as applicable. Results: The surgery could be completed successfully in all cases and iOCT could provide real-time assessment of the depth of dissection during the entire procedure. The duration of complete healing and disintegration of amniotic membrane varied from 7 to 12 days. Recurrence was not seen in any case till 2 months follow-up. Conclusion: iOCT provides continuous monitoring of the depth of dissection and allows for a safe and complete debridement of the shield ulcer with plaque.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Ophthalmol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - JUN
PY  - 2018
VL  - 66
IS  - 6
SP  - 816
EP  - 819
C7  - PMID 29785990
DO  - 10.4103/ijo.IJO_929_17
AN  - WOS:000433099600014
ER  -

TY  - JOUR
AU  - Sharma, P
AU  - Katiyar, V
AU  - Sharma, R
AU  - Gurjar, HK
AU  - Krishnan, S
TI  - Letter: Role of Tyrosine Kinase Inhibitors in Recurrent Meningiomas: Controversies and Promises
T2  - NEUROSURGERY
KW  - EPIDERMAL-GROWTH-FACTOR
KW  - PHASE-II TRIAL
KW  - UNRESECTABLE MENINGIOMA
KW  - REFRACTORY MENINGIOMAS
KW  - FACTOR RECEPTORS
KW  - NERVOUS-SYSTEM
KW  - EXPRESSION
KW  - CELLS
KW  - PROTEIN
KW  - PDGF
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - OXFORD UNIV PRESS INC
PI  - CARY
PA  - JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
DA  - JUN
PY  - 2018
VL  - 82
IS  - 6
SP  - E181
EP  - E183
DO  - 10.1093/neuros/nyy055
AN  - WOS:000439697700004
ER  -

TY  - JOUR
AU  - Sharma, R
AU  - Katiyar, V
AU  - Sharma, P
AU  - Gurjar, H
TI  - Systemic inflammatory response in pediatric central nervous system tumors
T2  - ACTA NEUROCHIRURGICA
KW  - LYMPHOCYTE RATIO
KW  - NEUTROPHIL
AD  - All India Inst Med Sci, Dept Neurosurg, CNC, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER WIEN
PI  - WIEN
PA  - SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
DA  - JUN
PY  - 2018
VL  - 160
IS  - 6
SP  - 1215
EP  - 1216
DO  - 10.1007/s00701-018-3542-8
AN  - WOS:000431942900016
ER  -

TY  - JOUR
AU  - Sharma, R
AU  - Sharma, P
AU  - Katiyar, V
AU  - Vora, Z
AU  - Gurjar, H
TI  - Can diabetic ketoacidosis (DKA) precipitate posterior reversible encephalopathy syndrome (PRES)?
T2  - CHILDS NERVOUS SYSTEM
AD  - AIIMS, Dept Neurosurg, CNC, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Radiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - JUN
PY  - 2018
VL  - 34
IS  - 6
SP  - 1107
EP  - 1108
DO  - 10.1007/s00381-018-3799-5
AN  - WOS:000433025700004
ER  -

TY  - JOUR
AU  - Singh, PK
AU  - Sharma, S
AU  - Ghosh, M
AU  - Shastri, SS
AU  - Gupta, N
AU  - Kabra, M
TI  - Spectrum of <i>GJB2</i> gene variants in Indian children with non-syndromic hearing loss
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
KW  - MUTATIONS
KW  - IMPAIRMENT
KW  - FAMILIES
KW  - POPULATION
KW  - PREVALENCE
KW  - FREQUENCY
KW  - KERALA
AD  - All India Inst Med Sci, Dept Pediat, Div Genet, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - JUN
PY  - 2018
VL  - 147
SP  - 615
EP  - 618
DO  - 10.4103/ijmr.IJMR_76_16
AN  - WOS:000443203500014
ER  -

TY  - JOUR
AU  - Singh, P
AU  - Arora, A
AU  - Strand, TA
AU  - Leffler, DA
AU  - Catassi, C
AU  - Green, PH
AU  - Kelly, CP
AU  - Ahuja, V
AU  - Makharia, GK
TI  - Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis
T2  - CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
KW  - Epidemiology
KW  - Gluten
KW  - Diet
KW  - Autoimmune Disorder
KW  - HEALTHY BLOOD-DONORS
KW  - TISSUE-TRANSGLUTAMINASE ANTIBODY
KW  - TURKISH SCHOOL-CHILDREN
KW  - GENERAL-POPULATION
KW  - ADULT-POPULATION
KW  - SAUDI-ARABIA
KW  - ANTIGLIADIN ANTIBODIES
KW  - UNITED-STATES
KW  - RISK GROUPS
KW  - URBAN AREA
AB  - BACKGROUND & AIMS: Celiac disease is a major public health problem worldwide. Although initially it was reported from countries with predominant Caucasian populations, it now has been reported from other parts of the world. The exact global prevalence of celiac disease is not known. We conducted a systematic review and meta-analysis to estimate the global prevalence of celiac disease.
   METHODS: We searched Medline, PubMed, and EMBASE for the keywords celiac disease, celiac, celiac disease, tissue transglutaminase antibody, anti-endomysium antibody, endomysial antibody, and prevalence for studies published from January 1991 through March 2016. Each article was cross-referenced with the words Asia, Europe, Africa, South America, North America, and Australia. The diagnosis of celiac disease was based on European Society of Pediatric Gastroenterology, Hepatology, and Nutrition guidelines. Of 3843 articles, 96 articles were included in the final analysis.
   RESULTS: The pooled global prevalence of celiac disease was 1.4% (95% confidence interval, 1.1%-1.7%) in 275,818 individuals, based on positive results from tests for anti-tissue transglutaminase and/or anti-endomysial antibodies (called seroprevalence). The pooled global prevalence of biopsy-confirmed celiac disease was 0.7% (95% confidence interval, 0.5%-0.9%) in 138,792 individuals. The prevalence values for celiac disease were 0.4% in South America, 0.5% in Africa and North America, 0.6% in Asia, and 0.8% in Europe and Oceania; the prevalence was higher in female vs male individuals (0.6% vs 0.4%; P < .001). The prevalence of celiac disease was significantly greater in children than adults (0.9% vs 0.5%; P < .001).
   CONCLUSIONS: In a systematic review and meta-analysis, we found celiac disease to be reported worldwide. The prevalence of celiac disease based on serologic test results is 1.4% and based on biopsy results is 0.7%. The prevalence of celiac disease varies with sex, age, and location. There is a need for population-based prevalence studies in many countries.
AD  - Beth Israel Deaconess Med Ctr, Div Gastroenterol & Hepatol, Boston, MA 02215 USAAD  - Lady Hardinge Med Coll & Hosp, New Delhi, IndiaAD  - Innlandet Hosp Trust, Lillehammer, NorwayAD  - Univ Bergen, Ctr Int Hlth, Bergen, NorwayAD  - Takeda Pharmaceut Inc, Gastroenterol Res & Dev, Cambridge, MA USAAD  - Univ Politecn Marche, Dept Pediat, Ancona, ItalyAD  - Columbia Univ, Med Ctr, Dept Med, New York, NY USAAD  - Columbia Univ, Med Ctr, USA Celiac Dis Ctr, New York, NY USAAD  - All India Inst Med Sci, Dept Gastroenterol & Human Nutr, New Delhi 110029, IndiaC3  - Harvard UniversityC3  - Beth Israel Deaconess Medical CenterC3  - Lady Hardinge Medical College & HospitalC3  - Innlandet Hospital TrustC3  - University of BergenC3  - Marche Polytechnic UniversityC3  - Columbia UniversityC3  - Columbia UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - JUN
PY  - 2018
VL  - 16
IS  - 6
SP  - 823
EP  - +
DO  - 10.1016/j.cgh.2017.06.037
AN  - WOS:000432676600017
ER  -

TY  - JOUR
AU  - Singh, S
AU  - Taneja, N
AU  - Bala, P
AU  - Verma, KK
AU  - Devarajan, LSJ
TI  - Aicardi-Goutieres syndrome: cold-induced acral blemish is not always cryoglobulinaemic vasculitis or chilblain lupus
T2  - CLINICAL AND EXPERIMENTAL DERMATOLOGY
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neuroradiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUN
PY  - 2018
VL  - 43
IS  - 4
SP  - 488
EP  - 490
DO  - 10.1111/ced.13376
AN  - WOS:000431979500029
ER  -

TY  - JOUR
AU  - Singla, R
AU  - Katiyar, V
AU  - Sharma, R
AU  - Gurjar, H
TI  - Is decision-making easier post RESCUE ICP trial?
T2  - ACTA NEUROCHIRURGICA
KW  - TRAUMATIC BRAIN-INJURY
KW  - DECOMPRESSIVE CRANIECTOMY
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER WIEN
PI  - WIEN
PA  - SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
DA  - JUN
PY  - 2018
VL  - 160
IS  - 6
SP  - 1301
EP  - 1302
DO  - 10.1007/s00701-018-3533-9
AN  - WOS:000431942900030
ER  -

TY  - JOUR
AU  - Singla, R
AU  - Kamra, D
AU  - Sharma, R
AU  - Katiyar, V
AU  - Gurjar, H
TI  - Do Gliomas Behave Differently in Patients with Human Immunodeficienicy Virus?
T2  - WORLD NEUROSURGERY
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - JUN
PY  - 2018
VL  - 114
SP  - 431
EP  - 431
DO  - 10.1016/j.wneu.2018.03.104
AN  - WOS:000432959600238
ER  -

TY  - JOUR
AU  - Srivastava, V
AU  - Dalal, D
AU  - Kumar, A
AU  - Prakash, S
AU  - Dalal, K
TI  - <i>In vivo</i> automated quantification of quality of apples during storage using optical coherence tomography images
T2  - LASER PHYSICS
KW  - optical coherence tomography
KW  - machine learning
KW  - texture analysis
KW  - support vector machine
KW  - MALUS-DOMESTICA BORKH.
AB  - Moisture content is an important feature of fruits and vegetables. As 80% of apple content is water, so decreasing the moisture content will degrade the quality of apples (Golden Delicious). The computational and texture features of the apples were extracted from optical coherence tomography (OCT) images. A support vector machine with a Gaussian kernel model was used to perform automated classification. To evaluate the quality of wax coated apples during storage in vivo, our proposed method opens up the possibility of fully automated quantitative analysis based on the morphological features of apples. Our results demonstrate that the analysis of the computational and texture features of OCT images may be a good non-destructive method for the assessment of the quality of apples.
AD  - Thapar Univ, Dept Elect & Instrumentat Engn, Patiala, Punjab, IndiaAD  - All India Inst Med Sci, Dept Biophys, New Delhi, IndiaAD  - Univ Pretoria, Dept Elect Elect & Comp Engn, Pretoria, South AfricaAD  - All India Inst Ayurveda, New Delhi, IndiaC3  - Thapar Institute of Engineering & TechnologyC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of PretoriaPU  - IOP Publishing Ltd
PI  - BRISTOL
PA  - TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
DA  - JUN
PY  - 2018
VL  - 28
IS  - 6
C7  - 066207
DO  - 10.1088/1555-6611/aab485
AN  - WOS:000431797100001
ER  -

TY  - JOUR
AU  - Subbiah, A
AU  - Bagchi, S
AU  - Bhowmik, D
AU  - Mahajan, S
AU  - Yadav, RK
AU  - Chhabra, Y
AU  - Agarwal, S
TI  - Dengue fever in renal allograft recipients: Clinical course and outcome
T2  - TRANSPLANT INFECTIOUS DISEASE
KW  - dengue
KW  - outcome
KW  - renal transplantation
KW  - TRANSPLANT PATIENTS
KW  - CASE SERIES
KW  - INFECTION
AB  - BackgroundThere are annual outbreaks of dengue infection in tropical and subtropical countries. This retrospective study aimed to assess the clinical manifestation of dengue and outcome in renal transplant recipients.
   MethodsRenal transplant recipients diagnosed with dengue in the nephrology department during the outbreak from August 2015 to December 2015 were included in the study.
   ResultsTwenty patients developed dengue presenting during the outbreak. Mean age was 31.98.8years and all were males. Two patients had severe dengue (dengue hemorrhagic fever, dengue shock syndrome). Clinical presentation included febrile illness (95%), myalgia (65%), headache (30%), retro-orbital pain (10%), and mucocutaneous bleeding manifestations (10%). Three (15%) had third space fluid accumulation and 2 (10%) had hypotension. Ninety percent patients had thrombocytopenia, with 4 requiring platelet transfusion. Leucopenia (WBC<4000/mm(3)) developed in 50% patients. About 60% had transient transaminitis. One patient with severed dengue expired and 1 recovered with IV immunoglobulin therapy. About 40% patients had rise in serum creatinine, with complete recovery in all patients.
   ConclusionClinical manifestations of dengue infection in renal transplant recipients were similar to that in general population. However, leucopenia necessitating temporary withdrawal of immunosuppression was common. Renal dysfunction was frequent but completely reversible.
AD  - All India Inst Med Sci AIIMS, Dept Nephrol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - JUN
PY  - 2018
VL  - 20
IS  - 3
C7  - e12875
DO  - 10.1111/tid.12875
AN  - WOS:000434280600016
ER  -

TY  - JOUR
AU  - Sudhanshu, S
AU  - Riaz, I
AU  - Sharma, R
AU  - Desai, MP
AU  - Parikh, R
AU  - Bhatia, V
TI  - Newborn Screening Guidelines for Congenital Hypothyroidism in India: Recommendations of the Indian Society for Pediatric and Adolescent Endocrinology (ISPAE) - Part II: Imaging, Treatment and Follow-up
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Clinical practice guidelines
KW  - Cord blood
KW  - Dried blood spot
KW  - Newborn thyroid screening
KW  - LEVOTHYROXINE
KW  - CHILDREN
AB  - The Indian Society for Pediatric and Adolescent Endocrinology has formulated Clinical Practice Guidelines for newborn screening, diagnosis and management of congenital hypothyroidism (CH). This manuscript, part II addresses management and follow-up. Recommendations: Screening should be done for every newborn using cord blood, or postnatal blood ideally at 48 to 72 h of age. Neonates with screen TSH > 20 mIU/L serum units (or >34 mIU/L for samples taken between 24 and 48 h of age) should be recalled for confirmation. For screen TSH > 40 mIU/L, immediate confirmatory venous T4/FT4 and TSH, and for mildly elevated screen TSH, a second screening TSH at 7 to 10 d of age, should be taken. Preterm and low birth weight infants should undergo screening at 48-72 h age. Sick babies should be screened at least by 7 d of age. Venous confirmatory TSH >20 mIU/L before age 2 wk and >10 mIU/L after age 2 wk, with low T4 (<10 mu g/dL) or FT4 (<1.17 ng/dL) indicate primary CH and treatment initiation. Imaging is recommended by radionuclide scintigraphy and ultrasonography after CH is biochemically confirmed but treatment should not be delayed till scans are performed. Levothyroxine is commenced at 10-15 mu g/kg in the neonatal period. Serum T4/FT4 is measured at 2 wk and TSH and T4/FT4 at 1 mo, then 2 monthly till 6 mo, 3 monthly from 6 mo-3 y and every 3-6 mo thereafter. Babies with the possibility of transient CH should be re-evaluated at age 3 y, to assess the need for lifelong therapy.
AD  - Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrinol, Lucknow, Uttar Pradesh, IndiaAD  - SAT Hosp, Govt Med Coll, Dept Pediat, Thiruvananthapuram 695011, Kerala, IndiaAD  - All India Inst Med Sci, Dept Pediat, Div Pediat Endocrinol, Room 3058,Teaching Block, New Delhi, IndiaAD  - Bai Jerbai Wadia Hosp Children, Inst Child Hlth & Res Ctr, Div Pediat Endocrinol, Bombay, Maharashtra, IndiaC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUN
PY  - 2018
VL  - 85
IS  - 6
SP  - 448
EP  - 453
DO  - 10.1007/s12098-017-2576-x
AN  - WOS:000432220600009
ER  -

TY  - JOUR
AU  - Temkar, S
AU  - Karuppaiah, N
AU  - Takkar, B
AU  - Bhowmik, D
AU  - Tripathi, M
AU  - Ramakrishnan, S
AU  - Sharma, YR
AU  - Vohra, R
AU  - Chawla, R
AU  - Venkatesh, P
TI  - Impact of estimated glomerular filtration rate on diabetic macular edema
T2  - INTERNATIONAL OPHTHALMOLOGY
KW  - Diabetic macular edema
KW  - Estimated glomerular filtration rate
KW  - Diabetic nephropathy
KW  - Diabetic retinopathy
KW  - RISK-FACTORS
KW  - CLINICAL-RESPONSE
KW  - RETINOPATHY
KW  - MICROALBUMINURIA
KW  - ASSOCIATION
KW  - PREVALENCE
KW  - SEVERITY
KW  - PATTERNS
AB  - Diabetic macular edema (DME) is a major cause of visual impairment in patients with diabetes and is influenced by various systemic factors. This study evaluates the effect of renal status on DME using estimated glomerular filtration rate (eGFR) as a study marker.
   This was a prospective observational cross-sectional study. One hundred and ninety-five patients of diabetic retinopathy (DR) were included. Group 1 had patients of DR without DME (n = 100), and group 2 had patients of DR with DME (n = 95). All patients were evaluated for DR/DME-related risk factors. eGFR was calculated in all patients. Spectral domain optical coherence tomography (SDOCT) was done to identify the various patterns and severity of DME.
   Group 2 patients had significantly higher comorbidities than those in group 1 (p < 0.001). Hba1c, total cholesterol, triglycerides, LDL/HDL ratio, systolic and diastolic blood pressures were significantly higher in group II (p < 0.001 in each). There was no significant difference between the groups in terms of blood urea, serum creatinine or eGFR. eGFR did not show a significant association with a specific SDOCT pattern or severity of DME.
   Comorbidities are more common and more severe in patients with DME. However, eGFR as a marker was not useful in predicting either the severity or pattern of DME. eGFR, in its present form, may not be useful in the evaluation and management of patients with DME.
AD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, Retina Serv, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, Uvea Serv, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Nephrol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Cardiol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - JUN
PY  - 2018
VL  - 38
IS  - 3
SP  - 1043
EP  - 1050
DO  - 10.1007/s10792-017-0557-8
AN  - WOS:000434373500018
ER  -

TY  - JOUR
AU  - Thergaonkar, R
AU  - Narang, A
AU  - Gurjar, B
AU  - Tiwari, P
AU  - Puraswani, M
AU  - Saini, H
AU  - Sinha, A
AU  - Varma, B
AU  - Mukerji, M
AU  - Hari, P
AU  - Bagga, A
TI  - Targeted exome sequencing in anti-factor H antibody negative HUS reveals multiple variations
T2  - CLINICAL AND EXPERIMENTAL NEPHROLOGY
KW  - Hemolytic uremic syndrome
KW  - Next-generation sequencing
KW  - Multiplex ligation-dependent probe amplification
KW  - HEMOLYTIC-UREMIC SYNDROME
KW  - MEMBRANE COFACTOR PROTEIN
KW  - MUTATION DATABASE
KW  - GENETIC-ANALYSIS
KW  - COMPLEMENT
KW  - VARIANTS
KW  - ASSOCIATION
KW  - GUIDELINES
KW  - OUTCOMES
KW  - AHUS
AB  - Genetic susceptibility to atypical hemolytic uremic syndrome (aHUS) may lie within genes regulating or activating the alternate complement and related pathways converging on endothelial cell activation.
   We tested 32 Indian patients of aHUS negative for antibodies to complement factor H for genetic variations in a panel of 15 genes, i.e., CFH, CFHR1-5, CFI, CFB, C3, CD46, MASP2, DGKE, ADAMTS13, THBD and PLG using next-generation DNA sequencing and for copy number variation in CFHR1-3.
   Despite absence of a public database of exome variations in the Indian population and limited functional studies, we could establish a genetic diagnosis in 6 (18.8%) patients using a stringent scheme of prioritization. One patient carried a likely pathogenic variation. The number of patients carrying possibly pathogenic variation was as follows: 1 variation: 5 patients, 2 variations: 9 patients, 3 variations: 5 patients, 4 variations: 9 patients, 5 variations: 2 patients and 6 variations: 2 patients. Homozygous deletion of CFHR1-3 was present in five patients; none of these carried a diagnostic genetic variation. Patients with or without diagnostic variation did not differ significantly in terms of enrichment of genetic variations that were rare/novel or predicted deleterious, or for possible environmental triggers.
   We conclude that genetic testing for multiple genes in patients with aHUS negative for anti-FH antibodies reveals multiple candidate variations that require prioritization. Population data on variation frequency of the Indian population and supportive functional studies are likely to improve diagnostic yield.
AD  - All India Inst Med Sci, Dept Pediat, Div Nephrol, New Delhi 110029, IndiaAD  - CSIR, Inst Genom & Integrat Biol, New Delhi, IndiaAD  - Natl Inst Immunol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Department of Biotechnology (DBT) IndiaC3  - National Institute of Immunology (NII)PU  - SPRINGER
PI  - NEW YORK
PA  - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
DA  - JUN
PY  - 2018
VL  - 22
IS  - 3
SP  - 653
EP  - 660
DO  - 10.1007/s10157-017-1478-6
AN  - WOS:000432518900019
ER  -

TY  - JOUR
AU  - Titiyal, JS
AU  - Kaur, M
AU  - Brar, AS
AU  - Falera, R
TI  - "Meniscus Sign" to Identify the Lenticule Edge in Small-Incision Lenticule Extraction
T2  - CORNEA
KW  - small-incision lenticule extraction
KW  - lenticule misdissection
KW  - meniscus sign SMILE
KW  - cap lenticular adhesions SMILE
KW  - COMPLICATIONS
AB  - Purpose: To describe our technique of lenticule edge identification in small-incision lenticule extraction using the "meniscus sign" to prevent lenticule misdissection.
   Methods: Femtosecond laser application for small-incision lenticule extraction was performed. A "double ring" was visible, signifying the edge of the cap cut (outer ring) and lenticule cut (inner ring). The anterior and posterior lamellar planes were delineated in 2 different directions. During creation of the posterior lamellar channel, the lenticule edge was slightly pushed away from the surgeon to create a gap between the inner ring (diameter of the lenticule cut) and the lenticule edge. The lenticule edge assumed a frilled wavy appearance, and the meniscus sign was observed as a gap between the lenticule edge and the inner ring. The meniscus-shaped gap served as a landmark to identify the lenticule edge, and the relationship between the frilled lenticule edge and surgical instruments further acted as a guide to identify the correct plane of dissection.
   Results: This technique was successfully undertaken in 50 eyes of 25 patients. The meniscus sign was observed in all cases, and no case had cap lenticular adhesions.
   Conclusions: The meniscus sign helps to identify the lenticule edge and correct dissection planes and provides a visual landmark during the entire surgical procedure.
AD  - All India Inst Med Sci, Cornea Cataract & Refract Surg Serv, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - JUN
PY  - 2018
VL  - 37
IS  - 6
SP  - 799
EP  - 801
DO  - 10.1097/ICO.0000000000001538
AN  - WOS:000443069100026
ER  -

TY  - JOUR
AU  - Tyagi, A
AU  - Pramanik, R
AU  - Chaudhary, S
AU  - Chopra, A
AU  - Bakhshi, S
TI  - Cytogenetic Profiles of 472 Indian Children with Acute Myeloid Leukemia
T2  - INDIAN PEDIATRICS
KW  - Childhood cancers
KW  - Chloroma
KW  - Chromosomal translocation
KW  - Karyotype
KW  - ADULTS
KW  - CLASSIFICATION
KW  - AML
AB  - To analyze the cytogenetic abnormalities of a large cohort of consecutive pediatric Acute Myeloid Leukemia (AML) patients, treated on a uniform protocol.
   Review of case records.
   Pediatric Cancer Center of tertiary care hospital between June 2003 and June 2016.
   617 consecutive de novo pediatric AML patients were screened and 472 patients were found eligible. Eligibility criteria included non M3 patients, successful cytogenetic profile and availability of complete records
   Cytogenetic profile.
   Gum-hypertropy, chloromas and rate of complete remission were significantly different between European Leukemia Network classification (ELN) cytogenetic risk groups (P < 0.01). t (8;21) (141, 29.8%), loss of Y chromosome (61,12.9%) and trisomy 8 (39, 8.3%) were the most common abnormalities. Among the chromosomal gains, trisomy 8 and trisomy 21 (both P < 0.01) were significantly different among the three ELN risk groups. Among the chromosome losses, monosomy 5, 7 (both P < 0.01) and 9 (P=0.03), loss of X and loss of Y (both P < 0.01) were statistically different amongst three cytogenetic risk groups. Event-free survival (P < 0.01) and overall survival (P < 0.01) were found to be significantly different among the three risk groups.
   The higher frequency of t (8; 21) and its association with chloroma in Indian pediatric patients is different from other studies around the world.
AD  - All India Inst Med Sci, Dept Med Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Lab Oncol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - JUN
PY  - 2018
VL  - 55
IS  - 6
SP  - 469
EP  - 473
DO  - 10.1007/s13312-018-1335-z
AN  - WOS:000439992700003
ER  -

TY  - JOUR
AU  - Venkatesh, P
AU  - Kashyap, S
AU  - Temkar, S
AU  - Gogia, V
AU  - Garg, G
AU  - Bafna, RK
TI  - Endoillumination (chandelier) and wide-angle viewing-assisted fine-needle aspiration biopsy of intraocular mass lesions
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Biopsy
KW  - chandelier
KW  - endoillumination
KW  - fine-needle aspiration
KW  - intraocular mass
KW  - UVEAL MELANOMA
KW  - CYTOGENETICS
KW  - TUMORS
AB  - Fine-needle aspiration biopsy (FNAB) of intraocular mass lesions is an important intervention in the presence of diagnostic difficulty. FNAB of intraocular mass lesions is also likely to become more commonly recommended for prognostication of tumors such as choroidal melanoma. The most commonly described approach for tumor localization and visualization during FNAB is transillumination and indirect ophthalmoscopic viewing. Herein, we report endoillumination (chandelier) and wide-angle viewing assisted, microscope-based approach for FNAB in two patients using two port minimally invasive vitreoretinal surgical approach. The submission is supported by a video demonstration. The entire procedure was completed under the microscope. Adequate sample was obtained. In the first patient, the inflammatory nature of the lesion was confirmed though magnetic resonance imaging had been reported as melanoma. In the second patient, a clinical diagnosis of amelanotic melanoma was confirmed. Endoillumination-assisted FNAB of intraocular mass lesions is easier to learn and more precise and hence carries lesser risks.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - JUN
PY  - 2018
VL  - 66
IS  - 6
SP  - 845
EP  - 847
C7  - PMID 29785997
DO  - 10.4103/ijo.IJO_1306_17
AN  - WOS:000433099600021
ER  -

TY  - JOUR
AU  - Zhou, B
AU  - Bentham, J
AU  - Di Cesare, M
AU  - Bixby, H
AU  - Danaei, G
AU  - Hajifathalian, K
AU  - Taddei, C
AU  - Carrillo-Larco, RM
AU  - Djalalinia, S
AU  - Khatibzadeh, S
AU  - Lugero, C
AU  - Peykari, N
AU  - Zhang, WZ
AU  - Bennett, J
AU  - Bilano, V
AU  - Stevens, GA
AU  - Cowan, MJ
AU  - Riley, LM
AU  - Chen, ZM
AU  - Hambleton, IR
AU  - Jackson, RT
AU  - Kengne, AP
AU  - Khang, YH
AU  - Laxmaiah, A
AU  - Liu, J
AU  - Malekzadeh, R
AU  - Neuhauser, HK
AU  - Soric, M
AU  - Starc, G
AU  - Sundström, J
AU  - Woodward, M
AU  - Ezzati, M
AU  - Abarca-Gómez, L
AU  - Abdeen, ZA
AU  - Abu-Rmeileh, NM
AU  - Acosta-Cazares, B
AU  - Adams, RJ
AU  - Aekplakorn, W
AU  - Afsana, K
AU  - Aguilar-Salinas, CA
AU  - Agyemang, C
AU  - Ahmad, NA
AU  - Ahmadvand, A
AU  - Ahrens, W
AU  - Ajlouni, K
AU  - Akhtaeva, N
AU  - Al-Raddadi, R
AU  - Ali, MM
AU  - Ali, O
AU  - Alkerwi, A
AU  - Aly, E
AU  - Amarapurkar, DN
AU  - Amouyel, P
AU  - Amuzu, A
AU  - Andersen, LB
AU  - Anderssen, SA
AU  - Ängquist, LH
AU  - Anjana, RM
AU  - Ansong, D
AU  - Aounallah-Skhiri, H
AU  - Araújo, J
AU  - Ariansen, I
AU  - Aris, T
AU  - Arlappa, N
AU  - Arveiler, D
AU  - Aryal, KK
AU  - Aspelund, T
AU  - Assah, FK
AU  - Assunçao, MCF
AU  - Avdicová, M
AU  - Azevedo, A
AU  - Azizi, F
AU  - Babu, BV
AU  - Bahijri, S
AU  - Balakrishna, N
AU  - Bamoshmoosh, M
AU  - Banach, M
AU  - Bandosz, P
AU  - Banegas, JR
AU  - Barbagallo, CM
AU  - Barceló, A
AU  - Barkat, A
AU  - Barros, AJD
AU  - Barros, MV
AU  - Bata, I
AU  - Batieha, AM
AU  - Batyrbek, A
AU  - Baur, LA
AU  - Beaglehole, R
AU  - Ben Romdhane, H
AU  - Benet, M
AU  - Benson, LS
AU  - Bernabe-Ortiz, A
AU  - Bernotiene, G
AU  - Bettiol, H
AU  - Bhagyalaxmi, A
AU  - Bharadwaj, S
AU  - Bhargava, SK
AU  - Bi, YF
AU  - Bikbov, M
AU  - Bista, B
AU  - Bjerregaard, P
AU  - Bjertness, E
AU  - Bjertness, MB
AU  - Björkelund, C
AU  - Blokstra, A
AU  - Bo, S
AU  - Bobak, M
AU  - Boeing, H
AU  - Boggia, JG
AU  - Boissonnet, CP
AU  - Bongard, V
AU  - Borchini, R
AU  - Bovet, P
AU  - Braeckman, L
AU  - Brajkovich, I
AU  - Branca, F
AU  - Breckenkamp, J
AU  - Brenner, H
AU  - Brewster, LM
AU  - Bruno, G
AU  - Bueno-de-Mesquita
AU  - Bugge, A
AU  - Burns, C
AU  - Bursztyn, M
AU  - de León, AC
AU  - Cacciottolo, J
AU  - Cai, H
AU  - Cameron, C
AU  - Can, G
AU  - Cândido, APC
AU  - Capuano, V
AU  - Cardoso, VC
AU  - Carlsson, AC
AU  - Carvalho, MJ
AU  - Casanueva, FF
AU  - Casas, JP
AU  - Caserta, CA
AU  - Chamukuttan, S
AU  - Chan, AW
AU  - Chan, QEN
AU  - Chaturvedi, HK
AU  - Chaturvedi, N
AU  - Chen, CJ
AU  - Chen, FF
AU  - Chen, HS
AU  - Chen, SH
AU  - Chen, ZM
AU  - Cheng, CY
AU  - Dekkaki, IC
AU  - Chetrit, A
AU  - Chiolero, A
AU  - Chiou, ST
AU  - Chirita-Emandi, A
AU  - Chirlaque, MD
AU  - Cho, BL
AU  - Cho, Y
AU  - Christofaro, DG
AU  - Chudek, J
AU  - Cifkova, R
AU  - Cinteza, E
AU  - Claessens, F
AU  - Clays, E
AU  - Concin, H
AU  - Cooper, C
AU  - Cooper, R
AU  - Coppinger, TC
AU  - Costanzo, S
AU  - Cottel, D
AU  - Cowell, C
AU  - Craig, CL
AU  - Crujeiras, AB
AU  - Cruz, JJ
AU  - D'Arrigo, G
AU  - d'Orsi, E
AU  - Dallongeville, J
AU  - Damasceno, A
AU  - Danaei, G
AU  - Dankner, R
AU  - Dantoft, TM
AU  - Dauchet, L
AU  - Davletov, K
AU  - De Backer, G
AU  - De Bacquer, D
AU  - de Gaetano, G
AU  - De Henauw, S
AU  - de Oliveira, PD
AU  - De Smedt, D
AU  - Deepa, M
AU  - Dehghan, A
AU  - Delisle, H
AU  - Deschamps, V
AU  - Dhana, K
AU  - Di Castelnuovo, AF
AU  - Dias-da-Costa, JS
AU  - Diaz, A
AU  - Dickerson, TT
AU  - Djalalinia, S
AU  - Do, HTP
AU  - Dobson, AJ
AU  - Donfrancesco, C
AU  - Donoso, SP
AU  - Döring, A
AU  - Dorobantu, M
AU  - Doua, K
AU  - Drygas, W
AU  - Dulskiene, V
AU  - Dzakula, A
AU  - Dzerve, V
AU  - Dziankowska-Zaborszczyk, E
AU  - Eggertsen, R
AU  - Ekelund, U
AU  - El Ati, J
AU  - Elliott, P
AU  - Elosua, R
AU  - Erasmus, RT
AU  - Erem, C
AU  - Eriksen, L
AU  - Eriksson, JG
AU  - Escobedo-de La Peña, J
AU  - Evans, A
AU  - Faeh, D
AU  - Fall, CH
AU  - Farzadfar, F
AU  - Felix-Redondo, FJ
AU  - Ferguson, TS
AU  - Fernandes, RA
AU  - Fernández-Bergés, D
AU  - Ferrante, D
AU  - Ferrari, M
AU  - Ferreccio, C
AU  - Ferrieres, J
AU  - Finn, JD
AU  - Fischer, K
AU  - Föger, B
AU  - Foo, LH
AU  - Forslund, AS
AU  - Forsner, M
AU  - Fouad, HM
AU  - Francis, DK
AU  - Franco, MD
AU  - Franco, OH
AU  - Frontera, G
AU  - Fuchs, FD
AU  - Fuchs, SC
AU  - Fujita, Y
AU  - Furusawa, T
AU  - Gaciong, Z
AU  - Galvano, F
AU  - Garcia-de-la-Hera, M
AU  - Gareta, D
AU  - Garnett, SP
AU  - Gaspoz, JM
AU  - Gasull, M
AU  - Gates, L
AU  - Geleijnse, JM
AU  - Ghasemian, A
AU  - Ghimire, A
AU  - Giampaoli, S
AU  - Gianfagna, F
AU  - Gill, TK
AU  - Giovannelli, J
AU  - Goldsmith, RA
AU  - Gonçalves, H
AU  - Gonzalez-Gross, M
AU  - González-Rivas, JP
AU  - Gorbea, MB
AU  - Gottrand, F
AU  - Graff-Iversen, S
AU  - Grafnetter, D
AU  - Grajda, A
AU  - Grammatikopoulou, MG
AU  - Gregor, RD
AU  - Grodzicki, T
AU  - Grontved, A
AU  - Grosso, G
AU  - Gruden, G
AU  - Grujic, V
AU  - Gu, DF
AU  - Guan, OP
AU  - Gudmundsson, EF
AU  - Gudnason, V
AU  - Guerrero, R
AU  - Guessous, I
AU  - Guimaraes, AL
AU  - Gulliford, MC
AU  - Gunnlaugsdottir, J
AU  - Gunter, M
AU  - Gupta, PC
AU  - Gupta, R
AU  - Gureje, O
AU  - Gurzkowska, B
AU  - Gutierrez, L
AU  - Gutzwiller, F
AU  - Hadaegh, F
AU  - Halkjaer, J
AU  - Hambleton, IR
AU  - Hardy, R
AU  - Kumar, RH
AU  - Hata, J
AU  - Hayes, AJ
AU  - He, J
AU  - He, YN
AU  - Hendriks, ME
AU  - Henriques, A
AU  - Cadena, LH
AU  - Herrala, S
AU  - Heshmat, R
AU  - Hihtaniemi, IT
AU  - Ho, SY
AU  - Ho, SC
AU  - Hobbs, M
AU  - Hofman, A
AU  - Dinc, GH
AU  - Horimoto, ARVR
AU  - Hormiga, CM
AU  - Horta, BL
AU  - Houti, L
AU  - Howitt, C
AU  - Htay, TT
AU  - Htet, AS
AU  - Htike, MMT
AU  - Hu, YH
AU  - Huerta, JM
AU  - Huisman, M
AU  - Husseini, AS
AU  - Huybrechts, I
AU  - Hwalla, N
AU  - Iacoviello, L
AU  - Iannone, AG
AU  - Ibrahim, MM
AU  - Wong, NI
AU  - Ikeda, N
AU  - Ikram, MA
AU  - Irazola, VE
AU  - Islam, M
AU  - Ismail, AA
AU  - Ivkovic, V
AU  - Iwasaki, M
AU  - Jackson, RT
AU  - Jacobs, JM
AU  - Jaddou, H
AU  - Jafar, T
AU  - Jamrozik, K
AU  - Janszky, I
AU  - Jasienska, G
AU  - Jelakovic, A
AU  - Jelakovic, B
AU  - Jennings, G
AU  - Jeong, SL
AU  - Jiang, CQ
AU  - Joffres, M
AU  - Johansson, M
AU  - Jokelainen, JJ
AU  - Jonas, JB
AU  - Jorgensen, T
AU  - Joshi, P
AU  - Józwiak, J
AU  - Juolevi, A
AU  - Jurak, G
AU  - Juresa, V
AU  - Kaaks, R
AU  - Kafatos, A
AU  - Kajantie, EO
AU  - Kalter-Leibovici, O
AU  - Kamaruddin, NA
AU  - Karki, KB
AU  - Kasaeian, A
AU  - Katz, J
AU  - Kauhanen, J
AU  - Kaur, P
AU  - Kavousi, M
AU  - Kazakbaeva, G
AU  - Keil, U
AU  - Boker, LK
AU  - Keinänen-Kiukaanniemi, S
AU  - Kelishadi, R
AU  - Kemper, HCG
AU  - Kengne, AP
AU  - Kerimkulova, A
AU  - Kersting, M
AU  - Key, T
AU  - Khader, YS
AU  - Khalili, D
AU  - Khang, YH
AU  - Khateeb, M
AU  - Khaw, KT
AU  - Kiechl-Kohlendorfer, U
AU  - Kiechl, S
AU  - Killewo, J
AU  - Kim, J
AU  - Kim, YY
AU  - Klumbiene, J
AU  - Knoflach, M
AU  - Kolle, E
AU  - Kolsteren, P
AU  - Korrovits, P
AU  - Koskinen, S
AU  - Kouda, K
AU  - Kowlessur, S
AU  - Koziel, S
AU  - Kriemler, S
AU  - Kristensen, PL
AU  - Krokstad, S
AU  - Kromhout, D
AU  - Kruger, HS
AU  - Kubinova, R
AU  - Kuciene, R
AU  - Kuh, D
AU  - Kujala, UM
AU  - Kulaga, Z
AU  - Kumar, RK
AU  - Kurjata, P
AU  - Kusuma, YS
AU  - Kuulasmaa, K
AU  - Kyobutungi, C
AU  - Laatikainen, T
AU  - Lachat, C
AU  - Lam, TH
AU  - Landrove, O
AU  - Lanska, V
AU  - Lappas, G
AU  - Larijani, B
AU  - Laugsand, LE
AU  - Laxmaiah, A
AU  - Bao, KLN
AU  - Le, TD
AU  - Leclercq, C
AU  - Lee, J
AU  - Lee, J
AU  - Lehtimäki, T
AU  - León-Muñoz, LM
AU  - Levitt, NS
AU  - Li, YP
AU  - Lilly, CL
AU  - Lim, WY
AU  - Lima-Costa, MF
AU  - Lin, HH
AU  - Lin, X
AU  - Lind, L
AU  - Linneberg, A
AU  - Lissner, L
AU  - Litwin, M
AU  - Liu, J
AU  - Lorbeer, R
AU  - Lotufo, PA
AU  - Lozano, JE
AU  - Luksiene, D
AU  - Lundqvist, A
AU  - Lunet, N
AU  - Lytsy, P
AU  - Ma, J
AU  - Machado-Coelho, GLL
AU  - Machi, S
AU  - Maggi, S
AU  - Magliano, DJ
AU  - Magriplis, E
AU  - Majer, M
AU  - Makdisse, M
AU  - Malekzadeh, R
AU  - Malhotra, R
AU  - Rao, KM
AU  - Malyutina, S
AU  - Manios, Y
AU  - Mann, JI
AU  - Manzato, E
AU  - Margozzini, P
AU  - Marques-Vidal, P
AU  - Marques, LP
AU  - Marrugat, J
AU  - Martorell, R
AU  - Mathiesen, EB
AU  - Matijasevich, A
AU  - Matsha, TE
AU  - Mbanya, JCN
AU  - Posso, AJM
AU  - McFarlane, SR
AU  - McGarvey, ST
AU  - McLachlan, S
AU  - McLean, RM
AU  - McLean, SB
AU  - McNulty, BA
AU  - Mediene-Benchekor, S
AU  - Medzioniene, J
AU  - Meirhaeghe, A
AU  - Meisinger, C
AU  - Menezes, AMB
AU  - Menon, GR
AU  - Meshram, II
AU  - Metspalu, A
AU  - Meyer, HE
AU  - Mi, J
AU  - Mikkel, K
AU  - Miller, JC
AU  - Minderico, CS
AU  - Francisco, J
AU  - Miranda, JJ
AU  - Mirrakhimov, E
AU  - Misigoj-Durakovic, M
AU  - Modesti, PA
AU  - Mohamed, MK
AU  - Mohammad, K
AU  - Mohammadifard, N
AU  - Mohan, V
AU  - Mohanna, S
AU  - Yusoff, MFM
AU  - Mollehave, LT
AU  - Moller, NC
AU  - Molnár, D
AU  - Momenan, A
AU  - Mondo, CK
AU  - Monyeki, KDK
AU  - Moon, JS
AU  - Moreira, LB
AU  - Morejon, A
AU  - Moreno, LA
AU  - Morgan, K
AU  - Moschonis, G
AU  - Mossakowska, M
AU  - Mostafa, A
AU  - Mota, J
AU  - Motlagh, ME
AU  - Motta, J
AU  - Msyamboza, KP
AU  - Mu, TT
AU  - Muiesan, ML
AU  - Müller-Nurasyid, M
AU  - Murphy, N
AU  - Mursu, J
AU  - Musil, V
AU  - Nabipour, I
AU  - Nagel, G
AU  - Naidu, BM
AU  - Nakamura, H
AU  - Námesná, J
AU  - Nang, EEK
AU  - Nangia, VB
AU  - Narake, S
AU  - Nauck, M
AU  - Navarrete-Muñoz, EM
AU  - Ndiaye, NC
AU  - Neal, WA
AU  - Nenko, I
AU  - Neovius, M
AU  - Nervi, F
AU  - Neuhauser, HK
AU  - Nguyen, CT
AU  - Nguyen, ND
AU  - Nguyen, QN
AU  - Nguyen, QV
AU  - Nieto-Martínez, RE
AU  - Niiranen, TJ
AU  - Ning, G
AU  - Ninomiya, T
AU  - Nishtar, S
AU  - Noale, M
AU  - Noboa, OA
AU  - Noorbala, AA
AU  - Norat, T
AU  - Noto, D
AU  - Al Nsour, M
AU  - O'Reilly, D
AU  - Oda, E
AU  - Oehlers, G
AU  - Oh, K
AU  - Ohara, K
AU  - Olinto, MTA
AU  - Oliveira, IO
AU  - Azahadi, M
AU  - Onat, A
AU  - Ong, SK
AU  - Ono, LM
AU  - Ordunez, P
AU  - Ornelas, R
AU  - Osmond, C
AU  - Ostojic, SM
AU  - Ostovar, A
AU  - Otero, JA
AU  - Overvad, K
AU  - Owusu-Dabo, E
AU  - Paccaud, FM
AU  - Padez, C
AU  - Pahomova, E
AU  - Pajak, A
AU  - Palli, D
AU  - Palmieri, L
AU  - Pan, WH
AU  - Panda-Jonas, S
AU  - Panza, F
AU  - Papandreou, D
AU  - Park, SW
AU  - Parnell, WR
AU  - Parsaeian, M
AU  - Patel, ND
AU  - Pecin, I
AU  - Pednekar, MS
AU  - Peer, N
AU  - Peeters, PH
AU  - Peixoto, SV
AU  - Peltonen, M
AU  - Pereira, AC
AU  - Peters, A
AU  - Petersmann, A
AU  - Petkeviciene, J
AU  - Peykari, N
AU  - Pham, ST
AU  - Pigeot, I
AU  - Pikhart, H
AU  - Pilav, A
AU  - Pilotto, L
AU  - Pitakaka, F
AU  - Piwonska, A
AU  - Plans-Rubió, P
AU  - Polasek, O
AU  - Porta, M
AU  - Portegies, MLP
AU  - Pourshams, A
AU  - Poustchi, H
AU  - Pradeepa, R
AU  - Prashant, M
AU  - Price, JF
AU  - Puder, JJ
AU  - Puiu, M
AU  - Punab, M
AU  - Qasrawi, RF
AU  - Qorbani, M
AU  - Bao, TQ
AU  - Radic, I
AU  - Radisauskas, R
AU  - Rahman, M
AU  - Raitakari, O
AU  - Raj, M
AU  - Rao, SR
AU  - Ramachandran, A
AU  - Ramos, E
AU  - Rampal, L
AU  - Rampal, S
AU  - Reina, DAR
AU  - Redon, J
AU  - Reganit, PFM
AU  - Ribeiro, R
AU  - Riboli, E
AU  - Rigo, F
AU  - de Wit, TFR
AU  - Ritti-Dias, RM
AU  - Robinson, SM
AU  - Robitaille, C
AU  - Rodríguez-Artalejo, F
AU  - Rodriguez-Perez, MD
AU  - Rodríguez-Villamizar, LA
AU  - Rojas-Martinez, R
AU  - Romaguera, D
AU  - Ronkainen, K
AU  - Rosengren, A
AU  - Roy, JGR
AU  - Rubinstein, A
AU  - Ruiz-Betancourt, BS
AU  - Rutkowski, M
AU  - Sabanayagam, C
AU  - Sachdev, HS
AU  - Saidi, O
AU  - Sakarya, S
AU  - Salanave, B
AU  - Martinez, ES
AU  - Salmerón, D
AU  - Salomaa, V
AU  - Salonen, JT
AU  - Salvetti, M
AU  - Sánchez-Abanto, J
AU  - Sans, S
AU  - Santos, DA
AU  - Santos, IS
AU  - dos Santos, RN
AU  - Santos, R
AU  - Saramies, JL
AU  - Sardinha, LB
AU  - Sarganas, G
AU  - Sarrafzadegan, N
AU  - Saum, KU
AU  - Savva, S
AU  - Scazufca, M
AU  - Schargrodsky, H
AU  - Schipf, S
AU  - Schmidt, CO
AU  - Schöttker, B
AU  - Schultsz, C
AU  - Schutte, AE
AU  - Sein, AA
AU  - Sen, A
AU  - Senbanjo, IO
AU  - Sepanlou, SG
AU  - Sharma, SK
AU  - Shaw, JE
AU  - Shibuya, K
AU  - Shin, DW
AU  - Shin, Y
AU  - Si-Ramlee, K
AU  - Siantar, R
AU  - Sibai, AM
AU  - Silva, DAS
AU  - Simon, M
AU  - Simons, J
AU  - Simons, LA
AU  - Sjöström, M
AU  - Skovbjerg, S
AU  - Slowikowska-Hilczer, J
AU  - Slusarczyk, P
AU  - Smeeth, L
AU  - Smith, MC
AU  - Snijder, MB
AU  - So, HK
AU  - Sobngwi, E
AU  - Söderberg, S
AU  - Solfrizzi, V
AU  - Sonestedt, E
AU  - Song, Y
AU  - Sorensen, TIA
AU  - Soric, M
AU  - Jérome, CS
AU  - Soumare, A
AU  - Staessen, JA
AU  - Starc, G
AU  - Stathopoulou, MG
AU  - Stavreski, B
AU  - Steene-Johannessen, J
AU  - Stehle, P
AU  - Stein, AD
AU  - Stergiou, GS
AU  - Stessman, J
AU  - Stieber, J
AU  - Stöckl, D
AU  - Stocks, T
AU  - Stokwiszewski, J
AU  - Stronks, K
AU  - Strufaldi, MW
AU  - Sun, CA
AU  - Sundström, J
AU  - Sung, YT
AU  - Suriyawongpaisal, P
AU  - Sy, RG
AU  - Tai, ES
AU  - Tammesoo, ML
AU  - Tamosiunas, A
AU  - Tan, EJ
AU  - Tang, X
AU  - Tanser, F
AU  - Tao, Y
AU  - Tarawneh, MR
AU  - Tarqui-Mamani, CB
AU  - Tautu, OF
AU  - Taylor, A
AU  - Theobald, H
AU  - Theodoridis, X
AU  - Thijs, L
AU  - Thuesen, BH
AU  - Tjonneland, A
AU  - Tolonen, HK
AU  - Tolstrup, JS
AU  - Topbas, M
AU  - Topór-Madry, R
AU  - Tormo, MJ
AU  - Torrent, M
AU  - Traissac, P
AU  - Trichopoulos, D
AU  - Trichopoulou, A
AU  - Trinh, OTH
AU  - Trivedi, A
AU  - Tshepo, L
AU  - Tulloch-Reid, MK
AU  - Tullu, F
AU  - Tuomainen, TP
AU  - Tuomilehto, J
AU  - Turley, ML
AU  - Tynelius, P
AU  - Tzourio, C
AU  - Ueda, P
AU  - Ugel, EE
AU  - Ulmer, H
AU  - Uusitalo, HMT
AU  - Valdivia, G
AU  - Valvi, D
AU  - van der Schouw, YT
AU  - Van Herck, K
AU  - Minh, HV
AU  - van Rossem, L
AU  - Van Schoor, NM
AU  - van Valkengoed, IGM
AU  - Vanderschueren, D
AU  - Vanuzzo, D
AU  - Vatten, L
AU  - Vega, T
AU  - Velasquez-Melendez, G
AU  - Veronesi, G
AU  - Verschuren, WMM
AU  - Verstraeten, R
AU  - Victora, CG
AU  - Viet, L
AU  - Viikari-Juntura, E
AU  - Vineis, P
AU  - Vioque, J
AU  - Virtanen, JK
AU  - Visvikis-Siest, S
AU  - Viswanathan, B
AU  - Vlasoff, T
AU  - Vollenweider, P
AU  - Voutilainen, S
AU  - Wade, AN
AU  - Wagner, A
AU  - Walton, J
AU  - Bebakar, WMW
AU  - Mohamud, WNW
AU  - Wanderley, RS
AU  - Wang, MD
AU  - Wang, Q
AU  - Wang, YX
AU  - Wang, YW
AU  - Wannamethee, SG
AU  - Wareham, N
AU  - Wedderkopp, N
AU  - Weerasekera, D
AU  - Whincup, PH
AU  - Widhalm, K
AU  - Widyahening, IS
AU  - Wiecek, A
AU  - Wijga, AH
AU  - Wilks, RJ
AU  - Willeit, J
AU  - Willeit, P
AU  - Williams, EA
AU  - Wilsgaard, T
AU  - Wojtyniak, B
AU  - Wong-McClure, RA
AU  - Wong, JYY
AU  - Wong, TY
AU  - Woo, J
AU  - Woodward, M
AU  - Wu, AG
AU  - Wu, FC
AU  - Wu, SL
AU  - Xu, HQ
AU  - Yan, WL
AU  - Yang, XG
AU  - Ye, XW
AU  - Yiallouros, PK
AU  - Yoshihara, A
AU  - Younger-Coleman, NO
AU  - Yusoff, AF
AU  - Zainuddin, AA
AU  - Zambon, S
AU  - Zampelas, A
AU  - Zdrojewski, T
AU  - Zeng, Y
AU  - Zhao, D
AU  - Zhao, WH
AU  - Zheng, W
AU  - Zheng, YF
AU  - Zhu, D
AU  - Zhussupov, B
AU  - Zimmermann, E
AU  - Cisneros, JZ
A1  - NCD Risk Factor Collaboration
TI  - Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants
T2  - INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
KW  - Blood pressure
KW  - hypertension
KW  - population health
KW  - global health
KW  - non-communicable disease
KW  - CARDIOVASCULAR RISK-FACTORS
KW  - HEALTH EXAMINATION SURVEYS
KW  - HYPERTENSION PREVALENCE
KW  - SECULAR TRENDS
KW  - SYSTEMATIC ANALYSIS
KW  - URBAN COMMUNITIES
KW  - POTASSIUM INTAKE
KW  - GLOBAL TRENDS
KW  - UNITED-STATES
KW  - SODIUM-INTAKE
AB  - Background: Change in the prevalence of raised blood pressure could be due to both shifts in the entire distribution of blood pressure (representing the combined effects of public health interventions and secular trends) and changes in its high-blood-pressure tail (representing successful clinical interventions to control blood pressure in the hypertensive population). Our aim was to quantify the contributions of these two phenomena to the worldwide trends in the prevalence of raised blood pressure.
   Methods: We pooled 1018 population-based studies with blood pressure measurements on 88.6 million participants from 1985 to 2016. We first calculated mean systolic blood pressure (SBP), mean diastolic blood pressure (DBP) and prevalence of raised blood pressure by sex and 10-year age group from 20-29 years to 70-79 years in each study, taking into account complex survey design and survey sample weights, where relevant. We used a linear mixed effect model to quantify the association between (probit-transformed) prevalence of raised blood pressure and age-group-and sex-specific mean blood pressure. We calculated the contributions of change in mean SBP and DBP, and of change in the prevalence-mean association, to the change in prevalence of raised blood pressure.
   Results: In 2005-16, at the same level of population mean SBP and DBP, men and women in South Asia and in Central Asia, the Middle East and North Africa would have the highest prevalence of raised blood pressure, and men and women in the high-income Asia Pacific and high-income Western regions would have the lowest. In most region-sex-age groups where the prevalence of raised blood pressure declined, one half or more of the decline was due to the decline in mean blood pressure. Where prevalence of raised blood pressure has increased, the change was entirely driven by increasing mean blood pressure, offset partly by the change in the prevalence-mean association.
   Conclusions: Change in mean blood pressure is the main driver of the worldwide change in the prevalence of raised blood pressure, but change in the high-blood-pressure tail of the distribution has also contributed to the change in prevalence, especially in older age groups.
AD  - Imperial Coll London, London W2 1PG, EnglandAD  - Univ Kent, Canterbury, Kent, EnglandAD  - Middlesex Univ, London, EnglandAD  - Harvard TH Chan, Sch Publ Hlth, Boston, MA USAAD  - Cleveland Clin, Cleveland, OH USAAD  - Univ Peruana Cayetano Heredia, Lima, PeruAD  - Univ Tehran Med Sci, Tehran, IranAD  - Minist Hlth & Med Educ, Qods, IranAD  - Brandeis Univ, Waltham, MA USAAD  - Mulago Hosp, Kampala, UgandaAD  - Uganda Heart Inst, Kampala, UgandaAD  - World Hlth Org, Geneva, SwitzerlandAD  - Univ Oxford, Oxford, EnglandAD  - Univ West Indies, Kingston, BarbadosAD  - Univ Auckland, Auckland, New ZealandAD  - South African Med Res Council, Pietermaritzburg, South AfricaAD  - Seoul Natl Univ, Seoul, South KoreaAD  - Natl Inst Nutr, Hyderabad, Telangana, IndiaAD  - Capital Med Univ, Beijing Zhen Hosp, Beijing, Peoples R ChinaAD  - Robert Koch Inst, Berlin, GermanyAD  - German Ctr Cardiovasc Res, Munich, GermanyAD  - Univ Zagreb, Zagreb, CroatiaAD  - Univ Ljubljana, Ljubljana, SloveniaAD  - Uppsala Univ, Uppsala, SwedenAD  - Univ New South Wales, Kensington, NSW, AustraliaAD  - Caja Costarricense Seguro Social, San Jose, Costa RicaAD  - Al Quds Univ, Al bireh, PalestineAD  - Birzeit Univ, Birzeit, IsraelAD  - Inst Mexicano Seguro Social, Mexico City, DF, MexicoAD  - Univ Adelaide, Adelaide, SA, AustraliaAD  - Mahidol Univ, Salaya, Nakhon Pathom, ThailandAD  - BRAC, Dhaka, BangladeshAD  - Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, MexicoAD  - Univ Amsterdam, Amsterdam, NetherlandsAD  - Minist Hlth Malaysia, Putrajaya, MalaysiaAD  - Non Communicable Dis Res Ctr, Shiraz, IranAD  - BIPS, Leibniz Inst Prevent Res & Epidemiol, Bremen, GermanyAD  - Natl Ctr Diabet & Endocrinol, Amman, JordanAD  - Kazakh Natl Med Univ, Alma Ata, KazakhstanAD  - King Abdulaziz Univ, Jeddah, Saudi ArabiaAD  - Univ Malaysia Sabah, Kota Kinabalu, MalaysiaAD  - Luxembourg Inst Hlth, Strassen, LuxembourgAD  - World Hlth Org Reg Off Eastern Mediterranean, Nasr City, EgyptAD  - Bombay Hosp & Med Res Ctr, Bombay, Maharashtra, IndiaAD  - Med Res Ctr, Bombay, Maharashtra, IndiaAD  - Lille Univ & Hosp, Lille, FranceAD  - London Sch Hyg Trop Med, London, EnglandAD  - Western Norway Univ Appl Sci, Bergen, NorwayAD  - Norwegian Sch Sport Sci, Oslo, NorwayAD  - Bispebjerg Hosp, Copenhagen, DenmarkAD  - Frederiksberg Univ Hosp, Frederiksberg, DenmarkAD  - Madras Diabet Res Fdn, Madras, Tamil Nadu, IndiaAD  - Komfo Anokye Teaching Hosp, Kumasi, GhanaAD  - Natl Inst Publ Hlth, Tunis, TunisiaAD  - Univ Porto, Porto, PortugalAD  - Norwegian Inst Publ Hlth, Oslo, NorwayAD  - Strasbourg Univ & Hosp, Strasbourg, FranceAD  - Nepal Hlth Res Council, Kathmandu, NepalAD  - Univ Iceland, Reykjavik, IcelandAD  - Univ Yaounde I, Yaounde, CameroonAD  - Univ Fed Pelotas, Pelotas, BrazilAD  - Reg Author Publ Hlth, Banska Bystrica, SlovakiaAD  - Univ Porto, Med Sch, Porto, PortugalAD  - Shahid Beheshti Univ Med Sci, Tehran, IranAD  - Indian Council Med Res, New Delhi, IndiaAD  - Univ Sci & Technol, Taizi, YemenAD  - Univ Autonoma Madrid, Madrid, SpainAD  - Univ Palermo, Palermo, ItalyAD  - Pan Amer Hlth Org, Washington, DC USAAD  - Univ Mohammed V Rabat, Rabat, MoroccoAD  - Univ Pernambuco, Recife, PE, BrazilAD  - Dalhousie Univ, Halifax, NS, CanadaAD  - Jordan Univ Sci & Technol, Irbid, JordanAD  - Univ Sydney, Sydney, NSW, AustraliaAD  - Univ Tunis El Manar, Tunis, TunisiaAD  - CAFAM Univ Fdn, Bogota, ColombiaAD  - Univ Utah, Sch Med, Salt Lake City, UT USAAD  - Univ Peruana Cayetano Heredia, Lima, PeruAD  - Lithuanian Univ Hlth Sci, Kaunas, LithuaniaAD  - Univ Sao Paulo, Sao Paulo, BrazilAD  - BJ Med Coll, Ahmadabad, Gujarat, IndiaAD  - Chirayu Med Coll, Bhopal, IndiaAD  - SL Jain Hosp, Delhi, IndiaAD  - Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R ChinaAD  - Ufa Eye Res Inst, Ufa, RussiaAD  - Univ Southern, Odense, DenmarkAD  - Univ Greenland, Nuuk, GreenlandAD  - Univ Oslo, Oslo, NorwayAD  - Univ Gothenburg, Gothenburg, SwedenAD  - Natl Inst Publ Hlth & Environm, Bilthoven, NetherlandsAD  - Univ Turin, Turin, ItalyAD  - UCL, London, EnglandAD  - German Inst Human Nutr, Berlin, GermanyAD  - Univ Republica, Montevideo, UruguayAD  - CEMIC, Buenos Aires, DF, ArgentinaAD  - Toulouse Univ, Sch Med, Toulouse, FranceAD  - Univ Hosp Varese, Varese, ItalyAD  - Minist Hlth, Victoria, SeychellesAD  - Univ Lausanne, Lausanne, SwitzerlandAD  - Univ Ghent, Ghent, BelgiumAD  - Univ Cent Venezuela, Caracas, VenezuelaAD  - Bielefeld Univ, Bielefeld, GermanyAD  - German Canc Res Ctr, Heidelberg, GermanyAD  - Univ Southern Denmark, Odense, DenmarkAD  - Cork Inst Technol, Cork, IrelandAD  - Hadassah Hebrew Univ, Med Ctr, Jerusalem, IsraelAD  - Univ La Laguna, San Cristobal la Laguna, SpainAD  - Univ Malta, Msida, MaltaAD  - Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USAAD  - Canadian Fitness & Lifestyle Res Inst, Ottawa, ON, CanadaAD  - Istanbul Univ, Istanbul, TurkeyAD  - Univ Fed Juiz De Fora, Juiz De Fora, BrazilAD  - Cardiol Mercato S Severino, Mercato San Severino, ItalyAD  - Karolinska Inst, Solna, SwedenAD  - Univ Santiago Compostela, Santiago, SpainAD  - Duke NUS Med Sch, Singapore, SingaporeAD  - Natl Inst Med Stat, New Delhi, IndiaAD  - Acad Sinica, Taipei, TaiwanAD  - Capital Inst Pediat, Beijing, Peoples R ChinaAD  - Duke Univ, Durham, NC USAAD  - Kailuan Gen Hosp, Tangshan, Peoples R ChinaAD  - Gertner Inst Epidemiol & Hlth Policy Res, Tel Aviv, IsraelAD  - Univ Bern, Bern, SwitzerlandAD  - Minist Hlth & Welf, Taipei, TaiwanAD  - Victor Babes Univ Med & Pharm Timisoara, Timisoara, RomaniaAD  - Murcia Reg Hlth Council, Murcia, SpainAD  - Seoul Natl Univ, Coll Med, Seoul, South KoreaAD  - Korea Centers Dis Control & Prevent, Cheongju, South KoreaAD  - Univ Estadual Paulista, Sao Paulo, BrazilAD  - Med Univ Silesia, Katowice, PolandAD  - Charles Univ Prague, Prague, Czech RepublicAD  - Carol Davila Univ Med & Pharm, Bucharest, RomaniaAD  - Katholieke Univ Leuven, Leuven, BelgiumAD  - Agcy Prevent & Social Med, Vienna, AustriaAD  - Univ Southampton, Southampton, Hants, EnglandAD  - IRCCS Ist Neurol Mediterraneo Neuromed, Pozzilli, ItalyAD  - Inst Pasteur, Lille, FranceAD  - CIBEROBN, Madrid, SpainAD  - Natl Council Res, Rome, ItalyAD  - Univ Fed Santa Catarina, Florianopolis, SC, BrazilAD  - Eduardo Mondlane Univ, Maputo, MozambiqueAD  - Bispebjerg & Frederiksberg Hosp, Copenhagen, DenmarkAD  - Erasmus MC, Rotterdam, NetherlandsAD  - Univ Montreal, Montreal, PQ, CanadaAD  - French Publ Hlth Agcy, St Maurice, FranceAD  - Univ Do Vale Do Rio Dos Sinos, Sao Leopoldo, BrazilAD  - Natl Council Sci & Tech Res, Buenos Aires, DF, ArgentinaAD  - Univ Queensland, Brisbane, Qld, AustraliaAD  - Ist Super Sanita, Rome, ItalyAD  - Univ Cuenca, Cuenca, EcuadorAD  - Helmholtz Zentrum Munchen, Oberschleissheim, GermanyAD  - Minist Sante & Lutte Contre Sida, Abidjan, Cote IvoireAD  - Cardinal Wyszynski Inst Cardiol, Warsaw, PolandAD  - Univ Zagreb, Zagreb, CroatiaAD  - Univ Latvia, Riga, LatviaAD  - Natl Inst Nutr & Food Technol, Tunis, TunisiaAD  - Inst Hosp Del Mar dInvest Med, Barcelona, SpainAD  - Univ Stellenbosch, Stellenbosch, South AfricaAD  - Karadeniz Tech Univ, Trabzon, TurkeyAD  - Natl Inst Hlth & Welf, Helsinki, FinlandAD  - Queens Univ Belfast, Belfast, Antrim, North IrelandAD  - Univ Zurich, Zurich, SwitzerlandAD  - Centro Salud Villanueva Norte, Villanueva de la Serena, SpainAD  - Univ West Indies, Kingston, JamaicaAD  - Hosp Don Benito Villanueva Serena, Badajoz, SpainAD  - Minist Hlth, Buenos Aires, DF, ArgentinaAD  - Council Agr Res & Econ, Arezzo, ItalyAD  - Pontificia Univ Catolica Chile, Santiago, ChileAD  - Univ Manchester, Manchester, Lancs, EnglandAD  - Univ Tartu, Tartu, EstoniaAD  - Univ Sains Malaysia, George Town, MalaysiaAD  - Umea Univ, Umea, SwedenAD  - Dalarna Univ, Falun, SwedenAD  - Univ Fed Sao Paulo, Sao Paulo, BrazilAD  - Hosp Univ Son Espases, Palma de Mallorca, SpainAD  - Hosp Clin Porto Alegre, Porto Alegre, RS, BrazilAD  - Univ Fed Rio Grande, Porto Alegre, RS, BrazilAD  - Kindai Univ, Higashiosaka, Osaka, JapanAD  - Kyoto Univ, Kyoto, JapanAD  - Med Univ Warsaw, Warsaw, PolandAD  - Univ Catania, Catania, ItalyAD  - CIBER Epidemiol & Salud Publ, Madrid, SpainAD  - Univ KwaZulu Natal, Durban, South AfricaAD  - Geneva Univ Hosp, Geneva, SwitzerlandAD  - Australian Bur Stat, Canberra, ACT, AustraliaAD  - Wageningen Univ, Wageningen, NetherlandsAD  - B P Koirala Inst Hlth Sci, Dharan, NepalAD  - Univ Insubria, Varese, ItalyAD  - Univ Politecn Madrid, Madrid, SpainAD  - Andes Clin Cardio Metab Studies, Merida, VenezuelaAD  - Natl Inst Hyg Epidemiol & Microbiol, Havana, CubaAD  - Univ Lille 2, Lille, FranceAD  - Norwegian Inst Publ Hlth, Oslo, NorwayAD  - Inst Clin & Expt Med, Prague, Czech RepublicAD  - Childrens Mem Hlth Inst, Warsaw, PolandAD  - Alexander Technol Educ Inst, Thessaloniki, GreeceAD  - Jagiellonian Univ, Med Coll, Krakow, PolandAD  - Azienda Ospedaliera Univ Policlinico Vittorio Ema, Catania, ItalyAD  - Univ Novi Sad, Novi Sad, SerbiaAD  - Natl Ctr Cardiovasc Dis, Beijing, Peoples R ChinaAD  - Singapore Eye Res Inst, Singapore, SingaporeAD  - Iceland Heart Assoc, Reykjavik, IcelandAD  - Univ Icesi, Cali, ColombiaAD  - Univ Estadual Montes Claros, Montes Claros, BrazilAD  - Kings Coll London, London, EnglandAD  - Int Agcy Res Canc, Lyon, FranceAD  - Healis Sekhsaria Inst Publ Hlth, Navi Mumbai, IndiaAD  - Eternal Heart Care Ctr & Res Inst, Jaipur, Rajasthan, IndiaAD  - Univ Ibadan, Ibadan, NigeriaAD  - Inst Clin Effectiveness & Hlth Policy, Buenos Aires, DF, ArgentinaAD  - Danish Canc Soc Res Ctr, Copenhagen, DenmarkAD  - Kyushu Univ, Fukuoka, Fukuoka, JapanAD  - Tulane Univ, New Orleans, LA USAAD  - Chinese Ctr Dis Control & Prevent, Beijing, Peoples R ChinaAD  - Univ Amsterdam, Acad Med Ctr, Amsterdam, NetherlandsAD  - Natl Inst Publ Hlth, Cuernavaca, Morelos, MexicoAD  - Oulu Univ Hosp, Oulu, FinlandAD  - Chron Dis Res Ctr, Tehran, IranAD  - Univ Hong Kong, Hong Hom, Hong Kong, Peoples R ChinaAD  - Chinese Univ Hong Kong, Hong Hom, Hong Kong, Peoples R ChinaAD  - Univ Western Australia, Perth, WA, AustraliaAD  - Celal Bayar Univ, Manisa, TurkeyAD  - Heart Inst, Sao Paulo, BrazilAD  - Fdn Oftalmol Santander, Bucaramanga, ColombiaAD  - Univ Oran 1, Oran, AlgeriaAD  - Independent Publ Hlth Specialist, Yangon, MyanmarAD  - Peking Univ, Beijing, Peoples R ChinaAD  - Vrije Univ Amsterdam, Med Ctr, Amsterdam, NetherlandsAD  - Vrije Univ Amsterdam, Amsterdam, NetherlandsAD  - Birzeit Univ, Birzeit, PalestineAD  - Amer Univ Beirut, Beirut, LebanonAD  - Cairo Univ, Cairo, EgyptAD  - Aga Khan Univ, Karachi, PakistanAD  - UHC Zagreb, Zagreb, CroatiaAD  - Niigata Univ, Niigata, JapanAD  - Hadassah Univ Med Ctr, Jerusalem, IsraelAD  - Norwegian Univ Sci & Technol, Trondheim, NorwayAD  - Univ Zagreb, Coll Med, Zagreb, CroatiaAD  - Heart Fdn, Melbourne, Vic, AustraliaAD  - Natl Hlth Insurance Serv, Jeonju, South KoreaAD  - Guangzhou 12th Hosp, Guangzhou, Peoples R ChinaAD  - Simon Fraser Univ, Burnaby, BC, CanadaAD  - Heidelberg Univ, Heidelberg, GermanyAD  - Res Ctr Prevent & Hlth, Glostrup, DenmarkAD  - World Hlth Org Country Off, Delhi, IndiaAD  - Czestochowa Tech Univ, Czestochowa, PolandAD  - Univ Crete, Iraklion, GreeceAD  - Univ Kebangsaan Malaysia, Bangi, MalaysiaAD  - Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USAAD  - Univ Eastern Finland, Kuopio, FinlandAD  - Natl Inst Epidemiol, Madras, Tamil Nadu, IndiaAD  - Univ Munster, Munster, GermanyAD  - Israel Ctr Dis Control, Tel Hashomer, IsraelAD  - Res Inst Primordial Prevent Non communicable Dis, Esfahan, IranAD  - South African Med Res Council, Durban, South AfricaAD  - Kyrgyz State Med Acad, Bishkek, KyrgyzstanAD  - Res Inst Child Nutr, Bonn, GermanyAD  - Univ Cambridge, Cambridge, EnglandAD  - Med Univ Innsbruck, Innsbruck, AustriaAD  - Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, TanzaniaAD  - Natl Canc Ctr, Goyang, South KoreaAD  - Inst Trop Med, Antwerp, BelgiumAD  - Tartu Univ Clin, Tartu, EstoniaAD  - Minist Hlth & Qual Life, Port Louis, MauritiusAD  - Polish Acad Sci, Anthropol Unit, Wroclaw, PolandAD  - Univ Groningen, Groningen, NetherlandsAD  - North West Univ, Potchefstroom, South AfricaAD  - Natl Inst Publ Hlth, Prague, Czech RepublicAD  - Univ Jyvaskyla, Jyvaskyla, FinlandAD  - Amrita Inst Med Sci, Kochi, Kerala, IndiaAD  - Cardinal Wyszynski Inst Cardiol, Warsaw, PolandAD  - All India Inst Med Sci, New Delhi, IndiaAD  - African Populat & Hlth Res Ctr, Nairobi, KenyaAD  - Minist Salud Publ, Havana, CubaAD  - Sahlgrens Acad, Gothenburg, SwedenAD  - Endocrinol & Metab Res Ctr, Tehran, IranAD  - Food & Agr Org United Nat, Rome, ItalyAD  - Natl Univ Singapore, Singapore, SingaporeAD  - Tampere Univ Hosp, Tampere, FinlandAD  - Univ Cape Town, Rondebosch, South AfricaAD  - West Virginia Univ, Morgantown, WV USAAD  - Oswaldo Cruz Fdn Rene Rachou Res Inst, Rio De Janeiro, BrazilAD  - Natl Taiwan Univ, Taipei, TaiwanAD  - Univ Chinese Acad Sci, Beijing, Peoples R ChinaAD  - Uppsala Univ, Uppsala, SwedenAD  - Bispebjerg & Frederiksberg Hosp, Copenhagen, DenmarkAD  - Univ Gothenburg, Gothenburg, SwedenAD  - Childrens Mem Hlth Inst, Warsaw, PolandAD  - Capital Med Univ, Beijing An Zhen Hosp, Beijing, Peoples R ChinaAD  - Univ Med Greifswald, Greifswald, GermanyAD  - Univ Sao Paulo, Sao Paulo, BrazilAD  - Consejeria Sanidad Junta de Castilla & Leon, Valladolid, SpainAD  - Lithuanian Univ Hlth Sci, Kaunas, LithuaniaAD  - Natl Inst Hlth & Welf, Helsinki, FinlandAD  - Univ Porto, Porto, PortugalAD  - Uppsala Univ, Uppsala, SwedenAD  - Peking Univ, Beijing, Peoples R ChinaAD  - Univ Fed Ouro Preto, Ouro Preto, MG, BrazilAD  - Jikei Univ, Sch Med, Tokyo, JapanAD  - CNR, Rome, ItalyAD  - Baker Heart & Diabet Inst, Melbourne, Vic, AustraliaAD  - Agr Univ Athens, Athens, GreeceAD  - Univ Zagreb, Zagreb, CroatiaAD  - Hosp Israelita Albert Einstein, Sao Paulo, BrazilAD  - Shiraz Univ Med Sci, Shiraz, IranAD  - Duke NUS Med Sch, Singapore, SingaporeAD  - Natl Inst Nutr, Hyderabad, IndiaAD  - Inst Internal & Prevent Med, Moscow, RussiaAD  - Harokopio Univ, Kallithea, GreeceAD  - Univ Otago, Dunedin, New ZealandAD  - Univ Padua, I-35100 Padua, ItalyAD  - Pontificia Univ Catolica Chile, Santiago, ChileAD  - Lausanne Univ Hosp, Lausanne, SwitzerlandAD  - Univ Fed Santa Catarina, Florianopolis, SC, BrazilAD  - CIBERCV, Madrid, SpainAD  - Emory Univ, Atlanta, GA USAAD  - UiT Arctic Univ Norway, Tromso, NorwayAD  - Univ Sao Paulo, Sao Paulo, BrazilAD  - Cape Peninsula Univ Technol, Cape Town, South AfricaAD  - Univ Yaounde I, Yaounde, CameroonAD  - Gorgas Mem Inst Hlth Studies, Panama City, PanamaAD  - Univ West Indies, Kingston, JamaicaAD  - Brown Univ, Providence, RI USAAD  - Univ Edinburgh, Edinburgh, Midlothian, ScotlandAD  - Stat Canada, Ottawa, ON, CanadaAD  - Univ Coll Dublin, Dublin, IrelandAD  - Univ Oran 1, Oran, AlgeriaAD  - Lithuanian Univ Hlth Sci, Kaunas, LithuaniaAD  - INSERM, Paris, FranceAD  - Helmholtz Zentrum Munchen, Munich, GermanyAD  - Univ Fed Pelotas, Pelotas, BrazilAD  - Indian Council Med Res, New Delhi, IndiaAD  - Univ Tartu, Tartu, EstoniaAD  - Univ Oslo, Oslo, NorwayAD  - Capital Inst Pediat, Beijing, Peoples R ChinaAD  - Lusofona Univ, Lisbon, PortugalAD  - Univ Peruana Cayetano Heredia, Lima, PeruAD  - Kyrgyz State Med Acad, Bishkek, KyrgyzstanAD  - Univ Firenze, Florence, ItalyAD  - Ain Shams Univ, Cairo, EgyptAD  - Univ Tehran Med Sci, Tehran, IranAD  - Hypertens Res Ctr, Tehran, IranAD  - Madras Diabet Res Fdn, Madras, Tamil Nadu, IndiaAD  - Minist Hlth Malaysia, Putrajaya, MalaysiaAD  - Univ Southern Denmark, Odense, DenmarkAD  - Univ Pecs, Pecs, HungaryAD  - Shahid Beheshti Univ Med Sci, Tehran, IranAD  - Mulago Hosp, Kampala, UgandaAD  - Univ Limpopo, Polokwane, South AfricaAD  - Seoul Natl Univ, Childrens Hosp, Seoul, South KoreaAD  - Univ Fed Rio Grande do Sul, Porto Alegre, RS, BrazilAD  - Univ Med Sci, Havana, CubaAD  - Univ Zaragoza, Zaragoza, SpainAD  - RCSI Dublin, Dublin, IrelandAD  - La Trobe Univ, Bundoora, Vic, AustraliaAD  - Int Inst Mol & Cell Biol, Warsaw, PolandAD  - Ahvaz Jundishapur Univ Med Sci, Ahvaz, Khuzestan, IranAD  - Gorgas Mem Inst Publ Hlth, Panama City, PanamaAD  - WHO, Country Off, Lilongwe, MalawiAD  - Dept Publ Hlth, Pyinmana, MyanmarAD  - Univ Brescia, Brescia, ItalyAD  - Int Agcy Res Canc, Lyon, FranceAD  - Univ Eastern Finland, Kuopio, FinlandAD  - Bushehr Univ Med Sci, Bushehr, IranAD  - Ulm Univ, Ulm, GermanyAD  - Kobe Univ, Kobe, Hyogo, JapanAD  - Reg Author Publ Hlth, Banska Bystrica, SlovakiaAD  - Natl Univ Singapore, Singapore, SingaporeAD  - Suraj Eye Inst, Nagpur, Maharashtra, IndiaAD  - Healis Sekhsaria Inst Publ Hlth, Navi Mumbai, IndiaAD  - CIBER Epidemiol & Salud Publ, Madrid, SpainAD  - West Virginia Univ, Morgantown, WV USAAD  - Jagiellonian Univ, Med Coll, Krakow, PolandAD  - Karolinska Inst, Stockholm, SwedenAD  - Robert Koch Inst, Berlin, GermanyAD  - German Ctr Cardiovascular Res, Gottingen, GermanyAD  - Natl Inst Hyg & Epidemiol, Hanoi, VietnamAD  - Univ Pharm & Med Ho Chi Minh City, Ho Chi Minh City, VietnamAD  - Hanoi Med Univ, Hanoi, VietnamAD  - Natl Hosp Endocrinol, Hanoi, VietnamAD  - Miami Vet Affairs Healthcare Syst, Miami, FL USAAD  - Univ Turku Tyks, Turku, FinlandAD  - Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R ChinaAD  - Kyushu Univ, Fukuoka, JapanAD  - Heartfile, Islamabad, PakistanAD  - Univ Republica, Montevideo, UruguayAD  - Imperial Coll London, London, EnglandAD  - Univ Palermo, Palermo, ItalyAD  - Eastern Mediterranean Publ Hlth Network, Amman, JordanAD  - Queens Univ Belfast, Belfast, Antrim, North IrelandAD  - Tachikawa Gen Hosp, Tachikawa, Tokyo, JapanAD  - Acad Hosp Paramaribo, Paramaribo, SurinameAD  - Korea Ctr Dis Control & Prevent, Cheongju, South KoreaAD  - Univ Vale Rio dos Sinos, Sao Leopoldo, RS, BrazilAD  - Istanbul Univ, Istanbul, TurkeyAD  - Minist Hlth, Bandar Seri Begawan, BruneiAD  - Univ Fed Santa Catarina, Florianopolis, SC, BrazilAD  - Pan Amer Hlth Org, Washington, DC USAAD  - Univ Madeira, Funchal,, PortugalAD  - MRC Lifecourse Epidemiol Unit, Southampton, Hants, EnglandAD  - Univ Novi Sad, Novi Sad, SerbiaAD  - Bushehr Univ Med Sci, Bushehr, IranAD  - Fdn Oftalmol Santander, Bucaramanga, ColombiaAD  - Aarhus Univ, Aarhus, DenmarkAD  - Kwame Nkrumah Univ Sci & Technol, Kumasi, GhanaAD  - Nstitute Social & Prevent Med, Bern, SwitzerlandAD  - Univ Coimbra, Coimbra, PortugalAD  - Univ Latvia, Riga, LatviaAD  - Canc Prevent & Res Inst, Naples, ItalyAD  - Ist Super Sanita, Rome, ItalyAD  - Acad Sinica, Taipei, TaiwanAD  - Heidelberg Univ, Heidelberg, GermanyAD  - IRCCS Casa Sollievo Sofferenza, San Giovanni Rotondo, ItalyAD  - Zayed Univ, Abu Dhabi, U Arab EmiratesAD  - Catholic Univ Daegu, Daegu, South KoreaAD  - Jivandeep Hosp, Ahmadabad, Gujarat, IndiaAD  - Univ Zagreb, Sch Med, Zagreb, CroatiaAD  - Univ Hosp Ctr Zagreb, Zagreb, CroatiaAD  - South African Med Res Council, Cape Town, South AfricaAD  - Univ Med Ctr Utrecht, Utrecht, NetherlandsAD  - Fundacao Oswaldo Cruz, Rene Rachou Res Inst, Rio De Janeiro, BrazilAD  - Natl Inst Hlth & Welf, Helsinki, FinlandAD  - Heart Inst, Sao Paulo, BrazilAD  - Minist Hlth & Med Educ, Tehran, IranAD  - Vietnam Natl Heart Inst, Hanoi, VietnamAD  - Leibniz Inst Prevent Res & Epidemiol BIPS, Bremen, GermanyAD  - UCL, London, EnglandAD  - Univ Sarajevo, Sarajevo, Bosnia & HercegAD  - Cardiovasc Prevent Ctr, Udine, ItalyAD  - Minist Hlth & Med Serv, Honiara, Solomon IslandsAD  - Cardinal Wyszynski Inst Cardiol, Warsaw, PolandAD  - Publ Hlth Agcy Catalonia, Catalonia, SpainAD  - Univ Split, Split, CroatiaAD  - Inst Hosp Mar Invest Med, Barcelona, SpainAD  - Erasmus MC, Rotterdam, NetherlandsAD  - Digest Oncol Res Ctr, Tehran, IranAD  - Digest Dis Res Inst, Tehran, IranAD  - Lausanne Univ Hosp, Lausanne, SwitzerlandAD  - Victor Babes Univ Med & Pharm Timisoara, Timisoara, RomaniaAD  - Tartu Univ Clin, Tartu, EstoniaAD  - Al Quds Univ, Jerusalem, PalestineAD  - Alborz Univ Med Sci, Alborz, IranAD  - Minist Hlth, Hanoi, VietnamAD  - Univ Novi Sad, Novi Sad, SerbiaAD  - BRAC, Dhaka, BangladeshAD  - Univ Turku, Turku, FinlandAD  - Amrita Inst Med Sci, Coimbatore, Tamil Nadu, IndiaAD  - Natl Inst Epidemiol, Madras, Tamil Nadu, IndiaAD  - India Diabet Res Fdn, New Delhi, IndiaAD  - Univ Porto, Med Sch, Porto, PortugalAD  - Univ Putra Malaysia, Serdang, MalaysiaAD  - Univ Malaya, Kuala Lumpur, MalaysiaAD  - Gorgas Mem Inst Hlth Studies, Panama City, PanamaAD  - Univ Valencia, Valencia, SpainAD  - Univ Philippines, Quezon City, PhilippinesAD  - Minas Gerais State Secretariat Hlth, Belo Horizonte, MG, BrazilAD  - Imperial Coll London, London, EnglandAD  - Hlth Ctr San Agustin, San Agustin, SpainAD  - PharmAccess Fdn, Amsterdam, NetherlandsAD  - Univ Nove de Julho, Sao Paulo, BrazilAD  - Univ Southampton, Southampton SO9 5NH, Hants, EnglandAD  - Publ Hlth Agcy Canada, Ottawa, ON, CanadaAD  - Univ Autonoma Madrid, Madrid, SpainAD  - Canarian Hlth Serv, Tenerife, SpainAD  - Univ Ind Santander, Bucaramanga, ColombiaAD  - Inst Nacl Salud Publ, Cuernavaca, Morelos, MexicoAD  - CIBEROBN, Madrid, SpainAD  - Univ Eastern Finland, Kuopio, FinlandAD  - Univ Gothenburg, Gothenburg, SwedenAD  - Stat Canada, Ottawa, ON, CanadaAD  - Inst Clin Effectiveness & Hlth Policy, Buenos Aires, DF, ArgentinaAD  - Inst Mexicano Seguro Social, Mexico City, DF, MexicoAD  - Med Univ Gdansk, Gdansk, PolandAD  - Singapore Eye Res Inst, Singapore, SingaporeAD  - Sitaram Bhartia Inst Sci & Res, New Delhi, IndiaAD  - Univ Tunis El Manar, Tunis, TunisiaAD  - Marmara Univ, Istanbul, TurkeyAD  - French Publ Hlth Agcy, St Maurice, FranceAD  - Natl Inst Publ Hlth, Cuernavaca, Morelos, MexicoAD  - CIBER Epidemiol & Salud Publ, Barcelona, SpainAD  - Natl Inst Hlth & Welf, Helsinki, FinlandAD  - Univ Helsinki, Helsinki, FinlandAD  - Univ Brescia, Brescia, ItalyAD  - Natl Inst Hlth, Lima, PeruAD  - Catalan Dept Hlth, Catalonia, SpainAD  - Univ Lisbon, Lisbon, PortugalAD  - Univ Fed Pelotas, Pelotas, RS, BrazilAD  - Univ Sao Paulo, Clin Hosp, Sao Paulo, BrazilAD  - Univ Porto, Porto, PortugalAD  - South Karelia Social & Hlth Care Dist, Lappeenranta, FinlandAD  - Univ Lisbon, Lisbon, PortugalAD  - Robert Koch Inst, Berlin, GermanyAD  - Isfahan Cardiovasc Res Ctr, Esfahan, IranAD  - German Canc Res Ctr, Heidelberg, GermanyAD  - Res & Educ Inst Child Hlth, Nicosia, CyprusAD  - Univ Sao Paulo, Clin Hosp, Sao Paulo, BrazilAD  - Hosp Italiano Buenos Aires, Buenos Aires, DF, ArgentinaAD  - Univ Med Greifswald, Greifswald, GermanyAD  - Univ Amsterdam, Acad Med Ctr, Amsterdam, NetherlandsAD  - North West Univ, South African Med Res Council, Potchefstroom, South AfricaAD  - Minist Hlth, Naypyidaw, MyanmarAD  - Norwegian Univ Sci & Technol, Trondheim, NorwayAD  - Lagos State Univ, Coll Med, Lagos, NigeriaAD  - Univ Tehran Med Sci, Tehran, IranAD  - BP Koirala Inst Hlth Sci, Dharan, NepalAD  - Baker Heart & Diabet Inst, Melbourne, Vic, AustraliaAD  - Univ Tokyo, Tokyo, JapanAD  - Samsung Med Ctr, Seoul, South KoreaAD  - Singapore Eye Res Inst, Singapore, SingaporeAD  - Minist Hlth, Bandar Seri Begawan, BruneiAD  - Amer Univ Beirut, Beirut, LebanonAD  - Univ Fed Santa Catarina, Florianopolis, SC, BrazilAD  - India Diabet Res Fdn, Madras, Tamil Nadu, IndiaAD  - St Vincents Hosp, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sydney, NSW, AustraliaAD  - Karolinska Inst, Stockholm, SwedenAD  - Bispebjerg & Frederiksberg Hosp, Copenhagen, DenmarkAD  - Med Univ Lodz, Lodz, PolandAD  - Int Inst Mol & Cell Biol, Warsaw, PolandAD  - London Sch Hyg & Trop Med, London, EnglandAD  - Univ Oxford, Oxford, EnglandAD  - Acad Med Ctr, Amsterdam, NetherlandsAD  - Univ Hong Kong, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ Yaounde I, Yaounde, CameroonAD  - Umea Univ, Umea, SwedenAD  - Univ Bari, Bari, ItalyAD  - Lund Univ, Lund, SwedenAD  - Peking Univ, Beijing, Peoples R ChinaAD  - Univ Copenhagen, Copenhagen, DenmarkAD  - Univ Zagreb, Zagreb, CroatiaAD  - Inst Reg Sante Publ, Ouidah, BeninAD  - Univ Bordeaux, Talence, FranceAD  - Univ Leuven, Leuven, BelgiumAD  - Univ Ljubljana, Ljubljana, SloveniaAD  - INSERM, Paris, FranceAD  - Heart Fdn, Melbourne, Vic, AustraliaAD  - Norwegian Sch Sport Sci, Oslo, NorwayAD  - Univ Bonn, Bonn, GermanyAD  - Emory Univ, Atlanta, GA USAAD  - Sotiria Hosp, Athens, GreeceAD  - Hadassah Univ, Med Ctr, Jerusalem, IsraelAD  - Helmholtz Zentrum Munchen, Munich, GermanyAD  - Natl Inst Hyg, Natl Inst Publ Hlth, Warsaw, PolandAD  - Univ Amsterdam, Amsterdam, NetherlandsAD  - Univ Fed Sao Paulo, Sao Paulo, BrazilAD  - Fu Jen Catholic Univ, Taipei, TaiwanAD  - Uppsala Univ, Uppsala, SwedenAD  - Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R ChinaAD  - Mahidol Univ, Bangkok, ThailandAD  - Univ Philippines, Quezon City, PhilippinesAD  - Natl Univ Singapore, Singapore, SingaporeAD  - Univ Tartu, Tartu, EstoniaAD  - Lithuanian Univ Hlth Sci, Kaunas, LithuaniaAD  - Univ Sydney, Sydney, NSW, AustraliaAD  - Peking Univ, Beijing, Peoples R ChinaAD  - Univ KwaZulu Natal, Durban, South AfricaAD  - Minist Hlth, Amman, JordanAD  - Natl Inst Hlth, Lima, PeruAD  - Carol Davila Univ Med & Pharm, Bucharest, RomaniaAD  - Univ Adelaide, Adelaide, SA, AustraliaAD  - Karolinska Inst, Stockholm, SwedenAD  - Alexander Technol Educ Inst, Sindos, GreeceAD  - Univ Leuven, Leuven, BelgiumAD  - Bispebjerg & Frederiksberg Hosp, Copenhagen, DenmarkAD  - Danish Canc Soc Res Ctr, Copenhagen, DenmarkAD  - Natl Inst Hlth & Welf, Kuopio, FinlandAD  - Univ Southern Denmark, Odense, DenmarkAD  - Karadeniz Tech Univ, Trabzon, TurkeyAD  - Jagiellonian Univ, Coll Med, Warsaw, PolandAD  - Hlth Serv Murcia, Murcia, SpainAD  - IB SALUT Area Salut Menorca, Ciutadella De Menorca, SpainAD  - Inst Rech Dev, Marseille, FranceAD  - Harvard TH Chan Sch Publ Hlth, Boston, MA USAAD  - Hellen Hlth Fdn, Athens, GreeceAD  - Univ Pharm & Med Ho Chi Minh City, Ho Chi Minh City, VietnamAD  - Govt Med Coll, New Delhi, IndiaAD  - Sefako Makgatho Hlth Sci Univ, Tshwane, South AfricaAD  - Univ West Indies, Kingston, JamaicaAD  - Addis Ababa Univ, Addis Ababa, EthiopiaAD  - Univ Eastern Finland, Kuopio, FinlandAD  - Dasman Diabet Inst, Kuwait, KuwaitAD  - Minist Hlth, Thorndon, New ZealandAD  - Karolinska Inst, Stockholm, SwedenAD  - Univ Bordeaux, Bordeaux, FranceAD  - Univ Centrooccidental Lisandro Alvarado, Barquisimeto, VenezuelaAD  - Med Univ Innsbruck, Innsbruck, AustriaAD  - Univ Tampere, Tays Eye Ctr, Tampere, FinlandAD  - Pontificia Univ Catolica Chile, Santiago, ChileAD  - Univ Utrecht, Utrecht, NetherlandsAD  - Univ Ghent, Ghent, BelgiumAD  - Hanoi Univ Publ Hlth, Hanoi, VietnamAD  - Univ Med Ctr Utrecht, Utrecht, NetherlandsAD  - Amsterdam Publ Hlth Res Inst, Amsterdam, NetherlandsAD  - Acad Med Ctr, Amsterdam, NetherlandsAD  - Katholieke Univ Leuven, Leuven, BelgiumAD  - Cardiovasc Prevent Ctr, Udine, ItalyAD  - Norwegian Univ Sci & Technol, Oslo, NorwayAD  - Consejeria Sanidad Junta Castilla & Leon, Madrid, SpainAD  - Univ Fed Minas Gerais, Belo Horizonte, MG, BrazilAD  - Univ Insubria, Varese, VA, ItalyAD  - Natl Inst Publ Hlth & Environm, Bilthoven, NetherlandsAD  - Inst Trop Med, Antwerp, BelgiumAD  - Univ Fed Pelotas, Pelotas, RS, BrazilAD  - Finnish Inst Occupat Hlth, Helsinki, FinlandAD  - Imperial Coll London, London, EnglandAD  - Univ Miguel Hernandez, Elche, SpainAD  - Univ Eastern Finland, Kuopio, FinlandAD  - INSERM, Paris, FranceAD  - Minist Hlth, Victoria, SeychellesAD  - North Karelian Ctr Publ Hlth, Joensuu, FinlandAD  - Lausanne Univ Hosp, Lausanne, SwitzerlandAD  - Univ Witwatersrand, Johannesburg, South AfricaAD  - Univ Strasbourg, Strasbourg, FranceAD  - Cork Inst Technol, Cork, IrelandAD  - Univ Sains Malaysia, George Town, MalaysiaAD  - Inst Med Res, Kuala Lumpur, MalaysiaAD  - Univ Pernambuco, Recife, PE, BrazilAD  - Publ Hlth Agcy Canada, Ottawa, ON, CanadaAD  - Xinjiang Med Univ, Urumqi, Peoples R ChinaAD  - Capital Med Univ, Beijing, Peoples R ChinaAD  - Minist Hlth & Welf, Taipei, TaiwanAD  - UCL, London, EnglandAD  - Univ Cambridge, Cambridge, EnglandAD  - Univ Southern Denmark, Copenhagen, DenmarkAD  - Minist Hlth, Thorndon, New ZealandAD  - St Georges Univ London, London, EnglandAD  - Med Univ Vienna, Vienna, AustriaAD  - Univ Indonesia, Depok, IndonesiaAD  - Med Univ Silesia, Katowice, PolandAD  - Natl Inst Publ Hlth & Environm, Eindhoven, NetherlandsAD  - Univ West Indies, Kingston, JamaicaAD  - Med Univ Innsbruck, Innsbruck, AustriaAD  - Komfo Anokye Teaching Hosp, Kumasi, GhanaAD  - UiT Arctic Univ Norway, Tromso, NorwayAD  - Natl Inst Hyg, Natl Inst Publ Hlth, Warsaw, PolandAD  - Caja Costarricense Seguro Social, San Jose, Costa RicaAD  - Minist Hlth, Bandar Seri Begawan, BruneiAD  - Duke NUS Med Sch, Singapore, SingaporeAD  - Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ New South Wales, Sydney, NSW, AustraliaAD  - Univ Oxford, Oxford, EnglandAD  - Lund Univ, Lund, SwedenAD  - Univ Manchester, Manchester, Lancs, EnglandAD  - Kailuan Gen Hosp, Tangshan, Peoples R ChinaAD  - Minist Agr, Inst Food & Nutr Dev, Beijing, Peoples R ChinaAD  - Fudan Univ, Childrens Hosp, Shanghai, Peoples R ChinaAD  - Chinese Ctr Dis Control & Prevent, Beijing, Peoples R ChinaAD  - Univ Chinese Acad Sci, Beijing, Peoples R ChinaAD  - Univ Cyprus, Nicosia, CyprusAD  - Niigata Univ, Niigata, JapanAD  - Univ West Indies, Kingston, JamaicaAD  - Minist Hlth Malaysia, Putra Jaya, MalaysiaAD  - Univ Teknol MARA, Shah Alam, Selangor, MalaysiaAD  - Univ Padua, Padua, ItalyAD  - Agr Univ Athens, Athens, GreeceAD  - Med Univ Gdansk, Gdansk, PolandAD  - Duke Univ, Durham, NC USAAD  - Peking Univ, Beijing, Peoples R ChinaAD  - Capital Med Univ, Beijing An Zhen Hosp, Beijing, Peoples R ChinaAD  - Chinese Ctr Dis Control & Prevent, Beijing, Peoples R ChinaAD  - Vanderbilt Univ, Nashville, TN USAAD  - Singapore Eye Res Inst, Singapore, SingaporeAD  - Inner Mongolia Med Univ, Hohhot, Peoples R ChinaAD  - Kazakh Natl Med Univ, Alma Ata, KazakhstanAD  - Bispebjerg & Frederiksberg Hosp, Copenhagen, DenmarkAD  - Gorgas Mem Inst Publ Hlth, Panama City, PanamaC3  - Imperial College LondonC3  - University of KentC3  - Middlesex UniversityC3  - Harvard UniversityC3  - Harvard T.H. Chan School of Public HealthC3  - Cleveland Clinic FoundationC3  - Universidad Peruana Cayetano HerediaC3  - Tehran University of Medical SciencesC3  - Ministry of Health & Medical Education (MOHME)C3  - Brandeis UniversityC3  - Mulago National Referral HospitalC3  - World Health OrganizationC3  - University of OxfordC3  - University of AucklandC3  - South African Medical Research CouncilC3  - Seoul National University (SNU)C3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Nutrition (NIN)C3  - Capital Medical UniversityC3  - Robert Koch InstituteC3  - German Centre for Cardiovascular ResearchC3  - University of ZagrebC3  - University of LjubljanaC3  - Uppsala UniversityC3  - University of New South Wales SydneyC3  - Al-Quds UniversityC3  - Birzeit UniversityC3  - Instituto Mexicano del Seguro SocialC3  - University of AdelaideC3  - Mahidol UniversityC3  - Bangladesh Rural Advancement Committee BRACC3  - Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - MexicoC3  - University of AmsterdamC3  - Kementerian Kesihatan MalaysiaC3  - Leibniz AssociationC3  - Leibniz Institute for Prevention Research & Epidemiology (BIPS)C3  - Asfendiyarov Kazakh National Medical UniversityC3  - King Abdulaziz UniversityC3  - Universiti Malaysia SabahC3  - Luxembourg Institute of HealthC3  - World Health OrganizationC3  - Bombay Hospital & Medical Research CentreC3  - Universite de LilleC3  - CHU LilleC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - Western Norway University of Applied SciencesC3  - Norwegian School of Sport SciencesC3  - University of CopenhagenC3  - Bispebjerg HospitalC3  - Madras Diabetes Research FoundationC3  - Kwame Nkrumah University Science & TechnologyC3  - Universidade do PortoC3  - Norwegian Institute of Public Health (NIPH)C3  - CHU StrasbourgC3  - Universites de Strasbourg Etablissements AssociesC3  - Universite de StrasbourgC3  - University of IcelandC3  - University of Yaounde IC3  - Universidade Federal de PelotasC3  - Regional Authority of Public Health Banska BystricaC3  - Universidade do PortoC3  - Shahid Beheshti University Medical SciencesC3  - Indian Council of Medical Research (ICMR)C3  - Autonomous University of MadridC3  - University of PalermoC3  - Pan American Health OrganizationC3  - Mohammed V University in RabatC3  - Universidade de Pernambuco (UPE)C3  - Dalhousie UniversityC3  - Jordan University of Science & TechnologyC3  - University of SydneyC3  - Universite de Tunis-El-ManarC3  - Utah System of Higher EducationC3  - University of UtahC3  - Universidad Peruana Cayetano HerediaC3  - Lithuanian University of Health SciencesC3  - Universidade de Sao PauloC3  - B. J. Medical College & Civil Hospital, AhmedabadC3  - Shanghai Jiao Tong UniversityC3  - Ufa Eye Research InstituteC3  - University of OsloC3  - University of GothenburgC3  - Netherlands National Institute for Public Health & the EnvironmentC3  - University of TurinC3  - University of LondonC3  - University College LondonC3  - Leibniz AssociationC3  - Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE)C3  - Universidad de la Republica, UruguayC3  - Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)C3  - Universite Federale Toulouse Midi-Pyrenees (ComUE)C3  - University of InsubriaC3  - University of LausanneC3  - Ghent UniversityC3  - University of Central VenezuelaC3  - University of BielefeldC3  - Helmholtz AssociationC3  - German Cancer Research Center (DKFZ)C3  - University of Southern DenmarkC3  - Munster Technological University (MTU)C3  - Hebrew University of JerusalemC3  - Hadassah University Medical CenterC3  - Universidad de la LagunaC3  - University of MaltaC3  - Vanderbilt UniversityC3  - Canadian Fitness & Lifestyle Research InstituteC3  - Istanbul UniversityC3  - Universidade Federal de Juiz de ForaC3  - Karolinska InstitutetC3  - Universidade de Santiago de CompostelaC3  - National University of SingaporeC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Medical Statistics (NIMS)C3  - Academia Sinica - TaiwanC3  - Capital Institute of Pediatrics (CIP)C3  - Duke UniversityC3  - University of BernC3  - Victor Babes University of Medicine & Pharmacy, TimisoaraC3  - Murcia Regional Health CouncilC3  - Seoul National University (SNU)C3  - Korea Disease Control & Prevention Agency (KDCA)C3  - Universidade Estadual PaulistaC3  - Medical University SilesiaC3  - Charles University PragueC3  - Carol Davila University of Medicine & PharmacyC3  - KU LeuvenC3  - University of SouthamptonC3  - IRCCS NeuromedC3  - Pasteur NetworkC3  - Universite de LilleC3  - Institut Pasteur LilleC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBEROBNC3  - Consiglio Nazionale delle Ricerche (CNR)C3  - Universidade Federal de Santa Catarina (UFSC)C3  - Eduardo Mondlane UniversityC3  - University of CopenhagenC3  - Bispebjerg HospitalC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - Universite de MontrealC3  - Universidade do Vale do Rio dos Sinos (Unisinos)C3  - University of QueenslandC3  - Istituto Superiore di Sanita (ISS)C3  - Universidad de CuencaC3  - Helmholtz AssociationC3  - Helmholtz-Center Munich - German Research Center for Environmental HealthC3  - Institute of Cardiology - PolandC3  - University of ZagrebC3  - University of LatviaC3  - Universite de Tunis-El-ManarC3  - Institut National de Nutrition Technologie AlimentaireC3  - Stellenbosch UniversityC3  - Karadeniz Technical UniversityC3  - Finland National Institute for Health & WelfareC3  - Queens University BelfastC3  - University of ZurichC3  - University West Indies Mona JamaicaC3  - Consiglio per la Ricerca in Agricoltura e L'analisi Dell'economia Agraria (CREA)C3  - Pontificia Universidad Catolica de ChileC3  - University of ManchesterC3  - University of TartuC3  - Universiti Sains MalaysiaC3  - Umea UniversityC3  - Dalarna UniversityC3  - Universidade Federal de Sao Paulo (UNIFESP)C3  - Hospital Universitari Son EspasesC3  - Universidade Federal do Rio GrandeC3  - Kindai University (Kinki University)C3  - Kyoto UniversityC3  - Medical University of WarsawC3  - University of CataniaC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERESPC3  - University of Kwazulu NatalC3  - University of GenevaC3  - Wageningen University & ResearchC3  - B.P. Koirala Institute of Health SciencesC3  - University of InsubriaC3  - Universidad Politecnica de MadridC3  - Universite de LilleC3  - Norwegian Institute of Public Health (NIPH)C3  - Institute for Clinical & Experimental Medicine (IKEM)C3  - Children's Memorial Health InstituteC3  - International Hellenic UniversityC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - University of Novi SadC3  - Chinese Academy of Medical Sciences - Peking Union Medical CollegeC3  - Fu Wai Hospital - CAMSC3  - National University of SingaporeC3  - Singapore National Eye CenterC3  - Icelandic Heart AssociationC3  - Universidad ICESIC3  - Universidade Estadual de Montes ClarosC3  - University of LondonC3  - King's College LondonC3  - World Health OrganizationC3  - International Agency for Research on Cancer (IARC)C3  - Eternal Heart Care Centre & Research InstituteC3  - University of IbadanC3  - Danish Cancer SocietyC3  - Kyushu UniversityC3  - Tulane UniversityC3  - Chinese Center for Disease Control & PreventionC3  - University of AmsterdamC3  - Academic Medical Center AmsterdamC3  - Instituto Nacional de Salud PublicaC3  - University of OuluC3  - University of Hong KongC3  - Chinese University of Hong KongC3  - University of Western AustraliaC3  - Celal Bayar UniversityC3  - Universidade de Sao PauloC3  - Peking UniversityC3  - Vrije Universiteit AmsterdamC3  - Vrije Universiteit AmsterdamC3  - Birzeit UniversityC3  - American University of BeirutC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Aga Khan UniversityC3  - University of ZagrebC3  - Niigata UniversityC3  - Hebrew University of JerusalemC3  - Norwegian University of Science & Technology (NTNU)C3  - University of ZagrebC3  - National Health Insurance ServiceC3  - Simon Fraser UniversityC3  - Ruprecht Karls University HeidelbergC3  - World Health OrganizationC3  - Technical University CzestochowaC3  - University of CreteC3  - Universiti Kebangsaan MalaysiaC3  - Johns Hopkins UniversityC3  - Johns Hopkins Bloomberg School of Public HealthC3  - University of Eastern FinlandC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Epidemiology (NIE)C3  - University of MunsterC3  - South African Medical Research CouncilC3  - Ministry of Health - KyrgyzstanC3  - Kyrgyz State Medical AcademyC3  - University of CambridgeC3  - Medical University of InnsbruckC3  - Muhimbili University of Health & Allied SciencesC3  - National Cancer Center - Korea (NCC)C3  - Institute of Tropical Medicine (ITM)C3  - University of TartuC3  - Polish Academy of SciencesC3  - University of GroningenC3  - North West University - South AfricaC3  - National Institute of Public Health (SZU) - Czech RepublicC3  - University of JyvaskylaC3  - Amrita Vishwa VidyapeethamC3  - Amrita Vishwa Vidyapeetham KochiC3  - Institute of Cardiology - PolandC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - African Population & Health Research CentreC3  - University of GothenburgC3  - Tehran University of Medical SciencesC3  - Food & Agriculture Organization of the United Nations (FAO)C3  - National University of SingaporeC3  - Tampere UniversityC3  - Tampere University HospitalC3  - University of Cape TownC3  - West Virginia UniversityC3  - National Taiwan UniversityC3  - Chinese Academy of SciencesC3  - University of Chinese Academy of Sciences, CASC3  - Uppsala UniversityC3  - University of CopenhagenC3  - Bispebjerg HospitalC3  - University of GothenburgC3  - Children's Memorial Health InstituteC3  - Capital Medical UniversityC3  - Greifswald Medical SchoolC3  - Universidade de Sao PauloC3  - Lithuanian University of Health SciencesC3  - Finland National Institute for Health & WelfareC3  - Universidade do PortoC3  - Uppsala UniversityC3  - Peking UniversityC3  - Universidade Federal de Ouro PretoC3  - Jikei UniversityC3  - Consiglio Nazionale delle Ricerche (CNR)C3  - Baker Heart and Diabetes InstituteC3  - Agricultural University of AthensC3  - University of ZagrebC3  - Hospital Israelita Albert EinsteinC3  - Shiraz University of Medical ScienceC3  - National University of SingaporeC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Nutrition (NIN)C3  - Harokopio University AthensC3  - University of OtagoC3  - University of PaduaC3  - Pontificia Universidad Catolica de ChileC3  - University of LausanneC3  - Centre Hospitalier Universitaire Vaudois (CHUV)C3  - Universidade Federal de Santa Catarina (UFSC)C3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERCVC3  - Emory UniversityC3  - UiT The Arctic University of TromsoC3  - Universidade de Sao PauloC3  - Cape Peninsula University of TechnologyC3  - University of Yaounde IC3  - Instituto Conmemorativo Gorgas de Estudios de la SaludC3  - University West Indies Mona JamaicaC3  - Brown UniversityC3  - University of EdinburghC3  - Statistics CanadaC3  - University College DublinC3  - Lithuanian University of Health SciencesC3  - Institut National de la Sante et de la Recherche Medicale (Inserm)C3  - Helmholtz AssociationC3  - Helmholtz-Center Munich - German Research Center for Environmental HealthC3  - Universidade Federal de PelotasC3  - Indian Council of Medical Research (ICMR)C3  - University of TartuC3  - University of OsloC3  - Capital Institute of Pediatrics (CIP)C3  - Lusofona UniversityC3  - Universidad Peruana Cayetano HerediaC3  - Kyrgyz State Medical AcademyC3  - Ministry of Health - KyrgyzstanC3  - University of FlorenceC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - Tehran University of Medical SciencesC3  - Madras Diabetes Research FoundationC3  - Kementerian Kesihatan MalaysiaC3  - University of Southern DenmarkC3  - University of PecsC3  - Shahid Beheshti University Medical SciencesC3  - Mulago National Referral HospitalC3  - University of LimpopoC3  - Seoul National University (SNU)C3  - Seoul National University HospitalC3  - Universidade Federal do Rio Grande do SulC3  - University of ZaragozaC3  - Royal College of Surgeons - IrelandC3  - La Trobe UniversityC3  - Miedzynarodowy Instytut Biologii Molekularnej i KomorkowejC3  - Ahvaz Jundishapur University of Medical Sciences (AJUMS)C3  - Instituto Conmemorativo Gorgas de Estudios de la SaludC3  - World Health OrganizationC3  - University of BresciaC3  - World Health OrganizationC3  - International Agency for Research on Cancer (IARC)C3  - University of Eastern FinlandC3  - Ulm UniversityC3  - Kobe UniversityC3  - Regional Authority of Public Health Banska BystricaC3  - National University of SingaporeC3  - Suraj Eye InstituteC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERESPC3  - West Virginia UniversityC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - Karolinska InstitutetC3  - Robert Koch InstituteC3  - German Centre for Cardiovascular ResearchC3  - National Institute of Hygiene & Epidemiology (NIHE)C3  - Hanoi Medical UniversityC3  - Shanghai Jiao Tong UniversityC3  - Kyushu UniversityC3  - Universidad de la Republica, UruguayC3  - Imperial College LondonC3  - University of PalermoC3  - Queens University BelfastC3  - Tachikawa HospitalC3  - Anton de Kom Universiteit van SurinameC3  - Academisch Ziekenhuis ParamariboC3  - Korea Disease Control & Prevention Agency (KDCA)C3  - Universidade do Vale do Rio dos Sinos (Unisinos)C3  - Istanbul UniversityC3  - Universidade Federal de Santa Catarina (UFSC)C3  - Pan American Health OrganizationC3  - Universidade da MadeiraC3  - University of Novi SadC3  - Aarhus UniversityC3  - Kwame Nkrumah University Science & TechnologyC3  - Universidade de CoimbraC3  - University of LatviaC3  - Istituto Superiore di Sanita (ISS)C3  - Academia Sinica - TaiwanC3  - Ruprecht Karls University HeidelbergC3  - IRCCS Casa Sollievo Della SofferenzaC3  - Zayed UniversityC3  - Catholic University of DaeguC3  - University of ZagrebC3  - University of ZagrebC3  - UNIVERSITY ZAGREB HOSPITALC3  - South African Medical Research CouncilC3  - Utrecht UniversityC3  - Utrecht University Medical CenterC3  - Fundacao Oswaldo CruzC3  - Finland National Institute for Health & WelfareC3  - Universidade de Sao PauloC3  - Ministry of Health & Medical Education (MOHME)C3  - Leibniz AssociationC3  - Leibniz Institute for Prevention Research & Epidemiology (BIPS)C3  - University of LondonC3  - University College LondonC3  - University of SarajevoC3  - Institute of Cardiology - PolandC3  - University of SplitC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - University of LausanneC3  - Centre Hospitalier Universitaire Vaudois (CHUV)C3  - Victor Babes University of Medicine & Pharmacy, TimisoaraC3  - University of TartuC3  - Al-Quds UniversityC3  - University of Novi SadC3  - Bangladesh Rural Advancement Committee BRACC3  - University of TurkuC3  - Amrita Vishwa VidyapeethamC3  - Amrita Vishwa Vidyapeetham CoimbatoreC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Epidemiology (NIE)C3  - Universidade do PortoC3  - Universiti Putra MalaysiaC3  - Universiti MalayaC3  - Instituto Conmemorativo Gorgas de Estudios de la SaludC3  - University of ValenciaC3  - University of the Philippines SystemC3  - University of the Philippines DilimanC3  - Imperial College LondonC3  - Atencio Primaria de MallorcaC3  - Universidade Nove de JulhoC3  - University of SouthamptonC3  - Public Health Agency of CanadaC3  - Autonomous University of MadridC3  - Universidad Industrial de SantanderC3  - Instituto Nacional de Salud PublicaC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBEROBNC3  - University of Eastern FinlandC3  - University of GothenburgC3  - Statistics CanadaC3  - Instituto Mexicano del Seguro SocialC3  - Fahrenheit UniversitiesC3  - Medical University GdanskC3  - Singapore National Eye CenterC3  - National University of SingaporeC3  - Sitaram Bhartia Institute of Science & ResearchC3  - Universite de Tunis-El-ManarC3  - Marmara UniversityC3  - Instituto Nacional de Salud PublicaC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERESPC3  - Finland National Institute for Health & WelfareC3  - University of HelsinkiC3  - University of BresciaC3  - Instituto Nacional de Salud - PeruC3  - Universidade de LisboaC3  - Universidade Federal de PelotasC3  - Universidade de Sao PauloC3  - Universidade do PortoC3  - Universidade de LisboaC3  - Robert Koch InstituteC3  - Helmholtz AssociationC3  - German Cancer Research Center (DKFZ)C3  - Universidade de Sao PauloC3  - Hospital Italiano de Buenos AiresC3  - University of Buenos AiresC3  - University of Buenos Aires HospitalC3  - Greifswald Medical SchoolC3  - University of AmsterdamC3  - Academic Medical Center AmsterdamC3  - North West University - South AfricaC3  - South African Medical Research CouncilC3  - Norwegian University of Science & Technology (NTNU)C3  - Lagos State UniversityC3  - Tehran University of Medical SciencesC3  - B.P. Koirala Institute of Health SciencesC3  - Baker Heart and Diabetes InstituteC3  - University of TokyoC3  - Sungkyunkwan University (SKKU)C3  - Samsung Medical CenterC3  - Singapore National Eye CenterC3  - National University of SingaporeC3  - American University of BeirutC3  - Universidade Federal de Santa Catarina (UFSC)C3  - NSW HealthC3  - St Vincents Hospital SydneyC3  - University of New South Wales SydneyC3  - Karolinska InstitutetC3  - University of CopenhagenC3  - Bispebjerg HospitalC3  - Medical University LodzC3  - Miedzynarodowy Instytut Biologii Molekularnej i KomorkowejC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - University of OxfordC3  - University of AmsterdamC3  - Academic Medical Center AmsterdamC3  - University of Hong KongC3  - University of Yaounde IC3  - Umea UniversityC3  - Universita degli Studi di Bari Aldo MoroC3  - Lund UniversityC3  - Peking UniversityC3  - University of CopenhagenC3  - University of ZagrebC3  - Universite de BordeauxC3  - KU LeuvenC3  - University of LjubljanaC3  - Institut National de la Sante et de la Recherche Medicale (Inserm)C3  - Norwegian School of Sport SciencesC3  - University of BonnC3  - Emory UniversityC3  - Hebrew University of JerusalemC3  - Hadassah University Medical CenterC3  - Helmholtz AssociationC3  - Helmholtz-Center Munich - German Research Center for Environmental HealthC3  - National Institute of Hygiene (NIH)C3  - National Institute of Public Health (NIPH)C3  - University of AmsterdamC3  - Universidade Federal de Sao Paulo (UNIFESP)C3  - Fu Jen Catholic UniversityC3  - Uppsala UniversityC3  - Chinese University of Hong KongC3  - Mahidol UniversityC3  - University of the Philippines SystemC3  - University of the Philippines DilimanC3  - National University of SingaporeC3  - University of TartuC3  - Lithuanian University of Health SciencesC3  - University of SydneyC3  - Peking UniversityC3  - University of Kwazulu NatalC3  - Instituto Nacional de Salud - PeruC3  - Carol Davila University of Medicine & PharmacyC3  - University of AdelaideC3  - Karolinska InstitutetC3  - International Hellenic UniversityC3  - KU LeuvenC3  - University of CopenhagenC3  - Bispebjerg HospitalC3  - Danish Cancer SocietyC3  - Finland National Institute for Health & WelfareC3  - University of Southern DenmarkC3  - Karadeniz Technical UniversityC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - Atencio Primaria de MenorcaC3  - Institut de Recherche pour le Developpement (IRD)C3  - Harvard UniversityC3  - Harvard T.H. Chan School of Public HealthC3  - Sefako Makgatho Health Sciences UniversityC3  - University West Indies Mona JamaicaC3  - Addis Ababa UniversityC3  - University of Eastern FinlandC3  - Dasman Diabetes Institute (DDI)C3  - Karolinska InstitutetC3  - Universite de BordeauxC3  - Medical University of InnsbruckC3  - Tampere UniversityC3  - Pontificia Universidad Catolica de ChileC3  - Utrecht UniversityC3  - Ghent UniversityC3  - Hanoi University of Public HealthC3  - Utrecht UniversityC3  - Utrecht University Medical CenterC3  - Vrije Universiteit AmsterdamC3  - University of AmsterdamC3  - Academic Medical Center AmsterdamC3  - KU LeuvenC3  - Norwegian University of Science & Technology (NTNU)C3  - Universidade Federal de Minas GeraisC3  - University of InsubriaC3  - Netherlands National Institute for Public Health & the EnvironmentC3  - Institute of Tropical Medicine (ITM)C3  - Universidade Federal de PelotasC3  - Finnish Institute of Occupational HealthC3  - Imperial College LondonC3  - Universidad Miguel Hernandez de ElcheC3  - University of Eastern FinlandC3  - Institut National de la Sante et de la Recherche Medicale (Inserm)C3  - University of LausanneC3  - Centre Hospitalier Universitaire Vaudois (CHUV)C3  - University of WitwatersrandC3  - Universites de Strasbourg Etablissements AssociesC3  - Universite de StrasbourgC3  - Munster Technological University (MTU)C3  - Universiti Sains MalaysiaC3  - Kementerian Kesihatan MalaysiaC3  - Universidade de Pernambuco (UPE)C3  - Public Health Agency of CanadaC3  - Xinjiang Medical UniversityC3  - Capital Medical UniversityC3  - University of LondonC3  - University College LondonC3  - University of CambridgeC3  - University of Southern DenmarkC3  - City St Georges, University of LondonC3  - St Georges University LondonC3  - Medical University of ViennaC3  - University of IndonesiaC3  - Medical University SilesiaC3  - Netherlands National Institute for Public Health & the EnvironmentC3  - University West Indies Mona JamaicaC3  - Medical University of InnsbruckC3  - Kwame Nkrumah University Science & TechnologyC3  - UiT The Arctic University of TromsoC3  - National Institute of Hygiene (NIH)C3  - National Institute of Public Health (NIPH)C3  - National University of SingaporeC3  - Chinese University of Hong KongC3  - University of New South Wales SydneyC3  - University of OxfordC3  - Lund UniversityC3  - University of ManchesterC3  - Ministry of Agriculture & Rural AffairsC3  - Fudan UniversityC3  - Chinese Center for Disease Control & PreventionC3  - Chinese Academy of SciencesC3  - University of Chinese Academy of Sciences, CASC3  - University of CyprusC3  - Niigata UniversityC3  - University West Indies Mona JamaicaC3  - Kementerian Kesihatan MalaysiaC3  - Universiti Teknologi MARAC3  - University of PaduaC3  - Agricultural University of AthensC3  - Fahrenheit UniversitiesC3  - Medical University GdanskC3  - Duke UniversityC3  - Peking UniversityC3  - Capital Medical UniversityC3  - Chinese Center for Disease Control & PreventionC3  - Vanderbilt UniversityC3  - National University of SingaporeC3  - Singapore National Eye CenterC3  - Inner Mongolia Medical UniversityC3  - Asfendiyarov Kazakh National Medical UniversityC3  - University of CopenhagenC3  - Bispebjerg HospitalC3  - Instituto Conmemorativo Gorgas de Estudios de la SaludPU  - OXFORD UNIV PRESS
PI  - OXFORD
PA  - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
DA  - JUN
PY  - 2018
VL  - 47
IS  - 3
SP  - 872
EP  - +
DO  - 10.1093/ije/dyy016
AN  - WOS:000438342200023
ER  -

TY  - JOUR
AU  - Deshpande, S
AU  - Singh, N
TI  - Probing the nanoparticle-AGO2 interaction for enhanced gene knockdown
T2  - SOFT MATTER
KW  - STABILIZED GOLD NANOPARTICLES
KW  - INDUCED SILENCING COMPLEX
KW  - RISC-LOADING COMPLEX
KW  - SIRNA DELIVERY
KW  - IN-VIVO
KW  - RNA INTERFERENCE
KW  - HUMAN ARGONAUTE2
KW  - MAMMALIAN-CELLS
KW  - PLASMON RULERS
KW  - GRAPHENE OXIDE
AB  - RNAi is emerging as a promising technology for treatment of various diseases due to its ability to silence specific target genes. To date, a number of nanoparticle based formulations have been reported for the delivery of small interfering RNA (siRNA), with continuous modifications in the nanoparticle design for enhancing their efficiency. While majority of the design aspects are focused on avoiding or overcoming endosomal entrapment, limited studies are available that address the role of interaction of nanoparticles with the RNA induced silencing complex (RISC) machinery, which is a crucial aspect deciding the outcome. Here, we systematically probed the effect of steric hindrance of nanoparticles on RISC interaction, by modulating two parameters, nanoparticle size and hardness. An assay was developed for quantifying the extent of RISC interaction of different nanoparticles in vitro, which was then correlated with their gene knockdown efficiency. The results suggest that the soft and small nanoparticles were most efficacious in knocking down polo-like-kinase 1 (PLK1) siRNA, a gene overexpressed in a variety of cancer types.
AD  - Indian Inst Technol Delhi, Ctr Biomed Engn, New Delhi 110016, IndiaAD  - All India Inst Med Sci, Biomed Engn Unit, New Delhi 110029, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ROYAL SOC CHEMISTRY
PI  - CAMBRIDGE
PA  - THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND
DA  - MAY 28
PY  - 2018
VL  - 14
IS  - 20
SP  - 4169
EP  - 4177
DO  - 10.1039/c8sm00534f
AN  - WOS:000433430900016
ER  -

TY  - JOUR
AU  - Pachauri, N
AU  - Dave, K
AU  - Dinda, A
AU  - Solanki, PR
TI  - Cubic CeO<sub>2</sub> implanted reduced graphene oxide-based highly sensitive biosensor for non-invasive oral cancer biomarker detection
T2  - JOURNAL OF MATERIALS CHEMISTRY B
KW  - ENHANCED PHOTOCATALYTIC ACTIVITY
KW  - ELECTRONIC TRANSPORT-PROPERTIES
KW  - ELECTROCHEMICAL IMMUNOSENSOR
KW  - ZIRCONIA NANOPARTICLES
KW  - CERIA NANOPARTICLES
KW  - GLUCOSE BIOSENSOR
KW  - AMORPHOUS-CARBON
KW  - OXIDATIVE STRESS
KW  - SENSOR
KW  - NANOCOMPOSITES
AB  - Herein, we report a cerium oxide nanocubes (ncCeO(2))-reduced graphene oxide (RGO)-based nanocomposite for the detection of oral cancer biomarker, cytokeratin fragment-21-1 (Cyfra-21-1), using the electrochemical technique. Nanocomposite of ncCeO(2)-RGO was prepared by the in situ reduction of graphene oxide (GO), in the presence of ncCeO(2), using hydrazine hydrate. Raman spectra confirmed the presence of ncCeO2 in the matrix of RGO. The chemical composition of the ncCeO(2)-RGO nanocomposite was determined by X-ray photoelectron spectroscopy (XPS). X-ray diffraction (XRD) studies have indicated the presence of crystalline ncCeO(2) and the amorphous nature of RGO. Thin films of ncCeO(2)-RGO composites were spin coated onto the indium tin oxide (ITO) coated glass surface and used for the co-immobilization of specific antibody of Cyfra-21-1 by N-ethyl-N-(3-dimethyl aminopropyl) carbodiimide hydrochloride and N-hydroxysuccinimide (EDC-NHS) coupling chemistry. Electrochemical response studies were monitored by using the differential pulse voltammetry (DPV) technique in the range of 0.625 pg mL(-1) to 15 ng mL(-1). The best linear response was observed in the range of 0.625 pg mL(-1) to 0.01 ng mL(-1), with a low detection limit of 0.625 pg mL(-1). The sensitivity was found to be 14.5 mA ng(-1) mL cm-2 with R2 0.98, which was an improvement compared to the results from previously reported work. This BSA/ anti-Cyfra-21-1/ncCeO(2)-RGO/ ITO immunosensor shows selectivity towards Cyfra-21-1 in the presence of glucose, sodium chloride (NaCl), mucin 16 (MUC-16) and interleukin 8 (IL-8).
AD  - Jawaharlal Nehru Univ, Special Ctr Nanosci, New Delhi 110067, IndiaAD  - All India Inst Med Sci, New Delhi 110608, IndiaC3  - Special Centre for Nanoscience, Jawaharlal Nehru UniversityC3  - Jawaharlal Nehru University, New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ROYAL SOC CHEMISTRY
PI  - CAMBRIDGE
PA  - THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND
DA  - MAY 21
PY  - 2018
VL  - 6
IS  - 19
SP  - 3000
EP  - 3012
DO  - 10.1039/c8tb00653a
AN  - WOS:000436234900008
ER  -

TY  - JOUR
AU  - Ashraf, S
AU  - Kudo, H
AU  - Rao, J
AU  - Kikuchi, A
AU  - Widmeier, E
AU  - Lawson, JA
AU  - Tan, WZ
AU  - Hermle, T
AU  - Warejko, JK
AU  - Shril, S
AU  - Airik, M
AU  - Jobst-Schwan, T
AU  - Lovric, S
AU  - Braun, DA
AU  - Gee, HY
AU  - Schapiro, D
AU  - Majmundar, AJ
AU  - Sadowski, CE
AU  - Pabst, WL
AU  - Daga, A
AU  - van der Ven, AT
AU  - Schmidt, JM
AU  - Low, BC
AU  - Gupta, AB
AU  - Tripathi, BK
AU  - Wong, J
AU  - Campbell, K
AU  - Metcalfe, K
AU  - Schanze, D
AU  - Niihori, T
AU  - Kaito, H
AU  - Nozu, K
AU  - Tsukaguchi, H
AU  - Tanaka, R
AU  - Hamahira, K
AU  - Kobayashi, Y
AU  - Takizawa, T
AU  - Funayama, R
AU  - Nakayama, K
AU  - Aoki, Y
AU  - Kumagai, N
AU  - Iijima, K
AU  - Fehrenbach, H
AU  - Kari, JA
AU  - El Desoky, S
AU  - Jalalah, S
AU  - Bogdanovic, R
AU  - Stajic, N
AU  - Zappel, H
AU  - Rakhmetova, A
AU  - Wassmer, SR
AU  - Jungraithmayr, T
AU  - Strehlau, J
AU  - Kumar, AS
AU  - Bagga, A
AU  - Soliman, NA
AU  - Mane, SM
AU  - Kaufman, L
AU  - Lowy, DR
AU  - Jairajpuri, MA
AU  - Lifton, RP
AU  - Pei, Y
AU  - Zenker, M
AU  - Kure, S
AU  - Hildebrandt, F
TI  - Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment
T2  - NATURE COMMUNICATIONS
KW  - MULTIPOINT LINKAGE ANALYSIS
KW  - TUMOR-SUPPRESSOR DLC1
KW  - SCAFFOLD PROTEIN
KW  - RHO GTPASES
KW  - ACTIN
KW  - CAVEOLIN-1
KW  - CILIOPATHY
KW  - EXPRESSION
KW  - MIGRATION
KW  - MAGI-2
AB  - No efficient treatment exists for nephrotic syndrome (NS), a frequent cause of chronic kidney disease. Here we show mutations in six different genes (MAGI2, TNS2, DLC1, CDK20, ITSN1, ITSN2) as causing NS in 17 families with partially treatment-sensitive NS (pTSNS). These proteins interact and we delineate their roles in Rho-like small GTPase (RLSG) activity, and demonstrate deficiency for mutants of pTSNS patients. We find that CDK20 regulates DLC1. Knockdown of MAGI2, DLC1, or CDK20 in cultured podocytes reduces migration rate. Treatment with dexamethasone abolishes RhoA activation by knockdown of DLC1 or CDK20 indicating that steroid treatment in patients with pTSNS and mutations in these genes is mediated by this RLSG module. Furthermore, we discover ITSN1 and ITSN2 as podocytic guanine nucleotide exchange factors for Cdc42. We generate Itsn2-L knockout mice that recapitulate the mild NS phenotype. We, thus, define a functional network of RhoA regulation, thereby revealing potential therapeutic targets.
AD  - Harvard Med Sch, Boston Childrens Hosp, Dept Med, Boston, MA USAAD  - Jamia Millia Islamia, Dept Biosci, New Delhi, IndiaAD  - Tohoku Univ, Dept Pediat, Sch Med, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, JapanAD  - Yonsei Univ, Dept Pharmacol, Brain Korea PLUS Project Med Sci 21, Coll Med, Seoul 03722, South KoreaAD  - Natl Univ Singapore, Dept Biol Sci, Singapore, SingaporeAD  - Natl Univ Singapore, Mechanobiol Inst, Singapore, SingaporeAD  - NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USAAD  - Icahn Sch Med Mt Sinai, Div Nephrol, New York, NY 10029 USAAD  - Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Ctr Genom Med, St Marys Hosp, Manchester, Lancs, EnglandAD  - Univ Hosp Magdeburg, Inst Human Genet, Magdeburg, GermanyAD  - Tohoku Univ, Sch Med, Dept Med Genet, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, JapanAD  - Kobe Univ, Dept Pediat, Grad Sch Med, Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, JapanAD  - Kansai Med Univ, Dept Internal Med 2, 2-3-1 Shin Machi, Hirakata, Osaka 5731191, JapanAD  - Hyogo Prefectural Kobe Childrens Hosp, Dept Nephrol, Chuo Ku, 1-6-7 Minatojima Minamimachi, Kobe, Hyogo 6500047, JapanAD  - Himeji Red Cross Hosp, Dept Pediat, 1-12-1 Shimoteno, Himeji, Hyogo 6708540, JapanAD  - Gunma Univ, Grad Sch Med, Dept Pediat, 3-39-22 Showa Machi, Maebashi, Gunma 3718511, JapanAD  - Univ Bristol, Sch Clin Sci, Acad Renal Unit, Dorothy Hodgkin Bldg,Whitson St, Bristol BS1 3NY, Avon, EnglandAD  - Tohoku Univ, Grad Sch Med, United Ctr Adv Res & Translat Med, Div Cell Proliferat, Sendai, Miyagi 9808575, JapanAD  - Childrens Hosp, Dept Pediat Nephrol, Memmingen, GermanyAD  - King Abdulaziz Univ, Pediat Nephrol Ctr Excellence, Jeddah, Saudi ArabiaAD  - King Abdulaziz Univ, Pediat Dept, Jeddah, Saudi ArabiaAD  - King Abdulaziz Univ, Pathol Dept, Jeddah, Saudi ArabiaAD  - Univ Belgrade, Fac Med, Dept Nephrol, Inst Mother & Child Hlth Care Serbia Dr Vukan Cup, Belgrade 11000, SerbiaAD  - Univ Gottingen, Dept Paediat 2, Gottingen, GermanyAD  - Asfendiyarov Kazakh Natl Med Univ, Dept Nephrol, Alma Ata, KazakhstanAD  - Luzerner Kantonsspital, Dept Nephrol, Luzern, SwitzerlandAD  - Univ Med Ctr Innsbruck, Dept Pediat, Innsbruck, AustriaAD  - Hannover Med Sch, Dept Pediat Nephrol, Hannover, GermanyAD  - TN Dr MGR Med Univ, Inst Child Hlth, Dept Pediat Nephrol & Med Genet, Madras, Tamil Nadu, IndiaAD  - TN Dr MGR Med Univ, Hosp Children, Madras, Tamil Nadu, IndiaAD  - All India Inst Med Sci, Dept Pediat, Div Pediat Nephrol, New Delhi, IndiaAD  - Cairo Univ, Kasr Al Ainy Sch Med, Ctr Pediat Nephrol & Transplantat, Dept Pediat, Cairo, EgyptAD  - Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USAAD  - Rockefeller Univ, Lab Human Genet & Genom, New York, NY 10065 USAAD  - Univ Hlth Network, Div Nephrol, Toronto, ON, CanadaAD  - Univ Toronto, Toronto, ON, CanadaC3  - Harvard UniversityC3  - Harvard Medical SchoolC3  - Boston Children's HospitalC3  - Jamia Millia IslamiaC3  - Tohoku UniversityC3  - Yonsei UniversityC3  - Yonsei University Health SystemC3  - National University of SingaporeC3  - National University of SingaporeC3  - National Institutes of Health (NIH) - USAC3  - NIH National Cancer Institute (NCI)C3  - Icahn School of Medicine at Mount SinaiC3  - University of ManchesterC3  - University Hospital MagdeburgC3  - Tohoku UniversityC3  - Kobe UniversityC3  - Kansai Medical UniversityC3  - Gunma UniversityC3  - University of BristolC3  - Tohoku UniversityC3  - King Abdulaziz UniversityC3  - King Abdulaziz UniversityC3  - King Abdulaziz UniversityC3  - University of BelgradeC3  - University of GottingenC3  - Asfendiyarov Kazakh National Medical UniversityC3  - Lucerne Cantonal HospitalC3  - Hannover Medical SchoolC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Yale UniversityC3  - Rockefeller UniversityC3  - University of TorontoC3  - University Health Network TorontoC3  - University of TorontoPU  - NATURE PUBLISHING GROUP
PI  - LONDON
PA  - MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - MAY 17
PY  - 2018
VL  - 9
C7  - 1960
DO  - 10.1038/s41467-018-04193-w
AN  - WOS:000432343700002
ER  -

TY  - JOUR
AU  - Bijalwan, A
AU  - Patel, BP
AU  - Marieswaran, M
AU  - Kalyanasundaram, D
TI  - Volumetric locking free 3D finite element for modelling of anisotropic visco-hyperelastic behaviour of anterior cruciate ligament
T2  - JOURNAL OF BIOMECHANICS
KW  - 3-D finite element
KW  - Visco-hyperelastic solid
KW  - Volumetric locking
KW  - J-Bar method
KW  - Anterior Cruciate Ligament (ACL)
KW  - VISCOELASTIC RHEOLOGICAL MODEL
KW  - COMPUTATIONAL ASPECTS
KW  - PROJECTION METHODS
KW  - KNEE
KW  - FORMULATION
KW  - THERMOPLASTICS
KW  - ELASTICITY
KW  - ELASTOMERS
KW  - MECHANICS
KW  - MESHFREE
AB  - Solids such as polymers, soft biological tissues display visco-hyperelastic, isochoric and finite deformation behaviour. The incompressibility constraint imposed severe restriction on the displacement field results in volumetric locking. Many techniques have been developed to address the issue such as reduced integration, mixed formulation, B-Bar and F-Bar methods, each of them with their own merits and demerits. In this work, we have developed a 3D finite element (hereby referred as j-Bar method) to counter volumetric locking in visco-hyperelastic solids. To validate the proposed J-Bar method, rheological characteristics of the human anterior cruciate ligament (ACL) were predicted and compared with the experimental results. (C) 2018 Elsevier Ltd. All rights reserved.
AD  - Indian Inst Technol Delhi, Dept Appl Mech, New Delhi 110016, IndiaAD  - Indian Inst Technol Delhi, Ctr Biomed Engn, New Delhi 110016, IndiaAD  - All India Inst Med Sci, Dept Biomed Engn, New Delhi 110029, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - MAY 17
PY  - 2018
VL  - 73
SP  - 1
EP  - 8
DO  - 10.1016/j.jbiomech.2018.03.016
AN  - WOS:000432770400001
ER  -

TY  - JOUR
AU  - Nayak, S
AU  - Aich, M
AU  - Kumar, A
AU  - Sengupta, S
AU  - Bajad, P
AU  - Dhapola, P
AU  - Paul, D
AU  - Narta, K
AU  - Purkrait, S
AU  - Mehani, B
AU  - Suri, A
AU  - Chakraborty, D
AU  - Mukhopadhyay, A
AU  - Sarkar, C
TI  - Novel internal regulators and candidate miRNAs within miR-379/miR-656 miRNA cluster can alter cellular phenotype of human glioblastoma
T2  - SCIENTIFIC REPORTS
KW  - BREAST-CANCER CELLS
KW  - MICRORNA CLUSTER
KW  - EXPRESSION
KW  - MIGRATION
KW  - DIFFERENTIATION
KW  - PROLIFERATION
KW  - REPRESSES
KW  - INVASION
KW  - MUTATION
KW  - GROWTH
AB  - Clustered miRNAs can affect functioning of downstream pathways due to possible coordinated function. We observed 78-88% of the miR-379/miR-656 cluster (C14MC) miRNAs were downregulated in three sub-types of diffuse gliomas, which was also corroborated with analysis from The Cancer Genome Atlas (TCGA) datasets. The miRNA expression levels decreased with increasing tumor grade, indicating this downregulation as an early event in gliomagenesis. Higher expression of the C14MC miRNAs significantly improved glioblastioma prognosis (Pearson's r = 0.62; p < 3.08e-22). ENCODE meta-data analysis, followed by reporter assays validated existence of two novel internal regulators within C14MC. CRISPR activation of the most efficient internal regulator specifically induced members of the downstream miRNA sub-cluster and apoptosis in glioblastoma cells. Luciferase assays validated novel targets for miR-134 and miR-485-5p, two miRNAs from C14MC with the most number of target genes relevant for glioma. Overexpression of miR-134 and miR-485-5p in human glioblastoma cells suppressed invasion and proliferation, respectively. Furthermore, apoptosis was induced by both miRs, individually and in combination. The results emphasize the tumor suppressive role of C14MC in diffuse gliomas, and identifies two specific miRNAs with potential therapeutic value and towards better disease management and therapy.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaAD  - CSIR, Inst Genom & Integrat Biol, Genom & Mol Med Unit, Mathura Rd, New Delhi 110020, IndiaAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, IndiaAD  - CSIR, Inst Genom & Integrat Biol, Prote & Struct Biol Unit, Mathura Rd, New Delhi 110020, IndiaAD  - CSIR, Inst Genom & Integrat Biol, GN Ramachandran Knowledge Ctr Genome Informat, New Delhi 11020, IndiaAD  - Acad Sci & Innovat Res AcSIR, Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, Bhubaneswar 751019, Odisha, IndiaAD  - Univ Salford, Sch Environm & Life Sci, Manchester, Lancs, EnglandC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Academy of Scientific & Innovative Research (AcSIR)C3  - All India Institute of Medical Sciences (AIIMS) BhubaneswarC3  - University of SalfordC3  - University of ManchesterPU  - NATURE PORTFOLIO
PI  - BERLIN
PA  - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
DA  - MAY 16
PY  - 2018
VL  - 8
C7  - 7673
DO  - 10.1038/s41598-018-26000-8
AN  - WOS:000432273000021
ER  -

TY  - JOUR
AU  - Al-Mallah, MH
AU  - Pascual, TNB
AU  - Mercuri, M
AU  - Vitola, JV
AU  - Karthikeyan, G
AU  - Better, N
AU  - Dondi, M
AU  - Paez, D
AU  - Einstein, AJ
AU  - Einstein, AJ
AU  - Pascual, TNB
AU  - Paez, D
AU  - Dondi, M
AU  - Better, N
AU  - Bouyoucef, SE
AU  - Karthikeyan, G
AU  - Kashyap, R
AU  - Lele, V
AU  - Magboo, VPC
AU  - Mut, F
AU  - Mahmarian, J
AU  - Meeks, JB
AU  - Mercuri, M
AU  - Rehani, MM
AU  - Vitola, JV
AU  - Alexánderson, E
AU  - Allam, A
AU  - Al-Mallah, MH
AU  - Better, N
AU  - Bouyoucef, SE
AU  - Bom, H
AU  - Flotats, A
AU  - Jerome, S
AU  - Kaufmann, PA
AU  - Lele, V
AU  - Luxenburg, O
AU  - Mahmarian, J
AU  - Shaw, LJ
AU  - Underwood, SR
AU  - Vitola, J
AU  - Amouri, W
AU  - Essabbah, H
AU  - Gassama, SS
AU  - Makhdomi, KB
AU  - El Mustapha, GIE
AU  - El Ouchdi, N
AU  - Qaïs, N
AU  - Soni, N
AU  - Vangu, W
AU  - Abazid, RM
AU  - Adams, B
AU  - Agarwal, V
AU  - Alfeeli, MA
AU  - Alnafisi, N
AU  - Bernabe, L
AU  - Bural, GG
AU  - Chaiwatanarat, T
AU  - Chandraguptha, JM
AU  - Cheon, GJ
AU  - Cho, I
AU  - Dogan, AS
AU  - Eftekhari, M
AU  - Frenkel, A
AU  - Garty, I
AU  - George, S
AU  - Geramifar, P
AU  - Golan, H
AU  - Habib, S
AU  - Hussain, R
AU  - Im, H
AU  - Jeon, HJ
AU  - Kalawat, T
AU  - Kang, WJ
AU  - Keng, F
AU  - Klaipetch, A
AU  - Kumar, PG
AU  - Lee, J
AU  - Lee, WW
AU  - Lim, I
AU  - Macaisa, CMM
AU  - Malhotra, G
AU  - Mittal, BR
AU  - Mohammad, MH
AU  - Mohan, P
AU  - Mulyanto, ID
AU  - Nariman, D
AU  - Nayak, UN
AU  - Niaz, K
AU  - Nikolov, G
AU  - Obaldo, JM
AU  - Ozturk, E
AU  - Park, JM
AU  - Park, S
AU  - Patel, CD
AU  - Phuong, HK
AU  - Quinon, AP
AU  - Rajini, TR
AU  - Saengsuda, Y
AU  - Santiago, J
AU  - Sayman, HB
AU  - Shinto, AS
AU  - Sivasubramaniyan, V
AU  - Son, MH
AU  - Sudhakar, P
AU  - Syed, GMS
AU  - Tamaki, N
AU  - Thamnirat, K
AU  - Thientunyakit, T
AU  - Thongmak, S
AU  - Velasco, DN
AU  - Verma, A
AU  - Vutrapongwatana, U
AU  - Wang, Y
AU  - Won, KS
AU  - Yao, Z
AU  - Yingsa-nga, T
AU  - Yudistiro, R
AU  - Yue, KT
AU  - Zafrir, N
AU  - Adrian, SC
AU  - Agostini, D
AU  - Aguadé, S
AU  - Armitage, G
AU  - Backlund, M
AU  - Backman, M
AU  - Baker, M
AU  - Balducci, MT
AU  - Bavelaar, C
AU  - Berovic, M
AU  - Bertagna, F
AU  - Beuchel, R
AU  - Biggi, A
AU  - Bisi, G
AU  - Bonini, R
AU  - Bradley, A
AU  - Brudin, L
AU  - Bruno, I
AU  - Busnardo, E
AU  - Casoni, R
AU  - Choudhri, A
AU  - Cittanti, C
AU  - Clauss, R
AU  - Costa, DC
AU  - Costa, M
AU  - Dixon, K
AU  - Dziuk, M
AU  - Egelic, N
AU  - Eriksson, I
AU  - Fagioli, G
AU  - de Faria, DB
AU  - Florimonte, L
AU  - Francini, A
AU  - French, M
AU  - Gallagher, E
AU  - Garai, I
AU  - Geatti, O
AU  - Genovesi, D
AU  - Gianolli, L
AU  - Gimelli, A
AU  - del Giudice, E
AU  - Halliwell, S
AU  - Hansson, MJ
AU  - Harrison, C
AU  - Homans, F
AU  - Horton, F
AU  - Jedrzejuk, D
AU  - Jogi, J
AU  - Johansen, A
AU  - Johansson, H
AU  - Kalnina, M
AU  - Kaminek, M
AU  - Kiss, A
AU  - Kobylecka, M
AU  - Kostkiewicz, M
AU  - Kropp, J
AU  - Kullenberg, R
AU  - Lahoutte, T
AU  - Lang, O
AU  - Larsson, YH
AU  - Lázár, M
AU  - Leccisotti, L
AU  - Leners, N
AU  - Lindner, O
AU  - Lipp, RW
AU  - Maenhout, A
AU  - Maffioli, L
AU  - Marcassa, C
AU  - Martins, B
AU  - Marzullo, P
AU  - Medolago, G
AU  - Mendiguchía, CG
AU  - Mirzaei, S
AU  - Mori, M
AU  - Nardi, B
AU  - Nazarenko, S
AU  - Nikoletic, K
AU  - Oleksa, R
AU  - Parviainen, T
AU  - Patrina, J
AU  - Peace, R
AU  - Pirich, C
AU  - Piwowarska-Bilska, H
AU  - Popa, S
AU  - Prakash, V
AU  - Pubul, V
AU  - Puklavec, L
AU  - Rac, S
AU  - Ratniece, M
AU  - Rogan, SA
AU  - Romeo, A
AU  - Rossi, M
AU  - Ruiz, D
AU  - Sabharwal, N
AU  - Salobir, BG
AU  - Santos, AI
AU  - Saranovic, S
AU  - Sarkozi, A
AU  - Schneider, RP
AU  - Sciagra, R
AU  - Scotti, S
AU  - Servini, Z
AU  - Setti, LR
AU  - Starck, SÅ
AU  - Vajauskas, D
AU  - Vesely, J
AU  - Vieni, A
AU  - Vignati, A
AU  - Vito, IM
AU  - Weiss, K
AU  - Wild, D
AU  - Zdraveska-Kochovska, M
AU  - Agüro, RN
AU  - Alvarado, N
AU  - Barral, CM
AU  - Beretta, M
AU  - Berrocal, I
AU  - Cuellar, JFB
AU  - Chang, TMC
AU  - Rodríguez, LOC
AU  - Canessa, J
AU  - Mora, GC
AU  - Claudia, AC
AU  - Clavelo, GF
AU  - Cruz, AF
AU  - Faccio, FF
AU  - Fernández, KM
AU  - Garibo, JRG
AU  - Gonzalez, U
AU  - González, P
AU  - Guzzo, MA
AU  - Jofre, J
AU  - Kapitán, M
AU  - Kempfer, G
AU  - Lopez, JL
AU  - Massardo, T
AU  - Colaco, IM
AU  - Mesquita, CT
AU  - Montecinos, M
AU  - Neubauer, S
AU  - Pabon, LM
AU  - Puente, A
AU  - Vazquez, LMR
AU  - Macias, JAS
AU  - Pino, AGS
AU  - Huber, FZT
AU  - Tovar, AP
AU  - Vargas, L
AU  - Wiefels, C
AU  - Aljizeeri, A
AU  - Alvarez, RJ
AU  - Barger, D
AU  - Beardwood, W
AU  - Behrens, J
AU  - Brann, L
AU  - Brown, D
AU  - Carr, H
AU  - Churchwell, K
AU  - Comingore, GA
AU  - Corbett, J
AU  - Costello, M
AU  - Cruz, F
AU  - Depinet, T
AU  - Dorbala, S
AU  - Earles, M
AU  - Esteves, FP
AU  - Etherton, E
AU  - Fanning, RJ
AU  - Fornace, J
AU  - Franks, L
AU  - Gewirtz, H
AU  - Gulanchyn, K
AU  - Hannah, CL
AU  - Hays, J
AU  - Hendrickson, J
AU  - Hester, J
AU  - Holmes, K
AU  - Jerome, S
AU  - Johnson, A
AU  - Jopek, C
AU  - Lewin, H
AU  - Lyons, J
AU  - Manley, C
AU  - Meden, J
AU  - Moore, S
AU  - Moore, WH
AU  - Murthy, V
AU  - Nace, R
AU  - Neely, D
AU  - Nelson, L
AU  - Niedermaier, O
AU  - Rice, D
AU  - Rigs, R
AU  - Schiffer, K
AU  - Schockling, E
AU  - Schultz, T
AU  - Schumacker, T
AU  - Sheesley, B
AU  - Sheikh, A
AU  - Siegel, B
AU  - Slim, AM
AU  - Smith, J
AU  - Szulc, M
AU  - Tanskersley, N
AU  - Tilkemeier, P
AU  - Valdez, GD
AU  - Vrooman, R
AU  - Wawrowicz, D
AU  - Winchester, DE
AU  - Alcheikh, A
AU  - Allen, B
AU  - Atkins, E
AU  - Bevan, J
AU  - Bonomini, C
AU  - Christiansen, J
AU  - Clark, L
AU  - Craig, E
AU  - Dixon, H
AU  - Duncan, I
AU  - Fredericks, S
AU  - Gales, S
AU  - Hampson, R
AU  - Hanley, T
AU  - Hartcher, K
AU  - Hassall, J
AU  - Kelley, B
AU  - Kelly, S
AU  - Kidd, T
AU  - de Kort, T
AU  - Larcos, G
AU  - Macdonald, W
AU  - McGrath, C
AU  - Murdoch, E
AU  - O'Malley, S
AU  - O'Rourke, M
AU  - Pack, M
AU  - Pearce, R
AU  - Praehofer, R
AU  - Ramsay, S
AU  - Scarlett, L
AU  - Smidt, K
AU  - Souvannavong, F
AU  - Taubman, K
AU  - Taylor, G
AU  - Tse, K
AU  - Unger, S
AU  - Weale, J
AU  - Westcott, J
A1  - INCAPS Investigators Grp
TI  - Impact of age on the selection of nuclear cardiology stress protocols: The INCAPS (IAEA nuclear cardiology protocols) study
T2  - INTERNATIONAL JOURNAL OF CARDIOLOGY
KW  - Myocardial perfusion maging
KW  - Ionizing radiation
KW  - Age
KW  - Guidelines
KW  - RADIATION-EXPOSURE
KW  - REDUCTION
AB  - Background: There is growing concern about radiation exposure from nuclear myocardial perfusion imaging (MPI), particularly among younger patients who are more prone to develop untoward effects of ionizing radiation, and hence US and European professional society guidelines recommend age as a consideration in weighing radiation risk from MPI. We aimed to determine how patient radiation doses from MPI vary across age groups in a large contemporary international cohort.
   Methods: Data were collected as part of a global cross-sectional study of centers performing MPI coordinated by the International Atomic Energy Agency (IAEA). Sites provided information on each MPI study completed during a single week in March-April 2013. We compared across age groups laboratory adherence to pre-specified radiation-related best practices, radiation effective dose (ED; a whole-body measure reflecting the amount of radiation to each organ and its relative sensitivity to radiation's deleterious effects); and the proportion of patients with ED <= 9 mSv, a target level specified in guidelines.
   Results: Among 7911 patients undergoing MPI in 308 laboratories in 65 countries, mean ED was 10.0 +/- 4.5 mSv with slightly higher exposure among younger age groups (trend p value < 0.001). There was no difference in the proportion of patients with ED <= 9 mSv across age groups, or in adherence to best practices based on the median age of patients in a laboratory.
   Conclusions: In contemporary nuclear cardiology practice, the age of the patient appears not to impact protocol selection and radiation dose, contrary to professional society guidelines. (C) 2018 Published by Elsevier B.V.
AD  - King Saud bin Abdulaziz Univ Hlth Sci, Div Adv Cardiac Imaging, Riyadh, Saudi ArabiaAD  - IAEA, Div Human Hlth, Sect Nucl Med & Diagnost Imaging, Vienna, AustriaAD  - Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY 10032 USAAD  - McMaster Univ, Dept Med, Hamilton, ON, CanadaAD  - Quanta Diagnost & Terapia, Curitiba, Parana, BrazilAD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaAD  - Univ Melbourne, Royal Melbourne Hosp, Dept Nucl Med, Melbourne, Vic, AustraliaAD  - Columbia Univ, Med Ctr, New York Presbyterian Hosp, Dept Radiol, New York, NY 10032 USAC3  - King Saud Bin Abdulaziz University for Health SciencesC3  - International Atomic Energy AgencyC3  - NewYork-Presbyterian HospitalC3  - Columbia UniversityC3  - McMaster UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of MelbourneC3  - Melbourne HealthC3  - Royal Melbourne HospitalC3  - NewYork-Presbyterian HospitalC3  - Columbia UniversityPU  - ELSEVIER IRELAND LTD
PI  - CLARE
PA  - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
DA  - MAY 15
PY  - 2018
VL  - 259
SP  - 222
EP  - 226
DO  - 10.1016/j.ijcard.2018.02.060
AN  - WOS:000428300900053
ER  -

TY  - JOUR
AU  - Rai, R
AU  - Dutta, RK
AU  - Singh, S
AU  - Yadav, DK
AU  - Kumari, S
AU  - Singh, H
AU  - Gupta, RD
AU  - Pratap, R
TI  - Synthesis, biological evaluation and molecular docking study of 1-amino-2-aroylnaphthalenes against prostate cancer
T2  - BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
KW  - Naphthalene
KW  - Prostate cancer
KW  - Oxidative damage
KW  - Apoptosis
KW  - Cytotoxicity
KW  - NEO-TANSHINLACTONE
KW  - ANTITUMOR AGENTS
KW  - INTERCALATORS
KW  - DERIVATIVES
KW  - DNA
KW  - DESIGN
KW  - DRUGS
AB  - A series of functionalized naphthalene was synthesized and screened against human prostate cancer cell line (PC-3). The in vitro antiproliferative activity of the synthesized compounds was evaluated by monitoring their cytotoxic effects against PC-3 cells by using MTT assay. We observed that compound 5f resulted in more than 50% cell death at 14 mu M. Treatment of PC-3 cells with 5f provides apoptosis by flow cytometry. Western blotting showed decreased expression of pro-caspase 8 and 9. Our study shows that cancer cell treated with 5f has higher concentration of reactive oxygen species as compare to untreated sample, which facilitate cancerous cell to enter apoptosis. Exact mechanism by which ROS is generated after 5f treatment is still under study. Molecular docking study further strengthens the results obtained from in vitro experiments. Compound 5f can be considered as a promising leads for anticancer agent against prostate cancer cells due to its potent cytotoxic activity and apoptotic effect. (C) 2018 Elsevier Ltd. All rights reserved.
AD  - AIIMS, Dept Biochem, New Delhi 110029, IndiaAD  - South Asian Univ, Fac Life Sci & Biotechnol, New Delhi 110021, IndiaAD  - Univ Delhi, Dept Chem, North Campus, Delhi 110007, IndiaAD  - Cent Drug Res Inst, Biochem Div, Lucknow 226001, Uttar Pradesh, IndiaAD  - Indian Council Med Res, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - South Asian University (SAU)C3  - University of DelhiC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Central Drug Research Institute (CDRI)C3  - Indian Council of Medical Research (ICMR)PU  - PERGAMON-ELSEVIER SCIENCE LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
DA  - MAY 15
PY  - 2018
VL  - 28
IS  - 9
SP  - 1574
EP  - 1580
DO  - 10.1016/j.bmcl.2018.03.057
AN  - WOS:000432493900025
ER  -

TY  - JOUR
AU  - Kalra, P
AU  - Dhiman, A
AU  - Cho, WC
AU  - Bruno, JG
AU  - Sharma, TK
TI  - Simple Methods and Rational Design for Enhancing Aptamer Sensitivity and Specificity
T2  - FRONTIERS IN MOLECULAR BIOSCIENCES
KW  - aptamers
KW  - SELEX
KW  - affinity
KW  - K-d
KW  - selectivity
KW  - specificity
KW  - limit of detection
KW  - sensitivity
KW  - DNA-APTAMER
KW  - RNA APTAMERS
KW  - GOLD NANOPARTICLES
KW  - NANOZYME ACTIVITY
KW  - STRUCTURAL BASIS
KW  - SSDNA APTAMERS
KW  - SANDWICH ASSAY
KW  - SELECTION
KW  - PROTEIN
KW  - AFFINITY
AB  - Aptamers are structured nucleic acid molecules that can bind to their targets with high affinity and specificity. However, conventional SELEX (Systematic Evolution of Ligands by EXponential enrichment) methods may not necessarily produce aptamers of desired affinity and specificity. Thus, to address these questions, this perspective is intended to suggest some approaches and tips along with novel selection methods to enhance evolution of aptamers. This perspective covers latest novel innovations as well as a broad range of well-established approaches to improve the individual binding parameters (aptamer affinity, avidity, specificity and/or selectivity) of aptamers during and/or post-SELEX. The advantages and limitations of individual aptamer selection methods and post-SELEX optimizations, along with rational approaches to overcome these limitations are elucidated in each case. Further the impact of chosen selection milieus, linker-systems, aptamer cocktails and detection modules utilized in conjunction with target-specific aptamers, on the overall assay performance are discussed in detail, each with its own advantages and limitations. The simple variations suggested are easily available for facile implementation during and/or post-SELEX to develop ultrasensitive and specific assays. Finally, success studies of established aptamer-based assays are discussed, highlighting how they utilized some of the suggested methodologies to develop commercially successful point-of-care diagnostic assays.
AD  - All India Inst Med Sci, Dept Biotechnol, New Delhi, IndiaAD  - Uttarakhand Tech Univ, Fac Pharm, Dehra Dun, Uttar Pradesh, IndiaAD  - Queen Elizabeth Hosp, Dept Clin Oncol, Kowloon, Hong Kong, Peoples R ChinaAD  - Operat Technol Corp, San Antonio, TX 78264 USAAD  - Translat Hlth Sci & Technol Inst, Ctr Biodesign & Diagnost, Faridabad, IndiaAD  - AptaBharat Innovat Private Ltd, Translational Hlth Sci & Technol Inst Incubator, Faridabad, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Uttarakhand Technical UniversityC3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)PU  - FRONTIERS MEDIA SA
PI  - LAUSANNE
PA  - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
DA  - MAY 14
PY  - 2018
VL  - 5
C7  - 41
DO  - 10.3389/fmolb.2018.00041
AN  - WOS:000455242900001
ER  -

TY  - JOUR
AU  - Vinny, PW
AU  - Vishnu, VY
AU  - Srivastava, MVP
TI  - Thrombectomy for Stroke with Selection by Perfusion Imaging
T2  - NEW ENGLAND JOURNAL OF MEDICINE
AD  - Indian Naval Hosp Ship Asvini, Bombay, Maharashtra, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MASSACHUSETTS MEDICAL SOC
PI  - WALTHAM
PA  - WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
DA  - MAY 10
PY  - 2018
VL  - 378
IS  - 19
SP  - 1849
EP  - 1849
AN  - WOS:000431774400019
ER  -

TY  - JOUR
AU  - Vashist, A
AU  - Kaushik, A
AU  - Vashist, A
AU  - Sagar, V
AU  - Ghosal, A
AU  - Gupta, YK
AU  - Ahmad, S
AU  - Nair, M
TI  - Advances in Carbon Nanotubes-Hydrogel Hybrids in Nanomedicine for Therapeutics
T2  - ADVANCED HEALTHCARE MATERIALS
KW  - biomaterials
KW  - biosensors
KW  - carbon nanotubes
KW  - drug delivery
KW  - hydrogel hybrids
KW  - imaging systems
KW  - tissue engineering
KW  - DRUG-DELIVERY SYSTEMS
KW  - ENGINEERING CARDIAC CONSTRUCTS
KW  - NANOCOMPOSITE HYDROGELS
KW  - BIOMEDICAL APPLICATIONS
KW  - MECHANICAL-PROPERTIES
KW  - IN-VIVO
KW  - GUAR GUM
KW  - ELECTRICAL-CONDUCTIVITY
KW  - REGENERATIVE MEDICINE
KW  - COLLAGEN HYDROGELS
AB  - In spite of significant advancement in hydrogel technology, low mechanical strength and lack of electrical conductivity have limited their next-level biomedical applications for skeletal muscles, cardiac and neural cells. Host-guest chemistry based hybrid nanocomposites systems have gained attention as they completely overcome these pitfalls and generate bioscaffolds with tunable electrical and mechanical characteristics. In recent years, carbon nanotube (CNT)-based hybrid hydrogels have emerged as innovative candidates with diverse applications in regenerative medicines, tissue engineering, drug delivery devices, implantable devices, biosensing, and biorobotics. This article is an attempt to recapitulate the advancement in synthesis and characterization of hybrid hydrogels and provide deep insights toward their functioning and success as biomedical devices. The improved comparative performance and biocompatibility of CNT-hydrogels hybrids systems developed for targeted biomedical applications are addressed here. Recent updates toward diverse applications and limitations of CNT hybrid hydrogels is the strength of the review. This will provide a holistic approach toward understanding of CNT-based hydrogels and their applications in nanotheranostics.
AD  - Florida Int Univ, Herbert Wertheim Coll Med, Dept Immunol, Ctr Personalized Nanomed, Miami, FL 33199 USAAD  - All India Inst Med Sci, Dept Biotechnol, New Delhi 110029, IndiaAD  - Jawaharlal Nehru Univ, Sch Biotechnol, New Delhi 110067, IndiaAD  - All India Inst Med Sci, Dept Pharmacol, New Delhi 110029, IndiaAD  - Jamia Millia Islamia, Dept Chem, Mat Res Lab, New Delhi 110025, IndiaC3  - State University System of FloridaC3  - Florida International UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jawaharlal Nehru University, New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jamia Millia IslamiaPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - MAY 9
PY  - 2018
VL  - 7
IS  - 9
C7  - 1701213
DO  - 10.1002/adhm.201701213
AN  - WOS:000431960000007
ER  -

TY  - JOUR
AU  - Cuviello, A
AU  - Goyal, A
AU  - Zick, A
AU  - Ahlawat, S
AU  - Rodriguez, FJ
AU  - Belzberg, AJ
AU  - Pratilas, CA
TI  - Sporadic Malignant Glomus Tumor of the Brachial Plexus With Response to Targeted Therapy Directed Against Oncogenic <i>BRAF</i>
T2  - JCO PRECISION ONCOLOGY
KW  - MUTATIONS
KW  - MELANOMA
KW  - CANCER
KW  - VEMURAFENIB
KW  - PHASE-3
KW  - NERVE
KW  - GENE
AD  - Johns Hopkins Univ, Sch Med, Baltimore, MD USAAD  - Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USAAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Hebrew Univ Jerusalem, Sharett Inst Oncol, Hadassah Med Ctr, Jerusalem, IsraelC3  - Johns Hopkins UniversityC3  - Johns Hopkins UniversityC3  - Johns Hopkins MedicineC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Hebrew University of JerusalemC3  - Hadassah University Medical CenterPU  - AMER SOC CLINICAL ONCOLOGY
PI  - ALEXANDRIA
PA  - 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
DA  - MAY 4
PY  - 2018
VL  - 2
SP  - 1
EP  - 7
DO  - 10.1200/PO.17.00261
AN  - WOS:000462112000001
ER  -

TY  - JOUR
AU  - Reddy, VP
AU  - Chinta, KC
AU  - Saini, V
AU  - Glasgow, JN
AU  - Hull, TD
AU  - Traylor, A
AU  - Rey-Stolle, F
AU  - Soares, MP
AU  - Madansein, R
AU  - Rahman, MA
AU  - Barbas, C
AU  - Nargan, K
AU  - Naidoo, T
AU  - Ramdial, PK
AU  - George, JF
AU  - Agarwal, A
AU  - Steyn, AJC
TI  - Ferritin H Deficiency in Myeloid Compartments Dysregulates Host Energy Metabolism and Increases Susceptibility to <i>Mycobacterium tuberculosis</i> Infection
T2  - FRONTIERS IN IMMUNOLOGY
KW  - ferritin H chain
KW  - bioenergetics
KW  - immunometabolism
KW  - tuberculosis
KW  - iron
KW  - energy metabolism
KW  - IRON-METABOLISM
KW  - CELLULAR IRON
KW  - LADEN MACROPHAGES
KW  - STORAGE
KW  - EXPRESSION
KW  - INNATE
KW  - LUNG
KW  - QUANTIFICATION
KW  - PATHOGENESIS
KW  - HEMOSIDERIN
AB  - Iron is an essential factor for the growth and virulence of Mycobacterium tuberculosis (Mtb). However, little is known about the mechanisms by which the host controls iron availability during infection. Since ferritin heavy chain (FtH) is a major intracellular source of reserve iron in the host, we hypothesized that the lack of FtH would cause dysregulated iron homeostasis to exacerbate TB disease. Therefore, we used knockout mice lacking FtH in myeloid-derived cell populations to study Mtb disease progression. We found that FtH plays a critical role in protecting mice against Mtb, as evidenced by increased organ burden, extrapulmonary dissemination, and decreased survival in Fth(-/-) mice. Flow cytometry analysis showed that reduced levels of FtH contribute to an excessive inflammatory response to exacerbate disease. Extracellular flux analysis showed that FtH is essential for maintaining bioenergetic homeostasis through oxidative phosphorylation. In support of these findings, RNAseq and mass spectrometry analyses demonstrated an essential role for FtH in mitochondrial function and maintenance of central intermediary metabolism in vivo. Further, we show that FtH deficiency leads to iron dysregulation through the hepcidin-ferroportin axis during infection. To assess the clinical significance of our animal studies, we performed a clinicopathological analysis of iron distribution within human TB lung tissue and showed that Mtb severely disrupts iron homeostasis in distinct microanatomic locations of the human lung. We identified hemorrhage as a major source of metabolically inert iron deposition. Importantly, we observed increased iron levels in human TB lung tissue compared to healthy tissue. Overall, these findings advance our understanding of the link between iron-dependent energy metabolism and immunity and provide new insight into iron distribution within the spectrum of human pulmonary TB. These metabolic mechanisms could serve as the foundation for novel host-directed strategies.
AD  - Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USAAD  - Univ Alabama Birmingham, Div Cardiothorac Surg, Birmingham, AL USAAD  - Univ Alabama Birmingham, VA Med Ctr, Nephrol Res & Training Ctr, Birmingham, AL USAAD  - Univ CEU San Pablo, Fac Farm, Ctr Metabol & Bioanal CEMBIO, Madrid, SpainAD  - Inst Gulbenkian Ciencias, Oeiras, PortugalAD  - Univ KwaZulu Natal, Inkosi Albert Luthuli Cent Hosp, Durban, South AfricaAD  - AHRI, Durban, South AfricaAD  - Univ KwaZulu Natal, Inkosi Albert Luthuli Cent Hosp, Natl Hlth Lab Serv, Dept Anat Pathol, Durban, South AfricaAD  - Univ Alabama Birmingham, UAB Ctr AIDS Res, Birmingham, AL 35294 USAAD  - Univ Alabama Birmingham, UAB Ctr Free Rad Biol, Birmingham, AL 35294 USAAD  - AIIMS, Dept Biotechnol, New Delhi, IndiaC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - San Pablo CEU UniversityC3  - Instituto Gulbenkian de CienciaC3  - University of Kwazulu NatalC3  - Africa Health Research InstituteC3  - University of Kwazulu NatalC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - FRONTIERS MEDIA SA
PI  - LAUSANNE
PA  - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
DA  - MAY 3
PY  - 2018
VL  - 9
C7  - 860
DO  - 10.3389/fimmu.2018.00860
AN  - WOS:000431334100001
ER  -

TY  - JOUR
AU  - Aggarwal, B
AU  - Gupta, N
TI  - Familial Hypercholesterolemia: Nip the Evil in the Bud
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - CONTROLLED-TRIAL
KW  - EFFICACY
KW  - GUIDANCE
KW  - CLINICIAN
KW  - INHIBITOR
KW  - CHILDREN
KW  - DISEASE
KW  - SAFETY
KW  - PANEL
AD  - All India Inst Med Sci, Dept Pediat, Div Genet, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - MAY
PY  - 2018
VL  - 85
IS  - 5
SP  - 331
EP  - 332
DO  - 10.1007/s12098-018-2664-6
AN  - WOS:000432219000002
ER  -

TY  - JOUR
AU  - Aggarwal, S
AU  - Das, SN
TI  - Response to Aggarwal and Das, Thiodigalactoside shows antitumour activity by beta-galactoside-binding protein and regulatory T cells inhibition in oral squamous cell carcinoma
T2  - ORAL DISEASES
AD  - All India Inst Med Sci, Dept Biotechnol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - MAY
PY  - 2018
VL  - 24
IS  - 4
SP  - 674
EP  - 674
DO  - 10.1111/odi.12673
AN  - WOS:000430127700023
ER  -

TY  - JOUR
AU  - Agrawal, R
AU  - Garg, A
AU  - Malgulwar, PB
AU  - Sharma, V
AU  - Sarkar, C
AU  - Kulshreshtha, R
TI  - p53 and miR-210 regulated NeuroD2, a neuronal basic helix-loop-helix transcription factor, is downregulated in glioblastoma patients and functions as a tumor suppressor under hypoxic microenvironment
T2  - INTERNATIONAL JOURNAL OF CANCER
KW  - glioblastoma
KW  - NeuroD2
KW  - miR-210
KW  - p53
KW  - hypoxia
KW  - CENTRAL-NERVOUS-SYSTEM
KW  - BREAST-CANCER
KW  - STEM-CELLS
KW  - EXPRESSION
KW  - AGGRESSIVENESS
KW  - FIBROBLASTS
KW  - CONVERSION
KW  - PROTEINS
KW  - PATTERNS
AB  - The factors involved in cell differentiation have recently garnered interest for their role in inhibition of pathogenesis in various tumors. However, their role in glioblastoma (GBM) remains poorly understood. We analyzed The Cancer Genome Atlas (TCGA) GBM data and found significant downregulation of neurogenic differentiation factor NeuroD2 in GBM patients. Low levels of NeuroD2 were found to be correlated with poor overall survival of GBM patients in TCGA dataset as well as in our cohort. Interestingly, NeuroD2 was shown to be transcriptionally induced by p53 and post-transcriptionally targeted by hypoxia- inducible miRNA, miR-210. NeuroD2 overexpression diminished GBM aggressiveness by inhibiting cell proliferation, migration and promoting apoptosis under hypoxia. NeuroD2 overexpressing GBM cells failed to form three-dimensional (3D)-tumor spheroids and displayed reduced migration in a 3D gelatin matrix. NeuroD2 gene signature was enriched in pathways belonging to cytokine-cytokine receptor interaction, TNF-signaling, PI3K-AKT signaling, focal adhesion and ECM-receptor interaction. Overall, our study identifies a novel role of NeuroD2 as a tumor suppressor and prognostic biomarker in GBM the levels of which are tightly regulated by p53 and miR-210. Overexpressing NeuroD2 may potentially be a simple and efficient therapeutic strategy to inhibit the malignant phenotype of GBM cells.
AD  - Indian Inst Technol Delhi, Dept Biochem Engn & Biotechnol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - MAY 1
PY  - 2018
VL  - 142
IS  - 9
SP  - 1817
EP  - 1828
DO  - 10.1002/ijc.31209
AN  - WOS:000426730600010
ER  -

TY  - JOUR
AU  - Alhazzani, AA
AU  - Kumar, A
AU  - Selim, M
TI  - Association between Factor V Gene Polymorphism and Risk of Ischemic Stroke: An Updated Meta-Analysis
T2  - JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
KW  - Factor V gene polymorphism
KW  - meta-analysis
KW  - ischemic stroke
KW  - cerebrovascular disorder
KW  - stroke
KW  - ACTIVATED PROTEIN-C
KW  - INHERITED PROTHROMBOTIC CONDITIONS
KW  - COAGULATION-FACTOR-V
KW  - YOUNG-ADULTS
KW  - CEREBRAL-ISCHEMIA
KW  - LEIDEN MUTATION
KW  - ARTERIAL THROMBOSIS
KW  - RESISTANCE
KW  - DISEASE
KW  - G20210A
AB  - Background: Ischemic stroke is a complex, multifactorial, and polygenic disease. Reports on relationship between Factor V G1691A single nucleotide gene polymorphism and ischemic stroke have revealed inconsistent results. We conducted an updated meta-analysis to determine the role of Factor V single nucleotide gene polymorphism in ischemic stroke. Methods: We searched the literature using academic electronic databases that is, PubMed, Trip Data Base, EBSCO, and Google Scholar, last search up to September 2017. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated from fixed or random effects models whichever applicable using software STATA version 13 (StataCorp LP, College Station, TX). Results: Forty case-control studies met the inclusion criteria, which included 6860 cases and 18,025 controls. Altogether, 19 studies in young adults (age < or = 40 years) and 17 studies were conducted in old stroke (age > 40). Four studies did not report the mean age at recruitment. Significant association between Factor V G1691A gene polymorphism and risk of ischemic stroke were observed under dominant model (OR 1.40; 95% CI: 1.22 to 1.62, P value <. 001). Stratified analysis suggested substantial association of Factor V gene polymorphism and risk of ischemic stroke in cases with onset at young age (OR 1.84; 95% CI: 1.47 to 2.30), but was not statistical significant in cases at old age (> 40 years). Conclusions: Factor V G1691A single nucleotide gene polymorphism was associated with risk of ischemic stroke mainly in young adults. Further research with adequately powered prospective studies in homogenous subjects are required to determine the nature of association in young stroke. (c) 2018 National Stroke Association. Published by Elsevier Inc. All rights reserved.
AD  - King Khalid Univ, Dept Neurol, Coll Med, Abha, Saudi ArabiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaAD  - Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Neurol, Stroke Div, Boston, MA USAC3  - King Khalid UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Harvard UniversityC3  - Harvard Medical SchoolC3  - Beth Israel Deaconess Medical CenterPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - MAY
PY  - 2018
VL  - 27
IS  - 5
SP  - 1252
EP  - 1261
DO  - 10.1016/j.jstrokecerebrovasdis.2017.12.006
AN  - WOS:000428778400021
ER  -

TY  - JOUR
AU  - Arora, G
AU  - Sharma, P
AU  - Sharma, A
AU  - Mishra, AK
AU  - Hazari, PP
AU  - Biswas, A
AU  - Garg, A
AU  - Aheer, D
AU  - Kumar, R
TI  - 99mTc-Methionine Hybrid SPECT/CT for Detection of Recurrent Glioma: Comparison With 18F-FDG PET/CT and Contrast-Enhanced MRI
T2  - CLINICAL NUCLEAR MEDICINE
KW  - glioma
KW  - recurrence
KW  - Tc-99m-methionine
KW  - SPECT
KW  - CT
KW  - F-18-FDG
KW  - PET
KW  - CT
KW  - MRI
KW  - LOW-GRADE GLIOMAS
KW  - BRAIN-TUMORS
KW  - COMPUTED-TOMOGRAPHY
AB  - Objectives Posttherapy changes in treated glioma patients cannot be reliably differentiated from tumor recurrence. We evaluated the role of Tc-99m-methionine SPECT/CT for the detection of recurrent glioma and compared the same with F-18-FDG PET/CT and contrast-enhanced MRI (CeMRI).
   Methods Forty-four patients with histologically proven, previously treated glioma and clinical suspicion of recurrence were prospectively enrolled in the study. Of these 44 patients, 39 (28 male and 11 female subjects; age, 38.05 9.7 years) underwent Tc-99m-methionine SPECT/CT, F-18-FDG PET/CT, and CeMRI of the brain and were included for final analysis. Combination of repeat imaging, biopsy, and/or clinical follow-up (6-36 months) was taken as reference standard. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated. Diagnostic values among modalities were compared.
   Results Positive predictive value and negative predictive value for Tc-99m-methionine SPECT/CT, F-18-FDG PET/CT, and CeMRI were 95.6% and 56.2%, 92.3% and 61.5%, and 79.4% and 42.9%, respectively. Sensitivity and specificity for the 3 modalities were 75.9% and 90%, 82.8% and 80%, and 87.1% and 30%. Specificity of Tc-99m-methionine SPECT/CT was significantly higher than that of CeMRI (P < 0.0001) but not of F-18-FDG PET/CT (P = 0.36). No significant difference was seen between the modalities for sensitivity and accuracy.
   Conclusions Tc-99m-methionine is a promising tracer for detection of recurrent glioma. Diagnostic values of Tc-99m-methionine SPECT/CT are similar to F-18-FDG, although it is more specific than CeMRI. So it may be used as a cost-effective alternative and also where PET/CT is not available.
AD  - All India Inst Med Sci, Dept Nucl Med, Div Diagnost Nucl Med, New Delhi 110029, IndiaAD  - Apollo Gleneagles Hosp, Dept Nucl Med & PET CT, Kolkata, IndiaAD  - Def Res & Dev Org, Inst Nucl Med & Allied Sci, Div Cyclotron & Radiopharmaceut Sci, Delhi, IndiaAD  - Inst Rotary Canc Hosp, Dept Radiat Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neuroimaging & Intervent Neuroradiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Defence Research & Development Organisation (DRDO)C3  - Institute of Nuclear Medicine & Allied Sciences (INMAS)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - MAY
PY  - 2018
VL  - 43
IS  - 5
SP  - e132
EP  - e138
DO  - 10.1097/RLU.0000000000002036
AN  - WOS:000431177200001
ER  -

TY  - JOUR
AU  - Arora, S
AU  - Damle, NA
AU  - Parida, GK
AU  - Singhal, A
AU  - Nalli, H
AU  - Dattagupta, S
AU  - Bal, C
TI  - Recurrent Medullary Thyroid Carcinoma on <SUP>68</SUP>Ga-Prostate-Specific Membrane Antigen PET/CT: Exploring New Theranostic Avenues
T2  - CLINICAL NUCLEAR MEDICINE
KW  - medullary thyroid carcinoma
KW  - PET
KW  - CT
KW  - prostate-specific membrane antigen (PSMA)
KW  - PSMA EXPRESSION
KW  - GA-68-PSMA PET/CT
AB  - The prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer cells. Few other malignancies have shown expression of PSMA. We present a case of 35-year-old man with medullary thyroid carcinoma, post total thyroidectomy and bilateral neck dissection, now presenting with rising calcitonin levels (doubling time 9 months) and local neck recurrence with negative I-131-MIBG scan. We decided to perform Ga-68-PSMA-HBED-CC PET/CT scan to assess PSMA expression and explore the therapeutic option in view of rising serum calcitonin. It revealed intense PSMA uptake in the soft tissue mass in left thyroid bed and cervical lymph nodes.
AD  - All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - MAY
PY  - 2018
VL  - 43
IS  - 5
SP  - 359
EP  - 360
DO  - 10.1097/RLU.0000000000002010
AN  - WOS:000431177200028
ER  -

TY  - JOUR
AU  - Arunraj, ST
AU  - Parida, GK
AU  - Damle, NA
AU  - Arora, S
AU  - Reddy, S
AU  - Chakraborty, D
AU  - Prabhu, M
AU  - Tripathi, M
AU  - Bal, C
TI  - 68Ga-DOTANOC PET/CT in Medulloblastoma
T2  - CLINICAL NUCLEAR MEDICINE
KW  - medulloblastoma
KW  - Ga-68-DOTANOC PET-CT
KW  - somatostatin
KW  - BRAIN-TUMORS
KW  - CHILDREN
AB  - Medulloblastoma, also known as cerebellar primitive neuroectodermal tumor, is the most common brain tumor in children and arises in the posterior cranial fossa. We present the case of a patient with desmoplastic type of medulloblastoma, which showed recurrence more than once. When Ga-68-DOTANOC PET-CT was done, the lesions showed somatostatin receptor expression, opening another potential therapeutic option for this patient.
AD  - All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - MAY
PY  - 2018
VL  - 43
IS  - 5
SP  - E145
EP  - E146
DO  - 10.1097/RLU.0000000000002021
AN  - WOS:000431177200004
ER  -

TY  - JOUR
AU  - Bahrani, K
AU  - Singh, MB
AU  - Bhatia, R
AU  - Prasad, K
AU  - Vibha, D
AU  - Shukla, G
AU  - Vishnubhatla, S
AU  - Patterson, V
TI  - A response to S. Basu (2017)
T2  - SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
AD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - UCL, Dept Clin & Expt Epilepsy, London, EnglandC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of LondonC3  - University College LondonPU  - W B SAUNDERS CO LTD
PI  - LONDON
PA  - 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
DA  - MAY
PY  - 2018
VL  - 58
SP  - 164
EP  - 164
DO  - 10.1016/j.seizure.2018.01.004
AN  - WOS:000436884500029
ER  -

TY  - JOUR
AU  - Bhandari, A
AU  - Bansal, A
AU  - Singh, A
AU  - Sinha, N
TI  - Numerical Study of Transport of Anticancer Drugs in Heterogeneous Vasculature of Human Brain Tumors Using Dynamic Contrast Enhanced-Magnetic Resonance Imaging
T2  - JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME
KW  - human brain tumor
KW  - heterogeneous vasculature
KW  - liposome-encapsulated drug
KW  - doxorubicin
KW  - DCE-MRI
KW  - CFD
KW  - ENCAPSULATED DOXORUBICIN
KW  - TREATMENT PROTOCOLS
KW  - DCE-MRI
KW  - DELIVERY
KW  - MODEL
KW  - LIPOSOMES
KW  - TIME
KW  - PERFUSION
KW  - FLUID
KW  - PHARMACOKINETICS
AB  - Systemic administration of drugs in tumors is a challenging task due to unorganized microvasculature and nonuniform extravasation. There is an imperative need to understand the transport behavior of drugs when administered intravenously. In this study, a transport model is developed to understand the therapeutic efficacy of a free drug and liposome-encapsulated drugs (LED), in heterogeneous vasculature of human brain tumors. Dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI) data is employed to model the heterogeneity in tumor vasculature that is directly mapped onto the computational fluid dynamics (CFD) model. Results indicate that heterogeneous vasculature leads to preferential accumulation of drugs at the tumor position. Higher drug accumulation was found at location of higher interstitial volume, thereby facilitating more tumor cell killing at those areas. Liposome-released drug (LRD) remains inside the tumor for longer time as compared to free drug, which together with higher concentration enhances therapeutic efficacy. The interstitial as well as intracellular concentration of LRD is found to be 2-20 fold higher as compared to free drug, which are in line with experimental data reported in literature. Close agreement between the predicted and experimental data demonstrates the potential of the developed model in modeling the transport of LED and free drugs in heterogeneous vasculature of human tumors.
AD  - Indian Inst Technol, Dept Mech Engn, Kanpur 208016, Uttar Pradesh, IndiaAD  - Indian Inst Technol, Dept Mech & Ind Engn, Roorkee 247677, Uttar Pradesh, IndiaAD  - Indian Inst Technol, Ctr Biomed Engn, Delhi 110016, IndiaAD  - All India Inst Med Sci, Dept Biomed Engn, Delhi 110016, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - KanpurC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - RoorkeeC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ASME
PI  - NEW YORK
PA  - TWO PARK AVE, NEW YORK, NY 10016-5990 USA
DA  - MAY
PY  - 2018
VL  - 140
IS  - 5
C7  - 051010
DO  - 10.1115/1.4038746
AN  - WOS:000428700000010
ER  -

TY  - JOUR
AU  - Bhatia, R
AU  - Gupta, V
AU  - Sharma, VK
TI  - Positive Patch Test to Metals in a Patient With Symmetrical Intertriginous Skin Eruptions: Systemic Contact Dermatitis or Lichen Planus Pigmentosus Inversus?
T2  - DERMATITIS
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - MAY-JUN
PY  - 2018
VL  - 29
IS  - 3
SP  - 166
EP  - 167
DO  - 10.1097/DER.0000000000000333
AN  - WOS:000432582200012
ER  -

TY  - JOUR
AU  - Chakrabarty, B
TI  - Acute Encephalitis Syndrome: Current Trends and the Future
T2  - INDIAN JOURNAL OF PEDIATRICS
AD  - AIIMS, Dept Pediat, Child Neurol Div, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - MAY
PY  - 2018
VL  - 85
IS  - 5
SP  - 335
EP  - 336
DO  - 10.1007/s12098-018-2653-9
AN  - WOS:000432219000004
ER  -

TY  - JOUR
AU  - Chandan, S
AU  - Shukla, G
AU  - Gupta, A
AU  - Srivastava, A
AU  - Vibha, D
AU  - Prasad, K
TI  - Acute-onset Restless legs syndrome in acute neurological conditionsa prospective study on patients with the Guillain-Barre syndrome and acute stroke
T2  - ACTA NEUROLOGICA SCANDINAVICA
KW  - acute
KW  - Guillain-Barre syndrome
KW  - Restless legs syndrome
KW  - stroke
KW  - PERIODIC LIMB MOVEMENTS
KW  - PERIPHERAL NEUROPATHY
KW  - LACUNAR STROKE
KW  - INFARCTION
KW  - SEVERITY
KW  - LESION
KW  - RISK
KW  - IRON
AB  - ObjectivesWhile the Restless legs syndrome (RLS) is usually recognized as a chronic condition, it has often been diagnosed among patients with acute neurological illnesses, in which limb discomfort is reported. This study was conducted to determine how many among these, actually have acute-onset RLS, and also to evaluate characteristics of this subgroup of patients with Guillain-Barre syndrome (GBS) and stroke developing acute-onset RLS.
   MethodsConsecutive patients diagnosed with GBS and eligible stroke patients, admitted to our Neurology services over a 1-year period, were enrolled. They were evaluated for symptoms of RLS based on IRLSSG consensus criteria and the AIIMS RLS Questionnaire for Indian patients (ARQIP).
   ResultsForty adults with GBS and 58 with stroke were included. A total of 10 of the 40 (25%) patients with GBS developed definite acute RLS, which was mostly monophasic. Seven (70%) of these had demyelinating type of GBS, a significant association with acute RLS (P=.024). Six of the 58 stroke patients (10%) developed definite acute-onset, often persistent RLS. Subcortical location showed significant association with increased risk of developing acute RLS (P<.001). All patients diagnosed with acute-onset RLS had an immediate and good response to dopamine agonists.
   ConclusionThis is the first study showing that acute-onset RLS is common, affecting nearly 25% of patients with GBS and 10% patients with acute stroke. Recognizing and treating it can majorly contribute toward symptom relief and early improvement in the quality of life for this population.
AD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - MAY
PY  - 2018
VL  - 137
IS  - 5
SP  - 488
EP  - 499
DO  - 10.1111/ane.12890
AN  - WOS:000429693800006
ER  -

TY  - JOUR
AU  - Chhablani, J
AU  - Roh, YJ
AU  - Jobling, AI
AU  - Fletcher, EL
AU  - Lek, JJ
AU  - Bansal, P
AU  - Guymer, R
AU  - Luttrull, JK
TI  - Restorative retinal laser therapy: Present state and future directions
T2  - SURVEY OF OPHTHALMOLOGY
KW  - laser photocoagulation
KW  - subthreshold laser
KW  - micropulse laser
KW  - retinal laser
KW  - microsecond laser
KW  - panretinal photocoagulation
KW  - PASCAL
KW  - NAVILAS
KW  - pattern scanning lasers
KW  - nanosecond laser
KW  - selective retina therapy
KW  - endpoint management
KW  - 2RT
KW  - DIABETIC MACULAR EDEMA
KW  - MICROPULSE DIODE-LASER
KW  - CENTRAL SEROUS CHORIORETINOPATHY
KW  - PANRETINAL PHOTOCOAGULATION
KW  - PIGMENT EPITHELIUM
KW  - CONVENTIONAL PHOTOCOAGULATOR
KW  - MATRIX METALLOPROTEINASES
KW  - SCANNING LASER
KW  - VEIN OCCLUSION
KW  - PULSE DURATION
AB  - Because of complications and side effects, conventional laser therapy has taken a back seat to drugs in the treatment of macular diseases. Despite this, research on new laser modalities remains active. In particular, various approaches are being pursued to preserve and improve retinal structure and function. These include micropulsing, various exposure titration algorithms, and real-time temperature feedback control of short-pulse continuous wave lasers, and ultra-short pulse nanosecond lasers. Some of these approaches are at the preclinical stage of development, whereas others are available for clinical use. Cell biology is providing important insights into the mechanisms of action of retinal laser treatment. We outline the technological bases of current laser platforms, their basic science, therapeutic concepts, clinical experience, and future directions for retinal laser treatment. (C) 2017 Elsevier Inc. All rights reserved.
AD  - LV Prasad Eye Inst, Dept Ophthalmol, Retina Div, Kallam Anji Reddy Campus, Hyderabad, Andhra Prades, IndiaAD  - Catholic Univ Korea, Coll Med, Yeouido St Marys Hosp, Dept Ophthalmol & Visual Sci, Seoul, South KoreaAD  - Univ Melbourne, Dept Anat & Neurosci, Melbourne, Vic, AustraliaAD  - All India Inst Med Sci, Retina Div, Dept Ophthalmol, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaAD  - Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Surg Ophthalmol, Ctr Eye Res Australia, Melbourne, Vic, AustraliaAD  - Ventura Cty Retina Vitreous Med Grp, 3160 Telegraph Rd,Suite 230, Ventura, CA 93003 USAC3  - L. V. Prasad Eye InstituteC3  - Catholic University of KoreaC3  - University of MelbourneC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - University of MelbourneC3  - Royal Victorian Eye & Ear HospitalC3  - Centre for Eye Research AustraliaPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - MAY-JUN
PY  - 2018
VL  - 63
IS  - 3
SP  - 307
EP  - 328
DO  - 10.1016/j.survophthal.2017.09.008
AN  - WOS:000431835900003
ER  -

TY  - JOUR
AU  - Choudhry, VP
TI  - Economic Burden of Transfusion Dependent Thalassemia
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - BETA-THALASSEMIA
AD  - Fortis Escorts Hosp, Dept Hematol, Neelam Bata Rd, Faridabad 121001, Haryana, IndiaAD  - Batra Hosp & Med Res Ctr, 1 Tughlakabad Inst Area,Mehrauli Badarpur Rd, New Delhi, IndiaAD  - AIIMS, Dept Hematol, New Delhi, IndiaC3  - Fortis Escorts HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - MAY
PY  - 2018
VL  - 85
IS  - 5
SP  - 329
EP  - 330
DO  - 10.1007/s12098-018-2642-z
AN  - WOS:000432219000001
ER  -

TY  - JOUR
AU  - Claeys, C
AU  - Zaman, K
AU  - Dbaibo, G
AU  - Li, P
AU  - Izu, A
AU  - Kosalaraksa, P
AU  - Rivera, L
AU  - Acosta, B
AU  - Basanta, MLA
AU  - Aziz, A
AU  - Cabanero, MA
AU  - Chandrashekaran, V
AU  - Corsaro, B
AU  - Cousin, L
AU  - Diaz, A
AU  - Diez-Domingo, J
AU  - Dinleyici, EC
AU  - Faust, SN
AU  - Friel, D
AU  - Garcia-Sicilia, J
AU  - Gomez-Go, GD
AU  - Gonzales, MLA
AU  - Hughes, SM
AU  - Jackowska, T
AU  - Kant, S
AU  - Lucero, M
AU  - Malvaux, L
AU  - Bermudez, JM
AU  - Martinon-Torres, F
AU  - Miranda, M
AU  - Montellano, M
AU  - Sambola, MAP
AU  - Prymula, R
AU  - Puthanakit, T
AU  - Ruzkova, R
AU  - Sadowska-Krawczenko, I
AU  - de la Cueva, IS
AU  - Sokal, E
AU  - Soni, J
AU  - Szymanski, H
AU  - Ulied, A
AU  - Schuind, A
AU  - Jain, VK
AU  - Innis, BL
A1  - Flu4VEC Study Grp
TI  - Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomised trial across five influenza seasons
T2  - LANCET CHILD & ADOLESCENT HEALTH
KW  - YOUNG-CHILDREN
KW  - STREPTOCOCCUS-PNEUMONIAE
KW  - ANTIBIOTIC-RESISTANCE
KW  - DOUBLE-BLIND
KW  - PHASE-III
KW  - IMMUNOGENICITY
KW  - INFECTION
KW  - SAFETY
KW  - HOSPITALIZATIONS
KW  - COMMUNITIES
AB  - Background Despite the importance of vaccinating children younger than 5 years, few studies evaluating vaccine prevention of influenza have been reported in this age group. We evaluated efficacy of an inactivated quadrivalent influenza vaccine (IIV4) in children aged 6-35 months.
   Methods In this phase 3, observer-blinded, multinational trial, healthy children from 13 countries in Europe, Central America, and Asia were recruited in five independent cohorts, each in a different influenza season. Participants were randomly assigned (1: 1) to either IIV4 (15 mu g haemagglutinin antigen per strain per 0.5 mL dose; a single dose on day 0 for vaccine-primed children, and two doses, on days 0 and 28, for vaccine-unprimed children) or to one or two doses of a non-influenza control vaccine. Primary endpoints were moderate-to-severe influenza or all influenza (irrespective of disease severity) confirmed by RT-PCR on nasal swabs. Cultured isolates were further characterised as antigenically matched or mismatched to vaccine strains. Efficacy was assessed in the per-protocol cohort and total vaccinated cohort (time-to-event analysis), and safety was assessed in the total vaccinated cohort.
   Findings Between Oct 1, 2011, and Dec 31, 2014, 12 018 children were recruited into the total vaccinated cohort (6006 children in the IIV4 group and 6012 children in the control group). 356 (6%) children in the IIV4 group and 693 (12%) children in the control group had at least one case of RT-PCR-confirmed influenza. Of these 1049 influenza strains, 138 (13%) were A/H1N1, 529 (50%) were A/H3N2, 69 (7%) were B/Victoria, and 316 (30%) were B/Yamagata. Overall, 539 (64%) of 848 antigenically characterised isolates were vaccine-mismatched (16 [15%] of 105 for A/H1N1; 368 [97%] of 378 for A/H3N2; 54 [86%] of 63 for B/Victoria; 101 [33%] of 302 for B/Yamagata). Vaccine efficacy was 63% (97.5% CI 52-72) against moderate-to-severe influenza and 50% (42-57) against all influenza in the per-protocol cohort, and 64% (53-73) against moderate-to-severe influenza and 50% (42-57) against all influenza in the total vaccinated cohort. There were no clinically meaningful safety differences between IIV4 and control.
   Interpretation IIV4 prevented influenza A and B in children aged 6-35 months despite high levels of vaccine mismatch. Vaccine efficacy was highest against moderate-to-severe disease, which is the most clinically important endpoint associated with greatest burden.
AD  - GSK, B-1300 Wavre, BelgiumAD  - Icddr B, Dhaka, BangladeshAD  - Amer Univ Beirut, Beirut, LebanonAD  - GSK, King Of Prussia, PA USAAD  - GSK, Rockville, MD USAAD  - Khon Kaen Univ, Khon Kaen, ThailandAD  - Natl Autonomous Univ Santo Domingo, Santo Domingo, Dominican RepAD  - Dr Castroviejo Primary Hlth Care Ctr, Madrid, SpainAD  - Univ Complutense Madrid, Madrid, SpainAD  - Jaume I Univ, Castellon De La Plana, SpainAD  - Illes Columbretes Hlth Ctr Castellon, Castellon De La Plana, SpainAD  - Natl Autonomous Univ Honduras, Tegucigalpa, HondurasAD  - FISABIO Publ Hlth, Valencia, SpainAD  - Eskisehir Osmangazi Univ, Eskisehir, TurkeyAD  - Univ Southampton, Southampton, Hants, EnglandAD  - Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, EnglandAD  - Hosp Infantil Univ La Paz, Madrid, SpainAD  - Mary Chiles Gen Hosp, Manila, PhilippinesAD  - Univ Philippines, Philippine Gen Hosp, Manila, PhilippinesAD  - Royal Manchester Childrens Hosp, Manchester, Lancs, EnglandAD  - Ctr Postgrad Med Educ, Warsaw, PolandAD  - All India Inst Med Sci, Ctr Community Med, New Delhi, IndiaAD  - Res Inst Trop Med, Manila, PhilippinesAD  - Paediat Inst Mares Riera, Blanes, SpainAD  - Hosp Clin Univ Santiago, Santiago, SpainAD  - Hosp Antequera, Malaga, SpainAD  - IIB St Pau, EAP Sardenya, Barcelona, SpainAD  - Univ Hradec Kralove, Hradec Kralove, Czech RepublicAD  - Chulalongkorn Univ, Bangkok, ThailandAD  - Medicentrum 6 Sro, Prague, Czech RepublicAD  - Nicolaus Copernicus Univ Torun, Coll Med, Bydgoszcz, PolandAD  - Univ Hosp 2, Bydgoszcz, PolandAD  - Inst Hispalense Pediat, Seville, SpainAD  - Catholic Univ Louvain, Clin Univ St Luc, Brussels, BelgiumAD  - GSK, Bangalore, Karnataka, IndiaAD  - St Hedwig Silesia Hosp, Trzebnica, PolandAD  - EBA Centelles, Barcelona, SpainC3  - GlaxoSmithKlineC3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - American University of BeirutC3  - GlaxoSmithKlineC3  - Glaxosmithkline USAC3  - GlaxoSmithKlineC3  - Khon Kaen UniversityC3  - Universidad Autonoma de Santo DomingoC3  - Complutense University of MadridC3  - Universitat Jaume IC3  - Universidad Nacional Autonoma de HondurasC3  - Eskisehir Osmangazi UniversityC3  - University of SouthamptonC3  - University of SouthamptonC3  - University Hospital Southampton NHS Foundation TrustC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - Royal Manchester Children's HospitalC3  - Centre of Postgraduate Medical Education - PolandC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Research Institute for Tropical Medicine - PhilippinesC3  - Complexo Hospitalario Universitario de Santiago de CompostelaC3  - University of Hradec KraloveC3  - Chulalongkorn UniversityC3  - Nicolaus Copernicus UniversityC3  - Universite Catholique LouvainC3  - Cliniques Universitaires Saint-LucC3  - GlaxoSmithKlinePU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - MAY
PY  - 2018
VL  - 2
IS  - 5
SP  - 338
EP  - 349
DO  - 10.1016/S2352-4642(18)30062-2
AN  - WOS:000434768900016
ER  -

TY  - JOUR
AU  - Dash, C
AU  - Singla, R
AU  - Agarwal, M
AU  - Kumar, A
AU  - Kumar, H
AU  - Mishra, S
AU  - Sharma, BS
TI  - Craniovertebral junction evaluation by computed tomography in asymptomatic individuals in the Indian population
T2  - NEUROLOGY INDIA
KW  - Computed tomographic scan
KW  - craniovertebral junction
KW  - Indian
KW  - normal parameters
KW  - osteometry
KW  - ATLANTOAXIAL JOINT DISTRACTION
KW  - MALFORMATION TYPE-I
KW  - BASILAR INVAGINATION
KW  - ADULT-POPULATION
KW  - LATERAL MASS
KW  - CRANIOCERVICAL JUNCTION
KW  - OCCIPITAL CONDYLE
KW  - SCREW FIXATION
KW  - CT
KW  - MORPHOLOGY
AB  - Background: The available literature on the anatomy and imaging of the craniovertebral junction (CVJ) focusses on the osteometric indices described for the detection of abnormal relationships between the components of CVJ. However, a knowledge of the normal osteometry of this region in the Indian population is critically important for the operating surgeon as it may influence the surgical technique as well as the choice, size and configurations of the implants. It is also important to determine whether critical differences exist between the osteometric data of Indians and the rest of the world for this part of the anatomy. Accordingly, the present study is an attempt to quantitate the osteometric indices for the anatomically normal CVJ in Indian subjects
   Materials and Methods: We retrospectively studied the imaging data of 49 consecutive adult patients (31 males, 18 females) who underwent a computed tomographic (CT) angiogram for suspected vascular conditions unrelated to the craniovertebral junction. Several parameters related to the atlanto-dental relationship, foramen magnum, atlas and axis vertebrae were recorded, including the dimensions of the commonly instrumented bony regions and also the indices related to the CVJ bony relationships. The data was also compared between the two genders, statistically through the Student's t-test using the statistical program "R".
   Results: No patient had an atlanto dens interval >2.5 mm. The mean distance of the odontoid tip from the McRae line in this series was 5.11 mm and no patient had the odontoid tip above the McRae line. Female subjects had significantly smaller diameters of C1 lateral masses and odontoid screw trajectory length when compared to males. Additionally, in the Indian population, the length range of odontoid screw trajectory and the thickness of the narrowest part of the C2 pedicles was smaller with respect to similar data from other geographical regions. However, the rest of the parameters resembled the data from studies conducted on populations with other ethnicities.
   Conclusion: The osteometric parameters of the CVJ in the Indian population are largely similar to those described globally. However, there are some important differences too which can influence the design of surgical implants suited to the Indian population.
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - MAY-JUN
PY  - 2018
VL  - 66
IS  - 3
SP  - 797
EP  - 803
DO  - 10.4103/0028-3886.232288
AN  - WOS:000432404000036
ER  -

TY  - JOUR
AU  - Dhillon, M
AU  - Khurana, A
AU  - Prabhakar, S
AU  - Sharma, S
TI  - Crush Fractures of the Anterior end of Calcaneum
T2  - INDIAN JOURNAL OF ORTHOPAEDICS
KW  - Anterior process of calcaneum
KW  - calcaneal fracture
KW  - lateral column foot injury
KW  - midfoot abduction injury
AB  - The anterior end of calcaneum fractures can present as inversion injuries, stress fractures or as a part of displaced intraarticular calcaneum fracture. Rarely, these may occur due to abduction injury from a laterally directed force that crushes the anterior calcaneum instead of the cuboid, and has associated medial column injuries which are unrecognized. Compression fractures of the anterior calcaneum are actually lateral column shortening injuries with poor outcomes in the few published reports. We describe three patients with compression fractures of the anterior end of calcaneum resulting from foot abduction injury which were managed by reduction and column length restoration via distraction by external fixator. All three fractures showed good to excellent outcomes using the American Orthopedic Foot and Ankle Society midfoot score at followup > 1 year. Awareness of this injury pattern is important, and appropriate measures to reduce and maintain the fracture reduction are needed to avoid long term disability.
AD  - PGIMER, Dept Phys Med, Chandigarh, IndiaAD  - PGIMER, Dept Orthopaed, Chandigarh, IndiaAD  - AIIMS, Dept Orthopaed, New Delhi, IndiaC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - MAY-JUN
PY  - 2018
VL  - 52
IS  - 3
SP  - 244
EP  - 252
DO  - 10.4103/ortho.IJOrtho_575_17
AN  - WOS:000432020000005
ER  -

TY  - JOUR
AU  - Dwivedi, DK
AU  - Kumar, R
AU  - Dwivedi, AK
AU  - Bora, GS
AU  - Thulkar, S
AU  - Sharma, S
AU  - Gupta, SD
AU  - Jagannathan, NR
TI  - Prebiopsy multiparametric MRI-based risk score for predicting prostate cancer in biopsy-naive men with prostate-specific antigen between 4-10ng/mL
T2  - JOURNAL OF MAGNETIC RESONANCE IMAGING
KW  - prostate cancer
KW  - statistical model
KW  - risk calculator
KW  - multiparametric MRI
KW  - magnetic resonance spectroscopic imaging
KW  - diffusion-weighted imaging
KW  - DIGITAL RECTAL EXAMINATION
KW  - MAGNETIC-RESONANCE-SPECTROSCOPY
KW  - 4-10 NG/ML
KW  - TRANSRECTAL ULTRASONOGRAPHY
KW  - PERIPHERAL ZONE
KW  - DENSITY
KW  - STRATIFICATION
KW  - MALIGNANCY
KW  - DIAGNOSIS
KW  - PERFORMANCE
AB  - BackgroundRisk calculators have traditionally utilized serum prostate-specific antigen (PSA) values in addition to clinical variables to predict the likelihood of prostate cancer (PCa).
   PurposeTo develop a prebiopsy multiparametric MRI (mpMRI)-based risk score (RS) and a statistical equation for predicting the risk of PCa in biopsy-naive men with serum PSA between 4-10ng/mL that may help reduce unnecessary biopsies.
   Study TypeProspective cross-sectional study.
   SubjectsIn all, 137 consecutive men with PSA between 4-10ng/mL underwent prebiopsy mpMRI (diffusion-weighted [DW]-MRI and MR spectroscopic imaging [MRSI]) during 2009-2015 were recruited for this study.
   Field Strength/Sequence1.5T (Avanto, Siemens Health Care, Erlangen, Germany); T-1-weighted, T-2-weighted, DW-MRI, and MRSI sequences were used.
   AssessmentAll eligible patients underwent mpMRI-directed, cognitive-fusion transrectal ultrasound (TRUS)-guided biopsies.
   Statistical TestsAn equation model and an RS were developed using receiver operating characteristic (ROC) curve analysis and a multivariable logistic regression approach. A 10-fold crossvalidation and simulation analyses were performed to assess diagnostic performance of various combinations of mpMRI parameters.
   ResultsOf 137 patients, 32 were diagnosed with PCa on biopsy. Multivariable analysis, adjusted with positive pathology, showed apparent diffusion coefficient (ADC), metabolite ratio, and PSA as significant predictors of PCa (P < 0.05). A statistical equation was derived using these predictors. A simple 6-point mpMRI-based RS was derived for calculating the risk of PCa and it showed that it is highly predictive for PCa (odds ratio=3.74, 95% confidence interval [CI]: 2.24-6.27, area under the curve [AUC]=0.87). Both models (equation and RS) yielded high predictive performance (AUC 0.85) on validation analysis.
   Data ConclusionA statistical equation and a simple 6-point mpMRI-based RS can be used as a point-of-care tool to potentially help limit the number of negative biopsies in men with PSA between 4 and 10ng/mL. Level of Evidence: 1 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018;47:1227-1236.
AD  - Univ Texas Southwestern Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USAAD  - King Georges Med Univ, Dept Radiodiag, Lucknow 226003, Uttar Pradesh, IndiaAD  - Postgrad Inst Med Educ & Res, Dept Urol, Chandigarh 160012, IndiaAD  - All India Inst Med Sci, Dept NMR & MRI Facil, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Urol, New Delhi, IndiaAD  - Texas Tech Univ, Hlth Sci Ctr, Div Biostat & Epidemiol, Dept Biomed Sci, El Paso, TX USAAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - University of Texas SystemC3  - University of Texas Southwestern Medical Center DallasC3  - King George's Medical UniversityC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Texas Tech University SystemC3  - Texas Tech UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - MAY
PY  - 2018
VL  - 47
IS  - 5
SP  - 1227
EP  - 1236
DO  - 10.1002/jmri.25850
AN  - WOS:000430109700008
ER  -

TY  - JOUR
AU  - Garg, M
AU  - Kumar, A
AU  - Sawarkar, DP
AU  - Singh, PK
AU  - Agarwal, D
AU  - Kale, SS
AU  - Mahapatra, AK
TI  - Traumatic Lateral Spondyloptosis: Case Series
T2  - WORLD NEUROSURGERY
KW  - Coronal spondyloptosis
KW  - Lateraloptosis
KW  - Surgical reduction and fixation
KW  - Thoracolumbar spine trauma
KW  - SPINE FRACTURE-DISLOCATION
KW  - UPPER THORACIC SPINE
KW  - CORD INJURY
KW  - NEUROLOGICAL DEFICIT
KW  - CLASSIFICATION
KW  - MANAGEMENT
KW  - JUNCTION
KW  - L4
AB  - OBJECTIVE: To apprise readers about this rare but severest form of traumatic spine injury and its surgical management.
   BACKGROUND: Complete fracture dislocation and subluxation (>100%) of 1 vertebral body in the coronal or sagittal plane with respect to the adjacent vertebra is defined as spondyloptosis. In coronal spondyloptosis the subluxated vertebral bodies lie beside each other, and the condition is lateraloptosis.
   Patients with lateraloptosis present unique surgical challenges because reduction and achieving realignment of spinal column require meticulous planning and execution.
   METHODS: A retrospective analysis of patients admitted with lateraloptosis over a 4-year period (2013-2016) was done. Lateraloptosis was defined on computed tomography as complete subluxation of the spinal column with more than 50% of adjacent vertebral bodies lying directly lateral to each other.
   RESULTS: Five men, ranging from 18 to 50 years (mean, 35.2 years) old were included in the study. Three patients had thoracic spine lateraloptosis, and in 2 the injury was at the thoracolumbar junction. All patients underwent single-stage posterior surgical reduction and fixation. Intraoperatively, cord transection was seen in 3 patients, and dural tear with cerebrospinal fluid leak was seen in 1 patient. The mean follow-up period was 14 months (range, 1-36 months), during which 1 patient died of complications arising from bedsores. All patients remained at American Spinal Injury Association grade A neurologically.
   CONCLUSION: Lateraloptosis is difficult to treat, and the aim of surgery is to stabilize the spine. Rehabilitation remains the most crucial factor, but the scarcity of proper rehabilitation centers results in high mortality and morbidity.
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - MAY
PY  - 2018
VL  - 113
SP  - E166
EP  - E171
DO  - 10.1016/j.wneu.2018.01.206
AN  - WOS:000432942700023
ER  -

TY  - JOUR
AU  - Garg, PK
AU  - Jakhetiya, A
AU  - Pandey, R
AU  - Chishi, N
AU  - Pandey, D
TI  - Adjuvant radiotherapy versus observation following lumpectomy in ductal carcinoma in-situ: A meta-analysis of randomized controlled trials
T2  - BREAST JOURNAL
KW  - adjuvant radiotherapy
KW  - breast cancer
KW  - ductal carcinoma in-situ
KW  - meta-analysis
KW  - randomized controlled trials
KW  - BREAST-CONSERVING TREATMENT
KW  - LOCAL RECURRENCE
KW  - POSTMENOPAUSAL WOMEN
KW  - RADIATION-THERAPY
KW  - SECTOR RESECTION
KW  - RISK-FACTORS
KW  - DOUBLE-BLIND
KW  - CANCER
KW  - ANASTROZOLE
KW  - MASTECTOMY
AB  - The role of adjuvant radiotherapy (RT) following lumpectomy for ductal carcinoma in-situ (DCIS) was addressed in four major randomized controlled trials (RCTs) which were conducted two to three decades ago. Initial results of these trials suggested the protective role of RT in reducing the ipsilateral breast recurrences. Long-term results of all these four trials, based on more than 10-years follow-up data, have recently been published. A meta-analysis of four published RCTs which have addressed the role of adjuvant RT following lumpectomy for DCIS was conducted. Review manager (Cochrane Collaboration's software) version RevMan 5.2 was used for analysis. Evaluated events were ipsilateral breast recurrences (both DCIS and invasive), regional recurrences, contralateral breast events, distant recurrences, and overall mortality. The events were entered as dichotomous variable. The present meta-analysis included four RCTs and a total of 3680 patients - 1710 received adjuvant RT following lumpectomy while 1970 patients did not receive any adjuvant treatment. Patients who received RT had almost half of risk of ipsilateral breast recurrence (RR=0.53, 95% CI=0.45-0.62) and regional recurrence (RR=0.54, 95% CI=0.32-0.91) compared to those who did not receive adjuvant treatment - there was absolute risk reduction in 15% (95% CI=12%-17%) for ipsilateral breast recurrences in adjuvant RT treated patients. There was no significant difference in distant recurrence (RR=1.06, 95% CI=0.74-1.53), contralateral breast events (RR=1.22, 95% CI=0.98-1.52) and overall mortality (RR=0.93, 95% CI=0.79-1.09). Though addition of postoperative RT to lumpectomy does not reduce overall mortality, the present meta-analysis confirms that it decreases the ipsilateral breast and regional recurrence by almost half.
AD  - Univ Delhi, Univ Coll Med Sci & Guru Teg Bahadur Hosp, Dept Surg, New Delhi, IndiaAD  - Vardhaman Mahaveer Med Coll & Safdarjung Hosp, Dept Surg Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dr BRA Inst Rotary Canc Hosp, Dept Radiat Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Surg Oncol, Dr BRA Inst Rotary Canc Hosp, New Delhi, IndiaC3  - University of DelhiC3  - University College of Medical SciencesC3  - Vardhman Mahavir Medical College & Safdarjung HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalPU  - WILEY-HINDAWI
PI  - LONDON
PA  - ADAM HOUSE, 3RD FL, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND
DA  - MAY-JUN
PY  - 2018
VL  - 24
IS  - 3
SP  - 233
EP  - 239
DO  - 10.1111/tbj.12889
AN  - WOS:000434280800002
ER  -

TY  - JOUR
AU  - Goyal, KK
AU  - Saha, A
AU  - Sahi, PK
AU  - Kaur, M
AU  - Dubey, NK
AU  - Goyal, P
AU  - Upadhayay, AD
TI  - Hepcidin and proinflammatory markers in children with chronic kidney disease: A case-control study
T2  - CLINICAL NEPHROLOGY
KW  - hepcidin
KW  - IL-6
KW  - TNF-alpha
KW  - children
KW  - CKD
KW  - IRON
KW  - ANEMIA
KW  - INFLAMMATION
KW  - RISK
KW  - IL-6
AB  - Background: Hepcidin is the main regulator of hepcidin-ferroportin axis and is elevated in children with chronic kidney disease (CKD). Anemia of CKD and its relation to hepcidin, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and high-sensitivity C-reactive protein (hs-CRP) in iron-and erythropoietin (EPO)-naive, non-dialyzed children with CKD is understudied. Materials and methods: This case-control study aimed to study the levels of hepcidin and other proinflammatory markers (IL-6, TNF-alpha, hs-CRP) and their relation with anemia in iron- and erythropoietin-naive, non-dialysis CKD (stage 3 - 5) patients. 32 pediatric CKD stage 3 - 5 patients aged 2 - 18 years without previous iron or EPO therapy were compared with 32 gender- and age-matched healthy controls. The CKD cases were also divided into three categories based on their serum ferritin levels and transferrin saturation (%TSAT): true iron deficiency, impaired iron trafficking, and no iron deficiency. The baseline iron status was then correlated with the serum hepcidin levels. Results: Serum hepcidin, IL-6, and TNF-alpha levels were significantly elevated compared to controls. As CKD stage progressed, hemoglobin levels decreased, while serum hepcidin, IL6, TNF-alpha and hs-CRP levels increased significantly. Serum hepcidin levels correlated positively with IL-6 (r = 0.57, p = 0.001), TNF-alpha (r = 0.34, p = 0.05), hs-CRP (r = 0.36, p = 0.03), and ferritin (r = 0.07, p = 0.001), while being inversely correlated with Total iron binding capacity (TIBC) (r = -0.50, p = 0.003), hemoglobin (r = -0.52, p = 0.001), and glomerular filtration rate (GFR) (r = -0.71, p = 0.000). Serum hepcidin levels were highest in those with impaired iron trafficking, followed by those with no iron deficiency, followed by those with absolute iron deficiency (55.16 vs. 49 vs. 11.8, p = 0.005). Amongst those with no iron deficiency, hepcidin correlated negatively with hemoglobin (r = -0.752, p-value = 0.007). Conclusion: A positive correlation between hepcidin and other inflammatory biomarkers in non-dialyzed, iron-and EPO-naive pediatric CKD patients suggests a role of these markers in higher hepcidin production and its contribution to iron-restricted erythropoiesis across the spectrum of CKD. Median hepcidin levels were highest in those with impaired iron trafficking, followed by those with no iron deficiency, followed by those with absolute iron deficiency, suggesting that in an iron-replete state, high hepcidin levels inhibit iron absorption from the gut and release from iron storing cells, thus restricting erythropoiesis leading to anemia.
AD  - Dr Ram Manohar Lohia Hosp, Postgrad Inst Med Educ & Res, Div Pediat Nephrol, Dept Pediat, New Delhi, IndiaAD  - Dr Ram Manohar Lohia Hosp, Postgrad Inst Med Educ & Res, Dept Biochem, New Delhi, IndiaAD  - Kalawati Saran Childrens Hosp, Div Pediat Nephrol, Dept Pediat, New Delhi, IndiaAD  - Lady Hardinge Med Coll & Hosp, New Delhi, IndiaAD  - AIIMS, Dept Biostat, New Delhi, IndiaC3  - Lady Hardinge Medical College & HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - DUSTRI-VERLAG DR KARL FEISTLE
PI  - DEISENHOFEN-MUENCHEN
PA  - BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
DA  - MAY
PY  - 2018
VL  - 89
IS  - 5
SP  - 363
EP  - 370
DO  - 10.5414/CN109132
AN  - WOS:000430458800008
ER  -

TY  - JOUR
AU  - Gupta, A
AU  - Shukla, G
TI  - Polysomnographic determinants of requirement for advanced positive pressure therapeutic options for obstructive sleep apnea
T2  - SLEEP AND BREATHING
KW  - Obstructive sleep apnea
KW  - Adaptive servo ventilation
KW  - Bi-level-ST
KW  - Cyclic alternating pattern
KW  - Non-REM instability
KW  - ADAPTIVE SERVO-VENTILATION
KW  - ADULTS PRACTICE PARAMETERS
KW  - AIRWAY PRESSURE
KW  - METAANALYSES
AB  - Background A small percentage of adult patients with severe obstructive sleep apnea (OSA) has been recognized to be extraordinarily difficult to treat with conventional continuous or Bi-level positive airway pressure (together referred to as PAP) therapy.
   Aim and objectives The aim of this study was to determine polysomnographic (PSG) characteristics, which may help predict the requirement for advanced therapeutic options for OSA.
   Methods Consecutive patients who underwent PAP titration at our sleep laboratory over a 2-year period were included. Patients with technically inadequate studies, those with incomplete titration due to intolerance, mask-related problems, or lack of sleep and those with significant co-morbidity and with other primary sleep disorders, were excluded. The PSGs (diagnostic + titration parts) were categorized into three types: type A (respiratory events evenly distributed over all sleep stages), type B (REM dominant respiratory events), and type C (non-REM dominant respiratory events, mainly during cyclic alternating pattern [CAP] sleep). Group A was further subdivided into A1 (those whose hypnogram normalized after adequate titration) and A2 (those whose hypnogram converted to a type C pattern on titration). These were categorized again into treatment group I (adequately PAP titrated) and group II (poor response to conventional PAP) for studying factors determining poor response to PAP.
   Results Among 249 patients evaluated in the sleep laboratory over the study period, 123 (103 males, mean age 49.9 +/- 10.8 years, mean BMI 29.3 +/- 4) fulfilled inclusion criteria. These could be grouped as type A (n = 85), B (n = 33), and C (n = 5). On titration, 57 patients of type A and 21 of type B could be successfully titrated, while 24 in type A and 11 in type B, converted into type C. Therefore, in group II (n = 43), 38 patients fell in type C, overtly and after titration. Twelve of these had been successfully treated using adaptive servo ventilation (ASV) while another 28 could be treated using the Bi-level PAP-ST mode. The only PSG feature predicting poor response to conventional PAP was the presence of post-arousal central apnea (p = 0.001). The main difference between the A1 + B groups and A2 + C groups was the significantly higher non-REM apnea hypopnea index in the latter. Among these, on 1-year follow-up, eight patients were using Bi-level PAP-ST mode, while four patients were using ASV and were asymptomatic.
   Conclusion Non-REM sleep instability and the presence of post-arousal central apneas may be important determinants of poor response to conventional PAP and requirement for advanced therapeutic options among patients with severe OSA.
AD  - All India Inst Med Sci, Dept Neurol, Neurosci Ctr, Comprehens Sleep Disorders Facil, Room 2,6th Floor, New Delhi 110049, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER HEIDELBERG
PI  - HEIDELBERG
PA  - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
DA  - MAY
PY  - 2018
VL  - 22
IS  - 2
SP  - 401
EP  - 409
DO  - 10.1007/s11325-017-1556-8
AN  - WOS:000430993000017
ER  -

TY  - JOUR
AU  - Kapil, U
AU  - Pandey, RM
AU  - Sharma, B
AU  - Ramakrishnan, L
AU  - Sharma, N
AU  - Singh, G
AU  - Sareen, N
TI  - Prevalence of Vitamin D Deficiency in Children (6-18 years) Residing in Kullu and Kangra Districts of Himachal Pradesh, India
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Vitamin D deficiency
KW  - Parathyroid hormone
KW  - Children
KW  - India
KW  - PREVENTION
KW  - CANCER
KW  - INFANTS
KW  - SCHOOLGIRLS
KW  - EXPOSURE
KW  - SUNLIGHT
KW  - RICKETS
KW  - CALCIUM
KW  - HEALTH
KW  - IMPACT
AB  - Objective To assess the prevalence of Vitamin D deficiency (VDD) and associated risk factors amongst children in the age group of 6-18 y residing at an altitude of 1000 mts and above.
   Methods A community based cross-sectional study was conducted in the year 2015-2016. Two districts (namely: Kangra and Kullu) of Himachal Pradesh state, India was selected for the present study. In each district thirty clusters/schools were identified using Population Proportionate to Size (PPS) sampling methodology. In the identified school, all the children in schools were enlisted. Twenty children per school were selected by using random number tables. A total of 1222 children (Kangra: 610; Kullu: 612) in the age group of 6-18 y were enrolled. The data on socio economic status, physical activity and sunlight exposure was collected. The blood samples were collected and serum 25-hydroxyvitamin D, intact parathyroid hormone, serum calcium, phosphorous, albumin and alkaline phosphate were assessed using standard procedures.
   Results Eighty one percent (Kangra) and 80.0% (Kullu) of school age children were found Vitamin D deficient as per serum 25(OH) D levels (less than 20 ng/ml).
   Conclusions A high prevalence of VDD was found in children residing in 2 districts located at high altitude regions of Himachal Pradesh, India.
AD  - All India Inst Med Sci, Dept Human Nutr, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - Indira Gandhi Med Coll, Dept Gastroenterol, Shimla, Himachal Prades, IndiaAD  - All India Inst Med Sci, Dept Cardiac Biochem, New Delhi, IndiaAD  - Indira Gandhi Med Coll, Dept Physiol, Shimla, Himachal Prades, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indira Gandhi Medical College & Hospital ShimlaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indira Gandhi Medical College & Hospital ShimlaPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - MAY
PY  - 2018
VL  - 85
IS  - 5
SP  - 344
EP  - 350
DO  - 10.1007/s12098-017-2577-9
AN  - WOS:000432219000007
ER  -

TY  - JOUR
AU  - Khanna, A
AU  - Bhushan, B
AU  - Chauhan, PS
AU  - Saxena, S
AU  - Gupta, DK
AU  - Siraj, F
TI  - High mTOR expression independently prognosticates poor clinical outcome to induction chemotherapy in acute lymphoblastic leukemia
T2  - CLINICAL AND EXPERIMENTAL MEDICINE
KW  - Acute lymphoblastic leukemia (ALL)
KW  - Gene expression
KW  - Induction chemotherapy
KW  - Mechanistic target of rapamycin (mTOR)
KW  - Multivariate analysis
KW  - CHILDHOOD
KW  - EFFICACY
KW  - SUBTYPES
KW  - PATHWAY
KW  - ADULT
KW  - PCR
AB  - In acute lymphoblastic leukemia (ALL), limited data are available on mTOR gene expression in clinical samples and its role in predicting response to induction chemotherapy. mRNA expression of mTOR gene was determined quantitatively by real-time PCR in 50 ALL patients (30 B-ALL and 20 T-ALL) and correlated with clinical outcome after induction chemotherapy. Expression level of mTOR was upregulated in more than 50% of cases of ALL. In T-ALL, high expression of mTOR was commonly seen, more in adults than children (82 vs. 55% cases), while in B-ALL it was same (similar to 63% cases) in both adults and children. Mean fold change of mTOR expression was significantly higher in non-responders compared to responders of both adult B-ALL (7.4 vs. 2.7, p = 0.05) and T-ALL (13.9 vs. 2.4, p = 0.001). Similar results were seen in pediatric non-responders when compared to responders of both B-ALL (14.5 vs. 2.5, p = 0.006) and T-ALL (24.2 vs. 1.7, p = 0.002). Interestingly, we have observed that mTOR expression was two times higher in non-responders of children compared to adults in both B-ALL (14.5 vs. 7.4, p = 0.05) and T-ALL (24.2 vs. 13.9, p = 0.01). Multivariate analysis with other known prognostic factors revealed that mTOR expression independently predicts clinical response to induction chemotherapy in ALL. This study demonstrates that high mTOR expression is associated with poor clinical outcome in ALL and can serve as a potential target for novel therapeutic strategies.
AD  - Safdarjung Hosp Campus, Natl Inst Pathol ICMR, New Delhi 110029, IndiaAD  - Symbiosis Int Univ, Symbiosis Sch Biomed Sci, Pune 412115, Maharashtra, IndiaAD  - All India Inst Med Sci, DR BR Ambedkar Inst Canc Hosp, Dept Med Oncol, New Delhi 110029, IndiaAD  - Safdarjang Hosp, Dept Hematol, New Delhi, IndiaC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Pathology (IOP)C3  - Symbiosis International UniversityC3  - Symbiosis School of Biological Sciences (SSBS)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Vardhman Mahavir Medical College & Safdarjung HospitalPU  - SPRINGER-VERLAG ITALIA SRL
PI  - MILAN
PA  - VIA DECEMBRIO, 28, MILAN, 20137, ITALY
DA  - MAY
PY  - 2018
VL  - 18
IS  - 2
SP  - 221
EP  - 227
DO  - 10.1007/s10238-017-0478-x
AN  - WOS:000430980400008
ER  -

TY  - JOUR
AU  - Khanna, G
AU  - Pathak, P
AU  - Suri, V
AU  - Sharma, MC
AU  - Chaturvedi, S
AU  - Ahuja, A
AU  - Bhardwaj, M
AU  - Garg, A
AU  - Sarkar, C
AU  - Sharma, R
TI  - Immunohistochemical and molecular genetic study on epithelioid glioblastoma: Series of seven cases with review of literature
T2  - PATHOLOGY RESEARCH AND PRACTICE
KW  - BRAFV600E
KW  - Epithelioid glioblastoma
KW  - EGFR amplification
KW  - TERT
KW  - BRAF V600E MUTATION
KW  - ASTROCYTOMA
AB  - Epithelioid glioblastoma (e-gbm) is a recently described variant of glioblastoma (GBM) which is associated with short survival and now added as a provisional entity to WHO 2016 classification of CNStumors. About half of these tumors show characteristic BRAF-V600E mutation. However, unlike conventional GBMs, e-gbm lack specific diagnostic and prognostic markers. Hence, we aimed to molecularly characterize these tumors. An extensive review of literature was performed.In a multi-institutional effort, all the cases of glioblastoma of year 2017 were reviewed. Cases with predominant epithelioid morphology were analysed. Seven cases of e-gbm (adults:4 and pediatric: 3) were identified. Duration of symptoms varied from 2 weeks to one month. Radiologically, all cases were supratentorial, contrast enhancing with solid and cystic appearance. Majority of the cases were immunopositive for GFAP (71%), EMA (71%), S100 (71%) and vimentin (85%). All the cases showed ATRX, INI-1 and H3K27me3 expression. BRAFV600Emutation was seen in 28% of cases. TERT mutation was seen in 40% cases, while one case showed EGFR amplification. H3F3A mutations and PTEN deletions were seen in none. Although e-gbms are rare, epithelioid morphology of a CNS tumor in a young adult or children with areas of necrosis needs thorough histomorphological and genetic workup.
AD  - AIIMS, Dept Pathol, New Delhi 110029, IndiaAD  - Inst Human Behav & Allied Sci, Dept Pathol, New Delhi, IndiaAD  - PGIMER, Dept Pathol, New Delhi, IndiaAD  - Dr RML Hosp, New Delhi, IndiaAD  - AIIMS, Dept Neuroradiol, New Delhi, IndiaAD  - AIIMS, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI  - JENA
PA  - OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
DA  - MAY
PY  - 2018
VL  - 214
IS  - 5
SP  - 679
EP  - 685
DO  - 10.1016/j.prp.2018.03.019
AN  - WOS:000435427500011
ER  -

TY  - JOUR
AU  - Kruszka, P
AU  - Porras, AR
AU  - de Souza, DH
AU  - Moresco, A
AU  - Huckstadt, V
AU  - Gill, AD
AU  - Boyle, AP
AU  - Hu, T
AU  - Addissie, YA
AU  - Mok, GTK
AU  - Tekendo-Ngongang, C
AU  - Fieggen, K
AU  - Prijoles, EJ
AU  - Tanpaiboon, P
AU  - Honey, E
AU  - Ho-Ming, L
AU  - Lo, IFM
AU  - Thong, MK
AU  - Muthukumarasamy, P
AU  - Jones, KL
AU  - Belhassan, K
AU  - Ouldim, K
AU  - El Bouchikhi, I
AU  - Bouguenouch, L
AU  - Shukla, A
AU  - Girisha, KM
AU  - Sirisena, ND
AU  - Dissanayake, VHW
AU  - Paththinige, CS
AU  - Mishra, R
AU  - Kisling, MS
AU  - Ferreira, CR
AU  - de Herreros, MB
AU  - Lee, NC
AU  - Jamuar, SS
AU  - Lai, A
AU  - Shien, TE
AU  - Lim, JY
AU  - Wen-Min, CB
AU  - Gupta, N
AU  - Lotz-Esquivel, S
AU  - Badilla-Porras, R
AU  - Hussen, DF
AU  - El Ruby, MO
AU  - Ashaat, EA
AU  - Patil, SJ
AU  - Dowsett, L
AU  - Eaton, A
AU  - Innes, AM
AU  - Shotelersuk, V
AU  - Badoe, E
AU  - Wonkam, A
AU  - Obregon, MG
AU  - Chung, BHY
AU  - Trubnykova, M
AU  - La Serna, J
AU  - Jugo, BEG
AU  - Pastor, MC
AU  - Barriga, HHA
AU  - Megarbane, A
AU  - Kozel, BA
AU  - van Haelst, MM
AU  - Stevenson, RE
AU  - Summar, M
AU  - Adebowale, AA
AU  - Morris, CA
AU  - Moretti-Ferreira, D
AU  - Linguraru, MG
AU  - Muenke, M
TI  - Williams-Beuren syndrome in diverse populations
T2  - AMERICAN JOURNAL OF MEDICAL GENETICS PART A
KW  - Africa
KW  - Asia
KW  - diverse populations
KW  - facial analysis technology
KW  - Latin America
KW  - Middle East
KW  - syndrome
KW  - Williams
KW  - Williams-Beuren
KW  - SUPRAVALVULAR AORTIC-STENOSIS
KW  - FACIAL DYSMORPHOLOGY
KW  - DOWN-SYNDROME
KW  - DIAGNOSIS
KW  - DELETION
KW  - PHENOTYPE
KW  - CHILDREN
KW  - COHORT
KW  - ICA
AB  - Williams-Beuren syndrome (WBS) is a common microdeletion syndrome characterized by a 1.5Mb deletion in 7q11.23. The phenotype of WBS has been well described in populations of European descent with not as much attention given to other ethnicities. In this study, individuals with WBS from diverse populations were assessed clinically and by facial analysis technology. Clinical data and images from 137 individuals with WBS were found in 19 countries with an average age of 11 years and female gender of 45%. The most common clinical phenotype elements were periorbital fullness and intellectual disability which were present in greater than 90% of our cohort. Additionally, 75% or greater of all individuals with WBS had malar flattening, long philtrum, wide mouth, and small jaw. Using facial analysis technology, we compared 286 Asian, African, Caucasian, and Latin American individuals with WBS with 286 gender and age matched controls and found that the accuracy to discriminate between WBS and controls was 0.90 when the entire cohort was evaluated concurrently. The test accuracy of the facial recognition technology increased significantly when the cohort was analyzed by specific ethnic population (P-value<0.001 for all comparisons), with accuracies for Caucasian, African, Asian, and Latin American groups of 0.92, 0.96, 0.92, and 0.93, respectively. In summary, we present consistent clinical findings from global populations with WBS and demonstrate how facial analysis technology can support clinicians in making accurate WBS diagnoses.
AD  - NHGRI, Med Genet Branch, NIH, Bethesda, MD 20892 USAAD  - Childrens Natl Hlth Syst, Sheikh Zayed Inst Pediat Surg Innovat, Washington, DC USAAD  - Sao Paulo State Univ UNESP, Inst Biosci, Dept Genet, Sao Paulo, BrazilAD  - Hosp Pediat Garrahan, Serv Genet, Buenos Aires, DF, ArgentinaAD  - Univ Hong Kong, LKS Fac Med, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ Cape Town, Div Human Genet, Cape Town, South AfricaAD  - Greenwood Genet Ctr, Greenwood, SC 29646 USAAD  - Childrens Natl Med Ctr, Rare Dis Inst, Washington, DC 20010 USAAD  - Univ Pretoria, Dept Genet, Pretoria, South AfricaAD  - Dept Hlth, Clin Genet Serv, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ Malaya, Dept Paediat, Fac Med, Kuala Lumpur, MalaysiaAD  - Childrens Hosp Kings Daughters, Div Med Genet & Metab, Norfolk, VA USAAD  - Hassan II Univ Hosp, Med Genet & Oncogenet Unit, Fes, MoroccoAD  - Univ Sidi Mohammed Ben Abdellah, Fac Sci & Tech, Lab Microbial Biotechnol, Fes, MoroccoAD  - Manipal Univ, Kasturba Med Coll, Dept Med Genet, Manipal, IndiaAD  - Univ Colombo, Fac Med, Human Genet Unit, Colombo, Sri LankaAD  - Natl Secretariat Rights People Disabil SENADIS, Fernando De La Mora, ParaguayAD  - Natl Taiwan Univ Hosp, Dept Pediat & Med Genet, Taipei, TaiwanAD  - KK Womens & Childrens Hosp, Dept Paediat, Genet Serv, Singapore, SingaporeAD  - All India Inst Med Sci, Dept Pediat, Div Genet, New Delhi, IndiaAD  - Hosp San Juan de Dios CCSS, Dept Res, San Jose, Costa RicaAD  - Hosp Nacl Ninos CCSS, Med Genet & Metab Dept, San Jose, Costa RicaAD  - Natl Res Ctr, Dept Human Cytogenet, Cairo, EgyptAD  - Natl Res Ctr, Clin Genet Dept, Cairo, EgyptAD  - Narayana Hlth City, Mazumdar Shaw Med Ctr, Bangalore, Karnataka, IndiaAD  - Kapiolani Med Ctr Women & Children, Honolulu, HI USAAD  - Univ Calgary, Cumming Sch Med, Dept Med Genet, Calgary, AB, CanadaAD  - Univ Calgary, Cumming Sch Med, Alberta Childrens Hosp Res Inst, Calgary, AB, CanadaAD  - Chulalongkorn Univ, Dept Pediat, Fac Med, Ctr Excellence Med Genet, Bangkok, ThailandAD  - Univ Ghana, Coll Hlth Sci, Sch Med & Dent, Accra, GhanaAD  - Inst Nacl Salud Nino, Lima, PeruAD  - Inst Jerome Lejeune, Paris, FranceAD  - NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USAAD  - Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USAAD  - Univ Med Ctr, Dept Genet, Utrecht, NetherlandsAD  - NHGRI, Ctr Res Genom & Global Hlth, NIH, Bethesda, MD 20892 USAAD  - Univ Nevada, Sch Med, Dept Pediat, Div Genet, Las Vegas, NV 89154 USAC3  - National Institutes of Health (NIH) - USAC3  - NIH National Human Genome Research Institute (NHGRI)C3  - Children's National Health SystemC3  - Universidade Estadual PaulistaC3  - Hospital de Pediatria Doctor Juan GarrahanC3  - University of Hong KongC3  - University of Cape TownC3  - Greenwood Genetic CenterC3  - Children's National Health SystemC3  - University of PretoriaC3  - Universiti MalayaC3  - Sidi Mohamed Ben Abdellah University of FezC3  - Hassan II University Hospital Center of FezC3  - Sidi Mohamed Ben Abdellah University of FezC3  - Manipal Academy of Higher Education (MAHE)C3  - Kasturba Medical College, ManipalC3  - University of ColomboC3  - National Taiwan UniversityC3  - National Taiwan University HospitalC3  - KK Women's & Children's HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Egyptian Knowledge Bank (EKB)C3  - National Research Centre (NRC)C3  - Egyptian Knowledge Bank (EKB)C3  - National Research Centre (NRC)C3  - University of CalgaryC3  - University of CalgaryC3  - Chulalongkorn UniversityC3  - University of GhanaC3  - National Institutes of Health (NIH) - USAC3  - NIH National Heart Lung & Blood Institute (NHLBI)C3  - Washington University (WUSTL)C3  - Utrecht UniversityC3  - Utrecht University Medical CenterC3  - National Institutes of Health (NIH) - USAC3  - NIH National Human Genome Research Institute (NHGRI)C3  - Nevada System of Higher Education (NSHE)C3  - University of Nevada Las VegasPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - MAY
PY  - 2018
VL  - 176
IS  - 5
SP  - 1128
EP  - 1136
DO  - 10.1002/ajmg.a.38672
AN  - WOS:000433440600009
ER  -

TY  - JOUR
AU  - Kumar, RV
AU  - Bhasker, S
TI  - A peek into epidemiology, screening, management of breast cancer in developing countries: Experience from two regional cancer centers in India
T2  - BREAST JOURNAL
AD  - Kidwai Canc Inst, Dept Radiat Oncol, Bangalore, Karnataka, IndiaAD  - All India Inst Med Sci, Dept Radiotherapy, New Delhi, IndiaC3  - Kidwai Memorial Institute of OncologyC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY-HINDAWI
PI  - LONDON
PA  - ADAM HOUSE, 3RD FL, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND
DA  - MAY-JUN
PY  - 2018
VL  - 24
IS  - 3
SP  - 422
EP  - 423
DO  - 10.1111/tbj.12965
AN  - WOS:000434280800045
ER  -

TY  - JOUR
AU  - Kumari, R
AU  - Vaishya, V
AU  - Khanna, G
AU  - Chauhan, M
AU  - Sharma, JB
AU  - Kriplani, A
TI  - Tuberculosis of the cervix: An uncommon cause of vaginal discharge in a post-menopausal woman
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
AB  - Discharge per vaginum is a common symptom of a variety of gynaecological diseases. Among post-menopausal women, atrophic vaginitis, cervicitis and cervical carcinoma are common causes of this symptom. We present a 64-year-old woman who had foul-smelling discharge per vaginum for the past 1 year. Per speculum examination revealed an unhealthy-looking cervix and white discharge. On bi-manual examination, the cervix was flush with the vagina. There was no obvious growth felt, the exact uterine size could not be ascertained and the finger was stained with thick discharge. A biopsy of the cervix showed epithelioid cell granulomas and a diagnosis of tuberculosis was made. The patient responded to antitubercular therapy. Tuberculosis of the cervix may be a rare cause of foul-smelling discharge per vaginum in post-menopausal women but there should be a high index of suspicion of this condition, especially in areas where tuberculosis is common. We report this post-menopausal woman owing to the rarity of tuberculosis of the cervix mimicking a gynaecological malignancy.
AD  - All India Inst Med Sci, Dept Obstet & Gynaecol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - MAY-JUN
PY  - 2018
VL  - 31
IS  - 3
SP  - 149
EP  - 150
C7  - PMID 31044761
DO  - 10.4103/0970-258X.255757
AN  - WOS:000469074400006
ER  -

TY  - JOUR
AU  - Kusuma, YS
AU  - Kaushal, S
AU  - Sundari, AB
AU  - Babu, BV
TI  - Access to childhood immunisation services and its determinants among recent and settled migrants in Delhi, India
T2  - PUBLIC HEALTH
KW  - Immunisation
KW  - Migrants
KW  - Child health
KW  - Determinants
KW  - Healthcare access
KW  - India
KW  - DISADVANTAGED MIGRANTS
KW  - MIGRATION
KW  - CARE
KW  - COVERAGE
KW  - CHILDREN
AB  - Objectives: Childhood immunisation is one of the important public health interventions, and poor migrants are vulnerable to forego these services. The objective of the study is to understand the access of childhood immunisation services to the socio-economically disadvantaged migrants and the determinants of full immunisation uptake up to the age of 1 year.
   Methods: In a cross-sectional survey, 458 migrant households with a child aged up to 2 years were identified. Data on sociodemographics, migration history, receipt of various vaccines and maternal healthcare services were collected through interviewer-administered pretested questionnaires. Multiple logistic regression analysis was performed to identify the determinants of full immunisation status.
   Results: Childhood immunisation coverage rates were low as only 31% of recent-migrant children and 53% of settled-migrant children were fully immunised against seven vaccine-preventable diseases (VPDs) by 12 months of age. Lack of awareness of the immunisation schedule and location of health facilities, mobility, illness of the child, fear of vaccines and side-effects were the main reasons for incomplete or no immunisation. Mother's educational attainment, TV viewership, hospital birth and receipt of information on childhood immunisation from the health workers during postnatal visits increased chances of getting the child fully immunised against seven VPDs by 1 year of age.
   Conclusion: The migrants, particularly the recent migrants, are at the risk of foregoing immunisation services because of livelihood insecurity, mobility and non-familiarity of services in the new urban environment. There is a need to deliver services with a focus on recent migrants. Investing in education and socio-economic development and providing secured livelihoods and equitable services are important to improve and sustain access to healthcare services in the long run. (c) 2018 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.
AD  - All India Inst Med Sci, Ctr Community Med, New Delhi 110029, IndiaAD  - Indian Council Med Res, Sociobehav & Hlth Syst Res Div, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Council of Medical Research (ICMR)PU  - W B SAUNDERS CO LTD
PI  - LONDON
PA  - 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
DA  - MAY
PY  - 2018
VL  - 158
SP  - 135
EP  - 143
DO  - 10.1016/j.puhe.2018.03.006
AN  - WOS:000432707100020
ER  -

TY  - JOUR
AU  - Macedo, E
AU  - Cerda, J
AU  - Hingorani, S
AU  - Hou, JY
AU  - Bagga, A
AU  - Burdmann, EA
AU  - Rocco, VM
AU  - Mehta, LR
TI  - Recognition and management of acute kidney injury in children: The ISN 0by25 Global Snapshot study
T2  - PLOS ONE
KW  - ACUTE-RENAL-FAILURE
KW  - INTERNATIONAL SOCIETY
KW  - DEVELOPING-COUNTRY
KW  - MORTALITY
KW  - DIALYSIS
KW  - EPIDEMIOLOGY
KW  - ASSOCIATION
KW  - OLIGURIA
KW  - AKI
AB  - Background
   In low and middle-income countries, reliable data on the epidemiology of childhood acute kidney injury (AKI) is lacking. The Global Snapshot, conducted by the ISN "0by25" AKI initiative, was a world-wide cross-sectional, observational study to evaluate AKI in hospitalized patients. Here we report the pediatric results of this study.
   Patients and methods
   We prospectively collected data on children who met the Kidney Disease Improving Global Outcomes AKI criteria during a 10-week window in late 2014. AKI risk factors, etiological factors, management and outcomes were recorded using standardized forms and protocols. Countries were classified according to their 2014 gross national income (GNI) per person into high-income countries (HIC), upper-middle income countries (UMIC) and low and low-middle income countries (LLMIC). Need for renal replacement therapy, mortality, and renal recovery were assessed 7 days after AKI diagnosis or at hospital discharge, whichever came first.
   Results
   92 centers from 41 countries collected data on 354 pediatric AKI patients; 53% of the children developed AKI while hospitalized and 47% in the community. The most common etiological factors for AKI differed across GNI categories as well as between patients with community-acquired vs. hospital-acquired AKI. Children from HIC were younger, and larger proportion of AKI in this group were due to post-surgical complications vs. other etiologies when compared to other income categories. In patients with hypotension as the cause of AKI, the adjusted risk of death was almost 10-fold higher compared to patients without hypotension as an etiological factor for AKI development. Mortality was similar within AKI stages in HIC and UMIC. In LLMIC, patients with the highest AKI level of severity had higher mortality than patients in higher income categories. Patients from LLMIC and UMIC had a 57-fold and 11 fold higher adjusted risk of death, respectively, compared to patients from HIC.
   Conclusion
   In resource-limited countries, pediatric AKI-associated mortality is disproportionately higher when compared to high-resource areas, especially among patients with more severe AKI.
AD  - Univ Calif San Diego, Dept Med, Div Nephrol, San Diego, CA 92103 USAAD  - Albany Med Coll, Dept Med, Div Nephrol, Albany, NY 12208 USAAD  - Univ Washington, Dept Pediat, Seattle Childrens Hosp, Div Nephrol, Seattle, WA 98195 USAAD  - Univ Calif San Diego, Altman Clin & Translat Res Inst, San Diego, CA 92103 USAAD  - All India Inst Med Sci, Div Pediat Nephrol, New Delhi, IndiaAD  - Univ Sao Paulo, Med Sch, Div Nephrol, LIM 12, Sao Paulo, BrazilAD  - Wake Forest Sch Med, Sect Nephrol, Dept Internal Med, Winston Salem, NC USAC3  - University of California SystemC3  - University of California San DiegoC3  - Albany Medical CollegeC3  - Seattle Children's HospitalC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of California SystemC3  - University of California San DiegoC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Universidade de Sao PauloC3  - Wake Forest UniversityPU  - PUBLIC LIBRARY SCIENCE
PI  - SAN FRANCISCO
PA  - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
DA  - MAY 1
PY  - 2018
VL  - 13
IS  - 5
C7  - e0196586
DO  - 10.1371/journal.pone.0196586
AN  - WOS:000431281100033
ER  -

TY  - JOUR
AU  - Mahajan, S
AU  - Gupta, K
AU  - Sinha, S
AU  - Malhotra, A
AU  - Mahajan, S
TI  - Effect of kidney transplantation on sleep-disordered breathing in patients with End Stage Renal Disease: a polysomnographic study
T2  - SLEEP MEDICINE
KW  - Sleep-disordered breathing
KW  - ESRD
KW  - Renal transplant
KW  - Desaturation index
KW  - AHI
KW  - CARDIOVASCULAR-DISEASE
KW  - HEMODIALYSIS-PATIENTS
KW  - APNEA SYNDROME
KW  - RISK
KW  - RECIPIENTS
KW  - DIALYSIS
KW  - PREDICTORS
AB  - Background: Sleep-disordered breathing (SDB) is common in patients with end-stage renal disease (ESRD). SDB is associated with comorbidities such as hypertension, diabetes mellitus, and obesity, interplaying with metabolic derangements in the form of uremia, acidosis, and hypervolemia. Renal transplant has been observed to correct most of these metabolic derangements and to control progression of comorbidities. While SDB is highly prevalent among patients in the pretransplant stage, it remains to be seen whether the beneficial aspects of transplant are extended to improvement in SDB in patients with ESRD.& para;& para;Methods: Eighteen patients undergoing thrice-weekly hemodialysis (HD) for ESRD at the transplant clinic of All India Institute of Medical Sciences (AIIMS), New Delhi, underwent detailed clinical, laboratory, and polysomnographic evaluation. The average number of apneas and hypopneas per hour of sleep, ie, Apnea-Hypopnea Index (AHI), was used to define the severity of sleep apnea. All patients underwent polysomnography (PSG) within 24 h of the last HD and after three months of living-donor transplant.& para;& para;Results: Of 18 patients, there were 14 males and four females. The median age was 28 years (range 19-50 years). They had already spent a median period of six months (range 3-31 months) on HD before inclusion. The prevalence of SDB (AHI >= 5/h) was 44.4% (8/18) before transplant, which decreased to 5.6% (1/18) after transplant (p = 0.016). The oxygen desaturation index had a median value of 5.8 events/h (range 0.1-35.4) in the pretransplant stage, which decreased to 0 events/h (range 0-6.6) in the post-transplant stage (p = 0.035).& para;& para;Conclusion: There was a significant improvement in the prevalence and severity of SDB after transplant. Whether improvement in SDB is sustained on a long-term follow-up remains to be seen. (C) 2018 Elsevier B.V. All rights reserved.
AD  - AIIMS, Dept Nephrol, New Delhi 110029, IndiaAD  - AIIMS, Dept Med, New Delhi 110029, IndiaAD  - Univ Calif San Diego, Dept Med, San Diego, CA USAC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of California SystemC3  - University of California San DiegoPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - MAY
PY  - 2018
VL  - 45
SP  - 140
EP  - 145
DO  - 10.1016/j.sleep.2017.11.1151
AN  - WOS:000430474800023
ER  -

TY  - JOUR
AU  - Makkar, JK
AU  - Kumar, B
AU  - Jain, K
AU  - Dhutt, SS
AU  - Batra, YK
AU  - Singh, PM
TI  - Effect of Different Volumes on Pain Relief in Patient Receiving Fluoroscopic Guided Interlaminar Lumbar Epidural Steroid Injection
T2  - PAIN PHYSICIAN
KW  - Epidural steroid
KW  - volume
KW  - low back pain
KW  - interlaminar
KW  - LOW-BACK-PAIN
KW  - PARTICULATE-STEROIDS
KW  - EFFICACY
KW  - CONTRAST
KW  - BLOCKADE
AB  - Background: Epidural steroids injections (ESI) are frequently used to treat lumbar radicular pain Although different volume have been used for interlaminar ESI in adults, there is no controlled trial comparing the effect of different volumes on pain relief for the same dose of steroid.
   Objective: To compare the effect of increase in volume of epidural drug on pain relief in lumbar ESI
   Study design: Randomized double blind trial
   Settings: Pain OR of a tertiary care centre
   Methods: Sixty patients were randomly allocated to 1 of 3 groups: Group A (4 mL), Group B (6 mL), and Group C (8 mL). Pain was evaluated using visual analog scale (VAS) and improvement in disability using modified Oswestry Disability Questionnaire scores (MODQS) at 2, 4, 8, 12, and 24 weeks. Patients having less than 50% pain relief from baseline received an additional epidural injection of the same volume with a maximum of 3 injections at least 15 days apart. The primary objective of the study was incidence of patients attaining more than 50% pain relief at 6 months. Secondary outcome included MODQS and pattern of spread of iodinated contrast on fluoroscopy.
   Results: At the end of 6 months, there was no significant difference in the effective pain relief between the 3 groups (Group A-16/22 (72.7%), Group B-15/20 (75%), Group C-13/18 (72 2%); P= 0.98, chi- square test). All groups demonstrated a significant reduction in mean VAS scores. There was no significant intergroup difference in VAS sores and MODQS at all the time intervals The pattern of contrast spread did not differ between the 3 groups.
   Limitation: Not a placebo controlled trial.
   Conclusions: An increase in volume of the injectate from 4 mL to 8 ml did not increase the efficacy of interlaminar ESI.
AD  - Post Grad Inst Med Educ & Res, Dept Anesthesia & Intens Care, Chandigarh, IndiaAD  - Post Grad Inst Med Educ & Res, Dept Orthoped, Chandigarh, IndiaAD  - All India Inst Med Sci, Dept Anaesthesia & Intens Care, New Delhi, IndiaC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI  - PADUCAH
PA  - 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
DA  - MAY-JUN
PY  - 2018
VL  - 21
IS  - 3
SP  - 243
EP  - 249
AN  - WOS:000435191300016
ER  -

TY  - JOUR
AU  - Malgulwar, PB
AU  - Nambirajan, A
AU  - Pathak, P
AU  - Faruq, M
AU  - Rajeshwari, M
AU  - Singh, M
AU  - Suri, V
AU  - Sarkar, C
AU  - Sharma, MC
TI  - <i>C11orf95</i>-<i>RELA</i> fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin
T2  - JOURNAL OF NEURO-ONCOLOGY
KW  - RELA fusions
KW  - YAP1 fusions
KW  - Nestin
KW  - L1CAM
KW  - Ependymoma
KW  - PEDIATRIC INTRACRANIAL EPENDYMOMAS
KW  - STEM-CELLS
KW  - PATHOLOGICAL ACTIVATION
KW  - CLASSIFICATION
KW  - COMPARTMENTS
KW  - MUTATIONS
KW  - GRADES
KW  - TUMORS
KW  - GAIN
KW  - VEGF
AB  - Ependymomas (EPN) show site specific genetic alterations and a recent DNA methylation profiling study identified nine molecular subgroups. C11orf95-RELA and YAP1 fusions characterise the RELA and YAP1 molecular subgroups, respectively, of supratentorial (ST)-EPNs. Current guidelines recommend molecular subgrouping over histological grade for accurate prognostication. Clinicopathological features of ST-EPNs in correlation with C11orf95-RELA and YAP1 fusions have been assessed in only few studies. We aimed to study these fusions in EPNs, and identify diagnostic and prognostic markers. qRT-PCR and Sanger Sequencing for the detection of C11orf95-RELA, YAP1-MAMLD1 and YAP1-FAM118B fusion transcripts, gene expression analysis for NFKBI, and immunohistochemistry for p53, MIB-1, nestin, VEGF, and L1CAM were performed. 88 EPNs (10-Grade I and 78-Grade II/III) from all sites were included. RELA fusions were unique to Grade II/III ST-EPNs, detected in 81.4% (22/27) and 18.5% (5/27) of pediatric and adult ST-EPNs respectively. ST-EPNs harbouring RELA fusions showed frequent grade III histology (81.5%), clear cell morphology (70.3%), upregulated NFKB/expression, MIB-1 labelling indices (LI) >= 10% (77.8%), and immunopositivity for nestin (95.7%), VEGF (72%), L1CAM (79%), and p53 (64%). Presence of RELA fusions, L1CAM immunopositivity and MIB-1 LI >= 10% associated with poor outcome. L1CAM showed 81% concordance with RELA fusions. YAP1-MAMLD1 fusion was identified in a single RELA fusion negative adult anaplastic ST-EPN. RELA fusions are frequent in ST-EPNs and associate with poor outcome. L1CAM is a surrogate immunohistochemical marker. RELA fusion positive ST-EPNs strongly express nestin indicating increased stemness. Further evaluation of the interactions between NFKB and stem cell pathways is warranted.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaAD  - CSIR, IGIB, Genom & Mol Med Unit, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - MAY
PY  - 2018
VL  - 138
IS  - 1
SP  - 29
EP  - 39
DO  - 10.1007/s11060-018-2767-y
AN  - WOS:000431211800003
ER  -

TY  - JOUR
AU  - Mary, MCH
AU  - Singh, D
AU  - Deepak, KK
TI  - Impact of respiration on cardiovascular coupling using Granger causality analysis in healthy subjects
T2  - BIOMEDICAL SIGNAL PROCESSING AND CONTROL
KW  - Deep breathing
KW  - RR interval
KW  - Systolic blood pressure
KW  - Respiration
KW  - Spectral analysis
KW  - HEART-RATE-VARIABILITY
KW  - POWER SPECTRAL-ANALYSIS
KW  - BLOOD-PRESSURE
KW  - SINUS ARRHYTHMIA
KW  - FREQUENCY
KW  - PATTERN
KW  - MODELS
AB  - This quantitative study delineates the influence of respiratory rate on cardiovascular signal in healthy subjects using granger causality approach. Electrocardiogram (RR), arterial blood pressure (SBP) and respiration (RESP) were simultaneously recorded for 5 min from 20 subjects during normal (13-20 cycles/min) and deep breathing (5 cycles/min) with equal inspiration and expiration time. During deep breathing mean RR remains same but the variance increases. Also deep breathing lowers blood pressure, increases baroreflex sensitivity and improves oxygen saturation. The traditional frequency domain methods based power spectrum analysis and coherence analysis lacks to measure coupling changes among physiological subsystems. Therefore, frequency domain Granger causality method based on directed coherence is proposed to detect the changes in coupling strength among cardiovascular signals under different respiration rates. Directed coherence spectrum can separate RESP, SBP and RR components from each recorded signals. The RESP component of both RR (RRRESP) and SBP (SBPRESP) increases (coherence > 0.5) significantly during deep breathing indicate that respiration affects both cardiac and vascular system but at normal breathing only cardiac system (RRRESP) get affected by respiration. Also a significant increase in coherence is observed on baroreflex direction (RRSBP) indicating that deep breathing controls blood pressure. Hence, the observed directed coherence spectrum helps to detect coupling changes among cardiac, vascular and respiratory signal during autonomic regulation. (C) 2018 Elsevier Ltd. All rights reserved.
AD  - Dr BR Ambedkar Natl Inst Technol Jalandhar, Dept Instrumentat & Control, Jalandhar 144011, Punjab, IndiaAD  - All India Inst Med Sci, Dept Physiol, New Delhi 110029, IndiaC3  - National Institute of Technology (NIT System)C3  - Dr B R Ambedkar National Institute of Technology JalandharC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - MAY
PY  - 2018
VL  - 43
SP  - 196
EP  - 203
DO  - 10.1016/j.bspc.2018.03.008
AN  - WOS:000432508100018
ER  -

TY  - JOUR
AU  - Mokdad, AH
AU  - Charara, R
AU  - El Bcheraoui, C
AU  - Khalil, I
AU  - Moradi-Lakeh, M
AU  - Afshin, A
AU  - Kassebaum, NJ
AU  - Collison, M
AU  - Krohn, KJ
AU  - Chew, A
AU  - Daoud, F
AU  - Charlson, FJ
AU  - Colombara, D
AU  - Degenhardt, L
AU  - Ehrenkranz, R
AU  - Erskine, HE
AU  - Ferrari, AJ
AU  - Kutz, M
AU  - Leung, J
AU  - Santomauro, D
AU  - Wang, HD
AU  - Whiteford, HA
AU  - Abajobir, AA
AU  - Abd-Allah, F
AU  - Abraha, HN
AU  - Abu-Raddad, LJ
AU  - Kiadaliri, AA
AU  - Ahmadi, A
AU  - Yimam, K
AU  - Beshir, M
AU  - Al Lami, FH
AU  - Alam, K
AU  - Alasfoor, D
AU  - Alizadeh-Navaei, R
AU  - Alkaabi, JM
AU  - Al-Maskari, F
AU  - Al-Raddadi, R
AU  - Altirkawi, KA
AU  - Anber, N
AU  - Ansari, H
AU  - Asayesh, H
AU  - Asghar, RJ
AU  - Atey, TM
AU  - Ayele, TA
AU  - Bärnighausen, T
AU  - Bacha, U
AU  - Barac, A
AU  - Barker-Collo, SL
AU  - Baune, BT
AU  - Bazargan-Hejazi, S
AU  - Drew, CR
AU  - Geffen, D
AU  - Bedi, N
AU  - Bensenor, IM
AU  - Berhane, A
AU  - Beyene, AS
AU  - Bhutta, ZA
AU  - Boneya, DJ
AU  - Borschmann, R
AU  - Breitborde, NJK
AU  - Butt, ZA
AU  - Catalá-López, F
AU  - Ciobanu, LG
AU  - Danawi, H
AU  - Deribew, A
AU  - Dharmaratne, SD
AU  - Doyle, KE
AU  - Endries, AY
AU  - Faraon, EJA
AU  - Faro, A
AU  - Farvid, MS
AU  - Fekadu, W
AU  - Fereshtehnejad, SM
AU  - Fischer, F
AU  - Gebrehiwot, TT
AU  - Giref, AZ
AU  - Gishu, MD
AU  - Carvalho, A
AU  - Habtewold, TD
AU  - Hamadeh, RR
AU  - Hambisa, MT
AU  - Hamidi, S
AU  - Haro, JM
AU  - Hassanvand, MS
AU  - Horita, N
AU  - Hsairi, M
AU  - Huang, H
AU  - Husseini, A
AU  - Jakovljevic, MB
AU  - James, SL
AU  - Jonas, JB
AU  - Kasaeian, A
AU  - Khader, YS
AU  - Khan, EA
AU  - Khoja, ATA
AU  - Khosravi, A
AU  - Khubchandani, J
AU  - Kim, D
AU  - Kim, YJ
AU  - Kokubo, Y
AU  - Koyanagi, A
AU  - Defo, BK
AU  - Larson, HJ
AU  - Latif, AA
AU  - Lee, PH
AU  - Leshargie, CT
AU  - Leung, R
AU  - Lo, LT
AU  - Lunevicius, R
AU  - Abd El Razek, HM
AU  - Abd El Razek, MM
AU  - Majdzadeh, R
AU  - Majeed, A
AU  - Malekzadeh, R
AU  - Martinez-Raga, J
AU  - Farid, HM
AU  - Mazidi, M
AU  - McGrath, JJ
AU  - Memish, ZA
AU  - Mendoza, W
AU  - Mengesha, MM
AU  - Mengistie, MA
AU  - Mezgebe, HB
AU  - Miller, TR
AU  - Mitchell, PB
AU  - Mohammadi, A
AU  - Mohammed, S
AU  - Obermeyer, CM
AU  - Ogbo, FA
AU  - Castillo, EP
AU  - Papachristou, C
AU  - Patten, SB
AU  - Patton, GC
AU  - Pervaiz, A
AU  - Phillips, MR
AU  - Pourmalek, F
AU  - Qorbani, M
AU  - Radfar, A
AU  - Rafay, A
AU  - Rahimi-Movaghar, V
AU  - Rai, RK
AU  - Rawaf, DL
AU  - Rawaf, S
AU  - Refaat, AH
AU  - Rezaei, S
AU  - Rezai, MS
AU  - Roshandel, G
AU  - Safdarian, M
AU  - Safiabadi, M
AU  - Safiri, S
AU  - Sagar, R
AU  - Sahraian, MA
AU  - Salamati, P
AU  - Samy, AM
AU  - Sartorius, B
AU  - Saylan, MI
AU  - Seedat, S
AU  - Sepanlou, SG
AU  - Shaikh, MA
AU  - Shamsizadeh, M
AU  - Silva, DAS
AU  - Singh, JA
AU  - Sobaih, BHA
AU  - Stein, DJ
AU  - Abdulkader, RS
AU  - Sykes, BL
AU  - Tabarés-Seisdedos, R
AU  - Tabb, KM
AU  - Tehrani-Banihashemi, A
AU  - Temsah, MH
AU  - Terkawi, AS
AU  - Topor-Madry, R
AU  - Ukwaja, KN
AU  - Uthman, OA
AU  - Vollset, SE
AU  - Wakayo, T
AU  - Wang, YP
AU  - Werdecker, A
AU  - Westerman, R
AU  - Workicho, A
AU  - Yaghoubi, M
AU  - Yimam, HH
AU  - Yonemoto, N
AU  - Younis, MZ
AU  - Yu, CH
AU  - Zaki, ME
AU  - Zein, B
AU  - Jumaan, AO
AU  - Vos, T
AU  - Hay, SI
AU  - Naghavi, M
AU  - Murray, CJL
A1  - GBD 2015 Eastern Mediterranean Reg
TI  - The burden of mental disorders in the Eastern Mediterranean region, 1990-2015: findings from the global burden of disease 2015 study
T2  - INTERNATIONAL JOURNAL OF PUBLIC HEALTH
KW  - Mental health
KW  - Eastern Mediterranean region
KW  - Burden of disease
KW  - Depressive disorders
KW  - Anxiety disorders
KW  - SYSTEMATIC ANALYSIS
KW  - HEALTH
KW  - INJURIES
AB  - Mental disorders are among the leading causes of nonfatal burden of disease globally.
   We used the global burden of diseases, injuries, and risk factors study 2015 to examine the burden of mental disorders in the Eastern Mediterranean region (EMR). We defined mental disorders according to criteria proposed in the diagnostic and statistical manual of mental disorders IV and the 10th International Classification of Diseases.
   Mental disorders contributed to 4.7% (95% uncertainty interval (UI) 3.7-5.6%) of total disability-adjusted life-years (DALYs), ranking as the ninth leading cause of disease burden. Depressive disorders and anxiety disorders were the third and ninth leading causes of nonfatal burden, respectively. Almost all countries in the EMR had higher age-standardized mental disorder DALYs rates compared to the global level, and in half of the EMR countries, observed mental disorder rates exceeded the expected values.
   The burden of mental disorders in the EMR is higher than global levels, particularly for women. To properly address this burden, EMR governments should implement nationwide quality epidemiological surveillance of mental disorders and provide adequate prevention and treatment services.
AD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - Amer Univ Beirut, Beirut, LebanonAD  - Iran Univ Med Sci, Prevent Med & Publ Hlth Res Ctr, Gastrointestinal & Liver Dis Res Ctr, Dept Community Med, Tehran, IranAD  - Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, Seattle, WA USAAD  - Univ Queensland, Sch Publ Hlth, Brisbane, Qld, AustraliaAD  - Queensland Ctr Mental Hlth Res, Brisbane, Qld, AustraliaAD  - Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, AustraliaAD  - Cairo Univ, Dept Neurol, Cairo, EgyptAD  - Mekelle Univ, Mekelle, EthiopiaAD  - Weill Cornell Med Coll Qatar, Infect Dis Epidemiol Grp, Doha, QatarAD  - Lund Univ, Orthoped Clin Epidemiol Unit, Dept Clin Sci Lund, Lund, SwedenAD  - Kermanshah Univ Med Sci, Kermanshah, IranAD  - Debre Markos Univ, Debre Markos, EthiopiaAD  - Jimma Univ, Coll Hlth Sci, Dept Epidemiol, Jimma, EthiopiaAD  - Baghdad Coll Med, Baghdad, IraqAD  - Univ Melbourne, Murdoch Childrens Res Inst, Parkville, Vic, AustraliaAD  - Univ Melbourne, Melbourne, Vic, AustraliaAD  - Univ Sydney, Sydney, NSW, AustraliaAD  - Minist Hlth, Al Khuwair, OmanAD  - Mazandaran Univ Med Sci, Gastrointestinal Canc Res Ctr, Sari, IranAD  - United Arab Emirates Univ, Coll Med & Hlth Sci, Al Ain, U Arab EmiratesAD  - Joint Program Family & Community Med, Jeddah, Saudi ArabiaAD  - King Saud Univ, Riyadh, Saudi ArabiaAD  - Mansoura Univ, Mansoura, EgyptAD  - Zahedan Univ Med Sci, Dept Epidemiol & Biostat, Hlth Promot Res Ctr, Zahedan, IranAD  - Qom Univ Med Sci, Sch Paramed, Dept Med Emergency, Qom, IranAD  - South Asian Publ Hlth Forum, Islamabad, PakistanAD  - Univ Gondar, Gondar, EthiopiaAD  - Harvard Univ, Dept Global Hlth & Populat, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USAAD  - Africa Hlth Res Inst, Mtu batuba, Mtubatuba, Kwazulu Natal, South AfricaAD  - Heidelberg Univ, Inst Publ Hlth, Heidelberg, GermanyAD  - Univ Management & Technol, Sch Hlth Sci, Lahore, PakistanAD  - Univ Belgrade, Fac Med, Belgrade, SerbiaAD  - Univ Auckland, Sch Psychol, Auckland, New ZealandAD  - Univ Adelaide, Sch Med, Adelaide, SA, AustraliaAD  - Charles R Drew Univ Med & Sci, Coll Med, 1621 E 120th St, Los Angeles, CA 90059 USAAD  - Univ Calif Los Angeles, Sch Med, Los Angeles, CA USAAD  - Coll Publ Hlth & Trop Med, Jazan, Saudi ArabiaAD  - Univ Sao Paulo, Sao Paulo, BrazilAD  - Debre Berhan Univ, Coll Hlth Sci, Debre Berhan, EthiopiaAD  - Haramaya Univ, Coll Hlth & Med Sci, Harar, EthiopiaAD  - Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, PakistanAD  - Hosp Sick Children, Ctr Global Child Hlth, Toronto, ON, CanadaAD  - Debre Markos Univ, Dept Publ Hlth, Debre Markos, EthiopiaAD  - Ohio State Univ, Columbus, OH 43210 USAAD  - Al Shifa Trust Eye Hosp, Rawalpindi, PakistanAD  - Univ Valencia, INCLIVA Hlth Res Inst, Dept Med, Valencia, SpainAD  - CIBERSAM, Valencia, SpainAD  - Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, CanadaAD  - Walden Univ, Minneapolis, MN USAAD  - Univ Oxford, Nuffield Dept Med, Oxford, EnglandAD  - KEMRI Wellcome Trust Res Programme, Kilifi, KenyaAD  - Univ Peradeniya, Dept Community Med, Fac Med, Peradeniya, Sri LankaAD  - RMIT Univ, Bundoora, Vic, AustraliaAD  - Australian Natl Univ, Canberra, ACT, AustraliaAD  - Arba Minch Univ, Arba Minch, EthiopiaAD  - Univ Philippines Manila, Coll Publ Hlth, Manila, PhilippinesAD  - Dept Hlth, Manila, PhilippinesAD  - Univ Fed Sergipe, Aracaju, BrazilAD  - Harvard Univ, Dept Nutr, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USAAD  - Massachusetts Gen Hosp, Harvard MGH Ctr Gen Vulnerable Populat & Hlth Dis, Mongan Inst Hlth Policy, Boston, MA 02114 USAAD  - Bahir Dar Univ, Bahir Dar, EthiopiaAD  - Karolinska Inst, Dept Neurobiol Care Sci & Soc NVS, Stockholm, SwedenAD  - Univ Bielefeld, Sch Publ Hlth, Bielefeld, GermanyAD  - Jimma Univ, Jimma, EthiopiaAD  - Addis Ababa Univ, Addis Ababa, EthiopiaAD  - Haramaya Univ, Dire Dawa, EthiopiaAD  - Kersa Hlth & Demog Surveillance Syst, Harar, EthiopiaAD  - Univ Sao Paulo, Hosp Univ, Ctr Clin & Epidemiol Res Center, Sao Paulo, BrazilAD  - Ctr Check Hosp Sirio Libanes, Sao Paulo, BrazilAD  - Univ Groningen, Groningen, NetherlandsAD  - Debre Berhan Univ, Debre Berhan, EthiopiaAD  - Arabian Gulf Univ, Manama, BahrainAD  - Hamdan Bin Mohammed Smart Univ, Dubai, U Arab EmiratesAD  - Parc Sanitari St Joan CIBERSAM, St Boi De Llobregat, Barcelona, SpainAD  - Univ Tehran Med Sci, Inst Environm Res, Ctr Air Pollut Res, Tehran, IranAD  - Yokohama City Univ, Dept Pulmonol, Grad Sch Med, Yokohama, Kanagawa, JapanAD  - Salah Azaiz Inst, Dept Epidemiol, Tunis, TunisiaAD  - Cambridge Hlth Alliance, Cambridge, MA USAAD  - Birzeit Univ, Inst Community & Publ Hlth, Birzeit, PalestineAD  - Univ Kragujevac, Fac Med Sci, Kragujevac, SerbiaAD  - Univ Washington, Ctr Hlth Trends & Forecasts, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - Univ Colorado, Denver Health, Denver, CO 80202 USAAD  - Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, GermanyAD  - Univ Tehran Med Sci, Hematol Oncol & Stem Cell Transplantat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Endocrinol & Metab Populat Sci Inst, Tehran, IranAD  - Jordan Univ Sci & Technol, Dept Community Med Publ Hlth & Family Med, Irbid, JordanAD  - Hlth Serv Acad, Islamabad, PakistanAD  - Mohammed Ibn Saudi Univ, Riyadh, Saudi ArabiaAD  - Iranian Minist Hlth & Med Educ, Tehran, IranAD  - Univ Tehran Med Sci, Noncommunicable Dis Res Ctr, Tehran, IranAD  - Ball State Univ, Dept Nutr & Hlth Sci, Muncie, IN 47306 USAAD  - Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USAAD  - Southern Univ Coll, Fac Chinese Med, Skudai, MalaysiaAD  - Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Suita, Osaka, JapanAD  - Parc Sanitari St Joan Deu CIBERSAM, Res & Dev Unit, Barcelona, SpainAD  - Univ Montreal, Sch Publ Hlth, Dept Social & Prevent Med, Montreal, PQ, CanadaAD  - Univ Montreal, Dept Demog & Publ Hlth Res Inst, Montreal, PQ, CanadaAD  - London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, EnglandAD  - Lahore Coll Women Univ, Dept Zool, Lahore, Punjab, PakistanAD  - Hong Kong Polytech Univ, Hong Kong, Hong Kong, Peoples R ChinaAD  - SUNY Albany, Albany, NY 12222 USAAD  - UnionHlth Associates LLC, St Louis, MO USAAD  - Alton Mental Hlth Ctr, Alton, IL USAAD  - Aintree Univ Hosp NHS Fdn Trust, Natl Hlth Serv Fdn Trust, Liverpool, Merseyside, EnglandAD  - Univ Liverpool, Sch Med, Liverpool, Merseyside, EnglandAD  - Fac Management Med, Mansoura, EgyptAD  - Aswan Univ Hosp, Aswan Fac Med, Aswan, EgyptAD  - Univ Tehran Med Sci, Knowledge Utilizat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Community Based Participatory Res Ctr, Tehran, IranAD  - Imperial Coll London, Dept Primary Care & Publ Hlth, London, EnglandAD  - Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, IranAD  - Hosp Univ Doctor Peset, Valencia, SpainAD  - CEU Cardinal Herrera Univ, Moncada, SpainAD  - State Welf Org, Tehran, IranAD  - Chinese Acad Sci, Inst Genet & Dev Biol, Key State Lab Mol Dev Biol, Beijing, Peoples R ChinaAD  - Queensland Ctr Mental Hlth Res, Pk Ctr Mental Hlth, Wacol, Qld, AustraliaAD  - Univ Queensland, Queensland Brain Inst, St Lucia, Qld, AustraliaAD  - Aarhus Univ, Aarhus Sch Business & Social Sci, Natl Ctr Register Based Res, Aarhus, DenmarkAD  - Saudi Minist Hlth, Riyadh, Saudi ArabiaAD  - Alfaisal Univ Riyadh, Coll Med, Riyadh, Saudi ArabiaAD  - United Nations Populat Fund, Lima, PeruAD  - Jimma Univ, Jimma, EthiopiaAD  - Mekelle Univ, Mekelle, EthiopiaAD  - Pacific Inst Res & Evaluat, Calverton, MD USAAD  - Curtin Univ, Ctr Populat Hlth, Perth, WA, AustraliaAD  - Univ New South Wales, Kensington, NSW, AustraliaAD  - Baqiyatallah Univ Med Sci, Neurosci Res Ctr, Tehran, IranAD  - Ahmadu Bello Univ, Hlth Syst & Policy Res Unit, Zaria, NigeriaAD  - Heidelberg Univ, Inst Publ Hlth, Heidelberg, GermanyAD  - Amer Univ Beirut, Ctr Res Populat & Hlth, Fac Hlth Sci, Beirut, LebanonAD  - Western Sydney Univ, Ctr Hlth Res, Sydney, NSW, AustraliaAD  - Minist Hlth, Mexico City, DF, MexicoAD  - Univ Nacl Autonoma Mexico, Mexico City, DF, MexicoAD  - Charite, Berlin, GermanyAD  - Univ Calgary, Dept Community Hlth Sci, Calgary, AB, CanadaAD  - Univ Melbourne, Dept Paediat, Murdoch Childrens Res Inst, Melbourne, Vic, AustraliaAD  - Postgrad Med Inst, Lahore, PakistanAD  - Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R ChinaAD  - Emory Univ, Atlanta, GA 30322 USAAD  - Univ British Columbia, Vancouver, BC, CanadaAD  - Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, IranAD  - AT Still Univ, Kirksville, MO USAAD  - Contech Int Hlth Consultants, Lahore, PakistanAD  - Contech Sch Publ Hlth, Lahore, PakistanAD  - Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, IranAD  - Soc Hlth & Demog Surveillance, Suri, IndiaAD  - WHO Collaborating Ctr, Imperial Coll London, London, EnglandAD  - North Hampshire Hosp, Basingstoke, EnglandAD  - Imperial Coll London, London, EnglandAD  - Walden Univ, Minneapolis, MN USAAD  - Suez Canal Univ, Ismailia, EgyptAD  - Kermanshah Univ Med Sci, Sch Publ Hlth, Kermanshah, IranAD  - Mazandaran Univ Med Sci, Infect Dis Res Ctr Focus Nosocomial Infect, Sari, Mazandaran, IranAD  - Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, IranAD  - Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, IranAD  - Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, IranAD  - Baqiyatallah Univ Med Sci, Student Res Comm, Tehran, IranAD  - Maragheh Univ Med Sci, Sch Nursing & Midwifery, Dept Publ Hlth, Managerial Epidemiol Res Ctr, Maragheh, IranAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Univ Tehran Med Sci, Neurosci Inst, Res Ctr, Tehran, IranAD  - Ain Shams Univ, Cairo, EgyptAD  - Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Publ Hlth Med, Durban, South AfricaAD  - SAMRC, UKZN Gastrointestinal Canc Res Ctr, Durban, South AfricaAD  - Bayer Turkey, Istanbul, TurkiyeAD  - Stellenbosch Univ, Cape Town, South AfricaAD  - Hamadan Univ Med Sci, Sch Nursing & Midwifery, Dept Med Surg Nursing, Hamadan, IranAD  - Univ Fed Santa Catarina, Florianopolis, SC, BrazilAD  - Univ Alabama Birmingham, Vet Affairs Med Ctr, Birmingham, AL USAAD  - Univ Cape Town, Dept Psychiat, Cape Town, South AfricaAD  - South African Med Res Council Unit Anxiety & Stre, Cape Town, South AfricaAD  - Minist Hlth, Riyadh, Saudi ArabiaAD  - Univ Calif Irvine, Dept Criminol Law & Soc, Irvine, CA USAAD  - Univ Calif Irvine, Dept Sociol & Publ Hlth, Irvine, CA USAAD  - Univ Valencia, Dept Med, INCLIVA Hlth Res Inst, Valencia, SpainAD  - CIBERSAM, Valencia, SpainAD  - Univ Illinois, Sch Social Work, Champaign, IL USAAD  - Iran Univ Med Sci, Prevent Med & Publ Hlth Res Ctr, Tehran, IranAD  - Univ Virginia, Dept Anesthesiol, Charlottesville, VA USAAD  - King Fahad Med City, Dept Anesthesiol, Riyadh, Saudi ArabiaAD  - Cleveland Clin, Outcomes Res Consortium, Cleveland, OH USAAD  - Jagiellonian Univ, Inst Publ Hlth, Fac Hlth Sci, Med Coll, Krakow, PolandAD  - Wroclaw Med Univ, Fac Hlth Sci, Krakow, PolandAD  - Fed Teaching Hosp, Dept Internal Med, Abakaliki, NigeriaAD  - Univ Warwick, Warwick Med Sch, Coventry, W Midlands, EnglandAD  - Norwegian Inst Publ Hlth, Ctr Dis Burden, Bergen, NorwayAD  - Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, NorwayAD  - Jimma Univ, Oromia, EthiopiaAD  - Univ Sao Paulo, Sch Med, Sao Paulo, BrazilAD  - Fed Inst Populat Res, Competence Ctr Mortal Follow Up, German Natl Cohort, Wiesbaden, GermanyAD  - Fed Inst Populat Res, Wiesbaden, GermanyAD  - German Natl Cohort Consortium, Heidelberg, GermanyAD  - Jimma Univ, Jimma, EthiopiaAD  - Univ Ghent, Ghent, BelgiumAD  - Univ Saskatchewan, Sch Publ Hlth, Saskatoon, SK, CanadaAD  - Mizan Tepi Univ, Mizan Teferi, EthiopiaAD  - Kyoto Univ, Sch Publ Hlth, Dept Biostat, Kyoto, JapanAD  - Jackson State Univ, Jackson, MS USAAD  - Wuhan Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan, Hubei, Peoples R ChinaAD  - Wuhan Univ, Global Hlth Inst, Wuhan, Hubei, Peoples R ChinaAD  - Mansoura Univ, Fac Med, Mansoura, EgyptAD  - Georgetown Univ, Dept Neurosci, Washington, DC USAAD  - Univ Oxford, Oxford Big Data Inst, Li Ka Shing Ctr Hlth Informat & Discovery, Oxford, EnglandC3  - University of WashingtonC3  - University of Washington SeattleC3  - Institute for Health Metrics & EvaluationC3  - American University of BeirutC3  - Iran University of Medical SciencesC3  - Seattle Children's HospitalC3  - University of QueenslandC3  - Queensland Centre for Mental Health ResearchC3  - University of New South Wales SydneyC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Mekelle UniversityC3  - Qatar Foundation (QF)C3  - Weill Cornell Medical College QatarC3  - Lund UniversityC3  - Kermanshah University of Medical SciencesC3  - Jimma UniversityC3  - University of MelbourneC3  - Murdoch Children's Research InstituteC3  - University of MelbourneC3  - University of SydneyC3  - Mazandaran University of Medical SciencesC3  - United Arab Emirates UniversityC3  - King Saud UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Zahedan University of Medical SciencesC3  - University of GondarC3  - Harvard UniversityC3  - Harvard T.H. Chan School of Public HealthC3  - Africa Health Research InstituteC3  - Ruprecht Karls University HeidelbergC3  - University of Management & Technology (UMT)C3  - University of BelgradeC3  - University of AucklandC3  - University of AdelaideC3  - Charles R. Drew University of Medicine & ScienceC3  - University of California SystemC3  - University of California Los AngelesC3  - University of California Los Angeles Medical CenterC3  - David Geffen School of Medicine at UCLAC3  - Universidade de Sao PauloC3  - Haramaya UniversityC3  - Aga Khan UniversityC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - University System of OhioC3  - Ohio State UniversityC3  - University of ValenciaC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERSAMC3  - University of OttawaC3  - Ottawa Hospital Research InstituteC3  - Walden UniversityC3  - University of OxfordC3  - University of PeradeniyaC3  - Royal Melbourne Institute of Technology (RMIT)C3  - Australian National UniversityC3  - Arba Minch UniversityC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - Philippine Department HealthC3  - Universidade Federal de SergipeC3  - Harvard UniversityC3  - Harvard T.H. Chan School of Public HealthC3  - Harvard UniversityC3  - Massachusetts General HospitalC3  - Bahir Dar UniversityC3  - Karolinska InstitutetC3  - University of BielefeldC3  - Jimma UniversityC3  - Addis Ababa UniversityC3  - Haramaya UniversityC3  - Universidade de Sao PauloC3  - University of GroningenC3  - Arabian Gulf UniversityC3  - Tehran University of Medical SciencesC3  - Yokohama City UniversityC3  - Universite de Tunis-El-ManarC3  - Institut Salah AzaiezC3  - Harvard UniversityC3  - Cambridge Health AllianceC3  - Birzeit UniversityC3  - University of KragujevacC3  - University of WashingtonC3  - University of Washington SeattleC3  - Institute for Health Metrics & EvaluationC3  - University of Colorado SystemC3  - University of Colorado DenverC3  - Ruprecht Karls University HeidelbergC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Jordan University of Science & TechnologyC3  - Health Services AcademyC3  - Ministry of Health & Medical Education (MOHME)C3  - Tehran University of Medical SciencesC3  - Ball State UniversityC3  - Northeastern UniversityC3  - National Cerebral & Cardiovascular Center - JapanC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERSAMC3  - Universite de MontrealC3  - Universite de MontrealC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - Hong Kong Polytechnic UniversityC3  - State University of New York (SUNY) SystemC3  - University at Albany, SUNYC3  - Aintree University Hospitals NHS Foundation TrustC3  - University of LiverpoolC3  - Egyptian Knowledge Bank (EKB)C3  - Aswan UniversityC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Imperial College LondonC3  - Tehran University of Medical SciencesC3  - Universidad CEU Cardenal HerreraC3  - Chinese Academy of SciencesC3  - Institute of Genetics & Developmental Biology, CASC3  - Queensland Centre for Mental Health ResearchC3  - University of QueenslandC3  - Aarhus UniversityC3  - United Nations Population FundC3  - Jimma UniversityC3  - Mekelle UniversityC3  - Pacific Institute for Research & Evaluation (PIRE)C3  - Curtin UniversityC3  - University of New South Wales SydneyC3  - Baqiyatallah University of Medical Sciences (BMSU)C3  - Ahmadu Bello UniversityC3  - Ruprecht Karls University HeidelbergC3  - American University of BeirutC3  - Western Sydney UniversityC3  - Universidad Nacional Autonoma de MexicoC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - University of CalgaryC3  - Murdoch Children's Research InstituteC3  - University of MelbourneC3  - Shanghai Jiao Tong UniversityC3  - Emory UniversityC3  - University of British ColumbiaC3  - A.T. Still University of Health SciencesC3  - Tehran University of Medical SciencesC3  - Imperial College LondonC3  - World Health OrganizationC3  - Imperial College LondonC3  - Walden UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Suez Canal UniversityC3  - Kermanshah University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Golestan University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Baqiyatallah University of Medical Sciences (BMSU)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Tehran University of Medical SciencesC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - University of Kwazulu NatalC3  - Stellenbosch UniversityC3  - Hamadan University of Medical SciencesC3  - Universidade Federal de Santa Catarina (UFSC)C3  - US Department of Veterans AffairsC3  - Veterans Health Administration (VHA)C3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - University of Cape TownC3  - Ministry of Health - Saudi ArabiaC3  - University of California SystemC3  - University of California IrvineC3  - University of California SystemC3  - University of California IrvineC3  - University of ValenciaC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERSAMC3  - University of Illinois SystemC3  - University of Illinois Urbana-ChampaignC3  - Iran University of Medical SciencesC3  - University of VirginiaC3  - King Fahad Medical CityC3  - Cleveland Clinic FoundationC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - Wroclaw Medical UniversityC3  - University of WarwickC3  - Norwegian Institute of Public Health (NIPH)C3  - University of BergenC3  - Jimma UniversityC3  - Universidade de Sao PauloC3  - Jimma UniversityC3  - Ghent UniversityC3  - University of SaskatchewanC3  - Kyoto UniversityC3  - Jackson State UniversityC3  - Wuhan UniversityC3  - Wuhan UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Georgetown UniversityC3  - University of OxfordPU  - FRONTIERS MEDIA SA
PI  - LAUSANNE
PA  - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
DA  - MAY
PY  - 2018
VL  - 63
SP  - 25
EP  - 37
DO  - 10.1007/s00038-017-1006-1
AN  - WOS:000433519400006
ER  -

TY  - JOUR
AU  - Mokdad, AH
AU  - Khalil, I
AU  - Collison, M
AU  - El Bcheraoui, C
AU  - Charara, R
AU  - Moradi-Lakeh, M
AU  - Afshin, A
AU  - Chew, A
AU  - Daoud, F
AU  - Krohn, KJ
AU  - Colombara, D
AU  - Ehrenkranz, R
AU  - Kutz, M
AU  - Wang, HD
AU  - Abajobir, AA
AU  - Abd-Allah, F
AU  - Abraha, HN
AU  - Abu-Raddad, LJ
AU  - Kiadaliri, AA
AU  - Ahmadi, A
AU  - Ahmed, KY
AU  - Ahmed, MB
AU  - Al Lami, FH
AU  - Alam, K
AU  - Alasfoor, D
AU  - Alizadeh-Navaei, R
AU  - Alkaabi, JM
AU  - Al-Maskari, F
AU  - Al-Raddadi, R
AU  - Altirkawi, KA
AU  - Anber, N
AU  - Ansari, H
AU  - Asayesh, H
AU  - Asghar, RJ
AU  - Atey, TM
AU  - Ayele, TA
AU  - Bärnighausen, T
AU  - Bacha, U
AU  - Barac, A
AU  - Barker-Collo, SL
AU  - Baune, BT
AU  - Bazargan-Hejazi, S
AU  - Geffen, D
AU  - Bedi, N
AU  - Bensenor, IM
AU  - Berhane, A
AU  - Beyene, AS
AU  - Bhutta, ZA
AU  - Boneya, DJ
AU  - Borschmann, R
AU  - Breitborde, NJK
AU  - Butt, ZA
AU  - Catalá-López, F
AU  - Ciobanu, LG
AU  - Danawi, H
AU  - Deribew, A
AU  - Dharmaratne, SD
AU  - Doyle, KE
AU  - Endries, AY
AU  - Faraon, EJA
AU  - Faro, A
AU  - Farvid, MS
AU  - Fekadu, W
AU  - Fereshtehnejad, SM
AU  - Fischer, F
AU  - Gebrehiwot, TT
AU  - Giref, AZ
AU  - Gishu, MD
AU  - Goulart, AC
AU  - Habtewold, TD
AU  - Hamadeh, RR
AU  - Hambisa, MT
AU  - Hamidi, S
AU  - Haro, JM
AU  - Hassanvand, MS
AU  - Horita, N
AU  - Hsairi, M
AU  - Huang, H
AU  - Husseini, A
AU  - Jakovljevic, MB
AU  - James, SL
AU  - Jonas, JB
AU  - Kasaeian, A
AU  - Khader, YS
AU  - Khan, EA
AU  - Khoja, ATA
AU  - Khosravi, A
AU  - Khubchandani, J
AU  - Kim, D
AU  - Kim, YJ
AU  - Kokubo, Y
AU  - Koyanagi, A
AU  - Defo, BK
AU  - Larson, HJ
AU  - Latif, AA
AU  - Lee, PH
AU  - Leshargie, CT
AU  - Leung, R
AU  - Lo, LT
AU  - Lunevicius, R
AU  - Abd El Razek, HM
AU  - Abd El Razek, MM
AU  - Majdzadeh, R
AU  - Majeed, A
AU  - Malekzadeh, R
AU  - Martinez-Raga, J
AU  - Farid, HM
AU  - Mazidi, M
AU  - McGrath, JJ
AU  - Memish, ZA
AU  - Mendoza, W
AU  - Mengesha, MM
AU  - Mengistie, MA
AU  - Mensah, GA
AU  - Mezgebe, HB
AU  - Miller, TR
AU  - Mitchell, PB
AU  - Mohammadi, A
AU  - Mohammed, S
AU  - Obermeyer, CM
AU  - Ogbo, FA
AU  - Castillo, EP
AU  - Papachristou, C
AU  - Patten, SB
AU  - Patton, GC
AU  - Pereira, DM
AU  - Pervaiz, A
AU  - Phillips, MR
AU  - Pourmalek, F
AU  - Qorbani, M
AU  - Radfar, A
AU  - Rafay, A
AU  - Rahimi-Movaghar, V
AU  - Rai, RK
AU  - Rawaf, DL
AU  - Rawaf, S
AU  - Refaat, AH
AU  - Rezaei, S
AU  - Rezai, MS
AU  - Roshandel, G
AU  - Safdarian, M
AU  - Safiabadi, M
AU  - Safiri, S
AU  - Sagar, R
AU  - Sahraian, MA
AU  - Salamati, P
AU  - Samy, AM
AU  - Sartorius, B
AU  - Saylan, MI
AU  - Seedat, S
AU  - Sepanlou, SG
AU  - Shaikh, MA
AU  - Shamsizadeh, M
AU  - Silva, DAS
AU  - Singh, JA
AU  - Sobaih, BHA
AU  - Sreeramareddy, CT
AU  - Stein, DJ
AU  - Abdulkader, RS
AU  - Sykes, BL
AU  - Tabarés-Seisdedos, R
AU  - Sufiyan, M
AU  - Tabb, KM
AU  - Tehrani-Banihashemi, A
AU  - Temsah, MH
AU  - Terkawi, AS
AU  - Topor-Madry, R
AU  - Ukwaja, KN
AU  - Uthman, OA
AU  - Vollset, SE
AU  - Wakayo, T
AU  - Wang, YP
AU  - Werdecker, A
AU  - Westerman, R
AU  - Workicho, A
AU  - Yaghoubi, M
AU  - Yimam, HH
AU  - Yonemoto, N
AU  - Younis, MZ
AU  - Yu, CH
AU  - Zaki, ME
AU  - Jumaan, AO
AU  - Vos, T
AU  - Hay, SI
AU  - Naghavi, M
AU  - Kassebaum, NJ
AU  - Murray, CJL
A1  - GBD 2015 Eastern Mediterranean Reg
TI  - Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study
T2  - INTERNATIONAL JOURNAL OF PUBLIC HEALTH
KW  - Maternal mortality
KW  - Maternal health
KW  - Eastern Mediterranean Region
KW  - Burden of disease
KW  - SYSTEMATIC ANALYSIS
KW  - LIFE EXPECTANCY
KW  - HEALTH
KW  - DETERMINANTS
KW  - INFANT
AB  - Assessing the burden of maternal mortality is important for tracking progress and identifying public health gaps. This paper provides an overview of the burden of maternal mortality in the Eastern Mediterranean Region (EMR) by underlying cause and age from 1990 to 2015.
   We used the results of the Global Burden of Disease 2015 study to explore maternal mortality in the EMR countries.
   The maternal mortality ratio in the EMR decreased 16.3% from 283 (241-328) maternal deaths per 100,000 live births in 1990 to 237 (188-293) in 2015. Maternal mortality ratio was strongly correlated with socio-demographic status, where the lowest-income countries contributed the most to the burden of maternal mortality in the region.
   Progress in reducing maternal mortality in the EMR has accelerated in the past 15 years, but the burden remains high. Coordinated and rigorous efforts are needed to make sure that adequate and timely services and interventions are available for women at each stage of reproductive life.
AD  - Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USAAD  - Amer Univ Beirut, Lebanon, NH USAAD  - Univ Med Sci, Dept Community Med Preventat Med, Gastrointestinal & Liver Dis Res Ctr GILDRC, Tehran, IranAD  - Univ Med Sci, Dept Community Med Preventat Med, Publ Hlth Res Ctr, Gastrointestinal & Liver Dis Res Ctr GILDRC, Tehran, IranAD  - Cairo Univ, Dept Neurol, Cairo, EgyptAD  - Mekelle Univ, Mekelle, EthiopiaAD  - Weill Cornell Med Coll Qatar, Infect Dis Epidemiol Grp, Doha, QatarAD  - Lund Univ, Dept Clin Sci Lund, Clin Epidemiol Unit, Orthoped, Lund, SwedenAD  - Kermanshah Univ Med Sci, Kermanshah, IranAD  - Debre Markos Univ, Debre Markos, EthiopiaAD  - Jimma Univ, Coll Hlth Sci, Dept Epidemiol, Jimma, EthiopiaAD  - Baghdad Coll Med, Baghdad, IraqAD  - Univ Melbourne, Murdoch Childrens Res Inst, Parkville, Vic, AustraliaAD  - Univ Melbourne, Melbourne, Vic, AustraliaAD  - Univ Sydney, Sydney, NSW, AustraliaAD  - Minist Hlth, Al Khuwair, OmanAD  - Mazandaran Univ Med Sci, Gastrointestinal Canc Res Ctr, Sari, IranAD  - United Arab Emirates Univ, Coll Med & Hlth Sci, Al Ain City, U Arab EmiratesAD  - Joint Program Family & Community Med, Jeddah, Saudi ArabiaAD  - King Saud Univ, Riyadh, Saudi ArabiaAD  - Mansoura Univ, Mansoura, EgyptAD  - Zahedan Univ Med Sci, Dept Epidemiol & Biostat, Hlth Promot Res Ctr, Zahedan, IranAD  - Qom Univ Med Sci, Sch Paramed, Dept Med Emergency, Qom, IranAD  - S Asian Publ Hlth Forum, Islamabad, PakistanAD  - Mekelle Univ, Mekelle, EthiopiaAD  - Univ Gondar, Gondar, EthiopiaAD  - Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA USAAD  - Africa Hlth Res Inst, Mtubatuba, Kwazulu Natal, South AfricaAD  - Heidelberg Univ, Inst Publ Hlth, Heidelberg, GermanyAD  - Univ Management & Technol, Sch Hlth Sci, Lahore, PakistanAD  - Univ Belgrade, Fac Med, Belgrade, SerbiaAD  - Univ Auckland, Sch Psychol, Auckland, New ZealandAD  - Univ Adelaide, Sch Med, Adelaide, SA, AustraliaAD  - Charles R Drew Univ Med & Sci, Coll Med, 1621 E 120th St, Los Angeles, CA 90059 USAAD  - Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USAAD  - Coll Publ Hlth & Trop Med, Jazan, Saudi ArabiaAD  - Univ Sao Paulo, Sao Paulo, BrazilAD  - Debre Berhan Univ, Coll Hlth Sci, Debre Berhan, EthiopiaAD  - Haramaya Univ, Coll Hlth & Med Sci, Harar, EthiopiaAD  - Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, PakistanAD  - Hosp Sick Children, Ctr Global Child Hlth, Toronto, ON, CanadaAD  - Debre Mar kos Univ, Dept Publ Hlth, Debre Markos, EthiopiaAD  - Univ Melbourne, Melbourne, Vic, AustraliaAD  - Murdoch Childrens Res Inst, Melbourne, Vic, AustraliaAD  - Ohio State Univ, Columbus, OH USAAD  - Al Shifa Trust Eye Hosp, Rawalpindi, Punjab, PakistanAD  - Univ Valencia, Dept Med, INCLIVA Hlth Res Inst, Valencia, SpainAD  - CIBERSAM, Valencia, SpainAD  - Ottawa Hosp, Res Inst, Clin Epidemiol Program, Ottawa, ON, CanadaAD  - Univ Adelaide, Sch Med, Adelaide, SA, AustraliaAD  - Walden Univ, Minneapolis, MN USAAD  - Univ Oxford, Nuffield Dept Med, Oxford, EnglandAD  - KEMRI Wellcome Trust Res Programme, Kilifi, KenyaAD  - Univ Peradeniya, Fac Med, Dept Community Med, Peradeniya, Sri LankaAD  - RMIT Univ, Bundoora, Vic, AustraliaAD  - Australian Natl Univ, Canberra, ACT, AustraliaAD  - Arba Minch Univ, Arba Minch, EthiopiaAD  - Univ Philippines Manila, Coll Publ Hlth, Manila, PhilippinesAD  - Dept Hlth, Manila, PhilippinesAD  - Univ Fed Sergipe, Aracaju, BrazilAD  - Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USAAD  - Massachusetts Gen Hosp, Harvard MGH Ctr Gen Vulnerable Populat & Hlth Dis, Mongan Inst Hlth Policy, Boston, MA 02114 USAAD  - Bahir Dar Univ, Bahir Dar, EthiopiaAD  - Karolinska Inst, Dept Neurobiol Sci & Soc NVS, Stockholm, SwedenAD  - Univ Bielefeld, Sch Publ Hlth, Bielefeld, GermanyAD  - Jimma Univ, Jimma, EthiopiaAD  - Addis Ababa Univ, Addis Ababa, EthiopiaAD  - Haramaya Univ, Dire Dawa, EthiopiaAD  - Kersa Hlth & Demog Surveillance Syst, Harar, EthiopiaAD  - Univ Sao Paulo, Ctr Clin & Epidemiol Res Ctr, Hosp Univ, Sao Paulo, BrazilAD  - Ctr Check Hosp Sirio Libanes, Sao Paulo, BrazilAD  - Univ Groningen, Groningen, NetherlandsAD  - Debre Berhan Univ, Debre Berhan, EthiopiaAD  - Arabian Gulf Univ, Manama, BahrainAD  - Haramaya Univ, Coll Hlth & Med Sci, Harar, EthiopiaAD  - Hamdan Bin Mohammed Smart Univ, Dubai, U Arab EmiratesAD  - Parc Sanitari St Joan de Deu, CIBERSAM, St Boi De Llobregat, Barcelona, SpainAD  - Univ Tehran Med Sci, Inst Environm Res, Ctr Air Pollut Res, Tehran, IranAD  - Yokohama City Univ, Dept Pulmonol, Grad Sch Med, Yokohama, Kanagawa, JapanAD  - Salah Azaiz Inst, Dept Epidemiol, Tunis, TunisiaAD  - Cambridge Hlth Alliance, Cambridge, MA USAAD  - Birzeit Univ, Inst Community & Publ Hlth, Birzeit, PalestineAD  - Univ Kragujevac, Fac Med Sci, Kragujevac, SerbiaAD  - Univ Washington, Inst Hlth Metr & Evaluat, Ctr Hlth Trends & Forecasts, Seattle, WA 98195 USAAD  - Univ Colorado, Denver Hlth, Denver, CO 80202 USAAD  - Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, GermanyAD  - Univ Tehran Med Sci, Hematol Oncol & Stem Cell Transplantat Res Ctr, Tehran, IranAD  - Jordan Univ Sci & Technol, Dept Community Med, Publ Hlth & Family Med, Irbid, JordanAD  - Hlth Serv Acad, Islamabad, PakistanAD  - Mohammed Ibn Saudi Univ, Riyadh, Saudi ArabiaAD  - Iranian Minist Hlth & Med Educ, Tehran, IranAD  - Univ Tehran Med Sci, Noncommunicable Dis Res Ctr, Tehran, IranAD  - Ball State Univ, Dept Nutr & Hlth Sci, Muncie, IN 47306 USAAD  - Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USAAD  - Southern Univ Coll, Fac Chinese Med, Skudai, MalaysiaAD  - Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Suita, Osaka, JapanAD  - Res & Dev Unit, Parc Sanitari Sant Joan Deu CIBERSAM, Barcelona, SpainAD  - Univ Montreal, Sch Publ Hlth, Dept Social & Prevent Med, Montreal, PQ, CanadaAD  - Univ Montreal, Dept Demog & Publ Hlth Res Inst, Montreal, PQ, CanadaAD  - London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, EnglandAD  - Lahore Coll Women Univ, Dept Zool, Lahore, Punjab, PakistanAD  - Hong Kong Polytech Univ, Hong Kong, Hong Kong, Peoples R ChinaAD  - Debre Markos Univ, Debre Markos, EthiopiaAD  - SUNY Albany, Albany, NY 12222 USAAD  - UnionHealth Associates LLC, St Louis, MO USAAD  - Alton Mental Hlth Ctr, Alton, IL USAAD  - Aintree Univ Hosp NHS Fdn Trust, Natl Hlth Serv Fdn Trust, Liverpool, Merseyside, EnglandAD  - Univ Liverpool, Sch Med, Liverpool, Merseyside, EnglandAD  - Mansoura Fac Med, Mansoura, EgyptAD  - Aswan Univ Hosp, Aswan Fac Med, Aswan, EgyptAD  - Univ Tehran Med Sci, Knowledge Utilizat Res Ctr, Tehran, IranAD  - Univ Tehran Med Sci, Community Based Participatory Res Ctr, Tehran, IranAD  - Imperial Coll London, Dept Primary Care Publ Hlth, London, EnglandAD  - Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, IranAD  - Hosp Univ Doctor Peset, Valencia, SpainAD  - CEU Cardinal Herrera Univ, Moncada, SpainAD  - State Welf Org, Tehran, IranAD  - Chinese Acad Sci, Inst Genet & Dev Biol, Key State Lab Mol Dev Biol, Beijing, Peoples R ChinaAD  - Queensland Ctr Mental Hlth Res, Pk Ctr Mental Hlth, Wacol, Qld, AustraliaAD  - Univ Queensland, Queensland Brain Inst, St Lucia, Qld, AustraliaAD  - Aarhus Univ, Aarhus Sch Business & Social Sci, Natl Ctr Register Based Res, Aarhus, DenmarkAD  - Saudi Minist Hlth, Riyadh, Saudi ArabiaAD  - Alfaisal Univ, Coll Med, Riyadh, Saudi ArabiaAD  - United Nations Populat Fund, Lima, PeruAD  - Haramaya Univ, Coll Hlth & Med Sci, Harar, EthiopiaAD  - Jimma Univ, Jimma, EthiopiaAD  - NHLBI, Ctr Translat Res & Implementat Sci, NIH, Bethesda, MD USAAD  - Mekelle Univ, Mekelle, EthiopiaAD  - Pacific Inst Res Evaluat, Calverton, MD USAAD  - Curtin Univ, Ctr Populat Hlth, Perth, WA, AustraliaAD  - Univ New South Wales, Kensington, NSW, AustraliaAD  - Baqiyatallah Univ Med Sci, Neurosci Res Ctr, Tehran, IranAD  - Ahmadu Bello Univ, Hlth Syst & Policy Res Unit, Zaria, NigeriaAD  - Heidelberg Univ, Inst Publ Hlth, Heidelberg, GermanyAD  - Amer Univ Beirut, Ctr Res Populat & Hlth, Fac Hlth Sci, Beirut, LebanonAD  - Western Sydney Univ, Ctr Hlth Res, Sydney, NSW, AustraliaAD  - Minist Hlth, Mexico City, DF, MexicoAD  - Univ Nacl Autonoma Mexico, Mexico City, DF, MexicoAD  - Charite, Berlin, GermanyAD  - Univ Calgary, Dept Community Hlth Sci, Calgary, AB, CanadaAD  - Univ Melbourne, Murdoch Childrens Res Inst, Dept Paediat, Melbourne, Vic, AustraliaAD  - Univ Porto, REQUIMTE LAQV, Dept Quim, Fac Farm,Lab Farmacognosia, Porto, PortugalAD  - Postgrad Med Inst, Lahore, PakistanAD  - Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R ChinaAD  - Emory Univ, Atlanta, GA 30322 USAAD  - Univ British Columbia, Vancouver, BC, CanadaAD  - Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, IranAD  - AT Still Univ, Kirksville, MO USAAD  - Contech Int Hlth Consultants, Lahore, PakistanAD  - Contech Sch Publ Hlth, Lahore, PakistanAD  - Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, IranAD  - Soc Hlth & Demog Surveillance, Suri, IndiaAD  - WHO Collaborating Ctr, Imperial Coll London, London, EnglandAD  - North Hampshire Hosp, Basingstroke, EnglandAD  - Univ Coll London Hosp, London, EnglandAD  - Imperial Coll London, London, EnglandAD  - Walden Univ, Minneapolis, MN USAAD  - Suez Canal Univ, Ismailia, EgyptAD  - Kermanshah Univ Med Sci, Sch Publ Hlth, Kermanshah, IranAD  - Mazandaran Univ Med Sci, Sari, IranAD  - Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, IranAD  - Baqiyatallah Univ Med Sci, Student Res Comm, Tehran, IranAD  - Maragheh Univ Med Sci, Sch Nursing & Midwifery, Dept Publ Hlth, Managerial Epidemiol Res Ctr, Maragheh, IranAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Univ Tehran Med Sci, Neurosci Inst, Res Ctr, Tehran, IranAD  - Ain Shams Univ, Cairo, EgyptAD  - Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Publ Hlth Med, Durban, South AfricaAD  - SAMRC, UKZN Gastrointestinal Canc Res Ctr, Durban, South AfricaAD  - Bayer Turkey, Istanbul, TurkeyAD  - Stellenbosch Univ, Cape Town, South AfricaAD  - Hamadan Univ Med Sci, Sch Nursing & Midwifery, Dept Med Surg Nursing, Hamadan, IranAD  - Univ Fed Santa Catarina, Florianopolis, SC, BrazilAD  - Univ Alabama Birmingham, Birmingham, AL USAAD  - Birmingham Vet Affairs Med Ctr, Birmingham, AL USAAD  - King Saud Univ, Riyadh, Saudi ArabiaAD  - Int Med Univ, Dept Community Med, Kuala Lumpur, MalaysiaAD  - Univ Cape Town, Dept Psychiat, Cape Town, South AfricaAD  - South African Med Res Council Unit Anxiety & Stre, Cape Town, South AfricaAD  - Minist Hlth, Riyadh, Saudi ArabiaAD  - Univ Calif Irvine, Dept Criminol Law & Soc, Irvine, CA USAAD  - Univ Calif Irvine, Dept Sociol & Publ Hlth, Irvine, CA USAAD  - Univ Valencia, INCLIVA Hlth Res Inst, Dept Med, Valencia, SpainAD  - CIBERSAM, Valencia, SpainAD  - Ahmadu Bello Univ, Zaria, NigeriaAD  - Univ Illinois, Sch Social Work, Champaign, IL USAAD  - Iran Univ Med Sci, Prevent Med & Publ Hlth Res Ctr, Tehran, IranAD  - Univ Virginia, Dept Anesthesiol, Charlottesville, VA USAAD  - King Fahad Med City, Dept Anesthesiol, King, WI, Saudi ArabiaAD  - Cleveland Clin, Outcomes Res Consortium, Cleveland, OH USAAD  - Jagiellonian Univ Med Coll, Inst Publ Hlth, Fac Hlth Sci, Krakow, PolandAD  - Wroclaw Med Univ, Fac Hlth Sci, Wroclaw, PolandAD  - Fed Teaching Hosp, Dept Internal Med, Abakaliki, NigeriaAD  - Univ Warwick, Warwick Med Sch, Coventry, W Midlands, EnglandAD  - Norwegian Inst Publ Hlth, Ctr Dis Burden, Bergen, NorwayAD  - Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, NorwayAD  - Jimma Univ, Jimma, EthiopiaAD  - Univ Sao Paulo, Med Sch, Sao Paulo, BrazilAD  - Fed Inst Populat Res, Competence Ctr Mortal Follow Up, German Natl Cohort, Wiesbaden, GermanyAD  - Fed Inst Populat Res, Wiesbaden, GermanyAD  - German Natl Cohort Consortium, Heidelberg, GermanyAD  - Univ Ghent, Ghent, BelgiumAD  - Univ Saskatchewan, Sch Publ Hlth, Saskatoon, SK, CanadaAD  - Mizan Tepi Univ, Mizan Teferi, EthiopiaAD  - Kyoto Univ, Sch Publ Hlth, Dept Biostat, Kyoto, JapanAD  - Jackson State Univ, Jackson, MS USAAD  - Wuhan Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan, Hubei, Peoples R ChinaAD  - Wuhan Univ, Global Hlth Inst, Wuhan, Hubei, Peoples R ChinaAD  - Mansoura Univ, Fac Med, Mansoura, EgyptAD  - Univ Oxford, Oxford Big Data Inst, Li Ka Shing Ctr Hlth Informat & Discovery, Oxford, EnglandAD  - Seattle Childrens Hosp, Dept Anesthesiol Pain Med, Seattle, WA USAC3  - Institute for Health Metrics & EvaluationC3  - University of WashingtonC3  - University of Washington SeattleC3  - American University of BeirutC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Egyptian Knowledge Bank (EKB)C3  - Cairo UniversityC3  - Mekelle UniversityC3  - Qatar Foundation (QF)C3  - Weill Cornell Medical College QatarC3  - Lund UniversityC3  - Kermanshah University of Medical SciencesC3  - Jimma UniversityC3  - Murdoch Children's Research InstituteC3  - University of MelbourneC3  - University of MelbourneC3  - University of SydneyC3  - Mazandaran University of Medical SciencesC3  - King Saud UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Zahedan University of Medical SciencesC3  - Mekelle UniversityC3  - University of GondarC3  - Harvard UniversityC3  - Harvard T.H. Chan School of Public HealthC3  - Africa Health Research InstituteC3  - Ruprecht Karls University HeidelbergC3  - University of Management & Technology (UMT)C3  - University of BelgradeC3  - University of AucklandC3  - University of AdelaideC3  - Charles R. Drew University of Medicine & ScienceC3  - University of California SystemC3  - University of California Los AngelesC3  - University of California Los Angeles Medical CenterC3  - David Geffen School of Medicine at UCLAC3  - Universidade de Sao PauloC3  - Haramaya UniversityC3  - Aga Khan UniversityC3  - University of TorontoC3  - Hospital for Sick Children (SickKids)C3  - University of MelbourneC3  - Murdoch Children's Research InstituteC3  - University System of OhioC3  - Ohio State UniversityC3  - University of ValenciaC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERSAMC3  - University of OttawaC3  - Ottawa Hospital Research InstituteC3  - University of AdelaideC3  - Walden UniversityC3  - University of OxfordC3  - University of PeradeniyaC3  - Royal Melbourne Institute of Technology (RMIT)C3  - Australian National UniversityC3  - Arba Minch UniversityC3  - University of the Philippines SystemC3  - University of the Philippines ManilaC3  - Philippine Department HealthC3  - Universidade Federal de SergipeC3  - Harvard UniversityC3  - Harvard T.H. Chan School of Public HealthC3  - Harvard UniversityC3  - Massachusetts General HospitalC3  - Bahir Dar UniversityC3  - Karolinska InstitutetC3  - University of BielefeldC3  - Jimma UniversityC3  - Addis Ababa UniversityC3  - Haramaya UniversityC3  - Universidade de Sao PauloC3  - University of GroningenC3  - Arabian Gulf UniversityC3  - Haramaya UniversityC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERSAMC3  - Tehran University of Medical SciencesC3  - Yokohama City UniversityC3  - Universite de Tunis-El-ManarC3  - Institut Salah AzaiezC3  - Harvard UniversityC3  - Cambridge Health AllianceC3  - Birzeit UniversityC3  - University of KragujevacC3  - Institute for Health Metrics & EvaluationC3  - University of WashingtonC3  - University of Washington SeattleC3  - University of Colorado SystemC3  - University of Colorado DenverC3  - Denver Health Medical CenterC3  - Ruprecht Karls University HeidelbergC3  - Tehran University of Medical SciencesC3  - Jordan University of Science & TechnologyC3  - Health Services AcademyC3  - Ministry of Health & Medical Education (MOHME)C3  - Tehran University of Medical SciencesC3  - Ball State UniversityC3  - Northeastern UniversityC3  - National Cerebral & Cardiovascular Center - JapanC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERSAMC3  - Universite de MontrealC3  - Universite de MontrealC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - Hong Kong Polytechnic UniversityC3  - State University of New York (SUNY) SystemC3  - University at Albany, SUNYC3  - Aintree University Hospitals NHS Foundation TrustC3  - University of LiverpoolC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Aswan UniversityC3  - Tehran University of Medical SciencesC3  - Tehran University of Medical SciencesC3  - Imperial College LondonC3  - Tehran University of Medical SciencesC3  - Universidad CEU Cardenal HerreraC3  - Chinese Academy of SciencesC3  - Institute of Genetics & Developmental Biology, CASC3  - Queensland Centre for Mental Health ResearchC3  - University of QueenslandC3  - Aarhus UniversityC3  - Alfaisal UniversityC3  - United Nations Population FundC3  - Haramaya UniversityC3  - Jimma UniversityC3  - National Institutes of Health (NIH) - USAC3  - NIH National Heart Lung & Blood Institute (NHLBI)C3  - Mekelle UniversityC3  - Pacific Institute for Research & Evaluation (PIRE)C3  - Curtin UniversityC3  - University of New South Wales SydneyC3  - Baqiyatallah University of Medical Sciences (BMSU)C3  - Ahmadu Bello UniversityC3  - Ruprecht Karls University HeidelbergC3  - American University of BeirutC3  - Western Sydney UniversityC3  - Universidad Nacional Autonoma de MexicoC3  - Berlin Institute of HealthC3  - Free University of BerlinC3  - Humboldt University of BerlinC3  - Charite Universitatsmedizin BerlinC3  - University of CalgaryC3  - University of MelbourneC3  - Murdoch Children's Research InstituteC3  - Universidade do PortoC3  - Shanghai Jiao Tong UniversityC3  - Emory UniversityC3  - University of British ColumbiaC3  - A.T. Still University of Health SciencesC3  - Tehran University of Medical SciencesC3  - Imperial College LondonC3  - World Health OrganizationC3  - University of LondonC3  - University College LondonC3  - University College London Hospitals NHS Foundation TrustC3  - Imperial College LondonC3  - Walden UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Suez Canal UniversityC3  - Kermanshah University of Medical SciencesC3  - Mazandaran University of Medical SciencesC3  - Golestan University of Medical SciencesC3  - Baqiyatallah University of Medical Sciences (BMSU)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Tehran University of Medical SciencesC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - University of Kwazulu NatalC3  - Stellenbosch UniversityC3  - Hamadan University of Medical SciencesC3  - Universidade Federal de Santa Catarina (UFSC)C3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - US Department of Veterans AffairsC3  - Veterans Health Administration (VHA)C3  - Veterans Affairs Medical Center - BirminghamC3  - King Saud UniversityC3  - International Medical University MalaysiaC3  - University of Cape TownC3  - Ministry of Health - Saudi ArabiaC3  - University of California SystemC3  - University of California IrvineC3  - University of California SystemC3  - University of California IrvineC3  - University of ValenciaC3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERSAMC3  - Ahmadu Bello UniversityC3  - University of Illinois SystemC3  - University of Illinois Urbana-ChampaignC3  - Iran University of Medical SciencesC3  - University of VirginiaC3  - King Fahad Medical CityC3  - Cleveland Clinic FoundationC3  - Jagiellonian UniversityC3  - Collegium Medicum Jagiellonian UniversityC3  - Wroclaw Medical UniversityC3  - University of WarwickC3  - Norwegian Institute of Public Health (NIPH)C3  - University of BergenC3  - Jimma UniversityC3  - Universidade de Sao PauloC3  - Ghent UniversityC3  - University of SaskatchewanC3  - Kyoto UniversityC3  - Jackson State UniversityC3  - Wuhan UniversityC3  - Wuhan UniversityC3  - Egyptian Knowledge Bank (EKB)C3  - Mansoura UniversityC3  - University of OxfordC3  - Seattle Children's HospitalPU  - FRONTIERS MEDIA SA
PI  - LAUSANNE
PA  - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
DA  - MAY
PY  - 2018
VL  - 63
SP  - 47
EP  - 61
DO  - 10.1007/s00038-017-1004-3
AN  - WOS:000433519400008
ER  -

TY  - JOUR
AU  - Patnaik, R
AU  - Chhabra, A
AU  - Subramaniam, R
AU  - Arora, MK
AU  - Goswami, D
AU  - Srivastava, A
AU  - Seenu, V
AU  - Dhar, A
TI  - Comparison of Paravertebral Block by Anatomic Landmark Technique to Ultrasound-Guided Paravertebral Block for Breast Surgery Anesthesia: A Randomized Controlled Trial
T2  - REGIONAL ANESTHESIA AND PAIN MEDICINE
KW  - REGIONAL ANESTHESIA
KW  - GENERAL-ANESTHESIA
KW  - CANCER SURGERY
KW  - SURGICAL-MANAGEMENT
KW  - ANALGESIA
KW  - QUALITY
KW  - PAIN
AB  - Background and Objectives Paravertebral block (PVB) is an established technique for providing anesthesia for breast surgery. The primary objective was to compare anatomical landmark technique (ALT) to the ultrasound-guided (USG) PVB block for providing surgical anesthesia. Secondary objectives included comparison of perioperative analgesia and complications.
   Methods This randomized, controlled, observer-blinded study included 72 females, aged 18 to 65 years, American Society of Anesthesiologists physical status I or II, undergoing elective unilateral breast surgery. Study participants were randomized to the ALT group or USG group. Ipsilateral PVB was performed with the respective technique from T1 to T6. Five milliliters of local anesthetic mixture (0.5% ropivacaine, 5 g/mL adrenaline, 1 g/kg clonidine) was administered at each level. Paravertebral catheter was inserted at T4/T3 level. After confirming sensory loss, patients were taken up for surgery with propofol sedation (20-50 g/kg per minute).
   Results More patients in the USG group (34/36 [94.44%]) had a successful block as compared with the ALT group (26/36 [72.22%]) (P = 0.024). Difference in proportion was 18.1 (95% confidence interval, 0.15-36.0) (P = 0.024) after adjustment for age. More dermatomes were blocked in the USG group (P = 0.0018) with less sparing of upper T2 and T3 dermatomes (P = 0.003, P = 0.006, respectively). Median time to first postoperative analgesic requirement was 502.5 minutes (range, 195-1440 minutes) in the USG group versus 377.5 minutes (range, 215-1440 minutes) in the ALT group. Pain at rest and movement 2 and 4 hours postoperatively and number of catheter top-ups in 24 hours postoperatively were lesser in the USG group (P = 0.012). Complications were comparable.
   Conclusions Ultrasound-guided PVB provided better anesthesia and perioperative analgesia than the landmark technique for breast surgery.
   Clinical Trial Registration The trial was registered retrospectively at the Clinical Trial Registry of India, CTRI/2015/05/005774.
AD  - All India Inst Med Sci, Dept Anesthesiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Surg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - BMJ PUBLISHING GROUP
PI  - LONDON
PA  - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
DA  - MAY
PY  - 2018
VL  - 43
IS  - 4
SP  - 385
EP  - 390
DO  - 10.1097/AAP.0000000000000746
AN  - WOS:000457839100009
ER  -

TY  - JOUR
AU  - Prabhakar, S
AU  - Dhillon, MS
AU  - Khurana, A
AU  - John, R
TI  - The "Open-Envelope" Approach: A Limited Open Approach for Calcaneal Fracture Fixation
T2  - INDIAN JOURNAL OF ORTHOPAEDICS
KW  - American Orthopaedic Foot and Ankle Score
KW  - calcaneum fracture
KW  - displaced intraarticular calcaneal fractures
KW  - minimally invasive surgery
KW  - open-envelope approach
KW  - SINUS TARSI APPROACH
KW  - EXTENSILE LATERAL APPROACH
KW  - INTRAARTICULAR FRACTURES
KW  - SURGICAL-TREATMENT
KW  - INTERNAL-FIXATION
KW  - OPEN REDUCTION
KW  - INCISION
AB  - Background: Minimally invasive surgery (MIS) has a significant and evolving role in the treatment of displaced intra articular calcaneal fractures (DIACFs), but there is limited literature on this subject. The objective was hence to assess the clinicoradiological outcomes of DIACFs fixed with an innovative open-envelope MIS technique. Materials and Methods: 42 closed Sanders Type 2 and 3; DIACFs were included in this study. The Open-envelope approach was developed, which is essentially a limited open, dual incision, modified posterior longitudinal approach allowing excellent visualisation and direct fragment manipulation. The main outcome measures were American Orthopaedic Foot and Ankle Score (AOFAS) hindfoot score and preoperative and postoperative radiological angles. Results: The Bohler angle improved from a preoperative mean of 14.3 degrees (range 0 degrees-28 degrees) to a postoperative mean of 32.46 degrees (range 22 degrees-42 degrees). The Gissane angle improved from a preoperative mean of 135.83 degrees to a postoperative mean of 128.33 degrees. The postoperative improvement in Bohler and Gissane angles was highly significant (P < 0.001). The AOFAS scores at 6 months were excellent in nine patients, good in 15 patients, and fair in six patients. Three patients had residual valgus deformity of the heel. Conclusions: Open-envelope technique minimized soft tissue complications and achieved acceptable radiological reductions with good clinical outcomes.
AD  - Post Grad Inst Med Educ & Res, Dept Orthopaed, Chandigarh, IndiaAD  - All India Inst Med Sci, Dept Orthopaed, New Delhi, IndiaAD  - St Parmanand Hosp, Delhi Inst Trauma & Orthopaed, Dept Orthopaed, New Delhi, IndiaC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - MAY-JUN
PY  - 2018
VL  - 52
IS  - 3
SP  - 231
EP  - 238
DO  - 10.4103/ortho.IJOrtho_576_17
AN  - WOS:000432020000003
ER  -

TY  - JOUR
AU  - Prakash, P
AU  - Kumar, R
AU  - Khadgawat, R
AU  - Dinda, AK
AU  - Sharma, S
AU  - Agarwal, G
TI  - A 45-year-old woman with episodic anxiety, hypertension and diabetes mellitus
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
KW  - PHEOCHROMOCYTOMA
AD  - All India Inst Med Sci, Dept Urol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Radiodiagnosis, New Delhi 110029, IndiaAD  - Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrine & Breast Surg, Lucknow, Uttar Pradesh, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Sanjay Gandhi Postgraduate Institute of Medical SciencesPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - MAY-JUN
PY  - 2018
VL  - 31
IS  - 3
SP  - 160
EP  - 163
C7  - PMID 31044765
DO  - 10.4103/0970-258X.255755
AN  - WOS:000469074400010
ER  -

TY  - JOUR
AU  - Pramanik, R
AU  - Vishnubhatla, S
AU  - Bakhshi, S
TI  - Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors Reply
T2  - JAMA ONCOLOGY
KW  - RECURRENT
KW  - TRIAL
AD  - All India Inst Med Sci, Dept Med Oncol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER MEDICAL ASSOC
PI  - CHICAGO
PA  - 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
DA  - MAY
PY  - 2018
VL  - 4
IS  - 5
SP  - 744
EP  - 744
DO  - 10.1001/jamaoncol.2017.4891
AN  - WOS:000431868700031
ER  -

TY  - JOUR
AU  - Rajeshwari, M
AU  - Singh, V
AU  - Nambirajan, A
AU  - Mridha, AR
AU  - Jain, D
TI  - Carcinoma showing thymus like elements: Report of a case with <i>EGFR T790M</i> mutation
T2  - DIAGNOSTIC CYTOPATHOLOGY
KW  - CASTLE
KW  - EGFR T790M
KW  - EGFR
KW  - sequencing
KW  - thyroiditis
KW  - DIFFERENTIATION
KW  - CASTLE
KW  - TUMORS
AB  - Carcinoma showing thymus-like differentiation of the thyroid (CASTLE) is a rare tumor involving the thyroid and perithyroidal soft tissues. It shares morphological, immunohistochemical and molecular similarities with thymic carcinomas. Due to its relatively better prognosis, it needs differentiation from other primary and metastatic tumors of this region. A 40-year-old lady presented with a gradually progressive anterior neck swelling for one year. Imaging showed bulky right and left lobes of thyroid along with a solid soft tissue mass in the pretracheal region. Fine needle aspiration smears showed features of poorly differentiated carcinoma. Total thyroidectomy with excision of the mass revealed histopathological features characteristic of CASTLE, with evidence of thyroiditis in adjoining thyroid. Epidermal growth factor receptor (EGFR) assay revealed presence of EGFR T790M somatic mutation in exon 20. The same was not detectable on direct sequencing. We present a rare case of CASTLE, occurring in association with Hashimoto thyroiditis, with emphasis on cytological features and report for the first time the presence of a low level somatic mutation in EGFR (EGFR T790M mutation).
AD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - MAY
PY  - 2018
VL  - 46
IS  - 5
SP  - 413
EP  - 418
DO  - 10.1002/dc.23859
AN  - WOS:000430058600007
ER  -

TY  - JOUR
AU  - Ranjit, S
AU  - Sankar, J
TI  - Fluid Overload in Acute Asthma Exacerbation and Clinical Outcomes Is There an Association?
T2  - AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
KW  - MECHANICAL VENTILATION
KW  - CHILDREN
KW  - PRESSURE
KW  - OUTPUT
AD  - Apollo Childrens Hosp, Dept Pediat Intens Care & Emergency Serv, Madras, Tamil Nadu, IndiaAD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER THORACIC SOC
PI  - NEW YORK
PA  - 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
DA  - MAY 1
PY  - 2018
VL  - 197
IS  - 9
SP  - 1095
EP  - 1096
DO  - 10.1164/rccm.201801-0091ED
AN  - WOS:000431196700002
ER  -

TY  - JOUR
AU  - Ravani, R
AU  - Chawla, R
AU  - Azad, SV
AU  - Gupta, Y
AU  - Kumar, V
AU  - Kumar, A
TI  - Midline sclerotomy approach for intraocular foreign body removal in phakic eyes using endoilluminator: A novel technique
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Endoilluminator-assisted technique
KW  - intraocular foreign body
KW  - midline approach
KW  - midline sclerotomy
KW  - retained intraocular foreign body
KW  - MANAGEMENT
KW  - BODIES
KW  - VITRECTOMY
KW  - FORCEPS
KW  - SNARE
AB  - Purpose: The objective of this study is to describe the removal of retained intraocular foreign body (RIOFB) by bimanual pars plana vitrectomy through midline sclerotomy in phakic patients. Technique: Four eyes with RIOFB and clear lens underwent microincision vitrectomy surgery. A chandelier illumination was placed through one of the existing ports. The foreign body (FB) was localized by direct visualization (intravitreal) or indentation (pars plana), stabilized using an intraocular magnet/FB forceps introduced through a midline sclerotomy and freed of vitreous from all sides using a vitrectomy cutter through the other port bimanually, reoriented along their long axis and extracted through the midline sclerotomy. Results: All four FBs were removed successfully without slippage or damage to the clear lens. Conclusion: Chandelier illumination-assisted removal of FB through midline sclerotomy helps in easier localization, stabilization and removal, avoiding lens touch even in anteriorly located FBs such as at pars plana.
AD  - AIIMS, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - MAY
PY  - 2018
VL  - 66
IS  - 5
SP  - 687
EP  - 690
DO  - 10.4103/ijo.IJO_1090_17
AN  - WOS:000430949700019
ER  -

TY  - JOUR
AU  - Sagar, R
AU  - Sahu, A
AU  - Pattanayak, RD
AU  - Chatterjee, B
TI  - Assessment of cognitive functions in bipolar I disorder: A 1-year naturalistic follow-up study
T2  - BIPOLAR DISORDERS
KW  - bipolar I disorder
KW  - cognitive functions
KW  - India
KW  - longitudinal study
KW  - RATING-SCALE
KW  - LONGITUDINAL COURSE
KW  - IMPAIRMENT
KW  - PERFORMANCE
KW  - DEPRESSION
KW  - DEFICITS
KW  - LIFE
AB  - ObjectiveAvailable findings from cross-sectional studies have demonstrated cognitive impairments in bipolar I disorder (BD-I) during various phases of illness. However, very little is known about the longitudinal course of these cognitive impairments. The purpose of the study was to explore the longitudinal pattern of changes in cognitive functioning of BD-I patients.
   MethodsA total of 129 BD-I subjects (manic, depressed and euthymic groups) and 49 healthy controls were recruited using predefined selection criteria. All four study groups were assessed on various clinical and cognitive parameters (for attention, memory, executive functions and working memory) at study intake and at 3-monthly intervals over the next year.
   ResultsAll three patient groups performed poorly compared to controls on all cognitive measures at study intake and on some cognitive measures at the 3-, 6-, 9- and 12-month assessments. No significant time effects were observed for any cognitive test. A significant group by time interaction effect was found for executive functions (=-44.74; P=.018) and working memory (=0.77; P.019) in the depressed group at 12months; for visual memory (=1.21; P=.039) and working memory (=1.17; P.029) in the manic group at 12months; and for working memory (=-0.52; P.036) in the euthymic group at 12months.
   ConclusionThe patient groups showed significant impairments in all or some test domains relative to controls at all time-points. The cognitive functions largely remained stable in all patient groups, with slight improvement over time in a few tests. Further investigation is warranted in larger samples in longitudinal studies.
AD  - All India Inst Med Sci, Dept Psychiat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - MAY
PY  - 2018
VL  - 20
IS  - 3
SP  - 248
EP  - 259
DO  - 10.1111/bdi.12584
AN  - WOS:000431621200007
ER  -

TY  - JOUR
AU  - Samala, R
AU  - Garg, K
AU  - Kedia, S
AU  - Satyarthee, GD
TI  - Endovascular management of epidural hematomas
T2  - JOURNAL OF NEUROSURGERY
KW  - SURGERY
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ASSOC NEUROLOGICAL SURGEONS
PI  - ROLLING MEADOWS
PA  - 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
DA  - MAY
PY  - 2018
VL  - 128
IS  - 5
SP  - 1601
EP  - 1602
DO  - 10.3171/2017.9.JNS172067
AN  - WOS:000440650000052
ER  -

TY  - JOUR
AU  - Shalimar
AU  - Sonika, U
AU  - Kedia, S
AU  - Mahapatra, SJ
AU  - Nayak, B
AU  - Yadav, DP
AU  - Gunjan, D
AU  - Thakur, B
AU  - Kaur, H
AU  - Acharya, SK
TI  - Comparison of Dynamic Changes Among Various Prognostic Scores in Viral Hepatitis-Related Acute Liver Failure
T2  - ANNALS OF HEPATOLOGY
KW  - Hepatitis E virus
KW  - Hepatitis B virus
KW  - Paracetamol
KW  - Cryptogenic
KW  - Liver transplant
KW  - COLLEGE HOSPITAL CRITERIA
KW  - MODEL
KW  - VALIDATION
KW  - OUTCOMES
KW  - PREDICTION
KW  - MORTALITY
KW  - SURVIVORS
AB  - Introduction and aim. Multiple prognostic scores are available for acute liver failure (ALF). Our objective was to compare the dynamicity of model for end stage liver disease (MELD), MELD-sodium, acute liver failure early dynamic model (ALFED), chronic liver failure (CLIF)-consortium ACLF score and King's College Hospital Criteria (KCH) for predicting outcome in ALF. Materials and methods. All consecutive patients with ALF at a tertiary care centre in India were included. MELD, MELD-Na, ALFED, CLIF-C ACLF scores and KCH criteria were calculated at admission and day 3 of admission. Area under receiver operator characteristic curves (AUROC) were compared with DeLong method. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), likelihood ratio (LR) and diagnostic accuracy (DA) were reported. Results. Of the 115 patients included in the study, 73 (63.5%) died. The discrimination of mortality with baseline values of prognostic scores (MELD, MELD-Na, ALFED, CLIF-C ACLF and KCH) was modest (AUROC: 0.65-0.77). The AUROC increased on day 3 for all scores, except KCH criteria. On day 3 of admission, ALFED score had the highest AUROC 0.95, followed by CLIF-C ACLF 0.88, MELD 0.81, MELD-Na 0.77 and KCH 0.52. The AUROC for ALFED was significantly higher than MELD, MELD-Na and KCH (P < 0.001 for all) and CLIF-C ACLF (P = 0.05). ALFED score >= 4 on day 3 had the best sensitivity (87.1%), specificity (89.5%), PPV (93.8%), NPV (79.1%), LR positive (8.3) and DA (87.9%) for predicting mortality. Conclusions. Dynamic assessment of prognostic scores better predicts outcome. ALFED model performs better than MELD, MELD, MELD-Na, CLIF-C ACLF scores and KCH criteria for predicting outcome in viral hepatitis-related ALF.
AD  - All India Inst Med Sci, Dept Gastroenterol & Human Nutr, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MEXICAN ASSOC HEPATOLOGY
PI  - MEXICO
PA  - PUNTE DE PIEDRA 150, COLONIA TORIELLO GUERRA, MEXICO, DF CP 14040, MEXICO
DA  - MAY-JUN
PY  - 2018
VL  - 17
IS  - 3
SP  - 403
EP  - 412
DO  - 10.5604/01.3001.0011.7384
AN  - WOS:000460748500008
ER  -

TY  - JOUR
AU  - Sharma, A
AU  - Khan, R
AU  - Gupta, N
AU  - Sharma, A
AU  - Zaheer, MS
AU  - Abbas, M
AU  - Khan, SA
TI  - Acute phase reactant, Pentraxin 3, as a novel marker for the diagnosis of rheumatoid arthritis
T2  - CLINICA CHIMICA ACTA
KW  - Rheumatoid arthritis
KW  - Pentraxin 3
KW  - CRP
KW  - Diagnostic marker
KW  - DISEASE-ACTIVITY SCORE
KW  - INFLAMMATION
KW  - PTX3
AB  - Introduction: Pentraxins are a group of highly conserved acute-phase reactant proteins and play crucial role as modulators of inflammatory processes. Pentraxin 3 (PTX3) is primarily produced and released by vascular cell wall, hence, we attempt to establish the role of PTX3 as a biomarker for Rheumatoid Arthritis (RA) compared to CRP.
   Methods: Thirty patients having active RA as cases and 30 osteoarthritis (OA) patients as controls were recruited. Paired serum and synovial fluid samples were analysed for concentrations of both PTX3 and CRP by using high sensitivity ELISA kit and ROC curve was plotted.
   Results: Concentrations of PTX3 and CRP were significantly higher in RA patient serum (p < 0.0001) as well as in synovial fluid (p < 0.0001) and correlated with disease severity. Upon correlation analysis, positive correlation was found between serum and synovial fluid concentrations of PTX3 and CRP. The diagnostic potential of PTX3 was observed in synovial fluid while combination of PTX3 and CRP showed better sensitivity in serum.
   Conclusion: PTX3 found to be sensitive non-invasive indicator of clinical arthritic activity in RA patients when compared to traditional markers like CRP. Combination of PTX3 and CRP could serve as better differential diagnostic markers for RA after validation in larger patient cohort.
AD  - Aligarh Muslim Univ, JN Med Coll & Hosp, Dept Med, Aligarh, Uttar Pradesh, IndiaAD  - All India Inst Med Sci, Dept Biochem, New Delhi, IndiaAD  - Aligarh Muslim Univ, JN Med Coll & Hosp, Dept Orthopaed, Aligarh, Uttar Pradesh, IndiaC3  - Aligarh Muslim UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Aligarh Muslim UniversityPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - MAY
PY  - 2018
VL  - 480
SP  - 65
EP  - 70
DO  - 10.1016/j.cca.2018.01.035
AN  - WOS:000428826100009
ER  -

TY  - JOUR
AU  - Sharma, P
AU  - Gaur, N
TI  - How do we tackle a child's spectacle?
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - EMMETROPIZATION
AD  - AIIMS, Dr RP Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - MAY
PY  - 2018
VL  - 66
IS  - 5
SP  - 651
EP  - 652
C7  - PMID 29676307
DO  - 10.4103/ijo.IJO_369_18
AN  - WOS:000430949700010
ER  -

TY  - JOUR
AU  - Sharma, R
AU  - Phalak, M
AU  - Katiyar, V
AU  - Borkar, S
AU  - Kale, SS
AU  - Mahapatra, AK
TI  - Microvascular decompression versus stereotactic radiosurgery as primary treatment modality for trigeminal neuralgia: A systematic review and meta-analysis of prospective comparative trials
T2  - NEUROLOGY INDIA
KW  - Gamma knife therapy
KW  - meta-analysis
KW  - microvascular decompression
KW  - stereotactic radiosurgery
KW  - trigeminal neuralgia
KW  - SURGERY
AB  - Objective: The current opinion among neurosurgeons regarding the selection between microvascular decompression (MVD) and gamma knife radiosurgery for trigeminal neuralgia is not based on clear evidence. In this meta-analysis, we have attempted to synthesize the findings of the prospective trials comparing the efficacy and complications of the two procedures as primary treatment modality for medically refractory trigeminal neuralgia.
   Materials and Methods: The authors performed a systematic review of PubMed for manuscripts comparing the efficacy or complications of MVD and stereotactic radiosurgery for medically refractory trigeminal neuralgia. The data of the identified studies was pooled and a meta-analysis was done.
   Results: Five prospective studies fulfilling the eligibility criteria were identified. The mean age of the patients subjected to gamma knife therapy (GKT) was more than those who underwent MVD. The initial success rate in the pooled data with MVD was 96% (95% confidence interval [C.I.] 93.3%-98.6%) as compared to GKT which was 71.8% (95% C.I. 64.9%-78.7%) with the ratio of 1.309 (95% C.I. 1.217-1.409; P = < 0.001). This superiority was sustained till the last follow up available in all the studies. Out of the complications common to both procedures, MVD had a lower rate of facial numbness, with a risk ratio of 0.481 (95% C.I. 0.297-0.778); and dysesthetic pain, with a risk ratio of 0.470 (95% C.I. 0.172-1.286).
   Conclusions: MVD seems to be more efficacious than GKT as a first line treatment for trigeminal neuralgia immediately as well as on a long term basis. However, the dilemma regarding the choice of treatment to be adopted still remains for special subgroups of patients, like the elderly patients and those in whom no vascular compression has been found during surgery. Further studies are needed for elucidating the unequivocal treatment plan under these circumstances.
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - MAY-JUN
PY  - 2018
VL  - 66
IS  - 3
SP  - 688
EP  - 694
DO  - 10.4103/0028-3886.232342
AN  - WOS:000432404000019
ER  -

TY  - JOUR
AU  - Sharma, VK
AU  - Gupta, V
AU  - Ramam, M
TI  - Dermoscopy of lichen planus pigmentosus in Indian patients - Pitfalls to avoid reply
T2  - INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - MAY-JUN
PY  - 2018
VL  - 84
IS  - 3
SP  - 314
EP  - 315
C7  - PMID 29600797
DO  - 10.4103/ijdvl.IJDVL_103_18
AN  - WOS:000430432800014
ER  -

TY  - JOUR
AU  - Shukla, G
AU  - Gupta, A
TI  - High time we focus on sleep in amyotrophic lateral sclerosis
T2  - NEUROLOGY INDIA
KW  - RILUZOLE
AD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - MAY-JUN
PY  - 2018
VL  - 66
IS  - 3
SP  - 664
EP  - 665
DO  - 10.4103/0028-3886.232309
AN  - WOS:000432404000009
ER  -

TY  - JOUR
AU  - Sikri, K
AU  - Duggal, P
AU  - Kumar, C
AU  - Batra, SD
AU  - Vashist, A
AU  - Bhaskar, A
AU  - Tripathi, K
AU  - Sethi, T
AU  - Singh, A
AU  - Tyagi, JS
TI  - Multifaceted remodeling by vitamin C boosts sensitivity of <i>Mycobacterium tuberculosis</i> subpopulations to combination treatment by anti-tubercular drugs
T2  - REDOX BIOLOGY
KW  - Mycobacterium tuberculosis
KW  - Vitamin C
KW  - Dormancy
KW  - Viable but non-culturable
KW  - Heterogeneous subpopulations
KW  - TB drugs
KW  - Antibiotic tolerance
KW  - IN-VITRO
KW  - ANTIBIOTIC TOLERANCE
KW  - THERAPY
KW  - PYRAZINAMIDE
KW  - SUPEROXIDE
KW  - EXPRESSION
KW  - STRESS
KW  - ACID
KW  - PH
KW  - TRIACYLGLYCEROL
AB  - Bacterial dormancy is a major impediment to the eradication of tuberculosis (TB), because currently used drugs primarily target actively replicating bacteria. Therefore, decoding of the critical survival pathways in dormant tubercle bacilli is a research priority to formulate new approaches for killing these bacteria. Employing a network-based gene expression analysis approach, we demonstrate that redox active vitamin C (vit C) triggers a multifaceted and robust adaptation response in Mycobacterium tuberculosis (Mtb) involving similar to 67% of the genome. Vit C-adapted bacteria display well-described features of dormancy, including growth stasis and progression to a viable but non-culturable (VBNC) state, loss of acid-fastness and reduction in length, dissipation of reductive stress through triglyceride (TAG) accumulation, protective response to oxidative stress, and tolerance to first line TB drugs. VBNC bacteria are reactivatable upon removal of vit C and they recover drug susceptibility properties. Vit C synergizes with pyrazinamide, a unique TB drug with sterilizing activity, to kill dormant and replicating bacteria, negating any tolerance to rifampicin and isoniazid in combination treatment in both in-vitro and intracellular infection models. Finally, the vit C multi-stress redox models described here also offer a unique opportunity for concurrent screening of compounds/combinations active against heterogeneous subpopulations of Mtb. These findings suggest a novel strategy of vit C adjunctive therapy by modulating bacterial physiology for enhanced efficacy of combination chemotherapy with existing drugs, and also possible synergies to guide new therapeutic combinations towards accelerating TB treatment.
AD  - All India Inst Med Sci, Dept Biotechnol, New Delhi 110029, IndiaAD  - Natl Inst Immunol, New Delhi, IndiaAD  - Indraprastha Inst Informat Technol, Delhi, IndiaAD  - Indian Inst Sci, Microbiol & Cell Biol, Ctr Infect Dis Res, Bangalore, Karnataka, IndiaAD  - Translat Hlth Sci & Technol Inst, Ctr Biodesign & Diagnost, Faridabad, Haryana, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Department of Biotechnology (DBT) IndiaC3  - National Institute of Immunology (NII)C3  - Indraprastha Institute of Information Technology DelhiC3  - Indian Institute of Science (IISC) - BangaloreC3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)PU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - MAY
PY  - 2018
VL  - 15
SP  - 452
EP  - 466
DO  - 10.1016/j.redox.2017.12.020
AN  - WOS:000436226600042
ER  -

TY  - JOUR
AU  - Singal, A
AU  - Mittal, H
AU  - Aggarwal, A
AU  - Das, S
AU  - Manchanda, S
TI  - Phacomatosis pigmentovascularis type 2b (phacomatosis cesioflammea) with double superior vena cava, abdominal varicosities, and natal tooth: Novel associations
T2  - PEDIATRIC DERMATOLOGY
KW  - double superior vena cava
KW  - natal tooth
KW  - phacomatosis pigmentovascularis
KW  - CLINICAL FINDINGS
KW  - HYPOPLASIA
KW  - IIB
AB  - Phacomatosis pigmentovascularis is characterized by coexistent extensive cutaneous vascular (capillary) and pigmentary anomalies. We describe a 2-month-old infant presenting with classic features of phacomatosis pigmentovascularis 2b (phacomatosis cesioflammea). He was also found to have hitherto unreported associations in the form of extensive venous anomalies presenting as striking abdominal wall varicosities and persistent left superior vena cava and natal tooth.
AD  - Univ Delhi, Univ Coll Med Sci, Dept Dermatol & Sexually Transmitted Dis, New Delhi, IndiaAD  - Univ Delhi, GTB Hosp, New Delhi, IndiaAD  - Dr RML Hosp, Dept Pediat, New Delhi, IndiaAD  - Postgrad Inst Med Educ & Res, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi, IndiaC3  - University of DelhiC3  - University College of Medical SciencesC3  - University of DelhiC3  - University College of Medical SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - MAY-JUN
PY  - 2018
VL  - 35
IS  - 3
SP  - E151
EP  - E154
DO  - 10.1111/pde.13427
AN  - WOS:000432027900003
ER  -

TY  - JOUR
AU  - Singh, A
AU  - Seth, R
AU  - Gupta, A
AU  - Shalimar
AU  - Nayak, B
AU  - Acharya, SK
AU  - Das, P
TI  - Chronic hepatitis E - an emerging disease in an immunocompromised host
T2  - GASTROENTEROLOGY REPORT
KW  - chronic hepatitis E
KW  - immunosuppression
KW  - chronic liver disease
KW  - ribavirin
KW  - E VIRUS-INFECTION
KW  - RIBAVIRIN THERAPY
AB  - Chronic hepatitis E virus (HEV) infection is increasingly being reported in immunosuppressed individuals with HIV, patients with haematological malignancy and transplant recipients. The diagnosis of cirrhosis and liver failure post chronic HEV is controversial due to lack of standard diagnostic criteria. The treatment benefits of ribavirin in chronic HEV of genotype 1 are not well reported. We report a case of chronic HEV infection of genotype 1 leading to chronic liver disease in a child cured of acute leukaemia. Our report also highlights the successful use of ribavirin for eradicating chronic HEV infection and its subsequent survival benefits. Chronic hepatitis E may be an emerging disease of immunosuppressed patients and should be suspected in the presence of cryptogenic transaminitis. Ribavirin is an effective therapy for controlling HEV.
AD  - All India Inst Med Sci, Dept Paediat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - OXFORD UNIV PRESS
PI  - OXFORD
PA  - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
DA  - MAY
PY  - 2018
VL  - 6
IS  - 2
SP  - 152
EP  - 155
DO  - 10.1093/gastro/gow024
AN  - WOS:000449355200013
ER  -

TY  - JOUR
AU  - Singhal, S
AU  - Roy, KK
AU  - Kumar, S
AU  - Meena, J
AU  - Bharti, J
AU  - Shekhar, B
TI  - Pregnancy with massive splenomegaly: A case series
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
KW  - NONCIRRHOTIC PORTAL-HYPERTENSION
KW  - WOMEN
AB  - Background. Pregnancy with massive splenomegaly is a rare entity and is associated with increased risk to both mother and foetus. There is paucity of studies in the literature to guide clinicians for the management of this condition.
   Methods. We reviewed the course of pregnancy, maternal and foetal outcomes of 5 pregnant women with massive splenomegaly who were managed in our unit during 2015-16.
   Results. All 5 women had anaemia and thrombocytopenia, and had different causes for splenomegaly. One patient had chronic malaria, 2 had portal hypertension with cirrhosis and the remaining 2 had non-cirrhotic portal hypertension. Life-threatening complications were present in 2 patients; one of them had severe pre-eclampsia complicated by pulmonary oedema, cardiac arrest and the other patient developed spontaneous bacterial peritonitis. Intrauterine growth restriction and meconium-stained liquor were the most common perinatal complications. Two patients had vaginal delivery and 3 required emergency caesarean section. Postpartum haemorrhage was present in 2, and the hospital stay was prolonged in all the patients. All mothers and babies were discharged in a satisfactory condition.
   Conclusion. Pregnancy with massive splenomegaly poses a challenge because of diverse aetiology and potentially adverse outcomes. Multidisciplinary care in a tertiary centre can help optimize the outcome.
AD  - All India Inst Med Sci, Dept Obstet & Gynaecol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - MAY-JUN
PY  - 2018
VL  - 31
IS  - 3
SP  - 146
EP  - 148
C7  - PMID 31044760
DO  - 10.4103/0970-258X.255756
AN  - WOS:000469074400005
ER  -

TY  - JOUR
AU  - Srujana, D
AU  - Kaur, M
AU  - Urkude, J
AU  - Rathi, A
AU  - Sharma, N
AU  - Titiyal, JS
TI  - Long-term Functional and Anatomic Outcomes of Repeat Graft After Optically Failed Therapeutic Keratoplasty
T2  - AMERICAN JOURNAL OF OPHTHALMOLOGY
KW  - PENETRATING KERATOPLASTY
KW  - CHANGING INDICATIONS
KW  - ENDOTHELIAL KERATOPLASTY
KW  - DIAMETER
AB  - PURPOSE: To evaluate the functional and anatomic outcomes of repeat penetrating keratoplasty (PK) in optically failed therapeutic grafts.
   DESIGN: Prospective interventional case series.
   METHODS: All cases admitted at the apex tertiary care center for repeat keratoplasty following optically failed therapeutic PK were enrolled over a period of 1 year. Repeat optical PK was performed in all eyes. Primary outcome measures were postoperative graft clarity and visual acuity. Secondary outcome measures were complications including graft rejection, infections, failure, and secondary glaucoma. Follow-up examinations were undertaken on day 1; on day 7; at 1, 3, 6, and 12 months; and yearly thereafter.
   RESULTS: Thirty-two eyes underwent repeat PK with mean follow-up of 18.4 +/- 8.9 months. Clear grafts were observed in 63.14% of cases 1 year after regraft, and graft survival further decreased to 50% at last follow-up. Visual acuity >= 20/200 was achieved in 43.8% of cases, and no case had a visual acuity of >= 20/40. Multivariate Cox regression analysis analyzed risk factors for regraft survival, and observed a hazard ratio of 3.56 with size of initial therapeutic graft >= 8.75 mm, and 10.99 with deep vascularization in 1 or more quadrants. Graft survival (P = .004), visual acuity (P = .039), and rejection rates (P = .036) were significantly better in cases with initial therapeutic graft size < 8.75 mm. Secondary glaucoma was present in 59.4% (19/32) after regrafts.
   CONCLUSION: Regraft after therapeutic PK is associated with suboptimal visual outcomes and long-term graft survival. Large size of initial therapeutic graft and deep vascularization adversely affect graft survival. (C) 2018 Elsevier Inc. All rights reserved.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Cornea Cataract & Refract Surg Serv, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - MAY
PY  - 2018
VL  - 189
SP  - 166
EP  - 175
DO  - 10.1016/j.ajo.2018.03.011
AN  - WOS:000431473300024
ER  -

TY  - JOUR
AU  - Subhadarshani, S
AU  - Gupta, V
AU  - Taneja, N
AU  - Yadav, S
AU  - Gupta, S
TI  - Efficacy and Safety of a Novel Method of Insulated Intralesional Radiofrequency Ablation for Deep Dermal and Subcutaneous Lesions: A 3-Year Institutional Experience
T2  - DERMATOLOGIC SURGERY
KW  - REDUCTION
AB  - BACKGROUND Although insulated intralesional radiofrequency ablation (IL-RFA) is being increasingly used in other specialties, not much information on its safety and efficacy in dermatology is available.
   OBJECTIVE To describe our experience with insulated IL-RFA for various dermatological conditions.
   METHODS This is a retrospective review of the patients who underwent IL-RFA in the past 3 years. Our technique involved creating a small window in the proximal end of plastic sheath of an intravenous cannula using a surgical blade, and then touching the RF probe to the cannula through the window to deliver the electric current. Information regarding diagnosis, number of sessions, adverse effects, and follow-up was recorded. Clinical improvement was assessed on a visual analog scale by the patient and 2 independent observers.
   RESULTS Data on 19 patients with lymphangioma circumscriptum (n = 9), venous or capillary-venous malformation (n = 4), angiolymphoid hyperplasia with eosinophilia (n = 3), arteriovenous malformation, hidradenitis suppurativa, and hypertrophic scar (n = 1 each) was available. The mean number of IL-RFA sessions was 2.26 +/- 1.61. The mean patient and physician global assessment scores were 7.6 +/- 2.22 and 7.3 +/- 2.42, respectively. Adverse effects were seen in 9 (47.4%) patients. All patients, except 1, had sustained improvement in the mean follow-up period of 11.4 +/- 11.6 months.
   CONCLUSION Insulated IL-RFA seems to be safe and effective in selectively targeting deep-seated cutaneous lesions.
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - MAY
PY  - 2018
VL  - 44
IS  - 5
SP  - 714
EP  - 720
DO  - 10.1097/DSS.0000000000001437
AN  - WOS:000440272000015
ER  -

TY  - JOUR
AU  - Tandon, PN
TI  - Management of tuberculosis of the central nervous system: Our experience
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
KW  - EXTRAPULMONARY TUBERCULOSIS
KW  - SPINAL MENINGITIDES
KW  - RAPID DIAGNOSIS
KW  - BRAIN
KW  - APPEARANCE
KW  - RADICULOMYELOPATHY
KW  - PATHOLOGY
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, IndiaAD  - Natl Brain Res Soc, Manesar, Haryana, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Department of Biotechnology (DBT) IndiaC3  - National Brain Research Centre (NBRC)PU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - MAY-JUN
PY  - 2018
VL  - 31
IS  - 3
SP  - 151
EP  - 155
C7  - PMID 31044762
DO  - 10.4103/0970-258X.255758
AN  - WOS:000469074400007
ER  -

TY  - JOUR
AU  - Tandon, V
AU  - Lang, M
AU  - Chandra, PS
AU  - Sharan, A
AU  - Garg, A
AU  - Tripathi, M
TI  - Is Edema a Matter of Concern After Laser Ablation of Epileptogenic Focus?
T2  - WORLD NEUROSURGERY
KW  - Edema
KW  - Epilepsy
KW  - Laser ablation
KW  - Laser interstitial thermal therapy
KW  - Quantitative analysis
KW  - INTERSTITIAL THERMAL THERAPY
KW  - LITT
AB  - BACKGROUND: A stereotactically placed laser fiber can deliver thermal energy to an epileptogenic focus in the brain. This procedure is done under intraoperative (thermography) magnetic resonance imaging (MRI) guidance. Thermoablation can lead to edema in the surrounding area and can cause a secondary insult. In this report of 3 cases, we have quantified the edema produced after laser ablation by sequential MRI in the immediate postoperative period.
   CASE DESCRIPTIONS: Three patients with intractable epilepsy underwent detailed neurologic and neuroradiologic workup to localize the site of epileptogenic foci. Two of the patients had mesial temporal lobe sclerosis, and the other patient had hypothalamic hamartoma. A laser fiber was placed stereotactically in the epileptogenic zone, and MRI-guided thermoablation was done. Postoperatively, T1-weighted and fluid-attenuated inversion recovery (FLAIR)based volumetric MRI sequences were performed on postoperative days 1, 3, and 5 to quantify the edema. I-Plan software was used for volumetric analysis. Targeted volumes were 0.22, 42, and 3.5 mL, and lesions were 0.3, 6.5, and 6 mL, respectively. FLAIR hyperintensity was 2.3, 11.8, and 8.4 mL on the first postoperative day and 1.5, 12.6, and 6.3 mL on postoperative day 8. All patients remained seizure-free during the postoperative period. No complications were observed.
   CONCLUSIONS: Laser ablation of epileptic focus is safe. FLAIR hyperintensity in the postoperative period is 3-5 times the targeted volume. However, no significant increase occurs during the first 8 days, and thus steroids can be stopped within 5 days of surgery.
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neuroradiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaAD  - Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USAC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Thomas Jefferson UniversityPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - MAY
PY  - 2018
VL  - 113
SP  - 366
EP  - +
DO  - 10.1016/j.wneu.2018.01.201
AN  - WOS:000432942700156
ER  -

TY  - JOUR
AU  - Tewari, R
AU  - Kumar, V
AU  - Ravani, R
AU  - Dubey, D
AU  - Chandra, P
AU  - Kumar, A
TI  - Macular hole-associated retinal detachment in Best vitelliform dystrophy: Series of two cases and literature review
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Best vitelliform dystrophy
KW  - inverted internal limiting membrane flap
KW  - macular hole
KW  - pars plana vitrectomy
KW  - retinal detachment
KW  - OPTICAL COHERENCE TOMOGRAPHY
KW  - BESTS-DISEASE
KW  - LESION
AB  - Two eyes of 2 patients with macular hole-associated retinal detachment in clinically diagnosed vitelliruptive stage of Best vitelliform dystrophy were surgically managed by 25-gauge sutureless pars plana vitrectomy, internal limiting membrane (ILM) peeling with inverted ILM flap, and short-acting (SF6) gas tamponade. The patients were assessed with respect to best-corrected visual acuity, color fundus photographs, shortwave fundus autofluorescence, and swept source optical coherence tomography. Surgical intervention led to Type 1 closure of macular hole, resolution of retinal detachment, and improvement in vision in both patients.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - MAY
PY  - 2018
VL  - 66
IS  - 5
SP  - 708
EP  - 711
C7  - PMID 29676326
DO  - 10.4103/ijo.IJO_1046_17
AN  - WOS:000430949700029
ER  -

TY  - JOUR
AU  - Vanidassane, I
AU  - Gogia, A
AU  - Kumar, L
TI  - Contemporary hormonal contraceptives and breast cancer risk: What do we learn?
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
AD  - All India Inst Med Sci, Dr BR Ambedkar Inst, Rotary Canc Hosp, Dept Med Oncol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - MAY-JUN
PY  - 2018
VL  - 31
IS  - 3
SP  - 156
EP  - 157
C7  - PMID 31044763
DO  - 10.4103/0970-258X.255759
AN  - WOS:000469074400008
ER  -

TY  - JOUR
AU  - Yadav, S
AU  - Gupta, S
TI  - A simple device for ablation of keloidal tissue and serial deposition of intralesional drugs
T2  - JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MOSBY-ELSEVIER
PI  - NEW YORK
PA  - 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - MAY
PY  - 2018
VL  - 78
IS  - 5
SP  - E107
EP  - E109
DO  - 10.1016/j.jaad.2017.10.029
AN  - WOS:000430421900006
ER  -

TY  - JOUR
AU  - Yoganathan, S
AU  - Bagga, A
AU  - Gulati, S
AU  - Toteja, GS
AU  - Hari, P
AU  - Sinha, A
AU  - Pandey, RM
AU  - Irshad, M
TI  - Prevalence and predictors of peripheral neuropathy in nondiabetic children with chronic kidney disease
T2  - MUSCLE & NERVE
KW  - axonal neuropathy
KW  - chronic kidney disease
KW  - demyelinating neuropathy
KW  - nerve conduction studies
KW  - nondiabetic
KW  - peripheral neuropathy
KW  - CHRONIC-RENAL-FAILURE
KW  - NERVE-CONDUCTION VELOCITY
KW  - MEMBRANOUS GLOMERULONEPHRITIS
KW  - SERUM
KW  - POLYNEUROPATHY
KW  - HYPERKALEMIA
KW  - HEMODIALYSIS
KW  - ASSOCIATION
KW  - DYSFUNCTION
KW  - POPULATION
AB  - Introduction: This study sought to determine the prevalence and predictors of peripheral neuropathy in nondiabetic children with chronic kidney disease (CKD). Methods: Fifty-one consecutive normally nourished children, 3-18 years of age, with CKD stages IV and V of nondiabetic etiology were enrolled from May to December 2012. Nerve conduction studies were performed in 50 children. Blood samples were analyzed for the biochemical parameters, trace elements, and micronutrients. Results: The prevalence of peripheral neuropathy in our cohort was 52% (95% confidence interval 37.65, 66.34). The majority (80.8%) of the children had axonal neuropathy, and 11.5% had demyelinating neuropathy. Isolated motor neuropathy was identified in 92.3% of the children, and sensorimotor neuropathy was identified in 7.6%. The significant risk factors associated with peripheral neuropathy were older age, low serum copper, and dialysis therapy. Discussion: Electrodiagnostic studies should be performed in children with CKD to assess for peripheral neuropathy for the purpose of optimizing medical care. Muscle Nerve57: 792-798, 2018
AD  - All India Inst Med Sci, Dept Pediat, New Delhi 110029, IndiaAD  - Govt India, Indian Council Med Res, Div Nutr, Minist Hlth & Family Welf, New Delhi 110001, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Lab Med, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Council of Medical Research (ICMR)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - MAY
PY  - 2018
VL  - 57
IS  - 5
SP  - 792
EP  - 798
DO  - 10.1002/mus.26027
AN  - WOS:000430469600026
ER  -

TY  - JOUR
AU  - Saha, S
AU  - Gupta, V
AU  - Dawood, FS
AU  - Broor, S
AU  - Lafond, KE
AU  - Chadha, MS
AU  - Rai, SK
AU  - Krishnan, A
TI  - Estimation of community-level influenza-associated illness in a low resource rural setting in India
T2  - PLOS ONE
KW  - RESPIRATORY-INFECTIONS
KW  - NORTHERN INDIA
KW  - CHILDREN
KW  - SURVEILLANCE
KW  - BANGLADESH
KW  - MULTISITE
KW  - COST
AB  - Objective
   To estimate rates of community-level influenza-like-illness (ILI) and influenza-associated ILI in rural north India.
   Methods
   During 2011, we conducted household-based healthcare utilization surveys (HUS) for any acute medical illness (AMI) in preceding 14days among residents of 28villages of Ballabgarh, in north India. Concurrently, we conducted clinic-based surveillance (CBS) in the area for AMI episodes with illness onset <= 3days and collected nasal and throat swabs for influenza virus testing using real-time polymerase chain reaction. Retrospectively, we applied ILI case definition (measured/reported fever and cough) to HUS and CBS data. We attributed 14days of risk-time per person surveyed in HUS and estimated community ILI rate by dividing the number of ILI cases in HUS by total risk-time. We used CBS data on influenza positivity and applied it to HUS-based community ILI rates by age, month, and clinic type, to estimate the community influenza-associated ILI rates.
   Findings
   The HUS of 69,369 residents during the year generated risk-time of 3945 person-years (p-y) and identified 150 (5%, 95% CI: 4-6) ILI episodes (38 ILI episodes/1,000 p-y; 95% CI 32-44). Among 1,372 ILI cases enrolled from clinics, 126 (9%; 95% CI 8-11) had laboratoryconfirmed influenza (A (H3N2) = 72; B = 54). After adjusting for age, month, and clinic type, overall influenza-associated ILI rate was 4.8/1,000 p-y; rates were highest among children <5 years (13; 95% CI: 4-29) and persons >= 60 years (11; 95% CI: 2-30).
   Conclusion
   We present a novel way to use HUS and CBS data to generate estimates of community burden of influenza. Although the confidence intervals overlapped considerably, higher point estimates for burden among young children and older adults shows the utility for exploring the value of influenza vaccination among target groups.
AD  - India Off, US Ctr Dis Control & Prevent, Influenza Program, New Delhi, IndiaAD  - All India Inst Med Sci, Ctr Community Med, New Delhi, IndiaAD  - US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USAAD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaAD  - Natl Inst Virol, Pune, Maharashtra, IndiaAD  - SGT Med Coll, Hosp & Res Inst, Gurgaon, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Centers for Disease Control & Prevention - USAC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Virology (NIV)PU  - PUBLIC LIBRARY SCIENCE
PI  - SAN FRANCISCO
PA  - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
DA  - APR 26
PY  - 2018
VL  - 13
IS  - 4
C7  - e0196495
DO  - 10.1371/journal.pone.0196495
AN  - WOS:000431007600087
ER  -

TY  - JOUR
AU  - Singh, R
AU  - Pandey, D
AU  - Dhariwal, S
AU  - Sood, P
AU  - Chand, D
TI  - Bioconversion of acrylonitrile using nitrile hydratase activity of <i>Bacillus</i> sp APB-6
T2  - 3 BIOTECH
KW  - Nitrile hydratase
KW  - Bioconversion
KW  - Immobilization
KW  - Acrylonitrile
KW  - Acrylamide
KW  - RHODOCOCCUS-RHODOCHROUS PA-34
KW  - PSEUDONOCARDIA-THERMOPHILA
KW  - CATALYZED PRODUCTION
KW  - RESTING CELLS
KW  - ACRYLAMIDE
KW  - NICOTINAMIDE
KW  - BIOPROCESS
KW  - AMIDASE
KW  - ACID
KW  - GENE
AB  - Bacillus sp. APB-6 harboring nitrile hydratase was used in the production of acrylamide from acrylonitrile. Bacillus sp. APB-6, for maximum production of Co++ containing nitrile hydratase, was cultured in the medium containing lactose (18.0 g l(-1)), peptone (1.0 g l-1), yeast extract (2.0 g l(-1)), MgSO4 (0. 5 g l(-1)), K2HPO4 (0.6 g l(-1)), urea (9.0 g l(-1)), and CoCl2 (0.01 g l(-1)), pH 7.0, and incubated at 35 degrees C for 24 h in an incubator shaker (160 rpm). Nitrile hydratase exhibited relatively high specificity for aliphatic nitriles. Free cells were immobilized using 2% (w/v) agar solution to enhance enzyme stability and reusability in repetitive cycles of acrylamide production. Under optimized conditions, nearly complete bioconversion of acrylonitrile was achieved with a fair recovery of 85% using free and immobilized cells equivalent to 500 mg dcw l(-1). An efficient nitrile hydratase-mediated bioconversion of acrylonitrile to acrylamide at l(-1) scale was achieved with time and space productivity of 426 g h(-1) g(-1) dcw using free cells.
AD  - Himachal Pradesh Univ, Dept Biotechnol, Summer Hill, Shimla 171005, IndiaAD  - All India Inst Med Sci, Dept Reprod Biol, Delhi 110029, IndiaC3  - Himachal Pradesh UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER HEIDELBERG
PI  - HEIDELBERG
PA  - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
DA  - APR 26
PY  - 2018
VL  - 8
IS  - 5
C7  - 225
DO  - 10.1007/s13205-018-1207-1
AN  - WOS:000431719300001
ER  -

TY  - JOUR
AU  - Dutta, M
AU  - Singh, B
AU  - Joshi, M
AU  - Das, D
AU  - Subramani, E
AU  - Maan, M
AU  - Jana, SK
AU  - Sharma, U
AU  - Das, S
AU  - Dasgupta, S
AU  - Ray, CD
AU  - Chakravarty, B
AU  - Chaudhury, K
TI  - Metabolomics reveals perturbations in endometrium and serum of minimal and mild endometriosis
T2  - SCIENTIFIC REPORTS
KW  - SQUAMOUS-CELL CARCINOMA
KW  - EUTOPIC ENDOMETRIUM
KW  - ORTHOGONAL PROJECTIONS
KW  - LATENT STRUCTURES
KW  - NMR-SPECTROSCOPY
KW  - EX-VIVO
KW  - BIOMARKERS
KW  - METABOLISM
KW  - CANCER
KW  - GLUTAMINE
AB  - Endometriosis is a common benign gynecological disease, characterized by growth and proliferation of endometrial glands and stroma outside the uterus. With studies showing metabolic changes in various biofluids of endometriosis women, we have set upon to investigate whether endometrial tissue show differences in their metabolic profiles. H-1 NMR analysis was performed on eutopic endometrial tissue of women with endometriosis and controls. Analysis was performed on spectral data and on relative concentrations of metabolites obtained from spectra using multivariate and univariate data analysis. Analysis shows that various energy, ketogenic and glucogenic metabolites have significant altered concentrations in various stages of endometriosis. In addition, altered tissue metabolites in minimal and mild stages of endometriosis were explored in serum of these patients to assess their role in disease diagnosis. For Stage I diagnosis alanine was found to have 90% sensitivity (true positives) and 58% specificity (true negatives). For Stage II diagnosis alanine, leucine, lysine, proline and phenylalanine showed significant altered levels in serum. While sensitivity of these serum metabolites varied between 69.2-100% the specificity values ranged between 58.3-91.7%. Further, a regression model generated with this panel of serum markers showed an improved sensitivity and specificity of 100% and 83%, respectively for Stage II diagnosis.
AD  - Indian Inst Technol, Sch Med Sci & Technol, Kharagpur, W Bengal, IndiaAD  - Birla Inst Technol Pilani, Dept Biotechnol, Dubai Campus, Dubai, U Arab EmiratesAD  - Tata Inst Fundamental Res, Natl Facil High Field NMR, Bombay, Maharashtra, IndiaAD  - Jawaharlal Nehru Univ, Sch Biotechnol, Delhi, IndiaAD  - Natl Inst Technol, Dept Chem & Biotechnol, Papum Pare, Arunachal Prade, IndiaAD  - All India Inst Med Sci, Deapt NMR, Delhi, IndiaAD  - Indian Inst Technol, Dept Chem, Kharagpur, W Bengal, IndiaAD  - Inst Post Grad Med Educ & Res, Obstet & Gynecol, Kolkata, W Bengal, IndiaAD  - Inst Reprod Med, Sect 3, Kolkata, W Bengal, IndiaAD  - DSPM IIIT Naya Raipur, Dept Elect & Commun Engn, Naya Raipur, CG, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - KharagpurC3  - Tata Institute of Fundamental Research (TIFR)C3  - Jawaharlal Nehru University, New DelhiC3  - National Institute of Technology (NIT System)C3  - National Institute of Technology Arunachal PradeshC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - KharagpurC3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataPU  - NATURE PORTFOLIO
PI  - BERLIN
PA  - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
DA  - APR 24
PY  - 2018
VL  - 8
C7  - 6466
DO  - 10.1038/s41598-018-23954-7
AN  - WOS:000430662200011
ER  -

TY  - JOUR
AU  - Dabas, Y
AU  - Mohan, A
AU  - Xess, I
TI  - Serum galactomannan antigen as a prognostic and diagnostic marker for invasive aspergillosis in heterogeneous medicine ICU patient population
T2  - PLOS ONE
KW  - CRITICALLY-ILL PATIENTS
KW  - PULMONARY ASPERGILLOSIS
KW  - RISK-FACTORS
KW  - BRONCHOALVEOLAR LAVAGE
KW  - RESPIRATORY-TRACT
KW  - PIPERACILLIN
KW  - INFECTIONS
KW  - DISEASE
AB  - Objective & para;& para;This study was conducted to get a complete clinical and mycological picture of invasive aspergillosis (IA) in respiratory medicine ICU of a tertiary care hospital.& para;& para;Patients & para;& para;From the cohort of 235 patients only one had proven IA. Based on AspICU algorithm, 21 had putative IA (8.9%), 12 were colonised (5.1%).& para;& para;Results & para;& para;Adjusting the confounding factors, significant risk factors for IA were chronic obstructive pulmonary disease (COPD), temperature of >= 38 degrees C, pneumonia and acute respiratory distress syndrome (ARDS). The best predictor of IA was AspICU algorithm (AUC, 1) followed by serum galactomannan antigen (GM) cut-off (>= 1.24) calculated based on AspICU algorithm (AUC, 0.822). For 37% of patients, IA diagnoses was made earlier with serum GM than radiology. There were 70/235 (29.8%) deaths within 30 days of enrolment in the study. Aspergillus culture positivity (34/235, 14.5%) was associated with very high mortality (27/34, 79.4%), (p<0.05). The best predictor of mortality was GM cut-off (>= 1.24) calculated based on AspICU algorithm (AUC, 0.835).& para;& para;Conclusion & para;& para;This study imparts the focus on relatively underestimated Aspergillus infections prevalent in ICUs. The AspICU algorithm was found to be useful over others for IA diagnosis. The prognostic usefulness of serum GM antigen detection test highlighted overlooking the same may not be rewarding for the outcome of IA suspected ICU subpopulation.
AD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pulm Med & Sleep Disorders, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - PUBLIC LIBRARY SCIENCE
PI  - SAN FRANCISCO
PA  - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
DA  - APR 23
PY  - 2018
VL  - 13
IS  - 4
C7  - e0196196
DO  - 10.1371/journal.pone.0196196
AN  - WOS:000430660600042
ER  -

TY  - JOUR
AU  - Sehrawat, P
AU  - Biswas, A
AU  - Kumar, P
AU  - Singla, P
AU  - Wig, N
AU  - Dar, L
AU  - Sood, R
TI  - Role of Cytokines as Molecular Marker of Dengue Severity
T2  - MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
KW  - Dengue infection
KW  - Cytokine storm
KW  - TNF-alpha
KW  - IFN-gamma
KW  - HEMORRHAGIC-FEVER
AB  - Objective: Dengue infection is a rapidly spreading vector-borne disease and is endemic in the Indian subcontinent. It has varied manifestations ranging from subclinical infection to severe fatal shock syndrome. This study aimed to estimate cytokine level in dengue patients and correlate them with dengue severity.
   Methods: Cases of dengue fever diagnosed in the department of medicine of our institute from July 2015 to November 2016 were included in the study. The clinical features, biochemical, hematological and radiological parameters along with cytokine levels (Interferon-gamma, Interleukin-6, and Tumour Necrosis Factor-alpha) were recorded in all patients.
   Results: Out of 80 confirmed cases of dengue included in the study, 50 had nonsevere dengue (Group 1), and 30 patients had severe dengue (Group 2). The median level of serum TNF-alpha in group 2 (62.5 pg/mL) was significantly higher than the median level in group 1 (20 pg/mL), (p=0.043). Similarly, the median level of serum IFN-gamma in group 2 (10.25 pg/mL) was significantly higher than the median level in group 1 (8.5 pg/mL), (p=0.002). The median level of IL-6 was also higher in group 2 (29 pg/ml) as compared group 1(14.2 pg/ml), but this result was not significant (p>0.05).
   Conclusion: Some cytokines may play a role in the pathogenesis of severe manifestations of dengue.
AD  - All India Inst Med Sci, Dept Med, Third Floor,Teaching Block, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - PAGEPRESS PUBL
PI  - PAVIA
PA  - MEDITGROUP, VIA G BELLI, 4, PAVIA, 27100, ITALY
DA  - APR 20
PY  - 2018
VL  - 10
C7  - e2018023
DO  - 10.4084/MJHID.2018.023
AN  - WOS:000435447800001
ER  -

TY  - JOUR
AU  - Kumar, S
AU  - Saini, V
AU  - Maurya, IK
AU  - Sindhu, J
AU  - Kumari, M
AU  - Kataria, R
AU  - Kumar, V
TI  - Design, synthesis, DFT, docking studies and ADME prediction of some new coumarinyl linked pyrazolylthiazoles: Potential standalone or adjuvant antimicrobial agents
T2  - PLOS ONE
KW  - SOLVENT-FREE SYNTHESIS
KW  - ANTIBACTERIAL ACTIVITY
KW  - PHARMACOLOGICAL EVALUATION
KW  - MOLECULAR HYBRIDIZATION
KW  - BIOLOGICAL EVALUATION
KW  - PYRAZOLE
KW  - DERIVATIVES
KW  - ANTIOXIDANT
KW  - BACILLAMIDE
KW  - CANDIDIASIS
AB  - The control of antimicrobial resistance (AMR) seems to have come to a dead end. The major consequences of the use and abuse of antibacterial drugs are the development of resistant strains due to genetic mutability of both pathogenic and nonpathogenic microorganisms. We, herein, report the synthesis, characterization and biological activities of coumarin-thiazole-pyrazole (CTP) molecular hybrids with an effort to explore and overcome the increasing antimicrobial resistance. The compounds were characterized by analyzing their IR, Mass, H-1 and C-13 NMR spectral data and elemental analysis. The in vitro antimicrobial activity of the synthesized compounds was investigated against various pathogenic strains; the results obtained were further explained with the help of DFT and molecular orbital calculations. Compound 1b and 1f displayed good antimicrobial activity and synergistic effects when used with kanamycin and amphotericin B. Furthermore, in vitro cytotoxicity of compounds 1b and 1f were studied against HeLa cells (cervical cancer cell) and Hek-293 cells. The results of molecular docking study were used to better rationalize the action and prediction of the binding modes of these compounds.
AD  - Panjab Univ, Dept Chem, Chandigarh, IndiaAD  - Panjab Univ, Ctr Adv Studies Chem, Chandigarh, IndiaAD  - AIIMS New Delhi, Dept Biotechnol, Delhi, IndiaAD  - Panjab Univ, Dept Microbial Biotechnol, Chandigarh, IndiaAD  - KM Govt Coll, Narwana, IndiaAD  - Kurukshetra Univ, Dept Chem, Kurukshetra, Haryana, IndiaAD  - MM Univ, Dept Chem, Mullana Ambala, IndiaC3  - Panjab UniversityC3  - Panjab UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Panjab UniversityC3  - Kurukshetra UniversityC3  - Maharishi Markandeshwar UniversityPU  - PUBLIC LIBRARY SCIENCE
PI  - SAN FRANCISCO
PA  - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
DA  - APR 19
PY  - 2018
VL  - 13
IS  - 4
C7  - e0196016
DO  - 10.1371/journal.pone.0196016
AN  - WOS:000430446800068
ER  -

TY  - JOUR
AU  - Marieswaran, M
AU  - Sikidar, A
AU  - Goel, A
AU  - Joshi, D
AU  - Kalyanasundaram, D
TI  - An extended OpenSim knee model for analysis of strains of connective tissues
T2  - BIOMEDICAL ENGINEERING ONLINE
KW  - Musculoskeletal model
KW  - OpenSim
KW  - Ligament
KW  - Strain
KW  - Differential intra-bundle strain
KW  - ANTERIOR CRUCIATE LIGAMENT
KW  - MECHANICAL-PROPERTIES
KW  - ACL INJURIES
KW  - LOWER-LIMB
KW  - IN-VIVO
KW  - JOINT
KW  - RECONSTRUCTION
KW  - SURGERY
KW  - TENDON
KW  - KINEMATICS
AB  - Background: OpenSim musculoskeletal models provide an accurate simulation environment that eases limitations of in vivo and in vitro studies. In this work, a bio-mechanical knee model was formulated with femoral articular cartilages and menisci along with 25 connective tissue bundles representing ligaments and capsules. The strain patterns of the connective tissues in the presence of femoral articular cartilage and menisci in the OpenSim knee model was probed in a first of its kind study.
   Methods: The effect of knee flexion (0 degrees-120 degrees), knee rotation (-40 degrees to 30 degrees) and knee adduction (-15 degrees to 15 degrees) on the anterior cruciate, posterior cruciate, medial collateral, lateral collateral ligaments and other connective tissues were studied by passive simulation. Further, a new parameter for assessment of strain namely, the differential inter-bundle strain of the connective tissues were analyzed to provide new insights for injury kinematics.
   Results: ACL, PCL, LCL and PL was observed to follow a parabolic strain pattern during flexion while MCL represented linear strain patterns. All connective tissues showed non-symmetric parabolic strain variation during rotation. During adduction, the strain variation was linear for the knee bundles except for FL, PFL and TL.
   Conclusions: Strains higher than 0.1 were observed in most of the bundles during lateral rotation followed by abduction, medial rotation and adduction. In the case of flexion, highest strains were observed in aACL and aPCL. A combination of strains at a flexion of 0 degrees with medial rotation of 30 degrees or a flexion of 80 degrees with rotation of 30 degrees are evaluated as rupture-prone kinematics.
AD  - Indian Inst Technol Delhi, Ctr Biomed Engn, New Delhi 110016, IndiaAD  - All India Inst Med Sci, Dept Biomed Engn, New Delhi 110029, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - BMC
PI  - LONDON
PA  - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - APR 17
PY  - 2018
VL  - 17
C7  - 42
DO  - 10.1186/s12938-018-0474-8
AN  - WOS:000430730600001
ER  -

TY  - JOUR
AU  - Chaudhary, A
AU  - Kumar, V
AU  - Singh, PK
AU  - Sharma, P
AU  - Bairagya, HR
AU  - Kaur, P
AU  - Sharma, S
AU  - Chauhan, SS
AU  - Singh, TP
TI  - A glycoprotein from mammary gland secreted during involution promotes apoptosis: Structural and biological studies
T2  - ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
KW  - Crystal structure
KW  - Signalling protein
KW  - Conformation
KW  - Apoptosis
KW  - Breast cancer
KW  - OUTER-MEMBRANE PERMEABILIZATION
KW  - CARBOHYDRATE-BINDING PROPERTIES
KW  - CHITIN-LIKE OLIGOSACCHARIDES
KW  - SIGNALING GLYCOPROTEIN
KW  - ANGSTROM RESOLUTION
KW  - CRYSTAL-STRUCTURES
KW  - CYTOCHROME-C
KW  - 4 COMPLEXES
KW  - PROTEIN
KW  - BCL-2
AB  - Secretory signalling glycoprotein (SPX-40) from mammary gland is highly expressed during involution. This protein is involved in a programmed cell death during tissue remodelling which occurs at the end of lactation. SPX-40 was isolated and purified from buffalo (SPB-40) from the samples obtained during involution. One solution of SPB-40 was made by dissolving it in buffer containing 25 mM Tris-HCl and 50 mM NaCl at pH 8.0 Another solution was made by adding 25% ethanol to the above solution. The biological effects of SPB-40 dissolved in above two solutions were evaluated on MCF-7 breast cancer cell lines. Free SPB-40 indicated significant pro-apoptotic effects while ethanol exposed SPB-40 showed considerably reduced effects on the apoptosis SPB-40 was crystallized in the native state. The crystals of SPB-40 were soaked m four separate solutions containing 25% acetone, 25% ethanol, 25% butanol and 25% MPD. Four separate data sets were collected and their structures were determined at high resolutions. In all the four structures, the molecules of acetone, ethanol, butanol and MPD respectively were observed in the hydrophobic binding pocket of SPB-40. As a result of which, the conformation of Trp78 was altered thus blocking the binding site in SPB-40 leading to the loss of activity
AD  - All India Inst Med Sci, Dept Biophys, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Biochem, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - APR 15
PY  - 2018
VL  - 644
SP  - 72
EP  - 80
DO  - 10.1016/j.abb.2018.03.006
AN  - WOS:000430448600009
ER  -

TY  - JOUR
AU  - Gupta, S
AU  - Sankar, J
AU  - Lodha, R
AU  - Kabra, SK
TI  - Comparison of Prevalence and Outcomes of Pediatric Acute Respiratory Distress Syndrome Using Pediatric Acute Lung Injury Consensus Conference Criteria and Berlin Definition
T2  - FRONTIERS IN PEDIATRICS
KW  - Pediatric Acute Lung Injury Consensus Conference definition
KW  - PALICC criteria
KW  - Berlin definition
KW  - pediatric acute respiratory distress syndrome
KW  - acute respiratory distress syndrome
KW  - oxygenation index
KW  - oxygen saturation index
KW  - INTENSIVE-CARE
KW  - MULTICENTER
KW  - TRIAL
AB  - Objectives: Our objective was to compare the prevalence and outcomes of pediatric acute respiratory distress syndrome using the Pediatric Acute Lung Injury Consensus Conference (PALICC) criteria and Berlin definitions.
   Methods: We screened case records of all children aged 1 month to 17 years of age admitted to the Pediatric Intensive Care Unit (PICU) over a 3-year period (2015-2017) for presence of any respiratory difficulty at admission or during PICU stay. We applied both PALICC and Berlin criteria to these patients. Data collection included definition and outcome related variables. Data were compared between the "PALICC only group" and the "Berlin with or without PALICC" group using Stata 11.
   Results: Of a total of 615 admissions, 246 were identified as having respiratory difficulty at admission or during PICU stay. A total of 61 children (prevalence 9.9%; 95% CI: 7.8-12.4) fulfilled the definition of acute respiratory distress syndrome (ARDS) with either of the two criteria. While 60 children (98%) fulfilled PALICC criteria, only 26 children (43%) fulfilled Berlin definition. There was moderate agreement between the two definitions (Kappa: 0.51; 95% CI: 0.40-0.62; observed agreement 85%). Greater proportion of patients had severe ARDS in the "Berlin with or without PALICC group" as compared to the "PALICC only" group (50 vs. 19%). There was no difference between the groups with regard to key clinical outcomes such as duration of ventilation (7 vs. 8 days) or mortality [51.4 vs. 57.7%: RR (95% CI): 0.99 (0.64-1.5)].
   Conclusion: In comparison to Berlin definition, the PALICC criteria identified more number of patients with ARDS. Proportion with severe ARDS and complications was greater in the "Berlin with or without PALICC" group as compared to the "PALICC only" group. There were no differences in clinical outcomes between the groups.
AD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - FRONTIERS MEDIA SA
PI  - LAUSANNE
PA  - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
DA  - APR 9
PY  - 2018
VL  - 6
C7  - 93
DO  - 10.3389/fped.2018.00093
AN  - WOS:000429479400001
ER  -

TY  - JOUR
AU  - Sadhu, S
AU  - Mitra, DK
TI  - Emerging Concepts of Adaptive Immunity in Leprosy
T2  - FRONTIERS IN IMMUNOLOGY
KW  - polarized immunity
KW  - natural killer T cells
KW  - regulatory T cells
KW  - Th 17
KW  - programmed death-1-programmed death ligand-1
KW  - REGULATORY T-CELLS
KW  - NKT CELLS
KW  - LEPROMATOUS LEPROSY
KW  - MYCOBACTERIUM-TUBERCULOSIS
KW  - AUTOIMMUNE-DISEASES
KW  - PD-1 EXPRESSION
KW  - POTENTIAL ROLE
KW  - LIFE-STYLE
KW  - INFECTION
KW  - INFLAMMATION
AB  - Leprosy is a chronic intracellular infection caused by the acid-fast bacillus, Mycobacterium leprae. The disease chiefly affects the skin, peripheral nerves, mucosa of the upper respiratory tract, and the eyes. The damage to peripheral nerves results in sensory and motor impairment with characteristic deformities and disability. Presently, the disease remains concentrated in resource-poor countries in tropical and warm temperate regions with the largest number of cases reported from India. Even though innate immunity influences the clinical manifestation of the disease, it is the components of adaptive immune system which seem to tightly correlate with the characteristic spectrum of leprosy. M. leprae-specific T cell anergy with bacillary dissemination is the defining feature of lepromatous leprosy (LL) patients in contrast to tuberculoid leprosy (TT) patients, which is characterized by strong Th1-type cell response with localized lesions. Generation of Th1/Th2-like effector cells, however, cannot wholly explain the polarized state of immunity in leprosy. A comprehensive understanding of the role of various regulatory T cells, such as Treg and natural killer T cells, in deciding the polarized state of T cell immunity is crucial. Interaction of these T cell subsets with effector T cells like Th1 (IFN-gamma dominant), Th2 (interluekin-4 dominant), and Th17 (IL-17+) cells through various regulatory cytokines and molecules (programmed death-1/programmed death ligand-1) may constitute key events in dictating the state of immune polarization, thus controlling the clinical manifestation. Studying these important components of the adaptive immune system in leprosy patients is essential for better understanding of immune function, correlate(s) the immunity and mechanism(s) of its containment.
AD  - All India Inst Med Sci AIIMS, Dept Transplant Immunol, New Delhi, IndiaAD  - All India Inst Med Sci AIIMS, Dept Immunogenet, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - FRONTIERS MEDIA SA
PI  - LAUSANNE
PA  - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
DA  - APR 9
PY  - 2018
VL  - 9
C7  - 604
DO  - 10.3389/fimmu.2018.00604
AN  - WOS:000429467000001
ER  -

TY  - JOUR
AU  - Kumar, R
AU  - Arora, R
AU  - Agarwal, A
AU  - Gupta, YK
TI  - Protective effect of <i>Terminalia chebula</i> against seizures, seizure-induced cognitive impairment and oxidative stress in experimental models of seizures in rats
T2  - JOURNAL OF ETHNOPHARMACOLOGY
KW  - Terminalia chebula
KW  - Experimental seizure models
KW  - Cognitive impairment
KW  - Oxidative stress
KW  - INDIAN MEDICINAL-PLANTS
KW  - MITOCHONDRIAL DYSFUNCTION
KW  - AMELIORATES SEIZURES
KW  - ANTIEPILEPTIC DRUGS
KW  - AQUEOUS EXTRACT
KW  - ANTIOXIDANT
KW  - EPILEPSY
KW  - CURCUMIN
KW  - ACID
KW  - PHENYTOIN
AB  - Ethnopharmacological relevance: Teminalia chebula (TC) has been traditionally used in the Ayurvedic system of medicine primarily for gastrointestinal disorders. Its fruit extract has also been used to treat epilepsy and other CNS disorders.
   Aim of the study: To evaluate the effect of hydroalcoholic fruit extract of Terminalia chebula (HETC) on experimental models of seizures, seizure-induced cognitive impairment and oxidative stress in rats.
   Materials and methods: In vitro antioxidant activity of HETC was evaluated by using ABTS, NO and DPPH radical scavenging assay. For in-vivo study, seizures were induced in Wistar rats (200-225 g) by pentylenetetrazole (PTZ) and maximal-electroshock. (MES). The anticonvulsant effect of the HETC (250, 500, and 1000 mg/kg, orally) was evaluated in seizure models. The therapeutic and sub-therapeutic dose of valproate and phenytoin were also assayed. The potential effect of co-administration of HETC (500 mg/kg) with sub-therapeutic dose of valproate and phenytoin were also evaluated in PTZ and MES seizures model respectively. Effect on cognition was assessed using elevated plus maze (EPM) and passive avoidance test (PA). The in- vivo oxidative stress parameters (malondialdehyde and glutathione) were assessed in the cerebral cortex and hippocampus part of rat brain.
   Results: The IC50 value of HETC in in vitro antioxidant assays i.e. ABTS, DPPH and NO radical scavenging assay was found to be 2.27 pg/ml, 6.04 pg/ml and 4.37 pg/ml respectively. In experimental study, PTZ and MES treated groups exhibited 100% seizures with increased oxidative stress (p < 0.001) and cognitive deficits (p < 0.01) as compared to control group. HETC at highest dose (1000 mg/kg) showed 83.33% (5/6) protection in MES induced seizures while 66.66% (4/6) protection in PTZ induced seizures. However, HETC (1000 mg/kg) and co-administration of sub-therapeutic dose of HETC with valproate and phenytoin showed complete protection. In addition, it also attenuated the seizure induced oxidative stress and cognitive impairment as indicated by significant (p < 0.01) improvement in the transfer latencies in EPM and PA as compared to PTZ and MES treated group.
   Conclusions: The findings suggest that HETC exhibited significant anticonvulsant activity and also potentiated the subtherapeutic dose of phenytoin and valproate indicate its usefulness as an adjuvant to antiepileptic drugs with an advantage of preventing cognitive impairment and oxidative stress.
AD  - All India Inst Med Sci, Dept Pharmacol, New Delhi 110029, IndiaAD  - Nat Remedies Pvt Ltd, Bangalore, Karnataka, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Natural Remedies Pvt. Ltd.PU  - ELSEVIER IRELAND LTD
PI  - CLARE
PA  - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
DA  - APR 6
PY  - 2018
VL  - 215
SP  - 124
EP  - 131
DO  - 10.1016/j.jep.2017.12.008
AN  - WOS:000427213500012
ER  -

TY  - JOUR
AU  - Srivastava, RK
AU  - Dar, HY
AU  - Mishra, PK
TI  - Immunoporosis: Immunology of Osteoporosis-Role of T Cells
T2  - FRONTIERS IN IMMUNOLOGY
KW  - immunoporosis
KW  - osteoimmunology
KW  - bone loss
KW  - T lymphocytes
KW  - osteoporosis
KW  - OSTEOCLASTIC BONE-RESORPTION
KW  - IN-VIVO
KW  - IMMUNE-SYSTEM
KW  - RHEUMATOID-ARTHRITIS
KW  - PARATHYROID-HORMONE
KW  - HELPER-CELLS
KW  - TNF-ALPHA
KW  - INFLAMMATORY DISEASES
KW  - PERIPHERAL-BLOOD
KW  - SYNOVIAL-FLUIDS
AB  - The role of immune system in various bone pathologies, such as osteoporosis, osteoarthritis, and rheumatoid arthritis is now well established. This had led to the emergence of a modern field of systems biology called as osteoimmunology, an integrated research between fields of immunology and bone biology under one umbrella. Osteoporosis is one of the most common inflammatory bone loss condition with more than 200 million individuals affected worldwide. T helper (Th) cells along with various other immune cells are major players involved in bone homeostasis. In the present review, we specifically discuss the role of various defined T lymphocyte subsets (Th cells comprising Th1, Th2, Th9, Th17, Th22, regulatory T cells, follicular helper T cells, natural killer T cells, gamma delta T cells, and CD8(+) T cells) in the pathophysiology of osteoporosis. The study of the specific role of immune system in osteoporosis has now been proposed by our group as "immunoporosis: the immunology of osteoporosis" with special emphasis on the role of various subsets of T lymphocytes. The establishment of this new field had been need of the hour due to the emergence of novel roles of various T cell lymphocytes in accelerated bone loss observed during osteoporosis. Activated T cells either directly or indirectly through the secretion of various cytokines and factors modulate bone health and thereby regulate bone remodeling. Several studies have summarized the role of inflammation in pathogenesis of osteoporosis but very few reports had delineated the precise role of various T cell subsets in the pathobiology of osteoporosis. The present review thus for the first time clearly highlights and summarizes the role of various T lymphocytes in the development and pathophysiology of osteoporosis, giving birth to a new field of biology termed as "immunoporosis". This novel field will thus provide an overview of the nexus between the cellular components of both bone and immune systems, responsible for the observed bone loss in osteoporosis. A molecular insight into the upcoming and novel field of immunoporosis would thus leads to development of innovative approaches for the prevention and treatment of osteoporosis.
AD  - Dr Hari Singh Gour Vishwavidyalaya, Sch Biol Sci, Dept Zool, Sagar, IndiaAD  - All India Inst Med Sci, Dept Biotechnol, New Delhi, IndiaAD  - ICMR Natl Inst Res Environm Hlth, Dept Mol Biol, Bhopal, IndiaC3  - Dr. Hari Singh Gour UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute for Research in Environmental Health (NIREH)PU  - FRONTIERS MEDIA SA
PI  - LAUSANNE
PA  - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
DA  - APR 5
PY  - 2018
VL  - 9
C7  - 657
DO  - 10.3389/fimmu.2018.00657
AN  - WOS:000429276100001
ER  -

TY  - JOUR
AU  - Tewari, VV
AU  - Mehta, R
AU  - Sreedhar, CM
AU  - Tewari, K
AU  - Mohammad, A
AU  - Gupta, N
AU  - Gulati, S
AU  - Kabra, M
TI  - A novel homozygous mutation in POLR3A gene causing 4H syndrome: a case report
T2  - BMC PEDIATRICS
KW  - Congenital hypomyelinating leukodystrophy
KW  - 4H syndrome
KW  - POLR3A gene
KW  - Hypodontia
KW  - Hypogonadotropic hypogonadism
KW  - LEUKODYSTROPHY
KW  - HYPOMYELINATION
KW  - HYPODONTIA
KW  - ATAXIA
KW  - BOY
AB  - Background: 4H syndrome is a congenital hypomyelinating leukodystrophy characterized by hypodontia, hypomyelination and hypogonadotropic hypogonadism belonging to the Pol III-related leukodystrophies which arise due to mutations in the POLR3A or POLR3B gene. The clinical presentation is of neurodevelopmental delay or regression with ataxia, dystonia, nystagmus, delayed deciduous dentition and abnormal order of eruption of teeth. MRI brain shows a characteristic hypomyelination pattern. Several mutations have been described in the implicated genes but there are no reports on mutations seen in patients from India.
   Case presentation: We report a 1 1/2 year old girl, only child of a non-consanguinous couple who presented with delayed developmental milestones and delayed dentition. On physical examination she had downward slanting palpebral fissures, low set ears, smooth philtrum, hypodontia, prominent body hair and clitoromegaly. There was prominent horizontal nystagmus, hypertonia of both upper and lower limbs, exaggerated deep tendon jerks and flexor planter response. She had not attained complete head control and required support to sit. She showed absent waves on brainstem evoked response audiometry and her fundus examination showed bilateral optic atrophy with prolongation of P100 latencies on visual evoked potentials. MRI Brain showed hyperintensity of entire white matter with involvement of the internal and external capsule, frontal deep white matter and corpus callosum. Her karyotype was 46 XX and her endocrinal profile was unremarkable. Clinical exome sequencing identified an unreported mutation in the POLR3A gene. The same mutation was identified by Sanger sequencing in heterozygous state in both parents. The child is being managed with physiotherapy and developmental therapy. She has been provided with hearing aids and started on speech therapy. Parents were provided anticipatory guidance and genetic counselling about autosomal recessive nature of inheritance, risk of recurrence and need for follow-up.
   Conclusion: 4H syndrome is a rare congenital hypomyelinating leukodystrophy inherited as an autosomal recessive disorder due to mutations in the POLR3A and POLR3B gene. Delay or regression of milestones, abnormalities in dentition and endocrinal perturbations are its hallmark. A novel mutation in the POLR3A gene resulting in amino acid substitution of arginine for glutamine at codon 808 (p.R808Q) was detected in exon 18 in our case.
AD  - Army Hosp Referral & Res, Dept Pediat, New Delhi 110010, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - Army Hosp Referral & Res, Dept Radiol, New Delhi, IndiaAD  - Base Hosp, Dept Anesthesia, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - BMC
PI  - LONDON
PA  - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - APR 4
PY  - 2018
VL  - 18
C7  - 126
DO  - 10.1186/s12887-018-1108-9
AN  - WOS:000429416000002
ER  -

TY  - JOUR
AU  - Patnaik, SK
AU  - Kumar, P
AU  - Bamal, M
AU  - Patel, S
AU  - Yadav, MP
AU  - Kumar, V
AU  - Sinha, A
AU  - Bagga, A
AU  - Kanitkar, M
TI  - Cardiovascular outcomes of Nephrotic syndrome in childhood (CVONS) study: a protocol for prospective cohort study
T2  - BMC NEPHROLOGY
KW  - Nephrotic syndrome
KW  - Prediction
KW  - Outcome
KW  - Endothelial dysfunction
KW  - Laser Doppler Flowmetry
KW  - Cardiovascular disease
KW  - Children
KW  - Study protocol
KW  - INTIMA-MEDIA THICKNESS
KW  - ENDOTHELIAL DYSFUNCTION
KW  - VASCULAR FUNCTION
KW  - CHILDREN
KW  - DISEASE
KW  - RISK
KW  - FLOW
KW  - CAPILLAROSCOPY
KW  - ULTRASOUND
KW  - MANAGEMENT
AB  - Background: Nephrotic syndrome (NS) is characterized by dyslipidemia which is a well-known risk factor for atherogenesis. Atherosclerosis in childhood is mostly subclinical and endothelial dysfunction is known to precede this. Evidence for screening for endothelial dysfunction and cardiovascular risk factors and early identification of premature onset of atherosclerosis in childhood NS remains tenuous in the absence of well-designed prospective studies addressing cardiovascular comorbidity in NS. The objective of our study is to examine endothelial dysfunction and short-term cardiovascular outcomes in a carefully phenotyped cohort of patients with Nephrotic syndrome as compared to healthy controls.
   Methods: In a multi-centric prospective cohort study, 70 Steroid Resistant NS (SRNS), 70 Steroid Sensitive (SSNS) patients along with 70 Healthy Controls are being recruited. After a baseline assessment of functional and structural status of heart (2D Echocardiography), arteries (Carotid Doppler and Intima Media Thickness measurements) and microcirculation [a combination of 2D Echocardiography, Laser Doppler Flowmetry (LDF) and Brachial Artery Flow mediated dilation (FMD) and Nail Fold Capillaroscopy (NFC)], the patients are being investigated for endothelial dysfunction. Venous blood sample (15 ml) is being collected for routine investigations and assay of biochemical endothelial markers through Flow Cytometry. The patients will be followed up at 12 months and 24 months after the recruitment to look for any change from baseline period.
   Discussion: This study will able to provide a better understanding of the epidemiology of endothelial dysfunction and associated subclinical cardiovascular co-morbidity in childhood NS. Findings on characterization of prevalence of endothelial dysfunction and subclinical markers may be used to design future randomized controlled trials for evaluating the efficacy of preventive and therapeutic interventions in reducing the incidence of cardiovascular disease.
AD  - Army Hosp Res & Referral, Dept Pediat, Delhi, IndiaAD  - All India Inst Med Sci, Div Pediat Nephrol, New Delhi, IndiaAD  - All India Inst Med Sci, ICMR Ctr Adv Res Nephrol, Dept Pediat, New Delhi, IndiaAD  - Armed Forced Med Coll, Pune, Maharashtra, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Armed Forces Medical CollegePU  - BMC
PI  - LONDON
PA  - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - APR 3
PY  - 2018
VL  - 19
C7  - 81
DO  - 10.1186/s12882-018-0878-5
AN  - WOS:000429075700003
ER  -

TY  - JOUR
AU  - Aboutalib, SS
AU  - Abdelfadeel, AMG
AU  - Schreuder, A
AU  - Jang, JK
AU  - Pandey, P
AU  - Shiradkar, R
AU  - Galimzianova, A
AU  - Qi, XL
AU  - Larimer, B
AU  - McDonald, RJ
AU  - Orita, E
AU  - Dercle, L
AU  - Khosravi, M
AU  - Kim, JR
AU  - Harrison, AP
AU  - Ng, SP
AU  - Chen, MJ
AU  - Braman, N
AU  - Tang, AJ
AU  - Chen, YH
AU  - Lebovic, J
AU  - Singh, V
AU  - Wang, CX
AU  - Kundu, S
AU  - Armstrong, T
AU  - Ji, X
AU  - Van Wickle, J
AU  - Zhong, BY
AU  - Lin, LLY
AU  - Lin, L
AU  - Capaldi, D
AU  - Hemachandran, N
AU  - Motkoski, JW
AU  - Hectors, S
AU  - Adams, SJ
AU  - Jambor, I
AU  - Daye, D
AU  - Kunz, WG
AU  - Mihal, DC
AU  - Jahromi, AH
AU  - Fritz, B
AU  - Scipione, R
AU  - Bai, HX
AU  - Winzeck, S
AU  - Rathore, H
AU  - Tajmir, SH
AU  - Hardy, A
AU  - Silva, S
AU  - Thompson, SM
TI  - Trainee Research Prizes from the 2017 RSNA Scientific Assembly and Annual Meeting
T2  - RADIOLOGY
AD  - Univ Pittsburgh, Pittsburgh, PA 15260 USAAD  - NIH, Bldg 10, Bethesda, MD 20892 USAAD  - Radboudumc, Nijmegen, NetherlandsAD  - Asan Med Ctr, Seoul, South KoreaAD  - Johns Hopkins Univ, Sch Med, Baltimore, MD USAAD  - Case Western Reserve Univ, Cleveland, OH 44106 USAAD  - Stanford Univ, Sch Med, Stanford, CA USAAD  - Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R ChinaAD  - Massachusetts Gen Hosp, Charlestown, MA USAAD  - Mayo Clin, Rochester, MN USAAD  - Nippon Med Sch, Bunkyo Ku, Tokyo, JapanAD  - Columbia Univ, Med Ctr, New York, NY USAAD  - Thomas Jefferson Univ, Philadelphia, PA 19107 USAAD  - Asan Med Ctr, Seoul, South KoreaAD  - NIH, Ctr Clin, Bethesda, MD 20892 USAAD  - MD Anderson Canc Ctr, Houston, TX USAAD  - Univ Washington, Seattle, WA 98195 USAAD  - Case Western Reserve Univ, Cleveland, OH 44106 USAAD  - Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USAAD  - Shaanxi Univ Tradit Chinese Med, Coll Med Technol, Xianyang, Peoples R ChinaAD  - Harvard Med Sch, Boston, MA USAAD  - Thomas Jefferson Univ, Philadelphia, PA 19107 USAAD  - Southeast Univ, Nanjing, Jiangsu, Peoples R ChinaAD  - Carnegie Mellon Univ, Univ Pittsburgh, Pittsburgh, PA 15213 USAAD  - Univ Calif Los Angeles, Los Angeles, CA USAAD  - Univ Wisconsin, Madison, WI USAAD  - Med Coll Wisconsin, Milwaukee, WI 53226 USAAD  - Southeast Univ, Zhong Da Hosp, Nanjing, Peoples R ChinaAD  - NYU, Sch Med, New York, NY USAAD  - Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R ChinaAD  - Robarts Res Inst, London, ON, CanadaAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Univ British Columbia, Vancouver, BC, CanadaAD  - Icahn Sch Med Mt Sinai, New York, NY 10029 USAAD  - Univ Saskatchewan, Saskatoon, SK, CanadaAD  - Univ Massachusetts, Med Sch Baystate, Springfield, MA USAAD  - Massachusetts Gen Hosp, Boston, MA 02114 USAAD  - Ludwig Maximilians Univ Munchen, Munich, GermanyAD  - Univ Cincinnati, Univ Hosp, Cincinnati, OH USAAD  - Univ Calif San Diego, San Diego, CA 92103 USAAD  - Balgrist Univ Hosp, Zurich, SwitzerlandAD  - Univ Sapienza Roma, Rome, ItalyAD  - Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USAAD  - Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USAAD  - Jaslok Hosp & Res Ctr, Bombay, Maharashtra, IndiaAD  - Loyola Univ, Med Ctr, 2160 S 1st Ave, Maywood, IL 60153 USAC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - National Institutes of Health (NIH) - USAC3  - Radboud University NijmegenC3  - Johns Hopkins UniversityC3  - University System of OhioC3  - Case Western Reserve UniversityC3  - Stanford UniversityC3  - Southern Medical University - ChinaC3  - Harvard UniversityC3  - Massachusetts General HospitalC3  - Mayo ClinicC3  - Nippon Medical SchoolC3  - Columbia UniversityC3  - Thomas Jefferson UniversityC3  - National Institutes of Health (NIH) - USAC3  - NIH Clinical Center (CC)C3  - University of Texas SystemC3  - UTMD Anderson Cancer CenterC3  - University of WashingtonC3  - University of Washington SeattleC3  - University System of OhioC3  - Case Western Reserve UniversityC3  - Harvard UniversityC3  - Brigham & Women's HospitalC3  - Shaanxi University of Chinese MedicineC3  - Harvard UniversityC3  - Harvard Medical SchoolC3  - Thomas Jefferson UniversityC3  - Southeast University - ChinaC3  - Pennsylvania Commonwealth System of Higher Education (PCSHE)C3  - University of PittsburghC3  - Carnegie Mellon UniversityC3  - University of California SystemC3  - University of California Los AngelesC3  - University of Wisconsin SystemC3  - University of Wisconsin MadisonC3  - Medical College of WisconsinC3  - Southeast University - ChinaC3  - New York UniversityC3  - Sun Yat Sen UniversityC3  - Western University (University of Western Ontario)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of British ColumbiaC3  - Icahn School of Medicine at Mount SinaiC3  - University of SaskatchewanC3  - University of Massachusetts SystemC3  - Harvard UniversityC3  - Massachusetts General HospitalC3  - University of MunichC3  - University System of OhioC3  - University of CincinnatiC3  - University of California SystemC3  - University of California San DiegoC3  - University of ZurichC3  - Sapienza University RomeC3  - University of PennsylvaniaC3  - Loyola University ChicagoPU  - RADIOLOGICAL SOC NORTH AMERICA
PI  - OAK BROOK
PA  - 820 JORIE BLVD, OAK BROOK, IL 60523 USA
DA  - APR
PY  - 2018
VL  - 287
IS  - 1
SP  - 1
EP  - 4
DO  - 10.1148/radiol.2018184002
AN  - WOS:000427992600001
ER  -

TY  - JOUR
AU  - Agarwal, K
AU  - Brunetto, M
AU  - Seto, WK
AU  - Lim, YS
AU  - Fung, S
AU  - Marcellin, P
AU  - Ahn, SH
AU  - Izumi, N
AU  - Chuang, WL
AU  - Bae, H
AU  - Sharma, M
AU  - Janssen, HLA
AU  - Pan, CQ
AU  - Çelen, MK
AU  - Furusyo, N
AU  - Shalimar
AU  - Yoon, KT
AU  - Trinh, H
AU  - Flaherty, JF
AU  - Gaggar, A
AU  - Lau, AH
AU  - Cathcart, AL
AU  - Lin, LJ
AU  - Bhardwaj, N
AU  - Suri, V
AU  - Subramanian, GM
AU  - Gane, EJ
AU  - Buti, M
AU  - Chan, HLY
A1  - GS-US-320-0110 & GS-US-320
TI  - 96 weeks treatment of tenofovir alafenamide <i>vs</i>. tenofovir disoproxil fumarate for hepatitis B virus infection
T2  - JOURNAL OF HEPATOLOGY
KW  - Chronic hepatitis B virus
KW  - Bone safety
KW  - Renal safety
KW  - BONE-MINERAL DENSITY
KW  - NATURAL-HISTORY
KW  - DOUBLE-BLIND
KW  - ANTIVIRAL ACTIVITY
KW  - FANCONI SYNDROME
KW  - KIDNEY TOXICITY
KW  - SAFETY
KW  - DISEASE
KW  - EMTRICITABINE
KW  - MONOTHERAPY
AB  - Background & Aims:Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir disoproxil fumarate (TDF) through more efficient delivery of tenofovir to hepatocytes. In 48-week results from two ongoing, double-blind, randomized phase III trials, TAF was non-inferior to TDF in efficacy with improved renal and bone safety. We report 96-week outcomes for both trials.
   Methods:In two international trials, patients with chronic HBV infection were randomized 2:1 to receive 25 mg TAF or 300 mg TDF in a double-blinded fashion. One study enrolled HBeAg-positive patients and the other HBeAg-negative patients. We assessed efficacy in each study, and safety in the pooled population.
   Results:At week 96, the differences in the rates of viral suppression were similar in HBeAg-positive patients receiving TAF and TDF (73% vs. 75%, respectively, adjusted difference -2.2% (95% CI -8.3 to 3.9%; p = 0.47), and in HBeAg-negative patients receiving TAF and TDF (90% vs. 91%, respectively, adjusted difference -0.6% (95% CI -7.0 to 5.8%; p = 0.84). In both studies the proportions of patients with alanine aminotransferase above the upper limit of normal at baseline, who had normal alanine aminotransferase at week 96 of treatment, were significantly higher in patients receiving TAF than in those receiving TDF. In the pooled safety population, patients receiving TAF had significantly smaller decreases in bone mineral density than those receiving TDF in the hip (mean % change -0.33% vs. -2.51%; p < 0.001) and lumbar spine (mean % change -0.75% vs. -2.57%; p < 0.001), as well as a significantly smaller median change in estimated glomerular filtration rate by Cockcroft-Gault method (-1.2 vs. -4.8 mg/dl; p < 0.001).
   Conclusion:In patients with HBV infection, TAF remained as effective as TDF, with continued improved renal and bone safety, two years after the initiation of treatment. (C) 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights
AD  - Kings Coll Hosp London, London, EnglandAD  - Univ Pisa, Pisa, ItalyAD  - Univ Hong Kong, Hong Kong, Hong Kong, Peoples R ChinaAD  - Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South KoreaAD  - Toronto Gen Hosp, Toronto, ON, CanadaAD  - Hop Beaujon, Clichy, FranceAD  - Yonsei Univ, Seoul, South KoreaAD  - Musashino Red Cross Hosp, Tokyo, JapanAD  - Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Kaohsiung, TaiwanAD  - St Vincents Med Ctr, Asian Pacific Liver Ctr, Los Angeles, CA USAAD  - Inst Liver & Biliary Sci, New Delhi, IndiaAD  - Toronto Western Hosp, Toronto, ON, CanadaAD  - Erasmus MC, Rotterdam, NetherlandsAD  - NYU, Sch Med, Langone Med Ctr, New York, NY USAAD  - Dicle Univ Hosp Infect Dis, Diyarbakir, TurkeyAD  - Kyushu Univ Hosp, Fukuoka, JapanAD  - All India Inst Med Sci, Delhi, IndiaAD  - Pusan Natl Univ, Yangsan Hosp, Yangsan, South KoreaAD  - San Jose Gastroenterol, San Jose, CA USAAD  - Gilead Sci, Foster City, CA USAAD  - Auckland Clin Studies, Auckland, New ZealandAD  - Hosp Univ Valle Hebron, Barcelona, SpainAD  - Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R ChinaC3  - King's College Hospital NHS Foundation TrustC3  - King's College HospitalC3  - University of PisaC3  - University of Hong KongC3  - University of UlsanC3  - University of TorontoC3  - University Health Network TorontoC3  - Toronto General HospitalC3  - Universite Paris CiteC3  - Assistance Publique Hopitaux Paris (APHP)C3  - Hopital Universitaire Beaujon - APHPC3  - Yonsei UniversityC3  - Kaohsiung Medical UniversityC3  - Kaohsiung Medical University HospitalC3  - Institute of Liver & Biliary Sciences (ILBS)C3  - University of TorontoC3  - University Health Network TorontoC3  - Erasmus University RotterdamC3  - Erasmus MCC3  - New York UniversityC3  - NYU Langone Medical CenterC3  - Kyushu UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Pusan National UniversityC3  - Pusan National University HospitalC3  - Gilead SciencesC3  - Hospital Universitari Vall d'HebronC3  - Chinese University of Hong KongPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - APR
PY  - 2018
VL  - 68
IS  - 4
SP  - 672
EP  - 681
DO  - 10.1016/j.jhep.2017.11.039
AN  - WOS:000427594900009
ER  -

TY  - JOUR
AU  - Ahuja, A
AU  - Tyagi, S
AU  - Seth, T
AU  - Pati, HP
AU  - Gahlot, GPS
AU  - Tripathi, P
AU  - Somasundaram, V
AU  - Saxena, R
TI  - Comparison of Immunohistochemistry, Cytochemistry, and Flow Cytometry in AML for Myeloperoxidase Detection
T2  - INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
KW  - Acute myeloid leukemia (AML)
KW  - Myeloperoxidase (MPO)
KW  - Cytochemistry
KW  - Immunohistochemistry (IHC)
KW  - Flow cytometry (FMC)
KW  - Bone marrow aspirate (BMA)
KW  - Bone marrow biopsy (BMB)
KW  - CD34
KW  - Blasts
KW  - ACUTE MYELOID-LEUKEMIA
KW  - IMMUNOLOGICAL CLASSIFICATION
KW  - ENZYME CYTOCHEMISTRY
KW  - DIAGNOSIS
KW  - THRESHOLD
AB  - Acute Myeloid Leukemia (AML) as per World Health Organization (WHO 2008) classification is on the basis of the antigenic characterization, enzymes restriction in the neoplastic myeloid cells and the specific translocations/mutations. AML can be assessed and differentiated by flowcytometry (FCM)/immunohistochemistry (IHC)/cytochemistry techniques. Myeloperoxidase (MPO) is an unequivocal marker to differentiate AML from the acute lymphoblastic leukemia. Despite FCM popularity, it has its limitations, in form of 'dry-tap', cost, and inability of being performed by retrospective analysis. IHC, though an old technique has overcome these disadvantages of FCM. Cytochemistry, on the other hand has its own advantages in being cost-effective; technically easy to do while its disadvantages are its inability to be carried out in the old samples, 'dry-tap' conditions in aleukemic leukemia. There has been non-uniformity in the literature among these techniques especially concerning their sensitivity for MPO. A prospective study was done at All India Institute of Medical Sciences New Delhi from 01 July 2014 to 30 Nov 2015 to include 120 diagnosed acute myeloid leukemia cases. Myeloperoxidase stain was done by cytochemistry, immunohistochemistry and flow cytometry and results were compared. There were 28 cases which showed discrepancies. Out of these 28 cases immunohistochemistry showed positivity in majority (22 cases) followed by flow cytometry (14 cases). Therefore it is important to employ more than one technique and IHC must be included for detection of MPO in all suspected cases of AML especially when negative with FCM .
AD  - Army Hosp Res & Referral, Dept Lab Sci & Mol Med, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Haematol, New Delhi, IndiaAD  - Armed Forces Med Coll, Dept Pathol, Pune, Maharashtra, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Armed Forces Medical CollegePU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - APR
PY  - 2018
VL  - 34
IS  - 2
SP  - 233
EP  - 239
DO  - 10.1007/s12288-017-0849-1
AN  - WOS:000429245600005
ER  -

TY  - JOUR
AU  - Akhter, MZ
AU  - Rajeswari, MR
TI  - Anticancer activity of HMGA1 promoter targeting triplex forming oligonucleotide in HeLa cell line
T2  - INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY
KW  - Cancer
KW  - DNA triplex
KW  - Energetic
KW  - HMGA1 expression
KW  - Triplex forming oligonucleotide
KW  - MOBILITY GROUP A1
KW  - GENE-EXPRESSION
KW  - DNA TRIPLEXES
KW  - CROSS-LINKING
KW  - HELICAL DNA
KW  - TRANSCRIPTION
KW  - PROTEINS
KW  - CARCINOMA
KW  - SEQUENCES
KW  - CANCER
AB  - High mobility group protein Al (HMGA1) acts as an architectural transcription factor and regulates transcription of various genes. Upregulation of HMGA1 has been described in a large number of human malignancies and serves as a 'tumor marker'. Due to its role in neoplastic transformation and tumor progression, hmgal is considered as a promising therapeutic target. In the present study, we investigated the interaction of triplex forming oligonucleotide (TFO) of 18 bps targeted to hmgal promoter (-1917 to 1940) and its influence on the expression of HMGA1 in HeLa cells. Stability of DNA triplex was characterized using various biophysical and thermodynamic methods and was confirmed by gel retardation assay using gamma-P-32 [ATP]. Treatment of HeLa cells with hmgal specific TFO significantly downregulated HMGA1 expression at mRNA, protein levels (similar to 48%) and inhibited cell proliferation as investigated by RT-PCR, Western blot and Flow cytometiy. The findings of the study suggest that TFO-mediated inhibition of hmgal expression can be a promising strategy for modulation of gene expression and for inhibition of cancer cell proliferation. Moreover, DNA triplex-based therapeutic approaches hold promise in combating cancers associated with HMGA1 overexpression.
AD  - All India Inst Med Sci, Dept Biochem, New Delhi 110029, IndiaAD  - Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USAC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of Illinois SystemC3  - University of Illinois ChicagoC3  - University of Illinois Chicago HospitalPU  - NATL INST SCIENCE COMMUNICATION-NISCAIR
PI  - NEW DELHI
PA  - DR K S KRISHNAN MARG, PUSA CAMPUS, NEW DELHI 110 012, INDIA
DA  - APR
PY  - 2018
VL  - 56
IS  - 4
SP  - 219
EP  - 229
AN  - WOS:000429890800001
ER  -

TY  - JOUR
AU  - Akhter, MZ
AU  - Sharawat, SK
AU  - Kumar, V
AU  - Kochat, V
AU  - Equbal, Z
AU  - Ramakrishnan, M
AU  - Kumar, U
AU  - Mathur, S
AU  - Kumar, L
AU  - Mukhopadhyay, A
TI  - Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM<SUP>+</SUP>CD45<SUP>+</SUP> phenotype
T2  - ONCOGENE
KW  - MARROW-DERIVED CELLS
KW  - STEM-CELLS
KW  - MESENCHYMAL TRANSITION
KW  - SIGNALING PATHWAY
KW  - TUMOR PROGRESSION
KW  - BREAST-CANCER
KW  - THERAPY
KW  - CONTRIBUTE
KW  - EXOSOMES
KW  - CHEMORESISTANCE
AB  - Epithelial ovarian carcinoma (EOC) patients often acquire resistance against common chemotherapeutic drugs like paclitaxel and cisplatin. The mechanism responsible for the same is ambiguous. We have identified a putative drug-resistant tumour cell phenotype (EpCAM(+) CD45(+)) in the ascitic fluid of EOC patients, which appears to originate from the primary tumour. These cells represent the major tumour burden and are more drug resistant compared to EpCAM(+) tumour cells due to the over-expression of SIRT1, ABCA1 and BCL2 genes. We have found that the entire EpCAM(+) CD45+ population is highly invasive with signature mesenchymal gene expression and also consists of subpopulations of ovarian cancer stem cells (CD133(+) and CD117(+) CD44(+)). Additionally, we demonstrate that the EpCAM(+) CD45(+) tumour cells over-express major histocompatibility complex class I antigen, which enable them to evade the natural killer cell-mediated immune surveillance. Preliminary evidence obtained in OVCAR-5 cells suggests that exosomes, secreted by non-tumour cells of the ascitic fluid, play an important role in rendering drug resistance and invasive properties to the cancer cells. Identification of such aggressive tumour cells and deciphering their origin is important for designing better drug targets for EOC.
AD  - Natl Inst Immunol, Stem Cell Biol Lab, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Med Oncol, New Delhi, IndiaAD  - Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL USAAD  - All India Inst Med Sci, Dept Med Oncol, New Delhi, IndiaAD  - Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USAAD  - Inst Tumor Biol & Expt Therapy, Georg Speyer Haus, Frankfurt, GermanyAD  - Univ Delhi, Dept Biochem, Genom Facil, South Campus, New Delhi, IndiaC3  - Department of Biotechnology (DBT) IndiaC3  - National Institute of Immunology (NII)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of Illinois SystemC3  - University of Illinois ChicagoC3  - University of Illinois Chicago HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of Texas SystemC3  - UTMD Anderson Cancer CenterC3  - University of DelhiPU  - NATURE PUBLISHING GROUP
PI  - LONDON
PA  - MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - APR
PY  - 2018
VL  - 37
IS  - 16
SP  - 2089
EP  - 2103
DO  - 10.1038/s41388-017-0106-y
AN  - WOS:000430589000002
ER  -

TY  - JOUR
AU  - Arora, G
AU  - Bandopadhyaya, G
TI  - Paradigm shift in theranostics of neuroendocrine tumors: conceptual horizons of nanotechnology in nuclear medicine
T2  - ANNALS OF NUCLEAR MEDICINE
KW  - Neuroendocrine tumors
KW  - Nanoparticles
KW  - Radionuclide therapy
KW  - Drug delivery
KW  - RECEPTOR RADIONUCLIDE THERAPY
KW  - BIODEGRADABLE PCL/PEG NANOPARTICLES
KW  - RADIOLABELED PEPTIDES
KW  - TYR(3) OCTREOTATE
KW  - TARGETED THERAPY
KW  - SOMATOSTATIN
KW  - CANCER
KW  - DOSIMETRY
KW  - PET
KW  - BIODISTRIBUTION
AB  - We present a comprehensive review of Neuroendocrine Tumors (NET) and the current and developing imaging and therapeutic modalities for NET with emphasis on Nuclear Medicine modalities. Subsequently, nanotechnology and its emerging role in cancer management, especially NET, are discussed. The article is both educative and informative. The objective is to provide an insight into the developments made in nuclear medicine and nanotechnology towards management of NET, individually as well as combined together.
AD  - All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - APR
PY  - 2018
VL  - 32
IS  - 3
SP  - 151
EP  - 164
DO  - 10.1007/s12149-018-1235-2
AN  - WOS:000427631800001
ER  -

TY  - JOUR
AU  - Bagri, NK
AU  - Bagri, N
AU  - Jana, M
AU  - Gupta, AK
AU  - Wadhwa, N
AU  - Lodha, R
AU  - Kabra, SK
AU  - Chandran, A
AU  - Aneja, S
AU  - Chaturvedi, MK
AU  - Sodhi, J
AU  - Fitzwater, SP
AU  - Chandra, J
AU  - Rath, B
AU  - Kainth, US
AU  - Saini, S
AU  - Black, RE
AU  - Santosham, M
AU  - Bhatnagar, S
TI  - Efficacy of Oral Zinc Supplementation in Radiologically Confirmed Pneumonia: Secondary Analysis of a Randomized Controlled Trial
T2  - JOURNAL OF TROPICAL PEDIATRICS
KW  - zinc
KW  - chest X-ray
KW  - radiological pneumonia
KW  - children
KW  - DOUBLE-BLIND
KW  - YOUNG-CHILDREN
KW  - VITAMIN-A
KW  - PREVENTION
KW  - MORTALITY
KW  - ADJUNCT
AB  - To evaluate the effect of zinc as an adjuvant therapy in radiologically confirmed pneumonia in children 2-24 months of age.
   We analyzed data of 212 children with pneumonia for whom chest X-ray films were available at enrollment and at least two radiologists agreed on the diagnosis of pneumonia. We compared the time to recovery in the two groups (n = 121, zinc group and n = 91, placebo group) using a Cox proportional hazards regression model.
   Time to recovery was similar in both groups [median interquartile range: zinc, 84 h (64, 140 h); placebo, 85 h (65, 140 h)]. The absolute risk reduction for treatment failure was 5.2% (95% confidence interval: -4.8, 15.1) with zinc supplementation.
   There was no significant beneficial effect of zinc on the duration of recovery or risk of treatment failure in children with radiologically confirmed pneumonia.
AD  - All India Inst Med Sci, Dept Pediat, New Delhi 110029, IndiaAD  - Mahajan Imaging, New Delhi 110024, IndiaAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pediat, Ctr Diarrheal Dis & Nutr Res, New Delhi 110029, IndiaAD  - Translat Hlth Sci & Technol Inst, Pediat Biol Ctr, Faridabad 121001, Haryana, IndiaAD  - Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21218 USAAD  - Johns Hopkins Bloomberg Sch Publ Hlth, Dept Pediat, Baltimore, MD 21218 USAAD  - Kalawati Saran Childrens Hosp, Dept Pediat, Lady Hardinge Med Coll, New Delhi 110001, IndiaAD  - Deen Dayal Upadhyay Hosp, Dept Pediat, New Delhi 110064, IndiaAD  - Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Amer Indian Hlth, Baltimore, MD 21218 USAC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)C3  - Johns Hopkins UniversityC3  - Johns Hopkins Bloomberg School of Public HealthC3  - Johns Hopkins UniversityC3  - Johns Hopkins Bloomberg School of Public HealthC3  - Lady Hardinge Medical College & HospitalC3  - Johns Hopkins UniversityC3  - Johns Hopkins Bloomberg School of Public HealthPU  - OXFORD UNIV PRESS
PI  - OXFORD
PA  - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
DA  - APR
PY  - 2018
VL  - 64
IS  - 2
SP  - 110
EP  - 117
DO  - 10.1093/tropej/fmx036
AN  - WOS:000429484200005
ER  -

TY  - JOUR
AU  - Balhara, YPS
AU  - Harshwardhan, M
AU  - Kumar, R
AU  - Singh, S
TI  - Extent and pattern of problematic internet use among school students from Delhi: Findings from the cyber awareness programme
T2  - ASIAN JOURNAL OF PSYCHIATRY
KW  - Behavioral addictions
KW  - Internet addiction
KW  - Problematic intent use
KW  - Adolescents
KW  - Students
KW  - NATIONALLY REPRESENTATIVE SAMPLE
KW  - RISK-FACTORS
KW  - ADDICTION
KW  - PREVALENCE
KW  - ADOLESCENTS
AB  - The student population is likely to be vulnerable to problems associated with increased online activity. We present the findings on extent and pattern of problematic internet use based on observations from a cyber awareness initiative undertaken in national capital city of New Delhi. A total of 25 schools were enrolled in the first phase of the initiative. The students in the middle, high, secondary and senior secondary grades were eligible for inclusion in the initiative. The Generalized Problematic Internet Use Scale 2 was used to assess problematic internet use. Correlation analysis was done using Pearson's correlation. A binary logistic regression was carried to see how various variables predicted the GPIUS scores. The level of statistical significance was kept at p < 0.05 for all the tests. A total of 6291 students participated in first phase. Around 19% of study participants reported problematic internet use and 37% used internet for mood regulation. Male gender, older age, studying in senior grades, and owning a personal device were associated with higher rates of problematic internet use. Use of internet for accessing social media, online gaming, and recreational surfing is associated with problematic internet use, while use of internet for educational activities was associated with lesser problems. There is a need to cover all students under cyber awareness program in order to facilitate safe and healthy use of internet.
AD  - AIIMS, Natl Drug Dependence Treatment Ctr, Dept Psychiat, BAC, New Delhi, IndiaAD  - South East Dist Delhi Police, Delhi, IndiaAD  - AIIMS, Natl Drug Dependence Treatment Ctr, Dept Psychiat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - National Drug Dependence Treatment Centre (NDDTC)PU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - APR
PY  - 2018
VL  - 34
SP  - 38
EP  - 42
DO  - 10.1016/j.ajp.2018.04.010
AN  - WOS:000430846800011
ER  -

TY  - JOUR
AU  - Bansal, R
AU  - Hague, MA
AU  - Yadav, P
AU  - Gupta, D
AU  - Ethayathulla, AS
AU  - Hassan, MI
AU  - Kaur, P
TI  - Estimation of structure and stability of MurE ligase from <i>Salmonella enterica</i> serovar Typhi
T2  - INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
KW  - MurE ligase
KW  - Fluorescence spectroscopy
KW  - Circular dichroism
KW  - Chemical denaturation
KW  - Protein stability
KW  - SECONDARY STRUCTURE ANALYSES
KW  - LINEAR EXTRAPOLATION METHOD
KW  - HUMAN SERUM-ALBUMIN
KW  - PEPTIDOGLYCAN BIOSYNTHESIS
KW  - CIRCULAR-DICHROISM
KW  - STAPHYLOCOCCUS-AUREUS
KW  - ESCHERICHIA-COLI
KW  - FREE-ENERGY
KW  - ALPHA-LACTALBUMIN
KW  - CYTOCHROME-C
AB  - MurE ligase catalyzes the assembly of peptide moiety, an essential component of bacterial cell wall. We have explored the conformational stability and unfolding equilibrium behaviour of the protein MurE ligase by determining the conformational free energy, entropy and enthalpy parameters under stress conditions. MurE from Salmonella enterica Serovar Typhi was cloned, expressed and purified. Conformational changes associated with increasing concentration of GdmCI- and urea-induced denaturation of MurE were monitored using Circular Dichroism (CD) and fluorescence spectroscopies. The secondary structural content of protein estimated by CD experiment is in close agreement with the predicted MurE ligase structure by homology modeling. Denaturant-induced transition curve was analyzed for thermodynamic parameters. Average values for MurE ligase of Delta G(D)(0) =3.13 kcal mol(-1), m =1.52 kcal mol(-1) M-1 and C-m (=Delta G(D)(0)/m)= 2.05 M were calculated in the presence of GdmCl whereas in the case of urea these were Delta G(D)(0) = 3.04 kcal mol(-1), m= 1.20 kcal mol(-1) M-1 and C-m (=A Delta G(D)(0)/m)= 2.53 M. The observed superposition of normalized transition curve of two independent optical properties suggested that GdmCland urea-induced denaturation follow a two-state process. (C) 2017 Elsevier B.V. All rights reserved.
AD  - All India Inst Med Sci, Dept Biophys, New Delhi 110029, IndiaAD  - Delhi Technol Univ, Delhi 110042, IndiaAD  - Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, New Delhi 110025, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Delhi Technological UniversityC3  - Jamia Millia IslamiaPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - APR
PY  - 2018
VL  - 109
SP  - 375
EP  - 382
DO  - 10.1016/j.ijbiomac.2017.12.087
AN  - WOS:000428099900038
ER  -

TY  - JOUR
AU  - Barwad, A
AU  - Ramteke, PP
AU  - Gamanagattil, S
TI  - Papillary Carcinoma Thyroid Presenting as Huge Scalp Metastases
T2  - JOURNAL OF CYTOLOGY
KW  - SKULL METASTASIS
AD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - APR-JUN
PY  - 2018
VL  - 35
IS  - 2
SP  - 126
EP  - 127
DO  - 10.4103/JOC.JOC_133_17
AN  - WOS:000428589400014
ER  -

TY  - JOUR
AU  - Basnet, B
AU  - Bhushan, A
AU  - Khan, R
AU  - Kumar, G
AU  - Sharma, VK
AU  - Sharma, A
AU  - Gupta, S
TI  - Plasma & urinary catecholamines & urinary vanillylmandelic acid levels in patients with generalized vitiligo
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
KW  - Dopamine
KW  - epinephrine
KW  - melanocyte transfer
KW  - norepinephrine
KW  - vanillylmandelic acid
KW  - vitiligo
KW  - SUCTION
KW  - MELANOCYTES
KW  - SKIN
AB  - Background & objectives: Vitiligo is an acquired skin disease characterized by depigmented areas of the skin. Increased release of catecholamines from autonomic nerve endings in microenvironment of melanocytes in affected skin might he involved in the aetiopathogenesis of vitiligo. Levels of catecholamines are considered as being related to onset or worsening of the disease. Therefore, in this study, the role of catecholamines was evaluated in mapping disease stability and outcome of vitiligo patients undergoing melanocyte transfer.
   Methods: In this study, circulatory and urinary levels of catecholamine (CA) and vanillylmandelic acid (VMA) were determined in 45 individuals (30 vitiligo patients and 15 healthy controls) using ELISA.
   Results: A significant increase for plasma and urinary catecholamines along with VMA was observed as compared to healthy controls. When the pre- and post-intervention levels were analyzed in responders and non-responders, respectively, only dopamine showed significant decline in urine, rest of the molecules in plasma as well as urine showed non-significant decline except VMA which showed insignificant increase.
   Interpretation & conclusions: Levels of plasma/urinary epinephrine, and plasma dopamine, could not be established as biomarkers for disease stability or successful outcome of autologous melanocyte transfer in generalized vitiligo patients. However, dopamine (urine) might be of help in determining the stability in patients with generalized vitiligo undergoing melanocyte transfer. Further studies need to be done on a large sample of patients to confirm our findings.
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Biochem, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - APR
PY  - 2018
VL  - 147
SP  - 384
EP  - 390
DO  - 10.4103/ijmr.IJMR_657_16
AN  - WOS:000439219400010
ER  -

TY  - JOUR
AU  - Bhardwaj, S
AU  - Goyal, S
AU  - Yadav, AK
AU  - Goyal, A
TI  - Multi-organ IgG4-related disease: Demystifying the diagnostic enigma
T2  - JOURNAL OF POSTGRADUATE MEDICINE
KW  - Castleman's disease
KW  - IgG4-related disease
KW  - lymphoma
AB  - IgG4-related disease (IgG4-RD) is a multisystemic mass forming immune-mediated disease entity, commonly creating confusion and diagnostic challenges. We present a case of a 25-year-old female who presented with bilateral orbital masses, lymphadenopathy, paraspinal and renal masses, which clinicoradiologically simulated lymphoma. The lymph node biopsy revealed interfollicular sheets of plasma cells creating confusion with Castleman's disease and marginal zone lymphoma. The orbital biopsy revealed ductular destruction, periductular plasma cells, and fibrosis, mimicking Sjogren's syndrome and Castleman's disease. However, the correlation of the clinical features with histopathological findings, IgG4 immunopositivity, and serum studies helped in clinching the diagnosis. This case presents an uncommon combination of clinical features infrequently reported in literature. Furthermore, and more importantly, it highlights the need to keep a differential of IgG4-RD in mind, to aid early and correct treatment of the disease.
AD  - Vardhman Mahavir Med Coll & Safdarjung Hosp, Dept Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi, IndiaC3  - Vardhman Mahavir Medical College & Safdarjung HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - APR-JUN
PY  - 2018
VL  - 64
IS  - 2
SP  - 119
EP  - 122
DO  - 10.4103/jpgm.JPGM_778_16
AN  - WOS:000430959400013
ER  -

TY  - JOUR
AU  - Chauhan, R
AU  - Sazawal, S
AU  - Pati, HP
TI  - Laboratory Monitoring of Chronic Myeloid Leukemia in Patients on Tyrosine Kinase Inhibitors
T2  - INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
KW  - Chronic Myeloid Leukemia
KW  - Monitoring
KW  - Tyrosine kinase inhibitors
KW  - Reverse transcriptase quantitative polymerase chain reaction
KW  - RESIDUAL DISEASE DETECTION
KW  - POLYMERASE-CHAIN-REACTION
KW  - FUSION GENE TRANSCRIPTS
KW  - MOLECULAR-BIOLOGY
KW  - RECOMMENDATIONS
KW  - MANAGEMENT
KW  - PCR
KW  - QUANTIFICATION
KW  - THERAPY
KW  - STANDARDIZATION
AB  - Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm characterized by translocation of genetic material from chromosome 9 to chromosome 22 to form a fusion gene (BCR-ABL1) that is responsible for abnormal tyrosine kinase activity and alteration of various downstream signaling pathways. In addition to morphological diagnosis of CML phase, it is essential to detect BCR-ABL1 fusion by either metaphase cytogenetics or reverse transcriptase polymerase chain reaction that also determines type of mRNA transcript. Once treatment begins, monitoring the response to Tyrosine Kinase Inhibitor (TKI) using standardized techniques and guidelines is important to check for failure of response and thus, plan timely intervention by increasing the dose of TKI or opting for second line TKIs. The goal is to stop evolution of CML to accelerated phase or blast crisis that has poor response to treatment. Also, it is desirable to achieve good outcomes and even treatment free remission in patients of CML on TKI. Thus, molecular monitoring by reverse transcriptase quantitative PCR (RT-qPCR) is done at regular intervals. There are international recommendations and quality control measures to standardize the reporting of fusion gene transcript levels by quantitative PCR (RT-qPCR) in CML to achieve and maintain sensitivity in molecular detection of CML disease burden. Various state-of-the-art molecular techniques have emerged to accurately determine the number of fusion-gene transcript levels. This review highlights various methodologies and their practical implications in management of CML patients on TKI.
AD  - All India Inst Med Sci, Dept Hematol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - APR
PY  - 2018
VL  - 34
IS  - 2
SP  - 197
EP  - 203
DO  - 10.1007/s12288-018-0933-1
AN  - WOS:000429245600001
ER  -

TY  - JOUR
AU  - Chauhan, R
AU  - Tyagi, S
AU  - Mirgh, S
AU  - Mishra, P
AU  - Seth, T
AU  - Mahapatra, M
AU  - Pati, H
AU  - Saxena, R
TI  - Expect the unexpected - Loss of surface CD3 on flow cytometry in hepatosplenic T-cell lymphoma: An eye opener
T2  - INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY
KW  - CD3
KW  - hepatosplenic
KW  - lymphoma
AB  - Hepatosplenic T-cell lymphoma (HSTCL) is a rare extranodal T-cell lymphoma that shows preferential sinusoidal infiltration of spleen and liver. It usually shows bright expression of surface CD3 (sCD3) with restriction for.d-T cell receptors (TCR). We present a case of a 34-year-old male who presented with hepatosplenomegaly and B symptoms. His peripheral blood and bone marrow (BM) was involved by atypical lymphoid cells that were CD2+, CD7+, CD56+, cytoplasmic CD3+, and sCD3-on immunophenotyping by flow cytometry. As sCD3 is a lineage marker for T-cell lymphomas, the loss of sCD3 posed a diagnostic dilemma. However, typical pattern of sinusoidal BM and liver involvement by CD3+ cells and TCR gene rearrangement positivity led to final diagnosis of HSTCL. The differential diagnosis, workup, and clinical course of the case are discussed. To the best of our knowledge, only one case of de novo HSTCL with negative sCD3 has been reported before in the literature.
AD  - All India Inst Med Sci, Dept Hematol, Room 202, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - APR-JUN
PY  - 2018
VL  - 61
IS  - 2
SP  - 275
EP  - 277
DO  - 10.4103/IJPM.IJPM_442_17
AN  - WOS:000430851900028
ER  -

TY  - JOUR
AU  - Damle, NA
AU  - Bal, C
AU  - Singh, TP
AU  - Gupta, R
AU  - Reddy, S
AU  - Kumar, R
AU  - Tripathi, M
TI  - Anaplastic thyroid carcinoma on 68 Ga-PSMA PET/CT: opening new frontiers
T2  - EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
KW  - MEMBRANE ANTIGEN
KW  - EXPRESSION
KW  - CANCER
KW  - NEOVASCULATURE
AD  - All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - APR
PY  - 2018
VL  - 45
IS  - 4
SP  - 667
EP  - 668
DO  - 10.1007/s00259-017-3904-0
AN  - WOS:000426318200018
ER  -

TY  - JOUR
AU  - Dhooria, S
AU  - Mehta, RM
AU  - Srinivasan, A
AU  - Madan, K
AU  - Sehgal, IS
AU  - Pattabhiraman, V
AU  - Yadav, P
AU  - Sivaramakrishnan, M
AU  - Mohan, A
AU  - Bal, A
AU  - Garg, M
AU  - Agarwal, R
TI  - The safety and efficacy of different methods for obtaining transbronchial lung cryobiopsy in diffuse lung diseases
T2  - CLINICAL RESPIRATORY JOURNAL
KW  - bronchoscopy
KW  - cryoprobe
KW  - diffuse parenchymal lung disease
KW  - interstitial lung disease
KW  - IPF
KW  - lung biopsy
KW  - sarcoidosis
KW  - DIAGNOSTIC YIELD
KW  - FLEXIBLE CRYOPROBE
KW  - BIOPSY
KW  - TRIAL
AB  - IntroductionMost data on transbronchial lung cryobiopsy (TBLC) are from single centers, with little evidence on the outcome of different methods for performing TBLC.
   ObjectiveTo report the diagnostic yield and safety of TBLC with different procedural techniques.
   Materials and MethodsRetrospective multicenter study of subjects who underwent TBLC for the diagnosis of diffuse parenchymal lung diseases (DPLDs). The procedure was performed using various methods: flexible or rigid bronchoscopy, with or without the use of fluoroscopy or occlusion balloon.
   ResultsIn total, 128 subjects (59% women) with a mean age of 48.9years were included. The overall diagnostic yield of TBLC was 78.1%, with a definite diagnosis on multidisciplinary discussion made in 57 (44.5%) subjects. On a multivariate analysis, the diagnostic yield was associated with the number of biopsies taken {ajdusted odds ratio [AOR] [95% confidence interval (CI)], 2.17 [1.29-3.67]}. The incidence of pneumothorax was lower in subjects who underwent TBLC with fluoroscopic guidance (5.9% vs 20.9%), [AOR (95% CI), 0.26 (0.07-0.94)]. Moderate-to-severe bleeding occurred less frequently when an occlusion balloon was used [1.8% vs 35.7%; AOR (95% CI), 0.02 (0.001-0.18)], after adjusting for age, use of fluoroscopy, number of biopsies obtained and number of lobes sampled. Four deaths occurred; 2 because of acute exacerbation of idiopathic pulmonary fibrosis.
   ConclusionsTransbronchial lung cryobiopsy was found to offer a reasonable yield in the diagnosis of DPLDs. The incidence of pneumothorax and moderate-to-severe bleeding was lower with the use of fluoroscopy and an occlusion balloon, respectively.
AD  - Postgrad Inst Med Educ & Res, Dept Pulm Med, Chandigarh, Punjab, IndiaAD  - Apollo Hosp, Dept Pulm Crit Care & Sleep Med, Bengaluru, Karnataka, IndiaAD  - Royal Care Hosp, Dept Pulmonol Allergy & Sleep Med, Coimbatore, Tamil Nadu, IndiaAD  - All India Inst Med Sci, Dept Pulm Med & Sleep Disorders, New Delhi, IndiaAD  - Postgrad Inst Med Educ & Res, Dept Histopathol, Chandigarh, Punjab, IndiaAD  - Postgrad Inst Med Educ & Res, Dept Radiodiag & Imaging, Chandigarh, Punjab, IndiaC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - APR
PY  - 2018
VL  - 12
IS  - 4
SP  - 1711
EP  - 1720
DO  - 10.1111/crj.12734
AN  - WOS:000429581600049
ER  -

TY  - JOUR
AU  - Dutt, V
AU  - Saini, V
AU  - Gupta, P
AU  - Kaur, N
AU  - Bala, M
AU  - Gujar, R
AU  - Grewal, A
AU  - Gtipta, S
AU  - Dua, A
AU  - Mittal, A
TI  - <i>S</i>-allyl cysteine inhibits TNFα-induced skeletal muscle wasting through suppressing proteolysis and expression of inflammatory molecules
T2  - BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
KW  - TNF alpha
KW  - SAC
KW  - Myotuhes
KW  - Skeletal muscle atrophy
KW  - FACTOR-KAPPA-B
KW  - OXIDATIVE STRESS
KW  - ALLYLCYSTEINE PREVENTS
KW  - UBIQUITIN LIGASES
KW  - GENE-EXPRESSION
KW  - PROPYL CYSTEINE
KW  - CATHEPSIN-L
KW  - ATROPHY
KW  - PROTEIN
KW  - ACTIVATION
AB  - Background: Elevated levels of inflammatory molecules are key players in muscle wasting/atrophy leading to human morbidity. TNF alpha is a well-known pro-inflammatory cytokine implicated in the pathogenesis of muscle wasting under diverse clinical settings. S-allyl cysteine (SAC), an active component of garlic (Allium sativum), has established anti-oxidant and anti-inflammatory effects in various cell types. However, the impact of SAC on skeletal muscle pathology remains unexplored. Owing to the known anti-inflammatory properties of SAC, we investigated whether pre-treatment with SAC has a protective role in TNF alpha-induced atrophy in cultured myotubes.
   Methods and results: C2C12 myotubes were treated with TNF alpha (100 ng/ml) in the presence or absence of SAC (0.01 mM). TNF alpha treatment induced atrophy in myotubes by up-regulating various proteolytic systems i.e. cathepsin L, calpain, ubiquitin-proteasome E3-ligases (MuRF1/atroginl), caspase 3 and autophagy (Beclin1/LC3B). TNF alpha also induced the activation of NF kappa B by stimulating the degradation of hcBa (inhibitor of NF kappa B), in myotubes. The alterations in proteolytic systems likely contribute to the degradation of muscle-specific proteins and reduce the myotube length, diameter and fusion index. The SAC supplementation significantly impedes TNF alpha-induced protein loss and protects myotube morphology by suppressing protein catabolic systems and endogenous level of inflammatory molecules namely TNF alpha, IL-6, IL-1 beta, TNF-like weak inducer of apoptosis (TWEAK), fibroblast growth factor-inducible 14 (Fn14) and Nox.
   Conclusion and general significance: Our findings reveal anti-atrophic role for SAC, as it prevents alterations in protein metabolism and protects myotubes by regulating the level of inflammatory molecules and multiple proteolytic systems responsible for muscle atrophy.
AD  - Kurukshetra Univ, Univ Coll, Skeletal Muscle Lab, Kurukshetra 136119, Haryana, IndiaAD  - Univ Alabama Birmingham, Ctr Free Radical Biol, Dept Microbiol, Birmingham, AL 35205 USAAD  - All India Inst Med Sci, Dept Biotechnol, New Delhi 110029, IndiaAD  - CSIR Inst Microbial Technol, Sect 39A, Chandigarh 160036, IndiaAD  - Kurukshetra Univ, UIET, Biotechnol Dept, Kurukshetra 136119, Haryana, IndiaC3  - Kurukshetra UniversityC3  - University of Alabama SystemC3  - University of Alabama BirminghamC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Microbial Technology (IMTECH)C3  - Kurukshetra UniversityPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - APR
PY  - 2018
VL  - 1862
IS  - 4
SP  - 895
EP  - 906
DO  - 10.1016/j.bbagen.2017.12.015
AN  - WOS:000427312900012
ER  -

TY  - JOUR
AU  - Fehlings, MG
AU  - Kopjar, B
AU  - Ibrahim, A
AU  - Tetreault, LA
AU  - Arnold, PM
AU  - Defino, H
AU  - Kale, SS
AU  - Yoon, ST
AU  - Barbagallo, GM
AU  - Bartels, RHM
AU  - Zhou, Q
AU  - Vaccaro, AR
AU  - Zileli, M
AU  - Tan, G
AU  - Yukawa, Y
AU  - Brodke, DS
AU  - Shaffrey, CI
AU  - de Moraes, OS
AU  - Woodard, EJ
AU  - Scerrati, M
AU  - Tanaka, M
AU  - Toyone, T
AU  - Sasso, RC
AU  - Janssen, ME
AU  - Gokaslan, ZL
AU  - Alvarado, M
AU  - Bolger, C
AU  - Bono, CM
AU  - Dekutoski, MB
TI  - Geographic variations in clinical presentation and outcomes of decompressive surgery in patients with symptomatic degenerative cervical myelopathy: analysis of a prospective, international multicenter cohort study of 757 patients
T2  - SPINE JOURNAL
KW  - Geographic variation
KW  - Myelopathy
KW  - Surgical
KW  - Treatment efficacy
KW  - Treatment outcome
KW  - POSTERIOR LONGITUDINAL LIGAMENT
KW  - NECK DISABILITY INDEX
KW  - SPONDYLOTIC MYELOPATHY
KW  - OSSIFICATION
KW  - MANAGEMENT
AB  - BACKGROUND CONTEXT: Degenerative cervical myelopathy (DCM) is a progressive degenerative spine disease and the most common cause of spinal cord impairment in adults worldwide. Few studies have reported on regional variations in demographics, clinical presentation, disease causation, and surgical effectiveness.
   PURPOSE: The objective of this study was to evaluate differences in demographics, causative pathology, management strategies, surgical outcomes, length of hospital stay, and complications across four geographic regions.
   STUDY DESIGN/SETTING: This is a multicenter international prospective cohort study.
   PATIENT SAMPLE: This study includes a total of 757 symptomatic patients with DCM undergoing surgical decompression of the cervical spine.
   OUTCOME MEASURES: The outcome measures are the Neck Disability Index (NDI), the Short Form 36 version 2 (SF-36v2), the modified Japanese Orthopaedic Association (mJOA) scale, and the Nurick grade.
   MATERIALS AND METHODS: The baseline characteristics, disease causation, surgical approaches, and outcomes at 12 and 24 months were compared among four regions: Europe, Asia Pacific, Latin America, and North America.
   RESULTS: Patients from Europe and North America were, on average, older than those from Latin America and Asia Pacific (p=.0055). Patients from Latin America had a significantly longer duration of symptoms than those from the other three regions (p<.0001). The most frequent causes of myelopathy were spondylosis and disc herniation. Ossification of the posterior longitudinal ligament was most prevalent in Asia Pacific (35.33%) and in Europe (31.75%), and hypertrophy of the ligamentum flavum was most prevalent in Latin America (61.25%). Surgical approaches varied by region; the majority of cases in Europe (71.43%), Asia Pacific (60.67%), and North America (59.10%) were managed anteriorly, whereas the posterior approach was more common in Latin America (66.25%). At the 24-month follow-up, patients from North America and Asia Pacific exhibited greater improvements in mJOA and Nurick scores than those from Europe and Latin America. Patients from Asia Pacific and Latin America demonstrated the most improvement on the NDI and SF-36v2 PCS. The longest duration of hospital stay was in Asia Pacific (14.16 days), and the highest rate of complications (34.9%) was reported in Europe.
   CONCLUSIONS: Regional differences in demographics, causation, and surgical approaches are significant for patients with DCM. Despite these variations, surgical decompression for DCM appears effective in all regions. Observed differences in the extent of postoperative improvements among the regions should encourage the standardization of care across centers and the development of international guidelines for the management of DCM. (C) 2017 Elsevier Inc. All rights reserved.
AD  - Toronto Western Hosp, Dept Surg, 399 Bathurst St, Toronto, ON M5T 2S8, CanadaAD  - Univ Washington, Dept Hlth Serv, 1959 NE Pacific St, Seattle, WA 98195 USAAD  - Univ Coll Cork, Grad Entry Med, Cork, IrelandAD  - Univ Kansas, Med Ctr, Dept Neurosurg, 3901 Rainbow Blvd, Kansas City, KS 66160 USAAD  - Univ Sao Paulo, Dept Med, BR-03178200 Ribeirao Preto, SP, BrazilAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, IndiaAD  - Emory Univ, Dept Orthopaed Surg, 201 Dowman Dr, Atlanta, GA 30322 USAAD  - Policlin G Rodolico Univ Hosp, Dept Neurosurg, Via S Sofia, I-95125 Catania, ItalyAD  - Radboud Univ Nijmegen, Med Ctr, Dept Neurosurg, Geert Grooteplein Zuid 10, NL-6625 Nijmegen, NetherlandsAD  - Third Mil Med Univ, Affiliated Hosp 1, Southwest Hosp, Dept Orthoped, Gaoyan Rock St 30, Chongqing, Peoples R ChinaAD  - Thomas Jefferson Univ Hosp, Rothman Inst, 925 Chestnut St, Philadelphia, PA 19107 USAAD  - Ege Univ, Dept Neurosurg, Genclik Caddesi, TR-35040 Izmir, TurkeyAD  - Alexandra Hosp, Dept Orthopaed, 378 Alexandra Rd, Singapore 159964, SingaporeAD  - Chubu Rosai Hosp, Dept Orthopaed Surg, Minato Ward, 1 Chome 10-6 Komei, Nagoya, Aichi 4558530, JapanAD  - Univ Utah, Dept Orthopaed, 590 Wakara Way, Salt Lake City, UT 84108 USAAD  - Univ Virginia, Dept Neurol Surg, 1215 Lee St, Charlottesville, VA 22908 USAAD  - Hosp Santa Marcelina, Dept Neurosurg, BR-08260005 Sao Paulo, BrazilAD  - New England Baptist Hosp, Dept Surg, 125 Parker Hill Ave, Boston, MA 02120 USAAD  - Univ Politecn Marche, Dept Neurosurg, Umberto Gen Hosp 1, Via Conca 71, I-60126 Ancona, ItalyAD  - Okayama Univ Hosp, Dept Orthoped Surg, 2 Chome 5-1 Shikatacho, Okayama 7008558, JapanAD  - Teikyo Univ, Dept Orthopaed Surg, Chiba Med Ctr, 2 Chome 11-1 Kaga, Tokyo 1738606, JapanAD  - Indiana Spine Grp, 13225 N Meridian St, Carmel, IN 46032 USAAD  - Spine Educ & Res Inst, 9005 Grant St, Denver, CO 80229 USAAD  - Johns Hopkins Univ, Dept Neurosurg, Spine Div, 3400 N Charles St, Baltimore, MD 21218 USAAD  - Hosp San Juan Dios, Dept Surg, Calle C, Caracas, VenezuelaAD  - Beaumont Hosp, Dept Neurosurg, POB 1297,Beaumont Rd, Dublin 9, IrelandAD  - Brigham & Womens Hosp, Dept Orthoped, 75 Francis St, Boston, MA 02115 USAAD  - CORE Inst, 14520 W Granite Valley Dr, Sun City West, AZ 85375 USAC3  - University of TorontoC3  - University Health Network TorontoC3  - University of WashingtonC3  - University of Washington SeattleC3  - University College CorkC3  - University of KansasC3  - University of Kansas Medical CenterC3  - Universidade de Sao PauloC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Emory UniversityC3  - Radboud University NijmegenC3  - Army Medical UniversityC3  - Rothman InstituteC3  - Thomas Jefferson UniversityC3  - Ege UniversityC3  - Utah System of Higher EducationC3  - University of UtahC3  - University of VirginiaC3  - New England Baptist HospitalC3  - Marche Polytechnic UniversityC3  - Okayama UniversityC3  - Teikyo UniversityC3  - Johns Hopkins UniversityC3  - Harvard UniversityC3  - Brigham & Women's HospitalPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - APR
PY  - 2018
VL  - 18
IS  - 4
SP  - 593
EP  - 605
DO  - 10.1016/j.spinee.2017.08.265
AN  - WOS:000430584300006
ER  -

TY  - JOUR
AU  - Goyal, V
TI  - Multiple Sclerosis in India
T2  - ANNALS OF INDIAN ACADEMY OF NEUROLOGY
KW  - NERVE-FIBER LAYER
KW  - OPTIC NEURITIS
KW  - EXPERIENCE
KW  - BOMBAY
KW  - POLYMORPHISM
KW  - ASSOCIATION
KW  - POPULATION
KW  - FATIGUE
KW  - KASHMIR
KW  - PROFILE
AD  - All India Inst Med Sci, Dept Neurol, Room 706, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - APR-JUN
PY  - 2018
VL  - 21
IS  - 2
SP  - 95
EP  - 97
DO  - 10.4103/aian.AIAN_296_18
AN  - WOS:000439857300001
ER  -

TY  - JOUR
AU  - Gulati, S
AU  - Sondhi, V
AU  - Chakrabarty, B
AU  - Jauhari, P
AU  - Lodha, R
AU  - Sankar, J
TI  - High dose phenobarbitone coma in pediatric refractory status epilepticus; a retrospective case record analysis, a proposed protocol and review of literature
T2  - BRAIN & DEVELOPMENT
KW  - High dose phenobarbitone
KW  - Refractory status epilepticus
KW  - Pediatric
KW  - Protocol
KW  - BURST-SUPPRESSION
KW  - MIDAZOLAM
AB  - Background: Ongoing refractory status epilepticus is associated with significant morbidity and mortality. Therapeutic coma induction with midazolam, thiopentone, phenobarbitone or propofol is indicated when conventional antiepileptics fail to abort seizure. Of these, the most extensively studied is midazolam. Amongst the remaining three, phenobarbitone has the most favourable pharmacological profile, but has not been studied adequately, more so in the pediatric age group. The current retrospective case records analysis is an attempt to describe use of phenobarbitone coma in pediatric refractory status epilepticus.
   Methods: Case records of patients, admitted with status epilepticus to the pediatric inpatient services of a tertiary care teaching hospital of North India between January 2014 and December 2016 were reviewed. Those with refractory status epilepticus who failed to respond to midaolam infusion and phenobarbitone coma was used were included for analysis.
   Results: Overall, 108 children presented in status, of which 34 developed refractory status epilepticus. Of these 34, 21 responded to midazolam infusion and in 13 high dose phenobarbitone coma following a standardised protocol was used. Amongst these 13 (8 males and 5 females, median age 6 years, IQR: 2.5-9.5), 12 responded and 1 succumbed. The median time to clinical seizure resolution and desired electroencephalographic changes post phenobarbitone initiation were 16 (IQR: 12-25) and 72 h (IQR: 48-120) respectively.
   Conclusion: High dose phenobarbitone appears to be an effective therapeutic modality in pediatric refractory status epilepticus. The current study provides a protocol for its use which can be validated in future studies with larger sample size. (C) 2018 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.
AD  - All India Inst Med Sci, Child Neurol Div, Dept Pediat, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Div Pulmonol & Intens Care, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - APR
PY  - 2018
VL  - 40
IS  - 4
SP  - 316
EP  - 324
DO  - 10.1016/j.braindev.2017.11.009
AN  - WOS:000429294700007
ER  -

TY  - JOUR
AU  - Gupta, A
AU  - Kumar, L
TI  - 3q26 chromosomal anomalies in acute myeloid leukemia: First descriptions from India
T2  - JOURNAL OF POSTGRADUATE MEDICINE
KW  - 3q26
KW  - acute myeloid leukemia
KW  - cytogenetics
KW  - inversion
KW  - translocation
KW  - 3Q21Q26 SYNDROME
KW  - EVI1
KW  - REARRANGEMENTS
KW  - ABNORMALITIES
KW  - EXPRESSION
KW  - FEATURES
AB  - Cytogenetic anomalies involving the 3q26 chromosomal region are rare in acute myeloid leukemia (AML). There is no such description of these anomalies from the Indian sub-continent. A total of 174 AML patients were admitted to our hospital for therapy between January 2001 and January 2008. Cytogenetic studies could be done in 115 patients; which revealed three cases with 3q26 anomalies. All were males. In the first two cases, the anomaly was detected in all the metaphases. The common features seen were the presence of only mild thrombocytopenia (relatively high platelet counts when assessed against the background of AML with high blast percentages), monosomy 7, myeloperoxidase positive blasts, mild eosinophilia, and poor therapeutic response. In the third case, the chromosome 3 anomaly was present in only one metaphase. Such an anomaly has not been reported. Only the third patient responded to induction therapy but subsequently relapsed after being in complete remission for 15 months. 3q26 anomalies are associated with monosomy 7, relatively higher platelet counts at diagnosis as compared with other non-3q rearranged AML's and poor prognosis. The precise mechanisms underlying leukemogenesis need to be elucidated and better treatments devised since these patients respond poorly to therapy.
AD  - All India Inst Med Sci, Inst Rotary Canc Hosp, Dept Med Oncol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - APR-JUN
PY  - 2018
VL  - 64
IS  - 2
SP  - 109
EP  - 111
C7  - PMID 29067925
DO  - 10.4103/jpgm.JPGM_727_16
AN  - WOS:000430959400010
ER  -

TY  - JOUR
AU  - Gupta, N
AU  - Verma, G
AU  - Kabra, M
AU  - Bijarnia-Mahay, S
AU  - Ganapathy, A
TI  - Identification of a case of <i>SRD5A3</i>-congenital disorder of glycosylation (CDG1Q) by exome sequencing
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
KW  - CONGENITAL DISORDERS
KW  - DIAGNOSIS
AD  - All India Inst Med Sci, Div Genet, Dept Pediat, New Delhi, IndiaAD  - Sir Ganga Ram Hosp, Dept Med Genet, New Delhi, IndiaAD  - Strand Life Sci, Bengaluru, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - APR
PY  - 2018
VL  - 147
SP  - 422
EP  - 426
DO  - 10.4103/ijmr.IJMR_820_16
AN  - WOS:000439219400015
ER  -

TY  - JOUR
AU  - Gupta, V
AU  - Ganesan, VL
AU  - Kumar, S
AU  - Chaurasia, AK
AU  - Malhotra, S
AU  - Gupta, S
TI  - Visual Disability Among Juvenile Open-angle Glaucoma Patients
T2  - JOURNAL OF GLAUCOMA
KW  - juvenile open-angle glaucoma
KW  - visual disability
KW  - visual impairment
KW  - blindness
KW  - RURAL-POPULATION
KW  - SOUTHERN INDIA
KW  - BLINDNESS
KW  - VISION
KW  - IMPAIRMENT
KW  - BURDEN
KW  - RISK
KW  - LIFE
AB  - Aim:Juvenile onset primary open-angle glaucoma (JOAG) unlike adult onset primary open-angle glaucoma presents with high intraocular pressure and diffuse visual field loss, which if left untreated leads to severe visual disability. The study aimed to evaluate the extent of visual disability among JOAG patients presenting to a tertiary eye care facility.Methods:Visual acuity and perimetry records of unrelated JOAG patients presenting to our Glaucoma facility were analyzed. Low vision and blindness was categorized by the WHO criteria and percentage impairment was calculated as per the guidelines provided by the American Medical Association (AMA).Results:Fifty-two (15%) of the 348 JOAG patients were bilaterally blind at presentation and 32 (9%) had low vision according to WHO criteria. Ninety JOAG patients (26%) had a visual impairment of 75% or more.Conclusions:Visual disability at presentation among JOAG patients is high. This entails a huge economic burden, given their young age and associated social responsibilities.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 374, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Ctr Community Med, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - APR
PY  - 2018
VL  - 27
IS  - 4
SP  - E87
EP  - E89
DO  - 10.1097/IJG.0000000000000887
AN  - WOS:000429201000005
ER  -

TY  - JOUR
AU  - Gupta, V
AU  - Arava, S
AU  - Ramam, M
TI  - Blaschkoid Acute Graft-vs-Host Disease
T2  - JAMA DERMATOLOGY
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, Fourth Floor,Teaching Block, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER MEDICAL ASSOC
PI  - CHICAGO
PA  - 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
DA  - APR
PY  - 2018
VL  - 154
IS  - 4
SP  - 494
EP  - +
DO  - 10.1001/jamadermatol.2017.6023
AN  - WOS:000429690800033
ER  -

TY  - JOUR
AU  - Gupta, V
AU  - Khandpur, S
AU  - Arava, S
AU  - Ramam, M
TI  - Alternating histopathologic pattern in blaschkoid dermatoses with epidermal changes: A retrospective series of 61 cases
T2  - JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
KW  - NEVUS
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MOSBY-ELSEVIER
PI  - NEW YORK
PA  - 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - APR
PY  - 2018
VL  - 78
IS  - 4
SP  - 812
EP  - 813
DO  - 10.1016/j.jaad.2017.09.069
AN  - WOS:000427404200034
ER  -

TY  - JOUR
AU  - Haghighi, RR
AU  - Chatterjee, S
AU  - Vani, VC
AU  - Kumar, P
AU  - Tabin, M
AU  - Ray, R
AU  - Jalli, R
AU  - Sefidbakht, S
AU  - Zarei, F
AU  - Shakibafard, AR
AU  - Bardeji, SG
AU  - Dodangeh, M
AU  - Bijan, B
TI  - Non-Calcified Coronary Artery Plaque Characterization by Dual-Energy Computed Tomography
T2  - IRANIAN JOURNAL OF RADIOLOGY
KW  - Dual-Energy Computed Tomography
KW  - Non-Calcific Plaque
KW  - Plaque Characterization
KW  - Coronary Artery Disease
KW  - ATOMIC-NUMBER
KW  - CT
KW  - DENSITY
AB  - Background: Inversion of dual-energy computed tomography (DECT) data for obtaining the electron density and effective atomic number of substances has been a work in progress for the past forty years. It has been the practice to characterize the material in terms of Hounsfield Unit (HU) values obtained by two different energies.
   Objectives: Since HU values are equipment-dependent quantities, it is necessary to develop a method that characterizes the substance in terms of certain physical quantities that are equipment independent.
   Materials and Methods: The process that we adopt is to find a calibration method by which all equipment-dependent quantities are eliminated and we directly deal with quantities that are representative of the sample, namely its electron density and effective atomic number. We collect the DECT data from 21 samples of non-calcified coronary artery plaques in human cadavers.
   Results: With our standardized inversion method, we have obtained the electron density and effective atomic number of these samples. With physical models of lipids and proteins, it becomes possible to conclude that non-calcified plaque samples can have calcium dispersed in the lipid part of the plaque in trace amounts that cannot be observed by light based microscopy or by CT images alone.
   Conclusion: This characterization, may give a new insight in characterization of non-calcified coronary artery plaque and in medical diagnostics.
AD  - Shiraz Univ Med Sci, Med Imaging Res Ctr, Shiraz 7134845794, IranAD  - Indian Inst Sci, BGVS Chem Engn Bldg Old, Bangalore, Karnataka, IndiaAD  - Indian Inst Sci, Dept Instrumentat & Appl Phys, Bangalore, Karnataka, IndiaAD  - All India Inst Med Sci, Med Phys Unit, IRCH, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Forens Med, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - Univ Calif Davis, Dept Radiol, Sutter Med Grp, Sacramento, CA 95817 USAC3  - Shiraz University of Medical ScienceC3  - Indian Institute of Science (IISC) - BangaloreC3  - Indian Institute of Science (IISC) - BangaloreC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of California SystemC3  - University of California DavisPU  - KOWSAR PUBL
PI  - HOENSBROEK
PA  - PATERSWEG 22,, HOENSBROEK, LIMBURG 6431 GC, NETHERLANDS
DA  - APR
PY  - 2018
VL  - 15
IS  - 2
C7  - e13970
DO  - 10.5812/iranjradiol.13970
AN  - WOS:000435801600007
ER  -

TY  - JOUR
AU  - Jajodia, A
AU  - Kaur, H
AU  - Srivastava, A
AU  - Kumari, K
AU  - Baghel, R
AU  - Guin, D
AU  - Sood, M
AU  - Satyamoorthy, K
AU  - Jain, S
AU  - Chadda, RK
AU  - Kukreti, R
TI  - Schizophrenia susceptibility and neuregulin signaling pathway genes: A rare haplotype combination based association study in Indian population
T2  - PSYCHIATRY RESEARCH
AD  - CSIR, Inst Genom & Integrat Biol, Genom & Mol Med, Mall Rd, Delhi 110007, IndiaAD  - All India Inst Med Sci, Dept Psychiat, New Delhi 110029, IndiaAD  - Manipal Univ, Sch Life Sci, Dept Biotechnol, Manipal 576104, IndiaAD  - Natl Inst Mental Hlth & Neurosci, Dept Psychiat, Mol Genet Lab, Hosur Rd, Bengaluru 560029, IndiaC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Manipal Academy of Higher Education (MAHE)C3  - National Institute of Mental Health & Neurosciences - IndiaPU  - ELSEVIER IRELAND LTD
PI  - CLARE
PA  - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
DA  - APR
PY  - 2018
VL  - 262
SP  - 628
EP  - 630
DO  - 10.1016/j.psychres.2017.10.005
AN  - WOS:000430646700100
ER  -

TY  - JOUR
AU  - Kakkar, A
AU  - Rajeshwari, M
AU  - Sakthivel, P
AU  - Sharma, MC
AU  - Sharm, SC
TI  - Biphenotypic sinonasal sarcoma: A series of six cases with evaluation of role of β-catenin immunohistochemistry iii differential diagnosis
T2  - ANNALS OF DIAGNOSTIC PATHOLOGY
KW  - Nasal cavity
KW  - Paranasal sinus
KW  - Spindle cell tumor
KW  - Biphasic
KW  - beta-catenin
KW  - Immunohistochemistry
KW  - MYOGENIC FEATURES
KW  - EXPRESSION
KW  - FUSION
KW  - TRACT
KW  - CHALLENGE
KW  - TUMORS
AB  - Introduction: Biphenotypic sinonasal sarcoma (BSNS) is a recently described mesenchymal tumor exclusive to the sinonasal region. It is a low grade sarcoma, displaying evidence of myogenic and neural differentiation. Role of beta-catenin immunohistochemistry in distinguishing it from its morphological mimics is not well-established. We conducted this study to identify cases of BSNS from our archives, and to examine immunopositivity for beta-catenin in them as well as in its close differential diagnosis.
   Methods: All cases of nasal cavity and paranasal sinus mesenchymal neoplasms were identified. Histopathological features were reviewed. Cases showing smooth muscle actin (SMA) and S-100 immunopositivity, and typical morphology were reclassified as BSNS. beta-catenin immunoexpression was assessed.
   Results: Twenty-one mesenchymal tumors, including 12 sinonasal hemangiopericytoma (SNHPC), five solitary fibrous tumors (SFT), three BSNS, and one synovial sarcoma were identified. Three SNHPC cases were reclassified as BSNS. BSNS patients included one male and five females, with mean age of 51 years. Five BSNS cases (83.3%) showed nuclear beta-catenin immunopositivity. SNHPC cases also were beta-catenin positive (60%).
   Conclusion: BSNS is a rare sinonasal neoplasm, frequently misdiagnosed as SNHPC and SFT. beta-catenin immunopositivity is seen in majority of cases, indicating a role in pathogenesis. However, due to positivity in other tumors like SNHPC, it has limited role in differential diagnosis.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Otolaryngol & Head & Neck Surg, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - APR
PY  - 2018
VL  - 33
SP  - 6
EP  - 10
DO  - 10.1016/j.anndiagpath.2017.11.005
AN  - WOS:000429294200002
ER  -

TY  - JOUR
AU  - Kaur, M
AU  - Titiyal, JS
AU  - Falera, R
AU  - Sinha, R
AU  - Sharma, N
TI  - Indications for explant of implantable collamer lens
T2  - EYE
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - NATURE PUBLISHING GROUP
PI  - LONDON
PA  - MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - APR
PY  - 2018
VL  - 32
IS  - 4
SP  - 838
EP  - 840
DO  - 10.1038/eye.2017.307
AN  - WOS:000430224300029
ER  -

TY  - JOUR
AU  - Kaur, M
AU  - Verma, S
AU  - Gupta, R
AU  - Pant, L
AU  - Singh, S
TI  - CD10 expression pattern in prostatic adenocarcinoma: Elucidation of differences between Gleason's grades
T2  - MALAYSIAN JOURNAL OF PATHOLOGY
KW  - CD10
KW  - immunostaining
KW  - carcinoma
KW  - prostate
KW  - Gleason's grade
KW  - NEUTRAL ENDOPEPTIDASE
KW  - CANCER
KW  - PROGRESSION
AB  - CD10, a transmembrane endopeptidase, has been shown to be lost as an early event in prostate cancer. We aimed at evaluating the pattern of expression of CD10 in various Gleason's grades of prostatic adenocarcinoma in comparison with nodular hyperplasia of prostate. This retrospective study included 30 cases of nodular hyperplasia and 30 of prostatic adenocarcinoma of various Gleason's grades. Immunohistochemical staining for CD10 was performed on all cases and positivity evaluated as percentage of cells as well as location (membranous or cytoplasmic or both). Of prostatic adenocarcinomas, grade 3 was seen in 10 foci, grade 4 in 28 and grade 5 in 22 foci. CD10 positivity in carcinoma was lower than in nodular hyperplasia, with the lowest positivity in grade 5. The pattern of expression of CD10 also changed from membranous in grade 3 to cytoplasmic in grade 5. Loss of CD10 expression appears to be associated with increasing tumour grade in carcinoma prostate and this can potentially be useful in stratification of such patients.
AD  - Hindu Rao Hosp, Dept Pathol, Delhi 110007, IndiaAD  - All India Inst Med Sci, Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MALAYSIAN JOURNAL PATHOLOGY
PI  - KUALA LUMPUR
PA  - UNIV MALAYSIA, FAC MEDICINE, DEPT PATHOLOGY, KUALA LUMPUR, 59100, MALAYSIA
DA  - APR
PY  - 2018
VL  - 40
IS  - 1
SP  - 57
EP  - 60
AN  - WOS:000434057100007
ER  -

TY  - JOUR
AU  - Khan, MFJ
AU  - Little, J
AU  - Abelli, L
AU  - Mossey, PA
AU  - Autelitano, L
AU  - Nag, TC
AU  - Rubini, M
TI  - Muscle fiber diameter assessment in cleft lip using image processing
T2  - ORAL DISEASES
KW  - cleft lip
KW  - cleft lip and palate
KW  - FFPE tissue samples
KW  - image processing
KW  - muscle fiber diameter
KW  - ORBICULARIS-ORIS MUSCLE
KW  - MASSETER MUSCLES
KW  - EMG ACTIVITY
KW  - ARRANGEMENT
KW  - SUPERIOR
KW  - INFERIOR
KW  - DEFECTS
AB  - ObjectiveTo pilot investigation of muscle fiber diameter (MFD) on medial and lateral sides of the cleft in 18 infants with cleft lip with or without cleft palate (CL/P) using image processing.
   Material and MethodsFormalin-fixed paraffin-embedded (FFPE) tissue samples from the medial and lateral sides of the cleft were analyzed for MFD using an image-processing program (ImageJ). For within-case comparison, a paired Student's t test was performed. For comparisons between classes, an unpaired t test was used.
   ResultsImage processing enabled rapid measurement of MFD with majority of fibers showing diameter between 6 and 11m. There was no significant difference in mean MFD between the medial and lateral sides, or between CL and CLP. However, we found a significant difference on the medial side (p=.032) between males and females.
   ConclusionThe image processing on FFPE tissues resulted in easy quantification of MFD with finding of a smaller MFD on the medial side in males suggesting possible differences in orbicularis oris (OO) muscle between the two sexes in CL that warrants replication using larger number of cases. Moreover, this finding can aid subclinical phenotyping and potentially in the restoration of the anatomy and function of the upper lip.
AD  - Univ Ferrara, Sect Med Biochem Mol Biol & Genet, Dept Biomed & Specialty Surg Sci, Ferrara, ItalyAD  - Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, CanadaAD  - Univ Ferrara, Dept Life Sci & Biotechnol, Sect Biol & Evolut, Ferrara, ItalyAD  - Univ Dundee, Dent Hosp & Sch, Craniofacial Dev World Hlth Org Collaborating Ctr, Dundee, ScotlandAD  - Univ Milan, San Paolo Hosp, Reg Ctr Orofacial Clefts & Craniofacial Anomalies, Dept Craniomaxillofacial Surg, Milan, ItalyAD  - All India Inst Med Sci, Dept Anat, New Delhi, IndiaC3  - University of FerraraC3  - University of OttawaC3  - University of FerraraC3  - University of DundeeC3  - World Health OrganizationC3  - University of MilanC3  - San Paolo-Polo Universitaria HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - APR
PY  - 2018
VL  - 24
IS  - 3
SP  - 476
EP  - 481
DO  - 10.1111/odi.12790
AN  - WOS:000428027900023
ER  -

TY  - JOUR
AU  - Khandelwal, P
AU  - Birla, S
AU  - Bhatia, D
AU  - Puraswani, M
AU  - Saini, H
AU  - Sinha, A
AU  - Hari, P
AU  - Sharma, A
AU  - Bagga, A
TI  - Mutations in <i>membrane cofactor protein</i> (<i>CD46</i>) gene in Indian children with hemolytic uremic syndrome
T2  - CLINICAL KIDNEY JOURNAL
KW  - complement
KW  - hemolytic uremic syndrome
KW  - membrane cofactor protein
KW  - FACTOR-H-AUTOANTIBODIES
KW  - HUS
KW  - DEFICIENCY
KW  - RECURRENCE
KW  - IMPACT
KW  - CFH
KW  - MCP
AB  - Background: Mutations in the CD46 gene account for an important proportion of patients with atypical hemolytic uremic syndrome (aHUS) who characteristically show multiple relapses, no response to plasma exchange and low recurrence risk in allograft. We screened for mutations in CD46 in patients with and without circulating anti-factor H (FH) antibodiesassociated aHUS.
   Methods: We estimated CD46 surface expression by flow cytometry and sequenced the CD46 gene in 23 and 56 patients with and without circulating anti-FH antibodies, respectively. Human Splicing Finder and PolyPhen2 were used for in silico prediction of pathogenicity.
   Results: Two novel and three known (c.286 + 2T > G, c.104G > A and c.565T > G) mutations in CD46 were found in nine (11.4%) patients; one patient had a variant of unknown significance and two patients presented during the first year of life. Novel intronic (c.1127 + 46C > G) and exonic (c.911C > T) mutations are proposed to activate cryptic splicing sites or alter protein conformation. Markedly reduced CD46 surface expression was found in homozygous states in five patients.
   Conclusion: Patients with mutations in CD46 present at all ages, including the first year of life. Mutations in intron 2, (c.286 + 2T > G) may be a potential hot spot in Indian children. Flow cytometry for CD46 expression is a satisfactory screening tool enabling early diagnosis.
AD  - All India Inst Med Sci, Div Nephrol, Dept Pediat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Anat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - OXFORD UNIV PRESS
PI  - OXFORD
PA  - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
DA  - APR
PY  - 2018
VL  - 11
IS  - 2
SP  - 198
EP  - 203
DO  - 10.1093/ckj/sfx078
AN  - WOS:000449483800008
ER  -

TY  - JOUR
AU  - Kilambi, R
AU  - Singh, AN
TI  - Duct-to-mucosa versus dunking techniques of pancreaticojejunostomy after pancreaticoduodenectomy: Do we need more trials? A systematic review and meta-analysis with trial sequential analysis
T2  - JOURNAL OF SURGICAL ONCOLOGY
KW  - duct-to-mucosa
KW  - dunking
KW  - invagination
KW  - meta-analysis
KW  - pancreaticoenteric
KW  - pancreatoduodenectomy
KW  - systematic review
KW  - whipple
KW  - INTERNATIONAL STUDY-GROUP
KW  - POSTOPERATIVE PANCREATIC FISTULA
KW  - INVAGINATION PANCREATICOJEJUNOSTOMY
KW  - SURGERY
KW  - STENT
KW  - COMPLICATIONS
KW  - RECONSTRUCTION
KW  - ANASTOMOSIS
KW  - DEFINITION
KW  - RESECTION
AB  - BackgroundPancreaticojejunostomy (PJ is the most widely used reconstruction technique after pancreaticoduodenectomy. Despite several randomized trials, the ideal technique of pancreaticojejunostomy remains debatable. We planned a meta-analysis of randomized trials comparing the two most common techniques of PJ (duct-to-mucosa and dunking) to identify the best available evidence in the current literature.
   MethodsWe searched the Pubmed/Medline, Web of science, Science citation index, Google scholar and Cochrane Central Register of Controlled Trials electronic databases till October 2017 for all English language randomized trials comparing the two approaches. Statistical analysis was performed using Review Manager (RevMan), Version 5.3. Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2014 and results were expressed as odds ratio for dichotomous and mean difference for continuous variables. P-value0.05 was considered significant. Trial sequential analysis was performed using TSA version 0.9.5.5 (Copenhagen: The Copenhagen Trial Unit, Center for Clinical Intervention Research, 2016).
   ResultsA total of 8 trials were included, with a total of 1043 patients (DTM: 518; Dunking: 525). There was no significant difference between the two groups in terms of overall as well as clinically relevant POPF rate. Similarly, both groups were comparable for the secondary outcomes. Trial sequential analysis revealed that the required information size had been crossed without achieving a clinically significant difference for overall POPF; and though the required information size had not been achieved for CR-POPF, the current data has already crossed the futility line for CR-POPF with a 10% risk difference, 80% power and 5% error.
   ConclusionThis meta-analysis found no significant difference between the two techniques in terms of overall and CR-POPF rates. Further, the existing evidence is sufficient to conclude lack of difference and further trials are unlikely to result in any change in the outcome. (CRD42017074886).
AD  - Inst Liver & Biliary Sci, Dept Hepatobiliary Surg & Liver Transplant, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Gastrointestinal Surg & Liver Transplantat, Room 1005,Teaching Block, New Delhi 110029, IndiaC3  - Institute of Liver & Biliary Sciences (ILBS)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - APR 1
PY  - 2018
VL  - 117
IS  - 5
SP  - 928
EP  - 939
DO  - 10.1002/jso.24986
AN  - WOS:000434145500015
ER  -

TY  - JOUR
AU  - Kilambi, R
AU  - Singh, AN
AU  - Das, P
AU  - Madhusudhan, KS
AU  - Pal, S
TI  - Somatostatinoma Masquerading as Chronic Pancreatitis
T2  - PANCREAS
KW  - DUODENAL SOMATOSTATINOMA
AD  - AIIMS, Dept Gastrointestinal Surg & Liver Transplantat, New Delhi, IndiaAD  - AIIMS, Dept Pathol, New Delhi, IndiaAD  - AIIMS, Dept Radiodiag, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - APR
PY  - 2018
VL  - 47
IS  - 4
SP  - E19
EP  - E20
DO  - 10.1097/MPA.0000000000001011
AN  - WOS:000428083700004
ER  -

TY  - JOUR
AU  - Knowles, J
AU  - Kupka, R
AU  - Dumble, S
AU  - Garrett, GS
AU  - Pandav, CS
AU  - Yadav, K
AU  - Nahar, B
AU  - Touré, NK
AU  - Amoaful, EF
AU  - Gorstein, J
TI  - Regression Analysis to Identify Factors Associated with Household Salt Iodine Content at the Sub-National Level in Bangladesh, India, Ghana and Senegal
T2  - NUTRIENTS
KW  - iodine deficiency
KW  - iodised salt
KW  - single variable regression
KW  - multiple variable regression
KW  - IODIZED SALT
KW  - COUNTRIES
AB  - Regression analyses of data from stratified, cluster sample, household iodine surveys in Bangladesh, India, Ghana and Senegal were conducted to identify factors associated with household access to adequately iodised salt. For all countries, in single variable analyses, household salt iodine was significantly different (p < 0.05) between strata (geographic areas with representative data, defined by survey design), and significantly higher (p < 0.05) among households: with better living standard scores, where the respondent knew about iodised salt and/or looked for iodised salt at purchase, using salt bought in a sealed package, or using refined grain salt. Other country-level associations were also found. Multiple variable analyses showed a significant association between salt iodine and strata (p < 0.001) in India, Ghana and Senegal and that salt grain type was significantly associated with estimated iodine content in all countries (p < 0.001). Salt iodine relative to the reference (coarse salt) ranged from 1.3 (95% CI 1.2, 1.5) times higher for fine salt in Senegal to 3.6 (95% CI 2.6, 4.9) times higher for washed and 6.5 (95% CI 4.9, 8.8) times higher for refined salt in India. Sub-national data are required to monitor equity of access to adequately iodised salt. Improving household access to refined iodised salt in sealed packaging, would improve iodine intake from household salt in all four countries in this analysis, particularly in areas where there is significant small-scale salt production.
AD  - Iodine Global Network, Ottawa, ON K1N 5C8, CanadaAD  - UNICEF, New York, NY 10017 USAAD  - Stat Sustainable Dev, Reading RG1 4QS, Berks, EnglandAD  - Global Alliance Improved Nutr, CH-1202 Geneva, SwitzerlandAD  - All India Inst Med Sci, New Delhi 110029, IndiaAD  - Int Ctr Diarrhoeal Dis Res, Dhaka 1212, BangladeshAD  - Cellule Lutte Malnutrit, BP 45001, Dakar, SenegalAD  - Ghana Hlth Serv, Nutr Dept, Accra, GhanaAD  - Iodine Global Network, Seattle, WA 98107 USAC3  - UNICEFC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - Ghana Health ServicePU  - MDPI
PI  - BASEL
PA  - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
DA  - APR
PY  - 2018
VL  - 10
IS  - 4
C7  - 508;
DO  - 10.3390/nu10040508
AN  - WOS:000435182900124
ER  -

TY  - JOUR
AU  - Knowles, J
AU  - Kupka, R
AU  - Dumble, S
AU  - Garrett, GS
AU  - Pandav, CS
AU  - Yadav, K
AU  - Touré, NK
AU  - Amoaful, EF
AU  - Gorstein, J
TI  - Regression Analysis to Identify Factors Associated with Urinary Iodine Concentration at the Sub-National Level in India, Ghana, and Senegal
T2  - NUTRIENTS
KW  - iodine deficiency
KW  - iodised salt
KW  - single-variable regression
KW  - multiple-variable regression
KW  - urinary iodine
KW  - IODIZED SALT
KW  - HOUSEHOLD COVERAGE
KW  - COUNTRIES
KW  - CHILDREN
AB  - Single and multiple variable regression analyses were conducted using data from stratified, cluster sample design, iodine surveys in India, Ghana, and Senegal to identify factors associated with urinary iodine concentration (UIC) among women of reproductive age (WRA) at the national and sub-national level. Subjects were survey household respondents, typically WRA. For all three countries, UIC was significantly different (p < 0.05) by household salt iodine category. Other significant differences were by strata and by household vulnerability to poverty in India and Ghana. In multiple variable regression analysis, UIC was significantly associated with strata and household salt iodine category in India and Ghana (p < 0.001). Estimated UIC was 1.6 (95% confidence intervals (CI) 1.3, 2.0) times higher (India) and 1.4 (95% CI 1.2, 1.6) times higher (Ghana) among WRA from households using adequately iodised salt than among WRA from households using non-iodised salt. Other significant associations with UIC were found in India, with having heard of iodine deficiency (1.2 times higher; CI 1.1, 1.3; p < 0.001) and having improved dietary diversity (1.1 times higher, CI 1.0, 1.2; p = 0.015); and in Ghana, with the level of tomato paste consumption the previous week (p = 0.029) (UIC for highest consumption level was 1.2 times lowest level; CI 1.1, 1.4). No significant associations were found in Senegal. Sub-national data on iodine status are required to assess equity of access to optimal iodine intake and to develop strategic responses as needed.
AD  - Iodine Global Network, Ottawa, ON K1N 5C8, CanadaAD  - United Nations Childrens Fund, New York, NY 10017 USAAD  - Stat Sustainable Dev, Reading RG1 4QS, Berks, EnglandAD  - Global Alliance Improved Nutr, CH-1202 Geneva, SwitzerlandAD  - All India Inst Med Sci, New Delhi 110029, IndiaAD  - Cellule Lutte Malnutr, BP 45001, Dakar, SenegalAD  - Ghana Hlth Serv, Nutr Dept, Accra, GhanaAD  - Iodine Global Network, Seattle, WA 98107 USAC3  - UNICEFC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Ghana Health ServicePU  - MDPI
PI  - BASEL
PA  - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
DA  - APR
PY  - 2018
VL  - 10
IS  - 4
C7  - 516
DO  - 10.3390/nu10040516
AN  - WOS:000435182900132
ER  -

TY  - JOUR
AU  - Kumar, A
AU  - Trikha, V
AU  - Mittal, S
TI  - Letter to the Editor concerning "Pilon fractures: A new classification system based on CT-scan" by Danilo Leonetti, *, Domenico Tigani (2017). Injury. 2017 Oct;48(10):2311-2317
T2  - INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
AD  - AIIMS, Dept Orthopaed, New Delhi 110029, IndiaAD  - AIIMS, JPN Apex Trauma Ctr, Dept Orthopaed, New Delhi 110095, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterPU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - APR
PY  - 2018
VL  - 49
IS  - 4
SP  - 881
EP  - 882
DO  - 10.1016/j.injury.2018.02.019
AN  - WOS:000429922100021
ER  -

TY  - JOUR
AU  - Kumar, A
AU  - Mittal, S
AU  - Mohan, A
AU  - Madan, K
TI  - Comparison of sedation regimens during flexible bronchoscopy
T2  - CLINICAL RESPIRATORY JOURNAL
AD  - All India Inst Med Sci AIIMS, Dept Pulm Med & Sleep Disorders, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - APR
PY  - 2018
VL  - 12
IS  - 4
SP  - 1775
EP  - 1775
DO  - 10.1111/crj.12720
AN  - WOS:000429581600063
ER  -

TY  - JOUR
AU  - Kumar, V
AU  - Singh, S
TI  - Multimodal imaging of choroidal nodules in neurofibromatosis type-1
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Choroidal hamartoma
KW  - infrared imaging
KW  - neurofibromatosis-1
KW  - optical coherence tomography angiography
KW  - swept source
KW  - ABNORMALITIES
AB  - Choroidal nodules in neurofibromatosis type-1 are common and are best imaged with near-infrared reflectance (NIR) imaging. The authors describe swept-source optical coherence tomography angiography (SSOCTA) of choroidal nodules. These nodules are seen as hyperflow areas on SSOCTA and correlate well to bright patches on NIR imaging. The utility of multicolor scanning laser imaging in detecting these abnormalities is also described.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - APR
PY  - 2018
VL  - 66
IS  - 4
SP  - 586
EP  - +
C7  - PMID 29582830
DO  - 10.4103/ijo.IJO_1095_17
AN  - WOS:000428858100026
ER  -

TY  - JOUR
AU  - Kumar, V
AU  - Kumawat, D
TI  - Multimodal imaging in a case of butterfly pattern dystrophy of retinal pigment epithelium
T2  - INTERNATIONAL OPHTHALMOLOGY
KW  - Multimodal imaging
KW  - Butterfly pattern dystrophy
KW  - Optical coherence tomography
KW  - Autofluorescence
KW  - Enface
KW  - DEGENERATION
AB  - Aims To report multi-modal imaging findings in a case of butterfly pattern dystrophy of retinal pigment epithelium.
   Methods A middle-aged female with butterfly pattern dystrophy, who presented with progressive loss of vision, was examined using coloured fundus photographs, short wave autofluorescence, swept source optical coherence tomography (SS-OCT), fundus fluorescein angiography and enface optical coherence tomography.
   Results Multi-modal imaging was useful in the characterization of the various disease features. Autofluorescence pattern was opposite to that of fluorescein angiogram and SS-OCT showed disruption in the outer retinal layers. Enface OCT images depicted the pigment deposition prominently.
   Conclusion The features of butterfly pattern dystrophy on these modalities correlated well with the histopathological findings described in the literature. Enface imaging highlights the deposition of pigment/lipofuscin and has never been described in BPD.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - APR
PY  - 2018
VL  - 38
IS  - 2
SP  - 775
EP  - 779
DO  - 10.1007/s10792-017-0497-3
AN  - WOS:000431304900043
ER  -

TY  - JOUR
AU  - Kumar, V
AU  - Kumawat, D
AU  - Bhari, A
AU  - Chandra, P
TI  - TWENTY-FIVE-GAUGE PARS PLANA VITRECTOMY IN COMPLEX RETINAL DETACHMENTS ASSOCIATED WITH GIANT RETINAL TEAR
T2  - RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
KW  - giant retinal tears
KW  - perfluorocarbon liquid
KW  - PFCL-oil exchange
KW  - 25-gauge
KW  - pars plana vitrectomy
KW  - TRANSCONJUNCTIVAL SUTURELESS VITRECTOMY
KW  - POSTERIOR SEGMENT DISEASE
KW  - PERFLUORO-N-OCTANE
KW  - SURGICAL OUTCOMES
KW  - SILICONE OIL
KW  - CLINICAL CHARACTERISTICS
KW  - 25-GAUGE VITRECTOMY
KW  - RISK-FACTORS
KW  - CASE SERIES
KW  - MANAGEMENT
AB  - Purpose: To study the structural and functional outcomes of 25-gauge pars plana vitrectomy in giant retinal tear-associated retinal detachments.
   Methods: Seventeen eyes of 17 patients with giant retinal tear, who underwent 25-gauge pars plana vitrectomy over a period of 15 months at a tertiary eye care center by a single surgeon, were recruited in this retrospective interventional study.
   Results: Giant retinal tears were mostly traumatic (35.3%) or associated with myopia (35.3%) and occurred in young (mean age 25.7 years) males (94.1%). Most eyes had best-corrected visual acuity <= 20/1,200 (in 82.3%), foveal detachment (in 88.2%), and proliferative vitreoretinopathy <= Grade B (in 82.3%). The giant retinal tear extent was more than 180 degrees in 29.4% and the fellow eye was involved in 35.2% of eyes. All eyes underwent 25-gauge pars plana vitrectomy with encircling band in 41.1%, perfluorocarbon liquid use in 82.3%, and endotamponade with sulphur hexafluoride (23.6%) or silicone oil (76.4%). At mean follow-up of 10.2 months, reattachment rate was 88.2%. Only 35.2% of eyes achieved final visual acuity >= 20/80 with a cause of poor vision being cataract, secondary glaucoma, macular pucker, and corneal edema.
   Conclusion: Twenty-five-gauge pars plana vitrectomy can achieve excellent attachment rates in eyes with giant retinal tear-associated retinal detachment. It can be as efficient as larger-gauge vitrectomy, at the same time retaining all advantages of smaller-gauge surgery.
AD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - APR
PY  - 2018
VL  - 38
IS  - 4
SP  - 670
EP  - 677
DO  - 10.1097/IAE.0000000000001592
AN  - WOS:000440623400010
ER  -

TY  - JOUR
AU  - Kumar, V
AU  - Bora, GS
AU  - Kumar, R
AU  - Jagannathan, NR
TI  - Multiparametric (mp) MRI of prostate cancer
T2  - PROGRESS IN NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
KW  - Prostate cancer
KW  - Multiparametric MRI
KW  - Diffusion weighted imaging
KW  - Magnetic resonance spectroscopy
KW  - Dynamic contrast enhanced MRI
KW  - APPARENT DIFFUSION-COEFFICIENT
KW  - DIGITAL RECTAL EXAMINATION
KW  - MAGNETIC-RESONANCE-SPECTROSCOPY
KW  - ULTRASOUND-GUIDED BIOPSY
KW  - CONTRAST-ENHANCED MRI
KW  - ISUP CONSENSUS-CONFERENCE
KW  - PROTON NMR-SPECTROSCOPY
KW  - TO-NOISE RATIO
KW  - PERIPHERAL ZONE
KW  - FOCAL THERAPY
AB  - Prostate cancer (PCa) is one of the most prevalent cancers in men. A large number of men are detected with PCa; however, the clinical behavior ranges from low-grade indolent tumors that never develop into a clinically significant disease to aggressive, invasive tumors that may rapidly progress to metastatic disease.
   The challenges in clinical management of PCa are at levels of screening, diagnosis, treatment, and follow-up after treatment. Magnetic resonance imaging (MRI) methods have shown a potential role in detection, localization, staging, assessment of aggressiveness, targeting biopsies, etc. in PCa patients. Multiparametric MRI (mpMRI) is emerging as a better option compared to the individual imaging methods used in the evaluation of PCa. There are attempts to improve the reproducibility and reliability of mpMRI by using an objective scoring system proposed in the prostate imaging reporting and data system (PIRADS) for standardized reporting. Prebiopsy mpMRI may be used to detect PCa in men with elevated prostate-specific antigen or abnormal digital rectal examination and to enable targeted biopsies. mpMRI can also be used to decide on clinical management of patients, for example active surveillance, and may help in detecting only the pathology that requires detection. It can potentially not only guide patient selection for initial and repeat biopsy but also reduce false-negative biopsies. This review presents a description of the MR methods most commonly applied for investigations of prostate. The anatomical, functional and metabolic parameters obtained from these MR methods are discussed with regard to their physical basis and their contribution to mpMRI investigations of PCa. (C) 2018 Elsevier B.V. All rights reserved.
AD  - All India Inst Med Sci, Dept NMR & MRI Facil, New Delhi 110029, IndiaAD  - Postgrad Inst Med Sci, Dept Urol, Chandigarh 160012, IndiaAD  - All India Inst Med Sci, Dept Urol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - PERGAMON-ELSEVIER SCIENCE LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
DA  - APR
PY  - 2018
VL  - 105
SP  - 23
EP  - 40
DO  - 10.1016/j.pnmrs.2018.01.001
AN  - WOS:000429631300002
ER  -

TY  - JOUR
AU  - Makwana, T
AU  - Takkar, B
AU  - Venkatesh, P
AU  - Sharma, JB
AU  - Gupta, Y
AU  - Chawla, R
AU  - Vohra, R
AU  - Kriplani, A
AU  - Tandon, N
TI  - Prevalence, progression, and outcomes of diabetic retinopathy during pregnancy in Indian scenario
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Diabetes mellitus in pregnancy
KW  - diabetic retinopathy
KW  - insulin-dependent diabetes mellitus
KW  - WOMEN
KW  - IDDM
AB  - Purpose: The objective of this study is to evaluate pattern of diabetic retinopathy (DR) during pregnancy in females with pregestational diabetes mellitus (DM). Methods: This is an ambispective observational cohort study conducted at an Indian tertiary care centre. A total of 50 pregnant females with pregestational DM were included while those with gestational DM were excluded from the study. Ocular examination (inclusive of fundus photography) was conducted and systemic parameters (inclusive of Glycated hemoglobin) were assessed during each of the 3 trimesters and 3 months postpartum. The prevalence and progression of DR during pregnancy in the study cohort were the main outcome measures. Results: Three of the 50 patients had type 1 DM while 47 had type II DM. All the patients with type I DM were insulin dependent while 19 patients with type II DM were insulin dependent. Overall prevalence of DR was 8% (4/50); 2 cases had nonproliferative DR (NPDR), and 2 had proliferative DR (PDR). During the study period, worsening was seen in both the patients with PDR and one required vitrectomy. Mean visual acuity in patients with PDR decreased from 0.77 logMAR units at presentation to 1.23 logMAR at final follow-up. There was no change in the mean visual acuity of patients with NPDR. None of the patients with NPDR converted to PDR. There was no new onset DR in the patients without DR at presentation. Assessment of risk factors for DR revealed significantly higher duration of DM (14 +/- 6.32 years vs. 3.43 +/- 1.43 years, P = 0.0008). The median age was also higher in the DR patients (31 years vs. 29 years, P = 0.32). Conclusion: No new onset cases were seen during the course of pregnancy and no conversion from NPDR to PDR was seen; however, a worsening of the two PDR cases was observed. No cases of DR were seen in noninsulin-dependent DM. None of the four participants with DR showed a spontaneous resolution of DR postpartum. Patients with PDR and long-standing DM require careful observation during pregnancy. A registry of diabetic mothers should be set up for development of guidelines for managing such cases.
AD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Obstet & Gynaecol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - APR
PY  - 2018
VL  - 66
IS  - 4
SP  - 541
EP  - 546
DO  - 10.4103/ijo.IJO_1062_17
AN  - WOS:000428858100012
ER  -

TY  - JOUR
AU  - Manasa, S
AU  - Kakkar, P
AU  - Kumar, A
AU  - Chandra, P
AU  - Kumar, V
AU  - Ravani, R
TI  - Comparative Evaluation of Standard ILM Peel With Inverted ILM Flap Technique In Large Macular Holes: A Prospective, Randomized Study
T2  - OPHTHALMIC SURGERY LASERS & IMAGING RETINA
KW  - INTERNAL LIMITING MEMBRANE
KW  - PORCINE NEURORETINA
KW  - SURGERY
KW  - OUTCOMES
KW  - CLASSIFICATION
KW  - CLOSURE
KW  - REPAIR
KW  - MULLER
KW  - SIZE
AB  - BACKGROUND AND OBJECTIVE: To compare the outcomes of inverted internal limiting membrane (ILM) flap technique (IFT) with the standard ILM peel (SIP) for large macular holes (MHs).
   PATIENTS AND METHODS: This is a prospective, randomized study in which 100 patients with idiopathic MHs with minimum linear dimension of 600 mu m or greater were recruited. Group 1 underwent SIP and group 2 underwent IFT. Best-corrected visual acuity (BCVA), type of MH closure, and multifocal electroretinogram (mfERG) were evaluated at presentation, 1 week, 1 month, and 3 months postoperatively.
   RESULTS: Mean postoperative BCVA was 0.86 +/- 0.19 in group 1 and 0.67 +/- 0.3 in group 2 at 3 months postoperatively (P = .001). Type 1 closure was observed in 34.04% of patients in group 1 and in 62.79% of patients in group 2 (P = .02). mfERG showed improvement in both groups.
   CONCLUSION: IFT provides superior outcomes compared to SIP and, hence, could be considered as the surgical modality of choice in large MH.
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SLACK INC
PI  - THOROFARE
PA  - 6900 GROVE RD, THOROFARE, NJ 08086 USA
DA  - APR
PY  - 2018
VL  - 49
IS  - 4
SP  - 236
EP  - 240
DO  - 10.3928/23258160-20180329-04
AN  - WOS:000430534800004
ER  -

TY  - JOUR
AU  - Mathur, P
TI  - Prevention of Healthcare-Associated Infections in Low- and Middle-Income Countries: The 'Bundle Approach'
T2  - INDIAN JOURNAL OF MEDICAL MICROBIOLOGY
KW  - Bundle approach
KW  - healthcare-associated infections
KW  - patient care
KW  - VENTILATOR-ASSOCIATED PNEUMONIA
KW  - BLOOD-STREAM INFECTIONS
KW  - SURGICAL SITE INFECTION
KW  - NOSOCOMIAL INFECTIONS
KW  - UNIT
KW  - INTERVENTION
KW  - REDUCTION
KW  - ARGENTINA
KW  - IMPACT
KW  - RATES
AB  - Background: Healthcare-associated infections (HCAI/HAls) are one of the most common adverse events in patient care and account for substantial morbidity and mortality. The high rates of HCAIs in a facility are an indicator of poor quality of healthcare services. According to the World Health Organization, at any time, up to 7% of patients in developed and 10% in developing countries will acquire at least one HAI. These infections also present a significant economic burden at the societal level. However, a large percentage of HAIs are preventable through effective infection prevention and control measures. Objectives: Prevention of these infections also needs to be prioritised in view of the growing antimicrobial resistance in HAIs. The bundle approach to the prevention of HAIs is a relatively new concept that is revolutionising the care of high-risk patients in the Intensive Care Units. This report details the bundle approach for the prevention of HAIs, particularly the device-associated infections, for low- and middle-income countries. Conclusion: With the escalating amiamentarium of antimicrobial resistance, healthcare sector has to go back to the very basics of hospital infection control; develop, assess and implement bundles of prevention. These are cost-effective and easily adaptable ; to cater to the increasing HCAIs and MDR infections in the LMICs.
AD  - All India Inst Med Sci, Dept Lab Med, Jai Prakash Narayan Apex Trauma Ctr, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - APR-JUN
PY  - 2018
VL  - 36
IS  - 2
SP  - 155
EP  - 162
DO  - 10.4103/ijmm.IJMM_18_152
AN  - WOS:000441827600002
ER  -

TY  - JOUR
AU  - Mathur, VP
TI  - Dental Caries: A Disease Which Needs Attention - Correspondence Reply
T2  - INDIAN JOURNAL OF PEDIATRICS
AD  - All India Inst Med Sci, CDER, Div Pedodont & Prevent Dent, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - APR
PY  - 2018
VL  - 85
IS  - 4
SP  - 328
EP  - 328
AN  - WOS:000429379400024
ER  -

TY  - JOUR
AU  - Mishra, N
AU  - Mohata, M
AU  - Aggarwal, H
AU  - Chaudhary, O
AU  - Das, BK
AU  - Sinha, S
AU  - Hazarika, A
AU  - Luthra, K
TI  - Expression of complement receptor 3 (CR3) and regulatory protein CD46 on dendritic cells of antiretroviral naive and treated HIV-1 infected individuals: Correlation with immune activation status
T2  - MOLECULAR IMMUNOLOGY
KW  - HIV-1
KW  - CR3
KW  - CD46
KW  - Antiretrovirals
KW  - Complement
KW  - Dendritic cells
AB  - During infection and budding, human immunodeficiency virus-1 (HIV-1) acquires regulators of Complement Activation (RCAs) along with the host cell membrane on the viral envelope. Activation of host complement system results in opsonization of virus by complement fragments, however the virus evades complement mediated lysis (CoML) by virtue of the RCAs on the viral envelope. The RCAs on HIV-1 envelope process complement protein C3 into various fragments that promote viral entry and infection of cells through different complement receptors. Complement opsonized HIV-1 has been shown in vitro to infect dendritic cells (DCs) in a CR3 dependent manner, although the role of CR3 and CD46 in natural HIV-1 infection is not clear. Surface expression of CR3 and CD46 on DC subsets of 30 antiretroviral naive, 31 treated (cART) HIV-1 infected individuals and 30 seronegative controls was measured by flow cytometry and plasma levels of cytokines and complement activity (C3c levels) were quantitated by sandwich ELISA. Significantly lower surface expression of CR3 and CD46 was observed on DC subsets in naive and treated HIV-1 infected individuals compared to controls. Significantly higher complement activation and plasma levels of IL-4, IL-8, IL-10 and IFN-gamma were observed in treatment naive HIV-1 infected individuals than controls. Significantly lower plasma levels of IL-4, IL-6, IL-8 and IL-10 were observed in treated vs. naive HIV-1 infected individuals. Our findings suggest that alterations in expression of CR3 and CD46 on DCs along with complement activity could be factors that influence viral persistence and HIV-1 disease progression and need to be further evaluated.
AD  - All India Inst Med Sci, Dept Biochem, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Microbiol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Med, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Blood Bank CN Ctr, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - PERGAMON-ELSEVIER SCIENCE LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
DA  - APR
PY  - 2018
VL  - 96
SP  - 83
EP  - 87
DO  - 10.1016/j.molimm.2018.02.011
AN  - WOS:000430647700010
ER  -

TY  - JOUR
AU  - Moka, P
AU  - Goswami, P
AU  - Kapil, A
AU  - Xess, I
AU  - Sreenivas, V
AU  - Saraya, A
TI  - Impact of Antibiotic-Resistant Bacterial and Fungal Infections in Outcome of Acute Pancreatitis
T2  - PANCREAS
KW  - acute pancreatitis
KW  - multidrug resistant
KW  - ACUTE NECROTIZING PANCREATITIS
KW  - CONTEMPORARY ANALYSIS
KW  - INCREASED MORTALITY
KW  - ESCHERICHIA-COLI
KW  - ORGAN FAILURE
KW  - NECROSIS
KW  - COMPLICATIONS
KW  - PREVALENCE
KW  - CANDIDA
KW  - CLASSIFICATION
AB  - Objectives The knowledge about pathogens and their antibiotic susceptibility patterns is essential to select an appropriate antibiotic.
   Methods We investigated the microbiological profile in pancreatic and extrapancreatic infections, and antibiotic sensitivity pattern in patients with acute pancreatitis.
   Results Of 556 patients with acute pancreatitis, only 189 developed bacterial infection; however, bacteremia was present in 42 patients (7.6%). Culture-proven infected pancreatic necrotic collection was present in 161 patients (29%). Escherichia coli and Klebsiella pneumoniae were the most common organisms. Among the bacterial infection cohort, 164 patients developed multidrug-resistant bacterial infection. Infection with multidrug-resistant bacteria, especially at multiple sites, increased mortality. Nearly 50% of patients (n = 94) acquired extremely drug-resistant bacterial infection at some time and emerged as key reason for prolonged hospital and intensive care unit stay. Colistin resistance and tigecycline resistance were documented in 2.1% and 17.2% of the specimens at admission and in 4.6% and 21% of specimens during the hospital stay. Of 556 patients, 102 patients developed fungal infection and 28 patients had only fungal infection without bacterial infection.
   Conclusions Colistin and tigecycline are best reserved as last-resort antibiotics. Fungal infection was found to be associated with increased mortality, median hospital stay, and intensive care unit stay.
AD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Human Nutr Unit, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - APR
PY  - 2018
VL  - 47
IS  - 4
SP  - 489
EP  - 494
DO  - 10.1097/MPA.0000000000001019
AN  - WOS:000428083700026
ER  -

TY  - JOUR
AU  - Naithani, R
AU  - Seth, T
AU  - Tandon, N
AU  - Chandra, J
AU  - Pati, H
AU  - Choudhry, VP
TI  - Safety of Zoledronic Acid in Patients with Thalassemia Associated Low Bone Mineral Density
T2  - INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
KW  - INDUCED OSTEOPOROSIS
KW  - TRIAL
AD  - Max Superspecial Hosp, Hematol & Bone Marrow Transplantat Unit, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Hematol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi, IndiaAD  - Lady Hardinge Med Coll & Hosp, Div Pediat Hematooncol, Dept Pediat, New Delhi, IndiaAD  - Kalawati Saran Childrens Hosp, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Lady Hardinge Medical College & HospitalPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - APR
PY  - 2018
VL  - 34
IS  - 2
SP  - 345
EP  - 346
DO  - 10.1007/s12288-017-0858-0
AN  - WOS:000429245600023
ER  -

TY  - JOUR
AU  - Nalwa, A
AU  - Walia, R
AU  - Singh, V
AU  - Madan, K
AU  - Mathur, S
AU  - Iyer, V
AU  - Jain, D
TI  - Comparison of Conventional Smear and Liquid-based Cytology Preparation in Diagnosis of Lung Cancer by Bronchial Wash and Transbronchial Needle Aspiration
T2  - JOURNAL OF CYTOLOGY
KW  - Cytology
KW  - respiratory tract
KW  - thin prep
KW  - ON-SITE EVALUATION
KW  - THINPREP
KW  - CYTOMORPHOLOGY
KW  - GALLBLADDER
KW  - EXPERIENCE
KW  - CARCINOMA
KW  - SPECIMENS
KW  - UTILITY
KW  - TUMORS
KW  - TBNA
AB  - Introduction: Liquid-based cytology (LBC), initially developed for screening gynecologic specimens, is now being used in nongynecologic aspiration and exfoliative specimens. In this study, the diagnostic yield and utility of thin-prep (TP) was compared with conventional preparations to ascertain its utility in improving the diagnosis of respiratory lesions. Materials and Methods: Bronchial washings (BW) and transbronchial needle aspirates (TBNA) (bronchoscopy/endobronchial ultrasound-guided) from 70 consecutive patients of mediastinal masses and endo/peribronchial growths were included. The diagnostic yields of both conventional smears and thin-prep were compared. Immunocytochemistry (ICC) was performed on direct/cytospin smears of TBNA/BW and TP slides when the tumor could not be subtyped by morphology. Histopathologic correlation was done. Results: Although well-preserved morphological features and cleaner background in TP allowed accurate diagnosis of malignancies, diagnostic yield was comparable to conventional preparations. Immunocytochemistry was successfully employed on TP smears which helped in accurate subtyping of the tumors. Few shortcomings of TP smears were uneven distribution of cells, thick cell clusters, and inadequate cellularity. Conclusion: Liquid-based TP preparation is an effective diagnostic tool for respiratory tract cytology, however, results are comparable to conventional smears.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pulm Med & Sleep Disorders, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - APR-JUN
PY  - 2018
VL  - 35
IS  - 2
SP  - 94
EP  - 98
DO  - 10.4103/JOC.JOC_248_16
AN  - WOS:000428589400006
ER  -

TY  - JOUR
AU  - Nambirajan, A
AU  - Kaur, H
AU  - Jangra, K
AU  - Kaur, K
AU  - Madan, K
AU  - Mathur, SR
AU  - Iyer, VK
AU  - Jain, D
TI  - Adenocarcinoma predominant pattern subtyping and nuclear grading in cytology: Is there a role in prognostication of advanced pulmonary adenocarcinomas?
T2  - CYTOPATHOLOGY
KW  - cytology
KW  - lung adenocarcinoma
KW  - nuclear grade
KW  - patterns
KW  - small biopsy
KW  - PROPOSED INTERNATIONAL ASSOCIATION
KW  - I LUNG ADENOCARCINOMA
KW  - IASLC/ATS/ERS CLASSIFICATION
KW  - HISTOLOGIC PATTERN
KW  - SYSTEM
KW  - DIAGNOSIS
KW  - DISEASE
KW  - UTILITY
KW  - CYTOPATHOLOGY
KW  - CHEMOTHERAPY
AB  - IntroductionPrimary lung adenocarcinomas (ADs) show varied architectural patterns, and pattern-based subtyping of ADs is currently recommended due to prognostic implications. Predicting AD patterns on cytology is challenging; however, cytological nuclear features appear to correlate with histological grade and survival in early stage lung ADs. The feasibility and value of AD pattern prediction and nuclear grading on cytology in advanced lung ADs is not known. We aimed to predict patterns and analyse nuclear features on cytology and evaluate their role in prognostication.
   MethodsOne-hundred patients of Stage III/IV lung AD with available matched cytology and histology samples were included. Cyto-patterns based on cell arrangement patterns (flat sheets vs three-dimensional clusters vs papillae) and cyto-nuclear score based on nuclear features (size, shape, contour), nucleoli (macronucleoli vs prominent vs inconspicuous), and nuclear chromatin were determined, and correlated with predominant histological-pattern observed on the matched small biopsy and outcome.
   ResultsHigher cyto-nuclear scores were observed with high-grade histo-patterns (solid, micropapillary and cribriform), while the predicted cyto-patterns did not correspond to the predominant pattern on histology in 77% cases. Highest cyto-histo agreement was observed for solid pattern (72%). High grade histo-patterns and cyto-nuclear scores > 3 showed a trend towards inferior survival (not significant).
   ConclusionsNuclear grade scoring on cytology is simple to perform, and is predictive of high grade patterns. Its inclusion in routine reporting of cytology samples of lung ADs may be valuable.
   High cytologic nuclear grade scores correlate with high grade histological patterns in advanced lung adenocarcinomas. Adenocarcinoma predominant pattern subtyping on cytology shows poor concordance with histology.
AD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pulm Med, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - APR
PY  - 2018
VL  - 29
IS  - 2
SP  - 163
EP  - 171
DO  - 10.1111/cyt.12519
AN  - WOS:000428388400006
ER  -

TY  - JOUR
AU  - Parida, GK
AU  - Tripathy, S
AU  - Gupta, SD
AU  - Singhal, A
AU  - Kumar, R
AU  - Bal, C
AU  - Shamim, SA
TI  - Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of <SUP>18</SUP>F-FDG PET/CT and <SUP>68</SUP>Ga-DOTANOC PET/CT Over <SUP>68</SUP>Ga-PSMA PET/CT
T2  - CLINICAL NUCLEAR MEDICINE
KW  - neuroendocrine tumor
KW  - prostate malignancy
KW  - FDG PET/CT
KW  - DOTANOC PET/CT
KW  - PSMA PET/CT
KW  - POSITRON-EMISSION-TOMOGRAPHY
KW  - CANCER
AB  - Ga-68-PSMA PET/CT is the upcoming imaging modality for staging, restaging and response assessment of prostate cancer. However, due to neuroendocrine differentiation in some of patients with prostate cancer, they express somatostatin receptors instead of prostate specific membrane antigen. This can be exploited and other modalities like Ga-68-DOTANOC PET/CT and F-18-FDG PET/CT should be used in such cases for guiding management. We hereby discuss a similar case of 67-year-old man of adenocarcinoma prostate with neuroendocrine differentiation, which shows the potential pitfall of Ga-68-PSMA PET/CT imaging and benefit of Ga-68-DOTANOC PET/CT and F-18-FDG PET/CT in such cases.
AD  - All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - APR
PY  - 2018
VL  - 43
IS  - 4
SP  - 248
EP  - 249
DO  - 10.1097/RLU.0000000000002013
AN  - WOS:000427793000015
ER  -

TY  - JOUR
AU  - Priya, S
AU  - Thomas, R
AU  - Nagpal, P
AU  - Sharma, A
AU  - Steigner, M
TI  - Congenital anomalies of the aortic arch
T2  - CARDIOVASCULAR DIAGNOSIS AND THERAPY
KW  - Aortic arch
KW  - vascular ring
KW  - computed tomography angiography (CTA)
KW  - magnetic resonance angiography (MRA)
KW  - LEFT SUBCLAVIAN ARTERY
KW  - ULTRASHORT ECHO TIME
KW  - MAGNETIC-RESONANCE
KW  - COMPUTED-TOMOGRAPHY
KW  - PULMONARY-ARTERY
KW  - VASCULAR RINGS
KW  - MRI
KW  - COARCTATION
KW  - DIAGNOSIS
KW  - CHILDREN
AB  - Congenital anomalies of the aortic arch include diverse subgroups of malformations that may be clinically silent or may present with severe respiratory or esophageal symptoms especially when associated with complete vascular rings. These anomalies may be isolated or may be associated with other congenital heart diseases. Volume rendered computed tomography (CT) and magnetic resonance angiography (MRA) help in preoperative surgical planning by providing information about the complex relationship of aortic arch and its branches to the trachea and esophagus. Three dimensional capabilities of both computed tomography angiography (CTA) and MRA are helpful in determining evidence of tracheal or esophageal compression or other high-risk features in patients with a complete vascular ring.
AD  - Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Div Noninvas Cardiovasc Imaging, Boston, MA 02115 USAAD  - Univ Iowa Hosp & Clin, Dept Radiol, Iowa City, IA 52242 USAAD  - All India Inst Med Sci, Dept Cardiovasc Radiol, New Delhi, IndiaC3  - Harvard UniversityC3  - Brigham & Women's HospitalC3  - Harvard Medical SchoolC3  - University of IowaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AME PUBLISHING COMPANY
PI  - SHATIN
PA  - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA
DA  - APR
PY  - 2018
VL  - 8
SP  - S26
EP  - S44
DO  - 10.21037/cdt.2017.10.15
AN  - WOS:000431655700004
ER  -

TY  - JOUR
AU  - Pujari, A
AU  - Bajaj, MS
AU  - Sen, S
AU  - Goel, S
TI  - Conjunctival angiomyxoma-rare but needs observation
T2  - CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 212,Second Floor, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - CANADIAN OPHTHAL SOC
PI  - OTTAWA
PA  - 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
DA  - APR
PY  - 2018
VL  - 53
IS  - 2
SP  - E60
EP  - E62
DO  - 10.1016/j.jcjo.2017.07.005
AN  - WOS:000429619200009
ER  -

TY  - JOUR
AU  - Rai, N
AU  - Venugopalan, G
AU  - Pradhan, R
AU  - Ambastha, A
AU  - Upadhyay, AD
AU  - Dwivedi, S
AU  - Dey, AB
AU  - Dey, S
TI  - Exploration of Novel Anti-Oxidant Protein Sestrin in Frailty Syndrome in Elderly
T2  - AGING AND DISEASE
KW  - Serum
KW  - Surface Plasmon Resonance
KW  - Protein marker
KW  - Immunoblot
KW  - SARCOPENIA
KW  - EXERCISE
KW  - PEROXIREDOXINS
KW  - IDENTIFICATION
AB  - Frailty in elderly is very much familiar with a decline in the musculoskeletal system. Muscle degeneration in the lower organism was observed due to loss of anti-oxidant protein Sestrin. The aim of the study is to determine the level of Sestrin1 and Sestrin2 in the serum of frail and non-frail elderly to associate their impact in frailty syndrome. Subjects with age >= 65 years were enrolled from Geriatric Medicine OPD of All India Institute of Medical Sciences, New Delhi (N=92). Among them, 51 subjects were identified as frail and rest 41 were regarded as non-frail according to "deficit accumulation model of Rockwood." The study was performed by surface plasmon resonance and validated by western blot. Sestrin1 and Sestrin2 were found to be significantly reduced in frail compare to non-frail elderly. Furthermore, even after the adjustment for age, gender and education, the level of Sestrin1 and Sestrin2 remain significantly lower across the groups. The Sestrin1 level was significantly lower in various categories like age, gender, BMI, education, ADL, number of co-morbidity along with other clinico-pathological features. ROC analysis also revealed the distinction of frail and non-frail in respect to serum Sestrin1 and Sestrin2. This study highlighted the new and promising role of serum Sestrin in frail and non-frail elderly. In future, it can be utilized as molecular marker to assess the potential diagnostic value for clinical purpose.
AD  - All India Inst Med Sci, Dept Biophys, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Geriatr Med, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - INT SOC AGING & DISEASE
PI  - FORT WORTH
PA  - EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA
DA  - APR
PY  - 2018
VL  - 9
IS  - 2
SP  - 220
EP  - 227
DO  - 10.14336/AD.2017.0423
AN  - WOS:000428962400005
ER  -

TY  - JOUR
AU  - Rathi, A
AU  - Chakrabarti, A
AU  - Agarwal, T
AU  - Pushker, N
AU  - Patil, M
AU  - Kamble, H
AU  - Titiyal, JS
AU  - Mohan, R
AU  - Kashyap, S
AU  - Sharma, S
AU  - Sen, S
AU  - Satpathy, G
AU  - Sharma, N
TI  - Pythium Keratitis Leading to Fatal Cavernous Sinus Thrombophlebitis
T2  - CORNEA
KW  - Pythium
KW  - keratitis
KW  - panophthalmitis
KW  - cavernous sinus thrombophlebitis
KW  - INSIDIOSUM KERATITIS
KW  - DIAGNOSIS
AB  - Purpose:To report a case of Pythium insidiosum keratitis leading to fatal cavernous sinus thrombophlebitis.Methods:Case report.Results:A 70-year-old man presented with excruciating pain, redness, and diminution of vision in his left eye for 2 weeks after washing his hair with tap water. A total corneal ulcer with surrounding infiltrates and associated corneal thinning was present. Corneal scraping revealed the presence of Gram-positive cocci. KOH wet mount and in vivo confocal microscopy revealed branching hyphae. Combined antibacterial and antifungal treatment was started, but 4 days later, the ulcer showed signs of worsening with perforation for which a large therapeutic penetrating keratoplasty was done. The host cornea showed branching septate hyphae on Sabarouds Dextrose Agar. Two weeks later, the patient developed left eye proptosis with associated extraocular movement restriction. Magnetic resonance imaging of the head and orbit revealed cavernous sinus thrombophlebitis. Lid sparing partial exenteration was performed. Polymerase chain reaction revealed P. insidiosum. The patient subsequently developed a cerebrovascular attack and died of its complications.Conclusions:Ocular pythiosis may lead to cavernous sinus thrombophlebitis and can even be life threatening. Timely diagnosis and early radical surgery are of value. A high index of suspicion must be kept for P. insidiosum in cases with suspected fungal etiology not responding to conventional treatment.
AD  - All India Inst MAd Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Ophthalmol, New Delhi, IndiaAD  - Postgrad Inst Med Educ & Res, Dept Med Microbiol, Chandigarh, IndiaAD  - MM Eye Tech Inst, New Delhi, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Ocular Pathol, New Delhi, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Radiodiag, New Delhi, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Ocular Microbiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - APR
PY  - 2018
VL  - 37
IS  - 4
SP  - 519
EP  - 522
DO  - 10.1097/ICO.0000000000001504
AN  - WOS:000429590300030
ER  -

TY  - JOUR
AU  - Reddy, S
AU  - Swamy, R
AU  - Irugu, DVK
AU  - Ramji, KVV
TI  - Transtracheal endoscopic-assisted resection of a rare inflammatory myofibroblastic tumour in adult trachea: a case report
T2  - ACTA OTORHINOLARYNGOLOGICA ITALICA
KW  - Strider
KW  - Inflammatory myofibroblastic tumour
KW  - Trachea
KW  - Bronchus
KW  - Spindle cell proliferation
AB  - Inflammatory myofibroblastic tumours (IMTs) are rare and clinically benign in childhood, and malignant in adults. The aetiology of IMTs is not clear, and recent studies report it as true neoplasm rather than a reactive or inflammatory lesion. IMTs can involve any part of the body, but are usually common in lungs. These are rarely seen in adults and tracheal involvement is also rare in both adults and children. We describe an 18-year-old woman who presented with respiratory difficulty to the emergency department. On clinical examination, the patient had complete absence of breath sounds on the right side of the chest. CT of the chest and virtual bronchoscopy revealed a polypoidal soft tissue mass lesion involving the carina with occlusion of right main bronchus. Endoscopic-assisted resection was performed under general anaesthesia and the final pathological diagnosis was tracheal IMT.
AD  - Govt ENT Hosp, Osmania Med Coll, Dept Otorhinolaryngol & Head & Neck Surg, Hyderabad, IndiaAD  - All India Inst Med Sci, Dept Otorhinolaryngol & Head & Neck Surg, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - PACINI EDITORE
PI  - PISA
PA  - VIA DELLA GHERARDESCA-ZONA INDUSTRIALE OSPEDALETTO, 56121 PISA, ITALY
DA  - APR
PY  - 2018
VL  - 38
IS  - 2
SP  - 170
EP  - 173
DO  - 10.14639/0392-100X-1278
AN  - WOS:000453584400014
ER  -

TY  - JOUR
AU  - Saini, I
AU  - Bagri, N
AU  - Gupta, N
TI  - My phenotype speaks: please do not harm me with biopsy needle
T2  - ACTA REUMATOLOGICA PORTUGUESA
KW  - FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
AD  - All India Inst Med Sci, Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - PUBLISAUDE-EDICOES MEDICAS LDA
PI  - ALGES
PA  - ALAMEDA ANTONIO SERGIO 22, 4 B EDIF AMADEO SOUZA-CARDOSO, ALGES, 1495-132, PORTUGAL
DA  - APR-JUN
PY  - 2018
VL  - 43
IS  - 2
SP  - 156
EP  - 158
AN  - WOS:000441341500010
ER  -

TY  - JOUR
AU  - Saini, I
AU  - Chouhan, P
AU  - Bagri, NK
TI  - Starry Sky Calcifications
T2  - JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
KW  - JUVENILE DERMATOMYOSITIS
KW  - CALCINOSIS
AD  - AIIMS, Dept Pediat, Div Rheumatol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - APR
PY  - 2018
VL  - 24
IS  - 3
SP  - 150
EP  - 151
DO  - 10.1097/RHU.0000000000000643
AN  - WOS:000431178600008
ER  -

TY  - JOUR
AU  - Satyarthee, GD
TI  - Ideally, How Early Should Cranioplasty Be Performed-Days, Weeks, or Months Following Decompressive Craniectomy Surgery to Label as "Optimal Early Cranioplasty"? Big Enigma
T2  - WORLD NEUROSURGERY
KW  - TRAUMATIC BRAIN-INJURY
KW  - INCREASED COMPLICATIONS
KW  - CLINICAL ARTICLE
KW  - REDUCE
AD  - All India Inst Med Sci, Neurosci Ctr, Dept Neurosurg, New Delhi, IndiaAD  - Jai Prakash Narayan Apex Trauma Ctr, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jai Prakash Narayan Apex Trauma CenterPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - APR
PY  - 2018
VL  - 112
SP  - 302
EP  - 303
DO  - 10.1016/j.wneu.2017.11.136
AN  - WOS:000432932700163
ER  -

TY  - JOUR
AU  - Shambanduram, SS
AU  - Sebastian, LJD
AU  - Jain, N
AU  - Garg, A
AU  - Gaikwad, SB
TI  - Management of a rare case of posterior condylar canal dural arteriovenous fistula presenting with subarachnoid haemorrhage: A case report and review of literature
T2  - INTERVENTIONAL NEURORADIOLOGY
KW  - Posterior condylar canal
KW  - dural arteriovenous fistula ( dAVF)
KW  - medulla bridging vein
KW  - subarachnoid haemorrhage (SAH)
KW  - glue embolisation
KW  - transarterial
KW  - ANATOMY
AB  - Posterior condylar canal dural arteriovenous fistula (PCC dAVF) is a rare entity with only three cases having been reported so far in the English literature. We describe the clinical presentation, imaging, and endovascular management of an elderly man with left PCC dAVF presenting with subarachnoid haemorrhage (SAH). Endovascular management of such cases requires thorough understanding of the vascular anatomy around the craniovertebral junction (CVJ) and variable bridging vein draining patterns. The fistula in our case was fed by the posterior meningeal branch of the left vertebral artery and was draining through a dilated and tortuous medullary bridging vein into the antero-lateral pontomedullary venous system. Transarterial glue embolisation was performed with complete exclusion of the fistula and venous pouches. The patient developed intractable hiccough and left-sided facial pain on the second post-procedural day, and MRI showed focal diffusion restriction in the left dorso-lateral medulla. He recovered completely after a short course of steroids.
AD  - All India Inst Med Sci, Dept Neuroimaging & Intervent Neuroradiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SAGE PUBLICATIONS INC
PI  - THOUSAND OAKS
PA  - 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
DA  - APR
PY  - 2018
VL  - 24
IS  - 2
SP  - 206
EP  - 209
DO  - 10.1177/1591019917743703
AN  - WOS:000429853200014
ER  -

TY  - JOUR
AU  - Sharma, HB
AU  - Kailashiya, J
TI  - EFFECTS OF 6-WEEK SPRINT-STRENGTH AND AGILITY TRAINING ON BODY COMPOSITION, CARDIOVASCULAR, AND PHYSIOLOGICAL PARAMETERS OF MALE FIELD HOCKEY PLAYERS
T2  - JOURNAL OF STRENGTH AND CONDITIONING RESEARCH
KW  - double-product
KW  - vertical jump
KW  - ball-hitting speed
KW  - 505-agility test
KW  - VO(2)max
KW  - training adaptation
KW  - POSTEXERCISE OXYGEN-CONSUMPTION
KW  - SHUTTLE RUN TEST
KW  - RESISTANCE EXERCISE
KW  - PHYSICAL-FITNESS
KW  - AEROBIC CAPACITY
KW  - PERFORMANCE
KW  - ENDURANCE
KW  - POWER
KW  - INTENSITY
KW  - METAANALYSIS
AB  - Optimal physiological and cardiovascular characteristics are essential for optimal physical performance. Different types of training regimes affect these characteristics and lead to trainees' adaptation and changes in relevant parameters. In the present interventional study, we have evaluated the effects of 6-week sprint-strength and agility training on such parameters. Twenty-four young Indian national hockey players volunteered for this study. Body weight (BW), body mass index (BMI), percentage body fat, lean body mass (LBM), resting heart rate (rHR), resting blood pressure (rBP), resting double-product (rDP), P/power (using Running-based Anaerobic Sprint Test), vertical jump (VJ), seated shot put test (SP), ball-hitting speed (BS), Tm (505-agility test), and VO(2)max were measured, and changes (d) after specified training regime were studied. The training proved to be "short yet effective." Significant improvements after training were found in body composition, cardiovascular, aerobic, anaerobic, strength, agility, and performance-related parameters; but not in BW, BMI, P/LBM, SP/LBM, and VO(2)max/LBM. Change in VJ (dVJ) was associated with change in Tm (dTm); change in SP (dSP) with change in VO(2)max, which also related to change in rHR, rBP and rDP. Change in BS (dBS) was more among those with lower initial BW, BMI, and BF. dBS, along with change in VO(2)max/ LBM, was more mainly among those with lower initial anaerobicaerobic fitness. The findings will be useful for coaches, sports managers, players, and also for general population for better, individual, and sport-based designing of "short yet effective" train-ing programs and monitoring of outcomes. Specific physiological parameter improvement-targeted training can also be designed based on this research.
AD  - All India Inst Med Sci, Dept Physiol, New Delhi, IndiaAD  - Banaras Hindu Univ, Inst Med Sci, Dept Biochem, Varanasi, Uttar Pradesh, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Banaras Hindu University (BHU)PU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - APR
PY  - 2018
VL  - 32
IS  - 4
SP  - 894
EP  - 901
DO  - 10.1519/JSC.0000000000002212
AN  - WOS:000431392300003
ER  -

TY  - JOUR
AU  - Sharma, JB
AU  - Kachhawa, G
AU  - Kriplani, A
AU  - Mishra, S
AU  - Kriplani, I
TI  - Successful pregnancy outcome in Eisenmenger's syndrome during pregnancy
T2  - EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
AD  - AIIMS, Dept Obstet & Gynecol, New Delhi, IndiaAD  - AIIMS, Dept Cardiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE BV
PI  - AMSTERDAM
PA  - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
DA  - APR
PY  - 2018
VL  - 223
SP  - 146
EP  - 147
DO  - 10.1016/j.ejogrb.2018.02.016
AN  - WOS:000430775400033
ER  -

TY  - JOUR
AU  - Sharma, K
AU  - Bahl, S
AU  - Singh, B
AU  - Kumar, P
AU  - Lochab, SP
AU  - Pandey, A
TI  - BaSO<sub>4</sub>:Eu as an energy independent thermoluminescent radiation dosimeter for gamma rays and C<SUP>6+</SUP> ion beam
T2  - RADIATION PHYSICS AND CHEMISTRY
KW  - Gamma radiation
KW  - Nanoparticles
KW  - Energy independence
KW  - Thermoluminescence
KW  - Ion beams
KW  - ORDER KINETICS
KW  - NANOPARTICLES
KW  - PHOTOLUMINESCENCE
KW  - PHOSPHOR
KW  - TL
KW  - BA0.97CA0.03SO4-EU
KW  - LUMINESCENCE
KW  - THERAPY
AB  - BaSO4:Eu nanophosphor is delicately optimized by varying the concentration of the impurity element and compared to the commercially available thermoluminescent dosimeter (TLD) LiF:Mg,Ti (TLD-100) and by extension also to CaSO4:Dy (TLD-900) so as to achieve its maximum thermoluminescence (TL) sensitivity. Further, the energy dependence property of this barite nanophosphor is also explored at length by exposing the phosphor with 1.25 MeV of Co-60, 0.662 MeV of Cs-137, 85 MeV and 65 MeV of Carbon ion beams. Various batches of the phosphor at hand (with impurity concentrations being 0.05, 0.10, 0.20, 0.50 and 1.00 mol%) are prepared by the chemical co-precipitation method out of which BaSO4:Eu with 0.20 mol% Eu exhibits the maximum TL sensitivity. Further, the optimized nanophosphor exhibits a whopping 28.52 times higher TL sensitivity than the commercially available TLD-100 and 1.426 times higher sensitivity than TLD-900, a noteworthy linear response curve for an exceptionally wide range of doses i.e. 10 Gy to 2 kGy and a simple glow curve structure. Furthermore, when the newly optimized nanophosphor is exposed with two different energies of gamma radiations, namely 1.25 MeV of Co-60 (dose range- 10-300 Gy) and 0.662 MeV of Cs-137 (dose range- 1-300 Gy), it is observed that the shape and structure of the glow curves remain remarkably similar for different energies of radiation while the TL response curve shows little to no variation. When exposed to different energies of carbon ion beam BaSO4:Eu displays energy independence at lower doses i.e. from 6.059 to 14.497 kGy. Finally, even though energy independence is lost at higher doses, the material shows high sensitivity to higher energy (85 MeV) of carbon beam compared to the lower energy (65 MeV of C6+) and saturation is apparent only after 121.199 kGy. Therefore the present nanophosphor displays potential as an energy independent TLD.
AD  - Univ Delhi, Sri Venkateswara Coll, Dept Phys, Benito Juarez Rd, New Delhi 110021, IndiaAD  - AIIMS, IRCH, Med Phys Unit, New Delhi 110029, IndiaAD  - Interuniv Accelerator Ctr, Aruna Asaf Ali Marg, New Delhi 110067, IndiaC3  - University of DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalC3  - Inter-University Accelerator CentrePU  - PERGAMON-ELSEVIER SCIENCE LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
DA  - APR
PY  - 2018
VL  - 145
SP  - 64
EP  - 73
DO  - 10.1016/j.radphyschem.2017.12.019
AN  - WOS:000427213200011
ER  -

TY  - JOUR
AU  - Sharma, R
TI  - Growth Hormone Therapy and Lipid Profile
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - FOR-GESTATIONAL-AGE
KW  - CARDIOVASCULAR RISK-FACTORS
KW  - INTIMA-MEDIA THICKNESS
KW  - GH DEFICIENCY
KW  - METABOLIC PROFILE
KW  - CHILDREN
KW  - ADOLESCENTS
KW  - ADULTS
KW  - REPLACEMENT
KW  - IMPACT
AD  - AIIMS, Div Pediat Endocrinol, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - APR
PY  - 2018
VL  - 85
IS  - 4
SP  - 253
EP  - 254
DO  - 10.1007/s12098-018-2638-8
AN  - WOS:000429379400003
ER  -

TY  - JOUR
AU  - Sharma, R
AU  - Phalak, M
AU  - Katiyar, V
TI  - The efficacy of local vancomycin for reducing surgical site infections after cranioplasty
T2  - JOURNAL OF NEUROSURGERY
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ASSOC NEUROLOGICAL SURGEONS
PI  - ROLLING MEADOWS
PA  - 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
DA  - APR
PY  - 2018
VL  - 128
IS  - 4
SP  - 1263
EP  - 1263
DO  - 10.3171/2017.7.JNS171589
AN  - WOS:000429045500276
ER  -

TY  - JOUR
AU  - Sharma, S
TI  - Thoracoscopic Blebectomy and Pleurodesis for Primary Spontaneous Pneumothorax
T2  - INDIAN JOURNAL OF PEDIATRICS
AD  - All India Inst Med Sci, Dept Pediat Surg, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - APR
PY  - 2018
VL  - 85
IS  - 4
SP  - 251
EP  - 252
DO  - 10.1007/s12098-018-2641-0
AN  - WOS:000429379400002
ER  -

TY  - JOUR
AU  - Sharma, VK
AU  - Gupta, V
AU  - Jangid, BL
AU  - Pathak, M
TI  - Modification of the Fitzpatrick system of skin phototype classification for the Indian population, and its correlation with narrowband diffuse reflectance spectrophotometry
T2  - CLINICAL AND EXPERIMENTAL DERMATOLOGY
KW  - BROWN SKIN
KW  - ERYTHEMA
KW  - COLOR
AB  - BackgroundThe Fitzpatrick classification for skin phototyping is widely used, but its usefulness in dark-skinned populations has been questioned by some researchers. Recently, skin colour measurement has been proposed for phototyping skin colour objectively.
   AimsTo modify the Fitzpatrick system of skin phototyping for the Indian population and to study its correlation with skin colour using narrowband diffuse reflectance spectrophotometry
   MethodsAnswer choices for three items (eye colour, hair colour, colour of unexposed skin) out of 10 in the original Fitzpatrick questionnaire were modified, followed by self-administration of the original and the modified Fitzpatrick questionnaire by 70 healthy Indian volunteers. Skin colour (melanin and erythema indices) was measured from two photoexposed and two photoprotected sites using a narrowband reflectance spectrophotometer.
   ResultsThe mean SD scores for the original and modified Fitzpatrick questionnaires were 25.40 +/- 4.49 and 23.89 +/- 4.82, respectively (r = 0.97, P < 0.001). The two items related to tanning habits were deemed irrelevant based on the subjects' response and were removed from the modified questionnaire. The Melanin Index (MI) of all sites correlated moderately well with both the modified (r = 0.61-0.64, P < 0.001) and original Fitzpatrick questionnaire scores (r = 0.64-0.67, P < 0.001), while the Erythema Index showed poor correlation with both. An MI value of 42 was found to be the cut-off between skin phototypes I-III and IV, and 47 between IV and V-VI.
   ConclusionsOur modification of the Fitzpatrick questionnaire makes it more relevant to the Indian population. Spectrophotometry can be a useful objective tool for skin phototyping.
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - APR
PY  - 2018
VL  - 43
IS  - 3
SP  - 274
EP  - 280
DO  - 10.1111/ced.13365
AN  - WOS:000427243800006
ER  -

TY  - JOUR
AU  - Shekhar, S
AU  - Yadav, SK
AU  - Rai, N
AU  - Kumar, R
AU  - Yadav, Y
AU  - Tripathi, M
AU  - Dey, AB
AU  - Dey, S
TI  - 5-LOX in Alzheimer's Disease: Potential Serum Marker and In Vitro Evidences for Rescue of Neurotoxicity by Its Inhibitor YWCS
T2  - MOLECULAR NEUROBIOLOGY
KW  - Alzheimer's disease
KW  - A beta(25-35)
KW  - Surface plasmon resonance
KW  - Neurodegenerative disease
KW  - Neuroprotective
KW  - CELLS
KW  - CDK5
KW  - GENE
AB  - The inflammatory process plays a key role in neurodegenerative disorder. The inflammatory molecule, 5-lipooxygenase (5-LOX), protein is involved in the pathologic phenotype of Alzheimer's disease (AD) which includes A beta amyloid deposition and tau hyperphosphorylation. This study determined the level of 5-LOX in serum of AD patients, mild cognitive impairment (MCI) patients, and the normal elderly, and the rescue effect by YWCS, a peptide inhibitor of 5-LOX on neurotoxicity by A beta amyloid(25-35) (A beta(25-35)) in neuroblastoma cells. The concentration of serum 5-LOX was estimated by surface plasmon resonance and western blot. The neuroprotective effect of 5-LOX peptide inhibitor YWCS in A beta(25-35)-induced neurotoxicity was analyzed by MTT assay and western blotting. We found significant upregulated serum 5-LOX in AD patients and also in MCI patients compared to the normal control group. The peptide inhibitor of 5-LOX, YWCS, prevented the neurotoxic effect of A beta(25-35) by reducing the expression of gamma-secretase as well as p-Tau(181) in SH-SY5Y cells. However, YWCS was nontoxic towards normal HEK cells. The differential expression of serum 5-LOX among the study groups suggests it can be one of potential serum protein marker and a therapeutic regimen for AD and MCI. The negative correlation with neuropsychological parameters, i.e., MoCA and HMSE, increases its importance and makes it useful during the clinical setup which is very needful in developing countries. Peptide YWCS can serve as a new platform as a 5-LOX inhibitor which can prevent neurotoxicity developed in AD.
AD  - All India Inst Med Sci, Dept Biophys, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Geriatr Med, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - APR
PY  - 2018
VL  - 55
IS  - 4
SP  - 2754
EP  - 2762
DO  - 10.1007/s12035-017-0527-1
AN  - WOS:000427097500004
ER  -

TY  - JOUR
AU  - Sihota, R
AU  - Gupta, S
AU  - Angmo, D
TI  - Evaluation of macular ganglion cell analysis compared to retinal nerve fiber layer thickness for pre-perimetric glaucoma diagnosis
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - OPTICAL COHERENCE TOMOGRAPHY
KW  - FOURIER-DOMAIN OCT
KW  - VISUAL-FIELD LOSS
KW  - HIGH MYOPIA
KW  - HIGH-SPEED
KW  - COMPLEX
KW  - ABILITY
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - APR
PY  - 2018
VL  - 66
IS  - 4
SP  - 491
EP  - 493
C7  - PMID 29582806
DO  - 10.4103/ijo.IJO_235_18
AN  - WOS:000428858100002
ER  -

TY  - JOUR
AU  - Sihota, R
AU  - Angmo, D
AU  - Ramaswamy, D
AU  - Dada, T
TI  - Simplifying "target" intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Advanced Glaucoma Intervention Study
KW  - Collaborative Initial Glaucoma Treatment Study
KW  - Collaborative Normal-Tension Glaucoma Study
KW  - Early Manifest Glaucoma Trial
KW  - glaucoma
KW  - long-term glaucoma
KW  - primary open-angle glaucoma/primary angle-closure glaucoma
KW  - randomized control trials
KW  - success in glaucoma
KW  - target intraocular pressure
KW  - LONG-TERM PROGRESSION
KW  - SCANNING LASER OPHTHALMOSCOPY
KW  - SOUTH INDIAN POPULATION
KW  - RURAL-POPULATION
KW  - TRABECULECTOMY
KW  - OUTCOMES
KW  - PHACOEMULSIFICATION
KW  - PREDICTORS
KW  - BAERVELDT
KW  - SURGERY
AB  - Lowering of intraocular pressure is currently the only therapeutic measure for Glaucoma management. Many longterm, randomized trials have shown the efficacy of lowering IOP, either by a percentage of baseline, or to a specified level. This has lead to the concept of 'Target" IOP, a range of IOP on therapy, that would stabilize the Glaucoma/prevent further visual field loss, without significantly affecting a patient's quality of life. A clinical staging of Glaucoma by optic nerve head evaluation and perimetric parameters, allows a patient's eye to be categorized as having - mild, moderate or severe Glaucomatous damage. An initial attempt should be made to achieve the following IOP range for both POAG or PACG after an iridotomy. In mild glaucoma the initial target IOP range could be kept as 15-17 mmHg, for moderate glaucoma 12-15 mmHg and in the severe stage of glaucomatous damage 10-12 mmHg. Factoring in baseline IOP, age, vascular perfusion parameters, and change on perimetry or imaging during follow up, this range may be reassessed over 6 months to a year. "Target" IOP requires further lowering when the patient continues to progress or develops a systemic disease such as a TIA. Conversely, in the event of a very elderly or sick patient with stable nerve and visual field over time, the target IOP could be raised and medications reduced. An appropriate use of medications/laser/surgery to achieve such a "Target" IOP range in POAG or PACG can maintain visual fields and quality of life, preventing Glaucoma blindness.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Glaucoma Res Facil & Clin Serv, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - APR
PY  - 2018
VL  - 66
IS  - 4
SP  - 495
EP  - 505
C7  - PMID 29582808
DO  - 10.4103/ijo.IJO_1130_17
AN  - WOS:000428858100004
ER  -

TY  - JOUR
AU  - Singh, A
AU  - Dawman, L
AU  - Seth, R
TI  - Malignancy associated hemophagocytic lymphohistiocytosis in children
T2  - JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
KW  - Childhood malignancy
KW  - cytokine storm
KW  - HLH 2004
KW  - immune dysregulation
AB  - Aim of Study: Hemophagocytic lymphohistiocytosis (HLH) is a rare disorder of immune dysregulation resulting in abnormal T-cell activation and inflammatory cytokine production which produces a constellation of clinical features unique to HLH. Pediatric secondary HLH is usually triggered by infection, malignancy, or rheumatological disorders. The diagnosis of malignancy-associated HLH (MA-HLH) poses a difficult challenge as clinical features may be attributed to the underlying disease or chemotherapy. Our study aimed to see the occurrence of this rare entity at our centre.
   Materials and Methods: Data were collected from all pediatric oncology patient treated at our center with the diagnosis of MA-HLH from January 2012 to December 2014. Data were collected for age, sex, underlying disease, treatment protocol, stage of chemotherapy, any underlying infection, treatment given for HLH, and outcome.
   Results: There were five patients with a diagnosis of MA-HLH in the study period. Age ranged from 18 months to 9 years. Of the five MA-HLH, two patients had acute lymphoblastic leukemia, two acute myeloid leukemia, and one had Hodgkin lymphoma. The three patients who had documented microbiological infection also did not improve after appropriate treatment. Two patients died during treatment. One patient improved completely on steroid alone. One patient received HLH 2004 induction.
   Conclusion: The delay in the diagnosis of MA-HLH in pediatric patients may be due to decrease awareness about the condition the timely diagnosis of MA-HLH is crucial for a better outcome. Herein, we discuss our experience with this rare entity in pediatric oncology patients with review of literature.
AD  - All India Inst Med Sci, Dept Pediat, Div Pediat Oncol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - APR-JUN
PY  - 2018
VL  - 14
IS  - 3
SP  - 559
EP  - 562
DO  - 10.4103/0973-1482.188437
AN  - WOS:000435353000014
ER  -

TY  - JOUR
AU  - Singh, AN
AU  - Kilambi, R
AU  - Madhusudhan, KS
AU  - Pal, S
TI  - An Alternative Approach to Life-Threatening Gastrointestinal Bleeding After Corrosive Ingestion
T2  - INDIAN JOURNAL OF SURGERY
KW  - Corrosive injury
KW  - Gastrointestinal bleed
KW  - Angioembolization
KW  - Hematemesis
KW  - Left gastric artery
AB  - Massive gastrointestinal bleeding after corrosive intake is a rare complication that generally mandates a surgical intervention for control. Angioembolization for control of gastrointestinal bleeding in the setting of acute corrosive injury has not been described. Here, we present our experience of a case of acute corrosive injury presenting with massive upper gastrointestinal bleeding in the delayed phase which was successfully managed by angioembolization. We discuss the case in light of the literature available and describe markers which may serve to identify potential candidates for angioembolization.
AD  - All India Inst Med Sci, Dept Gastrointestinal Surg & Liver Transplantat, New Delhi, IndiaAD  - Inst Liver & Biliary Sci, Dept Hepatopancreatobiliary Surg, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiol, Room 81A, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Institute of Liver & Biliary Sciences (ILBS)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - APR
PY  - 2018
VL  - 80
IS  - 2
SP  - 187
EP  - 189
DO  - 10.1007/s12262-018-1739-y
AN  - WOS:000434724900015
ER  -

TY  - JOUR
AU  - Singh, A
AU  - Chauhan, SS
AU  - Tripathi, V
TI  - Quinic Acid Attenuates Oral Cancer Cell Proliferation by Downregulating Cyclin D1 Expression and Akt Signaling
T2  - PHARMACOGNOSY MAGAZINE
KW  - Cisplatin
KW  - head-and-neck cancer
KW  - nutraceuticals
KW  - oral cancer
KW  - quinic acid
KW  - squamous cell carcinoma
KW  - NUTRACEUTICALS
KW  - PHYTOCHEMICALS
KW  - MECHANISMS
KW  - PI3K
AB  - Background: Quinic acid (QA), a natural compound found in fruits, for example in apple, berries, and coffee beans, is a neutraceutical chiral compound used to synthesize new pharmaceutically important chemical compounds. Platinum-based drugs such as cisplatin are widely used in the therapy, including oral cancer, one of the most prevalent cancer. Due to their severe side effects and acquired resistance to the treatment, phytotherapies are being explored to find out strong anticancer compounds that can alone and synergistically prevent and cure cancer without side effects. Objective: This study aimed to find out the mechanism behind the anticancer property of QA, a natural compound alone and synergistically with cisplatin in oral cancer cells (squamous cell carcinoma-4 [SCC-4]). Materials and Methods: Oral cancer cells were treated with QA alone and synergistically with cisplatin. MTT assay was performed to investigate the cytotoxic effect of QA and QA + cisplatin combination. Apoptotic effects of QA and QA + cisplatin combination were analyzed using DAPI and real-time-polymerase chain reaction for the expression of apoptotic marker genes. Effect of QA and QA + cisplatin combination was assessed by flow cytometry and immunoblotting technique. Results: Our result shows that QA promotes apoptosis in oral cancer cells by downregulating the expression of anti-apoptotic genes and attenuating the expression of cyclin D1 and Akt signaling pathway. Moreover, OA shows synergistic effect with cisplatin in these cells. Conclusion: GA inhibits cell proliferation and promotes apoptosis in oral cancer cells (SCC-4) alone and with cisplatin.
AD  - Gautam Buddha Univ, Sch Biotechnol, Greater Noida, IndiaAD  - All India Inst Med Sci, Dept Biochem, New Delhi, IndiaC3  - Gautam Buddha UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - APR-JUN
PY  - 2018
VL  - 14
IS  - 55
SP  - S14
EP  - S19
DO  - 10.4103/pm.pm_36_18
AN  - WOS:000442782500004
ER  -

TY  - JOUR
AU  - Singh, K
AU  - Chandrasekaran, AM
AU  - Bhaumik, S
AU  - Chattopadhyay, K
AU  - Gamage, AU
AU  - De Silva, P
AU  - Roy, A
AU  - Prabhakaran, D
AU  - Tandon, N
TI  - Cost-effectiveness of interventions to control cardiovascular diseases and diabetes mellitus in South Asia: a systematic review
T2  - BMJ OPEN
KW  - ALONGSIDE CLINICAL-TRIALS
KW  - BLOOD-PRESSURE CONTROL
KW  - TASK-FORCE REPORT
KW  - GLOBAL BURDEN
KW  - ECONOMIC-EVALUATION
KW  - PREVENTION PROGRAM
KW  - INSULIN GLARGINE
KW  - RANDOMIZED TRIAL
KW  - LOW-INCOME
KW  - HEALTH
AB  - Objectives More than 80% of cardiovascular diseases (CVD) and diabetes mellitus (DM) burden now lies in low and middle-income countries. Hence, there is an urgent need to identify and implement the most cost-effective interventions, particularly in the resource-constraint South Asian settings. Thus, we aimed to systematically review the cost-effectiveness of individual-level, group-level and population-level interventions to control CVD and DM in South Asia.
   Methods We searched 14 electronic databases up to August 2016. The search strategy consisted of terms related to 'economic evaluation', 'CVD', 'DM' and 'South Asia'. Per protocol two reviewers assessed the eligibility and methodological quality of studies using standard checklists, and extracted incremental cost-effectiveness ratios of interventions.
   Results Of the 2949 identified studies, 42 met full inclusion criteria. Critical appraisal of studies revealed 15 excellent, 18 good and 9 poor quality studies. Most studies were from India (n=37), followed by Bangladesh (n=3), Pakistan (n=2) and Bhutan (n=1). The economic evaluations were based on observational studies (n=9), randomised trials (n=12) and decision models (n=21). Together, these studies evaluated 301 policy or clinical interventions or combination of both. We found a large number of interventions were cost-effective aimed at primordial prevention (tobacco taxation, salt reduction legislation, food labelling and food advertising regulation), and primary and secondary prevention (multidrug therapy for CVD in high-risk group, lifestyle modification and metformin treatment for diabetes prevention, and screening for diabetes complications every 2-5 years). Significant heterogeneity in analytical framework and outcome measures used in these studies restricted metaanalysis and direct ranking of the interventions by their degree of cost-effectiveness.
   Conclusions The cost-effectiveness evidence for CVD and DM interventions in South Asia is growing, but most evidence is from India and limited to decision modelled outcomes. There is an urgent need for formal health technology assessment and policy evaluations in South Asia using local research data.
AD  - All India Inst Med Sci, Dept Endocrinol & Metab, Delhi, IndiaAD  - Ctr Chron Dis Control, Clin Trials Unit, Delhi, IndiaAD  - Publ Hlth Fdn India, Ctr Chron Condit & Injuries, Delhi, IndiaAD  - Publ Hlth Fdn India, Hlth Promot Div, Delhi, IndiaAD  - Univ Nottingham, Sch Med, Div Epidemiol & Publ Hlth, Nottingham, EnglandAD  - London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, EnglandAD  - Minist Hlth, Management Dev & Planning Unit, Colombo, Western, Sri LankaAD  - Natl Inst Hlth Sci, WHO Collaborating Ctr Publ Hlth Workforce Dev, Kalutara, Sri LankaAD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Public Health Foundation of IndiaC3  - Public Health Foundation of IndiaC3  - University of NottinghamC3  - University of LondonC3  - London School of Hygiene & Tropical MedicineC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - BMJ PUBLISHING GROUP
PI  - LONDON
PA  - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
DA  - APR
PY  - 2018
VL  - 8
IS  - 4
C7  - e017809
DO  - 10.1136/bmjopen-2017-017809
AN  - WOS:000435176700015
ER  -

TY  - JOUR
AU  - Singh, P
AU  - Agrawal, T
AU  - Yadav, S
AU  - Nayak, B
AU  - Seth, A
AU  - Dogra, PN
TI  - A comparative study of the effects of medical versus surgical androgen deprivation therapy on health-related quality of life in patients with metastatic carcinoma prostate
T2  - INDIAN JOURNAL OF CANCER
KW  - Androgen deprivation therapy
KW  - health-related quality of life
KW  - medical versus surgical castration
KW  - metastatic carcinoma prostate
KW  - SURVEY SF-36
KW  - CANCER
KW  - OUTCOMES
AB  - INTRODUCTION: Androgen deprivation therapy (ADT) is known to adversely affect the quality of life (QoL). One may choose between surgical and medical forms depending on his economic status, education status, and taboos. The aim of this study was to assess the impact of medical versus surgical ADT on health-related quality of life (HRQoL) in patients with metastatic cancer prostate in Indian population. MATERIALS AND METHODS: From July 2012 to December 2014, 50 patients (10 medical castration and 40 surgical castration) of hormone-nave metastatic prostate cancer who were started on combined ADT were included in this study. Before starting therapy, baseline data and QoL score (short form [SF-36] scale) were noted and all patients were followed up at 3 months, 6 months, and 1 year. Baseline data and HRQoL at all time intervals between surgical and medical castration groups were compared. RESULTS: All patients, except two, completed the 1-year follow-up period. Patients who opted for medical castration were more educated and belonged to higher socioeconomic status. For all the domains of SF-36 QoL questionnaire, a similar improvement in the score was noted at first 3-month follow-up which deteriorated in the next follow-up at 6 months and then further at 1 year. There was no difference in HRQoL after medical or surgical castration. CONCLUSIONS: In patients with metastatic cancer, prostate initiation of ADT, irrespective of method, causes an initial improvement in HRQoL followed later by a more gradual decline below the baseline.
AD  - All India Inst Med Sci, Dept Urol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - APR-JUN
PY  - 2018
VL  - 55
IS  - 2
SP  - 148
EP  - 153
DO  - 10.4103/ijc.IJC_531_17
AN  - WOS:000455035400006
ER  -

TY  - JOUR
AU  - Singh, P
AU  - Arora, A
AU  - Strand, TA
AU  - Sommerfelt, H
AU  - Lodha, R
AU  - Kabra, SK
AU  - Aneja, S
AU  - Natchu, UCM
AU  - Chandra, J
AU  - Rath, B
AU  - Sharma, VK
AU  - Kumari, M
AU  - Saini, S
AU  - Bhatnagar, S
AU  - Wadhwa, N
TI  - Predictors of death in infants with probable serious bacterial infection
T2  - PEDIATRIC RESEARCH
KW  - C-REACTIVE PROTEIN
KW  - RISK-FACTORS
KW  - NEONATAL-MORTALITY
KW  - COWS MILK
KW  - CHILDREN
KW  - LEVEL
KW  - INDIA
AB  - BACKGROUND: Bacterial infections account for a significant proportion of neonatal and infant mortality globally. We aimed to identify predictors of death in infants with probable serious bacterial infection (PSBI) defined as signs/symptoms of possible serious bacterial infection along with baseline C-reactive protein (CRP) >= 12 mg/l.
   METHODS: We did a secondary analysis using the data collected from 700 infants with PSBI who participated in a randomized controlled trial in India in which zinc or placebo was given in addition to the standard antibiotics. Logistic regression was used to estimate the associations between relevant variables and death within 21 days.
   RESULTS: Those infants who were fed cow's milk or formula before the illness episode had 3.7 fold (95% confidence interval (Cl) 1.5-9.3) and 5.3-fold (95% Cl 2.0-13.6) higher odds of death, respectively. Lethargy (odds ratio (OR) 2.4, 95% Cl 1.1-5.4) and CRP (OR 1.9, 95% Cl 1.1-3.3) were also independent predictors of death. In the model including only clinical features, female gender (OR 2.25, 95% Cl 1.0-5.0), abdominal distention (3.7, 95% Cl 1.1-12.3), and bulging fontanelle (5.8, 95% Cl 1.1-30.5) were also independent predictors for death.
   CONCLUSION: Formula or cow milk feeding prior to the illness, lethargy at the time of presentation, and high serum CRP levels predicted death in infants with PSBI.
AD  - Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USAAD  - Lady Hardinge Med Coll & Hosp, Dept Med, New Delhi, IndiaAD  - Innlandet Hosp Trust, Lillehammer, NorwayAD  - Univ Bergen, Ctr Intervent Sci Maternal & Child Hlth, Ctr Int Hlth, Bergen, NorwayAD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaAD  - Lady Hardinge Med Coll & Hosp, Dept Pediat, New Delhi, IndiaAD  - Kalawati Saran Childrens Hosp, New Delhi, IndiaAD  - Translat Hlth Sci & Technol Inst, Pediat Biol Ctr, Gurgaon, IndiaAD  - Deen Dayal Upadhyay Hosp, Dept Pediat, New Delhi, IndiaC3  - Harvard UniversityC3  - Beth Israel Deaconess Medical CenterC3  - Lady Hardinge Medical College & HospitalC3  - Innlandet Hospital TrustC3  - University of BergenC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Lady Hardinge Medical College & HospitalC3  - Department of Biotechnology (DBT) IndiaC3  - Translational Health Science & Technology Institute (THSTI)PU  - NATURE PUBLISHING GROUP
PI  - NEW YORK
PA  - 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
DA  - APR
PY  - 2018
VL  - 83
IS  - 4
SP  - 784
EP  - 790
DO  - 10.1038/pr.2017.299
AN  - WOS:000433024100008
ER  -

TY  - JOUR
AU  - Singh, S
AU  - Kumar, R
AU  - Roy, M
AU  - Mridha, AR
TI  - Glottic neurogenic tumor: A highly uncommon site for schwannomas
T2  - JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
KW  - Glottic
KW  - schwannoma
KW  - surgery
KW  - LARYNX
AB  - Schwannomas are benign encapsulated neurogenic tumors, arising from Schwann cells embedded in neurilemal sheath as multinucleated syncytial network. Head and neck schwannomas account for 25%-45% of all schwannomas, majority developing in parapharyngeal space. Laryngeal schwannoma in itself is a rarity, and a glottic origin further complicates its diagnosis. To the best of our knowledge, this is the second case of glottic schwannoma being reported in medical literature. Symptomatology is attributable to mass effect of a slow-growing laryngeal tumor, ranging from sore throat to stridor. The gold standard method for their excision is still debatable. For small tumors, endoscopic or direct laryngoscopic approach is preferred, but for large glottic tumors, external approach is advocated for better exposure and facilitating mucosal grafting. Index case is being presented not only for its rare site of origin, but also to stress on the importance of meticulous histopathological examination to advocate appropriate treatment.
AD  - All India Inst Med Sci, Dept Otorhinolaryngol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - APR-JUN
PY  - 2018
VL  - 14
IS  - 3
SP  - 687
EP  - 689
DO  - 10.4103/jcrt.JCRT_878_14
AN  - WOS:000435353000039
ER  -

TY  - JOUR
AU  - Takkar, B
AU  - Tandon, N
AU  - Venkatesh, P
TI  - De novo ossification of the choroid in a case of multifocal fibrosclerosis
T2  - CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
KW  - OSTEOMA
KW  - ASSOCIATION
KW  - INFLAMMATION
KW  - EYE
AD  - All India Inst Med Sci, Dr R P Ctr Ophthalm Sci, Retina & Uvea Serv, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Endocrinol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - CANADIAN OPHTHAL SOC
PI  - OTTAWA
PA  - 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
DA  - APR
PY  - 2018
VL  - 53
IS  - 2
SP  - E62
EP  - E65
DO  - 10.1016/j.jcjo.2017.07.022
AN  - WOS:000429619200010
ER  -

TY  - JOUR
AU  - Talwar, S
AU  - Sankhyan, L
AU  - Patel, C
AU  - Sreenivas, V
AU  - Choudhary, SK
AU  - Airan, B
TI  - Evaluation of differential pulmonary perfusion using <SUP>99m</SUP>Tc macroaggregated albumin after the Fontan procedure
T2  - INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY
KW  - Fontan
KW  - Lung perfusion
KW  - Fontan modifications
KW  - TOTAL CAVOPULMONARY CONNECTIONS
KW  - COMPUTATIONAL FLUID-DYNAMICS
KW  - BLOOD-FLOW
KW  - LUNG PERFUSION
KW  - TRICUSPID-ATRESIA
KW  - SURGICAL REPAIR
KW  - RADIONUCLIDE
KW  - CIRCULATION
KW  - GEOMETRY
AB  - OBJECTIVES: The Fontan procedure [total cavopulmonary connection (TCPC)] is the final palliation for patients with univentricular physiology. We studied differential perfusion ratio and percentage uptake of a radiotracer in different zones of each lung following TCPC.
   METHODS: Between July 2015 and June 2017, 45 patients underwent Tc-99m macroaggregated albumin lung perfusion scan at a mean follow-up period of 49.3 +/- SD 26.1 days following TCPC. Differential perfusion ratio and percentage uptake of the radiotracer in the upper, middle and lower zones of each lung were calculated.
   RESULTS: Post-foot injection [inferior vena cava (IVC) injection], preferential flow to the lungs was as follows: left lung (n = 13, 30.2%), right lung (n = 13, 30.2%) and uniformly to both lungs (n= 17, 39.6%). Post-arm injection [superior vena cava (SVC) injection], preferential flow to the lungs was as follows: left lung (n = 13, 30.2%), right lung (n = 22, 51.2%) and uniformly to both lungs (n= 8, 18.6%). The middle zone was perfused the most in both lungs. Total lower zone mean perfusion was higher than the upper zone following both SVC injection and IVC injection (34.1 +/- SD 5.3% vs 17. +/- SD 4.1% and 33 +/- SD 5.0% vs 17.5 +/- SD 4.1%, respectively). In patients with bilateral SVC, post-IVC injection, 6 (75%) patients had preferential flow to the right lung, whereas post-SVC injection, preferential flow to the left lung was visualized in 7 (87.5%) patients.
   CONCLUSIONS: Following TCPC, IVC blood was distributed uniformly in both lungs. SVC blood preferentially perfused the right lung. The middle zone was perfused the most in both lungs.
AD  - All India Inst Med Sci, Cardiothorac Ctr, Dept Cardiothorac & Vasc Surg, New Delhi, IndiaAD  - All India Inst Med Sci, Nucl Med, New Delhi, IndiaAD  - All India Inst Med Sci, Biostat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - OXFORD UNIV PRESS
PI  - OXFORD
PA  - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
DA  - APR
PY  - 2018
VL  - 26
IS  - 4
SP  - 651
EP  - 659
DO  - 10.1093/icvts/ivx377
AN  - WOS:000429012700018
ER  -

TY  - JOUR
AU  - Tandon, V
AU  - Chandra, PS
AU  - Doddamani, RS
AU  - Subianto, H
AU  - Bajaj, J
AU  - Garg, A
AU  - Tripathi, M
TI  - Stereotactic Radiofrequency Thermocoagulation of Hypothalamic Hamartoma Using Robotic Guidance (ROSA) Coregistered with O-arm Guidance-Preliminary Technical Note
T2  - WORLD NEUROSURGERY
KW  - Hypothalamic hamartoma
KW  - O-arm
KW  - Radiofrequency
KW  - Robotic
KW  - Stereotactic
KW  - Technical report
KW  - Thermocoagulation
KW  - GAMMA-KNIFE SURGERY
KW  - LASER-ABLATION
KW  - RADIOSURGERY
KW  - COMPLICATIONS
KW  - IMPLANTATION
AB  - INTRODUCTION: Treatment options for hypothalamic hamartoma (HH) include microvascular surgery, stereotactic radiofrequency thermocoagulation (SRT), laser interstitial thermal therapy, or Gamma Knife surgery. During SRT, thermographic monitoring cannot be performed and therefore highly accurate placement of electrode and confirmation of its position are required. We have used robotic guidance (ROSA) and coregistered it with O-arm for performing ablation of hamartoma.
   METHODS: Five patients with HH and gelastic seizures underwent SRT. Robotic guidance (ROSA) was used for placement of electrodes. An O-arm was used for coregistering and confirming the robotic trajectory with realtime intraoperative imaging. Intraoperative computed tomography was merged with preoperative magnetic resonance imaging to confirm the exact position and trajectory of the electrode. Ablation was performed using a radiofrequency generator (70 degrees C for 60 seconds). Multiple target sites were ablated to achieve proper ablation and disconnection.
   RESULTS: Most patients (4/5) had International League Against Epilepsy class I outcome. One patient 2 sittings of lesioning. All but 1 electrode could be placed in the planned trajectories. One electrode was detected to have a medial deviation, and it had to be revised. No permanent complication was observed.
   CONCLUSIONS: SRT is a cost-effective method of treating HH when compared with laser interstitial thermal therapy. With the use of a robotic arm we have demonstrated accurate placement of electrodes. Intraoperative computed tomography acquired using an O-arm can be merged with preoperative magnetic resonance imaging. This confirms electrode location and trajectory on a realtime basis by performing intraoperative imaging. This method is safe and can be used for radiofrequency ablation of HH.
AD  - All India Inst Med Sci, Dept Neurosurg & Gamma Knife, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neuroradiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - APR
PY  - 2018
VL  - 112
SP  - 267
EP  - 274
DO  - 10.1016/j.wneu.2018.01.193
AN  - WOS:000432932700153
ER  -

TY  - JOUR
AU  - Temkar, S
AU  - Damodaran, S
AU  - Chawla, R
AU  - Behera, S
AU  - Bafna, RK
AU  - Parmanand, K
TI  - Floating venous loop in regressed retinopathy of prematurity
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Retinopathy of prematurity
KW  - vascular loop
KW  - vitreous hemorrhage
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - APR
PY  - 2018
VL  - 66
IS  - 4
SP  - 568
EP  - 569
DO  - 10.4103/ijo.IJO_1017_17
AN  - WOS:000428858100018
ER  -

TY  - JOUR
AU  - Tewari, N
AU  - Mathur, VP
AU  - Singh, N
AU  - Singh, S
AU  - Pandey, RK
TI  - Long-term effects of traumatic dental injuries of primary dentition on permanent successors: A retrospective study of 596 teeth
T2  - DENTAL TRAUMATOLOGY
KW  - avulsion
KW  - crown dilacerations
KW  - long-term sequelae
KW  - root dilacerations
KW  - root duplication
KW  - sequestration
KW  - PRIMARY PREDECESSORS
KW  - EMERGENCY SERVICE
KW  - LUXATION INJURIES
KW  - PRIMARY INCISORS
KW  - ANTERIOR TEETH
KW  - SEQUELAE
KW  - INTRUSION
AB  - Background/AimsTraumatic dental injuries of the primary dentition (TDI-p) have a global prevalence of approximately 11%-47%. They have immediate and long-term effects. Original research analysing the long-term sequelae of TDI-p on permanent dentition (LSP) are few in number. The aim of this study was to explore the correlation between age of TDI-p, type of TDI-p and LSP.
   Material and MethodsRetrospective analysis of patient data from 2008-2017, reporting with LSP due to TDI-p, was performed. Uniform protocols and complete radiographic-photographic records were analysed. There were 638 LSP reported with 596 teeth having complete records.
   ResultsThere were 286 children with 153 males (53.5%) and 133 females (46.5%). Mean age of TDI-p causing LSP was 36.5711.51months, with severity increasing in the younger age group. The highest number of LSP was associated with avulsion injuries (218, 36.58%), and the odds ratio of the type of TDI-p affect the severity of LSP was 2.0163. Mean age of reporting was 8.54 +/- 2.19years and was lowest for enamel discolorations. Most LSP were not associated with any associated feature (AF), although impaction was highest among all AF (63, 10.57%).
   ConclusionAge and type of TDI-p affect LSP, with the former being the stronger determinant of its severity. Mean age of reporting of LSP is dependent upon both type of LSP and AF. LSP due to TDI-p can further be graded in terms of severity.
AD  - All India Inst Med Sci, Pedodont & Prevent Dent, Ctr Dent Educ & Res, New Delhi, IndiaAD  - Babu Banarasi Das Univ, Pedodont & Prevent Dent, Lucknow, Uttar Pradesh, IndiaAD  - King Georges Med Univ, Pedodont & Prevent Dent, Lucknow, Uttar Pradesh, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Babu Banarasi Das UniversityC3  - King George's Medical UniversityPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - APR
PY  - 2018
VL  - 34
IS  - 2
SP  - 129
EP  - 134
DO  - 10.1111/edt.12391
AN  - WOS:000430806500009
ER  -

TY  - JOUR
AU  - Thakar, A
AU  - Gupta, MP
AU  - Srivastava, A
AU  - Agrawal, D
AU  - Kumar, A
TI  - Nonsurgical Treatment for Posttraumatic Complete Facial Nerve Paralysis
T2  - JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
KW  - TEMPORAL BONE-FRACTURES
KW  - MANAGEMENT
KW  - PALSY
KW  - INJURIES
KW  - OUTCOMES
KW  - SURGERY
KW  - TRAUMA
AB  - IMPORTANCE Current recommendations envisage early surgical exploration for complete facial nerve paralysis associated with temporal bone fracture and unfavorable electrophysiologic features (response to electroneuronography, <5%). However, the evidence base for such a practice is weak, with the potential for spontaneous improvement being unknown, and the expected results from alternative nonsurgical treatment also undefined.
   OBJECTIVE To document the results of nonsurgical treatment for posttraumatic complete facial paralysis with undisplaced temporal bone fracture and unfavorable electrophysiologic features.
   DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study recruiting from April 2010 to April 2013 at a tertiary care university hospital. Follow-up continued until 9 months or until complete recovery if earlier. Study group included 28 patients with head injury-associated complete unilateral facial nerve paralysis with unfavorable results of electroneuronography (<5% response) with or without undisplaced temporal bone fracture. Undisplaced temporal bone fractures were documented in 26 patients (24 longitudinal fractures and 2 transverse fractures).
   INTERVENTIONS Patients received prednisolone, 1 mg/kg, for 3 weeks combined with clinical monitoring every 2 weeks and electromyography monitoring every 4 weeks. As per study protocol, surgical exploration was limited to patients demonstrating motor end plate degeneration on results of electromyography, or having no improvement until 18 weeks.
   MAIN OUTCOMES AND MEASURES Facial nerve function was evaluated by the House-Brackmann grading system; Forehead, Eye, Mouth, and Associated defect grading system; and the modified Adour system. Observations were completed at 40 weeks.
   RESULTS Among the 28 patients in the study (3 women and 25 men; mean [SD] age, 32.2 [8.7] years), facial nerve recovery with conservative treatment alone was noted in all patients. No recovery was seen in any patient at the initial 4-week review. The first signs of clinical recovery were noted in 4 patients by 8 weeks, in 27 patients by 12 weeks, and in all patients by 20 weeks. No patient required surgical exploration. At 40 weeks, 27 patients recovered to House-Brackmann grade I/II and 1 patient to grade III. All 24 patients with longitudinal fractures had grade I/II recovery.
   CONCLUSIONS AND RELEVANCE For undisplaced temporal bone fractures, nonsurgical treatment leads to near-universal recovery to House-Brackmann grade I/II and is superior to reported surgical results. Recovery is delayed and usually first manifests at 8 to 12 weeks after the fracture. In the current era of high-resolution computed tomography, surgical exploration should not be first-line treatment for undisplaced longitudingal temporal bone fractures associated with complete facial nerve paralysis and unfavorable electrophysiologic features.
AD  - All India Inst Med Sci, Dept Otolaryngol Head & Neck Surg, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Radiodiag, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER MEDICAL ASSOC
PI  - CHICAGO
PA  - 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
DA  - APR
PY  - 2018
VL  - 144
IS  - 4
SP  - 315
EP  - 321
DO  - 10.1001/jamaoto.2017.3147
AN  - WOS:000430575900007
ER  -

TY  - JOUR
AU  - van der Haar, F
AU  - Knowles, J
AU  - Bukania, Z
AU  - Camara, B
AU  - Pandav, CS
AU  - Mwai, JM
AU  - Toure, NK
AU  - Yadav, K
TI  - New Statistical Approach to Apportion Dietary Sources of Iodine Intake: Findings from Kenya, Senegal and India
T2  - NUTRIENTS
KW  - universal salt iodization
KW  - native dietary iodine
KW  - processed foods
KW  - household salt
KW  - population iodine intake apportionment
KW  - UNIVERSAL SALT IODIZATION
KW  - SODIUM-INTAKE
KW  - HOUSEHOLD COVERAGE
KW  - URINARY IODINE
KW  - NUTRITION
KW  - PREVALENCE
KW  - BIOMARKERS
KW  - CHILDREN
KW  - IMPACT
KW  - FOODS
AB  - Progress of national Universal Salt Iodization (USI) strategies is typically assessed by household coverage of adequately iodized salt and median urinary iodine concentration (UIC) in spot urine collections. However, household coverage does not inform on the iodized salt used in preparation of processed foods outside homes, nor does the total UIC reflect the portion of population iodine intake attributable to the USI strategy. This study used data from three population-representative surveys of women of reproductive age (WRA) in Kenya, Senegal and India to develop and illustrate a new approach to apportion the population UIC levels by the principal dietary sources of iodine intake, namely native iodine, iodine in processed food salt and iodine in household salt. The technique requires measurement of urinary sodium concentrations (UNaC) in the same spot urine samples collected for iodine status assessment. Taking into account the different complex survey designs of each survey, generalized linear regression (GLR) analyses were performed in which the UIC data of WRA was set as the outcome variable that depends on their UNaC and household salt iodine (SI) data as explanatory variables. Estimates of the UIC portions that correspond to iodine intake sources were calculated with use of the intercept and regression coefficients for the UNaC and SI variables in each country's regression equation. GLR coefficients for UNaC and SI were significant in all country-specific models. Rural location did not show a significant association in any country when controlled for other explanatory variables. The estimated UIC portion from native dietary iodine intake in each country fell below the minimum threshold for iodine sufficiency. The UIC portion arising from processed food salt in Kenya was substantially higher than in Senegal and India, while the UIC portions from household salt use varied in accordance with the mean level of household SI content in the country surveys. The UIC portions and all-salt-derived iodine intakes found in this study were illustrative of existing differences in national USI legislative frameworks and national salt supply situations between countries. The approach of apportioning the population UIC from spot urine collections may be useful for future monitoring of change in iodine nutrition from reduced salt use in processed foods and in households.
AD  - Emory Clin, Rollins Sch Publ Hlth, Atlanta, GA 30322 USAAD  - Global Alliance Improved Nutr, Large Scale Food Fortificat Initiat, CH-1211 Geneva, SwitzerlandAD  - Kenya Govt Med Res Ctr, Ctr Publ Hlth Res, Nairobi 00202, KenyaAD  - Univ Cheikh Anta Diop Dakar, Com Sci, Ecole Doctorale, BP 5005, Dakar, SenegalAD  - All India Inst Med Sci, Iodine Global Network, New Delhi 110029, IndiaAD  - Minist Hlth, Nutr & Dietet Unit, POB 43319-00100, Nairobi, KenyaAD  - Cellule Lutte Malnutr, BP 45001, Dakar, SenegalAD  - All India Inst Med Sci, Ctr Community Med, New Delhi 110029, IndiaC3  - Emory UniversityC3  - Rollins School Public HealthC3  - Kenya Medical Research InstituteC3  - University Cheikh Anta Diop DakarC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MDPI
PI  - BASEL
PA  - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
DA  - APR
PY  - 2018
VL  - 10
IS  - 4
C7  - 430
DO  - 10.3390/nu10040430
AN  - WOS:000435182900046
ER  -

TY  - JOUR
AU  - Vanathi, M
AU  - Goel, S
AU  - Ganger, A
AU  - Agarwal, T
AU  - Dada, T
AU  - Khokhar, S
TI  - Corneal tomography and biomechanics in primary pterygium
T2  - INTERNATIONAL OPHTHALMOLOGY
KW  - Pterygium
KW  - Visual acuity
KW  - Corneal topography
KW  - Wavefront aberrations
KW  - Biomechanics
KW  - QUANTITATIVE-ANALYSIS
KW  - ASTIGMATISM
KW  - SURFACE
KW  - SURGERY
KW  - ABERRATIONS
KW  - ANTERIOR
KW  - FRONT
KW  - CELLS
AB  - Purpose To study the Scheimpflug's imaging and corneal biomechanics in primary pterygium.
   Methods A prospective observational study of 55 patients with unilateral primary nasal pterygium was done. The normal fellow eyes of patients with pterygium were taken as controls. Clinical parameters noted included visual acuity, values of corneal curvature by doing Scheimpflug imaging, wavefront aberrations in terms of higher and lower-order aberrations and corneal hysteresis (CH) as well as corneal resistance factor (CRF) values by using ocular response analyzer.
   Results Of the total 55 patients, mean age was 43.0 + 11.4 years (range: 20-72 years). Mean Log-Mar uncorrected visual acuity in pterygium eyes and control eyes was 0.21 + 0.20 and 0.12 + 0.15, respectively (p = 0.016). On Scheimpflug imaging the mean anterior corneal curvature values (Ka1/Ka2 D) were 41.09 + 3.38/44.33 + 2.29 in pterygium eyes, 43.13 + 1.79/43.98 + 2.17 in control eyes(p < 0.0005) and mean posterior corneal curvature (Kp1/Kp2 D) values were 6.14 + 0.39/6.53 + 0.43 in pterygium eyes and 6.13 + 0.28/6.46 + 0.47 in control eyes (p > 0.05). Analysis of corneal aberrations showed significantly higher corneal wavefront aberrations in pterygium eyes. Highest correlation of corneal astigmatism was noted with corneal area encroached by pterygium (rho = 0.540 for LOA and 0.553 for HOA) and distance from pupillary center (rho = 0.531 for LOA and 0.564 for HOA). Corneal biomechanical parameters including CH and CRF were found to be lower in the pterygium eyes, though not statistically significant (p value 0.60 and 0.59, respectively).
   Conclusion Pterygium leads to deterioration of visual performance not only by causing refractive and topographic changes but also by causing a significant increase in corneal wavefront aberrations.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Cornea Cataract & Refract Serv, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - APR
PY  - 2018
VL  - 38
IS  - 2
SP  - 663
EP  - 671
DO  - 10.1007/s10792-017-0514-6
AN  - WOS:000431304900027
ER  -

TY  - JOUR
AU  - Vasan, SK
AU  - Roy, A
AU  - Samuel, VT
AU  - Antonisamy, B
AU  - Bhargava, SK
AU  - Alex, AG
AU  - Singh, B
AU  - Osmond, C
AU  - Geethanjali, FS
AU  - Karpe, F
AU  - Sachdev, H
AU  - Agrawal, K
AU  - Ramakrishnan, L
AU  - Tandon, N
AU  - Thomas, N
AU  - Premkumar, PS
AU  - Asaithambi, P
AU  - Princy, SFX
AU  - Sinha, S
AU  - Paul, TV
AU  - Prabhakaran, D
AU  - Fall, CHD
TI  - IndEcho study: cohort study investigating birth size, childhood growth and young adult cardiovascular risk factors as predictors of midlife myocardial structure and function in South Asians
T2  - BMJ OPEN
KW  - LEFT-VENTRICULAR MASS
KW  - CORONARY-HEART-DISEASE
KW  - INTIMA-MEDIA THICKNESS
KW  - INSULIN-RESISTANCE
KW  - ARTERIAL COMPLIANCE
KW  - GLUCOSE-TOLERANCE
KW  - AMERICAN SOCIETY
KW  - UNITED-KINGDOM
KW  - INDIAN ADULTS
KW  - WEIGHT-GAIN
AB  - Introduction South Asians have high rates of cardiovascular disease (CVD) and its risk factors (hypertension, diabetes, dyslipidaemia and central obesity). Left ventricular (LV) hypertrophy and dysfunction are features of these disorders and important predictors of CVD mortality. Lower birth and infant weight and greater childhood weight gain are associated with increased adult CVD mortality, but there are few data on their relationship to LV function. The IndEcho study will examine associations of birth size, growth during infancy, childhood and adolescence and CVD risk factors in young adulthood with midlife cardiac structure and function in South Asian Indians.
   Methods and analysis We propose to study approximately 3000 men and women aged 43-50 years from two birth cohorts established in 1969-1973: the New Delhi Birth Cohort (n=1508) and Vellore Birth Cohort (n=2156). They had serial measurements of weight and height from birth to early adulthood. CVD risk markers (body composition, blood pressure, glucose tolerance and lipids) and lifestyle characteristics (tobacco and alcohol consumption, physical activity, socioeconomic status) were assessed at age similar to 30 years. Clinical measurements in IndEcho will include anthropometry, blood pressure, biochemistry (glucose, fasting insulin and lipids, urinary albumin/creatinine ratio) and body composition by dual energy X-ray absorptiometry and bioelectrical impedance. Outcomes are LV mass and indices of LV systolic and diastolic function assessed by two-dimensional and Doppler echocardiography, carotid intimal-media thickness and ECG indicators of ischaemia. Regression and conditional growth models, adjusted for potential confounders, will be used to study associations of childhood and young adult exposures with these cardiovascular outcomes.
   Ethics and dissemination The study has been approved by the Health Ministry Steering Committee, Government of India and institutional ethics committees of participating centres in India and the University of Southampton, UK. Results will be disseminated through scientific meetings and peer-reviewed journals.
AD  - Univ Southampton, Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Southampton, Hants, EnglandAD  - Univ Oxford, Radcliffe Dept Med, Oxford Ctr Diabet Endocrinol & Metab, Oxford, EnglandAD  - Ctr Chron Dis Control, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaAD  - Christian Med Coll & Hosp, Dept Cardiol, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp, Dept Biostat, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp, Dept Endocrinol, Vellore, Tamil Nadu, IndiaAD  - Christian Med Coll & Hosp, Dept Clin Biochem, Vellore, Tamil Nadu, IndiaAD  - Sunder Lal Jain Hosp, Dept Paediat, New Delhi, IndiaAD  - Sitaram Bhartia Inst Sci & Res, Dept Paediat, New Delhi, IndiaAD  - Publ Hlth Fdn India, New Delhi, IndiaC3  - University of SouthamptonC3  - University of OxfordC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Christian Medical College & Hospital (CMCH) VelloreC3  - Sitaram Bhartia Institute of Science & ResearchC3  - Public Health Foundation of IndiaPU  - BMJ PUBLISHING GROUP
PI  - LONDON
PA  - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
DA  - APR
PY  - 2018
VL  - 8
IS  - 4
C7  - e019675
DO  - 10.1136/bmjopen-2017-019675
AN  - WOS:000435176700084
ER  -

TY  - JOUR
AU  - Venkatesh, P
AU  - Takkar, B
AU  - Temkar, S
TI  - Clinical manifestations of pachychoroid may be secondary to pachysclera and increased scleral rigidity
T2  - MEDICAL HYPOTHESES
KW  - Pachychoroid
KW  - Polypoidal choroidal vasculopathy
KW  - Central serous chorioretinopathy
KW  - Scleral thickness
KW  - OPTICAL COHERENCE TOMOGRAPHY
AB  - Current imaging advancements have led to emergence of pachychoroid as an association of important vision threatening diseases like chronic serous chorioretinopathy and polypoidal choroidal vasculopathy. While the precise relation between thick choroid and such disorder is being investigated, the etiology behind pachychoroid remains elusive. We hypothesize pachychoroid to be a resultant of impeded vascular outflow due to thick sclera and increased scleral rigidity. We discuss our hypothesis in the perspective of other choroidal manifestations of anomalously thick scleral structure.
AD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, Retina & Uvea Serv, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - CHURCHILL LIVINGSTONE
PI  - EDINBURGH
PA  - JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
DA  - APR
PY  - 2018
VL  - 113
SP  - 72
EP  - 73
DO  - 10.1016/j.mehy.2018.02.024
AN  - WOS:000429759400017
ER  -

TY  - JOUR
AU  - Verma, S
AU  - Kumar, VL
TI  - Artesunate affords protection against aspirin-induced gastric injury by targeting oxidative stress and proinflammatory signaling
T2  - PHARMACOLOGICAL REPORTS
KW  - Artesunate
KW  - Aspirin
KW  - Gastric ulcer
KW  - Inflammation
KW  - Oxidative stress
KW  - NF-KAPPA-B
KW  - LOW-DOSE ASPIRIN
KW  - MUCOSAL DAMAGE
KW  - INFLAMMATION
KW  - ACID
KW  - MYELOPEROXIDASE
KW  - RAT
KW  - PREVALENCE
KW  - MANAGEMENT
KW  - THERAPY
AB  - Background: Prolonged use of aspirin, a commonly prescribed non steroidal anti-inflammatory drug, is well known to produce gastrointestinal toxicity which could be minimized by various anti-secretory agents. The present study was carried out to evaluate the protective effect of artesunate against aspirin induced gastric injury in rats.
   Methods: Gastric injury was induced in fasted Wistar rats by oral administration of aspirin. The effect of 50 and 150 mg/kg of artesunate was studied on macroscopic changes, gastric secretions, histology, oxidative stress and inflammatory markers in the stomach tissue after 5 h of induction of gastric injury. Immunohistochemical analysis for the expression of IL-1 beta, IL-6, NF-kappa B(p65) and COX-2 was also carried out. The effect of artesunate was compared with that of standard anti-ulcer drug famotidine (20 mg/kg).
   Results: Artesunate pretreatment produced a dose-dependent reduction in aspirin induced gastric injury and restored the gastric juice parameters. It normalized the tissue levels of oxidative stress markers (glutathione, malondialdehyde and superoxide dismutase activity) and mediators of inflammation (myeloperoxidase and TNF-alpha). The protection afforded by artesunate was evident from the histoarchitecture of stomach tissue and marked reduction in tissue expression of IL-1b, IL-6, NF-kB (p65) and COX-2. The effect of artesunate was found to be comparable to that of standard drug famotidine.
   Conclusion: Artesunate markedly ameliorated aspirin induced gastric injury in rats by targeting oxidative stress and COX-2 dependent as well as COX-2 independent proinflammatory signaling pathways and could have a therapeutic potential in gastric ulcer disease. (C) 2017 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z o. o. All rights reserved.
AD  - All India Inst Med Sci, Dept Pharmacol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - POLISH ACAD SCIENCES INST PHARMACOLOGY
PI  - KRAKOW
PA  - SMETNA 12, 31-343 KRAKOW, POLAND
DA  - APR
PY  - 2018
VL  - 70
IS  - 2
SP  - 390
EP  - 397
DO  - 10.1016/j.pharep.2017.06.003
AN  - WOS:000429216400028
ER  -

TY  - JOUR
AU  - Wadhwani, M
AU  - Vashist, P
AU  - Singh, SS
AU  - Gupta, N
AU  - Malhotra, S
AU  - Gupta, A
AU  - Shukla, P
AU  - Bhardwaj, A
AU  - Gupta, V
TI  - Diabetic retinopathy screening programme utilising non-mydriatic fundus imaging in slum populations of New Delhi, India
T2  - TROPICAL MEDICINE & INTERNATIONAL HEALTH
KW  - diabetic retinopathy
KW  - slums
KW  - non-mydriatic fundus imaging
KW  - urban underserved population
KW  - URBAN MUMBAI SLUMS
KW  - MAJOR RISK-FACTORS
KW  - EYE CARE SERVICES
KW  - GLOBAL PREVALENCE
KW  - CAMERA
KW  - SEVERITY
KW  - OBESITY
AB  - ObjectivesTo develop and implement a community-based programme for screening of diabetic retinopathy (DR) in urban populations of Delhi.
   MethodsKnown diabetics (KDs) aged 40 years and older were identified through house-to-house surveys, volunteers and publicity. All KDs were referred to DR screening camps organised locally where procedures included brief medical history, ocular examination and non-mydriatic fundus photography using portable handheld camera. Fundal images were graded on the spot by trained optometrists for DR. Patients with DR were referred to tertiary centre for management.
   ResultsA total of 11 566 KDs were identified, of whom 9435 (81.6%) visited DR screening camps and 8432 (89.4%) had DR gradable images. DR was identified in 13.5% of subjects; 351 cases were mild NPDR, 567 moderate, 92 severe. Seventy-seven had PDR, and 49 had DME, and 2.7% of participants were blind (presenting visual acuity <3/60 in better eye). Non-use of lifestyle management, presence of systemic complications, BMI <18.5 kg/m(2), disease duration of >5 years and uncontrolled diabetes were associated with increased odds of DR. All cases with DR were referred, and 420 (37%) successful referrals to base hospital were observed.
   ConclusionThe programme of creating awareness about DR, identifying KDs and optometrist-led DR screening using non-mydriatic fundus camera based in slums was successful.
AD  - AIIMS, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - APR
PY  - 2018
VL  - 23
IS  - 4
SP  - 405
EP  - 414
DO  - 10.1111/tmi.13039
AN  - WOS:000429729500007
ER  -

TY  - JOUR
AU  - Woodhouse, LJ
AU  - Scutt, P
AU  - Hamdy, S
AU  - Smithard, DG
AU  - Cohen, DL
AU  - Roffe, C
AU  - Bereczki, D
AU  - Berge, E
AU  - Bladin, CF
AU  - Caso, V
AU  - Christensen, HK
AU  - Collins, R
AU  - Czlonkowska, A
AU  - de Silva, A
AU  - Etribi, A
AU  - Laska, AC
AU  - Ntaios, G
AU  - Ozturk, S
AU  - Phillips, SJ
AU  - Prasad, K
AU  - Szatmari, S
AU  - Sprigg, N
AU  - Bath, PM
TI  - Route of Feeding as a Proxy for Dysphagia After Stroke and the Effect of Transdermal Glyceryl Trinitrate: Data from the Efficacy of Nitric Oxide in Stroke Randomised Controlled Trial
T2  - TRANSLATIONAL STROKE RESEARCH
KW  - Dysphagia
KW  - Glyceryl trinitrate
KW  - Outcome
KW  - Randomised controlled trial
KW  - Stroke
KW  - PREVENT PNEUMONIA
KW  - ENOS
KW  - COMPLICATIONS
KW  - SAFETY
AB  - at day Post-stroke dysphagia is common, associated with poor outcome and often requires non-oral feeding/fluids. The relationship between route of feeding and outcome, as well as treatment with glyceryl trinitrate (GTN), was studied prospectively. The Efficacy of Nitric Oxide in Stroke (ENOS) trial assessed transdermal GTN (5 mg versus none for 7 days) in 4011 patients with acute stroke and high blood pressure. Feeding route (oral = normal or soft diet; non-oral = nasogastric tube, percutaneous endoscopic gastrostomy tube, parenteral fluids, no fluids) was assessed at baseline and day 7. The primary outcome was the modified Rankin Scale (mRS) measured 90. At baseline, 1331 (33.2%) patients had non-oral feeding, were older, had more severe stroke and more were female, than 2680 (66.8%) patients with oral feeding. By day 7, 756 patients had improved from non-oral to oral feeding, and 119 had deteriorated. Non-oral feeding at baseline was associated with more impairment at day 7 (Scandinavian Stroke Scale 29.0 versus 43.7; 2p < 0.001), and worse mRS (4.0 versus 2.7; 2p < 0.001) and death (23.6 versus 6.8%; 2p = 0.014) at day 90. Although GTN did not modify route of feeding overall, randomisation ae<currency>6 h of stroke was associated with a move to more oral feeding at day 7 (odds ratio = 0.61, 95% confidence intervals 0.38, 0.98; 2p = 0.040). As a proxy for dysphagia, non-oral feeding is present in 33% of patients with acute stroke and associated with more impairment, dependency and death. GTN moved feeding route towards oral intake if given very early after stroke.
AD  - Univ Nottingham, Div Clin Neurosci, Stroke Trials Unit, City Hosp Campus,Hucknall Rd, Nottingham NG5 1PB, EnglandAD  - Univ Manchester, Ctr Gastrointestinal Sci, Salford, Lancs, EnglandAD  - Princess Royal Univ Hosp, Elderly Med, Orpington, EnglandAD  - Northwick Pk Hosp & Clin Res Ctr, Elderly Med, Harrow, Middx, EnglandAD  - Keele Univ, Inst Sci & Technol Med, Stoke On Trent, Staffs, EnglandAD  - Semmelweis Univ, Neurol, Budapest, HungaryAD  - Oslo Univ Hosp, Oslo, NorwayAD  - Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Austin Campus, Heidelberg, Vic, AustraliaAD  - Osped Santa Maria della Misericordia Perugia, Stroke Unit, Perugia, ItalyAD  - Bispebjerg Hosp, Neurol, Copenhagen, DenmarkAD  - Univ Copenhagen, Copenhagen, DenmarkAD  - Tallaght Hosp, Stroke Serv, Tallaght Dublin, IrelandAD  - Inst Psychiat & Neurol, Neurol 2, Warsaw, PolandAD  - Univ Kelaniya, Clin Trials Unit, Ragama, Sri LankaAD  - Ain Shams Univ, Neurol, Cairo, EgyptAD  - Karolinska Inst, Clin Sci, Stockholm, SwedenAD  - Univ Thessaly, Med, Larisa, GreeceAD  - Selcuk Univ, Neurol, Konya, TurkeyAD  - Halifax Infirm, Div Neurol, Halifax, NS, CanadaAD  - All India Inst Med Sci, Neurol, New Delhi, IndiaAD  - Clin Cty Emergency Hosp, Neurol, Targu Mures, RomaniaAD  - Nottingham Univ Hosp NHS Trust, Stroke, Nottingham, EnglandC3  - University of NottinghamC3  - Nottingham University Hospital NHS TrustC3  - Nottingham City HospitalC3  - University of ManchesterC3  - Imperial College LondonC3  - Keele UniversityC3  - Semmelweis UniversityC3  - University of OsloC3  - Florey Institute of Neuroscience & Mental HealthC3  - University of CopenhagenC3  - Bispebjerg HospitalC3  - University of CopenhagenC3  - Trinity College DublinC3  - Institute of Psychiatry & NeurologyC3  - University KelaniyaC3  - Egyptian Knowledge Bank (EKB)C3  - Ain Shams UniversityC3  - Karolinska InstitutetC3  - University of ThessalyC3  - Selcuk UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Nottingham University Hospital NHS TrustPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - APR
PY  - 2018
VL  - 9
IS  - 2
SP  - 120
EP  - 129
DO  - 10.1007/s12975-017-0548-0
AN  - WOS:000427517600005
ER  -

TY  - JOUR
AU  - Yogendrakumar, V
AU  - Smith, EE
AU  - Demchuk, AM
AU  - Aviv, RI
AU  - Rodriguez-Luna, D
AU  - Molina, CA
AU  - Blas, YS
AU  - Dzialowski, I
AU  - Kobayashi, A
AU  - Boulanger, JM
AU  - Lum, C
AU  - Gubitz, G
AU  - Padma, V
AU  - Roy, J
AU  - Kase, CS
AU  - Bhatia, R
AU  - Ali, M
AU  - Lyden, P
AU  - Hill, MD
AU  - Dowlatshahi, D
A1  - Prediction Haematoma Growth Out
A1  - Virtual Int Stroke Trials Archive
TI  - Lack of Early Improvement Predicts Poor Outcome Following Acute Intracerebral Hemorrhage
T2  - CRITICAL CARE MEDICINE
KW  - critical care
KW  - intracranial hemorrhage
KW  - mortality/survival
KW  - quality and outcomes
KW  - prognosis
KW  - HEALTH STROKE SCALE
KW  - NEUROLOGIC DETERIORATION
KW  - MORTALITY
KW  - SCORE
AB  - Objectives: There are limited data as to what degree of early neurologic change best relates to outcome in acute intracerebral hemorrhage. We aimed to derive and validate a threshold for early postintracerebral hemorrhage change that best predicts 90-day outcomes.
   Design: Derivation: retrospective analysis of collated clinical stroke trial data (Virtual International Stroke Trials Archive). Validation: retrospective analysis of a prospective multicenter cohort study (Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign [PREDICT]).
   Setting: Neurocritical and ICUs.
   Patients: Patients with acute intracerebral hemorrhage presenting less than 6 hours. Derivation: 552 patients; validation: 275 patients.
   Interventions: None.
   Measurements and Main Results: We generated a receiver operating characteristic curve for the association between 24-hour National Institutes of Health Stroke Scale change and clinical outcome. The primary outcome was a modified Rankin Scale score of 4-6 at 90 days; secondary outcomes were other modified Rankin Scale score ranges (modified Rankin Scale, 2-6, 3-6, 5-6, 6). We employed Youden's J Index to select optimal cut points and calculated sensitivity, specificity, and predictive values. We determined independent predictors via multivariable logistic regression. The derived definitions were validated in the PREDICT cohort. Twenty-four-hour National Institutes of Health Stroke Scale change was strongly associated with 90-day outcome with an area under the receiver operating characteristic curve of 0.75. Youden's method showed an optimum cut point at -0.5, corresponding to National Institutes of Health Stroke Scale change of greater than or equal to 0 (a lack of clinical improvement), which was seen in 46%. Early neurologic change accurately predicted poor outcome when defined as greater than or equal to 0 (sensitivity, 65%; specificity, 73%; positive predictive value, 70%; adjusted odds ratio, 5.05 [CI, 3.25-7.85]) or greater than or equal to 4 (sensitivity, 19%; specificity, 98%; positive predictive value, 91%; adjusted odds ratio, 12.24 [CI, 4.08-36.66]). All definitions reproduced well in the validation cohort.
   Conclusions: Lack of clinical improvement at 24 hours robustly predicted poor outcome and showed good discrimination for individual patients who would do poorly. These findings are useful for prognostication and may also present as a potential early surrogate outcome for future intracerebral hemorrhage treatment trials.
AD  - Univ Ottawa, Div Neurol, Dept Med, Ottawa, ON, CanadaAD  - Ottawa Hosp Res Inst, Ottawa, ON, CanadaAD  - Univ Calgary, Hotchkiss Brain Inst, Dept Radiol, Calgary Stroke Program,Dept Clin Neurosci, Calgary, AB, CanadaAD  - Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Neuroradiol, Toronto, ON, CanadaAD  - Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med Imaging, Toronto, ON, CanadaAD  - Hosp Univ Vall dHebron, Dept Neurol, Barcelona, SpainAD  - Inst Invest Biomed Girona IDIBGi Fdn, Dr Josep Trueta Univ Hosp, Dept Neurol, Girona, SpainAD  - Tech Univ Dresden, Elblandklinikum Meissen Acad Teaching Hosp, Dept Neurol, Dresden, GermanyAD  - Inst Psychiat & Neurol, Dept Neurol 2, Warsaw, PolandAD  - Inst Psychiat & Neurol, Dept Expt & Clin Pharmacol, Warsaw, PolandAD  - Univ Sherbrooke, Dept Med, Charles LeMoyne Hosp, Montreal, PQ, CanadaAD  - Univ Ottawa, Ottawa Hosp Res Inst, Neuroradiol Sect, Dept Diagnost Imaging, Ottawa, ON, CanadaAD  - Dalhousie Univ, Dept Neurol, Halifax, NS, CanadaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaAD  - Apollo Gleneagles Hosp, Dept Neuromed, Kolkata, IndiaAD  - Boston Med Ctr, Dept Neurol, Boston, MA USAAD  - Univ Glasgow, Inst Cardiovasc Sci, Glasgow, Lanark, ScotlandAD  - Univ Glasgow, Inst Med Sci, Glasgow, Lanark, ScotlandAD  - Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA 90048 USAC3  - University of OttawaC3  - University of OttawaC3  - Ottawa Hospital Research InstituteC3  - University of CalgaryC3  - University of TorontoC3  - Sunnybrook Research InstituteC3  - Sunnybrook Health Science CenterC3  - University of TorontoC3  - Sunnybrook Research InstituteC3  - Sunnybrook Health Science CenterC3  - Hospital Universitari Vall d'HebronC3  - Universitat de GironaC3  - Girona University Hospital Dr. Josep TruetaC3  - Institut d'Investigacio Biomedica de Girona (IDIBGI)C3  - Technische Universitat DresdenC3  - Institute of Psychiatry & NeurologyC3  - Institute of Psychiatry & NeurologyC3  - University of SherbrookeC3  - University of OttawaC3  - Ottawa Hospital Research InstituteC3  - Dalhousie UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Boston Medical CenterC3  - University of GlasgowC3  - University of GlasgowC3  - Cedars Sinai Medical CenterPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - APR
PY  - 2018
VL  - 46
IS  - 4
SP  - E310
EP  - E317
DO  - 10.1097/CCM.0000000000002962
AN  - WOS:000427775500005
ER  -

TY  - JOUR
AU  - Iuliano, AD
AU  - Roguski, KM
AU  - Chang, HH
AU  - Muscatello, DJ
AU  - Palekar, R
AU  - Tempia, S
AU  - Cohen, C
AU  - Gran, JM
AU  - Schanzer, D
AU  - Cowling, BJ
AU  - Wu, P
AU  - Kyncl, J
AU  - Ang, LW
AU  - Park, M
AU  - Redlberger-Fritz, M
AU  - Yu, HJ
AU  - Espenhain, L
AU  - Krishnan, A
AU  - Emukule, G
AU  - van Asten, L
AU  - da Silva, SP
AU  - Aungkulanon, S
AU  - Buchholz, U
AU  - Widdowson, MA
AU  - Bresee, JS
AU  - Azziz-Baumgartner, E
AU  - Cheng, PY
AU  - Dawood, F
AU  - Foppa, I
AU  - Olsen, S
AU  - Haber, M
AU  - Jeffers, C
AU  - MacIntyre, CR
AU  - Newall, AT
AU  - Wood, JG
AU  - Kundi, M
AU  - PopowKraupp, T
AU  - Ahmed, M
AU  - Rahman, M
AU  - Marinho, F
AU  - Proschle, CV
AU  - Mallegas, N
AU  - Feng, LZ
AU  - Sa, L
AU  - Barbosa-Ramírez, J
AU  - Sanchez, DM
AU  - Gomez, LA
AU  - Vargas, XB
AU  - Herrera, BA
AU  - Llanés, MJ
AU  - Fischer, TK
AU  - Krause, TG
AU  - Molbak, K
AU  - Nielsen, J
AU  - Trebbien, R
AU  - Bruno, A
AU  - Ojeda, J
AU  - Ramos, H
AU  - an der Heiden, M
AU  - Signor, LDC
AU  - Serrano, CE
AU  - Bhardwaj, R
AU  - Chadha, M
AU  - Narayan, V
AU  - Kosen, S
AU  - Bromberg, M
AU  - Glatman-Freedman, A
AU  - Kaufman, Z
AU  - Arima, Y
AU  - Oishi, K
AU  - Chaves, S
AU  - Nyawanda, B
AU  - Al-Jarallah, RA
AU  - Kuri-Morales, PA
AU  - Matus, CR
AU  - Corona, MEJ
AU  - Burmaa, A
AU  - Darmaa, O
AU  - Obtel, M
AU  - Cherkaoui, I
AU  - van den Wijngaard, CC
AU  - van der Hoek, W
AU  - Baker, M
AU  - Bandaranayake, D
AU  - Bissielo, A
AU  - Huang, S
AU  - Lopez, L
AU  - Newbern, C
AU  - Flem, E
AU  - Groneng, GM
AU  - Hauge, S
AU  - de Cosío, FG
AU  - de Moltó, Y
AU  - Castillo, LM
AU  - Cabello, MA
AU  - von Horoch, M
AU  - Osis, JM
AU  - Machado, A
AU  - Nunes, B
AU  - Rodrigues, AP
AU  - Rodrigues, E
AU  - Calomfirescu, C
AU  - Lupulescu, E
AU  - Popescu, R
AU  - Popovici, O
AU  - Bogdanovic, D
AU  - Kostic, M
AU  - Lazarevic, K
AU  - Milosevic, Z
AU  - Tiodorovic, B
AU  - Chen, M
AU  - Cutter, J
AU  - Lee, V
AU  - Lin, R
AU  - Ma, S
AU  - Cohen, AL
AU  - Treurnicht, F
AU  - Kim, WJ
AU  - Sanz, CD
AU  - Ontañón, SD
AU  - Larrauri, A
AU  - León, I
AU  - Vallejo, F
AU  - Born, R
AU  - Junker, C
AU  - Koch, D
AU  - Chuang, JH
AU  - Huang, WT
AU  - Kuo, HW
AU  - Tsai, YC
AU  - Bundhamcharoen, K
AU  - Chittaganpitch, M
AU  - Green, HK
AU  - Pebody, R
AU  - Goñi, N
AU  - Chiparelli, H
AU  - Brammer, L
AU  - Mustaquim, D
A1  - Global Seasonal Influenza-Associat
TI  - Estimates of global seasonal influenza-associated respiratory mortality: a modelling study
T2  - LANCET
KW  - EXCESS MORTALITY
KW  - UNITED-STATES
KW  - PANDEMIC INFLUENZA
KW  - DEATHS
KW  - VIRUS
KW  - BURDEN
KW  - EPIDEMIOLOGY
KW  - CAPACITY
KW  - NUMBERS
KW  - AFRICA
AB  - Background Estimates of influenza-associated mortality are important for national and international decision making on public health priorities. Previous estimates of 250 000-500 000 annual influenza deaths are outdated. We updated the estimated number of global annual influenza-associated respiratory deaths using country-specific influenza-associated excess respiratory mortality estimates from 1999-2015.
   Methods We estimated country-specific influenza-associated respiratory excess mortality rates (EMR) for 33 countries using time series log-linear regression models with vital death records and influenza surveillance data. To extrapolate estimates to countries without data, we divided countries into three analytic divisions for three age groups (< 65 years, 65-74 years, and >= 75 years) using WHO Global Health Estimate (GHE) respiratory infection mortality rates. We calculated mortality rate ratios (MRR) to account for differences in risk of influenza death across countries by comparing GHE respiratory infection mortality rates from countries without EMR estimates with those with estimates. To calculate death estimates for individual countries within each age-specific analytic division, we multiplied randomly selected mean annual EMRs by the country's MRR and population. Global 95% credible interval (CrI) estimates were obtained from the posterior distribution of the sum of country-specific estimates to represent the range of possible influenza-associated deaths in a season or year. We calculated influenza-associated deaths for children younger than 5 years for 92 countries with high rates of mortality due to respiratory infection using the same methods.
   Findings EMR-contributing countries represented 57% of the global population. The estimated mean annual influenza-associated respiratory EMR ranged from 0.1 to 6.4 per 100 000 individuals for people younger than 65 years, 2.9 to 44.0 per 100 000 individuals for people aged between 65 and 74 years, and 17 .9 to 223.5 per 100 000 for people older than 75 years. We estimated that 291 243-645 832 seasonal influenza-associated respiratory deaths (4.0-8.8 per 100 000 individuals) occur annually. The highest mortality rates were estimated in sub-Saharan Africa (2.8-16.5 per 100 000 individuals), southeast Asia (3.5-9.2 per 100 000 individuals), and among people aged 75 years or older (51. 3-99.4 per 100 000 individuals). For 92 countries, we estimated that among children younger than 5 years, 9243-105 690 influenza-associated respiratory deaths occur annually.
   Interpretation These global influenza-associated respiratory mortality estimates are higher than previously reported, suggesting that previous estimates might have underestimated disease burden. The contribution of non-respiratory causes of death to global influenza-associated mortality should be investigated.
AD  - Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USAAD  - Emory Univ, Dept Biostat & Bioinformat, Rollins Sch Publ Hlth, Atlanta, GA 30322 USAAD  - Univ New South Wales, Dept Biostat & Bioinformat, Sydney, NSW, AustraliaAD  - Pan Amer Hlth Org, Washington, DC USAAD  - Natl Hlth Lab Serv, Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Johannesburg, South AfricaAD  - Oslo Univ Hosp, Oslo Ctr Biostat & Epidemiol, Oslo, NorwayAD  - Univ Oslo, Oslo, NorwayAD  - Norwegian Inst Publ Hlth, Domain Infect Control & Environm Hlth, Oslo, NorwayAD  - Publ Hlth Agcy Canada, Infect Dis Prevent & Control Branch, Ottawa, ON, CanadaAD  - Univ Hong Kong, Sch Publ Hlth, Li Ka Shing Fac Med, WHO Collaborating Ctr Infect Dis Epidemiol & Cont, Hong Kong, Hong Kong, Peoples R ChinaAD  - Natl Inst Publ Hlth, Dept Infect Dis Epidemiol, Prague, Czech RepublicAD  - Minist Hlth, Dept Infect Dis Epidemiol, Singapore, SingaporeAD  - Med Univ Vienna, Dept Virol, Vienna, AustriaAD  - Chinese Ctr Dis Control & Prevent, Key Lab Surveillance & Early Warning Infect Dis, Div Infect Dis, Beijing, Peoples R ChinaAD  - Statens Serum Inst, Dept Infect Dis Epidemiol, Copenhagen, DenmarkAD  - All India Inst Med Sci, New Delhi, IndiaAD  - Ctr Dis Control & Prevent Kenya, Nairobi, KenyaAD  - Natl Inst Publ Hlth & Environm, Bilthoven, NetherlandsAD  - Natl Hlth Inst Doutor Ricardo Jorge, Dept Epidemiol, Lisbon, PortugalAD  - Minist Publ Hlth, Int Hlth Policy Program, Nonthaburi, ThailandAD  - Robert Koch Inst, Dept Infect Dis Epidemiol, Berlin, GermanyAD  - Univ New South Wales, Sch Publ Hlth & Community Med, Sydney, NSW, AustraliaAD  - Univ New South Wales, Sydney, NSW, AustraliaAD  - Med Univ Vienna, Inst Environm Hlth, Ctr Publ Hlth, Vienna, AustriaAD  - Int Ctr Diarrheal Dis Res, Dhaka, BangladeshAD  - Inst Epidemiol Dis Control & Res, Dhaka, BangladeshAD  - Minist Hlth Brazil, Brasilia, DF, BrazilAD  - Minist Hlth Santiago, Dept Epidemiol, Santiago, ChileAD  - Chinese Ctr Dis Control & Prevent, Div Infect Dis, Key Lab Surveillance & EarlyWarning Infect Dis, Beijing, Peoples R ChinaAD  - Natl Influenza Ctr, Div Influenza & Other Resp Viruses, Bogota, ColombiaAD  - Natl Inst Hlth Colombia, Bogota, ColombiaAD  - Caja Costarricense Seguro Social, San Jose, Costa RicaAD  - Natl Influenza Ctr, Inst Pedro Kouri, Dept Virol, Havana, CubaAD  - Minist Salud Publ, Direcc Nacl Epidemiol, Viceminist Higiend Epidemiol & Microbiol, Havana, CubaAD  - Statens Serum Inst, Dept Microbiol Diagnost & Virol, Copenhagen S, DenmarkAD  - Univ Southern Denmark, Dept Infect Dis, Copenhagen S, DenmarkAD  - Univ Southern Denmark, Ctr Global Hlth, Copenhagen S, DenmarkAD  - Statens Serum Inst, Dept Infect Dis Epidemiol, Copenhagen S, DenmarkAD  - Ctr Referencia Nacl Influenza & Otros Virus Resp, Inst Nacl Invest Salud Publ Dr Leopoldo Izquieta, Guayaquil, EcuadorAD  - Univ Agr Ecuador, Guayaquil, EcuadorAD  - Minestro Salud Publ, Direcc Nacl Vigilancia Epidemiol, Quito, EcuadorAD  - Minist Hlth, Sanit Surveillance Div, San Salvador, El SalvadorAD  - Robert Koch Inst, Dept Infect Dis Epidemiol, Berlin, GermanyAD  - Natl Hlth Lab, Barcenas, GuatemalaAD  - Off Registrar Gen India, SRS Div, New Delhi, IndiaAD  - 133 Natl Inst Virol, Pune, Maharashtra, IndiaAD  - NIHRD, Jakarta, IndonesiaAD  - Minist Hlth, Israel Ctr Dis Control, Tel Hashomer, IsraelAD  - Tel Aviv Univ, Sackler Fac Med, Dept Epidemiol & Prevent Med, Tel Aviv, IsraelAD  - Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo, JapanAD  - Ctr Dis Control & Prevent, Kenya Country Off, Nairobi, KenyaAD  - KEMRI, CGHR, Kisumu, KenyaAD  - Kuwait Univ, Stat & Operat Res Dept, Coll Sci, Safat, KuwaitAD  - UNAM Mexico, Undersecretary Prevent & Hlth Promot, Minist Hlth Sch Med, Mexico City, DF, MexicoAD  - Direcc Gen Epiemiol, Secretaria Salud, Mexico City, DF, MexicoAD  - Minist Hlth, Natl Influenza Ctr, Natl Influenza Surveillance Div, Ulaanbata, MongoliaAD  - Univ Mohammed 5, Dept Publ Hlth, Fac Med & Pharm, Rabat, MoroccoAD  - Minist Hlth, Directorate Epidemiol & Dis Control, Rabat, MoroccoAD  - RIVM Natl Inst Publ Hlth & Environm, Bilthoven, NetherlandsAD  - Univ Otago, Dept Publ Hlth, Wellington, New ZealandAD  - Inst Environm Sci & Res, Upper Hutt, New ZealandAD  - Norwegian Inst Publ Hlth, Infect Control & Environm Hlth, Oslo, NorwayAD  - Norwegian Inst Publ Hlth, Dept Infect Dis Epidemiol, Oslo, NorwayAD  - Norwegian Inst Publ Hlth, Oslo, NorwayAD  - Pan Amer Hlth Org, Hlth Informat & Anal, Washington, DC USAAD  - Minist Hlth, Dept Epidemiol, Panama City, PanamaAD  - Minist Hlth, Monitoring & Evaluat Unit, Asuncion, ParaguayAD  - Minist Hlth, Gen Directorate Epidemiol, Lima, PeruAD  - Natl Hlth Inst Doutor Ricardo Jorge INSA, Dept Epidemiol, Lisbon, PortugalAD  - Romania Natl Ctr Stat & Informat Publ Hlth, Natl Inst Publ Hlth, Bucharest, RomaniaAD  - Natl Res Inst Dr Ioan Cantacuzino, Bucharest, RomaniaAD  - Romania Natl Ctr Communicable Dis Surveillance &, Natl Inst Publ Hlth, Bucharest, RomaniaAD  - State Univ Novi Pazar, Nish, SerbiaAD  - Publ Hlth Inst Nis, Nish, SerbiaAD  - Univ Nis Med Sch, Nish, SerbiaAD  - Natl Univ Singapore, Singapore, SingaporeAD  - Minist Hlth, Singapore, SingaporeAD  - WHO, Dept Immunizat Vaccines & Biol, Strateg Informat Grp, Expanded Programme Immunizat, Geneva, SwitzerlandAD  - Ctr Resp Dis & Meningitis, Natl Inst Communicable Dis, Natl Hlth Lab Serv, Johannesburg, South AfricaAD  - Korea Univ Coll Med, Div Infect Dis, Dept Internal Med, Seoul, South KoreaAD  - CIBERESP, Natl Ctr Epidemiol, Carlos III Hlth Inst, Madrid, SpainAD  - Fed Off Publ Hlth, Bern, SwitzerlandAD  - Fed Stat Off, Neuchatel, SwitzerlandAD  - Fed Off Publ Hlth, Div Communicable Dis, Bern, SwitzerlandAD  - Taiwanese Ctr Dis Control, Taipei, TaiwanAD  - Int Hlth Policy Program, Nonthaburi, ThailandAD  - Thai Natl Inst Hlth, Nonthaburi, ThailandAD  - Publ Hlth England, London, EnglandAD  - Minist Hlth, Natl Influenza Reference Ctr, Dept Publ Hlth Lab, Montevideo, UruguayC3  - Centers for Disease Control & Prevention - USAC3  - Emory UniversityC3  - Rollins School Public HealthC3  - University of New South Wales SydneyC3  - Pan American Health OrganizationC3  - National Institute for Communicable Diseases (NICD)C3  - National Health Laboratory ServiceC3  - University of OsloC3  - University of OsloC3  - Norwegian Institute of Public Health (NIPH)C3  - Public Health Agency of CanadaC3  - World Health OrganizationC3  - University of Hong KongC3  - National Institute of Public Health (SZU) - Czech RepublicC3  - Ministry of Health-SingaporeC3  - Medical University of ViennaC3  - Chinese Center for Disease Control & PreventionC3  - Statens Serum InstitutC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Netherlands National Institute for Public Health & the EnvironmentC3  - Instituto Nacional de Saude Dr. Ricardo JorgeC3  - Ministry of Public Health - ThailandC3  - Robert Koch InstituteC3  - University of New South Wales SydneyC3  - University of New South Wales SydneyC3  - Medical University of ViennaC3  - International Centre for Diarrhoeal Disease Research (ICDDR)C3  - Chinese Center for Disease Control & PreventionC3  - Statens Serum InstitutC3  - University of Southern DenmarkC3  - University of Southern DenmarkC3  - Statens Serum InstitutC3  - Robert Koch InstituteC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute of Virology (NIV)C3  - National Institute of Health Research & Development - IndonesiaC3  - Tel Aviv UniversityC3  - Sackler Faculty of MedicineC3  - National Institute of Infectious Diseases (NIID)C3  - Kuwait UniversityC3  - Universidad Nacional Autonoma de MexicoC3  - Ministry of Health MongoliaC3  - Mohammed V University in RabatC3  - Ibn sina University Hospital Center of RabatC3  - Netherlands National Institute for Public Health & the EnvironmentC3  - University of OtagoC3  - Institute of Environmental Science & Research (ESR) - New ZealandC3  - Norwegian Institute of Public Health (NIPH)C3  - Norwegian Institute of Public Health (NIPH)C3  - Norwegian Institute of Public Health (NIPH)C3  - Pan American Health OrganizationC3  - Ministerio de Salud de la Republica de PanamaC3  - Instituto Nacional de Saude Dr. Ricardo JorgeC3  - National University of SingaporeC3  - Ministry of Health-SingaporeC3  - World Health OrganizationC3  - National Institute for Communicable Diseases (NICD)C3  - National Health Laboratory ServiceC3  - Korea UniversityC3  - Korea University Medicine (KU Medicine)C3  - CIBER - Centro de Investigacion Biomedica en RedC3  - CIBERESPC3  - Ministry of Public Health - ThailandC3  - Public Health EnglandPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - MAR 31
PY  - 2018
VL  - 391
IS  - 10127
SP  - 1285
EP  - 1300
DO  - 10.1016/S0140-6736(17)33293-2
AN  - WOS:000428791600027
ER  -

TY  - JOUR
AU  - Paliwal, S
AU  - Chaudhuri, R
AU  - Agrawal, A
AU  - Mohanty, S
TI  - Regenerative abilities of mesenchymal stem cells through mitochondrial transfer
T2  - JOURNAL OF BIOMEDICAL SCIENCE
KW  - Mesenchymal stem cells
KW  - Mitochondrial transfer mechanism
KW  - Regenerative medicine
KW  - MULTIPOTENT STROMAL CELLS
KW  - TUNNELING NANOTUBES
KW  - IN-VITRO
KW  - HEMATOPOIETIC STEM
KW  - ORGANELLE TRANSFER
KW  - RESCUE
KW  - MECHANISMS
KW  - DIFFERENTIATION
KW  - CARDIOMYOCYTES
KW  - REPERFUSION
AB  - The past decade has witnessed an upsurge in studies demonstrating mitochondrial transfer as one of the emerging mechanisms through which mesenchymal stem cells (MSCs) can regenerate and repair damaged cells or tissues. It has been found to play a critical role in healing several diseases related to brain injury, cardiac myopathies, muscle sepsis, lung disorders and acute respiratory disorders. Several studies have shown that various mechanisms are involved in mitochondrial transfer that includes tunnel tube formation, micro vesicle formation, gap junctions, cell fusion and others modes of transfer. Few studies have investigated the mechanisms that contribute to mitochondrial transfer, primarily comprising of signaling pathways involved in tunnel tube formation that facilitates tunnel tube formation for movement of mitochondria from one cell to another. Various stress signals such as release of damaged mitochondria, mtDNA and mitochondrial products along with elevated reactive oxygen species levels trigger the transfer of mitochondria from MSCs to recipient cells. However, extensive cell signaling pathways that lead to mitochondrial transfer from healthy cells are still under investigation and the changes that contribute to restoration of mitochondrial bioenergetics in recipient cells remain largely elusive. In this review, we have discussed the phenomenon of mitochondrial transfer from MSCs to neighboring stressed cells, and how this aids in cellular repair and regeneration of different organs such as lung, heart, eye, brain and kidney. The potential scope of mitochondrial transfer in providing novel therapeutic strategies for treatment of various pathophysiological conditions has also been discussed.
AD  - CSIR, Inst Genom & Integrat Biol, Mol Immunogenet Lab, Delhi 110007, IndiaAD  - CSIR, Inst Genom & Integrat Biol, Ctr Excellence Translat Res Asthma & Lung Dis, Delhi 110007, IndiaAD  - All India Inst Med Sci, DBT Ctr Excellence Stem Cell Res, Stem Cell Facil, New Delhi 110029, IndiaC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - BMC
PI  - LONDON
PA  - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - MAR 30
PY  - 2018
VL  - 25
C7  - 31
DO  - 10.1186/s12929-018-0429-1
AN  - WOS:000428908600001
ER  -

TY  - JOUR
AU  - Paul, G
AU  - Deshmukh, A
AU  - Chourasia, BK
AU  - Kalamuddin, M
AU  - Panda, A
AU  - Singh, SK
AU  - Gupta, PK
AU  - Mohmmed, A
AU  - Chauhan, VS
AU  - Theisen, M
AU  - Malhotra, P
TI  - Protein-protein interaction studies reveal the <i>Plasmodium</i> <i>falciparum</i> merozoite surface protein-1 region involved in a complex formation that binds to human erythrocytes
T2  - BIOCHEMICAL JOURNAL
KW  - INHIBIT PARASITE GROWTH
KW  - RED-BLOOD-CELLS
KW  - IN-VITRO
KW  - TERMINAL FRAGMENT
KW  - MALARIA PARASITES
KW  - ESCHERICHIA-COLI
KW  - INVASION
KW  - ANTIBODIES
KW  - ANTIGEN
KW  - IDENTIFICATION
AB  - Plasmodium falciparum merozoite surface protein (PfMSP) 1 has been studied extensively as a vaccine candidate antigen. PfMSP-1 undergoes proteolytic processing into four major products, such as p83, p30, p38, and p42, that are associated in the form of non-covalent complex(s) with other MSPs. To delineate MSP1 regions involved in the interaction with other MSPs, here we expressed recombinant proteins (PfMSP-1(65)) encompassing part of p38 and p42 regions and PfMSP-1(19). PfMSP-1(65) interacted strongly with PfMSP-3, PfMSP-6, PfMSP-7, and PfMSP-9, whereas PfMSP-1(19) did not interact with any of these proteins. Since MSP-1 complex binds human erythrocytes, we examined the ability of these proteins to bind human erythrocyte. Among the proteins of MSP-1 complex, PfMSP-6 and PfMSP-9 bound to human erythrocytes. Serological studies showed that PfMSP-1(65) was frequently recognized by sera from malaria endemic regions, whereas this was not the case for PfMSP-1(19). In contrast, antibodies against PfMSP-1(19) showed much higher inhibition of merozoite invasion compared with antibodies against the larger PfMSP-1(65) fragment. Importantly, anti-PfMSP-1(19) antibodies recognized both recombinant proteins, PfMSP-1(19) and PfMSP-1(65); however, anti-PfMSP-1(65) antibody failed to recognize the PfMSP-1(19) protein. Taken together, these results demonstrate that PfMSP-1 sequences upstream of the 19 kDa C-terminal region are involved in molecular interactions with other MSPs, and these sequences may probably serve as a smoke screen to evade antibody response to the membrane-bound C-terminal 19 kDa region.
AD  - ICGEB, Malaria Biol Grp, New Delhi, IndiaAD  - Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Ctr Med Parasitol, Copenhagen, DenmarkAD  - Copenhagen Univ Hosp, Rigs Hosp, Dept Infect Dis, Copenhagen, DenmarkAD  - Jamia Millia Islamia, Dept Biotechnol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaAD  - Statens Serum Inst, Dept Clin Biochem Immunol & Genet, Copenhagen, DenmarkAD  - ICGEB, Mammalian Biol Malaria Grp, New Delhi, IndiaC3  - Department of Biotechnology (DBT) IndiaC3  - International Center for Genetic Engineering & Biotechnology (ICGEB)C3  - International Center for Genetic Engineering & Biotechnology (ICGEB), New DelhiC3  - University of CopenhagenC3  - University of CopenhagenC3  - Jamia Millia IslamiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Statens Serum InstitutC3  - Department of Biotechnology (DBT) IndiaC3  - International Center for Genetic Engineering & Biotechnology (ICGEB)C3  - International Center for Genetic Engineering & Biotechnology (ICGEB), New DelhiPU  - PORTLAND PRESS LTD
PI  - LONDON
PA  - CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
DA  - MAR 30
PY  - 2018
VL  - 475
SP  - 1197
EP  - 1209
DO  - 10.1042/BCJ20180017
AN  - WOS:000431967100012
ER  -

TY  - JOUR
AU  - Joenvaara, S
AU  - Saraswat, M
AU  - Kuusela, P
AU  - Saraswat, S
AU  - Agarwal, R
AU  - Kaartinen, J
AU  - Järvinen, A
AU  - Renkonen, R
TI  - Quantitative N-glycoproteomics reveals altered glycosylation levels of various plasma proteins in bloodstream infected patients
T2  - PLOS ONE
KW  - C-REACTIVE PROTEIN
KW  - CRITICALLY-ILL PATIENTS
KW  - ACUTE-PANCREATITIS
KW  - BACTEREMIA
KW  - SEPSIS
KW  - SERUM
KW  - PROCALCITONIN
KW  - MORTALITY
KW  - OUTCOMES
KW  - DISEASE
AB  - Bloodstream infections are associated with high morbidity and mortality with rates varying from 10-25% and higher. Appropriate and timely onset of antibiotic therapy influences the prognosis of these patients. It requires the diagnostic accuracy which is not afforded by current gold standards such as blood culture. Moreover, the time from blood sampling to blood culture results is a key determinant of reducing mortality. No established biomarkers exist which can differentiate bloodstream infections from other systemic inflammatory conditions. This calls for studies on biomarkers potential of molecular profiling of plasma as it is affected most by the molecular changes accompanying bloodstream infections. N-glycosylation is a post-translational modification which is very sensitive to changes in physiology. Here we have performed targeted quantitative N-glycoproteomics from plasma samples of patients with confirmed positive blood culture together with age and sex matched febrile controls with negative blood culture reports. Three hundred and sixty eight potential N-glycopeptides were quantified by mass spectrometry and 149 were further selected for identification. Twenty four N-glycopeptides were identified with high confidence together with elucidation of the peptide sequence, N-glycosylation site, glycan composition and proposed glycan structures. Principal component analysis, orthogonal projections to latent structures-discriminant analysis (S-Plot) and self-organizing maps clustering among other statistical methods were employed to analyze the data. These methods gave us clear separation of the two patient classes. We propose high-confidence N-glycopeptides which have the power to separate the bloodstream infections from blood culture negative febrile patients and shed light on host response during bacteremia. Data are available via ProteomeXchange with identifier PXD009048.
AD  - Univ Helsinki, Transplantat Lab, Haartmaninkatu 3, Helsinki, FinlandAD  - Helsinki Univ Hosp, HUSLAB, Helsinki, FinlandAD  - HUSLAB, Div Clin Microbiol, Helsinki, FinlandAD  - Univ Helsinki, Dept Bacteriol & Immunol, Helsinki, FinlandAD  - All India Inst Med Sci, Dept Reprod Biol, New Delhi, IndiaAD  - Helsinki Univ Hosp, Emergency Med & Serv, Helsinki, FinlandAD  - Univ Helsinki, HUH Inflammat Ctr, Div Infect Dis, Helsinki, FinlandC3  - University of HelsinkiC3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - University of HelsinkiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of HelsinkiC3  - Helsinki University Central HospitalC3  - University of HelsinkiPU  - PUBLIC LIBRARY SCIENCE
PI  - SAN FRANCISCO
PA  - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
DA  - MAR 29
PY  - 2018
VL  - 13
IS  - 3
C7  - e0195006
DO  - 10.1371/journal.pone.0195006
AN  - WOS:000428630000065
ER  -

TY  - JOUR
AU  - Gahane, AY
AU  - Ranjan, P
AU  - Singh, V
AU  - Sharma, RK
AU  - Sinha, N
AU  - Sharma, M
AU  - Chaudhry, R
AU  - Thakur, AK
TI  - Fmoc-phenylalanine displays antibacterial activity against Gram-positive bacteria in gel and solution phases
T2  - SOFT MATTER
KW  - AMINO-ACID
KW  - ANTIMICROBIAL ACTIVITY
KW  - OXIDATIVE STRESS
KW  - HYDROGELS
KW  - ANTIBIOTICS
KW  - GLUTATHIONE
KW  - INFECTIONS
KW  - PARAMETERS
KW  - MECHANISM
KW  - ACCURATE
AB  - In the quest for new antimicrobial materials, hydrogels of Fmoc-protected peptides and amino acids have gained momentum due to their ease of synthesis and cost effectiveness; however, their repertoire is currently limited, and the mechanistic details of their function are not well understood. Herein, we report the antibacterial activity of the hydrogel and solution phases of Fmoc-phenylalanine (Fmoc-F) against a variety of Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). Fmoc-F, a small molecule hydrogelator, reduces the bacterial load both in vitro and in the skin wound infections of mice. The antibacterial activity of Fmoc-F is predominantly due to its release from the hydrogel. Fmoc-F shows surfactant-like properties with critical micelle concentration nearly equivalent to its minimum bactericidal concentration. Similar to Fmoc-F, some Fmoc-conjugated amino acids (Fmoc-AA) have also shown antibacterial effects that are linearly correlated with their surfactant properties. At low concentrations, where Fmoc-F does not form micelles, it inhibits bacterial growth by entering the cell and reducing the glutathione levels. However, at higher concentrations, Fmoc-F triggers oxidative and osmotic stress and, alters the membrane permeabilization and integrity, which kills Gram-positive bacteria. Herein, we proposed the use of the Fmoc-F hydrogel and its solution for several biomedical applications. This study will open up new avenues to enhance the repertoire of Fmoc-AA to act as antimicrobial agents and improve their structure-activity relationship.
AD  - Indian Inst Technol, Dept Biol Sci & Bioengn, Kanpur 208016, Uttar Pradesh, IndiaAD  - Ctr Biomed Res, SGPGIMS Campus, Lucknow 226014, Uttar Pradesh, IndiaAD  - CSK HPKV, DGCN Coll Vet & Anim Sci, Palampur 176062, Himachal Prades, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - KanpurC3  - Ch. Sarwan Kumar Himachal Pradesh Krishi VishvavidyalayaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ROYAL SOC CHEMISTRY
PI  - CAMBRIDGE
PA  - THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND
DA  - MAR 28
PY  - 2018
VL  - 14
IS  - 12
SP  - 2234
EP  - 2244
DO  - 10.1039/c7sm02317k
AN  - WOS:000428989100004
ER  -

TY  - JOUR
AU  - Kaur, A
AU  - Kapil, A
AU  - Elangovan, R
AU  - Jha, S
AU  - Kalyanasundaram, D
TI  - Highly-sensitive detection of <i>Salmonella typhi</i> in clinical blood samples by magnetic nanoparticle-based enrichment and <i>in-situ</i> measurement of isothermal amplification of nucleic acids
T2  - PLOS ONE
KW  - IMMUNOMAGNETIC SEPARATION
KW  - RAPID DETECTION
KW  - DIAGNOSIS
KW  - CULTURE
KW  - FEVER
KW  - FOODS
KW  - ASSAY
KW  - DNA
AB  - Enteric fever continues to be a major cause of mortality and morbidity globally, particularly in poor resource settings. Lack of rapid diagnostic assays is a major driving factor for the empirical treatment of enteric fever. In this work, a rapid and sensitive method 'Miod 'has been developed. Miod includes a magnetic nanoparticle-based enrichment of target bacterial cells, followed by cell lysis and loop-mediated isothermal amplification (LAMP) of nucleic acids for signal augmentation along with concurrent measurement of signal via an in situ optical detection system. To identify positive/negative enteric fever infections in clinical blood samples, the samples were processed using Miod at time = 0 hours and time = 4 hours post-incubation in blood culture media. Primers specific for the STY2879 gene were used to amplify the nucleic acids isolated from S. typhicells. A limit of detection of 5 CFU/mL was achieved. No cross-reactivity of the primers were observed against 106 CFU/mL of common pathogenic bacterial species found in blood such as E. coli, P. aeruginosa, S. aureus, A. baumanni, E. faecalis, S. Paratyphi A and K. pneumonia. Miod was tested on 28 human clinical blood samples. The detection of both pre- and post-four-hours incubation confirmed the presence of viable S. typhicells and allowed clinical correlation of infection. The positive and negative samples were successfully detected in less than 6 hours with 100% sensitivity and specificity.
AD  - Indian Inst Technol Delhi, Ctr Biomed Engn, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaAD  - Indian Inst Technol Delhi, Dept Biochem Engn & Biotechnol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biomed Engn, New Delhi, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - PUBLIC LIBRARY SCIENCE
PI  - SAN FRANCISCO
PA  - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
DA  - MAR 28
PY  - 2018
VL  - 13
IS  - 3
C7  - e0194817
DO  - 10.1371/journal.pone.0194817
AN  - WOS:000428603100076
ER  -

TY  - JOUR
AU  - Tikhomirov, AS
AU  - Lin, CY
AU  - Volodina, YL
AU  - Dezhenkova, LG
AU  - Tatarskiy, VV
AU  - Schols, D
AU  - Shtil, AA
AU  - Kaur, P
AU  - Chueh, PJ
AU  - Shchekotikhin, AE
TI  - New antitumor anthra[2,3-<i>b</i>]furan-3-carboxamides: Synthesis and structure-activity relationship
T2  - EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
KW  - Anthra[2,3-b]furan-3-carboxamides
KW  - Antiproliferative activity
KW  - Topoisomerase 1
KW  - Multidrug resistance
KW  - p53
KW  - Reactive oxygen species
KW  - Apoptosis
KW  - RING FUSION STRATEGY
KW  - HETEROCYCLIC-ANALOGS
KW  - P53-INDEPENDENT MANNER
KW  - MULTIDRUG-RESISTANCE
KW  - DERIVATIVES
KW  - INHIBITORS
KW  - APOPTOSIS
KW  - DESIGN
KW  - CANCER
KW  - DNA
AB  - Chemical modifications of the anthraquinone scaffold are aimed at optimization of this exceptionally productive class of antitumor drugs. In particular, our previously reported anthra[2,3-blfuran-3-carboxamides demonstrated a high cytotoxic potency in cell culture and in vivo. In this study, we expanded our series of anthra[2,3-blfuran-3-carboxamides by modifying the key functional groups and dissected the structure-activity relationship within this chemotype. The majority of new compounds inhibited the growth of mammalian tumor cell lines at submicromolar to low micromolar concentrations. We found that 4,11-hydroxy groups as well as the carbonyl moiety in the carboxamide fragment were critical for cytotoxicity whereas the substituent at the 2-position of anthra[2,3-b]furan was not. Importantly, the new derivatives were similarly potent against wild type cells and their variants resistant to doxorubicin due to P-glycoprotein (Pgp) expression or p53 inactivation. The most cytotoxic derivatives 6 and 9 attenuated plasmid DNA relaxation by topoisomerase 1. Finally, we demonstrated that 6 and 9 at 1 mu M induced intracellular oxidative stress, accumulation in G2/M phase of the cell cycle, and apoptosis in gastric carcinoma cell lines regardless of their p53 status. These results further substantiate the potential of anthra[2,3-b]furan-3-carboxamides as antitumor drug candidates. (C) 2018 Elsevier Masson SAS. All rights reserved.
AD  - Gause Inst New Antibiot, 11 B Pirogovskaya St, Moscow 119021, RussiaAD  - Mendeleyev Univ Chem Technol, 9 Miusskaya Sq, Moscow 125190, RussiaAD  - Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, TaiwanAD  - Blokhin Natl Med Res Ctr Oncol, 24 Kashirskoye Shosse, Moscow 115478, RussiaAD  - Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Leuven, BelgiumAD  - ITMO Univ, 49 Kronverksky Ave, St Petersburg 197101, RussiaAD  - All India Inst Med Sci, Biophys, New Delhi 110029, IndiaAD  - China Med Univ, Grad Inst Basic Med, Taichung 40402, TaiwanAD  - China Med Univ Hosp, Dept Med Res, Taichung 40402, TaiwanAD  - Asia Univ, Dept Biotechnol, Taichung 41354, TaiwanC3  - Russian Academy of SciencesC3  - Gause Institute of New AntibioticsC3  - Mendeleev University of Chemical Technology of RussiaC3  - National Chung Hsing UniversityC3  - KU LeuvenC3  - ITMO UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - China Medical University TaiwanC3  - China Medical University TaiwanC3  - China Medical University Hospital - TaiwanC3  - Asia University TaiwanPU  - ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI  - ISSY-LES-MOULINEAUX
PA  - 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
DA  - MAR 25
PY  - 2018
VL  - 148
SP  - 128
EP  - 139
DO  - 10.1016/j.ejmech.2018.02.027
AN  - WOS:000428824700011
ER  -

TY  - JOUR
AU  - Vinny, PW
AU  - Vishnu, VY
AU  - Srivastava, MVP
TI  - Thrombectomy 6 to 24 Hours after Stroke
T2  - NEW ENGLAND JOURNAL OF MEDICINE
AD  - Indian Naval Hosp Ship Asvini, Bombay, Maharashtra, IndiaAD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MASSACHUSETTS MEDICAL SOC
PI  - WALTHAM
PA  - WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
DA  - MAR 22
PY  - 2018
VL  - 378
IS  - 12
SP  - 1161
EP  - 1161
DO  - 10.1056/NEJMc1801530
AN  - WOS:000427942300017
ER  -

TY  - JOUR
AU  - Pal, J
AU  - Patil, V
AU  - Kumar, A
AU  - Kaur, K
AU  - Sarkar, C
AU  - Somasundaram, K
TI  - Loss-of-Function Mutations in Calcitonin Receptor (<i>CALCR</i>) Identify Highly Aggressive Glioblastoma with Poor Outcome
T2  - CLINICAL CANCER RESEARCH
KW  - PROTEIN-COUPLED RECEPTORS
KW  - CELL LUNG-CANCER
KW  - WHOLE EXOME
KW  - ACTIVATION
KW  - PATHWAYS
KW  - GROWTH
KW  - EXPRESSION
KW  - LANDSCAPE
AB  - Purpose: Despite significant advances in the understanding of the biology, the prognosis of glioblastoma (GBM) remains dismal. The objective was to carry out whole-exome sequencing (WES) of Indian glioma and integrate with that of TCGA to find clinically relevant mutated pathways.
   Experimental Design: WES of different astrocytoma samples (n = 42; Indian cohort) was carried out and compared with that of TCGA cohort. An integrated analysis of mutated genes from Indian and TCGA cohorts was carried out to identify survival association of pathways with genetic alterations. Patient-derived glioma stem-like cells, glioma cell lines, and mouse xenograft models were used for functional characterization of calcitonin receptor (CALCR) and establish it as a therapeutic target.
   Results: A similar mutation spectrum between the Indian cohort and TCGA cohort was demonstrated. An integrated analysis identified GBMs with defective neuroactive ligand-receptor interaction pathway (n = 23; 9.54%) that have significantly poor prognosis (P < 0.0001). Furthermore, GBMs with mutated calcitonin receptor (CALCR) or reduced transcript levels predicted poor prognosis. Exogenously added calcitonin (CT) inhibited various properties of glioma cells and pro-oncogenic signaling pathways in a CALCR-dependent manner. Patient-derived mutations in CALCR abolished these functions with the degree of loss of function negatively correlating with patient survival. WT CALCR, but not the mutant versions, inhibited Ras-mediated transformation of immortalized astrocytes in vitro. Furthermore, calcitonin inhibited patient-derived neurosphere growth and in vivo glioma tumor growth in a mouse model.
   Conclusions: We demonstrate CT-CALCR signaling axis is an important tumor suppressor pathway in glioma and establish CALCR as a novel therapeutic target for GBM. (C) 2017 AACR.
AD  - Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore, Karnataka, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - Indian Institute of Science (IISC) - BangaloreC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ASSOC CANCER RESEARCH
PI  - PHILADELPHIA
PA  - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
DA  - MAR 15
PY  - 2018
VL  - 24
IS  - 6
SP  - 1448
EP  - 1458
DO  - 10.1158/1078-0432.CCR-17-1901
AN  - WOS:000427627400022
ER  -

TY  - JOUR
AU  - Roychoudhury, A
AU  - Prateek, A
AU  - Basu, S
AU  - Jha, SK
TI  - Preparation and characterization of reduced graphene oxide supported nickel oxide nanoparticle-based platform for sensor applications
T2  - JOURNAL OF NANOPARTICLE RESEARCH
KW  - NiO nanoparticles
KW  - Reduced graphene oxide
KW  - Dopamine
KW  - Epinephrine
KW  - Simultaneous electrochemical detection
KW  - GLASSY-CARBON ELECTRODE
KW  - CHEMILUMINESCENCE DETECTION
KW  - VOLTAMMETRIC DETERMINATION
KW  - DOPAMINE
KW  - EPINEPHRINE
KW  - ACID
KW  - ELECTROCHEMISTRY
KW  - NOREPINEPHRINE
KW  - PERFORMANCE
KW  - NANOTUBES
AB  - A nanostructured composite film comprising reduced graphene oxide (rGO) and nickel oxide (NiO) nanoparticles (NPs) has been prepared and utilized for development of a simple yet efficient sensor for detection of dopamine and epinephrine in a single run. The hybrid material rGO-NiO nanocomposite was synthesized chemically, and the formation of nanocomposite was confirmed via X-ray diffraction (XRD), transmission electron microscopy (TEM), Raman, UV-Vis, and Fourier transform infrared (FTIR) spectroscopic techniques. The incorporation of NiO NPs on rGO support was found to provide improved sensing characteristics at electrode interface due to enhanced electron mobility on rGO sheet and high catalytic activity of NiO NPs. Subsequently, the synthesized rGO-NiO nanocomposite was deposited onto indium tin oxide (ITO)-coated glass substrate by simple drop-casting method, and the electrode was characterized through atomic force microscopy (AFM) and scanning electron microscopic (SEM) studies. After optimization of experimental conditions electrochemically for its high sensitivity, the fabricated rGO-NiO/ITO electrode was used for simultaneous detection of dopamine and epinephrine by square wave voltammetry (SWV) method. The results showed high sensitivity of 0.545 and 0.638 mu A/mu M for dopamine and epinephrine respectively in a broad linear range of 0.5-50 mu M. Moreover, remarkable detection limits of 0.495 and 0.423 mu M were found for dopamine and epinephrine, and the developed sensor exhibited a wide separation of 380 mV between the respective detection peaks of dopamine and epinephrine. Beside this, the proposed sensor was successfully applied in presence of high concentration of interfering agents, ascorbic acid and uric acid, and validated with real serum samples.
AD  - Indian Inst Technol Delhi, Ctr Biomed Engn, Hauz Khas, New Delhi 110016, IndiaAD  - All India Inst Med Sci, Dept Biomed Engn, New Delhi 110029, IndiaAD  - Indian Inst Technol Delhi, Dept Chem Engn, Hauz Khas, New Delhi 110016, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiPU  - SPRINGER
PI  - DORDRECHT
PA  - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
DA  - MAR 12
PY  - 2018
VL  - 20
IS  - 3
C7  - 70
DO  - 10.1007/s11051-018-4173-y
AN  - WOS:000427322500002
ER  -

TY  - JOUR
AU  - Karthikeyan, G
TI  - Direct visualisation of thrombi for diagnosis of tissue valve thrombosis
T2  - LANCET
KW  - TRANSESOPHAGEAL ECHOCARDIOGRAPHY
AD  - All India Inst Med Sci, Dept Cardiol, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - MAR 10
PY  - 2018
VL  - 391
IS  - 10124
SP  - 938
EP  - 938
DO  - 10.1016/S0140-6736(18)30537-3
AN  - WOS:000427363100025
ER  -

TY  - JOUR
AU  - Giri, AK
AU  - Parekatt, V
AU  - Dwivedi, OP
AU  - Banerjee, P
AU  - Bandesh, K
AU  - Prasad, G
AU  - Tandon, N
AU  - Bharadwaj, D
TI  - Common variants of <i>ARID1A</i> and <i>KAT2B</i> are associated with obesity in Indian adolescents
T2  - SCIENTIFIC REPORTS
KW  - BODY-MASS INDEX
KW  - EPIGENETICS
KW  - OVERWEIGHT
KW  - CHILDHOOD
KW  - MUTATIONS
KW  - GENETICS
KW  - CHILDREN
KW  - LOCI
AB  - Obesity involves alterations in transcriptional programs that can change in response to genetic and environmental signals through chromatin modifications. Since chromatin modifications involve different biochemical, neurological and molecular signaling pathways related to energy homeostasis, we hypothesize that genetic variations in chromatin modifier genes can predispose to obesity. Here, we assessed the associations between 179 variants in 35 chromatin modifier genes and overweight/obesity in 1283 adolescents (830 normal weight and 453 overweight/obese). This was followed up by the replication analysis of associated signals (18 variants in 8 genes) in 2247 adolescents (1709 normal weight and 538 overweight/obese). Our study revealed significant associations of two variants rs6598860 (OR = 1.27, P = 1.58 x 10(-4)) and rs4589135 (OR = 1.22, P = 3.72 x 10(-4)) in ARID1A with overweight/obesity. We also identified association of rs3804562 (beta = 0.11, P = 1.35 x 10(-4)) in KAT2B gene with BMI. In conclusion, our study suggests a potential role of ARID1A and KAT2B genes in the development of obesity in adolescents and provides leads for further investigations.
AD  - CSIR, Inst Genom & Integrat Biol, Genom & Mol Med Unit, Sukhdev Vihar, Mathura Rd, New Delhi 110025, IndiaAD  - CSIR, Inst Genom & Integrat Biol Campus, Acad Sci & Innovat Res, Sukhdev Vihar, Mathura Rd, New Delhi 110025, IndiaAD  - All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi 110608, IndiaAD  - Jawaharlal Nehru Univ, Sch Biotechnol, Syst Genom Lab, New Mehrauli Rd, Delhi 110067, IndiaC3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - CSIR - Institute of Genomics & Integrative Biology (IGIB)C3  - Council of Scientific & Industrial Research (CSIR) - IndiaC3  - Academy of Scientific & Innovative Research (AcSIR)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jawaharlal Nehru University, New DelhiPU  - NATURE PORTFOLIO
PI  - BERLIN
PA  - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
DA  - MAR 2
PY  - 2018
VL  - 8
C7  - 3964
DO  - 10.1038/s41598-018-22231-x
AN  - WOS:000426467900063
ER  -

TY  - JOUR
AU  - Aggarwal, A
AU  - Garg, K
AU  - Gulati, P
TI  - Letter to the Editor Regarding "Optic Nerve Meningioma Mimicking Cavernous Hemangioma"
T2  - WORLD NEUROSURGERY
AD  - Doctor Gulati Imaging Inst, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - MAR
PY  - 2018
VL  - 111
SP  - 435
EP  - 435
DO  - 10.1016/j.wneu.2017.12.083
AN  - WOS:000432908700199
ER  -

TY  - JOUR
AU  - Agrawal, S
AU  - Kapil, A
AU  - Dhawan, B
AU  - Sharma, BS
TI  - <i>Burkholderia cepacia</i>: An uncommon cause of bilateral primary psoas abscesses in a patient with a Pott spine that cannot be ignored
T2  - NATIONAL MEDICAL JOURNAL OF INDIA
AD  - All India Inst Med Sci, Dept Microbiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ALL INDIA INST MEDICAL SCIENCES
PI  - NEW DELHI
PA  - ANSARI NAGAR, NEW DELHI 110 029, INDIA
DA  - MAR-APR
PY  - 2018
VL  - 31
IS  - 2
DO  - 10.4103/0970-258X.253158
AN  - WOS:000460206700021
ER  -

TY  - JOUR
AU  - Arora, S
AU  - Gupta, P
AU  - Arya, VK
AU  - Bhatia, N
TI  - Efficacy of preoxygenation using tidal volume breathing: a comparison of Mapleson A, Bain's and Circle system
T2  - REVISTA BRASILEIRA DE ANESTESIOLOGIA
KW  - Anesthesia
KW  - Preoxygenation
KW  - Tidal volume
KW  - Breathing systems
KW  - PATIENT
KW  - OXYGENATION
AB  - Background: Efficacy of preoxygenation depends upon inspired oxygen concentration, its flow rate, breathing system configuration and patient characteristics. We hypothesized that in actual clinical scenario, where breathing circuit is not primed with 100% oxygen, patients may need more time to achieve EtO2 > 90%, and this duration may be different among various breathing systems. We thus studied the efficacy of preoxygenation using unprimed Mapleson A, Bain's and Circle system with tidal volume breathing at oxygen flow rates of 5 L.min(-1) and 10 L.min-1.
   Methods: Patients were randomly allocated into one of the six groups, wherein they were pre-oxygenated using either Mapleson A, Bain's or Circle system at 02 flow rate of either 5 L.min(-1) or 10 L.min(-1). The primary outcome measure of our study was the time taken to achieve EtO2 > 90% at 5 and 10 L.min(-1) flow rates.
   Results: At oxygen flow rate of 5 L.min-1, time to reach EtO2 > 90% was significantly longer with Bain's system (3.7 +/- 0.67 min) than Mapleson A and Circle system (2.9 +/- 0.6, 3.3 +/- 0.97 min, respectively). However at oxygen flow rate of 10 L.min(-1) this time was significantly shorter and comparable among all the three breathing systems (2.33 +/- 0.38 min with Mapleson, 2.59 +/- 0.50 min with Bain's and 2.60 +/- 0.47 min with Circle system).
   Conclusions: With spontaneous normal tidal volume breathing at oxygen flow rate of 5 L.min(-1), Mapleson A can optimally preoxygenate patients within 3 min while Bain's and Circle system require more time. However at O-2 flow rate of 10 L.min(-1) all the three breathing systems are capable of optimally preoxygenating the patients in less than 3 min. (C) 2017 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda.
AD  - PGIMER, Dept Anaesthesia & Intens Care, Chandigarh, IndiaAD  - AIIMS, New Delhi, IndiaC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - MAR-APR
PY  - 2018
VL  - 68
IS  - 2
SP  - 128
EP  - 134
DO  - 10.1016/j.bjan.2017.09.006
AN  - WOS:000426733600003
ER  -

TY  - JOUR
AU  - Badhwar, S
AU  - Chandran, DS
AU  - Jaryal, AK
AU  - Narang, R
AU  - Deepak, KK
TI  - Regional arterial stiffness in central and peripheral arteries is differentially related to endothelial dysfunction assessed by brachial flow-mediated dilation in metabolic syndrome
T2  - DIABETES & VASCULAR DISEASE RESEARCH
KW  - Arterial stiffness
KW  - pulse wave velocity
KW  - endothelial dysfunction
KW  - metabolic syndrome
KW  - vascular function
KW  - flow-mediated dilation
KW  - CARDIOVASCULAR-DISEASE ENTERPRISES
KW  - PULSE-WAVE VELOCITY
KW  - IN-VIVO
KW  - MAJOR SHAREHOLDERS
KW  - BLOOD-PRESSURE
KW  - NITRIC-OXIDE
KW  - AGE
KW  - ATHEROSCLEROSIS
KW  - OBESITY
KW  - HEART
AB  - The interrelationship between endothelial function and arterial stiffness may be different for central and peripheral arteries due to their structural and functional differences. The study aims to assess the interrelationship between central and peripheral vascular function and haemodynamics in metabolic syndrome. Thirty-seven patients [63.0 (57.5-66.0) years, 68.4% males] of metabolic syndrome (National Cholesterol Education Program - Adult Treatment Panel-III criteria) were studied. Carotid-femoral, carotid-radial pulse wave velocity and augmentation index (AI(x)@75) were assessed using applanation tonometry. Endothelial function was evaluated by brachial flow-mediated dilation using B-mode ultrasonography. Central and peripheral pressures were measured by radial tonometry and sphygmomanometer, respectively. Carotid-radial pulse wave velocity correlated significantly with peripheral diastolic blood pressure (r=0.33, p=0.04) and inversely with flow-mediated dilation (r=-0.61, p=0.0001). AI(x)@75 correlated significantly with carotid-femoral pulse wave velocity (r=0.35, p=0.03) and with aortic pulse pressure (r=0.43, p=0.01). In principal component analysis, an inverse relationship was observed between flow-mediated dilation and carotid-radial pulse wave velocity but not with carotid-femoral pulse wave velocity. Regional arterial stiffness assessed by pulse wave velocity in central-elastic and peripheral-muscular arteries differentially relates to endothelial dysfunction. The central arteries might be predominantly influenced by endothelial dysfunction-induced structural changes, while the peripheral arteries are majorly affected by functional alterations.
AD  - All India Inst Med Sci, Dept Physiol, Auton & Vasc Funct Lab, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Cardiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SAGE PUBLICATIONS LTD
PI  - LONDON
PA  - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
DA  - MAR
PY  - 2018
VL  - 15
IS  - 2
SP  - 106
EP  - 113
DO  - 10.1177/1479164117748840
AN  - WOS:000429787200002
ER  -

TY  - JOUR
AU  - Bajaj, J
AU  - Tripathi, M
AU  - Dwivedi, R
AU  - Sapra, S
AU  - Gulati, S
AU  - Garg, A
AU  - Tripathi, M
AU  - Bal, CS
AU  - Chandra, SP
TI  - Does surgery help in reducing stigma associated with drug refractory epilepsy in children?
T2  - EPILEPSY & BEHAVIOR
KW  - Epilepsy
KW  - Neurological rehabilitation
KW  - Social stigma
KW  - Surgery
KW  - QUALITY-OF-LIFE
KW  - INDIA
AB  - Introduction: Epilepsy has several comorbidilies and associated stigma. Stigma associated with epilepsy is well known and prevalent worldwide. Surgical treatment is an established treatment for drug refractory epilepsy. Following surgery in children, it is possible that the stigma may reduce, but such an effect has not been studied earlier.
   Materials and methods: Analysis of prospectively collected data was performed for pediatric patients at a single tertiary center for treating epilepsy. Child stigma scale, as described by Austin et al., was used to evaluate stigma both pre- and postoperatively. Analysis was done using Paired t test.
   Results: In this study, following surgery, there was significant reduction of stigma (P < 0.001). This was proportional to the reduction in seizures, though there were 9 (30%) patients, who due to persistent neurodisability did not have any reduction of stigma despite having good seizure outcome.
   Conclusion: Surgery in drug-resistant epilepsy helps in reducing stigma. Seizure reduction is probably not the only factor responsible for a change in stigma outcome. (C) 2013 Elsevier Inc All rights reserved.
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neuroradiol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Nucl Med, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ACADEMIC PRESS INC ELSEVIER SCIENCE
PI  - SAN DIEGO
PA  - 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
DA  - MAR
PY  - 2018
VL  - 80
SP  - 197
EP  - 201
DO  - 10.1016/j.yebeh.2018.01.010
AN  - WOS:000428016400031
ER  -

TY  - JOUR
AU  - Bandivadekar, P
AU  - Agarwal, T
AU  - Temkar, S
TI  - Shave Excision With Keratopigmentation for Limbal Dermoid
T2  - EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE
KW  - Limbal dermoid
KW  - Tattooing
KW  - Keratopigmentation
KW  - Cosmesis
KW  - AMNIOTIC MEMBRANE TRANSPLANTATION
KW  - SURGICAL-MANAGEMENT
KW  - CORNEAL
AB  - Objectives: To describe a modified technique of corneal tattooing for concomitant cosmetic rehabilitation in eyes with limbal dermoid.
   Study: Case series.
   Methods: Three patients between 12 and 20 years of age with grade I limbal dermoid underwent shave excision with corneal tattooing. All patients had dark brown irides. Chemical keratopigmentation was performed over the bed using 2% gold chloride with 1% hydrazine hydrate as reducing agent to yield a dark brown color. Bandage contact lens was applied.
   Results: Epithelium over the operated area healed by day 10. Visual acuity was maintained in all eyes with minimal change in keratometry. The dye was well retained in the tattooed area at 1 year. No complications such as infection, pseudopterygium, or local limbal stem-cell deficiency were observed.
   Conclusion: Corneal tattooing along with simple shave excision provides good cosmetic results in cases of limbal dermoids.
AD  - Doctor Eye Inst, Dept Ophthalmol, Div Cornea & Refract Surg, 1st Floor Spenta Mansion,SV Rd, Bombay 400058, Maharashtra, IndiaAD  - All India Inst Med Sci, Rajendra Prasad Inst Ophthalm Sci, Dept Ophthalmol, Div Cornea & Refract Surg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - MAR
PY  - 2018
VL  - 44
IS  - 2
SP  - E7
EP  - E9
DO  - 10.1097/ICL.0000000000000257
AN  - WOS:000441175400001
ER  -

TY  - JOUR
AU  - Baranwal, AK
AU  - Goswami, S
AU  - Bhat, DK
AU  - Kaur, G
AU  - Agarwal, SK
AU  - Mehra, NK
TI  - Soluble Major Histocompatibility Complex Class I related Chain A (sMICA) levels influence graft outcome following Renal Transplantation
T2  - HUMAN IMMUNOLOGY
KW  - Soluble MICA
KW  - Kidney transplantation
KW  - Acute cellular rejection
KW  - Antibody mediated rejection
KW  - Sandwich ELISA
KW  - HEART ALLOGRAFT-REJECTION
KW  - ANTI-MICA ANTIBODIES
KW  - T-CELLS
KW  - NK CELLS
KW  - EXPRESSION
KW  - NKG2D
KW  - ACTIVATION
KW  - MOLECULES
KW  - RECEPTOR
KW  - LIGANDS
AB  - Background Since soluble isoforms of MICA play an important role in modulating the immune response, we evaluated a possible correlation between their levels and development of acute rejection following renal transplantation.
   Methods: Serum samples collected at pre- and different time points post-transplant from 137 live related donor renal transplant recipients were evaluated retrospectively for sMICA levels and for the presence of MICA anti-bodies. Samples from 30 healthy volunteers were also tested as controls.
   Results: Significantly higher levels of sMICA were observed in the pretransplant sera of allograft recipients as compared to healthy controls. Patients with acute cellular rejection experienced a significant fall in their levels at the time of diagnosis as compared to their pretransplant values and posttransplant follow up time points (p=.01,.003,.005 and.04 respectively at pre vs biopsy (Bx), POD7 vs Bx, POD 30 vs Bx, POD 90 vs Bx). However, no such difference was noted in patients undergoing antibody mediated rejection. Further the study did not reveal any correlation on the presence/absence of MICA antibodies with either an increase or decrease in 5M1CA levels.
   Conclusions: Estimating circulating levels of soluble MICA could provide useful information of prognostic importance in assessing graft outcome following renal transplantation.
AD  - All India Inst Med Sci, Dept Transplant Immunol & Immunogenet, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Nephrol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - MAR
PY  - 2018
VL  - 79
IS  - 3
SP  - 160
EP  - 165
DO  - 10.1016/j.humimm.2018.01.001
AN  - WOS:000427809700005
ER  -

TY  - JOUR
AU  - Behari, M
TI  - Movement disorders: The genesis and progression in India: Neurological perspective
T2  - NEUROLOGY INDIA
AD  - Fortis Flt Lt Rajan Dhall Hosp, Dept Neurol, Vasant Kunj, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - MAR-APR
PY  - 2018
VL  - 66
SP  - S3
EP  - S4
DO  - 10.4103/0028-3886.226452
AN  - WOS:000426971400002
ER  -

TY  - JOUR
AU  - Bhadada, SK
AU  - Arya, AK
AU  - Mukhopadhyay, S
AU  - Khadgawat, R
AU  - Sukumar, S
AU  - Lodha, S
AU  - Singh, DN
AU  - Sathya, A
AU  - Singh, P
AU  - Bhansali, A
TI  - Primary hyperparathyroidism: insights from the Indian PHPT registry
T2  - JOURNAL OF BONE AND MINERAL METABOLISM
KW  - Hypercalcaemia
KW  - Multicentre study
KW  - Primary hyperparathyroidism
KW  - Registry
KW  - ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM
KW  - SYMPTOMATIC PRIMARY HYPERPARATHYROIDISM
KW  - ABNORMAL PARATHYROID-GLANDS
KW  - CALCIUM-SENSING RECEPTOR
KW  - VITAMIN-D DEFICIENCY
KW  - NORTH-INDIA
KW  - DISEASE
KW  - SURGERY
KW  - ULTRASONOGRAPHY
KW  - GENDER
AB  - The presentation of primary hyperparathyroidism (PHPT) is variable throughout the world. The present study explored retrospective data submitted to the Indian PHPT registry (http://www. indianphptregistry. com) between July 2005 and June 2015 from 5 centres covering four different geographical regions. The clinical, biochemical, radiological and histopathological characteristics of PHPT patients across India were analysed for similarity and variability across the centres. A total of 464 subjects (137 men and 327 women) with histopathologically proven PHPT were analysed. The mean age was 41 +/- 14 years with a female: male ratio of 2.4: 1. The majority (95%) of patients were symptomatic. Common clinical manifestations among all the centres were weakness and fatigability (58.7%), bone pain (56%), renal stone disease (31%), pancreatitis (12.3%) and gallstone disease (11%). Mean serum calcium, parathyroid hormone and inorganic phosphorus levels were 11.9 +/- 1.6 mg/dL, 752.4 +/- 735.2 pg/mL and 2.8 +/- 0.9 mg/dL, respectively. Sestamibi scanning had better sensitivity than ultrasonography in the localisation of parathyroid adenoma; however, when these two modalities were combined, 93% of the cases were correctly localised. Mean parathyroid adenoma weight was 5.6 +/- 6.5 g (0.154 g). It was concluded that the majority of PHPT patients within India are still mainly symptomatic with > 50% of patients presenting with bone disease and one-third with renal impairment. Compared to Western countries, Indian patients with PHPT are younger, biochemical abnormalities are more severe, and adenoma weight is higher. As our observation is largely derived from a tertiary care hospital (no routine screening of serum calcium level), the results do not reflect racial differences in susceptibility to PHPT.
AD  - Postgrad Inst Med Educ & Res PGIMER, Dept Endocrinol, Chandigarh 160012, IndiaAD  - Inst Postgrad Med Educ & Res IPGMER, Dept Endocrinol, Kolkata, IndiaAD  - AIIMS, Dept Endocrinol & Metab, New Delhi, IndiaAD  - Fortis Hosp, Dept Endocrinol, Jaipur, Rajasthan, IndiaAD  - MMM Hosp, Vijaya Hosp, Chennai, Tamil Nadu, IndiaC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhC3  - Institute of Post Graduate Medical Education & Research (IPGMER), KolkataC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER JAPAN KK
PI  - TOKYO
PA  - CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN
DA  - MAR
PY  - 2018
VL  - 36
IS  - 2
SP  - 238
EP  - 245
DO  - 10.1007/s00774-017-0833-8
AN  - WOS:000426280600011
ER  -

TY  - JOUR
AU  - Bhargava, A
AU  - Tamrakar, S
AU  - Aglawe, A
AU  - Lad, H
AU  - Srivastava, RK
AU  - Mishra, DK
AU  - Tiwari, R
AU  - Chaudhury, K
AU  - Goryacheva, IY
AU  - Mishra, PK
TI  - Ultrafine particulate matter impairs mitochondrial redox homeostasis and activates phosphatidylinositol 3-kinase mediated DNA damage responses in lymphocytes
T2  - ENVIRONMENTAL POLLUTION
KW  - Air pollution
KW  - Mitochondrial dysfunction
KW  - Oxidative stress
KW  - Immunotoxicity
KW  - Environmental health
KW  - OUTDOOR AIR-POLLUTION
KW  - LONG-TERM EXPOSURE
KW  - OXIDATIVE STRESS
KW  - INFLAMMATORY RESPONSE
KW  - GLOBAL BURDEN
KW  - ROAD DUST
KW  - PM2.5
KW  - DYSFUNCTION
KW  - TOXICITY
KW  - CADMIUM
AB  - Particulate matter (PM), broadly defined as coarse (2.5-10 mu m), fine (0.1-2.5 mu m) and ultrafine particles (<= 0.1 mu m), is a major constituent of ambient air pollution. Recent studies have linked PM exposure (coarse and fine particles) with several human diseases including cancer. However, the molecular mechanisms underlying ultrafine PM exposure induced cellular and sub-cellular repercussions are ill-defined. Since mitochondria are one of the major targets of different environmental pollutants, we herein aimed to understand the molecular repercussion of ultrafine PM exposure on mitochondrial machinery in peripheral blood lymphocytes. Upon comparative analysis, a significantly higher DCF fluorescence was observed in ultrafine PM exposed cells that confirmed the strong pro-oxidant nature of these particles. In addition, the depleted activity of antioxidant enzymes, glutathione reductase and superoxide dismutase suggested the strong association of ultrafine PM with oxidative stress. These results further coincided with mitochondrial membrane depolarization, altered mitochondrial respiratory chain enzyme activity and decline in mtDNA copy number. Moreover, the higher accumulation of DNA damage response proteins (gamma H2AX, pATM, p-p53), suggested that exposure to ultrafine PM induces DNA damage and triggers phosphatidylinositol 3 kinase mediated response pathway. Further, the alterations in mitochondrial machinery and redox balance among ultrafine PM exposed cells were accompanied by a considerably elevated pro-inflammatory cytokine response. Interestingly, the lower apoptosis levels observed in ultrafine particle treated cells suggest the possibility that the marked alterations may lead to the impairment of mitochondrial-nuclear cross talk. Together, our results showed that ultrafine PM, because of their smaller size possesses significant ability to disturb mitochondrial redox homeostasis and activates phosphatidylinositol 3 kinase mediated DNA damage response pathway, an unknown molecular paradigm of ultrafine PM exposure. Our findings also indicate that maneuvering through the mitochondrial function might be a viable, indirect method to modulate lymphocyte homeostasis in air pollution associated immune disorders. (C) 2017 Elsevier Ltd. All rights reserved.
AD  - ICMR Natl Inst Res Environm Hlth, Dept Mol Biol, Kamla Nehru Hosp Bldg,Gandhi Med Coll Campus, Bhopal 462001, IndiaAD  - All India Inst Med Sci, Dept Biotechnol, New Delhi, IndiaAD  - Narsee Moonjee Inst Management Studies, Sch Pharm & Technol Management, Shirpur, IndiaAD  - Indian Inst Technol, Sch Med Sci & Technol, Kharagpur, W Bengal, IndiaAD  - Saratov NG Chernyshevskii State Univ, Dept Gen & Inorgan Chem, Saratov, RussiaC3  - Indian Council of Medical Research (ICMR)C3  - ICMR - National Institute for Research in Environmental Health (NIREH)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - SVKM's NMIMS (Deemed to be University)C3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - KharagpurC3  - Saratov State UniversityPU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - MAR
PY  - 2018
VL  - 234
SP  - 406
EP  - 419
DO  - 10.1016/j.envpol.2017.11.093
AN  - WOS:000426225100042
ER  -

TY  - JOUR
AU  - Chawla, R
AU  - Pujari, A
AU  - Mittal, K
AU  - Rakheja, V
AU  - Markan, A
TI  - Retinal Arteriovenous Malformation Assessment Using Swept-Source OCT Angiography
T2  - OPHTHALMIC SURGERY LASERS & IMAGING RETINA
KW  - WYBURN-MASON-SYNDROME
KW  - BRAIN
AB  - Swept-source optical coherence tomography angiography (SS-OCTA) is a promising new imaging modality for assessing retinal and choroidal vasculature. Faster scanning speed, large number of A-scan acquisition, and enhanced depth penetration has enhanced the detailed analysis of retinal layers. The authors discuss SS-OCTA features of a rare case of retinal arteriovenous malformation. Image analysis revealed the anomalous large-caliber vessels occupying up to the entire retinal thickness with associated echolucent changes in the inner retinal layers surrounding the retinal vessels, along with disruption of the outer retinal layers, including the inner/outer segments of photoreceptors beneath the large tortuous vessels outside the foveola in absence of any capillary nonperfusion areas or lack of significant macular edema. At the fovea, the outer retinal layers were intact due to a smaller caliber and less-deep extension of the anomalous vessels.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Room 212,Second Floor, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SLACK INC
PI  - THOROFARE
PA  - 6900 GROVE RD, THOROFARE, NJ 08086 USA
DA  - MAR
PY  - 2018
VL  - 49
IS  - 3
SP  - 216
EP  - 219
DO  - 10.3928/23258160-20180221-12
AN  - WOS:000428278300013
ER  -

TY  - JOUR
AU  - Chopra, S
AU  - Kaur, H
AU  - Pandey, RM
AU  - Nehra, A
TI  - Development of neuropsychological evaluation screening tool: An education-free cognitive screening instrument
T2  - NEUROLOGY INDIA
KW  - Cognition
KW  - illiterates
KW  - India
KW  - neuropsychological assessment
KW  - neuropsychological screening
KW  - MINI-MENTAL-STATE
KW  - TRAUMATIC BRAIN-INJURY
KW  - ALZHEIMERS-DISEASE
KW  - PARKINSONS-DISEASE
KW  - ASSESSMENT SCALE
KW  - 7-MINUTE SCREEN
KW  - YOUNG-ADULTS
KW  - TEST BATTERY
KW  - DEMENTIA
KW  - IMPAIRMENT
AB  - Background: Due to the paucity of quick, cognitive screening tools available in India that are independent of cultural and educational influences, a 6-item paper and pencil test, covering areas of memory, executive functioning, attention, and visuospatial ability domains - the Neuropsychological Evaluation Screening Tool (NEST) was developed.
   Aim and Method: NEST was administered to 84 healthy controls to analyze, revise, and review items. In the second phase, 408 patients, above 16 years of age, with their educational level ranging from being illiterate to having greater than 25 years of education, with various neurological and psychiatric conditions were independently administered NEST, Hindi Mental State Examination (HMSE), and a detailed cognitive evaluation using PGI Memory Scale (PGIMS).
   Results: Using receiver operating characteristics analysis for 341 patients, >= 3 was identified as the optimum cut-off for NEST. NEST could correctly classify 87.9% of the patients with an impaired vs. an intact cognition. The diagnostic characteristics of NEST with PGIMS were sensitivity (95% CI): 94.78% (91.1, 97.3); specificity (95% CI): 60.31% (51.3, 68.7); positive predictive value (95% CI): 80.74% (78.1, 93.0); and negative predictive value (95% CI): 86.81% (75.6, 85.3). NEST had an 82.5% agreement (95% CI: 78.1, 86.2) with PGIMS. On the other hand, the diagnostic characteristics of HMSE with PGIMS were sensitivity (95% CI): 73.79% (67.5, 79.3); specificity (95% CI): 82.44% (74.8, 88.5); positive predictive value (95% CI): 88.02% (82.5, 92.2); and negative predictive value (95% CI): 64.3% (56.5, 71.5). HMSE had a 76.95% (95% CI: 72.2, 81.1) agreement with PGIMS.
   Conclusions: NEST has better sensitivity compared to HMSE for detecting cognitive impairment when compared to a detailed evaluation at all educational levels.
AD  - All India Inst Med Sci, Dept Clin Neuropsychol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - MAR-APR
PY  - 2018
VL  - 66
IS  - 2
SP  - 391
EP  - 399
DO  - 10.4103/0028-3886.227304
AN  - WOS:000427989900021
ER  -

TY  - JOUR
AU  - Choudhury, MI
AU  - Singh, P
AU  - Juneja, R
AU  - Tuli, S
AU  - Deepak, KK
AU  - Prasad, A
AU  - Roy, S
TI  - A Novel Modular Tonometry-Based Device to Measure Pulse Pressure Waveforms in Radial Artery
T2  - JOURNAL OF MEDICAL DEVICES-TRANSACTIONS OF THE ASME
KW  - TRANSLUMINAL CORONARY ANGIOPLASTY
KW  - BLOOD-PRESSURE
KW  - NONINVASIVE MEASUREMENT
KW  - RECORDING FORCE
KW  - VALIDATION
KW  - STIFFNESS
KW  - DISEASE
KW  - SENSOR
AB  - The paper presents the development of a new device for measuring continuous pulse pressure waveforms (PPW) from the radial artery via applanation tonometry. The development focuses on improved accuracy, open and affordable design using off-the-shelf components, and greater user control in setting operational and calibration parameters to address user variability. The device design parameters are optimized through a tissue device interaction study based on a computational model. The design incorporates modular components and includes a sensor module for arterial flattening and pressure pick-up, a differential screw mechanism and a related algorithm for controlled stepwise motion and data collection during flattening, and a brace for wrist-flexion adjustment. Maximum pulse amplitude (PA) was used as an indicator of the optimum level of arterial flattening for recording the PPW. The PPW was observed to distort due to changes in parameters like gel-head placement, hold-down pressure (HDP), and wrist extension. The pressure waveforms collected using the device were validated using limited data against established products and showed good correlation within +/- 1.96 standard deviation of the mean difference in a Bland-Altman plot. This paper thus details the development of a simple and validated mechanical design to measure PPW using arterial tonometry.
AD  - Indian Inst Technol Delhi, Dept Appl Mech, Block 4,Acad Bldg, New Delhi 110016, IndiaAD  - All India Inst Med Sci, Dept Cardiol, Neurosurg & Cardiac Surg Bldg, New Delhi 110016, IndiaAD  - Indian Inst Technol Delhi, Ctr Appl Res Elect, Block 3,Acad Bldg, New Delhi 110016, IndiaAD  - All India Inst Med Sci, Dept Physiol, New Delhi 110016, IndiaAD  - South Dakota State Univ, Dept Mech Engn, Brookings, SD 57007 USAC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - South Dakota State UniversityPU  - ASME
PI  - NEW YORK
PA  - TWO PARK AVE, NEW YORK, NY 10016-5990 USA
DA  - MAR
PY  - 2018
VL  - 12
IS  - 1
C7  - 011011
DO  - 10.1115/1.4039010
AN  - WOS:000425355900011
ER  -

TY  - JOUR
AU  - Dhiman, A
AU  - Solanki, D
AU  - Bhasin, A
AU  - Das, A
AU  - Lahiri, U
TI  - An intelligent, adaptive, performance-sensitive, and virtual reality-based gaming platform for the upper limb
T2  - COMPUTER ANIMATION AND VIRTUAL WORLDS
KW  - physiology
KW  - stroke
KW  - upper limb
KW  - virtual reality
KW  - MOTOR REHABILITATION
KW  - STROKE REHABILITATION
KW  - FUNCTIONAL RECOVERY
KW  - SYSTEM
AB  - Stroke is a leading cause of adult disability, characterized by a spectrum of muscle weakness and movement abnormalities related to the upper limb. About 80% of individuals who had a stroke suffer from upper limb dysfunction. Conventional rehabilitation aims to improve one's ability to use paralyzed limbs through repetitive exercise under one-on-one supervision by physiotherapists. This poses difficulty given the limited availability of healthcare resources and the high cost of availing specialized services at healthcare centers, particularly in developing countries like India. Thus, the design of cost-effective, home-based, and technology-assisted individualized rehabilitation platform that can deliver real-time feedback on one's skill progress is critical. This paper describes the design of a novel, multimodal, virtual reality (VR)-based, and performance-sensitive exercise platform that can intelligently adapt its task presentation to one's performance. Here, we aim to address unilateral shoulder abduction and adduction that are essential for the performance of daily living activities. We designed an experimental study in which six individuals who had chronic stroke (post-stroke period: >6months) participated. While they interacted with our VR-based tasks, we recorded their physiological signals in a synchronized manner. Preliminary results indicate the potential of our VR-based, adaptive individualized system in the performance of individuals who had a stroke suffering from upper limb movement disorders.
AD  - Indian Inst Technol Gandhinagar, Dept Elect Engn, Gandhinagar 382355, Gujarat, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi 110029, IndiaAD  - AMRI Inst Neurosci, Dept Neurorehabil, Kolkata 700099, IndiaC3  - Indian Institute of Technology System (IIT System)C3  - Indian Institute of Technology (IIT) - GandhinagarC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - MAR-APR
PY  - 2018
VL  - 29
IS  - 2
C7  - e1800
DO  - 10.1002/cav.1800
AN  - WOS:000430170900002
ER  -

TY  - JOUR
AU  - Dubey, K
AU  - Srivastava, V
AU  - Dalal, K
TI  - <i>In vivo</i> automated quantification of thermally damaged human tissue using polarization sensitive optical coherence tomography
T2  - COMPUTERIZED MEDICAL IMAGING AND GRAPHICS
KW  - Optical coherence tomography
KW  - Machine learning
KW  - Thermal damaged tissue (human skin)
KW  - HUMAN SKIN
KW  - THERMOGRAPHIC ASSESSMENT
KW  - DIAGNOSIS
AB  - Over the decades numerous technologies have been performed for the quantification of skin injuries, but their poor sensitivity, specificity and accuracy limits their applications. Optical coherence tomography (OCT) can be potential tool for the identification but the modern high-speed OCT system acquires huge amount of data, which will be very time-consuming and tedious process for human interpretation. Our proposed method opens the possibility of fully automated quantitative analysis based on morphological features of thermally damaged tissue, which will become biomarker for the removal of non-viable skin. The proposed method is based on multi-level ensemble classifier by dissociating morphological features (A-line, B-scan, phase images) extracted from Polarization Sensitive Optical Coherence Tomography (PS-OCT) images. Our proposed classifier attained the average sensitivity, specificity and accuracy is 92.22%, 87.2% and 92.5%, respectively, in detecting the thermally damaged human skin. Moreover, we show that our classifier is one of the best possible classifier based on features extracted from PS-OCT images, which demonstrates the significance of PS-OCT data in detecting abnormality in human skin.
AD  - Thapar Univ, Dept Elect & Instrumentat Engn, Patinla, Punjab, IndiaAD  - All India Inst Med Sci, Dept Biophys, New Delhi, IndiaC3  - Thapar Institute of Engineering & TechnologyC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - PERGAMON-ELSEVIER SCIENCE LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
DA  - MAR
PY  - 2018
VL  - 64
SP  - 22
EP  - 28
DO  - 10.1016/j.compmedimag.2018.01.002
AN  - WOS:000426234300003
ER  -

TY  - JOUR
AU  - Fernandes-Rosa, FL
AU  - Daniil, G
AU  - Orozco, IJ
AU  - Göppner, C
AU  - El Zein, R
AU  - Jain, V
AU  - Boulkroun, S
AU  - Jeunemaitre, X
AU  - Amar, L
AU  - Lefebvre, H
AU  - Schwarzmayr, T
AU  - Strom, TM
AU  - Jentsch, TJ
AU  - Zennaro, MC
TI  - A gain-of-function mutation in the <i>CLCN2</i> chloride channel gene causes primary aldosteronism
T2  - NATURE GENETICS
KW  - SOMATIC MUTATIONS
KW  - PREVALENCE
KW  - ADENOMAS
KW  - VOLTAGE
KW  - ATP1A1
KW  - CELLS
AB  - Primary aldosteronism is the most common and curable form of secondary arterial hypertension. We performed whole-exome sequencing in patients with early-onset primary aldosteronism and identified a de novo heterozygous c.71G>A/p.Gly24Asp mutation in the CLCN2 gene, encoding the voltage-gated ClC-2 chloride channel(1), in a patient diagnosed at 9 years of age. Patch-clamp analysis of glomerulosa cells of mouse adrenal gland slices showed hyperpolarization-activated Cl- currents that were abolished in Clcn2(-/-) mice. The p.Gly24Asp variant, located in a well-conserved 'inactivation domain'(2,3), abolished the voltage- and time-dependent gating of ClC-2 and strongly increased Cl-conductance at resting potentials. Expression of ClC-2(Asp24) in adrenocortical cells increased expression of aldosterone synthase and aldosterone production. Our data indicate that CLCN2 mutations cause primary aldosteronism. They highlight the important role of chloride in aldosterone biosynthesis and identify ClC-2 as the foremost chloride conductor of resting glomerulosa cells.
AD  - Paris Cardiovasc Res Ctr, INSERM, UMRS 970, Paris, FranceAD  - Univ Paris 05, Sorbonne Paris Cite, Paris, FranceAD  - Hop Europeen Georges Pompidou, AP HP, Serv Genet, Paris, FranceAD  - Leibniz Forsch Inst Mol Pharmakol FMP, Berlin, GermanyAD  - Max Delbruck Centrum Mol Med MDC, Berlin, GermanyAD  - All India Inst Med Sci, Dept Pediat, Div Pediat Endocrinol, New Delhi, IndiaAD  - Hop Europeen Georges Pompidou, AP HP, Unite Hypertens Arterielle, Paris, FranceAD  - Normandie Univ, UNIROUEN, Rouen, FranceAD  - INSERM, DC2N, Rouen, FranceAD  - Univ Hosp Rouen, Dept Endocrinol Diabet & Metab Dis, Rouen, FranceAD  - Helmholtz Zentrum Munchen, Inst Human Genet, Neuherberg, GermanyAD  - Tech Univ Munich, Inst Human Genet, Munich, GermanyC3  - Universite Paris CiteC3  - Institut National de la Sante et de la Recherche Medicale (Inserm)C3  - Universite Paris CiteC3  - Assistance Publique Hopitaux Paris (APHP)C3  - Universite Paris CiteC3  - Hopital Universitaire Europeen Georges-Pompidou - APHPC3  - Helmholtz AssociationC3  - Max Delbruck Center for Molecular MedicineC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Assistance Publique Hopitaux Paris (APHP)C3  - Universite Paris CiteC3  - Hopital Universitaire Europeen Georges-Pompidou - APHPC3  - Universite de Rouen NormandieC3  - Universite de Rouen NormandieC3  - Institut National de la Sante et de la Recherche Medicale (Inserm)C3  - Universite de Rouen NormandieC3  - CHU de RouenC3  - Helmholtz AssociationC3  - Helmholtz-Center Munich - German Research Center for Environmental HealthC3  - Technical University of MunichPU  - NATURE PORTFOLIO
PI  - BERLIN
PA  - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
DA  - MAR
PY  - 2018
VL  - 50
IS  - 3
SP  - 355
EP  - +
DO  - 10.1038/s41588-018-0053-8
AN  - WOS:000427933400010
ER  -

TY  - JOUR
AU  - Gandedkar, NH
AU  - Koo, CS
AU  - Sharan, J
AU  - Chng, CK
AU  - Vaid, N
TI  - The temporary anchorage devices research terrain: Current perspectives and future forecasts!
T2  - SEMINARS IN ORTHODONTICS
KW  - ORTHODONTIC MINI-IMPLANTS
KW  - CORTICAL BONE THICKNESS
KW  - ANTERIOR OPEN BITE
KW  - SKELETAL ANCHORAGE
KW  - MINISCREW IMPLANTS
KW  - MAXILLARY PROTRACTION
KW  - HISTOMORPHOMETRIC EVALUATION
KW  - TITANIUM IMPLANTS
KW  - PRIMARY STABILITY
KW  - STAINLESS-STEEL
AB  - Temporary anchorage devices (TADs) have gained profound applications in contemporary orthodontic protocols to treat almost every genre of malocclusion; be it arising from dentoalveolar component, from a skeleton component, or a combination of both. The versatility of TADs has allowed the horizons of orthodontic treatment to be expanded by utilizing bone as an anchor unit. This review dwells into the journey of TADs through Kuhn's Paradigm; from its humble beginnings in the form of animal studies to case reports, randomized control trials and meta-analyses. This article also weighs in the potential future of TAD applications in orthodontics and dentofacial orthopedics. (C) 2018 Elsevier Inc. All rights reserved.
AD  - KK Womens & Childrens Hosp, Cleft & Craniofacial Ctr, 100 Bukit Timah Rd, Singapore 229899, SingaporeAD  - KK Womens & Childrens Hosp, Dent Serv, 100 Bukit Timah Rd, Singapore 229899, SingaporeAD  - All India Inst Med Sci, Dept Orthodont & Dentofacial Deform, CDER, New Delhi, IndiaAD  - European Univ Coll, DHCC, Dubai, U Arab EmiratesC3  - KK Women's & Children's HospitalC3  - KK Women's & Children's HospitalC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER INC
PI  - SAN DIEGO
PA  - 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
DA  - MAR
PY  - 2018
VL  - 24
IS  - 1
SP  - 191
EP  - 206
DO  - 10.1053/j.sodo.2018.01.014
AN  - WOS:000430650100014
ER  -

TY  - JOUR
AU  - Garg, N
AU  - Sindwani, G
AU  - Suri, A
AU  - Shamim, R
AU  - Pandey, CK
TI  - Flexible gastroendoscope as a rescue device for an anaesthetist
T2  - JOURNAL OF CLINICAL ANESTHESIA
KW  - Intravenous sedation
KW  - Nasal gastroscope
KW  - Temporomandibular joint ankylosis
KW  - INTUBATION
AD  - Inst Liver & Biliary Sci, Dept Anesthesia, New Delhi, IndiaAD  - AIIMS, Dept Oncoanesthesia, New Delhi, IndiaC3  - Institute of Liver & Biliary Sciences (ILBS)C3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - MAR
PY  - 2018
VL  - 45
SP  - 73
EP  - 74
DO  - 10.1016/j.jclinane.2017.12.026
AN  - WOS:000428361100029
ER  -

TY  - JOUR
AU  - Ghosh, A
AU  - Kandasamy, D
TI  - Predictive Modeling and Feature Selection: The Way Forward in Texture Analysis
T2  - RADIOGRAPHICS
AD  - All India Inst Med Sci, Dept Radiodiag, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - RADIOLOGICAL SOC NORTH AMERICA
PI  - OAK BROOK
PA  - 820 JORIE BLVD, OAK BROOK, IL 60523 USA
DA  - MAR-APR
PY  - 2018
VL  - 38
IS  - 2
SP  - 659
EP  - 660
DO  - 10.1148/rg.2018170197
AN  - WOS:000432390900025
ER  -

TY  - JOUR
AU  - Gipson, DS
AU  - Selewski, DT
AU  - Massengill, SF
AU  - Modes, MM
AU  - Desmond, H
AU  - Lee, L
AU  - Kamil, E
AU  - Elliott, MR
AU  - Adler, SG
AU  - Oh, G
AU  - Lafayette, RA
AU  - Gipson, PE
AU  - Sinha, A
AU  - Bagga, A
AU  - Pesenson, A
AU  - Courtlandt, C
AU  - Spino, C
AU  - Eikstadt, R
AU  - Pitter, R
AU  - Attalla, S
AU  - Waldo, A
AU  - Winneker, R
AU  - Carlozzi, NE
AU  - Troost, JP
AU  - Smokler, I
AU  - Stone, M
TI  - NephCure Accelerating Cures Institute: A Multidisciplinary Consortium to Improve Care for Nephrotic Syndrome
T2  - KIDNEY INTERNATIONAL REPORTS
KW  - clinical trials
KW  - electronic health record
KW  - glomerular disease
KW  - nephrotic syndrome
KW  - patient advisory
KW  - patient-reported outcomes
KW  - GLOMERULAR-DISEASE
KW  - CLINICAL-TRIALS
KW  - UNITED-STATES
KW  - CHILDREN
KW  - NETWORK
KW  - NEPHROLOGY
KW  - OUTCOMES
KW  - DESIGN
KW  - ESRD
AB  - Introduction: NephCure Accelerating Cures Institute (NACI) is a collaborative organization sponsored by NephCure Kidney International and the University of Michigan. The Institute is composed of 7 cores designed to improve treatment options and outcomes for patients with glomerular disease: Clinical Trials Network, Data Warehouse, Patient-Reported Outcomes (PRO) and Endpoints Consortium, Clinical Trials Consulting Team, Quality Initiatives, Education and Engagement, and Data Coordinating Center.
   Methods: The Trials Network includes 22 community-and hospital-based nephrology practices, 14 of which are trial-only sites. Eight sites participate in the NACI Registry, and as of October 2017, 1054 patients are enrolled with diagnoses including but not limited to focal segmental glomerulosclerosis, minimal change disease, membranous nephropathy, IgA nephropathy, and childhood-onset nephrotic syndrome. By using electronic health record data extraction, robust and efficient clinical data are captured while minimizing the burden to site-based network staff.
   Results: The Data Warehouse includes her-extracted data from registry patients, PRO development data, and data from completed observational studies and clinical trials. The Clinical Trial Consulting Team provides support for trial design in rare diseases leveraging these data. The PRO and Endpoints Consortium develops shorter-term endpoints while capturing the patient-reported significance of interventions under study. The Quality Initiatives and Education/Engagement cores elevate the level of care for patients. The Data Coordinating Center manages the analysis and operations of the Institute.
   Conclusion: By engaging with patients, academia, industry, and patient advocate community representatives, including our Patient Advisory Board, NACI strives for better outcomes and treatments using evidence-based support for clinical trial design.
AD  - Univ Michigan, CS Mott Childrens Hosp, Dept Pediat & Communicable Dis, Div Nephrol, Ann Arbor, MI 48109 USAAD  - Levine Childrens Hosp, Div Pediat Nephrol, Charlotte, NC USAAD  - NephCure Kidney Int, King Of Prussia, PA USAAD  - Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Div Pediat Nephrol,Dept Pediat, Los Angeles, CA 90095 USAAD  - Metrolina Nephrol Associates, Charlotte, NC USAAD  - Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Los Angeles, CA USAAD  - Stanford Univ, Sch Med, Dept Pediat, Div Nephrol, Stanford, CA 94305 USAAD  - Stanford Univ, Div Nephrol & Hypertens, Stanford, CA 94305 USAAD  - All India Inst Med Sci, Dept Pediat, Div Nephrol, New Delhi, IndiaAD  - Polyclin Seattle, Seattle, WA USAAD  - Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USAAD  - Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USAC3  - University of Michigan SystemC3  - University of MichiganC3  - Cedars Sinai Medical CenterC3  - University of California SystemC3  - University of California Los AngelesC3  - University of California Los Angeles Medical CenterC3  - David Geffen School of Medicine at UCLAC3  - University of California SystemC3  - University of California Los AngelesC3  - University of California Los Angeles Medical CenterC3  - Stanford UniversityC3  - Stanford UniversityC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of Michigan SystemC3  - University of MichiganC3  - University of Michigan SystemC3  - University of MichiganPU  - ELSEVIER SCIENCE INC
PI  - NEW YORK
PA  - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
DA  - MAR
PY  - 2018
VL  - 3
IS  - 2
SP  - 439
EP  - 446
DO  - 10.1016/j.ekir.2017.11.016
AN  - WOS:000427638100025
ER  -

TY  - JOUR
AU  - Giridhar, P
AU  - Mallick, S
AU  - Kashyap, L
AU  - Rath, GK
TI  - Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases
T2  - EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
KW  - NUT midline carcinoma
KW  - Surgery
KW  - Pattern of care
KW  - Radiotherapy
KW  - BET inhibitor
KW  - Adjuvant
KW  - LUNG-CANCER
KW  - CHILD
AB  - NUT midline carcinoma is a rare tumour occurring in young adults which is frequently misdiagnosed as poorly differentiated squamous cell carcinoma or germ cell tumour. Though considered highly aggressive, there is limited information about the clinical behaviour of such patients. We intended to perform this review of published literature to assess the demographic profile, pattern of care and assess survival outcomes.
   Two authors independently searched PubMed and Google search for eligible studies from 1950 till July 1 2017 published in English language using MESH terms NUT midline carcinoma; NUT midline carcinoma and radiotherapy and translocation 15:19 tumour.
   Data of 119 patients were retrieved from 64 publications for statistical analysis. Median age of the entire cohort was 23 years (range 0-68 years). The analysis revealed equal incidence in males and females (60:58). The present analysis revealed that the most common location is the lung (n = 42) followed by head and neck (n = 40). Median OS for the entire cohort was only 5 months with 1 and 5 year OS for the entire cohort was 24.99 and 7.09% respectively. Radiotherapy and chemotherapy inclusion in primary treatment had a significant impact on overall survival on univariate analysis while surgery did not affect survival significantly. No impact on overall survival was found based on type of molecular translocation, i.e., NUT-BRD4, NUT-BRD3 or other variants. Inadequate data were available for identify impact of BET inhibitors and HiDAc on PFS and OS.
   NUT midline carcinoma has dismal prognosis. Radiotherapy and chemotherapy improves survival, but do not provide long term control except in anecdotal cases. Further research is needed to improve outcomes in future.
AD  - All India Inst Med Sci, Dept Radiat Oncol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - MAR
PY  - 2018
VL  - 275
IS  - 3
SP  - 815
EP  - 821
DO  - 10.1007/s00405-018-4882-y
AN  - WOS:000425281500020
ER  -

TY  - JOUR
AU  - Goel, N
AU  - Kumar, V
AU  - Arora, S
AU  - Jain, P
AU  - Ghosh, B
TI  - Spectral domain optical coherence tomography evaluation of macular changes in Eales disease
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Eales disease
KW  - epiretinal membrane
KW  - macula
KW  - macular edema
KW  - retinal vasculitis
KW  - spectral domain optical coherence tomography
KW  - PREMACULAR SUBHYALOID HEMORRHAGE
KW  - DOUBLE-RING SIGN
KW  - NDYAG LASER
KW  - MANAGEMENT
AB  - Purpose: The purpose of the study was to describe macular changes in treatment-naive eyes with Eales disease using spectral domain optical coherence tomography (SD-OCT). Methods: A cross-sectional study was done on 79 eyes of 66 patients with Eales disease. Best-corrected visual acuity (BCVA), slit-lamp biomicroscopy (SLB), indirect ophthalmoscopy, fundus fluorescein angiography (FFA), and quantitative (central macular thickness [CMT]) and qualitative analysis on SD-OCT were performed. Results: Forty-six (58.2%) eyes had macular involvement as assessed with SD-OCT, while in 33 (41.8%) eyes, macula was not affected. Macular edema was the most common feature when macula was affected followed by epiretinal membrane. Mean CMT was higher (315.3 +/- 102.3 mu m) in eyes with macular involvement than those without it (243.8 +/- 19.3 mu m). Eyes with active vasculitis involving larger vessels and neovascularization had greater chance of macular involvement. SLB and FFA alone missed 28.3% and 50% eyes with macular abnormalities on SD-OCT, respectively. Conclusion: While the clinical description of Eales disease points mainly to a peripheral location, macular involvement can be commonly picked up when SD-OCT is used. Macular involvement when present is associated with a poorer BCVA.
AD  - ICARE Eye Hosp & Postgrad Inst, Noida, Uttar Pradesh, IndiaAD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, New Delhi, IndiaAD  - Maulana Azad Med Coll, Guru Nanak Eye Ctr, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - Maulana Azad Medical CollegePU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - MAR
PY  - 2018
VL  - 66
IS  - 3
SP  - 433
EP  - 438
DO  - 10.4103/ijo.IJO_845_17
AN  - WOS:000426338800018
ER  -

TY  - JOUR
AU  - Goyal, A
AU  - Srivastava, DN
AU  - Ansari, T
TI  - MRI in De Quervain Tenosynovitis: Is Making the Diagnosis Sufficient?
T2  - AMERICAN JOURNAL OF ROENTGENOLOGY
KW  - 1ST EXTENSOR COMPARTMENT
KW  - WRIST
AD  - All India Inst Med Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - AMER ROENTGEN RAY SOC
PI  - RESTON
PA  - 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
DA  - MAR
PY  - 2018
VL  - 210
IS  - 3
SP  - W133
EP  - W134
DO  - 10.2214/AJR.17.19078
AN  - WOS:000426017600009
ER  -

TY  - JOUR
AU  - Gulla, KM
AU  - Sahoo, T
AU  - Sankar, J
TI  - Developing and Testing Fidelity of Manikins for Training in Cardio-Pulmonary Resuscitation: Need of the Hour!
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - SIMULATION
KW  - METAANALYSIS
KW  - TECHNOLOGY
AD  - All India Inst Med Sci, Dept Pediat, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - MAR
PY  - 2018
VL  - 85
IS  - 3
SP  - 168
EP  - 169
DO  - 10.1007/s12098-017-2573-0
AN  - WOS:000429378100003
ER  -

TY  - JOUR
AU  - Gupta, SK
AU  - Anderson, RH
TI  - Totally anomalous systemic venous connection: where is the coronary sinus?
T2  - CARDIOLOGY IN THE YOUNG
AD  - All India Inst Med Sci, Dept Cardiol, Room 9,8th Floor, New Delhi 110029, IndiaAD  - Newcastle Univ, Inst Genet Med, Newcastle Upon Tyne, Tyne & Wear, EnglandC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Newcastle University - UKPU  - CAMBRIDGE UNIV PRESS
PI  - CAMBRIDGE
PA  - EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
DA  - MAR
PY  - 2018
VL  - 28
IS  - 3
SP  - 516
EP  - 516
DO  - 10.1017/S1047951117002414
AN  - WOS:000429627500033
ER  -

TY  - JOUR
AU  - Gupta, V
AU  - Patra, S
AU  - Arava, S
AU  - Sharma, VK
TI  - Image Gallery: A hard "pebbly' plaque stuck on the upper eyelid
T2  - BRITISH JOURNAL OF DERMATOLOGY
AD  - All India Inst Med Sci, Dept Dermatol & Venereol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - MAR
PY  - 2018
VL  - 178
IS  - 3
SP  - E226
EP  - E226
DO  - 10.1111/bjd.16242
AN  - WOS:000428701000017
ER  -

TY  - JOUR
AU  - Jain, A
AU  - Bakhshi, S
AU  - Thakkar, H
AU  - Gerards, M
AU  - Singh, A
TI  - Elevated mitochondrial DNA copy numbers in pediatric acute lymphoblastic leukemia: A potential biomarker for predicting inferior survival
T2  - PEDIATRIC BLOOD & CANCER
KW  - acute lymphoblastic leukemia
KW  - copy number
KW  - deletion ratio
KW  - mitochondrial DNA
KW  - prognostic markers
KW  - survival
KW  - CANCER-RISK
KW  - MUTATIONS
KW  - MAINTENANCE
KW  - DELETION
KW  - STAGE
KW  - CELLS
AB  - BackgroundStudies on mitochondrial DNA copy number reveal an increase or decrease in copy number that appears to be cancer specific, but data on acute lymphoblastic leukemia have been inconsistent regarding the significance of changes in mitochondrial DNA copies. The purpose of this pilot study was to analyze mitochondrial DNA copy number and mitochondrial DNA integrity.
   ProcedureCopy number and mitochondrial deletion ratios were estimated in the bone marrow of 51 patients and peripheral blood of 30 healthy controls using quantitative real-time PCR. The copy number values were correlated with prognostic markers in patients.
   ResultsSignificantly increased mitochondrial DNA copy number (P-value<0.0001) and increased mitochondrial deletion ratios (P-value=0.0018) were observed in patients compared with controls. The copy numbers were significantly decreased in patients after chemotherapy (P-value=0.0232). Patients with higher copy numbers exhibited significantly inferior survival than patients with lower copy numbers (for event-free survival,P-value =0.04 and overall survival,P-value =0.1175).
   ConclusionsSignificant decreases in mitochondrial DNA copy number with therapy indicates that copy number could be evaluated as a potential marker for therapeutic efficacy and a higher mitochondrial DNA copy number could be a poor prognostic marker.
AD  - All India Inst Med Sci, Dept Biochem, New Delhi 110029, IndiaAD  - AIIMS, BR Ambedkar Inst Rotary Canc Hosp, Dept Med Oncol, New Delhi, IndiaAD  - Maastricht Univ, Maastricht Ctr Syst Biol MaCS Bio, Maastricht, NetherlandsC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Maastricht UniversityPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - MAR
PY  - 2018
VL  - 65
IS  - 3
C7  - e26874
DO  - 10.1002/pbc.26874
AN  - WOS:000419979000012
ER  -

TY  - JOUR
AU  - Jain, D
AU  - Tamm, M
AU  - Savic, S
AU  - Bubendorf, L
TI  - Alveolar herniation in transbronchial lung biopsy: a newly recognised diagnostic pitfall
T2  - HISTOPATHOLOGY
AD  - All India Inst Med Sci, Dept Pathol, New Delhi, IndiaAD  - Univ Hosp Basel, Pulm Med, Basel, SwitzerlandAD  - Univ Hosp Basel, Inst Pathol, Basel, SwitzerlandC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - University of BaselC3  - University of BaselPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - MAR
PY  - 2018
VL  - 72
IS  - 4
SP  - 710
EP  - 712
DO  - 10.1111/his.13411
AN  - WOS:000424875500019
ER  -

TY  - JOUR
AU  - Jain, S
AU  - Kedia, S
AU  - Sethi, T
AU  - Bopanna, S
AU  - Yadav, DP
AU  - Goyal, S
AU  - Padhan, R
AU  - Venigalla, PM
AU  - Sahni, P
AU  - Dash, NR
AU  - Pal, S
AU  - Makharia, G
AU  - Travis, SPL
AU  - Ahuja, V
TI  - Predictors of long-term outcomes in patients with acute severe colitis: A northern Indian cohort study
T2  - JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
KW  - acute severe colitis
KW  - colectomy
KW  - prediction
KW  - SEVERE ULCERATIVE-COLITIS
KW  - EVIDENCE-BASED CONSENSUS
KW  - PARAMETERS
KW  - COLECTOMY
KW  - MANAGEMENT
KW  - DIAGNOSIS
KW  - THERAPY
AB  - Background and AimKnowledge of long-term outcomes following an index episode of acute severe colitis (ASC) can help informed decision making at a time of acute exacerbation especially when colectomy is an option. We aimed to identify long-term outcomes and their predictors after a first episode of ASC in a large North Indian cohort.
   MethodsHospitalized patients satisfying Truelove and Witts' criteria under follow-up at a single center from January 2003 to December 2013 were included. Patients avoiding colectomy at index admission were categorized as complete (3 non bloody stool per day) or incomplete responders, based upon response to corticosteroids at day 7. Random Forest-based machine learning models were constructed to predict the long-term risk of colectomy or steroid dependence following an index episode of ASC.
   ResultsOf 1731 patients with ulcerative colitis, 179 (10%) had an index episode of ASC. Nineteen (11%) patients underwent colectomy at index admission and 42 (26%) over a median follow-up of 56 (1-159) months. Hazard ratio for colectomy for incomplete responder was 3.6 (1.7-7.5, P=0.001) compared with complete responder. Modeling based on four variables, response at day 7 of hospitalization, steroid use during the first year of diagnosis, longer disease duration before ASC, and number of extra-intestinal manifestations, was able to predict colectomy with an accuracy of 77%.
   ConclusionsDisease behavior of ASC in India is similar to the West, with a third undergoing colectomy at 10years. Clinical features, especially response at day 7 hospitalization for index ASC, can predict both colectomy and steroid dependence with reasonable accuracy.
AD  - All India Inst Med Sci, Dept Gastroenterol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Gastrointestinal Surg, New Delhi, IndiaAD  - Indraprastha Inst Informat Technol, New Delhi, IndiaAD  - Oxford Univ Hosp, Translat Gastroenterol Unit, Oxford, EnglandC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Indraprastha Institute of Information Technology DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - MAR
PY  - 2018
VL  - 33
IS  - 3
SP  - 615
EP  - 622
DO  - 10.1111/jgh.13921
AN  - WOS:000425735300012
ER  -

TY  - JOUR
AU  - Jat, KR
AU  - Gupta, S
TI  - Bordetella and Bronchiolitis: A Chance Association or More Than That?
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - PERTUSSIS
AD  - All India Inst Med Sci, Dept Pediat, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - MAR
PY  - 2018
VL  - 85
IS  - 3
SP  - 170
EP  - 171
DO  - 10.1007/s12098-017-2572-1
AN  - WOS:000429378100004
ER  -

TY  - JOUR
AU  - Jose, A
AU  - Nagori, SA
AU  - Roychoudhury, A
TI  - Surgical Management of Migraine Headache
T2  - JOURNAL OF CRANIOFACIAL SURGERY
KW  - Headache
KW  - migraine
KW  - surgery
KW  - CORRUGATOR SUPERCILII MUSCLE
KW  - TOXIN TYPE-A
KW  - BOTULINUM TOXIN
KW  - DECOMPRESSION
KW  - EXPERIENCE
KW  - RESECTION
KW  - PLACEBO
KW  - ANATOMY
AB  - Migraine surgery has been recently reported as an alternative to medical management to provide long-term relief in migraine sufferers. A prospective study was designed wherein patients diagnosed with migraine were screened for surgery by injecting botulinum toxin type A at the primary trigger site. Surgery consisted of corrugator supercilii muscle resection to decompress supra-trochlear and supra-orbital nerves with avulsion of zygomaticotemporal branch of trigeminal nerve. Using pre and postsurgery questionnaires, information regarding the degree of reduction of migraines with regard to severity and frequency; and surgical site problems was acquired. Thirty patients volunteered for migraine surgery. Mean migraine headaches reduced from 15.2 +/- 6.3 episodes per month to 1.9 +/- 2.4 episodes per month (P<0.0001) postsurgery. The mean intensity of migraine headache also reduced from a preoperative 7.3 +/- 3.5 to a postoperative of 1.3 +/- 1.4 (P<0.0001). Fourteen (46.7%) patients reported complete elimination of migraine after surgery while an equal number reported significant relief of symptoms. Two (6.6%) patients failed to notice any significant improvement after surgery. The mean follow-up period was 11.1 +/- 2 months with no major surgical complications. Results of the authors' study confirm prior published results that surgical treatment of migraine is a reality. Surgeons can easily incorporate this simple surgical procedure in their armamentarium to offer relief to numerous migraine patients.
AD  - All India Inst Med Sci, Corps Dent Unit 15, New Delhi, IndiaAD  - All India Inst Med Sci, Field Hosp 303, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Oral & Maxillofacial Surg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - MAR
PY  - 2018
VL  - 29
IS  - 2
SP  - E106
EP  - E108
DO  - 10.1097/SCS.0000000000004078
AN  - WOS:000427989400002
ER  -

TY  - JOUR
AU  - Kant, L
AU  - Guleria, R
TI  - Pandemic Flu, 1918: After hundred years, India is as vulnerable
T2  - INDIAN JOURNAL OF MEDICAL RESEARCH
KW  - SEASONAL INFLUENZA
AD  - All India Inst Med Sci, Publ Hlth Fdn India, New Delhi 110029, IndiaAD  - All India Inst Med Sci, Dept Pulm Med & Sleep Disorders, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Public Health Foundation of IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SCIENTIFIC SCHOLAR LLC
PI  - PITTSFORD
PA  - 50, WOODGREEN DR, PITTSFORD, NY 14534 USA
DA  - MAR
PY  - 2018
VL  - 147
SP  - 221
EP  - 224
DO  - 10.4103/ijmr.IJMR_407_18
AN  - WOS:000436501200002
ER  -

TY  - JOUR
AU  - Katiyar, V
AU  - Sharma, R
AU  - Gurjar, HK
TI  - Impact of post craniectomy cranioplasty on cerebral perfusion and clinical outcome
T2  - JOURNAL OF CLINICAL NEUROSCIENCE
AD  - All India Inst Med Sci, Dept Neurosurg, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER SCI LTD
PI  - OXFORD
PA  - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
DA  - MAR
PY  - 2018
VL  - 49
SP  - 87
EP  - 88
DO  - 10.1016/j.jocn.2017.08.052
AN  - WOS:000426029600016
ER  -

TY  - JOUR
AU  - Khanna, K
AU  - Sharma, S
AU  - Gupta, DK
TI  - Hydrometrocolpos etiology and management: past beckons the present
T2  - PEDIATRIC SURGERY INTERNATIONAL
KW  - Hydrometrocolpos
KW  - Hydrocolpos
KW  - Cloaca
KW  - Urogenital sinus
KW  - Vaginal atresia
KW  - Imperforate hymen
KW  - MCKUSICK-KAUFMAN-SYNDROME
KW  - VAGINAL PULL-THROUGH
KW  - WERNER-WUNDERLICH-SYNDROME
KW  - BARDET-BIEDL SYNDROME
KW  - UROGENITAL SINUS
KW  - PRENATAL-DIAGNOSIS
KW  - FETAL HYDROMETROCOLPOS
KW  - CLOACAL MALFORMATIONS
KW  - IMPERFORATE HYMEN
KW  - UTERUS DIDELPHYS
AB  - Hydrometrocolpos is a rare condition in which the uterus and the vagina are grossly distended with a retained fluid other than pus or blood. It may present during the neonatal period or later at puberty. Most cases reported earlier were stillbirths and were diagnosed only on autopsy. Antenatal diagnosis is now possible with the advent of ultrasound. An early diagnosis and speedy management is the key to survival. Many previous case reports have focused on the varied clinical presentations, multiple causes, associated syndromes and/or the radiological diagnosis of this condition. However, management options for different types of hydrometrocolpos have not yet been concisely discussed. We have reviewed the literature and tried to summarize the management options applicable to most case scenarios of hydrometrocolpos.
AD  - All India Inst Med Sci, Dept Pediat Surg, R 4002,4th Floor, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER
PI  - NEW YORK
PA  - 233 SPRING ST, NEW YORK, NY 10013 USA
DA  - MAR
PY  - 2018
VL  - 34
IS  - 3
SP  - 249
EP  - 261
DO  - 10.1007/s00383-017-4218-9
AN  - WOS:000425737300001
ER  -

TY  - JOUR
AU  - Khilnani, GC
AU  - Tiwari, P
TI  - Air pollution in India and related adverse respiratory health effects: past, present, and future directions
T2  - CURRENT OPINION IN PULMONARY MEDICINE
KW  - air pollution
KW  - ambient air pollution
KW  - household air pollution
KW  - India
KW  - respiratory adverse effects
KW  - AMBIENT PM2.5 POLLUTION
KW  - GLOBAL BURDEN
KW  - PREMATURE MORTALITY
KW  - RISK-ASSESSMENT
KW  - SOLID-FUEL
KW  - DISEASE
KW  - QUALITY
KW  - COOKING
KW  - DELHI
KW  - CITY
AB  - Purpose of review
   The review describes current status of air pollution in India, summarizes recent research on adverse health effects of ambient and household air pollution, and outlines the ongoing efforts and future actions required to improve air quality and reduce morbidity and mortality because of air pollution in India.
   Recent findings
   Global burden of disease data analysis reveals more than one million premature deaths attributable to ambient air pollution in 2015 in India. More than one million additional deaths can be attributed to household air pollution. Particulate matter with diameter 2.5 mu m or less has been causatively linked with most premature deaths. Acute respiratory tract infections, asthma, chronic obstructive pulmonary disease, exacerbations of preexisting obstructive airway disease and lung cancer are proven adverse respiratory effects of air pollution. Targeting air quality standards laid by WHO can significantly reduce morbidity and mortality because of air pollution in India.
   Summary
   India is currently exposed to high levels of ambient and household air pollutants. Respiratory adverse effects of air pollution are significant contributors to morbidity and premature mortality in India. Substantial efforts are being made at legislative, administrative, and community levels to improve air quality. However, much more needs to be done to change the 'status quo' and attain the target air quality standards.
AD  - All India Inst Med Sci, Dept Pulm Med & Sleep Disorders, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - LIPPINCOTT WILLIAMS & WILKINS
PI  - PHILADELPHIA
PA  - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
DA  - MAR
PY  - 2018
VL  - 24
IS  - 2
SP  - 108
EP  - 116
DO  - 10.1097/MCP.0000000000000463
AN  - WOS:000435517900003
ER  -

TY  - JOUR
AU  - Khokhar, S
AU  - Pillay, G
AU  - Sen, S
AU  - Agarwal, E
TI  - Clinical spectrum and surgical outcomes in spherophakia: a prospective interventional study
T2  - EYE
KW  - INTRAOCULAR-LENS IMPLANTATION
KW  - ANGLE-CLOSURE GLAUCOMA
KW  - ISOLATED MICROSPHEROPHAKIA
KW  - MARCHESANI SYNDROME
KW  - SECONDARY GLAUCOMA
KW  - ANTERIOR-CHAMBER
KW  - MARFAN-SYNDROME
KW  - ECTOPIA LENTIS
KW  - FOLLOW-UP
KW  - LENSECTOMY
AB  - Purpose To study the varied clinical presentations of patients with spherophakia, their management using surgical methods, and the clinical outcomes.
   Patients and methods A prospective interventional study of 13 patients of spherophakia who presented to us from January 2014 and were followed up over the course of their treatment, and the data were documented for analysis.
   Results In all, 26 eyes of 13 patients were reviewed and the median age of presentation was 12 +/- 12.05 years. All patients had a bilateral presentation with 22 eyes having lenticular myopia with a mean refractive error of -11.5 +/- 12.945 DS. Ten eyes presented with glaucoma of which six had raised intraocular pressure (IOP) >21 mm Hg. A total of 23 eyes underwent lens extraction for dislocation/subluxation. Lens extraction helped lower overall IOP. Refractive rehabilitation was done with ACIOL, posterior chamber intraocular lens (PCIOL) with capsular tension ring, and scleral-fixated intraocular lens (SFIOL) in respective cases with ACIOLs being the most commonly used option.
   Conclusions Spherophakia is a rare condition, which exhibits a varying degree of lenticular myopia, glaucoma, and subluxation of the crystalline lens. Lensectomy with proper rehabilitation using ACIOL, PCIOL, or SFIOL is a method of managing subluxation and unacceptable myopia. Lensectomy may also be a viable option of controlling glaucoma alongside medications and glaucoma surgery for the management of glaucoma in such cases.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Ophthalmol, Cataract & Refract Surg Serv, New Delhi 110049, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - NATURE PUBLISHING GROUP
PI  - LONDON
PA  - MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
DA  - MAR
PY  - 2018
VL  - 32
IS  - 3
SP  - 527
EP  - 536
DO  - 10.1038/eye.2017.229
AN  - WOS:000427051200008
ER  -

TY  - JOUR
AU  - Khokhar, S
AU  - Pillay, G
AU  - Agarwal, E
TI  - Pediatric Cataract - Importance of Early Detection and Management
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - Pediatric cataract
KW  - Early detection
KW  - Management
KW  - Role of pediatrician
KW  - SEVERE VISUAL IMPAIRMENT
KW  - DEVELOPING-WORLD
KW  - BRUCKNER TEST
KW  - CHILDREN
KW  - SURGERY
KW  - BLINDNESS
KW  - ACUITY
KW  - STRABISMUS
AB  - Pediatric cataract is often diagnosed and managed late. This delay may be due to the ignorance on the part of the community, financial constraints, delay in the diagnosis and lack of tertiary care facilities. There is an urgent need to include rubella vaccination in the universal immunization program. A Simple Red Reflex test to detect a cataract and guiding the parent for early intervention will go a long way in achieving the target of eliminating cataract as a cause of childhood blindness. The importance of early detection and quick referral to a multispecialty center can save the child of lot many blind-years. These children have the potential to achieve the best possible visual acuity if managed early.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - MAR
PY  - 2018
VL  - 85
IS  - 3
SP  - 209
EP  - 216
DO  - 10.1007/s12098-017-2482-2
AN  - WOS:000429378100012
ER  -

TY  - JOUR
AU  - Khokhar, S
AU  - Jose, CP
AU  - Sihota, R
AU  - Midha, N
TI  - Unilateral Congenital Cataract: Clinical Profile and Presentation
T2  - JOURNAL OF PEDIATRIC OPHTHALMOLOGY & STRABISMUS
KW  - PERSISTENT FETAL VASCULATURE
KW  - OUTCOMES
KW  - CHILDREN
KW  - SURGERY
AB  - Purpose: To study the clinical profile and presentation of children with unilateral cataract.
   Methods: In this hospital-based, observational, cross-sectional study, patients 15 years of age or younger who presented with unilateral cataract were recruited. Cases of cataract secondary to causes such as trauma or uveitis were excluded. Age at detection and presentation, distance from the treatment center, presenting complaints, cataract morphology, and biometry were noted for each case.
   Results: A total of 76 patients were recruited. Most patients presented with complaints of leukocoria. Persistent fetal vasculature accounted for 27.6% of cases and was the most common identifiable cause of cataract in this study. Subsequently, patients were divided into two groups: no persistent fetal vasculature (control) and persistent fetal vasculature. A male predominance was noted in both groups. The mean age at detection was 27.58 +/- 37.02 and 6.17 +/- 8.42 months and the mean age at presentation was 55.613 +/- 45.21 and 14.83 +/- 17.75 months in the control and persistent fetal vasculature groups, respectively. In the persistent fetal vasculature group, a significant difference was noted in the axial length, keratometry, and corneal diameter between the affected and normal eyes (P = .027, .00176, and .0114, respectively). In the control group, this difference was observed only in keratometry readings (P = .0464). The mean distance traveled by patients to reach the treatment center was 211 km.
   Conclusions: Persistent fetal vasculature is an important and less identified cause of unilateral cataract. A significant delay is noted in the detection and presentation of unilateral cataract.
AD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Ophthalmol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - SLACK INC
PI  - THOROFARE
PA  - 6900 GROVE RD, THOROFARE, NJ 08086 USA
DA  - MAR-APR
PY  - 2018
VL  - 55
IS  - 2
SP  - 107
EP  - 112
DO  - 10.3928/01913913-20170703-11
AN  - WOS:000427823200007
ER  -

TY  - JOUR
AU  - Khurana, A
AU  - Dhillon, MS
TI  - Surgical Treatment of Sanders Type 2 Calcaneal Fractures Using a Sinus Tarsi Approach
T2  - INDIAN JOURNAL OF ORTHOPAEDICS
KW  - EXTENSILE LATERAL APPROACH
AD  - AIIMS, Dept Orthopaed, New Delhi, IndiaAD  - PGIMER, Dept Orthopaed, Chandigarh, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Post Graduate Institute of Medical Education & Research (PGIMER), ChandigarhPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - MAR-APR
PY  - 2018
VL  - 52
IS  - 2
SP  - 209
EP  - U127
DO  - 10.4103/ortho.IJOrtho_484_17
AN  - WOS:000429265000017
ER  -

TY  - JOUR
AU  - Kothiwala, AK
AU  - Rai, HIS
AU  - Garg, K
AU  - Singh, M
AU  - Singh, P
AU  - Sharma, BS
AU  - Sood, R
TI  - Giant anterior interhemispheric fissure amoebic abscess: A rare case
T2  - NEUROLOGY INDIA
KW  - BRAIN-ABSCESS
KW  - ENTAMOEBA-HISTOLYTICA
KW  - CEREBRAL AMEBIASIS
KW  - INFECTION
KW  - ENCEPHALITIS
KW  - CHILD
AD  - AIIMS, Dept Neurosurg, New Delhi 110029, IndiaAD  - AIIMS, Dept Internal Med, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI  - MUMBAI
PA  - B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA
DA  - MAR-APR
PY  - 2018
VL  - 66
IS  - 2
SP  - 548
EP  - +
DO  - 10.4103/0028-3886.227320
AN  - WOS:000427989900053
ER  -

TY  - JOUR
AU  - Krishnamurthy, A
AU  - Vishnu, VY
AU  - Hamide, A
TI  - Clinical signs in hypothyroidism-myoedema and Woltman sign
T2  - QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
AD  - All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Neurol, New Delhi, IndiaAD  - Jawaharlal Inst Post Grad Med Educ & Res, Dept Gen Med, Pondicherry, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Jawaharlal Institute of Postgraduate Medical Education & ResearchPU  - OXFORD UNIV PRESS
PI  - OXFORD
PA  - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
DA  - MAR
PY  - 2018
VL  - 111
IS  - 3
SP  - 193
EP  - 193
DO  - 10.1093/qjmed/hcx205
AN  - WOS:000427013000013
ER  -

TY  - JOUR
AU  - Kumar, J
AU  - Singh, A
AU  - Seth, R
AU  - Xess, I
AU  - Kabra, SK
TI  - Galactomannan Antigen Test for Early Diagnosis of Invasive Aspergillus Infection in Pediatric Febrile Neutropenia
T2  - INDIAN PEDIATRICS
KW  - Cancer chemotherapy
KW  - Immunosuppression
AB  - Invasive aspergillosis is a major concern in neutropenic patients. We studied the utility of Galactomannan antigen detection test in serum using ELISA technique for early detection of invasive aspergillosis. Diagnostic accuracy of Galactomannan index (GMI) test was maximum at a cut-off of > 1.5 with a negative predictive value of more than 95%.
AD  - AIIMS, Dept Pediat, New Delhi, IndiaAD  - AIIMS, Dept Microbiol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - MAR
PY  - 2018
VL  - 55
IS  - 3
SP  - 257
EP  - 258
DO  - 10.1007/s13312-018-1329-x
AN  - WOS:000435869400016
ER  -

TY  - JOUR
AU  - Kumar, L
AU  - Harish, P
AU  - Malik, PS
AU  - Khurana, S
TI  - Chemotherapy and targeted therapy in the management of cervical cancer
T2  - CURRENT PROBLEMS IN CANCER
KW  - Cervix cancer
KW  - Neo-adjuvant chemotherapy, adjuvant chemotherapy
KW  - Concurrent chemo-radiation
KW  - Targeted therapy
KW  - Bevacizumab
KW  - Immune check point inhibitor
KW  - SQUAMOUS-CELL CARCINOMA
KW  - PHASE-II TRIAL
KW  - NEOADJUVANT CHEMOTHERAPY
KW  - RANDOMIZED-TRIAL
KW  - PELVIC RADIATION
KW  - RECURRENT
KW  - CISPLATIN
KW  - BEVACIZUMAB
KW  - PERSISTENT
KW  - CHEMORADIATION
AB  - Management of cervical cancer has undergone refinement in the past two decades; concurrent chemo-radiation (CCRT) (with cisplatin alone or in combination) is currently the standard treatment approach for patients with locally advanced disease (FIGO stage IIB-IVA). About 30%-40% of such patients fail to achieve complete response; alternative approaches are needed to improve outcome for them. Treatment with bevacizumab (an inhibitor of vascular endothelial growth factor) along with chemotherapy is associated with improved survival in patients with recurrent or metastatic cervical cancer. Weekly paclitaxel and carboplatin for 4-6 weeks as dose dense chemotherapy prior to CCRT is currently under study in a phase III, multicentric trial. Role of adjuvant chemotherapy after CCRT in patients with positive lymph nodes, larger tumor volume and those with stage III-IVA disease needs further exploration. Novel agents targeting molecular pathways are currently being studied. Recent development of immune check point inhibitors is exciting, results of ongoing studies are awaited with interest. (C) 2018 Elsevier Inc. All rights reserved.
AD  - All India Inst Med Sci, Inst Rotary Canc Hosp, Dept Med Oncol, Room 234,2nd Floor, New Delhi 110029, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - DR. B.R.A. Institute Rotary Cancer HospitalPU  - MOSBY-ELSEVIER
PI  - NEW YORK
PA  - 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
DA  - MAR-APR
PY  - 2018
VL  - 42
IS  - 2
SP  - 120
EP  - 128
DO  - 10.1016/j.currproblcancer.2018.01.016
AN  - WOS:000435621600001
ER  -

TY  - JOUR
AU  - Kumar, P
AU  - Jain, M
AU  - Kalsi, AK
AU  - Halder, A
TI  - Molecular characterisation of a case of dicentric Y presented as nonobstructive azoospermia with testicular early maturation arrest
T2  - ANDROLOGIA
KW  - AZF (AZFa
KW  - AZFb and AZFc) gains
KW  - Dicentric Y
KW  - PAR 1 & 2 CNVs
KW  - testicular maturation arrest
KW  - ROBERTSONIAN TRANSLOCATIONS
KW  - DNA-REPLICATION
KW  - SACCHAROMYCES-CEREVISIAE
KW  - FUNCTIONAL CENTROMERES
KW  - PSEUDOAUTOSOMAL REGION
KW  - SEX-CHROMOSOMES
KW  - INFERTILE MEN
KW  - PROTEIN
KW  - GENE
KW  - INACTIVATION
AB  - The dicentric Y chromosome is the most common cytogenetically visible structural abnormality of Y chromosome. The sites of break and fusion of dicentric Y are variable, but break and fusion at Yq12 (proximal to the pseudoautosomal region 2/PAR 2) is very rare. Dicentric Y chromosome is unstable during cell division and likely to generate chromosomal mosaicism. Here, we report a case of infertile male with nonmosaic 46,XY where chromosome Y was dicentric with break and fusion at Yq12 (proximal to PAR 2). Clinical presentation of the case was nonobstructive azoospermia due to early maturation arrest at the primary spermatocyte stage. Various molecular techniques such as FISH, STS-PCR and DNA microarray were carried out to characterise genetic defect leading to testicular maturation arrest in the patient. The break and fusion was found at Yq12 (proximal to PAR 2) and resulted in near total duplication of Y chromosome (excluding PAR 2). The reason for maturation arrest seems due to CNVs of PARs (gain in PAR 1 and loss of PAR 2) and azoospermia factors (gain).
AD  - All India Inst Med Sci, Dept Reprod Biol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - WILEY
PI  - HOBOKEN
PA  - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
DA  - MAR
PY  - 2018
VL  - 50
IS  - 2
C7  - e12886
DO  - 10.1111/and.12886
AN  - WOS:000424997800044
ER  -

TY  - JOUR
AU  - Kumar, P
AU  - Misra, P
AU  - Thakur, CP
AU  - Saurabh, A
AU  - Rishi, N
AU  - Mitra, DK
TI  - T cell suppression in the bone marrow of visceral leishmaniasis patients: impact of parasite load
T2  - CLINICAL AND EXPERIMENTAL IMMUNOLOGY
KW  - bone marrow aspirate (BMA)
KW  - Leishmania donovani
KW  - T regulatory cells (T-reg)
KW  - visceral leishmaniasis (VL)
KW  - DIAGNOSIS
AB  - Visceral leishmaniasis (VL) is a disseminated and lethal disease of reticulo-endothelial system caused by protozoan parasites Leishmania donovani and L. infantum, which are known to induce host T cell suppression. To understand the impact of parasite load on T cell function, the present was focused on parasite load with T cell function in bone marrow of 26 VL patients. We observed significant enrichment of forkhead box protein 3 (FoxP3)(+) (P = 0.0003) and interleukin (IL)-10(+) FoxP3(+) regulatory T cells (T-reg) (P = 0.004) in the bone marrow (BM) of patients with high parasite load (HPL) compared with low parasite load (LPL). Concordantly, T effector cells producing interferon (IFN)-gamma (P = 0.005) and IL-17A (P = 0.002) were reduced in the BM of HPL. Blocking of T-reg-cell derived suppressive cytokines [(IL-10 and transforming growth factor (TGF)-beta] rescued the effector T cells and their functions. However, it was observed that TGF-beta levels were dominant, favouring T-reg cell differentiation. Furthermore, the low ratio of IL-6/TGF-beta favours the suppressive milieu in HPL patients. Here we show the change in levels of various cytokines with the parasitic load during active VL, which could be helpful in devising newer immunotherapeutic strategies against this disease.
AD  - AIIMS, Dept TII, New Delhi, IndiaAD  - Amity Univ, Amity Inst Virol & Immunol, Noida, IndiaAD  - Balaji Utthan Sansthan, Patna, Bihar, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Amity University NoidaPU  - OXFORD UNIV PRESS
PI  - OXFORD
PA  - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
DA  - MAR
PY  - 2018
VL  - 191
IS  - 3
SP  - 318
EP  - 327
DO  - 10.1111/cei.13074
AN  - WOS:000424335000008
ER  -

TY  - JOUR
AU  - Kumar, P
AU  - Kumar, V
AU  - Ravani, R
AU  - Agarwal, S
TI  - Subretinal tissue plasminogen-assisted vitrectomy for posttraumatic full-thickness macular hole with submacular hemorrhage
T2  - INDIAN JOURNAL OF OPHTHALMOLOGY
KW  - Closed globe injury
KW  - full-thickness macular hole
KW  - pars plana vitrectomy
KW  - subretinal hemorrhage
KW  - subretinal tissue plasminogen activator
KW  - MANAGEMENT
KW  - OUTCOMES
AB  - A young male presented with diminution of vision left eye, attributable to full-thickness macular hole, and submacular hemorrhage, following closed globe injury 2 weeks ago. The patient was managed successfully with 25-gauge vitrectomy, subretinal injection of tissue plasminogen activator and aspiration of liquefied blood through the macular hole, internal limiting membrane peeling, short-acting gas tamponade, and prone positioning. This resulted in good visual improvement, type 1 macular hole closure, and restoration of foveal architecture. The outcome and rationale of treatment in this unique scenario is discussed.
AD  - All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI  - MUMBAI
PA  - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
DA  - MAR
PY  - 2018
VL  - 66
IS  - 3
SP  - 474
EP  - 476
DO  - 10.4103/ijo.IJO_815_17
AN  - WOS:000426338800035
ER  -

TY  - JOUR
AU  - Madaan, P
AU  - Jauhari, P
AU  - Gupta, A
AU  - Chakrabarty, B
AU  - Gulati, S
TI  - A quinidine non responsive novel KCNT1 mutation in an Indian infant with epilepsy of infancy with migrating focal seizures
T2  - BRAIN & DEVELOPMENT
KW  - MMPSI
KW  - KCNT-1 gene: Quinidine
KW  - Ketogenic diet
KW  - Infantile epileptic encephalopathy
KW  - GAIN
AB  - Epilepsy of infancy with migrating focal seizures {a.k.a malignant migrating partial seizures of infancy (MMPSI)} is an uncommon epileptic encephalopathy with a poor prognosis. Migrating focal seizures with autonomic features, developmental stagnation and refractoriness to treatment are its key features. It is caused by genetic defects in various ion channels, most common being sodium activated potassium channel (KCNT1), found in up to 50% of cases. With advent of genetic diagnosis and precision medicine, many targeted therapies have been identified. Antagonist of KCNT1 coded ion channel like Quinidine has shown promising results in MMPSI. Here we report first mutation proven case of MMPSI from India. This child had a novel heterozygous missense mutation in exon10 of the KCNT1 gene (chr9:138650308; c.808C > G/G (p.Q270E)) which was pathogenic. Neither quinidine nor ketogenic diet could control his seizures. Ultimately, the child succumbed to his illness at nine months of age. (C) 2017 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.
AD  - All India Inst Med Sci, Dept Pediat, Child Neurol Div, Room 3056,Third Floor,Teaching Block, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - ELSEVIER
PI  - AMSTERDAM
PA  - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
DA  - MAR
PY  - 2018
VL  - 40
IS  - 3
SP  - 229
EP  - 232
DO  - 10.1016/j.braindev.2017.09.008
AN  - WOS:000426533600011
ER  -

TY  - JOUR
AU  - Malhotra, S
AU  - Vashist, P
AU  - Kalaivani, M
AU  - Gupta, N
AU  - Senjam, SS
AU  - Rath, R
AU  - Gupta, SK
TI  - Prevalence and causes of visual impairment amongst older adults in a rural area of North India: a cross-sectional study
T2  - BMJ OPEN
KW  - PRADESH EYE DISEASE
KW  - BLUE MOUNTAINS EYE
KW  - QUALITY-OF-LIFE
KW  - NATIONAL BLINDNESS
KW  - RAPID ASSESSMENT
KW  - LOW-VISION
KW  - AVOIDABLE BLINDNESS
KW  - CATARACT-SURGERY
KW  - SOUTH-INDIA
KW  - POPULATION
AB  - Objectives To determine the prevalence, causes and associated factors for visual impairment (VI) in rural population of Jhajjar district, Haryana, north India.
   Methods A community-based, cross-sectional study was conducted in two blocks of Jhajjar district. A total of 34 villages were selected using probability proportionate to size sampling method. Adults aged 50 years and above were selected using compact segment cluster sampling approach. Presenting visual acuity using LogMAR E chart was measured along with collection of other demographic details as part of the house-to-house survey. Subjective refraction and torch light examination were performed at a clinic site within the village to ascertain VI and its cause. VI was considered when presenting visual acuity was less than 6/18 in the better eye. Common causes of VI viz uncorrected refractive errors, cataract, central corneal opacity and others were noted by optometrists. Descriptive analysis was undertaken. Multivariate logistic regression analysis was performed for determining associated factors with VI.
   Results Out of 2025 enumerated adults, 1690 (83.5%) were examined at the household level and 1575 (78%) completed all study procedures. The prevalence of VI was found to be 24.5 % (95% CI 21.1 to 26.3) and blindness was 5% (95% CI 3.9 to 6.1). The most common causes of VI were uncorrected refractive errors (50%) and cataract (37%). The VI in study participants was found to be associated with age, gender, marital and educational status.
   Conclusions VI is still a public health problem in rural population of Jhajjar district, Haryana. Provision of spectacles and cataract surgical services are simple interventions to address this issue.
AD  - All India Inst Med Sci, Ctr Community Med, New Delhi, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Community Ophthalmol, New Delhi, IndiaAD  - All India Inst Med Sci, Dept Biostat, New Delhi, IndiaAD  - All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Ophthalmol, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - All India Institute of Medical Sciences (AIIMS) New DelhiC3  - Dr. Rajendra Prasad Centre for Ophthalmic SciencesPU  - BMJ PUBLISHING GROUP
PI  - LONDON
PA  - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
DA  - MAR
PY  - 2018
VL  - 8
IS  - 3
C7  - e018894
DO  - 10.1136/bmjopen-2017-018894
AN  - WOS:000433881200073
ER  -

TY  - JOUR
AU  - Malik, R
TI  - The Role of Zinc in Childhood Infectious Disease
T2  - INDIAN JOURNAL OF PEDIATRICS
KW  - ACUTE DIARRHEA
KW  - CHILDREN
AD  - All India Inst Med Sci, Dept Pediat, Pediat Gastroenterol Hepatol & Clin Nutr, New Delhi, IndiaC3  - All India Institute of Medical Sciences (AIIMS) New DelhiPU  - SPRINGER INDIA
PI  - NEW DELHI
PA  - 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
DA  - MAR
PY  - 2018
VL  - 85
IS  - 3
SP  - 166
EP  - 167
DO  - 10.1007/s12098-017-2597-5
AN  - WOS:000429378100002
ER  -

